<SEC-DOCUMENT>0000950170-23-004875.txt : 20230228
<SEC-HEADER>0000950170-23-004875.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228080636
ACCESSION NUMBER:		0000950170-23-004875
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Phathom Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001783183
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824151574
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39094
		FILM NUMBER:		23678520

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE,
		STREET 2:		SUITE 102
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(877) 742-8466

	MAIL ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE,
		STREET 2:		SUITE 102
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>phat-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-02-27T18:39:08.4464+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:phat="http://www.phathompharma.com/20221231" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_d7201b82-ce21-4ec4-8499-cb8a67775133" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_775de606-9680-4686-a097-1b7b610892fa" format="ixt-sec:durwordsen">two years</ix:nonNumeric><ix:nonFraction id="F_7fcc0224-faaf-4025-b8d0-b563e26ab94e" name="us-gaap:TreasuryStockCommonValue" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_5ecefc5a-5125-41a1-a2fa-e831971495b3" name="us-gaap:TreasuryStockCommonValue" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_25935211-6394-4672-be26-784afbac5207" name="dei:EntityCentralIndexKey" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac">0001783183</ix:nonNumeric><ix:nonFraction id="F_2b850787-a6cf-4d02-9e61-c00a1a4fa91d" name="phat:RepurchaseRightLapseShares" contextRef="C_f7b89cb0-d7ca-4959-aed2-3aad49062bc4" unitRef="U_pure" decimals="6" scale="0" format="ixt:numdotdecimal">0.000208</ix:nonFraction><ix:nonNumeric id="F_64043701-fa2f-4405-b716-ab32b4abb5f6" name="dei:DocumentFiscalPeriodFocus" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac">FY</ix:nonNumeric><ix:nonFraction id="F_fc069ec2-b698-4009-b7c4-39ae24bbf4da" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_5bb1eb62-773c-4190-b511-c6ec9b1a614e" name="dei:CurrentFiscalYearEndDate" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac">--12-31</ix:nonNumeric><ix:nonFraction id="F_558505f2-45b8-41f3-be82-00543a9fac5f" name="us-gaap:PreferredStockValue" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_79fc89c8-d053-4eeb-8afd-78914e3ef4c7" name="us-gaap:PreferredStockValue" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_3abb8ab1-3f5f-4db4-be11-cc9877b7d465" name="dei:AmendmentFlag" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac">false</ix:nonNumeric><ix:nonFraction id="F_b6395ef0-f70f-4750-896d-fd899c227d0b" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="phat-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_ef56eeb8-d434-4c33-8a0e-a4c074a8edd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a9abbdc-846c-4903-a0f4-53dd7476cd04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9d8f01d-3d43-4934-ad2b-b3a53489fec5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_537af902-fc9d-4888-8d37-6ee0bf5d7d50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3089a359-e1ec-4cf0-8d42-a935b7b8080d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9864647f-dae0-400c-981a-2e1ad206fde6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4160e414-35f2-4edb-94aa-a3ea7eeab964"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_290088e4-cd92-4018-a07a-9b31182a5ae0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52ad1a5c-6e1b-4d4e-9cf1-f8d7bea71a22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f067a4b-daf1-4028-b748-712e3b729620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e83352c-1021-49ea-be17-abda53fad0d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da396882-6f6e-44fb-b650-cc0b5c7ed2f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">phat:UnvestedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fee0ce51-9e93-47f2-b416-b68d0ab99ce8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b1269f3-0919-4f09-919c-ae285bdda990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25cca5a5-3215-4f01-9b29-0229a260c11b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5376a47a-2a6e-4c10-a523-6c29d3b5be8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5a1d5b1-793a-4122-8486-ddd80632f18a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab5a798d-ceb3-45b5-9852-43c7c13434c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">phat:StockOptionsAndPerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_775de606-9680-4686-a097-1b7b610892fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">phat:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad628062-bdfb-4035-85ce-04fb1a93328a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b629611d-f479-44c6-9f1c-cdfdf6c74fcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b02900cd-2272-4953-b251-9b37853719fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d53f3397-a799-4e1e-97d8-9158ecf94191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2b4f91b-545a-498d-a89e-550afedc7031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a456270a-d53b-42d3-8702-a89087e2879e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74c344c6-6814-4821-8338-28c9c0250e05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc2a8230-0abf-4380-a0cf-1aee92ac8c64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesAndSvbTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ad3d68e-7eb3-4452-8fce-3d43389eeafa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7da2e53f-060f-4407-97fc-6ab72ec3f967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7acebd49-8754-4509-8ad2-aef189b7a108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_085d1c47-e6cb-4591-b010-3194bae40e70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9d3b85f-d90c-44ea-828c-6eca6895c78b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8f8b7b4-5d19-4a59-808a-7620c9d1ce95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementAndTemporaryServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4d64b0f-a1db-4cfd-9a23-da10238263c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b200a58a-3188-46aa-b5e6-de3a179abb6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b1aa0b6-a160-4d39-a073-61b00c5a103f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92b2fe60-4ace-4d6c-acc6-c79dfb6818d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d67cf6e-bd93-4d42-8971-522a9d32c0c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_254b2caf-becb-447f-bfa2-61ac97d82407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-07</xbrli:startDate><xbrli:endDate>2019-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d1f03d4-1220-447c-ab69-93821c543913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4ab7858-b04f-4eaf-90c2-cde3b6e2669c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1e29e67-db80-4194-babb-a6fb361ff631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99f14810-3a35-4382-9ab0-3938fb54794d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a303df35-50f8-4246-ac81-15cdd055190d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f484751c-237f-4a58-8796-c8018a28b609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:OpenMarketSaleAgreementWithJefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07f31873-c2a3-405b-826f-e016bf0d6ce1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3625bbc7-e0d2-4ae5-80c9-2c2a001c24c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2769f622-b2f5-4b1e-9bfc-9d6f83d30fcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">phat:InitialInvestorsNqSagardAndHerculesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b76ff2f4-ff03-419e-b174-84d981f8d356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ef9f4d9-0de2-4f1f-843d-3ab853904bf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5dcc212e-21a7-4a55-bc25-9c94fd4f27d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cddf29a-b8e2-483a-a1a6-cb58b2eba169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50a28e01-3143-418a-81bb-bfbdc824e6bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02d741c1-6ff5-434c-88d1-b60b946959c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16374c27-e9d9-4deb-990b-aa5e9aac1074"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a3f3bfa-6949-4f34-b6ab-a42581ad38fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">phat:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e81a5d21-6780-4696-8613-7d86dd579083"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d4560ac-5448-4f06-a2c0-c13d0498a9d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d783f53-5bda-4abc-8b88-b5d7f5533766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">phat:PrepaidLeasePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_193ec4b9-a149-4c59-b451-7fd82670dde2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2db8e6c-935d-488d-812e-7446da50b3c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71d680e8-6689-4309-bb74-70d6d934372b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70ed3e4f-7d42-4f15-94f8-e35d5e32239e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e45ec0f4-8be2-4007-a0b7-cc5a7fb0e0af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d34ef88d-9f9b-4614-9c60-3fd356fe4846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9397005-df60-4c46-9331-f164df01ca76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ded604e-c94b-436f-a89c-9b03fda0e603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f71a8436-7cab-4cb1-a0b4-4ed9b66f0382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-29</xbrli:startDate><xbrli:endDate>2019-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a0f9f10-e984-46bf-897d-9ef4dd6e2854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:OpenMarketSaleAgreementWithJefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb1ec5a6-fae4-47b9-b672-953a87241f7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2de0626c-2b10-4fe9-bbfd-1a4334ffe153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">phat:PaymentInKindPikInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dbb0e01-68b5-401c-ac47-a5ebd40a700f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d957629-8d64-4447-931c-6471c184bdc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b41ac6a5-4e17-4e1f-8bae-c1f1f8f391c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f20982d1-f9ce-4d58-8f02-7abadfb18a90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_161d27a8-0c36-4e47-af8a-c85124a58e31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">phat:InitialInvestorsNqSagardAndHerculesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-03</xbrli:startDate><xbrli:endDate>2022-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4898bc84-418b-459b-b337-70ce6a60f7c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_def31b4c-f4a8-4c99-b8ff-05f2befd1e4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9286bf5-ac0b-46f5-a136-ec84fcb2ae44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c879136-27f6-49d8-8690-7a4079f865e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ca84d6f-4ec7-4ca7-a80c-ce5f47b70bdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec823b74-ab4b-4334-a3c0-fe989b5ea271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28e002f0-fa91-457e-80d6-bc784dddc517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">phat:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d795b93-dc29-4dc9-8b77-44a4e74f6b8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29dfdd85-afb5-4d2f-a86b-48a3fd158ccc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">phat:InitialInvestorsNqSagardAndHerculesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7d27a7b-55b4-4782-b9ee-1496eed56e8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91b73800-dbc6-43cf-9117-11565d545493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3f07980-4a45-4835-8463-e1d119c8e5c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef443912-c72b-4729-a5ae-6e27ef16ba5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d02c08d8-d888-4a97-a17b-d64dc2a21728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-03</xbrli:startDate><xbrli:endDate>2022-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b9e40bc-f2d9-4495-a973-c2657257e971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fffdef7-2c4e-4f8c-a14d-47e0a16bf641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f292b92d-3d3f-4b55-9f26-2611aa4dd13c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">phat:StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9072564-13ae-4ea1-84c1-9febe815dd19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementAndTemporaryServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_921713e0-e38d-456b-b30a-55995a73ff55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b8aa030-2775-49eb-a555-98fc9d14d1bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85f57980-d393-4162-ae13-987929e0df5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15355aaa-f30b-4175-9505-232bcaaa97e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_997ec618-b563-491c-9eca-1c0da676ff3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_778accf5-7d44-4bf3-a402-bbbaf11a7645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d0461f1-b88c-4662-9709-e549cfb4144e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8157197-9c77-483d-a07b-d1d03a212eab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">phat:FoundersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85297e90-674e-4311-8d12-99f75d773722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">phat:ShareBasedPaymentArrangementEmployeeAndNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7e1b33c-ea56-4599-a9c9-30b1918239b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementAndTemporaryServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab4915e2-d84a-4fe8-8537-63d674acad7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12faa295-829a-4324-8f79-7c114d53f496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0784f7e-b027-403a-a3cd-28ff1f784844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">phat:FrazierLifeSciencesIXLimitedPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1e91519-0f55-42f3-a32a-9502a07575d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_808be0ce-b254-4e5d-b14f-728aa82ef026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:AmendmentToLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c25918b9-523a-4430-8c67-527934999f5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5734daa-3179-4da2-9c0d-ec26dd01ffa7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">phat:InitialInvestorsNqSagardAndHerculesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-03</xbrli:startDate><xbrli:endDate>2022-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee4ba230-41b0-4d69-921e-1d90ed587bd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d98949a-30e1-4a98-8bd5-692271892f22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanFirstAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12f1ae54-8af7-498f-b9c2-d3ecab67150a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementAndTemporaryServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3d62e8f-6837-4e80-a47d-75eba6bca352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0487172a-df33-4c7a-b44b-85c791ea9f49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bde66df6-9f96-4711-b5ca-d8e549c121ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7b89cb0-d7ca-4959-aed2-3aad49062bc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e19ddc7-d662-491a-b517-1a7dc60b7d07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b18d59c-b688-4dad-a3c3-0feef824fd50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0498a544-7235-40af-ade1-7542eee8d333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d27b5644-2ffe-49a5-bcac-f51f4f379e72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e655aad-b411-4446-8d28-57f008fc0793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c6526c3-fe53-437c-8a64-5ef862e523ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3416de9-775d-4af4-b997-f1e2dce25917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">phat:InitialInvestorsNqSagardAndHerculesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-03</xbrli:startDate><xbrli:endDate>2022-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0baa7388-d9e1-478c-86d2-1a3bfcdf4327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e93f3f8-5fa9-4e0e-9be2-05e4b1b44b52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-05</xbrli:startDate><xbrli:endDate>2020-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84f52c9e-524b-4bd9-9018-6cb27dd75205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1fa0f90-b682-4d91-b3c5-62f796e1a9cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2605f8bc-b7a3-4e6a-b47e-dad76807d9a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85e62724-a4f3-446d-a80e-ee240301cda0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8952b2b3-05be-4dbb-bb15-29a22754c147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f23428e3-ba82-4280-becf-c920e6849705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd48d243-f6ad-429e-b82e-626144871206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d987563-e4a1-47c2-a958-218433edf069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">phat:UnvestedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9b385aa-6a5f-45cc-a03d-80389e7fbcf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementAndTemporaryServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5943d02e-5414-489b-b249-8e8202898837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdabcc96-9593-40cb-bc06-20ae0d8af269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_316e751d-ea37-4523-950e-d005edde6cbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cceeb3e-ff40-49d0-b18c-96a61d412299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1345e6a-366c-4155-83c9-889619f08e7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55b184ca-7a41-480d-a822-5e3317a65984"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff181df1-43b0-434d-b3db-83c48fa28c00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-29</xbrli:startDate><xbrli:endDate>2019-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1da1354-c115-4771-a4a8-bb35b2ea792f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd528633-09ca-45e1-a4f8-8be7636e9b54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2a8d3e4-8302-40ab-8531-be80c035a7d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb899363-81cb-4d24-aa66-4956be36544e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38a3ce84-f57c-409f-8929-19e767dc49e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9960ff79-ef61-47f2-b12d-b0b42bd290e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9f3b61c-edfe-4524-8536-373c8a65e8a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_836f3b27-9cf0-4ba9-abe3-f68ffa72e1e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Option"><xbrli:measure>phat:Option</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>phat:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_27598d45-f07e-41c0-a7d2-ba450d82de0e" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4dc8046a-3656-4f30-8d00-cac92918113d" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7bdcc32b-f872-4332-8a72-763f59605f43" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d115b92-2108-4859-b9ef-bbbea14c0ef6" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b14a6650-36b4-4ad8-bb30-780c324ad2fc" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the transition period from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission file number: </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c4012fd5-0e3e-49bf-904d-39a30412794f" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39094</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_88ffe565-14fa-4b6b-84c0-33eedbf0df32" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PHATHOM PHARMACEUTICALS, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.981%;"></td>
    <td style="width:2.037%;"></td>
    <td style="width:48.981%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_01d8fe28-cf1b-49cf-8e82-00672bfcb022" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_941b573b-315e-4a8e-aa23-df8a723889fb" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82-4151574</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporation or Organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_688a2db4-c842-4e5f-84e2-e382045b279c" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100 Campus Drive</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e6255b3f-17e8-4633-aebd-ade13d48f197" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 102</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0fdb2bc6-9236-4393-ae0b-0eaf422caf2f" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Florham Park</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8363ef67-d061-4b02-a57e-63f63122b584" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New Jersey</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ad92f2e6-2867-4ba2-a4e8-3f45e4e2bcd2" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">07932</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code: (</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6235d1a8-d541-4b24-8e45-db2c5b80cd14" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">877</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dfda004d-7c02-45b6-bec2-12a5f8104f36" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">742-8466</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.009%;"></td>
    <td style="width:1.009%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:38.981%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:21.85pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:18.65pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_05ba0fde-53a9-479a-b45c-9c30e1ced326" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9c1788a1-e800-4a7d-b8e1-90f9ce7aea45" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PHAT</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c50ff34-f50d-456f-a631-6d768ce3253f" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  &#9744;    </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0a875de0-07c1-41a3-a01e-21ba3ddefd2e" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  &#9744;    </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_433ff177-5a0e-426c-81ef-66a96a0baab5" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d073ca72-fa99-42a0-b5d2-280887b9fdac" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d039544-d2fe-4ecb-90b5-163756bf3eae" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:22.444%;"></td>
    <td style="width:2.056%;"></td>
    <td style="width:51.019%;"></td>
    <td style="width:22.444%;"></td>
    <td style="width:2.037%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2a6cf3f9-9094-4b27-bbd1-ab9e73a882f0" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_786d9d2a-3114-42ab-b7dc-8f3ba8d12e3a" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_647b7ef2-14cc-4ef3-8c39-b3f66976f788" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_908b5772-3927-49c4-aacb-9552dee45f29" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C. 7262 (b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8bde42cd-f36b-478c-812c-26db3b64dcf8" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes  &#9744;    No  </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8eb49300-e898-46e9-af2d-1ff3b53b438a" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30, 2022, the aggregate market value of the registrant&#x2019;s common stock held by non-affiliates of the registrant was approximately $</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_920af6b4-6c35-4bc1-8e25-21959155a89b" contextRef="C_07f31873-c2a3-405b-826f-e016bf0d6ce1" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">198.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, based on the closing price of the registrant&#x2019;s common stock on the Nasdaq Global Select Market of $8.44 per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 24, 2023, the registrant had </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5be22763-f5ce-444d-8828-f199b614ca3a" contextRef="C_316e751d-ea37-4523-950e-d005edde6cbd" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">41,973,271</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock ($0.0001 par value) outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_36465543-ec91-48fa-ab62-9f3abd8e3396" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain sections of the registrant&#x2019;s definitive proxy statement for the 2023 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PHATHOM PHARMACEUTICALS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">TABLE OF CONTENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">FORM 10-K</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For the Year Ended December 31, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INDEX</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:82.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.168%;"></td>
    <td style="width:1.235%;"></td>
    <td style="width:79.836%;"></td>
    <td style="width:6.76%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PART I</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">66</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PART II</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5__market_for_registrants_common_eq"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">144</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">145</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">146</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a__quantitative_qualitative_disclo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8__financial_statements_supplementa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9__changes_in_disagreements_with_ac"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a__controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">161</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b__or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">161</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">161</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PART III</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10__directors_executive_ficers_corp"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">162</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11__executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">162</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12__security_ownership_certain_bene"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">162</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13__certain_relationships_related_t"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">162</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14__principal_accounting_fees_servi"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">162</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PART IV</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15__exhibits_financial_statement_sc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">170</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> I</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">This annual report on Form 10-K contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this annual report, including statements regarding our future results of operations and financial position, business strategy, research and development plans and costs, the timing and likelihood of regulatory filings and approvals, commercialization plans, pricing and reimbursement, the potential to develop future product candidates, the timing and likelihood of success of the plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This annual report on Form 10-K also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;could,&#x201d; &#x201c;intend,&#x201d; &#x201c;target,&#x201d; &#x201c;project,&#x201d; &#x201c;contemplates,&#x201d; &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;potential&#x201d; or &#x201c;continue&#x201d; or the negative of these terms or other similar expressions. The forward-looking statements in this annual report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, and short term and long term business operations and objectives. These forward-looking statements speak only as of the date of this annual report and are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, &#x201c;Risk Factors.&#x201d; The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">This annual report includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this annual report appear without the &#174; and &#153; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We maintain a website at www.phathompharma.com, to which we regularly post copies of our press releases as well as additional information about us. Our filings with the Securities and Exchange Commission, or SEC, are available free of charge through our website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained in our website does not constitute a part of this report or our other filings with the SEC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 1. Bu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">siness</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial approved products, VOQUEZNA TRIPLE PAK&#153; and VOQUEZNA DUAL PAK&#153;, and our current product candidate, VOQUEZNA&#153;, contain vonoprazan, an oral small molecule potassium-competitive acid blocker, or PCAB. PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan is the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or Canada in over 30 years, and has shown rapid, potent, and durable anti-secretory effects. Vonoprazan has also demonstrated clinical benefits over the current standard of care as a single agent in the treatment of erosive gastroesophageal reflux disease, or erosive GERD, and in combination with antibiotics for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Helicobacter pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in numerous countries in Asia and Latin America as well as Russia. Vonoprazan generated approximately $850 million in net sales in its seventh full year on the market since its approval in Japan in late 2014. In May 2019, we in-licensed the U.S., European, and Canadian rights to vonoprazan from Takeda.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In 2021 we reported positive topline data from two pivotal Phase 3 clinical trials for vonoprazan: one for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, or PHALCON-HP, and a second for the treatment of erosive GERD, also known as erosive esophagitis or EE, PHALCON-EE. In April 2021, we reported positive topline data from PHALCON-HP, and in October 2021, we reported positive topline data from PHALCON-EE. These data are supplemented by the extensive existing clinical data generated by Takeda as part of their development program for vonoprazan in Japan and other markets. In September 2021, we submitted two new drug applications, or NDAs, for combination packs that contain vonoprazan for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection in adults, one in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) and the other in combination with amoxicillin alone (vonoprazan dual therapy).  In May 2022, the U.S. Food and Drug Administration, or FDA, approved the NDAs for vonoprazan triple therapy, under the brand name VOQUEZNA TRIPLE PAK, and vonoprazan dual therapy, under the brand name VOQUEZNA DUAL PAK.  Prior to these approvals, in May 2021, we received qualified infectious disease product, or QIDP, designations for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which, upon approval of these products, added five years of regulatory exclusivity to the five years of new chemical entity, or NCE, exclusivity for vonoprazan to which these products were, and future products we develop containing vonoprazan will be, entitled.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In March 2022, we submitted an NDA for vonoprazan as a treatment for adults for the healing of all grades of erosive GERD, maintenance of healing of all grades of erosive GERD, and relief of heartburn associated with erosive GERD. If approved, we expect to market the product under the brand name VOQUEZNA. In August 2022, prior to the launch of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, we announced that, consistent with current FDA Guidance for Industry: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Control of Nitrosamine Impurities in Human Drug Products</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, we initiated testing to determine whether nitrosamine impurities were present in our initial commercial drug product for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. These tests revealed trace levels of a nitrosamine impurity, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">N</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-nitroso-vonoprazan, or NVP, that is not described within the FDA Guidance document. In January 2023, we announced that, although the FDA established an acceptable daily intake, or AI, for NVP at 96 ng/day, the FDA (Division of Gastroenterology) advised us that it would not be acting on our erosive GERD NDA on or prior to the Prescription Drug User Fee Act, or PDUFA, target action date of January 11, 2023. Rather, the FDA requested additional stability data demonstrating that the levels of NVP will remain at or below the AI throughout the proposed shelf life of the product.  In February 2023, we received complete response letters from the FDA relating to our erosive GERD NDA and post approval supplement relating to our approved </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">NDAs, both of which address specifications and controls for NVP. These letters formalized FDA&#x2019;s prior request that we provide additional stability data to demonstrate that levels of NVP will remain at or below the AI throughout the proposed shelf life of the product.  No additional deficiencies were cited by the FDA in either letter.  We have scheduled a meeting with the FDA in March of 2023 to discuss our resubmission plan and timeline. If we are unable to demonstrate to the FDA that we will be able to maintain NVP levels at or below the AI, launches of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PAK will be further delayed and approval of our erosive GERD NDA will continue to be delayed, which could substantially increase our costs and delay or put at risk our ability to generate revenue and adversely affect our commercial prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Also in January 2023, we reported positive topline results from PHALCON-NERD-301, a Phase 3 study evaluating the efficacy and safety of vonoprazan for the daily treatment of adults with symptomatic non-erosive gastroesophageal reflux disease, or non-erosive GERD. This study will continue through a 20-week extension period to evaluate long term safety and efficacy before its completion. We are also in discussions with the FDA regarding the design of a Phase 3 trial to evaluate the novel dosing regimen of vonoprazan as an as needed treatment for episodic heartburn relief in patients with non-erosive GERD, a dosing regimen not approved in the United States for proton pump inhibitors. This trial would constitute our fourth Phase 3 trial for vonoprazan. In February 2022, we reported positive topline results from PHALCON-NERD-201, the Phase 2 study evaluating proof-of-concept efficacy from this novel dosing regimen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We plan to independently commercialize vonoprazan in the United States. In addition, we plan to seek commercial partnerships for vonoprazan in Europe and Canada, expand development of vonoprazan into other indications, dosing regimens and alternative formulations and packaging, and in-license or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases in a capital efficient manner.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">GERD and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection are two of the most common acid-related GI diseases and impact millions of people. The prevalence of GERD is estimated to be 20% of the U.S. population and 15% of the population in the five major countries in Europe (France, Germany, Italy, Spain and the United Kingdom) (collectively, the &#x201c;EU5&#x201d;). GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. Approximately 30% of GERD patients have erosive GERD. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> is a bacterial pathogen that infects approximately 35% of the U.S. population and 45% of the EU5 population. As a result of the chronic inflammation induced by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection, approximately 20% of infected patients will develop a range of pathologies, including dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Over the last thirty years, the proton pump inhibitor, or PPI, class, has been the standard of care for the treatment of acid-related GI diseases. PPIs are generally used as a single agent for the treatment of GERD and in combination with antibiotics for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection. The PPI class includes drugs such as Prilosec (omeprazole), Nexium (esomeprazole), and Prevacid (lansoprazole). Prior to the introduction of generic and over-the-counter, or OTC, alternatives, annual PPI class sales reached approximately $12.5 billion in the United States, with peak sales for individual brands of approximately $3.7 billion for Prilosec, $3.5 billion for Nexium, and $3.4 billion for Prevacid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">While PPIs are the current standard of care and have experienced significant commercial success, they have significant limitations that result in a large unmet medical need. In GERD, PPI therapy is suboptimal for many patients due to the slow onset and insufficient duration of acid control which can lead to inadequate symptom relief. Approximately 15% to 45% of GERD patients remain inadequately treated with PPIs. In the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, the standard of care consists of a combination of a PPI and at least two oral antibiotics. However, increasing antibiotic resistance has resulted in declining eradication rates with PPI-based therapy. We believe these unmet medical needs are in part driven by limitations associated with the mechanism of action and pharmacokinetics of PPIs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PPIs reduce gastric acid secretion by irreversibly binding to and inhibiting active proton pumps expressed on the parietal cells. PPIs require activation by gastric acid, but they are unstable in the presence of acid. This instability, combined with the short circulating half-life of PPIs, limits their efficacy. Additionally, because proton pumps continuously switch between active and inactive states, multiple doses of PPIs are required to inhibit enough proton pumps to achieve a clinical benefit. As a result, PPIs have a relatively slow onset of action and limited potency and duration of effect, which may result in patients experiencing only partial relief, increasing PPI dosage, and/or cycling through multiple PPIs seeking relief. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan has a differentiated mechanism of action from PPIs. Unlike PPIs, vonoprazan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">does not require activation by gastric acid; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">is stable in the presence of acid; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">is designed to selectively concentrate in the parietal cells in both the resting and stimulated states, bind to the active pumps and remain associated with the active and inactive pumps;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">binds to the pumps in a noncovalent and reversible manner; and  </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">has a long plasma half-life that replenishes the drug at the site of action over the course of the day. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">These factors have enabled vonoprazan to demonstrate more rapid and potent acid suppression versus the PPIs esomeprazole and lansoprazole in human subjects two hours after oral dosing and maintain target acid inhibition over a 24-hour period in randomized, open-label, crossover clinical trials. In contrast, PPIs require three to five days to reach steady state acid suppression and do not reliably maintain target acid inhibition over a 24-hour period. In addition, vonoprazan demonstrated approximately 10-to-100-fold better acid control compared to lansoprazole and esomeprazole.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan has demonstrated clinical advantages over the PPI lansoprazole in the treatment of erosive GERD and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection in completed Phase 3 clinical trials conducted in the United States and Europe, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">faster and more complete healing of erosive GERD in patients with moderate to severe disease; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">more durable healing of erosive GERD in patients with all grades of disease;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">higher </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">eradication rates in combination with antibiotics compared to standard of care triple therapy; and </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">more flexible dosing, including dosing independent of food and time of day</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Moreover, we believe that vonoprazan&#x2019;s anti-secretory mechanism has the potential to contribute to additional clinical advantages over PPIs such as rapid symptom relief through as needed dosing in the treatment of patients with non-erosive GERD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Erosive GERD</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.  Our NDA seeking approval of vonoprazan, under the brand name VOQUEZNA, for the treatment of adults with erosive GERD was based on the results from PHALCON&#x2011;EE, our Phase 3 clinical trial conducted in the United States and Europe. This trial assessed vonoprazan versus lansoprazole in the healing and maintenance of healing of adult patients with erosive GERD.  In PHALCON-EE, vonoprazan met its primary healing endpoint demonstrating non-inferiority to lansoprazole in the number of patients who showed complete healing of erosive GERD after eight weeks of treatment. Further, in a pre-specified secondary endpoint, vonoprazan demonstrated superior healing after two weeks of treatment in patients with moderate to severe erosive GERD compared to lansoprazole. After two weeks of treatment, 70% of patients with moderate to severe erosive GERD were healed after treatment with vonoprazan versus 53% with lansoprazole (p=0.0008). In the maintenance phase of the trial both doses of vonoprazan (10 mg and 20 mg) met the primary endpoint of non-inferiority compared to lansoprazole in the number of all patients who maintained healing of erosive GERD through week 24. Further, both vonoprazan doses also met a pre-specified secondary endpoint demonstrating superiority of maintenance of healing versus lansoprazole (79% for vonoprazan 10 mg, 81% for vonoprazan 20 mg compared to 72% for lansoprazole 15 mg) (p&lt;0.0001 for both non-inferiority comparisons; p=0.0436 for vonoprazan 10 mg superiority comparison; p=0.0272 for vonoprazan 20 mg superiority comparison). Both vonoprazan doses also met the pre-specified secondary endpoint of demonstrating superiority of the percentage of patients with moderate-to-severe disease who maintained healing of erosive GERD through week 24 (75% vonoprazan 10 mg, 77% vonoprazan 20 mg v. 61% lansoprazole 15 mg) (p=0.0490 for vonoprazan 10 mg superiority comparison; p=0.0196 for vonoprazan 20 mg superiority comparison).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In PHALCON-EE, vonoprazan 20 mg met the secondary endpoint of showing non-inferiority to lansoprazole 30 mg in the mean percentage of 24-hour heartburn free days over the healing period, and both vonoprazan doses met the secondary endpoint of showing non-inferiority to lansoprazole 15 mg in the mean percentage of 24-hour heartburn free days over the maintenance period. Finally, vonoprazan 20 mg was also compared to lansoprazole 30 mg in a superiority test for onset of sustained resolution of heartburn by day three of the healing phase but did not achieve statistical significance (p=0.2196).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A p-value is the probability that the reported result was achieved purely by chance, such that a p-value of less than or equal to 0.05 or 0.01 means that there is a 5.0% or 1.0% or less probability, respectively, that the difference between the control group and the treatment group is purely due to chance. A p-value of 0.05 or less typically represents a statistically significant result.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The results from PHALCON-EE were consistent with the results of four Phase 3 clinical trials previously conducted by Takeda, two in each of Japan and China, assessing vonoprazan versus lansoprazole in the healing and maintenance of healing of erosive GERD in which vonoprazan met its primary endpoint in demonstrating non-inferiority to lansoprazole.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Symptomatic non-erosive gastroesophageal reflux disease.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In PHALCON-NERD-301, a Phase 3 study evaluating the efficacy and safety of vonoprazan for the daily treatment of adults with non-erosive GERD, both doses of vonoprazan (10 mg and 20 mg) met the primary endpoint evaluating the mean percentage of 24-hour heartburn -free days through week four by demonstrating statistical significance versus placebo (mean 46.4% vonoprazan 10 mg, 46.0% vonoprazan 20 mg, compared to 27.5% for placebo; p&lt;0.0001 for both vonoprazan 10 mg and 20 mg versus placebo). The median percentage of 24-hour heartburn-free days was 48.3%, 46.7% and 17.0% for vonoprazan 10 mg, vonoprazan 20 mg, and placebo, respectively. We anticipate full results from this trial will be available in the second half of 2023 after the completion of the 20-week extension period, which is currently ongoing to further evaluate the safety and efficacy of both doses of vonoprazan after six months of continuous use. Pending receipt of these results, we expect to submit an application to the FDA in the second half of 2023 seeking approval of vonoprazan as a daily treatment of adults with non-erosive GERD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In PHALCON-NERD-201, a Phase 2 study evaluating three doses of vonoprazan (10 mg, 20 mg, and 40 mg) as an as needed therapy for relief of episodic heartburn in subjects with non-erosive GERD, all three vonoprazan doses successfully met the primary endpoint evaluating the percentage of heartburn episodes completely relieved within three hours with relief sustained for over 24 hours and were statistically significant (p&lt;0.0001) when compared to placebo. Within three hours, vonoprazan 10 mg, 20 mg, and 40 mg achieved complete and sustained relief in 56.0%, 60.6% and 70.0% of evaluable heartburn episodes, respectively, as compared to 27.3% of episodes for placebo. An evaluable heartburn episode is a heartburn episode for which the participant completes a minimum of one timed assessment after taking study medication.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Further, based on the positive PHALCON-NERD-201 results, we are in discussions with the FDA regarding the design of a Phase 3 trial, which would be our fourth Phase 3 trial for vonoprazan, to evaluate the novel dosing regimen of vonoprazan as an as needed treatment for episodic heartburn relief in patients with non-erosive GERD, a dosing regimen not approved in the United States for PPIs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. The FDA&#x2019;s approval of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK was based on the results from PHALCON-HP, our Phase 3 clinical trial in the United States and Europe studying two vonoprazan-based treatment regimens for the eradication of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, both of which successfully met their primary endpoints and all secondary endpoints. The trial studied vonoprazan triple therapy and vonoprazan dual therapy compared to lansoprazole in combination with amoxicillin and clarithromycin, or lansoprazole triple therapy. The objective of the PHALCON-HP trial was to compare eradication rates in all treated subjects as well as in two pre-identified subgroups of patients: those patients with clarithromycin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">and those patients who did not have clarithromycin or amoxicillin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> For regulatory purposes, the primary endpoint of this study was a non-inferiority comparison in the non-resistant subgroup for each of vonoprazan triple therapy and vonoprazan dual therapy compared to lansoprazole triple therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In PHALCON-HP, both vonoprazan-based regimens successfully met their primary endpoints. In the modified intent-to-treat (mITT) population, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> eradication rates were 84.7% for vonoprazan triple therapy and 78.5% for vonoprazan dual therapy compared to 78.8% with lansoprazole triple therapy (p&lt;0.0001 and p=0.0073, respectively, for non-inferiority). In the pre-specified per protocol population, a subset of the mITT population comprised of patients who were protocol compliant, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> eradication rates were 90.4% with vonoprazan triple therapy and 81.2% with vonoprazan dual therapy compared to 82.1% with lansoprazole triple therapy (p&lt;0.0001 and p=0.0155, respectively, for non-inferiority).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In PHALCON-HP vonoprazan triple therapy and vonoprazan dual therapy also met all secondary endpoints, demonstrating superior eradication rates versus lansoprazole triple therapy in all patients and in the subgroup of patients with clarithromycin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Among all patients, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> eradication rate of vonoprazan triple therapy was superior to that of lansoprazole triple therapy in both the mITT population (80.8% vs. 68.5%; p=0.0001) and the per protocol population (85.7% vs. 70.0%; p&lt;0.0001). In the subset of patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> strains resistant to clarithromycin, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">eradication rate with vonoprazan triple therapy was superior to that of lansoprazole triple therapy in both the mITT population (65.8% vs. 31.9%; p&lt;0.0001) and the per protocol population (67.2% vs. 29.0%; p&lt;0.0001).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Among all patients, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> eradication rate of vonoprazan dual therapy was superior to that of lansoprazole triple therapy in both the mITT population (77.2% vs. 68.5%; p=0.0127) and the per protocol population (81.1% vs. 70.0%; p=0.0027). The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> eradication rate of vonoprazan dual therapy was also superior to that of lansoprazole triple therapy in the subset of patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> strains resistant to clarithromycin in both the mITT population (69.6% vs. 31.9%; p&lt;0.0001) and the per protocol population (79.5% vs. 29.0%; p&lt;0.0001).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The vonoprazan triple therapy results of PHALCON-HP were consistent with the results of a Phase 3 clinical trial previously conducted by Takeda in Japan assessing vonoprazan in combination with the antibiotics amoxicillin and clarithromycin versus lansoprazole in combination with these same antibiotics in first line treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection at antibiotic doses and treatment duration (7 days) consistent with local practice in Japan. Vonoprazan dual therapy was not tested in this study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our management team has deep expertise in developing GI therapeutics, including anti-secretory agents, and direct experience developing vonoprazan at Takeda. Our Chief Executive Officer, Terrie Curran, has more than 20 years of experience in the biopharmaceutical industry. Ms. Curran served as President, Global Inflammation and Immunology (I&amp;I) Franchise and as a member of the Executive Committee at Celgene Corporation from 2017 to 2019. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&amp;I Franchise, where she built the capabilities and recruited the teams that executed the successful launch of OTEZLA, which was sold to Amgen in November 2019 for $13.4 billion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Azmi Nabulsi, M.D., M.P.H., our Chief Operating Officer, is the former Deputy Chief Medical and Scientific Officer at Takeda. Our Head of Regulatory, Tom Harris, is the former Senior Vice President and Head of Global Regulatory at Takeda. Dr. Nabulsi and Mr. Harris were extensively involved with the development of vonoprazan at Takeda.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following chart summarizes our current development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img46421407_0.jpg" alt="img46421407_0.jpg" style="width:624px;height:301px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our mission is to improve the lives of people suffering from gastrointestinal diseases. Our strategy is initially focused on developing and commercializing vonoprazan as a first-in-class PCAB in the United States for the treatment of acid-related GI diseases. Key elements of this strategy include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Obtain marketing approval of VOQUEZNA for treatment of erosive GERD and initiate commercial launch of VOQUEZNA, VOQUEZNA TRIPLE PAK and DUAL PAK in the U.S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.  In May 2022, the FDA approved VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection in adults. In February 2023, we received complete response letters from the FDA relating to our erosive GERD NDA and post approval supplement relating to our approved </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">NDAs, both of which address specifications and controls for NVP.  We have scheduled a meeting in March 2023 with the FDA to discuss our resubmission plan and timeline.  Following potential approval of resubmissions and launch, we expect all our approved products containing vonoprazan will benefit from a 10-year period of marketing exclusivity that commenced upon approval of our initial products for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection in May 2022.  This 10-year period of exclusivity is the result of vonoprazan being approved as new chemical entity, or NCE, which provided a five-year period of marketing exclusivity for all our products containing vonoprazan commencing with approval of VOQUEZNA TRIPLE PAK and DUAL PAK in May 2022.  And, because those products received QIDP designations, the five-year NCE period of marketing exclusivity for all our products containing vonoprazan was automatically extended by five years, until May 2032.                         </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Advance the clinical development of vonoprazan in non-erosive GERD and seek marketing approval. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Symptomatic non-erosive gastroesophageal reflux disease, or non-erosive GERD, is a major subcategory of GERD and is characterized by reflux-related symptoms in the absence of esophageal mucosal erosions. We are pursuing development of vonoprazan for treatment of non-erosive GERD as both an as needed and once-daily therapy. In January 2023, we reported positive topline results for the primary endpoint of PHALCON-NERD-301, a Phase 3 study evaluating the efficacy and safety of vonoprazan for the daily treatment of non-erosive GERD in adults. We are also in discussions with the FDA regarding the design of a Phase 3 trial in order to evaluate the novel dosing regimen of vonoprazan as an as needed treatment for episodic heartburn relief in patients with non-erosive GERD, a dosing regimen not approved in the U.S. for PPIs. The pursuit of this novel dosing regimen is supported by the positive topline results we reported in February 2022 for PHALCON-NERD-201, a Phase 2 study evaluating various doses of vonoprazan and placebo as an as needed treatment for adults with non-erosive GERD.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Commercialize vonoprazan in the United States</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. We plan to independently commercialize VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, and if approved, VOQUEZNA, in the United States by building a leading gastroenterology commercial infrastructure to support the adoption of vonoprazan. We believe we can successfully commercialize these products in the United States with a focused sales force targeting prescribers of treatments for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">and GERD, particularly gastroenterologists. Prescriptions for treatments for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">and GERD are both highly concentrated, with approximately 76% of prescriptions in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and 65% of prescriptions in erosive GERD being written by 10% of the PPI prescribers. We believe we have an opportunity to achieve significant share of voice and exposure to physicians given the scarcity of actively marketed anti-secretory medicines. Given the limitations of PPIs and current unmet need, we believe the commercial opportunity for VOQUEZNA, VOQUEZNA TRIPLE PAK and DUAL PAK is substantial.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Seek commercial partnerships to maximize the vonoprazan opportunity outside of the United States</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.  To address the opportunity for vonoprazan in Europe and Canada, we plan to seek one or more partners with existing commercial infrastructure and expertise in these markets. We believe this strategy will allow us to realize the value of the market opportunity in Europe and Canada while focusing our resources on the U.S. market.  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Further expand the development of vonoprazan across indications, dosing regimens, and alternative formulations and packaging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. In addition to both daily and as needed dosing for the treatment of symptoms related to non-erosive GERD, we plan to pursue vonoprazan lifecycle extension strategies in areas with clear unmet need, clinical rationale, and commercial justification.  For example, we are planning discussions with the FDA on our proposed development plan to study vonoprazan as a treatment for eosinophilic esophagitis, or EoE.  These strategies may include: (i) potential indications in addition to EoE, including treatment of gastric and duodenal ulcers, and Barrett&#x2019;s esophagus; and (ii) alternative formulations and packaging, such as orally disintegrating tablets and other oral dosage forms for patients with difficulty swallowing, and an intravenous formulation for in-hospital applications. Additionally, we believe that vonoprazan has the ideal profile for an OTC product because of the potential for as needed symptom relief and a well-tolerated safety profile.     </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">In-license or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases in a capital efficient manner</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. We intend to take advantage of our management team&#x2019;s GI expertise to opportunistically in-license or acquire additional innovative therapies for diseases treated by gastroenterologists. We plan to leverage our development and planned commercial infrastructure to support multiple assets targeting GI indications. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Acid-Related GI Diseases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Gastric acid is a digestive fluid formed in the stomach. The highly acidic environment of the stomach causes the unfolding, or denaturing, of food proteins that are subsequently broken down by gastric enzymes. Gastric acid is secreted by the hydrogen potassium ATPase enzyme, which is known as the proton pump. Proton pumps are expressed on the channeled surfaces, or canaliculi, of parietal cells in the stomach, which secrete acid. Proton pumps are continuously synthesized and switch between active and inactive states in response to various stimuli, such as food. When activated, proton pumps increase acid secretion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">GI diseases where treatment is related to acid control, such as GERD, peptic ulcer disease, Zollinger Ellison syndrome, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, are significant medical problems because of their high prevalence, chronic nature and clinical sequelae. GERD results from the effects of acid on compromised mucosal defenses in the gastrointestinal tract. The reflux of gastric acid into the esophagus produces frequent and/or severe heartburn, indigestion, and reflux symptoms. Chronic GERD may damage esophageal tissue and progress to more severe diseases including erosive GERD, Barrett&#x2019;s esophagus, and esophageal cancer. GERD and related diseases are associated with impaired quality of life and substantial costs to the healthcare system given their chronic nature and sequelae. In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, gastric acid limits the effectiveness of antibiotics used to eradicate infection. Chronic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection can lead to dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Prevalence</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The prevalence of GI diseases is high. Approximately 20% to 40% of Western adults report chronic heartburn or regurgitation symptoms potentially related to GERD. We estimate that there are approximately 65 million individuals in the United States and 50 million individuals in the EU5 with GERD. In the United States, GERD is the most common gastroenterology-related outpatient diagnosis. Additionally, approximately 35% of the U.S. population and 45% of the EU5 population are infected with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. We estimate that there are approximately 115 million individuals in the United States and 145 million individuals in the EU5 infected with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prevalence of GERD and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Infection</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_1.jpg" alt="img46421407_1.jpg" style="width:612px;height:218px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Treatments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Treatments of acid-related GI diseases aim to provide relief of acute symptoms, healing of damaged tissue, and prevention of long-term clinical sequelae associated with chronic acid exposure. Gastric acidity is measured by the pH scale, a logarithmic scale where 7.0 describes a neutral state and lower levels indicate a higher level of acidity. The pH of the stomach typically ranges from 1.5 to 3.5. In patients with acid-related GI diseases, increasing gastric pH has been shown to improve mucosal healing rates and provide more rapid symptom relief for patients. For example, the duration of time that intra-gastric acidity is greater than pH 3.0 correlates with the healing of duodenal and gastric ulcers, and pH greater than 4.0 is correlated with the healing of erosive GERD. Similarly, in patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, a more neutral gastric pH of 6.0 to 8.0 preserves antibiotic function and is optimal for successful eradication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Drug-induced gastric acid suppression is a key component of the management of acid-related GI diseases. Three classes of drugs with distinct mechanisms of action are principally used for treatment in the United States and Europe: antacids, histamine receptor antagonists, or H2RAs, and PPIs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Antacids</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Antacids, first commercially available in the 1930s, directly neutralize gastric acid to raise intra-gastric pH and can alleviate intermittent, mild symptoms of acid-related GI diseases, such as heartburn, but they are only effective for a short duration and require frequent administrations per day. In addition, antacids do not significantly help heal or prevent complications of acid-related diseases. Antacids include commonly known OTC products, such as Alka-Seltzer, Pepto-Bismol, Rolaids, and TUMS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Histamine Receptor Antagonists (H2RAs)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">H2RAs, first commercially available in the 1970s, decrease gastric acid secretion in order to raise gastric pH. H2RAs represented a dramatic improvement over antacids in the control of gastric acid and consequently in the management of acid-related GI diseases. H2RAs are also generally safe and well-tolerated. Among the H2RA class were the first commercial blockbuster drugs, Pepcid (famotidine), Tagamet (cimetidine), and Zantac (ranitidine). Zantac was the world&#x2019;s highest-selling prescription drug in the mid-1990s, with peak global sales of $3.7 billion and U.S. sales of $2.2 billion. Prior to the launch of generic H2RAs and increasing competition from PPIs, the H2RA class achieved sales of approximately $3.5 billion in the United States. H2RAs achieved commercial success despite clinical limitations, including unreliable 24-hour acid control, poor control of post-meal symptoms, and loss of efficacy over time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Proton Pump Inhibitors (PPIs)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PPIs, first commercially available in 1989, offered improved acid control over H2RAs. Pharmacodynamic data demonstrated that PPIs maintain gastric pH above target levels for a longer duration than H2RAs. A commonly used benchmark of anti-secretory activity is the percentage of time in a 24-hour period that gastric pH exceeds 4.0, which we refer to as time above pH 4.0, which ranges from 40% to 71% for PPIs versus 33% for H2RAs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Given this improved pharmacodynamic profile, PPIs demonstrated improved clinical symptom relief and healing over H2RAs. In a meta-analysis of results from 33 randomized clinical trials with over 3,000 GERD patients, a reduction in symptoms was achieved in 83% of patients taking PPIs versus 60% of those on H2RAs. In a second meta-analysis, the eight-week healing rate in patients with erosive GERD was 82% for PPIs versus 52% for H2RAs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The PPI class is currently the first-line treatment of acid-related GI diseases. Prior to the introduction and adoption of generic and OTC alternatives, annual PPI class sales reached approximately $12.5 billion in the United States, with peak sales for individual brands of approximately $3.7 billion for Prilosec, $3.5 billion for Nexium, and $3.4 billion for Prevacid. As recently as 2015, the last branded PPI, Dexilant (dexlansoprazole), reached approximately $530 million in sales in the United States despite limited differentiation from other PPIs. While Dexilant demonstrated a modest improvement in time above pH 4.0 compared to other PPIs, the approved dose did not demonstrate consistent superiority in Phase 3 trials against other PPIs for the healing of erosive GERD and has not been tested against PPIs in other indications. We believe that the commercial success of Dexilant highlights the value to physicians and patients of even incremental improvements over other PPIs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">History of Pharmaceutical Agents for Control of Gastric Acid</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_2.jpg" alt="img46421407_2.jpg" style="width:624px;height:270px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PPI Limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">While PPIs provide clinically meaningful symptom relief and healing for millions of patients suffering from acid-related GI diseases, they are inadequate for many patients. The suboptimal anti-secretory profile of PPIs results in slow onset of symptom relief, breakthrough nighttime or postprandial heartburn, and treatment failure. A recent population-based survey with over 70,000 participants in the United States showed that 55% of patients who reported having GERD symptoms were taking PPIs, with 68% taking them daily, and 54% of those daily PPI users reporting persistent symptoms. This is consistent with earlier studies that have shown that approximately 15% to 45% of GERD patients are inadequately treated with PPIs, experiencing persistent, troublesome symptoms, such as heartburn and regurgitation. In approximately two-thirds of symptomatic GERD patients, reflux symptoms are not adequately controlled after the first dose of a PPI, and nearly 50% of patients still suffer from symptoms three days later. Given these limitations, more than 20% of GERD patients on PPI therapy take their PPI twice daily, which is not FDA approved, or purchase OTC heartburn treatments in addition to their prescription medicine. In a survey of approximately 1,000 GERD patients and 1,000 physicians, approximately one third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy and 35% of physicians perceived patients as somewhat satisfied to completely dissatisfied with PPI treatment. In addition, in a real world study conducted in 2020 and 2021 evaluating the perspectives and unmet needs of over 400 physicians and patients in the U.S. in the management of acid related disorders, fewer than one-third of the physician participants were satisfied with current treatment options for their patients. Moreover, fewer than 50% of patients in the study reported they were satisfied with their current treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In patients with more severe grades of erosive GERD, studies with PPIs have reported failure rates of healing of esophageal erosions exceeding 25%. Additionally, recurrence of erosions is common in healed erosive GERD patients receiving maintenance PPI therapy. One study reported recurrence in 15% to 23% of patients with less severe erosive GERD and 24% to 41% of patients with more severe erosive GERD. We believe that these limitations of PPIs are in part driven by their mechanism of action and pharmacokinetics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Mechanistic Differences Between PPIs and Vonoprazan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">PPIs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">After oral dosing, PPIs reach the gastric parietal cells through the bloodstream. PPIs are prodrugs that are converted to their active form in the acidic environment of the secretory canaliculus of the parietal cell but degrade quickly because their active form is unstable in acid. For example, the half-life of omeprazole (Prilosec) is less than 10 minutes at pH 2.0. The active form of a PPI blocks acid production by covalently binding to active proton pumps that have moved to the surface of the secretory canaliculi after activation of the parietal cell with stimuli, such as a meal. Because PPIs bind only to actively secreting pumps, it is generally recommended that they be administered 30 to 60 minutes before a meal to achieve maximal efficacy. Once covalently bound to the proton pumps, the active PPI molecule is no longer available to bind to newly synthesized or activated proton pumps. Furthermore, given the relatively short plasma half-life of most PPIs of one to two hours, resupply of additional PPI molecules from the bloodstream is limited, and newly activated pumps are not inhibited. Due to this profile, PPIs must be dosed over several days to inhibit enough proton pumps to increase gastric pH to a clinically meaningful threshold.  Moreover, PPIs have a limited window of efficacy leading to incomplete acid suppression over the 24-hour dosing interval. In addition, PPIs are primarily metabolized by CYP2C19, an enzyme which has significant interpatient metabolic variability based on genotype. As a result, PPI exposure levels in some patients may not achieve target levels, potentially reducing clinical efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Vonoprazan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan, a PCAB, has a differentiated mechanism of action relative to PPIs. Vonoprazan is designed to selectively concentrate in the parietal cell in both the resting and stimulated states. In contrast to most PPIs, vonoprazan does not require gastric acid for activation, remains stable in the presence of gastric acid, binds to the active proton pumps in a noncovalent and reversible manner, remains associated with the active and inactive proton pumps, and remains in the secretory canaliculus where it continues to inhibit acid secretion over an extended period. Vonoprazan&#x2019;s prolonged effect is also maintained through a slow dissociation rate from the proton pumps and resupply from the bloodstream due to its seven-hour half-life. These characteristics allow vonoprazan to rapidly achieve target 24-hour acid suppression within two hours of a single dose, unlike PPIs that require three to five days to achieve stable acid suppression. In addition, vonoprazan is primarily metabolized by CYP3A4/5, an enzyme which has less genetic variability than CYP2C19, and may exhibit more consistent activity than PPIs across U.S. and European populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The mechanistic and pharmacologic differences of PPIs and vonoprazan are summarized in the table below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_3.jpg" alt="img46421407_3.jpg" style="width:427px;height:289px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan Pharmacodynamics vs. PPIs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan&#x2019;s more rapid, potent, and durable anti-secretory effects versus the PPI lansoprazole (Prevacid&#174;) were demonstrated in a randomized, open-label, crossover clinical trial comparing 20 mg of once daily, or QD, vonoprazan to 30 mg QD of lansoprazole for 7 days in 41 healthy volunteers. As shown below, vonoprazan had a significantly higher 24-hour holding time ratio than lansoprazole for pH&gt;4.0 on Day 1 (62.4% vs. 22.6%) and Day 7 (87.8% vs. 42.3%) and for pH&gt;6.0 on Day 1 (33.1 vs. 7.4) and Day 7 (62.5% vs. 16.4%). Mean 24-hour intragastric pH for vonoprazan and lansoprazole was 4.6 and 2.8, respectively, on Day 1, and 5.9 and 3.8, respectively, on Day 7. Gastric pH levels are measured on a logarithmic scale from 0.0 to 14.0, in which each point represents a 10-fold change in acidity and higher pH values represent less acidity. In this study, vonoprazan maintained an average pH approximately two points higher than lansoprazole at Day 7.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">     </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Improved Onset and Potency of pH Control of Vonoprazan vs. Lansoprazole at Day 1 and Day 7</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_4.jpg" alt="img46421407_4.jpg" style="width:624px;height:279px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">This improved potency and duration of pH control with vonoprazan, as measured by 24-hour pH hold time and time above pH 4.0, was evident not only at Day 1, but also at Day 7 when lansoprazole had reached its steady state (see table below).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24-hr Hold Time &gt; pH 4.0 and Mean pH of Vonoprazan vs. Lansoprazole at Day 1 and Day 7</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_5.jpg" alt="img46421407_5.jpg" style="width:560px;height:194px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan demonstrated similarly greater time above pH 4.0 versus the PPI esomeprazole (Nexium) in a randomized, open-label, crossover clinical trial comparing 20 mg QD vonoprazan to 20 mg QD of esomeprazole in 20 healthy volunteers. In that trial, greater duration of pH control with vonoprazan, as measured by time above pH 4.0 was observed both on Day 1 and Day 7 (see table below).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24-hr Hold Time &gt; pH 4.0 of Vonoprazan vs. Esomeprazole at Day 1 and Day 7</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_6.jpg" alt="img46421407_6.jpg" style="width:419px;height:150px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan for the Potential Treatment of Acid-Related GI Diseases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Given the shortcomings of PPI therapy, we believe that there is a significant unmet medical need for a safe and effective anti-secretory agent with rapid, potent, and durable effects. In May 2022, we received FDA approval for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, each for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection in adults. In March 2022, we submitted an NDA seeking approval of vonoprazan, under the brand name VOQUEZNA, for the treatment of erosive GERD in adults. At present, have been unable to initiate commercial launch of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, or obtain FDA approval of VOQUEZNA due to the presence of trace levels of a nitrosamine impurity detected in our intended commercial drug product. Before we developed and obtained our initial approvals for products containing vonoprazan in the United States, vonoprazan was developed in markets outside of the United States by Takeda through an extensive clinical program, including 19 Phase 3 clinical trials. As of December 2022, over 9,000 subjects were exposed to vonoprazan in completed and ongoing clinical trials. Vonoprazan received marketing approval in Japan in late 2014 and generated approximately $850 million in net sales in its seventh full year on the market in Japan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan in GERD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Based on the significant unmet medical need, previous Phase 3 trial results from Japan and elsewhere in Asia, and commercial potential, we have prioritized the development and commercialization of vonoprazan in GERD, specifically for:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the healing of erosive GERD and relief of associated heartburn; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the maintenance of healing of erosive GERD and relief of associated heartburn. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In January 2023, we also reported positive topline data for the primary endpoint from our first Phase 3 trial for vonoprazan as a once-daily treatment for patients with non-erosive GERD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">GERD Disease Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">GERD is one of the most prevalent diseases of any kind and is the most prevalent GI disease, affecting approximately 20% of the U.S. population and approximately 15% of the European population. We estimate there are approximately 65 million individuals with GERD in the United States and 50 million individuals with GERD in the EU5. GERD is a disease that develops when the reflux of acidic stomach contents into the esophagus causes troublesome symptoms and/or complications. The term covers a spectrum of diseases, the main categories of which are erosive GERD, or EE, and non-erosive reflux disease, or non-erosive GERD. These diseases are detailed below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Erosive GERD</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">: Approximately 30% of GERD patients have erosive GERD, which is classified by erosions in the gastric mucosa caused by acidic reflux of stomach contents into the esophagus. Erosive GERD is commonly graded by the Los Angeles (LA) classification system, which characterizes the extent of erosions in the esophagus and is graded on a scale of increasing severity from A to D, with D being the most severe. Approximately 20% to 30% of erosive GERD patients have moderate-to-severe disease with LA grade C or D erosions. Erosive GERD can have serious consequences. If left untreated, esophagitis may develop into peptic stricture, Barrett&#x2019;s esophagus or esophageal cancer.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Symptomatic non-erosive gastroesophageal reflux disease (non-erosive GERD)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">: Approximately 70% of GERD patients have non-erosive GERD, which is classified by an endoscopically normal esophagus, but abnormal gastric acid exposure in the esophagus and persistent symptoms.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_7.jpg" alt="img46421407_7.jpg" style="width:624px;height:230px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">GERD patients typically present with heartburn and reflux symptoms. Based on these symptoms, patients are typically treated first-line with PPIs prior to a diagnostic endoscopy for specific disease classification of erosive GERD or non-erosive GERD. Clinical guidelines suggest that endoscopy be performed in patients who continue to have symptoms despite a four- to-eight-week course of daily PPIs or have alarm symptoms, including GI bleeding, anemia, weight loss, chest pain, or difficult or painful swallowing. Our market research suggests that most patients are treated empirically based on symptoms rather than based on endoscopic characterization of disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">GERD Treatment Paradigm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Approximately 80% of GERD patients are pharmacologically treated with prescription or OTC medications. PPIs are currently the most effective anti-secretory agents available in the United States and Europe for relieving GERD symptoms and healing erosions in gastric mucosa. Our market research suggests that approximately 80% of patients who are pharmacologically treated receive PPIs, and more than 80% of PPI use is prescription rather than OTC. The majority of PPI use is chronic, with more than 70% of patients prescribed PPIs for daily use. According to IQVIA NSP, there were approximately 7.8 billion prescription PPI doses dispensed during the 12 months ended December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">There are few treatment options for GERD patients who are inadequately managed on PPI therapy. In a real world study conducted in 2020 and 2021 evaluating the perspectives and unmet needs of over 400 physicians and patients in the U.S. in the management of acid related disorders, only half of physicians reported that their patients are getting long-lasting relief from a PPI resulting in approximately 25% of patients taking a PPI more than once a day despite patients&#x2019; concerns about long term side effects of PPI use. A limited number of patients proceed to a surgical procedure, such as Nissen fundoplication. However, this procedure results in postoperative morbidity of 5% to 20%, as well as a two- to six-week recovery period and a median hospital stay of two days.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our U.S. market research survey reported that 55% to 60% of physicians included in the survey believed that vonoprazan has demonstrated superior efficacy in the healing and maintenance of healed esophageal erosions compared to existing erosive GERD treatments, provides faster onset of action compared to existing GERD treatments, and has superior duration and magnitude of gastric pH control compared to existing GERD treatments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Clinical Data for Vonoprazan in GERD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our Development Program in Erosive GERD</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Five Phase 3 clinical trials have been completed comparing vonoprazan to PPIs in erosive GERD: our healing and maintenance of healing trial in the United States and Europe; a healing trial in Japan; a maintenance of healing trial in Japan; a healing trial in Asia (China, Taiwan, and Korea); and a maintenance of healing trial in Asia. In addition to these Phase 3 trials, several published investigator-sponsored studies have compared vonoprazan to PPIs across dosing regimens and endpoints. Results of these clinical trials are summarized below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Healing and Maintenance of Healing of Erosive GERD in the United States and Europe (PHALCON-EE)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In October 2021, we announced that vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, our pivotal Phase 3 trial evaluating vonoprazan versus lansoprazole for the treatment of erosive GERD.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PHALCON-EE was a randomized, double-blind, two-phase, multicenter, Phase 3 trial that enrolled 1,024 patients with EE in the U.S. and Europe. PHALCON-EE was modeled after the successful Phase 3 clinical trials conducted in Japan and Asia with limited differences, including the combination of the healing and maintenance phases into one single study whereas in Japan and Asia separate clinical trials were conducted for each of these indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The first phase of the trial, the Healing Phase, evaluated the efficacy and safety of vonoprazan 20 mg QD compared to lansoprazole 30 mg QD for the healing of erosive GERD for up to eight weeks. In the Healing Phase, patients were assessed via endoscopy to determine complete healing following 2 weeks of treatment and, if complete healing was not achieved, a second endoscopy occurred at 8 weeks of treatment. Patients who achieved complete healing were re-randomized into the second phase of the trial, the Maintenance Phase, where vonoprazan 10 mg and 20 mg were compared to lansoprazole 15 mg to assess maintenance of healing of erosive GERD via endoscopy following 24 weeks of treatment. Heartburn symptom relief was assessed via secondary endpoints in both the Healing and Maintenance Phases of the study based on twice daily e-diary data collection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Design of US/EU Phase 3 Clinical Trial for the Healing and Maintenance of Healing of Erosive GERD</span><img src="img46421407_8.jpg" alt="img46421407_8.jpg" style="width:624px;height:295px;" /></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Healing Phase</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The primary endpoint analysis of the Healing Phase was non-inferiority of vonoprazan 20 mg compared to lansoprazole 30 mg in the percentage of all patients who have complete healing of erosive GERD by Week 8. Vonoprazan met the non-inferiority criteria for the primary comparison with a healing rate of 93% compared to 85% for lansoprazole (p&lt;0.0001). Based on a prespecified exploratory comparison test, the difference in healing rates in all patients between vonoprazan and lansoprazole was also significant (nominal p&lt;0.0001). Non-inferiority analyses are conducted to evaluate whether the effect of an agent is not worse than the active control by more than a specified margin, while superiority analyses are conducted to evaluate whether an agent outperformed a comparator by a statistically significant margin.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan met the secondary superiority endpoint of healing in patients with moderate-to-severe disease, defined as patients with esophageal erosions classified as Grades C or D by the Los Angeles (LA) Classification System, at Week 2, demonstrating significantly faster healing than lansoprazole (70% for vonoprazan 20 mg and 53% for lansoprazole 30 mg) (p=0.0008). Vonoprazan also met the secondary endpoint of showing non-inferiority to lansoprazole 30 mg in the mean percentage of 24-hour heartburn free days over the healing period. In additional pre-specified secondary endpoint superiority comparisons, vonoprazan 20 mg healing rates were numerically greater than lansoprazole 30 mg in all patients at Week 2 (nominal p=0.0348) and in moderate-to-severe patients by Week 8 (nominal p&lt;0.0001), although these superiority comparisons were not tested in the pre-specified testing hierarchy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan 20 mg was also compared to lansoprazole 30 mg in a superiority test for onset of sustained resolution of heartburn by day 3 but did not achieve statistical significance (p=0.439).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Results of US/EU Phase 3 Clinical Trial in the Healing of Erosive GERD</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_9.jpg" alt="img46421407_9.jpg" style="width:624px;height:272px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Maintenance Phase</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan met the primary and all secondary endpoints in the Maintenance Phase. The primary endpoint of the Maintenance Phase was non-inferiority of vonoprazan 10 mg and 20 mg compared to lansoprazole 15 mg in the percentage of all patients who maintained healing of erosive GERD through Week 24.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Both vonoprazan doses met the Maintenance Phase primary endpoint of non-inferiority while also meeting the pre-specified secondary comparison demonstrating superiority of maintenance of healing versus lansoprazole (79% for vonoprazan 10 mg, 81% for vonoprazan 20 mg compared to 72% for lansoprazole 15 mg) (p&lt;0.0001 for both non-inferiority comparisons; p=0.0438 for vonoprazan 10 mg superiority comparison; p=0.0136 for vonoprazan 20 mg superiority comparison).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Both vonoprazan doses also met the secondary endpoint of demonstrating superiority of the percentage of patients with moderate-to-severe disease who maintained healing of erosive GERD through Week 24 (75% vonoprazan 10 mg, 77% vonoprazan 20 mg v. 61% lansoprazole 15 mg) (p=0.0490 for vonoprazan 10 mg superiority comparison; p=0.0196 for vonoprazan 20 mg superiority comparison). Additionally, both vonoprazan doses also met the secondary endpoint of showing non-inferiority to lansoprazole 15 mg in the mean percentage of 24-hour heartburn free days over the maintenance period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Results of US/EU Phase 3 Clinical Trial in Maintenance of Healing of Erosive GERD</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_10.jpg" alt="img46421407_10.jpg" style="width:624px;height:274px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Healing and Maintenance of Healing of Erosive GERD Clinical Trials in Japan and Asia</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The results of PHALCON-EE were consistent with the results of earlier Phase 3 trials of vonoprazan in healing and maintenance of healing of erosive GERD after which it was modeled. These trials were conducted in Japan as well as other countries in Asia.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In two Phase 3 trials in healing of erosive GERD comparing vonoprazan 20 mg QD to lansoprazole 30 mg QD for up to eight weeks, one conducted in Japan and the other in several countries in Asia, vonoprazan achieved the primary endpoint of non-inferiority versus lansoprazole on the percent of patients with healed erosive GERD up to Week 8. Exploratory testing suggested higher healing rates for vonoprazan versus lansoprazole in the moderate to severe patients at Week 2 in both studies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Similarly, in two Phase 3 trials in maintenance of healing of erosive GERD comparing two doses of vonoprazan (10 mg and 20 mg QD) to lansoprazole 15 mg QD for 24 weeks, one conducted in Japan and the other in several countries in Asia, both vonoprazan doses achieved the primary endpoint of non-inferiority versus lansoprazole on the percent of patients with recurrence of erosive GERD during the 24-week maintenance period. In both studies, exploratory testing suggested higher maintenance of healing rates for both vonoprazan doses versus lansoprazole in all patients and in the moderate to severe patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our Development Program in Symptomatic Non-Erosive Gastroesophageal Reflux Disease (Non-Erosive GERD)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We believe that there is an opportunity to broadly position vonoprazan&#x2019;s use in GERD with an indication in symptomatic GERD in patients without erosions, non-erosive GERD, in addition to an indication in erosive GERD. We are evaluating vonoprazan as a treatment for non-erosive GERD with both daily and as needed dosing regimens. Non-erosive GERD patients do not have esophageal erosions which require chronic treatment to prevent recurrence of erosions and their potential sequelae. We believe the rapid onset of acid control of vonoprazan may enable as-needed use for the management of heartburn in non-erosive GERD patients as an alternative to chronic daily treatment with PPIs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Daily Dosing of Vonoprazan for the Treatment of Non-Erosive GERD(PHALCON-NERD-301)</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In January 2023, we reported positive topline data from the primary endpoint in PHALCON-NERD-301, our Phase 3 study evaluating the efficacy and safety of vonoprazan for the daily treatment of non-erosive GERD in adults. In this trial, patients in each vonoprazan treatment group, 10 mg and 20 mg, had a significantly higher mean percentage of 24-hour heartburn-free days (without daytime or nighttime heartburn as assessed by daily diary) compared to placebo after four weeks. This is the same endpoint used in other Phase 3 trials for PPIs that are approved in the U.S. for the treatment of non-erosive GERD.  Results from the full trial are expected in the second half of 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PHALCON-NERD-301 is a Phase 3 study evaluating the efficacy of vonoprazan 10 mg and 20 mg as a daily dosing (QD) treatment, as compared to placebo (QD), in the relief of heartburn over four weeks in participants with symptomatic non-erosive reflux disease, or non-erosive GERD. The trial also includes a blinded 20-week long-term extension period, which is currently ongoing, to further evaluate the safety and efficacy of both doses of vonoprazan after six months of continuous use. A total of 772 patients with non-erosive GERD were enrolled, randomized and dosed in the multisite U.S. trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Design of PHALCON-NERD-301 Phase 3 Non-Erosive Daily Dosing Clinical Trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img46421407_11.jpg" alt="img46421407_11.jpg" style="width:624px;height:328px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Primary Endpoint of Phase 3 Clinical Trial in the Treatment of  Non-Erosive GERD</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The primary endpoint of the study, measured during the four-week, double-blind, placebo-controlled period, is the mean percentage of 24-hour heartburn free days. The topline results from the study showed both doses of vonoprazan, 20 mg and 10 mg, met the primary endpoint and demonstrated a significantly greater mean percentage of 24-hour heartburn-free days versus placebo (46.4% vonoprazan 10 mg, 46.0% vonoprazan 20 mg, 27.5% for placebo; p&lt;0.0001 for both vonoprazan doses versus placebo).  Additionally, the median percentage of 24-hour heartburn-free days was 48.3%, 46.7% and 17.0% for vonoprazan 10 mg, vonoprazan 20 mg, and placebo, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan was generally well tolerated in the initial four week double-blind, placebo-controlled phase of the trial. The overall adverse events for all vonoprazan arms were comparable to placebo and consistent with what was reported in previous studies. The most commonly reported adverse event was nausea (2.3% vonoprazan 10 mg, 3.1% vonoprazan 20 mg, 0.4% placebo) with no other events reported above 3.0% in either vonoprazan dose arm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Results of Phase 3 Clinical Trial in the Treatment of Non-Erosive GERD</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img46421407_12.jpg" alt="img46421407_12.jpg" style="width:624px;height:287px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">As Needed Dosing of Vonoprazan for the Treatment of Non-Erosive GERD</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In February 2022, we announced that vonoprazan (10 mg, 20 mg and 40 mg), successfully met the primary endpoint in PHALCON-NERD-201, a Phase 2 trial evaluating three doses of vonoprazan versus placebo as an as needed treatment of non-erosive GERD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PHALCON-NERD-201 was a Phase 2, randomized, double-blind, multicenter study that enrolled 458 subjects in the U.S. to evaluate the efficacy and safety of vonoprazan 10 mg, 20 mg, and 40 mg administered as needed for relief of episodic heartburn compared to placebo in subjects with non-erosive GERD (as confirmed by endoscopy).  After an initial four-week vonoprazan 20 mg QD dose open-label run-in period, two hundred and seven subjects without a heartburn episode during the last 7 days of the run-in period and who also met drug and diary compliance requirements were randomized to receive vonoprazan 10 mg, 20 mg, 40 mg or placebo as needed for six weeks. Subjects completed an electronic diary to assess presence and severity of heartburn symptoms and use of rescue antacid (if needed).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Design for PHALCON-NERD Phase 2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Non-Erosive GERD As Needed Dosing Trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_13.jpg" alt="img46421407_13.jpg" style="width:624px;height:319px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In this Phase 2 proof -of-concept trial, the primary endpoint was the percentage of heartburn episodes completely relieved within three hours and with no further heartburn reported for 24 hours after taking study drug.  All three vonoprazan doses met this primary endpoint and were statistically significant (p&lt;0.0001) when compared to placebo. Within three hours, vonoprazan 10 mg, 20 mg and 40 mg achieved complete and sustained relief in 56.0%, 60.6% and 70.0% of evaluable heartburn episodes, respectively, as compared to 27.3% of episodes for placebo.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the PHALCON-NERD open-label daily dosing run-in phase, where all enrolled participants received vonoprazan 20 mg QD for four weeks, the mean percentage of 24-hour heartburn free days observed was 65.4% (median 76.0%).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Based on the results of PHALCON-NERD-201, we are in discussions with the FDA regarding the design of a Phase 3 trial to evaluate the novel dosing regimen of vonoprazan as an as -needed treatment for episodic heartburn relief in patients with non-erosive GERD, a dosing regimen not approved in the U.S. for PPIs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Results of Phase 2 Non-Erosive GERD As Needed Dosing Trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_14.jpg" alt="img46421407_14.jpg" style="width:614px;height:375px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan in Combination with Antibiotics for the Treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Infection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Disease Burden and Outcomes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> is a bacterial pathogen that infects approximately 35% of the U.S. population, 45% of the EU5 population, and more than 50% of the global population. We estimate that there are approximately 115 million individuals in the United States and 145 million individuals in the EU5 infected with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, and we believe there are approximately 2.5 million patients treated for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection in the United States each year. As a result of the chronic inflammation induced by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, approximately 20% of infected patients develop a range of pathologies including dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. Gastric cancer is the third most common cause of cancer-related death worldwide, and over 80% of gastric cancers are attributed to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection. Globally there are more than one million new cases of gastric cancer and approximately 782,000 deaths each year. Eradication of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection has been proven to reduce the incidence of gastric cancer, and the American College of Gastroenterologists, or ACG, guidelines recommend treatment for all patients diagnosed with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> eradication rates from the 1990s have fallen to current rates of &lt;80% due to increasing antibiotic resistance. In 2017, the World Health Organization (WHO) listed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> as a Class 1 carcinogen, meaning that it is a definite known cause of cancer. In 2014, the FDA added </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> to the agency&#x2019;s list of qualifying pathogens that have the potential to pose a serious threat to public health under the GAIN Act. We believe that vonoprazan-based treatment regimens have the potential to restore eradication rates to their original rates in the United States and Europe given the clinical and post-marketing experience in the Japanese market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A recent study compiled real-world health insurance claims data in Japan from 2008 to 2016 for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> eradication. Prior to vonoprazan&#x2019;s approval in late 2014, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> eradication rate across Japan fell to below 80% as shown in the figure below. Approximately one year after vonoprazan&#x2019;s launch, the eradication rate increased to greater than 85%. From January 2015 to March 2016, the eradication rate with PPI-containing regimens in Japan was between 78% and 82% while the eradication rate with vonoprazan-containing regimens was 91% across all patients in this analysis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Eradication Rate of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Infection in Japan Before and After Launch of Vonoprazan</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_15.jpg" alt="img46421407_15.jpg" style="width:467px;height:251px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Results were similar in a real-world study using a different Japanese health insurance claims database. Among patients initiating vonoprazan or a PPI between January 2015 and January 2020 to treat H. pylori infection, 80% of PPI-treated patients and 93% of vonoprazan-treated patients did not receive a second line of triple therapy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In Japan, vonoprazan-containing regimens have become the most common first line treatment. One-year post launch, approximately 80% of all treated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-infected patients received vonoprazan-based regimens. In the study of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-infected patients, vonoprazan-based regimens overtook PPI-based regimens as the most common first-line treatment between 2015 and 2019. Within this Japanese database, the number of patients using vonoprazan-based regimens increased from 6,594 to 28,956 patients, while the number of patients using a PPI-based regimen decreased from 11,238 to 2,629, shown in the figure below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Uptake of Vonoprazan-Based vs. PPI-Based Therapy for First Line Treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Infection in Japan from 2015-2019</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_16.jpg" alt="img46421407_16.jpg" style="width:539px;height:327px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Current Treatment Paradigm in the United States and Europe</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The ACG treatment guidelines for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection recommend using PPIs in conjunction with antibiotics to improve antibiotic efficacy against </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection. The use of anti-secretory agents enhances the effect of antibiotics in two ways. First, anti-secretory agents increase gastric pH, which in turn increases the stability of the antibiotics. For example, amoxicillin and clarithromycin are chemically unstable at the low pH typically found in the human stomach. Second, several antibiotics, including amoxicillin and clarithromycin, are most potent against </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> at the time of maximum bacterial replication, which occurs at pH 6.0 to 8.0. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> is in a dormant state at lower pH values, which reduces the effectiveness of the antibiotics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The table below shows the minimum inhibitory concentration of antibiotic required to eradicate 90% of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> in vitro, or MIC90. As pH increases, the amount of antibiotic required for 90% eradication decreases substantially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> MIC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:sub;font-size:6.7pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Values as a Function of pH</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_17.jpg" alt="img46421407_17.jpg" style="width:359px;height:141px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A triple therapy regimen (PPI, clarithromycin, and either amoxicillin or metronidazole) is the regimen most commonly used in clinical practice for the first-line treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection. However, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">eradication rates with PPI triple therapy in the 1990s have fallen to current levels of &lt;80%, primarily due to increased resistance of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> to clarithromycin and metronidazole. A recent meta-analysis indicates that U.S. resistance rates measured from 2012 to 2016 were 20% for clarithromycin, 29% for metronidazole, and 19% for levofloxacin. Additionally, in a U.S.-based study from 2021, 65.6% of tested </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> was resistant to at least one antibiotic currently used for treatment, with resistance rates of 33% for clarithromycin and approximately 30% for metronidazole and levofloxacin. These figures represent a marked increase from 2009 to 2011 for both clarithromycin and metronidazole, for which resistance was 9% for clarithromycin, 21% for metronidazole, and 11% for levofloxacin. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> resistance to amoxicillin remains low despite its use in most triple therapy regimens; resistance is generally &lt;2% among isolates in the United States and Europe. There is a similar trend of increasing resistance to key antibiotics in Europe.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Given the declining eradication rates for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, bismuth quadruple therapy is recommended as first-line treatment in areas with known high rates of clarithromycin or metronidazole resistance; however, our U.S. market research study reported that physicians prescribe quadruple therapy to only 17% of first-line patients. Due predominantly to considerations of convenience and patient compliance, approximately 75% of physicians surveyed in our market research expressed a preference for convenience, or combination packs compared to individual bottles for both dual and triple therapy. Further, geographic patterns of resistance in the United States are poorly understood and treatment is largely empiric, with susceptibility testing rarely conducted prior to first-line treatment. Our U.S. market research study reported that only 8% and 16% of physicians conduct resistance testing prior to prescribing treatment for first-line and second-line </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In our U.S. market research study, physicians highlighted the need for more effective and simpler first-line treatment options. For the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, surveyed physicians highlighted the need for improved eradication rates and more convenient dosing as key unmet needs. In fact, on average, 53% and 52% reported a preference to use vonoprazan first line in patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection, and in patients with refractory </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our H. pylori Phase 3 Clinical Trial in the United States and Europe &#x2013; PHALCON-HP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In April 2021, we announced that in PHALCON-HP, our pivotal Phase 3 clinical trial for the eradication of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, both vonoprazan-based regimens successfully met their primary endpoints and met all secondary endpoints. The trial studied vonoprazan triple therapy and vonoprazan dual therapy compared to lansoprazole triple therapy. We believe PHALCON-HP was the largest U.S. Phase 3 registration trial ever conducted in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, randomizing 992 patients with confirmed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PHALCON-HP was a randomized, multicenter, Phase 3 trial that enrolled 1,046 patients of which 992 patients with a confirmed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection were randomized to one of three arms:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">vonoprazan dual therapy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">: vonoprazan 20 mg BID and amoxicillin 1 g TID for 14 days (n=324); </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">vonoprazan triple therapy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">: vonoprazan 20 mg BID, amoxicillin 1000 mg BID and clarithromycin 500 mg BID for 14 days (n=338); and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">PPI triple therapy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">: lansoprazole 30 mg BID, amoxicillin 1000 mg BID and clarithromycin 500 mg BID for 14 days (n=330). </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The objective of the PHALCON-HP trial was to compare eradication rates in all treated subjects as well as in two pre-identified subgroups of patients: those patients with clarithromycin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">and those patients who did not have clarithromycin or amoxicillin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> For regulatory purposes, the primary endpoint of this study was a non-inferiority comparison in the non-resistant subgroup for each of vonoprazan triple therapy and vonoprazan dual therapy compared to lansoprazole triple therapy. All endpoints measured the percentage of patients with successful eradication of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection as assessed by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">C-urea breath test four weeks after completion of treatment. The primary analysis in the non-resistant population assessed the non-inferiority of vonoprazan dual therapy compared to lansoprazole triple therapy and vonoprazan triple therapy compared to lansoprazole triple therapy. Secondary analyses for superiority were conducted in all patients and in the subgroup of patients with clarithromycin-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection. Further efficacy analyses were conducted using the pre-specified per protocol population (n=822), which is comprised of patients who were protocol compliant as defined by FDA established criteria.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Design for PHALCON-HP Phase 3 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Clinical Trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_18.jpg" alt="img46421407_18.jpg" style="width:624px;height:285px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Primary endpoint analysis</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Both vonoprazan-based regimens successfully met their primary endpoints in the subset of patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> strains that were not shown to be resistant to clarithromycin or amoxicillin. In the mITT population</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">, H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">eradication rates were 84.7% with vonoprazan triple therapy and 78.5% for vonoprazan dual therapy compared to 78.8% with lansoprazole triple therapy (p&lt;0.0001 and p=0.0073, respectively, for non-inferiority).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In the per protocol population, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">eradication rates were 90.4% with vonoprazan triple therapy and 81.2% with vonoprazan dual therapy compared to 82.1% with lansoprazole triple therapy (p&lt;0.0001 and p=0.0155, respectively, for non-inferiority).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Secondary endpoint analysis</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan triple therapy and vonoprazan dual therapy also met all secondary endpoints, and demonstrated superior eradication rates versus lansoprazole triple therapy in all patients and patients with clarithromycin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Patients with clarithromycin resistant strains comprised 20.3% of the PHALCON-HP study population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan triple therapy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">eradication rate of vonoprazan triple therapy was superior to that of lansoprazole triple therapy among all patients in both the mITT population (80.8% vs. 68.5%; p=0.0003) and the per protocol population (85.7% vs. 70.0%; p&lt;0.0001).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">eradication rate of vonoprazan triple therapy was superior to that of lansoprazole triple therapy in the subset of patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">strains resistant to clarithromycin in both the mITT population (65.8% vs. 31.9%; p&lt;0.0001) and the per protocol population (67.2% vs. 29.0%; p&lt;0.0001).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan dual therapy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">eradication rate of vonoprazan dual therapy was superior to that of lansoprazole triple therapy among all patients in both the mITT population (77.2% vs. 68.5%; p=0.0127) and the per protocol population (81.1% vs. 70.0%; p=0.0027).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">eradication rate of vonoprazan dual therapy was superior to that of lansoprazole triple therapy in the subset of patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">strains resistant to clarithromycin in both the mITT population (69.6% vs. 31.9%; p&lt;0.0001) and the per protocol population (79.5% vs. 29.0%; p&lt;0.0001).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Results of US/EU Phase 3 Clinical Trial in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Infection</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Primary Endpoint Analysis &#x2013;Subjects without clarithromycin or amoxicillin resistant strains</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_19.jpg" alt="img46421407_19.jpg" style="width:624px;height:224px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Secondary Endpoint Analyses &#x2013; All subject and subjects with clarithromycin resistant strains</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_20.jpg" alt="img46421407_20.jpg" style="width:624px;height:309px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Antibiotic resistance and declining eradication rates are significant clinical issues, and we believe that vonoprazan triple therapy and vonoprazan dual therapy have the potential to provide improvements over PPI-based therapies in addressing each of these issues. Vonoprazan dual therapy also has potential to spare the use of clarithromycin, representing an opportunity both for effective treatment and sound antibiotic stewardship through the avoidance of an additional antibiotic. As an alternative to multi-antibiotic drug regimens, vonoprazan dual therapy might also help to limit the spread of resistance among other pathogenic bacteria within populations. In addition, vonoprazan triple therapy and vonoprazan dual therapy will both be available in daily dosing blister cards inclusive of the appropriate antibiotic. We believe this convenience pack has the potential to enhance compliance in a category where full adherence to treatment regimen is often a challenge.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Convenience Packs for H. pylori</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In September 2021, we submitted NDAs for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection in adults, each as a pre-packaged convenience, or combination pack with either clarithromycin and amoxicillin or amoxicillin alone.  On May 3, 2022, the FDA approved both NDAs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img46421407_21.jpg" alt="img46421407_21.jpg" style="width:624px;height:269px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Convenience packs have the potential to improve patient adherence and treatment outcomes, and we believe there is a meaningful market opportunity for such a product. In the United States, PrevPac was formerly marketed as a pre-packaged convenience pack of lansoprazole, clarithromycin, and amoxicillin and achieved peak sales of $150 million. In Japan, vonoprazan is marketed both as a stand-alone medicine as well as in pre-packaged convenience packs with either clarithromycin and amoxicillin (Vonosap) or metronidazole and amoxicillin (Vonopion).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Phase 3 Clinical Trial in Japan of Vonoprazan in Combination with Antibiotics to Treat H. pylori Infection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The results of PHALCON-HP were consistent with the results of a Phase 3 clinical trial in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-positive patients completed in Japan. In that trial, patients were treated with either vonoprazan triple therapy (vonoprazan 20 mg BID, amoxicillin 750 mg BID, and clarithromycin (200 mg or 400 mg) BID) or lansoprazole triple therapy (lansoprazole 30 mg BID, amoxicillin 750 mg BID, and clarithromycin (200 mg or 400 mg) BID) for seven days as is customary in Japan. The primary endpoint of the clinical trial was confirmed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> eradication determined by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">C-urea breath test. The primary analysis was non-inferiority, and additional analyses of the second line eradication rate and eradication rate in antibiotic-resistant subgroups were also conducted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan-based triple therapy demonstrated a non-inferior eradication rate of 93% compared to 76% for lansoprazole-based triple therapy (p&lt;0.0001). Post hoc analyses suggested that vonoprazan-based triple therapy was superior to lansoprazole-based triple therapy (p&lt;0.0001). Patients who were not eradicated on vonoprazan-based triple therapy or lansoprazole-based triple therapy were treated with a different triple therapy regimen of vonoprazan, amoxicillin, and metronidazole. In this second-line setting, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> eradication rate with the different vonoprazan triple therapy was 98%. Exploratory analysis suggested that vonoprazan-based triple therapy had significantly higher eradication rates versus the lansoprazole-based triple therapy in the subgroup of subjects with clarithromycin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Summary of Vonoprazan Safety Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Safety in Clinical Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 2022, over 9,000 subjects have been exposed to vonoprazan in completed and ongoing Phase 1 to 3 clinical trials. The doses studied have ranged from 1 to 120 mg with durations up to one year.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In PHALCON-HP, both vonoprazan-based regimens were generally well tolerated with safety results comparable to patients who received lansoprazole triple therapy. The most common adverse events (&#x2265;2.0%) reported in the vonoprazan triple therapy, vonoprazan dual therapy, and lansoprazole triple therapy arms, respectively, were diarrhea (4.0%, 5.2%, and 9.6%), dysgeusia (4.3%, 0.6%, and 6.1%), abdominal pain (2.3%, 2.6% and 2.9%), headache (2.6%, 1.4%, 1.4%), vulvovaginal candidiasis (2.3%, 1.4%, 1.2%), hypertension (2.0%, 1.1%, 0.9%), and nasopharyngitis (0.3%, 2.0%, 0.9%). Overall rates of discontinuation due to adverse events were 2.3% for vonoprazan triple therapy-treated patients, 0.9% for vonoprazan dual therapy-treated patients, and 1.2% for lansoprazole triple therapy-treated patients.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additionally, the safety results for vonoprazan observed in PHALCON-EE were consistent with the results observed in prior clinical studies. In the healing phase of the study, the most common adverse events (&#x2265;2%) were abdominal pain (2.1% for vonoprazan and 1.2% for lansoprazole), diarrhea (2.1% for vonoprazan and 2.5% for lansoprazole). Rates of discontinuation due to adverse events in the healing phase were 1% for vonoprazan 20 mg and 2.2% for lansoprazole 30 mg.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In the maintenance phase of the study, the most common adverse events (&#x2265;2%) were gastritis (2.7% vonoprazan 10 mg, 6.4% vonoprazan 20 mg, 2.7% lansoprazole), diarrhea (1.0% vonoprazan 10 mg, 2.7% vonoprazan 20 mg, 4.4% lansoprazole), abdominal pain (4.1% vonoprazan 10 mg, 5.4% vonoprazan 20 mg, 2.4% lansoprazole), dyspepsia (3.7% vonoprazan 10 mg, 4.1% vonoprazan 20 mg, 2.7% lansoprazole), gastroesophageal reflux disease (2.4% vonoprazan 10 mg, 3.7% vonoprazan 20 mg, 2.0 lansoprazole), hypertension (3.0% vonoprazan 10 mg, 3.4% vonoprazan 20 mg, 2.0% lansoprazole), liver function test (1.0% vonoprazan 10 mg, 2.0% vonoprazan 20 mg, 3.0% lansoprazole), and nausea (2.0% vonoprazan 10 mg, 1.4% vonoprazan 20 mg, 1.0% lansoprazole). Rates of discontinuation due to adverse events in the maintenance phase were 0.7% for vonoprazan10 mg, 2.7% for vonoprazan 20 mg, and 0.7% for lansoprazole.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Frequency of serious adverse events, or SAEs, in the healing phase were similar between vonoprazan 20 mg and lansoprazole at 0.6%. In the maintenance phase, SAEs were reported in 4.7% of patients for vonoprazan 20 mg, 3.4% for vonoprazan 10 mg and 2.4% for lansoprazole. Further, this clinical trial was conducted during the 2020-2021 global pandemic, and coronavirus infection was reported in 2.1% of the vonoprazan 20 mg-treated patients and 1.8% of the lansoprazole-treated patients in the healing phase whereas it was reported in 6.1% of the vonoprazan 10 mg-treated patients, 10.1% of the vonoprazan 20 mg-treated patients and 6.7% of the lansoprazole-treated patients in the maintenance phase. There were 2 deaths in the vonoprazan 20 mg-treated patients due to coronavirus infection. None of the coronavirus infection events reported were considered related by the investigator.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In PHALCON-NERD-301, vonoprazan was generally well tolerated in the initial four-week double-blind, placebo-controlled phase of the trial. The overall adverse events for all vonoprazan arms were comparable to placebo and consistent with what was reported in previous studies. The most commonly reported adverse event was nausea (2.3% vonoprazan 10 mg, 3.1% vonoprazan 20 mg, 0.4% placebo) with no other events reported above 3.0% in either vonoprazan dose arm. There was a total of three SAEs reported in the four-week period of the study, one in the vonoprazan 10 mg arm and two in the vonoprazan 20 mg arm. Full safety data from this study will be available following the completion of the 20-week long-term extension period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In PHALCON-NERD-201, vonoprazan was generally well tolerated. In both phases of the trial, no adverse event was reported in more than three percent of the participants in a treatment group. There was a total of four SAEs in the daily dosing phase, only one of which was related to study drug, and no SAEs in the as needed phase. The safety data for all vonoprazan arms were comparable to placebo and consistent with what was reported in previous studies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Certain earlier generation PCABs previously under development by other companies may have been discontinued in-part due to their hepatic safety profile. These hepatic safety concerns may be compound-specific and not generalizable to the PCAB class. It is notable that vonoprazan is based on a pyrrole chemical structure and is chemically distinct from previously discontinued PCABs that were based on an imidazole structure. Vonoprazan has had a similar hepatic safety profile to lansoprazole across all clinical studies conducted by Takeda, in which 1.0% of subjects treated with vonoprazan 10 mg or 20 mg and 0.8% of subjects treated with lansoprazole 15 mg or 30 mg had ALT or AST elevations greater than three times the upper limit of normal or bilirubin elevations greater than two times the upper limit of normal. Similarly, in the healing phase of PHALCON-EE, transient elevations in ALT or AST greater than 3 times the upper limit of normal were observed in 0.4% of subjects treated with vonoprazan 20 mgs and 0.2% of subjects treated with lansoprazole. In the maintenance phase, transient ALT or AST elevations greater than three times the upper limit of normal were observed in 1% of subjects treated with vonoprazan 10 mg, 0.3% of subjects treated with vonoprazan 20 mg, and 2% of subjects treated with lansoprazole.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Vonoprazan Post-Marketing Safety in Japan and Asia</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The most recent post-marketing safety report from December 2022 includes an estimate of over 50 million patients who have received vonoprazan in Japan and other countries in Asia since its launch. Based on the post-marketing experience, the clinically significant adverse reactions section of the Japanese prescribing information for vonoprazan was updated to include shock, anaphylaxis, hepatic impairment, skin reactions such as toxic epidermal necrolysis, Steven-Johnson syndrome, and erythema multiforme; and events of pancytopenia, agranulocytosis, leukocytopenia, and thrombocytopenia. The incidence of these reactions was considered extremely rare (less than 1 in 100,000 patients) and a causal relationship to vonoprazan could not be ruled out. Although serious hepatic adverse events have been observed among patients exposed to vonoprazan in Japan in the post-marketing setting, these cases were typically confounded by comorbidities or other concomitant medications and believed to be idiosyncratic reactions. Post-marketing safety data, including the December 2022 post-marketing safety report, has been submitted to the PMDA. Moreover, the four year interim results from the VISION trial, a five year randomized, open-label, multicenter study conducted by Takeda evaluating the long-term efficacy and safety of vonoprazan compared with the PPI lansoprazole in patients with EE, further demonstrate that the safety profile of vonoprazan is generally comparable to lansoprazole.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan Launch in Japan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Vonoprazan Regulatory Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan first received approval in Japan on December 26, 2014, and was launched shortly thereafter in February 2015, as TAKECAB&#174; for the following indications:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Healing and maintenance of healing of erosive esophagitis; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Adjunct to antibiotics in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> treatment; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Gastric ulcer; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Duodenal ulcer; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prevention of recurrence of gastric ulcer or duodenal ulcer during nonsteroidal anti-inflammatory drug (NSAID) administration. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan was subsequently approved in Japan in February 2016 for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> in combination packs with antibiotics (Vonosap Pack 400, Vonosap Pack 800, and Vonopion Pack), and has since been approved in numerous other countries in Asia and Latin America as well as Russia.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Vonoprazan Commercialization in Japan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan was approved in Japan in December 2014. In 2021, its seventh full year on the market, vonoprazan generated approximately $850 million in net sales in Japan, a 17% increase over the prior year. In addition, in the quarter ended December 31, 2021, vonoprazan generated over $249 million in net sales, a 16% increase over the corresponding quarter from the prior year. Finally, based on sales during the 12 month period ending September 2022, vonoprazan had achieved a 26.5% market share based on volume and 45.7% market share based on sales among prescription acid suppression therapies in Japan.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img46421407_22.jpg" alt="img46421407_22.jpg" style="width:570px;height:338px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We believe that the market dynamic for anti-secretory agents in Japan is similar to that in the United States. In both countries, the anti-secretory market is largely genericized. Ahead of the vonoprazan launch in Japan, all PPIs, other than Nexium, were available as generics. As of September 2021, generic drugs in Japan represent approximately 80% of the market by volume, compared to the United States where generics are currently approximately 90% of the market by volume. Although vonoprazan and Dexilant are priced at a premium to generic PPIs in Japan and the United States, respectively, both have experienced commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan Commercial Opportunity and Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The market for prevention and treatment of acid-related GI diseases in the United States and Europe is large. There were approximately 7.8 billion prescription PPI doses dispensed during the 12 months ended December 31, 2022. We estimate that there are approximately 65 million individuals with GERD in the United States and 50 million individuals with GERD in the EU5, of whom 15% to 45% are inadequately treated with PPIs. In addition, we estimate that there are approximately 115 million individuals in the United States infected with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, of which 2.5 million are treated each year, and 145 million individuals in the EU5 infected with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Over many decades of use, multiple drug classes and individual drugs have demonstrated the substantial commercial opportunity for therapies treating acid-related GI diseases. H2RAs including Axid, Pepcid, Tagamet, and Zantac provided the first significant improvement in disease management over antacids and as a class reached approximately $3.5 billion in annual sales. After H2RAs, PPIs emerged as the new standard of care. Prior to the introduction of generic and OTC alternatives, annual PPI class sales reached approximately $12.5 billion in the United States, and peak sales for individual brands were approximately $3.7 billion for Prilosec, $3.5 billion for Nexium, and $3.4 billion for Prevacid.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We believe the results of our Phase 3 clinical trials in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and, subject to FDA approval, erosive GERD, support the differentiation of products containing vonoprazan from the PPI-based standard of care, which could result in attractive market access and formulary positioning.  For example, following approval of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, and although these products are not yet available in the U.S. market, we believe our interactions with payers highlight the commercial potential of these products. For example, as of February 2023, 51% of commercial lives have coverage for both VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK.  Moreover, if approved for the treatment of GERD, we believe vonoprazan has the potential to improve the standard of care for acid-related GI diseases by providing a safe and effective treatment option for the millions of patients in need of more potent, rapid, or durable acid suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In May 2022, we conducted a U.S. market research study with 90 gastroenterologists, 90 primary care physicians and 45 advanced practice providers who treat GERD. Before seeing the vonoprazan clinical data, 82% of these clinicians strongly agreed that PPIs are the most potent class of acid suppressing agents.  After review of vonoprazan clinical data and messages, only 34% strongly agreed that PPIs are the most potent class of acid suppressing agents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Sales and Marketing</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are in the process of building marketing, sales, and distribution capabilities. We plan to independently commercialize vonoprazan in the United States by building a leading specialty gastroenterology-focused commercial infrastructure to support the adoption of vonoprazan. We believe we can successfully launch vonoprazan in the United States with a focused sales force targeting high prescribers of PPIs, particularly gastroenterologists and primary care physicians. PPI prescribing is highly concentrated with approximately 76% of prescriptions in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and 65% of prescriptions in erosive GERD being written by 10% of the PPI prescribers (approximately 50,700 prescribers), according to IQVIA data. We believe we have an opportunity to achieve significant share of voice and exposure to physicians given the scarcity of actively marketed anti-secretory medicines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">To address the commercial opportunity for vonoprazan in Europe and Canada, we plan to seek one or more partners with existing commercial infrastructure and expertise in these markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additional Vonoprazan Development Opportunities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Eosinophilic esophagitis and other indications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">While we are initially focused on the development of vonoprazan for the treatment of GERD and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, we believe there are opportunities to expand the use of vonoprazan to other indications, such as eosinophilic esophagitis (EoE), in our licensed territories. Eosinophilic esophagitis is an autoimmune disease with significant unmet need. Although not approved for this indication, PPIs are prescribed for the treatment of eosinophilic esophagitis. Vonoprazan demonstrated similar efficacy to PPIs in an investigator-sponsored EoE clinical trial in Japan. In this clinical trial, 112 patients with eosinophilic esophagitis were treated with vonoprazan, or the PPI rabeprazole or esomeprazole. Of patients treated with vonoprazan, 82% had complete relief of symptoms compared to 70% for esomeprazole and 76-78% for rabeprazole. Similarly, 35% of patients treated with vonoprazan demonstrated complete remission of eosinophilic esophagitis by histology, compared to 37% for esomeprazole and 31-38% for rabeprazole. We are planning discussions with the FDA regarding the design of a Phase 2 clinical trial studying vonoprazan as a treatment for eosinophilic esophagitis in adults.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition to eosinophilic esophagitis, Barrett&#x2019;s esophagus and Zollinger Ellison syndrome are severe diseases related to acid secretion where PPIs are the current standard of care. The improved acid control of vonoprazan relative to PPIs may lead to use in these indications improved results over PPIs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Formulations and Packaging</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Orally Disintegrating Tablet</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. An orally disintegrating tablet, or ODT, formulation for vonoprazan is currently in development by Takeda. We may conduct one or more Phase 1 trials to support potential approval of the ODT formulation. We believe that the ODT represents a meaningful commercial opportunity for patients with difficulty swallowing, as estimated peak U.S. sales of the lansoprazole ODT formulation were over $450 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Intravenous Formulation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. We are exploring the potential to develop an intravenous formulation of vonoprazan for use in acute bleeding, critically ill patients, or other in-hospital applications. Several PPIs have approved intravenous formulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Pediatric Formulation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. We are exploring the potential to develop an oral formulation, in addition to an ODT formulation, for pediatric use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Over the Counter Use</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We believe that vonoprazan has the ideal profile for an OTC product, including the potential for as needed symptom relief and a well-tolerated safety profile. Sales of OTC heartburn relief products in the United States are substantial, constituting a multi-billion-dollar market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and strong emphasis on proprietary products. We face potential competition from many sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and government agencies and public and private research institutions. VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, if launched, VOQUEZNA, if approved and launched, and vonoprazan, if it receives marketing approval in Europe or Canada, will all compete with existing therapies and new therapies that may become available in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Some of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. These same competitors may invent technology that competes with vonoprazan. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and subject recruitment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for, or initiate commercial launch of, their products more rapidly than we may obtain approval for or launch products containing vonoprazan, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, we expect that VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, if launched, and VOQUEZNA, if approved, will be priced at a premium over competitive generic products and our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We expect that vonoprazan for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection in adults, if launched, and, if approved, for the treatment of patients with erosive GERD, will primarily compete with generic PPIs marketed by multiple pharmaceutical companies in both the prescription and OTC markets. Additionally, in March 2020, RedHill Biopharma Ltd. launched Talicia, a co-formulated capsule comprising generic omeprazole, amoxicillin, and rifabutin for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are aware of other PCABs in development in the United States, as well as a number of other PCABs in territories outside of the United States that if developed and approved in our territories may compete with vonoprazan. In the United States, Neurogastrx previously announced its intention to commence a Phase 3 erosive GERD trial for fexuprazan, under an exclusive license from Daewoong Pharmaceutical Co., Ltd., or Daewoong.  In addition, Cinclus Pharma AG, or Cinclus, received qualified QIDP designation for linaprazan glurate in combination with antibiotics for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection, completed a Phase 2 dose selection study for erosive GERD in November 2022, and plans to initiate Phase 3 studies in 2023 for the treatment of GERD and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection.  Finally, Sebela Pharmaceuticals, which acquired development and commercialization rights in United States and Canada to tegoprazan from HK inno.N, a South Korean company, has initiated two Phase 3 studies in the United States, one for non-erosive GERD and the other for healing and maintenance of healing of erosive GERD.  The earliest estimated completion date for any these studies is May 2024 and December 2024, respectively. Outside the United States, in 2022 Daewoong launched fexuprazan in South Korea for the treatment of erosive GERD under the brand name Fexuclue, has submitted applications for regulatory approval in additional countries in Asia and Latin America, and has out-licensed rights to develop fexuprazan in China to Shanghai Haini, a subsidiary of China&#x2019;s Yangtze River Pharmaceutical Group. Also outside the United States, revaprazan is marketed by Yuhan Corporation in South Korea, and tegoprazan is marketed by HK inno.N in South Korea, is also marketed in China and Indonesia, and is currently in development by RaQualia Pharma, Inc. in Japan. Additionally, Jeil Pharm has initiated a Phase 3 trial in South Korea of its PCAB candidate, JP-1366, in erosive GERD, and Cinclus&#x2019; linaprazan glurate has completed a Phase 2 clinical trial in Europe. To our knowledge, none of these compounds have demonstrated superiority to PPIs in a Phase 3 clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additionally, we are aware of several clinical-stage PPIs in territories outside of the United States that if developed and approved in our licensed territories may compete with vonoprazan. These include Dexa Medica&#x2019;s DLBS-2411, currently launched in the Philippines and in Phase 3 in Indonesia, Sihuan Pharmaceutical&#x2019;s anaprazole, currently in Phase 3 in China, and Eisai&#x2019;s azeloprazole, currently in a Phase 2 in China.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Intellectual property, including patents, trade secrets, trademarks and copyrights, is important to our business. Our commercial success depends in part on our ability to obtain and maintain proprietary intellectual property protection for vonoprazan, as well as for future product candidates and novel discoveries, product development technologies, and know-how. Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to develop and maintain protection of our proprietary position by, among other methods, licensing or filing U.S. and foreign patents and applications relating to our technology, inventions, and improvements that are important to the development and implementation of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our patent portfolio, comprising patents and patent applications exclusively licensed to us, is built with a goal of establishing broad protection that generally includes, for the product candidate compound, claims directed to composition of matter, pharmaceutical compositions or formulations, methods of synthesis, and methods of treatment using such pharmaceutical compositions or formulations. As of December 31, 2022, our patent portfolio covering vonoprazan consists solely of exclusively licensed patents and patent applications from Takeda. Subject to the terms of the license agreement we entered into with Takeda on May 7, 2019, or the Takeda License, we have licensed from Takeda exclusive rights in the United States, Europe, and Canada to patents and patent applications covering the composition of matter, formulation, use and/or manufacture of vonoprazan. Our patent portfolio comprises 10 distinct patent families protecting the technology relating to the compound vonoprazan and its synthetic intermediates, methods of synthesizing vonoprazan and related compounds, various formulations of vonoprazan products, as well as methods of treating diseases with vonoprazan and related compounds. As of December 31, 2022, our portfolio consists of approximately 23 issued U.S. patents, 6 pending U.S. applications, 14 issued European patents subsequently validated in individual European countries, 3 pending European applications, 5 issued Canadian patents, and 3 pending Canadian applications. The issued patents and pending applications have nominal expiration dates ranging from 2024 to 2038 without accounting for any available patent term adjustments or extensions. The issued U.S. patent covering the composition of matter of vonoprazan is expected to expire in August 2028, not including patent term extension. The issued U.S. patent covering the formulation of vonoprazan is expected to expire in August 2030, not including patent term extension.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The term of individual patents in our portfolio depends upon the legal term of patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent may be eligible for patent term adjustment, which permits patent term restoration as compensation for delays incurred at the USPTO during the patent prosecution process. In addition, for patents that cover an FDA-approved drug, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. While the length of the patent term extension is related to the length of time the drug is under regulatory review, patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent per approved drug may be extended under the Hatch-Waxman Act. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek any available patent term extension to any issued patents we may be granted in any jurisdiction where such extensions are available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our licensed pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us or Takeda in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, issued patents do not guarantee the right to practice our technology in relation to the commercialization of our products. Issued patents only allow us to block potential competitors from practicing the claimed inventions of the issued patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Further, patents and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing vonoprazan and any future product candidates and practicing our proprietary technology, and any issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for vonoprazan and any future product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to vonoprazan and any future product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us, and for employees and consultants to enter into invention assignment agreements with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual&#x2019;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Where applicable, the agreements provide that all inventions to which the individual contributed as an inventor shall be assigned to Phathom, and as such, will become our property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Further, we have filed for and have received trademark registrations for our company name &#x201c;Phathom Pharmaceuticals&#x201d; in the United States, European Union, and other foreign jurisdictions, and are pursuing trademark protection in certain other foreign jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">License Agreement with Takeda Pharmaceutical Company Limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On May 7, 2019, we and Takeda entered into the Takeda License, pursuant to which, Takeda granted us an exclusive, sublicensable (with Takeda&#x2019;s reasonable consent) license under certain patents and know how relating to vonoprazan and owned or controlled by Takeda during the term of the Takeda License to commercialize vonoprazan products using specified formulations for all human therapeutic uses in the United States, Europe and Canada, and a non-exclusive license under such patents and know how to develop and manufacture such vonoprazan products anywhere in the world (subject to Takeda&#x2019;s consent as to each country) for the purposes of commercializing the vonoprazan products in the United States, Europe and Canada. We granted Takeda a non-exclusive, royalty-free, sublicensable license under our rights in any patents and know-how that are necessary or useful to enable Takeda to develop and manufacture vonoprazan products anywhere in the world for the purposes of commercialization outside United States, Europe and Canada. We also granted Takeda an exclusive, royalty-free license under our rights in certain patents and know-how owned or controlled by us and necessary for the exploitation of vonoprazan products, in each case for Takeda to commercialize any vonoprazan product outside of the United States, Canada, and Europe and for purposes other than human therapeutic use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the term of the Takeda License, we and our affiliates are not permitted to commercialize any pharmaceutical product, other than vonoprazan, that treats acid-related disorders, except for certain generic and OTC competing products in specified circumstances. We will be responsible, at our cost, for the development, manufacture and commercialization of the vonoprazan products. We are required to use commercially reasonable efforts to develop and commercialize the vonoprazan products in our licensed territory.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under the Takeda License, Takeda has the sole right and authority, with our input, to prepare, file, prosecute, and maintain all Takeda and joint patents on a worldwide basis at its own cost. We are responsible, at our cost, for preparing, filing, prosecuting, and maintaining patents on inventions made solely by us in connection with vonoprazan, subject to input from Takeda. We have the first right to enforce the licensed patent rights with respect to certain infringing products in the United States, Europe and Canada.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We paid Takeda upfront consideration consisting of a cash payment of $25.0 million, 1,084,000 shares of common stock and a warrant to purchase 7,588,000 shares of common stock, or the Takeda Warrant. We agreed to make milestone payments to Takeda upon achieving certain tiered aggregate annual net sales of licensed products in the United States, Europe and Canada up a total maximum milestone amount of $250.0 million. We also agreed to make tiered royalty payments in the low double digits to the mid-teens on net sales of licensed products, subject to specified offsets and reductions. Royalties will be payable, on a product-by-product and country-by-country basis from the first commercial sale of such product in such country, until the latest of expiration of the licensed patents covering the applicable product, expiration of regulatory exclusivity in such country, or 15 years following first commercial sale in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Takeda License will continue until the expiration of the obligation to pay royalties in all countries and on all products. We may terminate the Takeda License in its entirety without cause upon six months&#x2019; prior written notice. We and Takeda may terminate the Takeda License in the case of the other party&#x2019;s insolvency, or upon prior written notice within a specified time period for the other party&#x2019;s material uncured breach. Takeda may terminate the Takeda License in its entirety if we challenge the licensed patents, or if we assist any third party in challenging such patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of vonoprazan. Vonoprazan is a small molecule that can be manufactured using commercially available technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">With respect to any future product candidates, we expect to continue to rely on third-party contract manufacturers to manufacture clinical supplies and commercial quantities of any approved product. Although we rely on contract manufacturers, we have personnel with manufacturing experience to oversee our relationships with Takeda, Sandoz, Catalent and Evonik.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Takeda Commercial Supply Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In April 2020, we entered into a Commercial Supply Agreement with Takeda, or the Takeda Supply Agreement, pursuant to which Takeda will supply us with commercial quantities of vonoprazan bulk drug. Pursuant to the Commercial Supply Agreement, Takeda has agreed to supply us certain quantities of vonoprazan bulk drug product according to approved specifications at a fixed price per batch of bulk drug product in order to commercialize vonoprazan in accordance with the Takeda License. The Takeda Supply Agreement sets forth a minimum and maximum number of batches of vonoprazan bulk drug product that we are required to order each year, and if we do not purchase the minimum number of batches in a year, other than as a result of Takeda&#x2019;s inability to supply such batches for any reason, or as a result of force majeure, we are required to pay Takeda the amount corresponding to the shortfall. Takeda has no obligation to supply bulk drug product above the maximum number of batches specified in the Takeda Supply Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, under the Takeda Supply Agreement, Takeda will provide certain services and materials, including vonoprazan drug substance, to support the transfer of technology and Takeda manufacturing know-how to our contract manufacturing organizations, or CMOs, that we designate. Takeda has agreed to negotiate in good faith to provide reasonable additional support, including technical advice and supply of materials, to assist us with technology transfers to the CMOs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Takeda Supply Agreement will continue until the earlier of (a) two years from the date we place an order for bulk drug product for the first commercial launch of vonoprazan in any jurisdiction in the United States, Europe or Canada, and (b) December 31, 2023. The Takeda Supply Agreement may be terminated upon written notice by either party if the other party has failed to remedy a material breach within a specified cure period following written notice of such breach. The Takeda Supply Agreement will terminate immediately upon the termination of the Takeda License in accordance with its terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Sandoz Supply and Packaging Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In December 2020, we entered into a Supply and Packaging Services Agreement with Sandoz GmbH, or the Sandoz Supply Agreement, pursuant to which Sandoz has agreed to supply commercial quantities of amoxicillin capsules and clarithromycin tablets, to package these antibiotics with vonoprazan drug product in finished convenience packs, and to supply us with these convenience packs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pursuant to the Sandoz Supply Agreement, we agreed to purchase certain quantities of convenience packs from Sandoz at an agreed upon price per pack. The price per pack is fixed for the first two (2) years following launch of the convenience pack in the United State and may be adjusted thereafter based on Sandoz&#x2019;s cost increases, subject to an annual cap. The Sandoz Supply Agreement sets forth an annual minimum number of convenience packs that we must purchase each year following launch of the convenience pack product, and if we do not meet the minimum order in a given year, we are required to pay Sandoz the amount corresponding to the shortfall. Sandoz has no obligation to supply convenience packs above a maximum number of packs above a certain percentage of our forecasts. We have agreed to purchase convenience packs, amoxicillin capsules and clarithromycin tablets, in each case intended for sale in the United States, exclusively from Sandoz during the five-year period following launch.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Sandoz Supply Agreement will continue for five years from launch of the convenience pack in the U.S. and may be terminated effective at the end of the initial five-year term upon written notice by either party prior to the end of the third year following launch. In the absence of such notice, the Sandoz Supply Agreement will extend automatically for an additional three-year period, and thereafter as mutually agreed upon by the parties. The Sandoz Supply Agreement may also be terminated at any time upon written notice by either party for uncured material breach following written notice of such breach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Catalent Commercial Supply Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In July 2021, we entered into a Commercial Supply Agreement, or the Tablet Supply Agreement, with Catalent Pharma Solutions, LLC, or Catalent, pursuant to which Catalent has agreed to supply us with commercial quantities of vonoprazan fumarate tablets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pursuant to the Tablet Supply Agreement, Catalent has agreed to supply us with, and the Company has agreed to purchase from Catalent, finished vonoprazan tablets at an agreed upon price per unit. The price per unit may be adjusted annually based on increases in costs incurred by Catalent. The Tablet Supply Agreement requires us to purchase a specified percentage of its requirements of finished vonoprazan tablets from Catalent, which percentage is subject to adjustment following the third anniversary of the first day of the calendar quarter during which Catalent is scheduled to deliver the initial finished vonoprazan tablets to us intended for commercial sale, excluding validation batches, or the Commencement Date.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unless terminated earlier, the term of the Tablet Supply Agreement extends for a period of five years from the Commencement Date. The Tablet Supply Agreement will extend automatically for additional two year periods unless terminated by either party upon at least 24months prior written notice. The Tablet Supply Agreement may also be terminated at any time upon written notice by either party if the other party has failed to remedy a material breach of the terms of the Tablet Supply Agreement within a specified period following receipt of written notice of such breach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Evonik Commercial Supply Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In August 2022, we entered into a Commercial Supply Agreement, or the API Supply Agreement, with Evonik Operations GmbH, or Evonik, pursuant to which Evonik has agreed to supply us with commercial quantities of vonoprazan drug substance, or API.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pursuant to the API Supply Agreement, Evonik has agreed to supply us with, and we have agreed to purchase, certain quantities of API at an agreed upon price which varies based on the volume of product ordered. The price may also be adjusted based on actual changes in costs incurred by Evonik.  Subject to pre-existing purchase obligations to Takeda, we have agreed to purchase a percentage of our annual requirements of API from Evonik, for which the percentage of our annual API requirements is subject to adjustment based upon the price of API under the API Supply Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unless terminated earlier, the API Supply Agreement has an initial period that expires in August 2027. This initial term will be extended by two additional years if Evonik successfully qualifies a second manufacturing facility to produce API no later than December 31, 2024. The API Supply Agreement may be terminated effective at the end of the initial period on at least 24-months written notice by either party.  In the absence of such notice, the API Supply Agreement will extend automatically for additional 2-year periods which may be terminated upon 18 months&#x2019; notice.  The API Supply Agreement may also be terminated at any time upon written notice by either party if the other party has failed to remedy a material breach of the terms of the Supply Agreement within a specified period following receipt of written notice of such breach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the NDA process before it may be legally marketed in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">U.S. Drug Development Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with Good Laboratory Practice, or GLP, regulations and other applicable regulations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;  </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice, or GCP, regulations to establish the safety and efficacy of the proposed drug for its intended use; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">submission to the FDA of an NDA; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCPs; and  </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Prior to beginning the first clinical trial with a product candidate in the United States, a sponsor must submit an IND to the FDA. The sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of one or more qualified investigators in accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND as well as any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing suggesting a significant risk to humans exposed to the drug, and any clinically important increased rate of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Furthermore, an IRB at each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Phase 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">: The product candidate is initially introduced into healthy human volunteers or patients with the target disease or condition. These studies test for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness.  </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.  </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of the product&#x2019;s effectiveness for its intended use(s) and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling.  </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing suggesting a significant risk to humans exposed to the drug, and any clinically important increased rate of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">NDA Review and Approval Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#x2019;s identity, strength, quality and purity. Under current PDUFA guidelines, the FDA has a goal of ten months from the date of &#x201c;filing&#x201d; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#x201c;filing&#x201d; decision after the application is submitted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as additional clinical trials or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase 4 testing, which involves clinical trials designed to further assess a drug&#x2019;s safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, fails to keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The FDA has a Fast Track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, product candidates are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review. A Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Any marketing application for a drug submitted to the FDA for approval, including a product candidate with a Fast Track designation or Breakthrough Therapy designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product candidate is eligible for priority review if it is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, a product candidate may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA will generally require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled confirmatory clinical trials verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory studies in a timely manner, or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Fast Track designation, Breakthrough Therapy designation, accelerated approval, and priority do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Any drug products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market and imposes requirements and restrictions on drug manufacturers, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved labeling (known as &#x201c;off-label use&#x201d;), industry-sponsored scientific and educational activities, and promotional activities involving the Internet. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA-approved labelling.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Non-Patent and Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Data and market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additionally, under the GAIN Act, the FDA may designate a product as a &#x201c;qualified infectious disease product,&#x201d; or QIDP. In order to receive this designation, a drug must qualify as an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by either (1) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens, or (2) a so-called &#x201c;qualifying pathogen&#x201d; found on a list of potentially dangerous, drug-resistant organisms established and maintained by the FDA under the law. The FDA interprets QIDP designation to apply to a specific drug product, including a specific dosage form of the product. A sponsor must request such designation before submitting a marketing application, and the FDA will respond to a request for QIDP designation within 60 days of the date the FDA receives the request. The GAIN Act permits the FDA to revoke a QIDP designation only if the request for such designation contained an untrue statement of material fact.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The benefits of QIDP designation include potential eligibility for priority review and Fast Track designation, and an extension by an additional five years of any non-patent marketing exclusivity period awarded, such as a five-year exclusivity period awarded for a new molecular entity. This extension is in addition to any pediatric exclusivity extension that may be awarded, and the extension will be awarded only to a drug first approved on or after the date of enactment. The GAIN Act provisions prohibit the grant of an exclusivity extension where the application is a supplement to an application for which an extension is in effect or has expired, is a subsequent application for a specified change to an approved product, or is an application for a product that does not meet the definition of QIDP based on the uses for which it is ultimately approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition to FDA regulation of pharmaceutical products, U.S. federal and state healthcare laws and regulations restrict business practices in the pharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and constrain the business or financial arrangements and relationships with healthcare providers and other parties. These laws include anti-kickback and false claims laws, civil monetary penalties laws, and transparency laws regarding drug pricing and payments or other items of value provided to physicians and other healthcare providers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payers and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration of pharmaceutical sales representatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Violation of any of such laws or any other governmental regulations that apply may result in significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">U.S. Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval. Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payers, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for vonoprazan and any future product candidates can be subject to challenge, reduction or denial by third-party payers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The process for determining whether a third-party payer will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payer will pay for the product. In the United States, there is no uniform policy among payers for coverage or reimbursement. Decisions regarding whether to cover a product, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Third-party payers often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that can require manufacturers to provide scientific and clinical support for the use of a product to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Third-party payers may not consider vonoprazan or any future product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally, decreases in third-party reimbursement for any product or a decision by a third-party payer not to cover a product could reduce physician usage and patient demand for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Medicaid is a joint federal and state program administered by the states for low&#x2011;income and disabled beneficiaries. Medicare is a federal program that is administered by the federal government covering individuals age 65 and over as well as those with certain disabilities. Under the Medicaid Drug Rebate Program, or MDRP, as a condition of having federal funds being made available to the states for covered outpatient drugs under Medicaid, pharmaceutical manufacturers must enter into an agreement with the Secretary of Health and Human Services to pay a rebate to state Medicaid programs for each unit of covered outpatient drug dispensed to a Medicaid beneficiary and paid for by the state Medicaid program. Medicaid drug rebates are based on pricing data that pharmaceutical manufacturers report on a monthly and quarterly basis to the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, which is the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the average manufacturer price, or AMP, for each drug and, in the case of innovator products, the Best Price, or BP, which represents the lowest price available from the manufacturer to any entity in the United States in any pricing structure, calculated to include all applicable sales and associated rebates, discounts and other price concessions. If a manufacturer becomes aware that its MDRP government price reporting submission for a prior quarter was incorrect or has changed as a result of recalculation of the pricing data, the manufacturer must resubmit the corrected data for up to three years after those data originally were due. If a manufacturer fails to provide information timely or is found to have knowingly submitted false information to the government, the manufacturer may be subject to civil monetary penalties and other sanctions, including termination from the MDRP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Federal law requires that a manufacturer that participates in the MDRP also participate in the Public Health Service&#x2019;s 340B drug pricing program, or the 340B program, in order for federal funds to be available for the manufacturer&#x2019;s drugs under Medicaid. The 340B program is administered by the Health Resources and Services Administration, or HRSA, and requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B &#x201c;ceiling price&#x201d; for the manufacturer&#x2019;s covered outpatient drugs used in an outpatient setting. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low&#x2011;income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. Manufacturers must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B&#x2011;eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if passed, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In order to be eligible to have drug products paid for with federal funds under Medicaid and purchased by certain federal agencies and grantees, a manufacturer must also participate in the U.S. Department of Veterans Affairs, or VA, Federal Supply Schedule, or FSS, pricing program. Under the VA/FSS program, a manufacturer must report the Non-Federal Average Manufacturer Price, or Non-FAMP, for its covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These federal agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). The manufacturer must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If a manufacturer participating in the FSS program fails to provide timely information or is found to have knowingly submitted false information, the manufacturer may be subject to civil monetary penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered by manufacturers in taking such increases, wholesale acquisition cost disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">U.S. Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In the United States, there has been, and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Among policy makers and payers in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act, or the Affordable Care Act, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The Affordable Care Act, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#x201c;branded prescription drugs&#x201d; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Since its enactment, there have been judicial and political challenges to certain aspects of the Affordable Care Act, or ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021, through August 15, 2021, for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013, and, due to subsequent legislative amendments to the statute will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products.  Most recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). Individual states in the U.S. have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs. Furthermore, there has been increased interest by third-party payers and governmental authorities in reference pricing systems and publication of discounts and list prices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">      </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The likelihood of implementation of additional reform initiatives is uncertain. Moreover, in the coming years, additional legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies and the success of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Foreign Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, or EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Regulation and Procedures Governing Marketing Authorization of Medicinal Products in the EU</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Non-clinical studies and clinical trials</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Similarly to the United States, the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Non-clinical studies are performed to demonstrate the health or environmental safety of new biological substances. Non-clinical studies must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in EU Directive 2004/10/EC. In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Conference on Harmonization, or ICH, guidelines on good clinical practices, or GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#x2018;no fault&#x2019; compensation to any study subject injured in the clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A clinical trial application, or CTA, must be submitted to competent national health authorities and independent ethics committees, much like the FDA and IRB, respectively. Once the CTA is approved by the national health authority and the ethics committee has granted a positive opinion in relation to the conduct of the trial in the relevant member state(s), in accordance with a country&#x2019;s requirements, clinical study development may proceed. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Currently, CTAs must be submitted to the competent authority in each EU member state in which the trial will be conducted. Under the new Clinical Trials Regulation, which became applicable on January 31, 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only limited involvement. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on the duration of the individual clinical trial from January 31, 2022 onward. If an ongoing clinical trial continues for more than three years from January 31, 2022 the Clinical Trials Regulation will begin to apply to the clinical trial as of January 31, 2025.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Medicines used in clinical trials must be manufactured in accordance with good manufacturing practice, or GMP. Other national and EU-wide regulatory requirements may also apply.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Marketing Authorizations</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In the EU, medicinal product candidates can only be commercialized after obtaining a marketing authorization, or MA. To obtain regulatory approval of a product candidate in the EU, we must submit a Marketing Authorization Application, or MAA. The process for doing this depends, among other things, on the nature of the medicinal product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">There are two types of MAs:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#34;Centralized MAs&#34; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the EMA and are valid throughout the EU. The centralized procedure is mandatory for certain types of products, such as (i) medicinal products derived from biotechnological processes, (ii) designated orphan medicinal products, (iii) advanced medicinal therapy products, or ATMPs, such as gene therapy, somatic cell-therapy or tissue-engineered medicines and (iv) medicinal products containing a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for any products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or for which the granting of a MA would be in the interest of public health in the EU. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#34;National MAs&#34; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this National MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a National MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the EU member states make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">MAs have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance. Under the centralized procedure and in exceptional cases, the CHMP might perform an accelerated review of a MA in no more than 150 days (not including clock stops).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Data and marketing exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The EU also provides opportunities for market exclusivity. Upon receiving marketing authorization, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#x2019;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Pediatric investigation plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In the EU, MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#x2019;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU member states and study results are included in the product information, even when negative, the product is eligible for six months&#x2019; supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity is granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the EU. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to governmental control in many countries. In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Failure to comply with the aforementioned EU and member state laws may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The United Kingdom, or UK, left the EU on January 31, 2020, following which existing EU medicinal product legislation continued to apply in the United Kingdom during the transition period under the terms of the EU-UK Withdrawal Agreement. The transition period, which ended on December 31, 2020, maintained access to the EU single market and to the global trade deals negotiated by the EU on behalf of its members. The transition period provided time for the UK and EU to negotiate a framework for partnership for the future, which was then crystallized in the Trade and Cooperation Agreement, or TCA, and became effective on the January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#x201c;retained EU law&#x201d;. However, new legislation such as the EU Clinical Trials Regulation or in relation to orphan medicines will not be applicable. The UK government has passed a new Medicines and Medical Devices Act 2021, which introduces delegated powers in favor of the Secretary of State or an &#x2018;appropriate authority&#x2019; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, is the UK&#x2019;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in England, Wales, and Scotland, together, Great Britain, or GB; broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA. The MHRA has published a guidance on how various aspects of the UK regulatory regime for medicines will operate in GB and in Northern Ireland following the expiry of the Brexit transition period on December 31, 2020. The guidance includes clinical trials, importing, exporting, and pharmacovigilance and is relevant to any business involved in the research, development, or commercialization of medicines in the UK. The new guidance was given effect via the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019, or the Exit Regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January 1, 2021, unless the MA holder chooses to opt-out. After Brexit, companies established in the UK cannot use the centralized procedure and instead must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in the UK. The MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure) MA when determining an application for a GB authorization; or use the MHRA&#x2019;s decentralized or mutual recognition procedures which enable MAs approved in EU member states (or Iceland, Liechtenstein, Norway) to be granted in GB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Data privacy and security laws</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pharmaceutical companies may be subject to federal, state and foreign data privacy, security and data breach notification laws governing the collection, use, disclosure and protection of health-related and other personal information. For example, in the U.S., HIPAA imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#x201c;covered entities&#x201d; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to the Department of Health and Human Services, or HHS, to affected individuals and if the breach is large enough, to the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured personal health information, or PHI, a complaint about privacy practices or an audit by the HHS may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers&#x2019; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act, or CCPA, the California Privacy Rights Act, or CPRA, similar laws in Colorado, Connecticut, Virginia and Utah, and the EU General Data Protection Regulation, or GDPR, govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Human Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of February 24, 2023, we had 112 full-time employees, 10 of whom have a Ph.D. or M.D. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and developing our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Corporate Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We were originally incorporated under the laws of the state of Delaware on January 9, 2018 under the name North Bridge IV, Inc. On March 13, 2019, we changed our name to Phathom Pharmaceuticals, Inc. and merged YamadaCo IIA, Inc., a Delaware corporation, or YamadaCo, with and into our company, with Phathom Pharmaceuticals, Inc. as the surviving entity, or the Merger. References throughout this annual report to Phathom Pharmaceuticals, Inc. include North Bridge IV, Inc. prior to the Merger. Our principal executive offices are located at 100 Campus Drive, Suite 102, Florham Park, New Jersey 07932, and our telephone number is (877) 742-8466.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Available Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our internet address is www.phathompharma.com. Our investor relations website is located at https://investors.phathompharma.com. We make available free of charge on our investor relations website under &#x201c;Financials and Filings&#x201d; our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, our directors&#x2019; and officers&#x2019; Section 16 reports and any amendments to those reports as soon as reasonably practicable after filing or furnishing such materials to the SEC. They are also available for free on the SEC&#x2019;s website at www.sec.gov.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We use our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor such website, in addition to following our press releases, SEC filings and public conference calls and webcasts. Information relating to our corporate governance is also included on our investor relations website. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 1A.	Ri</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">sk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">You should carefully consider the following risk factors, together with the other information contained in this annual report on Form 10-K, including our financial statements and the related notes and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before making a decision to purchase or sell shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and growth prospects. If that were to happen, the trading price of our common stock could decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations or financial condition. In this section, we first provide a summary of the more significant risks and uncertainties we face and then provide a full set of risk factors and discuss them in greater detail.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">SUMMARY RISKS FACTORS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We may not be successful in demonstrating to the FDA that we are able to maintain the level of the nitrosamine impurity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">N</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-nitroso-vonoprazan below the acceptable daily intake established by the FDA;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our Revenue Interest Financing Agreement could limit cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We currently depend entirely on the success of products containing vonoprazan including VOQUEZNA TRIPLE PAK and VOQEUZNA DUAL PAK, which have not been launched but are our only approved products, and, if approved, VOQUEZNA for the treatment of erosive GERD. If we are unable to obtain approval of vonoprazan for treatment of erosive GERD, and launch and successfully commercialize these products, or experience significant delays in doing so, or are unable to advance the clinical development of, and obtain regulatory approval for, vonoprazan to treat non-erosive GERD, our business will be materially harmed;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of prior clinical trials and other investigator-initiated clinical trials of vonoprazan are not necessarily predictive of our future results. Vonoprazan may not have favorable results in our clinical trials, or receive additional regulatory approvals on a timely basis, if at all;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan and any future product candidates are subject to extensive regulation and compliance obligations, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize vonoprazan and any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We may not be successful in our efforts to expand our pipeline by identifying additional indications and formulations for which to investigate vonoprazan in the future. We may expend our limited resources to pursue a particular indication or formulation for vonoprazan and fail to capitalize on product candidates, indications or formulations that may be more profitable or for which there is a greater likelihood of success;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We currently have a limited commercial organization, no field sales representatives, and have no experience as a company in commercializing products, and we may have to invest significant additional resources to develop these capabilities. If we are unable to establish the necessary commercial capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We rely on third parties to conduct our preclinical and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain additional regulatory approvals for or commercialize vonoprazan and our business could be harmed;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;" id="page5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We currently engage third-party manufacturers for all of our clinical and commercial supplies. The loss of any of these suppliers, or any future single source suppliers, could harm our business;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We rely on the Takeda License to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada. If the license agreement is terminated, we would lose our rights to develop and commercialize vonoprazan;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The successful commercialization of VOQUEZNA TRIPLE PAK and </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Voquezna Dual Pak</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> (or, if approved, VOQUEZNA for the treatment of erosive GERD or any future product candidates) will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products successfully and decrease our ability to generate revenue;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If following commercialization of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK (and if approved, VOQUEZNA for the treatment of erosive GERD or any future product candidates) we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are subject to various foreign, federal, and state healthcare and privacy laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our business is subject to risks arising from epidemic diseases, such as the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are highly dependent on the services of our key executives and personnel, and if we are not able to retain these members of our management or recruit additional management, clinical and commercial personnel, our business will suffer; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The trading price of our securities is likely to be volatile, and purchasers of our securities could incur substantial losses.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a late clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We commenced operations in 2018, and to date, we have focused primarily on organizing and staffing our company, business planning, raising capital, in-licensing our initial product candidate, vonoprazan, meeting with regulatory authorities, conducting our Phase 3 clinical trials of vonoprazan, preparing applications for regulatory approval for vonoprazan and preparing for a potential commercial launch. As a company, we have not yet demonstrated an ability to initial commercial launch a product launch, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully obtaining regulatory approvals for and commercializing biopharmaceutical products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have incurred significant operating losses since our inception. If vonoprazan is not successfully developed, approved and commercially launched in the United States, Europe and/or Canada, we may never generate any revenue. We have incurred cumulative net losses since our inception and, as of December 31, 2022, we had an accumulated deficit of $727.1 million. Substantially all of our losses have resulted from expenses incurred in connection with in-licensing and developing vonoprazan, commercial activities in preparation for a potential product launch, and from general and administrative costs associated with our operations. Vonoprazan will require substantial additional time and resources before we will be able to begin generating revenue from product sales, and any future product candidates will require substantial additional development time and resources before we will be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek additional regulatory approvals for, and potentially commercialize vonoprazan and seek to identify, assess, acquire, in-license, or develop additional product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of vonoprazan and any future product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products. We are still in the early stages of a number of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. For example, we have not been able to demonstrate to FDA that we can produce commercial product in which the level of an identified nitrosamine impurity remains below its acceptable daily intake limit throughout the shelf-life of the product. Because of this and the other numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to initiate product commercialization and achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, continue our product development efforts, diversify our product candidate pipeline or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The development and commercialization of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we prepare to commercialize vonoprazan for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">and, if approved, erosive GERD and progress our non-erosive GERD development program. In addition, if one or more products containing vonoprazan are commercialized, we will be required to make milestone and royalty payments to Takeda, from whom we have in-licensed the rights to develop and commercialize vonoprazan in the United States, Europe, and Canada pursuant to the Takeda License. Furthermore, if and to the extent we seek to acquire or in-license additional product candidates in the future, we may be required to make significant upfront payments, milestone payments, and/or royalty payments. If we obtain additional regulatory approvals for vonoprazan or regulatory approval for any future product candidate, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of vonoprazan or any future product candidate. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We believe that our existing cash and cash equivalents together with the drawdown of the remaining $100 million under our loan and security agreement, or the Loan Agreement, with Hercules Capital, or Hercules, are sufficient to fund operations for at least the next twelve months and receipt of the $175 million milestone under our revenue interest financing agreement following approval of vonoprazan for the treatment of erosive GERD, will enable us to fund our operations through 2024. In particular, we expect that these funds will allow us to launch vonoprazan for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and erosive GERD subject to approval of our resubmissions. We have based these estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs and timing of establishing or securing additional sales and marketing capabilities in advance of initiating commercial launch of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, and, if approved, VOQUEZNA for the treatment of erosive GERD or any future product candidate;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the initiation, type, number, scope, results, costs and timing of, our clinical trials of vonoprazan, and preclinical studies or clinical trials of other potential product candidates we may choose to pursue in the future, including feedback received from regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs and timing of manufacturing for vonoprazan or any future product candidates, including commercial scale manufacturing if any product candidate is approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs, timing and outcome of regulatory review of our resubmissions following receipt of complete response letters for our post approval supplement for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK and our NDA for VOQUEZNA for the treatment of erosive GERD, and the costs, timing and outcome of regulatory review of any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs associated with hiring additional personnel and consultants as our business grows particularly commercial personnel;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the timing and amount of the milestone or other payments we must make to Takeda and any future licensors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payers and adequate market share and revenue for any approved products;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">patients&#x2019; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs associated with any products or technologies that we may in-license or acquire.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Conducting clinical trials and preclinical studies is a time consuming, expensive, and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, and, if approved, VOQUEZNA for the treatment of erosive GERD or any future product candidate, may not achieve commercial success. Our commercial revenues, if any, would initially be derived from sales of products containing vonoprazan in the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, our Loan Agreement with Hercules, our revenue interest financing agreement, other debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Our Loan Agreement and our Revenue Interest Financing Agreement include, and any future debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures or declaring dividends.  For example, our Loan Agreement with Hercules contains minimum cash financial covenants. If on or prior to March 31, 2024, we have not received FDA approval of our NDA for vonoprazan for the treatment of erosive GERD, raised additional funding, or significantly reduced our operating expenses, we may be in violation of these covenants. If we default on such indebtedness, with Hercules or a future lender, we could lose such assets and intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If we raise funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risks Related to the Development and Regulatory Approval of Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We currently depend entirely on the success of vonoprazan, which is contained in our only approved products and product candidate. If we are unable to successfully launch and commercialize vonoprazan, obtain additional, required regulatory approvals and advance the clinical development of vonoprazan in additional indications, or experience significant delays in doing any of the foregoing, our business will be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We currently have two approved products and one product candidate, all of which contain vonoprazan, which we in-licensed from Takeda. Our current business depends entirely on our ability to successfully develop, obtain regulatory approval for, and commercialize products containing vonoprazan in a timely manner. This may make an investment in our company riskier than similar companies that have multiple approved products or product candidates in active development that may be able to better sustain failure of a single product. In May 2022, the FDA approved the NDAs for vonoprazan triple therapy, under the brand name VOQUEZNA TRIPLE PAK and vonoprazan dual therapy, under the brand name VOQUEZNA DUAL PAK. In August 2022, prior to the launch of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, we announced that, consistent with current FDA Guidance for Industry: Control of Nitrosamine Impurities in Human Drug Products, we initiated testing to determine whether nitrosamine impurities were present in our initial commercial drug product for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. These tests revealed trace levels of a nitrosamine impurity, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">N</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-nitroso-vonoprazan, or NVP, that is not described within the FDA Guidance document. In January 2023, we announced that, although the FDA established an acceptable daily intake (AI) for NVP at 96 ng/day, the FDA (Division of Gastroenterology) advised us that it would not be acting on our erosive GERD NDA on or prior to the Prescription Drug User Fee Act (PDUFA) target action date of January 11, 2023. Rather, the FDA requested additional stability data demonstrating that the levels of NVP will remain at or below the AI throughout the proposed shelf life of the product.  In February 2023, we received complete response letters from the FDA relating to our erosive GERD NDA and post approval supplement relating to our approved </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">NDAs, both of which address specifications and controls for NVP. These letters formalize FDA&#x2019;s prior request that we provide additional stability data to demonstrate that levels of NVP will remain at or below the AI throughout the proposed shelf life of the product.  No additional deficiencies were cited by the FDA in either letter.  We have scheduled a meeting with the FDA in March 2023 to discuss our resubmission plan and timeline. If we are unable to demonstrate to the FDA that we will be able to maintain NVP levels at or below the AI, launches of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK will be further delayed and approval of our erosive GERD NDA will continue to be delayed, which could substantially increase our costs and delay or put at risk our ability to generate revenue and adversely affect our commercial prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Also in January 2023, we reported positive topline results from PHALCON-NERD-301, a Phase 3 study evaluating the safety and efficacy of vonoprazan for the daily treatment of adults with non-erosive GERD. We are also in discussions with the FDA regarding the design of a Phase 3 trial to evaluate the novel dosing regimen of vonoprazan as an as needed treatment for episodic heartburn relief in patients with non-erosive GERD, a dosing regimen not approved in the U.S. for PPIs. This trial would constitute our fourth Phase 3 trial for vonoprazan. In February 2022, we reported positive topline results from PHALCON-NERD-201, a Phase 2 proof-of-concept study evaluating this novel dosing regimen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Our assumptions about the commercial potential of vonoprazan are based in part on the commercial experience of vonoprazan in Japan. However, our assumptions may prove to be wrong, and we may encounter a materially and adversely different development and commercial experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The success of vonoprazan will depend on several factors, including the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">demonstrating safety and efficacy to the satisfaction of applicable regulatory authorities, including without limitation, demonstrating to the FDA that levels of NVP will remain below the AI throughout the shelf-life of our products;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">acceptance by the FDA or comparable foreign regulatory authorities of the proposed design of our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the willingness of the FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities to accept the data from the clinical trials and preclinical studies and clinical trials conducted outside of our licensed territories by Takeda and independent investigators as part of the basis for review and approval of vonoprazan;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA, and other comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">receipt of additional regulatory approvals, including approvals required to initiate distribution and sale of products containing vonoprazan, from applicable regulatory authorities including the FDA;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">making and/or maintaining arrangements with Takeda, Catalent, Sandoz, Evonik or any future third-party manufacturers for, or establishing, commercial manufacturing capabilities and receiving/importing commercial supplies approved by FDA and other regulators from Takeda, Catalent, Sandoz, Evonik or any future third-party manufacturer;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">establishing sales, marketing and distribution capabilities and, following required approval, commercializing vonoprazan, whether alone or in collaboration with others;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">establishment and maintenance of patent and trade secret protection or regulatory exclusivity for vonoprazan;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">maintaining an acceptable safety profile of vonoprazan following approval; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">maintaining and growing an organization of people who can develop and, if approved, commercialize, market, and sell vonoprazan to physicians, patients, healthcare payers, and others in the medical community.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If we are unable to demonstrate to FDA&#x2019;s satisfaction our ability to maintain the level of NVP below the AI throughout the shelf-life of our products, the launches of our approved products may be further delayed and approval and launch of our erosive GERD NDA may also be further delayed, which could substantially increase our costs and put at risk our ability to generate revenue and adversely affect our commercial prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful completion of clinical development, regulatory approval and commercialization of vonoprazan, including successfully addressing, to the FDA&#x2019;s and the medical community&#x2019;s satisfaction, the formation of nitrosamine impurities in commercial batches of vonoprazan drug product, which may be significantly delayed beyond our current expectations and may never occur. Although we have obtained marketing approval of two vonoprazan-based treatment regimens for one indication, we have not yet succeeded in launching and successfully commercializing vonoprazan. Any inability to obtain required, additional regulatory approvals for, or, if approved, successfully commercialize vonoprazan, would materially and adversely affect our business, financial condition, prospects and operating results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Even if we believe the results of our clinical trials are positive, obtaining regulatory approval may not occur on a timely basis, if at all. The results from clinical trials or preclinical studies of a product candidate may not predict the results of later clinical trials of the product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after the product candidate achieved promising results in earlier clinical trials. The results of our trials may not be comparable to those achieved previously, whether as a result of differences in trial design, patient population or otherwise.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For example, in our Phase 3 clinical trial for the treatment of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, the vonoprazan dual therapy arm was not double-blinded because patients in this arm were administered amoxicillin three times daily, versus twice daily for the triple therapy regimens. Both triple therapy regimens were double-blinded. The inability to double-blind the dual therapy arm may impact how regulatory agencies or healthcare payers interpret such results. For example, the EMA has noted that it expects additional analyses of treatment compliance and drop-out rates in the dual therapy arm because it will not be double-blinded.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Further, in July 2019, we received scientific advice from the EMA on our Phase 3 clinical trial of vonoprazan in the healing and maintenance of healing of erosive GERD. For the healing phase of the study, the EMA recommended that we include an endoscopy to assess healing at Week 4 in addition to the planned endoscopies at Week 2 and Week 8 because the summary of product characteristics for lansoprazole suggests four weeks of treatment to assess healing in erosive GERD. We decided not to incorporate this change into the study design given the additional burden on study subjects to return for a third endoscopy in an eight-week period. This decision may impact the future summary of product characteristics for vonoprazan or may cause the EMA to require us to conduct additional clinical trials for vonoprazan to support marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, Takeda, a third party over which we have no control, has the right to develop and commercialize vonoprazan outside of the United States, Europe, and Canada. Takeda has marketing approval for vonoprazan in certain countries in Asia and Latin America, and Takeda has ongoing clinical trials of vonoprazan in certain indications that we are also pursuing. If such ongoing trials fail to meet their primary endpoints, have serious adverse events or encounter other problems, the development potential of vonoprazan could be materially and adversely affected. In addition, if serious adverse events or other problems occur with patients using vonoprazan marketed outside of our licensed territories, or if the results of ongoing or future clinical trials of vonoprazan conducted by Takeda or others generate negative results or results that conflict with the results of our clinical trials, the FDA or other regulatory authorities may delay, limit, or deny approval of vonoprazan, require us to conduct additional clinical trials as a condition to marketing approval, or withdraw their approval of vonoprazan or otherwise restrict our ability to market and sell vonoprazan, if approved. In addition, treating physicians may be less willing to prescribe vonoprazan due to concerns over such trial results or adverse events, which would limit our ability to commercialize vonoprazan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For the foregoing reasons, our ongoing and future clinical trials and our efforts to obtain additional regulatory approvals for vonoprazan may not be successful. Further, any safety concerns observed in any one of our ongoing or future clinical trials for the targeted indications could limit the prospects for additional regulatory approvals of vonoprazan or any future product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Any difficulties or delays in the commencement or completion, or termination or suspension, of our ongoing or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Before obtaining marketing approvals from regulatory authorities for the sale of vonoprazan for additional indications or approval of any future product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of vonoprazan in such new indication or of any future product candidates in humans. We do not know whether any ongoing studies will be completed on schedule, if at all, or if any future clinical trials will begin on time. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the FDA, EMA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials and reaching consensus among the FDA and EMA over the design of the same clinical trial;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">any failure or delay in obtaining regulatory authorizations to commence a trial;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">any failure or delay in reaching an agreement with contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">institutional review boards, or IRBs, or other reviewing bodies refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">changes to clinical trial protocols;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">clinical sites deviating from trial protocols or dropping out of a trial;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">manufacturing or obtaining sufficient quantities of vonoprazan and any future product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">inability to obtain and deliver sufficient quantities of vonoprazan and any future product candidates to clinical sites;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post- treatment follow-up;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">subjects choosing an alternative treatment for the indication for which we are developing vonoprazan and any future product candidates, or participating in competing clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">lack of adequate funding to continue the clinical trial;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">subjects experiencing severe or unexpected drug-related adverse effects;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a facility manufacturing vonoprazan or any future product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">any changes to our manufacturing process that may be necessary or desired;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">third-party contractors not performing data collection or analysis in a timely or accurate manner; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted or by the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may impose a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing, or successful completion of a clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we have done for vonoprazan and may do for any future product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Moreover, principal investigators for our clinical trials currently serve and may continue to serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the clinical trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If we experience delays in the completion of, or termination of, any clinical trial of vonoprazan or any future product candidates, the commercial prospects of vonoprazan and any future product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. We may make formulation or manufacturing changes to vonoprazan or any future product candidates, in which case we may need to conduct additional preclinical studies to bridge our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize vonoprazan or any future product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of vonoprazan and any future product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We may not be able to initiate or continue clinical trials for vonoprazan or any future product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, competing clinical trials and clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating as well as any drugs under development. We will be required to identify and enroll a sufficient number of patients for each of our clinical trials. Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for our clinical trials and monitoring such patients adequately during and after treatment. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. The eligibility criteria of our clinical trials further limits the pool of available trial participants. If patients are unwilling to participate in our trials for any reason, including the existence of concurrent clinical trials for similar patient or the availability of approved therapies, or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting trials and obtaining regulatory approval of vonoprazan and any future product candidates may be delayed. Further, public health emergencies, such as the COVID-19 pandemic have and may continue to negatively affect site activation, as well as patient enrollment and retention. Our inability to enroll a sufficient number of patients for any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our assumptions used in determining expected clinical trial timelines may not be correct, and we may experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of vonoprazan or any future product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with vonoprazan&#x2019;s or any future product candidates&#x2019; use. Results of our ongoing or future clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by vonoprazan and any future product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Moreover, if vonoprazan or any other future product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate, if approved. We may also be required to modify our study plans based on findings in our clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 2022, more than 9,000 subjects have been exposed to vonoprazan in completed and ongoing Phase 1 to 3 clinical trials. The doses studied have ranged from 1 to 120 mg with durations up to one year. In our Phase 3 clinical trial for EE, the most common adverse reactions (&#x2265;2%) in vonoprazan-treated patients in the healing phase were abdominal pain and diarrhea and in the maintenance phase were gastritis, diarrhea, abdominal pain, dyspepsia, gastroesophageal reflux disease, hypertension, abnormal liver function test, and nausea. Of these, only two adverse events, both in the maintenance phase, exceeded 5%: gastritis (6.4%, vonoprazan 10 mg) and abdominal pain (5.4%, vonoprazan 20 mg). In our Phase 3 clinical trial evaluating vonoprazan in combination with amoxicillin and clarithromycin or amoxicillin, most common adverse reactions (&#x2265;2%) in vonoprazan triple therapy-treated patients were dysgeusia, diarrhea, headache, abdominal pain, vulvovaginal candidiasis and hypertension and with vonoprazan dual therapy-treated patients were diarrhea, abdominal pain and nasopharyngitis.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Certain earlier generation PCABs previously under development by other companies may have been discontinued in part due to their hepatic safety profile. These hepatic safety concerns may be compound-specific and not generalizable to the PCAB class. Vonoprazan has shown similar hepatic safety results to lansoprazole across all comparative clinical studies conducted by Takeda, in which 1.0% of subjects treated with vonoprazan 10 mg or 20 mg and 0.8% of subjects treated with lansoprazole 15 mg or 30 mg had ALT or AST elevations greater than three times the upper limit of normal or bilirubin elevations greater than two times the upper limit of normal. Similarly, in the healing phase of PHALCON-EE, transient elevations in ALT or AST greater than 3 times the upper limit of normal were observed in 0.4% of subjects treated with vonoprazan 20 mgs and 0.2% of subjects treated with lansoprazole. In the maintenance phase, ALT or AST greater than three times the upper limit of normal were observed in 1% of subjects treated with vonoprazan 10 mg, 0.3% of subjects treated with vonoprazan 20 mg, and 2% of subjects treated with lansoprazole. The most recent post-marketing safety report from December 2022 includes an estimate of over 50 million patients who have received vonoprazan in Japan and other countries in Asia since launch. Based on the post-marketing experience, the clinically significant adverse reactions section of the Japanese prescribing information for vonoprazan was updated to include shock, anaphylaxis, hepatic impairment, skin reactions such as toxic epidermal necrolysis, Steven- Johnson syndrome, and erythema multiforme, and events of pancytopenia, agranulocytosis, leukocytopenia, and thrombocytopenia. The incidence of these reactions was considered extremely rare (less than 1 in 100,000 patients) and a causal relationship to vonoprazan could not be ruled out. Although serious hepatic adverse events have been observed among patients exposed to vonoprazan in Japan in the post-marketing setting, these cases were typically confounded by comorbidities or other concomitant medications and are believed to be idiosyncratic reactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> The post-marketing safety data, including the December 2022 post-marketing safety report and the reported hepatic safety events, have been submitted to the PMDA. We may also observe hepatic-related events in our clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">It is possible that as we continue to test vonoprazan and any future product candidates in our clinical trials, or as the use of vonoprazan and any future product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If any such side effects become known later in development or upon approval, such findings may harm our business, financial condition and prospects significantly. Further, if a serious safety issue is identified in connection with use of vonoprazan commercially or in third-party clinical trials in Asia or elsewhere, such issues may adversely affect the development potential of vonoprazan or result in regulatory authorities restricting our ability to develop vonoprazan.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, if vonoprazan or any future product candidate receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">regulatory authorities may withdraw, suspend or limit approvals of such product, or seek an injunction against its manufacturer;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">we may be required to recall a product or change the way such product is administered to patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">regulatory authorities may require additional warnings on the label, such as a &#x201c;black box&#x201d; warning or a contraindication;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or similar risk management measures or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">we may be required to change the way a product is distributed or administered, conduct additional clinical trials or change the labeling of a product or be required to conduct additional post-marketing studies or surveillance;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">sales of the product may decrease significantly or the product could become less competitive; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">As a company, we have only received regulatory approval for two products, VONOPRAZAN TRIPLE PAK and VONOPRAZAN DUAL PAK, for which we have not initiated commercial launch, and may be unable to obtain additional regulatory approvals for vonoprazan or approval of any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Although we have completed our pivotal Phase 3 clinical trials for vonoprazan for treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection, erosive GERD, and non-erosive GERD, and have obtained regulatory approvals for VONOPRAZAN TRIPLE PAK and VONOPRAZAN DUAL PAK for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection, we still need to obtain regulatory approval from the FDA for VOQUEZNA for the treatment of erosive GERD and have not yet submitted our submission for regulatory approval for non-erosive GERD. Moreover, due to the formation of the nitrosamine NVP in vonoprazan drug product, we have not been able to launch either of our approved products.  As a company, we may be unable to successfully control the formation of NVP and as a result would not be able to launch our approved products or obtain approval of vonoprazan for erosive GERD.  In addition, we may not be able to obtain regulatory approval of any future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to timely obtain regulatory approvals could delay us in commercializing vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Vonoprazan and any future product candidates are subject to extensive regulation and compliance obligations, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of vonoprazan and any future product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in other foreign markets. In the United States, we are not permitted to market vonoprazan and any future product candidates until we receive the necessary regulatory approval from the FDA and in the EU, we are not permitted to market vonoprazan and any future product candidates until we receive a marketing authorization from the European Commission or competent authorities of the EU member states. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels and the ability to hire and retain key personnel. In addition, approval policies or regulations may change, and the FDA and EMA and comparable regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. For example, in February 2023, we received complete response letters from the FDA relating to our erosive GERD NDA and post approval supplement to our approved </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">NDAs, both of which address nitrosamine specifications and controls.  As a result, the approval of vonoprazan for treatment of erosive GERD and our ability to launch our approved products for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection have been delayed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or internationally, we must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for vonoprazan and any future product candidates are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for vonoprazan and any future product candidates either prior to or post- approval, or may object to elements of our clinical development program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The FDA, EMA or other comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">such authorities may disagree with the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA, EMA, or other comparable foreign regulatory agencies for approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or in clinical trials conducted by Takeda or others outside of our licensed territories, or by patients using vonoprazan or drugs similar to vonoprazan;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of such authorities that a product candidate is safe and effective for its proposed indication and that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">such authorities may not agree that the data collected from clinical trials of vonoprazan, including data collected from clinical trials conducted by Takeda and independent investigators outside of our licensed territories, and any future product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">such authorities may disagree regarding the formulation, labeling and/or the specifications of vonoprazan and any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">such authorities may find deficiencies in the manufacturing processes or facilities of Takeda, Sandoz, Evonik, Catalent or any future third-party manufacturers with which we contract for clinical and commercial supplies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#x2019; clinical data insufficient for approval; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA, EMA, and other comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy, or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the FDA, EMA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market vonoprazan and any future product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Even if we eventually receive approval of an NDA or foreign marketing application for vonoprazan and any future product candidates, the FDA or other comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including confirmatory Phase 3 clinical trials, Phase 4 clinical trials, and/or the implementation of a REMS or risk management measures, which may be required to ensure safe use of the drug after approval. The FDA or other comparable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or other comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to expand our pipeline by identifying and successfully developing vonoprazan for additional indications and formulations. We may expend our limited resources to pursue a particular indication or formulation for vonoprazan and fail to capitalize on product candidates, indications or formulations that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on specific indications and formulations for vonoprazan. As a result, we may fail to generate additional clinical development opportunities for vonoprazan for a number of reasons, including, vonoprazan may in certain indications, on further study, be shown to have harmful side effects, limited to no efficacy, or other characteristics that suggest it is unlikely to receive marketing approval and achieve market acceptance in such additional indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For example, we believe the rapid onset of action of vonoprazan may enable as needed use for the management of non-erosive GERD. However, no proton pump inhibitor has received approval from the FDA for this indication. We may be incorrect in our belief regarding the potential of vonoprazan as an as needed treatment for non-erosive GERD and any future clinical trial we conduct studying as needed dosing of vonoprazan in non-erosive GERD patients may not succeed including as a result of our design and enrollment criteria.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Furthermore, research programs to identify additional indications for vonoprazan require substantial technical, financial and human resources. We may also pursue additional formulations and packaging for vonoprazan, such as orally disintegrating tablets and other oral dosage forms for patients with difficulty swallowing, and an intravenous formulation for in-hospital applications. However, we may not successfully develop these additional formulations for chemistry-related, stability-related or other reasons. If we do not accurately evaluate the commercial potential or target market for vonoprazan or any future product candidates, we may relinquish valuable rights to that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additionally, we may pursue additional in-licenses or acquisitions of development-stage assets or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a particular product candidate, potentially resulting in a diversion of our management&#x2019;s time and the expenditure of our resources with no resulting benefit.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We enrolled patients in Europe in our erosive GERD and H. pylori trials. Additionally, we may conduct future clinical trials outside of the United States. However, the FDA and other comparable foreign regulatory authorities may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We enrolled patients in Europe in our erosive GERD and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">trials, and we may conduct one or more of our future clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States and not subject to an IND, acceptance of this data is subject to certain conditions imposed by the FDA. For example, where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the United States population and United States medical practice; the trials were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Similar requirements may apply in foreign jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For trials that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in accordance with GCP and the FDA must be able to validate the data from the clinical trial through an on-site inspection if it deems such inspection necessary. For such trials not subject to an IND, the FDA generally does not provide advance comment on the clinical protocols for the trials, and therefore there is an additional potential risk that the FDA could determine that the trial design or protocol for a non-United States clinical trial was inadequate, which could require us to conduct additional clinical trials. In addition, such foreign trials would be subject to the applicable local laws of the foreign regulatory agency and legal requirements where the trials are conducted. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA or comparable regulatory authority does not accept data from our clinical trials of vonoprazan and any future product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">additional foreign regulatory requirements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">foreign exchange fluctuations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">cultural differences in medical practice and clinical research; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">diminished protection of intellectual property in some countries.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Interim, top-line and preliminary data from clinical trials that we or others announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">From time to time, we or others, such as Takeda, may publicly disclose preliminary or top-line data from clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we or others report may differ from future results of the same clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">From time to time, we or others may also disclose interim data from clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, top-line or interim data and final data could significantly harm our business prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, vonoprazan and any future product candidates may be harmed, which could harm our business, operating results, prospects, or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The ability of the FDA and other government agencies to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, a government agency&#x2019;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the government agency&#x2019;s ability to perform routine functions. Average review times at the FDA and other government agencies have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA, may also slow the time necessary for new drugs and or modifications to approved drugs or to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the United States government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed stand inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays.  Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We rely on the Takeda License to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada. If the license agreement is terminated, we would lose our rights to develop and commercialize vonoprazan.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pursuant to the Takeda License, we have secured an exclusive license from Takeda to commercialize vonoprazan products using specified formulations for all human therapeutic uses in the United States, Europe, and Canada, and a non-exclusive license to develop and manufacture vonoprazan products anywhere in the world (subject to Takeda&#x2019;s consent as to each country) for the purposes of commercializing the vonoprazan products in the United States, Europe, and Canada.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Takeda License will continue until the expiration of the obligation to pay royalties in all countries and on all products, unless terminated earlier. We may terminate the Takeda License in its entirety without cause upon prior written notice. We and Takeda may terminate the Takeda License in the case of the other party&#x2019;s insolvency or for the other party&#x2019;s material uncured breach. Takeda may terminate the Takeda License in its entirety if we challenge the licensed patents, or if we assist any third party in challenging such patents. In addition, if any of the commercial milestones or other cash payments become due under the terms of the Takeda License, we may not have sufficient funds available to meet our obligations, which would allow Takeda to terminate the Takeda License. If the license agreement is terminated, we would lose our rights to develop and commercialize vonoprazan, which in turn would have a material adverse effect on our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our clinical trials. Any failure by a third party to conduct the clinical trials according to GCPs and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are dependent on third parties to conduct our preclinical and clinical trials, including our completed and ongoing Phase 3 clinical trial of vonoprazan. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties will play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for vonoprazan and any future product candidates that reach clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP or similar regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">CROs, investigators or other third parties may not devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed, or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable regulatory authority concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA or similar marketing application we submit by the FDA or by comparable regulatory authority. Any such delay or rejection could prevent us from commercializing vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, we may encounter challenges or delays in the future and these delays or challenges may have a material adverse impact on our business, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We currently rely on Catalent and Takeda for the manufacture of vonoprazan for clinical development and expect to rely on Catalent, Evonik and other third parties for clinical supplies for the foreseeable future, and we expect to rely on Takeda, Catalent, Evonik and other third parties to produce commercial supplies of vonoprazan drug substance and drug product, and on Sandoz for commercial supplies of amoxicillin and clarithromycin for our convenience packs. This reliance on third parties increases the risk that we will not have sufficient quantities of vonoprazan, amoxicillin, and/or clarithromycin, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We do not own or operate manufacturing facilities and have no plans to build our own clinical or commercial scale manufacturing capabilities. Pursuant to the Takeda License, we entered into a clinical manufacturing and supply agreement with Takeda for the supply of vonoprazan for our clinical trials. In addition, we entered into a commercial supply agreement with Takeda for the commercial supply of bulk drug product and/or drug substance, a commercial supply agreement with Catalent for the commercial supply of drug product, a commercial supply agreement with Evonik for the supply of drug substance, and a commercial supply and packaging agreement with Sandoz for commercial supply of amoxicillin, clarithromycin and finished convenience packs containing vonoprazan and one or both of those antibiotics. As a result, we currently rely, and expect to continue to rely, on third parties for the manufacture of vonoprazan and related raw materials for clinical development and commercial supply. If Takeda, Catalent, Evonik or Sandoz fails to fulfill its obligations under its respective supply agreement(s), or if any of the vonoprazan drug product or drug substance supplied by Takeda, Catalent or Evonik cannot be utilized due to quality or cGMP or similar concerns, adverse findings during regulatory inspections or other reasons, our development plans and commercialization of vonoprazan, if approved, could be significantly delayed or otherwise adversely affected. The facilities used by Takeda, Catalent and Evonik to manufacture vonoprazan and by Sandoz to manufacture amoxicillin and clarithromycin and to package the antibiotics and vonoprazan must be approved by the FDA and foreign regulatory authority pursuant to inspections that may be conducted after we submit marketing authorizations to the FDA and comparable foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, Takeda, Catalent, Evonik and Sandoz for compliance with applicable cGMP or similar requirements. If Takeda, Catalent, Evonik, Sandoz, or any other third-party manufacturer we contract with in the future, cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, including requirements related to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">manufacturing of high potency compounds, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over Takeda&#x2019;s, Catalent&#x2019;s, Evonik&#x2019;s, Sandoz&#x2019;s, or any other third-party manufacturer&#x2019;s ability to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve of facilities of the third-party manufacturer for the manufacture of vonoprazan or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market vonoprazan, if approved. For example, in June 2020, the FDA issued a warning letter to Takeda following a routine inspection of aseptic (sterile) drug product manufacturing at Takeda&#x2019;s manufacturing facility located in Hikari, Yamaguchi, or the Hikari Facility. Although it is not an aseptic product, Takeda also manufactures vonoprazan drug substance and drug product at the Hikari Facility. The warning letter indicated that the FDA was not satisfied with Takeda&#x2019;s response to an FDA Form 483 issued to Takeda following the inspection and cited significant violations of cGMP for finished aseptic pharmaceuticals. Due to the issues relating to the Hikari Facility, we did not include the Hikari Facility, as a contract manufacturing site in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">NDAs we submitted to FDA in September 2021. In October 2021, the FDA revised the inspection classification of the Hikari Facility to Voluntary Action Indicated, or VAI. Takeda has reported that this revision means the FDA determined that the conditions in the warning letter dated June 2020 have been sufficiently addressed. We have not experienced any clinical supply constraints to date as a result of the issues at the Hikari Facility, and we currently do not expect these issues will have an effect on our ongoing or future clinical trials or commercial supplies. Our failure, or Takeda&#x2019;s, Catalent&#x2019;s, Evonik&#x2019;s, Sandoz&#x2019;s or any other third-party manufacturer&#x2019;s failure, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. Furthermore, Takeda may choose to prioritize the manufacture of vonoprazan for its markets over the manufacture of vonoprazan for our licensed markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our or Takeda&#x2019;s, Catalent&#x2019;s, Evonik's or Sandoz&#x2019;s failure, or the failure of any future third-party manufacturer, to execute on our manufacturing requirements, to do so on commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">an inability to initiate and continue clinical trials of vonoprazan or any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">delay in submitting regulatory applications, or receiving marketing approvals, for vonoprazan and any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">requirements to cease development or to recall batches of vonoprazan and any future product candidates; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">in the event of approval to market and commercialize vonoprazan or any future product candidates, an inability to meet commercial demands for vonoprazan or any future product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Reliance on third-party manufacturers entails additional risks, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">breach of the manufacturing agreement by the third party;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">failure to manufacture our product according to our specifications;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">failure to manufacture our product according to our schedule or at all;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. Moreover, there may be a limited number of manufacturers that operate under cGMP or similar regulations and that might be capable of manufacturing for us.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Any performance failure on the part of Takeda, Catalent, Evonik, Sandoz or any future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of vonoprazan and any future product candidates. If Takeda, Catalent, Evonik, or Sandoz cannot perform as agreed, we may be required to replace them and we may be unable to replace them on a timely basis or at all. Further, Takeda, Catalent, Evonik, Sandoz and any other third-party manufacturers we may use may experience manufacturing or shipping difficulties due to resource constraints or as a result of natural disasters, labor disputes, unstable political environments, or public health emergencies such as the COVID-19 pandemic or ongoing hostilities in the Ukraine. If Takeda, Catalent, Evonik, Sandoz or other third-party manufacturers were to encounter any manufacturing or shipping difficulties or delays due to these factors, our ability to provide vonoprazan to patients in clinical trials, or to provide product for treatment of patients if approved, would be jeopardized.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of vonoprazan or any future product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our reliance on third parties, including Takeda, Catalent and Evonik, requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Because we rely, and expect to continue to rely on Takeda, Catalent and Evonik to manufacture vonoprazan and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#x2019;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may seek to enter into collaborations, licenses and other similar arrangements and may not be successful in doing so, and even if we are, we may not realize the benefits of such relationships.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We may seek to enter into collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of vonoprazan and any future product candidates, due to capital costs required to develop or commercialize vonoprazan and any future product candidates or manufacturing constraints. We may not be successful in our efforts to establish such collaborations for vonoprazan and any future product candidates because vonoprazan and any future product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view vonoprazan and any future product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time consuming and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. Following a strategic transaction or license, we may not achieve an economic benefit that justifies such transaction.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed, the safety of a product candidate is questioned or sales of an approved product candidate are unsatisfactory.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, any potential future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of vonoprazan and any future product candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to vonoprazan or any future product candidates, could delay the development and commercialization of vonoprazan or any future product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risks Related to Commercialization of Vonoprazan and Any Future Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">With respect to our approved products, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, and, if approved, VOQUEZNA and any future product candidates, the FDA, EMA or other comparable regulatory authority may impose significant restrictions on a product&#x2019;s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA and comparable regulatory authorities may also require a REMS or similar risk management measures as a condition of approval of any additional products containing vonoprazan or future product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, for our approved products or future products that obtain approval, particularly following commercial launch of any such products, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and similar requirements and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">refusal by the FDA or comparable foreign regulatory authority to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of our products; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize products containing vonoprazan and any future product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of additional products containing vonoprazan and any future product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, may be subject to enforcement action, and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For instance, the EU has adopted the Clinical Trials Regulation, or CTR, in April 2014, which became applicable on 31 January 2022. The CTR is directly applicable in all EU member states, repealing the current Clinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Trials Directive. The CTR harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which will notably contain a centralized EU portal and database.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">It is currently unclear to what extent the United Kingdom, or UK, will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). A decision by the UK not to closely align its regulations with the new approach that will be adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization in the EU for our product candidates on the basis of clinical trials conducted in the UK.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additionally, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. A proposal for revision of several legislative instruments related to medicinal products (potentially revising the duration of regulatory exclusivity, eligibility for expedited pathways, etc.) is expected to be adopted by the European Commission by the end of 2022. The proposed revisions, once they are agreed and adopted by the European Parliament and European Council (not expected before the end of 2024) may have a significant impact on the biopharmaceutical industry in the long term.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">The commercial success of vonoprazan or any future product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payers and others in the medical community.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vonoprazan and any future product candidates may not be commercially successful. The commercial success of vonoprazan or any future product candidates, if approved, will depend significantly on the broad adoption and use of such product by physicians and patients for approved indications. The degree of market acceptance of vonoprazan or any future products, if approved, will depend on a number of factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">demonstration of clinical efficacy and safety compared to other more-established products;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the indications for which vonoprazan or any future product candidates are approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling or comparable approved labeling;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">acceptance of a new drug for the relevant indication by healthcare providers and their patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage or adequate reimbursement;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">any restrictions on the use of our products, and the prevalence and severity of any adverse effects;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">potential product liability claims;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the timing of market introduction of our products as well as competitive drugs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the effectiveness of our or any of our potential future collaborators&#x2019; sales and marketing strategies; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">unfavorable publicity relating to the product.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If either of our current approved products, and if approved, any additional product containing vonoprazan or any future product candidate, does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payers or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payers regarding the benefits of our products may require significant resources and may never be successful.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Takeda has the right to develop and commercialize vonoprazan outside of the United States, Europe, and Canada and has received marketing approval for vonoprazan in certain countries in Asia and Latin America as well as in Russia. We have little or no control over Takeda&#x2019;s commercialization activities with respect to vonoprazan outside of our licensed territories even though those activities could impact our ability to successfully commercialize vonoprazan. For example, Takeda can make statements or use promotional materials with respect to vonoprazan outside of our licensed territories that are inconsistent with our positioning of the product in the United States, Europe, and Canada, and could sell vonoprazan in foreign countries at prices that are dramatically lower than the prices we would charge in our licensed territories. These activities and decisions, while occurring outside of our licensed territories, could harm our commercialization strategy. In addition, product recalls or safety issues with vonoprazan outside our licensed territories could result in serious damage to the brand and impair our ability to successfully market vonoprazan in our licensed territories.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products such as our currently approved products, and any additional products containing vonoprazan and any future product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#x2019;s approved labeling. For example, the FDA has approved both VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection in adults, and we are not currently permitted to promote these products for any other uses, unless and until such uses are approved by the FDA. For any product for which we have obtained a marketing approval, however, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of products containing vonoprazan or any future product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">The successful commercialization of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, or if approved, VOQUEZNA or any future product candidates, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs, such as Medicare and Medicaid, private health insurers and other third-party payers are essential for most patients to be able to afford prescription medications such as VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, or, if approved, VOQUEZNA or any future product candidates. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third-party payers will have an effect on our ability to successfully commercialize those products. Even if we obtain coverage for a given product by a third-party payer, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Third-party payers increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payers may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payer may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payers may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">There is significant uncertainty related to third-party payer coverage and reimbursement of newly approved products. In the United States, third-party payers, including private and governmental payers, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payers may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payers will decide with respect to the coverage and reimbursement for our products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payers and other governmental payers develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payers in the United States. Therefore, coverage and reimbursement for products can differ significantly from payer to payer. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payers in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">If following commercialization of products containing vonoprazan (or any future product candidates, if approved) we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If we successfully commercialize products containing vonoprazan and, if approved, any future product candidates, we will likely participate in governmental programs, such as Medicaid, that impose extensive drug price reporting and payment obligations on pharmaceutical manufacturers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Medicaid is a joint federal and state program that is administered by the states for low-income and disabled beneficiaries. Medicare is a federal program that is administered by the federal government covering individuals age 65 and over as well as those with certain disabilities. Under the Medicaid Drug Rebate Program, or MDRP, as a condition of having federal funds being made available to the states for covered outpatient drugs under Medicaid, pharmaceutical manufacturers must enter into an agreement with the Secretary of Health and Human Services to pay a rebate to state Medicaid programs for each unit of covered outpatient drug dispensed to a Medicaid beneficiary and paid for by the state Medicaid program. Medicaid drug rebates are based on pricing data that pharmaceutical manufacturers report on a monthly and quarterly basis to the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, which is the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the average manufacturer price, or AMP, for each drug and, in the case of innovator products, the Best Price, or BP, which represents the lowest price available from the manufacturer to any entity in the United States in any pricing structure, calculated to include all applicable sales and associated rebates, discounts and other price concessions. If a manufacturer becomes aware that its MDRP government price reporting submission for a prior quarter was incorrect or has changed as a result of recalculation of the pricing data, the manufacturer must resubmit the corrected data for up to three years after those data originally were due. If a manufacturer fails to provide information timely or is found to have knowingly submitted false information to the government, the manufacturer may be subject to civil monetary penalties and other sanctions, including termination from the MDRP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Federal law requires that any company that participates in the MDRP also participate in the Public Health Service&#x2019;s 340B drug pricing program, or the 340B program, in order for federal funds to be available for the manufacturer&#x2019;s drugs under Medicaid. The 340B program is administered by the Health Resources and Services Administration, or HRSA, and requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B &#x201c;ceiling price&#x201d; for the manufacturer&#x2019;s covered drugs used in an outpatient setting. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low&#x2011;income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. Manufacturers must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B&#x2011;eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if passed, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In order to be eligible to have drug products paid for with federal funds under Medicaid and purchased by certain federal agencies and grantees, a manufacturer must also participate in the U.S. Department of Veterans Affairs, or VA, Federal Supply Schedule, or FSS, pricing program. Under the VA/FSS program, a manufacturer must report the Non-Federal Average Manufacturer Price, or Non-FAMP, for its covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These federal agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). The manufacturer must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If a manufacturer participating in the FSS program fails to provide timely information or is found to have knowingly submitted false information, the manufacturer may be subject to civil monetary penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered by manufacturers in taking such increases, wholesale acquisition cost disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by pharmaceutical manufacturers, governmental or regulatory agencies, and the courts, which can change and evolve over time. Such pricing calculations and reporting, along with any necessary restatements and recalculations, could increase costs for complying with the laws and regulations governing the MDRP and other governmental programs, and under the MDRP could result in an overage or underage in Medicaid rebate liability for past quarters. Price recalculations under the MDRP also may affect the ceiling price at which manufacturers are required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of ASP, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid for our covered outpatient drugs. We cannot assure you that our submissions will not be found to be incomplete or incorrect.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with vonoprazan. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of GI diseases for which we may attempt to develop vonoprazan or any future product candidates. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling patients for clinical trials and in identifying and in-licensing new product candidates. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We expect that VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection, and, if approved, VOQUEZNA, for the treatment of erosive GERD, will primarily compete with generic PPIs marketed by multiple pharmaceutical companies in both the prescription and OTC markets. Additionally, in March 2020, RedHill Biopharma Ltd. launched Talicia, a co-formulated capsule comprising generic omeprazole, amoxicillin, and rifabutin for the treatment of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are aware of other PCABs in development in the United States, as well as a number of other PCABs in territories outside of the United States that if developed and approved in our territories may compete with vonoprazan. In the United States, Neurogastrx previously announced its intention to commence a Phase 3 erosive GERD trial for fexuprazan, under an exclusive license from Daewoong Pharmaceutical Co., Ltd., or Daewoong.  In addition, Cinclus Pharma AG, or Cinclus, received QIDP designation for linaprazan glurate in combination with antibiotics for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection, completed a Phase 2 dose selection study for erosive GERD in November 2022, and plans to initiate Phase 3 studies in 2023 for the treatment of GERD and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection.  Finally, Sebela Pharmaceuticals, which acquired development and commercialization rights in United States and Canada to tegoprazan from HK inno.N, a South Korean company, has initiated two Phase 3 studies in the United States, one for non-erosive GERD and the other for healing and maintenance of healing of erosive GERD.  The estimated completion date for these studies is May 2024 and December 2024, respectively. Outside the United States, in 2022 Daewoong launched fexuprazan in South Korea for the treatment of erosive GERD under the brand name Fexuclue, has submitted applications for regulatory approval in additional countries in Asia and Latin America, and has out-licensed rights to develop fexuprazan in China to Shanghai Haini, a subsidiary of China&#x2019;s Yangtze River Pharmaceutical Group. Also outside the United States, revaprazan is marketed by Yuhan Corporation in South Korea, and tegoprazan is marketed by HK inno.N in South Korea, is also marketed in China and Indonesia, and is currently in development by RaQualia Pharma, Inc. in Japan. Additionally, Jeil Pharm has initiated a Phase 3 trial in South Korea of its PCAB candidate, JP-1366, in erosive GERD, and Cinclus&#x2019; linaprazan glurate has completed a Phase 2 clinical trial in Europe. To our knowledge, none of these compounds have demonstrated superiority to PPIs in a Phase 3 clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additionally, we are aware of several clinical-stage PPIs in territories outside of the United States that if developed and approved in our licensed territories may compete with vonoprazan. These include Dexa Medica&#x2019;s DLBS-2411, currently launched in the Philippines and in Phase 3 in Indonesia, Sihuan Pharmaceutical&#x2019;s anaprazole, currently in Phase 3 in China, and Eisai&#x2019;s azeloprazole, currently in a Phase 2 in China.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In July 2012, the Food and Drug Administration Safety and Innovation Act was passed, which included the GAIN Act. The GAIN Act is intended to provide incentives for the development of new, qualified infectious disease products. In December 2016, the 21st Century Cures Act was passed, providing additional support for the development of new infectious disease products. These incentives may result in more competition in the market for new antibiotics and may cause pharmaceutical and biotechnology companies with more resources than we have to shift their efforts towards the development of product candidates that could be competitive with vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we initial commercial launch of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, or if approved, VOQUEZNA or any future product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing vonoprazan or any future product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">If the market opportunities for vonoprazan or any future products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The precise incidence and prevalence for all the conditions we aim to address with vonoprazan or any future product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment of vonoprazan or any future product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across vonoprazan and any future product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of vonoprazan and any future product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of vonoprazan and any future product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We currently have a limited marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have limited internal marketing, sales or distribution capabilities, and we have never commercialized a product. In order to initiate commercial launch for VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, or, if approved, VOQUEZNA or any future product candidates, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We plan to independently commercialize vonoprazan in the United States by building a leading specialty gastroenterology commercial infrastructure to support the adoption of vonoprazan and we plan to seek one or more partners with existing commercial infrastructure and expertise in Europe and Canada. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a marketing and sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing vonoprazan or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our future growth may depend, in part, on our ability to operate in foreign markets, particularly Europe and Canada, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our future growth may depend, in part, on our ability to develop and commercialize vonoprazan and any future product candidates in foreign markets, particularly Europe and Canada. We are not permitted to market or promote vonoprazan and any future product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for vonoprazan or any future product candidates. To obtain separate regulatory approval in any other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of vonoprazan and any future product candidates. If we obtain regulatory approval of vonoprazan and any future product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">different regulatory requirements for approval of drugs in foreign countries;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the existence of additional third-party patent rights of potential relevance to our business;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">economic weakness, including inflation, public health emergencies or political instability in particular foreign economies and markets;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling internationally;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">workforce uncertainty in countries where labor unrest is common;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities internationally; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risks Related to Our Business Operations and Industry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, VOQUEZNA or any future product candidates, which may change from time to time;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">coverage and reimbursement policies with respect to VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, and, if approved, VOQUEZNA or any future product candidates, and potential future drugs that compete with such products, if approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the cost of manufacturing vonoprazan or any future product candidates, which may vary depending on the quantity of production and the terms of our agreements with Takeda, Catalent, Evonik, Sandoz and any future third-party manufacturers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war, such as the ongoing hostilities in the Ukraine, and terrorism, or natural disasters such as earthquakes, typhoons, floods and fires or public health emergencies or pandemics such as the ongoing COVID-19 pandemic;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the timing and amount of the milestone or other payments we will be required to pay to Takeda pursuant to the Takeda License;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the level of demand for any approved products, which may vary significantly;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the timing and success or failure of preclinical studies or clinical trials for vonoprazan or any future product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our business is subject to risks arising from epidemic diseases, such as the ongoing COVID-19 pandemic.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A public health pandemic, such as COVID-19, has the potential to impact worldwide economic activity and poses the risk that we or our employees, contractors, including our CROs, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. In March 2020, due to efforts to combat the COVID-19 pandemic, we announced a temporary pause in randomization of new patients in our Phase 3 trials and did not recommence randomizations in either trial until June 2020. While it is not possible at this time to estimate the full impact that COVID-19 or a future public health pandemic could have on our business, the measures taken by the governments of countries affected could, in addition to disrupting our clinical trials, disrupt the supply chain and the manufacture or shipment of drug substance and finished drug product of vonoprazan for use in our clinical trials or in commercial distribution, which could delay our ongoing clinical trials and increase development costs, or impair our ability to successfully commercialize vonoprazan following regulatory approval, and in either case have a material adverse effect on our business, financial condition and results of operations. The COVID-19 pandemic and mitigation measures had had an adverse impact on global economic conditions and mitigation measures regarding a future public health pandemic could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which COVID-19 or a future public health pandemic impacts our results will depend on future developments that are highly uncertain and cannot be predicted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our indebtedness may limit our flexibility in operating our business and adversely affect our financial health and competitive position, and all of our obligations under our indebtedness are secured by substantially all of our assets, excluding our intellectual property and certain other assets. If we default on these obligations, our lenders could foreclose on our assets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In September 2021, we entered into the Loan Agreement with Hercules. We borrowed $100.0 million at the inception of the Loan Agreement and may be eligible to borrow up to an additional $100.0 million. All obligations under the Loan Agreement are secured by a first priority lien on substantially all of our assets, including intellectual property and certain other assets. As a result, if we default on any of our obligations under the Loan Agreement, Hercules could foreclose on its security interest and liquidate some or all of the collateral, which would harm our business, financial condition and results of operations and could require us to reduce or cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In order to service our current indebtedness and any additional indebtedness we may incur in the future, we need to generate cash from our operating activities or other financings. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. Our business may not be able to generate sufficient cash flow from operations, and future borrowings or other financings may not be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are required to use cash from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital or other general corporate purposes, we will be less able to plan for, or react to, changes in our business, industry and in the economy generally. This could place us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Loan Agreement contains customary affirmative and negative covenants that limit our ability to engage in certain transactions that may be in our long-term best interest. The affirmative covenants include, among others, covenants requiring us to maintain certain levels of cash subject to a control agreement in favor of Hercules, and commencing on November 15, 2023, certain levels of trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding our operating accounts. The negative covenants include, among others, limitations on our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">While we believe we are currently in compliance with the covenants contained in the Loan Agreement, we may breach these covenants in the future. Our ability to comply with these covenants may be affected by events and factors beyond our control. In the event that we breach one or more covenants, the lenders may choose to declare an event of default and require that we immediately repay all amounts outstanding under the applicable agreement, terminate any commitment to extend further credit and foreclose on the collateral. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our Revenue Interest Financing Agreement could limit cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In May 2022, we entered into a Revenue Interest Financing Agreement with the Initial Investors pursuant to which we can receive up to $260 million in funding from the Initial Investors, and in October 2022, we entered into the Joinder Agreement under which we can receive up to $40 million from the Additional Investor, bringing the total funding available under the Revenue Interest Financing Agreement to up to $300 million.  Under the terms of the Revenue Interest Financing Agreement and Joinder Agreement, we received $100 million at the initial closing and can receive an additional $175 million upon FDA approval of vonoprazan for treatment of erosive GERD on or before March 31, 2024. In addition, we are eligible for $25,000,000 in additional funding for achievement of a sales milestone.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under the Revenue Interest Financing Agreement, the investors are entitled to receive a 10% royalty on net sales of products containing vonoprazan. The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and if we receive FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with non-erosive GERD. The investors&#x2019; right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for erosive GERD regulatory approval is made, we have the right to make a cap payment equal to 200% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If the investors have not received aggregate payments of at least 100% of the Investment Amount by December 31, 2028, and at least 200% of the Investment Amount by December 31, 2037, each a Minimum Amount, then we will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pursuant to the Revenue Interest Financing Agreement, we also agreed to specified affirmative and negative covenants, including covenants to use commercially reasonable efforts to promote products containing vonoprazan in the United States and covenants requiring us to maintain certain levels of cash. The Revenue Interest Financing Agreement also contains representations and warranties, other covenants, indemnification obligations, and other provisions customary for transactions of this nature.  In the event of an event of default under the Revenue Interest Financing Agreement, the investors may be entitled to foreclose on the pledged collateral which includes the applicable royalty under the Royalty Interest Financing Agreement from net sales of product containing vonoprazan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We are dependent on the services of our current management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our current senior management team and our development personnel. The loss of services of any of these individuals or personnel could delay or prevent the successful development of our product pipeline, completion of our ongoing clinical trials, initiation or completion of future clinical trials, or the commercialization of vonoprazan or any other future product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#x201c;key person&#x201d; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We will continue to expand and need to effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have recently substantially increased the size of our organization, and we may encounter difficulties in managing our growth and expanding our operations successfully.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have substantially increased our organization from seventy-three full-time employees in December 2021 to one hundred and twelve full-time employees as of December 31, 2022. As we continue development and pursue the potential commercialization of vonoprazan and any future product candidates, as well as function as a public company, we will continue to expand our marketing, sales, financial, regulatory, and manufacturing capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize vonoprazan and any future product candidates and to compete effectively will depend, in part, on our ability to manage our recent substantial growth and any future growth effectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We are subject to various foreign, federal, and state healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payers, patient organizations and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include, but are not limited to:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the U.S. civil and criminal federal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to certain payments and other &#x201c;transfers of value&#x201d; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) , certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives)and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers, or by the patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We may also be subject to additional regulation in the conduct of our business. For example, we may be subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Enacted and future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize vonoprazan and any future product candidates and may affect the prices we may set.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, was enacted in the United States. Among the provisions of the Affordable Care Act of importance to our potential product candidates, the Affordable Care Act includes:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">an extension of a manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Since its enactment, there have been judicial and political challenges to certain aspects of the Affordable Care Act. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. At the federal level, such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.   Most recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The likelihood of implementation of these and other reform initiatives is uncertain. In the coming years, additional legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies and the success of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third party payers and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for vonoprazan and any future product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We expect that these healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize vonoprazan and any future product candidates, if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We and any of our third-party manufacturers or suppliers will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Although we maintain workers&#x2019; compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work- related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical trials of vonoprazan and any future product candidates and will face an even greater risk if we commercialize vonoprazan or, following approval, any future product candidates. For example, we may be sued if vonoprazan or any future product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">decreased demand for our products;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">costs to defend the related litigation;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a diversion of management&#x2019;s time and our resources;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">significant negative financial impact;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the inability to commercialize vonoprazan and any future product candidates; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a decline in our stock price.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our inability to maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, and, if approved, VOQUEZNA and additional products we may develop. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. As a result of receiving marketing approval for, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, we have expanded our insurance coverage to include the commercialization of these products as well as, if approved, vonoprazan; however, we may be unable to continue to obtain this liability insurance on commercially reasonable terms and such insurance may be insufficient to cover our exposure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We and others, including any of our potential future collaborators, will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If we or any of our potential future collaborators are successful in commercializing VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, or, if approved, VOQUEZNA or any future product candidates, the FDA and foreign regulatory authorities would require that we and Takeda (with respect to products containing vonoprazan) and any of our current or potential future collaborators, report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We, Takeda and any of our potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we, Takeda or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval of future products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, California enacted the CCPA on June 28, 2018, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. It provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the CPRA recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia, Connecticut, Colorado and Utah and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Furthermore, the FTC and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#x2019; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In Europe, GDPR, went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#x20ac;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. In addition, the GDPR increases the scrutiny of transfers of personal data from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#x201c;adequate&#x201d; data protection laws. In 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States called the Privacy Shield, but in July 2020 the Court of Justice of the EU, or the CJEU, limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on use of the standard contractual clauses, or SCCs. While the CJEU upheld the adequacy of the SCCs, it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the SCCs must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. The CJEU went on to state that if a competent supervisory authority believes that the SCCs cannot be complied with in the destination country and the required level of protection cannot be secured by other means, such supervisory authority is under an obligation to suspend or prohibit that transfer. The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. The revised SCCs apply only to the transfer of personal data outside of the EEA and not the UK; the UK&#x2019;s Information Commissioner&#x2019;s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. The new SCCs apply only to the transfer of personal data outside of the EEA and not the United Kingdom; the United Kingdom&#x2019;s Information Commissioner&#x2019;s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our internal computer systems, or those of any of our CROs, manufacturers, service providers, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The United States federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data. Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other service providers, contractors, consultants and collaborators are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the increased number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. If such an event were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as GDPR), it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture vonoprazan and any future product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development and commercialization of vonoprazan and any future product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate: (i) the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies, (ii) manufacturing standards, including cGMP and similar requirements, or (iii) federal and state healthcare, security, fraud and abuse laws, data privacy and security laws, and other similar non-U.S. laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#x2019;s Office of Foreign Assets Controls, and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, clinical research organizations, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We have engaged, and may engage in the future, third parties for clinical trials outside of the United States, and may engage third parties to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, clinical research organizations, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of intellectual property, products or technologies, similar to our approach in in-licensing and acquiring our current product candidates. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although we may not undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for vonoprazan and any future product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or vonoprazan or any future product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to vonoprazan or any future product candidates, proprietary technologies and their uses that are important to our business. We do not currently own any issued patents or pending patent applications. We also seek to protect our proprietary position by acquiring or in-licensing relevant issued patents or pending patent applications from third parties. We have in-licensed from Takeda a number of United States, European, and Canadian patents and patent applications relating to the compound vonoprazan as well as the use and manufacture of vonoprazan products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our future patent applications or the patent applications of our current and future licensors will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around or invalidated by third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to vonoprazan and any future product candidates could have a material adverse effect on our financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We cannot be certain that the claims in our licensor&#x2019;s U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our licensor&#x2019;s issued patents will not be found invalid or unenforceable if challenged.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting vonoprazan and any future product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">patent applications may not result in any patents being issued;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell vonoprazan and any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The patent prosecution process is also expensive and time consuming, and we and our licensor may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensor will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances such as under the Takeda License, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, including our rights in vonoprazan licensed from Takeda, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are a party to the Takeda License under which we are granted rights to intellectual property that are important to our business and we may enter into additional license agreements in the future with other third parties. The Takeda License imposes, and we expect that any future license agreements where we in-license intellectual property, will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. Additionally, if a future license agreement includes a sublicense from a third party who is not the original licensor of the intellectual property at issue, then we must rely on our direct licensor to comply with its obligations under the primary license agreements under which such licensor obtained rights in the applicable intellectual property, where we may have no relationship with the original licensor of such rights. If such a licensor fails to comply with its obligations under its upstream license agreement, the original third-party licensor may have the right to terminate the original license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize vonoprazan and any future product candidates incorporating the relevant intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We may need to obtain further licenses from third parties to advance our research or allow commercialization of vonoprazan and any future product candidates, and we cannot provide any assurances that third-party patents do not exist which might be enforced against vonoprazan and any future product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our right to sublicense patents and other rights to third parties;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of vonoprazan and any future product candidates, and what activities satisfy those diligence obligations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our right to transfer or assign the license; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, if we choose to sublicense or assign to any third parties our rights under our existing license agreement with Takeda with respect to any licensed product, we may be required to wait for a certain period or until the occurrence of certain funding or development milestones.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our in-licensed pending and future patent applications may not result in patents being issued which protect vonoprazan or any future product candidates or which effectively prevent others from commercializing competitive product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own in the future or license currently issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any future patents that we own or license, now or in the future, may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether vonoprazan or any future product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our future patents or the patents of our current and future licensors by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our future patents or the patents of our current and future licensors may not cover vonoprazan or any future product candidates or may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our predecessors and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our in-licensed patents and patent applications has been found. There is also no assurance that there is not prior art of which we, our predecessors or licensors are aware, but which we do not believe affects the validity or enforceability of a claim in our in-licensed patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize vonoprazan or any future product candidates and compete directly with us, without payment to us. It is possible that defects of form in the preparation or filing of our or our current and future licensors&#x2019; patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution, or enforcement of our future patents or future patent applications or our current and future licensors&#x2019; patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Any loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of vonoprazan or any future product candidates, which could materially and adversely impact our business. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our future patents and future patent applications or the patents and patent applications of our current and future licensors is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">The patent protection and patent prosecution for vonoprazan or any future product candidates may be dependent on third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We may rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under certain current and future license agreements, such as the Takeda License. Under such arrangements, we may not have primary control over these activities for certain of licensed patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. In addition, our current and future licensors may not be fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, which could compromise such patent rights. We may in the future enter into license agreements where the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering vonoprazan or any future product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, even where we have the right to control prosecution of patent applications or enforcement of patents we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over such activities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Third parties may retain certain rights to the technology that they license to us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. For example, under the Takeda License, Takeda retained the rights to the inventions in all countries other than the United States, Europe, and Canada. Takeda also retained the right to develop certain drug products that contain vonoprazan where vonoprazan is not the only active pharmaceutical ingredient. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">others may be able to develop products that are similar to vonoprazan or any future product candidates but that are not covered by the claims of the patents that we own in the future or license;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">we or our current and future licensors or predecessors might not have been the first to make the inventions covered by the issued patents or patent applications that we own in the future or license;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">we or our current and future licensors or predecessors might not have been the first to file patent applications covering certain of the claimed inventions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">it is possible that the pending patent applications we own or license will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">issued patents that we own in the future or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import vonoprazan and any future product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/ or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that vonoprazan and any future product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of vonoprazan and any future product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that vonoprazan and any future product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">result in costly litigation that may cause negative publicity;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">divert the time and attention of our technical personnel and management;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">cause development delays;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">prevent us from commercializing vonoprazan and any future product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">subject us to significant liability to third parties; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Although no third party has asserted a claim of patent infringement against us as of the date of this annual report, others may hold proprietary rights that could prevent vonoprazan and any future product candidates from being marketed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to vonoprazan and any future product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop vonoprazan and any future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign vonoprazan and any future product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing vonoprazan and any future product candidates, which could harm our business, financial condition and operating results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to vonoprazan and any future product candidates through acquisitions and in-licenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Because our development programs may in the future require the use of proprietary rights held by other third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for vonoprazan and any future product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our future patents or the patents of our current and future licensors, which could be expensive, time consuming and unsuccessful. Further, our future issued patents or the patents of our current and future licensors could be found invalid or unenforceable if challenged in court.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Competitors may infringe our intellectual property rights or those of our current and future licensors. To prevent infringement or unauthorized use, we and/or any such licensors may be required to file infringement claims, which can be expensive and time consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our current and future licensors were to initiate legal proceedings against a third party to enforce a patent directed at vonoprazan and any future product candidates, the defendant could counterclaim that our patent or the patent of our current or future licensor is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement, or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our future patents and future patent applications or those of our current and future licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Derivation or interference proceedings provoked by third parties or brought by us or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our future patents or future patent applications or those of our current and future licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring vonoprazan and any future product candidates to market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our future patent applications or those of our current and future licensors and the enforcement or defense of our future issued patents or those of our current and future licensors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#x201c;first inventor to file&#x201d; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we may not be certain that we or our current and future licensors are the first to either (1) file any patent application related to vonoprazan and any future product candidates or (2) invent any of the inventions claimed in the patents or patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our future patent applications or those of our current and future licensors and the enforcement or defense of our future issued patents or those of our current and future licensors, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In 2012, the European Patent Package, or EU Patent Package, regulations were passed with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court, or UPC, for litigation involving European patents. Implementation of the EU Patent Package will likely occur in the first half of 2023. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, will by default automatically fall under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the EU Patent Package as currently proposed, we will have the right to opt our patents out of the UPC over the first seven years of the court&#x2019;s existence, but doing so may preclude us from realizing the benefits of the new unified court.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our future patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. Evolving judicial interpretation of patent law could also adversely affect our business. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce the existing licensed patents and the patents we might obtain or license in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our future patents, the patents of our current and future licensors, or other intellectual property</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We may also be subject to claims that former employees or other third parties have an ownership interest in our future patents, the patents of our current and future licensors or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on vonoprazan and any future product candidates for an adequate amount of time.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering vonoprazan and any future product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting vonoprazan and any future product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension for vonoprazan and any future product candidates, our business may be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA marketing approval of vonoprazan and any future product candidates, one or more of our U.S. patents or those of our current and future licensors, may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch- Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of vonoprazan and any future product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout our licensed territories.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Although we have issued patents and pending patent applications in the United States and certain other countries in which we intend to commercialize our products, filing, prosecuting and defending patents in all relevant countries throughout our licensed territories could be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with vonoprazan or any future product candidates, and our patents, the patents of our current and future licensors or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our intellectual property rights or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our future patents or the patents of our current and future licensors at risk of being invalidated or interpreted narrowly and our future patent applications or the patent applications of our current and future licensors at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our future patents and/or future applications and those of our current and future licensors. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to protect our trade secret information may be jeopardized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of vonoprazan and any future product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Any collaboration arrangements that we have or may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators and partners. Under the Takeda License, for example, Takeda has certain obligations with respect to assisting with the transition of information and materials to us as well as providing clinical and commercial supply of the vonoprazan product. Collaborations and partnerships are subject to numerous risks, which may include that:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future products;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a collaborator&#x2019;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#x201c;march-in&#x201d; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We may acquire or license in the future intellectual property rights that have been generated through the use of U.S. government funding or grant. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#x201c;march-in rights&#x201d;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">The trading price of the shares of our common stock has been, and is likely to continue to be, highly volatile, and purchasers of our common stock could incur substantial losses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price at which they paid. Our common stock has a limited trading history and the market price has fluctuated widely, and may in the future fluctuate widely, depending upon many factors such as those discussed in this &#x201c;Risk Factors&#x201d; section and many others, some of which are beyond our control, including the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a relatively low-volume trading market for our shares of common stock that could cause trades of small blocks of shares to have a significant impact on the price of our shares of common stock;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#x2019; reports or recommendations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">establishment of short positions by holders or non-holders of our common stock;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">an inability to obtain additional funding;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">sales of our stock by insiders and stockholders, including Takeda;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our ability to enroll patients in our ongoing and any future clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">results of our clinical trials and preclinical studies, the results of clinical trials conducted by Takeda and others for vonoprazan, and the results of trials of our competitors or those of other companies in our market sector;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">regulatory approval of vonoprazan and any future product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">any termination or loss of rights under the Takeda License;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">regulatory developments in the United States and foreign countries;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">changes in the structure of healthcare payment systems, especially in light of reforms to the U.S. healthcare system;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the success or failure of our efforts to acquire, license or develop additional product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">innovations or new products developed by us or our competitors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">manufacturing, supply or distribution delays or shortages;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">achievement of expected product sales and profitability;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">general economic, industry and market conditions, public health emergencies or other events or factors, many of which are beyond our control;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">additions or departures of key personnel;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">intellectual property, product liability or other litigation against us;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">changes in accounting standards, policies, guidelines, interpretations or principles.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies&#x2019; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#x2019;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval. Furthermore, many of our current directors were appointed by our principal stockholders.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our executive officers, directors and greater than 5% stockholders, in the aggregate, own a majority of our outstanding common stock. As a result, such persons acting together have the ability to control or significantly influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, under the terms of the Loan Agreement, we are prohibited from paying any cash dividends without the consent of the lenders. Any return to stockholders will therefore be limited to the appreciation of their stock. Shares of our common stock may not appreciate in value or even maintain the price at which stockholders have purchased their shares.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders, including Takeda, in the public market could cause our stock price to fall.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, up to 8,780,741 shares of common stock that are either subject to outstanding options, warrants or other rights or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, exercise limitations, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Further, we filed a registration statement, which became effective on November 17, 2020, registering the resale of up to 14,499,416 shares of common stock held by Takeda and Frazier Life Sciences IX, L.P., or Frazier, including all shares of our common stock underlying the Takeda Warrant, which warrant has since been exercised in full. As a result of the registration statement, Takeda and Frazier are each able to freely sell some or all of their shares of our common stock. Any sales by these stockholders could have a material adverse effect on the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting company may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of our IPO. However, if certain events occur prior to the end of such five-year period, including if we become a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act, our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three- year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; disclosure;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements, unless the SEC, determines the new rules are necessary for protecting the public;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">reduced disclosure obligations regarding executive compensation; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Investors may find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">an exclusive forum provision providing that the federal district courts will be the exclusive forum for actions and proceedings a cause of action arising under the Securities Act of 1933, as amended, and that the Court of Chancery of the State of Delaware will be the exclusive forum for certain other actions and proceedings;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#x2019; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#x2019;s own slate of directors or otherwise attempting to obtain control of us.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf under Delaware statutory or common law, including any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. The choice of forum provisions in our amended and restated certificate of incorporation may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to these provisions, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our ability to use net operating loss carryforwards and other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire (if at all).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under recently enacted U.S. tax legislation, federal net operating loss, or NOL, carryforwards generated in periods after December 31, 2017, may be carried forward indefinitely but may only be used to offset 80% of our taxable income annually. Our NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service, or the IRS, and state tax authorities. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, our federal NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percentage points. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential changes in connection with our IPO or future offerings. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from our IPO or other transactions, or any resulting limitations on our ability to utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future tax liability to us and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Tax Act has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate and revising the rules governing NOLs. Many of these changes became effective beginning in 2018, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and may continue to be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury Department and the IRS, which have lessened or increased certain adverse impacts of the legislation and may do so in the future. We continue to work with our tax advisors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce vonoprazan and any future product candidates. Our ability to obtain clinical supplies of vonoprazan and any future product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our failure to meet the continued listing requirements of the Nasdaq could result in a delisting of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If we fail to satisfy the continued listing requirements of the Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, any action taken by us to restore compliance with listing requirements may not allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#x2019;s listing requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#x201c;say on pay&#x201d; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The costs we incur as a public company will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage in the future. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. If securities or industry analysts do not continue coverage of our company, the trading price for our stock would be negatively impacted. In addition, if one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pursuant to Section 404 of Sarbanes-Oxley, our management is required to report upon the effectiveness of our internal control over financial reporting. When we lose our status as an &#x201c;emerging growth company&#x201d; and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we are in the process of implementing additional financial and management controls, reporting systems and procedures; and hiring additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">There could be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">We could be subject to securities class action litigation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us, because we, like many other biotechnology and pharmaceutical companies, have recently experienced significant stock price volatility. If we face such litigation, it could result in substantial costs and a diversion of management&#x2019;s attention and resources, which could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 1B.	Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">d Staff Comments</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 2.	Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">operties</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our corporate offices are located in Buffalo Grove, Illinois, and Florham Park, New Jersey. We believe that our facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For additional information, see Note 6, Lease Commitments included in Item 15 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 3.	Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are not currently subject to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 4.	Mine Safe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ty Disclosures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">143</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> II</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5__market_for_registrants_common_eq"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 5.	Market for Registrant&#x2019;s Common Equity, Related Sto</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ckholder Matters and Issuer Purchases of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Market Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#x201c;PHAT&#x201d; since our initial public offering on October 25, 2019, which was completed at a price to the public of $19.00 per share. Prior to our initial public offering, there was no public market for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Holders of Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of February 24, 2023, there were 41,973,271 shares of our common stock outstanding held by approximately 59 holders of record of our common stock. This number was derived from our shareholder records and does not include beneficial owners of our common stock whose shares are held in the name of various dealers, clearing agencies, banks, brokers and other fiduciaries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Dividend Policy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, under the terms of our Loan Agreement, we are prohibited from paying any cash dividends without the consent of the lenders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">See Item 12 of Part III of this annual report on Form 10-K for information about our equity compensation plans which is incorporated by reference herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Performance Graph</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unregistered Sales of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Use of Proceeds</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On October 24, 2019, our registration statement on Form S-1 (File No. 333-234020) was declared effective by the SEC for our initial public offering. At the closing of the offering on October 29, 2019, we sold 10,997,630 shares of common stock, which included the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares, at an initial public offering price of $19.00 per share and received gross proceeds of $209.0 million, which resulted in net proceeds to us of approximately $191.5 million, after deducting underwriting discounts and commissions of approximately $14.6 million and offering-related transaction costs of approximately $2.9 million. None of the expenses associated with the initial public offering were paid to directors, officers, persons owning ten percent or more of any class of equity securities, or to their associates, or to our affiliates. Goldman Sachs &amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C. acted as joint book-running managers for the offering.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2021 the net proceeds from our initial public offering and follow on offering had been applied as follows: $151.7 million toward the clinical development of vonoprazan and $79.7 million towards working capital and general corporate purposes. As of December 31, 2021, we had used all of the net proceeds from our IPO of approximately $191.5 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Issuer Repurchases of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 6. R</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">eserved</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this annual report. This discussion and analysis contains forward-looking statements based upon our current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#x201c;Risk Factors&#x201d; or in other parts of this annual report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We are a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial approved products, VOQUEZNA TRIPLE PAK and VONOPRAZAN DUAL PAK, as well as our current product candidate, VOQUEZNA, contain vonoprazan, an oral small molecule PCAB. PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over the current standard of care as a single agent in the treatment of erosive gastroesophageal reflux disease, or erosive GERD, and in combination with antibiotics for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> infection. Takeda developed vonoprazan and has received marketing approval in numerous countries in Asia and Latin America as well as Russia. Vonoprazan generated approximately $850 million in net sales in its seventh] full year on the market since its approval in Japan in late 2014. In May 2019, we in-licensed the U.S., European, and Canadian rights to vonoprazan from Takeda.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In 2021 we reported positive topline data from two pivotal Phase 3 clinical trials for vonoprazan: one for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection, or PHALCON-HP, and a second for the treatment of erosive GERD, PHALCON-EE. In April 2021, we reported positive topline data from PHALCON-HP, and in October 2021, we reported positive topline data from PHALCON-EE. These data are supplemented by the extensive existing clinical data generated by Takeda as part of their development program for vonoprazan in Japan and other markets. In September 2021, we submitted two new drug applications, or NDAs, for combination packs that contain vonoprazan for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">infection in adults, one in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) and the other in combination with amoxicillin alone (vonoprazan dual therapy).  In May 2022, the FDA approved the NDAs for vonoprazan triple therapy, under the brand name VOQUEZNA TRIPLE PAK, and vonoprazan dual therapy, under the brand name VOQUEZNA DUAL PAK.  Prior to approval, in May 2021, we received qualified infectious disease product, or QIDP, designations for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which, upon approval of these products, added five years of regulatory exclusivity to the five years of new chemical entity, or NCE, exclusivity for vonoprazan to which these products were, and future products we develop containing vonoprazan will be, entitled.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In March 2022, we submitted an NDA for vonoprazan as a treatment for adults for the healing of all grades of erosive GERD, maintenance of healing of all grades of erosive GERD, and relief of heartburn associated with erosive GERD.  If approved, we expect to market the product under the brand name VOQUEZNA. In August 2022, we announced that, consistent with current FDA recommendations for all chemically synthesized drug compounds, we previously initiated post-approval testing to determine whether nitrosamine impurities were present in our initial commercial drug product for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. These tests revealed trace levels of a nitrosamine impurity, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">N</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-nitroso-vonoprazan, or NVP, that is not described within the FDA guidance document entitled &#x201c;Control of Nitrosamine Impurities in Human Drugs &#x2013; Guidance for Industry.&#x201d; In January 2023, we announced that, although the FDA established an acceptable daily intake level (AI) for NVP at 96 ng/day, the FDA advised us that it would not be acting on our erosive GERD NDA on or prior to the Prescription Drug User Fee Act (PDUFA) target action date of January 11, 2023. Rather, the FDA requested additional stability data demonstrating that the levels of NVP will remain at or below the AI throughout the proposed shelf life of the product.  In February 2023, we received complete response letters from the FDA relating to our erosive GERD NDA and post approval supplement relating to our approved </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">NDAs, both of which address specifications and controls for NVP. These letters formalize FDA&#x2019;s prior request that we provide additional stability data to demonstrate that levels of NVP will remain at or below the AI throughout the proposed shelf life of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">No additional deficiencies were cited by the FDA in either letter.  We have scheduled a meeting with the FDA in March 2023 to discuss our resubmission plan and timeline. If we are unable to demonstrate to the FDA that we will be able to maintain NVP levels at or below the AI, launches of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK will be further delayed and approval of our erosive GERD NDA will continue to be delayed, which could substantially increase our costs and delay or put at risk our ability to generate revenue and adversely affect our commercial prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Also in January 2023, we reported positive topline results from PHALCON-NERD-301, a Phase 3 study evaluating the safety and efficacy of vonoprazan for the daily treatment of adults with non-erosive GERD. We are also in discussions with the FDA regarding the design of a Phase 3 trial to evaluate the novel dosing regimen of vonoprazan as an as needed treatment for episodic heartburn relief in patients with non-erosive GERD, a dosing regimen not approved in the U.S. for PPIs. This trial would constitute our fourth Phase 3 trial for vonoprazan. In February 2022, we reported positive topline results from PHALCON-NERD-201, a Phase 2 proof-of-concept study evaluating this novel dosing regimen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We plan to independently commercialize VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK and, if approved, VOQUEZNA, in the United States. We plan to seek commercial partnerships for vonoprazan in Europe and Canada, expand development of vonoprazan into other indications, dosing regimens and alternative formulations and packaging, and in-license or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases in a capital efficient manner.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We commenced our operations in 2018 and have devoted substantially all of our resources to date to organizing and staffing our company, business planning, raising capital, in-licensing our initial product candidate, vonoprazan, meeting with regulatory authorities, conducting our Phase 3 clinical trials of vonoprazan, preparing applications for regulatory approval for vonoprazan and preparing for a potential commercial launch. Our operations to date have been funded primarily through the issuance of convertible promissory notes, commercial bank debt, the proceeds from our initial public offering and our follow-on public offering. From our inception through December 31, 2022, we have raised aggregate gross proceeds of $90.3 million from the issuance of convertible promissory notes, $100.0 million of debt, net proceeds from our initial public offering of $191.5 million from the sale of 10,997,630 shares of common stock, which included the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares at a public offering price of $19.00 per share, after deducting underwriting discounts, commissions and offering costs, and net proceeds of $88.6 million from the sale of 2,250,000 shares of common stock at a public offering price of $39.48 per share after deducting underwriting discounts and commissions, and an additional $0.2 million in offering costs. As of December 31, 2022, we had cash and cash equivalents of $155.4 million. Based on our current operating plan, we believe that our existing cash and cash equivalents together with the drawdown of the remaining $100 million under our Loan Agreement with Hercules are sufficient to fund operations for at least the next twelve months and receipt of $175 million in additional milestone payments under our Revenue Interest Financing Agreement, will be sufficient to fund our operations through the end of 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have not initiated commercial launch of any products and have incurred net losses since our inception. Our net losses for the years ended December 31, 2022 and 2021 were $197.7 million and $143.9 million, respectively. As of December 31, 2022, we had an accumulated deficit of $727.1 million.  Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical development activities, other research and development activities and pre-commercialization activities. We expect our expenses and operating losses will increase as we continue to advance vonoprazan through clinical trials, seek additional regulatory approvals for vonoprazan, expand our quality, regulatory, manufacturing and commercialization capabilities, incur significant commercialization expenses for marketing, sales, manufacturing and distribution if we obtain marketing approval for VOQUEZNA for erosive GERD in the U.S., protect our intellectual property, expand our general and administrative support functions, including hiring additional personnel, and incur additional costs associated with operating as a public company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">147</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have never generated any revenue and do not expect to generate any revenues from product sales unless and until we obtain regulatory approval for VOQUEZNA, or approval of our resubmission for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, in the U.S.  Accordingly, until such time as we can generate significant revenue from sales of products containing vonoprazan, if ever, we expect to finance our cash needs through equity offerings, our Loan Agreement, our Revenue Interest Financing Agreement, additional debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all, and this risk could be exacerbated by the impact of the ongoing hostilities in the Ukraine on global economic conditions. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">License Agreement with Takeda</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On May 7, 2019, we and Takeda entered into the Takeda License, pursuant to which we in-licensed the U.S., European, and Canadian rights to vonoprazan fumarate. During the term of the Takeda License, we and our affiliates are not permitted to commercialize any pharmaceutical product, other than vonoprazan, that treats acid-related disorders, except for certain generic and OTC competing products in specified circumstances. We will be responsible at our cost for the development, manufacture and commercialization of vonoprazan products. We are required to use commercially reasonable efforts to develop and commercialize the vonoprazan products in our licensed territory.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under the Takeda License, Takeda has the sole right and authority, with our input, to prepare, file, prosecute, and maintain all Takeda and joint patents on a worldwide basis at its own cost. We are responsible, at our cost, for preparing, filing, prosecuting, and maintaining patents on inventions made solely by us in connection with vonoprazan, subject to input from Takeda.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We paid Takeda upfront consideration consisting of a cash fee of $25.0 million, 1,084,000 shares of our common stock, the Takeda Warrant to purchase 7,588,000 shares of our common stock at an exercise price of $0.00004613 per share, and issued Takeda a right to receive an additional common stock warrant, or the Takeda Warrant Right, if Takeda&#x2019;s fully-diluted ownership of the Company represented less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately prior to the closing of our IPO. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of our IPO, and no additional warrant was issued. We agreed to make milestone payments to Takeda upon achieving certain tiered aggregate annual net sales of licensed products in the United States, Europe and Canada up to a total maximum milestone amount of $250.0 million. We also agreed to make tiered royalty payments at percentages in the low double digits on net sales of licensed products, subject to specified offsets and reductions. Royalties will be payable, on a product-by-product and country-by-country basis from the first commercial sale of such product in such country, until the latest of expiration of the licensed patents covering the applicable product, expiration of regulatory exclusivity in such country, or 15 years following first commercial sale in such country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Components of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and Development</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">To date, our research and development expenses have related to the development of vonoprazan. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development expenses include:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in research and development efforts;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">external research and development expenses incurred under agreements with CROs, and consultants to conduct and support our ongoing clinical trials of vonoprazan; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">costs related to the manufacturing of vonoprazan for our clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We plan to increase our research and development expenses for the foreseeable future as we continue the development of vonoprazan. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future clinical trials and nonclinical studies of vonoprazan or any future product candidates due to the inherently unpredictable nature of clinical and preclinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our future clinical development costs may vary significantly based on factors such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">per patient trial costs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the number of trials required for approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the number of sites included in the trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the countries in which the trials are conducted;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the length of time required to enroll eligible patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the number of patients that participate in the trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the number of doses evaluated in the trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the drop-out or discontinuation rates of patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">potential additional safety monitoring requested by regulatory agencies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the duration of patient participation in the trials and follow-up;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the phase of development of the product candidate; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the efficacy and safety profile of the product candidate;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">General and Administrative</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative expenses consist of salaries and employee-related costs, including stock-based compensation, for personnel in executive, finance, accounting, legal, human resources and other administrative functions, legal fees relating to intellectual property and corporate matters, and professional fees for accounting and consulting services. We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities, pre-commercial preparation activities for vonoprazan and, if any future product candidate receives marketing approval, commercialization activities. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Interest Income</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest income consists of interest on our money market funds.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning on May 3, 2022, interest expense includes interest on the Revenue Interest Financing Agreement, which is based on the imputed effective rate derived from expected future payments and the carrying value of the obligation. The Company recalculates the effective interest rate each period based on the current carrying value and the revised estimated future payments. Changes in future payments from previous estimates are included in current and future financing expense.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning on September 17, 2021, interest expense consists of (i) cash interest at a variable annual rate equal to the greater of (a) 5.50% and (b) the Prime Rate (as reported in the Wall Street Journal) plus 2.25% (the &#x201c;Interest Rate&#x201d;), (ii) payment-in-kind interest at a per annum rate of interest equal to 3.35%, and (iii) amortization of the Hercules Loan Agreement debt discount recorded in connection with the fair value of warrants issued to the lenders, the debt issuance costs incurred, and the obligation to make a final payment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prior to September 17, 2021, interest expense consisted of interest on our outstanding commercial bank debt with SVB at a variable annual rate equal to the greater of (a) 7.25% and (b) Prime Rate (as reported by the Wall Street Journal) plus 1.75% and amortization of the SVB Term Loan debt discount recorded in connection with the fair value of warrants issued to the lenders, the debt issuance costs incurred, and the obligation to make a final payment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2022 and 2021 (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.964%;"></td>
    <td style="width:1.341%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.692%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.328%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.679%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.328%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.666%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br />December 31,</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">71,441</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">72,338</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(897</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">100,999</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">62,742</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">38,257</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">172,440</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">135,080</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">37,360</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(172,440</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(135,080</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(37,360</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,132</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">41</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,091</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(27,305</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(6,788</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(20,517</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(110</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(2,056</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,946</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total other income expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(25,283</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(8,803</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(16,480</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(197,723</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(143,883</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(53,840</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and Development Expenses.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Research and development expenses were $71.4 million and $72.3 million for the years ended December 31, 2022 and 2021, respectively. The decrease of $0.9 million consisted of consisted of a reduction of $3.2 million of expenses related to regulatory requirements and $0.4 million of chemistry manufacturing and controls, or CMC, costs related to vonoprazan, partially offset by increases $2.7 million of personnel-related, consulting and other research expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> General and administrative expenses were $101.0 million and $62.7 million for the years ended December 31, 2022 and 2021, respectively. The increase of $38.2 million was due to increases of $21.0 million in professional services expenses for commercial, medical affairs and other services, $15.7 million in personnel-related expenses, $1.7 million in legal and other expenses in 2022, partially offset by a $0.2 million reduction in consulting fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Other Income (Expense).</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Other expense of $25.3 million for the year ended December 31, 2022 consisted of $27.4 million of interest expense under the Hercules Loan and Revenue Interest Financing Agreements, partially offset by $2.1 million of interest income on deposits. Other expense of $8.8 million for the year ended December 31, 2021 consisted of $6.8 million of interest expense and $2.0 million of charges related to early extinguishment of debt.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of December 31, 2022, we had cash and cash equivalents of $155.4 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Loan Agreement with Hercules</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On September 17, 2021, (the &#x201c;Closing Date&#x201d;), we entered into a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender (in such capacity, the &#x201c;Agent&#x201d; or &#x201c;Hercules&#x201d;) and the other financial institutions that from time to time become parties to the Loan Agreement as lenders (collectively, the &#x201c;Lenders&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Loan Agreement provides for term loans in an aggregate principal amount of up to $200.0 million (the &#x201c;Term Loan&#x201d;) under multiple tranches. The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $100.0 million, all of which was funded on the Closing Date (the &#x201c;First Advance&#x201d;), (ii) a second tranche consisting of up to an additional $50.0 million, which became available to us upon achievement of the protocol-specified primary efficacy endpoints in our Phase 3 trial studying vonoprazan for the healing and maintenance of healing of erosive GERD with acceptable safety data, such that the results support the submission of a New Drug Application (&#x201c;NDA&#x201d;) or supplemental NDA without the need to conduct another Phase 3 study and will be available, if specified conditions are met, through December 15, 2022, see amendment to later date below, (iii) a third and fourth tranches consisting of an additional total $50.0 million, which became available to us in May 2022 upon the achievement of (a) FDA approval of our NDA for vonoprazan and amoxicillin, or its NDA for vonoprazan, amoxicillin and clarithromycin, in each case for an indication relating to the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">with an approved indication on the claim that is generally consistent with that sought in our NDA submission&#x37e; and (b) filing of an NDA or supplemental NDA for vonoprazan for indications relating to the healing and maintenance of healing of erosive GERD. The third and fourth tranches will remain available until September 30, 2023, and March 31, 2024, respectively. We intend to use the proceeds of the Term Loan advances for working capital and general corporate purposes. In addition, approximately $54 million of the proceeds from the First Advance was used to satisfy in full and retire our indebtedness under its previously outstanding credit facility with Silicon Valley Bank (the &#x201c;SVB Term Loan&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On September 27, 2022, the Company entered into an amendment to the Loan Agreement, or the Second Loan Amendment, pursuant to which the date the second tranche of funding of $50 million will remain available to the Company has been moved until May 15, 2023, rather than December 15, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Term Loan will mature on October 1, 2026 (the &#x201c;Maturity Date&#x201d;). The Term Loan bears (i) cash interest at a variable annual rate equal to the greater of (a) 5.50% and (b) the Prime Rate (as reported in the Wall Street Journal) plus 2.25% (the &#x201c;Interest Rate&#x201d;) and (ii) payment-in-kind interest at a per annum rate of interest equal to 3.35%. We may make payments of interest only through October 1, 2024, which was extended to October 1, 2025, upon the achievement of the Second Performance Milestone in May 2022 prior to September 30, 2024 and the condition that no default or event of default exists, and which is further extendable to October 1, 2026, subject to FDA approval of our NDA (or supplemental NDA) for vonoprazan for an indication relating to the healing and maintenance of healing of erosive GERD with an approved indication on the label that is generally consistent with that sought in our NDA submission (or supplemental NDA submission) (the &#x201c;Third Performance Milestone&#x201d;) on or prior to September 30, 2025 and no default or event of default exists (the &#x201c;interest only period&#x201d;). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring us to maintain certain levels of cash subject to a control agreement in favor of the Agent (minus accounts payable not paid within 120 days of invoice) (&#x201c;Qualified Cash&#x201d;), and commencing on May 15, 2023, trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan. The revenue covenant will be waived at any time in which we maintain Qualified Cash equal to at least 60.0% (prior to the Third Performance Milestone), and 35% (following the Third Performance Milestone) of the total outstanding Term Loan principal amount, or our market capitalization is at least $900.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under the Second Loan Amendment, the commencement date for the covenant based on trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan was moved from May 15, 2023, to November 15, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As collateral for the obligations, we granted to Hercules a senior security interest in all of our right, title, and interest in, to and under substantially all of our property, inclusive of intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In connection with the entry into the Loan Agreement, we issued to Hercules a warrant (the &#x201c;Warrant&#x201d;) to purchase a number of shares of our common stock equal to 2.5% of the aggregate amount of the Term Loan advances funded, and will issue to Hercules additional warrants when future Term Loan advances are funded. On the Closing Date, we issued a Warrant for 74,782 shares of common stock. The Warrant will be exercisable for a period of seven years from the date of issuance at a per-share exercise price equal to $33.43, which was the closing price of our common stock on September 16, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Interest Financing Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On May 3, 2022, we entered into a Revenue Interest Financing Agreement (the &#x201c;Revenue Interest Financing Agreement&#x201d;), with entities managed or advised by NovaQuest Capital Management (&#x201c;NQ&#x201d;), Sagard Holdings Manager LP (&#x201c;Sagard&#x201d;) and Hercules Capital, Inc. (&#x201c;Hercules&#x201d; together with NQ and Sagard, the &#x201c;Initial Investors&#x201d;) pursuant to which we can receive up to $260 million in funding from the Initial Investors. Under the terms of the Revenue Interest Financing Agreement, we received $100 million at the initial closing and can receive an additional $160 million upon FDA approval of vonoprazan for treatment of erosive GERD on or before March 31, 2024. In addition, we had the right to obtain a written commitment from a third party for up to (i) at any time prior to December 31, 2022, $15,000,000 in additional funding upon FDA approval of vonoprazan for erosive GERD (&#x201c;Approval Additional Funding&#x201d;), and (ii) at any time prior to June 30, 2024, $25,000,000 in additional funding for achievement of a sales milestone (&#x201c;Milestone Additional Funding&#x201d;, and, together with the Approval Additional Funding, the &#x201c;Additional Investor Funding&#x201d;).The Initial Investors had a right of first offer for any Additional Investor Funding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On October 31, 2022, we entered into a Joinder and Waiver Agreement with the Initial Investors and CO Finance LVS XXXVII LLC (&#x201c;the Additional Investor&#x201d;), and Hercules Capital, Inc. in its capacity as administrative agent and collateral agent for itself and the lenders under that certain Loan Agreement (the &#x201c;Joinder Agreement&#x201d;) in respect of the Revenue Interest Financing Agreement.  Under the terms of the Joinder Agreement, the Initial Investors waived their rights of first offer regarding the Additional Investor Funding and the Additional Investor joined the Revenue Interest Financing Agreement to extend commitments for the Additional Investor Funding. The total amount funded by the Initial Investors and any subsequent investors is referred to herein as the &#x201c;Investment Amount.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under the Revenue Interest Financing Agreement, the Initial Investors, and subsequent to the payment of the Approval Additional Funding, the Additional Investor, are entitled to receive a 10% royalty on net sales of products containing vonoprazan. The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and if we receive FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with non-erosive GERD. The investors&#x2019; right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for erosive GERD regulatory approval is made, we have the right to make a cap payment equal to 200% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If the investors have not received aggregate payments of at least 100% of the Investment Amount by December 31, 2028, and at least 200% of the Investment Amount by December 31, 2037, each a Minimum Amount, then we will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Upon the occurrence of an event of default taking place prior to April 1, 2025, between April 1, 2025, and April 1, 2028, and after April 1, 2028, we are obligated to pay 1.30 times Investment Amount, 1.65 times Investment Amount, and 2.0 times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement. Upon the occurrence of a change in control event taking place prior to the earlier of April 1, 2024, or FDA approval of vonoprazan for erosive GERD, we are obligated to pay 200% of the Investment Amount plus either 15% of the Investment Amount if occurrence prior to May 3, 2023, or plus 30% of the Investment Amount if occurrence thereafter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">At-the-Market-Offering</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On November 10, 2020, we entered into an Open Market Sale Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $125.0 million through the Sales Agent, or the ATM Offering. Sales of our common stock made pursuant to the Sales Agreement, if any, will be made under our shelf registration statement on Form S-3 which was filed on November 10, 2020 and declared effective by the SEC on November 16, 2020. We are not obligated to, and we cannot provide any assurances that we will, make any sales of the shares under the Sales Agreement. The Sales Agreement may be terminated by the Sales Agent or us at any time. For the year ended December 31, 2022, we sold 2,414,897 shares of our common stock under the ATM Offering for net proceeds of approximately $24.6 million after deducting $0.8 million of issuance costs. As of December 31, 2022, we utilized $25.4 million of the available $125.0 million under the ATM Offering.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Underwritten Public Offering</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On December 16, 2020, the Company completed an underwritten public offering, in which it sold 2,250,000 shares of its common stock at a price of $42.00 per share for total gross proceeds of $94.5 million. The net purchase price after deducting underwriting discounts and commissions was $39.48 per share, which generated net proceeds of $88.8 million. We incurred an additional $0.2 million of offering expenses in connection with the public offering.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Funding Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Based on our current operating plan, we believe that our existing cash and cash equivalents together with the drawdown of the remaining $100 million under our Loan Agreement with Hercules are sufficient to fund operations for at least the next twelve months and receipt of $175 million in additional milestone payments under our Revenue Interest Financing Agreement, will be sufficient to fund our operations through the end of 2024. We expect such amounts will allow us to complete our ongoing Phase 3 clinical trial studying vonoprazan for non-erosive GERD (daily dosing), and , if our post-complete response letter resubmissions concerning NVP are approved by FDA, launch vonoprazan for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">and erosive GERD. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the initiation, type, number, scope, results, costs and timing of our clinical trials of vonoprazan, and preclinical studies or clinical trials of other potential product candidates we may choose to pursue in the future, including feedback received from regulatory authorities;  </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs and timing of manufacturing for vonoprazan or any future product candidates, including commercial scale manufacturing if any product candidate is approved; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs, timing and outcome of regulatory review of vonoprazan or any future product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development personnel;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the timing and amount of the milestone or other payments we must make to Takeda and any future licensors; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the costs and timing of establishing or securing sales and marketing capabilities for vonoprazan or any future product candidate; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payers and adequate market share and revenue for any approved products; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">patients&#x2019; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">costs associated with any products or technologies that we may in-license or acquire.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through equity offerings, the Loan Agreement, the Revenue Interest Financing Agreement, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Including our existing cash and cash equivalents, we believe that we have sufficient working capital on hand to fund operations such that there is no substantial doubt as to our ability to continue as a going concern at the date the financial statements were issued. There can be no assurance that we will be successful in acquiring additional funding, that our projections of future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years. Based on our current operating plan, we believe that our existing cash and cash equivalents together with the drawdown of the remaining $100 million under our Loan Agreement with Hercules  are sufficient to fund operations for at least the next twelve months and receipt of $175 million in additional milestone payments under our Revenue Interest Financing Agreement, will be sufficient to fund our operations through the end of 2024.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table sets forth a summary of the net cash flow activity for each of the periods indicated (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:82.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.514%;"></td>
    <td style="width:1.232%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.752%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.232%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.559000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.232%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.479999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$ Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(146,530</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(148,457</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,927</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(1,041</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(328</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(713</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">120,042</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">44,708</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">75,334</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net decrease in cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(27,529</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(104,077</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">76,548</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net cash used in operating activities was approximately $146.5 million and $148.5 million for the years ended December 31, 2022 and 2021, respectively. The net cash used in operating activities for the year ended December 31, 2022 was due to approximately $152.0 million spent on ongoing research and development and general and administrative activities offset by a $5.5 million change in operating assets and liabilities. The net change in operating assets and liabilities primarily related to a $7.7 million increase in accounts payable and accrued expenses in support of the growth in our operating activities, partially offset by a $2.2 million increase in prepaid assets and other assets. The net cash used in operating activities for the year ended December 31, 2021 was due to approximately $121.1 million spent on ongoing research and development and general and administrative activities and a $27.4 million net change in operating assets and liabilities. The net change in operating assets and liabilities primarily related to a $28.2 million decrease in accounts payable and accrued expenses (including clinical trial expenses) in support of the growth in our operating activities, partially offset by a $0.8 million decrease in prepaid and other assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net cash used in investing activities for the years ended December 31, 2022 and 2021 was primarily due to the cash we paid for acquiring property, plant and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2022 was $120 million, was due to the net proceeds from the revenue interest financing liability and issuance of common stock under the ATM Offering. Net cash provided by financing activities for the year ended December 31, 2021 was $44.7 million, due to $96.9 million of net proceeds from the loan agreement with Hercules and $1.9 million of proceeds related to stock option exercises partially offset by the $54.1 million repayment of the SVB Term Loan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes our contractual obligations as of December 31, 2022 (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.372%;"></td>
    <td style="width:1.355%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.824%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.368%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.824%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.368%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.065000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.368%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.829%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.368%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.259%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Payments Due by Period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less than</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1-3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3-5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">More than</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1 Year</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5 Years</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total debt, including interest<br />&#160;&#160;&#160;and final payment fee </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Calibri&quot;, sans-serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">124,471</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">29,707</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">94,764</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Minimum operating lease<br />&#160;&#160;&#160;payments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">734</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,266</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">126,471</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">734</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">30,973</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">94,764</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="20" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Calibri&quot;, sans-serif;position:relative;min-width:fit-content;">(1) Our outstanding long-term debt bears interest at a variable rate. The interest amounts included herein are based on the interest rate in effect as of December 31, 2022.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition to the contractual obligations summarized above, on May 5, 2020, we entered into a Commercial Supply Agreement with Takeda, pursuant to which Takeda will supply commercial quantities of vonoprazan bulk drug product. We incurred $0.7 million and $1.8 million of expenses related to the Commercial Supply Agreement during the years ended December 31, 2022 and 2021, respectively. We have no remaining minimum purchase obligation related to this agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additionally, on December 30, 2020, we entered into a Supply and Packaging Services Agreement with Sandoz, pursuant to which Sandoz has agreed to supply commercial quantities of amoxicillin capsules and clarithromycin tablets, to package these antibiotics with vonoprazan, in finished convenience packs, and to supply us with these convenience packs. The supply agreement commits the Company to a minimum purchase obligation of approximately $3.8 million during the first 24-month period following the launch of the final product. As of December 31, 2022, we are unable to estimate the timing of future expenses and, therefore, any related payments are not included in the table above. We have not incurred any expenses under the agreement during the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additionally, on May 3, 2022, we entered into a Revenue Interest Financing Agreement (the &#x201c;Revenue Interest Financing Agreement&#x201d;), with entities managed or advised by NovaQuest Capital Management (&#x201c;NQ&#x201d;), Sagard Holdings Manager LP (&#x201c;Sagard&#x201d;) and Hercules Capital, Inc. (&#x201c;Hercules&#x201d; together with NQ and Sagard, the &#x201c;Initial Investors&#x201d;) and received $100 million at the initial closing (the &#34;Investment Amount&#34;). Under the Revenue Interest Financing Agreement, the Initial Investors are entitled to receive a 10% royalty on net sales of products containing vonoprazan. The investors&#x2019; right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. We have not made any payments under the Revenue Interest Financing Agreement during the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We enter into contracts in the normal course of business for our contract research services, contract manufacturing services, professional services and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">While our significant accounting policies are more fully described in Note 1 to our financial statements, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments, if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our research and development activities include estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur. We use the Black-Scholes valuation model to determine the fair value of our stock awards. Through December 31, 2022, our stock-based compensation expense consisted of recognized fair value related to our issuance of restricted stock awards, for which the fair value is determined based on the fair value of the underlying common stock, stock options, and ESPP awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other Company Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">JOBS Act</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of the consummation of our IPO, (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which we are deemed to be a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year, or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The information required by this item is included in Note 1, Organization, Basis of Presentation and Summary of Significant Accounting Policies included in Item 15 of this annual report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Off-Balance Sheet Arrangements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a__quantitative_qualitative_disclo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 7A.	Quantitative and Qualita</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">tive Disclosures About Market Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our cash and cash equivalents consist of cash in readily available checking accounts and money market funds. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes. Our long-term debt bears interest at a variable rate. A 10% increase or decrease in the interest rate on our long-term debt would not have a material effect on our financial position, results of operations or cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Effects of Inflation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8__financial_statements_supplementa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 8.	Financial Stateme</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">nts and Supplementary Data</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The financial statements required pursuant to this item are incorporated by reference herein from the applicable information included in Item 15 of this annual report and are presented beginning on page F-1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9__changes_in_disagreements_with_ac"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 9.	Changes in and Disagreements with Acco</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">untants on Accounting and Financial Disclosure</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a__controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 9A.	Control</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">s and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this annual report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Management&#x2019;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control&#x2014;Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of December 31, 2022, our internal control over financial reporting was effective.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">This annual report does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">There have been no changes in our internal control over financial reporting during the fourth quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b__or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 9B.	Oth</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">er Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 9C.	Disclosure Regarding Foreign</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Jurisdiction that Prevent Inspection</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10__directors_executive_ficers_corp"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 10.	Directors, Executive O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">fficers and Corporate Governance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The information required by this item will be contained in our definitive proxy statement to be filed with the SEC in connection with our 2023 Annual Meeting of Stockholders, or the Definitive Proxy Statement, which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2022, under the headings &#x201c;Election of Directors,&#x201d; &#x201c;Executive Officers,&#x201d; and &#x201c;Section 16(a) Beneficial Ownership Reporting Compliance,&#x201d; and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Code of Conduct and Ethics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have adopted a Code of Conduct and Ethics that applies to our officers, directors and employees, which is available on our website at www.phathompharma.com. The Code of Conduct and Ethics contains general guidelines for conducting the business of our company consistent with the highest standards of business ethics and is intended to qualify as a &#x201c;code of ethics&#x201d; within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. In addition, we intend to promptly disclose (1) the nature of any amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11__executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 11.	Execut</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ive Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The information required by this item will be set forth in the section headed &#x201c;Executive Compensation and Other Information&#x201d; in our Definitive Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12__security_ownership_certain_bene"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 12.	Security Ownership of Certain Beneficial O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">wners and Management and Related Stockholder Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The information required by this item will be set forth in the section headed &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; in our Definitive Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The information required by Item 201(d) of Regulation S-K will be set forth in the section headed &#x201c;Executive Compensation&#x201d; in our Definitive Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13__certain_relationships_related_t"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 13.	Certain Relationships and Relat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ed Transactions, and Director Independence</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The information required by this item will be set forth in the section headed &#x201c;Certain Relationships and Related Person Transactions,&#x201d; &#x201c;Board Independence&#x201d; and &#x201c;Committees of the Board of Directors&#x201d; in our Definitive Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14__principal_accounting_fees_servi"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 14.	Principal Acco</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">unting Fees and Services</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The information required by this item will be set forth in the section headed &#x201c;Independent Registered Public Accountants&#x2019; Fees&#x201d; in our Definitive Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">162</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15__exhibits_financial_statement_sc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 15. Exhibits, Finan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">cial Statement Schedules</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">All financial statements.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The financial statements of Phathom Pharmaceuticals, Inc., together with the report thereon of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_6b28b55a-6732-4f5b-80c0-05bc2733b084" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, an independent registered public accounting firm, are included in this annual report on Form 10-K beginning on page F-1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial statement schedules.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Calibri;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Exhibits</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this annual report on Form 10-K and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phathom Pharmaceuticals, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Index to Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.996%;"></td>
    <td style="width:6.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#external_auditor_opinion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;(PCAOB ID: </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_03cb2e5b-b82d-40ca-8586-0efcb3adffe4" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheet"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statement_of_operation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statement_of_stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Statements of Stockholders&#x2019; Equity (Deficit)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#combined_statement_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_financials"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="external_auditor_opinion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Report of Inde</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">pendent Registered Public Accounting Firm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">To the Stockholders and Board of Directors of Phathom Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have audited the accompanying balance sheets of Phathom Pharmaceuticals, Inc. (the Company) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, stockholders' equity (deficit) and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. </span><span style="background-color:rgba(0,0,0,0);color:rgba(3,3,3,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:rgba(3,3,3,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(3,3,3,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">/s/ Ernst &amp; Young  LLP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">                                                                    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_4698f196-0af2-4450-8d6c-b2de1aaa9b07" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Iselin, New Jersey</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">February 28, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PHATHOM PHARMACEUTICALS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheet"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Bal</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(in thousands, except share and par value amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.911%;"></td>
    <td style="width:1.585%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.441%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.597%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.466000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br />2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_da4aa7fd-81b0-4df9-adba-a55b63b38cd3" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">155,385</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d97e774b-6c2b-46d7-aef1-c07225f94cf3" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183,259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c1434198-1b2a-4f0a-8b37-8d3501b9d8e2" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,127</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_86dbab16-1466-47c1-9ca5-332e35a6f988" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,267</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b2fb0633-ec57-4343-a62f-ffa27de6d0e0" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,512</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_553b68c8-3fd0-46ed-867c-e4e93620f1a7" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186,526</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Property, plant and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d2e8697c-f421-4166-8e1a-5a7f88bcf121" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aa559c69-b804-4831-aa93-896beb943c7d" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9103ffbe-cd9a-4eb3-a760-9ea6aa633acb" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cae837f5-55a0-4af8-a8d8-9ef59339c7d4" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1e9d7bf4-1bba-4019-a515-1218675739b0" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">505</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ee2a2aed-dee1-4964-b528-374ec673c9e3" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9bb56c62-eba7-41ee-850c-143d014d9e84" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9519c440-6000-42b3-9e9b-257e01c245fa" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_892b62a6-a47f-42ac-977e-1bfff7975773" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,810</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c26118c4-ff39-4983-a749-b60b610f76e5" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">189,431</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accounts payable (including related party amounts of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b7716aef-0dee-4c42-ba70-2678f55e0ae0" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:AccountsPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2a47e65b-b97a-4ba5-88c8-0f0059055825" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:AccountsPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,343</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d2ec92f1-cf54-432e-8fde-16cf02adf083" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,997</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6aa94b81-1003-40a7-ae0d-5d9bcd58e1e6" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued clinical trial expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1f19574c-1891-46d8-8f01-20e2e67f6e54" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="phat:AccruedClinicalTrialExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,402</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued expenses (including related party amounts of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fbcc532b-6d2c-4480-99ba-a0547dfd2da6" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:AccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,499</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_faa55c68-62c2-4bf4-a50f-563a813b89d4" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="phat:AccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,330</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6fbe175c-19ee-4714-893d-3723e4cb3a45" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f4dbb1b6-fbb0-42b5-a529-409c54962356" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,405</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued interest</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_04204714-1ea3-49f2-976e-3a440614e7c9" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">854</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_58fea3a4-9cc2-4936-9acc-047177104c2c" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">477</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9eb070a8-3be5-4714-9953-274131f1088c" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3156cb22-fa0d-444c-a36e-ae4e8634c42e" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d6e91811-4b3e-43c6-8cba-8708d4f2cd4e" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4310120a-5377-4725-b5f6-f267b7ffcf34" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Long-term debt, net of discount</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ba7af4b6-2a1c-4154-9cd7-d08e2f0bde52" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,264</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_42b40316-c805-459c-9938-f35fc99f3f5d" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,671</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Revenue interest financing liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_34b214f8-e2c4-463d-b067-ad816d1d537a" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:RevenueInterestFinancingLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1858b68b-2802-42f5-94c2-6f4c4827f0ab" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_522bf1bf-90b4-4d87-8730-078b65531d74" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,183</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7e700a4d-faa8-4d68-8e02-4615595c4014" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ab270021-7778-4aa6-8297-014fed1c6bc6" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4abd2040-fd8d-4d2d-9a6f-643ee7a9bf70" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">239,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7c91131c-da74-4aa8-9b2b-cc6ec5eb831d" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">117,275</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="-sec-ix-hidden:F_fc069ec2-b698-4009-b7c4-39ae24bbf4da;"><span style="-sec-ix-hidden:F_b6395ef0-f70f-4750-896d-fd899c227d0b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;(Note 4)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0759afab-8ded-4fb8-8387-8a413e5a745e" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_0686a444-9e8e-45bb-9468-ac714e519506" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;par value; authorized shares &#x2014; </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_721988b4-b96b-4e32-8b59-e32c2deee599" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_f2ff4c33-506f-421c-99f1-3489fec27c81" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">40,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;at December 31, 2022 and 2021; </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_717a9a18-5813-4ff9-98cd-37bf0594a050" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_71184019-4b34-4f62-afc0-84ab523555e2" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a5df8b3a-cd2b-4171-ae9b-8e20a5ddf88f" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ee7fe8a5-9139-42ef-ad85-9b493ed9ef4e" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022 and 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="-sec-ix-hidden:F_558505f2-45b8-41f3-be82-00543a9fac5f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="-sec-ix-hidden:F_79fc89c8-d053-4eeb-8afd-78914e3ef4c7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a8d436f6-8157-44af-a8d6-9e52e953448d" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_ddd24c05-b0d7-4959-8dfd-eac62a7df650" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;par value; authorized shares &#x2014; </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_db4bf909-f2ae-4663-a437-9450dc47be36" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_fddd90fd-2f75-4c60-a69e-422e73eb3751" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">400,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;at December 31, 2022 and 2021; issued shares &#x2014; </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_660a0d4d-1b25-44dc-9af8-03555ea75740" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">41,723,308</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c8e0160c-45ff-45ad-baf7-12196a974526" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,656,035</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;at December 31, 2022 and 2021, respectively; outstanding shares &#x2014; </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_271e0446-5547-4ddf-b340-137e70303109" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">41,468,871</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_520b1939-42da-4bd1-8737-74b63738311a" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,511,226</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;at December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_244d99a5-e4b1-4fca-91a7-24f3ad22ab8c" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6ce4ceea-18b0-4a64-b6fc-063494101ecf" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Treasury stock &#x2014; </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1fd43e01-d675-4be5-9eb2-91c7aaa0765f" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dec9e0cc-ad20-4718-8280-a2b191cb88ff" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;shares at December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="-sec-ix-hidden:F_5ecefc5a-5125-41a1-a2fa-e831971495b3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="-sec-ix-hidden:F_7fcc0224-faaf-4025-b8d0-b563e26ab94e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d90473bd-82d0-4014-8bdf-ced690d43460" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">652,276</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d517412c-7752-4ae2-bd5d-4c614e815817" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">601,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b7f4f615-e632-44f9-a364-8f57fe9a5f42" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">727,093</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_18474656-974d-44a1-bf8e-0938a386878e" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">529,370</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total stockholders&#x2019; (deficit) equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f5843383-2b28-42f7-972e-323225072cea" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d51bf6dc-b924-420b-a999-2cd9de8dea0f" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e82799a4-e26a-4751-b02d-2ff2e5b77ee9" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,810</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d9aee523-7bb1-4364-8bd5-a9539ac6cb71" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">189,431</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PHATHOM PHARMACEUTICALS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statement_of_operation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Statements of Opera</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">tions and Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.418%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.471%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.64%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.471%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development (includes related party amounts of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f4af29c8-acdd-46bb-934c-5c6c49435d7e" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:ResearchAndDevelopmentExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,123</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5b6776ed-e33e-46a4-a892-0351ed1a15c6" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:ResearchAndDevelopmentExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,933</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bc436dd7-ae77-4152-b557-139e16664fb5" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,441</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c45e172d-a0ee-4433-844d-d1e0bd1d51ba" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative (includes related party amounts of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d1e75d3f-a3b4-42ed-90b0-407de87bae39" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:GeneralAndAdministrativeExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a8b0cd65-9029-4b16-a547-2343c4ee1441" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:GeneralAndAdministrativeExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8f7c2e7d-9290-4f4c-a0c6-3bd9d22003a0" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8300a747-f23e-4d4e-b88b-8616aba21ed3" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,742</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2d9396aa-f80a-4e24-9be2-dde6f4fc9cf6" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">172,440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_52c4fa30-c29b-424a-9729-ec71ece740a2" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135,080</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3436d391-8aa4-46cd-bfc9-7afb67df7307" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">172,440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_54bda2b4-f320-4af9-8e94-2579ae56e3f1" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">135,080</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_69ec85ec-41d1-4590-b579-45213e543864" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,132</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7e670695-91a0-4dd6-a675-8768a4654ad0" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e1b13a87-e782-4c60-918e-fa488797e848" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,305</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_095a7c3e-ec3a-406c-b88c-cefeb9d9d6a9" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7146cee6-be5a-4e48-aafa-14158b4654ae" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_84710c33-3004-4645-910b-85c2e7b351a9" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,056</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total other expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9ecb44d5-32a1-4f33-bfc3-e57844627f4c" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">25,283</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c83c576b-5da8-408c-8f85-b78577d7c986" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,803</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6bad0aba-33f4-4e77-93b6-5dd69cca6f26" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">197,723</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6a921738-fcce-49dd-be6f-949586336280" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_785c9083-1579-45d5-ae5a-b36f82211808" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_639653ef-c531-4c49-bce0-db2ed8696850" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">5.05</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a0a0c2ba-7427-45a4-8038-36463ebab63a" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_95d6c793-ac5d-4a24-a11f-5326ee4375f6" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">3.89</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-average shares of common stock outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5f65f45b-c5d5-41ad-9223-2ed20a5751cf" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_7fc53703-99c9-45a0-b089-f9c8ee388bab" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">39,118,215</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a086bdb9-2b97-441b-bb7e-bea6640b04cb" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_469e6bea-4010-4be6-8474-88ba24421e38" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">37,002,959</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PHATHOM PHARMACEUTICALS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statement_of_stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Statements of Sto</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ckholders&#x2019; Equity (Deficit)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(in thousands, except share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:22.876%;"></td>
    <td style="width:0.616%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.901%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.985%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.884%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.616%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.251999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.631%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.161999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.631%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.101%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.246%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.101%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Treasury Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Additional<br />Paid-in</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total<br />Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f8c6982b-c745-4795-b97a-e0e84d5602f9" contextRef="C_fdabcc96-9593-40cb-bc06-20ae0d8af269" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,516,010</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e5a915d0-06b6-4989-aeab-d02b65455b57" contextRef="C_fdabcc96-9593-40cb-bc06-20ae0d8af269" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_91f4955e-183e-4d62-ab0e-f9038ac2bf5d" contextRef="C_38a3ce84-f57c-409f-8929-19e767dc49e2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">579,755</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3dcd032d-acc2-4ac8-b204-76a203fdb7c8" contextRef="C_e45ec0f4-8be2-4007-a0b7-cc5a7fb0e0af" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">385,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_01cebd85-fe6a-4d76-88c6-a476d0ad4f8c" contextRef="C_3625bbc7-e0d2-4ae5-80c9-2c2a001c24c0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,271</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Issuance of common stock from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_04d90dac-8820-48b9-944b-02495ee14e8a" contextRef="C_9c879136-27f6-49d8-8690-7a4079f865e8" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">107,583</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1563bd8b-001c-4667-96d6-7225cb856fc0" contextRef="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_40dc4b10-867b-4263-b912-186580ca911d" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cashless exercise of common stock warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_024dfd0e-2d12-4526-a42a-b176b46b2a8c" contextRef="C_9c879136-27f6-49d8-8690-7a4079f865e8" name="phat:StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">228,696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7e182e78-62c6-4489-ad27-ce0ffe550606" contextRef="C_b5a1d5b1-793a-4122-8486-ddd80632f18a" name="phat:CashlessExerciseOfCommonStockWarrants" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">401(k) matching contribution</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b273c38c-c94e-4f40-8f1e-fdf19e232210" contextRef="C_9c879136-27f6-49d8-8690-7a4079f865e8" name="phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e2def9b1-2c57-456e-a3bd-f322dc092b28" contextRef="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_94182f63-348c-40bf-91bb-214d831c01ea" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vesting of restricted shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_415869b5-b64c-4e5d-86de-3cbd19b8171d" contextRef="C_9c879136-27f6-49d8-8690-7a4079f865e8" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,601,950</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_913fc582-086d-498c-9921-dad13a0ad6ea" contextRef="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,812</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7a3c1e0b-0fa8-4299-9607-ba18e83ee50a" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,812</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ESPP shares issued</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_616b18a1-b341-468a-96d7-41dbcdd034c3" contextRef="C_9c879136-27f6-49d8-8690-7a4079f865e8" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_33d4839e-0752-44f2-9776-dcfc9f56fa14" contextRef="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">819</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a2b4f246-eb8b-4098-aa1e-54e12b4a1a46" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">819</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Issuance of common stock warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_29e02d41-305c-45b7-bf44-6810830a88bf" contextRef="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0dea465e-a3e4-48fe-b5aa-bceb044c2abc" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3e01f5bc-7e3d-4b8e-9b1d-6d7460756787" contextRef="C_c9d3b85f-d90c-44ea-828c-6eca6895c78b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f4cb8481-b751-4ee2-b70d-be417ff62e75" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9450b39b-3642-4d94-a3c8-261c893849d1" contextRef="C_ad628062-bdfb-4035-85ce-04fb1a93328a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,511,226</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_af0be737-ad43-4944-bb42-8a05f92977cb" contextRef="C_ad628062-bdfb-4035-85ce-04fb1a93328a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ded0bb45-07d2-42ba-b3e7-dcc101e56cf8" contextRef="C_0e19ddc7-d662-491a-b517-1a7dc60b7d07" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a3c40efd-a7b5-4f3e-a61b-9f454d058480" contextRef="C_c4ab7858-b04f-4eaf-90c2-cde3b6e2669c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">601,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a2df3e28-0fcb-4966-aa95-a0f61f3b3584" contextRef="C_12faa295-829a-4324-8f79-7c114d53f496" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">529,370</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_95b7a7fd-d3cd-4d06-b308-de971aa49c91" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cashless exercise of common stock warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_91ceb24c-936b-4e13-bb9e-13de19ec5886" contextRef="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba" name="phat:StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,359,285</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_93ff6315-740b-47dc-9366-3e922a210c8c" contextRef="C_7ad3d68e-7eb3-4452-8fce-3d43389eeafa" name="phat:CashlessExerciseOfCommonStockWarrants" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">401(k) matching contribution</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_217bf58e-f702-4b42-a5ba-3f0d8d76bf70" contextRef="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba" name="phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">101,540</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_12a82260-907e-477d-a896-37a86a120745" contextRef="C_997ec618-b563-491c-9eca-1c0da676ff3e" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4f6a8df0-7bf4-4654-bf2a-2fb451ffc9cb" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vesting of restricted shares and restricted stock units</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e999919a-a2c6-4528-bc22-91e1633846e4" contextRef="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">992,825</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Issuance of common stock under ATM facility</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_06d9a8a1-52c6-41a6-98bf-6c387587f9e9" contextRef="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,414,897</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d29f17f9-8a54-4de7-a246-94bf8954cfd8" contextRef="C_997ec618-b563-491c-9eca-1c0da676ff3e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7e75b072-3f62-43e7-bae0-93f29facee3e" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f1aeb5f8-7122-4cab-a0a9-72bdd98192f5" contextRef="C_997ec618-b563-491c-9eca-1c0da676ff3e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ba9dd415-080d-4160-a2ba-c9f8b8b14be2" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ESPP shares issued</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_152b29cd-75f5-4184-864d-765b9558f559" contextRef="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">89,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_773d19fe-d87b-4e38-a29a-d6e845e8bd85" contextRef="C_997ec618-b563-491c-9eca-1c0da676ff3e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9abe67b5-1bc8-4b95-9d9f-f4e22f458bc9" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_44b4fa87-acca-4bc8-acd4-dd70ba84cf02" contextRef="C_d53f3397-a799-4e1e-97d8-9158ecf94191" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">197,723</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2de48f77-49f1-4804-a877-9cd6b46b0fa2" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">197,723</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bc3f8a0c-9209-48c4-9e62-56e2e47e9a72" contextRef="C_b200a58a-3188-46aa-b5e6-de3a179abb6b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">41,468,871</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_628d80a1-7276-47ad-baf6-b5fb857132e9" contextRef="C_b200a58a-3188-46aa-b5e6-de3a179abb6b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c7857bfa-467a-4417-b37a-8d317785fac2" contextRef="C_2c6526c3-fe53-437c-8a64-5ef862e523ec" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2ae3471a-5167-4319-8eb0-7a0388a199e5" contextRef="C_a303df35-50f8-4246-ac81-15cdd055190d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">652,276</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_af227d9e-89e9-40d8-8e6f-c6e889b79fad" contextRef="C_8a9abbdc-846c-4903-a0f4-53dd7476cd04" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">727,093</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a3a5dfa0-e7e9-4f48-a6ad-e5eb0df76503" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PHATHOM PHARMACEUTICALS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="combined_statement_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Statemen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ts of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.961%;"></td>
    <td style="width:1.637%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.814%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.637%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.952%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dc78fe0f-94f5-4255-be39-d3d4fc111448" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">197,723</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_47ba4cc8-ef25-42d8-861a-6f623fd47bdf" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f6f95705-e6a8-49c7-adfe-244937f13f29" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">620</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f9ad93b0-191c-4867-a190-588cb1f252eb" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e8396e86-514e-4e7f-a3bf-db61c2ab6b63" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7d76b49e-1ddf-4e4c-8993-d449e5957ec2" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,812</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Issuance of PIK interest debt</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b065337f-1acf-48da-8c7f-9a96e75b328c" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:PaidInKindInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,484</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_06b63293-6922-46f5-98e5-d54881a8bbed" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:PaidInKindInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">990</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;Accrued interest on revenue interest financing liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_20992ac6-2615-4fd9-a887-d0f7ab147fb8" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:AccruedInterestOnRevenueInterestFinancingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,079</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amortization of debt discount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5ed37be9-ca8c-4fdd-a018-10f90ba8ed3a" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_275aa87c-3bc2-475c-8ec0-ab6ecf7c9f0a" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e358bbce-d088-4df2-ba89-666dbf84c58b" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5259590e-0ecf-4a17-a5ab-19004487e447" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">823</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prepaid expenses and other current assets (includes changes in related party amounts<br />&#160;&#160;&#160;of $</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fa59d5ad-cb4a-4a66-bc06-75ae6438e714" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;and $</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4640522e-2e57-4c4d-a4b0-1e4faa5d4d9b" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0c81b18b-2bc0-4e17-a9d4-3de237567521" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,860</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cf924615-5119-4885-8a76-803cc8c0fb0b" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">605</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accounts payable and accrued expenses (includes changes in related party amounts of<br />&#160;&#160;&#160;$</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_baeee31d-83af-4e41-a7c9-5e4ddd17b44a" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,139</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;&#160;and $</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c48bbffa-bfac-4579-b7ec-69fe9b13a0c0" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,766</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7b15e909-2b3a-45b3-8580-e93005cb5475" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,679</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f3fbe920-6739-4251-91d0-a61f4ff27f25" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,791</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued clinical trial expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d6cd0b79-9717-4ddf-9327-99dfc85c1923" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:IncreaseDecreaseInClinicalAccruedTrialExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,402</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_166b0a24-42db-4048-8dcc-d1ae8b968614" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:IncreaseDecreaseInClinicalAccruedTrialExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">18,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued interest</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7fd9758e-20df-4898-8d9c-78867af19ae2" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">377</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_45e66f2e-5ea6-4bdb-a3a0-a97b0f44bfac" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating right-of-use assets and lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dc96c450-10e1-4863-82e3-189c118d6e63" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_30c71846-8094-4a42-8f44-c83ac2c25222" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8f36b61d-7afb-4802-84ef-6ffac46677d3" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_53c71861-04c2-4438-a12a-30a2c7d85646" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_27b14526-5106-48f2-abba-4ccd52974e18" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">146,530</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ce023376-b13a-4f5a-8d58-623845c81f7a" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">148,457</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash paid for property, plant and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2c93fae5-9616-4c54-ad1a-a1406b8459dc" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5c409625-0a13-4fff-8ef5-8cedb65bc328" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ea4a1bc7-b3ec-4917-9a5b-a059390a3da7" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e74d0eba-82a0-49d2-86f7-a04b400d22e0" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Proceeds from issuance of common stock from exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b7b73664-bd8d-48a7-ae54-33a6e8af0fff" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Repayment of long-term debt</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_66148624-7fdb-418f-9d34-4c65317530b3" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net proceeds from issuance of long-term debt</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0376fc2e-c970-4c4a-870d-e57c2bb60cd2" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,889</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net proceeds from revenue interest financing transaction</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_34fc05da-03f6-43f5-9ef4-6d00ecb008b4" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:NetProceedsFromRevenueInterestFinancingTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,446</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net proceeds from issuance of common stock under ATM facility</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ea38a112-70c5-4392-b33e-7968631abe0f" contextRef="C_16374c27-e9d9-4deb-990b-aa5e9aac1074" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,596</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bcd9daef-8a56-4098-a606-5a0fa7a7ddbb" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,042</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e562685e-f530-4b5d-acd4-2d5e7b9c6390" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net decrease in cash and cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_81ca2f5a-e75f-4abf-9d04-618f38092f51" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,529</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2192c283-ef08-41d0-b9e6-aeb9eeeb9921" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">104,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents and restricted cash &#x2013; beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ee2ea7dd-d3b6-426a-a2f7-6828914849d1" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183,419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_45b24c1f-4c49-45c6-bdc7-6307429c622c" contextRef="C_3625bbc7-e0d2-4ae5-80c9-2c2a001c24c0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287,496</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents and restricted cash &#x2013; end of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cd640bf1-7049-41c0-a26a-b11f44a03364" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">155,890</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a4c3e962-1c81-4dcd-8cd3-38c6b0cc2242" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183,419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Supplemental disclosure of cash flow information</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interest paid</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_62eabdaf-e3db-4328-836e-51cbf80dcf45" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,033</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b2234550-5e87-4651-ad47-c651d0e987ad" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Supplemental disclosure of noncash investing and financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Issuance of common stock warrants in connection with long-term debt</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cb36f7ec-36ba-440f-9884-a91eb9ba311a" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Property and equipment purchases included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0b15abdb-20a0-479f-b8ec-07ead8a0ad1e" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">138</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b82e32c1-4571-4f35-9e60-32ae712b50f3" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Final interest payment fee</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e66eeb0d-b321-4d5c-acd8-e84940b3721e" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:NonCashFinalInterestPaymentFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Settlement of ESPP liability in common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9192bced-0280-4196-808f-ca2fd5b3a23c" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_664b7e5d-11f4-4f72-bf83-8245e74e1e20" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">819</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Settlement of 401(k) liability in common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4c197eac-aade-4e9d-b8df-58a56be7ac3d" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_169f9a90-146c-4a57-96f6-1e6e83eab547" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities arising from obtaining right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3efcf56b-df70-4aad-be2d-9ac8f2b212a1" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">554</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PHATHOM PHARMACEUTICALS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_financials"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Notes to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial Statements</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_17fc58be-374a-4c74-adac-d2a0571f3fe0" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1. Organization, Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_4817754c-34f8-4c95-9093-462d06a773b3" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:OrganizationAndBasisOfPresentationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Organization and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company&#x2019;s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_3dda8fb3-e556-4926-ab44-733de2af4701" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:LiquidityAndCapitalResourcesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">From inception to December 31, 2022, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the clinical trials of vonoprazan, preparing for commercialization of its initial products containing vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur additional net losses in the future as it continues to develop and prepares for commercialization of vonoprazan. From inception to December 31, 2022, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, revenue interest financing debt, the sale of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_53174c99-ebae-4821-a38d-cebfb927d1a4" contextRef="C_f71a8436-7cab-4cb1-a0b4-4ed9b66f0382" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,997,630</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c2165514-b956-4d0c-9a79-262d80578371" contextRef="C_f71a8436-7cab-4cb1-a0b4-4ed9b66f0382" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">191.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in its 2019 IPO, the sale of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_48daa5a5-2939-4485-8c4f-c54b07b8e7f2" contextRef="C_193ec4b9-a149-4c59-b451-7fd82670dde2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4a3f4784-6c15-470f-ab34-46cec55aad5d" contextRef="C_193ec4b9-a149-4c59-b451-7fd82670dde2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">88.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in its December 2020 follow-on public offering, and the sale of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f1a90958-7104-4b79-a8f8-0661844a49d3" contextRef="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,414,897</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8d363f30-eab2-4235-92f9-e5733fc00b33" contextRef="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">24.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in its September 2022 issuance of common stock under the ATM Offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company&#x2019;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company&#x2019;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_235326c4-51b9-4460-ac70-a23003e9dcbc" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_fb3f7960-d5bd-4fae-be21-e5e5f57e4bb7" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Level 1: Observable inputs such as quoted prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The carrying amounts of the Company&#x2019;s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_118299ef-2ff8-4bbd-83dc-04caece64521" contextRef="C_d1da1354-c115-4771-a4a8-bb35b2ea792f" name="phat:FinancialAssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> financial assets measured at fair value on a recurring basis. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_50cd2763-6777-490a-bb76-96404ca6f3e7" contextRef="C_d1e29e67-db80-4194-babb-a6fb361ff631" name="phat:NonfinancialAssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d51c7f70-9bc5-4815-8e41-00650ab3bfbe" contextRef="C_d1e29e67-db80-4194-babb-a6fb361ff631" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">None</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b2f2dab4-e229-4403-9e5c-8c9d282dc91b" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">n-recurring basis. No transfers between levels have occurred during the periods presented.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the estimated fair value of the Company&#x2019;s long-term debt approximated the carrying amount given its floating interest rate basis. The fair value of the Company&#x2019;s long-term debt was estimated for disclosure purposes only and was determined based on quoted market data for valuation, and thus categorized as Level 2 in the fair value hierarchy.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_e0827f46-46be-4c98-9f89-0e77b480a2ed" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_b3806b3f-0046-4b38-80e4-c4750caad5ef" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_8924a678-26d8-4ca7-acfb-f20848592bcb" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Property, Plant, and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="-sec-ix-hidden:F_d7201b82-ce21-4ec4-8499-cb8a67775133;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_66692ad5-5602-4ced-8113-18e10960546e" contextRef="C_6a3f3bfa-6949-4f34-b6ab-a42581ad38fb" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Furniture and fixtures are depreciated over</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_7594b741-b53c-4194-95ce-0dac509fbf99" contextRef="C_9b1aa0b6-a160-4d39-a073-61b00c5a103f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_883ec4c1-ad79-4d20-809a-ada7917593d7" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6fdc394f-46ec-418b-8ad8-937886e7435b" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> impairment losses have been recorded through December 31, 2022.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_14ea5fb0-50b4-44d0-85d4-27e6a43827b4" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:LessorLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company&#x2019;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_f896d7b0-3f51-4e07-abcf-04f9567e985a" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:RevenueInterestFinancingLiabilityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Interest Financing Liability</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company entered into a revenue interest financing agreement, or the Revenue Interest Financing Agreement, with entities managed or advised by NovaQuest Capital Management, or NQ, Sagard Holdings Manager LP, or Sagard, and Hercules Capital, Inc., or Hercules, together with NQ and Sagard, the Initial Investors, in which the Company received funds in return for royalties on net sales of products containing vonoprazan. The net proceeds received under the transaction were recognized as short-term and long-term liabilities with interest expense based on an imputed effective rate derived from the expected future payments. The Company recalculates the effective interest rate each period based on the current carrying value and the revised estimated future payments. Changes in future payments from previous estimates are included in current and future financing expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_36d101d5-91f5-4568-8b98-db8ab294556c" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_36d101d5-91f5-4568-8b98-db8ab294556c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#x2019;s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:continuation id="F_36d101d5-91f5-4568-8b98-db8ab294556c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_b2227a44-957b-4fc9-ab02-8b832e2d0d82" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:InProcessResearchAndDevelopmentPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">In-Process Research and Development</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_227dc8c7-3eec-4474-a882-d3c2ec46e200" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_ce28305a-58f7-4851-adc7-7acb94d89086" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company also maintains an employee stock purchase program, or ESPP, under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_557d6ad6-9c44-4566-99ea-22f7dfa4f0d5" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning in 2022, the Tax Cuts and Jobs Act, or TCJA, eliminates the option to deduct research and development expenditures currently and requires taxpayers to amortize domestic and foreign research and development expenditures over </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_027cd8de-6bf8-484f-9c2a-fa884ac32c4d" contextRef="C_4160e414-35f2-4edb-94aa-a3ea7eeab964" name="phat:TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_1fa67c76-b2be-438c-a2af-0301cea0b8df" contextRef="C_d9d8f01d-3d43-4934-ad2b-b3a53489fec5" name="phat:TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years, respectively. The requirement did not impact cash from operations in the current period.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_5e74eb20-34c5-4e0f-b3f7-21f9fd272cda" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods presented.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_417d6629-8b13-45c2-9254-50ce7c23535d" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fbbaf46c-daa9-44e5-82e2-bf81dbf38789" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> operating segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_400c8ad8-a736-448b-8a8f-0814e51ab308" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d08e3028-5394-4a81-b3b8-44b14056cdec" contextRef="C_0cceeb3e-ff40-49d0-b18c-96a61d412299" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,588,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock under its warrant (the &#x201c;Takeda Warrant&#x201d;) issued to Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;) in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company&#x2019;s IPO until its exercise because the Takeda Warrant was exercisable for little consideration. As of December 31, 2022, all Takeda Warrants has been exercised and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f4171e9e-9261-4b6c-a2b8-5b941530cbb0" contextRef="C_3d0461f1-b88c-4662-9709-e549cfb4144e" name="phat:NumberOfWarrantsRemainingExercisable" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Takeda Warrants remain exercisable. For the years ended December 31, 2022 and December 31, 2021, the Company has excluded weighted-average unvested shares of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_37abb465-c3d3-4c97-81b9-cb9f63f49417" contextRef="C_0d987563-e4a1-47c2-a958-218433edf069" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">686,703</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_476c8887-20a7-4fa1-8195-bd5b0898293c" contextRef="C_da396882-6f6e-44fb-b650-cc0b5c7ed2f3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,939,252</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_f19c8460-2bf4-4056-b2f1-18a7456d48cb" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Recently Adopted Accounting Standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">There were no recently adopted accounting standards which would have a material impact on the Company's financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">     </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2022 that impacted the Company.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_8ad8614f-ee95-4ede-a395-40430c4373b9" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:ComponentOfBalanceSheetDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2. Balance Sheet Details</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Property, Plant and Equipment, net</span></p><div style="font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_0d79c5c5-e0e6-4811-a100-2f46ba4586b5" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Property, plant and equipment, net, consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.276%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.023000000000003%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.023000000000003%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_07684906-56f9-485a-897c-3d9a8650ec99" contextRef="C_50a28e01-3143-418a-81bb-bfbdc824e6bb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,078</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dedc80d0-905b-49db-a4ff-83ab587ad01a" contextRef="C_52ad1a5c-6e1b-4d4e-9cf1-f8d7bea71a22" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">646</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b40e3ab4-ff92-4352-9435-ebdb491a602b" contextRef="C_7acebd49-8754-4509-8ad2-aef189b7a108" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,086</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_953224b3-8acd-44ae-8243-a1823738c0de" contextRef="C_2605f8bc-b7a3-4e6a-b47e-dad76807d9a5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">780</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e08e8424-89e7-4948-89f8-f19a893bfdc2" contextRef="C_085d1c47-e6cb-4591-b010-3194bae40e70" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bc9116f2-a29a-4685-a6ec-bb7ced9f82f7" contextRef="C_7d957629-8d64-4447-931c-6471c184bdc3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Construction in process</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b95f476a-23a2-4267-a0b0-b79988ca35a5" contextRef="C_3b1269f3-0919-4f09-919c-ae285bdda990" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">399</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total property, plant and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_520b3e73-1821-4485-987f-c0da0fdc861f" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,678</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ed9c16bb-464f-4bcc-8320-210485aea962" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c63586f1-47f7-45e1-a7f2-64e692035713" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,471</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_777f2179-af0d-4118-acba-ed0e5184dfdd" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">852</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total property, plant and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_af153e61-37b9-4e0c-8fec-46bd4470906f" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,207</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ea4e395e-2067-41ba-b3f4-804386e5928b" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Depreciation expense for the years ended December 31, 2022 and 2021 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_603bc7ce-8dae-45ea-806b-74730b2cb026" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_acc9c76e-5975-4386-8a8e-7eea3e03085c" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3248d07d-287a-4848-ac32-22e1a58e28ce" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:PropertyPlantAndEquipmentDisposals" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_36ac3e85-2b52-46f5-a784-c71e77e28d9d" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:PropertyPlantAndEquipmentDisposals" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> property, plant or equipment was disposed of during the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Accrued Expenses</span></p><div style="font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_28fdeb09-3181-4af8-96e9-d6c9607219aa" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued expenses consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.471%;"></td>
        <td style="width:1.343%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.913999999999998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.343%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.929%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7a771e21-3476-40df-9f84-ce4d53735a9f" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,080</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_447787e7-ed7d-4d35-9bc4-80761e2a0580" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="phat:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued compensation expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d0d429b4-3923-43f7-8046-f1fb8bac657c" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,447</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7d77b958-b876-4bc9-8b0d-dc00d4f8c7ed" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,344</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued professional &amp; consulting<br />&#160;&#160;&#160;expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c96586bc-133b-48a6-8f58-c910715b2eab" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d7a91621-38eb-4d42-a720-1b9ac7c5d2c8" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,855</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a20b0b38-b323-4f70-a7ba-ba904a7a9ec9" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3cad7c47-fa25-4cf4-b77c-cb4a821cb4d5" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_91716bdd-1a17-42a1-a13c-26e0a0c18d16" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,678</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_52c10231-8529-4753-9787-3ead0849d63c" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,405</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_4930eeef-737a-4f9d-9f11-21aeb8cd3943" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Frazier is a principal stockholder of the Company and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> is a principal stockholder in PCI Pharma Services, or PCI. In the third quarter of 2019, the Company engaged PCI for clinical manufacturing services. As of December 31, 2022 and 2021, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_803dbbac-456c-4d7e-b384-b89e1d59beab" contextRef="C_1ca84d6f-4ec7-4ca7-a80c-ce5f47b70bdf" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bd4e0cc9-3a08-40aa-a21d-b63d64baa3cc" contextRef="C_921713e0-e38d-456b-b30a-55995a73ff55" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, in outstanding accounts payable and accrued expenses related to these manufacturing services. For the years ended December 31, 2022 and 2021, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4c905daf-718f-478a-8f2b-60a32b9bd40b" contextRef="C_d27b5644-2ffe-49a5-bcac-f51f4f379e72" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_576bd877-92d4-4610-800c-31375471141f" contextRef="C_15355aaa-f30b-4175-9505-232bcaaa97e6" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, of expenses related to services performed by PCI.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Takeda became a common stockholder of the Company in connection with the May 2019 license agreement (see Note 4). In conjunction with this license, Takeda provides proprietary supplies for the Company&#x2019;s ongoing clinical development of vonoprazan in addition to the exclusive license for the commercialization of vonoprazan in the United States, Canada and Europe. On May 5, 2020, the Company entered into a Commercial Supply Agreement, or the Commercial Supply Agreement, with Takeda, pursuant to which Takeda agreed to supply commercial quantities of vonoprazan bulk drug product or drug substance. Pursuant to the Commercial Supply Agreement, Takeda agreed to supply the Company with, and the Company agreed to purchase from Takeda, certain quantities of vonoprazan bulk drug product according to approved specifications at a fixed price per batch of bulk drug product in order to commercialize vonoprazan in accordance with the Takeda License. Unless terminated earlier, the term of the Commercial Supply Agreement extends for a period of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_dc48d7ad-4320-40c8-a85c-07a342c42c71" contextRef="C_3e93f3f8-5fa9-4e0e-9be2-05e4b1b44b52" name="phat:AgreementExtendsPeriodForTermination" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> from the date the Company places an order for bulk drug product or drug substance for the first commercial launch of vonoprazan in any jurisdiction in the licensed territory, provided that this two-year period will expire no later than December 31, 2023. The Commercial Supply Agreement will terminate immediately upon the termination of the Takeda License in accordance with its terms. In connection with the Takeda License, the Company entered into a temporary services agreement, or the Temporary Services Agreement, with Takeda on November 24, 2020. Pursuant to the Temporary Services Agreement, Takeda agreed to provide or procure the provision of services related to the ongoing clinical development of vonoprazan. The Temporary Services Agreement will terminate immediately upon termination of the Takeda License in accordance with its terms. As of December 31, 2022 and December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_331b35d1-5dea-4dd7-a897-362a6e33849a" contextRef="C_12f1ae54-8af7-498f-b9c2-d3ecab67150a" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4fe27633-8595-4a68-873f-33417346fa1f" contextRef="C_d8f8b7b4-5d19-4a59-808a-7620c9d1ce95" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, in outstanding accounts payable and accrued expenses related to these agreements.  For the years ended December 31, 2022 and 2021, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f5bb01e7-f758-4f7b-864e-accd02990f93" contextRef="C_d9072564-13ae-4ea1-84c1-9febe815dd19" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5bda577c-f3ed-42f8-8f40-5ad8dcef39ad" contextRef="C_a9b385aa-6a5f-45cc-a03d-80389e7fbcf7" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, of expenses related to these agreements. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d9e2880d-6516-4efb-bd9b-99a63c4fccee" contextRef="C_e7e1b33c-ea56-4599-a9c9-30b1918239b4" name="us-gaap:PurchaseObligation" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> remaining minimum purchase obligation related to these agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_ad19cdbc-cc2a-49d4-854b-9fa0857e6448" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">n May 7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe, or, the Takeda License. The Company also has the right to sublicense its rights under the agreement, subject to certain conditions. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_8f8d4ea2-4144-4908-b895-2abe2b4e6c8a" contextRef="C_ee4ba230-41b0-4d69-921e-1d90ed587bd8" name="phat:LicenseAgreementDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_17c401a6-8fd0-4f82-8cb3-be7c7a81bfb2" contextRef="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a" name="phat:AgreementExpirationTermFromDateOfFirstCommercialSale" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months&#x2019; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#x2019;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">n consideration of the Takeda License, the Company (i) paid Takeda $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fa57000b-be1b-4021-9e69-e89d4b7254ff" contextRef="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a" name="phat:PaymentForLicenseAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in cash, (ii) issued Takeda </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_707ec201-6823-4cc1-91ec-93f9921d2ebb" contextRef="C_a1345e6a-366c-4155-83c9-889619f08e7d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,084,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of its common stock at a fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ba6da91c-4e5b-4ec7-900a-7a38012346c5" contextRef="C_a1345e6a-366c-4155-83c9-889619f08e7d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, (iii) issued the Takeda Warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d0e033c5-e24a-4f0b-bf20-35490392e17b" contextRef="C_0cceeb3e-ff40-49d0-b18c-96a61d412299" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,588,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of its common stock at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e436bd05-6d35-41b6-aef7-446e0a07411c" contextRef="C_a1345e6a-366c-4155-83c9-889619f08e7d" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="8">0.00004613</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per share at an initial fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1959e847-c02c-45d1-8e54-a60860252283" contextRef="C_a1345e6a-366c-4155-83c9-889619f08e7d" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">47.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, and (iv) issued a right to receive an additional common stock warrant, or, the Takeda Warrant Right, should Takeda&#x2019;s fully-diluted ownership of the Company represent less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately before the closing of the Company&#x2019;s IPO, with a nominal initial fair value due to the low probability of issuance. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of the IPO, and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_67232506-8442-4e27-b6e3-a51a98d5b7f2" contextRef="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a" name="phat:AdditionalWarrantIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> additional warrant was issued. In addition, the Company is obligated to pay Takeda up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a82a0e0e-85cb-4c2c-a96b-d964c33a483c" contextRef="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a" name="phat:MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in sales milestones upon the achievement of specified levels of product sales, and a low double-digit royalty rate on aggregate net sales of licensed products, subject to certain adjustments. The Takeda Warrant had an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f38173bb-ad2a-43db-99eb-ce367f9113f8" contextRef="C_a1345e6a-366c-4155-83c9-889619f08e7d" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="8">0.00004613</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per share, and was to expire on</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_5c065644-0cbe-4873-ac6e-38f435657d52" contextRef="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a" name="phat:WarrantsExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> May 7, 2029</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and became exercisable upon the consummation of the IPO. As of December 31, 2022 all Takeda Warrants have been exercised.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Purchase Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In December 2020, the Company entered into a supply agreement with Sandoz pursuant to which Sandoz will supply commercial quantities of amoxicillin capsules and clarithromycin tablets, package these antibiotics with vonoprazan, and provide in finished convenience packs. The supply agreement commits the Company to a minimum purchase obligation of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_39f62df9-25fd-474e-9cd8-14ad1782197d" contextRef="C_d2db8e6c-935d-488d-812e-7446da50b3c3" name="phat:PurchaseObligationDueInFirstTwentyFourMonths" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in the first 24-month period following the launch of the final product. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5f1fa60b-2b88-4474-b492-e14b64e7383d" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:PurchaseCommitmentExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_dd76b691-5065-4a88-8bd3-7dbd25de12c2" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:PurchaseCommitmentExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">t incurred any expenses under the agreement during the years ended December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_448cdb70-c7d4-4242-83d7-0362a6cf2cf5" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5. Lease Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company had operating leases for office space in both Buffalo Grove, Illinois and Florham Park, New Jersey, with weighted average remaining lease terms of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_59e454a2-c46a-4a94-9d9d-33ef98251298" contextRef="C_ab4915e2-d84a-4fe8-8537-63d674acad7a" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_8cf3cdd1-a98b-4cc1-b006-376010c0435a" contextRef="C_b3d62e8f-6837-4e80-a47d-75eba6bca352" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.7</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years, respectively. All</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_8f4198bc-ab1c-494d-aa95-d8c37e47e815" contextRef="C_5dcc212e-21a7-4a55-bc25-9c94fd4f27d5" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><ix:nonNumeric id="F_bbda5aa2-829e-4b9d-9aa6-c8a28a49cdaa" contextRef="C_eb1ec5a6-fae4-47b9-b672-953a87241f7b" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> operating leases contain an option to extend the term for </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fdebb4cd-c166-49d7-b9eb-9cc766c17180" contextRef="C_5dcc212e-21a7-4a55-bc25-9c94fd4f27d5" name="phat:LesseeOperatingLeaseNumberOfOptionToExtend" unitRef="U_Option" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e6616361-fc0b-4ddb-a495-908eed76d83c" contextRef="C_eb1ec5a6-fae4-47b9-b672-953a87241f7b" name="phat:LesseeOperatingLeaseNumberOfOptionToExtend" unitRef="U_Option" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> additional </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_5e0530a2-1221-4eab-adb9-e4670432f22a" contextRef="C_ab4915e2-d84a-4fe8-8537-63d674acad7a" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_a10bdc80-dd53-4a24-b064-ecf1c989c5c6" contextRef="C_b3d62e8f-6837-4e80-a47d-75eba6bca352" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">five-year</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> period</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, which was not considered in the determination of the right-of-use asset or lease liability as the Company did not consider it reasonably certain that it would exercise such options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">     </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The total rent expense for the years ended December 31, 2022 and 2021 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9bfa8b79-543c-4993-898f-b172b99576a0" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_798474db-bd36-4f72-9e83-8f87092acc80" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_d44cf582-11c2-4ac7-b66b-877c03fe55ab" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.173%;"></td>
        <td style="width:1.511%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.893999999999998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.528%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.893999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_545a7294-1e6a-42f6-8c84-d114d7112425" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,287</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_10839017-4e39-41db-a305-c4dab2119129" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,914</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f252e010-9a55-422c-9579-9cde74ced272" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,287</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_079b9c5a-d3c9-4ae0-97bb-2e208903640f" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,914</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_61c1b462-b1ff-4e22-ba6e-ad25b4c244fe" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">708</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_39fe6095-1210-4e5e-87fe-71b89c223d8a" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_63401e22-ab7d-4624-b248-9c3c932621be" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dc29384b-5179-45cb-9a8e-6b7f437c1731" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,183</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ea7457d2-5edd-4da9-8ea9-15537ada3b00" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_07bb0ec2-e6fa-4fd9-988e-025a8da0d7b7" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,670</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_8a258ca5-7412-4e3d-b6d8-2821ea4554ff" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the future minimum annual lease payments under the operating leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.12%;"></td>
        <td style="width:1.493%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.387999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_02773585-04ab-4fde-8825-77b3fd5f4d46" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">734</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4921134f-dd38-4a7a-a3c7-7e12b8a62403" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">753</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f0d63076-d52b-40f7-aa2d-fa1ce80cafaa" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">513</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_de8fbd16-a477-40ae-ad26-c77e7e3eecd7" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c090632a-157d-4e9c-9280-87b1f47de75d" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_beba01a0-de84-4f8c-969b-ed0383181348" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_79894850-cd39-4ef4-8da9-bcfc6504c064" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">708</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_46d452f3-00f0-4fc6-a403-092b34a9fa73" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_8d7b1fd2-9296-46d1-b0de-e3a209576257" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_21c5e799-8427-4d4e-b6d9-743d343b24b8" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">8.20</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating cash flows for the years ended December 31, 2022 included $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_83889325-620b-4b73-bed3-7ca001d867c6" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in cash payments for operating leases, none of which were prepaid lease payments. Operating cash flows for the years ended December 31, 2021 included $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e40e07d2-75b1-46f2-921f-f760f2d813c3" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in cash payments for operating leases, $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b7fc12e2-a8ce-4fa5-b050-2f3993d9b638" contextRef="C_8d783f53-5bda-4abc-8b88-b5d7f5533766" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of which were prepaid lease payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_4404e88c-46ce-4695-be11-5e9dea29c342" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6. Debt</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_d35006b5-7a50-4b28-a9a0-47513f02fe88" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total debt consists of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.352%;"></td>
        <td style="width:1.516%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.131999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Long-term debt, current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Long-term debt, non-current portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d00d6336-f5c4-4545-a539-85b4739d4723" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104,474</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unamortized debt discount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4c0e1fc4-34dc-4e36-a82d-f27775f40d87" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,210</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total debt, net of debt discount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d94ccd2c-d5b1-41eb-a929-3fc3b529d33a" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,264</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On September 17, 2021, or the Closing Date, the Company entered into a Loan and Security Agreement, or, the Loan Agreement, with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender, or, in such capacity, the Agent or Hercules, and the other financial institutions that from time to time become parties to the Loan Agreement as lenders, or, collectively, the Lenders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Loan Agreement provides for term loans in an aggregate principal amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b69e852a-e7ed-475a-8e0e-f8487be818c8" contextRef="C_5376a47a-2a6e-4c10-a523-6c29d3b5be8d" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">200.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, or the Term Loan, under multiple tranches. The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ba779819-0121-4da7-9707-6dca833daa71" contextRef="C_70ed3e4f-7d42-4f15-94f8-e35d5e32239e" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, all of which was funded to the Company on the Closing Date, or First Advance, (ii) a second tranche consisting of up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_47ce03bd-a0ea-4346-86b7-0ea0f8de038f" contextRef="C_f3f07980-4a45-4835-8463-e1d119c8e5c1" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, which became available to the Company upon achievement of the protocol-specified primary efficacy endpoints in the Company&#x2019;s Phase 3 trial studying vonoprazan for the healing and maintenance of healing of erosive GERD with acceptable safety data, such that the results support the submission of a New Drug Application, or NDA, or supplemental NDA without the need to conduct another Phase 3 study and will be available, if specified conditions are met, through December 15, 2022, see amendment to later date below, (iii) a third and fourth tranches consisting of an additional total $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8d32730c-f95d-4ba2-bd51-75c7fdfa2721" contextRef="C_91b73800-dbc6-43cf-9117-11565d545493" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, which became available to the Company in May 2022 upon the achievement of (a) Food and Drug Administration, or FDA, approval of the Company&#x2019;s NDA for vonoprazan and amoxicillin, or its New Drug Application for vonoprazan, amoxicillin and clarithromycin, in each case for an indication relating to the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Helicobacter pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">with an approved indication on the claim that is generally consistent with that sought in the Company&#x2019;s NDA submission&#x37e; and (b) filing of the Company&#x2019;s NDA or supplemental NDA for vonoprazan for indications relating to the healing and maintenance of healing of erosive GERD. The third and fourth tranches will remain available until September 30, 2023, and March 31, 2024, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On September 27, 2022, the Company entered into an amendment to the Loan Agreement, or the Second Loan Amendment, pursuant to which the date the second tranche of funding of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_56aff4d5-9e20-4694-9cdb-740760e9faca" contextRef="C_808be0ce-b254-4e5d-b14f-728aa82ef026" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million will remain available to the Company has been moved until May 15, 2023, rather than December 15, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company paid a $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_29e0326c-aa0b-46d2-884b-87cdaf96ce1d" contextRef="C_8952b2b3-05be-4dbb-bb15-29a22754c147" name="phat:PaymentForFacilityCharge" unitRef="U_USD" scale="6" decimals="-4" format="ixt:numdotdecimal">1.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million facility charge in connection with closing of the Loan Agreement and would need to pay </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f1d30784-8b60-45a4-979d-a15149ac162a" contextRef="C_8952b2b3-05be-4dbb-bb15-29a22754c147" name="phat:DebtInstrumentFacilityChargePercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of any advances made under the third and fourth tranches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">he Term Loan will mature on </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_cd2e17bb-4c24-4e3b-9294-b7f26a64d800" contextRef="C_8952b2b3-05be-4dbb-bb15-29a22754c147" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">October 1, 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, or the Maturity Date. The Term Loan bears (i) cash interest at a variable annual rate equal to the greater of (a) </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9b8ae78c-b7f8-4e68-b9e7-2c47a9eb0564" contextRef="C_4f067a4b-daf1-4028-b748-712e3b729620" name="phat:DebtInstrumentInterestRatePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% and (b) the Prime Rate (as reported in the Wall Street Journal) plus </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c627c8de-08a3-41f1-b469-3659ffdffd08" contextRef="C_d34ef88d-9f9b-4614-9c60-3fd356fe4846" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%, or the &#x201c;Interest Rate&#x201d;, and (ii) payment-in-kind interest at a per annum rate of interest equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dcdc8048-02cb-497f-8818-6cff1fc73da7" contextRef="C_2de0626c-2b10-4fe9-bbfd-1a4334ffe153" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">3.35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%. Phathom may make payments of interest only through October 1, 2024, which was extended to October 1, 2025, upon the achievement of the Second Performance Milestone in May 2022 prior to September 30, 2024 and met the condition that no default or event of default exists, and which is further extendable to October 1, 2026, subject to FDA approval of the Company&#x2019;s NDA (or supplemental NDA) for vonoprazan for an indication relating to the healing and maintenance of healing of erosive GERD with an approved indication on the label that is generally consistent with that sought in the Company&#x2019;s NDA submission (or supplemental NDA submission), or the Third Performance Milestone, on or prior to September 30, 2025 and no default or event of default exists (the &#x201c;interest only period&#x201d;). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, the Company is obligated to pay a final payment fee of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e1eae7c0-f46d-47c6-8b17-be6963cfb2bc" contextRef="C_0baa7388-d9e1-478c-86d2-1a3bfcdf4327" name="phat:DebtInstrumentFinalPaymentFeePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the original principal amount of amounts actually advanced under the Term Loan, or, each a Term Loan Advance and together, the Term Loan Advances. As of December 31, 2022, the aggregate final payment fee for the first Term Loan Advance of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e9403f82-3bc6-4606-bcd4-712371e3db09" contextRef="C_f20982d1-f9ce-4d58-8f02-7abadfb18a90" name="phat:DebtInstrumentFinalPaymentFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million has been recorded as an other long-term liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company may elect to prepay all or a portion of the Term Loan Advances prior to maturity, subject to a prepayment fee of up to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8dbf6e5f-a350-432e-854b-c6c5e44cb03e" contextRef="C_254b2caf-becb-447f-bfa2-61ac97d82407" name="phat:DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the then outstanding principal balance of the Term Loan Advances being prepaid. After repayment, no Term Loan amounts may be borrowed again.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As collateral for the obligations, the Company has granted to Hercules a senior security interest in all of Company&#x2019;s right, title, and interest in, to and under substantially all of Company&#x2019;s property, inclusive of intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring the Company to maintain certain levels of cash subject to a control agreement in favor of the Agent (minus accounts payable not paid within 120 days of invoice), or Qualified Cash, and commencing on May 15, 2023, trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan. The revenue covenant will be waived at any time in which the Company maintains Qualified Cash equal to at least </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c4c49a05-6341-45b8-9576-26d3e4bd16ab" contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793" name="phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% (prior to the Third Performance Milestone), and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_16b7ec00-e803-4a4e-b810-c437e63ae535" contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793" name="phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% (following the Third Performance Milestone) of the total outstanding Term Loan principal amount, or the Company&#x2019;s market capitalization is at least $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bc85edd4-a76d-4475-a4a9-0fcb52dff088" contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793" name="phat:MinimumMarketCapitalizationAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">900.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company may be declared immediately due and payable by Hercules, as collateral agent. As of December 31, 2022, the Company was in compliance with all applicable covenants under the Loan Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under the Second Loan Amendment, the commencement date for the covenant based on trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan was moved from May 15, 2023, to November 15, 2023.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In connection with the entry into the Loan Agreement, the Company issued to Hercules a warrant, or, the Warrant, to purchase a number of shares of the Company&#x2019;s common stock equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6d328868-7473-485c-87c2-8c30e9469484" contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793" name="phat:PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the aggregate amount of the Term Loan advances funded, and will issue to Hercules additional warrants when future Term Loan advances are funded. On the Closing Date, the Company issued a Warrant for </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8459351d-49f6-4e92-bdf5-060139fe45c0" contextRef="C_3089a359-e1ec-4cf0-8d42-a935b7b8080d" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">74,782</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock. The Warrant will be exercisable for a period of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_2e1aa561-4134-4a84-9305-1521e2da3da5" contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793" name="phat:ClassOfWarrantOrRightExpireTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> from the date of issuance at a per-share exercise price equal to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e387e3fb-27e3-452e-b164-ad23544991fe" contextRef="C_0487172a-df33-4c7a-b44b-85c791ea9f49" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">33.43</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, which was the closing price of the Company&#x2019;s common stock on September 16, 2021. The Warrant is exercisable any time until </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_27ab064c-60d3-4799-b099-420c93a6c9ee" contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793" name="phat:ClassOfWarrantOrRightExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">September 17, 2028</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and had an initial fair value of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ff930d1c-b826-47c5-ba0d-ff4e2ba6eb1b" contextRef="C_0487172a-df33-4c7a-b44b-85c791ea9f49" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The initial $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d23a4142-74b4-47ef-888e-dda527315dcb" contextRef="C_0487172a-df33-4c7a-b44b-85c791ea9f49" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million fair value of the Warrant, the $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_658b9fac-ad8c-4967-943c-2863ecb4b6a6" contextRef="C_0487172a-df33-4c7a-b44b-85c791ea9f49" name="phat:DebtInstrumentFinalPaymentFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million final interest payment fee and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_eb9ecb4a-2509-4731-b490-c7cd0ccf78ae" contextRef="C_0487172a-df33-4c7a-b44b-85c791ea9f49" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of debt issuance costs have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the term of the Term Loan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_ecbaf961-9122-4bde-89b5-0611433eaecf" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Future minimum principal payments under the Term Loan, including the final payment fee, as of December 31, 2022 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.599%;"></td>
        <td style="width:1.521%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.88%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Year ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e78c8b6d-df0b-4937-b7c9-a83b11e92ab3" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7b5f5bd4-f947-4f23-aa91-b3eaaff35efa" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_506483bd-fe45-4e4d-b997-31af47fa8b92" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,707</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_10af8233-8af5-4976-b1ef-21dfe20ea96e" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,764</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total principal and interest payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cd218baa-00cb-4ecf-b96e-afcb0c91c345" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:LongTermDebtAndInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">124,471</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less payment-in-kind and final payment fee</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c4c1f27d-b178-4696-8641-d262d5b134a8" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:DebtInstrumentInterestAndFinalPaymentFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,471</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total term loan borrowings</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b2689a84-d5ef-4463-8fc7-aa4ff787ae95" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prior to the Loan Agreement with Hercules, the Company had a loan with SVB and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_02cdb2d0-427a-47ab-a647-3ad6886d805d" contextRef="C_2d98949a-30e1-4a98-8bd5-692271892f22" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">54.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of the proceeds from the First Advance was used to satisfy in full and retire the Company&#x2019;s indebtedness under the SVB Term Loan with SVB, including accrued interest through the payoff date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f2d4ef9d-8678-441d-9e04-810cf33549de" contextRef="C_f4d64b0f-a1db-4cfd-9a23-da10238263c0" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fdc2b883-ec92-4d06-aa8e-699958a556c6" contextRef="C_9960ff79-ef61-47f2-b12d-b0b42bd290e2" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, of interest expense, including amortization of the debt discount, in connection with the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Hercules Loan Agreement and SVB Term Loan. As of December 31, 2022, the Company had outstanding </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">loan balance of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b6378123-2385-4ba8-ab76-e312173ca2bc" contextRef="C_fc2a8230-0abf-4380-a0cf-1aee92ac8c64" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">104.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and accrued interest of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_65b97414-1888-4754-8e8f-5a58271934c0" contextRef="C_fc2a8230-0abf-4380-a0cf-1aee92ac8c64" name="phat:AccruedInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_516b0ae9-88b9-4051-9d74-c54336915171" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:RevenueInterestFinancingLiabilityTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7. Revenue Interest Financing Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On May 3, 2022, Phathom entered into a Revenue Interest Financing Agreement with Initial Investors NQ, Sagard, and Hercules pursuant to which the Company will receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_648b3630-035e-4941-8b9b-21606c86d36d" contextRef="C_f3416de9-775d-4af4-b997-f1e2dce25917" name="phat:InvestorsFundingAmount" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">260</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in funding from the Initial Investors. Under the terms of the Revenue Interest Financing Agreement, the Company received $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2c622098-5b99-4390-bbcc-bc0254fce54a" contextRef="C_29dfdd85-afb5-4d2f-a86b-48a3fd158ccc" name="phat:FundsReceivedFromInitialClosing" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million at the initial closing and can receive an additional $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a771fdf7-16f8-4cb2-87b6-071e6fd1f237" contextRef="C_161d27a8-0c36-4e47-af8a-c85124a58e31" name="phat:InvestorAdditionalFundingAmountUponApproval" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">160</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million upon FDA approval of vonoprazan for treatment of erosive GERD on or before March 31, 2024. At any time prior to December 31, 2022, the Company also has the right to obtain a written commitment from a third party for up to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2a51aecf-8c68-46d5-ac1f-c85f7b1ffb57" contextRef="C_d5734daa-3179-4da2-9c0d-ec26dd01ffa7" name="phat:PotentialAdditionalInvestorFundingAmount" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of funding upon FDA approval of vonoprazan for erosive GERD. In addition, the Company has the right at any time prior to June 30, 2024, to obtain a written commitment from a third party for up to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a8acb31a-b563-487e-8702-e5832dab96d3" contextRef="C_2769f622-b2f5-4b1e-9bfc-9d6f83d30fcd" name="phat:InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of funding upon achievement of a sales milestone. The Initial Investors have a right of first offer if the Company seeks to obtain such additional funding. The total amount funded by the Initial Investors and any subsequent investors is referred to herein as the Investment Amount.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On October 31, 2022, the Company entered into a Joinder Agreement with the Initial Investors and CO Finance LVS XXXVII LLC (&#x201c;the Additional Investor&#x201d;), and Hercules Capital, Inc. Under the terms of the Joinder Agreement, the Initial Investors waived their rights of first offer regarding the Additional Investor Funding and the Additional Investor joined the Revenue Interest Financing Agreement to extend commitments for the Additional Investor Funding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under the Revenue Interest Financing Agreement, the investors are entitled to receive a </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6751b150-0c5b-4ddc-9ad3-aba79955ea75" contextRef="C_d02c08d8-d888-4a97-a17b-d64dc2a21728" name="phat:PercentageOfInvestorShareOfRoyaltyInNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% royalty on net sales of products containing vonoprazan. The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and if the Company receives FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with non-erosive GERD. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_70cfee9e-32c6-4315-a488-92d731df594d" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:InvestorsRightToReceiveRoyaltiesTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The investors&#x2019; right to receive royalties on net sales will terminate when the investors have aggregate payments equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ae44aae7-edc4-4c95-9998-17efd5e31c6f" contextRef="C_5943d02e-5414-489b-b249-8e8202898837" name="phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">200</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for erosive GERD regulatory approval is made, the Company has the right to make a cap payment equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3ed28baf-9845-483f-87a0-7e4620365085" contextRef="C_5943d02e-5414-489b-b249-8e8202898837" name="phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">200</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_bbac96f8-6d4c-44f1-9095-c348ebfd3cf9" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:InvestorsReceiptDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If the investors have not received aggregate payments of at least </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4344b90c-e7ee-4289-b896-8bda40b03dd3" contextRef="C_c1fa0f90-b682-4d91-b3c5-62f796e1a9cd" name="phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount by December 31, 2028, and at least </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0cbce535-f957-411e-b53f-59f53e349d94" contextRef="C_6e83352c-1021-49ea-be17-abda53fad0d3" name="phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">200</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_7eaac107-3258-44d8-ac64-2cc04dc89752" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:DefaultObligationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Upon the occurrence of an event of default taking place prior to April 1, 2025, between April 1, 2025, and April 1, 2028, and after April 1, 2028, the Company is obligated to pay </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6cf3d37d-5abf-46c4-8f7e-f9db088349de" contextRef="C_4b9e40bc-f2d9-4495-a973-c2657257e971" name="phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> times Investment Amount, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_feccade3-818c-4ae7-8f3b-f023afbe1dba" contextRef="C_a456270a-d53b-42d3-8702-a89087e2879e" name="phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> times Investment Amount, and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3ef9ae2f-70e8-4778-b654-1ea9c8935b29" contextRef="C_1fffdef7-2c4e-4f8c-a14d-47e0a16bf641" name="phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_77de78aa-7f68-481e-96aa-1961ccbe6e60" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:ChangeInControlDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Upon the occurrence of a change in control event taking place prior to the earlier of April 1, 2024, or FDA approval of vonoprazan for erosive GERD, the Company is obligated to pay </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7369c31e-2ec3-46ce-a93e-81d2fbda0f29" contextRef="C_a7d27a7b-55b4-4782-b9ee-1496eed56e8e" name="phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">200</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount plus either </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b339bda5-79a8-4362-8384-63b5b8f7909b" contextRef="C_bd528633-09ca-45e1-a4f8-8be7636e9b54" name="phat:AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount if occurrence prior to May 3, 2023, or plus </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f9f993bf-5fc1-4777-bade-63bc2a4c519c" contextRef="C_e81a5d21-6780-4696-8613-7d86dd579083" name="phat:AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount if occurrence thereafter.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022, the Company received gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_20e8c292-7a80-41b7-8ad7-028d9ebe8a0d" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:GrossProceedsFromRevenueInterestFinancingAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million before deducting transaction costs of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4b23c50f-2ffb-4392-9a9f-3fe206999bb8" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:PaymentOfTransactionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, which resulted in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d02c978a-1fa7-486c-9548-fdc5461fc288" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:NetProceedsFromRevenueInterestFinancingTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">95.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has evaluated the terms of the Revenue Interest Financing Agreement and concluded that the features of the Investment Amount are similar to those of a debt instrument. Accordingly, the Company has accounted for the transaction as a debt obligation with interest expense based on an imputed effective rate derived from the initial carrying value of the obligation and the expected future payments. The Company recalculates the effective interest rate each period based on the current carrying value and the revised estimated future payments. Changes in future payments from previous estimates are included in the current and future financing expense. The carrying value of the revenue interest financing liability was $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a8c3661e-d73e-4097-8f52-88c7905662ac" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:RevenueInterestFinancingLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">109.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_6662d588-f5aa-4eb7-9060-863abd4b1c53" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total revenue interest financing liability consists of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.164%;"></td>
        <td style="width:1.726%;"></td>
        <td style="width:17.569%;"></td>
        <td style="width:1.54%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning liability balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Proceeds from the Revenue Interest Financing Agreement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_61715334-9810-4dee-9473-81a5706859ed" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:GrossProceedsFromRevenueInterestFinancingAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: transaction costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e50fe814-74dd-4c0f-bd8b-82b7a4cd8e73" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:PaymentOfTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: royalty payments and payables</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Plus: interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_49d204cf-8b58-4368-9a46-2b023c199f41" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:InterestExpenseRelatedToRevenueInterestFinancingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,079</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Ending liability balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b927baf5-3ef1-4c49-a3b9-8c777bfac02f" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="phat:RevenueInterestFinancingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,525</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e068a79c-552e-4b00-8ccc-797498f9091d" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:InterestExpenseRelatedToRevenueInterestFinancingLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of interest expense in connection with the revenue interest financing liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company will record liabilities associated with additional funding upon FDA approval of vonoprazan for erosive GERD and achievement of the sales milestone when such contingent events occur. To determine the accretion of the liability related to the Revenue Interest Financing Agreement, the Company is required to estimate the total amount of future royalty payments and estimated timing of such payments based on the Company&#x2019;s revenue projections. As royalty payments are made, the balance of the debt obligation will be effectively repaid. Based on the Company&#x2019;s periodic review, the exact timing of repayment is likely to be different in each reporting period as compared to those estimated in the Company&#x2019;s initial revenue projections. A significant increase or decrease in actual net sales of vonoprazan compared to the Company&#x2019;s revenue projections could impact the interest expense associated with the revenue interest financing liability. Also, the Company&#x2019;s total obligation can vary depending on change in control or default events and the achievement of FDA approval of vonoprazan for erosive GERD and achievement of the sales milestone.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_6cc1f1a5-fc96-4a8d-a0db-634c5720ead9" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8. Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In March 2019, subsequent to the Merger, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4cd589f4-755e-4ded-a117-ff3a037aab7b" contextRef="C_b0784f7e-b027-403a-a3cd-28ff1f784844" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,491,072</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock to Frazier.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In March 2019, the founders granted the Company a repurchase right for the </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_419ebcca-39e5-47f7-a4e5-0050b0222101" contextRef="C_92b2fe60-4ace-4d6c-acc6-c79dfb6818d9" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,373,408</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock originally purchased in 2018. The Company has the right, but not the obligation, to repurchase unvested shares in the event the founder&#x2019;s relationship with the Company is terminated, subject to certain limitations, at the original purchase price of the stock. The repurchase right lapsed for </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_747228a3-019b-4d48-8610-d7054e10998c" contextRef="C_92b2fe60-4ace-4d6c-acc6-c79dfb6818d9" name="phat:StockRepurchaseProgramNumberOfSharesRightLapse" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">843,352</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares in March 2019 and the repurchase right for the remaining </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bc28b741-802f-41c1-9669-f850b045187b" contextRef="C_92b2fe60-4ace-4d6c-acc6-c79dfb6818d9" name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,530,056</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares lapses in equal monthly amounts over the following </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_b193db3a-3d0a-4cb1-97a9-81c52bbee9ae" contextRef="C_3b18d59c-b688-4dad-a3c3-0feef824fd50" name="us-gaap:StockRepurchaseProgramPeriodInForce1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">48-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> period ending in </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_ba0fce1c-c05a-45fd-887b-81361e33e192" contextRef="C_3b18d59c-b688-4dad-a3c3-0feef824fd50" name="phat:StockRepurchaseProgramExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">March 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. The fair value of the founder shares at the date the repurchase right was granted is being recognized as stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e40512a0-4675-4660-96ef-17b6e01aa3fb" contextRef="C_a8157197-9c77-483d-a07b-d1d03a212eab" name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">79,064</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock were subject to repurchase by the Company and the associated repurchase liability was not significant. The amount of recognized and unrecognized stock-based compensation related to the founder stock was immaterial for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In May 2019, the Company issued Takeda </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9059593a-5662-49f5-887d-94c3e4641b4d" contextRef="C_9864647f-dae0-400c-981a-2e1ad206fde6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,084,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock in connection with the Takeda License.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For the period from January 1, 2019 to May 6, 2019, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2860fe35-22fd-47f4-a80e-5bd787e2ad38" contextRef="C_778accf5-7d44-4bf3-a402-bbbaf11a7645" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,524,852</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock to various employees and consultants of the Company for aggregate proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ee496846-fc23-49cb-b121-61384d198d7e" contextRef="C_778accf5-7d44-4bf3-a402-bbbaf11a7645" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Upon issuance, these shares were subject to a repurchase option by the Company at the original purchase price of the shares. The repurchase rights generally lapse as to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cbf6fcad-937c-4375-ae96-53808b37837d" contextRef="C_9cddf29a-b8e2-483a-a1a6-cb58b2eba169" name="phat:RepurchaseRightLapseRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the shares on the first anniversary of the vesting commencement date, and the repurchase right lapses as to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="-sec-ix-hidden:F_2b850787-a6cf-4d02-9e61-c00a1a4fa91d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1/48</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">th of the shares each one-month period thereafter, subject to the purchaser remaining continuously an employee, consultant or director of the Company. In November 2019, the Company repurchased </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7ebc9597-daaa-4447-9f71-577114abb6ba" contextRef="C_9d4560ac-5448-4f06-a2c0-c13d0498a9d1" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,560</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares at the original purchase price for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ec1422d4-80e9-4310-8a6b-230f0bfd9e2b" contextRef="C_74c344c6-6814-4821-8338-28c9c0250e05" name="phat:SharesAggregateRepurchasePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_be774f5c-0e53-4274-8f15-9a4557ea1ad6" contextRef="C_28e002f0-fa91-457e-80d6-bc784dddc517" name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">175,373</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares remain available for repurchase by the Company and the associated repurchase liability was not significant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On October 29, 2019, upon completion of the IPO, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bda7e0a2-88aa-4f33-8a11-704ce23ec0b5" contextRef="C_f71a8436-7cab-4cb1-a0b4-4ed9b66f0382" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,997,630</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock, which included the exercise in full by the underwriters of their option to purchase </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c954a861-6d8b-491c-855c-cd598b61d762" contextRef="C_ff181df1-43b0-434d-b3db-83c48fa28c00" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,434,473</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> additional shares at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2e32bbc5-e0e8-4f31-9636-ad5ce3681143" contextRef="C_55b184ca-7a41-480d-a822-5e3317a65984" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">19.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per share. The net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fba7e658-a252-4047-af57-432f3681ad70" contextRef="C_f71a8436-7cab-4cb1-a0b4-4ed9b66f0382" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">191.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts, commissions and offering costs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In November 2020, the Company entered into an Open Market Sale Agreement, or, the Sales Agreement, with Jefferies LLC, or, the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_00443348-19db-43a1-a8e2-710fe735d9b4" contextRef="C_9a0f9f10-e984-46bf-897d-9ef4dd6e2854" name="phat:AggregateOfferingPriceThroughEquityFinancing" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million through the Sales Agent, or, the ATM Offering. Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3112f6f0-206a-4e70-a74d-951900827852" contextRef="C_f484751c-237f-4a58-8796-c8018a28b609" name="phat:SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the gross sales price per share sold. In September 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3455aae1-6c42-48fd-9103-f25f03620050" contextRef="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,414,897</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a329e586-0bd9-47bf-ad39-19a561323d2c" contextRef="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">24.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million under the ATM offering after deducting $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d0a1e056-6bf5-4237-800e-2ac6430efb05" contextRef="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of issuance costs. As of December 31, 2022, the Company has utilized $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b4b3bec8-185c-4153-8452-8c5e8f1e9047" contextRef="C_16374c27-e9d9-4deb-990b-aa5e9aac1074" name="phat:AmountUtilizedOfEquityFinancing" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of the available $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bb9bf883-4f19-4664-8d1e-75aadea1a845" contextRef="C_16374c27-e9d9-4deb-990b-aa5e9aac1074" name="phat:AvailableAggregateOfferingPriceThroughEquityFinancing" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million under the ATM Offering.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On December 16, 2020, the Company completed an underwritten public offering, in which it sold </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d6d032a3-ac4b-4dc2-ac02-e09cd28e27df" contextRef="C_b02900cd-2272-4953-b251-9b37853719fc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cca98fec-2bb8-4016-ba94-8d8f7f0ee105" contextRef="C_b629611d-f479-44c6-9f1c-cdfdf6c74fcc" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">42.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per share for total gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_20505fea-0e48-48de-bee5-924336b8206a" contextRef="C_b02900cd-2272-4953-b251-9b37853719fc" name="phat:ProceedsFromIssuanceInitialPublicOfferingGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">94.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million. The net purchase price after deducting underwriting discounts and commissions was $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5fbd1be8-03c5-420f-acaa-385d298ef63e" contextRef="C_b629611d-f479-44c6-9f1c-cdfdf6c74fcc" name="phat:SharesIssuedPricePerShareAfterDeductions" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">39.48</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per share, which generated net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5b4ff124-7180-495c-9f69-a26be9ae49a8" contextRef="C_b02900cd-2272-4953-b251-9b37853719fc" name="phat:NetProceedsAfterDeductingUnderwritersCommission" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">88.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million. The Company incurred an additional $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f9ad617f-978a-42dc-8733-d5d933989a08" contextRef="C_b02900cd-2272-4953-b251-9b37853719fc" name="phat:PurchaseOfAdditionalOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of offering expenses in connection with this public offering.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_36527f87-2555-4dae-9e0d-5dc321e00fe1" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A summary of the Company&#x2019;s unvested shares is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:64.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.08%;"></td>
        <td style="width:1.553%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.368%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9424c5d3-0342-4bad-b3b9-bb1d150b1d14" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,144,809</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Share vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0284068e-b171-40a5-98b6-9c14912b0d43" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">890,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9d0ceae6-ebbb-4b49-a187-51259a0f10d7" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">254,437</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For accounting purposes, unvested awards are considered issued, but not outstanding until they vest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_593471ba-a3d6-4388-a3ee-a44e5ca7b0af" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:CommonStockReservedForFutureIssuancesTableTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Common stock reserved for future issuance consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.051%;"></td>
        <td style="width:1.594%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.355%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c9edaf0a-8dcd-487b-9622-ba186820eeda" contextRef="C_e9f3b61c-edfe-4524-8536-373c8a65e8a7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">91,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock options and performance-based awards outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e56bde73-4c2a-4b18-8922-606170d4ba36" contextRef="C_ab5a798d-ceb3-45b5-9852-43c7c13434c9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,876,237</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Shares available for issuance under the 2019 Incentive Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_923130fc-9e2b-4cc8-a989-9b02bc560f69" contextRef="C_b41ac6a5-4e17-4e1f-8bae-c1f1f8f391c8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">957,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Shares available for issuance under the ESPP Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cc4374d1-6ff5-44ae-8644-cac7c014c126" contextRef="C_a9286bf5-ac0b-46f5-a136-ec84fcb2ae44" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">752,938</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9200e7cf-8e38-4126-bb86-15896ef0f003" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,678,288</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company is authorized to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_52a4464e-8df8-4fdc-a926-f58da29e2f02" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="6" decimals="INF" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million shares of preferred stock. As of December 31, 2022, and December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6de74bb4-4f9a-49fc-9039-d9dcf946b541" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7446cc8e-3a7e-4864-9f06-e4021837c332" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5b5d3cfc-7761-4d98-8dfc-5bdb574476b4" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b272c267-804b-4ee3-97f2-5708e7209eda" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of preferred stock issued or outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s 2019 Equity Incentive Plan, or the Existing Incentive Plan, provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards to eligible recipients, including employees, directors or consultants of the Company. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_46212042-b182-4652-ae84-922663762c47" contextRef="C_85e62724-a4f3-446d-a80e-ee240301cda0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,231,739</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock authorized for issuance under the Existing Incentive Plan, of which, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_654c6572-30cf-4628-8335-c92ba1fe7a83" contextRef="C_9b8aa030-2775-49eb-a555-98fc9d14d1bf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,400,528</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> stock options and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_872ca575-1838-4196-b05e-3eaba9e45caf" contextRef="C_eb899363-81cb-4d24-aa66-4956be36544e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,260</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> restricted stock awards were granted in 2019. As a result of the adoption of the 2019 Incentive Award Plan, or the 2019 Plan, in October 2019, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_067d5f48-b170-484f-84b8-8b79418aff92" contextRef="C_ef56eeb8-d434-4c33-8a0e-a4c074a8edd9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> further shares are available for issuance under the Existing Incentive Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">2019 Incentive Award Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In October 2019, the board of directors adopted, and the Company&#x2019;s stockholders approved, the 2019 Plan, which became effective in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_44cb4af4-3a7b-4d6e-8a5e-1e671ce01839" contextRef="C_2ded604e-c94b-436f-a89c-9b03fda0e603" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above or equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_87b422b6-35e3-4873-ba0e-c79ee0b05149" contextRef="C_e2b4f91b-545a-498d-a89e-550afedc7031" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,416,788</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_08297c95-b0ce-417a-8c6b-c8bdcb08f4da" contextRef="C_537af902-fc9d-4888-8d37-6ee0bf5d7d50" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_418c905a-0818-456b-aaf2-0fd9910d7a29" contextRef="C_b41ac6a5-4e17-4e1f-8bae-c1f1f8f391c8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">957,885</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares remain available for issuance, which reflects </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3fe671b8-de9c-4686-bb01-39ae938ee965" contextRef="C_f292b92d-3d3f-4b55-9f26-2611aa4dd13c" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,789,868</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> stock options and performance-based units, or PSU, and restricted stock unit, or RSU, awards granted, and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e989e09c-2c7f-46a8-9cad-49b2d76c8fc9" contextRef="C_f292b92d-3d3f-4b55-9f26-2611aa4dd13c" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">392,207</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> of awards cancelled or forfeited, during the year ended December 31, 2022 as well as an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">annual increases of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_58137dc4-12ac-4582-87bf-c91d95581859" contextRef="C_ef443912-c72b-4729-a5ae-6e27ef16ba5a" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,582,802</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares authorized on January 1, 2022. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Performance-based Units</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During 2020, the Company granted the initial PSUs whereby vesting depends upon the approval by the FDA of vonoprazan for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and then, or concurrent with, erosive GERD. In 2022, the Company granted an additional </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b8b1c286-94a4-420a-8c70-4685f85743cf" contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> PSUs to employees. As of December 31, 2022, the PSU milestones had not been achieved. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bcf3cf13-ad80-48ee-8add-262af5800826" contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> related compensation cost had been recognized. </span><span><ix:nonNumeric id="F_20105b14-f2e8-4a17-baf5-bce675fff2ab" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" escape="true" continuedAt="F_20105b14-f2e8-4a17-baf5-bce675fff2ab_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2022.</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:continuation id="F_20105b14-f2e8-4a17-baf5-bce675fff2ab_1"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.961%;"></td>
        <td style="width:1.494%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.59%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.494%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.462%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Number of<br />Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br />Average Grant<br />Date Fair Value<br />Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7784eb0b-891c-4d41-befb-f44e8848d37d" contextRef="C_99f14810-3a35-4382-9ab0-3938fb54794d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">394,300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f19110e7-195b-4e25-ac00-f8be119df280" contextRef="C_99f14810-3a35-4382-9ab0-3938fb54794d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">32.23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d4bfafbd-199a-4c96-b55f-a68c939e7c46" contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8ffb362d-10d0-4094-8d19-94493d18e17d" contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">20.06</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_470efda2-41ac-450d-85ac-96b10d4d0d63" contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f6cab501-26fc-412f-8345-8db23af76c55" contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">35.39</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_825a8023-1bef-4d91-a164-65aeee643d7d" contextRef="C_6d1f03d4-1220-447c-ab69-93821c543913" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">412,300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8588a272-80d1-4f49-9bd9-52ef9ba98c38" contextRef="C_6d1f03d4-1220-447c-ab69-93821c543913" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">30.97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022 there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ff1aa5cd-76a3-46a3-bfa9-b246c8d62c36" contextRef="C_6d1f03d4-1220-447c-ab69-93821c543913" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of related unrecognized compensation cost, which will be recognized upon vesting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_589a488a-6ad7-488a-a04a-8b3f337855d5" contextRef="C_5d67cf6e-bd93-4d42-8971-522a9d32c0c8" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During 2022, the Company granted </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_976c3858-7b5d-4aec-878f-1846caad24ce" contextRef="C_c25918b9-523a-4430-8c67-527934999f5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,010,437</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> RSUs with vesting over time. The following table summarizes RSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.366%;"></td>
        <td style="width:1.393%;"></td>
        <td style="width:1.408%;"></td>
        <td style="width:14.524%;"></td>
        <td style="width:1.408%;"></td>
        <td style="width:1.408%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:14.524%;"></td>
        <td style="width:1.408%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Number of<br />Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br />Average Grant<br />Date Fair Value<br />Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fba60a0a-322e-41b1-94cb-559bbacf3092" contextRef="C_25cca5a5-3215-4f01-9b29-0229a260c11b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,010,437</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4dc10a72-4601-4479-a4a3-5292d62ff8b6" contextRef="C_c25918b9-523a-4430-8c67-527934999f5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c3a3eeec-f82c-4d3f-ab95-bf6a9b12e311" contextRef="C_c25918b9-523a-4430-8c67-527934999f5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">102,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_809d1e30-37ee-49fa-9fc8-acf3b88b019d" contextRef="C_c25918b9-523a-4430-8c67-527934999f5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_509e048c-6edc-44f2-a67f-55dc197c7dd9" contextRef="C_c25918b9-523a-4430-8c67-527934999f5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,517</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1a950cff-1d1c-4bed-80bb-985c3d5d7b6a" contextRef="C_c25918b9-523a-4430-8c67-527934999f5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a470382b-2ed9-4fdc-8c10-11376f79d28f" contextRef="C_71d680e8-6689-4309-bb74-70d6d934372b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">877,467</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f2ac883c-20b4-45de-aef3-bbe2f3e408c3" contextRef="C_71d680e8-6689-4309-bb74-70d6d934372b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.03</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_24c10ea3-9cad-4f2b-9fb2-475c1e3f8e25" contextRef="C_def31b4c-f4a8-4c99-b8ff-05f2befd1e4c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_d421953b-54d7-426f-a348-f5ab77b6dbf4" contextRef="C_5d67cf6e-bd93-4d42-8971-522a9d32c0c8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In October 2019, the board of directors adopted, and the Company&#x2019;s stockholders approved, the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_88ec6352-df9e-4e61-9660-71bb92368bd2" contextRef="C_0498a544-7235-40af-ade1-7542eee8d333" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of their eligible compensation, which includes a participant&#x2019;s gross base compensation for services to the Company, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A total of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b7a0a463-caee-4ffa-8966-1e371114dfb2" contextRef="C_836f3b27-9cf0-4ba9-abe3-f68ffa72e1e7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">270,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock was initially reserved for issuance under the ESPP. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_01ca0d16-3e06-49c6-a1d0-e311d9d13fc2" contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c705afce-6736-4ea8-835c-9bb3fa8a32cf" contextRef="C_b1e91519-0f55-42f3-a32a-9502a07575d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_02f14bdc-089f-4757-b2c2-40bb50d400bb" contextRef="C_a9286bf5-ac0b-46f5-a136-ec84fcb2ae44" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">752,938</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock remain available for issuance, which reflects </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f5fa9485-bdb7-44cd-b455-a5719762ed0e" contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">89,098</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares sold to employees during the year ended December 31, 2022. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The ESPP is considered a compensatory plan, and the Company recorded related stock-based compensation of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_810bd781-29e7-4e39-953a-ec270ad234fc" contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3513cb95-087b-4cb8-b1ee-76bc6c7bd200" contextRef="C_bd48d243-f6ad-429e-b82e-626144871206" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_f9d31372-fe57-4cfa-88db-2513a8a5e089" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_f9d31372-fe57-4cfa-88db-2513a8a5e089_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:continuation id="F_f9d31372-fe57-4cfa-88db-2513a8a5e089_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.081%;"></td>
        <td style="width:1.377%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.076%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.377%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.090999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_3cba10ac-44f6-458b-8bdf-f4fe36d86ae5" contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.50</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_2015a8e3-2dbe-43c1-bbe0-6ea32f2c66e0" contextRef="C_bd48d243-f6ad-429e-b82e-626144871206" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.69</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6b89b375-f730-4951-ab9d-5764cc1cba3b" contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">68.59</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9159bc30-1223-4440-a1e6-cc8c8f5dab47" contextRef="C_bd48d243-f6ad-429e-b82e-626144871206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">76.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5609774a-9a5d-49ca-b29c-b85604d95324" contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_70f6d632-5f40-4155-b36c-083ba14d7d88" contextRef="C_bd48d243-f6ad-429e-b82e-626144871206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.09</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c76cc07a-561f-4ead-89c7-8a37e366e8a5" contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_767b8c79-c205-4aac-b609-7698c36a9d93" contextRef="C_bd48d243-f6ad-429e-b82e-626144871206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The estimated weighted-average fair value of ESPP awards during 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a35699f3-2b4a-48df-9bf8-f52ec1e4fcb2" contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.98</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_55c51cbb-8a3e-4ee8-8569-c83cb15b5e5c" contextRef="C_bd48d243-f6ad-429e-b82e-626144871206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.66</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively. As of December 31, 2022, the total unrecognized compensation expense related to the ESPP was $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f2f47e60-1425-477b-b8d1-f652859ee90b" contextRef="C_a9286bf5-ac0b-46f5-a136-ec84fcb2ae44" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">31,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_fcd3b64b-94bf-4d7a-8030-0ed7220b083c" contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">401(k) Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company established a 401(k) savings plan during the year ended December 31, 2020. The Company&#x2019;s contributions to the plan are discretionary. During the years ended December 31, 2022 and December 31, 2021, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c9603be9-f6f6-40e3-817b-30566944cfd9" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7229b5b9-c9e9-4645-9b3b-ac9d48321bdd" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, of expense related to estimated employer contribution liabilities, which was based on a </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0d7a9053-b677-4cac-8aee-1d4019aec5c8" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% match of employees&#x2019; contributions during the periods. In August 2021, the Board of Directors approved a semi-annual discretionary match for 2021, which was settled by contributing </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7eb02219-4657-418e-a27f-89c3cdb9e81c" contextRef="C_e2a8d3e4-8302-40ab-8531-be80c035a7d2" name="phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,394</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares. In January 2022, the Board of Directors approved a second semi-annual discretionary match for 2021, which was settled by contributing </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_eee8159e-a75f-4219-9690-cdd7a6edcdd8" contextRef="C_b76ff2f4-ff03-419e-b174-84d981f8d356" name="phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,756</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares. In July 2022, the Board of Directors approved a semi-annual match for 2022, which was settled by contributing </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_81bf953b-aa47-4beb-85b6-a1c7e2382504" contextRef="C_02d741c1-6ff5-434c-88d1-b60b946959c7" name="phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">84,784</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company, prior to the IPO on October 29, 2019, was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected volatility based on the historical volatility of a publicly-traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company&#x2019;s stock options for employees was determined utilizing the &#x201c;simplified&#x201d; method for awards. The expected term of stock options granted to non-employees was equal to the contractual term of the option award. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_562d6c2b-b20a-40f4-ac77-d42faea2529e" contextRef="C_6dbb0e01-68b5-401c-ac47-a5ebd40a700f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_c257177c-a102-4a01-861b-e217f705d024" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A summary of the Company&#x2019;s stock option activity and related information is as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.033%;"></td>
        <td style="width:0.725%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.727%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.544%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.243%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.742%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.715%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.742%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.528%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options<br />Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value (in<br />thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f5a55311-cb3a-47d5-8484-ccc166d71ed2" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,186,729</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8e155270-cc82-4329-8cd3-73fcb13d5cb0" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">27.53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_c9d28bcb-e0eb-45f0-a37f-4091a83a615b" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.91</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cf6d4bc1-c935-4dc8-af1a-424580b08579" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,973</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bfcd6615-79d6-46de-be4e-2702cbd53be3" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,741,931</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_db5fc1fa-1277-479c-b4ad-d616e0972afe" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">14.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_44263c15-36d3-44bc-9d26-a15f68827f37" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">342,190</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5d3b64d6-2220-4684-b634-83f8cd5d7db0" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">29.32</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6d1b4679-b825-4a9c-8994-f6ad1f669897" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,586,470</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a911cdb0-9a5a-4e9b-ae05-52c25b34b888" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">23.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_ed8ef67e-ed82-4447-8348-b073dd9698f0" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.90</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e3ba3b3b-ecbe-4755-a37b-d08e76ac305b" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,476</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options exercisable as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d6c6cabe-6bd1-4e2e-8d7c-41dee45a9dfb" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,455,735</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d1b60f14-76c9-45e4-935c-00814d0db1f8" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">25.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_25fc646b-ae0e-4da7-8f27-1a63fe468be9" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.18</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6ac8618c-debb-460e-b3d7-64cf17ea26be" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,867</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The estimated weighted-average fair value of employee and nonemployee director stock options granted during 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_937ba3f5-64bc-4ade-9aaf-b0c6a03ba8da" contextRef="C_85297e90-674e-4311-8d12-99f75d773722" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">8.40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per option. As of December 31, 2022, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6a9179d4-8bfc-4eb5-b96a-247da6f2683d" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_350a7f50-b815-46fa-b596-410fefcafd16" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.1</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years.</span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_23740d51-6a3f-4924-bd5f-6186f3c5cfd8" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.06%;"></td>
        <td style="width:1.057%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:22.405%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.072%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:22.405%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_ec00a35e-f100-4257-952e-f7b4f124df59" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5.88</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_06ec0956-a833-4772-bd7a-806b62f21cb8" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5.93</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cd109813-4194-4d7d-8a92-3de9970d605b" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">66.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_57a60f7c-7051-4732-8f13-7b7f4ab6dfd8" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">67.46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_35272fb1-f655-4329-831a-c92bf517f60c" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.06</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f6fd7ef2-ec53-48cd-8506-43f9737f9f5f" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_88e783b9-8f4c-4131-b98c-16b695a68963" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_51a816f4-bc70-45ac-9483-c2c37a47f157" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_5971b3b8-fe6a-4644-8b9e-1463e2530421" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.164%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.879%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.879%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4ff6e6ca-520a-407b-9461-caef0d5b57aa" contextRef="C_c9397005-df60-4c46-9331-f164df01ca76" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,534</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_76289b66-9949-48cc-b7b8-7e6736a3b20f" contextRef="C_84f52c9e-524b-4bd9-9018-6cb27dd75205" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,838</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fe32ec5a-64c7-4ffa-b449-82f3e61abcb9" contextRef="C_85f57980-d393-4162-ae13-987929e0df5f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,599</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_225ef051-4ec6-4830-bd78-04612b650f75" contextRef="C_fee0ce51-9e93-47f2-b416-b68d0ab99ce8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_103731e1-aa05-42c4-8380-86c428409c2f" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,133</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f7a0eb3e-cba8-4858-9f35-8a509527b0a8" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,812</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9</span><span><ix:nonNumeric id="F_75ab4f99-a0a3-44d0-ab5d-06992f1e4569" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_75ab4f99-a0a3-44d0-ab5d-06992f1e4569_1"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Income Taxes</span></ix:nonNumeric></span></p>
  <div><ix:continuation id="F_75ab4f99-a0a3-44d0-ab5d-06992f1e4569_1"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c959263d-9f74-435b-a9b9-ca68b859e1e0" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e4ffcff1-b0d2-4404-97c0-3abcec226329" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">t record a provision for income taxes due to a full valuation against its deferred taxes. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_086b2f93-2dcf-4d34-9758-8afb2e03026a" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_086b2f93-2dcf-4d34-9758-8afb2e03026a_1"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:continuation id="F_086b2f93-2dcf-4d34-9758-8afb2e03026a_1"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.792%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.712%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.698%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Income taxes computed at the statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f2b3c2bf-4363-4c16-a76b-1aaff8f551c2" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">41,522</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0f9ede31-0401-4304-bac1-396a5a78fb4c" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">30,216</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_abd888e6-9b71-429d-b5fc-d481773de2d1" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="phat:IncomeTaxReconciliationPermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,713</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aa4ebcd9-5dcd-4ee4-ac5c-424f90c79b1c" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="phat:IncomeTaxReconciliationPermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cbf55a4e-cce2-410d-8859-1d8f454d5286" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5cc7f580-91f1-4a35-a36b-fcfae894ad7b" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,950</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_88e1c2f9-f1f2-41c7-8e42-15b3c0a7f179" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,137</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b80343b0-1ec6-4bdc-b987-b492f6fe1f4c" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,783</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f83eea37-6951-464d-892d-fa763e4b7569" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d7e09c99-20e5-47ce-906f-39f41fe68aad" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3fb370f7-c266-480e-a7f3-6b1fbc08daed" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c094efe1-0707-431c-a34f-e654b4150bd9" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_235dbfec-dbb1-40cd-a707-d56bbe392e5c" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.484%;"></td>
        <td style="width:1.286%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.965%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.286%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.98%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_81d507e3-6918-4b48-aaac-741a99b4b4f4" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,918</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_64c053c9-d9d3-46b4-bc3d-af17e95c073d" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,936</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fb1106ee-a690-4ba6-b9ac-9710007ee21e" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,897</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b55f1867-c7d5-406d-93a6-9fc4d35849eb" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,694</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e5fe06d2-f6a9-438f-8f8e-fc8ed9290429" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,319</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ffb96d6f-ba32-4605-a637-d12930cb86ef" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,809</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_722079d1-a137-49b8-aafe-d5ffccaa4e76" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,517</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2dd45b5c-e29d-4d1a-aa65-4acc630579a5" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,996</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_47f9d9ed-9c51-4d43-ae33-6f6dadecd555" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,651</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_677ecf0b-5c54-4fb1-8af4-8f3a597c5bbc" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,435</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cc8e0474-7ef7-41fd-89ae-6fba66c44d66" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,170</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f62fc546-53bb-4031-9b51-a6462e1605f7" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,033</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_af20086f-eb87-4fd5-b486-18a7079b8b48" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aa61e907-2e2c-4ce2-acbe-8797a1824a5b" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5f787ee7-bdd6-414f-8c83-dd892b2a2ee0" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_11478920-ce49-4688-b0d1-b09b00adea52" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_163f671b-35d9-4e68-909a-90514c146312" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3cb4f984-c63b-418e-8bf2-6e3e02fa3759" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Based upon the Company&#x2019;s history of operating losses, the Company is unable to conclude that it is more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December 31, 2022 and 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e7c74ffc-1527-4c4d-a689-79ce57982e51" contextRef="C_8ef9f4d9-0de2-4f1f-843d-3ab853904bf4" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">408.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d7681e95-efaf-4379-b809-d41d7caffccf" contextRef="C_8d795b93-dc29-4dc9-8b77-44a4e74f6b8f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">290.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, which are carried over indefinitely.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_77405ea7-b2a1-48d0-ba74-7f9051728c34" contextRef="C_bde66df6-9f96-4711-b5ca-d8e549c121ca" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of state net operating loss carryforwards that begins to expire in </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_205162c5-0ee4-4d1c-a62b-ec5f2f867730" contextRef="C_ec823b74-ab4b-4334-a3c0-fe989b5ea271" name="phat:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company has available federal research and development credits of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_01df3d79-0da3-4f2b-8373-639dd6c97c36" contextRef="C_8ef9f4d9-0de2-4f1f-843d-3ab853904bf4" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million which begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_39d68d99-7d05-4578-9a28-47518cb80ca4" contextRef="C_4160e414-35f2-4edb-94aa-a3ea7eeab964" name="phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2038</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bcac0906-973f-4f7d-9e2f-4cef1ad3649d" contextRef="C_bde66df6-9f96-4711-b5ca-d8e549c121ca" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of state research and development credits, some of which, begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_0ccbf2f9-ce4b-4012-a827-efdd6d010e92" contextRef="C_ec823b74-ab4b-4334-a3c0-fe989b5ea271" name="phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has not completed a formal analysis of the potential impact of Section 382 on its deferred tax assets as of December 31, 2022. Until this analysis has been completed, the Company has not adjusted any of its deferred tax assets, including net operating losses or research and development credits. The Company will reassess the amount of net operating losses and credits subject to limitation under Section 382 when a study is complete.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Due to the existence of the valuation allowance, future changes in the deferred tax assets related to these tax attributes will not impact the Company&#x2019;s effective tax rate.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_d75168ab-59c4-41fc-b990-478b9dd28dfc" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes the activity related to the Company's gross unrecognized tax benefits:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.936%;"></td>
        <td style="width:1.466%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.559000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.559000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_741c2f96-ec6d-4212-849c-e31d498d57ab" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4b45c0df-35ee-41ff-99d0-5625bb832a8f" contextRef="C_3625bbc7-e0d2-4ae5-80c9-2c2a001c24c0" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">938</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Increases related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6b3d92be-e58e-4155-98b6-ad06603f5d6b" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7c73f7ea-d2f8-4ea6-a185-65fa89dd9c58" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Increases related to current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_638d4214-9d47-415d-8859-0c0161392b07" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">623</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d798710a-a683-4815-86af-ca2f55c5ee32" contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">702</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Ending balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_85bb8470-28af-46f1-99b5-e9d5c99c9f19" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,327</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_155de565-a3cd-4833-a246-d8faa199d7ba" contextRef="C_f23428e3-ba82-4280-becf-c920e6849705" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company has gross unrecognized tax benefits of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f90e9564-5ed1-469c-a209-07218b271c51" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,327</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9f4cbe3e-1d29-4508-ae1e-0bf492c5fc96" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> of which would affect the effective tax rate due to a full valuation allowance.  The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months.  The Company's policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense.  The Company has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c2aeb312-0f12-45d3-9da7-912e0815d792" contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> accrual for interest or penalties on its balance sheet at December 31, 2022, and has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_50abbeaf-1543-4448-81e2-57a9c8119677" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">t recognized interest and/or penalties in its statement of operations for the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company is subject to taxation in the United States and various states. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.</span></p></ix:continuation></div>
  <div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_1fc62422-1afe-441b-be48-4e94ad37f8c2" contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10. Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">At-The-Market Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">From January 1, 2023 through February 27, 2023, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_93513e95-e925-40a4-9031-0e90e7e25d3f" contextRef="C_7da2e53f-060f-4407-97fc-6ab72ec3f967" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,514,219</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock in a single trade under the ATM Sale Agreement generating gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9d65271f-024e-41e2-a7ca-6b14919dadd5" contextRef="C_7da2e53f-060f-4407-97fc-6ab72ec3f967" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e7a6b9c2-986f-4fb2-b8a3-8689ac510759" contextRef="C_7da2e53f-060f-4407-97fc-6ab72ec3f967" name="phat:NetProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, after offering expenses.</span><span style="color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">EXHIBIT INDEX</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.996%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:34.145%;"></td>
    <td style="width:12.425%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:7.575%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.502%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.118%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:10.224%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519277761/d795888dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-29-19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312520254563/d10693dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amended and Restated Bylaws</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-25-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519267053/d63338dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Form of Common Stock Certificate</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-15-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Warrant to purchase shares of common stock issued to Takeda Company Limited, dated May 7, 2019</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex43.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Warrant to purchase stock issued to Silicon Valley Bank, dated May 14, 2019</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex44.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Warrant to purchase stock issued to WestRiver Innovation Lending Fund VIII, L.P., dated May 14, 2019</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519267053/d63338dex45.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Note Purchase Agreement, dated May 7, 2019, by and among the Registrant and the other parties party thereto, as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-15-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex4_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Description of Registered Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.1#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.2#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under the Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.3#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Form of Restricted Stock Grant Notice and Restricted Stock Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.4#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519267053/d63338dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan and form of stock option grant notice and stock option agreement thereunder</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-15-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.5#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459020037296/phat-ex103_248.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under the Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-6-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.6#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459020037296/phat-ex104_77.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Form of Performance Share Unit Grant Notice and Performance Share Unit Agreement under Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-6-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.7#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519267053/d63338dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phathom Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-15-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.8#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519267053/d63338dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-15-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.9#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459020024514/phat-ex101_133.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phathom Pharmaceuticals 2020 Bonus Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5-12-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.10#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Letter Agreement, dated May 7, 2019, by and between Tadataka Yamada, M.D. and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">166</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.996%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:46.571%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:7.575%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.502%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.118%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:10.224%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.11#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Employment Letter Agreement, dated July 21, 2019, by and between David Socks and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.12#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amended and Restated Employment Letter Agreement, dated September 25, 2019, by and between Azmi Nabulsi, M.D., M.P.H. and the Registrant</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.13#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312520191565/d54915dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Employment Letter Agreement, dated June 25, 2020, by and between Todd Branning and the Registrant</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7-13-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.14#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Form of Indemnification Agreement for Directors and Officers</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.15&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">License Agreement, dated May 7, 2019, by and between Takeda Pharmaceuticals Company Limited and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Loan and Security Agreement, dated May 14, 2019, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P. and the Registrant</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459020024514/phat-ex102_134.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amendment to the Loan and Security Agreement, dated March 11, 2020, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P. and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5-12-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.18#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Employment Letter Agreement, dated August 29, 2019, by and between Terrie Curran and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.19&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459020037296/phat-ex101_79.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Commercial Supply Agreement, by and between Takeda Pharmaceuticals Company Limited and the Registrant, dated as of April 30, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-6-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.20&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021016682/phat-ex1020_1409.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amendment No. 1 to Takeda License Agreement, dated September 21, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3-30-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.21&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021016682/phat-ex1021_1410.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated December 30, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3-30-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021016682/phat-ex1022_2100.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amendment No. 1 to Commercial Supply Agreement by and between Takeda Pharmaceuticals Company Limited and the Registrant, dated as of December 1, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3-30-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.23</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021026309/phat-ex101_241.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Second Amendment to the Loan and Security Agreement, dated March 11, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registran</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">t</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5-11-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.1</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.24</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021042895/phat-ex102_106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Third Amendment to the Loan and Security Agreement, dated May 26, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-10-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.25#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021042895/phat-ex103_174.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Separation and Release Agreement dated June 4, 2021, between the Registrant and Todd Branning</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-10-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.26&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021042895/phat-ex104_267.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Commercial Supply Agreement with Catalent Pharma Solutions, LLC entered into on July 2, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-10-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.27#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021042895/phat-ex105_416.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-10-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.28</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021055073/phat-ex101_211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">11-8-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.996%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:46.571%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:7.575%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.502%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.118%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:10.224%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.29</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021055073/phat-ex102_212.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Warrant to purchase stock issued to Hercules Capital, dated September 17, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">11-8-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.30&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000095017022002536/phat-ex10_30.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">First Amendment to the Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated December 4, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3-1-2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.30</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.31#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000095017022008741/phat-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Employment Letter Agreement, dated March 22, 2022, by and between Molly Henderson and the Company</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5-10-2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.32</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000095017022013743/phat-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Form of Restricted Stock Grant Notice and Restricted Stock Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-1-2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.31&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000095017022013743/phat-ex10_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Revenue Interest Financing Agreement, dated May 3, 2022, by and among NovaQuest Capital Management, Sagard Holding Manager, Hercules Capital and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-1-2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.32</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000095017022013743/phat-ex10_4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-1-2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.33#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000095017022013743/phat-ex10_5.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-1-2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.34#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000095017022013743/phat-ex10_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Transition and Separation Agreement and Release of Claims, dated April 5, 2022, by and between the Registrant and Anthony Guzzo</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8-1-2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.35&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000095017022023372/phat-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Commercial Supply Agreement with Evonik Operations GmbH entered into on August 1, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">11-9-2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.36</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000095017022023372/phat-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Second Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">11-9-2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.37&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex10_37.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Joinder and Waiver agreement dated October 31, 2022 by and among Hercules Capital, CO Finance LVS XXXVII LLC and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Consent of independent registered public accounting firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex24_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Power of Attorney</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Certification of Chief Executive Officer of Phathom Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Certification of Principal Financial Officer of Phathom Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">32.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">32.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Calculation Linkbase Document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.996%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:46.571%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:7.575%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.502%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.118%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:10.224%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inline XBRL Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"># Indicates management contract or compensatory plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#134; Portions of this exhibit have been omitted for confidentiality purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">* These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TURES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this annual report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PHATHOM PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Terrie Curran</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terrie Curran</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.231%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:39.519%;"></td>
    <td style="width:1.122%;"></td>
    <td style="width:29.124%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Terrie Curran</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terrie Curran</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and</span></p><p style="text-indent:-10.0pt;padding-left:10.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director (Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Molly Henderson</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Molly Henderson</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial and Business Officer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:-10.0pt;padding-left:10.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael F. Cola</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Frank Karbe</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Heidi Kunz</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asit Parikh, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David Socks</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mark Stenhouse</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">James Topper, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*By: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Terrie Curran</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terrie Curran, Attorney-in-fact</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">170</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>2
<FILENAME>phat-ex4_6.htm
<DESCRIPTION>EX-4.6
<TEXT>
<html>
 <head>
  <title>EX-4</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 4.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:13.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, Phathom Pharmaceuticals, Inc. (&#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: our common stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following description summarizes some of the terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you and is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation (the &#x201c;certificate of incorporation&#x201d;), and amended and restated Bylaws (&#x201c;bylaws&#x201d;), which are filed as exhibits to our most recent Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our certificate of incorporation and our bylaws for additional information.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our authorized capital stock consisted of 400,000,000 shares of common stock, $0.0001 par value per share, and 40,000,000 shares of preferred stock, $0.0001 par value per share.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividend Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rights and Preferences</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fully paid and nonassessable</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The outstanding shares of common stock are duly authorized, validly issued, fully paid and nonassessable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Transfer Agent and Registrar</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Nasdaq Global Market Listing</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is listed and traded on the Nasdaq Global Select Market under the ticker symbol &#x201c;PHAT.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer&#x37e; an acquisition of us by means of a proxy contest or otherwise&#x37e; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares. These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Undesignated Preferred Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of our board of directors, without action by the stockholders, to issue up to 40,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stockholder Meetings</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board of directors, chief executive officer or president, or by a resolution adopted by a majority of our board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Elimination of Stockholder Action by Written Consent</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written consent without a meeting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Staggered Board of Directors</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Removal of Directors</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stockholders Not Entitled to Cumulative Voting</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delaware Anti-Takeover Statute</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#x201c;interested stockholders&#x201d; from engaging in a &#x201c;business combination&#x201d; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Choice of Forum</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum under Delaware statutory or common law for: (i) any derivative action or proceeding brought on our behalf&#x37e; (ii) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, creditors or other constituents&#x37e; (iii) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our amended and restated certificate of incorporation or amended and restated bylaws&#x37e; (iv) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws&#x37e; or (v) any action asserting a claim governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;), or any other claim for which the federal courts have exclusive jurisdiction.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our bylaws provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;).  Our certificate of incorporation and bylaws each provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendment of Charter Provisions</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>phat-ex10_37.htm
<DESCRIPTION>EX-10.37
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.37</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY &#x201c;[***].&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JOINDER AND WAIVER AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This JOINDER AND WAIVER AGREEMENT, dated as of October 31, 2022 (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joinder Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is entered into by and among Phathom Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), Hercules Capital, Inc. in its capacity as administrative agent and collateral agent for itself and the Lenders (as defined in the Hercules Loan Agreement) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), the Required Lenders (as defined in the Hercules Loan Agreement), CO Finance LVS XXXVII LLC, a Delaware limited liability company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Investor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and the other entities set forth on the signature pages hereto (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Investors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). All capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Financing Agreement (as defined below).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, the Company and the Initial Investors are parties to that certain Revenue Interest Financing Agreement, dated as of May 3, 2022 (as may be amended, supplemented or otherwise modified from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;);</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, the Company, the Initial Investors and the Agent entered into that certain Subordination Agreement, dated as of May 3, 2022 (as may be amended, supplemented or otherwise modified from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subordination Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;);</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, pursuant to Sections 2.1(b)(ii) and 2.1(c) of the Financing Agreement, the Company has the right to seek written commitments from a third party for an Additional Regulatory Milestone Payment in an amount up to $15,000,000 and a Sales Milestone Payment in an amount up to $25,000,000;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, the Additional Investor desires to commit to provide an Additional Regulatory Milestone Payment in an amount equal to $15,000,000 and a Sales Milestone Payment in an amount equal to $25,000,000, each payable in accordance with the terms and conditions set forth in the Financing Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Section 2.1(b)(ii) of the Financing Agreement provides that before obtaining a written commitment from a third party for an Additional Regulatory Milestone Payment, the Company shall first grant the Initial Investors the right to extend commitments for the Additional Regulatory Milestone Payment (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory Milestone Payment Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) by delivering to the Initial Investors a written notice of such intended transaction with the Additional Regulatory Milestone Investor;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Section 2.1(c) of the Financing Agreement provides that before obtaining a written commitment from a third party for an Additional Sales Milestone Payment, the Company shall first grant the Initial Investors the right to extend commitments for the Sales Milestone Payment (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales Milestone Payment Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) by delivering to the Initial Investors a written notice of such intended transaction with the Additional Sales Milestone Investor;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, the Initial Investors wish to waive their rights in connection with the Regulatory Milestone Payment Option and the Sales Milestone Payment Option; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, the Additional Investor is willing to subordinate (i) all of Company&#x2019;s indebtedness and obligations to the Additional Investor under the Financing Agreement, whether presently existing or arising in the future, to all of Company&#x2019;s indebtedness and obligations to Agent and the Lenders (as defined in the Hercules Loan Agreement), and (ii) all of Additional Investor&#x2019;s security interests, if any were to arise, in Company&#x2019;s property (other than the Revenue Interest Collateral), to all of the Agent&#x2019;s security interests in the same, in each case in the circumstances and on the terms set forth in the Subordination Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company, the Additional Investor and the Initial Investors agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Each Initial Investor hereby waives its Regulatory Milestone Payment Option and its Sales Milestone Payment Option and all other rights of such Initial Investor set forth in Section 2.1(b)(ii) and Section 2.1(c) of the Financing Agreement with respect thereto (including without limitation all notice and election periods set forth therein).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joinder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Upon execution and delivery of this Joinder Agreement, the Additional Investor hereby becomes:</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) a party to the Financing Agreement as an Investor for all purposes thereunder as if originally named in the Financing Agreement as an Investor and (ii) assumes, as an Additional Regulatory Milestone Investor and Additional Sales Milestone Investor, all obligations with respect to the Additional Regulatory Milestone Payment and the Sales Milestone Payment as set forth in the Financing Agreement. Notwithstanding the foregoing, the representations and warranties set forth in Sections 4.2 and 4.3 of the Financing Agreement are hereby made to the Company by the Additional Investor as of the date hereof rather than as of the Effective Date; and</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a party to the Subordination Agreement as a Creditor for all purposes thereunder and assumes all rights and obligations of a Creditor thereunder as of the date of this Joinder Agreement as if it were originally named in the Subordination Agreement as a Creditor.</font></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Joinder Deliverables</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </font></div></div>
  <div style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrently with the delivery of this Joinder Agreement, the Company shall deliver to the Additional Investor a certificate of an officer of the Company, dated as of the date hereof, (i) certifying as to the Company&#x2019;s organizational documents and the attached resolutions adopted by the board of directors of the Company authorizing the Financing Agreement and the transactions contemplated thereby and (ii) setting forth the incumbency of the officer or officers of the Company who have executed and delivered the Financing Agreement and this Joinder Agreement, including therein a signature specimen of each such officer.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:3.333%;text-indent:6.897%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrently with the delivery of this Joinder Agreement, the Additional Investor shall deliver to the Company its (i) Applicable Withholding Certificate and (ii) Investor Account Information Document.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company Representations, Warranties, Covenants and Other Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:4.13%;text-indent:6.119%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:5.87%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company represents and warrants to the Additional Investor that as of the date of this Joinder Agreement (i) the representations and warranties of the Company in the Financing Agreement are true and correct (except to the extent that such representations and warranties relate specifically to an earlier date, in which case they are true and correct as of such earlier date), (ii) no Default or Event of Default has occurred and is continuing, (iii) none of the Company, any of its Subsidiaries, or, to the Knowledge of the Company, any of the Company&#x2019;s or its Subsidiaries&#x2019; Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by the Financing Agreement is (x) in violation of any Anti-Terrorism Law, Anti-Corruption Law or Sanctions, (y) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, Anti-Corruption Law or Sanction, or (z) is a Blocked Person and (iv) none of the Company, any of its Subsidiaries, or to the Knowledge of the Company, any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law, Anti-Corruption Law or Sanction.</font></div></div>
  <div style="margin-left:4.13%;text-indent:6.119%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:5.87%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Blocked Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, for purposes of this Joinder Agreement and the Financing Agreement, any Person: (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports &#x201c;terrorism&#x201d; as defined in Executive Order No. 13224, or (e) a &#x201c;specially designated national&#x201d; or &#x201c;blocked person&#x201d; on the most current list published by OFAC or other similar list of sanctioned entities maintained by the United Nations, the United Kingdom, the United States, or the European Union, and any other relevant jurisdiction including but not limited to the following lists: the U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List, all administered by the U.S. Department of Commerce; the Chinese Military-industrial Complex Companies; the consolidated list of Persons, Groups and Entities Subject to EU Financial Sanctions, as implemented by the EU Common Foreign &amp; Security Policy; and similar lists of restricted parties maintained by other relevant governmental authorities.</font></div></div>
  <div style="margin-left:4.13%;text-indent:6.119%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:5.87%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company represents and warrants to the Agent that as of the date of this Joinder Agreement (i) the representations and warranties of the Company in the Hercules Loan Agreement are true and correct in all material respects (except to the extent that such </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:4.13%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:5.87%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">representations and warranties relate specifically to an earlier date, in which case they are true and correct in all material respects as of such earlier date, and except for such representations qualified by materiality or Material Adverse Effect (as defined in the Hercules Loan Agreement), which are true and correct in all respects), and (ii) no Default (as defined in the Hercules Loan Agreement) or Event of Default (as defined in the Hercules Loan Agreement) has occurred and is continuing.</font></div></div>
  <div style="margin-left:4.13%;text-indent:6.119%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:5.87%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company shall file one or more financing statements in such manner and such jurisdictions as are necessary or appropriate to perfect the Additional Investor&#x2019;s security interest in the Revenue Interest Collateral.  </font></div></div>
  <div style="margin-left:4.13%;text-indent:6.119%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:5.87%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company shall use its good faith and commercially reasonable efforts to assist the Additional Investor in complying with its or its Affiliates&#x2019; obligations under the Anti-Terrorism Laws, Anti-Corruption Laws and Sanctions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. All notices and other communications to be provided to the Additional Investor pursuant to Section 9.2 of the Financing Agreement shall be addressed as follows:</font></div></div>
  <p style="margin-left:23.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CO Finance LVS XXXVII LLC<br>[***]</font></p>
  <p style="margin-left:23.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Joinder Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8457544394060026%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provisions of Sections 9.2, 9.5, 9.9 and 9.12 of the Financing Agreement are hereby incorporated by reference herein as if set forth in full force herein, mutatis mutandis. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Joinder Agreement is a &#x201c;Loan Document&#x201d; for the purposes of the Hercules Loan Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Additional Investor shall do all acts and execute all such documents as the Agent may reasonably specify from time to time as necessary to give effect to the provisions of this Joinder Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">{</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Remainder of page intentionally left blank</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">}</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.37</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY &#x201c;[***].&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, the undersigned have caused this Joinder Agreement to be duly executed and delivered as of the date first above written.</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COMPANY:</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PHATHOM PHARMACEUTICALS, INC.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Terrie Curran	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: Terrie Curran<br>	Title: President and Chief Executive Officer</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.37</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY &#x201c;[***].&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ADDITIONAL INVESTOR:</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CO FINANCE LVS XXXVII LLC, a Delaware limited liability company<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: [***]<br>	Title: Authorized Person</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.37</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY &#x201c;[***].&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INITIAL INVESTORS:</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NQ PROJECT PHARAOH, L.P.</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: NQ POF V GP, Ltd., its general partner<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: [***]	Title: Director</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.37</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY &#x201c;[***].&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INITIAL INVESTORS:</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SAGARD HEALTHCARE PARTNERS (DELAWARE), LP<br>By: Sagard Healthcare Royalty Partners GP LLC, its general partner<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: [***]	Title: Manager</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.37</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY &#x201c;[***].&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INITIAL INVESTORS:</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HERCULES CAPITAL, INC.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: [***]<br>	Title: Chief Financial Officer</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P.<br>By: Hercules Adviser LLC, its Investment Adviser<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: [***]<br>	Title: Authorized Signatory</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AGENT:</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HERCULES CAPITAL, INC.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: [***]<br>	Title: Chief Financial Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REQUIRED LENDERS:</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HERCULES FUNDING IV LLC<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: [***]<br>	Title: Chief Financial Officer</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HERCULES CAPITAL IV, L.P.<br>By: Hercules Technology SBIC Management, LLC, its General Partner<br>By: Hercules Capital, Inc., its Manager<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: [***]<br>	Title: Chief Financial Officer</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HERCULES PRIVATE CREDIT FUND 1 L.P.<br>By: Hercules Adviser LLC, its Investment Adviser<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: [***]<br>	Title: Authorized Signatory</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P.<br>By: Hercules Private Global Venture Growth Fund GP I LLC, its general partner<br>By: Hercules Adviser LLC, its sole member<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>	Name: [***]<br>	Title: Chief Financial Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">DB1/ 132849063.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Tahoma&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>phat-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-234357) pertaining to the 2019 Equity Incentive Plan, 2019 Incentive Award Plan, and 2019 Employee Stock Purchase Plan of Phathom Pharmaceuticals, Inc., </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-3 No. 333-250014) of Phathom Pharmaceuticals, Inc., and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263420) pertaining to the 2019 Incentive Award Plan and 2019 Employee Stock Purchase Plan of Phathom Pharmaceuticals, Inc.;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our report dated February 28, 2023, with respect to the financial statements of Phathom Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Phathom Pharmaceuticals, Inc. for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> /s/ Ernst &amp; Young</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Iselin, New Jersey</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>5
<FILENAME>phat-ex24_1.htm
<DESCRIPTION>EX-24.1
<TEXT>
<html>
 <head>
  <title>EX-24</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 24.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIMITED POWER OF ATTORNEY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	KNOW ALL PERSONS BY THESE PRESENTS, that each person or entity whose signature appears below constitutes, designates and appoints each of Terrie Curran and Larry Miller, each of whom are officers of Phathom Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;), as its true and lawful attorneys-in-fact and agent, each with power of substitution, with full power to act without the other and on behalf of and as attorney for me, for the purpose of executing and filing with the Securities and Exchange Commission the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022, and any and all amendments thereto, and to do all such other acts and execute all such other instruments which said attorney may deem necessary or desirable in connection therewith.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.312%;"></td>
    <td style="width:33.344%;"></td>
    <td style="width:33.344%;"></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</font></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Michael Cola</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Cola</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Frank Karbe</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Frank Karbe</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Heidi Kunz</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Heidi Kunz</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 24, 2023</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Asit Parikh</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asit Parikh</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 24, 2023</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David Socks</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David Socks</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Mark Stenhouse</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mark Stenhouse</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 24, 2023</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ James Topper</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">James Topper</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 24, 2023</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">|</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>phat-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Terrie Curran, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Phathom Pharmaceuticals, Inc.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange act rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.163%;"></td>
    <td style="width:50.837%;"></td>
   </tr>
   <tr style="height:1.45pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>/s/ Terrie Curran</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terrie Curran</font></p></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and President</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>7
<FILENAME>phat-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:right;" id="doc_1_7"><font id="doc_1_6"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Molly Henderson, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Phathom Pharmaceuticals, Inc.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange act rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:7.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:79.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.841%;"></td>
    <td style="width:54.159%;"></td>
   </tr>
   <tr style="height:1.45pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Molly Henderson</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Molly Henderson</font></p></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial and Business Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>phat-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:right;" id="doc_1_7"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:7.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Phathom Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Terrie Curran, as Chief Executive Officer of the company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:13.2pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:13.2pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:-7.914%;padding-left:7.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.12%;"></td>
    <td style="width:51.88%;"></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Terrie Curran</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terrie Curran</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and President</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>9
<FILENAME>phat-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:7.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Phathom Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Molly Henderson, as Principal Financial Officer of the company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:13.2pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:13.2pt;min-width:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:-7.914%;padding-left:7.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:82.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:43.982%;"></td>
    <td style="width:56.018%;"></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Molly Henderson</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Molly Henderson</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial and Business Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:7.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img46421407_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2XX17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(S.C R.C(T(#$R.C(V.C$Y   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,SHP,CHR-" Q,CHR-3HQ,  R,#(S.C R.C(T(#$R.C(U.C$P      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  '(L         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ >P$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M@_[_ !_^)H\W4O\ GU@_[_'_ .)KGYJW\J^\Z.6C_,_N#S=2_P"?6#_O\?\
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MCI5A%NI'D9([%X2?W949QSSGUXS0XQ7<:E)E\00_\\DZ_P!T4OD0_P#/)/\
MOD5D:AY$/_/)/^^13EC1#E45?H,4 97DRCQ*)0H$9C.3LY/ [YZ9[=:N3Z=;
MW$CO(&W.,'!_S_D"BM!323%1DX-M%1].M9E90DR%]WS8XRPI_P!AM2H'E3 [
M]^=O.17+[*/F=/M)>01Z1:.@.'(V[>3VIUVS"[ 6Z\O" E?)#9Z]^M;TJ:CL
M959N6Y6>1QS]O=54#(6U!I3)R!]N<-QNQ;CD_P"3^E;&(X7(>9T6[=!_#F =
M2>/RJ/[449@=0?Y>#FV'/OQ18+BL"T8F%[*8U'(6'OQ4]EJ$311P[I6=AP[)
MC/ZT-70+1DGV.]Q_R%)/^_2?X4?8[W_H*2?]^D_PKFY*G\WX'3ST_P"7\0^Q
MWO\ T%)/^_2?X4AL[W:?^)I)T_YY)_A2Y*G\WX!ST_Y?Q%^QWO\ T%)/^_2?
MX4?8[W_H*2?]^D_PHY*G\WX!ST_Y?Q#['>_]!23_ +])_A2&SO=I_P")I)T_
MYY)_A1R5/YOP#GI_R_B(UA=OC=J3G'3,*?X4@TZZ'34I/^_2?X4^6K:W/^ <
MU*]^3\1PL;P=-3D_[])_A574[.]_LRYS?R2#RS\GE)\WMP*B=.IROWOP+A.G
MS+W?Q+,L4)F)DT_<2>'"@Y_SS0L,''_$NQM;C@<>]=J;MN<32OL!M[8,5&GJ
M03UVC!J:&7RT6*.U=%'0#&!2=VM6"LGHBTIR,D8]J6H- HH RIL?\)) =@+"
M!@&##UZ$?X>]:6Z3_GG_ ./5<NA$>H;I/^>?_CU&Z3_GG_X]4%!ND_YY_P#C
MU)N?_GE_X]0 ;G_YY_\ CU&Y_P#GG_X]0 ;G_P">?_CU&Y_^>?\ X]3 -TG_
M #S_ /'J"SX_U7_CU  &DQ_J_P#QZEW2?\\__'J0!ND_YY_^/4UFDVG]WV_O
M4 .W2?\ //\ \>HW2?\ //\ \>H 0NX&3'C_ ($*:)6=&*ID<C.Z@!^Z3_GG
M_P"/4;I/^>?_ (]0 ;I/^>?_ (]36:3:?W?;^]0,KM!&[,Q5NOS 2GK1Y$:G
M.PC=QS*>:OF9G9"FVCVX,6 .?]9TJ6-/*!"0XSU^:DV4DAX:3G]WW_O4NZ3_
M )Y_^/5(PW2?\\__ !ZE4L?O+C\:!F?*5_X2* ;UW&!LK@YZ\>WK^5.N(+SS
MW>"<*I'R@^O'^'ZFIK*32Y1TG%-\PR5-35'*3H6^8J,#\!TIVS4, BY4G<./
ME^[^76L/WO<W_==AHBU0C'VE =GHI^;\JEN8V-P'6.9B%P=KX&/\:UH\_P!L
MRJ\GV"H8F8;O)O@,C@R"I0"H#"*Z.X;<;AQGO6Y@-=&9$_<7G'^WZ^M((F,>
M1!>#)Q@R#@<?Y_"BX6'& F0.8KH9.XJ)!C/I5N*T2$B3S)3@='?.*3920@U3
M3\?\?UM_W]7_ !H_M33_ /G^MO\ OZO^-8^VI_S(V]E4_E8?VII__/\ 6W_?
MU?\ &D.J:?M/^G6W3_GJO^-'MJ?\R#V53^5E+4=063RUL]2MHQSO/FIGMCK^
M-55O;CS&)U:UV@,%S(G<\9_2M%7HJ.K)]C5OLR43Q3[OM6J6CX'R?.G'^1C_
M .M4RW]E8:=*$O;>9D!9460#/MU-<_MH)RES>B+5&;:5F:ZG<@;U&:6NA;&0
M4C?=/TH HRVY>1_]$5LYPWF=?K4D5I&T7[V *QZC=GI6CEIHS-1UU0];*!22
M$//7YC5BH;;W+22V$'?ZTM(844 4&M9VUI+D[/(2+:.3G/\ *K<R;X\;58]@
MW2G-W6@H*SU(C"QP3#$<4"%E'$,70?G67*^QK==R2)2K.2BKGN.]5;R%GG#+
M:R2Y7!99BOZ9K2&AG/4CBMM[$26<B@\9:8GOGUJM':218$>F;?E*DBX[8_\
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M?UH /(C&,+TZ<T>1'_=_6@ \F/'W>V*>B*@PHQ0 ZB@ HH ** "B@ HH **
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH **** "BBB@
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M?FZT 6Z*** "BF[J3S/\YH$/HIGF>@_6D,GH,T!<DHINZC=B@8ZBF[J-WM0
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M0WQ$^*OA+X2Z*-5\7:[9Z%9,=L;7+G?*1R5C0 LY [*":^,?V_M"TWPSXR^
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M>]'7 !#.<G'RDX/ /E_QXTC6+S]GO3]5M?@7X9^&WA&/[))::N]W%<:K<!P
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M9@\81,QN7F9 RW0<6NX@G#;-^,';R*5/ QDFZEUK;HK>M_T'4QTDTH6VOU_
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MW'AJ"T>_?4K1O/B\A%+,Z[,E@ #T!/'K7F%Y^VM\%['3=(OKCQQ;I;ZLKO:
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M4DY#'G/(\9G_ ."<.HZQX9FT/7_C+X@US3[:)4T>QN('-I8,ORJWDM<,&PG
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M8+0?13=U&ZH-1U5-4_X]5_ZZQ?\ HQ:L[JJZFV;4?]=8_P#T-: +E%-W4;J
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MP\3?]%=\8?\ @'HW_P KZ]##>U&[MBGS,.1?TV>>?\*P\3?]%=\8?^ >C?\
MROH_X5AXF_Z*[XP_\ ]&_P#E?7H18]<<4;_;BCF?](.2/?\ $\]_X5AXF_Z*
M[XP_\ ]&_P#E?1_PK#Q-_P!%=\8?^ >C?_*^O0M_'2EW\XI<[_I!R1[_ (GG
MG_"L/$W_ $5WQA_X!Z-_\KZ/^%8>)O\ HKOC#_P#T;_Y7UZ%YGM0),D@"CG#
MD7],\]_X5AXF_P"BN^,/_ /1O_E?1_PK#Q-_T5WQA_X!Z-_\KZ]",F/I2[O;
MBCG#D7],\\_X5AXF_P"BN^,/_ /1O_E?1_PK#Q-_T5WQA_X!Z-_\KZ]"\SVI
M/-'3J:.=AR+^F>??\*P\3?\ 17?&'_@'HW_ROH_X5AXF_P"BN^,/_ /1O_E?
M7H>[OCBES3YF'(OZ;/._^%8>)O\ HKOC#_P#T;_Y7T?\*P\3?]%=\8?^ >C?
M_*^O1:*.9A[-?TV>=?\ "L/$W_17?&'_ (!Z-_\ *^C_ (5AXF_Z*[XP_P#
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M_*^O1:*.9A[-?TV>=?\ "L/$W_17?&'_ (!Z-_\ *^C_ (5AXF_Z*[XP_P#
M/1O_ )7UZ+11S,/9K^FSSK_A6'B;_HKOC#_P#T;_ .5]'_"L/$W_ $5WQA_X
M!Z-_\KZ]%HHYF'LU_39YU_PK#Q-_T5WQA_X!Z-_\KZK:C\,?$BVZD_%KQ>P\
MR,<VFC?WU_ZA]>G54U3_ (]5_P"NL7_HQ:.9A[-?TV<+_P *P\3?]%=\8?\
M@'HW_P KZ/\ A6'B;_HKOC#_ , ]&_\ E?7HM%',P]FOZ;/.O^%8>)O^BN^,
M/_ /1O\ Y7T?\*P\3?\ 17?&'_@'HW_ROKT6BCF8>S7]-GG7_"L/$W_17?&'
M_@'HW_ROH_X5AXF_Z*[XP_\  /1O_E?7HF:,T<S#D7],\[_X5AXF_P"BN^,/
M_ /1O_E?1_PK#Q-_T5WQA_X!Z-_\KZ]$HS1S,.1?TSSO_A6'B;_HKOC#_P
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M;_Y7UZ%OI0WK1SL.1?TV>>?\*P\3?]%=\8?^ >C?_*^C_A6'B;_HKOC#_P
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M;=_]<7_]!- %E/NK]*=34^ZOTIU !1110 4444 %%%% !1110 4444 %%%%
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MJ3W:0J)IE7A0[@98+VR>*K7'A71+O6[?69](L9M7MT\N'4)+9#/&O(VK(1N
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M^U6-K73=-@$T\B+'AG&YE10"<?,PSVS@X]*_8[_Y.D_:$[_Z1=8]/^/R7_\
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MB%>/KE2><CI@&KOPW^$5UX2\4:KXGU[Q)-XK\3:A"ML]Y);+;1Q0J<A(XE)
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MGG_BIV_\%]U_\;KKO^%)> /^A+T#_P %D'_Q-'_"D_A__P!"5X?_ /!9!_\
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M@"6'_5I_NBGTR'_5I_NBGT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 53U3_CS;_?3_T,5<JGJG_'FW^^G_H8H N4444 %%%% !1110 4444
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M6O\ \<HY9=@]I#N>BT5YU_PT=\)_^BF^#_\ P?6O_P <H_X:.^$__13?!_\
MX/K7_P".4<LNP>TAW/1:*\Z_X:.^$_\ T4WP?_X/K7_XY1_PT=\)_P#HIO@_
M_P 'UK_\<HY9=@]I#N>@X[UR_C#X:Z%XV4-J-HIN5&$NHQMD7G.,]Q['BL7_
M (:-^%'_ $4[P=_X/K7_ ..4?\-'?"?_ **;X._\'UK_ /'*N#JTI<T+I^1A
M5C0KQY*MFC-T3X=^(_ 5PQT+4X[^P8Y-I=97CV[9]QCZ5N>*])\5^)O,LK2X
M@TBQ( :97)D;(YZ#UX[53_X:*^$W_13?!_\ X/K7_P".4']HSX4=OB=X/_\
M!]:__'*K$RJ8I?O%KW6E_4YJ6%H4(.G"7NOI<SM _9_T/PZS:C-%_;NKQJ6A
M%Y@0AP/E 7TR!USBO1M%DO+C2[:2_LTL;QE'FV\<@D5&Z<, ,_E7%_\ #1GP
MH_Z*=X._\'UK_P#'*3_AHOX4?]%.\'G_ +CUK_\ '*Y*>'5&-J<;'73C1I:0
MLCT>EKSK_AH[X3_]%-\'_P#@^M?_ (Y1_P -'?"?_HIO@_\ \'UK_P#'*UY9
M=C7VD.YZ+6?K%K/=Z3>06LQMKF2%TBF4X,;D85NG8\UQ7_#1WPH_Z*;X/_\
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M^2.1[8K?->=?\-%_"?\ Z*=X.'_<>M?_ (Y1_P -&_"?G_BYW@__ ,'UK_\
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M_P#HIO@__P 'UK_\<HY9=@]I#N>BT5YU_P -'?"?_HIO@_\ \'UK_P#'*/\
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MI\LNP<\.YZ'Y8W9I=@KSS_AH[X3_ /13?!__ (/K7_XY1_PT=\)_^BF^#_\
MP?6O_P <HY9=@YX=ST)8PO0X'IVH\L9KSS_AHWX3_P#13?!__@^M/_CE'_#1
MWPG_ .BF^#__  ?6G_QRERR[![2'<]"V=C1LS7GO_#1OPG_Z*;X/_P#!]:?_
M !RC_AHSX3_]%-\'_P#@^M?_ (Y1RR[!SP[H]"\O=UYI=GO7GO\ PT=\)_\
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M'UK_ /'*/^&COA/_ -%-\'_^#ZU_^.4<LNP>TAW/1:*\Z_X:.^$__13?!_\
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M4Y Z$'O63X=^,7A[5M0?3+W5-,TC6FU&ZL+?2[B_C^T7/E321!T0X8[O+)P
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MQL,GR[<NU^"EQ)9ZZ^H:O8?VIK%W87,\NE:5]DM0MK.LJ_N3*[-(X!5I#(>
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M=,ET;2;FWNM/T]DO()8KZ:59$AGCYDB^21HFC9\#&QB0I]QC@6)550%11A5
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MUHJT&GS_ /;NK^]'KGPWU[4_$G@ZPU35XX8KJZ!D"VZLJ;"?D/S$GD8/XUU
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M .-T?ZQ99_S]_!_Y!_J_F?\ SZ_%?YGO%%>#_P##4#_]"VO_ (''_P"-T?\
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M_P!"VO\ X''_ .-T?ZQ99_S]_!_Y!_J_F?\ SZ_%?YGO%4]4_P"/)C_M(?\
MQX5XG_PU _\ T+:_^!Q_^-U#=?M,M<PF,^'0H)SG[:>Q!_YYT?ZQ99_S]_!_
MY!_J_F?_ #Z_%?YGOU%>#_\ #4#_ /0MK_X''_XW1_PU _\ T+:_^!Q_^-T?
MZQ99_P _?P?^0?ZOYG_SZ_%?YGO%%>#_ /#4#_\ 0MK_ .!Q_P#C='_#4#_]
M"VO_ (''_P"-T?ZQ99_S]_!_Y!_J_F?_ #Z_%?YGO%%>#_\ #4#_ /0MK_X'
M'_XW1_PU _\ T+:_^!Q_^-T?ZQ99_P _?P?^0?ZOYG_SZ_%?YGO%%>#_ /#4
M#_\ 0MK_ .!Q_P#C='_#4#_]"VO_ (''_P"-T?ZQ99_S]_!_Y!_J_F?_ #Z_
M%?YGO%%>#_\ #4#_ /0MK_X''_XW1_PU _\ T+:_^!Q_^-T?ZQ99_P _?P?^
M0?ZOYG_SZ_%?YGO%%>#_ /#4#_\ 0MK_ .!Q_P#C='_#4#_]"VO_ (''_P"-
MT?ZQ99_S]_!_Y!_J_F?_ #Z_%?YGO%%>#_\ #4#_ /0MK_X''_XW1_PU _\
MT+:_^!Q_^-T?ZQ99_P _?P?^0?ZOYG_SZ_%?YGO%%>#_ /#4#_\ 0MK_ .!Q
M_P#C='_#4#_]"VO_ (''_P"-T?ZQ99_S]_!_Y!_J_F?_ #Z_%?YGO%%>#_\
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M=S=#_=%<+_PT\W_0MC_P./\ \;I/^&G6_P"A;'_@<?\ XW3_ -:,OM;VJ_\
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MOM]WZ'GFG_#K4%^-E[XPNIK0Z7%HZ:7I]O&S&2/+[Y'92NU<D8!!.1Z52O\
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M_P#0&/\ X%3?_%UWU%']FX+_ )\Q^Y?Y!_:&,_Y_2_\  G_F<#_PHOP3_P!
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M =L5E^()/"]O\$?$UO\ #^SUG3]*\2:K:Z1I\.I;OLTSR,N^2U1V+A67<26
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M/J.F,#W\5"$<,N6%MNU_SNE^>Y\YA)3EBGS3OOWM^5O\CU6BBBO /HPHHHH
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M !XO]5_]"% %RBDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
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MO_E?1RKO^8<[_E?X'H=%>>?\*O\ $W_17?&'_@)HW_ROH_X5?XF_Z*[XP_\
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M\*O\3?\ 17/&'_@)HW_ROI6\_P Q\S_E?X'H=%>>?\*O\3?]%=\8?^ FC?\
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M#HKSS_A5_B;_ **[XP_\!-&_^5]'_"K_ !-_T5WQA_X":-_\KZ.5=_S#G?\
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MN_YASO\ E?X'H=%>>?\ "K_$W_17?&'_ (":-_\ *^C_ (5?XF_Z*[XP_P#
M31O_ )7T<J[_ )ASO^5_@>AT5YY_PJ_Q-_T5WQA_X":-_P#*^C_A5_B;_HKO
MC#_P$T;_ .5]'*N_YASO^5_@>AT5YY_PJ_Q-_P!%=\8?^ FC?_*^C_A5_B;_
M **[XP_\!-&_^5]'*N_YASO^5_@>AT5YY_PJ_P 3?]%=\8?^ FC?_*^C_A5_
MB;_HKOC#_P !-&_^5]'*N_YASO\ E?X'H=%>>?\ "K_$W_17?&'_ (":-_\
M*^C_ (5?XF_Z*[XP_P# 31O_ )7T<J[_ )ASO^5_@>AU4U3_ (\G^J_^A"N'
M_P"%7^)O^BN^,/\ P$T;_P"5]5M0^&/B5;-RWQ:\8.,KP;31O[P_ZA]'*N_Y
MASO^5_@>F45YY_PJ_P 3?]%=\8?^ FC?_*^C_A5_B;_HKOC#_P !-&_^5]'*
MN_YASO\ E?X'H=%>>?\ "K_$W_17?&'_ (":-_\ *^C_ (5?XF_Z*[XP_P#
M31O_ )7T<J[_ )ASO^5_@>AT5YY_PJ_Q-_T5WQA_X":-_P#*^C_A5_B;_HKO
MC#_P$T;_ .5]'*N_YASO^5_@>AT5YY_PJ_Q-_P!%=\8?^ FC?_*^C_A5_B;_
M **[XP_\!-&_^5]'*N_YASO^5_@>AT5YY_PJ_P 3?]%=\8?^ FC?_*^C_A5_
MB;_HKOC#_P !-&_^5]'*N_YASO\ E?X'H=%>>?\ "K_$W_17?&'_ (":-_\
M*^C_ (5?XF_Z*[XP_P# 31O_ )7T<J[_ )ASO^5_@>AT5YY_PJ_Q-_T5WQA_
MX":-_P#*^C_A5_B;_HKOC#_P$T;_ .5]'*N_YASO^5_@>AT5YY_PJ_Q-_P!%
M=\8?^ FC?_*^C_A5_B;_ **[XP_\!-&_^5]'*N_YASO^5_@>AT5YY_PJ_P 3
M?]%=\8?^ FC?_*^C_A5_B;_HKOC#_P !-&_^5]'*N_YASO\ E?X'H=5-4_X\
MG^J_^A"N'_X5?XF_Z*[XP_\  31O_E?5;4/ACXE6S<M\6O&#C*\&TT;^\/\
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M&'_@)HW_ ,KZ3_A6/B;_ **YXP_\!-&_^5]+E7<.=_RO\#T6BO//^%8>)O\
MHKGC#_P$T;_Y7TG_  K'Q-_T5SQA_P" FC?_ "OHY5W#GE_*_P #T2BO._\
MA6/B7_HKOC'_ ,!-&_\ E?1_PK'Q-_T5WQC_ . FC?\ ROI\J[_F'.^WY'HE
M%>=_\*Q\3?\ 17?&'_@)HW_ROH_X5CXF_P"BN^,/_ 31O_E?2Y5W_,.:7\K_
M  /1**\[/PQ\3?\ 17/&/_@)HW_ROH_X5CXF_P"BN^,?_ 31O_E?3Y5W_,.9
M_P K_ ]$HKSO_A6/B;_HKGC#_P !-&_^5]'_  K'Q-_T5WQA_P" FC?_ "OI
M<J[AS2_E?X'HE%>=_P#"L/$W_17?&'_@)HW_ ,KZ/^%8^)O^BN^,/_ 31O\
MY7T^5=_S#G?\K_ ]$HKSS_A6'B;_ **YXQ_\!-&_^5])_P *Q\3?]%=\8?\
M@)HW_P KZ.5=_P PYG_*_P #T2BO._\ A6/B;_HKGC'_ ,!-&_\ E?1_PK'Q
M-CCXN^,/_ 31O_E?2Y5W#FE_*_P/1**\\_X5CXF_Z*YXQ_\  31O_E?2#X8^
M)^_Q<\8_^ FC?_*^CE7?\PYW_*_P/1*J:?\ =G_Z[/\ SKA_^%7^)O\ HKGC
M#_P$T;_Y7U6L?ACXE99L?%KQ>N)G'%IHWK_V#Z?*N_YASO\ E?X'IE%>>?\
M"K_$W_17?&'_ (":-_\ *^C_ (5?XF_Z*[XP_P# 31O_ )7T<J[_ )ASO^5_
M@>AT5YY_PJ_Q-_T5WQA_X":-_P#*^C_A5_B;_HKOC#_P$T;_ .5]'*N_YASO
M^5_@>AT5YY_PJ_Q-_P!%=\8?^ FC?_*^C_A5_B;_ **[XP_\!-&_^5]'*N_Y
MASO^5_@>AT5YY_PJ_P 3?]%=\8?^ FC?_*^C_A5_B;_HKOC#_P !-&_^5]'*
MN_YASO\ E?X'H=%>>?\ "K_$W_17?&'_ (":-_\ *^C_ (5?XF_Z*[XP_P#
M31O_ )7T<J[_ )ASO^5_@>AT5YY_PJ_Q-_T5WQA_X":-_P#*^C_A5_B;_HKO
MC#_P$T;_ .5]'*N_YASO^5_@>AT5YY_PJ_Q-_P!%=\8?^ FC?_*^C_A5_B;_
M **[XP_\!-&_^5]'*N_YASO^5_@>ATW</\FO/O\ A5_B;_HKOC#_ ,!-&_\
ME?5G2?AWX@T[4K:YG^)WBC4X(I [V=U;:4L4PSDHQCL4< _[+ ^A%'*NX<[_
M )7^!WE%%%0:!13=W0XI/,'I0 ^BL#_A/?#?]H?8/[?TO[?O\K[+]LC\W?\
MW=N<Y]JVUESVY],U4HN/Q*Q,91E\+N24445)044W<?2EW4 +13=U+F@!:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIN[\Z-U #J*** "BBB@
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M!Z  #@"O"_"O@?\ 9T\5:#J>K?VIJ^E0:<5\^/4KCRY,,"5*  [\[6X7)XY
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M(C.%*1KM)*+N^[E@:;X!D/B[]FF[:\UR^UZ.:WU-1J_VQDGN8UN)Q&_FQE2
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M/_US;^50:BVW-O%_N+_*IJ@L_P#CU@_W%_E4] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %4]6.+&3ZK_ .A"KE4M6_X\)?\ @/\ Z$* +M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]6/\ H,GL5/\
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M3LVS=TWX8^#]'T*\T2P\+:+9:->C;<Z=;Z=#';SC &'C"[6& !R.U2:=\/\
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M .!Q_P#C='^L66?\_?P?^0?ZOYG_ ,^OQ7^9[Q17@_\ PU __0MK_P"!Q_\
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MS[+8;U[^J?\ D3+(<RE_RYM\U_F>Z[:7;[YKPG_AIYO^A;'_ (''_P"-T?\
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M$4AVEL*[L 3M!;@] 3THO/&.G6<NFR/J.EIIUY"TR74U\J&1<QA&B7&)%/F
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M+_GS'[E_D']H8S_G]+_P)_YG _\ "B_!/_0&/_@5-_\ %T?\*+\$_P#0&/\
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M\$_] 8_^!4W_ ,71_P *+\$_] 8_^!4W_P 77?44?V;@O^?,?N7^0?VAC/\
MG]+_ ,"?^9P/_"B_!/\ T!C_ .!4W_Q='_"B_!/_ $!C_P"!4W_Q==]11_9N
M"_Y\Q^Y?Y!_:&,_Y_2_\"?\ F<#_ ,*+\$_] 8_^!4W_ ,71_P *+\$_] 8_
M^!4W_P 77?44?V;@O^?,?N7^0?VAC/\ G]+_ ,"?^9P/_"B_!/\ T!C_ .!4
MW_Q='_"B_!/_ $!C_P"!4W_Q==]11_9N"_Y\Q^Y?Y!_:&,_Y_2_\"?\ F<#_
M ,*+\$_] 8_^!4W_ ,71_P *+\$_] 8_^!4W_P 77?44?V;@O^?,?N7^0?VA
MC/\ G]+_ ,"?^9P/_"B_!/\ T!C_ .!4W_Q='_"B_!/_ $!C_P"!4W_Q==]1
M1_9N"_Y\Q^Y?Y!_:&,_Y_2_\"?\ F<#_ ,*+\$_] 8_^!4W_ ,71_P *+\$_
M] 8_^!4W_P 77?44?V;@O^?,?N7^0?VAC/\ G]+_ ,"?^9P/_"B_!/\ T!C_
M .!4W_Q='_"B_!/_ $!C_P"!4W_Q==]11_9N"_Y\Q^Y?Y!_:&,_Y_2_\"?\
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M/_@5-_\ %T?\*+\$_P#0&/\ X%3?_%UWU%']FX+_ )\Q^Y?Y!_:&,_Y_2_\
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M.'RY"J@AE;<20V6&!MM:M+)JW@./Q!)XBOK'Q'K$ZV=E]GOY(H[=Y9O+6!8
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M1L]Z7M6U:P>P5[W/%O$7@75=8M_C?'I-K)9ZUKD4=M97;#RC<!=/C5 LC#!
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M2.+S P</L QN#*K9QG(!["J7C&UM6BBNM4UN32M%MU)FCAN&M6E=B F9E8,
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M-7N6W27=NFTJY?\ C(+,-W?%<'JVH>-OB-\4/$U]\.]#\*Z>- N3IL^MZQ;
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M0"A#94;25#8+*"WPO\9O"/C/4;:TT?4IKS[6ADM+O[#<)9W8 W$07+1B*9@
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M "J2HK@_Z/+_ +A_E0 EC_QYV_\ US7^0JQ5>Q_X\[?_ *YK_(5/0 M%)10
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M44 %%%% !1110 4444 %4]/^]=?]=V_D*N53T_[UU_UW;^0H N4444 %%%%
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MGTZQB@>;YBWSLB@M\S,>>Y)JQXM\56'@GPQJNOZI(8M/TVUDN[AAU"(I8X_
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M9(%>SJ;V)]K26AZA_8MBNI+J(L[<:BL'V87?E+YHBW;O+#XSMW<[<XSVJ@?
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M <_^!4W_ ,71_P **\$_] <_^!4W_P 71]5X@_Y_Q^[_ .U#ZUD'_/B?W_\
MVQPG_#3S?]"T/_ X_P#QNC_AIYO^A:'_ (''_P"-UW?_  HKP3_T!S_X%3?_
M !='_"BO!/\ T!S_ .!4W_Q='U7B#_G_ !^[_P"U#ZUD'_/B?W__ &QPG_#3
MS?\ 0M#_ ,#C_P#&Z/\ AIYO^A:'_@<?_C==W_PHKP3_ - <_P#@5-_\71_P
MHKP3_P! <_\ @5-_\71]5X@_Y_Q^[_[4/K60?\^)_?\ _;'"?\-/-_T+0_\
M X__ !NC_AIYO^A:'_@<?_C==W_PHKP3_P! <_\ @5-_\71_PHKP3_T!S_X%
M3?\ Q='U7B#_ )_Q^[_[4/K60?\ /B?W_P#VQPG_  T\W_0M#_P./_QNC_AI
MYO\ H6A_X''_ .-UW?\ PHKP3_T!S_X%3?\ Q='_  HKP3_T!S_X%3?_ !='
MU7B#_G_'[O\ [4/K60?\^)_?_P#;'"?\-/-_T+0_\#C_ /&Z/^&GF_Z%H?\
M@<?_ (W7=_\ "BO!/_0'/_@5-_\ %T?\**\$_P#0'/\ X%3?_%T?5>(/^?\
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M^%%^"?\ H#'_ ,"IO_BZ?U7B#_G_ !^[_P"U#ZUD'_0/+[__ +8X+_AIQO\
MH6Q_X&__ &NG?\-/-_T+8_\  X__ !NN[_X45X)_Z Q_\"IO_BZ/^%%^"?\
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MF(&< \>QK6^E<#\9M4\$:+X.:\\>PVMSHT,RM'#=0^;OFVMM"+CEL;OH,DX
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M?Z?UJY5/5?\ D'S_ $_K0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH]PO/M_7W'H?%'%>>?\ #./PG_Z)EX/_ /!#:_\ QNC_ (9Q^$__ $3+P?\
M^"&U_P#C=%H]PO/M_7W'H?%'%>>?\,X_"?\ Z)EX/_\ !#:__&Z/^&<?A/\
M]$R\'_\ @AM?_C=%H]PO/M_7W'H?%'%>>?\ #./PG_Z)EX/_ /!#:_\ QNC_
M (9Q^$__ $3+P?\ ^"&U_P#C=%H]PO/M_7W'H?%'%>>?\,X_"?\ Z)EX/_\
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MX7GV_K[CT/BCBO._^&<?A1_T3+P?_P""&T_^-T?\,X_"C_HF/@__ ,$-I_\
M&Z/=[A>?;\?^ >B<4<5YY_PSC\)_^B9>#_\ P0VO_P ;H_X9Q^$__1,O!_\
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M&U_^-T6CW"\^W]?<>A\4<5YY_P ,X_"?_HF7@_\ \$-K_P#&Z/\ AG'X3_\
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M?21&WUS3]9A.F.1$B^9>6LTGRD%2K>3"[L@3#YX2[?> =:N/B&^I+IZM8_\
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M41^_Z4[%>9B,54Q37/W;^]W9Z^%P=/"7Y.R7W(6J=C_K+S_KM_[*M7*IV/\
MK+S_ *[?^RK7(=Q<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!HKR/]HCQ=J_@W1_"DNC7SV,EYXBL[*<JBG?"^_<G(X' YXZ=:]<VUQWQ
M.^%.B?%KP_#HVO"<V<-PMR@MI/+8.JLHYQTPQK?#RA"K%U%IU.;$1G.DXTWJ
M<G?>/-4A_:/T[PVFI+_PCTGA][Z2WV1D&;SBH;?C<. !C./:H/V;_$.I^(K'
MQRVIZA<7[6GBB\MH#<2%S%$H3:BYZ*,\#W]ZP?\ AASX;9)*ZK_X&?\ V->G
M_"[X2Z'\(="GTG0!<+:37#73BXDWMO*JIP<# P@KT*\\+[%PI-MZ=+;7_,\W
M#T\7[;GJI)7;WON=K1117D'MF?K6DPZ[I-YIUP,PW430O]""/ZUY[\+?@G#\
M.-5NM0?4AJ<\L7DH?L_E;!G)_B.<X'Y5ZAM/K1MKS:^787$8BGBJL+SAL^W]
M>9UT\97HT9T(2M&6Z..^(7PRTOXB6,4-[O@N8"3!=0XWQY'/7J#QQ[5QFG_L
M[B;4+>;Q%XEO?$-M;_ZNUE#(H]B2[?+TX&.E>R;?>C;[URXC)<!BJWMZU-.7
MSUMW6S^9O1S+%X>G[*G-I:_CV>Z^1P/Q"^%8\=:AH5Q'J(T]-+<N(Q!YF_E3
MC.X8^[[]:F^*7PW/Q*TFSL1J']G?9YO.\SR?-W?*5QC<N.OZ5V^T^M+MXK:I
ME6$JJJIP_B6YM];;&<<=B(.GRR^"_+MI?<XGQM\*]*\=:+:65ZSQW-HNV"\A
M #IQ@]>QP./:N1T[]G<3ZA;S>(O$M[XAMK?_ %=M*&11_LDEV^7IP,=*]D"T
M;?>L*^1X#$5/:U:=WIWUMM=7L_F:TLSQ=&'LZ=1I:_CO;M\CP']I&SAN-8\&
MVI0>2\DD10< *6C&/RK5?]G-KZZ@2_\ %>HWFCPD&*PER2B@<*'+8'X+7K.I
M>&],UB2"2^T^UO)+<[H6N(5<QGCE<CCH.GI6AMKSGP[AZV+K8C$I24W&RUTL
MK6>NJ\CL6<5Z>'I4:#Y7"^N^[OIV."^(GPM@\;>%[#1;6[72(+.16CVP^8 J
MJ5"XW#UZY[5U0T6&3P^-*N/](@-O]F?^'>NW:>_&1[UI[:-O6O>A@</3JSJQ
MCK))/M9=+'DRQ-:4(TY2TBVUZO<\:T_]GN?3A<64/B[4(="N&W26,*A&8>A<
M''/?"C-3V7P$DL_!.J>'%U\F*]N$G$YM.4"D94CS/FSM'ICKBO7MO.:7;7EQ
MX>RV'PT^C6\MGNM]CO>;XV6\^J>RW6SV/"M/_9SU?2H6ALO'=W:0L=Q2WMW0
M$GO@2]:Z76/@FOB#P7IND:CKES=:G8/(\.J,I+$L2<,I8Y ^7N#\HP17I^WK
M0$P*5+AW+:,)4X4])*S7-)JWS?XCJ9OC:LU4G/WD[WLD_P $>+:Q^SQ=^(+*
M)=4\8WM_>PD"*:>'=&B]P$+]3QEMW:NF\<_"F3QI<>'9I-6%L^DD,W^C;O..
M5S_&-OW??K7H>WUHVUK'(<OC&<?9Z3M?5N]MNI#S7&<T9<_PWMHM+[].IP_Q
M4^&W_"R-'L[$:C_9QMYO.\PP^;N^4KC&X8Z_I78V=O\ 9+2&'=O\M F[&,X
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MD_* N.% 'LG_  @?AS^T=1U#^P=,^WZD8FO;K[%'YMT8B#$96VY<H0"N[.W
MQBK\^AZ?=37$LUC;32W$'V6:22%2TL(+$1L2.4R[?*>/F/J:GVJZK^M"O8.V
MC./\(Z)H_A'Q9<Z/IWB'5KRXFLENVTO4M2N-1\I0VP3"6=G>/=]W9OPVTD+D
M,:;:ZO-!\9?$=G=7TD=@GA[3[F&"24B(,+B]$TBJ3@''DAF'.-F?X:Z7POX'
M\/>";62U\.Z'IN@VTC!WATRTCMT=@  2$ !P !]!BH_$WP_\->-)+)_$/A[2
MM=>R<R6K:G91W!@<XRR%P=IX'(QT%9<ROJ:\DN5)'A^EW&J_$#PKX&FM-9EU
MNVNH-1N9--A\37.E7=Y']H 2YBFA^>41JVS8S*G[U6SE5J2^\4:KXQF\ :'I
M#7TVEW=EJ#R+JGB";2[NXNK2>.+RVN[2.0R%1YS$*P$@7<2P!KVG6/ASX5\1
M:/#I.J^&]'U+2X7,D5C>6$4L*,<Y9492 3N;D#N:FU;P-X=U_1(-&U30M,U+
M2(/+,6GW=G'+!'L^YMC92HV]L#CM6WM8]NYC[&=M^QS?P=_M2'0-0MM2U"UU
M!;74);>V^SZE)J+01*%S#)<RQH\KH^\98%L8#,S FO0*J:7H]EHFGP6&GVD%
MA8VZ>7#;6L2QQQ(.BJH& !Z 8JW7/)\SN=<5RQL+1114E!1110 VF3*/+;Z$
MU)39O]6_^Z:0%?3XQ]AMN/\ EDO\JL>6/2HM/_X\;;_KDO\ (58HLNP:C/+'
MI1Y8]*?119=@&>6/2CRQZ4^BBR[ ,\L>E'ECTI]%%EV 9Y8]*/+'I3Z*++L
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M2>>]MO >G_;(9(S/#!'%-'Y4<\JNS22"1V,BN&.2#U)R3["GV?@O3[>ZNY9
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M855%6&>1$(7[H958*V/<'TINJ:+I]]<)-<F6"8@0B:WN9+=W'.%+1LI8 L<
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M6?=>,KVS6V2;2HA<79C^SQK=Y4AW53O;9\I&Y2<!A[UJ2:!IZWCWKQ$.Q,C
MR-Y1;:07,>=N<<9QGWJO:^'M%BDB6,>9(P6:'?<NYVQD%2FYCA 2O ^7D4 9
MLWCF]L[&:YNM)A4(EQL2*\+EGB?81S&,*3G#?3(&:L#Q=>VUQ,+[38(;>"<V
M\LD%VTASY0D!4&-<C! .2"#GJ!DWVT+2M2MBGEK+ 6F!\N5L;G<F49!_O Y'
M8CM5J31[.:221X@Y>83ON8D%P@0'&<?= XZ=^M '-Q_$)[BW'V>TL[JYD:%8
MHX+\.@\Q]N)'"':5X) #<=,XK477+^?[0RZ>@MH2T<DRW/S[U7)(4I@KN^7.
M<]]M21Z#I=NXME,CRADG2&2ZD<KL;*E0S<*#C@8'05)-X?TW[5)>21,&8EWS
M,XCSMVERF=N[;_%C- '(ZM\1+BUTJ'R8L/<0J([I6,K+(83+\^(O+!PIXW9Z
M';@\;.F^)[Z9[)%M(IXIGE,DLEUB2*-'96<J(@N,@ 9(R3[$B;_A"-!O(8B+
M=I+; >-5NI#%RFP,HW8R4.-PY.XGG)JS#X-TJUN))8HKB,R'YT%W-Y;=3@IN
MVX^9N,8^8\4 8%UXZOKJWECM+6&*ZBGL?F,DGEO%-/Y9*LT(#< C*Y'.03C%
M6].\87,EG/<+9_:+>U9OM,LEP!(!O(^10@#84 \E>N!FM"/PGHUF&A*R;KCR
MXP9;N5W/E$R1JK%]PVG+#!XJ?_A$=*5D(MG"J<F-9Y-C_,7^==V'Y)/S ]:
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M-0JL 57S-RM\[?,'SSBJO_"OY)-0M;F;45N6MG+I-<6V^Y.83$5,I?[OS%L
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M-G?C"JV-P ZDA: )?^$5U*6UN(;C5+266>83R/\ 86 E((^60>;\R;?E"\<
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M HHHH **** "BBB@ HHHH **** "DVTM% $4=O'"TC(BHTC;W91RS8 R?4X
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M@Z;9V\D$&GVL,$O^LBCA54?'J ,&IX["VAV>7!&FS=MVH!MW'+8],]_6K%%
M&7#X7T>W>1HM*L8VD#*Y2V0%PWW@>.0>_K5\V\;3+*44R*"JN0,@'&0#Z<#\
MJEHH S+7PUI-C,\UOIEG;S/NW216Z*S;OO9('.:9)X4T:2W2!M)L6A1BZQM;
M(55B,%@,<$COUK6HH S?^$<TOS;>3^SK3S+<!87\A-T8!R IQ\N#SQZUI444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img46421407_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &G!*$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]17@/F2?\]'_ .^C1YDG_/1_^^C0![]17@/F2?\ /1_^^C1YDG_/1_\ OHT
M>_45X#YDG_/1_P#OHT>9)_ST?_OHT >_45X#YDG_ #T?_OHT>9)_ST?_ +Z-
M 'OU%> ^9)_ST?\ [Z-'F2?\]'_[Z- 'OU%> ^9)_P ]'_[Z-'F2?\]'_P"^
MC0![]17@/F2?\]'_ .^C1YDG_/1_^^C0![]17@/F2?\ /1_^^C1YDG_/1_\
MOHT >_45X#YDG_/1_P#OHT>9)_ST?_OHT >^YI17 _#1F:/4]S$X:/&3G^]7
M?4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3&LI2*./+9 ^M176CZE8Q>;=6,\,><;G3 H I458M+&[OY#'9V\D[@9*QC)
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MQZ_X?U[2+>VUYGBGA !< _,>F00#UK-\4ZSI%W8V^GZ5;JR0\"8IC Q]T=Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "JU__P @ZZ_ZXO\ R-6:K7__ "#KK_KB_P#(T">Q\@)]
MQ?I3J<D$WEK^XEZ#_EF?\*=Y$W_/";_OV:]NZ/&LR.BI/(F_YX3?]^S1Y$W_
M #PF_P"_9HN@LR.BI/(F_P">$W_?LT>1-_SPF_[]FBZ"S(Z*D\B;_GA-_P!^
MS1Y$W_/";_OV:+H+,CHJ3R)O^>$W_?LT>1-_SPF_[]FBZ"S(Z*D\B;_GA-_W
M[-'D3?\ /";_ +]FBZ"S(Z*D\B;_ )X3?]^S1Y$W_/";_OV:+H+,CHJ3R)O^
M>$W_ '[-'D3?\\)O^_9HN@LR.BI/(F_YX3?]^S1Y$W_/";_OV:+H+,CHJ3R)
MO^>$W_?LT>1-_P \)O\ OV:+H+,CHJ3R)O\ GA-_W[-'D3?\\)O^_9HN@LR.
MBI/(F_YX3?\ ?LT>1-_SPE_[]FBZ"S[$=%2>1-_SPE_[]FCR)O\ GA+_ -^S
M1<+/L1T5)Y$W_/"7_OV:/(F_YX3?]^S1=!9D=%2>1-_SPF_[]FCR)O\ GA-_
MW[-%T%F1T5)Y$W_/";_OV:/(F_YX3?\ ?LT7069'14GD3?\ /";_ +]FCR)O
M^>$W_?LT7069'14GD3?\\)O^_9H\B;_GA-_W[-%T%F1T5)Y$W_/";_OV:/(F
M_P">$W_?LT7069'14GD3?\\)O^_9H\B;_GA-_P!^S1=!9D=%2>1-_P \)O\
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MT ,HI_E2?\\W_P"^31Y4G_/-_P#ODT ,HI_E2?\ /-_^^31Y4G_/-_\ ODT
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MYC_WW_[Z-'F/_??_ +Z-'U-]P^MKL?8>1ZBC(]17QYYC_P#/1_\ OLT>8_\
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M;\Z-S?WV_.@#W^BO -S?WV_.C<W]]OSH ]_HKP#<W]]OSHW-_?;\Z /?Z*\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "JU_P#\@ZZ_ZXO_ "-6:K7_
M /R#KK_KB_\ (T">Q\@)]Q?I3J:GW%^E.KW#QNH4444""BBB@ HHHH ****
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M_OK_ .@+6'0 4'I110!Z+!8^'=/\*6>I:AIBR[U"LR+EB23[CTJB=8\#\_\
M$EF_[]#_ .*K:672XO EB^KPO+:_*-B@YW9..A'O6&U_X#VMMTV?=@X^5_\
MXJ@#ETLY=3U&6/3;9W#.2D:CHN>,^E2WGA[5M/A,UU82QQ9P6X('Y$UT7@74
MM/MEO;*YG$$MQQ'*3@XQC /K70MH^IV&GW<>FWT=_#*#F*\R[ 8.<,#_ $H
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M)['R"GW%^E+34^XOTIU>V>-U#I7JNF_#+P[+X6LM:U77KBQ2X0%B[1J@8D\
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M9C(6&W&X\Y]*ZGQ7XEMM&^+MCJ\<L<]ND2I*T3!L*1AL8[XKR; (QCB@  <
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M%CMVI  .@Q0!Z9J.CZ'XEO(=4&K)&A \R,D?-CMR1BLB35-#T/Q=!/IB?Z,
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MJ.2&^O2J$5A:>*?'5Y)G=9Q8+[>-^!C^8H X?<N<9I:]&D\2Z#%JHTI=(C,
M?RFFVKP>G3&2/?-9>K:#;Z3XNT\6ZC[+<R!EC89"\\CZ<T <9N&,Y&/K2CGH
M:]0\0ZIHOAZ_CSI,4]S*@R  H5<GGIC/6L?Q;IEA=:+;Z[IT2Q!R-X48R#QT
M]C0!PV0>AY]*7(SC/-=QXKMX(_!^D21PQH[!-S*@!/R=R*DT:V@?X<WDK0Q-
M*&<!R@+#D=Z ,+3O#0O_  Y=:L;LQF!B/*V9W8QWS[U@9&,]/K7>>'?^2<ZE
M_OO_ "6LOP[>6%GILHAT][W5Y#\BO#NC7T'6@#E@0>AK9L?#MQ>:+<:KYB);
M0@XYR6([5UVM:<E]X.:_O=-CL[^(9PB;<<^GH:TM*UFWD\&O?BP18H05,&1A
M\8&>F.?I0!P&@Z+;:Q%=//J*6GD@%0P!WYSZD>E8[#:Q&<X.,^M=]X2-KJL^
MNW364(5@K)&R!MG!X'%4/!^A6E[)=ZC?J'MK9B AZ%NI)^G% '';E]12DX&2
M17HUAK^@Z]J!TMM'CCBERJ2$ ;OR (_.LS2]&CTSX@K8.!-" S)YB@_*5.,^
M] '%[AZBEKTN\U?0](\0'3UTE)'E<>;*5&%)Z8&/Y8KG_'FEVVG:K#):QB-9
MDRR+TSD\T <I1110!Z%\,O\ 5ZG_ +T7\FKOJX'X9?ZO4_\ >B_DU=]0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5K_\
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M_P *\T/_ *>O^_W_ -:C_A7FA_\ 3U_W^_\ K5UE% ')_P#"O-#_ .GK_O\
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M#4MKP:A"I9I65?*.%#<'=GH?2H/A!_R2G0?^N+_^C&KSS0O^3IM3_P"N3_\
MHE: />10>E>$^,/''C33_C'-H7A^?[2LD:+!9R*/+#,G+'C/'7K6?<^+?B3\
M/_&.EV_BB_AOK6_<#RTP4VE@#M(4$$9% 'K7C/Q_I?@>338]2M[N8Z@[)%]G
M53M(VYSN8?WA6GX@\4Z/X7TQ;_5KM;>)^(P1EG/H .IKSGXV>(-1T>?PN=-N
M%B6YG<2!H4?(RF/O XZGI7(?M VNNC4=,NKB[1M(EPMK "-R2A1O)&._'<T
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MWGAK5/"N@0VOA6SU6!KJ >6RDGYY.K9;&"Q/;.: .RHI!UI: "BBB@ HHHH
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M*%#A?3/?VKKO#%]X<\'VEMX;GUF!M5+;KIVR3)._+%FQ@$DG@F@#NJ*;UIU
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MG)Q&B\#&,DDD]!0![32$XYKQGP_JOQ!UG5-6\%MJ]M#=:9)^_P!;\G>Y5N5
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MUU-=T[62Z)(\ B>)E&3@ ^XKUH4 +1110 4444 %%%% !1110 4444 %%%%
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M_P --9\;V&G^&?!=W<LKK,+UKN5!"5^;<5+'IC\:]YN](TV_L!8WEA;7%H
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MV$&H37\-E;QWDZA9;A8P'<#H"W4B@#RSX5?\B+XN_P"O^[_]!K LO^36Y/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 8\]AK+SR-#JRQQEB43R =H],TS^SM=_P"@TO\
MX#K6W10!B?V=KO\ T&E_\!UH_L[7?^@TO_@.M;=% &)_9VN_]!I?_ =:/[.U
MW_H-+_X#K6W10!B?V=KO_0:7_P !UH_L[7?^@TO_ (#K6W10!B?V=KO_ $&E
M_P# =:/[.UW_ *#2_P#@.M;=% &)_9VN_P#0:7_P'6C^SM=_Z#2_^ ZUMT4
M8G]G:[_T&E_\!UH_L[7?^@TO_@.M;=% &)_9VN_]!I?_  '6C^SM=_Z#2_\
M@.M;=% &)_9VN_\ 0:7_ ,!UH_L[7?\ H-+_ . ZUMT4 8G]G:[_ -!I?_ =
M:/[.UW_H-+_X#K6W10!B?V=KO_0:7_P'6C^SM=_Z#2_^ ZUMT4 8G]G:[_T&
ME_\  =:/[.UW_H-+_P" ZUMT4 8G]G:[_P!!I?\ P'6C^SM=_P"@TO\ X#K6
MW10!B?V=KO\ T&E_\!UH_L[7?^@TO_@.M;=% &)_9VN_]!I?_ =:/[.UW_H-
M+_X#K6W10!B?V=KO_0:7_P !UH_L[7?^@TO_ (#K6W10!B?V=KO_ $&E_P#
M=:/[.UW_ *#2_P#@.M;=% &)_9VN_P#0:7_P'6C^SM=_Z#2_^ ZUMT4 8G]G
M:[_T&E_\!UH_L[7?^@TO_@.M;=% &)_9VN_]!I?_  '6C^SM=_Z#2_\ @.M;
M=% &)_9VN_\ 0:7_ ,!UH_L[7?\ H-+_ . ZUMT4 8G]G:[_ -!I?_ =:/[.
MUW_H-+_X#K6W10!B?V=KO_0:7_P'6C^SM=_Z#2_^ ZUMT4 8G]G:[_T&E_\
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M_H-+_P" ZUMT4 8G]G:[_P!!I?\ P'6C^SM=_P"@TO\ X#K6W10!B?V=KO\
MT&E_\!UH_L[7?^@TO_@.M;=% &)_9VN_]!I?_ =:/[.UW_H-+_X#K6W10!B?
MV=KO_0:7_P !UH_L[7?^@TO_ (#K6W10!B?V=KO_ $&E_P# =:/[.UW_ *#2
M_P#@.M;=% &)_9VN_P#0:7_P'6C^SM=_Z#2_^ ZUMT4 8G]G:[_T&E_\!UH_
ML[7?^@TO_@.M;=% &)_9VN_]!I?_  '6C^SM=_Z#2_\ @.M;=% &)_9VN_\
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M_OW)_P#$T =O14<$T=S;QSPN'BD4,C#N#R#4E !1110 4444 %%%% !1110
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M#P:7PO\ \EU\6_\ 7G%_Z$* (?AE?7EUX*\52W%W/-)'>W8C>21F90%X )/
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M5<1I??#WX8:7=$_V=>7>VY&3M8!N ?S- 'H>F?&3P?J>IQ6*75S TK;(Y;B
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M'N=<U&RUW0]1&FZ]8@B&8KE)%/57'I^==K10!YOIO@+Q%JGB"TU?QQK=O?\
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M [[_ +YH W**P_[>N_\ H!WW_?-']O7?_0#OO^^: -RBL/\ MZ[_ .@'??\
M?-']O7?_ $ [[_OF@#<HK#_MZ[_Z =]_WS1_;UW_ - .^_[YH W**P_[>N_^
M@'??]\T?V]=_] .^_P"^: -RBL/^WKO_ * =]_WS1_;UW_T [[_OF@#<HK#_
M +>N_P#H!WW_ 'S1_;UW_P! .^_[YH W**P_[>N_^@'??]\T?V]=_P#0#OO^
M^: -RBL/^WKO_H!WW_?-']O7?_0#OO\ OF@#<HK#_MZ[_P"@'??]\T?V]=_]
M .^_[YH W**P_P"WKO\ Z =]_P!\T?V]=_\ 0#OO^^: -RBL/^WKO_H!WW_?
M-']O7?\ T [[_OF@#<HK#_MZ[_Z =]_WS1_;UW_T [[_ +YH W**P_[>N_\
MH!WW_?-']O7?_0#OO^^: -RBL/\ MZ[_ .@'??\ ?-']O7?_ $ [[_OF@#<H
MK#_MZ[_Z =]_WS1_;UW_ - .^_[YH W**P_[>N_^@'??]\T?V]=_] .^_P"^
M: -RBL/^WKO_ * =]_WS1_;UW_T [[_OF@#<HK#_ +>N_P#H!WW_ 'S1_;UW
M_P! .^_[YH W**P_[>N_^@'??]\T?V]=_P#0#OO^^: -RBL/^WKO_H!WW_?-
M']O7?_0#OO\ OF@#<HK#_MZ[_P"@'??]\T?V]=_] .^_[YH W**P_P"WKO\
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M [[_ +YH W**P_[>N_\ H!WW_?-']O7?_0#OO^^: -RBL/\ MZ[_ .@'??\
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M-']O7?\ T [[_OF@#<HK#_MZ[_Z =]_WS1_;UW_T [[_ +YH W**P_[>N_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img46421407_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_2.jpg
M_]C_X  02D9)1@ ! @$ P #   #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\O/T]?;W^/GZ_\  $0@#.0=U P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@"AY[^OZ#_"@ \]_7]!_A0 >>_K^@_P * #SW]?T'^% !Y[^OZ#_"
M@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_
M  H //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^
M@_PH //?U_0?X4 'GOZ_H/\ "@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GO
MZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_P * #SW]?T'^% !
MY[^OZ#_"@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\* #SW]?T'^%
M!Y[^OZ#_  H //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_
MA0 >>_K^@_PH //?U_0?X4 'GOZ_H/\ "@ \]_7]!_A0 >>_K^@_PH //?U_
M0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_P * #SW
M]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\* #S
MW]?T'^% !Y[^OZ#_  H //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@
M \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\ "@ \]_7]!_A0 >>_K^@_
MPH //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@
M_P * #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ
M_H/\* #SW]?T'^% !Y[^OZ#_  H //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y
M[^OZ#_"@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\ "@ \]_7]!_A0
M >>_K^@_PH //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A
M0 >>_K^@_P * #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_PH //?U_0
M?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_  H //?U_0?X4 'GOZ_H/\* #SW]
M?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\ "@ \
M]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@
M\]_7]!_A0 >>_K^@_P * #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_P
MH //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_  H //?U_0?X4 'GOZ_H
M/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_
MH/\ "@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[
M^OZ#_"@ \]_7]!_A0 >>_K^@_P * #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0
M>>_K^@_PH //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_  H //?U_0?X
M4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_PH //?U_0?
MX4 'GOZ_H/\ "@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\* #SW]?
MT'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_P * #SW]?T'^% !Y[^OZ#_"@ \]
M_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_  H
M//?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_PH
M //?U_0?X4 'GOZ_H/\ "@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/
M\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_P * #SW]?T'^% !Y[^O
MZ#_"@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^
MOZ#_  H //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >
M>_K^@_PH //?U_0?X4 'GOZ_H/\ "@ \]_7]!_A0 >>_K^@_PH //?U_0?X4
M 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_P * #SW]?T'
M^% !Y[^OZ#_"@ \]_7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\* #SW]?T
M'^% !Y[^OZ#_  H //?U_0?X4 'GOZ_H/\* #SW]?T'^% !Y[^OZ#_"@ \]_
M7]!_A0 >>_K^@_PH //?U_0?X4 'GOZ_H/\ "@ \]_7]!_A0 >>_K^@_PH /
M/?U_0?X4 'GOZ_H/\* (J "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M5NZZ?)W/I&UNHKV%+BW8212J'1U.0RL,@CV(->.TXMIZ-'L)II-;/8L4AA0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MT/9WU0^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_P#V\O\ @Z$I_5JWDG;_ +=?_ U/M@$,,CD'D$5\V?2'P_\ $*REU'Q?=6<
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M<2(?H>5)^\A5L#->!&FZ5>,'TDK>:Z,]^515:$IK^5W79]4>9_L^?\?6H?\
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M#7#7H.@UK>+V?Z,[J%=5DU:TENOU1Z17&=@4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Q3\4_P#D
M<KK_ *Z6G_I-;U]'AOX$?27YL^<Q'\>7K'\D?9=\+=H)!>^7]GVGS/-V^7M[
M[]WR[?7/%?/*]URWOTMN?0NUGS6MUOL?$/@T)_PEMK]@SY/V_P#=X_YX[V]>
M<>5G.><9[U])5_@RYM^77UM_F?-TOXT>3;FT]+_Y'W37S)],% 'Q%XUNI_&7
MBV2T1L[KM;&#NJJDGD@C'&TMND)_VB<XKZ2BE1HJ7]WF?W7_ . ?-U6ZU9Q_
MO<J^^W_!/L#0?#EAX;M4L[")(T10K-M&^0]VD;&79CR<\#H %  \"=251\TG
M_DO0]^%.--<L%;\WZGFOC7X/VOB>\CO+)X].)#"XV1;A(<@JRHK(H?[P=B?F
M^4G)!SV4<4Z47&2<NVNWYZ''5PJJ24HM1[Z;_+34]-\.Z.= TZ#33*US]F3R
MQ(X 8J"=HP,@!5(11D_*HYKBG+GDYVM?6QVTX^SBH7O;2Y\]?'SQ#YL]MHD3
M?+"/M$P!_C?*Q*>V53>W?B0=._K8*%DZCZZ+]?Z\CR<;/54ETU?KT_KS/+_%
M'ARX\&OIUPN4DN+6&Z##/RSAMS+G^]'F,G' R,<5VTZBK<ZZ*37R_P"#J<52
MFZ/(]FXI_/\ X&A]J>'-9C\0Z;;ZE%P+F)7('\+])%[_ ''#+U[5\Y4A[.3@
M^C_X;\#Z.G/VD5-=5_P_XGSC^T#_ ,A&R_Z]W_\ 1AKV,%\,O7]#Q\;\4?1_
MF>L>!O%>C6>@V$%Q?V44L=M&KH]S"CJP'(96<%2.X(!K@K4YNI)J$FKO51?^
M1WT:D(TXIRBFDM')?YGS_P#%G4-.U_74.A[;AFB2.1X5R)9R[XVX_P!8VUE7
M< =QP,G%>KAHRITW[336ZOT5OP/*Q,HSJ+V6NEG;J[_B?4B7\?@_P]%<:F2!
M86<"38Y8NJ)'M'8L\F%'(&2,D#FO$Y?:U&H?:D[>EV_R/;O[&FG/[,5?ULE^
M9X@/C+XCU=W?1-+26",\XAN;EE';>T+1JO'/*_\ U_3^J4H652=GZJ/YW/,^
MM59W]G#3T;_*QU_@/XOKXEO!I6I0"TNI-PB9"QC=E!)C96^:-\ XRS!B-ORG
M ;GK87V4>>#O%;]UY^9T4<5[27)-6?2VWIY'MM>:>D% !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!2U'
M_CUF_P"N4G_H!JH[KU1,MGZ,^'OAQX;M?%>L)IU\9!"T4CDQL%;*+D<E6&/7
MBOI:]1TH<\;7NMSYJA356?)*]K/8^A_^%%>'O[]Y_P!_D_\ C->3]<J?W?N?
M^9ZWU.G_ 'OO7^1X'X/M4L?&-O;1YV0W[QKGD[4=U&3QDX'/ KU*KYJ#;ZQN
M>727+745LI6^X^W+FYBLHGN+AUBBB4L[L0%50,DDG@ "OFTFW9;OH?2-J*N]
M$CY%\=^.[WXA7JZ-HJ2&S,@6.-00]RX/$D@XVQC[RJV H&^3!QL]^C1CAX^T
MJ6YK:OMY+S_X9'@5JTL1+V=._+?1=_-^7_#L][^'/@*+P39D2%9;ZXP9Y!T&
M.D49Z[%)))X+L=QX"A?+KUG6EII%;+]7YGJT**H1U^)[O]%Y'HU<9UG*>-M?
M'AG1KK4,XD2,K%[RR?)']<,P8_[(/3K6]&'M)QATOKZ+5F%:?LH2GUMIZO8^
M._A]XAT_PUJZZKJJ3S"))#&(51V\UQMW-YDD8P$9^<D[BIQWKZ"O"52')3LK
MVO>ZT7HGY'S]"<:4^>=W:]K=WZM>9>^)GBG3/&%_%J&F1SPOY7ES"=(UW%"2
MC+LEDR=K%6SC 5<9YJ</3G1BX3:>MU:_SW2*Q%2%62G!-:6=[?+9L^E_A1XA
M_P"$@T"'S#F>S_T67U_=@>6Q[_-$4RQZL&Y)!KQL33]G4=MGJOGO^)[.&G[2
MFN\='\MOP/ ]=_Y**G_84LO_ $.WKU8?[M_VY+]3RY_[S_V_']#8^-7@]M(O
M5\06(*0W3_OMN08[D<B3(^Z)<9R.DBL<Y85GA*O-'V4MUMYKM\OR+Q=+DE[6
M.SW\GW^?YGF_C7Q4WBZ6SO)?^/B&QCMYSC :6.:<EQ_OHZ.<<!F*CI792I^Q
M4HK9R;7HTCDJU/:N,GNHI/U3?YGW#H?_ "#K7_KWA_\ 1:U\S/XI>K_,^EA\
M,?1?D>,?'_\ Y!=I_P!?1_\ 13UZ."^.7^']4>=C?@C_ (OT9N_!#_D6U_Z^
M)OYK6>+_ (OR1IA/X7S8WXU^(/[(T/['&<3:B_E#'7REPTI^A^2,^TE&$AS5
M.9[1U^?3_/Y!BY\E/E6\M/EU_P OF>)?"[QMI/@DW,]_%<RW%P$1#"D3*L:Y
M9@2\T9RS8R ",*.:]+$49UK*#22[WW^29YN'K0HW<TVWVMM\VCD/$^MVMYKD
MNKZ,)8$DF6XC$JHKI-P[G".ZX\T%UYS@X/(R>BG!QIJG4L]+.VUOG;H<]2:=
M1U*=TKW5]T_EYGU9XGOAXM\$SWML/^/BS$Y4<[3&RR2IWY0QNIZ]*\*FO95U
M%])6^_1?F>[4?M:#E'K&_P!VK_(\A^ 6H1V^J75FY"O<VZM'G^(Q/EE'J=KE
ML>BD]J]#&Q;A&2Z/7YGGX*24Y1[K3Y'JWQ0\ 7GCG[']CEAA^R>?N\W?SYOD
M[=NQ6Z>6<YQU&,\UPX>O&AS<R;O;;RO_ )G=B*$J_+RM*U]_.W^1\K^+O"MQ
MX.OO[.NGCED\M9-T6[;ARP ^95.?EYXKVZ515H\\4TKVU/$JTW1ER2:;M?0]
M\^+MF\WA/3[A,D6[6V_CHKV[+N)[?-M7_@5>7A7:M-=[_@SU,4KT8-=+?BB[
M\ ]2BETFXL 0)H+DR%>Y25$"MC_>C<'TX]:G&Q:FI=&K?-/_ ()6"DG!QZIW
M^37_  #WBO+/4/BOXQ7\>I>)9DM_G^SI%;G;SF102RCW5G*$?WE(KZ/"QY:2
MOU;?R/G,5+FJM+HDOF>Q?%6U:Q\&06S_ 'H#9QM]43:?U%>?AGS5VUUYG^)Z
M&)7+047TY5]QSOP_\+1>+_!4^GR867[7,\$A_P"6<RQQ;3_NGE'_ -ECCG%:
MUZCHUU-;<JNNZNS*A356@X/?F=GV=D>3:)XAN?"\&IZ%>*R1WD,T+QD<Q7*!
ME4X[9(,;XX.58G""N^<%5<*L=TTT^Z?]7."$W24Z4MFFFNS7]6/3/V?/^/K4
M/^N4'_H<E<6-VAZO]#MP6\_1?J<5\9O^1HN?^N=O_P"B$KIPG\)>K_-G-BOX
MK]%^2/KG7?$6F^'HEDU69+>.4E5WAFW$#D *K$\'D8Z5X,*<JCM35VCWISC3
M5YNR9Y3)\-/"GCN$ZGHLCVZR,PWVX98RZG# P3("OT3RP>",@\]WUBM0?)45
M_7?[U_P3A^KT:ZYZ;MZ;?<_^ >.^.OAA=^!HDOTG6YMFE$8=5,4B.067*;F'
M.TX97.".0,BO0HXB-9\EK.U[;H\^MAW07,G=7MV:/H'X0>([CQ%HFZ]<RSVD
MS0%V.7=0J.C,>I.'*Y/)V9/.37E8JFJ=3W=$U>WWW/5PM1U*?O:M.WY/]3#^
M/G_(!M_^O^+_ -)[FM,%_$?^%_G$SQO\-?XE^4BS\"O^1>?_ *_)O_0(:6,_
MB?\ ;J_-CP?\/_MY_DCTK7?$6F^'HEDU69+>.4E5WAFW$#D *K$\'D8Z5QPI
MRJ.U-7:.R<XTU>;LF>4R?#3PIX[A.IZ+(]NLC,-]N&6,NIPP,$R K]$\L'@C
M(//=]8K4'R5%?UW^]?\ !.'ZO1KKGINWIM]S_P" >.^.OAA=^!HDOTG6YMFE
M$8=5,4B.067*;F'.TX97.".0,BO0HXB-9\EK.U[;H\^MAW07,G=7MV:/H'X0
M>([CQ%HFZ]<RSVDS0%V.7=0J.C,>I.'*Y/)V9/.37E8JFJ=3W=$U>WWW/5PM
M1U*?O:M.WY/]3U2N$[@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@"EJ/_ !ZS?]<I/_0#51W7JB9;/T9\$>$_#MWXIOUT_3Y(X9V1W#2,
MZ+A!DC*([9/;Y<>N*^IJ5(TH\\DVO+_@V/EJ5.567)!I/ST_*YZK#\!-:GDS
M=W=HJ\99&GE;'T>*('V&\?A7"\;!+W8R_!?JSN6"F_BE'\7^B/H#P9X-L_!5
ME]CM"9'D.^:9N&D?& <#A54<*H)P,Y)8ECY56K*M+FEIV78]6E2C1CRQ^;[G
MQI-I<^M^(YM/M66.:XOIT1G+*H8ROR2JLP'T4GVKZ%24*2E+917Y(^><7.JX
M1T;D[?>STA?@/KTS#[1=V>T=Q)<.P^@:!!_X\*X_KE-;1E]R7ZG9]3J/>4?O
M;_0]P\!?#VT\#1.8W-Q=S@"68KM^4<A$3+;4SR<DEC@DX"@>;6KNLUI:*V7Z
ML]*C05!::R>[_1'S/XD_Y'B3_L)Q?^C8Z]FG_ 7^!_DSQJG\=_XU^:/>/C%X
M-O/%-C!/IR^;<6+2'R@<%XY0F_;D@%E,:D+U(W8YP#Y>%JQI2:GHI6U[-?\
M#GJ8JE*K%.&KC?3R?_#'A>F?$7Q'X/@72;B-6@B#1BWO;<C"'.Y#_JW*\D88
MD ''3BO3E0I57SIZ[WB_QZH\R->K17LVM%I:2_#HSW'X7>-]+\1L]I!90:9>
MQ1[BL"(L<D8*ABA5588.W<ASQ@AFP=OFXBC.G:3DY1;ZMW3_ *ZGI8>M"I[J
MBHR2Z)6:\O\ (]EKSCT0H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /B3XM(9/%UXB\%C:@?4VMN!7
MTF&THQ_[>_\ 2F?-XG6M)?X?_24=0?@3XAEP);JR*Y[RW#8]P#;@9_$5A]<I
MK:,ON7^9O]3J=91^]_Y'J_@#X4VW@Z;[?<2_:[W:51@NR.$,,-L!)+,P)4NV
M/E) 49)/#7Q+K+D2M'\6=U##*B^9N\ON2.5\?_%G5O"FLS:99Q6CPQ+$P:5)
MF?+QJYR4G1>I.,*..N>M;T,-"K!3DY7=]FK:/T9A7Q,Z4W"*C96W3ZKU1:^&
M_P 4]4\8:K_9U[%:QQ>3))F%)5?<I0 9>:08^8Y^7/3FIKX:%&'/%RO=+6WZ
M)%4,1.K/DDHI6;T3_P V>+RN/#OC0R7/$=MJN]B>/W9N-V__ +]D-C/X]Z])
M?O*%H]8?C;_,\U_NZ]WLI_A?_(^XP<\CI7S)],<OXC\8Z7X3,(U27R?M)8(0
MK/\ =QN9@@9@HW 9VGDUO3I3JWY%>WR,*E6%*W.[7V_I&G8Z[8ZE9G4K699;
M0*[&49V@)G>>0#\N#GC(P1UJ'"49<DE:7;U+4XRCSQ=X]_0^&;_7H=<\0-JV
MIB1[:6Z$DB( S^0K +$H9E7(B58^6 '7VKZ:,'3I^SA:ZC9=K]_OU/FI34ZG
MM)WLW=KK;M]VAZ)\3/B)HOC:QBAM(KN.ZMY=\;2QPJFQAMD4E)W89PK#"]5&
M:X\/0G0DW)QY6M;-_+HCKQ%>%:*45)-/2Z7SZLZWX!^(?,AN=#E/S1'[3"/]
MAB%E ]E?8WU=C6&-A9JJNNC_ $_7[C?!3T=)]-5^O]>9@_M _P#(1LO^O=__
M $8:UP7PR]?T,L;\4?1_F/\ #GP1AUW3;;46OGB-U"DI00!@NX9QN\T9QZX%
M*IBW3DX<M[.V_P#P!T\(IQ4^:UU>UO\ @G)>)O"NI_":^MKZTN5D\S?Y,RH%
M.4V[T>)C(,$,/XF!&1QBNBG4CBHN,HVMNK_D]#GJ4Y822E&7H[?FM3WJ8O\
M%/P<3&%BNKE 0N2$%Q;R\C/9)"AQG=M5QDEES7EK_9:VNJ7Y-?I?\#U'_M5#
M31M?BG^MOQ/GG3-=\3_#)I+41O;([[GCGAW1,P&W<CXP<C W1OAL#.<#'K2A
M2Q-I7OYIZ_=_FCR8SJX:\;679K3^O1GI_@/XG:?J^I);:EIUI:WMW+\EU;Q*
M-\[GC?N#2!G; #^8Y+$9QUKBK8>4(MPG)Q2^%O9>73Y6.VCB(SDE.$5)OXDN
MK[]?G<^D*\<]@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M<*NU3W"JBKGN02."*\:O5]M/F6RT7H>S0I>QARO>]WZLXKX^?\@&W_Z_XO\
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M1>A[-"E[&'*][W?JSNZY3J"@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#SWX
M?>//^$Z@GG^S?8_LSJF/-\W=N4MG/E18QC&,'ZUUUZ/L&E>]UVM^K.2A6]NF
M[<MGWO\ HCT*N0ZPH YSQ5XGM/"-@VHWNXHI"(B#+22,"50=ES@DLQ  !ZG
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MHWV?8[BN8Z0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M*3<=WI]YX^&BIU$I;+7[C[BKYH^E/&/CK_R+R?\ 7Y#_ .@35Z.#_B?]NO\
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?/?[/O\
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M?@GQS;^,+.2?8;2>T;;<PN?]6<$AMQ"_(=K\L%(*,&'&3S5J+HR2W3V:Z_\
M!.FC656+>S6Z[?\  .*C^(VN>*;F6+PC8136UNVUKJ[9@C'V"R18R,$+N=]I
M#,JYP.GV%.DDZ\FF^D=_R9S>WJ56UAXII=9;?FO\S4T#XA7R:HF@>*+1=/O9
MP#!)&<PRDY  ^9\;B"%(D<%OD;:W!B="/)[6A+FBMT]U^7Y>9<*\E/V5:/+)
M[-;/\_S\C7\=>/%\)F&SM83>ZE>G$$"Y P6VAFP"QRWRHJC+D'E0":SHT?:W
ME)\L([LTK5O96C%7G+9'-2>,O%V@(+_7],MSIX(\YK1\S0J3C<RF:4,%X)P
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MA;Q7<!W13QI+&WJCJ&4_B"#7FM.+<7NG9_(])-22DMFKKYEJI*"@#P/X>?\
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M8,J,EE SC14J#?)[1\VU]E?[OU,W5KI<_LTH[VZV^_\ 0]+\'^*(?%^FQZE
MIB+$I)&3DQR+]Y=V!D<AE.!E2"0#D#CJTW1DX/Y/NCLI5%5BIK3NNS.HK W"
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MP[DEB\!:P\&0XDO,$=0/L=ON(^BY.>W6O9KV^L4T^T?_ $IGC4+K#U+=Y?\
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M&./;M7IXC^%1_P *_P#24>9A_P"+6_Q/_P!*9[Y7EGJ!0 4 % !0 4 % !0
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MHNEOQU.;%I7IOK?\-"3XH#_BJ/#I[?:X_P#TJMZ6'_A5O\+_ /26/$?Q:/\
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M .E,]\KRSU H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ #@ 5RG5L.H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M5O@1JS@ <!3YYW*!V"ME<=!CCBO5KMNC2;WT_(\J@DJU5+;_ ())\'!C5?$
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M.Z^.2H\>EK-CRS>$/G@;2$W9/IC.:Y<'O.V_*=.,VA?;F/=U4( J@  8 '
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MZ-6V[E4*<J;J.:M>5UJMM>Q#\7_"^I>*;"VM]*A^T217!=U\R*/"^6RYS*Z
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M9I6NE=/[D_ZZF*IU<.VJ-I0;O9NS7XK^NA<LO!^N^+=5M]7\6^3;06!#6]E
MP<;\ALN0TB@%E4N?,<OM" *M2ZM.E!T\/=N6\GII^'RT*5*I5FJE>R4=HKO^
M/SU-+QEX&U&;4X_$OAN5(=2C4+)')PDZ@;1SR,E/D96PK*%(9&7)BE6BH.C6
M5X=&MU_6Y=6C)S5:B[36Z>S,?4H_'WBF!M,GMK32H)QLGG656+(W#JH2:9@&
M7@C:"PXW@$UI'ZO2?.G*;6RMU^Y&<OK%5<CC&">[OT^]G>Q>!+&/P_\ \(RQ
M9X#&5,A W^83O\T#H"LF&5>@ "9(%<OMI>T]MUOMY=ON.I48JG['I;?SWO\
M>>?:3:>._!T/]E6EO:ZK:Q$K!,\JH43/ 96FB?:!_!ABO*JY4**ZY/#U7SR<
MH-[JW_ ?]=#DBL117LXJ,XK9WM9?>OZZF=IW@7Q*OBBSU[5=ESN8R7+Q.@2W
M^1T2%59U=@J[?N(0,_>8AF-RK4O92I4[KHDT[O9M]OO9,:-7VL:L[/J[6LMT
MEW^Y'T37D'K'E?Q=\-ZAXHTB&TTJ+[1,EXDK+OCCPBPSJ6S*Z+PSJ, YYSC
M..["U(TIN4W9<K6S>MUV]#AQ5.56"C!7?,GNEI9][!\7?#>H>*-(AM-*B^T3
M)>)*R[XX\(L,ZELRNB\,ZC .><XP#@PM2-*;E-V7*ULWK==O0,53E5@HP5WS
M)[I:6?>QZI7"=QY%X#\+ZEHNO:S?WL/E6]]<.]N_F1-YBFXF<':CLR_*RG#J
MIYQC((KOK5(SITXQ=W%)/1Z:)?U8X*-.4*E24E92;:U6NK9Z[7 =X4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!YO\0_!]YXL^P_8WAC^Q7/G2><SKE?EX39&^6X/!VCWKLH58TN;FOJK*W_#
MHXZ]*57EY;>Z[N__  S/2*XSL"@ H * "@ H * "@ H * "@ H * "@ H *
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M'B;2;F7[/#>VDDQ./+2XA9\^FT.6S[8K1TYI7<9)=[.QFJD&[*4;]KHW*S-
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * *E[?VVFQ&XO)8[:%2 9)76- 2
M< %G(4$G@<\FJ47)VBFWV2N2Y**O)I+NW86SO;?4(EN+26.XA?.V2)UD1L$J
M=KJ2IPP*G!X((/(H:<7:2:?9Z,$U)7BTUW6J)9IH[=#+,RQQJ,LS$*H'J2<
M#ZTDKZ(;=M7HC,L?$&F:E)Y-E=VMS(/X(9XI&XZ_*C$\?2K<)1UE%I>::(4X
M2TC)-^33-BLS0R;_ %[3=*8)?7=M:L>BS3Q1$_0.RFM(PE+X8M^B;_(SE.,-
M)22]6D7;6\@OHQ-:R)-&>CQNKJ?HRDC]:AIQT::?GH6FI:Q::\B=F" LQ  &
M23P !U)/8"D,Q8/$VDW,OV>&]M))B<>6EQ"SY]-H<MGVQ6CIS2NXR2[V=C-5
M(-V4HW[71N5F:!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M#(((Y!!P1R*\UJVCT9Z2=]5L2TAA0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M&"NH/8E0#6<Z<Z>DTU_7<TA4A4^!I_UV-ZLC4* "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MYGS7UJM_-^$?\@_X6_XK_P"?[_R6M/\ XQ1]5H_R_C+_ ##ZU6_F_"/^0?\
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M\WX1_P @_P"%O^*_^?[_ ,EK3_XQ1]5H_P OXR_S#ZU6_F_"/^0?\+?\5_\
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ME:WZLSK5Y5X64;15FWO^B._^$FHP:1X/O+W4/FM8;F=F7 .Y## NS'0EW)4
MG!+#) Z<F)BYUHQANTOON]?D=6&DH492GLF_NLM/F>4^%/#.K^*[NZO/"Y.D
MVRMM/^DRH%#<B'S(P9)#@9(*[1D9(R,]]2I"DHQK>^_\*^^ST1PTZ<ZKE*A[
MB]6OE=:LV_AW<Q>"_$[:?KT!%](_D)<%RWE/+C:<=&6<,/WOW@K@_=+5E73K
M4N>D_=2O:VZ7^78TH-4:O)57O7M>^S?^?<K_ !BW?\)6,YQY=MMSZ>WMG/3O
MGOFGA?X/SD+%?QOE$^D?B'C_ (1S4<_\^LGYXX_7I[UX]#^+#_$CV*_\*?\
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M(&>,9P3GNPM.-6;C-77*WNUK==K'#BJDJ4%*#L^9+9/2S[^A\Z?\+?\ %?\
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M6JW\WX1_R#_A;_BO_G^_\EK3_P",4?5:/\OXR_S#ZU6_F_"/^0?\+?\ %?\
MS_?^2UI_\8H^JT?Y?QE_F'UJM_-^$?\ (/\ A;_BO_G^_P#):T_^,4?5:/\
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M6/\ V\_^E<]<V*_C2^7_ *2CIPO\&/S_ /2F>#^&=W_"Q7\C_H)7^-N,;/\
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MR,$ UTT(J=2,)JZ=]-NC?0YJ\G3IRG!V:M;YM+J?+'_"W_%?_/\ ?^2UI_\
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M /'Z[/K5;^;\(_Y'']5H_P OXR_S#_A4'A3_ )\?_)F[_P#C]'UJM_-^$?\
M(/JM'^7\9?YA_P *@\*?\^/_ ),W?_Q^CZU6_F_"/^0?5:/\OXR_S#_A4'A3
M_GQ_\F;O_P"/T?6JW\WX1_R#ZK1_E_&7^8?\*@\*?\^/_DS=_P#Q^CZU6_F_
M"/\ D'U6C_+^,O\ ,/\ A4'A3_GQ_P#)F[_^/T?6JW\WX1_R#ZK1_E_&7^8?
M\*@\*?\ /C_Y,W?_ ,?H^M5OYOPC_D'U6C_+^,O\P_X5!X4_Y\?_ "9N_P#X
M_1]:K?S?A'_(/JM'^7\9?YA_PJ#PI_SX_P#DS=__ !^CZU6_F_"/^0?5:/\
M+^,O\P_X5!X4_P"?'_R9N_\ X_1]:K?S?A'_ "#ZK1_E_&7^8?\ "H/"G_/C
M_P"3-W_\?H^M5OYOPC_D'U6C_+^,O\P_X5!X4_Y\?_)F[_\ C]'UJM_-^$?\
M@^JT?Y?QE_F'_"H/"G_/C_Y,W?\ \?H^M5OYOPC_ )!]5H_R_C+_ ##_ (5!
MX4_Y\?\ R9N__C]'UJM_-^$?\@^JT?Y?QE_F'_"H/"G_ #X_^3-W_P#'Z/K5
M;^;\(_Y!]5H_R_C+_,/^%0>%/^?'_P F;O\ ^/T?6JW\WX1_R#ZK1_E_&7^8
M?\*@\*?\^/\ Y,W?_P ?H^M5OYOPC_D'U6C_ "_C+_,/^%0>%/\ GQ_\F;O_
M ./T?6JW\WX1_P @^JT?Y?QE_F'_  J#PI_SX_\ DS=__'Z/K5;^;\(_Y!]5
MH_R_C+_,/^%0>%/^?'_R9N__ (_1]:K?S?A'_(/JM'^7\9?YA_PJ#PI_SX_^
M3-W_ /'Z/K5;^;\(_P"0?5:/\OXR_P P_P"%0>%/^?'_ ,F;O_X_1]:K?S?A
M'_(/JM'^7\9?YDUO\*/#%I*D\5EMDB970_:+HX92&4X,Y!P0#@@@]Q2>)JM6
M<M'Y1_R&L-23NHZKSE_F>BUR'6% !0!X?\?/^0#;_P#7_%_Z3W->E@OXC_PO
M\XGFXW^&O\2_*1TOP@_Y%2Q_[>?_ $KGK'%?QI?+_P!)1MA?X,?G_P"E,X_X
MG>-/$7@[48GM=G]F2A"I\H'++_K8GD(;:S 9! !VGY<E6-=&'I4JT6G?G5^O
MW.QSXBK4HR7+;D=NGWJYP'CWXE'Q_;P:/I5K,I>57=3AY)' (2.-4W97+%B>
M"2%X SGKHX?ZNW4G);>B2[NYR5L1[=*G3B]_FWV5CZ)\!>'&\*Z+;Z?)CSE!
MDFP<CS9#N8 C@A,A 1U"@]Z\BM4]K-S6VR]%_5SUZ-/V4%![[OU?]6/G3X@'
M_A(?'<>GM\T:S6=J/0(VQY!@]@TLF?7G'6O7H?N\.Y+>TI?/6WY(\BO^\Q"A
MTO&/Y-_FSZ\KP#WSYJ^/'AB>22#7K="T:1^1<%1RF&9XW8#G:=[(7/ (12>1
M7LX.HE>D][W7ZK^O,\?&4WI52TM9^79_UY&%XG^,2^(=!.DQV\B7EPD<<\C%
M2F%*ES'CYB9"N,,H"AB,L0#6E/"^SJ<]URJ[2Z_/T,JF*]I3]FD^9V3?3Y>I
MZ1\,O#FH>%_#<]RD0_M*[W7$<,N0,*F(8W (8%\,<9!&\ X(-<>(J1J55&_N
M+1M>NK7]=#LP].5*DVE[[U2?IHG_ %U/.+7Q_H^MW$Z>-]-A$X("26\#)(NT
M;6CE)E$^1@%27..1A1BNQT)P2^K3=NS>GJM+'&JT)MK$P5^Z5GZ/6YA^"M.C
MU?Q?%/X=BFATZVG6;]X<F*%5&\.V3_K&W*BEF;# $MAFK6K)PHM5FG)JVG5^
M7IU,J,5.LG1344[Z]%Y^O0^S:^=/H@H P]?\-Z?XHMUM-4B^T0I()57?)'AU
M5E#9B=&X5V&"<<YQD#&L*DJ3YH.SM;9/3Y^AE.G&JN6:NKWW:U^5CD/^%0>%
M/^?'_P F;O\ ^/UO]:K?S?A'_(P^JT?Y?QE_F'_"H/"G_/C_ .3-W_\ 'Z/K
M5;^;\(_Y!]5H_P OXR_S#_A4'A3_ )\?_)F[_P#C]'UJM_-^$?\ (/JM'^7\
M9?YA_P *@\*?\^/_ ),W?_Q^CZU6_F_"/^0?5:/\OXR_S#_A4'A3_GQ_\F;O
M_P"/T?6JW\WX1_R#ZK1_E_&7^8?\*@\*?\^/_DS=_P#Q^CZU6_F_"/\ D'U6
MC_+^,O\ ,/\ A4'A3_GQ_P#)F[_^/T?6JW\WX1_R#ZK1_E_&7^8?\*@\*?\
M/C_Y,W?_ ,?H^M5OYOPC_D'U6C_+^,O\P_X5!X4_Y\?_ "9N_P#X_1]:K?S?
MA'_(/JM'^7\9?YA_PJ#PI_SX_P#DS=__ !^CZU6_F_"/^0?5:/\ +^,O\P_X
M5!X4_P"?'_R9N_\ X_1]:K?S?A'_ "#ZK1_E_&7^8?\ "H/"G_/C_P"3-W_\
M?H^M5OYOPC_D'U6C_+^,O\P_X5!X4_Y\?_)F[_\ C]'UJM_-^$?\@^JT?Y?Q
ME_F'_"H/"G_/C_Y,W?\ \?H^M5OYOPC_ )!]5H_R_C+_ ##_ (5!X4_Y\?\
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M7\9?YA_PJ#PI_P ^/_DS=_\ Q^CZU6_F_"/^0?5:/\OXR_S#_A4'A3_GQ_\
M)F[_ /C]'UJM_-^$?\@^JT?Y?QE_F'_"H/"G_/C_ .3-W_\ 'Z/K5;^;\(_Y
M!]5H_P OXR_S#_A4'A3_ )\?_)F[_P#C]'UJM_-^$?\ (/JM'^7\9?YA_P *
M@\*?\^/_ ),W?_Q^CZU6_F_"/^0?5:/\OXR_S#_A4'A3_GQ_\F;O_P"/T?6J
MW\WX1_R#ZK1_E_&7^8?\*@\*?\^/_DS=_P#Q^CZU6_F_"/\ D'U6C_+^,O\
M,/\ A4'A3_GQ_P#)F[_^/T?6JW\WX1_R#ZK1_E_&7^8?\*@\*?\ /C_Y,W?_
M ,?H^M5OYOPC_D'U6C_+^,O\R2+X2^%H'66.RPZ,&4_:+HX*G(.#.1P1WXH>
M)JO1R_"/^0+#4EJH_C+_ #/1ZXSL"@ H \/^/G_(!M_^O^+_ -)[FO2P7\1_
MX7^<3S<;_#7^)?E(Z7X0?\BI8_\ ;S_Z5SUCBOXTOE_Z2C;"_P &/S_]*9Q_
MQ.\:>(O!VHQ/:[/[,E"%3Y0.67_6Q/(0VUF R" #M/RY*L:Z,/2I5HM._.K]
M?N=CGQ%6I1DN6W([=/O5S@/'OQ*/C^W@T?2K692\JNZG#R2. 0D<:INRN6+$
M\$D+P!G/71P_U=NI.2V]$EW=SDK8CVZ5.G%[_-OLK'K:^ 9[?P2_AZ/!O)(O
M-;D8,_FK.8PPXQE1$&Z$ $G!)K@]LG755_"G;Y6M?]3O]BU0=%?%:_SO>WZ'
MCWPY^(,7P]%SINK6T^'E#GRU42QN%VLK1R-&,$!2#N!'/#9&/0KT'B.6=-K;
MKLUZJYY]"NL/S0J)[]-T_1V*]@;KXF^+UU*UA:&!9H))#U$4,&P NWW?,<)P
MHZLV!E033=L-1Y).[LTO-OMY*XHWQ-;GBK*Z;\DN_F['9_'CPQ/))!KUNA:-
M(_(N"HY3#,\;L!SM.]D+G@$(I/(KGP=1*])[WNOU7]>9TXRF]*J6EK/R[/\
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MR_C+_,/^%0>%/^?'_P F;O\ ^/T?6JW\WX1_R#ZK1_E_&7^8?\*@\*?\^/\
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M1_R#ZK1_E_&7^8?\*@\*?\^/_DS=_P#Q^CZU6_F_"/\ D'U6C_+^,O\ ,/\
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M1_X5!X4_Y\?_ "9N_P#X_4?6JW\WX1_R+^JT?Y?QE_F'_"H/"G_/C_Y,W?\
M\?H^M5OYOPC_ )!]5H_R_C+_ #/&OB/:^#O"X;3M,LEGU(\,?M%VT=O[O_I&
M&DP?ECZ*>9. $;T:#K5??G*T/2-W^&WG]QYU=4:7N0C>?K*R_'?R^\\7TG2;
MO7+E+*PC::>4X55_5F/15'5F8A0.2:]&4E!<TG9(\Z,7-J,%=GU=X;^">C6-
MHJZS']NNV^9V$LT:)_L1B-X\@=V<$L>0%'%>%4Q<V_W;Y8^B;^=TSW:>$A&/
M[Q<TO5I?*S1O_P#"H/"G_/C_ .3-W_\ 'ZR^M5OYOPC_ )&OU6C_ "_C+_,/
M^%0>%/\ GQ_\F;O_ ./T?6JW\WX1_P @^JT?Y?QE_F>-?$>U\'>%PVG:99+/
MJ1X8_:+MH[?W?_2,-)@_+'T4\R< (WHT'6J^_.5H>D;O\-O/[CSJZHTO<A&\
M_65E^._E]YXOI.DW>N7*65A&TT\IPJK^K,>BJ.K,Q"@<DUZ,I*"YI.R1YT8N
M;48*[/J[PW\$]&L;15UF/[==M\SL)9HT3_8C$;QY [LX)8\@*.*\*IBYM_NW
MRQ]$W\[IGNT\)",?WBYI>K2^5FC?_P"%0>%/^?'_ ,F;O_X_67UJM_-^$?\
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M_P"%0>%/^?'_ ,F;O_X_1]:K?S?A'_(/JM'^7\9?YA_PJ#PI_P ^/_DS=_\
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MC_+^,O\ ,/\ A4'A3_GQ_P#)F[_^/T?6JW\WX1_R#ZK1_E_&7^8?\*@\*?\
M/C_Y,W?_ ,?H^M5OYOPC_D'U6C_+^,O\P_X5!X4_Y\?_ "9N_P#X_1]:K?S?
MA'_(/JM'^7\9?YA_PJ#PI_SX_P#DS=__ !^CZU6_F_"/^0?5:/\ +^,O\P_X
M5!X4_P"?'_R9N_\ X_1]:K?S?A'_ "#ZK1_E_&7^8?\ "H/"G_/C_P"3-W_\
M?H^M5OYOPC_D'U6C_+^,O\P_X5!X4_Y\?_)F[_\ C]'UJM_-^$?\@^JT?Y?Q
ME_F'_"H/"G_/C_Y,W?\ \?H^M5OYOPC_ )!]5H_R_C+_ ##_ (5!X4_Y\?\
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M/KLB18U_[Y0 ?I4N3EK)MOS=RE%1TBDEY*Q;J2@H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * *-_IEIJL8AOH(;J-6#A)HTE4, 0&"N& 8!F .,X)'0FJC)PUBVGY.
MWY$RBI:22:\U?\R2SLK?3HEMK2*.WA3.V.)%C1=Q+':B@*,L2QP.223R:&W)
MWDVWW>K!)15HI)=EHA]Q;17<9AG1)8V^\CJ&4_56!!_$4DW'5.S\AM)Z-710
ML-!TW2F+V-K;6K'@F&&.(D>Y15)JY3E+24F_5MD1A&&L8I>B2_(UJS-#*O\
M0M.U5@U]:VUTPZ&:&.0CZ%U;%7&<H?#)KT;7Y$2A&7Q13]4F6[2RM]/C\FTB
MCMXP<A(D5%!]=J@#]*3;EK)MOSU&DHJT4DNRT+#*'!5@"",$'D$'J".X-248
MT'AK2;67[1#96D4P.?,2WA5\^NX(&S[YK1U)M6<I6[7=C-4X)W48I][*YMUF
M:&1?:!INIMYE[:6UR_\ >F@BD/' Y=2>G%:1G*&D9->C:_(S<(RUE%/U29<L
M["VTZ/R;.*.WCZ[(D6-?^^4 'Z5+DY:R;;\W<I14=(I)>2L6ZDH* "@ H *
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M8 /(?0==L8/W4!]R6;FOGJM:59W>B6R[?\$^AI48T5:._5]7_P  [6N8Z0H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#G-5\7:3HDHM[ZYCBE.#L^9F&>FX(K%<]1NQQSTH VK2
M\AOXEN+9UFBD&5="&4CIP1Z'@CJ""#R* +- !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % '.:KXNTG1)1;WUS'%*<'9\S,,]-P16*Y
MZC=CCGI0!M6EY#?Q+<6SK-%(,JZ$,I'3@CT/!'4$$'D4 6: "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H R=6URQT*,2ZA,ENK'"[CRQ[[5 +
M-CO@''>@!-(UVPUV,RZ?,DZJ0&VDAESTW*P#+GG&0,X..AH UZ "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H M
M?9O?]/\ Z] !]F]_T_\ KT 'V;W_ $_^O0 ?9O?]/_KT 'V;W_3_ .O0 ?9O
M?]/_ *] !]F]_P!/_KT 'V;W_3_Z] !]F]_T_P#KT 'V;W_3_P"O0 ?9O?\
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MH /LWO\ I_\ 7H /LWO^G_UZ #[-[_I_]>@ ^S>_Z?\ UZ #[-[_ *?_ %Z
M#[-[_I_]>@ ^S>_Z?_7H ^$]:%PM_<"]S]H$T@EW9SO#'=UYZ]/;%4(]]^",
M5Q)97?F9%L)4\K(.-Y5O-V]N@CSCOUI#/;_LWO\ I_\ 7I 'V;W_ $_^O0 ?
M9O?]/_KT 'V;W_3_ .O0 ?9O?]/_ *] !]F]_P!/_KT 'V;W_3_Z] !]F]_T
M_P#KT 'V;W_3_P"O0 ?9O?\ 3_Z] !]F]_T_^O0 ?9O?]/\ Z] !]F]_T_\
MKT 'V;W_ $_^O0 ?9O?]/_KT 'V;W_3_ .O0 ?9O?]/_ *] !]F]_P!/_KT
M'V;W_3_Z] !]F]_T_P#KT 'V;W_3_P"O0 ?9O?\ 3_Z] !]F]_T_^O0 ?9O?
M]/\ Z] !]F]_T_\ KT 'V;W_ $_^O0 ?9O?]/_KT 'V;W_3_ .O0 ?9O?]/_
M *] !]F]_P!/_KT 'V;W_3_Z] !]F]_T_P#KT 'V;W_3_P"O0 ?9O?\ 3_Z]
M !]F]_T_^O0 ?9O?]/\ Z] !]F]_T_\ KT 'V;W_ $_^O0 ?9O?]/_KT 'V;
MW_3_ .O0 ?9O?]/_ *] !]F]_P!/_KT 'V;W_3_Z] !]F]_T_P#KT 'V;W_3
M_P"O0 ?9O?\ 3_Z] !]F]_T_^O0 ?9O?]/\ Z] !]F]_T_\ KT 'V;W_ $_^
MO0 ?9O?]/_KT 'V;W_3_ .O0 ?9O?]/_ *] !]F]_P!/_KT 'V;W_3_Z] !]
MF]_T_P#KT 'V;W_3_P"O0 ?9O?\ 3_Z] !]F]_T_^O0 ?9O?]/\ Z] !]F]_
MT_\ KT 'V;W_ $_^O0 ?9O?]/_KT 'V;W_3_ .O0 ?9O?]/_ *] !]F]_P!/
M_KT 'V;W_3_Z] !]F]_T_P#KT 'V;W_3_P"O0 ?9O?\ 3_Z] !]F]_T_^O0
M?9O?]/\ Z] !]F]_T_\ KT 'V;W_ $_^O0 ?9O?]/_KT 'V;W_3_ .O0 ?9O
M?]/_ *] !]F]_P!/_KT 'V;W_3_Z] !]F]_T_P#KT 'V;W_3_P"O0 ?9O?\
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M ^K_ +-[_I_]>D,/LWO^G_UZ #[-[_I_]>@ ^S>_Z?\ UZ #[-[_ *?_ %Z
M#[-[_I_]>@ ^S>_Z?_7H /LWO^G_ ->@ ^S>_P"G_P!>@ ^S>_Z?_7H /LWO
M^G_UZ #[-[_I_P#7H /LWO\ I_\ 7H /LWO^G_UZ #[-[_I_]>@ ^S>_Z?\
MUZ #[-[_ *?_ %Z #[-[_I_]>@ ^S>_Z?_7H /LWO^G_ ->@ ^S>_P"G_P!>
M@ ^S>_Z?_7H /LWO^G_UZ #[-[_I_P#7H /LWO\ I_\ 7H /LWO^G_UZ #[-
M[_I_]>@ ^S>_Z?\ UZ #[-[_ *?_ %Z #[-[_I_]>@"U0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y+\2
M= T^YFTVYE@0S7.J6=M,XRK20OYFY'*D9R% W'Y@  "!3 ]0LK*#3H5MK6-8
M88QA40!5 ^@]>I/4GD\T@+5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'DOQ)T#3[F;3;F6!#-<ZI9VTSC*M)"_F;D<J1G(4#<?F
M   (%,#U"RLH-.A6VM8UAAC&%1 %4#Z#UZD]2>3S2 M4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H \]^(/_,(_P"PY8_^U: /0J "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#SWX@_\PC_L.6/_
M +5H ]"H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y[Q=
M_P @34/^O&Z_]$24 'A'_D":?_UXVO\ Z(CH Z&@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M#SWX@_\ ,(_[#EC_ .U: /0J "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#SWX@_P#,(_[#EC_[5H ]"H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H Y[Q=_R!-0_Z\;K_P!$24 'A'_D":?_
M ->-K_Z(CH Z&@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#SWX@_\PC_ +#EC_[5H ]"H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * //?B#_S"
M/^PY8_\ M6@#T*@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#GO%W_ "!-0_Z\;K_T1)0 >$?^0)I__7C:_P#HB.@#H: "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * //?B#_P PC_L.6/\ [5H ]"H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * //?B#_ ,PC_L.6/_M6@#T*@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M]^(/_,(_[#EC_P"U: /0J "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M _MF;^ZGY-_\50 ?VS-_=3\F_P#BJ #^V9O[J?DW_P 50 ?VS-_=3\F_^*H
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MJ^[=E#N.X#:QXPPH V?[9F_NI^3?_%4 ']LS?W4_)O\ XJ@ _MF;^ZGY-_\
M%4 ']LS?W4_)O_BJ #^V9O[J?DW_ ,50 ?VS-_=3\F_^*H /[9F_NI^3?_%4
M ']LS?W4_)O_ (J@ _MF;^ZGY-_\50 ?VS-_=3\F_P#BJ #^V9O[J?DW_P 5
M0 ?VS-_=3\F_^*H /[9F_NI^3?\ Q5 !_;,W]U/R;_XJ@ _MF;^ZGY-_\50
M?VS-_=3\F_\ BJ #^V9O[J?DW_Q5 !_;,W]U/R;_ .*H /[9F_NI^3?_ !5
M!_;,W]U/R;_XJ@ _MF;^ZGY-_P#%4 ']LS?W4_)O_BJ -/3KU[O?O"C;MQC(
MZY]2?2@#3H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^*H /[9F_NI^3?\ Q5 !_;,W]U/R;_XJ@ _MF;^ZGY-_\50 ?VS-_=3\F_\
MBJ #^V9O[J?DW_Q5 !_;,W]U/R;_ .*H /[9F_NI^3?_ !5 %/4;M]3M9K*4
M!8[F*2%RN0P61"C%220& )P2",]0>E !IUV^F6L-E$ T=M%'"A;)8K&@12Q!
M +$ 9( &>@'2@"Y_;,W]U/R;_P"*H /[9F_NI^3?_%4 ']LS?W4_)O\ XJ@
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M30 ?V--_>3\V_P#B: #^QIO[R?FW_P 30 ?V--_>3\V_^)H /[&F_O)^;?\
MQ- !_8TW]Y/S;_XF@ _L:;^\GYM_\30 ?V--_>3\V_\ B: #^QIO[R?FW_Q-
M !_8TW]Y/S;_ .)H /[&F_O)^;?_ !- !_8TW]Y/S;_XF@ _L:;^\GYM_P#$
MT ']C3?WD_-O_B: #^QIO[R?FW_Q- !_8TW]Y/S;_P")H /[&F_O)^;?_$T
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H XJ[_UTG^^W_H1H DM;)[O=L*C;C.<CKGT!]* +?\
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M?\>R?\"_]"- %^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
MXJ[_ -=)_OM_Z$: -_1O]2W^^?\ T%: -:@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H Y+4_^/E_^ _^@B@"_H?_ "T_X#_[-0!O4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <5=_
MZZ3_ 'V_]"- &OH?_+3_ (#_ .S4 ;U !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 8.M_\L_^!?\ LM %#3/^/E/^!?\ H)H ZV@ H * "@ H * "@ H
M* "@ H * "@ H * "@""[_U,G^XW_H)H XJ@#K=,_P"/9/\ @7_H1H OT %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H XJ[_UTG^^W_H1H U]#_Y:?\!_]FH
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M-9XA6DM.GWETMOF?0U<9N% !0 4 % !0 4 % !0 4 % '):G_P ?+_\  ?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * .*N_P#72?[[?^A&@#7T/_EI
M_P !_P#9J -Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M+[1U$>F1;(+<)G85+$J1GV4L,\C=[UV5FU"*E\74PI_$VMCZHK@.D* "@ H
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M6ET<C7*[%BMB3DM3_P"/E_\ @/\ Z"* +^A_\M/^ _\ LU &]0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Q5W_KI/
M]]O_ $(T :^A_P#+3_@/_LU &]0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % &#K?_ "S_ .!?^RT 4-,_X^4_X%_Z": .MH * "@ H * "@ H * "@ H
M* "@ H * "@ H @N_P#4R?[C?^@F@#BJ .MTS_CV3_@7_H1H OT % !0 4 %
M !0 4 % !0 4 % 'S9XB']O_ !3TVSZII5H9F] Q#R#\R4%=L?=HR?=G.]9I
M=CL?C"T=[#I6B2_<U35K:.0>L<;>8Z_0X _&LZ6G-+M%ESZ+NRM\>M2O-'\*
M2#3]T:RRQ03.F04@;.[D?=#$*A/HV.].@DYZ^OS%4;4=#XU^'>FW>J^(;"'3
M,^<ES'*SIG]W&C!I'9AT7:".>N<=Z]*HU&+YNQQP3;5C[V\?^5=16.ES8*:A
MJ-M&RG^)(V,[+]#Y0!'<'%>33TO)=$_\CNET7=G _M%:I>:;X<2.S+1Q7-RD
M5PZ9&(]K,$)'W5=@ >@/W>]:X=)RUZ+0BJVHZ'S+\&-.N]0\5V+V ;;;2&6=
MUSM6$*P8.1Q\^0H4]37=6:4'?Y'-33YE8^S?'?EWVI:)I,N"D]^UPRG^(6D+
MR*".X\PH?PKS8:*4ET5OO9V2WBO/\CSG]I35+VRT>UMK<M':W5P5N'7(!"KN
M2-B.BNW.#P=N*VPZ3DV]TM#.JVE9'@/P0TV[O_%=I+8AA':%I+AUSM6+8RE6
M(X^<D *>O7M776:4&GUV.>FGS*Q]7?$[_B8ZCH&C#D7.IBXD7_IG:1M(<^V2
M*\^GHIR[*WWG7+=+S.4_:2UA[+0[?3XV*F^N1O .-T<2ER#[%MN16F'5Y-]D
M15=E8J_LRV#0:->W9X6XN]JCM^Z0 D?4M^E/$OWDNR%15DV?/7Q-OI/$_C&[
M4,7'VN.TA[[51EC 7T^;)X[\UV4UR4UZ7,)N\OF?<'C"..+1H].F.4NI;2S.
M3]X/(BL/^!*I'OFO+A\5UTNSLEM;T1'X_P!3\/Z/I8M_$GRZ=<,L.T*Y4D#<
MJ'R^0,+T/!QBBFI-WANAR:2][8\>TG6_A9IMU'>:;$%N;9A(CQ07+,AZ _*#
MCKCD8-=+C6:L]O5&2<-U^I/XM\6Z1\1-:T#2M-9Y6CU$7,HDADBVQQ(7SB15
M)W%<<#'%*$)4XSD^U@;4FDNYH_M&73/I-CI,?W]1OXDP.ZH#_P"S,M+#KWG+
MLAU=DN[/:/#?ANP\+6:V6G01VR  N(U WOM +L>I)QU-<TI.3NV:I**LC?J"
M@H * "@ H * "@ H * "@ H Y+4_^/E_^ _^@B@"_H?_ "T_X#_[-0!O4 %
M!0 4 07?^ID_W&_]!- '%4 =;IG_ ![)_P "_P#0C0!=;H:.MB9:)M'QUX\O
M!J&N7)3./-2/H1D[57\LU[--J$#\UQBE4Q+DUI<^I?#]G'9Z=;H%5"D2 X ^
M]M&?UKS*DG)W3/NL+2C&FK)?<>,_&>['G6MMR2 SG )].>/3%=^%?+N?-YM=
MOD@M#EH]+1_"$M_U<7"N&QDA<JF..V:VY_WENAYE/#I864FO>OV+GP_\0KIE
MKJ%JYP!"9DSQ@XQ@'I\V[('7BE52<DUT*P=5T:52$KZH\YL[N33YH[J+!G@<
M.&)RN0<\XZXKKNIQ46>,IRC4YXI[]CZ#^&WBS4O$T\WVQE:&-1@*A&&STR21
MTYKRJU.,-8L^UP&)J8AN-1:)'DWQ"7RM>NB2OS>6?H-OIUS7=AW:.I\WF--N
MNU%,Z7PG -"T2XU9PWGWH,$*XPP7'+KZ#YN?7%<M:7.[=#[GA?+FZBK5%]Y#
MHV@W.O,RVN!Y:@L3TR3SCG@\]ZP;LK'[=B<72PD5&3^2,_4;-M+G,$XW21,O
M0''/?/3CO1<ZJ=2%>ES0MJO0ZSQ-HTR"'4(D+Q21#?CDK2O8\K!8M*I4HR:O
M%M(QM.US48PEE:RMM=U R""J[@3^.,U3LSHQ&%H5%*M.W-9LD\43F?4&0EG*
M;$R>_&#3YK:!@K0P[C&RW9-XI<)<068'$%NF .F6R#_+BGH9X!>Y.3MS.;^X
MS([N\O85L(49U7[J*"-Q]6/(Q^53HCKE&EAY?6*C5UU/8? GAB31XS<W0Q/+
M_#_<'I_C6$I'Q&9XU8F7+3^%'HV*P/F1:!G%7?\ KI/]]O\ T(T ;^C?ZEO]
M\_\ H*T :U %+4;I;&WDN&Z1HS?D.!^)P!7'B:BI4I2?9EP7-)(^?+>WN-4G
M*P@R3.2^!]<D_K7Y9&,\15?L]7>Y[S<:<;29U;^'=<U9@+LG:O0R/P/H!7M_
M4<5B+0JW27Y'+[6G#X46O$%A#X<TY;.([IKI\R/W*I@X]ADJ!]36F,I1P-%4
ME;F>[\B:;=6=^B.>\/V-QJ+/;6WR^8 )9?[D><D?\"...X%>7@:,ZLN2"LGH
MWY'35DH:O[CTE=$LO#,+WT0/F11$;F.<DXZ#L21CCL<5]=+"4\#3E57Q<NYY
MJJ.K)0>USSKPO:'4M31GY"$S/_P'D9^K$5\K@8?6,3SRV3YCOJOV<+?(/%5X
M=1U)PG*QD1)^'!_-L_A1CI^WK\BV3L.E'EIWZFAX@U(V5O%HUN<+$B^<1_$Q
M^8K^9R?4_2M\17<(1PM+317,Z<+MU&=?H7AZVTZQ\ZY57D>,N[,,[5(S@9Z
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M2 \0L?V@/#^H745G%!J >XE2)"T5N%W2,$4DBZ)"Y()PI..Q/%,#W*D 4 %
M!0 4 <[IGBO3=9OKC3;"87$]DJF<IRB%V90F_P"ZS@J=P7(7H2&R  =%0!FZ
MMK%GH5L][J,R6UO']YW.!D] !U9B>%5068\ $T >.3_M#>&89/+1+Z9<X\Q(
M8PG7KB2=),=_N9QVSQ3 ]*\*^-M)\9PM-I,PD,>/,B8%)8\]-R-S@]F7<A/
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MB7IO@[4+?2[V*YDFO%1HVA2)D >0Q#>7FC8'<"3A6X]3Q0!Z'0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <5=_ZZ3_?;_P!"- &O
MH?\ RT_X#_[-0!O4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!@ZW_P L
M_P#@7_LM %#3/^/E/^!?^@F@#K: "@ H * "@ H * "@ H * "@ H * "@ H
M * (+O\ U,G^XW_H)H XJ@#K=,_X]D_X%_Z$: +] !0 4 % !0 4 % !0 4
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M,$_/[5HFXO0PE2C4?O10YKS7-#A-E=I9WR:AM^Q&)%$:NQ!99%50"(URX(#
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M16@T[4B2J;0ZHSA=QC9)"S1LR_-&=[JXX!!*[@#S_P :_P#)4+#_ *ZV'\Z
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MK,H* "@ H * "@ H * "@ H * "@#DM3_P"/E_\ @/\ Z"* +^A_\M/^ _\
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MIT845RP6GR_2Q#DY:LFK<@* .2U/_CY?_@/_ *"* +^A_P#+3_@/_LU &]0
M4 % !0 4 % '-^(?%NF>%D#ZC*$9@2D2@M(X''RH.V>-S;5SQNH \@N]&OOB
M%<I>Z?IZ:+$K!A?R;X[E^OS*D10,3G.Y@W0;9@.*>PCWVVB:")(V8R,B*I=N
MK$  L>O+$9/)Y-(9-0 4 ?%?PET8>(9/$&F$9-S9NB].)#*QC//'RR!3SZ4P
M/-$UN\U#2;;PDBGC4&F4'(^>5$ACCQVP[2L<C@OW[ 'K7Q.TZ/2/%V@V$/\
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M;#_2(U"JS&:$LN%DE *,2A^<\@YP>*8'H7[0J++X@T]&Y5K5 1Z@W$@/3VH
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MZOI % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <5=_ZZ3_?;_T(T :^A_\
M+3_@/_LU &]0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !2 *8!0
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MQ-86<?GKTEES+(/HSYQ^&*SE5G+1O3[BU!1V/1*Q+"@ H * "@ H * "@ H
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M,NV2XDP&*@YV(HX1,@$C+%B 68X4! >BT % !0 4 % !0 4 % !0 4 % !0
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M =;IG_'LG_ O_0C0!?H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#DM3_
M ./E_P#@/_H(H OZ'_RT_P" _P#LU &]0 4 % !0!!=_ZF3_ '&_]!- '%4
M=;IG_'LG_ O_ $(T 7Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#BKO_72?[[?^A&@#?T;_ %+?[Y_]!6@#6H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * .2U/_ (^7_P" _P#H(H OZ'_RT_X#_P"S4 ;U
M !0 4 % !0 4 % !0 4 % !0!%+'O''4=* *% !0 4 % !0 4 % !0 4 % %
MZ"3<,'J* )B,\&@#.D3RSC\J &4 % !0 4 % !0 4 % '*:OX(T;7KZ+5+^W
M\Z[M@BQ2>;,FT1NTB#8DBH=KLS?,ISG!R !0!V$4GEGV/6@"_0!!/'N&X=10
M!2H * "@ H * "@ H * "@ H OPR;QSU% $C*&&#0!FLI0X- "4 % !0 4 %
M !0 4 % !0!/!)M.T]#_ #H NT % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M)3=Y-MGI1BHZ(UL 5F6+0 4 % !0 4 % !0 4 % !0 4 8.M_P#+/_@7_LM
M%#3/^/E/^!?^@F@#K: "@ H * "@ H * "@ H * "@ H * "@ H * (+O_4R
M?[C?^@F@#BJ +<5_/"H1&PHZ#"GJ<]QGK0!)_:=S_?\ _'5_PH /[3N?[_\
MXZO^% !_:=S_ '__ !U?\* #^T[G^_\ ^.K_ (4 ']IW/]__ ,=7_"@ _M.Y
M_O\ _CJ_X4 ']IW/]_\ \=7_  H /[3N?[__ (ZO^% !_:=S_?\ _'5_PH /
M[3N?[_\ XZO^% !_:=S_ '__ !U?\* #^T[G^_\ ^.K_ (4 ']IW/]__ ,=7
M_"@ _M.Y_O\ _CJ_X4 ']IW/]_\ \=7_  H /[3N?[__ (ZO^% !_:=S_?\
M_'5_PH /[3N?[_\ XZO^% !_:=S_ '__ !U?\* #^T[G^_\ ^.K_ (4 ']IW
M/]__ ,=7_"@ _M.Y_O\ _CJ_X4 ']IW/]_\ \=7_  H /[3N?[__ (ZO^% !
M_:=S_?\ _'5_PH /[3N?[_\ XZO^% !_:=S_ '__ !U?\* #^T[G^_\ ^.K_
M (4 ']IW/]__ ,=7_"@ _M.Y_O\ _CJ_X4 ']IW/]_\ \=7_  H /[3N?[__
M (ZO^% !_:=S_?\ _'5_PH /[3N?[_\ XZO^% !_:=S_ '__ !U?\* #^T[G
M^_\ ^.K_ (4 ']IW/]__ ,=7_"@ _M.Y_O\ _CJ_X4 ']IW/]_\ \=7_  H
M/[3N?[__ (ZO^% !_:=S_?\ _'5_PH /[3N?[_\ XZO^% %.65IF+N<L>IX'
M08[8'2@#;T/_ ):?\!_]FH WJ "@ H * (+O_4R?[C?^@F@#BJ +<5_/"H1&
MPHZ#"GJ<]QGK0!)_:=S_ '__ !U?\* #^T[G^_\ ^.K_ (4 ']IW/]__ ,=7
M_"@ _M.Y_O\ _CJ_X4 ']IW/]_\ \=7_  H /[3N?[__ (ZO^% !_:=S_?\
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M3N?[_P#XZO\ A0 ?VG<_W_\ QU?\* #^T[G^_P#^.K_A0 ?VG<_W_P#QU?\
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MQX&1RJ#+'()V@YH [:@ H * "@ H <C%#D4 :*D,,CI0!%-'O&1U% %&@ H
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M: #^QH?[S_FO_P 30!A7D*V\K1KDA<=>O(![8]: -70_^6G_  '_ -FH WJ
M"@ H * (+O\ U,G^XW_H)H XJ@#<L],BN(5D8L"V>A&."1W!]* +7]C0_P!Y
M_P U_P#B: #^QH?[S_FO_P 30 ?V-#_>?\U_^)H /[&A_O/^:_\ Q- !_8T/
M]Y_S7_XF@ _L:'^\_P":_P#Q- !_8T/]Y_S7_P")H /[&A_O/^:__$T ']C0
M_P!Y_P U_P#B: #^QH?[S_FO_P 30 ?V-#_>?\U_^)H /[&A_O/^:_\ Q- !
M_8T/]Y_S7_XF@ _L:'^\_P":_P#Q- !_8T/]Y_S7_P")H /[&A_O/^:__$T
M']C0_P!Y_P U_P#B: #^QH?[S_FO_P 30 ?V-#_>?\U_^)H /[&A_O/^:_\
MQ- '.SH(Y&0=%8@9]B10!IZ?I\=W&7<L"&(X(] >X/K0!?\ [&A_O/\ FO\
M\30 ?V-#_>?\U_\ B: #^QH?[S_FO_Q- !_8T/\ >?\ -?\ XF@ _L:'^\_Y
MK_\ $T ']C0_WG_-?_B: #^QH?[S_FO_ ,30 ?V-#_>?\U_^)H /[&A_O/\
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M-2S'\%!- 'R_IWCOQQX_NYG\.".UM8""5*0%0#]Q7EG1RTC $D1[1U.%&#3
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M?_+3_@/_ +-0!O4 % !0 4 % !0 4 % !0 UT$BE& *L""#R"#P01Z&FG;5
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MWU_QJU&3V3^YF;G!;R2^:!=0MG;8LT1;T#J3^0.:KV<UO&7W/_(GVM/^>/\
MX$O\RPLJ-]U@?H14.+6Z:^12G![2C]Z'YJ2[]@H&% !0 4 % !0 4 % !0 4
M % !0 4 <EJ?_'R__ ?_ $$4 7]#_P"6G_ ?_9J -Z@ H * "@ H * "@ H
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M4%^A(#?+D \]$!YY\2O%VKW/B6+PO87G]E6S&!&G4[&+3 ,7:0%7 4,%5%9
MS9W-R-K \U^*?A>R\,/;11ZA-J=[*)&G,LBOY:+L"< LR%V+\,[9V'ICD ]0
M^-LF[PKI /420_\ I*U 'J(4+\.L  #_ (1TGCCDZ=DG\2<GU/-(#S3]G7_D
M'W__ %\1_P#HLTP/8O'%G+?Z!J%O -TLEI,%7NQ"$A1[G&![D9(ZT@/#?V?]
M>L;.TO-/N)HX)S,LZB1E3>A0(2I8@'85^8=@P/3-,#C_ !)K5IKOQ$M+BP99
M84O]/B\Q<%9&CEB#,I'W@#\H;D,%R"5(H D^+-K+;^-4D>=M/6X%JT=V-P\D
M "(R@J58>6Z,3M8$ 9H L>*O#,EC:*-8\5-=6T[*!%OGN@V/F#^4+A\JI ._
M:0"5YR10!TOB#38M)^&@@M[C[; 94DBF\N2$,DEUOXCEPZC)/4#=]X<'- '?
M?!;4K67PS9V231-<Q"Y+PAU,J@W4S M'G<!AU.<8^8<\T@/7: /CGX5:]9Z'
MXMO/MSI ET+B%)9"%57^T+(%+' 4.$(Y(!8*.I%,#8^/NMV>KSV&GV#I=7$/
MG,_E,)-OG>4L<>5S\SE"2N<@!"0=PH R?C1IEQIE_HSSLT*II=K;^<N24EMY
M',K+M.2R"1&&ULGC!Z&@#2\1>%[BTTTW6H^+FNK.8*OEB6>X\Y7(P!$+IC(!
M]YAM. I)Z4 ;^EZ5;Z5\.]2%G=?VA!.TLJ2B&6 #B"-D"2_,=KQMEA\I)(&2
M": -GX!ZE:KH;61FB%R;N9A"742E?+B.X1D[BN 3D C@\\' !Q/BBYBL_B;!
M-<.L4226NYW8*J@P*,EC@ 9(Y)Q0!9_:$3[6NF:A;LLUJPN(Q)&P9-Q,;#YE
MRIW!6Q@G.QLXQR 9\_A^[&D_VC-XM=K*2')C\Z=RRLN##Y/VHEGYV-%MR#D,
M ,T =!X'T>TTWPCKTUA>?VA#/:7 +"": 1R1VDI9<2_>)61"2F0. 30!H_L[
M1J-+O9 /F:Z52?4+$I _ LWYT ?0U(#Y6_:*LY1<V%YM_<F.6+=Z.&5\'TRK
M97UVMZ4P/8]3^)^B:;I"ZQ'/%.'5#';QR)YS,VW,>S.5://S[@-N#GME >=?
M$_7?^$_\$1:O8P310V]^DCB4+N\M$F@,B[&<%/-E5<G!R&R !DL#L_A9XST1
M/"UM%/=P6[V,31SQRR)&Z%68[MK$%E<$,K*#DG;]\$  \A^%'_$Z\;7VJVBG
M[)NO)MQ& J7$Q\I2.,,P;(7KA6]#0!;^'8!^(NJ9[2ZECV_TK'\C0!7^//\
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M !0 4 % !0 4 % !0 4 % $%W_J9/]QO_030!Q5 '6Z9_P >R?\  O\ T(T
M7Z "@ H * "@ H * "@ H * "@!&8*,DX ZD\"@"'[5#_P ]$_[Z7_&@ ^U0
M_P#/1/\ OI?\: #[5#_ST3_OI?\ &@"575QE2"/4'(_2@!U !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!R6I_\?+_\!_\
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M !0 4 % !0 4 % !0!R6I_\ 'R__  '_ -!% %_0_P#EI_P'_P!FH WJ "@
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M  GX6M?!NG)I5BTLD,3.P:9D9\R,7.2B1KC)XPHXZYZT =)0 4 % !0 4 %
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MN.R]POJW?H/6OF\PS.-!>RHN\W^!]'EV5RQ#5:LK170^B[.SBL(E@MU6.-
MJJ, "OSZ<Y5).4VVWU9^D4Z<:45""22[%NLS4* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#!UO_EG_ ,"_]EH H:9_Q\I_P+_T$T =;0 4 % !0 4
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M H * "@ H * "@ H Y+4_P#CY?\ X#_Z"* +^A_\M/\ @/\ [-0!O4 % !0
M4 % !0 4 % !0 4 % !0 4 %  1D8- &=(GEG'Y4 5YH8[A&BF59(W!5D<!E
M8'J&4Y!![@C!H SM/T'3=(8O86EM:,W#&""*(GZE%4G\: -:@ H * "@ H *
M "@":&38<'H: +U %:XC_B'XT <W?^'=+U5_,OK.UNGX^::"*5N.!RZ,>!P*
M +MEI]MIL?DV<,5M&/X(HUC7_OE !^E %R@ H * "@ H * "@ !QR* -&-]X
MSW[T .90PP>] &<ZE#@T -H * "@ H * "@ H * "@">"38<'H: +M %.>/:
M=PZ'K0!7H * "@ H * "@ H * "@!58H<CM0!HHP<9% #J "@ H * "@ H *
M "@ H * "@ H * "@ H XJ[_ -=)_OM_Z$: -?0_^6G_  '_ -FH WJ "@ H
M * "@ H * "@ H * "@ H * "@ H * &.=HI>2$WRJY\I^/-?/B'56$9W6UI
MF*+T)&/,?_@3< _W0/6OU7*,(L-1]I)>_+7_ (!^5YQC/;U'3B_=B8-N HRW
M  R37MSE9'P\DY.T>I@7EV;V3/\  O"#^9_'].E>??6[/IL-15"%^K'6X[GM
M3;Y=>@*]VSU[P/X(;62+Z]799J<HIX,Q'0^T?_H7TZ_,9AF*I_NJ+]YZ7['U
M.7Y;[5^WKK3HCZ&AA2!52,!%4   8  Z"OAY-R?-+5GW<(J"Y8Z);(FJ2PI@
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!@ZW_ ,L_^!?^RT 4-,_X
M^4_X%_Z": .MH * "@ H * "@ H * "@ H * "@ H * "@ H @N_]3)_N-_Z
M": .*H ZW3/^/9/^!?\ H1H OT % !0 4 % !0 4 % !0 4 % !0!XM\5_C)
MI_PYA-M#MN]7D7,=N#\L0(XDG(Y5>ZIP[]L+\P /SSUK6]5\<:D;N]>2]OKI
MPJJ 6.2<+'%&OW5&<*BC'XYH ^P/A9\#;3P=;'Q/XO59+FWC,Z6Q&^.V5!NW
MR 9$DP R%&40]-S8( /%/&?QC\3_ ! U(V.D/<6MK(YCMK.TW"609P/-,?SR
M.P&YESL3H!@$D XWQ%X-\7^%[==1UB"[MH'8*)7EW#<>@;9(Q4GMN YXZT >
M@_ _XF:WI_B&STB:YENK&^E6!H9G:14+\*\>XDH5;!.W 8#!H F^+OQ;UT>*
M+RWT;4+FTL[1A;HD$K(A:(8D8JIQN\PLI/<** ,:P^.'BR'1Y+"TGN9[AI&D
MGOI"T\D<6T!8XL@K"O#,SGYB2-I7!R <!%\1_$\,XN5U2^\T'.XW$AR?<%B"
M/4$8/3% 'KWC/Q=\1+^UB\2*U]INF?9+=6DBF$4,C$!3-Y:2#F:1N,+G&  !
MB@#YXMK>XU:Y6"%6GN;F0*JCEI)'; '/5F8]^YH ^HO L/C7P+,-1\4/J-KH
M6CV\DGV<SYCE95*P6R1H[#YY648*[0 22!0!YMK'Q%\9_%'43:V;W)\TDQV-
MD76-$']X+C=M'WI93^(&  #EO$GAKQ3X+,<FLQW5EYY/ENTNX,1R1NCD8!AU
MP2#WQ0![W^SK\2]8N=8_L#4KB2[LY8)9$,[%V@:%=^5=LD(5# J3MR01B@!G
MQ5_:+O;JYDTKPG)]FM8B4>]4 RS,#@F$G_5QY^ZX^=OO!E4X(!\]W?\ PDU]
M;G6;G^T9;8GF[?[0T62<9\T_+UXSNQGCK0!ZI\%OBKJVD:U;:1?7,MSIM_(M
MN\<KE_*,AVK)&6R4VL1N X9<Y&<$ 'V'#X!E2Y!9T\H!8S)\Q=K= H6-8R-L
M<NU C7 <EE+_ "#=P >HT % !0 4 % !0 4 % !0 4 % '):G_Q\O_P'_P!!
M% %_0_\ EI_P'_V:@#>H * "@ H @N_]3)_N-_Z": .*H ZW3/\ CV3_ (%_
MZ$: +] !0!\T>(O^2FV7^Y%_Z*EKVJ>F%DO7\SNCI29@^.K63X<>+H-=M5(M
M;M_.8+T.3MN8O3)!\P#H"Z^E:T7]9HNF_B7](J'[R+3W$\&7^_7O$%[9-NW6
MMY+$R]\N64@_D13KQM"G&7\PYQLDF8WPCGU^)[QO#T5K-(?+\XW#%2!E]NW'
M."=V[WQ6N)]G:*J;=-_T'4Y;)2._\+> O$=IXJ7Q#J$=O"DTDKSB&0D?O%.0
MJXR?FP<$^]<56M3=+V4'T5MS&4UR<J9E?'FVL$O;6:UR-6;EEC&28TY1VQR'
M4@[3UVCT K7!.3BU+X"J-[6?PFC\!);&Y:\GF8R:N[9D:0Y8PGNA/)RWW^^?
M:HQJ:LE\'ZA7OI_*<Y\9?^1LLO\ <@_]&BM<+_!E\RJ7P,F^/_\ R$=/_P"N
M#?\ HQ:>"^&=N['1ZGHWQ7_Y$H?[MG_-*X<-I7?J_P SGI_&_5_F<+X=_P"2
M9WW^]<?^TZZZG^]QMY&TOXJ.D^ $:OHUUN /^DGJ!_<'%8XYM5$K]"*[M)6.
M!^%<:KXVN4  4->@#'  =L #H,=JZ\4W["/R-*CM!?(?\9X$A\56K1J%+PP,
MQ QDB9P"<=\ "IPVM"5_,*?P,^H;[P]8ZC*+BXCW/@*V&90Z@A@K@$!U!'1L
MCMTKPU-Q5EL<-VM$;0&!@5F2+0 4 <5=_P"ND_WV_P#0C0!OZ-_J6_WS_P"@
MK0!K4 4[F*64%48*I&#PP;ZAE92/P_.J32,Y*YAW&A3R#$=Q)&<YSYEP?PYG
MK:,XK='-*E)[,S)O"=Y.I5KZ8*>P,A_/,QSSS6\:\([01RRPLY;S:7J8D_PS
M%T,7%[<-[C@_3YV? ]L5TQQO+\-.)RSR^]VZCMZDEM\*M,BQOFNI,?\ 34*/
M_'%7^=$L?4V2BOD$,NIIWYF=!:> ]%LSE;978<YE+2G/K\[-S7%+$U)/5V]#
MT(X.G"W7U.I@MHK9=D*+&H[* !^0Q7-*3>K=SKC",=(Q2)\CI4VZFG,KV_ 6
M@KT"D'J)GM3)NKV%Z4DK:#N IVL).^PM!0G2EZ &:-@.>U7Q##I3^6X9B!EB
M. O4C)]2 3[ 9)%=4*3FKHX:N(5)V9L65VE[$)8\@'((/!4C@J1Z@_XCBL&N
M5V9UPDIKF1:J2SDM3_X^7_X#_P"@B@"_H?\ RT_X#_[-0!O4 % !0 4 % !0
M 4 % !0 4 % 'C7@CXE3^,_$=[IR1+;V-C"^P'YI7D29(R[MT P6VHO S\S,
M<$,#G?BOXZUKPUX@T_3],N/(MKF.)I4\J!]Q:X9&^:2-V7* #Y6'J.>: /H>
MD 4 1RQ[Q[CI0!G]* /*O!/_  F/]J77_"2?\@_:_P!E_P"//[WFC9_Q[_O?
M]5G_ %G'K\V* /5: "@ H * "@ H * "@"[!)N&T]10!/0!GRQ^6?8]* (Z
M"@#Q[0_B-/K_ (MN- BB6&TL5N49CS)++!(L9;/1$!W;5')!!8_PJ >PT %
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MDNKA<32$X^8H-[#.<*@ Z4 ?"/AK1)?$>IVNE6XS)=SQQ#VW, 2?8#))[ 4
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MDM3_ ./E_P#@/_H(H OZ'_RT_P" _P#LU &]0 4 % !0!!=_ZF3_ '&_]!-
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M#T ]!7'*7,[GH4X>SCRFA4&QR6I_\?+_ / ?_010!?T/_EI_P'_V:@#>H *
M"@ H * "@ H * "@ H YKQAX:C\7Z5/H\TC0)<^7F1 "R^7+'*, \<F, ^QH
M ^*_A]\.K?QEK%YI4T\D"622,KHJLS;)EB (/ R#GCO3 [O]H+S1XBT[[/\
MZ[[-'Y??Y_M,FWKQ][% %3XC_#&[\(Z<GB234I[O41-&L[MN4[I-Q+12;O,&
MU^!G&5);Y"-I /3A\2+S3?A[;^()")=0F4VR.XR#*LTL/FN.A(2)I#GAG&",
M$B@#Q[0?"&G>+[(ZSXA\106^HW!=HXYKF R1%6(5IO,F#C<5R(U";$VX/\(
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M0Y':@#25@PR* (Y8]XXZCI0!0H * "@ H * "@ H * "@ H N02;AM/4?RH
ML4 % !0 4 % !0 4 % !0 4 % !0 4 % '%7?^ND_P!]O_0C0!KZ'_RT_P"
M_P#LU &]0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #6X% F[:O8^3?'VOG7
M]7?RSFWM,PQ8Z$C_ %CCZOP/917ZOD^%6&HJI)>]+7Y/H?E^<8KVU7DC\,=#
ME3)]GC+]^WN?\]:]NK/E7J?(QA[2270Q3\Q)/4\_XUY#UU9]#&T%RH]&^'_@
MAO$\_P!IN05L(6^8]/-<?\LU_P!G^^>V<=<U\YC\:J,72IOWG^!]%@,$ZS]I
M57NK4^JK>W2V18X@$1 %55&  .@ ]NU?$RDY/F>[W/N8Q4%RK;H6*DL* "@
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M1BJN$51N=G!"\G<1D  ^_P")]X]QUI /90PP: ,YT*'!H ;0 4 % !0 4 %
M!0 4 % $T,FPX/0T 7J *D\>/F'XT 5J "@ H * "@ H * "@ H 525.1VH
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M.T'=@;V.T$X)QUP,]* .=UGX#^%->O9M2OH)Y;FZ<R2/]IG&6/H ^  ,  <
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MGC(*/=/YH4CD$1X6+(/()0D'I0![0!C@4 % !0 4 % !0 4 % !0 4 % !0
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MT&!TK-NY+=RS2$% !0!Q5W_KI/\ ?;_T(T ;^C?ZEO\ ?/\ Z"M &M0 4 %
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MZ$%[EV_,U@L1*7[RR7D)+X5O=>U+[9K;1_8[<YM[6)F92?[\I94RW3@ CMD
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MO<QI-#(,/'(JNC#T96!5A[$&@"'3],M-)C\BP@AM8MQ;RX(TB3<< MM0*,D
M9.,G ]* *^GZ%IVDNTMA:VUK)(,.T,,<3.,YPS(JEAGGDGGF@!/^$?TS[5_:
M/V2V^V9W?:/(B\[.-N?-V[\[?ESNSCCI0!:OM.M=3C\F]ABN8_[DT:2+Z?=<
M$=/:@"#3M$T_2,_V?:V]INX/D0QQ9'7!V*N>?6@#7C?RSG\Z -$'/(H BFCW
MCCJ.E %"@ H * "@ H * "@ H * "@"[!)N&T]10!.1D8- &=(GEG'Y4 ,H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M<EJ?_'R__ ?_ $$4 7]#_P"6G_ ?_9J -Z@ H * "@""[_U,G^XW_H)H XJ@
M#K=,_P"/9/\ @7_H1H OT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % '%7?\ KI/]]O\ T(T ;^C?ZEO]\_\ H*T :U !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!R6I_\?+_ / ?_010!?T/_EI_P'_V:@#>
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ (SQ0!G21^6<=NU #*
M"@ H * "@ H * "@ H EADV'GH: +] %>>/(W#J.M %.@ H * "@ H * "@
MH * #I0!H12;Q[CK0 \@$8- &<Z&,XH ;0 4 % !0 4 % !0 4 % $L,FPX/
M0T 7Z *EQ'CYA^- %:@ H * "@ H * "@ H *  $J<CM0!I(X<9% #J "@ H
M * "@ H * "@ H * "@#BKO_ %TG^^W_ *$: -?0_P#EI_P'_P!FH WJ "@
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M_030!Q5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;VA_\M/\
M@/\ [-0!O4 % !0 4 % !0 4 % !0 4 % 'E'CCXOZ1X)E-DP>]O0 6@A( C
MR,CS9#PA(YV@.X!!*@$$@'G-G^TK:O*%N]-EABSR\5RLK@>NQH803[>8/K3
M^A]#URS\1V<>HZ=()K>895AD$$'#*RGE64Y#*1D'VP:0'SO??M(?8KB6V_LK
M=Y,CQ[OMN,[&*YQ]D.,XSC)QZFF 6/[2'VVXBMO[*V>=(D>[[;G&]@N<?9!G
M&<XR,^HH ]*^)GQ,_P"%=?9/]$^V_;?/_P"6_D[/)\G_ *8R[MWF_P"SC;WS
MP@/,F_:/EC >31G5./F-X0.?K9@?3GFF!ZYX!^)>F^/D=;57M[J !I;>3!(4
MG =&7ATS@$X5E) 90"I9 >;^+?CR/#NJ7.D_V;Y_V24Q^;]KV;L '.S[,^WK
MTW'ZTP,.T_:,MWD NM-DBC[M'<K*P^B-#"#_ -]B@#W[0]=L_$=G'J&G2"6"
M4<'H5(^\CJ>5=3P0?J,@@E :] !0 4 % !0!CZ[KUGX;LWU#49!#!%U."26/
MW551RS,> !]3@ D $/AG7H_$VG0ZI C11W(<HKXW!5D=!NQP"=N2 3C.,G&2
M <1X!^)G_"<7ES9?9/LGV-=V_P _S=_SE,;?)CV^O5O3WH ]A@DR-IZCI]*
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M 'RO^% !]DA_YYI_WRO^% !]DA_YYI_WRO\ A0 ?9(?^>:?]\K_A0 ?9(?\
MGFG_ 'RO^% !]DA_YYI_WRO^% !]DA_YYI_WRO\ A0 ?9(?^>:?]\K_A0 ?9
M(?\ GFG_ 'RO^% !]DA_YYI_WRO^% !]DA_YYI_WRO\ A0 ?9(?^>:?]\K_A
M0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^% !]DA_YYI_WRO\ A0 ?9(?^>:?]
M\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^% !]DA_YYI_WRO\ A0 ?9(?^
M>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^% !]DA_YYI_WRO\ A0 ?
M9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^% !]DA_YYI_WRO\
MA0 ?9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^% '+ZBBI<,J@
M*!MX P/NCL* -'0_^6G_  '_ -FH WJ "@ H * (+O\ U,G^XW_H)H XJ@#I
M].MXGMU9D5B=W)4$_>/<B@"]]DA_YYI_WRO^% !]DA_YYI_WRO\ A0 ?9(?^
M>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^% !]DA_YYI_WRO\ A0 ?
M9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^% !]DA_YYI_WRO\
MA0 ?9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^% !]DA_YYI_W
MRO\ A0 ?9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^% !]DA_Y
MYI_WRO\ A0 ?9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^% !]
MDA_YYI_WRO\ A0 ?9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_WRO^
M% !]DA_YYI_WRO\ A0 ?9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_YYI_
MWRO^% !]DA_YYI_WRO\ A0 ?9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO^% !]DA_
MYYI_WRO^% !]DA_YYI_WRO\ A0 ?9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO^% !
M]DA_YYI_WRO^% !]DA_YYI_WRO\ A0 ?9(?^>:?]\K_A0 ?9(?\ GFG_ 'RO
M^% !]DA_YYI_WRO^% !]DA_YYI_WRO\ A0!R^HHJ7#*H"@;> ,#[H["@#1T/
M_EI_P'_V:@#>H * "@ H * "@#@_%ESXCTZXCO-%CBO+1(\36K8$A8,3O0\,
M3M( "LW(_P!6V: %T'XA:;K,GV68M87H.UK:Y'EON]%8X5O8<.?[@H [N@ H
M SM8O3IMC<WBC)MH)90/4QQLX'XXH ^2?@5X?@\6:M?:SJRK=R6OEN!* P:>
MY:5C*RD%6*^4V,\!F# 94$,#Z#\;KX7UBUET36[NPMI=F$$L]O'-;L5S'(BN
MZLA'# <*Z_*<J2"@*GPRT/0O#=M/8Z#J*ZF'=990+BWF\MB-@(6 #RPX4 [B
MVXKP>,4 ?,'@/QK9>!/$U_J&H)/+%*ES ! J,^]KJ*0$B22(;<1,"0Q.2.,9
M(8'T)HGQWT+7;Z#3;>"_26[E2%&DC@"!G. 6*W+,%R><*3[&@#@?VF?^83_V
M_?\ MG0!WEE\9O"-IID4$MV9GCMHXWA%M<$L1&JLGSPK$>X^9PI'?% 'DWP'
MTZ:_\2W6KVL1@T^*.<=/D7SG4Q0 ]"57YB!T" GJN0"?1?\ DK3_ /7S>?\
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M&+$!B%8[S@@'J-UX\;5_!UQXBTH_9KB.%N"%D,,R,H9?G4HX&<J2F&5E) /
M0'C>B^/_ ![XLMA#HH\Z2U!-Q<B*U!<LS%%Q*J0C"  (B&1B"Q)R &!Z/XR^
M)&H>#--L;)T2YU^]@1Y 4PD1;@GRT*[F,A,<:C"DHS-T"L <EJ7B'XC>$;==
M9U7R9[,,GFPE+<^6'( $GD(CKDD)N#N Q )R0" >_P#A7Q%!XKTR#5;8%5G4
M[D)R4=25D0_[K X.!N7#8 -(#H: "@ H * +=O)GY3VZ4 6: "@ H * "@ H
M * "@ H * .*N_\ 72?[[?\ H1H U]#_ .6G_ ?_ &:@#>H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MS2R+NB*J&+ L&9L*%QT8'52,'O\ PRRG(:&Y(([@Z>,&@#5\<_>TG_L,VO\
MZ+GI )XZ07?]G6 SON=2MS@=?+AW2RL.PVJHY.>HXQG !WE !0 4 % &#K?_
M "S_ .!?^RT 4-,_X^4_X%_Z": .MH * "@ H * "@ H * "@ H * "@ H *
M "@ H @N_P#4R?[C?^@F@#BJ .MTS_CV3_@7_H1H OT % !0 4 % !0 4 %
M!0 4 % !0 4 ?,GCSQUXC\+:Q-80W:M#Q)%^X@R$D&X*<QDDIRN226QN/)K[
M+!X/#8FC&K*F^;5/WI;KKOUW/B\9C,3A:TJ4:BY=''W8Z)]-NFQEZ?XW\<ZK
M;27MD6GMX20[I;P'!50Q&/+W'"D$X!X-;3PF I25.I:,GLG.773O;<QAB\?5
MBZE.\HQW:A#2VO:^W8U/"GQIO5NDM]<$<MO(P4S(H1X\G&Y@N$9!_$ JL!D@
MG&TXXG*H<KEAKJ25^5NZ?DKZI]M6C;#9M44E#$V<6[<R5FO-I:-=]$SZ;!!&
M1R#7QI]H% !0 4 % !0 4 % 'R_\<KN__M""U;>MCY(:,#(1Y2S;R<<%U 4
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M0H * "@ H * "@ H * "@ H * "@#DM3_P"/E_\ @/\ Z"* +^A_\M/^ _\
MLU &]0 4 % !0!!=_P"ID_W&_P#030!Q5 '6Z9_Q[)_P+_T(T 7Z "@ H *
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M'_V:@#>H * "@ H * "@"N;2$S"Y,:&=5V"3:OF!<D[0^-P7))QG&2>* +%
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M% !0 4 8&DZ3)I-S<^45-G=/]H1.0\4[_P"N4#;M,<A D!W JY<;2"" #?H
M* "@ H * "@#E_%^B3Z_8BTMF1'$\$N9"P7;'(KL,JK') XXQGJ1UH ZB@ H
M * "@ H * "@ H * .?72))M5.IW15E@B\FT12QV!\&>5\@ 22$",!<@1H.<
MNP !T% !0 4 % &#K?\ RS_X%_[+0!0TS_CY3_@7_H)H ZV@ H * "@ H *
M"@ H * "@ H * "@ H * "@""[_U,G^XW_H)H XJ@#K=,_X]D_X%_P"A&@"_
M0 4 % !0 4 % !0 4 % !0 4 % !0!\5_%6^%]XDNROW82D(_P"V:*&_\?W5
M^AY=#V>&I^=Y?>W;\+'YSF,^?%5+=+1^Y*_XW/HGX2V']G^&[=FX-PTD[?\
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MX#_[-0!O4 % !0 4 07?^ID_W&_]!- '%4 =;IG_ ![)_P "_P#0C0!?H *
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MD\\T :U !0 4 % !0 4 3P1[CD]!0!=H K7$F/E'XT 5* "@ H * "@ H *
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M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H P=;_P"6?_ O_9:
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M_010!?T/_EI_P'_V:@#>H * "@ H @N_]3)_N-_Z": .*H ZW3/^/9/^!?\
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M'XC0:/KEGX<@B,MU=RPK*[?+'%'*P&1W=R,X PJ\$DGY: /2J "@ H * "@
MH * +L$>P9/4T 3T % !0 4 % !0 4 % !0 4 % '%7?^ND_WV_]"- &OH?_
M "T_X#_[-0!O4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!@ZW_RS_P"!
M?^RT 4-,_P"/E/\ @7_H)H ZV@ H * "@ H * "@ H * "@ H * "@ H * "
M@""[_P!3)_N-_P"@F@#BJ .MTS_CV3_@7_H1H OT % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0!R6I_\ 'R__  '_ -!% %_0_P#EI_P'_P!FH WJ "@
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M%7?^ND_WV_\ 0C0!KZ'_ ,M/^ _^S4 ;U !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 8.M_\ +/\ X%_[+0!0TS_CY3_@7_H)H ZV@ H * "@ H * "@
MH * "@ H * "@ H * "@""[_ -3)_N-_Z": .*H ZW3/^/9/^!?^A&@"_0 4
M % !0 4 % !0 4 % !0 4 % '.^*?#D?BJP;39Y'ACD9&9H]NX[#N ^8$8R
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M_010!?T/_EI_P'_V:@#>H * "@ H @N_]3)_N-_Z": .*H ZW3/^/9/^!?\
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M H * "@ H * "@#DM3_X^7_X#_Z"* +^A_\ +3_@/_LU &]0 4 % !0 4 %
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MQ#XLOO$,:&.UW7,I)Z![J4LD6>A8*68X)P%Y^\,@$WP[_P"2BZK_ -==2_\
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MMI5W$#[Q4D'.W( +/Q9MI?!?BBR\56BY6<JS@< R0@)*I(Z>; RCU)WGDYH
MV_@)HLDRWOB2[^::[D,,;GJ1N\R=_H\A0=>J-0!C>+O^2FZ?_P!=;'_T*@#=
M_:6_X]M,_P"NES_Z##0!T'Q7DW>!$4=!'8_GF*@#FO"O_),;K_KA??\ H;T
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M5DG?J? 8;"5G6IJI3FH\R;;A)*R=W=M6Z'VG7YX?HP4 % !0 4 % !0 4 %
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M&(?#$[L999@TL>WR6" $%6#*9/[[#'7CO3YA<H\>&YED-T)5^U2;A*^SY2C
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MVEE SD9599'53SP5 ([8P* '0>#=)\):=?C2(#;"XMY/,'G3R!BD<FTXED<
MC<>5 )[YP, 'A?P/\.:=XEL-1M=4@2YB66W90V05;9,,HZE70XX)5AD=:8'T
M+X?\$:+X69GTJUCMY'&"^7DDP>JB25G<*>ZA@.G%( U?P1HVO7T6J7]OYUW;
M!%BD\V9-HC=I$&Q)%0[79F^93G.#D "@#<U+2[36(&M+^*.X@?&4D4,N1T.#
MT([$8([&@#BK3X4>%K&87$6GQEU.X>8\TJ9SG_5RR/'CVVX]J .[N+."[A:V
MGC26!UVM&ZAD*_W2I!!'MC% '!I\(?"KS>:-/3?G./-GV?\ ?OS?+Q[;<>U
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M H * "@ H * "@#BKO\ UTG^^W_H1H U]#_Y:?\  ?\ V:@#>H * "@ H *
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M?\>R?\"_]"- %^@ H * "@ H * "@ H * "@ H * "@ H * "@ H ,"@ Q0
M8H ,4 &!0 4 &* #% !B@ Q0 8H ,4 &* # H * "@ H * "@ H * "@ H *
M "@#DM3_ ./E_P#@/_H(H OZ'_RT_P" _P#LU &]0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!%-)L&!U- %"@ H * "@ H * "@ H * "@"]#'L&3U-
M$Q..30!G2/O.?RH 90 4 % !0 4 % !0 4 % $D4>\^PZT :% $$\FT;1U-
M%*@ H * "@ H * "@ H * "@"_#'L'/4T 2,P09/:@#-9BYR: $H * "@ H
M* "@ H * "@">"/<<GH* +M !0 4 % !0 4 % !0 4 % !0 4 % !0!Q5W_K
MI/\ ?;_T(T :^A_\M/\ @/\ [-0!O4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!@ZW_RS_X%_P"RT 4-,_X^4_X%_P"@F@#K: "@ H * "@ H * "@ H
M * "@ H * "@ H * (+O_4R?[C?^@F@#BJ -RSU.*WA6-@Q*YZ 8Y)/<CUH
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M #^V8?[K_DO_ ,50 ?VS#_=?\E_^*H /[9A_NO\ DO\ \50 ?VS#_=?\E_\
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MF'^Z_P"2_P#Q5 &%>3+<2M(N0&QUZ\ #MGTH U=#_P"6G_ ?_9J -Z@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H WM#_P"6G_ ?_9J -Z@ H * "@""[_U,G^XW_H)H XJ@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * -[0_^6G_ ?_9J -Z@ H * "@
MH * "@ H * "@ H \A\1?&[PYX=N7LF:>\EB8K)]EC1U1AP5+R21(Q!X.PL
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M2!S0!SO@SQO9>.;:2[T])XD@D\IA.J*Q;:&R!')(,88=2#GM0!V- !0 4 %
M!0!QGC+XA:=\/1;MJ<=S*;WS?+^SI&VWR?+W;_,EBQGS5VXW=#G'&0#T.&43
MQK*N0KJ&&>N&&1GKSSZT 5)I-YP.@H P/$6NP>&=/FU2Z61X;90SK$%+D,ZH
M-H9D4\L.K#C/TH I^$_%5KXQL!J5BDL<+.\86945\I@'A'D7'/'S9]A0!TU
M!0 4 % !0 4 % #D3><"@#1 "C [4 0SR;!@=30!2H * "@ H * "@ H * "
M@ H O0Q[!D]30!-0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '%7?^ND_P!]
MO_0C0!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 7],_P"/E/\
M@7_H)H ZV@ H * "@ H * "@ H * "@ H * "@ H * "@""[_P!3)_N-_P"@
MF@#BJ "@ H * "@ H * &LP4$DX Y)/  %&^B#;5D<%Q%=()8'66-LX9&#*<
M$@X8$@X((.#U!%5*+@^6:::W35G]S)C)37-!II[-.Z^]$U24% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MR< D; NT\H 3G,@H V- \6Z9XF3=I\RNX&6B;Y)4_P!Z,\X']Y<KZ,: .DH
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MKYTV;]_S]=VU.FWD [CQKX]M?!&D17LZ;YIU18($^7<Y0,1GG9&@^\V#@84
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 07?^ID_W&_\ 030!Q5 !0!S\/B&
MR&"Z#6LH. )1A6YX*MTP?4X]LUX5/,Z/.Z&)4J%2]DJBM%ZZ-2VL_.WS/7GE
M]3D]K0<:T+;P=VO)QWNO*YO@AAD<@\@BO<335UJGL>2U;1[BTQ%.YU"VLB%N
M)HH2W02.J$_0,1G\*UC3G4UIQE*V]DW;[D92J0IZ3E&-]KM+\RPLJ,OF*P*8
MSN!!&/7/3'O6=FGRM._;J:)IJZ:MWZ'D_C2\>]U&+3GF\FS,8<D'"N6#D$GH
M<X"+G*@DGN:^EP4%3HRKJ/-4YK>:M;[K7N^K/FL;-U*T:#ERT^6_D[W^^]K+
MH)X-T*^B%MJ=I,H@EW>?$[,,A9'0[5"LK':H92Q4AN,XHQM>D_:8>K%\\;<D
MDEUBGJVTUJ[.U]/,,%0JQ]GB*4ER._/%MK:36B2:>BNKVU\C:\4Z+JFNW<=O
M$?*L !N;<,;L$LS1[@S8X51COG(!)')A*]##4W.6M7HK/;HD[67=_P##'7BJ
M%?$U%"/NTNKNM^K:NF^R_P"'.?\ "XGT37#I4<PN("&#E?N<1EPV,D*P;"M@
MGDE237=BN7$8;ZS*'+/2U]_BLU?2Z:U7WG%A>;#XGZM&7-#6]MOANG;6SOH_
MN/8Z^6/J#QOQC&NK:Y'9/(MNB1!6D<C:G#R%CDJ!P5 !89..>0*^IP3=##2J
MJ+DW)M16[VC;1/K=['RV-2K8F-)R44HI.3V6\F]UTLMS;\,>$8+"[6_M[V.[
M6(,"(T7'S*5^\LK@8SGISBN3%8R52#HSI.FW;=OHT]G%'7A<'&E-5H55-*^B
M2ZIK=29Q]SH_]N>(+BSW^3NDD;=MWXVC.-NY>OUKU(UOJV$A5MS6C%6O;?SL
M_P CS)4?K&+G2ORWE)WM?;RNOS)-=\(OX8A6\BN]S!@  IB?ZH1(Q..IZ8'-
M3A\8L7)TI4[*W?F7ST5O(JO@WA(JK&I=W[<K^6K^9ZUX<NYK[3H+BX_UKIEC
MTS@D!O\ @0 ;\>*^:Q,(TZTX0^%/3R\OD]#Z3#3E4HPG/XFM?/S^:U'ZWK<&
M@PK<7(<H\BQ?(%."V2"=S* HP<G.1Z5R'6<^?'^GH0S1W2VS-M6Z,!%N3G&0
MV=Q'_ ,X[4P.FO\ 5K73;8WMQ(%@ !#==V[[H4#EBW8#Z],FD!S<?CRQ+)Y\
M5W:Q2G"33P[(6^CAFX]\8'4D"@#H-6UJUT2 7%T^U6(5 HW,['HJ*.I/Y <D
M@4 <^OCNS65(KJ"\LQ*0$>X@\M#GH<[F.#ZXP!R<#- &?XC_ .1BTK_MK_*F
M!TLOB2V74!I422W%QC+^4JE(AQS*S.NW@@X&X\@8W$ H#H: //-(_P"1JU+_
M *XV_P#Z+AI@=3XD_P"05>_]>EQ_Z*>D!Q.GW\^F>#ENK7_6QQ-M.,[=T[*6
MQ_LJQ;TXI@-T;P9I6M6D=W--+>7$BJ\DHF)9789(QR5*GC#9;(YH Z#PQI^I
M:1-<65TS3V2$&UF=U9\'JA&=_&<?,  5.WY6%(#LJ .)D\=V>YQ;P7EU'$2K
MS00;XE(ZY<LO'OC!ZC(H W[/7+.^L_[1BD'V8 EG;*[=OW@P/((]._&,@@D
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M*/0PF$C1G[:%535FM$K:^:DSEM*U>WT37=0N;HD)NN5 499F-RI"@=,X!/)
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M6D5G;^:A'[X2R[OFV@;?EZ9SP/PZ4"-+QRMS)J^G+8%5N'641LW12V 6_P"
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MA7;NP-VT$D+NZXR2<9QDDU\;=VY;NU[VZ7[V[GV5E?FLKVM?K;M?L>5?"_\
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MH V* "@ H S]7LY=0LI[2"7[-+/#)$DVW>8F="HD"[DW%,[@-PY R: /F?\
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M=1-OB+((XT?.1)LW2,SJ>5+28!^;;NVE6![12 ^4_C^@DU?34895HB"/4&8
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M".2<[1U % '0VVA:S+K$&K7IL5$*-&XMS."Z,K 9#J0Q4L",L!P/2@ \)?\
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M*UYV:<M%?1I6_EUN[+30Y,+@>3EJ5[\T;VAI:.KMLW?^;2RN]=3:\1^$;?Q
MRRES!.HV[PH8%><!ERN<$\'<#CCD8QR8;&3PJ<;<T'K:]K/R>OY'5B<'#$VE
M?EFM+I7NO-:?F5- \#6^BS"ZDD-Q*GW,J$52<C=MW-EL'@DX'7&<$:8C'SKQ
M]G&/)%[ZW;\KV6GRU,\/@(8>7M)2YY+;2R7G:[U^9:G\*^=JZZQYV-I4^5Y>
M?NIL^_O'7K]SV]ZSCB^7#O"\F]_>YN[OM;]326$YL0L5S[6]WE[*V]_T*OB#
MP/;ZW,;J.0VTK??(4.K8X!VY4AL=2&Y],Y)TP^.GAX^S<>:*VULUY7L]/D9X
MC PQ$O:1ER2>^ET_.UUK\R?P[X,M] D^T%S//@A6*[0H/!VKEN2."2QXX&.<
MSB<;/$KD248=5>[?J[+\B\-@H89\]^:?1VLEZ*[_ #,?5/A[_:5U+=_:O+\Y
MR^WR=V,]L^:,_7 KII9C[&$:?L[\JM?FM?Y<K.6KEWM9RJ>TMS.]N6]OGS(I
MI\,%!&^[)7N!"%/YF5L?D:U>:/I3L_.5_P#VU&2RM=:FGE&W_MS/2=/L(=+M
MTM;<;8XQ@=R>Y)/<L22?<\ #BO!J5)59.I-^\_ZLO)'O4Z<:,53@K17]7]6<
M1\3%#Z7&IZ&ZB!_%9*S-263P7<SQBRGU&>33U(Q!L0.5&,(TP.YE& ,%<# P
M!0!T&J>&[/5;)=/=?+BB"^44X:(H,*5)ST'!!SD$]^0@.?F\'W][&+6^U.:>
MTXW1B)$=P#G#RAF9O^!!OI3 T=8\)1:@+=[25[*>Q&V&1!OPN -K*2-W3KN!
M.6SG-(#)U'P/<:S$4U'4);B08,1\I(XHSD9;R48!F*Y7.X8W$\TP-NZ\-FYO
M+*],V#IZE2OE_P"L)4#.=_R>N,/Z9[T@#5?#7VZ_@U2UF^RW-OPQV;Q*G]QA
MO3L6&<DX/L, '4T <KKOA6+694O(I9+.\A&%GBZ[?1AD9 R<8(/)!)'% &._
M@FZORJ:KJ,UW;J03"$$2MCD;B';//MGT(/-,#L[G3+:[M382(#;L@CV#@!1C
M:!CIMP-I'0@$4@.,B\%WUB/)L-4G@MQG;&T8DVCT5MZ@?\!4<\XI@;V@^&H=
M#,DV^2YNKC_6SRG+MCL/[J^HR22!DD  (#HF4."K $$8(/((/4$=P: .#A\'
M7>F[HM*U&6TMG8MY)A27;GJ$=F!7V(&>Y)/)8%Q?!-F-,DTMF=O.?S7F)'F&
M7C#],<8QM]"><DFD!57PC>SQBTOM2FGM -IB2)(F9?[KR@L[#'!SU&>F:8#1
MX((T4Z)]HX\SS!+Y70;@VTIYG/.>=P^G'(!M:SX:AUFWBAD=XIK7!AGCX=&
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M/X*NK_$>J:C/=VX()B5!$&QR Q#MD?AGN"#@TP.\AB2W18HP%2-0JJ.@51@
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ML8W83&-C*2-RC)P,CJP.0<4@*UKX4F>[COM5O'OY+8DPKY:0QHQQ\VQ"02,
MYXY )SB@#LZ .9T_P[]@N;^Y\W?_ &D5.W9CR]HD'7>=^=_HO3WX )_#>B?\
M(]9+8^9YVQF;?MV9W'.-NY^GUYH 9HV@_P!D7-Y<^9YGVZ42[=FWR^7.W.YM
MWWNN%Z=.: .BH * "@ H * "@ H * +^F?\ 'RG_  +_ -!- '6T % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * +^F?\?*?\"_]!- '6T % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 07?^ID_P!QO_030!Q5 !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 ;VA_\M/^ _\ LU &]0 4 % !0!!=_P"ID_W&_P#030!Q5 !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;VA_P#+3_@/_LU &]0
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MJ^3/9AD\V$I;GRPY  D\A$=<DA-P=P&(!.2 6!ZC>_$VSM_"Z^*(TW>:H2.
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MU$=Q:76,3HL2E5+!3(C0K&C",D>9&Z!]N"",C< ?4 .>1TI % !0 4 % !0
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M #4EUFP@V^9<P)YJADW2QKO5N59<L-P8'((R#VH T%8. RD$$9!'((/0@^E
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H WM#_Y:?\!_]FH
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MHP54!K:- I#<Y!C)],$4@/,?V=+ZS@2_M[B>*&::6V$4;R(CR$B8816(+G)
MPH)R1ZBF!Y]>:5.OCJ_LC?MH<L]Y=-'=;G3"S.TT2ET>(J)49<$L%+%5YR*
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M%5^4 %@%)&-IH ^U-/@:UMH8&;>T42(6Y&XJH4M@\\D9YY]:0%N@ H * "@
MH * "@ H XJ[_P!=)_OM_P"A&@""@ H * "@ H \\\8_\A+1_P#K[/\ .*F
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M2#<@+22%V*'*DD!0"0< 4 7=%L8=.\1WNG0*%M9K19&AZQYS&I&TY!!#OQT
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M% &9X8^#/AWPM<K>PI-=7$1S&]TZOY;=F5$CC3</X6925/*X/- 'J] !0 4
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M % !0 4 % !0!!=_ZF3_ '&_]!- '%4 % !0 4 % !0 4 % !0 4 % !0 4
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M $U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 <5=_P"ND_WV_P#0C0!!0 4 % !0 4 % !0 4 <[;:#]GU:?5_,S]HB6
M+RMF-NW9\V_<<YV=-HZ]>.0#HJ "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * (9XVEC9$8QLRLH<=5)! 8>X/(^E '-:'X9;2[B2^N[A[
MZ[E41^:ZA-B YVJH9L9.,\]N ,G(!U= !0 4 % !0 4 % !0 4 % !0!?TS_
M (^4_P"!?^@F@#K: "@ H * "@ H * "@ H * "@ H * "@ H * (+O_ %,G
M^XW_ *": .*H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#>T/_
M ):?\!_]FH WJ "@ H * (+O_4R?[C?^@F@#BJ "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H WM#_Y:?\!_]FH WJ "@ H * "@ H * "@ H *
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M(O#5GJ6I2>?=3^?YDFU$W;+F:-?EC5$&$11PHSC)R224!W] !0 4 % !0 4
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M H * "@ H * "@ H * +^F?\?*?\"_\ 030!UM !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % $%W_J9/]QO_030!Q5 !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 ;VA_\M/\ @/\ [-0!O4 % !0 4 07?^ID_P!QO_030!Q5
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MUNNTA>BBD!WU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MJWWM^XGDC(.,#G( (!H Z+Q'IBWMVCZK=1V^E(AQ"9C$99?5S\H*X/&&)&
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M H * "@ H * "@ H * +^F?\?*?\"_\ 030!UM !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % $%W_J9/]QO_030!Q5 !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 ;VA_\M/\ @/\ [-0!O4 % !0 4 07?^ID_P!QO_030!Q5
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;VA_\M/^ _\ LU &
M]0 4 % !0 4 % !0 4 % !0!EZ[IO]LZ==:=NV?;+::#=_=\V-H\_ANS0!\A
M_#7QLOPHN[W1?$5O-$)'4ED4%DD3*_=)7?%(I#)(A/0$!E?*L!+F\F^,GC.W
MN=.ADBLK/R%:1P,I;PRO*SR8)57D9W6--Q))49X; !I_M)_\A*P_Z]I/_1M
M'U]2 \K^-G_(G:A_VZ_^EEO0!D_ +_D5D_Z^9_YK3 ]JI ?'O_-6?^WK_P!L
MZ8'V%2 \5^/O_(K/_P!?,'\VI@9?@C5;K1/AO;WMG:#47B6YWVY) :(WMP)2
M0%?>%0EF3'*@^F" >+RW_@'6]-DN;JWGTG5BDI$-GYK0F0;C$4$F^,(WRAE_
M= '=C PQ /7/V<[.]M]*NYIPZVL\Z&WW9 8JK"5D![$[%+#@E2.JF@#Z*I %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 <5=_P"ND_WV_P#0C0!!0 4 % !0!Q?B_2+J]%M?Z> ]UI\ID6,G =3M
M+KDD#)V+QW&0#G% &1JNM:EKUJVG6>GW5O+<+Y<LDZ^7%&C</M<_?!7(Z X)
MPI. 6 FJ:'+92:);6Z/,EG,!(Z(S!<&++N0"$!(8_-@=?2@#7^(%I->:1)%;
M1O-(7C(2-6=B X)(503QWXI =9:*5@C!&"$4$'@@A1P: ..U2SGD\2Z?<)&[
M0QQ3AY C%$)CE #.!M4DD  D9)&.M, \5V<]QJ&E20QO(D-R6D9$9@BYBY<@
M$*.#R<#@^E #/'-G/=_8?L\<DOEWD;/L1FVJ.K-M!PH[DX% &-K=C);ZZ]_?
M64VIV3Q*L2Q)YWE, N<Q'@_,'/S8'SYY.: *EW%>7FI:?=P:=)96=O/C B D
M^<KODDCB!\M J@ MP""<GL".GL+.=/$]Y<M&ZPO;1JLA1@C,!%D*^-I(P<@'
M/!]*!C-7L)9_$FGS^4[P11R[WV%HT;9(4W-@JK;MI7)!W8QSB@"JEE<>%]:,
MEI%)+IVI',JQ(SB"7/W]J [4R<YZ;68#[@H CBCO?"&H7,D=K+>V%])YP^SK
MNDB<DEE\L8X^8@= 5"X8$,M &]I6L:EJMX2;1K.P53EKE66=WYQM4-A1TR"&
M& ?GR0 @,72OM&BZ[>K+;7$D.H2Q&.>.,M$N-_,C X51YF">HVG(P<TP/1Z0
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 7],_X^
M4_X%_P"@F@#K: "@ H * "@ H * "@ H * "@ H * "@ H * (+O_4R?[C?^
M@F@#BJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H WM#_Y:?\!_
M]FH WJ "@ H * (+O_4R?[C?^@F@#BJ "@ H * "@ H * "@ H * "@ H *
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MMG))SF@#>1%C4(@"JH   P !P  .  . !TH =0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Q5W_KI/]]O_ $(T
M 04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %_3/^/E/^!?^@F@#
MK: "@ H * "@ H * "@ H * "@ H * "@ H * (+O_4R?[C?^@F@#BJ "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H WM#_Y:?\  ?\ V:@#>H *
M "@ H @N_P#4R?[C?^@F@#BJ "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H WM#_ .6G_ ?_ &:@#>H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H XJ[_UTG^^W_H1H @H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * +^F?\?*?\"_]!- '6T % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 07?^ID_P!QO_030!Q5 !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 ;VA_\M/^ _\ LU &]0 4 % !0!!=_P"ID_W&
M_P#030!Q5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;VA_P#+
M3_@/_LU &]0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!Q5W_KI/]]O_0C0!!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 7],_X^4_X%_Z": .MH * "@ H * "@ H * "@ H * "@ H *
M "@ H @N_P#4R?[C?^@F@#BJ "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H WM#_ .6G_ ?_ &:@#>H * "@ H @N_\ 4R?[C?\ H)H XJ@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * -[0_\ EI_P'_V:@#>H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H X
MJ[_UTG^^W_H1H @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * +^F
M?\?*?\"_]!- '6T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 07?\ J9/]
MQO\ T$T <50 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &]H?\
MRT_X#_[-0!O4 % !0 4 07?^ID_W&_\ 030!Q5 !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ;VA_\ +3_@/_LU &]0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Q5W_KI/\ ?;_T(T 0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %_3/\ CY3_ (%_Z":
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M_P#II_X[_P#94 ']A_\ 33_QW_[*@ _L/_II_P"._P#V5 !_8?\ TT_\=_\
MLJ #^P_^FG_CO_V5 !_8?_33_P =_P#LJ #^P_\ II_X[_\ 94 ']A_]-/\
MQW_[*@ _L/\ Z:?^._\ V5 !_8?_ $T_\=_^RH /[#_Z:?\ CO\ ]E0 ?V'_
M --/_'?_ +*@ _L/_II_X[_]E0 ?V'_TT_\ '?\ [*@ _L/_ *:?^.__ &5
M!_8?_33_ ,=_^RH /[#_ .FG_CO_ -E0 ?V'_P!-/_'?_LJ #^P_^FG_ ([_
M /94 7[&Q^Q;OFW;L=L8QGW/K0!?H * "@ H 9*GFHR9QN4C/ID8H Q/[#_Z
M:?\ CO\ ]E0 ?V'_ --/_'?_ +*@ _L/_II_X[_]E0 ?V'_TT_\ '?\ [*@
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M_II_X[_]E0 ?V'_TT_\ '?\ [*@ _L/_ *:?^.__ &5 !_8?_33_ ,=_^RH
M/[#_ .FG_CO_ -E0 ?V'_P!-/_'?_LJ #^P_^FG_ ([_ /94 ']A_P#33_QW
M_P"RH /[#_Z:?^.__94 ']A_]-/_ !W_ .RH /[#_P"FG_CO_P!E0 ?V'_TT
M_P#'?_LJ #^P_P#II_X[_P#94 ']A_\ 33_QW_[*@ _L/_II_P"._P#V5 !_
M8?\ TT_\=_\ LJ #^P_^FG_CO_V5 !_8?_33_P =_P#LJ #^P_\ II_X[_\
M94 7[&Q^Q;OFW;L=L8QGW/K0!?H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H Q9='\UV?S,;F)QMZ9.?[U $?\ 8?\
MTT_\=_\ LJ #^P_^FG_CO_V5 !_8?_33_P =_P#LJ #^P_\ II_X[_\ 94 '
M]A_]-/\ QW_[*@ _L/\ Z:?^._\ V5 !_8?_ $T_\=_^RH /[#_Z:?\ CO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img46421407_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *A ^$# 2(  A$! Q$!_\0
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M+%_\37&T4>QI]@]K/N=E_P +5\9_]!9?_ 6+_P")H_X6KXS_ .@LO_@+%_\
M$UQM%'L:?8/:S[G9?\+5\9_]!9?_  %B_P#B:/\ A:OC/_H++_X"Q?\ Q-<;
M11[&GV#VL^YV7_"U?&?_ $%E_P# 6+_XFC_A:OC/_H++_P" L7_Q-<;11[&G
MV#VL^YV7_"U?&?\ T%E_\!8O_B:/^%J^,_\ H++_ . L7_Q-<;11[&GV#VL^
MYV7_  M7QG_T%E_\!8O_ (FC_A:OC/\ Z"R_^ L7_P 37&T4>QI]@]K/N>C>
M&OB5XLU#Q3I-E=:FKV]Q=QQR)]GC&Y2P!&0N17T!7RIX-_Y'?0O^O^'_ -"%
M?5=<6*C&,E9';A9.47<KV/\ QYQ_0_SKE_%&M:AI^II#:S[(S$&(V \Y/J/:
MNHL?^/*/Z'^=<1XT_P"0U'_UP'\S7A9M4E3P[E!V9Z^ A&==1DKHJ?\ "4:Q
M_P _8_[]K_A1_P )1K'_ #]C_OVO^%8]%?*_7<1_.SW_ *I0_E1L?\)1K'_/
MV/\ OVO^%'_"4:Q_S]C_ +]K_A6/11]=Q'\[#ZI0_D1L?\)1K'_/V/\ OVO^
M%'_"4:Q_S]C_ +]K_A6/11]=Q'\[#ZI0_D1L?\)1K'_/V/\ OVO^%'_"4:Q_
MS]C_ +]K_A6/11]=Q'\[#ZI0_D1L?\)1K'_/V/\ OVO^%'_"4:Q_S]C_ +]K
M_A6/11]=Q'\[#ZI0_D1L?\)1K'_/V/\ OVO^%'_"4:Q_S]C_ +]K_A6/11]=
MQ'\[#ZI0_D1L?\)1K'_/V/\ OVO^%'_"4:Q_S]C_ +]K_A6/11]=Q'\[#ZI0
M_D1L?\)1K'_/V/\ OVO^%'_"4:Q_S]C_ +]K_A6/1D>M"QF(>O,P^JT/Y4;'
M_"4:Q_S]C_OVO^%'_"4:Q_S]C_OVO^%8^:*/KF(_G8?5:'\J-C_A*-8_Y^Q_
MW[7_  H_X2C6/^?L?]^U_P *QZ*7UW$?SL/JE#^5&Q_PE&L?\_8_[]K_ (4?
M\)1K'_/V/^_:_P"%8]%/Z[B/YV'U2A_(C8_X2C6/^?L?]^U_PH_X2C6/^?L?
M]^U_PK'HI?7<1_.P^J4/Y$;'_"4:Q_S]C_OVO^%'_"4:Q_S]C_OVO^%8]%'U
MW$?SL/JE#^5&Q_PE&L?\_8_[]K_A1_PE&L?\_8_[]K_A6/13^NXC^=A]4H?R
MHV/^$HUC_G['_?M?\*/^$HUC_G['_?M?\*QZ*/KN(_G8?5*'\B-C_A*-8_Y^
MQ_W[7_"C_A*-8_Y^Q_W[7_"L>BCZ[B/YV'U2A_(C8_X2C6/^?L?]^U_PH_X2
MC6/^?L?]^U_PK'HH^NXC^=A]4H?R(V/^$HUC_G['_?M?\*/^$HUC_G['_?M?
M\*QZ*/KN(_G8?5*'\B-C_A*-8_Y^Q_W[7_"C_A*-8_Y^Q_W[7_"L>BCZ[B/Y
MV'U2A_(C8_X2C6/^?L?]^U_PH_X2C6/^?L?]^U_PK'HH^NXC^=A]4H?R(V/^
M$HUC_G['_?M?\*/^$HUC_G['_?M?\*QZ*/KN(_G8?5*'\B-C_A*-8_Y^Q_W[
M7_"C_A*-8_Y^Q_W[7_"L>BCZ[B/YV'U2A_(C8_X2C6/^?L?]^U_PH_X2C6/^
M?L?]^U_PK'HH^NXC^=A]4H?R(V/^$IUC_G['_?M?\*/^$HUC_G['_?M?\*QZ
M*7UW$?SL/JE#^5'8^&-:U#4-5:&ZGWQB(MC8!SD>@KL:\_\ !?\ R'&_ZX-_
M,5Z!7U>45)5,-S3=W=G@9A3C"NXQ5D%%%%>F<04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\X_%S_DHU[_UQA_\
M0:^CJ^<?BY_R4:]_ZXP_^@UTX3^(<V*_AG#T445Z1YH4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% #H_]:G^\/YU]">(O$4OAC2=(-IX;&IF>%=Y
M1#\GRCT4U\]Q_P"M3_>'\Z]Y\:^-]3\(:1HG]G16LAGA ?ST8XPHZ8(KEQ"N
MTMSJP[23;9F^-8;7Q%\,6U^YT<Z9?PE2B, &P6 QV.#GN :V;W7'\->"M%N;
M70%U.2:-59$0Y7C.>%->1>*/'FN>*X%@OY(H[=3GR8%*HS>IR23^=>J:_P"+
MM0\(^!=!N=.BMY'E1483J2,;<\8(K.5.44HLTC.+;:*VO_9O%WPROM7OM".E
MW=JK/%N7!R,<C@'!SW':LCQ_9-<> _!\-K K7$ZQJJHH!=C&M<AXE^(FO>*+
M,6MY)#%;9RT5NA4/]<DFN^\5R7T/A;P)+IL(FO8FB>&/^\PC7 ZBGRRIM7%S
M1G>QRB_"772RQO?:3'=,NX6K7)$OKC&VN+U#3[K2K^:QO8C%<0G:Z'L?;UKV
M.YOM'\2ZS!:^(_#&J:9KLNV*.XMR2R9X!#C@#Z@UYQXZT$^'/%$MB;Z2\&Q7
M625LN >S'UXK6C4DY6D95814;Q.:HHHKH.<**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#;\&_\ ([Z%_P!?\/\ Z$*^JZ^5/!O_ ".^A?\ 7_#_
M .A"OJNO/QGQ(]#!_"RO8_\ 'E']#_.N(\:?\AJ/_K@/YFNWL?\ CRC^A_G7
M$>-/^0U'_P!<!_,U\]G/^ZL]K+?]X1SE%%%?''TO4**** "BBB@ HHHH ***
M* "BBB@ HHHH&':NLO434O!\5RBKYL!&_ QTX_PKDZZ;PG,)5N]-<\3)E0?7
M_.*[\O:E-TFOB5OF<6-34546\7<DT=(]/\-7.H.@9Y21'D9SV'ZYK/B\,7TL
M2/))!"9/NI*^&-:^JR0Z=-I.E[AY<3*\H_K^>:I^)[>]DUR-HUD96"^25[''
M.*]"M0IJ"BU?ELK>NYPTZM1R;3MS:W?D8YTNZ34EL)%"3,<#/0^^?2M ^%+\
M3>2TMLK_ ,.7^]]!C-;.J.G]NZ0C$&X7[^.O2J6K.Q\:6_S'@J![=:S>#H4U
M)RUU2^\U6*K3MRNVC?W'/W%A<VU\;-XR9@0 J\YSZ5I#PM?D8\RW$I&?*,GS
M?EBMNX:-/'4)DP,Q87/KVK,EMK__ (3#<%DW&;<K=MF?7TQ2^I4H2=TW[UO0
M?UNK-*S2TN95GI-S>7[62[8YESD2'&,5='A6_.X;[?S%Y\L/\WY8K?C>)_&S
M>7@D0X?'K6?:6UZOC5F99,;R6<]"N/Y4U@J44DU>\K7)>+JMW3M97,73]&NM
M2N)8(]B21<L)"1CVZ5)<:#=V[Q1[X9)96VB.-LD'W]*Z32V1O%&JF,_+M'(]
M<5@:5:+J'B)XY9' +LS%6()_&HE@Z45&*5VVT6L34E)RV25QX\*WK%E6:T:4
M#)C$GS?3&*I6FDRW<DJ&:"!HCAA,^VNNTJ4+K=Q:P:?Y,<>0\S9+-Z<FL.#1
MVU;Q'=!A^XCES(W]*TJX&DN1TU=MM6,Z>+J-24W:RN07'AB\M[*2[,]LT2+N
M)1R<CVXJ&UT"[N;5;DO!!$WW6F?;FM#Q'J;3;=/LHG2TAX.$(#$?T%6I((-*
MTJRD6S:]EE P9&)"DCTZ4OJE!UI**TBM?4?UBO&DFWJWIZ&#?:/=:?/%',$/
MF$!'4Y4FKC^%;]'57EME##Y69\#/ITK8\4;C'I9=0K&09 [&JOBYF^WZ>NX@
M  CGW%%3!4*;FVKVM^(0Q5::BD[7O^!@:AIMQIEQY-P!DC(*G((JI74>,>7L
MCW,?Y]*Y>O.QE*-*JXQV._"U'4I*4MPHHHKE-PHHHH **** "BBB@ HHHH *
M*** "BBB@#HO!?\ R'&_ZX-_,5Z!7G_@O_D.-_UP;^8KT"OL<E_W5>K/F\S_
M -X?H@HHHKUCSPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@!*^<OBY_P E&O?^N,/_ *#7T;VKP+XHZ#K-_P"/;NXL
M])OKB%H8@)(;=W4D+SR!BNC"M*=V<V*3<+(\WHK7_P"$5\1?] '5/_ 1_P#"
MC_A%?$7_ $ =4_\  1_\*]'GCW//Y)=C(HK7_P"$5\1?] '5/_ 1_P#"C_A%
M?$7_ $ =4_\  1_\*.>/<.278R**U_\ A%?$7_0!U3_P$?\ PH_X17Q%_P!
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M/^$5\1?] '5/_ 1_\*.>/<.278R**U_^$5\1?] '5/\ P$?_  H_X17Q%_T
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M(!,"C I:*+(!,"C I:,T60"8%&!1GVI:+(!,"C I:*+(!,"C HS1FBR ,"C
M]*6BBR 3 HP*6BBR 3 ]*-HI:*+(!,"C I:*+(!,"C HS2T60"8'I1@4M%%D
M F!1@4M&:+(!,"C I:*+(!,"C I:*+(!,#THP*,TM%D F!1@49I:+(!,"C H
MS1FBR ,"C HS1FBR ,"C I:3-%D 8%&!2T460"8%!4&EHHL@$P*6BBF 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Q^NZ[XCC\3?V3H5C87&VV$[FY=E(R2."#[5':>)/$=AJ
M=G;>)-)M(8;R3RHI[.0L%<] V?6J>MW.M6OQ$9]#T^"]G-@H=)I?+"KN;G/>
MK$%CXI\0:I9/KUE::?96<HG\N&42-*XZ<]AF@#MMRKU8>G6@NJ]6 ^IKS_3?
M#UEK?C+7+B_$DJ6=VCPQ!R%#\G<0.O2HM'\,6/C1+S5M<DGN)3=21Q1K,RK
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MXEG-O&D+,9@,E!CJ!W(KQG4-->+2CK5EHFJ)/&5D.JWMT5D/S#Y@@/?/3WH
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M7M6@O5+P!=S1AB _'0XYQ5CPQ9PZ)\6M0TS3P8;,PD^2"<#OP* /5:*3O2T
M%%%% !1110 4444 %%%% &4NC*OB9]9\\[FMQ!Y6WC@DYS^-:@J.:XAMQF::
M.,'H78#^=.1UD171U92.&4Y!H S=-T9=-U'4[P3F0WTHD*E<;, C'OUK#OO
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M;.EZ,NFZCJ=V)VD-]*)"A7&S / ]>M7X[B";=Y4T<FWKL8''UQ4O>@!:***
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MMX="GTF&]D6*2[%R',8)7I\O7GIUK8M]&6W\0WFKB<LUU$D9B*\+M[YK5HH
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MAQ%\(_\ "/\ VIMGE&/SMG/7.<5K65N+2Q@M@VX0QK&&(QG QFIZ* "BBB@
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MMKQ-Z@T <'X<ANK#Q-8G3/"6IZ-9R$QW2R2F2)@>C8/((]:[[Q'SX:U,=?\
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M*M6OP\M(+N(S:KJ-S80L&BL)IB8DQ]WCOBMU-#@77;K5&D=VN(! T3 ;=HH
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M';UKV>:)9H7B<91U*L/8UP5O\,Y+7[1:0>(+R+2+AB9+.- "P/;?G^E '/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 %%%% !1110!7L?\ CRC^A_G5BJ]C_P >4?T/\ZL4 %%%% !1110
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MT?X4<M/N'-4['=_VYI/_ $$[+_P(7_&C^W-)_P"@G9?^!"_XUPG_  I30/\
MG]U#_OZ/\*/^%*:!_P _NH?]_1_A1RT^X<U3L=W_ &YI/_03LO\ P(7_ !H_
MMS2?^@G9?^!"_P"-<)_PI30/^?W4/^_H_P */^%*:!_S^ZA_W]'^%'+3[AS5
M.QW?]N:3_P!!.R_\"%_QH_MS2?\ H)V7_@0O^-<)_P *4T#_ )_=0_[^C_"C
M_A2F@?\ /[J'_?T?X4<M/N'-4['=_P!N:3_T$[+_ ,"%_P :/[<TG_H)V7_@
M0O\ C7"?\*4T#_G]U#_OZ/\ "C_A2F@?\_NH?]_1_A1RT^X<U3L=W_;FD_\
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M\_NH?]_1_A1RT^X<U3L=W_;FD_\ 03LO_ A?\:/[<TG_ *"=E_X$+_C7"?\
M"E- _P"?W4/^_H_PH_X4IH'_ #^ZA_W]'^%'+3[AS5.QW?\ ;FD_]!.R_P#
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M@?\ /[J'_?T?X4<M/N'-4['=_P!N:3_T$[+_ ,"%_P :/[<TG_H)V7_@0O\
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MPA=A_P ]KC_ONCVN,_D7WAR8?^9_<;GV^T_Y^8?^^Q1]OM/^?F'_ +[%8?\
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MR* %HI,TN: "BC-)D#K0 M%4]3U2UTBS-U>2%(@P7(7/).!5S- !129%+F@
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M\%_/'<G6?*24R$E03P/I[=* /4*#S7 FPU/PSXITACKE[?0ZC*T5Q'<,"H.
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MKUP_@2"[MM;\20WTXGN$N(P\P&-_R\''KC%=Q0 4444 %%%% !1110 4444
M%%%% !1110 AJM#?VEQ=36L-Q')-"!YB*<E,] ?0^U+?P27%E-##<-;RNA"S
M(,E#ZBO)?AOIM]+XBU29=8GC2TN/WZ!01<X)^]SQT_6@#V*CITKS2PO_ !#X
M\U34'L-8;2-,M)#%&84#.Y]\_G6GX-\0ZD^MW_AO6G$UY9Y,=P!_K%!QS^=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M['QG'X5V=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:;?FPU"S9C%*4#J0>H([]*SM+\(ZM;^)+76]2US[=<1QO'(IBVKM(P-H'W:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% %>Q_X\H_H?YU8JO8_P#'E']#_.K% !0:*0T '-%<
M)KNF/K/Q"AL3>3VUN^GL9A"V&D7<OR@]NW/M2:=IQ\*>*/[&L[N>73KRRDF$
M,S[S$Z]P??/Z4 =Y0:X?1G)^%4SF0Y\BX^8G_::LZ6">_;P=9QW4MOY]HRR.
MA^;;Y9SCW(XS0!Z31UKS:V\+BW\47/AJVU.^CTB6V%S+'YI+LV<8#=0#G/X4
M65JVC:?XMT>&YFDL[6-6@$K99-P.1G\* /2>U'6O-(?!@F\*VVMMK%Z-5CLT
MEBG$I"1@*"%V^@'&:;XB;4]<T+0M2GM+RZTQ[<27L%E)LDWD<,/4>U 'IM+7
M _#^ZTY+FZLK*YU.)=@==/U%,/'C@LK9Y!S7?4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 5[>TM[42"W@CB$KEW
MV*!N8]2?4\"K%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -
M<;E9?48KG/"GA8^&?M_^F"Y^USF;_5[-N>W4YKI,48H , TN*** "BBB@ Q6
M%XL\/'Q/H4NFBZ^S%V!\S9OQ@^F16[10!5TZT^PZ=;VF_?Y,83=C&<>U6<4M
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-8XU5$4855& !Z 4[% '-Z%X5ETW47U/4M4FU+46C\H3.@0*F0< #Z5TM%%
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M^?3#V%/_ )^(ZW(]:,CUKDO^$=US_H+G_OH_X4?\([KG_07/_?1_PH^MUO\
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MX;Y@4;)^8"@#O6O]1;7]*'_"0:?!;2VZ/+82*OG2DJ22O?'^!KF=5\;:G?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD5$,F_[1Y/)^8MC;N]_6NSHH JZ=9_V?IEK9^9O\B)8]^,;L#&<5C^,?"O\
MPENE16)O#:[)1)O\O?G@C&,CUKHJ* .3G\$B?Q5I>N?V@0;"%(O)\G[^T$9S
MGCKZ5+:>$!:^-KOQ']N+&X3;]G\K&W@#[V?;TKIZ* ./U3P)Y^M2:OH^K3Z3
M>S#$KQ('#_@2*T?#'A2U\,V\PCE>XNKAM\]Q(,-(?Z"M^B@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *3%+10 F#1BEHH 3%&#2T4 )BC'K2T4 )@^
MM&*6B@!,48I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O8_\>4?T/\ZL57L?^/*/
MZ'^=6* "BBB@ HHHH 3%&*6B@!,&C!^M+10 F#1CTI:* $Q1BEHH 2E HHH
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MSXD_Z!:_]\FNL_"C\*/J=3_GZP^L0_Y]HY/^V?$G_0+7_ODT?VSXD_Z!:_\
M?)KK/PH_"CZG4_Y^L/K$/^?:.3_MGQ)_T"U_[Y-']L^)/^@6O_?)KK/PH_"C
MZG4_Y^L/K$/^?:.3_MCQ)_T"Q_WR:3^V/$9_YA@_[Y-=;^%&!2^IU/\ GZP^
ML0_D1A:/?ZO=73)?60AB"Y#8(Y_&MZFTZNNC!PCRN5S"<E)W2L%%%%:D!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^M #Z*** "BBB@ HHHH **** "BBB@"O8_\ 'E']#_.K%5['_CRC^A_G5B@
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M'7\*[_3]&TW2MW]GV%M:[OO>3&%S]<4Y=(TY;R>[6QMQ<3KMEE$8W./0GN*
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MGV]J .-U&U@3X/0JL2A5MX7&!_%N7GZU:-Y!9_$+36NITA6;2S'&9&P&8LG
MSWKK6T^RDL18O:PM:@!1"4&S Z#%,NM+T^\>![FS@F:W.82Z!O+/MZ=J ..T
M2UUBZT?5(]%U"*QN1JLI:26$2 K@9&#3=?L9(M'T]/$VOF/48[DO;:A;P[$C
M/^UQ@#W-=S;6EM9JZV\$<(D<R.$7&YCU)]Z+JUM[VV>WNH4FA<8:.1<@_44
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M-298XC8*JSNN5C.1U/;/3-+97EMKWC'4M2T@>9:1Z<T,EP@^69R00!ZX /-
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M ?VA-P!@=JZR@ HHHH **** "BBB@"O8_P#'E']#_.K%5['_ (\H_H?YU8H
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M/).4(P/7!Y '4DU>\6Q*GQ'\,1'#*JA<8XXQ0!O6/Q"@F\0Q:/?:5>Z=+/\
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MYO/!FH16H8R; V%') .2/RKG-%\4Z!#\,5AEO+=98K-H9+=F =GVXX'4\]Z
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MRD>F#Q45OIEA:1/%;6-M#'(,.D<2J&^H YKEKCXBV:7$HM-*U.]M86*27=O
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M.* .@_X1[0O^@-IV?^O5/\*TU4*H55 4#  [5@13Z:GC.]_=2I>I9*TL[/\
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M*,HFPC 0D@9.>:]"J&"VM[8%;>"*('J(T"Y_*I$E20$HZL <':<X- #J***
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MF\H9/KDXJ5$2- D:A%4855& /PH X.Q\0:;X3UW7+?7)#:/<71G@D="1,AZ
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M&UEIE[X?OKZRA0[8D<JLQ(^^,<_+W^E6M>\6:=XNT]-&T1)[J\GE3</)91
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M'M?M<.@:A-;1,RW,R ;(<'KG'/'-,MM;@UWX@6MS:1R_9?[/D$4LB%/-Y.2
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M&VAC@8G,:( ISUXJ"ST72]/E:6RTZTMY&X+10JI/X@4 /U3_ )!-YQ_RQ?\
ME7GWAKP)'J'AK3[L^(-<B\V%6,4-UM1<CH!C@5Z6Z+(A1U#*PP01D$4R"WAM
MH$A@B2*)!A41<*H] .U ',ZKHUEH/@#5;.RC*QBUD9F=BS.Q4Y8D]2:R-+^'
ML5UI-I,WB+70LD2DQK=X7D= ,=*[Z:"*XA>&:-)(G!5D<9# ]01WIT<:0QK'
M&BHBC"JHP /:@#EO$6EVFC?#O4+&RB\N".W.!G))SR23U-;6F!F\/687J;5,
M?]\"KL]O#=0/#/$DL3C#(Z[E8>X-*D:QQI&BJJ* JJHP !V% 'GOA;Q!H.C^
M&)-*U*2**]A:2.XM''SRMG!P/XLUC6@0?#G3KMH&:QM]4\V>(#I'DCD>Q(XK
MU*;2=/N+Q+R:QMI+I/N3/$"Z_0]:D@L;6VMS;P6\44)))C1 %.>O% '">+O$
M&AZ[I5KI^EW,%[?2W$?D)"<M$0<Y..G%0^)/L5MXGNI[/Q.VA:J8T$YN$_=3
M#'!&>M=U::+I>GS--9:=:6\K<%XH54G\0*?>Z3IVI;?MUC;76S[OG1!]OTS0
M!YD]YJ&L^ ];@_<3&VG0F]M(0JW"@@LY4<'C)-4[R[N+W2DMIO']C<POL5;6
M+3U:3.1@!1R"#BO8(;:&V@6&")(HE&%1%  'L!52'0]*MKK[5!IMG%<DY\U(
M5#'\<9H PO&:E/ K0L2TI$2#(P2V1V_.NI@5EMXE;[P0 _7%9.JZ;-JFJZ>C
MH/L%LYN')/WY!PHQZ#)/Y5M4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% %>Q_X\H_H?YU8JO8_\>4?T/\ZL4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112&@!:*3M7"
M^*OB*WAG63IXT6YN\(K^;'G'/;H:<8N3LB9245=G=T5Y3_PN=O\ H6+W\S_\
M31_PN9O^A8O?S/\ \36GL9]B/;0[GJU%>4_\+F;_ *%B]_,__$T?\+F;_H6+
MW\S_ /$T>QGV#VT.YZM17E/_  N9O^A8O?S/_P 31_PN9O\ H6+W\S_\31[&
M?8/;0[GJU%>4_P#"YF_Z%B]_,_\ Q-'_  N9O^A8O?S/_P 31[&?8/;0[GJU
M%>4_\+F;_H6+W\S_ /$T?\+F;_H6+W\S_P#$T>QGV#VT.YZM17E/_"YF_P"A
M8O?S/_Q-'_"YF_Z%B]_,_P#Q-'L9]@]M#N>K45Y3_P +F;_H6+W\S_\ $T?\
M+F;_ *%B]_,__$T>QGV#VT.YZKBC%>5?\+F;_H6+W\S_ /$T?\+F;_H6+W\S
M_P#$T>QGV#VT.YZM17E/_"YF_P"A8O?S/_Q-'_"YF_Z%B]_,_P#Q-'L9]@]M
M#N>K45Y3_P +F;_H6+W\S_\ $T?\+F;_ *%B]_,__$T>QGV#VT.YZM17E/\
MPN9O^A8O?S/_ ,31_P +F;_H6+W\S_\ $T>QGV#VT.YZM17E/_"YF_Z%B]_,
M_P#Q-'_"YF_Z%B]_,_\ Q-'L9]@]M#N>K45Y3_PN9O\ H6+W\S_\31_PN9O^
MA8O?S/\ \31[&?8/;0[GJU%>4_\ "YF_Z%B]_,__ !-'_"YF_P"A8O?S/_Q-
M'L9]@]M#N>K45Y3_ ,+F;_H6+W\S_P#$T?\ "YF_Z%B]_,__ !-'L9]@]M#N
M>J@4M>4_\+F;_H6+W\S_ /$T?\+F;_H6+W\S_P#$T>QGV#VT.YZM17E/_"YF
M_P"A8O?S/_Q-'_"YF_Z%B]_,_P#Q-'L9]@]M#N>K45Y3_P +F;_H6+W\S_\
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MO^%'_"8O_P! Z;]?\*/[1P_?\ ^IUNQUE%<G_P )B_\ T#IOU_PH_P"$Q?\
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MQWKA&DSP,]* /1M(\0Z5KT3/IE['<;?O*,AA]0>:T\\UY-J^E6W@OXB:)/I
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M3LOER1JQ\K/9U)ZGV->AZ;</=Z9:W$F-\D2NVT8&2* +=%%% !1110 4444
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MZCJ7BS3=,L]:O--CDMI9&:W/WBI7&1^-4[[3O$OA.U_M6'Q!<ZM!"P:XM[L
M9C[E3ZUIZK-#!\1=)>:6.-/L4_S.P4?>3N:=XQU^PA\/7%M#<PSW5V/(@AC<
M,68^PH U[SQ%IFG:7%J-_=I;6\JAD+]2",\ <GK3=&\3Z/XA5SI=]'<%/O*
M58#Z$ X]ZY2XMK73_%?ANUU@K]GATX1PF4C9YPX.<]\8JQ=2:<WQ%T?^R6B:
MX$4GVHV^"OE;3C=CWQ0!KW7COPS9:B;"XU:%+D-M*[6(!]V Q^M6=3N(3J6C
MG^U9+?S)&\N*(;EN>!P2.W>O/OL=S86UW_8NJ:'J.E2/(\D-^NV0?WE]3]:V
M(KZ+4AX*N8+7[+&TT@6$'(0 8X/IQ0!T-YXY\-Z>\BW6J11O'(8F38Q8,.O
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M<TC3YC+9V,<+F'R"4)'[OTZ_KUKB_ >L0ZM?ZAJEUKE[),@=Y+:0E;>*//#
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M3PE_T"8OSH_X5IX2_P"@3%^==;11[27</9Q[')?\*T\)?] F+\Z/^%:>$O\
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M)?\ 0)B_.C_A6GA+_H$Q?G76YHS1[27</9Q[')?\*T\)?] F+\Z/^%:>$O\
MH$Q?G76T4>TEW#V<>QR7_"M/"7_0)B_.C_A6GA+_ *!,7YUUM%'M)=P]G'L<
ME_PK3PE_T"8OSH_X5IX2_P"@3%^==;11[27</9Q[')?\*T\)?] F+\Z/^%:>
M$O\ H$Q?G76T4>TEW#V<>QR7_"M/"7_0)B_.C_A6GA+_ *!,7YUUM%'M)=P]
MG'L<Q:?#[PQ8WL%W;Z9&D\#B2-A_"P.0:Z>BBI<F]RE%+8KV/_'E']#_ #JO
M=Z+87L_G7$"O)C&35BQ_X\H_H?YU8K.<(S5I*Y<92B[Q=C(_X1G2O^?5:/\
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MT/Y$'MZO\S,C_A&=*_Y]5H_X1G2O^?5:U\T9H^JT/Y$'MZO\S,C_ (1G2O\
MGU6C_A&=*_Y]5K7HS1]5H?R(/;U?YF9'_",Z5_SZK1_PC.E?\^JUKT9H^JT/
MY$'MZO\ ,S(_X1G2O^?5:/\ A&=*_P"?5:UZ*/JM#^1![>K_ #,R/^$9TK_G
MU6C_ (1G2O\ GU6M>BCZK0_D0>WJ_P S,C_A&=*_Y]5H_P"$9TK_ )]5K7HH
M^JT/Y$'MZO\ ,S(_X1G2O^?5:/\ A&=*_P"?5:UZ*/JM#^1![>K_ #,R/^$9
MTK_GU6C_ (1G2O\ GU6M>BCZK0_D0>WJ_P S,C_A&=*_Y]5H_P"$9TK_ )]5
MK7HH^JT/Y$'MZO\ ,S(_X1G2O^?5:/\ A&=*_P"?5:UZ*/JM#^1![>K_ #,R
M/^$9TK_GU6C_ (1G2O\ GU6M>BCZI0_D0>WJ_P S*%GH]C83&6V@".1M)'I5
M^BBMH0C!6BK(B4I2=Y.X44451(4444 %%07;M%:3R(<,L;,I]"!7%?#_ ,4W
M6I>'+[4=>OX]L%P4\UU6-57:#S@#UH [RBLB3Q/H4,<,DFKV2I,,QL9E^<>W
MK4?B'Q/I_AS2S?74JN2,Q1(PW2^PH VZ*Q?#OB*T\0:6EU#-"9-H::)'!,6<
M\'TZ5-;>(M&O+LVEMJEI+<9(\I)06R/:@#4HJC>:MI^G2PQ7E[!!),=L2RN%
M+GT'K18ZMI^IF46-[!<F([9/*<-M/OCI0!>HJM>7UKIUJ]S>W$=O GWI)&"J
M/J:IOXDT1)X86U6S$LP!C0RC+@],4 :M%1231PPM++(J1J,EV. !6=:>)=$O
M[E;:TU:SGG/2-)@2?PH UJ*Y/Q)X[T[P_?V]@626YE<+)\^%@7^\U+=ZJ]SX
MBTMK#Q1816,R@FS*JSW/)&4;KSC''I0!U=%4-0UG3-)"?VA?VUKO^[YL@7/Y
MU/!>6UU;+=6\\<MN1D2(P*D?6@"Q160?$^A?9FN?[8LO(5]C/YRX#>F?6II=
M;TR'2CJ;7T!L@,B8."I^AH T:*Y?PMXUL/$_FK&T<,P<B*W=P9&0#[V/2NHH
M **** "BBB@ HHHH Y&Z\77%GXY&BRV\9LV$8\X9#(S],_4U=\7>(9/#NC_:
M((!/=.2(XV. <#+'Z  FN9UZT>[\2>(_*SY\%E!/%C^^A)%)K%ZGB2.^OXO^
M/6RTAW7GCS9$Z?\ ?)(H [O3+PW6DVUY.45I8@[8X S5E)HIE+12HX'4JP.*
M\P\27-Q)8^&M,%E>7UI+;&6:ULW*O+@  $_W>>:/#<,]GXCM8].\*ZMI-A.&
MBNXYV+Q$$<-ST/;/O0!W>C:[#K%QJ$**J&TN# /G!+X .X>W/Z5IBY@,GEB:
M,OTVAAG\J\WT#2='T>'Q3J.)+5K6>2!+B)B7CCV@X4'()R3R1WKF]1TF6QTN
M+6+/P[<6,D;QL=0NKQFG8DCG;G!)[\=Z /5/[9G7QD^DN(EM5LS<;R,-NW =
M<XQS6U%)'*FZ-U=?53D5P6I:3!KOQ!CM;R600'3=TL:.5\T;E^4D<X[\>E%I
M91>$?%<]AI#.+.?3Y+C[(7+")TQ@C)/7/Z4 =V]Q CA'FC5_[I8 UD:_JUQI
M=QI4<"QD7=VL$F\$X4^F#UKE-"\%Z/X@\/Q:QJ;376HW0:7[3Y[@Q')P% .
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M7@;<9SG-:F*,4 )VYKF-:\'1:GJ)U"QU*\TJ\=0LLMH^/- Z9']:ZC%)CG-
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MC7_A)OM4WG^7Y?D[1M^[MSGK6=:?#FSM-"U72EU"Y:/4'1W<JN4VG.!7:T4
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M1>EV86J^1C_\+;\(?\_S_P#?NC_A;?A#_G^?_OW6Q_P@OAC_ * UK_WR:/\
MA!?#'_0&M?\ ODT7I=F%JOD8_P#PMOPA_P _S_\ ?NC_ (6WX0_Y_G_[]UL?
M\(+X8_Z UK_WR:/^$%\,?] :U_[Y-%Z79A:KY&/_ ,+;\(?\_P __?NC_A;?
MA#_G^?\ []UL?\(+X8_Z UK_ -\FC_A!?#'_ $!K7_ODT7I=F%JOD8__  MO
MPA_S_/\ ]^Z/^%M^$/\ G^?_ +]UL?\ ""^&/^@-:_\ ?)H_X07PQ_T!K7_O
MDT7I=F%JOD8__"V_"'_/\_\ W[H_X6WX0_Y_G_[]UL?\(+X8_P"@-:_]\FC_
M (07PQ_T!K7_ +Y-%Z79A:KY&/\ \+;\(?\ /\__ '[H_P"%M^$/^?Y_^_=;
M'_""^&/^@-:_]\FC_A!?#'_0&M?^^31>EV86J^1C_P#"V_"'_/\ /_W[H_X6
MWX0_Y_G_ ._=;'_""^&/^@-:_P#?)H_X07PQ_P! :U_[Y-%Z79A:KY&/_P +
M;\(?\_S_ /?NC_A;?A#_ )_G_P"_=;'_  @OAC_H#6O_ 'R:/^$%\,?] :U_
M[Y-%Z79A:KY&/_PMOPA_S_/_ -^Z/^%M^$/^?Y_^_=;'_""^&/\ H#6O_?)H
M_P"$%\,?] :U_P"^31>EV86J^1C_ /"V_"'_ #_/_P!^Z/\ A;?A#_G^?_OW
M6Q_P@OAC_H#6O_?)H_X07PQ_T!K7_ODT7I=F%JOD8_\ PMOPA_S_ #_]^Z/^
M%M^$/^?Y_P#OW6Q_P@OAC_H#6O\ WR:/^$%\,?\ 0&M?^^31>EV86J^1C_\
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<% !1110 AI%ZT44#0II:** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img46421407_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_4.jpg
M_]C_X  02D9)1@ ! @$ P #   #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\O/T]?;W^/GZ_\  $0@#( ;[ P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M .>-Y_W[A_\ DBC^S*W\T/OE_P#(A_:='^6?W1_^2#_A<>C_ //&\_[]P_\
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M<>C_ //&\_[]P_\ R11_9E;^:'WR_P#D0_M.C_+/[H__ "0?\+CT?_GC>?\
M?N'_ .2*/[,K?S0^^7_R(?VG1_EG]T?_ )(/^%QZ/_SQO/\ OW#_ /)%']F5
MOYH??+_Y$/[3H_RS^Z/_ ,D'_"X]'_YXWG_?N'_Y(H_LRM_-#[Y?_(A_:='^
M6?W1_P#D@_X7'H__ #QO/^_</_R11_9E;^:'WR_^1#^TZ/\ +/[H_P#R0?\
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M^>-Y_P!^X?\ Y(H_LRM_-#[Y?_(A_:='^6?W1_\ D@_X7'H__/&\_P"_</\
M\D4?V96_FA]\O_D0_M.C_+/[H_\ R0?\+CT?_GC>?]^X?_DBC^S*W\T/OE_\
MB']IT?Y9_='_ .2#_A<>C_\ /&\_[]P__)%']F5OYH??+_Y$/[3H_P L_NC_
M /)!_P +CT?_ )XWG_?N'_Y(H_LRM_-#[Y?_ "(?VG1_EG]T?_D@_P"%QZ/_
M ,\;S_OW#_\ )%']F5OYH??+_P"1#^TZ/\L_NC_\D'_"X]'_ .>-Y_W[A_\
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MHIMV<KV2OI[I<,QI5)1IJ,[R:2NHVNW;7WCT?[2/0UXY[ GV@>AH /M ]#0
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M_9E;^:'WR_\ D0_M.C_+/[H__)!_PN/1_P#GC>?]^X?_ )(H_LRM_-#[Y?\
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M^2#_ (7'H_\ SQO/^_</_P D4?V96_FA]\O_ )$/[3H_RS^Z/_R0?\+CT?\
MYXWG_?N'_P"2*/[,K?S0^^7_ ,B']IT?Y9_='_Y(/^%QZ/\ \\;S_OW#_P#)
M%']F5OYH??+_ .1#^TZ/\L_NC_\ )!_PN/1_^>-Y_P!^X?\ Y(H_LRM_-#[Y
M?_(A_:='^6?W1_\ D@_X7'H__/&\_P"_</\ \D4?V96_FA]\O_D0_M.C_+/[
MH_\ R0?\+CT?_GC>?]^X?_DBC^S*W\T/OE_\B']IT?Y9_='_ .2#_A<>C_\
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M]IT?Y9_='_Y(/^%QZ/\ \\;S_OW#_P#)%']F5OYH??+_ .1#^TZ/\L_NC_\
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M,K?S0^^7_P B']IT?Y9_='_Y(/\ A<>C_P#/&\_[]P__ "11_9E;^:'WR_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H V_#7_(6LO\ K[M__1R5RXC^#4_P3_\ 26=.'_C4
M_P#'#_TI'U_7P!]^% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'RA\2'QXCNQ_P!</_2:&OLL"_W$%_B_]*D?'8Y?
MOYO_  _^DQ.27I7K(\@=3 * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9?\ 7W;_ /HY*Y<1_!J?X)_^DLZ</_&I_P".'_I2/K^O@#[\* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /DSXD_\
MC+=_]L/_ $FAK[# _P "'_;W_I3/C\;_ !Y_]N_^DHY9.E>PCR&.IB"@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@"Y86;ZC<Q6<1427$J1*6R%#2,$!8@$@ D9P"<= >E9SDJ<9
M3>T4V[;V2OH7"+J2C36\FDK[7;MJ>D2?"34XCM>YL%/H9I0?R,%>2LQI/:%3
M_P !C_\ )'K/+JJT<Z:_[>?_ ,B0R_"?6%0O!):7)4?=BF;)/H-\:+D]LL![
MU2S&C>TE./FXK]&W^!+RZM:\7"7E&3_5)?B>=WEE/ITS6UTC0RQG#(XP1_\
M6(Y!'!&""0<UZL91FE.#3B]FCRI1E3;A---;IE6K)"@ H * "@ H ZS0/",W
MB"%IXKFSMPC["MQ*T;DA5;( C;*_-C.>H(QQ7#6Q,:$E%PG*ZO>,;KMW6IVT
M<-*O%RC.$;.UI2L_R>FIN_\ "L[K_G^TS_P)?_XS7/\ 7X?\^ZO_ ( O_DCI
M^HS_ .?E+_P-_P#R)!JOPXOM'L7U*:XLW@C .8Y9&+98* F855B2>FX55/'4
MZLU1C&:D^Z2MUU]ZZ^XBI@:E*#K2E!Q79MWZ:>ZE^)Y[7J'F!0 4 % !0 4
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M<N(_@U/\$_\ TEG3A_XU/_'#_P!*1]?U\ ??A0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\F?$G_ )&6[_[8?^DT
M-?88'^!#_M[_ -*9\AC?X\_^W?\ TE'+)TKV$>.QU,04 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MY[7J'F!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'W%:G*U^<,_1D7*DH* "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H P]=_P!2O^^/_06K.>WS ^0M=_Y"-U_U
M\S?^C&K]"PW\"E_U[A_Z2CX#$?QJO_7R?_I3,JNLY@H * "@ H * "@ H *
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M/.UDODOS/'Z]T\(* /;O 7_(K:Q_USN?_26OG<9_O5#UA_Z6?0X/_=:_I/\
M](/$:^B/G@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#;\-?\ (6LO^ONW_P#1R5RXC^#4
M_P $_P#TEG3A_P"-3_QP_P#2D?7]? 'WX4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?)GQ)_Y&6[_P"V'_I-#7V&
M!_@0_P"WO_2F?(8W^//_ +=_])1RR=*]A'CL=3$% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &]
MX6_Y#%A_U^6W_HY*YL1_!J?]>Y_^DLZ</_&I_P".'_I2.W^,'_(:C_Z](_\
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M]&)KYN?^U8Q4]X4]_EJ_OE:+\CZ.'^RX-S6DZFWST7W1O)>9X77TA\X% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'W!9_=K\X9^C(O5)04 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!AZ[_ *E?]\?^@M6<]OF!\A:[_P A&Z_Z^9O_ $8U
M?H6&_@4O^O</_24? 8C^-5_Z^3_]*9E5UG,% !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Z3\
M*?\ D/1_]<IO_0:\G,/X#_Q1_,];+_XZ])?D0^/-)O;C7;N2&WGD1I%PRQ.R
MG]V@X(4@\\<4\)4A&A!2E%.ST;2>[\R<73G*O-QC)JZU2;6R\BIX=\!:GKEP
MJ20RVUN&'FRRJ8\+GYM@< N^,@  @'&X@<UI7QE*C%M24I6TBG?7SMLOZ1G0
MP=6M))Q<8WU;5M/*^[_IG2?%3Q#!>2PZ/9,&AL<^85Y7S<; @/?RE!!(/WF*
MGE37)E]&4%*O45I3VOO;>_S?X*_4[,PK1DXT*?PPWMM?:WR7XNW0ZGX@7-YI
M.D62:$6AT\I^\DM\C"[4,677YE5\N6;^,\,><-Q8.,*M:H\39U+Z*7J[Z/JM
M++IT\NS&2G2HTUAKJG;5Q]%;5;)ZZ]>OGE?"_P /:BVH-K%\LB1K&RJTVX/(
M[X&5#?,5"YRQXS@+GYMN^/K4U35"FTW=-J-K)+TTO?I]_2^& HU/:.O432LT
MG*]VWZZVMU_X)P/C*:2R\174T9*217/F(>X(VLI_D17IX5*>'A%ZIPL_Q3/-
MQ+<,1.2T:G=?@T?0<$-GJLMIXM;:B0V4I8G&5)"MDG.!Y0-PC9/!;KQ7R[<Z
M2G@5>[J*WGO_ .E>ZT?4)0JN&.=DE3=_+;_TGWDSY=UC4GUB]FOI,[IY&?!_
MA!/RK]%7"CV K[&E!4H1IK:*2_S?S>I\;5FZLY5']IM^G9?):&96QD% 'MW@
M+_D5M8_ZYW/_ *2U\[C/]ZH>L/\ TL^AP?\ NM?TG_Z0>(U]$?/!0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % &WX:_Y"UE_P!?=O\ ^CDKEQ'\&I_@G_Z2SIP_\:G_ (X?
M^E(^OZ^ /OPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % 'W!9?=K\X9^C(O5)04 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!AZ[_ *E?]\?^@M6<]OF!\A:[_P A&Z_Z
M^9O_ $8U?H6&_@4O^O</_24? 8C^-5_Z^3_]*9E5UG,% !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!I:3J]UH<XN[%_)F4%0VU&X88(PZLO(]OI6-2G"M'DJ*\>UVMO1IFM.I
M.C+GINTN]D]_5-'5?\+,\1?\_?\ Y MO_C-<?U##_P G_DT__DCM^O8C^?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MP"[#%Y8^ZO(0'CKR:[50I_6'2<?<4;VN]].M[G$Z]7ZO&JI>^Y6O9;:]+6_
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 ?<%E]VOSAGZ,B]4E!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M.E"C'DI)17]=7JR*E2=:7/4;;_KHM%\C-K8R"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MYPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M:'LU1O+E3YMU>_W6Z]C4\3>!M.\67%K=7WF![)MRB-E59%+(_ERAD8M'N0'
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M* L'E"@+!Y0% 6$\H4!87R@* L)Y0H"POE 4!83RA0%A?* H"PGE"@+!Y0%
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M%%PL'E"@+">4* L+Y0%%PL C H"Q9B&!2&24 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 &* "@!* %Z4 )0 O2@!* %Z4 )0 =* "@ Z4 % !0
M4 % !0 4 )0 4 % !0 4 '2@ H .E "4 +TH 2@ H * "@ H .E "4 +TH 2
M@!>E "4 '2@ H * "@!* "@ H * #I0 E "]* $H 6@!* "@ H * $H 7I0
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M))D^[(H8?1AD?SK[Z$E4C&<=I)->C5SX.<73E*G+>+:?JG8FQ6A 4 )B@!:
M$H * "@ Z4 % !TH * "@ H * "@!* %H 2@ H ,T &* "@ H .E "4 +TH
M2@ H * "@ H * #% !0 E "]* $H .E !0 =* "@!* "@ H * "@ H .E "4
M +TH 2@ H * "@ H 2@ H .E !0 =* "@!* "@ H 2@!>E "4 '2@":/I0 ^
M@ H * "@ H * "@ H * "@ H * "@ H \G^'*_VIJ&LZ\_+7%\UK$2<D0VH
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M@!* "@ H * "@ H .E "4 +TH 2@ H * "@ H 2@ H .E "4 +TH 2@ H *
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M_ 3\R_S('^[5Y75]I0Y'O3;7R>J_5?(C,Z7LZ_.MIJ_S6C_1_,ZZO</$%Q0
ME !0 4 % !0 4 % !0 4 % !0 4 )0 M "4 '2@ H .E !0 8H * "@ H 2@
M H * "@ H 2@!>E "4 &,4 % !B@ H * "@ H 2@ H * #I0 4 &* "@!* %
MZ4 )0 4 % "4 +0 E !B@ H 2@!: $H * "@ H ,4 % "4 '2@ H FCZ?C0
M^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#%UW_4+_ -=!_P"@
MM6<]OF,TK/\ U$?_ %S3_P!!%6MEZ"+%, H * "@ H * "@ H * #I0 4 '2
M@!* %Z4 )0 O2@!* %Z4 )0 O2@!* "@ H * "@ H * "@ H * $H 7I0 E
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M H * "@ H * "@#AO$WA>XO]0L=;TMHX[ZP?8XE+*DUJ^1)$S(CD,-S&,["
MS,3V(ZJ=11C*E._++MNI+9]/F<E6DY3A5IV4XO6^SB]UHG\M#K;O3[;4 @NX
M8IQ$XD02HKA)%^ZZ[@=KKDX88(SP:YU)Q^%M7T=G;3L=+BI6YDG9W5U>S[^I
M<J2C/U5;M[29=.,8NVC80F4L(U<C"LQ57;"GYL!3G&.,Y%QY5)<]^6^MM[?@
M1/FY7R6YK:7VO^)B^#?#*>$],CT\-YDN6DGEY_>SR<R/SSCHJYYV*N><UI6J
M>UFY[+9+LELC*C2]C!0W>[?=O=_UT.JK Z H * "@ H * "@#(;_ (^F_P"
M_P#H(H Z2#I0!/0 4 % !0 4 % !0 4 % '#^+?$+Z?_ *';'$KKEG'5%.0
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M[+S/DL9A/J<HQ4N923:=K;/5;OR.@KU#S!>E "4 '2@ H * "@ H * "@ H
M* $H .E !0 =* "@ Z4 % !TH 2@!>E "4 % !0 4 % !0 E "]* $H 7I0
ME !TH * "@ H 2@ H .E !0 =* $H 7I0 E !0 4 % !0 4 )0 O2@!* #I0
M 4 % !0 E !0 4 )0 O2@!* "@ H * "@":/I0 ^@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#%UW_ %"_]=!_Z"U9SV^8S2L_]1'_ -<T_P#0
M15K9>@BQ3 * "@ H * "@ H * "@ H * "@ H 2@!>E "4 +TH 2@!>E "4
M'2@ H * "@ H * "@ H * $H * "@ Z4 % !TH * #I0 E "]* $H * "@ H
M * "@!* %Z4 )0 O2@!* #I0 4 % !0 E !0 4 % !TH 2@!>E "4 % !0 4
M % !0 E "]* $H .E !0 4 % "4 % !0 E "]* $H * "@ H * "@!IZ'Z4
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MFI0JK[,OPDO\TCU.OLSXX* "@ H .E !0 4 % !0 4 )0 M "4 % !F@ Q0
M4 % !TH 2@!>E "4 % !0 4 % !0 4 % "4 +TH 2@ Z4 % !0 4 )0 4 %
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M "@ H * "@ Q0 4 )B@ H * #I0 4 '2@ H 2@ H * "@ H * #I0 E "]*
M$H * "@ H 2@ H * #I0 E "]* $H * "@ Z4 )0 O2@!* #I0 4 % !0 G2
M@ H #T/TH JT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % &0W_'RW_ ?_010!TD'2@">@ H * "@ Z4 % !TH *
M.'\<:C]GMEM$.&G.6]D7!_\ 'FQ^ (KYW-:_LZ:H1WF]?\*_S=ON9]#E='GJ
M.M+:"T_Q/_)7^]%[PCIOV"R#L,27'[QO]W^ ?E\WU8UTY;0]A04FO>J>\_3[
M*^[7YLYLQK^VK.*^&'NKU^T_OT^2.JZ5[)XXE "]* $H 7% "4 % 'DJ?\2O
MQ#CHK3D>VV8<?@-X_*OB%_LV86V3J?A4V_\ 2C[5_P"T8"_54_QI[_\ I)ZM
M-*MO&TLAPB*68^@ R?TK[24E3BYRT44V_1:GQL8N<E".[:2]7H>4+XVOT=F
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M:I\S6LDELNZ[VZZ+TT9V->\>$% !0 4 )0 M "4 '2@ H .E !0 8H * "@
MH 2@ H * "@ H 2@!>E "4 &* "@ H * "@ H * $H 6@!* #I0 4 &* #-
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M E !TH * "@ H 2@ Q0!/'T_&@!] !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % &+KO^H7_KH/\ T%JSGM\QFE9_ZB/_ *YI_P"@BK6R]!%BF 4
M% !TH * #I0 4 '2@!* %Z4 )0 O2@!* %H 2@ Z4 % !0 4 % !0 4 % !0
M 4 % "4 +0 E !TH * #I0 4 &* "@ H * $H * "@ H * $H 7I0 E "XH
M2@ Q0 4 % !0 4 )0 4 % !TH * #% !F@!* "@ H * "@!* %Z4 )0 8H *
M $H 7I0 E !0 4 % !B@ H 2@ H * "@ H 2@ Q0 9H 0]#]* *U "4 &: $
MW"@ W"@ W"@ W"@ W"@ W"@ W"@ W"@ W"@ W"@ W"@ W"@ W"@ W"@ W"@
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M0 4 % !TH * #I0 4 '2@!* %H 2@ H * "@ H .E "4 +TH 2@!>E "4 %
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MW^\@OOCT?JMG\GU.;,<+["?M8+W)O_P&75>CW7S70ZVO=/#"@ H * #I0 E
M!0 4 % !0 4 )0 =* "@":+I^- $E !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % &+KO^H7_ *Z#_P!!:LY[?,9HV?\ J(_^N:?^@BK6R]!%FF 4
M % !B@ H * "@!* %Z4 )0 O2@!* %Z4 )0 O2@!* #I0 4 % !0 4 % !0
M4 % "4 '2@ H .E !0 =* "@ Z4 )0 M "4 % !0 4 % !TH 2@!>E "4 +T
MH 2@ Z4 % !0 4 )0 4 '2@ H .E "4 +TH 2@ H * "@ H * $H 7I0 E !
MTH * "@ H 2@ H * $H 7I0 E !0 4 % !0 4 )0 =* "@ H 0]#]* *U '(
M>,_^/-/^NR_^@25\]F_\"/\ U\7_ *3,^@RG^/+_ *]O_P!*@>9U\2?:!0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ':^#Y/+,
MP]?+_P#9Z^IRAV]K_P!N?^WGR^;+^%_V_P#^V'H,;9KZU'RCT,QO^/IO^ _^
M@BF(Z6#I0!/0 =* "@ Z4 % !0 4 9.MWAT^REN%X95PO^\Q"J?P)S^%<6*J
M^PHSJ+=*R]7HON;N=N%I>VK0IO9N[]%J_O2L<9X#L<F6];M^Z7]&<_\ H(_$
MUX&44OCQ#Z>XOP<OT_$][-JMN3#K_&_Q4?U_ ](Q7UA\H+0 E "]* $H * "
M@ Z4 </XYM#/;12H"S)+MP!DX<=OJRJ/QKYW-J;G3A.*NXSMIO[R_P TCZ'*
MJBA4G!NR<;^7NO\ R;,W0_!A;$^H_*.HA!Y/^^1T_P!T<^I'(KDPF5MVJ8K1
M;J'_ ,D^GHM>[6QUXK,TKT\+J^L^W^%=?5Z=D]STA5" *HP , >@'05]8DDK
M+9;'RC=W=[L=3$% !0!YCXJT%K*3^T;,%5R&<+QL?/#C'0$]?[K<]#Q\?F&$
M=&7UO#JRO>27V9?S+R;W[/R>GUV7XM58_5:^KM:+?VE_*_-+;NO-:Y]GX:U#
M6PUU<-L+<JTN2S^G'55]#_WR"*YJ6!Q&,O6JRY;[.=[R^71?TE8Z:F.H8.U&
ME&]MU"UH_/J_Z;N/7PYK=O\ NHBPC']R?:A^@W*?S452P6-I^Y!OE_NU+1^Z
MZ?X">-P4_?FES?WJ=Y??9K\2[X-U"5+R2TG9BTB\;B20\9.1S[%B?I6^65I1
MK3H56VY+J[OFC?37R;^XY\SHQ=&%:DDE%]%9<LK:Z>:7WGIN*^P/D0H ,4 %
M !0 C,$!8D  9)/  '4D^E)M)7>B6[&DV[+5O9'E.L^*+B[N0-/9DBA)*E1R
MY .688Y7&< C&.3[?%XK'U*M5+"MJ$+M6^U;=M?RVV3Z:OR^SPN ITJ;>)2<
MIV3O]F^R3[WW:ZZ+SZ#1/&,5V1!> 0RG@./N,??/W"??*^XX%>GA<SC5M3Q%
MH3V4OLOU_E?X>:V/,Q66RI7J4+RANX_:7I_,OQ\GN=M7T1\\% !0 4 % !0
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MJQ_L_&)QTA=27^"6Z^6J^1]S2E]?PC4M9V<7_CCL_GH_F>MCGD5]WZ'PVP4
M)0 O2@!* #I0 4 % !0 E !0 =* $H 6@":+I^- $E !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % &+KO^H7_KH/_06K.>WS&:-G_J(_^N:?^@BK
M6R]!%GI3 * #I0 4 '2@ H ,4 % !B@ H 3% "T )0 4 % !0 4 '2@ H *
M"@ H * $H 6@!* "@ S0 8H * "@ Z4 )0 O2@!* "@ H * "@ H * "@!*
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M.E !0 4 % "4 % !0 E "]* $H GBZ?C0!)0 4 % !0 4 % !0 4 % !0 4
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M4 % !0 4 % !0 4 % !0 4 % !0 E "T )0 =* "@ Z4 % !0 4 )0 M "4
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MNWYZW_IWWIX6G+!NNT_:<DI*5W=<M[)>6EOZ5N/U^W2UOYHHAM17X Z#(#8
M[ $\#L.*\+&0C2KU(05HJ6B[72=EY:Z'N82<JE"G.;O)QU?>S:U\]-3'K@.X
M* "@ H ZOPOPTO\ P#_V>OI\I_Y>_P#;G_MY\UFO_+K_ +?_ /;3T6 \5]:C
MY)E)O^/IO^ _^@BK).EA^[0!/0 =* "@ Z4 )0 O2@!* /)_%KF_U1+1/X!'
M$/\ ><Y_]F4?A7Q.8MU\5&A'IRP^<G?]5]Q]IER5#"RK2Z\T_E%6_1_>>JQQ
MB)1&O"J H'H ,"OM(I12BMDDEZ(^-DW)N3W;;?JR3I5$B4 +TH 2@ Z4 % !
M0 4 % !0 4 % !0 E !TH * #I0!Q'C;3FNX(YXE+O&^W"@DE7]AR<,!CZFO
MGLUH.I"%2";E&5K)7=I>GFE]Y]!E=94IRIS:491O=NR3C_P&_N.=MO!=[<1-
M+,RQ28^1&Y8^@8@X3CIU(Z$"O)AE=:I!SFU&5O=B]6_5[1TVW\TCU9YG1IR4
M()RC?62T2]%UU]/)L9IGB*[\/L;.Z0NB'&QCAT_W6Y!7N!R#_"0.LT,;5P+]
MA6BW%?9>DH^CUT\MNS15?!4L:O;T9*,G]I:QEZK37SW[IGHFDZW;:PI,!(9,
M;D88(ST]01P>A/OC(KZK#XNGBT_9-W5KIJS5_P '\F?+8C"U,(TJB5G>S3NG
M;\5\T:]=YPATY/% 'D0_XJ76?6'?^'E1_P#Q>/S>OA?^1AC.\+_^21_^2_.1
M]Q_R+\'VG;_R>7^7Y1/70,5]T?#A0!G:CI5MJB;+E V/NL.&7Z-U_#D'N#7)
M7P]/$KEJQOV>S7H_TV\CJHXBIAGS4I6[K=/U7Z[^9YIJWAZY\/G[7:R,T:G[
MZY5TSTW8Z@],C@]"!D9^1Q&"JX%^WHR;BG\2TE'UMT>U]NZ1];A\92QJ]A6B
ME)KX7K&7I?KUMOV;.[\/:XNL0?-A9X^)%]?1P/0_H>/0GZ7!8M8N&ME4C\2_
M]N7D_P 'IV/G,9A'A)Z:TY?"_P#VU^:_%:]SH*]0\L7I0 E &3KM\=-LI9U.
M' VI_O,=H/X9W?A7#BZWU>A.HM)6M'U>B^[?Y'=A*7MZT*;^&]Y>BU?W[?,-
M&U5-7MUG7 <<.O\ =8=?P/5?;W!HPN(CBJ:J+1[279_Y/=>0L5AWA:CIO;>+
M[K_-;/S-:NXX@H * "@!* "@ H * #I0 4 '2@!* "@ H * "@ H X+Q3K]Q
M93K:6;;6VY<A0QRQ^51D'!P,\#/S"OF<PQE2C-4,.[.UY-)-W>R5T^FOS1]+
ME^#IU8.O75U>T5=I66[=K==/DS&A\.:IJLJR7Q94R,M(X+!>X5<G'L" ,UY\
M<#BL5)2Q+:75RE=I=;*[MZ:(]"6-PN%BXX9)OHHQLF^EW97]=6>GV]NEK&L,
M0VH@ 4>P_J>I/<\U]E"$:453@K1BK)'QTYRJ2=2;O)N[9-6AF(>>#TH#8YC1
MM &EWD\XQY;8$7LK'<P]L$!1[#/>O&PN#6&K5:B^%V4/)/5KY.R7D>SBL8\3
M1I4_M*[GYM:)_--M^9U%>R>,)0 4 % &7K-G]OLY8 ,ED)7_ 'E^9?U %<>*
MI>WHSI]7&Z]5JOQ1V86K["M"IT4K/T>C_!GD-E?WBQ&PM2V)GR53[Q)&" 1R
M 0!G&.!R<9KX*E6K*#PM!NTY7M'=NUK>CZ^FNA]W5HT7)8FLE>"M>6R5[W]>
MWKIJ=3%X,9+21YFS<["413\JD<X)_B)QMXX&>,\&O:CE35&4JC_>\MXQ6R:U
ML^[>W97Z[GBRS1.M&--6I7M*3W:>EUV2W[NW38F\#W_$EDQZ?O$_0./_ $$X
M^IK7**WQX=_XX_E)?D_O,\VH_!B(_P"&7YQ?YK[CT*OJCY8* "@ H 2@ Z4
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M-/\ T$5:V7H(LTP"@ Z4 )0 O2@!* %Z4 )0 O2@!* %Z4 )0 =* "@ H *
M"@ H * ,W5[QM/LY;A,;HT)7/3<>!G\2/K7)B:KH49U8[Q6E^[T7XLZL-25:
MK"D]F];=EJ_P1Y8ESK6LJTL3RR(GWMC!!D#. JE=QQV )Z5\8JF-Q:<X2G*,
M=^5J*[VLK7?DKL^R<,'A&H3C",GMS)R?:]W>R\W9&OIGC5[:(Q7RM+(@PC#
M+=L/GH1_>P2>XSR>^AFCIP<,1%RDOA:T;\I7_/7S5]^&OE:J34\.U&+W3V7G
M&WY:>3ML:9XRN)KU5N=@@D;;M QLSPIW=3@XW9XQDX'&%0S.I*LE5Y53D[62
M^&^SOOOO?2U]@KY93A1;I7]I%7NW\5MU;;;:W6VYZ;7V!\B'2@ H .E !0 =
M* $H 6@!* "@ H I:C<_8K:6<=8XV8?4 X_7%<]>I[&E.JMXQ;7JEI^)T48>
MUJPIO:4DGZ-Z_@>>^!K3SKB6[?DQ@*,_WGR2?J "/^!5\ME-/GJ3KR^RK+UE
M>[^Y?B?3YK4Y*<*$=%)W?I&UE][_  +WCG3@8X[U!@J=CX]#RI/T.1_P(5TY
MM1O&.(BM4^67H]4_D[KYG/E5:TI8>3T:YH^JW7S5G\CH_#=__:%C&Y.7C'EO
M_O+@9/U7#?C7K8&M[>A&3^*/NR]8_P":L_F>5C:/L*\HKX7[T?1_Y.Z^1O=*
M](\T2@!>E "4 '2@ H * "@!* "@ H * #I0 E "]* $H * "@ H * "@!*
M%Z4 )0 =* "@ H * $H * "@ H .E "4 % !0 4 % !0 E !TH * "@ H 2@
M H * ,+Q),\&GS/$S(X"8925(S*@.",$9!(/L:\S'RE3PTY0;C)<MFFTU[\5
MNM=CTL!&,\1",TI1?-=-)KX)/9Z;CO\ A&%_Y^[[_O\ C_XBH^I?]/\ $?\
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M=R:YMM&[/8YH87$PG5K<\/:5(V3]Y6=U_=V44^7?5*ZW*VJZCI^K3>=*]TH
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MXHO=?YKL_P!=#Y7$8:IA9<M1:/X9+9_Y/NO^'-6NTX@Z4 )0 =* $H 6@!*
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MI.Z5VM5=7T:[LI5SG0% !0 4 % !0 4 % !0 4 % !0 4 =IX/\ O3?]L_\
MV>OI\I_Y>_\ ;G_MY\UFO_+K_M__ -M/4;?I7UJ/DF>;6QQ?7/\ U]3?^AFO
M'PF]?_L(J?H>QB]J'_8/3_4]%L^5%>RCQV7NE42)0 O2@!* %H 2@#GO%%]]
M@T^0@X>7]TOU?K^2[C]:\O'U?8X>36\O<7_;V_X7/4P%+VU>*>T???\ V[M^
M-C#\"6/E027;#F5MB_[J=<?5CC_@->=E-+EA*N]Y/E7I'?[V_P #T,VJ\TXT
M5M%7?K+;[DOQ.]Q7TI\V% !0 4 % !0 4 % !0 4 % "4 +0 E !TH * #%
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M?,9HV?\ J(_^N:?^@BK6R]!%BF O2@!* %Z4 )0 N* $H * "@ H * "@ H
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M )0 4 % !0 F* "@#G?%/_(-F_[9_P#HV.O)S'_=:G_;O_I<3U<N_P!ZI_\
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M0C4FXM2=ERMOI>^R5K>8J&,IXF<J<%).*N^9)=;6W;O\C"KS3T0H * "@ H
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M=?S_ "9]GC(+&855J:NTE-=[6]Y?+\T>LU]P?$A0 4 '2@ H .E "4 % !0
M4 % !0 E 'E?B2Y?5]16QA.5C81@=MY/SL?]WH?0*:^)QU26+Q*PU-Z1:@NW
M,_B?RV^1]I@:<<)AGB*BUDG)]^5?"OGO\ST+3-+ATF$0P#W9C]YSZG^@Z 5]
M7A\/#"P]G37J^LGW?Z+H?+8C$3Q,_:5'Z+I%=E^KZFEBNLY H * "@!* "@
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MA6#_ +:?^BI*Y\N_WJG_ -O_ /I$CHS'_=:G_;O_ *7$VO#3%M<G)ZGS\_\
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MGMZ7/5*^S/C@Z4 % !TH * "@ H * "@!* "@ H ,4 % !0 =* "@ Z4 )0
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M<E?S*K7Q&$_V?'.ETYIP^6K7WV1]KB_W^"53KRPG\]$_S9ZK7VY\4% "4 %
M!TH 2@!>E "4 % %B+I^- $E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % &+KO^H7_KH/\ T%JSGM\QFC9_ZB/_ *YI_P"@BK6R]!%C%,!: $H
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M,%XSO5HSH-*=M=FMC"C7A73<+Z;IZ/R?S.TS7,=(8H * $H 6@!* "@ H *
M"@!* %H 2@ Q0 4 % !TH * #I0 S8N[?@;L8SCG'7&?3/.*5E?FMK:U^MNP
M[NW+?2][=+]QU,0M #6 <%2,@C!!Z$'J*32:L]F-.SNM&CRGPZ?[-UEK8\ F
M6'\LE?S*C'UKXG _[/C'1>S<X?=JOOY5]Y]IC?\ :,&JJW2A/[]']W,SU?-?
M;GQ08H * $H 7I0 E !0 4 % !0 E 'F_C:_,DD=C'SM^=P.['A!]0,G_@0K
MY'-JW-*.&CT]Z2\WI%?==_-'UF54>6,L3+K[L?1:R?WZ?)G::-8#3+2.W_B
MR_\ OMRWY'@>P%?0X6C]6HPI=4KR_P 3U?\ EZ(^?Q5;ZQ5E5Z7M'_"M%_GZ
MLTZ[3C%Z4 )0 4 % !0 4 '2@!* #I0 4 % !0 E !0 4 )0!Y9KO_$OUI9^
M@+12_AP&_,J:^(QG^SXU5=E>$_EHG]]F?:X/]_@G2ZVG#YZM?FCU.OMSXH*
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MG77_ #QE_P"_;_X4?5ZW_/JI_P" 2_R#ZQ1_Y^4__ X_YA_9UU_SQE_[]O\
MX4?5ZW_/JI_X!+_(/K%'_GY3_P# X_YA_9UU_P \9?\ OV_^%'U>M_SZJ?\
M@$O\@^L4?^?E/_P./^8?V==?\\9?^_;_ .%'U>M_SZJ?^ 2_R#ZQ1_Y^4_\
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M[7JM&OS^9Y&%J.C57-HI63]'JG^7R/NWI7RY]8% !0 4 )0 4 % !0 4 )0
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MST^%ZK_+Y?D>AAJRK05_CCI+_/Y_F>F=*XCN$H * "@ H * "@!* %Z4 )0
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M9I0YXQQ4-;:2MUB]G\F[?-=CT:OKSY(7I0 E !0 4 )0 4 '2@!* .?\4_\
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MXPH * "@ Z4 )0 =* "@ H * $H * #I0 E "]* $H * "@ Z4 )0 O2@!*
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MDH)SEHDFWY):LJ,7-J$=6VDEYO1'D^CQ-XAU8W,H^16\U@>P4@1I_P"@C'<
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M/%K,<*T[<]K/RG'5>E]/DSUQ6#@,IR",@CN#7W2::NMGL?#M6=GNAW2F(2@
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M 8H * "@ H * $H * "@!* %Z4 6(>GXT 2T % !0 4 % !0 4 % !0 4 %
M!0 4 96MZ):>(;233]0C$L$HY'0@CE65ARK*>01]#D$@@')V7PWL+>YANKJX
MOM1-H0UO'>W'FQPL/NLB!$R5P,%RW0'J : -S_A%;7^VO^$AWR_:OL_V;9N3
MRMF<YV[-^[/?S,?[- &/J'P\LKRZFO+>YO\ 3VO#NN4L[CRHYVZ%I$*/\Q&0
M2I4G)/4DD ZK1]'M= M(]/L4$4$ PJCD\G)9B>69B2S$\DDF@#3H Q==_P!0
MO_70?^@M6<]OF,T+/_41_P#7-/\ T$5:V7H(LTP"@ H * "@ H * "@ H 2@
M!>E "4 '2@ H .E !0 =* .0\:7IMK'RE.#.X4_[H^9OY 'V->%FE7V=#D6\
MVE\EJ_T7S/<RRE[2OSO:";^;T7ZOY!X,L!:V7GG[]P2Q_P!U254?S;_@5&5T
M52H>T^U4=_DKI+\W\PS.K[2M[-?#35OF[-O\E\CKZ]T\,2@ H * "@ H 2@!
M>E "4 +TH C5%0DJ I8Y. !D^I]34J*C=I)7WLM_4IMNR;;MMY>A2U+2X-5B
M\JX7/]UAPRGU4_S'0]Q7/7P]/$QY*J]&MT^Z?])]3HH5YX:7/2=NZZ-=FOZ:
MZ'F\OA_5=&E9K$NR=GC(!8=@R9R2/3##T-?)2P6+PDV\,Y./\T':Z\XW_1KL
M?5QQF%Q<4L0HJ7\LEL_*5OU3)_#.F7<VHF[NXY%V;W9I%*Y=LCN!D_,6XX&!
MTXK7 4*LL3[>O&2Y>:3<DU>3TZI=V]-K>AGCJ]*&']C0E%WY8I1:=HK7I?M;
M7>_J>HU]D?'"4 % !0 4 '2@ H .E #)(UE4QN RL""",@@]01Z5,HJ2<9)-
M-6:>S3*C)Q:E%V:=TUNF<K/X+T^8Y3S(?9&R/_'PW\Z\6>5X>6L>:'^%_P#R
M29[,,TQ$-)<LO56_]):-W3]-M]+C\JV7:.YZLQ]6/?\ D.P%>G1H4\-'DI*R
MZOJ_-O\ I+H>;6KU,1+GJN_9=%Y)=/S[E^NDYCR:;_B1ZYN^[&90WMLE^]^"
M[B/JM?#R_P!BQU]H\]_^W9[_ '7?W'V\?]LP/+O+DM_V]#;[[+[SUFON#X@2
M@!>E "4 &* "@ H * $H * "@ H ,4 % "4 <OXJU=M,MQ'"<2SY4'NJ@?,P
M]^0!Z9SU%>+F.)>&IJ-/2<[I/LENUYZI+UOT/9R[#+$5'*?P0LVN[>R?EHV_
M2W4R_".AB%1?SCYW'[H'^%3_ !_5NWHO/?CBRS"<J6*J+WG\"[)_:]7T\O4[
M,RQ?,WA:3]U?&^[7V?1=?/T.\KZ<^:"@!* "@ S0 E "]* $H * "@!* #%
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M3=-[Q?X/7\[GO72O*/7$H 7I0 E "]* $H .E !0!\X?M&3;;'3X?[\\K_\
M?$:C_P!GKV, O>F_)?B_^ >)F#M&"\W^"_X)ZK\,X?L_AC34Z9MD?_OLE_\
MV:N'$.]6?K^6AZ&&5J,%_=_/4[FN4ZSY3_:'T4P75GK,8QYJ-;R$<8:,^9&?
MJRNX!ZX0>E>[@9W4J;Z:KYZ/]/O/G\PA:4:JZJS^6J_-_<?0W@W7%\1Z-::D
M"&:>%/,QVE4;)1^$BL*\BK#V<Y0[/3TZ?@>S1G[6G&?=:^O7\3IJQ-PZ4 %
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M\^K].B\M>IU5>V>*)0 O2@!* "@ H * "@ H 2@ Z4 % !0 4 )0 4 % "4
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M4850 !Z # _2OM8I12C'1))+T1\6VY-R>[;;]6/JB1* #I0 4 % !0 E !0
M4 )0 O2@!* "@#S#Q5:-IMZE[#\OFG>".TB8S^?!]SNKXO,:3PU>.)IZ<SYO
M2<;7^_1^>I]GEU18BA+#5->5<OK"5[?=JO+0]%LKD7D$<XX$B*V/3(R1^!XK
MZZE456G&JM.:*=NUUM\CY*K3]C4E2?V9-?<]_F6:V,0Z4 )0 N* $H * "@#
MGO%/_(-F^D?_ *-CKR<Q_P!UJ?\ ;O\ Z7$]7+O]ZI_]O?\ I$CKZ]8\H* "
M@ H * "@ H * "@ H * "@ H * (I(5E9&;K$Q=?8E&3\?E=OY]JB45)Q;WB
M[KUY7'\I,N,G%22VDK/TYE+\XHEJR H * "@ H * "@ H * "@ H * "@ H
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M* "@ H * $H * #I0 E "]* $H * "@ H 2@!>E "4 % !0 G2@ H .E "4
M+TH 2@ H * +,/3\: ): "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * ,77?]0O\ UT'_ *"U9SV^8S0L_P#41_\ 7-/_ $$5:V7H(LTP"@ H * "
M@ H 2@!: $H .E !0 8H * #% !0 E "]* /)+3_ (G&O>9U02E_^ Q?<_/:
MH_&OAZ?^U8_FW2FY?*'P_DOO/MJG^RX#EV?(E\Y_%^;/6J^X/B0H * "@ H
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ME^/W-GV>+@L=AE6I_$ESQ_\ ;H_A]Z1ZQ7W!\0'2@!* %Z4 )0 4 % !0 4
M'2@!* #I0!#<3K;1/,_W8U+'Z*,FLYS5.,JDMHIM^B5S2$'4E&G'>327JW8X
MRV\;0RA_.C,3 ,4YW!B 2%. ""3QTQZD5\_3S:$E+VD7!I-QUNG9:)Z*S>W;
MS1[]3*IQ<?9R4DVE+3E:N]6M7=+?OY,RO!MJ;J[DO).?+!Y_VY,\_P#?.[/U
M%<&5TW5K3Q$]>5/7^].^OW7^\[LTJ*E1CAX:<SV_NQMI]]ON/3:^S/C@H .E
M "4 +TH 2@ H * "@!* %Z4 )0 4 % ''>-8M]FCCJDH_(JP_GBOG\VC>A&7
M\LU]S37YV/?RJ7+6E'O!_>FG^5R_X5E\W3HO5-RG\&./T(KJRZ7-AH>7,OND
M[?@T<V8QY<3/SY7]\5?\4SH>E>L>2)0 O2@!* "@ H .E &#XCB>?3YDC5G8
MA,*H))Q*A. .> "3[#->9CXRGAIQ@G*3Y;))M_'%[+R/3P$HPQ$)3:C%<UVV
MDE[DENQQ\5Q+UMKP?]L1_P#%UG]>7_/C$?\ @O\ ^V+^HO\ Y_X?_P &?_:B
M?\)=!_S[W?\ WZ7_ ..4?7E_SXQ'_@O_ .V#ZB_^?^'_ /!G_P!J)_PET'_/
MO=_]^E_^.4?7E_SXQ'_@O_[8/J+_ .?^'_\ !G_VH?\ "70?\^]W_P!^E_\
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M^HO_ )_X?_P9_P#:A_PET'_/O=_]^E_^.4?7E_SXQ'_@O_[8/J+_ .?^'_\
M!G_VH?\ "70?\^]W_P!^E_\ CE'UY?\ /C$?^"__ +8/J+_Y_P"'_P#!G_VH
M?\)=!_S[W?\ WZ7_ ..4?7E_SXQ'_@O_ .V#ZB_^?^'_ /!G_P!J'_"70?\
M/O=_]^E_^.4?7E_SXQ'_ (+_ /M@^HO_ )_X?_P9_P#:A_PET'_/O=_]^E_^
M.4?7E_SXQ'_@O_[8/J+_ .?^'_\ !G_VH?\ "70?\^]W_P!^E_\ CE'UY?\
M/C$?^"__ +8/J+_Y_P"'_P#!G_VH?\)=!_S[W?\ WZ7_ ..4?7E_SXQ'_@O_
M .V#ZB_^?^'_ /!G_P!J'_"70?\ /O=_]^E_^.4?7E_SXQ'_ (+_ /M@^HO_
M )_X?_P9_P#:A_PET'_/O=_]^E_^.4?7E_SXQ'_@O_[8/J+_ .?^'_\ !G_V
MH?\ "70?\^]W_P!^E_\ CE'UY?\ /C$?^"__ +8/J+_Y_P"'_P#!G_VH?\)=
M!_S[W?\ WZ7_ ..4?7E_SXQ'_@O_ .V#ZB_^?^'_ /!G_P!J'_"70?\ /O=_
M]^E_^.4?7E_SXQ'_ (+_ /M@^HO_ )_X?_P9_P#:A_PET'_/O=_]^E_^.4?7
ME_SXQ'_@O_[8/J+_ .?^'_\ !G_VH?\ "70?\^]W_P!^E_\ CE'UY?\ /C$?
M^"__ +8/J+_Y_P"'_P#!G_VHO_"70?\ /O=_]^E_^.4?7E_SXQ'_ (+_ /M@
M^HO_ )_X?_P9_P#:G)V+&6ZFEVL@EG=PKC:P#G<,CUP>Q(]ZRP=VJLY1E'GK
M3DE)6=I6:T_I7-<99.E",HRY*,(MQ=U=73U_K0])L^%%>TCQF7:HD* "@ H
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MPUJF!'?11,?X9]T!!]"90J$_1B/>@#M[>ZANT\RW=)4/1D8,OYJ2* )Z "@
MH * "@ H * "@ H Q==_U"_]=!_Z"U9SV^8S0L_]1'_US3_T$5:V7H(LTP"@
M H * "@!* %H 2@ Z4 % !TH * #I0 4 % !0!GZK=?8K26?H4C8C_>QA?\
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M+(G_  %PP&>2,'O7AU:;I3<'T?WKH_N/H*51581J+JON?5?>=#6)L% !0 4
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M?J]6.JB1>E "4 % !0 4 % !0 E !TH * "@ H 2@ H * $H 7I0 E !0 4
M)0 4 '2@ H ,4 % "4 % !0 E !0!:A^[^- $M !0 4 % !0 4 % !0!POCW
M0]/N]%U"XGMH))H[*YD25HD,BND+LKJ^W<&! ((/Z4 <3X?^%6D7^DV-];O=
M6%W/9VTKRVMPZ%I'A1F8A]X&6).%VCGC% 'LNGVK65M#;/(\[0Q)&99#F20H
MH4R.>[N1N8]R30!;H * "@ H * "@ H * ,77?\ 4+_UT'_H+5G/;YC-"S_U
M$?\ US3_ -!%6MEZ"+-, H * "@!* "@ H * "@ Z4 % !TH 2@!>E "4 %
M'$>.;SRK5+8'F9\G_=3G_P!"*_E7SN;5>6E&DMYRN_2.OYM?<?0Y52YJLJKV
MA&R]9?\  3^\T_"EG]CT^/(PTV93_P "^[_XX%KLRZE[+#QOO/WW\]O_ "5(
MY,PJ>UQ$K;0]Q?+?_P F;.DKUCR0Z4 )0 O2@!* %Z4 )0 =* "@ H * $H
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MB@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@
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MDY:UN=X]DF08'_?<<A_$UTXZ-IQEW7Y/_@HY<OE>$H=I7^37_ 9] 5Y)[ 4
M% 'S9^T/KWE6]IHL9YF8W,H']Q,I$#[,S2'ZQBO9P,-95'TT7SU?Z?>>'F%2
MRC277WG\M%^OW&O^SYJGVK1;BQ8Y:SN20/2.9 RC_OM)3^-9XZ-IJ7=?BO\
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MAE)4X(P<'K3:<7:2:?9Z,2:DKQ::[IW19Q4E!0 4 '2@ H .E !0 E !0 4
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MUV/!_P#A?NO_ //"P_[]7'_R37J_4:?>?WK_ .1/'^OU>T/N?_R0?\+]U_\
MYX6'_?JX_P#DFCZC3[R^]?\ R(?7ZO:'W/\ ^2#_ (7[K_\ SPL/^_5Q_P#)
M-'U&GWE]Z_\ D0^OU>T/N?\ \D'_  OW7_\ GA8?]^KC_P"2:/J-/O+[U_\
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M_P B'U^KVA]S_P#D@_X7[K__ #PL/^_5Q_\ )-'U&GWE]Z_^1#Z_5[0^Y_\
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M[,7%5:2JQZ6?R?\ 2.+!R=*JZ,M+W7_;T?Z9]AU\\?2"4 % !0 =* /C>_\
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M7)4E3?5?C%_\.?7N*^?/HPH 2@!: $H * "@ H ,4 % "4 '2@ H * "@!*
M#%  3B@#Y-L?C=?)XC9KJ16T5YVB$81!Y<.XK','"[RRC#OEB&4LH ^3;[[P
M<?9>ZOWEKWN]7U5MO)'SL<;+VOO/]W>UK+1='??S9]8(ZNH="&5@""#D$'D$
M$<$$<@CK7@[:'T7H<AXL\=:5X+6(ZF[!KAB$2-=[X7&YR,C"+D9.<DG"AB#C
M>E1G6OR+;OI\CFJUX4+<[WV2W]?0ZFVN8[V%+B!@\4R+(CCHR. RL/8@@BL&
MG%M/=:,Z$U)*2V>J]&3TAB4 &* "@ H * "@!* "@ H 2@!>E "4 % !0 E
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MZ?K]YYV J6<J+Z^\O7K^%ON/JJO"/H H * "@ H 2@ H * "@ Z4 % !0 4
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MK.2A37VGK?T77_/0UK#X<V'B-)4\-ZK'J%Y AD^RS6LEH\BCKY3/)(KGMC@
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M%TY.$M&MSV(352*G#5/8T:@L* "@ H 2@ Z4 % "8H 6@!* "@ H 2@ H *
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M%R7!8DG!'4G/'RUY_*MST"Y:VJV:%$)()SSC.< =@/2J2MHA%>YTR*Z?S'+
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M\'/4?_$U/(AFG(@D4H>C @X]QBKWT$9?]C0_WG_-?_B:SY%YC-.-!&H0=%
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M)K/D7F,T((5MT$:YPN>O7DD^WK5I6T0BG+ID4SEV+ L<\$?X5+BMP+%M:I:
MA"3DYYQ_0"FER[ 17-BETP=RP(&."/4GN#ZT.*>H"VUA':L70L21CDCU![ >
ME"BH[ /N;5;H .2-ISQC^H-#5P*\6F10N'4ME3D9(_PI**6H%N:$3H8VR <=
M.O!!]_2J:OH!0_LB$=W_ #'_ ,34<B\QFDPW @]QBM!&;_9$/J_YC_XFL^1>
M8S0BC$*!%SA1@9ZU:5M!%&32XI&+DMEB3P1W.?[M3R+<9:M[9;9=B9()SSCT
M [ >E4E;1"()[".X;>Q8'IP1CC\#4N*>H#K:S2U)*%CD8YQ_0"FH\NP&M!]W
M\?\ "J FH * "@ H * "@ H * "@ H * "@ H * .4OO"_VS7;37O.V?8898
M?)\O._S0PW>9O&W;NZ;&SCJ* )O[#NO[:_M;[;+]E^S^3]A^?RM^<^=_K=F[
M''^JS_M4 <Y+X%O;*YN9M"U-],@OY#-/!]FBG42MP[PL[*8BW? 89P>BJ  =
M5X:\/6WA>Q33[3<RH2SNYR\DCG+R.>[,?R "C@"@#>H Q==_U"_]=!_Z"U9S
MV^8S0L_]1'_US3_T$5:V7H(L4P"@ H ,4 % !0 4 )0 O2@!* "@ H * "@
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MJ\DSS,<[47ZH/@3%Y?AA&_YZ7$[?^/!?_9:,9_%?H@P*M17JSV2O./3$H *
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M*][:W6^OF9T\3)5^=R?*Y6M?3E>VGEN?9-Y>0:?"]S=.D,,0W/([!54#N2<
M?U/'6OG$G)\L5=O9(^F;44Y2=DMVR+3=2M=7@6[L94N(),[9(V#*<'!&1T(/
M!!Y!X(!IRBX/EDFFNC%&49KF@TUW1>J"Q* %Z4 )0 4 % "4 % !TH 2@ H
M* "@!*8!0!;@^[^/^%(":@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MOER?EY<?_?5>CCXV<9^37W:K\V>;E\])T^S37ST?Y(^ENE>*>X)0 4 % !0
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MCXF*J9IB+O2"W[0AV]7^+N]MOM&Z>5X>RUD]N\I]_1?@M-]_6401J$0850
M.P' 'Y5]VDHI1CHDK)>2/AFW)N3U;=V_-C^E,0E !0 4 )0 8H * "@ H *
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M_P#;M_[7KS,7M'Y_H>M@]Y?]N_J?7.F?<%>!(^AB>(>#?^0AK/\ V'+_ /\
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MRJ-^!,#9]<FOHL-^\P[A_BC]^OZGS.)_=8E3_P ,ONT_0^Q\YZ=*^=/IA>E
M"4 % !0 4 % !0 E !TH * "@ H 2@#*US5$T33[C49,;;6&27![E%)"_5B
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M 4 % "4P"@ H MP?=_'_  I 34 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 8NN_P"H7_KH/_06K.>WS&:%G_J(_P#KFG_H(JULO018I@'2@ H
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M.'O3=H1OOYWLK(Z7A4IRBI^[!7G*WP]E:[N]/Z91L_ EO+;+KNAWW]I065W
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MXL>"I?&6D>79J'OK5Q+ "0NX'Y9(]S$*-ZX89(!=$!(&37=AJRHSO+X6K/\
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MKH&)(5@1R1]UF!Z(5ITDX0=D]_\ @=CGG0IU9*<XW:VW_'N=;7.= E !0 4
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MN_ZA?^N@_P#06K.>WS&:%F/W$?\ N)_Z"*M;+T$6*8!0 =* $H 7I0 E !0
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M/&H8MT(^SE'F2>FMK>6SZGM'ASXZ:'K,OV>]5]-=L;6F(:$GT,BXV?5U5/\
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M:"]* $H * "@ H 2@ Z4 % "4 % "$ C!Y![4K7T8]M4006L-H"L"+&"<D*
MN3ZG'^<<5G"E"DK4XJ*;NTDEK\C2=2=5WJ2<FE97;>GS)ZV,@H * "@ H \R
M^,7_ "*=_P#2V_\ 2RWKMPG\:'_;W_I+.#&?P)_]N_\ I2/7JX3O/ _VB/\
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M.2OIXJ@JB]O3U=M;=5W^2_#T/+PE=TG]7JZ*]E?H^WHW^/J?6'2O!/H0H *
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M8!0 4 % !0 4 6X/N_C_ (4@)J "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * ,77?]0O_70?^@M6<]OF,OVG^HC_ .N:?^@BK6R]!%FF 4 )0 M
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MR/I</4]M3C/KL_5?Y[_,[BN4ZPH * "@!* #% !0 E "]* $H * "@!* #%
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M!-0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!BZ[_J%_P"N@_\
M06K.>WS&:%GQ!'_N)_Z"*M;+T$3TP%H 2@ H * "@ H * $H 7I0 E "]* $
MH .E 'DMI_Q.M=\SJ@E+_P# (ON?GM4?C7P]+_:\=S[Q4W+_ +=A\/WV7WGV
MU3_9,#R;2Y%'_MZ?Q?==_<>M5]P?$A0 E !0!\;_ !L_TOQ=!!Z06L?_ 'U+
M(W_L]?183W:+?G)_@O\ (^:QNM=+RBOQ?^9]D5\Z?2ATH 2@!>E "4 % !0
M4 >'?&[P3_;^G#5[1<WFG*2P RTEMR77CJ8B3(O^SY@&2PKT\'6]G+V<OAE^
M#_X.WW'E8VC[2'M(_%'\8]?NW^\A^!_C;^V]/.BW;YN]/4>66/S26V<+]3"2
M(S_L&/J<FGC*/LY>TBO=EOY2_P"#O]XL%6YX^RE\4=O./_ V^X]VKRSUA>E
M"4 '2@#Y%_:(ESJUG%_=M"W_ 'U,X_\ 9*^@P"]R3_O?HCYS,'[\5_=_5GU;
MIL7D6D,739%&OY(!_2O!EJV_-GT,5:*7DOR+M24)0 4 % !0 =* $H P?$^@
MQ>)=+N=+FP%N8RJL?X''S1O_ , D"M^%:TYNE-371_AU7W&-6"JPE3?5?CT?
MR9\R?!#79?#^M7'AV]_=BZ+(%;^"ZM]P*^Q90ZGU94 R<5[>,@JE-5H]/_27
M_2_$\+!3=*HZ,M+_ (27]/\  ^N:^?/HPH * $H .E !0 4 % "4 % !0 E
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MW/GVY^!3VYP+_=_VZX_]N#7K+&7^Q_Y-_P  \=X*WV__ "7_ .V*?_"E)/\
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M!]3?\W_DO_!#_A2DG_/[_P"2W_V^CZVOY?Q_X ?4W_-_Y+_P0_X4I)_S^_\
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MMC'?/')6K>UMI:U^M][>2['90H>QOK>]NEMK^;[GO>GH40"O*D>M$\+\&_\
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M9#]5)+*U>17HNA+EZ/5/R_S74]G#UE7AS+22TDNS_P GT.YKE.LXOXA>(_\
MA%=#N;]3MFV>5!Z^=+\J$?[F3(?9#730I^UJ1ATW?HM_\CEQ%3V-.4UO:R]7
MM]V_R/G#X%>));77)-/N)&:/48V(#,3F>/\ >!N2>602@GJQ*\\5[.-IITU-
M+6+_  >GYV/$P-1JHX-Z27XK7\KGV'7SI]*)0 4 % !0 E "]* /+OC!K_\
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M>.YC2:%@\<BJZ,.0RL 58'N"""/:OFVK.SW1]0FFKK9[$M(84 )0 4P"@ H
M* "@ H * "@"W!]W\?\ "D!-0 4 % !0 4 % !0 4 % !0 4 % !0!S_ (B\
M3V7A>%9KTN6E?RX8HD,DTSG^"-!U/U( X!.2 0#,T?QQ::K>#3)8+S3KQT,D
M<-[#Y+2HN=QC(=U;: 20&S@'CY6P =F3CD\8H \UD^*>F+OFC@OYK&%RCW\=
ML6M%(;:3YF\,5!P"RQD<C&<B@#T6WGCNHTGA8/'*JNC*<AE8!E8'N"""#Z4
M2T 8NN_ZA?\ KH/_ $%JSGM\QE^S_P!1'_N)_P"@BK6R]!%GI3 2@ H * "@
M H * #% !0 E "]* $H .E &7K5W]ALIIAP50A?]YOE7_P >(KCQ53V-"I4Z
MJ+2]7HOQ:.S"T_;5J=/HY*_HM7^"9QO@.TYFNCVQ$O\ Z$W_ +)7S^44_P")
M6?E!?G+_ -M/>S>I_#HKSD_R7_MQZ-7UA\J)0 4 % 'QO\1/]+^(<4'7%QIT
M?_?0@;_V>OHJ'NX9ORF_S/FL1KBDO."_+_,^R*^=/I0H .E "4 +TH 2@ H
M* $8!@01D'@@]"* /BSQAI5S\)O%$6IZ<N+21S/;KR$*$XGM3CLH;:.I"-&W
MWNGTE*2Q=)PG\2T?KTE_76Y\O6@\'64X?"W==K=8_P!=+'V#HVKV^NV4.HV;
M;X+E Z'N,]5([,IRK#LP(KYZ<73DX2W3L?20FJD5..S5T:50:!TH * /CGX]
M?Z3XFMX1VLX$_%IYS_[,*^BP6E)O^\_R1\UCM:R7]U+\6?8H&.!VKYT^E"@
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MZL"K+V8$5\].#IR<)*S1]+"<:D5.#NF?,GQ[U]]1U"V\/VV7^S@22*O):>8
M1)CU6,Y'_7:O:P4.6,JSZZ+T6_X_D>%CZG-*-&/35^KV_#\SB/%&@S?"[7+"
M>,EC'%:W.1T:6/"W" ^C.C''99 ,UU4YK%4YI]Y+Y/;\'^!R5:;PE2#711E\
MU\2^]?B?;]M<)=Q)/$=T<J*Z,.ZL RG\00:^8:LVGNM#ZM--)K9ZDU(84 %
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M\;8_B1@5/N,C@BO%J0=*3A+=?U?YGNTYJK%5([/\.Z^1LUD:B]* $H * "@
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M1T_WN&Y>O*U\X[?DCYFI^YQ7-TYD_E+?\V?8M?.GTP4 % !0 4 % !0 4 %
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M 2@!>E "4 '2@ H ^-/B4I\)^.H]47Y4>2UO1CNH(24?\":*3/\ O&OH\/\
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MY(^\F<,",,W!7P\J+OO!O1]O)_UJ>AA\3&NN7::6J[^:_K0]-KB.\* "@ H
M* "@ H * "@ H \R^,7_ "*=_P#2V_\ 2RWKMPG\:'_;W_I+.#&?P)_]N_\
MI2/7JX3O"@ H * "@#Q#XA^/VM=33PS:7<>E;T$EY?R<M#&W(C@4 _OG7!#'
M[H8%2O+KZ="A>#K2BYZVC%=7W?D>7B*_+-4(R4-+RF^B[+S_ *\S9\%:OX1T
ME5TG0;N&6ZN6)+,7>:XEP6+RN5!8_>.,A5!.T#-958UI?O*L6DODDNR1I1G0
MA^[HR3D_5MONV,T7XH6\,<]OXIV:3J-K(ZM"5DVR(#\CP$AC-N''R9+'! PP
MISP[T=#WX-;Z:/K?L$,2DFJ]H33>FNJZ-=_D5OA!IUS!%J6HRPO:6FIW\EQ:
M02+L98F+$-LXVAE95' R(P0-NTEXJ2;A!.\HQ2DUW]?ZW)PD6E.;3C&<VXIZ
M:>G];$NH?\5UXF33E^;2O#[+/===DU\?]3">JL(!\SCLQ=&'(HC^XI.?VZFB
M\H]7\QR_?UE#[%/67G/HOE_FCQ;_ $5/"<^A31,?%+:EE8O+8W9G\]&\Y6 W
M;# '429VDGCJ#7HZ^V55/]SR;W]VUGI]_0\S1472:_?\^UO>O=:_=U/KVQ65
M+>);@[IEC02'U<* Q_%LFO =KNVU]/0^BC=)7WLK^I9J2@H Y?Q!_P ?VD?]
MA&3_ -->I5O#X:G^!?\ I<#"I\5/_&__ $W,ZBL#<* "@#S6W^'UQ8WUUJ=G
MJMU#<:@^^9O(LI3@9V1JTUO(RQH,*J*0H '' KL==2C&$H1:BM-9+YZ-:LX5
M0<92G&I).3UTB_1:IZ(\W^&5R^@0:YJ]U=2M:V%[=&:'RX,3NJ\2%A&'61C@
M!8V2+) V 5V8A>T=*G&*O*,;.[T\M[6]=3BPS]FJM24GRQE*ZLM?/:]_2R*N
MD^)M%\7SKK'C'4+<+&Y:TTH%_(@ X5YP%_?3$<_-D 'D 'RTJ5.=%>SP\'_>
MGU?DNR_KS)A4IUG[3$S6GPT^B\WW?]>2^B-'UFRUZW%WILJ7%ON*!TSMRN,C
MD#ID=J\B4)4WRS5F>S"<:BYH.Z\CQJ[AN/B#>:EJUKEK72+6[LM*"Y EOGA=
M9+E<\':Q6.)QQPC+AE->BFL/&%.7Q3E&4_*-]%^K/-:>(E.I'X81E&GYS:UE
M^B?H<);R6=_I?AW2]#3;KUI>QM.J1E9K=4,GVIK@X!16DV.=_#(I[ BNI\T9
MUIU7^[<7;71WMRV^5UH<BY90HTZ2_>QDKV6JM?FOVUL]3ZTKP3Z$* "@ H *
M /G?P;_R$-9_[#E__P"AK7I5]J?_ %ZA^IY=#>K_ -?9_H>[V7W!7G,])%ZD
M4% !0 4 ?('QXU.36->MM$M_G-K&B[1_SWNF4XQ[QB''^\?Q^@P45"G*J^K_
M  C_ ,&Y\YCI.=2-*/1?C+_@6,SX-ZD/"_B"]ANCA8[.Z60=/FM665C^"Q2?
MG5XN/M:<7'^:-O\ M[3]49X.7LJLE+I&5_\ MW7]&7O@79OK7B6XU>?DP12R
MEO\ IM<OM_5&FJ<8^2DJ:ZM+Y+^D7@ESU95'T3?SD_\ AS[$Z5\\?2"4 '2@
M H * "@!* "@ Z4 % !TH 2@#R3XK7S)#;V2Y D9I6]#L 51G_@;$CZ&@#)T
M3Q-/X5GM](N8DCM\(TK-D.&G ?S,YQMCW!2-IX0C(;H >Y4 )0 4 % !0 E
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MO5)[R\WY?GZ'UE'&L2A$ 1% "JH   &  !P !P . *\#S9]%MHA_2D,2@!:
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ME_DSW_\ 9ZTG[)H]SJ###7EQM!]8X%PI_P"_DDH_"O)QTKS4/Y5^+_X"1Z^
MARTY3_F?X+_@MGO]>4>P'2@ H .E !0 E "T )0 4 &: #% !0!QD7B#2=>U
M Z6\8FE@9BC21JR%T^]Y9.2",'DJH8 X)XR <Q\4=&,T46I1*2T/[J7 S\AR
MRL?0*V0?]\>E '<>%+F:\TJVEN05E,>TYZD(2BL<\Y=5#>^<]* .AH * "@
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M%"JJC 55&  !P  , #H*^:;OJSZE*VBV1)TI#$H 7I0 E !0 4 % "4 '2@
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M97=EZ(A1BFY))-[NRN_5E^H+/ ?$:_VIXK6V8;D\ZWB(Z_)A"_X<L<4 >_4
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M.JJ#UKRJU3VLW/ILO1;?YGKT*?L:<8==WZO?_(ZZN<Z0Z4 )0 4 % !0 E,
MH * "@".6))T:*0!D=2K*>A4C!!]B#@T)VU0FKZ/8^./#$K_  U\;-83$K;-
M,UJQ/&Z"<AH)#VX)B=CS@!AGO7T=1?6:',M[<WS6Z_-'S-)_5<1R/X;\OR>S
M_)GV77SA].% !0 4 % !0 4 % !0!YE\8O\ D4[_ .EM_P"EEO7;A/XT/^WO
M_26<&,_@3_[=_P#2D>O5PG>% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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ML4$<&?*54W-N;:H7+$ %C@#)( !)YP!Z5DVWN;));:$N:0Q* %Z4 )0 4 %
M"4 % !TH 2@ H * "@!*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 6X/N_C
M_A2 FH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Q==_P!0O_70
M?^@M6<]OF,OVG^HC_P!Q?_015K9>@B>F O2@!* %Z4 )0 4 % !0 4 )0 4
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MNSAU"T;?!<QK(A[X/4$=F4Y5AV8$=J^?E%TY.$MT['T<)*I%3CLU=&C4%A0
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M^?M7_P #_P" '_"#77_0:U[_ ,&#?_&Z/;K_ )]TO_ /^"'L'_S]J_\ @?\
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M95*,,JP((]01@_I0!X-X$+:1K\EB^<L)X#]8SOS_ .0S@^_O0![W0 O2@!*
M#I0 4 % !0 E !0 4 )0 O2@#RS3_&-]J/B V$00V@>2/;CG;&&S)OZY)7..
M5P=N,_-0!3T'QA?)K4FGZJPV22-&J[0HBD!(0*0 2C?=^;.<JP/7< >O4 %
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M_"A(\QO^ H"Q^E?55)>SA*?9/_@?B?(4X>TG&GW:7RZ_@?H]&BQ*$0!54!5
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M 4 '2@!* %Z4 )0 4 % "4 % !TH 2@!>E "4 % !0 =* $H .E !0 E !0
M4 )3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@"W!]W\?\*0$U !0
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M\]__ "'+_P#&Z+ '_";:3_SW_P#(<O\ \;HL ?\ ";:3_P ]_P#R'+_\;HL
M?\)MI/\ SW_\AR__ !NBP!_PFVD_\]__ "'+_P#&Z+ '_";:3_SW_P#(<O\
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M "@ H * "@ H * "@ H * "@!<4 %("U!]W\?\* )J "@ H * "@ H * "@
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M<-[^8[;#_P!^@E=V*ES59>5E]R_SN<.$CR48^=W][T_"QZ?7$=XE !0 4 %
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MGBF!Q#7GAO2$_MJ",2F:4JIC4LPD^\VU)"HB(!W'[G!&."!0!WEE>1:A ES
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M@ H * "@ H * "@#K?"EX;5Y .-^S]-W^-)C/9+";S5!J0(7_P"/IO\ @/\
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M9VP%+>B@9PW09.2,C* WO#&AP>&8_LIF#W%P=Y4D*3M&#L3.2%YR><]3CI3
MZR@ H * "@ H * "@ H * "@ H * %Z4@"@!<4 6H>GXT 2T % !0 4 % !0
M 4 % !0 4 % !0 4 <=XE\(IXHNK.2[ES963O))9E-R7#E<1EVWC C/.THX8
M%EXR30!PVK65A!XNTRWT&*."\A$KW_V95C1;4J-JSJ@"[F)^3(W<IG@QX /4
M?$=Z^F:5>7L7^LMK6XF3_>CB=U_4"@#S/0/ ^F7GA)#=6\4EU>V9NI+EE#3^
M;,AF602G+@KN7 #8X(8'<P(!UGPUU2;6/#EC=7#%Y3&T;,>K>3+)""3W)$8)
M)Y)Y/)- '<T 8NN_ZA?^N@_]!:LY[?,9>M/]1'_N+_Z"*M;+T$6.E, H * "
M@!* "@#R3XHZNNF0B1NEO$\N/5F(5!^++@?6OG,;3>,Q.'P4-Y.[\DWJ_P#M
MV,9,^AP=18/#8C&SVBM/-I:+_MZ4HH^2_".L26^L)-,Y/VIC'*2?O&3[I/T?
M:>>@S7VF;82-7 3I4XI>QBI026RANE_VY='Q.48R5+'PJ5)-^VDXS;>[GLW_
M -OV9]X>'+Q)].B8L,Q)L;D?+LR/F]/E //8YKYO U5/#0=U[L>5Z[<NFO;1
M)^A]1C:3IXB:2?O2YEIOS:Z=]6UZG 7,A\3ZL%3)BR%'M$G+-[9^8CW8#K7R
M\W_:.+2C?DNDO*$=WY7U?S2/IH1_L["-RMSV;?G.6R^6B^39XC\4KF3QGXPB
MT2T/R6[1628Z!V8&9\=MA;:WM%7Z[AHK#T.=Z:.7R6R_R]3\AQ4GB,0J:Z-1
M^;W?^?H?85G:1V$$=K -L4$:1(OHB*%4?@ !7S[;DW)[MW?S/HTE%**V227R
M+524)0 4 % !0 E "]* .,\?77V;19^QDV1C_@3KG_QT-0!Y]X=\,RZ]X?DB
MA=8I'N_,7=G:PCC"X8@$CEF.0#RHXYS0!ZMX;T<Z%8163,'9-Q9AP"S,6.,\
MX&<#/) S@=* -V@ H :P# @\@\$>U 'B\OPKF>Y?RYXTM2Q*9#-(%/(4KPI(
MZ;M_S8S@9Q0!V6D:?8^ K4K=7/$\OWW!4$XP J N1@#+-D^Y P* .TCD650Z
M$,C ,K*0001D$$<$$<@C@B@!_2@!* "@ H * "@ H S-6U2+1K62]GSY<0!P
MN,DDA5 R0,DD#KQUH I>'-6M-:MC=V<?DAG974JJG> "2=O#9!!W9/!P<$$
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MC \R-QAESW&"0RDY (.?[P4D"F!T5 !0 4 % !0 4 % !0 4 % "T@%H 6@
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M4.>IWJ"%;/<D9/<\F@#)?QK#;:M_9$D1CC#+$)<XP[ ;?DQ@(<@!L\#YL8Z
M'=T 8OB*ZNK+3YIK%=\Z*-H W$98!F"]RJDL![=#TH XWP1XPGU64Z??_-,
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M[B65E7 )#;$R07;('/7 ''4D [2@ H 2@ Q0 4 % !0 4 )0 4 % "4 +TH
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M0 4 % !0 4 % &+KO^H7_KH/_06K.>WS&7K3_41_[B_^@BK6R]!%BF E !0
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MO-C<RE@."CF0%]OS= PX+ %3R0#*M+:_724BN)H=-L5E9A(2XFE8%LX$>XR
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M_:K0DIN*L&&&5A@E6&2,X(/!(((YH DUC45TFSFO'Z0H6 ]6Z*O_  )B!^-
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M 2@ H * *MY9PZA$UO<HLD4@PRMT/.1]"" 01@@@$$$4 <9J?B33_!+PZ;'
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M8M"WIYD9.P^X/S*OKO!Z4@/=*8"T@"@!<4 +0 4 %, I 68>GXT 2T % !0
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MAM=VDAGTB3>H.5C9MDJ^ROPK>Q)0XQG/)H ]$\-M>V.G+_;<BK,&(#.ZY"G
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M\'>Y#?W=N#GJ,9H ]"E\2Z;;W7V"6=$G'4-D*#UVER-@8CH"V>W7B@#:5UD
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M8 EB,@?*,#)R2> #T2@!:0%'4M.AU:W>TN03'(,'!P00000>Q! (ZCCD$9%
M%?1-$M] MOLMMN*[BY9SEF8X!)P .@ X &!Z\T ;% !0 4P"D O2@#D_&_\
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M.>H)%*P%2/Q':V*2_P!G62V\TRE?,>4S;%/41JR*![$D\XSD#% '(4Q!0 4
M% !0 4 % '1>'?\ 6M_P'^M)C/>='_U8^E2!YA:?\A*\_P"OV?\ ]&&F!ZQ8
M?<%(#0H * "@ H \3U;POK/B76)!=YBM49@DA(,:PY^41J#R[#!(X.<[\8Q0
M!WOAK0+;PHK6OGB26Z?<H<JA8*, (FXDD _,1G/'   H T/$>DQZ]9OIYD\I
MWPRD8)RIR,KD$KZX(]<\4 )X;T&/P[9BTC;S&W%W?&W<YP,XR<    9/ ZT
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M0]<S./IE(_\ V<_@#0!W_A?3CI>F6]LW#*FYAZ-(2[#\"Q'X4 =!TH 2@ H
M* *.IZ=#JML]I<C='*,''!!ZA@>S*0"/<<@C(H X6VL[;X;V<UQ*[W)N)$50
M%"\@.57[Q .-Q9N,X  Z"@#CKKQOK6OR?9]-0P@_PP*7DQGC=(1Q[D!!Z\4
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M@'N* -TJI() )7.#CD9ZX/;/>@!: %Z4 )0 8QTH * "@ H .E "4 '2@ H
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MN6F@/#JH04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!T7AW_6M_P !_K28SWG1_P#5CZ5('F%I_P A*\_Z_9__ $8:8'J]A]P4
M@-&@ H .E !0 8H \I\=>$K_ %:\BOM.^=@@1EWA"A5B5=2Q QST!R",@'/
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MU^?)(F@FD+&8L R*S9/F!B"6 /50P;KP3M ![;#$MO&L48PD:A5'H%& /R%
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M0 N* $H L1=/QH DH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
MQ==_U"_]=!_Z"U9SV^8R[:?ZF/\ W%_]!%6MEZ"+'2F E "]* $H * "@ H
M* "@!* %Z4 )0 =* "@ H * $H * "@!* %Z4 )0 4 % !0 4 % "4 '2@ H
M * "@"&2".4JSJK%#E2R@E3ZJ2.#[B@"6@ H 2@!>E "4 % !0 E !0 =* "
M@ Q0 4 )0 4 % "4 % !0 E %*^TZVU./R;N-9H\YPPS@^H/53VR"#C(SS0
MFGZ9;:3%Y%G&L,>2V!GDGN2223T&23P .@H NT %, H * "@ H * "@ H *
M"@ H * "@ H * "@ H 7I2 * %Q0 M !0 4P"D O2@!: %Q0 E !B@#D_''_
M "![C_ME_P"CHZ: [BD!G:C8PWT?ESQI*H.0'4, <$9 8$9P2,]<$^M 'GM_
MX7A9OW<4:C_911_(4 97_"*K_<7_ +Y% !_PBJ_W%_[Y% !_PBJ_W%_[Y% !
M_P (JO\ <7_OD4 '_"*K_<7_ +Y% !_PBJ_W%_[Y% !_PBJ_W%_[Y% !_P (
MJO\ <7_OD4 '_"*K_<7_ +Y% !_PBJ_W%_[Y% !_PBJ_W%_[Y% !_P (JO\
M<7_OD4 '_"*K_<7_ +Y% !_PBJ_W%_[Y% !_PBJ_W%_[Y% !_P (JO\ <7_O
MD4 '_"*K_<7_ +Y% !_PBJ_W%_[Y% !_PBJ_W%_[Y% !_P (JO\ <7_OD4 '
M_"*K_<7_ +Y% !_PBJ_W%_[Y% !_PBJ_W%_[Y% !_P (JO\ <7_OD4 :-AX=
M%NV54+ZX&/Y4 >B6$'E*!0!Y+:?\A*\_Z_9__1AI@>KZ>/D%(#1H * #I0 E
M "]* $H * "@ H 2@!: $H .E !0 =* "@!* "@ Z4 )0 O2@!* #I0 4 %
M!0 E !0 =* $H 145,X &3DX&,GU- "T % !0 4 )0 O2@!* "@ H 2@ H .
ME "4 +TH 2@ H * #I0 E !TH P[GPWIMW.+J:WC:8-NW8(RWJX! <_[X:@#
M;H * "@!* "F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 +TI % #J "
M@ H *8!2 6@!: %Z4 )3 7%(">+I^- $E !0 4 % !0 4 % !0 4 % !0 4
M% !0!7AO(+AY(H9(Y)("%E175FC8C<%=024)4Y 8 D<CB@"Q0!D2>(-,AN/L
M4EW;)<DX\EIXA+D]!Y9;?GVQ0!KT % &+KO^H7_KH/\ T%JSGM\QEVT_U$?^
MXO\ Z"*M;+T$6*8!TH 2@!>E "4 % !0 4 )0 4 % !TH 2@!>E "4 % !0
M=* $H 7I0 E !TH * "@ H 3I0 4 '2@!* %Z4 )0 4 % !TH 2@!>E "4 %
M !0 G2@ H .E "4 +TH 2@ H * #I0 E !TH * $H * "@!* "F 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 +2 6@!>E !0 4 %,!<4@"@!: %Z4 )3
M 7%( H Y+QQ_R![C_ME_Z.CIH#N*0 1F@"$P*>U #?LR^E !]F7TH /LR^E
M!]F7TH /LR^E !]F7TH /LR^E !]F7TH /LR^E !]F7TH /LR^E &?>?N);9
M$ Q/.T;\?PBWGDX]#NC7GTR.] &A]F7TH /LR^E !]F7TH /LR^E !]F7TH
M/LR^E !]F7TH /LR^E !]F7TH /LR^E !]F7TH /LR^E "BW4=J )@NV@#Q.
MT_Y"5Y_U^S_^C#3 ]7L/N"D!HXH ,T )0 M "4 % !0 E "]* $H ,4 % !0
M =* $H * "@ H ,4 % "4 '2@ H * "@!* #% !0 E "]* $H * "@!* #%
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M* "@!* "@ H * "@!* #% !F@!* %Z4 )0 4 % "4 &* "@ H * "@!* "@
MH 2@!>E "4 % !0 E !0 =* $H * "@ H 2F 4 % !0 4 % !0 4 % !0 4
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M 'B5I_R$KS_K]G_]&&F!ZOI_""D!H4 % !0 4 % !0 E "]* $H .E !0 4
M% "4 % !0 4 '2@!* "@ H * "@ H 2@ Z4 % !0 4 )0 4 % "4 +TH 2@
MH * "@!* #I0 4 )B@!: $H * "@!* #% !0 E !0 4 % "4P"@ H * "@ H
M * "@ H * "@ H * "@ H * "@!<4@"@!<4 +0 4 %, I +TH 6@!<4 )0 4
MP%I % #J )H^GXT /H * "@ H * "@ H * "@ H * "@ H * /*/AU_R%/$'
M_83;_P!GH WY-9MO&":QX?MEECGM8FM97D"A"US',BF,J[,0-IW;E0], \X
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M * "@ H * "@ H * %Q2 * %Q0 M !0 4P"D M "T +B@!* #%,!:0"T +0
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M .E "4 +TH 2@ H * $H * #I0 E "T )0 4 % !0 E !TH * $H * "@!*
M"F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 +TI % "T +0 4 %, I +
M0 M "]* $I@+BD 4 +B@!: $H GCZ4 /H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H Q==_U"_]=!_Z"U9SV^8R[:<01_[B_P#H(JULO01/3 *
M"@ H 2@ H * #I0 4 % "4 % !0 4 )0 O2@!* #I0 4 % !0 E !0 =* $H
M 6@!* "@ H * $H 7I0 E !0 4 )0 4 '2@!* %Z4 )0 4 % !0 E !TH *
M$H * "@!* "F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 +TI % #J "
M@ H *8!BD M "T +TH 2F N*0!0 N* %H 2F M(#D?''_('N/^V7_HZ.F@.W
MI % !0 4 % !0 4 8/A[0_[!ADA\SSO-G>;.W9C<J#;C<V<;>N1G/3BF!%<:
M/-?:I'>7!0VMHN8(P6+&8XS(X*A1M_APQ.0IXY% %.Z\+RM/<S65R;5;Y0LZ
M&(29.""R$NNPD%NS8+$C'  !T&EZ='I-K'9PY*1+@$]222Q)QW+$G\:0%^@
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M 4 &* "@!* "@ H * "@!* #% !0 E "]* $H * "@!* #% !0 4 % !0 E
M!0 4 )0 O2@!* "@ H 2@ H .E "4 % !0 4 )3 * "@ H * "@ H * "@ H
M * "@ H * "@ H * %Q0 4@%H 6@ H *8!2 7% "T &* %H 2F M( H 7I0
M4 %,!:0!0!R7CG_D#W'_ &R_]'1TT!VU( H * "@ H * "@ H * "@ H * "
M@ H C>))"K, 3&VY2?X6*LF1Z':S+]": )* "@ H * "@ H * "@ H * "@
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M E !0 4 % "4 '2@ H 3% "T )0 4 % "4 &* "@!* "@ H * $I@% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % "XI % "XH 6@ H *8!2 7I0 M "XH
M2@ I@+2 * '4 )0 M, I +B@ H YSQ78S:CIDUO;+OE?R]JY5<[948\L0!@
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M_ E?_C5 !_PG=W_T#S_X$K_\:H /^$[N_P#H'G_P)7_XU0 ?\)W=_P#0//\
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M0 E !TH 2@!: $H * "@ H 2@!>E "4 % !0 E !0 =* $H 6@!* "@ H *
M$H * "@!* "@ H 2@ I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "T@
M"@!<4 +0 4 %, I +0 M "]* $I@&*0"T +B@!: $H 6@ H 7% !0!+'TH ?
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!BZ[_ *A?^N@_]!:L
MY[?,9<M/]3'_ +B_^@BK6R]!$],!: $H .E !0 4 % "4 % !TH 2@!>E "4
M '2@ H * "@!.E !0 =* $H 7I0 E !0 4 '2@!* %Z4 )0 4 % "4 % !TH
M 2@!>E "4 % !0 =* $H .E !0 E !0 4 )0 4P"@ H * "@ H * "@ H *
M"@ H * "@ H * "@!:0!0 O2@!: "@ I@%(!: %H 7I0 E,!<4@"@!<4 +0
ME,!:0!0 M !0 4P%"YX]J0&9<Z:LQY% %#^Q$]* #^PT]* #^PT]* #^PT]*
M #^PT]* #^PT]* #^PT]* #^PT]* #^PT]* #^PT]* #^PT]* #^PT]* #^P
MT]* #^PT]* #^PT]* #^PT]* #^PT]* #^PT]* #^PT]* #^PT]* #^PT]*
M#^PT]* #^PT]* #^PT]* #^PT]* #^PT]* #^PT]* #^PT]* )HM*6)L@4 ;
M$:;!@4 2T )0 8H * $H 7I0 E !0 4 % !B@ H 2@ Z4 % !0 4 )0 8H *
M $H 7I0 E !0 4 % "4 +TH 2@ H * $H * #I0 E "]* $H * "@!.E !0
M=* "@!* "@ H 2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "T@%H
M 7I0 4 %, H 7%(!: #% "]* $I@+TI % "XH 6@!*8"T@"@!: "@ I@2ITI
M /H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Q==_U"_P#70?\
MH+5G/;YC+EI_J8_]Q?\ T$5:V7H(GI@&* "@!* %Z4 )0 4 % !0 4 % "4
M'2@ H * "@!* #% !0 E "]* $H * "@ H 3% !0 4 % !0 E !0 4 )0 O2
M@!* "@ H 2@ H .E "4 % !0 4 )3 * "@ H * "@ H * "@ H * "@ H *
M"@ H * #% "T@%H 6@ H *8!2 7% "T &* %Z4 )3 6D 4 +B@!: $I@+2 *
M %H * "F 4@)$ZT 28H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4
M &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@"-QS0 WI0 E
M!B@ H * "@!* "@ H * #% "4 % !0 4 % !0 E !0 9H 2@!: $H * "@!*
M %Q0 E !0 4 % "4 % !0 E "]* $H * "@!* "@ H 2@ H * "@!*8!0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 N*0!0 N* %H * "F 4@%Z4 +0 8
MH 6@!*8"T@"@!>E !0 4P%I &* %H * "@ H F3@4 .H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H Q==_U"_\ 70?^@M6<]OF,MVG^IC_W%_\
M015K9>@BQTI@% !0 4 )0 4 % !0 =* $H * "@ H * "@!* #I0 4 % !0
ME !0 4 )0 O2@!* "@ H * $H .E !0 E "T )0 4 % "4 % !0 E !0 4 %
M "4P"@ H * "@ H * "@ H * "@ H * "@ H * "@!<4@"@!<4 +0 4 %, I
M +0 M !B@ H *8"T@"@!U "4 +3 *0"XH * "@ H 6@!>E #DZT 24 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M$;]: &4 '2@ H * "@!* "@ H 2@!>E "4 % !0 4 % !0 E !TH * "@ H
M2@ H .E "4 +TH 2@ H * $H * #I0 E "T )0 4 % !0 E !0 4 )0 4 %
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M@!>E "4 % !0 E !0 =* $H 6@!* "@ H * $H .E !0 E !0 4 )0 4P"@
MH * "@ H * "@ H * "@ H * "@ H * "@!>E( H 7% "T % !3 *0"T +0
MO2@!*8"XI % "XH 6@!*8"T@"@!: "@ I@%(!: %H * ')UH DH * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * (WZ
MT ,Z4 )0 O2@!* "@ H * "@ Z4 )0 =* "@ H * $H * "@!* %Z4 )0 4
M% !0 E "]* $H * "@!* "@ Z4 )0 O2@!* "@ H * $H .E !0 E !0 =*
M$I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M(!: %H * "@ I@+B
MD M !0 O2@!*8"T@"@!<4 +0 E,!:0!0 O2@ H *8!2 7% "T % $B=* '4
M% !0 4 % !0 4 % !0 4 % !0 4 >6^(RL?C+0VDX#0WZH3TW^3R >F<''_
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 1OUH 90 4 )0 4
M% !0 8Q0 4 )0 4 % !0 4 )0 =* #- "4 +0 E !0 4 )0 8H * "@ H *
M$H * #- "4 +TH 2@ H * $H * #I0 E !0 4 % "4P"@ H * "@ H * "@
MH * "@ H * "@ H * "@!<4 %(!<4 +0 4 %, I +B@!: #% "T )3 6D 4
M+0 4 %,!:0!B@!: "@ H * %Q0 M !0 4 2)TH =0 4 % !0 4 % !0 4 %
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M?^1$HN^WX@&;K_GA_P"1$HN^WX@&;K_GA_Y$2B[[?B 9NO\ GA_Y$2B[[?B
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MIH<FNGX@2^9=?\\/_(B47?;\0#S+K_GA_P"1$HN^WX@+YMU_SP_\B)1=]OQ
M/-NO^>'_ )$2B[[?B >;=?\ /#_R(E.[[?B >;=?\\/_ "(E*[[?B >;=?\
M/#_R*E%WV_$!?.NO^>'_ )%2B[[?B >;=?\ /#_R*E%WV_$ \VZ_YX?^14IW
M?;\0#SKK_GA_Y%2E=]OQ /.NO^>'_D5*+OM^("^==?\ /#_R*E%WV_$ \ZZ_
MYX?^14IW?;\0#SKK_GA_Y%2E=]OQ /.NO^??_P BI_A1=]OQ DCFN2P#0;5)
MP3YBG ]< <X]*=WV_$#0J@"@ H * "@ H * "@ H * "@ H * "@ H * "@
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MN^WX@'G77_/#_P BI2N^WX@*)KK/,&/^VB_X47?;\0-(#%6 M !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9<.N:=<3?
M98KJVDG!QY2S1M)D=1L#%LCZ4 :E !0 4 % !0 4 % &=;?\?5Q_VR_] -0M
MW\@-&K * "@ H * "@ H * ,^^U:RTO'VVX@MMWW?.E2//TWLN?PH N0S1W"
M"6)ED1AE64AE(]01D$>XH DH * "@ H * "@#.U;_CU?_@/_ *&M1+8#1JP"
M@ H * "@ H * "@ )QR>,4 06UU#>1B>W=)HGSM>-@Z'!(.&4D'!!!P>H(H
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M9!!'!!'((X(H =0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M94\$=0>#0!3NM=TZQE^SW-U;03''[N2:-'YZ?*S!N>W% &F"&&1R#R"* %H
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M=P0R.8@<\C$108/(Z4@.RH * "@ H * "@! H!R!R>OO0 M !0 4 % !0 4
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M1U&T@$>TZ)_R#[;_ *]X?_1:TAFG0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M \$Q&!S+$RD^KAB.,4 =10 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_P#D:Y/^P3#_ .E<_P#C0!P-[&LNB:ZCC*MKH4CU!N; $?E3$=WXXC5H+%&
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M9I,GZT .T??_ ,)-JNW_ %?D6._I]_9+M]\[,Y]MN>U '=T % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MX8$N&LII03MDRKBT*O@,6E4,,_,I(Y8'?^$]*ET32K>RN"#-$A,FWH'=FD8
M]PK,5![@9I 5_$UC,WV?4[13)<:;*91&HRTL+J4N(E&#EFC.Y .2Z*!R10!L
M)I]M)=+J@0_:3!Y <EU(A9Q+L,9( .\ DE X^Z2!D4 2'3K<W8U K_I*Q- '
MW-Q$SJY7;G9RZJ=VW=Q@'!(H BL-/MM!LUM;-#';VZL4C7?(P&2Y R7=B23@
M9)).!V% &3X7T^6".;4+M3'=ZE*9Y$;[T48 2"$^\<2KN]'9QT H ZB@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 8U
M-"96>K1#*S51!6:K)*SU9!6>K1!6>J1!6:K(*S5:)96:K1#*S5:(*S59)6>J
M1!6>K(*SU:)*K51!6:K1!6>K1+*S5:(*SU:(*SU1!6>K1)6>K1!6:K(*[U2(
M*SU:(97:J)&TP"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!R
M]:0%Z*LV:(T8ZR9JC0BK)FR-".LF:(OQUFS5%^.LF:(NQUFS5%Z.LV6BVE9L
MT1<CK-FB+:5#+1:2H9:+25#+196H*186I+186H+)UJ2B9:11*M2,E%(HD%2,
M>*0Q](8X4 .I#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@!C4T)E9ZM$,K-5$%9JLDK/5D%9ZM$%9ZI$%9JL@K-5HEE9JM$,K-5H@K
M-5DE9ZI$%9ZL@K/5HDJM5$%9JM$%9ZM$LK-5H@K/5H@K/5$%9ZM$E9ZM$%9J
ML@KO5(@K/5HAE=JHD;3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * '+UI 7HJS9HC1CK)FJ-"*LF;(T(ZR9HB_'6;-47XZR9HB['6;-47HZS
M9:+:5FS1%R.LV:(MI4,M%I*AEHM)4,M%E:@I%A:DM%A:@LG6I*)EI%$JU(R4
M4BB05(QXI#'TACA0 ZD,* "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MH4<-[:E4K<UN1/2U[VC?>ZMVV9Q%>B>>% !0 4 % '6:UX1N= EM;>\95FO
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MTACA0 ZD,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MD36ZV,P15?!=B^&+G:67:RA-@!/').6VKTTJ*I8.I-24G.-]-E;2VNMUK?\
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MN^ZN !7*J\JD95*F(E">MH)2MY;:*_\ P6=3H1IRC3IX>,H:7FW&_GOJ[?\
M 1QD&BQ^%/&EM;V1*P7"%U3).U)$E4H2<EE#Q[ESS]T$DC->@ZKQ."G*I\47
M:_FG%W\M'9G J2PV-A"GI&2O;LFI*WGJKGG?CFS2PUR\ACX7S=X'IYJK*1]
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M26BPM063K4E$RTBB5:D9**11(*D8\4ACZ0QPH =2&% !0 4 % !0 4 % !0
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M-UJ4J4;)M:7VW3Z7.7#U%1JQJRO:+UMOLUUL:'B+Q*+_ %U];T_?%\\+Q^8
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MUK75M]M;= Q&*I5J,:-.,H\K32=FK)-+6][V=]M^O4I_$+Q=:>+);=[-)HQ
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MPQ6L8J"48Z)))>BT1G*3DW*6[;;]7JR"J)"@ H * "@ H * "@ H * "@ H
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M.#H0:E&"NMKN3_!MHZY8RO-.$INSWLHK\4DSCJ[SA"@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M<O6D!>BK-FB-&.LF:HT(JR9LC0CK)FB+\=9LU1?CK)FB+L=9LU1>CK-EHMI6
M;-$7(ZS9HBVE0RT6DJ&6BTE0RT65J"D6%J2T6%J"R=:DHF6D42K4C)12*)!4
MC'BD,?2&.% #J0PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H ,4 )M'H*!">6OH/R%.["R$\I/[J_D*+ON%EV&^1'_=7\A_A1=]V*R[
M(3[/%_<3_OD?X4^9]W]X<J[+[A/LL/\ SS3_ +Y'^%',^[^\.5=E]PGV.#_G
MFG_?"_X4^:7=_>Q<L>R^Y"?8K?\ YY1_]\+_ (4<TN[^]AR1[+[D)]@MO^>4
M?_?"_P"%'/+^9_>PY(_RK[D)_9]K_P \8O\ OVO^%/GE_,_O8N2/\J^Y"?V;
M:_\ /&+_ +]I_A1SS_FE][#DA_+'[D-_LRT_YX0_]^T_PH]I/^:7WL/9P_EC
M]R$_LJS_ .>$/_?I/_B:?M)_S2^]B]G#^6/W(3^R++_GW@_[])_\31[2?\TO
MO?\ F'LX?RQ^Y?Y"?V/8_P#/M!_WZC_^)H]K/^>7_@3_ ,P]E#^2/_@*_P A
M/[%L/^?:W_[\Q_\ Q-/VM3^>7_@3_P Q>RI_R1_\!7^0G]B:?_SZV_\ WYC_
M /B:/:U/YY?^!/\ S#V5/^2/_@*_R$_L+3O^?6V_[\Q__$T>UJ?SR_\  G_F
M'LJ?\D?_  %?Y#?[!TW_ )]+;_OQ%_\ $T_;5/YY_P#@3_S%[&G_ "0_\!7^
M0G_"/Z9_SZ6O_?B+_P")H]M5_GG_ .!/_,/8TOY(?^ K_(3_ (1W2_\ GSM?
M^_$7_P 11[:K_P _)_\ @4O\P]C2_P"?</\ P&/^0G_".:5_SYVO_@/%_P#$
M4_;U?^?D_P#P*7^8O84O^?</_ 8_Y"?\(UI/_/E:?^ \7_Q%'MZO_/R?_@4O
M\P]A2_Y]P_\  8_Y"?\ ",Z3_P ^5I_X#P__ !%'MZO_ #\G_P"!R_S#V%+_
M )]P_P# (_Y"?\(OI'_/C9_^ T/_ ,13^L5O^?D__ Y?YB^KT?\ GW#_ , C
M_D)_PBVC_P#/C9_^ T/_ ,11]8K?\_)_^!R_S#ZO1_Y]P_\  (_Y!_PBVC_\
M^%G_ . T/_Q%'UBM_P _*G_@<O\ ,/J]'_GW#_P"/^0?\(MH_P#SX6?_ (#0
M_P#Q%'UBM_S\J?\ @<O\P^KT?^?</_ (_P"0?\(MH_\ SX6?_@-#_P#$4?6*
MW_/RI_X'+_,/J]'_ )]P_P# (_Y!_P (MH__ #X6?_@-#_\ $4?6*W_/RI_X
M'+_,/J]'_GW#_P  C_D'_"+:/_SX6?\ X#0__$4?6*W_ #\J?^!R_P P^KT?
M^?</_ (_Y!_PBVC_ //A9_\ @-#_ /$4?6*W_/RI_P"!R_S#ZO1_Y]P_\ C_
M )!_PBVC_P#/A9_^ T/_ ,11]8K?\_*G_@<O\P^KT?\ GW#_ , C_D'_  BV
MC_\ /A9_^ T/_P 11]8K?\_*G_@<O\P^KT?^?</_  "/^0?\(MH__/A9_P#@
M-#_\11]8K?\ /RI_X'+_ ##ZO1_Y]P_\ C_D'_"+:/\ \^%G_P" T/\ \11]
M8K?\_*G_ ('+_,/J]'_GW#_P"/\ D'_"+:/_ ,^%G_X#0_\ Q%'UBM_S\J?^
M!R_S#ZO1_P"?</\ P"/^0?\ "+:/_P ^%G_X#0__ !%'UBM_S\J?^!R_S#ZO
M1_Y]P_\  (_Y!_PBVC_\^%G_ . T/_Q%'UBM_P _*G_@<O\ ,/J]'_GW#_P"
M/^0?\(MH_P#SX6?_ (#0_P#Q%'UBM_S\J?\ @<O\P^KT?^?</_ (_P"0?\(M
MH_\ SX6?_@-#_P#$4?6*W_/RI_X'+_,/J]'_ )]P_P# (_Y!_P (MH__ #X6
M?_@-#_\ $4?6*W_/RI_X'+_,/J]'_GW#_P  C_D'_"+:/_SX6?\ X#0__$4?
M6*W_ #\J?^!R_P P^KT?^?</_ (_Y!_PBVC_ //A9_\ @-#_ /$4?6*W_/RI
M_P"!R_S#ZO1_Y]P_\ C_ )!_PBVC_P#/A9_^ T/_ ,11]8K?\_*G_@<O\P^K
MT?\ GW#_ , C_D'_  BVC_\ /A9_^ T/_P 11]8K?\_*G_@<O\P^KT?^?</_
M  "/^0?\(MH__/A9_P#@-#_\11]8K?\ /RI_X'+_ ##ZO1_Y]P_\ C_D'_"+
M:/\ \^%G_P" T/\ \11]8K?\_*G_ ('+_,/J]'_GW#_P"/\ D'_"+:/_ ,^%
MG_X#0_\ Q%'UBM_S\J?^!R_S#ZO1_P"?</\ P"/^0?\ "+:/_P ^%G_X#0__
M !%'UBM_S\J?^!R_S#ZO1_Y]P_\  (_Y!_PBVC_\^%G_ . T/_Q%'UBM_P _
M*G_@<O\ ,/J]'_GW#_P"/^0?\(MH_P#SX6?_ (#0_P#Q%'UBM_S\J?\ @<O\
MP^KT?^?</_ (_P"0?\(MH_\ SX6?_@-#_P#$4?6*W_/RI_X'+_,/J]'_ )]P
M_P# (_Y!_P (MH__ #X6?_@-#_\ $4?6*W_/RI_X'+_,/J]'_GW#_P  C_D'
M_"+:/_SX6?\ X#0__$4?6*W_ #\J?^!R_P P^KT?^?</_ (_Y!_PBVC_ //A
M9_\ @-#_ /$4?6*W_/RI_P"!R_S#ZO1_Y]P_\ C_ )!_PBVC_P#/A9_^ T/_
M ,11]8K?\_*G_@<O\P^KT?\ GW#_ , C_D'_  BVC_\ /A9_^ T/_P 11]8K
M?\_*G_@<O\P^KT?^?</_  "/^0?\(MH__/A9_P#@-#_\11]8K?\ /RI_X'+_
M ##ZO1_Y]P_\ C_D'_"+:/\ \^%G_P" T/\ \11]8K?\_*G_ ('+_,/J]'_G
MW#_P"/\ D'_"+:/_ ,^%G_X#0_\ Q%'UBM_S\J?^!R_S#ZO1_P"?</\ P"/^
M0?\ "+:/_P ^%G_X#0__ !%'UBM_S\J?^!R_S#ZO1_Y]P_\  (_Y!_PBVC_\
M^%G_ . T/_Q%'UBM_P _*G_@<O\ ,/J]'_GW#_P"/^0?\(MH_P#SX6?_ (#0
M_P#Q%'UBM_S\J?\ @<O\P^KT?^?</_ (_P"0?\(MH_\ SX6?_@-#_P#$4?6*
MW_/RI_X'+_,/J]'_ )]P_P# (_Y!_P (MH__ #X6?_@-#_\ $4?6*W_/RI_X
M'+_,/J]'_GW#_P  C_D'_"+:/_SX6?\ X#0__$4?6*W_ #\J?^!R_P P^KT?
M^?</_ (_Y!_PBVC_ //A9_\ @-#_ /$4?6*W_/RI_P"!R_S#ZO1_Y]P_\ C_
M )!_PBVC_P#/A9_^ T/_ ,11]8K?\_*G_@<O\P^KT?\ GW#_ , C_D'_  BV
MC_\ /A9_^ T/_P 11]8K?\_*G_@<O\P^KT?^?</_  "/^0?\(MH__/A9_P#@
M-#_\11]8K?\ /RI_X'+_ ##ZO1_Y]P_\ C_D'_"+:/\ \^%G_P" T/\ \11]
M8K?\_*G_ ('+_,/J]'_GW#_P"/\ D'_"+:/_ ,^%G_X#0_\ Q%'UBM_S\J?^
M!R_S#ZO1_P"?</\ P"/^0?\ "+:/_P ^%G_X#0__ !%'UBM_S\J?^!R_S#ZO
M1_Y]P_\  (_Y!_PBVC_\^%G_ . T/_Q%'UBM_P _*G_@<O\ ,/J]'_GW#_P"
M/^0?\(MH_P#SX6?_ (#0_P#Q%'UBM_S\J?\ @<O\P^KT?^?</_ (_P"0?\(M
MH_\ SX6?_@-#_P#$4?6*W_/RI_X'+_,/J]'_ )]P_P# (_Y!_P (MH__ #X6
M?_@-#_\ $4?6*W_/RI_X'+_,/J]'_GW#_P  C_D'_"+:/_SX6?\ X#0__$4?
M6*W_ #\J?^!R_P P^KT?^?</_ (_Y!_PBVC_ //A9_\ @-#_ /$4?6*W_/RI
M_P"!R_S#ZO1_Y]P_\ C_ )!_PBVC_P#/A9_^ T/_ ,11]8K?\_*G_@<O\P^K
MT?\ GW#_ , C_D'_  BVC_\ /A9_^ T/_P 11]8K?\_*G_@<O\P^KT?^?</_
M  "/^0?\(MH__/A9_P#@-#_\11]8K?\ /RI_X'+_ ##ZO1_Y]P_\ C_D'_"+
M:/\ \^%G_P" T/\ \11]8K?\_*G_ ('+_,/J]'_GW#_P"/\ D'_"+:/_ ,^%
MG_X#0_\ Q%'UBM_S\J?^!R_S#ZO1_P"?</\ P"/^0?\ "+:/_P ^%G_X#0__
M !%'UBM_S\J?^!R_S#ZO1_Y]P_\  (_Y!_PBVC_\^%G_ . T/_Q%'UBM_P _
M*G_@<O\ ,/J]'_GW#_P"/^0?\(MH_P#SX6?_ (#0_P#Q%'UBM_S\J?\ @<O\
MP^KT?^?</_ (_P"0?\(MH_\ SX6?_@-#_P#$4?6*W_/RI_X'+_,/J]'_ )]P
M_P# (_Y!_P (MH__ #X6?_@-#_\ $4?6*W_/RI_X'+_,/J]'_GW#_P  C_D'
M_"+:/_SX6?\ X#0__$4?6*W_ #\J?^!R_P P^KT?^?</_ (_Y!_PBVC_ //A
M9_\ @-#_ /$4?6*W_/RI_P"!R_S#ZO1_Y]P_\ C_ )!_PBVC_P#/A9_^ T/_
M ,11]8K?\_*G_@<O\P^KT?\ GW#_ , C_D'_  BVC_\ /A9_^ T/_P 11]8K
M?\_*G_@<O\P^KT?^?</_  "/^0?\(MH__/A9_P#@-#_\11]8K?\ /RI_X'+_
M ##ZO1_Y]P_\ C_D'_"+:/\ \^%G_P" T/\ \11]8K?\_*G_ ('+_,/J]'_G
MW#_P"/\ D'_"+:/_ ,^%G_X#0_\ Q%'UBM_S\J?^!R_S#ZO1_P"?</\ P"/^
M0?\ "+:/_P ^%G_X#0__ !%'UBM_S\J?^!R_S#ZO1_Y]P_\  (_Y!_PBVC_\
M^%G_ . T/_Q%'UBM_P _*G_@<O\ ,/J]'_GW#_P"/^0?\(MH_P#SX6?_ (#0
M_P#Q%'UBM_S\J?\ @<O\P^KT?^?</_ (_P"0?\(MH_\ SX6?_@-#_P#$4?6*
MW_/RI_X'+_,/J]'_ )]P_P# (_Y!_P (MH__ #X6?_@-#_\ $4?6*W_/RI_X
M'+_,/J]'_GW#_P  C_D'_"+:/_SX6?\ X#0__$4?6*W_ #\J?^!R_P P^KT?
M^?</_ (_Y!_PBVC_ //A9_\ @-#_ /$4?6*W_/RI_P"!R_S#ZO1_Y]P_\ C_
M )!_PBVC_P#/A9_^ T/_ ,11]8K?\_*G_@<O\P^KT?\ GW#_ , C_D'_  BV
MC_\ /A9_^ T/_P 11]8K?\_*G_@<O\P^KT?^?</_  "/^0?\(MH__/A9_P#@
M-#_\11]8K?\ /RI_X'+_ ##ZO1_Y]P_\ C_D'_"+:/\ \^%G_P" T/\ \11]
M8K?\_*G_ ('+_,/J]'_GW#_P"/\ D'_"+:/_ ,^%G_X#0_\ Q%'UBM_S\J?^
M!R_S#ZO1_P"?</\ P"/^0?\ "+:/_P ^%G_X#0__ !%'UBM_S\J?^!R_S#ZO
M1_Y]P_\  (_Y!_PBVC_\^%G_ . T/_Q%'UBM_P _*G_@<O\ ,/J]'_GW#_P"
M/^0?\(MH_P#SX6?_ (#0_P#Q%'UBM_S\J?\ @<O\P^KT?^?</_ (_P"0?\(M
MH_\ SX6?_@-#_P#$4?6*W_/RI_X'+_,/J]'_ )]P_P# (_Y!_P (MH__ #X6
M?_@-#_\ $4?6*W_/RI_X'+_,/J]'_GW#_P  C_D'_"+:/_SX6?\ X#0__$4?
M6*W_ #\J?^!R_P P^KT?^?</_ (_Y!_PBVC_ //A9_\ @-#_ /$4?6*W_/RI
M_P"!R_S#ZO1_Y]P_\ C_ )!_PBVC_P#/A9_^ T/_ ,11]8K?\_*G_@<O\P^K
MT?\ GW#_ , C_D'_  BVC_\ /A9_^ T/_P 11]8K?\_*G_@<O\P^KT?^?</_
M  "/^0?\(MH__/A9_P#@-#_\11]8K?\ /RI_X'+_ ##ZO1_Y]P_\ C_D'_"+
M:/\ \^%G_P" T/\ \11]8K?\_*G_ ('+_,/J]'_GW#_P"/\ D'_"+:/_ ,^%
MG_X#0_\ Q%'UBM_S\J?^!R_S#ZO1_P"?</\ P"/^0?\ "+:/_P ^%G_X#0__
M !%'UBM_S\J?^!R_S#ZO1_Y]P_\  (_Y!_PBVC_\^%G_ . T/_Q%'UBM_P _
M*G_@<O\ ,/J]'_GW#_P"/^0?\(MH_P#SX6?_ (#0_P#Q%'UBM_S\J?\ @<O\
MP^KT?^?</_ (_P"0?\(MH_\ SX6?_@-#_P#$4?6*W_/RI_X'+_,/J]'_ )]P
M_P# (_Y!_P (MH__ #X6?_@-#_\ $4?6*W_/RI_X'+_,/J]'_GW#_P  C_D'
M_"+:/_SX6?\ X#0__$4?6*W_ #\J?^!R_P P^KT?^?</_ (_Y!_PBVC_ //A
M9_\ @-#_ /$4?6*W_/RI_P"!R_S#ZO1_Y]P_\ C_ )!_PBVC_P#/A9_^ T/_
M ,11]8K?\_*G_@<O\P^KT?\ GW#_ , C_D'_  BVC_\ /A9_^ T/_P 11]8K
M?\_*G_@<O\P^KT?^?</_  "/^0?\(MH__/A9_P#@-#_\11]8K?\ /RI_X'+_
M ##ZO1_Y]P_\ C_D'_"+:/\ \^%G_P" T/\ \11]8K?\_*G_ ('+_,/J]'_G
MW#_P"/\ D'_"+:/_ ,^%G_X#0_\ Q%'UBM_S\J?^!R_S#ZO1_P"?</\ P"/^
M0?\ "+:/_P ^%G_X#0__ !%'UBM_S\J?^!R_S#ZO1_Y]P_\  (_Y!_PBVC_\
M^%G_ . T/_Q%'UBM_P _*G_@<O\ ,/J]'_GW#_P"/^0?\(MH_P#SX6?_ (#0
M_P#Q%'UBM_S\J?\ @<O\P^KT?^?</_ (_P"0?\(MH_\ SX6?_@-#_P#$4?6*
MW_/RI_X'+_,/J]'_ )]P_P# (_Y!_P (MH__ #X6?_@-#_\ $4?6*W_/RI_X
M'+_,/J]'_GW#_P  C_D'_"+:/_SX6?\ X#0__$4?6*W_ #\J?^!R_P P^KT?
M^?</_ (_Y!_PBVC_ //A9_\ @-#_ /$4?6*W_/RI_P"!R_S#ZO1_Y]P_\ C_
M )!_PBVC_P#/A9_^ T/_ ,11]8K?\_*G_@<O\P^KT?\ GW#_ , C_D'_  BV
MC_\ /A9_^ T/_P 11]8K?\_*G_@<O\P^KT?^?</_  "/^0?\(MH__/A9_P#@
M-#_\11]8K?\ /RI_X'+_ ##ZO1_Y]P_\ C_D'_"+:/\ \^%G_P" T/\ \11]
M8K?\_*G_ ('+_,/J]'_GW#_P"/\ D'_"+:/_ ,^%G_X#0_\ Q%'UBM_S\J?^
M!R_S#ZO1_P"?</\ P"/^0?\ "+:/_P ^%G_X#0__ !%'UBM_S\J?^!R_S#ZO
M1_Y]P_\  (_Y!_PBVC_\^%G_ . T/_Q%'UBM_P _*G_@<O\ ,/J]'_GW#_P"
M/^0?\(MH_P#SX6?_ (#0_P#Q%'UBM_S\J?\ @<O\P^KT?^?</_ (_P"0?\(M
MH_\ SX6?_@-#_P#$4?6*W_/RI_X'+_,/J]'_ )]P_P# (_Y!_P (MH__ #X6
M?_@-#_\ $4?6*W_/RI_X'+_,/J]'_GW#_P  C_D'_"+:/_SX6?\ X#0__$4?
M6*W_ #\J?^!R_P P^KT?^?</_ (_Y!_PBVC_ //A9_\ @-#_ /$4?6*W_/RI
M_P"!R_S#ZO1_Y]P_\ C_ )!_PBVC_P#/A9_^ T/_ ,11]8K?\_*G_@<O\P^K
MT?\ GW#_ , C_D'_  BVC_\ /A9_^ T/_P 11]8K?\_*G_@<O\P^KT?^?</_
M  "/^0?\(MH__/A9_P#@-#_\11]8K?\ /RI_X'+_ ##ZO1_Y]P_\ C_D'_"+
M:/\ \^%G_P" T/\ \11]8K?\_*G_ ('+_,/J]'_GW#_P"/\ D'_"+:/_ ,^%
MG_X#0_\ Q%'UBM_S\J?^!R_S#ZO1_P"?</\ P"/^0?\ "+:/_P ^%G_X#0__
M !%'UBM_S\J?^!R_S#ZO1_Y]P_\  (_Y!_PBVC_\^%G_ . T/_Q%'UBM_P _
M*G_@<O\ ,/J]'_GW#_P"/^0?\(MH_P#SX6?_ (#0_P#Q%'UBM_S\J?\ @<O\
MP^KT?^?</_ (_P"0?\(MH_\ SX6?_@-#_P#$4?6*W_/RI_X'+_,/J]'_ )]P
M_P# (_Y!_P (MH__ #X6?_@-#_\ $4?6*W_/RI_X'+_,/J]'_GW#_P  C_D'
M_"+:/_SX6?\ X#0__$4?6*W_ #\J?^!R_P P^KT?^?</_ (_Y!_PBVC_ //A
M9_\ @-#_ /$4?6*W_/RI_P"!R_S#ZO1_Y]P_\ C_ )!_PBVC_P#/A9_^ T/_
M ,11]8K?\_*G_@<O\P^KT?\ GW#_ , C_D'_  BVC_\ /A9_^ T/_P 11]8K
M?\_*G_@<O\P^KT?^?</_  "/^0?\(MH__/A9_P#@-#_\11]8K?\ /RI_X'+_
M ##ZO1_Y]P_\ C_D'_"+:/\ \^%G_P" T/\ \11]8K?\_*G_ ('+_,/J]'_G
MW#_P"/\ D'_"+:/_ ,^%G_X#0_\ Q%'UBM_S\J?^!R_S#ZO1_P"?</\ P"/^
M0?\ "+:/_P ^%G_X#0__ !%'UBM_S\J?^!R_S#ZO1_Y]P_\  (_Y!_PBVC_\
M^%G_ . T/_Q%'UBM_P _*G_@<O\ ,/J]'_GW#_P"/^0?\(MH_P#SX6?_ (#0
M_P#Q%'UBM_S\J?\ @<O\P^KT?^?</_ (_P"0?\(MH_\ SX6?_@-#_P#$4?6*
MW_/RI_X'+_,/J]'_ )]P_P# (_Y!_P (MH__ #X6?_@-#_\ $4?6*W_/RI_X
M'+_,/J]'_GW#_P  C_D'_"+:/_SX6?\ X#0__$4?6*W_ #\J?^!R_P P^KT?
M^?</_ (_Y!_PBVCC_EQL_P#P&A_^(H^L5O\ GY/_ ,#E_F'U>C_S[A_X!'_(
M</#&D#I8V8_[=X?_ (BCV];_ )^3_P# Y?YC]A1_Y]P_\ C_ )#AX;TH=+*T
M_P# >+_XBE[>K_S\G_X%+_,/84O^?</_  &/^0X>'M,'2SM?^_$7_P 12]M5
M_GG_ .!/_,?L:7_/N'_@*_R'#0=-'2TMO^_$7_Q-'MJG\\__  )_YA[&G_)#
M_P !7^0X:)IXZ6MO_P!^8_\ XFE[6I_/+_P)_P"8_94_Y(_^ K_(4:-8#I;0
M?]^H_P#XFE[6I_/+_P "?^8_94_Y(_\ @*_R'#2+(=+>#_OTG_Q-'M)_S2^]
M_P"8>SA_+'_P%?Y#AI=F.D$/_?M/_B:7M)_S2^]C]G#^6/W(7^S;0?\ +&+_
M +]I_A1SS_FE][#V</Y8_<APT^U'2&+_ +]K_A1SR_F?WL.2/\J^Y"_8;<?\
MLH_^^%_PI<\OYG]['R1_E7W(7[% /^6<?_?"_P"%'-+N_O8<L>R^Y#OLD(_Y
M9I_WRO\ A2YI=W]X^6/9?<+]FB'\"?\ ?(_PHYGW?WARKLON%^SQ#^!?^^1_
MA1=]W]X<J[+[A?(C_NK^0_PI7?=CLNR%\I!_"OY"B[[A9=@\M/[H_(47860N
MQ?0?D*+A878/0?E0 ;1Z"D,,"@!<4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M DT :- !0 4 -DD6)2[D*J@DD]  ,DGZ"@#*MM82X>-3%-"+@$PO($"R8!;
M"NS*2@+@2*A*@XY!% %R]O8[",22!CN9455&6=V.%51D#)]R !DD@ F@"*UU
M%;B5K=TD@F10^R39DH20&4QNZ$9&#AL@]0,B@!;?4H;JXFM8LE[8(7./ERY<
M *<\E3&P?C"GY<[@P  \WR+=+98;S&B:8' V[4=$()SG=EQ@8QC/(Z$ N4 %
M !0 4 % !0 4 5;*[2^A2XBR$D&5R,''N,F@"9'+,RE64*0 QVX?(!RN&+
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M4+0$1B3?,0(^?,\HJQ/#"0CKSQ3 LPZL'G6VFAFMI)0QC\SRB'V\L T4LH#
M<X8@XY%("&PUIM12.:&UN/)FP5D8VP 4G[Q'V@O@=2 A;'12>* +]G?QWD/V
MA<HH+JP? 9&C8JX?!(!!4YYZ<T 4;C7H+:R34)%D$<N"B;1YA# L#MW8^X"^
M-V=HZ;N*8%ZZU"&T@^TNV4.W;M&XN7^XJ <LS$C:!UZ],FD!5BU<&1(IX9K4
MS'$;2B/:S8)"9CDDVN0"0K[2<$ 9XH K_P#"0Q.L)ABFE:Y>9$1?*#9@9E<D
MO*B@?(2OS$D8X!XI@7+75%N)C;21RV\P7>$E"?,N0"R-&\B, 2 P#Y7(R!2
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M3@@G=Q@$%<*>=V6R2,*1A6W%3M# #Z "@"K97:7T*7$60D@RN1@X]QDT 6J
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MS,6W[B#_ !;G+$  2^LH;[688[A%E1;.9MK#*D^="!N4\,.2<$$9P>H% &1
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MD0O!&/)C:-70/&!'O9L L(U8C(QB@#H_#L<:>>8'22$NNWRHS' &"_/Y.9)
M5/&[:0@8'&<F@"GIME)=37VVXG@7[8X*Q>2 ?W,'.YX7D!.<95UP , ')(!2
MO-#CGOTTZ%V@A33V7Y<$D"4 !L_>&XAW!^^1AC@G(!T>FZHCQ^5=%(+B%U@D
M0D*#(>$\O.,K*,-$!R0=HR0: *_BL%M.< E29;89&,C_ $F'D9!&1VR"/4&@
M!\^DA ]U---<R1PRK'YOE@)N4[BJQ1Q+N(X+$$XXSBD!CV6M62:/#;K+'-.;
M2.,01LKRES"%V>6N6!W<'( 7^+%,#IM.VVT,-G(R^?'!'N3<"V%4(6QG.W<,
M;L8SQFD!SWB". W2M.]N/W) CO%/DD;CEHGR LW0$!68I@@#%,#.N+FWNC$)
MXX8 +6(J+TO,=K;AB",E6DD& 'DW"5LH,#.2 5+"(SFWE1 ]R-*G9&*@OYJ/
M$D9R<G>OW02=PY&>M %O2X+::2V$,D#2D'S4BMR)2A1A*MV6G;Y23@F5"QDQ
ML&<T +IQ@L]/@O8-@>QED-PJ8W".1BDH=5YW*@23#<XB7J,"@#K-%A=+?SI1
MB6Z8SR#T,F-J<_\ /.,)'_P&D!PR3Q-+;S1B"*9KQ-RC=)=@-+M<7$N5* YV
ME&4J<JJG@&F!8:SA%C=WFP?:(KZ<I+_&F+O@(W51R<A2 <G(.30 NH_85@U#
M[?M%Z6F\O?\ Z[9M/D>3_%LVXSY?R_>\SC=0!T>JPK-HDJLH?%FY4$ X80DJ
M0/[P/((Y!Z4 9TKZ6]TIN3 ;(VR_9MVS[-N\R7S]G_+/S,>5T^;&<?Q4 8@-
MR&;[/YF[[#>_9LY\SR?M,7E8SAL^7_J\_-C;WQ0!8"6QRUG+ Q%M<;UM8&3*
M&)@!<,9WP0^"N]3(7!'=C0!9-O:V6F6:B*("Y\EI'E.V$OY+/NN6 )D!8D(C
MG:7*C(  (!CM)"8I$9D-JNH6Q/D(Z1A6B'F&-=S,$.&RR'#89T S3 MZN;8K
M<?V9L^R^5!YOD[?)\W[3'LQM^3?LW;MO;;NYQ2 GMD62_1' 96U.]!!&00;,
M@@@\$$=10 [3C!9Z?!>P; ]C+(;A4QN$<C%)0ZKSN5 DF&YQ$O48% '6:+"Z
M6_G2C$MTQGD'H9,;4Y_YYQA(_P#@-(#CHC;_ &1/+V_VSYRY_P"?GS?-&_=G
MYO*V9W;OW/E^V*8'0>&+>* 7?E(J?Z9.ORJ%^56^5> .%R=HZ#)QUH I&)OM
M!T3!\IIOM6<?+]FSYAC_ !N1Y>,_ZMO3B@#.F^R_99O,Q_;'FR[,8^T^=YC>
M1L_B\K;L^Y^Z\O=WW4 *]A!+::K=.BM/#-=-'(1EXS'&'4QMU3#<G;C=_%D<
M4 7;C[!YUY_:NWSMX\G?CS/)\M/+^S9_BW[_ /5?-YGW^<4 9MB;+[5+_;>S
MSOLUID3XV[S#^]V[OE\W<.W[S'W>-U'H!-HUDMW>0B\3S/+L0Z+,-Q ^TRB)
MF5L_.(BN"PW*2>AH J23PM+',H@BF-[%D?-)>+_I*H_G297RD*%AM9638RHO
M)#  U8I-,U&_\\FUB2WE.SF)99[C/,AZ.41ON#^.3YSD!: ,E)XFEMYHQ!%,
MUXFY1NDNP&EVN+B7*E <[2C*5.553P#0!8:SA%C=WFP?:(KZ<I+_ !IB[X"-
MU4<G(4@')R#DT =/XC_U5O\ ]?UI_P"CTH YAK.$6-W>;!]HBOIRDO\ &F+O
M@(W51R<A2 <G(.30!U7B+_CV7=GR/.B\_&?]3N^?.WYMO3?C^'.>,T 8%X;'
M9)_9P_T?=;FZ-O\ ZCRO-'F8\L_?V9\SRQGR_O&@"GJZVCI.NF;1;FW F,&T
M0^89X/)P4^7S=GFYQSMVY[4 :_\ 8EB-4\CR(_)^R;S'M&PN)=H=EZ-)@D;V
M!?GK0!A6#V;S69U,J8_L'R^<<Q[A*0-Y;Y,A<A-_&>GS;: )A)$L:1D1?96N
M+EK9KIB+98U"!1L(PY+-(8 Q4! S*?NB@""RABOFM;>0+);_ &^[4(%9(R@@
M>156-F8K&3\P0D@J<=#B@"Y>00K<7D;,D$2360 :/=!A8,*DR@J!#T!)(53M
MSQQ0 1RP,D:2)$E@EV?/:%F-JY,.4(!X2(2;5=1^Y\P98G<: (;R.WFD\NT&
M;%[RR4!#B(R,9A.(BI VE#$'V\;MW?- '5Z?:Q6-_<0VR+#$8+:38@"H'9[I
M68*,*"P10< 9P">>: ,*_1(;K4!;A$NY+:-H=H42M\LOFF+^)FP!N*Y.=N><
M4 6K7^S_ +9:_P!D;,_/Y_DXQY/E/CS\<^9YWE[?,_>9WYYS0!9U>%Y]3LD2
M1X#Y5V=\8C+?\N_'[Q)%P?\ =SZ$4 4]8TM;2%"LDC37%]:%YF*&3(E55(&P
M1@)_"OE[ >JD<4 65@>SU2(WDKW*R(ZVSN$7RY,9D0K&J(S.@)1]H; =?0T
M9/AB\MH[*U5M1",$0&W,EH!G/^KP8O.YZ8W[^>#F@"[J"O!<RZ;&"$U1E92.
M-O&V\Y]?*56'/WY,\'J 3W(FN]1"6L44D.GQ[2LDC1)YLRXP-L,P;9#QMPN!
M+^% &9!)+:PQP7$>]M)NU:15+28MGBE6*13M5G$0D'1 ?W1.T8P #IUUVVN)
M(X;-ENG<C=Y3!A&F"6>1AD+C@;&(9B0 .M(#D+&YBM/[.EG=(HUN-2RSL%49
MDF RS$ 9/ YZTP.B%W%JNHP/9L)H[5)C)*G,8,@550./E9B06(!. O/.* +=
MWC^T[3?T\JZV^GF?N,?CY?FX_&D!R0DC4&.80[6OM08-=,1;J5FP RXVO(0Q
M,88J!M<@YQ3 AL8H[UK6W?$D'V^[55"LB%! \BJL;,Q6,GD(205./NG% %V[
MMH(&N+?=';V\5W"R(\>ZV!:VR5E0,H2)FY)R$63:<<\@#4DMV6%9EB2P2YE6
M4QLS6CMY2M&PW858=[,I7_4B12><@D J7WV4-^[XTW[=;A=F?*R8IO/\O;_R
MS^Z'V?)]_'>@!^JI;.MP-.V?8R+,2>20(O.-Y'C84^7?Y?WRG3Y=WS4 :FK0
MV=G/%:^5:PQ)$S*;@?N,EL,(X1M5YN 6.X/M.!G<: ,N&ZM9;"VM)O($\HE4
M2W"H/(A69T+ 3$D, -D<9).X?-D(<@&GY>E03I'.838I:JML9&5H"XDE%P0Q
MS&9<>5D_?/S8_BH R ;D,WV?S-WV&]^S9SYGD_:8O*QG#9\O_5Y^;&WOB@#7
MTE+8WD+6<L#$(^];6!DRA7 %PQG?!#X*[U,A<$=V- &UH&0MR/X!>7&STQO^
M;'_;3?G'&<T <I:VT=W>0Q3J)(VO-5W(W*MB0$!AT89 .#D9 R* .JT!%A%S
M#&-L<5U(J(.%12D;;5'15RQ(48 SP!0!B:C;7D$D4TJ0O++>1?.)GZ*7\N,+
MY'R(H/)#.2Q9B#NX -O6T 2!L .UW:[B.^)!@9P"0,G&?R% %S6O^/"Y_P"O
M>;_T6U(#E5LDLEL7L46.>:&4,R@!I&^RLZ^8W5_G"D;R<'I@4P*^E1P,]HT4
ML(N@RF18H&%S]T^:MRQG+ =0S2)][:4'2@"K!/$TUI-%Y$<SW*[E3<]T ^X2
M"YFRI!)(5D=""V%4X4&F!/IZV\9T^:X$:@3WZAY H^;SY3&-S=]V2@SG=RO-
M( MK&"+2OMRHHN5NV*RX^=?]/*85NH4KD%1\IR20<F@#4,+"Z.C8/D--]KSQ
MM^SY\PQXZ#_2AMVY'[L]-O4 TO$<J)'%'*L9224 F9BMNI".1YV =RDC"HV%
M9]N2, $ Y.!T,<R90V2WL#2B%&2'RFB&\JNYCY)E"[B#L;#-@*30 ^]^QM-=
M'3=K1);VSOY(S&"EUO<IM^3Y4&7V<9!S\^Z@!WB/4+>_-R;:19E73I<LAW+D
MS1<!A\I([@'(R,XS0!T6GK;P:O>+B-)I%B91A0[*5)D*]&(+ %R,C< 6YH S
M=?6W6Z=YFMV;R%Q%=JP! +G-M*#\LA/#!%9]P0@CB@"Q9ZG!87,\EV?LYGAM
MI(TD)+L!$0RKGYI'5OE(&7+=1S0!C:>;%9;8ZB4\O^RK+;YV/*W?OOO;ODWX
MSL!YQOV]Z '_ .D" ?9M^?LNI?9NN_R?M%KY>,X;.S_5\[L;>] $D"1%PVF2
MP-,+>;Y;6 H3F,A!<,9WPPDVE=ZF0N".[&@#0TU=)?[.ENJO<,A654 +D-&P
MD^V \E<]1+EC)MV@\T 8ULEHVGV8WVZ>69 Z3(&MS+M&5GPRA)@N#&7RW8*<
MB@#L] E62S7RT$2*SJH5F9" [#=&6PWEL<E!C"KA5^4"D!LT % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 $XY- %:UO(;U3);L)$5F0L.FY3@X/<9[C(/8F@"S0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #9$$BE#D!@1
ME25(R,<,,$'T(((/(H S(-*$4J3RRS7#Q*RQ^:4PF[ 8C9&FYB!@L^XXSSR:
M -6@ H * "@ H IVEBEDTK1EB;B4S-N(X8HB87 &%P@X.3G//0  N4 % %.T
ML4LFE:,L3<2F9MQ'#%$3"X PN$'!R<YYZ  %R@ H * "@ H B,"&03$?.JE
M<GA6*E@!G')5<G&3@<X% $M !0 4 % %&WL%MYI+AG>627"[GV_(BEBL:!54
M!06)YRS<%F8@4 7J "@ H * "@ H * "@#.N=/:X<ND\\&Y0K+&R;2!GD!T?
M8W)!:,H3P2<@$ %NWMTM(D@B&V.)0BCT51@#\A0!-0 4 % !0 4 130). L@
MR%97 R1\R$,I.",X8 @'(R <<4 2T % !0!#]G3S?/Q^\"[ <GA20Q &<#)
M).,G R>!0!-0 4 % !0!1OK!=0412.ZQ9^=%V@2#(.UR5+;>.0C(2"020<4
M7J "@ H * "@ H * "@ H * "@ H HWU@NH*(I'=8L_.B[0)!D':Y*EMO'(1
MD)!()(.* +U !0 4 % !0 4 % %.&Q2"XFNE+%[@1A@2-H\L$+M& 1D$YR3[
M8H N4 % !0 4 % !0 4 % !0 4 % %/["GVH7N6\P1&'&1MVEP^<8SNR.N<8
M[=Z +E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 5KFU2YV%LJT3B
M1&4X((R#V/#*61@1RK$<'! !9H * "@ H IWEBEZ8C(6'D2K,NT@990P .0?
ME^8Y P>G- %R@ H * "@ H 1@6! )4D$9&,CW&01D=L@CU!H @M+5+*)8(AA
M(Q@9Y)]23W8G)8]R2>] %B@ H * "@ H * "@ H * "@"C;V"V\TEPSO+)+A
M=S[?D12Q6- JJ H+$\Y9N"S,0* +U !0 4 % !0 4 % !0!2%D/M7VMG=F"&
M-$.W8BL4+[<*&)<QJ269NF%P.* +M !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % ",H8%2,@\$'D$'L: ,W3+=K1)1( @:>5UY&-C-E3P< 8['!'<"@#D!91
M64(DOK=LJ_F?VE R._+[A*S']ZJ;?O +)&!GMBF!9@GO+4ZE<6YA$<%S)(5D
M5V9RL$+,H9741C:!ABLF2?N@#D NZAKLL!<PO"NR%9%B,<LTCY3>=WE,/)7'
M +*^>7X48H K6<MU=ZC<2V9BB$EM9NWFJTF-PF*J CQ]<G+9.,#"G/ !T5A>
MG4+%+IL0F2+<3GA#CD@G' .2,XXZT@.3@M(=.2)KRV:&2-X_]/@9'WMN WR.
M3YH27HP=&3#D97"FF!JV%A!JTMS<7J+<,EQ)"BR ,D21D*H1&R%9OOLP&X[N
MN,"@#<T^VCLXS!"[.B.V S!O+SSY8/4*N?E5B6 (&<8 0'.G7[J16G@0NBR,
MJPBUN6=T1RC$3K^Z#'!8#8RCA6;.<,#3TD3BYO?-=&47"@!492#]FMB.3(PQ
MM(!&.6RV0&V@ K:KJ\MI*\<3PH8X]RH8Y9Y'."3E8F4Q+T 9@^<EL87! (].
MN/MFI_:,;?-TZV?'7&^69L9]LXH V]5N'L[.>XC^_%#*Z]_F1&8<?44@.>N-
M*TVUME:97>612WVN.*:6;?M!,IEB1W3D[@"P0] " 13 L7&L.HA$$T.)8$D5
MFAEEDE+CY2((F1XU. =Q!Y;8%RIH K'Q!<210382VCF@$C2O#+-'YN<&/,;)
MY8XW!G)R.-N0: '?:)SJ G#Q,HT\R80,Z$[LG8^\!@7 (?8,IA=H/S  EM=3
MOY;6VF?R/-OVC$2A7"Q*T3S,SDR$R'RT.%7R\-\I8]: $O-<N-.=K6=4DG)B
M\IXTDV%969?FB#22;D*,2J,V_(QMYP 07.O7EI%,Y02>6L;)(;>XMT):58VC
M9923N ;<K*Q'JO&" /U*[O8XKFTF:$LUE+,KQQNNW;\KH5,K%B0WR2!EP>2A
MQ@@#O[3N+?R+-"H?[.LKR"VGF&"2J*(HGW _*=S-)CC@<X  +J]_/);6Z)'!
M).+C>TL4N/W#1[7CC+1/MD5\[6(()'/RG< 3MJ5[)'<7,(A$5H\B>6RN7E\G
M_6'>'"Q[B#L!23H-QYX ,VUU"3[7<FT"[[RYME0R9VH#8K,695(+82-L*&&6
MP-P'- %^XUBZLI#92")[AVA\EU#)&5F=DRZ%W8%-C$X<[\C&WG  RYU34+&:
M6)Q!,(8!< HCH602 2KM,K[6"!BIRV6V\=5H V+:_-W=/'%M,$4<9+<Y,DGS
MJ%.<;1'M8Y&?G7!QFD!=N8/M,3PAFCWJ5W(0&7(QE20<'T.,CJ,'F@#E/+@B
MG\_2458[2*;SGC&$E8(=D61_K75QO9N=F-I;<Q%,"-;2*TMK"\A 6XDEMA)*
M/OR^?@2[VZN&W%@&R%(&T  "@"74;"WR;:V_>ZE))Y@FX,L.7W>9)( /+C1?
ME1.-X 14.6( +6N6[^?:S-(Q47<(6,8" G=ECCEV..,G:HSA<G- '1XD\S.Y
M?+VXV[3NW9Z[]^-N.-NS.>=^.*0&%IMNUMJ%P'D:9VM[5F9L#DR78PJC"JH
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MCGES"L2QRO;F5_G); C9($11C W MER<G (!?T?2FL+!;;<896RS,A5BK'&
MID5U.Q L8RI&U1Q0!J7MJ+V![<L\8D4J6C(#@'KM)# $CCH>M("I9Z:]GM7[
M1-)$@VB)DME3&, ?N[>-@!V 8#CG(XH B@T2. QCS)7BMSNBB<H4C."%QA [
M! 2$#NP48QT&&!';Z&UJ6\F[N4$CM(WRVIRS'))9K8L?098X4!1@ 4 :5W9I
M>>7O+#R95E7;CEDS@'(/'/.,'W%(!?+F^T[]_P"X\O;Y>!GS-P(?.W<,+D8W
MD'(^4$9( Y;54G>Y!.^2..,CC&(VE92.,Y)E;/)& N .<@&:NA1+A/,E-NL@
MD%N2GE!@V\#[GF% _P P0R% 0/EP *8"S:'%*9!YDJPW#;I85*>6YXW9RAD4
M/@;PCJ&YSU.4!J"-A(7WL5( "$)M4C^($*'R>^7(] * *ZZ?$LDTIRWVH*)%
M.-N%4I@# /(/.2?;% %*/0T3RD>6:2*W96CB<IM4I]S)6-9&V=5#NPR!G.!3
M :V@Q,&B\R46[N7-N"@B)+;RO^K\P(6Y*"0+R1C!Q0!HW=FEYY>\L/)E65=N
M.63. <@\<\XP?<4@+= %2^LTU"%K>0L%?&2N >&##&01U'ITH BNM.6XE6X1
MY()D4IOCV9*$@E6#HZ$9&1E<@]",T 26-BE@C*A9VD<R.[D%G=L L< *.
MJJH   H =:6:60=8R3YDCRG=C[TC%B!@#@$\=3CJ30 EI9I9^9L+'SI6E;=C
MAGQD# '''&<GW- %N@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img46421407_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &;!*0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#1M?&OC_5-
M<U2STE(;I;2=E*F-1M7<P7M[5I?VO\6!_P PNW_[X%)\*?\ D=O%W_78?^AO
M7KE=-2:B[**.2E!S5VV>2?VO\6/^@7;_ /? H_M?XL?] NW_ .^!7K=%1[5?
MRHT]B_YF>2?VO\6/^@7;_P#? H_M?XL?] NW_P"^!7K=%'M?[J#V+_F9Y)_:
M_P 6/^@7;_\ ? H_M?XL?] NW_[X%>MT4>U_NH/8O^9GDG]K_%C_ *!=O_WP
M*/[7^+'_ $"[?_O@5ZW11[7^Z@]B_P"9GDG]K_%C_H%V_P#WP*/[7^+'_0+M
M_P#O@5ZW11[7^Z@]B_YF>2?VO\6/^@7;_P#? H_M?XL?] NW_P"^!7K=%'M?
M[J#V+_F9Y)_:_P 6/^@7;_\ ? H_M?XL?] NW_[X%>MT4>U_NH/8O^9GDG]K
M_%C_ *!=O_WP*/[7^+'_ $"[?_O@5ZW11[7^Z@]B_P"9GDG]K_%C_H%V_P#W
MP*/[7^+'_0+M_P#O@5ZW11[7^Z@]B_YF>2?VO\6/^@7;_P#? H_M?XL?] NW
M_P"^!7K=%'M?[J#V+_F9Y)_:_P 6/^@7;_\ ? H_M?XL?] NW_[X%>MT4>U_
MNH/8O^9GDG]K_%C_ *!=O_WP*/[7^+'_ $"[?_O@5ZW11[7^Z@]B_P"9GDG]
MK_%C_H%V_P#WP*/[7^+'_0+M_P#O@5ZW11[7^Z@]B_YF>2?VO\6/^@7;_P#?
M H_M?XL?] NW_P"^!7K=%'M?[J#V+_F9Y)_:_P 6/^@7;_\ ? H_M?XL?] N
MW_[X%>MT4>U_NH/8O^9GDG]K_%C_ *!=O_WP*/[7^+'_ $"[?_O@5ZW11[7^
MZ@]B_P"9GDG]K_%C_H%V_P#WP*/[7^+'_0+M_P#O@5ZW11[7^Z@]B_YF>2?V
MO\6/^@7;_P#? H_M?XL?] NW_P"^!7K=%'M?[J#V+_F9Y)_:_P 6/^@7;_\
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MO\6/^@7;_P#? H_M?XL?] NW_P"^!7K=%'M?[J#V+_F9Y)_:_P 6/^@7;_\
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MO\6/^@7;_P#? H_M?XL?] NW_P"^!7K=%'M?[J#V+_F9Y)_:_P 6/^@7;_\
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M;DD*?ZI1T ]J*Y2W_P"/B^_Z^7_I172Z<;['+&K*VYZA\*?^1V\7_P#78?\
MH;UZY7D?PI_Y';Q?_P!=A_Z&]>N5S5_B.K#_  !1116)N%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4E+0>E 'RG;_ /'Q??\ 7R_]**2W_P"/B^_Z^G_I17I/<\Q;'J/PI_Y'
M;Q?_ -=A_P"AO7KE>1_"G_D=O%__ %V'_H;UZY7%7^([,/\  %%%%9&X4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45QO
MB#XI>$O"^K/IFK:A)#=HH9D6WD<8/3D BLO_ (7GX _Z"TW_ (!R_P#Q- 'H
MU%9N@Z[I_B31X-6TN9I;.?=Y;LA0G!(/! /4&M*@ HHR*,T %%%% !15*PU:
MPU7SS8W4=PL$ABD:-MP##J,^M7,B@!:*,T9H **,T9H **,T9Q0 453O-6L+
M"YMK:ZNHXY[I]D$1;YI#[#J:N4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'
MI10>E 'RE;_\?%]_U]/_ $HHM_\ CXOO^OI_Z45Z3W/,6QZC\*?^1V\7_P#7
M8?\ H;UZY7D?PI_Y';Q?_P!=A_Z&]>N5Q5_B.S#_  !11161N%%%% !1110
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MXJU]_C3:ZM+X?D&H6V%ATXR$[P%(!!QQD<]*^F-%O;G4=%M+R\M#:7,T8:2
MG/EGTKPGQGJ-II'[2-A?ZA.MM:Q11%YGSA?W9'\S7OUI=P7UI%=6LJRP2KNC
M=>C#UH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "@]*** /E.W_X^+[_KY?\
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M_P!!RS_[^5/]BM?^?:'_ +X%'V*U_P"?:'_O@4>T#V9!_P )QX7_ .@Y9_\
M?RC_ (3CPO\ ]!RS_P"_E3_8K7_GVA_[X%'V*U_Y]H?^^!1[0/9D'_"<>%_^
M@Y9_]_*/^$X\+_\ 0<L_^_E3_8K7_GVA_P"^!1]BM?\ GVA_[X%'M ]F0?\
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MC_A./"__ $'+/_OY4_V*U_Y]H?\ O@4?8K7_ )]H?^^!1[0/9D'_  G'A?\
MZ#EG_P!_*/\ A./"_P#T'+/_ +^5/]BM?^?:'_O@4?8K7_GVA_[X%'M ]F0?
M\)QX7_Z#EG_W\H_X3GPO_P!!RR_[^5/]BM?^?:'_ +X%*ME:[A_HT/7^X*/:
M"]F?-%M+&9KQ@XVM<,5/J..:*=:@>=>C' N7Q^E%>N]SR%L>H_"G_D=O%_\
MUV'_ *&]>N5Y'\*?^1V\7_\ 78?^AO7KE<5?XCLP_P  4445D;A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:]_U
M_P!ZJ-7KW_4#_>JC3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "H>]35#WK2F95!****U,@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6#[Y^E3U!!]\_2IZX:WQ
MG;1^ ****Q-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "E
M7[P^M)2K]X?6F@/F2U_U][_U\O\ THHM?]?>_P#7R_\ 2BO;>YX2V/4/A3_R
M.WB__KL/_0WKURO(_A3_ ,CMXO\ ^NP_]#>O7*XJ_P 1V8?X HHHK(W"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *
MU[_J!_O51J]>_P"H'^]5&F 4444 %%%% !1110 4444 %%%% !1110 4444
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M/97\O2DO"\D)^7!,?;'/YUQOPU_Y+AXI_P!R;_T:M)X)_P"3A_$'_7*7^:4
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M^%8>E?#O6X?A8GAU]3.FZI'.TR3VLI*X/&TD8.#[>U=9_P (_KO_ $.VI?\
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M22-W/H.WT%;%MX7UBTM8K:'QIJ2Q1($1396IPH& .8ZD_P"$?UW_ *'74O\
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MKG(?AMX\\(WUVO@K78%L+EMQCG*J5ZXZ@@D>HQ7H_P#PC^N_]#KJ7_@%:_\
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MH *A[U-4/>M*9E4$HHHK4R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.O$.M^,?'&M:HVHW7]@VS,EO;9_=DDX7CZ<T >L44R:6.W@DGE;;%&I=VP<
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MWUWYD^"MM"7*8=^OIG^E>C_\)A*/^9;US_P$-<=?XSLP_P !U%%<O_PF$O\
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MI9_#'P?87L5Y;:-&D\3;T?S'.#Z]:M_\)5+_ -"YK?\ X"FC_A*I?^A<UO\
M\!30!T4G,;^NT_RKQCX)6\\/B3Q.TL$L89LJ70KGY^V:]&_X2N7_ *%S6_\
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M*QT-%<]_PE,O_0NZU_X"FC_A*9?^A=UK_P !31=!8Z&BN>_X2F7_ *%W6O\
MP%-'_"4R_P#0NZU_X"FBZ"QT-%<]_P )3+_T+NM?^ IH_P"$IE_Z%W6O_ 4T
M706.AHKGO^$IE_Z%W6O_  %-'_"4R_\ 0NZU_P" IHN@L=#17/?\)3+_ -"[
MK7_@*:/^$IE_Z%W6O_ 4T7069G?%6-Y?AOJR1HSN50!57)/SK7E_@WXH7GA/
MPU;Z0?"MW=&(L?-$C)G)STV'^=>PCQ5,.1X=UL?]NII?^$MN,_\ (OZY_P"
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MJRO([*.D3HZ*YS_A+)?^A<US_P !#1_PEDO_ $+FN?\ @(:RLS:Z.CHKG/\
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MXO\ ^NP_]#>O7*\C^%/_ ".WB_\ Z[#_ -#>O7*XJ_Q'9A_@"BBBLC<****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K
M7O\ J!_O51J]>_Z@?[U4:8!1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 44A.T%O09KS]/B[HTXF2STG6;VYAF>*2VMK<.Z!3C<2#M
M)!QSGVII7$W8]!HKFO#_ (XTOQ+I-[?6$5UYEGD3VDD>V9& SMQW/T-<_P#\
M+<@_Z$WQ7_X #_XJGRL7,CT6L[4=?T;2)%CU/5K&R=QE5N)U0D?0FL?PSXW3
MQ1=S6L6A:SIS1Q[Q)J%KY:-VP.3D^U8UGX(\.:,;[4?&%QI]_>WL[R?:+]@H
M5.R*&/8>E"7<+]COK>XANK=)[>5)H7&4DC8,K#U!'6J%_P")-"TNY^S:AK6G
MVEQC/E7%RJ-CZ$UPGPS@FBN/%#:,CKH+S$Z;Y@(0OCG9G^#/X5C^!++P<=$O
M#XPAL1KZSR-??VKA93SD%=W4$>F:?*+F/9(Y$EB66-U>-QE74Y##V-.KS?X0
M07$%AK7E)<)HC7A.F"<$$IW(!YV]*](J7H4G<****0PHHHH *5?O#ZTE*OWA
M]:: ^9+7_7WO_7R_]**+7_7WO_7R_P#2BO;>YX2V/4/A3_R.WB__ *[#_P!#
M>O7*\C^%/_([>+_^NP_]#>O7*XJ_Q'9A_@"BBBLC<**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K7O^H'^]5&KU[_J
M!_O51I@%%%% !1110 4444 %%%%  >A^E><_"BWB2X\6700><^KRJ7[X!/%>
MC5C>'_#5GX;&H"TEGD^W7+74GFD'#'J%P!QSWS0!QVF!U^.'B,0!%D.EJ5R,
M*7W#!./?O5MV^,&]MC^%=O;)ESBNDM_"]G:^+KOQ(DTYN[J 0/&2/+"@@Y'&
M<\>M;= '&Z9/\1XC=2ZVFASQ+;L88K$OYC2?PCYN,5QGAJZ\;>'HM0N+CX?7
M=[J=_(TEU>->(N[T4+@X4>F:]EI&4.I4]",4 >0?!C6=4C\/S6LFA2C3(Y)Y
MSJ"R@_/D$QA,9)_&NVLQX7^)>DPW\NGK>P0N\:I<KAHF[@@'CH*T/"WAFT\)
M:/\ V;8S3RPF9YMT^"V6Y(X XK"O_A?I%SJ$U[8:AJNCO<$O.FGW'EI(?4J0
M1GZ8H R?A](=-\>^)O#>G3-+H=EY;P(7W"!F'*@_7C'M7IM8_ASPOI7A:R>V
MTR KYK;YI7<M)*WJQ/)K8_'- !1110 4444 %%%% !1110 5#WJ:H>]:4S*H
M)1116ID%%%% !1110!P/QA19? 4B-RK74"D>H\Q:WO$L$47P_P!1@2-!$E@P
M5,<#">E6?$GAVU\4:3_9UY--%%YBR[H2 V5(('((QD>E7-0T^+4=*GTZ5W6*
M>$PLRD;@",<=LU-M;E7TL<)X8;Q2?A?X</AAM.\\PGS3J!;&W)QC'>K&[XO_
M //3PK_Y$KK="T>W\/Z'::3:R2R06J;$:4@L1DGG  [UHT<H<QYEXV@\<:AX
M;TW3I-*34))GW:HNG2;%= >$#-R,CJ<&N6\<ZWXBEL?#]M<^"9=)@M=0A-LO
MVI6$K#.V,8'&?6O=JQ?$?ABR\3+8+>33Q"RNDNH_)(&77H#D'BDXC4CA/&U]
M?30^$->U;2WTLV^H[9[9Y YCW< Y ]J['XA7D=GX!UJ9Y%&^V9(R3PQ;H!ZY
MK6UG1['7M,FT[4H!+;2@!E/!]B#V-<G:_"K1XKB!KO4M7U&W@8-%:7=SOB4C
MIP ,X]Z=F%T;?@>T>Q\#Z+;RKM=;2,L/0E0:WZ!TXQCVHIHEA1113$%%%% !
M1110 4444 %%%% !1110 5YWXTMXKKXG>"HYD#IYDK8(R,@+7HE8^H^'+34M
M?TO69IIUN-.+&%$(VMNQG=QGMVQ2:N-.QRGQEY\'VS$99;Z':V.1\W:MG7CX
M]%ZG_"--H@LO+7/V[?OW=^G:M#Q-X9L_%>EI87LT\422K*&A(!RIR!R#Q6R!
MA0OIUI6*YC@U;XN9&Y_"VWOCS>E9/BZ+Q7=>-+"=O"TVL:7IZ+)%%%.L:/.1
MRQSG('88KU.BCE%S'A]WXD\3O\6-.OW\&3IJ"6+QII_VM2TB9.7W8P,<\>U=
M1YC6?QPM9KM1#_:.F;8E9NC*.5SZ\5ULWABSG\76WB5IIQ>6]NUNL8(\LJ<Y
M)XSGGUI/$OA/3/%5M%'?":.:!M\%S ^R6(^H-)197,CF?BR?/L]!TN,C[1<Z
MI%B/^+:,DFO0578BIW4 ?E7*:'\/M+T755U.2\O]3OHUVQ3:A-YAB!Z[1P*Z
MS_\ 75*][LA[6"BBBF(**** "BBB@"6#[Y^E3U!!]\_2IZX:WQG;1^ ****Q
M-PHHHH **** /-] MXI/CCXFG= 9(K*$(Q'*YQG%'BG ^-7@YA@%HIPQ'4C
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MB@ HHHH **** "BBB@ HHHH **** "H>]35#WK2F95!****U,@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6#[Y^E3U!!]\_2IZX:
MWQG;1^ ****Q-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-, HHHH **** "BBB@ HHHH **** "BF2RQP0O+-(D<:*69W(  '4DUYI/\
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M>PIK6K^)[>W;4=;F#SVNT.D<:C"H<]3ZUU,.@Z/I\GVFSTBSBG0':T5NJM]
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M/(!R"N*ZSPYHNO>(O'B^,O$.G?V7%:VYAL;%I-\BD\,S\>F?SH Y+2D\8/\
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M&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!6O?]0/]ZJ-7KW_ % _WJHTP"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J'O4U0]ZTIF502BBBM3(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH E@^^?I4]0
M0??/TJ>N&M\9VT?@"BBBL3<**** "BBB@ HHHH **** "BBB@ HHHH ****
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MW"BBBF(**** "BBB@"6#[Y^E3U!!]\_2IZX:WQG;1^ ****Q-PHHHH ****
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M)(XKO;_7-(T?3#?WE_;P6,9"^<&R@). /ES7G'Q;@M9IO"?B&5!<:3;70$S
M94(Y!#'V^6DMQO89J_B_P1X@T^+0]1T;5-.TV1E6VU"2S\J)2/NE6'(S]*]5
MM(D@LH(8I&EC2-561FW%@!P<]\^M<5\3-6T*;X;:@KW5O-'<Q!+-(F5BSG[N
MT=JZ#P?!=6O@W1X+T$7*6D:N&ZCY1P?I1+8([FW1114%A1110 4444 %%%%
M!1110 4444 %%%% !5#6=8L]!T>YU2_D$=O;IN;U/L/4GTJ_7G_Q%\->*/$=
MYI?]C'3I;&T?SI;:^D94ED!XW!>2!]13CN)O0X#5=/U*[\4^$_%NL,\=UJVK
M1^1:$\6]L""BD?WB.3]:]:\3^$(O%&H:3+=WCK:6$WGM:>7E9W'3<<\8_&O+
M/'+?$+^U_"PUB+P^LXU%?L(M=^WS>,;\G[OTKT+7_&5YX0\+6;ZQ%:S>(;HB
M&*VM6(C>4\ Y/11_]:M)+:QG%F?\8/[+3P:+(V\7]I7$R+IR1*!(),_>&.<
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M_P#"%^%_^A>TO_P%3_"C_A"_"_\ T+VE_P#@*G^%/]UV8OWO='-_\+F\(?\
M/>\_\!FK*TKXA?#K1;[4+W3TO(;C49!+=/Y,C>8PS@X)P.IZ8KN?^$+\+_\
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M_@*U9.A?$#X<^&DN4TB.\MDN9/-D012,I;U )('X8KNO^$+\+_\ 0O:7_P"
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M $+VE_\ @*G^%%Z79A:KW1QW_"VO"7_/Q>?^ K4?\+:\)?\ /Q>?^ K5V/\
MPA?A?_H7M+_\!4_PH_X0OPO_ -"]I?\ X"I_A1>EV86J]T<7+\5?!T\3Q32W
M4D3@JR-:$AAZ$=Q7)QW7P>BO_MJZ3+YV[?@P2%,_[A;;^E>P?\(7X7_Z%[2_
M_ 5/\*/^$+\+_P#0O:7_ . J?X47I=F%JO='G.M>-_AYXATU-.U2.ZGM(V5D
MB6!XPI7I]TC@>E37_P 0? .J:6=-ODN+BS*A?*DM"0 .G/7/O7H'_"%^%_\
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M^J.(_P"%K^%/^>]W_P" QI?^%K^%/^>]W_X#&NV_X0OPO_T+VE_^ J?X4?\
M"%^%_P#H7M+_ / 5/\*?M:?9D^SJ=T<3_P +7\*?\][O_P !C1_PM?PI_P ]
M[O\ \!C7;?\ "%^%_P#H7M+_ / 5/\*/^$+\+_\ 0O:7_P" J?X4>UI]F'LZ
MG='$_P#"U_"G_/>[_P# 8T?\+7\*?\][O_P&-=M_PA?A?_H7M+_\!4_PH_X0
MOPO_ -"]I?\ X"I_A1[6GV8>SJ=T<3_PM?PI_P ][O\ \!C65KGC'X>>);=(
M-7MYKI$.5+6S*R_1@01^!KTO_A"_"_\ T+VE_P#@*G^%)_PA?A?_ *%[2_\
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MZ/-]'\<> = TL:9IJ74-D,GRC [CGK]XG-8DES\(I+XWC:5+YI;<0L,@3/\
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M_ 5/\*/^$+\+_P#0O:7_ . J?X4>UI]F'LZG='$_\+7\*?\ />[_ / 8T?\
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M/^@3>?\ D?\ ^+K=N?%?PSO'TMIX+QCI8 L_W4@\K&/1N>@ZYKTO_A"_"_\
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M_P !31_PMSPC_P _%Y_X"FNN_P"$+\+_ /0O:7_X"I_A1_PA?A?_ *%[2_\
MP%3_  HY*/9_>'/7[K[CD?\ A;GA'_GXO/\ P%:@?%WPB"#]HO/_  %:NN_X
M0OPO_P!"]I?_ ("I_A0/!?A?_H7M+_\  5/\*.6BNC^\.>N^J/FRRF21KJ1<
DE7G9EX['%%?2R>$?#D8(30M.4$Y.+9!_2BMW7CV.=4)6W/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img46421407_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $; Q8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ H-%!H \D^-MY=6L>BFVN9H=QFW
M>6Y7/W/2O(?[7U/_ *"-Y_W^;_&O6/CM_J]$^LW_ +)7C5>IADO9H\W$2:J,
MN_VOJ?\ T$;O_O\ -_C1_:^I_P#01N_^_P W^-4J*WLNQAS/N7?[7U/_ *"-
MW_W^;_&C^U]3_P"@C=_]_F_QJE119=@YGW+O]KZG_P!!&[_[_-_C1_:^I_\
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M-']KZG_T$;O_ +_-_C5*BBR[!S2[EW^U]3_Z"-W_ -_F_P :/[7U/_H(W?\
MW^;_ !JE119=@YGW+O\ :^I_]!&[_P"_S?XT?VOJ?_01N_\ O\W^-4J/QHLN
MP<S[EW^U]3_Z"-W_ -_F_P :/[7U/_H(W?\ W^;_ !JE119=@YGW+O\ :^I_
M]!&[_P"_S?XT?VOJ?_01N_\ O\W^-4J*++L',^Y=_M?4_P#H(W?_ '^;_&C^
MU]3_ .@C=_\ ?YO\:I44K+L',^Y=_M?4_P#H(W?_ '^;_&C^U]3_ .@C=_\
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M#ADD7:P^H-6+'1]3U0,=/TZ[NPIPQ@A9\'\!7K7Q+TZTU[2/#NLHBQ7%Y/'
MQ7C*O_/&*M^./%$WP\T[3-&T"V@B<QY\QTW  >W<G)I^W<DDEJQ>P2;;>AXI
M=V5W87'V>\MIK><=8Y4*M^1J6\TG4=.2-[ZPN;99!E#-$5#?0GK7KVJ7$?CW
MX33:Q>P1IJ%B&<2*,?,OI[$8XJK>;?&?P8BG5=]]I8 /<_)P?S44_;OJO)B=
M%='YGED6CZG/8-?Q:==2629W7"1$QC'7YNE)8:1J>J!SI^G75V$^]Y$+/CZX
MZ5ZIXU/_  C/PWTCPQ$RK/>;/.([C@D_]]8KKKNVN?#OA?3+#P]J&C:8VT,\
MFHOMW\#.!W.3R>W%2\0TKV]"E05[7/G:ZM;BRG:"Z@E@F7[T<J%6'U!J*O9?
MB:=/U/P=:W<M]I<^LV[*KM:3JVX'KCN17C7\JVI3YXW,JD.25D:)T#60L#'2
M;[;<'$+>0V)3C/R\<\5%?:1J6EE?[0T^ZM"WW?/B9,_F*]SUSQ//X4^&>D7E
MI#&]U+''%&T@R$.W.<=^!5/0=8?XB^ -7@UF&(W%NI_>HN 3@D$#L>*Q6(EN
MUH:NA':^IR?@WPEHVL> =6U:]MWDO+:1Q&XE8  (I' ..I-<EX1TZVU;Q3IU
MA>(7MII5610Q&1]17J7PH2U?X=:LM^Q6U-PXE(SD+L7/3FF>&K+X8)XBL6T?
M4+E]0$@,"L9<%NW5<5+JVYD[LI4[\K5D<#\1-#L/#WBQ]/TV)HK=8D8*SECD
MCGD\URG:N]^,'_(_S?\ 7"+^5<IX?T6X\0ZY:Z;;#YIGPS9QM7N?RKHIRM33
M?8PJ1]]I'8_#/P%%XGFFO]4C<Z;%\BJ&*F5_J.<#^M<SXRTRUT?Q9?Z?91M'
M;PN B%BQ P.YKVO3+B:Q\8:=X:TVPN8='L+9_,G:%E223C^+&#W/U)]*\D^)
M-K<0^.-2EEMY8XI9 4=D(5N!T)ZUC2FY5+OL:U*:C3T[G/Z3IDVL:M;:=;_Z
MVXD"*?0=S^'6O7_^$%^']GJ,'AZ[GF;6)H\A_-<$GUX^4'@X%<)\+=I^(FF;
ML8Q(1G_KFU;'B0L/C;$4W;A<Q=.M.KS.?*G:RN*E90YFNIR'BKP_)X9\17.F
M._F*AW1OW9#T-9,$$ES<1P0H7DD8*J@<DGH*]$^-87_A,K?!Y^QKG_OIJQ/A
MG9I>>/\ 3D<#$9,HR.Z\BM(U/W?-Y$2A^\Y?,V/$?@K2].U3P]X<M@1J=T5^
MV77F,W4@'"G@>HK1\2>!O#R:!K+Z/#<17VCLHE9Y2PESUX)X]>/2L;Q]J]QI
M_P 5I=0C"M)9O$45NA"@<?C6^WC#3_%KR:'HVFW,-WK4R&]EF8;55>6VX)[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+XN_Z#EQ^2_X4?\ "Q?%W_0<N?R7_"N7HH]E#L'M9]SJ/^%B^+O^@Y<?DO\
MA1_PL7Q=_P!!RX_)?\*Y>BCV4.P>UGW.H_X6+XN_Z#EQ^2_X4?\ "Q?%W_0<
MN/R7_"N7HH]E#L'M9]SW'X1>)=9UZ\U--4OY+I8HT*!\?*23GI7JG:O%?@7_
M ,A#6?\ KE'_ #->UUYN(251I'HT&W!-G-^/-0NM*\$ZG>V4S0W,2*4D7JI+
MJ/Y&O!?^%B^+O^@Y<?DO^%>X_$S_ ))WJ_\ US3_ -#6OF;M71A81E%W1ABI
MRC)69U'_  L7Q=_T'+C\E_PH_P"%B^+O^@Y<?DO^%<O175[*'8Y?:S[G4?\
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M.*\3  .0 *"JGJH_*G]7]U),7M];M'KWB[Q[ID7CW1KVR=;I-/#+<RQCAMV
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M2&BJ12/L>BC-%>$>R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444F: %I#P*6
MC&: /'?CKS%HGUF_]DKQNOJGQ#X1TCQ3]G_M6%Y?L^[R]LA7&[&>GT%8?_"H
M_"'_ #Y3?^!#?XUVTL3&$%%G'5P\IRNF?.5%?1O_  J3PA_SY3?^!#_XT?\
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MT;_PJ3PA_P ^4W_@0_\ C1_PJ3PA_P ^4W_@0_\ C1];AV#ZI/N?.5%?1O\
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M0_\ C1_PJ3PA_P ^4W_@0W^-'UN'8/JD^Y\Y?C1^-?1O_"I/"'_/E-_X$/\
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M6Y10!A_V+J/_ $'KG_OV/\:/[%U'_H/7/_?L?XUN44 8?]BZC_T'KG_OV/\
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MJ]VJJZ'>/F)"\YZ<$=:])\!Z;HFL_!/3$\2PQW&G6P:9A,Y"IM)P<@CL3^=
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M^@[U[C=W,=G9S7,K!8XD+L3Z 9KS?X1V,FHQ:IXUO5S>:U<.T6[JD ;"K^E
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M#/&N3%*I(SCNIQTK'\0Z;>Z!=RW\FIKJ'BW70NG631P^5' G\3*F6(QG))-
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M.#_P$5[/63X<\.:9X5T>/2])M_)MD);!.2S'J2>YK6H **** "BBB@ HHHH
M**** "BBB@ HHHH *Y#XE>']0\3^#I=-TQ(VN6FB<"1]HPKACS]!77GI28H
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MO!_AT>%?"UEH_G>>\"8>3& S'J0.PK=QQBC% "T444 %%%% !1110 45E_\
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M?\)%I'_/_%^M &I167_PD6D?\_\ %^M'_"1:1_S_ ,7ZT :E%9?_  D6D?\
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M)%I'_/\ Q?K0!J45E_\ "1:1_P _\7ZT?\)%I'_/_%^M &I167_PD6D?\_\
M%^M'_"1:1_S_ ,7ZT :E%9?_  D6D?\ /_%^M'_"1:1_S_Q?K0!J45E_\)%I
M'_/_ !?K1_PD6D?\_P#%^M &I167_P )%I'_ #_Q?K1_PD6D?\_\7ZT :E%9
M?_"1:1_S_P 7ZT?\)%I'_/\ Q?K0!J45E_\ "1:1_P _\7ZT?\)%I'_/_%^M
M &I167_PD6D?\_\ %^M'_"1:1_S_ ,7ZT :E%9?_  D6D?\ /_%^M'_"1:1_
MS_Q?K0!J45E_\)%I'_/_ !?K1_PD6D?\_P#%^M &I167_P )%I'_ #_Q?K1_
MPD6D?\_\7ZT :E%9?_"1:1_S_P 7ZT?\)%I'_/\ Q?K0!J45E_\ "1:1_P _
M\7ZT?\)%I'_/_%^M &I167_PD6D?\_\ %^M'_"1:1_S_ ,7ZT :E%9?_  D6
MD?\ /_%^M'_"1:1_S_Q?K0!J45E_\)%I'_/_ !?K1_PD6D?\_P#%^M &I167
M_P )%I'_ #_Q?K1_PD6D?\_\7ZT :E%9?_"1:1_S_P 7ZT?\)%I'_/\ Q?K0
M!J45E_\ "1:1_P _\7ZT?\)%I'_/_%^M &I167_PD.D'I?Q?K10!<^P6?_/I
M!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJ
MQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/
M_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^
MD'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L
M44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_
M .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I
M!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJ
MQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/
M_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^
MD'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L
M44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_
M .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I
M!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJ
MQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/
M_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^
MD'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L
M44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_
M .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I
M!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJ
MQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/
M_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^
MD'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L
M44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_
M .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I
M!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJ
MQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/
M_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^
MD'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L
M44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_
M .?2#_OV/\*L44 5_L%G_P ^D'_?L?X458HH *3-+7FGQ?\ '>L>!=,TZYTE
M;5GN)C&_VB,L,!<\8(H ]+I,UX<GBSXWR1JZ>%K(JP!!\H<@_P#;6O0/A]J7
MC+4K&[?QCID5C.D@$"Q* &7'/\3=Z .RHJD^KZ;%,89-0M$E!P4:=00?3&:N
MYH **JW&IV%K(([B^MH9#_#)*JG\B:L!U9 X8%2,A@>"* '454&J:>87F%];
M&*,[7?SEVJ?0G/!J1;VU>U-TES"UN!DRB0%/SZ4 3T5#;WEM>1F2UN(IT!P6
MB<,,_44VYO[2S"FZNH8 WW3+($S],T 6**9%-%/&LD4BR1MR&1@0?Q%0#4[!
MO-VWML?)_P!;B5?D_P![GC\: +5%06UY:WB%[6YAG4<%HG# ?E2/?V<<Y@>[
M@68+N,;2 ,!ZXSG% %BBH(+ZTN8FEM[F&6-?O/'(& _$5'#JNG7,WE07]K+*
M?X$F5C^0- %NBJUSJ%E9,HNKRW@+<J)957/TR:A77-)9@JZI9%B< "X3)/YT
M 7Z*9)+'#&TDKK&BC+,YP!^-0VVH65Z6%K>6\Y7J(I5;'Y&@"QFC->>_%SQK
MJO@?PY9W^DK;---="%A/&6&W:3Q@CG(%=OIMTUSI%K=S%5:2%9'(X )&30!<
MHJK;ZE8W<ACMKVWF<=5BE5B/P!JUF@ / I,UPWQ-^(<?@+2(7AMA=:A=L4@A
M)P!_M'U ].]>?I\7?'/AJ^L9/&?AZ&'3KPC8\2;"!QDYW,. <X.* /><T9KS
MWXB_$M/!^CV#Z=;K>:CJ0!M8V. %('S''U'%<QX?^*OBK3_%EEH?CK1HK(7^
M!#+&A7:3P"1D@C/7D8H ]JHH'2H+B\M;0H+FYAA+G"^8X7<?09ZT 3T56.H6
M0NA:F[M_M!Z1>:N_\LYHEU"R@G6":\MXYF^[&\@#'Z G- %FBBJL6I6,TS0Q
M7MO)*@)9$E4LH'7(S0!:HJ"VO+:\5FMKB*95."8G# 'TXJ>@ HHHH **** "
MBBB@ HHHH *3-*:\U^(GQ4M?"T8T_2&BN]7:1%<8+QVZEADO@]3T SU- 'I.
M:,U4:_@MM,%[>S101+$'DD<[57C)ZUP?AGXF?\)9\1;G2-.B']CQ6AD29XR'
MF<-C<O\ L]NG:@#T?-&:Y#QAXIO-*U/1]"TE(CJ>JS;$EF4LD"#JY48W?3(I
MGA3Q1?7OB/6/#.LB!M2TW:XGMU*I/$W1MI)VGD<9- '9YHKE?#7B.[\1Z_J\
MEOY7]A6;"VAD"'=-,/OD-G[HX'3O754 %%%% !1110 4444 %%%% !1110 4
M44&@!,T9KBO&WC*]T74=/T'0K..\UW4<F))6Q'$@XWMCMU_*L(>,O&OA/6M-
MM_&MCI<VGZC,MO'=Z:S 0N>!N#=: /4Z3-(TB(A=F"H!N+$X 'K7F_A;XDR^
M*_B3J&C6<<?]C6]L7BE*'?*P8 L#G&WD]NU 'I.>:,UQ&L>)M6N_&W_"+>'V
MM8)X+7[3=7=S$957/W4"@KR<=<\>E6/!WC-->\.WE[J:Q6EUIDTD%]M8F-&3
M.6!]"!GVH ["BN9\%:SJ7B'2)-7O8XX;:YF9[&,(5<0?PECGDD<]JZ7(H 6B
MBB@ HHHH **** "BBB@ HHHH **** "DSFLCQ-XAM/"WA^ZU>]#-%;KD(OWG
M8]%'N:\]/B/XJOI?_"0KHFCKII7SAIQ9VNO+ZXR.,XY_I0!ZU167HVN6^K>'
MK;6&1[2*6(2.EQ\ABXY#9]*XBS^*4>N_$RQ\/Z*J2Z6T<GG73(?WK*,CRSZ#
MN?>@#TK-&>O%<IXY\53>&;"RBL8$FU'4;E;:V63[JD]6/J .U5-"\3ZI#XVN
M?"6OM:SW0MA=6UU;1F-94Z,"A)VD$'N<^U ';9YI:Y33_$5WK'CF^TZQ\DZ1
MID8CNI2I+/<'G8ISP .O'45U= !1110 4444 %%%% !7AW[2?_(!T7_KZ;_T
M$U[@:\>^/NAZMKFBZ1'I.FW=\\=PS.MM"TA4;3R<#B@#+MO'OQ@CM84C\#V[
M1JBA3]EEY&./^6E=G;:OXUUCX7:O=7VEC3?$ 61+>&)"A( &" Q//+?E7&P_
M$OXHP6\<*_#N8K&H49LY^PQ76>&?$/COQ9H6M1WFD'P[J,2+]AEDMV 9CG/$
MF0>@'XT >$:1J/@R70;C3_$NFWUMKS;BNL!WE8.3P3'D=*]LL?$4GA;X*7.I
M6WB"'77M8REO>;"""3M4,"2<J2/RKE[Z?7[_ $BXTSQ;\-+C5]=.Z-=3MK90
MK9^Z2Z#C'L>U;_@;X7WMI\+M4T#6G$-SJ>YP@.[R#CY2<=><$B@#DO!/PA3Q
M]X?_ .$C\1ZU?M=7A8P^6X.T>K%@<\]ABM7X4:SJNE>(O$/@;4[I[N.TBDD@
M>1B2N." 3V(*\=JS-$O?BG\.+23P_;^&GU2V5B8)D@>54SZ,GYX/2NL^&/@#
M6-(EU?Q-XBS_ &OJ,;!80<E >3G'<\<=L4 >;?#;P)%X[OM?L[[4KRVT^WG+
MF"V<+O<DX)R".,#M1\/_  G?>)?$.L>"KG7+Z#0["21YHH' ,A#;!C(('/)'
M2O0/@AH.KZ/?^)&U/3+RR6>4&(W$+)O&6Z9'-1_"K0=8TSXH>+;V_P!+O+6U
MN#)Y,TT+*DF9LC:2.>.>* ,3X31S>%?BWK_AB&ZFEL(4D&UVX)1AAL>N./QK
MC;O6M+\:^,M5N_&E_JZ6D3E+6#3XP^SDCN"%&!Z9.?:O2_"OA_6+;X_:_J=S
MI5Y'ITWG>7<R0L(G!(QAL8.:QWT3QO\ "OQCJ=YX:T>36-+U$[O+2)I.Y(W!
M>01D^W- #?@QKD]CXXO?#MG=7MSH,T;26INXRK+M [=CSCTXKGO"G@MO&_Q+
M\3Z;+J-Q9V$=S-)<K;MM:4>80%].O/(->Q?#R?Q_JD]WJ?BUEL[*0'[-I_D(
MC+GUXW#';)S7COA6Z\5:?\1_%>H^%K9+R6VFF:XM&&?.C,I& !R2#SQS0!KO
MI5Q\'OBOHMIIFH7-QI6I.J-#*PR0Q"'<  "02"" .E,\=Z++XA^/L>CQ74EJ
MMW$B22QG#!,$D#\JUM$\.>,?B)\0K'Q'XKTQ]+L-/(9()(V0DJ<@*K<\G!)/
MI6EJ&@:P_P"T78ZLFEWC:<J -=B%O*'RL/O8QZ4 :6N?#W3?"WP[ET73O$S:
M+82W/FW=Y=_,\F0!MRNW'3L*\A\;W/@K2XM+;P-+=1ZC:OMGO4+A9<#[P).,
MYYP,5ZW\<_"FM>(]+TNYTFVDO%LI6::UC&6<'&"!WZ&N)\=V'B3Q7X5L+?1_
MA]=:38V,F7A6#;(\A&,K&!DK[XH ]'\:>"- \9Z%IVM^)=2N[-+*TW-)"Z*N
M& ))W*?2O$O W@5/%_CUSH'VF/0K"=96N;K#-M!R!P "3@\>E=M\6H/&&M:-
MH.DZ5H^JR:=]D26XBBMG)\S PKX'&/0]Z9X6\5^/O#&EVND:=\-9(+5&&]OL
MD^6)ZLQ[F@"S\1KK5?'/Q4MO MI?O9V$*@SE"?F)&YB1WX(P*R_''P]?X46=
MEXE\+ZQ? Q3*LRSN.3GC[H (]CFNE^(?@OQ.GBBQ\=>%8M]^D*&XM5&6W =E
M/WL@XQ[5AZM;_$CXLRVFDZGH)T33H9 \TDD+Q@^_S\G'H* +_P ;=4&M_"CP
MYJ@4*+N>.;:.V8V-1_&+Q/?:=X8\,Z%:W,MM%?0*]S+%]XH HVC'/\6<=\5M
M?&CPM>S?#[1=(T+3KN]^R7"J([>)I&5!&PR0/\\T_P")/@'5/$7A70=0TB,C
M6-)C0K"1AF& 2!G^(%1Q]: /'KXZ!X=^Q:CX*U+Q#_:D3J91<VX1&'<C Z9[
M'/6OJ[0M0;5O#^G:@RA7N;:.5EQC!902,?6O';+Q3\8O$%S9Z=;Z&=&,>!/>
MSVA <# )/F C/4X6O;H5DC@C260R.J@-(5 W'')P.!F@#'UWPMH&NS6]YK-C
M'.]D=\4KNR^7@YSP1W'>O&_&VK2_%WQ;8^%/#D9ETJQE\VZO,?+QP2#Z $@>
MI-=)\;[GQ5=Z;;:'X>TO4KB"Z4O=S6D+O\HX\LE1WZGU%<CX8\3^/?".CIIV
MD_#*2*-1EW^QSEY6_O,>YH N?$*!;7XT>#=/'S06]M B*PR.&8=/P%6OVALQ
MW/AF:(?OA,P4@\\8Q6M\4?"&O^(+70?%6BVY&LV,:O-;+D/R V #W!R,=>:Y
MR+1_&_Q3\8:5=>)=$?2=,T\@R*\31;L')QNY)/3T% 'T!&28T)ZD#->'_M&;
MQ;>'C&VV07#;6]#@8KW(=*\>^.^AZMK4&A#2],N[TQ7!:06\+2;1QR<=* .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6_QH_M74/^?ZY_[^M_C0!ZI17E?]JZA_S_7/_?UO\:/[5U#_ )_KG_OZW^-
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M?^_K?XT >J45Y7_:NH?\_P!<_P#?UO\ &C^U=0_Y_KG_ +^M_C0!ZI17E?\
M:NH?\_US_P!_6_QH_M74/^?ZY_[^M_C0!ZI17E?]JZA_S_7/_?UO\:/[5U#_
M )_KG_OZW^- 'JE%>5_VKJ'_ #_7/_?UO\:/[5U#_G^N?^_K?XT >J45Y7_:
MNH?\_P!<_P#?UO\ &C^U=0_Y_KG_ +^M_C0!ZI17E?\ :NH?\_US_P!_6_QH
M_M74/^?ZY_[^M_C0!ZI17E?]JZA_S_7/_?UO\:/[5U#_ )_KG_OZW^- 'JE%
M>5_VKJ'_ #_7/_?UO\:/[5U#_G^N?^_K?XT >J45Y7_:NH?\_P!<_P#?UO\
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A=0_Y_KG_ +^M_C0!ZI17EG]JZA_S_7/_ '];_&B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img46421407_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2.417AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(S.C R.C(T(#$R.C,P.C,Q   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,SHP,CHR-" Q,CHR.3HU-@ R,#(S.C R.C(T(#$R.C(Y.C4V      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  $><         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ 7P$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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MC_KM_P!]_P#UZS=[EK8,?]=O^^__ *]&/^NW_??_ ->EJ,38N_=B7=C&=_\
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MM_+E0,X\U0K9P<].O'/3O4)\.6!+$^9EA@_,!@<'CCCH*  ^'-/**H5Q@8W
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M$U?P5\-](T>:^T2*&;5-6\132K:Q-*-R1)'%\[$KSNZ @@],D ]IW=J6O&/
M_P 6_%=E\2+?P#\1=%TVQUN^M'N].U/0IWDLKP("9$"R?.C* 3SUQ[C/LN[I
M0 ZBF>8./2EWCO0 ZBF[JY.3XC6:_%2'P*+6<Z@^D-K+7/ B6,3"(*.<EB2>
MP  '7/ !UF_G%.KG]%;Q'_;FMG5O[,_L<RQ_V5]B\S[1Y>P;_M&_Y=V[IL[=
M>>*W5;H,<=* 'T4SS,].?QI0V>U #J*Y'P#\2+/XA3^)DL;6>W70]7FT>5K@
MKF26(+N8!2<+EL#G.!D@9Q76;J '44E+0 4444 %%%% !1110 4444 %%%%
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MZMO_ (NC_A>?PW_Z*#X5_P#!U;?_ != '<45P_\ PO/X;_\ 10?"O_@ZMO\
MXNC_ (7G\-_^B@^%?_!U;?\ Q= '<45P_P#PO/X;_P#10?"O_@ZMO_BZ/^%Y
M_#?_ **#X5_\'5M_\70!W%%</_PO/X;_ /10?"O_ (.K;_XNC_A>?PW_ .B@
M^%?_  =6W_Q= '<45P__  O/X;_]%!\*_P#@ZMO_ (NC_A>?PW_Z*#X5_P#!
MU;?_ != '<45P_\ PO/X;_\ 10?"O_@ZMO\ XNC_ (7G\-_^B@^%?_!U;?\
MQ= '<45P_P#PO/X;_P#10?"O_@ZMO_BZ/^%Y_#?_ **#X5_\'5M_\70!W%%<
M/_PO/X;_ /10?"O_ (.K;_XNC_A>?PW_ .B@^%?_  =6W_Q= '<45P__  O/
MX;_]%!\*_P#@ZMO_ (NC_A>?PW_Z*#X5_P#!U;?_ != '<45P_\ PO/X;_\
M10?"O_@ZMO\ XNC_ (7G\-_^B@^%?_!U;?\ Q= '<45P_P#PO/X;_P#10?"O
M_@ZMO_BZ/^%Y_#?_ **#X5_\'5M_\70!W%%9/A[Q9HOBZQ>]T+5[#6K%7,37
M.GW23QAP 2I9"1D CCW%:M "T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!XK\:/A7\0OB5XFMU\/?$"X\$:!:VJOBQ1S-<76]\
M[BCH=@39U9ADGY:XOPAIW[25OXBTKP[KMSHMQX<M;V&6Z\41NGVBYMD=6>$
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MO8?6N?F_9I\37GAQ?!]W\5=2G\!JBV_]E_V7 MV;=2,0F[!R5P /N\@8Z<4
M>\VMQ'=6L,\,JSPR(KI*I!#J1D$$<<BI:KZ?8P:78VUE:QK#:V\:PQ1KT1%
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M^Q^]!]1Q7_/J7W,[ZBN!_P"%Z>"O^@PW_@)-_P#$4?\ "]/!7_08;_P$F_\
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MAD&Y)(V!5AV((KHI8BC6O[*:E;L[F%2A5H_Q8N/JK$]%)2UT& 4444 %%%%
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MLN3G&SRSO_-:I^/OC?\ \)Q\)_!'@K^Q?L1\-!A]N^U^9]HW#'^KV#9_WT:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM4_\%-U_\;H]M0_F0>QJ_P K-_RT_NK^5'EI_=7\JP/^$]TK_GEJG_@INO\
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M(/8U?Y6;_EI_=7\J/+3^ZOY5@?\ ">Z5_P \M4_\%-U_\;H_X3W2O^>6J?\
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M^05'H%8<?C72VOC;3+V\@M8_MD4T[%(_M-C/"K,%+$!G0#HI/7M4W_",V_\
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MK^#/_0F_^52]_P#CU%PL?EIBC%?J7_PQ7\&?^A-_\JE[_P#'J/\ ABOX,_\
M0F_^52]_^/47"Q^6F*,5^I?_  Q7\&?^A-_\JE[_ /'J/^&*_@S_ -";_P"5
M2]_^/47"Q^6F*,5^I?\ PQ7\&?\ H3?_ "J7O_QZC_ABOX,_]";_ .52]_\
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M *$W_P JE[_\>H_X8K^#/_0F_P#E4O?_ (]1<+'Y:8HQ7ZE_\,5_!G_H3?\
MRJ7O_P >H_X8K^#/_0F_^52]_P#CU%PL<-_P3K;'P3UL?]3#/S_V[6U?5%>5
M? GP3HWP\N/B!X>\/VG]GZ/9>(5$%MYLDNS?IMC(WS.S,<L['D]Z]4J2A:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"1M^)O_8PP_P#IIT^NXH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#A_A[_R-OQ-_P"QAA_]-.GUW%</\/?^1M^)O_8PP_\ IIT^NXH
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M:=GVI@+132V.U ;\J '44FZC=0 M%)FC- "T4T-ZTNX=*5T M%)FDW'/3BF
MZBBB@ HHHH **** "BBB@ HHHH **** "BBB@#A_A[_R-OQ-_P"QAA_]-.GU
MW%</\/?^1M^)O_8PP_\ IIT^NXH **** "BBB@ HHHH **** "BBB@ HHHH
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MZT<@7%MY@E!+?="L ,DGC\14OA_XCZKJ&H6$.H^%+S2[2^0R072R"90 ,_O
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MU _\)1INB0VX_P!'LXXUGFE.,_/E<J3QC'3-;.B^%/%\NM6-QK6JV4-G9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M78ZE0& <\L.WXU>L=4@T/7O$ OK"_8S7:21O!82S*R>3&.&52.H/>NYVC_\
M6*3:*YEA.5\T7KZ:&_UER5FM/74X_P 07B>(O#T8L;2\ CO;;='):2Q-M$R,
MQ"LH.,9YQCBIO&&BO!'%K>EVV=5T]A)LA7YKB+^.(X'.1DCW"UU17TXI<?EG
MI6GU=2OS;F:K.-N7;_,XJ36%TKQE<7D]G?>1<6$"HT%E+*,AI"0=BG!&X<&I
M&DN/&&M:8ZV5S::98SFY::[C,+RR!2J*J-A@!N)R0!Q78;%/4<>G:@*!BI6'
MEM*5TW<KVRW4=;6.8O(C>?$#3=A_X\[.9I,'@>8R*@/UV/\ E74#GFJ=GI<5
MG=7=PK,\UTVYW?!. ,!>G0#.![FKE=%.')=]V93ES6786BBBM3,**** "BBB
M@ HHHH P_$/_ "&/"_\ V$7_ /26XKJSVKE/$/\ R&/"_P#V$7_]);BNK/:B
MA\4_D16VC_743_"O.KG_ )+E_P!R]_[<5Z)GKQ7G=XP7XX9)P/\ A'N__7Q7
M-CM(T[_S(Z,%\4_\+.TED6&,N[!44$LWIBN!^$-Q%?0>)[F!UD@EUVYDC=3D
M,IV$$?@:BO+BX^*VJR:9ILCP>&+=]E[?(<&Z8=8HS_=]3_\ 6S#\.KS3_"NC
M^+Y)GCM-/L]<N5'940;  /RP!7FSQ'M,3"3^!<VO?3\CT8T53P\X?;?+IVUZ
M^9W>O:]9^&],FO[Z58;>,;B3U/H .Y)[5RGA?P]>^,=6B\3>(8FA@C^;3=,<
M?ZE>TCCNYX^GY8B\.:+=?$/58=?UN)H=)A/F:;ID@Z^DT@[GT';/Y^FJN,8/
MZ5V4Z;QDO:5%[BV7=]W^AQU*BPL?9P^/J^WDOU8;1CK3O>EQ1BO9/*"EHHI@
M</\ #W_D;?B;_P!C##_Z:=/KN*X?X>_\C;\3?^QAA_\ 33I]=Q0!'MYSZ<T,
MN[H>*?1BEJ +T%+113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X?X>_
M\C;\3?\ L88?_33I]=Q7#_#W_D;?B;_V,,/_ *:=/KN* "F[CZ4ZFE: . L_
MCMX4U"UANK5?$%U:SHLL5Q;^&-3DCD1AE65UMR&4@@@@D$'(J7_A=7AO_GU\
M3?\ A)ZK_P#(U8WP5/\ Q9OP'_V +#N?^?>.NSS0!B_\+J\-_P#/KXF_\)/5
M?_D:C_A=7AO_ )]?$W_A)ZK_ /(U;6:,T 8O_"ZO#?\ SZ^)O_"3U7_Y&H_X
M75X;_P"?7Q-_X2>J_P#R-6UFC- &+_PNKPW_ ,^OB;_PD]5_^1J/^%U>&_\
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M75X;_P"?7Q-_X2>J_P#R-6UFC- &+_PNKPW_ ,^OB;_PD]5_^1J/^%U>&_\
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MGQP2S65V;@QW$IC5E\F6/&Y5;!S(#T[5SXA-TG8UHV4T:5%8GG^*/^@/I?\
MX,Y/_D>CSO%'_0'TO_P9R?\ R/7/[1=G]S.CE\U]Z-NBL3SO%'_0'TO_ ,&<
MG_R/1YWBC_H#Z7_X,Y/_ )'H]HNS^YAR^:^]&W16)YWBC_H#Z7_X,Y/_ )'H
M\[Q1_P! ?2__  9R?_(]'M%V?W,.7S7WHVZ*Q/.\4?\ 0'TO_P &<G_R/1YW
MBC_H#Z7_ .#.3_Y'H]HNS^YAR^:^]&W16)YWBC_H#Z7_ .#.3_Y'H\[Q1_T!
M]+_\&<G_ ,CT>T79_<PY?-?>C;HK$\[Q1_T!]+_\&<G_ ,CT>=XH_P"@/I?_
M (,Y/_D>CVB[/[F'+YK[T;=%8GG>*/\ H#Z7_P"#.3_Y'H\[Q1_T!]+_ /!G
M)_\ (]'M%V?W,.7S7WHVZ*Q/.\4?] ?2_P#P9R?_ "/1YWBC_H#Z7_X,Y/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9?B-^T-\UXU[\,/A]+R+:([=9U)#V=O^7=",\#GG'S YKJ_A[^SWIWAS6O\
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M_33I]=Q7#_#W_D;?B;_V,,/_ *:=/KN* "BBB@ HHHH **** "BBB@ HHHH
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MHH ***R;3Q9H]_X@O]#M]2M9M8L51[JQ253-"K %2R]0""#^(]: -:BDW44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X?X>_\C;\3?\ L88?
M_33I]=Q7#_#W_D;?B;_V,,/_ *:=/KN* "BBB@ HHHH **** "BBB@ HHHH
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MFG3Z[B@ HINZEW>U "T4F31F@!:**3\* %HI*,T +1129H 6BDHH 6BDHS0
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ML0PD;4M+U&ZOI;L@D$QM*X@@0G/RQQ-Z9( J?1M)^,7[/MY-!:^&;'XJZ%'
MEO;ZI#*EKJBVZ%BD#L<LP7<=HP^,\$=*?X7^('QEL_#MOH'A/X,MHH2261;O
MQ%JZRQQB21I"" L1(!<@ 9P !@T >U10^"?V=_ARVS[/X>\-::I<_,2SN?4_
M>DD8_4GBO$OACI>I?M/?%6V^*.OV,MAX'T,E/#6EW7WIY0>;AAWP1GCC(4 G
M8<W_  [^RGKOCOQ!!XC^-'B=O%5Y"_F0:%9DI80_[)&U<CU50,XY9A7TI:6<
M%E:PV]O$D%O$H2.*-0JHHZ  < #V]* +%%)1F@!:*;NY(Q2T +1110 4444
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M*#8P(.136#JMV_5>H/'4K77Y,^TA2TB\J*6N(] **** "BBB@ HHHH ****
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M8)W58U+XM:[IMOKEIYK_ -IZY965[X52:! 8VN@D/D$ ?,892)"7&=LG)(%
M$GB3P;\1/AGX@U'Q'X%U.;Q=H]Y.]U?^$=8F&Y2Q+,;.<CY#DG$9^4>AS@=E
M\,/CAX;^*2S6MF\VF>(+7Y;W0=3C,%[;-W!C/W@/[RY'/..E=QI]O-;V-M%<
M7)O+B.-5DN&4*96  +X7 &3S@#'-<+\4/@;X<^*)AO;E)M)\16HS9:_I;^1>
MVS8X(<?>'^RV1@G&#S0!Z%N%+7S]%\5/&?P.F2P^*=J=<\-;A'!XVTF#Y8P3
MA?MD YC/^VN1D@?,>:]RT37K#Q'I=MJ.EWEOJ.GW";XKJVD#QN/4$4 :%%)2
MT %%%% !1244 +12<^E'/I0 M%)SZ4<^E "T4G/I1SZ4 +12<^E'/I0 M%)S
MZ4<^E "T4G/I1SZ4 +12<^E'/I0 M%)SZ4<^E "T4G/I1SZ4 +12<^E'/I0
MM%)SZ4<^E "T4G/I1SZ4 +12<^E'/I0 M%)SZ4<^E "T4G/I1SZ4 +12<^E'
M/I0 M%)SZ4<^E "T4G/I1SZ4 +1124 +1110 4444 %%%% !1110 4444 </
M\/?^1M^)O_8PP_\ IIT^NXKA_A[_ ,C=\3?^QAA_]-.GUV] 'P_\8;Z_T/\
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M4-TZUYA\3/B!K>N6/P8L?$OQ5\!^(M/TS7]/-O#X?F?S1 H7_3+^27;Y+JN
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MO%-V\YZT >4_#O\ :"TOQ3K/_",>(["?P5XWBXDT35" )C_>MY?NRJ<'&.2
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M , ]8R*,BO)_^%(^'?\ H)^,?_"VUK'_ *5T?\*1\.\_\3/QEQU_XK;6N/\
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M5$0"!.I)P.H_2@#L/!/BZW\:^%[+6+>&2V$X99+:;'F02HYCEC;'\2.K*?\
M=JEXHOO%%QJ]KIGAV.SLT:!Y[C5M4MWN(8B&4)$L221EW;+$Y=0H /S9Q7'?
M#;2O$[?#>*]T.YT_1;K5=4O=7$>L:?+.JV]Q/))$HC66)D8HR,03QDC%=4U]
M'?R0>#_$5ZS:U>61NC/I9FT])U5\.(&64R*5RF[#]''.#B@#'@^)]YIOA'Q;
M>:MI\5QJGAV\:P:.P)2*^E,<3P^7OR4W^?&I4EMK;N2!DN3Q-XK\)Z]H$'B>
M31[_ $_7+C[$KZ5:RP-8W'EO(BN7E?SD;8R;]L>&V_+\WR\%J-E#8^ _'^C:
M.QO/#WA[5[*[ADQYQ'ERP75W&9/O3,I5BS,6?+$,217<_$F^MM:U#X?66G3K
M>2WFMPZA&;5PP^S0Q/(\V1QY>-BYZ$R(,_,,@$_Q ^)%]X;U32M.TK29;WS=
M3L[2_OKF)DMK:.:9$ 5CCS9#NX"9"X)8CY5;T,MBN!^,'_(!T0?>_P"*BTD$
MD9X^VQ5UWB#SO[!U+[/N,_V>3R]O7=M.,?C0!E^#O%'_  E6GWVK*88]*:ZE
MCLI1G,D,9*&5B3C#.KE>/N[3WK#\!_$2\\9^+O$EI]CBM]&M8+2XTV<;O-N8
MI3,#*V> K&+<@ SM()^]@<[H^BZSJWP/\ :=X;MM/NK!M.L_M]MJ%]):^?;B
M!28UD2&4_,V P*\KN7C=D.\#7'BE_C)XJCU#1=$TV/\ LK3UE:RU26X\D W7
ME;%-M%OR<@@E=H P6R0 #UBZU*UT_P @7-Q%;^=*((O.D"^9(>BC/5C@X'?%
M(NJV;:C)IXNH3?1Q+.]KYB^:L9)57*YR%)5@">,J?2O-_%'AOQKJ7@[65UG4
M]%U*YMX5O=.BTG3)K1Q=P.)HLM)<R @M& 0 #\QY['AV\<6UGJ<OQ;@)N-/O
MY)]'MV;@F!;96A7ZF[@E0 #.Z<#F@#V[5/'7AS0]+&I:CK^EZ?IQF:V^UW5Y
M''#YJLRM'O)QN#*P*YR"I':KD?B'3)M'_M:/4+5]*\OSOMRSJ8/+ SOWYQMP
M,YSC%>%Z#X9\1>&_B3I6C0:QHFFWUOX:M_LDNK:6]X9YS)*U\T&RYBVL7,3/
M][(*= .<75--N--M8C9^)]!N]*N/&H;5)?[#FCTJSN!:[0IA:YPZFX$3%A*%
M$S<Y92* />8?'FC:]X=U/5/#NL:9KD=I%(QDL;I+B,.JE@K%&./S%'AGQ5#J
M7A?PS>ZC<VEGJ&L6D,D<)<())6A\QDC5CD\;C@9. 3VKS>^T>\C\?ZG<ZMXG
MT6]UV/PU=K-8Z/HLUJ\MNQ38\\C7,J_*RD(& )#28X!JA\$8K_0=0\--XNFM
M]0OM8T.V70]0AC9(;=$A1I;%58G:^%64OP9 'X B  !ZWX/\1RZY;WUM>+'%
MJVF736=Y''D+O 5E=0>0KHR. <XW8R<9/0UY]X65E^,?CLQ!?LQLM,\S;G)G
MQ/NS[^7Y/X8KT&@!:*** .'^'O\ R-OQ-_[&&'_TTZ?7<5P_P]_Y&WXF_P#8
MPP_^FG3Z[B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IN[GIFG5R'Q0U3Q/HW@V^U#PA86N
MK:W:[9DT^ZW8N(U8&2-2I&'*A@N>,XH T=6_X1K_ (2;0O[3_LK_ (2+]_\
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M@\L]4\O&W;[8Q4FFZQ9:S8P7NGW4%]97""2*YMI5DBD4_P 2L#AA[BK>\<4
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MO':65M&L,,$*[5C10 % '0  ?E5G;G\>O%.H 6BF[J-U #J*3-&: %HI,T4
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M^O[/[2N_M$K^?MR%^1F*KU_A JM#\%_!=O\ $^7XB1Z%$GC*6'R'U,2R9*[
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MJOPC\!:QX+T+5K+Q)J$&N7=QJDMTEXJDF6(I&D;2 @ 2%4RV,C).#S0!QWQ
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M<D],XQD9R,,105*48Q=[I?B=&'Q$JL92DK6;_ Z7=GVI-WH,U^=VF_M7>/?
M?Q*\!Z???%_PY\3X=<OX;/6-'TO3(TAT]9)53=#=1(/-(W$ YSE>5.<CL_VD
MOVE/&'A3X_7?@J7QXGPA\,6^GQW-EK3^'AJO]IS,J$J0RG8H9F7*C@QG)Y &
M[P%524;[^O\ E<P684G!SL]/Z]#[@W=Z6O+OV<_%VN>-OA3I.J^(=;\.^)-1
M<LIU7PO*[VMPH. Q#(A20<AEQP1VZ#U =.*\^47"3B^AZ-.:J14EU'44E+4F
M@4444 %%%% !1110 4444 %%%% !1110 E>9_%[_ )&[X2?]C3-_Z9M3KTRO
M,_B]_P C?\)/^QIF_P#3-J=:4_C1A6_AL[*BBBMS,**** "BBB@#E/BS;7]Y
M\+?&$&D^8-3ET>[CM?*^_P":87";??=C%?,?[%?B'4!^Q[<6OP[@TN^\=:?=
M7 EL=2)6$S/-D&4 HP!A(P<C[N,\$5]C^G4'VKYT\??L'_#3QQXHO/$%M)K?
MA+4;TLUU_P ([>K;QS%B2Q*NC@9/)"X!/..3GLHU(*#IU/4\_$4JCFJE/7\/
MN.&^"?[0'BJ_^(7Q5\/_ !#TGPSX0N/#^CRZCJ6I^&+1C.K@(3(SEY1(RJV<
M8)R,<]*^8_B1H]CH7PUL?B7X&\-^-X;HZH)1\1_$&LQQ7-TQ=P +=7)8$CAP
M!]WG/2OT$^&W[*GPU^%?AK5M&T?0?.CUBU:RU&ZOIFEN+J%@04+Y&T'/(0*#
M@'&>:\]N/^"?/@&]\-R:!=^)O&UWHJOYEC83ZRK0::Q;<6MX_*V D%E)<-PQ
M[\UVT\50C-M+3^O,X*F%Q$H)==3AOVN/"?BSQMXJ^'VM?\(_)\1O!Z:7YU]X
M+M-5:TFFG(),P6,AV&&C^95;&PC"AN>+\-VW@3QM^RI\7/#D-AXKTJZ\+"35
M?^$7\379D_L:X$<GE"W8)&WE@ALI)SE22,DEOJCXB_LM>%/B1=>']2GU+7M#
M\2Z':I96OB+0KX6E]Y2J5VE@A7G<_(4'YVP0#BKO@/\ 9I\%^ ?!_B70+>.^
MU0^)DD76]4U2Z,U]?[U929)<#G#MC  RQ;&234K%4U"*U5G^I?U.JZCEHT_\
MCXOUGP+HW@W_ ()SVWB#2+0VFKZY=V5W?3&5W$DL=TZ1D*[$+@=E !X->J^+
MOA;#^RW^SCXR^(7AC5]6O/'.M:59Q7^L7]WYC"265!),G VG]ZV"22"%.>"3
MZ-9?L-^#++X8:QX#_P"$D\67.AZE/;SG[1?PN]L8F9E6$>3M0$L<_*2?6O<[
M[PCI6K>%)/#>I6B:CH\MK]BFM[@9$L6W:0V,=1W]>F*53%QDU9W5[OT'3P,D
MFI))VLO4_/[XA_!'2?@W^S;X<^,WA?Q1K$/Q$=;&_EUC[>SF^>XV&2(J?O*-
MQ..<A3NSDTGQ.\4>+/CY^T%/X<U3P/?>.])TO0K.^3P?:Z\-'CCDE@@DDGD9
MAF1@\Y48P?NCH#GZ%T7_ ()__#+2=:LKF>Y\1:QI%C<-<VOAW4]1$NFPN3GB
M/8&(SV+'/.[.:[;XK_LN^$/BQXCL_$<MWK/A?Q-:Q>0FM>&KT6=RT6"-C':P
M(P2,XS@XSCBM5BZ2>NN^MMKF3P59K2RVT[V^1\T_"OPW\6K7X-?&'PC92?\
M"'Z?"%_L"*\\1V]U)IC>8?M%G]H1AY?RKM!<)M)SP<FN2^!;:'\)?BUX!C\3
M> _&7POU^ZD2Q_MJQU1[G3=>N'VK^_62-@48MTB<A2P/;<OV'X5_93^'GA;X
M9ZUX'73)]2TO6W\W5+J_N&>[O)0<K(T@QAE(!&T  Y.,LQ.'X)_8R\&^#_$F
MAZO=ZWXI\6_V"0VC6'B/5/M-IIK#&TP1A%VXVK@$D#:#C(!$?6J;4ET?;T]?
MS*^IU5R6Z=W_ %^!X;X)^&FF_M>?';XNM\1]4U&[M?"^HG3-)T6WNVAAM(]T
ML8E"]FQ$.>A);<#D >6^(?%VMZA^R+\4_"VI:I=ZWIOA7Q7;Z?IFJ73%W>#S
MB F_N!L!')P) !@8Q]E?%+]CCP-\4?%T_B=KS7/"VN741AO;OPW>K:M>(0 1
M(&1@<@#. -V.<UY[^T]^S[8^!_V1[WP7\-_#-Y>$:A;W!M;""2ZNKA_,7?*^
MT%G; &6Q\H4#@#%:4\13E**]/E8BKA:T8R?K?S/*_CM\)=/_ &>_A[X$^+OA
M+Q%JTWCQ[VT^U:A-?&4:MYT1=@RDGY3LP%7@JQ!#<$=3X]^'FF_%_P#;T31=
M9GU&WTJ?PG'-=6MC=-;M<K_SQD9"&V'<"5!&=HKT_P &_L/^ +/5O#/B"^F\
M17XTN..XL_#VJ:@9K"REVJ3LC==Z_,H.TN1D8((XKU ? _0A\;#\4?M>H_V^
M=,_LK[-YJ?9?*R#G;LW[N.N_'M6<L5&-^5N]GKZFL,'*5N:*2TTOIH?'OPAU
MC3?A#;_M*>%+OQ-KGA_P-H%Q'#92Z?)YUW9"266,B#<"%=\HN[CLQ8'YJ\^N
M-''PI\9?!WQ3X-\'^*?!EIJNJVT3ZYK>L1M/KD<C1EA);(S>7N4D]E(<\$U]
MN']DCP+<77Q&EOFU+4HO';K+J5M<SH(X71V=&@V(K(0S9&XMT'OGE5_8-\%R
M1Z(;SQ9XWU6ZT2XBGTVZU#5TG:T6,AA#&C1&-8RRH2 F?D7D<YTCBZ*;;OKO
M]QD\'7LHI+3_ #/-?%W@ZS_:3_;;\2^"O&]]=R^&/#.DQ3Z=HL-P\*22,D3,
M^!@[LS,21@D;1D@8KG?@6MS\%_B)^TW_ &+J=QKEQX;TG?975_(9Y#Y4<AB6
M1@3NV *A]DQ@"NZ_:O\ !/VOXM:9KTOPZ\=3I'9^7'XN^&=Z/[0)P08)X/+.
M ,\29'#!<GE1:_8J^"=_X=USXB^)]2\(WGA/PWXA$5KIVBZY(9KMH5+B1IU?
M+#<3T?G); V[27[2*HW;TLM-"?9SE7Y4O>N]=3YAT/P;XR\<?#&+X@0^ ]7O
M/%MU,;J'XF7'C>"V\N43%%'D2;0J@CR]I;.1P0-HKW[XT7EE\1?^%4>%/']C
MXK\5>.+C1TOKGP/X<N(8;*YD*,#//,&4#E'(*N0H4XV@Y;TF;]@7X;RWCQIJ
M/BBW\-277VR3PI#JQ72WD]3'MW^@R'R   178?$_]EGPE\3-<T+6X[_7/!VM
MZ+;?8K34?"MZ+*5;< A8L[& 5<G&T \XY& (EBZ4I)KI?Y?C^5C2.#K1A)/K
M^/X'SE^Q]=:MH.M?';P3<V5[H6E:7;F2VT"\OQ>C369908UE VMD;<XZX&<G
MFO6?^"=O_)K^B'_I^O!SQ_RV:NQ^&?[*GA'X3ZSXIU'0[_6FD\268M+Z.]NU
MG!.#NF#LGF>8S,[$ER,N>.F.M^"_P?T;X&> [7PGH-S?7>G6\LDJR:@Z/*2[
MEF!*(@QD\<5SXBO"HI*/6QU8;#U*<HN?2YW-%%%>:>J%%%% !1110!P?Q$_Y
M'KX1_P#8T3?^F74Z]7KRCXB?\CU\(_\ L:)O_3+J=>KUE4Z%TOBD(>]?-E]_
MRD$_[IB/_3K7TGZU\VWW_*03_NF(_P#3K6N&^*7HS'%[1_Q(]XKY]_9!_P":
MU_\ 93-;_P#:-?05?/O[(/\ S6O_ +*9K?\ [1KHI_PI_(YZG\:G\SZ"HHHK
MF6QUF=XD\.Z9XNT*^T76;*+4=*OHF@N+6<;E=",$>Q]QR" 17SUX)\5ZI^R/
MXKL? OC&]EU#X5ZI-Y/AKQ-=-DZ3(<XL;I^R?W)#P.GW01']+5B^,O!NC_$#
MPSJ'A_7[&+4])OHS%/;3+D$=B.X(X((Y! (Q6T)JSA+9_P!71A4IN_M(:27]
M:G8+(KJ&7D$9!'2G^U?*WPU\=ZS^S1XQL/AE\0=1EU+P;J$GD>$O%UVW*G^&
MPNF[.!]QS@,/; 7ZH!''TKEJTG3=GJGL=5&LJJ[-;G%?#W_D;/B;_P!C##_Z
M:=/KN*X?X>_\C9\3?^QAA_\ 33I]=Q6)T%:\L8+^VFMKJ*.XMIE*20RH&1U(
MP5(/!!KP36OV#?@IK6JO?'PE_9[R'=)#IM]<6T+\YQY:.% ]E KZ#Q1MK6G5
MJ4_@DT8U*-.K_$BF<A\.OA/X3^$NBG2O".AVFAV3-O=;=/FD;^\['YF/N2:Z
MT8I=OK2[:SE*4G=LTC&,%:*LANSG.>:=2T4BAI3=W_2D\NGT4 ,V>AQ^%+M]
MZ=10 W;Z<?2C;^=.HH ;M_PHVTZB@!NWWXHV\YSSTIU% #=I]:-GO3J* $IO
ME\YSWS3Z* &[:-M.HH *;M[CK3J* &[10%]Z=10 W9\V<T;:=10!7CL889IY
M8XHXY9R&ED10&<@  L>Y   ST J;;UYIU% #=OO1M]Z=10 W;[T;?>G44 -9
M,_\ ZJ-N.].HH ;M%&WKS3J* (+BS@O(Q'/#'-&&5PLBA@&5@RG'J& (/8@'
MM4V*6B@#A_A[_P C9\3?^QAA_P#33I]=Q7#_  ]_Y&WXF_\ 8PP_^FG3Z[B@
M HHHH **** "BBB@ HHHH **** "BBB@ HIC28]A2&7;C([XH =7!?';P-?_
M !-^$'BWPII<MO!J.K6$EK!)=LRQ*S#@L55B!] :[O=@TA(Z=ZJ,N5J2(E%3
M3C+9GG_P!\ ZA\+/@YX4\)ZM+;3ZCI5FMO-+9LS1,P).5+*I(Y[@5Q:_ W7E
M_:\;XJ?:=._X1[_A'O[*%MYLGVH2[@<[=FS;COOS[5[F2!C)XI]:*K-2E)?:
M_4R]C%QC%[1/GK]H#]G/Q#XT^)/AGXF?#_6]/TGQOH4#6BPZU"TEC>0-NRDF
MT%EXDD!(!)##&T@&I/AK\#_'M_;^.9/BSXLM-67Q-9OIW]A>'T:/3[*%DV,T
M32*'W$8[#!!)+%N/?_YT=#5_6:BAR7V,_JM-S<[:L^ OB%\"/C-\(?V:?&G@
MV7QIX;N?AMI5G<7-O/#9R_VI-#O\PV[ XCC1B6RVYV&<#(P!T6D_L_ZQ\=?V
M/?@Q)X:UBVTCQ/X=$6IV$FH*Q@=U8_*^T,5Y"MG:WW<$<Y'V=K&CZ?K^EW.G
M:I96VI:=<H8Y[.[B66*5#U5T8$$>Q%&BZ'IWAO2[?3=)L+;3--MDV06=G"L4
M42CLJ*  /8"NCZ]/E5E[R=[G+_9\.9Z^ZU:Q\N:#^SI\6]:_:.\&?%#Q[XB\
M+W\>CV=Q:7&G:/'/$D"-#*BK#O4^9EI=[%RI'09  K&T_P#94^,'PEM?$OA?
MX7>+_#,/@K6KJ2YCDUR&7^T=+,@"MY#(C*Q"A<$D<J" I))^R/3/6F7%Q';0
MR332+%%&I=Y)#M55 R22> !6:QE6_3[M#7ZC27?[]=3YN^+W[,OBKQOX/^$V
MCVGB2WUB_P#"6LVVI:EJFMLT4EX$Y=D6-'PQ).%/;&6)&3M?$3X"^(/%W[4_
MP[^)-I=Z;%H7AVSEMKJWGED%T[,LP!C4(5(S(.K#O7LWAGQ5HWC328]4T#5K
M'6]-=F1+S3;I+B%F!P0'0D$@^]:F[./6I^LU8]=K_CN7]6I25TM';\-CY6^&
M_P"S;\1?AA\5OB-<:=K7AV?P#XON;N\E@D\[[>LDB2F)?N;5"O+R0QRJ]!G
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M!H\KAK]_Y'RE\*_V;/BEI7[2\'Q5\>>)M UMY=*DM+F'3%FB-NYX2*%&3#1
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M',(QA'VBU?;L?<'Q4_:"^'WP4DL8O&7B2'1Y[T%H(/)EGE91P6*1(S*N<C)
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M"5WX.X"N?ZK/F:;6]CJ^N1Y5))]_T/M+\"/J*YCXC_$OPW\)/"\WB+Q9J/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=/X^_:^UZ\/PX\._#7PM:ZQXX\;:5%J\5OJLS"UT^%T+9E*[2_W)>A7A,\Y
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MCDYXKX!^'?VH_@#\.Y/!^B?";2+J.2[DN5OM0UBU;RVD"@DHEP,@;1TYZU]
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M?K5M]GNXMKLG[R/)VYV[ASR"#WKRW_AJ3_JD?Q3_ /":_P#MM>W;:* /$/\
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MY'KD?_JI2,Y/?OP./?\ /\.]/ZU43OT]"/J=)I1[>9\O> _V:_B-X+_9EM_
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M-VS R,D#FA?$P_X;BDT3_A+?$6/^$7^T?\(WY7_$J'S_ .OW_:/];SC'D_\
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M(T#X@7UMIDLEW-J?B_5]7@MK*3RW1/+M[QOW\A\PK\J;55FRX/RL*$.7^O\
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M_P"!5C.S3^1O333C?^NQZC11].E%<QV!1110 4444 <'\1/^1Z^$?_8T3?\
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M2\99]?\ A-]:_P#DNO1=W)K#\;>.M#^'/A?4/$7B+4(M,T>QC\R>XE/ '0
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MT<M@12A&4E$=\[X\?("&QUS]#1E2<.:"5]M79^G_  3Y>O&LIN-23MY;>O\
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MTR\3S;2\@>WF0X^9'4JPYXZ$UPG_  I46NI1W^F^,_$FD77]FVNF3/:M9O\
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M,*H^@KE/%'PM/B3Q9!XB@\4ZYH5_#9FQ0:<+1D$9?>V/.@D*EB%R5(R$7TH
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M_P"1M^)O_8PP_P#IIT^NXH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#EO
MB5X+MOB-X!\1^%[QMEOJ]A-9,^,E"Z%0P]P2"/<5XW^RW\;-.F^&MIX0\9:G
M;:%XZ\(H-(U;3]2G6&3]UE(IEW$;U>,(=XX))]B?HHQ[NIK@O'GP!^'GQ/U*
M'4/%/A'2]:OXE\M;JX@'F;>REA@D#L#G&3CK713G'D=.>U[Z'+4ISYU5I[VL
M[FW_ ,+(\)?]#1HW_@PB_P#BJ/\ A8_A+_H:-&_\&$7_ ,57GO\ PQK\%?\
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M_P"*HM0[O[E_F%\1_*OO?^1Z%_PL?PE_T-&C?^#"+_XJC_A8_A+_ *&C1O\
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M&C1O_!A%_P#%4?\ "Q_"7_0T:-_X,(O_ (JO/?\ AC7X*_\ 1.]'_P"^&_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% '#_#W_D;?B;_ -C##_Z:=/KN*X?X>_\
M(V_$W_L88?\ TTZ?7<4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW%% '#_\*]U[_HIOBK_P&TG_ .0:/^%>Z]_T4WQ5_P" VD__ "#7<44 </\
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/ 2%!PN>I).:Z2BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img46421407_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\O/T]?;W^/GZ_\  $0@#<0=& P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#S?XC_$'_ (5_;V]Q]E^V?:9&3;YWD[=J
MALY\J7.<XQ@8]:[*%#ZPVN;ELK[7_5'%B*_U9)\O-=VWM^C/)?\ AI/_ *A/
M_D[_ /<E=_U#_IY_Y+_]L>=_:/\ T[_\F_\ M2W:?M(6SN!=Z;+$F>3%<+*V
M/]UHH1GVW#ZU+P#7PS7S5OU92S!?:@TO)W_1'NOAGQ5IWBZU^VZ7+YL8.UU(
MVR1MC.V1#RIQR.JL.5)'->94IRHOEFK/\'Z'K4ZL:T>:F[K\5ZGEGCCXU?\
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M?3=7J1P#^U-+T5_U1Y4LPBOA@VO-V_1EW2/VB-+NI!'J-I/9*QP9$=;A5]V
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M\K/F.%SOV28QG.-ISTXK2C3]M-4[VO?6U]OFC*O5]A!U+7M;2]M_DSE_AO\
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MKUIX+D@ZG/>RO;E_^V/'ACN>:I\EKNU^;S[<I]"5Y)[ 4 % !0 4 % !0 4
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M[K[#;2W.-_D1/)MSC=L4MC.#C.,9P<>AJHKF:CW:1,GRIR[)O[CQ'P7\;O\
MA+]7M]'_ +/^S?:?-_>_:O,V^7#)+]S[/'G=Y>W[XQG/.,'TJN#]C!U.>]K:
M<MMVEW?<\NCC?;35/DM>^O-?9-[<J['O->6>L% !0 4 % !0 4 ?/5A\>/MV
ML1:-_9NSS[Q+3S?M>=N^80^9L^S#.,[MN\9Z;AUKUI8+E@ZG/M%RMR]E>U^8
M\>..YJBI<F\E&_-W=KVY3Z%KR3V H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_P#D$6?_ %]G_P!$O7K8#XY?X?U1XV8?!'_%^C.'^!W@[2/%,-\VK6RW1@>
M1EFD7:'64M]QUSG:.N>G%=6,JSI./LW:][[>7<Y<%1A54_:1O9JV_GV/=_\
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MK:VWP=O/YGA1GA?:)1IRY^=6=W;FOO\ 'M?R^1]2.ZQJ7<A54$DDX  Y))/
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#YO_ &CO^/"P
M_P"OB7_T6*]C ?%/T7YGBYA\,/5_D>*>!OB;?> H9H+*&"9;EU=C-YF054J
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M%&% Z*,]3FO#Q,(TZCC35HV76_3SN>_AIRJ4U*H[RN^B77RL?*'QH_Y&^_\
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MSWX=^V:G/K,@^2QC\J(_]-I@02/]V(,#_P!=!S7IXZ?+%4U]IW?HO^#^1Y>
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * *-[JEIIN/M4L<.[IO8 G
MZ#K0!8M[B*Z02P.LB'HR$,#^(H FH JK?6[OY2RQEQU4.I;\LYH M4 % !0
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MC1_R-]__ -NW_I';U]3A/X,/^WO_ $IGR6,_CS_[=_\ 24?9?@?_ )%[2_\
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M!#*<9 RI5L8(KP:\7"I)/NVO--W1]%AYJ=*#C_*D_)I69\W?M":Q;WNK6UE
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M#AIT=[77W?(5#"1KP4U.SZJVS^_YDFO_  I\.>%IX[75=<:WEF4NJFT9_E!
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M_P C9=?]<[?_ -$1U[V#_@Q]7^;/GL;_ !I>D?R1]A>!_P#D7M+_ .P=9_\
MI/'7S];^)/\ QR_-GTE'^%3_ ,$?_24=16!N% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MCDGTH0'/0>';:]5=/TY#-.K W%Z<B*(C[RQ8X9ATX'OGT8'L<2I8P*KM\D*
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M5.W6Q\WI\&O&,9W)8E6'0BZM 1^(N*]CZU0_F_\ )9?Y'B_4ZZVA_P"31_\
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M<W(N75>XC2.20<X^[N0$\DYI?6J%)6I+Y)<OWW2_4/JE>J[UG;SE+F^Y)O\
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M;/:I)QIPC+1J,4_5))F]61L% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 ?)/CG_D;)?^N]O_ "6OO,)_ND?\,_U/@L9_
MO<O\</T/K5>@^E?!GWHM 'E7QB_Y 1_Z[Q?SKW,K_P!X_P"W9?D>%FO^[_\
M;T?S,SX)_P#(-N?^OG_V45MFW\2'^#]3+*?X<_\ '^A[17SI]$% !0 4 ><?
M$S_D'Q_]=A_(UZV _B/_  G!BO@7J8/PP_X^;G_KFO\ Z%75F'PP]7^1AA/B
MEZ(]EKY\]8* "@ H * "@ H * "@ H * "@#PC73?:GK9AV*\\;!(TZIM'S
M_-@8/5L]QWQ5;$G;Z-X/%M)_:.KR">XSNPQ_=H1W). Q'88"+V%(9M77BVQA
M;R;=FNYSP(H 7)/U'R@>IS@=Z+ >8ZWIMZM]_:5]:NT,S!VC1BQ"CC8SH,J<
M?AVS3 Z&W\;K$BVFE6#AAPL?& ?H@)/N3C/<BBP&O:Z+J&N%9]<?;$#D6D?R
MH?3S,$D^X+-Z<4O0#ND18U"( JJ,  8  Z  =!2&.H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H ^-/VB/^1AM_P#L'1?^E%U7T6!_AO\ QO\ *)\UF'\6/^!?^E2/
MHWX6_P#(K:=_U[_^SM7CXG^+/U/9PW\&'I^IWU<IV!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 5;ZZ
M%C;RW)!<01O(5'5MBEL#KR<8'!YJDN9J/=I?>3)\J<NR;^X^%?$?Q+\2>+K?
M^QKO 1V7?%#"4DD*D,JN!EB-V&VJ%!(!(.!7T]/#TJ+]I'Y-O1'RE3$U:R]E
M+YI*S?J>^?!/X?S^&;>35=3C,-[=@(D;C#Q0 AB'!Y5Y& +*>555# -D#RL7
M751JG!WBNO1O_@'KX.@Z2=2:M*6B75+_ #9[Q7EGK!0 4 % !0 4 % !0 4
M% !0 4 % !0!Y[\3O!S^-=&>RMRJW4+K/;[N%,B!E*$]@Z.R@] Q5CP*Z\/5
M]A/F?PM6?IW^1QXFC[>FXKXD[KU73YH^4M)\6>*_AC-)!(DD:L1NAO(Y'BRO
M1D.Y< YQNBD 88Y.%(]V5*CB4FFO6+2?S_X*/GX5:V%;337E)-KY?\!C->\7
M^*/B@8[,Q--$K[EM[.%_+WX(W,<NQV@G!=]J#)XY-$*5+"WE>S[R:O\ I^""
M=6MBK1M==HIVO^/XL^GOA+X%D\$Z6RWF/MUXXDF"D$(%&(XMPX8H"S$CC<[
M9 !/BXFLJT_=^&.B\^[_ *['NX6@Z$/>^*6K\NR_KN>J5PG>% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MXC6:,[DD4,IP1E6&0<'!&0>A /K6+3BW%[IV?JC9-22DMFKKT9)2&% !0 4
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M<BAT8=&5AD$?4&HDG%N,E9IV:[-%Q:DE*+NFKI^3):DH* "@ H * "@ H *
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MWV7WNR.:IB*5'2I-)]MW]RNRGI_CK0]4E$%M=H9&.%5UDBR?0&5$!)[ ')/
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MO5GK5>&>X% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M]1];>FA:CA2(810H]A7OT,)0PD>3#4H4UU48I7];*[?F[LPE*4M9-OU)*["
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#P[XU?ZJQ_WI_Y15]'E>]3TC_[<?.YIM3]9?\ MI[C7SA]$<MXW_Y =[_U
MP>NW"?QZ?^)'%B_X%3_"SE?A!_R!7_Z^I/\ T"*NW,OXR_P+\Y''EO\ !?\
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MHXQ3BZTHN%]4N7;Y13'_ !;_ .0'_P!O$7\GI9=_'_[=E^@\Q_@?]O+]3D-
MU_Q;:Z=!%8V$,ULD0$3E')9.Q.+A<GZ*/I7=6HX2523J59*;>JNM'_X"_P S
MAHUL7&G%4Z47!+1V>J_\"7Y&?-XR\2>(K@Z)_H^GSR9C92#"V3U7=*[L&(X
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M:3(R^I:=2A%\T%>47MHFEMTNFFT<WIEWING:]>GQ9$9)6E.QI$,D:'>Q):,
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MZQM.4?M*-_G>/Y6/;:^=/H0H * "@ H * "@ H * "@ H * "@ H * "@ H
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ML^7?'/\ R-DO_7>W_DM?:83_ '2/^&?ZGQ.,_P![E_CA^A]:KT'TKX0^]%H
M\J^,7_("/_7>+^=>YE?^\?\ ;LOR/"S7_=_^WH_F9GP3_P"0;<_]?/\ [**V
MS;^)#_!^IEE/\.?^/]#,^(&DRVFH/=D$P7(!#XX# 8*D]CW&>O:M<%44J:IK
MXH]/+N;XF#C-RZ/J;>A?$2*RM4MKV*1C$H4/%M.X#@95F3! XX)S7-6P3G)S
MIR2N[V=]/FDS:GB5&*C-/3JK?\ 9XB\>6FK64MG!%,IE7&Y]@ YSG"LQ/Z4Z
M&#G2G&I*4='LK_JD*KB(SBX13U[V_P S%^'9_P")N!_TR?\ E73C?X/S1EAO
MXGR9VWQ,_P"0?'_UV'\C7FX#^(_\)V8KX%ZF#\,/^/FY_P"N:_\ H5=68?##
MU?Y&&$^*7HC>^(.@2:C"E[;*7DMP0ZC[S(>20.Y4\X]*Y<%65.3IS=E+9]G_
M ,$WQ--S2G'==/(\V\.^*+GPZS"(+)$YR\;9'([@CE6['@CU%>O7P\:]KZ26
MS7]:H\^E5E2VU3W1VC_%$X^2TPWO+D?D(P?UKSUE_>>G^'_@G7];[1_'_@'9
M^'=3;Q-IS2W**GF%XRJ9QMQCN<YYKSZ]-8:HHP;=K.[.NE/VT+R5KW6AX?JF
MF77AF\"D%#&^Z&3'RL <J0>F1T(ZU]'3J1Q$+K6ZM)=NYX\X2HRMV>C._M?B
M>%C N;8F0#DHX"D^N",K],FO+EE^ON3T\UJCM6+T]Z.ODSBO$?B6?Q+*F4\N
M-,B.)26.X\9)P-S'H, 8%>C0H1PR=G=O=[?\,CDJU75:TLELCU3P)X?DT>U:
M:Y&V>XP2O=$'W0?<]2.W'O7BXRLJLE&'PQZ]WU/2P]-TXWEN_P $<3\2_P#D
M(1_]<?\ V:O1P'\-_P"+]#CQ7QKT.X^'G_((7_KI)_,5YN-_C/T1VX;^'\V=
MN_W3]#7G([#Y7E_X^V_Z[G_T97VJ^!?X?T/FG\7S_4^J(_NCZ#^5?%/<^D0Z
MD,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#R+XPZ9)=:=#>1@L+24[P >$E &X^P95!_WA[U[N65%"I*F].9:
M>JZ?<W]QX>94W*G&HOLO7T?7[TOO.P\-^+[#7+..43QK/L7SHW94=9 !O^4D
M94G)5@,$>AR!P5\-4HS<>5\MWRM)M-=->_='=0Q-.M!/F2E9<R;2:?73MV9S
MGQ'\4V-MI4UE%-'+<W($:HC!BJEAO9\9V@*"!G!+$8Z$CKP.'G*K&HXM1CK=
MJVMM$N^IRXW$0C2E3C).4M+)WLKZM]M#4^'6DR:9H444^Y))]\K#[K*)#\O/
M4'8%;L03CM6&-J*I7DXZJ-H^3MO^-T;8*FZ="*EHY7EVM?;\+,X7PEXMG\/:
ME=:3XCGE)+@)-,[NJ,N1U8G;'*I#!@ . 6ZY'I8G#1KTX5\)%;:QBDF[^F[3
MTM]QYN&Q$J%2=#%R>^DI-M*WKLFM;_>>RG6+%4\TW$ CZ[O-CVX^N['ZUX'L
MIWMR2OVY7?\ (]_VD+7YXV[\RM^9XCYT/B7QI#<Z2-\5OL::500K>6#N?..A
MRD0/1B!C(.:^BL\/@I0KZ.5U&/57V7YR\CYVZQ&-C.AJHV<FMG;=_E'S.EG'
M]N^-$CX:'2+?>>>/,89'_ @TJ<>L?/0BN1?N,$WM*K*WR7_ 3^\['^^QJ7V:
M4;_-_P#!:^X[WQ3_ ,@>_P#^O.Y_]$O7F8?^-3_Z^0_]*1Z6(_@U/\$__26<
M#\);N&#1G621$/VF0X9E4XV1<X)'%>GF,9.LFDW[BV7FSS,NE&-%IM+WWN[=
M$>G_ -HVO_/:+_OXO^->/R2_E?W,]CGC_,OO1-%<Q3Y$3H^.NU@V/K@FI<7'
M=->JL4I*7PM/T9X?X1O8=+\6ZG#=.L)N))_++G:&8S^8J@G RR$D9ZXP.2,_
M18F+J82C*";Y5&]NW+9OY,^=PTE2Q=:,VES.5KZ:\UTOFCJOBAK=K::1+8,Z
MFYN=BK&""P ='9F Y50J\$XR2 .^.+ 4I2K1J)/EC=M]-FK+SNSMQ]6,*,J=
MUS2LDNNZ=WY61!X4_P"1)/\ UZWW_HRXJ\1_OO\ V_3_ "@3A_\ <O\ MRI^
M<P^$'_(%?_KZD_\ 0(J,R_C+_ OSD&6_P7_C?Y1,7XIP2Z=?Z?KB*62V=5;
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M=K;>O;YGOSJPIQ]I*24>]]_3O\CR+X9K/J.H:EKP0[)C($4G 9Y)#,4#'CY
M$4DGC>M>[CN6G3HX:^JM=]DERWMYZ_<SP\#S3J5L3;1WLN[;YK7\M/O1M:3J
MVA?$)Y(M1M(H;J)MJI(^)77 &5D41/D,"I0$E>#WXYZE.O@$I4IMP:O=+W4_
M-.ZVUN;TZE#'-QJP2FG9)OWFO)JSWTL<)X\\,Z?X0:&YTBXDBO/-&(?,#.BA
M2PD4C#I@[5PQ.[=D'@Y]+"5ZF*YH5XIPM\5K)O:SZ/J]-K'FXNA3PO+.A)J=
M_AO=I;W75=-][G6_%-Y9?#MF]P-LS7$!D&,8<VTQ<8[8;(QVKAR])8BHH?"H
MRMZ<\;?@=V8-O#TW+XN:-_7DE?\ $]1TA0^G6ZL RM;Q @C((,:@@CN#W%>-
M4TJ3:_FE^;/9IZTX)_RQ_)'SM+J4G@C^V-"&0)P!;D]E<A<^F6MY.2.0R#!&
M*^J4%C/88G^7XO5:_A)?<SY5S>#]OAOYOA]'I^,7]Z/;/ 6C?V)HT$+#$LH\
M^3_?DP0#[JFQ3[K7SV,J^VK2DME[J]%_F[OYGT.#I>QHQB]W[S]7_DK+Y'D>
MEPV&@>*+NRUN*)[>X=_*>XC1T7>_F1.2ZE5#*2C,, -U( ./<J.I6PL*F'E)
M2BE=1;3=E:2T=]'JEV/#IJG0Q4Z>(C%QDW9R2:5W>+U5M5HWW/7-0T_PUI5L
M;RYMK!(0I8-Y$!W]\( GSD]@N<YKPX3Q-27LX3J.7;FEIZZZ?,]R<,-2C[2<
M*:C_ (8Z^FFOR#P;J>EZM!)<:/:_8XMP5SY$4(=@,X_=$AM@;DGINXZFC%4Z
MM*2C7GSNUU[SE9?/:_Z!A:E*K%RH0Y%>S]U1N_EO;]3L:X#O/'_BGH5P_D:]
M8@F:QP'V]517\R.0 <_NW+;N> P. %8U[V7UHKFPU3X9[>K5FOFMO3S1X684
M9/EQ-/XH;VZ).Z?R>_KY,ZGPWX]TW7X5+2QVUS@;X9&"$-WV%B ZGJ,$D#[P
M!KBKX.I0D[1<H=))7T\[;/\ I'90Q=.O%7DHSZQ;MKY7W7],W;_Q)IFF)YEU
M<PQJ.V\,Q_W47+M_P%37-"A5J.T(2?RLOO>B.F=>E35YSBOGK]RU?R/(O %Z
MFJ^*M0OK<-Y,T,K*6&.&F@*YZX) ) SG /H:]W&0=+"TJ<K<RE&_RC(\/!R5
M3%5:D;\KC*WSE$;XF=8_&]FS$*H^SDDG  RW))Z44%? U$O[WZ"KZ8VFW_=_
M4]M_M&U_Y[1?]_%_QKY[DE_*_N9]#SQ_F7WH/[1M?^>T7_?Q?\:.27\K^YAS
MQ_F7WH\]^+?_ " _^WB+^3UZF7?Q_P#MV7Z'EYC_  /^WE^ITO@C_D!V7_7!
M*Y,7_'J?XF=>$_@4_P#"CE_B7X2_M>U_M*T7%Y:#<=O#21#DKQU9/O)W^\HY
M(KLP.(]E/V,W[D]-=D_\GL_O./'8?VL/:P7OPUTW:_S6Z^XO?#KQ9_PD=CY-
MPV;RU 63)YD7^"7'O]U_]L9.-P%9XW#_ %>?-!>Y+5>3ZQ_5>7H:X+$>WARR
M?OQT?FNDOT?GZG!ZJZQ^/8V<A5#0Y). /]&'4FO2IJ^ :7:7_I9YE1VQZ;[Q
M_P#2#W(ZE:*,F:( =S(G^-?.>SG_ "R^YGT?/!?:C]Z/%_B1XFBUT0Z#I#"Z
MDDE4R&+YE)&0D:L.&Y.YR.%VK\WW@/H,#0=#FQ-=<B2TOH_-M=.R[W?D?/XZ
MNJW+AJ#YFWK;5>23Z]WVMZGK^@Z6NB6$%@ISY$:J2.A;J[#IPSEB/K7A5JGM
M:DJG\S;^73\#W:-/V-.-)?927SZ_>S6K W/#[1?[/\?2JYXN48J3QG= KXZ_
MWD*CUQTYX^BE[^ 37V6K_*37Y.Y\[']WCVG]I.WSC?\ -6/1/'.GR:IH=W;0
M M(45U4=3Y4B2X'J2$P!W/ KR\)-4J\)RT5[?>FOU/5Q<'4H3A'>U_N:?Z'G
M_P -FT+5K!;.[M[-KZ LK>;#$9)5+%E<%U)? .P\DC:,@ KGT\<J]*HZD)S]
MG*VTI63MJM'IW^9Y>!]A5IJG.$/:1OO&-VKW3U6O;Y'0>(;WPIX:*QW-G:22
MN<>5#:V[NH_O."%"C/ R=Q)X! )'+1AB\1=PJ32764YI/R6]SJK3PN'LITX-
MOI&$&UYO:QG?%(H?#L'E)Y,?G0;(BH3RU\J3:FU?E78,+M' Q@<"MLOO]8ES
M.[Y97=[W?,M;];[W,LPM]7CRJRYHV5K67*]++:VUCT7P]_R"[/\ Z]8/_125
MY-;^+4_QR_\ 2F>K1_A4_P#!'_TE'CJW2^#O&<\U[^[MK]6Q(0=H68H^[/HL
MJ;&/;DGBO?Y7BL'&-/64+:=;QNK?.+NCP>983&2E4TC.^O3WK.__ ($K,]FO
MM:LM.MC>W$T:P;2P;<I#X[)@_.3T 7.37S\*4YR]G&+YNUMO7M\SWYU84X^T
ME)*/>^_IW^1Y%\,UGU'4-2UX(=DQD"*3@,\DAF*!CQ\@"*23QO6O=QW+3IT<
M-?56N^R2Y;V\]?N9X>!YIU*V)MH[V7=M\UK^6GWHVM)U;0OB$\D6HVD4-U$V
MU4D?$KK@#*R*(GR&!4H"2O![\<]2G7P"4J4VX-7NE[J?FG=;:W-Z=2ACFXU8
M)33LDW[S7DU9[Z6.$\>>&=/\(-#<Z1<217GFC$/F!G10I82*1ATP=JX8G=NR
M#P<^EA*]3%<T*\4X6^*UDWM9]'U>FUCS<70IX7EG0DU._P -[M+>ZZKIOO<Z
MWXIO++X=LWN!MF:X@,@QC#FVF+C';#9&.U<.7I+$5%#X5&5O3GC;\#NS!MX>
MFY?%S1OZ\DK_ (GJ.D*'TZW5@&5K>($$9!!C4$$=P>XKQJFE2;7\TOS9[-/6
MG!/^6/Y(^=I=2D\$?VQH0R!. +<GLKD+GTRUO)R1R&08(Q7U2@L9[#$_R_%Z
MK7\)+[F?*N;P?M\-_-\/H]/QB_O1[9X"T;^Q-&@A88EE'GR?[\F" ?=4V*?=
M:^>QE7VU:4ELO=7HO\W=_,^AP=+V-&,7N_>?J_\ )67R/(]+AL- \47=EK<4
M3V]P[^4]Q&CHN]_,B<EU*J&4E&88 ;J0 <>Y4=2MA85,/*2E%*ZBVF[*TEH[
MZ/5+L>'35.ABIT\1&+C)NSDDTKN\7JK:K1ON>N:AI_AK2K8WES;6"0A2P;R(
M#O[X0!/G)[!<YS7APGB:DO9PG4<NW-+3UUT^9[DX8:E'VDX4U'_#'7TTU^0>
M#=3TO5H)+C1[7['%N"N?(BA#L!G'[HD-L#<D]-W'4T8JG5I24:\^=VNO><K+
MY[7_ $#"U*56+E0AR*]G[JC=_+>WZG8UP'>?/OBQ(=$\7)?ZG$DUC=JA82()
M$P(A QVD$$QLJN1@G&,=17U&&<JN$=*C)JI"]K.S^+F6OFG8^7Q"C1Q:JUHI
MTY6O=77P\KT\FKGJW]D^'/(^U_9].^SXSYODV^S'7[VW'ZUXGM,3S>SYJO-V
MYIW^ZY[?L\-R\_)2Y>_+"WWV,SPEK.A:K=3+HMHL#PJ0\Z6T42LI< *'0[R'
M*[U5E7(7) ( K;$TJ]*,7B)W3>D7.4FG;L]--KKN8X:K0J2DL/#E:6LE",4U
M?NM==[/L9%AKNC>.+B:PU:TB@N;=MJ+,X\Q\%E95<+&RE#C*!R3G(!VDC>=&
MM@XQJ4)N49:OE6BV:NKM:][?F80JT<9*5*O!1E'1<SU>Z=G9-6[7.)\?^$M*
M\+Q)=Z;,\%UYH"P>9N.T@G>O_+1=N!\Q8@Y ZGGT<'B:N);A5BG"WQ6M\GT=
M^UCSL9AJ6&2G1DXSO\-[_-=5;O<T_B#;7E]H6F:I,I,UNBF;U!F2,[V';+1K
MN]&8"L<'*$*]:C%^[)OE_P"W6]%\GIY(VQD9SH4:TE[T4N;_ +>2U?S6OFSU
MS0O$5GKUHMW;R)R@:1-PW1$#Y@X/*[3GD\$<@D$&O#JT9T)N$D][)VT?:Q[E
M*M"M!3@UMJKZKO<\>\7WL?B_Q%8Z;I[>=';,!(Z?,@)=6F92#@A$09;@%AMS
MP#7O8:#PF'J5:JLY+1/1[6BGZMGA8F:Q6(ITJ3NHO5K5;IR:]$B[\4;[^R]7
MTR\QG[.?,(]0DJ,1^(&*SR^'M*-:G_-I]\6B\?/V=:C4_EU^Z29ZY#KEA/:_
M;TGB^S8R9"ZA1QG#9/RMZJ><\8KPG2J1E[)Q?-VMK\O+S/=56FX^T4ER][Z?
M/S\CR'P@Y\2^*[O6X@?LT2D*Q&,Y18(Q[%HU9SW]>M>[B5]7PD,._B>Z^;D_
MN;L>%AG]8Q<\1'X5L_DHK[TKEBV_Y*#-_P!<A_Z1Q5,O^1?'U_\ <DBH_P#(
MPEZ?^XXGJ?B'_D%WG_7K/_Z*>O%H_P 6G_CC_P"E(]JM_"J?X)?^DL\R^'%U
M)8^%KNYA&9('NI$'7+) C*,>Y KV,;%3Q5.$MFH)^CDTSQ\%)PPLYQW3FUZJ
M*:.:\#>&[#QF)KS6+B2XO/,(\KS-K;=H(<]6()) "D*H4C'IUXNO4P?+3H14
M86WMI?MV^_5W.3"4*>+YJE>3E.^U[.W?O]VBL,^(MCX>T:U2STI(Q>-*&<H[
M2E(U# AF9W*EF*X7.2 3P,9>"GB*LG4K-\B5E=)7;MLDE?2^HL;##T8JG02Y
M[W=FW9:[MMVN[:'4^*=,DU'P99M$-QM;>SG('7:MOL8C_=60L?8&N/#U%3QM
M12TYI5(_-RNOOM8[<13=3!4W'[,:<ODHV?YW.P\#:_:ZOI5N(W02V\*1S1[A
MN0Q*$+$'!V-@,&Y7!QDD&N#%T94JLKIVE)N+Z.[O;U6UCNPE:-6E&S5XQ2DN
MJLK7]'O<\P^(.O6^JZW86EJZRK9RKO=2"OF22Q[E!'!VB-<XZ$D=0:]C!494
MJ%6<TTYIV3T=DGK\[L\?&5HU*]*$&FH-7:VNVKKY61O?&?\ X\+7_KNW_HLU
MS97_ !)_X5^9TYI\$/\ $_R.D\:#/A6;'_/O!_Z'%7)A?]ZC_BE^4CKQ7^ZR
M_P ,?SB2?#:ZADT*UB1T,B+(&0,"P/FN>5SD<$'D="#T(I8Z+5><FG9M6=M/
MA0\#).A"*:ND]+Z_$^AQ?PO_ .0QJO\ O'_T=)7H8_\ @T?3_P!M1Y^ _C5O
M7_VYFY;>(-'\8WDVEZQ:1P3VQ*)Y[@NY5F5U1PJ,A4X.T,=VXD?=)KFE1K82
M$:V'FW&6KY5HKI--J[3OWMI\SIC6HXJ<J->"C*.BYGJ[-W2=DU;M?6_D<;\0
M/!VD^&K<7FGRO;W/F+L@\S=D')W)G]ZNS&=Q9AT'4@UWX/$U<1+V=6*E"SO*
MUOO^SKVL<&,PU+#Q]I2DXSNK1O?[OM*W>Y[3X6N+B[TJUFO,^>\*%R>IR.&/
MNRX8^YKY_$1C"K.-/X5)V_R^6Q]!AY2E2A*I\3BK_P"?SW/,/%!-]XUTZ"(9
M-NL+-QTVO),WX!,'/&.>U>SA_<P563^TY6^:45^)X^(]_&THQ^RHW^3<G^![
M;7SI]"% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MZZ>;.FW*A"9 )Z#/)QZ#J<5QN2346US/97U=M[(Z$G:Z3LMWT0ZJ$% !0 4
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MDJ%*G@X[I*4_Z\W=_)'A8.+KU:F,ELVU#^O)67S9[%7@GO!0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MW75O4QHTE0A[.+;2O;F:=K]-$M#9KG.@* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H Y77O"%GXAN;>\N7F22S.4$;(%/S!_F#1
MN3RHZ%>/SKMHXF=",J<%%J>]T[[6TLT<5;#0KRC.;DG#:S5M[ZW3.JKB.T*
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M 8EY_K6_#^0K-[C*U2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;=G_ *I?Q_F:U6PB
MS3 * "@#-U#^'\?Z5$@,VH&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &EIW\7X?UJXB
M-*K * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#$O/]:W
MX?R%9O<96J0"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@#;L_]4OX_P S6JV$6:8!0 4
M9NH?P_C_ $J) 9M0,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * -+3OXOP_K5Q$:56 4
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M/B'P[XQ@T?3KOR+*3['NB\BW?/FOB3YY(7D&X>CC';%"6@'U94 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M ;=G_JE_'^9K5;"+-, H * ,W4/X?Q_I42 S:@84 % !0 4 % !0 4 % !0
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M7GA72'U^\U:)=0BC$S6[ HQ< ;TBN3/NDD'(7$0WMP",@U5^@CV7]G?Q;?\
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ME?:5AS;7$;*-RML6>5FC.""Q*@$A2IW52=Q'T?J^O3>)OAA-JEUS/<:<?-(
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!B7G^M;\/Y"LWN,K5(!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M;Q6<.<E8D"[C_>8_>=NVYB3CC.*0'QC\:0#\0;8'D'[!_P"C*M;"/J+XM?\
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M^J7\?YFM5L(LTP"@ H S=0_A_'^E1(#-J!A0 4 % !0 4 % !0 4 % !0 4
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M?-MW%BS3L!#X+_9XTKPQ>1ZA?W#ZI- P>)&B6& .#E7:/?*SE3@J#)LSR5/
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M!DV9Y*G@ N!]"U(!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % &W9_ZI?Q_F:U6PBS3 * "@#-U#^'\?Z5$@,VH&% !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 >#>//@E_P )MKBZ[_:'V3:L*^3]E\W_ %1SGS/M$?WO
M]SCWJD[ >\U(!0!X/\0?@/IWC:^?5;>Y?3KN;;YQ$8FBD*@+O,9>(JY4 $B3
M:< E=VXFD[ 8"?LSZ5%IDMJ+N5M0E*;;QX@4B"N&8);+(O\ K "I+3,1D;2
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MOX1:5\/&>Y@9[N^D78;B4*"B'&4B1>$#8!8DLYZ;MORTFP/5JD H * "@ H
M* "@ H * "@ H * "@ H * "@#2T[^+\/ZU<1&E5@% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!B7G^M;\/Y"LWN,K5(!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!PGC+X;Z'X["'5H"TT
M0VQSQ,8YE4G.W<.&7.2%D5U4DE0"22T[ >;VO[-7A:WD$DDFH3J/^6<D\00\
M]S%;QO[<..#ZX(=P/<M)TFTT*UCL-.B2VMH!MCC085022?4DEB69B2S,2222
M32 T:0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 ;=G_ *I?Q_F:U6PBS3 * "@#-U#^'\?Z
M5$@,VH&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % &EIW\7X?UJXB-*K * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#.GLWE<L",''7/H!Z5#0$7V
M"3U7\S_A2L,/L$GJOYG_  HL ?8)/5?S/^%%@#[!)ZK^9_PHL ?8)/5?S/\
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MJOYG_"BP!]@D]5_,_P"%%@#[!)ZK^9_PHL ?8)/5?S/^%%@#[!)ZK^9_PHL
M?8)/5?S/^%%@#[!)ZK^9_P *+ 'V"3U7\S_A18 ^P2>J_F?\*+ 'V"3U7\S_
M (46 /L$GJOYG_"BP!]@D]5_,_X46 /L$GJOYG_"BP!]@D]5_,_X46 /L$GJ
MOYG_  HL ?8)/5?S/^%%@#[!)ZK^9_PHL ?8)/5?S/\ A18 ^P2>J_F?\*+
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M@D]5_,_X46 /L$GJOYG_  HL ?8)/5?S/^%%@#[!)ZK^9_PHL ?8)/5?S/\
MA18 ^P2>J_F?\*+ 'V"3U7\S_A18 ^P2>J_F?\*+ 'V"3U7\S_A18 ^P2>J_
MF?\ "BP!]@D]5_,_X46 /L$GJOYG_"BP!]@D]5_,_P"%%@#[!)ZK^9_PHL ?
M8)/5?S/^%%@#[!)ZK^9_PHL ?8)/5?S/^%%@#[!)ZK^9_P *+ 6[6W:#=NQS
MCI[9]AZU25A%NJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /#?BY\:(?AL\6G6L'V[5+E/,6-F*QQ1EBBO
M)M!9V=E8)&NTD L77Y0X!Y):_M'^)M!NHAXNT86MI<<J4@NK279GYI(Q=/(L
MVW(.T; >F]<YH ^PK"^@U.VBO;1Q+;W,:2Q..CQR*'1A[%2#0!\[_&;XZR^
M+R+2-$CMKJ^ $ET;@2/'"C#,<>V*6)O-<$2'+86/;\K>8"H![GX3U677=%T_
M5+@(LU]96MS(L8(0/- DCA S,P4,Q"AF8@8RQ/- '04 % !0 4 % !0 4 %
M'@'QS^*NJ_#'^SO[)BM)OM_VKS/M22OM\C[-LV>5/#C/G-NW;LX7&,'(![CI
M=TU]9P7,@ >:&.1@N0 716(&23C)XR2<=S0!>H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#B_$GP[\/^+[B.\UFS2[G@54C=GF7:JN9 N(Y$4C>22"#N!VME>* /G_\
M:8\<6$MBGA"T_P!*U*:>&65(QN\A5R40XR?.E++MC +;"6;&Z,. >X_"CPW<
M>$?"NGZ3>#;<0Q.\J\91YY9+AHSC()C,I0D$@E<@F@"E\8/#UYXA\.SQV-_-
MI;6BRW4K0[\W$,5M.'M7V30_NY=X+;BZ_(,QMQ@ ^6/V;?"FH:U=2ZG::G<:
M?;Z=<VSSV<7F>7>@B1MDNV>)< *5^>.488\=00#NO%/C_P 2?$3Q;)X+\(7/
M]F6MHTD<]VG$C>2=L\ID WJB/^ZB2(J9&PS2;7'E@&;XK_X3CX&/;:NVL3>(
M=,FF$4T=WYA^<J7\LB62X>,.JOY<L4HPR_.F"%< ^M?#FNV_B;3;;5[//DWL
M*3*#]Y=PR4;_ &D;*-CC<#@D4 <9\8/"Q\7^%[S3TECMY%"3I),XCB#0L),2
M.Q"HK*&7>QVJ2&/ H ^4-#^.5KH'@B7PA+:R/J*075G'+&87M2D[2_O&<2$D
MH)6P$22.3:&W@.0 #Z#_ &=/#!\.^%EF>:*=]2F:Z/DNLB1@HD2Q%T)4R*(\
MR 'Y68IU0D@'M&L63ZE8W%G%*]M)<0RQ)-$S))$SH561'4AE="0RE2""!0!\
MP?L[>-]0G?5]&\1W4]Q<:>?M&^ZFDG>-(RT-RNZ1G8)&RQG .,NQQD\@'D/P
M^^+.M77C>VNKZ]O'T[4;^2(VLMQ*ULBW3,D:K$7,2"!Y8BNT (%'1: /4OB+
MXBU;Q%\2+#PIH]]>6=M#Y"726EQ-"&R#=7#-Y3KN*VNU1G.T@\C)H AUOQEX
ME^*GB^?PCX8O6T?3[#SA-<1;EE80.L4LQ="LI'G,(XHXY(U(*NYYRH!&OBCQ
M/\%_$]GHNOZB^N:/J6S$T^XRHKOY9D#2/)(C0N0SH99(WB/&'(* '4?&KXDZ
MS9ZQ9^"O"KBWO[XQ"6XP-RFX?9#&C$,(Q@&260*6"%=A7#9 ..\7VGCCX*16
MVO?VY-KEM),L5Q!=>:R!V5F"A9I9CY;!&'F1F%U;;\N#0!N?M$:Y#XE\!:7J
MUL"L5[?6LZJ>2N^RO&*-CC<A)5L<9!Q0!YU/\5K^7PYHW@?P>TO]IS0PQW$\
M#&.1'9B5MH9,J4<Y#32AE$:_)NR9-@!]>?#SPK>^$],6WU6_NM5OY<23S7-Q
M+,JOC_5P"5VV1ITR,-(V7;&55 #O* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M8GSWVBWM0">A;C@G(!WG[.UM/XO\2ZOXTOA\Y+(G=1+=.794)YQ#%&(Q_L2
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MS[/E$$3,! \>,MN@E12[YY\W=A5CR0#[>^&?C>+Q_H5OJR;1/CRKJ,?\L[A
M!(,=E;(D3/.QUSSF@#OJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /F']H'XO3^$47P[HKF+4;J/S)[A?O6
M\+$A5CX.)I<-\W#1)AE^=T9 #B/A-KGPV^'\2W]YJ:WFM2KF2=K._*P%A\\=
MOFUXZD/*?GDY^ZIV4 =G\5_AIJ?QCFT[7?#EW:"P%F#$;E[F$DR.9!*D:VSE
M=R>7DL$?*@%?E% 'S[\6? WB_P )VEM-XIU3^U(9IF2%/MEY<^6X3);;<QHJ
MY7C*DD]",4 ?5GP!\.ZYHFB"XUJ\^VVU_;V4]A'Y\\WV:W,!98MDR*D.$>-=
MD)9!MP#A5R >\4 ?F%X[6Z^'NKZ]X8MQY=GJ,D?RX(_<"9+RVVGH=J-Y38P#
MEAQ@K0!Z1\2?#D_PNA\*:_9*%N+&WCBG'(4SQO\ :V1L=I6GN48_>* @]!@
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M1!-"SV[ GD(<D&4* #[K\+^(K7Q9I=OK%B<P7<8<#()1NCQMC^.-PR-_M*:
M-Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M4G/RDT >OZ-(TMA;.Y+,UO"S,Q)))C4DDGDDGDD\DT :5 !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 >(P?\E*E_[!H_E'0!/\<8%N=)LH
M7^[)JENA^C0W(/Z&@"[\7)/[$\+S)8((0_DVN8P%V0,_S(,#A"!L(X&'/<T
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MM[_RU6YM[N!$D  ;8Y(:,GNO"L!V*C& 3D ]KH * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M)U#PS::#>2K%>6(5XKF'+".9"Q#*6$;%2&PP^0]",%5- %:?1/'5_!]@GO\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MCY3SUQ0!+XL\/7&N^'YM&MVC6>6**-6D+",%'C8Y*HS8PAQA"<XR!V ,?7/
M3ZQIFGPQSBTU/2$A^SW* LJR(B*ZD$*S1N4!Z \ E2-R$ S[C0?&NL*EI?:A
M96-N&4O-IXN%NI ISC+A50G SL*CL0RY4@&OK7A"ZO\ 7-)U2"2/[/I2R+*)
M7<S/O4*I7",';C+%W4D\\T 3_$3PM=>+=.CLK)HHY([J*<F9G5=L8<$ HCG<
M=PP, =<D4 5/&WA/4=7OK#6-&DMX[S3&D(6Z\SRI%D"C!,0+#&&Z $[OO*0*
M ._L_/\ (C^U^6+CRT\[RMQC\S:-_E[\-LW9V;@&VXSS0!Q>H>%KJZ\4V>OH
MT0MK2UD@="S^:6?S<%5"%"O[P9)=3P>#QD [R@#F?%WA>W\7Z=)IMRQCW$/'
M*HRT4J_=<#(SC)5AD95F *DA@ <0VB^.WMO[.-_IRQ%=AO%2?[9LQMSC:(@^
M.=X(<-\P<-S0!>\4^!KS5M(L-+MKGSY;"\@N)9[R1R\JQK,'.Y4D8N6D&Q3P
M%&W?P,@'2^-]#G\2:+=:7:M&DUPJ*C2E@@*R(YW%5=APIQA3SCZT 86M^ VU
MK2K"V6?[)J6DI";>YC!94ECC16X.TF-V13G /"DJ<%2 8NH>$O%7BJ)=-UZ\
ML8=.W*9OL*2^=<*C;@KF551,D _)\H(!V-C! -_Q5X%&K16<FE2_V??Z1@6<
MH&Y50!5\J0=60JH ZXYX(9@0#C?$G@?Q;XOAB34[O3T%M(DB0VXG6)V!P997
M=&?>%+!%5=F6/W>X![I0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % 'G?BWQ[_PBUVEG]F^T;X5EW>=Y>-SNFW'E/G&S.<]\8XR;4;ZG+4J
M^S?+:^E][?H<O_PN+_IQ_P#)G_[GJN3S,?K/]W\?^ '_  N+_IQ_\F?_ +GH
MY/,/K/\ =_'_ ( ?\+B_Z<?_ "9_^YZ.3S#ZS_=_'_@!_P +B_Z<?_)G_P"Y
MZ.3S#ZS_ '?Q_P" '_"XO^G'_P F?_N>CD\P^L_W?Q_X ?\ "XO^G'_R9_\
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MB_Z<?_)G_P"YZ.3S#ZS_ '?Q_P" '_"XO^G'_P F?_N>CD\P^L_W?Q_X ?\
M"XO^G'_R9_\ N>CD\P^L_P!W\?\ @!_PN+_IQ_\ )G_[GHY/,/K/]W\?^ '_
M  N+_IQ_\F?_ +GHY/,/K/\ =_'_ ( ?\+B_Z<?_ "9_^YZ.3S#ZS_=_'_@!
M_P +B_Z<?_)G_P"YZ.3S#ZS_ '?Q_P" '_"XO^G'_P F?_N>CD\P^L_W?Q_X
M ?\ "XO^G'_R9_\ N>CD\P^L_P!W\?\ @'HGA+Q+_P )3:/=^5]GV3-%MW^9
MG:B/NSL3&=^,8[9SS@0U;0ZJ<_:+FM;6W<ZBI-@H * "@ H * "@ H * "@
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M)_T^_P#*?_VX?\+'_P"G7_R-_P#:J/\ 63_J'_\ *O\ ]S#^Q/\ I]_Y3_\
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M /<P_L3_ *??^4__ +</^%C_ /3K_P"1O_M5'^LG_4/_ .5?_N8?V)_T^_\
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MZ.3S#ZS_ '?Q_P" '_"XO^G'_P F?_N>CD\P^L_W?Q_X ?\ "XO^G'_R9_\
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MB_Z<?_)G_P"YZ.3S#ZS_ '?Q_P" '_"XO^G'_P F?_N>CD\P^L_W?Q_X ?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % 'SO\ %O\ Y"T/_7HG_HZ>MH;'F8CX
MUZ?JSRZM#C"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H ^B/A)_R"9?^OM__1,%8SW/3P_P/U_1'J-9G8% !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!X3XR_P"0O/\
M]LO_ $3'7X_G7^_UO^X?_IJ!^CY9_NE/_M__ -+D<Q7SYZX4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'L7P]_
MY!\G_7PW_HN*OU#A[_=9_P#7Z7_I%,^$SG_>(_\ 7I?^E3.[K[ ^<"@ H *
M"@ H * "@ H * "@ H * /G?XM_\A:'_ *]$_P#1T];0V/,Q'QKT_5GEU:'&
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0![;\'?^7[_MV_]N*RGT._#?:^7ZGME9'H!0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % 'SO\ %O\ Y"T/_7HG_HZ>MH;'F8CX
MUZ?JSRZM#C"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H ^B/A)_R"9?^OM__1,%8SW/3P_P/U_1'J-9G8% !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!X3XR_P"0O/\
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MI^K/+JT.,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#VWX._\ +]_V[?\ MQ64^AWX;[7R_4]LK(] * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^=_BW_P A:'_KT3_T
M=/6T-CS,1\:]/U9Y=6AQA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * /G?XM_\ (6A_Z]$_]'3UM#8\S$?&O3]6>75H<84
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'MOP=_Y?O\ MV_]N*RGT._#?:^7ZGME9'H!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /G?XM_P#(6A_Z
M]$_]'3UM#8\S$?&O3]6>75H<84 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'T1\)/\ D$R_]?;_ /HF"L9[GIX?
MX'Z_HCU&LSL"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H \)\9?\ (7G_ .V7_HF.OQ_.O]_K?]P__34#]'RS_=*?_;__ *7(YBOG
MSUPH * "@ H * "@ H * "@ H * "@#KO#OBK^P(7A\GSO,??GS-F. ,8V-G
MIUR*^FR[-?[-IRI>R]IS2YK\_+;1*UN27;N>)C<O^NSC/VG)RQM;EYNK?\R[
MG(U\R>V% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >Q?#W_ )!\G_7PW_HN
M*OU#A[_=9_\ 7Z7_ *13/A,Y_P!XC_UZ7_I4SNZ^P/G H * "@ H * "@ H
M* "@ H * "@#YW^+?_(6A_Z]$_\ 1T];0V/,Q'QKT_5GEU:'&% !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0![;\
M'?\ E^_[=O\ VXK*?0[\-]KY?J>V5D>@% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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ML\NK0XPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /;?@[_ ,OW_;M_[<5E/H=^&^U\OU/;*R/0"@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M*19&C'&,JK,0H[H>G6,L!M+ ];MYX[J-9H6#QN,JRG((/<5('AWC+_D+S_\
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M -*F=/JFM6>BJKWLGE+(2JG:[9(&3]Q6(X]<5]@?.&+_ ,)WHG_/S_Y"G_\
MC5.P!_PG>B?\_/\ Y"G_ /C5%@#_ (3O1/\ GY_\A3__ !JBP!_PG>B?\_/_
M )"G_P#C5%@+-GXPTF_F6WMY]TLAPJF.5<GTRR!1[9(R>.M%@.EI % !0 4
M% !0 4 ?._Q;_P"0M#_UZ)_Z.GK:&QYF(^->GZL\NK0XPH * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /;?@[_R_
M?]NW_MQ64^AWX;[7R_4]LK(] * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H Y/QCJ=SI5FDUH_ENTRH3M5OE*2$C#
M!AU4<XSQ7S><XJM@\/&KAI<DG5C%NT9:.,W:TDUNETN>WEM"GB:TJ=:/-%0;
M2NUJI15]&GLV>:_\)EJ__/?_ ,A0_P#QNO@_[:Q__/[_ ,ITO_D#ZS^S,)_S
M[_\ )Y__ "0?\)EJ_P#SW_\ (4/_ ,;H_MK'_P#/[_RG2_\ D _LS"?\^_\
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M[_\ )Y__ "0?\)EJ_P#SW_\ (4/_ ,;H_MK'_P#/[_RG2_\ D _LS"?\^_\
MR>?_ ,D'_"9:O_SW_P#(4/\ \;H_MK'_ //[_P ITO\ Y /[,PG_ #[_ /)Y
M_P#R0?\ "9:O_P ]_P#R%#_\;H_MK'_\_O\ RG2_^0#^S,)_S[_\GG_\D'_"
M9:O_ ,]__(4/_P ;H_MK'_\ /[_RG2_^0#^S,)_S[_\ )Y__ "0?\)EJ_P#S
MW_\ (4/_ ,;H_MK'_P#/[_RG2_\ D _LS"?\^_\ R>?_ ,D'_"9:O_SW_P#(
M4/\ \;H_MK'_ //[_P ITO\ Y /[,PG_ #[_ /)Y_P#R0?\ "9:O_P ]_P#R
M%#_\;H_MK'_\_O\ RG2_^0#^S,)_S[_\GG_\D'_"9:O_ ,]__(4/_P ;H_MK
M'_\ /[_RG2_^0#^S,)_S[_\ )Y__ "0?\)EJ_P#SW_\ (4/_ ,;H_MK'_P#/
M[_RG2_\ D _LS"?\^_\ R>?_ ,D'_"9:O_SW_P#(4/\ \;H_MK'_ //[_P I
MTO\ Y /[,PG_ #[_ /)Y_P#R0?\ "9:O_P ]_P#R%#_\;H_MK'_\_O\ RG2_
M^0#^S,)_S[_\GG_\D'_"9:O_ ,]__(4/_P ;H_MK'_\ /[_RG2_^0#^S,)_S
M[_\ )Y__ "0?\)EJ_P#SW_\ (4/_ ,;H_MK'_P#/[_RG2_\ D _LS"?\^_\
MR>?_ ,D'_"9:O_SW_P#(4/\ \;H_MK'_ //[_P ITO\ Y /[,PG_ #[_ /)Y
M_P#R0?\ "9:O_P ]_P#R%#_\;H_MK'_\_O\ RG2_^0#^S,)_S[_\GG_\D'_"
M9:O_ ,]__(4/_P ;H_MK'_\ /[_RG2_^0#^S,)_S[_\ )Y__ "0?\)EJ_P#S
MW_\ (4/_ ,;H_MK'_P#/[_RG2_\ D _LS"?\^_\ R>?_ ,D=9X.U^^U6\>&[
ME\Q%A9P-D:_,'C .553T8\9QS7TF39AB<9B)4L34YHJDY)<L(ZJ4%>\8I[-]
M;'B9E@Z&&HQG0ARR<TF^:3TY9.VK:W2/2J^\/DPH * "@ H * "@ H * "@
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MQ]*^QR^/U?+<7B*FD:D7"-^ONN"M_P!O3M\O(^;QC]KC</1AJX-2?EJI._\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
MX3XA?\@^/_KX7_T7+7Q_$/\ NL/^OT?_ $BH?1Y-_O$O^O3_ /2H'CM?EY]V
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!W?P]_P"0A)_U[M_Z,BK[#A[_ 'J?_7F7_I=,^<SG_=X_]?5_Z3,]
MBK]0/A H * "@ H * "@ H * "@ H * "@#YW^+?_(6A_P"O1/\ T=/6T-CS
M,1\:]/U9Y=6AQA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?1'PD_Y!,O_ %]O_P"B8*QGN>GA_@?K^B/4:S.P
M* "@ H * "@ H ^*? _C?X?R2ZMJ7B\V<][J.JW,\*W.GR79CM3M$*K(+690
M/O?*&S@*6&: .QTM=%\6>*])O? >GBUL],:>6^U&"T-C;21/&46W \N(S.Y)
MX*9"MD90.5 .TB\<^*O&<L\_@FTT[^RK65X5O-3DG O7C.'-K';X*H&RJR2$
MH_7*L&10#N/A]XP?QGISW-Q!]BO;.YFL;RWW;Q%<VY D56_B7#*P],[<G&2
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M H * "@ H * "@#YW^+?_(6A_P"O1/\ T=/6T-CS,1\:]/U9Y=6AQA0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M >V_!W_E^_[=O_;BLI]#OPWVOE^I[961Z 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MZ>OGS25^O*[/TW.?T;01=:D=.O=\90/NV$ Y49&"0PP>N<<@Y%>+@L![;&/
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MR*OL.'O]ZG_UYE_Z73/G,Y_W>/\ U]7_ *3,]BK]0/A H * "@ H * "@ H
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M(7_(/C_Z^%_]%RU\?Q#_ +K#_K]'_P!(J'T>3?[Q+_KT_P#TJ!X[7Y>?=A0
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M.7*/]YGK?]W+7O[\-1NK<>&$_P"N-M_Z%'4XO_D30_Z]T/\ TJ!6'_Y&<O\
M'5_*12^'!.+H9X'DG';)\W/YX'Y"N3AMNV(73]UIZ^TO^2^XWSI?P7U_>?\
MMAYWJ("W4P' $L@'_?9KXC$JU>JELJD__2F?4T'>E3;_ )(_^DHIURFX4 %
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MW_D'R?\ 7PW_ *+BK]0X>_W6?_7Z7_I%,^$SG_>(_P#7I?\ I4SNZ^P/G H
M* "@ H \Z\:?\A/1_P#KZ/\ Z-MJ: ]%I % !0 4 % !0 4 ?._Q;_Y"T/\
MUZ)_Z.GK:&QYF(^->GZL\NK0XPH * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /;?@[_R_?\ ;M_[<5E/H=^&^U\O
MU/;*R/0"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * .$^(7_(/C_Z^%_]%RU\?Q#_ +K#_K]'_P!(J'T>3?[Q+_KT
M_P#TJ!X[7Y>?=A0 4 % &YH&MOH-P9U7S%92K)NVYZ$'.&Y!'H>,CC->OE^.
MEEU5UHQYTXN,H\W+?JG>SU379Z774\[&858RG[-OE:::E:]N^EUHUY]GT#7]
M;?7;@3LOE*JA%3=NQU).<+R2?0<8'.,T9ACI9C559QY$HJ,8\W-;=MWLM6WV
M6EET#!X58*FZ:?,VVW*UK]$K7>B7GO=]0T37[G0G+08:-\;XV^Z<=QCE6]Q^
M(.!1@<PK9=)NE9PE;FA+9VZ]T_-?-,,5@Z>,BE4NI+X9+=>7FO+[K'3'QVL>
MZ2WLHHIY!\TFX$D]BVV-&;'H6_&O?_MZ,>:='"TX59+6?,G=]'*T(N7HY?,\
MG^R7*T:M><J<=HVM9>5Y22^XY2#6)5OUU*?]](KAR,[<XX !P=H X'!P!7SD
M,9-8J..K?O)J2DU>U[=$[.R2T6FB/9EAHN@\)3]R+CRIVO:_7=7;W>I:\1:_
M_;\J2^5Y/EJ5QOWYR<YSM7'Y&NG,<?\ VE.%3V?L^2+C;FYKW=[_  QL8X+"
M?4HRAS\_,[WY>6VEN[+MQXJ\_2QI7D[<)&GF>9G[C*V=FP==N,;N,YYKJJ9K
M[3!++O96M&$>?GO\$HROR\G7EM\6E^IA#+^3%?7?:7]Z3Y>7^9-?%S=+]BMH
M7BBYT,&)0)8"<F-N,$]2K#IGN,$>V>:Y\#FE;+TZ<4ITF[\DM+/JXOI?JK->
M5]37%X"GC&IMN%1:<R[>:ZVZ;/SL;+^.O*C9;&TBM7<Y+ @\GJQ58TRWN2>>
MH/2O5>>\D91PF&IT92U<DT]7NVE"%WYMOSOL<"RGFDGB*TZD8Z)--:=KN4K+
MTM\BIX+E:;5Q)(2SNLC,3U)(R2?J:YLDE*>/4YMN4HU&V]VVKMLVS2*AA'"*
MLDX));))['3>(?$HTV^:VN+>.[C0(\>_ 9&(Y()1Q[C@$<\XP![V8YFL)B70
MK4(5H14)PYK)PDUJTW&7JM$UKKM;R<'@7B*"JTJLJ4FY1E:[4E?JE*/SU:?;
MOQ.O^)9]=*JZB*%#E8U.><8W,>,G&0.  ">.23\IC\SJYBU&24*<7=03OK:U
MV]+O=+1))[;L^@PF!A@KN+<IO1R>FG9+HN^KN6[[Q5]MTU-,\G9Y:1)YGF9S
MY849V[!C=CINXSWKIKYK[?!QR_V7+RQIQY^>]_9I:\O(M[?S:>9C2R_V6)EB
M_:7YI3?+RVMSWZ\SVOVU\C(T769M#G\^$!@1M=#G#+D'MT(QP><>A!(/F8+&
MU,OJ^VI6::M*+VDKW^371]/--I]N*PL,9#V<]+.\6MT_U7==?6S.JE\>?,98
M+2**9L!I"P9F4=LB-3TX&20/0U]%//O>=2CAJ<*CLI3;4I-+I=0B]M%=M+LS
MQHY3IR5*\Y05[12LDWUMS-;[V2OW(9_&B3WD-\;;#6ZR+CS<YW@8(/E?*5Y[
M'(;'%95,ZC4Q%+%O#^]2C.-O:7OS;._L]&M>CO?H:0RQPHU,.JVDW%WY+6Y?
M+GUOIVM8M7/CJWO,?:+".;;G;YDBOC/7&Z$XS@9Q714SVE7M[?!PG;;GG&5K
M[VO2=KF,,IJ4K^RQ,H7WY8N-[=[5$8M]XDBE:*6QM(K*6"0.'3:=W!&T[8T^
M4YY&>1QBO*KYE3DZ=3"8:GAZE.?/S1Y==&N5\L(:.^NNIWTL#.*G#$5IUH3C
MR\LKZ:WNKSEKVT-B7QZ)@KO9Q-/&/DD9L[2>Z@Q[A] ^?>O4EGZGRRGA:;JQ
M^&;E?E;ZQ3A=>BE\SACE#A>,:\U3EO%*UUV;YK/YQ^1FZQXM.LV0M)H0) 5;
MS _&Y<@D)LX!!88W\9ZG%<&,S=X_#K#5:24TXRYU/3F6C?)R]4VK<VE]V=>&
MR[ZI6=:G4]UIKE<=;/9<W-T:3ORZV&7?BK[5IBZ7Y.W:D:>9YF?]65.=FP==
MO3=QGO4ULU]M@EE_LK6C3CS\]_@<7?EY%O;^;3S'3R_V>)>,]I>\IOEY;?$G
M]KFZ7[:D'AOQ)_PCWF_NO.\[9_'LV[-_^PV<[_;&.^:QRW,O[,]I^[]I[3D^
MWRVY>;^[*]^;RM8UQN"^O<GO\G)S?9YK\W+_ 'E:UO/<YZYF^T3/-C;YCL^,
MYQN).,\9QGK@5XM6?M:DZMK<TI2MO;F;=KZ7M?L>G3C[.$87ORQ2OWLK$-8F
M@4 % '=_#W_D(2?]>[?^C(J^PX>_WJ?_ %YE_P"ETSYS.?\ =X_]?5_Z3,]B
MK]0/A H * "@ H * "@ H * "@ H * "@#YW^+?_ "%H?^O1/_1T];0V/,Q'
MQKT_5GEU:'&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!]$?"3_D$R_P#7V_\ Z)@K&>YZ>'^!^OZ(]1K,[ H
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MO;Y0W+?#UK1])6NOOJ?@CR/X.8I1VK4M?6-]?NA^+.+KY0]\* "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M *]V_P#1D5?8</?[U/\ Z\R_]+IGSF<_[O'_ *^K_P!)F>Q5^H'P@4 % !0
M4 % !0 4 % !0 4 % !0!\[_ !;_ .0M#_UZ)_Z.GK:&QYF(^->GZL\NK0XP
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M<_[Q'_KTO_2IG=U]@?.!0 4 % !0!YUXT_Y">C_]?1_]&VU- >BT@"@ H *
M"@ H * /G?XM_P#(6A_Z]$_]'3UM#8\S$?&O3]6>75H<84 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'MOP=_Y?
MO^W;_P!N*RGT._#?:^7ZGME9'H!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 96M6=Q?6CPV<IMIS@HXR.00<$CD!L8)'(ST(R
MI .5T+Q7)'-_96MC[/>)A5D. DOIR/E#-V(^1STP<*7Z =_2 * .$^(7_(/C
M_P"OA?\ T7+7Q_$/^ZP_Z_1_](J'T>3?[Q+_ *]/_P!*@>.U^7GW84 % !0
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MC@@]0:^6::=GHUNCWT[ZK82D 4 % !0 4 % !0!9L[.:_E6"W4O(_0#^9/0
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M 4 % !0 4 % '=_#W_D(2?\ 7NW_ *,BK[#A[_>I_P#7F7_I=,^<SG_=X_\
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M7J<&%P[P\92J-.K4DY3:VOT2VT733JS%KR3T H * "@ H * "@ H ]B^'O\
MR#Y/^OAO_1<5?J'#W^ZS_P"OTO\ TBF?"9S_ +Q'_KTO_2IG=U]@?.!0 4 %
M !0!YUXT_P"0GH__ %]'_P!&VU- >BT@"@ H * "@ H * /G?XM_\A:'_KT3
M_P!'3UM#8\S$?&O3]6>75H<84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % 'MOP=_P"7[_MV_P#;BLI]#OPWVOE^
MI[961Z 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '/>*
M-4N-%L'O+54=HV3(D!*A68+G 923D@#![],4P.5M]9\57423Q6=JT<JJZ'<!
ME6 93@W0(R"#@@$=Q1H!-_:7B[_GRM?^^E_^2J- #^TO%W_/E:_]]+_\E4:
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MQYF(^->GZL\NK0XPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M)$)6:VB)&2CR/N7V.V-DR.^&(]ZSYD=2P\[7T7S_ . >:GBM#E"@ H * "@
MH VKCP]>V=BNISQF*"618X]_#N65V#!>NS"'YCC.05R#D*^MC1P:CSM65[&O
MI'@B]UFP;4X'@6&/S,J[.'_=C+8"QLO/;YOKBDW9V+C2E*/.K6U_#Y''51@%
M !0 4 % &U%X>O9+"35?+*6L.WYV^7>6=8P(QU;!89/W0 1NW#%*^MC3D?*Y
MVT7_  VABTS,* "@ H * /;?@[_R_?\ ;M_[<5E/H=^&^U\OU/;*R/0"@ H
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MF?'INE1L?K7-DM3VV85:VW/&I.W;FJ1?ZFV9P]E@Z=+^64(_^ PDOT.&O/\
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M (5B "/Q%\5=+T"_?2H;?4-6O(%5[F+3+4W1M58$JUP0R*F0,[06<#!*@$4
M<5X(\7MX]\<WU[IMW-+HFGZ9;1QPAY$@>XN"LOFM 2%$J#SH6+IY@9,9PHH
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MK6'_ .?U+_P9'_,/J];_ )]S_P# )?Y!_P )-I'_ #^VG_@1#_\ %T?6L/\
M\_J7_@R/^8?5ZW_/N?\ X!+_ "#_ (2;2/\ G]M/_ B'_P"+H^M8?_G]2_\
M!D?\P^KUO^?<_P#P"7^0?\)-I'_/[:?^!$/_ ,71]:P__/ZE_P"#(_YA]7K?
M\^Y_^ 2_R#_A)M(_Y_;3_P "(?\ XNCZUA_^?U+_ ,&1_P P^KUO^?<__ )?
MY!_PDVD?\_MI_P"!$/\ \71]:P__ #^I?^#(_P"8?5ZW_/N?_@$O\@_X2;2/
M^?VT_P# B'_XNCZUA_\ G]2_\&1_S#ZO6_Y]S_\  )?Y!_PDVD?\_MI_X$0_
M_%T?6L/_ ,_J7_@R/^8?5ZW_ #[G_P" 2_R#_A)M(_Y_;3_P(A_^+H^M8?\
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MUXM-7[75]=48RA*F[3BXO>S33M\RU6A 4 % !0 4 >=>-/\ D)Z/_P!?1_\
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MG_V?]O\ M-OY^_[5Y&W]XZ;=OV>;/W<[MPZXQQF@#RU/VN%+ /HI"YY(U#)
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M:,$8&-K32+@<#% 'T#0 4 % !0!YU\3?^09%_P!?2?\ HJ:F@/1:0!0 4 %
M!0!\M?$?_D8+K_MC_P"D\5?F^9_[W4_[<_\ 3<3[7 _[O#_M[_TN1P]>.>D%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M_+]_V[?^W%93Z'?AOM?+]3VRLCT H * "@ H * "@ H * "@ H * "@ H *
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M @'EVG^(?BUX@TMO%UG+90V(1YH[#R8M\T29):-7ADE*D [0UTDC@ H#N7<
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M8[BNX=#0!RWPNLK+3?BI!::9.U[:03WR1W#L':7;8709]ZA5<%]V&4888(+
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MW2KZ)-M\E1;6[*5UHNKOT.6KYX]@* "@ H * "@ H * .[^'O_(0D_Z]V_\
M1D5?8</?[U/_ *\R_P#2Z9\YG/\ N\?^OJ_])F>Q5^H'P@4 % !0 4 >=:;_
M ,C=>_\ 7JO_ *#:T^@'HM( H * "@ H * "@#YW^+?_ "%H?^O1/_1T];0V
M/,Q'QKT_5GEU:'&% &[X=U^?PW>+>VX#'!1T;HZ-@E<CD<@$$="!D$9!EJ^A
MI";IOF1VB>)6\2 :#I5JE@NH3EIV60R,VX[Y6Y5,#:N6'/RKL7 XJ;6U?0Z.
M?VG[N$>7F>NM_4Z/7M+;Q->)X?L'6WL=(B4S2'Y@KE<*-N1N95!'+ 9,NXY
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MV59!^Z&'4$!A@D88'@GUH@&(;5DFTG>_X'AE:GGGT3X+O#IWA5KM1N:!+J0
M]"4+L ?;(Y]JQ>]CU*3Y:5^UV<;X$\6ZG=:S';W4[SQ76\.KG(4A&<-&.B8*
MXVJ I!/&<$5)*VASTJDG-)NZ?]:%[Q%;7>F>*1)H<2O<SPB4J44J"VY)&.=H
M3<%RS[E)9F^;YL%+;4J:<:MZ:U:O_F=1::7KYU"._P!3OX;9-\8^RQ.YC<9
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MW;_(X\32]M2E!;VO'U6J^_;YG=_%#P^[:E;W5LN3?[83CO,I"KDY_C0J!Q_
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MOE:Y\O5IP]K['#<TM;7;3N_*R6G_  ^QX7;>)["?Q!+JUY:O<)*P\F,;6*L
MB(Q1N'<JN0-V%8\9(4CXV.+I2Q<L55IN:D_<BK-IJR3L]&[+:^C>E]&?2RP]
M2.'C0IS46E[SU5T[MJZV5WVU1ZMH?B'6-7OC'+IQM],8L \J-'(H )5F#MM?
M<0 51,*6^^=I)^EP^)Q%>KRRH<F'U5Y)QDE;1M-V=^R6E]W8\2M0HTJ=XU>:
MMIHFFGW2LKJW=O6VVIP/B/3+?2_%UFMJ@B2::TE** %#&?:=H' !V;L#C)->
M)B:4*.84E32BI2I2LM$FYV=ETVOZGJ4*DJF#J.;NU&HKO>W+?7[SMO'?B./P
MO/#<V]O%-?3H4$LH)"11MNVC!!RS2-]UEZ MNPHKV,PQ*P4H5(4XRJR5N:72
M,7>RM9ZN3V:\[Z'G8.@\3&4)3:IQ=^5=9-6O\DNJ?E8I>,$@\1^&5U@Q!;A4
MBE4KRR[G5)5W8!* %C@\?*&[ UCC5'%X)8KE2FE&2MNKM*2ONU:_W)FF%<L/
MBGA^;W;R3[.R;3MWV^\^>Z^&/J@H * "@#Z*^$?_ "")O^OM_P#T3!7WF3?[
MO+_KZ_\ TF!\GF7\:/\ @7_I4CU.OI#Q H * "@ H \Z\:?\A/1_^OH_^C;:
MF@/1:0!0 4 % !0 4 % 'SO\6_\ D+0_]>B?^CIZVAL>9B/C7I^K/+JT.,*
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M]?5_Z3,]BK]0/A H * "@ H \ZTW_D;KW_KU7_T&UI] /1:0!0 4 % !0 4
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M7_VI7=_S+/\ N'_[<<O_ #'?]O\ Z'SQ7PI]6% !0 4 ?17PC_Y!$W_7V_\
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M?:^7ZGME9'H!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M <CX[_Y ES_VR_\ 1\5- :_A_P#Y!EI_UZP?^BEI :] !0 4 % !0!PGQ"_Y
M!\?_ %\+_P"BY:^/XA_W6'_7Z/\ Z14/H\F_WB7_ %Z?_I4#QVOR\^["@ H
M* "@ H * "@#L],?^T=%NK$<RVS"X0'N@QOQCD[0&[=7 SSQ]5A7]:R[$8-?
MQ*35:"_NJW-;KHE+IO)+T\"NO88RCB=H5$Z4G_>UY;^NG_@+^>?INL0V>G75
MDX<R7.W85 VC']XE@1^ -<6&QE.AA,1A9J7/5MRM)<JMW;:?W)G57PTZN(HX
MB+CRT[W3;OKVT:^]H;X:U:+1KEIYP[*T3( @!.6*D?>91C@]\^U3EF+IX"M*
MM64G%TY0]U)N[<7U<=-._P AX[#SQ=-4Z;BFIJ7O72LDUT3UU.>KQ#U H *
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M<.SG-JR^34;^4KG)F"]O.C@X[SGSR\HQO=_.[^:.,KY4]\* "@ H * "@ H
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M8IQA'4'DGDC-$FUL31IQFFY*^O=_H97PW\/V&ORW*:A%YPB2,H-\B8+%@?\
M5LN<X'7-.3:V(HPC-OF5[6[_ *'01Z/X2LM1_L:=)9[F23;O+2+&CN1LA!21
M3QD*"0_/WWSD!7E:YIRTHR]F[MW\[+RW..\>^%XO#5X@M2?L]PA9%8Y9"IPR
MY[KRI4GGD@],FHNYA5IJF]-F<+5G.% 'MOP=_P"7[_MV_P#;BLI]#OPWVOE^
MI[961Z 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\B>.OCKXJT+Q3=>&M$
ML;.]\B1$@3[/=S7$F8$E;Y8;E=Y&YC\D8PHR1P30!G?\+D^*?_0N?^4G5?\
MY(H ^A_A?XBUSQ/I!O?$MG_9EZ+B2,0^1/;?NE5"C^7<.\GS%F&[.TXX'!H
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M_GA_Y%A_^.5\'_8N/_Y\_P#E2E_\F?6?VGA/^?G_ ))/_P"1#_A#-7_YX?\
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MG_\ (A_PAFK_ //#_P BP_\ QRC^Q<?_ ,^?_*E+_P"3#^T\)_S\_P#))_\
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MR<C%(=G>UM>Q+>:==:<0+N&6W+Y*B6-XRP'7&X#.,\XH]!N+CNFO56*=,D*
M-"STF]U!2]I;SW"J<%HHG< ]<$JI ..<&E>Q2BY?"F_1&?3)"@ H * "@ H
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M4U- >BT@"@#/CU6TEN7LDE4W$0!:/HP! /&>O!!.W.,\XH T* "@#Y:^(_\
MR,%U_P!L?_2>*OS?,_\ >ZG_ &Y_Z;B?:X'_ '>'_;W_ *7(X>O'/2"@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M6P1AYD9A=6V_+@T ?6WAS7(?$NF6NK6P*Q7L$<ZJ>2N]0Q1L<;D)*MCC(.*
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MJ(H[C4+,[5X &H)''<#   #-/*VT<8(% 'WQ0 4 % !0 4 <CX[_ .0)<_\
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M3ORVU[F8VJRM?G5"$\XW'VG;@[-_F>9C&[=MW<8W9Q_%GFG;2Q/,^;GZWO\
MC<U/$GBR[\4F)KM(D\@.%\I77._;G=O=_P"Z,8QWZTDN78N=1U+<UM.QS%48
MA0![;\'?^7[_ +=O_;BLI]#OPWVOE^I[961Z 4 % !0 4 % !0 4 % !0 4
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M&/7KK[(UU);M$/)N)=P190QS!%(%P67[V"<\9YH ^CO^&@_ G_03_P#)._\
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M+8*D5*5W-1MLOUW1E_$>ZL-3TR$6]S;W5U!*@'E21N[AE*OA49F 9MK$#(X
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M0L"?=O2OJ*.N65>>]E/W?OIM?+FO?YGA5-,=3Y=^77[I_I;\#R.OESW0H *
M"@ H * /HKX1_P#((F_Z^W_]$P5]YDW^[R_Z^O\ ])@?)YE_&C_@7_I4CK->
M\)VGB&1);EY4,2E1Y;(!@G/.Y'Y^F*^EV/$,'_A66F?\];K_ +[B_P#C-%P#
M_A66F?\ /6Z_[[B_^,T7 /\ A66F?\];K_ON+_XS1< _X5EIG_/6Z_[[B_\
MC-%P.4\0>#[/2;RPMH7F9+V;RY"[(2!OA7*8C4 XD/4,,@<=<L#J_P#A66F?
M\];K_ON+_P",TK@'_"LM,_YZW7_?<7_QFBX!_P *RTS_ )ZW7_?<7_QFBX!_
MPK+3/^>MU_WW%_\ &:+@<3KGA[3K:<:=I1N+N^8X*[XRB>NXB)<D#K\P"#EB
M,8I@>F>$?"__  CL+&1R\\P&\ GRUQG 5>A(SRY&>PP,Y0'7T@/G?XM_\A:'
M_KT3_P!'3UM#8\S$?&O3]6>75H<84 % !0 4 % !0 4 % !0 4 % !0 4 %
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M -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\
MP,N/_CE'L:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'
ML:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\
MP%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K
M_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K_P _)_\
M@4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3
MCQ#_ -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!3
M4?\ P,N/_CE'L:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/
M_CE'L:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\
MD/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\ P%?Y
M![:K_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K_P _
M)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K_P _)_\ @4O\
MP_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_
M -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\
MP,N/_CE'L:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'
ML:?\D/\ P%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\
MP%?Y![:K_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K
M_P _)_\ @4O\P_X3CQ#_ -!34?\ P,N/_CE'L:?\D/\ P%?Y![:K_P _)_\
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M "@ H \Z^)O_ "#(O^OI/_14U- >BT@"@#BM0\*RZUJ'VC49=]E%CR;=<CG
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ME;\3C]3A2VNYX8QA(YI$49)PJN0!DY)P!U/-4C"2LVEW91IDA0 4 % !0 4
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M=7L^Z[,@J"@H * "@ H * "@ H * /HKX1_\@B;_ *^W_P#1,%?>9-_N\O\
MKZ__ $F!\GF7\:/^!?\ I4CU.OI#Q H * "@ H \Z\:?\A/1_P#KZ/\ Z-MJ
M: ]%I % !0 4 % !0 4 ?._Q;_Y"T/\ UZ)_Z.GK:&QYF(^->GZL\NK0XPH
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MXKVS011W.Y9$4 (LBX(('0;U)X QE">IJXOH<]>"BU*.B?YGE=:'&% !0 4
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M2U74O"L[&1_#EZ;:!F)9C8R@RV6XGDE(]T0Z_+&HH ]=H * /.OB;_R#(O\
MKZ3_ -%34T!Z+2 * "@ H * /EKXC_\ (P77_;'_ -)XJ_-\S_WNI_VY_P"F
MXGVN!_W>'_;W_I<CAZ\<](* "@ H * "@ H * % SP* +VHZ9<:3+]GNT\J4
M*K%-RL0&&1NVLVTXYVMA@",@9%;U:4Z$O9U5RRLG:Z=KZJ]F[/R>OD90J1JK
MGINZNU>S6W:]K^JT*%8&H4 % !0!8M;66]E6"W1I99#A449)/L!^9[ 9)XJX
M0E4DH03<GHDMV1*2@G*322W;.GN/ 6NVL9FDM'V*,G:\3M@?[".S_@%S7I2R
M[%0CSND[+71Q;^Y-O\#CCC*$GRJ:OYII?>TE^)S5G9S7\RV]LC2RR'"HHR3_
M ( #DDX &22 ":\Z$)59*G33E)[)?U][Z=3LE*--.<VE%;MF]J/@S6-)A-S=
M6S)$O+,K1R;1ZL(W8J/4D #N:[:N!Q%"/M*E-J*W:<96]>5NR\V<L,51JRY(
M33?16:OZ72N8EAIUQJDPMK.-II6Z*HR<=R>P [L2 .YKDITYUI*G2BY2?1?U
MHO-Z'3.<:2YZC44NK_K\#7U3PAJVBQ?:+RW:.+(!<,CA<]-WEL^T$\9; R0.
MI%=57!8C#QYZM-J/>Z:7KRMV^9ST\31K/DIS3?:S7W72O\C+M]+N;JWENX4W
MPVVWS2&7*!SA24SOVD_Q!2HYR17-&E.<)58*\86YG=75]G:][>=K&\JD8RC3
MD[2E?ET>MM]=K^5[F?6!J% !0 4 % !0 4 % !0!]%?"/_D$3?\ 7V__ *)@
MK[S)O]WE_P!?7_Z3 ^3S+^-'_ O_ $J1ZG7TAX@4 % !0 4 >=>-/^0GH_\
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M3<NY\'&X<'G !QT?Q;OM'N[:V\7Z+/H,-_((8+K[5#>0"1ONK,\2IY)/H<D
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M2I0@]^9?A%I_FB?]HMB-&LU[&\S^(AEQ_,TL#\<O\/ZH>8?PX_XOT9P/P0\
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M?$W_ )!D7_7TG_HJ:F@/1:0!0 4 % !0!\M?$?\ Y&"Z_P"V/_I/%7YOF?\
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M._\ +]_V[?\ MQ64^AWX;[7R_4]LK(] * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /#?CS>ROI-EH$#,C^(-3M;!F4X(A=]TF,<G+"-".A5F!
MXX(!9^.=Y<>'/!5Q)I,LMA);M:1Q/;R/"Z)Y\2;5=&5@-GRD \KP>* .;UKP
M;XD?0Y?$\FOZE#K45H]Z+:"18M.3;$9OLPM-N&VC]UYLCMN8!W0]* /6OAWX
MAE\5^';#5[G;Y]U;JTNT;5,BDI(0O8%U8X' S@$C!H E\8Z5KFJVT<7AW45T
M>=9-TDK6T5T'CVL/+V2@JOS%6W#GY<=": /._P#A#/B+_P!#5%_X*+/_ .)H
M ]6\-66HZ?I\5OK-V-2ODW^;=+"D DW2.R8BC 1-D92/@?-MW'DF@"77M&B\
M0V,NFW#S0Q7"A7:"0Q2[0P8JK@$J' V-CDHS $9S0!\]KX8TSPC\2=#T[1[=
M+2W72KH[4R2S8N 7D=B7D<@ %W9F( &< 4 ?3= '@/Q*'VKQSX2M)>85FO9]
MO;S8HXWC8^I1D!7TR<=: -SX^V:7G@C4MX&8A!*AQG:R7,/3W*EDSZ,: .IT
M30[#78])\2WL(DU.VL8C#.7DS']HMQYN%#"-MPD89=&(SD$$# !Y-\7M13XA
M7EO\/-%_TBX>XCGU*=/FCL8(B=P=AE1*2V=I/!"QD;I   =Q\2?$=Y))!X/\
M/MMUG6 =THS_ *#9#B>[?'*G&8X.5W2$[3N558 \_P# _AVS\)_$J;2-.3R[
M>U\-HBCNQ^U6I>1SW>1B7<]V)Z#B@#U#XQ?\B;JW_7H_\UH ](DC652C@,K
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MIY)FC+8FCC)6*5PRJ5E>((95&]1)NVNPP: .CH * "@ H * "@ H * "@ H
MIZC]J%M+]@$9N_+?R1,S+%YNT[/,9$=@F[&[:C'&<"@# \%>%T\(:5%IP<SS
M9>:YG(P9[F9C)/*1VW.3M'\*!5[4 =70 4 >=?$W_D&1?]?2?^BIJ: ]%I %
M !0 4 % 'RU\1_\ D8+K_MC_ .D\5?F^9_[W4_[<_P#3<3[7 _[O#_M[_P!+
MD</7CGI!0 4 % !0 4 % !0!Z9X$&_3M9B3EVLLJ!U("39P.IZ@8'J!7T.7Z
MT<7%;NEHNNBG_FCQ\9I4P[>RJ?K$3X4_\AD_]>\G\TI91_O/_;DOS09C_ _[
M>7ZG(^&F+:Q9$G)-Y;DD]2?.3DUYF%UQ%%O_ )^P_P#2T=]?2C42_P"?<_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]M^#O\
MR_?]NW_MQ64^AWX;[7R_4]LK(] * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * / _CPILHM#UQO]1I6N6<TY[)&6R7;I\H9%4\]7'N0 6OVC/\
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MHIXY\^4ZOL)5MK [6'53@G!'<'D4 2T % '@W[1'_(O6_P#V$8O_ $GNJ]3
M_P 1_P"!_G$\G,/X4?\ &O\ TF1\9U]$?,A0 4 % !0 4 % !0 4 % !0 4
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M9@>*/'%WXE06Y5;:U4@^4A)W$="[8&X+_"H55'4@D AJ-C.I5=339=B]X?\
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M $X_^3/_ -SU/)YFWUG^[^/_  #)U;XKWE["8;.%;0N"#)O,C@$?P';&%/\
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M8?+ I,NU [LRA51LT +X.\,6_@W1[71;3F.TC"EL8,DA):60CUDD9GQVS@<
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MZM#C"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H ^B/A)_R"9?\ K[?_ -$P5C/<]/#_  /U_1'J-9G8% !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!YU\3?^09%_U])_Z*FIH#T6D 4 %
M!0 4 <#K7PZT[7;R2_N)+E99MNX1O&%&Q%08#1,>B@G+'G/0<5XE?+*.)J2K
MSE-2E:Z3BEHDM+Q;V7<]2ECJE""I04&E>UT[ZMOI)=^QE?\ "H](_P">UW_W
MW#_\8KF_L;#_ ,U7[X__ "!O_:5;^6'W2_\ D@_X5'I'_/:[_P"^X?\ XQ1_
M8V'_ )JOWQ_^0#^TJW\L/NE_\D'_  J/2/\ GM=_]]P__&*/[&P_\U7[X_\
MR ?VE6_EA]TO_D@_X5'I'_/:[_[[A_\ C%']C8?^:K]\?_D _M*M_+#[I?\
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M2/\ GM=_]]P__&*/[&P_\U7[X_\ R ?VE6_EA]TO_D@_X5'I'_/:[_[[A_\
MC%']C8?^:K]\?_D _M*M_+#[I?\ R0?\*CTC_GM=_P#?</\ \8H_L;#_ ,U7
M[X__ " ?VE6_EA]TO_D@_P"%1Z1_SVN_^^X?_C%']C8?^:K]\?\ Y /[2K?R
MP^Z7_P D=IX<\.6_ABW:TM&D='D,I,I4MN*HI *H@QA!VSG//IZ^&PT,'!TJ
M3DTY.7O--W:2Z)::+H>=7KRQ,E.:2:5M+I6NWU;[F_7:<H4 % !0 4 >=>-/
M^0GH_P#U]'_T;;4T!Z+2 * "@ H * "@ H ^=_BW_P A:'_KT3_T=/6T-CS,
M1\:]/U9Y=6AQA0 4 % !0 4 % !0!]):;?R:7X02Z@.)(K5BAX.&+%0V#P<$
MYP>#CFL/M6/5B^6E=;I&/\+=;O=3>[BO)I)P@C=?,8L5+%PP!/(4X'RYVKCY
M0,FG)6V,Z$G*ZD[[$?@#2X1K>J3E1NM)GBC Z())9@=H[<1A0>RDCH31)Z(*
M,5SS?9V7S;_R.@AT?Q*FK_;GNH39F3!M_,EVB MT$?E;/,"\AL@EA@OMS2NK
M6-%&IS\UURWVN]O2VYQ_CVQFL->M+W34#W-P 538&W31MC<0>/NE>>-NS?D'
MD5':S,*J<9QE#=_FC<FTSQ->R1WFH7T&EQQ*#LB=MN0<GS4W"-_0YD90. !D
MTM%HE<UY:CM*4E&W;]>GXD/Q>B4V=M(0-ZS,H/<!D)(^A*J?P%$!8C9/S+'C
MS_D6(?\ MV_] HCN.K_#7R#_ )DC_MU_]J4?:#_ES\OU)OAU,;;PZ\P&3&\[
M@'N54$?RHEN.B[4[^IS?PY\2ZCJ>K217D[S1RPN^UCE5963!08P@P2-J[5.<
MD$@4Y)):&-&<I2:D[Z%NTTN&X\;W =05@47 7 P7,4."1CJ&DWY_O@'-%_=*
M44ZS\M?P7^9C>._%VI6>LO;VDSP16FP*J' 8E%=C(.CY+8VME< <9R2XI6(J
MU)*=HNR7]:G9^-[LZAX66[8;3.EK*0.Q<HQ'X9J8Z.QO5?-2OWLSYTK8\L*
M"@ H * "@ H * /;?@[_ ,OW_;M_[<5E/H=^&^U\OU/;*R/0"@ H * "@ H
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MO]S2_%,\ GA-O(\3$$QLRDJ<@E202#W''!]*]5.ZN>.U9V[$-,04 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'GDGAJ^
MU^^:?6F"VD+GR8$;(=<G!)!XR,;B?G.<80<4]M@._BA2W011*$1!A54   =@
M!P!2 DH \&_:(_Y%ZW_[",7_ *3W5>I@?XC_ ,#_ #B>3F'\*/\ C7_I,CXS
MKZ(^9"@ H * "@ H ]-O_AG=1Z#:>(M,D.I170_?10PMOMFQR#M9RX1P\;MM
M3:0IP0_R\4<0O:2HS7*ULV]_RMIJCNEAFJ<:T'S)[I+X?SOK=/8])^"%A?Z
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MRT_[!D'_ */NJYL%_#E_C?Y1.O'_ ,2/^!?G(/$/_)--&_Z_I_\ T;?T4_\
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M_P"O1/\ T=/6T-CS,1\:]/U9Y=6AQA0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?1'PD_Y!,O_ %]O_P"B8*QG
MN>GA_@?K^B/4:S.P* "@ H * "@ H * "@ H * "@ H * "@ H * "@#SKXF
M_P#(,B_Z^D_]%34T!Z+2 * "@ H * /F?X@_&;6?">NW.DV<-D\%MY.UI8YF
MD/F012MN*7"*<,Y PHXQG)R3[-#"0JTXU).5W?9JVC:[/L>'7QE2C4E3BHV5
MMT[ZI/HUW.,_X:(\0_\ /OIW_?JX_P#DJNGZC3[S^]?_ ")S?VA5_EA]TO\
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MW_E^_P"W;_VXK*?0[\-]KY?J>V5D>@% !0 4 % !0 4 % !0 4 % !0 4 %
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M;G=@JKEB%&6(&20!U) I-J*<GLE=^B*2<FHK=NR]6;_B3P;J_A Q+K$'V8W
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M[;\'?^7[_MV_]N*RGT._#?:^7ZGME9'H!0 4 % !0 4 % !0 4 % !0 4 %
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M\O :*?\ V[^IZ^8:NFE_>_\ ;3 @^!7V.TCNM?U6UTAYL#RY%1@K'D1^8]Q
MK/C[P3< <A2P^:M7C+MQI4W.W5?G9)Z&*P7+%2K5(POT?Y7;6IS?CWX27G@F
MU74H[A+^R9E1I$0QLA?.PLFZ1=C< .'/S$ CD$[4<3&L^1IQEVO?_+7Y&%?"
M2H1YTU*/>UK7\M=/F7_#WP7NO$V@0ZY8W2^?<%@MJ\6U %N6@=FN/-) 5%:8
MXA+'&Q0203$\6J51TI1T75/^[?:WRW\RZ>#=6DJL):O[+7]ZV]^VNWD;T7P#
M6_MY)-,UBUO)X<JT:1@QK*,YC>5)Y"AR,'=%D=UXQ67UWE:4Z;BGUOK;O9I?
MF;+ \R;A4C)KHEI?M=-V^X\J\+^!-2\4ZJ^C0*(9K<O]I:3[L C?8^[;G+!_
ME55SN;N%#,.^I6C2A[1ZI[6ZWU1Y]*A.K-TEHU>]^EM&>L)\![.:9K&'7;62
M^0$M;"%#(N.NY1=F0#U)C_"N#ZY)+F=)J/>^G_I-OQ/0^HQ;Y%5CS=K*_P#Z
M5?\  \9\4>$[[PEJ+:3>J&F^5HS'EEE1SA&3@,=Q!7! (8%<<5Z-.K&K'GCM
MUOTMW/,JTI49^SEOTMUOV/5+#X&3162WWB#4;;15?!VRJK;-V,+([S0(K\XV
MJS\\9SD#A>,7-R48.?I^EDW8]".":CSUIJGZ]/5MI7.?\;_"/4/!]L-1AE34
M;#C=-$I5H]W1G3<X\LY #J[#)PP7*EM:.*C5?(URR[/K\]-?*QC6PDJ*YTU*
M/=:6]5KIYW+G@[X/S>,M%;5[:[$<P:5([=H<AWCQM!F\Y=@8G!/EMM'.&Z5-
M7%*C/V;CIHV[]_*WZE4<(ZU/VD96>J2MV\[Z?<=);_ -+L206^LVLU_ H\VW
M2,,(W(X5V6<R("> S0 D<[>U8O&\MFZ<E%[-O?TTM^)NL#>ZC5BY+=);/SUN
MON/,M%\ W5]XD3PK?O\ 8;@M*KOL\T+Y<#SJRKOCWK(J#:=P^5@W;%=LZRC2
M]O#WEIIMNTO/8X84'*K]7G[KUUM?9-^6]CTN^^!-MI#,=3UNVL820L+SQ)&9
M3M#-\KW:A=I)7 9V.-Q !&>..,<O@I.3ZI-NWW1.V6!4/CJQBNC:2O\ ?(YK
MPC\'[CQ5#-J'VN.TTR.25(KEXR3,L3%3*(RZ!(\ Y+R A@5P<$UM5Q2I-0Y6
MYM*Z3VOTO9W?R,:6$=5.?,E!-VDUO;K:ZLO5F_<? @W5D][H.JVVK% =JQHJ
MJY7JBRQSSKO[ -@%L!F4<C)8RTE&K!P]7M\FEH:O WBY4:BGZ+?RNF]3A_!?
M@C2_$UI)<ZAK-KI$D<IC6&<1;G4(C>8/,N8#M)8KPI&5/S=ATU:TZ3484Y35
MKW5_NTBSEHT858N4ZL8-.UG;7SUDCTRP_9]M=5B^T6.N174)) DAMDD3(ZC<
MEZRY'<9R*XI8UP=I4FGV<K/_ -).Z. C-7A537=1NOPD>/67@:^U?7;CP_I9
M%Q):SSQ&9ODC$<,AC,SX+[$; . 7.6"KN)&?0=:,*:JST32=MW=J]EM^AYJH
M2G4=&GJTVK[*R=KO>WXGK'_"@X%E%D^MVRWY7<+;R5WD>H4W(D*_[7E?A7#]
M==N94GR][Z?^DV_$]#ZBK\OM8\W\MM?_ $J_X'C7BSPCJ'@R\-CJ2 ,1NCD3
M)BE3^]&Q )P>&! 93U'()]&E5C6CS0^:ZKU/-JTI4)<D_DUL_0^E_P!HO_D$
M6?\ U^'_ -$R5XN ^.7^']4>WF'P1_Q?HSROPU\&+G5=.76=7O8='LY$$B-*
MH8^6WW7?=)"D:L""F9"2#DJ.,]U3%J$O9TXN<EH[=^RT;?W'!3P;G#VE22A%
MZJ_;N]4E]YF^-OA+>>$K-=5MKB/4M.;;F>)=I7><*Q4/(IC8D .DC#) (&03
M='$QJR]FTXR[/^EKY6(K865&/M(M2AW7G]^GG<\FKO/."@ H ^S/V=_^1>N/
M^PC+_P"D]K7SN._B+_ OSD?39?\ PI?XW_Z3$]YKRSU@H * "@ H \Z\:?\
M(3T?_KZ/_HVVIH#T6D 4 % !0 4 % !0!\[_ !;_ .0M#_UZ)_Z.GK:&QYF(
M^->GZL\NK0XPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * /;?@[_P OW_;M_P"W%93Z'?AOM?+]3VRLCT H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MKGIQNMMTOS:-K_A2_B__ )\/_)FS_P#DBL_K='^?_P EE_D:?4Z_\G_DT?\
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MN&G]5HQG!+VE2^KU:CY?A]XFHW/_  LKPE=:U>QQC6-$E0-/$HC,]N^W/F@
M+D N_ &#'\FT.RDBOJU:-.+?LYK9ZV:[?A]XI/ZS0E5DE[2FUJM+I]_Q?RTW
M,70H/^$V\*W>G2#=?>'@;NS?JS6KY-Q!P"Q52I=!_?:-1A16LW["M&:^&I[L
MO\71_P!>9E!>WHR@_BI>]'_"]U_7D>.5Z!YH4 % !0 4 % !0 4 >]?L[_\
M(PW'_8.E_P#2BUKR\=_#7^-?E(]?+_XLO\#_ /2HGV77SI]*% !0 4 % !0
M4 % !0 4 % !0 4 ?._Q;_Y"T/\ UZ)_Z.GK:&QYF(^->GZL\NK0XPH * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M /HCX2?\@F7_ *^W_P#1,%8SW/3P_P #]?T1ZC69V!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >=?$W_D&1?]?2?^BIJ: ]%I % !0 4 % 'P9\:/
M^1OO_P#MV_\ 2.WKZG"?P8?]O?\ I3/DL9_'G_V[_P"DH\MKM. * .C\'_\
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M\[_%O_D+0_\ 7HG_ *.GK:&QYF(^->GZL\NK0XPH * "@ H * "@ H * "@
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M;]7]YXS7HGF!0 4 ?9G[._\ R+UQ_P!A&7_TGM:^=QW\1?X%^<CZ;+_X4O\
M&_\ TF)[S7EGK!0 4 % !0!YUXT_Y">C_P#7T?\ T;;4T!Z+2 * "@ H * "
M@ H ^=_BW_R%H?\ KT3_ -'3UM#8\S$?&O3]6>75H<84 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'MOP=_Y?O^
MW;_VXK*?0[\-]KY?J>V5D>@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M ->B?^CIZVAL>9B/C7I^K/+JT.,* "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M\BT_KU/M/[E_\D+^SZO>'WR_^1#_ (9W\0_\_&G?]_;C_P"1:/KU/M/[E_\
M)!_9]7O#[Y?_ "(?\,[^(?\ GXT[_O[<?_(M'UZGVG]R_P#D@_L^KWA]\O\
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MI)J2>J79KHWW.["X6>'FYS<6G%K1ONGU2['O]>4>N% !0 4 % !0 4 % !0
M4 % !0 4 ?._Q;_Y"T/_ %Z)_P"CIZVAL>9B/C7I^K/+JT.,* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#Z(^$
MG_()E_Z^W_\ 1,%8SW/3P_P/U_1'J-9G8% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!YU\3?\ D&1?]?2?^BIJ: ]%I % ",2H) W$ D =3[<\<^]
M'+Z!XKM];9H"K6UU&2&@D/S<==O SC^(8#+@Y&.:=K =32 ^#/C1_P C??\
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MCS,1\:]/U9Y=6AQA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 >V_!W_E^_[=O_ &XK*?0[\-]KY?J>V5D>@% !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?._Q;_Y"T/\
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M@:?A/QRNH%;'4"%N#A4E'"RGH 1@;7/;@*QX&UL*58#Y5^-'_(WW_P#V[?\
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M'N.""!Y$%[#$\D=(S5[?)O\ --+U/:F_;X7VDM9P=K]=TOR:;\T?-M>P>(%
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ME9'H!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'SO\
M%O\ Y"T/_7HG_HZ>MH;'F8CXUZ?JSRZM#C"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^B/A)_R"9?^OM__1,%
M8SW/3P_P/U_1'J-9G8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0U
M+2[;5XQ#>()8U8.%)888 @'Y2#T8CKCF@"O_ ,(_IG_/I:_]^(O_ (F@ _X1
M_3/^?2U_[\1?_$T '_"/Z9_SZ6O_ 'XB_P#B: .$U^\T^.7^S-'LK6XOG^4E
M8(BL7KGY<%AWR=J=7/!%,#<\+^#8=$ N+C;+=MSNP-L>>HC'3/8M@'LN!D$
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M<5Y%_:XI..J@K7^_]7^![5O8X1J6CF[I>K7_ +;'\3YQKUSQ0H * "@ H *
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M !0 4 % !0 4 % !0 4 % 'MOP=_Y?O^W;_VXK*?0[\-]KY?J>V5D>@% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?._P 6_P#D+0_]
M>B?^CIZVAL>9B/C7I^K/+JT.,* "@ H * "@ H * "@ H * "@ H * "@ H
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M$IQG:"2Q9L LS$DG@84*H[*5&-!6AUW;W9Q5JTZ[YI[+9+9''5T',% !0 4
M% !0!]F?L[_\B]<?]A&7_P!)[6OG<=_$7^!?G(^FR_\ A2_QO_TF)[S7EGK!
M0 4 % !0 4 % !0 4 % !0 4 % 'SO\ %O\ Y"T/_7HG_HZ>MH;'F8CXUZ?J
MSRZM#C"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H ]M^#O_ "_?]NW_ +<5E/H=^&^U\OU/;*R/0"@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /G?XM_\ (6A_Z]$_]'3U
MM#8\S$?&O3]6>75H<84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MIZVAL>9B/C7I^K/+JT.,* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#VWX._P#+]_V[?^W%93Z'?AOM?+]3VRLC
MT H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#YW^+?\
MR%H?^O1/_1T];0V/,Q'QKT_5GEU:'&% !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * /;?@[_P OW_;M_P"W%93Z'?AOM?+]3VRLCT H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#YW^+?_ "%H?^O1/_1T
M];0V/,Q'QKT_5GEU:'&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!]$?"3_D$R_P#7V_\ Z)@K&>YZ>'^!^OZ(
M]1K,[ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /
M@SXT?\C??_\ ;M_Z1V]?4X3^##_M[_TIGR6,_CS_ .W?_24>6UVG % !0 4
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MLCT H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#YW^+?
M_(6A_P"O1/\ T=/6T-CS,1\:]/U9Y=6AQA0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?1'PD_Y!,O_ %]O_P"B
M8*QGN>GA_@?K^B/4:S.P* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@#X,^-'_ "-]_P#]NW_I';U]3A/X,/\ M[_TIGR6,_CS_P"W
M?_24>6UVG % !0 4 % !0 4 % 'M'P:N8[J?4?#LI"#6K"6&-LX/FHC[0,@C
M.R21\GH4'!S7G8M.*A67V))OTT_5+[ST\&TW.B_^7D&EZJ_Z-_<9WPGUVR\'
M>('N-:D-I''!-"Q,<CE9=Z#85B1V!RK \8&.35XF$JU-*FKNZ>Z6FO>Q&%G&
MA5;JOE236S>NG:YP_A6]ATW6;"\N6\N"VO;:65L%ML<<R.[;5!8X4$X4$GH
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MT];0V/,Q'QKT_5GEU:'&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0![;\'?^7[_MV_]N*RGT._#?:^7ZGME9'H
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'A'Q0T>^U
M#4XI+2WGG06J*6BBD=0PEF)4E5(S@@XZX(/>M8M)'G5XRE).*;TZ)]V><?\
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M_P 11==PY)_RO[F'_",ZM_SY7?\ X#S?_$477<.2?\K^YA_PC.K?\^5W_P"
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MW3L%E1D8J8H0& 8 XR",],@CM6,M]#T:"<8M--:]=.B/1Z@Z@H * "@ H *
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M_P"@7J/_ (!W'_QNCVU/^>'_ ($O\P]C5_Y]S_\  9?Y!_P@_B'_ *!>H_\
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M_P! O4?_  #N/_C='MJ?\\/_  )?YA[&K_S[G_X#+_(/^$'\0_\ 0+U'_P
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M )]S_P# 9?Y!_P (/XA_Z!>H_P#@'<?_ !NCVU/^>'_@2_S#V-7_ )]S_P#
M9?Y'UE\"-*O-'T*>#4()K25K^1PD\3Q.4,%L P615)4E6 8#&5(SD&O"QDHS
MJ)P::Y5LT^LNQ]!@8RA3:FG%\[T::Z1[GM5>:>H% !0 4 % !0 4 % !0 4
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M-_\ $477<.2?\K^YA_PC.K?\^5W_ . \W_Q%%UW#DG_*_N8?\(SJW_/E=_\
M@/-_\11==PY)_P K^YA_PC.K?\^5W_X#S?\ Q%%UW#DG_*_N8?\ ",ZM_P ^
M5W_X#S?_ !%%UW#DG_*_N8?\(SJW_/E=_P#@/-_\11==PY)_RO[F>O\ PITR
M[T[[;]K@FM]_V?;YL;Q[MOGYV[P,XR,XZ9&>HK*3VL=N'BX\W,FMMU;N>OUF
M=P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?6T>-TL:[I/)7+J,R\CRASS)D$;!\W!XH M4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8]UI\D^H6
MMXI41VT=PK D[B9?*V[1@@@>6=V2,9&,\X .*UMKE/$@-I:1:@_]E\Q2RK"
M/M1^96:*52V<#!"\$G=Q@L#F+#5;K2M/-S9)Y-QK&J&-H+>-6-FRH1)$J3&*
M(W!\K@/M1BQ8!L#(!=O/$NMV%E?*S2Q20"S>">[BM$F3SKJ.&19(8'DC,94D
MI(50_?'558 &[J>H:IX=F-O+>?;/M%C>S(SPPQO#+;1AU91&@5HVW8VR!B"!
MEB,B@#*N-9UO3K"Q=[F2ZN-8,./*M[8&W7R&E=85<QI)))E0#,Q'RL43)"T
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
G@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img46421407_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2I&17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(S.C R.C(Q(#$W.C S.C,T   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,S,   DI(  @    ,S,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,SHP,CHR,2 Q-SHP,CHQ,0 R,#(S.C R.C(Q(#$W.C R.C$Q      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  &)H         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ < $  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M^(E@[QJJ7)$F<-L7:,!3RV[ 'S#D\=:-0+,GC>RAD"2F>,L4$9:+B0L@?CZ
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M8=>02Q]NW<^F3MQ2PR[C#)&_/S%&!_/%3&M3D[1DG\RG3FE=IDG?-%:$!10
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M'GT/7H:L):>(;N""XM/$<'DRQ;@6L0V<J=I'(XY!Q[=NE;&9N6D=Q%9QI=W
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M8ZRE0=H'&!Z"O)RS,,37Q"A4E=:]%_D>ACL'1I47*$;/YF[17TIX@5Y=KO\
MR';W_KJ:\'/_ .#'U_0];*/XDO0SJI_&*62/1_"7ER,F;>7.TXS\L53PM_O,
MO07$/^[+U/)_M5Q_SWE_[[->W_ R2231M6,CLV+A,;CG^&OM<4E[)GR>$;]J
MCU>BO*/7,V[(&M6&Z('(?:Y=N#CL,XJ:[;4!*JVB0E"O+29.#GTR./\ /;!
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MH?"TOC7J?4-<%XW_ .0U#_U[K_Z$U?'9U_NC]4?6Y9_O'R9S5:B_\D_\5?\
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M9FJ5+?*GS"^X]=LC4 *;=2Y8O)S_ --#2F!2N-\G!_OF@!!;(.C2_P#?QO\
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M%!04%!04%!04%!04%!04%!04%!3_P  1" ,V!U\# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHI* %HI** %HI** %HI** %HI**
M %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI**
M %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI**
M %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI**
M %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI**
M %HI** %HI** %HI** %HI** %HI** %HI** %HHHH **** "BBB@ HHHH *
M*** "BBD+ 4 +129ST-% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<CKW_(5G_P" _P#H(KKJY'7O^0K/_P !_P#016<]AHH4
M4E%8W8Q:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6B
MDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2
MBB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**
M+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHN
MP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[
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MP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[
M6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:
M*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI
M**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6BDHHNP%HI**+L!:*2BB[ 6NMT
M'_D%0?\  O\ T(UR-==H/_(*@_X%_P"A&M(;B9H4445L(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *Y'7O\ D*S_ / ?_01775R.O?\
M(5G_ . _^@BLY[#1GT445@4%%%% !1110 4444 %%%% !1110 4444 %%%%
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MYX%L_AM-X@N=-E6)9H-7*O/F)9"1$MNY& 3W/3/M3/ _[>7B/QAXU\/:#/\
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M$HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%*P4GINP>>0.E>C_ +/?[:GA/X[:TWAZ6QN?"WB?:S1Z=>R+(L^T981N,;F
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M!+^'](^$>O7"XN?$6L7-PLC?>,,=Q;Q*">_SI*1_O5]I?M7?'7QYJ7QH\/\
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MI))M.\16DRRK<Q1R*C#S5XD!WJZL>1\P)/0+EL%S[$QQ^N>U>3?'O]I'PS\
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MQA9&>(;CY1^7;E &.< @$FCENP/T; SP.2>@]/\ &CC;G/\ #N] *^$_B_\
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M3G\Z]7_:PM/&W[/W[+'A>PB^).O:OKZ>)42?Q$MW/:W4T3P73B)F\UF*@A,
MN1\@/'0/E6@C[#\&Z\?%GA'0]=^SFT74[&"],);=Y7F1J^W=@;L9QG Z=.U:
M_3)/8XV_GWKXO_:0_::\1_"SX*_#'1O#E\MOXM\4:-:S3:O=NK-#&(8P[[I#
MC>[.?G;. K'K@CRGQIXH\<? ?1['QAX?_:6TSXC:@MQ$M]X?_M=;U#N))V1M
M-)N3J"0L9 .1C'"Y+CN?I/CYOO#&<?C0HZ$\CN!U%?!O[:'Q\U^[^$WP>\9>
M$];U3PTFM1S74\&FWLL.3Y<)\J385WA6+CGW]:POV@M ^.OP0\'Z/\3=3^+^
MI7FI7EY'%>:+ SPVMF[HS@+&',4B@IM(,:]NO)I<H7/M7XR?&/P[\"_!;^)?
M$LTRV9E6V@AMXB\MS,RLRQIV!(1CEB  #SZ[G@/Q4OCGP)X<\2I;M9IK&FVV
MH+;,VYHQ-$LFW/&<;@,\5\&_MW6.N>./@U\,_BC/XBGATS6+/3$E\+1JYM%N
MI;>XN&N@2^W>%;R_N9V_Q8XKK[&Z\=?LX_L1MXKT[QA?^)+[6K'2Y]/^VQLZ
M:';S1(/+B#NZE5#A5P%7.WY>@I\JL(^X#WQU_P!KC&!GFE(Q_P#JK\S? _B3
MQ=XNT?0]9\,_M.R+XYNI0;KP_P")KR6VM8&/)5?,+QR8('W4PV3CT/Z/^&5U
M9?#NF#7C9G6Q;1_;FT]F:W,VT;S&653M+9(R,@5,H\HS2KKM!_Y!4'_ O_0C
M7(UUV@_\@J#_ (%_Z$:<-P9H4445N2%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<CKW_ "%9_P#@/_H(KKJY'7O^0K/_ ,!_]!%9SV&C
M/HHHK H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /-?VCOBBGP>^#/B;Q,) E[!;&&Q7UNI/DB/N S!B/12:
M^&?V:_V$K7XY?#&#QIKWB._TB6^NIOL\5O$LGFQ*0ID8L>ID$@^@![U^F/."
M,\'J.U#,6Z^N:M2:5@/RX^-GP-N_V'OB3\/_ !CX>U:ZUJR^T&1I9HQ&WF(1
MYD3;3P)(G('_  *O3OVH-<L_%'[7G[/.L:;*+G3K\Z1=6\JG[\;ZAN!_(U]\
M]L=L$?G1N/J1QCK5<_<1\*?M/<_\% O@WP?^/;3>?^WZZXK[KQ@=0>1P/I1^
M)/.>IHSP>^>M3S7L!^77Q*^*5K\%_P!O[7O&5Y93:G;Z;=/OM8&V._F:?Y0P
M6XX,@/X5[GH?_!3;PUK6M66FQ^"=5C>\G2!7-W%@;F R<#D#-?:/?/\ 0>N:
M#RNT]*KF74#X5_:>^;_@H%\&R!D-;:;TP1S?77'UKZ,_:R^$U_\ &?X(:WX=
MTHI_:X,5Y9JSA5EDC;)0GI\R[@,\9(SQ7L#,6;)))SGJ:3<>,G-3S; ?G=\+
M_P!MG4?@A\*;7X<ZUX#U4>-='BEM+..2/RE8ACL:6-OG!4G!"@[MO49X[']E
M'X3_ !%^#?P$\?\ B]/#JZAXO\0B*:U\.ZI&0T\$.\L9$X(=Q-*0AY;:H_BX
M^X,YP2,FCZ #\.?SI\W9 ?DOXQUSX1^,/!%]9S?#/7/"/Q@E+1I8:%%)'8M/
MN.,0R2,47'!0(#D<5ZA\8/!OB?P%_P $]/"NC^+$GM]2774DCLYP3+:0O]H9
M(G'8@<[?X<[>,8K]%V^;MBE#%6R./7WI\X'BOA/P%;_%#]CWPOX4O%58-5\&
MV$"NZY$<GV2,QR?\!<*PXZBOA/\ 91\"Z_\ $_X]>%/"GB!'?2OAY]HN)+23
MI"8[AGV-G@EIV0$?W5(QQ7ZJX]>1UP31C.<\GUQS24K ?"/[>_PAU6/XH>&/
MB;#X=D\6^&;:*&UUC3H0Y.V.5F(;9\RJR.5##A2.>H!\V7Q%\,/B=XET;0_A
M#^S])K%W-)LOCK<LZ1Q$X'WHKA@J@\EW(&!]VOTWZ=.!S2_Q XY!SZ_S_#\J
M?-H!0T'2X]#T+3M.AACMH;.VCMTAB9F2-44*%4MR0 ,<\\<U\9_MG? WQGH_
MQ0T;XU?#JRFU'5+#R6O+6VC,LJ20_=E$8Y="@"L!SQZ$X^VNG%'^<]ZA.SN!
M\"ZA_P %"M)\1VL%I??!S^UO%L<?E"VN'65%D/4 -&7QD [<9YQGO74_\$\/
M@_XQ\$2^,?$WBC0Y-!MM:6'[+:W0\J5BK.[GRSRB?. ,XSVXYK[2X]!2>W:J
MYE:R0'Y&?LB_M,:=^S;JOB2ZU#1KO6/[7@AB1+>1$*;"Q).X=]W%?:OP+_;P
MT+XX?$C3O"5AX7U#2[BY2:474]Q&Z+Y:%SPHSSBOI_TSSCU)H4[5QU^M#DGT
M _/3X#\?\%'?&?.-MWJPQZ\G_/X5?_;P\!WOPC^*/A'XU>%(_LLYNXTO3&N%
M-U'\R.V!C$L896'?9_M5]]X!ZJI_#Z_XTO7USC'4T<VMP/SF_P""C'C;3_B/
MX+^"OBG2I=]AJMKJ-S'N/*[A:90^ZG*GW!]*ZF'_ (*76S>'(M)\-^ M0O-=
M6W6"U$UPKQF0*%W%44L0#SM!&>F1UK[PS^7I2>N>?J,]L8H4E:S0CY"_8"^
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M?INWWCSGGO0ORMN[]SGK2#BE*7,,****@84444 %%%% !1110 4444 %%%%
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M!Y)   J X&"<@$U^D';'0=_?ZTK?-G(!^HI\_6P"<9'&W_/%?#7P^L7\&?\
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M$)!^8XY.*X7X(@-_P4<^(XQD?9[W/H03#UK[OX)!(W?6@8[@$_Y_S^%',NB
M^1/^"A'P3\1?$+P[X<\7>%[*34M1\-M,;BRMU,DS0N48.J8^;8R<J.2&)Z"O
M+?BU^VEJOQ]^&=Q\./#/@+5H_%^M"*VOXHU\P1X8&18U'S')4#YP, GKC-?H
M=QG)&>^#24*2M8#XC\8^$?&'[//[)_A'PX_@/2_B#8.\LOB*SO8))S9O(YE7
M8(R#A=Y4R#[K(#_$,?-OCK0/A[\5-;\.V'P%\&^*K/Q3)-F[M)Y"\%MGIAR[
MLA5NKDJH"Y^GZW=  #M YXI?Y>G]?K34P/@K]J>VNK7]L+]GR"]E^U7<3:0D
M\PX\QQJ&&;'U!->E?\%$OAH_BKX.V_BW3U9-7\*78NEEC'S_ &>0JLF,?W6$
M3YSP$:OJO)[$CCUI/Q.<YSGOZTN;8#XJ_P"">'A74/%FI>.OB]XB GU;7KQ[
M.&X*@9RPEG*C^Z7,:CL/+(^GC7Q ^&^C? #]HOQ1JGQ/\ 7WB[X=:W//=V5W
M;!OW32R>8I#!T!=?FC9&9>&#>F?TYVCMQZX[_6G'![#^5'/J!\!?LYV?A;XH
M?&ZSO_ WP3@T7P7I<RW2>)-4N+E+B%E!*L/WS1-(SX 09P,DFOOQEWJ-RJZL
MN!N/7CH1W[4N>PX&<@>E(<\\XR,4G*X'YPRZ'X[_ & ?C'K6NZ1X<F\2_#G5
M3LS"&\LP[B\:NX#>7+'RN6&&&>.>*GQA_:8C_:8\*W_A#P)\(9GU;5I8C<:G
M'"L]TA69)/E,<?\ $5&69N 3D<YK]*MQW9]\TG\.,<?2JYNHCX&^-/@'6/A?
M_P $[O#WAGQ!"EIK-I?H\\,;J^PRW4\JJ2#C(61<X)P<]:Y_X$?\% M!^$/P
ME\.^$+OPGJ6HW&EQ21O=0W4:K)NE=\@$9Z-^E?HUN(SR<$YZT@P.U',NHSY%
M\7?M#V'[1O[(OQ4UK3])N-&BL839M%<R+(S-B-]P*\8YQ3O^">.C67B3]F+5
M=*U.VBO=/O-6O(;BUF&Y)(VBB# ^Q&?>OKC^('H1T.:!Q@=0.U3S:6 _/']F
MK4[K]E?]K;7_ (6:I<2_V#KDZVUG+*,*TA.ZTD&>,LK&,X_B8#^'CS7P[\<+
M+]G_ /;(^)OBB^TV?5H&U?5[06]NZQN"]XQSENPVFOU9R>>>V#]/2D_#OGTJ
MN9"L?F[\9OVB?%G[:>E:9X!\ >!M0MK&6]CGN[F23S064':'=5V1(,[B6/.!
MZ8/WI\(_A]#\*OAGX<\)03"X&E6:023*,"27K(P'8%RQ ]ZZ_GUYSG=WI/PQ
M4M]$,_//_@J<K-XD^'W\2?8[S*G_ *Z15^AK,6Y[_7/ZT?4 _44GU.:'+2P'
MPE_P49T?5E\;?#O7=4TV^UCX=V) O[>S9@ PFW3*Q'",\6 K'^ZV.E>!_M5^
M+_"7CK2?"M]\//A[<>$_!VFO-!_:K:6EFE]<2JC;=R$ARJQ9R23\S=L9_6K/
M(/>D_A(P.>^*I2M85CX,_P""E6FW=Q<?#+Q?90/?Z%;B827$ +*NYHI(R3T&
M\!L>N#5?]LKXPZ?\=/V2/#?BC3+"[TZT?Q;' +>\5?,&VVN>>"1@@Y%??8 '
M08I<Y*D\D?K0I; ? '[6'P7U_P 7?!WX/^--!TF37DT70K6'4-/A1G?R3#"R
MOM7EER&#8Y&X'C!(\\U#QU\'O&4FE:/\-?V?;K5_%4TZK=V>HRSF*(=&5#%.
M6ZX&]P@ !)'I^H6X^O?-+N/'?!R,T*=D,_.[_@H%X;'A'X0_!W1ETRVT8VJ7
M2R:?8R-)#;.8X6=$9R690Q/)]/>O8_\ @I5D_L[VO&,ZY:@A2,_ZN85]6GYA
M@\KC 7)Q1DGJ2><]31S:H#X9_:?\-:IXB_8%^%4^GV4MU_9MIHM]<^4A<I%]
M@:(L< G :5<]*U/AS^T)JOCC]DV2R\$>!5\2ZEX1T[3](U+2]8@^T17T(@,<
MKQHA!D ,6=O4@D8SBOM+)SG.:3C@X&?7UI<VE@/R0\?W'PE\>^"[:R\'?#OQ
M)H?Q8E>$3:7IR2267FY'F[8WD=]I&=J@ @D9X'/Z6_L]^&]>\(?!/P;HWB9V
M?7++3XXKA9'#M'C.V,D$@E%VIP<?+7H0XQ['-+2<KJP"5UV@_P#(*@_X%_Z$
M:Y&NNT'_ )!4'_ O_0C3AN#-"BBBMR0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KD=>_Y"L__ ?_ $$5UU9%]H'VZZ>;S]F['R[,] !Z
MU$E=#.8HK?\ ^$5_Z>?_ !S_ .O1_P (K_T\_P#CG_UZRY6.Y@45O_\ "*_]
M//\ XY_]>C_A%?\ IY_\<_\ KT<K"Y@45O\ _"*_]//_ (Y_]>C_ (17_IY_
M\<_^O1RL+F!16_\ \(K_ -//_CG_ ->C_A%?^GG_ ,<_^O1RL+F!16__ ,(K
M_P!//_CG_P!>C_A%?^GG_P <_P#KT<K"Y@45O_\ "*_]//\ XY_]>C_A%?\
MIY_\<_\ KT<K"Y@45O\ _"*_]//_ (Y_]>C_ (17_IY_\<_^O1RL+F!16_\
M\(K_ -//_CG_ ->C_A%?^GG_ ,<_^O1RL+F!16__ ,(K_P!//_CG_P!>C_A%
M?^GG_P <_P#KT<K"Y@45O_\ "*_]//\ XY_]>C_A%?\ IY_\<_\ KT<K"Y@4
M5O\ _"*_]//_ (Y_]>C_ (17_IY_\<_^O1RL+F!16_\ \(K_ -//_CG_ ->C
M_A%?^GG_ ,<_^O1RL+F!16__ ,(K_P!//_CG_P!>C_A%?^GG_P <_P#KT<K"
MY@45O_\ "*_]//\ XY_]>C_A%?\ IY_\<_\ KT<K"Y@45O\ _"*_]//_ (Y_
M]>C_ (17_IY_\<_^O1RL+F!16_\ \(K_ -//_CG_ ->C_A%?^GG_ ,<_^O1R
ML+F!16__ ,(K_P!//_CG_P!>C_A%?^GG_P <_P#KT<K"Y@45O_\ "*_]//\
MXY_]>C_A%?\ IY_\<_\ KT<K"Y@45O\ _"*_]//_ (Y_]>C_ (17_IY_\<_^
MO1RL+F!16_\ \(K_ -//_CG_ ->C_A%?^GG_ ,<_^O1RL+F!16__ ,(K_P!/
M/_CG_P!>C_A%?^GG_P <_P#KT<K"Y@45O_\ "*_]//\ XY_]>C_A%?\ IY_\
M<_\ KT<K"Y@45O\ _"*_]//_ (Y_]>C_ (17_IY_\<_^O1RL+F!16_\ \(K_
M -//_CG_ ->C_A%?^GG_ ,<_^O1RL+F!16__ ,(K_P!//_CG_P!>C_A%?^GG
M_P <_P#KT<K"Y@45O_\ "*_]//\ XY_]>C_A%?\ IY_\<_\ KT<K"Y@45O\
M_"*_]//_ (Y_]>C_ (17_IY_\<_^O1RL+F!16_\ \(K_ -//_CG_ ->C_A%?
M^GG_ ,<_^O1RL+F!16__ ,(K_P!//_CG_P!>C_A%?^GG_P <_P#KT<K"Y@45
MO_\ "*_]//\ XY_]>C_A%?\ IY_\<_\ KT<K"Y@45O\ _"*_]//_ (Y_]>C_
M (17_IY_\<_^O1RL+F!16_\ \(K_ -//_CG_ ->C_A%?^GG_ ,<_^O1RL+F!
M16__ ,(K_P!//_CG_P!>C_A%?^GG_P <_P#KT<K"Y@45O_\ "*_]//\ XY_]
M>C_A%?\ IY_\<_\ KT<K"Y@45O\ _"*_]//_ (Y_]>C_ (17_IY_\<_^O1RL
M+F!16_\ \(K_ -//_CG_ ->C_A%?^GG_ ,<_^O1RL+F!16__ ,(K_P!//_CG
M_P!>C_A%?^GG_P <_P#KT<K"Y@45O_\ "*_]//\ XY_]>C_A%?\ IY_\<_\
MKT<K"Y@45O\ _"*_]//_ (Y_]>C_ (17_IY_\<_^O1RL+F!16_\ \(K_ -//
M_CG_ ->C_A%?^GG_ ,<_^O1RL+F!16__ ,(K_P!//_CG_P!>C_A%?^GG_P <
M_P#KT<K"Y@45O_\ "*_]//\ XY_]>C_A%?\ IY_\<_\ KT<K"Y@45O\ _"*_
M]//_ (Y_]>C_ (17_IY_\<_^O1RL+F!16_\ \(K_ -//_CG_ ->C_A%?^GG_
M ,<_^O1RL+F!16__ ,(K_P!//_CG_P!>C_A%?^GG_P <_P#KT<K"Y@45O_\
M"*_]//\ XY_]>C_A%?\ IY_\<_\ KT<K"Y@45O\ _"*_]//_ (Y_]>C_ (17
M_IY_\<_^O1RL+F!16_\ \(K_ -//_CG_ ->C_A%?^GG_ ,<_^O1RL+F!16__
M ,(K_P!//_CG_P!>C_A%?^GG_P <_P#KT<K"Y@45O_\ "*_]//\ XY_]>C_A
M%?\ IY_\<_\ KT<K"Y?T'_D%0?\  O\ T(UH57L;7[#:I#NW[<_-C'4DU8K=
M;$A1113 *Q=+_P"1CUO_ +8?^@5M5BZ7_P C'K?_ &P_] H V:6DI: "BBB@
M I!WI:3I0!Q6H?\ ']<_]=&_G5>NCN/#?VB:27S]N]BVW;GK^-1_\(K_ -//
M_CG_ ->N?E91@45O_P#"*_\ 3S_XY_\ 7H_X17_IY_\ '/\ Z]'*PN8%%;__
M  BO_3S_ ..?_7H_X17_ *>?_'/_ *]'*PN8%%;_ /PBO_3S_P".?_7H_P"$
M5_Z>?_'/_KT<K"Y@45O_ /"*_P#3S_XY_P#7H_X17_IY_P#'/_KT<K"Y@45O
M_P#"*_\ 3S_XY_\ 7H_X17_IY_\ '/\ Z]'*PN8%%;__  BO_3S_ ..?_7H_
MX17_ *>?_'/_ *]'*PN8%%;_ /PBO_3S_P".?_7H_P"$5_Z>?_'/_KT<K"Y@
M45O_ /"*_P#3S_XY_P#7H_X17_IY_P#'/_KT<K"Y@45O_P#"*_\ 3S_XY_\
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M_P#CG_UZ.5A<P**W_P#A%?\ IY_\<_\ KT?\(K_T\_\ CG_UZ.5A<P**W_\
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M45O_ /"*_P#3S_XY_P#7H_X17_IY_P#'/_KT<K"Y@45O_P#"*_\ 3S_XY_\
M7H_X17_IY_\ '/\ Z]'*PN8%%;__  BO_3S_ ..?_7H_X17_ *>?_'/_ *]'
M*PN8%%;_ /PBO_3S_P".?_7H_P"$5_Z>?_'/_KT<K"Y@45O_ /"*_P#3S_XY
M_P#7H_X17_IY_P#'/_KT<K"Y@45O_P#"*_\ 3S_XY_\ 7H_X17_IY_\ '/\
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M'O1CWJ&&Z6XA2:)XY(9 &21#E64]"".H/6LGQEXF/A'P?KFNFV%W_9=A/>F
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M];_[8?\ H% &S2TE+0 4444 %%%% "?C1CWI:* $Q[T8]Z6B@!,>]&/>EHH
M3'O1CWI:* $Q[T8]Z6B@!,>]&/>EHH 3'O1CWI:* $Q[T8]Z6B@!,>]&/>EH
MH 3'O1CWI:* $Q[T8]Z6B@!,>]&/>EHH 3'O1CWI:* $Q[T8]Z6B@!,>]&/>
MEHH 3'O1CWI:* $Q[T8]Z6B@!,>]&/>EHH 3'O1CWI:* $Q[T8]Z6B@!,>]&
M/>EHH 3'O1CWI:* $Q[T8]Z6B@!,>]&/>EHH 3'O1CWI:* $Q[T8]Z6B@!,>
M]&/>EHH 3'O1CWI:* $Q[T8]Z6B@!,>]&/>EHH 3'O1CWI:* $Q[T8]Z6B@!
M,>]&/>EHH 3'O1CWI:* $Q[T8]Z6B@!,>]&/>EHH 3'O1CWI:* $Q[T8]Z6B
M@!,>]&/>EHH 3'O1CWI:* $Q[T8]Z6B@!,>]&/>EHH 3'O1CWI:* $Q[T8]Z
M6B@!,>]&/>EHH 3'O1CWI:* $Q[T8]Z6B@!,>]&/>EHH 3'O1CWI:* $Q[T8
M]Z6B@!,>]+110 4444 %%%% !1110 4444 %%%% !1110 444F: %HIN_KZT
M;NO]: '44FZD#'GB@!U%)S2%B,\<4 .HI*6@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#X ^-7C2'X>?MF:EXBN+5[V+3YK65H8F"EP;*(;<GW.>]1?&+XK:E^U3JGAW
M1_#/A"ZCFM)9,/O\UF+X'+!0$0 9)8X]< <]5XDW'_@H#%@X'VRU&>O_ "X1
M\?RK[711M],_A7V^(QM/!1PU3V7--4U9W:MI;;J?#X?!5,;+$T_:\L'4E=63
MOKWZ'Q9^T?XJ\9_#/QU\/=!\-Z]?13PZ);6RV\-RP@GG#O&&:/(5R2%QN';G
MCBO0-#^'/Q'^&O@;XBZWXI\>7>LS'P]=&RBCO;A_L\PB=S(I;&QE*J%9?4GC
MORO[2^W_ (:N^% ])=/)_P# \U]%?&3_ )(_XZ/&#H-\<X_Z=WKEK5W"AAJ:
MBO?W=E=^]W.JC04Z^)FY/W-E=V7N]CY\^%/C3Q%J'[(?CC6+O7M4NM8M9KI8
M;^>\D>XC"QQ$;9"VX8)/0]S7$^ ]+^*WQ&^"VL^*D^).K:?::*+AX(!<S&>\
M\M?,DWS!PP&"0N<\C& .3M_!XA?V)_'XS_RVN\\\C]U#74?LYKN_9%\6 <CR
MM3VMZ_N.M>A5DJ"K3A%7]JELGI8X*47B'1C.3M[)O=K4X;X:R_%SXZ?#O5-1
M'Q!OM%L/#\;Q0R6^Y9[Z8+YA621&4\*5&XD\$?*3DUZ7^RM\3O&/Q%^%/B2!
M[N/4/$6FMY5A>ZI(VPF2,E/-8*S-M;)S@DC ]ZS?V,E)_9Y\79Y_XF5YQW_X
M](/;^E><?LZ:;K>K?L^_%JT\.K,VLS&$11VY.]Q@ET7U)0.,#DYQWI8F,*RQ
M%)QC%0G!+1*UWK?]1X:4Z+P]52DW.$V]6[V6G_ &^*KKQ3H6CZGJNO?'X6_B
M: /)%H&D7LL\<C G"%H7"QLQR,%,#C.!T]0\#_%OQ!XW_9'\5ZW=ZE(FNZ2L
M]D-1MR8I242-U?<I&&VR 9&.GKDUXA\/_%'A*P^$^L>&;7P#=:Y\1[J*YMVN
MGM1+Y2.K+YJL<M%L3L!U!)/)QV?P1ND?]CKXH6WF))<)=7$KIGD*T$ 5C]=C
M?E71BZ"]FN>.L9QL[16E^B7V7TON<V%KOVCY):2A)M7D];=;_:76VQ5^#^@?
M&7XW^%8+^S^(5]I.EZ7,;2.::_G$UR^[S'+LN2^W> "Y(P !T)KKXO%7B+X2
M?M<6^AZIXAUC4O#&M$):Q:A>R31*LP 0J'8J"LX*9&. 1WQ7;_L0@-\#Q@\'
M4KCJ/]WBL/\ ;D\$S7?A/1?&%@KB]T.Z"2/&N6$3D;6S_LR!,?[YK@EB(ULQ
MG@JD4H/FBK):-[/UO^9WQP\J67T\93;<URR=V]4MUZ6_(SO'WBWQ'\0?VL](
M\&Z'KVIZ9HNF"/\ M!-.O9($D"J9I=^QAG@K'[$8]:^KMH]37RI^Q/X?N_$&
MH>,?B1J@S?:M=-;1OCKEA+,1GL6,8'IL(KZJW';GI^%>)FO)3JQP\-J:2?F^
MK/;RKGJ4I8F;_B-M>2Z'YWZ7\2+CX4_M.^.-=M=#D\0.NJZG ;2*4Q-\]P?F
MR$?ICT[U]*?"#]I[4?BAXT@T&X\!WF@12Q22->S73R!2JYQ@PKG/3K7S5I?Q
M5MO@_P#M/>.?$%WI\VIQ#4]3MQ!#($;+7#8.3VXKWKP3^VYI7C3Q?HV@Q>%K
MRVDU.[CM4FDN4(3<P7<0%YQG-?2YEA95H*<</S>XO>YK6T[7Z'S66XJ-*;C+
M$<OOOW>6]]>]NIQ7Q$U_X@ZU^UIJ_@_POXKOM+CNEBB2)[IVM[:,V4;R.L1.
MT'AF&!G)R.>0NF:Q\0/@;^T=X;\):MXTO_%VFZR8 WVZ21PT4SM'G:[OY;*R
M,1M;D+Z$BK]IC_AX1><](0!S_P!0Q/UI?C^P_P"&QOA@!SF.PXS_ -/D]1%Q
M;IX=P7*Z*;T5[VWOOT+DFE4Q"D^95K+5V2OM;;J.^-/Q)\;?$3XZV_PO\$:S
M-H$,)"SWEO(T+EQ'YDCEQ\VU%. HQD@]<BO*/VGO"/C?P&WA[1?%/B:?Q=I9
M,T^G:A<*PE5_D65&9F9O[AY8CGC'->A?&6PU?X"_M(6_Q.CTR35?#]ZV^1X\
MX1FA\J6,MCY6ZNN>#D#LU>>?M-_&B;XT#0M0L=$OM,\.6)ECAGO4YGF?:6^[
ME?E"+P">N2>177E\)*IAG0C'V7+J]+\UG?7>_P#P3DS"473Q"KRE[7FT6MN6
MZMIM;];'M7[;WCGQ%X)NO 4N@ZQJ&E&9[QY8[.Y>)9]GV<J) C#<.6Z_WCZU
MS/Q*\'_&KX<^%5^(%W\1+RYN86CEOM*AG=8;?>X Q&3Y;@,<$!!@'C(&1>_X
M*!;_ +1\//)&9MU\8P<8SFVQUXZUD?&;]IN]^)'@2;X?VWA'4K+Q3?-'!J,$
MD6X1LCJS+$N2Q+,H'S 8![GFN3 TZCPN%=*$6FY<S:6W-Y^7Z'7C:E-8K%*K
M.2:4>5)O?E\NM_U.U^(W[4]_8_L_>%O$FD)#:>)/$6^W#%=Z6SQ$K,X5NIW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFO>!2 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ.O.>*]"I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9%?"-+*N%#;ACH1@9'_!,75/[!E^..N>(-4M(+ :A8B;5)IEBM&E#W>]@Q(
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MH<]DD"V32,'RTBN?,^94;[J\J.W% 'UB.E+2*-J@4M( HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L72_^1CUO_MA_Z!6U6+I?_(QZW_VP
M_P#0* -FEI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG568G"*3M4# PH..32 [ZEI!TI: "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%TO_D8];_[8?\
MH%;58NE_\C'K?_;#_P! H V:6DI: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !1110 4444 %8NE_\C'K?_;#_ - K:K%TO_D8];_[8?\
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MOV2A4]M2A5M;F2?WH_-:L/95)4[WLVON"BBBMS(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KYVM=/M_$'[=6KW&HV\=X_A_P7;'33(@;[,\US)YCIGHY"A=PY
MP2*^B:^?OB9^SOKOB[XQ7GC3PI\4[OP-JUQI<&G7-K9Z=#<L\,;NP)+MP"6]
M.W6F!P7[07PQ?Q=^U1X-T'2=6O/#%EXPT.[C\33:2YAGOK:U=)$3<!PS%O++
M]=C,.1Q7TC\._A;X3^$VAQZ/X1T&QT*Q7 *VL8#RD=&D<_-(WNQ)]Z^?[[]D
M#XBZEXJTWQ)<_M ZS)KNFP2VUI?'0;8/%'*5\Q0-V/FVCJ#72Z'\(?B#X,\4
M:#J'B/\ :&U#4M.-_'%_95]I5I;)J#$Y^SAPV=S!3@+S@'% 'T.OW1WI:0=*
M6D 4444 4]6U.#1=,O=1NFVVUI ]Q*P&2$52S'\@:^4_ASK'QW_:%\!M\1]
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M0 4444 %%%% !1110 4444 %%%% !7QW\?O^2M:[_P!L/_2>.OL2OCOX_?\
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M5M?ZMK_B#6WB;4M<UZZ%Q>7(C7;$A9550JC( 51UYSQ7H5+10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?'?Q^_Y*UKO_ &P_])XZ^Q*^._C]_P E:UW_ +8?^D\=?E_B'_R*J?\
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MIUO?>2#G9YL2OMSWQNQ6Y2 **** "BBB@ HHHH **** "BBB@"&ZN!:V\LS
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M*:-%I!USQ)JVE,$O7A:7RH;6&0Y\HN0S,P&=H'K@_0M?-WQ8UJ+X#?M$:?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7QW\?O^2M:[_P!L/_2>.OL2
MOCOX_?\ )6M=_P"V'_I/'7Y?XA_\BJG_ -?%_P"DS/N^#?\ ?Y_X'_Z5$\]H
MHHK^>C]B"BBB@ HHHH **** "BBB@ HHHH **** /8?V7/\ DH%__P!@R3_T
M;#7U(OW17RW^RY_R4"__ .P9)_Z-AKZD7[HK^D^!/^1-'_%(_$^+/^1F_1"T
M44QF.2!7Z$?'#Z*:&X[4N[Z?G0 M%)N^GYT;OI^= 'D'QZ_95\!?M%BRF\46
MMW;ZK8H8[;5M+G$-U$F2=NXJRLH)) 93@DXQDYS_ (#_ +'?P\_9[U:ZUC08
MM1U77[B,Q-J^MW(N+A4)RRKM557.!DA<D#&<5[?N^GYT;OI^= 'S1\5/^"?'
MPJ^*OC&]\2S_ -M>'M1U!S)?+H5XD,5V['+,Z/&^"W\6W;DY)Y)->S_"GX2>
M&/@MX.MO#'A+3QIVE0LTA4N7DFD;&Z21SRS' Y] !T %=AN^GYT;OI^= ' :
M+\%=$TCXOZY\29+S4-3\1:G91Z<@OI(VAL+9""8K=512H9@&;<S$GTR<^7^.
MOV!_AGX^\<:KXDN[CQ!IZZQ<B\U;1]-U$0V&HS EM\T>PL26);Y6'))&"37T
M?N^GYT;OI^= $&GV-OI=C;65I"EO:6\:PPPQC"HB@!5 [   58I-WT_.C=]/
MSH 6BDW?3\Z-WT_.@!:*86.>,&G*<KF@!:*** "BBB@ HHHH I:U_P @>^_Z
MX2?^@FC1?^0/8_\ 7"/_ -!%&M?\@>^_ZX2?^@FC1?\ D#V/_7"/_P!!% %V
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#%U3_D9-$_[;_P#H%;58NJ?\C)HG_;?_ - K:H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/?C[_R277?^V'_
M */CKT*O/?C[_P DEUW_ +8?^CXZ\3//^15BO^O<_P#TEGJ97_O^'_QQ_P#2
MD?'=%%%?R*?T2%%%% !1110 4444 %%%% !1110 4UNAIU-;H: /N;X=?\D^
M\,?]@NU_]%+715SOPZ_Y)]X8_P"P7:_^BEKHJ_LC _[K2_PQ_)'\V8K_ 'BI
MZO\ ,****[3E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\=_'[_DK6N_\
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M_0/8T_Y5]Q^<^VJ_S/[ST3_AHWXL_P#14/&7_A07?_QRC_AHWXL_]%0\9?\
MA07?_P <KSNBCV-/^5?</VU7^9_>>B?\-&_%G_HJ'C+_ ,*"[_\ CE'_  T;
M\6?^BH>,O_"@N_\ XY7G=%'L:?\ *ON#VU7^9_>>B?\ #1OQ9_Z*AXR_\*"[
M_P#CE'_#1OQ9_P"BH>,O_"@N_P#XY7G=%'L:?\J^X/;5?YG]YZ)_PT;\6?\
MHJ'C+_PH+O\ ^.4?\-&_%G_HJ'C+_P *"[_^.5YW11[&G_*ON#VU7^9_>>B?
M\-&_%G_HJ'C+_P *"[_^.4?\-&_%G_HJ'C+_ ,*"[_\ CE>=T4>QI_RK[@]M
M5_F?WGHG_#1OQ9_Z*AXR_P#"@N__ (Y1_P -&_%G_HJ'C+_PH+O_ ..5YW11
M[&G_ "K[@]M5_F?WGHG_  T9\5VQGXG>,L^O_"07?I_UTK]V0-HP*_GC7J*_
MH=KY7/81A[/E5M_T/KN'YRG[7F=]OU"BBBOE#ZX**** "BBB@"EK7_('OO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KSWX^_\ ))==_P"V'_H^.O0J\]^/O_))==_[8?\ H^.O
M$SS_ )%6*_Z]S_\ 26>IE?\ O^'_ ,<?_2D?'=%%%?R*?T2%%%% !1110 44
M44 %%%% !1110 4UNAIU-;H: /N;X=?\D^\,?]@NU_\ 12UT5<[\.O\ DGWA
MC_L%VO\ Z*6NBK^R,#_NM+_#'\D?S9BO]XJ>K_,****[3E"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *JZC:+J%E<6LC,D<\;1,R'# ,"#CWYJU5>\M_M4,L6]
MHO,0H7C;:ZYXR#V/7![&@#X"\=?%+3?A1\!?"_PH\;6UUX9\3^%M;TF-7ELI
M/LFIV=M?1O\ :[>95*,IB7<RD[@0PP<&O7]0^*=A^U3\1/ VE_#VUO-3\*>&
MM<B\0:OXJEM9(+0- CK';0F109)&>3YL# 4'!.<C?E^&WQD^'<+Q>'?%^G?%
M+0 ?^0'X]A\N]VCD!+Z)<2-P.98R.ISZ:WAG]I_28O%FE>"_&_AK5_AUXLU%
MA!8V&HQ">UNW) "V]U#NC89('S;><C%,#W =*6D7!7CI2T@"BBB@ HI"V*,]
M>] "T4F:0,>>* '44G-(6(SQQ0 ZBDI: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX[^/W_)6M=_[
M8?\ I/'7V)7QW\?O^2M:[_VP_P#2>.OR_P 0_P#D54_^OB_])F?=\&_[_/\
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M_J%%%%?(GV(4444 %%%% %+6O^0/??\ 7"3_ -!-&B_\@>Q_ZX1_^@BC6O\
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MM_\ T"MJL75/^1DT3_MO_P"@5M4 %%%% !1110 4444 %%%% !1110 4444
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M]K:ZA=VL=R(@ 7"HHQG&1]YLX(SGFC]HB\;3OBO9W*)'*8+2!Q',@=&P['#
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M "Z^?Z'V7#O_ "]_[=_4****^1/L0HHHH **** *6M?\@>^_ZX2?^@FC1?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O/?C[_R277?^V'_ */CKT*O/?C[
M_P DEUW_ +8?^CXZ\3//^15BO^O<_P#TEGJ97_O^'_QQ_P#2D?'=%+_G_/\
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M_NM+_#'\D?@.*_WBIZO\PHHHKM.4**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MKJ%NUY97%NDKV[RQLBS1G#(2, C!ZC\.E6JAN+A+6.2:5@D48+.[<!0!DDT
M?"IG\0:Y^S[X=_9QM_ WB'3O%;7-KHNLWC:>Z:;!9Q7"R3WBW0&QTDC3C!W$
MR$=<9]M^+E_)X[^+?P[^'_A[1KX_\(WK=IXBU351:F.QT^WBBD\N$2' :23S
M @1>B[L]\<_X+C^+O[2NDIXS@^(#?#'P9?NTNB:1I.FPW%Y/:\JDUS+*/E+@
M%@B#&&'I6OIFM?$KX%?$#POH_C+Q3#\0?!/B:]_LJUUB>P2TU#3;UD9H4D\L
M[)(Y-A7=@,"1TP P!]%KP.*6FK]T4Z@ HHHH 1E#=:^?[_\ 8K\)?;-6_L#Q
M3XT\$Z/JTK37V@>&M9^RZ?,S??/EE&*!AP0C*,<8QQ7T#10!YXWP!\!M\(W^
M&2Z!!'X,: P?V>I;C+;]X;.[?O\ GWYSNYKD/"?[(OAGP[XHT36]4\4>,/&K
MZ%+Y^D67BC5_M=K82?PO'&$7YE&-I8MC:,<C->Y44 <S\1O EM\2_!.J^%[W
M4-0TRQU.+[/<3:9(D<[1$C?&&96 #KE6XSM8X(ZUB_$+X'>&/B-X.TCPY=1W
M6D6VBS07.D76CS?9KG3985VQ/ ^#M*KP 01CM7H%% 'GGPM^".B?"N\UO4K:
M_P!6U_Q!K;Q-J6N:]="XO+D1KMB0LJJH51D *HZ\YXKT*EHH **** "BBB@
MHHHH **** "BBB@!K,5R>WO1N(QW/L*X+XX?#O6OBE\/;WP]X?\ &%_X#U.X
MDBD36]-W^=$$<,5&R2-L,!M.&'!-?GS\<OA;\6OA;\0/!W@+P_\ M%>-/&7C
M7Q++MBTM+N\M%M8>GG2R?:Y,+PQ^[TC8DC R ?J'N.?:D:0]L$]N:\S\3>.+
M#]G'X%V^K>,=9EU7_A'])@MI[Z=R;C4KE(U08+$EI)7&>2>I). 37R9^P7\;
M/B!\6?VD/B#-XSU;5#%-I/VV'0IKF7[)9;YH=@B@9MJ81@,@9())Y)RP/O\
MW'=TXH\SV./H:_+;Q]\;/B+J^D_%3XHQ_$_6?#VL^%?%<>E:;X1MKH)9"W$N
MS$D!.V0@#DE3DH^>O'U1XX\?>(?C3\4/AY\-O#>JWFA+#96_BGQG?:1<26TL
M%N44Q6:R*=R^:S\C.=NT\\T ?4=+3-VT'N.U.%(!:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OCOX_?\E:UW_MA_P"D\=?8E?'?Q^_Y*UKO_;#_ -)XZ_+_ !#_ .15
M3_Z^+_TF9]WP;_O\_P# _P#TJ)Y[C/7Z4=>I)XQ117\]'[$%%%% !1110 44
M44 %%%% !1110 4444 >P_LN?\E O_\ L&2?^C8:^I%^Z*^6_P!ES_DH%_\
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M)IL<#.LC@, 0X7:1EFQ\PZC.*\]O+[PQXQA\3Z[K6HW5GX@N)Y);&QC4E&3
M**QV$<?=^\/NUP.,C!YHYVXW-Z9S7;B>(,1C(\M:E!J[;T?O2:Y>9Z_$DM+6
M5^ART,GHX9WISDMDM5I%._*M-K[WN_,]ST_Q]X.\66/A*^\0:I=:9K'A[8?*
M2!I%N"NW!)53P2JGMU(]ZIZ-\8=)U3Q?XO\ [;6>WT+Q!"+42("[0JB,BDJ
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MM(O2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI_WR'S_)GYKG'^XU/E^:/SPI*6DK]$/S4**** "BBB@ HHHH **** "BBB@
MHHHH 5>HK^AVOYXEZBOZ':^2S_\ Y=?/]#[+AW_E[_V[^H4445\B?8A1110
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MY)]<=,T^O*/B9H_QBO/$?G^!O$WA32-"$"[H=:TZ:>;S.=S;D=1MQC'&>#^
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MX_\ !7#[OPJ_[BO_ +9U^AU?GC_P5P^[\*O^XK_[9U^LY3_OD/G^3/S7./\
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MZ=: /RI_:B_8S^'GPI\0>#/!'@2^\2Z[\1?%-VB6MCJ%W;&W@MR^TRR!+=2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%O;9,D+/N1A\HR-Z[6 _BKYDT"]OM#N_!NK^!(X/#=KXNU)/!7@JZO+<7/\
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M&D*Y[US_ /PL3PK_ -#+H_\ X'Q?_%4?\+$\*_\ 0RZ/_P"!\7_Q5/Z]A?\
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M_0RZ/_X'Q?\ Q5'U["_\_8_^!+_,/JN(_P"?;^YG0T5SW_"Q/"O_ $,NC_\
M@?%_\53H?'WANZN8H(/$.E3S2L(TCCO8V9V) "@!N2<]/>A8W"MV56/WH3PU
M=:NF_N9OT4BG(S2UVG,%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>>_'W_DDNN_]L/\ T?'7H5>>_'W_ ))+KO\
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MI:1>E+2 **** "N#\/\ P;T7P[\6O%7Q$@N;Z;7/$5M;6ES%,\9@ACA0*HB
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MX!6G_P E4?V=B_\ GVP_M+!_\_$?9=%?&G_#U/X3?]"_XR_\ K3_ .2J]*^
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M5Y,PL7L;"UDL=,B(P#$)+E"' )50% 1<XR6)'[@[105!_K[T ?EW\8O%%_\
ML_\ [;WA[]J&]\+:YKWPK\8>'K65[NV@62721)91Q;& ;:C *CX+ -YCA6)!
MJQX/\4WG[=7_  4"\!?%#P5X6U32?AWX)T]4N=>U:S\HW+(9W"!E)4DO*%5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN/(78S O=;'E(+*,'UP,UO>#?!WP:^%/[0S:+IWP_C\(^,+Z!Y](UAX"+74
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M?9?_  2M_P"3@_$/_8KW'_I7:5YN8_[I4]#T\M_WRGZGZI+TI:0=*6OS8_4
MHHHH **** "BBB@ HHHH *^._C]_R5K7?^V'_I/'7V)7QW\?O^2M:[_VP_\
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M/LN'?^7O_;OZA1117R)]B%%%% !1110!2UK_ ) ]]_UPD_\ 031HO_('L?\
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M+Y]_#AZGUG#_ /%GZ'HE%%%?&'VX4444 %%%% !1110 4444 %%%% !1110
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M  R_)G3A?X]/U7YGPY1117\;G]*A1110(**** "BBB@ HHHH **** "BBB@
MK[$^ /\ R270O^V__I1)7QW7V)\ ?^22Z%_VW_\ 2B2OU#P\_P"1K4_Z]O\
M]*@?"<9?[A#_ !K_ -)D>A4G>EI.]?T*?CI^$W[1G_)PGQ/_ .QHU3_TKEKS
MNO1/VC/^3A/B?_V-&J?^E<M>=U^JT?X4?1'Y%6_BR]6%%%%;&(4444 %%%%
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M@[GL*]H/.1_+BD_A['!Q0 \=*6D7[HI: "BBB@ HHHH **** "BBB@ HHHH
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MBBBOYZ/V(**** "BBB@ HHHH **** "BBB@ HHHH ]A_9<_Y*!?_ /8,D_\
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M -!% %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% !7GOQ]_Y)+KO_ &P_]'QUZ%7GOQ]_Y)+KO_;#_P!'QUXF>?\
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M;'C3]GS7;KXDZYXT\">/YO VI>(;.WLM:C.EQWT=T(05BE3<Z^7*J-M#?,,
M<=:^;O!=\OPYU+PE/X%TR#5K2'4'\!?#QM:9EMBQ=GU35Y2H!822AD CP2J-
MCKBF!]]V?GBS@%TT;W(11*T*E4+X^8J"20,YP"3]:FKQCX/_ !=\3ZQ\1O%O
MPZ\<6>DIXHT"WMK]+[0?-%G>6TP."$E):-U88(+$'/'3GV:D M%%% !1110
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M[5'^+WQ-UA;.=)CI^IZW#+;7&TYV2H(%+(>A&1D4 >TK]VG4B_=%+2 ****
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MTI<G_/\ *DHH$"Y4@J<8_&C:O]T XQFBB@ _#%%%% !7V)\ ?^22Z%_VW_\
M2B2OCNOL3X _\DET+_MO_P"E$E?J'AY_R-:G_7M_^E0/A.,O]PA_C7_I,CT*
MD[TM)WK^A3\=/PF_:,_Y.$^)_P#V-&J?^E<M>=UZ)^T9_P G"?$__L:-4_\
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M*)_C1_9>K_\ 0;_\E$_QH VL^U&?:L7^R]7_ .@W_P"2B?XT?V7J_P#T&_\
MR43_ !H VL^U&?:L7^R]7_Z#?_DHG^-4K9-8N=2O;3^UPOV<1_/]F0[MP)Z=
MJ .GS[49]JQ?[+U?_H-_^2B?XT?V7J__ $&__)1/\: -K/M1GVK%_LO5_P#H
M-_\ DHG^-']EZO\ ]!O_ ,E$_P : -K/M1GVK%_LO5_^@W_Y*)_C1_9>K_\
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M3>_AA_V*^E_^DD5?+Y]_#AZGUG#_ /%GZ'HE%%%?&'VX4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKSWX^_\ ))==_P"V'_H^.O0J\]^/O_))==_[8?\ H^.O$SS_ )%6*_Z]S_\
M26>IE?\ O^'_ ,<?_2D?'=%%%?R*?T2%%%% !1110 4444 %%%% !1110 4U
MNAIU-;H: /N;X=?\D^\,?]@NU_\ 12UT5<[\.O\ DGWAC_L%VO\ Z*6NBK^R
M,#_NM+_#'\D?S9BO]XJ>K_,^=_\ @H)_R:)X^_[</_2^VK\:J_97_@H)_P F
MB>/O^W#_ -+[:OQJK]&R/_=I?XG^2/SC/_\ >8_X5^;$HHHKZ(^9"BBB@ HH
MHH **** "BBB@ HHHH 4=_I7[L_LY_\ )O?PP_[%?2__ $DBK\)AW^E?NS^S
MG_R;W\,/^Q7TO_TDBKY?/OX</4^LX?\ XL_0]$HHHKXP^W"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "HY%5MRL%8,,%6Z$&I*K:A>)I]
ME<W<Q80PQM*^T<[5&3_*@!T4,=O D44:QQ1*$18P%50.  .P'I3^G!&*^7K'
MXW>-?#_[*7B/XP:W>6MYJ>L6RW^@Z/#;JD.FK.XAM("V<RG<\;L3SDL.F*=9
MZ#X^_9]U[X=ZCK'Q(UGQM;^)M6@T/7=-UCRY(H[B>-RDUH54&)4D0#8<@J>W
M% 'U"OW>.*=2#H*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YSXB
M_P#(@^)_^P9<_P#HIJZ.N<^(O_(@^)_^P9<_^BFKBQW^ZU?\,OR9TX7^/3]5
M^9\.4445_&Y_2H4444""BBB@ HHHH **** "BBB@ HHHH *^Q/@#_P DET+_
M +;_ /I1)7QW7V)\ ?\ DDNA?]M__2B2OU#P\_Y&M3_KV_\ TJ!\)QE_N$/\
M:_\ 29'H5)WI:3O7]"GXZ?A-^T9_R<)\3_\ L:-4_P#2N6O.Z]$_:,_Y.$^)
M_P#V-&J?^E<M>=U^JT?X4?1'Y%6_BR]6%%%%;&(4444 %%%% !1110 4444
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MBEKHJYWX=?\ )/O#'_8+M?\ T4M=%7]D8'_=:7^&/Y(_FS%?[Q4]7^9\[_\
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M]X6_[>O_ &C7Q/&G_(AQ'_;O_I<3Z?AG_D;4?^WO_26?/U%%%?S ?NP4444
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M%%% !1110 4444 %%%% !7V)\ ?^22Z%_P!M_P#THDKX[K[$^ /_ "270O\
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MKY+/_P#EU\_T/LN'?^7O_;OZA1117R)]B%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5BZ7_P C'K?_ &P_] K:K%TO_D8];_[8?^@4 ;-+24M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/7[67WO"W_;U_[1
MKZ%KYZ_:R^]X6_[>O_:-?$\:?\B'$?\ ;O\ Z7$^GX9_Y&U'_M[_ -)9\_44
M45_,!^[!1110 4444 %%%% !1110 4444 %=#\._^2@^&/\ L*6W_HU:YZNA
M^'?_ "4'PQ_V%+;_ -&K7;@?]ZI?XH_FCFQ7^[U/1_D?<B]*6D7I2U_9!_-9
MYS\7?VA/ 7P).E?\)QKW]B?VIYOV/_0[BX\WR]GF?ZJ-L8\Q.N.O&><>>_\
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M.Z_5:/\ "CZ(_(JW\67JPHHHK8Q"BBB@ HHHH **** "BBB@ HHHH *^R_\
M@E;_ ,G!^(?^Q7N/_2NTKXTK[+_X)6_\G!^(?^Q7N/\ TKM*\W,O]TJ>AZ>6
M_P"^4_4_5(=*6D'2EK\V/U **** "BBB@ HHHH **** "OCOX_?\E:UW_MA_
MZ3QU]B5\=_'[_DK6N_\ ;#_TGCK\O\0_^153_P"OB_\ 29GW?!O^_P _\#_]
M*B>>T445_/1^Q!1110 4444 %%%% !1110 4444 %%%% 'L/[+G_ "4"_P#^
MP9)_Z-AKZD7[HKY;_9<_Y*!?_P#8,D_]&PU]2+]T5_2? G_(FC_BD?B?%G_(
MS?HA:_/'_@KA]WX5?]Q7_P!LZ_0ZOSQ_X*X?=^%7_<5_]LZ_6<I_WR'S_)GY
MKG'^XU/E^:/SPI*6DK]$/S4**** "BBB@ HHHH **** "BBB@ HHHH 5>HK^
MAVOYXEZBOZ':^2S_ /Y=?/\ 0^RX=_Y>_P#;OZA1117R)]B%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5BZ7_R,>M_]L/_ $"MJL72_P#D8];_
M .V'_H% &S2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MSU^UE][PM_V]?^T:^A:^>OVLOO>%O^WK_P!HU\3QI_R(<1_V[_Z7$^GX9_Y&
MU'_M[_TEGS]1117\P'[L%%%% !1110 4444 %%%% !1110 5T/P[_P"2@^&/
M^PI;?^C5KGJZ'X=_\E!\,?\ 84MO_1JUVX'_ 'JE_BC^:.;%?[O4]'^1]R+T
MI:1>E+7]D'\UGYX_\%</N_"K_N*_^V=?GA7Z'_\ !7#[OPJ_[BO_ +9U^>%?
MHF4_[E#Y_FS\USC_ 'ZI\OR0E%%%>N>,%%%% !1110 4444 %%%% !1110!Z
M)^SG_P G!_#'_L:-,_\ 2N*OW:K\)?V<_P#DX/X8_P#8T:9_Z5Q5^[5?%Y]_
M%AZ,^XX?_A5/4****^8/JPHHHH **** "BBB@ KSWX^_\DEUW_MA_P"CXZ]"
MKSWX^_\ ))==_P"V'_H^.O$SS_D58K_KW/\ ])9ZF5_[_A_\<?\ TI'QW111
M7\BG]$A1110 4444 %%%% !1110 4444 %-;H:=36Z&@#[F^'7_)/O#'_8+M
M?_12UT5<[\.O^2?>&/\ L%VO_HI:Z*O[(P/^ZTO\,?R1_-F*_P!XJ>K_ #/G
M?_@H)_R:)X^_[</_ $OMJ_&JOV5_X*"?\FB>/O\ MP_]+[:OQJK]&R/_ ':7
M^)_DC\XS_P#WF/\ A7YL2BBBOHCYD**** "BBB@ HHHH **** "BBB@!1W^E
M?NS^SG_R;W\,/^Q7TO\ ])(J_"8=_I7[L_LY_P#)O?PP_P"Q7TO_ -)(J^7S
M[^'#U/K.'_XL_0]$HHHKXP^W"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O*/C1\3/&/@'<GA_P"'>I>+;6:S=_[2TZ^MX_LL@SPZ2D'@
M8;(R#^%>KU7OIH;>UN);DK]G2-FEW#(V@<Y]L9H ^4_@S^TM\4=3^$_A6\N?
M@YXD\5SS:="\FN1:A91K?,5!,P4L,!NN,#Z"NGD^)'Q=^(OBCPAI]G\,-9\!
MZ9!K,%YK&JZCJ5H\;62!O,AV(Q9BY* 8YX],D>=ZU\:/CI<_"$?$OPM8>!?"
M?@'=$VG:=>6]Q+>I9/.D23R[6$2@!_,*J 0H/4\5TMKXL_: \'_&+P3H'C[7
M/!\'A?7KIHH]2T73IG\Z9%,ALV,C#RGDC20J^"/EXYXH ^JU^[2T@]Z6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *YSXB_P#(@^)_^P9<_P#HIJZ.
MN<^(O_(@^)_^P9<_^BFKBQW^ZU?\,OR9TX7^/3]5^9\.4445_&Y_2H4444""
MBBB@ HHHH **** "BBB@ HHHH *^Q/@#_P DET+_ +;_ /I1)7QW7V)\ ?\
MDDNA?]M__2B2OU#P\_Y&M3_KV_\ TJ!\)QE_N$/\:_\ 29'H5)WI:3O7]"GX
MZ?A-^T9_R<)\3_\ L:-4_P#2N6O.Z]$_:,_Y.$^)_P#V-&J?^E<M>=U^JT?X
M4?1'Y%6_BR]6%%%%;&(4444 %%%% !1110 4444 %%%% !7V7_P2M_Y.#\0_
M]BO<?^E=I7QI7V7_ ,$K?^3@_$/_ &*]Q_Z5VE>;F7^Z5/0]/+?]\I^I^J0Z
M4M(.E+7YL?J 4444 %%%% !1110 4444 %?'?Q^_Y*UKO_;#_P!)XZ^Q*^._
MC]_R5K7?^V'_ *3QU^7^(?\ R*J?_7Q?^DS/N^#?]_G_ ('_ .E1//:***_G
MH_8@HHHH **** "BBB@ HHHH **** "BBB@#V']ES_DH%_\ ]@R3_P!&PU]2
M+]T5\M_LN?\ )0+_ /[!DG_HV&OJ1?NBOZ3X$_Y$T?\ %(_$^+/^1F_1"U^>
M/_!7#[OPJ_[BO_MG7Z'5^>/_  5P^[\*O^XK_P"V=?K.4_[Y#Y_DS\USC_<:
MGR_-'YX4E+25^B'YJ%%%% !1110 4444 %%%% !1110 4444 *O45_0[7\\2
M]17]#M?)9_\ \NOG^A]EP[_R]_[=_4****^1/L0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L72_\ D8];_P"V'_H%;58NE_\ (QZW_P!L/_0*
M -FEI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OGK]K+[W
MA;_MZ_\ :-?0M?/7[67WO"W_ &]?^T:^)XT_Y$.(_P"W?_2XGT_#/_(VH_\
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M_P"BEKHJYWX=?\D^\,?]@NU_]%+715_9&!_W6E_AC^2/YLQ7^\5/5_F?._\
MP4$_Y-$\??\ ;A_Z7VU?C57[*_\ !03_ )-$\??]N'_I?;5^-5?HV1_[M+_$
M_P D?G&?_P"\Q_PK\V)1117T1\R%%%% !1110 4444 %%%% !1110 H[_2OW
M9_9S_P"3>_AA_P!BOI?_ *215^$P[_2OW9_9S_Y-[^&'_8KZ7_Z215\OGW\.
M'J?6</\ \6?H>B4445\8?;A1110 4444 %%%% !1110 4444 %%%% !1110
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MY1117\;G]*A1110(**** "BBB@ HHHH **** "BBB@ K[$^ /_))="_[;_\
MI1)7QW7V)\ ?^22Z%_VW_P#2B2OU#P\_Y&M3_KV__2H'PG&7^X0_QK_TF1Z%
M2=Z6D[U_0I^.GX3?M&?\G"?$_P#[&C5/_2N6O.Z]$_:,_P"3A/B?_P!C1JG_
M *5RUYW7ZK1_A1]$?D5;^++U84445L8A1110 4444 %%%% !1110 4444 %?
M9?\ P2M_Y.#\0_\ 8KW'_I7:5\:5]E_\$K?^3@_$/_8KW'_I7:5YN9?[I4]#
MT\M_WRGZGZI#I2T@Z4M?FQ^H!1110 4444 %%%% !1110 5\=_'[_DK6N_\
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M%CO]UJ_X9?DSIPO\>GZK\SX<HHHK^-S^E0HHHH$%%%% !1110 4444 %%%%
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M_2B2OCNOL3X _P#))="_[;_^E$E?J'AY_P C6I_U[?\ Z5 ^$XR_W"'^-?\
MI,CT*D[TM)WK^A3\=/PF_:,_Y.$^)_\ V-&J?^E<M>=UZ)^T9_R<)\3_ /L:
M-4_]*Y:\[K]5H_PH^B/R*M_%EZL****V,0HHHH **** "BBB@ HHHH ****
M"OLO_@E;_P G!^(?^Q7N/_2NTKXTK[+_ ."5O_)P?B'_ +%>X_\ 2NTKS<R_
MW2IZ'IY;_OE/U/U2'2EI!TI:_-C]0"BBB@ HHHH **** "BBB@ KX[^/W_)6
MM=_[8?\ I/'7V)7QW\?O^2M:[_VP_P#2>.OR_P 0_P#D54_^OB_])F?=\&_[
M_/\ P/\ ]*B>>T445_/1^Q!1110 4444 %%%% !1110 4444 %%%% 'L/[+G
M_)0+_P#[!DG_ *-AKZD7[HKY;_9<_P"2@7__ &#)/_1L-?4B_=%?TGP)_P B
M:/\ BD?B?%G_ ",WZ(6OSQ_X*X?=^%7_ '%?_;.OT.K\\?\ @KA]WX5?]Q7_
M -LZ_6<I_P!\A\_R9^:YQ_N-3Y?FC\\*2EI*_1#\U"BBB@ HHHH **** "BB
MB@ HHHH **** %7J*_H=K^>)>HK^AVODL_\ ^77S_0^RX=_Y>_\ ;OZA1117
MR)]B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BZ7_ ,C'K?\
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MX^%?_"Z_A-XB\$?VG_8W]KQ1Q_;OL_G^5ME1\[-R[ON8QN'4'VKT*DVC.>]
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M>?\ 0"_\FX/_ (Y1_P *#\>?] +_ ,FX/_CE']AYK_T"U/\ P"7^0?VIE_\
MT$0_\"C_ )GGU%>@_P#"@_'G_0"_\FX/_CE'_"@_'G_0"_\ )N#_ ..4?V'F
MO_0+4_\  )?Y!_:F7_\ 01#_ ,"C_F>?5]B? '_DDNA?]M__ $HDKY\_X4'X
M\_Z 7_DW!_\ '*^D_A#H%_X7^'>DZ9J<'V:^@\[S(MZOMW3.PY4D=".]?HW
MN6XW!YE4J8FC*$7!J\HM*_-'35'Q?%>-PN(P4(4*L9/G6B:?278[*D[TM,9M
MK=,U^Z'Y2?A1^T9_R<)\3_\ L:-4_P#2N6O.Z^NOC1^P[\;/%WQB\=Z[I/@K
M[7I6IZ]?WMI<?VM9)YL,EP[HVUI@PRK X(!&>17&_P##OSX]_P#0A?\ E9L/
M_C]?I5'%X=4XIU([+JC\NK8/$NI)JE+=]&?.]%?1'_#OSX]_]"%_Y6;#_P"/
MT?\ #OSX]_\ 0A?^5FP_^/UK]<PW_/R/WK_,R^I8K_GU+[F?.]%?1'_#OSX]
M_P#0A?\ E9L/_C]'_#OSX]_]"%_Y6;#_ ./T?7,-_P _(_>O\P^I8K_GU+[F
M?.]%?1'_  [\^/?_ $(7_E9L/_C]'_#OSX]_]"%_Y6;#_P"/T?7,-_S\C]Z_
MS#ZEBO\ GU+[F?.]%?1'_#OSX]_]"%_Y6;#_ ./T?\._/CW_ -"%_P"5FP_^
M/T?7,-_S\C]Z_P P^I8K_GU+[F?.]%?1'_#OSX]_]"%_Y6;#_P"/T?\ #OSX
M]_\ 0A?^5FP_^/T?7,-_S\C]Z_S#ZEBO^?4ON9\[T5]$?\._/CW_ -"%_P"5
MFP_^/T?\._/CW_T(7_E9L/\ X_1]<PW_ #\C]Z_S#ZEBO^?4ON9\[U]E_P#!
M*W_DX/Q#_P!BO<?^E=I7GG_#OSX]_P#0A?\ E9L/_C]?2W[ ?[+_ ,3?@C\8
MM8USQIX9_L;3+G09K&*?[?;7&Z9KBW<+MBD9A\L;G.,<=>F?/Q^*H3PLXQJ)
MNW='H9?A<1#%4Y2IR2OV9]_CI2TB]..:6O@#]&"BBB@ HHHH **** "BBB@
MKX[^/W_)6M=_[8?^D\=?8E?-?Q>^$7BWQ1\1-6U/3-)^TV,_D^7+]HA3=MA1
M3PS@]0>U?G/'6%Q&,RVG3PU-SDIIVBFW;EEKH?:<*8BCA\;.=>:BN1ZMI=8]
MSPVBO0?^%!^//^@%_P"3<'_QRC_A0?CS_H!?^3<'_P <K\+_ +#S7_H%J?\
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M0?CS_H!?^3<'_P <H_X4'X\_Z 7_ )-P?_'*/[#S7_H%J?\ @$O\@_M3+_\
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MO_*S8?\ Q^ON_KF&_P"?D?O1^?\ U+%?\^I?<SYWHKZ(_P"'?GQ[_P"A"_\
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M?5Y%1JT?:^TBXWMNK=Q:***^7/JPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L72_^1CUO_MA_Z!6U6+I?_(QZW_VP_P#0* -FEI*6@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OGK]K+[WA;_ +>O_:-?0M?/
M7[677PN>N/M7?_KC7Q7&G_(AQ'_;O_I<3ZCAG_D;4?\ M[_TEGS]129]Q1GW
M'Y5_+Y^ZBT4F?<?E1GW'Y4 +129]Q^5&?<?E0 M%)GW'Y49]Q^5 "T4F?<?E
M1GW'Y4 +129]Q^5&?<?E0 M=#\._^2@^&/\ L*6W_HU:YW/N/RKH?AT?^+@^
M&>>1J=MV//[U:[<#_O5+_%'\T<N*_P!WJ>C_ "/N5>E+2+]T=J6O[(/YL/SQ
M_P""N'W?A5_W%?\ VSK\\*_0[_@K=S_PJL=A_:O/_@'7YX[2><5^B93_ +G#
MY_FS\USC_?JGR_)"44NT^E&T^E>L>.)12[3Z4;3Z4 )12[3Z4;3Z4 )12[3Z
M4;3Z4 )12[3Z4;3Z4 )12[3Z4;3Z4 >A_LY_\G!_#'_L:-,_]*XJ_=JOPE_9
MT^7]H+X8?*3_ ,53IF<8_P"?J*OW94Y%?&9[_%AZ,^WX?_A5/46BBBOF#ZL*
M*** "BBB@ HHHH *\]^/O_))==_[8?\ H^.O0J\\^/S?\6GUWT_<?^CXZ\3/
M/^15BO\ KW/_ -)9ZF5_[_A_\<?_ $I'QY11^(_*DS[C\J_D0_HD6BDS[C\J
M,^X_*F M%)GW'Y49]Q^5 "T4F?<?E1GW'Y4 +129]Q^5&?<?E0 M%)GW'Y49
M]Q^5 "TUNAI<^X_*C@GD\9&: /N7X=?\D^\,?]@NU_\ 12UT5<[\.?\ DG_A
MGC'_ !++;_T4M=%7]D8'_=:7^&/Y(_FS%?[Q4]7^9\[_ /!03_DT3Q]_VX?^
ME]M7XU5^RG_!00_\8C>/1_UX?^E]M7XV;3V'%?HN1_[M+_$_R1^<9_\ [S'_
M  K\V-HI=I]*-I]*^B/FA**7:?2C:?2@!**7:?2C:?2@!**7:?2C:?2@!**7
M:?2C:?2@!**7:?2C:?2@ '?Z5^[/[.?_ ";W\,/^Q7TO_P!)(J_"?';!)P<X
M[5^['[.7_)O?PP_[%?3/_22*OE\^_AP]3ZOA_P#BS]/U/1****^-/MPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHI"P% "TUHPW6ESGH:* #;1M]S11
M0 ;?<T;?<T44 &WW-&WW-%% !M]S1M]S110 ;?<T;?<T44 &WW-&WW-%% !M
M]S1M]S110 ;?<T444@%II4')Z4M%, Q1112T **** "BBB@ HHHH **** "B
MBB@ HHHH *-M%% !2TE%,!:*2B@!:*2B@!:*2B@!:*2B@!:3%%% !M]S1M]S
M110 ;?<T;?<T44 &WW-&WW-%% !M]S1M]S110 ;?<T;?<T44 &WW-&WW-%%
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M /CE'_#/_@+_ * /_DY/_P#'*]"S[49]J/[#RK_H$I_^ 1_R#^U<P_Z")_\
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M,\]_X9_\!?\ 0!_\G+C_ ..4?\,_^ O^@#_Y.3__ !RO0L^U&?:O(_L/*O\
MH$I_^ 1_R/2_M7,/^@B?_@4O\SSW_AG_ ,!?] '_ ,G)_P#XY1_PS_X"_P"@
M#_Y.3_\ QRO0L^U&?:C^P\J_Z!*?_@$?\@_M7,/^@B?_ (%+_,\]_P"&?_ 7
M_0!_\G)__CE'_#/_ ("_Z /_ ).3_P#QRO0L^U&?:C^P\J_Z!*?_ (!'_(/[
M5S#_ *")_P#@4O\ ,\]_X9_\!?\ 0!_\G)__ (Y1_P ,_P#@+_H _P#DY/\
M_'*]"S[49]J/[#RK_H$I_P#@$?\ (/[5S#_H(G_X%+_,\]_X9_\  7_0!_\
M)R?_ ..4?\,_^ O^@#_Y.3__ !RO0L^U&?:C^P\J_P"@2G_X!'_(/[5S#_H(
MG_X%+_,\]_X9_P# 7_0!_P#)R?\ ^.4?\,_^ O\ H _^3D__ ,<KT+/M1GVH
M_L/*O^@2G_X!'_(/[5S#_H(G_P"!2_S//?\ AG_P%_T ?_)R?_XY2_\ "@?
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M#6R[Y8 DD,R+G 8QR*K8SQG&/THU [VBAAM8C.<'%)2NP%HI**+L!:*2BB[
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M5>BB[ L?VA=?\_,W_?9H_M"Z_P"?F;_OLU7HHNP+']H77_/S-_WV:/[0NO\
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M@X #;B1]T!C4Z-7%J?0?Q&_:;\;:I\9+SX8_"+PMIVO:[I<7G:IJ&LRL+6
M*6 560\;T7.[EFP!QFI_A+^TCK?CS6O''PX\?^'(/#'CS1=/EN)(K-]UO<QF
M->5)+$'$D; !FW*V>,&O!/CM^S;?>&_VA/$OBK5?AMK7Q,\$:XS7*1^'Y)!=
M6\[X9MRQY;AM_!&"'!R""*[?]EOX)3Z?KWB3Q?\ \*LNOA]8KI\]KID5_?W,
MNH3^8OW'A=AV!Y*KR0 #@FEHE<-3QC]EK]I-?@?\&=;TC1+!==\>ZYX@6#2M
M)<,5W&*-1)(%()7<=H (+$XR "1^C7PY;Q?-X1L9O'*Z6GB6=3-<6^BQ.EO
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D'>EI.^._6@#BM0_P"/ZY_ZZ-_.J]6+_P":^N".!YC=?J:KX]Q7,]R@HHQ[
MBC'N*0PHHQ[BC'N* "BC'N*,>XH **,>XHQ[B@ HHQ[BC'N* "BC'N*,>XH
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MXHQ[B@ HHQ[BC'N* "BC'N*,>XH **,>XHQ[B@ HHQ[BC'N* "BC'N*,>XH
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M4<4AB44O%'% "44O%'% "44O%'% "44O%'% "44O%'% "44O%'% "44O%'%
M"44O%'% "44O%'% "44O%'% "44O%'% "44O%'% "44O%'% "44O%'% "44O
M%'% "48I>*.* #<6SD[L^M(><YYXQSS2\4<4 )USGG-+_$6ZD]:.*.*!!N/'
M-)@8QC-+Q1Q1J 9[#C\:,_C1Q1Q0,....^<Y-+N//I2<4<4:B$Z44O%'% Q*
M*7BCB@!**7BCB@!**7BCB@!**7BCB@!**7BCB@!**7BCB@!**7BCB@!**7BC
MB@!**7BCB@#IO#/_ !XR?]=#_(5K"LCPR?\ 09,?\]#_ "%:]=$=B!:***H
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I",_RI:* (&L;=V+-!&S$Y)* FD_L^U_Y]XO^^!_
MA5BB@"O_ &?:_P#/O%_WP/\ "C^S[7_GWB_[X'^%6** *_\ 9]K_ ,^\7_?
M_P */[/M?^?>+_O@?X58II8AO:@"'^S[7_GWB_[X'^%']GVO_/O%_P!\#_"I
M5?=R,8^M.# CUH @_L^U_P"?>+_O@?X4?V?:_P#/O%_WP/\ "IMXYSQ7RQX;
M^+7[0/QBO/$6L_#FR^'%MX*M=8NM,TV?Q.FH+=7<<+;#./)8H49@P!X/RD8X
MR2P'U#_9]K_S[Q?]\#_"C^S[7_GWB_[X'^%<-X;\5>(/!/PUGUSXP:GX7TF^
MLR\E[>:*\T>G11;@(\-.=Q8Y ]V8 #IGS3X-_M72?'?XYZOX<\-Z0UKX)TG1
M_MKZIJ5M)%=7LSR(L31*2-D)4N064LV!PM 'T)_9]K_S[Q?]\#_"C^S[7_GW
MB_[X'^%<]\1_B1H?PI\&ZCXF\1W8M-,LDR2HR\KGA8XUS\SL<!5'4FO-_P!E
M#XY^(?VA/"'B+Q/K&C6N@6$6MS:?IEE&',ZP1JF3,Q8AGW,RG:% *GBBP'M/
M]GVO_/O%_P!\#_"C^S[7_GWB_P"^!_A4X.X CI2T 5_[/M?^?>+_ +X'^%']
MGVO_ #[Q?]\#_"K%% %?^S[7_GWB_P"^!_A1_9]K_P ^\7_? _PJQ10!7_L^
MU_Y]XO\ O@?X4?V?:_\ /O%_WP/\*L44 5_[/M?^?>+_ +X'^%']GVO_ #[Q
M?]\#_"K%% %?^S[7_GWB_P"^!_A1_9]K_P ^\7_? _PJ9F([?2C<?2@"'^S[
M7_GWB_[X'^%']GVO_/O%_P!\#_"I@Q/I^%)N//3K0!%_9]K_ ,^\7_? _P *
M/[/M?^?>+_O@?X5YC^TE\6M5^$/PY&H^'K&VU/Q3J6HVFCZ+97BNT,]W/*%"
ML$96(V!VX.?EKE= _P"&I6UW3AK3?"%-&^TQ?;FL%U5K@0;QYAB#D*7V[MH8
M@9QDXHL![Q_9]K_S[Q?]\#_"C^S[7_GWB_[X'^%>3?'C]J+P=\!+"6/4YWU;
MQ&;=[FW\/:<#)=2(JLQD<#/E1 *Q,CX "MC.,4WX??':0_LTZ=\5/'ZVFDI)
MIKZK=)IZ-Y:Q,[&%$5V)9V0Q#K\S-Q@' + >M_V?:_\ /O%_WP/\*/[/M?\
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MYIWLJLVY0"<?,0<>XJ=PS0!!_9]K_P ^\7_? _PH_L^U_P"?>+_O@?X58HH
MK_V?:_\ /O%_WP/\*/[/M?\ GWB_[X'^%6** *_]GVO_ #[Q?]\#_"C^S[7_
M )]XO^^!_A5BB@"O_9]K_P ^\7_? _PH_L^U_P"?>+_O@?X58HH K_V?:_\
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M  H_L^U_Y]XO^^!_A5BB@"**WCASY:*F?[HQ_GK4M%% !1110 4444 %%%%
M!1110 4444 %%%% !4<T*W$;H_*L-I&>U244 9_]@V/_ #P_\>/^-']@V/\
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M-C_SP_\ 'F_QH_L&Q_YX?^/-_C6A119 9_\ 8-C_ ,\/_'F_QH_L&Q_YX?\
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M&NWTC2K;1=)L]/M%V6UI EO$.N$10JC\A3 N+]T?E2T@_.EI %%%% !1110
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MTQ\._%/Q:^#^K^#_  EJ-CH][J[1VUU=7[NJK:%P9@NQ6)9E!7!P"&/(KO\
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MHK@/CYX-USXB?!WQ=X7\.7%G;:QK%A)8Q2ZA(\<"K)A9-[(K,/W9?HIY([4
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MA>]?2%M;Q6=O%!!$D$$:A$BC4*J*!@  <  =J ):***0!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4FWG-+10 FWW-'2EHH
M 2C%+10 W;[FG444 )CG-+110 4444 %%%% !1110 4444 %%%% ";><Y_"C
M;[YI:* $I:** $QSG-&*6B@!"OOBC;2T4 -V@G.*44M% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 )CUYHV_C2T4 (/KFC;SFEHH :% Z<4N*
M6B@!,<YS2;!C%.HH ;L'2EI:* "BBB@ HHHH **** "BBB@!I7-&WW-.HH ;
MM[9-.HHH 3&:3:*=10 FWWQ12T4 )BEHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.<'&?04 /HI%.12T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M21B5B6(*!6VDG'T.*['P_;R:#X^U#2(KV^N+%M,@NQ'>W4ER8Y/-D1BKR,2
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ML?FO_>;:!D^YYI@>->&[?^S[R334O[RQT_4/%=[:W4_VZ7>0B.\<8D9B5+L
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MY/S$]!UP*H>&;S6=0T7P]KS:E%#>7EU 99)-<N'65V<"6W^R^3Y:\%E 7[A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MER(67E6P,("?N!>*Z#3? .HZ!'I;:5K44%S:Z7!I4[7-D98KB.'/EOL612K
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M,K;W&#CD*,_=- &/<?&!/[$U75[+2)[FPTV&/SS*QAD^TLRAK<*5.60'YCG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,O\ -M/RDJ-F<^H!Z9IOBC1]:NI+?3]7L;^XC&YX;6Y21T .,E5)(&>*-/\
M%&C:K>RV5CJ]C>74>2]O;W"/(F#@Y4$D<\5QFH21>)M+M]-TCPU?65_%I]Q#
M#<75J]JFG[H&155V4!R6*KA"1_%V%5[-3K$'@JPTW1;[3+G2;B.2Y>XLY+=+
M2)8V62,2%0'WY"X0L#U/'- ';6'C#0M4O([.SUK3KR\D02I;PW4<DC*5W;@H
M8DC'.?0UG^*/B%I/A^WG$5W9WVHPS11-IZ7:";YY40DKR1C=GIV[=:XKPYX;
MO+#X:_#BU_LR:WO+6_MI+B)8")(>'#LXQD#GDG'!YJA=VDMO\-[/PR_A[4I=
M;M]0A:1H].D:/>MR':X$V-A#+GD-N^;!'6@#UF?Q3HUKJR:;/J^GQ:DS*BV<
METBS$M]T!"<Y/;CFHKOQIX?T^\-G<Z[IL%V"089;N-7!4 G*EL\ @GZUY3XR
MAUB\T_7K**RU.*634VECTS3=((CE59U(N'N&#!RR -\A5@<#'RFNR\(>%TFF
M\?PW^GO%'JFJ2QEY(RAGMS;0K\I/5<EP".,[O>@#MIKRWAN(+>2:))I]WE0R
M, \F!EMHSS@<FJFK^(])\/B-M4U2RTWS,A/M=PD6['7!8C-<7\,8-0U;4+F]
MU;YY=$B.@P29)$K(W[Z8?[^V+T^X:C\16MWIOQ O]0GFUJWL;JPABM[C2-/6
M[P4,A>)@89&7.Y6&, ]SD"@#M-0\6:%H\:27^M:?9)(BR*UQ=1QJR'@,,D9!
M/&:?=^)M(L=/AO[G5;&WL9B EU-<HL3]> Q.#^!KSWP)X5ETOQGHDK:7>6]M
M;Z#*L<EZ%<PN]UN\LLJA%;83\HQ@<=J;H6GS>&=:TO4;O2KPZ;!+K%O&EM9/
M,ULTE\S1N(T4L%>(8#*IX*_PG-%@.OTGXA:5J$>HS7-Y9V%M;7CVT4\UVFRX
M58TDWJ3@8P_;. ,YK5M_$>DWFF2ZE!JEC-I\61+=1W*&)2,9W.#@8S^M>*I'
M%9:]H]W=^';V*RG\47EW#926A$NW[&"LJQ8RV"I? &1M/&X8K=UO3I]8UV\U
M^UT*];1TU#3Y9K>2U=)KOR1.))1 X#$#S(>V2(N <"F!Z))XMTVXT>34=.U+
M3+V!98XS.U\J0@LZK@R*&PWS<+CDD#C.1))XRT"'4$L7UO34O7D,2VYNXQ(7
M!VE0N<Y!!!&."*\T\;Z?>^)+C6-3TG3+Y+)TTV%EDM)(9;J5+Z-R_E,H8B.,
M'YV X)QD#-2S>';S_A /B'&NF3?;KO5KJ:%1;MYDZB13&RC&6''!'X4@.]T/
MQE8Z]XBUK2()(3<::Z(VR969\JI;Y1R-I8*<]\BKNJ>*-&T6Z@MM1U:QL+F4
M;HX;JY2-W&<94,03SQ6'X=62T\?^+DFM;J-;I[>Y@F:"3R9$6&-&Q)MV;@W&
MW.>,XP#7/>.K>XL=<UN>Q@U-)[NTB5X?[*_M"RU+:&"QMM4F/&2IRR@ALX-
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ME4R!C.-Q ^M=>OW1_6I -O?O0%"YQQ2T4 )M!Z\TFT<>W2G44 )M%&WK2T4
M)M%)M&<CBG44 )M%&T9S2T4 )M]>?K2;1@#%.HH ;M'7OZT;?>G44 -VC_)I
M<4M% ";1G-&T4M% #=@Y]_84%0:=10 FWKU_.DVC;CM3J* $V@X]J-O44M%
M"8HVBEHH 3:.:3:.?>G44 -V@TNVEHH ;M'7J?6C;UZ_G3J* $VBC:,YI:*
M$Z4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !28YS2T4 4-4T.RUG[']LA,IL[A;N#YV7;*H(#<'G[QX.
M15W:.O\ 6G44 (%QTI/+&<_Y-.HH 3:/Z4;1G/2EHH ;M X' QBC:./;FG44
M -V"E'%+10!0M=#LK'4[_4((=EW?%#<2;V.\HNU>"<# ] *N[?<TZB@!NWW-
M 7&!D\4ZB@"AJNAV6N1V\=[#YZ6]Q%=Q#<R[98V#HW!&<, <'CUJ[M'6G44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img46421407_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X25:17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(S.C R.C(Q(#$W.C S.C0W   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,S,0  DI(  @    ,S,0  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,SHP,CHR,2 Q-SHP,CHQ,0 R,#(S.C R.C(Q(#$W.C R.C$Q      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  $ZT         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ < $  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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MW<CKTXQUS3NP'#Q;:$,1),0NW)%NW<D#MR<C''3O3)O&%O$]N-MPRSH'1A&
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M.E!+X@523?PFA]DB]#^='V2+T/YUE9&H?9(O0_G1]DB]#^=%D Y84A.Y0<G
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MN?<50A&) SQU _6G4 %% !10 44 %% !10 44 %4;08U"]&=Q+*2WIQP/RH
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M3X&GZ!*$X?$K&9_;^F_;?LAN-LV_R_F0A=V6 &[&.J,.O:M.K("B@ HH **
M"J5HBK?WS \LR_+@C'R_ESSTH ?%?PSLJ*'5FZ;EZU:H ** .'\8^1_;,1F\
MS_CW7 3'/S-GK[5AJ=, ^<73'/8*./S-?&8[V/UJ?/??H?2X7VOL(\MCHM'Q
M_P (/K&T$#;/@$Y_Y9BO%;:Q@F3=+?V\&0"%;<3U YP/J?PKU(I/#TNFAS1;
M56IUU-&PLK2VUS3&AU&.X8W47RHA&/F%>Z:WXGT;PX8/[7OEM?/W>5N1FW;<
M9Z ^H_.O2R^#=XQU.#,:B5I2T.33XA:(MWYA\80O#YF?+:T;!3>Q(X0'.TJ
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MUFQ6#2DAD:\B*OYS-M&X<8-='\>OO:!]+C_VG7L9.TZFBM_PS/)SE-4M7?\
MX='C=>U? ;_CVUW_ 'X/Y/7NXK^$SP<)_&1[">E<UK?C&VT+Q!I&CRVDTLFI
M,J)(A&U,L%Y_.O,A#G=CU9SY%=EI]8T\M,KZ?=DQRE&_T-CEO7IR.3S4-KXH
MTM8?*M[6_$43F+_CSD W D$9(YY4\^O'6H+-&UU2&_D>*.&Z1D".3+ R @GL
M2,&M"@"*Y_X]9O\ <;^5>51I:;5,DTNXXR%3@<\\YYX]J^=SQ0<X<[[_ *'L
MY4Y<L^5=OU)X!9^= 8VF,OFKPV,=13OB^L33:$)W9(O](W,J[B/]7T%99=R>
MPJ\FWNFV*Y_;T^;?7\CSN--"R/,EU#&/X43K\WOT^Y^OM7I'PE^R>=K0LO.\
MG]Q@S8W$_/Z=*[\+R>UC;?\ X!ABN?V4K[?\$]-HKV#QPHH ** "J5JR-?WQ
M4'<&4,=N.@_6@!T$UXY7S[58U)YPX)'_ -:K= !10!P7C?\ Y#$/_7N/_0FK
MFJ^%S+_>Y^I]5@O]WAZ'7Z+_ ,B+J_\ N3?^BQ7A%>RO]VI>AQ0_C5/4OZ'_
M ,C!IO\ U]1?^ABNT^/7WM ^EQ_[3KV,E_B?UV/*SO\ A_UW1XW7M7P&_P"/
M;7?]^#^3U[^*_A,^?PG\9'L)Z4T$;1G'2O)/8*<MDSYQ?3QYDWC:_P!>/IST
M]A5BVC:&W2.2;S67JY[T /<Y QSR/YT^@"*Y_P"/6;_<;^5>15\UQ!\5/Y_H
M>YE&T_E^I-:?\?L'_71?YU/\9O\ F"?]M_\ VG665_[M5^1MC/\ >*?S/*J]
M6^#/W=:^L/\ [/7?@_XR_KH88S^"_P"NILZE\2_"4A$">(I+62*8%REI*2<9
MROW?\XIMI\3_  A;M/YGB)YU=RZ!K2;*9[9V\BOH_JM7L?.?6J/<[J*5)H4E
MC.4=0RG'4'I3ZYSH"B@ JI;%3?WN% (9,GU.WZ_T% %H]/QI: "B@#@O&_\
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M%!04%!04%!04%!04%!04%!04%!3_P  1" ,X!U,# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDR*,T +129HS0 M%
M)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +
M129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC-
M"T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS
M0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:
M,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)
MFC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +1
M29HS0 M%)FC(H 6BBB@ HHHH **3(]:,T +129HS0 M%)FC- "T4F:,T +12
M9HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T
M4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
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MHP?7]?\ Z])11=@+@^OZ_P#UZ,'U_7_Z])11=@+@^OZ__7HP?7]?_KTE%%V
MN#Z_K_\ 7HP?7]?_ *])11=@+@^OZ_\ UZ,'U_7_ .O24478"X/K^O\ ]>C!
M]?U_^O24478"X/K^O_UZ,'U_7_Z])11=@+@^OZ__ %Z,'U_7_P"O24478"X/
MK^O_ ->C!]?U_P#KTE%%V N#Z_K_ /7HP?7]?_KTE%%V N#Z_K_]>C!]?U_^
MO24478"X/K^O_P!>C!]?U_\ KTE%%V N#Z_K_P#7HP?7]?\ Z])11=@+@^OZ
M_P#UZ,'U_7_Z]&#Z4>M%V 8/K^O_ ->C!]?U_P#KTGI2]P.]%V 8/K^O_P!>
MC!]?U_\ KTE'I1=@+@^OZ_\ UZ,'U_7_ .O24478"X/K^O\ ]>C!]?U_^O24
M478"X/K^O_UZ,'U_7_Z])11=@+@^OZ__ %Z,'U_7_P"O24478"X/K^O_ ->C
M!]?U_P#KTE%%V N#Z_K_ /7HP?7]?_KT4@.<8YHNP%P?7]?_ *]&#Z_K_P#7
MI/X<]O6BB[ 7!]?U_P#KT8/K^O\ ]>DI1STYIZ@&#Z_K_P#7HP?7]?\ Z])G
M//:C^$GMZTKL!<'U_7_Z]&#Z_K_]>DS1UZ478"X/K^O_ ->C!]?U_P#KTE%%
MV N#Z_K_ /7HP?7]?_KTG;/:BB[ 7!]?U_\ KT8/K^O_ ->DHHNP%P?7]?\
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M2BB[ 7!]?U_^O1@^OZ__ %Z2BB[ 7!]?U_\ KT8/K^O_ ->DHHNP%P?7]?\
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M#X\_M!>'?V=_#^G:QXBLM4O;6_N_LD:Z5%%(ZML9LMYDB#&%/0GZ5R'[!_\
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M8RVT-O$%12#(WDHF5W))GOA% (W9"Y6!]O*0W3GZ4H!;@#)ZU\):GXZ_:O\
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M/G0DD]65 RY_VF]:FRUL,_0/6M4AT/1[W4IUD:&S@>YD6( L512Q S@9P.Y
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MY7:XSWRBBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8'BC_EW_P"!?TK
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M@7]L3X%:SXRT72M TR:TUG4;N&PM98M%6$B29A&HW@9 RW..U>(_%.WCN/\
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MT%X5^ FL>++GQ9->1Q:C;V\=N+.W,I+(TA.>1C[RUUW[2GQL'[:7B[P?\/\
MX:Z5J%Q!#<O.]S>)LS(V%\PJI.V.-2Q+-CKVQS]T_P##/OPM_P"B;>$/_!#:
M_P#QNND\,^"O#G@N!H/#WA_2]"A;EX],LX[93^"**IR5[V"Q+X4\/VWA'POI
M&AVQ+VVEV4-E$WW2R1QJ@.![**^*_%L9\/\ _!4#PQ>WA\JVO[)6A;^]NL)K
M=?\ Q]2*^Z*^7_VTOA3KVI3>#OB;X+L+K5?%'A&^BE-A:1&6:YM_,# *J@LQ
M5P,J!]V1ST%3%B9Y)_P53.?^%7X/;4S_ .DE<=_P4$TO4?AC\>O^$FT>8VZ>
M+="DM+DKP)#Y1MIH\CL8C$>>YZ'O^@FJ>#_"OQ2TO2;_ ,2>$]-U=?($UK!K
M^EI+-:^8JLR[)4)C8X4,.#E1GI5OQ9X \,^.X[2/Q+X=T?Q"EJ6, U2PBNA$
M6QN*[P=I.!G'7:/2FI):#L?FY^T1X#'P]_8[^"=@\8BO+RXN-1N2PRQDGC\S
MGW"LBGT"_GZ#^VEX?U?P7\1/A#\7H=-DU#0M'MM.AN?+Z1R6]P9T1C_#OWE0
M?5<?7[A\1_#_ ,+^,+2UL]?\.Z3KMK:G-O#J5A%<1PG &45U(4X ' '2M:;3
M[6XT^2RFM();*1/+-J\8:-EZ %3QCMC'2CF"Q^?_ .UQ^USX0^.WPSL?!/@2
M#4]8U?5KN&65'LV5H@GS! .2SEB!A>,!N?7GOVE?A-XC^"_AKX$>*[VR:]MO
M#%A;VFI);G*V]PD_GA&;T8NR!NF4[9&?T#\/_"_P=X2OWO="\(Z%HMZ^0USI
M^FP02G/7+HH/-;^H6%KJMG-9WMM#>6DJ[)8)XPZ2#W4\$9[8I\W8+'P!^V-^
MUYX%^+WP;B\-^#VO=1O+R>"[O#-9O$ME&CCAB1@L6*#Y,K\WWNQP?CC\/]5\
M4?L-_![7].MI+RWT*"1KT1)N:.*7_EJ0/X5,:YQT#9Z#C[VM?@[X L=*O=,M
M? _AVWTZ^Q]KLXM)MTAGVD,OF($P^&56&>X'I71:7H>FZ'H\&E:;I]KI^F6Z
M[(K*UB6*&)3V5%& .>@%'-V"Q^5NJ6G[+NG_  _L=4L9_%^K^*)HX_-\/QS>
M1Y,AQYF9FMS'M'S8*EB>!QDD>H_M0>#['P7^PYX"LM,TG4]$M)O$D=TNGZW(
MLMW!YL%XP#LJJ.00<8R,X/(K[BL?A'X#TO5_[5L?!/AZTU16WB]@TJWCGSZ^
M8%#9_&M7Q1X-T#QOIZV'B+0]-U^RCD65+?5+6.XC$@!4.$=2 0&89Z\GUHYN
MH6.8^&[7=G\ _#3Z5 DEY#X9M3;0X^5I!:+L7!XQD =AS7YR_ _7OA)XCO/%
MGB7]H'5-5UGQ3;W ^SZ?>-<'S1@EU41X^</\NQBJJ,#&"<?JE9V=MIMG#;6T
M$=M;6Z+%#! @5$C7 55 &     .F*P+CX8^#;SQ#_;UQX1T.;7=P;^U)-.A:
MY#9SN\TKNZ]\TE*UP/A#_@F[;M=ZU\6+:*#R);BPB5+>0X*;FF 4^F,@50_X
M)X_$?P]X3NO%7@76[JXL=<\3W$%M9Q"V<Y8),KACC"D;AUQDU^@VC^!/#'A_
M7K[6M+\.Z7INKWY8W>HVMC%%<W!9M[&215W.2P#').2,U4B^%O@JW\0'78_"
M&A)KID\T:FNF0BY\S.=WF[=V<]\]J.9.X6/RO^&?PY^&/A#QQXH\*?'6?7/#
M6H:>X6TNK!)&1\9!#*L4C$,-K(P&"">>17T%^Q=X9^&>N?&J_P!5\ ^&O%GV
M70XYU37]3OXGM7$BF-5,0B5@[!F*KG.%R>F*^UO%/P]\*^./*_X2/PWH^OF'
MY8CJFGQ7!7D]"ZMCJ?SK2T;0=,\.Z>FGZ1I]MI>G1GY;6T@2&).W"J .PZ#M
M3<[A8^-_%?\ P3.TWQ1XGUC6'\>7,+:C>37AA335(C\R0N5!,H)QNQGOC-9'
M_!3C19;'P#\-S'OFM+.XGM6F5< NT493/H2(V('L?2ONRJ'B#PWH_BK3)=/U
MS2[+6K"0AI+._MTGB;'0E&!4_E4J3O=A8^#?VLM0L_VD/V<_#7C3P&+G5[#P
MC>O9ZHOD,CQ P1%Y I'*K^[R1Q\V>@.-+XD?MY>!O%'[-NH:!IT-])XLU71_
M[*EL)+8A+=G0QR/YA!4@ L5QSG&0.2/MCP[X-\/^#].DT_0="TW1;"0EVM=.
MM([>,MC!)5 %SC'..U9=I\(_ VGZQ_;%MX.\/6VK;MWVZ'2H%GW?WMX3=G\:
M?,@L?(OPK_8QO_B1^RGX7\.>(]5F\,7,NJS:^L?V022HDB")$=&9<$JH;VR
M><UZ5\'OV1]3_9Q\.>.+GP?XL;5?$NK:<J:>;RPC1(;B+>T><NP(9B 2>@.:
M^G"3NR2<#Z?TI*GG; ^"OA5^W19V^EZSX7^/FF75UK-O=Y7?I,3)L( \J2'
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M2S.4)8D]S41=AGB7@7]L3X%:SXRT72M TR:TUG4;N&PM98M%6$B29A&HW@9
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M_A1RL#(S1FM?_A&KK^_#^O\ A1_PC5U_?A_7_"CE8&1FC-:__"-77]^']?\
M"C_A&KK^_#^O^%'*P,C-&:U_^$:NO[\/Z_X4?\(U=?WX?U_PHY6!D9HS6O\
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M6^EV8<%C/<SR".*-% ))+,.>@ +$@ FM^OG+]HCX8Z;'JWACQE>W-YJ^L_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQY;R;=SJB_*@).691P._I7RRW[5'Q>M-!C\677P]L1X08!S<)%,&,98 -O\
M,. >FXICD>M=U\4OBUHGQ&_93UWQ59Z9#J5FWV:.?2]0:142474(*.T3HQVD
MA@589^7/!(K;^RZU.I3557C*2B^5IV?;R?J8_P!J4:M.HZ3M)1<E=-77?S7H
M>V^%/%FE^.?#]KK>B77V[2[L,8)_+>/>%8J3M<!ARI'(K;W#U%?,>F_%:\^&
M_P"R'H7BK0-(TRTG5O*CL76:6V0-<R*<;I3(3U/+GD_A7.-^U%\6M0\#+XQT
M[P'IA\.6T8%WJ,V\AW!P[1IYJL$W97.&QCD]J?\ 95:I*3IV45)Q5VEJOU]!
M?VK2IQBJEW)Q4M$VK/\ 3U/KYI%52Q8!1R23Q6+X;\6Z1XPM[N?1=0AU.WMK
MEK62:W.Y!(H4LH;HV PY&1S[5\Z?$CXP>(_BA^S/)X@\-:+;B"Y6:UUU9I 3
M9QJ/F>(EUW'.TCAC@].*Q_V&=3\9?V1-8II=G)X'-S/*VILP^TBZV1@)CS,X
MP!_!WZT_[+E'"U*]224HNUKKIO\ /LNHO[4C+%4Z%.+<9*][/KM\N[^1]?T4
M45X9[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5"UU 7.I7]L(MIM_+R^?O;E
MST]JOUBZ7_R,>M_]L/\ T T ;5%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?('[;7Q3\+^.&\,Z?X?U2UUF>Q::>>ZM&#I&KA %#C@D[22!TP,]:V/VW?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"/'RXP:DHHH **** "BBB@ HHHH *CVXQ@''I4E
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5BZ7_P C'K?_ &P_] -;58NE_P#(QZW_ -L/_0#0!M4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444F<T +124M !1110 4444 %%%% !1110!@^%ONZQ_P!A&;^E;U8/A;[N
ML?\ 81F_I6]41^% %%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8NE_\C'K?_;#_P!
M-;58NE_\C'K?_;#_ - - &U1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5BZ7_P C'K?_ &P_] -;58NE_P#(
MQZW_ -L/_0#0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;U1'X4 44458!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5BZ7_R,>M_]L/_ $ UM5BZ7_R,
M>M_]L/\ T T ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%TO_D8]
M;_[8?^@&MJL72_\ D8];_P"V'_H!H VJ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P .]6^*_B[Q%#K'B;2M'\$>%!$_E:"DIO=3G9@ C3S#$<0'78@8YX+5ZQ0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA&;^E;U8/A;[NL?]A&;^E;U1'X4 44458!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BZ7_
M ,C'K?\ VP_] -;58NE_\C'K?_;#_P! - &U1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$_%;
MX<Z3\3/"\>GZOJ6H:/!9W4.I1ZAIET+::"6$[E<2$';C&2<?E7SSX@\#_#"V
M\)Z3\1+[XV?$34=&M;R2TT_5['6I;UEN'+0.L0A@9B6*LN0,$=\$5ZK^U4J7
M/PUL+"]D:+P]J7B'2;#6W!VJ+&6\C656;/RH^41CZ.?6NJ\??#H^*=-\)V.E
M&UTJUT36['4Q"L>V/R;=]QB15&!D8 [<4 >4? C1OAYXO\>#7M ^(OC;QEK/
MA^W919>*I[A?L\=R"I=8IX(V(;R\;ER,K@U]*5XOXJ\B/]JSX?G3CG4Y?#NK
M#5!">?L0DMO(,GH!.6"GU+_A[10 4444 %%%% !1110 4444 8/A;[NL?]A&
M;^E;U8/A;[NL?]A&;^E;U1'X4 44458!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BZ7_R,
M>M_]L/\ T UM5BZ7_P C'K?_ &P_] - &U1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_?Y?\: +M%4O[:T__G_M?^_R_P"-']M:?_S_ -K_ -_E_P : +M%4O[:T_\
MY_[7_O\ +_C1_;6G_P#/_:_]_E_QH NT52_MK3_^?^U_[_+_ (T^'4[.XD$<
M5W!+(>BI(I)_ &@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/*^#C(Q7O% !1110 4444 %%%% !1110!@^%ONZQ_P!A&;^E;U8/A;[NL?\
M81F_I6]41^% %%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%)N'K0 M%(&#<@Y%&X<\T +12;AZT9'
MK0 M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !5'6O^0/?_ /7"3_T$U>JCK7_('O\ _KA)_P"@
MF@"GH^DV,FDV+-8VS.T,98^2O)*@D]*N?V+I_P#SXVW_ 'Y7_"C1?^0/8?\
M7"/_ -!%7J */]BZ?_SXVW_?E?\ "C^Q=/\ ^?&V_P"_*_X5>HH H_V+I_\
MSXVW_?E?\*/[%T__ )\;;_ORO^%7J* */]BZ?_SXVW_?E?\ "C^Q=/\ ^?&V
M_P"_*_X5>HH H_V+I_\ SXVW_?E?\*/[%T__ )\;;_ORO^%7J* */]BZ?_SX
MVW_?E?\ "C^Q=/\ ^?&V_P"_*_X5>HH H_V+I_\ SXVW_?E?\*/[%T__ )\;
M;_ORO^%7J* */]BZ?_SXVW_?E?\ "C^Q=/\ ^?&V_P"_*_X5>HH H_V+I_\
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M*** "BDSGIS1D4 +129HR* %HI,T9'K0!A>%ONZQ_P!A&;^E;U8/A;[NL?\
M81F_I6]41^% %%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%4=:_P"0/?\ _7"3_P!!-7JHZU_R![__ *X2?^@F@ T7_D#V'_7"/_T$5>JC
MHO\ R![#_KA'_P"@BKU !117/?\ "Q/"G_0S:/\ ^!\7_P 56%2O2HV]K-1O
MW:1K"E4JW]G%OT5SH:*Y[_A8GA3_ *&;1_\ P/B_^*J2W\>>&;RXB@@\1:3/
M/*P2.*.^B9G8G   ;))/:LEC<*W958_>C1X6NM73?W,W:**2NPYA:**3- "T
M444 %%)FEH **3-% "T4F>U'2@!:**3- "T44F: %HHI,CUH 6BBB@ K%U3_
M )&/1/\ MO\ ^@"MJL75/^1CT3_MO_Z * -JBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *^==-^'.C_ !_^(/Q"E\=W-]JUOH&KC2+#PVNHS6]K
M:0BWAE6X:*)U+R2F1FWOG  "XVU]$Y%?.-[H_@WXL?$KQC#XF:X\!^-M!OA8
MVNH:-K<NF7U_IAAC>&=G1E\V,N\R#[VTH1P<B@#2\->$[/X+?';P]X7\)7]X
MOAWQ!I5[=7GARXO9;J*Q>W: 1W47F,S1!S*8V7.UB00,KS[[7FOPO^'/@7X?
M7EY)X>NO[3US4 !>:I?ZH^H:A=*I) >61V<J-Q.T849SC->E4 %%%% ' _%_
MX@WOP^T'33I.G1:IKFL:G;Z-IL%Q*8H?/F)P\K $A%578X&3MP.2*YW3_''C
MKP?\1O"WASQJN@:O9^)S<6]EJ6@6TUHUM<PP-<&.6*667<C1QR8=6'*@%1G(
MS_VH%_X2;3_!W@&!8X-4\5ZRL-GJ\H;_ (E+6\,ETUU$593YZB+$8R 6;G(R
MIYKQ!X0U;X1_%CX=>*==\5:A\0[:^OE\-0IK<<,<^F37,;?Z3;"W2./YO+V/
MO0OL;A^&# '8GQQ\0/B#XF\3P>!1X=TS1/#]\=*:\\06UQ=/J%TBJTZQK%+'
MY2(6";SO)96^7CG.;]H'5-6^&^B7NFZ/;67C;5/$)\)OIU\[R6UEJ$;RB=G*
M -)&B022#&"PV\KDD:7[,[I_8?CRW$8CGA\=:^)EXSE[V25"<>L<D9Y[$5QO
M@#P%'\4- \?OI]^=$O;/XCWVJ:/JD<"3+%<P&.(R%"0)$9EF1AD$AFY!Y !Z
M%X.^)FI6.L>.M$\<3Z9%<^$[6WU.?6-.A>WM9;*9)660Q/)(T;*;>8,N]QA5
M(/.!U'PUUS6/%'@^RUG6;./3)]0+W4%C&A5[>W=BT*2Y8YE\O:7Q@!B0!QD^
M!>./#E]I/B#Q2=5U*+Q7J'V"+Q+XMEM;4V=J+&Q25M.TV.,R2,BRS":1MSN6
M5)0>'45UGA+Q1XV\.^(_A8VO>)V\2VOCJ*9+NTDLH((["X%E)>(;9HD5O+"Q
M/&5E:1CE3N'(H ]>\+?=UC_L(S?TK>K!\+?=UC_L(S?TK>J(_"@"BBBK ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI-P
M]11F@!:*3-&: %KR?XH_LL_"SXS:P-5\8>#K75=4*K&UY'+-;3.H&%#O"Z%L
M#@;LXP!Z5ZOFC- ',^ ?AMX8^%N@1Z+X2T*ST#2U.XV]E'MW-@#<[=7;  W,
M2<#&:QO&_P "? _Q&\:>'/%GB+0CJ/B#P[+'/I=X+R>+[.R2K*IV)(JM\Z@X
M92#C!XXKO\T9H 0C<.?TKD_A[\*_"WPK\.W&A^&-*_L_3+FXENYXI)I+AIII
M,>8\CRLSNQP/O$^E=;FC- 'D'@O]DGX1_#OQL?%OAWP/8:9KZDM'<J\KI"2"
M,Q1,Y2,X[HHZU[!29HS0 M%)FC- "T4F:-P]10 M%%% !1110 4444 %8/C;
MQIHWP[\+:EXB\0W9L-&TZ+SKNY\IY/+3IG:@+'GT!-;U9VM:#I_B72[G3=7L
M+75--NE\N>SO(5FAE7(^5D8$,,CH10!X%_P\+_9]/(\?Y'_8&U#_ .,5Z?:_
M'/P'=_"^#XA_\)+:P>#;B,O%JMT'MU<!V3&V15?=N5@!C)QP*^-_VIOASX+\
M>_'+P1\"/ '@SPSX<O;YUU'7]:TO1;>&XM;50S[$=4!4[%=SR-Q:)<_,09O^
M"CW@6#P/\,?A)IVE:;);_#;0=1:WU"SM=Q1%VQB+=R,DJ+@;B>6?KD\NP'U3
M\,?VI?A9\9M:DTCP?XQM-6U.-2WV-H9;>1U R2BS(AD ')*YQ3/B)^U3\*/A
M+XJC\->*O&-II&ML%/V4P32^5OP5\PQHRQY!!^<C@@]*^"OVBOB9\*(/CU\$
MM;^"1TVVO=/NH_[0ET6S-K T9EA$,;#:N6VF=6!&=K*#VQU7QH^&WCKPI\0?
MC]IB_#+7?&W_  L4VYT/7-.LOM,-GARY#N/]4!N"\XYC7MS18#[Z\:_$_P +
M?#WP5+XN\0:Q#9>'(UB?[<JM.KB1E$>P1AF<L67 4'KFNCM;I+RUBGCW>3,B
MR)YB,C8(R,JP!!]B 0:^!K'5--75/ 7A/X@:Q:Z=\/O@KIMA/XDN)',D%SKQ
MBQ;VBA0?.\H!CA0?NN"*^QOA/\</ WQQTFZU'P/XA@UVUM'$=QY<<D,D)(.W
M?'(JNH.#@D8.#CI0!WE%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCK7_('O_P#KA)_Z
M":O51UK_ ) ]_P#]<)/_ $$T &B_\@>P_P"N$?\ Z"*O51T7_D#V'_7"/_T$
M5>H *_/FOT&K\^:_%/$C_F$_[?\ _;#]/X)_YB/^W?\ VX*WOAY_R4#PO_V$
M[7_T:M8-;WP\_P"2@>%_^PG:_P#HU:_(L#_O=+_%'\T?HF*_@5/\+_(^Z*X#
MXQ_'#P5^S_X3C\3>/-7DT/0Y+I+,7:V-Q=A9F#,JL((W900C?,0!G SD@'OZ
M\P_:4^#=K\?O@=XO\"W2IYNJV+I:2R#*PW2X>"3Z+(J'Z CO7]D'\V&A\0?C
MGX%^%GPU7X@^)O$$6G>$72"2/4EAEG$BS$>442-&=MVX'A3@9)P 36%XT_:L
M^%'PY\ Z%XS\2^,[31= UZU2\TR2ZAF%Q=PNJNKI;;/.(VLI/R9&X9ZU^5'@
M7QGXA_:Z\-_L_P#[+^H1W5K-X:UF[3Q/YJE66TM,B('&-IC@:>(<\N$Z'K[1
M\8K3PE8?\%7-'M_C%%I</P_BT.WC\.1ZRJC3E M<() _[L*+C[1@-QNV9[4
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M>^_X(Z_ F2XE>9QXOFC5G;)"(^KJBY] J@#V%>G_ /!2KX2^#? O[#/PBN]
M\,Z7I%]!J>GVJW=G:I'*8Y=.N))59U +%WC1F)R25R3GJ ?JI165X99I/#>D
ML[EV:TB)=NIR@Y/OFM6@ K%U3_D8]$_[;_\ H K:K%U3_D8]$_[;_P#H H V
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %4=:_Y ]__ -<)/_035ZJ.M?\ ('O_ /KA)_Z": #1?^0/8?\
M7"/_ -!%7JHZ+_R![#_KA'_Z"*O4 %?#7_"N_%?_ $+.L?\ @!+_ /$U]RT5
M\AQ!PY2X@]E[6HX\E]DM;V_R/HLGSJIE'M.2"ESVW\K_ .9\-?\ "N_%?_0L
MZQ_X 2__ !-;7@3P'XFL_''AR>?P[JT$$6HVSR2R6,JJBB52225P !WK[+HK
MY>CX>X6C5C55>7NM/9=#WJG&%>I"4'26J:W?4***KW^H6NEV%Q?7MS#9V5M&
MTT]S<2!(XHU&6=F)PJ@ DD\ "OU<_/SS3P;^S+\,_ 'Q4U_XD^'_  K#IWC7
M7A,-1U1;F=S-YKK)*1&SF-"SJI)102?J<W?C%^SW\.OC]I$&G?$#PI9>)+:W
M),#S;XYX,XW>7-&RR)G SM89P*Q='_:R^%>N:MI^GVWB9XSJ-PMK87UWIEY;
M6-Y*YPB0WDL2P2EC]T)(=W;-=G\0OBEX7^%>D0:CXGU9=,MKF<6MLBQ23SW,
MQ!(BAAC5I)7(4G:BDX!XH YCX,?LQ_"W]GO[6WP_\&V/AZ>Z41S72/)/<2(#
MD*9I7=]N>=N[' XX%3_#W]G/X>_"OQ]XM\9^%?#W]E>)/%<TESK%]]MN9C=2
M/*TKMLDD9$R[LV$"CG XK4^&_P :/!WQ::_C\,:N;N\T\I]LT^[M9[*\MMV=
MIDMYT25 V#@LH!P<5W&10!YS\._V>_ /PG\9>+_%?A303I6O^+KIKS6KO[9<
M3?:I3(\I;9)(RI\\KG"!1\V,8 KS[Q)_P3]_9\\7>+9?$>I_##3)-4ED,LAM
MY[BW@D<G)9H(I%B.2<G*<U]#Y!Z&C('4T ?'7_!2;X5:CK7[&TWA'X?^$KO4
M7MK^P2TT/P[IK3&*%'_@AB4X51Z# J3X*?L!?!?7?AC\+O$7C'X5V?\ PFD/
MAG2AJ,=]]H@_TE+2(2"XM-XC:3<"'$B$DYW<U]@Y'K1N!Z&@#S#XN?LU_#CX
M[6_AV#QOX936(/#\AFTR*.[N+5;9B$!P()$!&$7 .0,<5VOB[P?HOC[PU?\
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MZYXK\_\ XF?M3?M8_!OPJWB+QA\-O VBZ2LJ6_GO.)-SMG:JHFH,S'ACA02
MI/05[%>?$[]H[5/@/X$\1^%_A_X?OO'&JF675]*O";>"T@+,;=D62Z1@Q386
M4LQ!)X7H&!]/;AZT9K\^M4_:\_:A\+_%#PUX#UWX>>#+3Q%K<B&#3[4/<R^2
M6PTC>5?.(U #'<^!\C'H#7>_&+]L#X@Z5\0OB'I'PZ\-Z#J&A_#RSCN]=O-:
MDE\V7(RR0!&4 CD?-G[K'T! /LC<#T.:*^<_&7[5-P/@+X(\5^$M)CNO&?CI
MK:UT'0[TF1/M,A'F&0H58Q1C=EAC^#[N:^@--6\73[0:A)#+?K$GVB2U5DB:
M3 W%%8DA2<X!).,<GK2 NT444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>2^)_
MVJ_A)X-U^]T/6O'6EZ=JUE+Y-S9S.V^-P.APIKUJOG+P_P"-/!WPP^,WC^7X
MC7NG^'/$VJ:@)M)UO7'6"&YTL01K%%!<N0BA'$P:,$'<Q8@[@2 ==HO[6_P9
M\07R65E\1_#[7,C"-$FNQ%N8G 4%]H))[5ZZKK(H96#*>00<@U\QZIXL^'WC
M[XJW.N^'TLO$'@^PT.^3QGJ5C;&ZTZ]4F,VT)* K<S*1,PVAF56(R-X!]7_9
MXTO5]'^!O@FQUN&>WU*WTR%'@N23+"H'R1OGD,J;5())!4C)I@>CT444@"BB
MB@ HHHH **** ,'PM]W6/^PC-_2MZL'PM]W6/^PC-_2MZHC\* ****L HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&_P!J
M+_DG^G_]A-/_ $5-7R[7U%^U%_R3_3_^PFG_ **FKY=K^;>._P#D<R_PQ/VS
MA/\ Y%B_Q,****_/#[$**** "BBB@ HHHH **** "BBB@ KZB_9=_P"2?ZA_
MV$W_ /14-?+M?47[+O\ R3_4/^PF_P#Z*AK]#X$_Y',?\,CX[BS_ )%C_P 2
M/9****_I(_$PKY\^*7[:/@CX2^.M3\*ZQI6O7&I:=Y7FRV5O \+>9&D@VEIE
M/ =<Y4<Y^M?0=?E9^VQ_R<YXT_[<O_2*WKPLXQE7!4(U*6[=OP9[>482EC*[
MIUMDK_BCZG_X>-?#7_H!^*__  $MO_DBC_AXU\-?^@'XK_\  2V_^2*_.?GU
MHY]:^1_M[&]U]Q]A_8."[/[S]&/^'C7PU_Z ?BO_ ,!+;_Y(H_X>-?#7_H!^
M*_\ P$MO_DBOSGY]:.?6C^WL;W7W!_8."[/[S]&/^'C7PU_Z ?BO_P !+;_Y
M(H_X>-?#7_H!^*__  $MO_DBOSGY]:.?6C^WL;W7W!_8."[/[S]&/^'C7PU_
MZ ?BO_P$MO\ Y(H_X>-?#7_H!^*__ 2V_P#DBOSGY]:.?6C^WL;W7W!_8."[
M/[S]&/\ AXU\-?\ H!^*_P#P$MO_ )(H_P"'C7PU_P"@'XK_ / 2V_\ DBOS
MGY]:.?6C^WL;W7W!_8."[/[S]&/^'C7PU_Z ?BO_ ,!+;_Y(H_X>-?#7_H!^
M*_\ P$MO_DBOSGY]:.?6C^WL;W7W!_8."[/[S]&/^'C7PU_Z ?BO_P !+;_Y
M(H_X>-?#7_H!^*__  $MO_DBOSGY]:.?6C^WL;W7W!_8."[/[S]Q****_2S\
MT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%8'B[X@>%_ %O;W'BCQ)I'AN"X<QPRZO?Q6JRL!DJID8
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M7_B#5;FZENI 2TBHWDJ"W?!C<_5FIH#Q#]MJ2X\=?MF>'M'E\!:M\1-(T/1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV("JJB3)))  '4F@#T"BL'Q5X]\,^!+>*X\2^(M)\/02MMCEU6^BM5<^@,C
M$U=T#Q)I/BO3(M1T35++6-/E_P!7=Z?<)/$_T="0?SH T:*YO0OB7X0\4:U=
M:/HWBK1-7U:TS]HL+'489YX<'!WQJQ9<'U%7[[Q7HFF:YIVBWFL:?::SJ0=K
M+3Y[I$N+H(,N8HR=S[1R=H.!UH U:*** "BBB@ HHHH **** "BBB@ HHHH
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MZU.LN:G)27D[G/4I5*+Y:D7%^:L%%%%:F04444 %%%% !1110 4444 %%%%
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MUSPW>:9;6ML&#O% C6\<,08JA;+%F*+R<8KZ*H **** "BBB@ HHHH ****
M,'PM]W6/^PC-_2MZL'PM]W6/^PC-_2MZHC\* ****L HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&_VHO^2?Z?_P!A-/\
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MX!R<9H .?6CGUH_&CTYZ]* #GUHY]:.?7WH].>O2@ Y]:.?6@?,,@Y%'7O0
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M- 'ZE6_BS1+SP^VO6^L:?/H:PM<MJ<=TC6PB4$M(90=NT $ELX %<G)^T/\
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MX[_Y$TO\43['A/\ Y&:_PL\>HHHK^;3]L"BBB@ HHHH **** "BBB@ HHHH
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M0!=\+?=UC_L(S?TK>K!\+?=UC_L(S?TK>J(_"@"BBBK **** "BBB@ HHHH
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MW9O1HPH05.DK170*^HOV7?\ DG^H?]A-_P#T5#7R[7U%^R[_ ,D_U#_L)O\
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M0?%#_A7VF^#=$\-^&=9M'O\ 1+W1%$;SR0"(7$-RFT'S 9 ROD@IQP5Y]FI
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MPL(SG=\VUE=O2]_1+4\=]/?I1TZ\5W:_!W5[OQUJ7AZT\N4V$B^=>LVQ(XG
M*N?JI!P,]Q[U)\5/AS8^"/&&F:-IUW(\=W:Q2-/?2(J!VD="V0!M4!0?;G)J
MI9/C:=">(G3M&,N5W_FO:R[V:L_,F.986=6%&$[RDN;3M:]WVNM4<!D<>_2C
MKCWX%>XV/P9\%ZMJ,_AW3_$E[=^(H+;SVD0*;7=A>F%Z?,O 8]>I(KD_!/PV
MTV[\-ZGXB\57MQI^DV,OV41V:AI))> <$@C ) X!SSR *[)\/8V$XP?*[\VJ
MDFER_%S.]ERWU_ YHYSA91E+72VEG=\WPV76YYT/FZ<T5ZQ9_"WPSJ/CO2;;
M2/$=GJ.BS(MP\,\Y6X**06C^1>I7/]T@9],G%^*WA+2O"JZ$FER6LTMW"\\I
MM[AY"59]T; -T780%(Z[3GU.-;),50P]3$S<>6#MI).^VUKW^)/[S2GFN'K5
MH4(I\TE?:UM][^AP-?47[+O_ "3_ %#_ +";_P#HJ&OEVOJ+]EW_ ))_J'_8
M3?\ ]%0U])P)_P CF/\ AD>-Q9_R+'_B1[)1117])'XF%?E9^VQ_R<YXT_[<
MO_2*WK]4Z_*S]MC_ ).<\:?]N7_I%;U\KQ'_ +I'_$OR9]1P[_O<O\+_ #1X
M=SZUZ+\&?CEKOP-U+5;S0;33KN34;?[+*-2BDD4+G.5V.AS^)KSKGUHY]:_/
MZ=2=*:G3=FC]!J4X5HN$U=,.?6CGUHY]:.?6H- Y]:.?6CGUHY]: #GUHY]:
M.?6CGUH .?6CGUHY]:.?6@ Y]:.?6CGUHY]: #GUHY]:-W^U0.5R#D>M(#]Q
M****_;C\2"BBB@#^>&BBBOUL_' HHHH **** "BBB@ HHHH **** "BBB@#Z
M)_X)]_\ )W?@/_M__P#3?<U^RM?C5_P3[_Y.[\!_]O\ _P"F^YK]E:^&SW_>
M8_X?U9]]D'^ZR_Q?H@HHHKYT^E"BBB@ HHHH **** "J.M?\@>__ .N$G_H)
MJ]5'6O\ D#W_ /UPD_\ 030 :+_R![#_ *X1_P#H(J]5'1?^0/8?]<(__015
MZ@ HHHH **** "BBB@#X^^/'PY\06?Q@^"OB[Q3XMEUN\F^(L-CIFDV<'V73
MM-LWLKY]HCW,9IF\J/=,YSP0BQJ2#W_[4L:^,/$7P?\ AQ<[I=&\6^*&.K6V
M<)=V=G9W%XUNX[H[PQ;EZ,JD'K4O[51'_"2?L_\ /_-2K3_TVZC4G[4.DW^E
MWGPU^(VGV%QJ2>!?$7V_4[>SC:6<:=<6TUK=21QJ"7,:S+(5 R51\>A ,3]J
M;PSI7@-?AKX^T'3;/2]?\/\ BS2;!+BS@6)I;"\N4L[FT8J!F-DFW!3P&C4]
MJ^E*^4_BO\5/#'[35[X'\!_#?68/%C-XFT[6-<OM,!EM]*L+*=;ES-)C;'([
MQQQ)&?F)<G&%-?5E 'QY\*?CY\?OC9\';GQ]H&B>!='MK/[8D5OJ<5Y(^LO;
MRR(_D[)0+9/W90,YE)=6)51BK5G^T;\9/$/P'D^.6G^&O"6E>"K?2Y-=/A74
M7N9=5NK")&>607:,L43LB,Z(87!!4%@2<=1^QZHC_8O\/@ ;?L>J' &.MW<G
M_)KD/#?_ "BCD_[)-=?^FN2@#T_QQ\<->U;QAX5\#_#2RTV\\3ZYHQ\17%_K
MP?['I&F[E1)I(HV5Y9))&VI&K*#L<EU"\XOA_P",7Q.\/_M!>%/A?XYTCP_*
MFL:?J&IQ>(]#CFBM[N. 1 1I#)*S0RHS_.I,@97C*L#N%<C%KT7P3^*O@3XD
M>)@]MX$USX>6'ARZUI8F>#2KNWE:YB:Y8 ^7%*EQ(HD/RAH@&(W U))\;M#^
M+7[9'PC@\*[]5\-V>B^('3Q##$?L=Y.4M-\5O*1^]$:["S)E<RJ,DJP !]:T
M444 %%%% !1110 4444 %%%% !6+JG_(QZ)_VW_] %;58NJ?\C'HG_;?_P!
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M%%?5'RX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QO\
M:B_Y)_I__833_P!%35\NU]1?M1?\D_T__L)I_P"BIJ^7:_FWCO\ Y',O\,3]
MLX3_ .18O\3/JWXA>+O$7AWQ5X;MM%TE;BVO41+B;[.7,@WX\LL/N@ D_P#
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MW3S7#&2>5FDDE9LEF/)9O4GK6IXD\6ZMXNU"*\U>Y^U744*VZ.J(F%#$@#:
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MZ<T?C0 <^M'/K1UY!XI<$]* $Y]:.?6@<XP<YY%'X^U(#W']B?\ Y.<\%_\
M;[_Z17%?JG7Y6?L3_P#)SG@O_M]_](KBOU3K]$X<_P!TE_B?Y(_.N(?][C_A
M7YL****^J/EPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH P?"WW=8_[",W]*WJP?"WW=8_[",W]*WJB/PH HHHJP"BBB@ HHHH ****
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M_P#3?<U^RM?#9[_O,?\ #^K/OL@_W67^+]$%%%%?.GTH4444 %%%% !1110
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M6_FD4+1249'K0 M%)N'K1N!Z$&@!:*3<#T-&: %HHI,T +1249% "T4F:,T
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M[Q7*YI2YFN:22;EII>SUMIVB=7$T\/456JW:M9OF4&URK1-M*.NMKKU*VH?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M #GUHY]:.?6CGUH .?6CGUHY]:.?6@#]Q****_;3\2"BBB@#^>&BBBOUL_'
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M?M-_MI:1^SWXJT#P/HOA;4_B+\2==02V'AG2&",8R64/))M;8"4?&$8X1B<
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M(R21_%ZT=P>%Y^8@<G_([T<^M'/K0%@^4K@CA>F,BD/H._&<=/>EY]:.?6@
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M<(__ $$5>JCHO_('L/\ KA'_ .@BKU !7PC\1/\ @F"_C[XA>)?$_P#PLLV
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MCGUHY]: #GUHY]:.?6CGUH .?6CGUHY]:.?6@ Y]:.?6CGUHY]: /<?V)_\
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MA&;^E;U1'X4 44458!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >-_M1?\ )/\ 3_\ L)I_Z*FKY=KZB_:B_P"2?Z?_ -A-
M/_14U?+M?S;QW_R.9?X8G[9PG_R+%_B84445^>'V(4444 %%%% !1110 444
M4 %%%% !7U%^R[_R3_4/^PF__HJ&OEVOJ+]EW_DG^H?]A-__ $5#7Z'P)_R.
M8_X9'QW%G_(L?^)'LE%%%?TD?B85^5G[;'_)SGC3_MR_](K>OU3K\K/VV/\
MDYSQI_VY?^D5O7RO$?\ ND?\2_)GU'#O^]R_PO\ -'AW/K1SZT<^M'/K7YX?
MHH<^M'/K1SZT<^M !SZT<^M'/K1SZT '/K1SZT<^M'/K0 <^M'/K1SZT<^M
M!SZT<^M'/K1SZT '/K1SZT<^M'/K0!^XE%%%?MI^)!1110!_/#1117ZV?C@4
M444 %%%% !1110 4444 %%%% !1110!]$_\ !/O_ ).[\!_]O_\ Z;[FOV5K
M\:O^"??_ "=WX#_[?_\ TWW-?LK7PV>_[S'_  _JS[[(/]UE_B_1!1117SI]
M*%%%% !1110 4444 %4=:_Y ]_\ ]<)/_035ZJ.M?\@>_P#^N$G_ *": #1?
M^0/8?]<(_P#T$5>JCHO_ "![#_KA'_Z"*O4 %%%% !1110 4444 ?-'[0'@O
M0?!6O? N#0=&L=(2]^*D%]<K8P+$;BXDT_4FDFD(Y=V)R6.2:[C]H[X9^+?B
MGX>\)V'A#4M)TFZTWQ+8:Q<W&L1R31+#;%Y%*1)CS)%F$#!69%.TY88P;WQJ
M^%^J?$C5_AA=:=<6L,7A?Q=!K]X+IW4R6Z6EW"4C"JV7W7"8#;1@-SP ;7QH
M^'&N>.M*T>]\*:^OASQ;H.HIJ>FW5PCR6DS!622VN8T92\,J.RG!RI*L.5%
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M=2Q1%Q"H"Y#,P!]?4444 %%%% !1110 4444 %%%% !6+JG_ ",>B?\ ;?\
M] %;58NJ?\C'HG_;?_T 4 ;5%%% !1110 4444 %%%% !1110 4444 %%%%
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MH4\W*XX_NXQP?V7H ****0!1110 4444 %%%% !1110 4444 %%%% !1110
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MM?S;QW_R.9?X8G[9PG_R+%_B84445^>'V(4444 %%%% !1110 4444 %%%%
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MHG_;?_T 4 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !7RU^U)_R/\
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MYE]YZ)6+XF\'Z#XVTTZ=XBT/3M?L"=YM=5M$N8MV",['!&<$BN5_X:-^$_\
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M ,'PM]W6/^PC-_2MZL'PM]W6/^PC-_2MZHC\* ****L HHHH **** "BBB@
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M&SW_ 'F/^']6??9!_NLO\7Z(****^=/I0HHHH **** "BBB@ JCK?_('O_\
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M_P O^-)_8NG_ //C;?\ ?E?\*/[%T_\ Y\;;_ORO^% "_P!M:?\ \_\ :_\
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MIT.EV=K(KPV<,3CH\<:J1QCK]* +E%%% !1110 4444 %%%% !1110 4444
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M7[:?B04444 ?SPT445^MGXX%%%% !1110 4444 %%%% !1110 4444 ?1/\
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M %%%% 'Z#4445_:I_,04444 ?AWSZT<^M'/K1SZU^)'[:'/K1SZT<^M'/K0
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M*_6S\<"BBB@ HHHH **** "BBB@ HHHH **** /HG_@GW_R=WX#_ .W_ /\
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M/SKB'_>X_P"%?FPHHHKZH^7/G?\ X*!_\FB^/?\ MP_].%M7XTU^RW_!0/\
MY-%\>_\ ;A_Z<+:OQIK[C(O]VE_B?Y(^!S__ 'J/^%?FPHHHKZ,^:"BBB@ H
MHHH **** "BBB@ HHHH *_0__@DC_P U4_[A7_MY7YX5^A__  21_P":J?\
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M'K?_ &P_] -;58NE_P#(QZW_ -L/_0#0!M4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RU^U)_R/\
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M_P#V$T_]%35\NU_-O'?_ ".9?X8G[9PG_P BQ?XF%%%%?GA]B%%%% !1110
M4444 %%%% !1110 5]1?LN_\D_U#_L)O_P"BH:^7:^HOV7?^2?ZA_P!A-_\
MT5#7Z'P)_P CF/\ AD?'<6?\BQ_XD>R4445_21^)A7Y6?ML?\G.>-/\ MR_]
M(K>OU3K\K/VV/^3G/&G_ &Y?^D5O7RO$?^Z1_P 2_)GU'#O^]R_PO\T>'<^M
M'/K1SZT<^M?GA^BASZT<^M'/K1SZT '/K1SZT<^M'/K0 <^M'/K1SZT<^M !
MSZT<^M'/K1SZT '/K1SZT<^M'/K0 <^M'/K1SZT<^M '[B4445^VGXD%%%%
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MHHK];/QP**** "BBB@ HHHH **** "BBB@ HHHH ^B?^"??_ "=WX#_[?_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,CQ-XFTOP;H-]K>N7\&EZ38Q-/<W=P^U(T'4D_E
MTY)( ZUX)\._&GPO\>_%771HNNZ_I\_BVRD>Z\,:M82V-CJY$:1FZ@6>%6,G
ME* WEL-RX9E.,UT/[6.H:5IO@GPI-KMS!9Z GB[2'U![E]D/DI.)#YG;:"JD
MYX^6N#^.W[1GPE\0GP!<6/COP_?7>E^+=.O3)#>H7MX0[)-)D'A=C$-VP: /
M3?AO\ [OP7XETO5-8\::EXM@T"QDTS0+.]MXHA86[[ Q=XP#/)LC1-[=@>,D
MFO8*\^\&_'[X<?$+6UT?PUXUT77=39&<6EC=++(57J0!U KT&@ HHHH X/XK
M^!=8\8:?H]UX;U<:-XBT/4$U*QEGWFVG(5D>WN%0@M%(CLIQR#M8=,5S5MX"
M\=^//%?AO4OB WA_3M)\.W)U&UTCP]<3W/VJ\",D4LTLL<9"1AW81JIRQ!+?
M*!7L-% 'C"^ OB#\/?$_B2?P&WAS4]"\0:BVJRV7B&>XMY-/NI%43-$T4<@E
M1V4/L;9AF;YN>.N^#_P[;X8^#$TRYO?[4U>ZN[C4M3U!8R@NKRXE:65PN3M7
M+;5&3A57D]:[FB@#RO1_AS?>*U\>ZEXKADL;_P 3Q3:/#;I(CO9:6@DCA4,"
MRAWWR3-@GF15_@%8_A'X6^-IO$'@"3Q;<:&NG^!X9A9RZ/)*\NI3-;-:K+*C
MQJ+<"*1\QJ\F68'< ,5[910!@^%ONZQ_V$9OZ5O5@^%ONZQ_V$9OZ5O5$?A0
M!1115@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!XW^U%_R3_3_ /L)I_Z*FKY=KZA_:B/_ !0&GCO_ &G'_P"BIJ^7J_FW
MCO\ Y',O\,3]LX3_ .18O\3"BBBOSP^Q"BBB@ HHHH **** "BBB@ HHHH *
M^HOV7?\ DG^H?]A-_P#T5#7R[7U#^RZ1_P (!J SS_:<G_HJ&OT/@3_D<Q_P
MR/CN+/\ D6/_ !(]EHHHK^DC\3"ORL_;8_Y.<\:?]N7_ *16]?JG7Y5_ML?\
MG.>-/?[%C_P"MZ^5XC_W2/\ B7Y,^HX=_P![E_A?YH\/Y]:.?6C\:/QK\\/T
M4.?6CGUH_&C\: #GUHY]:/QH_&@ Y]:.?6C\:/QH .?6CGUH_&C\: #GUHY]
M:/QH_&@ Y]:.?6C\:/QH _<2BBBOVT_$@HHHH _GAHHHK];/QP**** "BBB@
M HHHH **** "BBB@ HHHH ^B?^"??_)W?@/_ +?_ /TWW-?LK7XU?\$^_E_:
MZ\!D\#_3O_3?<U^RM?#9[_O,?\/ZL^^R#_=9?XOT04445\Z?2A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BZ7_ ,C'K?\ VP_]
M -;58NE_\C'K?_;#_P! - &U1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %?+7[4G_(_Z=_V"T_]&RU]
M2U\M?M1G/C[3\'_F%Q_^C9J_/.._^1-+_%$^QX3_ .1FO\+/'J***_FT_; H
MHHH **** "BBB@ HHHH **** "BBB@#]!J***_M4_F(**** /P[Y]:.?6C\:
M/QK\2/VT.?6CGUH_&C\: #GUHY]:/QH_&@ Y]:.?6C\:/QH .?6CGUH_&C\:
M #GUHY]:/QH_&@ Y]:.?6C\:/QH ]Q_8G_Y.<\%_]OO_ *17%?JG7Y5_L2G/
M[3G@O'/_ !^_^D5Q7ZJ5^A\.?[I+_$_R1^=<1?[W'_"OS84445]4?+GSO_P4
M#_Y-%\>_]N'_ *<+:OQIK]E?^"@1!_9%\>8.?^/#_P!.%M7XU5]SD7^[2_Q/
M\D? Y_\ [U'_  K\V%%%%?1'S04444 %%%% !1110 4444 %%%% !7Z'_P#!
M)'_FJG_<*_\ ;ROSPK]#_P#@DC_S53_N%?\ MY7D9M_N<_E^:/9R?_?J?S_)
MGZ'T445^=GZ4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^1/_ *U',@-[-&:P?^$J_P"G7_R)_P#6H_X2K_IU_P#(G_UJ.9 ;V:,U@_\
M"5?].O\ Y$_^M1_PE7_3K_Y$_P#K4<R WLT9K!_X2K_IU_\ (G_UJ/\ A*O^
MG7_R)_\ 6HYD!O9HS6#_ ,)5_P!.O_D3_P"M1_PE7_3K_P"1/_K4<R WLT9K
M!_X2K_IU_P#(G_UJ/^$J_P"G7_R)_P#6HYD!O9HS6#_PE7_3K_Y$_P#K4?\
M"5?].O\ Y$_^M1S(#>S1FL'_ (2K_IU_\B?_ %J/^$J_Z=?_ ")_]:CF0&]F
MC-8/_"5?].O_ )$_^M1_PE7_ $Z_^1/_ *U',@-[-&:P?^$J_P"G7_R)_P#6
MH_X2K_IU_P#(G_UJ.9 ;V:,U@_\ "5?].O\ Y$_^M1_PE7_3K_Y$_P#K4<R
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M_P#&Z/\ A17PV_Z)YX4_\$MM_P#&ZW/^$J_Z=?\ R)_]:C_A*O\ IU_\B?\
MUJ/94?Y5]R#V]7^9_>S>S1FL'_A*O^G7_P B?_6H_P"$J_Z=?_(G_P!:NCF1
M@;V:,U@_\)5_TZ_^1/\ ZU'_  E7_3K_ .1/_K4<R YG_AG/X3_]$Q\&_P#A
M/VG_ ,;H_P"&<_A/_P!$Q\&_^$_:?_&ZZ;_A*O\ IU_\B?\ UJ/^$J_Z=?\
MR)_]:M?K%3^=_>8^QI?RK[CF?^&<_A/_ -$Q\&_^$_:?_&Z/^&<_A/\ ]$Q\
M&_\ A/VG_P ;KIO^$J_Z=?\ R)_]:C_A*O\ IU_\B?\ UJ/K%3^=_>'L:7\J
M^XYG_AG/X3_]$Q\&_P#A/VG_ ,;H_P"&<_A/_P!$Q\&_^$_:?_&ZZ;_A*O\
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MU+A.=-\T'9^14_X5SX3_ .A7T;_P7Q?_ !-'_"N?"?\ T*^C?^"^+_XFK?\
MPDUI_<F_(?XT?\)-:?W)OR'^-<WU/!_\^H_^ HW^M8C_ )^2^]E3_A7/A/\
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M ,31_P *Y\)_]"OHW_@OB_\ B:M_\)-:?W)OR'^-'_"36G]R;\A_C1]3P?\
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M\A_C6'L:/\J^Y&_MZO\ ,_O9SO\ PHGX;?\ 1//"O_@EMO\ XW1_PHGX;?\
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M=2TGP9H&E:C!N\F\LM,@AFCW JVUE4$9!(.#R":Z^L?_ (2:T_N3?D/\:/\
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M% !1110 5O\ A7_EX_X#_6L"M_PK_P O'_ ?ZU<=R6;]8NE_\C'K?_;#_P!
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M@ HHHH **** "BBB@ HHW#&<\4H^;IS0 E%&>GOTI'D6.-G=@J+U9C@#'6F
MM'O7DUQ^TAHBZ=<:S9^'?$VI>$[1F\WQ/9V2/8A$8AYDS()9(P0?WD<;+P3D
MBNK\<?$W3O!FCZ5?);7WB&35KF.WT^QT81/-=LZ/(-F^1%*B-'8DL.%/TIV
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MKK_"?BW3?&WAK2]>T>Y%WI>H0+<6\V""58'J#R&X((/0C%%@-6BBBI ****
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M?#_PSX8U:YT/5]>\0QA[RU8YBM8(I9YR0#AA\B#:V5;.&!'!SHM#N?AW\;/
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M2C#T8_2BX'B_CSXS1:#^SSJ]IIOA#Q!97]GH$EH]MJFBSV5I8E8?*PTSJ(I
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M%&G1%4  #V  _*D!+11168!1110 4444 %%%% !1110 4444 %%%% !1110
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MT<K H[3Z4;3Z5>_L&^_YX?\ CRT?V#??\\/_ !Y:.5@4=I]*-I]*O?V#??\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+I?\ R,>M_P#;#_T
MUM5BZ7_R,>M_]L/_ $ T ;5%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8NED?\)%K9[?N
M/_0#6U5>*TBAN)IUCQ+-M\Q_[V!@4 6**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3</6@!
M:*** "BBB@ HHHH ***0,#T.: %HHHH ***3- "T444 %%%% !1110 4444
M%%)2T %%)1F@!:*2EH **** "BDW#UHW#UH 6BDW ]Z6@ HI*6@ HI*,CUH
M6BBB@ HHHH **** "BBDS0 M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S7CCQG;^!
M]%?4KF"2>($)F,$J">FXJ"0#T!P>3VZUTM5;JQM[Y46X@CG56WJLB!PK#C<,
MC@X)'XF@#('C;1(]/@N;W4+;2EFC698=0F2%PC$A25)Z'!QZX-;=I>V]_;QS
MVT\=S!(NY)87#*P]01P17F6IW6G^'?C+;,^ES2QP^'TC@:QLVG^S 3N,".-2
MP&!C*KQC!ZU>\&>$]4DTR>X74]4\-VUQ?W-U;Z;#%;_)$\A*AUEB<H3RVU2
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MBRHBJ6=-W!*@]>^#5;5+;4M:U?5-7CTO6;?3XM=M;DXL@+B2%+-HO,2*1&W
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M;:7,;R^N[^2W3[.3)<8A!B9!C+?-]W'?IS7K= !1112 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG!(Y.>,9J]KGC/5H]=N](LI9G,FN?88I+58#-%"MA#.R)YI"%B[-RY. 3P>
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M3(71B4W,3@8/+?-C&,6T\<:MXFT^RGMK_4+>Z?389YK?1;.!UBE<$[Y9+@;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img46421407_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_11.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\O/T]?;W^/GZ_\  $0@#X == P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H 9+*D"F21@B*,EF(  ]23P* "
M.195#QD,IZ%2"#]".* 'T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!YQ\0M8$$"Z?&?GFP[^R _*/^!,,_1?>FA&
M]X-L6L=,C#YW2YE(/8-C;]/E"GZDT,#J:0PH * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H CFF6WC:60[4C4LQ] !DG\J /
M 8FD\4ZPIDZ3R\C^[&O) ^B+CW//>JV)/H%5"@ < < >@%24+0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9::U9O=FP60?:%Z
MISUQD@'H6 Y(!R/P. #4H * ..\=7OV/3&0'#3LL8^GWF_,+@_6FA'(?#BP,
MEQ+>,#MB78I[;GZ_B%'/^\*;!'L%2,* "@ H * "@ H * "@ H * "@ H *
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M5J1IR4;-]$[[?XF?4%>(>Z<EXY\3CP?HUQJF%:2)0L*-G:TSD+&" 02H)W.
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M/Y'C8C&.E+DI<KM\5[O7LK-?,]?\&:U-XBT:TU.Z5$FNHM[K&&" [B/E#,[
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M9-+D?*,8 []:Z,3AXT%%P;U;WMT]$CFPN(GB')3459*UD^OJV>VUYIZ@4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MZAD\V5B%9E(*G:J/@'OANJUZN,J.G!1B[.3Z;V7](\C TXU)N4E=16SVN_\
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M8[22I^89&X Y ]:$XS5X.Z3M?IIV/'G"5-I35FU>W77N?=WPM_Y%;3O^O?\
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MGM>^G+?9V[HJMC/83=/DO:VO-;=7VLRGXA_: T_29_LUA:M?E !(_G"*,/\
MQ*C>5(9 IXW[55CDKD8)J&"E)7E+E[*UW\]58BICXP?+"/-W=[*_EH[G0CXB
M6VN^$KKQ#<:=YMO"VQK2X9'CFQ)$N0QC<%%9^"T.=Z$8Z&L?8.G6C14[-Z\R
MNFM'YK\^IM]852A*LX72TY7:SU7D^_;H8WPH\;:7XFU">WT_1K71Y([<R-+
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M7H_R%C?X+]5^9Y=^SA_Q]ZC_ -<H/_0Y*[<?M#U?Z'!E_P 4_1?FSZOKPCZ
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MTUS1:DEO;1_=_P $WI8V%1J,DX-[7U7WZ?D>U22+$IDD(1$!9F8@  #)))X
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MXBG.I&,:,8MO1JUU_P"2K\SZ7U35+;1;:2^OI%@MX%W.[= /0=RQ. J@$L2
M 20*\:,7-J,5=O9'MRDH)RD[);L^>]1_:.M(92ECI\MQ$"0'EG6 G'<(L4V
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M=R2.C8Z>F1_$5%,1MZ1IB:1;+;1DMC+,QZN[?>8_7MZ  9/6D,TJ "@ H *
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M^,?:X^O][/R_CNQCWKZG$?PIV_E9\GA_XT+_ ,R/T-KY(^Q"@ H ^$OC;O\
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M4;*H[7VT;_(\"E0J5KNFKI;ZI?F=5_PI#Q9_SZQ_^!$'_P <K#ZY1_F?W/\
MR.CZE6_E7_@2_P SA+JTU#P7JHBG4V]_82QR 9!VNNV1""IPRD%6!!P5-=2<
M:T+K6,DU^C.1J5"=GI*+3_5'WS_;$6O^'7U*#_5W5C)(!_=+0MN0^Z-E3[@U
M\KRNG5Y'NI)?B?7<ZJ4G-;.+?X'PY\.+B*T\2:?-.ZQ1I<*6=V"JHP>69B !
M[DU]-73=*:6KMLCY7#M1JP;T5^I]X?\ "5Z+_P _]E_X$P__ !=?+^RG_)+_
M ,!?^1]9[6G_ #Q_\"7^9-;Z]I6HN+:"[M;B20$"))XI&8 $L BL2PV@D\'@
M$GC-)PG'5QDDNMFAJ<)>ZI1;?1-/\#X#\3Z+=>!==DM5S&]I,)K:3U0-O@D!
M/7@#/7#JRGD&OJJ<U7II]&K->>S1\C4@\/4<=G%WB_+=,^PO"GQ<T'Q!:))=
M7,.GW04>=#<.L0#@<F-Y"$=">5PQ;'W@#7S]3"U*;M&+E'HTK_>D?24L53J1
M3E)1EU3=ON;T./\ BA\7]/M;"73-"N!<WERIC::!LQP(>'995X:1ERJ>6QVD
M[RP(4-T8?"R<E.JK16MGNWZ=N]_0YL3BXQBX4G>3TNMDO7OVMZG,_ _6_$FO
M:DPN;RXGTRTB8S"8^:&=P5BC$D@9PP.9/E=?ECP3@[6VQD*5./NQ2FWI;33J
M[+3R^9A@IU:D_>DW!+6^NKV5WKY_(/V@_"DHFA\16ZEHB@M[DC/R,I)BD;V8
M,8R> "J#JU&!J*SHO?=?JOU^\,?2=U66UK/]'^GW%+X/?%6TT&W&A:T_DVZL
MS6UP065-YW-%( "54N2R.!@%F#X7!%8K#.;]K3U?5?JB<)BHTU[*KHNC[7Z/
M_,^@;SXC^&K*'SWU*T=0,[8IDED/&<>7$7?/L5'/!Q7E*A5;LH2^:LOO>AZ[
MQ%**NYQ^33?W+4^-OB7XX;QWJ@GA5DM+=?*MHV^\03EI& SAY#CY03A0BY)!
M)^AP]'V$+/XGJW^GR/FL36^L3NM(K2*_7U9]9_";PJ_A/0(H+A=EU=,;F=3U
M5G"A4/ND:H&'9]U>%B:GM:C:V6B^77[SZ'"TO8TTG\3U?SZ?=^)\@^-O^1LO
MO^PC)_Z.KWZ/\&/^!?D?.5OXT_\ &_S/N_Q#H-MXFT^;3+P9BN$*YP,HW5'7
M/1D8!E]QZ5\O";I24X[K^K?,^LJ056+IRV?X>?R/SPU[1[OPO?7&E764DB;R
MWQD+(F5=&'3*/A)%S_LG&1Q];"4:L5..SU7D]G\]T?'3A*E*5.6ZT?FMU\GH
MSW']G+_D)7W_ %[)_P"C17FX_P"&/J_R/4R_XY_X5^9ZIXT^#MKXTU)M4FNY
M;=W1$V(B, $& <DYYKAI8IT8\BBGJWOW/0K82->?M')K1*UNQSEI^SS8VD\=
MPM_.QB=7 ,4>"58-@\]\5L\=)IKE6JMNS!8",6GSO1WV1>_:(_Y%ZW_[",7_
M *3W51@?XC_P/\XEYA_"C_C7_I,C(_9Q_P"/"_\ ^OB+_P!%FM,?\4/1_F9Y
M?\,_5?D8/QZ\#?9Y!XELEQ'*5CO%4?=DZ1S8 Z/C8Y_O[#U<FM<%6NO8RW6L
M?3JOU1CCJ%G[>.STEZ]'\]GY^I\V22-*=SDL0%7).3A5"J.>RJ H'8  <"O9
MVV/$WW/T>O?^0%)_UX/_ .B#7QZ_B+_%^I]H_P"&_P#!^A\)_#BXBM/$FGS3
MNL4:7"EG=@JJ,'EF8@ >Y-?3UTW2FEJ[;(^4P[4:L&]%?J?>'_"5Z+_S_P!E
M_P"!,/\ \77R_LI_R2_\!?\ D?6>UI_SQ_\  E_F21>)M)N'6**]M)))&"HJ
MW$+,S,<*JJ')+$D  #)/ H=.:U<96]&-5(/12C?U7^9XG^T7_P @BS_Z^S_Z
M)>O1P'QR_P /ZH\O,/@C_B_1F;^S?_Q[ZE_UTMO_ $&:M,?O#TE^A&7;3]8_
MJ=)\<_!BZUI?]LVR?Z7IPRY Y>V_C!]?*)\P9^ZOF8^]6.#J\D_9OX9?@^GW
M[?<;XVCSP]I%>]'\8]?NW^\\S^ ?C Z;J#Z#<OBWOOG@!/"7"CD#L/-08/JR
M(!R:[,;2YH^UCO'?T_X#_-G#@:O+)T7M+;U_X*_)'I'[1'_(O6__ &$8O_2>
MZKCP/\1_X'^<3MS#^%'_ !K_ -)D<-^SUJUEI?\ :?VVXAMO,^Q[/.E2/=M^
MU;MN]ESC<,XSC(SU%=6.C*7)RIOXMDW_ "]CDP$HP]IS-+X=VE_-W/H+4OB!
MX>TF(S7&H6I"C.V.9)9#U^['$6<YQC(7&>":\F-"I)V4)?--+[WH>Q*O2@KN
M<?DTW]RU/A_Q?KLWCS7I;RWC8M=R)%;Q#EMH"QQ+Q_$V S<XW,<'%?2TH*A3
M46]DVW^+/EJLWB*CDENTDOP1]Y>%M&'A[2;33,Y-K!'&Q[%P,R$>Q<L1[&OE
MZD_:3E/NV_ET_ ^LI0]G",.R2^?7\3QK4?V?;'4;J:[:^G5KB624J(D(!D<L
M0.>@S@5Z,<;**4>5:)+=]#S98",FY<[U;>RZFWX.^#-IX.U./5H;N:=X5D4(
M\:*I\Q&0\@YXW9K*KBW6@Z;BE>W7L[FM'!QH3512;M?2RZJQQ_Q%^+VO>$M7
MGTFW@M%B38T4KI*[O&ZJP88E5,@[D;Y",@@=,GHH86G5@JC<K]4FE9_<<V(Q
M=2C-TXJ-NC:=[/Y_(]AT'X@:-K&FQZD;NWA_=AIDDE1&B<+EU=68$8.<<888
M*Y!%>?.A.$G#E;UTLGJNAZ4*].<%/F2TUNTK/J?#_C?5H?$>O7E_9!C%<SGR
MN"&< !%;;UR^W<!C/S8(S7TM&+ITXPENEK^?X'RU::J5)3CLWI^7XGU?\2_#
MMQ=>!Q;8+W&G0VLK#J28$5)CU/W8S(YY/W?QKPL/-1KWZ2<E]^WXV/H,33;P
M_+UBHO[E9_A=GB_P'\46N@:I<6E]*MO%?Q(%=V"IYL3$HK$D*NY7D"DGKA>K
M"O2QE-S@I15W%[+>S_X9'F8&K&G-QD[*2W>UU_P[.Q^/WBVRO+.VT:RFCN)/
M/^T3>4X<(J(R(K%21ES(6V]1L!.,C//@J4HR=22:5K*^F[U_+\3IQU6+C&E%
MIN]W9WM967WW_ V/V=M(DM-,N]1<%5O9D2//\26X<%A[;Y77ZJ?2L\=).<8+
M[*;?S_X"-,O@XPE-_::2^7_!;/H>O(/9/B?X_?\ (S#_ *](?_0I:^DP7\+_
M +>?Z'R^._C?]NK]3Z:^%O\ R*VG?]>__L[5XN)_BS]3W,-_!AZ?J=]7*=@4
M ?G'XX_Y&'5/^PC>?^E$E?7T?X</\$?R1\76_BU/\<O_ $IGZ.5\@?:!0!P/
MQ2_Y%;4?^O?_ -G6NK#?Q8>IQXG^#/T_4^<OV=_^1AN/^P=+_P"E%K7L8[^&
MO\:_*1XV7_Q9?X'_ .E1/>OC1_R*%_\ ]NW_ *66]>7A/XT/^WO_ $EGK8S^
M!/\ [=_]*1X?^SK_ ,AJ[_Z\C_Z.BKTL=\$?\7Z,\O+_ .)+_#^J..^,.N7>
MJ^([J"X<F&R?R88\G8BJHR0.FYSEF;J<@?=  Z,+!0I1:WDKMG-BYRG5DGM%
MV2[?\.>_Z3\(_"&B6":CJ!%Y&D0D>YFF983D!BZJC(FP_P "MO." =S<UY4L
M56G+DA[KO:R6OX_\ ]>&$H4XJ<_>5KN3>GKI96^\^4]&>.37K9X!MB:_B*#&
M,(;A2HQVP,#':O=G=4VGORN_W'S\+.I%K;G5OO/MGX@>.-%\+1+9:[#+<Q7R
M/B-(DD1U4C<#YCHN02IQG(RI&.H^;H49U7S4FDX];VM]USZBO6ITERU4VI+:
MR:?WM'DFB_"[PG\0K/\ M/1);K3R697MRZ2^2P)PKHVYQN4!U_?$%3P<@X[Y
MXBMAY<E1*79V:O\ I^!Y\,-1Q,>>DY1[JZ=OEOY[GA7C+PW_ ,(5J[Z=#<K<
MM!M=98_D9&/(5@&;9*F 2 QQP<@\#TZ53VT%-QM?H_ZV/)K4_83<%*]NJT_X
M9GN/QCM[O5?"NBZO,"SQQPFYXY#W-O&Q9O0>8A4Y_B8#O7F85J%:I36UW;TB
MW^C/5Q:E.C2J/HE?UE%?JCBOA3X/\-^,4EM=6FFAU".0&)$F2,2Q,% V*\;%
MG5PVX YPR?+U-=.)JU:-I4TG&VNC=G]^UCEPM*E6O&HVIIZ)-*Z^[>YU?C#P
M1X#\%>6M[-?S2R-M,-O- \J+@Y=U9$"J" O)!)/R@X-84JV(K7Y5%)=6FEZ;
MG15HX:A;F<F^R:;7GLCT7X/Z=X;1+J^\-&\97\N*;[6% #*"X5-J@%@&^;#-
MC*^H)Y,5*K[L:W+U:Y3MPD:2YI4.;HGS?>>U5YIZ9Y'\5_'6J>!(+:YTZ&":
M*X=XY&G61@C@*T8PDD?WU\SJ?X*[\-1A7;C-M-6:M;5==T_(\[%5YX=1E!)I
MW3O?1]-FM]2E\,?BK!XIMI(]9FM[;4(Y#A"1"CQ$ J8][G<5.X.-Q( #'@U6
M(PSI-.FFXV];/SL3AL4JJ:J-*:>VR:\KGD/Q[\46&NWUI9Z?(EP;!)O-EC(9
M-TQBQ&'&0Q01Y;!(!?;G<& ]#!4Y4XRE-6YK63\KZ_.YYN.JQJ2C&#3Y;W:V
MUMI\K?B>M? &SEM?#1DER%N+R:6//]P)%%Q[;XGZ=\_6N#&M.K9=(I/UU?Y-
M'HX%-4KOK)M>FB_-,]MKS3U#Y&_:+TR5-2LM2P?)EMC;Y[!XI7D(/H2LP(SU
MP<=#7OX"2Y90ZIW^])?H?.YA%J<9]'&WS3;_ %/2/@GXNT^ZT&'2Y)HX;NQ,
MB-&[A69&D:19$#$97#[6P3AE)( *UQXNE*-1S2;C*VOG:UOP.W!U8NFJ;:4H
MWTVTO>_XG _'_P 66.I"UTBRE2X>"1YIVC8,J';L1-RDC>07++U7"YY.!U8*
ME*/-4DK)JROU[LY,=5C+EIP:;3N[=.B1U'[.?_((O/\ K['_ *)2L,=\<?\
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MS?\ HN&L,;_%_P"W5^;-\!_"_P"WG^2/F;QM_P C9??]A&3_ -'5[-'^#'_
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M:+8?]>5K_P"B$KYVK\<_\4OS9]+2_AP_PQ_)'+?%W_D4]0_ZYQ_^CXJWPO\
M&AZO\F88O^#/T7YH\&_9U_Y#5W_UY'_T=%7J8[X(_P"+]&>3E_\ $E_A_5',
M?&K7+O4O$=Q9S.?L]B4CABR=JYC1F?'3>[,26QG;M7HHK?"04:2DMY:M_,Y\
M9.4JKB]HZ)?+]3V_P]\(_">G:9%J>HD7B^2LTEQ-.R0#< Q8+&R($&< .7XZ
MY:O,GBJTI.$/=ULDEK^)ZM/"4(P4Y^]I=MNR_"VA\JQ/!+K:O:#;;M? Q #
M$9GR@ [87 QVZ5[KNJ=I;\NOK;4\!6=2\=N;3TOH?8OQR_Y%2X_ZZV__ *-6
MOGL'_&7H_P CZ3&_P7ZK\SR[]G#_ (^]1_ZY0?\ H<E=N/VAZO\ 0X,O^*?H
MOS9]7UX1] >0_'#3)=1\,2M""QM)8KA@/[B[D<_15D+'V4FO0P<E&JK]4U^O
MZ'G8V+E1=NC3^6WZGBGP$\56>@W]U8WTB0+J"0^7)(0J^9"9,(6) 7>)6P3P
M2H&<D ^EC:<IQC*"ORWNEV=M?P/+P-6-.4H3=N:UF^ZOI\[GN7Q4\9:?H^@W
M=L)XI+J]@DMXH4=6<B93&[E0<A41F)8\9  R2!7EX:E*=2+LTHM-OTU/5Q5:
M,*<HW7-)-)>NC9\Z_ C_ )&F+_KWG_\ 0*]?&?PGZH\; _QEZ/\ (T?V@--E
MM?$"7C#]U=VR;&[;HB4=?J!M;Z.*G!23IN/5-_CJ7CXM55+HXK\-&='\/_AI
MX3\8Z5%=M/<"\5<742SQJ8Y%X9MAB+"-AAU;)&#C.0P&-?$5J,W&RY?LNSU7
MW[FU##4*T%*[YOM*ZT?I;;J8WB'0OAWX;OO[/FEU&X<*"[VTL$L<;$D%'.U3
MO  )"A\9PV#Q6D)XFI'G2@O)IIOS1G4AA:4N1N;\XM-+R9[CX<U#0_ _A9=3
ML?M;:5N,P,B;I_WL@CSMPF%+X )P,$,"5(->94C4K5N27+S[:;:*_F>I3E3H
M4>>'-R;ZK75V\NIYC9:=X'^*^HSQ6<5SI=YM\P,K10BX))#,L.9H\J<,P4([
MABQY#$=KE7PD4Y-2CMU=OGH_S.%1P^+DU%2A+?HK_+5?DSSWXF_#"'P#'#/!
M>"Y6X<H(74),H 9MXVL0R#&TG"X8J.<\=>'Q#KMIQM;JMO3U./$X98=)J5[O
M9Z/U]#V_]GZ^N;K0)89RS16UTZ0EL_*ICC=D4GC:K,6P.A<^U>;C4E436[C=
M_>]3U,!)NFT]E*R^Y.W]=SYL^&/_ ",^F_\ 7RO\C7L8C^%/T/$PW\:'^(]C
M_:-TR7S+#4@,P[9;=C_=?(D0'_?&_'^X:\_ 27OPZZ/]/Z]3TLPB[PGTU7SW
M_P _N.C^ ?BBSFTDZ))(L=W;3.R(Q ,D<IW!DR?F*N65@.0-I_BK'&TY*?M$
MO=:6O9KN;X&K%P]DW:2;T[I]OF8_[0'BRSGM(-"M9$FG\X3S;"&\I41U16(X
M#.7+;?O!5R0 RYTP5*2;JM65K+SO_P ,9X^K%Q5*+3=[NW2W^=QW[-__ ![Z
ME_UTMO\ T&:C'[P])?H&7;3]8_J>7?&__D;+K_KG;_\ HB.NW!_P8^K_ #9P
M8W^-+TC^2/LOPI_R!;#_ *\K;_T2E?.U?CG_ (I?FSZ6E_#A_AC^2/A[XL_\
MC7J/_75?_14=?38;^##T_5GRV*_C3]?T1]U:!_R#;3_KV@_]%+7S$_BEZO\
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M^;=6ORWVML?(SS&M'$O#KDY%5Y-G>W-;>^_R/?:^5/K@H * "@ H \"^(/\
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MSLOR;)AE\K_O))+^[=O\4CZ<T'0;/PS91Z=IT8B@A' ZLS'[SNW5G8\L3]
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M>P#?+*/V4TUZO=?@CY[,$E*$E\3337DMG^+.@_9W\._9[6ZUR48:X86T)/\
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M/-JX:G7EST)Q3>ZNFF^^FJ\]#)T3]G:\\\-K5W ENIRRVI=W91U >6.-8_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % $4_^K;_=/\C5+=>I,MGZ,^3?A3_R,<'^[/\ ^B7K[O,O]UEZ
MP_\ 2D?GV6?[U#TG_P"DL^MZ^"/T,Y3QU&LF@WRL,@6[M^*C<I_ @&N_!NV(
MI-?SK\=#S\:D\-53_D;^[5?B>*?!%R-2N4[&VR?J)$ _F:^CS=?NH/\ O_\
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M]#>G@/X<O\7Z(6+^-?X?U9T_PU_Y!TG_ %\-_P"BXZXL?_$7^%?FSIPGP/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MSS'@*HX5?0 <*H[DX'<GJ:ZE&GAH65HQ\]W_ )LP;G6EU;\NG^1[AX4\/_\
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MOLI*_=]7\WJ:E8&X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M2;;W=_4$DMM"2D,K-90.2S1QDGDDHI)/N<5?-):)O[V3RKLON+"J$ 50 !P
M. !["HW*V%H *  C/!Z4 '2@ H * .?TS0OL%_>:B[^8]\T948QY:1HJ;>IS
MN(R3@= .U==2MSTZ=%*R@G?S;;=_E_F<=.A[.K5K-W=1JW]U))6^>_W'05R'
M8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M]-/F8?58K>4E=:)I75H<[YM=+:+3N.OKZ1'CC3=%N+YR8E)"@ $%RRX+,/\
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M;E;FMRJ25UOS2<5_A;ZH?U1+F4YM.+L[*]KW:;MY)-^MAU_>3)/Y<)8 ",9
M0KO=C@.6^8+M'\/.3ZD56*KU8U?9T6TDJ:O:#C[2I)V4W+WE'E7V=;ONT31I
M0=/GJ)-MS>\N;EBE?EMI>[^UT7J1?VG-=H!$!'YCHJMNR0"6+ C!PP5<YQ@9
M]167URKB()4HJ'/.$5+FNTFY.2:L[248WNU97[HT^KPI2;FW+EC)M6T;5DNJ
MNG*7?IV8MMJQ50LF"Q(.68#Y6#ON(Q]U$"C/<^].CCFHJ-2SDVG>4DO<DIU.
M9JWPP@HJ_5^8JF%3;<+I)-62O[T7&-M]Y2;TZ(F.I/):/. (6R$&3RK$JI+
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MO:^FUG?R78]*A7CB(^TIWM>VNCOIV;[F]7,=(4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0!X1\;/\ F'_]O7_MO7TF5?\ +W_MS_V\
M^;S3_EU_V_\ ^V'K7_"+:/\ \^%G_P" T/\ \17B?6*W_/RI_P"!R_S/;^KT
M?^?</_ (_P"0?\(MH_\ SX6?_@-#_P#$4?6*W_/RI_X'+_,/J]'_ )]P_P#
M(_Y!_P (MH__ #X6?_@-#_\ $4?6*W_/RI_X'+_,/J]'_GW#_P  C_D'_"+:
M/_SX6?\ X#0__$4?6*W_ #\J?^!R_P P^KT?^?</_ (_Y&+XD\-Z5!I5[+%9
M6B2):7#*RV\2LK+$Y#*0@(((!!!R#R*Z*%>K*K33J3:<XIIRE9KF6CU.>O0I
M1I5&J<$U"3348IIJ+U6ASOP;_P"0/-_U^2?^B;>NK,_XT?\ KVO_ $J1RY9_
M!E_C?_I,3UFO$/;"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MM84YU+^SC*5M^5-VOWL93J0IV]I*,;[<S2O;M<H_\)3H_P#S_P!G_P"!,/\
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MC_\ /_9_^!,/_P 71]7K?\^ZG_@$O\@^L4?^?D/_  ./^8?\)3H__/\ V?\
MX$P__%T?5ZW_ #[J?^ 2_P @^L4?^?D/_ X_YA_PE.C_ //_ &?_ ($P_P#Q
M='U>M_S[J?\ @$O\@^L4?^?D/_ X_P"8?\)3H_\ S_V?_@3#_P#%T?5ZW_/N
MI_X!+_(/K%'_ )^0_P# X_YA_P )3H__ #_V?_@3#_\ %T?5ZW_/NI_X!+_(
M/K%'_GY#_P #C_F'_"4Z/_S_ -G_ .!,/_Q='U>M_P ^ZG_@$O\ (/K%'_GY
M#_P./^8?\)3H_P#S_P!G_P"!,/\ \71]7K?\^ZG_ (!+_(/K%'_GY#_P./\
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MPE.C_P#/_9_^!,/_ ,71]7K?\^ZG_@$O\@^L4?\ GY#_ ,#C_F'_  E.C_\
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MP]L\S[6NW.W'E3[L@ _<\K=CG[V-O49R#7H_4<1>WL_QC;[[V/.^NX>U^?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MR_QO_P!)B>LUXA[9X1\;/^8?_P!O7_MO7TF5?\O?^W/_ &\^;S3_ )=?]O\
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M^S*/\T_OC_\ (A_PIO1_^>UY_P!_(?\ Y'H_M.M_+3^Z7_R0?V91_FG]\?\
MY$/^%-Z/_P ]KS_OY#_\CT?VG6_EI_=+_P"2#^S*/\T_OC_\B'_"F]'_ .>U
MY_W\A_\ D>C^TZW\M/[I?_)!_9E'^:?WQ_\ D0_X4WH__/:\_P"_D/\ \CT?
MVG6_EI_=+_Y(/[,H_P T_OC_ /(A_P *;T?_ )[7G_?R'_Y'H_M.M_+3^Z7_
M ,D']F4?YI_?'_Y$/^%-Z/\ \]KS_OY#_P#(]']IUOY:?W2_^2#^S*/\T_OC
M_P#(A_PIO1_^>UY_W\A_^1Z/[3K?RT_NE_\ )!_9E'^:?WQ_^1#_ (4WH_\
MSVO/^_D/_P CT?VG6_EI_=+_ .2#^S*/\T_OC_\ (A_PIO1_^>UY_P!_(?\
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M#^S*/\T_OC_\B'_"F]'_ .>UY_W\A_\ D>C^TZW\M/[I?_)!_9E'^:?WQ_\
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M'^2.:O;Y_ D^KZ.F0EW&#;'T$C <'MB&1P3_ 'XABNN,%C8T*[W@_?\ DO\
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M^*Z?2+FPU"PRS2).JK+M W#(G1'SM( ,,F&;IAQ@=KFIN"KPJ4ZFEG%MQO\
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M?YHG,XW5*3^%.2?SY?\ )G/:_!I>F:OI;>%V0S,Z[Q#(9%(+QB/=RV"ZF02
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MM.$I.33W>[ND]?/6Q]/AIJI1A.,5%6V6RLVM/+2YTU<9V!0 4 >3?\*;T?\
MY[7G_?R'_P"1Z]O^TZW\M/[I?_)'B?V91_FG]\?_ )$/^%-Z/_SVO/\ OY#_
M /(]']IUOY:?W2_^2#^S*/\ -/[X_P#R(?\ "F]'_P">UY_W\A_^1Z/[3K?R
MT_NE_P#)!_9E'^:?WQ_^1#_A3>C_ //:\_[^0_\ R/1_:=;^6G]TO_D@_LRC
M_-/[X_\ R(?\*;T?_GM>?]_(?_D>C^TZW\M/[I?_ "0?V91_FG]\?_D0_P"%
M-Z/_ ,]KS_OY#_\ (]']IUOY:?W2_P#D@_LRC_-/[X__ "(?\*;T?_GM>?\
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M_P ;_P#28GK->(>V% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % 'A'QL_YA_P#V]?\ MO7TF5?\O?\ MS_V\^;S3_EU
M_P!O_P#MA[O7S9](>5>,O!DOG'6]$4"[ /GVY4,ERA^^"A^5F8<.A&)!R,2
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MB*Y54=O-)O[VK_B8/!8=OF=-7\FTON3M^!UT$$=K&L,*K''& JJH 50.@ '
M ]JX6W)N4G=O=O<[4E%*,59+1);(EJ2@H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#"\4_\@>__P"O.Y_]$O73A_XU/_KY#_TI
M'-B/X-3_  3_ /26<'\&_P#D#S?]?DG_ *)MZ]+,_P"-'_KVO_2I'FY9_!E_
MC?\ Z3$]9KQ#VPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H \(^-G_ ##_ /MZ_P#;>OI,J_Y>_P#;G_MY\WFG_+K_
M +?_ /;#W>OFSZ0* "@ H PO%/\ R![_ /Z\[G_T2]=.'_C4_P#KY#_TI'-B
M/X-3_!/_ -)9P?P;_P"0/-_U^2?^B;>O2S/^-'_KVO\ TJ1YN6?P9?XW_P"D
MQ/6:\0]L\(^-G_,/_P"WK_VWKZ3*O^7O_;G_ +>?-YI_RZ_[?_\ ;#W>OFSZ
M0* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H PO%/_('O_\ KSN?_1+UTX?^
M-3_Z^0_]*1S8C^#4_P $_P#TEG!_!O\ Y \W_7Y)_P"B;>O2S/\ C1_Z]K_T
MJ1YN6?P9?XW_ .DQ/6:\0]L* "@ H * "@ H * "@ H * "@ H * "@ H *
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MD5WE_DMW_FT=6%P[Q-106D5K)]H_YO9?Y)G/>"[RXN_M)N7>1E=.'8G:3OR
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#"\4_\ ('O_
M /KSN?\ T2]=.'_C4_\ KY#_ -*1S8C^#4_P3_\ 26<'\&_^0/-_U^2?^B;>
MO2S/^-'_ *]K_P!*D>;EG\&7^-_^DQ/6:\0]L* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M&4;8=0_F;?M+W]6[_+;R+?+'$.5\0YK[*2]G:WHE;Y[^9/KBR)IVGJS!V'F
M,"2"-R[,$@<;<=OTK3%*2P^&3:;7/9K56NN6UTNEB,*XO$8EI-+W+IZ-.SYM
MK];FIX=SI>IRVM^ ;F8 K*3DDD;B 3_?]>NY=I[ =F"OAL3.CB4O:S5U/>_5
MJ_\ >_-6./&6Q&&A6PSM2@[."TMT3LNWY.YZ/7U9\J5KRW^UP26^=OFQNF[&
M<;E*YQD9QG.,C/K656'M:<Z5[<T91OO:Z:O;3:YK2G[*<*EK\LHRMM>S3M?6
MVQP/_"OO^GG_ ,@__;:^9_L?_I]_Y3_^W/I?[8_Z<_\ D_\ ]H8FO>%_[$@6
MX\[S=T@3;Y>W&59LYWM_=QC'?K7GXO ?4Z:J^TYKR4;<O+NF[WYGV/0PF/\
MK<W3Y.6T7*_-?9I6MRKN>H:-_P >%M_UPB_]%K7V&&_@4O\ KW#_ -)1\?B?
MX]7_ *^3_P#2F:5=9RA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % &%XI_Y ]__P!>=S_Z)>NG#_QJ?_7R'_I2.;$?
MP:G^"?\ Z2S@_@W_ ,@>;_K\D_\ 1-O7I9G_ !H_]>U_Z5(\W+/X,O\ &_\
MTF)ZS7B'MA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!YU\0'95ME!(4F4D=B1Y>/RR?SKY7.&TJ2Z/GT].2WYGU.4
M)7JOJN2WSYK_ )#?^%??]//_ )!_^VTO['_Z??\ E/\ ^W'_ &Q_TY_\G_\
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MY7MU[$1Q%6--X>,K4WNK+\[7Z=SC-:BNO$-S':+;20Q0R-F9P0"N0"RD@#!
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M'%<ZPM%4WAU!>S;NU=[][WO?SN=+Q59U%B'-^T2LG9;=K6M;RL6[2SBL(A!
M"L:YP"S-C//!8DXSVSBMJ=.-&*ITU:*V5V[?>VS"I4E6DZE1WD]W9+\DD6:V
M,BA8Z7;::7-LGEF4@O\ ,S9(S_>)QU/3%<U*A3P_,Z,>7F=WJW=Z]V^[V.FK
M7J5^5597Y59:)66G9+MU+]=)S&;9Z1::>[RV\81Y?O'<QSSGHS$ 9[ "N2EA
MJ5"4ITH\KEOJW?6_5M+Y6.NIB:M:,85974=M$K:6Z)-_,73])M=+W?9$\OS,
M;OF8YQG'WB<8R>F.M.CAZ6&O[&/+S6OJW>U[;M]WL*MB*N(M[:7-RWMHE:]K
M[)=D07GA^POG,L\*LYZD%E)^NQER?<UE4P="M+GJ4TY=6FXW]>5J_P S6GC*
M]&/)3FU'HFD[>G,G;Y%ZWLH+2+R(45(N<J!P<]<YZYZ'.<CBNF%*%*/LJ<4H
M=K:.^]^]_,YIU9U)>TG)N7?JK;6[?(RO^$7TS?YGD+GKC<^W_OG=M_#&*XOJ
M&&OS>S5_65ONO;\#L^OXFW+[1V](W^^U_P 2]>Z3:Z@$%Q'O$7W &90N<=-A
M7T'!]*Z:N'I5^558W4?AU:MM_*UV1STL15H<SI2LY?%HG??NGW87FDVM](DT
MZ;I(ON,&=2.<CE67.#R,YQSCJ:*F'I5I1J5(WE'X6G)-:W^RUU[A3Q%6C&5.
MG*T9?$K)IZ6ZI].QHUU'*% !0!Q7CS_CPC_Z[K_Z+EKY_-_X$?\ KXO_ $F9
M[^4_QY?]>W_Z5 Z/1O\ CPMO^N$7_HM:]7#?P*7_ %[A_P"DH\K$_P >K_U\
MG_Z4S2KK.4* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H Q?$D3SZ5>Q1*SR/:7"JJ@LS,T3@*H&2220  ,D\"NB@U&
MK3;=DIQ;;T22DM6<]=.5*HDKMPDDENWRO1'%_"BPN=.TJ6*\BEMY#=NP65&C
M8J8H & < D$@C.,9!'8UZ&8SC4JQ=.2DN1*Z::OS2TT//RZ$J=*2G%Q?.W9I
MIVY8ZZGIU>.>P% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M.4* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /./B#_ ,NW_;;_ -I5\IG'_+G_ +B?^V'U63_\OO\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MS_W$_P#;#ZK)_P#E]_VY_P"WGH]?5GRH4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Q7CS
M_CPC_P"NZ_\ HN6OG\W_ ($?^OB_])F>_E/\>7_7M_\ I4#H]&_X\+;_ *X1
M?^BUKU<-_ I?]>X?^DH\K$_QZO\ U\G_ .E,TJZSE"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MH@1T_>!3N8DD#*C!.< 'LM !0 4 % !0 4 % 'F'B?QK>Z)XBT_18$@:WO\
MRO,9U<R+OF:,["LBJ/E (W(W/7(XH ]/H * "@ H * "@ H * "@ H * "@
MH * "@#SCXG>(I?#6G0W$,-O<F2X6,K<QF1 #'(VX .F&^7 .>A(QS6<Z<*J
MY:D8R6]I)-7[V=]=32$YTGS4Y.+VO%M.W;0M?#GQ+/XITQKNYCAA:*9H52!6
M5 B)&5P&9R/O$<$# & *M)12C%625DEHDELDNQ#;DW*3NV[MO5MO=OS.]IB"
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H SM7U.+1;.:_
MN,^5;1M(V.I"C.T>[' 'N10!X8?B?XFDLFU^'3K;^R%?;N+.9<!]A.1*#C>=
MA<0%0V>, X .ZUOXDVVF>'X=?AC,C7F%@A8[3YAW;@Y /RQE6W$?>P "-P(
M.;M/B+KFD7UI;>*+*&TM]1P(9(2V4)*CYP991\I9/,7Y&0-NP?NT >W4 % !
M0 4 % !0 4 >6Z7XWO;WQ9<^'9$@%K;H[*ZJXE)58R-S&0H1ESG$8[?B >I4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_/\ _P#*E/\ ^1#_ (2/7?\ GS_\EY__ (NCZ[CO^?'_ )2J?_)!]2P/_/\
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MUJ.8JRRC_4*1@-&IZ$D-'GCRPNQ0H.6 /?Z "@ H * "@ H * "@ H * "@
MH * "@#Q;XXG_B46P_Z?%_\ 1,U- 6_@H,:%)[WDO_HN&@#UZD 4 % !0 4
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MG8Z%E!(V%P<J6)+ >6RJRDY( !4\2:Q?:)XMU2?2T9[AHY$#*"QB3RHVDF
M/^K1&.3PI^8Y P0#V3X1:5IT.D+J5H3/>7>?M4S\R"0'+1=R%4X;KF3(D;JH
M4 ]8H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H IWVG6NIQ^3>
MPQ7,0(;9-&DB[AD!MK@C(!(!QGD^M 'G?BCX6:=KK6S6:VVFBVD+R"&TC_?@
ME,(^QHN!M/7>/F/'J >D6MI#8Q+;VL:00ID+'&JHBY))VJH"C)))P.I)H JZ
MSID>M64^GS<)<Q/&3C.W<I 8#(Y4X8<CD"@#SG1/A7!I&BWVC/<><^HXS/Y.
MS9L \K]WYK;O+DR_WUW9P-N-Q .@\%>!X/"&G2:<9!=_:'=Y7,?E[PRA-A3?
M)\H4$?>Y+,<#- '(?\*EGLO-M])U>ZL;*=B7MPF_[W! <2QXR/ESMR5P&+8H
M ZJ3X>:=+H?_  C\K2O$")/.9MTHF'24$Y48'RA -NSY>I)H YB/X4W<OE07
M^LWES8V[*4MPICP%X4>9YS]%^4$("JDA2M '1:WX!75M9L-82X\A=,$2K!Y6
M_>(I"X'F&52N0=OW'QC//2@!(_ 1LO$3>(K"Y^S+.,7%MY6Y9MWWSO\ -7;N
M8+)]QL2 MR#MH ]#H * "@ H * "@ H * "@ H * "@ H * //?B/X3N_%]C
M%:63Q1O%.)29F=5VA'7 *)(<Y8=0!C/- $_P\\,77A/3&L;UHGD:=Y08F9EV
MLL:CED0YRISQCIS0!W= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 >>_$?Q9=^#[&*ZLDBD>6<1$3*[*%*.V0$>,YRH
MZDC&>* +/P]\3W/BS36OKQ(HY%G>+$08+M548'#NYSECGG'3B@#N: "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MSC.5D=P!W)3COB@#K=:\:6.A7MEI\RRR2:HZI"\01HP7=(P78R*0N7!RJO\
M+D@'@$ 37/&MEH&HVFDW*3M/J#(D31JAC4O((AO+2*P&XY.U6XZ9/% 'B^I:
M[:^&_B%=W]Z6$21(N$4L[,]G;JJJHZDD]R!W) H ];\+?$;2?%D[6=KYT%RH
M+"*X0([*/O%=KNIV]2-P;!R 0"0 >;?"5UCUO6W<A561B23@ ">8DDG@ #DD
M]* .MG^,NA0RLB+=S0QMM:XCA!A!]<M(KX/;Y.>V: /3-/U"WU6WCO+-UF@F
M7<CKT(Z=\$$$$$$ J000""* /G_XC:C!I'C;3;VZ;9#;VT,CD DA5FNB< <D
M]@!U- 'HF@_%/1M?O!IT?GVT\AQ&+B-4$A[!2KO@D9*A]F>@^8@$ X3P]_R4
M:_\ ^N4G_H$% &EX U30-$L]5U#2QJ#16Q22Y%R+<N=OFD" 1LH/\6=[#^'G
MK0!I?\+LT/REF6*]93]_$*?N26*@2'S0N6 W#8S_ "D?Q94 ':W7C32K/24U
MV27_ $*4#RV"DL['($:IUWY5@0<!2K%B "0 >$_$CXBZ9XMT<6EHMQ#*MQ'(
M!/&%#HJR LC(\BG!9>"0>> >: /HS0_^0=:_]>\/_HM: / )OB0[^+A-*EZU
MA;(\4=JL:[P[($:4QB0*P+9(=F+",C &<4 >E:Y\5-'\.W]QIEXMP)K148E8
MT9)"ZQNJ1GS0=VV0$[U11M?YON[@"9_B=H\&EQ:S/YT,5TSK#$R+Y\AC;:Q5
M%=EV@C&XN%[9R0" .\/?$O2?$-T-/C$]I=,,I%=1B,OQG"E7=<XY )!(S@'%
M $&M_%+2-$NWT_9<W<\&1*+6)7$9'4,7>,9'1MNX \$@@@ %74_B78S^'Y]7
MTOSW<;X$ C4O!.T3M&\JLVT1J0&9@7&.@;D  YOX;>.DBT2X>_6[FELEFNYY
MBJL)0TAXC=I!O<9P0VT#& <"@#7/QLT/REF6*]96X?$*?NCN( D8S!<D#> C
M/\K#^+*@ LW'QDT""15'VJ2%R!]H2']RI(#$$LRN2N?F"QL00<9'- '6>(O&
M>F>&+:.[O9"5G&84C&]Y1@'*#(&,$$LQ5>0,Y(! ,CP]\2])\0W0T^,3VETP
MRD5U&(R_&<*5=USCD D$C. <4 4M1^+.D:9>SZ;-'=FXM6*82)'$KC'RQ8ER
M3@YRX08!YS@$ M:7\3M*U>TN;NV2Y+6*AY;<QKYY4MM!11(4;G@CS,COC(R
M<%\*/&DVJW]U!?\ VF>YOI=Z2E1Y,21([>6QW#R^.$1$(R>V2: /H&@ H *
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MK/-"ZA9D"J6^[NVG." 0Q7(P2#0!R$?QLT*7RECCO&DF;:(Q%%N4EMHW?O\
M;\QZ!69L=0,C( OAC^Q?^$PU'[']M_M+RI?/\WR/LNWS;?=Y6S][G=LV[^-N
M_/.* +6I_&+0M-N'ME%S=>42'DMXU:-2.#\SR1D@'/S*&4X.">,@'8V/B[2]
M0TUM:BF LHP3([ @QE<%E9<;@PR/E );(VYR,@'D'BWXK:/K^D7EA;K<QO-$
M4CDDB41.P8':&61V!(!QN51ZXH ]$^%O_(L6/^Y)_P"CY: ._H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H XGXCV4^H>';V"U!:4Q
MJP"\DK'(DCJ!W+(K# Y.< $\4 >-V'C/08O!+Z/*1]L^SRQ?9_+;)G9FV2A@
MNSAF67<6!&W'WAB@#%N+"YO/A[;/;[F2WOI))E49^3,J!SCG",PR.F&W'[M
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M&LV7C;Q%I$6@'[3-!(&EF1'4*@EC< EE#8A"22%@"!OX).10!H^'O^2C7_\
MURD_] @H Y3P7_R+WB3_ '%_E/0!U'AJ-/\ A7-WP/F2Z8\=6#X!/N-JX/;
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M[N.W2@#1^( "^,-"QQ\\8_ 7% 'L6O6TM[IMW;6_$TUM/'&?1WB95_\ 'B*
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M26165C&[>8BI@H"BMRIR=IQ]_C/. "IX:MW;PYXCOXXVBL[HQBW!&!A))68
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MY&UK-MN)<[YL3VW[QLX.6Y(R,XH D^&5O-=Q>)8+;(FE39&1U#L+Y4Q[[B*
M.,\+:M/IFF7%H=6CTI0T@FLY+%)I)-RA6PS1LS%A\FTL-F.=J\T = VF&R\
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M+?\ D6+'_<D_]'RT =_0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M&(3D[N8@NP_, WW>O/6@ DT6PFMEL9+:W>U3&V!H8S$N,D;8RNP8).,#C)H
MGDL+:: 6LD43VX 41,BF,*HPJA"-H  P!C '2@""PT:PTK)L;:WM=WWO)BCB
MS]=BKG\: '0Z396UP]Y#;P1W,H(DF2)%E<$@D/(%#L"54D$G) /84 +!I5G:
MSO=PP0Q7$W$DR1(LCY()WN%#-R ?F)Y /:@"./1-/BN3?1VUNET229UAC$Q+
M AB9 N\E@2#\W()S0!IT % !0!YY\1_%MWX/LH;JR2&1Y9O+83*[*%V.V0$>
M,YRHZDC&>* +?P^\37/BS3#?7:1QR"9X\1!@N%5"#AW<Y^8YYQTXH [B@ H
M* "@ H * "@ H * "@ H * ,^WTFRM)WNX+>"*XFSYDJ1(LDF3N.]U4,V6 )
MW$Y/)YH @N_#^F7\OGW5I:SRC_EI)!$[\=/F92WZT 7+FPMKR VEQ%%-;D*#
M%(BO&0I!4%&!7"E05&." 1T% $3:39/:_8&MX#:8 ^SF)##@,& \K;LP& 8#
M;PP!'- '(>,M&U62QB@\-_9XTARKV<D4)@FB.TJ@61"B^6RY4#8,,?F& * /
M-I?!>O>*+BTM[W3[+0]/M9?-D%L8<N3C=A87?YB!M7.T#<6); % 'T10!#<6
M\5W&T,Z++$XPR.H96'HRL""/8B@"K::18V$36]K;P00R??CBB1$;/!W*JA3D
M<<B@"&ST#3=.D\^TM+:WE.?GB@BC?G.?F10><G//.30!-)I%E-<K?26\#W48
M 6=HD,J@9 "R%=X R<8/<^M "W^E6>JJ([Z"&Z1#N59HDE"G&,@.K ''&1SB
M@!+O2+*_\L75O!.(#F+S8D?RSQRFY3L/ ^[CH/04 +<:59W<T=U/!#+/!@Q2
MO$C21X.1L=E+)@\C:1SSUH OT 94N@Z=//\ :Y;6V>X!!$S0QM(".AWE2V1V
MYH GL=,M-+5DLH(;97;<PAC2,,W3<P0*"V.YYH J'PYI9F^TFSM3/G/F_9XO
M,SZ[]F[/OF@#4N+>*ZC:&=%EC<89'4,K#T*L""/8B@#&_P"$5T;R_(^P6?E;
MMVS[-#LW $;MNS&[!(SC."1WH NW.CV-Y,MU<6T$TZ+L662*-Y%0[LJ'92P4
M[V^4''S-QR<@"6.BV&ELSV5M;VK/]XPPQQEN_P Q15)YYYH ='I%E#<M?1V\
M"73@AIUB02L#@$-(%WD' SD]AZ4 0WN@:;J,GG7EI;7$@QAY8(I&XZ?,ZD\=
MN: -..)(5$<:A$4 *J@!0!T  X '8"@!S*'!5@"",$'D$'J".X- &'_PBVC^
M4(/L%GY08N(_LT.P,0H+;=FW<0J@G&2%4$\"@#2?3[62W^QO#$UL5VF$QJ8M
MO7;Y9&S&><8Q0!4?0--EMDL7M+9K6)MZ0&"(Q(QW$LL978K$N_( /S-_>.0"
M2;1;"XDBFEMK>22VV^2[0QLT6P@KY3%28]I *[2,$ B@!]QI5G=S1W4\$,L\
M&#%*\2-)'@Y&QV4LF#R-I'//6@!+_2+'5=HOK>"ZV?=\Z))-OTWJV/PH ;;Z
M+86DWVF"VMXIPH3S4AC638  $WJH;:   N<8 &.* -$@,,'D'@@T 9%OX=TN
MTE^T6]G:Q3 Y$B6\2OGUWJ@;/XT 3W^CV.J%3?6T%T4^Z9HHY-O^[O5L?A0
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M.V@#T^@#*O=!T[4G$MY:VURXZ--#'(PQTP74F@#1AA2W011*L:(,*J@*H'H
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M,'.S+!@2"#D$'F@#3M;2&QB6WM8T@A3(6.-51%R23M50%&223@=230!8H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H \3^./\ R"[;_KZ_]I24T!H_!;_D M_U]2_^@14 >MT@"@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M]T?_ )(/^%QZ/_SQO/\ OW#_ /)%']F5OYJ?WR_^1#^TZ/\ +/[H_P#R0?\
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MA_:='^6?W1_^2#_A<>C_ //&\_[]P_\ R11_9E;^:G]\O_D0_M.C_+/[H_\
MR0?\+CT?_GC>?]^X?_DBC^S*W\U/[Y?_ "(?VG1_EG]T?_D@_P"%QZ/_ ,\;
MS_OW#_\ )%']F5OYJ?WR_P#D0_M.C_+/[H__ "0?\+CT?_GC>?\ ?N'_ .2*
M/[,K?S4_OE_\B']IT?Y9_='_ .2#_A<>C_\ /&\_[]P__)%']F5OYJ?WR_\
MD0_M.C_+/[H__)!_PN/1_P#GC>?]^X?_ )(H_LRM_-3^^7_R(?VG1_EG]T?_
M )(/^%QZ/_SQO/\ OW#_ /)%']F5OYJ?WR_^1#^TZ/\ +/[H_P#R0?\ "X]'
M_P">-Y_W[A_^2*/[,K?S4_OE_P#(A_:='^6?W1_^2#_A<>C_ //&\_[]P_\
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MOZ(I_P#"Q-5^P;OLT/\ :&_ISY.S/IYV[=C_ *:8]JT^I4O:6YY>SM_V]?\
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M@C_=5/K0\%#ECRR?-]OM;RT_5@L;/FE>"Y?L=[^>OZ(I_P#"Q-5^P;OLT/\
M:&_ISY.S/IYV[=C_ *:8]JT^I4O:6YY>SM_V]?\ \!M;Y$?7:OL_@C[2_P#V
M[;_P*]_F7)OB'>"XMQ%;I]G*C[26/SAN_E$2  ?57^M9K!0Y97D^;[':WGI^
MJ+>-GS1Y8+E^WWOY:_HPA^(=Y]HN!+;H+<*?LQ4_.6[>:?,((_W53ZT/!0Y8
M\LGS?;[6\M/U8+&SYI7@N7['>_GK^B*?_"Q-5^P;OLT/]H;^G/D[,^GG;MV/
M^FF/:M/J5+VEN>7L[?\ ;U__  &UOD1]=J^S^"/M+_\ ;MO_  *]_F7)OB'>
M"XMQ%;I]G*C[26/SAN_E$2  ?57^M9K!0Y97D^;[':WGI^J+>-GS1Y8+E^WW
MOY:_HPA^(=Y]HN!+;H+<*?LQ4_.6[>:?,((_W53ZT/!0Y8\LGS?;[6\M/U8+
M&SYI7@N7['>_GK^B*?\ PL35?L&[[-#_ &AOZ<^3LSZ>=NW8_P"FF/:M/J5+
MVEN>7L[?]O7_ / ;6^1'UVK[/X(^TO\ ]NV_\"O?YER;XAW@N+<16Z?9RH^T
MEC\X;OY1$@ 'U5_K6:P4.65Y/F^QVMYZ?JBWC9\T>6"Y?M][^6OZ,(?B'>?:
M+@2VZ"W"G[,5/SENWFGS""/]U4^M#P4.6/+)\WV^UO+3]6"QL^:5X+E^QWOY
MZ_HBG_PL35?L&[[-#_:&_ISY.S/IYV[=C_IICVK3ZE2]I;GE[.W_ &]?_P !
MM;Y$?7:OL_@C[2__ &[;_P "O?YER;XAW@N+<16Z?9RH^TEC\X;OY1$@ 'U5
M_K6:P4.65Y/F^QVMYZ?JBWC9\T>6"Y?M][^6OZ,(?B'>?:+@2VZ"W"G[,5/S
MENWFGS""/]U4^M#P4.6/+)\WV^UO+3]6"QL^:5X+E^QWOYZ_HBG_ ,+$U7[!
MN^S0_P!H;^G/D[,^GG;MV/\ IICVK3ZE2]I;GE[.W_;U_P#P&UOD1]=J^S^"
M/M+_ /;MO_ KW^9<F^(=X+BW$5NGV<J/M)8_.&[^41( !]5?ZUFL%#EE>3YO
ML=K>>GZHMXV?-'E@N7[?>_EK^C"'XAWGVBX$MN@MPI^S%3\Y;MYI\P@C_=5/
MK0\%#ECRR?-]OM;RT_5@L;/FE>"Y?L=[^>OZ(I_\+$U7[!N^S0_VAOZ<^3LS
MZ>=NW8_Z:8]JT^I4O:6YY>SM_P!O7_\  ;6^1'UVK[/X(^TO_P!NV_\  KW^
M9<F^(=X+BW$5NGV<J/M)8_.&[^41( !]5?ZUFL%#EE>3YOL=K>>GZHMXV?-'
ME@N7[?>_EK^C"'XAWGVBX$MN@MPI^S%3\Y;MYI\P@C_=5/K0\%#ECRR?-]OM
M;RT_5@L;/FE>"Y?L=[^>OZ(I_P#"Q-5^P;OLT/\ :&_ISY.S/IYV[=C_ *:8
M]JT^I4O:6YY>SM_V]?\ \!M;Y$?7:OL_@C[2_P#V[;_P*]_F7)OB'>"XMQ%;
MI]G*C[26/SAN_E$2  ?57^M9K!0Y97D^;[':WGI^J+>-GS1Y8+E^WWOY:_HP
MA^(=Y]HN!+;H+<*?LQ4_.6[>:?,((_W53ZT/!0Y8\LGS?;[6\M/U8+&SYI7@
MN7['>_GK^B*?_"Q-5^P;OLT/]H;^G/D[,^GG;MV/^FF/:M/J5+VEN>7L[?\
M;U__  &UOD1]=J^S^"/M+_\ ;MO_  *]_F7)OB'>"XMQ%;I]G*C[26/SAN_E
M$2  ?57^M9K!0Y97D^;[':WGI^J+>-GS1Y8+E^WWOY:_HPA^(=Y]HN!+;H+<
M*?LQ4_.6[>:?,((_W53ZT/!0Y8\LGS?;[6\M/U8+&SYI7@N7['>_GK^B*?\
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MOZ(I_P#"Q-5^P;OLT/\ :&_ISY.S/IYV[=C_ *:8]JT^I4O:6YY>SM_V]?\
M\!M;Y$?7:OL_@C[2_P#V[;_P*]_F7)OB'>"XMQ%;I]G*C[26/SAN_E$2  ?5
M7^M9K!0Y97D^;[':WGI^J+>-GS1Y8+E^WWOY:_HPA^(=Y]HN!+;H+<*?LQ4_
M.6[>:?,((_W53ZT/!0Y8\LGS?;[6\M/U8+&SYI7@N7['>_GK^B*?_"Q-5^P;
MOLT/]H;^G/D[,^GG;MV/^FF/:M/J5+VEN>7L[?\ ;U__  &UOD1]=J^S^"/M
M+_\ ;MO_  *]_F7)OB'>"XMQ%;I]G*C[26/SAN_E$2  ?57^M9K!0Y97D^;[
M':WGI^J+>-GS1Y8+E^WWOY:_HPA^(=Y]HN!+;H+<*?LQ4_.6[>:?,((_W53Z
MT/!0Y8\LGS?;[6\M/U8+&SYI7@N7['>_GK^B*?\ PL35?L&[[-#_ &AOZ<^3
MLSZ>=NW8_P"FF/:M/J5+VEN>7L[?]O7_ / ;6^1'UVK[/X(^TO\ ]NV_\"O?
MYER;XAW@N+<16Z?9RH^TEC\X;OY1$@ 'U5_K6:P4.65Y/F^QVMYZ?JBWC9\T
M>6"Y?M][^6OZ,(?B'>?:+@2VZ"W"G[,5/SENWFGS""/]U4^M#P4.6/+)\WV^
MUO+3]6"QL^:5X+E^QWOYZ_HBG_PL35?L&[[-#_:&_ISY.S/IYV[=C_IICVK3
MZE2]I;GE[.W_ &]?_P !M;Y$?7:OL_@C[2__ &[;_P "O?YER;XAW@N+<16Z
M?9RH^TEC\X;OY1$@ 'U5_K6:P4.65Y/F^QVMYZ?JBWC9\T>6"Y?M][^6OZ,(
M?B'>?:+@2VZ"W"G[,5/SENWFGS""/]U4^M#P4.6/+)\WV^UO+3]6"QL^:5X+
ME^QWOYZ_HBG_ ,+$U7[!N^S0_P!H;^G/D[,^GG;MV/\ IICVK3ZE2]I;GE[.
MW_;U_P#P&UOD1]=J^S^"/M+_ /;MO_ KW^9<F^(=X+BW$5NGV<J/M)8_.&[^
M41( !]5?ZUFL%#EE>3YOL=K>>GZHMXV?-'E@N7[?>_EK^C"'XAWGVBX$MN@M
MPI^S%3\Y;MYI\P@C_=5/K0\%#ECRR?-]OM;RT_5@L;/FE>"Y?L=[^>OZ(I_\
M+$U7[!N^S0_VAOZ<^3LSZ>=NW8_Z:8]JT^I4O:6YY>SM_P!O7_\  ;6^1'UV
MK[/X(^TO_P!NV_\  KW^9<F^(=X+BW$5NGV<J/M)8_.&[^41( !]5?ZUFL%#
MEE>3YOL=K>>GZHMXV?-'E@N7[?>_EK^C"'XAWGVBX$MN@MPI^S%3\Y;MYI\P
M@C_=5/K0\%#ECRR?-]OM;RT_5@L;/FE>"Y?L=[^>OZ(I_P#"Q-5^P;OLT/\
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MN7['>_GK^B*?_"Q-5^P;OLT/]H;^G/D[,^GG;MV/^FF/:M/J5+VEN>7L[?\
M;U__  &UOD1]=J^S^"/M+_\ ;MO_  *]_F7)OB'>"XMQ%;I]G*C[26/SAN_E
M$2  ?57^M9K!0Y97D^;[':WGI^J+>-GS1Y8+E^WWOY:_HPA^(=Y]HN!+;H+<
M*?LQ4_.6[>:?,((_W53ZT/!0Y8\LGS?;[6\M/U8+&SYI7@N7['>_GK^B*?\
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MY>SM_P!O7_\  ;6^1'UVK[/X(^TO_P!NV_\  KW^9Z9X>UR'Q!9I=P,K'A9
MO1) JED_#<#U/!')KQZU*5";A)-=5?JKZ/\  ]>C5C7@IQ:[.W1VU7XFW7.=
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!PGQ,_P"1=N_^V'_I3#7I8#_>(?\ ;W_I$CS<
M=_N\_P#MW_TN)\F5]N?$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $$\IB (QR>]>;C,1
M+#0C.FDVY6UOV;Z-'I8/#QQ,Y0FVDHWTLNJ75,],TK7+K6H(//MXHH[:$6Z3
M1J09!"L: .2S$L%QDC Z8  KR\/+GA.HW[TIMN/17UT^;/4Q$?9SC34?=C!)
M2ZNVFOR1K5U'*% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#V#P']O_ ++3^TMF[<?)V8_U.U=N['\6_?GVQ7A8OV?M
M7[&]K>]?^:[O\K6/=PGM/9+VMKW]VW\ME^-[G9UYYWA0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!ZK\-X;>#2<6UPUV&E9G+'/EN4C!B'L %;_@9KQ<<Y.K
M[\>3W5;S5WK^:^1[.!48TO<ES:N_D[+3\G\SOJ\P],* "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M:_)&M74<P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 >J_#>:WFTG-M;M:!965PPQYC[(R91[$%5_X :\7'*4:O
MORYO=5O)7>GYOYGLX%Q=+W(\FKOYNRU_)?([ZO,/3"@ H * "@ H * "@ H
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M0L/=&!CR^/1NE<F$:]DTHZ\WQ=U;8[,6G[5/FTY?A[.^YU==IQ!0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@#V#P']O_ ++3^TMF[<?)V8_U.U=N
M['\6_?GVQ7A8OV?M7[&]K>]?^:[O\K6/=PGM/9+VMKW]VW\ME^-[G9UYYWA0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M6URW4FX^S<I<O\O,[:;:7L%IJ]]I\9AM;B>"-R2R12R(K$@ DJK $D  DCH
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MY)13CV:37W/0F,Y0?-"34NZ;3U\UJ,N;J:]D,]S(\TKXW/(S.YP HRS$DX
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MO4IU:JG"_-R1;OV:4E\[-7.CK8Q"@ H * "@ H * "@ H * "@ H * "@ H
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M#UZUW4INI!3E:[OMY-HX*L%3FX1O96W\TF:=;F(4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0!ZK\-X;>#2<6UPUV&E9G+'/EN4C!B'L %;_@9KQ<<Y.K[\>3W5;S5WK^:^
M1[.!48TO<ES:N_D[+3\G\SOJ\P],* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M=SMC%05HFA2+"@ H * "@#A/B9_R+MW_ -L/_2F&O2P'^\0_[>_](D>;CO\
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MZ),6;Z98?S(KB:;PZMTE=^FJ_4[4TL0[]8V7KH_T.FT34+:/3TW.B>6I#@D
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MT[>KZO\ X!T6^K4[03<WV5]>[\ET7_!.NU+58M.M"]IY;["J*%(*KG.,A3T
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M=EK^2^1WU>8>F% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % ',>,_^01/_P!LO_1T=5'<PK? _E^:-30_^0?:_P#7O#_Z+6D]V7#X8^B_
M(TZ1H% !0 4 9>K:/!K,:PW._8CA\*VW) (P>#QS['T(IIVV,Y04U:7J7X((
M[5%BA4(B#"J!@ ?Y_.D6DDK+1$M PH * "@ H * .$^)G_(NW?\ VP_]*8:]
M+ ?[Q#_M[_TB1YN._P!WG_V[_P"EQ/DROMSXD* "@ H * "@ H * "@ H *
M"@"2*)YW6*,%G=@J@=2S'  ]R3BDVHIM[+5_(:3DTEN]$=YXJMO(NK7PS:D!
M;,1QNQR%>ZN-IEE;&XX&Y5'!**I49%>9AY7C/&3WG=I=5"-[);>;\[GI8B/+
M*&#AM"R?9SE:[?WI>5ADWP]O+-RE[<V-EAF5#<3F/S0IP7C&PL4SQEE3/7&"
M"6L9"2O3A4GHF^6-^6_1ZVOZ-B>"G!VJ3IPU:7-*W-;JM+V]4CGM5\.WFC7:
MV%PJ^;)M,95@4D5SA65S@;2>,MMQ@[L5U4ZT*L'4@W97O=:JVZ:[G+4HSI35
M*:5W:UGH[[-/L:__  K_ %O_ )X1_P#@5:?_ !^L/KE#^9_^ 3_^1-_J=?\
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M.TP:(F4+#W1@R98CT:N3"->R:4;/FUEWTV.O%I^U3YM.72/;7<ZJNTX@H *
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M&]!P>H]3@X/!Q6.)E%)*<6XOJG9IFV&C)MNG)*2Z-:-''W?]F10,MGYLDSX
M,G\ R"<8"C)QMZ'J>:\Z?L5%JGS.3MOT_+T/2A[9R3J<JBK[=?S]3T+0K=[2
MQBBD&U@"2#U&YBV#[X/->Q0BX4XQ>_\ FV_U/'KR4JDI1V_R27Z&M70<X4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0![!X#^W_ -EI_:6S=N/D[,?ZG:NW=C^+?OS[8KPL
M7[/VK]C>UO>O_-=W^5K'NX3VGLE[6U[^[;^6R_&]SLZ\\[PH * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M3A.W*IR2MW3<7\KIV.^O4IU:JG"_,X1;OV:4E\[-7.BK8R"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H 0@$8/(- $$%K#;9\F-(]V,[%5<XSC.
M,XR<?4U,8QA\*2]$E^14I2E\3;MW;?YEBJ)"@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@!KHL@*N RGJ",@_4&DTGH]@3:U6A6CL+:%M\<4:,.
MZHH/Y@9J%"$=5&*?DDC1SF]'*37FV6ZT,PH * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M]5^&\-O!I.+:X:[#2LSECGRW*1@Q#V "M_P,UXN.<G5]^/)[JMYJ[U_-?(]G
M J,:7N2YM7?R=EI^3^9WU>8>F% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % ',>,_^01/_P!LO_1T=5'<PK? _E^:-30_^0?:_P#7O#_Z
M+6D]V7#X8^B_(TZ1H% !0 4 % !0 4 % !0 4 % !0!PGQ,_Y%V[_P"V'_I3
M#7I8#_>(?]O?^D2/-QW^[S_[=_\ 2XGR97VY\2% !0 4 % !0 4 % !0 4 %
M !0!;L+MM/N8KM!EH)4E4'N48,/U%1.*G&4'M)-?>K%PDX2C-;Q:?W.YVOBD
M1:=KZ:G'EK2[>&_C*CED=E>3@X&[S _!([9QGCSL/>>'=%Z3BI4W?HUHOE:Q
MZ&(M3KJLO@DXU%;JGJ_G>YS_ (IU6+6]4N+^W#K%.P90X 8 (J\A68=0>C'B
MNK#TW1I1I2M>*UMMNWUL<N(J*M5E5C=)O2^^R72Y8US6H=2L=/M(E=7L89(Y
M"P4*2SA@4(8DC YW!3GM4TJ4J<ZLW:TY)JU[Z*VNGY7+JU8U(4H1O>$6G>UM
M7?37_(Y>NPXR:#R_,3SMWE;EW[<;MN1NVYP-V,XR0,]:EWL^6U[:7VOTOY#5
MKKFVOK;>W6QZ;KNO>&M>D1YO[4BC@C6.&&)+58HD4 813(<9P"QR2>!T50/'
MHT<3034?8MMMRDW/FDWW=OZ^\]BK6PU9IR]LE%)1BE!1BEV5SDM5&@"#_B5F
M_-QN'_'R+<1[?XO]6Q;=TQV]:[J?M^;]][/E_N\U[_/0X:GL.7]S[3F_O<MK
M?)W-1=>TS6+6&#7([@3V:"**YM?++O"N=L<J2E0=F?E8')SSCG=C[&K2E*6&
M<>6;NXSO92>[BUWZK^EM[:E5C&.)4N:"LI0M=QZ*2=MNC_IUM3U^SCL#I&C1
M20VTKK)/+.5,\[+RBL$^1$0X(53R1G@[MUTZ,W4]OB&G))J*C?EBGNU?5M]W
M_E:*E:"I^PPZ:@W>3E;FDULG;1)=E_G>MX8UN'0S>22"0R7%E-;0[ I"R2[<
M.Q9UPJ[>P8G/3CFZ])UO9I6M&I&4KWV5]%9/5W\B:%54>=N]Y4Y1C:VC=M7J
MM%;S.7KL.,[WP*PTQ[K7) -FGV[^63D9N)P8XD'!^\"^3_".2,5YF+_>*&&6
M]22O_ACK)_D>EA/W;GB7M3B[?XI:17YG!5Z9YH4 % !0 4 % !0 4 % !0 4
M % $$\IB (QR>]>9C,1+#1C*FDVW;6_;R:/2P>'CB92C-M)*^EEU\TSTW2];
MNM9M[<SV\<4=O ($FC4@R"$1H Y)8E@H&3P.!@ <5YF'ESPE4<O>E-MQZ*]W
MI\V>GB(^SG&FH^[&"2EU=K+7Y(U:ZCF"@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#U7X;S6\VDYMK=K0+*RN&&
M/,?9&3*/8@JO_ #7BXY2C5]^7-[JMY*[T_-_,]G N+I>Y'DU=_-V6OY+Y'?5
MYAZ84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <QXS_Y
M!$__ &R_]'1U4=S"M\#^7YHU-#_Y!]K_ ->\/_HM:3W9</ACZ+\C3I&@4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 >P> _M_\ 9:?VELW;CY.S'^IVKMW8_BW[\^V*\+%^S]J_
M8WM;WK_S7=_E:Q[N$]I[)>UM>_NV_ELOQO<[.O/.\* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * .8\9_\@B?_ME_Z.CJH[F%;X'\OS1J
M:'_R#[7_ *]X?_1:TGNRX?#'T7Y&G2- H * "@ H * "@ H * "@ H * .$^
M)G_(NW?_ &P_]*8:]+ ?[Q#_ +>_](D>;CO]WG_V[_Z7$^3*^W/B0H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@""XB,H &.#WKS,9AYXF,8TVE9WUNNGDF>G@\1##2E*:;
M35ERV[^;1Z!HNG0:6$A)W7K0K-)M+%!%.D,T0Y5?G".N_&0#D GK7!0IU*5)
MPG;E4Y)6[IN+^5T['=7J4ZM53A?F<(MW[-*2^=FKG15L9!0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!ZK\-X;>
M#2<6UPUV&E9G+'/EN4C!B'L %;_@9KQ<<Y.K[\>3W5;S5WK^:^1[.!48TO<E
MS:N_D[+3\G\SOJ\P],* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ7_R0?V91_FG]\?_ )$/^%-Z/_SVO/\ OY#_ /(]']IUOY:?W2_^2#^S*/\
M-/[X_P#R(?\ "F]'_P">UY_W\A_^1Z/[3K?RT_NE_P#)!_9E'^:?WQ_^1#_A
M3>C_ //:\_[^0_\ R/1_:=;^6G]TO_D@_LRC_-/[X_\ R(?\*;T?_GM>?]_(
M?_D>C^TZW\M/[I?_ "0?V91_FG]\?_D0_P"%-Z/_ ,]KS_OY#_\ (]']IUOY
M:?W2_P#D@_LRC_-/[X__ "(?\*;T?_GM>?\ ?R'_ .1Z/[3K?RT_NE_\D']F
M4?YI_?'_ .1#_A3>C_\ /:\_[^0__(]']IUOY:?W2_\ D@_LRC_-/[X__(A_
MPIO1_P#GM>?]_(?_ )'H_M.M_+3^Z7_R0?V91_FG]\?_ )$/^%-Z/_SVO/\
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M'>_GI^K*?_"N]5^P;?M,/]H;^O/D[,^OD[MV/^F>/>M/KM+VGP2]G;_MZ_\
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M7@^;[':WGK^C+>"GS1Y9+E^WWOY:?J@A^'EX+BX,MPGV<J?LP4?.&[>:/+
M_P!UG^E#QL.6/+!\WV^UO+7]$"P4^:5Y+E^QWOYZ?JRG_P *[U7[!M^TP_VA
MOZ\^3LSZ^3NW8_Z9X]ZT^NTO:?!+V=O^WK_^!6M\R/J57V=N>/M+_P#;MO\
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MWK_^!6M\R/J57V=N>/M+_P#;MO\ P&]_D7)OAY>?:+<Q7""W"C[2&'SEN_E
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M'>_GI^K*?_"N]5^P;?M,/]H;^O/D[,^OD[MV/^F>/>M/KM+VGP2]G;_MZ_\
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M[*_17T7XGKT:4:$%"*7=VZNVK_ VZYSH"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@#F/&?_ "")_P#ME_Z.CJH[F%;X'\OS1J:'_P @
M^U_Z]X?_ $6M)[LN'PQ]%^1ITC0* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /#?CG_QX6?_ %\-_P"BS30C=^#?_(OK_P!?$W_L
MM SU6D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 <QXS_Y!$_\ VR_]'1U4=S"M\#^7YHU-
M#_Y!]K_U[P_^BUI/=EP^&/HOR-.D:!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!YQ\2/&%YX/MH)[%(9&FE9&$RNP "[N-DD9SG
MU)^E,#3\ ^)+CQ5I8O[M8XY#+(F(@P7"XP<,SG///-(#M* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#F/&?\ R")_
M^V7_ *.CJH[F%;X'\OS1J:'_ ,@^U_Z]X?\ T6M)[LN'PQ]%^1ITC0* "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /"_CH?\ 0;,?
M]-W_ /1=- =#\'!CP\O_ %WF_F* /4Z0!0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MQ2>4XWO&L;;9/E^1VSU&5YI =73 * "@ H * "@ H * .8\9_P#((G_[9?\
MHZ.JCN85O@?R_-&IH?\ R#[7_KWA_P#1:TGNRX?#'T7Y&G2- H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \W^)'@Z\\86]O#8O#
M&T$C.QF9U!!7 QLCD.<^H'UH U/ /AVY\+:4NGWC1O*LDCYB+,N&((Y94.?7
MY: .TH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_+\T:FA_\@^U_P"O>'_T6M)[LN'PQ]%^1ITC0* "@ H * "@ H * "@ H *
M"@#R+Q1J=W;ZE-'%/-&B^7A5D=5&8D)P 0!DDD^YS7PV/KU88FI"%2<8KELE
M*22]R+V3MN?;X"A2GAX2G3A*3YKMQBW\<ENT<_\ VS?_ //S/_W]D_\ BJ\S
MZS7_ .?M3_P.7^9Z7U:A_P ^J?\ X!'_ "#^V;__ )^9_P#O[)_\51]9K_\
M/VI_X'+_ ##ZM0_Y]4__  "/^0?VS?\ _/S/_P!_9/\ XJCZS7_Y^U/_  .7
M^8?5J'_/JG_X!'_(/[9O_P#GYG_[^R?_ !5'UFO_ ,_:G_@<O\P^K4/^?5/_
M , C_D']LW__ #\S_P#?V3_XJCZS7_Y^U/\ P.7^8?5J'_/JG_X!'_(/[9O_
M /GYG_[^R?\ Q5'UFO\ \_:G_@<O\P^K4/\ GU3_ / (_P"0?VS?_P#/S/\
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M_P#O[)_\51]9K_\ /VI_X'+_ ##ZM0_Y]4__  "/^0?VS?\ _/S/_P!_9/\
MXJCZS7_Y^U/_  .7^8?5J'_/JG_X!'_(/[9O_P#GYG_[^R?_ !5'UFO_ ,_:
MG_@<O\P^K4/^?5/_ , C_D']LW__ #\S_P#?V3_XJCZS7_Y^U/\ P.7^8?5J
M'_/JG_X!'_(/[9O_ /GYG_[^R?\ Q5'UFO\ \_:G_@<O\P^K4/\ GU3_ / (
M_P"0?VS?_P#/S/\ ]_9/_BJ/K-?_ )^U/_ Y?YA]6H?\^J?_ (!'_(/[9O\
M_GYG_P"_LG_Q5'UFO_S]J?\ @<O\P^K4/^?5/_P"/^0?VS?_ //S/_W]D_\
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MJ:M';3\#-*,8SIJ*Y9N\M]?Q"-I(I99E=P]P,.<CD'\*$Y1E.HI/FFK2VU_
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MX?\ T6M)[LN'PQ]%^1ITC0* "@ H * "@ H * "@ H * "@#Q3Q=_P A6?\
M[9_^BHZ_/LQ_WJI_V[_Z1$^_R[_=:?\ V]_Z7(YNO)/5"@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * .)\;?ZF'_?;_ -!KZ?)_XE3_  K\SYK-_@I_XG^1V'P_=#IJ*(RK
MAI<R=F&Y<#\*Z<:X^WLHVER*\N^NWR.;!*2H7<KQYW:/;S^9WM<!W!0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!I:#)$NHHC1%Y&0[9.T?RN3GZ@%?^!5UX1Q6(C%P;DT[3Z1TE?[U=?,Y,6I?
M5Y-32BFKQ_FUC^3L_D>C5]6?+!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % %>\M(K^"2UN%WPSQO%(N2-R.I5AE2&&5)&001U!!H P
MO#'@_2?!D#VNBP?989G\QU\R:3+[0N<S22,/E4# ('&<9I; 9VK_  Z\/Z[J
M4>M7UHLM_"8RDPEGC.83NC++'*B.5(&"ZL2H"G*@ %@-W7/#NG>)K?['JMO%
M=PYW!9%SM;!&Y&&&1L$C<I!P2,X-,#G/#_PP\,^%IQ=Z9810SK]V1VEF="1C
M*-/)(4..,IM."?4Y5K :/B'P1HWBJ>WN]5M_M$UB28&\V:/82RL>(I$5OF13
M\X;ICH3D F\3^#])\90):ZU!]JAA?S$7S)HL/M*YS#)&Q^5B,$D<YQF@#H+>
M!+6)((AMCB5409)PJ@*HR22<  9))]33 E(SP: /,[OX.>$+VX-W+IL(D)W$
M(\T4><Y_U,4J1?ALQ[4K(#LY?#VG3::VBF!$T]XC ;>/,2>6P(95\LHRYR<E
M2&R2<Y.:8#/#OAK3O"=H-.TF+[-;*S.$WR2?,YRQW2N[\^F[ [ 4; 5O$?@_
M1_%T:PZS:Q7:QYV%MRNF[&[9(A61 <#(5AG ST% %/PU\/\ 0/"#F71[**VE
M8%3)EY)=IY*B69Y) I[J& .!D<"E:P$GB7P)H7C JVLV<5T\8VK)EXY0N<[?
M-B9)-N<D+NV@DG')R6 =X9\#Z)X.##1;2.U,@P[@N\C#.=IEE9Y"N>=N[;GG
M&:-@#2/!&C:#J%SK%A;^3>WYD:XE\V9_,,LGFN=CR-&NZ3YOD1<=!A>* '>*
M/!6C^-(XHM;MQ=+;LS1?O)8RI8 -AH9(VPP RI)4D XR 0 =%:VT5E#';0*(
MXH46.-!T5$ 55'L%  ^E,#@-6^$GA36[DWMYIT33NQ9FC>:$.Q.2SK#)&C,Q
MY8LI)).<Y-*P':Z3H]EH5LMEIT,=K;QYVQQ*%4$\DG'5B>68Y9CR233 T: "
M@ H * .8\9_\@B?_ +9?^CHZJ.YA6^!_+\T:FA_\@^U_Z]X?_1:TGNRX?#'T
M7Y&G2- H * "@ H * "@ H * "@ H * /%/%W_(5G_[9_P#HJ.OS[,?]ZJ?]
MN_\ I$3[_+O]UI_]O?\ I<CFZ\D]4* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@!R(TA"H"S'@ #))]@*I)R=HJ[>R6Y+:BKMV2ZO
M1%N;3KJW7S)898T'\31NH_,@"MI4*M-<TZ<XKNXR2^]HQC6I3?+"I!OLI1;^
MY,I5SG07GTV[C3S&AE5 ,[C&X7'KDC&/>NAT*L5SNG-1WNXR2MZVL<ZKTF^1
M5(.6UE*-[^E[E&N<Z H * "@ H * "@ H * .>\0Z1-JT<:0E%*,2=Y(ZC'&
M%:O9P&*A@Y3E44FI))<J3Z^;1Y&.PL\7&,:;BG%MOF;73R3.Q\)Z9>:3IT4-
MR4,3&5XRASU?!SD ]5/:O2KUI8B4:T5:DXOEO92NI6=[-]4['FT*,</&5&3O
M54ES6ORV<;JUTNC5SIZY3I"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#9\/?:?MH\K;]GVGS<_>Z-MQ_P+;GVS
M7?@_:>V]RWL[>_WZVM\['!C/9^Q]Z_M+^YVZ7O\ *YW]?3GS04 % !0 4 %
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M>;5[=%9/7KZ7.3$5XX6'M9J3C=+W4G:_>[6G3U(KW3Y;"X:TDP9$(7Y<D$L
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M4FN5I;OS3/'QV*GA(PE347S-I\R;V7DT=;X1O?[2LTN9''FGS%:)<[4"N,$
MDXSU//4UV5L/3PM14Z<Y2]WX9-.UWY)+7T..EB)XFFZE2$8^]\45:]EYMO3U
M.LK,T"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M5<N)!(,QB()DN7!RNWMEB0H)% >36G[1_A:YG$#K?0(3CSI(8_*'.,GRYY)
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M59' #-NEW\@<#EL<>E5L@/G3P#\&8O'GAN;5K>XDAU!)I8H8V"F!S&L;*&.
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M-[F-"W')18TV_P!TC(P:%L!A?!3_ ))]K7_774/_ $WV]"V T_V9&":%?,Q
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MUU\'4JXF&)BX\L7!M-N_NN[MHUZ:E?POKD&B/*TZNPD"@; IZ$YSN9?7WK+
M8J&#<W44GS))<J3VOO=KN:X["SQ:@J;BN5MOF;6]MK)G/WLRW-Q+,F0LDCN
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MI5S@HJ.A/&2"'RN>,KS^.*]:K73C%8_#2<EMRJ,HWZV:EI?MK\['E4Z#4I/
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_D>ERKN5[67_ #[?X_Y!_P )9J'_ $"[C_R)_P#(]'*NX>UE_P ^W^/^0?\
M"6:A_P! NX_\B?\ R/1RKN'M9?\ /M_C_D'_  EFH?\ 0+N/_(G_ ,CT<J[A
M[67_ #[?X_Y!_P )9J'_ $"[C_R)_P#(]'*NX>UE_P ^W^/^1R&O7TTKK?BQ
MGT^=&'[[+@,?]H&% 6]]V2,A@PQBTNE[G-.3OS\CB^_])'HOA?5[C5[7S+F,
MHR\"3&%E_P!I1U!'\6!MS]T]57-JVQVTIN:O)6\^YTM2;A0 4 % !0!XIXN_
MY"L__;/_ -%1U^?9C_O53_MW_P!(B??Y=_NM/_M[_P!+D<W7DGJA0 4 % !0
M 4 % !0 4 % !0!O:/XAN-$5T@6-A(03O#'H,<;77^M>EAL94PBE&FHM2:;Y
MDWMZ21YN)P=/%N,JCDN5-+E:6_JF8->:>D% !0 4 % !0 4 % !0 4 % !0
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MF@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!Y;\1;%HC;ZK#P\3!&([8.^,_@0PS[J*]K
MSOS4);-77Y/]#Q\;"W+6CNG9_FOU*GC/6#J]O8VEMRUX%F*CU;Y$7U^^7!'J
MHZU>%I>RE4G/:%XW]-6_NM]YGB:GM8TX0WG:5O71+[[_ '$'C#S+,66@6[;8
MQ&F[&0'9F* MZC<K-CU;/88K"VE[3%26MW;R25]/DTOD3B;P]GAH:*ROYMNV
MOS3?S+7B'P/::9I[75JT@FMPK,6;AQD!N /E/.1@]L<YS44<7.I44)I<LKK3
MI_F76PL*=-S@WS1L]>O^1#=ZG+JGA8R3G=)'*L18]6VLI!/J=I )[D9[U4::
MI8JT=$XMV[73_4F4W4PMY;II7]&AFA^$K2_T<W]P7:9DE9"&P$$9=5 '?E23
MG(YP,4ZN)G"M[*%E%.-]-[V?ZBI8>$Z/M97YK2MKM:Z_07P;JLMAI-](#D6P
M#Q@\@,ZL.GIN"DCZ^M&*IJ=6DOYM'Z)K]+CPU1PI5'_+JO5I_K8C\)^&(?$<
M4M_J+R2,TA08;!) !9V."2?F  Z<'((Q3Q.(>'<:5)))*^WW)?<+#T%73JU6
MV[VW_%_>/\/M+X<U]])#EH)&*X/O'YD;8Z!L$*Q'8GVI5K8C#JO:TEK^-FO3
MJ@HWP]=T+^Z]/PNGZF6FEKK'B*>TD9DC::8OM."55BVWTY('7IUZ@5LZGL<-
M&:5VHQM?NU:YDJ?M<1*#=DY2O;LM;%KQ5HT?A.XMKS369"Q;@MG#)M/7NK!L
M,#_(U&'JO%1G3JI/;I;1W_*Q6(I+#2A.DVM_O5OSN2?$"9KBXLY4^5I( PP>
M06;(Y]B>M+!+EC4B]E*WW(>,?-*G):7C?\3M=&\%6VC2+<QN[7"QLNYMI0.P
MP75=H/'( +<@\\\UYU7%2JIP:2C=.RO>RZ-W_0]&EA8TFIIOFLU=VM=];'!O
M9:#8RR_VA=27\S,3F)6!![DMDHS$_P"V1QR!FO34Z\U'V4%3BE]IK\MTOD>:
MX4(.7M9N;_NI_GLW\R[\.92\]U9@MY+Q[@I[88+G'0,5;!QZ>PK/'*T85-.9
M.U_E?[KHTP3]Z<->5J]OG;[]2MXMT;2-!C$4 D>[DY53)D(O]]@!WZ*.YY/
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H TM!CB.HH[2E)%0[8NS_ "N#GZ EO^ UUX11^L1;FU))VATEI*_W
M*[^1R8MR6'DE!.+:O+^76/YNR^9Z-7U9\L% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <IXI\$:-XT6*/
M6[?[4ML6:(>;-%M+A0Q_<R1DY"C[V<8XQS2 ZNF 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % ',>,_P#D$3_]LO\ T='51W,*WP/Y?FC4T/\ Y!]K_P!>\/\
MZ+6D]V7#X8^B_(TZ1H% !0 4 96L:Q#HL'GS9.3M11U9L$@#TZ<D\#ZX!:5]
M#.<U35V<E8Z/=>(Y1?ZQE(1S%;#(&.H+#J >^?F?OM7 -WY=$<\8.H^>IMTB
M>@(BQJ$0!54   8  Z #L!69V;:(=0 4 % !0 4 >*>+O^0K/_VS_P#14=?G
MV8_[U4_[=_\ 2(GW^7?[K3_[>_\ 2Y'-UY)ZH4 % !0 4 % !0 4 % !0 4
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M:W6B6C6L>MCLI57*I.A4LIQU5M%*#V>K>J>DNES*KB.P* "@ H * "@ H *
M"@ H * "@#B/&W^JA_WV_D*^HR?XZG^%?FSYG-_@I_XG^2.S\ .G]FQJ(RKA
MI29.S#>,#\/Z5OC7'ZQ91M)15Y=]M/D88-25"[E>/,[1[;Z_,[NN$[0H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M35KM/73J7AXU*4YN47?EE;1V;O>R:TUZ'.10ZN+[^T;BRGN9=V_$D$VW=V.
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MS_UT3_T$UEC_ (H>C_,TP'PS]5^1Z?7C'L!0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &E
MH,D2ZBB-$7D9#MD[1_*Y.?J 5_X%77A'%8B,7!N33M/I'25_O5U\SDQ:E]7D
MU-**:O'^;6/Y.S^1Z-7U9\L% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_I<CFZ\D]4* "@ H * "@ H * "@ H * "@#H/"]LMSJ$>\92+=*W_ !D?\
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MY.&[^:LGY'#B?W=:A6CUE[*7FI[+Y.[7F<Q7CGKA0 4 % !0 4 % !0 4 %
M!0 4 <[XBTB;5DC6$HIC8D[R1U '&%:O9P&*A@Y3E44GS))<J3V;WNT>/C\+
M/%QA&FXKE;;YFUNEM9,[3PIIUYI>G0P7)0Q?O6C*'/60@YR >H/45Z->M+$2
MC6BK4I1?)>RE=.SO9OJG;4\ZA1CAXRHMWJQDN:U^6S5U:Z71JYTM<QTA0 4
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M2H1Y%J]V^[-VN8Z0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#9\/?:?MH\K;]GVGS<_>Z
M-MQ_P+;GVS7?@_:>V]RWL[>_WZVM\['!C/9^Q]Z_M+^YVZ7O\KG?U].?-!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MD:!0 4 % !0 4 % !0 4 % !0 4 >*>+O^0K/_VS_P#14=?GV8_[U4_[=_\
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MW?AD_ANT^B2U].IQTJ\\33]I4A&/O?%%6O9-=6WIZG5UF:!0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M #!CM#IC.UZ-@/4-3@\2/<.=.N--BM3M\M+BTN991\HW;WCO84;+[BN(UPI
M.2"Q8$-G;^*%G0W=SI;VX8>8L5E=)(4S\P1WOY%5B.A9& /530!L>(=<@\-:
M=<:K=_ZFTB:1@.K$#Y47_:=B$7MN89I@>8_!_1)KBVE\8:OB35==/F[L?ZFU
MS^YACSG:C*%? ZIY0;)2DNX'H'C+Q-#X/T>ZUB?!%M&2B'^.5B$BC]</(R@D
M?=7+=!1L!QOPC\-2Z=IIUW4SYNKZX1=W,K#YE23YH81_=5$(8H,;68IT1<"
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MK? _E^:-30_^0?:_]>\/_HM:3W9</ACZ+\C3I&@4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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ME ((8*T<8?YAD$+]X'&#G%,#SSP'HMWJ^NZAXTU6&6U:X_T/3[>=&CECM(B
M9'C=0Z-,5# -@C,G574TO,#V6F 4 % !0 4 % !0 4 % ',>,_\ D$3_ /;+
M_P!'1U4=S"M\#^7YHU-#_P"0?:_]>\/_ *+6D]V7#X8^B_(TZ1H% !0 4 %
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M#^QK_P#Y]I_^_4G_ ,31]6K_ //JI_X!+_(/K-#_ )^T_P#P./\ F']C7_\
MS[3_ /?J3_XFCZM7_P"?53_P"7^0?6:'_/VG_P"!Q_S#^QK_ /Y]I_\ OU)_
M\31]6K_\^JG_ (!+_(/K-#_G[3_\#C_F']C7_P#S[3_]^I/_ (FCZM7_ .?5
M3_P"7^0?6:'_ #]I_P#@<?\ ,/[&O_\ GVG_ ._4G_Q-'U:O_P ^JG_@$O\
M(/K-#_G[3_\  X_YA_8U_P#\^T__ 'ZD_P#B:/JU?_GU4_\  )?Y!]9H?\_:
M?_@<?\P_L:__ .?:?_OU)_\ $T?5J_\ SZJ?^ 2_R#ZS0_Y^T_\ P./^8?V-
M?_\ /M/_ -^I/_B:/JU?_GU4_P# )?Y!]9H?\_:?_@<?\P_L:_\ ^?:?_OU)
M_P#$T?5J_P#SZJ?^ 2_R#ZS0_P"?M/\ \#C_ )A_8U__ ,^T_P#WZD_^)H^K
M5_\ GU4_\ E_D'UFA_S]I_\ @<?\P_L:_P#^?:?_ +]2?_$T?5J__/JI_P"
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M_P"?:?\ []2?_$T?5J__ #ZJ?^ 2_P @^LT/^?M/_P #C_F']C7_ /S[3_\
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MBI4DU*2O:.[L]/P*<6FHNUY;*ZU_$&F5%5SD+)PAVMS].*'))1D[VEL[/7\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H YCQG_ ,@B?_ME_P"CHZJ.YA6^!_+\T:FA_P#(/M?^O>'_ -%K2>[+
MA\,?1?D:=(T"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#S/XD^#+WQC%;1V+PQFW>1F\YG4$.% V[(Y,GY3G./QI@;?@3P_<>&-
M)CTZ[,;2QO(Q,19DP[EA@LJ'H>?E'/K2 [&@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H YCQG_ ,@B?_ME_P"CHZJ.
MYA6^!_+\T:FA_P#(/M?^O>'_ -%K2>[+A\,?1?D:=(T"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#S/XD^,[WP=%;26*0R&X>16
M\Y78 (%(V[)(\'YCG.?PI@;O@7Q!/XGTF/4;I8XY7>12L08)A'*C 9G/0<_,
M>:0'7T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % ',>,_\ D$3_ /;+_P!'1U4=S"M\#^7YHU-#_P"0?:_]>\/_ *+6
MD]V7#X8^B_(TZ1H% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % '@OQU_X]K'_ *Z3?^@QTT(ZWX1?\BY#_P!=)_\ T:U STVD 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <
MQXS_ .01/_VR_P#1T=5'<PK? _E^:-30_P#D'VO_ %[P_P#HM:3W9</ACZ+\
MC3I&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >
M9?$GP9>^,8K:.Q>",V[2,WG,ZYWA -NR.3/W3G..V,TP-WP)X?N/#&DQZ==E
M&EC>1B8R63YW+#!94/0C.5'.>HI =A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <QXS_Y!$__ &R_]'1U4=S"M\#^
M7YHU-#_Y!]K_ ->\/_HM:3W9</ACZ+\C3I&@4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0+(?2-BV'/LI-"IS;<5"5X[KE=UZJVGS!U()*3E%*6SYE9^COK\B7[?;>?\
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M=7[[;[%VLS0* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M .8\9_\ ((G_ .V7_HZ.JCN85O@?R_-&IH?_ "#[7_KWA_\ 1:TGNRX?#'T7
MY&G2- H * "@ H * "@ H * "@ H * /#/B;_P A.+_KU3_T;-5(#SFF(* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MY-M2>\=M%I^!*BDG%;2W5WK^(/:1R1QPMN,<!S&N]\(?4?-0I--R6\M]%K^
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* .8\9_\@B?_ +9?^CHZJ.YA6^!_+\T:FA_\@^U_Z]X?_1:TGNRX?#'T7Y&G
M2- H * "@ H * "@ H * "@ H * /#/B;_R$XO\ KU3_ -&S52 \YIB"@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * ,C5M/DOP@C*C83G<2.N.F ?2@#9\-V\-K$T2'=,N/
M.(W;<[GVA=P7HO#8&,C@D<U]+1A.%&"G:SO*-NTK/7[SYFM.$ZTW"]U:,O6-
MUI]QTE:F04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H ZGP3]O_M4>1L^Q>6?M&<;^C[-O?[^S..V:X\5[/V7O7Y[^
M[VZ7O\KG9A?:>U]VW);WN_6UOG8]JKYX^@"@ H * "@ H * "@ H * "@ H
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M:L%8/OC/#D!3M#E^21_#QWQ0,Q*!!0 4 % !0 4 :^E:#>ZWO^PQ^;Y6W?\
M.BXW;MOWV7.=IZ9QCGM0,RW0Q,4;AE)!'H0<'I0 R@04 % !0 4 % !0 4 %
M !0 4 % !0 4 9&K:A)8!#&%.XG.X$],=,$>M '3Z1JDVK0K--#' %CCC5HU
M*B01[DW'))+?+\QSRQ)P,XKZ##?P8N]W>5UVUT_ ^=Q&E:2M96C9][[_ (FM
M74<P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!O>#8;=M<BDDN&BF2-O+MP>)LI*#D?[*EG^J"
MN;$N2H-*-XMJ\OY=8_F[+YG1AE'VZ;E:23M'^;27Y:OY'NM?-GT@4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <QXS_Y!$__ &R_]'1U
M4=S"M\#^7YHU-#_Y!]K_ ->\/_HM:3W9</ACZ+\C3I&@4 % !0 4 % !0 4
M% !0 4 % 'AGQ-_Y"<7_ %ZI_P"C9JI ><TQ!0 4 % !0 4 % !0 4 % !0!
M:L;;[9<16^=OG2)'NQG&]@N<9&<9SC(SZB@9Z3+\,FA?Y[M$AQS(T>T[B>%"
M^9@\<Y+CJ  >2%<#G_$?@R?P_&+E9!<6Y(!=5*E2>FY<L-IZ!@QYX.,C)<#M
M]6_Y%"/_ *Y6_P#Z,2EU Y'1/ LVJ6PO;B9;.%N4++N)&<;B"R!5/\)+<]<8
MQEW ;KW@>71[;[;#,MU ,;BJ[2 Q # ;G#+D@$@Y&0<8R07 K^'?!EQKT9N2
MZV]N"0'8%BQ'7:N5!4<@L6 R,#.#@V T-6\ 2V-JUY:3I>)&"S!5VG:/O%<.
MX;;U(R#@'&3Q1<#'\.>$[GQ#ND1EA@C.&D89YQG"J,9(!!.2H /7/%/8#>O/
MAU*L+36%S'>%,DH%VDX&<*0\@+>@.W/K2N!J_"P8^V#_ *X?^UJ&!7/PY:Y=
MR]W''.Q9_*";]H8DC)WJ>A&2$(ST)')+@<%<Z#>6M]_9C)NN"P50O(;/(92<
M?*1SDXP =V"" P.[B^&3!5$]Y''*P^X(]PSZ!C(A/X+2N!Q.O>'[GP],(;C#
M*^3&Z_=< \]>01D;E/3(Y(()8&%0(* "@ H * "@ H * "@ H * .9\2=(OJ
MW_LM '3^%D=;-6:0.C [$[QXDD!!_P!X_-7T&&:]C%)6=Y7??7]-CY[$I^VE
M=W5HV7;3]=SI:ZCE"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * .=\3V7VNS9U&7A.\?0<,
M/RY_"N/$PYZ;:WCK_G^'Y'9AI\E1)[2T_P OQ_,YKP[&^IWHN)>1;QJ/Q"[$
M_'@M]17#ATZM3GE]E+\%9?YG=B&J5/DC]IO\[O\ R+/B&*33[^/4 NZ/*D_5
M>"I],KC!^OH:NNG3JQK6TT^]=/N,Z#52E*C>SU_'K]XS7-?AU. 6UJKLSL"<
MC'3H  3DDXZ>E*M7C5CR4T[M]AT*$J4N>;223ZCM9M6LM'MX7X99 2/0LLK$
M?@3BG6BZ="$7NI?FI/\ 4*,E.O.2VY7;Y.*_0U_^8'_V[_TKH_YA_P#MPYO^
M8C_M\Q=)LVOM'GB09?S2RCU*K$<?4@$#ZUS4H.I0G%;\UU\E%G55FJ=>$GMR
MV?S<D.T3Q##IUM]FN5<-$6Q@=026P<D8(8GK3HXB-*')-.ZO;3Y_F*MAY5)\
M\&K.W^7Y#_#<,E[>RZ@R[4)?'H6<]!Z[1G/X4\.G.I*LU9:_>_\ (6(:ITXT
M4]=/N7^9E:/J2:9>R22@F-MRL0,[<MD'Z9&/QX]*YZ-14JDG+;5/RU.BK3=6
MG&,=U9KST+&I70\07T4=J"54 9(Q_%EF([*!Z\_F*NI+ZQ4BJ>R_SU?H13C]
M6IR=3?>WRT7J6=9_Y#4'^]!_Z'6E;_>(>L/S,Z/^[S])_D=AJTDL5I*\&?,5
M"1CJ/4CW R17HU6XPDX;VT/.I).<5/:YYU8OIQA>6]+RW))VK\W/'RG(]^NY
MOP/?QH.ERN56[GK9:_+^FSV9JJI*-*RAIKIIW_I(T?"UTME#=S/R(UC; ZG'
MF<?F0/;-;8:2IQJ2?1)_F8XF+G*G%=6U^1DI?Q7MY]JU'<R#D(HR./NKR1A1
MW[G\2:YU-3GSUKV[+\%Z'0Z;IT_9T;)]W^+]3L)M?2]M9Q8!UDBC#<J!A=P#
M$8)Y"Y/MC->BZZG"7L;II7VZ7UM\CS8T'3G'VMK-VWZVT^]G*6;:=]G:2Z+R
MW9W;5^;DG[IR, \]=S'Z'I7!#V7*W4NYZV6OR_IL]"?M>91IV5/373Y_TD:O
MA;_CVN_]T?\ H+UT8;X*GI^C.?$_'3]?U19\%?<G^J?R:KP>TOE^I&,WC\_T
M*VF?\AR7_>F_K44_]XEZR+J?[O'TB>@UZYY!D:]_QX3?[G]17/7_ (<O0Z*'
M\2/J9OA#_CR/_75OY+6&$_A_]O/\D;XO^)_VZOS9B7#_ -AZN;B4'RI2S9 Z
MAQSCIRK=1Z?45RR?U>OSR7NN[^__ "9TQ7MZ')%^\K+[O\T,EE_X2'4XS"&\
MJ,+DD8PJG<Q/7&2<#UXI-_6:RY4^56^Y.[_R&E]6HM2MS._WM67^9Z/7M'C'
MGUY_R'D_WH__ $ 5Y$_]Y7K'\CUX?[L_27YC_%7_ !^6_P!!_P"AT\5_$A_7
M46%_AS_KH6?&G^JA_P!]OY"KQGPQ]61@_BEZ(H^(+1S:VMT@R(XD5O;*J5)]
MLY'UQZUE7B^2G472*3\M%8UH22G4IOK)M?>[EG4O$L%Y9M%$&\Z5<,N.%[L<
M]P #C'U.*NIB(SIN,4^9K5=NY%/#2A44I6Y4]'W[&CX0_P"/(_\ 75OY+6V$
M_A_]O/\ )&.+_B?]NK\V=37>< 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!O>#9K=-<BC
MDMVDF>-O+G XAPDI.3_M*&3ZN*YL2I>P;4K135X_S:Q_)V?R.C#.*KI.-Y-.
MTOY=)?GJOF>ZU\V?2!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!S'C/_D$3_P#;+_T='51W,*WP/Y?FC4T/_D'VO_7O#_Z+6D]V7#X8
M^B_(TZ1H% !0 4 % !0 4 % !0 4 % !0!X9\3?^0G%_UZI_Z-FJD!YS3$%
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M+1C.%&"G:SNXV[2L]?O/F:TH3K3<+W5E+UC=:?<='6ID% !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M.=G)RO=Z15[*^NFG<\*O3J2G4G"&D4K66LFU=VTUU[&C-H^K0V]O<"SE8W+
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MIC!<>ZAJT=6DI1C[2/O==+1]==/G8A4JKC*7LVN7IK>7HK:_*X3:/JT-O;W
MLY6-RP!C57+PY[RJ(R4'NP6A5:3E*/M(KEZZ6EZ:Z_*X.E548R]F_>Z:WCZJ
MVGSL7/\ A'=4^W_8/LS;=F_S_F\GIG;OV;-W;&[/M6?MZ7L_:\ZO>W+IS>MK
MWM\B_8U?:>RY':U^;7E]+VM?YE.'1]6EM[BX-G*AMF($;*X>7'>)3&"X]U#5
MHZM)2C'VD?>ZZ6CZZZ?.Q"I57&4O9M<O36\O16U^5PFT?5H;>WN!9RL;E@#&
MJN7ASWE41DH/=@M"JTG*4?:17+UTM+TUU^5P=*JHQE[-^]TUO'U5M/G8N?\
M".ZI]O\ L'V9MNS?Y_S>3TSMW[-F[MC=GVK/V]+V?M>=7O;ETYO6U[V^1?L:
MOM/9<CM:_-KR^E[6O\RG#H^K2V]Q<&SE0VS$"-E</+CO$IC!<>ZAJT=6DI1C
M[2/O==+1]==/G8A4JKC*7LVN7IK>7HK:_*X3:/JT-O;W LY6-RP!C57+PY[R
MJ(R4'NP6A5:3E*/M(KEZZ6EZ:Z_*X.E548R]F_>Z:WCZJVGSL7/^$=U3[?\
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M4M&KZI::GL]?/GOA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MFN[ QG&M^[M[-J\[O6^MK7\['%C90E1_>7]HG:%EI;2][>5ST2OJ3Y<* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,
MS5=)AUB(07&\(KA_D;;DC(P>#D')SW[@@\TT[;&<H*:L]MR[;V\=I&L,*B.-
M!A548 _SW/4GDTBTE%66B)J!A0 4 % !0 4 >&?$W_D)Q?\ 7JG_ *-FJD!Y
MS3$% !0 4 % !0 4 % !0 4 % !0!V/@D)'>RW;C/V*UGN!]54+_ "<_C@TF
M,F\!'S-6!D);=%-N.>3E3GGU/K0P&IXWO(IQY0CCL@P'V58X]GE _=^[DDKU
M.?O<\#BBP%?7?+T'69UMXHGC1OECE021C>BL1L/'!8[?3C% $7_"4-_SYZ?_
M . B4P,:]U!KR83A(K=@  ($$2C&><+W.>3U- %C2-%GUB0K%A(HQNEF?B.)
M1U9FZ9QT7.3] 2 #5U[4K:_NK>UA8_8;-4@5R#EE!'F2X SR.@ Z*" "<4@-
M+6]<T:XO))DM6O?,()D>:2$<*% 1$ (4  9?DG/&,4 9.MZ3!'#!J.G!_LUW
MN41M\S12J<&//\0/.P\DX.>U,#HM;?3HA#;ZV)9M0AC196M2JX4#*)*9"5=P
MIY95!.>O2EZ 9WBC;<65K<:?M&F)NBCC (>.8C<ZS99MSM@L&!P1GUW, 1:&
MIO-&U&U;&(?*N4XZ,I(?_OI%V_X]* .+IB"@ H * "@ H * "@ H * "@ H
MQ]6U&33]AB"G=NSN![8QC!'K2>NCV'>VJW/5_"M^^I:;#<2A58AE(7('R.R
M\DG)"@GGDY/'2OD<135*I*$=M']ZOT]3ZNA-U:<9RWU7W.WZ'15RG2% !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MGV) &:$_V/1]1N6Z2B*W3_:9BVX#W5#N^E '%TQ!0 4 % !0 4 % !0 4 %
M!0 4 <QXDZ1?5_\ V6@#UCP)_P @:#ZR_P#HUZ^5QG\:7_;O_I*/I\)_!C\_
M_2F=A7 =P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M"I5+<RO>VJU=_P!3HZP-PH * "@ H * "@ H * "@ H * "@ H * "@ H *
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MRT:5GN_^&%B<3&K#DIWW3>EK+_ASN?!G_('MO]U__1CUYN*_C3]5^2/1PO\
M!AZ/\V=17$=@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!L^'OM/VT>5M^S[3YN?O=&VX_
MX%MS[9KOP?M/;>Y;V=O?[];6^=C@QGL_8^]?VE_<[=+W^5SOZ^G/F@H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MYM22=H=):2O]RN_D<F+<EAY)03BVKR_EUC^;LOF>C5]6?+!0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'E/CKPUJ.LWT<]E%YL:P*A.^-<,))&(P[J>C YQCGKUJD!Q?_""
M:W_S[?\ D6#_ ..T7 /^$$UO_GV_\BP?_':+@'_"":W_ ,^W_D6#_P".T7 /
M^$$UO_GV_P#(L'_QVBX!_P ()K?_ #[?^18/_CM%P#_A!-;_ .?;_P BP?\
MQVBX!_P@FM_\^W_D6#_X[1< _P"$$UO_ )]O_(L'_P =HN ?\()K?_/M_P"1
M8/\ X[1< _X036_^?;_R+!_\=HN ?\()K?\ S[?^18/_ ([1< _X036_^?;_
M ,BP?_':+@'_  @FM_\ /M_Y%@_^.T7 /^$$UO\ Y]O_ "+!_P#':+@'_"":
MW_S[?^18/_CM%P#_ (036_\ GV_\BP?_ !VBX!_P@FM_\^W_ )%@_P#CM%P#
M_A!-;_Y]O_(L'_QVBX!_P@FM_P#/M_Y%@_\ CM%P#_A!-;_Y]O\ R+!_\=HN
M ?\ "":W_P ^W_D6#_X[1< _X036_P#GV_\ (L'_ ,=HN ?\()K?_/M_Y%@_
M^.T7 /\ A!-;_P"?;_R+!_\ ':+@'_"":W_S[?\ D6#_ ..T7 /^$$UO_GV_
M\BP?_':+@'_"":W_ ,^W_D6#_P".T7 /^$$UO_GV_P#(L'_QVBX!_P ()K?_
M #[?^18/_CM%P#_A!-;_ .?;_P BP?\ QVBX!_P@FM_\^W_D6#_X[1< _P"$
M$UO_ )]O_(L'_P =HN ?\()K?_/M_P"18/\ X[1< _X036_^?;_R+!_\=HN
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MW<;<J/J!0Z-:,83]G)\[V2=X_P")6T^=@56BY3A[2*Y%NVK2_P +OK\KD_\
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MJTO\+OK\KD_]E7GVG[-Y1QMW>;SY?TW;=N?;-:_5ZWM/8\CM:_-KR^E[6O\
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M.IA. I#!G]T&W+#Z UDJ-9QG/V<ER/9IWE_A5M?E<T=6C&4(>TB^9;IJT?\
M$[Z?.P26-['%%*(')F."H#;D]W&W*CZ@4.C6C&$_9R?.]DG>/^)6T^=@56BY
M3A[2*Y%NVK2_PN^ORN3_ -E7GVG[-Y1QMW>;SY?TW;=N?;-:_5ZWM/8\CM:_
M-KR^E[6O\S/V]'V?M>=7O;ETYO6U[V^1!'8WKQ2R^0ZF$X"D,&?W0;<L/H#6
M2HUG&<_9R7(]FG>7^%6U^5S1U:,90A[2+YENFK1_Q.^GSL$EC>QQ12B!R9C@
MJ VY/=QMRH^H%#HUHQA/V<GSO9)WC_B5M/G8%5HN4X>TBN1;MJTO\+OK\KD_
M]E7GVG[-Y1QMW>;SY?TW;=N?;-:_5ZWM/8\CM:_-KR^E[6O\S/V]'V?M>=7O
M;ETYO6U[V^1!'8WKQ2R^0ZF$X"D,&?W0;<L/H#62HUG&<_9R7(]FG>7^%6U^
M5S1U:,90A[2+YENFK1_Q.^GSL$EC>QQ12B!R9C@J VY/=QMRH^H%#HUHQA/V
M<GSO9)WC_B5M/G8%5HN4X>TBN1;MJTO\+OK\KD_]E7GVG[-Y1QMW>;SY?TW;
M=N?;-:_5ZWM/8\CM:_-KR^E[6O\ ,S]O1]G[7G5[VY=.;UM>]OD01V-Z\4LO
MD.IA. I#!G]T&W+#Z UDJ-9QG/V<ER/9IWE_A5M?E<T=6C&4(>TB^9;IJT?\
M3OI\[!)8WL<44H@<F8X*@-N3W<;<J/J!0Z-:,83]G)\[V2=X_P")6T^=@56B
MY3A[2*Y%NVK2_P +OK\KD_\ 95Y]I^S>4<;=WF\^7]-VW;GVS6OU>M[3V/([
M6OS:\OI>UK_,S]O1]G[7G5[VY=.;UM>]OD01V-Z\4LOD.IA. I#!G]T&W+#Z
M UDJ-9QG/V<ER/9IWE_A5M?E<T=6C&4(>TB^9;IJT?\ $[Z?.P26-['%%*('
M)F."H#;D]W&W*CZ@4.C6C&$_9R?.]DG>/^)6T^=@56BY3A[2*Y%NVK2_PN^O
MRN3_ -E7GVG[-Y1QMW>;SY?TW;=N?;-:_5ZWM/8\CM:_-KR^E[6O\S/V]'V?
MM>=7O;ETYO6U[V^1!'8WKQ2R^0ZF$X"D,&?W0;<L/H#62HUG&<_9R7(]FG>7
M^%6U^5S1U:,90A[2+YENFK1_Q.^GSL$EC>QQ12B!R9C@J VY/=QMRH^H%#HU
MHQA/V<GSO9)WC_B5M/G8%5HN4X>TBN1;MJTO\+OK\KFOI5G)9:DJ3V[,=IVS
M@$HGRL2"V-O(RO7JV*[L/2E1Q*C4I-NVE1)N,='UM;75;[LXL14C5P[=.JDK
MZTVTI2U72]]-]MD=W7TA\X% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!Y;\2_!%[XR%J+%X(_LOG;_ #F=<^9Y6W;LCDS]PYSCJ,9Y
MPP.G\$:'/X;T>#3;HHTT)EW&,L4^>:208+*AZ,,Y4<YZ]:0'5T % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y=\2_
M&][X-%H;%()/M)FW^<KMCR_*V[=DD>,[SG.>V,<Y8'3^"==G\2:1!J5RJ)+,
M9=RQA@@V2O&,!F8]%!.6/.>@XI =50 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'SY\>/NZ=];K_VWIH1W_PH_P"1
M9M/K/_Z4S4#/1*0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 >6_$OP1>^,A:BQ>"/[+YV_P YG7/F>5MV[(Y,_<.<
MXZC&><,#I_!&AS^&]'@TVZ*--"9=QC+%/GFDD&"RH>C#.5'.>O6D!U= !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MQ"XR=L2.0.0,D $\ D@T =)0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MDD@ $F@"MHFNV7B*V^V:;)Y\!9DW['3YEQD;9%1N,]<8]* ->@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M3)!&!N ,O5OB3JE]JDFC^$[..^DMMPEEE)\O*G:VW$D2A5;Y0[2?.WW5P 2
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M:ZD!^1Y5.P#(ZA6.Q!_$V]^54$ 'HGP4_P"1=7_KXF_]EH ];H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?MQM+G'E@\9W8X(!]!4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!R
M>J^!M%UN\&HWUL);I=@#^9,OW#E<JDBH<>ZG(X.1Q0!T-_80:G;R6=THD@G0
MI(A)&Y6&",J0P]BI!!Y!!YH RM \*Z9X661-*A^SK,5:3YY'W%00O,KN1C)X
M! Y- %?7/!6C>)'$VI6J32@ >8"\;D#H"\3(S =@20.U %O0_#&F>&D:/3+=
M+8/C<1EG;'0,[EG8#L"Q R?6@"IKG@K1O$CB;4K5)I0 /,!>-R!T!>)D9@.P
M)(':@"WH?AC3/#2-'IENEL'QN(RSMCH&=RSL!V!8@9/K0!'8>%-,TN_FU:UA
M\N\N@XEE\R5MPD=9'^1G,:Y=5/RJ,8P, D4 0KX-TF/4SK:0;+\DL95EF7)*
M["3&)!$=R\,"F&.2<DYH W+^QAU.WDL[E=\,Z-'(NYEW(PPPW(589'!P0: .
M#_X5)X6_Y\O_ "8NO_C] '2>'_".E>%?-_LJ#[/]HV>9^\EDW>7NV?ZUWQC>
MWW<9SSG P :NI:;;ZO;265XGFP3+M=-S+N&0<;D*L.0.A!H K:)H5EX=MOL6
MFQ^1 &9]F]W^9L9.Z1G;G'3./2@#7H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M>=G*E&QM*XR6W9&T*"6)  )- 'F*_&_P^TOE%;M4SCS3"NSZX$IDQ_VSS[4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MMZ -^RTZVB^'3[8TS)9R3,<#)DWLP<GJ64@;3V  ' H R/"G_).[[Z77\EH
MZCX'?\B^_P#U^2_^@0T >QT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M5_Z^)O\ V6@#UN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M:MN24\QB=N\7*$XSC.!GTH ETGX0W>F7MO>MJ\TRVT\4QC,+@2"-U<H2;I@
MP&TG:V,]#TH ZQ_ 6_Q0OBG[3C8N/L_D]?\ 1VM_];YO^UO_ -7VV_[5 !XD
M\!?\)!K5CK?VGR/[/:$^3Y._S/*G,WW_ #4V;L[?N-CKSTH 3QM\.;3QB\=T
M)&L[V$ +.B[LJ"2H==R9VL<HP=6&2,D8P <1>? \Z@@:YU2>>[R,S31&0>6
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M>5YG;/W?,_&@"OX<\#1:'H<OA^>;[5%<><'D$?E';,NTX7?)@KU#;NN#@8H
MPO!GPQE\'WHNDU"2X@ <?9S$40EQC<<3,I88'S; 3C''8 ]8H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MFX74)+F HZ"W,1C0;R#N/[YU+#:.0@SS^ !ZI0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M"9/\:++L'/+^:7WL/MNH?\_]]_X$R?XT678.>7\TOO8?;=0_Y_[[_P "9/\
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MNH?\_P#??^!,G^-%EV#GE_-+[V'VW4/^?^^_\"9/\:++L'/+^:7WL/MNH?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >!^+-0OAK=W
M#%=W4$47D;4BG=%&Z!"<*#@9.3P!DDD\FMHI6/+JRDIM)M+39OLC"^VZA_S_
M -]_X$R?XU5EV,>>7\TOO8?;=0_Y_P"^_P# F3_&BR[!SR_FE][#[;J'_/\
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M"9/\:++L'/+^:7WL/MNH?\_]]_X$R?XT678.>7\TOO8?;=0_Y_[[_P "9/\
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MNH?\_P#??^!,G^-%EV#GE_-+[V'VW4/^?^^_\"9/\:++L'/+^:7WL/MNH?\
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MEF)Y))Y)/)/)K![L]>&L8M]E^1KTBPH * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#PWXA?\AR/_ *\5_P#1\M;1V/,Q'QK_  _JSDZLY H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#U3X
M7?\ (/N?^OZ;_P!%PUE+<]/#_"_\3_)'I59G6% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?/7BO_D/WW_;M_P"D
MZ5O'9'D5OXDOE^2,:J, H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * *]U_J9/]QO\ T$T ?1?AG_D$V7_7I;_^B4KG>[/:A\$?
M1?D;=(T"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /#?B%
M_P AR/\ Z\5_]'RUM'8\S$?&O\/ZLY.K.0* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H ]4^%W_(/N?^OZ;_ -%PUE+<]/#_
M  O_ !/\D>E5F=84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M_P!>*_\ H^6MH['F8CXU_A_5G)U9R!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % 'JGPN_Y!]S_U_3?^BX:REN>GA_A?^)_D
MCTJLSK"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /#?B%_P AR/\
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M)DBD:(D*'",5))V@!@,9+' &<YXZT!RNUTG;O82XL;BSQ]HBDAW=-Z,F?IN
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M(MXI)2O7RT9\?7:#BC8$F_A3?HB.>WEM6V3(T3==KJ5./H0#0#36C5B*@D*
M/5/A=_R#[G_K^F_]%PUE+<]/#_"_\3_)'I59G6% !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M7BVUU/3C911/"^5VC"^6JH_R@$,#]P#C9@'@<#)%&SN3.K&4.5)I_AI_78X
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M?/7BO_D/WW_;M_Z3I6\=D>16_B2^7Y(QJHP"@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H W+WQ!<7]E%
MI\BQB*WV%2H8.=B%!N)8CHQSA1SZ=*5K.YM*HY14':R_30PZ9B% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % %>Z_U,G^XW_H)H ^B_#/_ "";+_KTM_\
MT2E<[W9[4/@CZ+\C;I&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!X;\0O^0Y'_UXK_Z/EK:.QYF(^-?X?U9R=6<@4 >B^)O$-I=V]L+*
M3?-!(CD;'7!5>#EE4'YL=#6:5KW.ZI4BU'D>J=^I=\3^*K.^T\V]I(7DE*!A
MM==J@[CRR@'D!< G.?2DHM/4JK5C*-HO5V[F-KVL6EYI%I:02;IH1%O7:XV[
M82K<E0IPW'!.>HXJDK-LRG.,H1BGJK7W[&B^N:5XAM(XM69[>>'^-%)R< $J
M0CX#X!967@C@G -*SCL7SPJ12J737;_AF8NO7^DBW6TTN%6(QNG92&P#G )
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?/7BO_D/WW_;M_P"DZ5O'9'D5OXDOE^2,:J,
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M>'R[^>QZ-93:E-,%GMX+>S(QL9LR]./NDQG)_AP,#OD5GI\SL3FWJDH]NO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?/7BO_ )#]]_V[?^DZ5O'9'D5OXDOE^2,:J, H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ 'OTH&>B?\)7IVFVTD6D6
M\D,LHP6?;@'&-V=[D[<DJO"Y_$'/E;W.SVL8IJFFF_Z[L\[K0X@H * "@ H
M* "@ H * "@ H * "@ H ] 7Q1INHVZ1:O;/+)%_''@;N,9R'C8$_P 0R03S
M[#/E:V.SVL))*I&[7;_AT4=>\3Q7ULNGV$1@ME()!P"<$D+M&0!G#$[B2>O?
M+2MJR9U5)<D%:)QM6<H4 % !0 4 % !0 4 % !0 4 5[K_4R?[C?^@F@#Z+\
M,_\ ()LO^O2W_P#1*5SO=GM0^"/HOR-ND:!0 4 % !0 4 % !0 4 % !0 4
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M1UX&:6C>B&^:$6YSUZ)6_P B#PUJ7]H:7]@MIA;WL((4D#D;MRD @[E(.QL
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MK"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?[C?^@F@#Z+\,_\ ()LO^O2W_P#1*5SO=GM0^"/HOR-ND:!0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'AOQ"_Y#D?_7BO_H^6MH['F8CX
MU_A_5G)U9R!0 4 % !0 4 % !0 4 % !0 4 .0!F 8[02 3C.!W.!R<=<"@9
MZ5'K>D>'[65=)=YIYNA96!!P=N2R(-J9) &22>3R2,[-[G=SPI1?L[MO^O+8
M\SZUH<(4""@ H * "@ H * "@ H * "@#H_#E_8V4KIJ,*S12A1N*AC&1GD
M\X.?FVG/ X.*EI]#>G*,7::NG^!U-A>>'=#D:\M9)9I<':A5OESU"[HT'3C+
M,3COUS+YGH=$72IOFBVWV_I(X#4KYM2N9+IQ@RL6QZ#HH_  #/?%6E;0XY2Y
MFY/J4J9 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >
MJ?"[_D'W/_7]-_Z+AK*6YZ>'^%_XG^2/2JS.L* "@ H * "@ H * "@ H *
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MF9EM86^JZ#)LAC2[M<JS+&H<F(ANH&XETX)R<MGKBGL_(S45.F[)<R\M=/\
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M1H% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >&_$+_ )#D
M?_7BO_H^6MH['F8CXU_A_5G)U9R!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M%4!Y&XGG)XYG2VB.B*DIWG+1WLO^!Z&/9ZI%IFO7<-R1&MQY>UFX 95!4$]
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ME<[W9[4/@CZ+\C;I&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H ^>O%?_ "'[[_MV_P#2=*WCLCR*W\27
MR_)&-5& 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '0Z!%I
M;L[:K(T84J8U4.0W7<&VHW'W>ZGKS4N_0WIJ&OM';M_5B[XMU]-9E2.VR+>
M';D$;F/5L=@  %R >O3.*458JK44VE'9'(U9S!0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %>Z_U,G^XW_H)H ^B_#/
M_()LO^O2W_\ 1*5SO=GM0^"/HOR-ND:!0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % 'BWQ L;R75XY[>VN+B/[&J%H8GD ;SI6P2HP"!@D9
MS@CCFM8NR/.KQDY)I-Z=%?JSC_L6H?\ /A??^ TG^%7==SFY)?RR^YA]BU#_
M )\+[_P&D_PHNNX<DOY9?<P^Q:A_SX7W_@-)_A1==PY)?RR^YA]BU#_GPOO_
M  &D_P *+KN')+^67W,/L6H?\^%]_P" TG^%%UW#DE_++[F'V+4/^?"^_P#
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?D:](L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M,L<B*\DB!V9\##%-BP^6)0RDDD.J@ ;_ ,)-IZI+([O$+>/SI!+!/$PBSCS
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M 0EOO<' !T%E:W,NL/J4D+P12V$$($C1%UD2>Y=D8122#(5T;*L4.[ 8D$!
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!%+;Q3E#*BN8FWH64,4?!7>N0
M=K;69=PP<,1G!- $M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
B0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img46421407_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2(*17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(S.C R.C(Q(#$W.C S.C V   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,R-@  DI(  @    ,R-@  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,SHP,CHR,2 Q-SHP,CHQ,0 R,#(S.C R.C(Q(#$W.C R.C$Q      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  $%T         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ =@$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M:1 P&2"PSB@!4=)%W(ZL,XRIS3J "B@ HH ** "B@#B_B?\ \BK'_P!?2?\
MH+5X]7N9?_!^9XF/_C?(**[3B-KPC_R-VE_]=UKW>?\ X]Y/]P_RKQLS^->A
M[.6? _4\JHK\_/O@HH ]-TG_ ) ]E_UP3_T$5<KZVG\"]#Y.I\;]0HJR HH
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M]<$_]!%7*^MI_ O0^4J?&_4**L@** "B@ HH *K273I.\8MY&"@'< <'/X4
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MLO\ K@G_ *"*N5];3^!>A\G4^-^H459 44 %% !10 4PS1*Q4R(& R06&0*
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MP4# R".3ZX_R:T[?37CN9&G^RRP'[BBW"E>?UH]E3_E0>UGW9H!$50JHH X
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MR'_"@-=<9CA[Y_>'\.WUH "UWVCAZ_\ /0_X5/0 44 %% !10 44 %% !10
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,B2,Q(R0#TP#GG&#TSR3&P4KQ5UTNKV[V.:&>8*?+[SL]+V=K]CZ\HHKRO\
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M 9QR1G%>41_MA?%#QA/?7/@WP!#=Z5:D[RUI<WCQKC(WO&Z*#@$XQ_+-<?\
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MC_LTZL(9HHC;^?Y.=[8SNVMT^E1? _XL'XR>!_\ A(?[,_LC-S);BW^T>?\
M=QSNVKUSZ5\C?&+]H;Q7XR^'.H>%O&_A*3P_J5PT%W9SK:S6ZNJR D%)23TZ
M,#CMWS7O'[#O_)$?^XG<?R2O4Q&6+"Y>ZM6/[SFM>]]+?<>7A\R>*S!4J4O<
MY;VM;6_WGT+1117S!].%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>[U"C1CAZ<:4-D)M'/%& 1C'%+16)L)@>E&T>@I:* $P/2C:/2EHH 3:/2C
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MHH 3 ]*,#TI:* $VCTHVCTI:* $VCT'Y48'I2T4 %%%% "4;1Z4M% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\
MUJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#U
MJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S
M?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z
M?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^
MGZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[
M^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^
M_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H
MTJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/
M['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW
M^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"G
MZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ
M\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^_
M_6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__
M %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -
M*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['
M_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_
M .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_
M +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_
M[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\
MUJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#U
MJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S
M?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z
M?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^
MGZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[
M^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^
M_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H
MTJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/
M['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW
M^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"G
MZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ
M\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^_
M_6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__
M %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -
M*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['
M_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_
M .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_
M +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_
M[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\
MUJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#U
MJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S
M?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z
M?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^
MGZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^_P#UJ/['_P"GZ\_[
M^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H TJ*S?['_ .GZ\_[^
M_P#UJ/['_P"GZ\_[^_\ UJ -*BLW^Q_^GZ\_[^__ %J/['_Z?KS_ +^__6H
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MF!Z4M !24M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8'I
M2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRL5N681()(9H82>P$K((_P#QZO7.>^:DH?1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_PWS\/_ /H#^)O_  %M_P#X_1_9.._Y],/[6P/_ #]1]+4E?-7_  WS\/\
M_H#^)O\ P%M__C]'_#?/P_\ ^@/XF_\  6W_ /C]']DX[_GTP_M; _\ /U'T
MK2U\T_\ #?/P_P#^@/XF_P# 6W_^/T?\-\_#_P#Z _B;_P !;?\ ^/T?V3CO
M^?3#^UL#_P _4?2M+7S3_P -\_#_ /Z _B;_ ,!;?_X_1_PWS\/_ /H#^)O_
M  %M_P#X_1_9.._Y],/[6P/_ #]1]+4F!UQS7S5_PWS\/_\ H#^)O_ 6W_\
MC]'_  WS\/\ _H#^)O\ P%M__C]']DX[_GTP_M; _P#/U'TM25\U?\-\_#__
M * _B;_P%M__ (_1_P -\_#_ /Z _B;_ ,!;?_X_1_9.._Y],/[6P/\ S]1]
M+45\T_\ #?/P_P#^@/XF_P# 6W_^/T?\-\_#_P#Z _B;_P !;?\ ^/T?V3CO
M^?3#^UL#_P _4?2U%?-/_#?/P_\ ^@/XF_\  6W_ /C]'_#?/P__ .@/XF_\
M!;?_ ./T?V3CO^?3#^UL#_S]1]+45\T_\-\_#_\ Z _B;_P%M_\ X_1_PWS\
M/_\ H#^)O_ 6W_\ C]']DX[_ )],/[6P/_/U'TM17S3_ ,-\_#__ * _B;_P
M%M__ (_1_P -\_#_ /Z _B;_ ,!;?_X_1_9.._Y],/[6P/\ S]1]+45R_P -
M_'^G_$[P7IOB;2H;F"PO_,\J.\55E&R1HSD*S#JAQR>,=.E=17ESC*G)PDK-
M;GIPG&I%3B[IZA1114%A1110 4444 %%%% !1110 4444 %%%% !7+>,OAKX
M6^(36?\ PDVA6.M?8]_V?[;$'\O?C?C/KL7\A74TE 'SM\>/V<_!EO\ "'Q/
M)X8\!V3^(%M<6?\ 9]D7GW[U^X%!).">@KSO]AOX(C3['6=3\9^"[BPUFROX
M9--N-:L'AF3"D[HS( >& Y]:^S<>U%,#Y!_;%_9K\1^+/$EG\0?!$+7>KVZ1
MI>64!Q.S1G,<\9_B8 *"O7Y5QGFO)O&?_#17[14&E^%M;\*7UE9V\HDEDFTY
MM/AD<9'FRR. IP,\)QSPN<5^B^ >U&T>E%Q'A4?@'6O@%^S#=Z)X-DGO_%5C
M:F9+BSM!/)/<O("[+$5;<!D@ @_*H[U7_9+\5_$[Q5H?B&7XF0ZG!>17,2V8
MU+2UL6V%"6VA8TW#..<''K7OOM1@<''(I#/S]\>_ OXE?L\_&*?QA\-]*N=;
MTN2666V^QVOVDQQR<O!)"HW$#) (Z@ Y!Z0:+\%?BI^U!\4[+Q!\1-+NM TB
M 1K<M=6S6RI A)\B")_FRQ))8Y R23G@_H32T[BL,CB2*-8T14C4;511@ >@
M%?*O[0'A;Q)\>OCCX8\"G1=5M/A_I,@O=4U:2VDBM;A]N6592-K$)^[4C)#2
M.>@-?5M%(9\]?M?_  -O_BE\+=/M_#-JLFHZ#/YUM81D()8?+*-&@/&X?(1G
M'W2.]?.'B;P[\8OV@M+\#>![WP!?>'K;P]&ML^IW=O+!&X")'YKM( .$0G"$
MDDG'4"OT3HP/2F(H:+I::'H^GZ=$=\5I!';JS=2$4*#^0K0I,#CBEI#"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *^:/V]O^20:/\ ]AV'_P!)[BOI
M>OFC]O;_ ))#I'_8=A_])[BO6RG_ '^EZGD9M_N-7T/@BBBBOV4_'@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /TJ_9"Y_9W\)YY_X^_\ TKGKV2O'/V0?^3=_"?\ V]_^ED]>QU^)
MYA_OE;_%+\V?M.7_ .YT?\,?R04445P'>%%%% !1110!%NZ]?P.:?GW_ $KP
MC]J #'AKC_GZ_P#:->$_A7Q.8\2?V?BIX;V/-RVUYK;I/:S[GVF7<-_7\+#$
M^VY>:^G+?9M=UV/NW/O^E&??]*^$OPH_"O-_UQ_ZA_\ R;_[4]+_ %/_ .G_
M /Y+_P#;'W;GW_2C/O\ I7PE^%'X4?ZX_P#4/_Y-_P#:A_J?_P!/_P#R7_[8
M^[<^_P"E&??]*^$OPH_"C_7'_J'_ /)O_M0_U/\ ^G__ )+_ /;'W;GW_2C/
MO^E?"7X4?A1_KC_U#_\ DW_VH?ZG_P#3_P#\E_\ MC[MS[_I1GW_ $KX2_"C
M\*/]<?\ J'_\F_\ M0_U/_Z?_P#DO_VQ]VY]_P!*,^_Z5\)?A1^%'^N/_4/_
M .3?_:A_J?\ ]/\ _P E_P#MC[MS[_I1GW_2OA+\*/PH_P!<?^H?_P F_P#M
M0_U/_P"G_P#Y+_\ ;'W;GW_2C/O^E?"7X4?A1_KC_P!0_P#Y-_\ :A_J?_T_
M_P#)?_MC[MS[_I1GW_2OA+\*/PH_UQ_ZA_\ R;_[4/\ 4_\ Z?\ _DO_ -L?
M=N??]*,^_P"E?"7X4?A1_KC_ -0__DW_ -J'^I__ $__ /)?_MC[MS[_ *49
M]_TKX2_"C\*/]<?^H?\ \F_^U#_4_P#Z?_\ DO\ ]L?=N??]*,^_Z5\)?A1^
M%'^N/_4/_P"3?_:A_J?_ -/_ /R7_P"V/NW/O^E&??\ 2OA+\*/PH_UQ_P"H
M?_R;_P"U#_4__I__ .2__;'W;GW_ $HS[_I7PE^%'X4?ZX_]0_\ Y-_]J'^I
M_P#T_P#_ "7_ .V/NW/O^E,#D\\_X5\*_A7V?X! _P"$%\.''/\ 9UM_Z*6O
M?R?._P"U:DX>SY>57WO^B/ S?)/[*A"?M.;F=MK?JSH****^I/F HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E
M!SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '
M/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I7V=X!_Y$7PW_V#
MK;_T4M?&//I7V=X!_P"1%\-_]@ZV_P#12U]_PA_'J^B_,^!XN_@4O5_D=!11
M17ZB?F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?.FA_%[PYK'Q O?%/BA-
M:LWT]Y++0]-?0-0D%M%]V6Y)2 J9)<$#GY4 '5FK.^"\VE_$C]E>[\(0ZS)H
M,YM9K*[OKFSE2.);BXF VM)L23<I*D*YP6 /) KZ;VCTKSCP[\%]/T_X-CX=
MZK>-JM@T,T$EQ''Y#D/*T@91EMK*6!!R>5!]J8',^*?A+J/@SP3J.MZ+XZ\3
M+X@TFR:ZCEO=0,EE*8E+>6]KQ$L; ;<*H*@C!XY]/\"^(/\ A,/ _A[7FA^S
MMJFG6UZ8L?<,D2OM_#=^E>>WWP=\7>(-%/A[Q!\1YM1\-R)Y-S!;Z4D%]=0X
M&8Y+CS#G(&&944L"?4UWFN>'=2FL]!M?#NM+X<M=.O;>2>..R2X%S9Q@A[0!
MO]6&&T>8O*[>*0'$_#0;/CI\8ED!#F;270LW6/[$ ,>VX2?K2*4?]JR4IRT?
M@M!(1SC-\Q4'ZX:MCQ9\,;[4/%\?BOPMKZ^&-?>T%C=R2V*WEO>0AMR"2,NA
MW*2<.&!P2.15KX>_#9_!^HZQK6JZL_B#Q/K#1_:]2>!8%$<8*QQ1Q@D(@R3C
M))+$DF@#S_6/A#_PA/@^2RU?QDQ^&6B3'4O["&G(MPT<<OGQVQN!)\Z!PH"A
M S8"YYJOX7O?'%OXHN],TZ#2;3Q?K5DGB36;K6(I9H[:)Y&AM;)(T=#F-(F!
M.[&X,<'=7I_C3P?>>-->\/0W#P#PQ8S_ &^]MF9C)=7$9!MT*[=OEJ^9#DY+
M)&,8R:H^,/AUJVJ>+H?%'AKQ&OAW6A9?V;<&YL%O8+B 2-(@*;T*LK,^&#='
M((-,"]\*_'$WCSPO)=WEJMCJUC>W&F:C:Q.9(X[J"0QR!&/525R/8\\BNSKE
M?A[X&MOA[X:CTN"ZEU">2:6[O+^YQYEW<2N7EE;' W,3P.@ '.*ZJD 5GR?V
MGYC^6;7R\_)NW9Q[^]:%)@>E &=NU7_IS_-J-VJ_].?YM6E10!F[M5_Z<_S:
MC=JO_3G^;5I44 9N[5?^G/\ -J-VJ_\ 3G^;5I44 9N[5?\ IS_-J-VJ_P#3
MG^;5I44 9N[5?^G/\VHW:K_TY_FU:5% &;NU7_IS_-J-VJ_].?YM6E10!F[M
M5_Z<_P VHW:K_P!.?YM6E10!F[M5_P"G/\VHW:K_ -.?YM6E10!F[M5_Z<_S
M:C=JO_3G^;5I44 9N[5?^G/\VHW:K_TY_FU:5% &;NU7_IS_ #:C=JO_ $Y_
MFU:5% &;NU7_ *<_S:C=JO\ TY_FU:5% &;NU7_IS_-J-VJ_].?YM6E10!F[
MM5_Z<_S:C=JO_3G^;5I44 9N[5?^G/\ -J-VJ_\ 3G^;5I44 9N[5?\ IS_-
MJ-VJ_P#3G^;5I44 9N[5?^G/\VHW:K_TY_FU:5% &;NU7_IS_-J-VJ_].?YM
M6E10!F[M5_Z<_P VHW:K_P!.?YM6E10!F[M5_P"G/\VHW:K_ -.?YM6E10!F
M[M5_Z<_S:C=JO_3G^;5I44 9N[5?^G/\VHW:K_TY_FU:5% &;NU7_IS_ #:C
M=JO_ $Y_FU:5% &;NU7_ *<_S:C=JO\ TY_FU:5% &;NU7_IS_-J-VJ_].?Y
MM6E10!F[M5_Z<_S:C=JO_3G^;5I44 9N[5?^G/\ -J-VJ_\ 3G^;5I44 9N[
M5?\ IS_-J-VJ_P#3G^;5I44 9N[5?^G/\VHW:K_TY_FU:5% &;NU7_IS_-J-
MVJ_].?YM6E10!F[M5_Z<_P VHW:K_P!.?YM6E10!F[M5_P"G/\VHW:K_ -.?
MYM6E10!F[M5_Z<_S:C=JO_3G^;5I44 9N[5?^G/\VHW:K_TY_FU:5% &;NU7
M_IS_ #:C=JO_ $Y_FU:5% &;NU7_ *<_S:OG#]NS[=_PJ31_M/V?R_[=A_U>
MX'/V>X]>U?4-?-'[>W_)(-(_[#L/_I/<5ZV4_P"_TO4\G-O]QJ^A\$4445^R
MGXZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!^CO[)/V_\ X9\\)^1]G$?^E_ZS<&_X^YZ]?W:K_P!.
M?YM7EO[(/_)N_A/_ +>__2R>O9*_$\P_WRM_BE^9^TY?_N='_#'\D9N[5?\
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M1110 4444 %%%% !2;0>",BEHH 2BEHH 3:,YQS2T44 )CVHI:* $Q[4M%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7S1^WM_R2'2/^P[#_Z3W%?2]?-'[>W_ "2'2/\ L.P_^D]Q
M7K93_O\ 2]3R,V_W&KZ'P11117[*?CP4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z5_L@_\F[^$_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:/V]O^20Z1
M_P!AV'_TGN*^EZ^:/V]O^20Z1_V'8?\ TGN*];*?]_I>IY&;?[C5]#X(HHHK
M]E/QX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#]*_V0?\ DW?PG_V]_P#I9/7L=>.?L@_\F[^$_P#M
M[_\ 2R>O8Z_$\P_WRM_BE^9^TY?_ +G1_P ,?R04445P'>%%%% !1110!X/^
MU!]WPU_V]?\ M&O">?2O=OVH/N^&O^WK_P!HUX3SZ5^*<1_\C2K_ -N_^DQ/
MVGAW_D5TO^WO_2F'/I1SZ4<^E'/I7S1]('/I1SZ4<^E'/I0 <^E'/I1SZ4<^
ME !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4
M '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0
M<^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E?9W@'_D1?#?\
MV#K;_P!%+7QCSZ5]G> ?^1%\-_\ 8.MO_12U]_PA_'J^B_,^!XN_@4O5_D=!
M1117ZB?F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\T?M[?\DATC_L.P_\ I/<5]+U\T?M[?\DATC_L
M.P_^D]Q7K93_ +_2]3R,V_W&KZ'P11117[*?CP4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z5_L@_\
MF[^$_P#M[_\ 2R>O8Z\<_9!_Y-W\)_\ ;W_Z63U['7XGF'^^5O\ %+\S]IR_
M_<Z/^&/Y(****X#O"BBB@ HHHH \'_:@^[X:_P"WK_VC7A//I7NW[4'W?#7_
M &]?^T:\)Y]*_%.(_P#D:5?^W?\ TF)^T\._\BNE_P!O?^E,.?2CGTHY]*.?
M2OFCZ0.?2CGTHY]*.?2@ Y]*.?2CGTHY]* #GTHY]*.?2CGTH .?2CGTHY]*
M.?2@ Y]*.?2CGTHY]* #GTHY]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2CGTHY
M]* #GTHY]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2CGTHY]* #GTHY]*.?2CGT
MH .?2CGTHY]*.?2@ Y]*^SO /_(B^&_^P=;?^BEKXQY]*^SO /\ R(OAO_L'
M6W_HI:^_X0_CU?1?F? \7?P*7J_R.@HHHK]1/S **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:/V]O\
MDD.D?]AV'_TGN*^EZ^:/V]O^20Z1_P!AV'_TGN*];*?]_I>IY&;?[C5]#X(H
MHHK]E/QX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#]*_V0?^3=_"?_ &]_^ED]>QUXY^R#_P F[^$_
M^WO_ -+)Z]CK\3S#_?*W^*7YG[3E_P#N='_#'\D%%%%<!WA1110 4444 >#_
M +4'W?#7_;U_[1KPGGTKW;]J#[OAK_MZ_P#:->$\^E?BG$?_ "-*O_;O_I,3
M]IX=_P"172_[>_\ 2F'/I1SZ4<^E'/I7S1]('/I1SZ4<^E'/I0 <^E'/I1SZ
M4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1
MSZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/
MI0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E?9W@'_ )$7
MPW_V#K;_ -%+7QCSZ5]G> ?^1%\-_P#8.MO_ $4M??\ "'\>KZ+\SX'B[^!2
M]7^1T%%%%?J)^8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0^"****_93\>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _2O\ 9!_Y-W\)_P#;W_Z63U['7CG[(/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH S-?UZQ\+Z)>ZOJMU'9:?91-///(<*JJ,D__
M %NO:L3P;\3-(\:?#^#QE 9M/T:6"6X9M058GBCC9PY<!B!C8QZ]*Y;S!\8O
M&A 97\#^&[K)7JFJ:A'[]X8&_!I .H3GR59#'^PG%'G8EQ*EK)[1R:L(W_\
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M;J>5=6!!![@]>M;U( HHK/DU7RY)$^RW3[6QN2/(/T]J -"BLS^V3_SXWO\
MWYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SX
MWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V
M3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.B
MLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^:
M -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_
M -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\
M^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_
MMD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\
MWYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SX
MWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V
M3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.B
MLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^:
M -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_
M -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\
M^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_
MMD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\
MWYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SX
MWO\ WYH_MD_\^-[_ -^: -.BLS^V3_SXWO\ WYH_MD_\^-[_ -^: -.BLS^V
M3_SXWO\ WYH_MD_\^-[_ -^: -.OFC]O;_DD.D?]AV'_ -)[BOH3^V3_ ,^-
M[_WYKYQ_;KO_ +7\(]'06UQ#_P 3V$[I8]H_X][C]:];*?\ ?Z7J>1FW^XU?
M0^$J***_93\>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _2O\ 9!_Y-W\)_P#;W_Z63U['7AW[).I&
MW_9\\)I]FN)/^/OYHX\K_P ?<_>O7O[9/_/C>_\ ?FOQ/,/]\K?XI?F?M.7_
M .YT?\,?R1IT5F?VR?\ GQO?^_-']LG_ )\;W_OS7 =YIT5F?VR?^?&]_P"_
M-']LG_GQO?\ OS0!IT5F?VR?^?&]_P"_-']LG_GQO?\ OS0!XU^U!]WPU_V]
M?^T:\)Y]*]N_:4O/M7_".?N98=OVC_7)MS_JNE>(\^E?B?$?_(TJ_P#;O_I,
M3]IX=_Y%=+_M[_TIASZ4<^E'/I1SZ5\V?2!SZ4<^E'/I1SZ4 '/I1SZ4<^E'
M/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^
ME !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4
M '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I7V=X!_Y$7PW_
M -@ZV_\ 12U\8\^E?8'@75/+\$Z GV2Z8KI]N-R1Y!_=KTK[_A#^/5]%^9\#
MQ=_ I>K_ ".NHK,_MD_\^-[_ -^:/[9/_/C>_P#?FOU$_,#3HK,_MD_\^-[_
M -^:/[9/_/C>_P#?F@#3HK,_MD_\^-[_ -^:/[9/_/C>_P#?F@#3HK,_MD_\
M^-[_ -^:/[9/_/C>_P#?F@#3HK,_MD_\^-[_ -^:/[9/_/C>_P#?F@#3HK,_
MMD_\^-[_ -^:/[9/_/C>_P#?F@#3HK,_MD_\^-[_ -^:/[9/_/C>_P#?F@#3
MHK,_MD_\^-[_ -^:/[9/_/C>_P#?F@#3HK,_MD_\^-[_ -^:/[9/_/C>_P#?
MF@#3HK,_MD_\^-[_ -^:/[9/_/C>_P#?F@#3HK,_MD_\^-[_ -^:/[9/_/C>
M_P#?F@#3HK,_MD_\^-[_ -^:/[9/_/C>_P#?F@#3HK,_MD_\^-[_ -^:/[9/
M_/C>_P#?F@#3HK,_MD_\^-[_ -^:/[9/_/C>_P#?F@#3HK,_MD_\^-[_ -^:
M/[9/_/C>_P#?F@#3HK,_MD_\^-[_ -^:/[9/_/C>_P#?F@#3HJE:ZA]JDV"W
MN8?ESNE3:/\ ]=7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /-7_9O^%TC%G\#:*S-R6:W!)KA?AW^SC:V?
M[/.H^%+W3(/#GB+6K=X[VYA\MW,B32/;,[*65PN5. >A(X-?0E)@>E 'AGB6
M7XH>/? \W@VZ\(1Z'=:E;BQU+Q$VI6\EJD3 +/+%$I\PLR[MJE5P6&3QD^E:
M@VH^#=*\-:;X;T#^VK5;FVT^X0WL=N;&S"E6N?F'[S8%7Y%Y;/'2NJI/:@#R
M;7-!\2^!?B=JGBSPWH;^)M.UVSA@U+3([N&WGBG@R(IHVE(5E*,5*[@00#ST
M%GX=^%?$&H>/M<\=>*;%-(O;RTATNPTE9UG:UM(V9R9'7Y2[R.6PN0  ,GMZ
MA@8QCBC ]* //OBA9ZEXLDTOP?907$>GZL[/K&H*CB.*Q3!>(28V[YB5CVYS
ML:0]JRO$^D^(_"/Q/3Q5X>\-?\)-87.B1Z/-8VEU!:RVQAFDDC<>:RJ4(F8$
M!LC:,"O5L>U&!Z4 <%\&_!^I>#_"MT-9\F/5]6U*\UB]M[=]\5O)<2F3RE8\
MD*"!GN0>V*[ZDP/2EH *2EHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .?2CGTHY]*.?2@ Y]*.?2CGTHY]* #GTHY]*.?2CGTH .?2CGTHY]*.?2@
MY]*.?2CGTHY]* #GTHY]*.?2CGTH .?2OL[P#_R(OAO_ +!UM_Z*6OC'GTK[
M.\ _\B+X;_[!UM_Z*6OO^$/X]7T7YGP/%W\"EZO\CH****_43\P"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "OFC]O;_DD.D?]AV'_P!)[BOI>OFC]O;_ ))#I'_8=A_])[BO6RG_ '^E
MZGD9M_N-7T/@BBBBOV4_'@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /TK_ &0?^3=_"?\ V]_^ED]>
MQUXY^R#_ ,F[^$_^WO\ ]+)Z]CK\3S#_ 'RM_BE^9^TY?_N='_#'\D%%%%<!
MWA1110 4444 >#_M0?=\-?\ ;U_[1KPGGTKW;]J#[OAK_MZ_]HUX3SZ5^*<1
M_P#(TJ_]N_\ I,3]IX=_Y%=+_M[_ -*8<^E'/I1SZ4<^E?-'T@<^E'/I1SZ4
M<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1S
MZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I
M0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E
M!SZ5]G> ?^1%\-_]@ZV_]%+7QCSZ5]G> ?\ D1?#?_8.MO\ T4M??\(?QZOH
MOS/@>+OX%+U?Y'04445^HGY@%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?-'[>W_ "2'2/\ L.P_^D]Q
M7TO7S1^WM_R2'2/^P[#_ .D]Q7K93_O]+U/(S;_<:OH?!%%%%?LI^/!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?-'[>W_)(=(_[#L/_I/<
M5]+U\T?M[?\ )(=(_P"P[#_Z3W%>ME/^_P!+U/(S;_<:OH?!%%%%?LI^/!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?I7^R#_R;OX3_P"WO_TLGKV.O'/V0?\ DW?PG_V]_P#I9/7L
M=?B>8?[Y6_Q2_,_:<O\ ]SH_X8_D@HHHK@.\**** "BBB@#P?]J#[OAK_MZ_
M]HUX3SZ5[M^U!]WPU_V]?^T:\)Y]*_%.(_\ D:5?^W?_ $F)^T\._P#(KI?]
MO?\ I3#GTHY]*.?2CGTKYH^D#GTHY]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2
MCGTHY]* #GTHY]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2CGTHY]* #GTHY]*.
M?2CGTH .?2CGTHY]*.?2@ Y]*.?2CGTHY]* #GTHY]*.?2CGTH .?2CGTHY]
M*.?2@ Y]*.?2CGTHY]* #GTHY]*.?2CGTH .?2OL[P#_ ,B+X;_[!UM_Z*6O
MC'GTK[.\ _\ (B^&_P#L'6W_ **6OO\ A#^/5]%^9\#Q=_ I>K_(Z"BBBOU$
M_, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM/G38S3$M(5_#A?IS7=>*?\ B6_LZ6HA_=E["T^YQ]\QEOSR0?J:[\'@<O\
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M5_)YEW-97C.VT!>-X  ] ./7CUKP/P+JUGHOB:SFU"[O;33PV;A[*9HY"HZ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;B($'!!<<?K5FJ[6%J[,S6T+,QR24&2: $_M&U_Y^H?^^Q_C1_:-K_S]0_\
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MV/\ &C^T;7_GZA_[['^-']FVG_/K#_W['^%']FVG_/K#_P!^Q_A0 ?VC:_\
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M['^%']FVG_/K#_W['^% !_:-K_S]0_\ ?8_QH_M&U_Y^H?\ OL?XT?V;:?\
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M/\:/[1M?^?J'_OL?XT?V;:?\^L/_ '['^%']FVG_ #ZP_P#?L?X4 ']HVO\
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MMVU".)H4NS$IE6-B"R!\9"DJI(S@D#TJS@=<4M% "8'I2T44 %%%% !1110
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M )$7PW_V#K;_ -%+7W_"'\>KZ+\SX'B[^!2]7^1T%%%%?J)^8!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M #GTHY]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2CGTHY]* #GTHY]*.?2CGTH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7S1^WM_R2'2/^P[#_Z3W%?2]?-'[>W_ "2'2/\ L.P_^D]Q7K93_O\
M2]3R,V_W&KZ'P11117[*?CP4444 %%%% !1110 4444 %%%% !1110 4444
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M@ Y]*.?2CGTHY]* #GTHY]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2CGTHY]*
M#GTK[.\ _P#(B^&_^P=;?^BEKXQY]*^SO /_ "(OAO\ [!UM_P"BEK[_ (0_
MCU?1?F? \7?P*7J_R.@HHHK]1/S **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KYH_;V_Y)#I'_ &'8?_2>XKZ7KYH_;V_Y)#I'_8=A_P#2>XKU
MLI_W^EZGD9M_N-7T/@BBBBOV4_'@HHHH **** "BBB@ HHHH **** "BBB@
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M_P!C_P#3]>?]_?\ ZU']C_\ 3]>?]_?_ *U:5% &;_8__3]>?]_?_K4?V/\
M]/UY_P!_?_K5I44 9O\ 8_\ T_7G_?W_ .M1_8__ $_7G_?W_P"M6E10!F_V
M/_T_7G_?W_ZU']C_ /3]>?\ ?W_ZU:5% &;_ &/_ -/UY_W]_P#K4?V/_P!/
MUY_W]_\ K5I44 9O]C_]/UY_W]_^M1_8_P#T_7G_ ']_^M6E10!F_P!C_P#3
M]>?]_?\ ZU']C_\ 3]>?]_?_ *U:5% &;_8__3]>?]_?_K4?V/\ ]/UY_P!_
M?_K5I44 9O\ 8_\ T_7G_?W_ .M1_8__ $_7G_?W_P"M6E10!F_V/_T_7G_?
MW_ZU']C_ /3]>?\ ?W_ZU:5% &;_ &/_ -/UY_W]_P#K4?V/_P!/UY_W]_\
MK5I44 9O]C_]/UY_W]_^M1_8_P#T_7G_ ']_^M6E10!F_P!C_P#3]>?]_?\
MZU']C_\ 3]>?]_?_ *U:5% &;_8__3]>?]_?_K4?V/\ ]/UY_P!_?_K5I44
M9O\ 8_\ T_7G_?W_ .M7SC^W7I_V7X1Z.WVFXF/]NPC;(^X?\>]Q[5]05\T?
MM[ ?\*AT?C_F.P_^D]Q7K93_ +_2]3R,V_W&KZ'P11117[*?CP4444 %%%%
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M^M1_8_\ T_7G_?W_ .M6E10!F_V/_P!/UY_W]_\ K4?V/_T_7G_?W_ZU:5%
M&;_8_P#T_7G_ ']_^M1_8_\ T_7G_?W_ .M6E10!F_V/_P!/UY_W]_\ K4?V
M/_T_7G_?W_ZU:5% &;_8_P#T_7G_ ']_^M1_8_\ T_7G_?W_ .M6E10!F_V/
M_P!/UY_W]_\ K4?V/_T_7G_?W_ZU:5% &;_8_P#T_7G_ ']_^M1_8_\ T_7G
M_?W_ .M6E10!F_V/_P!/UY_W]_\ K4?V/_T_7G_?W_ZU:5% &;_8_P#T_7G_
M ']_^M1_8_\ T_7G_?W_ .M6E10!F_V/_P!/UY_W]_\ K4?V/_T_7G_?W_ZU
M:5% &;_8_P#T_7G_ ']_^M1_8_\ T_7G_?W_ .M6E10!F_V/_P!/UY_W]_\
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M4RRH0&CD5< 1KP1GD\\BO&[S]O#XPZ?;O/<^$-#MH$P7FETV\5!SCDF?C/\
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M0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E
M!SZ5]G> ?^1%\-_]@ZV_]%+7QCSZ5]G> ?\ D1?#?_8.MO\ T4M??\(?QZOH
MOS/@>+OX%+U?Y'04445^HGY@%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM_N-7T/@BBBBOV4_'@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /TK_ &0?^3=_"?\ V]_^ED]>QUXY
M^R#_ ,F[^$_^WO\ ]+)Z]CK\3S#_ 'RM_BE^9^TY?_N='_#'\D%%%%<!WA11
M10 4444 >#_M0?=\-?\ ;U_[1KPGGTKW;]J#[OAK_MZ_]HUX3SZ5^*<1_P#(
MTJ_]N_\ I,3]IX=_Y%=+_M[_ -*8<^E'/I1SZ4<^E?-'T@<^E'/I1SZ4<^E
M!SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '
M/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^
ME'/I1SZ4<^E !SZ4<^E'/I1SZ4 '/I1SZ4<^E'/I0 <^E'/I1SZ4<^E !SZ5
M]G> ?^1%\-_]@ZV_]%+7QCSZ5]G> ?\ D1?#?_8.MO\ T4M??\(?QZOHOS/@
M>+OX%+U?Y'04445^HGY@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .?2CGTHY]*.?2@ Y]*.?2CGTHY]* #GTHY]*.?2CGTH .?2CGTHY]*.?2@
MY]*.?2CGTHY]* #GTHY]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2CGTHY]* #G
MTHY]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2CGTHY]* #GTK[.\ _\B+X;_P"P
M=;?^BEKXQY]*^SO /_(B^&_^P=;?^BEK[_A#^/5]%^9\#Q=_ I>K_(Z"BBBO
MU$_, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** *6I:I9Z+8R7E_>0V-G%CS+BZE
M6-$R0!N8G Y('U-8G_"T/!O_ $-VA?\ @R@_^*KF/VE/^2*>(_\ MW_]*8J^
M&*I*XC]#O^%H>#?^ANT+_P &4'_Q5'_"T/!O_0W:%_X,H/\ XJOSQHI\H7/T
M._X6AX-_Z&[0O_!E!_\ %4?\+0\&_P#0W:%_X,H/_BJ_/&BCE"Y^AW_"T/!O
M_0W:%_X,H/\ XJC_ (6AX-_Z&[0O_!E!_P#%5^>-%'*%S]#O^%H>#?\ H;M"
M_P#!E!_\51_PM#P;_P!#=H7_ (,H/_BJ_/&BCE"Y^AW_  M#P;_T-VA?^#*#
M_P"*H_X6AX-_Z&[0O_!E!_\ %5^>-%'*%S]#O^%H>#?^ANT+_P &4'_Q5'_"
MT/!O_0W:%_X,H/\ XJOSQHHY0N?H=_PM#P;_ -#=H7_@R@_^*H_X6AX-_P"A
MNT+_ ,&4'_Q5?GC11RA<_0[_ (6AX-_Z&[0O_!E!_P#%4?\ "T/!O_0W:%_X
M,H/_ (JOSQHHY0N?H=_PM#P;_P!#=H7_ (,H/_BJ/^%H>#?^ANT+_P &4'_Q
M5?GC11RA<_0[_A:'@W_H;M"_\&4'_P 51_PM#P;_ -#=H7_@R@_^*K\\:*.4
M+GZ'?\+0\&_]#=H7_@R@_P#BJ/\ A:'@W_H;M"_\&4'_ ,57YXT4<H7/T._X
M6AX-_P"ANT+_ ,&4'_Q5'_"T/!O_ $-VA?\ @R@_^*K\\:*.4+GZ'?\ "T/!
MO_0W:%_X,H/_ (JC_A:'@W_H;M"_\&4'_P 57YXT4<H7/T._X6AX-_Z&[0O_
M  90?_%4?\+0\&_]#=H7_@R@_P#BJ_/&BCE"Y^AW_"T/!O\ T-VA?^#*#_XJ
MM;1]>TSQ!:M=:5J5KJ=LKF-I;.=9E#<$KE21G!''N*_-NOL+]C__ ))IJG_8
M7E_]$P4FK >Z4445(PHHHH **** "OFC]O;_ ))#I'_8=A_])[BOI>OFC]O;
M_DD.D?\ 8=A_])[BO6RG_?Z7J>1FW^XU?0^"****_93\>"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#)N_A/_M[_ /2R>O8Z_$\P_P!\K?XI?F?M.7_[G1_PQ_)!1117 =X4444
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M^!2]7^1T%%%%?J)^8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8?M*?\ )%?$
M?_;O_P"E,5?#%?<_[2G_ "17Q'_V[_\ I3%7PQ5QV$PHHHJB0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
MPOV/_P#DFFJ?]AB7_P!$P5\>U]A?L?\ _)--4_[#$O\ Z)@J9;%(]THHHJ!A
M1110 4444 %?-'[>W_)(=(_[#L/_ *3W%?2]?-'[>W_)(=(_[#L/_I/<5ZV4
M_P"_TO4\C-O]QJ^A\$4445^RGX\%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^E?[(/_)N_A/\ [>__
M $LGKV.O'/V0?^3=_"?_ &]_^ED]>QU^)YA_OE;_ !2_,_:<O_W.C_AC^2"B
MBBN [PHHHH **** /!_VH/N^&O\ MZ_]HUX3SZ5[M^U!]WPU_P!O7_M&O">?
M2OQ3B/\ Y&E7_MW_ -)B?M/#O_(KI?\ ;W_I3#GTHY]*.?2CGTKYH^D#GTHY
M]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2CGTHY]* #GTHY]*.?2CGTH .?2CGT
MHY]*.?2@ Y]*.?2CGTHY]* #GTHY]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2C
MGTHY]* #GTHY]*.?2CGTH .?2CGTHY]*.?2@ Y]*.?2CGTHY]* #GTHY]*.?
M2CGTH .?2OL[P#_R(OAO_L'6W_HI:^,>?2OL[P#_ ,B+X;_[!UM_Z*6OO^$/
MX]7T7YGP/%W\"EZO\CH****_43\P"BBB@ HHHH **** "BBB@ HHHH ****
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M^;4;M5_Z<_S:@#2HK-W:K_TY_FU&[5?^G/\ -J -*BLW=JO_ $Y_FU&[5?\
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M2?\ PQC=?]#7%_X '_XNC_AC&Z_Z&N+_ , #_P#%T706/FRBOI/_ (8QNO\
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MJO\ TY_FU<AV&E16;NU7_IS_ #:C=JO_ $Y_FU &E16;NU7_ *<_S:C=JO\
MTY_FU 'C/[4'W?#7_;U_[1KPGGTKZD^)7PSU#XC?V=YFH6UD+/S,;8F??OV>
MXZ;/UKBO^&8;K_H/P_\ @,W_ ,57Y=G62X_%X^I6HT[Q=K.ZZ12ZL_3\ESG
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M(<^E'/I7M_\ PS#=?]!^'_P&;_XJC_AF&Z_Z#\/_ (#-_P#%4?ZNYI_SZ_\
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M.2T18R(#[9$J_P#;04 ?3/B+Q;H?@ZSCN]>UK3]$M9)/*2?4KI+=&?!.T,Y
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M@?-GPG^%/COQ!\<+WXJ_$33[3P_>0VGV/3]'LYUG* KM+,ZLPP%+=SDN>
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M?@J.90DAM9)%!!^ZTTCJ>?9@:]@J*UM8+&VAM[>&.WMX4$<442A410,!5 X
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MX8FU2T\>_$:^UW4KM;'2-*A\2R(MQ=RL?+0 #A1UP#T7'>E\2>+M$^.7QO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP=V .._:44M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB*N?PYZ_6@#S/X=_">X\ ^*H+E+V.\TRW\,V6BJ[Y6>2:&:>220IC:JL)E(
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M7CKY2HGFVZ3B3+2 E LB X&[)X4CFNER0#SSUH ?13-Q_P <=: V2><_YYH
M?13/;/ZTC-M!/;ZT 244SD8]*/Q)Y_*@!]%1\\8Z?6EW?,1CIR.>M #Z*9SG
M_P"O573+R:^LXYY[*?3I7+ VUT4,BX8@$F-F7D $88\'G!R  7:*Q]3\26FD
M:OHNG3F1KC5II(+?8N5W)$TK%CV&U#^)'X:NX_XXZT /HIF3M)Z^E/H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(^4$>81YF>*^K:2@#PRS\"^']%\7?#U+32+2$:UI]W%JW[I6.H@P))_I.?\
M7'=\V7R<D^IKIOV;Y-&/P5\)1Z*;+_1]-MHKY;+9\EX((_.64+TEW?>W?-D\
MUZ;1M'I[T@/D?6!X+D^&=@=1^SCXFKK-K_:'/_$T%P;Z/S3+GY_)QGK^[P4V
M_P -=%9^%X%\$_%OQ#IVG&3Q.-=U.V74+>,O>QVPF!DC@<?,GR&0[4P23D<X
MKU^;X8PWUY$U[X@US4=,BOEU&/2+J>-X!,DGFQ@OY?FLB2 ,JM(5!5>,  =O
M3 ^:?$ECX6U:3[%\*H;*Z-QH6IPZI%H(4QO$UJX@2XV_\MC,4"[_ -Y]_/>K
MNM?$#P]XLO?AW9Z-JMMJ=U!:7QN8[5_,^SL-,F&R3!_=ODD;&PW!XX-?1./:
MJE_8Q:A8W%I(6$4T312%>NUA@X)[XH ^8/AS_P (3)X#^%O_  BS02_$#SM+
M>=[<@ZCY>8C>_:#]_P CR/, W?)CRMO&VO5?CK?:?!:^'K35+339;&ZO6WW6
MO7!ATN!EB8K]H&"LF>0B,0I;!SD 'O?"GARU\'^%]'T"R>::RTNSAL87N&#2
M-''&J*6( !.%&< #/85L8'I2 ^5-)71M0\%Z[;3ZOH^GZ+9^,U>W632Y/[$9
M#IT3;)8&D^2U:1I&5RX0OL8#!"U['\#;VQN?#&IPZ=8Z=96=KJ,D4<FCSO+I
M]QF.-S);;@ L>7*[4^4,CX)ZUZ1M'I13 ^2?&FMZ5/>7>L6T>@:9XAB\2Q$1
MN)+KQ "E^B,SR;E^SP^7DA2'C\LJO.\5Z]^TQI-EJ7PQ=KNRM[PPZKI9C-Q$
MLFS=J%NC8STW*64XZAB.]>LTE 'R3\:+S0X;7XA%++P_I.L:7$\-BEXCW6L
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M%% !1110 4444 %%%% !1110 4444 1-_'_O#^E2T44 %%%% !1110 4444
M0MU/^^O]*FHHH **** "FM_4444 .HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img46421407_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_13.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\O/T]?;W^/GZ_\  $0@#O0=. P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MM"[F@"#)XR6 ]\5UO#58IS<=$KWO';[SCCBJ,I*$9:MV2M+?[CT*N0[ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJ;J2FXR4;V3::6FBU\['K85P5.%.,HN5KM)IO75Z>5ST^2185+N0BJ,EF(
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MZT^[3\K'I%<9VA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M#$:I6E'77=7TT?8=:C4PWNMWC+2ZV=M;-=^O],]4_9L_YBO_ &Y?^W=<./\
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MOO1]J?#[Q0?%^B6^IR +,P:.8#@"6-BK$#L&P' [!@.U?.5Z?L:C@MMUZ/\
MJQ]/0J^VIJ;WV?JOZN?#'B#4)==U^YO+8&26YO7:%0-Q.9<0J%.0QQM4#D'I
MBOIH15.FHO1*.OW:GRE23J592CNY.WWZ'JGB3X,ZM:Z7<>(=4OEFO8XS/-"R
MM(2.K@W!?EU'&!&4)&%?&#7#3Q<'-481M&]D]OPM^IZ%3!SC!UJD[R2NUO\
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M;I7 ]P:\G'2O.,.RO][_ . CV,OC:$I]Y6^Y?\%EK]HA1_PC]LV!N&H1@'N
M;>ZR,^AP,^N!Z4L#_$?^!_G$>8?PH_XU^4B3]GF0OX=G!Z)J$H'L/(MF_FQ-
M+':55_A7YR'@/X3_ ,;_ "B>[UY9ZP4 % !0 4 % !0 4 % !0 4 % !0 4
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M1W![BOK_ /EW_P!N_H?%_P#+S_M[]3] O^$4T7_GPLO_  &A_P#B*^4]K/\
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MJM=DE^OZG3@8\M%/^9M_I^A[)7G'I!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M!<3"&V4=3&I$4( ]7 #$?WF->E1@J--1>EE=^N[/+K3=>JY+J[1]-D?;.@>
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M6.6!3,+D<!L,KP28P0'&X8R <9KVFJ.(6O++\U^31X2=;"O3FA\M'^:8Z_\
M&'BOQN/L4L]U?*Y \F"(*KGL&CMXT#=1]X'M2C2HT/>2C'S;_5L)5:U?W6Y2
M\DOTBD>Q_"[X,W%I<QZSXA01F$AX+0D,V\<K)-C*@*>5C!+;@"^W;M;S\1BT
MTZ='KO+R[+_/[CTL-@W%JI65K:J/GW?^7WGT%XK_ .0+?_\ 7E<_^B7KR:7Q
MP_Q1_-'L5?X<_P##+\F?&GP0_P"1LM?^N=Q_Z(DKZ+&?P9>J_-'S6"_C1])?
MDS[BN[6*^A>VN%$D,R-'(C=&1@593[$$BOF4W%IK1K5'U32DG%[/1H_/;Q[X
M0E\%:M+I[Y:$_O+>0_QPL3M.>FY<%'_VE)Q@BOK*-55H*:WV:[/^M3XZO2="
M;ATW3[K^M&?57P&_Y%A?^OF?^:UX>-_B_)'OX'^#_P!O,]GKSCTPH ^-/VB/
M^1AM_P#L'1?^E%U7T6!_AO\ QO\ *)\UF'\6/^!?^E2/HWX6_P#(K:=_U[_^
MSM7CXG^+/U/9PW\&'I^IY[\=? O]KV0U^S7-U8KB=0.9+?));W:$DM_US+_W
M5%=>#K<DO92VEMY/_@_F<>-H<\?;1^*._G'_ ('Y'S_\)O\ D:]._P"NK?\
MHJ2O6Q/\&?I^J/(PO\:'K^C/IGX\_P#(L-_U\P?S:O%P7\7Y,]S'?P?^WD?)
M/ACQAJ?@Z62?29%A>9 CEHTDRH.X##JP'/<<U[]2E"LDIJZ6VK7Y'SU*K.BV
MZ;LWILG^9V?_  N_Q9_S]1_^ \'_ ,;KF^IT?Y7][_S.GZ[6_F7_ ("O\CUC
MX._$;6_%^L366JS++#'9R3*JQ11D.LUN@.453]V1AC..<]A7!BJ%.C!2IJSY
MDMV]+/OZ'H83$5*U1QJ.Z46]DM;I=/4\Y^/W_(S#_KTA_P#0I:[,%_"_[>?Z
M'%COXW_;J_4^D/A%_P BGI__ %SD_P#1\M>/BOXT_5?DCV\)_!AZ/\V8_P :
MO"?_  D6AM=0+NNM-S.F!RT6/WZ#_@($F.YC '6M,)5]G4Y7\,M/GT?Z?,RQ
ME+VE/F7Q0U7IU7Z_(\+^!7BS^Q-9_LN=MMMJ8"#/1;A<^41Z%\F+W9DSPM>G
MC*7/#G6\=?EU^[?[SRL%5]G4]F]IZ?/I]^WW%G]HC_D8;?\ [!T7_I1=4L#_
M  W_ (W^42LP_BQ_P+_TJ1Q.A?%/Q#X;LH]-T^=([:#?L4PQ.1O=I&^9D+'+
MNQY/&<#@5TSPU.I)SFM7YM;*QRPQ56E%0@TDMM%U=_U&ZEXN\5>/ +.66YO4
M8C]Q;P@(2#D!D@C4/@D$;]Q'!SP*(TJ-#WDE'S;_ %;_ ""56MB/=;E)=DM/
MN2_,]\^$/PHG\/2C6]:4)=A2+>#(8PAAAI'()'F%2550?D4MN^8X7R\5B547
MLJ?P]7W\EY'K83"ND_:U=)=%VOU?G^1]#UY![(4 5[NZCL8)+F8XC@1Y'/HJ
M*68_D#32YFHK=NQ+:BG)[)7^X_-WQ%KMQXDU"?4[LDR7#EL9)"+T2-<_PHN%
M7V%?8TX*E%0CLE_3^9\54FZLG.6[?W=E\C8TGX@Z_H5LMEIUV]M;IDJB)$!D
MG))S&223U)))]:SE0IS?-.-WWN_\S6%>I37+"5DNB2_R/1_AS\1O$6L>(K*R
MO;V2:WFD8/&5C 8"-V )5 >H!X-<=>A3A3E*,4FEH]>Z\SMP^(JSJQA*3:;U
M6G9^1] ?%+P,?'&E>3;[5OK5C+;EC@,2,/$3T42 #!/ =4)(7->5AJWL)W?P
MO1_H_E_F>OB:'MX6C\2U7ZKY_G8^2])\1^)OAC+-:1K)9&0CS(IX=R%@.'7>
M,9V]'0X=<<L ,>]*G2Q*4G9VV:?]?B?/0J5L*W%7C?=-:>O_  Q=\/\ @W7O
MB;JAO+L2B*9PUS>R)M0*, B/(57<* L<:# ^7=M0$B)U:>&ARQM=+2*_7]6R
MZ=&IBI\TKV;]Z3T^[]$OR/NBQLHM-MXK2V4)#;QI%&HZ*B*%4?@ *^9;<FY/
M=N[^9]5%**48[)67HBU4E'YTWO\ R,TG_83?_P!*C7UR_A+_  ?^VGQC_BO_
M !_^W'Z+5\B?9A0!Q7Q'_P"19U+_ *])?_0:Z:'\6'^)'+B/X,_\+/A7PII>
MJ:E>[M#W?;;2,W480XD/E,N?+[,_S9V'[X!7!)"GZ>I*$8_O?A;L[[:]SY2E
M&<I?NOBBN96WT[';:W\6?%>I6[Z1=,(&D4QRA(/*G=3PRGNN[D'8J$C(Z$BN
M:&&HQ?M(ZVU6MTOZ\SJGBJTDZ<M+Z.RL_P"O2QV_P9^&-ZM_'K^K0M;06PW6
MT<H*O+(P(60H<,L: [E+ %FV%<J":YL7B(\KI4W=O=K9+MZLZL'AI<RK5%9+
M9/=OO;LC0_:3_P"83_V^_P#MI48#_EY_V[_[<7F/_+O_ +>_]M.[^ W_ "+"
M_P#7S/\ S6N7&_Q?DCKP/\'_ +>9Y=^T;_R$K'_KV?\ ]&FN[ ?#+U7Y'!F'
MQP_PO\ST?X3Z<-8\"MIY;8+M+Z MUV^:9(]V/;=FN/$RY,1S]N5_=9G;A8\^
M&Y/YN=??='S7:C7/A3K"W4D'E3VY9!YJ,T$R,"IVN-H=&'(9&# XS@@BO8?L
M\5#E3T?;='B+VF$J<S5FNZT:]?\ (['7_%'BWXH63QK:"+3K9&N)3#&Z1MY2
M-)EI96;>V =D<9R6P=I.".>%.CA9)\WOO17:OKILMO-LZ:E6OBHM*-H)7=DT
MM-=WOY)$_P"SY?16VOS6\AVO<VCK'_M,CQR%1[[%=OHII8Y-TTUTDK_<U^8\
M!)*JT^L7;Y-/\A?BEX!UK0]7?6; 3W-I),;B*2/?(]K(6#E6 W,BH^/+<#9M
MVC(88HPU:$X*G*RE:S3TYE_6X\30J4YNK"[C>Z:UY7^FNS&O\>/$MQ;FQ6&V
M%RR[/-6*3S<XP6$?F%-^.?N;<\A . ?4J2?-=VWM=6^^VPOKU5KDLK[7L[_=
M>U_E\C<^#'PTU"+48]?U2)[6"V5F@20%))9'4J&V'#+&JL6#,!N;;M!7<:SQ
M>(CRNE!W;WMLEZ]S7!X:2FJU162V3T;;\NQT7QG^%]WKD_\ ;VCH9YRBI<P+
M]]P@VI+&/XB% 1D'S$*I4'D5CA,1&"]E4T71]->C-\9AI3?MJ2N]FNNFS7Y6
M/+-*^+OBCPI:KI+K&P@41Q_:X9/.B5> @^>,D*/E42*^U<*.  .Z6%I57[17
MUU?*U9_G^!Y\<76HQ]GIIHN9.Z_%?B,T#PMXH^(VJG49S/ LS SWKAHD5  -
ML0&P.0N%2.,8'&XJN6HG4I8:'(K.VT=_O_S84Z5;$SYW=7WEMIY;?)(^W;.U
M2Q@CMHRQ2%%C4N2S$* H+,>68XRS'ECDGDU\TW=MOJ[GU"7*E%=%8LTBCX)^
M+GB:3Q'XAN%W9M[%VM8%!RH$;%9'';,D@8[AU4(,D**^IPM-4Z:[R]Y_/;[D
M?)8NHZE5]H^ZOEO][.6T'QAJ_AA'CTJX:U64AGV)&2Q P,LR,Q [+G:"20,L
M<[SI0J6<U>VVYSPJSI75-VOOHO\ (Z:U^*WBF2:-&U"4AG4$;8NA8 _\LZQ>
M&HI/W%^/^9NL56NESO?R_P C[YKY4^N"@#Y ^/OAF]35EUB.)Y+2:!$:15++
M')'N!5R =H*;64M@-\P'W37T&"J1Y/9MI23>G=/L?.8ZG)3]HD^5I:]FNY/\
M(OB)K5UJ5AH,Q\S3HT>'Y8AN54B<Q;I ,X5@B]1QC)/0K%4*:C*JM)[[^>N@
M\)B*CG"D_@6FWD[:_<<M\=O^1IE_Z]X/_0*VP?\ "7JS#'?QGZ+\CZY\#_\
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M:$53BH+9)+[C2J"PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H XKXC_ /(LZE_U
MZ2_^@UTT/XL/\2.7$?P9_P"%GRY\ ?\ D9C_ ->DW_H45>WC?X7_ &\OU/!P
M/\;_ +=?Z'VQ7S9]0% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 4M2TZWU>VEL;Q/,M[A#'(FYEW*W!&Y"K#/JI!]#51DX-2CHUJ
MB914TX2U3T:_X8Y;0/AUH'A>Y^W:5:_9[C8T>_SKB3Y6P6&V65UYP.<9]#6\
MZ]2JN6<KK?9+\DCGIX>E2?-3C9[;M_FV=M7,=04 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 <'JGPP\,ZQ*9[K3X3(YRS1F2#)]3Y#Q@D]R
M1DGDY)KJCB*L%:,W;SL_S3.26&HS=Y05_*Z_)H72_ACX9T:036NGPB1>5:4O
M.5/4$>>\F".Q'(['BB6(JS5I3=O*R_*P1PU&#O&"OYW?YMG=URG6% !0 4 %
M !0!R/B/P'HGBR5+C5[87$L*;$?S9HR%R6V_NI(\@$DC=G&3C&3713K5*2:I
MRLGKLG^:9S5*%.JTZD;M:+5K\FCK57: !G &.22>/4G))]R<GO7.=(M !0 4
M % !0 4 % !0 4 % !0!@^(?#&G>*[=;/5HC<0)()0GF2Q_.%9028G0G 9N"
M2.<XR 1K3J2I/FINSM;9/3YIF-2G"JN6HKJ][7:U^31!X;\'Z3X122/1X/LR
MSE6D_>2R%BH(7F5W(P"< $#D\4ZE6=6SJ.]MM$OR2%3I0HW5-6OOJW^;9TM8
MFX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Q^H^ =#U?4%U>^M1<7B%-KR
M2SL@V?='DF3R=H/.WR]I)+$$DD]$:U2$?9QE:/DEU\[7_$YI4*<Y>TE&\O-O
MIY7M^!V%<YTA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &;
MJNJQ:/"+B<.RE@N$ )R03W91CCUKDQ&(CA8>UJ)M72]VU[N_=KL=>'P\L5/V
M5-I.S?O72LK=D^YSG_">6'_/.?\ [YC_ /CM>5_:]#^6I]T?_DSU/[)K_P U
M/[Y?_(&A8>++#4'$2LT3MP!( N3Z @LN?0$C/;-=5',*%=J";C)[*2M?YIM?
MB<U;+Z]!<[2E%;N+O;Y-)_@=+7K'DA0 4 <YJ'B>UTVY^QRK*7^7E0I7YNG)
M<'Z\5Y5;'TL/4]A-3<M-4E;7;>2?X'J4<#4KT_;P<%'71MWTWVBU^):UC7(-
M$"&=9&\TL!L"G&W&<[F7UXQFML3BX8-1=12?->W*D]K;W:[F6&PL\6Y*FXKE
MM?F;6]]K)]C0L[I+V%+B,$+(H8!L X/K@D9^A-=-*HJT(U8W2DKJ^_SM?\SE
MJ4W1G*E*UXNSMM\MOR+-;&04 % !0!#<SK:Q/.^2L2,Y ZX4%CC) S@<9(^M
M9U)JE"525[1BY.V]DKNWF:0@ZDXTXVO*2BK[7;LK^1F:/KD&M!S;K(OE%0=X
M4?>SC&UF].<XKDPV+ABU)TE)<MK\R2WOM9OL=>)PL\(XJHXOFO;E;>UM[I=S
M9KO. * "@ H * .<T_Q/:ZC<_8XEE5QNY8*%^7KR')^G%>51Q]*O4]A!34M=
M6E;3?:3?X'J5L#4H4_;S<''31-WUVWBE^)T=>J>6% !0 4 % !0 4 9]MJEO
M=SO;P-O>$ N1]T9)&,]SQSC('KGBN6%>G5G*E3=W!)RMLK]+]7Z?F=,Z%2E"
M-6HN52?NWW=NMNB]?R-"NHY@H * "@ H * "@#/O]4M]- ,[8+D!5'+,2<<#
MT]2< >M<M:O3PZ3J.S;LEU?HOUV.FC0J5VU36B5V]DO5_IN:%=1S!0 4 % !
M0 4 % !0 4 % %!]3MTN5LMV9W!.T<[0 6RWID#@=3Z8YKF=>FJBP][U'=V7
M1)7U[>77Y'2J%1TWB+6@K*[TNV[:=_/I\R_72<P4 % !0!A:QXAM]$9$G61C
M("1L"GH0.=S+Z^]>;B<93P;C&HI/F3:Y4GMZR1Z.&P=3%J4J;BN5I/F;6_HF
M;$$PN(TF7(61589ZX8 C.,\\\\FN^$E.,9K:235][-7.&<73E*#WBVG;:Z=B
M6K("@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M*2<IO517;NWT1Z>%P<\7=QM&"T<GW[)=6<O+XUAO[>>WEB,)DAE5"&W@L48
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M%=&&S&GB9>S:<)O9-W3\D]-?)I'/B<OJ8:/M$U."W:5FO-K73S39U5>T>,%
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0!P?C3P7)XO,*_:OLT4&X[/)\S<S8^8GS8\8
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ME2G[6F[.[?W]'W1WSI1J0]C45U9+[NJ[,\HE^"\9<^3?.D1/W&A#' / +"5
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M<D!=S8&<G[QZUPXBM]8J>UY>71*U[[>=D=V'H_5J:I<W-9MWM;?RNR'QO_R
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M?_0/_P#)J+_XFCZQB?\ H%_\K0_R#ZOAO^@G_P HS_S#^UM3_P"@?_Y-1?\
MQ-'UC$_] O\ Y6A_D'U?#?\ 03_Y1G_F']K:G_T#_P#R:B_^)H^L8G_H%_\
M*T/\@^KX;_H)_P#*,_\ ,/[6U/\ Z!__ )-1?_$T?6,3_P! O_E:'^0?5\-_
MT$_^49_YA_:VI_\ 0/\ _)J+_P")H^L8G_H%_P#*T/\ (/J^&_Z"?_*,_P#,
M/[6U/_H'_P#DU%_\31]8Q/\ T"_^5H?Y!]7PW_03_P"49_YA_:VI_P#0/_\
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M?]!/_E&?^8?VMJ?_ $#_ /R:B_\ B:/K&)_Z!?\ RM#_ "#ZOAO^@G_RC/\
MS#^UM3_Z!_\ Y-1?_$T?6,3_ - O_E:'^0?5\-_T$_\ E&?^8?VMJ?\ T#__
M ":B_P#B:/K&)_Z!?_*T/\@^KX;_ *"?_*,_\P_M;4_^@?\ ^347_P 31]8Q
M/_0+_P"5H?Y!]7PW_03_ .49_P"8?VMJ?_0/_P#)J+_XFCZQB?\ H%_\K0_R
M#ZOAO^@G_P HS_S#^UM3_P"@?_Y-1?\ Q-'UC$_] O\ Y6A_D'U?#?\ 03_Y
M1G_F']K:G_T#_P#R:B_^)H^L8G_H%_\ *T/\@^KX;_H)_P#*,_\ ,/[6U/\
MZ!__ )-1?_$T?6,3_P! O_E:'^0?5\-_T$_^49_YA_:VI_\ 0/\ _)J+_P")
MH^L8G_H%_P#*T/\ (/J^&_Z"?_*,_P#,/[6U/_H'_P#DU%_\31]8Q/\ T"_^
M5H?Y!]7PW_03_P"49_YA_:VI_P#0/_\ )J+_ .)H^L8G_H%_\K0_R#ZOAO\
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M .@?_P"347_Q-'UC$_\ 0+_Y6A_D'U?#?]!/_E&?^8?VMJ?_ $#_ /R:B_\
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M!D@G!QTKHIT*E5<U.-TG;=+7YM'-4KTZ+4:DK-J^S>GR3.?_ .%T>$/^?_\
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MR#_A='A#_G__ /):\_\ D>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\
M_P EKS_Y'H^J5OY/_)H_YA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5O
MY/\ R:/^8?7*'\__ )++_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\
M_P#Y++_(/^%T>$/^?_\ \EKS_P"1Z/JE;^3_ ,FC_F'URA_/_P"2R_R#_A='
MA#_G_P#_ "6O/_D>CZI6_D_\FC_F'URA_/\ ^2R_R#_A='A#_G__ /):\_\
MD>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\ _P EKS_Y'H^J5OY/_)H_
MYA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5OY/\ R:/^8?7*'\__ )++
M_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\_P#Y++_(/^%T>$/^?_\
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MR#_A='A#_G__ /):\_\ D>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\
M_P EKS_Y'H^J5OY/_)H_YA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5O
MY/\ R:/^8?7*'\__ )++_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\
M_P#Y++_(/^%T>$/^?_\ \EKS_P"1Z/JE;^3_ ,FC_F'URA_/_P"2R_R#_A='
MA#_G_P#_ "6O/_D>CZI6_D_\FC_F'URA_/\ ^2R_R#_A='A#_G__ /):\_\
MD>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\ _P EKS_Y'H^J5OY/_)H_
MYA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5OY/\ R:/^8?7*'\__ )++
M_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\_P#Y++_(/^%T>$/^?_\
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MR#_A='A#_G__ /):\_\ D>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\
M_P EKS_Y'H^J5OY/_)H_YA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5O
MY/\ R:/^8?7*'\__ )++_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\
M_P#Y++_(/^%T>$/^?_\ \EKS_P"1Z/JE;^3_ ,FC_F'URA_/_P"2R_R#_A='
MA#_G_P#_ "6O/_D>CZI6_D_\FC_F'URA_/\ ^2R_R#_A='A#_G__ /):\_\
MD>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\ _P EKS_Y'H^J5OY/_)H_
MYA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5OY/\ R:/^8?7*'\__ )++
M_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\_P#Y++_(/^%T>$/^?_\
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MR#_A='A#_G__ /):\_\ D>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\
M_P EKS_Y'H^J5OY/_)H_YA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5O
MY/\ R:/^8?7*'\__ )++_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\
M_P#Y++_(/^%T>$/^?_\ \EKS_P"1Z/JE;^3_ ,FC_F'URA_/_P"2R_R#_A='
MA#_G_P#_ "6O/_D>CZI6_D_\FC_F'URA_/\ ^2R_R#_A='A#_G__ /):\_\
MD>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\ _P EKS_Y'H^J5OY/_)H_
MYA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5OY/\ R:/^8?7*'\__ )++
M_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\_P#Y++_(/^%T>$/^?_\
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MR#_A='A#_G__ /):\_\ D>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\
M_P EKS_Y'H^J5OY/_)H_YA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5O
MY/\ R:/^8?7*'\__ )++_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\
M_P#Y++_(/^%T>$/^?_\ \EKS_P"1Z/JE;^3_ ,FC_F'URA_/_P"2R_R#_A='
MA#_G_P#_ "6O/_D>CZI6_D_\FC_F'URA_/\ ^2R_R#_A='A#_G__ /):\_\
MD>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\ _P EKS_Y'H^J5OY/_)H_
MYA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5OY/\ R:/^8?7*'\__ )++
M_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\_P#Y++_(/^%T>$/^?_\
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MR#_A='A#_G__ /):\_\ D>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\
M_P EKS_Y'H^J5OY/_)H_YA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5O
MY/\ R:/^8?7*'\__ )++_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\
M_P#Y++_(/^%T>$/^?_\ \EKS_P"1Z/JE;^3_ ,FC_F'URA_/_P"2R_R#_A='
MA#_G_P#_ "6O/_D>CZI6_D_\FC_F'URA_/\ ^2R_R#_A='A#_G__ /):\_\
MD>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\ _P EKS_Y'H^J5OY/_)H_
MYA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5OY/\ R:/^8?7*'\__ )++
M_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\_P#Y++_(/^%T>$/^?_\
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MR#_A='A#_G__ /):\_\ D>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\
M_P EKS_Y'H^J5OY/_)H_YA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5O
MY/\ R:/^8?7*'\__ )++_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\
M_P#Y++_(/^%T>$/^?_\ \EKS_P"1Z/JE;^3_ ,FC_F'URA_/_P"2R_R#_A='
MA#_G_P#_ "6O/_D>CZI6_D_\FC_F'URA_/\ ^2R_R#_A='A#_G__ /):\_\
MD>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\ _P EKS_Y'H^J5OY/_)H_
MYA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5OY/\ R:/^8?7*'\__ )++
M_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\_P#Y++_(/^%T>$/^?_\
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MR#_A='A#_G__ /):\_\ D>CZI6_D_P#)H_YA]<H?S_\ DLO\@_X71X0_Y_\
M_P EKS_Y'H^J5OY/_)H_YA]<H?S_ /DLO\@_X71X0_Y__P#R6O/_ )'H^J5O
MY/\ R:/^8?7*'\__ )++_(/^%T>$/^?_ /\ ):\_^1Z/JE;^3_R:/^8?7*'\
M_P#Y++_(/^%T>$/^?_\ \EKS_P"1Z/JE;^3_ ,FC_F'URA_/_P"2R_R#_A='
MA#_G_P#_ "6O/_D>CZI6_D_\FC_F'URA_/\ ^2R_R#_A='A#_G__ /):\_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@#S>'_DH/_<O?^Y"NM_[O_W%_P#;#C7^\_\ <'_V\]6K@/0"
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .4\*_
M\@R'_MI_Z->O%R__ ':G_P!O?^ER/:Q_^\U/^W?_ $B)T->H>6% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!SWBK_D&3?]L__1J5Y>8?[M4_[=_]+B>IE_\ O-/_ +>_](D=77M'
MBA0 4 >4S?\ )0?^Y>_]R%=Z_P!W_P"XO_MAY[_WG_N#_P"WGI%<AV!0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % 'F\/_ "4'_N7O_<A76_\ =_\ N+_[8<:_WG_N
M#_[>>K5P'H!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % '*>%?^09#_ -M/_1KUXN7_ .[4_P#M[_TN1[6/_P!YJ?\ ;O\ Z1$Z
M&O4/+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H Y[Q5_R#)O^V?_ *-2O+S#_=JG_;O_ *7$]3+_
M />:?_;W_I$CJZ]H\4* "@#RF;_DH/\ W+W_ +D*[U_N_P#W%_\ ;#SW_O/_
M '!_]O/2*Y#L"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /-X?^2@_P#<O?\ N0KK
M?^[_ /<7_P!L.-?[S_W!_P#;SU:N ] * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H Y3PK_ ,@R'_MI_P"C7KQ<O_W:G_V]_P"E
MR/:Q_P#O-3_MW_TB)T->H>6% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!SWBK_D&3?\ ;/\ ]&I7
MEYA_NU3_ +=_]+B>IE_^\T_^WO\ TB1U=>T>*% !0!Y3-_R4'_N7O_<A7>O]
MW_[B_P#MAY[_ -Y_[@_^WGI%<AV!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y
MO#_R4'_N7O\ W(5UO_=_^XO_ +8<:_WG_N#_ .WGJU<!Z 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!RGA7_D&0_]M/\ T:]>
M+E_^[4_^WO\ TN1[6/\ ]YJ?]N_^D1.AKU#RPH * "@ H * "@ H * "@ H
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MR]&PH /&20< 6/-[_P 11^)?%>EW2126[QM;PRQ2C#)(MQ*Q';(VNIS@'G!
M(I#/IFF2% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YO#_R4'_N7O\ W(5U
MO_=_^XO_ +8<:_WG_N#_ .WGJU<!Z 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!RGA7_D&0_]M/\ T:]>+E_^[4_^WO\ TN1[
M6/\ ]YJ?]N_^D1.AKU#RPH * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * .>\5?\@R;_ +9_^C4KR\P_
MW:I_V[_Z7$]3+_\ >:?_ &]_Z1(ZNO:/%"@ H \IF_Y*#_W+W_N0KO7^[_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MK=()895VNC="/PP0<\@@@@@$$$4 >;0_![0H9A,?M,B@Y\II5\OZ?+&LF/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F\/_ "4'_N7O_<A76_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /-X
M?^2@_P#<O?\ N0KK?^[_ /<7_P!L.-?[S_W!_P#;SU:N ] * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y3PK_ ,@R'_MI_P"C
M7KQ<O_W:G_V]_P"ER/:Q_P#O-3_MW_TB)T->H>6% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!SWB
MK_D&3?\ ;/\ ]&I7EYA_NU3_ +=_]+B>IE_^\T_^WO\ TB1U=>T>*% !0!Y3
M-_R4'_N7O_<A7>O]W_[B_P#MAY[_ -Y_[@_^WGI%<AV!0 4 % !0 4 % !0
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M[.()YP&165]I!8J"7"F-!D')=E  R<#F@#/L_'VA7]P+."[1IG;:H*R*K,>
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M$!7G:0"'7.TCC!I#/?J9(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M>;P_\E!_[E[_ -R%=;_W?_N+_P"V'&O]Y_[@_P#MYZM7 >@% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <IX5_Y!D/_;3_ -&O
M7BY?_NU/_M[_ -+D>UC_ />:G_;O_I$3H:]0\L* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#GO%7
M_(,F_P"V?_HU*\O,/]VJ?]N_^EQ/4R__ 'FG_P!O?^D2.KKVCQ0H * /*9O^
M2@_]R]_[D*[U_N__ '%_]L//?^\_]P?_ &\](KD.P* "@ H * "@ H * "@
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MAL*'+1J.B +M- &1X$BD@\5SVES#%;^;'<1S6T>#"H(#&,#+*4! &,E>PXH
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M8Z$KD@C- %3QWH5GH?B2Q%BBPI.T$C1(,*K"?;E5Z*& ' XR"1UH ^EZ9(4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >;P_P#)0?\ N7O_ '(5UO\
MW?\ [B_^V'&O]Y_[@_\ MYZM7 >@% !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 <IX5_P"09#_VT_\ 1KUXN7_[M3_[>_\ 2Y'M
M8_\ WFI_V[_Z1$Z&O4/+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H Y[Q5_R#)O^V?\ Z-2O+S#_
M ':I_P!N_P#I<3U,O_WFG_V]_P"D2.KKVCQ0H * /*9O^2@_]R]_[D*[U_N_
M_<7_ -L//?\ O/\ W!_]O/2*Y#L"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * .-\=>%W\6:;]BB=8I4E66,OG;N4,I#;02 5=N0#SCB@9S5AX/UQ
M=#N]'O[F"9I8HHK7#/LB2/@JQ\E6Q@*!A6/%(#J? ^@7'AG2TT^Z:-Y4>1B8
MBQ3#L2,%E0YQU^7\Z8')ZW\/[^/5&UOPY=)9W,VXR+*#L+-RY!"2 JY^9D>,
M@,-P/0*@+'ASP-J-OJ1UG7;S[5<C[J1%A'NQ@%OEC&U1]V-8U4'![8+ S)/A
M_K6D:I/J/AZ[@@CNRQ99@Q90[;RH!CE5]K<JQVMC@]R4!)X;^'NI:%KHU::X
MBNXV5_-=BZS,\B?.0NQD(\SIF0?)S@'B@"MJGP[UF/69M7T2[AMOM+,Q+EPZ
M[\&1<"*16!8$@Y4XP/<@&YJW@N]U#Q+;:ZCP+;VXBWH6?S,INW;0(RI^]QEE
MSW H D\4>#;S6M=L-6MWA6"R: R*[.)#Y<YE;8%C93E3@99>>N!S3 9XZ\%W
MOB:]L[JT>%$M,[Q*SAC\Z-\H6-P>%/4KSBD!+XS\!OK]S%JFG3?8]0M]H#G.
MU@I)0DKEE92>&PP*_*1P#3 PX? 6NZQ>17/B/4%ECMSE4MBRY!QE?EB@5-V
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MC$:@D8'4T6&>\TR0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \WA_Y
M*#_W+W_N0KK?^[_]Q?\ VPXU_O/_ '!_]O/5JX#T H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@#E/"O_(,A_[:?^C7KQ<O_P!V
MI_\ ;W_I<CVL?_O-3_MW_P!(B=#7J'EA0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M1G  S@<X ^E B:@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H \WA_Y*#_ -R]_P"Y"NM_[O\ ]Q?_ &PXU_O/_<'_ -O/
M5JX#T H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@#E/"O\ R#(?^VG_ *->O%R__=J?_;W_ *7(]K'_ .\U/^W?_2(G0UZAY84
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M/_/_ .2S_P#D0_X61X?_ .?K_P @W'_QJCZCB/Y/_)H?_)!]>P_\_P#Y+/\
M^1#_ (61X?\ ^?K_ ,@W'_QJCZCB/Y/_ ":'_P D'U[#_P __DL__D0_X61X
M?_Y^O_(-Q_\ &J/J.(_D_P#)H?\ R0?7L/\ S_\ DL__ )$/^%D>'_\ GZ_\
M@W'_ ,:H^HXC^3_R:'_R0?7L/_/_ .2S_P#D0_X61X?_ .?K_P @W'_QJCZC
MB/Y/_)H?_)!]>P_\_P#Y+/\ ^1#_ (61X?\ ^?K_ ,@W'_QJCZCB/Y/_ ":'
M_P D'U[#_P __DL__D0_X61X?_Y^O_(-Q_\ &J/J.(_D_P#)H?\ R0?7L/\
MS_\ DL__ )$/^%D>'_\ GZ_\@W'_ ,:H^HXC^3_R:'_R0?7L/_/_ .2S_P#D
M0_X61X?_ .?K_P @W'_QJCZCB/Y/_)H?_)!]>P_\_P#Y+/\ ^1#_ (61X?\
M^?K_ ,@W'_QJCZCB/Y/_ ":'_P D'U[#_P __DL__D0_X61X?_Y^O_(-Q_\
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M/_/_ .2S_P#D0_X61X?_ .?K_P @W'_QJCZCB/Y/_)H?_)!]>P_\_P#Y+/\
M^1#_ (61X?\ ^?K_ ,@W'_QJCZCB/Y/_ ":'_P D'U[#_P __DL__D0_X61X
M?_Y^O_(-Q_\ &J/J.(_D_P#)H?\ R0?7L/\ S_\ DL__ )$/^%D>'_\ GZ_\
M@W'_ ,:H^HXC^3_R:'_R0?7L/_/_ .2S_P#D0_X61X?_ .?K_P @W'_QJCZC
MB/Y/_)H?_)!]>P_\_P#Y+/\ ^1#_ (61X?\ ^?K_ ,@W'_QJCZCB/Y/_ ":'
M_P D'U[#_P __DL__D0_X61X?_Y^O_(-Q_\ &J/J.(_D_P#)H?\ R0?7L/\
MS_\ DL__ )$/^%D>'_\ GZ_\@W'_ ,:H^HXC^3_R:'_R0?7L/_/_ .2S_P#D
M0_X61X?_ .?K_P @W'_QJCZCB/Y/_)H?_)!]>P_\_P#Y+/\ ^1#_ (61X?\
M^?K_ ,@W'_QJCZCB/Y/_ ":'_P D'U[#_P __DL__D0_X61X?_Y^O_(-Q_\
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M/_/_ .2S_P#D0_X61X?_ .?K_P @W'_QJCZCB/Y/_)H?_)!]>P_\_P#Y+/\
M^1#_ (61X?\ ^?K_ ,@W'_QJCZCB/Y/_ ":'_P D'U[#_P __DL__D0_X61X
M?_Y^O_(-Q_\ &J/J.(_D_P#)H?\ R0?7L/\ S_\ DL__ )$/^%D>'_\ GZ_\
M@W'_ ,:H^HXC^3_R:'_R0?7L/_/_ .2S_P#D0_X61X?_ .?K_P @W'_QJCZC
MB/Y/_)H?_)!]>P_\_P#Y+/\ ^1#_ (61X?\ ^?K_ ,@W'_QJCZCB/Y/_ ":'
M_P D'U[#_P __DL__D0_X61X?_Y^O_(-Q_\ &J/J.(_D_P#)H?\ R0?7L/\
MS_\ DL__ )$/^%D>'_\ GZ_\@W'_ ,:H^HXC^3_R:'_R0?7L/_/_ .2S_P#D
M0_X61X?_ .?K_P @W'_QJCZCB/Y/_)H?_)!]>P_\_P#Y+/\ ^1#_ (61X?\
M^?K_ ,@W'_QJCZCB/Y/_ ":'_P D'U[#_P __DL__D0_X61X?_Y^O_(-Q_\
M&J/J.(_D_P#)H?\ R0?7L/\ S_\ DL__ )$U=(\6Z7KTQM]/G\Z54,A7RY4P
MH*J3ET4=648!SSTP#6-3#5:"YZL;)NV\7KJ^C?9F]+$TJSY*4KM*]K26FBZI
M=T='7(=04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!YO#_R4'_N7O_<A76_]W_[B_P#MAQK_ 'G_ +@_^WGJU<!Z 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!RGA7_D&
M0_\ ;3_T:]>+E_\ NU/_ +>_]+D>UC_]YJ?]N_\ I$3H:]0\L* "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#GO%7_ "#)O^V?_HU*\O,/]VJ?]N_^EQ/4R_\ WFG_ -O?^D2.KKVC
MQ0H * /*9O\ DH/_ '+W_N0KO7^[_P#<7_VP\]_[S_W!_P#;STBN0[ H * ,
M/Q/_ ,@B^_Z\[C_T2]=-#^-3_P </_2D<]?^#4_P3_\ 26?'=?>'P84 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!ZI\(?^0O-_P!><G_HZ"O%S+^#'_&O_29'LY;_ !I?X'_Z5$^C*^4/
MJPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#S>'_ )*#_P!R]_[D*ZW_ +O_ -Q?_;#C7^\_]P?_ &\]6K@/0"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .4\*_\ (,A_
M[:?^C7KQ<O\ ]VI_]O?^ER/:Q_\ O-3_ +=_](B=#7J'EA0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 <]XJ_Y!DW_;/_ -&I7EYA_NU3_MW_ -+B>IE_^\T_^WO_ $B1U=>T>*%
M!0!Y3-_R4'_N7O\ W(5WK_=_^XO_ +8>>_\ >?\ N#_[>>D5R'8% !0!A^)_
M^01??]>=Q_Z)>NFA_&I_XX?^E(YZ_P#!J?X)_P#I+/CNOO#X,* "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH ]4^$/_ "%YO^O.3_T=!7BYE_!C_C7_ *3(]G+?XTO\#_\ 2HGT97RA]6%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M>;P_\E!_[E[_ -R%=;_W?_N+_P"V'&O]Y_[@_P#MYZM7 >@% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <IX5_Y!D/_;3_ -&O
M7BY?_NU/_M[_ -+D>UC_ />:G_;O_I$3H:]0\L* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MT^9[:Y0Q2Q,5=&X((_SD$9!&""00:]:,E-*<'>+U31Y$HN#<)JS6C3*U62%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!ZI\(?^0O-_UYR?^CH*\7,O
MX,?\:_\ 29'LY;_&E_@?_I43Z,KY0^K"@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /-X?^2@_P#<O?\ N0KK?^[_ /<7
M_P!L.-?[S_W!_P#;SU:N ] * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H Y3PK_ ,@R'_MI_P"C7KQ<O_W:G_V]_P"ER/:Q_P#O
M-3_MW_TB)T->H>6% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!SWBK_D&3?\ ;/\ ]&I7EYA_NU3_
M +=_]+B>IE_^\T_^WO\ TB1U=>T>*% !0!Y3-_R4'_N7O_<A7>O]W_[B_P#M
MAY[_ -Y_[@_^WGI%<AV!0 4 8?B?_D$7W_7G<?\ HEZZ:'\:G_CA_P"E(YZ_
M\&I_@G_Z2SX[K[P^#"@ H * "@ H * "@ H * "@!RX!&X$KGD X)'?!P<'W
MP<>AI>@>IZMXN\"6.DZ3%K&E23S1R&,MYK1L!'*N58;(TP=Q53DG[W3@UXN&
MQ<ZM65"LHIJ]K)K5/5:M]+OY'M8G"0I4HUZ+DT[7NUM):/1+K9?,;X-\"V6L
M:7-JVJR3P11,^TQ,B@QQ+N=SOC?/.5&,<J>M/$XN=&K&A146W:]TWJWHM&O7
MYAAL)"K2E7K.44KVM9:):O5/T^1#X.^'G_"21-J-U(UK8AF"8P9'"Y#'<0$5
M5/!<J<LK?*H&:K$XWZNU2@N:I97[*_EO=]K]5JR<-@OK"=6;Y:=W;N[>>R2[
MV[Z(Z4_#'1M7AD.A7YFFC_O212H#S@/Y2(RAL'#?-W(5L8KC^OUJ37UFE:+[
M*47\KMIV[:?(Z_J%&JG]6JWDN[C)?/E2:OWU^9PWA/PBFK:Q)I&I^; 84D+"
M,JK!T91U9'!4YR"!R,$''7T<1B72HJO1L[M6O>UG?LUJ>=A\,JM9T*UXV3O:
MR=U;NGH=Y)\-?#]A=?9;Z_>.29AY$/F0K)M;Y5W%HSN+,&P0B#^$9()/FK'8
MB<>>G2327O2M)JZU=K/2R\WW/2>!P\)<E2JTV_=C>*=GHKW6MWY+L<)X[\&?
M\(C/'Y4AFMK@-Y98 .K)MW*V %/WE*L ,Y(VC;D^EA,5]:B[JTHVO;9I[-=>
MFJ_'4\W%X7ZK)<KO&5[7W36Z?3KH_P -#K=+^%UI;60OO$-T;0,%.Q62/R]W
M17>16!<\955&#D M7#4Q\Y3]EA8<UNK3=[=4DUIYW^X[J> A&'M,5/DOT32M
M?HVT]?*WWD&O?#&!+$ZEH%P;R)%+E&*2%U7.XQO$JJS+@Y3;DX.#N 4W1Q\N
M?V.)AR-NU]59O:Z>R?>_X:DUL!%0]MAI<Z2O;1W2WLUU7:WXZ%'P'X%L_%5E
M/<7+S)+%(8T$;(JGY PW;HW/4\X(X[5IC,7/#3C""BTU=W3OO;2S1EA,)#$P
ME*;DFG96:2VOK=,Z*U^&N@/)_9[ZBTFH $,D<D(PP&6 B*L_R\DKOW #)QS7
M++'8A+VJI)4^C:EMZW2^=K'7' X=OV3JMU.J3COUTLW\KW//+WPA)I&N0:->
M,6CN)X5$L?REXI9 F]0P8*P^8$$,%8?Q#!/J1Q*JT)8BFM8QD[/I**O9[77W
M778\J6&=*O'#U'I*45=:7C)VNM[/[]>YZ=<_"?1K"0S7=Y+!:855\R2%&,A)
MSF1HPF"-H50FXG<=W05X\<QK37+"FI3UO92:MZ)W[W=['L2RZC!\TZCC#2UW
M%._JU;M96N<AIGP_@UK6;JRLYV%A8LJM,VUI&8C!1<!5)#!P6Q@!02#N%=U3
M&2HT85*D5[2=VHZI)=WN]K:>?D<-/!QK5ITZ<G[.%DY:-M]ELM[Z_P"9T]O\
M./#>IN]KI^H2R7,8)*B2&3&, L46)25#$ X; )QG-<DL=B::4ZM)*#\I+\6W
MK\CKC@<-4;A2JMR7G%_@DM/F<#I/ABRBUF?2M>G^RQVZO^\62.,,P9-F&D5A
MAT8N%QNQZ8->G4KS=&-?#1YG)K2S=EK?1-;-6['FT\/!5I4,3+E44]4TKO2V
MZ>Z=^YZ/8?#3PSJA865[/<&/!;RI[=]N<XSM@.,X.,]<'TKR9X[$TK>TIQC?
M:\9*_P!\CU88'#5+^SJ2E;>THNWW1.)UGP) NO1:%I,K.'B5YGF96,39<MNV
M*@XC",J$9)<?, P(]"EBY>PEB:\4K-J*BFN;:V[?6Z;\O(\^KA(JO'#4)-W2
M<G)I\N]]DNEFEY^9UI^'/AJWG73[C4)1>M@>6)8%)9L;1L,3$%LC:I;<<C&:
MXOKN)E%U84E[/O:3T7G=;=78[OJ6&C)4I57[3M>*U?E9[]%<\]\4>#F\-:E%
M9,YEM[DJ8Y,!6VE]K*>HWKZC@@J<<X'J8?$_6*4JB5I1O==+VNGZ/_,\K$8;
MZO4C3;O&5K/9VO9KU7^1Z-JGPLT32]MQ<WLMM:C*N97BW,YP4"-Y:@<!R1M=
MFXP  <^33S"M4O&%-2GTY5*R76ZN_+JCUJF7T:5I3J.,.MW&[?2SLO/HS"\4
M_#>TL--.KZ/</<0H [!RC[HR0-Z.BH/ESD@@Y&<$$8/3A\=.=7V%>*C)Z*UU
M9]FFWN<V(P,*=/V^'DY16KO9W7=-);'CU>\>$>G>"M8T'P]9O?W\7VC4EF80
M( 6(0)&58;OW2?.7^<_O  =H.,5X^*I5Z\U2I/EI<JYGMK=W6GO/2VFW<]?"
MU:%"#J55S55)\J\K*S_E6M]=^QZ7X\O3J7A);Q@$-PEI*5'(4R%'(![@9Q7D
M8.'L\6Z:UY7.-_2Z/7QDO:815'IS*$K=KV9Q_P &+));N[NV&7@CC13Z>:S%
MC]?W0 /H2.]=^:3:A""V;;?_ &ZE_F<&5P3G.?6*27_;S?\ D06WBV_/B_8\
MTOV=KUK7R=[>7L+F!/W>=H.=KD@9W9-5+#4_J=U%<RIJ?-97O;F>N_=>A,<3
M4^MV<GR^T<.6[M:_*M-NS]1OQCL4@U&"Z7 -Q"58#N8FP&/J2K*OT44\LFW3
ME!_9EI\UM]Z;^89G!1J1FOM1U^3W^YI?(\OTFT2_O;>UD)"3SQ1L5P&"NZJ2
M"01G!XR",]0:]BI)PA*:WC%M7\DV>-3BISC![2DD[>;2/;=2^%^A:2ZS7E[+
M;6K#:/,>(.TA)/RMY04*%'38QZDE0.?GJ>/KU4XTZ:E/?12LEZ7O>_FCZ&>
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M/^-?^DR/9RW^-+_ _P#TJ)]&5\H?5A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % 'F\/_ "4'_N7O_<A76_\ =_\ N+_[
M8<:_WG_N#_[>>K5P'H!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % '*>%?^09#_ -M/_1KUXN7_ .[4_P#M[_TN1[6/_P!YJ?\
M;O\ Z1$Z&O4/+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H Y[Q5_R#)O^V?_ *-2O+S#_=JG_;O_
M *7$]3+_ />:?_;W_I$CJZ]H\4* "@#RF;_DH/\ W+W_ +D*[U_N_P#W%_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MEF( R2!R>I H K?VM9?9OM_VB#[)_P ]_-3R?O;/]9NV??\ D^]][Y>O%/R
MLVUU#>QK/;.DT3_=>-@Z-@D'#*2#@@C@]012 GH * "@"K>7UOIT?G7<L=O'
MD#?*ZQKD]!N8@9/89YH E@GCNHUF@=98W&5=&#*P/0JRD@@^H.* ): "@ H
MH7NJV>F%!>3PVQESL$TJ1[\8SMWL-V-RYQG&1GJ*8;%^D 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!SWBK_D&3?]L__1J5Y>8?[M4_[=_]+B>I
ME_\ O-/_ +>_](D=77M'BA0 4 >4S?\ )0?^Y>_]R%=Z_P!W_P"XO_MAY[_W
MG_N#_P"WGI%<AV!0 4 >4^(O#5QHT-S<:4Q6UGAD2X@/(5&1E9U!/(0$D?Q)
MSR4+ :4Y.$XSBKM232[M.]OF14BIPE"3LG%IOLFK7/GZXMGMFPW3L>Q_^O[5
M]M0Q$,1'FANMXO=?\#L_UT/B:^'GAI<LUH]I+9_Y/NOTU*U=9R!0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M=6<)P]P"RA1ZL%AD5,]0'D4XZXZ"N7S)YNR.FN/$MIXI\-7]Y9D@?8[I7C;
M>-Q ^58 D=""""00?7("M9CO='GW@7Q5;>$O"[W=Q\[M=RK#"#AI7V0\ X.U
M0.68@@#L20#35V).R/7?"VM76OV8OKFU^PK+S$AE\QG3^^1Y4>P'^$<EA\W
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MC564$A?+?><'.-R],=\U*5QMV.:D^+XM9H_MFFW-M:3',<[DAF3(^=8S$JL
M#DA96]B:?+YBYO([GQ3XRLO"UFEY-F8S_P"HC3&9. 2<G@( 02W/4  D@4DK
ME-V.!;XQ-;0^;=Z9/;F1=UOND/ES<C/[QH4P,9.Y5D&0 <9R'R^9/-Y'I_AK
M6O\ A(=.AU+R_(^T!CY>[?MVNR?>VIG.W/W1UQ[U+5M"D;M(84 % !0 4 %
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MTJS4JL;M:+62\^C1U4L15H)QI2LGJ](ORZIG.UUG*% !0 4 % !0 4 % !0
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M)U/3HY2NS;F/&<\)\H.<#D@#/O\ E0(Z*@04 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!C7'B/2[.1H+B\M894.&1[B)&4]<%6
M<$'!SR*!D]GK5AJ+;+.YM[AAVBFCD/Y(Q- C2H BGGCM8VFG=8HT&6=V"JH'
M4LQ( 'N3B@"*SOK?4(_.M)8[B/)&^)UD7(ZC<I(R.XS0!:H * "@ H * "@
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M3PK_ ,@R'_MI_P"C7KQ<O_W:G_V]_P"ER/:Q_P#O-3_MW_TB)T->H>6% !0
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M 9..<@KDX(."1AC5"M'$0YXZ/9KJFNA->B\//V<M5NGT:?4YZNHY@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]4^$/_(7F_Z\Y/\
MT=!7BYE_!C_C7_I,CV<M_C2_P/\ ]*B?1E?*'U84 % !0 4 % !0 4 % %/4
M?^/6;_KE)_Z":!G+^ ?^02G_ %TD_P#0J 9VE @H * "@ H * "@ H * "@
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MNE:):6MP-LJ1993U4NS2;3[C=@^XK)[FBT1U5(84 % !0 4 % !0 4 % !0
M4 % !0 4 <]XJ_Y!DW_;/_T:E>7F'^[5/^W?_2XGJ9?_ +S3_P"WO_2)'5U[
M1XH4 % 'E,W_ "4'_N7O_<A7>O\ =_\ N+_[8>>_]Y_[@_\ MYZ17(=@4 %
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MA7_D&0_]M/\ T:]>+E_^[4_^WO\ TN1[6/\ ]YJ?]N_^D1.AKU#RPH * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@"E>Z;::DH2\ABN54Y"S1I( ?4!P0#[BGL!-;6L-G&(;=$AC7[J1J$4=^%4
M #GT%(">@ H * "@ H * "@ H * "@".6))T,<BJZ,,,K %2#V(.01[&@#,M
MO#^F64@FM[2UAD!R'C@B1@?7<J@_K3N%C7I % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!SWBK_D&3?\ ;/\ ]&I7EYA_NU3_ +=_]+B>IE_^\T_^WO\ TB1U
M=>T>*% !0!Y3-_R4'_N7O_<A7>O]W_[B_P#MAY[_ -Y_[@_^WGI%<AV!0 4
M8?B?_D$7W_7G<?\ HEZZ:'\:G_CA_P"E(YZ_\&I_@G_Z2SX[K[P^#"@ H *
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M.TY/U4CJ*\2LN;&TDND;O_R=_C^I[='W<%5;ZRLO_)%^'Z'D5>X>&% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'JGPA_Y"\W_7G)_Z
M.@KQ<R_@Q_QK_P!)D>SEO\:7^!_^E1/HROE#ZL* "@ H * "@ H * "@"GJ/
M_'K-_P!<I/\ T$T#.7\ _P#()3_KI)_Z%0#.TH$% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <9%X&L8=:_P"$A5Y_M19FV%H_
M*R\1B/R^7OQM)(_>?>YY'% SLZ!')ZIX-L]7U2WUJ9YEN+,1A%1D$9\N1Y%W
M QLQRSD'#KQC&#R09N:KIL>L6DMC.66.X0HQ0@, >NTD, ?JI'M0(YZT\$65
MEI$N@QO.;:<L69F3S1N*DX81A/X1C*'O0,M:=X3M-,TF30XGE-O,DR,S,AD
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M[E[_ -R%=;_W?_N+_P"V'&O]Y_[@_P#MYZM7 >@% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <IX5_Y!D/_;3_ -&O7BY?_NU/
M_M[_ -+D>UC_ />:G_;O_I$3H:]0\L* "@ H * "@ H * "@ H * "@ H *
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M(V('7:)$3=@<G;G R>@-%F@NNAT](84 % !0 4 % !0 4 % !0 4 % !0 4
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MI%)R:LW*[W=WLUJSL#\7M5//V>Q_[]2__'ZX?[-I?S5/OC_\B=_]I5?Y:?\
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M97RA]6% !0 4 % !0 4 % !0!3U'_CUF_P"N4G_H)H&<OX!_Y!*?]=)/_0J
M9VE @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * ,S^Q-/\_[7]FM_M&=WG>3'YF[KNW[=V<\Y
MSF@#3H * "@ H * "@ H * *$NDV4TZWDEO"]RF-LS1(95QTVR%=PQDXP>,\
M4 7Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /-X?\
MDH/_ '+W_N0KK?\ N_\ W%_]L.-?[S_W!_\ ;SU:N ] * "@ H * "@ H *
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M_;W_ *7(]K'_ .\U/^W?_2(G0UZAY84 % !0 4 % !0 4 % !0 4 % !0 4
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M.3TXZX+Z6"VMSM*D9Y+:?#J=_#\^B7DL:S2W+7$<D6YT4_)M#!EC)SM8, .
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MF\/_ "4'_N7O_<A76_\ =_\ N+_[8<:_WG_N#_[>>K5P'H!0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '*>%?^09#_ -M/_1KU
MXN7_ .[4_P#M[_TN1[6/_P!YJ?\ ;O\ Z1$Z&O4/+"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H Y[3O#=MIFH76J1-*9K_ &^8K%2B[.FP! P]]S-^
M%._05K:G0TAA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!SWBK_D&3?\ ;/\
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MX5OX?_Y]?_(UQ_\ ':/KV(_G_P#)8?\ R(?4</\ R?\ DT__ )(/^%;^'_\
MGU_\C7'_ ,=H^O8C^?\ \EA_\B'U'#_R?^33_P#D@_X5OX?_ .?7_P C7'_Q
MVCZ]B/Y__)8?_(A]1P_\G_DT_P#Y(/\ A6_A_P#Y]?\ R-<?_':/KV(_G_\
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M'U'#_P G_DT__D@_X5OX?_Y]?_(UQ_\ ':/KV(_G_P#)8?\ R(?4</\ R?\
MDT__ )(/^%;^'_\ GU_\C7'_ ,=H^O8C^?\ \EA_\B'U'#_R?^33_P#D@_X5
MOX?_ .?7_P C7'_QVCZ]B/Y__)8?_(A]1P_\G_DT_P#Y(/\ A6_A_P#Y]?\
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MB'U'#_R?^33_ /D@_P"%;^'_ /GU_P#(UQ_\=H^O8C^?_P EA_\ (A]1P_\
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MV*X#!74J2"01G!XR",]0:8FKII]=#YUC01J$'10 ,^PQ6AXP^@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H BF<QQLXZJI(S[#-
M 'T+I-V]_96]U( 'G@BD8+D*&=%8@ DG&3QDDXZDUF>Q%W2;ZI,T*104 >;P
M_P#)0?\ N7O_ '(5UO\ W?\ [B_^V'&O]Y_[@_\ MYZM7 >@% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <IX5_P"09#_VT_\
M1KUXN7_[M3_[>_\ 2Y'M8_\ WFI_V[_Z1$Z&O4/+"@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y[
MQ5_R#)O^V?\ Z-2O+S#_ ':I_P!N_P#I<3U,O_WFG_V]_P"D2.KKVCQ0H *
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M;67]R?\ [Y3_ ..4?VQ0_EJ?='_Y,/[(K_S4_OE_\@'_  FUE_<G_P"^4_\
MCE']L4/Y:GW1_P#DP_LBO_-3^^7_ ,@'_";67]R?_OE/_CE']L4/Y:GW1_\
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MP_LBO_-3^^7_ ,@'_";67]R?_OE/_CE']L4/Y:GW1_\ DP_LBO\ S4_OE_\
M(!_PFUE_<G_[Y3_XY1_;%#^6I]T?_DP_LBO_ #4_OE_\@'_";67]R?\ [Y3_
M ..4?VQ0_EJ?='_Y,/[(K_S4_OE_\@'_  FUE_<G_P"^4_\ CE']L4/Y:GW1
M_P#DP_LBO_-3^^7_ ,@'_";67]R?_OE/_CE']L4/Y:GW1_\ DP_LBO\ S4_O
ME_\ (!_PFUE_<G_[Y3_XY1_;%#^6I]T?_DP_LBO_ #4_OE_\@'_";67]R?\
M[Y3_ ..4?VQ0_EJ?='_Y,/[(K_S4_OE_\@:6E^(K?5Y3#"LBLJ%R7"@8!4=G
M8YRP[>O-=N&Q]+%S=.FIIJ+E[R25DTNDGKJ<>)P-3"052HX-.2C[K;=VF^L5
MIH;U>J>4% !0 4 % !0 4 % !0!3U'_CUF_ZY2?^@F@9R_@'_D$I_P!=)/\
MT*@&=I0(* "@ H * "@ H * "@ H * "@#)U^1X=-NY(V*.EM.RLI(96$3$$
M$<@@\@CD'D4T1/2+:[/\CY^MB6B0GDE%))^@K0\@GH * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * &2()%*'HP(./<8H ^BK*T2P
MMXK6,DI!&D:EL%BJ*%!)  S@<X &>@%9GLI<J2730LTAA0!YO#_R4'_N7O\
MW(5UO_=_^XO_ +8<:_WG_N#_ .WGJU<!Z 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0!RGA7_D&0_]M/\ T:]>+E_^[4_^WO\
MTN1[6/\ ]YJ?]N_^D1.AKU#RPH * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .>\5?\@R;_ +9_^C4K
MR\P_W:I_V[_Z7$]3+_\ >:?_ &]_Z1(ZNO:/%"@ H \IF_Y*#_W+W_N0KO7^
M[_\ <7_VP\]_[S_W!_\ ;STBN0[ H * ,_5O^/*X_P"N$O\ Z U<F*_@5O\
MKW/_ -)9UX;^/2_Z^0_]*1X=7Y>?IH4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!V/@G_ (_7_P"N#?\
MH<=?1Y/_ !Y?]>W_ .E0/GLW_@1_Z^+_ -)F>H5]P?$!0 4 % !0 4 % !0
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MG0UZAY84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % '/>*O^09-_VS_P#1J5Y>8?[M4_[=_P#2XGJ9
M?_O-/_M[_P!(D=77M'BA0 4 >4S?\E!_[E[_ -R%=Z_W?_N+_P"V'GO_ 'G_
M +@_^WGI%<AV!0 4 9^K?\>5Q_UPE_\ 0&KDQ7\"M_U[G_Z2SKPW\>E_U\A_
MZ4CPZOR\_30H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M-=8OMW,K_A-[[^Y!_P!\O_\ '*X_[5K_ ,M/[I?_ "9V?V71_FJ??'_Y$/\
MA-[[^Y!_WR__ ,<H_M6O_+3^Z7_R8?V71_FJ??'_ .1#_A-[[^Y!_P!\O_\
M'*/[5K_RT_NE_P#)A_9='^:I]\?_ )$/^$WOO[D'_?+_ /QRC^U:_P#+3^Z7
M_P F']ET?YJGWQ_^1#_A-[[^Y!_WR_\ \<H_M6O_ "T_NE_\F']ET?YJGWQ_
M^1#_ (3>^_N0?]\O_P#'*/[5K_RT_NE_\F']ET?YJGWQ_P#D0_X3>^_N0?\
M?+__ !RC^U:_\M/[I?\ R8?V71_FJ??'_P"1#_A-[[^Y!_WR_P#\<H_M6O\
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M6_X\KC_KA+_Z U<F*_@5O^O<_P#TEG7AOX]+_KY#_P!*1X=7Y>?IH4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M7!\LBC3(-K2?#]YK)/V9/D7@NQVH#Z9Y)/J%!(XSC(I-I&L*<I_#MWZ&U<>
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MZ_\ 7%/_ $)ZVS;^.O\ KW'\Y&.5?P'_ (W^43C*\ ]X* "@ H * "@ H *
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M2@_]R]_[D*ZW_N__ '%_]L.-?[S_ -P?_;SU:N ] * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H Y3PK_R#(?\ MI_Z->O%R_\
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M0 4 % 'T+7ZB?F)SWBK_ )!DW_;/_P!&I7EYA_NU3_MW_P!+B>IE_P#O-/\
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MU&G-M;&%5&(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % $4SF.-G'55)&?89H ^A=)NWO[*WNI  \\$4C!<A0SH
MK$ $DXR>,DG'4FLSV(NZ3?5)FA2*"@#S>'_DH/\ W+W_ +D*ZW_N_P#W%_\
M;#C7^\_]P?\ V\]6K@/0"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MX/0J!EL^V*SR_E6$DZFL$YN2\DM?P-,?S?6XJGI.T%'U;T_$DT'Q FN2/9O
ML:*A8#(92H*J5(V@?Q#H,8S^-83&1QDI4)4U&*C=+=6NDTU9=UT(Q>#E@XQK
MQJ.4G*S>SO9M-.[[,\WUNT2QO9H(^$1SM'H" P'X9Q^%?*8JFJ-:I3A\*EIY
M)ZV^5['U>%J.K1A4ENXZ^JTO\[7*,%S+:MO@=XF(QE&*G'IE2#C@<>U<T)SI
M/FIRE%[7BVG;M='1.$:BY:D5);VDDU?O9G7>&](N-7NEU"X+&.-PY=NLCKT
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MDG)/))ZD^IKS&[ZO<])*VBV&TAA0 4 % !0 4 % !0 4 % !0!V/@G_C]?\
MZX-_Z''7T>3_ ,>7_7M_^E0/GLW_ ($?^OB_])F=1)X,TB5B[6^68DD^;-R2
M<GI)CK7W!\3<;_PA&C?\^_\ Y%F_^.4!</\ A"-&_P"??_R+-_\ '* N'_"$
M:-_S[_\ D6;_ ..4!</^$(T;_GW_ /(LW_QR@+A_PA&C?\^__D6;_P".4!</
M^$(T;_GW_P#(LW_QR@+A_P (1HW_ #[_ /D6;_XY0%P_X0C1O^??_P BS?\
MQR@+FK+9Q6%A);VZ[(HX9 JY)P"K'JQ)/)/4T 8'@'_D$I_UTD_]"H!G:4""
M@ H * "@ H * "@ H * "@ H R=?D>'3;N2-BCI;3LK*2&5A$Q!!'((/((Y!
MY%-$3TBVNS_(^?K8EHD)Y)122?H*T/()Z "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@!DB"12AZ,"#CW&* /HJRM$L+>*UC)*01
MI&I;!8JBA020 ,X'. !GH!69[*7*DETT+-(84 >;P_\ )0?^Y>_]R%=;_P!W
M_P"XO_MAQK_>?^X/_MYZM7 >@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MDKO7TZL*-\;C/;Q5HJ2EZ**2C?S=E^/1%:V_Y%@_[DG_ */:L8?\BQ_X9?\
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M34K#UXXF"J15GM*/6+73I\G_ ,,9=<9V!0 4 % !0 4 % !0 4 % !0 4 %
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M>5C.T#.,G&>F3ZU$>ITUXJ/+RI+?96['G5:'$% !0 4 % !0 4 % !0 4 %
M!0 4 % !0!Z%H.H:+!IXCO5A-S^\Y: NW).WYQ&W;&/FX]JS:=]#MA*FHVE:
M^O2_Z'GM:'$% !0 4 % !0 4 >J>-].M;33XI((8HG,R LD:*2#'(2"5 .,@
M''J!647J>A6BHQ322U6R\F>5UJ>>% !0 4 % !0 4 % !0!!<DK$Y'!",01V
MX- 'T#H$CS:;:22,7=[:!F9B2S,8E)))Y))Y)/)/)K,]>&L4WV7Y&M2+"@#S
M>'_DH/\ W+W_ +D*ZW_N_P#W%_\ ;#C7^\_]P?\ V\]6K@/0"@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .4\*_P#(,A_[:?\
MHUZ\7+_]VI_]O?\ I<CVL?\ [S4_[=_](B>>^*O^0G-_VS_]%)7R^8?[S4_[
M=_\ 2(GTV7_[M3_[>_\ 2Y'.UY1Z@4 % !0 4 % !0 4 % !0 4 % %N2^N9
MHQ#)+(\8QA&=BHQTPI.!CMQQ6\JM24>24Y.*M:+DVE;;1NVG0QC2IPESQA%2
M=[M12>N^J5]>I4K V+R:G>1+Y:3S*@X"B1P /3 .*Z57K17+&I-+LIR2^ZYS
M.A2D^:5.#?=PC?[[%(DL<GDGDDUS[ZLZ-M$6I[ZXN5"32R2*IR%=V8 XQD D
M@<<?2MI5:E1*-2<I);*4FTO1-F4:5.FW*G",6]W&*3?S2"*_N8$,44LJ1G.4
M5V53GK\H('/?CFB-:I"/)"<XQ[*32UWT3MJ*5&G-\\X1<N[BF]-M6KZ%96*$
M,I*D<@C@@^H/:LDW%W6C6S1LTFK-779ER74KN9?+DGF=#P5:1R/R)Q6\J]6:
MY9U)M=G*37W-F$:%*#YH4X)]U&*?WI%WP[*D&H0R2LJ(K'+,0H'RMU)P!6^"
ME&&(IRFTHIN[;LEH]VSGQL7/#U(P3;:5DE=O5=$;/BO4S]O$MC/QY*J6ADXR
M&<X)0]L],]Z]#,*_[]3P]33D2;A+SEI>+.#+Z'[APQ%/[;:4X^4=;21R,]Q+
M<MOF=I&Z9=BQ_,DFO#E.51\U23D^\FV_O9[<81IKEIQ45VBDE]R)!?7"Q?9Q
M+((>1Y>]MG)R?ESMY/)XZ\U7M:BC[)3ER?R\SY=[[7MOKMN3[*FY>T<(\_\
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MG/>*O^09-_VS_P#1J5Y>8?[M4_[=_P#2XGJ9?_O-/_M[_P!(D=77M'BA0 4
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M <@<GCN:4*> <(NI5J*=ES)+12MJE^[>E_-^HYU,<I25.E3<+OE;>KC?1O\
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MO*/4"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * /H6OU$_,3GO%7_(,F_[9_\ HU*\O,/]VJ?]N_\ I<3U
M,O\ ]YI_]O?^D2.KKVCQ0H * /*9O^2@_P#<O?\ N0KO7^[_ /<7_P!L//?^
M\_\ <'_V\](KD.P* "@#/U;_ (\KC_KA+_Z U<F*_@5O^O<__26=>&_CTO\
MKY#_ -*1X=7Y>?IH4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 =3X.D$>IQ@_Q*ZCZ[2?Z?G7LY8U'$Q3ZJ27K9O]#Q\R3>&E;HXO\
M%+]3.NT*:FZMU%RW7_KH>?QZURU$XXF2>_M7_P"EG53:>&BUM[)?^D&SXW_Y
M"'_;)/YM7?FO^\?]N1_-G#E?^[_]OR_)%J;_ )%J/_KJ?_1CUM+_ )%L/\?_
M +=(PC_R,9?X/_;8E&VNM!6)!/;SM*$4.0>"^!N(_?#@G)' X["N:%3 *$54
MI5'.RYFGHY6U:_>+2_DO0Z9T\<Y2=.I34+OE36JC?1/]V];>;]2;[9X=_P"?
M:X_[Z_\ M]:>UR[_ )]5?O\ _NAG[/,/^?M+[O\ [F9FG:)_:T=Q-;M@P998
MMN68')4 YZG!'?GZUQT<+]9C5G2=G#50M=M:M=?*W74ZZV*^K2IPJ+2>CG>R
M3T3Z>=^FA4T6WDN+Z%(@2RR(QQ_"%8%F/H !_0<D5CA82G7IQ@G=2BWY)--M
M^AOBIQIT:DIM).,DO-M-)+U.@\20-JVL?9K4;GVJA[ $#+$GT4'D]>,#)P*]
M/'0>)Q?LJ*O*RB^UTKMM]DGKZ6/,P4EAL)[6L[1NY+O9NR27=M:>MRS<WMMX
M5C-I8XEO6&)9B 0A[@#U'9>@X+EB,5M.K3RV+H8;WJ[5IS?V?)>?ET^U=Z&,
M*53,9*MB/=H)WA!=?-_Y]?LV6IPCNTC%W)9F))).22>I)]37S;;DW*3NWJV]
MVSZ-)12C%62T26R1VNG-Y/AZZ9AP\H5??/E#(^AY_ ]Z^@H/ER^LVMYV7SY%
M^'Z'@5ES8^BD]H7?_D[_ !_4X>OG3Z$* "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * .Q\$_\?K_]<&_]#CKZ/)_X\O\ KV__ $J!\]F_
M\"/_ %\7_I,SU"ON#X@* "@ H * "@ H * "@"GJ/_'K-_URD_\ 030,Y?P#
M_P @E/\ KI)_Z%0#.TH$% !0 4 % !0 4 % !0 4 % !0!6O;M+"WENI 2D$
M;R,%P6*HI8@ D#.!QD@9ZD4Q-\J;?34^=8W$BAQT8 C/N,UH>,/H * "@ H
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MGA7_ )!D/_;3_P!&O7BY?_NU/_M[_P!+D>UC_P#>:G_;O_I$3SWQ5_R$YO\
MMG_Z*2OE\P_WFI_V[_Z1$^FR_P#W:G_V]_Z7(YVO*/4"@ H * "@ H * "@
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M7+_]VI_]O?\ I<CVL?\ [S4_[=_](B>>^*O^0G-_VS_]%)7R^8?[S4_[=_\
M2(GTV7_[M3_[>_\ 2Y'.UY1Z@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MS_Y3G_F<'U+!?\_O_*D/\C&%M>>)-1VW*>2V%,GRE-D:]\-DY/0>I/IFO/\
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MM=/_ ,"2D_Q9.!DYX:G)[VM_X"W%?@C"KS3T0H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#Z%K]1/S$Y[Q5_R#)O^V?\ Z-2O+S#_ ':I
M_P!N_P#I<3U,O_WFG_V]_P"D2.KKVCQ0H * /*9O^2@_]R]_[D*[U_N__<7_
M -L//?\ O/\ W!_]O/2*Y#L"@ H S]6_X\KC_KA+_P"@-7)BOX%;_KW/_P!)
M9UX;^/2_Z^0_]*1X=7Y>?IH4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % $WVB7R_)WMY6=VS<=N[UVYQGWQFM.>7+[/F?+>_+=VOW
MMM?S,^2/-[3E7-:W-97MVOO;R(:S- H * "@ H * "@ H ?'(T3!XR493D,I
M((([@CD'W%4FXM2BVFM4UHT_)DM*2<9)-/1IZIKS022-*Q=R69CDDDDDGN2>
M2:&W)N4FVWJV]6_5@DHI1BDDM$EHEZ(94E!0 4 % !0 4 % !0 4 % !0 4
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MGGOBK_D)S?\ ;/\ ]%)7R^8?[S4_[=_](B?39?\ [M3_ .WO_2Y'.UY1Z@4
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MPW\>E_U\A_Z4CPZOR\_30H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#L?!/\ Q^O_ -<&_P#0XZ^CR?\
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MV?[;9SO]L8[YJ4[FU2G[*VM[WZ6VMYG,51SA0!;LK&?491!;(9';L.P[DGH
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M(4,Z*Q !).,GC))QU)K,]B+NDWU29H4B@H \WA_Y*#_W+W_N0KK?^[_]Q?\
MVPXU_O/_ '!_]O/5JX#T H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#E/"O_(,A_[:?^C7KQ<O_P!VI_\ ;W_I<CVL?_O-3_MW
M_P!(B>>^*O\ D)S?]L__ $4E?+YA_O-3_MW_ -(B?39?_NU/_M[_ -+D<[7E
M'J!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '36^HPW6F
MOI]VVQX3YEN^&//.8SM!(!R<$\#=_LBO7A7A4PTL-7=G!\U)V;UZQ=D][NS>
MFODCR9T9T\1'$T%=37+45TM/YE=KLKVUT\V<S7D'K!0 4 % !0 4 % !0 4
M% !0!TNDZC!I%I-+&V;V8>6@ /[M.I<L1MR3T )Y"Y&,X]?#UX86E4G%WKS]
MV*L_<CUE=JV_1-[+S/)Q%&>)JPA)6H0]Z3NO>ETC9.^W5I;OR.:KR#U@H *
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M C_D'UFO_P _:G_@<O\ ,/[)LO\ GW@_[])_\31]5H?\^:?_ (!'_(/K-?\
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M_@<O\P_LFR_Y]X/^_2?_ !-'U6A_SYI_^ 1_R#ZS7_Y^U/\ P.7^8?V39?\
M/O!_WZ3_ .)H^JT/^?-/_P  C_D'UFO_ ,_:G_@<O\P_LFR_Y]X/^_2?_$T?
M5:'_ #YI_P#@$?\ (/K-?_G[4_\  Y?YA_9-E_S[P?\ ?I/_ (FCZK0_Y\T_
M_ (_Y!]9K_\ /VI_X'+_ ##^R;+_ )]X/^_2?_$T?5:'_/FG_P" 1_R#ZS7_
M .?M3_P.7^8?V39?\^\'_?I/_B:/JM#_ )\T_P#P"/\ D'UFO_S]J?\ @<O\
MP_LFR_Y]X/\ OTG_ ,31]5H?\^:?_@$?\@^LU_\ G[4_\#E_F']DV7_/O!_W
MZ3_XFCZK0_Y\T_\ P"/^0?6:_P#S]J?^!R_S#^R;+_GW@_[])_\ $T?5:'_/
MFG_X!'_(/K-?_G[4_P# Y?YA_9-E_P ^\'_?I/\ XFCZK0_Y\T__  "/^0?6
M:_\ S]J?^!R_S#^R;+_GW@_[])_\31]5H?\ /FG_ . 1_P @^LU_^?M3_P #
ME_F']DV7_/O!_P!^D_\ B:/JM#_GS3_\ C_D'UFO_P _:G_@<O\ ,/[)LO\
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MUFO_ ,_:G_@<O\P_LFR_Y]X/^_2?_$T?5:'_ #YI_P#@$?\ (/K-?_G[4_\
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MN5A@@$=,Y(I/171M3BI2497U[%WQ%X?&DWL=K;;W695*%R"2S,5(R HZX[<
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M>L06LXPZ7,/3H09%(8'N".1W[$ @BKO=:',HN%11?\R_,Z[XD?\ +I_VW_\
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M26YQA<<]#6>M_,]",8J'*G[MGK=>=]=CQG7[.UL+D0V,OGP[ =V]'^8DY&4
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M0!YO#_R4'_N7O_<A76_]W_[B_P#MAQK_ 'G_ +@_^WGJU<!Z 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!RGA7_D&0_\ ;3_T
M:]>+E_\ NU/_ +>_]+D>UC_]YJ?]N_\ I$3SWQ5_R$YO^V?_ **2OE\P_P!Y
MJ?\ ;O\ Z1$^FR__ ':G_P!O?^ER.=KRCU H * "@ H * "@ H * "@ H *
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MWI/9LPO[(OO^?>?_ +]/_P#$UYWU:O\ \^JG_@$O\CT?K%'_ )^T_P#P./\
MF']D7W_/O/\ ]^G_ /B:/JU?_GU4_P# )?Y!]8H_\_:?_@<?\P_LB^_Y]Y_^
M_3__ !-'U:O_ ,^JG_@$O\@^L4?^?M/_ ,#C_F']D7W_ #[S_P#?I_\ XFCZ
MM7_Y]5/_  "7^0?6*/\ S]I_^!Q_S#^R+[_GWG_[]/\ _$T?5J__ #ZJ?^ 2
M_P @^L4?^?M/_P #C_F']D7W_/O/_P!^G_\ B:/JU?\ Y]5/_ )?Y!]8H_\
M/VG_ .!Q_P P_LB^_P"?>?\ []/_ /$T?5J__/JI_P" 2_R#ZQ1_Y^T__ X_
MYA_9%]_S[S_]^G_^)H^K5_\ GU4_\ E_D'UBC_S]I_\ @<?\P_LB^_Y]Y_\
MOT__ ,31]6K_ //JI_X!+_(/K%'_ )^T_P#P./\ F']D7W_/O/\ ]^G_ /B:
M/JU?_GU4_P# )?Y!]8H_\_:?_@<?\P_LB^_Y]Y_^_3__ !-'U:O_ ,^JG_@$
MO\@^L4?^?M/_ ,#C_F']D7W_ #[S_P#?I_\ XFCZM7_Y]5/_  "7^0?6*/\
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MI_\ @<?\P_LB^_Y]Y_\ OT__ ,31]6K_ //JI_X!+_(/K%'_ )^T_P#P./\
MF']D7W_/O/\ ]^G_ /B:/JU?_GU4_P# )?Y!]8H_\_:?_@<?\P_LB^_Y]Y_^
M_3__ !-'U:O_ ,^JG_@$O\@^L4?^?M/_ ,#C_F']D7W_ #[S_P#?I_\ XFCZ
MM7_Y]5/_  "7^0?6*/\ S]I_^!Q_S#^R+[_GWG_[]/\ _$T?5J__ #ZJ?^ 2
M_P @^L4?^?M/_P #C_F']D7W_/O/_P!^G_\ B:/JU?\ Y]5/_ )?Y!]8H_\
M/VG_ .!Q_P P_LB^_P"?>?\ []/_ /$T?5J__/JI_P" 2_R#ZQ1_Y^T__ X_
MYA_9%]_S[S_]^G_^)H^K5_\ GU4_\ E_D'UBC_S]I_\ @<?\P_LB^_Y]Y_\
MOT__ ,31]6K_ //JI_X!+_(/K%'_ )^T_P#P./\ F']D7W_/O/\ ]^G_ /B:
M/JU?_GU4_P# )?Y!]8H_\_:?_@<?\P_LB^_Y]Y_^_3__ !-'U:O_ ,^JG_@$
MO\@^L4?^?M/_ ,#C_F']D7W_ #[S_P#?I_\ XFCZM7_Y]5/_  "7^0?6*/\
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MI_\ @<?\P_LB^_Y]Y_\ OT__ ,31]6K_ //JI_X!+_(/K%'_ )^T_P#P./\
MF']D7W_/O/\ ]^G_ /B:/JU?_GU4_P# )?Y!]8H_\_:?_@<?\P_LB^_Y]Y_^
M_3__ !-'U:O_ ,^JG_@$O\@^L4?^?M/_ ,#C_F']D7W_ #[S_P#?I_\ XFCZ
MM7_Y]5/_  "7^0?6*/\ S]I_^!Q_S#^R+[_GWG_[]/\ _$T?5J__ #ZJ?^ 2
M_P @^L4?^?M/_P #C_F']D7W_/O/_P!^G_\ B:/JU?\ Y]5/_ )?Y!]8H_\
M/VG_ .!Q_P P_LB^_P"?>?\ []/_ /$T?5J__/JI_P" 2_R#ZQ1_Y^T__ X_
MYA_9%]_S[S_]^G_^)H^K5_\ GU4_\ E_D'UBC_S]I_\ @<?\P_LB^_Y]Y_\
MOT__ ,31]6K_ //JI_X!+_(/K%'_ )^T_P#P./\ F']D7W_/O/\ ]^G_ /B:
M/JU?_GU4_P# )?Y!]8H_\_:?_@<?\SW2OT8_.SGO%7_(,F_[9_\ HU*\O,/]
MVJ?]N_\ I<3U,O\ ]YI_]O?^D2.KKVCQ0H * /*9O^2@_P#<O?\ N0KO7^[_
M /<7_P!L//?^\_\ <'_V\](KD.P* "@#F/&W_(OZG_V#[S_TGDK>E_$A_BC^
M:,*W\*?^"7Y,_.^OJSXX* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MBTTAIS>2>5Y@CV_*[9V[\_<5L8R.N*<E?8SHSC"_,[7MW\^QE3W\#ZT+U6S
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MO_W%_P#;#C7^\_\ <'_V\]6K@/0"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * .4\*_\@R'_MI_Z->O%R__ ':G_P!O?^ER/:Q_
M^\U/^W?_ $B)T->H>6% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!SWBK_D&3?]L__1J5Y>8?[M4_
M[=_]+B>IE_\ O-/_ +>_](D=77M'BA0 4 >4S?\ )0?^Y>_]R%=Z_P!W_P"X
MO_MAY[_WG_N#_P"WGI%<AV!0 4 <QXV_Y%_4_P#L'WG_ *3R5O2_B0_Q1_-&
M%;^%/_!+\F?G?7U9\<% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M(H$W%4V9C,9;D.6P=IQ\N>F0*A1L[G9*K%T^17O9+RTMYG U9QA0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $%R"T3@
M<DHP 'T- 'T#H$;PZ;:1R*4=+:!65@0RL(E!!!Y!!X(/(/!K,]>&D4GV7Y&M
M2+"@#S>'_DH/_<O?^Y"NM_[O_P!Q?_;#C7^\_P#<'_V\]6K@/0"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .4\*_\@R'_ +:?
M^C7KQ<O_ -VI_P#;W_I<CVL?_O-3_MW_ -(B=#7J'EA0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M<]XJ_P"09-_VS_\ 1J5Y>8?[M4_[=_\ 2XGJ9?\ [S3_ .WO_2)'5U[1XH4
M% 'E,W_)0?\ N7O_ '(5WK_=_P#N+_[8>>_]Y_[@_P#MYZ17(=@4 % ',>-O
M^1?U/_L'WG_I/)6]+^)#_%'\T85OX4_\$OR9^=]?5GQP4 % !0 4 % !0 4
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M352*G#9GD3A*E)PGHT8]:&04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'NO[/O_(P7'_8/E_\ 2BUKS,;_  U_B7Y2/5P'\5_X'^<3["KP#Z,* "@
MH * "@ H * "@"GJ/_'K-_URD_\ 030,Y?P#_P @E/\ KI)_Z%0#.TH$% !0
M 4 % !0 4 % !0 4 % !0!GZM:/?V5Q:QD!YX)8U+9"AG1E!) )QD\X!..@-
M,F2NFEU31\]0H8XU0]54 X]ABM#QR6@ H LV]E<7>?L\4DN.OEHS8^NT'%&Q
M2BW\*;]$)<6D]F0MQ&\1/0.C(3CTW 4>@-..Z:]="O02306\MTWEP(TK]=J*
M6; Z\*">*-BDF]$K^@MQ:S6;;)T>)L9VNI0X/?# ''!Y]J/0&G'1IKUT(*"0
MH * "@ H * "@ H * "@ H * "@ H * "@ H * )(8)+EQ%"K2.V<*BEF.!D
MX !)P 2?89H&DWHM6/N+6:S;9.CQ-C.UU*'![X8 XX//M1Z#:<=&FO70@H)"
M@ H * "@ H * "@  +' Y)Z"@8KH8R58%64D$$8((X((/0CN* V$H$% %NVT
M^ZO 6MX9954X)CC9P#Z$J#@^U%[%J+?PIOT1592A*L"K*2"",$$<$$=B.XH)
MV$H$% !0 4 % !0!;MM/NKP%K>&655."8XV< ^A*@X/M1>Q:BW\*;]$52"I(
M(P1P0>H-!(E ADCB-2YZ*"3CV&: /HJRNTO[>*ZC!"3QI(H; 8*ZA@" 2,X/
M."1GH369[*=TFNNI9I#"@#S>'_DH/_<O?^Y"NM_[O_W%_P#;#C7^\_\ <'_V
M\]6K@/0"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * .4\*_\@R'_MI_Z->O%R__ ':G_P!O?^ER/:Q_^\U/^W?_ $B)T->H>6%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0!SWBK_D&3?]L__1J5Y>8?[M4_[=_]+B>IE_\ O-/_ +>_
M](D=77M'BA0 4 >4S?\ )0?^Y>_]R%=Z_P!W_P"XO_MAY[_WG_N#_P"WGI%<
MAV!0 4 <QXV_Y%_4_P#L'WG_ *3R5O2_B0_Q1_-&%;^%/_!+\F?G?7U9\<%
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MRIL^56.799 X*JVY@RM\Q!4+UX6NZR:G:\>NUT_\CBQ>'5!Q=._+*^F]FO\
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M_@'_ )!*?]=)/_0J 9VE @H * "@ H * "@ H * "@ H * ,_5KM["RN+J,
MO!!+(H;)4LB,P! (.,CG!!QT(IDR?*FUT39\]0N9(U<]64$X]QFM#QR6@!T8
M#, QVJ2 3C.!GDX'7'7'>@9ZQ<>+-/T>R2+20LI'RA2'4+@9+N"%+$GKS\Q)
M.[BLN5MZGH.K&$4J>OX?,VX)8_$^DF6ZC$8=7]]I0D!U)'&,9[]P<C.9^%Z&
MJ:JPO)6W_P"'/"JW/).P\"_\A1?^N<G_ *#42V.FA\?R9M^,-'O-5U(?9(FD
M"P)D\*H.^3C<Q"Y]LYQS2BTEJ:UH2G/W5?1?J</J&BWFDX-W$T8;@'(92?3<
MI*Y]LYJTT]CEE"4/B5BE;6TMW((8$:1VZ*H)/Z=AW)X'4T]B4FW9+4WF\(:L
MB[C;G'L\9/\ WR')_2IYD:^QGV_%?YG.R1M$Q1P493@JP((/H0>0:HQVT9L7
MWAV_TV+[1<Q>7'D#=OC;D].%<G]*2:>B-)4Y05Y*R]40:;HUWJ^_[''YGE;=
MWS(N-V<??9<YVGIGISVH;2W%&$I_"KV]"*'3+F>Z-C&F;@,Z%-RCYDW%AN)"
M\;3SNP<<9XHOU$HMOD2U[>AICPIJC2&$0'<H!/S1[1GI\^_9GCINR.,CD4N9
M&GLIWM;\BA+H]Y!<"S>)O/."$&&.#W^4D8]3G ')IW6Y#A)/EMKV-,^#]6 W
M?9SC_?B)_(/G]*7,B_8S[?BO\SG98G@8QR*4=3@JP((/H0>15&+5M&,H$;-A
MX>U#4D\VVA9T[,2J _0N5!].,\\=:5TC6-.4M8K3[OS&W^@7^EKYEU"R)TW
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M2*"@#S>'_DH/_<O?^Y"NM_[O_P!Q?_;#C7^\_P#<'_V\]6K@/0"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .4\*_\@R'_ +:?
M^C7KQ<O_ -VI_P#;W_I<CVL?_O-3_MW_ -(B=#7J'EA0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M<]XJ_P"09-_VS_\ 1J5Y>8?[M4_[=_\ 2XGJ9?\ [S3_ .WO_2)'5U[1XH4
M% 'E,W_)0?\ N7O_ '(5WK_=_P#N+_[8>>_]Y_[@_P#MYZ17(=@4 8NOV=W>
MVVW3YC;SHP<$<!\ _(3V!R#W&0 1@D@&<!K'BG[7H>IZ?J*_9KZ/3[Q2IX60
M_9Y/N]@Q&#C)#9W(2#@;4?XD/\4?S1A67[J?^"7Y,^(:^L/C0H * "@ H *
M"@ H * "@ H * /JSX+7T?BCP[?^%;LY\M9 @Z8AN0V=O?,<VY\]C(M>%BXN
ME4C7CY7]8_YK\CZ#!R56E/#RZ7MZ2_R>OS'?&*]3PEX8L/"ML?FF6-'/<PVP
M4LQQ@!I)]C=,'#\"C"KVM65=]+V]9?Y*_P" 8MJC1AAX];7](_YNWXFY:6LG
MB_X:K9:5^\N!:QQ; <,9+69&DCZCEUC(4'A@Z]C63:HXKFGHN9OY23L_Q-DG
M6PG)3WY4K><6KKYV.$^!/A75;'6I;^[MI[6WBMI(BTT;Q;G=TPBAPI; 5BQ
M(7 #$%ESU8RI"5-0C)-MIZ.^BOV.3!4IQJ.<HM))K56U;7<Z?P]>17WQ1U&6
M!@Z"W,>0<C=%#:Q2#_@+HRGW%8S3CA()Z:W^]R:_!F]-J6,FUVM]RBG^*/)_
MB2<^.Y\_\_-G_P"B;>N_#_[NO27YL\_$?[R_\4?R1[3\=+I+ Z-=2Y\N"_\
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MVP?P5/ZZ,PQW\2E_75#/VDV(&E*"=I-Z2,\$C[* 2/49.#VR?6G@/M_]N_\
MMP9C_P N_P#M[_VTVO#W_)*W_P"O._\ _2JYK*?^]K_%'_TE&E/_ '-_X9_^
ME2/D"OH#YP^N]$\<^!O^$:M=!U&XV1_985NH8XKZ/,VU7F#201J6W3;BY5RK
MY/WE->!.CB/:RJP6O,^5MQ>G31OMY:'T<*V']E&C-V7*N9)36N[U2[[ZZGH^
MA?\ ",?\(S-_9G_( \FZ\W_CZ_U6'^T_ZS_2>F_[OS?\\^<5QS]K[5<_\6\;
M?#OIR[:=OU.V'L?8OV?\*TK_ !;:\V_O=_T/,OA'J6BP>)=6L-!.+"YBMY;4
M?O<$0+B4?O\ ][GS)F(#\X#$?*!7;BHS=*G*K\2;4MNNVVFR.'"2IJK4A1^%
MJ+COTWWUW9R%EX U0?$ R26\WV2/47OOM&QA"8Q(;F/$A&PDDI&R@D[MP[$C
MH=>'U:R:YN3EM?6]K/3\3FC0G]9NXOE4^:]M+7YEKMY#/VA]4CN=7M;&/!:T
MMRSD'HTSY"'T(1%;GLXHP,6H2EW>GR_X<6/DG.,%]E:_-_\  _$\?\'_ /(<
MT[_K^M/_ $?'7H5?X<_\,OR9YU'^)#_%'\T>Z?M($_:M-';RKC_T**O,P&T_
M5?J>KF&\/1_H;_Q!8K\-M. ) -OI@/N/(4X/MD _4 UE0_WJ?K/\S:O_ +I#
MTI_D6? O_),[S_KSU3_T">IK?[U'_%#]!T/]TE_AJ?J2_"E1KO@2ZTNU8"X*
M7UL<\;9)T8QG_=Q*IR.X(Z@T8G]WB(SEM[K^2>OY#PO[S#2IQW]^/S:T_,\O
M^#_@[5X/$\-U<6TUM%8><9GEC>,9:&2((I8 ,S,XX!QLW-TP#VXJK!TG%--R
MM:SOU3O^!PX2C-5E)Q:4;WNK=&K?C]P?M!_\C'%_UXP_^C;BC _PG_B?Y(,?
M_%7^%?FSPNO3/)"@ H * "@ H * "@ H * "@#W7]GW_ )&"X_[!\O\ Z46M
M>9C?X:_Q+\I'JX#^*_\  _SB?85> ?1A0 4 % !0 4 % !0 4 4]1_X]9O\
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M:/Q#T^-5BOE 60MY3X_B&"RD^ZX(SU(('84HOH:8B*TDM]C8\<?\@H?[\?\
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MR'_MI_Z->O%R_P#W:G_V]_Z7(]K'_P"\U/\ MW_TB)T->H>6% !0 4 % !0
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M/!D9F(]-Q)_K6YY;=VV=7X%_Y"B_]<Y/_0:B6QO0^/Y,L?$#_D(K_P!<$_\
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M,$AN'NX[8E79MOR[\K(%** VU2">/O KQVM+3L<\I\M1.[:7Z[['5>)?#O\
MPD:Q75G(@=5P"2=CH3D?,H8\9)'!!R>E0GRZ,Z*E/VMI1:_1HU/#>C+H=L;8
MN))6;S)".@+   #KC"\$]3D\= F[FE.'LURWUW9X5>?Z^3_KH_\ Z$:W/)>[
M]2O02,D02*4/1@0<>XQ0!]%65HEA;Q6L9)2"-(U+8+%44*"2 !G YP ,] *S
M/92Y4DNFA9I#"@#S>'_DH/\ W+W_ +D*ZW_N_P#W%_\ ;#C7^\_]P?\ V\]6
MK@/0"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M.4\*_P#(,A_[:?\ HUZ\7+_]VI_]O?\ I<CVL?\ [S4_[=_](B=#7J'EA0 4
M % !0 4 % !0 4 >!>-]=LO#?CK3-0U.3R+:/3Y@S['?!<W"K\L:NYRQ X4X
MZG JUMH2]&1^-_BAHWB32I]$T$RZI?:@GD1Q1P3* 6(RQ\V-#\HRPVAOFQG
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MG_HUZ\7+_P#=J?\ V]_Z7(]K'_[S4_[=_P#2(G0UZAY84 % !0 4 % !0 4
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M6B[PDKQ?=?Y_\!G"5U'(% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % 'NO[/O_(P7'_8/E_]*+6O,QO\-?XE^4CU<!_%?^!_G$^PJ\ ^
MC"@ H * "@ H * "@ H IZC_ ,>LW_7*3_T$T#.7\ _\@E/^NDG_ *%0#.TH
M$% !0 4 % !0 4 % !0 4 % !0!DZ_&\VFW<<:EW>VG554$LS&)@  .22> !
MR3P*:(GK%I=G^1\_6P*Q(#P0B@@]N!6AY!/0 4 % !0 4 % !0 4 % !0 4
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MCVL?_O-3_MW_ -(B=#7J'EA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8O
MB"[O[&R>;2;87]V"NR!I4A# L Q,CD*-JY(&>2 *8>AR7@+PY?V$E[K>N!%U
M35I5:2-&#K!#&-L4(<%@=HZE6(("#)*DTWV0D>CU(PH * "@ H * "@ H *
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M H * "@ H * "@"GJ/\ QZS?]<I/_030,Y?P#_R"4_ZZ2?\ H5 ,[2@04 %
M!0 4 % !0 4 % !0 4 % %:]NTL+>6ZD!*01O(P7!8JBEB "0,X'&2!GJ13$
MWRIM]-3YUC<2*''1@",^XS6AXP^@ H * "@ H * "@ H * "@ H MV%F^H7$
M=K%]Z5@H)Z#/4GV R3WP..:'H7%<S45U/2IO!6DV05;JZ>-W'&YXD#$8SM5D
M)ZGIN/4#-9<SZ([71A'XI-/U2/+)-H8[,[<G;GKC/&??'6M3@]!M @H * "@
M">UMI+R5+>$;I)&"J/<_R ZD]AS1L4DY.RW9Z;%X#LK:-3?7#*YXRK)&N3V&
M]6)].Q/H.E9<SZ'<J$4O?E^2_,Q/$?@XZ1%]JM7,L*XWAL;ER<!LC 922 >
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MOR-:D6% 'F\/_)0?^Y>_]R%=;_W?_N+_ .V'&O\ >?\ N#_[>>K5P'H!0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '*>%?^09#
M_P!M/_1KUXN7_P"[4_\ M[_TN1[6/_WFI_V[_P"D1.AKU#RPH * "@ H * "
M@ H * "@ H * "@#/?5;2.[33FE07<B-*L.<OY:D N5'*KDX#-@$Y"Y(.&!H
M4@"@#%T[Q#8:M=75A:2^9<:<R)<ILD7RVDW;!N9%5\[&Y1F QR1D9>P&U2 *
M "@ H * ,C1->LO$5O\ ;--D\^ .\>[8Z?.APPVR*C<'OC![$T]@->D 4 %
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M&/7Y>!G&.,3S-,W5*#BG:VB;=WV,#7=.T;RHHM+*-<33)&"LS/@'@LP+-QG
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M[_\ <7_VPXU_O/\ W!_]O/5JX#T H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#E/"O_(,A_P"VG_HUZ\7+_P#=J?\ V]_Z7(]K
M'_[S4_[=_P#2(G0UZAY84 % !0 4 % !0 R2184,CG"H"Q/H ,D\<]/2@#Q/
M3O&GB[Q/:/K6A66G_P!G!I!%#<23&[F6,E25\MEB5B5("OCGIN&&-V2T9-WT
M-#Q+\1;W3?"D?B.VM?LUU))'&]M>1R_(2S*_ :%V!V[HWR RD$C.0$EK8+Z7
M/1?$>HR:/I5YJ$ 5I;2TN)T#@E"\43R*& *DJ2H# ,IQG!!YI(H\YF^(]Y#H
M&EWR6\4^J:XZ00Q M% )78C+%F9@@^4;=^26^\ "0[:^A-RU:>(_%>DZC:V>
MOV5K/:WS^4MQI@N'$#G&#.LFXA,GYGPJ*H9MQ"X)9=!Z]3SNZ_X2?_A/G^S?
MV7]O^P-Y7F?:OL_V3S3LW[?WGVCINV_N^N*K2Q.MSTSQ#XPU9M8_X1SPW;03
M7<<(GN)[MG6WA1B H(CP[L=RD[22,@!6PQ6;=65?HB+PWXRU?^W&\,^)+>VB
MNVM_M,$UFTAAEC#%3\LI+C.UL$D'*,"HR#1;2Z"_1C?"VO&YUCQ#"MM:0'3W
MAQ+##LEN"4N"#=/N/FE=GRG"X#/Z\'8.YS/AKQWXQ\8Z<E[I-CIZ["Z32W#2
MI'+('8A;>-92X"QF,,\DA!D+@8 P'9(5V]CL?"7Q"36=*N[_ %2,6,^D/+'>
MQ@[E5HAN)3//."H4DG>I4%N"4U;8:9@V'BOQEXCMO[7T>QT^&P?+00W<DWVJ
M= 2 RF-EB3=C(\S [@LN&)9+06O0W-.^)UE<^'[CQ!<QO;M8,T5S;$@R)<*5
M41*3C.]F4(Q ZG< 58 MK8=]+F-;>*/&CV@UQ].L#I[+YWV199A?^01NW!CF
M ML^8)M#D\; >*++86NY)\#I!-X<\Q<@/=W+#/7!<$9HEN"V.T\=:]/X8T2Z
MU6T6-YK9$9%E#%"6D1#N"LC'ACC##G'TI+L-Z'(>&?%?B?79(-2GL[2RT*6,
MR-+*[?:?+6,MYP42E521@-JLA*H=Q9EPQ=DO46OR*FG^,O%/C!7O_#-I8Q:8
MCND,FH-,);G8=K-&L) 09!'SY4$$;B58 LEN%WT+]EXR/BK0=7ANH#9:CIUO
M<PW=N6W!&,,NUD;NC[6Q[J0"PPS%K-#N<$NL_P!@_#6QN_LUI?88+Y-[#YT)
MW7$WS%-R_,/X3GBJZD[(]3\9>-)M#N;71])MQ?:MJ&3%$S;(XXU^]-,PYV##
M8 QD(Y+#: TI=2F[:(Y^7QIXA\)W-NOBVVLOL-[*L N]/:;;!(_W1,DQ+$'G
M)7  #$%BNUBR>PKM;G$>)X?$4_CNT15TI[G[/<FR$HN3#]E#7&TW(&6^T;,Y
M\K]WNQCC-4K6%K<^D;2-HH41PBN%&\1 B,/CYM@/.W=G&><=>:S+/--;\:ZG
M<ZP_AWPO;P7%U;(LEU<7;.+:#=@JA$1#NQ# G:<@Y 5B'*U;JQ7Z(;HWC;5+
M/6(_#WBFW@MKF[5FM+FT9S;3E?O(!)ET; .-QR3A2@W*6+=4%^C/--*M_$MQ
MXWO1*FCR7ZVL'VG<MRUN(/W'_'OD&03;=N=_R9W=L56EB=;GT^JA %4  #
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MW_(OZG_V#[S_ -)Y*WI?Q(?XH_FC"M_"G_@E^3/SOKZL^."@ H * "@ H *
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M0![K^S[_ ,C!<?\ 8/E_]*+6O,QO\-?XE^4CU<!_%?\ @?YQ/L*O /HPH *
M"@ H * "@ H * *>H_\ 'K-_URD_]!- SE_ /_()3_KI)_Z%0#.TH$% !0 4
M % !0 4 % !0 4 % !0!GZM=O865Q=1@%X()9%#9*ED1F (!!QD<X(..A%,F
M3Y4VNB;/GJ%S)&KGJR@G'N,UH>.2T % !0 4 % !0 4 % !0 4 % '0^$_\
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M\-AU&U6N[D@>@+ @?A3EN);&U\7?^13U#_KG'_Z/BH6XWL7HK.74?""VEO\
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M@ZZ)&5-UO9!=Q R?(M^F>OX571"ZL@T/5[33_B'K5K<ND4EW#9>27(4,T=M
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M4_\ !+\F?G?7U9\<% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 >Z_L^_\C!<?]@^7_P!*+6O,QO\ #7^)
M?E(]7 ?Q7_@?YQ/L*O /HPH * "@ H * "@ H * *>H_\>LW_7*3_P!!- SE
M_ /_ ""4_P"NDG_H5 ,[2@04 % !0 4 % !0 4 % !0 4 % %:]M$O[>6UD)
M"3QO&Q7 8*ZE202",X/&01GJ#3$U=-/KH?.L:"-0@Z* !GV&*T/&'T % !0
M4 % !0 4 % !0 4 % &KHE\FFWL5U*&*1,20H!;E2. 2!W[D4FKJQI"2A)2>
MR-CQ9K]OKKQ-;K(@B5@?,"C[Q!&-K-Z=\4HJQK5J*I;EOIW+OA_QHVF1"UNT
M,T*C"%2-ZC^Z0W#+Z<C XY& $XWU15.MR+EDKK\3:?QU86D;"PMF5VYP5CC7
M)[ML9B?7ID],CK4\KZFOMXQ7N1_)?D<-::PW]I)J5WER) [[0,X' "@D#@8
M!/0=:TMI9'*I^^IR[W-3Q9X@M]>,)MUD3R@X;S H^]MQC:S?W3G.*F*L75J*
MI;EOI?<Y"K.8VO#]];Z;>)=72NZ1@E0@4G?C"G#,HP,D]>H%)JZLC6G)1DI2
MZ=CT=_'^FN,-%.P]"D1_G+6?*SN]O#L_N7^9FZEXRTV[M98(H95>6-T4F.(
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M+'**=P0-QUP3D\@\S%U_X>>'_$\WVG4[..:? !D5I(G; P-[0O&7P.!O+8
M' %%VMA61NZ1H.GZ#;?8M.@CMH.<HB\,3P2Y.6<D<%G+$C S@4#V.37X4>%5
MN?M@TZ'S=V[!:4Q9Z_Z@R&''^SY>WVIW8K(VK;P7H]E:76GP6_EVNHN[W,0D
MFVNT@PY7]YF+( &(B@    P*5PL;FFZ=;Z1;16-FOE6]N@CC3<S;448 W.68
MX'=B3ZFD,YW5_ >AZ[>IJ=_:K+=Q%"LH>6-LQD%-PCD0/M(&-X;@8Z<4[V%8
M9JGP^T#69[BZOK-)YKWR_.=GER3"GEQE<.!$53Y<Q;"P^\2:+M!9%OP[X,T;
MPF&_LBU2V:08=P7>1AG.TR2L[[<\[=VW...!1>X6ML1>(O NB>*W675K1+B2
M,;5?=)&X7.=I>)XV*@DD*20"20!DY$[;!89IO@+0M'N8;VQM$MY[1'CB=&D&
M%?<'W+OVR,P8@O('?&!NPJX+L+6-73O#UAI-U=7]I%Y=QJ+(]R^^1O,:/=L.
MUG94QO;A%4'/(.!@&%SX>L+S4+?6)HMU[9*Z02[Y!L6165QL#B-MRNPRZ,1G
M(((&#R 36?#MAX@\C^T8O.^R3+<0_/(FR5/NM^[==V/[K;E/<&C8#;I % !0
M 4 % !0 4 % !0!SWBK_ )!DW_;/_P!&I7EYA_NU3_MW_P!+B>IE_P#O-/\
M[>_](D=77M'BA0 4 >4S?\E!_P"Y>_\ <A7>O]W_ .XO_MAY[_WG_N#_ .WG
MI%<AV!0 4 <QXV_Y%_4_^P?>?^D\E;TOXD/\4?S1A6_A3_P2_)GYWU]6?'!0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % 'NO[/O_(P7'_8/E_]*+6O,QO\-?XE^4CU<!_%?^!_G$^PJ\ ^
MC"@ H * "@ H * "@ H IZC_ ,>LW_7*3_T$T#.7\ _\@E/^NDG_ *%0#.TH
M$% !0 4 % !0 4 % !0 4 % !0!DZ_(\.FW<D;%'2VG964D,K")B"".00>01
MR#R*:(GI%M=G^1\_6Q+1(3R2BDD_05H>03T % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % #)$$BE#T8$''N,4 ?15E:)86\5K&24
M@C2-2V"Q5%"@D@ 9P.< #/0"LSV4N5)+IH6:0PH \WA_Y*#_ -R]_P"Y"NM_
M[O\ ]Q?_ &PXU_O/_<'_ -O/5JX#T H * "@ H * "@ H * "@ H * "@ H
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MD@4 2Q2I.BRQ,KQNH964AE96&596&000000<$<B@"2@ H * "@ H * "@ H
M* "@"-ID1EC9E5Y,[%) +8&3M'4X')QT')H DH * "@ H * "@ H * "@ H
M* "@ H * "@#GO%7_(,F_P"V?_HU*\O,/]VJ?]N_^EQ/4R__ 'FG_P!O?^D2
M.KKVCQ0H * /*9O^2@_]R]_[D*[U_N__ '%_]L//?^\_]P?_ &\](KD.P* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MD9Q?@[Q?_P )4+R.6#['<:==R6LL1D\S[F,2!O+CX<[@!MXVYR013:L),RO
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M_P#N:BX6#_A>7_4._P#)K_[FHN%@_P"%Y?\ 4._\FO\ [FHN%@_X7E_U#O\
MR:_^YJ+A8/\ A>7_ %#O_)K_ .YJ+A8/^%Y?]0[_ ,FO_N:BX6#_ (7E_P!0
M[_R:_P#N:BX6#_A>7_4._P#)K_[FHN%@_P"%Y?\ 4._\FO\ [FHN%@_X7E_U
M#O\ R:_^YJ+A8/\ A>7_ %#O_)K_ .YJ+A8/^%Y?]0[_ ,FO_N:BX6#_ (7E
M_P!0[_R:_P#N:BX6#_A>7_4._P#)K_[FHN%@_P"%Y?\ 4._\FO\ [FHN%@_X
M7E_U#O\ R:_^YJ+A8/\ A>7_ %#O_)K_ .YJ+A8/^%Y?]0[_ ,FO_N:BX6#_
M (7E_P!0[_R:_P#N:BX6#_A>7_4._P#)K_[FHN%@_P"%Y?\ 4._\FO\ [FHN
M%@_X7E_U#O\ R:_^YJ+A8/\ A>7_ %#O_)K_ .YJ+A8/^%Y?]0[_ ,FO_N:B
MX6#_ (7E_P!0[_R:_P#N:BX6#_A>7_4._P#)K_[FHN%@_P"%Y?\ 4._\FO\
M[FHN%@_X7E_U#O\ R:_^YJ+A8/\ A>7_ %#O_)K_ .YJ+A8/^%Y?]0[_ ,FO
M_N:BX6#_ (7E_P!0[_R:_P#N:BX6#_A>7_4._P#)K_[FHN%@_P"%Y?\ 4._\
MFO\ [FHN%@_X7E_U#O\ R:_^YJ+A8/\ A>7_ %#O_)K_ .YJ+A8/^%Y?]0[_
M ,FO_N:BX6#_ (7E_P!0[_R:_P#N:BX6#_A>7_4._P#)K_[FHN%@_P"%Y?\
M4._\FO\ [FHN%@_X7E_U#O\ R:_^YJ+A8/\ A>7_ %#O_)K_ .YJ+A8/^%Y?
M]0[_ ,FO_N:BX6#_ (7E_P!0[_R:_P#N:BX6#_A>7_4._P#)K_[FHN%@_P"%
MY?\ 4._\FO\ [FHN%CL/!7Q'_P"$PO7LOLOV;RX&FW^=YF=KQIMV^5'C/F9S
MD],8YR&(].H$% !0 4 % !0 4 % !0!3U'_CUF_ZY2?^@F@9R_@'_D$I_P!=
M)/\ T*@&=I0(* "@ H * "@ H * "@ H * "@#)U^-YM-NXXU+N]M.JJH)9F
M,3   <DD\ #DG@4T1/6+2[/\CY^M@5B0'@A%!![<"M#R">@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9&XSL@/]QIY"N!V!Y8>H.>]-[B6QF?&\!M-TX'D'6;0$'_KE<41_03%^//\
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MQ5_R#)O^V?\ Z-2O+S#_ ':I_P!N_P#I<3U,O_WFG_V]_P"D2.KKVCQ0H *
M/*9O^2@_]R]_[D*[U_N__<7_ -L//?\ O/\ W!_]O/2*Y#L"@ H P/%G_(%O
M_P#KRNO_ $0] SXBJ2@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#U_X+?\AJ;_KRD_\ 1]O30F?3M,D*
M "@ H * "@ H * "@"GJ/_'K-_URD_\ 030,Y?P#_P @E/\ KI)_Z%0#.TH$
M% !0 4 % !0 4 % !0 4 % !0!6O;M+"WENI 2D$;R,%P6*HI8@ D#.!QD@9
MZD4Q-\J;?34^<8;B.<#8P)(SC(R/J 3C&<'WK0\8<\T<9P[*IZX) _G0 Y)%
MD&4(8=,@@_RH C-S$IP70$<$%AQ^M $N]=N[(VXSG/&.N<],8[T 1"YB8X#H
M2>  P_QH D>18QER%'3)('\Z &I-'(<(RL>N 0?Y4 #S1QG#LJGK@D#^= #D
MD6090AATR"#_ "H C-S$IP70$<$%AQ^M $N]=N[(VXSG/&.N<],8[T 1"YB8
MX#H2>  P_P : )'D6,9<A1TR2!_.@!J31R'",K'K@$'^5  \T<9P[*IZX) _
MG0 Y)%D&4(8=,@@_RH C-S$IP70$<$%AQ^M $N]=N[(VXSG/&.N<],8[T 1"
MYB8X#H2>  P_QH D>18QER%'3)('\Z &I-'(<(RL>N 0?Y4 #S1QG#LJGK@D
M#^= #DD6090AATR"#_*@",W,2G!= 1P06''ZT 2[UV[LC;C.<\8ZYSTQCO0!
M$+F)C@.A)X ##_&@"1Y%C&7(4=,D@?SH :DT<APC*QZX!!_E0 /-'&<.RJ>N
M"0/YT .219!E"&'3((/\J (S<Q*<%T!'!!8<?K0!+O7;NR-N,YSQCKG/3&.]
M $0N8F. Z$G@ ,/\: )'D6,9<A1TR2!_.@!J31R'",K'K@$'^5  \T<9P[*I
MZX) _G0 Y)%D&4(8=,@@_P J (S<Q*<%T!'!!8<?K0!+O7;NR-N,YSQCKG/3
M&.] $0N8F. Z$G@ ,/\ &@"1Y%C&7(4=,D@?SH :DT<APC*QZX!!_E0 /-'&
M<.RJ>N"0/YT .219!E"&'3((/\J (S<Q*<%T!'!!8<?K0!+O7;NR-N,YSQCK
MG/3&.] $0N8F. Z$G@ ,/\: )'D6,9<A1TR2!_.@!J31R'",K'K@$'^5  \T
M<9P[*IZX) _G0!%,RS0OY9#_ "L/E.>=O3CO[4 ?0F@1O#IMI'(I1TMH%96!
M#*PB4$$'D$'@@\@\&LSUX:12?9?D:U(L* /-X?\ DH/_ '+W_N0KK?\ N_\
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M 98\9)QDGN:0R6@ H * "@ H * "@ H * "@ H * "@ H Y[Q5_R#)O^V?\
MZ-2O+S#_ ':I_P!N_P#I<3U,O_WFG_V]_P"D2.KKVCQ0H * /*9O^2@_]R]_
M[D*[U_N__<7_ -L//?\ O/\ W!_]O/2*Y#L"@ H P/%G_(%O_P#KRNO_ $0]
M SXBJ2@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#U_X+?\AJ;_KRD_\ 1]O30F?3M,D* "@ H * "@ H
M * "@"GJ/_'K-_URD_\ 030,Y?P#_P @E/\ KI)_Z%0#.TH$% !0 4 % !0
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M^WO_ $N1[6/_ -YJ?]N_^D1.AKU#RPH * "@ H * "@ H * "@ H * "@ H
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M7N$B/R^4'QM8D?O/O8)R.*0'D5, H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#U_X+?\AJ;_KRD_\ 1]O30F?3M,D* "@ H *
M"@ H * "@"GJ/_'K-_URD_\ 030,Y?P#_P @E/\ KI)_Z%0#.TH$% !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % 'F\/_)0?^Y>_]R%=;_W?_N+_ .V'&O\
M>?\ N#_[>>K5P'H!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M .XO_MAY[_WG_N#_ .WGI%<AV!0 4 8'BS_D"W__ %Y77_HAZ!GQ%4E!0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#S>'_DH/_<O?^Y"NM_[
MO_W%_P#;#C7^\_\ <'_V\]6K@/0"@ H * "@ H * "@ H * "@ H * "@ H
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M>IE_^\T_^WO_ $B1U=>T>*% !0!Y3-_R4'_N7O\ W(5WK_=_^XO_ +8>>_\
M>?\ N#_[>>D5R'8% &-KNKG1+?[5Y3SJ'"L$XV*<Y<G!X& /3) )&:!F7K>I
M6^J>'[ZXM6#HUE<_53Y#Y5AU!'H?J,@@T ?&%24% !0 4 % !0 4 % !0 4
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M.TM-+#;I_,\\@$96-$:,%AU&]G.WUV-Z4(9\XTQ!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 >O_!;_ )#4W_7E)_Z/MZ:$SZ=IDA0 4 %
M!0 4 % !0 4 4]1_X]9O^N4G_H)H&<OX!_Y!*?\ 723_ -"H!G:4""@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#S>'_DH/_<O?^Y"NM_[O_W%_P#;#C7^
M\_\ <'_V\]6K@/0"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M  !V@*%#!RNXNZ>XK-;&_P"%?!$VG2W>I:Y<#4-1U-/+G*J4@2$#;Y,2?W2
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M "@ H * "@ H IZC_P >LW_7*3_T$T#.7\ _\@E/^NDG_H5 ,[2@04 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 >;P_P#)0?\ N7O_ '(5UO\ W?\ [B_^
MV'&O]Y_[@_\ MYZM7 >@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F\/\ R4'_ +E[
M_P!R%=;_ -W_ .XO_MAQK_>?^X/_ +>>K5P'H!0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % '*>%?\ D&0_]M/_ $:]>+E_^[4_
M^WO_ $N1[6/_ -YJ?]N_^D1.AKU#RPH * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * .)\ ^+6\:Z:=4,0MU:>6-(P=Q"(0%+
M-P"QSDX  Z <9+:MH).YVU(84 % !0 4 % !0 4 % !0 4 % !0 4 <+IGB>
MYO/$U_H3K$+:QM[>6-E#"4M*JE@[%RA49.W:BGU)IVTN+K8[JD,* "@#A?"W
MB>YUO5-7L+A8EBTNXCBA*!@S*ZN29"SL"V5&-JH.O!IM6L([JD,* "@ H *
M"@ H * "@ H * "@ H Y[Q5_R#)O^V?_ *-2O+S#_=JG_;O_ *7$]3+_ />:
M?_;W_I$CJZ]H\4* "@#RF;_DH/\ W+W_ +D*[U_N_P#W%_\ ;#SW_O/_ '!_
M]O/2*Y#L"@#+U?1X-:A%O<[PBNK_ "-M)*Y&#P<@@G/?N"",T#,WQ';16>@W
MT,"B.-+&Y"JHP!^Y?_)/4GDT ?%-24% !0 4 % !0 4 % !0 4 % !0 4 %
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M,@%HR6)8[=P(+?-AMIRRL2 <%3 * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /7_@M_R&IO^O*3_P!'V]-"9].TR0H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M&U#4Q<^(D@=S=17DTTGVL(2%4(2-GF?*/,19"O+,I)(O7Y$:+U-?6=8U;4O
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M_P#;W_I$CJZ]H\4* "@#RF;_ )*#_P!R]_[D*[U_N_\ W%_]L//?^\_]P?\
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M % !0 4 % 'K_P %O^0U-_UY2?\ H^WIH3/IVF2% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >;P_P#)0?\ N7O_ '(5
MUO\ W?\ [B_^V'&O]Y_[@_\ MYZM7 >@% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 <IX5_P"09#_VT_\ 1KUXN7_[M3_[>_\
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MD%@H&Y P:BU]4PVT.E^'/AS4+*:_U_6D6"^UF59# K;O(A3=Y<;,.-V&Y'.
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MMGM)[RYAE 96$9RLI*Q.0%E6(,J%D+#(ZG.2GTL"ZGL]24% !0 4 % !0 4
M% !0 4 % !0 4 <]XJ_Y!DW_ &S_ /1J5Y>8?[M4_P"W?_2XGJ9?_O-/_M[_
M -(D=77M'BA0 4 >4S?\E!_[E[_W(5WK_=_^XO\ [8>>_P#>?^X/_MYZ17(=
M@4 % &!XL_Y M_\ ]>5U_P"B'H&?$524% !0 4 % !0 4 % !0 4 % !0 4
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M_P#!;_D-3?\ 7E)_Z/MZ:$SZ=IDA0 4 % !0 4 % !0 4 % !0 4 % !0 4
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ME#Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M58$H#S6F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M>O\ P6_Y#4W_ %Y2?^C[>FA,^G:9(4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!YO#_R4'_N7O\ W(5UO_=_^XO_ +8<
M:_WG_N#_ .WGJU<!Z 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@#U_X+?\AJ;_KRD_\ 1]O30F?3M,D* "@ H * "@ H * "@ H
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M6O\ GPO?_ 6?_P"(H /^$3UK_GPO?_ 6?_XB@ _X1/6O^?"]_P# 6?\ ^(H
M/^$3UK_GPO?_  %G_P#B* #_ (1/6O\ GPO?_ 6?_P"(H /^$3UK_GPO?_ 6
M?_XB@ _X1/6O^?"]_P# 6?\ ^(H /^$3UK_GPO?_  %G_P#B* #_ (1/6O\
MGPO?_ 6?_P"(H /^$3UK_GPO?_ 6?_XB@ _X1/6O^?"]_P# 6?\ ^(H /^$3
MUK_GPO?_  %G_P#B* #_ (1/6O\ GPO?_ 6?_P"(H /^$3UK_GPO?_ 6?_XB
M@ _X1/6O^?"]_P# 6?\ ^(H /^$3UK_GPO?_  %G_P#B* #_ (1/6O\ GPO?
M_ 6?_P"(H /^$3UK_GPO?_ 6?_XB@ _X1/6O^?"]_P# 6?\ ^(H /^$3UK_G
MPO?_  %G_P#B* #_ (1/6O\ GPO?_ 6?_P"(H /^$3UK_GPO?_ 6?_XB@ _X
M1/6O^?"]_P# 6?\ ^(H /^$3UK_GPO?_  %G_P#B* #_ (1/6O\ GPO?_ 6?
M_P"(H /^$3UK_GPO?_ 6?_XB@ _X1/6O^?"]_P# 6?\ ^(H /^$3UK_GPO?_
M  %G_P#B* #_ (1/6O\ GPO?_ 6?_P"(H /^$3UK_GPO?_ 6?_XB@ _X1/6O
M^?"]_P# 6?\ ^(H /^$3UK_GPO?_  %G_P#B* #_ (1/6O\ GPO?_ 6?_P"(
MH /^$3UK_GPO?_ 6?_XB@ _X1/6O^?"]_P# 6?\ ^(H /^$3UK_GPO?_  %G
M_P#B* #_ (1/6O\ GPO?_ 6?_P"(H /^$3UK_GPO?_ 6?_XB@ _X1/6O^?"]
M_P# 6?\ ^(H /^$3UK_GPO?_  %G_P#B* #_ (1/6O\ GPO?_ 6?_P"(H /^
M$3UK_GPO?_ 6?_XB@ _X1/6O^?"]_P# 6?\ ^(H /^$3UK_GPO?_  %G_P#B
M* #_ (1/6O\ GPO?_ 6?_P"(H /^$3UK_GPO?_ 6?_XB@ _X1/6O^?"]_P#
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /-X?^2@_]R]_[D*ZW_N__
M '%_]L.-?[S_ -P?_;SU:N ] * "@ H * "@ H * "@ H * "@ H * "@ H
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MIX;M'L=-MX98+>SE$8:2"T01P1.Y+NL:C@ ,QW$?>;<W>I+-ND 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % '/>*O^09-_VS_]&I7EYA_NU3_MW_TN
M)ZF7_P"\T_\ M[_TB1U=>T>*% !0!Y3-_P E!_[E[_W(5WK_ '?_ +B_^V'G
MO_>?^X/_ +>>D5R'8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MV4,44N^,[I%\G<NP.9!C8W+( <<'D9KI874]-J1A0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <]XJ_P"09-_VS_\ 1J5Y
M>8?[M4_[=_\ 2XGJ9?\ [S3_ .WO_2)'5U[1XH4 % 'E,W_)0?\ N7O_ '(5
MWK_=_P#N+_[8>>_]Y_[@_P#MYZ17(=@4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!
MYO#_ ,E!_P"Y>_\ <A76_P#=_P#N+_[8<:_WG_N#_P"WGJU<!Z 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!RGA7_ )!D/_;3
M_P!&O7BY?_NU/_M[_P!+D>UC_P#>:G_;O_I$3H:]0\L* "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M#GO%7_(,F_[9_P#HU*\O,/\ =JG_ &[_ .EQ/4R__>:?_;W_ *1(ZNO:/%"@
M H \IF_Y*#_W+W_N0KO7^[_]Q?\ VP\]_P"\_P#<'_V\](KD.P* "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H \WA_Y*#_W+W_N0KK?^[_]Q?\ VPXU_O/_ '!_]O/5
MJX#T H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M#E/"O_(,A_[:?^C7KQ<O_P!VI_\ ;W_I<CVL?_O-3_MW_P!(B=#7J'EA0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 <]XJ_Y!DW_;/_T:E>7F'^[5/^W?_2XGJ9?_ +S3_P"WO_2)
M'5U[1XH4 % 'E,W_ "4'_N7O_<A7>O\ =_\ N+_[8>>_]Y_[@_\ MYZ17(=@
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0!YO#_P E!_[E[_W(5UO_ '?_ +B_^V'&
MO]Y_[@_^WGJU<!Z 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!RGA7_D&0_P#;3_T:]>+E_P#NU/\ [>_]+D>UC_\ >:G_ &[_
M .D1.AKU#RPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * .>\5?\@R;_MG_P"C4KR\P_W:I_V[_P"E
MQ/4R_P#WFG_V]_Z1(ZNO:/%"@ H \IF_Y*#_ -R]_P"Y"N]?[O\ ]Q?_ &P\
M]_[S_P!P?_;STBN0[ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#S>'_DH/\ W+W_
M +D*ZW_N_P#W%_\ ;#C7^\_]P?\ V\]6K@/0"@ H * "@ H * "@ H * "@
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M$E\7_P#0M_\ E6L__B*.2C_S^_\ *<@]I7_Y\_\ E2(?\)+XO_Z%O_RK6?\
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M /$4<E'_ )_?^4Y![2O_ ,^?_*D0_P"$E\7_ /0M_P#E6L__ (BCDH_\_O\
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M1#_A)?%__0M_^5:S_P#B*.2C_P _O_*<@]I7_P"?/_E2(?\ "2^+_P#H6_\
MRK6?_P 11R4?^?W_ )3D'M*__/G_ ,J1#_A)?%__ $+?_E6L_P#XBCDH_P#/
M[_RG(/:5_P#GS_Y4B'_"2^+_ /H6_P#RK6?_ ,11R4?^?W_E.0>TK_\ /G_R
MI$/^$E\7_P#0M_\ E6L__B*.2C_S^_\ *<@]I7_Y\_\ E2(?\)+XO_Z%O_RK
M6?\ \11R4?\ G]_Y3D'M*_\ SY_\J1#_ (27Q?\ ]"W_ .5:S_\ B*.2C_S^
M_P#*<@]I7_Y\_P#E2(?\)+XO_P"A;_\ *M9__$4<E'_G]_Y3D'M*_P#SY_\
M*D0_X27Q?_T+?_E6L_\ XBCDH_\ /[_RG(/:5_\ GS_Y4B'_  DOB_\ Z%O_
M ,JUG_\ $4<E'_G]_P"4Y![2O_SY_P#*D0_X27Q?_P!"W_Y5K/\ ^(HY*/\
MS^_\IR#VE?\ Y\_^5(A_PDOB_P#Z%O\ \JUG_P#$4<E'_G]_Y3D'M*__ #Y_
M\J1#_A)?%_\ T+?_ )5K/_XBCDH_\_O_ "G(/:5_^?/_ )4B'_"2^+_^A;_\
MJUG_ /$4<E'_ )_?^4Y![2O_ ,^?_*D0_P"$E\7_ /0M_P#E6L__ (BCDH_\
M_O\ RG(/:5_^?/\ Y4B'_"2^+_\ H6__ "K6?_Q%')1_Y_?^4Y![2O\ \^?_
M "I$/^$E\7_]"W_Y5K/_ .(HY*/_ #^_\IR#VE?_ )\_^5(A_P )+XO_ .A;
M_P#*M9__ !%')1_Y_?\ E.0>TK_\^?\ RI$/^$E\7_\ 0M_^5:S_ /B*.2C_
M ,_O_*<@]I7_ .?/_E2(?\)+XO\ ^A;_ /*M9_\ Q%')1_Y_?^4Y![2O_P ^
M?_*D0_X27Q?_ -"W_P"5:S_^(HY*/_/[_P IR#VE?_GS_P"5(A_PDOB__H6_
M_*M9_P#Q%')1_P"?W_E.0>TK_P#/G_RI$/\ A)?%_P#T+?\ Y5K/_P"(HY*/
M_/[_ ,IR#VE?_GS_ .5(A_PDOB__ *%O_P JUG_\11R4?^?W_E.0>TK_ //G
M_P J1#_A)?%__0M_^5:S_P#B*.2C_P _O_*<@]I7_P"?/_E2(?\ "2^+_P#H
M6_\ RK6?_P 11R4?^?W_ )3D'M*__/G_ ,J1#_A)?%__ $+?_E6L_P#XBCDH
M_P#/[_RG(/:5_P#GS_Y4B'_"2^+_ /H6_P#RK6?_ ,11R4?^?W_E.0>TK_\
M/G_RI$/^$E\7_P#0M_\ E6L__B*.2C_S^_\ *<@]I7_Y\_\ E2(?\)+XO_Z%
MO_RK6?\ \11R4?\ G]_Y3D'M*_\ SY_\J1#_ (27Q?\ ]"W_ .5:S_\ B*.2
MC_S^_P#*<@]I7_Y\_P#E2(?\)+XO_P"A;_\ *M9__$4<E'_G]_Y3D'M*_P#S
MY_\ *D0_X27Q?_T+?_E6L_\ XBCDH_\ /[_RG(/:5_\ GS_Y4B'_  DOB_\
MZ%O_ ,JUG_\ $4<E'_G]_P"4Y![2O_SY_P#*D0_X27Q?_P!"W_Y5K/\ ^(HY
M*/\ S^_\IR#VE?\ Y\_^5(A_PDOB_P#Z%O\ \JUG_P#$4<E'_G]_Y3D'M*__
M #Y_\J1#_A)?%_\ T+?_ )5K/_XBCDH_\_O_ "G(/:5_^?/_ )4B'_"2^+_^
MA;_\JUG_ /$4<E'_ )_?^4Y![2O_ ,^?_*D0_P"$E\7_ /0M_P#E6L__ (BC
MDH_\_O\ RG(/:5_^?/\ Y4B'_"2^+_\ H6__ "K6?_Q%')1_Y_?^4Y![2O\
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MO_Z%O_RK6?\ \11R4?\ G]_Y3D'M*_\ SY_\J1#_ (27Q?\ ]"W_ .5:S_\
MB*.2C_S^_P#*<@]I7_Y\_P#E2(?\)+XO_P"A;_\ *M9__$4<E'_G]_Y3D'M*
M_P#SY_\ *D0_X27Q?_T+?_E6L_\ XBCDH_\ /[_RG(/:5_\ GS_Y4B'_  DO
MB_\ Z%O_ ,JUG_\ $4<E'_G]_P"4Y![2O_SY_P#*D0_X27Q?_P!"W_Y5K/\
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M>TK_ //G_P J1#_A)?%__0M_^5:S_P#B*.2C_P _O_*<@]I7_P"?/_E2(?\
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M(A_PDOB__H6__*M9_P#Q%')1_P"?W_E.0>TK_P#/G_RI$/\ A)?%_P#T+?\
MY5K/_P"(HY*/_/[_ ,IR#VE?_GS_ .5(A_PDOB__ *%O_P JUG_\11R4?^?W
M_E.0>TK_ //G_P J1#_A)?%__0M_^5:S_P#B*.2C_P _O_*<@]I7_P"?/_E2
M(?\ "2^+_P#H6_\ RK6?_P 11R4?^?W_ )3D'M*__/G_ ,J1#_A)?%__ $+?
M_E6L_P#XBCDH_P#/[_RG(/:5_P#GS_Y4B'_"2^+_ /H6_P#RK6?_ ,11R4?^
M?W_E.0>TK_\ /G_RI$/^$E\7_P#0M_\ E6L__B*.2C_S^_\ *<@]I7_Y\_\
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M^5(A_P )+XO_ .A;_P#*M9__ !%')1_Y_?\ E.0>TK_\^?\ RI$/^$E\7_\
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MYYZ(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M- 2=C;&#*Z,K8!PR.JNIP0>5'!!H MT % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M[JR2QS)Y#\*"T\+MG< "#Y<3%@%^;/0 U]9M9;B*-H%#O!-',$)"[PAY4,>
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MOC  #EPPQSN11Z$T 5;K3I7@U-43,EX'$7*C>/L<42C.<+^\#K\V,<G[I!(
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MM\Q%?&>N-P.,]\=: 'VTD4L*208\IT5H]HP-A *X&!@;<8&!@=J )J "@ H
M* (9KB.VV^8=OF.J+UY9N@X]?R]: )J "@ H * (9+B.*1(F.'EW;!SSM&YO
MR'KC\Z )J (I)DB9$<X,K%$'JP5G(_[Y1CSZ>N* ): &2RK C2.<*BEF/)P
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M2QS@ G@$GCT !)/H "3T H 1'$BAQD!@",@J>>>58!@?4$ CH0#0 Z@ H *
M"@".658$:60[412S'T51DG\ * '(XD4.O*L 0?8\B@!U !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!4M]/MK1B\$,43,,$HBJ2,YP
M2H!(SS]>: += !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &!JVC2ZG-&YE001#/V
M>2(O&\F<AWVRQ[L#&U&RH()YSPP*FKI/]MT]8GC64&?YFC9DR(?FQ&)48 \X
M'F?+QDMCD +RU>Q26[N9GDN+CR;=3 HBPOF?+''O=@F]G;=(\A*YRI! ! ,*
MZ:0QZC:2%U5+ R^7]JEG9'"S#YG8AAN !:(LZ,,$\,10!=UF[FTZ>5+>1PB6
M,;#=([!2USL:0EBYW*A/SD,0 .H&* &WIN;&.<I*$S8W$FT7<]P_RIE)D+QK
MY15N,APK;OE&Y<T 7HX&AGM$\V=A>12^=NFD.XB-7#+\W[H@YQY6P8.,8H H
MVL$GV'3DMW9PUL':#[5+"\A\N'F.122!%D_N@R( W&-N* .JT>83VJ,ID;!=
M"965GRCLC LGROAE(#C.Y0&))))0')V5G*]MILCW%R7O"@F/GR_.AMI9]N-V
M$(,:KO3:Y&XEB3FF!=MKAX)4B,DACCU*2$;W9B4-G(R(S,2SCS67;O+'=M[@
M4 17EQ+<7-S##, %GMD"&9HPQ,;%X4D3)B=R!RH!)&"1F@"M.$N%BA?[0CPW
M\2.KW#/LWH&VI*C!G&,$%R9$9F *C H Z7Q!YGV/;"[0N\UL@=#AEWW,*'!^
MC$$=""0<@FD!D2Z?LN;F(37/E0VL<J+]HFR)':X!;?OWD 0KA&8IDL=M,"K!
M<7.HR)&YSMLK>4 W,MKN,BL9),PQL7P0 <D*G]TEL@ ;;SW5Y)!:M(LX^SM(
M"MS-;B4B5TW>9'$))"D83/" EB^""#0 ZVC::YL6FD\TJ]TJNDTK K'RH+8C
M$A4Y1W"8D"X;<,B@#>UP2L(4B<*6EYB\UX#, C'8LJ LI!P^!@-MP2!0!BHJ
M736@8W"M%?2Q,KSL2A%K</M$B.-X!VA78M)M)C9L%EH =<W[Q:;?.9662.XG
M1&+D,N9/W:J<Y'!&T#MTXH ;=@74.H37$TD;P-(BJ)61(T6,%,Q@A&\W.29%
M;=G"XH C6[GL(5MD9BU];0?9LD_)*5CAD"DG@*&2; ( _>$#J2 =#K#M96!$
M<C1[3#&TI.76-I8XY)"Q_B6-F8L>A&ZD!SNK(MA-+]GFE+II=ZX#2N[1G,&V
M17=F==Y7C#8!3*@$G+ T(5:SFL!YLK"<2F0R2NP=S"& PS%1R"510%')5<YH
M KR7IN;IH!*RV\FH>2SI(5QLLHF\E7!RF^8,"$*L6W!2&8F@#0T?]W?7ENLL
MDT<0@VK)(TGEEA(64%B3Z$Y);H"3@4 9&MW+L+R:%I0+8%?,-R8(XG6)7"I$
MF?.9BP/[U,.6"*=O- %JTB?5;RY$TLZJD5L46*:2-5:2,EF 1ADY P#E.N5)
M- #-+E?52@O)9$VV-K*H25HMS2JQEE8HREMK!5Y)1<\KE@: -#PXY&E*\9\U
MAYY4_P!\^=*0>,#YO;'7B@#$=%>UT^Z:>22:>XMF<-*S*[,X9U6,G8GEMD 1
MJI4*5;/.0!;2ZENH((29YI2UXY59S""D=RR!I)@PDQ&"%6-,\8W *HH ALYY
MK]K2W>:3RS<WL;&*=R72++(IF&QW P )/E8KSD$DT :=U--9R2Z7&\F^[:,V
MSEF=T1QMGP[$M^Y5'D4Y)!=>>X -;7)6MX(U1VB22:**20'#)&S88[SG:3PN
M\\C=G.<&@#)U)ETXM!!<RJ':W$H9WD,$<DH1I!+(7,>Y3C#,0OWU ZT 5=;>
M33S-;VD\PW6WF,&DDD:)Q/"B,KNS,OF*\F4W8.S..3D N_V=C4?LGG77D_9O
M-*_:9LF3S-F[?OWKP>41EC)P=G% &=IDTFHW%I%<SR@/8F0HLK1F5UDVY)0J
MQ(7).T@MC+94$$ JM=RQS1M&[3_9CJ2P.Q+E@D494%NK[7W)NY)V\DF@#2LE
MG/V63S1BYX8F\GE,RM&Q?9'Y2K&Z_?#1L@CQM)P10!4TUY+2#3A S_O)+LLF
M]V#E89RJD%C\NY5(4<;OF W$F@"[ YCM;.]2XE>XN)( X:1G23S643((L^6G
ME*78;%4IY>"<YR 0:>LGV""_::=IVNHD.Z:0H4>\6 H8RWED;">2N_=SNQQ0
M!T6M2%1;Q;VACGN%CD=3M;;Y<CA0XP5WR(D>5(;YL @FD!D7SK9M]EAN90DE
MQ DN79FA602'"S.69?-**,%MR9^7;O6F!7U,S6\DMC:S2JC?8SN,CR/#)+=Q
MQD"1V9@)(R28V8C . %8@@%B73]ES<Q":Y\J&UCE1?M$V1([7 +;]^\@"%<(
MS%,ECMH ALG;4;N)+F>50VG6TWEI*\6]V:4/)F-E/ QNVD Y7<#M& #(-U,?
M.E$C,8M.U)8ILX=ECG01R;A@[L*,.,9(W#KF@"_?W,DD<\B--FV@CW2&Y:WC
MB<PK(,*A+3,Q923(A!8B,'&Z@"W8))J]W()YIPJVMHX6.5XAOE60LW[MEY^7
MI]T_Q X& !NE3/JIACNYI !9QR )(T1D=GE221FC*,Q0)'QG:#(3CD4 -\Z6
M[N(K2&8W,0@=E8SRVQE99GC)WPH7D,:JHX(#9\P[MP- '0Z&\C6W[V19MKR*
MKJS/E5<@ R,B;V7E"X7#;<\G-(#DK:6>+28;KS96ENI8XY)))Y JH9"O!^=8
MLX53($+_ #$DDX(8%JYDN+#SH_.$*%;?>HN);AX1)<)&\H>:-2@\IG."QP5#
MJ!R: #4P;"6:*UN)C_Q++N3RS-)(4=?)$<H9F9@QRVWGY<$KC<<@%_7+\K+"
ML$I&^"ZDPCD9 ARCX!Y /*MV/(YH IZ&)+ZY#32S%8;2QD""615+R(Y9G"L-
M^2@R&RK9.X-Q0!!837,T%M>F15DFDCW%KN8AF9@)(?LWD^4IQN0!<&,@-O(#
M;@"..&9[.&Y-Q<^;->^46$TF!$UP\10)N*<*.'VEU/(8    FO;F:P:XM89'
M$0GM$#23.3&LR_/^_?S)$#, -QW;-QV@$T 1:D]U817*)+Y6$@8(MS-<21L9
MT7>'EC4JKJ2"A8@XR%P30!:U2W^RFXM5DF:)]/GE(>:5SYD;* P9F++D,0R*
M0C#@KC(( ^:&7]S'"SRHMJK&%;N2"4$G_7;\_O%_A"R.%3C P> #I]-N%NK6
M*:,NRO&I#28WGCJ^WY=QZG;\I/3C%("[0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %6YO
MK>RQ]HECAW9QYCJF<=<;B,X[XZ4 2F*.4K*55F3)1L E=PP2K=MPX.#R/:@!
M9H8[A#'*JR(PPRL RD>A!R#^- %>+3K6 %8H8D#*58+&B@J>2I  RISR#P:
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MQ@@$T6DV4&3%;P)G.=L2+G<,-G"CJ"0?4'!H LQ6T4!S$B(2JJ2JA3M3(1>
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M 3MF"RQ(RXSC>$=C&<$[@!T)I@4];U)WCN9K65Q&=.26,HS##&60;UP1M;
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M$NQ\D#Y1(O7!..0!)M7G2-3/#Y"7*.(W67<ZOY;.BR+L4(653@H[@,,$C@T
M4;+Q#Y-M;0EHFF^QV\LCW-P(<ET&,$I(SNQ!9C@ 9!+9.* +=KJLVH75K)"J
MB":WN&93(<[DEMT8X6-E8QDE8R&PZNQRG 8 CA\51S&-P(/)F=47%RIG =@J
M.\.W@9(+@2,R*<L,!MI8"WX@N)K8VAM\EGNU4H'*!P89CM8\_)D!CD-TR%)
M% $4OB$VBR)<QI'/%)'$%\T>43*N]6\UD3:H4,6W1Y&W@-D4 /M]?\_S45(Y
M9H55U$$ZRQNKMMSYA5-FP\R;ERJ_,-PH K2>*!"EPS)%(]K'')B"<2HP=RA&
M_P M"K*1RK)R""#@\%@)9KN_^V6:21QPK(92Z+.S9 0'YOW*@L@)(4$J6XW
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M!B."X  ?'\8:D!@:'J]U'96SW,>^*:01><TQ:4L[LJL4*$;-V%SYI;&#LQ3
MT3KT@A-[Y ^Q!ROF>9^\V!]AE\KR\;,\X\S?MYV]J +$FM>7:7%WY>?LLDL>
MW=][RWVYSM^7=UQ@XZ9/6@"%=;F9[HK #!8F17?S/G=DC$FV.,1G).5!RZ@9
M!!8\4 6M+U-]1^8I%Y>T,'AG69<G^!QLC97QSP&7@_,#P4!0O+FY34)(EP(1
M9.XQ(P(.X_.%"8W[@%'S<+\P;/R%@0Z-JURMM9?:HODN4BC$IE+R%S"6#R(4
M'$FTG(D=N06 R< %G_A(#'/%#-''&)Y?*"^>K3KG.UI(=@"@XYVR,5##.>0
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M"=B=N. 6_C8%CU   RYNKM-7\FV42J;0-L>5HXU/G,"YPDAW$848C)(ZD 4
M2P:Z]YY26T(::1'=UDDV)&(W,1RZI(6)D!"[4.0,G:* );36_M$T=NT9CD9I
MTD!;/EO#Y9(!"_.K"0%6^7C&1G( !7GU^191;P0"21KE[=09-@^2(2ER=C8&
M"<@ D 9&XG% #GUN5;AK58HC)%Y>Y#<!)&+JK'R%>-1*J[L;F:+<5(P",4 =
M'2 XNYFC;4[F.Y:[*)%;F-;<WFU2WF[R1:G +87!?&<''1J8#[/4KVS6"V:)
MII+F2X\KSY/+=8HR"GG$(YW;&R< MPH())P 3C6GA+)% 7E:^^R[3.Q7=]G$
MI<%D.R,8P450 -T@!8E2 +)KUU"L[R6R*MFP68B<G[RJ_P"Z_<C?A'1B'\H\
MXY- %C5=<?3#(QCB\N)=V9)UB>3C<1"A1M^!Q\S)E\J/6@!5UB>XN9+>T@61
M84C<N\ICR)5W(%41.=QP>I"@#)8$XH G@UA;D6OE(2UV&8@G'E*BYDW<')20
MK'C RS=1BD W4M:2PF2V'E>8ZE\S3"! H./O%7)8GHJJ> 22!U8%"/Q(UR88
M[:%9)9VF0CS@(U:'82?,5&W(RMN#*N>@VY)P 6%UV1\0K"#=&=X#'YG[L&-0
M[/YNS.S:RD?N]Y)QLX- &9_;5S9W%QYL3.YFMH4A$N4!D1L,C,H&UB 3E4/)
MW<CD U)M<DLV>*Z@Q*J(\2Q2>8LOF2+"JAF2(JPD=%.5P P8$]* *VJ:U)8P
MRI>P[&\EY4$,[X<)M#KYJQQO&Z[E((4Y&2&X(H GGUJ=);E(+=9$L<%V:;86
M!B27Y%$3Y8!B,,57@'?\Q"@$EC>SW5_)@+]G:VMI%R[9 D:YPVSR\;GV@.-_
M 12&;.% *.JW,JZBD<F5M8;::Y;9/+$QV/$"S",#?L!(6,ML;<2Q& * -"'5
MI@86N8!#%=$*C"7>RLP+(LB>6H7<!C*/( W!('- $FB:E-JT"W3PK!'*H9!Y
MA=CGKN'EJ%&?ND,Q(Y*KTI 5AK%U,]PMM;"1;1RA+3;3(0JMB-1$V6PW1BHR
M5&XY.U@9]EJEU=7EP]FGVB%H;65%DF,84/&S (-D@WOG)X5<CYGZ4 :,NN-Y
M45Q$D:QS0I,'N)Q OSC<(U.R3<X'+9"JH(.[G% %?_A)1((?)2,&X@$P\^80
MKR<>6C;) \@/4?*,8;.#0!-=:^+>46^V&.41))(MQ<+"%+YQ&"%DWL-IW%1L
M P=QR!0!JZ=?+J5LES&-HD!X.&PRDJPR#A@&!P0<,.1UI <\^ZPNK: 2W#S/
M)B:64R"WD!1BRJK$Q!R<>4D0RO0DX:F!HZ]<7%N+?[-CY[F-6RY3(.<*<(_R
MMCYCVP/E;)P 5Y-9FE^U@0#R+(2J\GGLCL5B\S$86/()W %MZE,[E+$8H )M
M<>UA618XUC$"29GN?++$KNV1ED<R,!@%G*98CGDD #[*]:[U+<K,(9+"WF5"
M3@%Y)N=N<!BN 2.< #. * 'WVN_84N2T>Z2V>-50-CS1*%VLI*\<EP1AL>6Q
MSCH 17VM()4C1#)&9+3]XLK1X:XEP@PHRP"@.RD[74A6&&H RM/NYWOH4:1R
MINM34J68@K&X"*1G!"#[@Z+VQ0!KWMW<0ZI%#;J90]M(2C2%(UQ)'^\8A7Y
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MTB>^B>.YG#-(T)&R,K&@AE67"QF1B6<KAG9SVP !@L"34-%74)7D9R@> 1
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M+>8!%N')!$@#<_4 E&B3)!%;)-&T<4$<)2:W$J$Q@J)%7S%VN0<')=2 /EH
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M?'"Y8EB6)R:0%8Z3<)YD4%QY5O-(TA C_>KYC%Y%CE$@"AG+,"8V9=QP>F&
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M!577$B%6P<$$LIP,KGFF NGZ&NG3+,CE@MOY.&')8RM*TA;/5F8_+MP.Q[4
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MHVXSN\U57KD8V[<]#G/:@"G#HWE3&;S,YO'N\;<?>MC;[,[NV=^['/W=O\5
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ML N<!@1S^&V83I;RI$ERNTDP[YD7RA%L24R#";5&%*$KEL,,@@ FO-#ENHS
M9D,31JA62 .R$*$9H6\Q?++ 9^828;!![4 2?V1/;M+]CN/)CN,%PT?F,K[5
M0O&_F)M9E49W*XW?,!VH >=*GAD>6TG\OSD19/,C\TED78)%.],/M !W!U)
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
,@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img46421407_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )[!! # 2(  A$! Q$!_\0
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M'>><#L.U=F(HPPV$BFESMR3TU5K==O\ ,XL-B)XK&2:OR))K71WOT.B&=O\
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M])^(W@O]E71X?#VC%/%%C>S2S:/JMNT4ES!]I<O&OF;=C,IR&(Y'09(-?4E
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MS2T2\M7U/E3Q7X.U^X^"?P&L8M$U*6^T[5](EO;9;.0R6J)&0[2J%R@4]2V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<']I8S_GXS[+_P"'J'Q:_P"@!X-_\ ;O_P"2:/\ AZA\6O\ H >#?_ &[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:1NE 'Y5_\%3_
M /DX;0?^Q8M__2J[KXVK[)_X*H?\G#:#_P!BQ;_^E5W7QM7Z/EO^Z4S\QS/_
M 'NH%%%%>F>6%%%% !1110 4444 %%%% !1110 4M)10!Z%^SM_R<!\,O^QH
MTS_TJCK]VU^Z*_"3]G;_ ). ^&7_ &-&F?\ I5'7[MK]T5\7GO\ &AZ'W&0?
MPI^HM%%%?,GU04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4C=*6D;I0!^5?\ P50_Y.&T'_L6+?\ ]*KNOC:OLG_@JA_R<-H/_8L6_P#Z
M57=?&U?H^6?[I3/S',_][J!1117J'E!1110 4444 %%%% !1110 4444 %%%
M%(9Z%^SM_P G ?#+_L:-,_\ 2J.OW;7[HK\)/V=O^3@/AE_V-&F?^E4=?NVO
MW17Q>>_QH>A]QD'\*?J+1117S)]4%%%% !1110 4444 %%%% !1110 4444
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MZ*^+SW^-#T/N,@_A3]1:***^9/J@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *8Q_P#U=*?28'/'M0!\]_&#P+KFD:AIMS8?$WQ;IDOB'78;&)/M41M+
M/S2[D!/+#%0J,BC=U9<GU7Q=X%UCX;ZMX-U2/XG>+]4M)]<L[*?3;Z[BD^UB
M5PH";8AP/OLI!RBOR."/0/CE>:>O@O\ LR_\.P^*WUJZBTVUTB=Q''/,^2I9
M\$H$",Y8<@+D<XKQGX8Z79>#=0\.^(=5\)V]Q<KK5SX:EU)=8N[T:7*)C!"8
M5N6;Y'8%"Z[2-PXP30!]4J<K2TBYQS2T %%%% !1110 4444 %%%% !1110
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M:?I^I_"GX[>%?#5CXHU[Q-HOB?3[Z6_T_7KXWSV;VZQE+B-G^9%<LR%?N9/
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M&)U3S"R"V&_>S*=[8V\4 ?3B]*6D7[H[TM !1110 4444 %%%% !7R7\;O\
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M,)8E3#GRT$FWY5#%MJC- 'TJGW1Z4ZD7[H[4M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %-[TZD- "'GVHS7AWQ'
M_:]\(?#'QGJ/AG5-,UNXOK'R_,DM(86B.^-9!@M*IZ..H'.:YK_AOKP#_P!
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MM_\ X_1_PWUX _Z WB/_ ,![?_X_1_96._Y]/[@_M; ?\_4>_P#_  CFF_\
M"3_V^;?=J_V3["+AG8[8=Y<JJYVKEN20,G"Y.%&,#2/@[X0T+Q8?$=AI'D:K
MOFE0M<S/##)-S,\4#.8HG?G<R*"V3DG)KQ__ (;Z\ ?] 7Q'_P" ]O\ _'Z/
M^&^O '_0%\1_^ ]O_P#'Z/[*QW_/I_<']K8'_GZCZ65N*-U?-/\ PWUX!_Z
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MCK]VU^Z*^+SW^-#T/N,@_A3]1:***^9/J@HHHH **** "BBB@ HHHH ****
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MK%\<:]H_B;7!>Z+X:@\*P/"JRZ?:74L\1E'WW3S"656R,)D[<<&M5[7VCO\
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M,@L%+SSZA<"!I)'+_9X9&8C+"+YV4\YV$YYKTE#N4'.<\Y% #J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "D-+2-TH _-3]KS_DXCQ;];7_TDAKQ
MVO8OVO/^3B/%OUM?_22&O':_9\N_W.E_A7Y'XOF'^]U?\3_,****]$\\****
M "BBB@ HHHH **** "BBB@ HHHH#J>Q?LA_\G$>$OK=?^DDU?I97YI_LA_\
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M0 4444 %%%% !3&/UI]-;K0!X5\4O^%F>*-0L8M/^'FGR1Z+K46HZ?J$WB%
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MV?I?#7^Z2_Q/\D%%%%?)GUH5\E_&[_DJ&M_6'_T2E?6E?)?QN_Y*AK?UA_\
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M2^MU_P"DDU?I97YI_LA_\G$>$OK=?^DDU?I97YGQ+_OD?\*_-GZ7PU_NDO\
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MJ_H2.R/P$*1NE+2-TI@?E7_P50_Y.&T'_L6+?_TJNZ^-J^R?^"J'_)PV@_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2^&O]TE_B?Y(****^3/K0KY+^-W_ "5#6_K#_P"B4KZTKY+^-W_)4-;^L/\
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MM+>P^*VDR7"07GB;1K&6P^R \M+-(5:VEP"3B-P3V7M0!]&+]T=J6FK]T #
MIU !1110 44PL=V._P#G_/X4;NW?KSF@!]%1ECFESTP<YH ?14>[ISUZ?Y_S
MTIZ]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF?F.9_[W4"BBBO4/*"BBB@ HHHH **** "BBB@ HHHH ****0ST+]G;_ ).
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MC#%MK#GC&,$<5U&A:3#H.BV&F6Q<V]G EO&9#EBJJ%!/O@4 7J*** "BBB@
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MHHHK\D/U@**** "BBB@ HHHH **** "BBB@ HHHH *V_ _\ R.F@?]A"W_\
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M117R9]:%?)?QN_Y*AK?UA_\ 1*5]:5\E_&[_ )*AK?UA_P#1*5\5Q9_N,?\
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MZTM-7[H[TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D-+2-TH _-3]KS_DXCQ;];7_TDAKQVO8OVO/^3B/%OUM?
M_22&O':_9\N_W.E_A7Y'XOF'^]U?\3_,****]$\\**** "BBB@ HHHH ****
M "BBB@ HHHH#J>Q?LA_\G$>$OK=?^DDU?I97YI_LA_\ )Q'A+ZW7_I)-7Z65
M^9\2_P"^1_PK\V?I?#7^Z2_Q/\D%%%%?)GUH5\E_&[_DJ&M_6'_T2E?6E?)?
MQN_Y*AK?UA_]$I7Q7%G^XQ_Q+\F?9\*_[]+_  O\T<+1117Y(?K 4444 %%%
M% !1110 4444 %%%% !1110 5M^!_P#D=- _["%O_P"C5K$K;\#_ /(Z:!_V
M$+?_ -&K77@_]XI^J_,XL;_NU3T?Y'VBOW5IU-7[JTZOZ$CLC\!"D;I2TC=*
M8'Y5_P#!5#_DX;0?^Q8M_P#TJNZ^-J^R?^"J'_)PV@_]BQ;_ /I5=U\;5^CY
M9_NE,_,<S_WNH%%%%>H>4%%%% !1110 4444 %%%% !1110 4444AGH7[.W_
M "<!\,O^QHTS_P!*HZ_=M?NBOPD_9V_Y. ^&7_8T:9_Z51U^[:_=%?%Y[_&A
MZ'W&0?PI^HM%%%?,GU04444 %%%% !1110 4444 %%%% !1110 4444 %%%,
M8_6@#A_BYXEN=#T73K"QL+#4M0U[4(M)@@U3)M?W@9G:4 ?,H1'^7N<"O'/"
M^H_\(CXXU'Q#X:\(>$=*\)Q^(X_"K1Z?IWD:C)ND6)YQ*OR[5F;[F,%0>01D
M^E?$2U\0>,/"6HV-W\/K76FCU4+;69U_[*SP1_-'>).L>Z*3<!A1R,_>ZBN*
M\*^%-<@U+PC:M\&]-T_2_#]VS6LB^+C<+9M(P\VX,?E?O90"2"Y+9)Y!.: /
MH=?NBG4B_=_^M2T %132"%6=G5$499F(   R34M9^M:1::]I\UA?Q>?9S +)
M%N90X!S@[3DCCD=""0<@XH 31]?TWQ!;M/IFH6NHPJVUI+6=9%#8S@D'K@CB
MFZ?X@TW6+JYM['4;6\GMCMGCMYU=XFY&'4'*\@]?0UYGXSOK_1]6\4W=RB6%
M[<>'IQ8&QE+I(D1)+NQ53YH\P$ +@ G!)K=U*UM])UCX=BQC2 !Y+,+'M'[@
MVS,5Z=-T<9XXR!0!VFI:M9Z-9M=W][!8VBXW7%U*L:+GU8D 5%-X@TRVTM=3
MFU&UBTUE5Q>/.HA*M]T[R<8.>#7/ZY_I'Q,\,6\RAH8[.\N45B,>:#$H;'7(
M5WY_VC7/:?H]W?7VMKIHMV_LCQ(;JWMKAS'"Y:W0NA*JVW#2LX.T_,10!Z0-
M3M&CMI5NH3%<X$#^8"LN1D;3GYL@9X[5;%>3Z/?1^$6L;:>VN-5ELA<1VUKI
MJKS,29;J1 [*-D881 YSDN,9.*]/TO4+?5M-M;ZTD$MK<Q+-%(!@,C#*G'T(
MH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1124 +17FWC+XW6'AGQ5/X=TW0/$'C#6K6W6[O;7P[:QS?8HVSL\UY)(U5
MGP2J!BQ SC'57^-NG7W@"Q\6>'M#U_Q=:W-P;5K'1K-3>0.I<2"6*5X]FQD*
ML"<Y(P"#0!Z117D7@_\ :*MO%WQ$MO!DG@?QAH&K36;WY.L6=O%'' IV^8Q6
M=F"EAM'')X[&NX\>>/M)^&_AN;6M:FD6U1XX4BMXFEFGF=@D<44:_,[LQ "C
MW/0$T =+17GW@GXQ67C#7KO0KO0];\)Z[!:B_&G>(+>.)YK;<%,L;Q22(RJQ
M"M\VY21D#(JGX0^/>A^,]>T_3[33]6M;351<'1]7O($2TU3R2?,\DARXP 6'
MF(FY02N10!Z;17/>%?&-IXN?6#8Q3^1IM])IQN9 HCGEC $ACPQ)56)0Y ^9
M&'.,GH!0 M%%% !1110 4444 %(:6D;I0!^:G[7G_)Q'BWZVO_I)#7CM>Q?M
M>?\ )Q'BWZVO_I)#7CM?L^7?[G2_PK\C\7S#_>ZO^)_F%%%%>B>>%%%% !11
M10 4444 %%%% !1110 4444!U/8OV0_^3B/"7UNO_22:OTLK\T_V0_\ DXCP
ME];K_P!))J_2ROS/B7_?(_X5^;/TOAK_ '27^)_D@HHHKY,^M"ODOXW?\E0U
MOZP_^B4KZTKY+^-W_)4-;^L/_HE*^*XL_P!QC_B7Y,^SX5_WZ7^%_FCA:***
M_)#]8"BBB@ HHHH **** "BBB@ HHHH **** "MOP/\ \CIH'_80M_\ T:M8
ME;?@?_D=- _["%O_ .C5KKP?^\4_5?F<6-_W:IZ/\C[17[JTZFK]U:=7]"1V
M1^ A2-TI:1NE,#\J_P#@JA_R<-H/_8L6_P#Z57=?&U?9/_!5#_DX;0?^Q8M_
M_2J[KXVK]'RS_=*9^8YG_O=0****]0\H**** "BBB@ HHHH **** "BBB@ H
MHHI#/0OV=O\ DX#X9?\ 8T:9_P"E4=?NVOW17X2?L[?\G ?#+_L:-,_]*HZ_
M=M?NBOB\]_C0]#[C(/X4_46BBBOF3ZH**** "BBB@ HHHH **** "BBB@ HH
MHH **** "DI:* /(OVF-4M--\%Z3'JVIR:3X:O=9MK369H9S#(;1M^Y RG=A
MF"!MO.PN>U>6ZXOP6^&OB+PEJ/P^\1:!HFNR:G;Q3/8:T&MY;$MFX6Y_>% G
MEY92V"7"[37M?QJU9['0=*L;73=+U/5-7U2'3[%=9B$EK#*RLQE=>IVQI(0
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MD-+2-TH _-3]KS_DXCQ;];7_ -)(:\=KV+]KS_DXCQ;];7_TDAKQVOV?+O\
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MX/\ WBGZK\SBQO\ NU3T?Y'VBOW5IU-7[JTZOZ$CLC\!"D;I2TC=*8'Y5_\
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M'X/_ &<=+\*ZU9ZA=^)/$/B5;&[EU"UL]6N8V@CNI"2TY2.--\F6;YFS@MD
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M>=WVJ_"[Q!XN\$)\++729/%4.IV\_P!H\.V8A%MIX)%S]H9% "&,LH5_XF7
MKZ8=@A+,=JCDDFN/T'XK>!=>UY](T?Q1HE[JS,Q-I:7D3RNP!+  '+$#.<9Q
M@YH [-?NBEIL?W!Z4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH 2OA;XB?\E \3_\ 84NO_1K5]TU\+?$3
M_DH'B?\ ["EU_P"C6IH3.>HHHJB0HHHH **** "BBB@ HHHH **** "BBB@
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M2 YI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO^_2_P +_-'"T445^2'ZP%%%% !1110 4444 %%%% !1110 4444 %;?@?\
MY'30/^PA;_\ HU:Q*V_ _P#R.F@?]A"W_P#1JUUX/_>*?JOS.+&_[M4]'^1]
MHK]U:=35^ZM.K^A([(_ 0I&Z4M(W2F!^5?\ P50_Y.&T'_L6+?\ ]*KNOC:O
MLG_@JA_R<-H/_8L6_P#Z57=?&U?H^6?[I3/S',_][J!1117J'E!1110 4444
M %%%% !1110 4444 %%%%(9Z%^SM_P G ?#+_L:-,_\ 2J.OW;7[HK\)/V=O
M^3@/AE_V-&F?^E4=?NVOW17Q>>_QH>A]QD'\*?J+1117S)]4%%%% !1110 4
M444 %%%% !1110 4444 %%%% !28]J6B@!*,#TI:* $I:** "BBLOQ%K]MX9
MTJXU&\,GD0@?)"A9W8D!44#JS,0 /4T :E%<QIWCNUN;VYL[ZRO=$NH+<WAC
MU%$&^ 8#2*T;NI ) (SD9Y%+H_CB#5KZVMGL+[3OMD9FLI+Q$5;I ,DKM=BI
MP0VUPK8R<<' !TU%8VN>(H]":UA^SW-_>73%(+2U"F23:,L<LRJH Y)9AV'4
MC.=_PGUG_9L-W%;7D]U-<_81IJJ@N!<#)>,Y8("H!).[:0,@D$4 =517/Z?X
MQL]6M=*FMDGD;4&=4BV /'LSYF\$\!6&TD9Y*@9S6^OW1SGWH 6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** $KX6^(G_)0/$__ &%+K_T:
MU?=-?"WQ$_Y*!XG_ .PI=?\ HUJ:$SGJ***HD**** "BBB@ HHHH **** "B
MBB@ HHHH *]#_9__ .2N:#_V\?\ I/)7GE>A_L__ /)7-!_[>/\ TGDI#/L>
MEI*6I*"D-+2-TH _-3]KS_DXCQ;];7_TDAKQVO8OVO/^3B/%OUM?_22&O':_
M9\N_W.E_A7Y'XOF'^]U?\3_,****]$\\**** "BBB@ HHHH **** "BBB@ H
MHHH#J>Q?LA_\G$>$OK=?^DDU?I97YI_LA_\ )Q'A+ZW7_I)-7Z65^9\2_P"^
M1_PK\V?I?#7^Z2_Q/\D%%%%?)GUH5\E_&[_DJ&M_6'_T2E?6E?)?QN_Y*AK?
MUA_]$I7Q7%G^XQ_Q+\F?9\*_[]+_  O\T<+1117Y(?K 4444 %%%% !1110
M4444 %%%% !1110 5M^!_P#D=- _["%O_P"C5K$K;\#_ /(Z:!_V$+?_ -&K
M77@_]XI^J_,XL;_NU3T?Y'VBOW5IU-7[JTZOZ$CLC\!"D;I2TC=*8'Y5_P#!
M5#_DX;0?^Q8M_P#TJNZ^-J^R?^"J'_)PV@_]BQ;_ /I5=U\;5^CY9_NE,_,<
MS_WNH%%%%>H>4%%%% !1110 4444 %%%% !1110 4444AGH7[.W_ "<!\,O^
MQHTS_P!*HZ_=M?NBOPD_9V_Y. ^&7_8T:9_Z51U^[:_=%?%Y[_&AZ'W&0?PI
M^HM%%%?,GU04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %9NO:U:^'=+N-1O9/+MX1R54LS$\*H R222  .236E535-(L=<M&M=1L
MK>_M6(+0W42R(<=,JP(H \X\0>'-7\0:#XDU[4H6M[^;2+BTT_2UPS6T3#<=
MY!PTKD+G' P ,\FM#4KJ'5-:^'9LG64;Y+L&,@X@%JRENO3<Z#([D5U6E>#]
M T&Z-SINAZ;IUP5*&:UM(XGVG&1E0#C@?E4^F^'=)T6:XFT_2[.PFN#F:2VM
MTC:4Y)RQ4#/)/7U- '.ZX!#\3/#-Q*0(9+.[MD9@,>83$P4'/4JCG_@)K*T#
MP_%XDNO$]PMQ/:JNO&>SO+39O22.".-V7<K*1D2(00>XZUV]QX;TF[TL:;/I
M=E-IP.X6<ENC0YSG.PC'4D].M6;?3[6ULTLX;:&&T1/*2WCC"QJF,;0HX QQ
MB@#RB&\NM FL%T5K>-;J.Y2TO-31I8_L\"F21R%9/GFD8ONSC:JG!QBO3?#>
MK'7O#^FZF86MS>6T=P86.2FY0VT\#IFEO_#NE:K8Q65[IEG>6<)4QV]Q;H\:
M;1A<*1@8!(&.F:T  H  P!T% ",?3K4'FW7:"''_ %U;_P"(JS10!5\V[_YX
M0_\ ?YO_ (BCS;O_ )X0_P#?YO\ XBK5% %7S;O_ )X0_P#?YO\ XBCS;O\
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MDV[_ .ADA_\  0__ !=?1]% 'SA_PR;=_P#0R0_^ A_^+H_X9-N_^ADA_P#
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M2BK(K>;=_P#/"'_O\W_Q%'FW?_/"'_O\W_Q%6J*Y3K*OFW?_ #PA_P"_S?\
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MS+=_]!V'_P !3_\ %T?\,RW?_0=A_P# 4_\ Q=?0.*,4?ZO9=_S[#_6#,?\
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MVKB_YS/^R<'_ "'YT?\ #I6[_P"BGP_^"(__ "11_P .E;O_ **?#_X(C_\
M)%?HOMHVT?VKB_YP_LG!_P A^='_  Z5N_\ HI\/_@B/_P D4?\ #I6[_P"B
MGP_^"(__ "17Z+[:-M']JXO^</[)P?\ (?G1_P .E;O_ **?#_X(C_\ )%'_
M  Z5N_\ HI\/_@B/_P D5^B^VC;1_:N+_G#^R<'_ "'YT?\ #I6[_P"BGP_^
M"(__ "11_P .E;O_ **?#_X(C_\ )%?HOMHVT?VKB_YP_LG!_P A^='_  Z5
MN_\ HI\/_@B/_P D4?\ #I6[_P"BGP_^"(__ "17Z+[:-M']JXO^</[)P?\
M(?G1_P .E;O_ **?#_X(C_\ )%'_  Z5O/\ HIT/_@B;_P"2*_1?;2T?VKB_
MYP_LG!_R'P/\._\ @F'=> /B%X8\3'XB0WW]BZI:ZE]E_L9H_.\F59-F_P \
M[<[<;L'&>A[_ '<LEUM&(83_ -MF_P#B*L-SVS3JXJ^)J8F2E4=VCMP^%IX5
M.--63*WFW?\ SPA_[_-_\11YMW_SPA_[_-_\15JBN8ZRKYMW_P \(?\ O\W_
M ,11YMW_ ,\(?^_S?_$5:HH J^;=_P#/"'_O\W_Q%'FW?_/"'_O\W_Q%6J*
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M#'P/\:=.T_XD:?XVF\'2:!<6'CC^S+1!&;RZ5)[2Y2(>0VU!D%%5@LG)S@@
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M9_UGQ5X__P"$DTSXBV>L)?Z/)HUI;);-:(7BEBEB57+G8=P)*D,<(N!CT/\
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M7^N:=KEA97[:;IC6\RKMFN99$COH_*<,9+=HU!![$&KGPZ_:>^+.O? OQO\
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MKY2^ <\NDWWP3EM,BVUG1M<L O\ #)IL-RLVGN,=4CB*K'V"7!QUY^KE^Z*
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M-J-T<X!Z<Y48 /?M>^$W@?Q9::-;:YX-\/ZS;Z+@:9#J&EP3I8X"@>0'0B/
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ME"O&TC&.*R)?ACX.G\_S/">AR>?I@T67=IT)\S3QTM&^7F#D_NC\O/2NFI*
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M-\)?B!9:#:Z[X0CNHM"TU-&LFBO[J"06* ;;:5XY5:>(8!V2EQDDXRQKV.C
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M86,"Z5H=[=7\4$5JD@$DEW= 37$TC3.69EX"J 6Q7T6IRM+10 4444 %%%%
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M[4M7%O I$7EBVM($;RH -QSB26XD+=S,1T45U*]**6@ HHHH **** "BBB@
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M?NBFLWS #@YKRK_A;UXN@Z'?2-8))?\ A:37)=J2.JS#R H55)8H3*PVX+'
M (Y-<I_PFOBOQ%XLT72;_P#LVPUO3=?6**ZN+0I$RR:=</S;QW4IW##84R@G
M(R%QR >_Y/&#QBGBO [[XI7NG7MSXBOK6WOK_0=(UJWE%GE(+EX;FU7>FYCL
M4D<@LVTJPW';D]OX+\:>([AM<A\1V$"OI]K'=1M:^3%+(&#DJ8$NK@J#LRKE
MQNR0 -N2P/1J9(VWU_"O"].^-7BZ3PG>Z[>:9IT,$OAZ?7+'S6BBVE55D4JE
MU*\T>' :0+'@J/E^<!=C4O'6LZ?JRZ+K"Z'KS/)I5W#<6MF\<<:37BQ89&ED
MRZX,D;AADC[ORY* ]>7[HI:\2N/C1KNB?VY/J\&G)'':WESIT*Q.D,BPS!0_
MVQ99(Y$VLI?*Q,O/R'D+J:A\1/$FAZA=Z'<W6BWVIG^SOL^I06TL5O%]KF>%
M3+"9F)PT>5 E&_<%^7J0#U9FY(/\Z7)Q[UX%#XW\1>&?$'B+3[6.SU?Q!JWB
M86?GVMNIA CTJWE.(9+F/YMJ8VF;KN/.-M=3JWBK5==^$\<M_'!87^H:A#I$
M[V=RA4+)>+;NZM&\@1RK'Y-[%&^7<<9H ]3'UIR]*\JN_&OB33];OA;?V/%X
M?TW7+3139?9)/M$D<R6P#K*)0B;6G/'EL"%QE:N>']6NM'_X6)I]M+Y4>D7Q
MELY%L9KWRA-;QSLOD1,'DQ)(Y"(0<, ,4 >CLVWJ<#K2C./>N"^&_BK5_$%Q
M?)J=_P#;%B12@_X1'4=$P23D[[N1A)]%P1U/6N2\'>)M?\+QV)F;3[G0+_6-
M9MUM8;:1;N-DFNY@_FF0JP)B*[/+!&X<G!% 'M=+7B'AOXQ^)[S1FU?5+"QL
M["ZT5]6LV81ADY38OEQ74TDZ?O "P2+# # +C:FF_$WQUJ&L?\(XT>DV>L?V
MK'9M>7=BPC6%[.6?=Y$=W(=P,6,&4$AAD+0![:V=W'2G"OGSPO?>,M2\9Z>7
MU_1WU3;XAA2YO+"8QK'%J,*!!%YX+ %1C#C:H ^8C)Z*Q^-5_?>#]?UG[/96
MTEAX=M]6BC?<4::0W .3D;HR85*\*2&Z^@![%17DVL>.O&$=_K\EC)HJ:?9Z
MQ9:/;17%I,\KM.;4M*SK*  HG;"A<G .X=#U?@'7-8U1=;L];ELKC4-+U V;
M76GP/!%.ODQ2AA&\DA4@2X(WGIG/.  ==3';;G^E>0>%_BQXF\0:W!.=*M8O
M#]U>WMG%YKP1RIY!D&0_VIFE;=$=T8@0@,3D[,OD7/Q5\0GP39WVKQ^'];M]
M=\.76IQ6=M9R!(6CB5V24-,WG1'S AP$((QSNX />%SM&>O>EKR>[^)^M:1X
MVN+>^AM(_#_VB6UM?)MVE,[I;>;C[1'*PCDW!AY4D*<=&/&[/;XP:]H^BVVI
M:@VAZE'J6@S:Y;1V)>(6H0Q?+*Y=_,C'GKF4*GW#\OS8 ![*6^<C/09H+$>]
M>#:YXRU_P/XS\33W4FFZUK4MCH=A ]C;^1$C3W5VBEXI+CL6)QYJ[OE&5SD;
M6O>*O$NK?!GXB27\=KIFLZ99W<:S1>6QXMM_S0QW$ODR88@*96/W6Z': #V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 E<UJGPQ\':WK)U?4?">AW^K%E8W]
MUIL,D^5 "GS&4MD #'/&!7344 4)-!TR9K]I-.M)&U!!%>%H%)N4 *A9./G
M!(P<\$U4TKP3X=T)XWTW0-+T]XV#(UK9QQ%2 P!&U1@XD<?1V]36P3UIU '/
M:?\ #OPKI/VPV/AG1[(WBR)<_9["*/SU?&\/A?F#8&0>N!FHF^%_@V2Q>R;P
MEH;63D%K<Z;"8S@,!E=N. S#_@1]:Z:B@#-L_#>D:=;VT%II5E:PVL#6L$<-
MNB+%"V-T:@#Y4.U<J.#M'I3/#_A31/"-F]IH>CZ?HMK(_F/!I]JD",W]XJ@
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M,<YK5HH QY/!N@3:[!K<FAZ:^LP((HM1:TC-Q&@SA5DQN Y/ /<UH6VGVMG
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MV]MI6A:;IEM;RM/##9V<<212,I5G4*  Q4D$CD@D5LT4 9Z>']+C,!33;-3
MLB1;8$'EK(<R!>. QZXZ]ZJ:3X(\.>']/^P:7H&EZ;8^<MS]FM+*.*+S5(*R
M;54#<"JD-U&!Z5MT4 95_P"%-$U566]T?3[Q6N5O"MQ:HX,Z@!9>1]\!5 ;J
M !SQ6K110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img46421407_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Q R4# 2(  A$! Q$!_\0
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M%//?Z5'$@>WC!_NCO0!+14?D1^A_[Z-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
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M1_[HIY[_ $ID'^HC_P!T4 24444 %%%% !1110 4444 %%%% !1110 4444
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MP?5*W\IT=**YS_A+[;_GTF_,4?\ "7VW_/I-^8I_VAAOYT+ZI6_E.CHKG?\
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M3ZG/KFER<YR<^N:V[[1K=([2[LY7DM+B14.[[RY-:,^@Z-;ZI%8O/<^9*/D
M(X^I]Z<<OK.Z_7OL)XVDDG9_<<ER3G//K2DD]R?J:ZB+P]IC7TFFFYF:Z52P
M( "@=A]:JZ3H=K=07S7DSH;9L%E/' ZX[T_[/KIJ/?S[!]=I6<K;?J5K;5H8
M- N;!DD,LS95AC:.163DGN?SKI1HVD3:9_:,5Q<)!&<2!@"Q]AZ55U71[:"S
MM;RPDD:*<[=LG+9/2KK8;$."NU:*Z=B*.(HJ323NW^)B$D]3GMR:,D=#BNG_
M +!TZUD@M;Q[IKF4#+Q+\BD]C4%EX?1M?DTZZ=RJKN5DXR.QK-Y?7BTN^A2Q
MM%I^1@;FZAC^=&YC_$<?6MFXL-.>[6QL'G>Z,FPLY&W'<BKC:-HL=T]A)=S+
M=(N3(2 @/I26#JMNTOQZC>*II*Z?W?B<[Y4PB\PQR>5_>P=OYTS<V0=QS70W
M%KY?A0.MW(ZB;:%R-A^8\XQGWZU)8Z+I=SY,2M=W$C@%I(1A%_$U;P-24E&+
MZ7)^N047*2ZV.<BCEE;;$CNV.0@)./PII!!(/!'6NMT.Q_LWQ3<6N[>%B)4X
MQQD5RUU_Q]S?[[?SK&OAG2IJ4M[M&M*NJDW%;63(J[KPS_R XO\ >;^9KA:[
MKPS_ ,@.+_>;^9KKR?\ COT,,R_AKU-BE%)2BOI3PQ>U ZT=J!UJ@%HHHIB%
MI:2EIH0=Z44G>E%,!:***!"B@4"@50A:6DI: %HHHIB%H[44=J8A:04M(* '
M&B@T4Q%+5/[,6%7U,6_E@X!G (!]LU3L]&T0S1W5B I!WCR9F"G_ (#G%0^(
MXV6YL[K^RWU"./<KQJ VT''.WN>/YU2L!X8?5XF@@>PO@<+$RM!N/IMX!JA'
M6BEI*6@ HJM?7L.GV<MU<,5BB7+$#/Z5GVFN/+/!'>6$UF+C_CW=V5M_L<?=
M..QH V:*P[G7S%-.8+":YMK8XN)T8 (>^ >6P/2GW^NI;>2MI;/>O+$9@L;@
M8C Y;)_E0!LT5FIJ\,T=D]NCR_:^44<%5 Y8Y[#@?C6C0 'O]*9!_J(_]T4\
M]_I3(/\ 41_[HH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ H[T4=Z ,_6_^0)>_]<7_ )5Y;7J6M_\ ($O?^N+_ ,J\MKY?/OXD
M3W,H^&05UR):>)M-MXC<""[MUVX;T]:Y&BO)P^(]DVI*Z>Z/1KT/:6<79KJ=
M+J&D:7I6ENLUQYUZW*%#C'X>E/5!KOAVVM;>2-;FV.-DC8W#&*Y>BMOKD%)V
MA:+5K&7U67*KSNT[W.JNY8M/TVQTH2I)/YRO(5.0HS4FHLI\;V+;EQ\O.>.]
M<L;6<6XG,,@A/ D*_+^?2HL5I+'M:.-E=-?(B.#6K4K[_B=C:NH\<W+;EQL/
M.>/NU'8,HT_7_F&2S8YZ\&N2HI+,;;Q[O[P>!OM+M^!TELP'@6Y7(SYG3//4
M5)>S+%X7TQ@02D@)&?<UR]%3]??+91Z6+^J*][];G>7<FH7\D-SIFI1Q6KJ-
MX;;\IK/T6=Y/%$AFO%N2L97S=H4'VKD\45I+,FY1ER[:[F<< HQ<;[JVQI6M
MTEGX@%P_W$F.3GL>*VKS0H]0U66^:ZB%E*-Y=7&X<=,5RJ1O*X2-&9CP%4<F
MEEAD@D,<L;1N.JLN#6-/$I0:G&ZO?YFLZ#<DXRL[6.HG%O'X1CC642QK<=0,
M$C<>U:EPLTMU9SVM[##IBA6*JP&<'I]*X"C%;QS-)ZP[?@9/ -_:[_B=S"P_
MX36X?<NTVXP<\'FN+N>;J;_KHW\ZBQ17-B<7[>-K6U;^\VP^&]B[WOHD%=UX
M9_Y <7^\W\S7"UW7AG_D!Q?[S?S-=63_ ,=^AAF7\->IL4HI*45]*>(+VH'6
MCM0.M4 M%%%,0M+24M-"#O2BD[THI@+1110(44"@4"J$+2TE+0 M%%%,0M':
MBCM3$+2"EI!0 XT4&BF(QM:FNI+VSTZVN_LGV@,3,%RWRX^4>YS^E5PE_H][
M:_:KM;ZUFD$8,J 21L>A![BI-<)GM88+K2Y+K?EC]ED&Z/'0KG'K6;I<FE-J
M,(GFU1IT;$,5ZI(4_@,9_&J$=A2TE+0!F:]ITFJ://:Q,!*2KINZ94@@'\JP
M-7GU.];1XY[ V12\CW&256WM@_<VD\=>N.HKK+JUBO;62VF!,<@P<'!_.J%G
MH,%I<I/)<W5W)&NV(W,@;RQWQ@#VH SM!*KH&I>9CBYN=_'^VW]*@TK1I;WP
MWI-Q'=M:7"68B9P@;,9'(P>GKFM6Z\.6EU<RRF:YCCG(,\$4F(YNWS#'IQP1
M6C-:1S6;VN6CC9-G[LX('3B@#E+>ZDM)[=-.@BDEF5H[19V*J(4Y9L@$Y8D?
ME72Z3J U/38;P(4W@@J>Q!(/Z@U%>Z);7L,"!YK=X.(Y8&"NH(P1G!X-6[.S
MAL+2.UMUVQ1C '\S^?- $Q[_ $J.+=]GCV@9VCK4A[_2F0?ZB/\ W10 9F](
M_P S1F;TC_,U)10!'F;TC_,T9F](_P S4E% $>9O2/\ ,T9F](_S-244 1YF
M](_S-&9O2/\ ,U)10!'F;TC_ #-&9O2/\S4E% $>9O2/\S1F;TC_ #-244 1
MYF](_P S1F;TC_,U)10!'F;TC_,T9F](_P S4E% $>9O2/\ ,T9F](_S-244
M 1YF](_S-&9O2/\ ,U)10!'F;TC_ #-&9O2/\S4E% $>9O2/\S1F;TC_ #-2
M44 1YF](_P S1F;TC_,U)10!'F;TC_,T9F](_P S4E% $>9O2/\ ,T9F](_S
M-244 1YF](_S-&9O2/\ ,U)10!'F;TC_ #-&9O2/\S4E% $>9O2/\S1F;TC_
M #-244 1YF](_P S1F;TC_,U)10!'F;TC_,T9F](_P S4E% $>9O2/\ ,T9F
M](_S-244 1YF](_S-)F;TC_,U+1WH S-:,O]BWN0F/)?H3Z5YA7J6M_\@2]_
MZXO_ "KRVOE\^_B1/<RCX9!1117@'L!1110!TT__ "(T/_72N9') SBNQL;6
M#4O"L-H]Y' V[=DD$_ED50NO#UK80?:3J4<X0@F-0 2,_6O8Q&%J55"<=DD>
M90Q$*;E![W98LM%TRX\E$@O)]R@M.,H@/XXS^%5[/08&\07-A.S/'&FY2#CZ
M5M7)$]_:W4>IPQV"!6\L-@D^F*IK>P6_C.6229/+DC"AP<C\ZZYT**Y;I;_H
M<L*M5\UF]C'T33;>_P!3N()PWEHC,N&(Z&K&D:18W=I>S7)=1 Q"LK= /YUJ
M:380Z;J-W++>V[>8K>6%?)(]_2J6E2QKHNK*TB!F9L L 364*$(<O.E?7_@&
MDZTYJ3BWT(9=+TVZT2:_T_SD:$_,)&SG'M3(-+L+328K_4S*_G'Y(XS@X]?R
MJ329(U\)ZFC.H<DX4L,GY14JB+6_#]M;1W$45S;8RLK8!'3K4J%*34DES..W
MF4Y5(WBV[)[^1 MK8VVOV/V"?S(W8$J3DK^-:>H6NDW?B%K:X\]KF;HRG"KQ
MTK,^QV.G:W8I!=>8X8&4Y&T>^:GN)8SXYBD$B;-X.X,,8QZU4)1A!QE%:R6G
M8F2<FFF_A9@ZA:_8K^:VW;MC8'TJM6EK[K)KETZL&4D8(.1T%9M>/7BHU91C
MM<]6BW*FFPHHHK$T"NX\-%_[$BP%QN;J?<UP]=UX9_Y D7^\W\S7K9/_ !WZ
M'GYE_#7J:N9/1/S-+F7T3\S3J45]*>&,S+CHGYFE'FYZ)^9I] ZU0#<R^D?Y
MFC,OI'^9IXHIB&YE](_S-+F7TC_,TZEIH0S,OI'^9I<R^D?YFG=Z6F S,OI'
M^9I<R^D?YFGT4"&?O?2/\S2@R^D?YFGB@50AN9?2/\S1F7TC_,T^EH 9^^](
M_P S1^^](_S-244Q#,S>D?YFE_?8Z1_F:?1VIB&9F](_S-&9?2/\S4E)0 @\
MS^()^!-%.HIB.7UG2;"POTU1M5N;!B&7Y&W;B<= V0.G2HK&[^VW]LB^)X+F
M)) XC\L"1CZ9&!^E;6J6ERU]:7MLB2F+=&T3D#*MC)!/<8K#BM<:C9P#276\
MMKDLUR8OE,9)/WN_450CL12TE+0 4444 %%%% !1110 A[_2F0?ZB/\ W13S
MW^E,@_U$?^Z* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *.]%% &?K?_($O?^N+_P J\MKU+6S_ ,22]_ZXO_*O+:^7S[^)$]S*
M/AD%%%%>!8]@****+ & 3R!28'H*6BGJ F!Z4N!Z444.X"8'H*7 ]*** 0$
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI*
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M)/\ GK_XZ*-DG_/7_P =%244 1[)/^>O_CHHV2?\]?\ QT5)10!'LD_YZ_\
MCHHV2?\ /7_QT5)10!'LD_YZ_P#CHHV2?\]?_'14E% $>R3_ )Z_^.BC9)_S
MU_\ '14E% $>R3_GK_XZ*-DG_/7_ ,=%244 1[)/^>O_ (Z*-DG_ #U_\=%2
M44 1[)/^>O\ XZ*-DG_/7_QT5)10!'LD_P">O_CHHV2?\]?_ !T5)10!'LD_
MYZ_^.BC9)_SU_P#'14E% $>R3_GK_P".BC9)_P ]?_'14E% $>R3_GK_ ..B
MC9)_SU_\=%244 1[)/\ GK_XZ*-DG_/7_P =%244 1[)/^>O_CHHV2?\]?\
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MSN3DVV:I):(B:W#L&?8Q'0E!Q4FR3_GJ?^^13J6B[>X#-LF?]:?^^12[)/\
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MZ-]CLFT]PA$LDB>7]H&!P/\ GIZY]_>@#LGN(HY%C>6-7;[JLP!/T%+)/'"
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MQ:AIUO>0MF.:,.OT(JSD5YS5M#K6PM%)D>M&Z@"*XN(K6VDN)G"11J7=CT
MYKG/#OCO2O$E_-96OF1RH,J)!C>/45R_Q7\3_9[=="M7_>2C=<$'HO8?CUK@
M[G1-9\))I>M$F,RXD0CJA_NM]1772PZE"\GJ]C"=5J5D?1@I:PO"OB.W\2Z+
M%>1$"4?+-'G[C5N;A7+).+LS9.ZNA:*3(HW"D,6BL?Q!XET[PW8BYOI,;CA(
MUY9S["F^'O%&F^);(W%C)\R\/$WWE_"JY)6YK:"YE>QM4AHW#UJ"\O+>RM)+
MJYD6.&)2SLQZ"IW&5M8UBTT/39;Z\?;&@X'=CV KP+6O$NKZ]JTNK(TT4<#
MH(R=L2]JT]=UC4OB'XECL;%&%LKXAC[ =W:O6-'\(Z;I/AUM),22K,F+AR.9
M"?\ /%=L>7#J\M6SFDY5'IL0>!_%<7B?1U9R!?0@+.GJ?[P]C74UX%=P:A\-
MO&*RQ$O!G*$])HSV/O7MMAK=CJ&D1ZG%.@MF3<68XV^H-95Z5K2CLS2G.^CW
M1H9I:\R\0?%NWM+KR-'MUN@I^>5\[3_NX_G5G2/BWI%WMCU""2SD/4CYE_\
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M^3N!.3@D].U:UO:2:7H<=I:)YLD$(2,$XW$#CK6A10!S%UH]Y:'3KFU@-Y)
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M^5'DQ_\ /-?RI]% AHAB_P">:_E1Y,7_ #S7\J>*!5"&^3'_ ,\U_*E\F/\
MYYK^5.I: &>3'_SS7\J7R8_^>:_E3Z*8AODQ?\\U_*CR8\?ZM?RI]':F(9Y,
M?_/-?RH\F+_GFOY5)2"@!!&B]$4?A13S13$<W>W_ (BTE9KF:"RN[53\H1C&
M_)P.Q]:DAUE[J:W@U'1;RWD,@*-PR!NQR#_2JFM7VM26<EJ^AR.K,")()-W
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M%% !1110 4444 %%%% !1110 4444 %%%% !1BBB@!,"EHHH **** "BBB@
MHHHH *,444 &*3 I:* #%9+??;ZFM:LEOOM]36%?H:TMV%+24M<R-@I1UI*4
M=:H!12]Z04O>@04HI*44Q"TE+24P%I124HH$+VH'6CM0.M4 M%%%,0M+24M-
M"#O2BD[THI@+1110(44"@4"J$+2TE+0 M%%%,0M':BCM3$+2"EI!0 XT4&BF
M(P]?9WN[.V>ZEM+:7=NEB."7&-JY[9Y_*LFQ_M.WEL;A]:DGMI;@PR0R %LY
M('/'I6[K5Y+&\%G;6,=W<3995E.$4+C)/YBLNS@C@UJ.75-*6WN96_=S1S%H
MB_\ N]%-4(ZH#'2EI!2T 07=W!96[7%PQ6)>I"EOT'-9T?BG1I;B*W6\/FS-
MMC5HG4L?09%:WYUS^GYU;Q)=W\AW6]B?L]L.V[ +M^H'X4 7KKQ%I5G=/:SW
M1$R8W(L3MMR,C. :ENM:T^R@AGN;@1QS<H2K$D8ST R/QK)@L]<L[K4KN,V*
M)-,9-CJSLZ@ #Y@0%X'H:9.+G5EM-:TR".836K0F&9]NT-SG.#TZ8H Z%[VW
MC2%VE7;,P6,CG<2,\8^E3UQ]K<P:6;=9A-<+:*UO D";F=P,R,!Z 8&?>NHL
M[J&^M(KFW?=%(,J?\]Z )SW^E,A_U$?^Z*>>_P!*CC;;;QG:3\HZ"@"6BH_-
M_P"F<G_?-'F_],Y/^^: )**C\W_IG)_WS1YO_3.3_OF@"2BH_-_Z9R?]\T>;
M_P!,Y/\ OF@"2BH_-_Z9R?\ ?-'F_P#3.3_OF@"2BH_-_P"F<G_?-'F_],Y/
M^^: )**C\W_IG)_WS1YO_3.3_OF@"2BH_-_Z9R?]\T>;_P!,Y/\ OF@"2BH_
M-_Z9R?\ ?-'F_P#3.3_OF@"2BH_-_P"F<G_?-'F_],Y/^^: )**C\W_IG)_W
MS1YO_3.3_OF@"2BH_-_Z9R?]\T>;_P!,Y/\ OF@"2BH_-_Z9R?\ ?-'F_P#3
M.3_OF@"2BH_-_P"F<G_?-'F_],Y/^^: )**C\W_IG)_WS1YO_3.3_OF@"2BH
M_-_Z9R?]\T>;_P!,Y/\ OF@"2BH_-_Z9R?\ ?-'F_P#3.3_OF@"2BH_-_P"F
M<G_?-'F_],Y/^^: )**C\W_IG)_WS1YO_3.3_OF@"2BH_-_Z9R?]\T>;_P!,
MY/\ OF@"2BH_-_Z9R?\ ?-'F_P#3.3_OF@"2BH_-_P"F<G_?-'F_],Y/^^:
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MP^\IDLQXW$DD_ADFK]% "'O]*9!_J(_]T4\]_I3(/]1'_NB@"2BBB@ HHHH
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M><Y'7MBL)/A!X%C=770\,I!'^E3?_%5V]% #401HJ+PJC 'L.E.HHH ****
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M?^/)_P#?%04 %%%% !1110 5DZ_X:TGQ19)9ZS:FYMT?>J"5TPWK\I&:UJ*
M.5T?X;^$M U*+4=-TGR+N/.QS<2-C/L6(J5OA_X5?7_[<;1X3J&_S/,W-MW?
MWMF=N?PKI:* *FJ:99ZSID^G:A#YUI.NV2/<5W#.<9!!'2H6T+3'T,:+):))
MIPC\H0/EAM],GFM&B@#!\/\ @SP]X5:5]&TR.V>7[[EF=L>@9B2!["MZBB@
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6BB@ HHHH **** -*Q_U'XT444"/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img46421407_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *2!#P# 2(  A$! Q$!_\0
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M0 $ ]12  =!BEHH 3:#V%+@8QBBB@!, =A00#U%+10 8%)M'H*6B@ (!ZB@
M#H*** $P/04N!Z444 ( !T%! /4"EHH ,"DVCT%+10 A /44N .E%% ";1Z"
MEP#UHHH 0 #H*"H/4"EHH ,#&*3:!V%+10 A /44H '0444 )M'H*4@'J***
M $P!T%&T>@I:* # I H'04M% "8!Z@4N *** $VCT%*0#U%%% "  =!1M'H*
M6B@ P#28 ["EHH 0@'J!2XHHH 3:/04$ ]1FEHH 0 #H*-H]!2T4 & >U( !
MT%+10 A4'J!2X&,8HHH 3:!V%! /44M%   !T%)M'H*6B@ (!ZT@ '0"EHH
M0J#U I<444 )M .<"@@'J*6B@ P!VI-H]!2T4 &!2  =!2T4 )M'H*7 Q110
M F .@%! /44M% !@4FT>@I:* $(!ZC-* !T%%% ";1G.!2X!%%% "8 Z"@@'
MJ!2T4 &!C%)M ["EHH 0@'J*7 '2BB@!-H]!2X!'2BB@!  .@HV@]A2T4 &!
MC%(% Z 4M% "$ ]12X Z444 )M'H*" >HI:* $  Z"C:/04M% !@4@ '0"EH
MH 3 STI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KD?B1_R*,G_ %VC_G775R/Q(_Y%&3_KM'_.@#HM
M+_Y!5I_UR7^57*IZ7_R"K3_KDO\ *KE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7(_$C_D49/^NT?\ZZZN1^)'_(HR?]=H_P"=
M '1:7_R"K3_KDO\ *KE4]+_Y!5I_UR7^57* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N1^)'_(HR?]=H_YUUU<C\2/^11D_P"N
MT?\ .@#HM+_Y!5I_UR7^57*IZ7_R"K3_ *Y+_*KE !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 444G- "T4E% "T4F:,GTH 6BDS10
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M% #J*0,K#(.13?-CSC>,T /HI&95&6.*175ONL#0 ZBF&5 <%@#3MP SD8H
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MO]U@?I2&5 <%AF@!]%(64+DGCUI%D1C@,": '44TNJG!8 TZ@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "-]TUXU>>+->CU"ZC34&")*0!@
M<#->R-]T_2O ]0_Y"EY_UV;^==N"BI-W.3%2:2L:7_"7Z_\ ]!%OR%'_  E^
MO_\ 01;\A6+17H^RAV.+VDNYM?\ "7Z__P!!%OR%'_"7Z_\ ]!%OR%8M%'LH
M=@]I+N;7_"7^(/\ H(M^0I#XO\08/_$Q;\A6-2-T-'LH=@]I+N>T>$+VYO\
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M %<C\2/^11D_Z[1_SKKJY'XD?\BC)_UVC_G0!T6E_P#(*M/^N2_RJY5/2_\
MD%6G_7)?Y5<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP:W\1GK4O@04445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?Y5<H ***3\: %HHHS0 449HH **,T9H ***3- "T449H **3-+0 44F:7-
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D) ZTM!&:
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MS\Y^E '<YHKB_'WB76?#>FVT^FV:3EG5978\*":ZVRF:XL8)FQNDC5CCU(H
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M-A?QSF@"CX:L/[#\7W6E:8YDT9H?-92VX12$GY0:A\5Z!96%S:ZKHY%MJ7G
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M3K"BBB@ HHHH **** "BBB@ HHHH :WW3]*\#U#_ )"EY_UV;^=>^-]T_2O
M]0_Y"EY_UV;^=>A@-Y'%C-D5Z***](X0HHHH *1ONFEI&^Z:!GL/@3_D5X/J
M:Z:N9\"?\BO!]3735X-;^(SUJ7P(****S- HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV)MW$^YI]% $'V<[L^8WTI\D?F*!N(J2B@"**+RR3O)^M->W+MN\QA]*GHH
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M+QDD!A@D5YS\-+%--UWQ+:QR2.B79(+MDUZ/+)Y<3/M+;03@=37FW@*YO?\
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MZKIFIV\,HAVO:72#;*,<;<]/PKO?!>H-J?A6RNFL_L;,N#$!P,=Q0!T%%%%
M!1110 4444 %%%% !1110 4444 %<C\2/^11D_Z[1_SKKJY'XD?\BC)_UVC_
M )T =%I?_(*M/^N2_P JN53TO_D%6G_7)?Y5<H **** "BBB@ HHHH ****
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M_(+O/^NW]*\TKTOX8_\ (+O/^NW]*Y<9_"9T8;^(=W1117CGIA1110 4444
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M?10!XIXOS_PE-[GKN_I6)6WXP_Y&J]_WOZ5B5[U+^'$\>I\;"BBBM" HHHH
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M^Z:!GL/@3_D5X/J:Z:N9\"?\BO!]3735X-;^(SUJ7P(****S- HHHH ****
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M^+O^19O/]VO%%^Z*]3 _ SS\7\2%HHHKN.0**** "G1_\?$/_71?YBFTZ/\
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M]:E\""BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD?B1_P BC)_UVC_G
M775R/Q(_Y%&3_KM'_.@#HM+_ .05:?\ 7)?Y5<JGI?\ R"K3_KDO\JN4 %%%
M% !1110 4444 %%%% $4]M!=1[)X4E3^ZZ@BDM[.VM(S';01PH3DK&H4'\JE
M+ =3BDWK_>'YT 5X],L8I_.CLX$ESG>L8!S]:SH/#T::U=:A/(LWGC;Y;1C
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M7Y*G%>;#6=4_Y_IO^^J]%^)__((M_P#?KRVN.LWSGT.7PBZ*;1=_MC5/^?\
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M^=>A@-Y'%C-D5Z***](X0HHHH *1ONFEI&^Z:!GL'@8D>%H"!DY/%="DLC.
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MMKXCLY)85:*:%S'-"_WD;WJ%O%UA_P )<OAQ-S790NQ'1: ,3XG_ /((M_\
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MB6U,,&A65E/ %"LUQ*5*]N@'-=%BEQ0!D:#I3Z79%9F#W$IWRL!QDUKTE+0
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M110 5VOPQ_Y#EU_US%<57:_#'_D.77_7,5I3^-'+C?X$CUFBBBNX^7"BBB@
MHHHH P_%W_(LWG^[7BB_=%>U^+O^19O/]VO%%^Z*]3 _ SS\7\2%HHHKN.0*
M*** "E0@31L>BNI/X&DH/2E+8J*U1ZS%X^T-(44S-D* >*=_PL#0O^>S?E7C
MA49Z"DP/05\I*O*[/MXY92<4]3V3_A8.A?\ /9ORH_X6#H7_ #V;\J\;P/04
M8'H*GV\BO[+H^9[)_P +!T+_ )[-^5'_  L'0O\ GLWY5XW@>@HP/04>WD']
MET?,]D'Q T(D 3-DD ?+74QN)(U<=&&17SFH'FQ<#AU_G7T1:?\ 'G#_ +@K
M:E4<[W//QV%A0MR]2:B@45L>>%%%% !1110!XKXP_P"1JO?]X?RK#K<\8?\
M(U7O^\/Y5AU[U+^'$\>I\;"BBBM" HHHH *]+^&/_(+O/^NW]*\TKTOX8_\
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M^N2_RJY0 44AKF/$7C&#P_>1V\D+.6&<BJA"4W:),I**NSJ**X'_ (6=:_\
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M44 !KC?B3_R+:?\ 75:[(UQOQ)_Y%M/^NJUMA_XJ,JW\-GE=%%%>X>4%%%%
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M;1TKYZ7_ %D?^^/YU]#VH!M(<C/R"NG#]3QLV^R/CF60G;GBD>X1&P<Y^E2
M = !054]0*Z3QA"X";^U,2XC=L#.?I4F.,8XH"@=% H 9).D9PV?P%.1Q(NX
M9Q[TI4'J :, <#B@#Q7Q>0?%5Z1_>_I6)6WXP_Y&J]_WOZ5B5[U+^'$\>I\;
M"BBBM" HHHH *]*^&1 TJ])_YZC^5>:UV?@OQ+IVAV%Q#>NRM))N&!VQ7)C6
ME29U8.#G5M%'IBW",VT9S]*ISZ;9'4TU&5&-PJ[5.>!^%8@^(.@CGS&S_NTI
M^(6A'K(Q_P" UXO/'N>Q]6K?RLZE)%D&5S@4S[2@;;SGZ5S(^(6A#I(X_P"
MTG_"P=!_OM_WS1SQ[A]6K?RLZMY B[CTIL<RRDA<\>M<O_PL+0CP9'Q_NT@^
M(.@@\2./HM'/'N'U:M_*SJ'G2-BK9S]*>)!LW]JS-&UVQUZ*26S)=8VVL2.]
M:N.,52:>QC*+B[-$:7".VT9S]*6298R-V>?2G!5'112D ]0#3$-259%)&<4S
M[3'NV\Y^E2@ = !1M7^Z/RH ;)(J+DYQ7&_$659/#:[<_P"N%=H0#U%<;\2
M!X<3 Q^^6ML/_%1E6_AL\LHHHKW#R0HHHH **** -'P^<>(;$G_GJ*])\9VN
MFW.F2W6K27#64"',,)()/KQ7F_A[_D8K'_KJ*]0\2>);/1&2WN=.N;L3 _ZF
M+>/QKR\=\2/0PGPLROAK=(_A<2QW;SVQ<^4K\M&OH:Z/6K^2WMA!:D&[G!$8
MSTX^]^%<QX4M6\-Z/J6J3VKI;W$IFCMD'S*OTJ[J'AVQ\7&WUB.[NK=Q&0@1
MMI&>H(KA.LR/AHMW=^&-2MI[QVN3=2*92<XY[54U+0E\*^+M)N=&FG\VY;;=
M1LY8..YQVIOP[TN7PIH6KZC=17CND\FV$C)<9X('O5C0O%PU/55N;O1]0^V3
M-MA62+"Q+]: %\:WEJVL!-=TZ[DT>/ 6Y@. A/7-=QHYL(=,MH[!F:VVCRR3
MG(^M<_XB\36[&?0FTJ[N)IT* ^5F/)'<UO>'],_LK1+:T<#<B\CT]J -&298
ML;L_A2QRK(,KG\:<0#V!H  Z 4 1&YC#%3G/TJ1I%5=QSBEVKZ#\J, ]OSH
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MB@*!T H 8\R(P4YR?:I*3 /4"EH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** (YH8YXFBE17C8<JPR#1%#'!$L<2*B*.% P!4E%
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M>\?_ 'U1]NM?^>\?_?5%T')+L38&<X&:6H/MML?^6\?_ 'T*/MMM_P _$?\
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M,XO&B[#'R@_C7I]<YX:\,0Z,TU[,D+:C<_ZZ2- H [*,>E='0 4444 %%%%
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M_P#Z["O017GWPK_Y!M__ -=A7H(KNI? CYC'?QY!1116AR!1110 &N-^)/\
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M8^($D:R+$1G#;ABFIQ>B9,\/5@N:4;&Q10**HQ"BBB@ HHHH **** "BBB@
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M7^56JJ:;_P @RU_ZYK_*K=>@MCY"?Q,****9(444&@!K?=/TKP/4/^0I>?\
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M'_GT@_[]BCZ]/L'U2/<^=/[7@_YX7'_?%']KP?\ /"X_[XKZ+_LVQ_Y](/\
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MC_LK3_\ GQM_^_8H_LK3_P#GQM_^_0K8\\YS_A9'A_\ Y[2?]\4?\+(\/_\
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M_P ^D'_?L4?7I]@^J1[GSI_:\'_/"X_[XIDFK0DC$%Q_WQ7T=_9MC_SZ0?\
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MMC_SZ0?]^Q1_9UE_SZ0?]^Q1]>GV%]4CW/G-M7@*G]Q<?]\5%_:D7_/O<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ IDLB0QM)(P5%&68] *?4<T23Q/%*H9&&"I[T <*_B30/$NJ@2:C;_8
M;*3B,M_K9!56VO;7P]XWUJ]U&406]_ KP22=#@=/K75Q^#O#T4BR1Z7;JRMN
M!"=_6KU_HVG:JB)?6<4RH?EWJ#B@#CO""K:^&-5U.X;R;>Y,CJ9...>:?\*[
MVTNO#\ZV]PDK+<,2%/2NSEL+6>S^QR0(UOC;Y>T8QZ5!INB:;HX<:?9Q6X?[
MWEKC- '+^+T\-ZC93V_F6YU1#F+RSB4/_.NHT%+B/0K)+LDSK"H<GKG%1CPY
MI U W_V&'[43GS-HSFM6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #
M7,^)_%>GZ-Y>GO>0QWUS\J*Q^[[FNE-95_X:T?4[G[1>V$,TV,;W7)% '"^(
M;&QF\+0#2)5NEM;A9[B2/D,<\FK5S?VOB;QMHRZ;*)TM$\V5TY"\8P?>NXL]
M(L-/M6M;6UCBA;[R!1@TFGZ-IVE>9]AM(H"YRQ1<9H X;7-4T]/BQI,;WD2R
M)$592>0?2I?B/#&NI^'[^\C+Z;;W&9\= #C!-=;-X9T:XOOMTNGP/=9SYI7Y
MOSJ_<VEO>6[6]Q"DL+#!5AD4 >?:!%97'Q'NKS0M@L3"!,T0PC-C^=>CU4T_
M2['2H/)L;:.",G)"#%7* "BBB@ HHHH **** "BBB@ HHHH **** "BB@]*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#7>Z/X&T#0S=M9V*;[L8F9_F+?B:IV/PWT'3KT7-NMR,$E8C.Q12?1<X% '
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img46421407_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $@ MP# 2(  A$! Q$!_\0
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MVG_?@?XT?\+B\6?\];3_ +\#_&N!HH]C3_E#VU3N=]_PN+Q9_P ];3_OP/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4&B@T >"_&[_ )&ZR_Z\E_\ 0WKS.O3/C=_R-UE_UY+_ .AO7F=>O0_AQ/*K
M_P 1A1116IB%%%% !1110 4444 %%%% !1110 4444 %%%% !7LOPH.WP)K[
M9Q@,<^GR-7C5/2:6-2J2R(IZJKD _45E4I\ZY32G/D=SWGX1ZC%J'A.2VG =
M]/N692PSM4YP1_X]4?PWU-]6\3>++DMNWS#;ZX&Y1^BUX4DTL0(CFD0'J$<C
M/Y4)-+$28Y9$)ZE'(S]<5D\-OKN:K$;:;'LGPH!_X2[Q/Q_RT;_T,UA?#[Q9
M:^'?%VI6>H,([.]E(,IZ(X/!;V/3\:\X2>:-BT<TB%NI5R"?KBF'DDGG/K5>
MP3;OU)5:UK=#UW4?@U-J&I/>:3J]J=/G?S 7R6&3SM(!!'XUC>*?"_A/0M3T
MFPM-1DGN7E5;M=X90.Y8Y^4GTK@%NKE%"K<SJHZ 2L /UIJ,IF#3;F7(+X/)
M'?FA4YK>0.I#I$^@)+>_O/%MQX7FT:(^%C:81EAPJG;P0WKGC%<C9W#^ ?A_
M'J5C#$=0NK]H999$#?(I)P,^PJW9^+M T2!;ZT\4ZC>0Q6^VWT>X7+(Y&!N;
MOC]/>L+1]:T'7O!XT+Q#J1TZ2WNC<1SF,N'!/(X[X)%<ZC)+R-W*/0I_%'38
M++Q-#<VT*0I>6ZS%4&!O/4_RKJ?A5*+CP3X@L(\><"SX]BN!_P"@FN(\?>(;
M7Q%XB\ZRW&TMX5@B+<;@/XL>]/\ A[XG3PSXD62Z?;87*^5<YR0!V;\.?SK:
M4).DC*,DJIT/P1!_X26^XZ6P_F:E\$#_ (O3J/'_ "VN/ZUP6O/;0>(K]M)O
M"]H\S-%)$64%2<X['C./PK-661'+K+(KGJP8@_G5.ES-RONB?:62C;8].M@?
M^&@F_P"OM_\ T6:T=4UN#P_\</M5V_EV\D(A=^RA@.3[<5Y!YLOF>9YC^9UW
M[SN_/K6CH=_96VNV]SK-J=0L\XFCD))(]>3U%)T;*^^EAJM=]M;GJOB7X9PZ
MCXDE\02:S;0:1,RS3%C@CI]T]"#ZY[UH?$73?[4\3>%+%%RCS_,!_<')_2LF
M?_A5-[-#<G5)K9$ _P!$1Y!'QV*X/\ZY;XC^-;?Q/JML-+\V.UM%*K(?E+L>
MXP>!6$(SE)(VE*,8M]RO\4]1%]XWO(T),=H@MU'H5ZUZGXM\'7OC#PEHMM97
M%O"\,:.QGW8/R#T!KY[9BY+,2S'J2<YJ47=T  +JX '0"5O\:Z)4796=K&,:
MJN[J]ST"]^#6N6%E/=2:CI[)"A<A=^2 .GW:UO@V_P!DTK7[^3B"%?F/IA<G
M]*\I-W=$8:ZN".X,K<_K7<+XET_1OA<-'TZZ634[]R;L(IS&A['(YXXXJ9PG
MR\K=[CA.'-S+0X29_,GD?^\Y/ZTRBBNDYV%%%%,04444 %%%% !1110 4444
M %%%% !1110 4444 6=-_P"0I9_]=T_]"%?7M?(6F_\ (4L_^NZ?^A"OKVN#
M&;H[\'LPHHHKB.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ H-%(30!X-\;O\ D;K+_KR7_P!#:O,Z
M^E/%?P[TWQ?J<5]>7=U#)'$(@L6W& 2<\CWK"_X4AH7_ $$=0_-/_B:[Z6(A
M&"3.&KAYRFVCPBBO=_\ A1^A?]!'4/S3_P")H_X4?H7_ $$=0_-/_B:T^M4N
MYG]5J'A%%>[_ /"C]"_Z".H?FG_Q-'_"C]"_Z".H?FG_ ,31]:I=P^JU#PBB
MO=_^%'Z%_P!!'4/S3_XFC_A1^A?]!'4/S3_XFCZU2[A]5J'A%%>[_P#"C]"_
MZ".H?FG_ ,31_P */T+_ *".H?FG_P 31]:I=P^JU#PBBO=_^%'Z%_T$=0_-
M/_B:/^%'Z%_T$=0_-/\ XFCZU2[A]5J'A%%>[_\ "C]"_P"@CJ'YI_\ $T?\
M*/T+_H(ZA^:?_$T?6J7</JM0\(HKW?\ X4?H7_01U#\T_P#B:/\ A1^A?]!'
M4/S3_P")H^M4NX?5:AX117N__"C]"_Z".H?FG_Q-'_"D-"_Z".H?FG_Q-'UJ
MEW#ZK4/"**]W_P"%'Z%_T$=0_-/_ (FC_A2&A?\ 01U#\T_^)H^M4@^JU#PB
MBO=O^%(:%_T$=0_-/_B:7_A1^A?]!'4/S3_XFCZU2#ZK4/"**]W_ .%'Z%_T
M$=0_-/\ XFC_ (4?H7_01U#\T_\ B:/K5+N'U6H>$45[O_PH_0O^@CJ'YI_\
M31_PH_0O^@CJ'YI_\31]:I!]5J'A%%>[_P#"C]"_Z".H?FG_ ,31_P */T+_
M *".H?FG_P 31]:I!]5J'A%%>[_\*/T+_H(ZA^:?_$T?\*/T+_H(ZA^:?_$T
M?6J7</JM0\(HKW?_ (4?H7_01U#\T_\ B:/^%'Z%_P!!'4/S3_XFCZU3[A]5
MJ'A%+7NW_"C]"_Z".H?FG_Q-'_"C]"_Z".H?FG_Q-'UJGW#ZK4/"**]W_P"%
M'Z%_T$=0_-/_ (FC_A1^A?\ 01U#\T_^)H^M4NX?5:AX117N_P#PH_0O^@CJ
M'YI_\31_PI#0O^@CJ'YI_P#$T?6J7</JM0\(HKW?_A2&A?\ 01U#\T_^)I/^
M%(:%_P!!'4/S3_XFCZU3[A]5J'A-%>[_ /"D-"_Z".H?FG_Q-'_"D-"_Z"-_
M^:?_ !-'UJGW#ZK4/"**]W_X4?H7_01U#\T_^)H_X4?H7_01U#\T_P#B:/K5
M+N'U6H>$45[O_P */T+_ *".H?FG_P 31_PH_0O^@CJ'YI_\31]:I=P^JU#P
MBBO=_P#A1^A?]!'4/S3_ .)H_P"%'Z%_T$=0_-/_ (FCZU2[A]5J'A%%>[_\
M*/T+_H(ZA^:?_$T?\*/T+_H(ZA^:?_$T?6J7</JM0\(HKW?_ (4?H7_01U#\
MT_\ B:/^%'Z%_P!!'4/S3_XFCZU2[A]5J'A%%>[_ /"C]"_Z".H?FG_Q-'_"
MC]"_Z".H?FG_ ,31]:I=P^JU#PBBO=_^%'Z%_P!!'4/S3_XFC_A1^A?]!'4/
MS3_XFCZU2[A]5J'A%%>[_P#"C]"_Z".H?FG_ ,31_P */T+_ *".H?FG_P 3
M1]:I=P^JU#Q+3O\ D*6?_7=/_0A7UW7FD/P5T2WGBF74;\M&X< E.QSZ5Z5N
M]JY,35C-KE.K#TI03N.HHHKG.@**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2T&@#SOQY\1KGP=K,
M%C#I\5R)(!*6>0KC+$8X^E<M_P +SOO^@);_ /?YO\*I?&[_ )&ZR_Z\E_\
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M$*^O:Y,33C!KE.O#5)33N%%%%<ITA1110 4444 %%%% !1110 4444 %%%%
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MR"IKJZN+VY>XNIGFFD.7D<Y+&H:NG#DC8BI/GE<****T(L>Z? __ )%S4O\
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MKM&'LT1WM9@P/S-P<9%<U12=5<O8Z8.*I/F-7XA"+P]\,M-\.33K)>DJ<+Z
MDDX].<?A5CQ;J5]I?PET";3[V>UE,, +P2%#C8.,BO'+[4+S4[EKF_N9;F9N
MKRMDU8NM?U>^T^+3[K4;B:SA $<#ME5 X&/I0J#T]0=;5^AZI\'=<U;5=5U%
M-1U.[NT2$%%GF+A3D<C->2ZI_P A>]_Z[O\ ^A&I-,UK5-%D>33+^>T>0;7:
M)L%AZ52D=I9&D=BSL2S,>I)[UI"GRS<B)5.:"B=?\.=&T+7]<ET[6O,W21YM
MPLI3+#J,COTKO/!/P_U+POXSO-1NVBBTR!'$4AE!WJ<XSW&!US7BD<CQ2+)&
M[(Z'*LIP0?:M:[\5^(+^T-I=ZS>36[#!C=^#4U*4I/1Z,=.I&*U6IKZCIM]X
MY\<:NVA0+<?O&E&9%3Y,XSDD=R*M_#[PUHNM:W?:1KP=;M1B%5F*@L,[AP>3
MT/YUR6F:QJ6C3O/IE[-:2NNUGB."PSG!J 7=P+O[6)W%QNW^:#\V[US5.$K<
MJ>A*G&]VCVGP'X&U/PCXDU'4M1:**PBC98W\P'>N<Y/I@#O7DGB._CU/Q+J-
M[#S%-<.R'U7)P:??>*O$&IVAM;[6+NX@/6-WX-9%*G3DFY2>K'4J1:2BM@HH
MHK8Q+.F_\A2S_P"NZ?\ H0KZ]KY#TW_D*V?_ %W3_P!"%?7E<.-WB=^#V844
M49KB.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ I#2TA&: /!OC=_R-UE_UY+_ .AO7F=?0GCKX;S^
M,-9@OH]2CMEC@$6QHRQ)!)SG/O7+_P#"B[O_ *#D/_?@_P"->A2KPC!)LX*M
M"<IMH\CHKUS_ (47=_\ 0<A_[\'_ !H_X47=_P#0<A_[\'_&M/K%+N9?5JG8
M\BVC.<#-+7KG_"B[O_H.0_\ ?@_XT?\ "B[K_H.0_P#?@_XT_K-/N'U>IV/(
MZ*]<_P"%%W?_ $'(?^_!_P :/^%%W?\ T'(?^_!_QI?6*7</J]3L>1T5ZY_P
MHN[_ .@Y#_WX/^-'_"B[O_H.0_\ ?@_XT?6*7</JU3L>1T5ZY_PHN[_Z#D/_
M 'X/^-'_  HN[_Z#D/\ WX/^-'UBEW#ZM4['D=%>N?\ "B[O_H.0_P#?@_XT
M?\*+N_\ H.0_]^#_ (T?6*7</JU3L>1T5ZY_PHN[_P"@Y#_WX/\ C1_PHN[_
M .@Y#_WX/^-'UBEW#ZM4['D=%>N?\*+N_P#H.0_]^#_C1_PHN[_Z#D/_ 'X/
M^-'UFEW#ZM4[&Q\#O^1<U+_K['_H(KU$URG@+P?+X-TRZM);Q+DS3>8&5"N.
M ,=?:NL->?6DI3;1Z%*+C!)GG/QH_P"1'C_Z_(__ $%J^?Z^H/''A:3Q=H*Z
M;'=+;%9UEWLF[@ C'ZUYW_PHN[_Z#D/_ 'X/^-=.'JPA"TF<U>C.<KI'D=%>
MN?\ "B[O_H.0_P#?@_XT?\*+N_\ H.0_]^#_ (UO]8I]S#ZM4['D1 /49I:]
M<_X47=_]!R'_ +\'_&C_ (47=_\ 0<A_[\'_ !I_6:7<?U>IV/(Z*]<_X47=
M_P#0<A_[\'_&C_A1=W_T'(?^_!_QI?6*7<7U:IV/(Z*]<_X47=_]!R'_ +\'
M_&C_ (47=_\ 0<A_[\'_ !H^L4NX?5JG8\CHKUS_ (47=_\ 0<A_[\'_ !H_
MX47=_P#0<A_[\'_&CZQ2[A]6J=CR.BO7/^%%W?\ T'(?^_!_QH_X47=_]!R'
M_OP?\:/K%+N'U:IV/(Z*]<_X47=_]!R'_OP?\:/^%%W?_0<A_P"_!_QH^L4N
MX?5JG8\CHKUS_A1=W_T'(?\ OP?\:/\ A1=W_P!!R'_OP?\ &CZQ2[A]6J=C
M!^#O_(^Q_P#7M)_(5]#CK7F_@OX7W'A3Q"NJ2:G'<*(GC\M8BIY[YS7I &*X
M<1-3G>)W4(.$+,H:]_R+VI_]>DO_ * :^2:^O=0M3>Z;=6H8(9X7C#$9QN!&
M?UKQW_A15W_T'(?^_!_QK7#58P3YC/$TY3MRGDE%>N?\*+N_^@Y#_P!^#_C1
M_P *+N_^@Y#_ -^#_C73]8I=SE^K5.QY'VP:0  < #Z5Z[_PHN[_ .@Y#_WX
M/^-'_"B[O_H.0_\ ?@_XT_K%+N'U>IV/(Z*]<_X47=_]!R'_ +\'_&C_ (47
M=_\ 0<A_[\'_ !I?6:?</JU3L>1T5ZY_PHN[_P"@Y#_WX/\ C1_PHN[_ .@Y
M#_WX/^-'UBEW#ZM4['D=%>N?\*+N_P#H.0_]^#_C1_PHN[_Z#D/_ 'X/^-'U
MBEW#ZM4['D=%>N?\*+N_^@Y#_P!^#_C1_P *+N_^@Y#_ -^#_C1]8I=P^K5.
MQY'17KG_  HN[_Z#D/\ WX/^-'_"B[O_ *#D/_?@_P"-'UBEW#ZM4['D=%>N
M?\*+N_\ H.0_]^#_ (T?\*+N_P#H.0_]^#_C1]8I=P^K5.QY9IW_ "%+/_KN
MG_H0KZ\)YZ&O&[;X(7=O=0S?VW"?+=7QY!['/K7LF,UR8FI&;7*=>'IR@GS"
MUCW%UKB7$BP:= \0;",TV"1ZUL45S'28?VOQ#_T"[?\ [_\ _P!>C[7XA_Z!
M=O\ ]_\ _P"O6Y10!A_:_$/_ $"[?_O_ /\ UZ/M?B'_ *!=O_W_ /\ Z];E
M% &']K\0_P#0+M_^_P#_ /7H^U^(?^@7;_\ ?_\ ^O6Y10!A_:_$/_0+M_\
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M /UZ/M?B'_H%V_\ W_\ _KUN44 8?VOQ#_T"[?\ [_\ _P!>C[7XA_Z!=O\
M]_\ _P"O6Y10!A_:_$/_ $"[?_O_ /\ UZ/M?B'_ *!=M_W_ !6Y10!!9O<R
M6RM=Q+%-SE5;('XU/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% "9->-_$'XU7WA7Q9/HVEZ7;7J6T2M.\C-E6/)'';!'YUZSJE_
M%I>DW=_,0([>)I#GO@9KYV^'-IHWB6T\8:KK^IV,$VJ;X(5N;E$D7/S$@$YQ
MRHS[4 ?0'AO6H_$/AO3]6BV@74"R,JG(5B/F7\#D?A6H37BO[/NN[M)U+PU/
M,K3V,Q>/:<@H3S@]_FS7+:CINJZ]\>=8T;3=5ETX7>])YD)R(P,D >^,4 ?2
M?-&3Z5\N0:/XE\'_ !,D\$:'X@F1=254:=ACY2"Q;&>& 4\^_O6C;:7J/PO^
M,^DZ;!J]Q>6^H!&F9QM\U6+ @C)[CK0!])9]J,FOGCXQ+J<WQ@T.VT>Z:VOI
MH8XX) Y78Y<@'-5/&7P^USX9V47BS2_$US<7"2J+AF!0Y8_4[@3P<T >T^/O
M$&N^'-!BO/#^BOJUVTXC:!(W<JA#$MA>>H _&M_3;BXNM+M+BZ@\BXEB5Y(B
M"-C$<CGGBO%_B_K;:]\%M"UA-T9N[F*0@'')1\U;^(OB[4/#OPP\.6>ESO!>
MZG%'&)U."JA5S@]B=PYH ]GR<5R/C_Q'X@\.:5:W'A[0GUBXEFV21)&[[%P3
MNPG/7 KREO@OXITFTT_6= \02RZP[(\REM@3=R2&)^8#OQ6I\>VU"+X?>'_[
M0D07_P!I47#6Y(0OY9W8Z<9H [3XB^/+_P $^#K'6(;&"6YGF2*2&8L N49C
MTYX(I/&OCZ]\+_#NQ\26]E;S7%PT(:*1CM&]23C'/:N1^.63\)=%SR?M,/\
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M+^.:5V=56-5SR03R,D<#/2@"G:^(_BM<)#+_ ,(?I BE"MG[: 0I[XW>E>F
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M %%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444F: %K'G\.6EQ<23/-=!G8L0LN ,^@K8HH P_P#A%K+_ )[WG_?XT?\
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MY_W^-'_"+67_ #WO/^_QK<HH P_^$6LO^>]Y_P!_C1_PBUE_SWO/^_QK<HH
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MCH@&3=R,59!W8]0<]E_6N>U@C_AJ;3N>?(7_ -$M0!UGBU?'.L>+4T[3;IM
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M>,E&&.#C/0FG>*O$GQ1T>QLO&5W?P6NG7,BB/3X6)" @E0X([@=<UN_M%_\
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M,L89"!R,J>.U%I96NGVR6UE;0VT"?=BAC"*OT XJ>B@ HHHH **** "BBB@
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M+_0='U0QG4-)L;PQ#;']HMTDV#T&X''2M"B@#$_X0SPMG/\ PC6CY_Z\8O\
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M4 ;=%8F[Q+_SST[\VHW>)?\ GGIWYM0!MT5B;O$O_//3OS:C=XE_YYZ=^;4
M;=%8F[Q+_P \]._-J-WB7_GGIWYM0!MT5B;O$O\ SST[\VHW>)?^>>G?FU &
MW16)N\2_\\]._-J-WB7_ )YZ=^;4 ;=%8F[Q+_SST[\VHW>)?^>>G?FU &W1
M6)N\2_\ //3OS:C=XE_YYZ=^;4 ;=&:QX&U_ST\^.Q\K/S;"V<>U:_YT ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img46421407_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_18.jpg
M_]C_X  02D9)1@ ! @$ P #   #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\O/T]?;W^/GZ_\  $0@#8P=M P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MAFCN8UFA99(Y%#(Z$,K*1D,K#(((Y!!P1R* )* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@CD$'H0?2@!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M1EUY Y'6@#Z2\&?#;2O!6BOH5JIECN5<74K\27#2)L<MC[J[/E1%X1?5BS,
M>#Z-\#/&?@>]G'A+6K>UL;O =ID8S% 6V;H3;S0F1 Q E1XF.21L!VT 7?#'
MP&UKPEXOM?$D%[;W\$3,]R]R\R74KSPR173A5AE0DF5WCWS9;@.X.6H Z3]I
MBUL+GPD9;J1$N;>YB>T!/S22%O+EC4#DXB=W;L/+!/(% &?^S!X5_LGP_+K4
MJXFU:8["1R+>W+1IUY^:4S-QPR[#SQ0!],4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M"1NS0!\^V'PG^)/A^U_L31]?M8]*7(3(D2=%8DGRS]EEDBY)(6.Z4 DD$=:
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!X9KG[/?AGQ%K$VN7[7KRW4GFRP+-&D!8@ X"PB8 XR<39R
M3S0![5964&FP1VEHBPP0(L<4:#:J(@"JJ@=   !0!9H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * .*\3>(=8T>=(M+TI]4C:/<TJW*0A&W,-FUHW)X ;.1UQCB@#A;
M7XJ:U>WDVFP:"[W=H 9HA?)E V,9)MP#G(Z$]: /3O#6JW^KVS3:G9-I<RRE
M%A:99BR!4(DW*B  LS+MQD;,YYX .AH * "@ H P?$_B"'PMIL^JW*O)';!2
M43&YB[K&@&2  7=<GL,G!(P0#4L;G[;;Q7.-OG1I)MSG&]0V,X&<9QG SZ4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M<@!8TV[0 <G.<^U '84 % !0 4 5;Z\33[>6[ESY=O&\K[1D[8U+-@9&3@'
MR.>] &7X8UY/$VFPZI$C0I<ARJ,06 61T&2.,D+D@9 SC)QD@&]0 4 % !0
M4 % '+^+O%,/A"Q%]/&\V^5(41"!EY,XW,?NKA220&/HIH ZB@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M5MOS8( .<UF\7PM:G5=&\3'4KJW*M):7-[!<QW"E@'6*)6S&<$G"[FP/E92
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M6TCPS1PY22-F1U.Y>592&4^X(H XWPKIM[!IEOXKU?4[^5DM#=26OFXM6@6
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M-I8^==R^=,=QSAGVKD+T48X'% &M0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >(^#O^1YUW_KG%_*
M.@"[\;?^0)!_V$+?_P!!EH ZWXA>'I/$^A76GV^#.RJ\0)QF2)UD"YX'SA2@
M+< MDXQD 'E.E>*/!MG91P:UI<-MJD"+'+;-IB-+)*HVLT9\G;\Y!;]XR$9Q
MSC) -'7IM1;P=+=Z)IO]A2SRJTD%LJK,;;H9<111,K-\H(V[Q$"<[30!R3+X
M*FL)(=!LKC5-6EA=55X[EY(Y64CS9C)^X3RSEV,>1\IQUS0!KP(^J?"PQ6RF
M21$(*+EB/*U 2-P!G/EKOQCH<].: &^-?$5CXA\(6;Z?)YGV:\LH)05="DJP
MMN4AU7.,_>7<IYPQP< 'HOQB_P"13OO^W;_TK@H C\8_\B/-_P!@^'_T&*@#
MA_$&A2SZ)X<UV&U&HQZ9:VWVJUV"0RV\EO 6(C8,K;-A_A)&\.1M0D $]QXL
M\%S1K'H^CP:E?R$*MFNG)$ZDL 1([6[(N!DY3S!D8. =P -/QA"+?7/"L:PI
M:!9;@>1'MV1';:YC78%4JARH*J <9 % %WXY?\BTW_7S!_-J (/BE<+I6JZ#
MJ]R&6SLKF?SY%5F$8<0;20H)YV-QU.#@$T >NZ??P:I;1WEHWF07"+)&^"-R
M,,@X8!AQU# $'@@'B@#R;Q/&DOCS1$D4.IMKO(8 @_N;@\@\=>: /7(K." [
MHHT1NF515./J * //OBKX<N?$FB&*R02W%I-'=1Q$9\PQAU9,'AB4D8A3G<0
M%QDB@#A%\8>"!:YDTF!=2"X-A_9B>;YNWE0WD;-N[@,6W8Y*9^6@!?B$@7PE
M9N+&/1S+?P.UG&$ C+"7[P2.)=[  L-@89PWS @ 'I'Q._Y%G4/^N'_LZT >
M>ZSIEZ-$\-:_I\373Z-;VTDD"#+O#);V_F%0 22HB XY 8M@X- %OQ-\2K+Q
M+IDVD>'TN+S4;^-K?R1!(IA64%)#,SJ$&$+#*LR@D$L "0 5-9\-WO@R/0]9
MMXWO/[#B,%Y'$-S^7*A$DD8[A3)*/8%&.%#, #$^*7Q#L/$VB-9Z.);E2\3W
M$IBDCCMPK#",SJN96D*#"[EQN(8T ?3% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M#N7A@5=58$?3!Z@D<T ;% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MC/\ H)K_ /@ZI_\ )!]4P_\ SYI?^"X?Y!_;-_\ \_,__?V3_P"*H_M#&?\
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M!-?_ ,'5/_D@^J8?_GS2_P#!</\ (/[9O_\ GYG_ ._LG_Q5']H8S_H)K_\
M@ZI_\D'U3#_\^:7_ (+A_D']LW__ #\S_P#?V3_XJC^T,9_T$U__  =4_P#D
M@^J8?_GS2_\ !</\@_MF_P#^?F?_ +^R?_%4?VAC/^@FO_X.J?\ R0?5,/\
M\^:7_@N'^0?VS?\ _/S/_P!_9/\ XJC^T,9_T$U__!U3_P"2#ZIA_P#GS2_\
M%P_R#^V;_P#Y^9_^_LG_ ,51_:&,_P"@FO\ ^#JG_P D'U3#_P#/FE_X+A_D
M']LW_P#S\S_]_9/_ (JC^T,9_P!!-?\ \'5/_D@^J8?_ )\TO_!</\@_MF__
M .?F?_O[)_\ %4?VAC/^@FO_ .#JG_R0?5,/_P ^:7_@N'^0?VS?_P#/S/\
M]_9/_BJ/[0QG_037_P#!U3_Y(/JF'_Y\TO\ P7#_ "#^V;__ )^9_P#O[)_\
M51_:&,_Z":__ (.J?_)!]4P__/FE_P""X?Y!_;-__P _,_\ W]D_^*H_M#&?
M]!-?_P '5/\ Y(/JF'_Y\TO_  7#_(/[9O\ _GYG_P"_LG_Q5']H8S_H)K_^
M#JG_ ,D'U3#_ //FE_X+A_D']LW_ /S\S_\ ?V3_ .*H_M#&?]!-?_P=4_\
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MF_\ ^?F?_O[)_P#%4?VAC/\ H)K_ /@ZI_\ )!]4P_\ SYI?^"X?Y!_;-_\
M\_,__?V3_P"*H_M#&?\ 037_ /!U3_Y(/JF'_P"?-+_P7#_(/[9O_P#GYG_[
M^R?_ !5']H8S_H)K_P#@ZI_\D'U3#_\ /FE_X+A_D']LW_\ S\S_ /?V3_XJ
MC^T,9_T$U_\ P=4_^2#ZIA_^?-+_ ,%P_P @_MF__P"?F?\ [^R?_%4?VAC/
M^@FO_P"#JG_R0?5,/_SYI?\ @N'^0?VS?_\ /S/_ -_9/_BJ/[0QG_037_\
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MC/\ H)K_ /@ZI_\ )!]4P_\ SYI?^"X?Y!_;-_\ \_,__?V3_P"*H_M#&?\
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M+'_GE_X_)_\ %4<D>WY@']@6/_/+_P ?D_\ BJ.2/;\P#^P+'_GE_P"/R?\
MQ5')'M^8!_8%C_SR_P#'Y/\ XJCDCV_, _L"Q_YY?^/R?_%4<D>WY@']@6/_
M #R_\?D_^*HY(]OS /[ L?\ GE_X_)_\51R1[?F ?V!8_P#/+_Q^3_XJCDCV
M_, _L"Q_YY?^/R?_ !5')'M^8!_8%C_SR_\ 'Y/_ (JCDCV_, _L"Q_YY?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#SCX@?\ +M_VV_\ :5?FG%7_ #"_]QO_ '$?9Y%_R_\ ^X?_ +D/.*_-
M#[,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /?=&_X\+;_KA%_Z+6OZ#R__ '/#?]>*/_IN)^38
MO_>*W_7VI_Z6S1KTSB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZ #_ (79X._Z"'_DK>?_ "/0 ?\ "[/!W_00_P#)6\_^1Z #_A=G@[_H(?\
MDK>?_(] !_PNSP=_T$/_ "5O/_D>@ _X79X._P"@A_Y*WG_R/0 ?\+L\'?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H ]]T;_CPMO^N$7_ *+6OZ#R_P#W/#?]>*/_ *;B?DV+_P!XK?\
M7VI_Z6S1KTSB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * ,?0/^/&+_ ('_ .C&K.'PK^NHS8K01\$?&2,2^-;U#T9K
M13CK@VEL.*8')?V#!_>D_-?_ (FF(/[!@_O2?FO_ ,30 ?V#!_>D_-?_ (F@
M _L&#^])^:__ !- !_8,']Z3\U_^)H /[!@_O2?FO_Q- !_8,']Z3\U_^)H
M/[!@_O2?FO\ \30 ?V#!_>D_-?\ XF@ _L&#^])^:_\ Q- !_8,']Z3\U_\
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M'2_^E-I2&?:=(#'T#_CQB_X'_P"C&K.'PK^NHS8K004 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ><?
M$#_EV_[;?^TJ_-.*O^87_N-_[B/L\B_Y?_\ </\ ]R'G%?FA]F% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % 'ONC?\>%M_UPB_\ 1:U_0>7_ .YX;_KQ1_\ 3<3\FQ?^\5O^OM3_
M -+9HUZ9Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % &/H'_'C%_P #_P#1C5G#X5_749L5H(^"_C!_R/%W_P!=+/\
M])+:F!DTQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 =O\ LY?\C%<_]@Z7_P!*;2D,^TZ0&/H'_'C%_P #
M_P#1C5G#X5_749L5H(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /./B!_R[?\ ;;_VE7YIQ5_S"_\
M<;_W$?9Y%_R__P"X?_N0\XK\T/LPH * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]]T;_CPMO^N$7_
M *+6OZ#R_P#W/#?]>*/_ *;B?DV+_P!XK?\ 7VI_Z6S1KTSB"@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 ><?$#_ )=O^VW_ +2K\TXJ_P"87_N-_P"XC[/(O^7_ /W#_P#<
MAYQ7YH?9A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M098X22A;S' ,8W*%1A(#E& 4<'/8D Z=OAOX<T3R;/7M2DBU"X4$)$46,$Y
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M_@?_ *,:LX?"OZZC-BM!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YQ\0/^7;_MM_[2K\TXJ_YA?^
MXW_N(^SR+_E__P!P_P#W(><5^:'V84 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >^Z-_QX6W_7"+
M_P!%K7]!Y?\ [GAO^O%'_P!-Q/R;%_[Q6_Z^U/\ TMFC7IG$% !0 4 % !0
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MI(%;L2L5YD ],C(R.H!!Z$9 /%OB+(T/B6\D0E625&4C@@B.,@@]B#R*!'T
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M<>IV<P,*2*VY9-@!+RR#;B0Y& <@<]001Z%_S4/_ +<__:5 SD/!ISX]O/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'G'Q _Y=O^VW_M*OS3BK_F%_[C?^XC[/(O\ E_\ ]P__ '(><5^:'V84 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H ",C'3W_\ UT >-1^(-6\!WGV;7V>^TV=SY5X
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MHBL(_J^(JX#['\2GY*5N:*\DWIZ-]6<G7R)] % !0 4 % !0 4 % !0 4 %
M'ONC?\>%M_UPB_\ 1:U_0>7_ .YX;_KQ1_\ 3<3\FQ?^\5O^OM3_ -+9HUZ9
MQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % &/H'_'C%_P #_P#1C5G#X5_749L5H(^"_C!_R/%W_P!=+/\ ])+:F!DT
MQ!0 4 % !0 4 % '=ZKX2L]#U?\ LO4+[R(/*60W/V9WP77<$\F-V;KQNW8[
MD"D!PE, H * .B\+^')O%-Z+&!EC.QI'=LD*B8W$ <LW("KD9)Y91D@ IZ=:
M6=Q%.]W=?99(H]T$?DO+]H?!_=[E($7( WOD?-[&@#)H * "@ H * "@ H Z
M*#P[++H\NN%U6&&X6V"8)=G*AV/8*JJRX/)8DC QD@'.T % !0 4 % !0 4
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M_P C%<_]@Z7_ -*;2D,^TZ0&/H'_ !XQ?\#_ /1C5G#X5_749L5H(* "@ H
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M'4,""I&X$$9H X_X8ZAK$.H&TL4$MD7)N$+'R8@3C>DF7P^!\H!;S0.<X#J
M?3% 'G'Q _Y=O^VW_M*OS3BK_F%_[C?^XC[/(O\ E_\ ]P__ '(><5^:'V84
M % !0 4 % !0 4 % !0 4 >K:.%\0Z/]DE.&B(C)[C80R$=?X<+[D&OUK+U'
M.<K^IU7:5-JFWU7(U*#6_P!FT==VF? XN^78[ZQ!>[.\[=/>NI+IUU^:,KQS
M>A3%81\+&-[ =/[J#\!N./<5Y7$V(471R^GI&"YY);?RP7R2D[=FCOR6BVJF
M+GO)\J?XR?S=ON9JE#JGAT1VWS,L:#:.I,3+N&!W.TD#OQZUZKB\?D:IX97D
MJ<%RK=NE./,K+J^5M+KIW.!-87,W.MI%SD[O9*I%\KOVUL^VO8Y?P=93/J"S
M!2$@#[R00 2A7;G^]E@=O7 )[5\MP_AZLL=&LHM0I*ISMII)N#ARW_FO)/EW
MLF^A[F;5H1PTJ=US3Y>5)J]E)2OZ63UVNSIDN$N/$>(SGRXBA(Z;@I)_+.T^
MX(KZ>-6%;/K4W?DI.#:VYE%M_=?E?FFCQ73E3ROW].:HI)>3=E]]KKR:.6\:
M?\A)O]Q/Y5\KQ%_O\O\ !#\CW<H_W6/^*7YG4>-/^09#_P!=8_\ T5)7U7$7
M_(OH?]?:?_IJH>%E'^]U?\$__2X$GB:)M4TJ*:U!=5*2;5!)VE&7H.ZEN1V&
M?2M,YA+'Y;2K85.44Z=3E2;?*X2CLKZQ<M5T5^Q.726$QE2G7?*VI0N]%?F3
MW?1I:=].YC^ [243R71!$7EE Q! +%U/'8XVG..F1ZUXO#%"HJU3%.+5+V;@
MFTTI2<XO3H[<CO;:Z[GHYU5A[.%!-.?/S66Z2BUKVOS*W?4U?#]PEUJ][+$<
MH0 ".APP7(]B1D'N#7K955A7S3&U:3O!I)/H^62C=>3:NGU3.#'4Y4L%AJ<]
M))ZKM=-V?FKV9QWB#3KA-2DC"LYGD+1\$[@QSA?7;G!_NXYXKXS-<)6CF%2F
MH2DZU1RIZ-\RD^:T>_+?E?\ +;70^CP.(IO"0GS1BJ<%&>MN5QTN_6U_.YUW
MC=ECL8(6(W^8I ]DC8,?H"P_,5]CQ+)0P="A)KG]I%I>4*<E)^B<H_>CYW)D
MY8BK42]WD:OYRG%I?<G]P_QZ?]$B'_37_P!D;_&KXH?^S4E_T]_*$O\ ,G)/
MXU1_].__ &Y&)X/T2WU$27%R/,$;!50DXSC)+ =>P Z=<@\5X7#^6T,:JF(Q
M2YU"2C&#;M>UW*26_1);;W3T/4S;&5<-R4:#Y7)-N76U[)+MUN]]K'1:'JWV
MJZ:VM[,6L,>[>VW!!' # *H5B>HRQZ]<9KZ3+,=[?$RPN&P:P]&'-SRY>5IK
M1*248J,F]U>3M?>USQL;A?9457K8AU:DK<JO=-/=IMMN*76R6WH8'B#39-5U
MK[-%P61"S=E4#EC].WJ2!WKY[-<'4S#-OJU'1N$'*72,4M9/TZ+JVEU/7P.(
MAA,![:ITE))=92;T2_K17?0Z'6=2A\,6:V=I@3%<(.X'>1O<G.,]6[8!Q]'F
M&,I9%A8X/":57&T%I>*^U5EYMWM?XI=+)V\?"8>>9UY8BO\ PT[R?1]H1\K;
M]EYM'!^'--36+WR[@DH%:1N3E\$<9Z\ELD]<9YSS7P&48.&98OV6(;<5&526
MKO.S2M??5RNWO9/5/4^KS#$2P>'YZ*2E=0CII&Z>MMM$K);;>AVLE]'IE^NG
MV-DH8E 9-N"5.,L,+DJH/+%\9!STY^WGB88'&QR[ 8&*DW!.IRV;B[7DK1NX
MQ3UDYVNG?;7YF-&6)PSQF*Q+LN;W+Z75[+5V3=OA4=K6*'Q _P"7;_MM_P"T
MJX.*O^87_N-_[B.O(O\ E_\ ]P__ '(7?'/_ !X0_P#75?\ T6]=O$O^YT?^
MOL?_ $W,YLF_WBI_@?\ Z7$3P8,Z9,#_ ,]9/_14='#NN7UT_P#G[4_]-4PS
M?_>Z7^"'_I<SRROR<^\.S\"_\?[?]<7_ /0DK[7AG_?9?]>9_P#I=,^:SK_=
MH_\ 7R/_ *3(35E(U_.#C[1;\]ND=+')K.D[.WM\/KTVICPK7]FVZ^RJ_G,T
M_B ?FMA[2_\ M.O5XJ>N&7E5_P#<9PY%M6?G3_\ ;QWP_P#^7G_MC_[5JN%?
M^8K_ +@_^Y19[_RX_P"XG_N,B\*_\AFZ_P!V;_T<E8Y'_P C7%?X:W_I^!IF
M?^XT/6G_ .FY&)XGL)TU*0;&;SV#1X!.[('"XZE3QCJ,>F*\/.<+6CCZBY)2
M]K)2IV3?/=+2-MW%W5MU;M9GIY=7IO"P]Z*]FK3NTN6S>K]=[]?4ZWQ>PM]+
MB@?_ %A:-0/]Q3N/T' S[CUK[#/VJ.74<//XW*FDO\$'S/T6BOYKN?/Y4G4Q
M=2K'X4IN_P#BEHO5[_)AXT_Y!D/_ %UC_P#14E+B+_D7T/\ K[3_ /350,H_
MWNI_@G_Z7 UM6O8TL([H6ZWL7R-M;&%4J?GP4?I]T\9&>> :]C'8FG'!4\6L
M-'%4O<ERRM:$7%^_9PGM\+TNKN]DF>?A:,GB9X?VSH3]Y75[R:E\.DH[[K76
MWH<Y#XI-O 6@T[RH6R2R':AXP22L(4\=3Z"OFJ>=NC1<J&6^SHRNW*#Y:;TL
MVW&@HO3=]D>S++/:5$JN,YJBM925Y+6Z5G5;6IYQ7YH?9G>^ ?\ CXF_ZYC_
M -"K] X6_CUO^O:_]*/D\[_A4_\ &_R,^Z4C7P2"!]LCY_X&A_D0:\ZLFLZ3
M:=OKE/7_ +?@_P FG\SLIM?V:TG_ ,P\_P#TF1J^/_\ 66_^Z_\ -:];BG^)
MA_\ #4_.)P9'\-7UC^3-,J&\-X//[D'\0^1^1YKU6D\@L_\ GRG\U4NON>IP
MIVS73_GY^<;,O6EPC:)'(D(NQ'$@,)Q\Q0A6X*MRI!;&TDXXZBNZA6B\HIU8
M45B5"E!.D[6DX-1EHXRUBTY6Y6W;35HY:M-K'SA*HZ+E.3517T4DW'9QT=TM
MU:^IAV?B@0JTEIINQ3PS1<#CH&*P8XR>O2O!P^=>RC*I@\LY8[2E2T6E[*3A
M02TN]]M3U*N6\[4,1C;O>*GJ]>RE5Z^1/X(F^TS7LP&WS'C?;G.-QF.,X&<9
MQG ^E=/#=3VU7'5DN7GG3GRWO;FE6=KV5[7M>R]#+.(>RAAJ=[\L9QOM>RIJ
M]M=_4X.[C-Q?R1Y ,EPRY/0;I",_K7Y_7@ZV,J4[I.=><;O9<U1J[\E<^KI2
M]GAX3M=1I1=N]H)V/0]1ALO"T49AM!<.YQO< X88Y+%6PS9^55 !P<8QS^CX
MNGA,@I4G1PBKSD[<\DG:2MJY.,K2E?W8Q23L[6MK\?AYU\TG-5,0Z44K\L=+
MIWV2:NE;5MMZKN:.J2R3Z+)+,GE.\62F"-N6&!@\@XQG/?L.E>CC:DZN4U*M
M:'LYRI)N%FN6\E96>J=K7OUZ+8X\-&-/'PA3ESQC.REWLG=Z:;E'P_ UUH30
MQ_>D6=5[<MN S[9ZUPY52E7R>5"G\4XUXQZ:RYDK^5WJ=6.FJ68QJ2^&,J4G
MZ*S9R7A2RF_M-,HR^1N,F01MRC  YZ$DC ZGKT!KX_(\-5_M"%X27LN=U+IK
MEO"44G?9MM66[WV3/H,SK4_JDK23Y^50LT^;WDW;R23NS3\1:D+/6XYT.?LZ
MH'QZ$L6'U*/^M>IFV,6&S>EB(/\ @QIJ=NS<G)>KA/\ $XL!AW6P$Z4E;VCD
MX_*W*_\ P*)VQTN-]074\@@0E?QSPX/^X64^V.G?[EX*$\;#-+JRHN/3=O2:
M?^!RB_*VW7YA8F4<-+!6>M12^5M8_P#@23]3Q[6;[^T;R6X'W6;"_P"XORK]
M,@ GW)K\:S'$_7<55Q"^&4K1_P $?=CZ723?FV?HN$H_5J%.CU2][_$]9?B[
M>AF5Y1W'8>-?^/R/'3[.F/IN>OL^(_\ >J5MOJ].WIS5#YS)_P"!/O[65_7E
MB.\0N1ING(#\IC8D>X$8'Y9/YU6;2:P&6POHZ<VUYI4TG\N9_>+ )?6L9+JI
MQ7R;G?\ )#;;GP]-GG;=#'MQ%T].I_,U-'7(Z]^F)5O+2EMVW?WON.IIF=*W
M6B[^>M3?[E]QQ]?&'T9U*PZ#@;I+L' S@)U[_P %?61IY+9<U3%WLKV5.U^O
MV#P7+,;NT*%NFLMO_ BM?1Z0L+&S>X:;C:) FWJ,YP@/3..>M<F*AE<:4G@I
MXAUM.55%#DW5[V@GM>VN]C>A+&N:6)C15/6[AS<VVEKR:WM?38Y^OGCUS;N[
M.\\/2*0^PS1[E>)F *D@E=V%.<A20.Q'K7N5\/BLFG%JIRNK3O&=*4DG%M-Q
MYK1=[J+:71KN>92JT,PC).%U"5G&I%732WM=]VDWU3[&_JCMJ&C075W@7'F[
M$D(P63YADX'3C)_W<]^?H<;)XS*J&*QEE7]KR0FTDYP]Y7=EM97?G&_77R,-
M%8;'5:&'O[+DYI16JC+3;7?6WSMT,&[M[WPY-Y0D,;.JMNB9@&&3@9PN<'J,
M8^HKY^O2Q>25?9*HX2E&,N:E*2C)7=E>T;V=[JUO5'K4IX?,H<_(I*+:M.*N
MGZ7=KK9[G2:BHU*TT^XO0!/-*L;-]TO$6(W'&.HVG/0;LC :OI\6EC<+EV)Q
MJ2KU:L:<I?"YTG)IR=K;KEE?9<UU92L>+AV\-6Q='#-^RA3<HK=1J))V5_/F
M5NMM;V*OB75+NPO3;6[-;0P!/+2/Y%(V@Y..&&<C!RHQC&<YY,XQN*PF+>%P
MTY4*-)0]G&G[D6N5.[MI)7NK.\5:UKIWWR_#4*]#V]:*J5)N7/*7O-.[5M?A
M=K/OK>]K#/$RB>UM+V10EQ.A\S QO "D,1^/Y-CIBHSE*KAL'CJD5'$58/GL
MDG-)1:DU\]^TDMDBLN;IUL1AH-NE3DN6[ORW;O%/^MO499_\B]<Y_P"?A<?7
M]SG]*C#_ /(DQ-_^@B-O7]S?\"JO_(SHV_Y]2OZ?O/U./KXP^C"@ H * "@
MH * "@ H * "@#WW1O\ CPMO^N$7_HM:_H/+_P#<\-_UXH_^FXGY-B_]XK?]
M?:G_ *6S1KTSB"@ H SM7BNYK25-.=8;MEQ$[C*JV1RP*.,8S_ WTH \U_L?
MQY_T$K+_ +X3_P"0: #^Q_'G_02LO^^$_P#D&@ _L?QY_P!!*R_[X3_Y!H /
M['\>?]!*R_[X3_Y!H /['\>?]!*R_P"^$_\ D&@ _L?QY_T$K+_OA/\ Y!H
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M]\;0"N7- &1JNO:1KFG#SK..PU..4;7L8EC@DB.-WF1EQA@,E<9)8#YE5FP
M>A:? ]S-!%HWA^&72@(@\]];(+F16"F23S9' &,G:4WJ2,@E<* #4\,00>'_
M !?J&D6D,(@$)F1F3=+'F&&0Q)(3D1$R'*<YPO/% SB?#DEOXAM=;O;BTLXG
MAL,Q+#;HB1,J2_/&IW;'. 2RD$D ]J!!,MCX'T>QG%I;ZA?ZK&;AI+N,2Q11
MX4JB1DCG#@$YR6W$DC:J@%+Q%9V&N:%'XDL;>.QGCN/LMU#"-L+-M#+)&O\
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M+9SV^F3C6]$ALI5*FVNM.BC2-&R01.4D?Y&X W==W0.%:@#Q>F 4 % !0 4
M% !0!V_[.7_(Q7/_ &#I?_2FTI#/M.D!CZ!_QXQ?\#_]&-6</A7]=1FQ6@@H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@#R3X=_\ (9U__K]'_HZ\H ];
MH * "@ H * "@ H * "@ H *  G SZ?C^@H \3EEU3XF3M!%YFGZ)$Y5V((D
MG*GE2.,G/\/W(^K[W % 'K6DZ1:Z';K:6,8BB3L.K'NS'JS'')/TZ "@#2H
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MX*22,<4 5+U?"6H7YUI[R9(Y7^T2Z?\ 9I&D:0G>\8FSY05W)SR0 2H8 @J
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M_1C5G#X5_749L5H(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \D^'?_
M "&=?_Z_1_Z.O* /6Z "@ H * "@ H * "@ H * "@ H * "@ H \X^('_+M
M_P!MO_:5?FG%7_,+_P!QO_<1]GD7_+__ +A_^Y#SBOS0^S"@ H * "@ H *
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M[=68DD_4G)-1.<ZLG4JRE*;WE)N4GZMW;*C&--*$$HQ6R222]$M".LRPH *
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MQ?\  _\ T8U9P^%?UU&;%:"/@OXP?\CQ=_\ 72S_ /22VI@9-,04 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 H)4Y'4<T 7-1U&XU6=[N
M\<RS2$%F.!G     "@   *H     % %*@ H * "@ H * "@ H * "@ H * .
MZL_'UW!;0VES;6&H):+L@:[M_->-!C"*P=/E&!@$'@ '.!2 Y_7M?O/$ER;R
M^8,^T(JJ-J1H,D(B]E&3W)))))/-,#%H * "@ H * .L\.>+KCPNKFS@M'G<
MDK<2Q%YXLJ4(B?> H()R"I!R<Y'% '*LQ<EF)9F))).22>223U)[F@!M !0
M4 % !0 4 % !0 4 % !0 4 =O^SE_P C%<_]@Z7_ -*;2D,^TZ0&/H'_ !XQ
M?\#_ /1C5G#X5_749L5H(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \
MD^'?_(9U_P#Z_1_Z.O* /6Z "@ H * "@ H * "@ H * "@ H * "@ H \X^
M('_+M_VV_P#:5?FG%7_,+_W&_P#<1]GD7_+_ /[A_P#N0\XK\T/LPH * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MM*0S[3I 8^@?\>,7_ __ $8U9P^%?UU&;%:""@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /)/AW_ ,AG7_\ K]'_ *.O* /6Z "@ H * "@ H * "@ H
M * "@ H * "@ H \X^('_+M_VV_]I5^:<5?\PO\ W&_]Q'V>1?\ +_\ [A_^
MY#SBOS0^S"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MRN2\,JXV2K([2[5#[<@X4-M;*_-N (M/UBRU?2;"R@U27P]<62$%=LBPW!R
M9?,1HT)+ D[F."7&P\M0!HV-OJ,?CFQFU3[.[S0R-'/;#$<\8M;@+(<DDN1@
M-ST"A24VD@&+H>LV0L+W2);R;19Y+]Y1>1([+(.@B=T(9<;2<!HQC:<G+JP
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M"=I?/((8# !3^*&GP:;X@N([8!$<1RE%P KR(&8 #IN/SX_VN.,4 >?4P"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H [?\ 9R_Y&*Y_[!TO
M_I3:4AGVG2 Q] _X\8O^!_\ HQJSA\*_KJ,V*T$% !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MNY;Z[;?-.VYB!@>@ '95 "J.P %,#/H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#M_P!G+_D8KG_L'2_^E-I2&?:=(#'T#_CQB_X'_P"C
M&K.'PK^NHS8K004 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y)\._P#D
M,Z__ -?H_P#1UY0!ZW0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'G'Q _Y=
MO^VW_M*OS3BK_F%_[C?^XC[/(O\ E_\ ]P__ '(><5^:'V84 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 >^Z-_QX6W_7"+_T6M?T'E_^YX;_ *\4?_3<3\FQ?^\5O^OM3_TMFC7I
MG$% !0 4 % !0 4 % !0 4 % !0 4 >2:Q_R/FF_]>3_ /H%]0!ZW0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 8^@?\>,7_ __1C5G#X5_749L5H(^"_C!_R/
M%W_UTL__ $DMJ8&33$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0!V_[.7_(Q7/_ &#I?_2FTI#/M.D!CZ!_
MQXQ?\#_]&-6</A7]=1FQ6@@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M#R3X=_\ (9U__K]'_HZ\H ];H * "@ H * "@ H * "@ H * "@ H * "@#S
MCX@?\NW_ &V_]I5^:<5?\PO_ '&_]Q'V>1?\O_\ N'_[D/.*_-#[,* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /?=&_X\+;_KA%_P"BUK^@\O\ ]SPW_7BC_P"FXGY-B_\ >*W_
M %]J?^ELT:],X@H * "@ H * "@ H * "@ H * "@#R36/\ D?--_P"O)_\
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MHYFAE>>4QB+;$)3*Y*E1%AE7(8OO8?)MRP8&L_PNU-0LRSV+V;JSF]6Y'V5
MI .^0J#R3@;589SSP<(#G_$?A&\\-+#-.T-Q;W0)BN+9S+"V.H#[5YP01QAA
MG:3AL,#;@^&FH,D7VJXL;&:Y ,5O=7!CG;/0",(V">!M)!!.T@-Q2 SK/P+J
M-UJ,NC.8K:]A0NL4S,OG #.(65'5R5^89905R<_*V&!3T_PG>7UK=WSM':P:
M>=LK7!=,R=/)0*CDRYP-IQ@LH)YH T-<LM7.FZ2+J1+BVG686$,:_O(QNB#J
MV(D+,[%-OSRG@X([H#27X7ZB'2WEN=/@O)%#+:27.+@Y&0-BHRD]>CD'!P<"
M@"KHVE:W9VNKP6[I:):Q*+^&4 NZ#S<*A\J3GA_F5XPP92&(P0 =?>_\>OA'
M_KLW_I1:T ,UZWU2;7-?.ES1P1QVSM=B0 F2W$"[T3,4F'(R 08S_MB@#C]+
M^'U_JEA%JJS6D%I,9 9)YC$L7EN4S*2F!N8?+M+D]P* ,[Q%X0O?#20SSM#<
M6UR"8KBVD\R%B.P;:ISCD<8(SM)PV&!RM !0 4 % !0 4 % !0 4 % !0 4
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M<S6HEDA60J4#F,X9E#8;83]TL%)ZXQC(!T5 !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 >2?#O_D,Z_P#]?H_]'7E 'K= !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 <5XPTBZU7R/LB>9Y?F;OF1<;O+Q]YESG:>F>G-?
M#\08#$X_V'U2GS\GM>;WH1MS>SM\4HWORO:^VI]-E.*HX3VOUB7+S<EM).]N
M>_PI]UN<5_PB.J_\\/\ R)%_\77PW]@YC_SX_P#*E+_Y8?3?VI@_^?O_ ))4
M_P#D0_X1'5?^>'_D2+_XNC^P<Q_Y\?\ E2E_\L#^U,'_ ,_?_)*G_P B'_"(
MZK_SP_\ (D7_ ,71_8.8_P#/C_RI2_\ E@?VI@_^?O\ Y)4_^1#_ (1'5?\
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M_P"25/\ Y$/^$1U7_GA_Y$B_^+H_L',?^?'_ )4I?_+ _M3!_P#/W_R2I_\
M(A_PB.J_\\/_ ")%_P#%T?V#F/\ SX_\J4O_ )8']J8/_G[_ .25/_D0_P"$
M1U7_ )X?^1(O_BZ/[!S'_GQ_Y4I?_+ _M3!_\_?_ "2I_P#(A_PB.J_\\/\
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M ,_?_)*G_P B'_"(ZK_SP_\ (D7_ ,71_8.8_P#/C_RI2_\ E@?VI@_^?O\
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M/_*E+_Y8']J8/_G[_P"25/\ Y$/^$1U7_GA_Y$B_^+H_L',?^?'_ )4I?_+
M_M3!_P#/W_R2I_\ (A_PB.J_\\/_ ")%_P#%T?V#F/\ SX_\J4O_ )8']J8/
M_G[_ .25/_D0_P"$1U7_ )X?^1(O_BZ/[!S'_GQ_Y4I?_+ _M3!_\_?_ "2I
M_P#(A_PB.J_\\/\ R)%_\71_8.8_\^/_ "I2_P#E@?VI@_\ G[_Y)4_^1#_A
M$=5_YX?^1(O_ (NC^P<Q_P"?'_E2E_\ + _M3!_\_?\ R2I_\B'_  B.J_\
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M )$B_P#BZ/[!S'_GQ_Y4I?\ RP/[4P?_ #]_\DJ?_(A_PB.J_P#/#_R)%_\
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ML',?^?'_ )4I?_+ _M3!_P#/W_R2I_\ (A_PB.J_\\/_ ")%_P#%T?V#F/\
MSX_\J4O_ )8']J8/_G[_ .25/_D0_P"$1U7_ )X?^1(O_BZ/[!S'_GQ_Y4I?
M_+ _M3!_\_?_ "2I_P#(A_PB.J_\\/\ R)%_\71_8.8_\^/_ "I2_P#E@?VI
M@_\ G[_Y)4_^1#_A$=5_YX?^1(O_ (NC^P<Q_P"?'_E2E_\ + _M3!_\_?\
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M?^5*7_RP/[4P?_/W_P DJ?\ R(?\(CJO_/#_ ,B1?_%T?V#F/_/C_P J4O\
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M',?^?'_E2E_\L#^U,'_S]_\ )*G_ ,B'_"(ZK_SP_P#(D7_Q=']@YC_SX_\
M*E+_ .6!_:F#_P"?O_DE3_Y$/^$1U7_GA_Y$B_\ BZ/[!S'_ )\?^5*7_P L
M#^U,'_S]_P#)*G_R(?\ "(ZK_P \/_(D7_Q=']@YC_SX_P#*E+_Y8']J8/\
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M\-:!).0L2:J6<M]T()Y2Q.>, 9)]J .;^)UE=MXCG#)(_P!H,?V? 9O,7RT
M$>,[L-\NU>C9&,T ==XHL;^^UO1K*T8C5X+*V^T2CGRW7+,\A'4)AV8'[P8
M9W@4 7?B?-_;NEBZTB19;*RNI4O4C7;^_)"B=O[RY) (R#Y@8%ADJ -M)8H%
M\(O.0$S=#+= S&%4Z]/G*X/8X/:@#S?Q+IFI'Q-/;A)?MDUX[P==Q5I"T+HP
MS\@4 AAP@4@XVD  [K2;.]T^W\36^I2BYNX[6$2RAVDW$QRD?.P#':I"X(&W
M;M' H BO?^/7PC_UV;_THM: -R3_ )"_BG_L'2_^DXH XO621X'TP=OMDYQ]
M&N,?ED_F: #5/^1%L/\ L(2_RN* /*:8!0 4 % !0 4 % !0 4 % !0 4 %
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M+(57DQD R]>^.'C;P1=02^)]$MK73[HDQJCLTQ4;2R^>EQ+$)54YV/#&Q]%
M- &W^T'KFK:EX32XT>"&?0-0MX)[RZ<@31*\]I+9^6IG0GS795?$,V >2GWJ
M .?_ &<]8\166F!)[6W3PO"+N9KXL//$J89E*_:=VP8//V;H/O\ >@"]8_&G
MQKXYFGD\$:+;3V5J^UGNY/G.>4SFZM$#LOS&-#*1G[QZD [WX7_%35/%U]<:
M-KVERZ=>6H?=+&DIMB\;!9(F+AO*D&<I^\=7 ;# [0X![G0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0!Y)\._^0SK_ /U^C_T=>4 >MT % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % 'DFL?\CYIO_7D_P#Z!?4 >MT % !0 4 % !0
M4 % !0 4 % !0 4 % &/H'_'C%_P/_T8U9P^%?UU&;%:"/@OXP?\CQ=_]=+/
M_P!)+:F!DTQ&MH^N7V@3?:=.F:WD(VDK@AAZ,K JPSSA@<'D<T 7]:\7ZMXA
M18=0N&EC0Y"!4C3/J4B5%)'8D$C)QC)H 9+XKU26Z@OVN&%S9Q+##(JHA2--
MV$PBJK#YV!WABP)#$CB@#8?XE>(W=)#>,&B8LNV*!5)*E2718@LG#'_6!@#A
MA\P!" YT:_>K9RZ:) +2YE\^2,1Q@&3Y?F!";E VKA4*H,8VTP&V&MWFEP7%
MK:R>7%>H(YUVHV]1NP,LI9?O-RA4\]>!0!>L_%VJV%@^DP7!6RE5U:(I&PVR
M APK.C.@;)/R,O)+#!YH H:CK5YJR01W<GF+9Q+!"-J+LB4 *N452V !\S;F
M/<T 69?$VHS-9L\V3I806GR1CRO+*E.B#?@HI_>;\XYSDY ,W4+^?5+B2\NF
M\R>9B[MA5RQZG"A5'T  H ZFT^(GB"Q@6VAO'$<8VKN2)V4=,"1XVD&!P/FX
M' XI 8NG^(M0TN].IVTS+=MNS*X65COX;/FJX)/J03Z4P(M'UN\T"<W6GR>3
M*4:,MM1_E;&X8D5EYP.<9]#0 FE:U>:(\DEC)Y33Q-!(=J-NB<J67#JP&2J_
M,,,,<$<T =YX"BM- 8>);V\MU%NDWEV<<H-U)(5:)5>+ (1LE@<X^ZS;5R:0
M'G%U>2W=P]W(?WTLC2LPX^=F+DCT^8Y'I3 ZX_$?Q$8?LYO9-FW9G9$),8Q_
MK?+\W/\ M;]V><YI <[#KE[;VD^G)(1;7C(\Z%4)=D8.I+LI<$, ?E89[YYI
M@&H:W>:K%;V]W)YD=E'Y4"[478F -N552W"CERQXZ]: "_UN\U."WM;J3S(K
M)#' NU%V*=N1E55F^ZO+ECQUY- $.F:I=:-<+=V,C03)G:ZXZ$8((((((Z@@
M@]Q0!U3_ !*\1.ZR&\8%"2 (H%4E@5.Y!$$?@G&]6P>1@\T@.;&MWBV+Z4),
M6<DWGM$$3!EPJ[MVW>.% VA@O'W:8!%K=Y!82:4DF+.:02O'M0Y<;<-O*[Q]
MQ> P''3DY -72?'&M:% +2QNFCA!)5"D<@4GD[/,1RG.3\I'))ZDF@"AK'B3
M4=?$2ZC,UQ]GW^665 1YA#/EE4,V2!]XG &%P.* *>F:I=:-<+=V,C03)G:Z
MXZ$8((((((Z@@@]Q0!U3_$KQ$[K(;Q@4)( B@526!4[D$01^"<;U;!Y&#S2
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MM_V<O^1BN?\ L'2_^E-I2&?:=(#'T#_CQB_X'_Z,:LX?"OZZC-BM!!0 4 %
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M?C&",WC%X_.C5%DCE2(S#S!"Q@D1T7AHE7!92<KG !]64 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 >2?#O_D,Z_\ ]?H_]'7E 'K= !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!Y)K'_(^:;_ ->3_P#H%]0!ZW0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 8^@?\ 'C%_P/\ ]&-6</A7]=1FQ6@CX+^,'_(\7?\
MUTL__22VI@9-,04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M+ \<H55!=9,':&VA]S, <MK/[,4&LP*\^L7<^J&3=-?72-<F2,)M$2QM<(4
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MY4'MJG?\%_D'_"QM?_Y^O_(-O_\ &J.5![:IW_!?Y!_PL;7_ /GZ_P#(-O\
M_&J.5![:IW_!?Y!_PL;7_P#GZ_\ (-O_ /&J.5![:IW_  7^0?\ "QM?_P"?
MK_R#;_\ QJCE0>VJ=_P7^0?\+&U__GZ_\@V__P :HY4'MJG?\%_D'_"QM?\
M^?K_ ,@V_P#\:HY4'MJG?\%_D'_"QM?_ .?K_P @V_\ \:HY4'MJG?\ !?Y!
M_P +&U__ )^O_(-O_P#&J.5![:IW_!?Y!_PL;7_^?K_R#;__ !JCE0>VJ=_P
M7^0?\+&U_P#Y^O\ R#;_ /QJCE0>VJ=_P7^0?\+&U_\ Y^O_ "#;_P#QJCE0
M>VJ=_P %_D'_  L;7_\ GZ_\@V__ ,:HY4'MJG?\%_D'_"QM?_Y^O_(-O_\
M&J.5![:IW_!?Y!_PL;7_ /GZ_P#(-O\ _&J.5![:IW_!?Y!_PL;7_P#GZ_\
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MM?\ ^?K_ ,@V_P#\:HY4'MJG?\%_D'_"QM?_ .?K_P @V_\ \:HY4'MJG?\
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M_P#(-O\ _&J.5![:IW_!?Y!_PL;7_P#GZ_\ (-O_ /&J.5![:IW_  7^0?\
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M /QJCE0>VJ=_P7^0?\+&U_\ Y^O_ "#;_P#QJCE0>VJ=_P %_D'_  L;7_\
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M /CK_P#Q- !_:]K_ '__ !U__B: #^U[7^__ ..O_P#$T ']KVO]_P#\=?\
M^)H /[7M?[__ (Z__P 30 ?VO:_W_P#QU_\ XF@ _M>U_O\ _CK_ /Q- !_:
M]K_?_P#'7_\ B: #^U[7^_\ ^.O_ /$T ']KVO\ ?_\ '7_^)H /[7M?[_\
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MQ6@@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#R3X=_\AG7_ /K]'_HZ
M\H ];H * "@ H * "@ H * "@ H * "@ H * "@#Q/XQ?\N/_;S_ .V]:PZG
MGXG[/S_0\2K4X H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H ^OO#/_()LO\ KTM__1*5S/=GMP^"
M/HOR-ND:!0 4 % !0 4 % !0 4 % !0 4 % 'DFL?\CYIO\ UY/_ .@7U 'K
M= !0 4 % !0 4 % !0 4 % !0 4 % !0!CZ!_P >,7_ _P#T8U9P^%?UU&;%
M:"/(/%'P5T7Q;J4VKWLU['/<^7O6&2!8QY<21+M#V[L,J@)RQ^8DC P  8'_
M  SEX=_Y^=1_[^VW_P B4P#_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_
M]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* #_
M (9R\._\_.H_]_;;_P"1* #_ (9R\._\_.H_]_;;_P"1* .O\%?"?2? EZ^H
M:=+=RRRP- 1.\3)L9XY"0(X(CNS$H!+$8)XS@A >GT 8^@?\>,7_  /_ -&-
M6</A7]=1FQ6@@H * "@ H * "@ H * "@ H * "@ H * .!^(/B[4?!UG%=:
M7I5SKTLLWE-#;&0-&NQV\UO*M[@[<J%Y51EA\V>" :EOXIBM]"C\0:U&VDI]
MF2XN(IMY>V+ 9C<&-'+JQ"8\M69L )DXH I^ _'-I\0+&75-/22.VCN9+>,R
MX#R"-4/F%1G8&+_*I). "V"2J@'!_#WXS_\ ">>(+SP]]@^Q_88IY//^T^;O
M\BXB@QY?V>+;N\W?GS&V[=N#G( /<J "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H \D^'?\ R&=?_P"OT?\ HZ\H ];H * "@ H
M* "@ H * "@ H * "@ H * "@#Q/XQ?\N/\ V\_^V]:PZGGXG[/S_0\2K4X
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H ^OO#/_ "";+_KTM_\ T2E<SW9[</@CZ+\C;I&@4 %
M!0 4 % !0 4 % !0 4 % !0!Y)K'_(^:;_UY/_Z!?4 >MT % !0 4 % !0 4
M % !0 4 % !0 4 % &/H'_'C%_P/_P!&-6</A7]=1FQ6@@H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MGGXG[/S_ $/$JU. * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M".H(NY""/I0!]P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % 'DGP[_P"0SK__ %^C_P!'7E 'K= !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 >)_&+_EQ_P"WG_VWK6'4\_$_9^?Z'B5:G % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'U]X9_Y!-E_UZ6__ *)2N9[L]N'P1]%^1MTC0* "@ H * "@ H * "@ H *
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M'_\ %4 ']N:?_P _5O\ ]_H__BJ #^W-/_Y^K?\ [_1__%4 ']N:?_S]6_\
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M5O\ ]_H__BJ #^W-/_Y^K?\ [_1__%4 ']N:?_S]6_\ W^C_ /BJ #^W-/\
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M[M@X)R1F@#7\&_"#2/ ^L7.OZ?->27-['-'(D\D+1 331SL45((W!#QJ%R[
M*2""<$ !XZ^$&D?$'4+?5-2FO(IK.-8XUMY(50A9#("XD@E8G<Q!PRC';/-
M'JM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y)\.
M_P#D,Z__ -?H_P#1UY0!ZW0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'B?Q
MB_Y<?^WG_P!MZUAU//Q/V?G^AXE6IP!0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!]?>&?\ D$V7
M_7I;_P#HE*YGNSVX?!'T7Y&W2- H * "@ H * "@ H * "@ H * "@#R36/^
M1\TW_KR?_P! OJ /6Z "@ H * "@ H * "@ H * "@ H * "@#'T#_CQB_X'
M_P"C&K.'PK^NHS8K01Y?\2/^73_MO_[1IH1Y?3 * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#WCP9_R"+?_
M +:_^CI*D9U% &/H'_'C%_P/_P!&-6</A7]=1FQ6@@H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#R3X=_P#(9U__ *_1_P"CKR@#UN@ H * "@ H * "
M@ H * "@ H * "@ H * /$_C%_RX_P#;S_[;UK#J>?B?L_/]#Q*M3@"@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#Z^\,_\ ()LO^O2W_P#1*5S/=GMP^"/HOR-ND:!0 4 % !0
M4 % !0 4 % !0 4 % 'DFL?\CYIO_7D__H%]0!ZW0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 8^@?\>,7_ __ $8U9P^%?UU&;%:"/+_B1_RZ?]M__:--"/+Z
M8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_P!MZUAU//Q/V?G^AXE6IP!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M^W_#''U1@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!]?>&?^039?]>EO_P"B4KF>
M[/;A\$?1?D;=(T"@ H * "@ H * "@ H * "@ H * /)-8_Y'S3?^O)__0+Z
M@#UN@ H * "@ H * "@ H AN;B.SB>>=@D42L[L>BJHRQ/T S0!7TW4[75X%
MNK*19H6R R^HZ@@X*D=P0"/2@"]0 4 % !0!CZ!_QXQ?\#_]&-6</A7]=1FQ
M6@CR_P")'_+I_P!M_P#VC30CR^F 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MPR,C((!&001['- $5 !0!/;VTUTWEP(\KXSM12QP.IPH)Q[T -$$AD\D*WF
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M4+=1@]#R* /0?V:O \EI:3^,-2#->:J76!GY;R-^Z24YYW7$P)R>J1JPXDH
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M"*,*H  '0 < 4 .H * /*KCX/Z1<RO,TUX&D9G($D.,L23C,!.,GCDT 0_\
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M_P"1Z #_ (4SHW_/:]_[^0__ "/0 ?\ "F=&_P">U[_W\A_^1Z #_A3.C?\
M/:]_[^0__(] !_PIG1O^>U[_ -_(?_D>@ _X4SHW_/:]_P"_D/\ \CT '_"F
M=&_Y[7O_ '\A_P#D>@"&X^$6A6D;33W-W''&-S.TL 50.Y)M\"@#S2P\&0^)
M[\PZ#YZZ?"=LMU<E3DYYV*D<?)'W4.6(PS[ <4 ?3>D:9'HUI%8PL[I H4-(
MQ9C]2?T PJC 4  "@#1H \3^,7_+C_V\_P#MO6L.IY^)^S\_T/$JU. * "@
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MJ/V/1;-T=5D)N'SD*O!(+L\@#$@8.SKR >*EIVNV=%.4.;EIQ[Z_UJ9NI_\
M(\6_T3_T2]-?"3+^,OZZ&%\6V/\ :L*Y.!:(0.P)EFR<>IP,^N!Z4X;&>(^)
M>GZLZSQ -W@J$GG%O9X_[ZB'\N*E?%]YM/\ @KTC^AX!6QYI] >'E-QX+DC@
M!:3R;M2%Y).^0XP.<E" !U.1ZUB_B/2AK1:7:7ZG#?"V.1M9#(#M2&3>1T .
M ,_5L8'KSVJY;'/0^/Y,ZG4_^1XM_HG_ *)>I7PFTOXR_KH87Q;4C586P<&T
M0 ]LB6;(SZC(S]1ZTX;&>(^)>GZL[#Q7&T/@^&.0%72&R5E/4$",$'W!X-2O
MB^\WJ:44GVC^AB6WA#1_#^DIJNMK+<O(L;&-"0%,G*HH1DR0#AF:3:<'&,@%
MW;=D9JG"$.>I=[:>IW?A>^L]0TJ:;3[;[%;[I55< >9B-<R';P23\A.6/R=>
MPAZ/4Z*;4HMQ5EK^6YRGP@_X];O_ *ZQ_P#H)JI]#'#;2]4>)ZA_Q]3?]=9/
M_0C6IP/=^K.F^'W_ "'K3_>D_P#1,E*6QK1^./S_ "9N?%C_ )#"?]>L?_HR
M6ICL:8CX_DOS9VGQ.=DT&W ) :>$'W'DRG!]L@'Z@5,=S>O\"]5^3&?"H;M(
MN5/0W#_K#'1+<,/\#]?T1-\,3"VAS*%+$32^:JY#-F-.!R.2F ,$<]P>:);C
MH6Y'ZN_W'.Z7XJ\*:)/]ILK*\AF *[L[N#U&U[ME_,4VI/J91J4H.\8R3_K^
M\7/#.KVVN^*Y;ZT5XTEMCD2!0VY1$A.%9P,A1T/N>:&K1L5"2G5<H]NOR.,^
M)4QDUZ=3TB6%1]#$C_S<]*J.QSUW[[^7Y'4:=X0TC2-'36M:$MSYL<<GEHQ4
M 2X**H5D)8AAN+.%!Z8QDS=MV1M&G",/:5+O1.WJ>@^#[^RU&PEDTVV^Q6ZR
M,H4@ N0BY<[<Y/(7.YC\O7M4/1ZG33<91;@K(X?X._\ +]_V[?\ MQ5SZ'/A
MOM?+]3S>>WN$UTPL&\_[;Z88L9L@CI][(8'I@@@XYJ^GR.5I\]NO-^IZG\6;
MK[+]@DC.VXCEDDC..5V^6<_]]!>.^/:LX=3LQ#MRM;IMK\#>U328_&2Z7J<8
M^19%DD'!Q$R^8Z-UR1)&(R.Q9J2?+=&DHJKR37S]-_S5CSGXJ:M]LU%+)#E+
M-/FZ_P"LDPS>QPFP>QR*N*LKG+B)7ERKI^;/+ZT.0],\0@1>%M+2/[C/([?[
MQ+GK]6;^7:LUNSKGI2@EYBZ9*T7@R\V$KNO0IQQP5MLCZ'H?49%'VEZ!'2C+
M_%_D,\"DG3M90_=^PL<>XCFP:);KU%2^&I_A_1GFM:'*=UHVEV5Q:1R3:Q]A
MD;=F#RW;9AV Y$J@[@ _"C[V.>M0WY'1&,6DW.WE;_@EZXT;3DB=EUWS"%8A
M/*D^<@'"_P"N/WNG0]>E%WV*<8V_B?@_\SS>K.4WH+74="2WUE$\N-V/D2G8
MX+ $?=RV",'&]0,COBIT>AHE*%JBT[,] M]1?QKHEZVJ*K7&FIYL-PJA"<JS
M%"  O/EX8  $,#M#*&,VY6K=3I3]K"7/O'5/^O0Y#PSX3DUS==7#BUT^#F:=
MN.!R53/!;'4GA<@D,<*:;MIU,84^?5Z16[_R+?B3Q'#J2Q:/I2BVTVW8!-V5
M\QLD>;(3R%Y+<_-R7?YL*J2MJ]QSFI6A#2*_'S9U6LZ1!)8P:3I>HZ9%:1#?
M,9+M5>><]7<*KC:,?*-Q[#'R+B4^K3-I17*H0E%);^]NR+XG:5NDBO?/MAY-
MI#'Y)E_?O^\D&^./;\T?S?>R.%;CBG%]!5X[2NM$E:^N[V78S/AV!)#JD+_Z
MI[)MW8<!P.>W!;^?:B73U)H[373E/,ZT.0* "@ H * "@ H * "@ H * "@#
MZ^\,_P#()LO^O2W_ /1*5S/=GMP^"/HOR-ND:!0 4 17$*W,3PMD+(K(<=<,
M"#C.1G!XX- 'E/\ PIG1O^>U[_W\A_\ D>@ _P"%,Z-_SVO?^_D/_P CT '_
M  IG1O\ GM>_]_(?_D>@ _X4SHW_ #VO?^_D/_R/0 ?\*9T;_GM>_P#?R'_Y
M'H /^%,Z-_SVO?\ OY#_ /(] !_PIG1O^>U[_P!_(?\ Y'H /^%,Z-_SVO?^
M_D/_ ,CT '_"F=&_Y[7O_?R'_P"1Z .&O_A_I]KXEM-"22X-M=6[2NQ:/S0P
M6Y("D1!0/W*]4)Y;GD8 .Y_X4SHW_/:]_P"_D/\ \CT '_"F=&_Y[7O_ '\A
M_P#D>@ _X4SHW_/:]_[^0_\ R/0 ?\*9T;_GM>_]_(?_ )'H /\ A3.C?\]K
MW_OY#_\ (] !_P *9T;_ )[7O_?R'_Y'H /^%,Z-_P ]KW_OY#_\CT '_"F=
M&_Y[7O\ W\A_^1Z #_A3.C?\]KW_ +^0_P#R/0!QGBWP;X=\,((A+>W%]*/W
M5NLD)8D\!GQ;DJN>G\3GA0>2 #J?AU\/9M&D75M09H[C:1' K$;%88/G$'YB
M1_RS^ZO!;+<* >RT % !0!CZ!_QXQ?\  _\ T8U9P^%?UU&;%:"/+_B1_P N
MG_;?_P!HTT(\OI@>D^ 9H56XB5DCO' \MG&<C!P ,@G:W+*""1CTX0&[))K>
MGQRB^ACU.!P1B,JA5>X*^7E@1V"L1ZF@9PWA_P /0ZG%+>W<A@M("02,;B<
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MDF@"W0 4 >)_&+_EQ_[>?_;>M8=3S\3]GY_H>)5J< 4 % !0 4 % !0 4 %
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M!)YW,KG^=+E\S3V]G>,4N_G^!@WGC5;K6H=<6VV&%0&B\[.\@.H._P H;>&
MQM;[O7GA\ME8R=6\U4MMTO\ \ S/%OB7_A*;M+OROL^R%8MN_P S.UW?=G8F
M,[\8QVSGG :5M":D_:/FM;2W<U[_ ,=?;=$70_L^S9'#'YWFYSY10Y\ORQC=
MMZ;^,]3BERV=RW5O#V=NBUOV\K'G]6<QV'A7QE=>%F98U$UO(=SQ,2OS8QN5
M@#M;  /# @<C(!$M7-Z=1T]M5V.J3XI"VE#V=A#;QLY>=4<!Y3@@9=8E .2"
M6*.2!C(R34\OF;>WL_=BDNOG^!Q^M^*9-5U1=7@3[-)'Y95=^_#1]#G:F0<<
MC'3@YJDK*QA*IS2YUH]/P.RE^*:W*(;G3X)IXN5D9\JKX^\J-$S+^$F<<;N]
M3R^9O[>^\5=?UV_4RM>^(<FOZ:=.FMPDC%"TPDX)5@W$?E\ ] /,) ZDTU&S
MN1.MSQY6M>]_TL3:1\29+*Q73KZUCOHHU$:[F"YC4 *KJT<BOM P#@< 9!()
M*<>JT'&O:/)))K]/N9H6WQ7DBWQO91FW("Q11R>6(UP0P)\M@V[(QA4"@8P<
MYHY?,I8BVG*K=$G:WX&!X2\;CPHDT:VQG6=PPS-L*A00 <1-N//)POTIN-S.
MG5]E=6O?S_X!P]Q+Y\KRXQO9FQUQN).,\9QGTJCG>KN6])U.71KN*^@P9(6W
M -T.000>APRD@XYYXH:OH.,G!J2Z';>)/'L7B&U>!K&.*=PB_:-X=U5)%?:I
M\E6 .",;\?,>M2HVZG1.JIJW*D^_](@\4>.O^$DL(K#[/Y'DR))O\W?G9&Z8
MV^6F,[\YW'&,8.<@4;.XJE7VD5&UK/OY>@>%/'7_  C%I)9_9_/\V0R;O-\O
M&45,8\M\_=SG(ZXQWH<;ZA3J^S3C:]WWM^AB^&?%5UX7F:2WP\<@ DB;.UL=
M"".589."/4Y!IM7,X5'3=UMU1VO_  L^"(O+;Z9!%/*/GDWJ2Y]7VPHSC/."
M_P"/>IY?,Z/;I:J"3?7^D<GH?BU])U235I85F>574QH1"HW%?NX1P H7&,9/
M4L3DFFKJQC"IRR<VM^FQE^(]9_M_4)=0\OR?.V?)NW[=D:1_>VKG.W/W1C..
M<9II65B)RYY.5K7_ ,K'8:+\2)-.L1IM[:QWT*+Y:[F"9C[(X,<BN .!P.
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M4 % !0 4 % !0 4 % !0 4 % !0!Y)K'_(^:;_UY/_Z!?4 >MT % !0 4 %
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MD,?S#(R=^U6  YW;!SA0<D&@1?U/35\9V]O<V4L:M$I616SE=VW<#C)#*0<
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M:A$6"O([[0>IQ*^<>N,B@#.\/Q/X;U?^S[AE=;A C;3\NX\IU .<@IC ^_0
M>-'CTV"WT>WX2(&1A]20N?<DNQ]R#0!YW3 * "@ H * />/!G_((M_\ MK_Z
M.DJ1G44 8^@?\>,7_ __ $8U9P^%?UU&;%:""@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MMQC'),N!ZT >GQ2I.BRQ,KQNH964AE96&0RD9!!!!!!P1R* 'T % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!Y)\._^0SK_P#U^C_T=>4 >MT % !0
M 4 % !0 4 % !0 4 % !0 4 % !0!XG\8O\ EQ_[>?\ VWK6'4\_$_9^?Z'B
M5:G % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % 'U]X9_Y!-E_P!>EO\ ^B4KF>[/;A\$?1?D;=(T
M"@ H * "@ H * "@ H * "@ H * /)-8_P"1\TW_ *\G_P#0+Z@#UN@ H *
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M=4QRH!())8#[V,9.>,% 5K?2O/L)[_?M^SLB[-N=V\@9W;AC&?[IS[4P,B@
MH * "@ H * "@ H * "@ H * "@#WCP9_P @BW_[:_\ HZ2I&=10!CZ!_P >
M,7_ _P#T8U9P^%?UU&;%:""@ H * "@ H * "@#X<^%O_)6]6_Z^M8_]*7H
MQO'FAV_B3XOOI=YDV]S<V"RJI(+1BPMF9,@@@.%*$@@@$D'.* .K_:6\#Z+X
M>TNPOM)L[>PD^TFW;[/$L0D1HF<;PF [*8^'8%SN.6ZY .I^(EM:ZQ\)X-8N
MH8I[^+3=*"74L:/<(7GLTE*2D%T\W+;]K#<&(;J: (?@E#9:%X!N?$\=K;G4
M;*+4I5N?)C\\K#&T@C,VWS"AV@;=VW'% 'S_ /#/QCX4T2XO-1\9V5QK-[=/
MF,F&WN8E#%FFD=;B>,&:1R/F*,5 ^5E+-D ZGX6^*[&T^)"MX:CFM-&U9VA^
MRRA58*\&\ JDDJ 1W2EHL.Q$/R@KN8  W;6UA^)GQ9NK76@;BSL);F)8'SL*
M66Z)(\#^!ILS,O1R6W9#$$ ]P\2_ #1=9U6VU?37.A-:[24T^&*(-(CAXI5X
M\N)T/4B)M_RY^[R >5?M6Z59VJ:;>PP0I=W,LXGN%C19IA'% J>;(JAI-B@*
M@8D*.% '% 'I>OZ)I^D?#*YDL+:WM'N='MY)V@ACB,K^3&=\I15,C99CN?)R
MQYY- 'GGP/UN7PU\-M:U6W&9K2[O)(LC($@LK,(2.ZJQ#,.X!Y'6@"M^SCX#
MTOQ5:7WB37H8]4N7O'MU%VHG4$1Q32RLD@97DD:89=PS#:<8W-D Y_XE6$/P
MB\>:?J/AM?L<5TD4LMO&2(B&G:*>(+G BE10=G1'RR;<(% $_:5M!J'C?3;1
MB4$]A:1%AU4/?7:DCW&<B@#T/XZ_#;P]X?\ !S7.EV-O:3V$MN$FCC F=7D$
M3"64?/+D/N)E+G(!&#R #T?]G^\>]\$:<9"S-%]HBRQS\J74P0#_ &4CVH!V
M"XZ4 >RT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y)\._\ D,Z_
M_P!?H_\ 1UY0!ZW0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'B?QB_Y<?\
MMY_]MZUAU//Q/V?G^AXE6IP!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M)H=T2Y.0D0W;5 SCDJ<#.#GY0"[KNBB6*RE:!+*YN)1!*D>-F6;"L%4D#CG
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MCSPKNI!PJJK,H Q[@D8(!W9I 5H[>VFUFVC-JUL7'[Z"1!Y98*W,8)(*$].
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MV0%&T'A0V&89YP1WH$5%:#7-,NIFMX+>>S\ME>!/+!5R00P!.3A6Y)/4>AR
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MA)+DM%/&\4BAKB1E)2158!@01D<@@CB@#V.@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /)/AW_R&=?\ ^OT?^CKR@#UN@ H * "@ H * "@ H *
M"@ H * "@ H * /$_C%_RX_]O/\ [;UK#J>?B?L_/]#Q*M3@"@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#Z^\,_\@FR_P"O2W_]$I7,]V>W#X(^B_(VZ1H% !0 4 % !0 4 % !
M0 4 % !0 4 >2:Q_R/FF_P#7D_\ Z!?4 >MT % !0 4 % !0 4 % !0 4 %
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M!R>,$< GGH1F@#H=+U#3M-NUN;B^FO6&X*S1RA8\J07;>68DC*C8#C<<\<@
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M'&: (='U""UL+Z"5MLEPD0C7#'<5+EN0"!C(^\1[4 <U3 * "@ H * "@ H
M* "@ H * "@#WCP9_P @BW_[:_\ HZ2I&=10!CZ!_P >,7_ _P#T8U9P^%?U
MU&;%:""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /)/AW_R&=?\ ^OT?
M^CKR@#UN@ H * "@ H * "@ H * "@ H * "@ H * /$_C%_RX_]O/\ [;UK
M#J>?B?L_/]#Q*M3@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#Z^\,_\@FR_P"O2W_]$I7,]V>W
M#X(^B_(VZ1H% !0 4 % !0 4 % !0 4 % !0 4 >2:Q_R/FF_P#7D_\ Z!?4
M >MT % !0 4 % !0 4 % !0 4 % !0 4 % &/H'_ !XQ?\#_ /1C5G#X5_74
M9L5H(\O^)'_+I_VW_P#:--"/+Z8!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!M:EKDVI1);%(8(8B66.%
M"B[CW(+-SR>F!R: ,6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * />/!G_((M_^VO\ Z.DJ1G44 8^@?\>,7_ __1C5G#X5_749
ML5H(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \D^'?_ "&=?_Z_1_Z.
MO* /6Z "@ H * "@ H * "@ H * "@ H * "@ H \3^,7_+C_P!O/_MO6L.I
MY^)^S\_T/$JU. * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M<>N" : +*Z7>,GFK!,8\9WB-]N/7=MQCWS0!0H * "@ H * "@ H * "@ H
M* "@ H * />/!G_((M_^VO\ Z.DJ1G44 8^@?\>,7_ __1C5G#X5_749L5H(
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H \D^'?_ "&=?_Z_1_Z.O* /
M6Z "@ H * "@ H * "@ H * "@ H * "@ H \@^*VF7>H_8OL<$UQL^T;O*C
M>3;N\C&[8#C.#C/7!QT-:1=KG#B(N7+RIO?97['D'_",ZM_SY7?_ (#S?_$5
MK==SBY)_RO[F'_",ZM_SY7?_ (#S?_$477<.2?\ *_N8?\(SJW_/E=_^ \W_
M ,11==PY)_RO[F'_  C.K?\ /E=_^ \W_P 11==PY)_RO[F'_",ZM_SY7?\
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MW_/E=_\ @/-_\11==PY)_P K^YA_PC.K?\^5W_X#S?\ Q%%UW#DG_*_N8?\
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M%UW#DG_*_N8?\(SJW_/E=_\ @/-_\11==PY)_P K^YA_PC.K?\^5W_X#S?\
MQ%%UW#DG_*_N8?\ ",ZM_P ^5W_X#S?_ !%%UW#DG_*_N8?\(SJW_/E=_P#@
M/-_\11==PY)_RO[F'_",ZM_SY7?_ (#S?_$477<.2?\ *_N8?\(SJW_/E=_^
M \W_ ,11==PY)_RO[F'_  C.K?\ /E=_^ \W_P 11==PY)_RO[F'_",ZM_SY
M7?\ X#S?_$477<.2?\K^YA_PC.K?\^5W_P" \W_Q%%UW#DG_ "O[F'_",ZM_
MSY7?_@/-_P#$477<.2?\K^YA_P (SJW_ #Y7?_@/-_\ $477<.2?\K^YA_PC
M.K?\^5W_ . \W_Q%%UW#DG_*_N8?\(SJW_/E=_\ @/-_\11==PY)_P K^YA_
MPC.K?\^5W_X#S?\ Q%%UW#DG_*_N8?\ ",ZM_P ^5W_X#S?_ !%%UW#DG_*_
MN8?\(SJW_/E=_P#@/-_\11==PY)_RO[F'_",ZM_SY7?_ (#S?_$477<.2?\
M*_N8?\(SJW_/E=_^ \W_ ,11==PY)_RO[F'_  C.K?\ /E=_^ \W_P 11==P
MY)_RO[F'_",ZM_SY7?\ X#S?_$477<.2?\K^YA_PC.K?\^5W_P" \W_Q%%UW
M#DG_ "O[F'_",ZM_SY7?_@/-_P#$477<.2?\K^YA_P (SJW_ #Y7?_@/-_\
M$477<.2?\K^YA_PC.K?\^5W_ . \W_Q%%UW#DG_*_N8?\(SJW_/E=_\ @/-_
M\11==PY)_P K^YA_PC.K?\^5W_X#S?\ Q%%UW#DG_*_N8?\ ",ZM_P ^5W_X
M#S?_ !%%UW#DG_*_N8?\(SJW_/E=_P#@/-_\11==PY)_RO[F'_",ZM_SY7?_
M (#S?_$477<.2?\ *_N8?\(SJW_/E=_^ \W_ ,11==PY)_RO[F'_  C.K?\
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M[$K\N/:@#*M$$9UI%X"B0 >@$D@% %6ZU.>QT.QBMW:(S&X+,AVMA)C\N1R
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M@#6H * "@ H \Y\9^)[^SO+30-$5/[1U#+>;*,QP1+G<Y7G)PKGD$ *?E9F
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MR3X=_P#(9U__ *_1_P"CKR@#UN@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M;F-&CW@@/+_RS*9'(.[E@#V]#2 XZPU.?3KD7D3?O023GD-G[P;U#=^_<$$
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M +:_^CI*D9U% &/H'_'C%_P/_P!&-6</A7]=1FQ6@@H * "@ H * "@ H *
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MNVO[&VNI/OSP12-]7C5C^IH T: "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /)/AW_R&=?_ .OT?^CKR@#UN@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H \DUC_ )'S3?\ KR?_ - OJ /6Z "@ H * "@ H * "@ H * "@ H * "@
M#'T#_CQB_P"!_P#HQJSA\*_KJ,V*T$>7_$C_ )=/^V__ +1IH1Y?3 * "@ H
M * "@ H * "@ H * "@ H * "@"S)>3S1K#))(\<?W49V*K@8&U2<# XX'2@
M"M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MQ!;1+W)\P2$CV^0*QZ -[@T >B6%HMA;16J'*P1I&#TR$4*#CZ"@"U0 4 %
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M]!/4/_ RX_\ CE'LJ?\ )'_P%?Y![6I_/+_P)_YA_P )OX@_Z">H?^!EQ_\
M'*/94_Y(_P#@*_R#VM3^>7_@3_S#_A-_$'_03U#_ ,#+C_XY1[*G_)'_ ,!7
M^0>UJ?SR_P# G_F'_";^(/\ H)ZA_P"!EQ_\<H]E3_DC_P" K_(/:U/YY?\
M@3_S#_A-_$'_ $$]0_\  RX_^.4>RI_R1_\  5_D'M:G\\O_  )_YA_PF_B#
M_H)ZA_X&7'_QRCV5/^2/_@*_R#VM3^>7_@3_ ,P_X3?Q!_T$]0_\#+C_ ..4
M>RI_R1_\!7^0>UJ?SR_\"?\ F'_";^(/^@GJ'_@9<?\ QRCV5/\ DC_X"O\
M(/:U/YY?^!/_ ##_ (3?Q!_T$]0_\#+C_P".4>RI_P D?_ 5_D'M:G\\O_ G
M_F'_  F_B#_H)ZA_X&7'_P <H]E3_DC_ . K_(/:U/YY?^!/_,/^$W\0?]!/
M4/\ P,N/_CE'LJ?\D?\ P%?Y![6I_/+_ ,"?^8?\)OX@_P"@GJ'_ (&7'_QR
MCV5/^2/_ ("O\@]K4_GE_P"!/_,/^$W\0?\ 03U#_P #+C_XY1[*G_)'_P !
M7^0>UJ?SR_\  G_F'_";^(/^@GJ'_@9<?_'*/94_Y(_^ K_(/:U/YY?^!/\
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M#+C_ ..4>RI_R1_\!7^0>UJ?SR_\"?\ F'_";^(/^@GJ'_@9<?\ QRCV5/\
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M!_T$]0_\#+C_ ..4>RI_R1_\!7^0>UJ?SR_\"?\ F'_";^(/^@GJ'_@9<?\
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M !0 4 % !0 4 % !0 4 % !0 4 >2:Q_R/FF_P#7D_\ Z!?4 >MT % !0 4
M% !0 4 % !0 4 % !0 4 % &/H'_ !XQ?\#_ /1C5G#X5_749L5H(\O^)'_+
MI_VW_P#:--"/+Z8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 >\>#/^01;_ /;7_P!'25(SJ* ,?0/^/&+_
M ('_ .C&K.'PK^NHS8K004 % !0 4 % !0 4 % &/K^B6_B*QETZZ_U<RX##
M[R,#E'7_ &D8 CUZ'@F@"WIMO/:6L4%U+]IFC15>;9L\P@8WE=SX)ZM\QR<G
MC.  7: "@ H * "@ H * "@ H * "@#FKCPX+S6(M7N9/,6SB9+:#9A8I'_U
MDQ8LV]V7"KA4"J!]YN: .EH * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /)/AW_R&=?\ ^OT?^CKR@#UN@ H * "@ H * "@ H * "@ H * "
M@ H * /F']I#_F%?]OO_ +:5[.!^W_V[_P"W'CX[['_;W_MI\P5[!XP4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?HMX(_Y%_3/^P?9_P#I/'7RE7^)/_%+\V?5TOX</\,?R1T]
M8FP4 % !0 4 % !0 4 % !0 4 % !0!Y)K'_ "/FF_\ 7D__ *!?4 >MT %
M!0 4 % !0 4 % !0 4 % !0 4 % &/H'_'C%_P #_P#1C5G#X5_749L5H(\O
M^)'_ "Z?]M__ &C30CR^F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'O'@S_D$6_\ VU_]'25(SJ* ,?0/
M^/&+_@?_ *,:LX?"OZZC-BM!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'DGP[_ .0SK_\ U^C_ -'7E 'K= !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?,/[2'_,*_P"WW_VTKV<#]O\ [=_]N/'QWV/^WO\ VT^8*]@\8* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M?_D#_P"W47 /^%;?]/?_ ) _^W47 /\ A6W_ $]_^0/_ +=1< _X5M_T]_\
MD#_[=1< _P"%;?\ 3W_Y _\ MU%P#_A6W_3W_P"0/_MU%P#_ (5M_P!/?_D#
M_P"W47 /^%;?]/?_ ) _^W47 /\ A6W_ $]_^0/_ +=1< _X5M_T]_\ D#_[
M=1< _P"%;?\ 3W_Y _\ MU%P#_A6W_3W_P"0/_MU%P#_ (5M_P!/?_D#_P"W
M47 /^%;?]/?_ ) _^W47 /\ A6W_ $]_^0/_ +=1< _X5M_T]_\ D#_[=1<
M_P"%;?\ 3W_Y _\ MU%P#_A6W_3W_P"0/_MU%P#_ (5M_P!/?_D#_P"W47 /
M^%;?]/?_ ) _^W47 /\ A6W_ $]_^0/_ +=1< _X5M_T]_\ D#_[=1< _P"%
M;?\ 3W_Y _\ MU%P#_A6W_3W_P"0/_MU%P#_ (5M_P!/?_D#_P"W47 /^%;?
M]/?_ ) _^W47 /\ A6W_ $]_^0/_ +=1< _X5M_T]_\ D#_[=1< _P"%;?\
M3W_Y _\ MU%P#_A6W_3W_P"0/_MU%P#_ (5M_P!/?_D#_P"W47 [S1=-_LBS
MCL]_F>5N^;;MSN=G^[EL8W8ZG.,^U(9J4 8^@?\ 'C%_P/\ ]&-6</A7]=1F
MQ6@@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#R3X=_\AG7_ /K]'_HZ
M\H ];H * "@ H * "@ H * "@ H * "@ H * "@#YA_:0_YA7_;[_P"VE>S@
M?M_]N_\ MQX^.^Q_V]_[:?,%>P>,% !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z+>"/^1?TS_L'
MV?\ Z3QU\I5_B3_Q2_-GU=+^'#_#'\D=/6)L% !0 4 % !0 4 % !0 4 % !
M0 4 >2:Q_P CYIO_ %Y/_P"@7U 'K= !0 4 % !0 4 % !0 4 % !0 4 % !
M0!CZ!_QXQ?\  _\ T8U9P^%?UU&;%:""@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,?0/^/&+_
M ('_ .C&K.'PK^NHS8K004 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y
M)\._^0SK_P#U^C_T=>4 >MT % !0 4 % !0 4 % !0 4 % !0 4 % !0!\P_
MM(?\PK_M]_\ ;2O9P/V_^W?_ &X\?'?8_P"WO_;3Y@KV#Q@H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _1;P1_R+^F?]@^S_P#2>.OE*O\ $G_BE^;/JZ7\.'^&/Y(Z>L38* "@
M H * "@ H * "@ H * "@ H \DUC_D?--_Z\G_\ 0+Z@#UN@ H * "@ H *
M"@ H * "@ H * "@ H Q] _X\8O^!_\ HQJSA\*_KJ,V*T$% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 8^@?\>,7_  /_ -&-6</A7]=1FQ6@@H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@#R3X=_\AG7_P#K]'_HZ\H ];H * "@ H * "@ H * "@ H
M * "@ H * "@#YA_:0_YA7_;[_[:5[.!^W_V[_[<>/COL?\ ;W_MI\P5[!XP
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 ?HMX(_Y%_3/^P?9_\ I/'7RE7^)/\ Q2_-GU=+^'#_
M  Q_)'3UB;!0 4 % !0 4 % !0 4 % !0 4 % 'DFL?\CYIO_7D__H%]0!ZW
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 8^@?\>,7_ __ $8U9P^%?UU&;%:"
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * ,?0/^/&+_@?_ *,:LX?"OZZC-BM!!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % 'DGP[_ .0SK_\ U^C_ -'7E 'K= !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 ?,/[2'_,*_P"WW_VTKV<#]O\ [=_]N/'Q
MWV/^WO\ VT^8*]@\8* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * /T6\$?\B_IG_8/L__ $GCKY2K
M_$G_ (I?FSZNE_#A_AC^2.GK$V"@ H * "@ H * "@ H * "@ H * /)-8_Y
M'S3?^O)__0+Z@#UN@ H * "@ H * "@ H * "@ H * "@ H Q] _X\8O^!_^
MC&K.'PK^NHS8K01Q7C#5[K2O(^R/Y?F>9N^5&SM\O'WE;&-QZ8Z\T <3_P )
M=JO_ #W_ /(<7_Q% !_PEVJ_\]__ "'%_P#$4 '_  EVJ_\ /?\ \AQ?_$4
M'_"7:K_SW_\ (<7_ ,10 ?\ "7:K_P ]_P#R'%_\10 ?\)=JO_/?_P AQ?\
MQ% !_P )=JO_ #W_ /(<7_Q% !_PEVJ_\]__ "'%_P#$4 '_  EVJ_\ /?\
M\AQ?_$4 '_"7:K_SW_\ (<7_ ,10 ?\ "7:K_P ]_P#R'%_\10 ?\)=JO_/?
M_P AQ?\ Q% !_P )=JO_ #W_ /(<7_Q% !_PEVJ_\]__ "'%_P#$4 '_  EV
MJ_\ /?\ \AQ?_$4 '_"7:K_SW_\ (<7_ ,10 ?\ "7:K_P ]_P#R'%_\10 ?
M\)=JO_/?_P AQ?\ Q% !_P )=JO_ #W_ /(<7_Q% !_PEVJ_\]__ "'%_P#$
M4 '_  EVJ_\ /?\ \AQ?_$4 '_"7:K_SW_\ (<7_ ,10 ?\ "7:K_P ]_P#R
M'%_\10 ?\)=JO_/?_P AQ?\ Q% !_P )=JO_ #W_ /(<7_Q% !_PEVJ_\]__
M "'%_P#$4 '_  EVJ_\ /?\ \AQ?_$4 '_"7:K_SW_\ (<7_ ,10 ?\ "7:K
M_P ]_P#R'%_\10 ?\)=JO_/?_P AQ?\ Q% !_P )=JO_ #W_ /(<7_Q% !_P
MEVJ_\]__ "'%_P#$4 '_  EVJ_\ /?\ \AQ?_$4 '_"7:K_SW_\ (<7_ ,10
M ?\ "7:K_P ]_P#R'%_\10 ?\)=JO_/?_P AQ?\ Q% !_P )=JO_ #W_ /(<
M7_Q% !_PEVJ_\]__ "'%_P#$4 '_  EVJ_\ /?\ \AQ?_$4 '_"7:K_SW_\
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MQ?\ Q% !_P )=JO_ #W_ /(<7_Q% !_PEVJ_\]__ "'%_P#$4 '_  EVJ_\
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M.(]M)PY;65][]4NR.^MA_814^:]W:UK=+]V>15W' % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % 'KNN?"O^Q?#4/B;[9YOGPVLOV?[/MV_:0AV
M^;YS9V;^OEC=CHN>.&&(YZKH\MK.2O?M?I;]3NGA^2DJW->ZB[6[^=_T/(J[
MCA"@ H WO#?AJ^\5WBZ?IJ"29@6.XA51 0&=V/15+#. 6.0%!) K*=2-*/-/
M1?UH:PIRJRY(;_UJ2>*_#[^%=4FTF203/;>6&=5*J2\22' ))P"^T$\G&<#.
M 4Y^UBII6O?3YV"I#V4G!N]K?E<YVM3([OP3X3T_Q1]H_M'5+?1OL_E;//\
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MC'FR[L[O48QWK.A6]NF^7EM;K??Y(TKT?8-*][WZ6V^;/-JZSD"@ H * "@
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M&5K>YC>":,X>.161U/HRL RGV(!H335T[KN@:<79JS71Z$%,04 % !0 4 %
M!0 4 % !0!^BW@C_ )%_3/\ L'V?_I/'7RE7^)/_ !2_-GU=+^'#_#'\D=/6
M)L% !0 4 % !0 4 % !0 4 % !0 4 >2:Q_R/FF_]>3_ /H%]0!ZW0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 8^@?\>,7_ __1C5G#X5_749L5H(\X^('_+M
M_P!MO_:5 'G% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 >U^$?^05!_VT_P#1KT ='0!CZ!_QXQ?\#_\
M1C5G#X5_749L5H(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \D^'?\
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M\(S<@X!9BX-=&'KNHW3J*TU\KVWT[G/B*"I)5*;O!_A?;Y'J7CC_ ))K9_\
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MCHK$;LLI4_,P(QT8:NZMX3^):^J_S,,305*TX?"]+=G_ )'I_P =/^15L?\
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M1BEHN_=VZ>OS+7Q0LXM6U/1K"X:(:S/%!!J31;3MED,*(7V_+O!:0XZ[=O\
M 4I8=N$:DE?V:;<+]E?_ ( \0E*5.+MSM)3MW=O^"-^)OC34?#VLKHNASR:?
M9:1'#'''"=BLQB60LX'^L&'"[9-RDJ6VY8DE"E&</:5$I2FVVWZVT[?(*]65
M.?LZ;<8P222]+Z]_F4/BO"FHVFD>*$18Y]4ML71C "F>)8\-@<[CN=<DD[8U
M4_=YK#OE=2CTB]+]G?\ KYDXA<RIUEO):V[JW]?(K>-[<>)/#VG>+@/]*/\
MH%^0.7DB#"*9\8 9D3YB0/OQJ.%4&J3]G4G0Z?%'R3W7]>9-5>TIPK]?AEYM
M;/\ KR/':[S@"@ H * "@ H * "@ H * /T6\$?\B_IG_8/L_P#TGCKY2K_$
MG_BE^;/JZ7\.'^&/Y(Z>L38* "@ H * "@ H * "@ H * "@ H \DUC_ )'S
M3?\ KR?_ - OJ /6Z "@ H * "@ H * "@ H * "@ H * "@#'T#_CQB_P"!
M_P#HQJSA\*_KJ,V*T$><?$#_ )=O^VW_ +2H \XH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M.Z7YGI5_W>'C"7Q6BK>:LW^0>./^2:V?_7II?_H$%%+_ 'F7^*?ZA5_W:/\
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M&NHQ=TI;]]#:HW*@W)6;CMVU,'X<:?+JWP^EL;? FN8;^*/)P-\AE503V!)
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]K\(_\@J#
M_MI_Z->@#HZ ,?0/^/&+_@?_ *,:LX?"OZZC-BM!!0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!XK=3ZI\2;AK
M2U#V&C1/MED8;9)BIP5P>IR/N?=3K(2VU: /5M'T:TT&V6SL4$<2\^K,W=G;
MJS'N3VP!@   &I0!\P_M(?\ ,*_[??\ VTKV<#]O_MW_ -N/'QWV/^WO_;3Y
M@KV#Q@H * "@ H * "@ H * "@#T;Q?\3M3\:V<6GW\5K'%!(LJF!)58LJ,@
M!+S2#&').%!SCG'!Y*6'C1;E%N[5M;>O1(ZZM>59*,DDD[Z7].[-O1OCAXAT
M:T2R'V:Z6)0B27$<C2A0,*"R2QAL# W,K,<?,2<DYRPE.3YM5?HFK?BF:1Q=
M2"Y=';JT[_@T,_X77KTMO<V=XMI>17OF!Q-')\D<B"-HH_*FB"QA02,AFW,S
M%B31]5IIJ4>9.-MFMT[W=T]0^M5+.,N5IWW3V:M96:T,?PI\3M3\':?+I=C%
M:R0W$CRLTR2LX:2-(B%*31J %C!&5)R3DD8 TJ8>-62G)NZ5M+6T;?9]S.G7
ME2BX12LW?6]]4EW78YWPIXHNO!]^NIV*Q23(CH%F5F3#C!R$>-LXZ?-]0:UJ
M4U5CR2NEY?TS*G4=*7/&U_/S^XNZWXYU+6M77Q 2EI>QA C6P9%7RQM! =Y"
M<C(<%BK E2NTD5,*,80]EO'7?S]+%3JRG/VNTM-O+[SOX?V@/$<481H[&5@,
M>8\,H8G'4A)T3/?A ,]L<5S/!T^\EY77^1TK&5%I:/W/]&>:>*/%NI>,+D7>
MJ2^8R K&B@+'&I.2J(.!GC+'+M@;F.!CKITXTERP5N_=^IR5*DJKYIOT[+T.
MI\,?%S7_  K;BS@>*YMXQB..Y1G$8'\*,CQN%'92Y50,* *QJ8:G4?,TT^K6
ME_S1M3Q-2DN56:Z)]/R9'XJ^*^N^+H/L=T\5O;-]^*V1D63D$!R[R.0"/N[P
MIZL"0,.GAZ=)\T;M]WT]-A5,14JKE=DNRTO^9[-^SI_QXW__ %WB_P#1;5Y^
M-^*/H_S/0P7PR]5^1P+?'#Q%I+2V(^S7 AED1)9HW,H578*"4E16*C RR%CC
M+%CDGI^J4Y6EJKI:)Z?DSF^MU(7CH[-ZM:_FCR]_%.H7&K1Z]=2?:;V&>*<&
M4?*6A=712J%,1C:!M0KA> 0>:[?9Q4'2BK1::T\_U.+VDG-56[R33U\OT-7Q
MKX]O_'4D,NH1V\1M5=4\A9%!#E2=WF2R9/RC&".^<U%*C&A=0;U[V_1(TJUI
M5K.22MVOU]6R3P;\1M6\#B2/3FC>"8[VAG0O'OP!O&UD=6V@*<. P W X4A5
M:$*UG*Z:ZK?TZA2KSHW4+6?1[>O0ZYOCSXD:Y6YQ:!$5AY BD$3%L?,W[[S2
MRX^7]Z%&3E36'U.G:WO>MU?\K?@;_7*E[^[Z6=OSO^)3T[XSZQI=W=WL%O8B
M349(Y9E,<Y0-'&(P4 N01N W-EFRQ)&!Q52PL)*,6Y6BFEJNKOV)CBIQ<I)1
M]YIO1]%;N;7_  T+X@_Y]]/_ ._5Q_\ )59_4J?>7WK_ .1-/KM3M'[G_P#)
M'G/B+QSJ7B/5$UN0I:WD*(B-:[XPNPL0PW22-N^8@_-@CC'7/5"C&G%TUK%]
M[/?Y(Y9U95)*H])+:UUM\V=Y:_'SQ);1")ULYV4 >;)#('/N?+FCCR>IP@'M
M7,\'3;NN9>2:M^*;.E8RHE;W7YM/]&E^!YIXE\5:CXMN?MFJ2F5P"J* %CC4
MG.V-!PH]3RS8!9F/-=E.G&DN6"M^;]3CJ5)57S3=_P EZ'2:K\3M3U?0X_#D
MT5JMI!'!$KHDHF*VX4(2QF9,G8-V(P#S@+VQCAXPFZJ;NVWTMKOT_4VE7E*"
MHM*R276^GS_0A\(_$O6O!<9M[%TDMF);R)U+QJQZE=K(Z9[A7"D\D9YIU*$*
MNLKI]UHQ4Z\Z.D;6[/8W]:^-_B/6;=K4&WLUD!5FMHW60J1@@/)+*4R#]Y-K
M#LPK*&$IP=]7;N]/P2-98NI)<ND?1:_BV>05WG ;OAOQ'>^%+U-1TY@DT8*X
M8;D=6^\CKQE3QT(((!!! (RG"-6/)/8UA.5*7/#<[CQ!\8-8\2"U%U%:(+&[
MBO(Q''*-TL.[8'W3N2AW'<%*D\885SPPT*=^5R]Z+B[M;/Y'1/$SJ6NH^[)2
M5D]U\S#\:_$#4/';0-J$=O$;02!/(61<^9LW;O,EESC8,8QWSGC&E*C&A?D;
MUMO;IZ)=S.K6E6MS)*U]K]?5OL.\$_$+4/ ?VC^SH[>7[9Y6_P ]9&QY7F;=
MOERQ8SYK;L[LX&,<Y*M&->W.VK7M:W6W=/L%*M*A?D2UMO?I?LUW/1O@3>/J
M'BF]NY  ]Q9W$K!<A0SW5LQ"@DD $\9)..I-<F+7+2C%=))?=%G7A'S592?6
M+?WR1I^+OB[KGA+7;_3K;[//;QRCRUN(W8QAHT8A6CDB)&XD@.6QD@8& (IX
M:%6G&;NG;6SWU?=,NIB9TJDH*S5]+K;1=FCP_P 3^+-1\7W7VS4Y/,905C11
MMCB4G.V-!T]R27; W,<"O1ITXTERP5OS?J>=4J2JOFF_3LO0Z+Q7\3M3\8:?
M%I=[%:QPV\B2JT*2JY:.-X@&+S2*05D).%!R!@@9!RIX>-*3G%N[5M;6U:?9
M=C6I7E5BH22LFGI>^B:[ON'A+XIZWX.@^R6;QSVV25AN%9UC)Y;85>-U#'DK
MNVYRP4$L25,/"J^:5T^ZTOZ[A3Q$Z*Y8V:[/IZ;&EXA^,WB'Q#;/9.T%I%*"
MLGV:-D9T((*%Y))6"MGG85)Z$[208AA:=-\RNVMKO_)(N>*J5%RZ)/>R_P V
MSR>NXX3I/"OBJ^\'7HU'3642[&C977<CQL5)1AD'&Y5;*LK94<XR#C4IQJQY
M)[;Z=&;4ZDJ,N:&^WR.NU_XN:QXBFLY[F*T0Z;=1W<2QQRA6EC(*B3=,[%.,
M$*R$CN#@UA##0IJ23E[R<7=K9]M#>>)G4<6U'W6I*R>Z[ZF)XU\>W_CJ2&74
M([>(VJNJ>0LB@ARI.[S)9,GY1C!'?.:UI48T+J#>O>WZ)&=6M*M9R25NU^OJ
MV:/_  M'5/[!_P"$9\JU^Q^5Y._9+YVW=OSN\[9NSW\O&.W>H^KQ]I[:[YKW
MZ6_*_P")7UB7L_8V7+:W6_YV_ SO"'Q"U?P3O73I%:&4[F@F4O$6Z;P RLK8
M&"49=PQNSM7%5*,*WQK5=5HR:5:='X'IV>QUVJ?'7Q)J,#0)]FL]XP9+>)Q(
M!WVM++*%)'&X ,.JD-@C".$IQ=]7Y-Z?@D;RQ=22LK+S2U_%LY?P7\1-1\"F
MX-@EO,;WRC(;A9'(,7F;2NR6/KYK;MV[/&,<YWJT(UK<S:M>UK=;=T^QA2KR
MH7Y4G>U[WZ7[-=SC+Z\?4+B6[D #W$CRL%R%#.Q8A022 ">,DG'4FMTN5**Z
M*WW&#?,W)]7?[SUW3_CMXCL+9;9A:W)1=HFFBD,I Z;BDT:,0.,E,G&6).2>
M&6#IMWU7DFK?DSNCBZD5RZ/S:=_P:*-S\9M=O]/N-+O5M;F.\657>2.02*LH
M(PGERHBB/_EGE#@@;MW.:6%IQDIQNFK:)JVG>ZOKUU)>*J2BX2LT[[IWU[6:
M6G30]H^'US)9_#JXN(&,<L-MJ4D;J<,KH)F5@>Q4@$'U%>?62>(2>S<$_P #
MT*+:P[:W2G;\3R9_CSXE:V^SC[*LFW;]H$+>=G&-^#(8=W?_ %.W/\..*[OJ
M=*]_>MVOI^5_Q.'ZY5M;3UMK^=OP//-&T'5/&U[+%9*;N\96N)-\B*S#>H=R
M\K*"=T@)&<GD@'%=4IPHQ3EI'9:?Y>ARQA.M)J.LMWK_ )^I]4^+-2F\ ^!X
M].NIE.HO:I91["0<LH1]A'S8@A) DP,LJ'@L!7BTXJO7<HKW;\S_ $OZOH>U
M4DZ%!0;]ZW*OUMZ+J?&-?0'SX4 >R>)IO^$P\)V&K1DO=:(?L-XN<L(F $$S
M$G<0=JJ3SF21_P"Z37GTU[*K*F]I^]'UZK^NB/0J/VM*,UO#W9>G1_UU9P>N
M>+;O7[&PTZY2%(M)C>*$QJX=E<1@F0L[*3^Z7&U4')R#QCJA35.4IJ]YN[O\
M]M/,Y9U'.,8.UH*RMYVWU\@M_%MW;:'-X<1(3:7-P+EW*OYP<"(85@X0+^Z7
M@QD\M\W(P.FG-5=;I6\K:^7GW!5&H.CI9N_G?3S\NQR];&(4 % !0!Z/I'Q/
MU/3+%-*N(;+4[2 @PQW]OYXB ^Z$PZ<+_#NW%0=JD* !R2P\92<TY1;W<7:Y
MUQQ$HQ4&HRBME)7L87BKQEJ7C"9)=1==D(*PPQ+LAB! !"+R?FV@DLS-P!G:
M !I3I1HJT.N[>[,ZE655WGTV2T2]#H]/^*VJ6EI#8W<%CJ<=KCR#?6_G/%M&
M%V,'3E1PK$%@.-V,8R>'@VY1<HM[\KM?\#6.(DDHR49);<RO;\3EO$_BS4?%
M]R+K4I Y0;8XT&R*)>NV-!TSW))9L#<QP,;4Z<:2Y8+U?5^IC4J2JOFF_1=%
MZ'6:;\6=6L;6"TN(+'4!9X%O)>6YEEAP,+L<2)@J. Q!;'!8BL98:#;DG*-]
MU%V3^5C:.)G%*+496V<E=KTU.(U_7[WQ->/J&HR&6>3CT5%'W411PJ+V [DL
M269F/1"$:<>2"LOZU9SSG*H^:;U_K1'I7CB?_A&_#VF^$0<7(_T^^4'!227<
M8H6P2"45SN!)^Y&XZBN2DO:5)U^GPQ]%N_Z\SKJOV=.%#K\4O)O9?UY'CE=Y
MP!0 4 % !0 4 % !0 4 % 'Z+>"/^1?TS_L'V?\ Z3QU\I5_B3_Q2_-GU=+^
M'#_#'\D=/6)L% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 8^@?\>,7_  /_ -&-6</A7]=1FQ6@CSCX@?\ +M_VV_\
M:5 'G% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 >U^$?^05!_VT_]&O0!T= &/H'_ !XQ?\#_ /1C5G#X
M5_749L5H(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'M?A'_D%0?]M/\ T:] '1T
M8^@?\>,7_ __ $8U9P^%?UU&;%:""@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#YA_:0_YA7_;[_P"V
ME>S@?M_]N_\ MQX^.^Q_V]_[:?,%>P>,% !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]
M%O!'_(OZ9_V#[/\ ])XZ^4J_Q)_XI?FSZNE_#A_AC^2.GK$V"@ H * "@ H
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M8"G!(\X[@/JN>.XXYSB@"*&&6S\/S)?AER3Y:OG<H.P(,'D8DRP'8<\4 /\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H _1;P1_R+^F?]@^S_P#2>.OE*O\
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M2NAJ6H7:Q2P,N%;8A< 9&#E1CJ& 0Y'&>: ,;Q%J2ZI>O-&<QJ D?&/E7O\
MBQ8C/.#0!AT % !0 4 % 'M?A'_D%0?]M/\ T:] '1T 8^@?\>,7_ __ $8U
M9P^%?UU&;%:""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#YA_:0_YA7_;[_P"VE>S@?M_]N_\ MQX^
M.^Q_V]_[:?,%>P>,% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0!.MK*T37 4^4C!2_;<>@]SW(&<#!.,B@""@ H * "@ H * "@ H * "@
MH * "@ H * "@#VOPC_R"H/^VG_HUZ .CH Q] _X\8O^!_\ HQJSA\*_KJ,V
M*T$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % 'S#^TA_P PK_M]_P#;2O9P/V_^W?\ VX\?'?8_[>_]
MM/F"O8/&"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M*!G@Y/(H Q-<TM=)N!$C>9&Z+(C'@[6R!GMG(/3KUP.E $WA[2H]7N&@E9D
MB9P5Q]X%0,Y!XYY P?<4 2)9:9=SI#;S20H-QDEN#&%VKC'E@;3ECT#'('.#
MR* +MEIFE:I*;6UDN4F(8HT@C*,5!/10&Z#.,C@'OQ0!;T 6J:=>K,)@0$$X
M79TW/M\O(X/7=NXZ8H R;;2K1+8ZA>/*EN[E(40*97P3R2?E&,$'CJ#TX# #
M+W2K<VG]H:>\C0J^R1)0H=&/0DKA2#D#@=Q[@ &);KOE1<D991D<$9(Y!]?2
M@#L/[#CO-6N+.665A''O$CL&<D+'C>Q7D#=V . !F@"O:Z3IVJ>9!8R3_:(T
M9U,H01R;?0*-R@\8R<@'.#@B@#D: -^UL]/BMEN+V5V>0D"& H74#N^[.,]A
M@'Z\X ':II5O!:Q7]D[M#,Q0K*!O5AGJ5P#T/Y9!.> #N/\ F8)/^O;^BT >
M34 =1%I-G:V<5Y?&X;[1N*B )A #CYF<$9/8<>G8F@ 31K2:_@MX)C+;W SE
M2HD3Y2=K#! ;@=5'4C&1F@#+6Q0ZB+++>6;GR<Y&[;YFS.<8W8[XQGMVH Z;
M1+..*?4;0OLB2.6/>W)5%<KN., D 9.,9]J *$6DV&II(FG//]HB4N%F"8D5
M>NW:!@],;CW''4@ J/9DZ5%,KRL7N2@BW9CSM."J8^^>F<]#C% %RXTO3=*9
M;>^DG:XP#)Y(39'NY .X%C@'/')'.!D"@""3PW)]N2RA</',HD27''ED$EB!
MW&",9Y..1NX )EL=&FD:VCGFC<!@LTGEB L/H P![$D9^I&0#2MULDT-UD\X
MH+C#[#&290B\H<8,73&?FZ\]* ,PZ38V%M#/?&X8W*[QY 38@.,!BXY;!S@>
M_L2 8^JVD-E-LMI1/$RAU8$9 .?E;'1ACD<'ID#I0!FT % !0 4 % !0 4 %
M !0 4 % !0 4 % 'M?A'_D%0?]M/_1KT ='0!CZ!_P >,7_ _P#T8U9P^%?U
MU&;%:""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M?YOPE_D'U6M_+^,?\P_X4SXN_P"?#_R9L_\ Y(H^M4?YOPE_D'U6M_+^,?\
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M'_,/^%,^+O\ GP_\F;/_ .2*/K5'^;\)?Y!]5K?R_C'_ ##_ (4SXN_Y\/\
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MM_+^,?\ ,/\ A3/B[_GP_P#)FS_^2*/K5'^;\)?Y!]5K?R_C'_,/^%,^+O\
MGP_\F;/_ .2*/K5'^;\)?Y!]5K?R_C'_ ##_ (4SXN_Y\/\ R9L__DBCZU1_
MF_"7^0?5:W\OXQ_S#_A3/B[_ )\/_)FS_P#DBCZU1_F_"7^0?5:W\OXQ_P P
M_P"%,^+O^?#_ ,F;/_Y(H^M4?YOPE_D'U6M_+^,?\P_X4SXN_P"?#_R9L_\
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ME_D'U6M_+^,?\P_X4SXN_P"?#_R9L_\ Y(H^M4?YOPE_D'U6M_+^,?\ ,/\
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M]1J4Y26SDVO1L^@IIQA&+W44GZI&[61J% !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 8^@?\>,7_  /_ -&-6</A7]=1FQ6@
MCSCX@?\ +M_VV_\ :5 'G% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =%J6I6KV<5A9++L
MCD,C-+L#$D$8PA(QR>>.@ZT <[0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 >U^$?^05!_VT_P#1KT ='0!CZ!_QXQ?\#_\ 1C5G#X5_749L
M5H(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Q] _P"/&+_@
M?_HQJSA\*_KJ,V*T$><?$#_EV_[;?^TJ /.* "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]K\(_P#(*@_[
M:?\ HUZ .CH Q] _X\8O^!_^C&K.'PK^NHS8K004 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0!CZ!_P >,7_ _P#T8U9P^%?UU&;%:"/./B!_
MR[?]MO\ VE0!YQ0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % 'M?A'_ )!4'_;3_P!&O0!T= &/H'_'C%_P
M/_T8U9P^%?UU&;%:""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * ,?0/^/&+_ ('_ .C&K.'PK^NHS8K01YQ\0/\ EV_[;?\ M*@#SB@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * /:_"/_ ""H/^VG_HUZ .CH Q] _P"/&+_@?_HQJSA\*_KJ,V*T$% !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8^@?\>,7_  /_ -&-
M6</A7]=1FQ6@CSCX@?\ +M_VV_\ :5 'G% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >U^$?^05!_VT_]
M&O0!T= &/H'_ !XQ?\#_ /1C5G#X5_749L5H(* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H Q] _X\8O^!_\ HQJSA\*_KJ,V*T$<#XXLY[O[
M/]GCDEV^;NV(S8SY>,[0<9P<9ZX- ' _V-?_ //M/_WZD_\ B: #^QK_ /Y]
MI_\ OU)_\30 ?V-?_P#/M/\ ]^I/_B: #^QK_P#Y]I_^_4G_ ,30 ?V-?_\
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M8U__ ,^T_P#WZD_^)H /[&O_ /GVG_[]2?\ Q- !_8U__P ^T_\ WZD_^)H
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M_P"C&K.'PK^NHS8K004 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0!CZ!_QXQ?\#_]&-6</A7]=1FQ6@@H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#'T#_CQB_X
M'_Z,:LX?"OZZC-BM!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MQ_YZ?^.2?_$T<\>_YA8/[?L?^>G_ (Y)_P#$T<\>_P"86#^W['_GI_XY)_\
M$T<\>_YA8/[?L?\ GI_XY)_\31SQ[_F%@_M^Q_YZ?^.2?_$T<\>_YA8/[?L?
M^>G_ (Y)_P#$T<\>_P"86#^W['_GI_XY)_\ $T<\>_YA8/[?L?\ GI_XY)_\
M31SQ[_F%@_M^Q_YZ?^.2?_$T<\>_YA8/[?L?^>G_ (Y)_P#$T<\>_P"86#^W
M['_GI_XY)_\ $T<\>_YA8/[?L?\ GI_XY)_\31SQ[_F%@_M^Q_YZ?^.2?_$T
M<\>_YA8/[?L?^>G_ (Y)_P#$T<\>_P"86#^W['_GI_XY)_\ $T<\>_YA8/[?
ML?\ GI_XY)_\31SQ[_F%@_M^Q_YZ?^.2?_$T<\>_YA8/[?L?^>G_ (Y)_P#$
MT<\>_P"86#^W['_GI_XY)_\ $T<\>_YA8/[?L?\ GI_XY)_\31SQ[_F%@_M^
MQ_YZ?^.2?_$T<\>_YA8/[?L?^>G_ (Y)_P#$T<\>_P"86#^W['_GI_XY)_\
M$T<\>_YA8/[?L?\ GI_XY)_\31SQ[_F%@_M^Q_YZ?^.2?_$T<\>_YA8/[?L?
M^>G_ (Y)_P#$T<\>_P"86#^W['_GI_XY)_\ $T<\>_YA8/[?L?\ GI_XY)_\
M31SQ[_F%@_M^Q_YZ?^.2?_$T<\>_YA8/[?L?^>G_ (Y)_P#$T<\>_P"86#^W
M['_GI_XY)_\ $T<\>_YA8/[?L?\ GI_XY)_\31SQ[_F%@_M^Q_YZ?^.2?_$T
M<\>_YA8/[?L?^>G_ (Y)_P#$T<\>_P"86#^W['_GI_XY)_\ $T<\>_YA8/[?
ML?\ GI_XY)_\31SQ[_F%@_M^Q_YZ?^.2?_$T<\>_YA8/[?L?^>G_ (Y)_P#$
MT<\>_P"86#^W['_GI_XY)_\ $T<\>_YA8/[?L?\ GI_XY)_\31SQ[_F%@_M^
MQ_YZ?^.2?_$T<\>_YA8/[?L?^>G_ (Y)_P#$T<\>_P"86#^W['_GI_XY)_\
M$T<\>_YA8/[?L?\ GI_XY)_\31SQ[_F%@_M^Q_YZ?^.2?_$T<\>_YA8/[?L?
M^>G_ (Y)_P#$T<\>_P"86#^W['_GI_XY)_\ $T<\>_YA8/[?L?\ GI_XY)_\
M31SQ[_F%@_M^Q_YZ?^.2?_$T<\>_YA8/[?L?^>G_ (Y)_P#$T<\>_P"86#^W
M['_GI_XY)_\ $T<\>_YA8/[?L?\ GI_XY)_\31SQ[_F%@_M^Q_YZ?^.2?_$T
M<\>_YA8- _X\8O\ @?\ Z,:B'PK^NH&Q6@@H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#DY?&^EPO*A-T_V:1H97CL+^6))$.UU,T=L\7RG@D.0/6@#5
M_M^P^SP7:S*\%Y)'%!(F75Y)3M104#8RP*DM@*00Q4@T :] !0 4 % !0 4
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M$*.Y"@D@=@3T!H ?0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MDA5VA"6) .N\(ZC<W]M,EXXFFL[RYM3*$">:(9"JNR+\JL5QN"X4L"0%!V@
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MI 5YIM1\/7UB+F\>_M]1G:TD22&",Q2F":=)(##'&1'^X9'CF:9L.&$A*D,
M<G:>(-8M- CUZZNVN)KTPVT4"VJ-%"\UTL"S[((_M,\BIEVB1B)'.R.(97#
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M';W.YC'/;RO'*0ODS(2%4[]D<<@#*P/5Z0!0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MHW+KA=NX,"VW[VW: -N>: #4-#@U*YANY6=7M4N(T"E0I%RBHY8%220%&S!
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M8)H6"RPR ,NY"0RG*,R.CH\;HQ5D(H R3X/MYH+R&[GN;N;4K9[2:YE:(3+
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MC?YF$&2-HV[=@'<-0 :=X2M-+DM)87F)T]+Q(MS(0PO98YI=^$7)5HU$>W:
MI(8.<$ &@-$@ O5W/C5',DW*_*3:PVG[OY>!Y<"-\V\[RQSM(4  =$@(LEW/
MC2W$D/*_,1:S6G[SY>1Y<[M\NP[PISM!4@&.O@R",>1'<WB6&\R?85DB$&2V
M\J'\G[4L1;GR5N1%CY0@7Y: +%YX6CGGEN+:YN[$W>#<I;/$$F95";R)896C
MD*!4:2!H7957+$J#0!IZ)H\'A^RBTVTW>1;J53>=S;<EL$@#.,X!QG&,Y/-
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >2>)Q-IVHSZ
M9;;E'BB...-E'^KGC*P7LF?X3]@9)$XY:W.#G) !L:NUGH>M65UJ&R#3H+.:
M"WEDP+>VN-\7#,1LA:2!2D4CLHPDD8.6P0#B]5CM]3-S/;JLFE7VLZ(J87]S
M._VB&.[=!@+)')E$:1<I*RN06Y8L#I/$]K,VKR0Z:!'=3>'=22(IA295EM%M
M^0/^6;.=F>$W-C&32 HWFH:3J6GZ=INA&,7]O<V+06Z ">R$<\37+3QA0]NH
MMA.DIE1!)N*;6+@$ BT?6= TY-8@U0Q))/J-\)8I5!DNT\PA4@0C=<#!V"./
M>5DW<*6R6!)X2TJ1=3L8]6C62\MO#UJC>8 S(_GL&!R/OC:%9NN0?F.22 <]
MXJU5)=.UFW:Y@LY6:^1=-MK='O)RA=([F<R^9(4F"I/YT42+%"5*S"1=R@'3
MZSXIT[4IX]!O;ZVL[>.&"746GN(H7G$B+)':1[W5BLRD/<NO A(B!S,2B DU
M77;1-3S%=V.F6QL8#!=^7'++=QL\W[FTD9O),<6,F.-)W9I5.U5"[@#G?"\4
M=Y'X?2=3(([W6L+/&JNICDO/+\R(*JQR1@+\@11&P&U5VC# ]#T)5C\0:PJ
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M,(@1NJ[1MQBF!UJ:EI^A:UJ<FM216K77V?[-+<%426U6WC5H(G<!69;D7#O
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M4]1N$NKJ2)8%\J$V\,42NTA"1M-.^YV8%W:5L[$ "@<@'2T % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!0U.S>_MG@AE>VD;:4EC^\C*RN#C(W*2N
M'0G#H60\,: ,6QT*[^W)J6JW,=U+;Q210)!;M;11B4QF5RK7%PSR-Y:*&+A5
M7<%0;B: .IH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M9)< H^&?#&HZ:FD1W$$</V"ZU9YUB>,Q1I<O<M 8AD,8V$B!%"!T4@2(A!
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M=J@,\C8H VD;4=&U?4KF/3KF]AO3;-"\$MBJGRK=8V#"XNX)%^<$9V$8Y&:
M-+0--O'OKG6]31;>>ZCAMX;=7$AAMH#(ZB1UPC2R2S2.X3<B+L578[C0!U]
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0!2L=1M]1$AMGWB":2"3Y67;+$=KK\P&=IXW#
M*GL30!=H * "@ H I6.G6^FB06R>6)YI)Y/F9MTLIW.WS$XW'G:,*.P% %V@
M H * "@ H I'4;<78T_?_I)A,X3:W^J#B,MNQLX=@-N[=SG&.: +M #))4B
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M*P(!H K:=IMOI,"VMHGEQ*6;!9G8L[%W=W<L[N[,6=W9F9B2Q)- %Z@ H *
M*5_J5OIB))=/Y:RS10(=K-F6>18HE^4$C<[*NXX5<Y8@ F@"[0 4 % %*QTZ
MWTT2"V3RQ/-)/)\S-NEE.YV^8G&X\[1A1V H NT % !0 4 % !0!2M]1M[J>
M:TB?=-:%!,NUAL,B"1.2 K90@_*3CH<'B@"[0!F:IK-KHZHUTS RMMC2..2:
M61@"Q$<,*22O@ EMB':.3@4 0P>(+"XM)+]9@MO;EQ,T@:(PM&,NLL<JI)$Z
M@@E)%5L$''(R ,TSQ'8ZO*8+=I%F5/,\N:">V=H\[?,1+B*)I(]Q"^9&&3)
MW9(H 9J7AC3]5F-Q<)*LC*$=H;BYM_,122JRBWEB$RC<<"4. "1T)% &S;6T
M5E$EO;HL442JB(H 5%4855 X    % $U !0!S-YXOTZQN);-_M+S6P4S""QO
MKA8]Z!UW26]O+&,H=V-V<=: +,7B;39K6*_CG#6]Q-';QN%<YFEE$"1LNW>C
M^:0C!U78?O[0"0 5+OQCIME<36C_ &IY;0J)_(L;ZX2,O&LJAI(+:2,$QNKX
MW\ \X.: -G3=4M=8@%U92+-$Q*[ESPRG#*RD!E=3PRL RG@@4 7Z "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M=P +<6O75[%9Z?97HEEO+F>)[QK<13Q101M,R/;2JBK>8,:'= J*K&4P< 4
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MD6-8@8D2(I\BC )W$MDM\Q(!VA0 #%LIM3BU_6!IUO:W"E[+>;B[EMR#]D3
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M'.B-SE?F;(!J:9X?M])>.2)I&:&S@LAO*G,5N7*,=J+^\.\[B,*>,(M $?\
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M!!'!!H =0!S=]X:6YN7O;6YNM/FG54F-L8<3! 0A=+B"= Z@[1+&J2[<+OP
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M9[2:YF>/S5@=9%V1+'%'!$%,KL D(!8@N&P!0!+=^%1-=)?6MY=V,T=LEH3
M+1@\2.77<+FUN/FW,<E=OIB@"WH_AR#1Y9+HR3WEW.JI)<W+AY2B$E8U")'%
M'&"S-LBC0,QW-N(! !T% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
8!0 4 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img46421407_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_19.jpg
M_]C_X  02D9)1@ ! @$ P #   #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\O/T]?;W^/GZ_\  $0@"E <L P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MV>O:Q$9SPV$]K-N4[<UY-NSDTEOVNM.]SS)[WQ!IVEV_B8ZA,XN)RGD,S%
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M=];;M:>AE_#OQ0NIV6-0NXWOIIY,1O(@D(PI 2+((7KM"KCK@=:VQN']E/\
M=0:IJ*U2=OF^_>[,<%B/:0_>S3J.3T;5_DNWHCTRO(/7&R2+$I=R%51DDD
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M8S^)2:?JKH^KZ^)/M3R;XQ_\@>'_ *_(_P#T3<5[>6?QI?\ 7M_^E1/$S/\
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MK4D__)8FV9+EJP2Z4XK[I2-K4_AF!I$NKW-S-)J(A:ZEW;3&<)YCH<@N6 R
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M)C-54E'+J"A#XWHO.763]/\ )$TXRS"NYST@M7Y1Z17K_FST/XOQK#HEO'&
MJ)=Q*JC@ ""<  =@!P*\K+6W7DWNX/\ ]*B>IF22H12T2FK?^ R'>&]7;0O!
M*7Z %X8Y]F>F][J5$)]0&8$CN..]%>G[;&ND]FXW]%!-_@AT*GL<$JBW2E;U
M<VE^+. \%>#3XX:?4=3FFV"3:60CS))"-S?.ZL %!7C:?O #: *]/%8KZDHT
MJ,8WM>SV2V6B:WUZ_>>7A<+]<YJM:4K7M=;M[O5I[:=/N.F\.>!M;\,:WYMH
MRM8!PKNSJOFP-@MF,$G>F3C( WKD':<GCKXNAB*'+--5+722^&2\^S_)]SLH
M82MAJUX->SO9MNW-%^7=?FNQSWQC_P"0Q#_UYQ_^CKBNO+/X,O\ KX__ $F)
MRYG_ !H_X%_Z5([OXQ_\@>'_ *_(_P#T3<5YF6?QI?\ 7M_^E1/2S/\ @Q_Q
MK_TF0>'/^1$?_KSU#_T.YHK_ ._+_KY2_* 4/]Q?^"K^<S!^"?\ S$/^W7_V
MXKIS7_EU_P!O_P#MAS95_P O?^W/_;S"\.?\CV__ %^:A_Z!<UU5_P#<5_U[
MI?G YJ'^_/\ QU?RF+\8B5UF C@BSC(_[_7%++/X,O\ &_\ TF(9G_&C_@7_
M *5(T-0^&*Q:-)JLMQ+)?K";F0-M,9 3S'4Y!<N!GY]_S$?<&:RAC[UE0C%*
MGS<BM>^]D^UO*WS-9X"U%UG)NIR\[[;7:[W\[Z]C8^#%]+-;W=H[$Q0-"\8)
M^Z91+O ] ?+!QTR2>I.<,T@HRA-+62DGYVM;\S?*YMQG!O2+BUY7O?\ (]KK
MYX^A/&OC/_QX6O\ UW;_ -%FO?RO^)/_  K\SP,T^"'^)_D</X2^'4WBNU%_
M/<_9X@WEH/+,C,J8!QET"J#E1C=R#QZ^CB<;'"S]E&',[7>MDF_D[OKT/.PV
M">)A[64^57LM+MI?-673J6OB!J;:AJL7AZ&5;:QM###\S;8@Q5<R2$X!6)2%
M&>%"L5^\<Q@Z:ITI8J2<JDN:6BN[:Z+SD]?.ZOL7C*CG5CA8M1IPY8ZNROIJ
M_**T\K.VY0\3>%-(T>S%YI.I1W-Q$R[XQ/ S-DXWQ+&V\%202OSG;EMP"UK0
MQ%:K/V=>BXQ=[/EDDO*5U;7OIVMJ9U\/1I0YZ%92DK77-%M^<;:Z=M=-;Z'?
M6GB>^U+P;/>1LQO+8&!I ?F(#1[I,]0P@DR6SG<"^<GCS)8>%/&1IM+DE[R7
M39V7IS+;MH>G&O.I@Y5$WSQ]UOKNKOUY7OWU/.?!P\+R1.FO^8+EF.UR91&%
MPN,&(YW[MQ.\%>GTKU<3]:33PMN5+5:7O_V]TVVU/)PWU5IK$WYKZ/6UO^W>
MN^^AZQX+\'6.EW3:EI=^UU VX>4A0KL;.U92K$EDX(.U#N7H.5KQ,5B9U(*C
M6I<LE;5WO=;N/D_GHSV\+AH4Y.K1J\T==%:UGLI6ZKY:H\]^,?\ R&(?^O./
M_P!'7%>KEG\&7_7Q_P#I,3R\S_C1_P "_P#2I'7?&6[N8;2V@B++;S/)YV.
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M ^]@#[@'!KW:\/981T_Y8)?=8\*A/VF+53;FFW]]SZLKXH^U/)OC'_R!X?\
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MCC!-X155!O$M\S=TGT5EVT75V,\6Z7.HX9)12M==7=WWWZ*YZ3\5O^0/I_\
MO+_Z)KR<O_C5?1_^E'K9A_!I>J_]).V^&?\ R+MI_P!M_P#TIFKSL?\ [Q/_
M +=_](B>C@?]WA_V]_Z7(\F^,?\ R&(?^O./_P!'7%>YEG\&7_7Q_P#I,3Q,
MS_C1_P "_P#2I'H_Q:!.AG':>+/M]X?S->3EW\?_ +=E^AZV8_P/^WH_J9GP
MIUBR@TM;*2:-;E[F0+"6'F'<JD$)][& ?FQMXP3GBM<PI3=5U%%\JBKRMHK>
M>WRW,<OJPC25-R2DY.T;Z_=^NQQ?AS_D>W_Z_-0_] N:]&O_ +BO^O=+\X'G
MT/\ ?G_CJ_E,[OXQ_P#('A_Z_(__ $3<5YF6?QI?]>W_ .E1/2S/^#'_ !K_
M -)D4]*_Y$!O^N%S_P"E,M:5/]_7^*'_ *1$SI_[@_\ #/\ ]+D9OP3_ .8A
M_P!NO_MQ6N:_\NO^W_\ VPRRK_E[_P!N?^WE_P",VGR36MK>("8[=Y$?';SA
M'M)]LQXSTR0.XK/*YJ,YTWO))K_MV]_S-,S@W"%1;1;3_P"WK6_(V?!GCG2F
MTB"*ZGBMIK.%8G21@I(B4*K("<ON4 X7+;LC;7/BL)55:3A%RC.3::5_B=VG
MVL^_WG1A<72]C&,Y*,H12:;MLK77>Z['F$<A\;>+EN+528//C<G&,06X0%F_
MN[PG&>=SA>N!7LM?4\)RS?O<K7_;TKZ?*_W(\=/ZYB^:"]WF3_[=C;7RO;[V
M.^(O_(T#_MV_DM+!?[K_ .!_J&-_WK_P#]#U7XJ_\@&3_KK#_P"AUXN7_P =
M>DOR/:S#^ _6/YE/X0?\@5_^OJ3_ - BK3,OXR_P+\Y$9;_!?^-_E$\^\.?\
MCV__ %^:A_Z!<UZE?_<5_P!>Z7YP/+H?[\_\=7\IG??%O1_MNEK?(,R64F3T
M_P!5)A7]SAO+/'0 G'<>7EM7DJNF]IK\5JOPN>GF-+GI*HMX/\'H_P ;'CEM
M//XSO--TM\[8(TMR1D_(KLSR8]H0 >GW!SWKWY*.$A6K+JW+MJTDE_X%^9X,
M7+%SHT7]E*/R3;;_ / ?R/HGQQIK7N@75I;+RL2LB+Z0NDFU1_NI@ <GH.:^
M5PDU"O"<WU:;_P 2:O\ >SZG%P<Z$X071-)?W6G;[D>9?"?Q/9:;;SZ?>S1V
MQ:7SHVE8(K;D57&]L*"/+7 )&<\9YKU\QP\ZDHU:<7+3E:2NU9MK1:]6>1EU
M>%.,J522CKS)MV3NDGJ].B-K_A9T]WK2Z;ID,5U;22I&CY=';@>8^<E=JG<0
M=GW5S6'U",*/MJTG":3;6C2[+U>G7=G1]?E*LJ-&*E!M)/5-]WZ+7IL<=\8_
M^0Q#_P!><?\ Z.N*[\L_@R_Z^/\ ])B<&9_QH_X%_P"E2.[^,?\ R!X?^OR/
M_P!$W%>9EG\:7_7M_P#I43TLS_@Q_P :_P#29&]\,_\ D7;3_MO_ .E,U<V/
M_P!XG_V[_P"D1.G _P"[P_[>_P#2Y'DWAS_D>W_Z_-0_] N:]RO_ +BO^O=+
M\X'B4/\ ?G_CJ_E,[[Q1\,?^$DU"34?M?D>:$&SR-^-B*GWO.3.<9^Z,9QSU
MKR\/C_J]-4O9\UKZ\UMVWMRO\ST\1@/K%1U>?EO;3EOLDM^9?D:O@OP)_P (
M?+-+]I^T^>JKCRO+V[23G/FR9SGT%8XK%_6E&/)R\K;^*][_ "1MA<)]4<I<
M_-S)+X;6M\V>@UY9ZA\M^#M03P1X@DAU',:8DM9&(SLRZ,K\=5)1>1GY6R :
M^RQ,'C,.I4M7I-+OHTUZZOYH^-PTU@\0XU=%K!OMJFGZ:+Y,]!^)'C+3IM*?
M3[*:.YFNB@/E,'"(KAR69<J"=H7;G=SD@8KR\#A:D:JJU(N,8WW5KMJVB^=[
M['J8[$TW2=*G)2E*VSO9)WU>W2UMS+\/Z5)IW@N^FF4JUVDDJ@\'R]JJAQ_M
M89@>ZL#TQ6]:HJF-IQCM!I/UNV_T7J84:;IX*I*2LYIM>EDE^K] ^"?_ #$/
M^W7_ -N*6:_\NO\ M_\ ]L'E7_+W_MS_ -O/=Z^;/I#BOB%J5SI6B3SVA*2'
M8F]<Y17<*S C[IP=H;L6!'.*]#!0C4KQC/5:NW=I7M^IY^-G*E0E*&CT5^R;
MM?\ 0\=\#6GAJXMIKK7I$-TDA.R:1U&S"D,JJ096+%@1ESQ]T=3[V+EB8RC#
M#)\C6\4GKKHV_A5K=O4\'"1PTHRGB6N=/:3:TTU26[O?OZ&1X7G@N?%4,MH@
MBMWNI&B0#&V,A]@P.F%QQVK?$*4<+*,W>2@KON]+_B88=QEBHR@K1<W9=EK;
M\#2^(O\ R- _[=OY+66"_P!U_P# _P!37&_[U_X!^AZK\5?^0#)_UUA_]#KQ
M<O\ XZ])?D>UF'\!^L?S*?P@_P"0*_\ U]2?^@15IF7\9?X%^<B,M_@O_&_R
MB>?>'/\ D>W_ .OS4/\ T"YKU*_^XK_KW2_.!Y=#_?G_ (ZOY3$^(22Z'XH3
M567<C/;7">C>0(U9?KF/D<'# ]Q1@FJV%=%.S2G%^7-=I_C^ 8U.CBE6:TO"
M2\^6R:_#\3UR[^(>C06)OHKB.1BA*0@_O2^,A&C^\O/!8X4<_,:\*."K.?LW
M!I7UE]FW=/9^F_D>Y+&T8P]HI)NVD?M7[-;KUV/,?@_IDL]_/J;@^5%&8PW0
M&61E8@>NU <CMN7U%>SF511IQHK=N]O))_K^3/'RVFY5)5GLE:_FVOT_-!\3
M/$3Z[>QZ!I_[Q8I '"\^9<'Y0@]H\D>F\MG[H-+ 4%0@\35T;6E^D=[_ #_+
MU#'5G6FL-2U2>MNLMK?+\_0R_!NL3^!-8DTS4OW<,K".8'[J-_RSF4_W2#R>
M\;;NJBM\32CC:*K4=9)7CYKK'U_56ZF.&JRP59T:ND6[2\GTEZ?H[]#T+XQG
M.C0D=/MD?_HFXKRLL_C2_P #_P#2HGJ9G_!C_C7_ *3(S].L)-2\ ?9X06?R
MY7 '4^5>/*0/4D(<#J3P.36LYJGC^:6BO%?^!4TOU,H0=3 <L=[2?W5'+]#+
M^$_B>RTVWGT^]FCMBTOG1M*P16W(JN-[84$>6N 2,YXSS6V8X>=24:M.+EIR
MM)7:LVUHM>K,<NKPIQE2J24=>9-NR=TD]7IT1M?\+.GN]:73=,ABNK:25(T?
M+H[<#S'SDKM4[B#L^ZN:P^H1A1]M6DX32;:T:79>KTZ[LZ/K\I5E1HQ4H-I)
MZION_1:]-CCOC'_R&(?^O./_ -'7%=^6?P9?]?'_ .DQ.#,_XT?\"_\ 2I'=
M_&/_ ) \/_7Y'_Z)N*\S+/XTO^O;_P#2HGI9G_!C_C7_ *3(/#G_ "(C_P#7
MGJ'_ *'<T5_]^7_7RE^4 H?[B_\ !5_.9@_!/_F(?]NO_MQ73FO_ "Z_[?\
M_;#FRK_E[_VY_P"WF%X<_P"1[?\ Z_-0_P#0+FNJO_N*_P"O=+\X'-0_WY_X
MZOY3#XQ_\AB'_KSC_P#1UQ1EG\&7_7Q_^DQ#,_XT?\"_]*D>[^*?^0/?_P#7
MG<_^B7KYK#_QJ?\ U\A_Z4CZ3$?P:G^"?_I+/)?@G_S$/^W7_P!N*]O-?^77
M_;__ +8>)E7_ "]_[<_]O'R?!;>Q;[?C<2<?9?4Y_P"?BA9I96]E_P"3_P#V
MHWE=W?VO_DG_ -L97CSP_P#\(QH-GI_F^?LNI6W[/+SO4G&W<_3_ 'N?:ML'
M6^L5ZE6W+>"5KWV?>R_(PQ='ZM0ITK\UIMWM;==KL].^&?\ R+MI_P!M_P#T
MIFKQ\?\ [Q/_ +=_](B>Q@?]WA_V]_Z7(\6\=6::;XG:6_0R6DTD4S 97?$0
MHD ((.05=<@@Y&>,\?0823J851I.TTI1[VEK;]&?/XN*IXENJKP;C+M>.E_U
M1V.HV_@'3H4G"+<>81A()YWD /=U,ZE .X?#>BFN"#Q]1N-^6W648I?)\KO\
MM#OFL!32E;FOTC*3?S7,K?/4[+2-3T#0=$;4+".2+3I)"64I,[%VVQ'B0OP=
MJKG=Y>1C.XD5P5*=>M75*HTZJ6FL5HKOI;NWM?Y'?3J4*%!U:2:I-ZJTGJ[+
MK?LEO;YG#"Q\$^* \T<G]ER*3D-(D&?1E1R\94Y^ZFUN#D#K7H\^-PUHM>T7
MDG+Y-JS^;NCSN3!8F\D_9/S:C\TG=6\E9G&^$V.F>)HH-*F:>$S^5O ($L)^
M^67H0%RP/0%0XQQ7H8C]YAI2K1Y9<M[?RRZ6?KI\['GX?]WB8QHRYH\UK]X]
M=/37Y7-CXQ_\AB'_ *\X_P#T=<5AEG\&7_7Q_P#I,3HS/^-'_ O_ $J1[!XQ
M\1:1I$2VNL1M.EP"1&(MX.TCG+%5# D8PVX<'C()\'#4*U5N>':BX];VM?TN
M_P +'NXFM1I)0KIM2Z6OM]R_&YY7J?A_P?>V;7]C>_8WV%EA,BNP;;D(87S-
MG.%^5RO7!(YKVJ=;&0FJ52GSJ]N:UE;OS+W?O5SQJE'!S@ZM.IR.UU&]W?MR
MOWON99^#-U<FXNK;+&U$:N1U59=P"X]"R[LX^]M&<[1B,TC'EA/[=VO-JWZ.
MWI?S*RR4N:</L63\D[_JK^MO(YVZN([+QHTUPPBC2^W,S'"J,]23T'.<GC'/
M2NN*<\$HP5VZ>B1RR:AC7*3LE4U;Z'3_ !6\1M=06T.GS![.<R[WB;*R/&57
M9O'#*N[) )!)!YP*X\OH<LIRJQM./+9/=)W=[=&SLS"OS1A&E*\'S7:V;5E:
M_5*Y02#PEIV@_:5,=SJ$MN0%9V:5;AH\']UD*BQN20Q3&%R&<XSI?%SK\FL:
M:ENDDN5/^;=MKI?Y(R2PE.ASJTJCCLVV^9K^79)/K;YLF^"__'U>?]<H_P#T
M)JG-/AI^K_)%97\53T7YLSO#G_(]O_U^:A_Z!<UM7_W%?]>Z7YP,J'^_/_'5
M_*9W?QC_ .0/#_U^1_\ HFXKS,L_C2_Z]O\ ]*B>EF?\&/\ C7_I,BYX+!;P
M<@'),%Y@?]M;BHQ7^^/_ !4__28FF%_W-?X:G_I4CS/X4:K::3>W,E[-';JU
MO\ID8*"0X) SU;'11\Q[ UZ^8TYU(05.+DU+HK]/R\SQ\NJ0I3FZDE%<O5VZ
M_GY'TNCK(H=3E6 (/J",@_E7R+5M'T/KD[ZK8XWQCXBTC2(EM=8C:=+@$B,1
M;P=I'.6*J&!(QAMPX/&03WX:A6JMSP[47'K>UK^EW^%C@Q-:C22A73:ETM?;
M[E^-SRO4_#_@^]LVO[&]^QOL++"9%=@VW(0POF;.<+\KE>N"1S7M4ZV,A-4J
ME/G5[<UK*W?F7N_>KGC5*.#G!U:=3D=KJ-[N_;E?O?<RS\&;JY-Q=6V6-J(U
M<CJJR[@%QZ%EW9Q][:,YVC$9I&/+"?V[M>;5OT=O2_F5EDI<TX?8LGY)W_57
M];>1SMU<1V7C1IKAA%&E]N9F.%49ZDGH.<Y/&.>E=<4YX)1@KMT]$CEDU#&N
M4G9*IJWT.P^+-_;ZEIEK-:2)-%]I==Z$,I*H0<,.#@]P2#V-<&70E3JSC-.+
MY$[/1ZOL=^8SC4IPE!IKG:NMM$=M\,_^1=M/^V__ *4S5YV/_P!XG_V[_P"D
M1/0P/^[P_P"WO_2Y'CWCG4&U#Q+]CU.1XK"":*,J,@)$P0O(!@_,P8MNVDXQ
M@$ "O>PD/9X;VE%)U)1D_66MEZ*UK7/!Q<^?$^SK-JG&45Z1TN_5WO>Q+XZ3
MPU864=IH8BDN'D5WEC=I2(PK<-(68 NS*=JD8VG<!@ SA'B9S<\1=12:2:4=
M;KI9;*^K*Q:PT(*&&LY-IMIMZ6?6[W?1'9>$_P#D2+K_ *X7_P#Z!)7!B/\
M?8?XJ?YH[\/_ +E/_#4_)F;\$_\ F(?]NO\ [<5KFO\ RZ_[?_\ ;#+*O^7O
M_;G_ +>87AS_ )'M_P#K\U#_ - N:ZJ_^XK_ *]TOS@<U#_?G_CJ_E,[OXQ_
M\@>'_K\C_P#1-Q7F99_&E_U[?_I43TLS_@Q_QK_TF18\':O;:'X2M[R]W>0O
MG*VU"^=UU,H! &,'.,MA>V<D SB:<JV+G3I_%[K5W;:$7_5BL-4C1PD)U/A7
M->ROO.7]:G+"Q\$^* \T<G]ER*3D-(D&?1E1R\94Y^ZFUN#D#K79SXW#6BU[
M1>2<ODVK/YNZ./DP6)O)/V3\VH_-)W5O)69QOA-CIGB:*#2IFGA,_E;P"!+"
M?OEEZ$!<L#T!4.,<5Z&(_>8:4JT>67+>W\LNEGZZ?.QY^'_=XF,:,N:/-:_>
M/73TU^5SZLKXH^U"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H Y[Q+X:MO%5LMG>-*D:2B4&(JK;E5T
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M10ISG=2][6+LW[\M[IK\#T?PYX/T[PN&-DC&1QAI9"&D*Y!VY 4!<@'"J 2
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MN8 23LCD3:,]AYD<C8';YJ]".95XJSY'YM._X-+\#SY9;0D[KFCY)JWXIO\
M$Z7P[X+TSPP3)9HQF88,LC;GV\?*. JCCG:H)[D@#''6Q57$:5'[JZ)65^_=
M_-G91PM+#:TU[W=ZNW;LODCJZXCM"@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M))+9(LU!84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!'),D6-YQGIP
M?Z4KV B^V1?WOT/^%%T ?;(O[WZ'_"BZ /MD7][]#_A1= 'VR+^]^A_PHN@#
M[9%_>_0_X470!]LB_O?H?\*+H ^V1?WOT/\ A1= 'VR+^]^A_P *+H ^V1?W
MOT/^%%T ?;(O[WZ'_"BZ /MD7][]#_A1= 'VR+^]^A_PHN@#[9%_>_0_X470
M!]LB_O?H?\*+H ^V1?WOT/\ A1= 'VR+^]^A_P *+H ^V1?WOT/^%%T ?;(O
M[WZ'_"BZ /MD7][]#_A1= 'VR+^]^A_PHN@#[9%_>_0_X470!]LB_O?H?\*+
MH ^V1?WOT/\ A1= 'VR+^]^A_P *+H ^V1?WOT/^%%T ?;(O[WZ'_"BZ /MD
M7][]#_A1= 'VR+^]^A_PHN@#[9%_>_0_X470!]LB_O?H?\*+H ^V1?WOT/\
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M7][]#_A1= 'VR+^]^A_PHN@#[9%_>_0_X470!]LB_O?H?\*+H ^V1?WOT/\
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MO?H?\*+H ^V1?WOT/^%%T ?;(O[WZ'_"BZ /MD7][]#_ (470!]LB_O?H?\
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MO?H?\*+H ^V1?WOT/^%%T ?;(O[WZ'_"BZ /MD7][]#_ (470!]LB_O?H?\
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MO?H?\*+H ^V1?WOT/^%%T ?;(O[WZ'_"BZ /MD7][]#_ (470!]LB_O?H?\
M"BZ /MD7][]#_A1= 'VR+^]^A_PHN@#[9%_>_0_X470!]LB_O?H?\*+H ^V1
M?WOT/^%%T ?;(O[WZ'_"BZ /MD7][]#_ (470!]LB_O?H?\ "BZ /MD7][]#
M_A1= 'VR+^]^A_PHN@#[9%_>_0_X470!]LB_O?H?\*+H ^V1?WOT/^%%T!84
MA@".AY%,!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,W4/X?Q
M_I42 S:@84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!
M9L_]:OX_R-4MP-NM!!0 4 5[NX^RQ-+C=MQQG'4@=<'U]*3=E<"Q3 * "@#-
MU#^'\?Z5$@,VH&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 =!#_JU_W1_*M4(DI@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 9NH?P_C_ $J) 9M0,* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H LV?^M7\?Y&J6X&W6@@H * ,[5O\ CU?_ (#_ .AK42V T:L
MH * ,W4/X?Q_I42 S:@84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MJ'C(96&0RD$$'H01P0?44@'T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 6;/_6K^/\ (U2W VZT
M$% !0!G:M_QZO_P'_P!#6HEL!HU8!0 4 9NH?P_C_2HD!FU PH * "@ H *
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MC@8%6]A'UM4#,B[\0:9I]S'87=W:V]W/M\J"6>))I-[%$\N)F#OO<%%VJ=S
MJ,D8I@0/XIT>.Y^P/?6:W>=OD&YA$V?3RB^_/MMS0!O4@,34O$VDZ,XBU&]M
M+.1NBSW$,3'Z+(ZD_E3 U+:ZAO(UFMW2:)QE7C8.C#U#*2"/H:0&<?$.F"]_
MLHWEK]O_ .?7SXOM'W/-_P!3O\S_ %7[S[OW/G^[S3 BM?%&CWMP;*VOK.:Y
M!P88[F%Y01U!C5R_'TH OZCJEGH\)N=0GAM( 0IEGD2*,%N@+R,JY/89R>U
M#K#4+758%N[&:*ZMY,[)89%DC;:Q5MKH65MK*5."<,"#R#0!1TOQ)I6N,R:9
M>VEZ\8#.MO<13%03@%A&[%03P"< F@#YC^'WB35;WXDZCIUS>W<UG%<:FJ6\
MEQ*\*".=A&%B9RBA!P@"@*.!@53V$?4FI:S8:,@DU&Y@LT/1IY8XE..N#(R@
MU(R'3/$.EZT2--O+6\*?>^SSQ38^OENV/QH \6^-WQ3G\&V\=AHDUM_:$[.D
M_P Z23VJ[$=&,.3L:0.&1I5*[1E5;((:0'8VNL6GB?PF4M]7AMIQ80+<W\=P
MC/:2M$A:29UFC,<FX-G?)&V=W.0:-F!:^&-A_9VF2Q?VU_PD^;IV^U^;YOEY
MBA'V?=]INL;,>9M\P8\W.P9W,F!V&IZ]INB '4KNVL@WW3<3Q0@_3S&7/X4
M6;'4;75(A/8S17,1Z20R)(A^C(67]: *MWX@TS3[F.PN[NUM[N?;Y4$L\232
M;V*)Y<3,'?>X*+M4[F!49(Q0!!-XIT>VN?L$U]9QW><>0]S"LV?3RBX?/!XV
MT ;U( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@#H(?]6O^Z/Y5JA$E, H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@#-U#^'\?Z5$@,VH&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % %FS_P!:OX_R-4MP-NM!!0 4 9VK?\>K_P# ?_0UJ); :-6
M4 % &;J'\/X_TJ) 9M0,* "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MY[ES+,BRPLS9)Q#/+'&"3UQ$J#/?'/-)[C/4ZD H * "@ H * "@ H * "@
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M3Z;_ +%Z3_TW&EU&>7?LO?\ (+U#_KZC_P#15-@?4-0 4 % !0 4 % !0 4
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M&7)(5O7818CL-1^.?BJWU@VDMCH=@(AOF&#)%'(92BMC:\LSL01&62%,%F)
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MV ^FZ@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"S
M9_ZU?Q_D:I;@;=:""@ H SM6_P"/5_\ @/\ Z&M1+8#1JP"@ H S=0_A_'^E
M1(#-J!A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!\QZG\/=>N/B6OB6.USI0GMG,_G6X^6.SBB
M<^491-Q(K+CR\G&0"N#5WTL!].5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % 'S'\6_A[KWB?Q9I^JZ7:_:+.V@M4ED\ZWCVM'=SRN-DDJ.=J.K952#G )
M((%IV0'TY4 % !0 4 ?,>I_#W7KCXEKXECM<Z4)[9S/YUN/ECLXHG/E&43<2
M*RX\O)QD K@U=]+ ?3E0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '00_
MZM?]T?RK5")*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &;J'\
M/X_TJ) 9M0,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH LV?^M7\?Y&J6X&W6@@H * ,[5O^/5_^ _^AK42V T:L H * ,W4/X?Q_I4
M2 S:@84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!T$/
M^K7_ '1_*M4(DI@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 0S6
MZSXW9&,]/?\  ^E)JX$'V"/U;\Q_A2L ?8(_5OS'^%%@#[!'ZM^8_P *+ 'V
M"/U;\Q_A18 ^P1^K?F/\*+ 'V"/U;\Q_A18 ^P1^K?F/\*+ 'V"/U;\Q_A18
M ^P1^K?F/\*+ 'V"/U;\Q_A18 ^P1^K?F/\ "BP!]@C]6_,?X46 /L$?JWYC
M_"BP!]@C]6_,?X46 /L$?JWYC_"BP!]@C]6_,?X46 /L$?JWYC_"BP!]@C]6
M_,?X46 /L$?JWYC_  HL ?8(_5OS'^%%@#[!'ZM^8_PHL ?8(_5OS'^%%@#[
M!'ZM^8_PHL ?8(_5OS'^%%@#[!'ZM^8_PHL ?8(_5OS'^%%@#[!'ZM^8_P *
M+ 'V"/U;\Q_A18 ^P1^K?F/\*+ 'V"/U;\Q_A18 ^P1^K?F/\*+ 'V"/U;\Q
M_A18 ^P1^K?F/\*+ 'V"/U;\Q_A18 ^P1^K?F/\ "BP!]@C]6_,?X46 /L$?
MJWYC_"BP!]@C]6_,?X46 /L$?JWYC_"BP!]@C]6_,?X46 /L$?JWYC_"BP!]
M@C]6_,?X46 /L$?JWYC_  HL ?8(_5OS'^%%@#[!'ZM^8_PHL ?8(_5OS'^%
M%@#[!'ZM^8_PHL ?8(_5OS'^%%@#[!'ZM^8_PHL ?8(_5OS'^%%@#[!'ZM^8
M_P *+ 'V"/U;\Q_A18 ^P1^K?F/\*+ 'V"/U;\Q_A18 ^P1^K?F/\*+ 'V"/
MU;\Q_A18 ^P1^K?F/\*+ 'V"/U;\Q_A18 ^P1^K?F/\ "BP!]@C]6_,?X46
M/L$?JWYC_"BP!]@C]6_,?X46 /L$?JWYC_"BP!]@C]6_,?X46 /L$?JWYC_"
MBP!]@C]6_,?X46 /L$?JWYC_  HL ?8(_5OS'^%%@#[!'ZM^8_PHL ?8(_5O
MS'^%%@#[!'ZM^8_PHL ?8(_5OS'^%%@#[!'ZM^8_PHL ?8(_5OS'^%%@#[!'
MZM^8_P *+ 'V"/U;\Q_A18 ^P1^K?F/\*+ 'V"/U;\Q_A18 ^P1^K?F/\*+
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MU;\Q_A18 ^P1^K?F/\*+ 'V"/U;\Q_A18 ^P1^K?F/\ "BP!]@C]6_,?X46
M/L$?JWYC_"BP!]@C]6_,?X46 /L$?JWYC_"BP!]@C]6_,?X46 /L$?JWYC_"
MBP!]@C]6_,?X46 /L$?JWYC_  HL ?8(_5OS'^%%@#[!'ZM^8_PHL ?8(_5O
MS'^%%@#[!'ZM^8_PHL ?8(_5OS'^%%@#[!'ZM^8_PHL ?8(_5OS'^%%@#[!'
MZM^8_P *+ 'V"/U;\Q_A18 ^P1^K?F/\*+ 'V"/U;\Q_A18 ^P1^K?F/\*+
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &=JW_'J_\
MP'_T-:B6P&C5@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% $<<R2[MASL8J>",,.HY_F.*5[@24P"@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * ,[5O^/5_P#@/_H:U$M@-&K * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H Y;Q5XIC\+PHWD3WMS<,8[>VMXV=Y7 SR0"J(,C<[=
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#.U;_ (]7_P"
M_P#H:U$M@-&K * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /'O@W_QZZO_ -AZ^_\
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M_7>3^E1'KZL#1JP"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * ,[5O^/5_P#@/_H:U$M@-&K * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M *[R?TJ(]?5@:-6 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!G:M_QZO_P'_P!#6HEL!HU8!0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!G:=_RV_P"N\G]*B/7U8&C5@% !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9VK?\>K_\!_\
M0UJ); :-6 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9
MVG?\MO\ KO)_2HCU]6!HU8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % &=JW_'J__ ?_ $-:B6P&C5@% !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % &=IW_+;_ *[R?TJ(]?5@:-6 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!G:M_QZ
MO_P'_P!#6HEL!HU8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!G:=_RV_P"N\G]*B/7U8&C5@% !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 9VK?\>K_\!_\ 0UJ); :-6 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9VG?\MO\ KO)_2HCU]6!H
MU8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!2NKIH'2.-/,:3=@;@OW0#W!'0^W2I;MH
M@(_M-U_S[_\ D5/\*5WV_$ ^TW7_ #[_ /D5/\*+OM^(!]INO^??_P BI_A1
M=]OQ /M-U_S[_P#D5/\ "B[[?B ?:;K_ )]__(J?X47?;\0#[3=?\^__ )%3
M_"B[[?B ?:;K_GW_ /(J?X47?;\0#[3=?\^__D5/\*+OM^(!]INO^??_ ,BI
M_A1=]OQ /M-U_P ^_P#Y%3_"B[[?B ?:;K_GW_\ (J?X47?;\0#[3=?\^_\
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MG<"W5 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0!G:=_RV_Z[R?TJ(]?5@:-6 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#.T[_EM_UWD_I41Z^K T:L H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H SKG_ (^K?_MK_P"@"H>Z^8&C5@% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!G:=_RV_Z[R?TJ(]?5@:-6 4 % !0
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M8W_Y:9!YQGEFZCYB =EX+O;?S+CQ-J\T-K-J\FVU2>5(RMK$=L:KO89+D#(
MYV*X^]0,]:5@P#*001D$<@@]Q2 6@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH SM._Y;?]=Y/Z5$>OJP-&K * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@$DCDFF@/I"J * "@#.T[_EM_P!=Y/Z5$>OJP-&K * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M=_%O9WD8\ %7X &  >U_%+6[27PC<2PR+*-1BCCM0AR9FF=-HC R6.TEB!R
MI[T@.B;P3IVJ:=96FK0":2PMXXU=9)(Y$(B5'"RPNC[6VX90VUAU!H \IOIO
ML^GZCXGT>-8;/1;>2PT5$'R+F01WE\JD$$ER4C8YW)$Y?.\TP.KT47/A[Q!9
M:9'?76HVVI:?+/*+J9IRLL1C*S1,P#1I)N*^6,1^B[AP@/7Z "@#.T[_ );?
M]=Y/Z5$>OJP-&K * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * ,ZY_X^K?_MK_ .@"H>Z^
M8&C5@% 'BOB[_D*S_P#;/_T4E?AV??\ (QK_ /</_P!-4S],RO\ W.E_V_\
M^G)'-U\T>T% 'M?A'_D%0?\ ;3_T:]?N&0_\BZA_W$_]/5#\RS3_ 'RK_P!N
M?^FXG1U],>,?/7Q(^"TWC3Q!;ZQ:RP0VSK#'J".TBR2+$XRT02-E9C" F'=
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M?_<@_L+_ *?_ /E/_P"Z!_PL#_IV_P#(W_VJC_6K_J%_\K?_ '(/["_Z?_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ%X-TCPU(\VF6XADD41ER\LC",'<(U:5W*1@\B-"J9 ^7@4 =-0 4 9VG?\
M+;_KO)_2HCU]6!HU8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MGTV2?[Q/_KU+_P!+@>35^0GZ % !0 4 % !0 4 % !0 4 % !0 4 >L^ _\
MCPD_Z[M_Z+BK]>X8_P!SJ?\ 7^7_ *;I'Y_G?^\0_P"O4?\ TN9VM?<'S(4
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M !0 4 % &=IW_+;_ *[R?TJ(]?5@:-6 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!4OK^WTR!KJ[D6&&,99W. .WYD\ #DG@ F@#G=)\=Z'KDXM+&Z228Y
MVH5DC+8ZA?,1 QQSA23CF@#K&8("S$  9)/  '<T 8>B>)M-\1^;_9DPN/LY
M"R$)(H!;=C!=%# [3@KN''7D4 7=5U6UT.U>^OG\JWBV[WVLV-S*B_*BLQRS
M <*<9R>,F@#C?^%J^&?^?S_R7NO_ (Q0!TD_B?3+6P359IUCLY@&CD8,-X;D
M!4*^820"=H7=@$XXH 9H?BO2O$FX:9<+.T8RRX=' /&=DBHVW/&X#&2!GD4
M0ZUXST?P[*(-1N5AE8 [ LDC 'H66)'*@]BV,]J -.'7+&XLSJ<<\;684N9M
MWR +USGD$="I 8'C&>* *.A^+=*\2,Z:9<+.\0RR[71@,XW;9%0E<X&X C)
MSR* +MOK=G=7LNF0R;[JV57E0*^$#8VY?;Y>X@@[0Q;&3C@X -6@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MBWIJ7=SIMK::E?7MC/)!+;VELLTF(MNZ88E"B$LP56=D=F! C.*+@7Y/B?I
MT.7Q'"+BXM;6017,4<:BYMW+K&RS0R/&5*%E+\GY3N7<O-%P.B\0^*K'PUI4
MFN719[6-$<>4 SR>:RK&(PS*&9RZXRP&#DD $T]@-Z"4S1K(5:,NJL4? =<@
M':P!8!EZ-@D9!P2.: ): "@#.T[_ );?]=Y/Z5$>OJP-&K * "@ H * .*\>
M?\>$?_7=?_1<M?#\3_[G3_Z_Q_\ 3=4^FR3_ 'B?_7J7_I<#R:OR$_0 H *
M"@ H * "@ H * "@ H * "@#UGP'_P >$G_7=O\ T7%7Z]PQ_N=3_K_+_P!-
MTC\_SO\ WB'_ %ZC_P"ES.UK[@^9"@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H \:\2>/[3PGXH^SZU<[=/ELHVCB6(R"&X
M69CYLBK&TF70X1HRP^4AD!"FF!*/BKX$N+I;G[1"UWPJS&QN?-&> !(;7<!S
MC[P&#2 ]@H * "@ H * "@ H * "@ H * ,[3O\ EM_UWD_I41Z^K T:L H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?^BXJ_7N&/\ <ZG_ %_E_P"FZ1^?YW_O$/\ KU'_ -+F=K7W!\R% !0 4 %
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MR=X10^3SGYL]Z0R]0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MG:=_RV_Z[R?TJ(]?5@:-6 4 % !0 4 <5X\_X\(_^NZ_^BY:^'XG_P!SI_\
M7^/_ *;JGTV2?[Q/_KU+_P!+@>35^0GZ % !0 4 % !0 4 % !0 4 % !0 4
M >L^ _\ CPD_Z[M_Z+BK]>X8_P!SJ?\ 7^7_ *;I'Y_G?^\0_P"O4?\ TN9V
MM?<'S(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'E7B;4M?U77?^$>\/W,.FK;V:W<]S)"LSL9)&C2..-PR8&W+,0.I&?E
M 8 K1^%_'*L"_B&)E!!(_LZV&1GD9V<9'&: /7J "@ H * "@ H * "@ H *
M "@#.T[_ );?]=Y/Z5$>OJP-&K * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,ZY_X^K?
M_MK_ .@"H>Z^8&C5@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0!G:=_RV_P"N\G]*B/7U8&C5@% !0 4 % '%>//^/"/_
M *[K_P"BY:^'XG_W.G_U_C_Z;JGTV2?[Q/\ Z]2_]+@>35^0GZ % !0 4 %
M!0 4 % !0 4 % !0 4 >L^ _^/"3_KNW_HN*OU[AC_<ZG_7^7_IND?G^=_[Q
M#_KU'_TN9VM?<'S(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % 'C?Q!T"^748O$,&LV^A);0^0KRQ)D[F+LC,[!949@K+"Z
MN P)49)I@8.@W/B#7Y1'I_BVRNV7YFB2QM!(5!YPA0/C'!8# SUH ^@J0!0
M4 % !0 4 % !0 4 % !0!G:=_P MO^N\G]*B/7U8&C5@% !0 4 % !0 4 %
M!0 4 % !0 4 % !0!EZMJT6C1"><.RLX0! "<D,W\3*,84]_3BO*Q^/I9925
M>NIRC*:@E!)N[4I?:E%6M%]>VAW87"SQLW2I.*:BY>\VE9-+HGKJNASW_"=V
M'_/.?_OF/_X[7SG^L^#_ .?=?_P&G_\ +3V/[$Q'\]+_ ,"G_P#(!_PG=A_S
MSG_[YC_^.T?ZSX/_ )]U_P#P&G_\M#^Q,1_/2_\  I__ " ?\)W8?\\Y_P#O
MF/\ ^.T?ZSX/_GW7_P# :?\ \M#^Q,1_/2_\"G_\@'_"=V'_ #SG_P"^8_\
MX[1_K/@_^?=?_P !I_\ RT/[$Q'\]+_P*?\ \@'_  G=A_SSG_[YC_\ CM'^
ML^#_ .?=?_P&G_\ +0_L3$?STO\ P*?_ ,@'_"=V'_/.?_OF/_X[1_K/@_\
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MZV;]3YZI!TIRI2M>$G%VVO%M.VVFG8FK<R"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#.N?^/JW_[:
M_P#H J'NOF!HU8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 9VG?\MO\ KO)_2HCU]6!HU8!0 4 % !0!Q7CS_CPC_P"N
MZ_\ HN6OA^)_]SI_]?X_^FZI]-DG^\3_ .O4O_2X'DU?D)^@!0 4 % !0 4
M% !0 4 % !0 4 % 'K/@/_CPD_Z[M_Z+BK]>X8_W.I_U_E_Z;I'Y_G?^\0_Z
M]1_]+F=K7W!\R% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <)\1?%$_A/2OM=JJ
MM/+,L"%AE4+*[ER/XL+&0!TW$$Y ((!Y[%XI\4>&+ZP&O20W5KJA4!46,,@8
MH&&4CBP\?F(<$NC X#DY*L#>\5>)]<N=;7PYX>\N"14#R3RJ" 2H<_>5U"*C
M+G".Y9L #'( O@GQ9JTFKW'AS7]DMS A=9HPJYQL."$55*LCAU(52.0PR?E
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MB -Y>/,GW[?,(8XV@MM^9AC*T@.^H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /&==MK#4_&L-KX@$;VT>G"2PBGQY$EP9
MR)CM8['F"!0$8'Y &VD@&@"K\3=(T?18;6ZTV&WL];6\M18BW1(I9&:=5=&6
M/:7B,9DW;@5!PN1NY8'N%( H * "@ H * "@ H * "@ H SM._Y;?]=Y/Z5$
M>OJP-&K * "@ H * "@ H * "@ H * "@ H * "@#BO'G_'A'_UW7_T7+7P_
M$_\ N=/_ *_Q_P#3=4^FR3_>)_\ 7J7_ *7 \FK\A/T * "@ H * "@ H *
M"@ H * "@ H ]]T;_CPMO^N$7_HM:_H/+_\ <\-_UXH_^FXGY-B_]XK?]?:G
M_I;-&O3.(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MFM7GB'5[V:.3&DV1%M$@5,33KS))YFS?A>@"N%(9#CKE =]0 4 % !0 4 %
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M>S9#8SN[[0"/;K.Z6]@CN8\[)HTD7/7:ZAAG\#2&6: "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH SKG_CZM_\ MK_Z *A[KY@:-6 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % &=IW_ "V_Z[R?TJ(]?5@:-6 4 % !0 4
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M &=<_P#'U;_]M?\ T 5#W7S T:L H * "@ H * "@ H * "@ H * "@ H *
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MV!$C4$C@D@G!(!P3D ?XG^'6E>*YA=78EBG"A3) RJS = P='4X' .W=CC.
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M$7_HM:_H/+_]SPW_ %XH_P#IN)^38O\ WBM_U]J?^ELT:],X@H * "@ H *
M"@ H * "@ H * "@#QWQYX8\-:)9W.LW-H);F9V*@SW*B2XF8MT68 #):1@H
M4;58+CBF!7\!^#;G1M NKN/<NI:E:N85!V^5F-S;@9Z.68.2?NY5>-K$@'C
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M 'O<$*6T:PQ )'&H15'154 *![   4ADE !0 4 % !0 4 % !0 4 % !0 4
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M $7+7P_$_P#N=/\ Z_Q_]-U3Z;)/]XG_ ->I?^EP/)J_(3] "@ H * "@ H
M* "@ H * "@ H * /6? ?_'A)_UW;_T7%7Z]PQ_N=3_K_+_TW2/S_._]XA_U
MZC_Z7,[6ON#YD* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#Y=_:3_ .83_P!OO_MI
M7MX#_EY_V[_[<>#F/_+O_M[_ -M/ERO;/!"@ H * "@ H * "@ H * "@ H
M* /O3X+_ /(H6'_;S_Z67%?+XO\ C3_[=_\ 24?6X/\ @0_[>_\ 2F>HUPG>
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YGXH?1
MV\1:5%,ET^L EH3:;ALM]WS-=D<?92X((()W;N54L: .&\1>&M#TSQ+%'J!U
M.WL+^XCN@@;_ (E,FH,Y^608^21R%8YX.XC<B# 8'T+2 * "@#SS5?B38:=>
M3:?;VU_J<UF/])-C;^<EOWQ(Q=!NQR57<1@C&00 #HK#Q7IFHZ7_ &Y#.OV
M(TCRME?+"9WAU(W*Z$$%<9)^Z#D9 .2L_BOI=S+ )K>_LK:]<1VUY=6QCM9F
M;[FV3>Q ?^%G1%QR2%!( .C\0>+K;P_/#9>3<WUY<J[I;V<:R2^7']^5@SQH
MJ D#)?+,<*"<T 6K'Q3I^H:4=<BDVV2QR2.S@HT8BW"574\JZ%65E]1QD$$@
M&AI&I+K%G#?I'+ ES&LBQS*JRJK#*[U5G"DK@XW$@$ X.0 #1H * ,[3O^6W
M_7>3^E1'KZL#1JP"@ H * "@ H * "@ H * "@ H * "@ H XKQY_P >$?\
MUW7_ -%RU\/Q/_N=/_K_ !_]-U3Z;)/]XG_UZE_Z7 \FK\A/T * "@ H * "
M@ H * "@ H * "@ H ]]T;_CPMO^N$7_ *+6OZ#R_P#W/#?]>*/_ *;B?DV+
M_P!XK?\ 7VI_Z6S1KTSB"@ H * "@ H * "@ H * "@ H * /#?B:#J^NZ1H
M;_ZB2022?[0>0(?;A(WQ_O'K3 ]2\4VUU=:3=0:?E;EX'6/:=I)Q]U3Q@L,J
M#Q@D<CK2 ^6Q?Z;%HC:')ID@UO?@3&,>9GS"V<_ZX$)^[\D)L.-Q.:8CW6V\
M2#P)HFG1:XL\EQ,OE8C".R$<JKEY$^XC*AP6Y4B@96\<>)=8\)ZE;WJ*T^C,
M,3HD:$A\.&!D(++P4D0EE5F4H3@-D YGPX9/'/BH^((H)(-.@A>+=(-IEW0O
M"%)7@N1(6(5FV*J@MRN0#F]&\0S_  [M]0\/WUO,T\SN;9EQL9G01[\G!*,H
M1PR!B<;2 >0"-J'P1?'P.UMY;?:VN/MPAP0^ !'MV]=YB&X)UZ+C=P ##U;Q
M+<>.=/L/#-E;3+=PM$)V8?*#%&8MW'*I\QD<N%V8 ^;K0!]+%H=(M-TC;(+6
M+YF/9(TY)^BBD,\%O!>W.@ZIXLPT=SJ12.'!(>&P69$PN#D>8!A^.47S!]XF
MF(T?A]]GM/$$EKHTAET]].AEF D+H+@^5ELEF D)9MRY^4M(N!MP 9[O2 *
M"@ H * "@ H * "@ H * "@ H * (Y@Y1A$0'*G:3T#8X)X/ /7@_2@#@/AS
MX0N?"%G-#>O%)///YA:)F9=@10H)=(VW;MY/!&".<YH @\;^!KCQ!=0:MI=P
M+34+10B,^=A569UY4,5*LS9^5PP;! QRP,[PYX"U--777O$5U'>7,*E8EB!V
M@D%03F.( *&8A%C W'=G(Y .GL](UBYEU"#6KB*?3KP2QVT40"R10R%UVN1
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MR#N44 <YXH\.ZS'JUWJ&DP1WD>IV#6;AI4C,)8*A?#D;E 4':O4D@@8!+ ]
M\)Z.^@:3;:?*0TD$>'(Z;F)=@#W +$ \9 S@=*0'0T % !0 4 % !0 4 9US
M_P ?5O\ ]M?_ $ 5#W7S T:L H ^7/B-_P A^Z_[8_\ I/%6\=CR*W\1_+\D
M<35G.% 'U'\.?^0!:_\ ;;_THEKGEN>O1_AKY_FSMJDZ#X8\77MQ\-;WQ!X6
MM5;R->6*2S"CA4FD_>(JC'!C>:WXZF)<YJ-M /0?BCX3N/#/PWL]+M0<64UO
M)>[>AWK,96/7*_:Y8R,] %YP*;T0$7CWQ5X1O? *6-A+:O/Y-LMM;)L\^&96
MB\PL@P\9"AQ)(P D^89?=@FE@.7^(ME<1>"_"]KJ(82[U5E;(8(R?NU/<%8B
MBXX(QC QBD]D!VG[1%A;VEKHH@BCB$5V8HPBA0D>U#L4 #"#:,*.!BFP*?C^
M:UTGXEZ;?^(0/[+-LHB>4;H4=5G52P((_=W#*[?W-R2,=HHZ@5?'FIZ?XE\=
MZ$?#$L-U=Q31FYGM2KH4697^>6,E9!'"LQ< G"-M).=H.N@%&#5=*T?XKWUS
MK+Q0Q#(BEFP(XYS;P;'+-\L9VAU#G !8#(SFEU U-$N[/6?BO]K\/M'+:);2
M-=208\J0_9BC,&7Y7S.\(+CAG&<D\E]= )_V>[6)]9\0W#(IEBGB1'(^95DF
MO"X![!C&A/KM%" MKXFU7Q'XHU73_#*Z5H1L#(EWJ$T"-=SB*3RG<L5Q(H==
MP#KM5=I>0EE%'H!A? O7[3PUIWB#5M0FW6UM/ [S*N/,+&94*H.AF=E"+P 7
M .!S0M ,?P_?V'Q3UYO$?C"^LK+3K)]MIIT]W!&6 (959'9"8LX:9R!Y[_(!
MY:E56^X'H/BGQ;<:CXNM=$\+0:5'>O:H\>K7,:2/Y4D+2JMK*H),9A8[0GF"
M3>P 5-S%^@'-?"3[0/B)JPO+J/4;@6,PEN8D6-)'$]B&VHF% 0@IQUVY[T+<
M#7_9_L+>6_U^Y>-&E%V(@[*"1&SW!9 3T5R!O X;:N<[10@+'[/$:PSZ]'&
MJ)>QJJC@ !K@  >@' H0'TO5 % !0!G:=_RV_P"N\G]*B/7U8&C5@% !0 4
M% '%>//^/"/_ *[K_P"BY:^'XG_W.G_U_C_Z;JGTV2?[Q/\ Z]2_]+@>35^0
MGZ % !0 4 % !0 4 % !0 4 % !0 4 >L^ _^/"3_KNW_HN*OU[AC_<ZG_7^
M7_IND?G^=_[Q#_KU'_TN9VM?<'S(4 % !0 4 % !0 4 % !0 4 % 'D'Q6U.
M[T[[%]CGFM]_VC=Y4CQ[MOD8W;",XR<9Z9..IK2*W.'$2<>7E;6^SMV/(/\
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M&F2R7<LD[BZ=0TKL[!1%"0H+$G&23CIDD]ZQEH]#T:#<HMMMZ]?1'H]0=04
M% !0 4 % !0 4 % !0 4 % 'R[^TG_S"?^WW_P!M*]O ?\O/^W?_ &X\',?^
M7?\ V]_[:?+E>V>"% !0 4 % !0 4 % !0 4 % !0 4 ?>GP7_Y%"P_[>?\
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M_P#HN6OA^)_]SI_]?X_^FZI]-DG^\3_Z]2_]+@>35^0GZ % !0 4 % !0 4
M% !0 4 % !0 4 >^Z-_QX6W_ %PB_P#1:U_0>7_[GAO^O%'_ --Q/R;%_P"\
M5O\ K[4_]+9HUZ9Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % $-S;17D;07")-$XPR2*'1AZ,K @CV(H %MHDB%NJ((0GEB,* @0#:$"
MXV[=OR[<8QQC% %>QTRTTP,ME!#;!SEA#&D88CH2$ R>3R?6@"]0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!G7/_'U;_\ ;7_T 5#W7S T:L H ^7/B-_R'[K_ +8_^D\5;QV/
M(K?Q'\OR1Q-6<X4 ?4?PY_Y %K_VV_\ 2B6N>6YZ]'^&OG^;.VJ3H.6UGP3H
MWB"^MM4U&V6>[L"IMY"\J["KB1<JCJD@#C<%D5QUXP2"@.DG@CNHVAF198I%
M*NCJ&5E88*LI!#*1P0001P:8'GMG\(?"5A=B_@TV%9U;>NYI7C5@<@K"\C0K
M@C(Q&,'D8I6 Z+Q)X/TKQ<L*:Q!]I6UD\V(>9+'M?&-W[J2,MP.C9'M3 /$G
M@_2O%RPIK$'VE;63S8AYDL>U\8W?NI(RW Z-D>U %CQ!X9TSQ3;_ &35[>.[
MA!W*'!RC=-R.I#HV."4921P3B@#,\,^ -!\'LSZ-9QVTCC#2;I))".NWS)GD
M<+ZJ& /'' I6L!X9:^!WUKXBZJ^L:?+-I-S;L%EF@E%N[;+7;Y<VT+O!5MI1
MPP*M@\&EU ][\,>"M&\&QO%HMJEH)2#(0SN[XS@-)*SR$#)VJ6VC)P!FGL >
M'?!FD>%);F?2;?[-)?LKW!\V:3S&0R,IQ+(X3!ED.$"@[N0<#!L!DZS\+_#/
MB"].IZC813738+/OE0.0, R)'(D<AP ,NK$@ 'I18!J_"SPS'#>VL=D(X-5,
M;7<237"1R&*7SH\(LP6())DJ(1& "4QL)6BP&'_PHGP5_P! [_R;O?\ Y)HL
M@-[5OA=X9UR*VAOK%)5L(8[>W/F3(Z0Q+MCC:1)5DD51T$K/SDG)))+ 6M(^
M'?A_0+Y=4TRS2TNDB\D-$\JKY> "&B$GE,3@$LR%RP#%BW-%@+_A[P?I7A5K
MA])@^SM?2"6<^9+)O<%B&_>R.%Y=N$VCGIP,/8 \/>#]*\*M</I,'V=KZ02S
MGS)9-[@L0W[V1PO+MPFT<].!@V Z6@ H * ,[3O^6W_7>3^E1'KZL#1JP"@
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M51]1I]Y_>O\ Y$/[0J_RP^Z7_P D'_#1'B'_ )]]._[]7'_R51]1I]Y_>O\
MY$/[0J_RP^Z7_P D'_#1'B'_ )]]._[]7'_R51]1I]Y_>O\ Y$/[0J_RP^Z7
M_P D'_#1'B'_ )]]._[]7'_R51]1I]Y_>O\ Y$/[0J_RP^Z7_P D'_#1'B'_
M )]]._[]7'_R51]1I]Y_>O\ Y$/[0J_RP^Z7_P D'_#1'B'_ )]]._[]7'_R
M51]1I]Y_>O\ Y$/[0J_RP^Z7_P D'_#1'B'_ )]]._[]7'_R51]1I]Y_>O\
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MVFL]$MH;A'AE7SMR2*489GE(RK $9!!&1R"#T-82W/4I)J"3T>OYLZ^I-PH
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M_1<5?KW#'^YU/^O\O_3=(_/\[_WB'_7J/_I<SM:^X/F0H * "@ H * "@ H
M* "@ H * /$_C%_RX_\ ;S_[;UK#J>?B?L_/]#Q*M3@"@ H * "@ H * "@
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M^+_C3_[=_P#24?6X/^!#_M[_ -*9ZC7"=X4 % !0 4 % &=<_P#'U;_]M?\
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MPC_Z[K_Z+EKX?B?_ '.G_P!?X_\ INJ?39)_O$_^O4O_ $N!Y-7Y"?H 4 %
M!0 4 % !0 4 % !0 4 % !0!ZSX#_P"/"3_KNW_HN*OU[AC_ '.I_P!?Y?\
MIND?G^=_[Q#_ *]1_P#2YG:U]P?,A0 4 % !0 4 % !0 4 % !0 4 >)_&+_
M )<?^WG_ -MZUAU//Q/V?G^AXE6IP!0 4 % !0 4 % !0 4 % !0 4 % 'T1
M\)/^03+_ -?;_P#HF"L9[GIX?X'Z_HCU&LSL"@ H * "@ H * "@ H * "@
MH ^7?VD_^83_ -OO_MI7MX#_ )>?]N_^W'@YC_R[_P"WO_;3Y<KVSP0H * "
M@ H * "@ H * "@ H * "@#[T^"__(H6'_;S_P"EEQ7R^+_C3_[=_P#24?6X
M/^!#_M[_ -*9ZC7"=X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % 'D?Q&UK3IKB+0)M)D\07;1&Y$$8 \F+<4\PR\O&6*E1MQG !/
MS*& /,/"WB+3]&>UO-%\+- VHR>1:74EWN1I&)4JL\ZL(V)##;O1GVL@[BF!
M]5T@"@ H * "@ H * "@ H * "@#.T[_ );?]=Y/Z5$>OJP-&K * "@ H *
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MS_CPC_Z[K_Z+EKX?B?\ W.G_ -?X_P#INJ?39)_O$_\ KU+_ -+@>35^0GZ
M% !0 4 % %J"RN+H%H(I)57J41F [\D XKJI8:O73E0I5)Q6[A"4DNNKBFEI
MW,)UJ5)J-6<(-[*4E%OTNT5:Y3<M)97$D9G2*1HAG+A&*#'7+ 8&._/%=4<-
M7G3=>%*HZ2O>:A)P5M[R2LK===#!UJ49*E*<%-VM%R2D[[:7OKTT&V]I-=DB
M"-Y2O)"*S8^NT'%32H5<0VL/3G4:U:A"4K+SY4[#G5IT;.K.,$]N:2C?TNT,
M6"1Y/)5&,F2NP*2V1U&W&<CN,9J%2J2G[&,).I=QY%%N5UNN6U[KJK7*<XQC
M[1R2A:_,VE&SZWVMYBSVTMJVR9'B;&=KJ5./7! ./>G5HU,/+DKPG3E:_+.+
MB[/K:23MYBA4A57-2E&2VO%IJ_:ZN!MY5C$Q1A$QP'*G:3SP&Q@G@\ YX-#I
M5(P59PDJ;=E-Q?(WKHI6LWH]$[Z,:G!R=-2CSI7<;KF2[M;I:[DLEA/#"ES(
MA6*4D(QP-Q SP,YQZ'&#V-;3PM:E2ABJD'&E4;4).RYFE?17YK=G:SZ,RC7I
MSJ2H0DG.*O)*^GJ]K^5[KL>G> _^/"3_ *[M_P"BXJ_4N&/]SJ?]?Y?^FZ1\
M1G?^\0_Z]1_]+F=K7W!\R% !0 4 % !0 4 % !0 4 % !0!XG\8O^7'_ +>?
M_;>M8=3S\3]GY_H>)5J< 4 % !0 4 7X]*O)H3=1P3/;KDF58W,8"_>)<+M&
M.^3QWI7Z%<KM=)V[VT*%,DOOI5Y' +MX)EMS@B4QN(R"< ARNWD\#GD]*5^A
M7*TN:SMWMH0VMG/>OY=M'),X!;;&C.V!U.%!.!W/04;"2;T2OZ"VEC<:@YCM
M(I)W W%8D9V"@@%B%!.,D#/3) [T; DY:13?H33Z3>VLB0SV\\4DQQ&CQ.K.
M20 $4J"QR0,*#R0.]%QN+6C33>V@^YT34+*,S7-M<0QC +R0R(H)X&690.3P
M.>:+KH-QE'5II>:8V_TB[TM8GNXVA%PN^/=C)4'&2N=R_1@"1R!BB_83BXVN
MK7V/=_A)_P @F7_K[?\ ]$P5E/<]'#_ _7]$>HUF=@4 % !0 4 % !0 4 %
M!0 4 % 'R[^TG_S"?^WW_P!M*]O ?\O/^W?_ &X\',?^7?\ V]_[:?+E>V>"
M% !0 4 % !0 4 % !0 4 % !0 4 ?>GP7_Y%"P_[>?\ TLN*^7Q?\:?_ &[_
M .DH^MP?\"'_ &]_Z4SU&N$[PH * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * /EW]I/_F$_]OO_ +:5[> _Y>?]N_\ MQX.8_\
M+O\ [>_]M/ERO;/!"@ H * "@ H * "@ H * "@ H * /O3X+_\ (H6'_;S_
M .EEQ7R^+_C3_P"W?_24?6X/^!#_ +>_]*9ZC7"=X4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'BWB:ZUCP_XI_M;2]+N-5BFL$M
MIBK*BKME:1?*?#$$$GS$9"&RI# YI@7(_B%X@=@K>&[U02 29TX!/7_5]NM
M'KM( H * "@ H * "@ H * "@ H SM._Y;?]=Y/Z5$>OJP-&K * "@ H * "
M@ H * "@ H * "@ H * "@#BO'G_ !X1_P#7=?\ T7+7P_$_^YT_^O\ '_TW
M5/ILD_WB?_7J7_I<#R:OR$_0 H * "@ H * "@ H * "@ H * "@#WW1O^/"
MV_ZX1?\ HM:_H/+_ /<\-_UXH_\ IN)^38O_ 'BM_P!?:G_I;-&O3.(* "@
MH * "@ H * "@ H * "@#Y!\3?\ (6O?^ONX_P#1SUTK9'B3^.7J_P S$IF8
M4 % !0 4 % !0 4 % !0 4 % ';?#G_D/VO_ &V_])Y:B6QT4?XB^?Y,^HZP
M/7"@ H * "@ H * "@ H * "@ H \&_:(_Y%ZW_[",7_ *3W5>I@?XC_ ,#_
M #B>3F'\*/\ C7_I,CXSKZ(^9"@ H * "@ H * "@ H * "@ H * /O3X+_\
MBA8?]O/_ *67%?+XO^-/_MW_ -)1];@_X$/^WO\ TIGJ-<)WA0 4 % !0 4
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M ^7?VD_^83_V^_\ MI7MX#_EY_V[_P"W'@YC_P N_P#M[_VT^7*]L\$* "@
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MI)WB]GL'AOP[9ZU'(]W?PZ>8V 59=F7!&21NFBX'3@'ZT-VV00@IWO)1]?\
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M/@O_ ,BA8?\ ;S_Z67%?+XO^-/\ [=_])1];@_X$/^WO_2F>HUPG>% !0 4
M% !0!G7/_'U;_P#;7_T 5#W7S T:L H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * ,[3O\ EM_UWD_I41Z^K T:L H * "@
M H XKQY_QX1_]=U_]%RU\/Q/_N=/_K_'_P!-U3Z;)/\ >)_]>I?^EP/)J_(3
M] "@ H * "@ H * "@ H * "@ H * /6? ?_ !X2?]=V_P#1<5?KW#'^YU/^
MO\O_ $W2/S_._P#>(?\ 7J/_ *7,[6ON#YD* "@ H * "@ H * "@ H * "@
M#Q/XQ?\ +C_V\_\ MO6L.IY^)^S\_P!#Q*M3@"@ H * "@ H * "@ H * "@
M H * /HCX2?\@F7_ *^W_P#1,%8SW/3P_P #]?T1ZC69V!0 4 % !0 4 % !
M0 4 % !0 4 ?+O[2?_,)_P"WW_VTKV\!_P O/^W?_;CP<Q_Y=_\ ;W_MI\N5
M[9X(4 % !0 4 % !0 4 % !0 4 % !0!]Z?!?_D4+#_MY_\ 2RXKY?%_QI_]
MN_\ I*/K<'_ A_V]_P"E,]1KA.\* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * .6\;Z;<:OH5]8V:>;<7%M+'&FY5W.RD ;G*J,GNS >
MIH \1UNT\;ZUH46@-H:1I MJHE%_:$G[,4(ROF@#?LYYXSWQ3 TO%C>-O%]C
M_9D^AQVT;S0R&1;^U<J(I5?[OF#.=N.N?KTH ^A:0!0 4 % !0 4 % !0 4
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MW)23BUHKZ_-?U\CC/AS_ ,A^U_[;?^D\M5+8PH_Q%\_R9]1U@>N% !0 4 %
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M6OA^)_\ <Z?_ %_C_P"FZI]-DG^\3_Z]2_\ 2X'DU?D)^@!0 4 % !0 4 %
M!0 4 % !0 4 % 'K/@/_ (\)/^N[?^BXJ_7N&/\ <ZG_ %_E_P"FZ1^?YW_O
M$/\ KU'_ -+F=K7W!\R% !0 4 % !0 4 % !0 4 % !0!XG\8O\ EQ_[>?\
MVWK6'4\_$_9^?Z'B5:G % !0 4 % !0 4 % !0 4 % !0 4 ?1'PD_Y!,O\
MU]O_ .B8*QGN>GA_@?K^B/4:S.P* "@ H * "@ H * "@ H * "@#Y=_:3_Y
MA/\ V^_^VE>W@/\ EY_V[_[<>#F/_+O_ +>_]M/ERO;/!"@ H * "@ H * "
M@ H * "@ H * /O3X+_\BA8?]O/_ *67%?+XO^-/_MW_ -)1];@_X$/^WO\
MTIGJ-<)WA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % &=IW_+;_ *[R?TJ(]?5@:-6 4 %
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M_P#N>&_Z\4?_ $W$_)L7_O%;_K[4_P#2V:->F<04 % !0 4 % !0 4 % !0
M4 % 'R#XF_Y"U[_U]W'_ *.>NE;(\2?QR]7^9,/$MR-*.B;8OLY??NPWF9W!
M^N_;C(_N9QWI6UN/G?+[/2WXG/51D% !0 4 % !0 4 % !0 4 % ';?#G_D/
MVO\ VV_])Y:B6QT4?XB^?Y,^HZP/7"@ H * "@ H * "@ H * "@ H \&_:(
M_P"1>M_^PC%_Z3W5>I@?XC_P/\XGDYA_"C_C7_I,CXSKZ(^9"@ H * "@ H
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M?^7?_;W_ +:?+E>V>"% !0 4 % !0 4 % !0 4 % !0 4 ?>GP7_ .10L/\
MMY_]++BOE\7_ !I_]N_^DH^MP?\  A_V]_Z4SU&N$[PH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#.T[_EM_UWD_I41Z^K T:L H * "@ H * "@ H * "@ H * "@ H *
M .*\>?\ 'A'_ -=U_P#1<M?#\3_[G3_Z_P ?_3=4^FR3_>)_]>I?^EP/)J_(
M3] "@ H * "@ H * "@ H * "@ H * /?=&_X\+;_KA%_P"BUK^@\O\ ]SPW
M_7BC_P"FXGY-B_\ >*W_ %]J?^ELT:],X@H * "@ H * "@ H * "@ H * /
MD'Q-_P A:]_Z^[C_ -'/72MD>)/XY>K_ #,2F9A0 4 % !0 4 % !0 4 % !
M0 4 =M\.?^0_:_\ ;;_TGEJ);'11_B+Y_DSZCK ]<* "@ H * "@ H * "@
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MQ/\ [G3_ .O\?_3=4^FR3_>)_P#7J7_I<#R:OR$_0 H * "@ H * "@ H *
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M]R8&6Q0!T6CW<]_90W5W#]DFFC5W@W^88BPSL9]B98 C=\HPV1SC) -*@ H
MSM._Y;?]=Y/Z5$>OJP-&K * "@ H * "@ H * "@ H * "@ H * "@#BO'G_
M !X1_P#7=?\ T7+7P_$_^YT_^O\ '_TW5/ILD_WB?_7J7_I<#R:OR$_0 H *
M "@ H * "@ H * "@ H * "@#WW1O^/"V_ZX1?\ HM:_H/+_ /<\-_UXH_\
MIN)^38O_ 'BM_P!?:G_I;-&O3.(* "@ H * "@ H * "@ H * "@#Y!\3?\
M(6O?^ONX_P#1SUTK9'B3^.7J_P S$IF84 % !0 4 % !0 4 % !0 4 % ';?
M#G_D/VO_ &V_])Y:B6QT4?XB^?Y,^HZP/7"@ H * "@ H * "@ H * "@ H
M\&_:(_Y%ZW_[",7_ *3W5>I@?XC_ ,#_ #B>3F'\*/\ C7_I,CXSKZ(^9"@
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MSA_'?C^P^'MK%>ZE'<2QSR^2HMUC9@VQGRPDEB 7"GD$G...]+8#N*8!0 4
M% !0 4 % !0 4 % !0 4 % !0 4 <1K_ (^L/#FKV.A74=P]SJK!86C6,Q*2
MX3]X6E1@,G/RH_'OQ2 [>F 4 % &=IW_ "V_Z[R?TJ(]?5@:-6 4 % !0 4
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M H ^7?VD_P#F$_\ ;[_[:5[> _Y>?]N_^W'@YC_R[_[>_P#;3Y<KVSP0H *
M"@ H * "@ H * "@ H * "@#[T^"_P#R*%A_V\_^EEQ7R^+_ (T_^W?_ $E'
MUN#_ ($/^WO_ $IGJ-<)WA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!Y-\4[V>\2R\*V+&.XUZ<Q2.O+1VD0#W+
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M+_\ <\-_UXH_^FXGY-B_]XK?]?:G_I;-&O3.(* "@ H * "@ H * "@ H *
M"@#Y!\3?\A:]_P"ONX_]'/72MD>)/XY>K_,Q*9F% !0 4 % !0 4 % !0 4
M% !0!VWPY_Y#]K_VV_\ 2>6HEL=%'^(OG^3/J.L#UPH * "@ H * "@ H *
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MB-MPD592,NC#S%+J2REBNS#0'TA5 9VG?\MO^N\G]*B/7U8&C5@% !0 4 %
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M)[JO4P/\1_X'^<3R<P_A1_QK_P!)D?&=?1'S(4 % !0 4 % !0 4 % !0 4
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M9<JS;05AC!;<5RH%&H&7\8]/N5\8Z#9:,ZVURD%O':.V2D;I<2"+=PV5! #
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'S(4 % !0 4 % !0 4 % !0 4 % !0!]Z?!?_D4+#_MY_P#2RXKY?%_QI_\
M;O\ Z2CZW!_P(?\ ;W_I3/4:X3O"@ H * "@ H SKG_CZM_^VO\ Z *A[KY@
M:-6 4 <%K7PQ\.>(;R34=1M/.NIMN]_/N4W;$6-?ECF1!A$4<*,XR<DDGJAB
M*M.*A"5DME9==>J.2>&I5).<XWD]W>2V5NCML9?_  I?PA_SX?\ DS>?_)%:
M?6ZW\_\ Y+'_ ",_J=#^3_R:7^8?\*7\(?\ /A_Y,WG_ ,D4?6ZW\_\ Y+'_
M "#ZG0_D_P#)I?YG>Z+HMGX>LX].TZ/R+6#=Y<>YWV[W:1OFD9W.7=CRQQG
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M!\N_M)_\PG_M]_\ ;2O;P'_+S_MW_P!N/!S'_EW_ -O?^VGRY7MG@A0 4 %
M!0 4 % !0 4 % !0 4 % 'WI\%_^10L/^WG_ -++BOE\7_&G_P!N_P#I*/K<
M'_ A_P!O?^E,]1KA.\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H SM._Y;?]=Y/Z5$>OJP
M-&K * "@ H * "@ H * "@ H * "@ H * "@#BO'G_'A'_UW7_T7+7P_$_\
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MG_W.G_U_C_Z;JGTV2?[Q/_KU+_TN!Y-7Y"?H 4 % !0 4 % !0 4 % !0 4
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M[T^"_P#R*%A_V\_^EEQ7R^+_ (T_^W?_ $E'UN#_ ($/^WO_ $IGJ-<)WA0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % &=IW_+;_KO)_2HCU]6!HU8!0 4 % !0 4 % !0
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MNG:C<1JC7$^J7B7#8!;"N-D;<9V;&W!3QEV/>D@/(M>5;?P;XEM;3']GV_B
MI:A?N(OGPEXX^ /+0XVX)')/?+(#T37%U>Y^(CC2Q82W%KI4;6R:DTZQHCR_
MO9+<0HY\W=E68@':6&>.'U VM)T/7%\8V^KZO+HMK.UG+#+;6,\_VBZBY9':
M&:)3((I N9,C"J 2=H ?4#UK7_\ D&7?_7M/_P"BFI@?-'B7_DD-K_USM/\
MTI%3T [OXY6-OIO@MXK6-(4LI;3[.%4 1;945=G]TA25R.2"<]30]@,?7%U>
MY^(CC2Q82W%KI4;6R:DTZQHCR_O9+<0HY\W=E68@':6&>.#J!M:3H>N+XQM]
M7U>71;6=K.6&6VL9Y_M%U%RR.T,T2F012!<R9&%4 D[0 ^H!\"8H+7PY-<;5
M0O?7;ROCEMC@ GN=JJ,>F..30@*/A/6-0O\ 3W/@O1;.UT:XEG9+G4+Q\7!,
MC)+-)"B2S;=RLI#R,=J[5PH I>@'ED(CF^&4<5RRBW_MD(Y0X18C<Y<H><*
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MOB_XT_\ MW_TE'UN#_@0_P"WO_2F>HUPG>% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9V
MG?\ +;_KO)_2HCU]6!HU8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 <5X\_X
M\(_^NZ_^BY:^'XG_ -SI_P#7^/\ Z;JGTV2?[Q/_ *]2_P#2X'DU?D)^@!0
M4 % !0 4 % !0 4 % !0 4 % 'ONC?\ 'A;?]<(O_1:U_0>7_P"YX;_KQ1_]
M-Q/R;%_[Q6_Z^U/_ $MFC7IG$% !0 4 % !0 4 % !0 4 % !0!\@^)O^0M>
M_P#7W<?^CGKI6R/$G\<O5_F8E,S"@ H * "@ H * "@ H * "@ H [;X<_\
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M+7P_$_\ N=/_ *_Q_P#3=4^FR3_>)_\ 7J7_ *7 \FK\A/T * "@ H * "@
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M * "@ H * "@ H * "@ H * "@ H * ,[3O^6W_7>3^E1'KZL#1JP"@ H *
M"@ H * "@ H * "@ H * "@ H XKQY_QX1_]=U_]%RU\/Q/_ +G3_P"O\?\
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M'\*/^-?^DR/C.OHCYD* "@ H * "@ H * "@ H * "@ H ^]/@O_ ,BA8?\
M;S_Z67%?+XO^-/\ [=_])1];@_X$/^WO_2F>HUPG>% !0 4 % !0!G7/_'U;
M_P#;7_T 5#W7S T:L H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * ,[3O\ EM_UWD_I41Z^K T:L H * "@ H XKQY_QX1_
M]=U_]%RU\/Q/_N=/_K_'_P!-U3Z;)/\ >)_]>I?^EP/)J_(3] "@ H * "@
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M % !0 4 % !0 4 % !0!]Z?!?_D4+#_MY_\ 2RXKY?%_QI_]N_\ I*/K<'_
MA_V]_P"E,]1KA.\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H SM._Y;?\ 7>3^E1'KZL#1
MJP"@ H * "@ H * "@ H * "@ H * "@ H XKQY_QX1_]=U_]%RU\/Q/_N=/
M_K_'_P!-U3Z;)/\ >)_]>I?^EP/)J_(3] "@ H * "@ H * "@ H * "@ H
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MZ(^$G_()E_Z^W_\ 1,%8SW/3P_P/U_1'J-9G8% !0 4 % !0 4 % !0 4 %
M!0!\N_M)_P#,)_[??_;2O;P'_+S_ +=_]N/!S'_EW_V]_P"VGRY7MG@A0 4
M% !0 4 % !0 4 % !0 4 % 'WI\%_P#D4+#_ +>?_2RXKY?%_P :?_;O_I*/
MK<'_  (?]O?^E,]1KA.\* "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M *3W5>I@?XC_ ,#_ #B>3F'\*/\ C7_I,CXSKZ(^9"@ H * "@ H * "@ H
M* "@ H * /O3X+_\BA8?]O/_ *67%?+XO^-/_MW_ -)1];@_X$/^WO\ TIGJ
M-<)WA0 4 % !0 4 9US_ ,?5O_VU_P#0!4/=?,#1JP"@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H SM._Y;?\ 7>3^E1'K
MZL#1JP"@ H * "@#BO'G_'A'_P!=U_\ 1<M?#\3_ .YT_P#K_'_TW5/ILD_W
MB?\ UZE_Z7 \FK\A/T * "@ H * "@ H * "@ H * "@ H ]9\!_\>$G_7=O
M_1<5?KW#'^YU/^O\O_3=(_/\[_WB'_7J/_I<SM:^X/F0H * "@ H * "@ H
M* "@ H * /$_C%_RX_\ ;S_[;UK#J>?B?L_/]#Q*M3@"@ H * "@ H * "@
MH * "@ H * /HCX2?\@F7_K[?_T3!6,]ST\/\#]?T1ZC69V!0 4 % !0 4 %
M !0 4 % !0 4 ?+O[2?_ #"?^WW_ -M*]O ?\O/^W?\ VX\',?\ EW_V]_[:
M?+E>V>"% !0 4 % !0 4 % !0 4 % !0 4 ?>GP7_P"10L/^WG_TLN*^7Q?\
M:?\ V[_Z2CZW!_P(?]O?^E,]1KA.\* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H SM._P"6
MW_7>3^E1'KZL#1JP"@ H * "@ H * "@ H * "@ H * "@ H XKQY_QX1_\
M7=?_ $7+7P_$_P#N=/\ Z_Q_]-U3Z;)/]XG_ ->I?^EP/)J_(3] "@ H * "
M@ H * "@ H * "@ H * /?=&_P"/"V_ZX1?^BUK^@\O_ -SPW_7BC_Z;B?DV
M+_WBM_U]J?\ I;-&O3.(* "@ H * "@ H * "@ H * "@#Y!\3?\A:]_Z^[C
M_P!'/72MD>)/XY>K_,Q*9F% !0 4 % !0 4 % !0 4 % !0!VWPY_P"0_:_]
MMO\ TGEJ);'11_B+Y_DSZCK ]<* "@ H * "@ H * "@ H * "@#P;]HC_D7
MK?\ [",7_I/=5ZF!_B/_  /\XGDYA_"C_C7_ *3(^,Z^B/F0H * "@ H * "
M@ H * "@ H * "@#[T^"_P#R*%A_V\_^EEQ7R^+_ (T_^W?_ $E'UN#_ ($/
M^WO_ $IGJ-<)WA0 4 % !0 4 95_,D%Q!)(<*/,R<$]5 [9/4U#=FF_,9)_:
MUK_?_P#'7_\ B:.9"#^UK7^__P".O_\ $T<R /[6M?[_ /XZ_P#\31S( _M:
MU_O_ /CK_P#Q-',@#^UK7^__ ..O_P#$T<R /[6M?[__ (Z__P 31S( _M:U
M_O\ _CK_ /Q-',@#^UK7^_\ ^.O_ /$T<R /[6M?[_\ XZ__ ,31S( _M:U_
MO_\ CK__ !-',@#^UK7^_P#^.O\ _$T<R /[6M?[_P#XZ_\ \31S( _M:U_O
M_P#CK_\ Q-',@#^UK7^__P".O_\ $T<R /[6M?[_ /XZ_P#\31S( _M:U_O_
M /CK_P#Q-',@#^UK7^__ ..O_P#$T<R /[6M?[__ (Z__P 31S( _M:U_O\
M_CK_ /Q-',@#^UK7^_\ ^.O_ /$T<R /[6M?[_\ XZ__ ,31S( _M:U_O_\
MCK__ !-',@#^UK7^_P#^.O\ _$T<R /[6M?[_P#XZ_\ \31S( _M:U_O_P#C
MK_\ Q-',@#^UK7^__P".O_\ $T<R /[6M?[_ /XZ_P#\31S(!NEN)%E=>0TS
MD'V.TBB/7U TZL H * "@ H XKQY_P >$?\ UW7_ -%RU\/Q/_N=/_K_ !_]
M-U3Z;)/]XG_UZE_Z7 \FK\A/T * "@ H * "@ H * "@ H * "@ H ]9\!_\
M>$G_ %W;_P!%Q5^O<,?[G4_Z_P O_3=(_/\ ._\ >(?]>H_^ES.UK[@^9"@
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M'+,>[$GO2 TJ "@#.T[_ );?]=Y/Z5$>OJP-&K * "@ H * "@ H * "@ H
M* "@ H * "@#BO'G_'A'_P!=U_\ 1<M?#\3_ .YT_P#K_'_TW5/ILD_WB?\
MUZE_Z7 \FK\A/T * "@ H * "@ H * "@ H * "@ H ]]T;_ (\+;_KA%_Z+
M6OZ#R_\ W/#?]>*/_IN)^38O_>*W_7VI_P"ELT:],X@H * "@ H * "@ H *
M "@ H * /D'Q-_R%KW_K[N/_ $<]=*V1XD_CEZO\S$IF84 % !0 4 % !0 4
M % !0 4 % ';?#G_ )#]K_VV_P#2>6HEL=%'^(OG^3/J.L#UPH * "@ H *
M"@ H * "@ H * /!OVB/^1>M_P#L(Q?^D]U7J8'^(_\  _SB>3F'\*/^-?\
MI,CXSKZ(^9"@ H * "@ H * "@ H * "@ H * /O3X+_ /(H6'_;S_Z67%?+
MXO\ C3_[=_\ 24?6X/\ @0_[>_\ 2F>HUPG>% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 <5X\_X\(_^NZ_^BY:^'XG_P!SI_\ 7^/_ *;JGTV2?[Q/_KU+_P!+
M@>35^0GZ % !0 4 % !0 4 % !0 4 % !0 4 >L^ _\ CPD_Z[M_Z+BK]>X8
M_P!SJ?\ 7^7_ *;I'Y_G?^\0_P"O4?\ TN9VM?<'S(4 % !0 4 % !0 4 %
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M/K>'_P"?U+_P9#_,/[&O_P#GVG_[]2?_ !-']GXS_H&K_P#@FI_\B'UO#_\
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M_P"(HNNX<D_Y7]S#_A&=6_Y\KO\ \!YO_B*+KN')/^5_<P_X1G5O^?*[_P#
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H XKQY_QX1_\ 7=?_ $7+7P_$_P#N=/\ Z_Q_]-U3
MZ;)/]XG_ ->I?^EP/)J_(3] "@ H * "@ H * "@ H * "@ H * /6? ?_'A
M)_UW;_T7%7Z]PQ_N=3_K_+_TW2/S_._]XA_UZC_Z7,[6ON#YD* "@ H * "@
M H * "@ H * "@#Q/XQ?\N/_ &\_^V]:PZGGXG[/S_0\2K4X H * "@ H *
M"@ H * "@ H * "@#Z(^$G_()E_Z^W_]$P5C/<]/#_ _7]$>HUF=@4 % !0
M4 % !0 4 % !0 4 % 'R[^TG_P PG_M]_P#;2O;P'_+S_MW_ -N/!S'_ )=_
M]O?^VGRY7MG@A0 4 % !0 4 % !0 4 % !0 4 % 'WI\%_\ D4+#_MY_]++B
MOE\7_&G_ -N_^DH^MP?\"'_;W_I3/4:X3O"@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M2?\ [ZC_ /C5'^K&#_Y^5_\ P*G_ /*@_MO$?R4O_ 9__)A_P@=A_P ])_\
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MV'U>'=_A_D'_  J32?\ GK=_]]P__&*.=A]7AW?X?Y!_PJ32?^>MW_WW#_\
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MZ7[-=SDK8>.(MSMKEO:UNMNZ?8X/_AG?P]_S\:C_ -_;?_Y%KJ^O5.T/N?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M'6.3:O'F("%?';<#CM0!TDOQ"T&'+-<GRED\HSB"X-N'!P5^TB(V^0>O[S%
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M8$CY&(;!!Q@YH ZJ@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * .<U'Q9IFEW#6<\KM<(@D>.&">X:-#T:06\4OE@]07VY!!Z$&@!3XM
MTE=/_M@W47V'./.R<;LXV;0-^_/&S;O_ -F@!=+\5:;J\[6=K*WVE$$AAEBF
MMY=AZ.(YXXG9>1\R@CGK0!T- !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 <Q?>,M*TZ>2UFE=I;<!IEA@N)Q"&Y!F:"*18L@Y_>
M%>.>E $UQXLTFUL4U62YC^QS$+'(N7WL<X1%0,[/P1L52P(((&#0!)I7B73]
M:EDMK24F>WP989(Y8)D!X!,4Z1R8SQG;CD<\C(!NT % !0 4 % !0 4 % !0
M 4 <U_PE5K_;7_"/;)?M7V?[3OVIY6S.,;M^_=GMY>/]J@#I: "@ H * "@
MH * "@ H * "@#FO#GBJU\3_ &G[(DJ?8;A[:3S51<NG4IM=\KZ$[3_LB@#I
M: ,C6->L?#\:S:A*(5D<1H-KN[N>BI'&KR.WLJDT 1:3XDT_6Y)8;.4M-;D"
M6&2.6&://3?%,D<@!]2N/>@#+N/'VAVKR))<\02>3+(L,[P1R$D;)+A(F@1L
M@\-(".] '7(ZR*'0AE8 @@Y!!Y!!'!!'((H =0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MU3RK@DF"!(K>$R!,(KJ6+.VW&QG)4*,@,>6(V/AZ@_L_Q&V!DWEX"<<D"-\
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MBXB&4A@-L24>3H&?IY9.X$@$ MB@"/7$5/AC;!0 ,0'@8Y-P23]2223W))H
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M''!3!'T()!'<$BD,['QQXPA\&V(N7423SN(8(V8(ID(SND<\)&@^9V^@XSD
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M!5!!'S CD /"?B&Z\1^'1JNI7KZ>UJ\ZSSP);J'2(\,Z7%O.%X(^5%4EOJ%
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MD1W46PCGG"'*K-.9I P' )6)&;&22W- 'IM !0 4 % !0 4 % !0 4 % !0
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M0DR0Q3^<JB-\G[\#L 2-W)R ;.D^"(=&U@:K;2;88].33TM]GW51T<2&7?\
M,2$P1Y8))+%L\$ ALO WV.UUBT^T;O[=ENY=WE8\C[4C+MQYA\W9NSG,>[&,
M+F@#B+K2+3P3?V 2_;3KM+'[,]U/;![&YCB/"2@SQ^5,,!EQ+R @SDX8 L_"
MVRFEU76-6>5[J"YDBCBN7B\H7!7>9'C3M&I*J@&1M(&>#0![90 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 9W]G?]-I_^_G_UJCE\W]X!_9W_ $VG_P"_
MG_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_
M $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\
MW]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\
MOY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=
M_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY
M?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_
M +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']
MG?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ
M.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG
M_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!
M_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]
M:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-
MI_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_>
M ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?
M_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\
M3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?
MW@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_
MG_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_
M $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\
MW]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\
MOY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=
M_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY
M?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_
M +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']
MG?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ
M.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG
M_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!
M_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]
M:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-
MI_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_>
M ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?
M_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\
M3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?
MW@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_
MG_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_
M $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\
MW]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\
MOY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=
M_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY
M?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_
M +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']
MG?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ
M.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG
M_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!
M_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]
M:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-
MI_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_>
M ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?
M_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\
M3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?
MW@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_
MG_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_
M $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\
MW]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\
MOY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=
M_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY
M?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_
M +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']
MG?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ
M.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG
M_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!
M_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]
M:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-
MI_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_>
M ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?
M_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\
M3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?
MW@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_
MG_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_
M $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\
MW]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\
MOY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=
M_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY
M?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_
M +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']
MG?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ
M.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG
M_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!
M_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]
M:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-
MI_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_>
M ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\ 3:?_ +^?
M_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?W@']G?\
M3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_G_UJ.7S?
MW@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_ $VG_P"_
MG_UJ.7S?W@']G?\ 3:?_ +^?_6HY?-_> ?V=_P!-I_\ OY_]:CE\W]X!_9W_
M $VG_P"_G_UJ.7S?W@:-6 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H CE<QH656D(&0B[0S>PWLJY_WF ]Z )* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H Q[FU6RTZ:&,DJL4Q&[&?F#L>@ ZDXXZ4 <?>Q
MMIND&ZC!,-U8+%.H!.V0V^R*8#T)(BDZ<%&_A:F!JW7]G_:[O^U=F[,?D>;U
M\GRD_P"/?/.[SO-SY?S[MN?X:/0"+1T$=_"UZ%6\EL8N9 HE>16D#<]6D$0
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MB3*=VYVSG8I(EY+<T >DHV]0Q!4D X/49['W%(!U !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % %*XL5N9HIG=\0-O6,;=A?:RAV^7>2
MQP X7H2I(H NT % !0 4 % !0 4 % !0 4 % !0!3L[%+$RF,L?/E:9MQ'#,
M%! P!\ORC .3UYH N4 % !0 4 % !0!3T^Q33;>.TB+%(5"J6P6('J0 ,_0"
M@"Y0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
9 !0 4 % !0 4 % !0 4 % !0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img46421407_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_20.jpg
M_]C_X  02D9)1@ ! @$ P #   #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
M 0(#! 4&!P@)"@L0  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B
M<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'
M2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ
M\?+S]/7V]_CY^A$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B
M,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'
M2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:
MHJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ
M\O/T]?;W^/GZ_\  $0@#G =' P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H Y*S\4^??G3I8?)8,Z;O,W#<N<<;%^]CCGN/6O#I8_GK_59T^1W
ME&_-?57Z<JWMIJ>W4P')0^M0GS*T96Y;:.W7F>U]=#JW<1J78X5023Z <DU[
M;:BG)Z):OT1XJ3DU%;O1>IRVA^)FUN=H4@\M$4L7,F>X &W8.3]>,&O&PF.>
M+FZ<:?+%*[ES7ZV6G*M_4]C%8%82"FZG,V[*/+;I=Z\SV]#JZ]H\8* "@ H
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M_FBG\/+TOW.B.!YL-];Y[:2?+R_RMK?FZV['4U[)XX4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#RSQ
M? VFZC%?1<;]K_\  XR ?S&W/KS7QF90>'Q$,3#3FM+_ +>@U?\ "WXGV.72
M5?#SPT_LW7_;LKV_&_X'4>)=46/2C+$?^/I55.>SC<?_ !S(^IKV<=B%'"\\
M'_$24?22N_\ R6Z^9X^!H.6*Y)K^$VY>L79?^369A:+<)X<TDWTB[I;E_D7.
M,XR$S[#YF/L?4UYV%FL!A'B)*\JC]U=[74?ENWY,]'%0>.Q2P\7:-->\^U[.
M7SV7JB6VN/$.HP_;(7C1#RD>U 6&?X=RL<?[SKGMFJA/,*\/;TY1C%ZJ-HW:
M\KI_C)$3A@*$_83C)R6CE>5D_.S7X19L>&_$1U;=;W"A+B(9.. P!P3@\A@?
MO#ISD>@[\#C7B;TJJM5CO;1-;/3HT]T<.-P:PUJM)WIRV[I[K7JFMG_3YNU\
M0ZK<7DMI"5E9F=8PRHJQA6/S$JH)PHQR2.>A/!\FGC,5.M.A3:DVY*-U%*-G
MOHDW9+J_O/6J8/"PHPKU$XI*+E9R;E=;:MI7;Z+[B677-5T2\2'4&29'P3M5
M0-A)&5*JAR"#PP[>^:N6+Q6#K1IXIQG%V>B7PMVNFE%W7F1'"X7%T95,*I0D
MKK5O=*]FFY*S\CJ/$>O#1(AL >:7(0'H,=6;'.!D8 QD]^M>QC<7]3@N57G+
MX4]E;=OR_,\?!83ZW-W=H1^)K?79+S_(YXR^(A!]MWQ[,;_*VINVXSG&ST[;
M]WMFO,YLQ5/ZQS1M:_):-[6O>W+VZ<U_(]/ER_G^K\LKWMSWE:][6OS=^O+;
MS-[1=?&L6LDF!'/"IWJ.F<$JRYSP<=#G!&.>I]'"XSZU2E*W+4@M4MMG9J_3
M3J>=B<)]5JQCO3D]'UW5T[==>AR6D:[K.J%K:!D>0X;S'5%$:C@\*N#DD=58
M\<#J:\3#8O&8ENE3:<M'S244HKY+JVNC?9'M8C"8/#)5:B:CMRQ<FY/YOHD^
MJ7=EV'7]0TB]6TU;;(CX^<!1@,<!U*A05!Z@C/![C!Z(XS$86LJ&-M*+M[R2
M5D]%)-)75][JYSRP>'Q-%UL%>+5_=;;U6KBTV[.VUG8E\4Z]>:5>QQV[[8S$
MKLFU#N.]P>2I89"@<'CJ.:O,,76PU:,*4K1Y%)QM%W?-)/5IM722T)P&$HXF
MC*56-Y<SBG>2LN6+6B:3LW?4U],3658W%\Z-'L9A BJ'W8^5,[!C_OMN< ]Z
M[J"QB?M<1*+CRMJFDE*]M(WY5;_P)_F<-=X.WLL/&2ES)>T;?+:^KMS._P#X
M"C)CE\1:@SLFRT5#PKHHS[*61RWUX7/?M7%&685W)QM22V4HK7R3<9-^NB.V
M4<OH**E>JWNXR>GFTI12]-63^&?$%S?7#V5[M,B!B&  .5(5E(''?(( Z'.<
MBM,!C*E:I+#XBSDDVFE;5-)IVT\UMU\C/'8.G1IQQ&'NHMI--WT:;35]?)[]
M/,CO(]>LXWGDNX$CC!)^5>G8?\>_)/  [GBIJQQ]*,JDZ]-1CKLMO_!6_1>9
M5-X&K*-.%"HY/3=[_P#@W;J_(I>&-:U/5+Q4ED\R! QD^2-1]TA>50'._' /
M.#VS7/@,5B<3649RO32;E[L5T=M5%/XK=3HQV&PV&HN4(\M1M*/O2?57T<FM
MK]#4OKG6[J\:WLT%M$N<2.H*D _>+%7'S=E SCKT)'95J8VI6=*A'V<%>TI)
M--+JVU):]$E>WS..E3P5*DJE>7M)NUXQ;35^B2<7IU;=K_(H6FNZC8:BNGZB
MR2[V5,J%&-^ K*55>,D9!7./0US4\7B*&(CA<4XRNU&Z27Q;--)=^J.FIA,/
M6P[Q.%4H63=FV_AW33;_  9/XJUV[TF[B2W?;&4#,NU#N^=@>64D9 QQTZUI
MF&+JX:K"-*5H\J;5HZ^\[ZM-JZ5M#/ 82EB:4Y5(WDI-)WDK>ZK:)I/5WU*V
MI7^O6,0OI&CCB8C,2JI*9Z!MRD^W#D@]<5C7K8ZC!8B;C&#:]Q)-QOLG=7^Z
M3?H:T*.!K2>'@I2DD_?;:4K;M6=OOBEZG8Z)J7]JVB7)&UFR& Z;E)!Q['&1
MZ9Q7O86O]9I1JM6;NFO-.SMY/<\/%4?JU65).Z5FGY-75_/H6-1CN9+=ELG6
M.<[=C-RH^8%L_*_5<@?*>3VZC6LJDJ<EAY*-33E;V6JOTETNMF9473C43Q$7
M*GK=+=Z.W6/6SW1Y+X:AOI;IQ8R)%(%)<N 05WKD#*/SG!Z#ZU\1@8UY59+#
M2C&27O-[-<RNE[LNODC[7&RH1I1>(C*4;^ZENGRNS?O1Z>;.@UWQ!?V.IM;V
M[9C&P+'M0Y+(.,E=W+'/WO;(KU,7C*]'$NE2?N^[:-HZMQ76U]WW/,PF#H5L
M,JM56E[UY7EHDWTO;9=C:B&KV=O<7%[-&VR"1XU15RKA2P)_=J#MQTRP)ZY'
M7T(K%TJ=6KB*D7:G)Q44KJ23>ONI:=M4SSY?5*M2E2P].2O4BI.3=G%M+3WF
M]>^C0SPAJMSJD<K73^8490ORJN 0<_=5?UJ<MQ%3$1FZTN9II+1+=/LD5F.'
MIX:4%1CRIIMZM]?-LYO2-?UC4F:VA99)&PP=U11&HSN/RJ =Q*]0V,<#FO)P
MV,QF(;I4VI2=GS-12@E>[T2WNMT]M%J>KB,)A,.E5J)QBKKE3DW-NUEJ^EGL
MUOJ]"\NOZCHEXMOJI66-\?,H4?*3C>I55R >H8 _3BNA8S$8.LJ6-M*+ZI):
M/3F32CHNJ:OZ'.\)A\72=7!IQDNC;>J^RTV]^C3L4_'W_'S#_P!<S_Z$:PS?
M^)3_ ,#_ #9OE'\.?^)?D=9XEU_^Q8E6(!IY<[0>B@=6(')Y( '<Y],'V\=C
M/JD4H).I*]K[)+=O]%_D>+@<)];DW-M4X[VW;>R7ZO\ S,"XO=?TR$7MPT;Q
M9!:/:N4!(QNVJI&2<<,<'K7F3JX_#P6(JN+AI>-E>-^]DFNVC=GN>G"E@,1-
MX>DI*>MI7=G;M=M/OJE?H=MIFH)J=LES'P''(_NL#AA^!''J,'O7T-"LL13C
M6CHFMNS6C7W_ (:GS]>B\/4E1ET>C[IZI_=^.A#K4=U):L+)UCDZDL,C9@[A
M]U^3VX_$5GBHU94FL/)1EU;VY;.ZVEJ_3YFF%=*-5.O%RCT2WYKJSWC^?R/,
MO"45[).WV*1(@NPR[@#N3=T'R/SU_N_6OD,NC6E-_5Y1BER\]^L;[+W9:[]O
M4^MS"5&,%]8C*3?-R6Z2MN_>CIMW]";6I9(-?:2%?,D#Q;%]6,48 ^F3[?4=
M:TQ4I0Q[E37-)2ARKN^2-OQ,\+&,\"HU'RQ<9\S[+GE?\#2U+5-;T-XY;IXG
MCD_@55V@C!*D[5<''<,1[FNNOB,;@W&=:4'&7V4E;S3T4K^C:\SDH8?!8M2A
M1C.,H]6W?R:5W&WR3\CJ-4U]+"P2]5<M.J&-#ZNH;GOA1UQU.!QG(]BOC%0H
M1Q"5W-1<8OO)7U\DM_NTN>10P;K5Y8=NR@VI27:+MIYM[??K8YH7GB VW]H[
MH_*QO\O8N[9UW8VYVXY^_NQSBO)]KC_9_6KQY+<W+RJ_+O>UKVMK\5[:GK>S
MP"J?5;2Y[\O-=VYMK7O:]]/AM?0Z"TUTZCI<UY%^[FACER!@A75"P(!SD'@C
M(/<'.#7IT\7[?"U*\/=G",[K>TE%M-7Z;-7]-;'F5,)]7Q,*$_>A*4+=+Q<D
MFG;KNM/72YRVD:MK>L[HK>5 4^9I75  #PJX$9')#'[I)]0!SXV&Q&-Q=X4I
MQ3CJYRC%))[+2+[/H_E8]C$8?!82TZL)6>BA%R;;6[UDNZZKYW.BU2ZU>SAA
MAMT\^9A^]F505#$] N  !W9E Q@X!SCU<14Q=*$*=*//-KWYI)I.^R7ZM6M\
MSRZ%/"59SJ59<D$_<@W9VMNW^B=[_(P]1U'7-"V2W4L4J.<;0JXR.2IPB,..
MX)'H:\ZM6QV"Y9UIPE%O9)6OO9VC%_<_F>C1HX+&<T*,)Q:6[;OVNKRDOO7R
M-W6]9ECTN.^M&\IY?+/16P&!)7Y@1P>,X[<5Z6*Q,XX6.)H/E<N5[)VNM5JF
MOP/-PN&A+$RP]9<RCS+=J]GH]&GY[F/8WVNZQ;B6U:.-4&W<P3=*PZX!0J.N
M.B+QU)S7!2JX[%4^>BXQ2TNU&\VM[>ZTONBO.]SOJTL#A:G)64I-ZV3E:">U
M_>3_ !;\K6+FA>(+G4O-L+@B*[57V/M ^9>"&4@KN4X.,8(!X&.=\)C*F(Y\
M-5]VLE+EE9+5:.ZVNGY6:OV,,7@Z>'Y,32]ZBVN:-WL]='O9KSNG;N/\)ZW<
MZA)-;7K;I8\,ORJN #M<': .#M['J>:K+L54KRJ4L0[SCJM$M$[26B6SM]Y.
M886G0C"KAU:$M'JWJU=/5O=7(KK6;RYUE=/LY-D*E5?"H<[1ND.74D$#*\8&
M1P,GF*F)K5,8L+0E:":4K*+VUF[R3Z:>J+IX:C3P;Q->-YM-QUDM](JT6NNO
MS.[KZ0^<"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H Y?QE_R##_U\67_I;;UO2^+Y2_\ 2685O@^<?_2D=16!N% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 (0&&#R#P0:
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M9?FC'\#7<5O=21R$*94 0GC)!SM!]2#G'?'KBN#*JD8590DTG*-HW[I[?/\
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M^[7QOKUG9P<VXCB+8.<!U$\Q[ $)A#_M+CKQ37NILB;]K.,5MI^.K/?E4*
M, < #@ #L*Q/2%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H :Z+(I1QE6!!'J",$?E4M*2<7JFK/T92;BU)
M:-.Z]4<UIOA.STN=;F)I6=,X#E"!D8SPBG.#QS7DT,NHX::JP<W)7MS.+6JM
MTBOS/5K9A5Q$'2FH*+M?E33TUZR?Y'1S0I<(8I5#HPP5(R"*]648SBX32<7H
MT]CRXRE3:G!M26J:W1R4G@?3W;<#*@_NJXQ_X\A;_P >KQ'E6';NG-+LI*WX
MQ;_$]I9IB$K-0;[N+O\ @TOP.DL-.@TR/R;90B]3W)/J2>2?\C KUJ-&&'C[
M.DK+\6^[?<\JK6GB)<]5W?X)=DNAF6'ANVTZZ:\B:0R/NR&*E?G.3@! ?IS^
M=<E'!4Z%5UX.7,[Z-JWO.[VBG^)UU<;4KTE0FHJ*MJD[^ZK+>37X"ZOX=M]:
M=9)VD4HNT;"H&,YYW(W-&)P5/%R4ZCDG%67*TNM^L6+#XVIA(N--1:;N^9-^
M722-:[LX;Z,PW"AT;L?7U!Z@CL1@UVU*4*T73JI.+Z/\UV?FCBIU)T9*I2;C
M)=5^3[KR9R__  @VG[MV9L?W=ZX_] W?^/5X_P#9.'O>\[=N96_])O\ B>Q_
M:M>UK0OWY7?_ -*M^!T?V6*RM6A@41QJC84?0_B3ZD\FO5]G&C2=.FE&*B[)
M>AY7M)5:BG4;<G)7;]3R[PGI5OJQGAN 2 J%2#AE.3R#[CJ""#Z9 Q\=EV'I
MXKVD*JV46FM&G=[?\'0^PS#$5,+[.=)]9)IZIJRW7^6IWNF>%[+2I/.C#/(/
MNM(02OT 50#[XSZ'K7TM# 4<-+G@G*2V<FG;TLDOG:Y\W7QU;$1Y)-1CU44U
M?UNV_E>P_4_#MOJMPEU,TBO&JJ A4+A6+#(*,<Y8YY'%57P5/$U(UIN2E%)*
MS26C;ZQ;W?<FAC:F&IRHP47&3;=T[ZI+I)+9=C=DC652C@,K @@]"",$'V(K
MT6E).,E=-6:[I[GGIN+4HNS3NGV:V.1/@?3R^_,H&<[-XV_3[N['_ L^]>)_
M96'YN;W[?R\RM^5_Q/:_M3$6Y?<O_-RN_P"=OP+EOX6M+2X-S 9$)#+L!79A
MEVD %"WN/FZ_E6\,OI4JCK4W*+::Y4URV:M;X;^>^YA/'U:E-4:BBTFGS-/F
MNG>_Q6\MMC._X0.P_P">D_\ WU'_ /&JY?[(H?S5/OC_ /('5_:U?^6G]TO_
M ),LV?@ZSL9DN(WF+1,& 9DQD>N(P<?0BM:664:,XU8RG>+NKN-OG:*_,RJY
ME6K0E2E&"4E9V4K_ "]Y_D/O?!]A>RF<^9&SG+"-@%)/4X96QGOC%55RVA6F
MZCYHMN[46DF^KLT]_*Q-+,:]&*IKEDDK+F3NEVT:_&XUO!MB&C>,RQ-%@@HR
MY)!R&;<K9.?3 QVI/+*%XRASQ<;6<6M6G>[O%Z_<O(:S*O:49<DE*]TT]$U:
MRLUI]Y=U7P[;ZO*L\S2*T:A0$*@8!+<Y1CG)]16^(P5/%3C4J.2<59<K26[?
M6+[F&'QM3"P=.FHM2=WS)WVMTDNQHZC81ZG;M:REE23;DJ0&^5@PQD$=0,\=
M*ZZU&.(IRHS;496O:R>C3ZIK==CEHU98>HJT$G*-[7O;5-=&N_<CTO2XM(A^
MSPEF7<6RY!.3CT"C''I48>A'"P]E3;:NW[UKZ^B7Y%5Z\L3/VM1).R7NW2T]
M6_S-&NLY3DKCP787$IFS*FXY*HRA<GDXRI(^@/';%>)/*Z$Y.?OJ[O9-6_%-
M_B>U#,Z].*A[CLK)M._X-+\"_/X=M[B]&HLT@E5D8 %=F4  XV$XXY^;\JZ)
MX*G.LL4W+G3B[)KE]VUM.6_374YX8VI3HO"I1Y&I*[3YO>O?[5NNFAL7,"W4
M3P/D+*C(2.H# J<9!&<'C(/TKOJ052$J<KVE%Q=M[-6=O,X83=.<:D;7C)25
M]KIW5_(S='T2#1%=(&=A(03O*GH,<;57U]ZY,-A88-2C2<GS--\S3V[62.K$
MXJ>+<95%%<J:7*FM_5L\U\)Z7!JLDT-P,J(P00<,IW=0?IQSD'TKY++J%/$R
MJ4ZJNN5--:-.^Z9]9F%>>&C"I2=GS--/5-6ZH[_3?"MEI<@FC#R2+]TR$';[
M@!5&?<@D=L5]/0R^CAI>TBG*2V<FG;T225_.Q\U7Q];$1]G*T8O=135_5MMV
M\KDFK^';?6G62=I%*+M&PJ!C.>=R-S58G!4\7)3J.2<59<K2ZWZQ9&'QM3"1
M<::BTW=\R;\NDD:=]80:C$8+A0Z'GT(/8@CD$?\ UCQD5V5:,*\73JJ\?Q3[
MI]&<E*K/#R52D[/\&NS75',CP-IX;.Z8C^Z77'Z(#^M>.LIPZ=[S].96_P#2
M;_B>O_:M>UK07GRN_P#Z5;\#J[6UBLHQ# H2->BC_P"OR2>Y/)[U[5.G&E%4
MZ:48K9(\6=2563J5'>3W;)ZU,SDCX+L!-YRF5,-N"!EVC!S@94MC_@5>)_9=
M#G]HN=:WY4U;\4W;YGM_VG7Y/9OD>EKM._X-*_R+TOAVWEOO[2+2"4,K;05V
M950HXV;L8 S\W6NB6"IRK_6VY<]T[77+HDEIRWZ=SFCC:D:'U1*/)9J]GS:M
MMZ\UNO8LZOHT.M(L<[.H1MPV%0<XQSN5N*UQ.%ABXJ%1R2B[KE:72W5,RP^)
MGA).=-1;:M[R;ZWZ-$\>F0):BQ8>9"JA,/@D@>I '/N ,'D8K6-""I+#M<T$
MN6TNJ^5M?-6,W7FZKQ"?+-N_N]'\[Z>3N<X? VGEMP:8#^Z'7'ZH3^M>5_9.
M'O>\TNW,K?\ I-_Q/56:UTK6AZ\KO_Z5;\#?AT>VM[5[*%?+CE5E8@_,=Z[2
MV3GYL=,@@>F.*]*.&ITZ4L/37+&2:=M_>5F[N^OX>5CS98FI.K'$3=Y1::OL
MK.Z5E;3\?.Y%H^B0:(KI SL)""=Y4]!CC:J^OO48;"PP:E&DY/F:;YFGMVLD
M5B<5/%N,JBBN5-+E36_JV-U;0+76=IG#*Z# =#AL=<<@@C)SR..W4TL1@Z6+
MLZB:DM%*+L[=M4U;Y#P^+JX2ZIV<7JXR5U?OHT[_ #,L>"=/6,Q_O,L0=^Y=
MXQV'R[0#W^7/O7'_ &7AU%P]Z[M[UUS*W;2VO70[/[4Q',I^[97]VSY=>^M]
M.FI3\3V2Z=HZVT;,R1R* 7P6P2QP<!1QG XZ5ACZ2H8-4HMM1DK-VOU?1)?@
M;X&JZ^+=622<HNZ5[=%U;_,J:-X8L]6TZ":7>DF) 6C(!;$K@9#*PX'&<9QQ
MG@5AA<!1Q.'IU)\RE[UW%I7M.5KW37X&V)QU;#8BI3A9Q]VRDF[7A&]K-/\
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MBL#<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ! 88/(/44M]
M&/;5%:WL;>T),$4<1;J415S]=H&:RA2ITKNE",+[\L5&_P!R1K.K4J652<I6
MVYI-V^]EFMC$* "@ H * "@ H * "@ H * "@ H * "@ H * *MO8V]H2T$4
M<1(P2B*I(]"5 XK&%*G2=Z<(Q;WY8I?DD;3JU*BM4G*26W-)O\V6JV,0H *
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M^VK>E\7_ &[/_P!(D85O@_[>A_Z7$ZBL#<* "@ H * "@ H * "@ H * "@
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MMTM+1!'%&, =R3R23U+$\DGJ:6YM&*@N6.R+U(H* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@!"P49)P/4\4 ,\Z/^\OYBD >='_>7\Q0 >='
M_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='
M_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='
M_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='
M_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='
M_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='_>7\Q0 >='
M_>7\Q0 >='_>7\Q0 Y75_ND''H<TP'4 % !0 4 % !0 4 1F9!P64$>XH /.
MC_O+^8I 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G
M1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G
M1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G
M1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G
M1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G1_WE_,4 'G
M1_WE_,4 'G1_WE_,4 'G1_WE_,4  F0\!ES]13 DH * "@ H * "@ H * "@
M#E_&/_(. ];O3Q^>H6HK>E\7_;L__2)&%;X/^WH?^EQ.HK W"@ H * "@ H
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M$ &FP.P/Q2O=-N;2+7=(FTRWU)PD,IN8Y6!)4#S(0B-'C>I=7(=03\K$8I6
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M_KNG:4RQWUU;6KO]U9IHXBW^Z'92?PI ::.LBAT(96 ((.00>001P01R".M
M&3;>(=,O)S:6]Y:S7 )!ACGB>0$=045RP([\<4 6[_4K32H_.OIHK6/.-\TB
M1KGTW.5&?;- #[.^M]1B$]I+'<1-TDB=9$/T9"5/X&@#SCX5>-KWQQ83W>H)
M!$\$_E*(%=5*^6C9(DDD.<L>A QCBF] /0KS5;+3I(H;N>&WDN6V0I+*D;2M
ME1MC5F!=LNHPH)RRCN,H".QUO3]3=XK*YM[EXOOK#-'(R<X^8(Q*\\<@<T +
MJ.LV&D -J%S;V@?[IGECB!QZ;V7/X4 6/MUOY!O/-C^S*AD,V]?*"*"6<R9V
MA% )+9P "2>* ,L>*='Q&1?6>+C/DG[3#B7#%#Y?S_/AU*G;G# KU!% %^^U
M6STS9]MGAMO.;9'YTJ1[V_NIO8;F]ER?:@!+O5K*PEBM[JX@@FN#MACDE1'E
M8D*%C1F#.2S*N%!.2!U(H \^L?&U[<^,[KPPZ0"SMH%E1PK^<6,-O)AF,A0C
M,K#B,' 7G()+Z =K-XGTBVG-I-?6<=P#M,37$*R!O387#9]L9I <E\0_B)!X
M'CBC01SWERP"QM(J^6A)'G2*#O\ +R&"D !F4KO7!II &L>+[R/5=-M])?3K
MC3K\CS97N8/-(\W83;+]JC,N!D?NXIOG&W&?EH [?4=9L-( ;4+FWM _W3/+
M'$#CTWLN?PI 6/MUOY!O/-C^S*AD,V]?*"*"6<R9VA% )+9P "2>* ,L^*='
M58Y#?V82?/E-]IAQ)ABA\L[\/A@5.W.&!'4$4 ;P.>10 4 =##_JU_W1_*K$
M24P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MD H * "@ H * -/3OXO^ _UJD!I50@H * "@ H * "@#GYO]8W^\?YUF,BH
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M]1_C18 ^QR_W?U'^-%@#['+_ '?U'^-%@#['+_=_4?XT6 /L<O\ =_4?XT6
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M;YU,;.>7/W77C'X@'84 >?Z_\-]-UZ].J"6[L+QT\N2:RG\EY4P%VR95P1M
M4X +  ,2 ,.X%E?A]I46A2>&H!)!9S?ZQD9?.9MRN7+NC*7)1024("@*H  P
MK@=)HVE1:'8P:=;EVBM8UB0R$%RJ# +%552?7"@>U '&_%FQN-1\+WMM9Q27
M$[_9]L42-)(VVZ@9MJ("QPH+' X )/ -- <WH/PGTV\T[3I-0-Z%CM[>633Y
M)W%J+DPH96:W<;DD:0MYBJR#)92H!(HN!WFJ^#++5]4L]9F>9)]-SY*1L@B.
M3GYU,;,?;:Z4@+/B?PGIWBZV%KJ2%@C;XW1BDD3]-R,.AQP005/&02!@V QM
M ^'>G:!>?VF9+K4+X)L2XOIO/DC3&-J':@'!P#M+!20" 2"[@)?_  ZT^\UG
M_A((YKRTO&\OS?LTPCCF$>S"RKL9BI\M ZJRJVT$C/-%^@%75_A=I>J7DNH1
M2WFGS761<?8KCR5GS]X2J4<$-_$!M#')/)))<#I=.\):7I>F'1((%^PNK*\;
M9;S-X^=G8G<SM_>SD8&W:%4! <9:_![1K=XO-EOKJUMG\R&SGN-]I&V<_+%L
M4XSU!8[NC[@2"[@=%XF\!Z=XHGBO9S/:WMN,175I+Y,ZCDX#X88!)()7(R<$
M G*V G\+^"M.\)"5K/S9;BY.Z>YN'\V>4CGYWP!U))"JH).3DXH C\&>";+P
M-;26FGO/(DTGFL9V1F#;57 ,<<8QA1U!.<\T <!\6?#\^OZKH$:VTUU:+=NM
MV8XY&2.&26S#&5XQ^Z4H'^8LO"L01M)#0'8Z+\.--T;4/[7,MW?7:*4A>\G,
MY@0@C;%E00 I*C>7(!.",G)< U[X<:;KE[_:BR7>GWS+L>XL9_(DD7 7#G:X
M/R@ D $@ ,3@8+@0W7@ZS\-^&=2TW1H7+3V=W_>EGGE>W=5R0"SNQPJJHQDX
M5<GD \_\$_"JUU3P_:#5?[0LI',K75F)9((YF6XE$33V\BDAO*$85E$9*!6!
MSAJ+@>KZ_P"!]+\1:;'H]S&8[:WV>1Y)V/#L4HOEDAAPI*D,&!')!(!" YI/
MA'I8NK34);G4+BZT^5)4EGN!*TGENCQQR%XC^Z0I\JQ>5P[Y))4J[@;R^ M.
M&MW/B%FF>XO8?L\L3,A@,9CCB("B,/DI$N<R$9+<8( 7D!RH^"FB"*2U,VH&
MU<LR6QN?W$,C @2QIY?,B@_*TID_V@PIW W]1^&VF:IHUMH-R]PT-@5,$P=%
MG3:"!\PC$9^5MN#%C !^\-U%P(S\-;&2XT^\GN;ZXGT@EHI)IDD>4F8S9G=H
MBSX8[1M*80!1TS1<"77OAQINN7O]J+)=Z??,NQ[BQG\B21<!<.=K@_* "0 2
M  Q.!@N!>T[P+I>D:3<:)9J\4%['+'/)NW3OYR&-G+L&!<*?ERNQ3T3J"@*E
MO\/-/MO#[^%UDN#9R;LN6C\[YI1*<,(A']X8'[L_+QUYIW Z;0M&A\/6$.F6
MQ=X;5-B-(5+D D_,55%)Y[*![4@-:@#H8?\ 5K_NC^56(DI@% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #702
M#:W(- $'V.+^[^I_QI60!]CB_N_J?\:+( ^QQ?W?U/\ C19 'V.+^[^I_P :
M+( ^QQ?W?U/^-%D ?8XO[OZG_&BR /L<7]W]3_C19 'V.+^[^I_QHL@#['%_
M=_4_XT60!]CB_N_J?\:+( ^QQ?W?U/\ C19 'V.+^[^I_P :+( ^QQ?W?U/^
M-%D ?8XO[OZG_&BR /L<7]W]3_C19 'V.+^[^I_QHL@#['%_=_4_XT60!]CB
M_N_J?\:+( ^QQ?W?U/\ C19 'V.+^[^I_P :+( ^QQ?W?U/^-%D ?8XO[OZG
M_&BR /L<7]W]3_C19 'V.+^[^I_QHL@#['%_=_4_XT60!]CB_N_J?\:+( ^Q
MQ?W?U/\ C19 'V.+^[^I_P :+( ^QQ?W?U/^-%D ?8XO[OZG_&BR /L<7]W]
M3_C19 'V.+^[^I_QHL@#['%_=_4_XT60!]CB_N_J?\:+("6.%(<[!C/7D_UH
MV DI@% !0 4 % !0 4 5VM(F))7D\GD_XTK )]CB_N_J?\:+( ^QQ?W?U/\
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M  J<#). "0 2:)KEEXCLX]1TR47%K-NV2!67.UBC JZJZD,I!#*#QTQ0!JT
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M@X(/L0".] "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?D1_W5_(4 'D1_W5_(4 'D1_W5_(4 'D1_W5_(4 'D1_W5_(4 'D1_W5_(4
M'D1_W5_(4 'D1_W5_(4 'D1_W5_(4 'D1_W5_(4 'D1_W5_(4 'D1_W5_(4
M2 8X' %, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#Y2^)_Q;UO1
MM?DM-!DQ9:4L/VQ?*B=7D9UWJTCQNR#YT@^0JP?>1R,@ ^GM+U*'6+2&_M3N
MANHDFC/^S(H89]" <$=CD&@!-6U2WT2SFU"[8I;VL;2R, 6(5!DX5023Z 4
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MX*%E(9!V+!@ 6O!_Q NX-,UF7Q%(EQ)X<NI[=[A$6'[0(BRK^[7Y%>1UVJ%
M'SJ,9!) .R^'=QJU]HL-_KLOF75[FX">6D8@ADYAA 1$)VIAB9-SY8AF.!0!
MW% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % 'F/Q;\92>"M!DNK-Q'?7#I!:G"MAV.YGV,&5@D:N?F4KN*
MCF@#G_@QXZU#Q1#>:=KSEM5TZ<A]R)$WEME=I2-$0-%*CH^!GE,\\D ]NH \
M$^*GQ;D\.?:=&T*.235+=$>>?RPT-HCJCJYW!E=V61 NY?+#. 2S#RR >A>!
M]>FU#PS::QJ<GF2O:F:>3:B9V[BS;4"(/E7H !0!\[>&O%WCGQBGVBTUW2[
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M?+9&)5T;H, 'I] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M48X5E)] 10 ^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * *OVK_ &)/^^?_ *] !]J_V)/^^?\
MZ] !]J_V)/\ OG_Z] !]J_V)/^^?_KT 'VK_ &)/^^?_ *] !]J_V)/^^?\
MZ] !]J_V)/\ OG_Z] !]J_V)/^^?_KT 'VK_ &)/^^?_ *] !]J_V)/^^?\
MZ] ')^,_#-MXWL/[+OFO((#(LC?9_+5GV9VJQDCE&S<0V  =RJ<X!! /)_\
MAG7PW_SVU;_ONV_^1* .M\%_"G2O E^=2TV74FD:)HF29H&C=&*G#!((VX95
M9<,,$=QD4 >K_:O]B3_OG_Z] '$ZEX,L-4U^U\43?;%O+"(0QHGEB$J#,<NI
MC9RW[]_NR*.%XX.0#"\;?"W2O'MZE_J4FHQO%$(42!H5C"AF;(62"0[F+'<=
MW("C'% &5X:^"NA^%=2@U:SDU-Y[5BR+*T!C)9&0[@ENC$88]&'./I0!V/AS
MP7I_AG4=0U6U^UR3:Q*TLZR^6T:LTDDI$:K&C!=TC##LYV@#.<D@'$WOP)\+
M7MX;SR;V%6;<UO$ZK 23D@ HTJJ?[J2J!T7:,"@#V.QC@TV".TM(&A@@14CC
M5,*JJ,  9[#\3U/- '(^%O"BZ U_<WCR7]YJ\[2W$Q@\H>7@K' J>9(1'$I8
M+\^<-V   !Q>A_"1=(O+1Y;VZNM-TF>2YL;)K>-/*ED;?EYPY:4!@& *+\PX
MP&8, >V?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_
M[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_
M[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_
M[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_
M[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_
M[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_
M[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_
M[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'VK_8D_P"^?_KT >"7OP!T
M#4;B6[N)]7>:>1Y9&+VW+NQ9C_QZ=R2: *W_  SKX;_Y[:M_WW;?_(E 'OEF
M?L<$=OB>7R8T3?( 7?8H7<Y4*I=L98A5!). !Q0!E>)=(M_%6FSZ1>+<1P72
MJKM$%60!75QM+JZ@Y49RIXS]: #1-'M="TN+18HYIK6"(P@3*KLZ'.1)M54;
M(8@@( 1QB@#RP? ;PJ+S[7Y5\8]V[[-Y@\CKG;P@GV]L>=T[T =MXI\#Z;XM
M^PBZ6ZMTTI]]NEL(T7CR\*P>.3Y (U ";,#(STP 2>-?!=AX\CMX=1^UQI:2
MF5!!Y:[F(QA_,CE!7'8!3[T =M]J_P!B3_OG_P"O0!Q7B7PQ_P )/?Z?<W4D
M@LM,F-R;3R,B><#$3O(9  L1Y">6VX%@3AN #'\8^!)/$>H1ZQIUW<:5?);/
M9R2+;I.LEO)NRA1W3:WSOB0$D94@!D4@ ZSPIHEOX0TN#1[19FBME(WLHW.S
MLSNYQP-SLQ _A&%' H Z'[5_L2?]\_\ UZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?
M/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\ UZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?
M/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\ UZ #[5_L2?\ ?/\ ]>@!RW&X@;)!
MDXR5X_'F@"Q0 4 % !0 4 % !0 4 % '+^,/^/&+_L(Z3_Z=+.MZ7Q/_  5/
M_2)&%7X5_CI_^G(G45@;A0 4 % !0 4 % $9AC)R54D^PH 3R(_[J_\ ?(_P
MH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@
M \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #
MR(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(
MC_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/
M^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[
MJ_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK
M_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_
M 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\
M?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\
MC_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/
M\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_P
MH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@
M \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #
MR(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(
MC_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/
M^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[
MJ_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK
M_P!\C_"@ \B/^ZO_ 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_
M 'R/\* #R(_[J_\ ?(_PH /(C_NK_P!\C_"@ \B/^ZO_ 'R/\* '+$B'*JH/
MJ !0 ^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#E_&'_'C%_P!A'2?_
M $Z6=;TOB?\ @J?^D2,*OPK_ !T__3D3J*P-PH * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MAYSQLR-#&03&* /0J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#E_&'_'C%_P!A'2?_
M $Z6=;TOB?\ @J?^D2,*OPK_ !T__3D3J*P-PH * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .$M?
M"4P\-IH,\B+<1H"LJ NBS1S>?"X#!"RI(J,1A2<$ C@T 6X-,U/4;^VO=66U
MA33Q*T26TLLQDFEC,)E9I(8/*58FD41 2G+Y,IVX(!B?\(KJ?]G?\(U_HO\
M96?+\_?+]H^R>9N^S_9_)\K?Y7[GS_M&,?/Y&>* .RUK3Y=5B2T4JMM*X^U9
M)#/  2T2  @B9@L4N67]RTFW+$8 .:U7PS>W+WUO;&#[)J[0M,[LZS6_EQQ0
M2")%B=9@T4*F,-+"(Y"S8<$@@'?4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '+^+_^
M/.'_ +".E_\ IRM*WI?$_P#!/_TB1A5^%?XZ?_I<3J*P-PH * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#E_%_P#QYP_]A'2_
M_3E:UO2^)_X)_P#I$C"K\*_QT_\ TN)U%8&X4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!R_B__ (\X?^PCI?\ Z<K6MZ7Q
M/_!/_P!(D85?A7^.G_Z7$ZBL#<* "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H Y?Q=_QZ0#_J(Z9_Z<+8_P Q6]+=_P""?_I#
M,*OPK_'#_P!+B=16!N% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 <OXN_X]8/\ L(Z;_P"E]O6]+=_X)_\ I#,*OPK_ !P_
M]+B=16!N% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 <OXN_X]8/^PCIO_I?;UO2W?\ @G_Z0S"K\*_QP_\ 2XG45@;A0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '+^+?^
M/:W'KJ.G?I?0'^E;TMW_ ()_^DLPJ[+_ !P_]*1U%8&X4 % !0 4 % !0!&9
MHP<%E!'N* $\^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\
MO+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\
MOYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_
MF/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8
M_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_
M !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\
M&@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P :
M #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H
M//C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \
M^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX
M_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_
M +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\
MO+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\
MOYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_
MF/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8
M_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_
M !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\
M&@ \^/\ O+^8_P : #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P :
M #SX_P"\OYC_ !H //C_ +R_F/\ &@ \^/\ O+^8_P : #SX_P"\OYC_ !H
M//C_ +R_F/\ &@!RRHQPK*3Z B@!] !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 5?M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H /M7^Q)_WS_]
M>@ ^U?[$G_?/_P!>@ ^U?[$G_?/_ ->@!RW&X@;)!DXR5X_'F@"Q0 4 % !0
M 4 % !0 4 % '+^+?^/:W_[".G?^EL%;TMW_ ()_^DLPJ[1_QP_]*1U%8&X4
M % !0 4 % !0!&88R<E5)/L* $\B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]
M\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /
M(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]
M\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /
M(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]
M\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /
M(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]
M\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /
M(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]
M\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /
M(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]
M\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /
M(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]
M\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /
M(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]
M\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /
M(C_NK_WR/\* #R(_[J_]\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]
M\C_"@ \B/^ZO_?(_PH /(C_NK_WR/\* #R(_[J_]\C_"@!RQ(ARJJ#Z@ 4 /
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 <WXOUQO#>DW&I1J)'@5=BGINDD2-2>^ SAB 0
M2 0",YH \3E\8>+M$L[7Q!?2P3V%Y( ( D:L P9E!*QJR[T1BA$DFW'S@'"E
MB.W^)/BR]TB&PBTB5;:>_DSO=8VQ'M4882*ZJ"TJEF R-O!QD$&3>#3XCN;O
MS[[5+#4K% RNMHT3D.1\F6CMH\8/)&\?0T >A:M'=S6<T>G.L-VR$0R.,JK]
MBP*.,#_<;Z&D!X1XGU#QKX2MUN;[4[1O,<(D<44;2.>^U6LD&%'+$L .!R2
M6(Z;5_%^K>%_#-K<7P$FL7C%!N11MW,[JS(@1=R1>6NP 8<C<#AL@S.M/$WB
M7PMJEG:>)GBN+?4B$5D6,&)BRK]Z-(QF-G3S 0ZE6RK$\T 7_$?B?7-4UUO#
MWAIHH'MH]\TTBJPSA6.2Z2!57>B<(6+DY..@ GAWQ_?K9:I#JR(VHZ,DC':
M%D*[EPP0A?ED4!F3 *,"HR.0"'PMXHUIM3TZWU*XCNH=9MI9U40I&;<JLCJJ
ML@!<;8P"6S]XC^$,P!UNB:W>:_KEYY$FW2M/ MPH5#YUSU=O,*EL1\KA7 (\
MML<G* [Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H Y?Q;_Q[6__ &$=._\ 2V"MZ6[_ ,$__2685=H_
MXX?^E(ZBL#<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M,VGD7"O$J6B01PQ;)$9UD"P&)KB 012Y>0@E,9 !Z=0 4 % !0 4 % !0 4
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MNP7,:OM)SM)'S+GOM;(SQG&<"D!K4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <OXL_P"/>V'KJ.G_ *7D
M)_I6]+=_X)_^DLPJ[1_QP_\ 2D=16!N% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '+^+/]1;?]A&P
M_P#2J*MZ6\O\$_\ TEF%7:/^.'_I2.HK W"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#@/B5I\M_I ,<+7B6UU:7,UL@R]Q!#
M.CS1*O\ $2@)V]]N!DX% 'C.OWVDV7]JHUI)&=:BM[O1-MHXD^UB$1%8R$+0
MR)<11RLAV?*6_O*K,#Z<LC*UO$;D 3&-#(!T#[1O ]MV:0%F@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#BO'G_ !X1_P#7=?\ T7+7P_$_^YT_^O\ '_TW5/ILD_WB?_7J7_I<#R:O
MR$_0 H * "@ H * "@ H * /6? ?_'A)_P!=V_\ 1<5?KW#'^YU/^O\ +_TW
M2/S_ #O_ 'B'_7J/_I<SM:^X/F0H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y?Q9_J+7_ +"-A_Z51UO2
MWE_@G_Z2S"KM'_'#_P!*1U%8&X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % 'R]J-I;>(?$&IQ>)KY[!+0R_90Q"C8K$1%%<$,
M/+VOY: 23%LJP.:8CM_AIJ^J)X:N+EXY+Q[9W%HC;BT@"+\BGEF17) (''S*
M#\N%!G(Q-K$GC+39=>VI<3KYJ0H?E@B;SU6/ ) .4+'YF/S#<V[( (^F*0SR
MWXA7FO.)+#2(A%:"T:>YO"<;5'F[X8R>-Y1 ?E#/AQ]P?-3 H?"J[%AX6DNF
M&1 ]S(1ZA%#$?I0!YQIOA>?Q=I%[XIN[J;[="TTD(!^7$*"0CNPSDI&$*A-H
M^\#@ C:U?QQ?7'@ZT*2.+RZF:UEE!(=DBW9(8<[G4Q!CG+9?U- $&JZ!)\++
MW3KZSN995N)-ETK<*^"F\ *!E65FVA@S(RAMQ/0 =X]:"XUK5!J<K(;2RB?3
M5,C(/,*Q$F, @,Y<N,=_F.#LRH!T>H7MUXAT[1_#99_M.HQ0S7K'AUM8P&9F
M_P!J3;D$_>9=I^_0,]L@A2VC6&(!(XU"*HZ*J@!0/8  "D!)0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M45@;A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@"*>>.V1I9F6.-!EG<A5
M4#J68D  >I.* .:_X3KP[_T%=._\#;;_ ..4 =1'(LJAXR&1@&5E((((R"".
M"".01P10 Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#E/'.IS
MZ-HEW>6JAI8XP%#*& WNL;,5(*L%5BV&!4X^8$9H ^8I-+TBRT6'6;:^5]6\
MQ6-J1$R@[^5\@H2 @^;<^8G VA>13$=[XFU*1-4\/>(-17R4EAA,QP=J-OW2
M'C) VR[PN,@<<D&@#0U._M_$WCC3_P"S9%N(K2(-))&=R H9I6PPR",%%R#C
M>VWJ* /8;K7+817(LY8;BZLXI':!)%9U9%.%=%8NN6&TY .>.M(9\K6>G:3K
MNFWNLZG?+;ZH'D=+=1%&KMMW*!$%!?S&^7,> GWGR226(W?$5Y>:OX2TW4IT
M ^RW+Q95 BL@!6-]J@*HS'Y9V@+N'&,XH Z#XCZY9>+)=*LM*E6YDEFW$)R8
M]YC50X'W6Y8LIY4*2V!@D NW5Y#X?^($EU?NL$%W;J%DD^5!F".,$L> -\)4
ML<*#U(QF@8[PE-'X@\:ZCJ=N1):I!L#@91_EAA49/9A&[ ]P.!@T ;OB?2-'
M\$6SZEI5JD>J73?9[7:78^=-E<QHSE4*J2?D5><+T:@#FE?5?#TH\-://'9M
M8:>]_<RM&DIN)S\[K^\! 4DJBL/F502<A< $>L^#=:E\0Z/;:C. LLR-O"C
MW([QD@=@Q3=CMGCBD,Z:@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H XKQY_P >$?\ UW7_ -%RU\/Q/_N=/_K_ !_]-U3Z
M;)/]XG_UZE_Z7 \FK\A/T * "@ H * "@ H * "@#UGP'_QX2?\ 7=O_ $7%
M7Z]PQ_N=3_K_ "_]-TC\_P [_P!XA_UZC_Z7,[6ON#YD* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .7\5
M_P"JM/\ L(V/_I0E;T]Y?X)?D85=H_XX_F=16!N% !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >:?%DQ+H6ZYRUNEU://"-V;F&.97DMQM!YD13MW
M84LH!(R#0!SL7C'X>!% @MHQ@?+_ &1/\OM\MF5XZ<$CT)%,#V:U>.2%'@P(
MF13'@;1L(!7"D J,8X(&.F!2 GH * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H ;)&LJF.0!T<%65@""",$$'@@C@@\$4 <5'\-_#L4WVE;*/>#N
M+2E,_P#7(R&+'MLQ[4 =)JNC66MP?9;^%)X<@A6R,$< J00RD#(RI!P2.AH
MHZ'X4TKPWN.F6ZP-(,,V7=R.N-\C.P7/.T$#(!QP* );#PWI^EW<^HVL7EW-
MV29GWR-O);<?E9RB_-S\JKZ=* ,:[^'7AZ]G-U-91F1CN.UI44D\DF-'6,Y/
M)^7D]: .FDTNTEM?[/>&,VI3R_)VC9L'10O08P",<@@$<C- &'I'@?1=!G^U
M6%JD4W.'+22%<\';YCN$R./EQQQTH O:WX9TWQ&JIJ4"W'EYVDEE9<]0'1E<
M ]QNP?2@";1M!L/#T)M]-A6WC)R0N26.,99F+.QQP-S'':@"O?\ ARVU+4+;
M4[AI&>Q#>3%N7R0[=9"NS<7'&#O &U3MR.0#+\1>!K#Q).MW,]Q;SB,PL]M(
M(S)$<YCDRKAE.2", D'!)&  #I=,TV#1[6.QM%V0P*%09R<=223U))))[DDT
M 7J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M ,"(?_BZ+/L'/#^9?>@_X2;2?^?VT_\  B'_ .+HL^P<\/YE]Z#_ (2;2?\
MG]M/_ B'_P"+HL^P<\/YE]Z#_A)M)_Y_;3_P(A_^+HL^P<\/YE]Z#_A)M)_Y
M_;3_ ,"(?_BZ+/L'/#^9?>C;I&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '*
M^,M=G\/Z?YUDBS7EQ-#:VJ/D1F>XD6*/S"""$4MN;!!.-N1G( .'U2/QEX7M
M9-:FU*UU.*T0SW%D;-(%\F,;I1#.C&0LJ!F4R#&0,@]"P/7+:X2[A2>/)25%
M=<C!VL PR.W!Z4@)J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@"&>YBM5WSND2DX!=@HSR<98@9P"<>QK"K6I8>//7G"G%NR<Y**OJ[7DTKV
M3=O)FL*<ZKY:493=KVBG)V[V2>FJ*G]LV'_/S!_W]C_^*KC_ +0P?_030_\
M!U/_ .2.CZIB/^?-7_P7/_(/[9L/^?F#_O['_P#%4?VA@_\ H)H?^#J?_P D
M'U3$?\^:O_@N?^0?VS8?\_,'_?V/_P"*H_M#!_\ 030_\'4__D@^J8C_ )\U
M?_!<_P#(/[9L/^?F#_O['_\ %4?VA@_^@FA_X.I__)!]4Q'_ #YJ_P#@N?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M]MA_O?H?\* #[;#_ 'OT/^% !]MA_O?H?\* #[;#_>_0_P"% !]MA_O?H?\
M"@ ^VP_WOT/^% !]MA_O?H?\* #[;#_>_0_X4 'VV'^]^A_PH /ML/\ >_0_
MX4 'VV'^]^A_PH /ML/][]#_ (4 'VV'^]^A_P * #[;#_>_0_X4 'VV'^]^
MA_PH /ML/][]#_A0 ?;8?[WZ'_"@#C/B%<QR:#=*IR3Y/8_\_$7M5QW.>M_#
M?R_-'S'6YY 4 % !0 4 % !0 4 % !0!]G_;8?[WZ'_"N4]\/ML/][]#_A0
M?;8?[WZ'_"@ ^VP_WOT/^% !]MA_O?H?\* #[;#_ 'OT/^% !]MA_O?H?\*
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M"#MD.]: .KTV]FU*ZGF0XL82;>(87]]*C$3R[L;ML;CR$ (!9)6(8&,@ WJ
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M'VK_ &)/^^?_ *] !]J_V)/^^?\ Z] !]J_V)/\ OG_Z] !]J_V)/^^?_KT
M'VK_ &)/^^?_ *] !]J_V)/^^?\ Z] !]J_V)/\ OG_Z] !]J_V)/^^?_KT
M'VK_ &)/^^?_ *] !]J_V)/^^?\ Z] !]J_V)/\ OG_Z] !]J_V)/^^?_KT
M'VK_ &)/^^?_ *] !]J_V)/^^?\ Z] !]J_V)/\ OG_Z] !]J_V)/^^?_KT
M'VK_ &)/^^?_ *] !]J_V)/^^?\ Z] !]J_V)/\ OG_Z] !]J_V)/^^?_KT
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M%4-CJ=QYH$9MAK<GPMU;48+ZVEE@O7\RV9, -AI&C^9CC#+)MD(+,C)C:>:
M+?ACP??7OA74O-0I<ZHPEBC;*LPA82IP>09'#!<\$;23M- ',7'BJ?4_#\/A
M"&UN/[0#I$XV\%(Y-Z_+]\-N"A@RA5V[MQZ  ^E=#L!HNFVUFY ^RV\:.<\9
M1 ';)[%@3Z?04AGCYEN==BU?Q;!N'E02VNFXSE8DSYTZ=<,WS$$<@F0=A3$8
M_@0VUKK>F+I,K2"ZL'?45$C./.VR$F0%F"L) B@<8&TX&\Y /H^D,* "@ H
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MO_1<5?KW#'^YU/\ K_+_ --TC\_SO_>(?]>H_P#I<SM:^X/F0H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .*\>?\ 'A'_
M -=U_P#1<M?#\3_[G3_Z_P ?_3=4^FR3_>)_]>I?^EP/)J_(3] "@ H * "@
M H * "@ H ]9\!_\>$G_ %W;_P!%Q5^O<,?[G4_Z_P O_3=(_/\ ._\ >(?]
M>H_^ES.UK[@^9"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >'67P:ETEKJTT[5KBT
MTG4&)FLTAC+E"""BW+,Q0%"4++&&9<!RV*8%[2_A.^F^&;SPJ;X2)>R^8D_V
M;:8LF$E2GV@B0'RA@[T(+'J   "37/A3_;/AFR\+_;?*_L^5)/M'V?=YFQ)D
MQY7GKLSYV<^8V-N,'.0@/6;:'[/$D6=WEHJYQC.T 9QSC..F30!-0 4 % !0
M 4 % !0 4 % !0 4 % '!?$>_NK#2E%G,UFUS=VEL]RN,V\4\Z1R2@D$*0IQ
MN/3.00<4 >-ZEX=O;(:XHUK66?0A#<1I)J,FV>VDMQ.R2;0K"1RLL2NNU=VW
M]VW\3 ^E-,=)+2!HMWEM#&4WG+;2@*[CW;&,GN:0%V@ H * "@ H * "@ H
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M $7%7Z]PQ_N=3_K_ "_]-TC\_P [_P!XA_UZC_Z7,[6ON#YD* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M.7\4_=LA_P!1&T_]#)_F*WI_:_P2_(PJ_9_QQ_,ZBL#<* "@ H * "@ H *
M"@ H * (;FYCLX7N)CMBA1I';!.%0%F. "3@ G !)[ F@3=E=[(X_P#X6-H'
M_/U_Y!N/_C55RLP]M3[_ (/_ "#_ (6-H'_/U_Y!N/\ XU1RL/;4^_X/_(/^
M%C:!_P _7_D&X_\ C5'*P]M3[_@_\@_X6-H'_/U_Y!N/_C5'*P]M3[_@_P#(
M/^%C:!_S]?\ D&X_^-4<K#VU/O\ @_\ (/\ A8V@?\_7_D&X_P#C5'*P]M3[
M_@_\@_X6-H'_ #]?^0;C_P"-4<K#VU/O^#_R#_A8V@?\_7_D&X_^-4<K#VU/
MO^#_ ,@_X6-H'_/U_P"0;C_XU1RL/;4^_P"#_P @_P"%C:!_S]?^0;C_ .-4
M<K#VU/O^#_R.PMKF.\A2XA.Z*9%D1L$95P&4X(!&00<$ CN :DW3NKK9DU P
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P (\DF_4%B,TD:@D1H A'F-P S!U*J,M@@D $$@'1T % !0 4 % !0 4 %
M!0 4 <GXWO[.PTF7[=;F_CN&CMTM !FXFF=4BB!/"EG(.[JF-PRP (!Y;XJ\
M(6=EI=EJMUI.Y;")5O[:&\?=':1DR%2V<7:PG+G>P8H#\^.C ]XMY(YHDDA(
M,3JK(0, J0"N!Q@8Q@8I 34 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % '%>//^/"/_KNO_HN6OA^)_\ <Z?_ %_C_P"FZI]-DG^\3_Z]2_\
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M]2_]+@>35^0GZ % !0!ZKKEC!/J5O/)<10&%8V=9&VDJKLRE,X5B2&5AN&W
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M/S_._P#>(?\ 7J/_ *7,[6ON#YD* "@ H * "@ H * "@ H * "@ H * "@
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M?[G4_P"O\O\ TW2/S_._]XA_UZC_ .ES.UK[@^9"@ H * "@ H * "@ H *
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MUZ6__HE*YGNSVX?!'T7Y&W2- H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#B?B-_P @"Z_[8_\ I1%51W.>M_#?R_-'
MRY70>0% !0!TFF^$=5U>!;JS@,L+L4#!XAR#@Y#.& ![D >]3=+0UC3E)7BM
M/D4=7T*^T*18K^)H6<;ER596'?#(64D=P#D9&0,BFG?8F4)0TDK%C1_#&HZ\
MKOI\/G+$0K'?&F"1D#YW4GCTS2;2W'&$IZQ5[>A:U+P7J^D6[7=Y;^5#'MW-
MYL+8W,%'"2,QRQ X!ZY/%":>B*E2G%<TE9>J_P SEZHQ"@ H ^V:Y3WPH *
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MJCJQP=@R7Q@T ?0ED0UO$0BQ QH0B$,B?*/E5E 4JO12H ( (&*0%F@ H *
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M7ZSPQ_N=3_K_ "_]-TCX/._]XA_UZC_Z7,[6ON#YD* "@ H * "@ H * "@
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M *;I'S&=_P"\0_Z]1_\ 2YG:U]P?,A0 4 % !0 4 % !0 4 % !0 4 % !0
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M?1?D;=(T"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#GO%7AFV\7Z=)I-Z\L<$Y0L8657^1UD7ED=<;E!(*GIZ\T 4_!W@K3
MO ]HUEI@?;(^^225@\DC8"@L0JJ, 8 554<G&220#K: "@ H * "@ H * "@
M H * "@ H * "@#F/%^@2>(K#[/;2"WNH9H;FVE8$JD]O(LD9=1R4)7:W< Y
M&2 * /.M0G\4^)+9](OSI.GVMRIBNKJ&Y:5C"P*RB")L;6=25'F-A03DYYI@
M>R6<4=O!'% <Q1QHJ'.<HJ@*<]^ .>_6D!8H * "@ H * "@ H * "@ H *
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M<SM:^X/F0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MSRQQ/.VR)7=5:1N/E0,07;D<+D\CUH M4 % !0 4 % !0 4 % !0 4 % !0
M4 % '+>*/^7'_L(VW_L];T_M?X'^AA5^Q_CC^IU-8&X4 % !0 4 % !0 4 %
M !0 4 8GB;_D$WO_ %Z7'_HEZ:W1G/X)>C_(^0:Z3Q H * /3[;Q>NE>';>U
ML+@Q:C#.S,H1C\C-,3DLAB<$,IVDMS@XRO&=KO78ZU4Y::47:2?^?R."U35[
MO6IOM-]*TTF  3@  =E50%4=R%4 L2QRQ)-I6V.:4G)WD[LS:9(4 % !0 4
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M^)SZAJ]W<3(\+E;1$^ZIP71<-DA%4*-J;6).XMGJ]A%RR\<WJ>"I7\UC>17
MLDE).\(ZAPV[^\(_,16SN&T'KC(!EZMX:G\"Z?8>)K*YF:[E>(SJQ^4F6,R[
M>.63Y3&X<MOR#\O2@#;\;7%KJNL2_P!K2-%:+I#7-@K.T:FX90R$8P&D)+@#
MJQ14.0 I -"35+S5/#FE:"CNU_K \MV;)9;1';?(QY.#$%&3G<@<\F@#V^QL
MHM-MX[2W79% BQH/15&!^/')[G)I#+5 !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % 'G'Q5&=#(E+K9FZM!?&,L&%F;A!<'Y/FQL/S8_ASGC-
M 'A.K>'?"-D-;V&VC-O%;W^D2>:SB56@!\F,&0I<1M<QM$R_.0)#G&.&!]8:
M:V^TA8)Y(,49\L<;,H/DQ_L_=_"D!=H * "@ H * "@ H * "@ H * "@ H
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MS76SYK7TZ:E6N0Z#UGP'_P >$G_7=O\ T7%7Z]PQ_N=3_K_+_P!-TC\_SO\
MWB'_ %ZC_P"ES.UK[@^9"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M * "@ H * .6\4?\N/\ V$;;_P!GK>G]K_ _T,*OV/\ '']3J:P-PH * "@
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M'8\\@\@Y!Y%(#C_&_C3_ (0];?9;F\EO)&1(UD\L_*%Z8CD+$LZJ%"\D]>Q
M*_AGQEJ6N7GV6\TBYTZ+8S>=*9=N5QA?GMHAEL\?-GCH: ,+6/BREE=SVNGV
M,VH1V1(GF1RJ)M.UF^6*4; <C>Q121QQ@TP.PM_&VGSZ*?$&66V1274XWK("
M%\K&<%RQ"KS@[@<@&D!Q&G_&".:>%;ZQFLK2Z;;%<LY9#SC=@Q("H)&\H[[?
M0TP.D\2^.VT2\.G65F^H3PV[75QMD6)885ZL24?<0,': /O* 2QP$!>N_&]K
M;Z"OB%$9XY44Q0D[7>5FV"+(#8(<$%@&P%+ 'I0!U5C-+<6\<MQ'Y$KHK/%N
MW^6Q&2F[:F2O0G:.<T 6J "@ H * "@ H * "@#B?B-_R +K_MC_ .E$55'<
MYZW\-_+\T?+\4;3.L:#+.0JCU). /Q-=!Y&^B/:!X6T.VOHO#DT4CW<ML7-X
M)7!$N'; A'[L#:C%=P.!M5MS$N<KNW-^!W^S@I*DUJU\5^OIL>.WMJUC<2VS
MX+02/&Q'3*,5./Q%:'"URMKL['KR^&-$T^YM-"O(7FO+V$O)<B9T,3LK;=D8
M_=L-R,%W XPI<.#BL[O5H[O9PBXTY*\FM[[?+8QM.\*VFE0ZC?ZNAN8].E,$
M<2LT0E?*A6+(2RAO,C*X)VAF+ XQ3OLEU,XTU%2E/51=K;7_ *NAFL^'-*AD
ML-1#/9:9J";I5!:5H&5 Q5&P[MO^Z"5?:P9C\I"*)O5=4$H17++:$M^MO^'-
M*ST?0O$Z7T.F6SVILDWPW/G2N)<!\;HY,[%8KG&-Y7)^0@J2[C:Y2C"IS*"M
M;9W>OR9F^%(])UV>'3O[*#R[!YTYO9U&$ $DOEJN 6/W4! W,J[@/F [K6_X
M$T^6;4>37J^9_-V(I/#=EX@U::VT@I9V5L-A=G:0R2!)&_=([[W+^6Y #;1'
M&TA(R$+O9:[BY%.;4-(KYW>NWW?<KGG-6<I]LURGOA0 4 % !0 4 % !0 4
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M/^N[?^BXJ_7N&/\ <ZG_ %_E_P"FZ1^?YW_O$/\ KU'_ -+F=K7W!\R% !0
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MYS)'#&CG/7+*H;GOS0!8O[&'4K>2TN07AF4HZAF3<IZC<C*P!'!P1D9!X)H
M@&C6:V0TOR4-F(Q%Y)&5V 8 .223WW$[MWS9W<T 4-#\*:7X;+G3+=8&EP';
M<[L0.0-TC.P7/.T$#...!0!T- !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@#E_$_WK#_L(P?^@RUO3^W_ ('^AA4^Q_C7ZG45@;A0 4 % !0
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M;#_>_0_X4 'VV'^]^A_PH /ML/\ >_0_X4 'VV'^]^A_PH /ML/][]#_ (4
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MRHN%#/CY02Y50N<9R1P#CG I >7GP:\OA:;3F<?VI>L+N=F)PUQO60QLP!!
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MYW+D(%( /2: "@ H * *OVK_ &)/^^?_ *] !]J_V)/^^?\ Z] !]J_V)/\
MOG_Z] !]J_V)/^^?_KT <=XWF\RQ0;77]^IRPP/N25\/Q/\ [G3_ .O\?_3=
M4^FR3_>)_P#7J7_I<#RROR$_0 H * "@ H * "@ H * /4_!$WEV+C:[?OV.
M5&1]R.OU[AC_ '.I_P!?Y?\ IND?G^=_[Q#_ *]1_P#2YG8_:O\ 8D_[Y_\
MKU]P?,A]J_V)/^^?_KT 'VK_ &)/^^?_ *] !]J_V)/^^?\ Z] !]J_V)/\
MOG_Z] !]J_V)/^^?_KT 'VK_ &)/^^?_ *] %/4(8=4MI+.ZBD>&="CKMQD'
MT.<@CJ".00".10!X^GPC4$6[WUZ^G+)O%KY>!R>?F\TQAB."XA!/7BF!U7BG
MP'9>(4MS!Y]A/8HL4$L2;ML:?<0J74G8>4(=6!)R3V *OACP"FAWYU:^N+G4
MKP A))8RNW<-I8[I)69MI*@E\ $\9P0 =!I&C7-A>7MQ=W5S?6]\SE+:5'\N
M!&=VV)NF=2H5@GRH@VJ. .  <!/\)$WR1VE[>6UC.X9[41E@<<J"WG*K;?X2
M\;$#N3S0!VVI^#=.U#1X]"$4T4%O@PN%!='&27R>&+EF+C@-N.-O& #G= ^&
MZ:7?1:CJ%S=:B]J!]G62,JL>W[GWI920G5%78H;!QQB@#2\5^!H_$5VFIVLU
MSIU]&H7SHD)W <*<+)&P< E=RN,K@$' H T/!OA*W\'QRE#-<W-R099WC"EL
M9("C<Q49)8Y9BS'))P, "Z]HUQKVIV4DP_XEEBQG:+#&26X&?+W+MV>6G!Y?
M)RZE<'- &#XE\*ZI=ZC/J.C/'%_:%H;.Y6X1^$("EXB@;Y]JJ!NP 0>3G@ [
MCPY8+X?TZWTU5D?[/&%+;,;F)+.0,\ L20.PZDT@-K[5_L2?]\__ %Z #[5_
ML2?]\_\ UZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_
ML2?]\_\ UZ #[5_L2?\ ?/\ ]>@#CO&\WF6*#:Z_OU.6&!]R2OA^)_\ <Z?_
M %_C_P"FZI]-DG^\3_Z]2_\ 2X'EE?D)^@!0 4 % !0 4 % !0 4 >I^")O+
ML7&UV_?L<J,C[D=?KW#'^YU/^O\ +_TW2/S_ #O_ 'B'_7J/_I<SL?M7^Q)_
MWS_]>ON#YD/M7^Q)_P!\_P#UZ #[5_L2?]\__7H /M7^Q)_WS_\ 7H /M7^Q
M)_WS_P#7H /M7^Q)_P!\_P#UZ #[5_L2?]\__7H /M7^Q)_WS_\ 7H P_$'B
M[3O"UNMWJS/;0/((E<Q2/EV5G"XC5VY5&.2,<=<D9UITY57RTU=VONEI\[=S
M&I4A17-4=E>VS>OR3[''_P#"[/"7_/XW_@-<_P#QFNGZI6_E_P#)H_YG-]<H
M?S_^2R_R#_A=GA+_ )_&_P# :Y_^,T?5*W\O_DT?\P^N4/Y__)9?Y!_PNSPE
M_P _C?\ @-<__&:/JE;^7_R:/^8?7*'\_P#Y++_(/^%V>$O^?QO_  &N?_C-
M'U2M_+_Y-'_,/KE#^?\ \EE_D'_"[/"7_/XW_@-<_P#QFCZI6_E_\FC_ )A]
M<H?S_P#DLO\ (/\ A=GA+_G\;_P&N?\ XS1]4K?R_P#DT?\ ,/KE#^?_ ,EE
M_D'_  NSPE_S^-_X#7/_ ,9H^J5OY?\ R:/^8?7*'\__ )++_(/^%V>$O^?Q
MO_ :Y_\ C-'U2M_+_P"31_S#ZY0_G_\ )9?Y!_PNSPE_S^-_X#7/_P 9H^J5
MOY?_ ":/^8?7*'\__DLO\CN='\16FOVD>H:=YD]M-NV2"-EW;':-OE<*PPZL
M.0,XR.,&N6<)4Y.$U9K=>NO0ZX3C4BIP=XO9ZK9VZ^9I_:O]B3_OG_Z]9F@?
M:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT .6XW$#9(,G&2O'X\T 6* "@ H * "@
M H * "@ H Y?Q/\ >L/^PC!_Z#+6]/[?^!_H85/L?XU^IU%8&X4 % !0 4 %
M !0 4 % !0 4 8GB;_D$WO\ UZ7'_HEZ:W1G/X)>C_(^0:Z3Q H * "@ H *
M "@ H * "@#Z^\,_\@FR_P"O2W_]$I7,]V>W#X(^B_(VZ1H% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <3\1O^0!=?
M]L?_ $HBJH[G/6_AOY?FCY<KH/("@ H * "@ H * "@ H * /MFN4]\* "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Q7CS_CPC_P"NZ_\
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MA_Y]]._[]7'_ ,E4?4:?>?WK_P"1#^T*O\L/NE_\D'_#1'B'_GWT[_OU<?\
MR51]1I]Y_>O_ )$/[0J_RP^Z7_R0?\-$>(?^??3O^_5Q_P#)5'U&GWG]Z_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M )^3_P# I?YA_P )QXA_Z"FH_P#@9<?_ !RCV-/^2'_@*_R#VU7_ )^3_P#
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MX2?]=V_]%Q5^O<,?[G4_Z_R_]-TC\_SO_>(?]>H_^ES.UK[@^9"@ H * "@
MH * "@#P;]HC_D7K?_L(Q?\ I/=5ZF!_B/\ P/\ .)Y.8?PH_P"-?^DR/C.O
MHCYD* "@ H * "@ H * "@#[T^"__(H6'_;S_P"EEQ7R^+_C3_[=_P#24?6X
M/^!#_M[_ -*9ZC7"=X4 % !0 4 % !0 4 % !0 4 % !0!R_B;[^G_\ 81B_
M]%3UO3^W_@?YHPJ;P_QK\F=16!N% !0 4 % !0 4 % !0 4 % &)XF_Y!-[_
M ->EQ_Z)>FMT9S^"7H_R/D&ND\0* "@ H * "@ H * "@ H ^OO#/_()LO\
MKTM__1*5S/=GMP^"/HOR-ND:!0 4 % !0 4 % !0!R_CC_D7M4_[!UY_Z3R5
MO1_B0_QQ_-&%;^%4_P $O_26?G%7UY\4% !0 4 % !0 4 % !0 4 ?J+7Q)]
MX% !0 4 % !0 4 % !0!Q/Q&_P"0!=?]L?\ THBJH[G/6_AOY?FCY<KH/("@
M H * "@ H * "@ H * /MFN4]\* "@ H * "@ H * "@#P;]HC_D7K?_ +",
M7_I/=5ZF!_B/_ _SB>3F'\*/^-?^DR/C.OHCYD* "@ H * "@ H * "@#J?
M_P#R,.E_]A&S_P#2B.L*W\.?^"7Y,Z*/\6G_ (X_^E(_1ROD#[0* "@ H *
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M5/6]/[?^!_FC"IO#_&OR9U%8&X4 % !0 4 % !0 4 % !0 4 8GB;_D$WO\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * .*\>?\>$?_7=?_1<M?#\3_[G3_Z_Q_\
M3=4^FR3_ 'B?_7J7_I<#R:OR$_0 H * "@ H * "@ H * /6? ?_ !X2?]=V
M_P#1<5?KW#'^YU/^O\O_ $W2/S_._P#>(?\ 7J/_ *7,[6ON#YD* "@ H *
M"@ H * /!OVB/^1>M_\ L(Q?^D]U7J8'^(_\#_.)Y.8?PH_XU_Z3(^,Z^B/F
M0H * "@ H * "@ H * /LS]G?_D7KC_L(R_^D]K7SN._B+_ OSD?39?_  I?
MXW_Z3$]YKRSU@H * "@ H * "@ H XKQY_QX1_\ 7=?_ $7+7P_$_P#N=/\
MZ_Q_]-U3Z;)/]XG_ ->I?^EP/)J_(3] "@ H * "@ H * "@ H ]9\!_\>$G
M_7=O_1<5?KW#'^YU/^O\O_3=(_/\[_WB'_7J/_I<SM:^X/F0H * "@ H * "
M@ H \&_:(_Y%ZW_[",7_ *3W5>I@?XC_ ,#_ #B>3F'\*/\ C7_I,CXSKZ(^
M9"@ H * "@ H * "@ H ^]/@O_R*%A_V\_\ I9<5\OB_XT_^W?\ TE'UN#_@
M0_[>_P#2F>HUPG>% !0 4 % !0 4 % !0 4 % !0 4 <OXF_UFG_ /81B_\
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MQ?\ I/=5ZF!_B/\ P/\ .)Y.8?PH_P"-?^DR/C.OHCYD* "@ H * "@ H *
M"@#J? __ ",.E_\ 81L__2B.L*W\.?\ @E^3.BC_ !:?^./_ *4C]'*^0/M
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * .*\>?\>$?_ %W7_P!%RU\/
MQ/\ [G3_ .O\?_3=4^FR3_>)_P#7J7_I<#R:OR$_0 H * "@ H * "@ H *
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M "@ H Q/$W_()O?^O2X_]$O36Z,Y_!+T?Y'R#72>(% !0 4 % !0 4 % !0
M4 ?7WAG_ )!-E_UZ6_\ Z)2N9[L]N'P1]%^1MTC0* "@ H * "@ H * .7\<
M?\B]JG_8.O/_ $GDK>C_ !(?XX_FC"M_"J?X)?\ I+/SBKZ\^*"@ H * "@
MH * "@ H * /U%KXD^\"@ H * "@ H * "@ H XGXC?\@"Z_[8_^E$55'<YZ
MW\-_+\T?+E=!Y 4 % !0 4 % !0 4 % !0!]LURGOA0 4 % !0 4 % !0 4
M>#?M$?\ (O6__81B_P#2>ZKU,#_$?^!_G$\G,/X4?\:_])D?&=?1'S(4 % !
M0 4 % !0 4 % '4^!_\ D8=+_P"PC9_^E$=85OX<_P#!+\F=%'^+3_QQ_P#2
MD?HY7R!]H% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Q7CS_CPC_P"N
MZ_\ HN6OA^)_]SI_]?X_^FZI]-DG^\3_ .O4O_2X'DU?D)^@!0 4 % !0 4
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M++BOE\7_ !I_]N_^DH^MP?\  A_V]_Z4SU&N$[PH * "@ H * "@ H * "@
MH * "@#E_$O^MTW_ +",?_I/<UO3VG_@?YHPJ;P_QK\I'45@;A0 4 % !0 4
M % !0 4 % !0!B>)O^03>_\ 7I<?^B7IK=&<_@EZ/\CY!KI/$"@ H * "@ H
M * "@ H * /K[PS_ ,@FR_Z]+?\ ]$I7,]V>W#X(^B_(VZ1H% !0 4 % !0
M4 % '+^./^1>U3_L'7G_ *3R5O1_B0_QQ_-&%;^%4_P2_P#26?G%7UY\4% !
M0 4 % !0 4 % !0 4 ?J+7Q)]X% !0 4 % !0 4 % !0!Q/Q&_Y %U_VQ_\
M2B*JCN<];^&_E^:/ERN@\@* "@ H * "@ H * "@ H ^V:Y3WPH * "@ H *
M "@ H * /!OVB/\ D7K?_L(Q?^D]U7J8'^(_\#_.)Y.8?PH_XU_Z3(^,Z^B/
MF0H * "@ H * "@ H * .I\#_P#(PZ7_ -A&S_\ 2B.L*W\.?^"7Y,Z*/\6G
M_CC_ .E(_1ROD#[0* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P#R*%A_V\_^EEQ7R^+_ (T_^W?_ $E'UN#_ ($/^WO_ $IGJ-<)WA0 4 %
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M%;^'/_!+\F=%'^+3_P <?_2D?HY7R!]H% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0!Q7CS_ (\(_P#KNO\ Z+EKX?B?_<Z?_7^/_INJ?39)_O$_^O4O
M_2X'DU?D)^@!0 4 % !0 4 % !0 4 >L^ _^/"3_ *[M_P"BXJ_7N&/]SJ?]
M?Y?^FZ1^?YW_ +Q#_KU'_P!+F=K7W!\R% !0 4 % !0 4 % '@W[1'_(O6__
M &$8O_2>ZKU,#_$?^!_G$\G,/X4?\:_])D?&=?1'S(4 % !0 4 % !0 4 %
M'V9^SO\ \B]<?]A&7_TGM:^=QW\1?X%^<CZ;+_X4O\;_ /28GO->6>L% !0
M4 % !0 4 % '%>//^/"/_KNO_HN6OA^)_P#<Z?\ U_C_ .FZI]-DG^\3_P"O
M4O\ TN!Y-7Y"?H 4 % !0 4 % !0 4 % 'K/@/\ X\)/^N[?^BXJ_7N&/]SJ
M?]?Y?^FZ1^?YW_O$/^O4?_2YG:U]P?,A0 4 % !0 4 % !0!X-^T1_R+UO\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M2@ H * "@ H * "@ H XKQY_QX1_]=U_]%RU\/Q/_N=/_K_'_P!-U3Z;)/\
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MES_WXE_^)HNNX<D_Y7]S#^P-2_Y]+G_OQ+_\31==PY)_RO[F']@:E_SZ7/\
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M_P"@=?\ _@)/_P#&Z/;4_P">'_@2_P P]C5_Y]S_ / 9?Y!_PAVN_P#0.O\
M_P !)_\ XW1[:G_/#_P)?YA[&K_S[G_X#+_(/^$.UW_H'7__ ("3_P#QNCVU
M/^>'_@2_S#V-7_GW/_P&7^0?\(=KO_0.O_\ P$G_ /C='MJ?\\/_  )?YA[&
MK_S[G_X#+_(/^$.UW_H'7_\ X"3_ /QNCVU/^>'_ ($O\P]C5_Y]S_\  9?Y
M!_PAVN_] Z__ / 2?_XW1[:G_/#_ ,"7^8>QJ_\ /N?_ (#+_(/^$.UW_H'7
M_P#X"3__ !NCVU/^>'_@2_S#V-7_ )]S_P# 9?Y!_P (=KO_ $#K_P#\!)__
M (W1[:G_ #P_\"7^8>QJ_P#/N?\ X#+_ "/T7^VP_P![]#_A7R!]H'VV'^]^
MA_PH /ML/][]#_A0 ?;8?[WZ'_"@ ^VP_P![]#_A0 ?;8?[WZ'_"@ ^VP_WO
MT/\ A0 ?;8?[WZ'_  H /ML/][]#_A0!R/CMOMVB7,%L&EE?RMJ(C,QQ/$QP
M ,G !)]@351T9A53<&EJ]/S1\Z?V!J7_ #Z7/_?B7_XFM[KN>7R3_E?W,/[
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M;H]M3_GA_P"!+_,/8U?^?<__  &7^0?\(=KO_0.O_P#P$G_^-T>VI_SP_P#
ME_F'L:O_ #[G_P" R_R#_A#M=_Z!U_\ ^ D__P ;H]M3_GA_X$O\P]C5_P"?
M<_\ P&7^0?\ "':[_P! Z_\ _ 2?_P"-T>VI_P \/_ E_F'L:O\ S[G_ . R
M_P @_P"$.UW_ *!U_P#^ D__ ,;H]M3_ )X?^!+_ ##V-7_GW/\ \!E_D'_"
M':[_ - Z_P#_  $G_P#C='MJ?\\/_ E_F'L:O_/N?_@,O\@_X0[7?^@=?_\
M@)/_ /&Z/;4_YX?^!+_,/8U?^?<__ 9?Y!_PAVN_] Z__P# 2?\ ^-T>VI_S
MP_\  E_F'L:O_/N?_@,O\CH_!_A76;37=.GGL+V***^M'=WM9U5$6>-F9F*
M!5 ))/  R:RJU:;IS2G%MQE9<R[/S-J-&HJD&X324XW?*]-5Y'WI]MA_O?H?
M\*^5/K@^VP_WOT/^% !]MA_O?H?\* #[;#_>_0_X4 /2YCD.U3DGV/\ A0!/
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MS9O^>7_CXH /-F_YY?\ CXH P/$>FW6LVRP1(J,L@?+/Q@*ZXX!Y^85\YG.
MJYGAXT*#A&4:JFW-M*RC./V8R=[R73OJ>QEV*A@JLJM52:<''W4F[N47U:TT
M?4XK_A!]0]8O^^S_ /$U\)_JQC/^?E#_ ,"J?_*CZ?\ MO#_ ,E7_P !A_\
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M$<8P#ST![<-5C0FYSNTXM:>J?5KL<.*HRKP4(-)J2>M^S71/N>!_\,]^(_\
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MQ?\ ?9_^)H_U8QG_ #\H?^!5/_E0?VWA_P"2K_X##_Y,/^$'U#UB_P"^S_\
M$T?ZL8S_ )^4/_ JG_RH/[;P_P#)5_\  8?_ "8?\(/J'K%_WV?_ (FC_5C&
M?\_*'_@53_Y4']MX?^2K_P" P_\ DSM?#FFW6BVS02HKLTA?*OQ@JBXY Y^4
MU]WDV JY9AY4*[A*4JKFG!MJSC"/VHQ=[Q?3MJ?,9CBH8VK&K24DE!1]Y).Z
ME)]&]-5U-_S9O^>7_CXKZ,\</-F_YY?^/B@ \V;_ )Y?^/B@ \V;_GE_X^*
M#S9O^>7_ (^* #S9O^>7_CXH /-F_P">7_CXH /-F_YY?^/B@#S7XI^$=1\<
MZ7%I]B(89(KI)RTTA"E5BFC(&Q'.[,@(XQ@'GH#VX:K&A-SG=IQ:T]4^K78X
M<51E7@H0:34D];]FNB?<\#_X9[\1_P#/6P_[_3?_ "/7J_7J?:?W+_Y(\C^S
MZO>'WR_^1#_AGOQ'_P ];#_O]-_\CT?7J?:?W+_Y(/[/J]X??+_Y$/\ AGOQ
M'_SUL/\ O]-_\CT?7J?:?W+_ .2#^SZO>'WR_P#D0_X9[\1_\];#_O\ 3?\
MR/1]>I]I_<O_ )(/[/J]X??+_P"1#_AGOQ'_ ,];#_O]-_\ (]'UZGVG]R_^
M2#^SZO>'WR_^1#_AGOQ'_P ];#_O]-_\CT?7J?:?W+_Y(/[/J]X??+_Y$/\
MAGOQ'_SUL/\ O]-_\CT?7J?:?W+_ .2#^SZO>'WR_P#D0_X9[\1_\];#_O\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M>: +] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!R_B/_CXTL?\ 41'_ *1WA_F*WI[3
M_P '_MT3"IO3_P ?_MLCJ*P-PH * "@ H * "@ H * "@ H * "@ H * "@
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M)7H_R?(>&P: -'2=9L]<@^TV$@FB#,C'#*RNO#(Z.%='7C*NJL 0<8(H TZ
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M- '>4 % !0 4 % !0 4 % !0 4 % !0 4 <OXC_X^=+_ .PB/_2*]K>GM/\
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M"<66IZGIT]ZIM+WR([B2^,"1R1NBFW@L4++.FUCEIT#N"9&;*&@#I0TWBK4
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MG-J^^V2\O[FW^TVMB\>;33 V9(0D!#YP$:Y<#<3PV &R 6?& LQ)?#PSY?\
M9HTH_;?LNW[)YOFKY/W?W?GXQNV?/MSN_CH S](CM9X+Q/$$MO;S?9[?[,;F
MVDFN/LQMT$)T]A<188'!VPHS;^7R-P !]"V5U)HNA1W$PN;UK:U5B/+"W,H5
M0?FB9^)=N"ZE]V0<_/\ +2&>2:W<Q^)-4LKC1[E]3FN[>[0P2;&73TG@9?,
MB$8@D4GRSY^^1MN-Q/S%@4C>1:IX9TGP_;<ZG'>6\4MK@B6$P2,99)4(W1H!
MAB[ *0W!.#@$<W_8EF?#DFH>6/M<NN&(S#B41&4QM&KC#*C*S;E!PQ;)!(&
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M4$ % HB& Q^;J" =;'H]C$\4B6\"/:AE@98HPT*N"'$1"YC# D,$P&!(.<T
M07?A[2[^4W%U9VL\Q !DE@B=R "H!=D+$ $@#/0D=* *Z>$M%B&$T^R4>UK
M/Y)0 K^$]%D)9["R9F&&)M8"2.."2G(X'7T'H* -!-)LHC,R6\*F[ 6X(B0&
M90I4"4A?W@"L5 ?("D@<$T ..F6C6WV$P0FTVA/(,:>3L'1?+QLVCLNW'M0!
MF6_A/1;219X-/LHI8V#(Z6L"NK#D,K*@*D'D$$$4 6AH&F+.;H6EL+AB2TH@
MB\PEAAB7V[CD<')Y'6@"1=&L(TAA6VMUCM6WP((8PL+Y)WQ*%Q&V23N0 Y)Y
MYH S-9\-Q7\$D5H+>VDGE26=GM(9TN-O5;B-POF!AP7#I*O\,@YR 9WACP7%
MX=N[G4"T33W@C39;VZVL$4<?1(H5>0C<?F=F=BS#/'.0#MJ "@ H K7EE;ZC
M$UM=Q1W$+XW1RHLB-@AAN1@5.& 89'! (Y% &7-X6T>X=I9;&SDD?AF:VA9F
M& .24)/  Y/0 =J +T>DV4+R21V\*/.BQRLL2!I$5=BI(0N754 55;("_*!C
MB@"BWA;1WV;K&S/E +'FVA.P Y 7Y/E /( P : +%[H.FZDXDO+6VN7085IH
M8Y&4 Y !=20 ><#C/- '+Q?#^P.L7FKWB07B7JVZQV\MM&RV_D1+%E&<N#N"
M@\(FT8'.,T =>FEV<4RW*00K/''Y*2"-!(D0)(B5PNY8\DG8"%R2<4 4KCPS
MI%W(T\]C:2RR9WN]O"SMG@[F9"6R  <DYQ0!&GA/18QA+"R4>@M8 /T2@"RG
MA_3([C[:MI;+<[BWG""(2[CU;S N_)[G.30 DGA_3)5DCDM+5TGD,TJM!$5D
ME/65P5P\A[NV6/K0!=L[&WTZ,06<4=O$O2.)%C09]%0 #\J *5SX?TR]F^TW
M%I:S3Y!\R2")WROW3O92W';GCM0!)?:+I^J,KWMM;W+H,*TT,<A49SA2ZL1S
MSQWYH L)I]M',+I88EG6(0B4(HD$(;<(@X&X1AOF"9V[N<9H KQZ)I\4<4,=
MM;I':OYD"+#&%A?);?$H7$;[F)W( <DG.2: .!O_ (:KJLH-Y-;-']I^T.\>
MGPPW<JA]ZPRW,;A60'AF$"NX"[CD$D ]1H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * .?\,^&K;PI:&QLVE>,RO+F4JS;I#EAE$08';Y<^I- '04 % !
M0 4 % !0 4 % !0!SNJ>'CJ4KRK>7MJ)8O)>."2/RF7))8)-%,(Y""5,D7EN
M5[Y ( -#1](MM!LXM.LE*06Z[4!))ZDDDGJS,2Q/J3@ <4 :5 !0 4 % !0
M4 % '/>%_#5MX2L$TRS:62&-G8-*59\NQ8Y*(BXR>/E''7- '0T % !0 4 %
M !0 4 % !0!4O[,7]O);,\L(E4KYD+M%*F?XDD7!5AU!'T((R* ,"Q\)PVM^
MNJW$]S?7<4/D1/<-%^[C/WMJPPPKN;^)V#,<GG% '54 % !0 4 % !0!'-$)
MXVB;(#J5..N&&#CKSSZ4 8_AOP_;^%M/BTJT:1X;??M:4J7/F2/*=Q147[SD
M#"CC&<G)(!N4 % !0 4 % !0 4 % !0!R^K>%QJS3[KR^@BNXQ%-!%+'Y14
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .7\1?\?6E?\ 81/_
M *07U;T]I_X/_;XF%3XJ?^/_ -LF=16!N% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 <OXB_P"/K2O^PB?_ $@OJWI[3_P?
M^WQ,*GQ4_P#'_P"V3.HK W"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M (_0 >7=?\](O^_+_P#Q^@ \NZ_YZ1?]^7_^/T 'EW7_ #TB_P"_+_\ Q^@
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M[\O_ /'Z #R[K_GI%_WY?_X_0 >7=?\ /2+_ +\O_P#'Z #R[K_GI%_WY?\
M^/T 'EW7_/2+_OR__P ?H /+NO\ GI%_WY?_ ./T 'EW7_/2+_OR_P#\?H /
M+NO^>D7_ 'Y?_P"/T 'EW7_/2+_OR_\ \?H /+NO^>D7_?E__C] !Y=U_P ]
M(O\ OR__ ,?H /+NO^>D7_?E_P#X_0 >7=?\](O^_+__ !^@ \NZ_P">D7_?
ME_\ X_0 >7=?\](O^_+_ /Q^@ \NZ_YZ1?\ ?E__ (_0 >7=?\](O^_+_P#Q
M^@ \NZ_YZ1?]^7_^/T 'EW7_ #TB_P"_+_\ Q^@ \NZ_YZ1?]^7_ /C] !Y=
MU_STB_[\O_\ 'Z #R[K_ )Z1?]^7_P#C] !Y=U_STB_[\O\ _'Z #R[K_GI%
M_P!^7_\ C] !Y=U_STB_[\O_ /'Z #R[K_GI%_WY?_X_0 >7=?\ /2+_ +\O
M_P#'Z #R[K_GI%_WY?\ ^/T 'EW7_/2+_OR__P ?H /+NO\ GI%_WY?_ ./T
M 'EW7_/2+_OR_P#\?H /+NO^>D7_ 'Y?_P"/T 'EW7_/2+_OR_\ \?H /+NO
M^>D7_?E__C] !Y=U_P ](O\ OR__ ,?H /+NO^>D7_?E_P#X_0 >7=?\](O^
M_+__ !^@ \NZ_P">D7_?E_\ X_0 >7=?\](O^_+_ /Q^@ \NZ_YZ1?\ ?E__
M (_0 >7=?\](O^_+_P#Q^@ \NZ_YZ1?]^7_^/T 'EW7_ #TB_P"_+_\ Q^@
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M[\O_ /'Z #R[K_GI%_WY?_X_0 >7=?\ /2+_ +\O_P#'Z #R[K_GI%_WY?\
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M (_0 >7=?\](O^_+_P#Q^@ \NZ_YZ1?]^7_^/T 'EW7_ #TB_P"_+_\ Q^@
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M[\O_ /'Z #R[K_GI%_WY?_X_0 >7=?\ /2+_ +\O_P#'Z #R[K_GI%_WY?\
M^/T 'EW7_/2+_OR__P ?H /+NO\ GI%_WY?_ ./T 'EW7_/2+_OR_P#\?H /
M+NO^>D7_ 'Y?_P"/T 'EW7_/2+_OR_\ \?H /+NO^>D7_?E__C] !Y=U_P ]
M(O\ OR__ ,?H /+NO^>D7_?E_P#X_0 >7=?\](O^_+__ !^@ \NZ_P">D7_?
ME_\ X_0 >7=?\](O^_+_ /Q^@ \NZ_YZ1?\ ?E__ (_0 >7=?\](O^_+_P#Q
M^@ \NZ_YZ1?]^7_^/T 'EW7_ #TB_P"_+_\ Q^@ \NZ_YZ1?]^7_ /C] !Y=
MU_STB_[\O_\ 'Z #R[K_ )Z1?]^7_P#C] !Y=U_STB_[\O\ _'Z #R[K_GI%
M_P!^7_\ C] %F,,% D(9NY4%1^ +,1_WT?Z4 /H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .7\0_\?FD_P#81?\
M]-NH5O#X:G^#_P!O@85/BI_XW_Z1,ZBL#<* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H Y?Q#_Q^:3_V$7_]-NH5O#X:G^#_
M -O@85/BI_XW_P"D3.HK W"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * .7\0_\ 'YI/_81?_P!-NHUO#X:G^#_V^!A4^*G_
M (W_ .D3.HK W"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M, H * "@ H * "@ H * .7\0?\?VD?\ 81D_]->I5O#X:G^!?^EP,*GQ4_\
M&_\ TW,ZBL#<* "@ H * "@ H * "@ H KM=1*2"W(X/!_PI7 3[9%_>_0_X
M470!]LB_O?H?\*+H ^V1?WOT/^%%T ?;(O[WZ'_"BZ /MD7][]#_ (470!]L
MB_O?H?\ "BZ /MD7][]#_A1= 'VR+^]^A_PHN@#[9%_>_0_X470!]LB_O?H?
M\*+H ^V1?WOT/^%%T ?;(O[WZ'_"BZ /MD7][]#_ (470!]LB_O?H?\ "BZ
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MY#_&BX!_:$?HWY#_ !HN ?VA'Z-^0_QHN ?VA'Z-^0_QHN ?VA'Z-^0_QHN
M?VA'Z-^0_P :+@']H1^C?D/\:+@']H1^C?D/\:+@']H1^C?D/\:+@']H1^C?
MD/\ &BX!_:$?HWY#_&BX!_:$?HWY#_&BX!_:$?HWY#_&BX!_:$?HWY#_ !HN
M ?VA'Z-^0_QHN ?VA'Z-^0_QHN ?VA'Z-^0_QHN ?VA'Z-^0_P :+@']H1^C
M?D/\:+@']H1^C?D/\:+@']H1^C?D/\:+@']H1^C?D/\ &BX%U6W@,.A /YU0
MA: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MS:22_F22<C'4%1CM3>@'<6?B72=0E^S6E[:7$W/[N*XBD?CK\B.6XP<\<8I
M</JWQ0L=-\16_A\O L+"0W=W)-&L<!6*8K%G<%67S$16\P@C<%"EF!#L!HZ3
MXCU.\\2WFD3BR%A;0EX3%/$UV7S /WT*W+R(G[Q^6MXQGR_F^8;P#JKGQ!IE
ME,+6YN[6&X;&(I)XDD.>F$9@QSVP*0%G4-3M-)C\^^GAM8MP7?-(D2;CDA=S
ME1D@' SDX/I0!737M-DN/L27=LUU_P \!/$9?7_5AM_3GI0!K4 % !0 4 %
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MD8V;^7G:%P\\!RI..02 =CK_ (\T+PO*+?5+M()F /EA9)' /0LL2.R@]BP
M/:E8#13Q-ILFG-K,=PDEA&C2--'N<!4^]E4!?<O==NX'C;F@#F6^*_A9/+)U
M",>>,I^[FX&2/W@\K]UTS^]V'&&^Z0:=@/0(Y%E421D,C ,K*0001D$$<$$<
M@C@BD ^@#H8?]6O^Z/Y58B2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %:\_U3?A_,4F!AU PH * "@ H
M * /"?V@R1X?MR."-1B_])[JF@./^(_A+2],USP_IUK!'!#=2I;S^4H1ID,\
M$;&1EY9V61P78ECNP21BF@.@@TRUT+XDV]MIL26D,M@Q>.%0B$^7+GY5P.3&
MC'CEE#'GFCH!>^#7_'_X@_["'_M2YI, \7_\E"T3_KW?_P!N:.@'O%(#P?X-
M?\?_ (@_["'_ +4N:; ]MO\ _CVE_P"N3_\ H)I ?+_PP\+:/K'A/4;J]ABG
MN%:X7S' +P+' DB&)CS%\Q+EEQNY#%E&VJ8&#<ZU?_\ "N[6!G=(9-0:U>3)
M)^S*KR*AQSL#@C;W6,(/E.*.HCM?BMX?TWP=IVFZEX?B2TO;>[BCADAP))4,
M4CDN5^:<ED0%VW$ARI.'Q0AC_$FG6NL_$:QM=316BDLE9H7(*,ZI<.L;=G7>
MHX/ROC!!!P3H!<T:TB\/?$::PTI%@M+FSWS0QX6)3Y8<$1CA?G"E5 &WS&VX
M4XHZ 5OA$ZKH&MY(&V>Y)YZ#[/U/H.#S['TH8'#6'_),;O\ ["*_^AV]'41V
M]_?Z?+;^'-).F#6M6?3+66WBEG:*VC0VXW/(A)ADR(7+!XS\J?>^Z"#*'PXL
M67QGJVFWUO:PQR63^=9P*&M!^\M<($8;6 61@1MVY9P!MQ0]@*OPML+8Z+K]
MR8HO/B2YCCEV+YB(;>3*(^-RJ>Z@@'N*&!S+7]Q:?#NWAA9HH;K4Y(IW7/\
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MZ1M_S;G)(Y (!Q0AGU74@% !0 4 % !0!+#_ *Q?]X?SH Z"M!!0 4 % !0
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MSE\[BQ)).3F0.8TOX4Z3IMS!=2RWM_\ 8L&UBO+CS8;?'(\J,(@ 4@$ [@"
M<9 -.X''>)?"<NO^.X'N(+G[!]BP;J(2QK%*BS,A6X0!4D5]A4;NN 00<$Z
M>D^%_ FG^%)IKR![BZO+KB6ZNY?.G9<@[2VU!C(!/RY;:NXG:,(#"D^$FCM=
M3W,<M[!%>L6N+2*Y,=K*22QWQJNYER2=A?8.@4#BG<":'X6:7#H4GAI9;K[)
M-,)V<O%YP<%#@-Y.S;^['!C)Z\],%P)-4^&&EZI'8CS;NVGTJ".VM[JWF6*X
M\J)0J!G\LKD<MN5$(9FQ@'%%P)O#WPUTSPQJ1U>QDNO/DA:&422B19=[*[R2
M%D,AD9U5B1(%R/NXR"7 KV7PNTW3KBYN+6>]ABOEF66V6<?9LSH\;.(S&271
M7;RR[.$)Z$#%%P+^F_#O2=.T5O#K"2ZL9&9R)V4R;F(;(>-(]I4@%2 "/4TK
M@9NE_"G2=-N8+J66]O\ [%@VL5Y<>;#;XY'E1A$ "D @'< 0#C(!IW V[CP3
M97.OP^)W><7EM&8D0,GDE2DL>64QER<2L>) ,A>, @KR +?P396NOS>)T><W
MES&(G0LGDA0D4>541AP<1*>9",EN,$ 'D!V- !0 4 % !0 4 :>G?Q?\!_K5
M(#2JA!0 4 % !0 4 % '/S?ZQO\ >/\ .LQD5 '/Z'X6TSPTT[Z9#Y#7CB28
M^9*^]QN(/[QWV_>;A=HYZ<"@#?90P((R#P0>A'I0!PL'PQ\-6UV-0BL(EG5M
MZ\R>6&SD$0E_)&#R,1@#MBG<#=O_  SIVIWUOJEU#YEW8Y\B3?(NS)R?D5U1
MN?[ZM2 WJ /'/%_@R[U_Q7IM\ULMSI<$#Q71=HMHW>?\IC=P[??7E4;!.<@@
MX8'=^'O!>C>%2[:3:I;/*,.^7=R,YV[Y&=@N<':"%R <9 I 6M&\,Z=X>DN)
MM.A\E[V3S9SOD?>^6.[$CL%Y=N$"CGIP, &?K_@/0O$\HN-4M(YYE 'F!I(W
M('0,T3HS =@Q( X%&P&U8:+8Z7:?V=:01PVN&7RE4;"&^]N'\1;)W%LENY-
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M^Y7):1ARW'(PO(#GKKX/Z-/+*T,M[9V]RVZ>TMK@QVTISGYXRC'&>@# +T4
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M[0!T,/\ JU_W1_*K$24P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H JO<P\HQZ'!!!/3\* (_.M?]G_ +X_
M^M18 \ZU_P!G_OC_ .M18 \ZU_V?^^/_ *U%@#SK7_9_[X_^M18 \ZU_V?\
MOC_ZU%@#SK7_ &?^^/\ ZU%@#SK7_9_[X_\ K46 /.M?]G_OC_ZU%@#SK7_9
M_P"^/_K46 /.M?\ 9_[X_P#K46 /.M?]G_OC_P"M18 \ZU_V?^^/_K46 /.M
M?]G_ +X_^M18 \ZU_P!G_OC_ .M18 \ZU_V?^^/_ *U%@#SK7_9_[X_^M18
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M^M18 \ZU_P!G_OC_ .M18 \ZU_V?^^/_ *U%@#SK7_9_[X_^M18 \ZU_V?\
MOC_ZU%@#SK7_ &?^^/\ ZU%@#SK7_9_[X_\ K46 /.M?]G_OC_ZU%@#SK7_9
M_P"^/_K46 /.M?\ 9_[X_P#K46 /.M?]G_OC_P"M18 \ZU_V?^^/_K46 /.M
M?]G_ +X_^M18 \ZU_P!G_OC_ .M18 \ZU_V?^^/_ *U%@#SK7_9_[X_^M18
M\ZU_V?\ OC_ZU%@#SK7_ &?^^/\ ZU%@#SK7_9_[X_\ K46 /.M?]G_OC_ZU
M%@#SK7_9_P"^/_K46 /.M?\ 9_[X_P#K46 /.M?]G_OC_P"M18 \ZU_V?^^/
M_K46 !/;#D;01_LG_"BP$GVV'^]^A_PH /ML/][]#_A0 ?;8?[WZ'_"@ ^VP
M_P![]#_A0 ?;8?[WZ'_"@ ^VP_WOT/\ A0 ?;8?[WZ'_  H /ML/][]#_A0
M?;8?[WZ'_"@ ^VP_WOT/^% !]MA_O?H?\* #[;#_ 'OT/^% !]MA_O?H?\*
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MC618W:,LN"0#8L=1CU$R^2&*02M#O.-CN@'F>6022$<M$Q(7]XCJ,A<D OT
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M)R.0#0!WWB3QWI?AFQ@U"9I+E+UD2UCM5$TERT@W((5W*K;@002P!R #E@"
M3^%?&>G^+K22]LS)"+:1HKB*X3RI8)$&665<D*0.20Q Y!.0P !-X4\4VWC"
MS.HV,<T=L99(XVF54\T1G:98PKN?++952^QLJ<H,4 =+0 4 % !0 4 % !0
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M * "@ H * "@ H * "@ H * "@ H Y;QCXPL? ^GG5-1$C1"1(U2$*TCNY.
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M=QN8RLJ9 /H75?#NDZ]#;ZU';1W]Q9V_G:<S,Y!^3S(<*9$5@YV$>9[$D8R
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M:3_U^S?^FZ^K>'PU/\*_]+B83^*G_B?_ *1,ZBL#<* "@ H * "@ H * "@
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MP&VG:2N&P<$X- '34 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % %+4M-M]7M9;&\3S;>X1HY$W,NY&&"-R%6&
M1W5@?0T -U+2[;5X?L]XGF1[E<?,R,KJ<JZ.A5XW4\JZ,K#L: *^GZ#9:7')
M%!&2+@YF:9Y)Y)?EV?O99WDDD 7Y0'=@%X  )H JZ;X5TW295N+:-Q)&ACB\
MR>>984;&4@2:61(%( !6%4&!C&.* -?[%#]I^V;<SB/R0Q+'$9;>55<[5W,
M6(4,^U Q(1  #-M_#6GVMU]MBB*RAY)%'F2F)))01+)' 7,$<D@9M[QQJ[;W
M+$EWR ;E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'G?Q3L]8U
M/0)].T" W%U>E87Q)%'L@;)E8F:2-3N4>5@$M^\SC ) !XWX5A^)?@[38](L
M-%L&@AWG=+-$TCL[%F9RNI(I))QPH 4 8XH U/@SX4\4>$M5N_[5L1::?J"E
MR$GMW2&9&+1A$2XED";7>/HQ_P!7N8A<T >U^-?#9\6:/<Z2LIMY)U'ER@D;
M)$970G&"5+*%<#DH6QSB@#YTD\#_ !!UO38/!^H):P:5;/&/M@D1F:*+_5KA
M92[+&,>6I@B8E5#O@9H [KQW\.-55M+U/PG(/M>A0Q6\<$KA5DCA&(R-Q$>_
M!=9 Y4.C<,I7! (/"?@GQ)K?B5/%WC!8;66TB\NVM8&# ':ZC[LDP6-?,D?!
ME=FD;G"C! /0M'G\2ZG=:I9ZS;Q6%@#)'IUS;N/.>-GE196Q<RE9!'Y;C,<)
M#D\ C:H!XG<>%OB7<6=QX8N'AN[&ZD._49IU>3RB1E%+RF98VQDI]G++DJC!
M30!]$^$O#L7A/2;71X#N6TCVENF]V)>5\=M\C.V.V<9/6@#SOP[HU[XFUG4_
M$FHQ36>(Y--TN.>-XGC@ .^YV. R^<[94[0<&1>1B@#RKPMX:UEI=!T.33+F
MSET'4)KF[O7CVV[Q&82@139(E+JHC(7L$QD;BH!]=T % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?)/]@?$
M"R\47?BJTTJ">:X,B0K<W%LRQ0G:D>T1WT1#B% A)8KAG^7)! !3\5>'?B/X
MMOK/5;C2K6VN]-8-#);3VZ$[7610_F7\N0C@E<;?O-G.> #ZZLY)9H(Y)T\F
M5XT:2,E6,;E060LI96VME<JQ4XR"1S0!\]ZSX0\8>$_$-WKOA)8=0AU3<98+
MAU'ELS;SD22PY59"S1&.3@,49"!\P!/X8^$-Z-%U>+6IU75?$/S2LAWI"RNT
MR[B,!V>5BTNWC;A5)Y) .,?P=\19=&'@MK>R_LP$+]K\R+/EK*)0N?,\S8'
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M#'<()7:,D$QB6:214..X5P6'9BP[4 >BT % !0 4 % !0 4 % !0 4 % !0
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MW;0#W+P/I5QH>@V&GWG_ !\6UM$D@R#M8+RF1P=F=F1P<<$B@#JJ "@ H *
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MP >X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!R^N_\A#2?^OV;_TW7M;P^&I_A7_I<3"?Q4_\3_\ 2)'45@;A0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M1TG_ *^YS_Y(78_J:WA\-3_"O_2XF$_CI_XG_P"D2.HK W"@ H * "@ H *
M*[7<2D@MR#@\'M^% #?ML/\ >_0_X4 'VV'^]^A_PH /ML/][]#_ (4 'VV'
M^]^A_P * #[;#_>_0_X4 'VV'^]^A_PH /ML/][]#_A0 ?;8?[WZ'_"@ ^VP
M_P![]#_A0 ?;8?[WZ'_"@ ^VP_WOT/\ A0 ?;8?[WZ'_  H /ML/][]#_A0
M?;8?[WZ'_"@ ^VP_WOT/^% !]MA_O?H?\* #[;#_ 'OT/^% !]MA_O?H?\*
M#[;#_>_0_P"% !]MA_O?H?\ "@ ^VP_WOT/^% !]MA_O?H?\* #[;#_>_0_X
M4 'VV'^]^A_PH /ML/\ >_0_X4 'VV'^]^A_PH /ML/][]#_ (4 'VV'^]^A
M_P * #[;#_>_0_X4 'VV'^]^A_PH /ML/][]#_A0 ?;8?[WZ'_"@ ^VP_P![
M]#_A0 ?;8?[WZ'_"@ ^VP_WOT/\ A0 ?;8?[WZ'_  H /ML/][]#_A0 ?;8?
M[WZ'_"@ ^VP_WOT/^% !]MA_O?H?\* #[;#_ 'OT/^% !]MA_O?H?\* #[;#
M_>_0_P"% !]MA_O?H?\ "@ ^VP_WOT/^% !]MA_O?H?\* #[;#_>_0_X4 'V
MV'^]^A_PH /ML/\ >_0_X4 'VV'^]^A_PH /ML/][]#_ (4 'VV'^]^A_P *
M #[;#_>_0_X4 'VV'^]^A_PH /ML/][]#_A0 ?;8?[WZ'_"@ ^VP_P![]#_A
M0 ?;8?[WZ'_"@ ^VP_WOT/\ A0 ?;8?[WZ'_  H /ML/][]#_A0 ?;8?[WZ'
M_"@ ^VP_WOT/^% !]MA_O?H?\* #[;#_ 'OT/^% !]MA_O?H?\* #[;#_>_0
M_P"% !]MA_O?H?\ "@ ^VP_WOT/^% !]MA_O?H?\* #[;#_>_0_X4 'VV'^]
M^A_PH /ML/\ >_0_X4 'VV'^]^A_PH /ML/][]#_ (4 'VV'^]^A_P * #[;
M#_>_0_X4 'VV'^]^A_PH >ES'(=JG)/L?\* )Z "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y?7/^0CI/_7W/_Z07=;P
M^&I_A7_I<3"?QT_\3_\ 2)'45@;A0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '+ZY
M_P A'2?^ON?_ -(+NMX?#4_PK_TN)A/XZ?\ B?\ Z1(ZBL#<* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%CR0H &<  4@)* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .7UO_ )"6E#_I
MYG/_ )(W0_K6\/AJ>B_]*B83^.G_ (G_ .D2.HK W"@ H * "@ H * "@ H
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M-UHNLQ017EHD<H:V+^4Z.%/1RS97>G.<$DC QRAGH% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % '+ZW_ ,A/2O\ KXN/_2*XK>'PS]%_Z4C"?QT_5_\ I,CJ
M*P-PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M.4N/!]G<ZU%X@=I?M,";%3*>3C8Z9*F,OD>82"'&& .."" =!?V,&IV\EI=*
M)(9E*.I[@_3D'N".0<$<T >=:;\(M"TVY6[ GG*-N6.:16C!'(X6-&;!Y =F
M!QR#3 Z;Q%X0M/$T]I<7;S(^GNTD0B9 &+-&QW[HW)&8EQM*G!//3" K^*?
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M,X(." !?#'A!]#NKC4;RZ?4+Z[5$>9HUB 1  %"*S#H%R<_PC '.0#M: "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * *[7&TD;)#@XR%X_#F@!OVK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8
MD_[Y_P#KT 'VK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT .6XW$
M#9(,G&2O'X\T 6* "@ H * "@ H * .7UO\ Y">E?]?%Q_Z17%;P^&?HO_2D
M83^.GZO_ -)D=16!N% !0 4 % !0 4 5VNXE)!;D'!X/;\* &_;8?[WZ'_"@
M ^VP_P![]#_A0 ?;8?[WZ'_"@ ^VP_WOT/\ A0 ?;8?[WZ'_  H /ML/][]#
M_A0 ?;8?[WZ'_"@ ^VP_WOT/^% !]MA_O?H?\* #[;#_ 'OT/^% !]MA_O?H
M?\* #[;#_>_0_P"% !]MA_O?H?\ "@ ^VP_WOT/^% !]MA_O?H?\* #[;#_>
M_0_X4 'VV'^]^A_PH /ML/\ >_0_X4 'VV'^]^A_PH /ML/][]#_ (4 'VV'
M^]^A_P * #[;#_>_0_X4 'VV'^]^A_PH /ML/][]#_A0 ?;8?[WZ'_"@ ^VP
M_P![]#_A0 ?;8?[WZ'_"@ ^VP_WOT/\ A0 ?;8?[WZ'_  H /ML/][]#_A0
M?;8?[WZ'_"@ ^VP_WOT/^% !]MA_O?H?\* #[;#_ 'OT/^% !]MA_O?H?\*
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H Y?6O^0GI0_Z>+@_^25P/ZBMX?!/T7_I2,)_'3]7_
M .DLZBL#<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M-_\ %T678.>?\S^]A_PDVK?\_MW_ .!$W_Q=%EV#GG_,_O8?\)-JW_/[=_\
M@1-_\719=@YY_P S^]GU]7,>V% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MN78A@ 4!Y !V_B3Q]I7@BQ@GU25V>=%\J-%#3RX4%FVE@ !D;F=PN3C<21E
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJ,;N!25 !*I=V^U3CLN3M'09.* /I"D 4 % !0 4 ,DD6%3)(0B("S,Q 55
MR22>  .23P!0!S5CXVT/46"VM];R%Y?(4B08:4@L(U8X5F(!*A2=W;- '44
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M#F1_NL0*8%WX:6$-IJ5P=$U%+S2MO_'O(95N%)QMD,;Q1J"'W*70 ,I&0#@
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M8EB$,9W#!(9BY"LP!..#W 4!@>D4@"@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * .)^(W_( NO\ MC_Z4154=SGK?PW\
MOS1\N5T'D!0 4 % !0 4 % !0 4 % 'VS7*>^% !0 4 % !0 4 % !0 4 %
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ML9<%?,!$.2R9W+G/(&0>A8'K5I$\$$<4K&21$56<]68* 6/^\03^-("Q0 4
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MA4'<< ?,!CY<@@CZ&^U?[$G_ 'S_ /7I##[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@#S;Q1X#CUV]&JV,USIE\  TL2$[L#:&PLD3*^WY2R
MN 5 RN>2P-/P;X1MO""RNIGNKJY.99W3!(!) "[FP,DLV68LW)/   &>%?"H
M\-7M]?O))=2:C)OYAV&/YY'89\U]^XN,G"_<SWX +_BO2;OQ!!'#97=UI;QO
MN:2%7RXVD;3LFA.,G/)(R.G>@#E?%O@&X\4:BNI+>SVOE*BPHML6,13YMRN+
MB,AB^6R%!' R=H- %SP[X3U31KY+N[U6^OXD#@P2I+L;<I4$[KJ1?E)##*'D
M=NM &1J_POCO+N>YT^ZNM/CO"3/"D19'W'<R_++%\A/(1@ZJ3P,8  .O@\(Z
M=!HI\/\ E3-;,IW,5'F&0D-YN>@<, 5XP  N".* .)T_X41P7$+7UW=7MI:M
MNBMFB*JO.=N3,X"D@;PB)N]10!ZY?7-P;>06:'[0481>8"$#D?*7(#G:#@G"
MG/2D!P%MX*V>')M#F+_:KS,L\X0L&N"ZR!N=K,H9$7D E03@$TP(O#'AC4K3
M4DU76G262UM%L[=;=),;%XWN9 OS$%LA1@LY/  ! /3OM7^Q)_WS_P#7I 'V
MK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'V
MK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'V
MK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'V
MK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'V
MK_8D_P"^?_KT 'VK_8D_[Y_^O0 ?:O\ 8D_[Y_\ KT 'VK_8D_[Y_P#KT 'V
MK_8D_P"^?_KT 'VK_8D_[Y_^O0 Y;C<0-D@R<9*\?CS0!8H * "@ H * "@
MH Y?6/\ D*Z7_P!=+K_TF>MX?!/TC_Z4C"?QT_67_I+.HK W"@ H * "@ H
M* *[7<2D@MR#@\'M^% #?ML/][]#_A0 ?;8?[WZ'_"@ ^VP_WOT/^% !]MA_
MO?H?\* #[;#_ 'OT/^% !]MA_O?H?\* #[;#_>_0_P"% !]MA_O?H?\ "@ ^
MVP_WOT/^% !]MA_O?H?\* #[;#_>_0_X4 'VV'^]^A_PH /ML/\ >_0_X4 '
MVV'^]^A_PH /ML/][]#_ (4 'VV'^]^A_P * #[;#_>_0_X4 'VV'^]^A_PH
M /ML/][]#_A0 ?;8?[WZ'_"@ ^VP_P![]#_A0 ?;8?[WZ'_"@ ^VP_WOT/\
MA0 ?;8?[WZ'_  H /ML/][]#_A0 ?;8?[WZ'_"@ ^VP_WOT/^% !]MA_O?H?
M\* #[;#_ 'OT/^% !]MA_O?H?\* #[;#_>_0_P"% !]MA_O?H?\ "@ ^VP_W
MOT/^% !]MA_O?H?\* #[;#_>_0_X4 'VV'^]^A_PH /ML/\ >_0_X4 'VV'^
M]^A_PH /ML/][]#_ (4 'VV'^]^A_P * #[;#_>_0_X4 'VV'^]^A_PH /ML
M/][]#_A0!QGQ"N8Y-!NE4Y)\GL?^?B+VJX[G/6_AOY?FCYCK<\@* "@ H *
M"@ H * "@ H ^S_ML/\ >_0_X5RGOA]MA_O?H?\ "@ ^VP_WOT/^% !]MA_O
M?H?\* #[;#_>_0_X4 'VV'^]^A_PH /ML/\ >_0_X4 'VV'^]^A_PH /ML/]
M[]#_ (4 'VV'^]^A_P * #[;#_>_0_X4 'VV'^]^A_PH /ML/][]#_A0 ?;8
M?[WZ'_"@ ^VP_P![]#_A0 ?;8?[WZ'_"@ ^VP_WOT/\ A0 ?;8?[WZ'_  H
M/ML/][]#_A0 ?;8?[WZ'_"@ ^VP_WOT/^% !]MA_O?H?\* #[;#_ 'OT/^%
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M;#PWX&L8=-B\A+B_MKF0;Y'W326,P=\R.Y&0B_*I"C'"C)R 9/Q2^'^F^$M
ML-7L?-&HO<0I/<--([2O)!+,TAW,0KB2,%2@3@G.3S0!K?&*R&N:_P"'[.=B
MHODAAD9< @3W"(Y &!G#GCI^% %OXNZ/:>"='M-#T-/L%GJEV3=N'D<OL6-0
M)'=G8ISO*;@N8^%Y;(!4^*'PXT?P)H]OK&B&6UOK:XA59?.=FE)#'=AFVK("
MN\>4%7:&!0CE0"A\083XM\0>&X[[,?\ :=C9>>$^4CSY&,JCT^\R^WO0!4US
MP-IFG>.[7P[8B6VTZ^AC\^))I"70B1WCWLS/LD,*E@6."25QA0 #IO"^A6GA
M?XD7&DZ:IBLGLVS"69U*O#%(4)<LS+O^8;RQ[9Q0!G:!KY^%K>)-!=BOV53=
M6&3U:79%$1G[S%9K5FQSB-SR 2 "4V-UX*^&;3P%HKO5GCEF=<AUBN&4*-W4
M;H%53TP96'7J :MG\&O#MWX>T^^-RUA<R1V\\E\9>':55;RPLDBQ)\S!8RH#
M@@9WG.0";X@1&#QCX8C,C3E/)7S7(+28F4>8Q4!2SXW$J ,G@ 4 9&O>&[7Q
M7\3)=.O]YM6MXWE1&*>8([:-E0LI!"EPI."#\O!!P0 6?">B6WA+XE3Z7I>Z
M&S-H2(R[-@/#%+M+,2S*)/F7<21QR<9H ^H:0!0 4 % 'GWQ-NIK;1P(IWLH
MIKNTAN;F,E6@MI;A$FD#CE,*V"WH<=Z /$=2\(Z?:KKH2\NBVCI!=VNZ\D*3
M020+(8GP^7#RI)"'1E8,Z88' I@?4.EM&]G T*F.,PQE$))*J47:I)))*C )
M))..32 O4 % %>\NX[""2ZG.V*"-Y'/HB*68_@ 30!YA>Q31>&KW5K@^5?ZM
M"KS.3S##,0D4"$'Y5MX),?*?]<9)OO.30!O^(K.#3Y-)DME2!K:^B@B"@+B&
M6&6.2$ 8^0KAMO(W1JV,J" #FC;WVB1V:26I#:;=W,BS!X2M[)=)<PP11!)#
M.#-+=1S7!FB18S"SEG"AZ .@\.:S;VPCM"D[&ZN)XS?,J""ZO$\QK@)^\,RK
MNBE2$R1)&4B$<3LH3< =[0 4 % !0 4 % !0 4 % !0 4 5[JT@OHS#<QI/&
MW5)$5U/U5@0?RH CLM-M=,4QV<,5LA.2L,:1J3ZD( ,T 07>B:??R":ZM;>>
M5<8>6&-V&.F&921CMS0!:N;*WO(3;7$4<T#  Q2(KQD*05!1@5.T@$<<$ CD
M"@!!8VZP"T$48MPNT1!%\L+_ '=F-NWVQB@"O8Z+8:8Q>RMK>V9NIAACC)^I
M103^- $E]I5GJ8"WL$-R%Z":-) /H'4X_"@"S!;Q6L:PP(L4:#"HBA54>@50
M !]!0!0;0].:?[6;6W-QG/G&&/S,^N_;NS[YS0!J$9XH RM)T2ST* VUC'Y4
M3NTC L[EG?&YF:1F9B< <D\ #I0!E:;X(T72+K[?9VJ17'.'!<A=P(.Q&8HF
M02/D5>"1TH ZJ@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M .+HLNP<\_YG][#_ (2;5O\ G]N__ B;_P"+HLNP<\_YG][#_A)M6_Y_;O\
M\")O_BZ++L'//^9_>SZG\/2O-IEG)(Q=WM8&9F)+,QB0EF)Y))Y)/)/)KG>[
M/8AK&+?9?D:](L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H XGXC?\ ( NO^V/_ *4154=SGK?PW\OS1\N5T'D!0 4
M% !0 4 % !0 4 % 'VS7*>^% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M>Q - '/VWAV]DGMY=5O%O([ EX$2W\@M+Y;1":X;SI1*ZH[[1&D";FWE"0N
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M79V=FKIV::?FK'+.$J;<*D7&2W4DTU?75/7;4DK4@* "@ H * "@ H * "@
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M ,D'U3#_ //FE_X+A_D>^5_09^3!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!R^L?\A72_P#KI=?^DSUO
M#X)^D?\ TI&$_CI^LO\ TEG45@;A0 4 % !0 4 % !0 4 % !0!B>)O^03>_
M]>EQ_P"B7IK=&<_@EZ/\CY!KI/$"@ H * "@ H * "@ H * /K[PS_R";+_K
MTM__ $2E<SW9[</@CZ+\C;I&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!Q/Q&_P"0!=?]L?\ THBJH[G/6_AOY?FC
MY<KH/("@ H * "@ H * "@ H * /MFN4]\* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * .,\&^.K'QNEQ)I\<\0LY1$_GK&I+$$Y7
M9))D<=]I]J .SH YSQ+XKT[PE MSJ<GEB5Q'$B@L\CG^%%'7U))"J.684 ='
M0 4 % &78Z'I^F2//96MO;2S9,CPPQQNY)W'>R*"V3R=Q.3SUH H:)XKT[Q%
M/=6VG2>>=/=(YG (3>^_Y48_?V["&(&W. &/. #HZ "@ H * "@ H * "@""
MXM8;M/+N$25,YVNH9<CH<,",B@"A_8&F_P#/I;?]^(O_ (F@#550@"J  !@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MB[U7R\!V% '&> O$^N/X<U^]BFN+Z]M)3]G\YY)VC&#N**Y?A%S)L P2O(-
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M^LA0 4 % !0 4 % !0 4 % 'T=7]+'XR% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '+ZO_P A;3/]Z[_]
M)S6\?@G_ -N_F83^.'_;WY'45@;A0 4 % !0 4 % !0 4 % !0!B>)O^03>_
M]>EQ_P"B7IK=&<_@EZ/\CY!KI/$"@ H * "@ H * "@ H * /K[PS_R";+_K
MTM__ $2E<SW9[</@CZ+\C;I&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!Q/Q&_P"0!=?]L?\ THBJH[G/6_AOY?FC
MY<KH/("@ H * "@ H * "@ H * /MFN4]\* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#Q#XS>$-5\5_V;_9,'VC[+-(\W[R*/8K>5@_O9$W9VMP
MN3QR.13 ZKXG^"&\=:.;*!ECNH)!/ SYVEU5E*,1R%=6(S@X;:V"!BD!P>DQ
M?$V_EM[&\:VTNV@*K->(+::69%X)*,]P#(0."(H!DY8]:8'2^,M,\2G41<6D
M%MK^C2)A]+N1:Q&-\ %DFEBR02-X+NQ!++LP$(0'/_#OX=WVEZ_<>([RUBT:
M&2,QP:?#,)MFX1ABSI\A7Y"V >9&R%154%@-^'/@GQ%H.EZK;$_V3?7<XDM)
MB;>X7Y03EE!F4*WW&W+O56+*-P% ',Z]X+\2^)[(:=?:'8+J)9 ^M)<6T98*
MX+.T,*K(2RC:V5( +;8@<8 .C\??#35+SPYI>F:05N[G1RFX.RQF3"8)0R,$
M 5P-J,P^0X!RN" 8_BCP?XM\3/I>N:A96MW=V3,+C3?-C2)D$V]2&>5XR'3"
MR R-RB_*ZDK0!;T[PCXC/C&Q\27.G06=G&CQ&"VG@(M8VAFA4/S'YC;I3(QA
M1@5X&",  Z?PCX3U32_&6KZS=0^78WJ,()?,B;>3)$P^17,B\*Q^=%Z>I% !
MX1\)ZII?C+5]9NH?+L;U&$$OF1-O)DB8?(KF1>%8_.B]/4B@#G? GA3Q9X-U
M^YB6""32+^Z,LUSYD9;8IE,?EIYJR*Q\P;PT3#C"MW(!]$T@"@ H * "@ H
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MK_8D_P"^?_KT 'VK_8D_[Y_^O0!GZO<;K&X&R09@E&2O'W&Z\UYF8?[GB?\
MKQ6_]-R.W"?[Q1_Z^T__ $M'A=?SX?K(4 % !0 4 % !0 4 % !0!]"?:O\
M8D_[Y_\ KU_2Q^,A]J_V)/\ OG_Z] !]J_V)/^^?_KT 'VK_ &)/^^?_ *]
M!]J_V)/^^?\ Z] !]J_V)/\ OG_Z] !]J_V)/^^?_KT 'VK_ &)/^^?_ *]
M!]J_V)/^^?\ Z] !]J_V)/\ OG_Z] !]J_V)/^^?_KT 'VK_ &)/^^?_ *]
M!]J_V)/^^?\ Z] !]J_V)/\ OG_Z] !]J_V)/^^?_KT 'VK_ &)/^^?_ *]
M!]J_V)/^^?\ Z] !]J_V)/\ OG_Z] !]J_V)/^^?_KT 'VK_ &)/^^?_ *]
M!]J_V)/^^?\ Z] !]J_V)/\ OG_Z] !]J_V)/^^?_KT 'VK_ &)/^^?_ *]
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MVP_WOT/^%<I[X?;8?[WZ'_"@ ^VP_P![]#_A0 ?;8?[WZ'_"@ ^VP_WOT/\
MA0 ?;8?[WZ'_  H /ML/][]#_A0 ?;8?[WZ'_"@ ^VP_WOT/^% !]MA_O?H?
M\* #[;#_ 'OT/^% !]MA_O?H?\* #[;#_>_0_P"% !]MA_O?H?\ "@ ^VP_W
MOT/^% !]MA_O?H?\* #[;#_>_0_X4 'VV'^]^A_PH /ML/\ >_0_X4 'VV'^
M]^A_PH /ML/][]#_ (4 'VV'^]^A_P * #[;#_>_0_X4 'VV'^]^A_PH >ES
M'(=JG)/L?\* )Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@".::.V0RS,L<:#+,Y"J!ZDG  ^M $E !0 4 9SZQ8QW:Z<]Q M[(NY
M+8RQB=E 9BRQ%O,8;58Y"D85CT!H T: "@ H * "@ H * "@ H * "@ H *
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M7Y&W2- H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?O2-@^?-,#D[ZX\!06\DEG-J=W<*C&& 2:O&9I #LCWO%M3>V%W'(7.<'&"
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M_3<CMPG^\4?^OM/_ -+1X%7\^'ZR% !0 4 % !0 4 % !0 4 ?1U?TL?C(4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 <MJW_(8TS_ +>__1*UO'X)_P#;OYF$OCA_V]^1U-8&X4 % !0
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0\98'OEFS/!&SLLC%$+.GW6)499?]ECR/8T@+% !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * ,3Q-_P @F]_Z]+C_ -$O36Z,Y_!+T?Y'R#72>(%
M!0!Z?;>+UTKP[;VMA<&+489V9E",?D9IB<ED,3@AE.TEN<'&5XSM=Z['6JG+
M32B[23_S^1P6J:O=ZU-]IOI6FDP "<  #LJJ JCN0J@%B6.6))M*VQS2DY.\
MG=F;3)"@ H * "@#Z^\,_P#()LO^O2W_ /1*5S/=GMP^"/HOR-ND:!0 4 %
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M;#_>_0_X4 'VV'^]^A_PH /ML/\ >_0_X4 'VV'^]^A_PH /ML/][]#_ (4
M'VV'^]^A_P * #[;#_>_0_X4 'VV'^]^A_PH /ML/][]#_A0 ?;8?[WZ'_"@
M#C/B%<QR:#=*IR3Y/8_\_$7M5QW.>M_#?R_-'S'6YY 4 % &_+XCN9=+CT4K
M&+>*0R*P#>9N)=L$[]N,N>B ].>N9MK<TYWRJGI9._F8%49A0 4 % !0 4 ?
M9_VV'^]^A_PKE/?#[;#_ 'OT/^% !]MA_O?H?\* #[;#_>_0_P"% !]MA_O?
MH?\ "@ ^VP_WOT/^% !]MA_O?H?\* #[;#_>_0_X4 'VV'^]^A_PH /ML/\
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M_1KU^X9#_P BZA_W$_\ 3U0_,LT_WRK_ -N?^FXG1U],>,% !0 4 % !0 4
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MEB5)T)<RB[/1K7YI7]5=%&N$ZCZ.K^EC\9"@ H * "@ H * "@ H * "@ H
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M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .)^(W_(
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M8YJ<8ROS;V=E^IQ56<Y]LURGOA0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M>&?^039?]>EO_P"B4KF>[/;A\$?1?D;=(T"@ H * "@ H * "@ H * "@ H
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M=OO."H(9O]IAR?<T@+= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M7$X6I*M#&85P56*<6IWY91:?\NMU?YZ:KEUGO=:M+^[A\Z)_L%LA18QPY&W
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MKE/?"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H XGX@S6L>D-'J$'VFTGFMX9\N
MT2PQR3(IN6D569!;G$FX#@J.0.: .7U'X>:)JOEM_:-TBM#'!<[+U3]NAC.Z
M-;ESDR$ E0ZE3Y9*^A# ]:A1(HU2( 1JH"@= H&% ]L8Q[4@)* "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /G&OYI/V8* "@ H * "@ H * "@
M H ]K\(_\@J#_MI_Z->OW#(?^1=0_P"XG_IZH?F6:?[Y5_[<_P#3<3HZ^F/&
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * ,[6?^/"Y_ZX2_^BVKS,P_W/$_]>*W_IN1VX3_ 'BC_P!?:?\ Z6CP*OY\
M/UD* "@ H * "@ H * "@ H ^CJ_I8_&0H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y?4_P#D-:=_USO?
M_08*WC\$_6/ZF$OXD/27Z'45@;A0 4 % !0 4 % !0 4 % !0!B>)O\ D$WO
M_7I<?^B7IK=&<_@EZ/\ (^0:Z3Q H * "@ H * "@ H * "@#Z^\,_\ ()LO
M^O2W_P#1*5S/=GMP^"/HOR-ND:!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % '$_$;_D 77_ &Q_]*(JJ.YSUOX;^7YH
M^7*Z#R H * "@ H * "@ H * "@#[9KE/?"@ H * "@ H * "@ H * "@ H
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M,[4H [/0I[F\@-Y=907+F2&$@ Q0$ 1*V &+NH\V0.24>0QCA!0!M4 % !0
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M *] !]J_V)/^^?\ Z] !]J_V)/\ OG_Z] #EN-Q V2#)QDKQ^/- %B@ H *
M"@ H * "@#E]3_Y#6G#_ *97I_\ '8!_45O'X)^L?U,)?Q(>DOT.HK W"@ H
M * "@ H * *[7<2D@MR#@\'M^% #?ML/][]#_A0 ?;8?[WZ'_"@ ^VP_WOT/
M^% &+XDNXFTJ] ;DVEP!P?\ GD_M36Z,Y_!+T?Y'R572>(% !0 4 % !0 4
M% !0 4 ?6OAN[B72K(%N1:6X/![1)[5S/=GMP^"/HOR-K[;#_>_0_P"%(T#[
M;#_>_0_X4 'VV'^]^A_PH /ML/\ >_0_X4 'VV'^]^A_PH /ML/][]#_ (4
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MVV'^]^A_PH /ML/][]#_ (4 'VV'^]^A_P * 'I<QR':IR3['_"@">@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H ^>/^$D_X1RZ\065Q9:C,U_=3-"]O:/)
M$0]ND8)?('W@>@/'Y4P,C_A,5_X0S_A'/[/U7[9_9_V7/V*3RO,V;?O9SMSW
MVY]J /HK0T,>GVJL"K+;P@@C!!$:@@@]".XI :E !0!S'B#1;S59K6:TN(8!
M9N\ICN+9[B.23 $3D1W5J0T/SE 6==[J^T/&A !PEIX?UN[M->MIWA,ES=N\
M&+66W$LZVMD8Y4>2YF46[-&(2NUR)%D;S_\ EFK Z&XOY?$]Q80P6UW;"WN5
MNKMKBWEA6,11R;85>5%69WF=!FW:1-BNQ<# 9 7=3T*VO;]88;6*(3XGOKE8
M%5IHT8>7;-,%!D,LBJTJEF_<1E) !,F0#F-)TZ2.]M<6TT>J1W]U)?7;0R!)
M;9EN=N;DKY<T;A[800*[M#M4%(S"Q !ZW0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2H/W*8A?"&I7]IJ^F0/?3W\6K6+7$Z32&012;)''EY^X R!,#ONZC& 9[Q2
M* "@ H * "@ H * ,[6?^/"Y_P"N$O\ Z+:O,S#_ '/$_P#7BM_Z;D=N$_WB
MC_U]I_\ I:/ J_GP_60H * "@ H * "@ H * "@#Z.K^EC\9"@ H * "@ H
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M<D [+09[RZL()]26..ZE0/(D0943=R%PS.V54@-\Q^;..*0&O0 4 % !0 4
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M71K!K6*._A@N$M(U :>-'"A% +#>IV\+DD8I#/$[O4+I[#4O&< ,;/LLM..
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MT5GBW;_+8C)3=M3)7H3M'.: +5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M S=&\&Z/X?F:YTZV2"9P5+[I'(!.2%\QVV X&0N : .FH * "@ H * "@ H
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M\(#LO-8C?B87$>X'KP]R#]<-G/N1ZTP. TE6?PSX@>'/EM/;%,'C N S8_X
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M9[6!+BWGBC67RKF/RW:)\;9% 9P4.Y2#D9#*0"#FD,Z^@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H ^<:_FD_9@H * "@ H * "@ H * "@#VOPC_P @
MJ#_MI_Z->OW#(?\ D74/^XG_ *>J'YEFG^^5?^W/_3<3HZ^F/&"@ H * "@
MH * "@"K?7L.FV\MY<MY<%M&\LK8+;8XU+NVU06.%!.%!)Z $\523DU&.[:2
M]63)J*<I:))M^BW/./\ A='A#_G_ /\ R6O/_D>NSZI6_D_\FC_F<7URA_/_
M .2R_P @_P"%T>$/^?\ _P#):\_^1Z/JE;^3_P FC_F'URA_/_Y++_(/^%T>
M$/\ G_\ _):\_P#D>CZI6_D_\FC_ )A]<H?S_P#DLO\ (/\ A='A#_G_ /\
MR6O/_D>CZI6_D_\ )H_YA]<H?S_^2R_R#_A='A#_ )__ /R6O/\ Y'H^J5OY
M/_)H_P"8?7*'\_\ Y++_ "#_ (71X0_Y_P#_ ,EKS_Y'H^J5OY/_ ":/^8?7
M*'\__DLO\@_X71X0_P"?_P#\EKS_ .1Z/JE;^3_R:/\ F'URA_/_ .2R_P @
M_P"%T>$/^?\ _P#):\_^1Z/JE;^3_P FC_F'URA_/_Y++_(/^%T>$/\ G_\
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M./#W_04T[_P,M_\ XY1[&I_)/_P%_P"0>VI?\_(?^!1_S.HK W"@ H * "@
MH * "@ H XGXC?\ ( NO^V/_ *4154=SGK?PW\OS1\N5T'D!0 4 % !0 4 %
M !0 4 % 'VS7*>^% !0 4 % !0 4 % !0!E:[!>W-C-#ICI#=R(5BD<L%0MP
M6RJLP*KDJ0I^;':@#Q31/ 'C#PZ'73KVPA\UMSMM\QV/N\ED[X[[=VT$DXR2
M2Q'8>(/!.H^)M'MH+ZZ0:M:LS^<@(B<LQ^4A$C*C:(R&$>0R?=.<T#*>A> =
M4DU2+6?$MVE[-: "%(\[05SM8GRX@-I._ 3+/\S,><@'90VFN+K4MQ+<0G1V
M0"*W 'FJ^R,$D^2#CS!(W^N;AAQV" \YO?AMK-A<W1\/7L=K9Z@3YL4A<,JL
M22JD1R?=W,%8&-]IVENI+ ZJV^'5K%X=;P\[DF0^8TP'_+?((<+G[HVJNW.2
M@P2"<T@..@^&&MW[6UGK=_'/I=B1Y<4>\N57@)S&@'R_(&9Y"BDA1CBF![3J
M4MQ;VLKV4?GW"QMY4654,^/E!+LJA<XSDC@''.!2 \O/@&YE\+3:<Q']J7K"
M[G9F&&N-ZR&-F&00%&S.2GF$N#@YI@6/">@:JVLMK6K0)9>791VD<2RI(7*[
M TA,>5"G:2%/(W*.=N2 >K4@"@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ #[5_L2?]\__7H /M7^Q)_WS_\ 7H S]7N-UC<#9(,P2C)7C[C=>:\S,/\
M<\3_ ->*W_IN1VX3_>*/_7VG_P"EH\+K^?#]9"@ H * "@ H * "@ H * /H
M3[5_L2?]\_\ UZ_I8_&0^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
MUZ #[5_L2?\ ?/\ ]>@ ^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M1_Y!4'_;3_T:]?N&0_\ (NH?]Q/_ $]4/S+-/]\J_P#;G_IN)T=?3'C!0 4
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M %Z6_P#Z)2N9[L]N'P1]%^1MTC0* "@ H * "@ H * .7\<?\B]JG_8.O/\
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M+H\7_P#/_P#^2UG_ /(]'U2C_)_Y-+_,/KE?^?\ \EC_ )!_PNCQ?_S_ /\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 ?.-?S2?LP4 % !0 4 % !0 4 % !0![7X1_Y!4'_ &T_]&O7
M[AD/_(NH?]Q/_3U0_,LT_P!\J_\ ;G_IN)T=?3'C!0 4 % !0 4 % !0!R_C
MC_D7M4_[!UY_Z3R5O1_B0_QQ_-&%;^%4_P $O_26?G%7UY\4% !0 4 % !0
M4 % !0 4 ?H[X'_Y%[2_^P=9_P#I/'7R%;^)/_'+\V?:T?X5/_!'_P!)1U%8
M&X4 % !0 4 % !0 4 9VL_\ 'A<_]<)?_1;5YF8?[GB?^O%;_P!-R.W"?[Q1
M_P"OM/\ ]+1X%7\^'ZR% !0 4 % !0 4 % !0 4 ?1U?TL?C(4 % !0 4 %
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M0 4 <OXX_P"1>U3_ +!UY_Z3R5O1_B0_QQ_-&%;^%4_P2_\ 26?G%7UY\4%
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M*WH_Q(?XX_FC"M_"J?X)?^DL_.*OKSXH* "@ H * "@ H * "@ H _1WP/\
M\B]I?_8.L_\ TGCKY"M_$G_CE^;/M:/\*G_@C_Z2CJ*P-PH * "@ H * "@
MH SM9_X\+G_KA+_Z+:O,S#_<\3_UXK?^FY';A/\ >*/_ %]I_P#I:/ J_GP_
M60H * "@ H * "@ H * "@#Z.K^EC\9"@ H * "@ H * "@ H \N^-'_ "*%
M_P#]NW_I9;UW83^-#_M[_P!)9P8S^!/_ +=_]*1\%U]0?)!0 4 % !0 4 %
M!0 4 % 'ZBU\2?>!0 4 % !0 4 % !0 4 % !0 4 <O?_P#(>L/^O34/_0[&
MMX_PY_XH?E(PE_$A_AG^<#J*P-PH * "@ H * "@ H * "@ H Q/$W_()O?^
MO2X_]$O36Z,Y_!+T?Y'R#72>(% !0 4 % !0 4 % !0 4 ?7WAG_ )!-E_UZ
M6_\ Z)2N9[L]N'P1]%^1MTC0* "@ H * "@ H * .7\<?\B]JG_8.O/_ $GD
MK>C_ !(?XX_FC"M_"J?X)?\ I+/SBKZ\^*"@ H * "@ H * "@ H * /U%KX
MD^\"@ H * "@ H * "@ H XGXC?\@"Z_[8_^E$55'<YZW\-_+\T?+E=!Y 4
M% !0 4 % !0 4 % !0!]LURGOA0 4 % !0 4 % !0 4 >#?M$?\ (O6__81B
M_P#2>ZKU,#_$?^!_G$\G,/X4?\:_])D?&=?1'S(4 % !0 4 % !0 4 % '4^
M!_\ D8=+_P"PC9_^E$=85OX<_P#!+\F=%'^+3_QQ_P#2D?HY7R!]H% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0U+5+;2(A/
M=OY:,P10%9W=VSM2.-%:21S@X1%9C@X'!H JZ=X@L=365H)"OV;!F2:.6WDB
M!!8-)%<)%(BLH)5F0*P5B"<' !7TWQ5INJRK;VTC[Y5+Q>9!/"LR+C<T#S11
MI.H!!)A9P%(8\'- $MIXDL+VY-G!(S2[I%4F*58W:(XE6*9HQ#,T9!#K%(Y4
MJVX#:V #3M[V&Z:5(6W&W?RY, X#[5?:&("L0KKNVDA2=IPP( !9H * "@ H
M * "@ H * "@ H * "@#YQK^:3]F"@ H * "@ H * "@ H * /:_"/\ R"H/
M^VG_ *->OW#(?^1=0_[B?^GJA^99I_OE7_MS_P!-Q.CKZ8\8* "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MM_W_ +;_ ./4?6Z/\_\ Y++_ "#ZG7_D_P#)H_YA_P *=\6_] ]O^_\ ;?\
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MC^P<Q_Y\?^5*/_RP/[4P?_/W_P DJ?\ R(?\(OJ?_/!OS3_XJC^P<Q_Y\?\
ME2C_ /+ _M3!_P#/W_R2I_\ (A_PB^I_\\&_-/\ XJC^P<Q_Y\?^5*/_ ,L#
M^U,'_P _?_)*G_R(?\(OJ?\ SP;\T_\ BJ/[!S'_ )\?^5*/_P L#^U,'_S]
M_P#)*G_R(?\ "+ZG_P \&_-/_BJ/[!S'_GQ_Y4H__+ _M3!_\_?_ "2I_P#(
MA_PB^I_\\&_-/_BJ/[!S'_GQ_P"5*/\ \L#^U,'_ ,_?_)*G_P B'_"+ZG_S
MP;\T_P#BJ/[!S'_GQ_Y4H_\ RP/[4P?_ #]_\DJ?_(A_PB^I_P#/!OS3_P"*
MH_L',?\ GQ_Y4H__ "P/[4P?_/W_ ,DJ?_(A_P (OJ?_ #P;\T_^*H_L',?^
M?'_E2C_\L#^U,'_S]_\ )*G_ ,B>R_:O]B3_ +Y_^O7[@?F8?:O]B3_OG_Z]
M !]J_P!B3_OG_P"O0 ?:O]B3_OG_ .O0 ?:O]B3_ +Y_^O0 ?:O]B3_OG_Z]
M !]J_P!B3_OG_P"O0 ?:O]B3_OG_ .O0 ?:O]B3_ +Y_^O0!PGQ,TZ[\1>';
MO3=.@DEN9_(V(=J9V7,,C?,[*HPB,>2,XP.2!75AYQIU8SF[)7N_5-=#DQ,)
M5*4H05Y.UEHMI)]=#Y,_X4[XM_Z![?\ ?^V_^/5[_P!;H_S_ /DLO\CYWZG7
M_D_\FC_F'_"G?%O_ $#V_P"_]M_\>H^MT?Y__)9?Y!]3K_R?^31_S#_A3OBW
M_H'M_P!_[;_X]1];H_S_ /DLO\@^IU_Y/_)H_P"8?\*=\6_] ]O^_P#;?_'J
M/K='^?\ \EE_D'U.O_)_Y-'_ ##_ (4[XM_Z![?]_P"V_P#CU'UNC_/_ .2R
M_P @^IU_Y/\ R:/^8?\ "G?%O_0/;_O_ &W_ ,>H^MT?Y_\ R67^0?4Z_P#)
M_P"31_S#_A3OBW_H'M_W_MO_ (]1];H_S_\ DLO\@^IU_P"3_P FC_F'_"G?
M%O\ T#V_[_VW_P >H^MT?Y__ "67^0?4Z_\ )_Y-'_,/^%.^+?\ H'M_W_MO
M_CU'UNC_ #_^2R_R#ZG7_D_\FC_F'_"G?%O_ $#V_P"_]M_\>H^MT?Y__)9?
MY!]3K_R?^31_S/N[[5_L2?\ ?/\ ]>OECZT/M7^Q)_WS_P#7H /M7^Q)_P!\
M_P#UZ #[5_L2?]\__7H <MQN(&R09.,E>/QYH L4 % !0 4 % !0 4 <O??\
MAZP_Z\]0/_D33Q_4UNOX<O\ %#\IF$OXD/\ #/\ .!U%8&X4 % !0 4 % !0
M!7:XVDC9(<'&0O'X<T -^U?[$G_?/_UZ #[5_L2?]\__ %Z #[5_L2?]\_\
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M_P!>@ ^U?[$G_?/_ ->@ ^U?[$G_ 'S_ /7H YCQG;3ZOI$]G:12/-+Y6U2
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M1_G_ /)9?Y!]3K_R?^31_P P_P"%.^+?^@>W_?\ MO\ X]1];H_S_P#DLO\
M(/J=?^3_ ,FC_F'_  IWQ;_T#V_[_P!M_P#'J/K='^?_ ,EE_D'U.O\ R?\
MDT?\P_X4[XM_Z![?]_[;_P"/4?6Z/\__ )++_(/J=?\ D_\ )H_YA_PIWQ;_
M - ]O^_]M_\ 'J/K='^?_P EE_D'U.O_ "?^31_S-[PM\*O%&F:Q87MS8LD%
MM>6TTC>=;MM2.9'<X68L<*"< $GH 3653$TI0E&,M7&26DMVGY&U+"UHU(2E
M&R4HMZQV35^I]H?:O]B3_OG_ .O7S9].'VK_ &)/^^?_ *] !]J_V)/^^?\
MZ] !]J_V)/\ OG_Z] #TGWG;L=<]RN!_.@">@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@#G=>\.KKKV\AN+BU:RD,T9A%NP,A4HKLES;W"%
MHP6\M@H*%BP.<$ #H-!?RYK>_N[G4H+B-HGBN4LU3:P(;'V6TMF^925.YF&.
M@!YH K6'A6.SGAGGN;N]^QAA;)<O$R0%E\LLOEPQ/))Y99!).TT@5F ;+$D
MVGTZ.2\6^<LSQ1-%&A(V)O8%W4;<^8X55+%CA%VJ%W2;P#&M?"=O:7"3++.T
M,$TMQ#:LT9@AFF$@D=,1B4_ZV4HLDKQQF1O+1<)M .HH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H Y>^_Y#]A_UY:C_ .C=.K=?PY?XH?E,PE_%A_AG
M^<#J*P-PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MRLKKPR.CA71UXRKJK $'&"* -.@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MQEPVXG$>#BD,]6\"W,MWH%A/<.\LLEM&SN[%G9B.2S,26)[DDF@#JZ "@ H
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M0!YCK?B"X_LJ]U/3Y[U3:W$<"3R7Q@2.2,QJUO!8Q[DF3#')F17=29&;Y#3
MWU>ZUG6];$UW>Q1V=C;301074\,<<LEDCEU2-P/OY;:048L2ZL:0'/Z5K&HW
M6GRZQJ%Y<7L,5K;-(+._:UN;'"D,S6Q M[AIL;\R[RW3;DBF!U^GWW_"2ZAJ
MK7U]=VEO96UJ]J$G>U*12P>:;J1(3&)7S@G<&C&XILP5 0'&?#G5;OQ;>7K:
M]J%W;^5:0O'&EU-;*!Y04W(5'0#"A)6QB-VEWNK BF!/X.U+4O%&KZ?;ZE=W
MGD-I<LI6*XGMA<>7>7,4<L@ADC;<R!<L"&?8N21U +'BKQ!.++4]3TZ>]4VE
M[Y$=Q)?&!(Y(W13;P6*%EG3:QRTZ!W!,C-E#0!TH:;Q5J 329KR*TT\>;?3)
M>7FVXN=NX64*^>5"!C^^* %1\B%?E+(#F_[7O(O"L'B5+^Z?6)+H 0F>1HI9
M#<^4UI]DW>2JB(;P!&) >0V& I@8FEZA=IXAN=,BD:&VO-<U,R8N);3S7CVF
M*(W,*/(@))^5 #(2%R." #VKP.URDE_;S7<=Y%#.HB19Y;I[8E3O@DN)8XVD
MVX4KDLZY8.<\E <WXRFM=0T?55T>>VM([5Y?[1B^S>5+/, &D7S6VX><#8DQ
M@E\QQ\KD<@ H^!+RW@U'59;U1;+-8:9<)'(>5LUL\%1N"DB'(CE..7'//- '
M)_#VSN]2N=-TR>YO+:U719KHPP7,T <MJ5RD3_NG7GRY(V![JB*<I\M,";1=
M3U*#3-"U?[7>7%UJ%^\,RR7$SQR1*\L2Q>2SF+D1 [P@D+,Q+$XP 17NI7$G
MA6WUXZE>+J=Q>;)%2[E1,F9E:W%NKB.,1QJ'P$#X)R2C@4"/IRD,* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M 4 % !0 4 % !0 4 5+S3[;455+N&*X5'$BK*BR!77.UU# @.N3AAR,G!YH
MAU#1['50HO[>"Z"9VB:*.7;GKC>K8SWQUH 6'2+&VD2>&W@CEBC\E'2)%=(L
MEO+5@H*Q[B6V A<DG&30!"V@::\/V5K2V: N9/*,$1C\P\E]FW;O)Y+8W'UH
M YC6/A_8ZI=Z=,B006FEM<,;06T9AF\]8U(*@JB;3&#S&^[/08S0!TR^'],C
MB2W6TM5ABD$R1B"((DJ@A9%0+M60 D!P P!.#0!)?Z)I^J,KWUM;W3(,*TT,
M<A49SA2ZL0,C/'?F@"DOA+1$)9=/L03U(M8 3WY.SGGF@!S>%=&<@M861*#"
MDVT)*C).!\G RS'CN2>YH NV^C6%I(DT%M!%)#'Y,;I%&K)%DMY2,J@K'N).
MP$+DDXR: )K;3[:RC:"WABAB<LS)&BHC,_WR54 $M_$2,MWS0!B_\(7H'_0-
MT_\ \!+?_P"-T :%SH6G7DPNKBUMIKA<8EDAC>0;>F'92PQVYX[4 /?1;"2*
M6V>VMVAN9#+/&88RDLI*L9)4*[9)"RJQ=@6)523D"@"'4M%BO4F:$1V]W<0F
M'[5Y$,D@3J%82(PDC!Y,;Y4\]#R #E-%\ QZ;J<>K2M;>9;PM%%%9V:6<0+C
M$DKJ)92\C#(SN50#@#B@#T.@ H * &R1K*I1P&5@596 (((P00>""."#P10!
MB-X7T=P@:QLR(1MC!MH3Y:[B^U/D^4;B6PN!N)/4T 6K?0]/M&B>WM;>)K96
M6%DAC4Q*Y)=8RJ@HKEF+!<!BQ)SDT 03>&M)N0PFLK20/(\S![>)MTLF/,D;
M*',CX&]S\S8&XG% $T^AZ==0I:SVMO+!%_JXGAC:-/\ <1E*K^ % '+7_P /
M["_U.TOV2 6EC#+#]A-M&T+^9N(;&0B[6;<!Y39(SD'F@#J4T+3HEB1+6V5;
M9_,@40Q@1/\ WX@%Q&W ^9<'CK0 7NA:=J,@GO+6VN)4 "O+#'(Z@'( 9U)
M!Y !Z\]: *4?A'1(L[-/L4SUVVL SCITC[4 2R>&-(F*M)8V;F, (6MX24 Y
M 4E/E /( QB@"W)H]C-(\TEO \DT8BD=HHRTD8QB-V*Y9!@81B5X''% !I^C
MV.D@K86\%J'QN$$4<0;'3.Q5SCMGI0 FH:+8:J5-];6]T4!"F:&.7:#U WJV
M >^.M !<:-87<*VL]M!+!'C9$\4;1ICIM1E*KCM@#% "KHU@@B5;:!5M6+0
M11@0L>K1 +^[8]RF#0 CZ-82+-&]M;LEVP:=3#&1,PQAI05Q(1@8+Y(P* ./
M\0^!6UV2<^;:)'<1K$ADTZ&6XME";&%M<"2)DW@D@R+*8R?W948  .STK38M
M'LX;"WSY5K$D29ZD(H4%L8RQQDG R2: +] !0 4 5)M/M;B:.YFABDGM]WE2
MO&K21[AAO+<@LFX<-M(R.M %6]T'3=2D$UY:6UQ*H #RP1R. #D ,ZD@ @$8
M/44 31Z391&8I;P*;H!9R(D!F55*A9<+^\ 5BH#Y 4D#@F@"M/X=TNZCC@GL
M[66* ;8D>")DC7IM160A!CC"@"@#F9/A]87&M'5[A()[?[&MHEE);1M&A617
M$JEB5! !0*(A@,?FZ@@'6QZ/8Q/%(EO CVH98&6*,-"K@AQ$0N8PP)#!,!@2
M#G- $%WX>TN_E-Q=6=K/,0 9)8(G<@ J 79"Q !( ST)'2@"NGA+18AA-/LE
M'M:P#^24 *_A/19"6>PLF9AAB;6 DCC@DIR.!U]!Z"@#032;*(S,EO"INP%N
M"(D!F4*5 E(7]X K%0'R I('!- #CIEHUM]A,$)M-H3R#&GD[!T7R\;-H[+M
MQ[4 9EOX3T6TD6>#3[**6-@R.EK KJPY#*RH"I!Y!!!% %H:!IBSFZ%I;"X8
MDM*((O,)888E]NXY'!R>1UH D71K"-(85MK=8[5M\""&,+"^2=\2A<1MDD[D
M .2>>: ,S6?#<5_!)%:"WMI)Y4EG9[2&=+C;U6XC<+Y@8<%PZ2K_  R#G(!G
M>&/!<7AV[N=0+1-/>"--EO;K:P11Q]$BA5Y"-Q^9V9V+,,\<Y .VH * "@"M
M>65OJ,36UW%'<0OC='*BR(V"&&Y&!4X8!AD<$ CD4 9<WA;1[AVEEL;.21^&
M9K:%F88 Y)0D\ #D] !VH O1Z390O))';PH\Z+'*RQ(&D15V*DA"Y=50!55L
M@+\H&.* *+>%M'?9NL;,^4 L>;:$[ #D!?D^4 \@# !H L7N@Z;J3B2\M;:Y
M=!A6FACD90#D %U) !YP.,\T <O%\/[ ZQ>:O>)!>)>K;K';RVT;+;^1$L64
M9RX.X*#PB;1@<XS0!UZ:79Q3+<I!"L\<?DI((T$B1 DB)7"[ECR2=@(7))Q0
M!2N/#.D7<C3SV-I++)G>[V\+.V>#N9D);( !R3G% $:>$]%C&$L+)1Z"U@ _
M1* +*>'],CN/MJVELMSN+><((A+N/5O,"[\GN<Y- "2>'],E62.2TM72>0S2
MJT$1624]97!7#R'N[98^M %VSL;?3HQ!9Q1V\2](XD6-!GT5  /RH I7/A_3
M+V;[3<6EK-/D'S)((G?*_=.]E+<=N>.U $E]HNGZHRO>VUO<N@PK30QR%1G.
M%+JQ'//'?F@"PFGVT<PNEAB6=8A")0BB00AMPB#@;A&&^8)G;NYQF@"O'HFG
MQ1Q0QVUND=J_F0(L,86%\EM\2A<1ON8G<@!R2<Y)H X&_P#AJNJR@WDULT?V
MG[0[QZ?##=RJ'WK#+<QN%9 >&80*[@+N.020#U&@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H K/>0Q3);,P$LH)1.Y"C)/
M'0<'DX!(P,F@"S0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '+WG_(P
M6/\ UX:C_P"C],K=?PY?XH?E,P?\6'^"?YTSJ*P-PH * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MF^88&WD VJ0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 8MQI\DNJVU\NWRK>UNX6!)W;IY+-
MTP,8(Q;ON.1@[< Y.-%)*#CU;B_N4K_FC)Q?/&?11DOO<;?DS:K,U"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MC )#QOM8#Y=R;6QCG@8 '6FD06,HF@!3; EN%R-H1&=P>FXL2YW,6.>N,Y)
M+,]FD\L4[$AK<LR@8P2Z%#NX)/!.,$<^HXH J2:/#+%/ 2X6ZD\UR"N0WR<+
M\N /W8Z@GD\], $%WH,=UYP$T\,=U_K8XS&%8[0A;)C9U+*H#;74-CY@<G+
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MN2>] &A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
70 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img46421407_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_21.jpg
M_]C_X  02D9)1@ ! @$ P #   #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\O/T]?;W^/GZ_\  $0@#) =) P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * #- !F@!,
MB@ W#UH 3>OJ* $\Q1W% ">:GJ* #SD'<4 )YZ#O0 GVA/6@!/M"#O0 ?:8_
M6@!/M24 )]K3WH 3[6GO0 ?:T]Z $^V)Z&@!5NE8XP10!:H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * *=S>+;,J'&Y_NY.,GT^M $?VT_W: #[:>P'
MYT 8H\50&!K@JZHF\$,C!LQDAEP1]X$'COVH ?'XECF9EC4G:J/D_*"L@)4K
MG&>F#C[IX-  /$2LJ.J/B1G7+*5"E.NXM@ 'G8>C@$KF@"[#J9F4E0/E[ @_
M3H2.: ,VW\2/<NJ>1*A8L 64 #;_ 'N?ESC@GB@"1];N5'%N^1(4/*XQM#+(
MIS\RG.WCD,"#C% #FUFX\L2) Y.2"A!#9'<?[)[-TQ0 U=6NV*@P% RY8G^%
ML_<P,GISN^Z?7- %B#4;B1%9XS&S%@5)7Y<,0">>C#Y@!R <$9!% $"ZE>F7
MRVB CY!DR>O\.U<9(/<\8[9H 8-0U$_*8D#8;!W_ "@C.W=QG!X!V@D9Z4 2
M07MZQQ,BJ-N<JX(W<?+CKSR<X[8/)H <]S>AD*",H3B0%B&5<<%.,,0>H)'!
MXH CCN-0,H\Q8Q$<YVN2P]#@@ YZ$=J +WFOZF@8>8WJ:!";V]30 FYO4T &
M3ZT#$R?6@09H&% !0 @H 6@!* "@ H * "@ H * "@!>G- &A;3Y^4_A0(NT
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/6@!//D_O&@ \^3^\: #SI/[QH T[><2C!^\* +% !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M2!@#T'Q:/""6F"R,RA,_["D%0>Y8$ [CDYZ'% %G^S[<*8]ORL02,GDCIWH
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MK'H"">"?2M/8U+*7)*SV:3LR/:TTW'GCS+=-I&N"#R.16&QL% #D8HVY>HH
MV89A*,CKW% $M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%+W8R<5NW*U_30N*K<NLHJ73W?\ @F@VM3BR5RZ&21642(O.]5/[SRR>!QN
MW'/3-9_N^:]I6OHO+M?_ (!H_:)6]V_==^]O^"9HNM3NK188;R3[8@\UIEM0
M$:)B0$*>=_K 58YW#@CBM?:45)OV3<+?#S;/O>WX6,>2JXI*HN=/?ETMV:N6
MKR#5K6,7,=T]QM*EHXT7)!(SE2_;^(9X&:3J4;65+TUU7SL-4ZE[^TUZZ=/O
M*^L?;0Y-K<W2JP5CM2.0#=U"YD3;CTY^IHA4A'XJ:E\[!.$YZPJ-?(@TV"\@
M5_M,]W+N8P_,R$X(R)8\?=&>A.2.>#3G64OAI1C9W_X#\A1HN/Q5).ZMKMZC
M;"RU/2HP//N[Q][AB94"H,GRPWRDN)!@JWRYR.!3J5HSMRTH15M;;W[A"C*"
MUJR>NA)IWVN#4&OS<,\,ZF.2%CE(YE_@QP5."IW#(.>E*56$H*'(DUM)/4<:
M<HR<G-M/H]BJ-&_M:X:XU6ZF!E7$6Q]L288?ZH <,#CYB3]*TCB537+3A%+K
M?5OU,Y8?G;E*<K]+:6]#=MOMVC2"*>:2:U.4628[GSCC! &1TSG%<TYQGJH*
M+Z\NB^XZ(0E#3G;7F6(]8>3RH9BI-SO5MN<!5^]L;'S,-R\$+G)YXK"RV\FO
MO-;733ZJQRD>FV-O-&MM)*[)+N@#.V7>,_O$D^7"JI#8&2& '(S7#'"PC9IR
M]UW6O7_(XHX:$;6<O=?,M>I:N=.@OH;B^MI9'19%:13(T>V13F10NQB H*D8
MSNSCC%6\/%MN\E=W>I3P\9-R;E=N[U);C3X=1FF?5O.210' B<X"8Z@;1@CC
MH6SZ43P\*C<I.5WYVV^03PT*K<IN5W_>[?(L0SZ+:WJSJTWVA(TB+$$J4>-0
MF_CG*$9/;TJXT8QFJJOS)6O?MW-%1A&7M%>]N7?I:QH:3X'T?2"'MX ["0RH
MTA+E&;J4/RX_(UZM3%5:FCE96M9::+N9PPU*GK%7=[W>MF^PQ_ FD27/VYHW
M:<2B<,7/$@.00,=,]J:Q=51]FFN6UK6Z,/JM)RYVGS7O>_5#[SP)HE_/+=7-
MJDDUPP9W).2PZ$8Z4HXNO"*A&;26R"6&HS;E*.KZ['511B%%C7[J */H.E<;
M=W<ZTK*R'TAA0!)'(8CD?C0!M(X<;A0 Z@ H * "@ H * "@ H * "@ H *
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MN*0%ZF 4 +B@88H ,4!\@Q0(>C&,Y%(#5CE#C(_*F&Q+0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MQVH 8MM$F=J(-V=V% SGKGCG/?/7O0!"=.M2"##$<XS^[7G;RN>.=IY'H>E
M$GV2  @1Q@,<G"@9/J>.3[F@!1:0#.(H^<9^1><=,\=N,>E  UK"Y):-"2<G
M*@G(XSTZ^] #OL\0&W8N!VVC'X#M0!(5!&"!CT_E0 WRU P  ,YZ=_I0 [:
M,8&/3M0 O2@!: $Q0 N* "@-A* "@ H * %H FAF,!]CU% &PK;AD4 +0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M*/Y<U]/0?]K3Y5)1IW=_=O.^G_;MM>CO;N6)?%4L9"H$DD!7>BQ3<(PR9$R
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MS_A2]I+N+VT^_P"7^0S^VKO_ )['_P =_P *7/+N+VT_YOR_R&G6KK_GN?\
MQW_"CG?\P>VG_,_P_P CH_#_ (F\I_(O)-RN?E<D<$]C[&MH55?EDT=-&MKR
MS>_4](!R,BNH](44 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M=#CS7'_ C2]K/^9_>'-+N-_M"Y/_ "U?_OHT>TG_ #/[PYI+JQ/M]Q_ST?\
M[Z-+VD_YG]XN:7=C?MD__/1_^^C2YY?S/[PYGW8GVN;_ )Z/^9HYY?S/[Q7?
M=C?M$I_C;\S2YI=V%WW$\Z3^\WYT<S[L+ONQOF/_ 'C^=*[[B$WMZG\Z+ONP
M#<?4_G2N F3ZF@!*+L1[7X$\:B4)IE\Q\S[L4A_B Z*Q]>P->YAL1S)4I_%T
M??R]3W<+B$[4JGQ=/,]?%>L>P% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MR_'S/0*[ST H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * .2\0_ZU!_LG^= '-I(DF2A# $@X(.".H..X[CJ*!M..Z:NKJ_;
MOZ>8^@04 13P1W,;12J'C<$,I&00::?+[R=FM5;N)I23BU=-6:\CYZUC2Y-(
MNGMI 0%)V'LR'[I'X<'W!K[S"UUB*:E]I:27GWMV>Z?^1\#B:#PU1P?P[Q?=
M=K]UL_\ AC,"GL#7<<-T.$;=E/Y&E<+KNAP@D/1&_P"^3_A1=+J@NNX\6<YZ
M1R'_ ( W^%3S17VE]Z*L^P\:=='I#,?I$_\ \34^T@OM1^]?YE<DND7]Q(-)
MO3TM[@_2&3_XFE[6FMYQ_P# E_F7[*?2$O\ P%_Y$@T/43TM;G_OQ+_\32]M
M2_Y^0_\  H_YC]C5_P"?<_\ P&7^1(/#VIGI:7/_ 'YD_P#B:GV]+_GY#_P)
M?YC]A5_Y]S_\ E_D2#PUJIZ6=S_WZ?\ J*7UBBO^7E/_ ,"7^8>PJ_\ /NI_
MX!+_ ")%\*:NW2SN/^_9'\\5/UFBO^7D/O12P]9_\NZG_@$O\B=?!FM-TLYO
MR4?S85/UN@O^7D?O?^1?U2O_ ,^Y?<3KX&UP]+60?\"C'_L]3]=PZ_Y>+[I?
MY%?4\0_^7;_#]63+X UYN/LY&>N98A_[/S4/'89?;_"7^17U'$?\^W]\/_DB
M4?#S7VZP ?6:+KZ_?J?K^'_G_P#)9?Y#^H8GI3_\FA_\D2+\-M</6*-?K,G]
M":7]HX9?:?RB_P#)%++\3_);UE#]),G'PPUH]1 /K+T_):G^TJ'3F^XT66XC
MM%?]O(E'PKU<]6MA_P!M&_HE1_:=!=)_<O\ ,M997_N?^!?\ F7X4:H>LML/
M^!/_ /&ZG^TZ*^S/[E_F/^RZ_>'_ ($__D20?";4>\]L/QD_^(I?VI2Z0G]T
M?_D@_LNOWI_^!2_^0)E^$E[_ !7, ^BR'^@J?[4IK:G+[TOU+65U?M2@O1R?
M_MJ)U^$4_P#%>1CZ1N?YL*AYK'I3?_@2_P F:+*I]:D5Z)O_ "+"?"+^_>_E
M"?ZR"H_M7M2_\F_X!7]E/K57R@W_ .W(F7X11#K>O^$(_P#CE+^U7TI?^3O_
M .1'_9/_ $]_\I__ &Y,OPDM1UNY?PC4?^S&H_M6?_/N/_@3_P B_P"RH_\
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M'#P3H8_Y<X_^^I/_ (NE]=Q'_/Q_='_Y$?U##?\ /O\ \FG_ /)#AX,T5?\
MESB_\>_JU+ZWB/\ G[+\/\A_4L-_S[_\FE^LB0>$='7I:0C_ ("?\32^MU]_
M:2^__@#^IX=:*G'Y\S_4ZVSD\O$71  %'H!T&3ST]:XV[N[.Y)1225DE9+LC
M3I#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@P>"*Z3J+- !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M"@ P* L+0 4 % Q*!"T % !0,* $H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H .G2@04 :-M."-AZ]J +M !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!6O?^/>3_<;^1H \:\Q0P3/S$$@>PZ_E0.SMS6T0^@04
M % &AIMX;.4'^!N&'U[_ (?RH\@.[!!Y'(- !0 4 % !0 M "4 % !0 4 %
M!0 M "4""@84 % !0 4 % !0 4 % !0 4 % "T )0 4 % !0 4 % !0 4 %
M!0 JDJ<C@B@#8@G$H]".M $] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % '$^*VV<CC$9_G5QW2\R)NT6^MCF4BV7(EZ"2%5/^
M\I&W],UFU[S:.GG7LE![J5UZ.-G^)>IF(4 % %.QNQ=Q[_NL"0RYY&"0#]&
MW#V- &MI=TMI*;9_EBE):,]@Y.63VW?>7W) Z4 =-0,* "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H 4<<CK0!J6\_F#!^\*!%F@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@"K??\ 'O)_N-_(T ?.^H-)%JUJX!\K848]MSD@ _I4OH>K12>&JQ^VFI)=
MTM6=/5'E!0 4 )G)(]* .IT.]W V[MR.4SZ>@^G6@#HZ "@ H * "@ H * "
M@ H * %H 2@ H * "@ H * "@ H * "@ H * "@ H 6@!* %H 2@ H * "@
MH * "@ H * 'HYC.1Q0!LQ2B1<B@"2@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !H -U ";J!"[J!B;J!!NH 7=0 FZ@ W"@!-] "[Q0 Z.3##% &Z.E "T %
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MU% !Y;_\]%_*@">V=X'!W@@GD8ZB@#HP<C(H * "@ H * "@ H * "@ H *
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MQB@!Q<*0I(!;.T9&3@9.!WP!DXZ $F@!U #X^&'UH ZQ.@H =0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % %2_P#^/>3_ '&_D: /"87/F71'\+C_ -%H:VGI
M&/\ A_5G-%^]4MTDO_24R/2-52^WP,09H,!QW(.<-CWQ14@X6:V>Q<)\WN]5
MN;58FP4 9FI6X93,,Y16!'J&&#GOWSQ0 S2I,((>1M4%0QY'L.Y'?Z&@#L=$
M"B1R1DX H Z/<H[?J: %WKZ?SH 3>O\ =% !O'H* #S/84 +YN.PH /-]A^5
M !YQ]!^0H 7SCZ#\J #SC[?E0 >>WM^0H //;U_2@ \]QW_2@!/M#^M "^>_
MK0 GGOZT (9G]: #SG]: #S7]: $\UO6@ \QO4T 'F-ZF@!/,;UH -[>M !O
M/K0 FX^M !N/K0 9- !DT )F@ S0 4 % !0 4 % !0 @.* .NA.8U/\ LC^5
M $E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MVA0!SVH(UL_G  1%D!..1DC XZ8;/X$"@#KK3@F@#0H * "@ H * "@ H *
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MR_4@#!!8X )Q0!S T2[N/](BB5(I;^*\6UD.T+$D>TAEY5&D8^8T?8G! /%
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % %/4/^/:7_<;^5 '@ELV)+[V?_P!HI6U72$/\+_\ 2F<<'[U;U_\ ;(G!
M:?=OIEX;M!E))F6;U,8X&/HS#TKT91YX^SZI>[ZO_ACF@_9RY^\M?0]8'_UZ
M\G;Y=#U?,6D A 88/2@#G'CDLY &RWS[E8?W2< ,/;&.O04 =YHC!BQ'0@4
M=%0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 5KJ[BLD$D[!$
M+*@)Z;G8*H_%B!Z#.30 DUY%;RI YQ)*'*#'41@%_P @10!A6GBZPNS'_K84
MG_U4DL>U'STPP+8SVW8'O0!J7VJQV+I"%DGFD!(CA 9]HZL<LH"]<$GD] :
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M:E'IBQEO,5BTN1M1@I<)CN2H)[8Z&@#:H #0!U=L?W2?[H_E0!8S0 9H ,T
M&: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M.F>3W#>W- &[9]30!H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M .A4HH.1VR2 0.#0 ^PTM[602SSRW;1QF.,RK&"BDC)RB)N<X +GG;GCYCD
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MH_6@ _M1_P"Z/U_QH 3^TY/1?U_QH 3^TY?1?R/^- #?[2E]A^'_ ->@!O\
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MZMO=MW.6).P#Y02!P* /1.E #2: .KMFQ$GT'\J )]U !OH 4&@!: %H 6@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * #(% "9'K0 ;@.XH 3>H[T
M )YB^M ">:@[T .5PW0T .H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M:._^<TP*XI ;FDN2KKV!! ],Y_PH UZ "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H IZC_Q[2_[C?RH
M ^?==F\E"@^]<K'$ON2QS^AJ:CM327\WYV1QU79NWVHJ*];N_P"9DWC#6H%M
MYD+2V\V5QTR(WV,?;/##L2M=5&7(V[]/PNC6I%223[Z>MG8YFTO/[.\B6)M_
MD+(LG^S*Q9Y(S_NL2,>U>C*//S)JU[6_PK1/[C@C+D4==KW]7JU]YZXC!E5O
M[R@_F ?ZUXW6QZJV'T#*%S,(9HRP^7# MZ<?R/>@#I]$ !;;P,#% '14 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #60.,, 0#GGU'2@!&B1
MF#E067(#$#(!Z@'J >_K0!7@L+>V.Z&*.-AT*H 1]#V_"@"6>VBN0%F19 #D
M!E#8/J,]#0 ^.-85"1J$4= H"@?0#B@!B6\43%T1$9OO,JJ"?J0 ?\: 'M$C
M@JRJP/4%00?J",$^YH 3R8]H38FT=%VKM'T&,#\J %2-8_N*J_[J@?G@"@!5
M4(,* H]  !^0P* ,VZU2.VN%M/+DFF>,RA8TW?(K!23SUR1@=Z +%A>PZE"+
MBW(>-L@<<@JQ5@1V(8$'Z4 7,XH 8&##*D$9QG(/(XQ0!5N;Q+>&2X!#K$,D
M*1U! (SV/(H G:15R=PVJ<$YXSG&/KGB@!,[N!^E $WV.9NBG^5 '00$I&JD
M<@ 4 2[_ &H 7=[4 'F>U "^90 X38[4 'G'TH 7SCV% "><?2@ \YO04 )Y
MS>U "><WM0 >8WK0 >8WK0 !V]: #<P[T +N;U- "%F]: $R?6@ W'UH 3)]
M: #F@!>GK0 F<4 %  10  "@ ^E #2,>U $9Q^= "!AZCCT(X/O0!;AD)X)S
MZ&@"S0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!QFO?\? _P!T4 <O
M?V0OX3"6*9(8$=BIR,^Q/7VH Y729?+E;3K@E!*'C1"/XER21^ 9QGJ-H[4
M-TM)K&XDMYBI$TBH\?\ #@@_,#[@*<#@YSUIIV=T)I23B]GN<;XILI+"Z5XC
M@1L67/H2 I'J0>H]*]^E-3@HOJOQ1\W[)T:DG'9;7[/;YGMAKY_H?2[:$<L8
ME0H> <?H<_TH T+/J: -"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MJD_N_P CNA-/W6];_HC>K0W*&H6WGQDC.Y0< =\CI0!O^&)#+%O/!*B@#JJ
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!Q>O?\?/_  $4 <GJS&.W+!BFTJ<_1AP>"<-T(')' YH YZZ4
MWRIJT VM&'$@R5P0G!&>01E0?]D@D8H DN&.LVJSQ)^]4*LJAOF (R<$$?=[
M'[V#VQB@ N=(_P"$@TJ.*5CYP&4D(P<JW ;C.TX .>O7K711J.C+F6VUO4PJ
MTU5C;2_<Z^N<W"@"[9]: -"@ H * "@ H * "@ H * "@ H * "@ H * "@
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M:LVO-_F>I%W2?D34BC6T"/R@R>@'2@#I* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *  GUH 3/>@!&8]SF@
M"$L10!1BMXXI6=1AYF7><DYP-HQGH,=ACWH [0#  ]* %CE5#@8- &@* '4
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M=6$4B,1G^!T!)1CTY8%%/&6(H Z6)MRANF0#CTR,T :,?W1]* 'T % !0 4
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MF8L>3[DUPU:LJ\W4G:[[>B7Z'92IQH05.&ROOOJVW^9J9Q6)L(3B@!N:!#:
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!*
M$H C8T 0,<4 5E?]ZG^\/YT =A-)L4F@"M9C>@D]: -6*3'!H G5PW% #\4
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MQP%24KTXI*$;MMO6[>GY'MWG8XKYW8^@#SS0!F7UG%J&//7< K+CM\V.?J"
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M49)M=E@G9GV22[)2[;7#1+BW5/NJT!R6[Y]Z /4:8A!Q0,=0 E "T )0(&H
M04##% ART#(WI 68ON"D!KZ5]Y_H/ZT ;- !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4-4_X]9?\
M<- 'D0Z4 4[^S6^B,9X/53Z,/\: .?TZ<W1DL7^Z,^4V<E64?-GUPX)QV''M
M0 _3;/[0MU8W67B.%*D< G.=I]\ D \>V:J,G!J4=T3**DN5]3H[6 6L*0#D
M1J%!/H!BAOF;?=W"*Y5;L3U)1MZ+U?Z#^M &_0 4 % !0 4"VW,'4/$VGZ8_
ME32?..JJ"V/KM!P?8\U+DH[GK4,NQ.(C[2G!\KVYFE?TO9FE8:A;ZE'YUJX=
M._J#Z$'D?B*::>J..O0J867LZT7%^>S]&M/N9<IG,% !0 4 % !0 4 % !0
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MM<0N=DA9E*@;QDAG7G"@9 .<\IP!F@#I-*F-S#Y[#;YS%\=<=C],XSB@#2H
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MGI0EC.6*A&'+RQM?M;3[6]CN;KQ WA_2EO\ 6F6.<(-Z1GAYL?<C&3NR>^<
M<FO.C2]O5=+#ZQ<G9M;+N^WZGH.K[&E[2O92LKI6U?9?U8\^\(Z'>^)=1'BK
M6@-AS]E@8$X X1@IX5$ZJ3DLXW8 %>IB:M/#T_J6'W^W-?BK]W^"/,P]*=>I
M]:K[?9B_P^2_%F+X^MH[[Q;96\XWQ31P(X]5:68'GJ#CH?6NG!R<,)4G'1IS
M:MT:C&WEH8XN*GBH1EJFHW7JV<YJK7G@>.^\.7(,EI>H7MW&< EAAUST! Q(
MO9AGG)-=5-0QCI8N#M.#M)?+;_)G-4Y\(JF&EK&:]U_/1_HT=?X?\0#PWX+^
MU+_KGEEBA'_31\ '_@(RQ^E<%:B\1C>5[)1<GY*^GS.RE5]AA.9;N4DO5I:_
M(X2[N='B\.P6=M,7U..?[2Q$;CYG 5D#D;?D C.<X)4XZBO3C&L\1*<X_NG'
MD2NGMJFUYMM>AY\G25",(O\ >*7,]'U5FD_*R^9]#>#]?7Q+ID5X!MD \N5<
M])$X/X-U'?!KY3$T/J]65/INO1Z_AL_,^EP]7V]-5.JT?JCH+I_)B=SQM1C^
M0KFA'FFHKJTOO9K5E[.G.;Z1;^Y'G.GMY>D73=W=%_\ 03_(FOJ*RYL717:+
M?YK]#X:@^3 8A_S2A'[G%D][;QVVGV<2#:UPZ2.>>20O)_\ K<5G2FYUZ\F]
M(1DEMHKOL;5Z<:6%PL(*SJRC*3UU>FO_  VA#K6R2[NV8 ^3&J)GURBY'TW&
MKPUXTJ,5=<\G*7I:3L_6UOF98UQE7Q#E:].$8QOWO&-UYI2;^0L'-QIT1Z(J
MM^<CO_A1/2GB9+JVONBE_F%/6M@Z?113^^I.7^1GFVFU.>81!2S2YRSJIZG@
M!B"<]P,UU<\:$*;G=)0M9)O1+=V3L<?LIXNI5]FDVYW=Y1BU=O92:O\ (XS7
M-+OM7\4SV.FF,3);>4QD.%"&'9)R <'#D+QU[5C2JPI8:-6K>SFY*V]^:ZT=
MNQ]!.E.5?V-*UU!1UT2]RSV]27Q')<>&;6#PS#+$@@M);BXE9$;S7E9OW<?F
M*2IP<*RX<@YXQBHH*.(E+&.,M9J$5=JR25F[-?-.Z+K-T(K"*25HMR=D[MMZ
M*ZV[-69S6LOL\,:5;IRTDUU*0/\ >(Q]1S752UQ5>;Z1@O337[SGJ?[M1C_>
MF_Q._P#A-*ATRXC4 .EQECW(9?ES],'\Z\?,TU4@^G+I]^IZN7V]G+NI7_R/
M7(?]6/Q_G7AGLF??':%/^VO\Z0T;[4Q"D8%,"/I0!(.10 A% #"N: .>N_#4
M%[>2WLY9O/LVLF3HH1SEG!_O8)7OP3]* (=/\*BT+2SS2W,\C[WE=43<! ;9
M%VJ-H58SG/)9\L3SBD!4B\"6<+0MNG*0+%^[+#RY7@4K%+* F2T8XPK*K=P:
M $T7P[::=,_FRSS7,(A+23$B.-!.;F-(6*JFSS$!D&YVX 9E!% &#JFFZ#;R
MWHGCO&_<7<DR++(L1BW03W @4NHQ*\J/Q\I;>,C&V@#1ATK0)XTFN=T(MV\A
M&N;MT:0(P90Q,W[Y V/+#Y(Z8 XH Z64Z5X;19IFALHP\@5I'V@O,V^0+N;D
MN1N(YZ<<"@#-FN?#<TURLILWE*K+=AP"2L> DD@(PPCW*-PY&X!CSB@"O;ZM
MX8;R7MA;.\;F.$16S-)$W!.$6(O$.<[B$3!R#WH NZGJVF6Z^88X;B:/SI(U
M,:YWPE1,RN8SM=<KEARV!@G&0 -N/$VE0O,[(S>0Y4R"V8K+*DB0LD,A0"65
M)72,[2=I8#/!P 6]2ULV.G_VBL,@8E!Y4R.LB!S@ETC260;>I548GL* ,BZ\
M73-:?:[%8;F.&UDNI?GE0%8WVM''NC#*XPV?,1=K*%*\Y !,_B:X2>.14C-C
M+=Q68Y<3*\D(E67/W"FXE-F 0/G#')4 %)=:B^U2W5GIA:827,)N0;:-I&ME
MS,=V_?M(X!8 N>#0!-;>-XKRYM;>&(%;V01C,J"5"8//+F!0S>6!\F_<%+Y&
M>] '<&F Z@!!Q0(#0,0=: '-Q0 "@!V*0"8Q3 C>D!/#]P4@-C2OO-]!0!LT
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0!0U3_ (]9?]PT >1B@ Z4 <EJ&G-;72W,)VH[_,%.""1C
M*]?OG]30!JZ4K2%[EN/, 4CN64MDGMT(QQZT ;% !0!MZ-U?Z#^M &_0 4 %
M "$A1DG '4^E TKM+77MO\D><:SXDN=0E^QZ0'(&0S(,L_;CT7W[^V*3TV/L
ML)E]+#Q^L9AR]U%NRCZ]WY'/CP9JDPWE$4GD[WPWX\'G\:P<&]CU7FV$IVC%
MR:76,?=^6I7.E:SX:;[3&C*%Y9D.Y,?[73C]?>L6I0U70V^L8+,E[";3;V4O
M=DO-;GIGASQ%%KT.>$G0?O$_]F7_ &3^G3FNF$U->9\3C\!/ 3WYJ4M(2MKZ
M/L_S.DK4\<* "@ H ,4 '2@ H ,4 &* "@!,CU'YC'YT (75?XE'_ A_C3L^
MS^X5UW7WC&FC3[SJOU(']:+/HG]P72W9&;R!?^6D?_?0I\K[/[F*Z[K[Q[7,
M*.(F=5<]%) 8_0=:.5]M!W6P3SQVJ^9,XB0<%F.!S0HN3M%-OLE<3:BKR=EY
MCHI4G421$.C#(*G((]0:35O=::92LU>^G?H5;?4[2ZE:"":.66/.]%.67!P<
MCV/'UK25.<%S2C)1[M:&:G&3Y5)-^3+M9&EK>1'-*ENADE8(B\ECP!2;45>6
MB);45=Z+S*MKJMI>MLMYDD8#.%.3CUK.-2$W:$D_F9QJPF^6,HM^3+]:FPE
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#B-<_X^C_NK_*@#(H * *EY:_:
MXC'G8W\+#JK>O/'L<@\'UQ0!@^'7GA>2SFQB)00.ZG."!_L'.?KTH ZF@ H
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M7'A\1+"SYHZI[KH_^&Z'77H1Q$>5Z-/W7V_X<XU_A:LUI;6$MY(8+1Y)"H0
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MECN(W=, '=R7D$4B0-+&)9.8X]Z[W')!5<Y88!.0,=2#Q0!<V,>U,!PB;TH
M7RFH$((FS0,<8FH /)/K0(/*([T 'E$=Z!B>6#WI .C&U<>E(#7TO[S?3^M
M&U0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % &?JO\ QZ2_[AH \C% "T 130+<+L?ID$'T(.5;Z@X-
M '-Z3-/;W)M).48.2#U4J0<KZA@PSZ8X[T =30 4 ;FB]7_#^M &]0 4 % '
M-7MQ%K,TFDPRM&R*&D= "".\9.>N/PYQVKK="4*:KRT3=E??U^887'TZ.)<(
MP52<(W7\L&]TO-;^II:;I-MI*;+=<%OO,?O''J?3VKD.W$8JIBI<U9WMM'91
M]//SW-.@XA" 1@\@]10/;577IN<;<>$X+2Y_M*QD:T:+,CJHRK  E@!VR,\8
MQW[5SNFHOGB[6U9[ZS6<J$L/C(*K'E;3>DDUM?O;>YTFFZG!JT N;8[D/'3!
M4]P1V/?Z&M8S4US1>A\S3J1K1YX/3MV_K<I>)%O#ITYTUBEVJ%HB!GD<D<^V
M:[*')[2*K*\&[/YBK<_LY>R=I)71B> O$1U[2Q-=R#[5;LZW.>"N"<,P[?)@
MD^M=.,H?5ZO+37N2LX>;[?><^$K>UI\T[<\?BOOOH_N./L?%%]>W6I:V96_L
MK3U801 D1R2 8"^^",GCHPKNGAX0C1PW*O;5&N:751ON<,:\YRJ8AR?LH7Y5
MT<NWZ_,KZ+I_B'QQ!_:=UJ$EC$Y(B2(;00/XMJ\ =,'J?2JJSP^#E[*%-5'U
M<G?\7U"G&OBE[6=5P711T_!=";2M;UKPOK4.BZU+]JMKDA893R3N.U&#GYOO
M<,IP!C(R*52E1Q-!XBA'DG&[:Z66^GY!"I6P]:-"O+FC+1/KKHM?S*4FL:OX
MZUB;1[6<V5C;EBSQ##[5(&688)+$\*>..M:*E1P5&->I#GJ2Z/57?;LD0ZE7
M%U9483<*:>ZTT7?OZ"ZWH.L^ X?[6L+^6[BA8>;%,3@AB%Y7)4@D@'N,YQQ2
MI5J.-E["I24&T[-?U=66HZE*M@U[6G4<HJUT_/R(_$?B*75;G1;RW=X4NB#)
M&C$#.\A@0.HX_*JH4%2CB:<TFX)\K:3=K;^1-:LZDJ$X-Q4MTM-;GL/B(E=,
MNRI((@?!'!'';TKP:*3JP35_>6_^1[=72G.V_+N?/E_<3'P792;WWFZER=QR
M?8GTKZB*C]=J:*W)'HCYR3?U2F[Z\\B[%X9\-/&K2ZU*&906&P\$CD?@:AXC
M%)ODPZLGIK^/S'[##M+FKO5+[.W='?ZG\/M/UJ&WN'NY4AMK945P% :-5!$C
M$L,9 S7ET\;4HRG%4TW*3;6MTV]OO_$].>$IU5&7.U&,;)V6RZ[GE=GX1@UG
M61:Z))+<6-N5\^Z<!0#GG8,\^W<G)Z$$^W+$RHT/:8A*,Y+W8+=^OZGC1PZJ
M5>2@W*":YI/2QI_$*SO+SQ0?[.4M<Q6\4J[3\WR+DD<C)]1W&16&"E"&%M5T
MBY2B[[:OJ;XN,IXE^SU:C%JWDC4\2^*8_$WA1FD8"]ADB6XBQAE82@!L''#8
M!..A)!Z5CA\.\-BTH_PW&7*^EFMOD;5JZKX9N7QIQYEYI[_/<ZNQU@^'_!<%
MZF!(EJ%BST+L6 'UQG\JX9TO;8V5)[<S;]%;4ZX5'1PD:G51M'U=SRSPJ;OP
MQJ=AJ5SE8]4+ABW1@[;5)/J20_TKV\1R8BE5HPWI6:79I7?W?">10<L/4IU)
M;5/Q3=E]^Y]2$8Z5\7?J?7'+^,IO(TJ7_;PH_$@_TKBQ3Y:4O/1'!BW:C+[C
M@_#4*V6J1%,C;;O(^?\ KF6_+%>7AUR58V_D;?W'EX=*G6BX](-O[K_D:B>+
M[YXXF&S?-</']P?<4K^IW=:V6*J-1=U=R:VZ*QLL54<8NZO*36W16_S+7B'Q
M+>:=?&&UDB:(,J[=JLP)^\"?KQ[5K7KSISY82CRZ*UK^IK7Q$Z53EIN+C==%
M?;4LH?M/B-'/_+"V#'V)7=_,U7Q8E/M&Y:][%*3^S"_X7/FJ2..\<LOS7,UX
MH11G.TL<\?7:1]*_5+N"Y7\"IZ^I\VK2=U\;FK+RZGIOB/Q;JFCW8@L[V!XX
MC%%]G\LF12$17#L5V'Y]PX8GVKQ:.&I58<]2G)7YGS7\V[K6^QZU;$5:<N2$
MXNUO=2UO973^9S?C'5I=/\1O=Q_\?$42(G'"R, 02#Q@;CQ[UKAZ:GAU!_"V
M[^:(Q%1PKN:^))6\F>R:;Y\<, NW\V<^69&  &XD$@ <8!X&.M?,3Y>:7)'E
MBGHO+_@GT,+J*Y_>DTKOSZGJ,GW?PK,T%TK_ %&/1C0!>'WJ %().: $(H :
M0: $P: //?$=AJDNI1PV2DV=\JF>7('V>:V/F0R8)R0^Q(R%!ZT <=I/A.Z^
MR26LEBT#^5LN][1L+V7S79'!#DL%5N3)M.&  .* +Y\+W6F3W@M].2ZM9I;A
M+:(&%5A$Y9A.JLP"JIP"%^< \+0!6TSPOJ#:G+"+:.."*]M+AKT\2'R+:W5X
ME&,LCLA4$<9SG% "7_@367TJTTJ*2"*WACQ,AD>-5E$J2"1MJXE!"E=K\ D&
M@#K;O1M4O;BZE8VJ&YCBB219I5E5(PK/ -J?*DK*2S*2P#$@&@"OX7\#2Z!=
M&Y:6,AVN6,:%VV_:(X4VAW4,VPQ9+-@G=[4 ;=]X7:]T^SL%F,4FG-#)')M#
M!GA7;RI_A8$_2@"A<> EO))II95#W,=PDLBP)YK?:8O+;?)PQ$8YC4G'0<"@
M"S:>"%MY/M$UQ)/*1 N\Q*@\N".:-%VJ<<K.VY^N0* *^F^$=.TZ";0X'16>
M-) %@2.9$213&[NO,VUPO+G+=^M &VVB0_;X-3N)M\MM&\4(PD8PX4."P.9
M=@(7D*2<=: ,Z72;*POYYYYIW?4T(DAV22JT2@Q!1L5]B*'P,@#.#0!G:9IN
MA:?/-"DLTLLT:V!,OGLL<9Y2WCD9?+3A^ &')QUR* %T:+P]<,UC8N[&>U2(
M;O- EM[9R0T;LH5MCO\ ,P.3D=J *>E:;HNC:DVIC4TEG+3;TWQ N9G9CYI1
MR9/++84L,+@9QB@#O1K-D]R+)9D:<]$7).< \D J#@@G)!P0>AH T\8H 7%
M"\#B@!=PH ,B@ R* #<* $8\4 11\.* +IXH LQ?=H DH * "@ H * "@ H
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MY[1D]%<J#P>0><8- %+6_$6H6JV\ML@B:Y>SW12.K*D<[E<;ESEG'WB.%[4
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M.S?]\FF ?V@O97_[Y- #A?#^Z_Y4 ,^VC^ZWZ"@ -Z!U&/Q'^-(!IOU'H/\
M@0I@1'44'=?^^A0 D>I+(=JE<^F>: )HYMV2"/PYH MJ<"D!K:5]]OI_6@#;
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZ@@_C7HT9J>-JN+7*HI?-;_B<-6$H86DGU;?WC8=4\$1QJ'LYGD"C<?W@RP
MSW]:)4\<]JD4KZ+3;H"E@TE>,K_,V?'7C=%L8-)T]##;74$3,[9W+"0I5% P
M<[<;LYSR.]<^$PC]I*O6=YQD[+HWK=O^O,WQ6)]R-&DFHRBFWUMH[(A\,?$#
M1/"UJ+&T@N'W-NDD8J"[G SC;P!@ #L!ZYJL1@Z^)G[6<HK3W4MDNVY-'%4L
M/%4XQD^K;MJ^^VQTX;'CY".IM$/YH:XO^9?_ -Q'^9U+_?5;9P7Y'$?$[PFV
MBS-J=JW^C7KXD0#&QQ\W/JK-\RY_B.*]' 8E5HJC/XX*Z?=?\!;^1PXW#^Q?
MM8?#-ZKL]_QW"ZN)=?T_1_"UG@/+$DSN<[0<OL!]AAL_44U&-"IB,9.]E)Q5
MNNBO;\!-RJTZ&$ANTI.^W6WW:FYXK\*^()=+S>7,$L.GJ'CCCC"LNP;?E(.>
M%Y_"N;#8G#JK^[A)2J:-MW3N^OJSHKX>M[)<THM4U=)+5):?\$[#POXQ?4-*
MAN9(RS1;8IL?>!7C>!W&W:3[YK@Q&%]G5E!-*+UCYKM]]TCLH8GGI1E:[NHO
MR?\ P%9ECQQ(\^FQ!5.99%)4#.!M;_ZU?,8Y-04%K[W3T88R\J226[V7HSG_
M  _:7-Y-/<+&Z;;0Q)N& S>5Y?![D]?QKBH1E.4I\K7N6C?TY;''0C*4I3<6
MDH65^KY;6,[2=.O+BYM[<PR(('9G9E( W ?U ^M84J<Y2A#E:Y6VS*E3J.4(
M<C7*W=V*\FF7WG'=;2;A<[F?:>?FZ?3OFE[.HV[P=^>[=O,S=*HI>]!WY]7;
M?78[*&&[M-2O;@Q,5:V)1L'!(C "J?4G(QUKV*$7]9;FK1?+J]K)'IQ4X5:D
MG%V<='9]%HD<_P##;PA#;6XU*_MRM\)9-GFA@47^%MIX[\$BOJ\?B92DZ-*5
MZ=E>UM>^I."P\5%5:D7SW=KI_D>?77AW66O)0+-W0:@9VEVGYE9^,'NG\1QP
M.:]*->CR1M42_=*-KKHM[=[Z'G.C5YV^1_Q'*]M=_P B7Q;X7U#5-2OKV.&3
M"-&80%)$ORC.WCG:1V]:YJ&(ITJ5.FY+6ZE=K35[_>=%:A.I5G-1>C7+IOHC
MU:Q>3R;?S@4D"1;U/4-\N0?<&OG:EN>7*[J[L_*Y[T+\L>;1V5UYGJ[CY1CT
M_I698:5Q"1Z.: +Z]: ']#B@!"<4 -H  WK0!R6M^)1I-Y;V@"2&X>%609,B
MK+,L6\X/RHI;.2/F(VCDT <J/'.HS7"P16\*K(]VJ,[$G%H(BQ8*PR7$HV@8
M(VG.<B@">?QW<@F:"&+[,LMM P<MYNZYC+*^X,%"(V P*Y922"*!E:T\<3:E
M =1,2HEK<7, A#,79X$&XMSMVR-DQKMR%()))S0(RO%6HW>I:%;7UP8P]W$9
M!Y'F(J*986"\R'<>/O'/?&* )?$FK3:7B^@VF6.3>NXL0I_LCS =JL 03U!R
M,9(YYH [S0+B]>22&]F^TG[+;72ML5=IG\W* *!E!Y8VDY;DY)XP <3=ZZ[6
MD.=5,<U_/LD;?;HEB1'(YB;,>0 5VX<E]V/FZY .7OO%=^"DD>H2&9+:.2TB
MC5"MY*+N:!@1L+,'2-<A2,9R,9H ZA-<;3=7D$TTMQ$DT=Q<S*28K>,*RM \
M?.PAG4Y! ..G% &/8R7]S=7EQ )V%Y:78MYF1R&C6^=RJD8(S "8@""1MVX.
M#0!"FF&TMXKA$N=19)':UM7M[Y54E8LHK>=O4A@Q#S,Z9) 48- '>^/+*2>.
M*2"'4)+U8G6W:R+!8Y"RL//905"[@#\_R[0>,\T 9NF6FL1"+1KRTD8M<VMU
M)>J1Y.$$4DV<#B3S%=0N?F(! Q@4 +X=\+ZI;W5G;W,(AM]&M[FW6?>&^TF<
MJ5,:#!11M^;<3VH AT7X=3V1#30VX(LKZW)(0GS9YY)(FZ9/RL,MU7IF@"CH
MMK<6GB @12A/M6/LYCQLS!!')>&?&6B^0!4S@E30![<+?U- #O(]Z #R!0 >
M0!ZT .\A10 >0M !Y*B@!&4 =* (0!N&.M $YH LP_=H DH * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#R_6]2\O6'LY,!61"A_VMH)4^N>WIS7?["^'^
ML0W3:DO+HUZ'E+%<N*>$G9*23@[?:M=I]T^EMMAU<!ZH4 % !0 4 % %ZTH
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M,\(7^GW$$@-D1;7+3-/MD^TW"N3D2,1PP!X^9E)]!0!L+X7E%K:VWF)FUO\
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M-\@^8^IXZT ,46"3?:5C03;!'O"?-L4E@O3H&)(]R: +'V^#GC.>OR]?KZT
M']HQC@*V!Z+0 O\ :2#HC_D* $_M$#HC_I_C0 OV_P!$;]/\: %^VY_AQ_P(
M4 -^V^P_[ZH 0WV.R#_@7_UJ $.H8[I^9_PH C.I^Z?F?\* &'4SZI^O^% $
M;:FWJOY4 ,_M)_7_ ,=_^O0 PZA(?XF'_ 1_C0!&UY(0?F?Z ?\ UZ +$-R)
ME!RY/3DX_P : -.,@$@#&* )<T 6H?NT 2T % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MNA*?QRM^8?5IS=ZDK)]M6C<MM&BTJ!Q8*%F(XD8;V+#IG=Q^' 'I753I1I?
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MS_2IELS.?POT/%- O#/$8G.6C P?]GM^7-1!WT,J,N9.+W7Y&]6ITA0 4 %
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MG/8?K0 >9)Z#\J &[G/I_P!\C_"@ ^?V_P"^1_A0 OSCT_[Y'^% #OWG^0*
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MC[>E[J]Z.L?U7S6WF9Y?B/JM9.3M"2Y9>79_)[^1Z57QI^A^?3^MOZV"@ H
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M26P%S\S$_>ZT 4K7PO;6LL<D\TEQ]GA>"%)G7;'&Z[& '\3%?EW'G% #-/\
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M.QB#T(P1P10 ZU\7Z=>%EA,C.IA 0QLKN+CB-HU/+*3D$CA2"#0!U)3''I0
M;: $VT 12#E?K0!,OW2*8""@#7TG_6-_N_U%(#?H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#"\2@
M-IMP#P#'_45,MF9S^%^A\VV=PUE,&!P <-[K_P#7%<R?*SS(R=.2:^9Z&I#
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M[OXF@":@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M;VZ>U(D@MMVQ+B:)"J0-(0[@.P&77<<=* .:D\:ZIHUWI\>LCRT10NI*D+$
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M0A5@X*L6;G)!G8W?AJ&2^T^\MUCB33!*H7!+%'3"*K<GY&^;+$G)R#F@1U%
M!0 8H @EX*_6F!*.A_&@0@_I2&:^D_ZT_P"Y_44 ;] !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 87
MB7 TV?/38/\ T(5+V(G\+_KJ?.=Y%@!EZ#C\#S_6N9H\V2ZFUH%XT@-NYSL&
M5]<=Q^'%:P=].QTT97O!]#I*V.P* "@ H W=%'W_ *C^M &[0 4 % !0 9Q0
M%_O1!]FB!)V+EA@\#FK<Y-<DF^7=)ZF2ITXR<U%*36K2Z$J1K$-J */0#%9J
MRV-$E';\AU,9&D21DLBJI;J0,9QZ^N* &74XM89)B"PC1FP.IP#P/>@#PI+F
M:TE>XCG"IJ&G7,_E+</*R'RW=-^\_)*..%SCZ4 7[+0HKB]M[:6:Y>.?3?M,
MH,\GSRC=ASSVP !TXH LZ5#;:U:1/J\K%H+!6M]\QC!;9DMR0)'#!0.K<X[T
M 3:F\1>Q,[RCSX8$U H3@0[L0M)_<W-_K&ZE.6XH MQPPW*RP7AS9MK#*^XX
M3R_*^4,>FSUS\N<4 5=5AAM]0F2T&+9+"+8$Y0 7$1.".. ,\=J -W5F#F^V
M98/:697&3N&Z3./7WQ0!R5_I$,BZE>F(FYCU2+RI-I+*!* =AQG:03NQQZT
M>@>+%@=;0WBF2U%TAE&TNO5=A95!)4-R<C [\4 <]XEN;9W%JL:)9?8I'@=;
M7S=SD@>5&-A\OL>,,>N.* .5LY[(+'_:$3RO_8S1(&A=V6087;MVDJ^?E5B
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MD80\"7)Q^[.#AAZ&@"V?&5FNI2:2\<T9A+I]H8((6D12Q0$-O#$ D$J%..M
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MW=LJK#.>RR$<8[A10!Z=B@ % $*< GWH 7.6_"@!X&* +T'W?Q- $U !0 4
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ME9IV:]#]-A.-2,:E-IQDKI^O3^OF25!84 % %ZTH OT % !0 4 % !0 4 %
M&9K.G_VM8SV.[R_M$3QAL9VE@1G'<4 82V6I7=I##<Q0PR6<]JZ[92ZRK#\K
MG[@,>1\RCYO0GO0!B3^$KU[PW06VD=;X7:W$A;SGCR<0=#Y:QJ<#!*M@?**
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M1M(0PB\P!Q'M(+8PY  XP 3VO@G3K"21K0-;Q326\Q@CVK"LEN,*ZJ%X+_\
M+3GYO:@!\W@K3;C4EUB4.US%</<J=WRAWC6,C;_= 564'HP!H K#X?Z4K.Q$
MY66%+>2/[1*(I(XX5MTWQAPK,(E #$9!&[KS0!TZ:7:HQ=8UW& 6Q;NT"YPC
M'N!D\GGWH ?'I]O%#';(BB&$QF-.RF)@T9'NC*&7T(H 233;:82I)"DBW6WS
MPR@B7: J^8",-A5 &>F* (4T/3XY6N4M;=9I!M>01('8>C,%R1P,Y- %YK:)
MBQ*(3)@.2HRP'0-Q\P&3C/2@"0Q;L KG!RN5S@^H]/J.E "]* %R10 4 (?6
M@".21$C,[,!&BEF?JH4 DG(SP!G\!0!"MW"9(X58&2>,RQJ,Y>,;<NO^S\R^
M_P PXH AN]5L[ E;F:.$H4#!C@J9.$!]-QX6@#0__70 4 +T]J "@ H * "@
M H 3- $,O4?6F!*O - AH-(9KZ2?WI_W3_,4 =!0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '/^*O
M^07<_P#7/^HJ9;,SJ?"_0^>+:4/!L/&TC)]0?ZUSK:QP1=U;L0D/I\X*GE>0
M?5?_ *]+X61_#EH=]%()D61>C $?C74GU1ZB=U<DIE!0 4 ;VB]'^H_K0!N4
M % !0 4 % !0 4 % !0 F,\'I0!4&GVJ](81UZ1IWZCIT()&.A'% $ZPQJ0P
M1 5&T$* 0O\ =!QD#_9Z>U #&M(& 5HHB$^[F-#C_=&WY1],"@!Y@C.<HAW
M!LHIW = >.0.P.0/2@ ,$94J40J3D@HI!/J1C!/N1F@ $$:C 1 ,;>%7IZ<#
M&/;I[4 .\M1T5>!C[HZ>G3I[=* #8/0<\]!R??CK[G)H 4J&&" 0>H//Z&@
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MN]G60LC/$=Z@*&S&R$-@ $C&<<T :-SX>T^]2*.XA$JVR[(MS295>/E+!PS
MX&=Y;/?- %A='LE#H+>$+, LB[!AU "@-QT  &/ZT 78[=("3&JH3C<0 "<=
M,]SC/&: (S96_F&;RHO-/63RTWGC!^;;DY''7D<4 3A @"J H'0 8 _ < ?2
M@!-@&,  +]T   ?0#I^% "-$C8)521TR!QWSTX/TH > /3I0 N3C% "@G\*0
M!F@!!3 KH.&_WJ 'D?-^% #Q0!=M_N_C0!/0 4 % !0 4 % !0 4 % !0 4
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M_P!T_P!* .AH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#EO&LABT:Z<=5CS_X\M8U'RPDS"KI"3\C
MYLLKO>@DC/##!_J*Y82NKH\N,M+HW+R RQJT?S;!D^N#Z?3M6[74Z9*ZNBUH
M%X58VS'(/*>Q[C\N?K3@^C^1I0GKROY?Y'5UT'<% !0!O:+T?ZC^M &Y0 4
M% !0 4 % !0 4 % !0 4 % !TH * "@ Z4 % "4 +0 4 '2@ H * "@ H .E
M ![4 % !0 AH :>* (30!4DXH S)SQ0!BW!ZT 85R>OTH ]QTTYM8C_TS7^0
MH E/WS]!0 /_  T 2=J %(([4 -R10 X9H "#Z'\J $VGT/Y4 &#Z'\J *UY
M>0Z?"US<NL4,8^9V/RK]<9_QH JZAJUKIL7VBXD54RHX*G[_  I(!R ?4C%
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M'>@#K_I0 IH ,8H 2@!0* %Z4  I !H K+U;_>I@/;[WX4 .6@"];_=H GH
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M?)_!<<4 6@">@H 0 GI0 'C@T 9FLZA_9-I)=[0YC"X0G;NW.JG!P>@;/ -
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MK*%*E5/.[[JDT 9VJ?$.SLI85C\R1/M7V:Y!CF62'Y-ZLL13<X8'.0 -O)-
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MKMB8Y[.)T"0S)!YBR2K(4,H5D8KY;%9 K,&! (7) .TS0 M !0 4 % !0 4
M0S=OK3 E08S0 P=*0&II9_??\!- '1T % !0 4 % !0 4 % !0 4 % !0 4
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M6ASN!<CY>2: -4$%/,'W-N[<.1C&<Y'!&.<T 95KKME>>5Y+D_: 3"2C*L@
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M">@!P-  : $Z4 % $"#EA_M4 .;KQZ?UH >O2@"Y;]#0!8H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M<HJ\X.: ,^[U*VLC+/9/->0)!(952XED'F&6%(<2EG\LD-*TC(=P1=[#Y5H
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M"H1MW(!V>GV4<%Q=7'EA9)IS\^T!F0)&%&>NP'.%Z!LG&2<@'*7MA*RZA;-
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MD#?\LY00<!3T<9SD_*,4 4)[#44-[&((W75HU!=7SY#F$0NK_+\Z+RRD;<X
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M52JF,[E\MMK,"2''.<4 01^%K>)+F%'D2.\B2$X.&1401@AL?>(7)..I.,4
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M1GTH Z*@ I %,!:  4 % $2CEL>M  001]* '@8H MVW0T 6: "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M*\4V^KW(M8HIHQ(DDD<C[0DBQ.L;[0#N&&<8W 9&2,T =1TH 6D 4 %,!<4
M&,4 0@[6:@!S'D?2@!PH MVW?\* +- !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MC$1.3M5PQ!XYH NGQ'=:LL+V<MJLWVD,L'SM)$%@F)6Y"N,]AP$YP: ,N_\
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M@"W;=30!:H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M2[/I7RY]L7: ,O6M/;5+*6T0A'D4;6/(#*RNN?;*@'V- $=O?W<C+%+:2(^
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M^4!%4%@% WMER!R30!<N=#M;Q4CG4ND<$EMM)(!CD\O=G&#N_=(588*GD8-
M#;#1DL9?M#37%S($\I6GDW[8\YVC@=^=QRQ[L: &WNA0WSLTLEQY<H DA69Q
M#(!V:/. ".&"XW#ALB@":]T:"]97W2P,B>6#;RO"3'_SS/EE<J.=O=,G;C)R
M 7%M(5@%J%'DA/+V=1LQC;^7XT 92^&K 1-;LCO&VT /-,Y0(0R>4S.6BV,
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M@A#\M]QOE);?D<&@#1;7-'TNW@7>OE)$I@"H\A6(!D#C"LRJHB<.QQC:=WN
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M(Z,6>-1TV%6#  >6ZO\ ,H7:0#L-%OA=VZ*S;YDC1I."#\V=I)Q@[ASP3[T
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MR?@\@:=BXP+A)9!=;\;A-N^8L3V)SM/0]J ,WQ'J7E^;<6DTZ26DL4;8E"0
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MIUP;-W%Y]MEF"OC,D32M\@.>GEG*9QSC.* *-Y!XF+7(@:;+QRA#N4(H*1&
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M+QRT@,0W*LDHEG4/NRPDRRJ" $##&<4 =996ILHA"7>7;T9^6QV&?0#@>PH
MM4 *.* (C]YOH* $S@CZ&@!Z\4 6[;J: +5 !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M9/UJ@O\ E[#_ ,"0TZK9CK/%_P!]BG["K_S[E]S)^MX?_G]37_;R&G5[$?\
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M+#3]>MYH\%XK=Y+IY$0I_K9)6D5Y-W_+-U;@KRK#W% %N/1=36[L;N8R3^0
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M@!U "Y(Z4 )R:  9'':@!2QZ\\4 !)/.3F@!.?\ ZU !B@ Q0 8H ,&@ Q0
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M ;2 N67^N3_>% '64 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@1!."H!^?=D].* -^7PQ*EI':1!)(H+N698)'94>)W8H&?E@8LAU&#EE"^]
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M_GI0 N2* #F@ I %, H * %% $);:Y^@_K0 YN=O^>U #A2 LV_WC]*8%N@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M9HCNOAPV)KI?]B(_J]?/YAM#UE^A]5E6CJ>D?S9ZN*\$^I((NI^M #W'(^E
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M]:N^C*Z<>VQTTY:<IU<EWYT(0CE<#(],]Z[6]+'7S75C;TOB+\:S9S2-*LR
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MO_5?C0R9&E69F% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MRQS( 0"RLBL02#D ]<M?-6,+,J(4PHV,6!50 "<JNTGNO./[QH LT ** $H
M!0 M !0 4 &* "@".7A:: $H 3_&D!9M^)$_WE_F* .OH * "@ H * "@ H
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M>#AU^H_G0!V% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MAG8'7*NX_NJ=V 3C - &S::O:WEHVH0LQMT#,S%&5E"C)RC#=G'(&.001UH
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M?\BB)HRBX&5)8 2 -NVNO!7&23F@#KJ "@!0* '"D F* *TGW_PI@.8\#ZT
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M[O/]!0!4M;."Q#+;HL0D<R/M&-SG +'W( _*@"UF@!/Z4 % !0 X\4 +2 *
M*LI D&>XI@3%.,#L:  4@)X/O?A3 NT % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H X;XD_\ (O7G^Y'_ .C8ZYJ_\.7R_-'-7_AR]%^:/CJ3D'C[H_2O
M#1X*=K#+.0NF#G@=^M.2ML$E;8ZS1Y_-S;R_,B(Y4>I.?Y9S["MJ;O[KV2=C
M>F[^Z]K,QKNW-K*8SVY!]0>E8-<KL827*[?<5ZDD<G6@9TMO_JQ]:BIT,JFQ
M+7.8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M8,9H =2 F@^\*8%V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *!'Q]XZ_Y
M#MY_UV:OO<'_  (?X3X'%_QZG^)_F<-=*8R)4ZYYQW]/UK>2M[T=^OZ&$7?W
M7L,D"R@3'&0,#U!+8'Z'%#2=I_+\1J\?<_K8LV\GF)@]1UJXRNK=5N1)<K\B
MRS%NIZ  ?05IML9["4 % %R/I6;)96D^]5HH93 * "@ H * "@ H * "@ H
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M18!/,'3!_+_Z].P 9,=C^7_UZ5@%W>Q_2@8Y<D]#QS0&QV=( H * "@ H *
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MR1]"1GZT 4CH]F42+R4V1,S(HR I<Y8C!'WB22#P2>10 @T6Q (\B(AF#G*
M_,N=IR<G*Y.WTR<=: +1LX",&*,@$]44_>SNX(Q\V3N]<G- $JPQH J(BA>
M J@#'3  P.O:@"F=)M&G%T88_.&"'V\@@%01V!"D@'&<$C- &AS2 7)Z"F G
M- !0 8H * "@ H * "@ H 6@!10 9H 0F@!* "@!: % Q2 7I0 VF E "DT
M)0!-#]X4 7: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^//'/_(<O?\
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M/_/Z?WB1ZM=EUS-)U'\7O3="DD[0C]PEBZ]U>K-Z]SZ0':OC#],]!U PH *
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MW\N_Y>+_  _J?)9TM*+\Y_\ MAP8Z5[I\B+0 E,!>E A*0P(H * $H 6@ H
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M_68ZI/R1)2+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M5C_0UF\PET@B/KLND4O4JM\4=0/W8(!]=_\ \54?7ZG2$?Q_S)^NSZ1C^/\
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M]1_*IDK:DR5M2W4$#X^M-#1TT'^J'UK.IT,J@^N<P"@ H * "@ H * "@ H
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M?\S^\K-=3M]Z20_5C4\TN[^\7-+NR(R.>K-_WT?\:F[[O[R;ONQH)'<_F?\
M&@0N3ZG\S2 * #% 6#% 6#I0 E "T!8* #- !0 F: %S0 9H 3- !F@!<T '
M- "9Q0 ;AV(H&+1L+8^C? 1<Z+!YG8MM_P!W)Q^N:^JPB_<QO\O2Y]+AK^RB
MWY_AL<K9(L7C-PO\6YC]2I)KA2MBW;S_ !.):8I_UN>VU[A[ 4 % !0 4 %
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M(VF$> <9)P.<?_JH ?&PD. R _[P./RH*L/V,1P4SZ<G^5 6(O+E;[H!_P"
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MM82CUN::_#S2E_Y8(WU>0_UK182BOL_BREAJ2V1S^M_#G3)8F$47E.!P8Y)
M0?H2 :U^KTMN1&GL*2TY4>,W_AZZTN=44GR^!(LAR=N<%D/)) YP>]<-3!1=
MN334Y)X.+_AZ=SZ'M/$>F6>FK<HX2"!53:!AMV/NA<9))YR!CFO1E*%"%V[1
M6G]>IVRE&C!<SLHI;=SS7PKJ!U3Q,+LC;YSR,!Z JQ _"O!H3]IB?:?S-O\
M \:C/GK\_=L^B:^E/?"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M]Y_D=<::6^YL@ # X KJVT-A:!;!0,* "@ H * "@ H * "@ H * "@ H *
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M[/YFGU:DOL+\?\QTOA#18^%L0Q]MY_\ 9ZOZM17V%^/^97L*7\B_'_,Y;6O
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M@ H * "@ H * "@!,T &: %S0 9H ,T &: #- !F@ H * "@ H * "@ H *
M"@ H * "@ H ^-_&7_(:O?\ KXD_]"K[_"_P*?\ A7Y'Y[B/XU7_ !R_]*9S
M==ARF>Y:&?(^X1R,>O4Y]1UQZ9]:YW>,K]+=OU\NW8W5G&W7^OS&3(4?T_B7
M'; [].^:)+E=EZKR_JPXNZ_!EMQ]HCR#@D9!Q^?^%:M<RTWZ,R7NNSV*4 WJ
MR-P201VY'3\>U8PMJGIK_P ,:RTLUV_X<U!Q70C O)]VH>Y!5D^]5HH93 *
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MX4F@"MYE "^;0 >90 >90 OFXH 42T +YM "^90 OF4 +OH 7>* '!A0 N:
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M)J '>;0 [S* %\P4 *'H =N% "YH ,T +F@!: "@ H * /-?BQ_R 9?]^/\
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M >;0 HEQ0 OFT *): '"44 /\X4 *)10 X2B@!WFB@!XD% "B2@!XDH 7S*
M%\P4 +YE #PU #J /C?QC_R&[W_KXE_]"-??87^!3_PK\C\^Q/\ &J_XY?FS
MFZ[3D"@#/=# ^Y>%()X'?C\?? K!KD>FVINGS*SWT&S$K(DBG )!ST^H_$?Y
MS4RT<9(:V<67&5;A,?PL.WYUONM#%>Z_-#T&U0.F!BA:*PGO<T4^[2>Y!3?K
M5="A "3@<FGMJ!LVFDEOGFX']T=3]?0?K6;ET1C*?\IOJH0;5& .PXJ# 6@0
M4 % !0 8I; %, H\P"@ HV .E !TH * "@ HV * "CR .E !0 4 % !TH *
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MW\CY5KQ#P1K*'!'Y?6FM!IE" DJ83QCH3ZY_QJWI[QK+3WB6U<\H>QX/\_\
MZU$ELR6NJ'S#:0WKP?PI+L)=BU 2V">_^-+9A:S.JA_U0^M85#"H+6)B%(!\
M<32L$09)Z 523D[):]@2;T1U5AH0A(DN<.1T4=!]?6O1IT.76>OE_F=4:5M9
M'1  <#@>E=OD=&P4!L% PH * "@ H * "@ H * "@ H * "@ H * "@ H *
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M\-?5.S/0C7MHTRR-8@A&"^<>@_\ KUS_ %::^TOQ-?;I_98QO$-L 3N8_P#
M1_\ %57U>7\Z^X/;?W?Q*Q\36W8MQ[#_ .*H^K/^?\ ]M_=_$CB\16TCDJSD
M_0 #\=U4L,U]K\ =9[<J7S_X!8778IOE02'MU0?S:M?JS>BD_N,O;\O1?>65
MOH8SB3*Y/=E_HQK2.#\V9/$OHD3_ /"065H0 3(^,@ _ID UTQPJCJV<\J[>
MB1DZOXD>\B4D&",'[BGESU ;V_K75.<*$;RT_/Y'GU*D8+FF[>7=G$N[S.9)
M#R>@_NCT_P#KU\M7K.M+F>BZ+L?.5JKJRYK62V1U'@D[=;M/^NA_] :C"Z5H
M>OZ,>'_BQ]?T/J6OK3Z8* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * *]W_ *IOP_F* ,6@!* $S0 W=0 FZ@!-QH -QH -QH -YH 7>: %$AH
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M * "@ H * "@ H * "@ H * "@"O=_ZIOP_F* ,2@!I.* &$T )0 F: &YH
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M4 -WT &Z@ W4 )OH -] ";Z &EZ $W4 -+4#/FGQ$<ZG='_IO)_Z$:^_PO\
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M7^MAZ$_>8#KG@<C^7K0U;8#JZD# \2C-A)[;?_0A7H8/^-'Y_D>/F2_V6?\
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M\*-ZN0]$* "@ H * "@ H * .0U3_CY?_@/_ *"M &>: &&@!A- #": (B:
M&$T ,)H :30 PM0 S=0 TM0 W=0 FZ@!N_% ";Z $WT )YE !OH 3S* #S*
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M]=@W^04@V#'I^E/T#7H !SC!SZ8H ,>F<^E ??Z#6&.O!'X4T/88:8/6Q U
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M5/\ '+\S(KL.0* "@ H *  #FD,[+38]D0/K7/+<XYO4M-UIH@;3 * "@ H
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MX&Q0N/0<_C2L(WA<(!R:8@^U1^_Y4 'VI/>@ ^U+2 7[0OH:8%2[5+N-HF&
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MF2@!OF4 ,,E ##)0!RGBY\V./]L5Q8GX/F<.*_A_-'F->*>&% PH * "@":
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M % !0 4 % !0 4 % !0!6O/]4WX?S% & : $H C- #: &F@!M "4 -)H 90
MG2@!I- #: &DXH ;F@!": &[L4 )NH 86H 3=0 TM0 W=0,^=-:.;^X/_39_
M_0C7Z!A]*5/_  +\C\[K_P 6I_CE^9F5UG,% !0 4 % "CK0!WMLFR)1["N5
M[G"]V-;K5(!M, H * "@ H * "@ H * -#2]2ETFX6Z@QYB9 W#(YZUC5IJM
M!PEL^QO2JRH356GI);:7'6NJSV=V;Z+:)B7/(R/GR#Q^/%*=*,X>QE?ELE9/
M738(59TI^V@[2NW>VFM[Z?,99ZC-91RP1[3'<J%D5@"" 201Z,"3@]J)THU)
M1D[IQ;:L_*UO1JPH594XRA&W+-)235]G=/U3V9.FMW48MPK*/L))AX'!/7/]
M[\:ET8/VC:?[SXM6:*O4C[.S7[J_)IM=W^9FRR-,[2/]YV+'MR3D_K6Z2BN5
M;+]%8YVW)N3W;;?JW=FS8^)=0TV$6]K+Y<:DD#:#C<<GD^]<L\-2JRYYQNWI
M>[.RGBZU&/LZ<VHWO;UW&Q^)-1ADDFCG99)B#(1@9(&!^E-X>C)*+BK1V78F
M.)K0<IQJ24I;N^K]2G?ZI=:FRM=R-*4!"[NP.,X^N!6M.E"E=4X\J>]NIE4J
MU*UG5DY-;7=[7[%:.XDA5XXV*+* K@=& .X ^P(S]:MQ4FFUK';RZ?D9J3BG
M%-I/1KNDT]?FD_D/BO)X(G@C=EBE^^@.%;ZCOTI.$9-3:3E'9]5Z#4Y1BX1D
MU&6ZOH_4C6>1(VA5F$;D%D!^4D="1ZCM5<JNI65UL^JON+F:3@F^5V;71M;?
M<6_[7O0 //EP. -YXQTK+V-/?DC]QI[6I9+GE9:+5Z%0SR,NPLQ0G<5R<%O7
M'K[UJHQ3NDK]S&[VOH GD3&UV&T$##$8!Z@>@/?%'*NRUWTW'=KJ]//88K%#
MN4E2.X.#^8IM)JS6@MM4)N)&,G [9XIVZ@)0(*-P"@ H * "@ H 0TF,@>D4
MC/FK)FT3#NN]8'2CZOMCF%#_ +"_^@BOC);OU/T6/PKT7Y"R=OJ*@L>#UI@,
M'2D _I0!PGCFX_<P6@&3/+GZ!<9)]?O8Q5K2X=3#MIA"/>D4CT'15VQ;SU/]
M>:@9T*M3)) U #MU #@V* '!J '@T 2*U BKJ$ N(2#U7)'U_P#KTT(RK=2(
MU!Y(%(9FZZ,V,P_V/Y,*[,+I6AZ_H>=CE?#5?\/ZH\CZ5]@?FA)#*$\P=-T3
M_C@9P/?BO)QZO23[27XIK]3Z/*'RUY+^:$E^3_0REN,RG/0A2/I@&OF3[D]=
MT28/#O7OQ^5 '2Q/D4#)P] #@] AP:@!P:@8_=0,<&H$4-<(^P3;NFP_TKHH
M?Q(>IPXO2A4_PL\,%?:GY@'2@"!3@'ZTBB7M02+G% 'T!X0.=*M_]UOT=A7R
M.+_C3]?T1^CY=_NM/T?_ *4SI*X3U0H * "@ H * "@ H Y#5/\ CY?_ (#_
M .@K0!FF@!AH 8: (30!&U $9- $3&@"/I0!&30 TF@!A- #3Q0!&3B@",M0
M!&6Q0 PM0 W=0 PM0 TO0!&9* &^90 TR4 1EZ .8\4MFSQ_MBN+%?!\SAQ7
M\/YH\[KQ3PPH&% !0 4"+VFQ^9<(/0Y_*M::O)+S-(*\D>PV'^I%>G(Z9%RL
MS,* "@ H * "@ H * "@ H * .DL=0M1I[V5PSH7D+950W& .[#TK922C9G3
M&45!TYWU?17(I-3@@ACMK,.4CE$K,^ 6(/0 $\?C2YE%*,-KWN'/&*4(7LG=
MMZ,M?;]-%W_:'[X/G=Y>T8W>N=W3/M57@GS=2^>GS>UUOO82WUV"VCE_=>;+
M<2;G#\)M[#/)X^E+F23TNWT$JJBGI>4G>SVL/GU^WN1 [1&.2V<, F"NP'[H
M/!Z>W6CG3MIJOR!UHOENK.+OIV[(J:C>Z?>O).$F$LG(Y 4'&!D9Z>M*4HO6
MSN1.<)MR2E=_<9>GW(L[A)V&1&<D=SP1_6HB^5W9G3ER23Z%S3]26ROC>,I9
M<R' Z_/G'Y9JHRY97*A/DFYVTN_Q&V&HK9W9NB"P.[Y<_P![I^5).SN$)\L_
M:=-=/4M6VJ6PMOLMS$T@$CR##;?O$_T.*M25K-%QJ14>22OK<=#JUM:&46T3
M(LT6S!;.&RWS9QZ$<>U"DE>RZ JL8WY59-6,\:AYEH+28%_+<.C9Z#NI]<CI
MZ5'-I9]S/G]SDEJT[W-*3Q/=!QY&(XE"A4QD@  8S^'I5^T>RV-/;R7PZ+30
MBN];$XN L>PW03/S="N<GH,YS2<[WMU"=2_,DK7L8!K(YBXUYNM%L]OW7+[L
M^H QC\/6JOIRE\WN\GG>YGT(@8U4!"U(96>@HI2U0S/DH*1GRT#*$E,HI-3&
M:F@'%]']342V$]CU&N4S-_1=+BOUD,N05P%QQ@GUKHIP4T[^ATTJ<9J5^A>T
M[2(FBD\\9<,RKV^Z <_J*UA35GS;WT^1K3I+EES;W=OD9\=O&;**7 WF<*Q]
M1GI]*R27)%VUYC%17(G;7FM^)L3?8WNCI[0*H/1U.#DC/3'OZUN^7FY&DEW1
MT/EY_9N*79HYJ33)U\QE4LD1(+#_ &>]<CIO6RVZG*Z<NBVOJCH7U-K-;:,*
MK)+&NX$>IQQ75S<O*K732N=3FX\B:336OS!M,6+40T0^14$VT=CSP/KBER6G
MIM:XO9VJ:;6N&IW#0-;ZB%,;$;74]?<?ETHF^5QJ)6Z,4VX\M7:^C0S4TCTZ
M!WAX-X0?]U2 2!]<FB?N1NMY!4M3CS1^V<ET_"N(X!#0%@S3&%(0M !0 4 %
M !0 4 )0 4 (3B@ SW[4!L1R3K$,L3CV!/\ (4Q^A76^1AE%D8#T1OZ@4[/L
MRN5]BS;&2Z.V.*4^Y3'\S1ROLQ\DNS-5=)O&_P"6+CZ[1_[-3Y)=$'))[1?W
M$@T2\[QX^K+_ (T^275%^RF]HL7^P[LG'[L?5S_131R/R1:H5.Q7NM*NK925
M$4A Z!V!/MR@'ZU:IM]45]7FMSD3KXMW\N\ADML\!B-R_B1_A2=*4==S.5*4
M5>QT",' 92&4C((Y!%8G.6[$XN(_]]?YU4=UZEQ^)>I[57KGM!0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!6O/]4WX?S% & : &F@!AH :: &
M&@!* &F@!AH 2@!AH ;0 TT ,H :30 PF@!N[% #<T ,)H 3=0 TM0 W- 'S
MQJ__ !^S_P#79_\ T(U^@X?^%3_PK\C\\K_Q9_XI?F9U=1S!0 4 % !0 ^(9
M<#W'\Z0F>@J,*!Z"N4X2NU6AC:8!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0!F&@!IH C- $)H C- $1H B:@",T ,H 8: &F@",T 1MQ0!$QH C)H C)H
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M0 A- #": &DT (30 PG% T?/>JG_ $R?_KJ__H1K]"P_\*'^%?D?G5?^+/\
MQ2_,H5TG.% !0 4 % %S3T\R=!V!S^52]"):)G<CI7.<16:J10VF 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 (:0R!Z12,Z:LF;(Q+KO]/Z5SLZ8GU+I!W6-N?6&,_\ CHKX^II.2\V?
MH-'6E3:_DC^1<EZ#ZC^=9FY(IH 8*0$3]* .:UFV%W$T+=&';L1T/X&@I'&H
MX'S$?,ORN.^1QN^AI%G6Z-=*5,8Z#D?Y]J!-'4Q],@Y%!-BRC"@"4$4 /!%
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M 1DT ,)H 86H C+4 <WXC?\ T<#_ &Q_(UPXKX%ZG!B_X:_Q(XJO&/%"@ H
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MY?\ ;O\ Z2C]#RS_ '6GZS_]+D=97GGLA0 4 % !0 4 % !0!R&J_P#'R_\
MP'_T$4 9IH :: (S0!$PQ0!$PH C(H B84 1&@!A% $9H :: (S0!$PH B(H
M B:@"(T 56H @)Q0 W- #": (R: (B: (R: .>\0(6A!'9LG^5<>)CS4[KH[
MG%B8N5/3H[G&UXAX84 % !0 4".OT>/RX5/]XY/YX_E7IT5:/WL[*>B1Z#8_
MZD5JQS+=9F84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M.3UXZU[&#BHS=NB/-Q#O%7[LQM%!6UA+<$A6QTZD5K)WDWYGR4_BNN_ZGO\
M;G,2'U5?Y"O56Q[*V):8PH * "@ H * "@ H * "@ H * "@ H * "@ H *
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M5] *]B*LDNR1W15DD=I8_P"I%)DS+=09A0 4 % !0 4 % !0 4 % !0 4 %
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MMCQCVJR.;>,_],U_]!%>O'9>B/;CLO1?D6:HH* "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 5[O_5-^'\Q0!B4 )B@!I% #,4
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M?<0KJ-NO3^74^M8>UIKJ:>SJ=F(-4A7J,X]J7MZ?<?LI]AO]J1\8!XSVZ_\
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MGZR'\./Y5SNK-];&7/+N5'E>3[[%OJ2?YUFVWNVR;M[MD>,5 @IB"D,*8!0
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M4\D_X?K7#/$-_!9>IS2JO:)BSW,EP<R,6/O7'*3EJV8-M[L@J"0IC"@ H *
M"@ H * "@ H * "@ H * "@ H$-H #3*&&@!C50!',]N=T;%3['^E7&3C\+L
M6FX[&E#KKKQ.-X]1P1_/-=<:\HZ3U\T=$:C^T:R7<5QS&P/MT-=\9QEL_D=,
M9)[$$M:%HS9:"RA)3**IIC&].?>F(]@"[D'T'\JXC(HS6P:F,J"T*'<N5(]#
MBFG8I.Q>$USC!<D>X!_F*T]I+NS3VL^[&DS'^,_D!_2ESR[L7M)/JQOER'J[
M?G4\S[D\S[BBV)[M^9I7)N+]E^OYFD(>MH!0(LQP!:0RTJA:1(^@04#$H *
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MK79ILK'^[7VZX^O:O/E7D](^ZOQ.:51[1,1F+'+<D]ZY7KJ8>HE(84 % !0
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M>OOZUNMC9>M_,U[?_5C\?YTQDU !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M.: *K0T 5V@H K/!Z4 5GA- %9H2* (&3% $17% #"* &$4 ,*T 1E: (RM
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MY:#^%?R'^%%D@LNPH4#H /P% 6'9Q3&&30 $T )0 4 % !0 4 %( I@+0 4
M'2@ H  ,\"@"*XFCLT\R9@B#C)X&3VJ6U%7DTD2VHKFD[(\_\4ZG'8:1,UE*
M\HN)!'DMGRR<E@IZ]AU)Q7FUZBA1DZ<F^9I7[7N>?7FHTVX._-IZ'A(&!BOG
M?0\+;3J>A?#><KJ36ISY<\+[AD@?*.#QTZ]1@UZ6"?[QQ5]8O\#T<&[5'!;2
M6WH>W6Q*8B2)HT7H2>/UYY]237T,;IV2LD>Y%VT47Z]#>MON#\:LHGH * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H 0C(Q0!$4H A*8H C*4 0F/
M'2@"(QXH B*XH ;B@!I% #"M #<4 -Q0 TB@!I% #2M #2M #"E $96@",K0
M!$5H C9* (&7% $17% $9% $)&* /./'6F@!+Y!SG8_T/W37T665>64J+>CU
M7^1\WF=&ZCB(_P"%_HSS>OJ3Y<U-(7,Q/HI_4BHEL9ST7S.G%9G*32RB),MP
M*A;B2OL<U=:N>5A&/]H_T']?TK91.E4^K^XQ&8N=S')/>KV-MA*8!0 4 % !
M0 4 % !0 4 *.H^HI#/:_&WBJ_\ #US;VM@8HHFLX9"#$C'<VX'G_@(XKY["
MX>G7C.=7F;5227O/96M^9[N)KSH.$*5HKV<&_=CJVGY>1DW3Q^)=)AUN:)(;
MZUO8H)'C4(LZLZD$J.-PR.>N<\XK:-\-6EAX-NG*FY)-W<;)]S"35>E'$.*C
M4C5C%N*LI7LUIT:Z]S0\:>%$O]7DGDO[&T,P39%+(5D&%QE@%(4'L<UGA<2Z
M=&,%2JRY;ZQCH]>CW9MB<.I5I2=6E'FL[2E9K3K9-+;J>:W_ (?N-,U$:5<M
M''(S(HD+?NL28VOO_N8/)QD<C&>*]:%:-6G[:%VK/2WO75[JW<\J=*5*?LIV
M3NM;^[9VM*_\MG>_1;['00^"%O6>#3[^SN[F-6?R8S)EPO78Q0*Q_''O7,\7
MR)2JTJD(MVN[:7ZNSNOF;K#.;<:=2G*44W:/-=V[7BD_DRWX6T.UU+1M2-V8
MK:6%X@MQ,"!%RVX'&2,D;2 #48BM*E6H\EY1:E>,;>]M;?30TH4H5*-5S:C*
M+A:4KZ:ZK376UMFRGX?T^#.J6C7,2P"T4&YP_E8%S V0-NXY(VCY<EB.U:5I
MR7L9\DN;G;Y+I/6$UOM^)C2BFZL7))>S?O6E;2I3Z6YM>BL0P^$8M2@FGTF\
MCO'M4+R1&.2*0J.K('7##KSP./6AXETI1C7IN',[*5XM?.S*6'52,I49J3BK
MN-I)V\KJS^\S=,T!;FR?5+R86EHD@B5MC.\DA&2L:#&=HY8E@ *WJ5G&:H4X
M\T[<UKI67=O<QA2O#VTWRPORWW<I6O:*V];M:$E]X=2/3_[6L9Q=6JR^3("A
MCEB<C(W(<C:1C#!B,D5,*[]K["K'DFU=.]XR7D][^J'*E^[]M3=XWY6K6DG:
M^JVMYIO70LW?AVQTJ*VDU"ZE5KV%9U6& 2*B-T+,70\=PH)XXJ(UJE5S5&"]
MR3B[RLVUU22?XE.E"FH.K*7OQ4URQ3LGLG>2=_1,EU3P[INAO'%>7<TIGC66
M-K>!63RV^Z6+R1G)[JH.._-%.O5K)NG3BK/E:E)IW6Z2C%_>]RJE*%%J,YMM
MI27)%-<KVNY2CKY6=C$U[17T&Y%NSK*CQI-%(H(#Q2#*L >0>H([$'DC!K>C
M55:/,KIIM.+^RT[-&%6FZ4N5M--*49+9QDKI_H_.YBUTF 4 % !0 4 % !0
M4 --(9"U(I%&:L6;(RINM<\D=$3Z5^$D^[1 ';D7$@&2.><\>M?,8Q7J77\J
M/IL$U&EJTO>?W^7?Y'I[_=->8>J4Y;IH9XHBHV3;@'ST91D#TP5![]JWC!.$
MIIZPLVNZ>C^YV^\Y9U73J4Z5M)\R3ZJ25TO^WE?[BQ/]QQZJW_H)K&&DEZK\
MS>I\,M-.67_I+,>W_P"/6+_KFO\ *M:W\2?^)G/AOX-/_!'\CB=1:::\>,8\
MF*-=PQU=^1SZ!>2/>B48QI*3^.3=O**TO]Y4)U)5Y4U_#A%.2[REJONC9_,P
M8VDLBR#]Y$3GRV. /<'G&/48_&N3\ST/R,FRU879?R8I0B.5!)WJ3W*D8X'X
M45H.-E.VJO;MVN10J1GS.G>R=K]&^MC6%^V,&-N/4\?D:\_V<.AZ/M)=R1;X
MKTB/MS3]G#J@YI]P^W2]HP/U-/E@OLCO+N3QZC*/O1J?Q(_QIKD7V?P1#4G]
MH<+^8'*QH!Z<_P"%7>/\I/*_YATD]Y=#;'MA]U&?PYJN9=%^)/)W;.FTZTO9
M8UCEGPH&#M0!C_P+/!]P*UC)VT27F8R27<[*SM4M5P@QZGN<>I[UIKU=S-OL
M7*HS(I#5(3/&M9'^ES?[YK['#?P8?X4?FF,TQ-7_ !LYNXBW#_/%=+.:+L84
MUF6K)Q.E3L0C2_U].*CD^17M!?[,_E3Y.X>T#^RA1R(/:"C2A3Y$'M!XTM11
MR(7M&2#2UI\@O:,MPZ4 >!^E5RI;D.;>B-F&T,0^Z1CVJDULFOO,9*6[3^XN
MJ,#Z51@.H]!$L$SV[K+&=K(0P/N/\\U,HJ<7"2T>GR9I";IRC4@[2B[KU1ZI
MIVH)J<7G*-IP0R]=K#J/H>H]C7QU>B\/-P>JW3\G_6OF?I6%Q"Q=)54K/9KL
MUI^.Z]30V!XV5AE6&"/4&N=.S36C6J?F=C2DG&2O%JS7EU/+]9TDZ5( .8Y<
ME#Z8QD'W&1]:^NPU?ZQ'56E&U_/3<_.\=A/J<TD[PE=Q[JSUB_-71WGPV;Y;
ME?>,_HW^%>=F.\'_ (OT/9R9Z55_A?Y_Y'J%>"?6A0 4 % !0 4 % !0 8H
M:4% $9BH A:'VH @>'B@"H\(]* *KV] %62#VH J-$10!$RXH C(Q0 PB@",
MK0 PK0!&5H 84H B,= $12@",I0!$T= $#1T 5VCH KO'0!6=* *SI0!7=:
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M!F72RR?($D<>H) _6@#E=4NKO1OG7<#G(1^58=USV./0T ;VCZQ%JT0=/ED
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MLQ_APV+B<>J+^C-_C7O9C\$/\3_)'R63.U2HO[J_-GKE?.'VH4 % !0 4 %
M!0 4 % !0 4 % !0 4 % "%0: (S&* (6MP: *SVHH IR65 %.2R/:@"D]J5
MH JM$5H C*8H 9MH 0I0 PI0!&4H C9* (&CH K-'0!5>.@"HZ4 5'CH JNE
M %9DH RM1M/M,+)WZCZBI<>9-2V>A+2DG%[,S8)/,0$C!'!'H1U_6N5KE=CR
M91Y'R]B5Y/*1G]!^M9R?*K]B'IJ4Q_JEKPZF]V>94U&5B8A0 4 % !0 4 %
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M?.>:^A/&/2K3[I^M,"U0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M3^M>'6NIV?38\"I%PGROH; _U2UP5#AJ#*Q,0H * "@ H * "@ H * "@ H
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MU?+LBR&8-G?(1]T8ZJH_6NJUCGN>O*JH J@!0, #@ 4Q%ZS[T 7: "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H 3 H 88E- $+6JF@"K)8^E %*2T9>E %-XBO44 5&3% $#
M"@"!EH @88XH S[ZT6\A:%^C#\CV/X&M(3=*2G'=.YC5IJM!TI+22L>%:W&\
M%T89.#'\OU[Y_&OO:$U5IJHNJ_'J?GM2B\/.5*6Z?X=/P*;?=K?J8%$]:LL*
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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ME,'+$<W2,'^+2/:J^7/O0H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H ,4 &* $Q0 8H :4'I0!&UNC=10!6DT^-^U &=+HX(XXH RIM
M&D7H* ,B;3Y8\Y6@#+EA9.HQ0!0=* *;I0!3=<4 5'6@#AM:LA;S"51A7Z_6
MO/Q%.Z51=-'Z=#SL3"]IKIHR4?ZI:\.H>%4Z#*Q,0H * "@ H * "@ H * "
M@ H * "@ H * "@04#"@ H *0!3%L% !0,* $- A*!H0TQC#3$,(JAD9%!1
MU,9"PJAE5Q5(M%%UJRT4G6K195=35%H@*U0SZ"^!LQ"7L'^U&^/P8'^==^&?
MQ?(]'#/XCW&<!@589!X(/3%>@>B>1ZWX;^Q.\MNH$&=P(_@SU!']WN",]\XK
MEJ0;UB;0ERZ,Q+626 X<$K[8(/T(-<+HN>^YUJKRZK;L;\-XF.%;C_=']:A8
M6?2QI]8CYCWOE4<@C\1_C5?59^1/UE=BN=20<?U_PJOJC[H/K/D,.J;3@ 9]
MR?\ "J^J?WB/K/D0OJT@;&8QSCEO_K4_JBZR_ 7UF78N?;"HS)-"G_ E_P :
MT6$AU;(^L3Z%-]916VK-&WKCGG\.*M86GYD^WF2^=/?2)';$R;N HX+-_P"R
MX]3UQ6L:,(?"C)U)2^)GI6@Z(=.W27&'ED(Y/7 '&[MN!)Y!Z5O:VB,SI"*8
MBC-;[J .6O\ PK;7I9F78[?Q+USZD=_SYH YB?P'=<""Z  /1HQT[D88X;TJ
M;>2"[&6_P[ND8,]YT8GY8ARO'3YN'ZY;OQ3MY(+LZBV\'F-=DES(P/7"A<CL
M#\Q_.@"W#X*TY'\R4/.QZ[V^4XZ KT( ]Z8'5QQI"HCC 1%& !P /04 -<4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MN /^>BCG\<9_6O+E@H-W5UZ'N0S&I!6=I>JU-&7Q7J,G^KBMH_\ @#'^HI+
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MB*=GV8[/HG]Q&;F)>KH/^!#_ !I\LNS^X?++L_N8PWMNO66,?\#7_&J]G/\
MEE]S*]G/^67W,8=1M1_RVB_[[7_&G[*?\LON8_95/Y)?<QG]J68_Y;Q?]]K_
M (T_95/Y)?<P]E4_DE]S&_VO9#_EO%_WVO\ C3]C4_DE]S'[&I_)+[F-_MFR
M'_+>/_OL?XT_85?Y)?<Q^PJ_R2^YC?[<L1_RV3\Q3]A5_D?W#^KU?Y']PG]N
MV(_Y;+3^KU?Y6/ZO5_E8PZ_8#_EJ/R-'U>KTB/ZM5Z1$_P"$AL/^>O\ XZW^
M%/ZM6_D_%!]6K?R?BA/^$BL!_P M#_WPW^%'U6MTC^*']5K?R_BA/^$DT_\
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M= !Y= "^70 >70 NR@ V4 *$Q0 \ "@!>E "4 .12QP.M &K$GEKCOWH DH
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M H * "@ H * "@ H * "@ H * "@ H * #% $$EM')PP% &5<>'[:XZC'TH
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MC^0H E'PDTL=OT% $B_"C2U_A_2@"4?"S2U_A_2@"4?##3!_"* )E^&NF+_
M/RH E7X=:8O\ _2@"=/ &FK_  #\J +"^"-.3I&/R% #CX-L.R#\J *DG@VR
M[(/RH IMX2M8_P" ?E0 #PY:K_ /RH ?_8-L/X!^5 #3HMN.B#\J *[Z3 O\
M _*@#-GTN''W10!SMYHL+9PM '/3Z*B]!0!DOIJH>E '7>!5^R:HGI*K1_GA
MO_9: /;V7- $9CH ;Y0H !%0 OEXH 7RZ #90 NS% #@N* % Q0 M  * %H
M* #M0 4 % !0 4 &* #% !B@ VT )T[T !('>@ R*  _0T &#Z&@!0C]@: '
M>4Y[4 /%NY[4 2BT/<T 6HH1%TZT 2T % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 &* "@ H * "@ H * "@ H * "@ H * "@ H
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M% "XH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ,"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * $- #2
MM $31 ]J *[6ZT 5FM\4 5F@Q0!4DA]J ,^:WH R9K;KQ0!ERV8/:@#(GTWT
M% %:*U>V<21_*ZG*D=C0!ZMINKQ7B*'.V; W \ MW(/3GKB@#8 STH 7;B@!
MN0.I'YB@!ID1>K*/Q% ##<PKU=?S% $9O(1_&/PR?Y4 'VR+L?T/^% #Q<QG
MU_(_X4 .$RGH#^5 "[\]%:@!X+=E:@!P5S_ ?SH 7RI/[M #A;R^@% #OLTI
M]* %^R2>HH >+1O6@!PM#W- #A: =S0 [[*OO0 OV6/TH 7[-'Z4 +]G0=A0
M [R4'84 .\M1V% "[!Z"@ VCTH 7&* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!* $Q0 TK0!&5H A
M:.@"!X0: *DEL#0!GRV?M0!2:Q]J (#IV[M0 #1E:@"Q'H:CF@#3CTLJ,;G_
M #H L+I"GJS'_@1H E&C1=\_F: )1HT [9_.@"1=)MU_A% $PTZ!>BB@"06<
M2]%% $@@C7HHH <(U'0"@!P4#M0 N!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M#OC^TC^U^?=N0-QC6\,C?]^_,*L1_=7<>P!H ZKX>?$^?4[E=(UK'GO\L,^
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M'COQWP >^^#[R;4-&L[FY8R32P(SN<99B.2<8'Y"D,Z2@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#Y/^)-E)X7\3+J5M\HF:.\CQP/,5OW@/U=
M2Q]GQS3$>B?%KQ+&V@V\5LW&JE)!SUA55E/3_::('MU'M0,B\(:>WASP5=7Z
M@BXNX)YP1U4%"D)^@ \T?[QYH Y3X'V,4VHW-TX!DMX5$9/\)D8AB/0[5VY]
M&([T"/IRD,^1/B7&NC>*)+BU&QMT-SQQ^\PK%AZ%G&XG^\2:8C?^.5T[:G:V
MQ)\N.U\Q1VW22NK$>^(ES]!0@/??"MC%INDVEO  J+;Q'CNS(&=C[LQ+'W-(
M9C_$>SBO?#UX)0#Y47FH>ZO&0P(].X/L2.AH \P^!-VVZ^M3]S$,@YZ']XK<
M?[0V\_[/?/#$<G\*?^1G'^Y<?R- 'U-J/_'K-_URD_\ 032&?,OP0_Y#<_\
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MQ1X5O)+HAKJVM[B&5L8WX@9DD(' +*<''5E8@ $"@9Q?P+.+F^)XQ%%_Z$]
MC)N=0U/XJZT^GVTQM[!-[*O.Q(4(7S'12/,D<E< G@MM!5031L WQ#X=U/X5
MRP7^G7C20RL5/RE!N&&\N6/<R.C@$@YSP>%(#$ ^D]!U9-=T^#4(QM6XC5]O
M]UNC+[[6!7/?%(9D>//^0!?_ /7M)_*@#YP^'/CFV\%_:OM,4DWVKR=OEE1M
M\KS<YW$=?,&,>AIB(_&OB^;XA7=M!9VS((=ZQ1@^9([RE-Q^4 ?P* !G&"2>
M>#8#UW7-!\16>@66C:&/G2$+=NDJ1OG )CC9G7Y2S/N8,"0%'1F% SS37OAN
MWA[3CJ<^H1B^15=K<X5R6QE4?S-[.H/79\V#T')!'JGP@\076MZ;+%>NTSVD
MH19'.6*,N0K,>6*D-@DDX(':@9X7X-\10^%=4GU"8%]D,ZQH/XY&90JY[#NQ
M[*#C)P"Q'7>#?#=S\1M1DUS66WVL<F&3)_>, "L* '*1(",\Y(.!DEF" ]K\
M;>$CXITU-,MW2U$<L;J=F5"HKJ$"J5P,,,8X &,4AF%XT^'DOBN_6^2X6 +:
MBW"E"QW+))(KY!' +CCKQUI@)X*^'4GA/47OVG299+46^Q4*G=^X+/DL>"8F
M..OS#TH ]3I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 (RAP58!E8$$$9!!X((/4'N* /DC1
M2? ?C 6[G;"EP8&)X!@GXC<^P5HY._*]Z8CIOC;JYN;RVTB+GR5,K@=Y)3M1
M2/4*I(]I*$!U'C*Q;PMX)73H^&Q#%*1C[SOYDO([,X8=\@XH&0? VPB33[J^
MP/-DN/))QR$CCC< 'T+2DD=\#.<# ![@0&&#R#P0:0'R+I"#1/&RP6ORQQZC
M)"H'&(W=H]OT"MC\*8AWQ <ZMXN>WER(_.MK<#N$*Q@X^K,S#_>_&@#ZUAB2
MW18H@$2-0JJ. JJ,  =@ ,"D,\C^-5E%-HJ7+#][;W"!&[@2!@Z_1L*3[J*8
M&%X$N7G\#:DC=($OXU]E-J)./3YI&/U.>] C+^!7_'U??]<HO_0GH ]=^(O_
M "+M]_UQ_P#9UI#/-?@3_J;_ /W[?^4M-B/+KW4+G2?%=U>6,8FN(=0NVCC*
MLX8^;*""J%6/!)X(Z4 =]_PM+Q;_ - Z+_P$N_\ X]0![_HUU-?6%M=7*B.:
M>WBDD0 J%=XU9U"L2RA6)&&)(Q@DFD,\G^*OCS^R8FT;3VQ=S+^^=3_J8V'W
M01TDD'_?*<]64A@4_A/X"^Q(NN:BG[Z09MHV',:'_EJ0>CN/N?W4.[JPV@$_
MQR_Y!UI_U\G_ -%M0@/&[O2;KPO#IOB"S)"7"K(K_P!R="0R'_9=1N /W@77
MHM CM_BCK\/B72=+U"WX$AN Z=TD40AT/T/0]U(;H: /;_ ?_( L/^O:/^5(
M9\]:@Y^('C$1(=]OYPB4CI]FM\ER,] X5W&?XG QGBF(/%\4G@?Q;]O@!$;2
MK=H ,!DD)\Y!VP6\Q..@(Z4 ?5EO<)=1)/$=T<J*Z,.A5@&4_B"#2&>=0> I
M88M9B\]#_;<CNAV']UO:5L-S\V/, XQTI@<0_P %)G##[9&,Q1HH\ML*Z^4&
M?&[^)8R#WR1D\4"/=-+LSI]G!:,0QMX8XBP& 3&BKD#MG&<4AGG'QD_Y%\_]
M?$/_ +-3 @^"O_(!?_K[E_\ 0(J )?C+;)-H!E8#=!/$RGN-V4(!]PW/8X'H
M* .*\'RM)X#U-6Z1O<*OL## _P#Z$QH$7O@3_J;_ /W[?^4M# Y+XF_\C:O_
M &Z_^RT >S?$2V\07]JEIX?7B0MY[K*D4FT8VHC.R8#?,7((. %S@L*0SQ;7
MOANWA[3CJ<^H1B^15=K<X5R6QE4?S-[.H/79\V#T')8CU3X0>(+K6]-EBO7:
M9[24(LCG+%&7(5F/+%2&P22<$#M0,\N^$?\ R,K_ /7&X_\ 0EH$?5=(9\P?
M''_D*VW_ %Z#_P!&RTQ&[!\:[6RLH[>&TE>6*)(P7=%0LJ!<G&YL9&<8!QW%
M%@.;^$>CW6I:Y_;#(5@MQ,[28(5I)59-B'N0)&8C)V@<\E<@&[J'@?Q)XNU*
M277I18V8#,A$B2Q(H(VQI$L@ .,%G?;G!8EFXH X;S[CX>:XD.GW@NX5:,MY
M;?NY$8_-'(@=E#8R.I*G# @] #TOXZ?\>EE_UVE_] 6A >>7OC6>[T:R\,Z7
MN!9%CN&'RF1W<[85.1A/F&\G&X_+]T'< >\^ ? L/A"VWR;9+^8?O90/NCKY
M2$_P ]3P7/)X"@(8VU\$2V]WJUT9E(UB-T5=AS%N5QECGYL;NV.E ' #X*3!
M%3[9'E8F0_NVP7+R$/C=V1]O/.<X.*8CVKP]I;:)IUOI[,)&MHEC+@8#;>X!
MSC\Z0S8H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M)KN&'6+=2XME,4X R5C)W(_'\*L6#'MN4],D"&1>%/BE;)HOV&Y=8-1M8#%
MTH(AEV+B(EU5MI4!0X<#<5R&)8A01P^J_%34=3TJ?1[Q(GFEVH;F,@90-E\J
MN4+-@*&3:NTGY<X- 'J7P9T!],TR34)AM?4&4H._DQA@C>VYF<X_N[3WX!GD
M.CWP\!^*W:]4B*"::*3 .?+DW!9%!Y(P4D'=EX')H$>X^(/B;H<6G3&UN5GF
MDB=8HT5]Q=E(7.5 4 G+%L8'&">*!GGGP,L9&N[N]QB)(5ASV+NX? ]<!.?3
M<N>HH$<[\2G6/Q<[L0JJUH23T $<1)/L!0!]#_\ ">:!_P _]M_W\%(8V]\;
MZ7;Z=<ZI;3)=QV2KO6%LG=(P2-2?X=[D#.#@9..* /E^PF3QIK1O-?N8[:!F
MWRLSA/D'W88022./E!YVC+,2Q^9B/INV\9^&[*)+>WO;6.*)0J(K@!5 P !2
M&8/Q#U6TUCPI>W%C*EQ$&@7?&<C<+F D9]0"/SI@9?PBLXM0\-S6MPHDAFN)
MD=3T*M'$"/;V(Y!Y'- '@OBC1+GPE?3Z6[-Y389#VEBW;HWQTR,8./NL&7.,
MY8CWCX::G'HOA*6_F^Y;R7$A'3) 7:H]V;"CW(I#/%/#FA:SXPO9[W3GV7,;
M^?),9&B*O*S$%77+!B0Q&#G /- CK-;^'_BV:U>74+@W<-NK3;'NI9C\BDDH
MCY&_;D#&"<X[T =+\$->RMQHLIZ?Z1"#Z'"2J/H=C #U<XZT ?05(84 % !0
M!X#\=O\ 4V'^_<?RBIH1Z5\.O^1=L?\ KC_[.U(9X1\,O^1M;_MZ_P#9J8CZ
M8UO_ )!]S_U[S?\ HMJ0SYZ^!G_(0N_^O=?_ $8*8CG)-7BT'QM+?W S##?S
M[^-V%<NA8#N4#;ACG(XYQ0!ZW\1O&NDRZ'-;6ES#<S7:JB)$ZN0"RLS.%),>
M%!X;!W87'7 ,YKX:V,L'A;5;IQM2XCG$>>XCMV!8>VYBOU4T",[X(Q>?+J$1
M. \$:Y]-Q<9_6@#SC0]!LYM4?2];N#IVPO'YA VB5& VN7*A5(W8<G&0,\'(
M8'3ZWX7\+Z&Z1/J<URSYS]ECAF" 8Y<B4 9SP 2W? %(#Z0\&64.GZ-:P6S2
M/"(]R-*GEN5D9I 63)VG#>O3!I#(/'G_ " +_P#Z]I/Y4 >+_!;2+'5?M_VZ
MW@NO+^R[/.B27;N^T;MN]6V[MHSC&<#/04Q'T)9:/8Z;S9V\%MV_=11Q\?\
M %%(9XE\9_$=_I\EOIMK(\$$T1ED:,E6D.\J$+#G:H&2H(#;ANS@88CF-7\(
M^'-(T-K_ .V_:K^6)6B42QD-(^TG$2 OA<G)=B 1\V#Q0!UWP*_X]+W_ *[1
M?^@-0,\E\'>&H_%>M&QF<Q1#S9&*C+$(?NC/ R2.>>,\9IB.K\!:K-X$U^71
M=0.R&>3R9,\*LG_+&89. K@@$G^!PQ^[2 ^IJ0PH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_#KQ4/%&E))*V;NVQ%<#N6 ^63_MHHR3TWAP.!2&=Y0 4 % !0 4 % !0 4
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M2%&3SB@"Q0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M!WM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!RL?@C1HM0_M=+?%Z9&E\WS9OOMG<VPR>7SD\;,#L* .JH *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
2"@ H * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img46421407_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img46421407_22.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *V!),# 2(  A$! Q$!_\0
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M<36\K*MNTSDDXSG&>U:3H<L>:]R(8CFERVL>G44F:Q?%FOKX9\-7>JL@=HE
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MUHSO%<RA3--&V&&XX" ]O<_2N5^'/_)6'_WIOZU7^*5D8OB3)]J=HX;D1L)
M,[5/&1],&K<5*MKV(4FJ+MW-FZ^$>N6&DOJL.L%M3C3S#$A()(Y(#>M=+\+?
M&]UK>D7EEJ#M<7EC'YBR=6D3MGU.>,]ZP;SX3Z79:4VIW'C*=;,)O\WR@01[
M?-S6I\--'\-Z5>7^J:5XCDU%$M\3HUJT?EKUR?4^U1.490=W?Y%PC*,U96^9
MP=C=R^/?$T\7B+Q$;" @E-[A4R#@* > :[/PQX3\8>'?$B2Z7?QWNB%P&8W
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M'X"\?Q>(]*N9M5N+2UNXIB-A<*-F..O7O6"IR<>9;&[J14N5[GF%U_R6\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH!V%=313E6G)6;)A0A%W2/GSXL(LOQ)C1QE&2)3]#BNBO?@F9Y"=.UR6"TD
M/V>1"P7\F /Y5U/B3X:V/B3Q"FL3WMQ#*H0;$VX^7ZBNV1=J*O8#%:NO:,5'
MH9QH7E)R.9\&^!]/\'6<B6SM-<S8,T[CEL= !V%8GB+X8'7O%XUX:MY #(?)
M^S[ON@#[VX=<>E>AT5C[25^:^IM[*+7+8,5YEXD^$,6JZW+JNEZJ^GS2OO==
MFX;NY4@C%>G4E*$Y0=T.=.,U9GE4OP4MY]+:.?6IY=2:0,;N1"P"C/RA2W?/
M7/:M6]^&TU[X$L_#4FLC_1I=XN/LW49)QMW>_7->@453K3ZLA4(+9'C!^ I/
M7Q$#Z_Z'_P#9UH:#\%_[$UVSU/\ MM93;2!]@M-N[VSN.*]7HJG7J/=B6'IK
M5(\U\4_"2'6=:DU;3=3?3[B5M\B[-P+>H(((JHWP5@GTN1+K6YY]2=E(NY$+
M!%'50I;O]:]5HI*O-*R8W0IMW:.7T3PE-I/@J7P[+J(N-T<D:S^3MVA\_P .
M3G&?6L[P)\/#X,N[N<ZG]K^T(%V^1LV\Y_O'-=S2U'M):KN5[.-T^QP?CWX=
M'QM=VLXU/['Y$;)CR/,W9QS]X8Z5V6GVGV#3;6SW[_(A2+?C&[:H&<=NE6J2
MAR;23Z#4$FY+J8GBOP^?$WAVXTK[3]G\[;^]V;L8.>F15'P-X./@S3)[,WWV
MOS9/,W>5LQ[8R:ZFBCF?+R] Y%S<W4\[\1_"]M?\7QZZ-7\@(\;>3]GW9V'/
MWMPZ_2NM\1>'-/\ $^E/I^H1EHR<JR\,C>H-:]'>CVDG;R$J<5?S/&F^"%ZA
M>*#Q(ZVQ/"^60,>X#8-=SX-\ Z;X.B=X&:XO)0%DN'&#CT ["NMI*J5:<E9L
MF%&$7=(\_P#'?PSC\7ZC%J,%]]DNE01N2FX.!T[C!&36IX$\(7'A'3KBUN-2
M-Z9I-X)0KMXQCDG/2NLHI.I)QY7L4J<5+F6XUT61&1P"K#!![BO*M4^"\;:B
M]WH>LRV"N2?**D[<^C CCVKU?\**4*DH;!.G&?Q'F_AOX1V>DZHFI:IJ$FIW
M*'<@=2%#=B<DD_G5WQO\-+3Q==QWT5VUE?(NPR!-ZN!R,C(Y]Z[NBJ]M._-?
M47L8<O+;0\KM?@RDEM.-7URXO9VB*0$@[86(^]@L<X_"NF\">"Y?!=I=6K:D
M+V.9PX_<>7L.,?WCFNNHHE5G)681HPB[H\\\-_"\^'_%K:X=7\_)<^3]GV_>
M]]Q_E6[XP\$Z;XQLDCNLQ7$6?*N$'S+GL?4>U=-12=27-S#5."7*CQE?@A?/
MMBE\2N;<'[OE$C'L"V!7I/AKPGIOA;2C86,982',TDG+2'WK=HIRJSDK-BA1
MA!W1Y3JWP8ADU)[S1-6DT\.Q/E;2=N?1@0<>U7/#WPAL]-U--1U?49-4G0[E
M5U(7/8G))->E44_;S:M<2H03O8*QO%6@GQ+X>N=*%S]G\[;^]V;\8.>F16U1
M6:;3NC5I-69R?@7P:?!FFSVAOOM?FR;]WE;,>V,FL;0_A>=&\9'7_P"U_.!=
MW\C[/M^]_M;OZ5Z+15>TE=^9'LXV2['+^./")\9:/'8"]^R%)1)O\K?G';&1
M5KPAX=/A;PW;Z2;K[3Y+.WF^7LSN8MTR?6MVBES2Y>7H/DCS<W4@O;*#4+*:
MSN8Q)!,A1U/<&O([[X%!KMWL-:,5NQ.(Y(=S*/3(89_*O8Z6G"I*'PL4Z49_
M$CB/!7PVL/!\SW?VAKR^9=@E9=H5?0#)Q^='CCX<VGC&2*Y%TUI>Q+L$H3<&
M7T(R/YUV])1[67-S7U#V4>7EMH>5V/P:4QR?VQKEQ?'RF2%,$+&Q& Q!8YQU
MQQ70^ _ LO@H7B'5?MD5R5.WR-A4C/?<<]:[,T4Y59R5F]!1HPB[I:GS78Z1
M:Z]\4[O3;P,8)KF4-L.".>HKL&^!T[W"K)XBDDM5;(5H22!Z#YL?C75Z=\,K
M'3O%I\0I?7+3&5I?+8+MR?PS7=5M4Q#NN1]#&GAU9\QDZ'X>T_P]H\>EV,9$
M"@YWG)<GJ3]:\[U#X+?\362[T?7);&.1B=FPDIGKA@PX]J]9HQ6$:LD[I[F\
MJ49*S6QY1>_!&TN+*W6'6)EO59FGN98_,,N<8XW# &/4]:Z_5_"4NL>!X_#T
MNH;9%CC0W(AZ[<<[<^WK74=Z*;JS=KO82I05[=3E_ _A#_A#M)EL3??:_,D\
MS?Y6S'MC)K#U_P"%YUOQE'KXU;R0DD<GD?9]V=AS][<.OTKT2E%+VDDVQNG%
MI(2LCQ1I U[PW?Z:2 TT1",?X6QP:V*3%2G9W+DKJQY'\$=0,=OJNBS@K/!+
MY@0_PCH?UJ]XI^$\_B?Q#<:K)KWE>;@)']EW;%'09W#-;D/@06?CUO$UA>"!
M)01/;;,AR1R<_7GZUV0S6LZMI\T#"%*\.2:V/&/^%"'_ *&$?^ ?_P!G7<>!
M/ __  A5I=P?;Q=_:) ^[R?+V\8]3Z5V%)4RK3DK-E1HPB[I'G7B[X36/B'4
M&U&RNS874AW28CW*[>N,C!]ZK>&?@[9:1J::AJE\=1DC(9(S'M4-V)Y.:].H
MH]M/EY;Z!["#ES6 #C%<MXZ\'GQEI4-D+[[)Y<F_?Y6_/MC(KJJ*A2:=T:2B
MI*S,+PGX?/ACPY;:3]I^T>26/F[-F<DGID^OK1XM\/MXG\.7.DK=_9?/*YE\
MO?@!@W3(]*W*6CF=[]0Y5R\O0Y3P+X-_X0S2I[/[8+MI9?,,GE>7CVQDUU5+
M11*3D^9A&*BK(2N=\9^&9?%FA'3([_[&K.K2-Y>_<!SC&1WP?PKHZ*$VG=#:
M35F>+_\ "A6(P?$0_P# /_[.KFD?!,Z5K%IJ']NK)]GE$FS[)C=CMG?7K=%:
MO$5'NS%8:FMD8OB;PQI_BK2FL;]#@<QR+]Z-O45YHOP*<S;6\0'[,#D*+?G_
M -"Q^->S4E3&K."M%E3HPF[M&/HOARR\/:'_ &9IB^2NT_O#R2Y'WCZFO-)O
M@7+//)+)XDR\C%V)L^I)S_?KV.BE&K--M/<<J4)))H\8_P"%"'_H8A_X!?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:Q7\
M,VKW@F\^Z6#!S:B3]T<G)X^M;=% &;<Z-!<3&59;B L KB"38' XY'TXIUQI
M%O/'"B&2V, VQO;ML*CT!]*T** ,\Z/;?8?LO[S!?S#+N_>;_P"]N]:DL].C
MLF=UDEEE? :29]S$#H,^G)_.KE%  **,T4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 44AHH 7-%)2T %%%% !1110 4444 %%%% !124M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44AJD^KV
M$=^M@]Y MVX^6(N-WY4 7J*JW.H6=DRK=7<$!;[HED"Y^F:=<7MM:1"6YN8H
M8R<!Y'"@_B: +%%5Q>6QM?M0N(C;XW>;O&W'KGI2VUY;7L1DM;B*= <%HG#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JCK/_ " M0_Z]I/\ T$U>JCK/_("U#_KVD_\ 033CNB9;
M,^=U^Z/I2TB_='TI:^G/F0HHHH **** "BBB@ HHHH *]F^&O_(G1?\ 7:3_
M -"KQFO9OAK_ ,B=%_UVD_\ 0JX,P_AKU._+_P")\CKZ***\8]D**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA_#7J=^7_P 3Y'7T445XQ[(4444 %%%% !1110 4444 %%%% !1110 4444
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MG/>N@8X&:Y"8QVMRFHZ9>/%"(Y7,$G*$A@",'E<GTQ0!NSZE.;I[>QM%NFB
M\TM+Y87(R!T.3CFFR:M(P@2TM&FN)D\PQ._E[%[Y.#WXK*TZR%YJ&JO>37$1
M,J2I%',T6T&-><J1GG(Y]*ET>>6;4[>6X))DM&2*1L R /P?J1S0!>&MYMO^
M/8_;/.\C[/O_ (\9^]CI@$YQVJ>RU"6>XDM;NV%O<HH<()-X93D9!P/3^58I
M(_MX7?'D"^$98XP&$;@_J0/QK4.)/$Z[#_J;8B3&/XCQ_P"@F@"])_Q]V_T;
M^0JQ5>3_ (^X/^!?RJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 E1SN8X))!C*J6&?85+4-W_QYS_]<V_E0A/8\F7XI:YM!^S6
M'/\ TS?_ .*I?^%I:Y_S[6'_ '[?_P"*KAU^Z/I2U[ZPE&WPG@/%5K_$=O\
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M%_UVD_\ 0J\9KV;X:_\ (G1?]=I/_0JX,P_AKU._+_XGR.OHHHKQCV0HHHH
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MH6))./Q-;5 'D?BS3?#>@^)I+T>/K[0=3NFWS1K<>9NSR-R$\+Z#I76>#O\
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M *":O51UG_D!:A_U[2?^@FG'=$RV9\[K]T?2EI%^Z/I2U].?,A1110 4444
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MBBB@ HHHH **** ()?\ C[M_HW\JGJ"7_C[M_HW\JGH **** "BBB@ HHHH
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MO_Z"M>0UZ]\+O^16F_Z^W_\ 05KAQ_\ "^9VX#^*=O1117BGMA1110 4444
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M%%% !1110 5ZW\*_^1<NO^OMO_0%KR2O6_A7_P BY=?]?;?^@+7%C_X/S.S
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M?^@FG'=$RV9\[K]T?2EI%^Z/I2U].CYD*.^<444 %%%% !_G'K1110 4444
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M!N>!4AC\$:2MO9K9PF#*6ZS>:(P23C=DYZU)XJ\46OA73$NIX)KF::00V]K
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MLA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^0KJ7_7!/_0C7G]>@?"C_D*ZE_UP3_T(URXS^!(Z<)_'B>JT445X)[X4444
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M_P"1.B_Z[2?^A5P9A_#7J=^7_P 3Y'7T445XQ[(4444 %%%% !1110 4444
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M_0UW=% %73WO)+"%[^&*"[9<R112%U0^@8@9_(5:HHH **** "BBB@ HHHH
M**0YK&?Q):I>K#Y5PT)W;KI4S$I! Z_4XH VJ*SKG5XK:=H5@N;AT \SR(]P
M3/KS^-$NLVJ002Q"6X\\9C2!=S$>N* -&BL[^V+7[";K]X,/Y9BV_O _]W;Z
MU)9:C%?-(@CFAE0 M',FU@#T./3@_E0!-+_Q]V_T;^53U7D_X^[?_@7\JL4
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MHHH **** "BBB@ KU[X7?\BO-_U]O_Z"M>0UZ]\+O^16F_Z^W_\ 05KAQ_\
M"^9VX#^*=O1117BGMA1110 4444 %5-3_P"05=_]<7_]!-6ZJ:G_ ,@J[_ZX
MO_Z"::W)E\+/G1/N#Z4M(GW!]*6OIH['S3W"BBBF(**** "BBB@ HHHH *]C
M^&/_ "*/_;S)_2O'*]C^&/\ R*/_ &\R?TKAS#^%\SNR_P#B_([*BBBO%/:"
MBBB@ HHHH *HZS_R M0_Z]I/_035ZJ.L_P#("U#_ *]I/_033CNB9;,^=U^Z
M/I2TB_='TI:^G/F0HHHH **** "BBB@ HHHH *]F^&O_ ")T7_7:3_T*O&:]
MF^&O_(G1?]=I/_0JX,P_AKU._+_XGR.OHHHKQCV0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EIO>@#C/'
M+0^(O!NI0:64U&6TF5I[6!PS/Y;@O&1ZG!&*HZCXQ^'OB#P9.EWJ6FM:?9V_
MT:8J)8SC@!#R&!Z>]7]<^'EG>ZA)K&B7<VB:VQW-=6IPLISDB1.C ]\US9NK
M;1=7CD^(/A6Q6XR-FO6MKYL+L#P7P-T9SCJ,4 =KX#>\D\#Z0U_YGVDP<^9]
M[;D[<_\  <5T=0VMS;WEM'<6LT<T$B[DDC8,K#U!'6IJ "BBB@ HHHH ****
M "BBB@ HHHH 1N!SBN3D673;J*6TE@O-.$4K^6X&0NX9"D<'G/6NMK&?PS92
M7RW!DN!&,YMA*?*.2#]WIU&: 'S:C&FV.PMUEO+E!($48P,##.>W''/7&!57
M3K,:?K45N6+.MD2SXP"Q<$X_&K;Z!;M=3W"75]$TS!G$5RRKD  8 ]A4LNCP
M30PQM-<[XL[)A,1)]-W6@#&P!XD5@"(S>@ C/WO*DS_2M-QGQ1&5'2U.\_B,
M?UJ?^R+7[#]DP^TMO,F\[RW][=US[T^RTZ&Q+LCRR2/@-),Y=B!T&3V'/YT
M22?\?=O]&_E5BJ\G_'W;_1OY"K% !1110 4G:EI.U '@7BG_ )&S5O\ KY>L
MBM?Q3_R-FK?]?+UD5])1_AQ]#YNM_$8=.:]-\)0V-IIEQ=:?JRHKPHTR3,!Y
M+@_,2/2O,J,]?>IK4O:JUQT:OLW>QUFJ^)K*.ZU*VL-.MI+*Y<%FW-&7Q_ND
M8'M5[Q'-I6N:OI5LES:PQ>0GFW0FR(P!RO)Q_6N%HJ/J\4TT[-%_6&[IK0Z[
M678VC:;I4VGV^EQ]56\C,DY'\3'.3GTI-,MXK:33[G2?$*V\3E6NXY[@1E&'
M7Y>-P[5R7X44_J_N\MR?;>]=HU?$=Q9W>OW4]@H%N[?*5& 3W.*RJ**WA'EB
MD92ES2;"O0/A1_R%=2_ZX)_Z$:\_KT#X4?\ (5U+_K@G_H1KFQG\"1T83^/$
M]5HHHKP3WPHHHH **** "F3?ZE_]TT^F3?ZE_P#=--;BEL?-M%%%?2Q^%'S,
MMV%%%%4(**** "BBB@ HHHH *];^%?\ R+EU_P!?;?\ H"UY)7K?PK_Y%RZ_
MZ^V_] 6N+'_P?F=F _C'=4445XA[@4444 %%%% !4-W_ ,><_P#US;^535#=
M_P#'G/\ ]<V_E0MQ/8^;U^Z/I2TB_='TI:^H6Q\PPHHHH **** "BBB@ HHH
MH *]>^%W_(KR_P#7V_\ Z"M>0UZ]\+O^16F_Z^W_ /05KAQ_\+YG;@/XIV]%
M%%>*>V%%%% !1110 54U/_D%7?\ UQ?_ -!-6ZJ:G_R"KO\ ZXO_ .@FFMR9
M?"SYT3[@^E+2)]P?2EKZ:.Q\T]PHHHIB"BBB@ HHHH **** "O8_AC_R*/\
MV\R?TKQRO8_AC_R*/_;S)_2N',/X7S.[+_XOR.RHHHKQ3V@HHHH **** "J.
ML_\ ("U#_KVD_P#035ZJ.L_\@+4/^O:3_P!!-..Z)ELSYW7[H^E+2+]T?2EK
MZ<^9"BBB@ HHHH **** "BBB@ KV;X:_\B=%_P!=I/\ T*O&:]F^&G_(G1?]
M=I/_ $*N#,/X:]3OR_\ B?(Z^BBBO&/9"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,4M% '"ZEX1\7:GJ,
M\R^.IK"T:4F*WM;-<JG8;BW7'M4$OPET[4%']L:[KFI'^)9;H!&^J@5Z#10!
M2TG2K31-+M]-L(O*M;=-D:9S@=:NT44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!!+_Q]V_T;^53U!+_Q]V_T;^53T %%%% !2=J6D[4 >!>*
M?^1LU;_KY>LBM?Q3_P C9JW_ %\O617TE'^''T/FZW\1A1116AF%%%% !111
M0 4444 %>@?"C_D*ZE_UP3_T(UY_7H'PH_Y"NI?]<$_]"-<N,_@2.G"?QXGJ
MM%%%>">^%%%% !1110 4R;_4O_NFGTR;_4O_ +IIK<4MCYMHHHKZ6/PH^9EN
MPHHHJA!1110 4444 %%%% !7K?PK_P"1<NO^OMO_ $!:\DKUOX5_\BY=?]?;
M?^@+7%C_ .#\SLP'\8[JBBBO$/<"BBB@ HHHH *AN_\ CSG_ .N;?RJ:H;O_
M (\Y_P#KFW\J%N)['S>OW1]*6D7[H^E+7U"V/F&%%%% !1110 4444 %%%%
M!7KWPN_Y%>7_ *^W_P#05KR&O7OA=_R*\W_7T_\ Z"M<./\ X7S.W ?Q3MZ*
M**\4]L**** "BBB@ JIJ?_(*N_\ KB__ *":MU4U/_D%7?\ UQ?_ -!--;DR
M^%GSHGW!]*6D3[@^E+7TT=CYI[A1113$%%%% !1110 4444 %>Q_#'_D4?\
MMYD_I7CE>Q_#'_D4?^WF3^E<.8?POF=V7_Q?D=E1117BGM!1110 4444 %4=
M9_Y 6H?]>TG_ *":O51UG_D!:A_U[2?^@FG'=$RV9\[K]T?2EI%^Z/I2U].?
M,A1110 4444 %%%% !1110 5[-\-?^1.B_Z[2?\ H5>,U[-\-?\ D3HO^NTG
M_H5<&8?PUZG?E_\ $^1U]%%%>,>R%%%% !1110 4444 %%%% !1110 4444
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MJFI_\@J[_P"N+_\ H)IK<F7PL^=$^X/I2TB?<'TI:^FCL?-/<****8@HHHH
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MK7_("U#_ *]I/_033C\2)ELSYW7[H^E+2+]T?2EKZ<^9"BBB@ HHHH ****
M"BBB@ KV;X:?\B=%_P!=I/\ T*O&:]F^&O\ R)T7_7:3_P!"K@S#^&O4[\O_
M (AU]%%%>,>R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'M*T:2233K)('D #E23D?B:QKXV%2FXI/4VH8*=.HI-HU**!THKS3T@HHHH
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M&GV8?V=4[H\,KUOX5_\ (N77_7VW_H"UL?\ ""^&O^@3#_WTW^-:>F:38Z/
MT%A;K!$S[RJDG)Z9Y^@KGQ.,C5ARI&^&P<Z4^9LO4M)2UYQZ(4444P"BBB@
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MJ?RI?MD/J?RK/HHN(T/MD/J?RH^V0^I_*L^BBX&A]LA]3^5'VR'U/Y5GT47
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M'(^AKKZ* *6D:>-*TFULE.[R8PI;U/?]:NT44@"BBB@ HHHH **** "BBB@
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MG^IH^RP_\\_U-344 0_98?\ GG^IH^RP_P#//]34U% $/V6'_GG^IH^RP_\
M//\ 4U-10!#]EA_YY_J:/LL/_//]34U% $/V6'_GG^IH^RP_\\_U-344 0_9
M8?\ GG^IH^RP_P#//]34U% $/V6'_GG^IH^RP_\ //\ 4U-10!#]EA_YY_J:
M/LL/_//]34U% $/V6'^Y^IH^RP_W/U-344 0_98?[GZFC[+#_<_4U-10!#]E
MA_N?J:/LL/\ SS_4U-10!#]EA_YY_J:/LL/_ #S_ %-344 0_98?^>?ZFC[+
M#_SS_4U-10!#]EA_YY_J:/LL/_//]34U% $/V6'_ )Y_J:/LL/\ SS_4U-10
M!#]EA_YY_J:/LL/_ #S_ %-344 0_98?^>?ZFC[+#_SS_4U-10!#]EA_YY_J
M:/LL/]S]34U% $/V6'^Y^IH^RP_W/U-344 0_98?[GZFC[+#_<_4U-10!#]E
MA_YY_J:/LL/_ #S_ %-344 0_98?^>?ZFC[+#_SS_4U-10!#]EA_YY_J:/LL
M/_//]34U% $/V6'_ )Y_J:/LL/\ SS_4U-10!#]EA_YY_J:/LL/_ #S_ %-3
M44 0_98?^>?ZFC[+#_SS_4U-10!#]EA_YY_J:/LL/_//]34U% $/V6'_ )Y_
MJ:/LL/\ SS_4U-10!#]EA_N?J:/LL/\ <_4U-10!#]EA_N?J:/LL/]S]34U%
M $/V6'^Y^IH^RP_\\_U-344 0_98?^>?ZFC[+#_SS_4U-10!#]EA_P">?ZFC
M[+#_ ,\_U-344 0_98?^>?ZFC[+#_P \_P!34U% $/V6'_GG^IH^RP_\\_U-
M344 0_98?^>?ZFC[+#_SS_4U-10!#]EA_P">?ZFC[+#_ ,\_U-344 0_98?^
M>?ZFC[+#_<_4U-10!#]EA_N?J:/LL/\ <_4U-10!#]EA_N?J:/LL/]S]34U%
M $/V6'_GG^IH^RP_\\_U-344 0_98?\ GG^IH^RP_P#//]34U% $/V6'_GG^
MIH^RP_\ //\ 4U-10!#]EA_YY_J:/LL/]S]34U% $/V6'^Y14U%*P!1113 *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **3-&>: %HI,TM !1110 4444 %%%&: "
MBDS0#F@!:*3-&: %HI,TN: "BBB@ HHHH **** "BBC.* "BDSSBEH ****
M"BBB@ HHHH **** "BD)Q2T %%%% !129I: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]C:J-]YJ3P26[E RBWB13OZ@DD@9SVJ]J-W?+#XKFLSYD[IIBRDOM!C88?+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5%]:-=R6JW,7GQJ&>/
M>,@'."1^!K+'_"+"ZBU(1:7]HFN/)CN5B3>TI)&-V,[L@U6'@K3QK]SK&09[
MA'1E,$94 @ $ KU'//5LX.0!CG]1\+V?A:VT>.T<M')K=J[,Z*"OKR #C.2
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M%14N-@.[&_=QDY.*T9]>UWR;SQ!'J82SM=4%B--\E"CQ^:L98OC?O.[. <9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>33
<FILENAME>phat-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-27T18:39:09.3803+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RepurchaseRightLapseRate" xlink:label="phat_RepurchaseRightLapseRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ChangeInControlDescription" xlink:label="phat_ChangeInControlDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CashlessExerciseOfCommonStockWarrants" xlink:label="phat_CashlessExerciseOfCommonStockWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LanderWarrantsExpireTerm" xlink:label="phat_LanderWarrantsExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedClinicalTrialExpensesCurrent" xlink:label="phat_AccruedClinicalTrialExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits" xlink:label="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PurchaseOfAdditionalOfferingExpenses" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiabilityTextBlock" xlink:label="phat_RevenueInterestFinancingLiabilityTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonfinancialAssetsFairValueDisclosure" xlink:label="phat_NonfinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_GrossProceedsFromRevenueInterestFinancingAgreement" xlink:label="phat_GrossProceedsFromRevenueInterestFinancingAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommonStockWarrantMember" xlink:label="phat_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AgreementExpirationTermFromDateOfFirstCommercialSale" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsFromIssuanceOfCommonStock" xlink:label="phat_NetProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AdditionalWarrantIssued" xlink:label="phat_AdditionalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockOptionsAndPerformanceBasedUnitsMember" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementMember" xlink:label="phat_RevenueInterestFinancingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiabilityPolicyTextBlock" xlink:label="phat_RevenueInterestFinancingLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentForLicenseAmount" xlink:label="phat_PaymentForLicenseAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentInKindPikInterestRateMember" xlink:label="phat_PaymentInKindPikInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" xlink:label="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommitmentsAndContingenciesTable" xlink:label="phat_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:label="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LoanAgreementMember" xlink:label="phat_LoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsRightToReceiveRoyaltiesTerminationDescription" xlink:label="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PrepaidLeasePaymentsMember" xlink:label="phat_PrepaidLeasePaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ComponentOfBalanceSheetDisclosureTextBlock" xlink:label="phat_ComponentOfBalanceSheetDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfInvestorShareOfRoyaltyInNetSales" xlink:label="phat_PercentageOfInvestorShareOfRoyaltyInNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod" xlink:label="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockRepurchaseProgramExpirationMonthAndYear" xlink:label="phat_StockRepurchaseProgramExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedExpensesRelatedPartiesCurrent" xlink:label="phat_AccruedExpensesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LenderWarrantsExercisableSharesOfCommonStock" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InitialInvestorsNqSagardAndHerculesMember" xlink:label="phat_InitialInvestorsNqSagardAndHerculesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PurchaseObligationDueInFirstTwentyFourMonths" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ContractWithCustomerLiabilityTable" xlink:label="phat_ContractWithCustomerLiabilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MinimumMarketCapitalizationAmount" xlink:label="phat_MinimumMarketCapitalizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiability" xlink:label="phat_RevenueInterestFinancingLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentInterestRatePercentage" xlink:label="phat_DebtInstrumentInterestRatePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL" xlink:label="stpr_IL"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:label="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClosingMarketPriceOfCommonStock" xlink:label="phat_ClosingMarketPriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock" xlink:label="phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ResearchAndDevelopmentExpenseRelatedParty" xlink:label="phat_ResearchAndDevelopmentExpenseRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_GeneralAndAdministrativeExpenseRelatedParty" xlink:label="phat_GeneralAndAdministrativeExpenseRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsReceiptDescription" xlink:label="phat_InvestorsReceiptDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DrugProductOrSubstanceMember" xlink:label="phat_DrugProductOrSubstanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NumberOfWarrantsRemainingExercisable" xlink:label="phat_NumberOfWarrantsRemainingExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LiabilitiesLesseeAbstract" xlink:label="phat_LiabilitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:label="phat_LiquidityAndCapitalResourcesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClassOfWarrantOrRightExpireTerm" xlink:label="phat_ClassOfWarrantOrRightExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoanMember" xlink:label="phat_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AmountUtilizedOfEquityFinancing" xlink:label="phat_AmountUtilizedOfEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AvailableAggregateOfferingPriceThroughEquityFinancing" xlink:label="phat_AvailableAggregateOfferingPriceThroughEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AgreementExtendsPeriodForTermination" xlink:label="phat_AgreementExtendsPeriodForTermination"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockOptionsAndPerformanceBasedAwardsMember" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClinicalManufacturingServicesMember" xlink:label="phat_ClinicalManufacturingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsFundingAmount" xlink:label="phat_InvestorsFundingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SharesIssuedPricePerShareAfterDeductions" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InterestExpenseRelatedToRevenueInterestFinancingLiability" xlink:label="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LicenseAgreementTransactionCosts" xlink:label="phat_LicenseAgreementTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AssetsLesseeAbstract" xlink:label="phat_AssetsLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorAdditionalFundingAmountUponApproval" xlink:label="phat_InvestorAdditionalFundingAmountUponApproval"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JE" xlink:label="country_JE"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FollowOnPublicOfferingMember" xlink:label="phat_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClassOfWarrantOrRightExpirationDate" xlink:label="phat_ClassOfWarrantOrRightExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedInterest" xlink:label="phat_AccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember" xlink:label="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiabilityNoncurrent" xlink:label="phat_RevenueInterestFinancingLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_HerculesLoanAgreementMember" xlink:label="phat_HerculesLoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ComputerEquipmentAndSoftwareMember" xlink:label="phat_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentFinalPaymentFeePercentage" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FinancialAssetsFairValueDisclosure" xlink:label="phat_FinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesFourMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentFinalPaymentFee" xlink:label="phat_DebtInstrumentFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtAndInterest" xlink:label="phat_LongTermDebtAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DefaultObligationDescription" xlink:label="phat_DefaultObligationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonCashFinalInterestPaymentFee" xlink:label="phat_NonCashFinalInterestPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_WarrantsExpirationDate" xlink:label="phat_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentForFacilityCharge" xlink:label="phat_PaymentForFacilityCharge"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncomeTaxReconciliationPermanentItems" xlink:label="phat_IncomeTaxReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" xlink:label="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LicenseAgreementDescription" xlink:label="phat_LicenseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_HerculesAndSvbTermLoanMember" xlink:label="phat_HerculesAndSvbTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ" xlink:label="stpr_NJ"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OpenMarketSaleAgreementWithJefferiesLLCMember" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AggregateOfferingPriceThroughEquityFinancing" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FundsReceivedFromInitialClosing" xlink:label="phat_FundsReceivedFromInitialClosing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OperatingLossCarryforwardsExpirationYear" xlink:label="phat_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesOneMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AmendmentToLoanAgreementMember" xlink:label="phat_AmendmentToLoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockRepurchaseProgramNumberOfSharesRightLapse" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommercialSupplyAgreementsMember" xlink:label="phat_CommercialSupplyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentInterestAndFinalPaymentFee" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsAfterDeductingUnderwritersCommission" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FoundersMember" xlink:label="phat_FoundersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FrazierLifeSciencesIXLimitedPartnerMember" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PurchaseCommitmentExpense" xlink:label="phat_PurchaseCommitmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RepurchaseRightLapseShares" xlink:label="phat_RepurchaseRightLapseShares"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsFromRevenueInterestFinancingTransaction" xlink:label="phat_NetProceedsFromRevenueInterestFinancingTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount" xlink:label="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommitmentsAndContingenciesLineItems" xlink:label="phat_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TemporaryServicesAgreementMember" xlink:label="phat_TemporaryServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeesMember" xlink:label="phat_EmployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PCIPharmaServicesMember" xlink:label="phat_PCIPharmaServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentOfTransactionCosts" xlink:label="phat_PaymentOfTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoanFirstAdvanceMember" xlink:label="phat_TermLoanFirstAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedInterestOnRevenueInterestFinancingLiability" xlink:label="phat_AccruedInterestOnRevenueInterestFinancingLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoanAdvanceMember" xlink:label="phat_TermLoanAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember" xlink:label="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_UnvestedSharesMember" xlink:label="phat_UnvestedSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SiliconValleyBankTermLoanMember" xlink:label="phat_SiliconValleyBankTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone" xlink:label="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SharesAggregateRepurchasePrice" xlink:label="phat_SharesAggregateRepurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember" xlink:label="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedResearchAndDevelopmentExpenses" xlink:label="phat_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentFacilityChargePercentage" xlink:label="phat_DebtInstrumentFacilityChargePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PotentialAdditionalInvestorFundingAmount" xlink:label="phat_PotentialAdditionalInvestorFundingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentPenaltyFeePercentage" xlink:label="phat_DebtInstrumentPenaltyFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OrganizationAndBasisOfPresentationPolicyTextBlock" xlink:label="phat_OrganizationAndBasisOfPresentationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paid-in-Kind Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of PIK interest debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase right lapse rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Right Lapse Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase right lapse rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ChangeInControlDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in control description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ChangeInControlDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Control Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ChangeInControlDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in control description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under ATM facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest remainder of fiscal year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest Remainder Of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CashlessExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercise of common stock warrants, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CashlessExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cashless Exercise Of Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CashlessExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise of common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of qualified cash on principal amount prior to third performance milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage of Qualified Cash on Principal Amount Prior to Third Performance Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of qualified cash prior to Third performance milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer discretionary match number of shares settled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution pan employer discretionary match number of shares settled.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">401(k) matching contribution, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, prepayment fee percentage of outstanding principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Fee Percentage Of Outstanding Principal Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment fee percentage of outstanding principal amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales commission payable as a percentage of sale of gross sales price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Commission Payable as a percentage of sale of Gross Sales Price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales commission payable as a percentage of sale of gross sales price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating loss carryforwards which are carried over indefinitely</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LanderWarrantsExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expire term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LanderWarrantsExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lander Warrants Expire Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LanderWarrantsExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lander warrants expire term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedClinicalTrialExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedClinicalTrialExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedClinicalTrialExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits that would affect effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payments for operating lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP shares issued, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock initially reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted shares and restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award And Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, restricted stock award and restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value Per Share, Unvested Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, share vesting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of additional offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Additional Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of additional offering expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, options and other than options, grants in period gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options and Other than Options, Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Liability [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value adjustment of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonfinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonfinancial assets fair value disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonfinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonfinancial Assets Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonfinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-financial assets fair value disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-financial liabilities fair value disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonfinancial Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nonfinancial Liabilities Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_GrossProceedsFromRevenueInterestFinancingAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from the Revenue Interest Financing Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_GrossProceedsFromRevenueInterestFinancingAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_GrossProceedsFromRevenueInterestFinancingAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Revenue Interest Financing Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_GrossProceedsFromRevenueInterestFinancingAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from revenue interest financing agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement expiration term from date of first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Expiration Term From Date Of First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement expiration term from date of first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of eligible compensation contributed by participants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Treasury stock shares ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock shares ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Treasury Stock, Shares, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdditionalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional warrant issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdditionalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdditionalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional warrant issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options and performance-based units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock options and performance-based units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Performance-based Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average incremental borrowing rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue Interest Financing Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization basis of presentation and summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Liability [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining number of shares to be repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForLicenseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash consideration paid for license</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForLicenseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment For License Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForLicenseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for license amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentInKindPikInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment in kind PIK interest rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentInKindPikInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment in Kind PIK Interest Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentInKindPikInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment In Kind PIK Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related parties accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Expenses Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accounts payable and accrued expenses related parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock outstanding, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Arising From Obtaining Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, non-current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent Excluding Unamortized Debt Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt noncurrent excluding unamortized debt discount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets, related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Assets Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other assets related parties current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Outstanding, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options cancelled or forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase to shares available for issuance percentage of outstanding common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated weighted-average fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liability, transfers into level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Anniversary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investors right to receive royalties termination description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investors Right to Receive Royalties Termination Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investors right to receive royalties termination description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Lease Payments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid lease payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComponentOfBalanceSheetDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComponentOfBalanceSheetDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Component Of Balance Sheet Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComponentOfBalanceSheetDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Component of Balance Sheet Disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfInvestorShareOfRoyaltyInNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of investor share of royalty in net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfInvestorShareOfRoyaltyInNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Investor Share of Royalty in Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfInvestorShareOfRoyaltyInNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of investor share of royalty in net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenditures, amortization period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts and Jobs Act, Research and Development Expenditures Amortization Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cuts and jobs act, research and development expenditures amortization period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, net of discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Excluding Current Maturities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockRepurchaseProgramExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Repurchase Program Expiration Month and Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockRepurchaseProgramExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock repurchase program expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses, related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses related parties current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchase program, period in force</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Period in Force</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Balance Sheet Information Related to the Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of supplemental balance sheet information related to operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Warrants Exercisable Shares Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lender warrants exercisable shares of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, $0.0001 par value authorized shares 40,000,000 at December 31, 2020 and 2019 no shares issued and outstanding at December 31, 2020 and 2019</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InitialInvestorsNqSagardAndHerculesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Investors NQ, Sagard, and Hercules</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InitialInvestorsNqSagardAndHerculesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Investors NQ, Sagard, and Hercules [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InitialInvestorsNqSagardAndHerculesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Investors NQ, Sagard, and Hercules.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase obligation in the first 24-month period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation Due In First Twenty Four Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase obligation due in first twenty four months.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash issuance of common stock warrants in connection with long term debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Issuance Of Common Stock Warrants In Connection With Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants in connection with long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ContractWithCustomerLiabilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ContractWithCustomerLiabilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer, liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumMarketCapitalizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum market capitalization amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumMarketCapitalizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Market Capitalization Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumMarketCapitalizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum market capitalization amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning liability balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending liability balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue interest financing liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement Upon Occurrence of Event of Default between April 1, 2025, and April 1, 2028</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Upon Occurrence of Event of Default Between April One Two Thousand and Twenty Five and April One Two Thousand and Twenty Eight [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing agreement upon occurrence of event between April one two thousand and twenty five and April one two thousand and twenty eight.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Options exercisable as of December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentInterestRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentInterestRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentInterestRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, interest rate percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_IL_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ILLINOIS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_IL_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Buffalo Grove, Illinois</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Carry Forward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit carry forward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related parties prepaid expenses and other assets current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease)in prepaid expenses and other assets related parties current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClosingMarketPriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing market price of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClosingMarketPriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Closing Market Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClosingMarketPriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing market price of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Liability [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock outstanding, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization, Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization basis of presentation and summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Total Revenue Interest Financing Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Revenue Interest Financing Liability [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of revenue interest financing liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents &#8211; beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents &#8211; end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchases of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted-Average Assumptions Used to Estimate Fair Value of ESPP Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest, year one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of 401(k) liability in common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NonCash settlement of defined contribution plan liability in common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frazier</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Principal Owner [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ESPP Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrants and convertible debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Fair Value Of Warrants And Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation change in fair value of warrants and convertible debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision (benefit) for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses, related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for property, plant and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Expenses Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts payable and accrued expenses related parties current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under ATM facility, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_GeneralAndAdministrativeExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses, related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_GeneralAndAdministrativeExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_GeneralAndAdministrativeExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative expense related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsReceiptDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investors receipt description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsReceiptDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investors Receipt Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsReceiptDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investors receipt description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of qualified cash on principal amount following third performance milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage of Qualified Cash on Principal Amount Following Third Performance Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of qualified cash following third performance milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DrugProductOrSubstanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Drug product Or substance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DrugProductOrSubstanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Drug Product Or Substance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DrugProductOrSubstanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Drug Product or Substance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of debt funded to be issued as warrants to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Debt Funded to be Issued as Warrants to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of debt funded to be issued as warrants to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shared operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Shared Operating Expenses Due To Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction shared operating expenses due to transactions with related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of ESPP liability in common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NonCash settlement of employee stock purchase plan liability in common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, number of securities called by warrants or rights, remains exercisable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Remains Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to common stock remains exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants issued to common stock remains exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NumberOfWarrantsRemainingExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants remaining exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NumberOfWarrantsRemainingExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Warrants Remaining Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NumberOfWarrantsRemainingExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants remaining exercisable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional &amp; consulting expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Unvested Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Lessee [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities, lessee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options exercisable as of December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiquidityAndCapitalResourcesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Capital Resources</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiquidityAndCapitalResourcesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Capital Resources Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiquidityAndCapitalResourcesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and capital resources.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares remain available for issuance, annual increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Annual Increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant annual increase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Expire Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expire term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, expire term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Term Loans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AmountUtilizedOfEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount utilized of equity financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AmountUtilizedOfEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Utilized of equity financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AmountUtilizedOfEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount Utilized of equity financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercise of common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Cashless Exercise of Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares cashless exercise of common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' (deficit) equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BaseRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Base Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BaseRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Floor Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Stock Units, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Stock Units, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; authorized shares - 400,000,000 at December 31, 2022 and 2021; issued shares - 41,723,308 and 31,656,035 at December 31, 2022 and 2021, respectively; outstanding shares - 41,468,871 and 30,511,226 at December 31, 2022 and 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AvailableAggregateOfferingPriceThroughEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available equity financing amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AvailableAggregateOfferingPriceThroughEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available Aggregate offering price through equity financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AvailableAggregateOfferingPriceThroughEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available Aggregate offering price through equity financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses (includes changes in related party amounts of $1,139 and $2,766, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liability, transfers out of level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement Upon Occurrence of Event of Default Prior to April 1, 2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Upon Occurrence of Event of Default prior to April One Two thousand and Twenty Five [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing agreement upon occurrence of event of default prior to April one two thousand and twenty five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExtendsPeriodForTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement extends period for termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExtendsPeriodForTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Extends Period For Termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExtendsPeriodForTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement extends period for termination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Stock Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Reserved For Future Issuances Table Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock reserved for future issuances.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to additional paid-in-capital, warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Partner Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partner Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Performance-Based Awards Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options And Performance Based Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options and performance-based awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA Approval If Occurrence Prior to May Three Two Thousand and Twenty Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing agreement upon occurrence of a change in control event earlier of April one two thousand and twenty four or FDA approval If occurrence is prior to May three two thousand and twenty three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClinicalManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Manufacturing Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClinicalManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Manufacturing Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClinicalManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical manufacturing services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee and Nonemployee Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Payment Arrangement Employee And Nonemployee [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, employee and nonemployee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investors funding amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investors Funding Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investors funding amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA approval If occurrence is Thereafter to May 3, 2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA approval If occurrence is Thereafter to May Three Two Thousand and Twenty Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing agreement upon occurrence of a change in control event earlier of April one two thousand and twenty four or FDA approval If occurrence is thereafter to May three two thousand and twenty three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share after deducting underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share After Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued, price per share after deductions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Plus: interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense with revenue interest finance liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Related To Revenue Interest Financing Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest expense related to revenue interest financing liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock warrants shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock from exercise of warrants, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement transaction costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans, aggregate principal amount tranches two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Aggregate Principal Amount Tranches Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans, Aggregate Principal Amount Tranches Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AssetsLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AssetsLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Lessee [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AssetsLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets, lessee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorAdditionalFundingAmountUponApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorAdditionalFundingAmountUponApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investor Additional Funding Amount Upon Approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorAdditionalFundingAmountUponApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investor additional funding amount upon approval.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Principal Payments Under Term Loans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JE_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Florham Park, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JE_lbl" xlink:role="http://www.xbrl.org/2003/role/label">JERSEY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow on public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized to repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property, plant and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Options vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, PSUs and RSUs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Performance-based Unit and Restricted Stock Unit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option performance-based unit and restricted stock unit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate payments on investment amount to investors on net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Payments On Investment Amount To Investors On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate payments on investment amount to investors on net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue interest financing liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing liability noncurrent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_HerculesLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_HerculesLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules Loan Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_HerculesLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules loan agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Related Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans, aggregate principal amount tranches three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Aggregate Principal Amount Tranches Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans, Aggregate Principal Amount Tranches Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, final payment fee percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Final Payment Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument final payment fee percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrant liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial fair value of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets fair value disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets fair value disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans, aggregate principal amount tranches four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Aggregate Principal Amount Tranches Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans, Aggregate Principal Amount Tranches Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use assets and lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Right Of Use Asset And Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating right of use asset and lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement Funding upon Achievement of Sales Milestone at any Time Prior to June 30, 2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Funding Upon Achievement of Sales Milestone At Any Time prior To June Thirty Two Thousand and Twenty Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue &#8203;interest&#8203; financing&#8203; agreement&#8203; funding upon achievement of sales milestone at any time prior to June thirty two thousand and twenty four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount payable in sales milestones upon achievement of specified levels of product sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Payable In Sales Milestones Upon Achievement Of Specified Levels Of Product Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount payable in sales milestones upon the achievement of specified levels of product sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Final Payment Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument final payment fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, final payment fee or end of term charge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense, weighted-average period for recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total principal and interest payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt And Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt and interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefaultObligationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Default obligation description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefaultObligationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Default Obligation Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefaultObligationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Default obligation description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments Under Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate payment on investment amount to investors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Payments On Investment Amount To Investors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate payments on investment amount to investors.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to current year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 4)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda pharmaceutical company limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement Percentage on Investment Amount On December December 31, 2028</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Percentage on Investment Amount On December Thirty One Two Thousand And Twenty Eight [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing agreement percentage on investment amount on December thirty one two thousand and twenty eight.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity plan, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashFinalInterestPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final interest payment fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashFinalInterestPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Final Interest Payment Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashFinalInterestPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash final interest payment fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForFacilityCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for facility charge.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForFacilityCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Facility Charge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForFacilityCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for facility charge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options exercisable as of December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses (including related party amountsof $2,499 and $2,330, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Takeda License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation permanent items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options exercised and shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises And Shares Vested In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options exercises and shares vested in period weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_HerculesAndSvbTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules and SVB term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_HerculesAndSvbTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules and SVB Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_HerculesAndSvbTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules and SVB Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Clinical Accrued Trial Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in clinical accrued trial expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term debt, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Current Maturities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement Upon Occurrence of Event of Default after April 1, 2028</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Upon Occurrence of Event of Default After April One Two Thousand and Twenty Eight [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing agreement upon occurrence of event of default after April one two thousand and twenty eight.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development (includes related party amounts of $2,123 and $4,933, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NJ_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Florham Park, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NJ_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NEW JERSEY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open Market Sale Agreement with Jefferies LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Market Sale Agreement With Jefferies L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Open Market Sale Agreement with Jefferies LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate offering price through equity financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate offering price through equity financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease number of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Number Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease number of option to extend.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FundsReceivedFromInitialClosing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funds received from initial closing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FundsReceivedFromInitialClosing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funds Received from Initial Closing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FundsReceivedFromInitialClosing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funds received from initial closing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans, aggregate principal amount tranches one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Aggregate Principal Amount Tranches One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans, Aggregate Principal Amount Tranches One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative (includes related party amounts of $0 and $18, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AmendmentToLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment to Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AmendmentToLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment to Loan Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AmendmentToLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amendment to loan agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Nonrecurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Nonrecurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchase program, number of shares right lapse</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Number Of Shares Right Lapse</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock repurchase program, number of shares right lapse.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement Percentage On Investment Amount by December 31, 2037</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Percentage On Investment Amount On December Thirty One Two Thousand And Thirty Seven [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing agreement percentage on investment amount On December thirty one two thousand and thirty seven.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of warrant liability into equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Conversion Of Warrant Liability Into Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital conversion of warrant liability into equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of lender warrants into equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommercialSupplyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial supply agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommercialSupplyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Supply Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less payment-in-kind and final payment fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest And Final Payment Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest and final payment fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock from exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate repurchase price of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deducting underwriters commission</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds After Deducting Underwriters Commission</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds after deducting underwriters commission.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock - 19 and 1 shares at December 31, 2022 and 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options exercised and shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercised And Shares Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award stock options exercised and shares vested.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from Initial Public Offering (IPO)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frazier</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Frazier Life Sciences I X Limited Partner [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Frazier Life Sciences IX, limited partner member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseCommitmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses incurred related to purchase commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseCommitmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseCommitmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase commitment, expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase right lapse each month after first anniversary, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Right Lapse Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase right lapse shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA Approval [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing agreement upon occurrence of a Change in control event earlier of April one two thousand and twenty four or FDA Approval.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options exercisable as of December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsFromRevenueInterestFinancingTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from revenue interest financing transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsFromRevenueInterestFinancingTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsFromRevenueInterestFinancingTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Revenue Interest Financing Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsFromRevenueInterestFinancingTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from revenue interest financing transaction.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Related to Gross Unrecognized Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Payment Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional percentage to be paid with obligated payment on investment amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Percentage to be Paid with Obligated Payment On Investment Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional percentage to be paid with obligated payment on investment amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total debt, net of debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance initial public offering gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance initial public offering gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets (includes changes in related party amounts of $0 and $82, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TemporaryServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TemporaryServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Services Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TemporaryServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary services agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual for interest or penalties related to income tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Final payment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum purchase obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Purchase Obligation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PCIPharmaServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PCI Pharma Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PCIPharmaServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">P C I Pharma Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PCIPharmaServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PCI Pharma Services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentOfTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentOfTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentOfTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentOfTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of transaction costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Total Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument borrowed amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount of debt instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanFirstAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan first advance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanFirstAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan First Advance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanFirstAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan First Advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedInterestOnRevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest on revenue interest financing liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedInterestOnRevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest On Revenue Interest Financing Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedInterestOnRevenueInterestFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest on revenue interest financing liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant, and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan advance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Advance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement, Funding Commitment On or Before March 31, 2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Funding Commitment On Or Before March Thirty One Two Thousand And Twenty Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest financing agreement funding commitment on or before March thirty one two thousand and twenty four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_UnvestedSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_UnvestedSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_UnvestedSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SiliconValleyBankTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SVB term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SiliconValleyBankTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SiliconValleyBankTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SVB Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to prior year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) matching contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investors funding commitment potential amount available upon achievement of sales milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investors Funding Commitment Potential Amount Available Upon Achievement of Sales Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investors funding commitment potential amount available upon achievement of sales milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Incentive Award Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans Aggregate Principal Amount Tranches Three and Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Aggregate Principal Amount Tranches Three and Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans aggregate principal amount tranches three and four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal of property, plant or equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Disposals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, remaining lease terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties related income tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Stock Units, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Stock Units, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer matching contribution, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercise of stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted shares, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, basis spread on variable rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesAggregateRepurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares aggregate repurchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesAggregateRepurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Aggregate Repurchase Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesAggregateRepurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares aggregate repurchase price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Supply and Temporary Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Supply Agreement and Temporary Services Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial Supply Agreement and Temporary Services Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan employer contribution liabilities expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Partner Type of Partners' Capital Account, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partner Type of Partners' Capital Account, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total term loan borrowings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Term loans aggregate principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument additional borrowing capacity amounts.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Additional Borrowing Capacity Amounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, additional borrowing capacity amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-Based Stock Units (PSU)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, options and other than options forfeitures and expirations in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award, Options and Other Than Options Forfeitures and Expirations in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, cancelled or forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Financing Agreement Funding upon FDA Approval at any Time Prior to December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Financing Agreement Funding Upon FDA Approval At Any Time prior To December Thirty One Two Thousand and Twenty Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue &#8203;interest&#8203; financing&#8203; agreement&#8203; funding upon FDA approval at any time prior to December thirty one two thousand and twenty two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable (including related party amounts of $35 and $1,343 respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of PSU Activity Under the 2019 Incentive Award Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ATMOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ATM Sale Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ATMOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Offering Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ATMOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A T M Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ATMOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market offering program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes computed at the statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFacilityChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument facility charge percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFacilityChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Facility Charge Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFacilityChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, facility charge percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PotentialAdditionalInvestorFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential additional investor funding amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PotentialAdditionalInvestorFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Additional Investor Funding Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PotentialAdditionalInvestorFundingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential additional investor funding amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock awards, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Stock Units, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPenaltyFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument penalty fee percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPenaltyFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Penalty Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPenaltyFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument penalty fee percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number of shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested shares excluded from computation of weighted average earnings per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationAndBasisOfPresentationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and basis of presentation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationAndBasisOfPresentationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization and Basis of Presentation [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationAndBasisOfPresentationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RepurchaseRightLapseRate" xlink:to="phat_RepurchaseRightLapseRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ChangeInControlDescription" xlink:to="phat_ChangeInControlDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CashlessExerciseOfCommonStockWarrants" xlink:to="phat_CashlessExerciseOfCommonStockWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:to="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="phat_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" xlink:to="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" xlink:to="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LanderWarrantsExpireTerm" xlink:to="phat_LanderWarrantsExpireTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccruedClinicalTrialExpensesCurrent" xlink:to="phat_AccruedClinicalTrialExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits" xlink:to="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PurchaseOfAdditionalOfferingExpenses" xlink:to="phat_PurchaseOfAdditionalOfferingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingLiabilityTextBlock" xlink:to="phat_RevenueInterestFinancingLiabilityTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NonfinancialAssetsFairValueDisclosure" xlink:to="phat_NonfinancialAssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_GrossProceedsFromRevenueInterestFinancingAgreement" xlink:to="phat_GrossProceedsFromRevenueInterestFinancingAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommonStockWarrantMember" xlink:to="phat_CommonStockWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AgreementExpirationTermFromDateOfFirstCommercialSale" xlink:to="phat_AgreementExpirationTermFromDateOfFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NetProceedsFromIssuanceOfCommonStock" xlink:to="phat_NetProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AdditionalWarrantIssued" xlink:to="phat_AdditionalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockOptionsAndPerformanceBasedUnitsMember" xlink:to="phat_StockOptionsAndPerformanceBasedUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementMember" xlink:to="phat_RevenueInterestFinancingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingLiabilityPolicyTextBlock" xlink:to="phat_RevenueInterestFinancingLiabilityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PaymentForLicenseAmount" xlink:to="phat_PaymentForLicenseAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PaymentInKindPikInterestRateMember" xlink:to="phat_PaymentInKindPikInterestRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" xlink:to="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:to="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="phat_CommitmentsAndContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" xlink:to="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:to="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LoanAgreementMember" xlink:to="phat_LoanAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription" xlink:to="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PrepaidLeasePaymentsMember" xlink:to="phat_PrepaidLeasePaymentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ComponentOfBalanceSheetDisclosureTextBlock" xlink:to="phat_ComponentOfBalanceSheetDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PercentageOfInvestorShareOfRoyaltyInNetSales" xlink:to="phat_PercentageOfInvestorShareOfRoyaltyInNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod" xlink:to="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockRepurchaseProgramExpirationMonthAndYear" xlink:to="phat_StockRepurchaseProgramExpirationMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccruedExpensesRelatedPartiesCurrent" xlink:to="phat_AccruedExpensesRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LenderWarrantsExercisableSharesOfCommonStock" xlink:to="phat_LenderWarrantsExercisableSharesOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_InitialInvestorsNqSagardAndHerculesMember" xlink:to="phat_InitialInvestorsNqSagardAndHerculesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PurchaseObligationDueInFirstTwentyFourMonths" xlink:to="phat_PurchaseObligationDueInFirstTwentyFourMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:to="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ContractWithCustomerLiabilityTable" xlink:to="phat_ContractWithCustomerLiabilityTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_MinimumMarketCapitalizationAmount" xlink:to="phat_MinimumMarketCapitalizationAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingLiability" xlink:to="phat_RevenueInterestFinancingLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentInterestRatePercentage" xlink:to="phat_DebtInstrumentInterestRatePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_IL" xlink:to="stpr_IL_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" xlink:to="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:to="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ClosingMarketPriceOfCommonStock" xlink:to="phat_ClosingMarketPriceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock" xlink:to="phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" xlink:to="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_EmployeeStockPurchasePlanMember" xlink:to="phat_EmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" xlink:to="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ResearchAndDevelopmentExpenseRelatedParty" xlink:to="phat_ResearchAndDevelopmentExpenseRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:to="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_GeneralAndAdministrativeExpenseRelatedParty" xlink:to="phat_GeneralAndAdministrativeExpenseRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_InvestorsReceiptDescription" xlink:to="phat_InvestorsReceiptDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DrugProductOrSubstanceMember" xlink:to="phat_DrugProductOrSubstanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" xlink:to="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" xlink:to="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" xlink:to="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" xlink:to="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NumberOfWarrantsRemainingExercisable" xlink:to="phat_NumberOfWarrantsRemainingExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LiabilitiesLesseeAbstract" xlink:to="phat_LiabilitiesLesseeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:to="phat_LiquidityAndCapitalResourcesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ClassOfWarrantOrRightExpireTerm" xlink:to="phat_ClassOfWarrantOrRightExpireTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoanMember" xlink:to="phat_TermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AmountUtilizedOfEquityFinancing" xlink:to="phat_AmountUtilizedOfEquityFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants" xlink:to="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BaseRateMember" xlink:to="us-gaap_BaseRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AvailableAggregateOfferingPriceThroughEquityFinancing" xlink:to="phat_AvailableAggregateOfferingPriceThroughEquityFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AgreementExtendsPeriodForTermination" xlink:to="phat_AgreementExtendsPeriodForTermination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" xlink:to="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockOptionsAndPerformanceBasedAwardsMember" xlink:to="phat_StockOptionsAndPerformanceBasedAwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ClinicalManufacturingServicesMember" xlink:to="phat_ClinicalManufacturingServicesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" xlink:to="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_InvestorsFundingAmount" xlink:to="phat_InvestorsFundingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_SharesIssuedPricePerShareAfterDeductions" xlink:to="phat_SharesIssuedPricePerShareAfterDeductions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability" xlink:to="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LicenseAgreementTransactionCosts" xlink:to="phat_LicenseAgreementTransactionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AssetsLesseeAbstract" xlink:to="phat_AssetsLesseeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_InvestorAdditionalFundingAmountUponApproval" xlink:to="phat_InvestorAdditionalFundingAmountUponApproval_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JE" xlink:to="country_JE_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_FollowOnPublicOfferingMember" xlink:to="phat_FollowOnPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ClassOfWarrantOrRightExpirationDate" xlink:to="phat_ClassOfWarrantOrRightExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccruedInterest" xlink:to="phat_AccruedInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember" xlink:to="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" xlink:to="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingLiabilityNoncurrent" xlink:to="phat_RevenueInterestFinancingLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_HerculesLoanAgreementMember" xlink:to="phat_HerculesLoanAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ComputerEquipmentAndSoftwareMember" xlink:to="phat_ComputerEquipmentAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentFinalPaymentFeePercentage" xlink:to="phat_DebtInstrumentFinalPaymentFeePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_FinancialAssetsFairValueDisclosure" xlink:to="phat_FinancialAssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoansAggregatePrincipalAmountTranchesFourMember" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesFourMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" xlink:to="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember" xlink:to="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" xlink:to="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentFinalPaymentFee" xlink:to="phat_DebtInstrumentFinalPaymentFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtAndInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DefaultObligationDescription" xlink:to="phat_DefaultObligationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" xlink:to="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember" xlink:to="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NonCashFinalInterestPaymentFee" xlink:to="phat_NonCashFinalInterestPaymentFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_WarrantsExpirationDate" xlink:to="phat_WarrantsExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PaymentForFacilityCharge" xlink:to="phat_PaymentForFacilityCharge_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TakedaLicenseAgreementMember" xlink:to="phat_TakedaLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncomeTaxReconciliationPermanentItems" xlink:to="phat_IncomeTaxReconciliationPermanentItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" xlink:to="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LicenseAgreementDescription" xlink:to="phat_LicenseAgreementDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_HerculesAndSvbTermLoanMember" xlink:to="phat_HerculesAndSvbTermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" xlink:to="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NJ" xlink:to="stpr_NJ_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OpenMarketSaleAgreementWithJefferiesLLCMember" xlink:to="phat_OpenMarketSaleAgreementWithJefferiesLLCMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AggregateOfferingPriceThroughEquityFinancing" xlink:to="phat_AggregateOfferingPriceThroughEquityFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:to="phat_LesseeOperatingLeaseNumberOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_FundsReceivedFromInitialClosing" xlink:to="phat_FundsReceivedFromInitialClosing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OperatingLossCarryforwardsExpirationYear" xlink:to="phat_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoansAggregatePrincipalAmountTranchesOneMember" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AmendmentToLoanAgreementMember" xlink:to="phat_AmendmentToLoanAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockRepurchaseProgramNumberOfSharesRightLapse" xlink:to="phat_StockRepurchaseProgramNumberOfSharesRightLapse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember" xlink:to="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" xlink:to="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommercialSupplyAgreementsMember" xlink:to="phat_CommercialSupplyAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentInterestAndFinalPaymentFee" xlink:to="phat_DebtInstrumentInterestAndFinalPaymentFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="phat_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NetProceedsAfterDeductingUnderwritersCommission" xlink:to="phat_NetProceedsAfterDeductingUnderwritersCommission_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_FoundersMember" xlink:to="phat_FoundersMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_FrazierLifeSciencesIXLimitedPartnerMember" xlink:to="phat_FrazierLifeSciencesIXLimitedPartnerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PurchaseCommitmentExpense" xlink:to="phat_PurchaseCommitmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RepurchaseRightLapseShares" xlink:to="phat_RepurchaseRightLapseShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NetProceedsFromRevenueInterestFinancingTransaction" xlink:to="phat_NetProceedsFromRevenueInterestFinancingTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount" xlink:to="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="phat_ProceedsFromIssuanceInitialPublicOfferingGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_CommitmentsAndContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TemporaryServicesAgreementMember" xlink:to="phat_TemporaryServicesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_EmployeesMember" xlink:to="phat_EmployeesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PCIPharmaServicesMember" xlink:to="phat_PCIPharmaServicesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PaymentOfTransactionCosts" xlink:to="phat_PaymentOfTransactionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoanFirstAdvanceMember" xlink:to="phat_TermLoanFirstAdvanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccruedInterestOnRevenueInterestFinancingLiability" xlink:to="phat_AccruedInterestOnRevenueInterestFinancingLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoanAdvanceMember" xlink:to="phat_TermLoanAdvanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember" xlink:to="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_UnvestedSharesMember" xlink:to="phat_UnvestedSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_SiliconValleyBankTermLoanMember" xlink:to="phat_SiliconValleyBankTermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone" xlink:to="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_SharesAggregateRepurchasePrice" xlink:to="phat_SharesAggregateRepurchasePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember" xlink:to="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" xlink:to="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember" xlink:to="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccruedResearchAndDevelopmentExpenses" xlink:to="phat_AccruedResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ATMOfferingProgramMember" xlink:to="phat_ATMOfferingProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentFacilityChargePercentage" xlink:to="phat_DebtInstrumentFacilityChargePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PotentialAdditionalInvestorFundingAmount" xlink:to="phat_PotentialAdditionalInvestorFundingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentPenaltyFeePercentage" xlink:to="phat_DebtInstrumentPenaltyFeePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OrganizationAndBasisOfPresentationPolicyTextBlock" xlink:to="phat_OrganizationAndBasisOfPresentationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>34
<FILENAME>phat-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-27T18:39:06.5303+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="phat-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="phat-20221231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="phat-20221231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="phat-20221231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="phat-20221231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit" xlink:href="phat-20221231.xsd#StatementStatementsOfStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="phat-20221231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical" xlink:href="phat-20221231.xsd#Role_StatementStatementsOfCashFlowsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="phat-20221231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:href="phat-20221231.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="phat-20221231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="phat-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitments" xlink:href="phat-20221231.xsd#Role_DisclosureLeaseCommitments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebt" xlink:href="phat-20221231.xsd#Role_DisclosureDebt" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiability" xlink:href="phat-20221231.xsd#DisclosureRevenueInterestFinancingLiability" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="phat-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_Disclosure401KPlan" xlink:href="phat-20221231.xsd#Role_Disclosure401KPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="phat-20221231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="phat-20221231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:href="phat-20221231.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables" xlink:href="phat-20221231.xsd#Role_DisclosureLeaseCommitmentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtTables" xlink:href="phat-20221231.xsd#Role_DisclosureDebtTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityTables" xlink:href="phat-20221231.xsd#DisclosureRevenueInterestFinancingLiabilityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="phat-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:href="phat-20221231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:href="phat-20221231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:href="phat-20221231.xsd#Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:href="phat-20221231.xsd#Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" xlink:href="phat-20221231.xsd#Role_DisclosureDebtScheduleOfTotalDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" xlink:href="phat-20221231.xsd#Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" xlink:href="phat-20221231.xsd#DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" xlink:href="phat-20221231.xsd#DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" xlink:href="phat-20221231.xsd#DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" xlink:href="phat-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:href="phat-20221231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" xlink:href="phat-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="phat-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedClinicalTrialExpensesCurrent" xlink:label="phat_AccruedClinicalTrialExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiabilityNoncurrent" xlink:label="phat_RevenueInterestFinancingLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="phat_AccruedClinicalTrialExpensesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="phat_RevenueInterestFinancingLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:label="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedExpensesRelatedPartiesCurrent" xlink:label="phat_AccruedExpensesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="phat_AccruedExpensesRelatedPartiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ResearchAndDevelopmentExpenseRelatedParty" xlink:label="phat_ResearchAndDevelopmentExpenseRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_GeneralAndAdministrativeExpenseRelatedParty" xlink:label="phat_GeneralAndAdministrativeExpenseRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="phat_ResearchAndDevelopmentExpenseRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="phat_GeneralAndAdministrativeExpenseRelatedParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CashlessExerciseOfCommonStockWarrants" xlink:label="phat_CashlessExerciseOfCommonStockWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits" xlink:label="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_22"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_23"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodValueExerciseOfWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_CashlessExerciseOfCommonStockWarrants" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonCashFinalInterestPaymentFee" xlink:label="phat_NonCashFinalInterestPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsFromRevenueInterestFinancingTransaction" xlink:label="phat_NetProceedsFromRevenueInterestFinancingTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedInterestOnRevenueInterestFinancingLiability" xlink:label="phat_AccruedInterestOnRevenueInterestFinancingLiability"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_ATMOfferingProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashFinalInterestPaymentFee" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="phat_NetProceedsFromRevenueInterestFinancingTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="phat_AccruedInterestOnRevenueInterestFinancingLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:label="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" xlink:label="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ComponentOfBalanceSheetDisclosureTextBlock" xlink:label="phat_ComponentOfBalanceSheetDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="phat_ComponentOfBalanceSheetDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiability" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiabilityTextBlock" xlink:label="phat_RevenueInterestFinancingLiabilityTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="phat_RevenueInterestFinancingLiabilityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_Disclosure401KPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OrganizationAndBasisOfPresentationPolicyTextBlock" xlink:label="phat_OrganizationAndBasisOfPresentationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:label="phat_LiquidityAndCapitalResourcesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiabilityPolicyTextBlock" xlink:label="phat_RevenueInterestFinancingLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="phat_OrganizationAndBasisOfPresentationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="phat_LiquidityAndCapitalResourcesPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LessorLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="phat_RevenueInterestFinancingLiabilityPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock" xlink:label="phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_UnvestedSharesMember" xlink:label="phat_UnvestedSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ComputerEquipmentAndSoftwareMember" xlink:label="phat_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FollowOnPublicOfferingMember" xlink:label="phat_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FinancialAssetsFairValueDisclosure" xlink:label="phat_FinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonfinancialAssetsFairValueDisclosure" xlink:label="phat_NonfinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod" xlink:label="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NumberOfWarrantsRemainingExercisable" xlink:label="phat_NumberOfWarrantsRemainingExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="phat_UnvestedSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="phat_ComputerEquipmentAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_ATMOfferingProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_FinancialAssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NonfinancialLiabilitiesFairValueDisclosure" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_NonfinancialAssetsFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_NumberOfWarrantsRemainingExercisable" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedResearchAndDevelopmentExpenses" xlink:label="phat_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="phat_AccruedResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClinicalManufacturingServicesMember" xlink:label="phat_ClinicalManufacturingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PCIPharmaServicesMember" xlink:label="phat_PCIPharmaServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommercialSupplyAgreementsMember" xlink:label="phat_CommercialSupplyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DrugProductOrSubstanceMember" xlink:label="phat_DrugProductOrSubstanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember" xlink:label="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TemporaryServicesAgreementMember" xlink:label="phat_TemporaryServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AgreementExtendsPeriodForTermination" xlink:label="phat_AgreementExtendsPeriodForTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="phat_ClinicalManufacturingServicesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_PCIPharmaServicesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_CommercialSupplyAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="phat_DrugProductOrSubstanceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TemporaryServicesAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_AgreementExtendsPeriodForTermination" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PurchaseObligation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommitmentsAndContingenciesTable" xlink:label="phat_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommitmentsAndContingenciesLineItems" xlink:label="phat_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LicenseAgreementDescription" xlink:label="phat_LicenseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AgreementExpirationTermFromDateOfFirstCommercialSale" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentForLicenseAmount" xlink:label="phat_PaymentForLicenseAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AdditionalWarrantIssued" xlink:label="phat_AdditionalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LicenseAgreementTransactionCosts" xlink:label="phat_LicenseAgreementTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_WarrantsExpirationDate" xlink:label="phat_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PurchaseObligationDueInFirstTwentyFourMonths" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PurchaseCommitmentExpense" xlink:label="phat_PurchaseCommitmentExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="phat_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_LicenseAgreementDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_AgreementExpirationTermFromDateOfFirstCommercialSale" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PaymentForLicenseAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="phat_CommitmentsAndContingenciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_AdditionalWarrantIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_LicenseAgreementTransactionCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_WarrantsExpirationDate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PurchaseObligationDueInFirstTwentyFourMonths" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PurchaseCommitmentExpense" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL" xlink:label="stpr_IL"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PrepaidLeasePaymentsMember" xlink:label="phat_PrepaidLeasePaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JE" xlink:label="country_JE"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ" xlink:label="stpr_NJ"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_IL" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="phat_PrepaidLeasePaymentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JE" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="phat_LesseeOperatingLeaseNumberOfOptionToExtend" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NJ" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LiabilitiesLesseeAbstract" xlink:label="phat_LiabilitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AssetsLesseeAbstract" xlink:label="phat_AssetsLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_LiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="phat_AssetsLesseeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_AssetsLesseeAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_LiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="phat_LiabilitiesLesseeAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_LiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LoanAgreementMember" xlink:label="phat_LoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoanMember" xlink:label="phat_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_HerculesAndSvbTermLoanMember" xlink:label="phat_HerculesAndSvbTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentForFacilityCharge" xlink:label="phat_PaymentForFacilityCharge"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesOneMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentInKindPikInterestRateMember" xlink:label="phat_PaymentInKindPikInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AmendmentToLoanAgreementMember" xlink:label="phat_AmendmentToLoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentFacilityChargePercentage" xlink:label="phat_DebtInstrumentFacilityChargePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_HerculesLoanAgreementMember" xlink:label="phat_HerculesLoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SiliconValleyBankTermLoanMember" xlink:label="phat_SiliconValleyBankTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentInterestRatePercentage" xlink:label="phat_DebtInstrumentInterestRatePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesFourMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoanAdvanceMember" xlink:label="phat_TermLoanAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentFinalPaymentFeePercentage" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoanFirstAdvanceMember" xlink:label="phat_TermLoanFirstAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentFinalPaymentFee" xlink:label="phat_DebtInstrumentFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MinimumMarketCapitalizationAmount" xlink:label="phat_MinimumMarketCapitalizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClassOfWarrantOrRightExpireTerm" xlink:label="phat_ClassOfWarrantOrRightExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClassOfWarrantOrRightExpirationDate" xlink:label="phat_ClassOfWarrantOrRightExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentPenaltyFeePercentage" xlink:label="phat_DebtInstrumentPenaltyFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LanderWarrantsExpireTerm" xlink:label="phat_LanderWarrantsExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LenderWarrantsExercisableSharesOfCommonStock" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedInterest" xlink:label="phat_AccruedInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_BaseRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_LoanAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_HerculesAndSvbTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_PaymentForFacilityCharge" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="phat_PaymentInKindPikInterestRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_AmendmentToLoanAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFacilityChargePercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_HerculesLoanAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_SiliconValleyBankTermLoanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentInterestRatePercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesFourMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanAdvanceMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFinalPaymentFeePercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanFirstAdvanceMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFinalPaymentFee" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumMarketCapitalizationAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_ClassOfWarrantOrRightExpireTerm" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_ClassOfWarrantOrRightExpirationDate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentPenaltyFeePercentage" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_LanderWarrantsExpireTerm" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_LenderWarrantsExercisableSharesOfCommonStock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_AccruedInterest" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtAndInterest" xlink:label="phat_LongTermDebtAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentInterestAndFinalPaymentFee" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtAndInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_DebtInstrumentInterestAndFinalPaymentFee" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InitialInvestorsNqSagardAndHerculesMember" xlink:label="phat_InitialInvestorsNqSagardAndHerculesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ContractWithCustomerLiabilityTable" xlink:label="phat_ContractWithCustomerLiabilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsFundingAmount" xlink:label="phat_InvestorsFundingAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementMember" xlink:label="phat_RevenueInterestFinancingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FundsReceivedFromInitialClosing" xlink:label="phat_FundsReceivedFromInitialClosing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember" xlink:label="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorAdditionalFundingAmountUponApproval" xlink:label="phat_InvestorAdditionalFundingAmountUponApproval"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PotentialAdditionalInvestorFundingAmount" xlink:label="phat_PotentialAdditionalInvestorFundingAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone" xlink:label="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfInvestorShareOfRoyaltyInNetSales" xlink:label="phat_PercentageOfInvestorShareOfRoyaltyInNetSales"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsRightToReceiveRoyaltiesTerminationDescription" xlink:label="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsReceiptDescription" xlink:label="phat_InvestorsReceiptDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DefaultObligationDescription" xlink:label="phat_DefaultObligationDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ChangeInControlDescription" xlink:label="phat_ChangeInControlDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount" xlink:label="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_GrossProceedsFromRevenueInterestFinancingAgreement" xlink:label="phat_GrossProceedsFromRevenueInterestFinancingAgreement"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentOfTransactionCosts" xlink:label="phat_PaymentOfTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsFromRevenueInterestFinancingTransaction" xlink:label="phat_NetProceedsFromRevenueInterestFinancingTransaction"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiability" xlink:label="phat_RevenueInterestFinancingLiability"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InterestExpenseRelatedToRevenueInterestFinancingLiability" xlink:label="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="phat_InitialInvestorsNqSagardAndHerculesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_ContractWithCustomerLiabilityTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="phat_ContractWithCustomerLiabilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InvestorsFundingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_ContractWithCustomerLiabilityTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_FundsReceivedFromInitialClosing" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_ContractWithCustomerLiabilityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InvestorAdditionalFundingAmountUponApproval" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_ContractWithCustomerLiabilityTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_PotentialAdditionalInvestorFundingAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_PercentageOfInvestorShareOfRoyaltyInNetSales" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InvestorsReceiptDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_DefaultObligationDescription" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_ChangeInControlDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_GrossProceedsFromRevenueInterestFinancingAgreement" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_PaymentOfTransactionCosts" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_NetProceedsFromRevenueInterestFinancingTransaction" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_RevenueInterestFinancingLiability" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiability" xlink:label="phat_RevenueInterestFinancingLiability"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_GrossProceedsFromRevenueInterestFinancingAgreement" xlink:label="phat_GrossProceedsFromRevenueInterestFinancingAgreement"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentOfTransactionCosts" xlink:label="phat_PaymentOfTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InterestExpenseRelatedToRevenueInterestFinancingLiability" xlink:label="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiability" xlink:label="phat_RevenueInterestFinancingLiability_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="phat_RevenueInterestFinancingLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="phat_GrossProceedsFromRevenueInterestFinancingAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="phat_PaymentOfTransactionCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="phat_RevenueInterestFinancingLiability_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeesMember" xlink:label="phat_EmployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FrazierLifeSciencesIXLimitedPartnerMember" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FoundersMember" xlink:label="phat_FoundersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OpenMarketSaleAgreementWithJefferiesLLCMember" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockRepurchaseProgramNumberOfSharesRightLapse" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockOptionsAndPerformanceBasedUnitsMember" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember" xlink:label="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockRepurchaseProgramExpirationMonthAndYear" xlink:label="phat_StockRepurchaseProgramExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AmountUtilizedOfEquityFinancing" xlink:label="phat_AmountUtilizedOfEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AvailableAggregateOfferingPriceThroughEquityFinancing" xlink:label="phat_AvailableAggregateOfferingPriceThroughEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AggregateOfferingPriceThroughEquityFinancing" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RepurchaseRightLapseRate" xlink:label="phat_RepurchaseRightLapseRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RepurchaseRightLapseShares" xlink:label="phat_RepurchaseRightLapseShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SharesAggregateRepurchasePrice" xlink:label="phat_SharesAggregateRepurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SharesIssuedPricePerShareAfterDeductions" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsAfterDeductingUnderwritersCommission" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PurchaseOfAdditionalOfferingExpenses" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClosingMarketPriceOfCommonStock" xlink:label="phat_ClosingMarketPriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="phat_EmployeesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:to="phat_FrazierLifeSciencesIXLimitedPartnerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="phat_FoundersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_OpenMarketSaleAgreementWithJefferiesLLCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_ATMOfferingProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_StockRepurchaseProgramNumberOfSharesRightLapse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="phat_StockOptionsAndPerformanceBasedUnitsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_StockRepurchaseProgramExpirationMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_AmountUtilizedOfEquityFinancing" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_AvailableAggregateOfferingPriceThroughEquityFinancing" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_AggregateOfferingPriceThroughEquityFinancing" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_RepurchaseRightLapseRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_RepurchaseRightLapseShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SharesAggregateRepurchasePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ProceedsFromIssuanceInitialPublicOfferingGross" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SharesIssuedPricePerShareAfterDeductions" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_NetProceedsAfterDeductingUnderwritersCommission" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_PurchaseOfAdditionalOfferingExpenses" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ClosingMarketPriceOfCommonStock" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="49" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommonStockWarrantMember" xlink:label="phat_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockOptionsAndPerformanceBasedAwardsMember" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="phat_CommonStockWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="phat_StockOptionsAndPerformanceBasedAwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" xlink:label="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OperatingLossCarryforwardsExpirationYear" xlink:label="phat_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="phat_OperatingLossCarryforwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncomeTaxReconciliationPermanentItems" xlink:label="phat_IncomeTaxReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="phat_IncomeTaxReconciliationPermanentItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsFromIssuanceOfCommonStock" xlink:label="phat_NetProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_ATMOfferingProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="phat_NetProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>35
<FILENAME>phat-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-27T18:39:07.3060+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="phat-20221231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2" xlink:href="phat-20221231.xsd#DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="phat-20221231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="phat-20221231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:href="phat-20221231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:href="phat-20221231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:href="phat-20221231.xsd#Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:href="phat-20221231.xsd#Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" xlink:href="phat-20221231.xsd#Role_DisclosureDebtScheduleOfTotalDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" xlink:href="phat-20221231.xsd#Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" xlink:href="phat-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:href="phat-20221231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="phat_AccruedClinicalTrialExpensesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="phat_RevenueInterestFinancingLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCash" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedClinicalTrialExpensesCurrent" xlink:label="phat_AccruedClinicalTrialExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiabilityNoncurrent" xlink:label="phat_RevenueInterestFinancingLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="phat_NetProceedsFromRevenueInterestFinancingTransaction" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="phat_AccruedInterestOnRevenueInterestFinancingLiability" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="14" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsFromRevenueInterestFinancingTransaction" xlink:label="phat_NetProceedsFromRevenueInterestFinancingTransaction"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedInterestOnRevenueInterestFinancingLiability" xlink:label="phat_AccruedInterestOnRevenueInterestFinancingLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="phat_AccruedResearchAndDevelopmentExpenses" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedResearchAndDevelopmentExpenses" xlink:label="phat_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="phat_LongTermDebtAndInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="phat_DebtInstrumentInterestAndFinalPaymentFee" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtAndInterest" xlink:label="phat_LongTermDebtAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentInterestAndFinalPaymentFee" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="phat_IncomeTaxReconciliationPermanentItems" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncomeTaxReconciliationPermanentItems" xlink:label="phat_IncomeTaxReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>36
<FILENAME>phat-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-27T18:39:06.5184+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit" xlink:href="phat-20221231.xsd#StatementStatementsOfStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="phat-20221231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:href="phat-20221231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" xlink:href="phat-20221231.xsd#DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" xlink:href="phat-20221231.xsd#DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:href="phat-20221231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="phat-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="phat-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CashlessExerciseOfCommonStockWarrants" xlink:label="phat_CashlessExerciseOfCommonStockWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits" xlink:label="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_CashlessExerciseOfCommonStockWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonCashFinalInterestPaymentFee" xlink:label="phat_NonCashFinalInterestPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsFromRevenueInterestFinancingTransaction" xlink:label="phat_NetProceedsFromRevenueInterestFinancingTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedInterestOnRevenueInterestFinancingLiability" xlink:label="phat_AccruedInterestOnRevenueInterestFinancingLiability"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_ATMOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashFinalInterestPaymentFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="phat_NetProceedsFromRevenueInterestFinancingTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="phat_AccruedInterestOnRevenueInterestFinancingLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_UnvestedSharesMember" xlink:label="phat_UnvestedSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ComputerEquipmentAndSoftwareMember" xlink:label="phat_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FollowOnPublicOfferingMember" xlink:label="phat_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FinancialAssetsFairValueDisclosure" xlink:label="phat_FinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NonfinancialAssetsFairValueDisclosure" xlink:label="phat_NonfinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod" xlink:label="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NumberOfWarrantsRemainingExercisable" xlink:label="phat_NumberOfWarrantsRemainingExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="phat_UnvestedSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="phat_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_ATMOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_FinancialAssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NonfinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_NonfinancialAssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_NumberOfWarrantsRemainingExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClinicalManufacturingServicesMember" xlink:label="phat_ClinicalManufacturingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PCIPharmaServicesMember" xlink:label="phat_PCIPharmaServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommercialSupplyAgreementsMember" xlink:label="phat_CommercialSupplyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DrugProductOrSubstanceMember" xlink:label="phat_DrugProductOrSubstanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember" xlink:label="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TemporaryServicesAgreementMember" xlink:label="phat_TemporaryServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AgreementExtendsPeriodForTermination" xlink:label="phat_AgreementExtendsPeriodForTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="phat_ClinicalManufacturingServicesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_PCIPharmaServicesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_CommercialSupplyAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="phat_DrugProductOrSubstanceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TemporaryServicesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_AgreementExtendsPeriodForTermination" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PurchaseObligation" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommitmentsAndContingenciesLineItems" xlink:label="phat_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommitmentsAndContingenciesTable" xlink:label="phat_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LicenseAgreementDescription" xlink:label="phat_LicenseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AgreementExpirationTermFromDateOfFirstCommercialSale" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentForLicenseAmount" xlink:label="phat_PaymentForLicenseAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AdditionalWarrantIssued" xlink:label="phat_AdditionalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LicenseAgreementTransactionCosts" xlink:label="phat_LicenseAgreementTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_WarrantsExpirationDate" xlink:label="phat_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PurchaseObligationDueInFirstTwentyFourMonths" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PurchaseCommitmentExpense" xlink:label="phat_PurchaseCommitmentExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_LicenseAgreementDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_AgreementExpirationTermFromDateOfFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PaymentForLicenseAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_AdditionalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_LicenseAgreementTransactionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_WarrantsExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PurchaseObligationDueInFirstTwentyFourMonths" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PurchaseCommitmentExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL" xlink:label="stpr_IL"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PrepaidLeasePaymentsMember" xlink:label="phat_PrepaidLeasePaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JE" xlink:label="country_JE"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ" xlink:label="stpr_NJ"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_IL" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="phat_PrepaidLeasePaymentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JE" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="phat_LesseeOperatingLeaseNumberOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NJ" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LoanAgreementMember" xlink:label="phat_LoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoanMember" xlink:label="phat_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_HerculesAndSvbTermLoanMember" xlink:label="phat_HerculesAndSvbTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentForFacilityCharge" xlink:label="phat_PaymentForFacilityCharge"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesOneMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentInKindPikInterestRateMember" xlink:label="phat_PaymentInKindPikInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AmendmentToLoanAgreementMember" xlink:label="phat_AmendmentToLoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentFacilityChargePercentage" xlink:label="phat_DebtInstrumentFacilityChargePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_HerculesLoanAgreementMember" xlink:label="phat_HerculesLoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SiliconValleyBankTermLoanMember" xlink:label="phat_SiliconValleyBankTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentInterestRatePercentage" xlink:label="phat_DebtInstrumentInterestRatePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesFourMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoanAdvanceMember" xlink:label="phat_TermLoanAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentFinalPaymentFeePercentage" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TermLoanFirstAdvanceMember" xlink:label="phat_TermLoanFirstAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentFinalPaymentFee" xlink:label="phat_DebtInstrumentFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_MinimumMarketCapitalizationAmount" xlink:label="phat_MinimumMarketCapitalizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClassOfWarrantOrRightExpireTerm" xlink:label="phat_ClassOfWarrantOrRightExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClassOfWarrantOrRightExpirationDate" xlink:label="phat_ClassOfWarrantOrRightExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DebtInstrumentPenaltyFeePercentage" xlink:label="phat_DebtInstrumentPenaltyFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LanderWarrantsExpireTerm" xlink:label="phat_LanderWarrantsExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_LenderWarrantsExercisableSharesOfCommonStock" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AccruedInterest" xlink:label="phat_AccruedInterest"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_BaseRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_LoanAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_HerculesAndSvbTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_PaymentForFacilityCharge" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="phat_PaymentInKindPikInterestRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_AmendmentToLoanAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFacilityChargePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_HerculesLoanAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_SiliconValleyBankTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentInterestRatePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesFourMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanAdvanceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFinalPaymentFeePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanFirstAdvanceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFinalPaymentFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumMarketCapitalizationAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_ClassOfWarrantOrRightExpireTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_ClassOfWarrantOrRightExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentPenaltyFeePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_LanderWarrantsExpireTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_LenderWarrantsExercisableSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_AccruedInterest" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ContractWithCustomerLiabilityTable" xlink:label="phat_ContractWithCustomerLiabilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InitialInvestorsNqSagardAndHerculesMember" xlink:label="phat_InitialInvestorsNqSagardAndHerculesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsFundingAmount" xlink:label="phat_InvestorsFundingAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementMember" xlink:label="phat_RevenueInterestFinancingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FundsReceivedFromInitialClosing" xlink:label="phat_FundsReceivedFromInitialClosing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember" xlink:label="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorAdditionalFundingAmountUponApproval" xlink:label="phat_InvestorAdditionalFundingAmountUponApproval"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PotentialAdditionalInvestorFundingAmount" xlink:label="phat_PotentialAdditionalInvestorFundingAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember" xlink:label="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone" xlink:label="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfInvestorShareOfRoyaltyInNetSales" xlink:label="phat_PercentageOfInvestorShareOfRoyaltyInNetSales"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember" xlink:label="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsRightToReceiveRoyaltiesTerminationDescription" xlink:label="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InvestorsReceiptDescription" xlink:label="phat_InvestorsReceiptDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" xlink:label="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DefaultObligationDescription" xlink:label="phat_DefaultObligationDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ChangeInControlDescription" xlink:label="phat_ChangeInControlDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember" xlink:label="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount" xlink:label="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_GrossProceedsFromRevenueInterestFinancingAgreement" xlink:label="phat_GrossProceedsFromRevenueInterestFinancingAgreement"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PaymentOfTransactionCosts" xlink:label="phat_PaymentOfTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsFromRevenueInterestFinancingTransaction" xlink:label="phat_NetProceedsFromRevenueInterestFinancingTransaction"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RevenueInterestFinancingLiability" xlink:label="phat_RevenueInterestFinancingLiability"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_InterestExpenseRelatedToRevenueInterestFinancingLiability" xlink:label="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_ContractWithCustomerLiabilityTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="phat_InitialInvestorsNqSagardAndHerculesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_ContractWithCustomerLiabilityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InvestorsFundingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_ContractWithCustomerLiabilityTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_FundsReceivedFromInitialClosing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_ContractWithCustomerLiabilityTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InvestorAdditionalFundingAmountUponApproval" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_PotentialAdditionalInvestorFundingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_PercentageOfInvestorShareOfRoyaltyInNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InvestorsReceiptDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_DefaultObligationDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_ChangeInControlDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_GrossProceedsFromRevenueInterestFinancingAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_PaymentOfTransactionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_NetProceedsFromRevenueInterestFinancingTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_RevenueInterestFinancingLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeesMember" xlink:label="phat_EmployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FrazierLifeSciencesIXLimitedPartnerMember" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_FoundersMember" xlink:label="phat_FoundersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OpenMarketSaleAgreementWithJefferiesLLCMember" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockRepurchaseProgramNumberOfSharesRightLapse" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockOptionsAndPerformanceBasedUnitsMember" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember" xlink:label="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockRepurchaseProgramExpirationMonthAndYear" xlink:label="phat_StockRepurchaseProgramExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AmountUtilizedOfEquityFinancing" xlink:label="phat_AmountUtilizedOfEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AvailableAggregateOfferingPriceThroughEquityFinancing" xlink:label="phat_AvailableAggregateOfferingPriceThroughEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_AggregateOfferingPriceThroughEquityFinancing" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RepurchaseRightLapseRate" xlink:label="phat_RepurchaseRightLapseRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_RepurchaseRightLapseShares" xlink:label="phat_RepurchaseRightLapseShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SharesAggregateRepurchasePrice" xlink:label="phat_SharesAggregateRepurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_SharesIssuedPricePerShareAfterDeductions" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsAfterDeductingUnderwritersCommission" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_PurchaseOfAdditionalOfferingExpenses" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ClosingMarketPriceOfCommonStock" xlink:label="phat_ClosingMarketPriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="phat_EmployeesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:to="phat_FrazierLifeSciencesIXLimitedPartnerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="phat_FoundersMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_OpenMarketSaleAgreementWithJefferiesLLCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_ATMOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_StockRepurchaseProgramNumberOfSharesRightLapse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="phat_StockOptionsAndPerformanceBasedUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_StockRepurchaseProgramExpirationMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_AmountUtilizedOfEquityFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_AvailableAggregateOfferingPriceThroughEquityFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_AggregateOfferingPriceThroughEquityFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_RepurchaseRightLapseRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_RepurchaseRightLapseShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SharesAggregateRepurchasePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ProceedsFromIssuanceInitialPublicOfferingGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SharesIssuedPricePerShareAfterDeductions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_NetProceedsAfterDeductingUnderwritersCommission" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_PurchaseOfAdditionalOfferingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ClosingMarketPriceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="49" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_CommonStockWarrantMember" xlink:label="phat_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_StockOptionsAndPerformanceBasedAwardsMember" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="phat_CommonStockWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="phat_StockOptionsAndPerformanceBasedAwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_OperatingLossCarryforwardsExpirationYear" xlink:label="phat_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="phat_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20221231.xsd#phat_NetProceedsFromIssuanceOfCommonStock" xlink:label="phat_NetProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_ATMOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="phat_NetProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>37
<FILENAME>phat-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-27T18:39:07.1541+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.phathompharma.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:phat="http://www.phathompharma.com/20221231">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="phat-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="phat-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="phat-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="phat-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2" id="DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" id="Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical">
        <link:definition>100050 - Statement - Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit" id="StatementStatementsOfStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100070 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical" id="Role_StatementStatementsOfCashFlowsParenthetical">
        <link:definition>100080 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>100100 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100110 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitments" id="Role_DisclosureLeaseCommitments">
        <link:definition>100130 - Disclosure - Lease Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100140 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiability" id="DisclosureRevenueInterestFinancingLiability">
        <link:definition>100150 - Disclosure - Revenue Interest Financing Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100160 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_Disclosure401KPlan" id="Role_Disclosure401KPlan">
        <link:definition>100180 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>100210 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables" id="Role_DisclosureLeaseCommitmentsTables">
        <link:definition>100220 - Disclosure - Lease Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>100230 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityTables" id="DisclosureRevenueInterestFinancingLiabilityTables">
        <link:definition>100240 - Disclosure - Revenue Interest Financing Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100250 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100260 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100270 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails">
        <link:definition>100280 - Disclosure - Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Balance Sheet Details - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails">
        <link:definition>100300 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" id="Role_DisclosureLeaseCommitmentsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Lease Commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" id="Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails">
        <link:definition>100340 - Disclosure - Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" id="Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails">
        <link:definition>100350 - Disclosure - Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" id="Role_DisclosureDebtScheduleOfTotalDebtDetails">
        <link:definition>100360 - Disclosure - Debt - Schedule of Total Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" id="Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails">
        <link:definition>100380 - Disclosure - Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" id="DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Revenue Interest Financing Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" id="DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails">
        <link:definition>100400 - Disclosure - Revenue Interest Financing Liability - Schedule of Total Revenue Interest Financing Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails" id="Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails">
        <link:definition>100420 - Disclosure - Stockholders' Equity - Summary of Unvested Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" id="Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100430 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" id="DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails">
        <link:definition>100440 - Disclosure - Stockholders' Equity - Summary of PSU and RSUs Activity Under the 2019 Incentive Award Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" id="Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails">
        <link:definition>100450 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
        <link:definition>100460 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100470 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails">
        <link:definition>100490 - Disclosure - Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails">
        <link:definition>100500 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Subsequent Events - Additional Information - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="phat_AssetsLesseeAbstract" name="AssetsLesseeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_LiabilitiesLesseeAbstract" name="LiabilitiesLesseeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" name="AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AccruedClinicalTrialExpensesCurrent" name="AccruedClinicalTrialExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AccruedExpensesRelatedPartiesCurrent" name="AccruedExpensesRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AccruedInterest" name="AccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AccruedInterestOnRevenueInterestFinancingLiability" name="AccruedInterestOnRevenueInterestFinancingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount" name="AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_AdditionalWarrantIssued" name="AdditionalWarrantIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" name="AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AggregateOfferingPriceThroughEquityFinancing" name="AggregateOfferingPriceThroughEquityFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_AgreementExpirationTermFromDateOfFirstCommercialSale" name="AgreementExpirationTermFromDateOfFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_AgreementExtendsPeriodForTermination" name="AgreementExtendsPeriodForTermination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_AmountUtilizedOfEquityFinancing" name="AmountUtilizedOfEquityFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_AvailableAggregateOfferingPriceThroughEquityFinancing" name="AvailableAggregateOfferingPriceThroughEquityFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_CashlessExerciseOfCommonStockWarrants" name="CashlessExerciseOfCommonStockWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ChangeInControlDescription" name="ChangeInControlDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ClassOfWarrantOrRightExpirationDate" name="ClassOfWarrantOrRightExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ClassOfWarrantOrRightExpireTerm" name="ClassOfWarrantOrRightExpireTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_ClosingMarketPriceOfCommonStock" name="ClosingMarketPriceOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" name="DebtInstrumentAdditionalBorrowingCapacityAmounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_DebtInstrumentFacilityChargePercentage" name="DebtInstrumentFacilityChargePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DebtInstrumentFinalPaymentFee" name="DebtInstrumentFinalPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_DebtInstrumentFinalPaymentFeePercentage" name="DebtInstrumentFinalPaymentFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DebtInstrumentInterestAndFinalPaymentFee" name="DebtInstrumentInterestAndFinalPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_DebtInstrumentInterestRatePercentage" name="DebtInstrumentInterestRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DebtInstrumentPenaltyFeePercentage" name="DebtInstrumentPenaltyFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" name="DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DefaultObligationDescription" name="DefaultObligationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" name="DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_FinancialAssetsFairValueDisclosure" name="FinancialAssetsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_FundsReceivedFromInitialClosing" name="FundsReceivedFromInitialClosing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_GeneralAndAdministrativeExpenseRelatedParty" name="GeneralAndAdministrativeExpenseRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_GrossProceedsFromRevenueInterestFinancingAgreement" name="GrossProceedsFromRevenueInterestFinancingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" name="IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncomeTaxReconciliationPermanentItems" name="IncomeTaxReconciliationPermanentItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" name="IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" name="IncreaseDecreaseInClinicalAccruedTrialExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" name="IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" name="IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_InterestExpenseRelatedToRevenueInterestFinancingLiability" name="InterestExpenseRelatedToRevenueInterestFinancingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_InvestorAdditionalFundingAmountUponApproval" name="InvestorAdditionalFundingAmountUponApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_InvestorsFundingAmount" name="InvestorsFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone" name="InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_InvestorsReceiptDescription" name="InvestorsReceiptDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_InvestorsRightToReceiveRoyaltiesTerminationDescription" name="InvestorsRightToReceiveRoyaltiesTerminationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_LanderWarrantsExpireTerm" name="LanderWarrantsExpireTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_LenderWarrantsExercisableSharesOfCommonStock" name="LenderWarrantsExercisableSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_LesseeOperatingLeaseNumberOfOptionToExtend" name="LesseeOperatingLeaseNumberOfOptionToExtend" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_LicenseAgreementDescription" name="LicenseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_LicenseAgreementTransactionCosts" name="LicenseAgreementTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_LongTermDebtAndInterest" name="LongTermDebtAndInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" name="LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" name="MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_MinimumMarketCapitalizationAmount" name="MinimumMarketCapitalizationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" name="MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" name="MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_NetProceedsAfterDeductingUnderwritersCommission" name="NetProceedsAfterDeductingUnderwritersCommission" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NetProceedsFromRevenueInterestFinancingTransaction" name="NetProceedsFromRevenueInterestFinancingTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NonCashFinalInterestPaymentFee" name="NonCashFinalInterestPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" name="NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" name="NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" name="NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NonfinancialAssetsFairValueDisclosure" name="NonfinancialAssetsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NumberOfWarrantsRemainingExercisable" name="NumberOfWarrantsRemainingExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" name="OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_PaymentForFacilityCharge" name="PaymentForFacilityCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_PaymentForLicenseAmount" name="PaymentForLicenseAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_PaymentOfTransactionCosts" name="PaymentOfTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" name="PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" name="PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" name="PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_PercentageOfInvestorShareOfRoyaltyInNetSales" name="PercentageOfInvestorShareOfRoyaltyInNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_PotentialAdditionalInvestorFundingAmount" name="PotentialAdditionalInvestorFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" name="PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_ProceedsFromIssuanceInitialPublicOfferingGross" name="ProceedsFromIssuanceInitialPublicOfferingGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_PurchaseCommitmentExpense" name="PurchaseCommitmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_PurchaseObligationDueInFirstTwentyFourMonths" name="PurchaseObligationDueInFirstTwentyFourMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_PurchaseOfAdditionalOfferingExpenses" name="PurchaseOfAdditionalOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" name="RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_RepurchaseRightLapseRate" name="RepurchaseRightLapseRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_RepurchaseRightLapseShares" name="RepurchaseRightLapseShares" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_ResearchAndDevelopmentExpenseRelatedParty" name="ResearchAndDevelopmentExpenseRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" name="ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_RevenueInterestFinancingLiability" name="RevenueInterestFinancingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_RevenueInterestFinancingLiabilityNoncurrent" name="RevenueInterestFinancingLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" name="SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_SharesAggregateRepurchasePrice" name="SharesAggregateRepurchasePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_SharesIssuedPricePerShareAfterDeductions" name="SharesIssuedPricePerShareAfterDeductions" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants" name="StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits" name="StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_StockRepurchaseProgramExpirationMonthAndYear" name="StockRepurchaseProgramExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_StockRepurchaseProgramNumberOfSharesRightLapse" name="StockRepurchaseProgramNumberOfSharesRightLapse" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod" name="TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_WarrantsExpirationDate" name="WarrantsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" name="OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_AmendmentToLoanAgreementMember" name="AmendmentToLoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_ATMOfferingProgramMember" name="ATMOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_ClinicalManufacturingServicesMember" name="ClinicalManufacturingServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember" name="CommercialSupplyAgreementAndTemporaryServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_CommercialSupplyAgreementsMember" name="CommercialSupplyAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_CommonStockWarrantMember" name="CommonStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_DrugProductOrSubstanceMember" name="DrugProductOrSubstanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_EmployeesMember" name="EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_FoundersMember" name="FoundersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_FrazierLifeSciencesIXLimitedPartnerMember" name="FrazierLifeSciencesIXLimitedPartnerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_HerculesAndSvbTermLoanMember" name="HerculesAndSvbTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_HerculesLoanAgreementMember" name="HerculesLoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_InitialInvestorsNqSagardAndHerculesMember" name="InitialInvestorsNqSagardAndHerculesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_LoanAgreementMember" name="LoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_OpenMarketSaleAgreementWithJefferiesLLCMember" name="OpenMarketSaleAgreementWithJefferiesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_PaymentInKindPikInterestRateMember" name="PaymentInKindPikInterestRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_PCIPharmaServicesMember" name="PCIPharmaServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_PrepaidLeasePaymentsMember" name="PrepaidLeasePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember" name="RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember" name="RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember" name="RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementMember" name="RevenueInterestFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember" name="RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember" name="RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember" name="RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember" name="RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember" name="RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember" name="RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember" name="RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember" name="RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" name="ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_SiliconValleyBankTermLoanMember" name="SiliconValleyBankTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember" name="StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_StockOptionsAndPerformanceBasedAwardsMember" name="StockOptionsAndPerformanceBasedAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_StockOptionsAndPerformanceBasedUnitsMember" name="StockOptionsAndPerformanceBasedUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TakedaLicenseAgreementMember" name="TakedaLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TemporaryServicesAgreementMember" name="TemporaryServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoanAdvanceMember" name="TermLoanAdvanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoanFirstAdvanceMember" name="TermLoanFirstAdvanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoansAggregatePrincipalAmountTranchesFourMember" name="TermLoansAggregatePrincipalAmountTranchesFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoansAggregatePrincipalAmountTranchesOneMember" name="TermLoansAggregatePrincipalAmountTranchesOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember" name="TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" name="TermLoansAggregatePrincipalAmountTranchesThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" name="TermLoansAggregatePrincipalAmountTranchesTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TwoThousandNineteenIncentiveAwardPlanMember" name="TwoThousandNineteenIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_UnvestedSharesMember" name="UnvestedSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_ContractWithCustomerLiabilityTable" name="ContractWithCustomerLiabilityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" name="OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" name="CommonStockReservedForFutureIssuancesTableTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ComponentOfBalanceSheetDisclosureTextBlock" name="ComponentOfBalanceSheetDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_LiquidityAndCapitalResourcesPolicyTextBlock" name="LiquidityAndCapitalResourcesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_OrganizationAndBasisOfPresentationPolicyTextBlock" name="OrganizationAndBasisOfPresentationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_RevenueInterestFinancingLiabilityPolicyTextBlock" name="RevenueInterestFinancingLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_RevenueInterestFinancingLiabilityTextBlock" name="RevenueInterestFinancingLiabilityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock" name="ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" name="SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872039388832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PHATHOM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001783183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4151574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Campus Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Florham Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">742-8466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,973,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PHAT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain sections of the registrant&#8217;s definitive proxy statement for the 2023 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872033332672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 155,385<span></span>
</td>
<td class="nump">$ 183,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,127<span></span>
</td>
<td class="nump">3,267<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">160,512<span></span>
</td>
<td class="nump">186,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,287<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">164,810<span></span>
</td>
<td class="nump">189,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable (including related party amounts of $35 and $1,343 respectively)</a></td>
<td class="nump">9,997<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (including related party amountsof $2,499 and $2,330, respectively)</a></td>
<td class="nump">14,678<span></span>
</td>
<td class="nump">11,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">708<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,237<span></span>
</td>
<td class="nump">18,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount</a></td>
<td class="nump">95,264<span></span>
</td>
<td class="nump">89,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_RevenueInterestFinancingLiabilityNoncurrent', window );">Revenue interest financing liability</a></td>
<td class="nump">109,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">239,624<span></span>
</td>
<td class="nump">117,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; authorized shares - 400,000,000 at December 31, 2022 and 2021; issued shares - 41,723,308 and 31,656,035 at December 31, 2022 and 2021, respectively; outstanding shares - 41,468,871 and 30,511,226 at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock - 19 and 1 shares at December 31, 2022 and 2021, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">652,276<span></span>
</td>
<td class="nump">601,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(727,093)<span></span>
</td>
<td class="num">(529,370)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(74,814)<span></span>
</td>
<td class="nump">72,156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 164,810<span></span>
</td>
<td class="nump">$ 189,431<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_RevenueInterestFinancingLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest financing liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_RevenueInterestFinancingLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872039542176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable, related parties</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AccruedExpensesRelatedPartiesCurrent', window );">Accrued expenses, related parties</a></td>
<td class="nump">$ 2,499<span></span>
</td>
<td class="nump">$ 2,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">41,723,308<span></span>
</td>
<td class="nump">31,656,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">41,468,871<span></span>
</td>
<td class="nump">30,511,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccruedExpensesRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses related parties current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccruedExpensesRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872033307344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (includes related party amounts of $2,123 and $4,933, respectively)</a></td>
<td class="nump">$ 71,441<span></span>
</td>
<td class="nump">$ 72,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative (includes related party amounts of $0 and $18, respectively)</a></td>
<td class="nump">100,999<span></span>
</td>
<td class="nump">62,742<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">172,440<span></span>
</td>
<td class="nump">135,080<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(172,440)<span></span>
</td>
<td class="num">(135,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(27,305)<span></span>
</td>
<td class="num">(6,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(2,056)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(25,283)<span></span>
</td>
<td class="num">(8,803)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (197,723)<span></span>
</td>
<td class="num">$ (143,883)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (5.05)<span></span>
</td>
<td class="num">$ (3.89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (5.05)<span></span>
</td>
<td class="num">$ (3.89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic</a></td>
<td class="nump">39,118,215<span></span>
</td>
<td class="nump">37,002,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding, diluted</a></td>
<td class="nump">39,118,215<span></span>
</td>
<td class="nump">37,002,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872039283840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ResearchAndDevelopmentExpenseRelatedParty', window );">Research and development expenses, related party</a></td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="nump">$ 4,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_GeneralAndAdministrativeExpenseRelatedParty', window );">General and administrative expenses, related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_GeneralAndAdministrativeExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative expense related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_GeneralAndAdministrativeExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ResearchAndDevelopmentExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ResearchAndDevelopmentExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872034582304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 194,271<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 579,755<span></span>
</td>
<td class="num">$ (385,487)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,516,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants', window );">Cashless exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_CashlessExerciseOfCommonStockWarrants', window );">Cashless exercise of common stock warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">401(k) matching contribution</a></td>
<td class="nump">903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled', window );">401(k) matching contribution, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,601,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">ESPP shares issued</a></td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(143,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,883)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 72,156<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601,523<span></span>
</td>
<td class="num">(529,370)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">30,511,226<span></span>
</td>
<td class="nump">30,511,226<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants', window );">Cashless exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,359,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_CashlessExerciseOfCommonStockWarrants', window );">Cashless exercise of common stock warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">401(k) matching contribution</a></td>
<td class="nump">$ 1,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled', window );">401(k) matching contribution, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">992,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under ATM facility</a></td>
<td class="nump">24,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under ATM facility, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,414,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">ESPP shares issued</a></td>
<td class="nump">909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(197,723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197,723)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="num">$ (74,814)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 652,276<span></span>
</td>
<td class="num">$ (727,093)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="nump">41,468,871<span></span>
</td>
<td class="nump">41,468,871<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_CashlessExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_CashlessExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution pan employer discretionary match number of shares settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares cashless exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872039519008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (197,723)<span></span>
</td>
<td class="num">$ (143,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">24,133<span></span>
</td>
<td class="nump">16,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Issuance of PIK interest debt</a></td>
<td class="nump">3,484<span></span>
</td>
<td class="nump">990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AccruedInterestOnRevenueInterestFinancingLiability', window );">Accrued interest on revenue interest financing liability</a></td>
<td class="nump">14,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount</a></td>
<td class="nump">2,110<span></span>
</td>
<td class="nump">3,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets (includes changes in related party amounts of $0 and $82, respectively)</a></td>
<td class="num">(1,860)<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses (includes changes in related party amounts of $1,139 and $2,766, respectively)</a></td>
<td class="nump">8,679<span></span>
</td>
<td class="num">(9,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_IncreaseDecreaseInClinicalAccruedTrialExpenses', window );">Accrued clinical trial expenses</a></td>
<td class="num">(1,402)<span></span>
</td>
<td class="num">(18,595)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="nump">377<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities', window );">Operating right-of-use assets and lease liabilities</a></td>
<td class="num">(238)<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(118)<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(146,530)<span></span>
</td>
<td class="num">(148,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for property, plant and equipment</a></td>
<td class="num">(1,041)<span></span>
</td>
<td class="num">(328)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,041)<span></span>
</td>
<td class="num">(328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_NetProceedsFromRevenueInterestFinancingTransaction', window );">Net proceeds from revenue interest financing transaction</a></td>
<td class="nump">95,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">120,042<span></span>
</td>
<td class="nump">44,708<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents and restricted cash</a></td>
<td class="num">(27,529)<span></span>
</td>
<td class="num">(104,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents &#8211; beginning of period</a></td>
<td class="nump">183,419<span></span>
</td>
<td class="nump">287,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents &#8211; end of period</a></td>
<td class="nump">155,890<span></span>
</td>
<td class="nump">183,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">7,033<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt', window );">Issuance of common stock warrants in connection with long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued expenses</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_NonCashFinalInterestPaymentFee', window );">Final interest payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock', window );">Settlement of ESPP liability in common stock</a></td>
<td class="nump">909<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock', window );">Settlement of 401(k) liability in common stock</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">$ 903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember', window );">At-the-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 24,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccruedInterestOnRevenueInterestFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on revenue interest financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccruedInterestOnRevenueInterestFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncreaseDecreaseInClinicalAccruedTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in clinical accrued trial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncreaseDecreaseInClinicalAccruedTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating right of use asset and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NetProceedsFromRevenueInterestFinancingTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from revenue interest financing transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NetProceedsFromRevenueInterestFinancingTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NonCashFinalInterestPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash final interest payment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NonCashFinalInterestPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NonCash settlement of defined contribution plan liability in common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NonCash settlement of employee stock purchase plan liability in common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash issuance of common stock warrants in connection with long term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities arising from obtaining right-of-use assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036885600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent', window );">Related parties prepaid expenses and other assets current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties', window );">Related parties accounts payable and accrued expenses</a></td>
<td class="nump">$ 1,139<span></span>
</td>
<td class="nump">$ 2,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts payable and accrued expenses related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease)in prepaid expenses and other assets related parties current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036454832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization, Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1. Organization, Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Organization and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company&#8217;s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">From inception to December 31, 2022, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the clinical trials of vonoprazan, preparing for commercialization of its initial products containing vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur additional net losses in the future as it continues to develop and prepares for commercialization of vonoprazan. From inception to December 31, 2022, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, revenue interest financing debt, the sale of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10,997,630</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">191.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in its 2019 IPO, the sale of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">88.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in its December 2020 follow-on public offering, and the sale of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,414,897</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in its September 2022 issuance of common stock under the ATM Offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company&#8217;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company&#8217;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Level 1: Observable inputs such as quoted prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The carrying amounts of the Company&#8217;s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> financial assets measured at fair value on a recurring basis. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">None</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">n-recurring basis. No transfers between levels have occurred during the periods presented.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the estimated fair value of the Company&#8217;s long-term debt approximated the carrying amount given its floating interest rate basis. The fair value of the Company&#8217;s long-term debt was estimated for disclosure purposes only and was determined based on quoted market data for valuation, and thus categorized as Level 2 in the fair value hierarchy.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Property, Plant, and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="-sec-ix-hidden:F_d7201b82-ce21-4ec4-8499-cb8a67775133;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Furniture and fixtures are depreciated over</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> impairment losses have been recorded through December 31, 2022.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company&#8217;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Interest Financing Liability</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company entered into a revenue interest financing agreement, or the Revenue Interest Financing Agreement, with entities managed or advised by NovaQuest Capital Management, or NQ, Sagard Holdings Manager LP, or Sagard, and Hercules Capital, Inc., or Hercules, together with NQ and Sagard, the Initial Investors, in which the Company received funds in return for royalties on net sales of products containing vonoprazan. The net proceeds received under the transaction were recognized as short-term and long-term liabilities with interest expense based on an imputed effective rate derived from the expected future payments. The Company recalculates the effective interest rate each period based on the current carrying value and the revised estimated future payments. Changes in future payments from previous estimates are included in current and future financing expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#8217;s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">In-Process Research and Development</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company also maintains an employee stock purchase program, or ESPP, under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning in 2022, the Tax Cuts and Jobs Act, or TCJA, eliminates the option to deduct research and development expenditures currently and requires taxpayers to amortize domestic and foreign research and development expenditures over </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">15</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years, respectively. The requirement did not impact cash from operations in the current period.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss was the same as its reported net loss for all periods presented.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> operating segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7,588,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock under its warrant (the &#8220;Takeda Warrant&#8221;) issued to Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company&#8217;s IPO until its exercise because the Takeda Warrant was exercisable for little consideration. As of December 31, 2022, all Takeda Warrants has been exercised and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Takeda Warrants remain exercisable. For the years ended December 31, 2022 and December 31, 2021, the Company has excluded weighted-average unvested shares of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">686,703</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,939,252</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Recently Adopted Accounting Standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">There were no recently adopted accounting standards which would have a material impact on the Company's financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">     </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2022 that impacted the Company.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036574016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ComponentOfBalanceSheetDisclosureTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2. Balance Sheet Details</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Property, Plant and Equipment, net</span></p><div style="font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Property, plant and equipment, net, consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.276%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.023000000000003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.023000000000003%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,078</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">646</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,086</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">780</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">115</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Construction in process</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">399</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total property, plant and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">852</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total property, plant and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,207</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">650</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Depreciation expense for the years ended December 31, 2022 and 2021 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> property, plant or equipment was disposed of during the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Accrued Expenses</span></p><div style="font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued expenses consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.471%;"/>
        <td style="width:1.343%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.913999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.343%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.929%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,080</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued compensation expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8,447</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6,344</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued professional &amp; consulting<br/>&#160;&#160;&#160;expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,855</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">41</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">14,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">11,405</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ComponentOfBalanceSheetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Component of Balance Sheet Disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ComponentOfBalanceSheetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036454832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Frazier is a principal stockholder of the Company and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> is a principal stockholder in PCI Pharma Services, or PCI. In the third quarter of 2019, the Company engaged PCI for clinical manufacturing services. As of December 31, 2022 and 2021, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, in outstanding accounts payable and accrued expenses related to these manufacturing services. For the years ended December 31, 2022 and 2021, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, of expenses related to services performed by PCI.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Takeda became a common stockholder of the Company in connection with the May 2019 license agreement (see Note 4). In conjunction with this license, Takeda provides proprietary supplies for the Company&#8217;s ongoing clinical development of vonoprazan in addition to the exclusive license for the commercialization of vonoprazan in the United States, Canada and Europe. On May 5, 2020, the Company entered into a Commercial Supply Agreement, or the Commercial Supply Agreement, with Takeda, pursuant to which Takeda agreed to supply commercial quantities of vonoprazan bulk drug product or drug substance. Pursuant to the Commercial Supply Agreement, Takeda agreed to supply the Company with, and the Company agreed to purchase from Takeda, certain quantities of vonoprazan bulk drug product according to approved specifications at a fixed price per batch of bulk drug product in order to commercialize vonoprazan in accordance with the Takeda License. Unless terminated earlier, the term of the Commercial Supply Agreement extends for a period of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> from the date the Company places an order for bulk drug product or drug substance for the first commercial launch of vonoprazan in any jurisdiction in the licensed territory, provided that this two-year period will expire no later than December 31, 2023. The Commercial Supply Agreement will terminate immediately upon the termination of the Takeda License in accordance with its terms. In connection with the Takeda License, the Company entered into a temporary services agreement, or the Temporary Services Agreement, with Takeda on November 24, 2020. Pursuant to the Temporary Services Agreement, Takeda agreed to provide or procure the provision of services related to the ongoing clinical development of vonoprazan. The Temporary Services Agreement will terminate immediately upon termination of the Takeda License in accordance with its terms. As of December 31, 2022 and December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, in outstanding accounts payable and accrued expenses related to these agreements.  For the years ended December 31, 2022 and 2021, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, of expenses related to these agreements. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> remaining minimum purchase obligation related to these agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036547936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">n May 7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe, or, the Takeda License. The Company also has the right to sublicense its rights under the agreement, subject to certain conditions. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">15 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months&#8217; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#8217;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">n consideration of the Takeda License, the Company (i) paid Takeda $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in cash, (ii) issued Takeda </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,084,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of its common stock at a fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, (iii) issued the Takeda Warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7,588,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of its common stock at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.00004613</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per share at an initial fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">47.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, and (iv) issued a right to receive an additional common stock warrant, or, the Takeda Warrant Right, should Takeda&#8217;s fully-diluted ownership of the Company represent less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately before the closing of the Company&#8217;s IPO, with a nominal initial fair value due to the low probability of issuance. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of the IPO, and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> additional warrant was issued. In addition, the Company is obligated to pay Takeda up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in sales milestones upon the achievement of specified levels of product sales, and a low double-digit royalty rate on aggregate net sales of licensed products, subject to certain adjustments. The Takeda Warrant had an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.00004613</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per share, and was to expire on</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> May 7, 2029</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and became exercisable upon the consummation of the IPO. As of December 31, 2022 all Takeda Warrants have been exercised.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Purchase Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In December 2020, the Company entered into a supply agreement with Sandoz pursuant to which Sandoz will supply commercial quantities of amoxicillin capsules and clarithromycin tablets, package these antibiotics with vonoprazan, and provide in finished convenience packs. The supply agreement commits the Company to a minimum purchase obligation of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in the first 24-month period following the launch of the final product. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">t incurred any expenses under the agreement during the years ended December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036732240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Commitments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5. Lease Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company had operating leases for office space in both Buffalo Grove, Illinois and Florham Park, New Jersey, with weighted average remaining lease terms of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years, respectively. All</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> operating leases contain an option to extend the term for </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> additional </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> period</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, which was not considered in the determination of the right-of-use asset or lease liability as the Company did not consider it reasonably certain that it would exercise such options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">     </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The total rent expense for the years ended December 31, 2022 and 2021 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.173%;"/>
        <td style="width:1.511%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.893999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.528%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.893999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,287</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,914</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,287</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,914</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">708</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">487</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,098</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,183</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,806</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,670</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the future minimum annual lease payments under the operating leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.12%;"/>
        <td style="width:1.493%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.387999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">734</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">753</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">513</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">194</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,806</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">708</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,098</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.6</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8.20</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating cash flows for the years ended December 31, 2022 included $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in cash payments for operating leases, none of which were prepaid lease payments. Operating cash flows for the years ended December 31, 2021 included $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in cash payments for operating leases, $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of which were prepaid lease payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036387568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6. Debt</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total debt consists of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.352%;"/>
        <td style="width:1.516%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.131999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Long-term debt, current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Long-term debt, non-current portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">104,474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unamortized debt discount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9,210</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total debt, net of debt discount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">95,264</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On September 17, 2021, or the Closing Date, the Company entered into a Loan and Security Agreement, or, the Loan Agreement, with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender, or, in such capacity, the Agent or Hercules, and the other financial institutions that from time to time become parties to the Loan Agreement as lenders, or, collectively, the Lenders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Loan Agreement provides for term loans in an aggregate principal amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">200.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, or the Term Loan, under multiple tranches. The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, all of which was funded to the Company on the Closing Date, or First Advance, (ii) a second tranche consisting of up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, which became available to the Company upon achievement of the protocol-specified primary efficacy endpoints in the Company&#8217;s Phase 3 trial studying vonoprazan for the healing and maintenance of healing of erosive GERD with acceptable safety data, such that the results support the submission of a New Drug Application, or NDA, or supplemental NDA without the need to conduct another Phase 3 study and will be available, if specified conditions are met, through December 15, 2022, see amendment to later date below, (iii) a third and fourth tranches consisting of an additional total $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, which became available to the Company in May 2022 upon the achievement of (a) Food and Drug Administration, or FDA, approval of the Company&#8217;s NDA for vonoprazan and amoxicillin, or its New Drug Application for vonoprazan, amoxicillin and clarithromycin, in each case for an indication relating to the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Helicobacter pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">with an approved indication on the claim that is generally consistent with that sought in the Company&#8217;s NDA submission&#894; and (b) filing of the Company&#8217;s NDA or supplemental NDA for vonoprazan for indications relating to the healing and maintenance of healing of erosive GERD. The third and fourth tranches will remain available until September 30, 2023, and March 31, 2024, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On September 27, 2022, the Company entered into an amendment to the Loan Agreement, or the Second Loan Amendment, pursuant to which the date the second tranche of funding of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million will remain available to the Company has been moved until May 15, 2023, rather than December 15, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company paid a $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million facility charge in connection with closing of the Loan Agreement and would need to pay </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of any advances made under the third and fourth tranches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">he Term Loan will mature on </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">October 1, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, or the Maturity Date. The Term Loan bears (i) cash interest at a variable annual rate equal to the greater of (a) </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% and (b) the Prime Rate (as reported in the Wall Street Journal) plus </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%, or the &#8220;Interest Rate&#8221;, and (ii) payment-in-kind interest at a per annum rate of interest equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%. Phathom may make payments of interest only through October 1, 2024, which was extended to October 1, 2025, upon the achievement of the Second Performance Milestone in May 2022 prior to September 30, 2024 and met the condition that no default or event of default exists, and which is further extendable to October 1, 2026, subject to FDA approval of the Company&#8217;s NDA (or supplemental NDA) for vonoprazan for an indication relating to the healing and maintenance of healing of erosive GERD with an approved indication on the label that is generally consistent with that sought in the Company&#8217;s NDA submission (or supplemental NDA submission), or the Third Performance Milestone, on or prior to September 30, 2025 and no default or event of default exists (the &#8220;interest only period&#8221;). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, the Company is obligated to pay a final payment fee of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the original principal amount of amounts actually advanced under the Term Loan, or, each a Term Loan Advance and together, the Term Loan Advances. As of December 31, 2022, the aggregate final payment fee for the first Term Loan Advance of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million has been recorded as an other long-term liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company may elect to prepay all or a portion of the Term Loan Advances prior to maturity, subject to a prepayment fee of up to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the then outstanding principal balance of the Term Loan Advances being prepaid. After repayment, no Term Loan amounts may be borrowed again.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As collateral for the obligations, the Company has granted to Hercules a senior security interest in all of Company&#8217;s right, title, and interest in, to and under substantially all of Company&#8217;s property, inclusive of intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring the Company to maintain certain levels of cash subject to a control agreement in favor of the Agent (minus accounts payable not paid within 120 days of invoice), or Qualified Cash, and commencing on May 15, 2023, trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan. The revenue covenant will be waived at any time in which the Company maintains Qualified Cash equal to at least </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% (prior to the Third Performance Milestone), and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% (following the Third Performance Milestone) of the total outstanding Term Loan principal amount, or the Company&#8217;s market capitalization is at least $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">900.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company may be declared immediately due and payable by Hercules, as collateral agent. As of December 31, 2022, the Company was in compliance with all applicable covenants under the Loan Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under the Second Loan Amendment, the commencement date for the covenant based on trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan was moved from May 15, 2023, to November 15, 2023.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In connection with the entry into the Loan Agreement, the Company issued to Hercules a warrant, or, the Warrant, to purchase a number of shares of the Company&#8217;s common stock equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the aggregate amount of the Term Loan advances funded, and will issue to Hercules additional warrants when future Term Loan advances are funded. On the Closing Date, the Company issued a Warrant for </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">74,782</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock. The Warrant will be exercisable for a period of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">seven years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> from the date of issuance at a per-share exercise price equal to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">33.43</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, which was the closing price of the Company&#8217;s common stock on September 16, 2021. The Warrant is exercisable any time until </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">September 17, 2028</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and had an initial fair value of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The initial $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million fair value of the Warrant, the $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million final interest payment fee and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of debt issuance costs have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the term of the Term Loan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Future minimum principal payments under the Term Loan, including the final payment fee, as of December 31, 2022 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.599%;"/>
        <td style="width:1.521%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.88%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Year ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">29,707</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">94,764</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total principal and interest payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">124,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less payment-in-kind and final payment fee</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24,471</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total term loan borrowings</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">100,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Prior to the Loan Agreement with Hercules, the Company had a loan with SVB and approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">54.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of the proceeds from the First Advance was used to satisfy in full and retire the Company&#8217;s indebtedness under the SVB Term Loan with SVB, including accrued interest through the payoff date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">13.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, of interest expense, including amortization of the debt discount, in connection with the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Hercules Loan Agreement and SVB Term Loan. As of December 31, 2022, the Company had outstanding </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">loan balance of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">104.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and accrued interest of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036527632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_RevenueInterestFinancingLiabilityTextBlock', window );">Revenue Interest Financing Liability</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7. Revenue Interest Financing Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On May 3, 2022, Phathom entered into a Revenue Interest Financing Agreement with Initial Investors NQ, Sagard, and Hercules pursuant to which the Company will receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">260</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in funding from the Initial Investors. Under the terms of the Revenue Interest Financing Agreement, the Company received $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million at the initial closing and can receive an additional $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">160</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million upon FDA approval of vonoprazan for treatment of erosive GERD on or before March 31, 2024. At any time prior to December 31, 2022, the Company also has the right to obtain a written commitment from a third party for up to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of funding upon FDA approval of vonoprazan for erosive GERD. In addition, the Company has the right at any time prior to June 30, 2024, to obtain a written commitment from a third party for up to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of funding upon achievement of a sales milestone. The Initial Investors have a right of first offer if the Company seeks to obtain such additional funding. The total amount funded by the Initial Investors and any subsequent investors is referred to herein as the Investment Amount.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On October 31, 2022, the Company entered into a Joinder Agreement with the Initial Investors and CO Finance LVS XXXVII LLC (&#8220;the Additional Investor&#8221;), and Hercules Capital, Inc. Under the terms of the Joinder Agreement, the Initial Investors waived their rights of first offer regarding the Additional Investor Funding and the Additional Investor joined the Revenue Interest Financing Agreement to extend commitments for the Additional Investor Funding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Under the Revenue Interest Financing Agreement, the investors are entitled to receive a </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% royalty on net sales of products containing vonoprazan. The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and if the Company receives FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with non-erosive GERD. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The investors&#8217; right to receive royalties on net sales will terminate when the investors have aggregate payments equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">200</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for erosive GERD regulatory approval is made, the Company has the right to make a cap payment equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">200</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.</span></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">If the investors have not received aggregate payments of at least </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount by December 31, 2028, and at least </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">200</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.</span></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Upon the occurrence of an event of default taking place prior to April 1, 2025, between April 1, 2025, and April 1, 2028, and after April 1, 2028, the Company is obligated to pay </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> times Investment Amount, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> times Investment Amount, and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement. </span></span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"/></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Upon the occurrence of a change in control event taking place prior to the earlier of April 1, 2024, or FDA approval of vonoprazan for erosive GERD, the Company is obligated to pay </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">200</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount plus either </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount if occurrence prior to May 3, 2023, or plus </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the Investment Amount if occurrence thereafter.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022, the Company received gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million before deducting transaction costs of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, which resulted in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">95.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has evaluated the terms of the Revenue Interest Financing Agreement and concluded that the features of the Investment Amount are similar to those of a debt instrument. Accordingly, the Company has accounted for the transaction as a debt obligation with interest expense based on an imputed effective rate derived from the initial carrying value of the obligation and the expected future payments. The Company recalculates the effective interest rate each period based on the current carrying value and the revised estimated future payments. Changes in future payments from previous estimates are included in the current and future financing expense. The carrying value of the revenue interest financing liability was $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">109.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total revenue interest financing liability consists of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.164%;"/>
        <td style="width:1.726%;"/>
        <td style="width:17.569%;"/>
        <td style="width:1.54%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning liability balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Proceeds from the Revenue Interest Financing Agreement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">100,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: transaction costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4,554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: royalty payments and payables</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Plus: interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">14,079</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Ending liability balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">109,525</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">14.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of interest expense in connection with the revenue interest financing liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company will record liabilities associated with additional funding upon FDA approval of vonoprazan for erosive GERD and achievement of the sales milestone when such contingent events occur. To determine the accretion of the liability related to the Revenue Interest Financing Agreement, the Company is required to estimate the total amount of future royalty payments and estimated timing of such payments based on the Company&#8217;s revenue projections. As royalty payments are made, the balance of the debt obligation will be effectively repaid. Based on the Company&#8217;s periodic review, the exact timing of repayment is likely to be different in each reporting period as compared to those estimated in the Company&#8217;s initial revenue projections. A significant increase or decrease in actual net sales of vonoprazan compared to the Company&#8217;s revenue projections could impact the interest expense associated with the revenue interest financing liability. Also, the Company&#8217;s total obligation can vary depending on change in control or default events and the achievement of FDA approval of vonoprazan for erosive GERD and achievement of the sales milestone.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_RevenueInterestFinancingLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_RevenueInterestFinancingLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036454832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8. Stockholders&#8217; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In March 2019, subsequent to the Merger, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,491,072</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of the Company&#8217;s common stock to Frazier.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In March 2019, the founders granted the Company a repurchase right for the </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,373,408</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock originally purchased in 2018. The Company has the right, but not the obligation, to repurchase unvested shares in the event the founder&#8217;s relationship with the Company is terminated, subject to certain limitations, at the original purchase price of the stock. The repurchase right lapsed for </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">843,352</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares in March 2019 and the repurchase right for the remaining </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,530,056</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares lapses in equal monthly amounts over the following </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">48-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> period ending in </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">March 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. The fair value of the founder shares at the date the repurchase right was granted is being recognized as stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">79,064</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock were subject to repurchase by the Company and the associated repurchase liability was not significant. The amount of recognized and unrecognized stock-based compensation related to the founder stock was immaterial for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In May 2019, the Company issued Takeda </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,084,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock in connection with the Takeda License.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For the period from January 1, 2019 to May 6, 2019, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,524,852</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock to various employees and consultants of the Company for aggregate proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Upon issuance, these shares were subject to a repurchase option by the Company at the original purchase price of the shares. The repurchase rights generally lapse as to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the shares on the first anniversary of the vesting commencement date, and the repurchase right lapses as to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="-sec-ix-hidden:F_2b850787-a6cf-4d02-9e61-c00a1a4fa91d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1/48</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">th of the shares each one-month period thereafter, subject to the purchaser remaining continuously an employee, consultant or director of the Company. In November 2019, the Company repurchased </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">17,560</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares at the original purchase price for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5.20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">175,373</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares remain available for repurchase by the Company and the associated repurchase liability was not significant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On October 29, 2019, upon completion of the IPO, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10,997,630</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock, which included the exercise in full by the underwriters of their option to purchase </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,434,473</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> additional shares at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">19.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per share. The net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">191.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts, commissions and offering costs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In November 2020, the Company entered into an Open Market Sale Agreement, or, the Sales Agreement, with Jefferies LLC, or, the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">125.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million through the Sales Agent, or, the ATM Offering. Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the gross sales price per share sold. In September 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,414,897</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million under the ATM offering after deducting $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of issuance costs. As of December 31, 2022, the Company has utilized $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">25.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of the available $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">125.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million under the ATM Offering.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">On December 16, 2020, the Company completed an underwritten public offering, in which it sold </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">42.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per share for total gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">94.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million. The net purchase price after deducting underwriting discounts and commissions was $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">39.48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per share, which generated net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">88.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million. The Company incurred an additional $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of offering expenses in connection with this public offering.</span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A summary of the Company&#8217;s unvested shares is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:64.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.08%;"/>
        <td style="width:1.553%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.368%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,144,809</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Share vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">890,372</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">254,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For accounting purposes, unvested awards are considered issued, but not outstanding until they vest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Common stock reserved for future issuance consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.051%;"/>
        <td style="width:1.594%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.355%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">91,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock options and performance-based awards outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6,876,237</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Shares available for issuance under the 2019 Incentive Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">957,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Shares available for issuance under the ESPP Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">752,938</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8,678,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company is authorized to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million shares of preferred stock. As of December 31, 2022, and December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of preferred stock issued or outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s 2019 Equity Incentive Plan, or the Existing Incentive Plan, provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards to eligible recipients, including employees, directors or consultants of the Company. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,231,739</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock authorized for issuance under the Existing Incentive Plan, of which, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,400,528</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> stock options and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">16,260</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> restricted stock awards were granted in 2019. As a result of the adoption of the 2019 Incentive Award Plan, or the 2019 Plan, in October 2019, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> further shares are available for issuance under the Existing Incentive Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">2019 Incentive Award Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In October 2019, the board of directors adopted, and the Company&#8217;s stockholders approved, the 2019 Plan, which became effective in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above or equal to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,416,788</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">957,885</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares remain available for issuance, which reflects </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,789,868</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> stock options and performance-based units, or PSU, and restricted stock unit, or RSU, awards granted, and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">392,207</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> of awards cancelled or forfeited, during the year ended December 31, 2022 as well as an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">annual increases of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,582,802</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares authorized on January 1, 2022. </span></span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Performance-based Units</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During 2020, the Company granted the initial PSUs whereby vesting depends upon the approval by the FDA of vonoprazan for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and then, or concurrent with, erosive GERD. In 2022, the Company granted an additional </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">37,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> PSUs to employees. As of December 31, 2022, the PSU milestones had not been achieved. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> related compensation cost had been recognized. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2022.</span></span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.961%;"/>
        <td style="width:1.494%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.59%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.494%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.462%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Number of<br/>Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br/>Average Grant<br/>Date Fair Value<br/>Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">394,300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">32.23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">37,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">20.06</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">19,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">35.39</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">412,300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">30.97</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022 there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">12.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of related unrecognized compensation cost, which will be recognized upon vesting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During 2022, the Company granted </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,010,437</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> RSUs with vesting over time. The following table summarizes RSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.366%;"/>
        <td style="width:1.393%;"/>
        <td style="width:1.408%;"/>
        <td style="width:14.524%;"/>
        <td style="width:1.408%;"/>
        <td style="width:1.408%;"/>
        <td style="width:1.56%;"/>
        <td style="width:14.524%;"/>
        <td style="width:1.408%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Number of<br/>Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br/>Average Grant<br/>Date Fair Value<br/>Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,010,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">102,453</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8.51</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">30,517</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">12.14</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">877,467</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">11.03</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In October 2019, the board of directors adopted, and the Company&#8217;s stockholders approved, the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of their eligible compensation, which includes a participant&#8217;s gross base compensation for services to the Company, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A total of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">270,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock was initially reserved for issuance under the ESPP. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">752,938</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock remain available for issuance, which reflects </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">89,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares sold to employees during the year ended December 31, 2022. </span></span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"/></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The ESPP is considered a compensatory plan, and the Company recorded related stock-based compensation of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.081%;"/>
        <td style="width:1.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.076%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.090999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.50</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.69</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">68.59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">76.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.04</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.09</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The estimated weighted-average fair value of ESPP awards during 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3.98</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">14.66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively. As of December 31, 2022, the total unrecognized compensation expense related to the ESPP was $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">31,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">401(k) Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company established a 401(k) savings plan during the year ended December 31, 2020. The Company&#8217;s contributions to the plan are discretionary. During the years ended December 31, 2022 and December 31, 2021, the Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, of expense related to estimated employer contribution liabilities, which was based on a </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">% match of employees&#8217; contributions during the periods. In August 2021, the Board of Directors approved a semi-annual discretionary match for 2021, which was settled by contributing </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">18,394</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares. In January 2022, the Board of Directors approved a second semi-annual discretionary match for 2021, which was settled by contributing </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">16,756</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares. In July 2022, the Board of Directors approved a semi-annual match for 2022, which was settled by contributing </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">84,784</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company, prior to the IPO on October 29, 2019, was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected volatility based on the historical volatility of a publicly-traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company&#8217;s stock options for employees was determined utilizing the &#8220;simplified&#8221; method for awards. The expected term of stock options granted to non-employees was equal to the contractual term of the option award. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A summary of the Company&#8217;s stock option activity and related information is as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.033%;"/>
        <td style="width:0.725%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.727%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.544%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.243%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.742%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.715%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.742%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.528%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value (in<br/>thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4,186,729</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">27.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.91</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">13,973</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,741,931</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">14.62</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">342,190</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">29.32</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5,586,470</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">23.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.90</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4,476</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options exercisable as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,455,735</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">25.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.18</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,867</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The estimated weighted-average fair value of employee and nonemployee director stock options granted during 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8.40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> per option. As of December 31, 2022, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">37.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years.</span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.06%;"/>
        <td style="width:1.057%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.405%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.072%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.405%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5.88</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5.93</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">66.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">67.46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.06</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.68</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.164%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.879%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.879%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5,534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,838</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">18,599</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">12,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24,133</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">16,812</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036520336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Income Taxes</span><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">t record a provision for income taxes due to a full valuation against its deferred taxes. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.792%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.712%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.698%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Income taxes computed at the statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">41,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">30,216</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,713</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,387</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,950</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">41,137</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">31,783</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.484%;"/>
        <td style="width:1.286%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.965%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.286%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.98%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">85,918</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">60,936</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8,897</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6,694</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">25,319</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">13,809</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6,517</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,996</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">126,651</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">85,435</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">126,170</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">85,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">402</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">402</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Based upon the Company&#8217;s history of operating losses, the Company is unable to conclude that it is more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December 31, 2022 and 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">408.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">290.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, respectively, which are carried over indefinitely.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of state net operating loss carryforwards that begins to expire in </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2036</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company has available federal research and development credits of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million which begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2038</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million of state research and development credits, some of which, begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has not completed a formal analysis of the potential impact of Section 382 on its deferred tax assets as of December 31, 2022. Until this analysis has been completed, the Company has not adjusted any of its deferred tax assets, including net operating losses or research and development credits. The Company will reassess the amount of net operating losses and credits subject to limitation under Section 382 when a study is complete.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Due to the existence of the valuation allowance, future changes in the deferred tax assets related to these tax attributes will not impact the Company&#8217;s effective tax rate.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes the activity related to the Company's gross unrecognized tax benefits:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.936%;"/>
        <td style="width:1.466%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.559000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.559000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,704</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">938</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Increases related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">64</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Increases related to current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">623</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">702</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Ending balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,327</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company has gross unrecognized tax benefits of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,327</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">none</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> of which would affect the effective tax rate due to a full valuation allowance.  The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months.  The Company's policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense.  The Company has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> accrual for interest or penalties on its balance sheet at December 31, 2022, and has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">t recognized interest and/or penalties in its statement of operations for the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company is subject to taxation in the United States and various states. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036458064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10. Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">At-The-Market Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">From January 1, 2023 through February 27, 2023, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,514,219</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock in a single trade under the ATM Sale Agreement generating gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">14.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million and net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">14.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million, after offering expenses.</span><span style="color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872035159680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationAndBasisOfPresentationPolicyTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Organization and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company&#8217;s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LiquidityAndCapitalResourcesPolicyTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">From inception to December 31, 2022, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the clinical trials of vonoprazan, preparing for commercialization of its initial products containing vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur additional net losses in the future as it continues to develop and prepares for commercialization of vonoprazan. From inception to December 31, 2022, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, revenue interest financing debt, the sale of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10,997,630</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">191.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in its 2019 IPO, the sale of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">88.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in its December 2020 follow-on public offering, and the sale of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,414,897</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> million in its September 2022 issuance of common stock under the ATM Offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company&#8217;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company&#8217;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Level 1: Observable inputs such as quoted prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The carrying amounts of the Company&#8217;s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> financial assets measured at fair value on a recurring basis. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">None</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">n-recurring basis. No transfers between levels have occurred during the periods presented.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the estimated fair value of the Company&#8217;s long-term debt approximated the carrying amount given its floating interest rate basis. The fair value of the Company&#8217;s long-term debt was estimated for disclosure purposes only and was determined based on quoted market data for valuation, and thus categorized as Level 2 in the fair value hierarchy.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant, and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Property, Plant, and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="-sec-ix-hidden:F_d7201b82-ce21-4ec4-8499-cb8a67775133;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Furniture and fixtures are depreciated over</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> impairment losses have been recorded through December 31, 2022.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company&#8217;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_RevenueInterestFinancingLiabilityPolicyTextBlock', window );">Revenue Interest Financing Liability</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Interest Financing Liability</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company entered into a revenue interest financing agreement, or the Revenue Interest Financing Agreement, with entities managed or advised by NovaQuest Capital Management, or NQ, Sagard Holdings Manager LP, or Sagard, and Hercules Capital, Inc., or Hercules, together with NQ and Sagard, the Initial Investors, in which the Company received funds in return for royalties on net sales of products containing vonoprazan. The net proceeds received under the transaction were recognized as short-term and long-term liabilities with interest expense based on an imputed effective rate derived from the expected future payments. The Company recalculates the effective interest rate each period based on the current carrying value and the revised estimated future payments. Changes in future payments from previous estimates are included in current and future financing expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Accruals</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#8217;s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">In-Process Research and Development</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company also maintains an employee stock purchase program, or ESPP, under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning in 2022, the Tax Cuts and Jobs Act, or TCJA, eliminates the option to deduct research and development expenditures currently and requires taxpayers to amortize domestic and foreign research and development expenditures over </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">15</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> years, respectively. The requirement did not impact cash from operations in the current period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss was the same as its reported net loss for all periods presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> operating segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7,588,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> shares of common stock under its warrant (the &#8220;Takeda Warrant&#8221;) issued to Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company&#8217;s IPO until its exercise because the Takeda Warrant was exercisable for little consideration. As of December 31, 2022, all Takeda Warrants has been exercised and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> Takeda Warrants remain exercisable. For the years ended December 31, 2022 and December 31, 2021, the Company has excluded weighted-average unvested shares of </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">686,703</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,939,252</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Recently Adopted Accounting Standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">There were no recently adopted accounting standards which would have a material impact on the Company's financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">     </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2022 that impacted the Company.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LiquidityAndCapitalResourcesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and capital resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LiquidityAndCapitalResourcesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_OrganizationAndBasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_OrganizationAndBasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_RevenueInterestFinancingLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_RevenueInterestFinancingLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919352-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL119206284-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036471904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Property, plant and equipment, net, consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.276%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.023000000000003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.023000000000003%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,078</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">646</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,086</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">780</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">115</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Construction in process</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">399</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total property, plant and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">852</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total property, plant and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,207</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">650</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued expenses consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.471%;"/>
        <td style="width:1.343%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.913999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.343%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.929%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,080</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued compensation expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8,447</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6,344</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued professional &amp; consulting<br/>&#160;&#160;&#160;expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,855</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Accrued other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">41</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">14,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">11,405</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036406816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock', window );">Summary of Supplemental Balance Sheet Information Related to the Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.173%;"/>
        <td style="width:1.511%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.893999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.528%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.893999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,287</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,914</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,287</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,914</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">708</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">487</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,098</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,183</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,806</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,670</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments Under Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the future minimum annual lease payments under the operating leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.12%;"/>
        <td style="width:1.493%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.387999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">734</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">753</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">513</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">194</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,806</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">708</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,098</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.6</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8.20</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of supplemental balance sheet information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036653632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Total Debt</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total debt consists of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.352%;"/>
        <td style="width:1.516%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.131999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Long-term debt, current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Long-term debt, non-current portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">104,474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unamortized debt discount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">9,210</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total debt, net of debt discount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">95,264</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Principal Payments Under Term Loans</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Future minimum principal payments under the Term Loan, including the final payment fee, as of December 31, 2022 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.599%;"/>
        <td style="width:1.521%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.88%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Year ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">29,707</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">94,764</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total principal and interest payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">124,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less payment-in-kind and final payment fee</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24,471</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total term loan borrowings</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">100,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872036429200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock', window );">Schedule of Total Revenue Interest Financing Liability</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total revenue interest financing liability consists of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.164%;"/>
        <td style="width:1.726%;"/>
        <td style="width:17.569%;"/>
        <td style="width:1.54%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning liability balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Proceeds from the Revenue Interest Financing Agreement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">100,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: transaction costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4,554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less: royalty payments and payables</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Plus: interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">14,079</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Ending liability balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">109,525</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of revenue interest financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872029970640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Summary of Unvested Shares</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A summary of the Company&#8217;s unvested shares is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:64.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.08%;"/>
        <td style="width:1.553%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.368%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,144,809</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Share vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">890,372</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">254,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_CommonStockReservedForFutureIssuancesTableTableTextBlock', window );">Summary of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Common stock reserved for future issuance consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.051%;"/>
        <td style="width:1.594%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.355%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">91,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock options and performance-based awards outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6,876,237</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Shares available for issuance under the 2019 Incentive Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">957,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Shares available for issuance under the ESPP Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">752,938</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8,678,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Summary of PSU Activity Under the 2019 Incentive Award Plan</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2022.</span><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.961%;"/>
        <td style="width:1.494%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.59%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.494%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.462%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Number of<br/>Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br/>Average Grant<br/>Date Fair Value<br/>Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">394,300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">32.23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">37,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">20.06</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">19,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">35.39</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">412,300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">30.97</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Weighted-Average Assumptions Used to Estimate Fair Value of ESPP Awards</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.081%;"/>
        <td style="width:1.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.076%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.377%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.090999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.50</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.69</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">68.59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">76.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.04</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.09</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A summary of the Company&#8217;s stock option activity and related information is as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.033%;"/>
        <td style="width:0.725%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.727%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.544%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.243%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.742%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.715%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.742%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.528%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value (in<br/>thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4,186,729</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">27.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.91</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">13,973</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,741,931</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">14.62</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">342,190</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">29.32</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5,586,470</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">23.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.90</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4,476</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Options exercisable as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,455,735</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">25.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7.18</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,867</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.06%;"/>
        <td style="width:1.057%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.405%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.072%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.405%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5.88</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5.93</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">66.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">67.46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2.06</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">0.68</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.164%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.879%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.879%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5,534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,838</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">18,599</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">12,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">24,133</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">16,812</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Summary of Unvested Shares</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">During 2022, the Company granted </span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,010,437</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> RSUs with vesting over time. The following table summarizes RSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.366%;"/>
        <td style="width:1.393%;"/>
        <td style="width:1.408%;"/>
        <td style="width:14.524%;"/>
        <td style="width:1.408%;"/>
        <td style="width:1.408%;"/>
        <td style="width:1.56%;"/>
        <td style="width:14.524%;"/>
        <td style="width:1.408%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Number of<br/>Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Weighted-<br/>Average Grant<br/>Date Fair Value<br/>Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,010,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">10.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">102,453</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8.51</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">30,517</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">12.14</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">877,467</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">11.03</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_CommonStockReservedForFutureIssuancesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock reserved for future issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_CommonStockReservedForFutureIssuancesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872034293328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</span><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.792%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.712%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.698%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Income taxes computed at the statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">41,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">30,216</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,713</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,387</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research and development credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,950</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">41,137</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">31,783</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.484%;"/>
        <td style="width:1.286%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.965%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.286%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.98%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">85,918</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">60,936</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Research credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8,897</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6,694</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">25,319</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">13,809</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6,517</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3,996</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">126,651</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">85,435</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">126,170</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">85,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">402</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">402</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Activity Related to Gross Unrecognized Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The following table summarizes the activity related to the Company's gross unrecognized tax benefits:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.936%;"/>
        <td style="width:1.466%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.559000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.559000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,704</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">938</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Increases related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">64</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Increases related to current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">623</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">702</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Ending balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2,327</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872030310624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 29, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 06, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 07, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair value liability, transfers into level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod', window );">Research and development expenditures, amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod', window );">Research and development expenditures, amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=phat_UnvestedSharesMember', window );">Unvested Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Unvested shares excluded from computation of weighted average earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,703<span></span>
</td>
<td class="nump">1,939,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer Equipment and Related Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer Equipment and Related Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_FinancialAssetsFairValueDisclosure', window );">Financial assets fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Non-financial liabilities fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_NonfinancialAssetsFairValueDisclosure', window );">Non-financial assets fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,524,852<span></span>
</td>
<td class="nump">2,414,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Takeda License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Takeda License | Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,588,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_NumberOfWarrantsRemainingExercisable', window );">Number of warrants remaining exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="nump">10,997,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Initial Public Offering (IPO)</a></td>
<td class="nump">$ 191,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=phat_FollowOnPublicOfferingMember', window );">Follow-on Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember', window );">At-the-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,414,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_FinancialAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assets fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_FinancialAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NonfinancialAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonfinancial assets fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NonfinancialAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NumberOfWarrantsRemainingExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants remaining exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NumberOfWarrantsRemainingExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization basis of presentation and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax cuts and jobs act, research and development expenditures amortization period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonfinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=phat_UnvestedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=phat_UnvestedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=phat_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=phat_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=phat_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=phat_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872034323968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 2,678<span></span>
</td>
<td class="nump">$ 1,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,471)<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872039282160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposal of property, plant or equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872030011296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 3,080<span></span>
</td>
<td class="nump">$ 3,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation expenses</a></td>
<td class="nump">8,447<span></span>
</td>
<td class="nump">6,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional &amp; consulting expenses</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">1,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 14,678<span></span>
</td>
<td class="nump">$ 11,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872039467200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 05, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_CommercialSupplyAgreementsMember', window );">Commercial Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AgreementExtendsPeriodForTermination', window );">Agreement extends period for termination</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember', window );">Commercial Supply and Temporary Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Minimum purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_PCIPharmaServicesMember', window );">PCI Pharma Services | Clinical Manufacturing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent', window );">Outstanding accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expense related to services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Commercial Supply and Temporary Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent', window );">Outstanding accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expense related to services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued expenses related parties current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AgreementExtendsPeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement extends period for termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AgreementExtendsPeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_CommercialSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_CommercialSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_PCIPharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_PCIPharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=phat_ClinicalManufacturingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=phat_ClinicalManufacturingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872034515776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,723,308<span></span>
</td>
<td class="nump">31,656,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PurchaseCommitmentExpense', window );">Expenses incurred related to purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PurchaseObligationDueInFirstTwentyFourMonths', window );">Purchase obligation in the first 24-month period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember', window );">Takeda License | Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LicenseAgreementDescription', window );">License agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months&#8217; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#8217;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AgreementExpirationTermFromDateOfFirstCommercialSale', window );">Agreement expiration term from date of first commercial sale</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PaymentForLicenseAmount', window );">Cash consideration paid for license</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock fair value</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.00004613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Initial fair value of warrants</a></td>
<td class="nump">$ 47,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AdditionalWarrantIssued', window );">Additional warrant issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales', window );">Maximum amount payable in sales milestones upon achievement of specified levels of product sales</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_WarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">May  07,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember', window );">Takeda License | Takeda | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase shares</a></td>
<td class="nump">7,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AdditionalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional warrant issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AdditionalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AgreementExpirationTermFromDateOfFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration term from date of first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AgreementExpirationTermFromDateOfFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable in sales milestones upon the achievement of specified levels of product sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PaymentForLicenseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for license amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PaymentForLicenseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PurchaseCommitmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase commitment, expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PurchaseCommitmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PurchaseObligationDueInFirstTwentyFourMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase obligation due in first twenty four months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PurchaseObligationDueInFirstTwentyFourMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_WarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_WarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872034324288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Commitments - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating leases, rent expense</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for operating lease costs</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=phat_PrepaidLeasePaymentsMember', window );">Prepaid Lease Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Buffalo Grove, Illinois</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating leases, remaining lease terms</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LesseeOperatingLeaseNumberOfOptionToExtend', window );">Operating lease number of option to extend | Option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend description</a></td>
<td class="text"> operating leases contain an option to extend the term for one additional five-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Florham Park, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating leases, remaining lease terms</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LesseeOperatingLeaseNumberOfOptionToExtend', window );">Operating lease number of option to extend | Option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend description</a></td>
<td class="text"> operating leases contain an option to extend the term for one additional five-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LesseeOperatingLeaseNumberOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease number of option to extend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LesseeOperatingLeaseNumberOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=phat_PrepaidLeasePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=phat_PrepaidLeasePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872034399008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AssetsLesseeAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,287<span></span>
</td>
<td class="nump">$ 1,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LiabilitiesLesseeAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">708<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,806<span></span>
</td>
<td class="nump">$ 1,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AssetsLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets, lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AssetsLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities, lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872034546416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">$ 1,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: operating lease liabilities, current</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 1,098<span></span>
</td>
<td class="nump">$ 1,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872037173440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Total Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount', window );">Long-term debt, non-current portion</a></td>
<td class="nump">$ 104,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(9,210)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of debt discount</a></td>
<td class="nump">$ 95,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt noncurrent excluding unamortized debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872031074336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 17, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to additional paid-in-capital, warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoanMember', window );">Term Loan | Floor Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DebtInstrumentInterestRatePercentage', window );">Debt instrument interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DebtInstrumentFinalPaymentFee', window );">Debt instrument, final payment fee or end of term charge</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone', window );">Percentage of qualified cash prior to Third performance milestone</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone', window );">Minimum percentage of qualified cash following third performance milestone</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_MinimumMarketCapitalizationAmount', window );">Minimum market capitalization amount</a></td>
<td class="nump">$ 900,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock', window );">Percentage of debt funded to be issued as warrants to purchase common stock</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 33.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ClassOfWarrantOrRightExpireTerm', window );">Warrants expire term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ClassOfWarrantOrRightExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">Sep. 17,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant liabilities</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase shares</a></td>
<td class="nump">74,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PaymentForFacilityCharge', window );">Payment for facility charge</a></td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DebtInstrumentFacilityChargePercentage', window );">Debt instrument, facility charge percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">Oct.  01,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan | Payment In Kind PIK Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loans, Aggregate Principal Amount Tranches One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loans, Aggregate Principal Amount Tranches Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loans Aggregate Principal Amount Tranches Three and Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan Advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DebtInstrumentFinalPaymentFeePercentage', window );">Debt instrument, final payment fee percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DebtInstrumentFinalPaymentFee', window );">Debt instrument, final payment fee or end of term charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan Advance | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount', window );">Debt instrument, prepayment fee percentage of outstanding principal amount</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_HerculesAndSvbTermLoanMember', window );">Hercules and SVB Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_AmendmentToLoanAgreementMember', window );">Amendment to Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_HerculesLoanAgreementMember', window );">Hercules Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_SiliconValleyBankTermLoanMember', window );">SVB Term Loan | Term Loan First Advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Final payment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ClassOfWarrantOrRightExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ClassOfWarrantOrRightExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ClassOfWarrantOrRightExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, expire term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ClassOfWarrantOrRightExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentFacilityChargePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument facility charge percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentFacilityChargePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument final payment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentFinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument final payment fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentFinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment fee percentage of outstanding principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_MinimumMarketCapitalizationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum market capitalization amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_MinimumMarketCapitalizationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of qualified cash on principal amount following third performance milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of qualified cash on principal amount prior to third performance milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PaymentForFacilityCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for facility charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PaymentForFacilityCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of debt funded to be issued as warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=phat_PaymentInKindPikInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=phat_PaymentInKindPikInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoanAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoanAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=phat_HerculesAndSvbTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=phat_HerculesAndSvbTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=phat_AmendmentToLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=phat_AmendmentToLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=phat_HerculesLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=phat_HerculesLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=phat_SiliconValleyBankTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=phat_SiliconValleyBankTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoanFirstAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoanFirstAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872030034848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree', window );">2025</a></td>
<td class="nump">29,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour', window );">2026</a></td>
<td class="nump">94,764<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_LongTermDebtAndInterest', window );">Total principal and interest payments</a></td>
<td class="nump">124,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DebtInstrumentInterestAndFinalPaymentFee', window );">Less payment-in-kind and final payment fee</a></td>
<td class="num">(24,471)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total term loan borrowings</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentInterestAndFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest and final payment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentInterestAndFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt and interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest, year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872030875680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing Liability - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 03, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_InvestorsRightToReceiveRoyaltiesTerminationDescription', window );">Investors right to receive royalties termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The investors&#8217; right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for erosive GERD regulatory approval is made, the Company has the right to make a cap payment equal to 200% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_InvestorsReceiptDescription', window );">Investors receipt description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If the investors have not received aggregate payments of at least 100% of the Investment Amount by December 31, 2028, and at least 200% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DefaultObligationDescription', window );">Default obligation description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Upon the occurrence of an event of default taking place prior to April 1, 2025, between April 1, 2025, and April 1, 2028, and after April 1, 2028, the Company is obligated to pay 1.30 times Investment Amount, 1.65 times Investment Amount, and 2.0 times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ChangeInControlDescription', window );">Change in control description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Upon the occurrence of a change in control event taking place prior to the earlier of April 1, 2024, or FDA approval of vonoprazan for erosive GERD, the Company is obligated to pay 200% of the Investment Amount plus either 15% of the Investment Amount if occurrence prior to May 3, 2023, or plus 30% of the Investment Amount if occurrence thereafter.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_GrossProceedsFromRevenueInterestFinancingAgreement', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PaymentOfTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_NetProceedsFromRevenueInterestFinancingTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_RevenueInterestFinancingLiability', window );">Revenue interest financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_InterestExpenseRelatedToRevenueInterestFinancingLiability', window );">Interest expense with revenue interest finance liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PercentageOfInvestorShareOfRoyaltyInNetSales', window );">Percentage of investor share of royalty in net sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales', window );">Percentage of aggregate payments on investment amount to investors on net sales</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember', window );">Revenue Interest Financing Agreement Upon Occurrence of Event of Default Prior to April 1, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors', window );">Percentage of aggregate payment on investment amount to investors</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember', window );">Revenue Interest Financing Agreement Upon Occurrence of Event of Default between April 1, 2025, and April 1, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors', window );">Percentage of aggregate payment on investment amount to investors</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember', window );">Revenue Interest Financing Agreement Upon Occurrence of Event of Default after April 1, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales', window );">Percentage of aggregate payments on investment amount to investors on net sales</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember', window );">Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales', window );">Percentage of aggregate payments on investment amount to investors on net sales</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember', window );">Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount', window );">Additional percentage to be paid with obligated payment on investment amount</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember', window );">Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA approval If occurrence is Thereafter to May 3, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount', window );">Additional percentage to be paid with obligated payment on investment amount</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=phat_InitialInvestorsNqSagardAndHerculesMember', window );">Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_FundsReceivedFromInitialClosing', window );">Funds received from initial closing</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=phat_InitialInvestorsNqSagardAndHerculesMember', window );">Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement, Funding Commitment On or Before March 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_InvestorAdditionalFundingAmountUponApproval', window );">Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_InvestorsFundingAmount', window );">Investors funding amount</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement Funding upon FDA Approval at any Time Prior to December 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PotentialAdditionalInvestorFundingAmount', window );">Potential additional investor funding amount</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Initial Investors NQ, Sagard, and Hercules | Revenue Interest Financing Agreement Funding upon Achievement of Sales Milestone at any Time Prior to June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone', window );">Investors funding commitment potential amount available upon achievement of sales milestone</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revenue Interest Financing Agreement Percentage on Investment Amount On December December 31, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors', window );">Percentage of aggregate payment on investment amount to investors</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revenue Interest Financing Agreement Percentage On Investment Amount by December 31, 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Revenue Interest Financing Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors', window );">Percentage of aggregate payment on investment amount to investors</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional percentage to be paid with obligated payment on investment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ChangeInControlDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in control description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ChangeInControlDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DefaultObligationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Default obligation description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DefaultObligationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_FundsReceivedFromInitialClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from initial closing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_FundsReceivedFromInitialClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_GrossProceedsFromRevenueInterestFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_GrossProceedsFromRevenueInterestFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_InterestExpenseRelatedToRevenueInterestFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense related to revenue interest financing liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_InterestExpenseRelatedToRevenueInterestFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_InvestorAdditionalFundingAmountUponApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investor additional funding amount upon approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_InvestorAdditionalFundingAmountUponApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_InvestorsFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investors funding amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_InvestorsFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investors funding commitment potential amount available upon achievement of sales milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_InvestorsReceiptDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investors receipt description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_InvestorsReceiptDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_InvestorsRightToReceiveRoyaltiesTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investors right to receive royalties termination description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_InvestorsRightToReceiveRoyaltiesTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NetProceedsFromRevenueInterestFinancingTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from revenue interest financing transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NetProceedsFromRevenueInterestFinancingTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PaymentOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PaymentOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate payments on investment amount to investors on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate payments on investment amount to investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PercentageOfInvestorShareOfRoyaltyInNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of investor share of royalty in net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PercentageOfInvestorShareOfRoyaltyInNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PotentialAdditionalInvestorFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential additional investor funding amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PotentialAdditionalInvestorFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_RevenueInterestFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_RevenueInterestFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=phat_InitialInvestorsNqSagardAndHerculesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=phat_InitialInvestorsNqSagardAndHerculesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872039540880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing Liability - Schedule of Total Revenue Interest Financing Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_GrossProceedsFromRevenueInterestFinancingAgreement', window );">Proceeds from the Revenue Interest Financing Agreement</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PaymentOfTransactionCosts', window );">Less: transaction costs</a></td>
<td class="num">(4,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_InterestExpenseRelatedToRevenueInterestFinancingLiability', window );">Plus: interest expense</a></td>
<td class="nump">14,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_RevenueInterestFinancingLiability', window );">Ending liability balance</a></td>
<td class="nump">$ 109,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_GrossProceedsFromRevenueInterestFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_GrossProceedsFromRevenueInterestFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_InterestExpenseRelatedToRevenueInterestFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense related to revenue interest financing liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_InterestExpenseRelatedToRevenueInterestFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PaymentOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PaymentOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_RevenueInterestFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_RevenueInterestFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872020843360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 29, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 06, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,133,000<span></span>
</td>
<td class="nump">$ 16,812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,678,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan employer contribution liabilities expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, employer matching contribution, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled', window );">Employer discretionary match number of shares settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,784<span></span>
</td>
<td class="nump">16,756<span></span>
</td>
<td class="nump">18,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock, shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,231,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock awards, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase to shares available for issuance percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Equity plan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above or equal to 1,416,788 shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. As of December 31, 2022, 957,885 shares remain available for issuance, which reflects 2,789,868 stock options and performance-based units, or PSU, and restricted stock unit, or RSU, awards granted, and 392,207 of awards cancelled or forfeited, during the year ended December 31, 2022 as well as an annual increases of 1,582,802 shares authorized on January 1, 2022. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease', window );">Number of shares remain available for issuance, annual increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,582,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan | Performance-Based Stock Units (PSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock awards, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock awards, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,010,437<span></span>
</td>
<td class="nump">1,010,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan | Stock options, PSUs and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,789,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares, cancelled or forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase to shares available for issuance percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Equity plan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2022, 752,938 shares of common stock remain available for issuance, which reflects 89,098 shares sold to employees during the year ended December 31, 2022. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated weighted-average fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="nump">$ 14.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock, price per share | $ / shares</a></td>
<td class="nump">$ 42.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Proceeds from issuance initial public offering gross | $</a></td>
<td class="nump">$ 94,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_SharesIssuedPricePerShareAfterDeductions', window );">Purchase price per share after deducting underwriting discounts and commissions | $ / shares</a></td>
<td class="nump">$ 39.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_NetProceedsAfterDeductingUnderwritersCommission', window );">Net proceeds after deducting underwriters commission | $</a></td>
<td class="nump">$ 88,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_PurchaseOfAdditionalOfferingExpenses', window );">Purchase of additional offering expenses | $</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember', window );">At-the-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,414,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AmountUtilizedOfEquityFinancing', window );">Amount utilized of equity financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AvailableAggregateOfferingPriceThroughEquityFinancing', window );">Available equity financing amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember', window );">At-the-Market Offering Program | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember', window );">Employee and Nonemployee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated weighted-average fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_OpenMarketSaleAgreementWithJefferiesLLCMember', window );">Open Market Sale Agreement with Jefferies LLC | At-the-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare', window );">Sales commission payable as a percentage of sale of gross sales price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_OpenMarketSaleAgreementWithJefferiesLLCMember', window );">Open Market Sale Agreement with Jefferies LLC | At-the-Market Offering Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_AggregateOfferingPriceThroughEquityFinancing', window );">Aggregate offering price through equity financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,524,852<span></span>
</td>
<td class="nump">2,414,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,373,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_StockRepurchaseProgramNumberOfSharesRightLapse', window );">Stock repurchase program, number of shares right lapse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">843,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Remaining number of shares to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,530,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock repurchase program, period in force</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_StockRepurchaseProgramExpirationMonthAndYear', window );">Stock repurchase program expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_RepurchaseRightLapseShares', window );">Repurchase right lapse each month after first anniversary, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.000208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_SharesAggregateRepurchasePrice', window );">Shares aggregate repurchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled', window );">Employer discretionary match number of shares settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,540<span></span>
</td>
<td class="nump">26,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2019 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,416,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of eligible compensation contributed by participants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,997,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Initial Public Offering (IPO) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,434,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Remaining number of shares to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_RepurchaseRightLapseRate', window );">Repurchase right lapse rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Takeda License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Remaining number of shares to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Frazier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,491,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AggregateOfferingPriceThroughEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price through equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AggregateOfferingPriceThroughEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AmountUtilizedOfEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Utilized of equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AmountUtilizedOfEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AvailableAggregateOfferingPriceThroughEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available Aggregate offering price through equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AvailableAggregateOfferingPriceThroughEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution pan employer discretionary match number of shares settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NetProceedsAfterDeductingUnderwritersCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds after deducting underwriters commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NetProceedsAfterDeductingUnderwritersCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance initial public offering gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PurchaseOfAdditionalOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of additional offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PurchaseOfAdditionalOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_RepurchaseRightLapseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase right lapse rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_RepurchaseRightLapseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_RepurchaseRightLapseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase right lapse shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_RepurchaseRightLapseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales commission payable as a percentage of sale of gross sales price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant annual increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, options and other than options forfeitures and expirations in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, options and other than options, grants in period gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_SharesAggregateRepurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares aggregate repurchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_SharesAggregateRepurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_SharesIssuedPricePerShareAfterDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued, price per share after deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_SharesIssuedPricePerShareAfterDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_StockRepurchaseProgramExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program Expiration Month and Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_StockRepurchaseProgramExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_StockRepurchaseProgramNumberOfSharesRightLapse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock repurchase program, number of shares right lapse.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_StockRepurchaseProgramNumberOfSharesRightLapse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_OpenMarketSaleAgreementWithJefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_OpenMarketSaleAgreementWithJefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=phat_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=phat_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=phat_FoundersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=phat_FoundersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=phat_FrazierLifeSciencesIXLimitedPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=phat_FrazierLifeSciencesIXLimitedPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872030000176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Unvested Shares (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2021</a></td>
<td class="nump">1,144,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting', window );">Share vesting</a></td>
<td class="num">(890,372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2022</a></td>
<td class="nump">254,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, share vesting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872030810528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">8,678,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=phat_CommonStockWarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">91,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=phat_StockOptionsAndPerformanceBasedAwardsMember', window );">Stock Options and Performance-Based Awards Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">6,876,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">957,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember', window );">ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">752,938<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=phat_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=phat_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=phat_StockOptionsAndPerformanceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=phat_StockOptionsAndPerformanceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872030931520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of PSU and RSUs Activity Under the 2019 Incentive Award Plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2021</a></td>
<td class="nump">1,144,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2022</a></td>
<td class="nump">254,437<span></span>
</td>
<td class="nump">1,144,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan | Performance-Based Stock Units (PSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2021</a></td>
<td class="nump">394,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock awards, granted</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Stock Units, Forfeited</a></td>
<td class="num">(19,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2022</a></td>
<td class="nump">412,300<span></span>
</td>
<td class="nump">394,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Unvested Beginning Balance</a></td>
<td class="nump">$ 32.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Granted</a></td>
<td class="nump">20.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Forfeited</a></td>
<td class="nump">35.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance</a></td>
<td class="nump">$ 30.97<span></span>
</td>
<td class="nump">$ 32.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock awards, granted</a></td>
<td class="nump">1,010,437<span></span>
</td>
<td class="nump">1,010,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Stock Units, Vested</a></td>
<td class="num">(102,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Stock Units, Forfeited</a></td>
<td class="num">(30,517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2022</a></td>
<td class="nump">877,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Granted</a></td>
<td class="nump">$ 10.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Vested</a></td>
<td class="nump">8.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Forfeited</a></td>
<td class="nump">12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance</a></td>
<td class="nump">$ 11.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872034569376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">5 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">67.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.06%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">68.59%<span></span>
</td>
<td class="nump">76.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.04%<span></span>
</td>
<td class="nump">0.09%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872029802960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning Balance</a></td>
<td class="nump">4,186,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Options granted</a></td>
<td class="nump">1,741,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Outstanding, Options cancelled</a></td>
<td class="num">(342,190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending Balance</a></td>
<td class="nump">5,586,470<span></span>
</td>
<td class="nump">4,186,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Options exercisable as of December 31, 2022</a></td>
<td class="nump">2,455,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 27.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options granted</a></td>
<td class="nump">14.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options cancelled</a></td>
<td class="nump">29.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Ending Balance</a></td>
<td class="nump">23.40<span></span>
</td>
<td class="nump">$ 27.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options exercisable as of December 31, 2022</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">7 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Options exercisable as of December 31, 2022</a></td>
<td class="text">7 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Balance</a></td>
<td class="nump">$ 4,476<span></span>
</td>
<td class="nump">$ 13,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable as of December 31, 2022</a></td>
<td class="nump">$ 2,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872037485200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 24,133<span></span>
</td>
<td class="nump">$ 16,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">5,534<span></span>
</td>
<td class="nump">3,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 18,599<span></span>
</td>
<td class="nump">$ 12,974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872030087488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">8,897,000<span></span>
</td>
<td class="nump">6,694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">2,327,000<span></span>
</td>
<td class="nump">1,704,000<span></span>
</td>
<td class="nump">$ 938,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would affect effective tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties related income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrual for interest or penalties related to income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards which are carried over indefinitely</a></td>
<td class="nump">408,700,000<span></span>
</td>
<td class="nump">$ 290,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear', window );">Research and development credits expiration period</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear', window );">Research and development credits expiration period</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit carry forward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872034539024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income taxes computed at the statutory rate</a></td>
<td class="num">$ (41,522,000)<span></span>
</td>
<td class="num">$ (30,216,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_IncomeTaxReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">2,713,000<span></span>
</td>
<td class="nump">1,387,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">(2,453,000)<span></span>
</td>
<td class="num">(2,950,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">41,137,000<span></span>
</td>
<td class="nump">31,783,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872030113408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 85,918<span></span>
</td>
<td class="nump">$ 60,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credits</a></td>
<td class="nump">8,897<span></span>
</td>
<td class="nump">6,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">25,319<span></span>
</td>
<td class="nump">13,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,517<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">126,651<span></span>
</td>
<td class="nump">85,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(126,170)<span></span>
</td>
<td class="num">(85,033)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(481)<span></span>
</td>
<td class="num">(402)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872030008512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 1,704<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,327<span></span>
</td>
<td class="nump">$ 1,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139872034599120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information - (Details) - ATM Sale Agreement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Feb. 27, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under ATM facility, shares</a></td>
<td class="nump">2,414,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares</a></td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under ATM facility, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_phat_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>phat-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:phat="http://www.phathompharma.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="phat-20221231.xsd" xlink:type="simple"/>
    <context id="C_ef56eeb8-d434-4c33-8a0e-a4c074a8edd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_8a9abbdc-846c-4903-a0f4-53dd7476cd04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d9d8f01d-3d43-4934-ad2b-b3a53489fec5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_537af902-fc9d-4888-8d37-6ee0bf5d7d50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_3089a359-e1ec-4cf0-8d42-a935b7b8080d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_9864647f-dae0-400c-981a-2e1ad206fde6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="C_4160e414-35f2-4edb-94aa-a3ea7eeab964">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_290088e4-cd92-4018-a07a-9b31182a5ae0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_52ad1a5c-6e1b-4d4e-9cf1-f8d7bea71a22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4f067a4b-daf1-4028-b748-712e3b729620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_6e83352c-1021-49ea-be17-abda53fad0d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_da396882-6f6e-44fb-b650-cc0b5c7ed2f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">phat:UnvestedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fee0ce51-9e93-47f2-b416-b68d0ab99ce8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3b1269f3-0919-4f09-919c-ae285bdda990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_25cca5a5-3215-4f01-9b29-0229a260c11b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5376a47a-2a6e-4c10-a523-6c29d3b5be8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_b5a1d5b1-793a-4122-8486-ddd80632f18a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ab5a798d-ceb3-45b5-9852-43c7c13434c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">phat:StockOptionsAndPerformanceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_775de606-9680-4686-a097-1b7b610892fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">phat:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ad628062-bdfb-4035-85ce-04fb1a93328a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b629611d-f479-44c6-9f1c-cdfdf6c74fcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-16</instant>
        </period>
    </context>
    <context id="C_b02900cd-2272-4953-b251-9b37853719fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="C_d53f3397-a799-4e1e-97d8-9158ecf94191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e2b4f91b-545a-498d-a89e-550afedc7031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_a456270a-d53b-42d3-8702-a89087e2879e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_74c344c6-6814-4821-8338-28c9c0250e05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_fc2a8230-0abf-4380-a0cf-1aee92ac8c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesAndSvbTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7ad3d68e-7eb3-4452-8fce-3d43389eeafa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7da2e53f-060f-4407-97fc-6ab72ec3f967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <context id="C_7acebd49-8754-4509-8ad2-aef189b7a108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_085d1c47-e6cb-4591-b010-3194bae40e70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c9d3b85f-d90c-44ea-828c-6eca6895c78b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d8f8b7b4-5d19-4a59-808a-7620c9d1ce95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementAndTemporaryServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f4d64b0f-a1db-4cfd-9a23-da10238263c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b200a58a-3188-46aa-b5e6-de3a179abb6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9b1aa0b6-a160-4d39-a073-61b00c5a103f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_92b2fe60-4ace-4d6c-acc6-c79dfb6818d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_5d67cf6e-bd93-4d42-8971-522a9d32c0c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_254b2caf-becb-447f-bfa2-61ac97d82407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="C_6d1f03d4-1220-447c-ab69-93821c543913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c4ab7858-b04f-4eaf-90c2-cde3b6e2669c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d1e29e67-db80-4194-babb-a6fb361ff631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_99f14810-3a35-4382-9ab0-3938fb54794d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a303df35-50f8-4246-ac81-15cdd055190d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f484751c-237f-4a58-8796-c8018a28b609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:OpenMarketSaleAgreementWithJefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_07f31873-c2a3-405b-826f-e016bf0d6ce1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_3625bbc7-e0d2-4ae5-80c9-2c2a001c24c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2769f622-b2f5-4b1e-9bfc-9d6f83d30fcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">phat:InitialInvestorsNqSagardAndHerculesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_b76ff2f4-ff03-419e-b174-84d981f8d356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_8ef9f4d9-0de2-4f1f-843d-3ab853904bf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5dcc212e-21a7-4a55-bc25-9c94fd4f27d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9cddf29a-b8e2-483a-a1a6-cb58b2eba169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-06</instant>
        </period>
    </context>
    <context id="C_50a28e01-3143-418a-81bb-bfbdc824e6bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_02d741c1-6ff5-434c-88d1-b60b946959c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_16374c27-e9d9-4deb-990b-aa5e9aac1074">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6a3f3bfa-6949-4f34-b6ab-a42581ad38fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">phat:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e81a5d21-6780-4696-8613-7d86dd579083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_9d4560ac-5448-4f06-a2c0-c13d0498a9d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_8d783f53-5bda-4abc-8b88-b5d7f5533766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">phat:PrepaidLeasePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_193ec4b9-a149-4c59-b451-7fd82670dde2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d2db8e6c-935d-488d-812e-7446da50b3c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_71d680e8-6689-4309-bb74-70d6d934372b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_70ed3e4f-7d42-4f15-94f8-e35d5e32239e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_e45ec0f4-8be2-4007-a0b7-cc5a7fb0e0af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d34ef88d-9f9b-4614-9c60-3fd356fe4846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_c9397005-df60-4c46-9331-f164df01ca76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2ded604e-c94b-436f-a89c-9b03fda0e603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f71a8436-7cab-4cb1-a0b4-4ed9b66f0382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-29</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="C_9a0f9f10-e984-46bf-897d-9ef4dd6e2854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:OpenMarketSaleAgreementWithJefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_eb1ec5a6-fae4-47b9-b672-953a87241f7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2de0626c-2b10-4fe9-bbfd-1a4334ffe153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">phat:PaymentInKindPikInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_6dbb0e01-68b5-401c-ac47-a5ebd40a700f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7d957629-8d64-4447-931c-6471c184bdc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b41ac6a5-4e17-4e1f-8bae-c1f1f8f391c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f20982d1-f9ce-4d58-8f02-7abadfb18a90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_161d27a8-0c36-4e47-af8a-c85124a58e31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">phat:InitialInvestorsNqSagardAndHerculesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-03</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <context id="C_4898bc84-418b-459b-b337-70ce6a60f7c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_def31b4c-f4a8-4c99-b8ff-05f2befd1e4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a9286bf5-ac0b-46f5-a136-ec84fcb2ae44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9c879136-27f6-49d8-8690-7a4079f865e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1ca84d6f-4ec7-4ca7-a80c-ce5f47b70bdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ec823b74-ab4b-4334-a3c0-fe989b5ea271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_28e002f0-fa91-457e-80d6-bc784dddc517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">phat:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8d795b93-dc29-4dc9-8b77-44a4e74f6b8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_29dfdd85-afb5-4d2f-a86b-48a3fd158ccc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">phat:InitialInvestorsNqSagardAndHerculesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_a7d27a7b-55b4-4782-b9ee-1496eed56e8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_91b73800-dbc6-43cf-9117-11565d545493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f3f07980-4a45-4835-8463-e1d119c8e5c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ef443912-c72b-4729-a5ae-6e27ef16ba5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_d02c08d8-d888-4a97-a17b-d64dc2a21728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-03</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <context id="C_4b9e40bc-f2d9-4495-a973-c2657257e971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_1fffdef7-2c4e-4f8c-a14d-47e0a16bf641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_f292b92d-3d3f-4b55-9f26-2611aa4dd13c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">phat:StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d9072564-13ae-4ea1-84c1-9febe815dd19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementAndTemporaryServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_921713e0-e38d-456b-b30a-55995a73ff55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9b8aa030-2775-49eb-a555-98fc9d14d1bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_85f57980-d393-4162-ae13-987929e0df5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_15355aaa-f30b-4175-9505-232bcaaa97e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_997ec618-b563-491c-9eca-1c0da676ff3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_778accf5-7d44-4bf3-a402-bbbaf11a7645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-05-06</endDate>
        </period>
    </context>
    <context id="C_3d0461f1-b88c-4662-9709-e549cfb4144e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a8157197-9c77-483d-a07b-d1d03a212eab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">phat:FoundersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_85297e90-674e-4311-8d12-99f75d773722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">phat:ShareBasedPaymentArrangementEmployeeAndNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_6c9bf283-aa34-45fe-8828-7e01c81260ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e7e1b33c-ea56-4599-a9c9-30b1918239b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementAndTemporaryServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ab4915e2-d84a-4fe8-8537-63d674acad7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_12faa295-829a-4324-8f79-7c114d53f496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b0784f7e-b027-403a-a3cd-28ff1f784844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">phat:FrazierLifeSciencesIXLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_b1e91519-0f55-42f3-a32a-9502a07575d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_808be0ce-b254-4e5d-b14f-728aa82ef026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:AmendmentToLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-27</instant>
        </period>
    </context>
    <context id="C_c25918b9-523a-4430-8c67-527934999f5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d5734daa-3179-4da2-9c0d-ec26dd01ffa7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">phat:InitialInvestorsNqSagardAndHerculesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-03</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <context id="C_ee4ba230-41b0-4d69-921e-1d90ed587bd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2d98949a-30e1-4a98-8bd5-692271892f22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanFirstAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_12f1ae54-8af7-498f-b9c2-d3ecab67150a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementAndTemporaryServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b3d62e8f-6837-4e80-a47d-75eba6bca352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0487172a-df33-4c7a-b44b-85c791ea9f49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_bde66df6-9f96-4711-b5ca-d8e549c121ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f7b89cb0-d7ca-4959-aed2-3aad49062bc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-06</instant>
        </period>
    </context>
    <context id="C_0e19ddc7-d662-491a-b517-1a7dc60b7d07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3b18d59c-b688-4dad-a3c3-0feef824fd50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0498a544-7235-40af-ade1-7542eee8d333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_d27b5644-2ffe-49a5-bcac-f51f4f379e72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8e655aad-b411-4446-8d28-57f008fc0793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_2c6526c3-fe53-437c-8a64-5ef862e523ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f3416de9-775d-4af4-b997-f1e2dce25917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">phat:InitialInvestorsNqSagardAndHerculesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-03</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <context id="C_0baa7388-d9e1-478c-86d2-1a3bfcdf4327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_3e93f3f8-5fa9-4e0e-9be2-05e4b1b44b52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-05</startDate>
            <endDate>2020-05-05</endDate>
        </period>
    </context>
    <context id="C_84f52c9e-524b-4bd9-9018-6cb27dd75205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c1fa0f90-b682-4d91-b3c5-62f796e1a9cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_2605f8bc-b7a3-4e6a-b47e-dad76807d9a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_85e62724-a4f3-446d-a80e-ee240301cda0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_8952b2b3-05be-4dbb-bb15-29a22754c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_f23428e3-ba82-4280-becf-c920e6849705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bd48d243-f6ad-429e-b82e-626144871206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0d987563-e4a1-47c2-a958-218433edf069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">phat:UnvestedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a9b385aa-6a5f-45cc-a03d-80389e7fbcf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementAndTemporaryServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5943d02e-5414-489b-b249-8e8202898837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_fdabcc96-9593-40cb-bc06-20ae0d8af269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_316e751d-ea37-4523-950e-d005edde6cbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2023-02-24</instant>
        </period>
    </context>
    <context id="C_0cceeb3e-ff40-49d0-b18c-96a61d412299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="C_a1345e6a-366c-4155-83c9-889619f08e7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="C_55b184ca-7a41-480d-a822-5e3317a65984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-29</instant>
        </period>
    </context>
    <context id="C_ff181df1-43b0-434d-b3db-83c48fa28c00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-29</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="C_d1da1354-c115-4771-a4a8-bb35b2ea792f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bd528633-09ca-45e1-a4f8-8be7636e9b54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="C_e2a8d3e4-8302-40ab-8531-be80c035a7d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_eb899363-81cb-4d24-aa66-4956be36544e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_38a3ce84-f57c-409f-8929-19e767dc49e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9960ff79-ef61-47f2-b12d-b0b42bd290e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e9f3b61c-edfe-4524-8536-373c8a65e8a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_836f3b27-9cf0-4ba9-abe3-f68ffa72e1e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Option">
        <measure>phat:Option</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Segment">
        <measure>phat:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_775de606-9680-4686-a097-1b7b610892fa"
      id="F_d7201b82-ce21-4ec4-8499-cb8a67775133">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      id="F_7fcc0224-faaf-4025-b8d0-b563e26ab94e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      id="F_5ecefc5a-5125-41a1-a2fa-e831971495b3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_25935211-6394-4672-be26-784afbac5207">0001783183</dei:EntityCentralIndexKey>
    <phat:RepurchaseRightLapseShares
      contextRef="C_f7b89cb0-d7ca-4959-aed2-3aad49062bc4"
      decimals="6"
      id="F_2b850787-a6cf-4d02-9e61-c00a1a4fa91d"
      unitRef="U_pure">0.000208</phat:RepurchaseRightLapseShares>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_64043701-fa2f-4405-b716-ab32b4abb5f6">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      id="F_fc069ec2-b698-4009-b7c4-39ae24bbf4da"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_5bb1eb62-773c-4190-b511-c6ec9b1a614e">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PreferredStockValue
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      id="F_558505f2-45b8-41f3-be82-00543a9fac5f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      id="F_79fc89c8-d053-4eeb-8afd-78914e3ef4c7"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_3abb8ab1-3f5f-4db4-be11-cc9877b7d465">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      id="F_b6395ef0-f70f-4750-896d-fd899c227d0b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_27598d45-f07e-41c0-a7d2-ba450d82de0e">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_4dc8046a-3656-4f30-8d00-cac92918113d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_7bdcc32b-f872-4332-8a72-763f59605f43">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_7d115b92-2108-4859-b9ef-bbbea14c0ef6">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_b14a6650-36b4-4ad8-bb30-780c324ad2fc">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_c4012fd5-0e3e-49bf-904d-39a30412794f">001-39094</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_88ffe565-14fa-4b6b-84c0-33eedbf0df32">PHATHOM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_01d8fe28-cf1b-49cf-8e82-00672bfcb022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_941b573b-315e-4a8e-aa23-df8a723889fb">82-4151574</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_688a2db4-c842-4e5f-84e2-e382045b279c">100 Campus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_e6255b3f-17e8-4633-aebd-ade13d48f197">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_0fdb2bc6-9236-4393-ae0b-0eaf422caf2f">Florham Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_8363ef67-d061-4b02-a57e-63f63122b584">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_ad92f2e6-2867-4ba2-a4e8-3f45e4e2bcd2">07932</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_6235d1a8-d541-4b24-8e45-db2c5b80cd14">877</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_dfda004d-7c02-45b6-bec2-12a5f8104f36">742-8466</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_05ba0fde-53a9-479a-b45c-9c30e1ced326">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_9c1788a1-e800-4a7d-b8e1-90f9ce7aea45">PHAT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_2c50ff34-f50d-456f-a631-6d768ce3253f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_0a875de0-07c1-41a3-a01e-21ba3ddefd2e">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_433ff177-5a0e-426c-81ef-66a96a0baab5">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_d073ca72-fa99-42a0-b5d2-280887b9fdac">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_0d039544-d2fe-4ecb-90b5-163756bf3eae">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_2a6cf3f9-9094-4b27-bbd1-ab9e73a882f0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_786d9d2a-3114-42ab-b7dc-8f3ba8d12e3a">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_647b7ef2-14cc-4ef3-8c39-b3f66976f788">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_908b5772-3927-49c4-aacb-9552dee45f29">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_8bde42cd-f36b-478c-812c-26db3b64dcf8">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_8eb49300-e898-46e9-af2d-1ff3b53b438a">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_07f31873-c2a3-405b-826f-e016bf0d6ce1"
      decimals="-5"
      id="F_920af6b4-6c35-4bc1-8e25-21959155a89b"
      unitRef="U_USD">198000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_316e751d-ea37-4523-950e-d005edde6cbd"
      decimals="INF"
      id="F_5be22763-f5ce-444d-8828-f199b614ca3a"
      unitRef="U_shares">41973271</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_36465543-ec91-48fa-ab62-9f3abd8e3396">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain sections of the registrant&#x2019;s definitive proxy statement for the 2023 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_6b28b55a-6732-4f5b-80c0-05bc2733b084">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_03cb2e5b-b82d-40ca-8586-0efcb3adffe4">42</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_4698f196-0af2-4450-8d6c-b2de1aaa9b07">Iselin, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_da4aa7fd-81b0-4df9-adba-a55b63b38cd3"
      unitRef="U_USD">155385000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_d97e774b-6c2b-46d7-aef1-c07225f94cf3"
      unitRef="U_USD">183259000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_c1434198-1b2a-4f0a-8b37-8d3501b9d8e2"
      unitRef="U_USD">5127000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_86dbab16-1466-47c1-9ca5-332e35a6f988"
      unitRef="U_USD">3267000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_b2fb0633-ec57-4343-a62f-ffa27de6d0e0"
      unitRef="U_USD">160512000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_553b68c8-3fd0-46ed-867c-e4e93620f1a7"
      unitRef="U_USD">186526000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_d2e8697c-f421-4166-8e1a-5a7f88bcf121"
      unitRef="U_USD">1207000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_aa559c69-b804-4831-aa93-896beb943c7d"
      unitRef="U_USD">650000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_9103ffbe-cd9a-4eb3-a760-9ea6aa633acb"
      unitRef="U_USD">2287000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_cae837f5-55a0-4af8-a8d8-9ef59339c7d4"
      unitRef="U_USD">1914000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCash
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_1e9d7bf4-1bba-4019-a515-1218675739b0"
      unitRef="U_USD">505000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_ee2a2aed-dee1-4964-b528-374ec673c9e3"
      unitRef="U_USD">160000</us-gaap:RestrictedCash>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_9bb56c62-eba7-41ee-850c-143d014d9e84"
      unitRef="U_USD">299000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_9519c440-6000-42b3-9e9b-257e01c245fa"
      unitRef="U_USD">181000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_892b62a6-a47f-42ac-977e-1bfff7975773"
      unitRef="U_USD">164810000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_c26118c4-ff39-4983-a749-b60b610f76e5"
      unitRef="U_USD">189431000</us-gaap:Assets>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_b7716aef-0dee-4c42-ba70-2678f55e0ae0"
      unitRef="U_USD">35000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_2a47e65b-b97a-4ba5-88c8-0f0059055825"
      unitRef="U_USD">1343000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_d2ec92f1-cf54-432e-8fde-16cf02adf083"
      unitRef="U_USD">9997000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_6aa94b81-1003-40a7-ae0d-5d9bcd58e1e6"
      unitRef="U_USD">5150000</us-gaap:AccountsPayableCurrent>
    <phat:AccruedClinicalTrialExpensesCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_1f19574c-1891-46d8-8f01-20e2e67f6e54"
      unitRef="U_USD">1402000</phat:AccruedClinicalTrialExpensesCurrent>
    <phat:AccruedExpensesRelatedPartiesCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_fbcc532b-6d2c-4480-99ba-a0547dfd2da6"
      unitRef="U_USD">2499000</phat:AccruedExpensesRelatedPartiesCurrent>
    <phat:AccruedExpensesRelatedPartiesCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_faa55c68-62c2-4bf4-a50f-563a813b89d4"
      unitRef="U_USD">2330000</phat:AccruedExpensesRelatedPartiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_6fbe175c-19ee-4714-893d-3723e4cb3a45"
      unitRef="U_USD">14678000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_f4dbb1b6-fbb0-42b5-a529-409c54962356"
      unitRef="U_USD">11405000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_04204714-1ea3-49f2-976e-3a440614e7c9"
      unitRef="U_USD">854000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_58fea3a4-9cc2-4936-9acc-047177104c2c"
      unitRef="U_USD">477000</us-gaap:InterestPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_9eb070a8-3be5-4714-9953-274131f1088c"
      unitRef="U_USD">708000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_3156cb22-fa0d-444c-a36e-ae4e8634c42e"
      unitRef="U_USD">487000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_d6e91811-4b3e-43c6-8cba-8708d4f2cd4e"
      unitRef="U_USD">26237000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_4310120a-5377-4725-b5f6-f267b7ffcf34"
      unitRef="U_USD">18921000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_ba7af4b6-2a1c-4154-9cd7-d08e2f0bde52"
      unitRef="U_USD">95264000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_42b40316-c805-459c-9938-f35fc99f3f5d"
      unitRef="U_USD">89671000</us-gaap:LongTermDebtNoncurrent>
    <phat:RevenueInterestFinancingLiabilityNoncurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_34b214f8-e2c4-463d-b067-ad816d1d537a"
      unitRef="U_USD">109525000</phat:RevenueInterestFinancingLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_1858b68b-2802-42f5-94c2-6f4c4827f0ab"
      unitRef="U_USD">1098000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_522bf1bf-90b4-4d87-8730-078b65531d74"
      unitRef="U_USD">1183000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_7e700a4d-faa8-4d68-8e02-4615595c4014"
      unitRef="U_USD">7500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_ab270021-7778-4aa6-8297-014fed1c6bc6"
      unitRef="U_USD">7500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_4abd2040-fd8d-4d2d-9a6f-643ee7a9bf70"
      unitRef="U_USD">239624000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_7c91131c-da74-4aa8-9b2b-cc6ec5eb831d"
      unitRef="U_USD">117275000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_0759afab-8ded-4fb8-8387-8a413e5a745e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_0686a444-9e8e-45bb-9468-ac714e519506"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_721988b4-b96b-4e32-8b59-e32c2deee599"
      unitRef="U_shares">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_f2ff4c33-506f-421c-99f1-3489fec27c81"
      unitRef="U_shares">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_717a9a18-5813-4ff9-98cd-37bf0594a050"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_71184019-4b34-4f62-afc0-84ab523555e2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_a5df8b3a-cd2b-4171-ae9b-8e20a5ddf88f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_ee7fe8a5-9139-42ef-ad85-9b493ed9ef4e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_a8d436f6-8157-44af-a8d6-9e52e953448d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_ddd24c05-b0d7-4959-8dfd-eac62a7df650"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_db4bf909-f2ae-4663-a437-9450dc47be36"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_fddd90fd-2f75-4c60-a69e-422e73eb3751"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_660a0d4d-1b25-44dc-9af8-03555ea75740"
      unitRef="U_shares">41723308</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_c8e0160c-45ff-45ad-baf7-12196a974526"
      unitRef="U_shares">31656035</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_271e0446-5547-4ddf-b340-137e70303109"
      unitRef="U_shares">41468871</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_520b1939-42da-4bd1-8737-74b63738311a"
      unitRef="U_shares">30511226</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_244d99a5-e4b1-4fca-91a7-24f3ad22ab8c"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_6ce4ceea-18b0-4a64-b6fc-063494101ecf"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_1fd43e01-d675-4be5-9eb2-91c7aaa0765f"
      unitRef="U_shares">19</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_dec9e0cc-ad20-4718-8280-a2b191cb88ff"
      unitRef="U_shares">1</us-gaap:TreasuryStockCommonShares>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_d90473bd-82d0-4014-8bdf-ced690d43460"
      unitRef="U_USD">652276000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_d517412c-7752-4ae2-bd5d-4c614e815817"
      unitRef="U_USD">601523000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_b7f4f615-e632-44f9-a364-8f57fe9a5f42"
      unitRef="U_USD">-727093000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_18474656-974d-44a1-bf8e-0938a386878e"
      unitRef="U_USD">-529370000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_f5843383-2b28-42f7-972e-323225072cea"
      unitRef="U_USD">-74814000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_d51bf6dc-b924-420b-a999-2cd9de8dea0f"
      unitRef="U_USD">72156000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_e82799a4-e26a-4751-b02d-2ff2e5b77ee9"
      unitRef="U_USD">164810000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_d9aee523-7bb1-4364-8bd5-a9539ac6cb71"
      unitRef="U_USD">189431000</us-gaap:LiabilitiesAndStockholdersEquity>
    <phat:ResearchAndDevelopmentExpenseRelatedParty
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_f4af29c8-acdd-46bb-934c-5c6c49435d7e"
      unitRef="U_USD">2123000</phat:ResearchAndDevelopmentExpenseRelatedParty>
    <phat:ResearchAndDevelopmentExpenseRelatedParty
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_5b6776ed-e33e-46a4-a892-0351ed1a15c6"
      unitRef="U_USD">4933000</phat:ResearchAndDevelopmentExpenseRelatedParty>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_bc436dd7-ae77-4152-b557-139e16664fb5"
      unitRef="U_USD">71441000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_c45e172d-a0ee-4433-844d-d1e0bd1d51ba"
      unitRef="U_USD">72338000</us-gaap:ResearchAndDevelopmentExpense>
    <phat:GeneralAndAdministrativeExpenseRelatedParty
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_d1e75d3f-a3b4-42ed-90b0-407de87bae39"
      unitRef="U_USD">0</phat:GeneralAndAdministrativeExpenseRelatedParty>
    <phat:GeneralAndAdministrativeExpenseRelatedParty
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_a8b0cd65-9029-4b16-a547-2343c4ee1441"
      unitRef="U_USD">18000</phat:GeneralAndAdministrativeExpenseRelatedParty>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_8f7c2e7d-9290-4f4c-a0c6-3bd9d22003a0"
      unitRef="U_USD">100999000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_8300a747-f23e-4d4e-b88b-8616aba21ed3"
      unitRef="U_USD">62742000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_2d9396aa-f80a-4e24-9be2-dde6f4fc9cf6"
      unitRef="U_USD">172440000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_52c4fa30-c29b-424a-9729-ec71ece740a2"
      unitRef="U_USD">135080000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_3436d391-8aa4-46cd-bfc9-7afb67df7307"
      unitRef="U_USD">-172440000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_54bda2b4-f320-4af9-8e94-2579ae56e3f1"
      unitRef="U_USD">-135080000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_69ec85ec-41d1-4590-b579-45213e543864"
      unitRef="U_USD">2132000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_7e670695-91a0-4dd6-a675-8768a4654ad0"
      unitRef="U_USD">41000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_e1b13a87-e782-4c60-918e-fa488797e848"
      unitRef="U_USD">27305000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_095a7c3e-ec3a-406c-b88c-cefeb9d9d6a9"
      unitRef="U_USD">6788000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_7146cee6-be5a-4e48-aafa-14158b4654ae"
      unitRef="U_USD">-110000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_84710c33-3004-4645-910b-85c2e7b351a9"
      unitRef="U_USD">-2056000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_9ecb44d5-32a1-4f33-bfc3-e57844627f4c"
      unitRef="U_USD">-25283000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_c83c576b-5da8-408c-8f85-b78577d7c986"
      unitRef="U_USD">-8803000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_6bad0aba-33f4-4e77-93b6-5dd69cca6f26"
      unitRef="U_USD">-197723000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_6a921738-fcce-49dd-be6f-949586336280"
      unitRef="U_USD">-143883000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="2"
      id="F_785c9083-1579-45d5-ae5a-b36f82211808"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-5.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="2"
      id="F_639653ef-c531-4c49-bce0-db2ed8696850"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-5.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="2"
      id="F_a0a0c2ba-7427-45a4-8038-36463ebab63a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="2"
      id="F_95d6c793-ac5d-4a24-a11f-5326ee4375f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="0"
      id="F_5f65f45b-c5d5-41ad-9223-2ed20a5751cf"
      unitRef="U_shares">39118215</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="0"
      id="F_7fc53703-99c9-45a0-b089-f9c8ee388bab"
      unitRef="U_shares">39118215</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="0"
      id="F_a086bdb9-2b97-441b-bb7e-bea6640b04cb"
      unitRef="U_shares">37002959</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="0"
      id="F_469e6bea-4010-4be6-8474-88ba24421e38"
      unitRef="U_shares">37002959</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_fdabcc96-9593-40cb-bc06-20ae0d8af269"
      decimals="INF"
      id="F_f8c6982b-c745-4795-b97a-e0e84d5602f9"
      unitRef="U_shares">28516010</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_fdabcc96-9593-40cb-bc06-20ae0d8af269"
      decimals="-3"
      id="F_e5a915d0-06b6-4989-aeab-d02b65455b57"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_38a3ce84-f57c-409f-8929-19e767dc49e2"
      decimals="-3"
      id="F_91f4955e-183e-4d62-ab0e-f9038ac2bf5d"
      unitRef="U_USD">579755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e45ec0f4-8be2-4007-a0b7-cc5a7fb0e0af"
      decimals="-3"
      id="F_3dcd032d-acc2-4ac8-b204-76a203fdb7c8"
      unitRef="U_USD">-385487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3625bbc7-e0d2-4ae5-80c9-2c2a001c24c0"
      decimals="-3"
      id="F_01cebd85-fe6a-4d76-88c6-a476d0ad4f8c"
      unitRef="U_USD">194271000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9c879136-27f6-49d8-8690-7a4079f865e8"
      decimals="INF"
      id="F_04d90dac-8820-48b9-944b-02495ee14e8a"
      unitRef="U_shares">107583</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242"
      decimals="-3"
      id="F_1563bd8b-001c-4667-96d6-7225cb856fc0"
      unitRef="U_USD">1944000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_40dc4b10-867b-4263-b912-186580ca911d"
      unitRef="U_USD">1944000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <phat:StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants
      contextRef="C_9c879136-27f6-49d8-8690-7a4079f865e8"
      decimals="INF"
      id="F_024dfd0e-2d12-4526-a42a-b176b46b2a8c"
      unitRef="U_shares">228696</phat:StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants>
    <phat:CashlessExerciseOfCommonStockWarrants
      contextRef="C_b5a1d5b1-793a-4122-8486-ddd80632f18a"
      decimals="0"
      id="F_7e182e78-62c6-4489-ad27-ce0ffe550606"
      unitRef="U_shares">1</phat:CashlessExerciseOfCommonStockWarrants>
    <phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
      contextRef="C_9c879136-27f6-49d8-8690-7a4079f865e8"
      decimals="INF"
      id="F_b273c38c-c94e-4f40-8f1e-fdf19e232210"
      unitRef="U_shares">26750</phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242"
      decimals="-3"
      id="F_e2def9b1-2c57-456e-a3bd-f322dc092b28"
      unitRef="U_USD">903000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_94182f63-348c-40bf-91bb-214d831c01ea"
      unitRef="U_USD">903000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_9c879136-27f6-49d8-8690-7a4079f865e8"
      decimals="INF"
      id="F_415869b5-b64c-4e5d-86de-3cbd19b8171d"
      unitRef="U_shares">1601950</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242"
      decimals="-3"
      id="F_913fc582-086d-498c-9921-dad13a0ad6ea"
      unitRef="U_USD">16812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_7a3c1e0b-0fa8-4299-9607-ba18e83ee50a"
      unitRef="U_USD">16812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_9c879136-27f6-49d8-8690-7a4079f865e8"
      decimals="INF"
      id="F_616b18a1-b341-468a-96d7-41dbcdd034c3"
      unitRef="U_shares">30237</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242"
      decimals="-3"
      id="F_33d4839e-0752-44f2-9776-dcfc9f56fa14"
      unitRef="U_USD">819000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_a2b4f246-eb8b-4098-aa1e-54e12b4a1a46"
      unitRef="U_USD">819000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_f12ecef0-ae8b-44f6-a37f-df1088e1e242"
      decimals="-3"
      id="F_29e02d41-305c-45b7-bf44-6810830a88bf"
      unitRef="U_USD">1290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_0dea465e-a3e4-48fe-b5aa-bceb044c2abc"
      unitRef="U_USD">1290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="C_c9d3b85f-d90c-44ea-828c-6eca6895c78b"
      decimals="-3"
      id="F_3e01f5bc-7e3d-4b8e-9b1d-6d7460756787"
      unitRef="U_USD">-143883000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_f4cb8481-b751-4ee2-b70d-be417ff62e75"
      unitRef="U_USD">-143883000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ad628062-bdfb-4035-85ce-04fb1a93328a"
      decimals="INF"
      id="F_9450b39b-3642-4d94-a3c8-261c893849d1"
      unitRef="U_shares">30511226</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ad628062-bdfb-4035-85ce-04fb1a93328a"
      decimals="-3"
      id="F_af0be737-ad43-4944-bb42-8a05f92977cb"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0e19ddc7-d662-491a-b517-1a7dc60b7d07"
      decimals="INF"
      id="F_ded0bb45-07d2-42ba-b3e7-dcc101e56cf8"
      unitRef="U_shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c4ab7858-b04f-4eaf-90c2-cde3b6e2669c"
      decimals="-3"
      id="F_a3c40efd-a7b5-4f3e-a61b-9f454d058480"
      unitRef="U_USD">601523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_12faa295-829a-4324-8f79-7c114d53f496"
      decimals="-3"
      id="F_a2df3e28-0fcb-4966-aa95-a0f61f3b3584"
      unitRef="U_USD">-529370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_95b7a7fd-d3cd-4d06-b308-de971aa49c91"
      unitRef="U_USD">72156000</us-gaap:StockholdersEquity>
    <phat:StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants
      contextRef="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba"
      decimals="INF"
      id="F_91ceb24c-936b-4e13-bb9e-13de19ec5886"
      unitRef="U_shares">7359285</phat:StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants>
    <phat:CashlessExerciseOfCommonStockWarrants
      contextRef="C_7ad3d68e-7eb3-4452-8fce-3d43389eeafa"
      decimals="0"
      id="F_93ff6315-740b-47dc-9366-3e922a210c8c"
      unitRef="U_shares">18</phat:CashlessExerciseOfCommonStockWarrants>
    <phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
      contextRef="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba"
      decimals="INF"
      id="F_217bf58e-f702-4b42-a5ba-3f0d8d76bf70"
      unitRef="U_shares">101540</phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_997ec618-b563-491c-9eca-1c0da676ff3e"
      decimals="-3"
      id="F_12a82260-907e-477d-a896-37a86a120745"
      unitRef="U_USD">1116000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_4f6a8df0-7bf4-4654-bf2a-2fb451ffc9cb"
      unitRef="U_USD">1116000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba"
      decimals="INF"
      id="F_e999919a-a2c6-4528-bc22-91e1633846e4"
      unitRef="U_shares">992825</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba"
      decimals="INF"
      id="F_06d9a8a1-52c6-41a6-98bf-6c387587f9e9"
      unitRef="U_shares">2414897</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_997ec618-b563-491c-9eca-1c0da676ff3e"
      decimals="-3"
      id="F_d29f17f9-8a54-4de7-a246-94bf8954cfd8"
      unitRef="U_USD">24595000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_7e75b072-3f62-43e7-bae0-93f29facee3e"
      unitRef="U_USD">24595000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_997ec618-b563-491c-9eca-1c0da676ff3e"
      decimals="-3"
      id="F_f1aeb5f8-7122-4cab-a0a9-72bdd98192f5"
      unitRef="U_USD">24133000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_ba9dd415-080d-4160-a2ba-c9f8b8b14be2"
      unitRef="U_USD">24133000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_bda226b6-1afd-4033-92c5-ea9f85d3b4ba"
      decimals="INF"
      id="F_152b29cd-75f5-4184-864d-765b9558f559"
      unitRef="U_shares">89098</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_997ec618-b563-491c-9eca-1c0da676ff3e"
      decimals="-3"
      id="F_773d19fe-d87b-4e38-a29a-d6e845e8bd85"
      unitRef="U_USD">909000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_9abe67b5-1bc8-4b95-9d9f-f4e22f458bc9"
      unitRef="U_USD">909000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="C_d53f3397-a799-4e1e-97d8-9158ecf94191"
      decimals="-3"
      id="F_44b4fa87-acca-4bc8-acd4-dd70ba84cf02"
      unitRef="U_USD">-197723000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_2de48f77-49f1-4804-a877-9cd6b46b0fa2"
      unitRef="U_USD">-197723000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b200a58a-3188-46aa-b5e6-de3a179abb6b"
      decimals="INF"
      id="F_bc3f8a0c-9209-48c4-9e62-56e2e47e9a72"
      unitRef="U_shares">41468871</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b200a58a-3188-46aa-b5e6-de3a179abb6b"
      decimals="-3"
      id="F_628d80a1-7276-47ad-baf6-b5fb857132e9"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2c6526c3-fe53-437c-8a64-5ef862e523ec"
      decimals="INF"
      id="F_c7857bfa-467a-4417-b37a-8d317785fac2"
      unitRef="U_shares">19</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a303df35-50f8-4246-ac81-15cdd055190d"
      decimals="-3"
      id="F_2ae3471a-5167-4319-8eb0-7a0388a199e5"
      unitRef="U_USD">652276000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8a9abbdc-846c-4903-a0f4-53dd7476cd04"
      decimals="-3"
      id="F_af227d9e-89e9-40d8-8e6f-c6e889b79fad"
      unitRef="U_USD">-727093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_a3a5dfa0-e7e9-4f48-a6ad-e5eb0df76503"
      unitRef="U_USD">-74814000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_dc78fe0f-94f5-4255-be39-d3d4fc111448"
      unitRef="U_USD">-197723000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_47ba4cc8-ef25-42d8-861a-6f623fd47bdf"
      unitRef="U_USD">-143883000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_f6f95705-e6a8-49c7-adfe-244937f13f29"
      unitRef="U_USD">620000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_f9ad93b0-191c-4867-a190-588cb1f252eb"
      unitRef="U_USD">521000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_e8396e86-514e-4e7f-a3bf-db61c2ab6b63"
      unitRef="U_USD">24133000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_7d76b49e-1ddf-4e4c-8993-d449e5957ec2"
      unitRef="U_USD">16812000</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_b065337f-1acf-48da-8c7f-9a96e75b328c"
      unitRef="U_USD">3484000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_06b63293-6922-46f5-98e5-d54881a8bbed"
      unitRef="U_USD">990000</us-gaap:PaidInKindInterest>
    <phat:AccruedInterestOnRevenueInterestFinancingLiability
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_20992ac6-2615-4fd9-a887-d0f7ab147fb8"
      unitRef="U_USD">14079000</phat:AccruedInterestOnRevenueInterestFinancingLiability>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_5ed37be9-ca8c-4fdd-a018-10f90ba8ed3a"
      unitRef="U_USD">2110000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_275aa87c-3bc2-475c-8ec0-ab6ecf7c9f0a"
      unitRef="U_USD">3595000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_e358bbce-d088-4df2-ba89-666dbf84c58b"
      unitRef="U_USD">-1329000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_5259590e-0ecf-4a17-a5ab-19004487e447"
      unitRef="U_USD">-823000</us-gaap:OtherNoncashIncomeExpense>
    <phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_fa59d5ad-cb4a-4a66-bc06-75ae6438e714"
      unitRef="U_USD">0</phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent>
    <phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_4640522e-2e57-4c4d-a4b0-1e4faa5d4d9b"
      unitRef="U_USD">82000</phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_0c81b18b-2bc0-4e17-a9d4-3de237567521"
      unitRef="U_USD">1860000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_cf924615-5119-4885-8a76-803cc8c0fb0b"
      unitRef="U_USD">-605000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_baeee31d-83af-4e41-a7c9-5e4ddd17b44a"
      unitRef="U_USD">1139000</phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties>
    <phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_c48bbffa-bfac-4579-b7ec-69fe9b13a0c0"
      unitRef="U_USD">2766000</phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_7b15e909-2b3a-45b3-8580-e93005cb5475"
      unitRef="U_USD">8679000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_f3fbe920-6739-4251-91d0-a61f4ff27f25"
      unitRef="U_USD">-9791000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <phat:IncreaseDecreaseInClinicalAccruedTrialExpenses
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_d6cd0b79-9717-4ddf-9327-99dfc85c1923"
      unitRef="U_USD">-1402000</phat:IncreaseDecreaseInClinicalAccruedTrialExpenses>
    <phat:IncreaseDecreaseInClinicalAccruedTrialExpenses
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_166b0a24-42db-4048-8dcc-d1ae8b968614"
      unitRef="U_USD">-18595000</phat:IncreaseDecreaseInClinicalAccruedTrialExpenses>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_7fd9758e-20df-4898-8d9c-78867af19ae2"
      unitRef="U_USD">377000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_45e66f2e-5ea6-4bdb-a3a0-a97b0f44bfac"
      unitRef="U_USD">165000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_dc96c450-10e1-4863-82e3-189c118d6e63"
      unitRef="U_USD">-238000</phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities>
    <phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_30c71846-8094-4a42-8f44-c83ac2c25222"
      unitRef="U_USD">98000</phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_8f36b61d-7afb-4802-84ef-6ffac46677d3"
      unitRef="U_USD">118000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_53c71861-04c2-4438-a12a-30a2c7d85646"
      unitRef="U_USD">-203000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_27b14526-5106-48f2-abba-4ccd52974e18"
      unitRef="U_USD">-146530000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_ce023376-b13a-4f5a-8d58-623845c81f7a"
      unitRef="U_USD">-148457000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_2c93fae5-9616-4c54-ad1a-a1406b8459dc"
      unitRef="U_USD">1041000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_5c409625-0a13-4fff-8ef5-8cedb65bc328"
      unitRef="U_USD">328000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_ea4a1bc7-b3ec-4917-9a5b-a059390a3da7"
      unitRef="U_USD">-1041000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_e74d0eba-82a0-49d2-86f7-a04b400d22e0"
      unitRef="U_USD">-328000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_b7b73664-bd8d-48a7-ae54-33a6e8af0fff"
      unitRef="U_USD">1944000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_66148624-7fdb-418f-9d34-4c65317530b3"
      unitRef="U_USD">54125000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_0376fc2e-c970-4c4a-870d-e57c2bb60cd2"
      unitRef="U_USD">96889000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <phat:NetProceedsFromRevenueInterestFinancingTransaction
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_34fc05da-03f6-43f5-9ef4-6d00ecb008b4"
      unitRef="U_USD">95446000</phat:NetProceedsFromRevenueInterestFinancingTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_16374c27-e9d9-4deb-990b-aa5e9aac1074"
      decimals="-3"
      id="F_ea38a112-70c5-4392-b33e-7968631abe0f"
      unitRef="U_USD">24596000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_bcd9daef-8a56-4098-a606-5a0fa7a7ddbb"
      unitRef="U_USD">120042000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_e562685e-f530-4b5d-acd4-2d5e7b9c6390"
      unitRef="U_USD">44708000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_81ca2f5a-e75f-4abf-9d04-618f38092f51"
      unitRef="U_USD">-27529000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_2192c283-ef08-41d0-b9e6-aeb9eeeb9921"
      unitRef="U_USD">-104077000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_ee2ea7dd-d3b6-426a-a2f7-6828914849d1"
      unitRef="U_USD">183419000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_3625bbc7-e0d2-4ae5-80c9-2c2a001c24c0"
      decimals="-3"
      id="F_45b24c1f-4c49-45c6-bdc7-6307429c622c"
      unitRef="U_USD">287496000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_cd640bf1-7049-41c0-a26a-b11f44a03364"
      unitRef="U_USD">155890000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_a4c3e962-1c81-4dcd-8cd3-38c6b0cc2242"
      unitRef="U_USD">183419000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_62eabdaf-e3db-4328-836e-51cbf80dcf45"
      unitRef="U_USD">7033000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_b2234550-5e87-4651-ad47-c651d0e987ad"
      unitRef="U_USD">4069000</us-gaap:InterestPaidNet>
    <phat:NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_cb36f7ec-36ba-440f-9884-a91eb9ba311a"
      unitRef="U_USD">1290000</phat:NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_0b15abdb-20a0-479f-b8ec-07ead8a0ad1e"
      unitRef="U_USD">138000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_b82e32c1-4571-4f35-9e60-32ae712b50f3"
      unitRef="U_USD">2000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <phat:NonCashFinalInterestPaymentFee
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_e66eeb0d-b321-4d5c-acd8-e84940b3721e"
      unitRef="U_USD">7500000</phat:NonCashFinalInterestPaymentFee>
    <phat:NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_9192bced-0280-4196-808f-ca2fd5b3a23c"
      unitRef="U_USD">909000</phat:NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock>
    <phat:NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_664b7e5d-11f4-4f72-bf83-8245e74e1e20"
      unitRef="U_USD">819000</phat:NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock>
    <phat:NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_4c197eac-aade-4e9d-b8df-58a56be7ac3d"
      unitRef="U_USD">1116000</phat:NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock>
    <phat:NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_169f9a90-146c-4a57-96f6-1e6e83eab547"
      unitRef="U_USD">903000</phat:NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock>
    <phat:OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_3efcf56b-df70-4aad-be2d-9ac8f2b212a1"
      unitRef="U_USD">554000</phat:OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_17fc58be-374a-4c74-adac-d2a0571f3fe0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1. Organization, Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company&#x2019;s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;From inception to December 31, 2022, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the clinical trials of vonoprazan, preparing for commercialization of its initial products containing vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur additional net losses in the future as it continues to develop and prepares for commercialization of vonoprazan. From inception to December 31, 2022, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, revenue interest financing debt, the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,997,630&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;191.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in its 2019 IPO, the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;88.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in its December 2020 follow-on public offering, and the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,414,897&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;24.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in its September 2022 issuance of common stock under the ATM Offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company&#x2019;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company&#x2019;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; financial assets measured at fair value on a recurring basis. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;n-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022, the estimated fair value of the Company&#x2019;s long-term debt approximated the carrying amount given its floating interest rate basis. The fair value of the Company&#x2019;s long-term debt was estimated for disclosure purposes only and was determined based on quoted market data for valuation, and thus categorized as Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Property, Plant, and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_d7201b82-ce21-4ec4-8499-cb8a67775133;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. Furniture and fixtures are depreciated over&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; impairment losses have been recorded through December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company&#x2019;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Revenue Interest Financing Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company entered into a revenue interest financing agreement, or the Revenue Interest Financing Agreement, with entities managed or advised by NovaQuest Capital Management, or NQ, Sagard Holdings Manager LP, or Sagard, and Hercules Capital, Inc., or Hercules, together with NQ and Sagard, the Initial Investors, in which the Company received funds in return for royalties on net sales of products containing vonoprazan. The net proceeds received under the transaction were recognized as short-term and long-term liabilities with interest expense based on an imputed effective rate derived from the expected future payments. The Company recalculates the effective interest rate each period based on the current carrying value and the revised estimated future payments. Changes in future payments from previous estimates are included in current and future financing expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#x2019;s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company also maintains an employee stock purchase program, or ESPP, under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Beginning in 2022, the Tax Cuts and Jobs Act, or TCJA, eliminates the option to deduct research and development expenditures currently and requires taxpayers to amortize domestic and foreign research and development expenditures over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; years, respectively. The requirement did not impact cash from operations in the current period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; operating segment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,588,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock under its warrant (the &#x201c;Takeda Warrant&#x201d;) issued to Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;) in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company&#x2019;s IPO until its exercise because the Takeda Warrant was exercisable for little consideration. As of December 31, 2022, all Takeda Warrants has been exercised and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; Takeda Warrants remain exercisable. For the years ended December 31, 2022 and December 31, 2021, the Company has excluded weighted-average unvested shares of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;686,703&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,939,252&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;There were no recently adopted accounting standards which would have a material impact on the Company's financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;     &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2022 that impacted the Company.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <phat:OrganizationAndBasisOfPresentationPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_4817754c-34f8-4c95-9093-462d06a773b3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company&#x2019;s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</phat:OrganizationAndBasisOfPresentationPolicyTextBlock>
    <phat:LiquidityAndCapitalResourcesPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_3dda8fb3-e556-4926-ab44-733de2af4701">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;From inception to December 31, 2022, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the clinical trials of vonoprazan, preparing for commercialization of its initial products containing vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur additional net losses in the future as it continues to develop and prepares for commercialization of vonoprazan. From inception to December 31, 2022, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, revenue interest financing debt, the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,997,630&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;191.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in its 2019 IPO, the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;88.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in its December 2020 follow-on public offering, and the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,414,897&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;24.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in its September 2022 issuance of common stock under the ATM Offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company&#x2019;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company&#x2019;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</phat:LiquidityAndCapitalResourcesPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f71a8436-7cab-4cb1-a0b4-4ed9b66f0382"
      decimals="INF"
      id="F_53174c99-ebae-4821-a38d-cebfb927d1a4"
      unitRef="U_shares">10997630</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_f71a8436-7cab-4cb1-a0b4-4ed9b66f0382"
      decimals="-5"
      id="F_c2165514-b956-4d0c-9a79-262d80578371"
      unitRef="U_USD">191500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_193ec4b9-a149-4c59-b451-7fd82670dde2"
      decimals="INF"
      id="F_48daa5a5-2939-4485-8c4f-c54b07b8e7f2"
      unitRef="U_shares">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_193ec4b9-a149-4c59-b451-7fd82670dde2"
      decimals="-5"
      id="F_4a3f4784-6c15-470f-ab34-46cec55aad5d"
      unitRef="U_USD">88600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5"
      decimals="INF"
      id="F_f1a90958-7104-4b79-a8f8-0661844a49d3"
      unitRef="U_shares">2414897</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5"
      decimals="-5"
      id="F_8d363f30-eab2-4235-92f9-e5733fc00b33"
      unitRef="U_USD">24600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:UseOfEstimates
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_235326c4-51b9-4460-ac70-a23003e9dcbc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_fb3f7960-d5bd-4fae-be21-e5e5f57e4bb7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; financial assets measured at fair value on a recurring basis. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;n-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022, the estimated fair value of the Company&#x2019;s long-term debt approximated the carrying amount given its floating interest rate basis. The fair value of the Company&#x2019;s long-term debt was estimated for disclosure purposes only and was determined based on quoted market data for valuation, and thus categorized as Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <phat:FinancialAssetsFairValueDisclosure
      contextRef="C_d1da1354-c115-4771-a4a8-bb35b2ea792f"
      decimals="INF"
      id="F_118299ef-2ff8-4bbd-83dc-04caece64521"
      unitRef="U_USD">0</phat:FinancialAssetsFairValueDisclosure>
    <phat:NonfinancialAssetsFairValueDisclosure
      contextRef="C_d1e29e67-db80-4194-babb-a6fb361ff631"
      decimals="INF"
      id="F_50cd2763-6777-490a-bb76-96404ca6f3e7"
      unitRef="U_USD">0</phat:NonfinancialAssetsFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="C_d1e29e67-db80-4194-babb-a6fb361ff631"
      decimals="INF"
      id="F_d51c7f70-9bc5-4815-8e41-00650ab3bfbe"
      unitRef="U_USD">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="INF"
      id="F_b2f2dab4-e229-4403-9e5c-8c9d282dc91b"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_e0827f46-46be-4c98-9f89-0e77b480a2ed">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_b3806b3f-0046-4b38-80e4-c4750caad5ef">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_8924a678-26d8-4ca7-acfb-f20848592bcb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Property, Plant, and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_d7201b82-ce21-4ec4-8499-cb8a67775133;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. Furniture and fixtures are depreciated over&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_6a3f3bfa-6949-4f34-b6ab-a42581ad38fb"
      id="F_66692ad5-5602-4ced-8113-18e10960546e">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_9b1aa0b6-a160-4d39-a073-61b00c5a103f"
      id="F_7594b741-b53c-4194-95ce-0dac509fbf99">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_883ec4c1-ad79-4d20-809a-ada7917593d7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; impairment losses have been recorded through December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="INF"
      id="F_6fdc394f-46ec-418b-8ad8-937886e7435b"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LessorLeasesPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_14ea5fb0-50b4-44d0-85d4-27e6a43827b4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company&#x2019;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <phat:RevenueInterestFinancingLiabilityPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_f896d7b0-3f51-4e07-abcf-04f9567e985a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Revenue Interest Financing Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company entered into a revenue interest financing agreement, or the Revenue Interest Financing Agreement, with entities managed or advised by NovaQuest Capital Management, or NQ, Sagard Holdings Manager LP, or Sagard, and Hercules Capital, Inc., or Hercules, together with NQ and Sagard, the Initial Investors, in which the Company received funds in return for royalties on net sales of products containing vonoprazan. The net proceeds received under the transaction were recognized as short-term and long-term liabilities with interest expense based on an imputed effective rate derived from the expected future payments. The Company recalculates the effective interest rate each period based on the current carrying value and the revised estimated future payments. Changes in future payments from previous estimates are included in current and future financing expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</phat:RevenueInterestFinancingLiabilityPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_36d101d5-91f5-4568-8b98-db8ab294556c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#x2019;s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_b2227a44-957b-4fc9-ab02-8b832e2d0d82">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_227dc8c7-3eec-4474-a882-d3c2ec46e200">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_ce28305a-58f7-4851-adc7-7acb94d89086">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company also maintains an employee stock purchase program, or ESPP, under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_557d6ad6-9c44-4566-99ea-22f7dfa4f0d5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Beginning in 2022, the Tax Cuts and Jobs Act, or TCJA, eliminates the option to deduct research and development expenditures currently and requires taxpayers to amortize domestic and foreign research and development expenditures over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; years, respectively. The requirement did not impact cash from operations in the current period.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <phat:TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod
      contextRef="C_4160e414-35f2-4edb-94aa-a3ea7eeab964"
      id="F_027cd8de-6bf8-484f-9c2a-fa884ac32c4d">P5Y</phat:TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod>
    <phat:TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod
      contextRef="C_d9d8f01d-3d43-4934-ad2b-b3a53489fec5"
      id="F_1fa67c76-b2be-438c-a2af-0301cea0b8df">P15Y</phat:TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_5e74eb20-34c5-4e0f-b3f7-21f9fd272cda">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_417d6629-8b13-45c2-9254-50ce7c23535d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; operating segment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="INF"
      id="F_fbbaf46c-daa9-44e5-82e2-bf81dbf38789"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_400c8ad8-a736-448b-8a8f-0814e51ab308">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,588,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock under its warrant (the &#x201c;Takeda Warrant&#x201d;) issued to Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;) in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company&#x2019;s IPO until its exercise because the Takeda Warrant was exercisable for little consideration. As of December 31, 2022, all Takeda Warrants has been exercised and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; Takeda Warrants remain exercisable. For the years ended December 31, 2022 and December 31, 2021, the Company has excluded weighted-average unvested shares of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;686,703&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,939,252&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0cceeb3e-ff40-49d0-b18c-96a61d412299"
      decimals="INF"
      id="F_d08e3028-5394-4a81-b3b8-44b14056cdec"
      unitRef="U_shares">7588000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <phat:NumberOfWarrantsRemainingExercisable
      contextRef="C_3d0461f1-b88c-4662-9709-e549cfb4144e"
      decimals="INF"
      id="F_f4171e9e-9261-4b6c-a2b8-5b941530cbb0"
      unitRef="U_shares">0</phat:NumberOfWarrantsRemainingExercisable>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0d987563-e4a1-47c2-a958-218433edf069"
      decimals="0"
      id="F_37abb465-c3d3-4c97-81b9-cb9f63f49417"
      unitRef="U_shares">686703</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_da396882-6f6e-44fb-b650-cc0b5c7ed2f3"
      decimals="0"
      id="F_476c8887-20a7-4fa1-8195-bd5b0898293c"
      unitRef="U_shares">1939252</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_f19c8460-2bf4-4056-b2f1-18a7456d48cb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;There were no recently adopted accounting standards which would have a material impact on the Company's financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;     &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2022 that impacted the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <phat:ComponentOfBalanceSheetDisclosureTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_8ad8614f-ee95-4ede-a395-40430c4373b9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2. Balance Sheet Details&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Property, Plant and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property, plant and equipment, net, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.276%;"/&gt;
        &lt;td style="width:1.339%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.023000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.339%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.023000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total property, plant and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Depreciation expense for the years ended December 31, 2022 and 2021 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; property, plant or equipment was disposed of during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Accrued Expenses&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.471%;"/&gt;
        &lt;td style="width:1.343%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.913999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.343%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.929%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued professional &amp;amp; consulting&lt;br/&gt;&#160;&#160;&#160;expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;14,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;11,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</phat:ComponentOfBalanceSheetDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_0d79c5c5-e0e6-4811-a100-2f46ba4586b5">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property, plant and equipment, net, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.276%;"/&gt;
        &lt;td style="width:1.339%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.023000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.339%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.023000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total property, plant and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_50a28e01-3143-418a-81bb-bfbdc824e6bb"
      decimals="-3"
      id="F_07684906-56f9-485a-897c-3d9a8650ec99"
      unitRef="U_USD">1078000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_52ad1a5c-6e1b-4d4e-9cf1-f8d7bea71a22"
      decimals="-3"
      id="F_dedc80d0-905b-49db-a4ff-83ab587ad01a"
      unitRef="U_USD">646000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7acebd49-8754-4509-8ad2-aef189b7a108"
      decimals="-3"
      id="F_b40e3ab4-ff92-4352-9435-ebdb491a602b"
      unitRef="U_USD">1086000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2605f8bc-b7a3-4e6a-b47e-dad76807d9a5"
      decimals="-3"
      id="F_953224b3-8acd-44ae-8243-a1823738c0de"
      unitRef="U_USD">780000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_085d1c47-e6cb-4591-b010-3194bae40e70"
      decimals="-3"
      id="F_e08e8424-89e7-4948-89f8-f19a893bfdc2"
      unitRef="U_USD">115000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7d957629-8d64-4447-931c-6471c184bdc3"
      decimals="-3"
      id="F_bc9116f2-a29a-4685-a6ec-bb7ced9f82f7"
      unitRef="U_USD">76000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3b1269f3-0919-4f09-919c-ae285bdda990"
      decimals="-3"
      id="F_b95f476a-23a2-4267-a0b0-b79988ca35a5"
      unitRef="U_USD">399000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_520b3e73-1821-4485-987f-c0da0fdc861f"
      unitRef="U_USD">2678000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_ed9c16bb-464f-4bcc-8320-210485aea962"
      unitRef="U_USD">1502000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_c63586f1-47f7-45e1-a7f2-64e692035713"
      unitRef="U_USD">1471000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_777f2179-af0d-4118-acba-ed0e5184dfdd"
      unitRef="U_USD">852000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_af153e61-37b9-4e0c-8fec-46bd4470906f"
      unitRef="U_USD">1207000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_ea4e395e-2067-41ba-b3f4-804386e5928b"
      unitRef="U_USD">650000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-5"
      id="F_603bc7ce-8dae-45ea-806b-74730b2cb026"
      unitRef="U_USD">600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-5"
      id="F_acc9c76e-5975-4386-8a8e-7eea3e03085c"
      unitRef="U_USD">500000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="INF"
      id="F_3248d07d-287a-4848-ac32-22e1a58e28ce"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="INF"
      id="F_36ac3e85-2b52-46f5-a784-c71e77e28d9d"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_28fdeb09-3181-4af8-96e9-d6c9607219aa">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.471%;"/&gt;
        &lt;td style="width:1.343%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.913999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.343%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.929%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued professional &amp;amp; consulting&lt;br/&gt;&#160;&#160;&#160;expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;14,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;11,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <phat:AccruedResearchAndDevelopmentExpenses
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_7a771e21-3476-40df-9f84-ce4d53735a9f"
      unitRef="U_USD">3080000</phat:AccruedResearchAndDevelopmentExpenses>
    <phat:AccruedResearchAndDevelopmentExpenses
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_447787e7-ed7d-4d35-9bc4-80761e2a0580"
      unitRef="U_USD">3165000</phat:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_d0d429b4-3923-43f7-8046-f1fb8bac657c"
      unitRef="U_USD">8447000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_7d77b958-b876-4bc9-8b0d-dc00d4f8c7ed"
      unitRef="U_USD">6344000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_c96586bc-133b-48a6-8f58-c910715b2eab"
      unitRef="U_USD">3000000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_d7a91621-38eb-4d42-a720-1b9ac7c5d2c8"
      unitRef="U_USD">1855000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_a20b0b38-b323-4f70-a7ba-ba904a7a9ec9"
      unitRef="U_USD">151000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_3cad7c47-fa25-4cf4-b77c-cb4a821cb4d5"
      unitRef="U_USD">41000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_91716bdd-1a17-42a1-a13c-26e0a0c18d16"
      unitRef="U_USD">14678000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_52c10231-8529-4753-9787-3ead0849d63c"
      unitRef="U_USD">11405000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_4930eeef-737a-4f9d-9f11-21aeb8cd3943">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3. Related Party Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Frazier is a principal stockholder of the Company and&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; is a principal stockholder in PCI Pharma Services, or PCI. In the third quarter of 2019, the Company engaged PCI for clinical manufacturing services. As of December 31, 2022 and 2021, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, in outstanding accounts payable and accrued expenses related to these manufacturing services. For the years ended December 31, 2022 and 2021, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, of expenses related to services performed by PCI.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Takeda became a common stockholder of the Company in connection with the May 2019 license agreement (see Note 4). In conjunction with this license, Takeda provides proprietary supplies for the Company&#x2019;s ongoing clinical development of vonoprazan in addition to the exclusive license for the commercialization of vonoprazan in the United States, Canada and Europe. On May 5, 2020, the Company entered into a Commercial Supply Agreement, or the Commercial Supply Agreement, with Takeda, pursuant to which Takeda agreed to supply commercial quantities of vonoprazan bulk drug product or drug substance. Pursuant to the Commercial Supply Agreement, Takeda agreed to supply the Company with, and the Company agreed to purchase from Takeda, certain quantities of vonoprazan bulk drug product according to approved specifications at a fixed price per batch of bulk drug product in order to commercialize vonoprazan in accordance with the Takeda License. Unless terminated earlier, the term of the Commercial Supply Agreement extends for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; from the date the Company places an order for bulk drug product or drug substance for the first commercial launch of vonoprazan in any jurisdiction in the licensed territory, provided that this two-year period will expire no later than December 31, 2023. The Commercial Supply Agreement will terminate immediately upon the termination of the Takeda License in accordance with its terms. In connection with the Takeda License, the Company entered into a temporary services agreement, or the Temporary Services Agreement, with Takeda on November 24, 2020. Pursuant to the Temporary Services Agreement, Takeda agreed to provide or procure the provision of services related to the ongoing clinical development of vonoprazan. The Temporary Services Agreement will terminate immediately upon termination of the Takeda License in accordance with its terms. As of December 31, 2022 and December 31, 2021, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, in outstanding accounts payable and accrued expenses related to these agreements.  For the years ended December 31, 2022 and 2021, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, of expenses related to these agreements. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; remaining minimum purchase obligation related to these agreements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_1ca84d6f-4ec7-4ca7-a80c-ce5f47b70bdf"
      decimals="-5"
      id="F_803dbbac-456c-4d7e-b384-b89e1d59beab"
      unitRef="U_USD">1100000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_921713e0-e38d-456b-b30a-55995a73ff55"
      decimals="-5"
      id="F_bd4e0cc9-3a08-40aa-a21d-b63d64baa3cc"
      unitRef="U_USD">1700000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_d27b5644-2ffe-49a5-bcac-f51f4f379e72"
      decimals="-5"
      id="F_4c905daf-718f-478a-8f2b-60a32b9bd40b"
      unitRef="U_USD">700000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_15355aaa-f30b-4175-9505-232bcaaa97e6"
      decimals="-5"
      id="F_576bd877-92d4-4610-800c-31375471141f"
      unitRef="U_USD">3200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <phat:AgreementExtendsPeriodForTermination
      contextRef="C_3e93f3f8-5fa9-4e0e-9be2-05e4b1b44b52"
      id="F_dc48d7ad-4320-40c8-a85c-07a342c42c71">P2Y</phat:AgreementExtendsPeriodForTermination>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_12f1ae54-8af7-498f-b9c2-d3ecab67150a"
      decimals="-5"
      id="F_331b35d1-5dea-4dd7-a897-362a6e33849a"
      unitRef="U_USD">1400000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_d8f8b7b4-5d19-4a59-808a-7620c9d1ce95"
      decimals="-5"
      id="F_4fe27633-8595-4a68-873f-33417346fa1f"
      unitRef="U_USD">900000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_d9072564-13ae-4ea1-84c1-9febe815dd19"
      decimals="-5"
      id="F_f5bb01e7-f758-4f7b-864e-accd02990f93"
      unitRef="U_USD">1400000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_a9b385aa-6a5f-45cc-a03d-80389e7fbcf7"
      decimals="-5"
      id="F_5bda577c-f3ed-42f8-8f40-5ad8dcef39ad"
      unitRef="U_USD">1800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:PurchaseObligation
      contextRef="C_e7e1b33c-ea56-4599-a9c9-30b1918239b4"
      decimals="INF"
      id="F_d9e2880d-6516-4efb-bd9b-99a63c4fccee"
      unitRef="U_USD">0</us-gaap:PurchaseObligation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_ad19cdbc-cc2a-49d4-854b-9fa0857e6448">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;4. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;License Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;O&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;n May 7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe, or, the Takeda License. The Company also has the right to sublicense its rights under the agreement, subject to certain conditions. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months&#x2019; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#x2019;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;I&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;n consideration of the Takeda License, the Company (i) paid Takeda $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in cash, (ii) issued Takeda &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,084,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock at a fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, (iii) issued the Takeda Warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,588,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.00004613&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share at an initial fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;47.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, and (iv) issued a right to receive an additional common stock warrant, or, the Takeda Warrant Right, should Takeda&#x2019;s fully-diluted ownership of the Company represent less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately before the closing of the Company&#x2019;s IPO, with a nominal initial fair value due to the low probability of issuance. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of the IPO, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; additional warrant was issued. In addition, the Company is obligated to pay Takeda up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in sales milestones upon the achievement of specified levels of product sales, and a low double-digit royalty rate on aggregate net sales of licensed products, subject to certain adjustments. The Takeda Warrant had an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.00004613&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share, and was to expire on&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; May 7, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; and became exercisable upon the consummation of the IPO. As of December 31, 2022 all Takeda Warrants have been exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Purchase Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In December 2020, the Company entered into a supply agreement with Sandoz pursuant to which Sandoz will supply commercial quantities of amoxicillin capsules and clarithromycin tablets, package these antibiotics with vonoprazan, and provide in finished convenience packs. The supply agreement commits the Company to a minimum purchase obligation of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in the first 24-month period following the launch of the final product. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;t incurred any expenses under the agreement during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <phat:LicenseAgreementDescription
      contextRef="C_ee4ba230-41b0-4d69-921e-1d90ed587bd8"
      id="F_8f8d4ea2-4144-4908-b895-2abe2b4e6c8a">The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months&#x2019; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#x2019;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents</phat:LicenseAgreementDescription>
    <phat:AgreementExpirationTermFromDateOfFirstCommercialSale
      contextRef="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a"
      id="F_17c401a6-8fd0-4f82-8cb3-be7c7a81bfb2">P15Y</phat:AgreementExpirationTermFromDateOfFirstCommercialSale>
    <phat:PaymentForLicenseAmount
      contextRef="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a"
      decimals="-5"
      id="F_fa57000b-be1b-4021-9e69-e89d4b7254ff"
      unitRef="U_USD">25000000.0</phat:PaymentForLicenseAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a1345e6a-366c-4155-83c9-889619f08e7d"
      decimals="INF"
      id="F_707ec201-6823-4cc1-91ec-93f9921d2ebb"
      unitRef="U_shares">1084000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_a1345e6a-366c-4155-83c9-889619f08e7d"
      decimals="-5"
      id="F_ba6da91c-4e5b-4ec7-900a-7a38012346c5"
      unitRef="U_USD">5900000</us-gaap:CommonStockValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0cceeb3e-ff40-49d0-b18c-96a61d412299"
      decimals="INF"
      id="F_d0e033c5-e24a-4f0b-bf20-35490392e17b"
      unitRef="U_shares">7588000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_a1345e6a-366c-4155-83c9-889619f08e7d"
      decimals="8"
      id="F_e436bd05-6d35-41b6-aef7-446e0a07411c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00004613</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_a1345e6a-366c-4155-83c9-889619f08e7d"
      decimals="-5"
      id="F_1959e847-c02c-45d1-8e54-a60860252283"
      unitRef="U_USD">47900000</us-gaap:WarrantsAndRightsOutstanding>
    <phat:AdditionalWarrantIssued
      contextRef="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a"
      decimals="INF"
      id="F_67232506-8442-4e27-b6e3-a51a98d5b7f2"
      unitRef="U_shares">0</phat:AdditionalWarrantIssued>
    <phat:MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales
      contextRef="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a"
      decimals="INF"
      id="F_a82a0e0e-85cb-4c2c-a96b-d964c33a483c"
      unitRef="U_USD">250000000.0</phat:MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_a1345e6a-366c-4155-83c9-889619f08e7d"
      decimals="8"
      id="F_f38173bb-ad2a-43db-99eb-ce367f9113f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00004613</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <phat:WarrantsExpirationDate
      contextRef="C_2d69bcb0-41ef-4c19-8278-1b3fe1468c4a"
      id="F_5c065644-0cbe-4873-ac6e-38f435657d52">2029-05-07</phat:WarrantsExpirationDate>
    <phat:PurchaseObligationDueInFirstTwentyFourMonths
      contextRef="C_d2db8e6c-935d-488d-812e-7446da50b3c3"
      decimals="INF"
      id="F_39f62df9-25fd-474e-9cd8-14ad1782197d"
      unitRef="U_USD">3800000</phat:PurchaseObligationDueInFirstTwentyFourMonths>
    <phat:PurchaseCommitmentExpense
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="INF"
      id="F_5f1fa60b-2b88-4474-b492-e14b64e7383d"
      unitRef="U_USD">0</phat:PurchaseCommitmentExpense>
    <phat:PurchaseCommitmentExpense
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="INF"
      id="F_dd76b691-5065-4a88-8bd3-7dbd25de12c2"
      unitRef="U_USD">0</phat:PurchaseCommitmentExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_448cdb70-c7d4-4242-83d7-0362a6cf2cf5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5. Lease Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had operating leases for office space in both Buffalo Grove, Illinois and Florham Park, New Jersey, with weighted average remaining lease terms of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; years, respectively. All&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; operating leases contain an option to extend the term for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; period&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;, which was not considered in the determination of the right-of-use asset or lease liability as the Company did not consider it reasonably certain that it would exercise such options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;     &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The total rent expense for the years ended December 31, 2022 and 2021 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.173%;"/&gt;
        &lt;td style="width:1.511%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.893999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.528%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.893999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022, the future minimum annual lease payments under the operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.12%;"/&gt;
        &lt;td style="width:1.493%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.387999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-average incremental borrowing rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating cash flows for the years ended December 31, 2022 included $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in cash payments for operating leases, none of which were prepaid lease payments. Operating cash flows for the years ended December 31, 2021 included $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in cash payments for operating leases, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of which were prepaid lease payments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_ab4915e2-d84a-4fe8-8537-63d674acad7a"
      id="F_59e454a2-c46a-4a94-9d9d-33ef98251298">P2Y3M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_b3d62e8f-6837-4e80-a47d-75eba6bca352"
      id="F_8cf3cdd1-a98b-4cc1-b006-376010c0435a">P2Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_5dcc212e-21a7-4a55-bc25-9c94fd4f27d5"
      id="F_8f4198bc-ab1c-494d-aa95-d8c37e47e815"> operating leases contain an option to extend the term for one additional five-year period</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_eb1ec5a6-fae4-47b9-b672-953a87241f7b"
      id="F_bbda5aa2-829e-4b9d-9aa6-c8a28a49cdaa"> operating leases contain an option to extend the term for one additional five-year period</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <phat:LesseeOperatingLeaseNumberOfOptionToExtend
      contextRef="C_5dcc212e-21a7-4a55-bc25-9c94fd4f27d5"
      decimals="INF"
      id="F_fdebb4cd-c166-49d7-b9eb-9cc766c17180"
      unitRef="U_Option">1</phat:LesseeOperatingLeaseNumberOfOptionToExtend>
    <phat:LesseeOperatingLeaseNumberOfOptionToExtend
      contextRef="C_eb1ec5a6-fae4-47b9-b672-953a87241f7b"
      decimals="INF"
      id="F_e6616361-fc0b-4ddb-a495-908eed76d83c"
      unitRef="U_Option">1</phat:LesseeOperatingLeaseNumberOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_ab4915e2-d84a-4fe8-8537-63d674acad7a"
      id="F_5e0530a2-1221-4eab-adb9-e4670432f22a">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_b3d62e8f-6837-4e80-a47d-75eba6bca352"
      id="F_a10bdc80-dd53-4a24-b064-ecf1c989c5c6">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-5"
      id="F_9bfa8b79-543c-4993-898f-b172b99576a0"
      unitRef="U_USD">1000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-5"
      id="F_798474db-bd36-4f72-9e83-8f87092acc80"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseExpense>
    <phat:SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_d44cf582-11c2-4ac7-b66b-877c03fe55ab">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.173%;"/&gt;
        &lt;td style="width:1.511%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.893999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.528%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.893999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</phat:SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_545a7294-1e6a-42f6-8c84-d114d7112425"
      unitRef="U_USD">2287000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_10839017-4e39-41db-a305-c4dab2119129"
      unitRef="U_USD">1914000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_f252e010-9a55-422c-9579-9cde74ced272"
      unitRef="U_USD">2287000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_079b9c5a-d3c9-4ae0-97bb-2e208903640f"
      unitRef="U_USD">1914000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_61c1b462-b1ff-4e22-ba6e-ad25b4c244fe"
      unitRef="U_USD">708000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_39fe6095-1210-4e5e-87fe-71b89c223d8a"
      unitRef="U_USD">487000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_63401e22-ab7d-4624-b248-9c3c932621be"
      unitRef="U_USD">1098000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_dc29384b-5179-45cb-9a8e-6b7f437c1731"
      unitRef="U_USD">1183000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_ea7457d2-5edd-4da9-8ea9-15537ada3b00"
      unitRef="U_USD">1806000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_07bb0ec2-e6fa-4fd9-988e-025a8da0d7b7"
      unitRef="U_USD">1670000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_8a258ca5-7412-4e3d-b6d8-2821ea4554ff">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022, the future minimum annual lease payments under the operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.12%;"/&gt;
        &lt;td style="width:1.493%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.387999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-average incremental borrowing rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_02773585-04ab-4fde-8825-77b3fd5f4d46"
      unitRef="U_USD">734000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_4921134f-dd38-4a7a-a3c7-7e12b8a62403"
      unitRef="U_USD">753000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_f0d63076-d52b-40f7-aa2d-fa1ce80cafaa"
      unitRef="U_USD">513000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_de8fbd16-a477-40ae-ad26-c77e7e3eecd7"
      unitRef="U_USD">2000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_c090632a-157d-4e9c-9280-87b1f47de75d"
      unitRef="U_USD">194000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_beba01a0-de84-4f8c-969b-ed0383181348"
      unitRef="U_USD">1806000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_79894850-cd39-4ef4-8da9-bcfc6504c064"
      unitRef="U_USD">708000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_46d452f3-00f0-4fc6-a403-092b34a9fa73"
      unitRef="U_USD">1098000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      id="F_8d7b1fd2-9296-46d1-b0de-e3a209576257">P2Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="4"
      id="F_21c5e799-8427-4d4e-b6d9-743d343b24b8"
      unitRef="U_pure">0.0820</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-5"
      id="F_83889325-620b-4b73-bed3-7ca001d867c6"
      unitRef="U_USD">1100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-5"
      id="F_e40e07d2-75b1-46f2-921f-f760f2d813c3"
      unitRef="U_USD">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_8d783f53-5bda-4abc-8b88-b5d7f5533766"
      decimals="-5"
      id="F_b7fc12e2-a8ce-4fa5-b050-2f3993d9b638"
      unitRef="U_USD">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_4404e88c-46ce-4695-be11-5e9dea29c342">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;6. Debt&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total debt consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.352%;"/&gt;
        &lt;td style="width:1.516%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.131999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Long-term debt, current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Long-term debt, non-current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;104,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unamortized debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total debt, net of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;95,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;On September 17, 2021, or the Closing Date, the Company entered into a Loan and Security Agreement, or, the Loan Agreement, with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender, or, in such capacity, the Agent or Hercules, and the other financial institutions that from time to time become parties to the Loan Agreement as lenders, or, collectively, the Lenders.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Loan Agreement provides for term loans in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, or the Term Loan, under multiple tranches. The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, all of which was funded to the Company on the Closing Date, or First Advance, (ii) a second tranche consisting of up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, which became available to the Company upon achievement of the protocol-specified primary efficacy endpoints in the Company&#x2019;s Phase 3 trial studying vonoprazan for the healing and maintenance of healing of erosive GERD with acceptable safety data, such that the results support the submission of a New Drug Application, or NDA, or supplemental NDA without the need to conduct another Phase 3 study and will be available, if specified conditions are met, through December 15, 2022, see amendment to later date below, (iii) a third and fourth tranches consisting of an additional total $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, which became available to the Company in May 2022 upon the achievement of (a) Food and Drug Administration, or FDA, approval of the Company&#x2019;s NDA for vonoprazan and amoxicillin, or its New Drug Application for vonoprazan, amoxicillin and clarithromycin, in each case for an indication relating to the treatment of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Helicobacter pylori&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;, or &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;H. pylori, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;with an approved indication on the claim that is generally consistent with that sought in the Company&#x2019;s NDA submission&#x37e; and (b) filing of the Company&#x2019;s NDA or supplemental NDA for vonoprazan for indications relating to the healing and maintenance of healing of erosive GERD. The third and fourth tranches will remain available until September 30, 2023, and March 31, 2024, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;On September 27, 2022, the Company entered into an amendment to the Loan Agreement, or the Second Loan Amendment, pursuant to which the date the second tranche of funding of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million will remain available to the Company has been moved until May 15, 2023, rather than December 15, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company paid a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million facility charge in connection with closing of the Loan Agreement and would need to pay &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of any advances made under the third and fourth tranches.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; T&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;he Term Loan will mature on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;October 1, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;, or the Maturity Date. The Term Loan bears (i) cash interest at a variable annual rate equal to the greater of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% and (b) the Prime Rate (as reported in the Wall Street Journal) plus &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%, or the &#x201c;Interest Rate&#x201d;, and (ii) payment-in-kind interest at a per annum rate of interest equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%. Phathom may make payments of interest only through October 1, 2024, which was extended to October 1, 2025, upon the achievement of the Second Performance Milestone in May 2022 prior to September 30, 2024 and met the condition that no default or event of default exists, and which is further extendable to October 1, 2026, subject to FDA approval of the Company&#x2019;s NDA (or supplemental NDA) for vonoprazan for an indication relating to the healing and maintenance of healing of erosive GERD with an approved indication on the label that is generally consistent with that sought in the Company&#x2019;s NDA submission (or supplemental NDA submission), or the Third Performance Milestone, on or prior to September 30, 2025 and no default or event of default exists (the &#x201c;interest only period&#x201d;). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In addition, the Company is obligated to pay a final payment fee of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the original principal amount of amounts actually advanced under the Term Loan, or, each a Term Loan Advance and together, the Term Loan Advances. As of December 31, 2022, the aggregate final payment fee for the first Term Loan Advance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million has been recorded as an other long-term liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company may elect to prepay all or a portion of the Term Loan Advances prior to maturity, subject to a prepayment fee of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the then outstanding principal balance of the Term Loan Advances being prepaid. After repayment, no Term Loan amounts may be borrowed again.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As collateral for the obligations, the Company has granted to Hercules a senior security interest in all of Company&#x2019;s right, title, and interest in, to and under substantially all of Company&#x2019;s property, inclusive of intellectual property.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring the Company to maintain certain levels of cash subject to a control agreement in favor of the Agent (minus accounts payable not paid within 120 days of invoice), or Qualified Cash, and commencing on May 15, 2023, trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan. The revenue covenant will be waived at any time in which the Company maintains Qualified Cash equal to at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% (prior to the Third Performance Milestone), and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% (following the Third Performance Milestone) of the total outstanding Term Loan principal amount, or the Company&#x2019;s market capitalization is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;900.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company may be declared immediately due and payable by Hercules, as collateral agent. As of December 31, 2022, the Company was in compliance with all applicable covenants under the Loan Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Under the Second Loan Amendment, the commencement date for the covenant based on trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan was moved from May 15, 2023, to November 15, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In connection with the entry into the Loan Agreement, the Company issued to Hercules a warrant, or, the Warrant, to purchase a number of shares of the Company&#x2019;s common stock equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the aggregate amount of the Term Loan advances funded, and will issue to Hercules additional warrants when future Term Loan advances are funded. On the Closing Date, the Company issued a Warrant for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;74,782&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock. The Warrant will be exercisable for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; from the date of issuance at a per-share exercise price equal to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;33.43&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;, which was the closing price of the Company&#x2019;s common stock on September 16, 2021. The Warrant is exercisable any time until &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;September 17, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; and had an initial fair value of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The initial $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million fair value of the Warrant, the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million final interest payment fee and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of debt issuance costs have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the term of the Term Loan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Future minimum principal payments under the Term Loan, including the final payment fee, as of December 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.599%;"/&gt;
        &lt;td style="width:1.521%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.88%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;29,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;94,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total principal and interest payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;124,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less payment-in-kind and final payment fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;24,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total term loan borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Prior to the Loan Agreement with Hercules, the Company had a loan with SVB and approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;54.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of the proceeds from the First Advance was used to satisfy in full and retire the Company&#x2019;s indebtedness under the SVB Term Loan with SVB, including accrued interest through the payoff date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, of interest expense, including amortization of the debt discount, in connection with the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Hercules Loan Agreement and SVB Term Loan. As of December 31, 2022, the Company had outstanding &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;loan balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;104.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and accrued interest of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_d35006b5-7a50-4b28-a9a0-47513f02fe88">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total debt consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.352%;"/&gt;
        &lt;td style="width:1.516%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.131999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Long-term debt, current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Long-term debt, non-current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;104,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unamortized debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total debt, net of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;95,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <phat:LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_d00d6336-f5c4-4545-a539-85b4739d4723"
      unitRef="U_USD">104474000</phat:LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_4c0e1fc4-34dc-4e36-a82d-f27775f40d87"
      unitRef="U_USD">9210000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_d94ccd2c-d5b1-41eb-a929-3fc3b529d33a"
      unitRef="U_USD">95264000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_5376a47a-2a6e-4c10-a523-6c29d3b5be8d"
      decimals="-5"
      id="F_b69e852a-e7ed-475a-8e0e-f8487be818c8"
      unitRef="U_USD">200000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_70ed3e4f-7d42-4f15-94f8-e35d5e32239e"
      decimals="-5"
      id="F_ba779819-0121-4da7-9707-6dca833daa71"
      unitRef="U_USD">100000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_f3f07980-4a45-4835-8463-e1d119c8e5c1"
      decimals="-5"
      id="F_47ce03bd-a0ea-4346-86b7-0ea0f8de038f"
      unitRef="U_USD">50000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_91b73800-dbc6-43cf-9117-11565d545493"
      decimals="-5"
      id="F_8d32730c-f95d-4ba2-bd51-75c7fdfa2721"
      unitRef="U_USD">50000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_808be0ce-b254-4e5d-b14f-728aa82ef026"
      decimals="-6"
      id="F_56aff4d5-9e20-4694-9cdb-740760e9faca"
      unitRef="U_USD">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <phat:PaymentForFacilityCharge
      contextRef="C_8952b2b3-05be-4dbb-bb15-29a22754c147"
      decimals="-4"
      id="F_29e0326c-aa0b-46d2-884b-87cdaf96ce1d"
      unitRef="U_USD">1250000</phat:PaymentForFacilityCharge>
    <phat:DebtInstrumentFacilityChargePercentage
      contextRef="C_8952b2b3-05be-4dbb-bb15-29a22754c147"
      decimals="3"
      id="F_f1d30784-8b60-45a4-979d-a15149ac162a"
      unitRef="U_pure">0.005</phat:DebtInstrumentFacilityChargePercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_8952b2b3-05be-4dbb-bb15-29a22754c147"
      id="F_cd2e17bb-4c24-4e3b-9294-b7f26a64d800">2026-10-01</us-gaap:DebtInstrumentMaturityDate>
    <phat:DebtInstrumentInterestRatePercentage
      contextRef="C_4f067a4b-daf1-4028-b748-712e3b729620"
      decimals="4"
      id="F_9b8ae78c-b7f8-4e68-b9e7-2c47a9eb0564"
      unitRef="U_pure">0.0550</phat:DebtInstrumentInterestRatePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_d34ef88d-9f9b-4614-9c60-3fd356fe4846"
      decimals="4"
      id="F_c627c8de-08a3-41f1-b469-3659ffdffd08"
      unitRef="U_pure">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_2de0626c-2b10-4fe9-bbfd-1a4334ffe153"
      decimals="4"
      id="F_dcdc8048-02cb-497f-8818-6cff1fc73da7"
      unitRef="U_pure">0.0335</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <phat:DebtInstrumentFinalPaymentFeePercentage
      contextRef="C_0baa7388-d9e1-478c-86d2-1a3bfcdf4327"
      decimals="4"
      id="F_e1eae7c0-f46d-47c6-8b17-be6963cfb2bc"
      unitRef="U_pure">0.0750</phat:DebtInstrumentFinalPaymentFeePercentage>
    <phat:DebtInstrumentFinalPaymentFee
      contextRef="C_f20982d1-f9ce-4d58-8f02-7abadfb18a90"
      decimals="-5"
      id="F_e9403f82-3bc6-4606-bcd4-712371e3db09"
      unitRef="U_USD">7500000</phat:DebtInstrumentFinalPaymentFee>
    <phat:DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount
      contextRef="C_254b2caf-becb-447f-bfa2-61ac97d82407"
      decimals="4"
      id="F_8dbf6e5f-a350-432e-854b-c6c5e44cb03e"
      unitRef="U_pure">0.0125</phat:DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount>
    <phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone
      contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793"
      decimals="3"
      id="F_c4c49a05-6341-45b8-9576-26d3e4bd16ab"
      unitRef="U_pure">0.600</phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone>
    <phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone
      contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793"
      decimals="2"
      id="F_16b7ec00-e803-4a4e-b810-c437e63ae535"
      unitRef="U_pure">0.35</phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone>
    <phat:MinimumMarketCapitalizationAmount
      contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793"
      decimals="INF"
      id="F_bc85edd4-a76d-4475-a4a9-0fcb52dff088"
      unitRef="U_USD">900000000.0</phat:MinimumMarketCapitalizationAmount>
    <phat:PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock
      contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793"
      decimals="3"
      id="F_6d328868-7473-485c-87c2-8c30e9469484"
      unitRef="U_pure">0.025</phat:PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_3089a359-e1ec-4cf0-8d42-a935b7b8080d"
      decimals="INF"
      id="F_8459351d-49f6-4e92-bdf5-060139fe45c0"
      unitRef="U_shares">74782</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <phat:ClassOfWarrantOrRightExpireTerm
      contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793"
      id="F_2e1aa561-4134-4a84-9305-1521e2da3da5">P7Y</phat:ClassOfWarrantOrRightExpireTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0487172a-df33-4c7a-b44b-85c791ea9f49"
      decimals="2"
      id="F_e387e3fb-27e3-452e-b164-ad23544991fe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">33.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <phat:ClassOfWarrantOrRightExpirationDate
      contextRef="C_8e655aad-b411-4446-8d28-57f008fc0793"
      id="F_27ab064c-60d3-4799-b099-420c93a6c9ee">2028-09-17</phat:ClassOfWarrantOrRightExpirationDate>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_0487172a-df33-4c7a-b44b-85c791ea9f49"
      decimals="-5"
      id="F_ff930d1c-b826-47c5-ba0d-ff4e2ba6eb1b"
      unitRef="U_USD">1300000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_0487172a-df33-4c7a-b44b-85c791ea9f49"
      decimals="-5"
      id="F_d23a4142-74b4-47ef-888e-dda527315dcb"
      unitRef="U_USD">1300000</us-gaap:WarrantsAndRightsOutstanding>
    <phat:DebtInstrumentFinalPaymentFee
      contextRef="C_0487172a-df33-4c7a-b44b-85c791ea9f49"
      decimals="-5"
      id="F_658b9fac-ad8c-4967-943c-2863ecb4b6a6"
      unitRef="U_USD">7500000</phat:DebtInstrumentFinalPaymentFee>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_0487172a-df33-4c7a-b44b-85c791ea9f49"
      decimals="-5"
      id="F_eb9ecb4a-2509-4731-b490-c7cd0ccf78ae"
      unitRef="U_USD">3100000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_ecbaf961-9122-4bde-89b5-0611433eaecf">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Future minimum principal payments under the Term Loan, including the final payment fee, as of December 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:66.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.599%;"/&gt;
        &lt;td style="width:1.521%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.88%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;29,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;94,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total principal and interest payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;124,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less payment-in-kind and final payment fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;24,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total term loan borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_e78c8b6d-df0b-4937-b7c9-a83b11e92ab3"
      unitRef="U_USD">0</phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths>
    <phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_7b5f5bd4-f947-4f23-aa91-b3eaaff35efa"
      unitRef="U_USD">0</phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo>
    <phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_506483bd-fe45-4e4d-b997-31af47fa8b92"
      unitRef="U_USD">29707000</phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree>
    <phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_10af8233-8af5-4976-b1ef-21dfe20ea96e"
      unitRef="U_USD">94764000</phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour>
    <phat:LongTermDebtAndInterest
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_cd218baa-00cb-4ecf-b96e-afcb0c91c345"
      unitRef="U_USD">124471000</phat:LongTermDebtAndInterest>
    <phat:DebtInstrumentInterestAndFinalPaymentFee
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_c4c1f27d-b178-4696-8641-d262d5b134a8"
      unitRef="U_USD">24471000</phat:DebtInstrumentInterestAndFinalPaymentFee>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_b2689a84-d5ef-4463-8fc7-aa4ff787ae95"
      unitRef="U_USD">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_2d98949a-30e1-4a98-8bd5-692271892f22"
      decimals="-5"
      id="F_02cdb2d0-427a-47ab-a647-3ad6886d805d"
      unitRef="U_USD">54300000</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_f4d64b0f-a1db-4cfd-9a23-da10238263c0"
      decimals="-5"
      id="F_f2d4ef9d-8678-441d-9e04-810cf33549de"
      unitRef="U_USD">13000000.0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_9960ff79-ef61-47f2-b12d-b0b42bd290e2"
      decimals="-5"
      id="F_fdc2b883-ec92-4d06-aa8e-699958a556c6"
      unitRef="U_USD">6800000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_fc2a8230-0abf-4380-a0cf-1aee92ac8c64"
      decimals="-5"
      id="F_b6378123-2385-4ba8-ab76-e312173ca2bc"
      unitRef="U_USD">104500000</us-gaap:DebtInstrumentCarryingAmount>
    <phat:AccruedInterest
      contextRef="C_fc2a8230-0abf-4380-a0cf-1aee92ac8c64"
      decimals="-5"
      id="F_65b97414-1888-4754-8e8f-5a58271934c0"
      unitRef="U_USD">900000</phat:AccruedInterest>
    <phat:RevenueInterestFinancingLiabilityTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_516b0ae9-88b9-4051-9d74-c54336915171">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7. Revenue Interest Financing Liability&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;On May 3, 2022, Phathom entered into a Revenue Interest Financing Agreement with Initial Investors NQ, Sagard, and Hercules pursuant to which the Company will receive up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;260&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in funding from the Initial Investors. Under the terms of the Revenue Interest Financing Agreement, the Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million at the initial closing and can receive an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;160&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million upon FDA approval of vonoprazan for treatment of erosive GERD on or before March 31, 2024. At any time prior to December 31, 2022, the Company also has the right to obtain a written commitment from a third party for up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of funding upon FDA approval of vonoprazan for erosive GERD. In addition, the Company has the right at any time prior to June 30, 2024, to obtain a written commitment from a third party for up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of funding upon achievement of a sales milestone. The Initial Investors have a right of first offer if the Company seeks to obtain such additional funding. The total amount funded by the Initial Investors and any subsequent investors is referred to herein as the Investment Amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;On October 31, 2022, the Company entered into a Joinder Agreement with the Initial Investors and CO Finance LVS XXXVII LLC (&#x201c;the Additional Investor&#x201d;), and Hercules Capital, Inc. Under the terms of the Joinder Agreement, the Initial Investors waived their rights of first offer regarding the Additional Investor Funding and the Additional Investor joined the Revenue Interest Financing Agreement to extend commitments for the Additional Investor Funding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Under the Revenue Interest Financing Agreement, the investors are entitled to receive a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% royalty on net sales of products containing vonoprazan. The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and if the Company receives FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with non-erosive GERD. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The investors&#x2019; right to receive royalties on net sales will terminate when the investors have aggregate payments equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for erosive GERD regulatory approval is made, the Company has the right to make a cap payment equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;If the investors have not received aggregate payments of at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the Investment Amount by December 31, 2028, and at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Upon the occurrence of an event of default taking place prior to April 1, 2025, between April 1, 2025, and April 1, 2028, and after April 1, 2028, the Company is obligated to pay &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; times Investment Amount, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; times Investment Amount, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Upon the occurrence of a change in control event taking place prior to the earlier of April 1, 2024, or FDA approval of vonoprazan for erosive GERD, the Company is obligated to pay &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the Investment Amount plus either &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the Investment Amount if occurrence prior to May 3, 2023, or plus &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the Investment Amount if occurrence thereafter.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the year ended December 31, 2022, the Company received gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million before deducting transaction costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, which resulted in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;95.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has evaluated the terms of the Revenue Interest Financing Agreement and concluded that the features of the Investment Amount are similar to those of a debt instrument. Accordingly, the Company has accounted for the transaction as a debt obligation with interest expense based on an imputed effective rate derived from the initial carrying value of the obligation and the expected future payments. The Company recalculates the effective interest rate each period based on the current carrying value and the revised estimated future payments. Changes in future payments from previous estimates are included in the current and future financing expense. The carrying value of the revenue interest financing liability was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;109.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million as of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total revenue interest financing liability consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.164%;"/&gt;
        &lt;td style="width:1.726%;"/&gt;
        &lt;td style="width:17.569%;"/&gt;
        &lt;td style="width:1.54%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Beginning liability balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Proceeds from the Revenue Interest Financing Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: royalty payments and payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Plus: interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;14,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Ending liability balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;109,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the year ended December 31, 2022, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of interest expense in connection with the revenue interest financing liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company will record liabilities associated with additional funding upon FDA approval of vonoprazan for erosive GERD and achievement of the sales milestone when such contingent events occur. To determine the accretion of the liability related to the Revenue Interest Financing Agreement, the Company is required to estimate the total amount of future royalty payments and estimated timing of such payments based on the Company&#x2019;s revenue projections. As royalty payments are made, the balance of the debt obligation will be effectively repaid. Based on the Company&#x2019;s periodic review, the exact timing of repayment is likely to be different in each reporting period as compared to those estimated in the Company&#x2019;s initial revenue projections. A significant increase or decrease in actual net sales of vonoprazan compared to the Company&#x2019;s revenue projections could impact the interest expense associated with the revenue interest financing liability. Also, the Company&#x2019;s total obligation can vary depending on change in control or default events and the achievement of FDA approval of vonoprazan for erosive GERD and achievement of the sales milestone.&lt;/span&gt;&lt;/p&gt;</phat:RevenueInterestFinancingLiabilityTextBlock>
    <phat:InvestorsFundingAmount
      contextRef="C_f3416de9-775d-4af4-b997-f1e2dce25917"
      decimals="-6"
      id="F_648b3630-035e-4941-8b9b-21606c86d36d"
      unitRef="U_USD">260000000</phat:InvestorsFundingAmount>
    <phat:FundsReceivedFromInitialClosing
      contextRef="C_29dfdd85-afb5-4d2f-a86b-48a3fd158ccc"
      decimals="-6"
      id="F_2c622098-5b99-4390-bbcc-bc0254fce54a"
      unitRef="U_USD">100000000</phat:FundsReceivedFromInitialClosing>
    <phat:InvestorAdditionalFundingAmountUponApproval
      contextRef="C_161d27a8-0c36-4e47-af8a-c85124a58e31"
      decimals="-6"
      id="F_a771fdf7-16f8-4cb2-87b6-071e6fd1f237"
      unitRef="U_USD">160000000</phat:InvestorAdditionalFundingAmountUponApproval>
    <phat:PotentialAdditionalInvestorFundingAmount
      contextRef="C_d5734daa-3179-4da2-9c0d-ec26dd01ffa7"
      decimals="-6"
      id="F_2a51aecf-8c68-46d5-ac1f-c85f7b1ffb57"
      unitRef="U_USD">15000000</phat:PotentialAdditionalInvestorFundingAmount>
    <phat:InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone
      contextRef="C_2769f622-b2f5-4b1e-9bfc-9d6f83d30fcd"
      decimals="-6"
      id="F_a8acb31a-b563-487e-8702-e5832dab96d3"
      unitRef="U_USD">25000000</phat:InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone>
    <phat:PercentageOfInvestorShareOfRoyaltyInNetSales
      contextRef="C_d02c08d8-d888-4a97-a17b-d64dc2a21728"
      decimals="2"
      id="F_6751b150-0c5b-4ddc-9ad3-aba79955ea75"
      unitRef="U_pure">0.10</phat:PercentageOfInvestorShareOfRoyaltyInNetSales>
    <phat:InvestorsRightToReceiveRoyaltiesTerminationDescription
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_70cfee9e-32c6-4315-a488-92d731df594d">The investors&#x2019; right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for erosive GERD regulatory approval is made, the Company has the right to make a cap payment equal to 200% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.</phat:InvestorsRightToReceiveRoyaltiesTerminationDescription>
    <phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales
      contextRef="C_5943d02e-5414-489b-b249-8e8202898837"
      decimals="2"
      id="F_ae44aae7-edc4-4c95-9998-17efd5e31c6f"
      unitRef="U_pure">2</phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales>
    <phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales
      contextRef="C_5943d02e-5414-489b-b249-8e8202898837"
      decimals="2"
      id="F_3ed28baf-9845-483f-87a0-7e4620365085"
      unitRef="U_pure">2</phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales>
    <phat:InvestorsReceiptDescription
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_bbac96f8-6d4c-44f1-9095-c348ebfd3cf9">If the investors have not received aggregate payments of at least 100% of the Investment Amount by December 31, 2028, and at least 200% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.</phat:InvestorsReceiptDescription>
    <phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors
      contextRef="C_c1fa0f90-b682-4d91-b3c5-62f796e1a9cd"
      decimals="2"
      id="F_4344b90c-e7ee-4289-b896-8bda40b03dd3"
      unitRef="U_pure">1</phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors>
    <phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors
      contextRef="C_6e83352c-1021-49ea-be17-abda53fad0d3"
      decimals="2"
      id="F_0cbce535-f957-411e-b53f-59f53e349d94"
      unitRef="U_pure">2</phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors>
    <phat:DefaultObligationDescription
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_7eaac107-3258-44d8-ac64-2cc04dc89752">Upon the occurrence of an event of default taking place prior to April 1, 2025, between April 1, 2025, and April 1, 2028, and after April 1, 2028, the Company is obligated to pay 1.30 times Investment Amount, 1.65 times Investment Amount, and 2.0 times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement. </phat:DefaultObligationDescription>
    <phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors
      contextRef="C_4b9e40bc-f2d9-4495-a973-c2657257e971"
      decimals="4"
      id="F_6cf3d37d-5abf-46c4-8f7e-f9db088349de"
      unitRef="U_pure">0.0130</phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors>
    <phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors
      contextRef="C_a456270a-d53b-42d3-8702-a89087e2879e"
      decimals="4"
      id="F_feccade3-818c-4ae7-8f3b-f023afbe1dba"
      unitRef="U_pure">0.0165</phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors>
    <phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales
      contextRef="C_1fffdef7-2c4e-4f8c-a14d-47e0a16bf641"
      decimals="3"
      id="F_3ef9ae2f-70e8-4778-b654-1ea9c8935b29"
      unitRef="U_pure">0.020</phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales>
    <phat:ChangeInControlDescription
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_77de78aa-7f68-481e-96aa-1961ccbe6e60">Upon the occurrence of a change in control event taking place prior to the earlier of April 1, 2024, or FDA approval of vonoprazan for erosive GERD, the Company is obligated to pay 200% of the Investment Amount plus either 15% of the Investment Amount if occurrence prior to May 3, 2023, or plus 30% of the Investment Amount if occurrence thereafter.</phat:ChangeInControlDescription>
    <phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales
      contextRef="C_a7d27a7b-55b4-4782-b9ee-1496eed56e8e"
      decimals="2"
      id="F_7369c31e-2ec3-46ce-a93e-81d2fbda0f29"
      unitRef="U_pure">2</phat:PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales>
    <phat:AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount
      contextRef="C_bd528633-09ca-45e1-a4f8-8be7636e9b54"
      decimals="2"
      id="F_b339bda5-79a8-4362-8384-63b5b8f7909b"
      unitRef="U_pure">0.15</phat:AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount>
    <phat:AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount
      contextRef="C_e81a5d21-6780-4696-8613-7d86dd579083"
      decimals="2"
      id="F_f9f993bf-5fc1-4777-bade-63bc2a4c519c"
      unitRef="U_pure">0.30</phat:AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount>
    <phat:GrossProceedsFromRevenueInterestFinancingAgreement
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-5"
      id="F_20e8c292-7a80-41b7-8ad7-028d9ebe8a0d"
      unitRef="U_USD">100000000.0</phat:GrossProceedsFromRevenueInterestFinancingAgreement>
    <phat:PaymentOfTransactionCosts
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-5"
      id="F_4b23c50f-2ffb-4392-9a9f-3fe206999bb8"
      unitRef="U_USD">4600000</phat:PaymentOfTransactionCosts>
    <phat:NetProceedsFromRevenueInterestFinancingTransaction
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-5"
      id="F_d02c978a-1fa7-486c-9548-fdc5461fc288"
      unitRef="U_USD">95400000</phat:NetProceedsFromRevenueInterestFinancingTransaction>
    <phat:RevenueInterestFinancingLiability
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-5"
      id="F_a8c3661e-d73e-4097-8f52-88c7905662ac"
      unitRef="U_USD">109500000</phat:RevenueInterestFinancingLiability>
    <phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_6662d588-f5aa-4eb7-9060-863abd4b1c53">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total revenue interest financing liability consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.164%;"/&gt;
        &lt;td style="width:1.726%;"/&gt;
        &lt;td style="width:17.569%;"/&gt;
        &lt;td style="width:1.54%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Beginning liability balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Proceeds from the Revenue Interest Financing Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: royalty payments and payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Plus: interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;14,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Ending liability balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;109,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock>
    <phat:GrossProceedsFromRevenueInterestFinancingAgreement
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_61715334-9810-4dee-9473-81a5706859ed"
      unitRef="U_USD">100000000</phat:GrossProceedsFromRevenueInterestFinancingAgreement>
    <phat:PaymentOfTransactionCosts
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_e50fe814-74dd-4c0f-bd8b-82b7a4cd8e73"
      unitRef="U_USD">4554000</phat:PaymentOfTransactionCosts>
    <phat:InterestExpenseRelatedToRevenueInterestFinancingLiability
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_49d204cf-8b58-4368-9a46-2b023c199f41"
      unitRef="U_USD">14079000</phat:InterestExpenseRelatedToRevenueInterestFinancingLiability>
    <phat:RevenueInterestFinancingLiability
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_b927baf5-3ef1-4c49-a3b9-8c777bfac02f"
      unitRef="U_USD">109525000</phat:RevenueInterestFinancingLiability>
    <phat:InterestExpenseRelatedToRevenueInterestFinancingLiability
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-5"
      id="F_e068a79c-552e-4b00-8ccc-797498f9091d"
      unitRef="U_USD">14100000</phat:InterestExpenseRelatedToRevenueInterestFinancingLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_6cc1f1a5-fc96-4a8d-a0db-634c5720ead9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8. Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In March 2019, subsequent to the Merger, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,491,072&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock to Frazier.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In March 2019, the founders granted the Company a repurchase right for the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,373,408&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock originally purchased in 2018. The Company has the right, but not the obligation, to repurchase unvested shares in the event the founder&#x2019;s relationship with the Company is terminated, subject to certain limitations, at the original purchase price of the stock. The repurchase right lapsed for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;843,352&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares in March 2019 and the repurchase right for the remaining &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,530,056&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares lapses in equal monthly amounts over the following &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;48-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; period ending in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;March 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. The fair value of the founder shares at the date the repurchase right was granted is being recognized as stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;79,064&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock were subject to repurchase by the Company and the associated repurchase liability was not significant. The amount of recognized and unrecognized stock-based compensation related to the founder stock was immaterial for all periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In May 2019, the Company issued Takeda &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,084,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock in connection with the Takeda License.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;For the period from January 1, 2019 to May 6, 2019, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,524,852&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock to various employees and consultants of the Company for aggregate proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. Upon issuance, these shares were subject to a repurchase option by the Company at the original purchase price of the shares. The repurchase rights generally lapse as to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the shares on the first anniversary of the vesting commencement date, and the repurchase right lapses as to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_2b850787-a6cf-4d02-9e61-c00a1a4fa91d;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1/48&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;th of the shares each one-month period thereafter, subject to the purchaser remaining continuously an employee, consultant or director of the Company. In November 2019, the Company repurchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;17,560&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares at the original purchase price for an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;175,373&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares remain available for repurchase by the Company and the associated repurchase liability was not significant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;On October 29, 2019, upon completion of the IPO, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,997,630&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock, which included the exercise in full by the underwriters of their option to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,434,473&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; additional shares at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;19.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share. The net proceeds were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;191.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, after deducting underwriting discounts, commissions and offering costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In November 2020, the Company entered into an Open Market Sale Agreement, or, the Sales Agreement, with Jefferies LLC, or, the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million through the Sales Agent, or, the ATM Offering. Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the gross sales price per share sold. In September 2022, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,414,897&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;24.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million under the ATM offering after deducting $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of issuance costs. As of December 31, 2022, the Company has utilized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;25.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of the available $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million under the ATM Offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;On December 16, 2020, the Company completed an underwritten public offering, in which it sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;42.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share for total gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;94.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. The net purchase price after deducting underwriting discounts and commissions was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;39.48&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share, which generated net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;88.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. The Company incurred an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of offering expenses in connection with this public offering.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;A summary of the Company&#x2019;s unvested shares is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:64.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.08%;"/&gt;
        &lt;td style="width:1.553%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.368%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,144,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Share vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;890,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;254,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;For accounting purposes, unvested awards are considered issued, but not outstanding until they vest.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Common stock reserved for future issuance consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.051%;"/&gt;
        &lt;td style="width:1.594%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.355%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;91,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock options and performance-based awards outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,876,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shares available for issuance under the 2019 Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;957,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shares available for issuance under the ESPP Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;752,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,678,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company is authorized to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million shares of preferred stock. As of December 31, 2022, and December 31, 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of preferred stock issued or outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Equity Incentive Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s 2019 Equity Incentive Plan, or the Existing Incentive Plan, provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards to eligible recipients, including employees, directors or consultants of the Company. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,231,739&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock authorized for issuance under the Existing Incentive Plan, of which, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,400,528&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; stock options and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;16,260&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; restricted stock awards were granted in 2019. As a result of the adoption of the 2019 Incentive Award Plan, or the 2019 Plan, in October 2019, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; further shares are available for issuance under the Existing Incentive Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In October 2019, the board of directors adopted, and the Company&#x2019;s stockholders approved, the 2019 Plan, which became effective in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above or equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,416,788&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;957,885&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares remain available for issuance, which reflects &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,789,868&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; stock options and performance-based units, or PSU, and restricted stock unit, or RSU, awards granted, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;392,207&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; of awards cancelled or forfeited, during the year ended December 31, 2022 as well as an &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;annual increases of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,582,802&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares authorized on January 1, 2022. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Performance-based Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;During 2020, the Company granted the initial PSUs whereby vesting depends upon the approval by the FDA of vonoprazan for &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;H. pylori&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; and then, or concurrent with, erosive GERD. In 2022, the Company granted an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;37,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; PSUs to employees. As of December 31, 2022, the PSU milestones had not been achieved. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; related compensation cost had been recognized. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.961%;"/&gt;
        &lt;td style="width:1.494%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.59%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.494%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.462%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;394,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;32.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;37,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;19,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;35.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;412,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;30.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022 there was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;12.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of related unrecognized compensation cost, which will be recognized upon vesting.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;During 2022, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,010,437&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; RSUs with vesting over time. The following table summarizes RSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.366%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:14.524%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:1.56%;"/&gt;
        &lt;td style="width:14.524%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,010,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;102,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;30,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;12.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;877,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;11.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In October 2019, the board of directors adopted, and the Company&#x2019;s stockholders approved, the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of their eligible compensation, which includes a participant&#x2019;s gross base compensation for services to the Company, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;270,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock was initially reserved for issuance under the ESPP. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;752,938&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock remain available for issuance, which reflects &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;89,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares sold to employees during the year ended December 31, 2022. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The ESPP is considered a compensatory plan, and the Company recorded related stock-based compensation of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.081%;"/&gt;
        &lt;td style="width:1.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.076%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.090999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Assumptions:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.69&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;68.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;76.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The estimated weighted-average fair value of ESPP awards during 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.98&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.66&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;, respectively. As of December 31, 2022, the total unrecognized compensation expense related to the ESPP was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;31,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;, which is expected to be recognized over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;401(k) Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company established a 401(k) savings plan during the year ended December 31, 2020. The Company&#x2019;s contributions to the plan are discretionary. During the years ended December 31, 2022 and December 31, 2021, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, of expense related to estimated employer contribution liabilities, which was based on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;% match of employees&#x2019; contributions during the periods. In August 2021, the Board of Directors approved a semi-annual discretionary match for 2021, which was settled by contributing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,394&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares. In January 2022, the Board of Directors approved a second semi-annual discretionary match for 2021, which was settled by contributing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;16,756&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares. In July 2022, the Board of Directors approved a semi-annual match for 2022, which was settled by contributing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;84,784&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company, prior to the IPO on October 29, 2019, was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected volatility based on the historical volatility of a publicly-traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company&#x2019;s stock options for employees was determined utilizing the &#x201c;simplified&#x201d; method for awards. The expected term of stock options granted to non-employees was equal to the contractual term of the option award. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;A summary of the Company&#x2019;s stock option activity and related information is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.033%;"/&gt;
        &lt;td style="width:0.725%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.727%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.544%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.243%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.742%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.715%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.742%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.528%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,186,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;27.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;13,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,741,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;342,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;29.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,586,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;23.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options exercisable as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,455,735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;25.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.18&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The estimated weighted-average fair value of employee and nonemployee director stock options granted during 2022 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; per option. As of December 31, 2022, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;37.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.06%;"/&gt;
        &lt;td style="width:1.057%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.405%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.072%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.405%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Assumptions:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.88&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;66.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;67.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.164%;"/&gt;
        &lt;td style="width:1.54%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.879%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.54%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.879%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;24,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;16,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b0784f7e-b027-403a-a3cd-28ff1f784844"
      decimals="INF"
      id="F_4cd589f4-755e-4ded-a117-ff3a037aab7b"
      unitRef="U_shares">1491072</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_92b2fe60-4ace-4d6c-acc6-c79dfb6818d9"
      decimals="INF"
      id="F_419ebcca-39e5-47f7-a4e5-0050b0222101"
      unitRef="U_shares">3373408</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <phat:StockRepurchaseProgramNumberOfSharesRightLapse
      contextRef="C_92b2fe60-4ace-4d6c-acc6-c79dfb6818d9"
      decimals="INF"
      id="F_747228a3-019b-4d48-8610-d7054e10998c"
      unitRef="U_shares">843352</phat:StockRepurchaseProgramNumberOfSharesRightLapse>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_92b2fe60-4ace-4d6c-acc6-c79dfb6818d9"
      decimals="INF"
      id="F_bc28b741-802f-41c1-9669-f850b045187b"
      unitRef="U_shares">2530056</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="C_3b18d59c-b688-4dad-a3c3-0feef824fd50"
      id="F_b193db3a-3d0a-4cb1-97a9-81c52bbee9ae">P48M</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <phat:StockRepurchaseProgramExpirationMonthAndYear
      contextRef="C_3b18d59c-b688-4dad-a3c3-0feef824fd50"
      id="F_ba0fce1c-c05a-45fd-887b-81361e33e192">2023-03</phat:StockRepurchaseProgramExpirationMonthAndYear>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_a8157197-9c77-483d-a07b-d1d03a212eab"
      decimals="INF"
      id="F_e40512a0-4675-4660-96ef-17b6e01aa3fb"
      unitRef="U_shares">79064</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9864647f-dae0-400c-981a-2e1ad206fde6"
      decimals="INF"
      id="F_9059593a-5662-49f5-887d-94c3e4641b4d"
      unitRef="U_shares">1084000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_778accf5-7d44-4bf3-a402-bbbaf11a7645"
      decimals="INF"
      id="F_2860fe35-22fd-47f4-a80e-5bd787e2ad38"
      unitRef="U_shares">2524852</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_778accf5-7d44-4bf3-a402-bbbaf11a7645"
      decimals="0"
      id="F_ee496846-fc23-49cb-b121-61384d198d7e"
      unitRef="U_USD">1000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <phat:RepurchaseRightLapseRate
      contextRef="C_9cddf29a-b8e2-483a-a1a6-cb58b2eba169"
      decimals="2"
      id="F_cbf6fcad-937c-4375-ae96-53808b37837d"
      unitRef="U_pure">0.25</phat:RepurchaseRightLapseRate>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_9d4560ac-5448-4f06-a2c0-c13d0498a9d1"
      decimals="INF"
      id="F_7ebc9597-daaa-4447-9f71-577114abb6ba"
      unitRef="U_shares">17560</us-gaap:StockRepurchasedDuringPeriodShares>
    <phat:SharesAggregateRepurchasePrice
      contextRef="C_74c344c6-6814-4821-8338-28c9c0250e05"
      decimals="2"
      id="F_ec1422d4-80e9-4310-8a6b-230f0bfd9e2b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.20</phat:SharesAggregateRepurchasePrice>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_28e002f0-fa91-457e-80d6-bc784dddc517"
      decimals="INF"
      id="F_be774f5c-0e53-4274-8f15-9a4557ea1ad6"
      unitRef="U_shares">175373</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f71a8436-7cab-4cb1-a0b4-4ed9b66f0382"
      decimals="INF"
      id="F_bda7e0a2-88aa-4f33-8a11-704ce23ec0b5"
      unitRef="U_shares">10997630</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ff181df1-43b0-434d-b3db-83c48fa28c00"
      decimals="INF"
      id="F_c954a861-6d8b-491c-855c-cd598b61d762"
      unitRef="U_shares">1434473</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_55b184ca-7a41-480d-a822-5e3317a65984"
      decimals="INF"
      id="F_2e32bbc5-e0e8-4f31-9636-ad5ce3681143"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_f71a8436-7cab-4cb1-a0b4-4ed9b66f0382"
      decimals="-5"
      id="F_fba7e658-a252-4047-af57-432f3681ad70"
      unitRef="U_USD">191500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <phat:AggregateOfferingPriceThroughEquityFinancing
      contextRef="C_9a0f9f10-e984-46bf-897d-9ef4dd6e2854"
      decimals="-5"
      id="F_00443348-19db-43a1-a8e2-710fe735d9b4"
      unitRef="U_USD">125000000.0</phat:AggregateOfferingPriceThroughEquityFinancing>
    <phat:SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare
      contextRef="C_f484751c-237f-4a58-8796-c8018a28b609"
      decimals="2"
      id="F_3112f6f0-206a-4e70-a74d-951900827852"
      unitRef="U_pure">0.03</phat:SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5"
      decimals="INF"
      id="F_3455aae1-6c42-48fd-9103-f25f03620050"
      unitRef="U_shares">2414897</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5"
      decimals="-5"
      id="F_a329e586-0bd9-47bf-ad39-19a561323d2c"
      unitRef="U_USD">24600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5"
      decimals="-5"
      id="F_d0a1e056-6bf5-4237-800e-2ac6430efb05"
      unitRef="U_USD">800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <phat:AmountUtilizedOfEquityFinancing
      contextRef="C_16374c27-e9d9-4deb-990b-aa5e9aac1074"
      decimals="-5"
      id="F_b4b3bec8-185c-4153-8452-8c5e8f1e9047"
      unitRef="U_USD">25400000</phat:AmountUtilizedOfEquityFinancing>
    <phat:AvailableAggregateOfferingPriceThroughEquityFinancing
      contextRef="C_16374c27-e9d9-4deb-990b-aa5e9aac1074"
      decimals="-5"
      id="F_bb9bf883-4f19-4664-8d1e-75aadea1a845"
      unitRef="U_USD">125000000.0</phat:AvailableAggregateOfferingPriceThroughEquityFinancing>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b02900cd-2272-4953-b251-9b37853719fc"
      decimals="INF"
      id="F_d6d032a3-ac4b-4dc2-ac02-e09cd28e27df"
      unitRef="U_shares">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_b629611d-f479-44c6-9f1c-cdfdf6c74fcc"
      decimals="2"
      id="F_cca98fec-2bb8-4016-ba94-8d8f7f0ee105"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">42.00</us-gaap:SaleOfStockPricePerShare>
    <phat:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="C_b02900cd-2272-4953-b251-9b37853719fc"
      decimals="-5"
      id="F_20505fea-0e48-48de-bee5-924336b8206a"
      unitRef="U_USD">94500000</phat:ProceedsFromIssuanceInitialPublicOfferingGross>
    <phat:SharesIssuedPricePerShareAfterDeductions
      contextRef="C_b629611d-f479-44c6-9f1c-cdfdf6c74fcc"
      decimals="2"
      id="F_5fbd1be8-03c5-420f-acaa-385d298ef63e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">39.48</phat:SharesIssuedPricePerShareAfterDeductions>
    <phat:NetProceedsAfterDeductingUnderwritersCommission
      contextRef="C_b02900cd-2272-4953-b251-9b37853719fc"
      decimals="-5"
      id="F_5b4ff124-7180-495c-9f69-a26be9ae49a8"
      unitRef="U_USD">88800000</phat:NetProceedsAfterDeductingUnderwritersCommission>
    <phat:PurchaseOfAdditionalOfferingExpenses
      contextRef="C_b02900cd-2272-4953-b251-9b37853719fc"
      decimals="-5"
      id="F_f9ad617f-978a-42dc-8733-d5d933989a08"
      unitRef="U_USD">200000</phat:PurchaseOfAdditionalOfferingExpenses>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_36527f87-2555-4dae-9e0d-5dc321e00fe1">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;A summary of the Company&#x2019;s unvested shares is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:64.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.08%;"/&gt;
        &lt;td style="width:1.553%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.368%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,144,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Share vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;890,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;254,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_9424c5d3-0342-4bad-b3b9-bb1d150b1d14"
      unitRef="U_shares">1144809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="INF"
      id="F_0284068e-b171-40a5-98b6-9c14912b0d43"
      unitRef="U_shares">890372</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_9d0ceae6-ebbb-4b49-a187-51259a0f10d7"
      unitRef="U_shares">254437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <phat:CommonStockReservedForFutureIssuancesTableTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_593471ba-a3d6-4388-a3ee-a44e5ca7b0af">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Common stock reserved for future issuance consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.051%;"/&gt;
        &lt;td style="width:1.594%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.355%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;91,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock options and performance-based awards outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,876,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shares available for issuance under the 2019 Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;957,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shares available for issuance under the ESPP Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;752,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,678,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</phat:CommonStockReservedForFutureIssuancesTableTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e9f3b61c-edfe-4524-8536-373c8a65e8a7"
      decimals="INF"
      id="F_c9edaf0a-8dcd-487b-9622-ba186820eeda"
      unitRef="U_shares">91228</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ab5a798d-ceb3-45b5-9852-43c7c13434c9"
      decimals="INF"
      id="F_e56bde73-4c2a-4b18-8922-606170d4ba36"
      unitRef="U_shares">6876237</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b41ac6a5-4e17-4e1f-8bae-c1f1f8f391c8"
      decimals="INF"
      id="F_923130fc-9e2b-4cc8-a989-9b02bc560f69"
      unitRef="U_shares">957885</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a9286bf5-ac0b-46f5-a136-ec84fcb2ae44"
      decimals="INF"
      id="F_cc4374d1-6ff5-44ae-8644-cac7c014c126"
      unitRef="U_shares">752938</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_9200e7cf-8e38-4126-bb86-15896ef0f003"
      unitRef="U_shares">8678288</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_52a4464e-8df8-4fdc-a926-f58da29e2f02"
      unitRef="U_shares">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_6de74bb4-4f9a-49fc-9039-d9dcf946b541"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_7446cc8e-3a7e-4864-9f06-e4021837c332"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_5b5d3cfc-7761-4d98-8dfc-5bdb574476b4"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_b272c267-804b-4ee3-97f2-5708e7209eda"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_85e62724-a4f3-446d-a80e-ee240301cda0"
      decimals="INF"
      id="F_46212042-b182-4652-ae84-922663762c47"
      unitRef="U_shares">2231739</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_9b8aa030-2775-49eb-a555-98fc9d14d1bf"
      decimals="INF"
      id="F_654c6572-30cf-4628-8335-c92ba1fe7a83"
      unitRef="U_shares">1400528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_eb899363-81cb-4d24-aa66-4956be36544e"
      decimals="INF"
      id="F_872ca575-1838-4196-b05e-3eaba9e45caf"
      unitRef="U_shares">16260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_ef56eeb8-d434-4c33-8a0e-a4c074a8edd9"
      decimals="INF"
      id="F_067d5f48-b170-484f-84b8-8b79418aff92"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_2ded604e-c94b-436f-a89c-9b03fda0e603"
      id="F_44cb4af4-3a7b-4d6e-8a5e-1e671ce01839">The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above or equal to 1,416,788 shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. As of December 31, 2022, 957,885 shares remain available for issuance, which reflects 2,789,868 stock options and performance-based units, or PSU, and restricted stock unit, or RSU, awards granted, and 392,207 of awards cancelled or forfeited, during the year ended December 31, 2022 as well as an annual increases of 1,582,802 shares authorized on January 1, 2022. </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_e2b4f91b-545a-498d-a89e-550afedc7031"
      decimals="INF"
      id="F_87b422b6-35e3-4873-ba0e-c79ee0b05149"
      unitRef="U_shares">1416788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_537af902-fc9d-4888-8d37-6ee0bf5d7d50"
      decimals="INF"
      id="F_08297c95-b0ce-417a-8c6b-c8bdcb08f4da"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b41ac6a5-4e17-4e1f-8bae-c1f1f8f391c8"
      decimals="INF"
      id="F_418c905a-0818-456b-aaf2-0fd9910d7a29"
      unitRef="U_shares">957885</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross
      contextRef="C_f292b92d-3d3f-4b55-9f26-2611aa4dd13c"
      decimals="INF"
      id="F_3fe671b8-de9c-4686-bb01-39ae938ee965"
      unitRef="U_shares">2789868</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_f292b92d-3d3f-4b55-9f26-2611aa4dd13c"
      decimals="INF"
      id="F_e989e09c-2c7f-46a8-9cad-49b2d76c8fc9"
      unitRef="U_shares">392207</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease
      contextRef="C_ef443912-c72b-4729-a5ae-6e27ef16ba5a"
      decimals="INF"
      id="F_58137dc4-12ac-4582-87bf-c91d95581859"
      unitRef="U_shares">1582802</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641"
      decimals="INF"
      id="F_b8b1c286-94a4-420a-8c70-4685f85743cf"
      unitRef="U_shares">37500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641"
      decimals="INF"
      id="F_bcf3cf13-ad80-48ee-8add-262af5800826"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_20105b14-f2e8-4a17-baf5-bce675fff2ab">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2022.&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.961%;"/&gt;
        &lt;td style="width:1.494%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.59%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.494%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.462%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;394,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;32.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;37,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;19,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;35.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;412,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;30.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_99f14810-3a35-4382-9ab0-3938fb54794d"
      decimals="INF"
      id="F_7784eb0b-891c-4d41-befb-f44e8848d37d"
      unitRef="U_shares">394300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_99f14810-3a35-4382-9ab0-3938fb54794d"
      decimals="2"
      id="F_f19110e7-195b-4e25-ac00-f8be119df280"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">32.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641"
      decimals="INF"
      id="F_d4bfafbd-199a-4c96-b55f-a68c939e7c46"
      unitRef="U_shares">37500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641"
      decimals="2"
      id="F_8ffb362d-10d0-4094-8d19-94493d18e17d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641"
      decimals="INF"
      id="F_470efda2-41ac-450d-85ac-96b10d4d0d63"
      unitRef="U_shares">19500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641"
      decimals="2"
      id="F_f6cab501-26fc-412f-8345-8db23af76c55"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">35.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_6d1f03d4-1220-447c-ab69-93821c543913"
      decimals="INF"
      id="F_825a8023-1bef-4d91-a164-65aeee643d7d"
      unitRef="U_shares">412300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_6d1f03d4-1220-447c-ab69-93821c543913"
      decimals="2"
      id="F_8588a272-80d1-4f49-9bd9-52ef9ba98c38"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">30.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_6d1f03d4-1220-447c-ab69-93821c543913"
      decimals="-5"
      id="F_ff1aa5cd-76a3-46a3-bfa9-b246c8d62c36"
      unitRef="U_USD">12800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="C_5d67cf6e-bd93-4d42-8971-522a9d32c0c8"
      id="F_589a488a-6ad7-488a-a04a-8b3f337855d5">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;During 2022, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,010,437&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; RSUs with vesting over time. The following table summarizes RSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.366%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:14.524%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:1.56%;"/&gt;
        &lt;td style="width:14.524%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,010,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;102,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;30,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;12.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;877,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;11.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_c25918b9-523a-4430-8c67-527934999f5c"
      decimals="0"
      id="F_976c3858-7b5d-4aec-878f-1846caad24ce"
      unitRef="U_shares">1010437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_25cca5a5-3215-4f01-9b29-0229a260c11b"
      decimals="INF"
      id="F_fba60a0a-322e-41b1-94cb-559bbacf3092"
      unitRef="U_shares">1010437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c25918b9-523a-4430-8c67-527934999f5c"
      decimals="2"
      id="F_4dc10a72-4601-4479-a4a3-5292d62ff8b6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_c25918b9-523a-4430-8c67-527934999f5c"
      decimals="INF"
      id="F_c3a3eeec-f82c-4d3f-ab95-bf6a9b12e311"
      unitRef="U_shares">102453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c25918b9-523a-4430-8c67-527934999f5c"
      decimals="2"
      id="F_809d1e30-37ee-49fa-9fc8-acf3b88b019d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_c25918b9-523a-4430-8c67-527934999f5c"
      decimals="INF"
      id="F_509e048c-6edc-44f2-a67f-55dc197c7dd9"
      unitRef="U_shares">30517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_c25918b9-523a-4430-8c67-527934999f5c"
      decimals="2"
      id="F_1a950cff-1d1c-4bed-80bb-985c3d5d7b6a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_71d680e8-6689-4309-bb74-70d6d934372b"
      decimals="INF"
      id="F_a470382b-2ed9-4fdc-8c10-11376f79d28f"
      unitRef="U_shares">877467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_71d680e8-6689-4309-bb74-70d6d934372b"
      decimals="2"
      id="F_f2ac883c-20b4-45de-aef3-bbe2f3e408c3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_def31b4c-f4a8-4c99-b8ff-05f2befd1e4c"
      decimals="-5"
      id="F_24c10ea3-9cad-4f2b-9fb2-475c1e3f8e25"
      unitRef="U_USD">7200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_5d67cf6e-bd93-4d42-8971-522a9d32c0c8"
      id="F_d421953b-54d7-426f-a348-f5ab77b6dbf4">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_0498a544-7235-40af-ade1-7542eee8d333"
      decimals="INF"
      id="F_88ec6352-df9e-4e61-9660-71bb92368bd2"
      unitRef="U_pure">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_836f3b27-9cf0-4ba9-abe3-f68ffa72e1e7"
      decimals="INF"
      id="F_b7a0a463-caee-4ffa-8966-1e371114dfb2"
      unitRef="U_shares">270000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0"
      id="F_01ca0d16-3e06-49c6-a1d0-e311d9d13fc2">In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2022, 752,938 shares of common stock remain available for issuance, which reflects 89,098 shares sold to employees during the year ended December 31, 2022. </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_b1e91519-0f55-42f3-a32a-9502a07575d5"
      decimals="INF"
      id="F_c705afce-6736-4ea8-835c-9bb3fa8a32cf"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a9286bf5-ac0b-46f5-a136-ec84fcb2ae44"
      decimals="INF"
      id="F_02f14bdc-089f-4757-b2c2-40bb50d400bb"
      unitRef="U_shares">752938</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0"
      decimals="INF"
      id="F_f5fa9485-bdb7-44cd-b455-a5719762ed0e"
      unitRef="U_shares">89098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0"
      decimals="-5"
      id="F_810bd781-29e7-4e39-953a-ec270ad234fc"
      unitRef="U_USD">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bd48d243-f6ad-429e-b82e-626144871206"
      decimals="-5"
      id="F_3513cb95-087b-4cb8-b1ee-76bc6c7bd200"
      unitRef="U_USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_f9d31372-fe57-4cfa-88db-2513a8a5e089">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:72.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.081%;"/&gt;
        &lt;td style="width:1.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.076%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.377%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.090999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Assumptions:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.69&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;68.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;76.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0"
      id="F_3cba10ac-44f6-458b-8bdf-f4fe36d86ae5">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bd48d243-f6ad-429e-b82e-626144871206"
      id="F_2015a8e3-2dbe-43c1-bbe0-6ea32f2c66e0">P0Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0"
      decimals="4"
      id="F_6b89b375-f730-4951-ab9d-5764cc1cba3b"
      unitRef="U_pure">0.6859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_bd48d243-f6ad-429e-b82e-626144871206"
      decimals="4"
      id="F_9159bc30-1223-4440-a1e6-cc8c8f5dab47"
      unitRef="U_pure">0.7625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0"
      decimals="4"
      id="F_5609774a-9a5d-49ca-b29c-b85604d95324"
      unitRef="U_pure">0.0204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_bd48d243-f6ad-429e-b82e-626144871206"
      decimals="4"
      id="F_70f6d632-5f40-4155-b36c-083ba14d7d88"
      unitRef="U_pure">0.0009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0"
      decimals="2"
      id="F_c76cc07a-561f-4ead-89c7-8a37e366e8a5"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_bd48d243-f6ad-429e-b82e-626144871206"
      decimals="2"
      id="F_767b8c79-c205-4aac-b609-7698c36a9d93"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0"
      decimals="2"
      id="F_a35699f3-2b4a-48df-9bf8-f52ec1e4fcb2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_bd48d243-f6ad-429e-b82e-626144871206"
      decimals="2"
      id="F_55c51cbb-8a3e-4ee8-8569-c83cb15b5e5c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_a9286bf5-ac0b-46f5-a136-ec84fcb2ae44"
      decimals="0"
      id="F_f2f47e60-1425-477b-b8d1-f652859ee90b"
      unitRef="U_USD">31000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_290088e4-cd92-4018-a07a-9b31182a5ae0"
      id="F_fcd3b64b-94bf-4d7a-8030-0ed7220b083c">P0Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-5"
      id="F_c9603be9-f6f6-40e3-817b-30566944cfd9"
      unitRef="U_USD">1300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-5"
      id="F_7229b5b9-c9e9-4645-9b3b-ac9d48321bdd"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="2"
      id="F_0d7a9053-b677-4cac-8aee-1d4019aec5c8"
      unitRef="U_pure">0.75</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
      contextRef="C_e2a8d3e4-8302-40ab-8531-be80c035a7d2"
      decimals="INF"
      id="F_7eb02219-4657-418e-a27f-89c3cdb9e81c"
      unitRef="U_shares">18394</phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled>
    <phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
      contextRef="C_b76ff2f4-ff03-419e-b174-84d981f8d356"
      decimals="INF"
      id="F_eee8159e-a75f-4219-9690-cdd7a6edcdd8"
      unitRef="U_shares">16756</phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled>
    <phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
      contextRef="C_02d741c1-6ff5-434c-88d1-b60b946959c7"
      decimals="INF"
      id="F_81bf953b-aa47-4beb-85b6-a1c7e2382504"
      unitRef="U_shares">84784</phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6dbb0e01-68b5-401c-ac47-a5ebd40a700f"
      decimals="2"
      id="F_562d6c2b-b20a-40f4-ac77-d42faea2529e"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_c257177c-a102-4a01-861b-e217f705d024">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;A summary of the Company&#x2019;s stock option activity and related information is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.033%;"/&gt;
        &lt;td style="width:0.725%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.727%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.544%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.243%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.742%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.715%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.742%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.528%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,186,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;27.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;13,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,741,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;342,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;29.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,586,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;23.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Options exercisable as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,455,735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;25.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.18&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="INF"
      id="F_f5a55311-cb3a-47d5-8484-ccc166d71ed2"
      unitRef="U_shares">4186729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="2"
      id="F_8e155270-cc82-4329-8cd3-73fcb13d5cb0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      id="F_c9d28bcb-e0eb-45f0-a37f-4091a83a615b">P7Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_cf6d4bc1-c935-4dc8-af1a-424580b08579"
      unitRef="U_USD">13973000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="INF"
      id="F_bfcd6615-79d6-46de-be4e-2702cbd53be3"
      unitRef="U_shares">1741931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="2"
      id="F_db5fc1fa-1277-479c-b4ad-d616e0972afe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="INF"
      id="F_44263c15-36d3-44bc-9d26-a15f68827f37"
      unitRef="U_shares">342190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="2"
      id="F_5d3b64d6-2220-4684-b634-83f8cd5d7db0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">29.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_6d1b4679-b825-4a9c-8994-f6ad1f669897"
      unitRef="U_shares">5586470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="2"
      id="F_a911cdb0-9a5a-4e9b-ae05-52c25b34b888"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_ed8ef67e-ed82-4447-8348-b073dd9698f0">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_e3ba3b3b-ecbe-4755-a37b-d08e76ac305b"
      unitRef="U_USD">4476000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_d6c6cabe-6bd1-4e2e-8d7c-41dee45a9dfb"
      unitRef="U_shares">2455735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="2"
      id="F_d1b60f14-76c9-45e4-935c-00814d0db1f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_25fc646b-ae0e-4da7-8f27-1a63fe468be9">P7Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_6ac8618c-debb-460e-b3d7-64cf17ea26be"
      unitRef="U_USD">2867000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_85297e90-674e-4311-8d12-99f75d773722"
      decimals="INF"
      id="F_937ba3f5-64bc-4ade-9aaf-b0c6a03ba8da"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-5"
      id="F_6a9179d4-8bfc-4eb5-b96a-247da6f2683d"
      unitRef="U_USD">37300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_350a7f50-b815-46fa-b596-410fefcafd16">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_23740d51-6a3f-4924-bd5f-6186f3c5cfd8">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.06%;"/&gt;
        &lt;td style="width:1.057%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.405%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.072%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.405%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Assumptions:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.88&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;66.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;67.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_ec00a35e-f100-4257-952e-f7b4f124df59">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      id="F_06ec0956-a833-4772-bd7a-806b62f21cb8">P5Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="4"
      id="F_cd109813-4194-4d7d-8a92-3de9970d605b"
      unitRef="U_pure">0.6600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="4"
      id="F_57a60f7c-7051-4732-8f13-7b7f4ab6dfd8"
      unitRef="U_pure">0.6746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="4"
      id="F_35272fb1-f655-4329-831a-c92bf517f60c"
      unitRef="U_pure">0.0206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="4"
      id="F_f6fd7ef2-ec53-48cd-8506-43f9737f9f5f"
      unitRef="U_pure">0.0068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="2"
      id="F_88e783b9-8f4c-4131-b98c-16b695a68963"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="2"
      id="F_51a816f4-bc70-45ac-9483-c2c37a47f157"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_5971b3b8-fe6a-4644-8b9e-1463e2530421">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.164%;"/&gt;
        &lt;td style="width:1.54%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.879%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.54%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.879%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;24,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;16,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c9397005-df60-4c46-9331-f164df01ca76"
      decimals="-3"
      id="F_4ff6e6ca-520a-407b-9461-caef0d5b57aa"
      unitRef="U_USD">5534000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_84f52c9e-524b-4bd9-9018-6cb27dd75205"
      decimals="-3"
      id="F_76289b66-9949-48cc-b7b8-7e6736a3b20f"
      unitRef="U_USD">3838000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_85f57980-d393-4162-ae13-987929e0df5f"
      decimals="-3"
      id="F_fe32ec5a-64c7-4ffa-b449-82f3e61abcb9"
      unitRef="U_USD">18599000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fee0ce51-9e93-47f2-b416-b68d0ab99ce8"
      decimals="-3"
      id="F_225ef051-4ec6-4830-bd78-04612b650f75"
      unitRef="U_USD">12974000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_103731e1-aa05-42c4-8380-86c428409c2f"
      unitRef="U_USD">24133000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_f7a0eb3e-cba8-4858-9f35-8a509527b0a8"
      unitRef="U_USD">16812000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_75ab4f99-a0a3-44d0-ab5d-06992f1e4569">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. Income Taxes&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;For the years ended December 31, 2022 and 2021, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;t record a provision for income taxes due to a full valuation against its deferred taxes. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.792%;"/&gt;
        &lt;td style="width:1.399%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.712%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.399%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.698%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Income taxes computed at the statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;41,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;30,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;41,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;31,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.484%;"/&gt;
        &lt;td style="width:1.286%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.965%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.286%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.98%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;85,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;60,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;25,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;13,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;126,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;85,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;126,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;85,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Based upon the Company&#x2019;s history of operating losses, the Company is unable to conclude that it is more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, the Company had federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;408.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;290.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, which are carried over indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of state net operating loss carryforwards that begins to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company has available federal research and development credits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million which begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of state research and development credits, some of which, begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has not completed a formal analysis of the potential impact of Section 382 on its deferred tax assets as of December 31, 2022. Until this analysis has been completed, the Company has not adjusted any of its deferred tax assets, including net operating losses or research and development credits. The Company will reassess the amount of net operating losses and credits subject to limitation under Section 382 when a study is complete.&lt;/span&gt;&lt;span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Due to the existence of the valuation allowance, future changes in the deferred tax assets related to these tax attributes will not impact the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.&lt;/span&gt;&lt;span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes the activity related to the Company's gross unrecognized tax benefits:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.936%;"/&gt;
        &lt;td style="width:1.466%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.559000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.559000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company has gross unrecognized tax benefits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,327&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; of which would affect the effective tax rate due to a full valuation allowance.  The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months.  The Company's policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense.  The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; accrual for interest or penalties on its balance sheet at December 31, 2022, and has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;t recognized interest and/or penalties in its statement of operations for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company is subject to taxation in the United States and various states. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="INF"
      id="F_c959263d-9f74-435b-a9b9-ca68b859e1e0"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="INF"
      id="F_e4ffcff1-b0d2-4404-97c0-3abcec226329"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_086b2f93-2dcf-4d34-9758-8afb2e03026a">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.792%;"/&gt;
        &lt;td style="width:1.399%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.712%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.399%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.698%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Income taxes computed at the statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;41,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;30,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;41,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;31,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_f2b3c2bf-4363-4c16-a76b-1aaff8f551c2"
      unitRef="U_USD">-41522000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_0f9ede31-0401-4304-bac1-396a5a78fb4c"
      unitRef="U_USD">-30216000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <phat:IncomeTaxReconciliationPermanentItems
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_abd888e6-9b71-429d-b5fc-d481773de2d1"
      unitRef="U_USD">2713000</phat:IncomeTaxReconciliationPermanentItems>
    <phat:IncomeTaxReconciliationPermanentItems
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_aa4ebcd9-5dcd-4ee4-ac5c-424f90c79b1c"
      unitRef="U_USD">1387000</phat:IncomeTaxReconciliationPermanentItems>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_cbf55a4e-cce2-410d-8859-1d8f454d5286"
      unitRef="U_USD">2453000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_5cc7f580-91f1-4a35-a36b-fcfae894ad7b"
      unitRef="U_USD">2950000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_88e1c2f9-f1f2-41c7-8e42-15b3c0a7f179"
      unitRef="U_USD">41137000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_b80343b0-1ec6-4bdc-b987-b492f6fe1f4c"
      unitRef="U_USD">31783000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_f83eea37-6951-464d-892d-fa763e4b7569"
      unitRef="U_USD">125000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_d7e09c99-20e5-47ce-906f-39f41fe68aad"
      unitRef="U_USD">-4000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_3fb370f7-c266-480e-a7f3-6b1fbc08daed"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_c094efe1-0707-431c-a34f-e654b4150bd9"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_235dbfec-dbb1-40cd-a707-d56bbe392e5c">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.484%;"/&gt;
        &lt;td style="width:1.286%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.965%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.286%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.98%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;85,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;60,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;25,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;13,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;126,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;85,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;126,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;85,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_81d507e3-6918-4b48-aaac-741a99b4b4f4"
      unitRef="U_USD">85918000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_64c053c9-d9d3-46b4-bc3d-af17e95c073d"
      unitRef="U_USD">60936000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_fb1106ee-a690-4ba6-b9ac-9710007ee21e"
      unitRef="U_USD">8897000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_b55f1867-c7d5-406d-93a6-9fc4d35849eb"
      unitRef="U_USD">6694000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_e5fe06d2-f6a9-438f-8f8e-fc8ed9290429"
      unitRef="U_USD">25319000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_ffb96d6f-ba32-4605-a637-d12930cb86ef"
      unitRef="U_USD">13809000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_722079d1-a137-49b8-aafe-d5ffccaa4e76"
      unitRef="U_USD">6517000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_2dd45b5c-e29d-4d1a-aa65-4acc630579a5"
      unitRef="U_USD">3996000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_47f9d9ed-9c51-4d43-ae33-6f6dadecd555"
      unitRef="U_USD">126651000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_677ecf0b-5c54-4fb1-8af4-8f3a597c5bbc"
      unitRef="U_USD">85435000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_cc8e0474-7ef7-41fd-89ae-6fba66c44d66"
      unitRef="U_USD">126170000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_f62fc546-53bb-4031-9b51-a6462e1605f7"
      unitRef="U_USD">85033000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_af20086f-eb87-4fd5-b486-18a7079b8b48"
      unitRef="U_USD">481000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_aa61e907-2e2c-4ce2-acbe-8797a1824a5b"
      unitRef="U_USD">402000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_5f787ee7-bdd6-414f-8c83-dd892b2a2ee0"
      unitRef="U_USD">481000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_11478920-ce49-4688-b0d1-b09b00adea52"
      unitRef="U_USD">402000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_163f671b-35d9-4e68-909a-90514c146312"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_3cb4f984-c63b-418e-8bf2-6e3e02fa3759"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_8ef9f4d9-0de2-4f1f-843d-3ab853904bf4"
      decimals="-5"
      id="F_e7c74ffc-1527-4c4d-a689-79ce57982e51"
      unitRef="U_USD">408700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_8d795b93-dc29-4dc9-8b77-44a4e74f6b8f"
      decimals="-5"
      id="F_d7681e95-efaf-4379-b809-d41d7caffccf"
      unitRef="U_USD">290100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_bde66df6-9f96-4711-b5ca-d8e549c121ca"
      decimals="-5"
      id="F_77405ea7-b2a1-48d0-ba74-7f9051728c34"
      unitRef="U_USD">1700000</us-gaap:OperatingLossCarryforwards>
    <phat:OperatingLossCarryforwardsExpirationYear
      contextRef="C_ec823b74-ab4b-4334-a3c0-fe989b5ea271"
      id="F_205162c5-0ee4-4d1c-a62b-ec5f2f867730">2036</phat:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_8ef9f4d9-0de2-4f1f-843d-3ab853904bf4"
      decimals="-5"
      id="F_01df3d79-0da3-4f2b-8373-639dd6c97c36"
      unitRef="U_USD">10500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear
      contextRef="C_4160e414-35f2-4edb-94aa-a3ea7eeab964"
      id="F_39d68d99-7d05-4578-9a28-47518cb80ca4">2038</phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_bde66df6-9f96-4711-b5ca-d8e549c121ca"
      decimals="-5"
      id="F_bcac0906-973f-4f7d-9e2f-4cef1ad3649d"
      unitRef="U_USD">900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear
      contextRef="C_ec823b74-ab4b-4334-a3c0-fe989b5ea271"
      id="F_0ccbf2f9-ce4b-4012-a827-efdd6d010e92">2025</phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_d75168ab-59c4-41fc-b990-478b9dd28dfc">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes the activity related to the Company's gross unrecognized tax benefits:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.936%;"/&gt;
        &lt;td style="width:1.466%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.559000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.559000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_741c2f96-ec6d-4212-849c-e31d498d57ab"
      unitRef="U_USD">1704000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3625bbc7-e0d2-4ae5-80c9-2c2a001c24c0"
      decimals="-3"
      id="F_4b45c0df-35ee-41ff-99d0-5625bb832a8f"
      unitRef="U_USD">938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_6b3d92be-e58e-4155-98b6-ad06603f5d6b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_7c73f7ea-d2f8-4ea6-a185-65fa89dd9c58"
      unitRef="U_USD">64000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_638d4214-9d47-415d-8859-0c0161392b07"
      unitRef="U_USD">623000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_bee83f7f-9f50-4030-9a6d-e219ecbfe6a9"
      decimals="-3"
      id="F_d798710a-a683-4815-86af-ca2f55c5ee32"
      unitRef="U_USD">702000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_85bb8470-28af-46f1-99b5-e9d5c99c9f19"
      unitRef="U_USD">2327000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f23428e3-ba82-4280-becf-c920e6849705"
      decimals="-3"
      id="F_155de565-a3cd-4833-a246-d8faa199d7ba"
      unitRef="U_USD">1704000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="-3"
      id="F_f90e9564-5ed1-469c-a209-07218b271c51"
      unitRef="U_USD">2327000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_9f4cbe3e-1d29-4508-ae1e-0bf492c5fc96"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_4898bc84-418b-459b-b337-70ce6a60f7c5"
      decimals="INF"
      id="F_c2aeb312-0f12-45d3-9da7-912e0815d792"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      decimals="-3"
      id="F_50abbeaf-1543-4448-81e2-57a9c8119677"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_6c9bf283-aa34-45fe-8828-7e01c81260ac"
      id="F_1fc62422-1afe-441b-be48-4e94ad37f8c2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;10. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;At-The-Market Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;From January 1, 2023 through February 27, 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,514,219&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock in a single trade under the ATM Sale Agreement generating gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, after offering expenses.&lt;/span&gt;&lt;span style="color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7da2e53f-060f-4407-97fc-6ab72ec3f967"
      decimals="INF"
      id="F_93513e95-e925-40a4-9031-0e90e7e25d3f"
      unitRef="U_shares">1514219</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7da2e53f-060f-4407-97fc-6ab72ec3f967"
      decimals="-5"
      id="F_9d65271f-024e-41e2-a7ca-6b14919dadd5"
      unitRef="U_USD">14500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <phat:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_7da2e53f-060f-4407-97fc-6ab72ec3f967"
      decimals="-5"
      id="F_e7a6b9c2-986f-4fb2-b8a3-8689ac510759"
      unitRef="U_USD">14100000</phat:NetProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!A!5R/2"/XAJXO6U05V!&1)K +NH@%T<U[QFA$54YB.A)*8<U \H[7*#UN1
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M^[K_L*UP7$ID>K569$9M@BFU)K+:)CA'V81Y@J%7WF0<ON;*).. 3BLLH^[
ME%H35NT.''TJ/_7OGM X"R-!&1H+0;@HS$';*L$!O?:QS*@K,*76I%:[ N<H
M5S!- \K $.3$3G)+0!!P]"DDN)#?^C14NOP#ZI-;)4"C5L"46A-@;06<HZS
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MDL0H(<<_E:A5KVD<F_>OZE^*X#&8-5.P$,F??*/CN36QR :V+$_T-W'\"E5
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ML<\K;F-LQ4$: WR^%4*_#DRS5S?WX7]02P,$%     @ SD!<5JW.#9U%!
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ME  61)< B(.=(%35(U"W$2A:#(4F$]LI%,2L4(S1QHD^GHM\VZI>8?8XNMI
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MZ7K&&HI1H09MJQGT_7BV164]F=^H>PLZOR$[7I4U7E"/[;9;1%^_X(J\W$[
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M4R?,!\9VJ,ZQ+*J+AW^*G.)8!(V+#K/D-JRI@2((TW  U13*,M\.-#L S9Q
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MI(DK<\P&C-T&78 VT;**4;0IQ6\ 8H67B#FS A]#2-.'*(GUI/4UQ2XXF00
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M88N9DEM0%DUL=N%"==KD'*]M4IZ-HE-.>F9QQP2K<X1G5P$/:!@7>A88HK:
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M.*:II[JYV&V,;-PL6DE#D\TM-_17 I4%T'DII3ENK('^S\GB'U!+ P04
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M]Y]J/FF/W2V +TL<7<PNSB?]^C#\B*Z53PZ9B]'5<ED18O$L@.>EP[Q,/]C
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M,]0/^0H8%_U"PZL++2!U$F#KIZ0V+"C+>2Y:LWV@)20-Y7,O?D=DJ:1U7($
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M-!GK*I"M^G=POKM=^1.$Y'X"B%6??WGEO6/+V\\6/9_NSLP2I=(>- R.]CC
M&^?=RJ'*<!D?D61-GH?RN49COC?<H1<XK$I+4ECG&\1=?V3I&1Y4UTEBF_X8
M(([3F&&Y,5G& #86UTU;;WN \R.U/<X$5OUA?%]Q%%RKDJ,&1IAWU5*(U//Q
MD^[XJ#]4'PTGA3[*!B+X<)3]CG40OJ-](V1:U>:>/0/D@>J^L2 BY^@7F][[
MND:6O&_1@R]VG&T#\+K)^&D+EOM^4'+:^WE/H>R*?\1$J ]Q_2]]VKOM[Z2N
M_,^#NN7^1U8?I%U1[9ZK#%LGXXNS0]^2QHO:5/QCH:6IT0SRU[62<#%:@.>9
M,76\H!>TOQZ[_"]02P,$%     @ SD!<5G]+3.O*"0   AT  !D   !X;"]W
M;W)K<VAE971S+W-H965T,34N>&ULK5E9<]LX$G[WKT!I9J>2*D67Y1R.[2K9
M3F8RE6R\R4PV55O[ )&0B)@D& "THOGU^S4 7KJBS>Z+31&-1I]?=X,7*Z7O
M32*$9=^R-#>7O<3:XGPX-%$B,FX&JA Y5A9*9]SBIUX.3:$%C]VF+!U.1J.G
MPXS+O'=UX=[=Z:L+5=I4YN).,U-F&=?K:Y&JU65OW*M>?)#+Q-*+X=5%P9?B
MH[!_%G<:OX8UEUAF(C=2Y4R+Q65O-CZ_GA*](_@DQ<JTGAEI,E?JGGZ\B2][
M(Q)(I"*RQ('CWX.X$6E*C"#&U\"S5Q])&]O/%??73G?H,N=&W*CTGS*VR67O
M>8_%8L'+U'Y0J]]$T.>,^$4J->XO6WG:Z5F/1:6Q*@N;(4$F<_^??PMV:&UX
M/MJS81(V3)S<_B GY2VW_.I"JQ731 UN].!4=;LAG,S)*1^MQJK$/GOU03R(
MO!3L36Z%%L:RUS+G>23S)7LK^5RFTJXOAA8G$?TP"ERO/=?)'J[C"7NG<IL8
M]BJ/1=QE,(2(M9R32L[KR4&.MR(:L--QGTU&D\D!?J>UWJ>.W^D>?C<03R,D
M8&Z;L!MG:*'[C=+L7[.Y<23_WJ6_YS[=S9TRZ=P4/!*7/:2*$?I!]*Y^^6G\
M=/3R@.S36O;I(>X_[+/#7)\-V#&,V?N<O>-K=NI=T6=W";>)RIAPFV(F<ZL8
M/\1KMM1"(+&#\=_DTDJ>XO\#Z)0V[.__Z+./?,EUW&<\C]EO0D=E*@PK2FU*
MCHTX8I7(*&$V$>Q&907/U^"6I@"*2"#/65D0T<]L\G2$O$E3@@"9LT69QR3#
M0D-DVKQU^H#]B9C5;A&B9X:IA?MQC$;]CD!!EAABC$>-&-PZ*AE.CE)EB EI
M&O&\U@"//(XE@1>HP**E25G@S^O;&>-%H=4#UB'D@\I5H?E?V BT9A8@;9V9
ML28T#@'37U]]N&78B_6Y )6 ,S7L&%)K.F SRTAV"^AEA9;$2#&DG\CFL$J5
M@EU%>6H42[AQ+S4!(6U2<XNJ@%A8:6FMR%FDLDQZD9S].>BECEG!-0*+9*Z\
M-CZK587PE=..T;JMZ "^JFW8E;@K+-^E\^]E+MCIR-NE_S\J--FO$(\2B="J
M/,69X13K(*> S,6 _;$K3J$"!4G0@)A*;>AA 3?)14=;(\2]:6E@2KB\%5Q!
M'G^251:O>*9*4JLD &?S]>YD<4'K3BCG1GPM20=9+TI#=5MH@@4<GB!MR'PF
M\"(RI_7,G34@:'D?6;4_SC8PYG<E7:IN ,I^26_>AZ05[.VGC^SSY\^?WKQA
M;]_>L$>__/1\,AF]I+VSQC#5=K<Z?OEX X]N>"%AK#[HHKVXL25E?X^$*^[
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MO/&:S-M^55G<I<+&0MM8B-V.G6 ;-AZ<CEPDF6W?]+'Z]&S_*ATZ&53;94/
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M8X#L>@T,A'\!G&59]IR'Y]=K_)# G!6KP<%FG"MVM6I;^'E6=,HX?*YDE&>
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MF!%IBE*(685#<142>[E%*/I^ITL6.B2U@2W@W[0H4!&4 )X$E)/%Q>RMAWX
M0X$8]N%= B1V2YA$=L2=9GMDZ_S/*=9Z0.].>XM<A:<Z.VRV]+1Q;B#S!<L!
MIL"\WJQJ-'*V@=]0L%M@#HATQ!#"L_83;&75SSQO"S2KL)?>FTT@,3_@^8T+
M+"YF+U\^GSU[?%&X+6V=5FT:V!#(4/F)2('TA.5+K2MZ0.W@T[V!R%"#5?BO
M8O%R,7\*,5I=(R& Y+@]<"8OBZOKG_(%E[/ETXO9Q<57K??BQ?S9X7*!]D#W
M"X!2@XR=P\^[805&!:"L=4=F)Q5YQNC)XLGLQ<OG7X/1\LDQ1C?H:#Q*RP.^
M)O!1(MB17_[\8_&3(,JZA5Z*A(>,T9C_VRK0JI76;?2""E9J#BPP&,>ZCEI#
MAF-CR?Q:0*H#,W6W->66'M$-6.D>]0, @,M.-0" Z]XE5.R-6ZO2_UP;M3(U
MJ['H7HLY!*X]=(YV[TT)\Z*R*,^H2/50:3)/JOH5XG_>'Z@59"N8RA"P':@U
MJ8-H-/@A,@FV%61+,$P=X\ >L:P!98K:#[8 ;%4-Q@#NQ'/)7N;%C^@_B.9H
M 3L-3A=I#>B!&F.." 3M[^RYZS4:$U7O*:"[U5F,%F(9CV%JRHZ9DBW;#*3,
M'?Q7WZIZP$#N;JO)G>!_-,5"\";;0=X5&@.D(L2%Y'!UZM*!]L.J!UP@:?T*
M+(L'-[CIQ<-Y<;5F1\L8X^_(5%G_>&6D)")5S=+7,.BLG<V(#*"<03WQ.T8-
MPU@"GZWUK4%JT"H,F5%:/LPHN-*U 8((.N )T"*[ <(52-K@=TRCDX@$A6I+
M@F[);H]9;(!30\C*Y&OU/?QQIVM0R8:3.7)R^%O%"*([']7C.V+@K3*U0O&&
M)5?L"W1%I@!9JUK\LK6DX1T9$]K)D9ZOD,T0Z3JW'FJ.BI&4Y&:CF\0]D4DT
M:T!=5\B&0WA!%,#>_<KU!.=# E'!0ZJU9"0)#PH3T(@-'45M%-'  JSDAX@
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M\J_\X'-ZGC>)!"1?DH-G84*0BW&Q-Y>6J).CX_F\+[V$?6A[!ZE3(=>&C=_
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M&1>X4J#+/&?J>8F9/,Z".#@M//#]P=B%<#XMV![7:#X7*T6SL$;9\AR%YE*
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M6T?S'7:K35RVB:LN<;5-7/O$SKXN>0@4)>K".>E]Y7*'@"5B",R;OF^K/V;
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M,7V@^Y6&U4*1*D?U#+KM7J\+YQL/K=9,$($E6[MX \38&7XRX'-K)BKR:MJ
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MENH.]C[2FXK)_:.90A=ZX"SOS)U9<^01<SZ!][Q12PGG3<&*AP9FB&T 2'J
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MDO7_P7/]0&P-L,=[!MCU /NM YQZ@//6 6X]P-T=L.\^].L!_=T!HST#!O6
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M!_OF>/"J>%\\R/<?@^R;*N)-:ZU>,<ZS8-%:KM!$$*IY4(U"-0;5.%3SH9I
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MBXG:%%YU"ZL7R0K3/WMD4K+</.X I\"U@/J^84R^ON@)FI[M_%]02P,$%
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M=JJ/7:&UN:[U<6"5B<V@5N5G.BOKY,@.I5]$%6^B],N@[E=13@6P*[0V<[4
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M*2;BKZ>@"(WD&_0*48;N:13I83EPE?;#H+GS?,UQMJ9_9$WLHWO.5"C1KRR
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M (29H)\O.%>[&[- <7@[^@I02P,$%     @ SD!<5C#37)W! @  1 @  !D
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M^P"-H;'E6\I<5[]DUXSU'+(LM9&\ :,"SD3]3W\V@=@#!*-G $$#"#H _SE
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MNXA,%K)NSO5$BZ)JB$NA37NMAFMSGJ&T&\QZ)H3>36R/;4_(^"]02P,$%
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M :,0_#D;/1F"..V".+7+MQ+G'->3R9CQRAB'U<2V<=3&HEX<812%YBB\L9K
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M3"4QC<1T$C-(S"0QB\1L$G-(S"4Q;WJ2?N)T),Z'8BLER4$#$@LAK!&HL]=
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MM&;X5FW'<7_;\:KPO3D][GV,TV1[G*\MH;/GL*#=2%2344U!-175-%334<U
M-1/5+%2S4<U!-1?5O OQ,Q'6VTWVT/4^V4=W)$"UD-*:J5W5)<?]=4DY>4J6
M\68I/"?QJGN*%RU(HIJ,:@JJJ:BFH9J.:@:JF:AFH9J-:@ZJN:CFE5KSW/CV
MP?#EVP3H7H64U@C+255FG/2O&_A'<6;CMS3)LG@C^/O;5;(0O+N[N#A#KBLZ
M^[EKHQ/59%134$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"VDM&8<5]7$
MR;%7\W[=\@G:2$0U&=445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 LI
MK1G@4A7@_<7%KY=.+RNW;YPL*8U/SY;\O7^@JZ,5+2*BFHIJ&JKIJ&:@FHEJ
M%JK9J.:@FHMJ'JKYJ!:@6DAIS6BMZF63_GI9O19Q(SRFR?'*',>3R2Z>6#;I
M:))([<A%VV.HIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:2&G-R*V:
M:/F7?9'KI]M%'"]WPEVZ75=U^+*3)CP>YXNWY7RQ<)]N=[MS)Z&50]4#>#[J
M*OW]WK]35\<PJ2FHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%E):,X:K
M]MJDO[WV>L7G]D%O=)?E7R_CY7Z1%0&\?_DTK_AFF>P6Q=5#C@L+%M?3R .\
M6&[P\K'R<7<:IV///XYF[9Q&NVVHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>
MJOFH%J!:2&G-G*XJ<)/^"IP;9WE$EX?,9[,Y3G>U-#Y[N#PY.5R>S6:=A\MH
MR0W5%%1344U#-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+*:T9PU5G;M+?F7L]
M7-[>O5[O+UI5TQ1E8>/\3,5I<4;J#%ZT"(=J"JJIJ*:AFHYJ!JJ9J&:AFHUJ
M#JJYJ.:AFH]J :J%E-8,WJHO-^DOK'S)?LH>XI^<*/TS/Q)^.8U8\-/M?1JM
M.Z,6[;VAFHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%E-8,Y*H*
M-SFV1][Q=&*T2H=J,JHIJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!92
M6B/ IU4];]I?S[MX.G'_]M?F+ZK)I=8XU7DDCF;SUMJ_"CJLBFH:JNFH9J":
MB6H6JMFHYJ":BVH>JOFH%J!:2&G-:*VJ=M/^50#/G-M672+XS.QP/WMUXJ(%
MNE)KS%R/)AUSUPHZKHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ7N=OS7@^.;U6&CIN
M@&HAI37C5*KB]$+Q[;A:Q4N,%DO^G(]0=,4^5)-+K7'>16> HA4X5--034<U
M ]5,5+-0S48U!]5<5/-0S4>U -5"2FN&;%6!F_97X+X<EP/<9\GJ<$W*8H'!
MXTJIQ0I_FT7Q:=NYS$7764,U&=445%-134,U'=4,5#-1S4(U&]4<5'-1S2NU
MQA3<N&L%-1\=-T"UD-*:J5NUX/(O>U/W==G1D[ MUV<]E[F][M692VHRJBFH
MIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:5VKU=Y#B\0HOIZ%+#AR@6DAIS="M.F_3
M_LY;_[ED>>)^W=_N\CPN3E50GO+_[PQ@="TW5)-134$U%=4T5--1S4 U$]4L
M5+-1S4$U%]4\5/-1+4"UD-*:&5WUW::3=SZ];(HN!X=J,JHIJ*:BFH9J.JH9
MJ&:BFH5J-JHYJ.:BFH=J/JH%J!926C/ JZ;<M+\I=_GT,G3E.%2344U!-175
M-%334<U -1/5+%2S4<TIM?K,K#@61Y(X;\X1N.BP'JKYJ!:@6DAIS6BMNG#3
M_B[<=Y]>AC;B4$U&-0755%334$U'-0/53%2S4,U&-:?4&O.RG1<@=-%Q/53S
M42U M9#2FI%;M=VF_0N_*>O'U?8YC@_7.W.WF_CE>SE)XT6V33OS%BVPH9J,
M:@JJJ:BFH9J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA936R.1956";#=YYBGB&
M-N!0348U!=545--034<U ]5,5+-0S48U!]5<5/-0S4>U -5"2FL&>%63F_77
MY)1=EJRC+(_ED^7M[Z(D%9ZBU?[RZAO]@UP=TFAI#M445%-134,U'=4,5#-1
MS4(U&]4<5'-1S2NU^G7$9Q]'K7/@T"$#5 LIK9F]4I6]_9TZ+S]<%LHSX+Y&
MJUCX<I_&QT/F;TGV()CQX;2X>"?8]N]Y!E]__;7^';@ZE]$F'JHIJ*:BFH9J
M.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!926C/ J[[>;/C>LQ]HK0_59%134$U%
M-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"VDM&: 5]6__,O>$^3RH^[&:AV/
MT?.A"1CMA*A8B&F11W4Q%U*<UU$<H>?_/:Z"MSMLV5JPJ3/!>_?@Z@0G-1G5
M%%1344U#-;W4Q&'MG>_@XV#8?.MKH(.:J&:AFHUJ#JJYJ.:AFH]J :J%E-:,
MYJH@..LO"+*3(_D-G.BO9+WOGB9!>X2H)J.:@FHJJFFHIJ.:@6HFJEFH9J.:
M@VHNJGFHYJ-:@&HAI36CO.H1SMZ[1SA#>X2H)J.:@FHJJFFHIJ.:@6HFJEFH
M9J.:@VHNJGFHYJ-:@&HAI34#O.H1SOI[A%_N\V/O^RB+JT7VCC,?V4.ZW=\_
MO/DJ=?WC7)W3:-\0U1144U%-0S5]=KJ<XIGKX1CHP":J6:AFHYJ#:BZJ>:CF
MHUJ :B&E-4.X:AS.^AN'^9'S.C]F/ER(N3-;T68AJLFHIJ":BFH:JNFH9J":
MB6H6JMFHYJ":BVH>JOFH%J!:2&G-^*W:A[/W7FMOAE8544U&-0755%334$U'
M-0/53%2S4,U&-0?57%3S4,U'M0#50DIK!/B\JBK._^9:>_W;7YN_J":CFH)J
M*JIIJ*:CFH%J)JI9J&:CFH-J[KQCW<FQ-)J-I>9TD]=UPZX%*GUT_P)4"RFM
MF9I5/W#>WP]T]^O;.*U=URC:9P_;]+ \2;85TOAQGRX>\J/=SD1%:X&H)J.:
M@FHJJFFHIJ.:@6HFJEFH9I=:/8R&P^EP-)@UP\A!AW51S4,U']4"5 LIK1F[
M4A6[;UENKTI7X?%X'MN-L&D'<EK4MH55]'@F@]$*(*K)J*:@FHIJ&JKIJ&:@
MFHEJ%JK9I5;/X-EH.&P?.#KHJ"ZJ>:CFHUJ :B&E-2.X*O?-^Q?C"^-UE&R*
MDQE.(C<_\+V-:^G</9V 5O=0348U!=545--034<U ]5,5+-0S9YWK5,W' S&
MDW;RHJT\5/-0S4>U -5"2FLF;]7*R[_\OH/?QSA-MDLAV0AWVW31?;S;:U\=
MNZ0FHYJ":BJJ::BFHYJ!:B:J6:AF7_@]&\V$]7:3/71=TLM!]\1%-0_5?%0+
M4"VDM&825R6\>7\)[UP2"_%?CTEZ//_AF,F=48S6ZE!-1C4%U514TU!-1S4#
MU4Q4LU#-OO"+)@VDX4]%@;PCB-$*':IYJ.:C6H!J(:4U@[BJT,U[&Q[?O=Q(
M/WMU!*/%.%134$U%-0W5=%0S4,U$-0O5;%1S4,TMM4:)YJ0_XZ%C^J@6H%I(
M:<VXK0IO\_["6U@=\=8^7A/B:/%P?,LD1'=9G IW2;K+A&BS29[B=!>ESS<]
M%TGN'_/J+$;+;ZBFH)J*:AJJZ:AFH)J):A:JV:CFH)I;:N*H%L:#CWD:2^US
M-3QT8!_5 E0+*:T9R%7Y;=Y??JL">5<=]':&+-J"0S49U1144U%-0S4=U8Q2
M:ZS,.1U/6L=:)CJHA6HVJCFHYJ*:AVH^J@6H%E):,V"K>MN\?W&]LAT1O5[I
MH3'I6USKX=(:(/T#7)V\:'T-U1144U%-0S4=U8Q2JZ\7,?XHM7,7;:6AFHUJ
M#JJYJ.:AFH]J :J%E-;(77%0U=**K_N2MUS6-!66R6Z1QL5G:E'Z+*RC;/%P
M>NK9+LZR5?<)9Q<&NC:!64YF.87E5);36$YG.8/E3):S6,YF.8?E7);S7KC&
MFYN!.!ZUWMWX73>4)M-QZW8!NW\AQK725JRE;7^?K7X5G?R05AJ(<\'8%)=Y
M3Y[B\D(-_BK:= <LVF=C.9GE%)9364YC.9WE#)8S6<YB.9OE')9S6<YC.9_E
M I8+,:Z5UE(MK8\=C_>[Z,[+'F"9CA;D6$YA.97E-);36<Y@.9/E+):S6<YA
M.9?E/);S62Y@N1#C6ID^K&5Z?Z_NRW*9'"8Y5J>S&]%3E*P."S#=;=/7T]RZ
M<QNMU[&<S'(*RZDLI[&<SG(&RYDO7.,=]DB<3&>M<P,L=F";Y1R6<UG.8SF?
MY0*6"S&N%<FC6B2/KID4*6>DX_('_LOG@.?G17KYZ[.8Y&264UA.93F-Y726
M,UC.9#F+Y6R6<UC.93F/Y7R6"U@NQ+A68(]K@3U^]WD1M+S'<C++*2RGLIS&
M<CK+&2QGLIS%<C;+.2SGLIS'<C[+!2P78EPKTR>U3.^O^)7KD[96G8Y7R7U2
M3(@LZC&_V&ZR-+G=9WFNWSX+CU&:)8OD,=IDG:?F71CZ^C!'>X LI["<RG(:
MR^DL9["<^<*U%LJ63F9*T)X?RSDLY[*<QW(^RP4L%V)<*Z2GM9#N+P:V9DH,
MW^O.6[3JQW(RRRDLI[*<QG(ZRQDL9[*<Q7(VRSDLY[*<QW(^RP4L%V)<*Y=G
MM5R>O?N$"-HL9#F9Y1264UE.8SF=Y0R6,UG.8CF;Y1R6<UG.8SF?Y0*6"S&N
ME>GS6J:_J9)X?L&F"\#UD3P__6A_,)]/)\/6:?$R.[+"<BK+:2RGLYS!<B;+
M62QGLYS#<B[+>2SGLUS <B'&->-6K/40Q?X>8CFUL2NF-F[*SO=CG!Y/S;O8
M_KZ@7YW%)=>X(-:\G<+HF K+J2RGL9S.<@;+F2QGL9S-<@[+N2SGL9S/<@'+
MA1C72N%:/U'L[R<V+_1I;)(LB5:"O[]=)0O!N[N+TV)%DA\,W_OQW#4_+PQQ
M?12+'5$LC@>#DPL4RNS0"LNI+*>QG,YR!LN9+&>QG,UR#LNY+.>QG,]R <N%
M&-=*9*F6R/U+\;4^\OMCLXS3;VF29?&FG<O=:<P6#%%.9CF%Y526TUA.9SF#
MY4R6LUC.9CF'Y5R6\UC.9[F Y4*,:P5VK6 H#M_[LT"1+1^BG,QR"LNI+*>Q
MG,YR!LN9+&>QG,UR#LNY+.>QG,]R <N%&-?*]%I#L;C:]M_Z++ ?N#Z21Z>?
M!8Z&H]%T>#+E00ZLL)S*<AK+Z2QGL)S)<A;+V2SGL)S+<A[+^2P7L%R(<:VT
MK=4+Q?[5R,[TP<]\\,<6!5%.9CF%Y526TUA.9SF#Y4R6LUC.9CF'Y5R6\UC.
M9[F Y4*,:Z5SK2@H3MY]?H/M"Z*<S'(*RZDLI[&<SG(&RYDL9[&<S7(.R[DL
MY[&<SW(!RX48U\KT6J]0O+3@X#I*-L6I'2?7Q,NVPFU].98STQ]LXQ#E9)93
M6$YE.8WE=)8S6,YD.8OE;)9S6,YE.>^%:RUL-FS/6/KLN '+A1C7RN):EU#L
M7VNP-?NA'M9X_5*M\=J=OVP[$.5DEE-83F4YC>5TEC-8SF0YB^5LEG-8SF4Y
MC^5\E@M8+L2X5DK7VH'B_-UG0=AZ(<K)+*>PG,IR&LOI+&>PG,ER%LO9+.>P
MG,MR'LOY+!>P7(AQS4R7:A5$J;^"6*WR+:3)_4,FK*+'XNLHZUX#H)^[.J!1
M3F8YA>54EM-83F<Y@^5,EK-8SF8YA^7<%ZY]2<!Q<Y+"8X?U62Y@N1#C6LE;
MJQU*5RV+^!_1G_$R$NQDD1]6G\E>MF2(<C++*2RGLIS&<CK+&2QGLIS%<C;+
M.2SGLIS'<C[+!2P78EPKHJ5:1+_[6H@26U5$.9GE%)9364YC.9WE#)8S6<YB
M.9OE')9S6<YC.9_E I8+,:Z5Z;6JHM2_%N+E6DL_<'TDLTU#E%-83F4YC>5T
MEC-8SF0YZX5K7EIQ-CJY@HS-#NRPG,MR'LOY+!>P7(AQK;2ME0CSKZ\YL6.[
M+Z[ET=UJZ:>NSUV2DUE.83F5Y326TUG.8#F3Y2R6LUG.83F7Y3R6\UDN8+D0
MXUKA7.L<2N^^I*'$-A513F8YA>54EM-83F<Y@^5,EK-8SF8YA^5<EO-8SF>Y
M@.5"C&ME>JVI*/4O:?BW6RW]_O6)S?8044YA.97E-);36<Y@.9/E+):S6<YA
M.9?EO!>N/G,TG0\FHW:I!1TV8+D0XUI17"L82E<M7*BFT7\F<=H=NFR5$.5D
MEE-83F4YC>5TEC-8SF0YB^5LEG-8SF4YC^5\E@M8+L2X5C;7"H?2NR]>*+'U
M1)2364YA.97E-);36<Y@.9/E+):S6<YA.9?E/);S62Y@N1#C6IE>JR=*?W?Q
MPG[@^DAFVX4HI["<RG(:R^DL9["<R7(6R]DO7/.ZNW-Q,)6:;_@==F"7Y3R6
M\UDN8+D0XXYI^VGW$,>9'&71YU_6<7H?_QZO5CMAL=UOLN(@NO93(8WOBC#^
M^8OTX=/)SV7Q9UOL^+DG_AP<?OZIXC__\AC=QTZ4WB>;G;"*[_*A!A^G^>OP
MT$1\^2;;/N9_!SX(M]LLVZX/7S[$T3).BQOD_WZWW68OWQ0#?-NF?Q[NSN?_
M!U!+ P04    " #.0%Q60^\"0G<"  #+!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6R=5-MNVS ,_17" W8!UMI6'/<RQT#2"[:' D&#;@_#'A2;
ML87*DBLI2?OWD^3$RU8W#WNQ18D\YY 2F6VE>M0UHH'GA@L]"6ICVLLPU$6-
M#=6GLD5A3U92-=184U6A;A72T@<U/"11E(8-92+(,[\W5WDFUX8S@7,%>MTT
M5+W,D,OM)(B#_<8]JVKC-L(\:VF%"S0/[5Q9*^Q12M:@T$P*4+B:!-/X<I8Z
M?^_PG>%6'ZS!9;*4\M$9W\I)$#E!R+$P#H':WP:OD','9&4\[3"#GM(%'J[W
MZ+<^=YO+DFJ\DOP'*TT]"<X#*'%%U]S<R^U7W.4S=GB%Y-I_8=OYIE$ Q5H;
MV>R"K8*&B>Y/GW=U. @@\1L!9!= O.Z.R*N\IH;FF9);4,[;HKF%3]5'6W%,
MN$M9&&5/F8TS^<+(XK&6O$2E/\#-TYJ9%SB!17='(%?P(#:H#9:PJ*E"#1^O
MT5#&]:<L-%: @PF+'=FL(R-OD,4$[J0PM88;46+Y-T!HE??RR5[^C!Q%O,;B
M%$;Q9R 1(:"]PB.PH[XJ(P\[>JLJ#NAD9F^[A#E]L8_0P%0I*BKTZY_3I3;*
MOJA?0T7HL)-A;-=EE[JE!4X"VT8:U0:#_/V[.(V^'%&>],J38^CYC'(J"@1J
MP-8&FR6J?7WB(:T=VMBCN0;>Y'&<).?1119N!F2,>QGCHS)\ <$]'":J(=[Q
M*]Z3\XMH=$:&>=.>-_W?],F0C/25##).DM'9/RK"@P9K4%5^C&@HY%J8KM?Z
MW7Y23;L&_>/>C;D[JBHF-'!<V=#H],R2JVYT=(:1K6_7I32V^?VRMM,6E7.P
MYRLIS=YP!/W\SG\#4$L#!!0    ( ,Y 7%:937E<GP,  !D2   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;,U876_;.!#\*X0.:*_ -?JP9<FI+2!Q
M4C3 %3%BM'TH[H&1UC81251)*F[NU]^24F0K480FT!7)0TQ*W.'.<,=>:;;C
MXD9N 13YF:6YG%M;I8ICVY;Q%C(JCW@!.=Y9<Y%1A5.QL64A@"8F*$MMSW$F
M=D99;D4S<VTIHADO5<IR6 HBRRRCXNX44KZ;6ZYU?^&*;;9*7["C64$WL +U
MI5@*G-D-2L(RR"7C.1&PGELG[O'"]76 6?&5P4X>C(FF<LWYC9Y<)'/+T1E!
M"K'2$!0_;F$!::J1,(\?-:C5[*D##\?WZ!\->21S324L>/J-)6H[MT*+)+"F
M9:JN^.X3U(1,@C%/I?E/=O5:QR)Q*17/ZF#,(&-Y]4E_UD(<!+CC)P*\.L#[
MU8!1'3 R1*O,#*TSJF@T$WQ'A%Z-:'I@M#'1R(;E^AA72N!=AG$J6BD>WVQY
MFH"0;\GYCY*I._*>K*I3)7Q-%CS+4&^SD%R!!'$+"<$"(A]+50H@%U*6-(^!
M_'D&BK)4OD, N:4"Y,Q6F*/>R8[K?$ZK?+PG\CF#^(B,W+^(YWA>1_BB/_PR
M5O?A[K0=;J,RC3Q>(X]G\$9/X)UG1<KO ,@*:3/DN-*\R"D63J*503=):NKQ
M)$UY7 TOUZA3S#<Y^Q=7+4$PKA=+)<GWOW$#<J$@D_]TB5-E,^[.1EOZ6!8T
MAKF%GC4G845O_G GSH<NJ08":PDW:H0;]:%'==5(4S7BL&K65=6PIFI87E?+
MNRY%JFU\LXW^3KJ-PDD0>F$XLV\/R?:F\T*RXX;L^-?)[J@0-%>=M=\+\]SC
M'0BLQ=AO&/NORA?^D,(-!-82;M((-_D]OI@\\L74];R'KNA-YH54@X9JT$NU
M^L6X+/392T)S<^2F\4!Z[ZM2.4&W)))<EDHJ7,'R31?7WGV>>_H#@;4D"1M)
MPE=EFW!(X08":PDW;82;_A[;3!_99A(&$V\4/#!.;SHO).LZ^Z;,Z:6KNQ=R
M@71RW>16+B'+E.:=#54OUG-/>2BT-O.#=M1]50ZITQE*O('0VN+MFU6WMZ4;
MSB7U/JU?%S\(0_^!2_KS>2G??8_I]C>9YZOE\FE;#-01UDS_C_[2W3>8[OAU
MV6+03G4HM+9X^U[5[>WH!K2%_\@6@>]-1P^[KHYU7N#@7[.N8F(?/+?KER:?
MJ=@P[)526&.@<Q0@@JC>0U03Q0OS*'_-E>*9&6Z!XK.[7H#WUYRK^XE^.]"\
M#8K^ U!+ P04    " #.0%Q6_A5ETN0$  "-&0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6S%F6MOJS88Q[^*Q:;M'*D-V$ N71(IR;E5VIFB1NUY
M,>V%"TZ""CC'=I)3:1]^-E (EW@MH^N;-H"?R__Q8_,#QD?*'OB6$ %^1&',
M)\96B-V5:7)O2R+,>W1'8GEE35F$A3QD&Y/O&,%^8A2%)K*LOAGA(#:FX^3<
MDDW'="_"("9+!O@^BC![G).0'B<&-)Y.W 2;K5 GS.EXAS=D1<3M;LGDD9E[
M\8.(Q#R@,6!D/3%F\&J!7&60C+@+R)&?_ 9*RCVE#^K@VI\8ELJ(A,03R@66
M_PYD0<)0>9)Y?,^<&GE,97CZ^\G[IT2\%'./.5G0\%O@B^W$&!K )VN\#\4-
M/7XAF: D08^&//D+CME8RP#>G@L:9<8R@RB(T__X1U:($P/8/V. ,@-4-7#.
M&-B9@9T(33-+9'W  D_'C!X!4Z.E-_4CJ4UB+=4$L9K&E6#R:B#MQ'0EJ/>P
MI:%/&/\5?/R^#\0CN 2K=%8!78/EZA;@V <WJUL.9JKJ:LAM+"V V!* +#@"
MU[%'8C4A8';$S ?+$,?@W0<B<!#R]]+AS\ $?(L9X6-3R+Q5=-/+<IRG.:(S
M.4($OM)8;#GX**/Z90>F%)RK1D^JYTCK\0/Q>L"&%S)YA!H26CS?'&K2L?-)
ML!-_]KE)4(4!<]F-/EC02"Y1CI,FGS&&XPV1RT: ^2,X';?$C\GIM-Y__BY=
M@FM!(OY74X'3^$YS?+557/$=]LC$D'L!)^Q C.DO/\&^]5M3<3IR5BJ5DY?*
MT7F?SK'L+(\ +("<!1+=RRYLGHE4>.K-3;RI+>TPA=!QAM9H;!Y.-6FCMM3D
MYIK<MIJ:FG/NUC0AUW'L0452?5A5>BG;?IYM7YOM^?7^-U@2EMQ9Y-7+M$V3
M_47N%H'@X)W<2MXW"=(&?&EW=N2L5)M!7IO!&R_D09>EZLA9J53#O%3#3A?R
ML-;-]LBQ+:O2]-J@+26-<DDCK:2TU[&:1WX!-G+&1?5NE6H9U;4,W)H4;;"6
M4J!5<(&E%?/'/ID2"0 G2_@"2'9:D^",KLSEJ;!+.*HKTX=N*^T$>6"G^VWF
M[E26 U&]]QK&57JTG# J$D;:A+\E,"KWBMF!, G7X+/J+2"!CX!/.&#@#H=[
MHG;?=&>YD+-U(%Q9S,DFB.,@WH!,=:/ -/SP-''40W95GS;+MM-60!+4@D6+
M*GP^OP2S6+!T%[5Z5K^J^35@!Q:T _6X\W+-^@7JU%7;;L^NTI ^J[:J"QZ"
M>B#Z#_TNGQ#^K=G=>K-;O5&5GIJ&E=9$65M!3[ ]/MU(#2SP1)6;U*-7(SCI
M8[T4![KR5JY,P4[PK>$)=DI/77DKEZO@)Z@'J&?3!JRC$[2@57]@>,; <JX%
M&$$]&9V!B;MDS3;F7$>D2V@AQZW=DUZ#DE!!2:A[2D(-E&1;+JQ.ASYT6VD%
M):%N*0G5Z6<X&#C]FBQMV+:R"I9"7;.4AB)0'9R@U1M4;Z?ZE-I*+L )=0U.
MYQ<F:N"F8<^%5<6O@4VHP";TOV(3:L FB'K0J:I^#6Q"!3:A-\0F5.<A"'M6
M=3_6I_C2$I@G+[8CPC;)^WX./+J/1?JV-S^;?U.8)6_2*^?G\&J1?ADHW*0?
M*KYB)I^0. C)6KJ4BU<*8.F[__1 T%WR^OR>"D&CY.>68)\P-4!>7U,JG@Y4
M@/P+S/0?4$L#!!0    ( ,Y 7%;[*\+/@@,  ,T,   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0T+GAM;*U7VX[:,!#]E5$J]2*UFPL08 N1V%UZ>:B*%K5]
M]B8#L=:)4]O \O>UDQ N-=FMR@O$SIR3<\;Q>#+:</$H4T0%3QG+Y=A)E2JN
M75?&*69$7O$"<WUGP45&E!Z*I2L+@20I01ES \\+W8S0W(E&Y=Q,1".^4HSF
M.!,@5UE&Q/8&&=^,'=_93=S39:K,A!N-"K+$.:H?Q4SHD=NP)#3#7%*>@\#%
MV)GXU[=^QP#*B)\4-_+@&HR5!\X?S>!K,G8\HP@9QLI0$/VWQEMDS#!I';]K
M4J=YI@$>7N_8/Y7FM9D'(O&6LU\T4>G8&3B0X(*LF+KGFR]8&^H9OI@S6?["
MIH[U'(A74O&L!FL%&<VK?_)4)^( $(1G $$-"$X!O3. 3@TH,^=6RDI;=T21
M:"3X!H2)UFSFHLQ-B=9N:&Z6<:Z$ODLU3D5SQ>/'E+,$A7P#T]\KJK;P >;5
MJ@)?P*\R$YA\F*Q1Z)6%B=1K7IA%D/!#8@**PU0JJG.*\(E0 3\)6Z'!ENSP
MO0[^+$BNB8#D"4SGLQE,-D0D$M[>H2*4R7<C5VE+1I@;U_)O*OG!&?E^ -]X
MKE()TSS!Y)C U;EH$A+L$G(3M#+>87P%'?\]!%X06 3=OASNM\CI-.O3*?DZ
M9_@.DGUM2T^%[MK1I@9<RX+$.';T)I<HUNA$KU_YH??19NU"9$=&NXW1;AM[
M-'TJ],XV;Q.*#-[2'+9(A/V=:&?J54CP/<BJ=\/O0T*VTF;YA53^CJIK83KR
MVVO\]E[F=\T9493I?6>S6I'XU>MA:O(Z\J["<.2N#UW44<%Q5+^[CSO2&#8:
MPU:-]U0^PD(@ M4;5Z^Y J$WN4UG:%/@!=ZI4GN<%P[L2ON-TGZKTCNZI@GJ
MNK*ER!*;P+XED2?:6D..9 T:68/V1<X*QK<Z?U4AG*U$G.HS!V:,Y#:1K6S_
MNILO1'9D?-@8'_Y7V1I>TNB%R(Z,^M[^ /4N5KB>H0KK*F,S^0QTL"M0@^<*
ME'_0&OB7*%$URVGU&?2&)_O+'M@/@YY]E_G!7FEPJ4)5,_U=J;JG:NV!GC<\
MHW9_I/NM!^D+BE5-T%JMVF,J:>Y!8YBA6);]LH28KW)5M43-;-.33\I.]&3^
MQO3J9<.YIZD:_6]$+*EN[A@N-*5>3GT6B:IWK@:*%V7[^<"5;F;+RU1_;Z P
M ?K^@G.U&Y@'-%\PT1]02P,$%     @ SD!<5D-^P6-#!   !!(  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#4N>&ULM9A?<]HX$,"_BL;7N6MG$FSY+^2
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MJZX<JA=!5_K4/J="T$(WET#D,5T-D/\O*!7;%S5!<_$S_A]02P,$%     @
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MAARX#E#O%XS)[41O4+3XO7]02P,$%     @ SD!<5I[+W]2U!   S1D  !D
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M]H#* /]?<"Z?+]0 ]1><^?]02P,$%     @ SD!<5B?5@/!2 P  =PD  !D
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M>9GHUA&%F:"?;SA7]P,3H&E&@]]02P,$%     @ SD!<5A-X7>U> P  P!8
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M=^>!FG)SH@A6%?.&[6 <21(,@5ITUV@<([,3P\>]/M@NB:(D<2. N1U$$8;
M;L01S %XP) H,K^#.[]'P?IW*FC_9SWZ"U!+ P04    " #.0%Q6EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( ,Y
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M.=K<TTH7]3&?M7^@IY]02P$"% ,4    " #.0%Q6!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,Y
M7%;/4S'8[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( ,Y 7%:97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ SD!<5A^]CU>G
M"   V34  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( ,Y 7%8&JWRN=08  *@;   8              "
M@>H0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #.0%Q6
M%99\#%X#  #H"P  &               @(&5%P  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ SD!<5JW.#9U%!   70\  !@
M     ("!*1L  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M ,Y 7%8&/._-I0(  )D&   8              " @:0?  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " #.0%Q6CA$TL>(&  !G-   &
M            @(%_(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ SD!<5J"!I@X:"   IB8  !@              ("!ERD  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ,Y 7%9FEX>+FP(  )4&
M   8              " @><Q  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " #.0%Q6QT;?+:P<  "?50  &               @(&X-
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ SD!<5BU'$[_"
M P  J @  !D              ("!FE$  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " #.0%Q6&UG,AI\%   S$   &0
M@(&350  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,Y
M7%8%7)D=M@<  (\2   9              " @6E;  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ SD!<5L,J&*/&!   Z@L  !D
M         ("!5F,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " #.0%Q6 7=TLLX-  !))@  &0              @(%3:   >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,Y 7%9_2TSKR@D   (=
M   9              " @5AV  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ SD!<5L>*[F4S$P  /CP  !D              ("!68
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #.0%Q6@.>1
M>)$(  ":%@  &0              @('#DP  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( ,Y 7%97(916G (  ,L%   9
M  " @8N<  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MSD!<5E3S<T\-'@  $F   !D              ("!7I\  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " #.0%Q67C6L%(8#   ["   &0
M            @(&BO0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( ,Y 7%:<%K:RH ,   0)   9              " @5_!  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ SD!<5DFAIMU, P
ML@<  !D              ("!-L4  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " #.0%Q69J-[CM("  !#!@  &0              @(&Y
MR   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ,Y 7%9"
M1;/9IP8  !\4   9              " @<++  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ SD!<5GX[.[*H!   ;0L  !D
M     ("!H-(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,Y 7%;'1VZY' 0  +\5   9              "
M@5GM  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ SD!<
M5OE]5Y?W!@  #R,  !D              ("!K/$  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " #.0%Q63B%_1$T$  #(%0  &0
M        @(':^   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( ,Y 7%8PTUR=P0(  $0(   9              " @5[]  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ SD!<5HA)NUR$ P  ;0P
M !D              ("!5@ ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " #.0%Q6GK(^O54"   ]!0  &0              @($1! $
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,Y 7%;)@+[;
M6PH  '-E   9              " @9T& 0!X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ SD!<5F/LYZ6Z @  +0<  !D
M ("!+Q$! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #.
M0%Q6XHS82"X*  !Y0P  &0              @($@% $ >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,Y 7%8R02YUN0(  *4&   9
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M970T,RYX;6Q02P$"% ,4    " #.0%Q6^RO"SX(#  #-#   &0
M    @(%D50$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M ,Y 7%9#?L%C0P0   02   9              " @1U9 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ SD!<5C#$]RP[ P  [@L  !D
M             ("!EUT! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " #.0%Q6GLO?U+4$  #-&0  &0              @($)80$ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,Y 7%8GU8#P4@,
M '<)   9              " @?5E 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ SD!<5G#'589% P  +PL  !D              ("!
M?FD! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #.0%Q6
MI*;/9.4"  #F!P  &0              @('Z; $ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,Y 7%8)1AN680,  )@.   9
M      " @19P 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ SD!<5A-X7>U> P  P!8   T              ( !KG,! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #.0%Q6EXJ[',     3 @  "P
M@ $W=P$ 7W)E;',O+G)E;'-02P$"% ,4    " #.0%Q6N:</4#L$   G(@
M#P              @ $@> $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MSD!<5J&7ZI3) 0  H!X  !H              ( !B'P! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ SD!<5BBT:!/# 0  B1X  !,
M             ( !B7X! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #L
,.P 4$   ?8 !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>158</ContextCount>
  <ElementCount>367</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical</Role>
      <ShortName>Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Statement - Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Lease Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitments</Role>
      <ShortName>Lease Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Revenue Interest Financing Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiability</Role>
      <ShortName>Revenue Interest Financing Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Lease Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables</Role>
      <ShortName>Lease Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebt</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Revenue Interest Financing Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityTables</Role>
      <ShortName>Revenue Interest Financing Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiability</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Balance Sheet Details - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Details - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Lease Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails</Role>
      <ShortName>Lease Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Debt - Schedule of Total Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails</Role>
      <ShortName>Debt - Schedule of Total Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails</Role>
      <ShortName>Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Revenue Interest Financing Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails</Role>
      <ShortName>Revenue Interest Financing Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Revenue Interest Financing Liability - Schedule of Total Revenue Interest Financing Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails</Role>
      <ShortName>Revenue Interest Financing Liability - Schedule of Total Revenue Interest Financing Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stockholders' Equity - Summary of Unvested Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Unvested Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stockholders' Equity - Summary of PSU and RSUs Activity Under the 2019 Incentive Award Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails</Role>
      <ShortName>Stockholders' Equity - Summary of PSU and RSUs Activity Under the 2019 Incentive Award Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="phat-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Subsequent Events - Additional Information - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, phat:RepurchaseRightLapseShares, us-gaap:PropertyPlantAndEquipmentUsefulLife -  phat-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="phat-20221231.htm">phat-20221231.htm</File>
    <File>phat-20221231.xsd</File>
    <File>phat-20221231_cal.xml</File>
    <File>phat-20221231_def.xml</File>
    <File>phat-20221231_lab.xml</File>
    <File>phat-20221231_pre.xml</File>
    <File>phat-ex10_37.htm</File>
    <File>phat-ex23_1.htm</File>
    <File>phat-ex24_1.htm</File>
    <File>phat-ex31_1.htm</File>
    <File>phat-ex31_2.htm</File>
    <File>phat-ex32_1.htm</File>
    <File>phat-ex32_2.htm</File>
    <File>phat-ex4_6.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img46421407_0.jpg</File>
    <File>img46421407_1.jpg</File>
    <File>img46421407_10.jpg</File>
    <File>img46421407_11.jpg</File>
    <File>img46421407_12.jpg</File>
    <File>img46421407_13.jpg</File>
    <File>img46421407_14.jpg</File>
    <File>img46421407_15.jpg</File>
    <File>img46421407_16.jpg</File>
    <File>img46421407_17.jpg</File>
    <File>img46421407_18.jpg</File>
    <File>img46421407_19.jpg</File>
    <File>img46421407_2.jpg</File>
    <File>img46421407_20.jpg</File>
    <File>img46421407_21.jpg</File>
    <File>img46421407_22.jpg</File>
    <File>img46421407_3.jpg</File>
    <File>img46421407_4.jpg</File>
    <File>img46421407_5.jpg</File>
    <File>img46421407_6.jpg</File>
    <File>img46421407_7.jpg</File>
    <File>img46421407_8.jpg</File>
    <File>img46421407_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="492">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "phat-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 492,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 158,
   "dts": {
    "calculationLink": {
     "local": [
      "phat-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "phat-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "phat-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "phat-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "phat-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "phat-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 594,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 7,
    "http://www.phathompharma.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 12
   },
   "keyCustom": 101,
   "keyStandard": 266,
   "memberCustom": 47,
   "memberStandard": 29,
   "nsprefix": "phat",
   "nsuri": "http://www.phathompharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:ComponentOfBalanceSheetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Balance Sheet Details",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:ComponentOfBalanceSheetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Lease Commitments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitments",
     "shortName": "Lease Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:RevenueInterestFinancingLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Revenue Interest Financing Liability",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiability",
     "shortName": "Revenue Interest Financing Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:RevenueInterestFinancingLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:OrganizationAndBasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:OrganizationAndBasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Balance Sheet Details (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Lease Commitments (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables",
     "shortName": "Lease Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "phat:RevenueInterestFinancingLiabilityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Revenue Interest Financing Liability (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityTables",
     "shortName": "Revenue Interest Financing Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "phat:RevenueInterestFinancingLiabilityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails",
     "shortName": "Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Balance Sheet Details - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails",
     "shortName": "Balance Sheet Details - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_3e93f3f8-5fa9-4e0e-9be2-05e4b1b44b52",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:AgreementExtendsPeriodForTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_3e93f3f8-5fa9-4e0e-9be2-05e4b1b44b52",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:AgreementExtendsPeriodForTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "INF",
      "lang": null,
      "name": "phat:PurchaseCommitmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Lease Commitments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails",
     "shortName": "Lease Commitments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
     "shortName": "Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails",
     "shortName": "Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Debt - Schedule of Total Debt (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails",
     "shortName": "Debt - Schedule of Total Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Debt - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4f067a4b-daf1-4028-b748-712e3b729620",
      "decimals": "4",
      "lang": null,
      "name": "phat:DebtInstrumentInterestRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails",
     "shortName": "Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "phat:RevenueInterestFinancingLiabilityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:InvestorsRightToReceiveRoyaltiesTerminationDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Revenue Interest Financing Liability - Additional Information (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
     "shortName": "Revenue Interest Financing Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "phat:RevenueInterestFinancingLiabilityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:InvestorsRightToReceiveRoyaltiesTerminationDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock",
       "div",
       "phat:RevenueInterestFinancingLiabilityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:GrossProceedsFromRevenueInterestFinancingAgreement",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Revenue Interest Financing Liability - Schedule of Total Revenue Interest Financing Liability (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails",
     "shortName": "Revenue Interest Financing Liability - Schedule of Total Revenue Interest Financing Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_f23428e3-ba82-4280-becf-c920e6849705",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Stockholders' Equity - Summary of Unvested Shares (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails",
     "shortName": "Stockholders' Equity - Summary of Unvested Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "INF",
      "lang": null,
      "name": "phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_e9f3b61c-edfe-4524-8536-373c8a65e8a7",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_f23428e3-ba82-4280-becf-c920e6849705",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stockholders' Equity - Summary of PSU and RSUs Activity Under the 2019 Incentive Award Plan (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
     "shortName": "Stockholders' Equity - Summary of PSU and RSUs Activity Under the 2019 Incentive Award Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_57ad6cf7-3bc9-4eca-af0d-fc80892c2641",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails",
     "shortName": "Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_f23428e3-ba82-4280-becf-c920e6849705",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_c9397005-df60-4c46-9331-f164df01ca76",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_4898bc84-418b-459b-b337-70ce6a60f7c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:ResearchAndDevelopmentExpenseRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Operations and Comprehensive Loss (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical",
     "shortName": "Statements of Operations and Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:ResearchAndDevelopmentExpenseRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_f23428e3-ba82-4280-becf-c920e6849705",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "phat:LiquidityAndCapitalResourcesPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_91c3d758-8c6f-4ad9-ab70-274f0ae21ae5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Subsequent Events - Additional Information - (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_7da2e53f-060f-4407-97fc-6ab72ec3f967",
      "decimals": "-5",
      "lang": null,
      "name": "phat:NetProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_3625bbc7-e0d2-4ae5-80c9-2c2a001c24c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit",
     "shortName": "Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_3625bbc7-e0d2-4ae5-80c9-2c2a001c24c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Statements of Cash Flows (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical",
     "shortName": "Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20221231.htm",
      "contextRef": "C_6c9bf283-aa34-45fe-8828-7e01c81260ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 76,
   "tag": {
    "country_JE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JERSEY",
        "terseLabel": "Florham Park, New Jersey"
       }
      }
     },
     "localname": "JE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "verboseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "phat_ATMOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market offering program.",
        "label": "A T M Offering Program [Member]",
        "terseLabel": "At-the-Market Offering Program",
        "verboseLabel": "ATM Sale Agreement"
       }
      }
     },
     "localname": "ATMOfferingProgramMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payable and accrued expenses related parties current.",
        "label": "Accounts Payable And Accrued Expenses Related Parties Current",
        "verboseLabel": "Outstanding accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesRelatedPartiesCurrent",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AccruedExpensesRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses related parties current.",
        "label": "Accrued Expenses Related Parties Current",
        "terseLabel": "Accrued expenses, related parties"
       }
      }
     },
     "localname": "AccruedExpensesRelatedPartiesCurrent",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest.",
        "label": "Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedInterest",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AccruedInterestOnRevenueInterestFinancingLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest on revenue interest financing liability.",
        "label": "Accrued Interest On Revenue Interest Financing Liability",
        "terseLabel": "Accrued interest on revenue interest financing liability"
       }
      }
     },
     "localname": "AccruedInterestOnRevenueInterestFinancingLiability",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional percentage to be paid with obligated payment on investment amount.",
        "label": "Additional Percentage to be Paid with Obligated Payment On Investment Amount",
        "terseLabel": "Additional percentage to be paid with obligated payment on investment amount"
       }
      }
     },
     "localname": "AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_AdditionalWarrantIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional warrant issued.",
        "label": "Additional Warrant Issued",
        "terseLabel": "Additional warrant issued"
       }
      }
     },
     "localname": "AdditionalWarrantIssued",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital conversion of warrant liability into equity.",
        "label": "Adjustments To Additional Paid In Capital Conversion Of Warrant Liability Into Equity",
        "terseLabel": "Conversion of warrant liability into equity",
        "verboseLabel": "Conversion of lender warrants into equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AggregateOfferingPriceThroughEquityFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate offering price through equity financing.",
        "label": "Aggregate offering price through equity financing",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "AggregateOfferingPriceThroughEquityFinancing",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AgreementExpirationTermFromDateOfFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement expiration term from date of first commercial sale.",
        "label": "Agreement Expiration Term From Date Of First Commercial Sale",
        "terseLabel": "Agreement expiration term from date of first commercial sale"
       }
      }
     },
     "localname": "AgreementExpirationTermFromDateOfFirstCommercialSale",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "phat_AgreementExtendsPeriodForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement extends period for termination.",
        "label": "Agreement Extends Period For Termination",
        "terseLabel": "Agreement extends period for termination"
       }
      }
     },
     "localname": "AgreementExtendsPeriodForTermination",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "phat_AmendmentToLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to loan agreement.",
        "label": "Amendment to Loan Agreement [Member]",
        "terseLabel": "Amendment to Loan Agreement"
       }
      }
     },
     "localname": "AmendmentToLoanAgreementMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_AmountUtilizedOfEquityFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Utilized of equity financing.",
        "label": "Amount Utilized of equity financing",
        "terseLabel": "Amount utilized of equity financing"
       }
      }
     },
     "localname": "AmountUtilizedOfEquityFinancing",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AssetsLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, lessee.",
        "label": "Assets Lessee [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsLesseeAbstract",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_AvailableAggregateOfferingPriceThroughEquityFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available Aggregate offering price through equity financing.",
        "label": "Available Aggregate offering price through equity financing",
        "terseLabel": "Available equity financing amount"
       }
      }
     },
     "localname": "AvailableAggregateOfferingPriceThroughEquityFinancing",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_CashlessExerciseOfCommonStockWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of common stock warrants.",
        "label": "Cashless Exercise Of Common Stock Warrants",
        "terseLabel": "Cashless exercise of common stock warrants, shares"
       }
      }
     },
     "localname": "CashlessExerciseOfCommonStockWarrants",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ChangeInControlDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in control description.",
        "label": "Change in Control Description",
        "terseLabel": "Change in control description"
       }
      }
     },
     "localname": "ChangeInControlDescription",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_ClassOfWarrantOrRightExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, expiration date.",
        "label": "Class of Warrant or Right Expiration Date",
        "terseLabel": "Warrants expiration date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationDate",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "phat_ClassOfWarrantOrRightExpireTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, expire term.",
        "label": "Class of Warrant or Right Expire Term",
        "terseLabel": "Warrants expire term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpireTerm",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, number of securities called by warrants or rights, remains exercisable.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Remains Exercisable",
        "terseLabel": "Warrants issued to common stock remains exercisable",
        "verboseLabel": "Warrants issued to common stock remains exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ClinicalManufacturingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical manufacturing services.",
        "label": "Clinical Manufacturing Services [Member]",
        "terseLabel": "Clinical Manufacturing Services"
       }
      }
     },
     "localname": "ClinicalManufacturingServicesMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_ClosingMarketPriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing market price of common stock.",
        "label": "Closing Market Price Of Common Stock",
        "terseLabel": "Closing market price of common stock"
       }
      }
     },
     "localname": "ClosingMarketPriceOfCommonStock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "phat_CommercialSupplyAgreementAndTemporaryServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Supply Agreement and Temporary Services Agreement.",
        "label": "Commercial Supply Agreement and Temporary Services Agreement [Member]",
        "terseLabel": "Commercial Supply and Temporary Services Agreement"
       }
      }
     },
     "localname": "CommercialSupplyAgreementAndTemporaryServicesAgreementMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_CommercialSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial supply agreements.",
        "label": "Commercial Supply Agreement"
       }
      }
     },
     "localname": "CommercialSupplyAgreementsMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_CommonStockReservedForFutureIssuancesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock reserved for future issuances.",
        "label": "Common Stock Reserved For Future Issuances Table Table [Text Block]",
        "terseLabel": "Summary of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockReservedForFutureIssuancesTableTableTextBlock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrant [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_ComponentOfBalanceSheetDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of Balance Sheet Disclosure.",
        "label": "Component Of Balance Sheet Disclosure [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "ComponentOfBalanceSheetDisclosureTextBlock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Related Software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_ContractWithCustomerLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer, liability.",
        "label": "Contract with Customer, Liability [Table]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityTable",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_DebtInstrumentAdditionalBorrowingCapacityAmounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument additional borrowing capacity amounts.",
        "label": "Debt Instrument Additional Borrowing Capacity Amounts",
        "terseLabel": "Debt instrument, additional borrowing capacity amount"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalBorrowingCapacityAmounts",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_DebtInstrumentFacilityChargePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument facility charge percentage.",
        "label": "Debt Instrument Facility Charge Percentage",
        "terseLabel": "Debt instrument, facility charge percentage"
       }
      }
     },
     "localname": "DebtInstrumentFacilityChargePercentage",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_DebtInstrumentFinalPaymentFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument final payment fee.",
        "label": "Debt Instrument Final Payment Fee",
        "terseLabel": "Debt instrument, final payment fee or end of term charge"
       }
      }
     },
     "localname": "DebtInstrumentFinalPaymentFee",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_DebtInstrumentFinalPaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument final payment fee percentage.",
        "label": "Debt Instrument Final Payment Fee Percentage",
        "terseLabel": "Debt instrument, final payment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentFinalPaymentFeePercentage",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_DebtInstrumentInterestAndFinalPaymentFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest and final payment fee.",
        "label": "Debt Instrument Interest And Final Payment Fee",
        "negatedLabel": "Less payment-in-kind and final payment fee"
       }
      }
     },
     "localname": "DebtInstrumentInterestAndFinalPaymentFee",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_DebtInstrumentInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, interest rate percentage.",
        "label": "Debt Instrument, Interest Rate Percentage",
        "terseLabel": "Debt instrument interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRatePercentage",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_DebtInstrumentPenaltyFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument penalty fee percentage.",
        "label": "Debt Instrument Penalty Fee Percentage",
        "terseLabel": "Debt instrument penalty fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentPenaltyFeePercentage",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment fee percentage of outstanding principal amount.",
        "label": "Debt Instrument Prepayment Fee Percentage Of Outstanding Principal Amount",
        "terseLabel": "Debt instrument, prepayment fee percentage of outstanding principal amount"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_DefaultObligationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Default obligation description.",
        "label": "Default Obligation Description",
        "terseLabel": "Default obligation description"
       }
      }
     },
     "localname": "DefaultObligationDescription",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution pan employer discretionary match number of shares settled.",
        "label": "Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled",
        "terseLabel": "Employer discretionary match number of shares settled",
        "verboseLabel": "401(k) matching contribution, shares"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_DrugProductOrSubstanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product Or substance.",
        "label": "Drug Product Or Substance [Member]",
        "terseLabel": "Drug Product or Substance"
       }
      }
     },
     "localname": "DrugProductOrSubstanceMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees.",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_FinancialAssetsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets fair value disclosure.",
        "label": "Financial Assets Fair Value Disclosure",
        "terseLabel": "Financial assets fair value disclosure"
       }
      }
     },
     "localname": "FinancialAssetsFairValueDisclosure",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow on public offering.",
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Follow-on Public Offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_FoundersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founders.",
        "label": "Founders [Member]",
        "terseLabel": "Founders"
       }
      }
     },
     "localname": "FoundersMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_FrazierLifeSciencesIXLimitedPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frazier Life Sciences IX, limited partner member.",
        "label": "Frazier Life Sciences I X Limited Partner [Member]",
        "terseLabel": "Frazier"
       }
      }
     },
     "localname": "FrazierLifeSciencesIXLimitedPartnerMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_FundsReceivedFromInitialClosing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds received from initial closing.",
        "label": "Funds Received from Initial Closing",
        "terseLabel": "Funds received from initial closing"
       }
      }
     },
     "localname": "FundsReceivedFromInitialClosing",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_GeneralAndAdministrativeExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative expense related party.",
        "label": "General And Administrative Expense Related Party",
        "terseLabel": "General and administrative expenses, related party"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseRelatedParty",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_GrossProceedsFromRevenueInterestFinancingAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from revenue interest financing agreement.",
        "label": "Gross Proceeds from Revenue Interest Financing Agreement",
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Proceeds from the Revenue Interest Financing Agreement"
       }
      }
     },
     "localname": "GrossProceedsFromRevenueInterestFinancingAgreement",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_HerculesAndSvbTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules and SVB term loan.",
        "label": "Hercules and SVB Term Loan [Member]",
        "terseLabel": "Hercules and SVB Term Loan"
       }
      }
     },
     "localname": "HerculesAndSvbTermLoanMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_HerculesLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules loan agreement.",
        "label": "Hercules Loan Agreement [Member]",
        "terseLabel": "Hercules Loan Agreement"
       }
      }
     },
     "localname": "HerculesLoanAgreementMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation change in fair value of warrants and convertible debt.",
        "label": "Income Tax Reconciliation Change In Fair Value Of Warrants And Convertible Debt",
        "terseLabel": "Change in fair value of warrants and convertible debt"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncomeTaxReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation permanent items.",
        "label": "Income Tax Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentItems",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accounts payable and accrued expenses related parties.",
        "label": "Increase Decrease In Accounts Payable And Accrued Expenses Related Parties",
        "terseLabel": "Related parties accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncreaseDecreaseInClinicalAccruedTrialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in clinical accrued trial expenses.",
        "label": "Increase Decrease In Clinical Accrued Trial Expenses",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInClinicalAccruedTrialExpenses",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating right of use asset and lease liabilities.",
        "label": "Increase Decrease In Operating Right Of Use Asset And Lease Liabilities",
        "terseLabel": "Operating right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease)in prepaid expenses and other assets related parties current.",
        "label": "Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current",
        "terseLabel": "Related parties prepaid expenses and other assets current"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_InitialInvestorsNqSagardAndHerculesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Investors NQ, Sagard, and Hercules.",
        "label": "Initial Investors NQ, Sagard, and Hercules [Member]",
        "terseLabel": "Initial Investors NQ, Sagard, and Hercules"
       }
      }
     },
     "localname": "InitialInvestorsNqSagardAndHerculesMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_InterestExpenseRelatedToRevenueInterestFinancingLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense related to revenue interest financing liability",
        "label": "Interest Expense Related To Revenue Interest Financing Liability",
        "terseLabel": "Interest expense with revenue interest finance liability",
        "verboseLabel": "Plus: interest expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedToRevenueInterestFinancingLiability",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_InvestorAdditionalFundingAmountUponApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investor additional funding amount upon approval.",
        "label": "Investor Additional Funding Amount Upon Approval",
        "terseLabel": "Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis"
       }
      }
     },
     "localname": "InvestorAdditionalFundingAmountUponApproval",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_InvestorsFundingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors funding amount.",
        "label": "Investors Funding Amount",
        "terseLabel": "Investors funding amount"
       }
      }
     },
     "localname": "InvestorsFundingAmount",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors funding commitment potential amount available upon achievement of sales milestone.",
        "label": "Investors Funding Commitment Potential Amount Available Upon Achievement of Sales Milestone",
        "terseLabel": "Investors funding commitment potential amount available upon achievement of sales milestone"
       }
      }
     },
     "localname": "InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_InvestorsReceiptDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors receipt description.",
        "label": "Investors Receipt Description",
        "terseLabel": "Investors receipt description"
       }
      }
     },
     "localname": "InvestorsReceiptDescription",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_InvestorsRightToReceiveRoyaltiesTerminationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors right to receive royalties termination description.",
        "label": "Investors Right to Receive Royalties Termination Description",
        "terseLabel": "Investors right to receive royalties termination description"
       }
      }
     },
     "localname": "InvestorsRightToReceiveRoyaltiesTerminationDescription",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_LanderWarrantsExpireTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lander warrants expire term.",
        "label": "Lander Warrants Expire Term",
        "terseLabel": "Warrants expire term"
       }
      }
     },
     "localname": "LanderWarrantsExpireTerm",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "phat_LenderWarrantsExercisableSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lender warrants exercisable shares of common stock.",
        "label": "Lender Warrants Exercisable Shares Of Common Stock",
        "terseLabel": "Warrants exercisable shares of common stock"
       }
      }
     },
     "localname": "LenderWarrantsExercisableSharesOfCommonStock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_LesseeOperatingLeaseNumberOfOptionToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease number of option to extend.",
        "label": "Lessee Operating Lease Number Of Option To Extend",
        "terseLabel": "Operating lease number of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfOptionToExtend",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "phat_LiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, lessee.",
        "label": "Liabilities Lessee [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesLesseeAbstract",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_LicenseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement description.",
        "label": "License Agreement Description",
        "terseLabel": "License agreement description"
       }
      }
     },
     "localname": "LicenseAgreementDescription",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_LicenseAgreementTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement transaction costs.",
        "label": "License Agreement Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "LicenseAgreementTransactionCosts",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LiquidityAndCapitalResourcesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and capital resources.",
        "label": "Liquidity And Capital Resources Policy [Text Block]",
        "terseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesPolicyTextBlock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan agreement.",
        "label": "Loan Agreement [Member]",
        "terseLabel": "Loan Agreement"
       }
      }
     },
     "localname": "LoanAgreementMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_LongTermDebtAndInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt and interest.",
        "label": "Long Term Debt And Interest",
        "totalLabel": "Total principal and interest payments"
       }
      }
     },
     "localname": "LongTermDebtAndInterest",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 0.0,
       "parentTag": "phat_LongTermDebtAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest, year one.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 3.0,
       "parentTag": "phat_LongTermDebtAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year four.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 2.0,
       "parentTag": "phat_LongTermDebtAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year three.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 1.0,
       "parentTag": "phat_LongTermDebtAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year two.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest remainder of fiscal year.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest Remainder Of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt noncurrent excluding unamortized debt discount.",
        "label": "Long Term Debt Noncurrent Excluding Unamortized Debt Discount",
        "terseLabel": "Long-term debt, non-current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount payable in sales milestones upon the achievement of specified levels of product sales.",
        "label": "Maximum Amount Payable In Sales Milestones Upon Achievement Of Specified Levels Of Product Sales",
        "terseLabel": "Maximum amount payable in sales milestones upon achievement of specified levels of product sales"
       }
      }
     },
     "localname": "MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_MinimumMarketCapitalizationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum market capitalization amount.",
        "label": "Minimum Market Capitalization Amount",
        "terseLabel": "Minimum market capitalization amount"
       }
      }
     },
     "localname": "MinimumMarketCapitalizationAmount",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of qualified cash on principal amount following third performance milestone.",
        "label": "Minimum Percentage of Qualified Cash on Principal Amount Following Third Performance Milestone",
        "terseLabel": "Minimum percentage of qualified cash following third performance milestone"
       }
      }
     },
     "localname": "MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of qualified cash on principal amount prior to third performance milestone.",
        "label": "Minimum Percentage of Qualified Cash on Principal Amount Prior to Third Performance Milestone",
        "terseLabel": "Percentage of qualified cash prior to Third performance milestone"
       }
      }
     },
     "localname": "MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_NetProceedsAfterDeductingUnderwritersCommission": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds after deducting underwriters commission.",
        "label": "Net Proceeds After Deducting Underwriters Commission",
        "terseLabel": "Net proceeds after deducting underwriters commission"
       }
      }
     },
     "localname": "NetProceedsAfterDeductingUnderwritersCommission",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NetProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from issuance of common stock.",
        "label": "Net Proceeds From Issuance Of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NetProceedsFromRevenueInterestFinancingTransaction": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from revenue interest financing transaction.",
        "label": "Net Proceeds From Revenue Interest Financing Transaction",
        "terseLabel": "Net proceeds",
        "verboseLabel": "Net proceeds from revenue interest financing transaction"
       }
      }
     },
     "localname": "NetProceedsFromRevenueInterestFinancingTransaction",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NonCashFinalInterestPaymentFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash final interest payment fee.",
        "label": "Non Cash Final Interest Payment Fee",
        "terseLabel": "Final interest payment fee"
       }
      }
     },
     "localname": "NonCashFinalInterestPaymentFee",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NonCash settlement of defined contribution plan liability in common stock.",
        "label": "Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock",
        "terseLabel": "Settlement of 401(k) liability in common stock"
       }
      }
     },
     "localname": "NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NonCash settlement of employee stock purchase plan liability in common stock.",
        "label": "Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock",
        "terseLabel": "Settlement of ESPP liability in common stock"
       }
      }
     },
     "localname": "NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash issuance of common stock warrants in connection with long term debt.",
        "label": "Noncash Issuance Of Common Stock Warrants In Connection With Long Term Debt",
        "terseLabel": "Issuance of common stock warrants in connection with long-term debt"
       }
      }
     },
     "localname": "NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NonfinancialAssetsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonfinancial assets fair value disclosure.",
        "label": "Nonfinancial Assets Fair Value Disclosure",
        "terseLabel": "Non-financial assets fair value disclosure"
       }
      }
     },
     "localname": "NonfinancialAssetsFairValueDisclosure",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NumberOfWarrantsRemainingExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants remaining exercisable.",
        "label": "Number of Warrants Remaining Exercisable",
        "terseLabel": "Number of warrants remaining exercisable"
       }
      }
     },
     "localname": "NumberOfWarrantsRemainingExercisable",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_OpenMarketSaleAgreementWithJefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sale Agreement with Jefferies LLC.",
        "label": "Open Market Sale Agreement With Jefferies L L C [Member]",
        "terseLabel": "Open Market Sale Agreement with Jefferies LLC"
       }
      }
     },
     "localname": "OpenMarketSaleAgreementWithJefferiesLLCMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liabilities arising from obtaining right-of-use assets",
        "label": "Operating Lease Liabilities Arising From Obtaining Right Of Use Assets",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "phat_OrganizationAndBasisOfPresentationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and basis of presentation.",
        "label": "Organization and Basis of Presentation [Policy Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationPolicyTextBlock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization basis of presentation and summary of significant accounting policies.",
        "label": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization basis of presentation and summary of significant accounting policies.",
        "label": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_PCIPharmaServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCI Pharma Services.",
        "label": "P C I Pharma Services [Member]",
        "terseLabel": "PCI Pharma Services"
       }
      }
     },
     "localname": "PCIPharmaServicesMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_PaymentForFacilityCharge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for facility charge.",
        "label": "Payment for Facility Charge",
        "terseLabel": "Payment for facility charge"
       }
      }
     },
     "localname": "PaymentForFacilityCharge",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PaymentForLicenseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for license amount.",
        "label": "Payment For License Amount",
        "terseLabel": "Cash consideration paid for license"
       }
      }
     },
     "localname": "PaymentForLicenseAmount",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PaymentInKindPikInterestRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment in kind PIK interest rate.",
        "label": "Payment in Kind PIK Interest Rate [Member]",
        "terseLabel": "Payment In Kind PIK Interest Rate"
       }
      }
     },
     "localname": "PaymentInKindPikInterestRateMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_PaymentOfTransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of transaction costs.",
        "label": "Payment of Transaction Costs",
        "negatedLabel": "Less: transaction costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "PaymentOfTransactionCosts",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate payments on investment amount to investors on net sales.",
        "label": "Percentage Of Aggregate Payments On Investment Amount To Investors On Net Sales",
        "terseLabel": "Percentage of aggregate payments on investment amount to investors on net sales"
       }
      }
     },
     "localname": "PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate payments on investment amount to investors.",
        "label": "Percentage Of Aggregate Payments On Investment Amount To Investors",
        "terseLabel": "Percentage of aggregate payment on investment amount to investors"
       }
      }
     },
     "localname": "PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of debt funded to be issued as warrants to purchase common stock.",
        "label": "Percentage of Debt Funded to be Issued as Warrants to Purchase Common Stock",
        "terseLabel": "Percentage of debt funded to be issued as warrants to purchase common stock"
       }
      }
     },
     "localname": "PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_PercentageOfInvestorShareOfRoyaltyInNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of investor share of royalty in net sales.",
        "label": "Percentage of Investor Share of Royalty in Net Sales",
        "terseLabel": "Percentage of investor share of royalty in net sales"
       }
      }
     },
     "localname": "PercentageOfInvestorShareOfRoyaltyInNetSales",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_PotentialAdditionalInvestorFundingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential additional investor funding amount.",
        "label": "Potential Additional Investor Funding Amount",
        "terseLabel": "Potential additional investor funding amount"
       }
      }
     },
     "localname": "PotentialAdditionalInvestorFundingAmount",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other assets related parties current.",
        "label": "Prepaid Expenses And Other Assets Related Parties Current",
        "terseLabel": "Prepaid expenses and other current assets, related parties"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PrepaidLeasePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid lease payments.",
        "label": "Prepaid Lease Payments [Member]",
        "terseLabel": "Prepaid Lease Payments"
       }
      }
     },
     "localname": "PrepaidLeasePaymentsMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_ProceedsFromIssuanceInitialPublicOfferingGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance initial public offering gross.",
        "label": "Proceeds From Issuance Initial Public Offering Gross",
        "terseLabel": "Proceeds from issuance initial public offering gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingGross",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PurchaseCommitmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase commitment, expense.",
        "label": "Purchase Commitment Expense",
        "terseLabel": "Expenses incurred related to purchase commitments"
       }
      }
     },
     "localname": "PurchaseCommitmentExpense",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PurchaseObligationDueInFirstTwentyFourMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase obligation due in first twenty four months.",
        "label": "Purchase Obligation Due In First Twenty Four Months",
        "terseLabel": "Purchase obligation in the first 24-month period"
       }
      }
     },
     "localname": "PurchaseObligationDueInFirstTwentyFourMonths",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PurchaseOfAdditionalOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of additional offering expenses.",
        "label": "Purchase Of Additional Offering Expenses",
        "terseLabel": "Purchase of additional offering expenses"
       }
      }
     },
     "localname": "PurchaseOfAdditionalOfferingExpenses",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction shared operating expenses due to transactions with related party.",
        "label": "Related Party Transaction Shared Operating Expenses Due To Transactions With Related Party",
        "verboseLabel": "Shared operating expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_RepurchaseRightLapseRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase right lapse rate.",
        "label": "Repurchase Right Lapse Rate",
        "terseLabel": "Repurchase right lapse rate"
       }
      }
     },
     "localname": "RepurchaseRightLapseRate",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_RepurchaseRightLapseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase right lapse shares.",
        "label": "Repurchase Right Lapse Shares",
        "terseLabel": "Repurchase right lapse each month after first anniversary, shares"
       }
      }
     },
     "localname": "RepurchaseRightLapseShares",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "phat_ResearchAndDevelopmentExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense related party.",
        "label": "Research And Development Expense Related Party",
        "terseLabel": "Research and development expenses, related party"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseRelatedParty",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit carry forward expiration year.",
        "label": "Research And Development Tax Credit Carry Forward Expiration Year",
        "terseLabel": "Research and development credits expiration period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing agreement funding commitment on or before March thirty one two thousand and twenty four.",
        "label": "Revenue Interest Financing Agreement Funding Commitment On Or Before March Thirty One Two Thousand And Twenty Four [Member]",
        "terseLabel": "Revenue Interest Financing Agreement, Funding Commitment On or Before March 31, 2024"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue \u200binterest\u200b financing\u200b agreement\u200b funding upon achievement of sales milestone at any time prior to June thirty two thousand and twenty four.",
        "label": "Revenue Interest Financing Agreement Funding Upon Achievement of Sales Milestone At Any Time prior To June Thirty Two Thousand and Twenty Four [Member]",
        "terseLabel": "Revenue Interest Financing Agreement Funding upon Achievement of Sales Milestone at any Time Prior to June 30, 2024"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue \u200binterest\u200b financing\u200b agreement\u200b funding upon FDA approval at any time prior to December thirty one two thousand and twenty two.",
        "label": "Revenue Interest Financing Agreement Funding Upon FDA Approval At Any Time prior To December Thirty One Two Thousand and Twenty Two [Member]",
        "terseLabel": "Revenue Interest Financing Agreement Funding upon FDA Approval at any Time Prior to December 31, 2022"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Financing Agreement [Member]",
        "label": "Revenue Interest Financing Agreement [Member]",
        "terseLabel": "Revenue Interest Financing Agreement"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing agreement percentage on investment amount On December thirty one two thousand and thirty seven.",
        "label": "Revenue Interest Financing Agreement Percentage On Investment Amount On December Thirty One Two Thousand And Thirty Seven [Member]",
        "terseLabel": "Revenue Interest Financing Agreement Percentage On Investment Amount by December 31, 2037"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing agreement percentage on investment amount on December thirty one two thousand and twenty eight.",
        "label": "Revenue Interest Financing Agreement Percentage on Investment Amount On December Thirty One Two Thousand And Twenty Eight [Member]",
        "terseLabel": "Revenue Interest Financing Agreement Percentage on Investment Amount On December December 31, 2028"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing agreement upon occurrence of a change in control event earlier of April one two thousand and twenty four or FDA approval If occurrence is thereafter to May three two thousand and twenty three.",
        "label": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA approval If occurrence is Thereafter to May Three Two Thousand and Twenty Three [Member]",
        "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA approval If occurrence is Thereafter to May 3, 2023"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing agreement upon occurrence of a change in control event earlier of April one two thousand and twenty four or FDA approval If occurrence is prior to May three two thousand and twenty three.",
        "label": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA Approval If Occurrence Prior to May Three Two Thousand and Twenty Three [Member]",
        "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing agreement upon occurrence of a Change in control event earlier of April one two thousand and twenty four or FDA Approval.",
        "label": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA Approval [Member]",
        "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing agreement upon occurrence of event of default after April one two thousand and twenty eight.",
        "label": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default After April One Two Thousand and Twenty Eight [Member]",
        "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default after April 1, 2028"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing agreement upon occurrence of event between April one two thousand and twenty five and April one two thousand and twenty eight.",
        "label": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default Between April One Two Thousand and Twenty Five and April One Two Thousand and Twenty Eight [Member]",
        "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default between April 1, 2025, and April 1, 2028"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing agreement upon occurrence of event of default prior to April one two thousand and twenty five.",
        "label": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default prior to April One Two thousand and Twenty Five [Member]",
        "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default Prior to April 1, 2025"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_RevenueInterestFinancingLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing liability.",
        "label": "Revenue Interest Financing Liability",
        "periodEndLabel": "Ending liability balance",
        "periodStartLabel": "Beginning liability balance",
        "terseLabel": "Revenue interest financing liability"
       }
      }
     },
     "localname": "RevenueInterestFinancingLiability",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_RevenueInterestFinancingLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing liability noncurrent.",
        "label": "Revenue Interest Financing Liability Noncurrent",
        "terseLabel": "Revenue interest financing liability"
       }
      }
     },
     "localname": "RevenueInterestFinancingLiabilityNoncurrent",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_RevenueInterestFinancingLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing liability.",
        "label": "Revenue Interest Financing Liability [Policy Text Block]",
        "terseLabel": "Revenue Interest Financing Liability"
       }
      }
     },
     "localname": "RevenueInterestFinancingLiabilityPolicyTextBlock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_RevenueInterestFinancingLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest financing liability.",
        "label": "Revenue Interest Financing Liability [Text Block]",
        "terseLabel": "Revenue Interest Financing Liability"
       }
      }
     },
     "localname": "RevenueInterestFinancingLiabilityTextBlock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales commission payable as a percentage of sale of gross sales price per share.",
        "label": "Sales Commission Payable as a percentage of sale of Gross Sales Price per share",
        "terseLabel": "Sales commission payable as a percentage of sale of gross sales price per share"
       }
      }
     },
     "localname": "SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of revenue interest financing liability.",
        "label": "Schedule of Revenue Interest Financing Liability [Table Text Block]",
        "terseLabel": "Schedule of Total Revenue Interest Financing Liability"
       }
      }
     },
     "localname": "ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, share vesting.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting",
        "negatedLabel": "Share vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant annual increase.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Annual Increase",
        "terseLabel": "Number of shares remain available for issuance, annual increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, options and other than options forfeitures and expirations in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options and Other Than Options Forfeitures and Expirations in Period",
        "terseLabel": "Number of shares, cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, options and other than options, grants in period gross.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options and Other than Options, Grants In Period Gross",
        "terseLabel": "Number of shares, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award stock options exercised and shares vested.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercised And Shares Vested",
        "terseLabel": "Options Outstanding, Options exercised and shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award options exercises and shares vested in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises And Shares Vested In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options exercised and shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, employee and nonemployee.",
        "label": "Share Based Payment Arrangement Employee And Nonemployee [Member]",
        "terseLabel": "Employee and Nonemployee Director"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeAndNonemployeeMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_SharesAggregateRepurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares aggregate repurchase price.",
        "label": "Shares Aggregate Repurchase Price",
        "terseLabel": "Shares aggregate repurchase price"
       }
      }
     },
     "localname": "SharesAggregateRepurchasePrice",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "phat_SharesIssuedPricePerShareAfterDeductions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued, price per share after deductions.",
        "label": "Shares Issued Price Per Share After Deductions",
        "terseLabel": "Purchase price per share after deducting underwriting discounts and commissions"
       }
      }
     },
     "localname": "SharesIssuedPricePerShareAfterDeductions",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "phat_SiliconValleyBankTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SVB term loan.",
        "label": "Silicon Valley Bank Term Loan [Member]",
        "terseLabel": "SVB Term Loan"
       }
      }
     },
     "localname": "SiliconValleyBankTermLoanMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares cashless exercise of common stock warrants.",
        "label": "Stock Issued During Period Shares Cashless Exercise of Common Stock Warrants",
        "terseLabel": "Cashless exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfCommonStockWarrants",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares exercise of warrants.",
        "label": "Issuance of common stock from exercise of warrants, shares",
        "verboseLabel": "Issuance of common stock warrants shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares, restricted stock award and restricted stock units.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award And Restricted Stock Units",
        "terseLabel": "Vesting of restricted shares and restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardAndRestrictedStockUnits",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value exercise of warrants.",
        "label": "Issuance of common stock from exercise of warrants",
        "terseLabel": "Issuance of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option performance-based unit and restricted stock unit.",
        "label": "Stock Option Performance-based Unit and Restricted Stock Unit [Member]",
        "terseLabel": "Stock options, PSUs and RSUs"
       }
      }
     },
     "localname": "StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_StockOptionsAndPerformanceBasedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and performance-based awards.",
        "label": "Stock Options And Performance Based Awards [Member]",
        "terseLabel": "Stock Options and Performance-Based Awards Outstanding"
       }
      }
     },
     "localname": "StockOptionsAndPerformanceBasedAwardsMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_StockOptionsAndPerformanceBasedUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and performance-based units.",
        "label": "Stock options and performance-based units [Member]",
        "terseLabel": "Stock Options and Performance-based Units"
       }
      }
     },
     "localname": "StockOptionsAndPerformanceBasedUnitsMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_StockRepurchaseProgramExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchase Program Expiration Month and Year",
        "label": "Stock repurchase program expiration period"
       }
      }
     },
     "localname": "StockRepurchaseProgramExpirationMonthAndYear",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "phat_StockRepurchaseProgramNumberOfSharesRightLapse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock repurchase program, number of shares right lapse.",
        "label": "Stock Repurchase Program Number Of Shares Right Lapse",
        "terseLabel": "Stock repurchase program, number of shares right lapse"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesRightLapse",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of supplemental balance sheet information related to operating leases.",
        "label": "Summary Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Supplemental Balance Sheet Information Related to the Operating Leases"
       }
      }
     },
     "localname": "SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_TakedaLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda license agreement.",
        "label": "Takeda License Agreement [Member]",
        "terseLabel": "Takeda License",
        "verboseLabel": "Takeda License Agreement"
       }
      }
     },
     "localname": "TakedaLicenseAgreementMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda pharmaceutical company limited.",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax cuts and jobs act, research and development expenditures amortization period.",
        "label": "Tax Cuts and Jobs Act, Research and Development Expenditures Amortization Period",
        "terseLabel": "Research and development expenditures, amortization period"
       }
      }
     },
     "localname": "TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "phat_TemporaryServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary services agreement.",
        "label": "Temporary Services Agreement [Member]",
        "terseLabel": "Temporary Services Agreement"
       }
      }
     },
     "localname": "TemporaryServicesAgreementMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoanAdvanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan advance.",
        "label": "Term Loan Advance [Member]",
        "terseLabel": "Term Loan Advance"
       }
      }
     },
     "localname": "TermLoanAdvanceMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoanFirstAdvanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan first advance.",
        "label": "Term Loan First Advance [Member]",
        "terseLabel": "Term Loan First Advance"
       }
      }
     },
     "localname": "TermLoanFirstAdvanceMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan",
        "verboseLabel": "Term Loans"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoansAggregatePrincipalAmountTranchesFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans, aggregate principal amount tranches four.",
        "label": "Term Loans Aggregate Principal Amount Tranches Four [Member]",
        "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Four"
       }
      }
     },
     "localname": "TermLoansAggregatePrincipalAmountTranchesFourMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoansAggregatePrincipalAmountTranchesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans, aggregate principal amount tranches one.",
        "label": "Term Loans Aggregate Principal Amount Tranches One [Member]",
        "terseLabel": "Term Loans, Aggregate Principal Amount Tranches One"
       }
      }
     },
     "localname": "TermLoansAggregatePrincipalAmountTranchesOneMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans aggregate principal amount tranches three and four.",
        "label": "Term Loans Aggregate Principal Amount Tranches Three and Four [Member]",
        "terseLabel": "Term Loans Aggregate Principal Amount Tranches Three and Four"
       }
      }
     },
     "localname": "TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoansAggregatePrincipalAmountTranchesThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans, aggregate principal amount tranches three.",
        "label": "Term Loans Aggregate Principal Amount Tranches Three [Member]",
        "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Three"
       }
      }
     },
     "localname": "TermLoansAggregatePrincipalAmountTranchesThreeMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoansAggregatePrincipalAmountTranchesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans, aggregate principal amount tranches two.",
        "label": "Term Loans Aggregate Principal Amount Tranches Two [Member]",
        "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Two"
       }
      }
     },
     "localname": "TermLoansAggregatePrincipalAmountTranchesTwoMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TwoThousandNineteenIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen incentive award plan.",
        "label": "Two Thousand Nineteen Incentive Award Plan [Member]",
        "terseLabel": "2019 Incentive Award Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenIncentiveAwardPlanMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_UnvestedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested shares.",
        "label": "Unvested Shares [Member]",
        "terseLabel": "Unvested Shares"
       }
      }
     },
     "localname": "UnvestedSharesMember",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_WarrantsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expiration date.",
        "label": "Warrants Expiration Date",
        "terseLabel": "Warrants expiration date"
       }
      }
     },
     "localname": "WarrantsExpirationDate",
     "nsuri": "http://www.phathompharma.com/20221231",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r241",
      "r270",
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r277",
      "r398",
      "r417",
      "r436",
      "r437",
      "r450",
      "r452",
      "r460",
      "r493",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r277",
      "r398",
      "r417",
      "r436",
      "r437",
      "r450",
      "r452",
      "r460",
      "r493",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r273",
      "r277",
      "r304",
      "r305",
      "r306",
      "r397",
      "r398",
      "r417",
      "r436",
      "r437",
      "r450",
      "r452",
      "r460",
      "r489",
      "r493",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r273",
      "r277",
      "r304",
      "r305",
      "r306",
      "r397",
      "r398",
      "r417",
      "r436",
      "r437",
      "r450",
      "r452",
      "r460",
      "r489",
      "r493",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r241",
      "r270",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r217",
      "r218",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r451",
      "r459",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r423",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r451",
      "r459",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r487",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Buffalo Grove, Illinois"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "Florham Park, New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r458"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable (including related party amounts of $35 and $1,343 respectively)",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r11",
      "r118",
      "r119",
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Related Parties, Current",
        "terseLabel": "Accounts payable, related parties"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation expenses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses (including related party amountsof $2,499 and $2,330, respectively)",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional &amp; consulting expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r62",
      "r147"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r483",
      "r484",
      "r485",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r95",
      "r96",
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r68",
      "r71",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Adjustments to additional paid-in-capital, warrants issued",
        "verboseLabel": "Issuance of common stock warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation cost",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r27",
      "r260",
      "r371",
      "r477"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Unvested shares excluded from computation of weighted average earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r120",
      "r131",
      "r149",
      "r167",
      "r205",
      "r213",
      "r215",
      "r219",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r345",
      "r349",
      "r362",
      "r458",
      "r491",
      "r492",
      "r536"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r143",
      "r151",
      "r167",
      "r219",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r345",
      "r349",
      "r362",
      "r458",
      "r491",
      "r492",
      "r536"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Floor Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r44",
      "r145",
      "r438"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r39",
      "r44",
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents \u2013 end of period",
        "periodStartLabel": "Cash and cash equivalents \u2013 beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r39",
      "r112"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued to purchase shares",
        "verboseLabel": "Warrants issued to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Revenue Interest Financing Liability [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r124",
      "r136"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r223",
      "r224",
      "r424",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)",
        "verboseLabel": "Common stock initially reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r483",
      "r484",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Common stock, outstanding shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r458"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value; authorized shares - 400,000,000 at December 31, 2022 and 2021; issued shares - 41,723,308 and 31,656,035 at December 31, 2022 and 2021, respectively; outstanding shares - 41,468,871 and 30,511,226 at December 31, 2022 and 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Common stock fair value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r129",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r166",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r254",
      "r261",
      "r262",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r121",
      "r122",
      "r130",
      "r172",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r372",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r3",
      "r122",
      "r130",
      "r265"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt outstanding",
        "totalLabel": "Total term loan borrowings",
        "verboseLabel": "Term loans aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r114",
      "r116",
      "r238",
      "r372",
      "r446",
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate amount of debt instrument",
        "verboseLabel": "Debt instrument borrowed amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r16",
      "r114",
      "r267",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r16",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r152",
      "r445",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r18",
      "r172",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r372",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "auth_ref": [
      "r17",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.",
        "label": "Debt Instrument, Payment Terms",
        "terseLabel": "Debt instrument, description"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r18",
      "r72",
      "r73",
      "r74",
      "r75",
      "r113",
      "r114",
      "r116",
      "r128",
      "r172",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r372",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r113",
      "r116",
      "r494"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized debt discount",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r108",
      "r525"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "verboseLabel": "Operating loss carryforwards which are carried over indefinitely"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r108",
      "r525"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r106",
      "r108",
      "r525"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research credits",
        "verboseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r108",
      "r525"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan employer contribution liabilities expense"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "401(k) matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Defined contribution plan, employer matching contribution, percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_Disclosure401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r42",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r42",
      "r203"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r281",
      "r309",
      "r310",
      "r312",
      "r316",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "verboseLabel": "Domestic"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r160",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r186",
      "r188",
      "r190",
      "r191",
      "r192",
      "r194",
      "r352",
      "r353",
      "r412",
      "r415",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r160",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r188",
      "r190",
      "r191",
      "r192",
      "r194",
      "r352",
      "r353",
      "r412",
      "r415",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation expense, weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r71",
      "r141",
      "r156",
      "r157",
      "r158",
      "r173",
      "r174",
      "r175",
      "r177",
      "r183",
      "r185",
      "r195",
      "r220",
      "r272",
      "r313",
      "r314",
      "r315",
      "r335",
      "r336",
      "r351",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r387",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r42",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrant liabilities",
        "verboseLabel": "Fair value adjustment of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "terseLabel": "Fair value liability, transfers into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Fair value liability, transfers out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative (includes related party amounts of $0 and $18, respectively)",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r278",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r278",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r42",
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r322",
      "r328",
      "r333",
      "r337",
      "r339",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r169",
      "r184",
      "r185",
      "r204",
      "r320",
      "r338",
      "r340",
      "r416"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Provision (benefit) for income taxes",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r318",
      "r319",
      "r328",
      "r329",
      "r332",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income taxes computed at the statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses (includes changes in related party amounts of $1,139 and $2,766, respectively)",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets (includes changes in related party amounts of $0 and $82, respectively)",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r115",
      "r126",
      "r159",
      "r202",
      "r370"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r31",
      "r258",
      "r268",
      "r448",
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "totalLabel": "Interest Expense, Debt, Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r161",
      "r164",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r29",
      "r201"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments Under Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease, option to extend description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating leases, remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lease Commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Lessor, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r167",
      "r219",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r346",
      "r349",
      "r350",
      "r362",
      "r443",
      "r491",
      "r536",
      "r537"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r123",
      "r134",
      "r458",
      "r480",
      "r488",
      "r529"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r144",
      "r167",
      "r219",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r346",
      "r349",
      "r350",
      "r362",
      "r458",
      "r491",
      "r536",
      "r537"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r122",
      "r132",
      "r251",
      "r266",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total debt, net of debt discount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt",
        "totalLabel": "Long-term Debt, Current Maturities, Total",
        "verboseLabel": "Long-term debt, current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of discount",
        "totalLabel": "Long-term Debt, Excluding Current Maturities, Total"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r18",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r39",
      "r40",
      "r43"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r43",
      "r125",
      "r137",
      "r142",
      "r153",
      "r154",
      "r158",
      "r167",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r189",
      "r205",
      "r212",
      "r214",
      "r216",
      "r219",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r353",
      "r362",
      "r444",
      "r491"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.",
        "label": "Nonfinancial Liabilities Fair Value Disclosure",
        "terseLabel": "Non-financial liabilities fair value disclosure",
        "totalLabel": "Nonfinancial Liabilities Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "NonfinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Total other income (expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r205",
      "r212",
      "r214",
      "r216",
      "r444"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating leases, rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: operating lease liabilities, current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r375",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash payments for operating lease costs"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r380",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r379",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r50",
      "r56",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization, Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other",
        "totalLabel": "Other Noncash Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Issuance of PIK interest debt"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of partner's capital account. Examples of classes of partners include, but not limited to, general partners, limited partners, preferred partners, and other ownership interests.",
        "label": "Partner Type [Axis]",
        "terseLabel": "Partner Type"
       }
      }
     },
     "localname": "PartnerTypeOfPartnersCapitalAccountAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain": {
     "auth_ref": [
      "r78",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital accounts of each type or class of partner. Examples of classes of partners include, but are not limited to, general partners, limited partners, preferred partners, and other ownership interests.",
        "label": "Partner Type of Partners' Capital Account, Name [Domain]",
        "terseLabel": "Partner Type of Partners' Capital Account, Name"
       }
      }
     },
     "localname": "PartnerTypeOfPartnersCapitalAccountNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Aggregate repurchase price of warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Cash paid for property, plant and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-Based Stock Units (PSU)"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized shares",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued shares",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "verboseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, outstanding shares",
        "verboseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r458"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "verboseLabel": "Preferred stock, $0.0001 par value authorized shares 40,000,000 at December 31, 2020 and 2019 no shares issued and outstanding at December 31, 2020 and 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity.",
        "label": "Principal Owner [Member]",
        "terseLabel": "Frazier"
       }
      }
     },
     "localname": "PrincipalOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of issuance costs",
        "verboseLabel": "Proceeds from Initial Public Offering (IPO)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of shares",
        "verboseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Net proceeds from issuance of long-term debt",
        "totalLabel": "Proceeds from Issuance of Long-term Debt, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r93"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r142",
      "r153",
      "r154",
      "r162",
      "r167",
      "r176",
      "r184",
      "r185",
      "r205",
      "r212",
      "r214",
      "r216",
      "r219",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r344",
      "r347",
      "r348",
      "r353",
      "r362",
      "r413",
      "r444",
      "r455",
      "r456",
      "r474",
      "r491"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Disposals",
        "terseLabel": "Disposal of property, plant or equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r61",
      "r146"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property, plant and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r63",
      "r135",
      "r414",
      "r458"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant, and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Minimum purchase obligation",
        "totalLabel": "Purchase Obligation, Total"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r274",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r140",
      "r390",
      "r391",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expense related to services"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r274",
      "r390",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r388",
      "r389",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "verboseLabel": "Final payment of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt",
        "totalLabel": "Repayments of Long-term Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r98",
      "r139",
      "r544"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development (includes related party amounts of $2,123 and $4,933, respectively)",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses and Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r472",
      "r478",
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r76",
      "r133",
      "r421",
      "r422",
      "r458"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r141",
      "r173",
      "r174",
      "r175",
      "r177",
      "r183",
      "r185",
      "r220",
      "r313",
      "r314",
      "r315",
      "r335",
      "r336",
      "r351",
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r18",
      "r72",
      "r73",
      "r74",
      "r75",
      "r113",
      "r114",
      "r116",
      "r128",
      "r446",
      "r448",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Total Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r91",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Principal Payments Under Term Loans"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "terseLabel": "Summary of PSU Activity Under the 2019 Incentive Award Plan"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r278",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r85",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate Fair Value of ESPP Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Unvested Shares"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "terseLabel": "Equity plan, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Stock Units, Forfeited",
        "terseLabel": "Number of Stock Units, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Stock Units, Granted",
        "verboseLabel": "Stock awards, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance at December 31, 2022",
        "periodStartLabel": "Balance at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Unvested Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Stock Units, Vested",
        "terseLabel": "Number of Stock Units, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum percentage of eligible compensation contributed by participants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock, shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options Outstanding, Options exercisable as of December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options exercisable as of December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Outstanding, Options cancelled",
        "terseLabel": "Options Outstanding, Options cancelled",
        "verboseLabel": "Options cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options Outstanding, Options granted",
        "verboseLabel": "Stock options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Estimated weighted-average fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Outstanding, Ending Balance",
        "periodStartLabel": "Options Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted-Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options Outstanding, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Annual increase to shares available for issuance percentage of outstanding common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "First Anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable as of December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Options exercisable as of December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Options vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r71",
      "r141",
      "r156",
      "r157",
      "r158",
      "r173",
      "r174",
      "r175",
      "r177",
      "r183",
      "r185",
      "r195",
      "r220",
      "r272",
      "r313",
      "r314",
      "r315",
      "r335",
      "r336",
      "r351",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r387",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r195",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "ESPP shares issued, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common stock shares issued",
        "terseLabel": "Issuance of common stock under ATM facility, shares",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r71",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r76",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock from exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "ESPP shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under ATM facility"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r71",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Number of shares authorized to repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Stock repurchase program, period in force"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased",
        "terseLabel": "Remaining number of shares to be repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Repurchases of shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r57",
      "r458",
      "r480",
      "r488",
      "r529"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r369",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r369",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r369",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r369",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r394",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r101",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Gross Unrecognized Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r24",
      "r79",
      "r80"
     ],
     "calculation": {
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "terseLabel": "Treasury stock - 19 and 1 shares at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r22",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r22",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "periodEndLabel": "Treasury stock shares ending balance",
        "terseLabel": "Treasury stock shares ending balance",
        "totalLabel": "Treasury Stock, Shares, Total"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r317",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrual for interest or penalties related to income tax",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest or penalties related income tax",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would affect effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r196",
      "r197",
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Fair value of warrant liabilities",
        "verboseLabel": "Initial fair value of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r187",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r186",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares of common stock outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.phathompharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235116",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r462": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r463": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r464": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r465": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r466": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r467": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r468": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r469": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r471": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0000950170-23-004875-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-004875-xbrl.zip
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MT-YA4:6F=ZA' -E'X$7+,&_7L&MHZT&5AM._$U,A>@C@9('W>D\#Y;P4?'E
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ME -J*3-E JR?SMTTGI<3I2HO!GNFN/DMNO?/P[M-Y5AKT,]X1[0,M$3G0<J
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M2/5#9@_2CV,DS^>A3"6.2@6=J[OL^UEU.#S(F3A,O%NPV9)/NL^RQ05JLG*
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M?*R1G__/J,9K_=IS?6G+=U&<G=*?/Z47W014PKS?(@!Y;N/_BP08?XQB1^4
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M/,QF!]B:1H_R_A=[[QW5U->MC49146E*[ZB@@#2EUR J(" @(+TI2 U%>H!
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M^ 67Q2[TJY\!?G'10Y3.J>;)V"*5;\Y:]JEG#] HSE8[\<JKQG$<3: 'XG1
ML2(O=G,%3]$!O#TJKRE96+!ND&4=K%U7>8V'HMF,\;,,=:!%]]<5Z?*<0OE?
M35 3=_A$NN]=(9:';3I18Q@.G;OT.F8%KW34"+I_'J$JW[,GH^M ,&S!"BA
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MJ!I@^EM>$E-K1*3(42N?K];*OURM;-<\J@W5OWWV%C#1]=^TV-]3-(?><.&
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M77UU#QE:H^UQK\]ZKJ9 I=05#:_,++L3S9BD=C=PI9KQ((>;O*[\"BE'WC_
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M#*6'MFF7KP$9<$U#@\(YH&5'J01')JLKWI3Z3-"Y"S[[S /2:^:J042=;(C
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M\?K>:SR%DFQG6%Y '0EF4NM??!42+B:HGOTE'!DR']ND1 2M-&O,3\9X985
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MJO-UNXY]$:O":@]D[M[24G3QD77MSW%FM'7M+%&]S":)4M":"WED8 Q7+;,
M?G[<K]EWT\I-!,[OC# E[C(GP_$48)-T4K2^"7HN!F[+]'*3,G#(6D$?2\W1
M,06:?5MOH:M1XSZQQ:BW?BA=WC;JC7)FTA!/,/_A<C#,>>LKV=GOH'@-+BJS
M--F;'Z@7:NT"4+!1/'&*;(=K@DDRUQ7@9L8VM ('1) *4MO6&-6D"-6-[[\W
M7/F>_<#J_1>7-BILI)@@E5V#W&1,-6KUK8GYX*I1Q\;&CW.X?D%;/S*(@/M&
M$R<\/;P 2X?,S?OD**M6N-U@FA1FF8B?.P] <P5/<E(I JC0(L'SI;X3;'=%
M^308\),M;..ELB_SMSK5QN27F9\NGP%;A!U)[IU7A+0R?R-,U6/3":]R73]U
M6,,K7@%,,BJT5T]+D\[2=_*P@\J3UU. ?:?VAR:/JL)4!UWO!]_]X@054!Q3
MW@ D:()8"= CGZNI6R?]Y7*V]4=7'DXN?G7KJY-]_\--1K]?^GR;CI4.^P,C
M/-CEVQ+GYP,K24Q@3?'@4,W@50@3WB@J)074M[5+BDWY&V%Z/^_+<YI@W9!=
M/%EVR>))M[K;HTP919.T^UI%/VK>3]1,:P00<K'9;^)'DB3V<L?-=;Y= 6C=
MF]K=6D$4K:&+K9S;T+HF%V+[ X96D$:HIJE<.49]*_$E@\[XWG>GX:>WHX@S
M7I?\Q":8H&&[TQ 8:*YPA^[DW+.[NWK7C8&L_$O@L.'L?;]WOPQ@<AI&;9<I
M. F,1,<2%;HD;0"L*\OQYS(7<Y(XX378<!W,WIPZN<@!CHLMPW+IU3U-=W>+
M43NC9TP:-'K:GWCX3$T7S:L;LELQ22A*]!4 OE=W#OPL=@4HLU>.XGQYHK+:
M4=8G]8HS;L0()2N#*.'N;F!I@66;=^;;599N[CUPNDU,+-=._)'B-B=Q\MD^
MW+R;DG@3_P0+0[3>!8>KEB4?ZH%L2S;J-67FYWD4^*AD8G?3 ?T<394:F,22
M+/]']>B:T-QMR)R9Z*2 IV2QQZ!>_/J@LI?.DW**E(ZG9B$,#K$D6_B1Z,N9
M13%0;4WA_MZQC<3)U\Q]E5]I1\9;M<L'\MUH8!>4'*=<W=2 7OK5D$J;D.*3
M8Y!VHP\@R?35ZEVLXO/C7$QOES,%3KRRIA%#D7U"7_J+%GTK4L5,G_.!+J>>
MY7C9GARHH_7#HM;T&^P/)(1RUC:Y-MQCR]&A='=7+)],XG%YSP,O*ZY+9$CJ
MH1JV/1/2H7WQ:DYX6[H=VIG.FF (\I-)C.8*_J'+R>Z?BY:XZ]9&T%:<3A'?
MU:#6HFH^ IH_$C.8@]TIS*G?=^Z9EO]:T1SRMKRVH=;QCPG'((/58^5K0+D\
M7W51M'>-7>1#R@"9[?63V3[Y:^3YOVF9DF<',4;?P3/5-"I5Z'C)9(%T+R(+
M)J&R]R=6?<T[^.D,L6D(R%UPRT7WW!'CP];/#]5D5*I:;%$YL??NTNWU=;D%
M!2E+#8-XZ^A>"Z?F9N%;?X&4GIZ,17,RU5Z:XPF.6)>0)4SNRZ(XYN.LILHI
MIEI,KNS8:"01_S^]0"C5_5_O%@J"W]4LJ=^ZH2"[QY8&9D/]0 Q9_FUDNOMH
MU),O1ABQHQV[I(*RXN%.6GO=1<0<J^GKJR<<."@O8W73WV$Z3#$0U7L%X)H2
MSI](U6J&IL&2]6(?@1WDB#6['^V.+5^O<0%\ZX*GX1M*WUN7V-+\IZ])5R);
MEIG$D%< @KHKP&JR!O8#C.4$.PNC.OK';Y-#O$8?%,7<B0_*O5Z_7^)&<G!M
MG=%42RT.E[]DO4&_<"_0D/!C2NKMEONC1CQ[QTS-K#:Q6CD6#RZJK8'2M9JQ
M:EK8>_C'Z P4#0)*"&+EGY#5L+'\1=)5.[Q+%KZ[2\_72-/V+9PX^22%,K1C
M&=%3@ 2E8-Q.Q:FV3DX"%9<?T-0*"=;M/5GJ9#WF'\C1%TA./>;3'W:)%.7L
M%_![?2EEUBBG75UE$[$S]RTO/)!XFS$IQ-\=84ZU (X_6%8O:YH2_"#(G&ZG
M=Q"A8[4BK[Q3I1?^653.<D4_NHG<-0\[WL6(8QS.8TWSRP,E9=CK*3$W?'AN
MFI<:JZ[_I9YXO$7(GWLBD%OI9XQ(U\O.BBV)CV=<XB]61:-.*<8&Y,U\0Z;J
MPR[3JX>T,-4QD-YIH^4(?M1JR)NF^&Z+VC(!\:HBIVA"90))BT4791G%1YHI
MC@_GM4.H@KL+8;/CCKFLAH^^>G@GI@XMHDHNU0F1-MUJWH88VLQ"L/O;NC)T
M[\>]DJD3D-V<4(#;N"(K9\@AA\!SXGI9YLCS7TL>R4M2=_>4WK8G9=[TA-U*
M.'F*Y@,_KSH.,T<A':\]RU%V_/Z&Y:7=)V7JP^'E3KF=.9Q@]N!U)DAAYVMU
M:NZ8/#PGXUT_6SG$FZGJV-_CFFIUO*.O+J)VZ"GW)(_RNQ9,[Y>88 !W=H/Z
MOMJWXI)3)]"H&G^D1*#GGX"WVSR-];V^A'[_UFUZ&V#T."N(";?52+#?FPMT
MI Y" ZE!&50MU#N^)<=[&6Q=E#=,39K6^71) _)>#36^>XFOIF:F:);.]<ZX
MC;-;,6>PC3?!/JC"OHOKJA6O^9)S+^<3P<5,&S%00,*#G>P>WP8PH@Q'/!KX
MV!Z#K7P[C7M9,.C)E?0TPA15G#:\_GP-)<G00V!1U][M*YZ$UN\8AQ*!6^$2
MLPZT2^=23@+(YN\ED['*R<(DCB/CX>U][.F31S1V6AX<Z\G.)<49I:V1Y8=?
M[:=B?!Z+CFWYM29F!!_)47_5#PI@T'Y;'J5=7E>5YMTNZ\@<M9WS#CIPC8KP
MUML>T'#O)'V]^XLF0]*WHTR%60HI7,0+D;*!+QH=%\'=DFSVB()/G5,E=X[9
M4Y&5NQXOJ?32I+2B2QB<&F<Z,<X?/:!,6ZT6DR4MHXQI?>V?/9QU.:\ $W[3
M3-?VF5WN2*;(27(\:5;X$Z:\;Z7W3,F?-QHOQ>P!TX#;KA6EU^A_[)K2W='2
MBM\&:;!$9&O,:N=/7&=S\N)84!X8<?JZOCE]FT%T0_!N[0>""AU<^]>-/>A4
M!G(_7!K2I2:]-/(V'7'[9]*0ML, ?2K5\)KLNVF#Y]D[1B,$H<GYN;<N1J*&
MNY1HS&13*P+7E_1WW=.YT!10Q! KOX1V[>'*9TJ>3AH/=DMVZ!5 O\3-C.TR
M#<?W<YL/'#B9WV1%'7NB8'730U*7X9PY5EH_;\SI"G"GHT8_&*:I6Z0B)5"#
M*L^5]>+]RB*I8R\'6T!#YJ1OI9BAK=0;D3XYBEHRM-'Z"HX7$MC7+&_-A!?[
M*5 =W;FL&I:Q=*X,#.WV* \H&]BXRZ@F.W<KD&-,3$U;[8G@D]W]K&20%GW!
M(95!Q?M@8A?F:)UT&LQ^6),G>=<2,X;B&^)V28K5F)U^^4+Q&Q^"2*$YUYEI
M0OBNV!M3!S,.7O]A?E/'#^=ID'F:[/"\\&QN5N/=T\9ZU5YSBJIE5MN:!M.%
MRKEYX[X*]FK>O%!>8E[%IQKVRU&J87+B,K2LGA5=#_@>4:S-1[.9\:Z+&#!>
M>SL9-DF_=:P*2K4E75J0%U^;J"<QJB963EX5067P529,BC"=;R'V7K0-;]G'
MQM%S5I.BH6[MKU7&_L.\@K,C'7^699<^7!B).%\0F@1N;+4M0HMTBR#!1ORP
MT&/R6X+.W3%K'0LU9L(#@] &+X\5SY'71\6:-4TSJS\\ AEYS':<H)Z;7H/"
M/8-*NLT90P[@OLLDV:>*D"K/MXN?XP7Q$J:RR[?\@9XK\QH4)DP_4"B&=*;$
M+SY]OU6XV2U;7PB-EW@WULE:EWF8LX$MN^:Z\=]RP%$JDYYJLM^:*BM:(NU*
M/EOD*$=V92X(]3%C7B>^3-*,SE;_6*GW7ENT1\?5O7 O;:I9G55CMK+SOL'9
MO85MK:$ZFD:?B8%"D4]L HLM,[M\.1BECD6)[I&LYN-%1,M7]_LO-DDSDI(&
M4B_;QUEVJKK)_TQV<K=I?RKHB7^MUYI6\\@PC-=-ZYLBJO;;L#Z"N+,9B'B4
MXOP!(M=%U2F8^FOVZ[T9SNL$K;TT?FK6T3$K5(6/\=/-XS;Z@BWBJ>;;[PM>
M%!<I^(U5+V?V\U9^I1&_G/PCM3/VH]:;H>](%)_V^'Q:,X+YBX+H!RL%3V#'
M8+(R"AGSO9"WDCF>VNK27B/P8Y+GC37]YFI&2XH<"<X6!2Z7G,<T-);/1W5<
MM:SC8ABC32<6ZW,71]1YO-E> ]2^.N0NQCY>?-97^@3>$-TK:B=J$Q__^)WK
MKKVN:39A\%R2:.IZL"&Y@:Y[$''@+=;7!ZX?U7VU#Q7H2!]DR7J?NZI6:38D
MB9)9CVAG=&1%]BS1?LFARE:>7_P&>#([K"Z=G/$H>M2%Y<V'/"WKH/N#&R6W
M1*(/L5I[N8L*;4Z_3T_S,RO#&!Z"$;$27]86WQ(Y%[#8.[^6L[V[_3@K./0_
M[=V0I'_3T'U_F>*=$+SZM]DGO%B0<4XM ,YB/;>H.B+VM2^20KB;GN!LRCWA
MDTEBK@*/BD(*#P>*[2ENR[\;CX4EA+>S,;ZS?"5Y!8!]AV ;@'!E\#P^*/P*
M<./]%0"Q@VRM%6H](A;LQ4%A^*[K+.:/ X02KWS>^]M\/U+V'Q1:__F1OU_(
M/4 ZG]]@PY%<7XO*OO!FNBXTW7"0/LC,=^ Y^=^_>_2S&9Q%76*N,YAEF@-O
M' \E$^3/W2O RAL@SI0-G2/K>/W$R^M,Y>D5 .,!<4)"-BG,H6?$)X\H\2&6
M6,B!TI2\Q17 7_,Z#^KV3[L.3B][EH]N K'W*:\ =$K_0F^^;OF<, F)?WX9
M$7(%^#F#9\/%'4.OIZ;VN>;!G!O2\053>TE B;_9>07H'OU7:B=[$OB@M>M"
M^0O$XMT58%,<>"T65X#EW[E9_W*AW[_\7UC^9Y*7C3'7$TL% E?9_C^G MV)
M'&T'^??X&I'IT:D6@W^Q?D["2FW,@[<CV4]-H&>^X:6*0.@4%+7@?$DPB+D"
ML%^[%.3?/6KP_XU' <N?0HZ8V*Z9CI<O/Z2[0$"%("U\J_M8+5;Q:SD?7 ':
M_C=>O8E?[+GV9.96M@/*W3=LET2]U[7=*K3X+R*R_[)Q)H.G#H]IW;P-03]B
MPPM _Y5<K>N_82+DXC[Q%>!Y.0YXQKG#=CWUX[\\M*C_*\/_3.V?Q/\_0]3_
M+_^_R%^XK<53PW:-&6.&G<T=\R?_[-AC*FCC'M='&Z/?'P,/CRGS>S'_#$W!
M_X"FH<__$30G]\K[<IE //0/ZH>$)=^':M[E4 RY4P@@W-HRY[D"_ ]@._EW
ML,4!9\!\RSO_T.XV*BX]5R.7.XE"Z,"2OH=(R)SG?\+L7S*Y_\#L^W>036&V
M?T#6=*UK84T%I=F<6Q4=O<-$_6[P&QN?>]_1-D3Z3/]_,'IYZ]&M?QB=E/#:
MZ%_^P=;RXE[?A\4_Z>LI7'?[.MVROZ@P!>VW7_*M:?SW+KAMYA.5B.6Y5KM8
MW,K4S$S@WX#DEO48X @@([MC(E@X/?!?-?TO0;4VJO8BNI4-_^H_KROZCE!H
M(_:.9K6O,+2CY>U_ZXFA:4C:F6L><)^OP]HY\M^BJID%!!SHX5-T"3^;[F_]
M[WF8_$_&9R7]/XC++_X9"9JXEX>P9(CM%"6R2*L96#F>!SP8>VF0@<[Q!_TG
M;CR'L%&=C!F?]N-'=*LO^ <5N0Q.BW _WE'>C/TY'9ZR_CU:CV:\),Q%WZ@5
M^_C$+;J2,K2;MZI<**5R%-)9N0,DZ&3I[;PDXJ&QBCG:I(D+OTD_S<GZ33:0
M!+WK=>Y9Y<N:G#CGT1+PE<>.7M60@-L?%,WIYF/""N+K;&B29\-JY&V[IY49
MVFZY<K(.? GC/J YE+B6(LKL(=HY'&?I!]L^3=XK@-CD+=K62.A3BCL)1+?H
M:/+=[WF=$!L,.HZN)=6G"M4.F572,#\ \OQVU<FW\.'E6VQM.U]7(WZ3I(>?
M]"-5FN@BFC$3Y;4^<,\0#)1P')%QCY[RA'9FW)DQ[ 8YPDLXYJ9DXGP3,09=
M^;6 =Z^I!0ACAZ:7FHA7]"-EC>' \):GTYXJQX(L]J3%8C%5WD;).0\LF%0C
M'CF6*YI^OR<,-N,K'8?8WW:2)46:>AV^C"0=(9-U[0<Y%O2Z.[N,,;.KAIK8
MR+(E07UWTRF:'B&)/=*J M,D%E._8K[[QD7_*EYJ@$V/LO83A>09;2=)IXJ+
ME]M+O"Z0FWN19?<-_':/R$#0(9VWNC?40[79:=DP0[D\1;]60X#EA:J52$]3
M3-$#IJ S*.!4OGJMUKR*J#9G<ZI6&A8DL.O);P8NJ6+AOGC!73_!DN1.!["X
M:29LD##"RRM([V^"N07K #)O,TZ'"<HR%-O5#%&3GU0G\[#JSM_OE+9T)6N+
MBZ4@YI;L?P]:%-B;AVG431G\ELLP!E7*O0;>!+NQ").+B;*(>>SXM(R2_ZR"
M]L>^55DJB";JYV:W218;N8GUZYJ^:P)BI$TI7#"^ A0FGH]))<L_/U.]H<3.
M*L<WT$*!TYJVG&R26W&F!@>>#[Y->*7:5ZW:N%:?N&_[%L4;_-7"S<=:-L@%
M7 *++?M^M,/_4@LSV?L1QV_7O-]:J1)Y@#K)$)!<8^#,?*BKX@2YN3D1:F[#
M7;33NK9@7\VC>1(7&_5K.<-R]-B14FVZJM]C4;%C_NWX*D#%SO-._WW <P;%
MFZS/9&.S2I2877KB>@KC"G=UWP( 7C0'T%!/&.O.G'FP_ZT"D&]+C'RC'&JW
MX5/\S4G.<0M 5_3JO0HA[O5M@%DV^['\K0:,PDD41K#]I$4TF>#G-JDS"*%F
M$I %9K=:Y*V,;_SA53N\*+(K5/V&.K-I*AD' WW7[E5T5I;S.)L[D;,7_!1(
M5-MD7(=C^MGK 6NV41,&P"O45UYLR!WN&__!0E2KIW(GX>..G)./H .)9^P*
M/_Y8WC8A^_)4DKL,EH&G4$+(N9M@NN3I,(G5 7#*BMR:- 3EW?N^@0N2/NQD
M^KX48+CJN^C8IHV0)J4BK'=/(&\Y",8 [E0:/PI3>_EJ&NE3>DRR&A!Y4K-"
MJVR<\1U-L"%GOW0O^VO61J!N8#.DR&#(8JM'**FR5@2G>106X@D'WK>?-AJ.
M>00MV'85G,F;>&+$\TMA>)\GQZ2,8<-.SJ<;U/ES:ZJA^#S52WQT6^)V^1"X
M+#_QE7E#\8I5\,S];I_:M@ "]LI)_Y>NEN)I!?9J9/<,TJ2-Z4L>A(IWDZEP
M% GG>[&^)_32> 9@K30+^- O0=^8/9ZY/Z[UU>$WBV!;"].HF-0QB\RS\2=B
M)/W"B\:&O<P55JM[[PBDN)O-1CWD@)TU)!]R9XSM:EZK\C?G\%';JW!]*00P
M< -C;%%(:HL*MZ^UUN5Y]+NA69$\C/^H@O[K/NR;;'S*]97,9,#9^,EU:A-O
MFG4%F+$&7E+)!3 \G-#S"O08YHR@>[+K0DW0?VV*-* SY=G#!L'+,,LKP.C]
MZ7R<'?K6?M=(V*GOHXQ\\0P/.)=)/&>*L[S.]PU+#\D3621Q\DGJW&ZK]FK!
M1-J37B9IU_7X:$93/ >LVSDZD?7&& HQ_LFWI[7@D<<%?0Z]:_19Z6Q'UT_:
M)^I/*>64!RY3\1S@) 1=^+$4[OE-$25G-XNJ*7Y+6WB+F3>U'@"N/-](S\G2
M#F/ FJ*)-3%>):[.A;;Z>!HTCGS-GFKQC1%H2F]D]IW_C9J?N-F;B7UG*0#8
M=(-3$BAG"VUHV,E277R;,Y;^+2]'<!" Y1:O4\[:[Q/.)P7?K>DS2O6<J,<J
MH!#C6=P5(.\P[R-D%2OK<P5X]_D*<$0J?3I"A1U\B8X64BW9/I%^I2W>MW2^
M]H!L9I.4*N$(1HC6TT"U(T<N"'L@F$'I$DQ[T\M2,-*D6H-$37KK/%!T\"+@
MEO/2H9N(]-G!?>9GS#$IJLRI5E](&"2[JQ?Q-@+W&9Y0W*N",]7J99EC[]O\
M.4U_.BIZ(<-45&(TL+1TP6:=;/Q5)X6OSH$+7L> K!5CR8B5E2NP==\1;UC/
M<,]YF? 0IZ_\YY'T6ON<T#$LP>E)DEH"7#!,3(-\VXRC8M3#1RQ&0SEV^7>*
M,%QQ,^56C;*+98^++[/%#T2,A,ZX_RVD\0Z$? 2>CW,OFMF:T_LT\*6_VK>2
M6WGN6?%M.<H:$K/97#^('CY."W&G7\J//[%Q\\QY;FK]-$"CQ".#"0LQ:TWO
M59^JNKB8T9&M.9GFX8HKV#1\SD6A)'], X,VB07DOWSO"-M*HJM4X7*=5_)A
M4D:Q^G?K$G.54CS;B@5MP"@V@0Z8O6\PK#M\/1<NQ]9Q_F$V9:2<]I3QTPCM
M1*BEEI&)F[?56N6NVCX9CJEI#&(3==$,5%!NX;#WTAKD_QUW>U_B=7?RTU6B
MEV5()R5YW%3ZZ(ETP7K=0*W]-]3O_=*:FCFG>="JWW &$D:QPYC;DV)9NE6;
M'%/W"*0LD.UC"5A)?.8&.*7>QZK[RXI*5F>@AB3M[@$3DWKV@ ]2O(8R#ZO2
MVDH)MH7,)<$2'7P(Z'TL-=BOC3$CA+])=D@@L]!>SV+,$,.ZS.^S*' RO"Y7
MN>WN# =VLOAI840VD]<S7"WA0!+[)'TCW]?%1?EO#BI?K-P5COMH8,G)/YU_
MHX#[CTZE@ZD2_073XJR8G[G2I$/U195\R(2L*_R26S?D3?/4T86:HF.+;NJT
M9DZ%U8KC"S?WHP(Q#09;7Y:UDE^91;.&9HMI-2>G=+?CW_B^ITXM'\GUC[!$
MM^I/>ZKI*TY7"=Z7KRZR=VL^7O!U_%&M_#O$(<+GB4/;+?90Q9&!9X0M&Y^/
M2)O9NMBHWD_A6;>7A"?W+7L2\OGC%]H2!RFH7H7O/97]DNTJ1R [X6=W'/%Q
M1,@M*B%SH&E_?7>W=FRI^/P^7*/+$B/3Z;[#E\<B/XVJG)]GDU39Z&7:O7<Y
M6NM*O+9!OPVJY!XO<5F^Z2^P1([5AJ?Q&B23("H5D\5-BRO*EE:@IK]!#9JF
M=UMY6S8F5M(,WQ<T["_;F7CR4^NR9"K[,HJHM-9(_:1,W/771FB$+(EB$.;^
M@E-BSN0[OJG3&#.[0H&9L(X:M+"XO,0M+L=^>JE\B#4P>HD4C?JV'RZPE_/G
MV%'?+!DD=T]5Q=6AHJ+8)9RDRF/OV<WI"9QEQE3=%8 4F]+!1B?:=VSZ9':G
M9DK?6,^P1/U=VM.V8(Z/Q<)Y[-XT.TTZO&-?;32JYYQ_S2]@:"D\['MTMKTK
M0/MSO7:J"C2KK+/#X"N 648G*Q&&J-R^O'DJ(\_$M"/AAF8:I\W;MKO*?0R
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MON%Z^'3$804YUFK9>B:M,7>_]5QA2@Z(/#"_3BD^7 ':^5OAS!<VT*YEZRO
MIZ+?GWH>DFX$)*PO6(X,U0826D+K*.WSZ#O2S$#5>U]R>73R0-S[;(8XTLM<
M'-7%2[M3;:S9'GB?'R A[91)'[E.PQ74_9R]H%?70LX')G^9AE- )^A@D1CQ
M\79Y^LDJ")WQPFNQH1<G>K8"&2/O>MAM7(3/WG]2!_)B*(.+WD%6LI<DG(EN
MM\)9C$&98(>@ Q]E_Z%&<.\<Q 19;>-_ S]V7?#V7^A> 2S/,N;9K";E^U<O
MKP RPRG6(CW>E@RE/N\M63UIQRH@$'<P(D] B2M%#=98O@^ANJY(,Y=)6IBQ
MD0%,0Y--*IY.*.8#6Z_106IUBCO[\:_( L9=3DNGQD]JL#[%_NQ3+1Q;=+6,
M/=#L0J8=&8.@IN ?WUZ(.@U^5/4<IJ @Z083X^Z3^_/\;0O1G9+>W?1J+NJR
M]??\!JD&_\WWE5/\'1J::9/#^,X=Z^7JC6XD7/'Y2CG+<GQ-6T &'DC7SQ,K
MCCKTLHRI*GR?WYO&M4_1? 7H<^F:2@AIJ&KPN@*(2)S(799;3^)%P-<^>)J\
M5%\ _D\^:/?7!U_]+Q\\8ML]1 A^\H7U4D;4I-]&]Y1D@QN6$)JE]G1CE<\]
M\'Y$0H0RP4F#9!RN9_JQUT87$>]%4D;'J1P YW;Q>BM7@.(&8BB,+>8=CN ?
M*N[]AXI]_K<JCE:@?^U)[5%A[/#^157V'2<];^>)4\AG-K2FQJ>EFQC1<UYY
M&$**?Z%;;"G*D;EF$U[VS#M. CE)2!A+ C-#0WI'",$[\))IJ$>S%X.LB'6\
MW-I$X6AU08RWM/(G)SU 2+3[%\7G-W&-5X";0]>!'/T+9TQ]!9CM-+APKRDY
M24N9&QDP?])?!RF\ AA)]0WC?XC-8JT"1_"2EQDM')OIA!,H61ZX71;M>4W^
MR6$G2].P*ZF(.O&/L/F#L,UG9]YWD"7AN222CYL9I\]Q% -BVQ.1*?&3<L2"
M..ILN*K]BT?E&&D[1>3N%6#>\=?/JF&1C.-T:Z%A<:=>25B^*+];9]><6&Q)
M[J*2WZ_E%[6TIT+,.7%EMPS87$"'BG*"2.]VX,=^O[QE,! 1WA[E>O(I<IU>
M\,D;:Z?B^&+W^^O(-:UY \RXV.G?X])OC""\VR&DV/A>Q?!.M)EQQ17 >OZQ
MP4\KKYAO ,*U@7N2FPKJ@I1W7+7S:N:7]W=[/W6IYZ3R[K=,X>.VTLA?>OO1
M?!56DRE^VY.[I"2I^U9812Y4-6&L*:]K+A?:M<]BAKWQ7+*L(M@)9E.=X71Z
MTX*(_B+G*7?JZAU$GMI$HZF831Z*1SN54T]/;>:P];-Y%5V$K&&!1I:_^/B>
MP T66+X"0=S\1'X/M>_]LSL(45@4&YW\7;.'RY%5BZI:HZ:]J;4#!@ -W:2T
M/):(]B,8[$B0;"N=87QJ4+4RK&<6LI:J3!0P4G J.[F3\EB0?_4C.-[62@O&
M''FG3.XY:UA%TJF'?$NZ\Z=LRO=D3TRD:S% F2,;X K;9T:E+@C%_/:Y6%OB
MDF:8(AP1N-E9SI;T2\'#ZO@81C?9Q/D3/W)>/1)]U--8-09CX=_WB'(C(_L]
M8_@,Z &3I:A'F74QRKWX31TP^N8'67@YR_-B)-?:P*D\Z/X38(UKI_C4B5_1
MD=5\_8V8!;92ONO**HR-]I@R3-JFVYD"VZE9-U%->;O_X7')$#(I'C';NQ>F
M89*6$5U72OQR.I!C)_$*0(&[N\3;.G;LS$!R/*2J_<3(V,\R0X"^0K&]G*$F
M^ET9JMM/<]#&VX=/H'D2!JG#F$F3\/&;;_BQ.3L3?WF\()1>?6 >4P6D#?QM
M=!UV/8LHF7?,'O_QY->2DWD[[EG0A/#_#8]K9"9JZ[U)T<RK0;'5PG.9VQ2
M+"B5=2X&FW?Z$N6<FZ;%1G$G<%8D)%F?TF]3N,\S9\QN]<X51LW.^P%5C5TO
MW9=65T\O3-D,G/954RD@TMA& TQ23"!C+\8<CKH"1 J*E>=NJA9N&75%:VW3
M+#-^%9#:1+:B,\SD+$TQ B7.%TQ7 *='F6X-(SC.NPL!]5;RWM\MM,R]30Z3
M(U8>LIK[B#V*/YO-P\;2]PUL3]F9G,:L>&9#Q@]AP?ZF&#I-9VI_N>II?W>$
M'+%R SJF>K'K7+4I078#\EO'YF&9<$"C?KG_4S0JO&L__'PQ,1SSLD>;2W]4
M3:# EY$$/A=S4?V$N._YS2M  Y]1/2C[EI;;^.AIS:IVKY^A9 \PXJAG!9SM
M7>UOAP8]PP"C6T0&7>'[;%BH 9HX?(W4O<!>_V'"V[3GOS4?M_&,<YTPX!\8
M BOW>V$T8*5N(@W&91-[>3(,1:YX!JC 9,#J@F9,_D8YT%/Y'>6X7(Q.1;W?
M0H):3EK#SOA4A^''4Q_$6$  99VW7V 5G]51MW\Y.@K)LA]Z!;"!L6$K329^
M30I4H2P.^!0;DGX_C.PI5R3!LZ#.$S0#!^4%,) PG*OW"HS-WION/*S\U\O2
MK3%3Y>%.-_P!NW'=T0IYC(&J8*JEYJ)?!A12-VKYGN>Y,0)'6<3XK,DC=Q%E
M+HUSPXB7VR"C9G8]HYJEYS7&.>OFG1^\'6/X>" WV;MF2HP3Y$,!36I'4][$
MKBO4553XA3PB\?DB(@Y $@._^;>>A#[4[/ U?G[I=L?IWJ:?WO[T4DH3:T@R
MQN\*$'-=R4Q'5FDZVS\H+VNHBSP8V_$#! 496(;TG>L/ UGP'-B0Y^$=XGJ!
M@A.BAN_1\]OUD:C@NA\;\D:L@9;!RW^FBY+<U@V@16,!K"V?]'K'?]7'UY_V
M[*=$2NC_;M! "95LR<NBZ3X*5ET"M9)T*RM4!W.;NB>TFQZ/T7VF3+J93B&M
M)[$;BDDRPH1'BNU3-+G;NY2L+>7Y%)B95'ZG2=.CM]1.E[2<GFJ6^E"-)-'U
M>PA)N$8KK^2V6^J[6INIJJK%B>V#D5>/LR(!_S%>E^3#SLE'+MV<EB:MB[;9
M,$CW*X!)RADC()[9Q^XH#Z-">5YU!?#0WKR[]!B1I@"0B)3,TWQ&CHCEF7A+
M",Z.]*0&_-_?X/V5!ZT(8!6Y D C&W6.-;"'SJ?C5X"7U 2@_R=D_NE&H;W!
MQ8,K0 #P2$C?/OWOP;Z.^'/(ID40OZL2]?9C@B;-;NE(@#.UJWI6$%,WLW;^
M3R+,?WOCAEQ6B]UE=CUF,N\R!'D%&(W7'SL^U$ QSS=YVBM=$O[;I0%7P8N0
M8Z4)EV5<-.?FB%9"APCX<,6T-7RE%3^8H#4*K[W0_[:^JQ=#Z-^8),7 HF2T
MH7WB4 Y%J,<A6E%O2J\#\@='BZE.VV11'N;5O;.:D YD/K&GKV#GPA6@@P2^
MH@A$F#M? ;*F&@2$DL^+:3E*GLA:$CL"1:'?>MX7Z)5PBP5 M-NM+Y/,\53F
M1%OB^(>?U>!G>P)<\8>O55/\9A]9J#:18<GJSPP2:JM50!="9_+4$QX,LF^F
M[]K+LT,-&[\5TQC9OBV@[>(+DGI^^!C@]=P,%<G7NC,#73^<]<7;4)X$LIZN
MX0PWEJE;:/HQ-]2(KZ-KO:P,S-:;7"[V9^*.2T&]5T.5P[-WSUAZ7V\<4P8U
M)#:OC&:!S,1:I_8$/&W%^%_L';#T"RL^OY 5(B:]<>\GKKY]1#-(+ISE<?<'
M9C6#;@6YFM% O^1!TM=N;J" 8TA<YPQ.A+:5YIB-2:T@('-CW'*<O[@IJ-4F
MQMR/Y2(6-33\5&C$"![X #^"?X3I[3)HTB6&(L?Q/3>VID1L-4U[K247!KB^
M%+AURIR$_*$ ]-9K^6IJT.BEUB..JZM5-N]W:!:P*E8UGX*T!_R-T2!]#%DZ
MW=03G(UX$E*.=K$DMOXRC;K H_2G2L/"EZ*$^*?@?F9,K&J7>47)7@&<*>!.
M9\^8X9-I:,$.G82TVX)\D<=O>MF?#:5M2E1?E$J5AP)(8FU+.&-@Z@LPYX=X
M\^![;7_2SA+Q#@<@2,C20TAX!3;P$$&^?/)5@D0\HV!+CVIKT#8?8-#T_;,^
MM%0GW4WZ'6,C>AE.,_VI2;,0FV&&X5KBPXAGWIF76TT<=&1^6]"GC-!ZMGK#
M1S;Z5.IH*!M60I/2-1GOZE6YK'#I'Q5+^]4J)V'<T2#%3VME;#V^/K9]0LLI
M9_$9159\),"(1T*S(8BV8&MY>_T*4#H&V50LF325N319/I[3N+S]AW@84NON
MA#7^QWZH0 C^NX:I/["ZMB,WA@ C<X,(N,KF>07HV9GT'"&W"^0N%S=J2;,K
M-(RGGU]Z5I')F3G7%CTM<9W3J[:Q'3W$0JX M[Y< 3!B(=%GJ9F.#O[=)A3R
MZ>*_^$@D<T43M-10@4/>4@07QOZ/MZX )#*^D#[IS2L 2MH;)S;2D0Y!Y#GC
MZ!8AF(:=5K@*F!#_J9GP+T$(1A32D?"7^ O]\"L VI#X"G!??=*W^A32SI<@
M@_>%8,E:SSC;Y2FPC:J8$50 DL7]5;U$LN-4;,N;'G&HBZ9MWMJ[V^W:$_IC
M#=>+>!7PSF<FP\EBC]PZQSBQXXY77,X*"XH:<H64%%C"3K.[R2I5:L1J8P_C
MO)H2Q>,Z?M?WW<QG8)T\A* <KZ%)$A[Q85S]D#)<E*3:Z_8L*VC@\P_"],^]
MF/S&;-*]88;7-0I)$P5:XZDY:Q\\FC>\-[(:Y0[US&]A!;O5$*9Z)[W*D\>2
M>K]-S,UNXU9??OE<.N^;BLN6C9ZJ:823LW6=-JCMY=J=_#BJQT]:+X$>Q[ZQ
M]"(@J-MJ%#N 1.Q!>_8_IU-,YARR*2?IQ8ZH1DRO)<XMODER_[85YA))F>6^
M9<H6$RB*+1#[+B9(AHU'7 %4ZB;@9>75:E0<974/!X29?AC_=G-Q&\4<L(9P
MO2XN7HSFV:CS9HQ/$UQ<5BL]K[6>]CC:@Q8^O5^;^TAQS,_O");A[XHI,D&S
M09LLLZX7 >>&AJH*9W*[^;M"Z6JC9?0$WYW/8I'!T616^MG;(*(0=*PMGGVG
MQ9<_?5%;2_LD8"V,_G&T@+"Q[1UA,#W7U #(V$/^8Z*=8F,!/?][O^57Q7.5
M@5ZMF7]LER30^Y\%!9Y4E3BK33BA>JQK*QMBE:)M;E84<+GWBJ* /49$144F
M=GI&0Z%+!8X9TL-,7WVRVML7@E;=7/OVS074X#^.+KD-L.'P2X(FNBQ;7ZZ3
MY%</Q)<6*S^VVG[W)' S<!J\)W'/=_("0KIIQC"!)^Z$[ZB"Q>;#Z)*2O@ >
M)5)RB\A&2X<M^,BOZ 5.F4+O2:T%2!7DE#8T:\='@C1,SP5%MOA@3%BO7I,H
MA;JIHYT ,Q,?KWNF',-GJ^])%MRAK\5@C&"_3N\OQMOG4QF_%DT@!6%[6YP^
M4KT#]!]]CF"ISDV4/W'Z&*YDR$>/H&27R9[L(O# 9F55/.=:5K673,9U&3=3
MAY0B*L6]02\%8SB[&?'!<'(*.5!7TCY+2PE"%6%5,_8)?,9I/;+_K+>?58J]
M=K'-*:?X2"S1U3Q>ZQ/'<95GX,DYO]A6Z=P9FX; G8]U[$? J1R:-/@EVP7E
MR_$CN,APS1>N&X84AB?Y)@G;KD8$KDL-E"4A3CS5UM*1CW^6_ZI;CL S8 0C
M<$ R>1H,#[JEB+SCMP NF%<YTX!^5J6'A'V#_-17_P-VF@TCT[G$C:$+1X1W
MF'&9DVVCARM)\VH-$Q7NM/4,S +NM6T0[QV5V-84*BP*FK;X?=?3SWMH?2EQ
MYN!_D>W_!GN: QXW0B<;; 9*M(Z^$C93;G2<R2FJ%R^W3<IL/].0;P;-X4F6
M%^U96298KP!M<6 BC'.:5?DG@?FPF1\9O)%,0&_9RZ5JI"_P4Z"4ORAFJAP!
MW6VF[#GU;7+I])J:YEBLZ6K4B>EXFD>82HC5;_ 7Q/RJ1<;<V]XQ0^=.?W)V
MW$M>F%WHLUJZ47!(4R.@D\C)3G60#IKI=7,S2XXIKH[:<?0X/I!]0RQ15;7&
MMY/3[#&-)UD85:"!L[U2X.(1=8HMQ#2@/KS_\GS[=O[N+G\5MJG(@+,V2FKV
MWBV&X[:"DS%4MFFHU3$3U.S;(?=GX$HZA%1LA'X95-Y?NG5WN<^J<?2H<3)L
MP.VW8;!I:$>Y;&$=,QF!N;KCD:@#2]%K3QO5%:_Z;Z_?%CAY^K&*H)U/--'>
M;1E4X"0==.YPD2-%(V.W>(KLUL,JWIQO5&NR[;7N!/7S(</V?QN0S;9V0BI_
M)14;@-TN=)K#=>J,?Z3H)/+0/V5ZIA7WBTC.W:Q<04JO@&OO]/;H)\</Y:L0
M$J!U!AF."9,7U:29M6Q?:Q0>L2ZRI !YHG%/*&[U<D9Y(OC'[=5T0*GXR DY
MUC479U*+#<TS 25[Y1)E7OY*%#]UO4P87FS"E3 $Y"1\HXQU>2H)RRY70FK,
M3S3::V@%PM1R4KUDP^%YNX-P2&B+/"8IJJH(9;2AA=&)5_&C62T7%4J*RY%_
M:S !_0%=XN_V>7X%^/@!QR7-/$7NC5"J]\NH$L@]F0GM( -8 %ZN?47*9K)O
MW-2?JCO-=M1Q%<N:U_*-1U=9Q;L:L>JC^4X<T>:[ASFFAEBM,4MW+WV4[[>C
MC\8I,?5S#$$ @H2.(*EAD:'GZ,83._1(A_GG='Y,8ARD<-$^\%'<6E/8B4'R
M[4%E*WD#@\EPKEC#.IAQ^W$V#46)DE_SH(Y=SY0QFQ!.^6]?8!PW-@:A&N.@
M5 2VWU[[7=F;N:#$+%PO6]//Z=*J,">#%-MIO=U"C 6N.(>S*:)C$VONONE0
MC5C\G; @24^VYR.')@+TMS&4XF.JULR*D8,\,C==CN "X%[M#5+!&2"\)PGC
MM8R@37,MV9I+982>)!L8+_:>:,AX'1Y4?3B)5]>1EVIK0S1JA+96ZH<%WL.]
MPCA'5Z5<ZFUH8T2A_ L2%5U_%(U>/CCHZ"DF4B%\LJ!?@LJ*T"]Z:*>LF:DN
MG7^6(8A[=BV')^XAYC2B5*P:JH]>K:48&P%E+?2R-#8R)][&M(QDT1"6T>P$
MWL<2K !OX40:T!0I/Z^-<[L;(;UD-&RDV& #D.G;]::549)"VJ-ZB.3N%NS:
MN>Z_*IJ,5QE\1=4Y%N6HI.?_LQ6M!@WENY[3&?-\+'#T)&R4(B?#TG*<^#30
M1EVDU;LY0 R^3&Z73O7'P<.1<8!?1K4\]%U-=:A+W,]-XF,Y#6VC1KL;P6/?
M7D_RYOS:D_:P&W=L-R@) ">*2] )IY6_9%)&;0*X,L9:WEW&B=7+ZB(I&4'>
MW %#R(C^ZU)AMASK KQSKM1MY-_0&^;I*$]+PC^94\;)>NW6Q,>PB+^-NMVN
M "O79<J'FBG^#]5K)<[L[P>BH]G\[U+6;>V8*WP;U2T#?^]%VAD&<O?;&(2'
M]\*YQ?8>[9U[R6.R"F>V]<Z_I7J+5^1V-T75<T7OW0RD ?X8>7T6OE>3\7(7
M,9$D/'-(.?=:-&$%7V,0]+:K4W)GO43U0AH;@5-#0U^EZ_'S-U1GTTH!&RV*
M,K 4<P?[<Y6(#R4G*6QAHK-Z*Q&R\_V<4F_U)=\<]<EF_"S=/S'^ \,!T;\6
M!5?\K.OKXM<E5^D=PPG4Y4Y6_:C,%*0'?@G;4VQQ;B -1T3M&7L31Z8V^#'[
M)T9)B-,N%C;SBDF.L9+DQRC/[^HKTV^?1*Z0N:@3,)_SH"*W\,+^)!D]T^F,
MTTW\1; P?TWXT*"EFP4EU><@,J>65+]C)RF8Q<&6U\E0@'"OQ;V/ZUBGI&PY
MY\*QT[06S@U=+"ER^?,2[Q\QP8@6GG'GH[1[JZ;S6](*!3'6WP)WE TH5FPP
M/<*@)&SWM;(9 D>,TIN1(^&^/Y+>3#MKJ6DH)0ZB2,EB4G_7X9DW8H5:87E3
MQN =,P8$E '<,]Z5')MT$M4LHSR^CS1N-B*]Y77!WRYX7^GK!PXQ(G%)!U;E
M#4Y[@^U2T ]NMK6*U[UB)OR2W=6!3I?J2G"V]D:V2%:JOX4S[-[BSMQ(-+_5
M>&XKB!-THMS>,X-P5M21#W]W6G@0.+),MR]+3-<Y#V/>S$!_YE*QM5%]=*%9
MJR7$*NT!\-R4GEILC0[DZO^UN#WH&2!:ID93W9(^YV"?T/.G;\F/\HGXX>=E
M0!#)?! %;_-&%XRJ/5_%AC)*3*F:-F$DS[0F-LSQ!=PR]-.3%HU%BEWA&PEI
MC17U)>G"K3)?C6JV1--*JJN$=/(/<L9;$Y..)Y*Z,BJAD4?[;&#O+GFBZ:-%
M4=LY9J,G*@7S53F%>[<^,UM]!/*.8LP[,J+DQ; V16!W+4QL#/DQJNO=PLQL
M%:_CQ]H?#&W#AC6!@.A#79AL #+FL>VXR=*2DNO#S63$DC'56I6@UY_+=#%E
MDH=4WK0VVF%:E&*O=Q"02.2X15/Y5#53.?_%PHM:(]^0$TT.#F/A7N<$3H$M
MBM>.%/*6(=K'J2_7FE-BAP>N41:6^=RL?V?=WE\8JX^QA*-:(G*4$!!R!7C*
MO0C^DM+4@7UZH#C]%8#)/5%NV'XC!&+M=UTF->P'RZJY$F539$/D5KUI^YX'
MM<C6F"YWU>'3J]T[&VHC2_D]"4O,%Y>,ES>]IQU9NHM='Q9'"+UZQ?OSD(DL
MC"OM)V98(Y)5%L,:@D ]FE>,1]RF>F_H.%3YNA;T:,7P1M>R.W,"!Y(P)-TM
MD;=995$TQ7O46 ?$J&-)XS%G9._3$G7!O*.)DQIK(L\'QT\><4US37K25>D;
MVKQDY.BIOTEX4,YU]$0:T<"T/\L%]NY>HL< /^'4"B @.PG[,8CS8O5 O_,P
M=AI E9KAI*814(Q3'75<;ZJ=JN:W7I<QYLDN3U&OI1KD^J,^QC-+[\"7 R:H
MZR>60G1#H4WFE]6.MQ+S\D&,E">?7#4*3>QLX_F+E.[+9CO8DQBF#/8LT2RD
M?NV;,EC0=EXV6L)[+PR(NF#&OUT!.ID"I;$\A=C!'L:8LTE'U%'C\D,KZ* %
MWLAQ8"/OH0I.019WOZD.&RI0YBE)\76ZR&^UV.;W0N$+ =]W3KBBV''/UGO;
M9L0-5<WQYW)ZG._)6S[7T$/[G"L3O[.D1#GY$'ECHBTCBS+-P?%#_!QC+<N6
MLJ,S7:=J5L/HL)KRF!_^W;RWYQ]+;3X?>6DN?5!X+TED/[ Q9CS;[Z#94UJ0
M'#]\7A-U6<@UQ4]O9E<Q<RT2T:"DX]!Q^PA\2_''A4BG'T;F#88M(BSE>FUS
M"B7Z=BOZ!/_.T-+"__?3^<5&;Y@NUD<\UQ5>UM#<->W]97'1^.R4JMB9RW5!
M.:[Q%H&;ILXJ07KU. J5'F"/KK(,2O 0=31>]5 B5ARU8Q. [68@)%M$59"2
MN)>_FK]/.HG19_IYW:<4EPM6I7A:!Z"TW-%KN8$?;.' /B@UW_8Z/\GPECM)
M?O?#C)O7R1\%#T*NDO;"S(W.;9R;F>1VYM)M(@K4QA+T[/@3!]_W$KX0WE U
MUV("2AHK;'P5V35_VGOJ;9FJ&ZE65;V6!E>@?DOP'T/WF!*+J;^NO=5P,0:%
MY^$X\,(58/H17C'H8?BE$:2!YZ@/,IEWD97Q/Q_+H3T)1 ZU+FM<DND.Y!5"
M>E,@+1GG]#])OVHJ *C_AT&C\;>OF?B_[YGQ_N<],X'_Z1CTOV-YJAY(!R9^
MCJ'^>*HY/K:^]N(5E_4[K_VM]BN [;1Q3<$V"!\&^<N;GB[/B\*U5&TSZZ_;
MZE_K?\X%/K<!.>=L88R-V2/GYL1>O4'G$P$V_MPYS,46(![C1-@BG?R%\KKA
M4Q%.48]@G&:?Z6-*5JLK2G%WO<[2VY)WY!]4[^/8SQ=\K03%,\6*.IWR0S_'
M]71+,J_0]I\0U0U"PZ0AH6)0TNIHZ9[<W)QEJ_2._;?US;7AJXODO4E<T?F6
MX*\W *3K-LQDWIHQ8FP^K%X<NB;-TY<!O7[>2%-"]4GXF%-UB?RT;H;S-TNQ
M!3O1E,I:^_MU&\3T+#&RX,Z7^'E3N@N+SHL/E3% E,I)2.@"Q#MM05!.VMWL
MY=\O+Q?MC0S_P$IEW];6)@D^*G#RP'+4+%DM<GU<*T'OC-NI,)11D[V+*X'7
M)*MY#0QT:DSFEF6\33R_ FA,>\3$;>TM684BZAYGSJB-@]X$^G^DOL$S^E%]
MY!S?"N^+\6DTA9A/XX2VW4!Z0G.+)M5K#<9SM'3WJ@II[S65N:<*$)L<%9.K
M(A2AF=C(??5)YV*/?/;:,$UO/_"7HGY.9=DR)N:@2/<,I!G?Q]B#[8M."#KZ
M4531M=&V&5M0:NME/QSAD:K93WI'/I!P?#^D%ZKT- M);K:$06RV6P3J4CKF
M<H=A!69-XA&7J6L"F3$W-4/$1P1$G\2S+3V%UWJ\?Y%-X_=UIW]NCC6D%#SX
M OW;S+J\>.M<ZYWXSGP^G)X;@.OR%#7$=KYLG23ZX5@THU% ?:B0ZJT\3H^F
M0 5MT+-O_('^/3"2#&N]T^'EF[8SJ^*7;RO-TA)GT4'$+Z)$^8/[6X^A:1I=
M\)2L%[M4DSC^SE@39]Y6@]6(\\^M:?U=?OY!GX2<&V)0@-L!0XZ#YT-RP0\:
MH&U!1WT5L<QY$_#AJS%'RPS]*8\T<9X<S]IXU2,2WB)4G_7\"">[S4TD=XG1
M5-/[3.R']](ML+RM%\['YHX-RO[#SV2\J=*5M[;E0/VE3YQPG XUYXXUY5<
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M%F3^AO#"/VJA^C>9J4X_X*FKR[MIC <+_ZBJQK]2M> 2.!C9>M:II3O(G>@
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M7S@K_/ZT\HI-F41G&T6S$/Q\H$F-N"M%O<;#%C)R:Q2:G;YT&H[9BGR*^38
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M[64",1U;6LOJ6$!T448?I!@A<!!L >!+B[NF9+]\Z>14[1'?"%6WBK'L4<Q
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MF933RO^+O?<,:RK:UD:#**A4Z1V5WJ5WL-%%!.FAJ(#TWD(-@A2I @+2I=>
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MK]G>^K??WR[*?.JR< \F(@-<; *JZRSP?HZGOG0S30:_XNF2NX%FUG.DY2^
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M#/D5X+'9%>##:_"^^RSP"M #,]TE67VMEWF9&G@%R!2\2#IC"CT)$<:"U:X
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M@J;:PL4^+O'#YST@_'5 ?(:S,=%P>[IPCYXIR2(,;6J=C7ZM[/=L"(6%V!;
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MKB0"Y (I.IS(9<<1PE\=0Z%6@'C</<])Q_,U>-P<\&ZN66*%#4@S^TW$,"D
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MNX4=$S+@_@F+J!GF*"<<(#:B0-%J6.YW3<0]F8]_OZ:^2;"'/JR[ I398Z(
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M$'8 ^FA*0\-KBE&]UX]HS5'7)PVV_"L@;4P2'NO8?,VU2U6U&N#RJK4U':M
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MVJ[Y\/?2#1Q\D5VM3)Z$R'D!6=FG^-X\>3KB^X<BO?]]S-XTSQ-%!17M6T"
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M-.] N5#B4=-4.V-\&JXC]4SH3>&C<XDDN@:]EHUW]@?)L@(HO-YE5B<!G5O
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M#X>$T(79V#[JI:MWT[:AJX@_^>O?X:@9V'$$_J#-?\.=R*G=8N0MHEF=5G8
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M(U95: URF/8:WA QV'DUA:UX]\D,LD_J=/HJ)^C6B(W-!#0U1O>UT^8UR-0
MBXU-71:IXS.1\.&F-H9[ZH>C4@3=Z9]^_/;3BJ,'DUVN2B;3/84$@PM*9U_[
M-+5VO+]'6LM$+)H5)M>+(\HF#=!QUT+7$-04K +)VEU[EA9$=,TMQP4/3LH,
M1EMTDG+GHO"4<9[3Y$0&W#R?%UJ>8$)'R$<HU\]%/'L)B<[G(N;BY3=)&S?
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M+2 \T&S@+D[V.N&FZAW:WZ;2"7X1#^)M#LP&.I\9=C?/O4QN%M7Y]([OC;T
MYU-=Z@!>4$D5K(W^Q\DO0&MHNAU3W5&N_F5;\&'_U)VT]2] +?"/J]J??@$*
M^GX!S!<O<?(^?OF_DWVF]Y?LLR_T<]KWQ_Y(:>/\@$[:'+>*ZGXT'Z0>["X\
M7YM/D5(  WRZM/Z(ERQ17\?6>5L*_07 ^[JTG\>%MJL !_8;$5+EVOA0\.!Q
M?,?R?VJ5)?=)MLP<<UX+W[#9_V/SF56T-^7"6]KBP(6-648AMQO.'7HB\*P2
M,O,PAO0(5FOJ3&7?C8>39F7QT,91U#X,EZCD'=;M?5WT*DIP@$X -=)/[4Z
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M/ERNE[48-$0$#[]%Z#K?/9[YV44 >K:P,F0GT#[6#<Q, S]=*F8-Y/\]Y..
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M%]JMZ#3'8G34T8R9Y"K.-'-33I.)*A<JYEZB?&IM1Q2?]R?&6.G$"L+E*I'
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MW2^[,U2,X[9\QOS@ZA\F+ZK:^4EELDBQ<&Y1>.L$G&+E^6P>G<ND=K3AHDA
M\/GE*O;KGTOI95W.UCQ\)>W\6MUPVV6%>?ZU *R!=[5*!-L2Q-#FYM1V+]?R
M$M\\>7 %?<M0BL\&,UW(7AW.^ &%OUN4/.VM^&# QP21E_U;-Z+ KBG:DMG-
M'(@_/]L!M9]Y[\NT@R#7N(/Z4Y")MU,N'X-^7I\F:?YH=V?I=>IWY.'QOZO
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M2^Q19O58(BF+[Y</H&5^'+ZU@CZ9#W9[=K9OS_#;U [R30G>R0,,?TQP!_A
M2>G\;S$2-4#W[T*[J8A:)FS7HR1J25:3\][F] $)7]T"()?U'<04,6G+G)9%
M$9[B-9"MFL_5>'B(1(9OA@Q5LU4D@:"J^[2.. U+;2!F]7&5@^=>0+GTEOTS
M-,#?829!ZWJX&@T(, V!3!&K=]J#ONS,&D!Y!QE"2=[;T1S7>@8MY3U:]:Q\
M'8J[#R7=)!<&1[%7E%<;:IKY@CR+97FSYS>H.91<PZWBAF[#+;3ON&/H/7KY
M:;K+FOHA'[F2F'C/:"?5HZG]MW)Q.)$%Y"+Y=*)?22"?CC]PWB$_!_L<7-CU
MKE$3>WA!.\_YN8$HNL:J"=U7#3=)/7&N\T#ZI.3>3\M%=:<(J0OBS7Z&:H=L
MU!,SLH3)\\1EN9#09I?S1ZEBE/D!%ZX+OJS#+M(5@115^_TTT8Q#1FB !Y5@
MZ>@#I$YS\YBIVM2ILJ)EVS1#]<2>V9/N32T@X(&.1LY][";>B"^Q;G$)1(PA
M?I2[!BXFE *S;N[$.MP[9$&+8TFW#NU(:^,U)*:#4MX$.#WWMXS3?GJD^C$+
M 5Z+?+S9B2*=)>O 8SCN5&]*R([5 L@Z4FPL??0ILKC+MB$M@VP33\S.&6P[
M10-624_>4C0L9Q@+@U/%L#O]:.P? 3<@QMQ7"NET5NM54[3:,?=Z:7*XA3])
MX41TIEG2O*_( 'V^05DX?.AA04XI?;BOB\WVS>>;:/ACT8C^!]4?JEA860)4
M1;QN'4=EU#.:,^14[F@Z.1@MA,L2:J7<(527_,NA.8DZF[UVMU]G^?DOITP8
M/_^UG_[Y>+IE-4Q>B+D6Z27QH7&V"PV@:NLZ)+ VG3^R/NX&T=>G9QN^!NA-
MY=I(R2U^<! D&65H#;].LT%BFJTVK2,\P8Z%5CW7\T"[1$D=V]!Z/"XMJ)5)
M(,5L^FZ="1<B'5I!*+O*B><AM_!JS#XR;QA58T4&6D@@3?#0^=Z/28<Y=K")
M.=EFB0:0<H8W$[M8C.W[2)1LSY[H6;OQXW_X8)2_-%2_<X]U\?+=D>H8E"(O
MQ* UQ63;IRSO6C6YG:E42<?89K_D8D5SZL9Q+Z#; 6',3!AI!A&:ILK6R<"G
MVL![/<1B6+,4T+%H@ZHVRILJYF3P*MS#EO-9:_"R=JIVK)#R5,17FH5X;M?;
M-O<P,NZS"*[.&#WZ,0CRQ5[ZT5G065C2FTH+Q[K[2(&UC=S]R=/0!T88/":&
M/4Y-!F@ 3ZN@G;GWPKI71V;/IZ\VLT*KJ>&>O(E/:K^VVQ*6QM24) 9(^;O+
M]RX)]6 ! O5U4QY&Y?E"/ _V)]Q#DP:Y<2[>288X@5VKHC\[?S\E&ML55QA@
M=;XCZ_R2VYNR][/(D>_6"=;Y^XKG4RDB@X,RI4O;1_.*;[ EYVOJ4LD;'F[L
MTT^[X]>)VK6?#DN)E4IOW..+E%&]PIK3+J.;L='KZG4)"@CY]"; TX>+31=6
M;E\NLDW=-?=&NR9IU2M_[4);F5,G1*]*@(N5Q?.;?,AW(7DF+\O&E-5]\+>]
MS0\>41#2,IVYAQ'S8?>@(]L"MW7I0K!_GHE41GN-AK[UY5&(@D"65^1/[*5L
M#3#I3"PSW+#NS#Z,1"P=+L?UO-PN1%9L <_TYO+1 #S-&9]IDLW 22(EU6GH
M5$%+&._KF:H+O":*].(YBM-.O)YZ; ^7*ZYWKB(EWM&XJ(MLX--CFXE7^=\Q
MN>XX;A#10<L7'8VQ_%O[TYWWV'JF5GQ":E=8))JV6H(%>U4-9DB2M=+,ZI!<
M$85,/:I@A'/ILN"^?/)L%&)U%JLP$OO*4 L-^/!Q(7R4RZ\;'G [0V=J8?U\
M-#FS:63/6[/:F,XZ9;ID5XV]^V=KJDVWQ:T$"]SUKU@Y&()B<JIEIC/4$BRF
MT9M9XMU.2VV=QR+I<YM?\A:%40WE2MVF;XPUOH.HY.&"D2?P4L]GOOU5;@<\
M=6Z+,Z)N;O,?W'2.D//D.U\,6+B.Y_'MNMZ/+G(VWQJ+$E9GDXE(TT""RS!X
MM6)M4=0S!=F>[XOFH'E.PF[)[!E9I7-6A[8%SZJYGXG>58A/$/D:-ABQZB+F
MN=%H2&(7.\'7E"%T@+422Q)AY;F7]SE*;-A>Q0ZD92;(U$+J%,94-M3#^^8]
M5A;)MAX5)<)S#7S/Q-AXRX1\@M>PI V!R%2I#,-*W6 _^<;$?L)#Y1UKW1ON
MH_UF-1/'NA%5]#1<==+V75/]FZEGS&;1WW5C9:[4##LI^YL".Y,TR,E+FA1X
M\0CD"P=,[IDX$^X\4V6*CUA+&E*3P? [N*:]W^]=V./*W'XU!"^AY)]]61TU
M,[+,JJ37,Q5\^UZ8&$;4'2GJD-.^4ENV.)5J0Q%^G=JZ1YQ)]TT;U1V#:&N%
M=6_9PWBZW3/G:M4]Y%64O;5"#\ML+&;2S<*Z?;Z^JX\WI.8PGBB^4"_U3T.=
M %(*2I&N23)C4(%&V>#T\MX2CG#ONWDE'WFOA(:HO*J6+M[M>0QX6@[@#+-9
M:]\7,:U*[X=7[[EK(K Z!<095/&5UY88[!_)$7*4T4<HNS1)/;B=YPZX);C9
MPH4B0[Q4-MG4ML>Q&BXV?NYY:*CZ<905(_>);U/H'<TB%/X6Z^=6V'*^"QA[
MR=0*O[P,7"16RC\C/ [2<;07R2GM"QP._>"!\<+H"8X6(5&>)4QC16,2R>@,
M>C?BVK?L:1:KW/8FF&E0Y9B"(MXW)J9W"!HCS]:NDCQKL.V6R#5(65/*#WMY
MR!;33:+M[J3_PU^(39'NG"[.Z-*'\^BM5>56_YHROHN'3#80JOS!\(N[/L4]
M^/ZM=.TH+#K,*8OFW4YP-2H9\E!)SL4>MS6R=%'6WA(N@=_K6,R9(MTQ,?>Q
M9ZSK^(G\NSXZW_UTW2[6JR7=G@SB(]N\ZYDX4%&[>Z&IB7Y;DHB,_7I%;*RK
M]*'#AT9DN_I7*9' ]31SRR\M>4+RR=8N%:L2. )!JL%X(:<%1\OMU' >?3D;
M>/ B<?]"U:VOCE'-$T"_6T<CD05@RVT4]81-*582*A1D3NB(QU[7>\P"7;=/
M]L6C)=IL?=)VE!2,HI?Z@G"'&+>L;X[638FR%R,BSPPGN0M?PSQ/%'GM4O6X
M+8$:*F-RJG>.K'<[6FDF3H5J#-M"DTSH4O;/%WUSNE;F]FG2 S9D)<R/ZS$K
MDJ+P2(F,8NOX5FZ*(!SYZLB);[O7?HP3@P7S'%GT6P%/O6"E[ Z%HCV1BN;2
M2VX!0Y+;B>+5@[Y4/;.J5SC\GV3>R>!5R3\N?<%%WZK&%1BK6L30^B:NF^IQ
MB &LK#?LS/ZCXXZ:1QAD8L:6^]!8B7#PF=1CT5=L4XGF:N62@X#IZ2T4U4PS
M"&KZ$"@N/%53R$<B2GUGZ:PVNMQXNQ\^R=]/V=K/9KU9>)!#S4DHS#_] <0L
M0N\\RRL1XD=X-% !%PBN]J4#?/<-ZV!R(+GSYKAP!X"UQ3.1>[3B[\.UBCA\
M-N8CDKL5L_P<E#M9FE.GWT<R^$&]*8K;+Z'?@ZC"AQ7&:'P$VDF:KXUJ="TO
M>3V?T&EDM& ?JY?[8:"K.?3S^'NG(>QZNLCZN-YEP6AIF+6LV-#,I4Y(GG+%
MCI)=ER)W@%DPS2W2VZ%Z41N\6 '6[*QS/"963$LYI4>C_DB^U9I&*JHQWK([
M=G,FJ\!$]870SS@85X!%24'2?(3WVF80DM;3W?T+PEYAG*,<#8!"?(5[6-W_
M,>)XSTKD(=" +IU&5$(!HJ23WX!.N+.9G^#'3O[1Q2#YX,]7^20=7%$"-D4Q
M3J4\YTIZ"%WHL#/D2=#=!O#:KBVV4LM[AF_4\W>]DT;</6,N7A8V8^2*/+G]
M^!&R6G!@]G7>W;TV6HO>M<-@WK9'1J 9/\H)6[[!V&'Q@CL1BL[,-'?9F8R'
M/]UU\OQ>:"].AE!5\Q4J;^;),>9/R3 .354-'2Y>IZPT]Y-*T SJE=HVJFV
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MWM>+Y]_I7ZI+!WGT5[5F-X]J(Z8:'P;'>?MF&7WFBQ1G/FVWI$DXJ*!T]_V
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M1QP\^BIXIUHI$4K=5&P(B:.K3G9><<*H#FB7NX;^,!NW$JFLPHKGZP'*<,S
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MJE\+_$!X\R,S#:'.:TK K+AWD[(B1N3U![2LK:1<=:R?Y/C77P<\5Y:0/X(
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MTR9FJ?"0WEM(HW/1TIJILN"LF-&*5(XG3<XL>_IK[+18.38H1:BB*%:_K?T
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MIVR43)Q&!U;^N:QD2*K/>1)99[ZC)]%S:,Y8@^14CP$]$,8UW[A?97N5A R
M'P%E!8\ 9L=M:0C+(^#M^5U"Y4/W(Z#T:] N)/?C9<$8;>.Y.=(DY#93^MPF
M ='\"+@4"-D>ISLD>@3\] OJ>:AY!,R]D[HXU'SC/_T'W^B&YX%;^EZ=[H9?
M\3^H+I\2W2F)SHU'@/XCX. UG=]ER0])NPN,JL#T1P 9W4-Q C*CX#_(;OL?
M 7NTYFXA%4]]$>"WW\Z.T3;XA4,Z51\!,0F/@ ^*#VK3_TEW;Q'R%Y^G67K^
M$7#[-6HMR/Y)B'^497H$_(=V=O^%\J%6^A8C?87NX!%P_T[N5*KA20[:CY<U
MR8^ S:TG79Y8IPB$_%=2@[Q[U-$3_,N0AU^OKO.,GD1)>.._,!P"=W_2YNGY
M<*;T?Z&LU'SXO'.-<=OU%"!>WDU6/<FB^$/2<;OK/VWW7PC_W>CA]^;_:?/R
MS(+P$A.<1P!*36K7?W)>DH9].A)_!,!8EL+;I.T'>/ZO9@7]WYM5\_^CG6;^
M-[WC$:N3_??.41P__!X!36SF!B4KM#](X*3U]P7W9<)7-="N!N"%U%+;Q%T7
MMV_@NJ]S4 M58+ED1584.WMSMJFJ<4;)38Z)O/IT'XQM#5GK<+BM*D^LOT;W
M\O]8S>[#O^:H)^\BJ^;5C1]D0-(GE/^]>6Y=0=<;])5'0+/#JLY\US:5YP/L
M)Y[BEE!>U<$Z%O)#"<)C]A@ZO_.E"3*%22@YMF4O_B,"[9DFHU>--.+3'0-2
M\DPW/J+4%.A"54-DN-P_NVIB,LIW_Y/]Q)V*-^%5G0QVSR"OV5X0ZPI&D??,
M *1(>;KX**NM<7X"JYF=I()]7I]?9>0>_[M+,!8">K&1$-,PG>\GQ0[/^QH'
MR:=.?Y_B:+> \IG/]5738/MSQC DUC2B:J,K&EH2+;@J_FZVAJHO<=_>.5\J
MM6)Y4:'RM3C$AV'2L\WN/<6'S\E\!D&BS98TK5IM-/BTJ8OU8N4F$YBGTY>@
M/%6F/3=5UH+AH6+(LG'1(T"\*^-<\:L4!J(8W!V"^[>-!V-M=77/7Q4?9">&
M- HN^A1 /S;:,1Q7P"(1!A8=Q,#%:SG3WPR6HCL4&X^;C&N4I%-K;6P!S5P^
M HY&2YF3%BN^/:BOMRU3O?108CPY--?<DQ*;0JI7._IKI ==5=SCZ40^"'Z;
M_^2CK>O[DB1>[)B%!@_7)7X;!](%_1'M,A/6V;9>A?R[7A2KIQE1FA6[;.1M
MRK53O:K)C##>Z-"'Y?7EV#SPX&<@38-GS,>+F2NO%3:#VBP5FK,OH:44"123
M9AQCG80(_4VS,KC%0G\(82=MX\-/JT2Y2A/'IG''@D&95\Z5L^YHL \^F^ R
M2>7;'XEBES\_)^1/^"^P@]4#%#:S\DQ=VM-*G.KVI&V^0]_O5=G^^2O1=95Q
M!OK:[GSF:C*%Y+'CN52=)0S*FU"*Z6?Z0(^WS2HN<^"8TXX(J 9.;I;T<2GJ
MGD'W.VG.3E*YQM+J3.7%Y ,/2A,3J3@ML9M%GGN(+;12OQD4$<CRJ]RW9-<N
M+AO@XJDQ]S-\0&]T$SC4N4IV+2F.W[N9W;3]',S@0$<HX;C9A6U_%C-J^@R7
MH>_4G1$OI6V$L<5:WX(@=.3A#*!$(^^YAHO0AV/1?1O>K/KP;MXZ2NWL<FK6
M<EYPD7OG+@ 9)O%*:7.EY:X"1#YJB]6E]_RZY_!0I>S!'P(?*U?(J]\Q-KJ"
M+/L^5$\H[PC8?H"*J@9 #Q:D@F>EL(!AZU?RZ=U:)/5P>4@>@T8-:T]SLAQG
M4GT9_2X3YC!=A(5=+@;\.C;0_NRWXQJ@X2PJLIVY;FB32P4[BK 2Y36,MQ$;
MX-;62IWTV5S3SZ_PW&V).IBXX,>\R<3(\?"Z*75J3N/QRHRA*9M'P,0PD[.@
MEJ^I^*GEEB;>PZ04?^23[^WS[XJHKA&X5]7-/=1>P(BQB>P]H6!$ RTQ?!SG
M'L//>#N"DZV7D-")AY1K17PK.Z EF.)&\@>Y^[HD.;;Z?F6@]+J:CM!QK%!&
M\:-Y_U*'>R7INH7K<B'UPE:@T[R+9/J^QCPO9\#?T26'9[L]WO5(39J'A__R
MR:L%=6WDD2.MSM!_YYWE'G;2BP7G^%4B(OON^#7F&\DM8G3KZ\U>$Y)!<S\Q
MA4F):N7V.P&Q^Z$+ Y-Q8M?1'Z><7J7T=E(%<'!(2FO%[U$-*UO%51._B''6
M1WNF*^Q]F%!V.8F['\P\6_@;(G!HJC<HE][4\=DFKH.O\H5TJCQL'7/O@6#V
MH2=_WT=,,.V"9>F(*_G%-6V) X ?7*1_5;1WKD)[-7QEQ%*2J7?O3W"?X+ R
MG=?69KQZN#"_<M,)WM#\5O5 AF0XR]IW9%EJ+&W,(U2[)D@AT+,W5%Y-9_K!
M_8%AYZ_@)67<3RPMNJY]C0&_'[&Z:A],[I?O5I<.86Y>9^G;1^DK$>4^TH<\
MTH>@AY%&C[+%1T!E^R.@>OV.?>'5RG]G>WJ47^T)5U_A/C4;JW2]R7L+DY9,
MNU\KCTK8HWU[[ZY9&#YW[\;G."X(+=# Q6$:W^".?6=[T+/LI3XW$"M7X?FB
M6 7K+LV;05#?R,L*,BW[N3_]"IZ%6^H''KYK$O.O[@O^GN(6%W:=)2C#KCN3
MUZVL*-HW\T%;;ALHL5O0G_=92+DR1#08S%5V0$9V;+\9,VJ'VQ\QIL6J7MJR
M5R"!'^+?\PB(I$8X)ZL<="$H'@&+"R5(;H1J/O+55,F,%XI;4XJ)X&S,-^&F
M\_(2#%34%QQ3-1(\M6Z%R_Y>30O(26%\3;+CEH/"U.6UNYPJ8BTSF>.,6T@*
M7EOAFOT"ZIO5=U-=4V'257ZGO>MA;DB1>9=&C+G($HE:/];@R1TGBN$'ANR-
M8-T#*LTJ*L?QFO1/[N31P/+?[;#ZXWN_'"]XZMYTS@N5Z;2]K<Y7@7PS#Z\-
M!G!/$-P?&7N\\83!29-F/^'@1O?,D*,3YCFN/W"R;ZZ!<LZN#]60]T,%B\G'
MYW\W+(L"F-?]A>X6N!F8NBTJ OSG9M,GC7V-I3,ZJ$?)HDJ.RL:+:K:63CH5
M4>'8, ,X)#_?1+$T3E( Q,WPTB_KYD/L"?E=Y[V#:[0Y[F1_%?-$OP/=TKIM
MUL2%1)ZP[X@^^4KSX:V^:\/MS/%F4UGJ)_;R<K<'IA809)D"3/,UO&24)PS9
M9A\TP3*XCO6WAL:N*4V_$KX"Y5[D>040<P]?J.W>@K;0B%_Y$AV07@!C^D&=
MKYI 3VF*,ZN5UL,PT_+.?C=8Y>IM@_-U)<<V$$=>TU$O9RWGLFE!O_XF<V8,
M[O7I:'_.WA%QZK+.T!UB3R7B(IB #OU.JSK,*(\!8+,;E&:?#UD:KZG^^903
MDAP(9THPDE<R#;/^=,L?_1B,;59?!G15@S"&J1Y+0<Y5/5M)FR-,!H$['B)[
M8OYZD="+/#S8H<6A!2^;LOK@J"EGE6UUQ="1X8 _T%_'3DH?^[#SY-9'A.=K
M'O9'."CB2,#8N'&&OC[)2/+W32A[V?OF%4G_W49O.?E(3?PX]JW[UZBN5[8/
M-(<@^]-!Q0[[XP)7H^O\SWVS%6*U\77*4A!33C^^?LAW!@WM&:[&@VL)1\W[
MW-W9B('O4MQSKZ:JJ;S2WI0J?-HSH?9<Q^+_L!2(ECS9(U8216;.S+'\)5O#
M6?1MH;72A933,>V/P^C+X_8_Z<Y^[K"C)CI<J3A7KMS#H/CKK"WK]MN2NE6G
M*PD.S?OLRR!VTLA1L*]/8NV*]MKJ%&' ABJDU=1R(Q,1WN/ODE1ZF"YLE!,^
M='806UC+J=S'9IDH9;:!+$#3+SD^?*N&I=/LRU6 ^2%"DK%R02 3-/[ 4):U
MY3"NDWV_?1K ^ A  S;5WDF8(L)&F.8E+ -" C"?L95$>=EU=,O>:U(XKU84
MPR=[,R3LW6%+A?,1]?N,_"$%+A?Q^M*#0O?KP8U[ 4%VRT;@5Z-;%."E?7%S
MO5/GUL0+$UL!Z\FS-2@73Y=&"3[\ PR$Y(RC?1J:TDN#:Z[B8V]NVCJUFP=A
M\5U%/D(^CP"KADB:960#9AOY!("B@OBSNUF.! VE;LG7+\ZBAL+538NPM->5
M^PJQ>6U42_XG'Q'7[]MG O$WJ8Y%5<VA^PM$QJ4'5@8_2I'=-500@2#M]?<(
M%FN8ZKVT:DM\[^E(\UREV2UAGG5L+6O*.U7:-M EX\:?SL_ _FC=4&N&YTI#
M#!WNJ!L+$9<\N(M[9J^G!?*(]UN=XNYS\*I*Y-VX+":'*:-PI.1[T<F9=#U3
MDH/$/+6,'@%&M$$J+@$A1MFGT>G]M<8(?1FX4)?+V:%8O=':@10M*$M9ZGU3
MFA),3YAPF$HB*6(MF4T4ZXV&8R3B1_T^+2$B Y;#H]W:,7-T_+<MR[Y1M<45
M"CEP++EXQ2=^$Y]O&:D>>T/K@H*E@V\[&_P20:<PU8A+V-<#?1X?5_H( )_D
M.1?+T71,WGO%<B\\ CZCZL$0GC#'$)P5H </GCT!T'_+-Z>P*%86HC[> GI'
M9C^\O>WA/S]8:#'+G\JF+'COI'V6F['E2+5/U0]]"*\P_ &G%M.+$HRIV/X4
M,^SWAH'B1C8\)?NJG.ZY81<,,W.1$-)DU%1D:1> #:RQB6>B'2E_&<"D7H D
M.=/_8I/[".C-)3A;CQ2L1TN2*[._Y6K7?F?@?4.B3-'#D92MKPA+P(4B-&7J
M9IQ ]YDSO)0-49XM!X8)/A;*+"V,$!<C?H.>XFH@1N3?%UY^13,_YRYC:(3-
MX<7YUJ6K- Y[H[6$OO$B1?:8$;GRNEP4^DZ?VQ@MY09F':1H&^$U40*:+P^&
M/SER?[VZ_=+Z)5U?CW]EG3B70* H.X'+(BC>^)E3T,SS .?K\+_J'Y0[9TX%
M8K [^&XR3HYV&Q4C83]V8O*I#%*&&:GGC,P_!XK_LHLIV+\ES; LK/SE7=M4
M'R^"]KDOZGQ>]F0-U99B:-)H%EJQFA& _L^>[O?\# :FPK"0/E,S]Z#ROI+]
M-,]5R150G?F:PK/Z-$)3@8@?'F\]=-QXXSGZ+D^)@%&PSBXO@=E2PY45Q >=
M.0A8!TY\.S"<3!I:..YRM_6U+%GCE4?-R$:$29"T8(,OK\2'UZ-$97H*%'H?
MY@A6]/"C'J@1^KU.<?G_[%V4P=^P?T7P5I\>-2Y:+$+K[[-B$@:Z;R;EWXLX
M/-IH-2L0MBIGCX#^D"_C)8B4#W.9)[?G[GCYY:.!+E%70<,7LV,^B^A'%F]*
M [MY0YM-J08]P6=1&[,KAYXAC@X@,=V&4Z;IB^I"@C]>GMDM-W1N4E&"!T9T
MO:<80)N;4X$$K+U6W>4Q%\I-L$8D!:4L.1EG.:8%S: _\OC K@%A#L.5-FJ%
M< 5R_5IVN-;^=B+XHF$O;=,>U07O_/G*&%5V2O:%[C&17@ADFYU/4S5$3\)8
MYFRGN R.VIONJ5JJR"G% B?0!<UQT\<>I]E0Q OK.N6V?1X:$B79ZZ+A+LCJ
M%?+'B7&E!,;?"(0'!33WV)C2RJ=>\>4L%[P(Y?NC&&METWHLUQU,,U\ BK^3
MF3EE +4_3$=P<Q:XTT!4_0ZPLI736( W=<J3@B'Z4T<2,L4K^]"<G,Z"DM57
M\0'&S6D&11_F#0U>]BU&IVN)LOEP:3O@L7Q#,L.=UF@0165(Z04KRJZXPHA+
M&CG3M -&LJ;]G:IZQ6<HOX]]T.D+; 8MC,?U@Q,VS03QHVE1ITX$E^]?]VF!
MY@)'C:D6&AS!FO5US'^MW=ZN+6E3A?%'?@R(P^^6HCH;3RW*C8/=<R@WU*>6
M-(%J:Z/)84G?*\382['Z^9\I,A**S^.3!@K.2CAOXK)?&X3-:L\>'5=7%<[R
M.!,"2RZ,2''DK'"+"0;Q/)>)[PM-;GZDBBKDL9\ XZLV:?PG;G=[,C5*W$N!
M?H$ZF6+FZX>^I+,OEC7O9!K$P@KK72[.LBZZ_A"<KNK#'E9G+P_-,1TR%Q8E
M),L<X% 3Q1)@\LG#U70F9/,#9F<20R93ZE:4W6JS=5A=Y%O)OH>7TGCXV$\^
M0$" Y@W0<_2\JTX*3+<D9"L>F.TTZ#?(EOCT,SY&2Y'5EX0(4-'$5R-7+:R*
ME9WO$17_M=RP?>[!WE$9$&)ZKWS%WS5P[R/!HA,AP;&E^75JG_+XLJ];@I?@
M@L?,_ECW= <?6VW,RJDBV9=7W'I0"<HF8;\9\'5-FG1?6*R=M9,5- -Y!&C#
M&1/EN 6?-Z6]$$#XRKVV'-=<*U>.X#9(Q34[+@H4/^N,L'!J6,>S%R)5'$5?
M@PRR%DB91"H]Z+Z7TK=QW^M/"G,00MC"V 0#<G21O 5291[+)9W.4@P2A<X]
MMLLM"4,YFF<),II0</E# ]GOG(X%5X0/,']JO2\7 Q'''5-Q<.M]N1#SLXDL
M2CMW4TG.!)K/RN2+Y7:$3\X1NH1*$C)(1F:&LN M2:<.$71TIC:PYQWW#"HW
M,55VI!DL$/ E^F;K^[$'3SCE/+09]I9V^!'P@BY*NL&;1NX.0^TNN-#"<;FF
M5O'/*OE77@IC%Y-\0/71<?<@._*6-L];L+_>8%F=JY_..E/YE?9,+S8!%:&H
M6EM@2<*/V\P\A]::0]F.\*;8+23#+[L' KCU1$(),$JOO3ESV&59=:Z1(TYQ
MY/TR6J_ATIKDNJ\-4FA&=INW&'IP(0-/[_?QU9]1_)A+.WOR*4Q9Z>N;Y@XB
MI7(-%' R193(4AZL.KWW >/L.LS9JO'L)*IX3VCFC6^46D/\*DTH@/ EP U
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M'OB&U>_Q=A#?9$'8$O[,0-HW8+MJ-$)Z?T$9#3/YAJJ7[N0STG#KYY^F@NE
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MYAUU4E]4NX:B.SB>XBTZZ(?8-4?D:I<6?J-^1A##2D_MINH9_R>4KRK0VD]
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MB=XVV>Y97$T<#_<KT$0ZH8DI&*UI^KXR];4LT&?I/!%% KVXJ:5,L6#51)F
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M_#^'*LZ]R*'0:5[8$5CNJNU&[NZF&6#D751\UDH$ DI;X$6V3Z44\<7WNT\
M,ZP79#@#5@.2T<Y\[MWB'8$&LRG3+;%'Z0\.!ZO6H">Y'1)1:G\D69(F:?H_
MX8X@5^Z+RVO0 T59YP!!"8 3B8AX)HT<$H5<(K2T<TXP4BEU\A? \^[=+-ZD
M)OF"W,+!6G41EN.>46GY3<KLQU@OCBD6_VNWP0&YA]BSK2IA/1_N:J,IABXR
MR3DP,'_X31@OV:-.E/3H:9<@4NR!E/N5,^?*BJV?%X:T3UNZ?2$Y%C^54VWH
M7&=5]3]9)FT+Z6B'%M68.DM;[;QO47.UCI^42)>PLD#&H;9H%5;T2'/G/ON-
MEUM^CN;P,?JW[W1VWKE*>9H04T1?+(,*7&R[%TZ59)T\(BY5.&J0\!= . +F
M'FE3RSP"?MQ&GRGJ%D4)"U4'V"K<H!GF&>AK)#8B;W,%V$&(P^UM]/ 6>60Y
M"ZHMY"99*V1T;XZZ-?*99SL()%/\Q@_)3U*G8Z90&C=BF6@VV"BH5Z,6>R7*
M=PB 4\23C#)G(HWS*+90F?ZGK0&Q"8U>W?@F;(>MX4F;R.FFDS'6= CC%YSO
MXM)K5-'[BLLI8OLVWU#5K@GW\F-F26_&JAK.MX6&"OR^()\\8>WC'-E[!^SC
M.:U'OQALW1WOUFW% ,/93G"IE"?_.QYDR!-<V)%L5"JI>=<K4BXYCCB1*C%1
M'CKUBO?F):^\[)J@8"I8!!\4<OZ+L]GSH2B:_'[OF(% FY;PBR<L?M]Y7F5)
M0@RT2^+=QTH5MY3+6XK/'JBF$Q2L7Q^*,1TJK\J\ .)QKC>OZJRYE[+XI25)
MQRQ1++%9R@5H^GJHRE)#I0&=#1U/+5P!260>2&E(K!3W*'_0'-XX<;"Y$AX*
MIO'34*/I?4Z1.Z*;+NI). RE^7\^657BC/Y/?_79 +5TF_-;.=U^G^#F=Q"_
MP!(FU%:HREF!FRCYU-QO-N3,Y_?^NB?-N)=1JS-FZB>LZ<[ ,W[R15D@NZX8
MJMNHYX)"W@QLR<M8!RSM?,;C<EFO+<-AB *B%\T)Q:,3I=@M.C72]D5LT5@9
MH[=UC?HDVLVGJ(Y^#57+U/KB8P(Y*]A?JWH!_@X&-0/KLY&PQ+<GM<#T;';8
MD4!H@MP11)8D;UU+FKL[#Y,A>OVB8_H5U".63OA160\/(,K4?,Z9VJ/N>CZC
M$S/D=]_$"!;D2I]D!HW89S60QUB'"O/!Z4\;O(1?^:-//ZJM=J0RB4<8$ C_
M=W]H3?L7D(/_$?YS_H-I^XUB?A CUV>57 I=R4F@^G88ATY+0LW6AN40'/H!
MX,&WJ1[4N#GF\GO8H=)BX60.0D5&H*S,-:K2*JW_N:TC2)W)B;) ^!"_]=R'
M:(3FH,C%@\WR!#?,9F+6.QWF*"5Z^J8;_*@JN-#VI\!$0";'RJI93 =TS#N7
M6)>EC0:?.LO[HG3SH;+AN$0_Z:!PI;9,.;9]4_'LS:6V]]$;C^4F8J19AWO_
MPKL+X0<B)R5-4[E-&_.V;;+DBW,_GA-9J)T2%YHB7Q*GCY):7=VN_-JAH1'V
MV[6X@RG^ZY%POZ-:\G'-H-4&OT-<Z>';B^6/P^89S0:%:;P::/> 6OL_I9Q8
MVV-Z'91<L.8S=9#SGXI[P:0]"A$QQU&7X\#FA#0-L2FX6#&&H$0LR O;.#X'
MNC6_-"^!__@KD^+(C\#ZO \)/2S3]+MO0JJ/>;=:HLJO[RT["CB318Y]2=.&
MV(T:3'HZ3%+NHR]=^S;']DLOH*ISTA8UOK3%LMOX6*:@G,3I#NIJ/28:)* ]
M3:+CQ@]2V'VK)I%R#0&C')<Z%0] L@ZPB^?O4XRGDGD) EE#Q\^/SBZ]N ^Q
M62S=&GI!9L+]#[8N.+].R>NRUN,6YX*\<!&F.YWF_.N:*?GR!.$7^LD>D$[P
MAD=/2AG G)9_N3**!>:=:EA*/P7F *O@D:0_V'O[C8M*EY8N2?I5G'>0WF;E
M;4+GW@$3]]-=V*:5=Y[E$_;A0'MJ+=0BG%F&Y</E(T/46=Y8"AM%E#*!6C[6
MNJ_R!O;TZ2G\G+GY(R(/TFA15X45O5]4GP6%U^XOJ2KODMTL#.-Y-_KXOB?E
MG(<<<"VK1IR84&!?(*2GWA7@";PVN5Y8]_-]'HBI9^AYENBM/14%,VIRQZ@_
MXL,<)>3VJ7\&W,A2SS>@SB6D&T[\*779.B+N_.[E9CUK_FON95P[9 L+G_6K
M:$WI.=FRX[+Y4'5\3[PZYX*M  \%<\I, >';:@Y-^H0T?*.+RT!PN9ER.'LC
M!H0*S5DE'.01:37&2Y*L*$E-ZUO1<0/-%\#84KR%78)9*$R)>"8KBBRPT\IM
M]FUH?>< 5NJX<STJN(MKN 5V!Z#@Z>6>[.^97--J!,D]O9=_V+/$%2O\O(B[
M$[;RIA]>369(9A?'&9^%?77ID?X)VMOK<<B85Y;_75*)]]K:K8!J3Q>?>-TE
MO? :/=J0J(1*_>2+5P5.>0NLH*$]:V_/,=.#B=$V,I"437:>WY=B/P6+#&$6
M,BQ1-L+6IP_.4HLDZIEHU\"N_V#C J>8I! #_L3%Y=DVZFY).G]X5@%;MBU/
MCP,SR>9D?K2$?9UX'FI-NEN62?#L7!,X,2%-->UM:\TMQZK",7SC:D*T@U>V
MHIMY@U?PK:W.DY+O79JA;LR.?@@Z]4N5V)DL=;FW49LPNR2X1FKGAS<++E=B
M^_LN]=H)IX[OW;)3=T)2?6-C635@"& U*:9UOW[11(6=A12=8W!27T*,/N&A
M+KOH+1<#K+TSC*4K?'^L]8&(LZ6W>9R:/3ESY-3;;Q_GE GDE:]2JA2GM6>C
M[A:6&:VKC +EYU4^%X#N:*'35&Z?P[2F?$3N:S6I]=P5B&88#^*;4TC0<2")
M0ZWJ?<Y_ 2T1E,[XU9@&WWF>EIC(0_8M&A)>.A&*AUV-11]OO/-K5< X[JUS
M#-O/G;9\F%C@[1-B[,(J>FHB:*8=?)0RJ)Z;:YU1=+0)<Z]AI-K.<GG1X+02
MG:8:.3E/8DKP9:^Q'K2%^3I'$V_2&R[_G2TE$V>"FCT%-&%R5]UK6++@Y5Q%
M#.MS1(N7:C9 R=&W1L+2#=9R:UK!BX!R-H#)SIQ;^4TPS32Y+9Z!_=Z7/<W'
ME[L/[O[>TAGW-V:YW?C?>_QJT] ,@ PD\\1=VY$+SP;%> %ZX2?C*O7PUT5A
MD#N6";B[D^_DW6^[5VMVF4M4]/0-\A<!Q\#6*3\_DD,G$4J2VE:Q=%KWIYYU
M"GI19M%Y/^F[_CVAQ30Q6^<:4HS5C>DU!,:VY5-'LPD?]<]R*'X543*1@=V.
MR%89D0OVR>9LF)KP*GX7VK"FW<2G'[+4P=G_R&F/ZH9!=R7]<Y<!LSXWI[+!
MUG!YC=A3!#HZ=0+.?5UW9F.9;<,(R 46O?N1TUE@UU2<;??V&HG"7 H_9R0)
M37Q=X2\ 4P^Z;"+WFL4,T[57L!5VF]4AH9)V20F^\B=:SK.!\B]9&&Q6YEPK
M97!L39MP"*_;:74!1-"9$I*- ,-_ 9K/N*?I?^J]FGCDWN78&. O%*5\92\(
M^LY%=,Y1#G$6^31T_]G/)=K/2"@M((M-[XU^@&KU&';4?KB8Y/YA]Z7U:)8X
ME_5\ZF8>2ZX>&U0S%9)E5>O=Q'0BZ;%6M_$XH]&_E7^DXD$IBK!A:Q'5)IK=
M;BO*\93"$$2:==*G7)TBJ\3^[Z ''\A;#B,0:@VL#<L"NFNLXD93N<_I54:?
MJUOMF+)4,#^N,%D?UU=^DR=V%WC^*O 7\&;W<LXS&\JQ+'AG+33R$O40<Y F
M7X)'$Z,K^ND/?**/S(QEN?XC%D)U3M#<X4/XG@IF@O7)<,T@!4V0XPY.MHCY
M5G8(@OAUZ;8<(?Q49(-X&4B702S0/=Z?SP0$;">W?'#86MINW6[X82+YWW-"
M?(\S]5OAZ]VOE]16W;8WWAF77AT^*<8M9<HIRM.&H0RZX0=3.P,<1PAVF!G_
M,@CT\EW8D,HE^;BA-RK;3@2,Y!YJX[[Q0QGOLW[X7X#"MR8>QB(=?8-KG2GF
MT21=4LU=@LY]FLX1+]>CHV4OYR!%M=%TY63MM#7&<>$>(DR261XZ9V7L4,5!
M?!D^T:G&KX_9JMV+<W/PTJTTIDP6^6GRXJ J)BB^65&B,)A\DWD^'\?1@\G,
ME$J;<D^'+Y5*)4O/#(W8:W!HWHT-.=N9ZGFH<J=<)([[CM27X*0[M8QE[0-J
M0FV]5I=9<5CZ/!ZGYO!E=7O?7T ^S8HQ:#BC,^M0T;$?G"LY^M%^D;\7QWI
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M7^[IN[J)4<#1DSBP0\@<$9L* A*80 Q*-FN_' D61(0%<XR9AC@.T5HH?Z]
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M?!@JF>]V:$2-RVK6SZ0_,J:MS@.[YZD7.TQ/92RH,=#>GZ'PY/%N<3;DPK^
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M]S7GGY18<UZ:@R<&)X<UBK3DN$SQ#;UGMY(?U'238^JGS2TTX6PXZJ]][_+
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MK"-930B6R!R[2B.DOT?OW;9X(FC &Q+Q(@Q ;J(T?F?4WBZ=/ZTB-A4#R&H
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M[[&O*[2O&639$E'&'@%L5#>;*E0UMM34?U2M/DUK*GS@"X8AUO*73"2#FK/
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M$;S*Z/;I($-M,\!PT=29<7$GIIRI8M E]K;:\%TG[FM.UBT\O1^)N\0S 2*
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MN=+?#9IT(US>/_;*GMIJ\%2_XB[V\EJ/M.<Q-OYXPO(J0\TL:DD:YK;8".:
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M+'I]"N8*_!UMV*ZOFQ9R;70";E-)8[KQ(7&*?B)AK9E;DR$C4\HQXKE?/[S
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M]-@RXVJ78>^[AWRYQ">D%=[IZ/)(3[<# P"<<7YQOO]/>]\=U.37K?LB"*A
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M^[?L/:QFB]>MD/YVH;4D(#)=?!\-IF^K"BA]<[KT8N[=1$K ?-5:.C!/I/?
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MD$AO"E($Z57I0J@!0G*S]S[E/?N\WW?/>;_OWM\MK.29S,PSL_YKK5DSLR;
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M%?"WJ*B-$QQPL'&_$[2[C0,(L5F1YCKKTJ*T%1LX8+R(;/P !VP,&QH&W6X
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M\7W#")U99MT=O"C".;8XB<(4:V0?LU_T:3!L[B7@NB 7L&8;/ ^=K.^&T.(
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M"-6L%(@9]F1R>/KYLU,[?)=K\DX@\<$:E [[%;]>7XI$N Q2F:/E%BK:=7$
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M<D4JB*,Y; =R^'+'IN17LR/:>9'LH<S32:M%X0*^NS]#[ W2G_">SG60<2?
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MV4:^RDY+_!*$QJH_[#4LH*?>]'"^YHM'I]5G504^R<)Y_QC^RG<F$"_:*!S
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M@4A"\K+/?>\^OWW.>Y]WGWW.N7??<_8?ZWDFSS>S9M::M=:LSWSG._,GA"-
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MW\M+J@X?+.80 =#A:2J\JK&Z2."<;^<BS]F[<XNEUY0LP!9DOYTUY'[TO&)
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M_G!J-3%51_^K:!A"9YD$>'/S2P2ZG*<[#?CTVZ]6<>X^WO**'/<&+#GJZA,
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MP*%:!6752%@77AV)D7R(T8VN.WC9O6,P01@%%7T>%!$223,4_/WN2>]K!36
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MJOZG-L^U3(_]W0;'B/2$RM56QXP;CY9+TC4DWTZ6!'&JC,9=?LA;Y!44A\W
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M&LLQJFK%?(EFVVL52WMN:I^\:F<;X7V=V8?L=N]%>ZAN=X<LEN,UB/T: AV
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M+WJ!,\3MJ\6Q?^:##'F,28\-!TZBWT*TX*XO_=E;NZ8$Y>+U:?",0=US\U_
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M_VHY2G9]S;>3_%M*&#7O221(=L:MXWH]YD<Y>N0R5-J\_<5&53WV8MM#23V
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M5"D(C,P\8*M,])=D0PK'DP"O5S(UHA:$-(+%Q2F2NC^^<&# K[VOTI6Z20(
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M.F+>)M"LSS/!>!00>EH7]A?WY'GY]/?]\;^5@T-[YM&L1(4G?GW'>/^/:*1
M!"G-E)1XJ!,X/ /!GR0;#U&Y'&RX0],'9O7C,Y.QO [;[.-B]D9\[7K/CLH$
MR<<?,$!3PC7Q&1N0PP=PPPK2) Y)^N,1GIPPYD"$/@MN>V'8U0[Q%\6V:Z*F
M*M[%;\48:_KWKAL?:L$2'Y!D"&)F!.HG2.17=99K3;EUK$Y;,Y,M+/JB(?7>
M]]XQO8\7#?8?#2.5$$M)201+8C))1;&LJ 9_6)^:7&/''?;^HD2%:EF-=>/W
MSJM&/";/DEB",WF BBZ#?!K0H C7"_#(X*QE/#-!"J_W8Z-.B]USX!+_+)XH
MXW'LS),_=!I6*HGJAI1R.MAE^W1X]0D'HNR">QMXZW346^'(0R?2=G,Y^AI)
M"W^H1]#:>UF*X'7R:,E?FWA!U6K,4K@E%F>U"-K4ZQ5ZTPN$-,-9*+EE;F$(
M-NI5,#<L:JV5.'-T9/)VGQ?+"NN>:F)M0@N378/$GH+#>(>(O-#KHP'NA)MS
MFR%H!8=X1V&%OLS1"X\3NR.?V,?BGMF>%[WR_;U[ S\JSLN-&>9M (8EWB;Y
M8R<MH>'0H^MRBAU?;4&B3F@Q<[[FA)*$ ;X_G(<23L;WAXHS#X-+D"%D0RPX
MM!I&*"K+=[:1'?JP*WM7?RTO;7W[ED] NDASQ(#B1 WOR>./F1573?:1^ I<
M&[+TCO,<;ZPXZ?-74L$>3KA&\D,AR?M@7=_>F7=B #1=#QD^A:H18==L.X.X
M^WOIX/R_84DD_S1:1O>.].NE6@#G<K)%=A2 TO^LVT+'@@:\OD8#*,\3:<!U
M1;_\->@6,X:.>3D0RY)!;+Q432)XMQ%"83)9S<ZB >W"3=1*';KEBJJC3V<S
M>D86SL:,'7D'&D "\]( ;O/[J%NQ=5^'W*9SG$^:2,^.MV"T/#]F56V2S-.Y
M:,#'-'KF>A*&5) PVY;.7UL9=5Q=*Z=7_2O'U6QTY+NQ]P#P+,' J</V>>&X
M"7(F5IBG>G@0X:GLD)50P_[(@2Z9?VFRT=/DWU*K1>^1=QLZMP"+<SG=OWOG
M:1!/U/DKUQP8'/Z,!+S_>\7E#QI U_@'0&%!RS!DP;8?LH&A!IW[?S,0$.TU
M&"BT3 / 5!'RC90V'^6),O3++[&B34W.^=UNSH['*\),*AVRO.3$<[5=-M\#
M1^9= CCCH5=GEJELI&*"3.LETKO?'R]U.48RGU@54*JX^"X D<MG"[.WUX8J
M7=F\ JHK_2@D% 4,X$=?K5-9X-[XO5"R! *&/D,XEN3OY8OMC!YWS2KV]P[2
M\>)]V]7/?.7MN&=9)!,K2N/0QAF/P?:^# 3;V.AAUU ;USSO 39.*0?9JP*A
M Y_%F9-U[*65.4L?:7O&C'[ZBQ^)D8# L6TV;3#?4;W[@>=SD;/ !W1L;H/[
M^2BPQN/G6]^87IF8V;Y,K&!,D/DP2':?1S&3M?$5X>I.U<=0]CA/=S>[SPX\
M@Q:*95V7%!OBS#\E6[?WMTF>,??(Y.9O[Z7D\U(Y7" -,PPO;4/N$VR^?QM?
MW0JC 9'ZEDT2@]9_F+S97Q5MMA7A<?6XDI=*8'ZEZ/8*P:-Q!I9G33#]2&"?
M.-B'*YYT=F\2.G@R>KGBX,ZW"MWY_=HZ9!W+NBLXC)5A+$,(KDD*P;EQ-LP9
M8J?E_\!3" .IV\T\H[P&^=:B7^X6?S5J6Q3E.5&[*9&$ME'I<9M@OC^,%EQ.
MJ79%NMC-NQ@W2S6ZY4'5.ESL\K6W(L=_  /:D4P)K ^_3?Y8B/]T*%^->$3:
MFM(62P>?<<;9S:OXCTO<<%\3BD_W/VWE%J1^%-S"QMBVF3?[@8/8B[M&_)R]
M&E^?>,'L$A_N"I?XB=/OGFKS,X6Y7E\ _'A#T)).IJIM<:4&0@:Y6IY8-<N
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M]2_T Q=!C/H(LD'/]HT""4;\%*-.TX#)X JT,*)#$X^AO-I [#B-L+G!U6E
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M)IIY/.?=D%!_G]BJO*NX7T- ;_EODL10]>\N2OB^AZ$=AC]\OR&VNAJ=H5D
M$+E7: #>"/4*S8:76Y?'1VUJXGM2<J#7/Z\0O_C8.\7_L$VY6YE@8G^/A1?6
M__9]@IGX4C[SZB?N)&RRH[IR3DF5M[-NI/>J1TCB9NIPYI%B+X-]OAV#0S<Z
M 3XY\=7:F*I]C9,Z2;<=1X*4\O\)[Z[]=_LM:)R%+</8P:#*;X<(8GF98XYM
M]Q89=8VXG_'BU^2H&_\N]U+&J4 .^-D:4M)'RS4:P/XBP-:&8-?2H?JJW+WX
MRLT32:DW?,5#Z\44ZPZOPQ#-?GMA+T[47LZ^B/F\HB'R;1A1,K&JYJ9ZU:H$
M=)EZ#]$CTTTV_$JV(_ BU3EQ7"2%;VW8<91$PA0IMSO5374Z"SB%N2B?'J[
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M[M4;]UXD?RZ<O9<5A4+D6ZQX\_*.5EP:'[?4'C3P=!?1Q<5J/QB/;,P'$@R
MDQ0K,GG;X!BU"\-*9B 80TF)6'H]FO)@HS:<;#KW+=]-=?^L[CA_NN1M7TE!
M@N%UJ55/'_H [N'7YHGQQSX0&!N3;<3+*\3KM]WB8/*Q,U;]W]O?U?>,\-=_
MM083OY/,BIPF C-<</8QJ\HLSH\"?')M+,UG;BT=?SVCS]%PWG;OAJZ/=[<W
MXA3Z/ R*M8D_EHT+>/"BT_E=2^'W"T8&U[J:.43#^(9SDMJ-O+,2@V"9[+9S
M;>MM^ JB_Z$E'()W08;G51L*C>IN&;B+,K[.=;2>=?6=K!%BO\H-:9H=[_WM
MLP##*EH#N?%[1+-(=3.%%-66O4G7I\I&ZH4RY1WB3V[7E#PZ$O?\:J%!& T0
M4#]#<$3-XUN+7#<5MC*>#?[:L/]>6S[](5??MU]"<^SJA4PA(3/W>$UA3_PF
MT1\/:D3PPS M@5Q]=Y-0I.H5E.(73+G5'>+GV\CS+@FZ/S+4BYZ_U.F.>7AR
M>Y,#T0!!V/?RPLJAIU<1K H=BGI/KK2[+%56!.M(2:0>SS&/T^OXX0F]N2 <
M%O-RJ(^Y#8HW<@NUB"L[%+R#!8=3.6J&;":H#;(*$/:5PLM17(BY,(FK)L(A
M1W)(YP\9X+RC@7SDBP3>F$#N<;H<.X+"7GS,;PL@1D &C ;.BE26SH@Y*A\1
MTGV5^&%J=$Q%N-25^6,FZ!*IZE"1?)6TX88=4W?#OAD1P9/#7*Z<^_5+UG0\
M0O.Y2#P#GU:]"J.0F3-NDWD9K8$?I@'A9)U/ELZJDA_!25Z/?/D2SIN)S"$?
M,PB_.J)J.LW%L*V%(7/Z$]W*^MUV\JF\YI34_:1%'W2M;^L(*Y,G?TP\Z\O7
M,9E;[-<5401>(H@D2+"]-[!)?C"7,N*FT*W$)CKBJQA[0TG?_/II;>^[->T=
M^VD7/!/T4)GG,D$,),O#XV0VDLR\(((;IES_Y9/S:ZT+YST."C?:3XAR>5WN
ME/_XHUCH<\$I&M"@CK"W#+ W&N;$VB02TT@Y8?<=[1VXK6\5QW%*I9QNP&:;
M2/L:@11W7+@8L!-YZV9X3TL2))M\L0X?8C!W1Y12IB8K468Y=?/YC*O5+4D.
M\.X6^1.1O# O8IM#^G*H K]&&I\[(]40J$"?#+UAI9^S*DN*>2N4<.=%([&Q
M%2VB58VZ\TRO/1/;N5=*[QWUM[Q?4A8U<YQ<F:49\6K)Z660?.\G\W_.8D&B
MRDJWK"?TM)RZ7BZ)UZH*'Q"*_H)[ZR+NHO1C([A%8<Z.._(%P$D=H&@!+]YE
M/U]+E]FF 3C[C3N'YF1!_!=8="N8K98M:T5&VG)_\VJB9[EW0983:Q?,-I0I
M*&>'>]TL@Q/CL&$\!WFIKH-%A%/!:$)K@5V*V0#J1$7PP)$NEW$>_9R'+4H\
M1EW7I4*7^< &KL*E3S$:9083V\2/>$P+B T&LB;YSG4:G';V.!MB4 ;RE$NP
M9!/S->L1N\=XIO?EUN5E-A\,'^89*$+5K%DNPD^G"<6VK!H6CM_J4:OSWK9(
M@"I9Q7S7//WFB I8*7 -K*FIT3X%NIDJLP3A#QQ69IR3"U8WP\I*JJ'X22N%
MA2_.L.^\X]RX<OHG_TEN6RY;;W-;DL8OYV4V13=>@U*!5Z\[ XNE)L3+3'53
M;[.U<$>>U>MA$)\72B_]AU<)_]O];/1QB D45BK$ZW :9$$82<ES&C':5U;R
M5'.+K5]^GEOGA/:@V_)8]3/XIGEEY"(IUC^/Y-D\D9LI.>!5YSYRW/5%,9,S
MUSVKJN,?A6X+7+H^U1*A]E+DC'?TH269GW!TZ\$#N [^T*J]44&OJ-GR[?NC
M1XG!>ALVU47?S]D]_.'+)!0"O;R:?H$4,+\95:&Z&3[0V2P,^M:WF=CJEQ1;
M7#V(NO^VNU0\4\;S2KP\V\=W)A'M,PR[B/%Y_>$=Q$OTB>(1;/JL4<7@69W@
MA<0+TLP=@DNO?Z3=#]8[JMN1RYS=K\45]->PK>&?YU]G;*4!3G+[4@<(RBLZ
MS].Z [TX.@0MXR4G4B#41D<:D)6+2G'>KXBC 0N><OAF2LDK>LH<T]P8=0[5
M"RK^-]\P.H@F6M. !$0^8NP.#=BYK[BU$:!U>)$&=$"&(.N2=)F6%J" 7D(6
M/,'X=M*O"W1AMZ4!'-<2Z&6NB!$NH3(TS@=.:!PGZ<\7&C16MR:AK)PL?))^
M=MJY,3;./'$4F;"P4V>V6M11.1CM\]I_</@,T=$#&Z1.87:B9FHOS/.;';VA
M>-YU&G/,WU>;(_E*39[E$Q0I>Q5!@HTV00\82'3(R""+V1=%_OT%C,K^;G:&
MQ3YX8]W-:P_\B!(2O$[=WK&E"BOB1ZE!@3(TH%[?C:J;_?<74#V! 0Y+(\@_
M\S$3V5E*#GO[_Z'X?^]YD(KBNM$I\-C5B[V;$&T(=A[*AEAFQF'(3'0%N!#U
M#Q?(2TLC<0$.U)G6/>ASQ,.Y&D@MA8]NAF)_HZ9,<!2=:7/0J7#"N7_CFLQV
M1H:%RF[VH;_@=$##_XT&NM/G,.4"N>\_PH*E_P9].NT:CF 60 @Z_!2GP\\[
M@,!?H<]A':W?#NMPRG,D#;C.[?>O\W,A\!Q9<4!#CB1,QP5^VU,TP-:)[71U
MU(C6S2OBG\]&1C(O/'YI[F/4I#YJ;0,]U('?(( ;:< KOYDZ+)@=2LIK7ENT
M-'<D\G#.9%S1.^*+XI*VSHY]D/-0Y:S[:]U,=C!Q8*34'Q6BBFJZ^LQVA&P[
M[ZRB@&1WX%D5,*N2V9K: *_B*M2>.M[E5F+WT+SD>  _R-OX\-%QHBO[?DH#
MG;AS_)KPU9XG=G:.!/N.7N//_CZ97AD?[H=%GR;?PU<T<7I]A9(8Y\'1ZKX%
MHC3@&0QE3 K(3_M2,MIY?=$E^*CX>K"Z*-(X(8 3IX@NG,N(3><AM>62G,U&
M2]5FV3NPT_X&@\]276[UB$E/34RQN&^WG^[JKW5B0:6]+MR^QXB6L(P%$9M)
MEPO&SP5O6@TH=@L:QC,K\Q!TCG9)MZ$[3D<=^")7G8LI>?!'7^%JE ]4,5A&
MTQYB_.!7_$?KF7%K7SVIQ"M_/+"T#3-=L&<ZY3\*PLYNN,5EE"J'P=UIP/&9
M&BSJ*$GN%CJL$7K*7"]OVLDB%!M[)GGBGH1Y5IBD8([)U" \\V7J&L0Y%F1(
MD%IO(!C<&E X+#2[7XO?6.<9,;U7.F@@=J/!\/3UIX]A &LJ0 !%TM7O/KYW
M3A'3:HD4&+=Q(N+'H=9D#1?AF6L*3>K%'\L/[VKT21J>ZTI_>*,]4!-T)CRJ
MS" :S.0%8H!%-T-//2($I&-P=Y2;#C#AB.+"#1?9.^O!IR7>1Z"?;RW:74W5
M4[[XZWJ+*W58F']$_?JAV%JJ1N(GJ)-?;7*J1VZ&O>NVU67+-(]Z[<QB$1G.
M-@!\:X!24 LI@$4WT0"0[4#I9/==?6B$AE#=APMSOK=-"4ZGU;]7WO/..G>A
M"W;OA/B]8W)D<1MUT@KA9NN!\BNRG7)3[W'8E:UKPM8W#09=BC;+9/]H$-H&
M1L^+NS<)W.&8TW[PMG@*X(?8SPK ==&D:8)E/0TXI:AVS4+NY-AR8>[,V$1A
MM4UA)U3>Z@WCN?7BQKBT=S<U6RX)<G_(64W%K-,SX"#$E%!U'1SX**G7U.#T
MRD%%6&F5EXJLZ\3$N8NR12*O% KDW02S0V7"19)DNL'CJ):)I5B,DP'2(K<B
M<PKF;JF/'U@YL-X^7QTWQ*:;?;M 5\=;3K(KX>,0^.UI3;#QO[V9Q>??$=&1
M-,"%;AL8+$VB"Q#M;5F(200%N/>_O)<%^"3\KA0QC8)6A\RQO"2BCL$AY=3!
M(=DQURC_(.Z(1_UA>Q4Q(91Q9K]#-_.AC1>RHH=&=5[!/3W,E:G&_:>Y2L#U
MK*/1<$%*2F]C1FS&:;1H+\ZSL!>WLA!_ 5-"1A:+]3PY\=,W]N?#9U8;T*KW
MGB]7Z!2T5E"Y62Y<0Q)?ALY\$>E5J#1_]_!Y>/<64_%WGO$JGX>7YY\?1 '[
M<D3F05>-*S ZH#1HPYQJ^KDJD)MU8/-:$DBS]#K9]664SYCU84@_N&C>&M5"
M \8BR;[S*&Y86A/FM!>(:1+VG:F"()S&'675XB\0=)RU)U<]=&&[0R/'[$M@
M-X9)C)(>R+DR<_*.^5JLL\)V'0T8#^S]69H@3^GNCCG"NRDTK_Y"$,,'!WV!
MZY%<4#!;;0(S670T]>NQ_C*#[VG)<9(XS7SQVQPY11M33])+?S'7=Q!X)K'5
MUPG*3:GZSGZ\X7E([%Z3ON"^3HKG>=-#F^RS5IQU\4$R%1I/9U/<P/>H/32@
M%!P+MR78MLZR4,66_332YD%LDPVP/0UP@G9) C^/$DLD?]IS3FW/=(\I5L]B
M@@Q1!X]!:AQ=1K"N__H%O^:86<JY8A&;%98\ QM.Z;9KG[+T3^;GEWT?HH<'
M$6TSL."8VCOS!J=)K=MM:*517-S,FEE5J:76J;92Z0NWNGLX+NE)O;)BZ-&\
M-O/O>C<>PFIPS*%D!C<W=QR2PU%8,!C;];SSRVR+T_=O_-*YVL!KE?JBIY")
MF]@+ ^+N9$.\5=R24P$IN"\A -A6[6/.ZK?JC49+D93K.2VU<$B>Y4#!Y&5Y
MS53T)[8OM[B"6IABE '='M6G:5BYJ$ 6PFX7D<I'" S!J46<TKN@>C>/;; U
M9T[^^-AK^:D^9D,M3PN=YEYF4@BTLJ\4P[WLEUSAD@&Y4S+T*/GG!:]I@6*[
MMLI"-OT6/\GH+XZIIA^_.A)5T_-[RGG,E/6$1NV BZ+:9]_GBWS(G!=38/CR
M?Q%L'WE:*["UUX814#?&;:AI#<'EL9LG80@C:H?)B(+2L*N<J]&YG 1M8W5'
M <9S)G.)P0:&-A6X30&'F:.#CX84.QML'66;O8L[%M73<EYO:#6>%Y/"&%CL
M6[8%2N!G0ZARI$9JYSSQ\URLT<$+ZYMZW_&-5O5%4=QZLZ[+ T=/HA_NOY4.
MOMNO23?=<Q!FLB;^5][Q$;)]IM.$T.7O"'O'0#X7E>\Z/VY2"C0SA2=5=KF7
M#Q& ZF.T,XF7(#W93->09[\AYUNS"0RI)RP/>=::3IF+S7E0G2:UM6<JIWL_
MHC[E_P-&9FZ<]3&G =]B9@<JOOSU28$8/I..*+[^[\2%@00I^9B%#+HZ(7(:
M4+@5X350P\ AZ);!#@TX/)%'C4I%6Z-^SJC107$7IHF3V,-)3SVF*Q_Z@S#J
M&LW_YCY[JW+C/E0]ZD<:\$B9!O3?&^TLV^5=KZ$!=%ATCU[9-!JPG.^\H\'T
MNU1$D]A\90E5"TG6)=ZB%YJ#;&[$R$!<D/LJO0*(R11JO.7HZH= T\!)\)9G
MN@(-J)"CB%:@DG"0/5T:$!EX^R#N# WP3R%!?R+9_P2BOP_.VTT[]_[ES 'X
MCR49]SCH)&#2H#GX/Q)R]S<1DZB_B?;O8_C;D,G[+Z#[C&.(T>-T(W3:[!_&
M_%_&OIULAT]I-8+-WR,8!%'/*H<6*5X5#;DWJ!A[874"7GCJK&24G 9/F'5A
M611ZY&255<Q(7B,XA ZVOZ8U"^1F%UK!\EIFQ*OUN^VMJR//'MX4?WPU.TY\
M_W&4 H/),0/QY,=Z*-U_9Z.&O_)ZR#C]S7H7,/'_1>MR?CL!+/!@)(13_<X<
MAL]B;'D".;;QI%COG7I$QH4GKSE3C/S.S>=QSS\=+Q1*8R68OYIR34Y&HPN%
MDZ%!7]Z9'=3Q));MUI7NW-Z;ZD\E;5)Y]Y"0954(GAU$5=8ARVT*(_I>(.:$
MP&17M!A5E,>$!FBL!O33F4DOW;8;EX"6PF?EJ'\<<BH\1=/G<2AEOO> '4EF
MI'=++/TNEL.VC)TS8!(S,PT0S/Z;_$V4NUV0=# <L\^Y?OM_\F@D*>*!&?GP
M\QY]0!-!NVJ7J+" +7H9!L7RVL[S&!)T1IW>5\MT_G(50IH&XS&UOG0>0']*
MT',$H1J".VL'W?Z5-PVFWH8,K3?M8_<ZZ<*AT=S-CZ*372P"MDT-R:8!P!P-
MF'^!:*02EBC,.E0&.CQOI9<9$9J$Z*W.>('8O_3?H<4.=$:E2=+\ZXG;B[X(
M/X%7;G.!W"TFH,.\.BU/6/C;\29.OAU/<52)^D-*+(8SBB3? "FQ;T+$S);]
MS,N"\3:%Z)#<YR2A&_[YFZX7!8WKV#4C%(I(1LOU+JVF4BK[*6 $W)X 3V>@
M4W,HQXU#J8%2YYK*JS0@^3,G%WG2 94.F7N;SAFM0WD_:?-P $H*,:FJ3E[5
MU-?-G[D5/(VW]=Q]FAM$ $TZZ2//!(ZG"_<OXGD*"9RZ?3N:4GCJV\$;>W:O
M$CA_-G^*9]0[]I.1Y#Y38S >8DKR*8+YX&;#J0)DU:% ;K)UR(V:\I1;M<,7
M71>F3B=<B94/_IJH\"BL1>3[EF=;)MF-4JCN>*A"]N"A7L9G39//U@8%1%OV
MKR\X?XI/NB+AG=(I\81=Z=$)4U/^93A=$ZOT[Z)BP&7VS:"X\UDV#H%LF&!]
M:Q74_+A$Y^7(^_F_E+2J(B2N/\Q,OW-)G66N&QWNBT..;^KABUX&Y)!U\#-5
MBJ.QKC8]NN)1?59?2JQNC>W_<>1ZK^:M]$J(!5F$T!:N[DYPMB&MS4-/.08*
M]XD[JJO,.935C&V8;(C!#;SXDH)DQ=_Q,XH<,^XSLSZTH1,Z @?)?ZXBU/6V
MAB1A(4RP)J*C.^S-.V5Y)4CMQ]>,>R_=ASRW01O<6 0S^2SEHU0983;<M8@J
MU#9GL X]D3=N@^.[.,REG8G<=ZR]K=?CH\MW,# %&OAB62E7^+BJ/%4MVO>U
MGE#_I2=>8F=?"IW2<3<:[85^>QJ* [%3.]&@$H(0KVD*9H6CR<WO>+SLC+U#
M&$CZY&O-:PQ"WJB/CO_7-K3J)FWK$(2K,J]5A-;>9 Y3-(U_X/:K%!L8E4GN
M7.2]O> SW0+SB;Y8ZS.G]BJ\&5.*"89?4PBZHO,%YCHQ'/5^+FBO_K5W1ON!
MV4#95GHA?O0NP;2*T-OH-QLV,=\Z(VJ9ML%I5?W-D</?V)[+>XVMWRC_X1N7
MRPFUKS4?WKFDVOM*XVKMB+J[F[W[H29)#B?N<5,&\=A!P*O4C.WEWEZ;SWD&
M?W+MP6@?]U9;(Y@'9MP*%83+%Y! >DB#(6C3WB72P,3H76>MTG>WCQTO8M Z
M@GTB?P[L[THM.!I@H/OWUNR?N2NLNALQZ[='+H_.-NY =NX/_^F1,T1T0 9I
MP+IDQH&TT[XW)@VV2=6Y0@-8#2:O&E"UHLFWZ<\AXP]/9;W<MA7JI_+3ZZ4Z
MSX5&3SLPG,N$CXN]5NVO%)KK8] 2#!?JI_.R2A5&H8&G_P0'X(_>25OJ7<_6
M#.(B#<@QW3W(@R9EE+>1WR_%0C;H>EJW<&T1AJ0,0'#01(WL<,3,(I5W/[NI
MZK>O2>7W@8RG<*G\RQGP'TQ2FK.B9(B#!)&_,;%5O7QP/3RR:?8[HM$$]X&W
M"?ILENBV$:LM: !Y.GVHWBI87.49EQ9>^.A!8!^&15&F75960X*DL;J*'3GW
M,-RFS"=^+*B@0+Q#_#5P1B\3I)GU#6XR/\M*XIB107*0HO7P.QSE8XO#;EEE
M9AI![?6<9B] '(X:,H.B0R_N&'6:#]+[Q,PG;TJ< .GO>XU0!?JSJNI8<-!7
MZH:%U@X'RE&E=Z"FI;T3%RYX\=FG"PF=(7SAL0(;FFW6FF4YIO[\D#7C+!"0
M6_*9V5E6PS]'/SHSY.+CF ^]I1[>(2]'@A0=_H^YWW*F5!<>!_'\.;_O-(TD
M_Z]-W_\H#$(E8YP,]L$[FX='\ZBQR>A/?W<!HSY/-[KZ9$.-MM\^[:>8QEYA
M^G#OEU*^_7O-IQRCWW!XG_KXSXK)-"&PY1HL]);3!^3-EUFJO Y9J:T!<2"$
MV4JB]U&K<_C:F,'^(9A\ O%N<E<(2CY(H1ZAH] ]Z?]I5H<#(B<UL(T&'('^
M!!NVT(#>SX@Y.3+2[<RWXUQOU>GLYQ8!3')!!M/%2P6Q*$V'N3%T.,%6C(=2
MP^7(GVQH "%5HX[>L(QB.@)*V0\?<D=LKT))]&>*3>[O]0Z\":'ZHD T(&R,
M)$<#;J90C5 (4C<8/PD^2B<+'C3@A\DF#>#/_I<FO W0X:7#ED]T (79NE;+
MV+NF/3,U&H%H>@:G7_](E\KS9ACR4^3?UVIW78I,05*9,%T:V='T^AC1ZP/=
M%YXMW3MXG&$C^/>5AOQ]QXQ^R]@F0D@<-.#209P<-4"?!C @%OR3N+&8?Z@L
M5=!V#D-AA^[?JJ/#-H4 _Q,T $)7+2_EMD'Y.!JP-(3!\U)U*G\)EY8MS)R@
MY&OPP[4(BBGAM==P;AMGGFXCXMTH&5X\E(@!Y2["4;[[MAT;:S8EU@IKQE^K
M/G?H^:J]WSU_/VO?2:ME_\M1+D.+=_^U;YD7$OS;A-5'%1"1PN)]9&NI4 7P
MT566W$G'@X"O<M?(R]]*OUOI2Y=S[LU)BQC=6*@0 15<437KR"B]FS9WYV:+
MC62_;*#(V@PWX1C*Y3CA6$KFLH_ <.F8R:5.]<M-4HE*S3''6$/CS42B *(,
MDI,4W@06+J4<(U+/&#<)GRNN3#.H.%1MTWAWK:!1W'H-J72>*13][/NW5N_7
MS)_->C",BG(LJ^G7THQJ"- HN/O\EVB=BFC#475EWUQ+B\EC[ 3-6#>AR\>D
M0[^WO,W:<H\ZD/X':?^G1C=A_B&0:9=W0^M/4FQ )\6IB.7/7Q8GJ"YT/2#4
M2;X,>8:%[//($2ZU9]5UWJ[L5S^/AS0=D*E\@[O^^ZYV074MU>]_/O#U##9_
M! "'?D:DFEOXV-"EE[76OMFRR2D%VA9[!F5\M]]^#[V1U,[:=.T*\]VVSA3V
M,FW%:[5NG2=*?U79JHE/EI6BRU=0\=-"BZIQ[(EE2US#'Q99EI,/)@WDVQ5
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M"D@%P]JL<*5D/;RAPC2O*7I 7<<%99 C!)UH 2?W>TWW_.Q149__E3[/O2[
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MARK8*NJA<]JBWZ(^9@@'O.*=Z7PRB J]6O)(D&SMQQ'=0<+($B[,'CU]!PC
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M3(D&WNG&Y?)F]4\']EF*P;FLYC2"5</Q=8N#CL(G15ZN$X>B>,/2QC&\/SI
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MI:JPN57I=B5K\!L57](<"1QE=56)2A&^/!1\"#'UZ^8\;U5VQN-4+W0_/V)
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M<U],TN9"N+Y_ X?XTFYSPZYBI9.S?A[W;+!7Q+U6UKS%X]CPE9]6SL9DC[,
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M,@-4@:E0S<9V14$^Q@T\NIF],>YYZU$RZPWAP"3O"0#O2_CGT7^^3!2L\L0
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M--3#\:-,\UG+/9ZP-D[S)A^FM8:TM "/&K^!&K]^,D9.ZFBWX\&W 0I+F:H
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MG%EDV-O=M>G;GENI"M';_HQ]=EG,Z.G#BL5@,0C,"6=="-,8(;!:.HXQ?^E
M(5A4D#-4>5[BYKFY4WP\E,5)TR_>TU38R"@"7& ..+<2Z/K]@6V8$!(9HFC^
M84VH8+7:^-*.V8.OIKQ5M5%L6FTW%(2^_HC[+*>OS&T_?VJ-!F\LU<E$5$*
M?5BJK[M.!WZNM7EK$]JY%0?ZECJ)JV[.?)_=B("B1)-RSO"3=VEBCW<#!*S.
M?8;=PJ5B4PWZ7>!\X"!/\*65XX2F8NEX5%%JZFJE<X3/[E53NQ3!>[=OON+\
M6)0H>'%.PHH(4 :2$4A,K:PK$'X=_AWK/"-='M^>,KWAE^UX:&PLSI!]IUJ&
MZG)YVSFJWS[>^4;&[!&GS&2MCA- ;=H?D*>BEZI%"/584QB#&SI4T=G'__:(
M2,E\I7_H^8=;T^QJ^@Q/4"9"W_C"D 5P,IC "(&%T%=G_ZK2<6-+RM_<_UM.
MQL#TG(CDKD;-,\,G@+?VBVMT5GGDFK@KR%^$]CZ,GU:C(BZY@4XF&#Y<IO&<
M,'@  00LRASY_^+<Z 6'5 +<_')K3S_"I7%:7[G%O.LQKIES"M;,3NPWW25?
M.!V.>31<NF6H,4NM=3Z2!RSDJ&+C'1X$IUPA L@1SMM!CB@R_EB4DJ[F&%>#
M#&/FBG>U1N*''@@;$6"XQ//R1\V#]KQS80(?L/9MC0_;N$$XCR*H0KL\36:'
M%AUU4Q0HK%@QPA[I6.KK<CU$59SG[FUC4R8.AX3 :S1=0LYYN'6]TYHF]AEH
MM][ XO '3%6E@@,WM[BV<XY9^81:O.1.H:9PCY#737V6R_E4;W^V *W_Q56N
M_\GE"])OLB=O\Q\2Y14IT@D3>;N7S[0,SN?/VI/S> RMOIGU[[W^<_]<D[R&
M\(?=1_SG/_J6'P-I$75:>-T=]66+NX1#( ;9<R9J'L%J_FWBC)<%-@.Q/%JX
MV!-#<[PH%AGIJLB!J6^K<O0H.DTQ,JI+GF,0G#@WTZY)?V/3)=N7C+]9;7TW
M?CXJ)HA 3U*,JC<;'+&BNIH-3$A3=:7*_\7>=X UF6UKAR)(%Z2#@ *"%)$.
M HFH-)$JO04%I4GO-8 "T@4$%*1($9"FTFOH142J]!9Z)Z$&",D?YYPSXQEU
M[IVYYSSWWO_Z/&R>G2_YUEZ[K?V^NZR],/FNJB+88R-A@E:=B=.$4Z*1=Y'7
M<2@)[S/(% ,@MF2D?3?'4,^*T@$SH22?KI?U7F:/M]L]X".6"J41F_=\HWB-
MB=AY.P;,C1X'TP O^QC"VP**D#5-[STH&H2GJE<819LI'1W9(M* Z@V"4DR
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M<+XA]WTT9YQ2OPOO^+UB"\_\TYO STY9/N^SKAP**7Y0Y+7K>EGHI=8(9O'
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M :H%%I8:%EJ9J[];*^DF*^^9[;H9-5XGT>HA'N@"CD[B"I4VA&2VPM^O]NA
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M%SVE&Y,,J>I9.,P<[<0 IO-0&,!%OQ L!3H</5+_%\W2X+ ,I")%9].HTEI
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MTHRM0SZ.Z98L#"P7!D63#64H,Z,L]PB>>:HRG2*..:@P!]!QQ KJU9]%=L)
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MQW T%*: 8M<%3X?L80#$J3K"["(/RC  &&,U&@4J1FI@2=3GX0/8":0I2H=
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MT]Y92WHH'H1Z9<\Y87,1#33.6I*.DFE5SD8F*PSUPW8W=-I.^"M3"NTT9>G
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MD'OJ^%9L;TR[7[%4CT_N4HNP($VS.>Q86EQGPW\NB"2"HV@I,"\;6,R U'1
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M8UI!SF9IE+:<U(K0(0G&=L'?M^)"_*L+$[7A<J%W)Y9IKB.&C+UK<9,+P]
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M=71V=??T]O4/3$Q.3<_,_IV;7UO?V-S:WMG=VS\].[^XO+J&(V[(<2[?(B#
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M,X\7'+*A-AWP[@J6TQZ6AYJ;@D,PKQIP1[=<L4"NR:^"TTZ4!FJ\%;0VBA)
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M?.0%3BF3^H,VO=/ O3(PR-#->@O^;E"@)/U5.!:(]UG!=/"#]Z2F?;XSK\O
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M/ S\]P(*_Y*&$C];C$GLFP]VY9?A(*A:G9U0.9MP*#H[.+ '/]Q^W%A:H(9
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M XDWELV^3^UT0QE-?%L3EK+YV(_8:/P4"FJ>^=3]U>E%YLZ%^C<$".VB9;&
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M&O+\RW0XK=##=E42F*W.GIU,"JYE<CN%)6ZE.Y^WSHXZ]EU"*/=?V#0)+5W
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MJ&LS\)"6@>,8CN4%KH[>@2\X[79?@'#-0$/.KM^R!'SE:A^M5MA&A07Z*HK
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M97FFVIAO*6^X6SV;)5FVF\UWJ:W^,.WLL,GRNI/13+!<7]9M?/VM8H,D!6\
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MJ?:#KJ0BH._\MGVIEG!/F'E?\5C7[W-I]5Y$FK+0++.%DWP]_VC[1Q>LK%)
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MD^V A::I_;_O;,2A[66K**I1#:T"??H?!7)*[U2CN];"\I#C>Y(8H WM^GM
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M0CCD )'BB>,*66 8[)7QSP8L >-'Z>,[*]]?Z,BR+WY9JRR);=K,!V]=&4>
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M*Q[8?U\]=CJ/TSYJ@H3+COF#?G-@>,SI4@L+D_">+S-S#"CKH>IG!Y3E?YX
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MISRF8&BN//!!LDJP=(C@]^;/W^1NEW=&?3'3N*KU?&RIIUM^B^'A:WA)M\[
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MXFU]J7^JZNP#O_G $KT=Q^??TA2XQ+2VUK=!^MVY?NG5 Q"DR3C:[5/Q-;C
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M&YOI[W/N-K[]9N5]A=:)L[ C(R%' WFNQ-HU6Q3W?^ H:Q*"OTO-]'K^8NY
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MW=F$#<T4[%T?P]_\+S+4S\T6?,_:'6>EGQ\$-6E_^1_>H_^+RV;*:UT:1Y7
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M!]T.T5X;*..$NDT;M8W,ID<?'4]1C<]TGS0)!G9@9U8CM*/M:0A0!PSS78(
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MQ20N.4D]X(K9Z")Q[H.^@14)__OIF9BJ,(%W.FUS>^3J^;,_J JOYU6S&%*
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MBCI?B>\0[PGSK3I=$C?M+<#(U9N3-B6<G^N)EDK&IGI?$!8+FRM""8^%M>W
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M>%<=4\EQ,6@0TK0K-J[$Q'X^L\BZ#$8%?SP\OXFWO@>N-IGO?-$ *W>PQIB
MT@MMM8F>K'%]XM@-@S#'+;L4*%)N ._(PA-O=:L$L$)T[([=Y"6_;3:70.!_
MV8>]S5+P&JLW%GK\(-6LM-T) '7)3(1 \0O&9[.,]X!4/!ZG7^Q(+YU<X8R/
MIB\&2+'\+0 !W%6[HH(;+,*<':PL:_$':@GZ4(\"<$,K4/KZCEG;S5>B/59H
M+,';PWAWDM.MIP=X=V%ZP"%F"T3THDZ9[4UU0(78J[FOUDVB='+Q/1"LMAH%
MU[<=?#SH#E":A%(OC?$;481#_AO.MI3Q5R$ZX[%2ORF+Y+S&W.#11,VOY&8N
M6_97,#/77*/0DT@J)=)QM%_^QGD9MM5G"O^J^636U8^WKN[-;#^ %.U<)OR3
MB;_X6)SW1=XD3J[VJ^#!HS16;9<1$2!:8034#4B6W*A/""C53IX9+(ZBRV1/
M,SJ04TN3NO?(R\W7@=OI_  T0]4UP_ [VDSMB9MSAQ94E&?<J'M$579LE7""
M0E"RKT.D;ST 3KV K^>&R=1YGC:FZ#.F['N$%F-**[A'S$DV]]A+P\%D&"C(
M9Z,]PW@#NHGLTUJK1U@^V_MTF&1#I)#'*PP2 YT7%5DHP[T]RBB83^3G<@/Z
M:"T5$(ZYR"["H5+%K9_8E/B2/?("H&GWL)X/%H&<.8W-T0EI[XC#[3SD0 ,X
MON'X2KR:&S@;2"B?V(LC;MC1X[')=:(Y0YX!61>R\%;RC@0W@_5H3-3P%2HU
M-$[YM9&8_#>C^</4LW75;S\IQ'25\AYWASBJX#JNHH.VA%%1II..1!6G]KAL
M]V(WJD.#$A=Z6CS4YR5E"8EMW1F&^@["PY'V1EAB5H+%"!>T>V#.HKXEZ8.B
MA@<O1&%OLWQ!K$581H:!N0:6A9?U-X$6TUZ/NO&#M_[>16PG6V5QW3RY!Z*)
M[H&9A;_G@G/_7BY( UHABJ*T-CO$F)/XD\<"+FB]&,R:51FCJV\@2!/X)E."
MW]Y^F2$#05052>XJ \XG%ULOPV3M"&1&'2QHVCH8:8PM8ACF7LT"YA:4OB:]
M#&)FX%@)BBK&1W>&OR(.*22Q=B."^^7%[3B:.S!H%R%J&*:E[O-*A[<?]=*'
M\E;JL8P)(D99S'&P6-E[)C Y-'"0"@]ZL8[1,XQ3])-]*F910\XD7)Q2&'$Z
M+VAF&L09RU/7#]"T0FFDCSR[X[8IW*LJ^#L=7";<O]LHM'<6QHG&S#-8:8[P
M![Z&4OA0'O5DX@69?K<3^ZUC,\VNQ9]/H:M.-F*B:<''OG^)A[H:A@:D &$O
M+^JSWVL3S#4LS)'W$<"<"'-55,&X%>(@X4X>S0VS4*!UC3M$3SO@(#+=IS($
M5<IP.WA\97\NY]SW/+:.EFDA)A$, =ZU=@\SO7CVS EM:W:CSMJ<QD#TO @3
MLS>S]MTC<AR5W7![>Z#[HC_+^[-QW-XKF<MY^\,U$G!$)XXYFR<M^^]0H#G'
MZ_7X:?'&I*G^)\;4V]>J^#)Q=#%50>\NRX\3-7'<,9B)0=L; >1BH'[F:L!#
MHY7<^5&IW@_O?(7QFNH.&0JT+<J0)0C[3 QYWZ8C"SCQ@M;E262$MY/];V)>
M SLW4V31MT)(I@F4FN!B)@M3$:V1%WU^*UA[X!X8S[!H$6M:KP9<:.B/]E-7
M&UF>B7C-IUIWH"K;$E0F<&$N0XQQ\ S\V\$I0&KWW;.*0X-7REYQ?;4X?=EH
M<G0%J/M_-:#A408\2+O@<H\9>N;@>Y,V@4MSY%1(&%:E(1%2A/D;N# +3V;,
MAW5[[G9E,N=D[TOT&J\#15;T&9;F,FIX E[E"XPA*!T5<U#K1H[1@].R2OQY
MQ *NFA+GW&XP'TH,KA5ZAR)3!B=LLI3L-$^1Z7O=;H[31$4$I>X)*IV]B!RW
MJ[I$_=8B+T6N8^KX/$,SB8'NC,Y/PP_*N2-Q]%OHUC'N'H *@([O@4X\&JLE
MO,E2AB;=S43]B#5A!MQV5$OL<@M9L)CW[J%[%I[&$7?(KICV*N7UL,@@79AU
M\>,R2EOIZIDT*GQ)U$)JS/8V#*!U5N(0:94YGVE]+3&W.7\FP3QT(C:_:WO2
M8ICJMD4KN%>W+@#:H<CL>LS<@6ENY5PK;MA=94?Y40Z33"UK,$AK,:J)0?[L
M3Q;J^,.07"T>_RJH%9P<[#*R#*;O4X"@L>W+K8@;KCJ-.4*S,+U@1T(*A]TS
M/YA/]KF@:.NULH[)Y* P,5/A+2P=WWXP/5)LN4-ON#98S-NI8#:11]42:U_]
M*U:[3?C7+Y^UM5Y_-S,CY%' :'F?DMX28<UXNAZ<Y>LFBJ^"#B4#"&$0 .B'
M@*:18FO+Z[AA',&QO1YPXJ$GS"G MQH5/G*S=_,[KH<BPEF/EXF\I"9NV)_K
M+GC,D*JSF*!5O86AI*W4_)0E;W_J9MNV6(M*"#*"723E60O." D..K7T\$-J
M]LB(]JB\0JERJ(XB5OS#UQGH:$A7&E.YB=UC]9L-[<SK8G^959LQ#'YD[W^J
ME%8[D*K)H G5!LWX^D-IVCV/@J2KDE<C;$MCB8)2'B5\?N,0.TQ/R#\60'</
M8-(C^7V>WD@J.+.4"L 8.0OV"0QD<FR4*.48=<FBQQ6D]UZR&K?7JX.R,+81
MA%__M.+JOS&87R:N5O(4(9.GT9-$R>1U&\G+=OQB?0CKT3!3PW HNQCI[&RP
M^=#=F\S8=&<43X]E>#.UE"?=@ -'BQINH]X&9Y<WD$X?&02X=XWG^D* YT%J
M[0:LQF1@/S ^GA.4QJ782V^\JKB08XJKC&8A(:$D6UN&S;ZMLI]V4005J4UW
M J6T6E_D@Y.HXK>9)4Z 0YYH8&K6TL>S#177V;T^/]38(.H&'+^LO_GX!$*P
M]&D>E":5:FHZ,B-N25D^0H2@YH=29Y2L*[/+39I.[3,.5[>]QFVOWUP0 L)Z
MA3=KX=CAO!BAP.7Y&B+*^8#,ZNQ(]^OA(/'U@"J9E%K/NF.\!W'XBO>*!QFJ
M!4"K-8:1X>Z_9ANS>EWYY5M=8[UD,D-UA!GO41JOA6P?530F^XV. .C-P9I6
MND.V:M&O.^<>L2Y3&1IGOH;:Q EV'A"(,JS0 >E05PR 5NX>3>T*U)4^"PNN
M)C^U3'2%C;&WAQ"\-=P=(6NH"O@1;=\J)#P/)72G65;XSLE=]LS\.\T.NV>R
M>09?H"#RJP-?L8+*[ZBE2F#=5H2SAP4\+T998NE#<SBPK-_O0))..5BU>/G.
MU7&+C80V(4S0%6V+JN8!CYB2CX*DOI>J?P]+-1+QZX4<L?5TI>'PP9X":3@5
M!>24P5L I0_314#>A99S9=U)*5>N6@>V95<LFD@[?"B4WT]J?]&WT?81! 6!
M=?%;^<@C5I1;4"0+Z,?9)H1B]MA_W9%S%[;Q#_>-B<:U4[OH_ZQC\*(B+#6&
M8.ZXG4( ZN]_(A"L,'K$EB#1H0Q8O\\DK$KGZYC7ZCHG<8LTU7TJ*ZY?IIE@
MN&XN)@3P7E)&-48_5B5V'^GLT"I_8QC"J!2$2=CV9+$BKQ88\;<$S/9'=.UQ
M+<$%@=)L[ EF')]K:L!<<JXUF)1!TGYR'XB@-';%-SKC5:F%' FV=A!D#+N^
M3&E,@C!\:()Y48S7L(V&/X,%96^F*X+M,:/+#YD9K<!71,&OQ/K2_!S88!!/
M>WMA9L;X\,)%*(7>:(3 +9YBE$'J4.R< T&X'''?G>5"%KJ+0< @#Q</\2D#
M*IA=^R(Y;[M\/O5CO7587ZQ9=>0SJRDJ\Y=A/U'5/2Z].A9HA+.P6YX\+!=K
MOR!^HR.!:Z#ZU704!=*G2EY?=Z!O09<5F.148QC17DQ3JV,<U25R*Z*R< A7
M!P]V3'+0 'D\T:@K,6BW]3!E%F&"Z%"J0%3 ERO?>_PX\2IK_&DSLH^8]E[Z
M< 1]\NXB*'=N^_#W#+I"R7X(?L\ SLC 4)X4.]_1MUBE/3"YL0(J6$+FXDON
M;^V0+Z@-51FV#*2\;!C,66B0.-2S1:0J\,!K8M-V(;AW7$2*224F-E'$KL44
M![A]!'F\(2C?.&.I/WT+#P>EJ6%8P6_#'E3E^[7X_&W)YN/+8_'>VMUR4UL)
M[TQNNS="^W=4:NB!E4=V,N.E&8.W]/L*,$)*RZEQK#0>CF,YW,EV]CIPCQ.4
M<CKC^<3!G^3J02T/^)YFBH8FBCD;GT8.7T27HS@\U_D]L(%8=;7T41\J?U.1
MV1K\^AQ2K@81MS3X1AG8@XB/6AM XJE.5"MYOY\6_2UX0I?NQF <R2>)2B.)
M^H3N#UTHL'&C=$2J=)A^;#6'3!/[=KDF(VO9$4>/7&["JZN2 <J_;7K\1F*U
MT%[DY%P$'EH=>9Q-MEY5U\N&*WCC%[="',%PSC&S(RB)E_P1K>+A5-^W3ZI.
M+D@]2LNN2&1XQ'PZ,:'('%F-"!T*'\A)\F@I:8U==W\W^<3RZXG4#HD95E[+
M_MX783K\;D<>!0%0G_Q1I532@,YZDQ43/)N76#\^<4[(YQZP&_J ]L[&!<Q
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M$#:^M,GZ;&!JI2Z8T$OV,)94+<56#JN_2<1)OE5;!\8X87W5VM9.'[$?9V5
M\LW^1(H@@FAPF\?SFZ9=LL(*=KBZ8[!B*"J3J<PQ#?J?H@9P +);D#&,8K4'
MER?YGRZ/0?\N4#".X?.21BVM'B S)O!C+1:UJD:G]!&_'%TP))?*GSY@;H-&
MTMC>(PNSM<*F9? ,K[+][*7I[IVZA_!B(XW6XJ?%$U.[I:T20#'%^ZOK/6"J
M\%;?N%&&_AD!VN_:0? [_A'>4&#X(0#TY0D\:(TKC\,P>&]3J%.1QI2VPXW(
M=\ Z'3_@(0!JA)+77G$&%DFVU-0VL'=<CO4R8=2<VKB\8$'I<B49:X,SA K4
MLFET%63SE40/?GO<J$,4$TZ5-H8J.*><$/_8"FZ'*GALNTSL0"\W'SB]$/I9
M97.U E<>(Q2P>?XLH+I15QIN1UV5O(PE3=%UC7S<P/.9D@YPQ(62_X(2Z?V:
MKN&Y39PCR_+/7)2G@""$EBZ)T2XKG/YBK)(,W_Q?$^1[G)PEFR*#W:BOZD>-
M_J9<PX#2?]1!" S=$2];DO9(M1(K'\;F!<2/V>>YUU!>JQXP>B0[4F9BF7D8
MI=?MYM#$"J-FD(FR=A2"X4,$VX@%!;<BXT&#-_R'YKV!=!D'ZK.WGQ%,ERA[
M],_0@I4'CS>3DS\]G3^7%[4$3VZ#V<XE)ZN9"9?TY@WJMB>EJ<)Y)]&^IP#C
M@<2UDL2*Y=DX; 5861\ 'N",&*3^F&U@^J\%BJR4J2_6+(1$OA_UP/YS*@3%
MC:@/HQI@O(LQ+=HCG3XTM+EN<88Q+>?_K:M]#_'K$?!=:_IH)*S<7,=4]XE#
MQ.>.0.Q('ES>!Z_%*Y_@J!I>&UC"-F%%5V6"1'F0MWN'"A'$A6\5GF9A^7<^
METJB[QDCER0DL,,;P5.[!YB'\.R=H"2146_A 2&UR#EN!;&"FYA^,?E:XXVX
M\P^QGF-H)JLE$#8YCA)!J>YUH\KNX!_K'/[OGD1.]1O0QCNU96$>5"E+O':)
M/9M;VAPST;,TC8FW$%;?42#?BKP9 \_ *O1S?#A72&UX;%$5F!@L#<A=#Q@L
ML?V6G4%C:JAN<S3IA76Q9]-SFS,YRCB./%>DZO*K4)*4CMD5P0CB=PNEG9BR
MO DO-/(%]\YZ6%#(JL)8."/"70\9BU$HT$)0980X<$RD\'M+Y1]<QU-)6. B
M<6E">&_UY5XD1$.VG\.U")G#H42%"X,<6X+[;UZO*LMK'+EF%G7^#_;>.ZS)
MKML;O%4411$+(+WW(ETZV.@2I'>B B(@O1,@BH*"%.E(E4X($*D! D1ZD]Z$
MD- [H?>2?#SOF?-]<^9[YYJYSC/7G'?F\Y^L9&??._?^[;W6_JV]5NX-Q#?B
M:*)MKS<#S<@;/UM[&(-'S?#*I%*+)  %J*3_K7BE36DELM)F.HG&,NQ'3\"K
MT.SM"^?D5($(J)8. W\-S.4EKA".2\MUILQ!@(93WOCX8X<7P3S?63[<48;3
MDKP(#+TX%7&UC?W#0_(?YTM;_J\'PD_LZ45<O[9&\;X"!/0O!C;SD,Q* 9[G
MH^J>S&__J388=W7=FD1-].D7_L!'K'-DC._YL@-!JJ0_OE]U$B>7U/ZJZ67K
MX,+3RF3$%M4J$B8&DWMAF=;X3H(]_.7SJ'>A67^QWK_6%?D@P)*"W):O9Z:S
M3_Q["/W:YGS3#6&W,@&:.U>E29C>7 *-#-#3Q.-&Q ,IVXUF]9^:18.&GU-:
M18-(=32!_[7^M72IF2!%!-KO8PCUZ/W8V#XZQ<OHN8N3>WM"A/=4@"^6Y;_\
M#O__*&ZD>AE_:MK7L;O'AZ>4E;S:F""+M:2YT2GS@UM JE>WQ4D]!B&A3JV)
M&\4\G7QZXBD,UW_^ 2Y;7@1Q@FO S4_2?(C ]4@5(I FF7ZPSDQ01>B>B")W
M=$_FS\<R#;R?RCR?CCTO5IQV62(".ZT[A+,F(M!!"7UM0+"#^J&/;A$&LT[+
M3K+."TE/[\LS$[QQT,DJZ!%;Y%KG9+?61@(18&,>=X?&0]VA1RQ$(*CMO&HO
M?>_) 041X- ^^V9Z!#O;)@)S3TY D=N]ZY'GI<R;5;O0H]GS6PN8/O\F5+&,
M'RJA6 \^_0RU[2<8G_6?%WX@W&,ZKROGI+@QH7@:I;)O[;20=]!%!*(H\#**
M78HUBJ=?H8VSYU47PQ?/3CX1@6@>PJ^BTR'"$72;]2Q/Y<CFX+S;T12'9KZ*
MIUNU1 #M3 2VE9C'XM!)Z9-"A*>*Y><]%B"<OVP_^C^ E/4_,/KT!Z(_$/V!
MZ']IB"+E#B-G[87NC3VQMXIIW=)<$/FF;>C89D8>K>H6S_B0IE><")Q?)J[P
M'Q$1.)1L]@JXK2H>IVJC]@ [<1OMV^9"*:I\^XLR*E!TG9[AHO.UADP:RN5.
M#\;L[%EZ>?HOMI,:ZZF5UV:+=(1S$?>H>,V-<SB2*BO'X.M>MTZ?U)XH_8S'
M7J[2W7^5MRB(Z59X20*M@>UE3&5T,1DK."''<28!A1KT"K86UQ/6O-!IZ$Q>
M(M#8/!S0@%KK(P)OG)9[8\H4TCSQOXE ;N)^D4*.QKAIFD7/Y/X>$=BD-YU3
M&;4[40Q4&" "^WCT)O_D@EGR#.-4%?*V:=Y89V1YO**4(T'[#D Z#%XU+J24
MMO91<"H9Q_D&Y"/#T\5]7E0'3$*.[(^%/\TP+H[?)ZE<$FQ,+Z-2E';$V>Y<
M93\;UBJBN'S3:+MCQ[]^9'MP[T5)V4+<5'5 &^1H]9@M_51 TW"-OKZ;8C^8
MD'(D*[:\Z(B-/+:-M!M<T:O+J9Y?PQ,!)S 1N%!1_]3?$U%VR(X7(@*.&")P
ML8Y@W5'/BKO^Q86JQC\E_T3-<B=X8_XV"^"O3ZA(:G@2;QBS<,)8M)BW\L5[
M;$<E_GH"_@ =C\ZZ&L"*\\^<TG ,G. ]$='=B<<OI L'*F+UCOLVG\]'"J1+
M8O!.@HH&U_]@^@?3/YC^P?0/IG\P_8/I'TS_8/H'TS^8_L'T#Z9_,/V#Z1],
M_V#Z!],_F/[!] ^F?S#][YC:Y'I#S#XU4]MZ7>)GHGY8=^=A@;$B^<\]N=L=
M"*8*WN?)'V/,]8_A2T3@TFB6@<14'C5*UMUS.( +ZY;Z+Y$!_D_$A4:_9T0@
MRG.#\!NZ_$QB^84BCO4< NCR';D)KY-:(H"?/+O/W1&WO]@<]/=^[)86[^>+
M(AT;%HYBMP7$V65L'\P[.(W5AS/%4U P/)N_5AD=OENZDJ#7^VR@HJO([JK<
MB7=FQ/AMQQCE;%H2?CI@KNQ.@TNTL,P+@+^KJ2OM;OYD'6_E;#_87.'MGLCM
M?;=P"69/834->&72:531OQV#]5^.[G]*,,$W<?8^Y2D8TXKOQL9FPFV))^Q<
MVFN/](G .[HMETYM^$97,M9@V] WP&D!(G7OGL9$)%<QP;$+W.$7<5S;-/@O
MD.;PSY\><'?&YO0+$KK?1 347R(T+A"V*$X@1$ U:F$6C5T\US,BL.RB\ R!
M5.#XF[\&\SE0&3TV#/I&!&XRSY[1KL^G-Z<?*NIY6=R-T+8KMK["-O">PN/E
M_/S64E/H3*/$6M+\:/+,>E')V!>M\;SN/*&FL4FWPN+9S__EH/UG!<6+3>9S
MLU4Z>*+Q&M_6,1:Y)VOHN :E/CO:;_$V0MO@P25U11O@H^*-[8I(KVMX^>C]
MRKHS#%0P81:2FNJSZ/U?K@?_)\(Y_:[BG#GJKT,ZCG7)?8TH#CY#,9/'3R,E
M&0D;BB=>1$ C9-O:OWJ+]?]NLW/*48$L K\> C>BM0! FB,-H$RN1+Q0/Q;L
MM>Q7H X1KW;:<Y.HG692S5168M6_QO3FS>_@5PI++ 5G:R*L?G35006M<3>-
ME9>E9=<GQ\I,[I^!XPE[ O6[.3IH<>O70_KQ(?[P/+3CEUXGGD'WHPK[Q+6B
MX&4;YU"*9VG9:<X%HK]<?I*,(J4+M#VXR_4G]["[<D:/AJ/SR#&E!)27?+F?
M<)^#A2Q]U]'EW0*R[]ZZ+M) X;.(0XY;: 4U4H;1GK. VA@8*'K?OB@;OS*H
ML:GP:862;5@F#EP.X6\!]XM/SOAHA=9*2 8Y::;\XM#)F/UZ@_2Q*BG#]'L2
MT;FIB.Q;]IBFT0@NI@&^GGW[,B)PO^W+Y^^;@_NNPR;+!^"110ES&Y;_/6*/
MY)2? VVD=3Z)O^1*1,)LRY.\1E9S:KA\C>2>.@_$YB9KFFIXH0TBB,#3P8R!
M_<=M'K.-90H#+22ZV6)/%:S!*?SAO]M)WVDZ/\_3B>.^AHD#J9G6. K-NZ_Y
M4JWHPO5!]Q;FOGBM#40?C<%3&=^^^I>8=O\905IP*AF,(^>F'B7WI#.P$7";
MKU9M^ P!J-!3KVO-W&+@&VTQ6(,=0U^"_1Q$BHIFX("S&XZ.*1W<AHK5(X1W
M&_\5#,D_2QW\>'AN6-G.J<$/(C"0:#_P$UK[A( [?\_A4[5QX$,$,.AC,ZT8
M?GQO"!DPW"_$-KCQO:HJG"N( _Q ^I9J$>TT0;F=@Y?3K?^=/)RNQ.UCQI6A
M)$_;L;Q!_45T5 4OGUM8;DRHW3(\MV9Y&?EM>9+23X2J<#_!Q(J7P?!)QQ@9
M&VN";!:K'F"B_THL<FIN-#)AU#5LVD2SZF0TQ@%3?$:%OON[K4\[EEN9EQ=2
M&:H&SL6:G],R<*LO57S"R[PE@Z^F7T[&V#[VSGW_&O2[>.$AJL&'UJV7O\J]
M4+C"1B?'[-F\D,UE7M<=67L(O\4X!\%3LD4GB,_]1U^8?_:$97<G(J=XPWYE
M_,@,7= TC?CTH\G!Y35R\)>H1AM#\<.?-EQF!1>]]1^2DN9QE>9N22WR-F9]
M-'P]L#L(?=#-)_#@LO*=W#QN+-<I#N7#8>F-;CRV@&4A/I=+-0,\7N& OA6V
MI.&A>G;4 Z^WC5\17]NNU C_#BV'^^O>VBB*@>39%WG9:=@?,1RFR//%!E1\
M,JLQS\FTV_=]FP3!_%HJ<L??;&IZ<)R697,C4(HUJO-IH#%#'-GU=S3KKI*.
M;V^G'IE]Z. =3>-RM]6+KLV.FUN+1PXZ4(]8)*6Z!%U]F652)(52%ASGP^^.
M^EL<'R\IV><MI<GT%W.7E4:T&FEDBK;1B;9_9@0M_<1]<KY!X[OUM4B?=[3!
M(,Q.SPW4G8LQ<.Q5*1O4@/[D$LX(S^+5S?T^/&#+,:B^JE\S:DH$&J2AGW!W
M?L2WFD.-M#EN;?"$=SI\MIZS9H:F%&3,SG,$<[J,A34/Z4;0W\1SVU?4X3H4
M4C$[>U*;WG:.=YI'#4/K8L:[/$<M.J _902I%QMQ4C[BO]>H!QX&]<=+S;A^
M?Z=>:Q:L\XAOC,1F@[RQFJ^-*E =7C"'>%T\5V]GSNQQR.B>$]0JJ:3SW+.F
M5!O*S00O.P5!&YAH KN:D4GZIR[F.76HN#N9[7FBIHF3]H&7:"93;DH*DT34
M&=5LI]&EVFDV=*KO.\CG>'@,+,TW/@\3D> 94E<7\:S1=**75:A\C=TOFM:\
MI.,ON,;^M1Q=_RTS))HK-KAQXZ2DE9Z$1?^A\/>O]FF46Q[+!9UP$T@)2*V\
M? 2#=$2B=3,]A,OY9.Y'^YX,V ER[0V<< ;$(Y]0M.!N5O3MH:X)?KTNNYHX
MG,'NRG_-$E?U]C2BJ)'A??"E^9^,4F^?P9\7Y)X=*E4()IL5]X)@16<R*;]3
MQ-^,9D_5=71P,P[X=:[VYR$13ZJV'FZV?<R.6-ANY>6H @NRA5Y5#PJ+M]G&
M6+V8;TR8Q\Q?"I+:.5=LXQ9N,@\Z[6$DK\6&M8?7P/Z8_<1N";-!8X7TH&;7
MTUA+>T'3LM)5^_7=-9^1(/]I6P1"@E%)1QPW:56^G=QU.W.S18\&V7[EH@@9
MLU2'-?MPT0V=/% <%Z9T,5VT#C.^87I_->_7=GXOV:).D5XT:NX3?T4TKDNC
MOA?1ODO.KM5?:^,DIYG#*,5SP7K[#K4L\F56%)5KNZ% 'G_GHC.'88*.QP_7
M+_IG>1Z_YLJ7!IU4_)E.TE*EM%M:M=WE4RO]"F3W-#D+*N$[<J@FF86HZ9RJ
MLN%"@V/KU'>>H??&[\WQG^!4?F5/N?060226#9I=AS*T&^7@(%O!/31JSGN(
M;Z!I1Q>A"3+KM3!"F6K809[%CU.E)9_!H7DFXRIET 3.<J87O5B=B[.0K8\]
MRLZ_I2\M#L$[\W[D&+AZ50S-.TG6=U7OWA1GU<+HY5SEM^BYC8[&>/W>FKQF
M=NC M$($#/7%:#GL(4_H14D:G.^1L;U^Y5=NR'>E[R$M">1WXHP#F1XSRBI'
M-GNCLF:'<[C"OY>47$#4#6X.&744+K/#+.<)'G/@2Y9-+!*R#D<&O'OBW1N_
MD\2T&QFMD\!;5T)I8.!OJNR7GURDIYK3@YF22J$=\++%-IRYR[E8A#\SMF1U
M,$_EWC4AR[43!?U[Q=WB<?AA_Y.4R$9-MH$SQ  !1SM^UQ%(XOB:H>#]0A*&
M2<WR%$FYL4N%31Q*D8_)X54^G;QN1P3(*_>D7%><T\OUV6E-$V;4,#/U)V^=
M#@,VFF123Y8,CMV]/ZO"Q:-:UPC:38R+[A_DXEZ-L>?K.$O#5>ZJ)S5WPD=P
M*PXF)[:9>P8G/06B37KYFWW9Y779 UZ5QQM+&P=,DK.,;(+7#:M+D+UQ=WD?
M@E2-V=4N+L(PZ#?<'.\[N),.?@PSV@G#!,>]]C3AIWBWG\V#>O:@%$]-T_YL
M_':5MU8S>/,++GGZ5I638)1>Y<_K5$=E%34O-H$>WU 12H4R"IONK@*OBOWZ
MY.]-H\?E9WE"#\)-]G'C:[V^F^F?[]=J9$SB+.(FZZ>I]!ST'CG0DF7%O#..
M,(I6D]M%)#5K!S/5\;GOEYO6XW?JH#<_#4RO:MU^7*2>C%/CS-2(>E-/R(OS
MXWYO/:J?:-5RH[B^^=WYREEO-EJ16)DO7M/)2X!FS,QWR"S71\6 $U9D6Y$Z
M%/?$%A-?5US#5[ Y*DX]10XE&1DA"CAQ8NCNCH G+6IG#O4#0?7J0CLRD>%O
M+ADINMY_I-#4SDX$'BNFNLQK'<)/F4]<QI*$IA6WSKWWO$1OF:OK%<FJ-DKQ
MDM^>L.=;O^R]K,H2^8K_=S.23BS65%-IK(CN*$V!EM?@HU4,2'UYI7X6(Z?E
M-IU.-JG$<.PGJN$<:B2@?77FLRP/5*"XL7FCXWIUX(O*BZ%'*[>;9UYRTY6J
M"V)P7HX=XR<8Q\I1A]X,A, #.A>='.JYN+-AJ^)A?,7!LI?#/O,,BIG\4#Y!
M)ZF%*WKJR/9BT'8]^%MZIQ,VC/S[U[SHJDL"0S]VFF=BLNC">5;F-KJ+.U?!
M;;M,;#1O^?6M-24%*?6KW;%CRX<!>6);]QX.)JM5CHJWZXQV;X?HZ8>;\'ZM
MB5<Z\H*-BXHTW5)KG"V[;)()EY.PE38Y1D*D4+*21>E[0[.M_7EK&2%95/28
MIT79<2-?-!"C?>,Q:GT$YN5;O3"3G+TAS!.GIU_+@S2$P<)4JH,T[;1R=Z[3
M+>KSS\+5Q5]/7X885UA#[!U,;9[D/;FD+@J_+(VR6)9%F8\?<X3+\[4UC2_$
MN,&,C'\F1YNW;REW4\)HIUWI;2X;O65A"/[YRIXNIED;3B;!IZ%"+\$5&^/O
MB=9'Y+8.37\J4O> #88.&(+XMFS=<5BF-%2ZR.AO9A;*"R3;B>_8&=+V%BQ%
M[C0IB^:>\QO3?;1RI ;IIP@NG3",&O^R]0A65UY,?62](I%E!S\3*NO]])JX
MW:.OC]D?,D0W_W@NZLUP ^#_U=25=B=_?D/=H6K7$#6XT*MUF]E&:E#[P)(D
MM@9E;+^M7.'!T/"OP)O_4\(7T>13M##@YN X\M[:VKF)R7(M[)M*R65# F#?
MTL:KC$#?=_(P[3!?/D)_6YLR,Q=RE4M"':$$H9S;LBL[%,_^-:CU7T)DK\[T
MA/J"\RN?&&_#L?<EH #+=+\+?5;OHS3YEVRD3R2Z[0E!7=</)7@^[O]BI!_,
MEQ_^]+RI2M'BH[8]%2TO?]NK>;; ?V],2BLD??L^]J\#3<]X@^L$2$^:%?$;
M9VPJR>?^F5?ZV;DCG=-\)%H_<?CUO+;"]TVJ9B:>?H?H)=*$9]^ ]J6^L,;9
M:.CP#]KU)YZ(B%9E([M!YWZ]+R<Y6T)U 2J_7TRXB+_(@^=Q'K1-0]U.>P6W
M5$*1ASE.L?$?M)*DABYTJ*8?5'4TW&]]=CLR%N&2M.]\"'EIKEBA(X@V%O):
M-SC5HK_]N9Y7#TPNS5''=K91-[DI3]JF<#.A-=RIP%;TZ=&7EP)S_"K5J;2J
M-T2O_WCA[,.4B!"Z%F*DX"LQ%(_LMTOKED?Q,^4*W=CRB\L7/\/8[=J[CYQA
MVVN?S'OS-WY0B5:"P/JSR"APHM(^B3<NE5P2#69Q*Y,2U%<^K 4CU?*5)@<Z
M^RV*.S!#22,-T_X?;+OA_NO; :%X<)]C];F3PP#>:QPD LIM2D('!P1>(K L
MP$<$JE1.A<_=G:]^W$3@*^/BF5?"N;.KHFQYZ@N=!A_KWD =4BDV$X'=V$>;
MVRODT(=5FR=2H1[&L9=&K<9>LC XDJT] 4#"U>S.!:VM>B*W6SB]<4*+C(+S
M[N5$X!V(3!OQ*9YZ/RZ[7F=UVPE\R(&[LGEY,E@(K#.4':3#DVIH&:W@5+MF
M_)ROX,-HL5NKM%&ME8BPWAN8>06D&$N%@%LVOE@,3H8;MW"D%IZL8_'6KRA(
M[4I6+82'A%@6> 6_/2<"/I80HR:*U]>JO!IH%^!W-?L;!O($AX9/DW4]CRP:
MF_3T7>+L5&Q(G9Y.(78J.NM9#VT@A?:BYC^WDF6_/4%M-+6UW^$QSQ.XZE!7
M]N[W0G&$ F5^OIJ"-YS3@=D&@J\@ A?Y7W ;E*68S,6@O(:]#"I/,%OB!):5
MON["91/WMW1&CC/Q9LS5]:J-O <L8K=\+MFVTAA(R3B*V^O[<E_C7+1:)P):
MZ))BT4R/_ %36.YI\7#" F%]@;LU?6\?O-?C=':-/XO_T,ZW;=M&P79+=S=A
M(9PBB/HY]+6YA4FVCIW=>KX5@1D+"W'K,,+N5"=<_J$B>]DZL=-BA')A/,<*
M6[.ZH?@@ONNTV_6P;0SDK#:LF1.0!(%W2*),3R,.&L&8]=<)S5?$A9 =[^70
M7^_CYQ(/K![HTD;U,N W%F8"BJLM@U 51]D;17@'_&*_7Z\&.?YL^54APM$(
M;ENWCTXPW)8[^$FX_45GV$D"4BONB2QKHU2I[3PYJ)+_*A/'.!D37J60*W1G
M>2#O,9VT[A>GDR*3KI$>@D5>PL<FOC@[P[1^&$?"04S=9,YP[1DYE.%0PWS+
MO/VV?*WG^> 5A&<[:]S^%4'RU%&>TBK(@E2@>?IC<U]CFSZW]OJ J:<)?A*U
M>S[!)?R>U8U2:;XM/EC?G=RV*-3Z-"YCF^2Q7*%J/2*X4/7^6_5%U=*2[Y85
M'Y\]?!N.*G4-T"YOU??@TUUTU>.DZ3 M&ZZ'?W,8F11N&-!;'IK3]ICE5;%8
M?5JC8(C6.(U -;*;\XOC6*P,OR)B+EXE N[P*FDLTR.<^J9Y.V;(YM*GNVOW
M!)QA8^ DT#'2_LV)?3_C;R>G#0W* <>)$H-^_DG'8P\;BLU$*M3P^ZF0C%D"
MJ8=%A.7F>0=OH'F8/,VW1HD )50Z!=J$.*)C)N"@15ZS4*SA697S"S0N_:S>
M\A^QB]!_Q"[$)?K?G1NT3V=UYP:MO8F1L/6/O4#5D(;1;)^\OO0;1&#.N)X(
M%",5CS7(_2H5SQ;2#U_^5?<XC.*D0LOX7+-ORY7]]&WV92J[W(POI1:D#/.^
M8*63$=)^07^_C.GG78N1^S%%RL]#:^.2+.S!=?!L[RKU@O WG:#^8465O(G4
M9'DH^-#?!7X8*&]R[[,)ZA$')@2;6!E(]?CKDTP>4B\=-:9Z*@8KVY?8:]P]
ML;$0R"AV,LLI8WVDH;.8U?"+67A+5WW\F&F!!JS5SV+D)1H=W$E-L<\!%?[P
ME2.V6'>EX$OZX]]R@?QHP>QID#YGGJS!KN'HHJ?S:WV]%>44CSD0H7C<KS!"
M\B<1V&8L_>N@Z3/[OI9S3<P[-&[X2)!7W&)''+81 =;/T-4>Q3-&%S-IFTWK
M?SL3^RY*C" ._8G>A=&CZ147F/\*@YTXF54;GI[CB53<W\D3)P()X'TB0/AM
MOO7I-,0 O-=YWM;3T%YRPHGNJ;[B;M8SK9,X177HL1I\)E6PGG5I9-3$E%TU
MC(.L^_W._3%V[LR:!S);#7M72IJ&CH-L&TMM348MD%K=X@Z?\_96A%.IBU/7
MS@1&8YZAIB/).Z;#+RZ,3,<5<QC/?V6=R#<1+/@^!24+]%Y1)7E';F-1TVSX
M<2J=ST7]&(Q#02'B&8^F\T%W[+_!)!W3\-$G4=O=_M^V,AY2"2DL'8]^^$<8
M8.;?PP!0/:\ RG^$ <AOVSYNPM+0;!_N.L9U?+0?$\]"2+9@32W+J-,KM))!
MX$]E]8N&YGFW_E_A,)0;&YF#F6*_0/WO@-89+6N2L+0S7ZL1MZ0<)EN'P]-P
M5E(=LY+)38O,WSBN#+()91K^Q0L_*&[H+9)$9(WFW$J"44GA>M$Q/T W4U(X
M[8MQ=O/D*A85@_1=L66*.OD76)B^=0 V@])M4LO&>@@RK7A#IU)"5)',W0($
M/><Y07B6H#GB4/'LL]J-VMB7P6T(DD"%C[-H;7U0.=^I;'&DJYUVJM 7QU5+
M Z3PGSC%?Q>7[;O:W0]-9J8KGR9._.:F954ANR;-<?.R_.[3RLSB766*4RY?
ME=,#(M"N"]VJ\2OLPCQ!3YU_4IP6&U!<1!,>)Q.!\/[.IO\GB^V]VU2<]?-(
M;@?>T+WU:.7J]K%V9PL>=G#*?,3 V9ICDSEQ5O8DA=+MI.NUVN,H0H?5)4;?
MKYT!RRQX.N,ZVO9Y.J>DF+WP]".FA$S[^.,Y"RM%_F+)UH#MNZ=#.Q6?P)9?
M1>W:W+ERB^OM2\I4A_ZWL9Q6X(*VH\Y-[EO%W5RZW1_,&[?.+0=Z-X3)4?8,
M!]W?("3<G>L\<9MY?%ZYKW382;Q[TC+-WN$0.]>YM=[J@K*\,<M-NQP341&[
MW)A3EVW)[_ K!IG3S:KCOK$VSS,98#!,F'G/&:'%L:U6]*R;7O[5"4@GWNLN
M!B;-QFL5=G?EL3#)B$X.65+/[9B=4&B21+C:X$#*/-4\%YI+KZHF:>L7\N9V
MNV]MF'GD<&(T5*:JY9%K P>*T_J C9.;NYL+LXZ=G#'QMSC6<'E]<+?B!W#U
M62G-.QVR][0.B3H7+C'<$GD.>Z0QSJ.D<52MOS=I:H;4<53H[C1#=_W"YXY;
M--C")VVW$AT<N0,E.4J5!#X7J@+1!3_O/ 2B90">.![-'=#M&%-)RO&C\MLP
MJ?M&ZMI:[MD#)S&\3>+QZYQ!29*Z<=:<1LS/E:\JJE?&QF7'F*?E=TO>\ZY,
M6BFW/BER>EZOQ;>R,N-]>,21I&(AS<POPL"48N"2 Z)(NA4&]J!,GPJW-L@>
M%5CD0DD_J%_H69U6.JM,+>@2G"LQ;75@?**^2A<O^O-QX-Q%59)9Z9_<)0A)
MD8\%.J%Y][A[4J,=,/$F2[[2[K.@PI2YS&HZE"W_CHKFL_2[WH$KC":;RZ.N
M.;4Q911E/3.2/0HOYRM'>A'214O:'W*TQ@<C14,M=O5'<<5A_"-)<-TQS?QJ
MR?6.L;.>-KK[G,9^FVN<Y+5J51N3J1BDC2=^8KW'K<?-?-]@OK2BR-[6H<@1
MIW(9>Z[>$-SQ9-W)4;R0AVR=*JPVS3[P&YEUU!P?Q7/)F+ I&T:[ER!*(O")
MIO5D.QO--J_CH1C"JXYQ>X _""NOKQJ<["Z/U_!JE7RZ%A[Y#$;*-#1_M=O$
M1<<\23. +6Q>$W?'Q7_0EG"Y!&&G(3FNA&U/MM42ZXT):'S$C_;$9[]37Z0%
M9MG*]L7Q'1TW37$3!:,;]B;S)W8)BXOI$D4!-A#/NHV7?8<?="NQ<UBLRD)U
MU+X6WX;GS_N_7U:W ]32W)>X0QGI=)#B+&N%",HUE*"XQ1/]@M;3LB04JCP)
MY6^!.HJ!-NH60GO/%@DDW42@9>C,(O+T).^<[ZN<AAZW.!T=*9[>!"]H?]"O
MK8@K9DU[DQL;O<U17#R7$MU#(W9'C2/:%:0ED95WC?.:\GU^JP%;7\&H:)@4
MDJ=37<LS6?.X;DQT]3A:W9%Z?>Y95WD[=ZRTV:*M ^9SKQ0W[4+>[T&D$(>T
M%Y*OXF1\A!^CI_4-Y(<!?\-A$2[QX]UGR1V<==W-0M)8?A7QSP,/U";FC>Y)
MOY9^FU(BWRVMD\<1FT&=E0GBS:XM+A][RS,,NS+!S8$K@HEC=LI&O:HMQ@D+
M/>!RTRX.,0;"MJ05-'G#K_.)VV0:9+CS=O1<K&[DZQBP6U]BSW._OAB=]60M
ML$1^5S(,824VT;ZC?CBQ+2:; F0)-,>\ VCE -)'()'G9C_4.$O5N]8?QZ9,
MBF,<UC&HDS&+_!CE4<.ZTI B?#%W\#V.<I?.I3"CRYQQ1KR<#TG9OP)R9)UZ
MTP]RI%HZWD[HVHTOC9_;@ :I1AUM2 Y7S'+I:P\[*_LG"#N#_L^LJ.H(%F%V
MM3F]2WT\+T3PH0W]>=S=/(_JUWG1]:V=%:K%1CVVGCJV_J.B(;U<2!'.0!]!
M*^/OGJ%/I0V5^3K]]=^3,#O;F>B8E:KEU?@BJFRK*G@JD_[:28NQ $^LW.>L
MC3<-N8@GYR\/H[QSKG1?+W#,2G5P5\/"V#5-4O0,]M4X XZI>#NS:N?F]E$.
M*,\A_W6X#PQ_\G;'[,AG;%%UVP$;CO$J:746"[.Y)'^91S=(]D2J57(RCA/B
M]6-1QT,0S\EKZO@:BQB?S1W><&0Q52OFCL9># K)\0Q_',:C)Z!WF>$^Z:7W
MC_.N=J6)A,;4C8=J3OH[^/N&#Z5D9O"JM9AT=)075294IE* ^]@V]_8"Z66/
MW&4G6-(=!IMIAUY&<'SE9V<HC7N+ *;F[1L+MV[E'RWS]8TF3( Z\*4U]C8>
MB!E(K &3^VA9_I(6R,F_%>^$*M/RL,F;LK6368^9%J2;:6W=.5'?WOGU*_ 1
M_[THDM?*'A,%MX'Q[.CF"Q-183S#+09!ZK%G*:P.@IV%J6LQ9</KW7DF\=1A
MRX,P/+?L*@1585]9'!???K1?__WHW?>KW)\[ 9JI X08[:=X+I'P!S&@8ZP[
M\FFO!NGG"#J=V$%;N*WCP4K_Y%*2NXQ%N]%ZK;>!S;C1]U#WX#>??L%W@EQ0
MM,#FM6(RRA6=[&E95U@'OY=FRVEQ:N3C.G4/.UCCZ424XUF2#EA6PBVK*.SQ
MWTQV,9> S0[5-SB7?.Y@I;E",F<MJG&[%RO%#!FHTK?EJ^^T-<T:(9@'6.2Y
M9=W3&&] [9F8EBWO[#(6V[LN[R@YV.5OJPT)<\,:WU<DP'K!=OP&<=+*M]20
MD[U*98^4P^R4=9-M[X_L07*YBA"I\B/CE'?-;HE*CU]; IA%N/-IIVYW9!9!
M7P^Q(>3E)4X?QU&\29D[>HDH3G__R$_#RX8M-PL(!]<$DU"84;_XO7[A2NEQ
M\]1 $3WW^.J>E\1Q.5=R%G\%;C+30-SCS,Y<A WB',&)[;JH#.A<;1(R.QD9
M7I51OT_M57^PO=8?3L8'CTX=+JJH/<FU[IZ1?RQ^CPUK,#%[HZ'4K6].^*=\
MO8Z,JWWJ#%].;WNL+(H(I"\Y_MA-GEOT.XM#=^W)4(Z\?,!V5J_?QC^TWH/-
MFI27KUXV+RCW3Z^$>.Z,3_JT+G7H[?,'$$PGUZ7[9^25/<0:'',O]TIY2C$&
MO/C)X,7J72Q4J!_M]O$>WQXT?'3.\\PBUN3CPE&]QF;9:3=>R$031!JEW,'.
M+'HWK3E0QAHD'^GDNYICK/_%7AD)'GT2771/74U>=XP(F(-\!UON(7TB>'34
M?,,S H/6C:CEMR+T*/Q&&40DN-=;>;LZ]Y%IZ#E/#7(07:>F2L\H.CY]X<UR
M &N\?60)KI4U=E/X*FVK\R..L(A/4HKA#B"4Z[Z'H4 --#Y70GA%9#\V=?;,
M/N-*SHS:FI#%F#8C)?#]"LXX2K4#&^8H?W$N0F9'5_<VGP?#'4U^4P@V^^3
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M,GW@2+DYEY8]-!5MY&U:X'",C0MWF.$.".><*_Q"X#6H'G27$,A(PPZZ?2T
MHO2]1*;X(K(W2272F+&PS[8.'&O(,:0U-FE&?L7; R=HOH14,]]7MCEEC20"
MBL>&!%(EDS-;:&_!Y*%@XID^$>@=5SP4H:6K#!Y_G$7_12-U+LS4C*/%62S^
M^L&C-4@2+A5L[YXAA3F:F3TP:\P1LK;IO08^XLAQ,GUKNY1&8YJH6+ZGIM"2
MF]&Z+<8QQV2)!!5.W +3&\;L.+P0@8/C+5I#%PN.W2-3TK4T)^/Z*_@8^O>'
MTSDY1PMK,VN.UVK7.@EL6U>'3^&F1BW%Z6_(,#]O^J99?24"E(CA2*F.!HXR
MB;ZL-81TO5W,B,[9/:L::!,G%1QB^OAZ?(IX&-006X_>Q&.&_/0+<^KJ4UFC
M6_F]M;79[SP<8*$Q= 4MMG=,?>3FN.^3'\P4*5X U^S4K,1SI.O5"/7^&O .
M[13)WKA,DQU=:VI.OT($A-A?-ZX[W?;V)0@^^M6=>R1FVL4JR$;+&#>+ ZG_
M, /4&N1O#E]*<S'R4^)6,]9;",LL!W6(X['@8Y3DQU0_>7U][.!\K-6>'3X7
M<;[>F++3_Y2QLS/Y=5$[\86@"_?)C_!9A>]5#U6<-=TMN9;[$^YO'Q@6EI\6
MO_P0"#/A/16I3<_V.%US&Z_//*Z8&RVU<=\6F]HG.87OZC=&ON O2*'B44X:
MYQ7:@4K"NG0<"^>U-[@F3RFB^U84Z$6T;IF\[P\K4'EUXXX5L_;90XF6_S&C
MV<LNY;(Q[Q\0HGL4MB6"?=BU:J)E$ &7;DD?&_J9SR1C<XX8[AC$:%A-+AC
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MR\6'WPJ4"AVM"\$B)2]30!NY5S*_.W3M]PD-"K4(P8+ [4F_^WE5;]W# A&
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MX4T#2\B^8Z-8C?G&XO<CVGS?G\G)B4@"#5]V?BFV;[YD'3<"=KGHX<5^GO.
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MDB98CT&4GGU-2)T,ZA@0&'J,; ,4A+7'#:5\)9;X.EQ3_,<Z?84\TFS]&\Q
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ME\>OW_@1"A4+0_+YT5CGC30]M;)J,J=8SBNUI$FI2%+K=["4V!EIKL?Y9SV
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MTIKX"B 23D??H9!@OK/"\S'>Z4$>HVC9X" F:&&7J]X/8D<U499>T80<'MO
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MNL"IOJZM[S61OC8A9->/>'\^=W\=M>(2SUD>KMHN7@.-Q9\"R(JE=(O[\79
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M$U"!D\U36]L-+/MM6NQU_D0K_HE1GV:G52,9?U2V\ (N>9FP[OPCP:@<*O5
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M0IT'R6G%1-2/W5CEA?&9(3ZZ5/4<T-5N&AF2VKF8XYF +4$5,;$BX"U1[N:
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MGM?AL8&(03Q7PV=JQ,+-A]I2;4JN2"J$T7>'ICDO-Q_'FG;^F1=\M<68AWR
MI[1I_$L?Y$6IB:FZKWXOGT=?,[0?3H5L.CI<)_A)R25G5))P5>YAA2G_TV>!
M@:8"@HX )7,[9&)<_H+LS:?:4Z#H1MW;\S6'S _GZ"QV9;YW_EK]M.TK7?_:
M,IAD@$:6>I6ZK1 A3W0/DD6(?*[Y\];F8(A&*;=@4)]'$+_BU2F5:TYYSS_
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MA8Y\-[.>5NZ''N\2P,N3P-:\$;M^(Y"Y\H\9<2FF;ZWT]5M!E((#3L7WK9$
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M]("\@)J]!SHRSL9Y4;H)DY" ]6H'[39"^J,^9* _ *PGFF@$9IX\:3H"/QN
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M[I?;K?90[;SE)Z?R9<;U^L8IFWMU7>O:ZA%-J4?U]IXG);;[%:X79#.:&#S
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M-0>MU4/9GOGE3L]XQ,UH]UOZ8K#X7$9;1I^RQ.BR>M^M5_G:" TLT.5@8N]
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M>&Z)@B(?-O:H?MWF9+-@H(-#V]"2UPK)J^S(*P/TU[T.\].G]?'Y:,U)FPA
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M#G#RBR1+XS"9[.&OJJI2&:RJZ6.]/@I_;DE;4O*UK*%D^W.)]--_,<:+Y&N
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MLZ.Z%4ROAUM#BW<GFY<U5&^J^G V:Z@O"S[9UT<U=P 0:NMPN<].U2F97I%
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M,,?7&]ABTT7(\G'@09EWB6(P \AM%&BT5IKT%7E1YC(<Z;U;7SBBTJL+.O>
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M@RJFQL^#8G!3IUB91UN4%96,VF<:#?1PCCR=--EC;7DU49E#&G?O P /L/@
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MQL\7+(1#E/5QZU]JHML%"$8WT.3N2A@-9<8VD#-: 5BKQ)6'\]*LKEF0C^>
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M-P/R-H'^F,PJ6 P)'M"P<C6NO[-YE!)\ ]!VG+U &TVI*IGZE=SMG(G&OH@
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M8&<G4D5^P>+^]<2GS_3IB$/UD\YL:[&.S2A5FQC?B8'RGY9:G\D:'O#3*>(
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MNQ] IRV]C8DHI@)P0-&I]ZC:SOB@S,<F-K;Y=T7*VOA=M=L_Z+T T]>+S],
M.<TIP2,-\71TXW46]8-HCIA*0L?P>2&WSPO RV<WNM(T=S"F *B0> O6G47V
MN=#8",])H JQ'1;1%'U;2EWH8^B:#I$;(.P$O?$X%=E_3;RC ?%J X_PR$AN
M^4M(RV0Y; 8E4,.!7Q'1^7.W"TM=>REQL>P,<;-Y6EB_XXYVS/ <1YJ>[=)L
M_A;TH'SP(,3/2I8+O\ZA\I9PJ%I9 +:Y,\L#M^?FBS')SI,T;AJ#;QF@BA#Z
M[A>-5E=/*FTDEA3V8@":)'!>?2I,J==>[# C64-Y?A;MW,5-V.WD:T]?_+<\
M_,-KB+  N_5IXS5>,0GX_L70/DU2/M[<W&#@5V;BL7 H*R3(%C!?>A1YD TQ
M.>U;:+A[3U'G(3A*:^4W[9%+YOH"E(FU3\&5$WP7Z<#P^\V_L_-$EGWQV'&"
M[>;QV>+KTPKW63;*,^DICRYY*'OH3OK11WV/KLTW=[)?A^K6W 8"?TG9'00%
M1 "_3RVZB;PI/-D25./7 5*?C)Z/R(Y1?3A<R804?)W*G'U&F#K_<I7X/Z'4
MQ_9ZT<.VMG8T:@,&WO!,&N7B!N\0$5WAPJTZ>"-#9JG(#-9ALV:U;(Z3 JU$
MV1A]72OHQR+,?M=[]8SL*4/NCP7AL681C_/\V&A@E\65HFQTS->W",]O#!0N
MU!Y4%L26=.Y\55*VCA,';MIF_XYP7/E76? _ P\4X;1G_ MN'EVA\X\9MC#B
MPOL5GAW"L?OJC(UE?ZY'Q=,",A-5H?9T-[8DUQWG.@4=@N.#!KE4LHZPD"Z1
M56QY8+3JEI\\JVAA/]*/I691(4%IN_=7X3>?><SM($)JU/[$'1:=30;@N@0X
M'\/W9JD[P]NYSLP[MVHL/!G /L:0Z'3*V3"Z7:UI6A(*=)*#=U=?,Z@,M?>K
M9SNFF;+7IJ6)<RV)YTM9T)6QZ(-+'5WNIL2"\],\!5UGA94_REYGL1_^Y-ST
M$&[T\.K8*DSCVW%[O!#H\P0N=8'1&9<7X,@&-1U]V7!A-1G]%E8[$I7@NE1Q
MU%H;U2T E=4%MA]!JR_ [;NO-%47S[/;RI,GYX]E=M$TBXW#"0+G%YG=%9Q0
M.22_P,=_;&/E X/M+/A.7J]CK- /S8>Z'6P/M)Z8_+P<\U9%2@$_8IIMR&$+
MQX^/(-,Q3I(D""SED1.1 $D"E/Z:H8+ 6O:MX'7J1H+NU'&]@!&T7Y\+C+FZ
M=/'A'3G<:ZRX3NHB8$_$['1YL5?%WAEQI!#VJ:2/-"[;Z W&ID%K;! )MFII
MQ1($DQ#8XL4,/"G^VM0\;4?_2^M5(42<!U??5AH\3 0(B@QV[I#(JL'-W!ZL
M;?KRXI^3!%DY6[_&+O/J1F*2F]]^2V@VB'5') B# MSUXB%.^VEHQ&CW0:V+
M2T^Y1USO3<T'!_F^<F^B#<J)?>DD[!/,1A][XT[_X/<N5/)!-F&3!6'TO/'X
M',?^OH/3L;5R1=C36>+53:#O_%K.6DS=UT5<SJ?<P;'[5),$,>T?8M?#)L,;
M@@/0U_"2JR0RIX^^).W.SJ24ZV:&K-TI;I^P[&*9V<X%65[W4P9* PXKI_GY
M<?BCML;[2J(86HM?4'(%[YR%WV-^?B_JT0NX+KP _JSU2N@BHJ8OP)= ?!FM
M^>VLQ&I!D@W:C&IS6YC\NC^;XAHF=W?6:=3=;6]+U\Z='XSR^+QM]/:AW6)#
M N_2$+ZWP!)S;2@\JL>I;'#B^_G8B3QE\ H="O;K(2PY(L)U?\XVG-,90R18
M>O 43;-_;G8C)^&X/>6Q>/LW%K[H=V@7MX!G_K_>]_^_ KB^?3%@O-ZFN_CS
M0MD-FT9M6P+6HH3FL*]%LH0J$HH)@*8*^ER"]4H53P, " $, '!!J,I^]1]U
M:J=-<DV)NQ>5>+_J*5M"I^]AP&3!$*YC6LA"6%9_@]0D#=BU_'?0T__,@(E_
M&^#C@5%)BG_#CW_V%*5?QM5FU)C)M!DL0 .&=\R &\,KTPK-_*P&CE<J%Q+^
M9D%Q#9-Z]COI.*53.2NM.71V'KK+OZEZL,MY <1O5FYQZ&__F,T);CU./,SY
M-*J^ %D/)X_("8^6-8>DY\]6/H=BBT5^8T\WSX@#SSR?7#$\_'C:KRELI\1W
MGA]> /B_2Y*8I14DTI%FZ(79L$]Q\0+\=3,!7'Y1^ 9!$,,1]E^AB]\P[UZ
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M(B)IQ\.=;YLP2B]<U2H^BRQT#+N1$3LQM+-L:*1?8+<XO.I8^]4M<_:J/;-
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MK#@*X2 *=T5!C >NK<" UC, @1AJZ&WIEU@L?VH4=_,Y[YC9!_@M-00$CWT
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M@/$?Y_F>ABGS=,*6 BF  .XPS?V/3,SXUY6B_[#(7VO=!I:,,+9%H5.'*98
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M(]6^ "LO.Z#;'4D,ZIH!N%(SF8XDE=+J2(%)-JU KX!^F$7(TR)6?T/NG&3
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M0R(OZ(%0]C7PP12)ODM+B1 ;TZ>RGYRM*'S+K$X60TX<D 9VA+C=)'AP)YT
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M,[5[K5,,W0_&OIY0MNU:ZAV#@B/I+!=8M@P*1XY2H]3@H.K_WP0 4$L#!!0
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M=$ZNI\Y1/L='N+6B. 'A  ^#VFNO*DF^%/74!\5 B@U;U$;>S],EWQ$\7__
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M$(<GP6,8T&^/!0O2 EN]KY$EP3U4KV[(=#MXY'HM46HPN2B]99TE7FE*R3-
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M)Z6,)TN(Q(\"]VGA\Y.A:TBYR8.%7^-Z%TQ%OX;L9^]NW%S/:.;JPP\P,3<
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M^G<GA@VD\P@^+U"=6V\LL7<\S7@TJD!]"!H/I?JSP?+_=P]ZEGN7JV_S%U@
M*ME\A&N"C^F5HS%A8GU?1YSIG&]-3F*GH4)<H(ABM!FN\M^%PGK]OV[ICD"3
M>!/&%#^F.IB]Q<DH.(9^:;9@#38609JL-'J<=IP+C=N7\NK2&<ZWWK4B(Q-B
M+&,B.SY*"K@MZB01.O"Y<=9S]$C.4;"]KUJ<[,P@NC&@;[O@D#\$(;S:#B9
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M UTOTIQZ#K7X"]5>V?Q6'7P\-.5H+P/:K95.?5#6,=+91FO#7&>\.WVQ9T\
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M+JE5:Z<X4*:\;2AO@5+_V1(AQ%MO.-CUGKW8_@,O(ZTJ^<["SS,! 3VJ@E+
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MY;(UY+V1?<I.=[!)=K>I&Q$=1"SC+J$=-49.\@8DF*Y]?J._MN3VUB?66?5
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MCI4+)1M#3"8D>U(_:*CX)#% /*P4='A( !A%[T$O_!H(@.9FG U@+*,<6D8
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M_Y?)(,YO#,AN[T<) 27KZ+)?K&_8G]3K@_Q,7+AHM_P#?)TI(=,9GG$=WM!
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M8JGQ9UM/'@)@/[K>Y?!"&P8=:[J.O8>]1P"80'>(A0<Q)>P_Q1$[3VSW7(@
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MF!?OEQ^^Z?#7-#\723\/?HPBW\(R0.IL\#@21_$3/1'BMH;(KR C B>%_(G
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M<]9L$#PQ,K'^#7X>/_._CY_9<5QS2J,;GN@XKSB4%A:WE1S.1P1 CIL(4\(
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M-?M#GX93FI+,C8N,<I0OAN]K\C7(2WKWD]27#B_C-AXJ<ZFX:XTR.Y/O\J)
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M365PK*2IG69C1#LO#YNZ[T:+;*6TET<"),6K:PR\=38>CB.?@VSKB'L*F(S
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MULL;JM3KW6<YGA_65QV'?"Q&;82B0CFO5&!BHN1>9$^*MK+,Q888:-?<]#U
M_D3XH3W$J4L3)84(23S\H<(+W53OS=9]M[CX@[B,CAU=\;W6HTN<+J@,38F9
MEW+6[TDZ !_8-,92ID"#J-V7-<K+/DS[=:T-W(Y0:,PZV]!%JR]?N$;3-;NL
MKG(3<HK0#LZS"ZXZC#<LP6CFIWTN-O2,Z:GES$TT?\IXXT)=?3(;R=M]X66I
M"'CVX)2]F_3 S(5O,-P!Z=P!*#U=5?R:@)UK 9!5[_EN#)"DFN2=J'0SC<:1
M0TF[1V\R=+.)8=/P3O$[ZNRVAD\$R.:Q-MT#X+-RU%X]/K-*7;.7J>"46',-
M-"S :?&8:K&1B40M_<.1XPY[T]:7M*YZ1)EJX#3P)S!VC<-@!?1&:/KLMGZ
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M;UUN)%:QLJF9F_]TZ"1X^-U\/KM'?Q"LCFD8UMG/2 ! !,$,P5KY>Z^JHHB
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MT>;PSL.'M'F=U [Z;/+XAJ#X+4NF0]G*FF:VW0?N, M2[\;)TY1UFDW?DOA
M>PWER[-N,V:,7?[R03876BG:7J>XB!6?S])B@*2^C%>Z1>@,\&@GJR<&Z]R?
M<L/\B:PL.$<74Q"(6D9P1%@68/)Y AN,5NS<A(Q7^BG( #:?B:>;&;*_/L/?
M6?\?5]+]QW1!C +J_V=!9H18G#!!(&D?_)_GJ"B?EV6K#-\)*[7F:U4>JJ->
M2X/S72(G_:'.1FBZ^T:'WT.@[=,0Y!"39,I-:S*6X".U>H%]E/2?&1(*\LSO
M,3%]K<RA%<BV^89*N;<-R5HO.6>JDE=I49H38_*<@)]^=#/Q"FQ^,Q&Z@J(_
M$[K^5B=!Q<R-;WQN"V1I,"]&[^9S#=^T;NTQ>T[.O,O]NRVL< \ '92C\8ZP
MD/< &H@FFOFK+"7&66TF'18Q/.-)Y*9,6M_"4R/:NG&LIY/LWI" G>F%O2?)
MLRTC=ED[ZYD0#!5'T^W.+3G'03B%O>:70(-V?+#Z'FE4=TUO*'TSSTST=O4]
MP+XZ&DJ.ZOS:[HS0>@(.6._VG4GL@D1Q7!ORQO8KI#^G3&5,?==$@_,WO\L_
M5 ERBY9"[L2P8IJH85KA2Y3AE0AQ4-]:GF=YFW_FDN"O+DM#+>7W#Z&&IDOD
M0Q=S?4FDB)]SI"]>M+"4*?U -METR0PAU5;VG*?J*3Y]C)6K%D)"'^>9+Q7V
M[C /,H[D,A<S60WA<V9>PHC!W,!^6L!KCV(U/;59A@BP]E#J)Y-'QMXL20/8
M)9CT:R,'2=E05)T^*B#4^1=G[-267-T)]O<Y#P$5!MOAKL#*Q-!$-T _UV]F
M;1USN7UF,J@(QAV^T3IS0UHPCAB)4QQ\VY #"LNJ(B<?Z[>1\XG>$-QX^1G<
MW8LQOGX'AO6:DUXX S A S!ONOV]J=4%,TR =]IDT:<5UI17:^V)"CBD\6X$
M6.>KE.C N$Z[G'@H%EHO!1ZG",LF;D7CEB74V5WYFIB\4Q#7]1H/&Q<?NB-?
MSKPPCV:F@+[$^!E,GZ_BP:#,M6&.>HB_)FC*]=3/TT>Z:*4H"I26F_NX? O[
M5[]5RM/YB$ '$+!7KFXG[L8BT^P'7M2-@*0"&\^VNK7LCA)QL\M"MY,8<RNQ
MILOKD_\95W:['](-S;9K%6 "$/W+'^=X/9:SWIB_&.-I^Q9U_(4-D!3.ZF>=
M'IPR>%%IC^%'I ??.,#7XYEQ&JJ9,*DBM]Z?T#C<H"/RD?K:>)X8C;)G7?O6
MCC\)-SPW$TF:+^+<8+ E2/I2<9Y#\:+2WV-G=H,"\W*!KAM[1NP^(['H2J*U
MJ/*% ]%HK^_GU]^R7_N%#*M69W3:+\SWFS/=/0/S?/RSQMC6+$8M&CQ<L3E(
M$3YPS:TO,4B\</ )2K\[9_[D 1=95CU0FL:[<=1E24'YD!6]0!2CE0JA4+8"
MT0RZ(\*75^A@B6= SIX_UFB\FSE\ ASQIJFFK2-%.WIFH+2@W=*0[;-+?(2$
MPGKGN]-1J\LT3 =<CG%7EG%.FC*7OII<OKK(4,&;)8W*O>'M*17+D?AJ& ,0
M-P;KHH'RK+KG'K#$TSN%@0U :3%)A7NM9@5P#>G]NM$"6L* -[_:"*48DJLJ
MB)5]!BE[NZ^U(9]G91GW<T@KI,ES<QZ_87_F4SOLU,R.4T(&V$T(ZN).:0AB
M+05</XH^.PFZDYV!<MZPH_Y&71B +&9$:#9]6.OT#+Y55 5QV5A-JN@Z3/P7
MN_U0^>^[.1]9^.H\<!H[1;TV+D<.D@];;YY?V('17;-]CK=;3/29:?]9%Q;@
M))9L)*3+#4]'_1<8]F:B@8=(3'>N_DA.!^J2EI:N[SK U\U+@:-L8;(9W.\C
M<GK25W\/"!.X_HSAZ1^4SF+N4[O] 5GW?)MAH,8Y@8W]D'80:10<8?JN00YT
M[>OM$])8P,LO/N)*S;1F_OBI)1+W@&+I*UR\N7K]8=%[0/U GU9DVMT+-">L
M&G=WWNSIY.KTV&R1JZ=GC:*$?%4N8R%CL_@*KAJB$K-SV0EMO,V!2*#)>ZY
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MX>/E5OI;(>1"7D&)C/?-"%&CZ?$W] 7[SPQ7#13LWRV^"392LPI#LJ^)>%@
MF,%9*W1;TE9(1FQD25].V"08O[%.-*PL3D5GEN\HZT5=@[80^6"WB\&&XP6
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M1/-6<;1S7JIE/-JHD^"5AP71L]J>Z[G2)?^AE-^LZ=H[D"?3,1-#S2/T&JK
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MQF*S]]1VX4.FV&'Y_^XHPL<:'D/HR^%#+#.$E8F@1/HRR?8)*V0/2KCV^DC
M(J2YZDIY$O?EL15*=S3LW65[*^<V#?,%,F"JG1XBP461$?GHG?^K[M?L[SJ!
M:<]=1G^73>I6NY]>ZTJS(%4*)@LN<5_B<"-F/B"YA7,ORKJ*DN/K=)"AH"+:
MS2J/Z51TS#D]>D\HS.I(5YSH_JZL4N+X)A+#;@\:8==\!1][5_<T_/*6VPOM
M=E$))P[5;FE>#P_/;C5)S^2<HWI86U9DLIV -Q>R;LQ/6.7>TUR9B4<B1(8
MLK^41 ;MY?D5N4"I/]*1=7%C54+%EB&#09N!3< +M,L^\ N5TB"8*P2$XG=!
M%V!J3J.7EN35(;<,N3SY<WFW2W_P%Z,!  '$O.OBP4B=A@I7O=DC,V4E\HL_
M!2KY%[E(#B).Z$#C;3G2%+I\[/K2<ERHS@,=P[S0R>F%4RP-I*OK>2UD=O9Z
MSZI[:R)(:#UMB<BT0-8[7S/_$N.A8 WUND][:,DU+?QH !<FTE48_-?-Q 7^
MCR$C&3TF>X^5R!:>!&GX'0\>+3 L9PJ64+0ZO-]MF7!CG<CT_FCUS*RHZDNM
M!1,\S\]Q^%41LF@?W>QWIKG]]\@Q\@#'O#=_0/?U!=(]F,PKXR?61XB9:CLX
M,19I]ZU,1R;:S\(WY@0/^%@C'*=A4^HR.J<U %ML5G1$1S=%'PNQK9'>4^%?
MDI/++!.@$"NGR2%[U/B$KVM"5[6)P(V_@TS.&>9*;^#'!G_;B<&]/^%G)\ 3
MLW6"4-&OQP_2'(&1F\&*@3V%!%DK0MXE6#,J^/7'7#Q@+*;T4I#F:/EB>8-V
MLX9FK0=+\(J:B;\NDG[#\IWDW)IN";D4=R@,XRPZ4F^"%Q-!07A +1<+(+>Y
M9'(K<T=Q[?3$Z@C8BRA1@]PI;6<4"H%B67$G.U812K)XP*>\9QFZ+>^6=_Z*
MB?)\MYYYX>7=)X"K5-ZEBQK\!F.F59LU-$CXPW.N5'9F=43C36$U-^Z1UD5W
M7O;V7\<"))B1_[K['\P 71D9/U.+B<!)*()50\516SB5SW@ [!LP Q03CA/I
MR]Z4OP"BCY7>7G@B\( +T+GXPG4&$NH493>_%2CO,5\#Y7^]5?A$J6Y_.@<Y
MEB ME(6&[R;0T%CM#@VDI>_.SY\Z5H+_:. !$SQX  _X"M*HE(,'Z */K7 S
MI^!:\,XR3AL/F,L>.#HD)/8H>V?,&>AXQ9[B@<9996PYOO/4:/%/>R"^B7 ;
MCVL:D6'S#5+JT*1OFSQT\75IV0\*"%HVB<EJ>H=T6<X-3?/>U$U8/A:GN3S]
M@@<\3VTK_X\#8[8'\A?+Z-UK;9%;(5Z$%((T&L: ->VC:".'D[#)C8-%SG:_
MT.]HA)\2:B?[HKCL([K&5Q89EMFPX[8]EBH]TR&!$7%KG=H+;3*-0<!C_9<D
M:^1>^_4YN' *J.?,F;+;D1J)U$O.MY+^2N!."420:<J8_$V3]W=Q%4S!X0&#
M_>W"1HC]"4/;\RGD_ $V0>^"9L5\D6&H<E>TKJDIIC><Y^;K;@NN0$9=?H9<
M$DKB)Y0SMPT;'HC5.CJ_\J]I<7%!NO<8P(F?OVHS+;,PY6EK<#\RE@'.<>)4
MF<%79"IX0 &]T>0''#,>P(S-]7K#WI5P08]+X5QJ)\"N-\<&#W '7IIZ6EJ*
M7(S_H_JGR4$SP!5EW!(!J=]W*7-^&P/"GSQ;OQ,4KBCPZ1 HY>:9ZT*SP9K;
MCZI/G%$6G5,+DXH_0PLLA\/G$C83HL(VU-QK1/J@^6>HGOE_:OJ+'3]7CF^_
MR1/5';R9W$A8PIG=GI%]?38<N&<T)&!VL)3OU7U>#0_F'&@7#L#-=UR^:_;1
MANNU1R#BZ,LU.'C'@>=/23!V9<!G=2;Q^T)DQIKN*S$MH7/;<(,O]!;Z'\,O
MULO3["_AXX-'L ]LC!F&TZ2E_2J5Z>5=S:3I+^Q?L.63.M$4CD);B4Y1*??Y
MCGW3UNO<3Q4RJ:3YL\?W>TZ<^\(*" ![_$8.60[L2+WU9_=DF&8[O.@&W)_G
M^K!/Y$3D";@U&G>XN8QA6SW2YT[HD'K9RLBTD;$K7*A[??,I3/P!'A J(@#>
MX3U[XCS!24@G>.<EBGV.[^D4DIDE@X[DBGRS9R,),UWT <<"[[KD'!@$1K$?
MX<K1(^'>M4NTM51X@&#V*A'Z9-T&6KA/8RTPU%5FG)8%YPKZ)ATD>MR,-1T(
M4%MA@^8W+[KHXP%O7[9&&FF:?YSWT\%X_MZRS8Z-E4."F/F":Z?Y#Z>Q:8A=
M[[%?W6QGH,&K=_ A'-N7P7--VDX(__O2YB0 X!?@=29 GF@&5 O_!/^-!]1G
M<XZ5$:H;;B$L%M3+_N8^45<(00<2'0EW@FF 3YEV<K FX"B6QH25$:S@A=H?
M\E(+"SS \>W@GG=Q3MU#9IN V50U_057W472K^M4T;_;]9]=1F=&*YQ)Q<,5
MVZ]]3I3TH?)IW )+6FG:$HO8VNG>LRQS-'CR=)Z^Y?,:14GN<R2)\\I761O:
MGYAY1@ZZYS._UM\'<,9]*N@?USCSPP:'\>0HD"#HN<9=S 5PK'@ $9RDU=^[
MP-ES&R0F/K,$211@B7S#D<R7=%S^9=V!Y8&#-='P2PLZ7KDJXV3_$\NP#^&5
MJY*:NHNI2[H#TW:EU_EXP"8MX2G!KYQ,K($;6_]LG#4P;P*/#_^!_+RN[!'[
M>U]PI%^[VES80(&I^F\M/M^3_#_ M#N\K.@4X<&].DU>&1G6E#)EZL.!P+Z@
MM_4MV_'\]WFBC#=K'UW[!L\ZE8Q<;/T&@6DD&9#9-L*GM,\4K+L#;.7LDWT<
M1B@#^)4=/U0P576JU%:,%L&P<F(5JB9.O$O7!F;@/^+[T"]LCQI1])^1=8PG
MDG\U[NF\[^,2[J76H&A^6JK!);PI^PN6#=,V*.,5HANWU-B[8-?X4KRK'[M4
M7:,[5 &DW0PU^*TDAIJJIZYPEX1G(Z.X!\S-U<+G[^<X  !T1F&.(6[KJ; W
MDL6OBJ[JLYJ%YG'MB,X4IK/=,)1D&&PU&@-^J<L2\J#IR.W;7+5%P?JK;YT#
M&PRF"CUWP^&M7V6H^VD6962[B7+CA8S3:C8\W=!35RZSYL^,?S??04=K%+CL
MN%C,M[07Y82-9/,VM\5OO6CR%O3K33(_>)?\?)XKUC'K.V\_V6TM< #HL5QZ
M@I!ZF73>R?ZUSL)-$#>_OK^6T<8H3'D )WJ1?F**NMD-%8P0$K2_J_) /?8.
MZ0X#=>6@QL(SZT:]7UL-%#I/"@O3VKC]+B]9&)HA62#2ZYD6[O&)W4JE&XRU
M?T+S=D6=Q?G=#>,ECPLX[/.]RLN)V2)-K#/=9JA5*9B=CB<^1K<C=UOGJOX>
M27]1E"V1?Y>:T">/!UBJ!1[Y_\D6.*J%N92I;>Q 'CK$;<6K1K]>9YAD19?%
M?K&4Y9_IE1R(+E$M;9,^+&I+;SYI:U<SOI?EK-V=6\LTMS.+,85_'P[QO(CQ
M=?$(D2U4MS%2<6FZ\W6]<>'G9S+^EMLUB-0%^@A*YG>L)-/UZ?#CRG3?*[1H
M]QJ+U<]"9%'KU.7I58,LC I[8T*RC*2]I5GK019)8H>M6/T4H>XJ=W,*4GL0
MIS#T4GV5*HF+Y4(P-)FK'KJWJ(%_=623&D1GYN?Y^E2 X4;NG>NNAY*PC\TG
MYFDDW88#3#4,PC;6MV0XO%2?M_\=;>2L(LLIMMU9/@BU)5"]=4NG\'9!BUNS
M!MC*6VEW')8[*633UB"?TQ3%'7O*S?5J('%F)3:^N]U6S]--Q&<.S+F+X.8J
M8$W7#AE(X;Y?Z3.@]2<C\N$W*&:'"?@.?$>Q\=*(3P8K!%.S9;$3&@LK8<$#
M8A6L;%9BB(,#5#V,;X&8-SQD7K F>UBT[XHT&<GK%_"/;20,H56-2KL_!18<
M6YCC&O9#M%>03'L]V9Q/?U6EKRQ:-&Y78;+MRW5M.Y&67J;O8?EEDL^3CE]7
M6?I5*UG&<D>6MBY+0%,.1OXZ8\3W*;."M>6&,_R+!&[-'<\%$"=^+31)?])I
M;R^\C^"4Z791UX+H0=] %PX<94XZ7LVG"X7N]FR=QV$?XVY/S&M"C!KMX]B#
M2IZ=Q")(JA![5D:JL/H$.>/)LB#VAV9I/Z$U;I<\H0U*GR\,C@I=V=9Z.I$^
M$#7)XHS>NS^MA5V/Z<..R77%DQHR_6 \M%$&^GD#;PI<EC%66.*9CM77+ (G
M C)+4S@'@N4ZQ@/BEX\E!@C@.P)OT\U_Q-T[<Z26OQ@9#5-QI5U=CE+B>C'W
M*Z"U-="SSYM3&'5GAC-"C^LA+3/I<PZ.][-41G*G/T=F9Y?]('/7EF7@UF\V
MNVN@VK%Y'IZVVNKJ(*$6MEX%=IZ/2FQ6<Q;\%>M]7./(AY\1C_AY;29N3=+\
ML)W9]=X*-C*G)5=;U>8^=[G(3JOR>5(3V_XX QP&_;!E50/'QDJSHZG3""Y5
MR*6&%2N)D\2H(PCQQH@< :_Y>7)#G.M1JC]WBG8>3-,4"MH4O+WU.) !FCAJ
M'J@^0<GW^H&MNHSRZV]JFO19JLF'!9<B_?O[W?SCM7Q=Q^;FON"LQ$XG]IKA
MG%#;-&G_Q-D%]0]=31'0-ZM9U?!O&2PTK73L9)P\=.."/G;")EVUS4O+7@V[
M\2;6W+PGFII"IW6X<U_WIFS?5=8W>, O-DZ3AOTG%LSFO9-X@/^C\D(^0SR
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M=XY,L^C]^_._SH<Z-T;:5.CP'U:/BEA=V/7D?2Z):M.0%\#J&E\#5P?Q )8
MFE<75OZNGG33WZI3WPH_HJ*,1M$MW/YL^X4R_\X^M?J^\_94/+<$PL4MNW0P
M>H+[4[)9ZI5D7C.N!?IBIWH1:W[TJD%<J&YBPZ8IN7#%C-RH[W:!AX.1JK74
M>]/WS)Z6+R =H#887:EEV>D$VG8C]L\<.FFTQ0]<^:4']79SS]#B\2QVG/MO
M??S31JIF*R$K-PW T4S?+X3BWC9+!<W;TUJWZ7ZTDN?S$[3G]-*&[I8+]'4
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MX0$[)_;UVE<7I'?=ZC22*>K7W@*<>.G%,>'=(H0X<*^4RM-+PQXE[]:V_/!
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M72/<O"_J7*$M#$KN7#U'AK,TPU<#B]Y&L$LK49;!-(P2E/,?RSFDPRX;RO
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M\7/-O!?GK*%WJ#6K%9ABMN2:XR>W/$ZD-OXUWU0V\&<#([/^G^DFF<]H.3R
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M9I&%ZNUW345[$#%5E'CO4?4J8^.EQ09/<G//J7V$F\24:J2CY9UD4;='O)&
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MMBZ[5V).NS\J=BA)EL]Z-DO87DCNH>DM$%KK)7"TP@)Z([6%-.YQ*)A7HIZ
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M#/O9CF/X\<FAB#,YI]*C%F6[U333%T'\L"W3-13C?>I]_#V;;/?16**HAME
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M4:IXK+>!5'6TQGH*](39LBHS3/8,N)#(*7I4$BK9_[TA]CK%D_WK*\G9;B&
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M<"4[=,$R^0LRKKU];7^EB5@X+RZY7 A,6IL3GED?7&<1%4^=@W-[+)9]&V0
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M$P>*/J9MIH@-[YTX!-A/X/]A[RV XGK6?=%%"!HD! ^:X!XL. /A'S1H<"=
ML."N@X8$#1X< H00/,C@&MQU$MQ]<(>9N9-]SC[R[JU]]GGOO/_>53<4JWIJ
M:O6WNC__?=V]!I*>HG.!>*L3<7J3'OV' AY?;SH#5?Q3RZ6,8S1JSS+.CFC]
MCV'L3AEY S2:!@8M1;I[ [LO"\.=,Y8IC?5%&,^-J,1,'CP[V9Z0>U#5B-'Q
MA5-UN#"03Y4:.FJ>Q[:\(XM3+U 2;]_J[287%)QH]JZ0K88DO=&AS[>\F/>6
MV$:PH*E8W)&([PYZ,1N#]1HF>L12__9PDLC7N$2#Y B%LLCFF-OQ?';-D$+6
M/E9X<F;-L8C-*5Q);C)K8YH\8=,EBBA3L<4'MN4T=_S$KB>)6H68F+W:IM_X
M-$,_,MY69V%!=>#EC^@WDAR$#[5L927W-!/B(U6>SB#L1F0F!7Z^SIH1X2:W
M*,GS6:5PN/48,=3YH9:XJ<+WM?XUM*G4#J02WJL=]4A#/?_@+ASJN[UCYC6"
MD"Y'7(.WM#8VP/OC2( $S#\V %HP1U &R!'E&MHV^&'Z8M]>&O5:S)@0 )NV
M'SKI8^2P*"0P_,X?>'TEF7\AX+TTJ_+4I3I>_Z? >6VQ"IPPIZOSGKYMUF/#
M! 6!_3ROVM-&94=_VN:&%$XW);C+J=$.]EB.J8'/'B//'YKB@<Y1JX#%6E8S
M247-45)S"SLW;X/#;O*V/2D- AP]R+[RQ73KAIHSL>!U4K9@^H)R*:BTQ/IR
MH7ME7_<%D0*KUIM$V3<NHC LTJFT\2)MS7E6190153K,E/6N]^],%#R,R%^E
MJG&P8?*G\X@I[P?OM7+8+)X;-3IY.AQ70FA<LWBAXCHU_8CB/JNA/7L[NP E
M_=F%:]VC^I1I[_UZ_YH#?ZX1WT4[ X.,PF!.!RZFCR,D<9A:[6Z6(RR?E_B-
MN;44"]@TW1^Q&G&X/N^^;BZ+V]M(LIF,%E1Q3DIOY4RHC:SBXRH1Y,%?$/C0
M!@7>2CVK*F:C#TE:5T47Z7$>A>*QKKA<#[MMUQ<+I*DH?#[P%U3]PV.XC(KN
M^;."Y\KS3]/5;0KL[/+TO]$XC&A/SCOLTSM^)-&,IDA2'QG,<\5+%H>P9(60
M9K%G\=R?LJW.:F#MYJI.;BCP* _X_%'_HZ&HFXVFONTZ&V.ZC_5\0DT#C3'$
M$NQK@S?-Q?FF,HCQ41J?%UWG\6V_"[:$+&^&3DU$@7$INVMG?=>7 E:C+MBL
MLG918:M,=\=4KFRI_"N2ARX._-_B]2^@<GG*]I-=#9/NZ;OFYEQY#]K87(G7
M5JG7;G-;9Z[C8A;\%7_T3R+*10DU$Q)"&]RA2E>9IUM+6Y/7WSD*7L]$9/B<
M3AAX^V]*?[JTGK4YGIFGEAA90,=ZC36PIYC]<6E5W*/O]+".SBH\\^$BJ3*L
MG#O-I_ILS[LNPS;32SOO<&+FVM6N_).="ES%89C+O)/@2 8G2TCD2CW_)2J6
M9?/%BX;$HGB;I"(\V* 1)NIWY)AOF'!BV%"X>T%;JF#&C]WM6M3'V%!#UI3]
M-';](F7O,510*5>P4\&&0-IR'1/K,-\B(6$TF4[#BW1"5GA.V<1&JS^1NZPF
M F+=M>LY?_MS2%^74Y#'2D$V_ZQJ7 6^SE208GDL]PDZ1<?Y/XV?L;!653'Z
M5DYPX<5[8])U>\=^0X,_KMZ?F'<#;102"B."VV;.2O<&KT0R2LL%2U*44S=6
M*LI)^^NO-!T+N?87C<;&+GV?QW9.$]D<T:R0KA]!?!_H?8S*L'S?UM?6UM=M
MEURC8YS_M9EGPI<K7O3+N"9;=Z([Q*CLXHVX]*>>E7LX;E<J[7R'EW/J07@E
MF+).;1:__EY'"!KAQA73V$_8E:;A3B;YN.2?MAJ/N TK=;02]H1K;,SX!OG:
M^00QAN4>=\O*PA;LLAN^4P.NU9OL'(U$4>?[Q%$B+%CNW':WI?T-2$ _0]>/
M;FIRF<VUPW98O/9J,?4442TR&QL2QUER+C0^RV"U;GWQ@=!^@%./3OVLK""U
M4;] D&7A_/:A%</  \]"]2Z/&I3C&INZ5%T^2PG+%WHTL[$5_$D.[1G;;B6:
M,-=HY6OA)5/B+$Y9/J^D/DL*#_W%*230)N9T*6R6+3%7.+_M^!P)W#VP&Y3@
MHWK7,D;<E=GRZMMFF= =_AC^J.NIY\<UW$.@NE1NB]5YP8LL_Z61\,7#=_,*
M[N?9U5>5%+57DL9\.S]'TJYNZKJQ##>:7VCS[ZJKK:U7-5^5CY6O&XWPW NY
M+LFXNBHK=3!P5[W*-CU*Z3RX5"K+:[A1_=GT)=3 +YM?V./-YE LG2]%^W;&
M6%BWOS8W=0;4LU6P@>FVO.)5!5@_/AO$E50Z$%"*!/CVW2]F:&J+S.'I7BUO
M#$A=1X-S@!UO]K:H&-7<7D9:;*TDMAM]AV$8'$[GYHG*-61^3.IH*^WO-/+W
M,UWR4+JN+8K^H3IG+4.-WL;))"5_]A.:H5-;)>?HD^;8D-1*H'.5Q= _!9^)
MYAX6NO5.6?-L(3E\'AN&+H[QN>Z#O7<VY6P&3(OZ\>;=& 6&>"?@A)>B:.5-
M@25IM<[&3=5$Y[)96&/T7-8Q.'XO0I+]TM-\Q49RJK[4X1U:OA2E(5I0,PXE
MO2DF7B$ZEC %E# ZB])%3Y&&>'PA]K0RF0$#3V:S,>JZIA2NL^OF4IN-::J
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MVX*N3LL7TY% #5R5ZH8+/ )UF&N%0[9\'-\V<5@NZ^(]-4WVHV3R(W<1M0*
M/!;;H*"$R7C56!,B\1?UA=]^<J7<TO%#<\/?/A2OOO"%-"*!H#478^9+ ZMR
M0\'UIE(K@?SJC]*/^6E+(2ZDKT4X9>ZKBDGW24SRXXQ&%+(6=5G75"G5[)W"
M<CM->,)L1.,20K/*E3[?S.R,M'SFN66+='8POS& YU1(VH3:XZ+UO_N>E\Q(
MTRT3^(0\ RIWGE]?WEMO#WD*.? -(!-! M]6!QP\A_ROW"!V)N6^6;G+0W0(
M(K@DC=C@25-@9\!\.D0,-#_WHWO/?W5"<FI5IQBVHUA:.F3/XZO'U)SBT%/U
M+*6B\*%.*]=9#<0>YKE8#S'<E%X5S6[_P<-M40=IM/-:<T'HA0_.UJV%.0H2
MH+%0W@V*2IB\.3T1><;.%YR@"-VH@:V_]B+EZ^U744N/<#A?;R[?='.39#S$
MNF4D\] VL7F"!*QZU@]X'?G\XC[+GQ#;P!><DW=CYHY'NWUQ)HOZP-8'#G8&
MVC=B!VON.NTW7B\+1QQ?EP88+/[16/S&XR%M*CS:'.,M$A#:.PI=A#CL><XF
M]TPX7T,Q]+.F78KL7,5F+B C,BU)('/L\>8KK7([D_6BZ)5R3#VO4G(8U:>L
M)W^X,@L!*AX5XGR;&=3W%69D57R>7!8M&ZQ-\W@U-^N\=EUY4O&]8"@_>=S@
M6G+KY ?B7D^=-W3_*'99]TZ&#R9?'9U1UF6Y^D;, DP@.\ .05U\(EZ35'PS
M1664:']Y NH]HU+%LSG7=[4ADD-$[/0O950E[^S-*YT^:C0U!P!Q;YTB]HC&
M@&O;^:0&IA_G#,\RV!IP?*/%+CQW%ET'1]JK%2C:P9Q.$ SQ'-WR7&?VD,N>
M2YUR^&?8@8:*4OG3E-.JVQ&&&UZ6_2E;B7IW2"ETS2AD6<#'_U1HFMS^/L1Z
MCO'#55@J-J<2CCF%G]N]-G%BO::NX0>%&C@GS&4%=BSK5I"B3P-)(MT%;#7]
M$U71^]/7\XY;;@B^PS]H>70'Y*=/I.LX@V2"2Z.*F=='Z._+X+E"Q9V7G34Z
M()9#Y W--48OH<=BO,*Z*_&-ZXD>'BVQ>?H!EH3W;D%((-26JN[Y6#ILS-OJ
M0OJ.J3!^+.\ 4=-1'?AM7935-#53WT#OP9'QC<VW/:OP=KB1BOC%IO:EO?W9
M_ 7-T@B !#H>.7/US 1,;,H2.R:LK^)1B9Q8C+PP1]]5(HVZGM3T%GES<&12
MT$C?L80H9N$.L"OV>[H;L%>\ @JGF[TN/"^?:<KP-FD\]D0"Q3U'5\50NOG5
MA;*W0C\TSL53%HWM'-?[4>&!8ZFYV<1^Q+YZO67!;^!8U(3\T@KQH/&1^:9_
M^IMB;GB6U;R.H?U"IJ>5"&PB;:U3Y[H$7LCS-%K_?+ZLUC^F29FPI//GB<M.
M)LP_8=M]#AQV*]Q"/?'VX_&])+RUREA3TTTF13+G*&KJA&Q%W0C$0F&M4M)V
MP8&=>_.'PU/)<M4?D,&:;?MK_;VE,U#(= HQ90FW\9!N0D5A&KG$AZNX"A,I
M)3J?TZ*-EU'>MNVJP[>0L['RWA-;RXK$^B+E=H\:V/97<&KA<FM8K2C)KJ=X
MM+> A8!O(J-MYV7MG>\5XF6Z@=[MP@P/KT)WGT]$J$4N#,/*H!.;N35X+22,
MA<R;3+7)"A>UK5Q*"P*'++=,QYT\,P%#:QS<XN7\'BL$KAL]4>:CTUZ&)E,D
M>7U#@Q.7I79^J9\Y<,X**5V/CS^W4"T@ 0%WT$_0$0=B8!$)<+>^/GF*!"9X
M. *&%@^Y&ILAGF4\-C>+]HZ0$3LDX'/>W$KE%[-H=5-N#J[L\P5[0&M^G;$:
M-F@/N(M2&$F]@AO5&;\SK9ZD==B,PK#?3_Z,:UQ8URM$=1ZMBK'V8I?OXEH,
M)S?Q3HS&YL:&@M_3FI8WN2OE;Y]XQ9_58.\_G%:X\QXKF5&;/5>&,(NOT%K-
M6Z3;-PU*&)M,BYL0SJ=36VM[?>[_HI(">X5YI\@%8K?M_CEEWDUT$??2%T$4
MB5'Q(#VP;*BI;*3)1<IH*"@CN\D'2O 8,LWN:VQL]*#F )(9-Q^>=V9KFR(D
MF.Y9 SEN?'34>AMX -X-F3(#Q:K>RF>8'+*#P[)PEDPP9B\;%K84&*0Y"<F3
M=]#QA!.<+!@=Z%@9\/)I+WO+"[I6"L(2.1/SF#@*/T_79(]4GNB^X'16SYR-
MC(Q.@_HN[*[/T\;E^C%437"3;1Q[-!WW6L8.$#$O]W(+]>JB#_/E9-538O45
MIZKD&[)U/;L6\FU-CN@IE>,*$V&;3,BL49PVD3!" NA?C[)#P<O<P1Q@T-["
MB[ +[X#7+@7.L7SB[L,N 4D]8=_AVAHI/()3D)J:UM<>*Q6+^E'F0P-6_N7C
M\V/E?SMDC!B70XK8:R&"U<TPBV044J0:+=ACZTXZ&/"WMY_U-;K8=VXANW1%
M MC#.>YT-=Y7<B8\?3\O>D7F-UI?@#VS;4]Y*19+7IX;9C04!MC!UOM;^4<Z
MEUK*7\Z<G%A/U=NW9O/?OFM2.&R8-6RTN[&9&;91V094>94N3(6Z-;,*-^BS
MG$0*9>C8GV@6D@J7DM5ZP*I:Y]@OL:?3BW&$A8K'=^ 7VC>#19($!GUH^-X<
M1F1W!\?VC7+NZPR<H/7]"IQ1 !8S1"\CL?IS(M=AH57 !639G#SY>??"V,GB
MBIW2KU29*C,J "?8GDR"4"T!QH'I5Y\D7O@RF5V*B[[_+4??HY3@FK8CC6BK
M]_GU!@M<\Q+E8XYVUV=BTV3<$9U:?OUB"MS:$(A.#6RC@5KD4A#"FA92PKA6
M&)<!E__()GD#QCT%5U\W**6W"B$!N^LLQW/+:BT3'@<3Q.RI!$LG+6G584%]
M\(2K0"BEA9^#"Q8-@*;#8AN3*L(8KQKW+TG')P.F;T@@9#ZK&4_\R=CZVP./
M"_"A&$,,%$&B9PO!=[?BUVV*KD]24Z!=[6-O_/!9E1%S-KL!6&G<VN O(,7I
M4N8B;LYLFL]$K ;7&N'&NQ:R8)[90G6.=;1O>@7 H=K:_.\/"GWG"YV4@P58
M1*ZZKRC#O\RA'<3%:>GP9:P.J+"3[Z(4[SU/79K>FT?<MO&N$"4]OS//FQ$C
M=&H"H!SOXA_]8]*\@HN0JWOP5$2C%^.ZY/YT[_=LMKXN[\M6Q]Z6PJ,3NT.8
MU>V,H_EHAR^!YUEK2(IJI&_Y.M0NHS9RN1C2=!-0&-WO">,L&82_GU$,;)8E
M5,/D-7Y*CJXW?3W,[W9@]WFN0<C^@<%M?$VL.7%,_A>X 5:5=G.:HH1&2VES
MB_W"YB>=R6SN_R-DY=/]WCL&F7=G=]Z2Q7_QJ9 <JTH9))?[Z_=N#3ZGG>EG
M.0@H.\HGM;0AWE@%):MD?HO/0$<<;,ZTJ)LYU^F!BI72) 1C%IRSWE_[;T[Y
MVV&\C[@>]&:"*CBN+1<;MSI%+C>_U*W3<Y?%C@STUO (N5 WOY+U5YW<%]?0
MI59A_Y3%^Y/K3'FV6M--Y^!DTI'J;<>$4WLQI#::XR(AN7QB/7?;-A?0HL %
MT$<)@EMJ&..5+#])*M?.+QRHV[S[N]Y"FWTD&#43%BGMT+C&&8KW]9! E5,*
M;C?8HY'I0Y#)Y&W,#56RVAB7$,?752OYJN41H6H@U+"78&%,,K$Y\690B&.]
M/BZ=4GLI#%A7H(GUF_;VIUS>:G!/X:Q/KYD8*_A9,]K44<U+FKC5V)/$\;/4
MX2;_.I/+9S/^G^,-^_^]AD302%3">-R ,I+3-5>65<J4\$(!C_\,:UM_(KU
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MT3EC[1B@LE]JY# R.SOUCAYL_!:6T$^5^*CC7><IM>4(* EX94N'6VW_;/L
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MW'HD<_Q^NY5D03C]A7<%@T&;B<33X+ J6-1&4U2S$"S1<VT":D#;8CI^SFW
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MV281M*C).5M*:7I]OM<92][WVUGM1+S^;I)V*&?M6=9YE#9C18)?J:3QD8)
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MU4_*FRFW?T0_Q\"YVY^] ,@&VM(1@EP6RC0.]"DS(5#[B\=',HZH'JD?+G3
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MX\']Z:KQ!=#V2MXWU2^^3B^)K.ONKUY.[$(?8UXG5@D/_9^W48/OA.*T9;X
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MTH% FCPRD ^.-)A,%J #0.K]X$\5KI8)%\?>Q$.1&)COC1D+?@>(_Z^@)D6
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MB_,@EGD6++JH#3RM>3UA<IL/[(?UGPA@R)V"G46I?MV9%"\9[LO8<Y4F5RV
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MHG-VM#!\DU^IPRZ--?'^HR;%P+=%\]_(K",3P,_H@ED 1@^'[#O1:W0KLQ?
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M/NRS-/RZJU'..-Z$G,6O.F,UNW3)EF2J7-UB9%3C\[(+ 4]BMEP[J'[ B%4
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MD<8J\TSIRIS3O<*!2+WJG&T?X(2"X"@/PI4#2^:SO?4,!_!%X@ T)5*;^CA
ME^H6WKL>@R&6 UB[-%_(Z1T<X-WT^?E'R Q^H6ICQ8[ ,1785<B>Z46BW&F!
MWRZ>;3W_S74RS[61>T/GV3A 1^B1$?U2_C$^!,60G"AO(ZL)+O!N@G&)_E??
M1#_F!DG*G:''OI":$Z['+M ?=^$ NYU2E2 <@$NJQ@3SZ0\H?T#Y \H?4/Z
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M&= ,-)IMKG:;K1S02KBR*'\K$2?^%NPIK"F_\0K\7;W"=?EY06YO5B;T3ZL
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MQ\R]'7K,;#T3%?"QE@@': N0/-G675I3N;=(O<?"[8 "+SKNGF-Z7$+)16/
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M-2)AOYSYK507:#98NQ@/CM49.  IG=H5.4334,($A$I;W\4QW-Z7(J!_\I2
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MD,M2-W'2O/-\U;NGSE'H2]*P1Z[>;! 5M]UB<>$!<FAS7?W+.&7F<.@#PXE
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M J_.V)I;,][G*:.9;N<[[_F );^^U> IM^^[VMRQ4?C>( R@7TG3)DW?[*\
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MPFDC:C%.[M>#+<WBJPI[9J]U6CE>;JQCY)I[SNC9PB"N;?=44?UY(U43V<N
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M_A;Y_X%(@>OI_48OC,[K:RIPKJUW6Z_F'C&^L_LE3KK>/NX5UXZ%VV940Z\
MV?3IRF]&G]GFVC*[J&O?Z":B"GNZ9X9Z3"O7!\GF2U<DT-$/?PUN"@J1@-[2
MU<L!)3C:&%?R*2XL4 W1)(L$9"L_A=#_E=(5I=UZA29+Y?N^%Q&45EB6_[XR
M^FO1?J_[?N9SKN?B7/:=")(@"04DX-#."&XV/!4_Q>J)G=FZ6/*R'4!.^XBJ
M\;REX%YJE,[4,_,S[Y>.5;#[8+V=N]TF\2@^YL("9.IVF!="ZEB/2K0?/==+
MU"LW=1:J_#A"/JDZ5>CK_;A@PUT1.J5$)(EPN%)B?A/%=J'5?O&2]@K=4)R
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M,Z*I&>C07B0NO?PL3I>^%C?S-=58-=<"FZX\>@:X);UN_W)N?@X><O/]ZA4
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M%<JV:5,N7<F=-Y7OW7O [("X$',1(N=(YP<4^"<3IC?*6U4R;&UIMTK0J%U
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MQ-9WK^]GD0SV&Y'I@1<U%QCD[$M,BO/M_VEP7?!&LZ_?'>+W,KEB(J,$=1W
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M4UB#=3^SL%)SZ L$,G@J2&Y[+:2I[7KM Z/=O;4&54!3^YANLXR3W)LT%9>
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M"2;,NAURHL[GBZ.=/>:JCZ37IILU+/8=W'++[> (7O EG*^Q0W<%4E5]K(%
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M3E90^\20,NF*=2!IYC-[* XVJM08>3G@I9P@R)OFDTY6*U>48\U3K(U4Z+\
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M,7N"IA6NTWAGHAA(7[ZL\V-Z 7X]9@) XK9VOWXH,;LLZ5@@P2<9\F[VZJ-
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MG*6)@-0B>OA1N/?2P]O?<++6@OMX(;;%XZG%.<8Y1HU^>.Y@?CQ>=/J].TA
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M X?GR38"><FN\]YGS)5>"/3H4@W5M+;'TDC4)V'JB/.(5TST[\>@(>,'&;K
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MZLM&-PXTR*XY.&D#BV+4,2'(T-DY9E1M$9_#; R%)]R\*Y@J':80['PKA0R
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MS9@Y:!N^K.[URGX[ZV84SE!XY/S%@:D2 ^-MXJ!OYD[>PU=/?921')Q!#2@
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M!%IS6_5)4?P#/2<2*N>GB5_[J!H;ITZ9J%-3\S%JNHB*-MDI&+53"#TI(#E
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MQ\$[YM)06<L]*TC8X /(!A[5+=N8OP^6^C/52\#HM/6Y-2SQ<_\?\*D&Z^&
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MM@R;]EX:Z?_0CK"[ E3?79K6_)E,D..[OM+/%\\X3K*N@/VI2Y/XR%>Z6U?
M3_HK %M[+4('#$<U+R,C=^4(FI]?5VXDMDSMDMKN6DE-MUW7KM>M2ZY4G5O'
MYU< _XC2T\BS:]V9Q<7^!?/CY67LRXMJRRO@*VV@X357[\[NJ!P*7I^L^**2
M\@IXF'-M[KX)7]-I-74%Q)=BTBXNKWD+I/"PN[Q65[M:<1?0GFO7]MCO"A"8
MC[S08,F,W#^]-$X/U[D"CO>O/U2_M<G]-?(72>296=.?69"=TBO@UDML8<RR
M^?7I;IT9<5X!1*))UY[\VB:,M11? 52:W.QGOZX;X@[;[,N+L^M/T12_Z?A-
MQV\Z?M/QFX[?=/RFXS<=O^GX3<=O.G[3\9N.WW3\IN,W';_I^*O2D=9O)G]X
M!22\N_NV^>O35YV6C:;G)C>XWQWJRMH[]H%]-U1L2$G%UY F6;*S)I53><?'
M$2+R@2L5QBG:9L&>:NC P L=JV.[QQ^S]HOB_QK)[=_P&W[#;_@-O^$W_$4A
MX%(2L[7^EJ<M;Y-$RB$ZXNFI+$N['#'^'X8I2SOIXGJ@ZJJ[-OT!/EZ>3FJ!
M+J2S$"T@12998/3&W<(6 &J^0-\FZ!7AZ)+%NIU]TWW(J2_X7FB&+^V1V;H*
ML .&T0M_+]#--DF9^@SBLX2J^Y="AXX2TZ)&%U]C+];DRG"]:I<GGHT'E@UA
M(8I&#UU4,".6!CJT#O$I"8(CLG(E^&1_S."4:CFG#V#0+)+2A@N<)P)= FS=
M&4W(824+>NB\#X0P-.<X8T*%29M?_.OQ88I%[$[$ *A(,A]FU=2-NN0,\%YW
MOFV!#R!U&N 'H,W,Y&T"1D9<)F L;H"^"T(A6@"ML(VHX!FO<#4RXX#Z@W!9
M,'#)7JY<\@+K*%/N1-@':)!\22+<0[&V9./YZN(P>4UL:MA*0R-25\E!A'I9
MF]51AK*Y)H4EZ5$28XBY8U5\P<]Z^XWHE%AHO5!_K=5D2*GR%DH#GS&S4T3"
M:8WA.(QC2VD@FA"72HLX_X\NVI, 6QL7)J=FKF%^H=5">)1N.Q@SQN"/V-B,
M"CIWG1L[/DWO<<M*P1 I3IWM[_H<AVX_*I!Q*G3*AZD]\RPUZ"BBO0+,@21&
M<TW22]>-@Q\09CC(5%9NA](=Q[K6=7XTC]L5GX,TU@D]+X9@<WHBH8F>FNS?
M/>L,@A&1ET-[,"/X P'JF]T= />R_5)@E_36S<4@%'=TM@ ,*/IH&#V:+:>+
M2"4R44>P1+WYE&+;FOQ]2'(H"$;WSJ8IQ<E/K&T9G!L-39VJKVHG3GS=H0N8
M,\>]'AY;!.P.JU63N+K$T'FF9G)6>J.G?0D&(\21E'S27PN=#<"3SSTAVFKT
M-/2$U'*LBX_[TX0-1J2IXL92GJ'Z2H@SO.I1;=A0K1P:*6]U(TR78U8\!X]I
M_Y/H9#">T&!(=%]4=7 H7;*KY2(7#CX"BO$' 'I77F05D5(LA_C-6Y2#/AY"
M)^?Y%HDBPXFF K,L_&%CI0\A4/'E&OA;GP%B>R_AJ:7#AZ>^)0)';E3-:@3H
M\S:W8%D.'VB#KQC1,B615Z5*V"&MR\-X,"U&CLNGME!ZR9"A3H410(8I3N,'
M#[6VWH^Q'*/(%IXU76)IU+(L0UOO)LLMXH ?Q>!B5Z-NDZ346%4-'>RI2'Q.
MAF-T)DJKO5,LD8Q]4%(V"D4C0'ZP(E5.+<>R#>% K1FRTN\H91:9_N7,L/G+
MHA2(^>.\85E@'I'EN)"#$SHOCYQ15>#&*@6>#FHR;&,:WW8J/@]O/_,AL];,
MW$2B*8'_N-\J#2O\[5@#HT,Z.0/3S,>0P'N!RO!T^E0-\GB)UXS..#""6UW"
M0X0;LS@;W4E4K*LVA1I]9PDI3[]M[\#]"EC%WR!ADC0#^>$#(K@I.Y@JED$Q
M,R$BD,40F(V0,]#DRR*4V-ZN^0WG"Z'Z[#4VF>IAJ&]7HTDFVK!^45:VKZ^O
M##=4OJ6EM#E0TE>#]!R"@27>OR%>BLNPOP=)*W@F!:+-WRT,1"@L[2PV^J3*
M.2LP.,M2E;IH'<DR E@XC/E7DT_[K4?L&'O)7_.3TWVA9WDKR8]Z[KZ3#)WS
M 70Z7S^V9"P<XC0XXM;FLG_&(;U$QQ"M B #W_'M)P(6WY,LP8_V;O$K#E.7
MH2F+WPU4/:PXZJ6DP-U#7AM!/TWA-_1?BC$NZ,)1%O2CJH*LC E"XHS">E+Q
M56.<PYX&KWL?6;R7TFD8W7<T,L"\XZ$:FKW[.T[#2G)E>#]<+=_(HX"=B)&1
M56IRTU?U._Y:?0P0CFB8).>"]S-J":T05>;PW!T3HV<>MKLX-Z;4<3L.:!.!
M^Q_-'LJYB9]I[XEERW$IR/N2</$[%$F47+P3O<L',K=H$81(Y@X(L Y40F]7
M!:%6N$HIM3@HR:UW6;["2)EVBQ9<0_3Y!,7"GJ:T-A S0)XTB6SA[^+B^&N5
MD,RN#8+C=^QKG!"($68('VO">YRSA,)TQ,@( 4!7V^+E]8P*/L'ZIC$N5>NT
M8DB'D4HM*OT/HS".;WM([LXWG(T"F.QW/"%54(P<2?(C='4K/OR.F(3<'E*@
MI\LY@:7(@6L[-),.ZOK@(3Z(CN3(R-_<]ZC;WQ]D]M$N41RLTJF1OST:N:;;
M(5U] P\'WQ($X/HS1&L9T6Y&!?IXSJXMRX0P,T#J4^$IC U(;!7#-%:"$24A
MF9P($YYL\'(_9*E92@;S+.X$,/BJH-&,3B/[^Y#4^T$PJM;G?B2WG?.(U1T9
M3")B!*)+_86X)9QIJ2HX_%44I\'"-P,0]T\:?HUL:BJ@M],5%$@EVHWPI\M<
M\(,*T3!JFX_9(1A%:@4$&IC%2S1?+',+HH43YQX,Q+*.E!"L>$GG^#3RR@G8
MZD+CZZI37C-W5FF50K@9D01*?$#;O+#O(Z>4 @D<)V&6^$9[YS/?]Q4_6"Z2
MP_:O&Z[J_H!8&I_5HSV/[7A)30ZX63HD=X?3< DQ-._0)\O!9&^59(%4QR@6
M.63MFF ?YP0QK&5%#RB.*NNUAYR7I?1[UM,B<\Y=IX<:!;.IQ35,M9E4QQ_U
MCYE*X+2?86/\OCIQ(?EMO;["ZQ49T6[%8]Z:_(+-TE],1';3*0%-4/PHL6JA
MF%#*7<*8YD;4BH(JCB;/X09X-Y9YV1R,F:DC?%^*.PNRMFU,O76S3*#'+5-%
M&YP@9@&!F\@W@#GH&#=(,1(@SRD#U+G_P];W(^1U:<QU</@.VK 7DJZSD9I7
M0GQJ];HV0T)G@A3&2#P,J;''*@ZK.Z=!BA_%C1_?VT-*^'X?+>G$X%)E:G]R
MQ$6-6F?W8]1 Z<J;8'"[I[V7<HL'<^XXNN6BU0>#\/PE+?58\:EW.J$((13\
MFH-;_FGCDQ$[$NBZZHX8C^V@M!,C02!Z!)R\SR %9'BVSG\:.0J%C\6:LA:$
MUWTW-36R3;P8X' DX*4%L9^\?I;I*J):&C_"MP7;9]#GJ\@(&.%4=4Z%#4L!
MX\*&?G7ET;<Z2/W;)E)3V>"%$HWM1LH6,YET!*1WM"  ]9H7?>OM44%I)X.I
M5CDH5>5[9_>9+ G0+3EVT==S^<"K-Q=JW"\&T-8;PWAM1=K1",57NDBZZ:HJ
M!Y5CK7L[&Q>U*/RQCY1"AHH%IQ,%T4)&35_PMW>KI*)4%,5M6))IT)DXVG5+
M\ ;QP'?NY(Y$+*E3N^EU.%R2OD:]=!QB^VE9]:"0(^UL+A\#Q;(*@V'/E &<
MUX4L'-R):;G;[HS7C6KLQ+43,^G$TF,E>(86Y# :S'&J1$BWC7?\X6NN2!H(
M(ONO1)=E@:&^B:+[.?\:77!3+'L9^[CA% 1%_"!%IM@7HRHTJ&/TFAB%(#/7
M2U_BIJHL;VEMALUZD)E/R-CJ8:A"<@JE:2K<B<LIL*J*>L"7%33EO3&-T]KF
MGM*0AR*NIJ'MHBK$J89\6F*.&,]"9];![(EH0?</#@3Y)N;JU6V<"[_S H"$
M-A0)X&+\\=W!%$9?::5;F_3Q][(I;X5\U4DF^?)T)LN&<W]O\XXT:A56CE?P
M0E673%YW]%:X4(!"2OTX Q1?@(GKKM8"DJ7)/G"@XCVR0:36CWQZ2&_RZ2LA
MR6O"^UQ3G$22BD#!!OI@'B37Y=N4\C@GSM;\=8^)A]LXTFW 3CI=@*#OJ@0A
MJY@*X.05,A(QE"FDK%*,SZ_F37YC8C4 &X3LDI%6BVFKQ@E_X#J[FPA)5V54
MOH<1,W 2J>6JZB1-;L3@:RK.@M*]6D.I-8D5_(J5#=R?JG 03^I(/JGF,^7U
MY[X?E&V#Y+ZL/!$L"']0H]$OZT@-[S5Q9> K<_-GG%JS:0 B>D&?:Y;A>]*!
MTNTI!>/I0W5:S%8&14:%U[U![ XY&< _+VQFQQODN\ZUMCNZFT#4JR8RQ:>L
MQ1RZ#R5UWD)"9H-O'4)NC9F/YI4R:MZN&"):Q[>66R40'-J0( )$;GX4M&3C
MMT$A*W*HQL;9=LV,CBH,::MQ&'-%#0NK 1!W3X-'4#LD:['(8QT#)XT\GKF=
M^#CC5\O8M_U\P.)FN#6*L&9,)\=.0HZ+M)3168*+ *#4-O(GOQYZ&;$_4#?"
M[[4H],R)W>X.K&H.MVE2GZAX'GTC2TCL?B"9F)!:[<J9N(+VOE1?7D2N*_>K
M0GK*"HR&X73&4#@6#[@37 !#=W8$B#E&R^Z@XXU1"A!X0/.7)<.6'N.800[^
M\><:>U;QDE!S[VW_5&-DU06I*"FK?U\'C,B>@#/*(3CIGI%SNIRD+G5-@'9[
ML[<:1[)?J/@V!5=*'#/2 %8&_/R.X=)RYM Z9$K!W%@OY2;&77]^V<_G- 0:
M*2')#IU^)RB%^RBE(4:P5-">14*^NK*/((OE6OFN_36<U3\,**?\Z,8^Y=%K
MC"C8JI&FJO3A.K.I',(8EILE?]7-'C 4!;=YM%5).:!^G(@H+D$(,J9>S^;2
M^7K7M522Z#(VI\KRIHI]2OYTS/-Z@LO-5-WF"TL#;RL?B*QE#6MM/4Z0+IS'
MIAF:@DYV'Z,62YY4RQ@-UJLL(I(M(3;X<%I1=%O\-:XKD9%66;Z<PVARC1>^
M[8YA=[(O]@TO[KU>?%3,,WT7P>X/]<S6?%%CQ470=*UNZC^,QJ?4+J!;2+X/
M_JL>9 SNW0M>6C/;VIS40XX8L[4X-.W0I2^)((L$4E,*5+N9+6I?IUIWYFM-
M<@KSRLOU^8#=N.@F%X<Q%K'/^M:X1.WK12O()*3NR@8%=(N.#<O=#910<%,T
M *,R ET26AW,SXT#5KL?E#_X\DWN;*$(M#)3'U9"F/WJ;':Z[*Y)=FLH);OX
M$Q?JW V+2;I5"4E(^$;$00> 5)Y\]?&P=:X[Z&&"RS$;8CNH8QJ@EET=HJ5*
MKJJFABW3&N!2?@C5QBOZX?PZIX %73;.W-ENHTTS+)",H_RQVQL>6)J,M-*3
M=B_3?;]A_T$NZ$]5LRW6K)"OS1UVT=?%"8Y=Q,F3' %FYKC:97+,C0?LM1]R
MB4TD#X]3XU@[B1&@A[2&Q+1' $;YEI3O4\OIT%G$XVP*$??-&"_U&Q+(CX+M
M]H$,\F++'43IP,U/&T7KGR3A0W+"/MLB3(J05VZN9LS]+&>)M$_:)P-A>^EX
M$\8K=B0C3[SBUT$D E*>!Z;CT;AI3%D^ ^RYE+"-?11^<'96$-W.#2,. ZL3
M;<"%"R(7-WY[7\@_+HAOZ--)'P=53XY$4Y<:9.\ 0?<XSRF/'M9E282FK+:/
MT[0/B&E&P\B8@K^&^?K26Y[4S$A M_BSF#3<D^2U:0/%3'%4NG'\^P,82TBH
MEO1]ZR>R#SO\V$+C=: 93M;C@"OBZ?+4,:=]H\_PVB@!!U/G8'-3F1'LB6;;
M(YZE]*>]I&4X?Q@L^O0' .AH>) 6J;#YG:ZWN,<U/#SNCU&R:Z7K*[[TYB$"
MATQ(?%H_Z,7 1CH)N/0M!B%LZQ,YORN>TM$;+-K<SL?N>AC;8W"N_4&+U$=D
M:$OPI#UL3ZMG:A=5Y)*M>NFZG5YW$,.*P\)"O>B4:._!759J$O[D9:>712D9
M^G3>TC*'<>U58^$V@2)+C!9YX()F1[/8.-1H!%>8IHSFS A"=!V8N=S1;V,V
M4LZ,0,-6]E:74UVQ3D0L"<R(*6C(L6@A--2H8*\(-D$<LX?P[<@HE$"ZXPC+
M:'>AO#RXDTM2M[":$]&JU1+%HB(631F%-.-NW$B6:=S.NN)@N9>)?$E)(Z54
M/>]?'6DLF\;(MT._<>IL5X-A]"*U=2U.M'X$2V9TF4U-\-ZF/B@(@ETJ</M,
M@CEX>&B7HVA83]::>@)O2-0-21!FR+,MBT].\G TBF+-RVPZ;A<D3<MAC@>B
MR7AVI=:4%\NY6_/7=FU'L57B0D%=!.R?,/K>TP1JM.1M<W?@D##AF3N:0AB;
M)E(W"(ZZ'(1 D2;F(3[WZ^0O:S8Z]:_E5VG#)F2$"<VHH!K.=O*<R>4;!W6+
M4#:D,4Y1\=Z'MN-^LI>%D)9F5:Y@9D)J9)5;,(\R(;NX"^@/XT50@WN.EJXV
M:2!!2Z%4^,FS/.&9=FP4@?]R;:R_='3I'JL[3I!#I(!6?&-\S@A&MNYI*MS#
M\1&W "N3*E66]!]?IR94>AFE@%_&=SH7B/SXEN,?!ZL(PJTT0U(:SI^E"SF-
M]T%WLG%%"'AZA7^U[#V7LE]I:122X9O\3.-0GF2_# GA!AWY#Z>E!Y?@-<SM
M"OLV68^A<!C7=9]AQ$:>JL3B'F*TKX!L=(D)U+Z(#US6V&6]^'"L!ME4Q^P;
MF#JB/S911EU62:IB1'$?%A3P089]"7_.W7)@BL_H/-2G6[)B/4[ %@!%X>F2
MIJOT@YCO8':TAM[^B$6;[7W8<7/CFT@T\S"EV6$7%QA\14DKX@XJMN_)@JI;
MJNON:+.8&PU#I!IN8[+(4S@)QPK(3Q4+-TCS@;:*?D2UFI CB."HOL<+[HP
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MT!W#P&R1(T*@^D=7U1Z$%2%SJM!Q.F$H8@.*!\+*QBRNOG&]ADW_N$'M284
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M0@.[^/OI))H\M%>*U7@3/9O;1GUT)MVC..$QX<*KTT/CWKQ*J1G&QE%0P"0
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M+:3LF&)'Q$9G4N8VO8]O6EIRC,Q^!;F=SS]1"VW+U;'M/U6+;:/QM6;NYF+
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M%KPR T4BXN;>N0D8MEERR@I_V+#7G)MT%7M8ZNP>]C&U_M?5X(_B^T+FPCY
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M;$OW71_K.DQ]6E4,5]I]#?@U/1MO/^U>B=>@*'/W%69E6S*7M7G@/NCVP#Q
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MIRA:/) \\>PQH[XRW8O1%:KAA=45J-4OKE&Z_.=Q?.A9D^GALG6]NA6R5_-
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M_#U#Z\$ #^]^A64Z[=5UT&-L5D+E-<"Q+:+A7*S5GR161E1+)VZOJ.E30DS
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M(YFCC]KCD!]26SX!VC?V??JKWCDI&UP\Q9MA_"KE/AX#20+D.ALH?]3EX'6
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M\T62B/K4HD32>QXQ+GF!I&6K,R5>P1)W^Q-J.0C,_Z<4*\A%B,)PP'I*],
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M">);]T,ZKGF?OVCL]<K+<C@@J2%I=4=WO$- /'BGPY&3E+M(F(>%T9CUQ @
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MDEP%"*44Q:U_G_?NZ3YWW'X]WAC=/<:]Y\/^L-?8<Z4Y?S.L-?=:N@*U!+4
MYCI\V4'WL$S (6Y YN\@;GXO_W^MK>$)P$%1>:=Z"KHW !OMFNO[<Y<Z 4(H
M:NPSHN@;P.%#KQM D7DFM>P^7V'9Q_]=/35/KO-N %O5.":A;@#%IR:Y)@78
M"9S;8R+!=@7&L=+W(>D5*PX=Q?G_7*+[/WV);G#<;U/AY5Z5"BL+RF0@/8@^
MQ702%/"RT$7J_@_Q)]>Q7A"03>6RX/*GP"P/_A>$)ZG6HZ!/ 8<O!.A[I(+8
MT9_:""-]R\$&,]K(N;EOLTUI?IX7L$H@B"-C=GDTY!V3ZSRG&_O'4B+)NO*
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M * U-EECBS$:]:AO"^&.R/-,Q_C"Z2/Q>'_/<L7LO7NG+*F$Z@/&)+Q<+,6
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M-M&A[G-M2I+K3G2/]6R*WN+>^O3YU3V:N/N[OVI@_D-=E$)!),Y8!O086U@
M$'%$-V.T4,55-SV>6F06_F/AO62_T(,T W?F6\^IXXY>4>']$5$+>( :O2A
ME89U/AI98T#UMY6$EX#SU":%H23 ^U.>6Q8YN6]7+)^I]:?4IOAEO2L,QPOI
MRW2,#)()>)753Y?+TX(.;39G0/<HAUCTB13"!,6==QQ5QL3STW^HF+@\9/,$
MD24[X1]U48,KU)%6B>X5Z#"3NDEHUFO22UCJB$7//2Z N<8#$ZZ0X4J@+F(W
M!&I-O(BNT4?51%8&B/@9 ;W:<XR)#ZM)\*$:\C+JO$0,"AM_3#*#%CMYT< -
MZXAYUH?HI,*::/78KT]\\IU CRB:]MLMA2;5R1>4Y0-_V>NG#1J:?%\GQY 4
MH2D0RCU.G1QO<ZF[D&L5;+&-L16:K@_RU&8D25)CGMA3.XY>KPBZ*9H_[KB'
M<Q\ZYQ$"H^#2T*>9C#1R6DR$Q@;BQ)QEY2Z;NL%8011OB/)&AALX8?S47\A'
M"YGVQ;_$\E7A]S>F/X[>]MC=?A;5KZ9* .SNH=UI&QK436@+[(JV9:._XZ\<
MWK1.:?L)[-HMOL("KZ+FT_BX_$*;*(B0Q3\X*&;ZM5?-&"B*K7&]_]JB&T*+
M<;%!:>B@(?YP;4M615SXN^2=0M+4#HUPR.[8GVZ0?XXUM?Y([$N6K+$G5!G/
M7?EBW?<3]:\! ,X,_VV-]=,\MX=N25T^X3&O8M?$%\47AAZ9F*/K0@5WR)48
MY@5Z&PZDO2_0%>NG4U( ]TPDR;%RIM=M-51<ORR7/0GG97&9;=2-RI5#ZU:(
M]$Q\^ ,*9V] @S;\=4STVU#Z+: F=M)8@EMTEA\J!<<>'3/E,<E_I*AUJHGV
M BTS(7SB><ZP;,Y*M-.51'U\2NQMX%R2BFBCI2\4[TC%!QE88O W; G@#8W>
M7KJP9H1)_"^9RDY6IS7JF2\S 7?L-X&OT846T<8@:($7M%FT_AV>?L.C+;N0
M6B]VMM=3U@P:5Z\PNN@L1+QP'WP^"2[$/W\)7ZU)6,92%7AP)34,<WQK>N-)
M>H>8((-)Q>%!/8WV!@BVC# 9[&(%*S]'*J7 %3G59P.8;#;)#$#WLM*3EUAW
M-(6K$$ZK1EG\4O( PD%!\@T:_,.O HB:B*XF^L0 9]1=",FZ-9J<H5&$W/H@
MT[O5QCX(YIHQ?\9_E+EC1B7_$U-*:M?L-'O/_][;W3X<&A'CWY B@S@/_%?2
MAHQ$B#]+>IB7=HOP>05075FB_S)%C>M,T]9!8*O_BUV*,P/3["31DH1)+\SZ
MJ!'%:SY]"&TG4^Z]9.6#1'T$"]4<0U<?#XZ >:'.FRUTTRVY/$2N1K&N@$V\
M,(J"+H>\&"L^]&?X"5W?)I]$1L<3>![5.M@/L?E8RQ;:=OI,?"1:X!&/L=IM
M[6;V[(U@@&)P7L;9 (\FPS!/EZAD#2Q9F2UHA8T"8^11]M;;.(WZP(\U'!Y]
M'OM%=&=A)&)[<:"QN#4GP9NJ3HW98@0S-X4=H7-'.PZQ-8C$2)0?,_4K4YV#
M[DUL"@P+6YG,?8E]-\P%S]C>3,T@W A)O<BGF/JU9; P#(%:'SU$/8*?]$\P
MHB$]:4'4@=*]6 *<J1Q' /U(RKG3[4Z+/XJD\B=^UG?K#RCE.AXG(D&P+:<C
MK$/G_PR93';P*C54_95UKR!]X="J[2(UZXK]P?G-^\UTU*A 6K3M=V,F]?<
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M-P#2S'?2 E*YFRP&,C&5@:&OF+UV][>O"O_7PX$K]N\'5E?9>M@& LFV4W\
M22\N*:,YTZ1NFS'JDA93$2O<>SM @Q?KN%%#X=Q):TUJ[B1G7Q,QC_^V34'*
M_4O&AUVQJ,>'B^^#7MFFF!DK$V%N?T&_L"8Q0W/VI>4RIMFX\\02IKBFZ?+9
MVSSXP-/;DVHA,V[(.K<PI<+0 .;M:W[D\E(GW_G]6%5_[=MDQ6S[FDTCOG)9
M@:NYN\^"EP!4 J-8H: ?2DRHH1Y+#7A7N)!G362;T>I1U25&ZSPJ[7:R0%2)
M[=:@K<'$]FVAC^H>XV)6<\]=._\Z8<L)/W0FB ;S"%HW'R!6BE;N=5MZI4V+
M+2TRWTNK8$Y.6Z69Z:T(72X2K.R3?1XV=%^)'_UD0Y?M[<>WN;Q(W<@ M?(^
M? LUWPIG44L=9J%VL8KO'\+EL_C)E6P/K!7VK-A1PODPII]8CA;D8/FF;K3?
M3E:%M?GR$W>Y9;.>LB<$3L)43]5-SZ\"J-K?D]"^-I5<9J,*>+[0(7WA#[1
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M!H+DOZ&$RS?8HLQSL[&,VF,0HTE)BYI&Q7Z_\<0J+5#I=99N F'LNP])=V)
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M9U%6:14\:_+V4.6L#=\RF\MT(!;_6J(@N^]SUA2L&!-S2G(#B(45*U'.> F
M/7^#A ,XW1&$<2>+#FK!90SOHH93SV8Q1415:N7@JR%6EHXYI74/^-6H)<].
MCRO=@FZNK+!M6])+XN>'G';##W#C(BN?#U9,SEA:M;+?A$1EKB66@XNNE +O
MS\_TF=OYI?Z0"VT?]63[\4Z 2/4N@D=O2RN--Z3VN&##*R>('6?@R ZE3![!
MA@GNI=8O^3 KVX:">,?67JPT/TSL2CN! OQ.KZ>TK02D![JHG#M9=)[Y2K"H
MZVCTI<M=QQD_Y*/;><!$O/*9:5QWG>^,1F,D+WT'8(JB[S^A04MZ90G\/%^U
M>&DF,5N7I=OH9&O=]!R%QZ'M'LEG.Q[PO>\8?POG)$9DF'I,;+D,-X(8T-4'
M<+;$XVJEL6(7F%K59,0^)=,]XQ5-QL($A#6_:BY>4E<X*JRI*'(@B"M13\XX
M[SH<]/750=?2S+Y(J::M6]O;%49S[@RZ@#(K.WPG? 4]HEKR[.F%#SJHBG[L
M_4G;^<86B8HKEZI'>FTQ,[JAFJP/J\SH=Y*U3&D"?RS"OHB%6E2Y6&"T4.%5
MW[9S2YU+8/M"[C9 D*]X?S1E:U+1JE"'B4?3I K_\^@=.H'3HQ451=^L9(JS
M4M+-W,8="%F-<-4OMFCJ_71O$VFI/[V_%^ABIIZ$SQQICC3(/B<O\GB]N_<J
MM710Y/ZHPOSC"9V6MC8HM'-F2ZKBG?E#Q\4>F^0SSZK:[2<9C#'9#W\"%/=C
MD-=/-NFC-B</18#DN0@84[FD;U>#HV-X_J<'9&\=S J>$ZWL\]Y55[()7;!
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MG'??'N?<.\9I1@U*9GTU9ZVY9LU9J]:ZG;B=!SR6%I<2!R @ @ (\#_ [11
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M(3'G4PJ%-BF*X2F\,#>GM?A,LB%&#5)\APP7[7&&CW":*AH0* T$ &EIS0.
M?(H2%@8$X4I#& !E,91  S(Q*G,'%?*,*'8H  [QM^3_#W;DW:>;M^#=0$!D
M($T:XK\_]0'PE$QBO3'N3/Y?T_UL $<CYSP;LJNWCCD@M1AP2=;$?TCS#BF=
M92,&ZAY_C*MG0:;)@N"UPJ?KU6N":"6EP ?,%JA /@7>40!448SEH8R4C"P:
MWU"@W''&UX=WLR2&Z".<_Q@*C8;^)I"PH-EY)S*$ 7PCC,6N8)9-02Q+H5!M
M<+CE@H/H*HF/Z'/^T:)0:-)YJ.S;:.;((+<KU239/GW86$8"N'3 P=(45!7.
M_?Y5;C3[ST@>^G[)TWR@>!Q_'(&2UJ1&EH(05^ES_D#> JSJDSZ%T(;^91WA
M;P&SK*#,X,<6;:\8 409>7J;SC46%-K5R/T3@WBUU<>JSU.;@V2EQPYGI=+M
M'X"W<'YFIF\=T2[;;0D_=1 S^G7NUW^S2'"@&Q/WS,A2"A%GZWLQRYX\[XKW
MB&"S\7NFF\2ZRL.SDZG&9R[NINP(.0ET:+L+D;LRQ@;& 2AVGWR2EE+B%W/2
M'@C HCN%1B1@ZSDIMP!I([)-BEN H\*#:$4Q -Z_.WV,C?3&_,FK\C2.WM2<
ML876.$3F,=]B]8^E1+V+HU38I=Y!,6BBAITD7[H=6GI"MX7LD)]1K7<N9P5>
MZP?W@=O#[K/==]E2V' SF)?C,I;B0BX_< 6\P%-Q"TCEN05PW *(A?ZQ!-U/
M[?^TJ1&VPIM/'W,+^+PZ#O/(@5NBN&NS?RS=8V+G+@J%;^86J\.>P-DZO&<K
M\Z_Y*WGTZW7!S "8:'YASM7."0<<$[VOY/IBX*+D?%1T<<J@]296'_T$/T2[
M V/'/$'YQ[A6ZSJM93)\L,HIF*?)=1OS]:O*N:,MKE5ZLI*%6\#7J<V*QNAU
M<_=Q/CB44]7U9=]%H-ZY3%'CVIA-K_(EC.S"]T1ZKMM1)*[>(74_3@L\4#CW
M-1.&>V5S<9QXA.<)?G3]XY[ ,:-ZX%QFIW%MR*97$8[E"<>2O0@$3Q+:K(E<
M0FQ6>'GI[_AHGB([V( /;RC7("L^:$TA+F8@_JP$%;^(097X&Y2D=U.A0%97
MNJU&44J:/JU5=P0+ZISFE(]@EA%H0! ;&9OPV 6"E[PA]IH ?NN*!"(C1JNB
MT9K3FOTF"!U1G/SJFX4'_<.Z<.<Z5N]J3&F]BLZ@/?/,*M-<7*.F#VLY*(XX
M#J\)U 7VCNU*/GD97)@Y#;H:S#5SKCK\4B5C8UM/Y5-9M30!XY T WV]D ^P
M[C;]1F,S@"_"M6%1#ZGZQ3A&QBDEN7GXO.QR-!"PYI1\FG":G"^%^6VR-?(M
M#/B4);;]&5)*JYWF@91#WODG]2M,$_:4M@>RO-%8]BUVA--\H>*NQ:&PL<.%
MC,CV6\#VD'B'K>MUJZT[3KC79^(B C_2AXV5T] S+GV&*'*6!0GA3&J T]9(
M B 39X2?S]*@2MU.&[@;.M43^JA!S3;M4U(IV1M%77,NSA#ZSGT2#J:&J?".
M?L;D'X!VG@\N183'05VZR",VF=4?9V*6WGJWM\6E&WY?.\0''7;.REB3OGOS
MY"*$=*Y!8F9-(!1[09C0&=3+ZQ'VJ)6-KR[?NEB%-I2'+"/%Q1DIAZ@XI?HJ
M]1'1GHE3+;JI':L\/R)#.>_AZU_SIB2UZF^$$?:.<S/T*]?EO-9W$J+/+I7)
M;P&*9%<9WM@\0I-P19<EM8=[%8<6TC2(0CQP7^&"W:T+[@QTY=&DH5TOG]A<
M+0^N41> YZBR,KPICJ+@+D:41%(*W.'P2(@,!(3URZO]#\A_&@0V?E^!Q :,
MP0H"H8!'&O=3I8\P3AAM8,)QC2=MMX 8-RN/!L]KR91=Q7U)FHRDP9I<$W'
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M5JYUD3IK< MHILZZ!0R@W (:^LCVOVP('?UHW"O74E&\HR*_[+-9!;L%_06
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M&BWZ*CQ%[V*#9QK,E IQC%^--JA>"RP0K'DF'FSP\N7;1 HQ,1)\<=0-N8S
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M^^!7E+2ZFGOZ:+N%$*ZC)U?K(XC<M_"0;U(==$4;H75J X%.WZ^%%JX25RE
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MBT3E8<<BD<-N61%:!LUWYJ2'Y3@MAE79[B;>?/:;WZ>;3+/E@=KCU%9VR/G
M1[H;N"0"(FR]T^S+SS'/Z*JOM_)#WR:P1W)B!2/1(X5+5 "X_WZ>(<7]AA9^
MD7/E[W>2J"2*F"2* 'B*$5OB?_WO%T<Q%KXTHH":Y*&V/SYU7#'&.,PV94>#
MM"<.;EHZ*1!Z6"=S4Y!!PKMPY&3R.BM%$UOT'.SKHMSV?)^?U7NP$Z(I;PL:
M]YECW&L9(.X\G<[M"A,@Y3RY!L<X#=UL"Z2JEGV^Z7)X1H9W4C7*L>XH(Z+)
MN$_(?" YTX@0-E;/UUQ#[ IN&:LDQV91=RSDJUZ&5:PT/G)T&?>0YZQPY>I
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M98?"-I*3"'TC_ W1Z6(Y<$IEM!BZ4CO<EN1LCYXB2E=YBD2HD.,S7E+A&*V
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M(XF$PU3F+VGW5B^]'H@+22Z'X&0.%T?WJ5U%H2M 1V:A,<@[VJTTM'$F0>@
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MV$7U\*=O[[J=D7 S/O'EF[SX];.?V'8B[">_ K^=T4H')\L:U69-6.-&AT5
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MFS:%O+!Z8:=DD^2R C-])IG3D]7+_L0TI_0XWR,!'0 :B3GT)R&:5.C4EP/
M&)#B>!2Q!3N.:ECE&.-%J;>S(UQ>\+AN^L7OT4F]1*LQXYJH"D+3JU]6T>SR
MB?BX_KZM+O(%CI4["QQ* #Z'XIZ@/;7>5+6N7Y,:&1L=2"W=%\Y"^ DY)#U*
M^_#V;K;#R=W>V/P!GF%#E_8GKY0XA5@[T(T=#1%\"+7L$_MOR&9"QNZD.=Z&
M :K7#@"!<O(3!G$;SA*RM@FKI3;NC7 ;7O\E8:]C//DG[B@I/MD^=Z%[8;N3
MW=GV1@S<M3RA^WR@P3R<08@QZ!-5\4?8Y&5FI_?2$'"11C75^2DW^\4T"J*7
M%+6JZ$$C\T6XM=_A!B2HKKM'EV/;('K:Y/9@.O<69PZ'5^^>6;(\H&@0UX,X
MDVFLX0/[%^(19VU<E]EM7#3<<'6]Q'2IW9Y NE8<EU=<8)U138_],DKKK.NU
M?'_9XC/-_/SQ5)"\!,5P;2,1C7BE X 7C-SXGZQ(D9Q=2<^ROC:J:"(()R<>
MG_ZS+)ZAR&H5[W  (+[I$P6#/X.DY;_X 8PBXNXFBC"!E$T2A-\@WDWW9TN,
MOZ=CIP1P8UVY6P@8.=%(R/[;GQH<-W]6;F*R(G, H/';E-2Y3DU\EMB?K+F1
MJ3?B5::(%_$<#/P-4$L#!!0    ( ,] 7%:7JU(__6L   "A   2    :6UG
M-#8T,C$T,#=?,38N:G!G[+QU7)3=NC]\#R E(3A("@@HC70H+4.*=$HHH)1T
M@S"$U #2H" AC0A*MR"M2)>T=$DW#/#>@T^XG_WLL^.<_3GGO+\#G_L/9M:Z
M[G7U];W66IQ]/?L&7)*7EI,&(&@   %_@;-1X Z C8F)A7D!&PL+"P<'&Q</
MBH]W\2(>.?%E0NA5"AKJJQ145+0,'(RT=&ST5%1, LQLG%R\O+PTC$(B@MS"
M'#R\W"@B$!P<'+R+>&3X^&3<UZBN<?_3/V?U !$V6A2&,#J$#D C@J 30<Z:
M !IPG1<@YS_ +S\0-'2,"YA8V#BX%\$!I9< - @Z.AH&^H4+&!C@MY[@]P &
MT07B:UP2F)=5'F+1V4&Y?2)?8]-+%GXD4>W98. QLO?%P;U"2D9.<?T&(Q,S
M"R\?OX"@T*T[4C!I&5DY>35U#4TM;1U=8Y-'CTW-S"T<')V<75S=W/V>^0<$
M!@4CHJ)C8N/B7[Q,2$O/R,S*SLE]4U1<4EI67E%9U=#8U-S2VO;I<V]?_\#@
MT-?AD:GIF=FY^87%I>7-K>V=W;W]@\,C%%\0 !WRZ\^?\D4$\H6&@8&.@87B
M"X+F@AI A''A&A<FL80*UD.[RW3</MA0R<C7A1]QZ'E4-TB,['MPKS#P3EW?
M1+%VSMD_QICOO\39;XS]SM<(@(<. 96'3@2( ?M'3&G>N/_1<T=!U@P=][B%
MXDIB;FNV_F2&BRJGAMHKD[T.\TF+*U56T1/Z\H7U?M>/AI*1,NJ])6W3@3#B
M807;=RXNY3?XNABHT\KY5D7/ ,V-B61A$09"JH<F2F*1=#[UO)#RM(/PNYMX
M-SE>VBW04='$A'HYV9\!RJ6]J]3+>X\0T.55;0/"P9D!]FR?G9W"VC*KZ*8@
MJ&F_IE+HK( H]\9\+.>D*0]O%.-CUCY>R( YQ5KB.YW$?/ZEQ\^HB 7IE_&U
M2C:M@SWS1%_:P"G'LR1"W4\L_3:O?]K8#W8*_[Z(?.V07<P9^E ]Y]LWQ^R)
MK[K#KH22_=?*-2H)HDH0G%]:HZ/[N[&<\@ZRI;NS$?C2N]?B5/ES,<Z HSP#
M 3D5DS _>KP +%_6#F'^2%>$#9'^,F=&4<S7BSFWI6^;9CK2$%B;I#1>I%RX
M)-MSPQ-2GTI0A6 I7=W]D/3$FL,$YQ*MM6B6-UN/QG0UXI'TW8A&VF/UJ+N%
MQLYN.ZDX3%DR3)'V/(C0L53/"J%.)C1WYG#:,!>J/N.D1X+*< H@#N&_ILH_
M(M'5FS)/>!-N 7B2X.HQA'D3F)LD&='RPW'!$4:R5P7PIM./5:U'_5(R 248
MMQR&971*0Y10G&$5X8PXL8IRZ6=6*]J%)24.#(_#9D 4X<]Q17H$DAGE%/K-
M[T 9HT2-6'RIPI2$K%)RU-8,S9U%Z+IVRSVSYQHQQ)5(,S1Y%G1[G\( Y!OI
M"!9K(=1\A-"@=#W65IJ"?UA9Q/DB'D1 QSN90^Q#1\6%CI0Q^M7MY0N=NJ84
MJ'PE(A/ 54.JQ$=MAX_4PVEA> X(\ ,J![8,_R[JDJ$*[5$,"B !8?J"WV8!
MVE0I8Y5*U0T24+U;2 4R:"_+H-_("QRQ$);>6*T0RF6(D:X42L7J46GE_BRK
M=\H[5"EEE8&:H';76Z9F@81"CPT4CU(IH B#,:R0?\3:R&8-5&P4!*<H7XQA
M+\>ZD<*0=PEC(44>B$(\%]+4FQ%V[].=(RF+,$.S8 ZC51]S0#QQ>!OFC9)<
MCXJ<;6'9(!;O;@2W#7DS< OA;ZV2:(;%NW1#N[!:S!^0@\E0I8G+MF519N"7
M8_%"1*"M$72@C/B%!M7\L393<<QR#*;HK3(H7".@DYU,D!UU9MOGH^*H^4'C
MR9Y,:/+,D9]!!@5S3OL3R[XMB,:<DY#F=I"C:F>N[SK77NUG>BO:^91Y_,3*
M'\HC&37#C),;I(-@>E]/>Q&%I0K.;_Y\9=1/_'+/W2B-,'N' U49[L^"J 4P
MY:"8^P8JWQPM:^:5,OIB3GJ2R1.\'H85HH_G\XLP%<_G\UA!BD&;7,R9?6F$
M#IIGFI"FLBRH(<AU$DBE>+.M0V^&.=J-7TD\$M0[54=)A\ ,39?95]QX$J5^
M%&\0/A*J:#;M\92&.*$KL#:0!\*TU&-YS%$_56$?4KMS*:A\*8HN%W;O%6F@
M7Z5%*4\@+/&PF8N#:!04+D@ &LTFA=DE&C,;(5L=8/># ,A?0I2<U(/+R68@
M!;N[10O6KKM9I>?"\;Z1]L($361!,*OU5MM7H!NC1-V&._V"T*=<)B -\7<?
M]("!]$W-BB%=J3+^'O-R\K"L\;CAG7S6G<$2$8Z65O$2Q-2U4.D6S1:@(#D:
M"FG+T#*XVF.S&^)#NO?L#!!&M,YA]:;U/^% RF0L)8RG9;@GO=^F5]N_YX[X
M_BA *"(CIR#PS?NV3-E!7EQOEN?>CE!(D[DH>3^?G)/(G28%"CV#QEDVKE=!
M0T.;;_@G*#=)ONRYPS;]>4.PQJ)R#S/04_D6#S*: 5O=,I\"\_C]P,;"AFX+
M=)/7G<+I?;8%V8U5MQ;=V6N#K-9"XN'K @ZZ)4;>N+->#&= 6]H9L#LBMJ#O
M9"]&+#:K$GU:+8-<1$_KK3_]7#)SJG-S*\\5*^=-@B'2-U]L)>H,8*D4!P!'
M:*),:F::]R5O=P2 G@HM44:SPGJ?6=\JSY2*@8LESD1+G1:' #BQY!73NU5[
MQ"' +M0;TFT$?J:8N@>M(&L!\\EEP!EZB5!% 0:0_4(.#;+,!!#X(I@@G"(7
M.+ RH<IH ):$!+"+AB+&S!\N 0Z^!M*J0$=]9T7M&P_LIB$ <6"1B850F=DL
M%1V=+&,$Z^$OPU(AW2HPX$;/(K,L5@XX[B[X=XD[KBX34)^!BX4B=@.R?($#
MU"^ 6F<$H0H,"GC_/HCW!?K['USZ*"! SD9$+F"@]S^.^_%&\"]V*/" NA^<
M ?*(K4Z=JOK-F Q%+/57S@#P*W"9X QLK'Q:P!'%B&3J+EH\5$4<IP3]%2XV
M5@[X!CS(2+39#BA&B(\L<!5%%B60^F:0R0<$WLKB(C#4FWZA) E9YI$'1Z$D
M0-YY@0."HN5]"T7JG$*HJM6ORT;H07I!::($YRV#T@THW3!0 3^&7?BA.=1*
MO6_]$-0OBON)/54 2QP4+$9]E[PN4RH:XE]X*FF":;:8/IT!^NFG3D-:])OT
MIS!RL942>*?W+?:;IQ*:*;N?X+%Z;]Q_-K(+(%?_]X#/3WZY4E @,RV#1'##
MA\S.@"3 4?<GB:GOU!U>T(4/73_5L/^/Z[C_EQXPR,';TAE/G,,/A_3UPIO"
M#Z$F9T!!SQEP"U@L^5UBN4OP+=P2\!L%Y)LY  IZP_^>1ZX#8(?&**/UR"5P
M>S)!S#(ZH$#)OTKM66\O!1!6\$ .PX:%-1FAC6;>12?M/^Z;LZS]#7<K)8C?
MG3^)[VVY_9AHH9UC"'XW W:1*^-7S?*@[;P#OSL;M0.-<E;"F):!=\(%K&\?
MSWN+0!CDE(6?D!-*JT7*=^9DOO!.CU*2GZJY(1T^;273N-$VW\E)C6&<PN;^
M.&G&([YZL,2&@)Q"\.982?,]'(U5\:LE]JW<Z\$#0P/W8'S6U]SP+%EXGK\A
M,]%Z43MR0*@^L+-""B\\">VRP6$XM+YUZF1XS")" ^NM4;.Q8^KG,-'AN&[*
MZ&KM/.TM8J 0])"%(?92N6)':-^VP7V2I+KPFTXAHRT1(;#F-ZP1]$\\U_.=
M/ESHG^M'"EQ6NA:E3=;0Z5XVP2-^E>^/3JAT[H0FIXZ0'O.?#$>E=QQ>]+UE
M*IH8],B*SKS]("BPS$P2&R"!F3B?95?QV)L&1L^=\TD0BEANQ:WO1L_)>DET
M[R)@[L(Q-FOD?07Q();L&^>-V"2M=4[43'16/+](Q6WC3H'0;O3%C,<:Y,8(
MF)--U?E,<F6J*T!?.< 3B0!TF?/HN.H?*.+3,3?^F,E,CD67<#WT%184.&(F
M'Y#Y(IZAI7F<00$X0;OX("U3]]B 3\*@S2CJ$#TG\7F= 1-D@Z1BJ<B2$46X
M9@4KO\(D!^MA15.-XR\76*K>?XXP@YAEN17ZA37R3G].9_ &S2PK+\]S$-./
MCOGC WRP[E5LM'9HS>>5#[4ENPR68PD@]R]P-1X]C*5%+2_YB5O+5(+#.>]
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M+55.TFT$(F-IKHE-'&F)3">Q7&PK@>->3#?/8;C6^_V5%:TC9AD2/8^!XNI
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M;]_"K992ME&TF&;C'\R'V^^2OZ'Y?8)864FO..G[V611.QF&:BQ>C_@E\]0
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M\=V,:A%/J\X\A%C\-Y_O4D5=\T^V4QCQQF5&1Y/%(!9AQD$GIS7M[T;/R>@
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M!B!%*'W'P<SRC?%C4>,0;OS'@FA(;\X2=X?\!WFA^R\DHK,Z]^!.#?#*#TT
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ML*!E]53UL(.T)ZBK'!7V]V+(OU.1]I ZG:A% 7Y%@6J3=H),3*WR;+QU.0@
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M$F?Y\S"ED>8%KZE8M@=*@]?/Q3P5&$_*WC$<0Q'I$-TEM;480V7VG'78$-Y
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M9[Y^YW_[PGX%J(CPKEV8P<=C!RY0X>%3X6'; #:<G)?P?KV ?[_P+N!?O$1
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MR%7.WEGKAUMU":XZN%A7BLOB(@]O[LT'S>\)VIH='H$.J$QS394Y4$6'UEB
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M $4POE>9L8EQY;2OM.4\?^?$8R%2M,J(C/JGQC='^J>F'PO62&7OL0G,^JM
M 0^W%Y&K]2;+4*%F+/ B<DTZJFXK2Y%6SV9-G5MZ>60+%BB%LQC/4+GK&P$W
MFE+5C<"SXH]"/2O>HDV-0_WE=]66FB)\5$)+KH^D,#6H/'KCH$9*%/UZ^Y C
M$^.&-Z%MG/RR\=I&.E]=]6<U<)^T3I!G]W-_NF1>LUV+X=JI/][*Z=."N:>2
MXZM6CQ[RA0;#+LWL0.)9!BJ<*MD8W,!1T]8E;FD6#\MKG9*.QY.FK\>G_^*H
ML"7/FJAT[5IT2((!AA,I]FY17:""1<]14*"9ZK&G2+3/S:#108)^ZS[OOK@.
M<FX395(37168VZ-J^\_&MF(?)6;20T1'4'7M8HT4@YQCN]?2ET03.*CD\3SX
MG6Z_YL6'B.BG&: ?OS["3(UC+L?1*,![2D^^3#Z[ZHSORHP@< $/KN.-_L[*
MO$LZ94W]>1;+EV8G&7?<JE[HAI0'=V*!NWEH=L3'MQ_1H)%BI3>4GEYA3U;=
MR Q6EA'X-(5(Z981KZ:OQRGNQ2,>.>J +,.X3,"UE'TA/#^S4@0DW!P!C^07
M@A;;D2I')SCPBU\-)J:_E@(<&FF&IS.4(A508=,:!H>$TD&ZH<H=Q*03*?NR
M%AB-9 TL4$R*!;(,:]F(T'JC]5;+DOQN#7BQ$03J,]&/XSTM1IF/S& UVT_C
M4+;VTNE^H5A@2$">Q2I*OU.J,TI78\0A51YQH+V3_/@2L<<!4.E\XEGL^57N
MSOAV(\^<E[0N3-^H7*M#^AMY6V#.TY!HU^&:)JJY]B*T^:C; #-8O];A%=$S
MAX0N"V5\IKO+\=YP&OW%DR%SU)Z^@G*(&F^O+6>7H%BLLK<D#LK(&%K[QRYG
M%&-3F SH4^T[(\M[NGM&^5IJ9/AQ):*Y2,;=]CDRE$4V]*AVG+'5[%;ZVBUZ
MFIMM0M^D*"2_YM??@BQS'SHG''-B@<%+-I@A.(9W5@C3U'2DG$DF%.LQM=+(
M,.3.W:0W-,FN4CGC8L6K@;9@$??<'2Y6^.B5TKJ@UR38]$G%U]'Y.=,3=DG'
M&W<D)+5CYQKX%)8?W>E#^*I:+UL9P(-F\ON'5C]W'W73F&K2;YARHZX631H0
MHV?%6GCA^Q93XE?1/#('(GC?O+BGEY1+$'L7$>VSC:EY!N4O)>.+J@1>=[+=
MH&?H=%#R;"+V<R_TRFMA_++Y);QQ9/13/P%#V+#+W,(8%@CVP@*AJL\'<,'B
M0*R88P$D!8IR7H<<7)5G"" ?:^3UVG8H*B^Y_(M%>:K;N"=YV,H";\M[9&*<
M0\6XUW&G*5>XV6>$>*C1M[$4&CIQ2_+IB.^:^!\XST9!9>\('R)I*=$-*NB4
M,AFW\2;*@#NMRP2?7\,?UCV4YG&XU2H;T9("J&W[+EFU3/?R#5RQO0QF?/XM
MR))D]>@T\$'Q"(K*$ O0H1T+-PA;]>=81[EC23]S[0T&<NL&XRU7%_LN\;01
MR?%,VV"8$-#0U;;7_:S*2;(Y5(/NH'1;S6@?SR/1O& 1V-..89&7GW>K\$^U
M+LIQ(7G:V?!--VHQ5073O6!/[H#6JVP"7MW*] O+LL1Y7H5M&=1NODQ"#";S
MS> \XZXL63E:SFO7WE(0[1 :PW:W<;4@N\>K?_LYCU+%DQ]!F5/_ <[P*YM.
M!?(OL$7,\2%9PN(6(?0VAB]A1^)4G4=UCT!U_-[PV!,.!#0N*D"B9KC^:IY:
MIHDJS1J4G<G[&8?30X)S%;88'-:7WGZZB)LC#SGNB*7'$<NF*=\MX42Y.:#=
ME]G(-FI?<D'K0?@./+6%5S+CBFD#984[345@,L0+,5<UPUR]EYA6#>HW&BW>
M^_5-\W#B'18_:UIT0>GY2^M4UV,F(C=:4D4<A1V4G5JMISN\+P;AV+$>@&%1
M"DB6(G(9'TM4B@@+WO4@N4DM$&.(SGDFU+17,ZHUQ?A8*JJK4$:<.)0T^G(.
MJZH$_""3M(FQ7K5H0TH_C.=+BKH<N,!H(,+>G&)46O7: 6=DXK+9J\,2\G4I
M\OY$B&A.XD/%C^P$R"H)&3VASFYXS9#,=6=WQR.;E;2Y^Z0.MU]?3DA'%8"L
M_2C)O.QN8X$DN%R32Z"PC)H_TE-C,+&#SJ>(-LG"0O0-><^-:^2]T:[Q%$P-
MOCQ!,@I"D7X,>;;'5!'P=-#<IX,9"@K9P@Q4^04_QM$Q)VH% !\SQ:6. &-4
M/1(/'.'R+(?_H'QCUF^'WE,77XRMDE$,MU:49(V]EP$W3&<>*MJN)[7(B;CZ
MO>.;<I>RPH5Z^#A4N'.* Q7^=:KQW96=% /ZCNK-K7U>]-=B8054P^(TZ(*B
MXPXZS7QXON=U\YN3F)O1 .$'V?4+Q\VJD_5,WE;O.RT*!APO'\C?Q3\LA# X
MKGQ&6>6?6(8XZ<PDK,,)LE$6UG.,**_QTP[^OM'AS:LG>:PZ-<LR/GAZ:%<P
M8:P<@QD+ZZ/Z)^;[4$,YQ>CPZ #V0+&B S5>- U%Y%/-TO,(>0N^A*H7Y,X@
M$CO^>E5$+3E(KR)V9PJV=W]84H6-PZ_AI,.F,H,>+<D6=,7;(7*+:BJB/Z/\
MY./3ZJ^L[W8WM*U+47%?(03;)2+G<I*'EQ*WD_6^?'A!5=,;B,=VBWGP(H36
M3]]!)#6#2"5WYE[BF]!#I@BB\BKCN%]N=7=M#+J7J ]"E\L'W;:LK8PB/E3&
MBK[54 C,M&3ST\_8P@(T?BP%J)NKM*M"Q0[;Z(J1Q\1OZLCL^6)O@7-1-KEF
MUAF4(OX@G8&IY8ADW3'\VT^; J]I$3[YHSQ$IF.&&WIV=^[=N-.PR*B!ZY!:
M=.+IL)^VP7<9S06H.1>IFZABA2 AM_A"9$A;,M*+8^F\*L)Q+'O8W>BVO6B7
MCJ*.D/I\V,W&JA(#/T7D<5@Y]()9Y>1&%9MC75UTP+98W!O+6(W[F92F);>&
M/&R;6&44G*5V[05[F+P\(41VI>V>(^!:D\8R@CB!@QOY_;E+53QK[BSMWAW0
M B,ORF6RVLJ/C"P\1N6/P-"<(I</'4PLGY4 0]3+A(UYJGKR3RT?'+CKQ5PD
MF,NMF-F^C0LL[E)W.RX/T,ULG-+T5RT1EQCRLNM0F0?=D;.A))&@J?*'/D$K
MH#(6M_S)^^;2LDKK:^KO[CE^STP8>!"B-,8?P(3#P/6Q*4I-UA!2,67Z)>TE
M,_KE48<UOF,K*_=(Q3QC/>-Q6&S44M=U.;-?FK\E>$XM ^/9L14KKSX9>>TO
MLT;Y9Z[Y2RN&Z;KZ1$7,OG_**[LU?ND/=V)8GR']HKK];GSH(KV;;QO)9;SL
M9,S,UE_5R&,#&V\B=Z_^^(I$P7:XLW/&DD%']G9D#ZK)PO4\- ]<Z<2P-E1"
MNY(5G9;1!GG0C6QJFR4T01A/Z8?OJ&,*"I4%LBIB- Z$FN=N=PC+L\P'E5B.
MUI-^F'N@IBKZWJ[M6*) =(#$)OWZ:'G=K/R#W8]=S\-$_3AN[[0R+S,_]N6+
M$?^*H1P1. 1/V#^M#).&W%$(-&+A$UH"M1'),&0;E5.2VM+!GV>^61)E?J&,
M!2PM ]SP$I$I2W-G"E\08_7WX :C@KK?!X7X UG-)DCRD"]8'AFB5!Z.?.<:
MA<<B6>^WI'VQPV=*S0KV3;%ZZ3YPP?I.WZ?-@%NEH_5W/4##CI;F][! *7UG
M3_;A.5\V,BYFUT_(-6M3NYF\,ZPX@LZ3*'I8F:BGNKECQJ(">#;KU=293EY7
M68?T3W_KG#7SH%2FUML>UAZ+9]^:<GA_UE+)35(/"-GDZ\2P>[6J(!OC*%_Z
M"3N?Y_D7:-(+.>04$171E['.\HWS+XK!G.0U'FI_NKH5> G0_/UJB>QO0F!B
M/O5PC;I%D78#7WVC+..#-I((RJTSB03XH2)G[E5?*L*F+FTPWWZIC:*X23=T
MT"W*-9JA40X^I#?*OO!.OD/"SRJOP20KD-=LW4>YD%TU?T-//#:$:)QVX[KV
M=P-FG32Z!^")$J.'7\2=\@WR;@G]$NA&,M'%]J!!"=")4AY>'#72BE(O4X/3
M@]\&*<8<VEF.E!Q I1^'/ANU$W!DUYLI<"7IRCP-_#I6RWN!P5[@8[G8E^EV
MKC+!$=)KO/HCC@\?2_A)9QD9JML0Q.6UVTNT#>9^N:F*V0L*0<'>4N.9]K<,
M:%305HK%&TX7.U-3O;R;7D]QDU3@JNJ(WN//(_Q0/<?#+"(:?"S0$#2PK+^>
M2>+!J)R:RQ^59W.4!+X^LS1'$WW[4%J^3],5[.B-?]?]HF[+,CES/H/1)B6-
M #6>@N;@00S7N_)9P9YOU:U,8+?HJG%KZJUM)K4Q1K%1D6GIRH@U8><+75IG
MEL[ZUIDDGJ?*J9]:$FREW'-7[KN\<B;I^N0O_]19:>UMGBTMV,;W&=C5+H<F
MS/KQH$50* ?S8URU'H8\*ED"D:W#G%&@N[%GWM;I]-#)EWQQ;SY]!'9AI0%D
M* XMQ&SH42FTY=F8.\^,A039J_<+L6WISE,-:M3F@51#G,HJ6CVME^YWL9=!
M920_3!A'I<HR:52^9S[Y/)4EOD8 UH@$<B$Y-BGYT3\$6XC>N>M,TEU^&O-U
M*>J<[>$81ZRL@D9YW?U^"Z,(6OGPB<L_H! )%MD+V3,.[\"8HJP D3L=#$3,
MT07+%;1)>K7^7XR>&"G87_"?^!#-7C)(<=/GO^Y+_VA%DWZ@K#[(T8E;%+&0
M<-TVI5W8P],=#M%<)4!%Y/),"V+@BMK5:!D7WN?/UN]NJ5>45Y96JH'5O* +
MT<_87UVX&?=4@D:4&B_%3S:K\L/1T=#!OF_:O+58]YK5N(=PRG [M1:!G1S+
MD$!)P#1!3%Z[Y^LY/X^N+U;C3@S0FW]\BI9(\/NVXW;ZU-X44P3;KM(=0KW3
MD.;\[R)0Z0>OLD:*!.R6+5XG(8J>9ACSTCA$ D6G[M%50_.JSQV.$X(+G(9N
M)*ADVEF2&/4RJ2M/0DN@3VN#:MMEGHUB""-+E8#'I2/\(ET/I?S?5N0HKN36
MJS$F;H5>B-H6Z]0-Z1KEA^XL]?O5120I#0R&Z.5GDL ,_9-2'02^VVUO/R5D
ME^ @JCG%BRS[)_^9*?3NQ<M$,E1/CM+9ANP$4S8'[G^NK+%;L[9/8(:7?",
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MM;W[?9)4.<K2H0U" '@V50I:78U<E$NO9OJ,[1% W1N5 9&N]2R_R;7,;=
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M,^YSKS$Z1T'_]CP3^08-[Z?LU;W>(H*@GV/3+L:=&L ?^^+MDXDW,6VVW"H
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M1<=<0E/JE2!A[PYQ:K* S"BS^KQO^0&8NA^3&C+T*"8CN%E E-J #@%,_+I
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M"3*Y.RE() F4A3FDZ<5:Z2C\BM,36M'@[1R_[B(EZ^)XF#TD8C&GR*4^,;$
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M8O )72-N7>S@X._N>"EY4E%+87R_"., KN+*HB_K6VC%XVJP:J!W^4,DX+5
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MH.H-B/56&FIM=16^W.MO C:97GV9[S1N+"/?="^J1Y':]&*9\?,1D_3AQ^@
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M0G P5&&ZX*?;O=/3Y\(_KNE#[*-]14U4;/PBS80[8\T>:D<IR=/%D$&I?A6
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MD@V1YN53/!6!MBP3B_S@4RJY%P]^H;AUTG*%KO2D_^W\/LS8:R3IIF9TOT,
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M+@:=!:UC4Q5*:&O1P\&>+I8W75LR4+&Z SQ%QU4U?KYM32*RA1'6$LZ>*<R
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MXRN!A86%!N7:@3UML'7XU.GTPR[U,T=[F!;>%R(QW/#!Y!S&+?T8 >N[$9T
M?< !W/=2&=$LAGAK- Z^_S- V]'=7-)DHI/.<W3F.00G:0'2/"%,_LY-"(0I
MC)C-(Y13NPP(*C5X6%HVG6#TV I3=4N0Q\SX[7#!1\PM1K[)C0LTJ'#+PU6\
M90)6X='Q!6.3D.>-]<G#H1%[M"^RUA-[L4<G768MW&K_U&'_1Y_J;DB[KAOS
M _:Q92\XI:M8(ZF-7RDE"]%QHJDRFX!GML?R1$!K[8?? ^\@@5Q3?00<%G3L
M"/@R!B.$O=W[9AB?3Q6FTHXT3R]MHKN)@WFK/JG2IB#8]'FA!FAY5<#9"X #
MS&\XO><O]>+B.NL(9OQ :%)E'G(*;A;<*<ZK82 GZP%L#2\K!I'  R3P)FYY
MV(^_1M6CG8-4Y,DGP:_" '4(_?MTW]@>GPXLJ<.#M<#T(SZIR-KBBO?&]V*M
M;AX]>),.OC.WJ2X*F75/:OV<T\$0_T\*P7 8FA79,=O]]2 $6[<V2:63A/P5
MSS $O) !]!ZV1]4B 2H8O;*J^_WB5)6G"H7@=Z/4;T5IG\EY5&G[KE/U8SW\
M2T 2@^KA 4)1$@G<!L;?TOM &!K^'#WV>'>I?/GN'U_-GKYYE=EF9>)T?'21
M[IY=]-'7W9RHFPI?0VXV0#M7CKUNZ^(]K;N?E+]V[,'@>1LL5_WM6O&J3.4T
MV]#(@"/K@9,?G//".$L?SBQ9"3]$ OV)04>O#I=G)>+AETA@\&W[U;/39=@[
MN:L;))"DBP+GB@@2>GV$=]"&2OOE%[DJ=\:K(R20PAETW('XUHD$QI;A245(
M@)GQ,&*W_:0+]0T%27HF;E^_0UV+AY>H(8%4K/./1(A U+U2Y*Z(4>.DK(<$
M<ABO2/D1?/%[='T(_Z#-1^;P*KDZ@:"3"R3 6H)J5OB_;*!'D,66W,DZ$N#2
M1@*;P;<EKU'3J?V*31/Q0&Z5Y'O0=CCB 0KS1.??8 FBKC!>::,( 0_1_F-&
M^"T2&. *.KZ+!+#C/B$!:;EC5G.X*>._Z*]%T L+)+!]@%#50>$AHLL'K\RO
M5E'?4+1B;0?1.1RTW8?012V*(?"-#HH'R04=/\J%1P1]92E%]9 ('DF)!"B5
MSPDMD8"LW'$A/\* \;?Z?JOOM_I^J^^W^GZK[[?Z?JOOM_I^J^^W^OX7JH^]
MXD=":VL!B8IHBTMOF1 AM1::D! A]BX.0\H- V%6\6KQD^)R<>TB:NXB>R6<
M^Z\\]J9_U,W"+TCN:]<9)7C%E&JH[GMLP'Q_-KCM>]&]_W_S?+ML9WS 9R7Z
MDE?>Q[)=U>;!9DM"PFI4W*,P[44!4>$@G (L]H(?1F4PO?W]VH_+FA'L,#&5
MH[)M'HK['?/<: OOF:QG2K@?$YE\JRTY"R+YD3"_H&JEHQ2BG$K!?:_'OKHD
M#N<YY&YUX\#=S[5Y](=SM:IU)G;3^GX?(N'S0^F!.]*.=E."% GGK"0A>M[B
MP-KI1\X54T7TF.5>0JD8XRQ&)PY0&QH22+C7C@3,7)$ YPXH S4EHX259-[,
MY%[+&@'F$66!/>\K-#!30. J-C)VAB*P;"/#6]#DB]R?<!;$?A$BICZ/T-@X
M6Z</TS@,1*8#;19<85:EVLA=U:,Z19%_N0A/L?(UX[=6B1LY>@) V>,HO0>!
M9EC#P%=X4R>&[VL(0Q?>=N^T:Q.!M*1VP253(A^KS6+<C:'F^.O)X!R'PQ#]
M $]5ZDC/VJP:4E76:E+5757IC9,<.Q*BK_6\/L5)JJ,I'AI^V8?' 5=Y6-Z\
MFA&GCHI=0;[6:-?##&U6WH9W5%><:77=!%O'I,>Q+.GW6^.C:[-)11EM)E8=
M7#0P?T8Z+OO9!C<M= O&GT'7DR$,^JX%N_%K[+6A5NKRE=2)51UA0JED%$#V
M:]EGR>B.5TWD'?M/85MC73E,(>=/W-WO?/\PQ)$PU-1]A'DUO_6<",N+*82(
M.8%ZF3@2,3BN_*SH=7RI8NZ&W%T(5GS0!DY>T$Q6[B NT'/YJE#MT^Y'#B>;
M:I).UFI5$#>W4J'\P_T3"I,P= L/=G+0#R1 R/@PYUIS3XV[@&1>A;6Y,4U\
MP$3)\G'/E\=.N]C8+@564%LBFQY_+#<0DVAIWDW\/?#K72'0-=1/ZR[,%A[1
M@ 3.B>.OC,?1<RG6?2KW^=8PRMFKWT!^#@I@#.BQQ*P&]YD(R!  C,3O&QLF
M13@JNGB&'#BL+10Y;GN_6[C(Z\*PI4,$?/+P^<.-=+^TE3X/VW*X2T>JQII
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M1I\#T5'U$C]6$;@ YD<2<Q6#<TV('@')O7R3_I01GP=H/)/D,)JJM>0 ((_
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MD]7)'N2\="9S26"I)YDE^#4KSLYJ [T/ISU\K7(H^]F]\L>)F:J[']U$?_(
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M\-MM,(744<?"AS>6=;G3?1$IG/'(T3\"Q;CJ!@9N*A!GET2@*IOE.Z[3H9J
MG<4#_--E;/]&GX6&%Q0?:R4^MM..H3 &-W,E1R=[_<(BN>@J)GZ!LT%F]R4
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MXRBX$;3.* *2,ID5W_H&<_I#W#E:UD>];$"ZGR3\@[P'APH=>$8+EZ5H2KU
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M7)% 6JZ7-K+G5H5L\S9<U$\%9C.!["-P>I( _^87LNI_3P:N]]KR,&/;Q;U
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M"U=N^/(\DDQ/AC1OTKC^.2ALV;M=%E212@#:A-.ES^IJG&Q)A_[9=WGA\#L
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M:N1"1\9%67JVWO<BF;7U0X]A)+?B;@+CU4<F?HN]?$FG?*-!4137UQ5S MV
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MB[!PFV@L0'I\B4F6 K9&N.3%(A&DV$<L<$O'J?>B3^@<-<^&HR)8AUMA+/&
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M8>WD:-.K.Z@Z^MJ61UW=6<2/'UUB=\=^&"4SY]RX&;MRWR@YFH_*.9$\H5\
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M5WP;+].F^J0<N1345<:<T/$JF42*1Z[Q)427*>U#EV2VFD[\UW*OIB;L\?C
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MB-=R&&XU%#O8B70V^6PP71]ZQ=+;YY3BS##';ICG]?7E?(.P8/V!ZQPPG^T
M3(I+W>9_[;9I_ZA./6*45SO?]$U>"AX"AL<D#">0)AM'\@5_%'2^S+(O<$OM
MFS#N>^/:]SXV6N7P_)7=.$-GJ]W4@U#?W14D;C#1K#KMAB@$XL.$\MU^/AWE
M$X>K&C+*KV(M<=3[(L7B')8L"\>9^^%(-:<^'YVEG,[]@B2/O"OJ 1&-JCLI
M%7H%&/Y\3"GR 3<4I#O?/MHV2N3V3JB\+,NF'INVYO#&_QJ8PFZ^Y'[=-7VG
M5D/8@+AC2Q\*LCWT:1E;,&GYSK6TOR/;06XY3S.V4# F(HG:<D4;=I^B$8#N
MO>=&TAB\QL,8;X2LR>^'W^'?M0^M1W/&/;*@G8&PH1T@;>=#M94I+HWG?4[
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M&:I+T:C L @UOYG_$=ZO(;/;$.J:\0L[-X.@@X,M4&@DM? ,M^/#4$#,Y9=
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M$Y2,KDF6O'BU45J[[<H]H-*"T?JVKA%8&A4F=!(V2:]5HU5#BMR49S71X:D
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M5BYVBM:-01DI9P8+G9Q@5LDK>[AQT*;@RS%]WX!& 21SX68:V)RJ-[!U5&Y
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M./#I-O@3$:Y7H16#OG:=71NRVK,U($>B5"-H0#9CNB>--M(L4JJQEU7K*Y]
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M;<U;8W!#\2$SDP"'=VR_[C;"?B"&H ]FE-^K$>)TJ'[H>8Z*4+OP&Q KO><
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M?:O_"]Q8P?[D9FVUCTR?V\6ONVHQI'W&Z)@=T*THZ![R,6\ZNCKL6:[$[C'
M'A[FM?=\WRE?AMEH!,8*(B@A18;%4./Q +'9!J'$M;:7X8[R0N:=H+1/?LIA
MN%Q_-4]9*8$<UY4ITPHFF3!%X8 +T>!G/33EJMG S90GU<,U0@;WZYBWHV2F
M05-2XQH0W_YEA,R4C#J#S;[)_H2=0&$*S2WE@]V@P[YIL5CC+GBTQS]I%?GV
M_H([(0"M3ON-%_;4!DP0SW*1@M2H:8^33JWMO!!+.N\HH2)X9OT(WYT[-,0J
M("\PNN\_Z24)4G J)-O@W=,5E'09Z\=O'H]]:C&C(+OS\>5WZ#T#.<'GH\A#
MLSG^:R6$0"2J09S/ Z%G19B(OY_NDK3=%V_A$3-#-ISX2R&HT5L<6/$)*CM@
MI96WWD8>&#H\=X\HSH3XQHO(?\K0)R%";7-B$Z%^W_+K^=P9?0S$&V,.PY_[
M-<S:,WBW=.:F-E&5):$^V7Q(4A)A@<O\NEOG'9Y2J^/F&"!3^_%*&C*CQ]F2
M4SF=#PF&LW\)%582CD4S) /S7]_&-ZK>B?)_>8F\Z+K3DYDOFE"D5%A ,O55
M,H+(FAWL+T8+!/_A_3I47KOJ+3]G8_#L2>B2,_Y@\X3/@YF1[5JYG]JHEZ,T
ML:R&M?3^X2[NAQ+ A34]"*C1N$ IG^P./TAGQ=KP-Z]"EY#41I)%%V1_ 5TE
M?7.G1S(Q*Q!M=>+OT=3KFM?'UN%LUHL(F/9M-)O5&3_N<X7,DSJ)=H@9*QD8
MHMN-9\DV<<T!RC\7TW@K>WLQK&EPWW7L^E 4EK0EI9LC$3S#GJ#%OJP?RPP.
M-2-)?$$/J$ E'G1@%L.X1IE\V0Q<>?W&(M@1IH)CE&YXVZ=?.:;'"SB!@3-I
M;^7XKVCDV,FAOOZ'7#^W-N/V>P,GZ2%W=G!Q% OBSI8#1Q,0 ;GE3ZSMU#[=
M>[ZG1T<5[1US)Q&5!=.^:1 R2NBVMJ2Q7->N4HKV39W^@;H-N\(%4( A!O?V
MPRUK7.R1*32^@=X08BR\+I@OVQK%:$A%9,6O8\N3:.7.)U)"M)T7,]FH\Y3I
M4MA%E9_027>^VF'O$2'*Q1V+W0$*/M'3/=[2Q#UA,F^U^0O,B9](5"0I@#?:
M'DQSK'=[KKW@EB()=;S!#!*CC2[]^+&RL.DB-2(+-2(YZ<>U.G;Q=6!V7:Q5
M=YR#OJ%EE'-28%C$186YF>0M+?8OT'?7VVVU)ZV?YZ50A/W$BF:4B,98U@=]
M65!Q96]EV9.N]6_U]>T=;[N+%-(=5#7/[E\Y;/@=Z$NK??4,5G;\5D*%MTZ0
M.,HWD-:M^V?72\/$/ ]<T D'U+,T#%G-7=KSP_2$>0"AF3BD3IK&ZF>M;M@=
M<-1=GY!EVELDS!A-&E_>T8VT6<[!,4F,?&J6]"=/ZRRA>]77I3.42W/^T9<M
M+WXB)Z3!M55WJI93NT%=C"]!: ;#%I+@"'@#R[W-;$.L8M9'YV+]Q$HBC=W&
M)2KGQ=[ 6_6;3*A(:_,%7W^HZ_QVST*17@!FS:'O*S-3@''KT/Q)TJ\2OC3:
MGB[=X9![@;;+-W/\JNSU0NKOF1-]+R<\L/Y"[<&MUVO-2/:H.*#FTW:)T'"Y
M W]"4L#.YV]74*.^$^/UQ*.=I*OUA%4^D<_4'DH<)D: BU[UP86=:A%'\L2(
MG1*JK.>\!.9$4_G!+5MUL),1$I"3!EU3J1WH\'M'9&3=A\6C,Z,BL0ZT?'\F
MHU2QUSIC8J[C0@Z#T*]Q/,5\IQ+R,RZQ-4106/]/9'?8G4]P.US7TS<N!JY)
M"PXKWDP/VW$),@+6:G;H6 ZJ3E$$ASJY;H!<FBFNJ44NK2/!2:H#L:&7C9=N
MJ7R[\B6#="-"MNW*PQ//2XH%DQ?;_[AKE64@GT+FKL:.G<=<9?P%AM>B/K+&
M3.*>3=^_TFO+<PSE;'HI1YU_6+N9$AKBG0<=XSE+[??\RO7R?: >DJ'7C%A-
M3<<WM40Y";WZ\HR9$V[\S?/;80W'I03C:(@'K_C:J9)^A4I<-E>@/K\&<.!)
MG//UWPU>X;F(B?#:F::2#%U#Q3F\VM <BP1_-0(\C"]0MVP[.]OA!\)/2#L1
M0FY8P\2;$G(,*_[\+^1P)1D-W*T&W' ^,D4@Y?.6$7_E-E8D22RO\EIZ:'76
MN, R^Q'QTR%2:D>WUP5T<"(ANO)R[[R*\6J'A_U/5!G[(8PV+T205C.23D%1
M),G:F1V[TA0<'/]LFL/;A#!2K!Z!E5B^DZSTP@(AC<$<N- IT-;8O_:JL$FA
M)4@:'7>^(38T?F*HT;UP5K7N4+ESU9F@[]9LLT*+:E ,4"8(6S[ON[IIND7B
MH0KX_O"YWYT0W6-N:I%P:!KY%PCA"K!QBI77XH@!"-PXA'1:=['WC@4CJ*=F
M.4V3/^E-C2UJ=^3+&\'T0+54%ZHG((@)Z0%P?FCQ :>,#0_'&#T6[.KJQ!3R
M8]/Y%<QP._XO$'K25\$CXUU"C=2Z;*57ZJ34OV_81;5S;&[ZU!OQ2O'CRHA%
M84:!2[/O!E>.5SYG5#S8]I,6IKO7)D3VI#JA\5E[64_[_(-B7Z1ULXR1JO2Z
M@=B&AK$2(AIN?NG+IQ:3RE%8('!BPT6NWOL7>!&M._^KZ5L^AZQ[A]'9K[@Y
MF'N'"M8W0$SWR[;[QU=907Q"5'F]:;7V*X?*H5:-0S^#@OPD$2!N>&4=^]>Y
M)#,=*265+9NQ= @DOHK<NGY_B<T.DQO&Z)\P>Y(ZV:G[GK]-MX"1HW7[QFON
M,$7N.>("]-<//W^XSPT[ZSUS$6,394ZMY#2,+@WDBS"6!/$VSAPB4M^_?<D,
MJMS^>-B5G;8^6)$7P^EB)'5>B8U VCHBUB ^ 6);8]2BG5&<"F)U))$0.-7B
M8]HU9?$DYUG2O'?[NY\5]*[;2&Z[*]&VC_5&::Z^$BU"@VHC2@H?7)O"*OX"
M6F_G_: *;E&N.6;2\,XU*NC ?78XI1,:@4(3I\Q\B_[(LK>$56BHCXYFM-7A
MB]G'] M!^(K7UQY2)R42"P@:]\#UR0-\:GT4VC2X;/(I%I!=""_'; Y-2<*Q
M-I-LJIUF]43A;:KD$"XI*D"IF.)'B,G<2>B^>!EA<<D0AWE]FH:9A.Z@6ZI8
MEC%[6^%KG::IK#3J8!Z]A&^K:6I;YHC/\M"-LOF^".&/#&AT2L28P:,B838?
MOX <Q?<D<+:(+DQAA/RX]8*?&\7B'\-5W1E%AU8]A6(QR- $20IOU)1"UU6D
MQ0BYDL_G=2UM&%13<7!]@='[1@2)M,B)P[T ]!CF6$:'07(BD\26YMY>PXJN
M(IBN^^N?TD:=FH>CMY9/&O\,7NCS9]J4S%<JF$1-4AMP<H@[7"86Z6B#3\(A
M)F1E>L\:O>4C%.017A<_@Y#._$AR+P\$&]:4<W5<B(!0J@J0-N="6% DV,!I
M';S[8.,H>9L99;M'JG,("U\MIR=4&/:XC[UY_" -1UBX?+TD(+M*B?IN>%W+
MYFM]UYVP*A(1%22-!9!<-EN[Q$HC(R5THEK-;[_.-F? ?C<&',&X1.MM*MO9
M)'NJ"!!C99LR!._Y*'>\!W'PD/7$$:C^$UM'=KN7?[F-:Y95QFMK.F9J%7XJ
M>X CQW]%_E>9^GL#@!$XN_C-9_>VVY Z?UF"#\W0@T.J$U/I-W+XBQ^O<7<,
M,3^?E@7%*R2TBW:+7K&N^#TR69 ]3#Q"ZK]ZC5QB35-M'+-B$$MA1G25JX77
MT!#DA8B]N$QGVY_<V[VCO'O!->\[@V-<KBL667=Q[-L\H63[0N+AQ+[M#I=%
MT\J?G3:&]1BQ;D37?,8FK-OK.V'@(P>0L#[95D/9],\*O.*#UBX=,^2/_OM[
M1?[K@5241_>C*2.7QP8X3Q]R91L^SH _/ <55J?UBT0SJ;-Y_D_G7^E2#=LO
MT_ MLBGR$LS:=5\7JP[!3CQ0N!F>*G1$"CC\W^4!*CU3+)N+\<<_"">9%_B/
M!\\3Q_V'IGC@J]T12D-*_YG8.<JO#Q=_KW%;PYG,-M&2^,YR!G!@ (2HL_A^
M6WURIPJQ+B^W-A25OJNR(S7,$/ FXRW$M/$#_JUX$,( D#W6_6@9ZX^Z-1$_
M'N_7T"ETS!7X_C]#*/D*7%WI/8&%,-$G K?0ZV]SZ"/+U]OSO^19)$C%TSSU
M@NA,2<H@;VN B8X!9E"A&LK+;SL*0?-P# RO$8=D#$.ZM<".:O^NU3?Q5T&%
M T2@\G^[8]8[C_K.P-YIM$E97G0W-\>WA6?DHS '/@H?7-TA"W*.M-I4B!\G
MS;2EU(M<(R-A;-4=VUN^*UHN6MLO2@3ZI]S"\P,JWF$P23L#E?FDN<MM+1$1
M$6(G)Q.VZRNY;Q #6>IL-?_97>%'!U8_G2$YQCL-;3I$/ TKR"A6H9P=DK2I
ML>YTEA DF,CS/V'_C[-2_FC$2.U*&#@W4"V6D=]W4RGL=0[J.$<[Z3D*_<]%
M_[-SYMY'4VQ7D8]^<>AB/,EX>T(_+R43@@AC\IR0E?Z2/!GH5N?(JVKS*:^3
MFY>4QBS/*6[GV;(3#>C1"$.:X)1^B>'I#T@!+?)$,7$HY*UMW.IJ#I-L;)DD
MVD6\=5BD(E,YCM* !4;"'2P-3,H,A"OCJJC#,]TMSE4[2XI6\*K'YPSBO$D5
MKX*H=W4YI-77$4*@O)P$V=]6+D&!B(;44I[2CD[L.8.!2&M*E#.3T%H@/QT
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M;Y7"U+HVW>P'N,JQZOW$-'KJ1H-T6;1_*=NE^54-[_T'1WT7\WN2*FD^Q #
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MW'O*O7>,_>',?)ACC3G66N^:><OS/.^\'+V<!MS1 (%! *)K1( ?5S_ Y06
MYIF:\A-];>UG>NQ>HH^$'@$NQP'O =>O7R>[3D9%2DI%14Y.3G63ZFK<_%\8
M1-?)R"A(*?X^X"85Q?_2K?\:E[^(L@$ HNM$_PS OPVB:\0DUV^0DI%34!(!
MB(G^R_AO%N\ KA$1$U\C(;Y^G83D:B7P:@U 0GV=AD-$^<9=G9>D#UQI1=_&
M99%QJI2WT.D.;'&)6;N%D%/<HV=@9.+F><C+QR\N(2DE+2.K^D0-I/X4K*&G
M;V!H9&QB:F-K9^_P"NKH[N'IY>WCZ_?N_8?0CY_"PA'Q"8E)R9^_I&3GY.;E
M%WPK+*JHK*JN0=76U?]L_=76WO&[LVL0,S0\@AT=P\W,SLTO+"XMKZQN[^SN
M[1\<'AV?4%^9?(V$A)B$]*_)1->\_WX/-<EU#I$;-,HZI"]=[SX0?4M&JQ*7
M5=Y"SBFFNT5G[39 <8]+?(9[^Z_5_QC]/V=SR/^6T?]N\[^;?/D#0$UV+8%4
M@)CHRGIJ(F)JHDL<@(J8Z.J"F!J@!#@5>D,!X 5\O?9_IO\S_9_I_\TDWS';
M>-Z7GJ<FF%8Q_MMY0/,)@9E.1$L#\9Z&'# G_9OT.])&Z+VC 2)-/YG3"RH1
M]&JM<&Y1+%%6QV-^]GBPWDG.K1MR6W[KXN-L)HVIX'Y9P0-03Q=)<K)R10'I
M!R.&O>/BX5(CRH^9E>FT./"*UCWL<$YWCB;=IX]5'^P3<2.YFP79]M@S]B:1
M2\!7Y(769/!V_>+)Y.V+@$O @FSPHD>@'N,E0*EY)T][1R')[#20A^P24/4P
MG+A:+Z""_X9+PTPNL'9+&^EN2?&^J/.4%S4R !FSJFB,\>T3SVXL2?"SJ"HC
MX$>C]@F2[)&'7EV5-P?BY1]+=S*JF"TRDMBYB9+E?QORUKB+"?9<6<L/\2PL
MEI(&$C8% R6&FB4F)+>/=W['M;WQKN3/OZU:&RM#Z)= 1.8>6Z<&(K ;$FZ1
M1F)0(<)8X**'XH/!#1;UFPLET7[\VG=%3@#S(V4?C(N[T@8WYKA/&/F'<@E,
ML?"*!*O5UX8W%ITF*U^^N# 8[FVXY2<0#XKJKWRDE.?$9,"#) .7K0HB6QBZ
M2J7EM%PCUN?CSTQFE>@\N[N!IZXO/<5%P*_9#N_*<M[E>N?]^P?-8V+%-T9_
M%O:R^-T.OD<X>AUFIYH*2JCWV],Y4,0=Z"&TZ ]M!_T:/1P"Y\@VRJK\X153
MZOE=EO>@BW7^+G.=\7R+0IIB-&S0M>\H Z08U0P39BE_%:@Q$$E[M0>O#S1A
MQ^.%*[/Z"R"61#HIGTG=U _GV+P1PB8<N"<5P,;R9^4Y=V^759=\+Y:Z"Y/[
M)4E%!.@V#KJSM)$(_&,DR5U@J'7'Q=142+[4OWB]%-F<ON$Q$Z^?72 A53J?
MUY/9<(&9' \H<9QT/)!UI?1VO5XG_U:@D)%S5(ZB77Q)S]0EH?'!U'Q4GB[M
M7EH.FPGW<86_V;C__*Z@7;3'2KV4D?FY?IP>;]<MC)9P)43IU[<N,:-W$&^(
MQ-'MVKKP :K*^B?OBN6NZ^P+/,[-GB?0CJ\G3DU+<=/YBB=[K4>.!JCE34A'
M,W>;L.SI9_#8[!%UEEI0E!LERN3AVS7W1 T*P3@)]BD[WN:A5*-A]@%"QN+,
M7"1_3;_(R*,-NB\VNK_L4J$_&.5IB-KX/18,-:@A!'^>];)X/P^C^QIQ>?0R
MXJAJG)&7DZ ?FE5U.H9-L]A1ZBZ,_M&XZOQ;6N<U6@WO:'K_F_V19STFY<O2
M2'>Z=_J%[=(^&KJ+P[D+@O7C=@OE,S.NT:5@C88YAIWE5)UP;-YA<%C>7#=L
MK7@YMWR8L#<:51^TJKDBV)TIJK?X_K$J\!JM4N![#QV3%PMD+44)W#J["@82
M<J^JT&.EA*5%6$3D@O@*-DJBJ\J31;AXI-OCH#DY;FUXAG4ET;5L900^/V%A
MILH^G=/+)!F,MR?=*YT#Y2:+<TBBO]4TD]CP#TT?VTD7C'4^/)1\U2:J%?+T
MBP5SHAU'0LQSD/(9\%Z:14JE!6ODL 2W#[ILS3KJRL4+?G.@ZT(F040AF@*O
MVL#L=TI^Q#YEO_/H*6<U],K9Z[+(P=XZ3H$KC%VELO D]T@K!Z[,B=%DTY',
M?P4'C>L.6/S5Q-ZQR=LE>5<M\2*(Y9UXBR$SJQ#:(LR[A;0Y^BMKCBI!,O<,
M;C-2E8@R/F5_]R=$FOTDO#._RD_<,<5Q[>50J/W$FN$]W0C_U%0?.^E?;A F
MF?YGP$?._J[]CKBK1[JKT+AN9.-.!T4235T"*M/TKF+N-)46=D]0:>SZKQO3
M]_,Y!()>**9*.??7B&F.0=0S$>:-QQ9-I\9!(RP3:=N+%Y9VP?6'7 U#!/'I
MFQ-;X^\PO7&<_1A7QCPF]\P61LT!J>-;!AS:<PDVJX-GO]?W(^X_)E35ALQ\
M?)47K7H,9'++D_7KHXDI,3W[DZ-[=_!N9"-7YGR?38>B "M#A:#SG^HU.O*[
MM1-T$;>ENDG$>/D?RPOY99"5]? PK]VM2DB@VQ@<7,59V>[O2V_[Q!2K;+LN
M#78VOMXL1<&T585GIL+I]2K:L[R9IR#RGZ/FE3D8=*^IQ:KLX^A<L<2E3E&M
MIWP7JS?U=$QS";N!I_C/T^6L@VR-*9XL&5'%9\GP)WYT^/.:C":[H?+Q+.F;
MP"*A0-%?%#MSY! <M5L@ KZC -82'U[BIL-7-8LD^27F9U.:]-+]L,SGHWFL
MB"9OD]%+5WC(J#XL<1PN]OX2\)&W>Z#@F)XQY%J/2E$(^"& :"A^]-9B3B"U
MOV,/_ CLD3ZN. Y%YT]5J69V!\&"7QH%.\@%AUK-OR2L.!$X@K?5SWH_S9OH
MR][I:F4O)+GC'R+-N6(L/A(#<D[Q*_VHR[C43".O<<&*\3(KURRNL(GZ>)T6
M8.OB3T?"RQG;Q^"!U"-6-BKT!?YDJL;O62&SRQ?FBNMI":30?K7Y^F;,\$2Q
M4Z#O3"9YNLHB6$B82L4"@]8P6+(S_M@'IGB+ :8YWUQU7""S%@GJ(@?1+U3I
M1L=!&M%C:[A?(/?6EPHEXPF$7E_)]?E!LX-Z3&._J/_4'2C.HCDL.DLL(JS+
MEZKG.<"*ZCDJR2#R-06)^;5<5JVIE^JW92M:3GG+C*>^< >E.P4*53<'9T8O
M?"K0D.Z'/>P%NM40L'D$!X<\=$#CX-*ON+'E'+//UV\ZL;2(#2^H\;Y;[:%?
MZ7<\_OW'K73?9R\UZBS>.]BM;@]1EJ6^1G-A /2M*FDZM$D^@K)F><-X2@NU
MQ=L)_?$L"+D'[#9)3P0,O"55WMR@!DTRH47ZTKB^Z40:/3A, 4N>2L'0@F=C
M;6\-N.DMJW*/I^I3O33KS8#-+?<G*QT$SQ-&MIYN0;A><R*D>+NF[<CLV-_6
MWAR5+U/WVX6"55P3$*X0"PD/K 5;TJ1#GJ&02\*#"5M,I5:O8@I2X2Q&ZLAB
M-FS_:3Y&&#]?7\T]G,N=GB,82M7!]7EB3L ]5&< -M+S:#MWSA2A03/8_213
M4UCB6'$I\<TOC>Q$IM*Z#OU)@F=SSAG69J2X5:&<G$+4AQBA[0AHA].L\(XS
M'?R1@N3/WG'?FTI9/J#SUE^";W6?10?#P=!_<R&?>;"^_.O[9K%=RB1^(=(2
M[R!R"FPV'A@CTQS9F^Y:]>Y4](8[O]]&/( P/Z(\##.P?FPUR^4Z6>U1I.:N
M00->GS U)6 *$<5:VDEB$;!L!!RRUZSLM-^HN*']8')UTB2X-A[4?PD(*+Y[
MHL-OP%Z71\Z-;\L[K*+^UQV!"?'!;C9(B8C["N^]O>^8H=WNF=A$QJTSOE7Z
MP#N8-CQ##O95:^Z\RAH0W#]9L5G2*EHM4;5=%4@5JDO&OL<>3::870DM98UB
MXDFI'PV?7646%YV05658[6NA#1)X? YM%]).XD.- 9M_Z")"&E(TT5Y68;H8
MT^]#S-U5=:CT2P":=J!N#DGQ:P21IYO2,,.+E*X^SI$>+I!ZI25Z9=_9ER 3
M71*HG=W3 4TQ$8JB(E&3L"MB#^::O@6QC8\' U'9FEZGG(9#>DYC@F9^7,F&
M#BVET$.=AC_FX]TLQKOW>:(2I3PF6SZ9ST7&90P7Y^D*@IXCX+:SF*!PW!?^
MJOFT'.DJE",X;W7SZYJ"=<=SZZ3D.^:B.T]T.SB()SAI^#025M:D-8!]@D&O
M7 O)5[1<XW<0P?'B,$X]08E>6;!:A859U:]I$$]DG>);XK^IV4S6@&;))5DX
MR C>-")B $7]+F!UGNBZ!'AN2,,,;P271Z2ZNZ+A\4OJB\[WC;KQ:,717M:N
M F$EKCKOQ04OE#^NA0#=]5?TV77J[D$&C33V\O\:+?0-=BI@3]HQ+IT3K!(O
M*R^T)J>@C"5GOQNY!,AH+WN4J.[HZN8_QH-'+S\I8'+<183C"+G(<=VJ^L5,
M$JA\LN$*;0XO0?PEBP.CH0 QU7:+_'"1 ;/K\WB81_9&HT$5QW !;>X2;49O
MI\F)W*IY#3ITGZ1FD&L@(X896'@BBE R[=-)8!/ :%<:!KN+1^9(]-Y(V4B!
M;=UW=:?+9G3P"",U]*+(635^JQ(17Z4'KS *?B/#6]R9BT;9VK?."@K-_'*9
M-/V]E)V[+<;V]1;$<=D@O*&P5VA#U"H+4:JA-5!XXY1/[2(7UU1X(^;UH=1M
MEI<&-;[1Y1]=2KJ9DC@%QK4 G=.QM_CT"O@KGH?#86-2=AZIF.S:5?THWKK.
MO,:R070E%#8\NL-&XG-B8:93FVI<%XICXR++\3;.UFMP08\Z!S@L6O?&*+?Y
M?RYARM,2:?VIFRQ9^I#/:61<6##F-F6DI^-5@F7H2'Z"BS1L%$:?0819S:PL
MK-2XHY'P_%].F$-=*["S^3$B4_S!-4;C.UFGZYS9X=VDO*";^EG\,5]6"PO'
MU?(F>^%P)3%S<P>^ JT&:)E!SK>90,L:LX+JLX882R39X;/0[1M?6#(T+7 E
M7^=>9K"/[8VC90[:X.N.U3U9<MX+7J?K+PF%#[N6* \6C4[+8.\RU#5^3/1&
MF'S/<(?2]=QVR4OX6=%N2_5EDN*& ,7T!L/OECX1TWH#3E9O<MZ53>FJZG$S
M,\M0C5(I(37I.MA&(7"E*;DI'<33F-\I')OLU<LG31TV*YP)R4(YC--I13VI
M2WOH?%8V%1AF4(CJ*OC76Y7^$Z',]=W)%AA;IGA<&W7[?;R!#".;"+N;#,L.
M\(=.0J; E:-!FFL/)W+H>GD0&SC-3=Z6V?NB"^]=+$U_ST]?\1\:[<?7ZB1R
M<@SY=PK$T;75)XQ%5P2(L:6I"WR1W_C"65U\8)Q34TS ]:M WSS_M_N:(C\
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MR1]%1LIS, RQ6HP$>82OMKJ+4XJV,U2@NJA_QBK:5-UOS?,52_UIPU:A@5F
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M(9M_K$T&]@RX?="DZQIME-7KMABKB<C&XY444DZK3_M*RN!3^0>&L&[_\Y/
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MJP9AEZO] )#FP(9GT)D"V,;W!A# I^"ZW!QO?\'D_;H]_9GUKX7XKBZL_R7
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MD\THF6ZP8;(F)( 8%#M\WMBVLTJ((;]GG1I&?.]A27Y_!G0>D(__N9)-))
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M6:8LIW2NR5AGN8Q9;3G/Z?2LT_<Y1XJ?BIZ+,VUCF(MO/C@L1[XYF$&P9Y(
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M2]L!5M(?:T86ZM\8'$@++*K4.FMW2[A5VG410T!IR5/(+!FT&F?H:7^/?XV
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M_:LWZJ_V-TQA_HFIVO\Q3+%;AZEA J"GA'&U@^NI!TXDP _XZ;'._OO57R0
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M7N"9EP-?L5Q)=69%?_D9;U.S';5P(,/B'_N:_$<6X7J/GGRQ&TE@;[35@VR
MG6GN;UK%J,K=L*_!WH:YXV7+B,YK^W7BS]-ZU=X0IF,&^;U<>-^Z-3/8%/BF
M"D@7I_H^)9KN7*5O@^!MU^Y;?%.Y\&R)'93]Z7R%U;"<\X7[[%R_:"*D/G#+
M[P2*7K1AE5R)D8'/JG@>3"Y[V"QQ$3Z2U3%<GGSEO3I?_05]Q;^@O\4IL<L4
MF_>XMKX#K&AQ\?%KD7DL=_IW$VHJYG9G=DY)JAW7<:")LZ]WSM+$4<VY* EP
MG7.;KX95ZV$]6"<?CIAI8<L$%9] 6X]KP5";@".YWR]>20*_@>NNO@H<3%^
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MT"DXWUY3ZF;F9C9/W<,9YVE*R:13(DC47F>D'UW(J$\UZ0='B__.:QN[E4L
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M @>%]<]FG>76W?%>#7A8$>D\H/#*4L7C)"/C?]\50_X+5RC^A2M\4S^=]@O
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M)3A<(QPEG,A1]I>5@D2F*)1\S5GUT0UU5:4'MOV"GHR9.27A!X3AF57^AR^
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M:;-V:#%-P:/I*G)+A$*W^ ;COL?/H)3WVN2VJWR'($_/5,>ZK/WKY2=.*(+
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MF^Z8_0VWT5(5.%((SIB_VSJJB[4'H%X0J?H 8 N$"BP!6*$Q"Y(HRL%N*:Q
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M:ZJ-LVJ+_HBII3[O,A/HUX,(]=1XRO38U)]X 1P N9_((R-!#^^]TM >15X
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MX\UMZH'&K5G1@GJCR+U=<Q==7R^EEB%+1J03T5L[L*AS,_4@@2&!%\!A^PL
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M/S8QI^@JO+_Y=GUEZLGG1M@@1@++\\X3GQND:KU@U)"-F"CVA)C (WT7SQ<
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M>L<=X([J ?'(5#%!]#'']Q@U/K_O0N^!KP*<<QIC@*RM3\HJZO,BO/XMS0L
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M<$?)3AVBHZ^9X+7W3-'ZI!E)Y7B1 T1#"L]'/5T&5@);=QU*P_+/(1\761C
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MN=<[6BXWUA=") 2'$6>,S$\B%,;IC8+EJ/F@0!27S-S@;W X;'[MW%)H0;I
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MM+FQ_L/Z?[#!N/=GG\8?"V7Q131_932$>?HC=]AE7CA&->COW97UFP"&V>-
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MI)T^G=J?SG5J,6DQ*LXEK)(1U6U ;SV-W6^]>.4F'[M? %T*/D_-\2^ T1?
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MR(M1(Y09VVRKNG2T.&4<T? M5(4."Q8D[[!EB*98'II](-=4NUJS0QJVI++
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M'KO):K"5^/N][LB.^690/1Y'D&A?++)VTO&@V93EW;-;_]C3H%2;5T2\0*_
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MK)4C)#4:1$H$VR4BNF+"+9:=QY'(YAL<F/?U%HN47^$5?UAG=M!H%O_&)]S
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MW_#O$ZP=.8)N^*EEKN]C> =<0Q/<,9(=NJEK,5"[SD^N':IP$-.H$2&& IW
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M=>W3>,7U13 21:R;B=(AC0GIF;1[[93NF05?)S9%"2(1#:#JVL0I=ULMN:H
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MK$6@(+5V69N6JCK2 #)H%2F>]\YR=4G<S=9(B'.9@LM-N+2&^OSH_:AJ1A+
M:I5&;RTOHZ2*#RRRKD3<;2H*T9Y\T??*1P*FM*"(7V)NB:#GD;TPZ9.:%:&J
MFIL%5EKUXD=%?;4%2] HS95)UEOIIQ.\K0V:/3SLFR,A-E0F=4NN59R+K"B]
ML>Y@YS9G.0\FZY!O'\8)MDE[WMK'F*AQYEX=XF(9K9%:;\+RX7S=*.2,6JX
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ML_^DP+]#"ORWS1_J5@3$'E[R1T!$Y=&]QSQH>ZLXIHQ;'&I[ ?H>^&G@%U/
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MO;>,JJO)UH779N.N 8*[NTM@$SP$#1H@N+M#@&P"P=V#0X!@@037X.[N3H!
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M1JJ3M_/0,3@%.2Z&<X\9JOU>'-@;.*-JA_N LUS84C>4@>L.&7KW'MJ)8O(
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M0WBN8ENT 6S26R/X4&Z,(#(I\'*5$E(WUS=:TL<R,;KQW]0"ZH]FPH$X;"Q
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M=%P*+#/>T1R>K;"H[8.>O)Q FT?:,4H(SIUL9=KC6]3[>M<JNWW1-$JMX,C
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M,[6XC.0([ES$DZ/R"ML'P&'&P4G)AEN>WE.YF*'&3KR4>X[WR==/7!0U]F@
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MZB,VB2:E%E>IXLNXME,D^$?0#K_?('.FXC4^$6DG!&D?YI$V9.5EOW "DU2
M"_KPP+!PWJREK.JL"(74A.5QE()\)[5N(GIPT+15Y15AP-^]U_8W_.\!]&RS
MQ]$RPLJK&^NK&9DG\>(@1:OAMX ^0/C5NQ+: ,[Q/RNC,MK#_OPC;]]8\D>'
M;N=A0EQNE*&S*'#B7/K_I O_[W4OI@Y>*-?'3-+VT*B5ZB.%418 ?#\1 CC_
M%:K]&W[#/Q*@#PO_ U!+ P04    " #/0%Q6&>B!,*TW @"4(0, $0   &EM
M9S0V-#(Q-# W7S(N:G!G[+MW5%-=NR\:FBBB@/2N B)%>F\1E2X@O9-7D2Z]
M0R!*$>G2I8N 2(U(KY'>A$@-O7<($&H20G)X]][WC+'OO>.>;^\]QOW.'L>9
M/WXC:ZXG>>9\YE-^<\U%F"(L :@U5354 43$1("?5Q\  0^X\UQ%^9FAKNYS
M@[N^8B)"(@#"+" <0$9&=IWL.B4Y.27EC1LW*&]17K5;_X%&1';].@4YQ=\_
M<(N2XC\D^J^-T$7T!0 @(B/ZEP;XMT9$3$)*=HW\^@V*FT0 $J+_J_T_.JD!
MQ$0D),2D)&1DI*17/<%7?0!2&K([]T25K]'JO22_[T$G]BXQ_SK7DZIV>OV1
M0V[Q5YZA-R@8&)F867@>\#[DXY>0E)*6D95[^DQ%54U=0]/ T,C8Q-3,W.:U
MK9V]@Z.3E[>/KY]_0&!8>,3[R ]1T4G)*:EIZ9\R,K\4%!9]+?Y64OJCNJ:V
MKKZAL:FCLZN[I[>O?V!T;'QB$C$U/;.\LKJVOK&YM;V#.CH^.3T[1V.P-%<J
M$Y.2DI"2_ZTR$;'?W^.A(26[)WKMCK(>^4L/VOMB[Z[3/4G,KVJ_P26N?TC_
MRG.$@H%;8ID'];?6_Z+T/Z9SZ']*Z?^I\_]4F? 30'.=1);<AX3H2GL:(A(:
M(L(,@)*$Z.H+"0T "+@0>DL!> CX3/P'_L ?^ -_X _\4X""(PB+#\,]!!PO
M(DXXEQ^3Y^)AGPD "H#"^>DE.?H%T28,N@7L>$NE> E1QM,! @YVL52'GTG@
M$-!O2 3@C_0?Z3_2?Z3_2/^1_C]/^OJW?W;Z_@-_X _\@3_P!_[ ?S.@.-?_
M="_)J/UA;*>B6*DZ7$?F]&OJS)/ !_!K:#^4A1'*M3+39<TXL6ND;ZTCJ6R=
MD8MLTZ<7.HB./A58SM=D0WFV3B)],%R#^5$Y9D<:*@**R02 5#")M=Y.GKPC
M)\.I,P% \S6*6RIT'LHQ]Z.P0SMZ[_/:L(DOW>N]GB"3"D$)+JT97H&CXJ;Z
MM0#1KF&CX&2]>G$+>;Q]N?]83UK(C6I&$^7")%4!2O['CDR4N;H4I:*-WST^
M KC?64J4:-8TVGRQ:.OU,:\JX'!T&_%3H-"-QZZ%#Y'E?*O7)YI+;IL[$Q/\
M]CEW6OD$:K+C/1FO#^L/85" 51K.JTIA\'Z*D<OG765NK)'UWA>/3@1:O\PW
M6LF0K;XA>:M.66CK*?LR20&+]GMJ>,"(J-X;QC)%6&B9:Q7O)&A7<M4\)!D,
MX45C022S[6<\T19EZ6\$VS.,N3GEZ=54^^T>PT0X@RH%FJE4C-TR=_B\]_''
M,31FO[72YH9.]UH%[<'"Z%2/53.A1Y*DH:P?C%['/JDL16TZKRDDL170;3V^
MU^21;!HK]R4EWS<W_A+[)I$)_+1\SB[)V<@9B?"%VT 53JBRP#:H&)/#_6JO
MK[.==H<6ZJ5%HVXBH=&]@M6EFTE$-][U7FN--C4U#,WRU*Y,JU_S/_4P*)8F
M+7B-+8;\.F\E-Z]'W8J5B\O_97*=Z?;./#/K9>%?1LVO/1+#K"V7MOL[+* [
M!(#X>/B$>DFO_:7ID7 4C-8'2+;C83K5[<SM:5[8]2NIVM71[@F11@&K!\N2
M"R_W<2S18F1G1PU;X8SCK):O;FGP,*7J?</7!705SKLA2&_GJJI5.+M3"//8
M&^'R>^\=W1Z+"28.[#1&@=9OW*?IY]IXU N3S&$1+>%3U2YB+Q_==?TV6NNH
M'VM+FA4TK[3P_,A120X=?2^]]L=C2.NM/KR?Y.*IG!6/<"LDL?UTH&RO=Q^R
MP0_V1K&%>9I/BYQ2SR5B+4=.Y;206@>@-4[+LE'1BSQ,+O)PL^N\37!TYD(O
M7L:.MD7YE9K*3&DXF_K^-$^\SIZ[#%2H568T3Y#5J7_736E249.>QYAM3$.^
MM@CA>BZ3$ 6B=\5Q??N:]57-34!0>5.\/*XV>YW>5XM#2;EA4Y:RH>=VH#O:
M82)!8=9\VGQ>T4"VBBE=T_*CQK9?T.F) S*$S7^HQ?DK:\FDS'Y^8D$&%R4U
MY([8>[N_F*^S58,'YL[83K>#F#W+CFI](%W;^2:S3S.F)?:0:(YWEI%Z:VVR
MZ&J;93[MN*;@.HS:KW>AO32*I G]\_&^#WDY_2M5@[:6BXR\@+[ F),KZX76
M/9#(X[<<Q3%",1RJ(4J[04>/RI\$TF77 1>.?Q( O1"* VRJTA$.V+>$1>J,
MX""_3G6)<58U*,/=X@6U,X%> L#DV#5:_YIF&36%DAS7:RD1MBH*?^>75CQP
M1O_3_?@=F2*C(PW/P6*[H!LR:X=D 9N?_:5C0F3,MPTDO\91MR:)&7WUO4\9
MGT^,&P7XSZ<8X'C>WPI,^>ZJE5FP;M6$N^"PLGP5MOZU$F&=)[1YDZH7:0L2
M-Y]6@,RK9+#BL>(R5TH*E"SEC^K#!G&) U75NTRS&S#C(,@[//<V7O(:4WMM
MBW)CQ=I?&M9(VK<*W9S=1V6WBSS"K&W?*'QS.DWPP9XIRDFN6J@4-@/'&NU7
MA*.%6NX5YJCVOTK2$_18^>O7)_!FN/^P_^I&;U71D\PR)0TK >EBG#A[8'R*
M[*KS_"-(H<<B)9Y?>^6B1 *I?3=TK?("PF-E_/@S)OII_[V% DJ1Q_RL">FY
ML:K,>IKNS1;RLSJSW%[+**$R]TR-D]K3@V;[8O]BH_2GHZZU-]WC'M4(WR<G
MS;=E)@K]D:3H_O,"02]3,BP2).UR>R;)/?QKO4:KKBS: D7U E6#T /UNE'7
MJ4\KA"=J"/VZC3SJ3SR*_8NJIUF4CDM9I;W5K17V+/ZY8H"QI[Z&^2P(6F:O
MN$H Q,C51TAFU S*5' PI3VXQ?\<GAYGN5:XU:K10^>!4'0V9W(P"LW.KCRH
M-A[!BK.@,T:SP@W?5#0%FY0J(HPG7$ZT--P.6 =#Y[6:@[P!M_>Z(O3&JP ^
M4#%1+R>:^=SLPL_915_4AF;R>@>W[?@*ISNJUB*.<?W<?\FG1JU2> S_!G$N
M2.ZID='! G@A CSH.=1Z7"I2AW_!S^VPROXI&B.=?7^RPL8TBJBP;N&KDKM&
MM.K'[^P_W>?<;ZQ\]>=Q'DN&V;N$.'4_93EP2C3>;P+GP-71$:LQT-N.=4WQ
MT=_G*^;>$N]R?[!Q&"P33N>VS[ZMP47.-.3Q^TNIYHL2']O108O94GO;P.%L
M&SE?OQ W+5"!6EP_"M'E0=E:D12?(3+W+J]GHY6S9#1($Q1( ' -8]>-6FS.
M@<?T2G+^\<HIM3]>[MQKY#II+-CQ3I])7X#U*36:%/Y]@V)D>P@PR_!WI<]0
MP*L:"]EYJI2DNU-5'8,1B?,9TVL//U,S(5^()X&Q-71.JJD"S46M]<U[:6EJ
M^9K5J;)&9;9V9TVC@\V!\[DO2W#@MK17F=K9 ASJ(."O)%621M-<D6(V)!GJ
M<M6JJEU%>$%C<: _1%JFZ+\Z>84NKE]:(X0>36G0E;*SZSP5H Q5_""Y6K,R
M$R@1=.-KLH5B#-U[.L +HL=D@/]/(++>,2 5TVS@H?ED_]5(@WF[EZ-FM%E=
M]]GT42C8'T4:Z61A6G5"8TF+N9EY'E*L[7,U=1C:#NRZ3C30BP!8BZ'&!4Y^
M_GBS64M5+[:T'"6EF%'TD?),GNKWJ/]#R?T!4-@E]:24X\5(P@K,.)AH"<YL
M[C\ZB$S[W(.JZ\^W28MK>O<18/MRX#N)0B@),7FJ<7*!D!DXSVNBR%BR8(A=
MOK(W= ?">CHKOXV\5__#]GW J^?=LJ]HIE4]/(FX;[L#X(\%QN-O9T4G>T[P
M-NVT4@F9-B4F1^N-U%9O76IVKO:TDE#5F)LA3VCF[@&?C'V_BCRZ)\6G<FZ.
M6@>Z)XP(_D>KG(W0\3,"@ C\I ;5I4-SJW8.P'SO4?.Z KE:Q[[EH3^9#A$3
MOVZ6>=AGA&EKWA9<,\['2EY PQ5F&# ,1;D9?T>Q.B1V.KA,HAYUBCU_/35<
MJO-LV>]E_.U?]K4^O;=NZ)_%#> J]BLP;$E=PY+!27KU8G\70R.2:[G?_]?V
M^6\ Y,.Y\NCF,K2-1>-HQ;T:?Q=<186@EWB>V/4B63XY/DSVNP@V&UF%/.MX
M!GK'DOZ!_0M)%U:KEH3[=0^\2V545 =FBX/U@Q%>Z4!V\-/;E'5IFHT']!V;
M4[3NJA 2BV"=/(V_4[W-Z4",_]_%0""LDP"(GL2+9ETH;0C_L$8*1C/5>)&1
MMG4\YA^XAHS+2[G#M/2N$T2Y5>G?W(M2\Z'4+,>PU,"N!:Z[LR\_9G.+!;L5
MH_GGM .U!H7 GV@Y7H?[*!Q^$Y.67;('T+ZSHOLV4%WC:]'V8;/,7,)HO7GZ
MT?22-(2SUM[3Q>71_01>8F6)N/AIV[1[IQ@(_ZDQ!:>3/BPU?0O.MVI_9D/7
MLD\ &'KCF=$H]KE=MXK9BA^-)$CJM(?A!$"(U"#9J:TOUT5#/Y-A>T/9J-]1
M$"ZC5>&5ZP1]R^2B1/#M<K9K^LRFQ-=E23F427W(JZ"\-I.R$!;_6'\#]8;Q
MPPIN)P:Z-TA'2^3CQW=32??_NLY#_UU-KY4_9-*)70[K(U)F,*T,+YV=V/,_
M?]<FMNB,;9%S+:$O?S&W_\Q?W^BED#@3S\9'ZK4W/U_XB66_O1U,,64Z%I;-
MEF6%K+=*.E7 RI3H.-'J:9RU7<K!GFXU'5%9HD#1G#2GG*3S%K-3:B[WX;3J
M/=Z)'^Z=X9IY8HD27N@$(0HB\UGZ&Z7*D44P0[@\C;4ARPLMHV WK$3 =_3Z
MBBIK1%$B^<=GC#*]"*3D]*D<:$BX#;CF<>D)/>K=3\=DF9/W]N?Z))C71;WT
M)-%R:7T> /3O0=[S(?EF?&O\K>Z@&9PTJ57J8'H6E%E5*%IY]BVUN6S[:!QK
M+FUF*$<]\)-:[<GU/JZI:%3=[S._":K_$GDJ^G85'LH73P=T+P$3:CX[46GP
MD3Q:G!#B38ML)<]9$6^B:Y5FT9G\T6 $JXV)JVZ=HO.V*'6JIJN(B9]5^@9X
M@<.C6$_3=0 .VPJ6) !N0CKRCB\)@"0$!/>J!50ZB0?U #>"0.8%N,5P6!^F
MN,.$9AX]?&-9OB#]A9]J.[.QGZW,79J/RNV ^)76S-)QEJ!O/&BNGL(#*\GJ
M9$B,TD<4 ="IMUJ2GU$Y,V[1TU>R?L-$<#8&4AZ[]O9SPIF:Y.KOKB!2Q*/]
MB]D3^RH+*N0,>/('$C+!+OD^\>6RXG73.3IG>:U70NPI_'W$R>(_[BSNWEZM
MJ>9XLH8R'= O,\@ :V^O3X/C"IA&BP?P=+7'^WC[0>"UETEN=$\.B;FBY2,_
M^G39/5 A)0 0:@EYYN>BVOS:BK/&IS",)4JDI*ETEOM@V^VXZBP.O'RB_)B3
MR1^/UV7SK]^3ZO5VE/ 565ISOW@->1X0BVQP?R',38'EISFC"\@]\X1\N2@'
M(^V199Z]SM^@$Y?G_-/#B[<57CVUO5O7Y##E-50^?YO*\MGNW4W6%*^%$FCY
MBV,G N#LB  (R^>[-*]/\B4 ZD&X6[IU1)1BLN0?5<#3)Y%748*ZO&@<#/*Q
M!\P_ZOZEIWKCI_#]9]'BLX)JDB<U+'%,_7O);NM>&V7%_*/1\S7IP[V@0YN>
M6U] 4N_ FLJ^FX.+B>N6">F.Y)_36:\K<ALRL7Y"* FE*P27^UE@H&C.Q)'P
MLGYAVT>Y"[IXJ@T3-(8 N+<+P1[&$ ":0D[?09V0%4B*1L\56X9$A'@J%?V^
M2I?L5^39^I  V*J%WH;0M8(V@CZB;;9@7#U*0 *@3V@,WY: CPX\<0>QP3JQ
M!<,].!H"@'%K:#&4\^@1]!*LC9NL[KZZLA8GDM>!J9X4JK2ICMA_<.]^!(N:
MS8@1D1WO%I'DSV07GN;?!RXJ4F?F>7>V)FG!6BCN/5QPH>7P-.^Y$Y=MN'TN
MS:^'8AZQ/ELA22XO2[B;S )WH3OPK'#K!V4P"YBVQ"4-[!!DY7+3RD5L]6'Z
MSXX!3RDX\P.%!!",\_F^1]_&C^[.W#RY"SE<+@%0(-FA.SV^%LCG>&P14K81
M_'1EZ*\M%I6%+Y\6W6[^L&<ZOC[+X34;8!E_*=!5Q.DHT]F,D\N=UPB2T73^
M,H;(/XKL2*!46;UEIU%[U_[]]/.CLM>8'\W+3W.7DH9_7B(;9$D1S5'?MMH?
M.BS$] =P,+!DEDEMEIK#I#>"H^L8!JFFG^E]$*T?N/Y%(?!-SUR0#?WQN=]&
M,RQH)YB<O_Y1:K.%;@-J-B&4Q6O'Y=OLW) ]8^:/7DJ*F'6QY?A^5G\2?\&P
MP0YB.F( 5/G56D'?J.NDR^DIZ%!7<9EK:#A+\US#^P1R>"LO5FXODS=RS93U
M=?V/1]_O+H<VV'],*'?HTW7!-Y0??C?X!JTQ(@ &47X2W;I)677(61P!0&8S
M@+^!?C!F>ER;\T0RY^['IZ2NTKR?B)N;^9:CWS]^&RIFNGJ79CZF=-G)W=?%
MJG;6F4U&D]^O1-([)VD[>#]8-+C(;,>=5:O/)I=8"N/Z]AM3[X#H4>)4)<42
MM3)QB\/ "_"(B]+FCU5F(3-NA,U*WAW'(YPL2I1!\'%M*F\]]]$KCP8NCE6R
M+Y #0+#SUG;_*[Z@>0-=!&P'O*[>(@GR*] .]+VD@J#[/>MSZ2T^X-=&9]5A
M:F216\X#'97FD\&T:F71?@4^$U_!4-NS>=J]F8DV&V*[(UMVA2E?<3X<NX9!
MIX!-[N-S3L$#[;.) /%.R]^U*E^;@!+!/F7^\53T:/X#_; $L6&]^Q"XK)''
M?<[\=8V+/J/OXM:DCDU&J^2CF@O.!8H80R,'36>,%<)^@L/^0@G2.YE/ %A^
M)@!^KU7^<OU]"LGO#5T(B3F5@<8N'DE87L4>><@E=>I8./[.*21+M@K4'1)S
MI/8;PBSXM>5P'/_XT5H_724YZ)'%ALP^X[V$SZ1G4 &*<:>R4VUA@XGN!]OR
MWHZXA#MH Q2)UF&@MMNWCO9B]XX=R=OMOM^.LE]+==]M0LX?BPZ<2&Z_<M"I
MS>98M-T^MK;/>@^ED#:P. 6EYV]CSU*7$Z*/.GER<'I6JDSLT0P!AN\B7J</
M^M(@9>0M7-7[KC7D\S<\&_\R!R$[-C'/J8X3-- 1TX"VXG+J%+4Z68C];71B
MM*+5<N6#VSFTF[\/PVN0@+\8[GK\_(FTE.1%<F^,:I_)EW1.JRA+C>X'^/7"
M,8#9JX'C0%A=+ZL&X17@(6R8ET$:[8S3.DJT7S+!Q< ) % R9(MZM ="BY\'
M97%0H2%GQ[C$$E32@#/\ENX:\<+S1,TEGZ,K&\8O>S)A ;I.L0)ZI= )B5:M
M_XZSXC:IFO^/E*ATM9SHTRQ\HP8!\)GEVWZKGM@T5GSU(!1R)-9[M<YXK]:9
MP)8HI"/D&P;'BS(I4#Q?07]78L]#+H RI2[3?:4QLXA+$,K>U6\U+F.^.\#4
MVLVAT<VUM6(CL*$29(>I",DY6 MPV[O8"/Y! # ?M7SR"W1=N! _B$/CG)M9
M74W/FW&PY7@VQFZA21!BPX.#E0!(7 %>W!B\"IVO*S/S?D*60$FR)00 .R0.
M_P;;W$O\<ZO>QO (E_#@>< G L"LJJ4U8_/7?%Q6R)L3*$6"M$* <%!%LP_&
M3W%FKB5IL[;\_&!T(3CA$YX\(.\P,4%8/F1(.B-A'_<)7G>9%R\PTV,Q[3QO
M@3U1L.1$>>\=7 9FM''_K8/NQ8VK7%)@4U:,(\.38\3X(>P$0%R( S:YUUJJ
M[E#Q8V,&Y=CS[KOA[,U3E%5V[3/1U^?<=33?RO:A'H[X% W4:/E-G>T:&W+Y
ME05Q=0.7/?Q+EN7" U^#_F)6<IO>'P#(R&:K<RV=RI#,M'*6CN@F#AW[MKB=
MFV_FG);6;;RP;$4*!)]7[0*IVN[/HC=D:0>E$&E+S/>'U_EU2'JF2&,/!U0-
M$P>);[DC/F])5JR<00KDOYD8)1O7I.V>JA6:,$_]TYG/?Y4X=0/IKFH"SR8"
MH#(M#ZOM!E)[CR<-YL%4;XIR]J:70[B#T\&/9FZ0':2?!1?_.O;%! 4=S!\A
M3^'TQP/GEO4P+=?@F[5YDA63%YS4: E>'$\=["]X\A69G5_%^Q^X67NLV\MN
M,A^ -$S08AN+Z2 +2,:Q-RR.0[NQY@2&X?1&_,I[3D>$8HQS+4:EQ[RN41W>
MK:T*:RHMS%7G8G-YU/0$,L,K RW\DLK"#YK?@/@0 $N<TD9-$]F0UH&V"TB[
MTL_?8-F7R\V&U=^CN)Z]*)]5Q5#Y)E:EVRED'\I=C5#AQGBJVA O7NOW^;*.
M!$*0'B:]$P"-"Z&:0><>R0_R)NAPBS1,,RS?Z^,?B.[+QQ_Z\FY@-/K)%5,\
M=%(L7V<W.]=OYO>:4)1J:#Y2:\O"U8R?+-[>VGP\]GGL>877V>NCKGC J\\Y
M!21WR?1I5'4'"C)7LAO7-IU!%NPUJWLK^4&S6GF*8#"**DNQ+HH6_#VAYCD1
M7GJ@J[C.2+H^A)M='COUT$PNH3+F%-^2P,NJ:,0S9K([ACU6@'5SL#4<.F\C
M;J8DK4RR?NX$"B[7BVU>C&R(>?SLZZ6?U?E2,=S$)_EW!5K2K9]5T'?FRG>5
M\I<<@DN6A^R U-MUV!3+FY]2^S@[+KFM"0"/3F'KB>/4>WMK2U@@VNTG5L[K
M+-' R@0'7 &O7CR^JOU4!_&MBP2 *LN9"(BR%?*TMP>G=P+)V.6XAK*.L_\\
MI>P!L:6KFE6M3/"BD/O.]M[8W3!^Z:US:*UL4Y+3':<#(T:\6C#+QSB9XH=?
MDT;ZKRQ- '3G/-5!G([+<<R^=TB2Y:#O2_,\B&L@ $QGS4S<R3U^]G<'-C@,
MY$@C)29W+NEA) -= ^+?6M.:S&;+8"O!ZNDH-+!SQ-+I];N7]L3:\:9-7]1J
M? 6/7JK=?1W[419*FSXS[L3II+.0[G:DV'S!X@C?ZP9-]H?8?Z"*;>.:F%]\
M-CIJRJ6PPIJ5IC<;]&2D% 47N$IB)_@2308C7ON= LS<L5*ML=^9^]@(;* 7
MM 2,V5VQ:"]R>G%3JT3Z>L9-IOF4.S:V;IG2/V4&15Y)X8J)&G=?!J<$+!W0
MPWPV-[SUNH,T/+7-3NH6<M7J$)F!RO])/R1[I(97M+MR0GW(UK52>:CA\[J0
M6'30<N][)-BD_$$.^#5UC;ZLZ'?C 2$U'E,;1#36_)3]H5</HFD.4THW87:D
M>58]A>7$TYE$PF !!  DF0"(122?#N3-__ULHGY\FP (.@"M^7.&(?5[>Z3.
M1C9?2Q^P;";7LH^_1B6_@Q.W:D(SP]S*70.\TQ_YT/](;5M%#F9]*O\2%!-I
M^B5*2[Z*R.AQ/W<N@+C-Y<%\VD'^2=RWLM8[2BJHQ?B#D'O6E7%?"M__ZF.0
M&:<^%Z*ZHRXSRW0Q4/'VLULR.:LB5L(F,J&FQ-79Z2) &(A^[4]?ID4C;*^#
MJQ_Q.PX!'>Z=PR*5B&/:I5ZK&UOLQC*OL5^34V'>K=+@SKU9->=/P3@(-9M,
MRU1Y S/9"*QY6$J#6 F"C01PQ%G:FPWXSX(XF$<J:RE7GL666Q_U'ZF==HK8
MX/L4Y29/7B)YF;S;VF*,7YJ'#-S)LW#<.5.21P>OL ,[S9MVFDIU1:*X13\8
ML;<@6/VD,[AMB)@Q_?+1V7[0S] ;AI$\\@(SYTTC@;QKX,L;/2F833_GF?G%
M,FO;@ZA<OC&%EQ"&_*]J"L+K 5XW1B7G7B3%-O,D\SK3OUDE,F'>**;2\7ZU
M+)5;;PR#>T=W&4:8\;5+%N4@CZ:KMR$1'/<(@/"PQY&_9'/AEPP@T/R[]:J#
MXV<&@H'?736NM;S1!MKKS=J78@[0N<,L(:.9!^R<@VX_#Q7]\)K\D"G]J\3]
MM!YJS+F_>+8&,QC,NX!?PCA_3Z$GELY&A4VZ&.X62NM>(!NOR2?V)7/M1WED
MQR<)L*U'V(>7#7':/II<<*X?/!)FU$JRGI17Q.5!\C8"8'%@PP6AM.$C$!K]
MOD<^8%B$Q70C.YWSH* @VYTY.CYU6C.O2C]ZNK]V:U26?_RL4BSH6^&E 23C
M_'8D 7!W%X0]OT*5"O O/%\@[!?6%"QZ DI<Y>2\RBZ,CE>5H=I5KV*@C' \
M:/E2;],FY#H!$'-B=]!.A6% X-L>X)W-5JZN'*E^TET&3RW&A=S%]_W&]S)W
MS<1@GK*#BSHU0R+78B\T5.^P3<CFCB VQW!XY9@\'B6CEAK,5580SE@!W6QQ
M*41SS\$A]+_J&8EH*/EH^7L:[4A;1K*K;>X2BQ1DGE31V9L/W.)N7H0DV6=%
M5E!(>VG7S\R"9V2I:'=]ZS/7FMIB>=YQ9[ARW2D5*)R3S^9J6ATB0V0O+1V)
M!?*U]V06Z\.UY%W<<IK83A_DJ.GGC+9.G.NN;P2;K00MKRR2PH/> %=7?ND8
M>M7T#'*7+*:(-N6V"G1\;4WU81PUOC@!9>R/ATR&I01>,7)?Z)%"Y!)#/GM;
MB8_=FL#<;)E:WHJHDIE:R<QZU5;A&?0I*\,RLU "*&-SJ3!EG6-7-W%GD4Z!
M*& UK^HRWO3E!6]>\] B/&L-.5ME49SFE>W#!)?LC(2RL,WU-\^Z786YC/D/
M^?RXE@H!$$0>DG@$BVD1\%C:/=C;+8XW4ZA-]K:H6QX$*-D:Y*7G"LP6Z1DG
M*!AHGHVC^,>\;?L?9-6>*!ZO(+.&EA65EL54FBW<5K^T-@NM!(%G3?!DUM;T
M,S6((#SEJ:CFR5\(K9"'S8=4^M%6#U9^4C\(7>LS:=30(ZX#+L2UGZQ.%K,R
M?"T:*0./$0"AQA0:[;VE?AA) @!P'GT$?X&&KM+C M.C[+0@>7O;](VSPZ]?
M:#T\-_8,AP2H0PLZ>M.28,:+?9A?AHVE-4W<;?958*-:9\YKRF\(@$ 2>]9@
M/:F\<9.\]^")6:N O)5 IM1!9963=9#', YX6&,M?&B(!7\R"T&(MU]Y7)J7
MH(<+<#]7CP"8MHGW,$=\VT(86'B65>[L#41(&H>%+69,G_FJ)3ODWFL\;&')
MC? O3UQX*B',S-;M^2Y51_YU&.MJ6.HK]]#F33*CCG(_;8F+XDO+I?!Y'CG]
MZ:^9>XA3FS&@/1R-'0?NIG!BV5*[XV8XH"?R[A;PD9!B>E067C4F#[OI1@!\
MN=/DGM=A#3VVEQ) 0T="U+&;5BB&K.6M-&WCU_7Q^D9^[UVZ;C^F*-<E3XQ/
M7>K(+I4W,'$X+Y89,\GZ89_2?SC6D2L?OA,HF.#Z0_S6V7*:V([[SW8Q8MBS
MH_:EV#"XWZ3 "W J_:7?!0)'&[ESXEQYQ0BR@N%XHM4V.?1+OR6'I$M>BRR[
M%%5VP^[[LF3I?(V1\CK,EDOQC_N@3^+O2^;QE".#7!.4ZMA_6_;/6\]G*KU#
M*Z_()] X9$$M!Q4+AXA\9?U>?-OZ%9@<*9#</YT\K!U@6NJ4H^OW; )Y/G?J
M7LNN&7)6(1^B>RJ"5X+T75O$PZX<?#0H<XP,IX9GQ'3!67&2>!Z,>O6A %YE
MDP" ]L-.KCO: *,( %?H4 (Y#G@1@%<_J?#K,G>+_&(F:9:T(*MAM,!<3RT+
MX*]2X%"5,V'C&RBHE?2-[Q^6F-C8RU@7 TL<%L<OR^7&<,V6QW8&-]C&-F6+
MB#Q_"QU1^.[/=?=X_C1ZG)-'!6*%/R4 2)>QK2R[N5GU7Q>]"("W_@?Q;4Q6
M:!9NF,;DQG013:21J'J\LNV Z\OAL?<F,EP?Q01^%WR(L^]WEK>>+8!71'HS
MBOF9U-LE? ZA]H]?[3)_L(L0@SN*/[:*MQKGEQ/G*%P>6#OR?7V<;&W,GUEL
M,#\B&11\KFCY2$T_K[5,9S'Y4M>PDK;A']D;)DXK(  XJB$(/N )B1$[HO2!
M!5 53+,,O#V/_GKI?:FDOIR3."<1N]6@G"3V 9D\N]Y;*;#C9!CW\+A?J@6V
M-(5Q,EPWMOSH"%0$"N264?W4=@H0]_-S*.LQ8PFPX%2+OAO\'H4VN=G3+NPK
MAF/<&5X/S4(7<7;C/V!)VG-O51\:I4\A;R2NR6]D-#AR,I&31!BQ\8>ZBR>9
MIBD9F?^H$')TG/95-#<L4%6HPK1M]B0[>NV&<&7IUMK&.\=LCS /\K\7@W&7
M5A.=Z >7;1FF\/%IV=)CN#:S+7<:U%37D.?5HXQ+2JWB5#56TTCVKO3;G5LL
MI)SHPTI@I8&%*L@35#)]*I<0H';@=J+8^1-$Y:)PB_;3W)S5,"#M57.(7M^S
MYW7C<%[N-!GNI8<<+D[[U>;F K;8ZM$"Y1?FSKS-ES3'P"C@FG\ROL,#LC6U
M._VO;%.\IP3GAY?$%"PHB?I+'7=+B>@6"V=YO!KE?,C&&/\BZVSMK=ESIR>G
M7+ZR/Y6L&<H=-4JVBER"KD+7[<!/I?IE=,ME<2='D,/>B.T\&K#:$II1HR'.
M_'J8ZJ,#E[X.MOVG^(J!(U6FCT2].@)CJ11&(+G  W]8;ZE"'Z),)4BJQMQ<
MZW +[H&V6@T6[GIS]M%,^:MU-\?*]_N"GJH4[Q\:&;V_/=_GU7/=KGUV8^7A
M<$[AVCH#MM[[JD@L+KK*7;D[T;%)6ZF95P2 :]IY6)'Z?X^S7_]Y4.)&U[S7
M9;2^?V@Z\^Y4JF[)9/1E30'G11 !H&D_M.)3P8/GO.1A5T;3KC"[\S3]$,@]
MFI-2_"FU9(^BCT3P510(-T(R8.,[/BDAYWBU,C3)LG9]V->+X"Z8<^N,$9-0
MWS*ER"P1=[4(CU:=DOYCO23=6V"M\L8[-1 &OQ>=_,(9S8/[ZNM@",K>^/!K
MM52&/7U!YYVN]B*-C"-4679*#F.)3$>\W&:%V]-;%-\-DE/GSYQF@*HO0;1R
M!N[1<:GUNJ6G*M#W! #=J2Z3$VP:467>RYC,G1'!8S)7!& .*&3"Q(=8GFQ\
M;6.A>PEG%)A_Y(+E-J)\M@-/TN0S:Z4E *3\6RH5Y%>?\L!I9IV:IW*!OJ[2
M5[D"]EI*''T.U0@YBBB8Y(R#_3H&[>_.[Q6C0;B$AG8X5Q&X_Z17> 7(M!U"
M*Q*G#^)%\H12EQ, ?JP9H=?^*G!GG@F0;)4S* M1"0+'\AM%"'@U@]RV67SE
MD/%%=CX"9FD6CRM[]'(^/_#+?0P4NNW?U\[NQ,;#[*EA;M6J91!; &?T/S]1
M8H8A\A$*CV?JOG('.;J&)]T'P-<$ %4/[8SZHHR53(D0,VV9(M[;%S+F.U)6
MT,6#<4R)MDYQ3<[>_,RNZZ)OY!?P<W34%_1,ST.7^\WQ.PM6J)JJCI*J]]-T
M*3E3]A2=-R=4G1.HGGASSV4'F$\.X9JXH#36]%]2#)-UM8J.=X;KES@_@/M<
MO65UAV@NGG-=OK]G2S(-L@FVBGL9%Y%9VK1% .@B]J7;==4T3B9"8(B,L'_/
M:1%DAX.($[%_H;2?KEP83!-I->92R]#F'S?.QZ<,^*OYO4?S$'-O)1G_IWH=
M';;ZZCH"X)!<]WHQO9*SE?7D5?'B:?W@L++X,!,[@QU=?WTLC1'G)Y/5;AY9
ML;G;3@F,>L?,]JJ);SR>7T@LKJ()MG8BNV.0=D=3+[V@?J-6<>?5U<K L3U_
M^:JI\?&3M7!&AJ,C\6GNAQXYLT8]&K9# <Z7:75-11A)+.A040T_\52;%10-
MJ8#1;N:(6Z& G0^2QE7/^@X:5W/91\2)ZCV51#Q%I%71;R@W23AJ\K5H':WQ
MCKOGD$R%3\.5+*C:=+L:?"OS-IX$G5.\@TVR<#+W*:I SL%X)EHTI8<WXR["
MU)EG <!/:U7,O>8K%9$I]^=X>>G:&,ZLK92,Y1U6N&1Y9%0T8%%"4!@H!UXH
MT*OX]C_IVO_OR2OX4!>O:DH [(83 %BRX&O":-T)3F XGO_$?GKBN'B$\P[:
M#:_V@0#8XQ7&QR6U)14?<J(9UQ*RBG$^>&E,]0A>P?^+:2S+K69Z#5HD(Q/0
MGT& SIX=\'!X('!#//Z:_Z'W6*O)%LSD,B#GTT"<>=(IY,MER&HW3F!5:Y%<
M(FE[Y*?M)S)'GMCF"#:D0>N3$H5LRN38) #)2(FF9/G7^?1G>P'C.P-Q<W>:
M=T;V%@#HB@K_=*NZ,>$0^)KNIMLTLS'F;II*NY#'\5TXNYC ,/1]!+]GMIN/
M:^N,58+J^P<^_*IW:G/.K)*#X47.O8IA&\"$W'N+C^JB:%9$SS+> KNFU5,N
M(A9ZH;>+X_&3% PZ!2<@Z)9_P_0NB]97Z,FE3O%/X$V)J!H+YSCK<5T_SS8O
M!D>Z4HU?SA$^;&HUV;'[W"P==?>=7 Q2O]1LCX7D#&TM+_?EJ"_H6K?ZXFZ!
M[H"Y1WC'A R>UY@**WQU8+?6!W=C4MV'.ZGB(L/>=L5[F(UUC>M;'K6X5<X&
MSTM+E+S_NH+A<K30/K_ [OF?MU-1$P"VSK>^#OAV?WOPFPJ@RV$&/"A:R/G1
M'2QJ_5Z([?>F1>]1$#[V^#!Y+8]K!I0Y>WH7 5G[4GP9(0@[D0_\!FF&S"9=
MJ@#/\RY"@/FG\;4%L[N3!HX(&V_IZWJMRG@&D*IJ)]_>8^BU.]YKQ>PC^\/\
M'NYIO]"T72SLO>\/-L9<>[C?5>6^&S^*A^TU?>P<DU$( QG=*$TTB(=CJXZJ
MPXIY;[C"RO*"MR!'MVNOJD=_R(DY8@"^DEZ&@Y=&=G*J8#A$400 7MDW[_0$
M<F* * A%K^,Y)SA\I9<2T#!55]S5$!-=(+LK;ANUN<)H&+=C.)YQ*/<>RMD,
M0NL?.VV^H5(CX'@'BM*T.+\*& X#"Z &%:C6+2I;K8QM2 #6&R>)R75]$#(*
M%0P,*D- 5XO[L"2Z:(WEP2"'+XTU&AOJ(Z\_MG0&11 M$JN0>+U> EP+I#@J
MBBJ==3(V&3%S:%N=B&=)TI"9GS7Q*[L8IEU)Z-06UA[)>C%2T=U2%P\5FO1=
MO(%AC;1;ORFP9D/!*KO*+@-^MJZD&;^-O I-7%DTD>$OX=IF%>=3NF^QV'GS
MN2UI)K>'&2O&[=?XE,P,R'^TC:I!1,9ZG@P967F'E+GM]IG*SLOI?BT;.;@,
MR#:)56+96;@-PX_]3C-ST<--60/,+;RR]WR87Y7]5F(V4\+?N-_D^.J>N4+J
MFYSRL6DL)'W.:Z)S.+9QVZILWL+GBEIT@>(6>.*4!D9F)3KCD"117HC]* :%
M57R&36[.0VS1HWWD3@4&A**JF+!&IEZR$P#R(==<BL/ !BB&<R2B__X-$9:-
M=7"A(?D[-G_]GUZU-E:-PZ9WM"W*M*@X3&=U8DR.(1MV)49=6IDFIX'"25=C
MWK48(E[4&QV.\\FXZ\!P39%JX+- ?(.M[>U6]Y\^4#+MGI!1.?E%/-&!#-_3
MZ4%G4XSXBT-H5 BST[5CW3LUFNI:GPS ;LRRLV* =J]WC:^9YL1BW5E:I\:+
MHA($D2%PU;QT'$E'JER#H]>3L_TZYR%(AN?FJG34J?I03M-3RG*I]/K0I]+Y
M/P.X*19VWH:&6+*],KZ3 A)OMG:Q. )EZ-(;:Z6: ;D/,+"^K386L$!K+DJR
M(H"%:<5#T'WP5[5&3ONZ05)IQ3$UVL_ULY"?[8>N;I6QPOV%N(JD(\G.Y<*U
M4B-C+<-<)"8W$@7#JUQ9&?H!DF7R@ H->^!SQ9XBCE4@[T!'PL#+$&T"X/-3
M76:<[H5/R!M3X#(!, L_4F-%];9G,8/5'%JDIO9_LE/-Q]N<KD@KY5-Y.A>0
MF^ M!R>!I9<AQWG,FHMM"84P-6QP-V3Z&*]42X5=)\='\BC\_;#S\_=_@*X&
MK5"%1\;6I/]X<F=%ZLYLM3MI]/5.ZALS.[^*?W^<DO>P?D31UN-D)14266N=
M7A<I;%1ZJO37"$YY!121I.'TFVG%=PYEJ3IT4TKJ(&XD/4E$FBOUC="2[SOK
M\7PMNI1D1%,@5A+O@+*1:S!>=18:<MS)PXAI.W?A'Z _V_R(GVOAOY@4<,A6
M:[!]VL]5'?Q;?5#N,W<V22QUL=;- &FH[RE&&,UX8[PLJD9_[(<Y>/$DX:L2
MN[\VCKV0)_872P![<98;/[=[6:VN>VETX[XR5ZA #]1D5C?C38UU9/63]*I(
M@87SD/*5MG_'7+?:(3171L![R*)@G: 54$H,D!BV9@W!XK((@,?OT\31>6<[
MN*E#2"<!4)^W%@_[7\R1Y0G_!7.)]S26G7X[R,'SU!QJL'&+LXN#!VW&G59!
M%,_K J?O>O.[VL85/<\<P$7B*6O<L4_N0(_4I*O2T% ,*H86@#82&,3+(ERE
M?NQ-YI80 ,G<DRVZ*V[1U^0?(@<[H*VOZJ*Z@MX;*B3)2\^3QE:7$FO\E&FG
M\/Y>GQQX[@:Z<JEW[CF:#5DJC^1YBH<( '6LS3(B?+%]YHGIK_;BQ)F NJ,O
M:A3-AN<4W\IRU^[(W&]Q.@VNP:0-JFP%2? %,7FV'OCM#.\WZGS^AUX+,4_
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MJ5C.U/2H9R'&>#$/\\.0?\76#V+R16L0E[A' -QQO7LH'+XZ(JAAX$Y6:G_
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M5V0ZL_'J%:FIJ:QX'HVP_-.W-(CJA*H>&=')NT3*\5[=.ASZ-DZ1-DJJ?-;
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M2V]R$]+[BLBBG(/#Y$F6RY6:'Y,$/62%ON@P)LA@?DA"ARY3%N'T9#:-L-:
M+Y+(Z[E+@ BV9*:H3(G8Z 3+?99)(?G<1-X^ZX;6;T])D<H_]J>L>KFT=I32
MM0D<C*6]# !<X)FZ<^#&]0[A^7'K"[9%<K-@OZEVK&T@J4MN_^_TZ<K;TQU/
MR5RV2^4DA=/=A$:^V8]1*ON+I4]65ZB<(!>R6=OQK@$4\B%J#K ;>Y:O>_SS
MQE*7X2BO 7F_%J4CY+'*UP E^09%QK;\Z05M,K4?MYEQ.BM[V9MV14=JK74L
M$;\-6YMC%Y7[2$=)?J%WF=;K1'?&&U,Q%^V"?[](4+*,>K-%HCFS<M-?[I 4
M$3/[0H3+$^&&Y+O&8/" &_7I89)T*T5W!!+FL5VVX7!4-_$-7JF[N[<%/OPU
M;;.D0";SH@0CPU'E]WWZW.@K-K\A@?=YDPZKI02)S6J,9"JTW[X&N>0PNI',
M,B'-?6$Z%W03O&M!"88.=)M:5@=&QJ9MD;=FDN[__'+KKDJEG$<0*G>5R1S>
M.R!?9L4E02$W"CP\'=O*E<@";Y&[#CL#^]&R!84[)TQ+.YKC(,XT2>96)YJ.
M:X!@"FI3.RXM$ ^P3$9\[VY=[HDGC*W'0W7+X5#,XB2,E9+*H,1MZT@DB]1*
M+"L(2W"547A'S^B$F2E$XX%%)U/,R?32!$$3J"!]08]TD&3E> )'M5I$J-EZ
MJ'R.)#ES67<@DGTLIA+_&A!JV%Q%Q[?"3C GZ3*=/I&@B3ULP@X>2=JXJX<;
M.5=T'0R2MQ(!25WA$;<4/^@F$F_?Z2EA< XOB=DMSL1>/$9?5(],24J3C!YM
M,O]Z6;,#.LMZK9?H#0W!^EX#8A\BK\ WDRSO5&CC S+T9IAOM&*F_3_KR<?Z
M_LLO!/_O'P3_1[WYG5?C&]9D,@R$9!QLUP"+UQHCMW]LW_'JGZFYR S75>0)
M"?+E.?=56V2AQ7-CO0VEU*-:0L.\/6,6-*X!]Z\!PQJK9M> "".LVM^8:-)+
M\O[R7_8S!(/@JCVLYQQXPA-Y?-NT1G@Q)A<[R'IGOW?,7Q;Y]0\K)JE>2@I<
M@T\PY(N.?WV1;CEQ>QCZ^ JE?(G,X;S?N%EQ.5="?7 -B.+IB[Z'$)'LW,V,
MI.SDW<=E1YTQX7C_C/W+NP>J?Z9&RR[]1VIT!J;BIO6D\^IK_LU]N)?K_]W;
M(\K?4AL9? WX?<.TX6=,]K%G=G1R3ZU7W:7R7LI< Z)_E$<:->K6L^ LI4@-
MX_W0?Y>&QEYG+9JDFCC'H3\_FN%_GC'!H"C\<N,(;[8F^KN!\^G$'C [$M8N
MJYPSL@LNVLNS_#K<D#LFI;%?(O&4-3RWJ@NNRH@>,1-^\(+O2PPSCR,! \0'
M)E0DT^N/#$*2MT#S. MW1@Z0\SZL+6R+,2V8S[2^.!=1.N7SP]M9C@"&UYP#
M[4!4#T[WN%*2EAO"AA[<JQ=!1L6^X7'UJB5/2WKM\[WUC:H?)+2SX"BZ .$8
MA<K9<.C42GL"V6B"8P69SWY(+Q;N;^Q@:J\!Q\6S20QG.LB; #E.DI _L+H&
MA($W%$[#F/43Z],Y A6/ 9^R>AH:CR558%+69Q[,OSP?Z'ORTRIZ!8I]P8C[
MM?E1LDHB)JI,Y_0+LF[^O/'^H-#$;-.H 7F<Z,W:_"U(@L_^8\=I_'QOS-[Y
M0*X43K/S[&,=GP>F_ K2R(WS$-M/PBC-S%PYX'3%HXRM;RDPC_EWL>@Z5-%D
M<3J"$^'Q%LO"/7G;:U]VC(?6JK3/R\8GL'87&?S+B+45I#)Z'[GNNU\)4EEJ
M5+*CYP1%3,8%&%4VZSYZ]KJ[1F%@OU[;M\W6_=RKZZ3L3DA@(2H"9WK1Z&J9
ML'?UT3Y55?F\WJIZC*XIS]>OV+#?PL4R[[L]D^?<:H*XB5*\@./K9[2!,LV
M"4'_BB?YU*H;,W8X^?=-OY@7EQX(V3?Z6Y(O<A-H[2,#K@%5,$#QEG_>-\?-
MY[:URTZX^G3O^=-^UY%TCD71!6Q3ZC6@E7;L.8>^OR)8>.$:0.SW<"$T)T2Q
M4@% ^D#_E7F!1/ZSR[5RGX340QM@IMY<"LZR3+6'5-E>YYQ>=-'3+&*1)^G@
M@R+7_>$O,P%U.N:[&CI.5V-:<UEOTL"ZJ3ZLT(6+3+]W22^>S)2!R=?O'\9H
M[U\#8K(.\> WBOH,>9RYVLA%><!P!EPC[[^!P(?@,']-DG]IC_QG\Z/_TRI9
M@)KA9E1@6F"4E678+KPO]L&5+J!"M+YF3FM(J9OESWY%T!QO&/9=;@!/WKSK
MXN82K8][A1HIED-Z 7BA)-$G?0 "A_T-AM.>PT'U_U%6IPB=_$)(B)!1"J_]
MCL34FO.A-(I';E52]<F'W$DV #'@%B(WM 0_E]J NSKFG+:R=3C!.='-9XOW
MB!W<\F,?BCV[!BSWSUT#&(HOQAQ6L4RX=U>Z,8<X_FO RVM D,R"VOD-G'2G
M(7'2\N,E-\/#<$A2/(0#=@!7O=\YE2HQR02]?DSR^BY@+3,3UMD$_8RBK8'-
MVY&T\5B,<BTF:8W+($1IKM;"XM!HYD5XD$WB\;=4$SC0Y67&4S>A="T_#-C[
M%W'<_F7K!5&.#PU;O,Z*26]/CY]VWR&%U-9759U-%4--]W/>GI:H^ZXS2Q3@
M-.RNN\Z Z]^\X[=:(W8G$=9<#N3]\ SWKK04#Z*O45TZ(<]<GXW)J3Y4$A/Z
MQ1^>ZI0TZ)(Z)$6_+D5;1XFRJXAS+.YA&*CUIS(+GF)Q6_:Q'*[)\(90<JVX
MK2<O1YJ]R1#NOS=U@1S+R'?)N,M3O[!%0FX4(:G**P58?)VVK)8A ]B-&JHE
M\AP0778M>RZJZ?O'W<<5G)*^\#0BR6;+O^109.],F_[Q-2"+ 9MR8]F63H9.
MBN?ZS^2QT>#_>' ,^X42[-< *>ES 8]K0.?Z?SQXF1-#Z=ZS7FQ_!LWOIPPA
M*+V1LLB'+N1OGY,;\UFA\0MY.>U$;Z^:E(J_+%TQS%=VJ9^:L8)?1CU_DR%^
MR&EBL(FY['D"?" A %6C&VN,-?CA%O]*8+J6&,KAWM 'Q;\=K"E9/,M8FA"1
M%".? \Q^\%")6U%>IWCL&I"R+M3E%@3PNCIMF7MH(TQF,FUP-]7#FME,J.>N
MN^AG5 )'9+PBZL>G"<,VG7 -S2&K:N"RLX0DNS KG6F%+O*%G0V.9!B&5K#E
MG1<P0MD=QO;R0U!I=TV8]<SAD?5\DJIJ0HDV VDN7ZM\UAM]],>ULP6SA5QK
MQBX\;@"6Q%-9>3^G*_4]@R4YA)^$WT#X<1?PI/RL8^G4*?THDRW#8 PNWE@S
MQ-O]+(A-$UFEVW0!/Z]Q=0O[M3:!O+G;0C66L?98:ZA[O!SY] ^>3B[WO)Y<
MYH0@=<F2LH\<[6Q%5M6&O(>B]$\3TQ*B*_1*@ GB)2#7ZK!GH:2T"H4_JOCN
M_V#KY>/J!%A\3Y)49$U=L=_=<W=C^10_15M0\C<N1X-!O6R&<BL9PBU]?@;9
M5KT,+@E[1AV-"IQRJG/@-1="=:BD!06X_O"7;N="3+#K&ME;,](/SA+C\699
M>8//KB0W,QE+JYW!G+S=C+KTB6[J0'%D?Q7BG?XH(Z#X!P#P&^ (N!T F,<S
MANJV%OYW,>#_'<E8SE)N2/T-N,X"NY1+@@6G(S46I;\<QJQ[RW][IFQ'UL+6
M06'[-^>$C$Q5/%Y1*B_!V,UD4Q&Y"DZ94#1,)\/=H*S*@I04H\V\HU3/VL&<
M!8[UJ'P3N3MZ#;A14-VT@LA9&_"-@(CCF@)W*]7=7 G%-6!(71.\^^L:0+G9
M@9S-QS$,/?*U^6)?+JC/D)BT,Q12)50KG0W]YJ[S=(/AZ FWR8A:*;(+TZB2
MR2F*HF=6^,0>W?=HIW,I4B^-[E,%;&+56W.8!SV5*;G_1"0X3"+B*^>L2.Q-
MY[V/C? P-&'TV[,GZ^8..V0;/66G58/-1E,U\%6/R[C<@R:1K%;;87-OXS?F
M@R;+E>E@] VP!=LX)NO\8Z<82 2\<@(!/]EP^7H@ZE-R#2"4!_>I/<QVG'/M
MZICK(V"MNT<CB4C=A.:!:AV\C$:,_*%"*A8RRB#YO>&U$;?%S.YYAH?SP>CV
MBVW=,](2$8#CX_,UYR^3G!9.?\RC.<?*T;F*C<?8&(Y )9AVS34@4''?T5SG
M "!!ZL& BVK,#S]C!P?A-.@IETIP+.==50<8V:=T",M5X:[7&'T>/.DO9N?#
MS6!2Y"ZRGX0&*XAL0+[0.FL,$RJ[^R"3"[5VFG*91UWV+>6DA>$W^:;-3\2;
MDIAV.ZDUA[9TO4Y%Z>"+J\UKP)>]L1L7MDK/Y\>/EAN7KO3O@A<0^H]R8RO$
MN9S8LWJO5K?%R3XMD^^95->E;QP=.<\XSV(.8<>7T1P-Q1226;Q"64)E8'$T
ML.$H*R3!LVGD78"5.\(VR7ZXLJ'_&62RJ[DOS5(&POG3-W=99VL4HZ=M(K_#
M(L0MJ%LS(RC*)M:3BM$(X4'4S_DC<@9#L<)+:A3&AL:F:.O];C/>%!IT5\\U
MP(LJT-2 $/#C&=&'T]6"#*7'B8G&J?%5B)/#MT6JC7J4+(\7=TNO)*;\=<A]
M560<\4A1JX#9G)EH^=H7FI+W6&ML=+^;2*<!D3@J>#FG:=S([C4@1!*UR@8-
M6TR_&S:4]'K.-?<6%</'O#540S7*NNR"/DVQ('-&[>'970I7])\0#IXS27Z)
MO&:LK+?G7+CTPI6:P(WFQ@*S]X16,K,7+BBQB1EZN :F&V,MN'D,Q6VI8=6.
M4E9;KS:A9WHKM^CH9UZ<)1>)NP5WT_E];S5GP 7NC# DR3B[MS1[)&"7KP$R
M,D *:;:*'LX3L8I( ,-]TS7X5!?FQB $@!EES8)P@O[@"V7A=O!=(.\5.PV8
M)-I7'&J)\V.\.2%([&:>99VEY),LM&+9-H0>OIE3A/OTPDEE[N]Z/(O-+7#\
MD0G]*13Y<7GT8_EL%TI3755SB+OKN$P3;0B+ONC&HKV^\#7=W\4+7P,!6F,]
M/]S;Q5M,SYF?ML@U"N?74M*8VO:$ME:21,*V72Z[I94#2;9,H\#SFL? N#5U
MG!!0[SQI]:!Q9;7$S7R^G^=!6(X?7"_^3A3=Z,_SGN\1 #2FJL=@8+$H,AY"
MU4&:Q&C'NM\.<ACL+?CJEK?&MC"?!GR<&7%\M%6TAB3[>,"F3.TKSU+>62NE
M_60I\0.EBP#%6N#=V[47>J8,4SX]X4DH^)5_"+>;WHQ;NL<0[]:)>$6T4@Q]
M4I5YK_ W*4\:!94IJ>\#H&2"AATD^T@DBA+]_=1-/8 C $!U Z-T@!L5QG5"
M@K=_8 0.O4@UHOL)J[-V.O5X#/-ZX,[0Q,K=R1QYZ+(Y:"S(VWA\@UUE9_3:
M@FV#R2#0-2!^[N!%Y4$-M,S8^.V\'\>D4=XW13<V_6%YW+FVE<Q'T=NN,=7!
M%H#%A-Q[S <"'C5QAK!S7*A-=0&J5<;PHGL]:^6B*O: 5NS8G_E/6ILFNIMS
M]O7'Z&FSCT#8VUH^CKQXIV@CJLL94$X:=+OX\O'PBH=#!6+ .SRG1!DMY&_Q
M">'3M2WUXG>R%-L^5I,H5Y5?_!'KM_E+V@^7>E)T*(ANO7_D>AOG6%X6>(Q^
MJC 2U4>"/4SXFU:\VNFV&:-D)"WGN?=;X!I 1GU5L7(#P$_&ULW!H<@6I"B]
M_X,S!ZS:8=C.R6IF['\_"X$@VI=^OQRZ8&14"]/W'SA2BOS:%_X^X!OY]XS?
MS2?/)K+#B^Z7\Z0U)C1%^5O3^S])+V)G+S$IL<E:GG)9@ ?#Z&YMZ2:K1W0K
M]V8S$_@Z- KWN83.A.]OM09)',\O@D8CQX0(_/6GUL=J=G7N.Q=LBI:8ZAF6
MP;;?'H!;+I+#;;G+C@O]AYCU[LSX=N6VG-O6]94''+[^S7RIU3(:Q2XL; &R
MG0-R1E"HZGR$"+EGG"I#,Z*089F4=0?VD>.ZLOY#M$7\G'39F+N:]3$ B+.,
MQ">  @&3A*2LDN\PJM_[Z4=VQ,^5Z-/W@T/@A1>CKFGHA_8#-):7I,&CG5RV
M%BY$H>@#P? Z*5-"MA])@U3M:E-R3A!VX3V3&4F*D1'9U?>2I=ELVN&F.Y#4
ML:DR-W^YF%8ZXJ-6Q&-=L4A_V19%3GY[^=_6#]AG:,0.B3WMQ4<769]":'_L
MEM:79UJ8+7"XCGXNW;WT.&3#OM[GPC'%S^D,6SQ!E'WI4YVZOTGH]N:U",<Y
MAP*'!W]M<U<Q!41P0<A3&<P(&G+C%K,?B>Z4='$Y(-$*V%@='NCKRJ<_L%!]
M'/E$AURAJ^W3\CL%'(56H)#R0\K!?E8[+]N;D/?_K++XJ4[4G#Y] KAZX]7A
M^QY?=GPY\^C8#QSM;Z=!F6YI,6Y;=&I0J<7)2/)//Q'JUZTJD7++;V+@](>J
M<' D2F:>GC7L7=#[0#T]VI$D>4D3,M$/C50@O9VTE5P.I-)[W8\( '=1 V4!
MS1IA%!/L0VTL'&4M(+EA!/BK*)-J#5WML)*C=]Y,*E8C:)$7_PS9!D]"U.3$
M-L3UA7-_B!=2]M3Y*O D_C7U]Y-[P[\ZF0'%0E##*+:>=!H8W'H3IXR-A,K!
M%.7RAA&@&16K)@?LH-)9RGQO!46SG5.!6"<8JO IQ E55F_V@?@>\5.1*44:
MSV=+HK2>WL4)-J"9^"I<D^UVFZ:;IJ-[HLG$R:&\**/G-:!-G8[GD$:%GUKO
MTX3-YB$_:?!DW" /=8?+(2MK<*0K^BHS;2TB,75,W@*<"IQPX<6$1\0K\:G)
M\]2<"U^YO_)_[&EXVGK!W9%5^IO1:S??A=IS^2%Y,[[O]XP)_)(B_*^=[Q^I
MZJ?&%0F)V6.4372+X.,=WVV<H03WPR<<5.BC6/ZLV?IR+V:%C/0RA#RA4WN?
M^?89/*7-@5K"S2/R+HI".>3#@LPG_/M3H_FABN,-GR'ED)'+!!SB>[&;XT[Q
MJT2:QK0J8#@.0<G5P%!^!M>!CV&-EM$R']X:3;UN[L &]\8.L]V!*&?Q]>[<
MNU6F7**:2"<AB4XZ]+8^\ZUFURS2M<GW8:'+J<=)2ZKP4GO2:*1IQ;0UT4">
MC^:J5\JS$HI]J7;IZE:+@_PLS5;X9-$=KI/S8WU<+T0.#AQ?&<ME%3*,J![?
MV.[S4Y)F\"RX.\):4SW\(]TVTPVB7RE,7$QF_?VNZ3W4 V+A !5KAI)AWXT>
M.]NRB5TYYXMVG:XE*M9ZI%ICQK8I_J^8UFO ?N0ORX .[:[7<ZODR/[;/SA?
M4.O] +Q0H.C=R=^1A!OMK*!WQ2!4Q?Z=^?"CV1OQL(92@49CZ4@P.OF-Y24@
M4D[\08[L=X-XD((PS!<LU<>&XCKU',3R_@E0(OW'[.;</L/)G^7P-@W3 0Z!
M\*G9<: W#I&"\OCBJ]3$5C4!,TD6_][M?""&#S^G(Z/0=7._7^^_^$C@]'NP
MN7.9\I021+P\3' 78X>YG.++U4-UE&Y?U!OVNB:#ZQC>3<1Z=T*P)ONSV8M1
MC#0J'+S5[Y/#.'G.EEJX!(IL>]8;! I_BZZ)_!;9_0M==2I3SK J[QGW8Q$G
M[17=^R_U?+MWDY+\MADH?84+/7,5@D>4(G;(61:5>IM$]B.(-HWX$;Q$FR^)
MO09>$A-Q*PRG)<XD<QH)ETTXO&[7@NBS-9L<L2(,#4Y_;4):/.AEYZ4?;!KR
M-);.S;:N&,T9BZ.1*>1>X?8O'-USJWA[>APWH>GFS\+WRC0%H*I\'DZ*DO2I
M+%?Z\[FJZD6:FKJ:=F6ZB!KOG;^[BO^;*OY-%?^FBG]3Q;^IXM]4\;]$%?^?
M'/!6P/^%YR7^$\:D9*_E;EQF.PLW:22FU1'5"8RDF./WR<_/\B'S7&N%7W0&
MZ2E71O37$]H0^2R9FD\AUSRTEPC.ZG92M2VI=-82JOUV;"]F9\W+5+7RNRF\
M?!#6PQ.'XF5W4<K<8N,HLTI]N^RHB6<+PT*ZU/A? ^]U,=.WA:^FJ6J"/J.!
M7F/X2U10A*(_0;JG3\L%)"9*B.ZSI[O^C%&E+&\*Z71[F0(-15]$FT/O,UJW
M9<MR-R:.1P59#1FH*MRI"2+=$<HVD2'7.%Z:,7'J[3"4TO1B?RVT>HZ<@>S,
M_Y[#MS_W,MF9%3 +MVCWXKEBXJ@H/KK$RHD*J^:+:F*$C*(R=B'8BQ>R2FY,
M>FA-)3W=*O<K#5!'$\-X@Y*@^!=;I%5UBD7CNZ1GO\@^\,)]L\16&*S>[ 3@
M,9]H0^^;C@'ERNCHZS' 9;&?&6J?=HH]DDI4&JX!?1C#HYAW^UEG;QO>SMN]
M\1DD#'7@JJ!QF>IK?D6O@#)8 B:[X)L]$W<L+PL C6"JM]KE&I?8KO*OI'O_
M'$E"E,B<LRTI,:99*^<7477[66%-STQ>^ZK^M$;9E9QG602U-H1D]S)U\;=R
M-M1.EKK+Q[?!-)/HI,V\5$I,-AR:_8%\8CH@V$X9%:L/M\,9<G#9PU1B_XUG
M4XO(,PL8HNH#IG(^Z W@#O&L#LV#GD#MG)\$-&K<3V<[5!H_'H-.3L1*-#"_
M%*U92H$.O&]CPX\6V;[ITR@_?V:296^M?ND5]$33XW0P(?(:T"LU]F?\*79Z
MN 9; W;;N< .N!Z\6EZ)N@:D;NW!K@%JL8/!I@1CONPE0)7"A_O]5-JULR$#
M?@LS-2'6E,P)*12*FXZJ[(N<;TH9LW/5[%Q'AN<<S=8'$I?7J@PEA; .IY"]
M!O9%X'T0W' PF(QF4N@)KR 9HHAHVZ2J<7%]NR^RTI&JA'UW3$G'NB/C\^)2
M#@A'?3SWQD2LNE@I_W%>?HD:CLX-K95QD/45:[TDPE3?%(['K'DGO(602>,I
M_R^O3$6622..L"^<";6QI#(#U<5_<J8_SJ2.JTCZ<++X7Y%"#'6V6-A97(_#
M0:J[.VBXK@]EC"\E0Y3MG?*#AVW<JS+L^$&V'X)O9T2+B"P_*L7C_+HV5+S>
MF^9Z;'7,J:F3VUME6.#TY#2+U#;[R=WA@9516Z-QB!A #J/%+R#\AC#TT]6R
M;>H&B&A.6##Y]$:"])Z()K2U.Q^V7P.\M[ 3RZZFA&?^@C1&!6/&ID";^J9)
M+(3C$BZ7%]#IY,[3QK,H]_@.=0_,WX/A<YTY2<C*Q/Z?\2B2S_D#>^Q8H%16
M-)0%ZNGP5XC$HV7TA>Q>Z?'$O=^BC8OW6LD+O?L; +&4NT13A%$T%&NT,6_.
MDIMHWNB0&^:4R["57%(:"7EW(T3T3OXTFBT\!+<;EC55+%915+]B]6M,)*)R
MZ)+F(]K$X\@?_+[2\JWEG\0I1FEOU'T-4%[)X1 LUDDM,NV6MZK8VIO0<NB<
M)4",K\''JPUTT;J_+H-J#=3)WE1]F"\WHOFB2]0U2<#$(91(#M4P)<,^!&FX
MV.0+6W<Z"-Q=][QL<WR5XN1@F=_.?^YBPA6^K;Z/,\P;KDPRCJ0@R*03B](;
MVVAR77D!TX#!CH:HI4NUC:/D"-=7P#W]J5GWL-R%GIH]FW-:$=U>/!Z=1QV7
ML8SE>S/U7^+%R$A@<B_R;'IXB#&&Z^/PHU^>-L[YU.PEH *T4=<)8EY\D'/X
M!CD-S^;4QU<B[(+Z4V4?UR^)IW/'<OX4C?,*5S4 G'L?UNU"%!!_L2C?O11S
MBM@9H^6#LIBZ/3TUMLT8Q^VI7+S\KW3"HLGSC1VZQVY2(MFX6^\F\]199TVC
MPJVC>\9A]W@N5UB*:?W4^S1DM_I*4F(KI2$CK(Y<G(<QKLG20N:;KL3/@9?\
M"A000@XW)M%Z%G"[T)_Q!N.-GD=Z]N-&;FI%T/D=*3].V<K*>B"/)_>2(CD'
MVD#NWG1^XI4,TVQ.:2*47?XS6G8XXAL3M=6P8BJB/.W)+TNAH,Z+DN^9+SK5
MZ926?2*7Z=MN:U"+*"K:9_0F:B_.8VSFO.91GZ.6]NZ^0ZE"Z& G\55>_/5R
M1&9H)XY*%7(>1:XN71VB?KC$TQ,6"4G+G1?3%F.@BNFL=:^X8,9PC.MPHK>D
MX"7J2G5IH>++KB]',F5J6BDB^L?""H?S(XLTFI_\V[M]RP_K4'=?=Z^TZ>K8
M47&^$0<#XT9"<C9,M3P2X3BD0%+-_F 8EJ#(I'_A[-GHMANA1"MM/+.SG//V
MC^1X*3T?'AG'K< W<)49)9TE"IW:'HX)I8VK;ESP_0Q#LH2\Q%Q6'^'/31BD
M%D'[[/V#Y/ D2=43,Z^%1"XQ7W[&4HWTJJY/\:^#>CDX?7?[7CK?"BJSULE6
MVH_:'J^TWKPTX#SE+U%J-%+517C+"N7LN>^@BV '+4P^=OGMS_BHRY5^SB?R
M%-Z;A["X3,8JS"]6-5^6VX$LSI]^G. /]#9)9;L&/!)4D$MS<+ L+#7O#3_)
MT[$+,#-\YY7+,FI^1A-W1"WV_1I@F;9FK[&YY-!S,ZE,(JX!5H'+2OPUX7K8
M$=#A9?\@P/,^D(2['U/Q##$*XSK?SH/H?#2(%;Z3\GUE$L!/H14T/:5;6FPH
M.)9-A^P;#Z)4/2S<$W7 R3_/7J?G.?,<F;3"C%_D?QM.,?> ,+HR<ZQ\[:7N
MUE'?O!U9KA.LZLTJ)A*AE.L8K^L-/+:4>&Y$XJD5GFB$&)\K%G!3N^,)5Q_C
MDGCKRUA?&[S*"M(W%53V-(MCUM%->J?+\W;WOO$:?KWE2NU8+I52I,/CD3&H
M.PJ4PZ@-4G(JX7R5ZEN4%Z\B5;J+M5XHD]<]N!M5:-"^:J3?BU@X[:@G2*&Q
M!"'J'?.PX9TQABOYFB^AFF3NSH:<DJZ6.H;.$"67\&%>$]W4W!$'<^L/\8+4
MEE&CQ"DL"K<SQ2XFR(:@J^Z-6J;RJ5C&&ZVYX,<(4M'DK>H[C>$H/UONH?J@
M/A4V(]\7^5+5<^"EG(^3#I.NC;J'<9'M.-QOV\G,NB>1]G/I>=J,)%>]-WV1
M,:OC_Q]DW+\/__E [W! TGR:R75),CE+A6MW65-<$RC76UEX)7=N3T)@=5K>
M0V&NG)9Z4<();LV-;F3765F!(W;WK@%$@PKE C__%XOU<9C.H:U_T41TF]<$
M*=Q5-#%_K?C[3GH0?B:!1&H^):M5P=RG<N7X\(94Y7KW)P.8.?4P>VZ6Z$7*
M@2E&MS@:_"+4IE+Z2PY'SV=?N[*AE-8OLBQS_R_VWCJNRFW;&W\0%$2D!.E0
M4KH[1*0E):05I*4[%X(@(KDHZ>Z27))+NKN[N[L6:[UXSM[G<^]^[^_<\[OO
MWO?L<Z]_33[/9S+F^(Z:8ZSGF6.B#$<M#NF.YD2;I4/$F;I+6M.9NI_ED&<D
M "+EX/H RRF--$XF#[$L<Q57'@TG" ?6O+]+AI4 +*?YX#C?)M(Q4DO/+ UO
M@9F*>B[B!=39^?8'>5O'QV(8+LS403F!=P$KXT>2,L#;$TI5ZN4=O*GM"N8*
M?%>N&.<T-N@"9S]HG>8- GCOA !@=A6G:J)@_?-["("*U4+Q8NGF.>L1=6C+
M)6EO25O.>$T5>AY$Z:$Q'0!0=U#O \M)M\D[TT8:__(?E*?ELX&V".![S$4B
M,MM3S0   ^P"8&8D?5>G;64BIQVT,KH2XJT$OU 0*O_FERP2+Q[=5\DHI6"F
MVRKC7%82EWMG.Y/DM)J7D?/I[Z0L]!C(Z>0[R<7#5SNI*DA@C5?]N#9()H_$
MZ-[WT>9*=$P^@4PP@I?3BFG!NS-^9760X<?:GV4,O_D=54HGOI5L8'"J!F=C
MH">0HU$>TINU3,ID3ZPW<-.XE(\YYM'$F>[T=W$RV>9T<6+GH>;2 5B%U,5I
M)$XCZT%=%-AF<9%)\E$SA=V^YX^2GI"$0!G8A3P9IFG(C![&Q)GZ\<E)=_ N
M#_$P<HK3(@"](8>LNY[.EN9M:3U"R@^.,3LMI!M5S@WFTJP/.2.7[M-0UVE)
MW&0HK.D/M-HC)-V$K(JRUSNEK\V);0>RDI/\LC(+M"S:$[]0,C4#=V2$ %05
MQ==/,%I\FR?ENZ$F_J>#,I_:HF.PR]:&3.TF3EM,-WH8OW6PG#IQJE'.1*9[
MC4FN&)O^,95HWWERL],LWM#R\&X3E^UK%+%H9\,*51/@;9(,'_"@3[Q0P*H@
MDJHJ2C8P4F>EE(\5U4-_J/:E_2G1DH!G4\(SZC !6=>+Y_%*J$)O7MUOWE'I
M\7;+6S"2L:?KKI[0+(XQC(YFX-9GU"G.G U=R\HN&D.:O5GZCE=^;E.ZECS(
M0=I_DB?\-"B!OA?/F2Z%")GZ[?L>'8/58:H:I\<J2I\C)AB3I!;F@B^-2UR8
M=A<LA=\*&L3)(*=2>Z<]P_<HN 2WBW[ZOEJSYIM U4/08SFH#F)9NRVD0\>B
MR:+74R?B&6I1S'7L=V-LG">Z"F3$@Q97:<]Y!LI#R]\N2-JD5PD#[414U)CF
M2P0\J613);C@#SI)'3J'HI@PZR'NSPTFSO?,MAY-X0U*D]VEOHV+G;]B,APM
M!E- Y9X3(ET@-ZVWL *773CS/5E<X+?KL#NUW#C:=M=US<Y@OA$L:6D!_2#_
M9, ]]A_?9GY_J;7N5UFPO\4:2JS;<C:1Y:/M+FF9;]=-@IS V9P?];)MQIF2
M-+S%31&5FR0KH084@0#\A4:"?*/BS(5_=%EM2EK Z+#YS/2B5'*>HS2LLU-2
MG!'#!VT9VT;J<>UH8?I $MAYY)W<KZU!?U=+N2W8=67)+S1590 )O3JL;H6>
M#86):F42,#^.]Y)=KJ+?H@4?.3&^LHCSRI,=G]&>P5\., Y1$4DE*E%0BA2A
MK]B,@[40M>IC1!R;P24+Q8RYYP*.ZT3T'V\>CMYU<[6;?A[:=\6T )4=>)D0
MM43$/4/;/2,M,:D2Z!DO/1*HFH@2SE'-UED:INH[C1,F]2VGHMPHVU.9YE&L
ME,Y0]-:5T(SVY^ZE[553V';4-&I4C9<L;'SJS'5#HX/1_K!>[]3IZI0JB7=Y
M56>FJ/C,RGSXH7VI"U3<;Y*?FP3/@493:Q/H_#[O@Q&+0HXFY-M06!<EE?<!
MND\ EQ09C1OH%3W'10 <%J(/S(@_Y%N;>9K8<JZ]L]41IZI$,JS [R*E9[+A
M R*^9VST,AP&@7>'I,TSJ'>().H[LGHZVX?_7O1K.& -L(0Q9W?ESNRR-Z)V
M?IO>;F;(6WX/EEY.NJ-H/II IDDOY62D8O[#\82N&A  H</>@^G/1$N6(HL*
MCV<7EL+6/F!5\+1+S:@K$<)2/UO>'].XQR 7*V(TVMGC44,:6:*<=Z&UXLD]
M #L>_NN)\?]2H&:O%2ML6NBZ6R$8MH-?ZF_T]![I5R6 1HJI*1? M) 6&P9_
M</;L7N-68+$V&K^XUU8O,")DC96\7%$9CM* (RE;WEW4M2J*M#Q>]"QGBK!/
M19P7*AE$+ZAW9(X F'ETB\^2;IL/%11;B EZG,R<0:8]"?9]X1)R%%>N"&"P
M:JN]!42LSWI-0UY/<,Y^\9=OET&?+C/7 F$ODDC\NIT.Y.Y7LTB+,]7<>[&5
MP*Y[KB^A'WFK322:G#U39M1"/?Z")>"H!#=**R]P@#:FYP3DBMJ,Y;<Q;T'O
M:"FP:H8N&W!UFL^(+2M#0CN8PK%$^I4:>YK8@9U\4B%A,3H.%$%;3S$NH>KK
MC@#D7YWJWK$^UZS'Q=:M"M0<:T^2 )(YB/#V@(/86_DXWV^WDR+I.8R-Y.LQ
M;)C'1.BGKC=<&P=G;,\&7V1?)DC,?0_F:"2H^C9L'$*HG#B3_H(AI^M!WVN1
M^JC!$G"$LI*&&[-F][Y-H&5/1H4;50^<^)P7CNMIT0OAH$W.[BPM#P*<)J]2
M%424#BV[D,("2<!.:V4X&A,ORR!<485#/; 0(6%6,Y5-6(DS5)]FL^_I^<'B
MIU07+D;G)R1M:].6?"SW.*1(#,\E1PVR_3MQ^? [?+,J\D8AI=?Z)ZN.2PS<
MYG(6NO#/EX=L'HK[MAZB*8EJ+-3N70XA,DNOTX38E;;(15X;,BDL=A,^69#!
M+Q32*,_=WJ[2'?3T\LI28ZOO31:PCM6L&%I9=X,V0!_(+]XG;'%:E?M,) 3>
MMNLA4AIX*"R#;/?V\-DM&>JXA9:7JFLNZQG%1YO.;\P%PLHAGR%=J0.;R;A"
M@NDO1L><2PIR;#H_,[4HVLS*2B.1H5%CN_!Q!YFJQ=4:[!SJQTL.%LMB#H*A
M47/+L16IY\DO#H@)!G>IJNX&-\A@5JUK$C+F"']2NF\B8)^=,:0_9B^MZJ?X
M/OO:B3>?2NG_-6/!L,:VL#FW:[146!:4>)<:JW2KC0D/N*O<Q;;Y%#EN$-N1
M.I5LSIZ_Y^7G^ DGD6<'>R$5BB1-:Q?,EAEB;,^5P86<C*47H=]=>1C#\GA:
M.8?#>O8&TM$QQVHGH5WR,1;7:^^URK<8)_L5YH2=/7?.*"1@E @@7*4-/@LZ
M+G([9-=OC>E" #)2Q7YP#"_0Y4LA_46O7-=%Z ,Z_P5[LEJ5)JO/8.PNEL8A
M@34,#2^" 8T5H*0O\V.0F8ICW$@67"Y-:/MYIGI>6KE,YI&G_JS8 ?*"FPMQ
M)YFV0E7<,W":R'5>9S,N6+*C/ ?C6QO3713>.XD84I41V7R96<G+'<4?3W'4
M*&<1P)"Z<(SX069KYOP&=P5)L:5E-E:K/1?ZT[ @;#$DHS=!=E*W:C<&E8MR
M/:/'IB^]/J:C%ZF2*99'7(WI#^\C@(_D*!\7J69F-R&<NY_"*)@C._<H#>MF
M)4 Q*]])[-J$BF8]!4Z2***Y%BOV2B$2%N26Z(PX/4\Z-J8\W6JF*^;+;.>A
MQ&2XH\9),VL6KD^OBC+O,7($O:>60@EOG]P**VC,*LQ7.@6K.U4?(@#O-MEC
MBROZFOR)FX)]8 CF<O"\OY88OR8R>.EHER>!X'8L57 )C,J"_663T5U2]"94
M>0NU0FNC2^A6]QR1<KZ*MM;>L?Y8N.\BR/?SPC7*9JXMU:QVAITBR6V<A<"/
MKPZ.D(D,G!^^;E!$ERXT6ZS+5#0QZMR-V#HZX<CU.W6X&/+H["E*9A4?@=\_
MC[/&-FUEA'#HO.I8ODF.3#O] THVI4DBZ,#8N#+48Y@,<=F";1(TH.27-?>4
MA_TR:W7K=3%#5<_#%V:(C2MKZH*-Q/U5-8T9W/T/59ZBK8M1^C8T%!@^*QA9
M(K &PR9YHMR4G"*C8$4(@+JG$*OYTB2@OS[&EJS]A16ZM&/?L_8&7;%M66\+
M_J%$8=HX>$W<LPP&C_NB6R5UFL1^OW=JV7N>W>0$9QS*'&+Y)!%S6]?KV"J;
M?IX<$PO%MDI&)VC90B$]DX;O>&.&2#4KKZ51%W3'0VRQ^*[^N<#>-J3+V^Y-
MK/U*9\KULE6S;14F$0<'FVIR9K8Z=WH/1=QF:%RNK*H^4[UBNG#90G'+]KM!
M#W&Z-'&7N3 YWPLD=@10F5T0M6; 5C.<5F<(UU\Y<Q)F$F$T=]3/@/;!X/"U
M06]_(E+?]L>UAN,/O3DK+#GNFP]:W$O1(ODRR0O,+WQ4$UIXOZ* B89ZIXC#
M!ASIK+ L^^/R[IY7YZ%MY$CU^_*M-'<L^ D#K%0]"N<,0YRD4?>32%!27V.*
M@(--1[7,:*H1 ,OZ1?6PD=A6@9OHEK$SQ7TOIGJ_,KG1V,R2!8/X:'?;<5[G
M#VYV!R%X'-Z^\3C^:V<;&RSYZ0B [B*1ST.Q[(S!0YA"#0$@'XH4^[CL&FJF
M&H'Y@;<.CZ(B#]&_ME.&?+#5>R!O>FQZ]E)>]YV\M+%38998H9;\&X=[XO8D
MDO.DI&R;V0EL0KD-#<#\2*L"KDK(QO0G"046W(E\"ISSI>^\LW>_-:?TF%#A
MW.\,C:K9MNWM . /FEY',B&U#2H7$G?)4T/T5V8H>+6"<H0=0Z6NW_4NW<@Z
MIK_2S&V(JU*(Z:5=GY7@G=W]4 4]]D9_)6Q[ [9I^+4PS8@#:!D!<&9C?3KU
M6E'\F+X)G?>2&ME7).NVX&(JE:+$"/G 49HDIDZ$@M,?PMAH5D@>3+YIEE_X
M*1<CY!78P30#*7PX_\FZFC^:2#/I2RWS#R/')BUS.")$.N<BDC45]VVS!#U*
M'4WER''?><G1WBKY+OC*3U1"'#NO2"/CROE(?]ECQT,P[2*]0/#T$+0JNC#6
MO)6,^JVL9L8VBW\%E?6NL!YI>(-0^5L_45>G$IK <T>-V9"(O8%+!/!%J5E
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MJSO3*SL>:A4E8.L.F]HN<)L\O^,.0H%^3&^H!;-R5Q%R7N3S![$M$2EC6WT
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MZ\5M(@#D]_MS_M:U:DZ5 F[6]EU5[2$TNX<\(FIDU=%"]-3O==48),&K\0B
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M"68_N>O9A_&"P+1AF9&L6]"$.^F1EIQ"LJM#Y46RN ;1M__[@XOH[!L/844
M2#<>(@'H]R. E>P?\<,XY?[F7RV>L@8!O*2["O[+IKR8@UPX)+HT(3JO?^/
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MV!__GX=_6_!P'XM>F/TE>$SD(+O];DLTC-Z$H>0?::Y1"CKQ'U--/O[VWLK
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M9>\66TLYKN_:X$_27A%?;+\\CERWDDW#%%,\B#S7]]D@O0?S4!^H:617.,_
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M^0-FL)S<Q-O<D;TP^A9A>BD\]X?4>AO*LNY*2;0$AL-'$--SS?M&%1.%+C,
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MI(_LVS*,7G,%S+=KRO#.,T3SV\P1IR-S9:8IBHGB*NXB7"UL1'D@J0+P.PT
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M_3><(2C:KX""Z)?>/\7/VRM#S!ZD71RGG3._P(_#//Z5/G!_O??<./%97[7
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M;);%XCLFF&6K==W+-PY=8 PMHD(N!L^5CP [[O$M+(5? 3H(?@AKD9L TGX
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M#1(B+5J/48YQ<-EN[S=2D]:A76N8[5W93J(V/\/2(;F0A:&R09 S?/53#\.
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M__UG*?]KE_^]DF(^?_\O_WDJ[-__])]*9X16[&NVGW9*1_@/3V#V*999/$(
MOT'G9E!\GRY'@70 X[_$J+EEZZ'X.JV_E-OJKDI/_!D4W:NH)O"K?W)1A/RP
MK.(>SN/MZ <HP.ECI*K?"OX1GBLBX!FT\8;UZ?Y]LR&?V6P);C @R&GT X1Q
MBW.0/@ H_UUCY:&3Y*;>8# ?H.GO11;_4Z8 4@$2/81SGVIR313MJ3O1)2FM
M1JL+E5#$^<T&>X'J#K05NE0+SCOEM^W',*73>GA>]HA=+S3%:C?).0>(KP;)
MX'9WX*[*5..^!!=,2#S+@R%V9D;*I\$S+T@V>UOON;'B) A!E1"/=&E[]W-%
MB$&^EY>6V^Z8//XQ/C!WOQV]E.:H^T/HS22>PDX>XM_T(VS.R8&/==8Q?@,L
M$:OT,^^6')U,'O\^9*MD=MR3XDNIT'<F7S;+2EQQ++S#%V>!AKV;G!GFCP%'
M&C-]CT-+8=X$9>" D*.O! PNN:W;[I>C14,G;<WYKP";I!?KGJY70 O'CVM&
M#6_=#X0%?:<\.XEJ;PW2=4>^U909.C4\E0*;%$7Y+Z+JDL.%=P-KF)M3.'3%
M<CQDCK.8BS>IRSA^08GUG2M?36E2B!9HGU'Q/Q&$A<!P*L+*Y=@<?\FJV$]6
MNAW7P":V%8Q)^.7IGF>^=G$A8"%Q7K"Z[$(*Y7@?G@.TB>O+DH$**:FL*YGH
M7[V?'!4H*7:0]L3J1!YBL+_IVU 7$-T/=PF3_7*DH7IMHA*64W*?NJYNCH(=
ML;43R%Y-%+CM\!&I.2H+*+U>%';KBU^7<5W-%L):>^ECVG"ON4XOIWK5H\9L
M]^(S]+X<9%HUX'=R+1LP77YT.0\:=;PSK[/9F_K2H9A='?(4GN&4@M#WT4_C
M8%S"&@T$$_IQCW"4EWHZ2JH,UIF2VYUKX4"<CH]<$Z!J_.NOZ%A R1O7!=YC
M@X>$,3C&[A_^B$'W-X,J^1N+\R^K"C/V^ K0H>(C\"'2'CHNFY8 I%[R'%]>
M <_.OIU^R"?\:6=O-J8(C 'P-5]^!;SA?D+=\W2H)[F]IU? _>$K(!! O.@*
M7'L%]*D]TP# 4PW@5P"8KVU#&.XV9>SN;5^:>04@ (#5I[YM;VI5=J\ \3_R
M_SO*AY!3US!AVF/P2(43"9LGI(&R_8]Q"7]1B?.]O>X8PG?QSK  !(_D.]PC
M8;3_EX_ /RT?0_M7A<EV!<6+/)4?@Z@[8^-):*V_XSB1ARO<I!_5_X<Z^H_(
MIQVB_]RSO!.NU+[/N@25 [#^V_L=''+F_2M ]@*I0B@X#RNA>-.<\K<]UDXD
M.6NNN\-[PF' %Q"MU3; H57H/DX MTCCP&#J!&C]R9=][/+6-C:S=XQ*=K[W
MK+EAE.=(F"CEWQE&A&*%;9?T#Y1Z761^N R>O?QA,1!I(/M_:S=C2RQ54XFJ
MHQ6F*5"6.MF&'>2DVE6@*!."(901H\P@TP*;Q9!#KN=K+)W,,NO9CM5ZCR4X
M(HVV2+ N[_3005O4N.E(07X"<^U #-\-MAFFZ@#S6]T*\O+XL2ONXUB#M^8)
M-HP>GUH9X@B:0<WE0X(FCGD)/P!$A3'.SDZNF]R9F99%H1%T)&Q"L@JVJ/<!
M%*D *C\6+_+-(5M<#2E?H]((BC.$!!;<6SK")W&7@"8_.3LV.SD C*!:7Z)+
M?)&F&:YY6>FV&$T*F2I^0'_?M\C!]"$"?Y> 1,#)O\000?3W((D!S H0V?@4
MH)4DFHV<,2#$_PS.='M\F*:>\<UO5\3Z$5WZ\! 'Z+?X%>SX'&10"OE2$P"+
M4\SB.>8PZ]K^NS@["'+2P2A"[[9X1MG#S/Y/UR*,S%%:A>:08^CJ9UNJY2U^
MC%KV - 6;D=?1CH2]T9\M^_]UR]:#35/J%5F\42N*6W#2([@0L8F%]^:Y-M3
MB$.._YJ4+PB"RFSX2<D.5(PJ=A3,MWGK/@= O8WD]D3K3WDQQR'G-I 0_L1E
MFKEF G9H>407\,P(T1/T\L%#N5RII.F+CDU?FA)&P7X6U7/<CY@W_:_&\<H)
M*2:O@KG"/V=2$7G,P+S&<&A\KU'5=)QV/4;FEJPBO][+JN.9:EO@I=PTPT85
MY2ZR9QYOX+N&Z@?C.5T^;Z$+30:6B.?C:6SK+K 5=Y3=O(/;#F(%7U!?;3OX
MU.R+6P 1*GHO1VTWE>-7V<'H]&T;DFK[>8]U5T6W(& ES2N H_6:YB+T%6!+
MZWN2F':1,[P6,?M%HLAH8(OQ$U&%[UKV*P!"EOYT@9DV/93&R])[1<^VT/"!
M^$CE^'EAB"'WATSB^/WBMO>^GFVGR-O2>P5(^ZK)FTMNI*J+\VLM!/1]?;JM
M "-U/02H-Q.D3IE2E"MGC:_47LR\#;*ZU=;+'#08D ]V'F+X8%M%(3]ST"?F
MF%EQH1KOUH%*K2J4#T^LB!_>K9:FA/PS+\O^J6OA(Y_6R/2S;XXZ6MP Y5
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M9:0N.GIXD5&2$IWC^7]KSQ:>FAU>TLW@A'$WGYC*P*08II7"-QLRY3^F[*2
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M2NL9Z1)[!H9EE)Z!&JQGH) @%V,KI[U^YLB;;R#@#C?LX6O !',85K''T3/
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M0?Z\68<YT];*8$V5$M#1GD7U^!G<K$2@N ,)2UOTT.+CD+ZYY !0/EZDBP(
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M\KHP\W%@36,M]3L\L"2SKN<>K'G,?O)YL<N;K?CN!*A4/L(Q#?Q2TI)]JXA
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MHNLK]C?K+" Z-4--E(^.UY(<;97YTE-%)3HL=R7Y6JJY>5ZY$T>C E7B+$C
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M(;AUZC%RZ;>Q.EW167I# 34W$W#Y/TNY)CE;1ZPXV%#XG1B:6"[,#-6"J^#
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MQ_R/KS\6SZ?E6-+]PSEO_A+Z[,=PVIL5J,6\+6WO0(L?MHHSS#(V(;T/118
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M[EG<X[6MEV1++@0+^.X(T-_X*,RP<9M4MGA :H)V/.+58KPG$#J_91G@004
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M,;5C<U7Q&2A/7+U#FH:ZU#GJJFU(M.7\G.."^'A4K$44R2R!&N4HXZ-YX^?
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MC7AM^WC?M:)XZA&1!U<?[HXO7K&KC=QL*5R"!TZ*":SAT"KI&2&'Y][!,\
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M?ZYLW#_4=,T^ ]L9OP5@&6<BO#9]\"SX[?@7ZIP=_SMP[<\D3/[C#3>]W).
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M0CVF:3&9]R,!?H% #2!/"/%F=JU>67;RB*!!RVO"C1MJU"[B(FIG8?'M"W3
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M^X6$_T<>YC'!L$)5DU0[@>K'% MQ/O0+]94N"4K1FUZ, - -=-'3Y);AD6P
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M/:F[B\3@-<N!?8(W*!3_P$PH8>5UG['J*6\(+KRL&1HME1G,.S4#KGD"MVK
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MC*G"#WO\YJ3^^SN5Y(R(E 2^?R4E--THQ.C>:OYI9--_IW^EJ3]NX*D:JN0
M%5N#S68EM;=L5(9=4? EOR619STV4_WI&2B<A*<IA,=/0 NWM#0=2T ,#-SZ
MO!*D-N)&=K==X/HKGX&:7UNZ#\6.>T083.O;H7"TEV;BAQ=15?P>04L"P )
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MY0PI9F]-%A4 WN14_W<MQ[C[WZ*^O  L=7=K4Y0LHOGENA..S_GD1Y$NGH'
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MPT,KDJR)AXJK+<B3[S LI+-5IF*A+S.S)S9Y:X,TT6IE!5:Y>'5=(6]V^_L
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MH6/Q@>MD:>M@7^>U/-OP'V+#+/D?NG-'=#^YB&)4S+[#HYPE*(+ J$1:"&H
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M;K9FSJR#\3BF%%OC#0?!"':;>P?NF=5"L\Y:+H\M"3SVYW?*&N$^>G\RS&O
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M!YH91?-M+QAQNO_2CT77Z*;LHMDTX%-TSC-@8;!L<)ME!2O @\_7#6U!%X_
M*SX5A$4?K$$__]MH#/^F(Z)[08'>_BGJVU<CT08"I#^<AC+(\I@V&*(VIE21
M_R7B_2^Z*_ZODZ)_S];*M"G0FU/F'6FT3X$G%X*'/9*70L+-"$G3CP(%=R"
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M".JH<CJE/'3Z=5)W!0RX/"3[/.]$:/?=Z(&&!Z$:=X]LMB)M)J@MR*+'G K
MZ51W@W<SWESV&O2M80VZU4VS= 7@3[20R"9+>N;>U*"Q.WZ6_(K[<XQJ@1T'
M\8U<,4MP3%ZF/Z7P<3XX6^IG: F+"K<"QH3%BC.<DJ\XG^P*X/9,@WBR]L_1
MO<R6(WN_*-'J\MS\75GV]K>\_245EQ4546!S3F";D9E+%D+4(P!O$10Q)M4@
M5,JW,PI^M=4 E><83^T$KQ!KA3\M45<NAP'J!+F*LA_1$XYY[S9ZFC0SN:O[
MF4IF^5T;0F<P">-]T&ZM7GYXMTC>F=.7LDF/E\J1??X:8KME?O"],9NSCT.2
M*-?D^B":F"(?GT)#D_7[=U7YN#0)WH23I9HGE9DL <ZRU%P^;$+X0P.1QAOE
MW04&,^.&C_)8VU0<!SKH\"P]@ IVM-:(2S)@'I;[Y,3X0?7PH93V<_2HR\W-
M(AJ$"!,W+'CL-28!KDD O@Z5IRD[Z"6^>-6[$U*..LC'O]Y@<*.)KUHBE6NF
M!Y[4?@78 C:YD\\>NE#(;OVT1*2RO*39CO?L<$DR:>:A M&YYQ+]#)UAJ&BJ
M2=_;@]7Z2R/Z$2(?V G5;U<TI)9W=7A#H.DX#M[B]X8.D1KJ*&1-]**[:B:S
MF2N>GRSH1Q&\]_)H@'<N850K*8V:]D=+U(6"J]0:ULHE_7=:1/_V0NV"'W-^
M)$-^ O,Y45#N%6 ENY(*F8CXENMM/S-^H_A74FL!A\"2\HV*&-D9'84@?TH(
MN2 \W'%^<+G" 2&$5!##)J.;M?@2T')JF$]2>S[&12R[&@&,Q\.&SR6P-QXV
M994'3E%KO5HV& ]\3:0;'G^_7,*@\N:8J!B>&P-KT\Y6;_;NFMYINM0[L3<!
M<;P]=;S,^%\LH"O3?1I&UZ.J@!9._"A'=(KP$@I:+IV&DY>C5]E<NG))5,L&
MN0X:,T0M4&6ZR @JYT=;O>+9&FR)F0EV1(/_Z6WI?^![EG]7LYO_FK<Z__LE
MX/B3Q+F<4%\E]^-!KB,W914$TH3,)%;O+LRU\(G/D]=>=(D)2DST;"\OZ7_,
M@(G<T:G?V"?V>R:7K39J/&_KNG7A?X#,?7+FPS+M8"2JTJ#ER] ,7ZS3G>!A
M,J=K4(2/ZREV[OQ4X.PG%<TE\B<ZI]KY&;RM=P1+W_8.LYU9&_GR5(RH,/Y+
M1M)>,>:K.C7"[";@+BVR<S,TUCQD5BMA@?639_S-!H7\9),"KS2*W"CW%K#4
M#]#CG^V>W]/%^NGS*;_9<]]XK\6;7 @%N]S/V!',RG [%UU "9S?FC-FQ#)6
ML2E0DBSOXTWOF,^SOEG]$.BDDX-H#=_*W)] B5YXS9F&'':G-'S]FHCYFH6T
MC(9R/8M+D.<HT8#=&>F#LX.J=F(#A')P'NRN:=WVN9Z6H$ZO=OLI6]IB7NMP
MK&;:I /MNTYM:J .P8SNVJ6:^J?@]/%185_G&R%*4.M.V@C'%B 3"X7GK3%/
M&3!W%O#</F'*Y(ZGBNL&5#'[[6URT9'RCJT,5"]^%QJW[_:YT)"O>:'Q>DK%
M5.>]]#<=98W*0; 0K49) 7Z)<#!1XS,&6U#_#U#ON>!.G^I.R4>W$L-NUV.J
M(@YT1:,:Z2W51.&6N#QL:N!1@[DKL3H^8!/11+7V@G=X;I37JC[FN4Z,D,%C
MUJBPMSXZ9=Z63U00LNT!50 @!@.]W14)%IJE,KJ(U0U2@TC$+15US,Y$=U K
M_7!V;@_!T02G&E[V95-7IZIN^3CGKF*2+??ZQ%KW7L>H>IZ==CXS>W[#3AAI
M<Y%N'KMI+<.&GI!LYJ7U1*[5T#V)8X#/5AZ'T"QN@;:>2*ZB;Y6^BKJ82NT9
MV[IL$/V9;1<PZ&TSKQX[+Z5GXJ#N$)QLSG'*-0"!&CX2,Q@QUR=,)42AQ[1>
MUNXC2%1R29AWJ5IYB4]B#@\)Y+\6#_'[R%>%O8<F)EL;LB3BQG)7.JIK:"L!
M8;XW=PZH*&L\K==[C<EC0J@U?R:(28XD: C?59'>)$GZL(5U'W7M%=YY\R&)
M"Q?:LX;#1F[<;^0AP4:\+ \B]%.Y"@<DRMR@G,$>&&<^'R:Z]Q<YOGR.DE?
M03F#VY+/QK*%C)>T:5;,[$9ES.E**D,GLL#8<)([B@SF.5"07(Y+BVU!ZWG
M%(,OUJONEH@@81R^!$YLM#+[&">*V\E5]?9R8V%+\U81VGD#NH$Q**PH/BF2
MMB:BP49JD/$:7UAC&U$"/S=7D WMU!Z\:R(/OXY5A]P5M7)NL9,BM_NQ;[+T
MP<ZC5X1[D^*OX]C;?I+012C')@GW3\)QXB@ XF>K<^ 01Z:(Z9M3>.3+;V,,
MSKLBKT,?(\O@[P252P:C]V@SXU0L^:38ODB3E^U*9US$%W)*U8Y7%2'C:?B#
M/<SX($2Q];(X@?BB^6")N=C@7Z:H=\FKZ@GK^K6RM#Y["BWL9NW8HF^HT>NN
MSHB?<(90R?O>$W?0Q&_5Q>=#B,7W^]X"SMEX)RX%OC)GBD=/4P0N*C'[TOV[
MGR1S!!W[>-C+<^[5V'@Z\\>X8F4M- <Q,.YZM#;6*2%+3--8JSVB\Z5+2A(4
MC$<^X4F-S9EA=P9)4_R0OI&QY:G5=:\?A^N8"!:/!9' _J 0%"AK!9]4,AF#
MD1+X6NT,J>U^'OF\=5[#KV3;H G?Y8AO]N]AH"80.^#L7(737G+M5)=&N:\.
MEJ8;S+^*C[R/+B%Z2F=6CZA%KW)XK\548?65A(/;^XB^V;R;["Z2>YH@5I,V
MU),&\^W-SY<P)JN,R]::C<XR=@9.'7N=0JFVOZ?$VS][CL>V:<?234 -)KPT
M3<?J@@@P8WE#H5S$!7,E*1>5"T4?GV&F)M8^M5UG9*(:$DL1I,\$BQ^DM(JV
ML/V\R\1H.HA%+1=8C(5C]A+-=(CCA8>2M/\^IQ]:[ $Y5+%I#)]+8XMA39-\
MZ^[\ \]<8$L/!/K6"S:ZSH[,=R;E=^L,/2!ICF2>Q3ME,2:?DQ**2["Z--<G
M73T7V9CHCD.;\+V=VK]S>A=)+97SV5Z.L(CG$4>1BRXH,.V)A !S 7'XP(]S
MEYUCC=U?L@QYK%_N#V0E;F[1)%@2TEY/LW4@LP[^6;%-K/$)8^XDLDD%)826
MA?98%_YK65' !I0)"(YI@L$D[5("C&0YE,4U,DBNK>642'1W"[*O>^DT=>Q+
M[,S%M@\C-\ ;U41CUR127_.Y.7GE+C>5/3X#J[;(S].7[<QLTL'>YS] #SN:
M""MVIQ/L)E[V46BI5[X$L30=*D&!-&@2\DLQ@I 8ODJ- S)M_P5CH!N:&]PR
MG*'5V1O(YW@4E;A_6T?;9S/WN2;NQ@;DGH0/U_: =:#[7181!3T(T_$OLC_U
M2L#*):&IN<@YY\=%USI58P(JER2[ESW X*<J=^GKDA((NMZ!'\Z3A-#H!SH5
M#+NOUMKQQ.=9OGK#_Z8RG)^FD\C*60>WFY0JRB8=;G$2.A<:*BGG>AQ5.=[-
M296X6<'"62[&I8U8UH7M>>+B["DH"6'UGTC,ET3.N0ZNE3<\0C08^63X-KAE
MY0;KP#78GO!LWAQO:<%AX#LQ>7TR*NOF3_O5'7@HU8"_9":*M5<26^7\=B 5
MH*#/H\!*FX]]*4V_4XV9:4LT>?3 [3HK:4Z>3M."1HN0S%MKZ^S52O:#B_XL
M@@'?]KJLUSB>O +N"V']CQ_H;"*J'+KKD!XW11P>C=4Y<?>.Q!M34Z.!*+(N
M.O[3 &R40-[0/3]_K>K&$?,8S UL$Z@AI8*7J!B&$H(IU>;# NC2S22T!CTX
M;R(/(SF]#W'2[VEPYR-F6%[C:>4$9*6A<<Y[^,3C"%/J'1L^V%,:17_A[Z0O
M;C\FPT0-O+820&Q_U0T'B.ZH4^5*P3D>T=^7H9A6>\>A O/<30F>-$L0*,=^
M7<^)-]&2+2JV&(@__5)EN/J; KV<7C377$6WG&,%5_&@L+2-QZEW"Q0BPXZE
M8!!GQ>[^31\^O+V]Q0T=AGZ.0Y=8(_)C66.FFB44%O U7;&OUW9ZN[<. @YE
M]M\'.J#\DD_+Q>.QM_PBO/AL6"==V"'8?J( +0/-8$G5V9;R\Z!Q^I$6;_5E
MB10!M^ G^C^)(: ^]2J@;S.C]$1)INJ3_YN+E.Y]$;;9/K6&FDL)EY]P^H],
MDGUJ.Q<73>&%ADJ4X]O660MJNUF8-<C#6G[=KH?MI IBG10MF[YB=MPA&4BD
M<P-K!*O^HY>!8"@'0B: )8Z: 7PM_#DU4Z,&AT)M?,O4Q[TR5;H\OE5PU.KP
M0Y#^%STJH^@,>7-!XT=WB6.*=<C%\VZO.F#[^;0R!43 7<733UZ:5(D_/>*3
M6S%_/%^@*!LHL$:S/+Q8, .MYN.Q;[I=&\-)?5!C^LG.MC#;G-D*GBM0WM>=
M24>,1YW"V0K<X/X>7GTSKA-)F8&>E5"A."=N@&*5YRC@7 %5G^%XQV$'+XO7
M$@TOUI2M!9P%.7S1S['J0@CF  W(0ASUBQL#VU5C=VJ'0WB=6'G9>HKOE^*+
MW#5[5DF2.L<'CK/%CEPS*@@])/CIGIJP-W':V&5FAZ->89F V=J;2[:8+2$\
M__ UH.BM<)V/MR/OJ 2GO#;EN++R=J>H=1(HRN8$ 0:>+J7#Y>>1'!MJ=<.6
M=1K<CB4S!C'+2+0A^BDG>2-9N]F9)A;RK8GB@E@UI:I1ERV+_E1CK6W,=$--
MS.TZ#C"]#P66RH.A0VXJG0:\*14;/^<AGP4=/+[),1#UZ60RH3.>>&!;*I4O
MR5L3VR,!6>]LG6@7:$"=\;)9JIB">2\)=5]A+IYMNMI(=G7A8]4,L[J]\X*I
M4,^!/@RD8O$BEQU4G0^..8E]("+-$C'((IGU0/X>AE@4]6GA.8!I9-C6>%&L
MZ+\0#;XDOW'+/GI9.:JB;3KY 9JZ4Y2I8LE5,(Z83[,'ZK\0$KJY@+F=0_MB
M9+5S^:!CEX0[\WQJV>T<QT45[R2VO3[FM9UUZV)C0T6<$DNMP6+F$CF?< F>
M<-365'YBH O\]KU"2=F%&]1<P?EZ_)LX[[-@/H2DW73/G>-#S,2> *"?%H%8
M4MOA_F[$$3B*?E&?MIQO=.[AGY=].]Z9=8^[Y=+Y=!?.$(WXO0'MW]J ]L<
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MN\I[R?4J22)8/:P!/5:K$ULAE\+[H+MB^&/M@)__SD*[UI#[JU#MIE!]VO#
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MQ6_\QF_\QF_\QF_\QF_\QF_\QF_\QF_\QF_\QO_WP+H:_V]02P,$%     @
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M(35;H);92%#*9P>?7D]FO&Z6RU(RVA "=XQ@X-3?OZ655"LFTNRUVY-1P3C
MM\+AJ9R]8S8E<Z:8AH#"TQ#IAUO:\T"'MEL_EHYK9[$E6SJUC$?&=!CX%4U
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M'"!CQIA%1K;0#5TKX>_4J^!.J"0[C"YY4Z,Q:L)6#5_0>!]:^$JP),S@:TT
MO,10T^#4\'G#I"N_-V1L>W6&!&+8ECTTTO Z2><E/D_7765\CE_0\#)=VM\U
M;/;L":4Y)Y,N!YH%&44-?@ZB>ZZ/+"12U;N-^8XB:DRV*@9VMC;)T_ZIR@D_
M:3_IZ@OY=9 Q>-.YV55M^5P-!P#:4K>0IX&/\KRI/]7]^Z<(OMZEE?WRY^Y'
M>=^_ATODU/3BY^_CE+YDB#!,VVL6$G1G9F^:RGWP=[N>L+!(@O=B+QAQ@$Y&
MW6UI+9AN6)-;YAY!>_W5"=>)E38U=,S"K!(.[BE< F&#'BT=M;2P66";YK."
M=NL^B&JI#.^T!J41SGD$)EZO6W,[:Q<.\C?@ $F+KV^K.U6M3-#-8.9V:NWY
MY=#<A5WO3*:K<+2E4* O@@4.W@PIS )E/(--\J;<#.R^,> -0WO;/.%<M -=
M_2%Z&JOM:._5Y:"6PH%GLZ\O0 UQRG>,ZWO^C4,X622](Y82<O^C('4O1Q8@
MI<746RKQ.0Y@@\HQN?F6^&F?CL_D"#1EL&LC$E=2?QJUDAZ5$ 6)>6K-Y"8S
MZEY;5&>@$U1FC -8A &7+:F-SSX\/97R9QU.HK0*M(*NX^GY6AT!,KC8@J/L
MM'5-=D<8M,YR]KZF[&IDW =I]O,OOR9#2RC253)]UNPJ2:J6NFZ&N8-\;^)D
M2C(I7C3H;CVNJPMG$>9\ )?$Y"W5_I9]J/=36?6'HU7VH,=AF7ZY6RV*ZF:&
M]O'D(TTO-5O:M+I[64'H2=[#X3O"@"=\/=1!M1C/XM-9OI;^&_HC"5FAE4O7
MAT-.J^%E_/ZSD<@OSI>MXN,R'PD@W))$3_[DK3BK/S-6/X#9:D_)LQ2$0M4*
M^IW,G]U/?M.4/L+[\=Y5=2_OH]V5LW#\""J7\K<E'L _90VHODNCT=$K&[X.
MD7F,N"YH<G(D7+;W/N-E-+6V">?I8VQ-;%Q6YB^MJ3?]44IC'C\BU'QQ -)H
MKR#M%!O_,J^9-7CDU>CN4TX<P-6)OZ3[ PX0)6\I(N!R&DFO5G$47?%R/U+^
M654&9I+C$*N7")>ME#'^R<,I1>G,33:W2E&SG^PP2_\J)\6%1__O6N%9.-3T
M6:(SW9KD7YOT67U]IORH(D!@O'Y?8[+TJ$F#LT#F.5T(Y?[N%1N-IN.):_7W
M9>&DPZ _[3G8[H1?0\N>F4NROL3="<7>P;FP,IO;(+U(Q7'VBZT^T)F[S_EU
M/\?:JW8WAL?Z1GG.]1LJ3Q@6==$[VVH59=DT ELC*2&T^T=,S^K%A5^=)#VE
M+!YL$D<UU<]^%7PB>6O=M$@=]]K\MJI4M,/ %Y.S\,>AQ>*I[GA"2E0U;1IN
M(V'+ @+Q<50A>V2KGUY%371R]U&N.FJ<'F!=Q_N2EI-K8@DG,V4?]O;)5)+V
M7J.5PE^3YWT-'$-O]YR<+/ );/4?RQG,KLGTQ"T_:I#2-Z?U-0!\.:<;MJJ4
M*2G[O+8L(YGA_XO5G<O.ZB]W9/QYB'P"OH]A($N_[G)X V2R6S-CC?; >"(:
M_?+*YK$$B<*"FYPZJ-]YIAN[<SU=FW0\O=(D$<R4OT+=^$7>;-1,>H=64OP@
MC6(Z.BQ.Y&_LH.ZHN. 7G3+O:M<#NWS+L_5MZ5E[L!VJ145WZ- ]1I1K. F=
MAIT? TMBN*6\ZB<Q!\,SR%KX+MI*N?.&&P?XJG.O\"!D9*W^K7^&A6!^=7I,
MYMMWP2 VCV*]$Y",Q8T/*_BQ*1)$L66H^@&HK=I5&/C8:8EJZ:7LHS@J #%6
M$5;%7*-*DCMZ3<9[I9W9=ZDUQG[)[[[N'U4MG]KT.?D$I=\_NL8T/WL5/;^+
M P"VG6&78(J-L073N]KHM]%143W+PJIIUDRT#Y6U7K9*W7&VL_(6DY3B'SZ0
M)/^".+C& 5Q0E^Z&\F'\]-@@A.XLNR>=2!&_/I!$.N[N"P8F38VP36/&]0'X
M+'KNAL5<$<NF%AKWO-;)<N#<ZL5#6\'V$(E(Y2MS<MWFFLK5>@G=5,C"UOP6
MO'##"T6YRS;.*[J5O.1HS"J2&'I83[[31:9/[G206_;6RVFVT2/2U "E63<.
M/XOVNJ0-&;:2ZVRB4'PT1VD5$Y!3 @B",[[$Y\V[(#%KL2F>JS3X 6*MJ+J*
M4?HK^]IYF5ZA%HFF!AI3[Y$Z93TF6*?]0R#Q*N_1EY_/2NR]7SDX)@==17.O
M+WO([MY-LA.[Z(X;^EK4BOEC($5O=ZD.CW;C/@]L9-AIJ?UJ5G;M8Z>Y!*8U
M.<LV_O" =)^T2?/S"P[ZA)BF^L6T.WD?7_2PFZ#%"[7UD$H-#+#3CJ/?+1F=
MV"=-87X3B6;)3TP=/F88]M?A #7N2/=6L?[\ ?,08\D#;,'ES=WYBLAYWL)Q
M,5.IFHU%[N*JQP(\XFY%%0S*8QR%K.LD;O4![/;%&VC)NORSFWOK"DOV0R/T
M>6/LCEINMH?T[TYXGW*2UUX$-?/;8.?+L[ +., >V<KK?;F6Y@^G)WW]:!=R
M^H=/C U]A$7^T,Y.KX\]_<1G^CKGD6Z,\.;?I>T;GOQ9B!J7R6I5J5;GLY\M
M+^> %'?J6@&$'C,;@$%#OH:T+0IPU>X(!_CO^(@\RY^BA0?R)_/;'+;3V4BW
MA0 6&Q9KJ[\V;AIWE10YZ!U^1-EP]+/UX0 5K^9"))'EC"3+J%Z9/MX%E\49
M\_WT#*/N7X* !3?3)Z(>F^Z7EN 9F*O,];QTBCS_OHF?SKTUH?-=$:S1Z?;B
M'6.X<T@F9Y?4'!>;!T;O!"AC<2TNX94Z->ZTU)BH\*Q0,;Y_'F'O8K@V6\^F
MPH&FY6"$RHF*_E@#PAR/1+FH_EM7 ?X_97C]9RW=V)1 X<@F A4Y-TEP.XCU
MFJ=[ !IH)@-R)!IHIND\<SR0BVRHJ"J/GPW9.@X,D0X:%J81<>AW+"0_MU45
MN'K0D&EC(?=1[(#$LZ-84O_$- ('@&=NQ)2M?GLRV0D65L<!D"7'=J 51Q;J
M=$2"@C>^T\6=+"Z%TR$13/ 6:I#+8R2_I[E'WE(M+PE]EG'7T# %9@&.<$S=
M<48,[TF;TVC!DS0C7F!*J%0JXNZV%5-].UIU3[/^T!S$Y^#1WN8 Y&SC-LGO
M&ZU&.-?L^$L6B[%8N+D[]WFX5X4<N%SXHBRZJ9=")5(ZIMSQT?@\ZX640M/R
MA5+=6?*0PS-"K#N$Y_5BT_Q5'HK[./ J^8AV??MWPL;P2@UUTS($57B>HT *
M[G&PO'3& ;+'%Q50=CB N\)13B5JQPT'J -?J.  3/N>9 KKR3C WRC9?ZEX
MVR_B;S_)"L^25M56>HSM/GN(,(VVS!C,?SDFVO]S5#*X/+XY#F^T;0&A]C7W
M6+CBW*#J()[" P?4%\OP!4:#:9/KZH!S&<^TF+?8KI!3YV;/SF"6#IT32Z,U
ML\26+1CV1H!O)VBY??RDI1URN#!9O>MXX=W2G>G'/7\RKQFIC-X>+GD'9WXY
MA9%S7!.N4YTH#L[0L#1$+,*/E<=L/0US-;&>G@%\"!IX[J/6)/>7LK_K2<:X
MMSDB(7P0HO&=(9F5V41='4&HM =(*K\_I-95<2NX8=H?)J7Q$$HU^R5H<M,+
M%I*(RN_83RW#7AGL,1X0WGNQ3CKDUN2[&8M\'CE8#%M236V*TP9YN9@(:/4_
MRG_E[<"C"&==2&$K.:+ILO*! N1(M7& C1FNM8!E4,6.,@Z@]M,FY7VQPFX_
M#J 2OI&2O_0;EKBDM!9%C(_*&J[5T(0%:SS/S5;UUFF,-%4;+NRO/SCB*IYX
M#VSD$DT]V#K<]M])HA[^/@K<V37A7'$2=?#Y*$BV+%Q<,H3W=/7+YG#_WZBW
M078Z+<_:A (Z94#-LPU 1^OM$[NQ*8@L0:[&-T95=1![1?FDQB!\(F]RHV1Q
MKZ3X=^3.BSA"#N@36@X,#T-M/]6X^13O]F5)B8A3WRY)&B1]R7MF9I[R[(=>
MO&6#N7P_'UWM76F94ZN;MLC%HR[3 B&_N3>5, ,:\E+=VDP'<QR@K2%HAE96
MUDTO@X,B+Z4%82N'Z+BXBMV@XX]GBG%Y^O:Q;"/8O_$&/XLI8W5J;,EMOVU,
M;Z7E(!AUSA=[*)GVIE*?$6A?&[&-&*YO,T4MG,4=8V_^.K/@113OJ1#1*Y$D
MNF 3-]-(W2TE2":J24;SL>:<)3-\C/&P&A!\8;<EG3PWG5LJF';B1+6TIC&@
M!!:(25&#)3D')+-/\LC9WGO_<^BQG_#JE\2%O,@8C71-6=NZX#20%==8H;Q7
ML6Y31L,ASW6WJVSQ(D;#;=4E74T19-.'/4UID<0!8LX4ME)N.[2K?&[J[.BV
MI8BC G<;<"OTA@,'R,NMV/>]^ER( ]2"+\2E3T683TTR3W9ODAYU]",6H+?X
M@+IX$Y%!K+#/SS2J<%3J@3@%7P989M>";O9O@WOWL33FE/SAP3#!;]/-WJ<A
MFPVWW_(];I'@ 1E"@^6Z<8!\EFW/-_,D/C<VMR_[/?%"GB62^7S+!?ST6Z12
M?22X6^W@^_NC?O0-"2(MYN4D>*5M_:;NMM+*F6W)?'1%@CC> 5^HR5L]N JP
M/#Y@OM"18@: H9G71S=*3;*9B] ;SINWIR+@Z,PSF_-<YM8I=]-Y(,-7+@C@
ME5\OD<S+XZ?KC/M;$8M]Q4K4-L2B:;GVJ(; (!S@=:-8(==H9%:J=F+M1@H*
M?1'OMZQ?W_CM7O0YM<I3SV^V  '&L\VIV"T3VRI][K'\!]:0%'/D2,#Y$[2[
MUZ8>5.[Y_%B ?6+%V$!,]SVKE'ERMO=_KLBX/?7[I;6#G[G60R#R]OJ.I;MG
MC\X.V$V_LZT^>Y45/5 *O')K9ZH[*1/Q@^FDW0SS5:REHQ9',G19-\?#9G6:
MFU*JKI)=U/%VGI+S%P\29%F%8*/FR%."F-S_K#('+!A):9#H=DEH&)Q5]%VZ
MZJ!8:)=7B.O:[T)44$MPX5V8S-50R8NQN_'.JZ4YWOQFDO3*DK2TMCO2Z\V!
MDM+W'ZC-0 \+D.H\?,X%NW#/[LXIOY2,D?;8O'AUE.-6U>[T>#T.H(,#[$@<
MB,WH+B:=6:ZZMZ_$G"6M^<,_&O%6KWXZX+ \_7X#._!_K>HM<%5Y-7/L7]7$
MA3S//W^6A#@0(;_8(K^)4$U!' A;KMSZ4]X;+\2JR2WB*ESS*\%C$"NSS!<8
M\-$C\WK$WN:M5Q[9/=:^ N( 7XZ5^)OI6V*L!-BT?3*=BI!G[U68(6X?5CB^
MMFOF&(!%R\Z-=MLDNVF^?QMLK(CWO=HQJQ[);ZPV1M3,/[/&2TB<3GO7Y2E(
M:V%( %!V,CCZ756BJ'>Q"I&@2O%%1R>Z^Q8EIIJ@/H6^?0LR\+J!THBQCQFL
M)<)U# H6&G?/4GQ2A$%TSKM)@G7&[W^B]0#B73?1B^LL8_D^NNV\_/04_=IZ
M.H5\.E4&7QM5#>=6H>%^:8ID#BZID2NYOBZ',7Y=2.H@@!#5>LO1-3XXZGW\
ME9AE&IC=.?5*;RH!(<H1?EQ2M/M($QZ_O8&4 (XE2?:Z%!=+KQ!]45*@-A#+
M#<T7L,WD0\,[3A%O&I #?@Q\'$I&*94G49XF,E<\CMZN^5>1Y)2;:@7%3_@M
M,/YD*E8C[J>_C6,X:%D/AT20 ]WO)QD5^TJ@.IJFS1 X##F!A6Z^<VS8416%
M2+N;&'NW(-ER4*\=]7& 6!_4S0QX>V+C@\*JI=K-W+4&J<)5)#<8>1L\X4OW
M-RPU5-JY:^C;/[]HY362^/N-X6@HF.=OO\.?I17ZO*7!@1J#B<8+X]V%]<Q?
MHVGNE)!4730Z$/6F;,L;[L@P]#EDI@+H3CY("\KT=2Z#$.WS"EDH/3JMVYPH
M+'75,3SP5=MMD'.RW/DMF"_'YN"PX#!X/6D%NPTM7P--:-Z%8-Z9Q9@OEL24
M[Z;N,X*6F<>%BALL5G?9$9W> MV6=7HT4[]#VFZ.Y";0SE9GH-.DH$<.8[WR
M^0*\VUJ/YBI1SV[CNU)(3H-PL8L']$<&MB8S-6@4G+3LN1:O%27+*PHTKV"M
M_X!0:#V2OHA?^^>6T-%7M\#U=%3.Q4EY/=B))\"2IL_R0DVP; ^,_(L#C"[_
M<S-!6D1A0<9CI(],,94V:B&;TZ3OX]<CU\>C5J;N29],DF>O+[/8%C0K]*P?
M!RLV^9<8FW2G%TC&5LXDOTDB!=PL]MS"M#?0H\"&*Q#4R=]_-5.V;R4T;XP\
MJ.TEGB5ZX8MU"OQZ3V8_0AMCP:),/=I=*P:KF!ZL)S[1Y"R0G$$[=UND^IP>
MK57)W><QS4?@M\O3-/T:?VC7=RFN@D6LW3^+;<00P1SYP])?8WTJK99('5QV
MTC[5?WA![O9DR/VX]:HHV2CX-N13WNQV^:#]^.02P8_H< !NFO;3B  #B\IK
M@OUO_++&K@_6Q2^Q>G>7@FIM>.42ZMVZMWJZ[YQYD:1,J)J"3IE@RQO9\4I-
MQA^G:P^$U[.\=4964'YF@8L&CEX^XVIQAMLXP"+3ZR7EGV=6^@;#B?4S&9\B
M'IQ=B<?)_=DUD1MIUSSSW/9"W-.AL//8NJD;R&X(;OU8B%@0#@SPA2;7,DT&
M[UZ'%,HL$S[T&R5_2LCG;F_J6D*UH"$#D7(U6STNMB1.."HM6V -F.-1B$J4
M $#K:E@I?KJ3<A#X$E$)?-4Q+'.5O%$Y 5-@3BX8(Y-\U=:>MGT_DYF)OG-P
M[Y0U&L!!E&\-.5(.6LU^C)KS]RZO6'[@THM2K8']_OV>8X#Z!4LL.YZDR]?'
M1M],6:2(Z(SY3B7'BX&!L=K1B#UP"77(0W#W(.K:(P8'>.7 SBM^</3&\J&L
M.GNC5P-3:C*+\9V6H:#-ZH^Y$P_W-RSY>O1%E\M*J$&'"+L'"/$ R] K!:*O
MHLO6+(.S-O7QUW^!^-=?G^"/HQN7JUVVMPH)5:5W&^T>6"V7:9IEO%\JN>]G
MB#YD?Y>]'U_3:"O&>O"*XAF^CTAO297E(ZD)H#K"AJH)!RBYM=:2=[TF358S
M]Y2\37>*+KW:=8;Y="M^15;!#2,I=%[_%-Z(F.L/>1YENY^GLBB<C!4F?QI5
MZ:;LCB$GRLX.4O#7O1&V<+\F@R^O.GC5L;*LF>9K!>,K<K'L<R,@;R7$.X*X
MSF\B,4T/.X_4A,'KB0KL[Q1>ZO+-P 0^RX<R?\<^WY!@LGSU@1Q#,_AV9;]5
MSH\#P^#+#F_%HL]OD_?[+%%>SCUW3U+45[U9WY%>T]!>C/#U9N^!YM/XH^@4
M5WR,/NK3T!CA9\F_G<$?2]M'YIN>:=AOFFKL'E@WG%Y%CX"G C6O[TK3M$GA
M $\"NH^DR7]T7Y-,@\=L;Y'CP=L'[LPDQWSD#TW]P.WB.F8=<'8C"$MH)>P[
M0=P,Z9VBK3^R'Z57'S?Z,$N'2M96%'Q?.Z;?I7!(>=W'ARWUJB9V+B[.S\&(
M0WG;?>E5](@^2TH5YH38ZGBSW9]1>GQUWY(,O$I<=)M):5X_M$_<\ HAOLU
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M +8&1O)OEE.O"ML(OLZ;BX#+C7*)QW8>NXJ@BF(*5V;#?SQP;#FQW ._(H_
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M&8J$E>9#6)%Q>7?/C02[7C*^&&;D*8?1+G/U12*U(16.'+F:Q8[>T^A< Z.
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M3., MC.=KI'"Y9;7)^>I6Y_=Y#Y6%+:-7C33ZF 2$<L!B$[DW_-2=4M7$^\
MB<(S@Q][4^/CY>V1_]Q/ORR[% YN2R5X(_FU0&W99I#ER38.<!1.:W"F@-T
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M@)#I4$_-M#@'[,"!-;51T_A9*Z':[J#$]T/FU3B]'%B<^^1# V-!!@EK\F:
MH-=+>SX1B9.>F=<G=Z*D%0FS[3:T<E7$=]O&GY6[>ZZJ1L8)S?N $WP,0!=;
MJK+NEJ!9XWIILR?VJ(>G\OD.B< (3T3Z^U1QK[FU2*QCC5.#$,A$N>D$^Z>,
M1#.YC10T>=:T:3G3:UVOL-=!&C(D2 78>B<SG4V8X!>-$U_,6[SE&IM35<%*
MNKC?']>P;YM=IP14\QW$!MH+OCP)VSA8F>W5^BI$>;]B?&:\$GE[X9TON-"T
MO;!UL'1N,\JKB^6[01EOAWL"2T;[:!,X.C>ENIKK41]A([+F_],D/O.%,B^R
MD]G)NN94]O33;S(VVB5B&R."-%$TN#!")Y*NLGS,UK<\0L5\KGX*JZ3UG:%?
MIE>ZA$0_,20Z.1"'K;+BCD!4<5^,T3UZWL'+R P'A(Z)W[(_\L7R8J.DA$UV
M[R_Z6C\?LXWCR.3N$-=;&19U>DQC?FW<3U'=;L_S,/(OI)R)G66^.3S+&UQL
M=XXYG#^>[3*S:;-WA&CT(>)PH]JS<G3L][OH/'.]U8@[N^AO-Z&O8K4CC:T3
MV(B2POD5[V2N/+16YX^UOFJE>R><(B(%HY_@F.\^0F ;$K.0_U#PA:VO[$BD
MDC$N+43&T/$UU$'Z!CC&O'L:(.6MI:?$83ACP"UE?'97NR3(TC04[W$/!S 0
M")B(,3+1_3Z(XNIZI]T2[Q/)2JXT'>@KZ9RV^HS6[ B[>2UX?4MKL6G<#O?[
M[EZ^UB5*&ZWL/V]D@A6UEB-!E$J"G$3 L]U;CR!B*]P_(C>JMOKFE-'/=XUZ
MNN;>[E!4Y4('Z<RK%&8+P8Z$&5OO1C? 6B9!/_"A_U[*#P$JZ$O\X(X_\]V_
M?%! $Y&E=HKK#TZV!1S(E>NH[X0#=I)P0#%T4@-I[2^V!A.?S2N,='$@Q@E2
MMKX)QX@^<(0#;K^H-J2AHKT<E[XO8;Q:X+_OM37J*T]62L;D;DI7KWV'!W!1
MP;=FHK=LE^H$*Q?VJIPI)V^E%FZM'+Q?F?2-9 &\HPR.8#EWEA7D*M'-CSBB
M>,>^>+2:=O7SIU0H7A+T++58>[OM"#?T2F:2?L?J67F1A!+':F%<M$-M80D6
MZ.]5T$ P^*>^"(%;\M:E>]FK,4/L?]PE!+E2>DTU3:B$2+1!*2'8N$3BS_=6
MQ!;XEE =16^_)1[@A6[\,D"<>T?:_>6;\$B]D#LZ'AUU*-3<+D/)>B=9S&4F
MPH>:(A#P@+6>K"C/E+\HH&^J:'8^VTP=\*7?4GJTP*#>3B;^"HH.@/& S@9"
MS;6+1,) QJ!L/ D+_IL>&0/!-,=&QZ.(O'YIQ 1J)K1L@+,,63['ZJ6E*Z?5
M]-8\B]8TA!M'MP@#H5O]=98N$^4DJ.=.N[)ATHO#T\8"/_EQZ]Q%-QYO'-]"
M 4G=9X1>-'1R+ !R@LF+S)]]QSAAQWLHI"R^'!BUO*S->\WH\)9=B<G,O-ZA
M$6*%[A%6$D"?4( 8QH[L473%/:@YQ?HK)=,T2WDT+K8*)>J%CPM7-95-60*T
M>MT7=7>9O8[P:QPARL*&LW&<U#T_'58P.8[$JQX):L-9#!OPVG)&MKZO50I[
M+?IJ&M[ZC9VHW 3Q?/!;4'N;\ /(0@!1-T&3X0!6S>VP!0P/9;NYIMF.8_B6
MMT-@&_>@8Z"))"R+#5Q456R#&'$N?0/2U+S2R]M+CMO#5?3('W:)=;A@B::W
M&%W&*Y1%Y#\%U7#UB\3)VPOI"7>\T4_^0H&'0G3 7E).9M8\O+%C8>S&4W]9
M'>M7;ZD. O6\N:,<*UWFX-/9+]:Q.*>ISMSPSK5)OZNT?A7QZU'4470#'GH#
M!5%H,W*^^V?W<@N>^>6%"&D7*XYXH:@7X+4@$,1?DXX1$<&Q#L$7_8KEQ4E,
M8LG=G"W[B]TC6ZKA3#7!ZQ7 !1)3E!T?'Q\&1+=GHE:=/*U)2O4<I55F3.UQ
ME3%<4+?'<.CA"J20$!SE!;5Y:9_<W<"*LV7J)O3>L"V4SD4)DM %R5MWDNAS
MW>8Q46VS-K/@R(Q+BKL*<71&\LM,BM4.U;O-6.;1>/8/;2-21U::20!/F/F3
MJ1_[<SOJ@O6O'+[L)[?.A],O9WD-5AZQ6IQ!8NV)L%P;Q)B &! UT+5JV("S
MY"XTVNE#,EFS1$K$]BQCY3(OTT-_:<I1G/6H%ZTHAT1 O7\3/'KW^*3HP;3>
M9T_YUK#F.K'H:8>:^@NFV-+C\EZ</:%I_D2L\9*$B<!OA#3<;^\&#OC];,6U
MJOQQR?7QL/3"@U)^]N1 +7PKCM@^MQ"#&+<?$?H<G*KRX;W6UYI)^L9)=O::
M:[7729Y^+/);7T4<^O3I;G.?G)7H:V)=0Q*9CY#.KM!?D"Z-AFA_\0R?]1EE
M5>HSY/JX$0+]S'G]!&^'&S=NT1!*%$-></7D,TIN+<];I*E!;AVRK$5).@3$
MROSDH3#L@?$4L7F,)XN8][)K=2E%EM/SF(.+O'R/E!XC2V?P^2,/T>%F)=:M
M=D< /B=+TFT1=T\KXS94FC.W;]:]J9/"Y+_(4ZJ9\YB[68:+$A^2*1@!+R=X
M=5%=CH-);1L][PNJ]'8OAYHHUWM\:>6)0/8[[P+.H*@ 'H#Q @G=S_/%"7MR
MKA4_*7UJLZI^+ZM3?Y/S\0Y-9'H3TJ..K.0'?U=J#PTAK[5S6'2A\WC-)6YU
MKK^)_8V8\':"@GT'#=4R,563& >%1[Z]D VZ3'#G-,YN4O<RV>O92!JU3025
M(?67\CM5?H=RF&^!'T9P0*/U*'I+@U;!\&]]J@73&0^SM(\7A#R[#CO>\^U)
MC/EG+IP:N[+[09W"@4A"<2J3\-O60CA ROI@;H@N?5_!>+4?K ;'$2S_SK+J
M00,;+-VK7(V9@BX$6IMNLDX_]X$/''S=?HEM2/_O[I ^"C]8&(EG)O[><A;U
M"?1?!IY@?IP!DKAYYB&VH=#&^#_HC?[[=TA@0ZN&HB]+%_^ B=#QV_[R?-'#
M\J)$A0,&-P:P]$.6]P8/OAK&/QU4U[S:A0/_\9/J8#*#4\S@P(.%EU-FA--]
M WD#37<CK@6HI$V5$#B EHX1_YL"L4S=2@XYV)AT[I?N+EFHDR-(%M;*02@K
MVI-\@L@=T*NDBE0*V'^][!K%O#+?.1#*^&F_B&$;J::MS=.WLME+_5P"&>OU
M:L#W,&"?=TEA1K-><8%$;7WY94(<-XF6!3*B&R*.Q":.!! &=)V*13K[(I6H
ME.IZ)]JBL\H.I"IW(R3!@5?D'PPY;V='W!\LU,#"W=L3[\E0Q#=!N_1FTE1F
MS23FU$S]]8!I#+<<Y1<H?VUK2 OER=;>[M>, XU+Y9IK,U,;OPK-(6<9N2H4
MH^TJKUS^I6THWZ]17"L860WL^^07G 5;*2R"3=9Q<MK/4F5'6ID(A1NL/JIR
MP)P&%AAC->(,1>0FP!^[$HCZ"=3\1_123Z1!$I!ECPDPQE)=:I[A0T5"X,#7
MUIAL<%_T;?$U&O!?_1VE'H1H98I2$*;]$0JHDT!N 6Y+</));T0-%8E'ZVQU
MWLQ<G4=.?Q)MTZ6-0*I /_([QVR_"#PF<,D9'6P/]AQ*T\!W$2MR?NW0C9?L
M9O-)_;592N@J@"3/"XI<&\6QTF>MY9^7+!UN<(UH33B]V\.O6&"FLR=VJD<6
MH:P!8>6O1Q+)M-:-VS%$"2^<$2[CDC4)LN*;?N;N(8DBR&4J#6H7U@$H./[X
M\B#,]OJ:T)VLP2BFA*8FFP=SSCJD @#<\MD8=ECN 0JG9H4MXQ2V-ITU9G?Y
MT3NJ>4%S+\F@G1D-@JN_LC&\>=:1@UPRQ'<)^6.4W=%!Q+*@ 7\M63KJ,#6
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M=7'\Q<67[&%YU@H7%J_<=/+KWUV'[U&\2S>2(T/&7?K>HR29'B?WWP]EB>%
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MLS<GG["1BJP6R+6>"9I'.[;WOK?VWZ-F/A:M_0!%.5\?I'\K'887]':Q/53
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M%A'I?TJ(?OH+"\-AZ\TX7J.Y=S>^)^'P$2>$ _63#Q!T# <F797S^L67F>"
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M43L:9%^23?#$\S_:1J9U_CL_SE9H%.RSM.:_!F<XM24W_]J@?2L-\EO^H1N
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M]K<;<4K"C>]8YWMPC(D_P5 2=* ,^#9'UG0C<$"3W>W X)=Q*EF:#NY:&^G
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M9YF,0$[=$JA;5DB46W%9U&S8._CV<69]5N>6>#.N&Z&R-S662Y:![_N/?.%
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MRSI>CD7I:^6W<;B7-Z#([S'*EI,OAT^*SD= .[,OP8K&^:]HK/N5LJU)8J"
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MVR6P44(^O84"T,./7R"8IRA10,J[%\@+X)FFWO7'4$84L'T=*;V1!>UIA<Z
MSHH'!3P_;4C>OPJRIC83"J_\+Z(D2KB/CT%:(4LTV\GN3DA_5QHX"0$*N"Y?
MF(6(!B\W/,8N34<!$#J04'E$ _+J%C[TZ[T&\.'OSS=J.!2 1$'AN&#F?C@
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M"A(KW(WYJ$5B!NOHID!I3BN/R2;DL_&D!CC,3?IV[% :*]8%O^9RRJP3RI"
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MGDWP.9P-]C<7-ZVB-?L9E#8G(Z0L%.2OZJ]F?=]J8&1?^G?K)?V,_L5#O.J
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MDQ^C/I-+\QL5(&@#,&I4P)7_%9 LOGJ/$5[5\;=T'>/F<7F203%^02['E_$
MRUJ<0U=T' E-P(@@5@41+*A=Q @RQ?U&I2"+=2)/UU1G%D6(.YR!&#UZ)GJ\
M\$H7'VM+C&$&B^7((1.Q[\=BG6K8B16@(>C%HO2FWYC/;U_)BQC4ME:FSD"
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M(IC^L^\_'7Y)]/D,-A'C-6=;%%>$S$N]?*-PU7#U_=NC/R[L(.Y$5OHOTH_
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M>]T'(+V(_V]E'\#S!OI_J_H +AQD?BOZT 2=?0K\K8@D#_R[I/]W2>).ZQ:
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M@]"9.Z\!70#@!U8!"4#R%K=X'FOWLW4]QIFKRC9YH/C^=LG IS? HK!^/(+
M4"X7%W +P$%9<+>QN%L)+);<&JJ[HX>I5HD(2R+QK9>]!I3 5O:@>R(_:,A.
M@K5^;20*U[O7:\K  *7VL"E$PEA9R)0L5J7@9$K0DANF"4EG&:#WYT0Z^G#U
M_E)^8>:HT2=J9U^&2M1H5*54-2D(&B*;JHH5.4G09O$?:UK2EV$!GH-QII;Z
M:^6Z538UO^W(ZNE1ZFF),01C,@>+YV']-: 5_QZJ:/T52L%?TM./<M&5Z2KW
M\]QX.JD>W7'%=N J">ADZV=(A32-W6-H-,_'T.%A6*MI]@/_3P1Q:[C.[91"
MEP^@D'6D]&+U^RBMQI<G\XT]KE1JU'C?=B@UUC'S\&E0BVOW[/OUO!X'Q-P9
MHUJJFTE-%?LH\F9P:&5X5  6LK?4B0>":4)%BU #?>TXQ[2YH>M?&]KJ/[X<
M@#1\BZB6K(HAO=,'8H2QQ]8P2AH+-O=C0NBAYG%ZQZ*1E14?8>G&Z6%;4,*1
M>Y.>U#5>CB^%F;/? E^;()^!P"EG*=GBOB!G1S_Z9*AL6FOT1H-('[V&1A'P
M3+\OAE[[&!KN)#Q&)2.]OI6OU;H1]].>(>%H6K!2$FW#9?SPP20T,L>^_Q4T
M;^:SH;U1#KG (K6/+K8"6J+.(%/,Y?K+ [QS2VL]*/@EL--FM;H?H*ZOTSZY
MG_^!QU_-DK2VU1C&\U1/;/WTSE"<P!W656)N-:_%,& "VXEO3]CQOL^<\I%B
M?=NOD*],''?17C-$N*@Y6-ROP')>4=)W14/>F^DQ%9RZ-*<>*3 NFNZ&QZ-[
M>"SGM!:D$'8Z%MMQA75UB0F#9O[N;?1!:EHSCC_\#!V<B<<:FY1B%99&FBG,
M8@9UPY0]S9[C J):T_OU/@$3/KD(OY2!T<'A';>*V%!34>WA%L&J/5NT]E=Y
M\W:N0R2$B;QXUG:YJIMI6_,7\S:^L'CT<[BW&3D28$5R;K>3SGADZ*TOB!(I
MA8FU#7W-,%?JUX)D&A*A,P!ZI+)!T98O@;D+$AF["^NE<>83>:(!PM0577U)
M?7? (!3G0E. D0# 60S$M3MK?.+XDJDF/%&1#O$&EJBI4*,,<H>XJ5 VMKF6
M-OSD5O4>Q-CZ<R\.S;G4KIV]>P_MN20<N61BFA)Z#'NT%U1C96&=>%<RV=<
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M0U,=L!A9?_>=KT&VS%=(P\J6S]+/TU9KG=4F6HDY43630^$M<88)9@(F,PX
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M4F]["!^&[HX7FH1NAP$66.GT<(PRXTP7]$]JPKQ5%0ZI8$>VTDX;DG)-3>D
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M$,#UE>(?Q-WL$7X6*N#3PC^EG1SL.0']Q_8/TMX&;3P) C@^R/B#N(_>H51
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M;O*[>RCSE)/ZJ'&^=M?WR_Z.3S\R>7/\<XN1I!7*,"BM.!_WVQ[IN)N]42"
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MEQDH\D;YF]8-!.D>KW,_MEJZ;F%+AD@SR5"CI^)TO//BM<*U?1W=^1'[>3'
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M^N/;VY1YMM#8M!IG&=YLWM0-&8<I4)B&%E=\JXVX^W'GV]V9,B?G?AQ;;*9
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M/.XGE7AG_6]4 L&Y*5@&H0$)Z=/"22;BXW^8(H!N@*W7-:_VXTE_=3W<)PA
M,&/^+\%K4$GN*<:^U,E2Y)7.OGOG2#SX70C]X4,;^X@(<Q)'/9+MPEE&=(0[
MW)-]8T=)K*VKF)8*X[B*FR0P\\G* Y6+(?WBL,U+MR\-A#0HPHQ&?H,]T@ V
MRMIRY\"T_B),TX,:155=*'W^S,SR@84[36TK8F3)W^(+PKF^V-LL6PWSY9Q%
MD!R]8A*OF;$J1:KNCK=:?LIBF\^JB!.Q@)60RE4CR*U2CF+P.</G&%NEK" Q
M(KLO[.\^VRSGI$AY![S4OU#5!TUS>(E_>VD\4_?UQ[FNX-U;K)>C6X=.>@O)
M'"&Y,#5]S*D'5("G4^47;<J-=M6IQ,TN+6TP5V08DQ2!?1;GNC0SQ0ZHG5^H
MW_L=G+L4&<HXC2QZ#M<1JFPVS2S!O U1WK$^FU]Z]0;Y <]'J(0E&GG9:A&%
MI@?+Z ->]%?7Q5PV$3DRL1WX:3WM;>\!!06T @.6]9N5SADP4:N<G'KT>*86
M2E210&A? ;&:"*'H1S_W,_/0>C6_ A8UKXJ*H8WB,,PR3UX7[%UUD;KG$XMD
MF.8Q\PWI!U=K)U+CWI*S?\KGB,[\/>>1_+]L"8-S'6_(WIQ7MH#Z]E7DPX/$
MH<9?JF6SS^S\W'9 ?&BE:DB0BY1@)*P+$7_^Y<FV-<T"_/%"6,,/WXN=<M/Y
MQ<FTLV)W+8';1#S)]W\FD.1F?UHMC+'7G;_#@?^G6X*;V.;'F.:G^_[S!XK_
M(L>%C'*=E>#&M,=CB>-:;ZKT2'M-7_1IAE,5Q3:QBPX_EN&'K00.XXOW;S#>
MWOM\RT2$ /Q+NO@< OCK.\E%?*K<'NCA=HGQ)>N">@X9",=*6ET:#PE-^]XV
M?&:.0Z(^>:D".PRE]0.NZ2OR3:"!%76H=M@,"I3V']Y\4QP3):FV <12_@IB
M1VX_ OBZ70<QO?_ZLCPCN\MOA/3EBR/F=TJ4<OYIN:C1F7,D7Q=RB*CDF_RZ
MAOR_&+8?"HI[(&;1QI"64!_:>>%U>6B2+W;C?A7L)+H%S*?4$^>JC6C"^@Y/
M-?.3-I]HSHW:ZFO1@9!#7QM5AH@,NMCA/]>J<W,0?.H&ZJN4L6_"?;X*$,_>
M2[#S\I-()+2NL/[@W5[9562#U[C$P&2BI+@MPAPSPB']PT5H6L2H':GP_[(-
M3=J:&.Z1I:LC@C8$*CG0URQB3_7E!^-OM$Y&N%8T=O1HEF9@!62F[GTK->DG
M-5Y?XG6,;S/5=MIRGA7?.GVB-&0^6WP+'$B)Y!RG Y;PUJGM>LG4[ --/BE.
M4NG-/F>*'?##Z%X%B9 [-?DZ7Y=5R7(S* ]^;;1KI51I"EA/]HP>KYTP0+_+
M773_8>97A*S:O6%Z*)4^H&XE[*Y=PMBR,5DA,E&6"QYNG906!H9_(NP=4N!)
M95D\XA<3TCV3*LR!D_11ZMV*8-UG \7DE]$>9!^2Z9P+=%0XW]4L(=+F>M<$
M]!3<)[&HT65KM)9??;VN**M6K"S"'<SKS-=9] 39L+2'X:&7Y]@*EJ/[DFQD
M7?!=OE?A0]72)\<Y4DSKSR]=+R#J=J K_;"7>VR5-[<0J.1:M%&B?)TSD)T\
M+=/=O;LBS5.VY$)N]N'."ISEQO<"69(RB(+GO&V++I"*6)KH-HC4XN3"S*]G
MFV]1S"X[BS9W4CE!8.=:9T)>)R[/QRVO@=M""B?PV_LBKCT'ZO7D9C<-UN8Z
MC9;IP_Q\J^FJO7GG="M1'V9_Q6J<+R>YM2_I%T *B,C\FQI)VF'GZ!BZ)T6C
M(-G4V[>>D4NAL64GW?9+=2:F:9=25B^COQE6AC0I;RO8-<DE64QH++5:8<_L
M7G$\&+FT*3D%!RU@=]WP(:5M*;STE=TD7R?+;FZEJ!B.2 7*W%=O*#@[*^J[
M$%A-6/,J@,^.(A;S$UB>L0 M^15X=8 #R0>'7AY"0PT;BDU **^,!/?KI4K5
M8H);A!^_[ SP=OG,=D,)/PFS)]:E5,V-%%A4R6=!\?'9Y7V@. 3P?(_\&LI(
M%56%.8:%5Q@@@(6,.VLZ*8,WKAV_31? I)5" +T!HX^V"1" 1(U;TN?[=#IP
MLSH$,&DO8)MQC.NS?RC\R$R&8##Z>9_F_@G+CJJIG.90 *).5*99OE:0;KHM
M9XR?R.K&V+?52L);64)9:VN&LVD)QD,WF<*E?1./)IZXF#H:3WDF!I4*;MRE
M^/"ZY7[:@\8F+3T#1W$7,V[_0&)_]OH#N[%K>&.L(Q2\""I,#23EL:Z.;Y8Y
MM:/%%KL57/-<>=J$0<6QQGD$T][RK]Z> 3F6XRP]'%Z 1S&WZ;>B:]^1:PQ\
MS!!S.TS5T$<,9&F1>DPM.,2>44J@B3D6,L_S'MZW8C5"E]=]1<]:=G;&FQWK
M5OZ08[K4M"!&O$"<(O.0$ON>\]WJ0W<=&3)%U!P_$?S#'*DHM"=/@CIGK@@+
M9=3CTC*:MX8N@/E31T?E*=?E=?+/E,MDRX2!8LJ.,PG:]&<7P(7X01VNZJJY
M[.'M3U[O"3+LL*1O$+Z6A5TLX@7KNPX".$3V1,I+)37".B;O>IZ'AK_"B=M@
M-+ V(>(E=6P&:0"M)]CRPCO7Z0X*IQ3<=X&,"QX\(*\+&[F6&#12U'OER.':
MH$:X\(4X4:IR7HX=TM-TUWVY)_%&[%^NOELH*+4T-&3ASB\OGH4?SLS.RG^K
MY<4,3*@J4Y;4F9]POMQ26!$@4@@GQK55BXT2):2(0*8X0Q9\ZJX10S^ ;9ML
M%ZLCSVV:/)Z?7E20HVC4PDV=AY]LL5OV5M$T0W4PH=&J)UE5MR#>6&\ 147Z
M :5W;/5>PY0.R0!^@T25GV1C&'=1QW(TKLE=0)@J/>)Y/(W,6 )':-5XF3?0
M8%H/U])_[S^WMW>I>(N^VW:T[/.C?M_U 2KU=3X\[UG7Q<'+#[_Y7!2F8I-!
M]0W#8G?@/?,:Q\:-O2F<$)30AST2/AL]](RH*\.S!LV>0@!<>C?!EMQ#R5X!
MS3;<0^H-YAOJ+G!;Y$ZB? .\UHOC9*7%_:V:><[Q?8%S6@]$#@!U;!T]0U6*
MP#>"QIM.A*/\).]VLG(.47P0RHOV;TA;PDK,'#+GA\_DKE[$%NWE=F+ 7/1+
MDD0VUY/N"=REH4G)O[HUV(PPD@@X6#\EB6&9ZAI_F -4WDL2U.GM3E:QO PI
MN'IC6%I<M]W&,=)&;*![XVX.XVB'CTS*DTA:M1L GV%B(RXVL:6H(5/!.K;Y
MX% R:E6ZT@FDC&#\B.X O^$JK2P;OX<HQ\@016C;?JZ&E\U60EM 0Y#SU<?.
M87WT(6 #ZNAH0@ 7'Z:R*C4CP]U9A]/?:Y-\_B_(.)G,GP_=KV=.C-/*C^"0
M4B+]!GIYQMEM4[DEH9>WE.NQVJ(3[JZ(5@U\3(S/@B?&L7X,9HLBL8%';+^M
M?T?R9)7;9#*E:%?_W-'J2,>F9\=OU&A+OR9*V-D(V>A@BT-J7_LVW5+=L]7Y
MU9%<1_Z^<RMA(!\$4$5=PW 2JT(4,M#]/4J&[MU2S#F^Z8=*^#^T91!O$2(7
MO^"U(V!E(4B99Z$=$(7FG!!IA5N:E40I$P<@[B!G&R1C6Z'\<(A[#13JD?&@
M'U!>2>Z_TN#:'K>J.923GC(+YO2PGM0M)*>.Q+5K/"+%T+I=2NMKTJ$PC#M(
M/C!@2,VBK=/P=I9[&*CP!C/6S)39J.D"MS9KOA6:7[DUJ4D3">_YTH$Z$LEC
M?<D[+7%\S(M?>*5IQ%6 )2(_JS>J1:/!9P"GS&HX946(*>3[T+60/C-MV [R
M]LDAGQ4/:-QBA(0YN\1H>.L;S*ZZK7RZ2!-6Y0R=&.409^Q^NEAR)JDS9*8B
MM-N.C$F]N67/L&!IE)QJQ'AN8V9REZJF-?*OO*7F-YBASH?7DT<UI)2@$4Y'
MP_1EH)5H1Z/?B^CMNL,,=IA;Q>6>Y0N8;S>1/>JMK),T8XY++^\L!^L?$M?3
MQ]?DM)"_R3.%GTE<.7Q&SUV+A>D89GM5//*"PH]OVX;C=3C>ROT0+J*UVVT0
MW6GN3_\<MF4IE>"4NV7*;A0MC,L^NY'MPN2=:F1A)O(!U[X> Z6-$;KZ%S_I
M",()+OA+2B6&S6N^3-2KEV09^=+G6MH+"W*L=[V!A!MF.\("S_T6S_NA7O^I
MS=/8$2S/B2ST%,FS$#EXYO!N<<ZG#>U,TD2TO@R]N7/B]K/C"^T)*NB"^]@H
MFN_0N3ZZ1 ? @5SAQI00[GYMP0C956S'7!F:LYC46)T(='WOV30L($N")_%0
MGRI1[1Q,]]]14*]9HR,PFS@%+O0-.*ZIV4^'&==5@RP>#XX$#AW<VLS/R4?V
MMZVM'MFOJYH*2-WMU [W[A5+/63N]1X+!!N.+3TUMA?DK\;T!S+H*C<CJ\ *
M:H,M8&(=+^=%_"/'A%$M$EF'!/2.V]6'N5&J"JYI]_&BRZ"IY.)CMZ)^13WR
M%F\K];L]C#A>3.,U H0K70V6%(_:NE4.X&:]$?70!/_>B!Q.!!)US$15D;I3
M[IYZ:@%O<Q[="P'S&JL6+"5_((NLG7+(+BYHMM]<COFRJ^\Y2(N,NP<K+20,
M'?T%'R$)!A]>Z2GW7H=RB7IN48DV=FJJ6EQ<]H+LH(1)-F?X,Z68(F0Q3I?F
M6!7KNZ;JBI)%.8^%T#=!-"#F)6<!%KM) >D1^KS@LL#&SNDBA:LVZBVT!<NS
M&@\#N0A'X'1=C3^=54-VGN55HS,C3KJ\_7$)S\)KQ5=3LWSGN6X\Z"Q7IO.O
M$&7:[S0D9"\MS^XM8C(8JMVV7MB7#QS. ;]R!-"KM%7Y&WD9,*DT'1W$@8WQ
M1C[\3M(JG4\QZ3HCWGYB6N%M)9+:"B#Q\K(\RFQ)%^=]0BJ[?)V6AW>MS:BH
MOS/8?[X=K3*/^[C"ZM0V'7:J?&[E>)N21(:9U)3*9);1'?P@+^E\>W+KY;:O
MXOAJU\DYG*YB1,6'1U^S@=%P5TJZISPT>\;R3.[H"5^B(UH#3B!0#>5(]5:<
M_ TG9M=$1YL9:(-!7$:V]-V*!OXNH[NVB@$/8<!HTOLU9L/,S82,8U+P344#
M*6FII6WRFZ]/AII\Z<;$NKPE<"/%)UN\N)$EJ^U#:O V&T V7W-H6W>0:Z9?
M-:8SR[RT(4<&$@R [X*%6V2RTV.W]XY50]XV&+A2W+V(1II$:S]N+V="3Z?"
M29XH/B;R>#UY2*""-C$^_NI"2N$%@ZHM9WX9_5G-WA0U^+K"2C8Y+-P&$12=
M5G(F\_'Q>(D$ M@8A@"\2&9I6>QSI.@"Z ;)[9T-AN\+?![2#6YP&L8_AQ2]
M98N]]+ZPA@ 2KI-]-DN.Q"]+FJSHU$'KTJ_/"#?,.^ZS%5(BO'!AV0JV >$%
MVWB)LYU;<W&Z\K(,95(*J44%)ST%G<.,5V%OU4.O099QK29\+]7L7/F4 Q3-
M$/B+:IH"'TJFFP1J"IQR(GN^TC?6NA&XW[Y/LM>P70(UD(1%</"36@I1Q:I3
MH:GDNN7TY=$O]28Y+/7LJSGES938G[FVF>@_]:Q('E!7&(WOG_MQV%)K2A=L
M?&Y2%V.1?R]-;!'&L(D30!IK!G#&6S/CN(ICN^0W(OM @V+?K<W>:#VN][S"
MN)%J<C"G'W6LR;E+32.FR1FHUUIVZ35J4;&H./3/G>6&2Y@6WN3,C[QB502+
M!_EH+PO#0P"'*\.)<C=1%PF;$;]:&!&G:^4,I05*3.0B'[$O9GZ,^,"WD&]Z
M?M*C"[+Z :::<GRR,G?.]5RQN4EY*GK%LH3^51T @V_D!5?Z=G1JUDD3O!#U
MU+L6*WE:FYK6@[X.DK5Z"L87(IFVQ;@(A*@ @++)EQ?]<NEWUP2*IRPY>8K,
M2[G#N'7P2=*J#)N5'V)-7D3)=*#%]:/Y2C,,OGL;JV/G;&-?=E7I5KCXV+BM
MX>&K6IHTKP$<.%BHIIWL^XZ(H:@B+Z CRL\O9'K)Y:2(O]<X)6S:4@]\#D^:
M920BO=LT*,$<D<DC:>ON"Z2.[Y;-S2VC*QB\('ASZER6TW&E(Q 800(B^&!3
M7:>7-QX"Z_8MBA?[^Z(,30SR5"P!DUY"WTYN=)[AD9P ]M"0#'4,2$80I$B=
M+E/,P>5D97JLFZAKT+\]4/B49THQ%O\=6TA."4ZJ67K+"QJKT-C4I<VCH49C
M<@-7,[ HC\'EK@V4%JO\6VQRB4KD-P*Z[DWETP>[#_X. >R^5E->W"E[X#U[
M&#_G#A^OK _9?-*#@BWRTC@'L<>MQRXBKF&S8&#RX,CC\\)%BI>^(FYHWS.D
M6O)Z3##(]-MK@KX>D>^9V(I/SI\^)2"RM-8A"UC/WW=@U+&N6S :TAXA.MB<
ME5^4<[GR6Q_=6G:@$/A\#&=%' P!:(R1>80+1LC1IBF8>#P("QN,76SXY*WL
MQ8/I>*,D<'EZO9KX"&!%OK*,$S"UVPB["(3XI<35H5_*Q??JK6^6.%"#%LHN
M?SC,O!RN".9:>&0!9G]-7M\]6K,,Q.I2V]*@'^U;1*:(R&5C(&0T+#--2@:E
MFB!.6"T92#1D.:PW/2%7F61>CU*TR6\?D^?RX<C@X1)3C6S&,6S"7>I@:'@?
MHM[H;?(RVC\SIC&DRG(82U?^_=J@O+9J4UU3C!I+E!2\GZ1JS-"VB-"N\HL1
M5P%)C.WY)WK5W^5[DE-4%%.,,SR.KQ.%T2O*#KA?Y#;&\SV=E\[*<Y)@,O$/
M0 B"CT+IU87U4),S>OE$4KXV/M+K9<[G+U/67+U *X-!%\FPM.(Y*<+W@?#V
M A^COX?DI,GT:M[A D'_3<RNV_5>O67"<0H\Y.BW=[0W,\&?)EY*NVX2-J#6
MJCZ/TFZ3P-='%0(XW?_NJ6;.'7F3KBL]CQ*A(0J/;%;CBK^61(XT&$412]]9
M9 S7AHZ9?7&MQ?S>T3E.F[[/^7X$U8^H;?Y]_S67;]W?[<A?#HS\U>>_$[/M
MZ*Y? :\. LX.4NGT=4QG+[00XJTB"=@Z?SIPZ%B*N]/%%PH7Y-:M(W\&RN(I
M(%*QNXH"V37*VB3$G15L'N=L-WOJ*N#GEH@3!=BJ&:9JI]V:X&><[3OYI">7
MZYFUS)2Q'JV=9_M\T:&4"+/=M&H7Y-B(2D7J(2@:8<S!2ERK3$PFFX\%YXAA
M8.6GY<\RQUR;$%MD9:>5D2X=F$@AZ6!*%E2E>E>IZX[8K"E<6VHV_=@JB3BV
MSM;<YXG?=S!CLB<FCF?ZR',;?7[FM2Y*@;!9V:'D;6UAVQ#X+,Q.DV%JSTNV
M.8^>_NQ>UOT^ P=8'<MM[VRGN-S$4(M=(R6.HV!W-TR?1\=XIJCHL2:3Y\(,
M:DP0G?6FAO4P,@W[HNF+I1L^&H47NL' D6/>8P>:NZT-J4BET4$]48HU?X^M
M%#:_G381MGAK@^=:KF8Y?Z1QW: Z,;A255K)H5#FO)BJT42J$\E\L)1>?M4:
MFK=4DO%TKBN!]3U)B9U75Z!\UM.G+KCS<MAR."-"1DV"5J^<JCXP\QF:^1:H
M<Y^ZJSIL*OD!S^OMZV@78MP7ECUG)^/6%&'T57)(5%=WE690!1<GJG2+=0=F
MU'4,) 9GDZ2 Y7/]",W:_O;5\6_0Y?&'V B_M:XCD]!3.,UC2#W_FI6T9B:%
M*<=>H#:*1KT[D$"E(CL3=IL,!.).K,0)E"D[V:IMJ%2?V/N%N\Y;>,[S-D4R
MN._-M\Y:]+XJML LUFV9#,_K^_8IJA@1UZP-+N9C3,S'5(V1#3O[WG6ZD.0M
M>XMQA3UV&?J2RZ_:38Q-38S?+T^FJ/SSGF&Y;"T=.B\MW%]ISVGI?9\Z):O$
M*#_E@IF2()MLAAEQZ"&JAS*/X7-4K;!=!7\S/(4,QAUE[>4[^P%M]^]K@R<Q
M'3VY%O6M0 <6]>7X?<<(ZU;CJ\B<DCO-!^-_+@>6WPM*!K1='AV@-G[L7=G&
MB>*,<)%_6S"FC/?G7[TL+GC=YA9^&;J<\GK!P>Z6CF;"?OJ19T*BY3%=?W,H
M];Y3^ SEZT_RX/.('?=OI^=WG_W6S$&<4V*P"('!52\$(/N\^"^7'R0P9I[]
MC<LV5_YVY;\RA_C/UIABV)(L:GSOJ5?^A%O96@;+.!-[/\>+!B">5I1.JDP]
M!FJ$R#9TOJ76MH.+;ZT><QQ#QGH11@:GA:T#.1NY&QQB* %Q&'F*\;)W3]LO
M"Y6?AZM0P%MDTI/"?@R 6R#LK:&@_KN=^%]T9GD* MCD+O"9%5AY1$2%4ME'
MH[L_$MD?3G@?Z_]&C C3:7\&T8X?W75]?B3DUTDZW-#\@ "H-I_M"OZ2>/T7
MINS_U9@.D[=>G?P7)\!#1RO4U#SQ8&)3I&7A7,9<&VW;SX#_?]C[RK"ZLBSM
M Q=W$MS=W=T2+! T2)! < GN 7()&MR")DB"!W=W=PT$=TAP2=#+Y;NIGJFN
M2M?T]/145_?,-[_V\YSGG'W.V7NMM=]WK;77EFRR,KES^# BT/$34+9=B@?7
M:7 AV1ZZ.GW,7Q-'%ZA'6A6LF!LYZWZ ,E0QD*\J(W<D_N7EOIYR*'M"8U>Z
M!A\NOG+BIQR\H 5'E?&7<3Q.J5)6L-' JR:7(6=94FH,J&%*8@2QJ3A^^"!L
MZ4Z-BSQT,/ !E4H-.=TZG64J<Y(__$91JX2-8T.!2DV@AV1B0M=N-L;\;%!B
MEKZ?38EG58#%SZ;1Y@5E785W8>\4=?-;O07:3@1;O#BY?;*:+:(L-U5NA&?Q
M35U%+P."C9)!@@]G#CX6'9:4U';F&SR1Y6^D8\4OTCXV'&PV-+T+PJU1R.55
M6*G*7N.M9@)5CN75-_DM&9HC#J90!_IAJ.$@//@$%]X0+2"U\=H+PS00#Z[Z
M=TV:_ MEC>ZHW)ND-HQRVG(FI+VQO9XY$,:&A.>#%U1OQ-4@@WRPC@IO 7OP
ME[HT[)^38F8FTKG^Y5)R_K5O1GI1ZM30L_(LQ@)5[L'Q.6DI_Y8%Y8%GQM6Q
M_BWPL&^_ ]RD#GL$ADB_5GD:@B4HBWY<#'U1?W[?M^\5Y_ZU__>/N7FS;D%J
MEJJ_Y\'QQ:D4P5\B#4<8C-?)NP7(_<#J^KTK&45@353P'8JX&ZR_ZRPJ),Y0
MCC4[EJ](&W,&<.VW0+KJ_L\;!/JU_K1!X)>31JEW87] /U'TTEXVITZ,8IRQ
M^L]%^$K_/1^$5NI?.1'E']H3F647:_+&F'V"BN*)-^7E1?A<R<];%$R+1_]B
MR=J[!?[]E<[I%_]3__JO]O3<H)=Z+H_N&O8$ZN??:=?9=O2%HN0J6<,Q8D)W
M8A:OT:+R6'-S5C\NMGVLOQ&5[\IS4.^F,D;TA;(.%&?T0EZR\IM1#=CR)DG2
M)'[@5,#N>G9DX7P^PP:X8KUWCR+#I@BM8KX#A18!E\0?11SE@/FGO'X7"JIQ
M!_['Q195=<%P%H?,46NS![1QRG!W8\D_%F!BCZ@1N"WM7-_K"00<$],IIP_V
M^7>ME^[2#\\W$54G+BB)S,T2;<K';9D3[(V_>K#O3/>8%+:N)=JT?;;GW#P6
M[P[DTC><1_=.:&BT#?=ZJMNEWE^#[Z6N;>F5AF0W=_]327=;FQGBHJI,37.K
M[M/J,&H)QI9Z77P]J_&0I&>3B$CWV,**61(=%N0TI!#Z8[!,%2>SH\YF"";E
M/\B#W>B_S=^C4K1+L7??VBA-XK.G^"0-WU@E^@@OHJ,+>+[X6TB+4FCF5/'Z
MQ[UGR']GR@;<^I+X455J\>R4VYM.AW=Z/?51Y%MJO2#W=M)W[+2F+XB"T+BG
M@A$= AP\QY8P3Q1SV=[9D1@$"W$V6O6CH>UQ9.YC.38=9F*A]YXWG&7;E51[
M!B5D&=C5UD#92GA9 TXMD8$R#3A1-7@E>(F\;-Z.%@:#AP6VB124<>Y5Y?6R
M7KKD[U(V8KD45V)P$#$3,"YI<[AX^>[XH*]-C=EQT-65-< ])@_ \Y!CCLED
MBM7%2'@T($C[4BKL3(06HO&QFOG0GB%LJ1_2:*[\U'F"#<QJ!A"(3\!5IV4<
MH@G +P=!GGJ;KMHIC3B?B^BCO(^M&'IO@2O?OY&\L: CCC0F!Q,=0@K\#*4Q
MZF,?01W*.8POK&D+"'%2H:>^)[,LNI7X=O/N4=F@PF.*++LUTD6B70TBU\)&
M@G35M/?1^T@";*A$FT141OE S(*?;/:%_QDE\CV+B!.C'<U^<^NZM"5]+FUC
M%94IC3[2"U0#,DZ 8CGS\[$5 8[UD6\?#@>X:=%PM+&>[455L.W8WYTB0_VC
M=,CK?"V_^+$BW]_8.%\E08*_W@)7Z[Z0XD+/6P#K13E,;B+H(0K/56\!NS^J
M0I*8?.\3@FN[C8;:5Z5ZF!3TZ AJ7I$T]6@?T(@6X3SZ+8@9-S6T7I@;/[Y0
M=<G/C73A6S([.ZXDI?=)<OS0G?#B%)$-CXD8+GQ_E ^N8Y=09//P%9]WL9-L
M6>K)70>;O!L-]%?2;#PO//KZ35LW@2"X1_ 2&=F\;6+&I6L9!+*KN_,AU64*
M4T$RA$/NT4-""VA))N[,QFV(U#I.5.7H*TKU8H)KMM$8\HXSVD(.K$XCO;K3
M3[@[8G+68SA /-N 'Q,(67Z,_N+M57"IAQ./&(?V^-V#@G97 P$%6;4L&SL3
ME;79G6>(@YQD2WG^.6#^R T=^'YZND.4'3*!PT,42)?VR&H515T?TI/BU0((
M>MXGS]2!+8O&A#7>0LK7*:8\^^N)JJ][5@<=^B0Y'P#SQ]7=)85%2C?%M+)6
M#?<,/K&*RN6NON;!C4"*B5O!*E)7VP"R03(/-4X?'6TE9&8U&NV"!MV?)>K?
M=U^FI5#!D)93\:!RZ<_$=BBO"']8&S6QZ"X+SV8ECB^'O-[+6-^?S?/Q5T+R
MUS?U_4HV_CG[G/_&YD_A;N,?&>+?5ZL U"<FO^XV\2UIO.F> ^KXIJQKPGLO
MCW730I'-A 0Z;6VMB#+CXC'GMLX+/>UUPZD2URJK*@\$FI.[0Z=XO4'B**I\
M03MA[2I"F>A@DEM@Z@N,/ITL]UO)B%OJS10UB0*-4V8GU!PX KW@E)=4)OSN
M&\S;1.NE#^Z)E:XE;"7P?+H%K/65V*M'AY+*%#?[T6HFUFWO7Y\$"LF#W%%(
M%1B2R20#O]I)W +=,!MR%'TY87V&1I?H);UP\*[/!"U7L)'NJ3MU1^)\>Q^M
M?L<2=?6%]X>=:9'>%*(X=3HZ:KM5/8VZ-MB"6$#SVC20B/I5)MH+DC'[:DG4
MG7.TR :H;!P]N8&^ H-)5HO*)M%F6 R2DQ3>89.MM?<JBBN*1_4UT3M/?\I&
MLG<? TRM%ZL!-*6#/A9D.M"R*QA;/S?:,F\'1];IS),&(UXN#HY*NA7N)9F
MU-FA@F62JOOYR8X$?:66ON$=5':^CUJD"'XFCS\Z$J(0):PC/@@X9WYEA&*C
M<Y;:D@):5@43%)O,W,V>($;0>!;;FY11!Z)2QKINB# F/L3S^^74\U9G7!S5
MWP(E=V!&J*:4E^L6<.F"L=>PY2M[>?N[-VO1-[XPW)Z3U59X>73SH[<1]'D'
MFBA)_&MIHDTUJXW,B=E7F*JDE%6/ P.\4A1W7C!<A&A$^<HK3+[WY9FJ.8]W
MD?A(&CHP2$GM.()+:2S)31O7]IFSA>4>4A!2,0)]B?WB.P54H<>:-T_9A,T,
M"@R>OGD>_7K;"E%<<HVB/,^&2]<S?4"4KZ4M6*%"()&* S+(1,4-U[-A=8+.
M:0*W-^5W7*R_AE7N5F!@O412$77\C(?1"\3-EAW\B4#!KQ/^ \_!IJ+6OC)6
M=.<M@,/^S>Z.G8W;B=X05SJ]\.44_#O4[3OV:O6?NPHDF?G\5F;6$IL1N'?.
M15R5LI48NMTXMTR%5B,"W:FX@]0_&9-M)9/7M*ZC?VRJF.1#64E=5_-;*%Q(
MPGU5D_@$-Z&62_NPE\Q9 5#"?L7LM)IWC'%<Y'R?',,84LQ%K:[#Z#YCH>%%
M+W?0Z"PERH[D/5B(PCB5*'20(W5")YUPUX/:<6@_00/DT[LU(I2-U/Q;*Q59
M2\XM0-TL":U;!K/:+$EVPLC5V?IW=A4/6ZY4_JOAW1\=O]_.@\$;=\UO@2>)
ML+60GC7E8-2>$L&7<,-N@N]7UH)H6LP%,;=<(GSMC97<VP#?QN0G=K? Z?"B
MHIOQH[(!^=<QQNL(A?!)'?A>G/RB;_@\JU+H;SH$'+'.60C%IWE )\_SZ5\-
M TK'E% Y0V1HB\DM,)%L!9KZUGK'&DJ.6Y/#&<-H$@N)D]@BZKN9DQ")4D%N
MIA)+6O-)%4O-*:ZI=>!3[PL@";P##*0\>_>JDS,9]TCA>J"TWB4MYV70T;)B
M=<,Q7VV#2!_?(-&LAJ)+_>(Z[HFCA"6#(ORJ>R8QFB,3+J$_1-7AZ))?G%-S
M&7_(F2#(G6!I)P?H(R(MBRCZ)),=LP@'C%8>?1R\(+'UBWA\2+"O0Y9,*TUP
MQ/T6HS%^48HV*I.@27-MUP'_<ZI[2!YRXF4Z')TWRMQQU[@=,I'=2/OK BHJ
MT9KX,. *RY"DO=@D"DK$<6>"'RXODHQ)%BA;RG- CY-CQC@6;9;YLL?/2=R&
M\>R:K6K=3RQ<G:7G))\6S2#N@QR:!,31^M5G"+&OEWFI0,RYRX[ Q)=C0Q@0
MX\^*#32+Z8V);-HWDE/>B(BQK-#X6T+')YNN%%(_PI-Y_@'O7V=W(GHWYA<]
MC=MR1\5CFA"E"/N S@V!S3LQ.*)SJSY<N=Y7W.AI/6<5_'-XA(=$)B+4;R2^
M[B&;ED#N35;9"6 ^!!G<U(&S[K>R2G W.E'MH2AHKZ1U 5C..,3IY!?)J=57
M7_0BW\X93F42)6HH^/A+B6:%OBXC5GU=Z(KY%K[M&YJ4%U+YL3E;R7;UY)[%
M%&T%G2J/\*.'>;:"@WA9QL*DG]['":TC)9,'M49677[57,.HF*>)VW%J-D/@
M3(A8J3?!]VI?P)+B\UOCNP4B<(?%6'U-^1-R)NW"-M]64#@U(M$A2M-ZR?NV
M!">3,X;ZN,_1KTX6%2VKI9.Z-]3-TW25=33KQD77O0RH@CM_#:^[0L5I>+$T
MO2QMA/.>MY>%.>R.>^/ <)EL#"F"$%49IE^.GS@3Z$-YJGZXYV9==%_"^..U
MQ=9!$QY-]ZG^)X'[9%M^[']P*/@?$XC%*W6=?ZB(X!'3[>RWP3:>'8:=CX6"
MY,=04QT\P(U998UA.TZK)4LIJP9 \N'1%WDF-= XJ8(WY#RH4OGBK;\9KNQ+
MK"/Y47KGS=NH7PK&=+L04=<HD?0U!DN)&N#&H +K8AEZ &-934/(WF0W7AF
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M\>+DHHYC[L%'M%7@M.$\"HC!5I="/$BQ+D DC+GG3"L:\Y!$L>JJY,@]PRE
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M0%C6K_K#WE>FA-S .#@+^(3Z%D!I@?4J1GJJ"F6)WB/KA?J -Q](0LHDJ[G
MI^>W !VLF[Z07WR=9)D+Y>7Q+9  @U<G;?^K/BWT2SJ%HNLU2O%VE&RLX :
M_9@XA&K]'?Y5KGI(06"[1N<:[:"&V'GD9/6.BI)N3?5#<<HU'P&)(M8U&ZWL
M0^1!2XN:0,WQ['/5=Y5_WN5]0&'\.V]")PPS?:,Y?KA7_#YVN[ZR/IB_S7"4
MCN,53Q?3( Z/ JB 2KMJ+F*=L>*U_M>'1!]5'FT3':S3->M94Q*".]*.'6Y
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M,C4DP@AP96NM*8$G!9E@HK\+,L3;JTLR8^/9I=.F_:E/NJ#;MAWP^/APEK=
M,.0LDG9O^H5';'3%F^5JCDF"T<6#$]Y62]%:^RT_<='NQ ;M +<\Z]@Y/?UY
M$R]MI0K3R8\37$46H5)*;Q)E$?6T,;A03(8[B+?F.*HMZ0.OV$R&EA9V=-3G
M'[J0L D(B)J8LJ#[#Y-@M,ZN<*B<.#].PNIR%>3^3&(^\$5[T)2^..UE]_!>
MI!/&T(%8NYW#719%]Z$7[HK:SW!>X>-;$8>N%EI5?VEB=\B/KJ:5_< 6RCF$
M$K1M-=Z^4UB.-+V2#_@S@:9;2/)KDG0KPC=KJS\R*)@B[(=RM=)@KZK*$JE_
MPI@ W=4YUHH.WZH;A\Y;YUJK/S!I3-1_95K?R")W4;SNCDA-9^<=C%"WQB6W
MYZ<S<;CGP^Q5<L_Y"X:@^CWQT!'MK>6]35SV>;H':@F16HJF;_UTZ  OH\ F
M7CP1CF:!=RC7YFE5F 3?+C,M(W,QZHFCGN!P$YFWJP2]-!&)?#!@2%_4$QB)
M.;P<DA.GB74_OD_=,-M9PMI\,T5W\]S4@5H*J,B2AHX?C8]#2JN]_ PNO98;
MC1?/TJ'@E-8;RT/NQ@OW,>2)K\%_"NM27PB<],W.Z1O)VA225T^%2V1/B)>0
M;,;&H9MW]+M,LI&;?7+/_Y)(LQ2*9LN\ZJV_>O:JY>.''@WEC%@2!MU/W(Q6
M*\],7AB]WO3,1/<?&&&WV)E^O%)=73%E>2U>O/>0(=&GC_!Y_VFV&E?/T\78
MMX$J3""5B9.E;U]=?!W.Q!$Y..-DO<SCNK?5,.[8)Q_;'R@&T751'0)VBU(C
M<J?7HM [X0Z"T1B^%0Z5]J.SYUXXOEF#4,I*8DC3_LU,HJK=%$KMF@+[00E]
MN KQF/GTUZE0S7#WA)5Z0DF+^9-7_4(.G.AIC9[=P'/.L."$/)MQZV);4VL'
MQ(@XVJ5@ ETOM 9]/3E\N@:ZS62>@4>KTD+T&*?#Z!J5TU5OC+#K:\)VM),-
ME@U1 N8>%XV^6O<*=1!N9[WCP, G_"58F[:@K/9H/^<L#ZGLJ2V1W<I#3I?"
M=S6/:#3-9IDF+U<<K/J3AQL9G9XC>9UEN\6P^RQ+[B]_ @U=]X K;P'KX2EX
M2DGS^<:8>=ZZ@'BI:-.CZI94MT:O*MMD(O;"T/>3Q12L[A'YLV>U@CP?1HJK
M2J235T*14*@Q]GWDUTCU18,F2ADSE EQJ@I\<A'"F12L[E>BXIO/)UUF/0$^
M;48Q@;J;A--H=A]\Y) VY)B^!1[5*M7JJ-,8R!5B[N4DKRQ(?/405;]OF@G"
MD 7CZG6O8:IX=Y-^W5?M(F&O<BZ1&:*IK@]VCPS!2 $G3,6XQ%@1>VL?G:4A
M]H8%NA^__S(]'6WU4DK)(W5^.';U26RCF(T'P^24)3(>\%@BP_%\=*V"0GOR
M66K;@EEBQ%R!BY4JDHO 1+>DCY%X[1CM1PF\6Z"O&$9A#6!D=OQD@OCSHY\R
M*=G7A2V/:K)<G,RR:U\]ZRYZ"OY,%576(07R'QO2]1A25GD.8-@:DBH>0<L9
MWJQQ<NX1-#Q#-;&O>QDE.;%$M<R8?I+HD'2^ $G+!R5>6+]GJ"]1Q:I'K0]E
M0]?/&6/KN,NE\#C I>Y^E]SP*4L"D_R ]:O*U<?K#=$R8)PR7]:]I'=Z7RKM
MSK(;T]24#2[-BN"TN3G)@*8Q)(JTF[1; %59<NX^)FBD\1I[CO?,A4A8V>$6
M2#(2111\L2OI'?D5S@(&X+Z)VEJ];@D2:"BT"I'0I+Y_VD5U"PPB/4.</\&-
M$1U#=EJ;GK2K%HT4WR\JSJHI@Z=U)\\RC]FV2+.D3$RW<O$_;NAO.F[C"W86
MX3_+6(L4Z;R74DSMA&/W +K>_S@1+S90>VR0<<3<LX-C134!!S2%1 VE;YA(
MQ]0652C*).@0LIO3\0XO(*"[F?S$DH C_3*#1\"MC9/I6:P4.65(5:'J'<_7
MMX#-_:0P5U9F;J8E]";'  9LQ*/]X)WL PU2I)=I,QWS$$^YB8,3&6VF Z6^
MC;=T.G<CXOL[:/S$@6XJX7RW&]%>EW;V;YL)40D.0G%+W27&^F]2U,O)DE";
MB+(6!_0C*M,-5HH!%ULWBHQ50Z7.^(R+-Z3U[_2?W>7;Y]L9[R=Q-B1V]BAY
MA+BQ$5%.EA,28F<'H:O5D&NU$VG0K^H,17C:E!=)1V0>^?)9/A7WLQ@%(F#Y
M6/S=1#6F7J>*7.VD^M>\AN!//._G*S+$_>7]!7U:3)D&,0[ZAD$BD:BNYL=-
MX$\4JK,CR=?0T6C&H5/DQ?F3@_G:H?GQ.H<,-RKQM9]0:>1%R"U LY5U"SRI
M@/%2/KC3A:0:#Q+E73'ML87.'%UYTB=\E88/EDVU0ZLN7DK#P\/QR WQB/5K
M!6LG1^5UZMF5AOK(6O$K3'P#KY)4)8?*'4UDT*.7"6-T#KVHIX[R-$:Y)\P.
MZ-V\-EA6M1/MM',BT=L)I0X?4$H1N G;]F1V5,%!T(GUQN$.IJTNKYL\Y%>P
M.&:3-)]\H_!J]MZ+O:.>A=#78KW8$@L)EC>7RK@0(23')2P1QV.X6R P^:49
M.[T S?4!D<\9SF6+I=%BBD^I8'1C;0;'2\*OY +BFOH3Q0ZTUE6]C1]3!UC]
M=/G?.H6RM^M<]V_1DA<G"/6@I0+SQVG=(6F%;6-Z>H.V"(Z=9Z4\2B'S=XE4
MWL G3\_1MUVNL64YI+#@#XQQ)PJ2R$= .TT=I]W/IA-KXG8\-))IZQKK3]1N
M4NCL*O Q4.MCR!))>?(0V_$EU_1<[11+!3)PWM1+#%;= CDWJV>J%7:7T-&R
MM!;Y V6O7A@3HF]O(JG>GA^9!]=82\X]ZYNXCSV;VU^GL,0SANI!2/H1M4=U
M$0$TUX1N9TV0X\N0XABOS]-#(:IDBND_(!FV&'%**VQP^9XSGNZ.],J[\'7R
M%SW'G*[>C8V1%$J>@DA#3!S3LBLR"K&;:HX1L54:<9L*?0B 4SI&$VSLP)JU
MS=/C?'T.?%99@77<79$(;[N3&&V;;!A9MET(>CD<=<F60UR%OHE;*I,$BA:7
MVKO9]JTE>'I&3>)Z?G+.B7>?)C('416T V9Z=M6)X1SOX%$.]B$R5,%/H15,
M&FH$3,N'=*8N/F%2=!L!+_UD=D'*=M@Z(GU&%PJ(&T$^0S?9G,EBI:QB-V\&
M%S,XST5=TK\OQ5>$D(!B\.X<Y0U!5;#-#[F<2S!3^:(+/!GU'GPBD"I9;-\:
MPGE\[R0E ,HFV2DY@OP7M1(H]->*[<'(.\7Y@W31YEY/1;+9]DR5YLU/35$"
M]S6=*#31D+8-RC.Q7&1JIDBU:L:J&^>[=;]6NL_;YP9MU2=J;MFG&)J9UVK/
ME1>R<"82E0B:@1*.@K/ :ZIWR3D.KLX,)>98$UZNUZ=C5W5C#H7CC8R+$)K&
MY4K=XXK42O:3-K;V!!M,N3VN:F:Y.EBU,V^<,O72UHZR'J[!P&GNP(]_NQ)D
M[H%,/+( SV//[]US;"8"3)42*D2=*$P_=6%I3/0G]+;,</\B5N]TA[=2A!A5
M&_%EIED+P\=J=/WY2)J>J],]]9TK5R6>A0'SZ'T< ^+][G87NK BN+F]:V*D
MPS?YR.]LG7L=/C!$VM)#<N?Z#R@$ILRK0W$W6+>'/4_XIXKR@I2;U".X0 @(
MR+CO;6O3J2?8^7:M#RQG.$G,[H87YNC;ZFZY"6JR:?1$#$@H#%)9$V'.4B$9
MV^SJ/+2\R;*V=<L?F1-_:W4ZG-_\X1[SJ[X*S CSQE1M8II'9B/4T2B/-.#9
M2<[.NU)'$AR\/-S+AC.[77BD7?CK$I^R%6X)QGWV$("S,,S>!]):V8'GR)WD
M<MOJ$T1+#\ZQ$3]VH=.%N ;1QJ,W-U0"3G4G<DP@I+5I3K)Y\%.KLIR\D+4W
M-S2;ZNH,W,-;50+<)1*:3(.C05(>+$@;.!BLPJM58V*:B*<L"^'#]_M(B1FL
MIO2%$$#ERQ0ZY-)4:,!JE1>_D@.*C4A3TLSQDG6MD[Y,ALU;.FJ*67(,?4@-
M@K*.+3-ZF5VOL(E(!OY.0U+@P3=T4O3"O%"^747T8;Y:[+O]+F0\(Y&LPA&O
MV6.R:2K-'SUUQ-BY"Z5_P3[)5E1Z<&!7PLX0IVO>E+A*].K-8/*A._)0SQ%R
M']I!Y",2*6_^GYP@3QIO :K=TJNS-]_WM $^JZOB:J,Y\K882>9%KMMQ4K6Y
M'7/+/A,5HRVTVZJ,E72Q483V#[E)4@ERP&NLH]CS2T\,BSRT=3@=J>L20=S!
MBOZ$5FE$<;1J(RC.O*<8\5*HV0LV#4$WW4GSYHTAJBU3=HG]U:C%'$M$82A;
MUS(^DU[ZKVAT0+2,5&]!_%\C72_BU2:*[NQ Q47T]5.P4P3CG9R<\$J"F3G8
M(RQD0^5T!LW9,OF"DN,5L/05/Y;R<^+GADKD>+K6V7.\#YK>T9U;D3]E8^<1
M27G00C@TFCS@S@H9#*:>$2EY)U!($8EYLZ[+45-3P&,P0&^UB#<(EZ;OXT_K
MEY.2XF$I%@8<B$F[EQLM6D]7+'--%MUKV9?3U[4[A^R*JC8?V)MO0_50U>7N
MX@6[S&D7>ZT5BZI./BOAB"KU(+@>K&JHOU]5&R4GS2I/-HB;KJ66C[;9SR/)
M1E3&9Z><A%KR9ECF#&D\_)X=-(F'*"N,??PA30B%]TCGEG5@NH6"&@^7WZEW
MZYV=4-^;S)'I&<'4%VGD79W<>&&*M(L<*\6;7G[,2Q_<+U-DK]\G1[N,T394
MS&#6SHUG>DL=FLW,Z)PP+P@8%,5WY/([RKRVG)NO9?H,3UQ=L*BOY,N?^(:_
M.:KZS(EVE+WD_%I2J#/QE4CARLVE.M<]^70IY @?R42AZH?D*6+YB"WO'/ B
MKN-L$U)2'^,.Y$O8E,UEY2T2][+=1SS@<*NGJ:BKJZYL/4:(%9U7/D:5Z6IQ
MQ"3%V#BNLT0(1J;QX[3A>:*G=^&_Q;I[-"<^I#X;X.78P6^-5^8X02E)71,M
M.=3A)W(J16(T=W>7R[8V:>9<._Y+6[A9\):2:Z@V^;CBIEP?'6]]CX' FA,%
M%C/&-P?XA4&/3%U5QT.V"GVYD8/NM.0H)=X[NND;<5:@PI^(^;$DSDY#5(A3
MP>?QA[P+-L/V5_I\$<H67R#A@9'A!*'&+&92R;C^Q#)'"@@")OH%U<ENY#(G
ME'M6ZV$+Q5-EKV5#'.MCM=K3-LT7AKEC!-8RG_IE8@FV/P\N6 LWM+C6:&J)
MLB45,G]ITI".IV/K]59I,^L#^=(#B8D6?0?3LHVGKW::N#\87N1>H=OI':P1
MQ<OY;VH3;U3S*MP";)6-7>.-K[\N;A9B).R^YDT^$H#)C*%O4;6XW.E>S/SP
MF6^2IOY-L6E:+!W[W=Y$%(-$F:(E-3:5F4%<AM""'9*ERKPO+D9/Q*/G^14T
M= \8@@Z*BV.4T!7I5"(NC?N,1,\VD)!3D5PEF#[J@FU)F4M;UW0PG% IU;QU
MBW-T^Z7OT(K5QCUHL[>-Z=$>",4C_^J7.+VVWB/YM&RRA&,]>6[.T&:FW'"1
MI7M+)OK,,];\1-MK1!'MC:ER#.H"'BCCF/%5"=6D [^=@/?JAA'*N[KTRRS2
M+%?MVJAN].SQ#_;T>>BL& ,'779LF#.$>HDY:Q9Q)U?\$VORU5&L]6M1@K9>
M1H[W'?,P<2Y1F#P$-AD1J,0).Z\"GR<%VQWR9Y'%*IJ5NDXB,@W<W;;&B\S&
M07T:<7?,/1-+:X_#Q^G,>][J87!";I927B%FY<(0+3/"&^2K<+.5GKSM&.,8
MO,A,,DS(>&UGH:BM2WAI5;9Z#Q:]?D*]NSDH^#&2DCL5ES@*O=\-GY%$0N:B
MQ+O\E&K;4\1!WXJ5+0(/P[!<F?QVS5 \5! O^;(K$V)*=>&U]Z6KII<+5KI;
M58UUJA?&>,<X(4YX 7&.VAX7:KQC^USG5A]M[5%5J=W:L.K#J(.MG6ETJ\<T
MJ6N/NWBX-3YC1&W3BBMRP,UUK<6,ZOTDE:>J$90GS,O@^5IH0KL4A6GQA?_Z
M-<NYYN1VLZ:M$QFJ6%(/0I3"D,WTD6YO/8,R=W\*_J)B[)L-OK9EG89IM^9G
M#SV\\=S=!2:E\0@U.\F<^\VB##4$08>;-3'JX7=V>F+(H E%-H)Z/@T][[R<
MO#&T:X:I*EMM]=^0,6,,/Y.JK;,N;^4Y9)^T5\A%-LI;!G<HY=L4^_IZ6#N8
MV]F<O6/TUHA50DZUSU90-M$905T@X:[+'<*'@^OQ$?YH#]'W>CYW]L[#85-/
MYK@')J),%&J:SOCD0$=@0OFKQ9REG;8P8]65?26-8[G2O/D='8_T>];. ]JL
MH?M!O4E>+GC.?=1Q @M]A&PHEI_JZ=R \K52'!6V:G%5E?1O#W,.8\F[?OK[
M1;SY=I.@1->Y7G819$?EB-E[4N1,UDU:^0@3%DUADZH4=E_[O;QJUK;M5\W1
M+C=ED"1;F.#43ZB-7E> WD!GFL([RCP3. \R=.,^PZ&FRX4]QAQ]/9UAMKCQ
MX57P$8*)E!=F,'PR4>J3=^[IU/63-+'O:IIF^'D9..BK3I^(YS)%#C&=4-%E
M)  \=PAI_0'QPK9]YSBC^6$/\@VUD?=TCS<;O$T>'?HKA9I&9L\'L<:-U!MO
MB[U&%EQG+G;#I-0RI/"V5=A_8K1/U#*\J236AA3K,ST?\A8SE-O?B+MW8,,9
M8+JX<[*$*:^5^$VV8OAIK@&=,X7V\+.C1_9H"B$TPBK"3J-B8\B,1V<CAQKU
MDZ[]!P[LQ3JRJ9\[$8?&D-D+#+)5K_.>^-33&GM_H'F;-ZB,6F6HJA&@/%8-
MKEXR,+0A/,08I.\:)8ME';S3O5&97(\+:J**J>1F4^&"PS_(<6(,LONV7O"$
M(\_)JT)6J5Z=Q\+<ULF^A#9"GB2D3>J"D2[KI51T'C/&'QY' Z7/^/#;K:&R
MT]=;JWV945_LWDR RX[8O'<@-T"Q^J V"PWX;/7K1^"9U^[VC-\9('\0%Z$>
MO"*G]3I8F[C/6!H9@6P,F=EAY9/&SMS9P=8!]*&XKCYZ4FB@^8RM\,EJ:$Y,
M/LAGF-;I[<&6G^@/T8M]S4[MN>:;Q#S>!Y76=JPR^8]HB1/PF]K4D_UP[.;Z
M ]YNE_T05OO>N.B5!K=6TR5 9[V?)>&BF(<1TYZD>/5KI3+[Y)G3/U[EKL3*
M<T0 ;*WUS%O"K?&#4O?\%^%I-N* ;XQQBOV,]71CB%>_#!B]V.W4GGE>W5*W
MSU17$::0I:8SR,IDW-TNTQ792^1&SH,)N/ZXIT)>LXPDK7(NQ:+VE/MZW@M#
MXYTV!IK0B# 1E7]1=B%\MC]<;)[G$U+2\X\YJ=Z#L]0$T&=;G'$X\Y"Z":)W
MD8]JAUXHQX]X_;_NSC2:[77?X_](8HH:B\08$C47H8IJFZ@A05%%:6@1A%WS
M5.F8AMAH3"DIB@:E$[H14VD;5;.:JS54#4&KFFJTNNWNUNTYZ[ZX]]S[YJRS
MSEU[W5??M\_O6<_Z?']K_9[O\U@"[_[[)J]6;+S@G!MXOU#YMYEAD&Z^H+U.
MLR^G;?_'63:9XDM>'C8#C8S\8RI")?+N?$L"O0AVOVV5\S#/2>O!#41:CL>Z
M5VA1TF)_\K(#AGTXP?XHD"AZ52D%*^\! &^!>= Z%+#ZAW'TY@][F/H?&Q.7
M/U\J)#Y8&/C3[<\J_QW@JM2&ZV;5_\B8@MPW79LF/-WY\%IY%?Q]/8,K?G&-
M$\9(*]["KRAMD2+@5[?1]02W\A]S,';A])X,R\35VOWW20<_35(55#6[IVU+
ME9-0+)T_\^+3Y<<,6((7-%H=7ZM)2!%='#0",62'/9":.CDVQ=X;)&#(P/_L
M[+MX(_&C-O/5[,50<,'D(?57:]?/Q??FX,(J&SN5<1&(U*B#)'=QVIT;SOZ;
MROQA'&-$Q/FQ^C@JW7!R[$5 !@YCCTS3=&33<]WVOL@1PD:# 9== .%R>=@?
M%?IOB,37& G]HQ*Q\HBAW0_KP"CKLRM47:,4CJW6==<ZR!?-2<#UDLL0986J
M,B<_6DR;5+!E/[T6(::'<1'IXPZ8++5JM[)A37_LH]]*-U,8L4.;;)L\M%.J
MMV/.N6/NZ*LMNG!M>-<814#1C&M3?2:[.54G,':P3TD/9?I=X(F%-'^2Q;S>
MQ,*?;-#?JG_>-;X#;,B^V0$R1X3I0_3;IYSWUAI&5+7X!OIH9/*4SP5,.4DD
MKF9- %]'P]$91')3<VAD$&88D8IA]CO6,3WTFP@PO;I$:+HGFB<._.H^&OB(
M4"2C^NCULSWJC13I/J1+F3>>@6:H.4?E6W^VIDH>M]N0.!=Y6ZU&GTAA;7".
MV9%#6#%"2[*.:UIY[0R,::L'F&K!_L_T2GAN];UCW&!_SWPJDF:,$Z&)SB=W
M[ :ES2F.SB+/*&,TE$G"TW++M8O?CO.V[1>)L"LMUR9&H/<O2KER0DOG)N?V
M-'EY_RS$V9%WW;O_CDZMSU4H-_!9,6\$(I=TAM JL:>>DV.=;2K2G-[LM,>Z
M3UDG#C4?%;=I+KP8@Y5S+7OWTJVR>JM)T*'X1TLI?-IL!XA!.#Z8AP*Q+W<
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MLY0P]%[3XG2-_)*\:/.FCS=6X,H48/I_^S_EKR"!LV$"IWLSI_>^T9N;Y"M
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M?-ZF ,5D1C3T!_7+%)>S9N%RKR1UP(I^8V-&AIV]I]8$@P>6CX#A.HC$>_3
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M4@5$2SA4PKP,5Q\0G\4J43]3GI'?CB6;>KS,S#QGY\VLH. (2.V"ZOP71BN
M^Q(!*I&:*!E.<AE@+A:A[.8(ZLR;5"?F+"!2[Y!99+'=2 :"G1/MOC 0Z6N)
M '&,+ S/CSBC&X= ]'LT<<4[=\\;B,'U2N0O^^/(J_R!1(4G(U#'X>C3H;LT
M1=]2YU:89)KG& )5 =Z19]T8F,BSL'O[J5=)B.X=,;-X'S(",<YZ.I.,TG*^
MU'E 9&PL$J7R:DOI6M!4>E@P797PIPSBK8)5N":@6T6G0K!9._>4:,[=<5L
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M\WBV8L=FZ4V.-H\,M[=W5D/=Q/=+?6]DV=*D*VMJZ,O42@N8%GE_?NDJ_6)
MZ^:.:"N/IBU?^,$$,[UI:;7A;2MCDW=OO\ODIT36L$(MJ]<5[E9G\?OR+I\2
M7G:P1X8(O$5=^W7H#-V7NZ)]N](_TUR5BE96CRRG?KYM<$COUH^_6DM!C"M/
MGT+ULG%AP3)WA/6<6SD0O:]?C7Y^#AD(%N_DJ<&N$A5-?ZE[TVJ6](GT01ZI
M#I3_7AN4\Q/+#>![BEKZPBTG8K*W68!X061L)W]+OX>B=2\-8''#Y+"UD+F)
M0[,\0H:$M4F$I^1H_2[!#Z(J:D--C/D9B4!]X.=VBZG1'U?DDX'H0(9+>>9F
MC1X+3IOJ8-\QL8..-L]>=2;B_A?F\NR)'P0CNZY -OE([VT_N$R[$)\>S@AZ
M?*XXQ8=P[6IE$//C1/D#^M8NU9,WHC)>O@P!+09#;?PX/_ME4-I410#7Q(WU
M>P' ;E]W*/W"$60P(]W)&W')FT.)1\&S71PH('$Z,29W8?0Z7#O3(WFIM J<
M4</YE80//POKR0\PI1\V\=(I99!F=1 %TV1[1I!CR"C6:=BIZ7^(4C&F!^.,
M7OI>CG3_0T%QGK<,%&+$XVC/\Z6C;TESP^Z[]^#!_0^_#<9[\=(2DN! RN\"
M.=65,]V[=I GX7[A_GX18H9N4V1WXQJ4VF4.EQ.&,287M1>MGFI;EGX"&P=\
MMVM0ZMTW'C;U;'U52J!T8#5ZM-]2S3*JDF4@Y2)F8GIJ-9O)81PV]?/9:N'(
M!7KN6OK9!!\)G: SGS2%I<J55<;4^$V9W*6$XBP!\Y/*T!I5B6O#LUKC%]\Y
M?]%(V,5=JWW)]3HTUOR^0:$_$>4<4G-P;*@TB:OPV$E.3*%(?,IOH:=*.]LY
MA(XS]L'3IXS HDU4C7\$,!YFS=NQ,:5'\A\13/S?7,V=7\(-X 4EED7/%.B5
MC.ERZW"/CYW$4]YL"XR@$>BMKD_]VR;,)+[DGS)L<XD_[IF^T0V_<W^-_N/B
MLPB9,13SU*)G%>)I^M%T:,N% XHSB5]SIV[?ZG':N]9Z;L7G;5N52?99OD&J
M-,2M_1LQPBENE2?,'%F6!;,AA4VIMA<E.<_>?M-YC2R+S*%%E/2V/BJ[8?PH
MP4759$=M0MOKR7;;Y&J_I<>!+OMQ]8L@S2;3Q%\C:R7U9[PV4_#P&P(#:5*G
MXV_2P57O+BP>\@S\@N'X44FC.W<6GNC^BN*9.?R$!SH23<;,J5/>,L('-7SA
MJ]\<2Z.W9PJ7TIZC(QA',Y?PP,!3M^23*/N!XD2YZ]$X,44O*E^.0]H/Y K^
M+ &C2,,KG=Q,$MS#W/F8(\6@RCN#:7G5O<*?:_UX:B8=SU#'/W*KZ3N?/DC@
M8V\ADBMA02A#)68I/8N=)1;[U!)@SJ0"F@J">$!7V%#*.!$/_&&Y.\4LS?.T
MLOL6'JC]3">D?2&YS<7FX5PLABJ?&SVU=[W@7V5Y(ASB/*!O@@<ZGW:-G%RO
M%.V1N)GR]C'[Y9\6M]HONYAV*E/$1,Y'AG[QO+^D7;&Y-B&0%?_LK YGPFBK
MS[/%XSOP4T-8%>?+W\R6=1LZ@8H1#!';YVR;6J IY=/WH8XLS24FCQ;0==+*
MD?,3@%SP29W&;J[#%;#3HXL#6,K#SA*#.>;E6J_ ]5N.6;R%G[[T<84N*K5O
M7S[7:(/>SO1$<3L.:N !B8F@Q*BDN8?6XCM\=3X:@2>^OIB/7 ]#NZ9@/P37
M=RY__):?L-(E<.4^B.T53[0VK#(,61NB%61<@.DZ^U@K-GH2Y_IC[42 )DS!
MH.M!,7=-[/"HXA\,1,4K)&JSCDYJR\R $&4S)A]EDO(NTJF@L;BS!$N>M,?H
M9&1@D*"6Y#@+LW+  T1;:<V#VQ9VHU;&OQK:QI?>#K C-T@"AI$GS_;5\\>4
M[D92=1D;#1F^OA)1,>"$MG""WWTPX/:LS:-L=7/@L+:6F0MQ9_V)6*?\'4:N
MPJ 7 B09*XX?C=5;$'7".NGO RSN#>A%I31,8Y*RJF5-D_/Z)%S>9B/SOVI"
MJ"8+H[R?'TQ./GS)_J.K(U:]U8:;6^MR*S9;<G"052!KP[,4(2ANTE X6U3[
M(=!$RC79_+!A:[&DO^HBC>S][0C/*Q.R?E_D7XL>&'*\*^ D;6)W;1.9B@85
M<EL9/+&0R!D>22N7-.*\VET[:Z$0D-I^3%/4$Z<E6NGW:3];;\#EM<#<?*8Q
M50T)HWN"RZ_*L^G[-9QV]27PQA/1L\*;RPF36,6MJ$"81KAEHO3.:T%!5G.Q
MT 7/RP_KK8U]8K)H,\),VD1GRE!OTMA<M&6JIK%'(SB'!)'= I? D6E%<R^.
MNH'";>L #:IW,K8'9G>R:R87Z[8B8 )N]RJ./T+UNTD9%R+R*/FF982*^= I
M%=\>//%XAW+(&I>,.[2X,N/4#WMP;_X\3TNBKM EM%A971D;84==V $)]_S2
M_F(@^I9;[D:SJO;1DKF_DYV,7N1<;M>V0,[L+XNJW>+8P KVJ/G&2NU<XY5(
MH1GI1^/\=.<6#?RX*@NC":?UP0AG6"S8. =5.VA^.WOP?,?31*ZNP"VQ3'P^
M*[[;2;.L,'@7Q9[89".R&!\U>>$<U74V+GP_#L-9),!5?+B]C7/U,:G_8/4]
M38WYQ=B*W=MOST2Q8R;>U%?C$0UU,??:/,T'BV2EC*9KJGZR5'P9^DHK5.ZR
MD#]<$-CS0B9N9>OE#68AB&=-+%-69-AC%KZH8!S#0R):IP"G?7[3$\-:*]\:
M+3H-H^?1L!D)AYV!D4E7$X.A\JV4H@5CR>-M[B@E_647):[HV[2LV3?INBC:
M.U.CG>TC"IAE\@)^F%7&_Y0<7?;4 H6_OWK]DMJ=3JZ)X>R4F8OKL24I @%^
ME\W*[O_A,JDI]E7>+G5W#UE_D\1_Q)7>N%,W;?IV_"92Y<$\KQIM'(I-;?#)
M9$49YMKFC^A,ZK*F&'G8;6X[0;W D0Z(%\(JO3S!/]8D,MFT(7Y@2>N2FFNR
MUZ\)DSKS\:?%#Z^9FT]?Y'*C)YDHL#T<,9'4M_TOAIG(O^0>QR\=O^A+<'9>
MFYHV#$DJU]<TJ=@:=.WXZIUM9H5.\72E[B6;[KOQ=?)B*G9P,H<^3UI V4 K
M\*;YR4T4I3,O:M HI<IZ=EP2)O1L7NZZS;($QA#YWOW;_G,63ZT)74Q.PTR)
MZ>R00BHDX=FSQ.EWL?=C<M6';D5'9 &!P)K>9'Q]VJR/N29_IYF/RAHC([!D
M$\Y9 3QIEDI6^$[$\Q>?Y5"X/'^+!Z9<%QV).XN$DKM<1?T?4RO<D^\G?U'(
MK"+,?B@.$/P]T,K+E<H?B7Q$SK/_.>%0V:5KQSZO\\%IXZA)O;. F**2>FSO
ML$V#\JM1MD6'!JH/LN^=\LLV?CJ[WOV1A<@R+\LLL2M/V/*I4E^5?%BED0G+
M-KMXT;=FY8VTG3#,PL8%!?VTP ,:-]AKR2_\D>?V[4OHLZ%UF )K0SP>:,(#
MYP;:252*3EGM%QZ39Y@P!').)4$!PX7>YL8#M(9)(_56M:03YM/09=5;VP>V
M3V/[63[+7;G85O74*<WA9BX"&Q<UZ-YNY-;+S5C8E@A ^9X\6+_CRCGTZ,IX
M->_"DD<VXKN.K/_CO>+<"@&)JBGO-LULO[PZU,@DO(5E>+LL_\'=^Y7')]II
MN=UWH0?(6E;YSY,QE/,I.3YMC-PN3M6*>6UG?G(;ITR:WI^\\O)\GIB<#X?U
MY:^+CA6^X_Y0SRS&&4Y_J]@W]Q&ECQ*MA6.O]%6^GYY.!QYWD 07>1\RZ\%S
ME2TH;\M5:.&Z%9I7XUS:6]7VY&M8APF+1_:K;=$.U!.^U6GTY0:+%_P+:F6Y
MW-71OP*DA:TLWU9*Q8F)M#LMN;52KW"Y:YQ3=$\;NE769N_@5"J"+#2:=<Z<
MO%W1'J#B];A:U:<Q#Q--!#LY]'(H3;K>;QKM)5=?6*XO\6*D9_=J&+Q'(D2=
M"W1F0U]7CI1LWQFWKPVY5-1H%_#L':FQ]"-HLE0Z]$2W0LN+L6&L\[O+5!%<
M^U)$47=A9L[@-!X(<92LD"XU%0K3N/I>_5WOD>%YGV Z^<W@*<]!">0VIL3)
M_$Q8:!0/!#M>9)J<N$[[[KB>WG:L'=HNNL;DRG5N0R?QV4*//M-&23G=]ZS)
M.-J7EN)7Q?%[HY1C[6^S=))]#5NG#]KC"B(T,U=T@RSOC!<DEK /%]E>%YU6
M:!O(R8JZSL5P-T%X\C3L.7/VNGY%@K"V-TR.QC OX%S;?VUP1V #_(Q6N^C'
M0 &I;05G#,VT\O+]281.T.<W1J^#^)_ Y$CF93:HHEZ\$1\39C<]_^/$8]N6
MKJ=#AZ(C43[P9_KKQ>CGXBMF6O,Y3..S..)]1L=JK#'7=E'Q3-93P0H%?A'Y
M\[KVF?FW"409G?LM+[*K8QX5O*CIF#/,,[];=8=7U<+"-6B>2BQDI#"]EL%I
MUOF5GO.!6Q_UNFW<-1GU9=A<.ZD.55H+^TH.G_'KC$\=\18:"M ;'I&IJ9.Z
M66/YXJY;SF'5PRZ?R8Q;+<!/-<+ Z\$L(M*8MQ#- >D$;8_!UP8;@19'=Q/!
M:36:'F@M)U<5G\FM"?$0ON4X9\/W9K?ED-(+)*#809GOGCKNZ?E4PB5"[[9E
M.2A5='Q&/]HH6"_N?_J0)R4W7+D",MUY^O1%CY0PB9"'WZ\OI9.=)?4CH]J*
M^>U\;"FVKN+.S[B*.X56B>7L9^Z>M\8O?<N/&6/F"&:)'*5V^Q*5['%B.=(
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M-O^VF!A%R</#3]FQH"![WD_<V'?YIH\0^;,L</"6$L-5DD<O$;I+2C3[0]0
MT.OO>Z9'7!DL^A*A,P0T_+Z^$U6Z% 'PTKS^A\D%.1(Y.HB ;8?TR+Y5SL<J
M7?I/.&O[UY$;WR_A1J2*$LL2()'DUJZKL@IE1[CYL?T*EGHF\2!;]S LFMEH
MZU%O/EV6T"^Q0IGC7CGC7$T8M<6A-D[-((_*QYN':=;%B7=F<OO$4HO<L,RJ
M[!MDJQ".-8:5Y@U<(<3\]C@UF-DG/ !Q@L]UX($/+05C",SS<!Q.^%#\(A2&
M.8%@24OZ8>89506Z>( (MJSF_4,>WMT#.1G+/VMP>;]R<N6H7A8/)'TY[^A[
MXS5,*'U R^,!]B>)-\H(+Q[G;YY/B1$*7['PCL=8KMK']]Q>GY%Z8M\/!QJ@
ML>?.P]^#LN5;+H$Q_NA=9ERL+7S^]J"OG\TCF/0$9Y)/H.1F;^!7W?6$@;K0
MI"!'BYWE+^ARM[H [0 /(SRP"%?FV7-(8IX8?'3&& .70!WQXX'.TW9L)V[@
MVV$>'H@CT!S+%=]:J1?\L*NNR7[Z2O&2 M4V,7\ ?6R$%J6)Z9*^CT_0_N"P
MP!CWA_EY%U_I:4NKU(11;Z]BI-IK-JX*,3_^)#(EJ:?[8#?8SJ.%)3S@C&J
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MUNLISOTE6_)0GO(X#:N?07W3SD79R\6CCGE^Y7J*4A\DI1BRW>[S,TD]?25
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M2EPI%6++:@B][WI*"K=7K##MHL$#6QT?@^COR\Z@YRGPP,)[= 5,$X:1(V2
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MP\8EXUYM\'5OX/8Z($4%:!\"==\!61F1%D90K:P>T5_@HZZZHA=F=$]N8FX
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M^( Q#V90S)=W(CY:8*=<H*WQJJ%_'\;%Z-Z/>H*[?N]NX9AB3UZZ";I=%A]
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MHB/8S5-/_G*#>"Q*0LXGZ)H#OY?R;1 ;16\2$,XN("<+6B0;G &Y\]PI0JQ
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M_=F@PG>_D@).W?&<5B0%_F$A<GZ@M(%,=!B/ \$BHOK^2U=C$=G@70YJ]B<
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M2(O_+TV85,Q;W3!K'&:"/@FM Z:3_4(+)9T.(9,ULC3@&2-[W 9SZP:)HM%
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M(=<H7^Y:SD@A==3HP-_:?G9S_82DD06:L=MZY&5O\W/,#/'?OEP644C7CU[
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M7],;FY\<2_3=GSP3SIR9#UNR_FNS@/A6$#QS$+2VP?2#BSE([R_HT6Z3[\.
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MY5CR,F3F%4H1#-0[&UG/Y:FHEA80VK"DITM4KG<4&7 7T%='T''1-3/HC&]
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MXXMV+ U7UWADJ7E+V6KK5V!T"*1>6^^PFL%N&67)?.C;*@J_M&*^"@&,?P'
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M9;Y>;#I);."2=8 -8OA$Z[6!TRLB:IF,XUISE2D$1 ]=?X:J%@YQ?2%[3=/
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MI!;(#_?0SWF9@:@.ZQLP,XB)1:GDZXQ/]_EL1K^(DV]EXEBT"WUE_:DR"=>
MZ*\LA'S-?PA<PP"$0H2UP,4W48#P^R3$;E$6M"G@D@4OA!?$,PF]#Z+K>;"
ME/K?JGL"-7+7)CTR3S@N V/R_<\;."M!H.GL:,S]!7'KO>KSC)7T2*[>G_@J
MG<;"W^FQL7+(&U8+E@_R^?6+K@Z$1?]O=.*)%- AA.\>WBK@VF(:"Y&:ZB2%
MM..4V9JI/.>)O^NE7ORSEXY=K/!2;N':VOS=/":JAT]6P,IK-FA$WI-_H<(V
MBF>:HG&:8A4B5&6S%)+K'"'-P?]Y<V%F+I!/AELW'ZY&3YM]OV-K(CA"JI$G
M[;*5HD%6VW=&/O<#".(/DYW+FHW&'D0SWA=Y"+B(4CP4\[VTWJ7=.OCC%MOJ
M)9W?K%]SX4WD'=BOU-?GQ%9H[T5D*5!_03BF/]Z?[Y@1(O7\3L##2M<+Y ;"
M[=L;\!Y<WY4=L,LQ*/F34H^SS3@]>6:0;M-K^3IM2>I #X:RXQ 3MK%(XR-M
M>D%<W-Q92=4F)75W"*I-)/>J)GC2T]N2)-G?V)R]XFUQS$C,,L)2DJ(6^,\5
MX__CE!;/YGL78UZU5-?>UQLYIUX>,K2%5G5L2:(K8T]/A+\/R93"6<H08DX]
MV->]X=*.,O!;J^M:C%++T21(:K]WVM55)Y,'N)L$LAA6:^=^7?TG^#=M^=E6
M8?P;]JHZ-XZ8 8S8_E$EG/!J7@RC7Q=?<KF)7?9!],?K1,UM+>T93(V)O"*P
M&L"UMH0)U9I4\:8=*?XD'.^V-+W<@5L^&[4]6P./CX(0V8W#MQ3U#=H<$!3;
MWR?AY5S*#"HH%P^_]VOITI7\4+RP)GJWWE@LE<@5'/+[\!J#:& G.PNAG>8R
MXKS)W9%.WRR1-SB!Q/KG"U@J5GM85"EOZ.TU2'F"V !D\0&86N4JA2G06A/_
MQ,X.YZM&(?NJ7UMK1?(M??";;O P#+9.5192&VLWUK-O+QJ4B6C=B,S,6=P9
M)\+NKD2O0R>A@)F2+PQ@PQBXAUE?OVYD-O\!G)EL58[L)RURO2QR#>VP0;24
M+>GH]68:Q7S+^)1H8OFEU1/^4(2F.A9AT(NI"VH=Q,0NB*1[S,@#[F46]=SC
M6VI@9'B<@T43(5Y!I8)7^@0%\IZ$QB+\G+&[VKU@:,O^24TZN%=0<+B$8^";
M?Y+;NJ3:YM7@7D!^D8<6O[!9Q.YR[,3G41&CA@0Z9C(1!YNRJNJ</80*M0,R
M7"$-7/2ZS"69P=@03-5$/(]M59?QC37J'HC,;9M,1:'/<ZT\KKT2C)2,"*=F
MJJ'LQB0$*],BC;V2_=]_.DX% OKS+GGSAAKD[A&8HO%G""(8W I= 3 BP.,
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M"F$N2,[$RO.)( R!.&& UUS$)\?0?\2/4KHAO#M:J"I64B@7_VZGD#L+#H^
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MFYXL3"5YF'?'E^$ G_5I^D9]9BO1TUQ[R6PFKR54D)Y4(T^9\*O;9K5M7/1
MF@*4#Q[[W5EO ]:_(S$"FH+:1!'-LYQ3*@PM$)H13Y\ >5)>"[CE :@@/@/?
M;R$R':=!F*MFWQX_ %89A*283+IM$/'U:H5RN *LC8)/KW%VEEF96P\!U3_<
M,E=<!F$(\5,'ZQ,CSP(79/].GM]!6,,80 Z= N23YYD0XMZ+$H1/LP&A+D E
M;P7PM?[K-HM&(,V"N7XK JX/_S4(GQHAN$0+B!\N('T:$(:H#,SUORO_6C$
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M(%4<$]JJ^[PM^))\9;>PQ_UB+/FN6$9#.Y4UC-G?NO>IDMVZ]L<CJOOC/-1
M*0CH::S,Q9!20Z2.TLLG156..OQBB"'35;^Y/2C5?5]DZ<4MAC,/7?PP(><+
M!>1.#;Z5,*T%Q:DL"RA)?/21QW7I'Z"&JUM7R)Z20?$VQ8RO$\4Q&YE0V,46
MZ2JR=&711"BC")IR[H/E2A$;S:8H\L.;W$H4Y^(0BK\RM#;A9=U\IC IHF.]
MDDBWR6%ZR'6)"A,*7*.?NLMVL=8,NFL^S^(]P^<6J+^DF08.A75K9QCM2K#$
M%+?YE?N&ZUG!$I=],S"N!@3VS7,!*/DL6@E@IK[">\4 DXP27"(,K&_[C8[
MGJD9$IZ!D3@&5ZYZ(3!&:@#6N4<OQYH@"0'P\1X5SE_7> SQU43R"7BTCZ\
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MJW#S4A#FBD W@0GD[T&)?L0O!;#>3"$-?SNCS06>$KO8P>[K60^4,>MFN:S
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MF88TB3GNO)D@[TFPTXXXJNXL==]:CSV:OSBUH-6[C@LQU1\__R$><):(_?\
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ME9_BILEPB.$3*ZN^9[3G/G$CHBJC ]?'38.06R$50F5OD;]!M&-*0>P&YD,
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M@6T%NBH;"BT1!"[2ZXC?U2D3 T[E9'96H$RR%YRVIT6<=LT)1Q1QZ]U^+2B
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M6;&R:T<)8\*4P(;IG^=%7@IM5LNWEBF^$12%4=.2O\J*+8D_&U!')^,/^U\
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MS_&,?"QC=7*8+'70W-BXX<SB!:A?C:*-<X1<!$,0,_\1P#0\<J$^VB#"+1^
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MT9L*-Y;VH=5S(\AN=UN:6["9USK+L'0.4 VJ;DF:1K(E']S/(S%6HH'HZ6H
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MO),8,'%8")M*/GGWZE/_D!YE?_++0SZ0(K /(@^"\&!>6K>RZWRDB:X+U.#
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M!+ X7ET\Z<%1R.8U&;[2K! 7?:ZCJ:.5%3I'^"T<$;$K.!2)Y/M<%A;'9J"
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MK>MXD7%( 0=Z%&$$F^L@/Y#$3<[$ [Z399; @3&M"VF>D^U9%(KGW ")9RB
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MYWJ5[2YI=Q&3;%L\E*-E1@+H]5$JBKOCY^4!DKB[5ZF,#GI/"2*,5S^PC2!
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M3!4_?X(&J>6+HVIS4X-79 0BP(L?"*$/[,5<_(J5W[RA8.!PL5]55ZT2-T/
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M'TB%5"Q)]ED?>E#W]4_?379SL;Z6'VUKF=?:F]Y=3K=,X%5PK/!I:^AUMB6
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MEW63,4-V#(Q*$D2PJQ5^%5<5GZMX8-(OK)!#UV0BN""-<XXERP^/6I+9N7$
M14T:3[:(*(O6B5K4;62O(JF^KRS;565VC#PX#7CS:,W!"%P^9L.MKEEON&E<
MTNKJK-OR.6V^T3,A]A.JGUK.RUNTA##P\3WPE7MY5TZ*LKI>]:?6)(#7]:CH
MQD4LW#2SS$<Z?BR06T'R8'LLPC@G,<R7WB>G^UD&GVTO=87W/2!?=,5D=</Z
M+ 2A*"/Q5=>)V(M7VD7_'$!R.^'.$A9.Y#F_>94->]&3FS*?L!_]N.F[8;^+
MB:=?P"85>Y;6+WK[@L,?GN.^E^F4J_'L+Y,W/:6-/,HP>X)Z*!NO*A)_2\::
M]VB'T,P)LO*S3%=)+Q0?.HHMH(7LHK$(>Q0S[]<A(.T=&;5O+INVM9I3&8T+
MLX:W#&IW>;RXCEXKDHX8F$G0QQE0Z"P=0;>[7HYG3^_@6DGO^>-6E4?P52_5
M&'+%-M3JJMWB_*FS#)OEOP<^MRAY,\W]<>CL#?6$57P'6UGVCFHCX;GS*[FC
M/K_V2T0KCE['@6HB_$(Q!?8QY!5>2%KDGTI>$HJ.@]VG3@@4KE0TA3^\',4M
M42@-3>W$$MW%&EQ[4P]AWJTH#9WN?'K[6/5ZPL<K)\Q0XXS36\+Y:@3=#"W7
MK L#"B"#ZPIU)A-2JO#SH"4%'FV_%8R=?YMT+&\A4?NV%O =#(*D$,E.E")>
MCOUU$#'<Z%LE6Z<N!9=[H-S64" (R>UCN#Z<V0%^*2;6FZDR/9DI_Q\=T=-O
M*W)96$MF 'NJ.$;RWX*]N>I'H/"P&WD$CP=:S0"V&P"TZD=._-=2/=BM?S=7
MJ&O1Q/= S]^L#NT#BXKT03Y8PWN@O8WZ;$'FI/@>B#*\41<HWA>09:,^4ZE8
M4Z5U[@_?,.->9$KHX7RU-A+Q-+H[I=>K;UJ_E]D7O7S4#<%290$G4W[L>A1]
M/*A/I=02FK)+4_Q&*,073$ZJZ+B+#<)F<&,0S2*=)*F1$#V07/ OS?2LR/X;
M $%+M=9NMH7^/%26UZYB+3IT=JW'FSL5_7PA-CY68[/EZ'C.KI'\?ZD%05=<
MBH_=R(&3G8NM:.2;6 R6479S"2NB$CCXBPWKUN0+[4; K>EL()?FMNL88^[*
MR/>Z&]#C_E&D#$B$ID5[TZ>H!6,$S'1MGBNZX1MHW\&^)FM2$_,![4CV[R6>
MR_W,>H:A5XT/"L-U1CU^O'6RKF)5__;5:(2;[Z>AQ=\Q%UMP+2X9$*/.QW,A
MN9I,.V8N+8,S')1/[9*R+&(#W+_EH[NW1>M4%_KL>M*ET9FS5HQ'7A&@]+DW
M@G,*[YRI;K"U:Y+N ;P'4(6T@ ^L7>.!_QC&1PM0,&\/!V,!D8V4W[-RK$FD
M/SR3[EHW+]@WH0JM8*:0FO"'HGE([?Y(/O<P>*U6M#WA&GAIGY?XQ[>S%D]7
M8;T76792%RWN97KC.N@-$]T0U0:+[:3[!#:N/.$7^$G=IONKJ]N;+B\JR/?3
MS<0,[)(\K*;0DX6>!G*5A#[J%/G[G.3G3=R,5DQ 8A=^";%]P[+'86&)@J_K
M"T3=^5&TQ)UGRDT:W8N9N3PDVV*+LM^ $WNIDTK^L<'T89(]-?,M\ZSHQ[^J
MWT^=J*\-FQE(>!Z1,^"=N_J#5T&V]X#^FW_(/ B\^H^\E=<W,_ ><,N]!PQ6
M[H&\7-VFH9%_]T#YW+^(HS^ F0"_!95'=SE^N+4J*)<00'2$ <7WX>=](HZ]
M!0&^?%=Y!'\8 719&!ZUP!&G']$  9"]C3(?]%?L-OBP^9<"% LX,PRG.D5)
MNKN^!\Y?ZW^/7FE+VG18!0</Q^]U"..GW0--1KLH-&?S%? =75;-2.KBROFT
M-W8DOUZ=S%,7(3\'M?B+))M3&N,6@$DCDX6$"&UG<@GMA$QN)ELCB5C5K+,+
MB9:*]+Y%95!=2.[I:' 4L1H9_^VL8U])707U&PK%',1^R!@6ECFKYVVMPU*Z
M4C-C!1',3_:U,?O=3!X>B%^%/,$DSV&99TTYA\H(3#?E_V </+% 23!Y8_58
MVPJ+4>&#Q18/!:]06^JA6-'1!6'\#B.<TPR-.N)'3>QDZ*?3J A![:=9*[F(
M 7W]#X70=U*?BQG&1L'3F5>*G_16X#$BI:[/I2[#U%[?VA"="2,3NI^<R4FY
MC'0Q)Q>5%T+_*&R\#1+=:&;"]<E",51E=V!@KR[SO11=BA PSAV7NB)0G)KE
M7/3K]."A]>":+B2CEA^Z%?+W?,0\X*0_;:X>E2B3(U,ZD_-UXQ08?M32.)UM
M[9BAGJMU#[P,Z X]D/@9395TK7EGE20;<^&9.8"S:I$4&'U!X&-'00W'W:W>
M>RVV0@]\"3B#ND]2Y/ $MIY2BS**?/,%WWGV(R3N@==@=<,!+B1^ 7(5:7YK
M!:ZE.F5OB=ZUAF<NL]_25"NT%T</WUJ6.N?7:J\AC6]*36!@A]Y%#+YA#D14
MR)>K+K$$3V+7]:9,IXQBU5%G46<.UM8:%W+W.>+,^'6GG3OK_LYR'3'U]2J%
M1.6)?6]6YTJK4+V*1(1O&[)T[%?%$OW</?#M6.$J?-,3+7(XF<%I>.GVF:+G
MJ>]%BW(#Y$JI;\FGAV,)2E+++R_YU)DZLPRUNHJI%?>1WTO>3Z=KV:M?;3Q:
MJPJ*E_0-MR*,<-6>/VMM6B,<)ZSJ9;2+?O75R<.%3\70SB%B;7ZJU8GX2'4&
MKJ^NE-O@V)F_-7OQ)&R9W^(>(%+#V)52HI+SV3MF1I^PEJJIJZ)WDNY^?"XF
MOY?2+'HINL>714,1XL_<E>;;/W*@#!V?+V(0Z*15& AY\UD3>:%=!9H51K[S
MSBC(K +--,'>T,W^>)J!4O9:CKYQ(3TCH#="ZS!EH6]?RKU3F<:+T%41NV#%
MC[&(+33QCY.Q]-/&;0R:RT[/&4^OFH$2MB3AD*ZYHDG7^:ZW7]NA6SGD3=2%
M G#WVST;TTDF_1:#D !()JV8@,6WUL="+C##J_E[0*K%G1_$++D%Y^KNL-02
M$^NY@;16WAC]1TKKO[[*=0WF$"?1*P+^B*/? ,(#*B@/WC',X1\G&6:!TJXJ
MCGL6!##$JZ &YOA1;$( ]V\JC\(84%;E <-_F8L'/RK, PCZB?*=1-\&'X'W
M5@WOGDS_^03^JGS+?"HF^K\3"JGEX]\84$5&?B*2@EYE8/B*47EC_2J7*9A+
M+1PHO1JQ^5T:]B;MD<2P<M&M#'SP0ZU#+.EL9Q*)U@K'+8N0KTOKGB3A81NW
M"/HD:@$Z@RXSYI&3E.@!?1,:WY[F2#9 L^QH>5!$QILB9Y]AAW$EHWYQ3E7V
M>6.4N _<9U\<2*9A]*P#$H!B\?P? T"<7XGV%DOX)P.0:_0L_K\_/3GSL'T@
ME_]E(OX>_$<9+XZ%[ND4+:^]C1*PHVR_=[./$C"-00 V/+YK-9*_/.V"S5)H
MG!OGX0Y$:$"E8'05N^KA<KPIRN9_1OS&\;16:9+E&WN0AO)Z+]/K^1%W/,MH
M<9N&TZ?W )9 >:EKN^5.51!*YV^9L8\/II7CH[+Y]M#,]NAEM<_H.56/=GO-
MX;2R%/PI^(<8U89XMPEPQP <R6+\XV/%B5,BBQH_.'_J:\B^!W!5=V1K]QWC
M0-P8^(_RW,CO@6!PQTG>00VWKC7^8D:)W:+A8[>^"J3@ (Y9_\RVIE!*@':U
MZIE2P#SUC6I?]P$>T]Y+UBLSG.C#]0>;($--._%^U KSR[SM1!7YQB_5:U/O
M/Q_&-V@G]FU^D1@FPTUN?)C?ESKUUNOL:'QF!1[Y"1@2X9Y+/0"VDGL@J\43
M#CXQO#;<C$X?$EM<NP<,J>&R9W8)YX4=V.(X;_R8Y-/460EIFE)X9GR=*:)5
M]W&%?20J!.OQT[4'2PV3=KW<O7UT,=_MJH)H;SBH)_,:0%72FK]6:NZ!Z7+<
M_8L&(43;<D;%9<VB.N0>:,B\!]Y\R'@UX8D!'KX'*K2JKUWB$+%<'G5*,1!X
M U*JL2Y=_*RE3>P> -E5$B0>&GH:9O>S3+4I29V"2T-JQQ?QQV$"(A(FT7;\
M5/ENZKE*T;\HO"[@&5+>BOJ2=^NIH'J%C88E6?2_0.3E-_^O?EGB[@0HC[[D
MWEYEU7^0>APN'IWK+0Q>U?OKIZG_R=!_IKZ>_*O^N1/"0!XI(%NZ3Z4[G2A^
M_?OZ&D.&_=6N5,IWCU70V$7]7@QG/3[;1A%^&(0/Y?;!:1<2 #F[?A27*8![
M<R? #U)Y[+_K1T/T,0LCO!B(UW\8BHT$**\:"8 3_BR,L"! ;.CA#Y_$<76D
M 'D<P*.P,RX27?EFAPH9R/Q LOEVHX25C__TP+5^2/XB[2/'@_M8EJ$GOWLD
M_UV9>%NY'-Q5MG-$VJ_LGC@YS.!%B7MV#^RITM;0EA=Y=UCB[/VZ961K!X6K
MX,_0MUV/S0:5#A7_==4?-=X6L1H;$_AY.W"7XJ'+;:.I*2GU6L_@V[]WT2)]
M'AC&]F7=677$Q\=ZM% R26=O VFN8:FG0_$<^,)/F3"_[FQ#@/[_%X;_W[O'
M!:@X*L]3@/() K78[Z.IK)P1.WZ?_#D93IE[-MAK2_%'SI%'U]HL4)?H!=.5
MF<VTYU^DG^Q;I]J2<LQ+6VQWO[@'?BJ?EC)[BW'25TWJ@;#U0O-%\+K E&)E
M3F-7YD2;804'_*U30@KS<9O)$GU5U!?+2/WID6&OLN0KC3^<BD3?L..?_3@)
M,#"3JHCY@\D:,CN_;]=8(3*F>'1-D3$NF:^I(D S5947$YZZ+? .5S=?_O5
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M-,34&(>,&\,J9/,WTQI;6'@_:F^1,IEJ>49-!0<;BVD*L(%-.5SZ+.3V^</
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MAR/-P)<?!"B"H(@1M*_>#*C#H@P+8=Q\ACKJ\&E*^FO[27+WS)7;T3,>]\)
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MN?>>V+G?SE)+87]Y[>?-C]2]K)UK.ZWY9)K MMO#-DW7;03]QDDA?5%R>1"
MK*3#\2X54'SI-S!619#$A43  50$_8HC2!=8+]$?UV2+NY-^1&)$5HW_A#%.
MDR?4J40@[ 7[J#:VHB,>J^7[)NB&<3DY7.XF2LA.,OT*^Y':OOC)A!L(E+0(
ML]1]*"T$[42 EG#L'HB>3@8(DNR_N .41:["=Z70$%+E:=LZ_$7<PNF >K<^
M- Q\R''2B'-=Q7J0Z5:'\^:? []\CY3APGIPE#L@O1@P20(^I*,3B&#3>E/3
M>I/( :^2 #-.H T&#,+N]<H< C'RD!H.[R$#(5CH$N_7%$#8O7'8O<D,T]$O
M*X%V9L".DB.:WQ5T,FJ!D";@Q,Y@.&B04D[WV=(#$5\?3(""'A2IN<2\J@U]
M0'Y^@W.Y5"R@0TQLD7&CYY:-&ZYT<!N%^42=U"I3J+#ZE=J:A>ZG7X7Y8VJK
M:%3WI7T&U*VQE5[7SG+S&-H?K9/<;$67FSW)[DM6U^E^-R]K0/<5[ZDW362D
M[RN7&U.Y[@\2\H\/J8.=?,43,1\7U^+S#MF/A30LY$57*&GEVNM#\?6T&<*2
MZ3_X5;U.]I3DLLI*3?O64,Q=-#/5,U#;%+>JQ(?3C]OFS>:SO^6Y1?ZU?,=P
M949Z!R$ ?>63FL9>FH,^"Z^3TM1H>@Q#J&.EF9AN!' "M1IKT PB\HQ?NNQU
M/X?3!M!6BA3(\--96I_'KL"L7B1H5T0SAJ*?$-:E['M*VT=[#&X%&^X]3\U:
M@7,]QY<4:".1Z!0+*_8+#1>3/VNJ#^-YFCTE0?WVL)":#>OF%07.U*3_[G?:
MB;$M(2NC-W@8[[U76.21ANPP#%)-&ZI\=YGTY'KE,QWFC*/A5YR7:4[J@@WE
ME=&"WDQE[S.Q'@R-;@@QZ#5G<<](;UOZL]<A.>,3KF ?X.11A)'M"%E:Q==^
M_>*,[TQYN2Y<=YJNN??,?@BBVWAZ-4*\A]9TY7X',,H%;GXW$3K^$G,ZS7.)
M1C7-MGFE?/+(#<#@;1W.H0>Z<^PW13SA?AH&I:A>A"-G)&9^DQV/1!SK=#8H
M.TG-+HGJTIC!SS*%-;'HI=]FA(R33%RWU9;IM7OEM=6T]2;:Z^*M$\W@FOTR
MU#,FW"/&J4":"0EHWX'#M%D$M8)94/R18W_8>"O::KOX8ZDC.VHKX<)CO.GO
MMPQ"<)NGWNDHU-Z$R&[(7MZCUE3/<7O<:* +=#<,/T\@>P;?#RW8-I_> 0O,
M<"+M\AWX[XJ-P(=/_<9X[H!F.?*HC;1?PN^<0+>)#FYO%F+!)BP#'E$;"8N9
M\Y21/&LMRZH[N:-L1[)E5"/6D)N*[J7['G.G&[\HG2#)0&O(@<]%<.D'X4YW
M/J<7>MASJ=D82]"VM(GU%; 12SU!:8 QV.T-*.U"U5-71Q-4[MD;WQ9XD0WR
M+M!PG@B?OHPN#<!UC&U! RVKGCI.0O9 9=4[$2ZZ>).2-X$7XU>-[BT_O'J=
MR079K&_/P1'P2G@IY8Y7G]!/JH.)/ 2!366XU:4T.%/4T3A<[&?[.7R#.7Z&
MNP,_.%,\YN;4>3(V<T:*)[]JZZN1ICF30B]A5C@GO%;Y.Y.^ZM=YTCG$Y=^G
M!>M"_\H*;J/U)A5YQ G, );WA#(&02G1X]+1]]+1U^ZGB>3^^ 8>!62K=-0Y
MD0?U?Q%*@'9+]-9+<O#J<BC3[F]6.?*JI347C@G_,RVD\F<O#^J&QW^C&8"2
M)"; S"T4B;*M??1K^2NL<LXL WW\/^V54'? _<V."],2M?3,@^_HG")Q^]S-
M<7U;5YX_62BFP*[$4VB;Z>S7V=%6M.JBG(QVTG6-1_WVP?R"CXD4C,7J]""Z
M[^BEG3PN!S[QJNW1EVG*V!1SFT]/#H+E\G2R2LZVU"B+91(J"^3E&.28>BMK
M-)DM<_4]N9W**^H;ZANO/1[A>5,G&B*_0U=,D Y+?^\]O>?:TQH<J9POD\*O
MVR<CXVS.=J[>::%[OJ/#T)?"6&6A=O;=Q@&FG%S,5^HD)RW1^^YZWLU<>#@G
M$'X-Y9"!'A-OA&3? :]TR^^ L819@8O*,!FMPL)]?BZSP(A4"WPM&RPQP,_*
M?HJ4W&T\A4\MF\QAXZ@W[WH_5G/2DPN6Y&@06,HX86'?R7<=N6XYOTF;%>/0
MXEP6ZTD8[\:<_XG[XZ]?U3"E6=&//MZ/,<PW_!0Z5)2C=%>XW/0@W':PT-Q/
M&8M/;K?JQ;EC+]V]* -*'\UF3.MT.\4SHI896<*"?%J[^VR<KN!$J;20F?%8
M'HR]_G<MSE[;I0;:+VEVS+O*\^(Y6?(+AZY.S#87Q% Z7K5B!YT9-8@SVI]]
M%R.(/!=J\CS427"5D='>^VI6Z"Y4O[]FH_\,4YI1ID#.8E<)LFI8^7)C'#SM
M"$JLK0DA3P5[^%W:*K]C-9,4/Y3-@*NI/F+0![>";OEPCOE9,?NQS'CV78I?
M4I6<HOJVFQ\\E@#S+W9VR3<12><A=(<<ER<.!'F1G)M:57\5S<JTF+5&M0QM
M8BC--D,':B)RUE<Q&XC=68/_"R_*UB<IKZO(EG#"+)^'=*:7R6RSM&0I9J/_
MH?H6[!=^BL"\O/J4W-F60WV*K[;T4^[$%YM'^K=;PZM^ 2"6N?:]J_,2,GN;
MM>"2_!*SZQ+R8<^S+>>)C +>_JWRPCVQ!55M@G.UN/I9 \H^ <X1"D>\ES8/
MR[$Z?;=F/Z/0^6*\=CTKR:]/>R<?SA1?H;8V,WFT/[*23::G%-5AGW>M5V9E
M>*:U:77.9%XOH_M+PTS3!6Q /U;4L?>R2#2RW-;7VX"BEX2T,%MU/,S\M"7(
MD9BPV+B9:&-VH6>H"DW)Q8.;##[8V2O7<*R3RR=4W!>7[SGUDH.EVOKC<MTG
M ]O JB"/'PJMYX16J@IO#<Q:5Z[5S 3!Y06;?8)I'='5!>XUQO-1TX5%LL4R
M7,]8W/D5M<_E4RZ5Y-F"K5*6;G;7W7"A)K0AYO49 ^U#M9C45+AB'K-UY&YJ
M8V<M&GD'>V!LUD&O.<R0].^5<71IR_E6LKKGD^=LCGJX0=G5U\@DS[[? 8JU
M>U[I>P;[7Y+A7!.R.'TYA<)F*A?%U9/E)W7M6OC9C%YM@A&9-P(-5<5[L\>R
MXP.3AU5;@V>&WL]M!W%K(PU^H)OQZD]O]1$#J3:08OO?Z<M#ZT[+=)AU>E+=
M%GHY3> W#LM;^==<<A)L,31J,MPUE2F7I98STLR."W6MZM]=?/XN84(F]LQ-
MG(;?BHGA*<V3]:;W#LSAA=_ #6+PMOM)@"?G7D6WE *LXI</Z:R+J0-]0D=0
M.*0PL(#L?-V2M(_GCVUP;4^%V/;EF'PZ9K5?_ISK;WGI.6R=7H"BV]?Q]C>H
MGG\Y7S@-HOE)\9=F5_7OCPJU)^1PSB(:%VTJ\B1]G"K)_4L%I+.L\W2475DI
MM.O75V3O51I4&L(R/GAO2:XO'&R+4%IXYFAOCDDRM'/*1;1?+.\]_?5X3HBQ
MP]%<#/N+OZ$G([J^2Y#]!YY1Z,F+DAW:V&_;5QQ] T0'54+$\)AP^DY/U\O6
M;SFXY8F/P0ZARUL8H&+7A)]VBF:F*Y=>MU":7WV;!0DQ,V,/^O=&P4T9*K L
MY]M%@5J#4RO;"T.<MF:5Z^.:,94^NSE@S2?%P=+'IQ.%Y6$\"A I\F"=)_]F
M ^E-+FSD69NRR&-\!3:QT>]?GG;5"]K_K(+)/)'Z25K6M1C%[JEAM3U%<5&R
M\[R.2?PFG!7TV$-PRMI]3[#6H;04S(,%!'AM7MT!FN+X#H28FJB>&(MB*2P+
MM\-;%LN'FFII^5?R*/<A=JB: U>7VX=_7F#78YYV>'0''(!NT4Q1_L37/WE3
M&XC@1?_CB/N;S"+@R6H+L#)%"LA#RMY "MA $NP#K!-%,!&D-9$>J=D(>-4K
M@LVN@,&PM#[X!3Q+U!ET(6SRF.D"RND:YI+[B?"OG?)HO:ULA"#'!9IEW>Z4
MPSEY&H18IYKE4EM1Y:PJN/\E&$.35?:]BM]]09N)3QIK4<M*@GAJ6RNK3CMI
MRTD"3^772FDI)"+M9_446Z>C99.!F3_D:814[Q8F<CRC4XQ34Q&+5"]#UR:?
MYD!1M2+4[#8:5'_L9# K7,6M_:N)19+Q+#F%M8RY. 9D%?L"M#%YG5C'^^,'
MD-IT:Y95EV:H8D#I/'@@<?[$ C-:X<L+TIJ$3*IUM*<8I-M=MI.?XGGB+X-:
M&;*:B2U8:94F+<<FCS0^/%4D ?A^OZ>\@0V^J_Q<$&.\3&0TWM/PK=?R>9 %
MYT,:J>[UYZ'8!*'(&.:UG'-%.CQ/8.16UUMFTU\%9@]-F6.)R$2D7MK74#F?
MDA:HV:W6*)L>R>16K([J%6XTB8_?"&\Z:1J%MO$LBJ&<_"8_E!/3L?S0%M^X
M;Z7C\&*L.'Y'5U\<.\IUC.%8"@ @8I'CV7B:NOW.M<JRT8GB/,XM^A-92'NT
M[*+H)SXRU!]BDFMT(72YOQGC]C8MRVS5K0Z_!&\RA]Z^YN"**=?5ZC;=K.Q0
M]NVNW1XF3*IOD':BEJ[EX<VKJ@HA,TYY^"Z[R(] M[!YB>\M2LT!+TA3,;@\
M9&Z+WT:[ ,>5=G\Z_YLX<Z7Z!YIWM)_351V'P3S'V:ACGJ.$T<%Q\1;US'._
M$HKCMO;H,^J_B*YF>/.P>+V7'!=R4^4QG5=K.BFS=PI.CE*"R#XR+2H^+F;
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M!:TEP>-M!+G*W+HV2%"XW_SF"K,T-&X?=OL$C'6B%U'N=!7LV^TWF8!-P0#
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MN_2]LW_V8_MX'11GGLGR3CL/$F7E-+9_^/1#7G'*SWJJ[P+-VG> >^ZJM("
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MJJ)((K[>Q-E_C:P'(N@(20@\-S_N76E#X2/EX\42DBZFP> QM,"4<:.I&'=
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M[TZ8Z]V,(O16,$6N77:&*:CKZ\(P%=]*-EY0K4L';M/!0]TN7QK'KMX!5G?
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MOHIZ5<GJ0S5('A1K-KD%$-*Y>A1N4&*H<E'/9BG]^P^(QK%&P#XGUT%C-E.
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M6*V#O82T.D<CPS[F9+X8_LK/NJ(5UYD_NLB[]O((1(YEA$^M7VV.!)>N6FF
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M>ZHLIM9H'/5Q'Y)BK*,9O;]NS_YT!EF/=V25D-+7OGX4(YK<4<LA_!CP<'.
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MZ?IV,5'^BW.N[1;@=2*NS^A6Q'3^!4EQ"^"9LEZ#5O^_!1UOU3 4@P$AS?@
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M%334=]91UK7)+7WD Z//(-'R%T57KH?_UO?]NX3O3^7COP]Y!'F [,36_&M
M)TDU]D8-WZU.A!FC_ISVCUYOL>,\MI=\<YJ235QK9KG#)T5!SX[]&6,OW#L
M+?=L$EK],JK3.UIF)J43#<C78GGJ;B/7;N)[?_&^^Y'.KXXJM&O[YJ4M^N]Z
MY'\A9&I_)T24HNCXB7&XK8%DPTSLC\C&J-O^DB$LHJ&AH) :[WS9^NVM+J5\
MA;I[,3=%INW(6UU-+7U&+BV!+=Z@<K+4GY!*VM4C4TBFYS*LXT2"3@ !=<[
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M>A>8=250[P[7^Q);LE^*W^CTDD-;*P],-]GJKVB_?14B:L :K>3'+V(Y@5)
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M(4<%YXJ-J0OAYZ+PWJ8S0416O]M]S 6+F//=?7D;\D**1UA/952CN'U9NE
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M B:<J@?#.*$-38%J.$T#'&?9>#<L65\#&;AI)P+IN$E=I4BH CT%@<.RTD:
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M%U'&/'#;KHMW\K/@2B_J(HR6FRO5CI5J2SSQL1J<O.B7R)OX'6F,FEW:,,+
M-W>!BEV &<SHBA/:(I3UK87DS2TF&ZFDV,BORCX,UK/%-L*(7]MX1AF@"0UH
MQ=MR%YWOF@)CS5&BFV%'R#53IK[^3<^3X$JMPI,0T9+F@*-XW\EE%K-">!=P
M-A7YG"FR),7L5RQV2;\1;A!L\NZ3A9_K"?B["^!<]H\0>!1>W"5WU%VF4EVT
MABC>@=T%O&MBIQ5Z>R&=ENGE'^XK/K#Z8%+TQ.7U.PC+M'.^XQ"G>V?9SPL"
M:V4/EK90'_<%?SH_E%,>*QS@_UKK:IR753]\77TM1Z5E2WQBX8Y%3+GX0:.7
MG"1XRA'*U30%M&F(C+LY?AKODZ6S)+0AV9QDEFOZX8@:>61"<$#P_&PQBUQG
M=VQ*)23V,_5TQ,2/5]OYV=O1VJEE/U:VNXR2(G<D3\ )P;2,E\2_=L#*<WKF
MRO',GQL1NX#]4\A)=G;+X6LQV9A# \8CG3]2)4D5HDY$%G9-6BQ #HS:4Q/G
MD[7$M5?*6\N?N6\PY*$<P4*(DGU12E4,M"HM08^%RNW=4M=(G;B5)VWU<G1D
MU.J$0'N730$#-TJ*H>"#?=)L:6G/&UP\V@Q_N;R:[QO!U!L\NO]>*)A;F]I%
MZ%B\0)\)B>_M124N5Y2Z%%/2K@ZII4(3/IXD]T6[\)J_]V3 _>W<=8#;AUJ#
M!,;G5J[,5;S \Y\32-*EWW>"K3SB@?GDB1R%\E6Y]G !N!CK1@VQ?HPJ\Y?;
M\/-/498R@JW:Q%]ZS42>20\/JTA._T&\,<2*K;!S^GC0MS+KGV!CE;L;9W<!
MU)XC#8C&;7,["GRWDLI$^^_Y'Z.H<OLV?%M425EB/)MRY>PM!2>^F%1/3D.+
M$>VJQ,,)>D,)>C,93QD]"1XU 85E4"!<S2Z& /YDVD 0;B6V(4 K$1$F@5(W
M/8(:=0+9CQ_%7VR/%%X$V_UIV$K3DMV?,YWFC6FVI12W&;P]Z5W19[=:]%B
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M;T[(*3C8X%%<9PJM]:?2 @\;I%ZG.T'+_7?[GRV2*<A^)@^I%6=Q:18.#(1
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M:]_9)4=^%0U?HZNAM690;*X:E>3V*=Z/H5<XQ]\?=E(6V$N]X_()SQ!C)_&
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MO;8&JR@ 74%PP7\X,^<Z5:V.:!_7)_Z07RL TF:R K[$FX.L-B_+(I@D&5!
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M*JJ'D*!/M[LN$%Q^#-6)E!$XA@^^B8X3PAK",LRT^3)=^7> 1>6OP*+Y_\_
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MWONV!["/=F%&<>.K"/2\8N9;^4D,+^P3#+)4:$'!R @/Q.YG)@,U*KH"6]O
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M!Q>&'KW,IQT4X*JB6*5!0CY87/Z\-,R9=5+O5+B!K>!<,M10MO6LVH;P_BW
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M"_"(Y(VF:*ZTWR/^J$IQ_S/3>M6"!TO&/G887>4%E3$Z:V:@,LC[7>-#@_-
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M1]2*3QVE!W-;YXBP>*%#!)/5YMOQ4"?SHF01QUY'&DG'OJ^3ATWWCD3;1L?
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M9U7_JE>OWFQUU<S.K_MT]YS3IWOFS-Q/W2\!N'+2LM(  B( (#S\@/M90!)
M0T%!14%&0T5%14='>X1)@(6)@8%)BO\8AX"2C)J*DHR"@H:.C9'F*0LM!043
MWS.6%QS<W-S4C (B_)S";%S<G+\)04!'1\?$P"3!PB+A?$+QA/._O-VW 'AH
MB%] RR"$IP B'@((#^&^ Z!^T!,9X?<-^,N&@ A"0D9!14-_A/$ J,0%$!%
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MTM'$) W]\ZTTFYX<W52Y;TA:<9^ZAU.4'J-UO=X?!"NW,WVXK.]PZ'I1_HF
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M(?RL?,=VQ&R$T"_%S$8@_=M<KH++!-5Q5EJ';3!C7RTEI\0F(4R&Q2G3(\U
MK*$8[68[W!7"$L)_\-3]H' IHR^ W-L<)?NM2%I; N;1ISE04. +<'CR<C%,
M$V+NO@*1!O.0A*  +&8N(IZ=+KTK:-0=QU9?:<P"Y#=(41EI(-TEUK+N]AAA
M:S7A%*>:#CCK4&#SS!XM^B7S,T@E<R2EW.231POBHA;Z3FC;2N7PCVY0J=OB
MZ@MB+?<^3>_>7Z9=J)1 MTUYR<Z%H%]>UFQ+^:=#.P6U)-(G;ILQ8,-GRY^^
M15BM,8_3@B* S<,&:JR#Q#P]^KUS&-3G+4U#:*@^ILM=HI$"7&:*ITC1<%6S
MKK$A6,<LWARI/^[=8@"S_,N)4E?F?1/2CK>V!U$<>TCFOK]V=0M<[>E"^#?#
MUR@U]/'%'@%E1=O]1=;$O%C/PI12^(('Q1YE%UR:P#2&]UVFU^-T)]1[:V+7
M7<P!%.IDN9D/W\+[(',$J^X*UQ.LG"MKVW#>')Z\F=0J!:QC*B7>S3*23$Q*
MKE9V^P()WR)P<EU%53?OB@.AJ6@-I:+MMA?G=EU,GANC-=9IULM@QQ\ 7,1K
MXO* )L4]D=L)LEO^KAM&R.X%Z/[-(_K?%X!^])>\V>G4^NNJFXD(X!F.G*ZD
M.*F353]C.,VD\#D68;W$.F1I+2CUCE"R(QVO\HAP/7CVY["^3F_-ZT+LL[OM
MDE\6$<CSW 5DFT7?0&<Y,=H;XD>O2T.SF1'%!(%-UT5T+"T5 [GN-[6CAVV>
M$&Z*0Z.7S_UQ/$PHD3?3#C8;FVNZTUP%?GW"7FBKTMQ _=CQHV,4.Y_BP8D%
M%,G=>NE\WNHF3U%XU'R6?FW2C@8P7T:V'WF$]/'KKNA9?_D@C]QAY,5'87G,
M\&W?!YE%MS*IP',%8W:V7Y8/];,TJ7]]U-%9:;+:./YHV]$R]+$S)MM.\#L!
M(%W:6<=+LZC0QLLPU(NLEVB+J$ZSA\[MN,MK&%E1IA7',7_(-??!TVKZ5=>?
MC%MUR+^(> SH-<.#2V"A-*.LI1:5UT(L'^9 M1.M@P=>T(6D#31MEA_=Y'SB
M!RC^@LDE@(GU K6WB [/L[*UVE1=# NV .)65$^!W4X9R#+8VXA0'US$19R(
MAIM(KAK#]^*"!J>O*J<F!*O)=J0[/64.\\Z508*TIY6T)Q-;^0U<O]JKXRHF
MI71A&^(<6T$'X#T!D:X==1)1(566CU0:,.\G]-O[.2=3<UN2##H/"<.4*2<:
M2M6>K;@_=,;'<A>XW37"(P4J&'8.'&>9F!C4C_HAHHDBDR4\:U#/!' OR<]W
M(0"C2&':X;NOOB]7-E_#RBJ^UD).VE$>U7M%I3.7Q+Q*!'7M;'EQI@9I+]#!
ML#\O[^[./H.LU5:KO'Q<@RV^!DH_1="X(39K(K_KK(*^_M#'X/G)WM)G+2%#
M=W3BU'PB9VS-&BI6/L>RA#QXXW:>O]S0'+_1IQ4_8)L^+,\9_RKE*#5FUB:M
M+,R.IPQ'T3O7-YX\)S%.<T4A_]&UD^,8C46 H%SOB O_J3=SI!'W8,+@<=5Z
M]\(.LVSNZRP<X; @$'T*2$S]E;,4B_=J'.7O$6D+%.N/H$Q0#+4/=V6F%/F4
M8$GU*"I=7&!)LW+Q_>EN&4Y[]L:;F$44TB"+5V]'?NSJW@/@*F34F2>_[K86
M!*Z\QN,'")CKK/%YMFNG$,2IK(L]W RHW\!O!P[*W0OFJC+CBI-1$=21EG#R
M*6#RA1Y\^W6K-F[0RHWTT7SYC]7;G#'3^P9DM^G;JMV)G 5]W]H!W]@297&*
MCWXHU:$O,V1#SJ4BY,N=*+K0#3/8#;U<2R)]22$WDIY%X?T\X[*D8648U4U@
MS0A@[<P(160AF_4NL<30^O&@L]@T7%-R-VBAS'J!N.+[J-V>91*XW3/!F7L_
MZ4/ZW42C%. 0?\-OO6_V(Z.#[T0'N;.Q(=NI3482MM'IJFY-="&(/LK&>;X/
MO M;^H#"M:_+K8**(-9N7;HWD',87HD1Z4)=$_T1$A832KI).#:[]1++TU7=
M:7!E6(]@.L!!8CZC/<=659RD_-(-(=\&QO7:(E9-0^9]*6( VNYBB?.H#S_G
MK+PY8Q@/.O=^BG%E K*)2(SSB4E]'1-B27#9E,LN6'&]@Z/8.ZS+@0.ZR2.&
M,J=OHVYH[4?3-!JUZ3+2'J)E;ZA,.#DB3E'OP=!_AY<236J9X7*XT=@KX,Q(
MS;<]6CA_2;6Q#F&,[=#Z9N,@M=:XPS3_W"P5+\.O<EI5G"(F8<EEU.ZPM+F2
MS8ZNL?K%SS',^.[+DXS1@KSVW)A1<A(?R7RIM]7$1+T!/[S2F]G =5D!+];A
M\^49,F#W%U(Y\:;A6D_>D;3R?,Z_9-"QWZ@?.9N=I]W':O+8;WF^OQLT6G?%
M!&)_-6(\O!?=H-;/5?^9'FHQ-\JQHRC)%SH*L3E1NY8$.5M 'MF2J/A'\E1*
M 6_90_%\:'^_;3>38OG1]*3*&2;0"=;1BY0G80VRP^TJ#Z$E;>FR\?J[E8R(
MI=E(%[S$N'H_GR2][F,)=B)(/QOTT&NI$B1*FKPHU]TA9G_BGOX:@5&DMG??
MX&UW+ECTT&"4Q?*8[4R>G_YN[4=A1L_#O.F:@4@/"^/>UY.%8@G*2R.///EE
M!FQF=ML]NSH,_-HXN3IY&BU;,:^J!9;]X<5_H6X@9*2;DS%+MH$'KG9/U4>:
MW4W_5%BV0DG&9 )5U.TT3;[52PE&N L5'D;A"Q6F<(E66]4>MU?Z4CC(6[&.
M&$R]%S.AK@Q7O(M=$2K:%]/%FYKO,4N?7L;4$^"?GXT'5VA)B^^T?"'%Q)8@
M'/"([#@?OG17SW@]OF_65!56HSUOQB3C5 $L(ETJ&:'K+$BPKNBGA+\/*#9W
M[.(8GX1TMWLP'K7M+EI'Z7D&6E9-.>F[#_HZ>&D>!O$PEYBV5;G#OJ.ST2/5
M(S_"H7,A+'=VA9@C0'<\EL*]&F((<#J&490C? 1P(K@MOD$UPT+PI9[> QC8
MJ7X\?88W_!-G$$YF _F.(8?)*:(6<4("G$.$?A?*W;KOD]SSLI]M73'TLIH]
M))\WB=%JZV;$NJ0)=1#-2$!YW6V5N5XC.>!(BS[HC><A<".1:7W.[KLV/XW,
MS)FK\HV$KNP>,,Q?]*#6F+#CUDN3U(OPCA94/&2</O\5Y&#\ @V4RUR6H3&V
M#U';6#E?8/8$GK'$!Q3C*#QNS>I6_S8>!^TZ7EA_LQS%B0K:?4A8&B27AO9%
M=%DM%<:IE29HR5\5?DD,O99LY'L%-TNJ@YU/5A;PYA6\JQ+ ?(O/L9?=:'FI
MUPESUSUH)"KW1]31J=&>;NLBICNS/RJ=Q)@%[TJ*)(YSO9+H**\Q1]UA J6/
M-="SQD:7-8C;XZW6&F3AD2)[G UQZWG(Z?E3Z7O$[H>-]%.UHB8Y88LXWS+C
M/U@V>3J$M$,6<(2246 HXQ!),1E7H#T>ETB;Z]]5)E%D TNB(JNEHADKAN[0
M>8?9X4G.X4N_Q%Y(]1I&M1]@=7+W$QG9]Y''CF$,VQ1U[9=#<J3P'?5O-$!.
M*GI;0$S$5W7!(-:\UD-M#R- <(HHH,HSY=E+4EW0:QPW97_4@U$V[DIH]V]9
MC9PNQT.H7M'CYUDDF&^EBG8MD45\SCG@8%I=;<(50(R4BBO+V&AIG2P8DK;D
MZS7\&F)(OEZE$?&R#=GB4:OVR;N$B#U7>U!GOLWH#B^T*3NWGQ]Q&4(_0]_2
M,K2LMNV'.L8](*0Z5BWO:.DSF_Y,R>TH!D?_8@"0S+TD?O40B\\P0"*5/WWJ
MBSMNLVFS@SYX;49TCW%CL8E1>$2X5"#J6<6_UG/V*5Z^H&J$"TY6I2WQLU2B
MV=E50F148N:K]6;GY6N?VG7@O-4J%68E:*(5_*D%T]P[^N4L0>YWH!J(LKP/
M!=98EHG\". ;#4'4QC6.'"#4/FLT^Q;-Z@RL@]HR\-C/D6GK\WUKS!X$%QH+
M:?V+02G[F4NWF<5VUB_<L:RUTB_W4/8X&*]&<B]M^I7AJU91ABOS$TE:"8>B
M!U_C%J' <;2\3!+6XVM#6/OW&6%SZFOI@R/H\O=VK #QWJ$<UY(OULGW )[+
M=BE$4Y9N[&YT3R=D^TT^%FRA6*R='!RI65D+<]79%[_]R<ZF]G@J_[RDZ!Y
M[_9VSYWOSC?0TY_*C/WY/L!<253SG#\3^R7X<\D-1RG=8Q+1L1(2ND0/II(
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M6T9$4$L(; U>ODZQ=E7&LB'3'WZ=JZ@YZN;J)+C&*X':Z/46/I!:K5OQX\<
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M9**2(W_6)GD&,BU!$:\K6]&3G<EMM8 V=FK1C,%]@6<DC>^Q*52-EYIZUCL
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M[VWEV*/Z)FL["_T8<5\_[67+L,-[H9RE@<ERW1>*?Q^'\I5<\-3*E9;D#RT
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M%PM!*==:+\3IF-;[6'2UVTZ\I=;H.*),"AC3JF08TI"C+/S/1MQ_+TIA($Y
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M83Z?<\ 8&R8[Y"[WSY"W/,7OIP(R%EDC5GV?H^%;*":\3=(9-=9D>'&_1>Z
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MZ-<W[XVCXW*W"-)G,7H%#KNWQ,:J&$EB*QLU@.%SE28VWPY60C^2,SGS_13
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MF'H\7JNF:6^GRGFB]E%^F&) 6074'7<(6168:V0=HSPQE7IRHB6XP1JSH,!
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MC)O\=MBC^$J[3N&2P L1]W2>>)VJ9NV*V@BVF:+.^KX.1W\4S!S:2E>J=YH
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MM83'1;\<-1Z[0'>IA="!1 4*^A>HN+!&F7Z(/O%@/C+KD$S*))(@:)_J/PF
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MFYKY7^Q9U3]K#6L[G\"N 16(X^A*#XU3E.MIBOPVQ++DJ:$ZP3T?IM=D^]W
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MR(>M^_T?29-BA#M&($RYFD*["R0$UKJBC+Z\N?6*?1NWGK%N,_%/D4B!5AK
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MP$7F33,?/Y(=#%L/*R7P<_G8)=/B+46;:BHO*LHGGA6VJN\N5&L$[.CXS2'
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M\' 5!K@8.1-[81>9/R/^@I\P%45F,?V"/2^6$L*>H/6"1IOL"\INY%A<#T)
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M2>4I+AS'48(N?XR"4GYHJ[$-X/JC7#2*T+=4M0DH7H79_LZMMP&4L92P% '
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M^N:[P:GH1;6 "BP;O?U[WJ<4X&+=@ BK:W7#@*/-RZ'>O<_"0E(&<[#V (^
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M.\Y/[8T10\J>Z.B]A;3TON6\]*!;":JM7>3"&/F-/XQB_S0_^\#;W/%J',L
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MUXUO^FCKA/$3V2VD-4"ITQ+.8)/283.K8ENQPG%:]0MVU?"X/,&60MN+UNE
M([T6ZWG&P-=#/>7Q7B0RS_X!+Y873^ U-,#ZEE+&CTG3P$8?//TS>UV],=UQ
M4IE)Q^0J(?WW[)T>*'>,O!3:VMGQG0((5+KLG%BXP=T^D[1<UK^*D5Q0%A!W
M6:F7%WM*V,*,0?#27,(CH </XVMU?*?>'DQAC2'%8B)R\LXT$YMG?6 S,+X3
MOI@B::E#*5KZ9K44\UQ1;SY<9>H8;&*::#C_\[V*HI%OA<YE7RNX. Q<_LZ\
M-78?=4F$."4Y[B1@_U"&!G/T#^+^^WPW^.+P%$J0>C;P_B/W4_; L&AH@$%U
M]I@B-!A^Z;P,6\<6C%HW$\KQ+3$BXXE?DJ]MC2WT.B]'Q,5Q@P5QJKC..E2U
M7@O-;30$M[[SQ7DB_8 ]9F@@8(V2)5JI+\<4I3F[<+VL,!";.Y\$V$>K&73)
MHI%K]>>3F&4)N&(7N30WV$GU9O2U+!8ZR9\@@P7]K>1\Q/Y-L% *HZQG5$(S
MG[N$A9,'_13*=%4CWM=93GQ3=Q1]C2!G(CFOM40:<9"+2^@2Y8R<WC0QH/><
MC0Z4TG 58.9:#D1(AN8Y$ S.@UTE,,Q2;_#_&@);^Z./Y,H#E27]<[&-/]0E
MCNM+9K4!"=^]?,$NO2+2)\8IKLOZEPD:*HQXYL2(9;W#+TZDLF%^E6!)5QBF
M-,T&GZYU6/>_9D0+=-[AK WU./H2:YWAXL3N8K) TI6+*1B243DT$\\_ZLS.
M%ZWD"XSUH]8$VS=$]))PY0GAH/K/^[7EJ-MNN_K1ZMMX)?V1-?$M'2/^O3;*
MO4;R,%%NQ#YUV!2'9^-^8:]/59/'F8V]<:)8!7##02<98QW$!PFD+NWEOC$K
M5O=2K5 %[;1G5'C8,X^ZJ02$?@MM63Z4?/-A1N*M"Z3AOAC!OK0)"V2E%,'%
M62OK0[)\2 3I@,4U8X=6RJ-F_<.#<E;'G+-%<@F#'D@.\1[\$6Y^^]/2W8W3
M<J7:&F3X '$=](^[9>OBRXLJ*67F55Q/M6[;Z:FX5="Q7AF2X0.H-K]'@]I;
MB=GPW4^?0.6?VT](ZZ(S<\)9^5J1NHWB:SC U"LIMC@= CV9O\\6858BE(W1
MP-BNH>.D,4):%$<(".4CMFXN+)8@T(B.(3_OW4\,O3,WCX#0IM2^JI&L*8JC
M%[ 6M>H6HW\VV.F*,TR^_)[1$9K9[$2&OGA__U6T9,3,QEG"6=T&O;[OMP.K
M29I4<.RKN)"P.ZW6S_=> X^ W%EAUS7OYF^L R51! JJ#HQ]=<\V%O3\O!]V
M=G.\  <?<LS-K!&C"_UC6_R4*1B/@'8%L=NIR1Z"W]QD$ZQU(CTLI18L"]2;
M:\BJIH?\&]?.%#^A.7J.S7<TS !7R\/L:;JP\#,P43>%^VO9K_&J+ -@6VE/
MKICF#<*6+7\Q;T.I_BY=O;GY><S;;LKD-]>XF2&NC/X_HXD]JQW>(;^+=1;=
MYTAE^!4O\J?$BO^"4@'VY.57B*X!ZH\ XR0_,<!RT^39/L=["$0(>BJ,D1^B
MD=.+FSG_<Q;OZWB_E3:BGIS&_PRKFO,Y,+%+<(3 _G#3.S2KKZ'@"\L7\]HQ
MP31G).DDU=%*D,I4]6;C]P'^^9YF=H9>=1EVM%H799)$^?]++:[C8YS\9+Y<
MPBY$*22(7)<,5?$MO(HGN1P($C.G#LF !%HL%$93M_WG?2.?!.F>OY\>?YEG
MAC$4FVUJ65.'B\,&< *%MEX%>;;NJ0GW"*= W'[KJ(;%R_&+G2BR+/F+=8@K
MP%W"?WNY?A<:^J 4XR@_&E.\9-SEZVQ%!M/P*T\.^YVC,CIQ9UAB^T#G"^)V
M<""6^II43C+E/2OQ[>7PA5EI3>CQA^BJQJ5K?\=,*WOIIP@1]A+**#7L<G>W
M()LEINUCB?Y^H^T+^C#N$&P\KZ$G+1*]D$QU8]E"1'_5_P!_VY#S3H$"UJ;4
MJ26^O8$VNU2VO\0(\R.T_NL1UQWSALJG60N424_NYX%-]Q>.\)=\IC;1N$C/
M0I%E@5$OS*K0//*V],I987I#SY6 ?VE+?F?RI9K555P_13:=M[<V#'+ZL'ZO
M5BFI/G5!_ED%.89P#3_+,E/.46I/M21/ZPF[DZ$=Q](F(P%VU_91#Y!&HVOZ
M8TV6ZEVY*];^\-Y7$UNB@8WN:K[^X#6#6;&^.7FG?1]RGRS9&X+&(G=M938.
M'H!5B<LAYZ;:Y6Y>%A2J%R^%<$6Q!EP2=@;1DCS%80#5OAZIQT>9]#NCP4*$
MX"_QX%"^S)E^ZUS<2P@%[,+!RAU5S6Z=X!G1]TB@."=8:E)<54F+DH52:?P+
M^ZBMUW_8?(R6-)GLMVJZ?P!8O/# ]#ZK9MX1BENC,^(\)E_:00450UY#-M?3
ME'\Q=695S/9J5E8QQJ#!EKZT)QS94GUI://C\5C)@C>4FK9<2+*CC8!7M$\8
M(GAF-=H[8U>G[O/W%N2WB'NXVC.#LE=T?L44(\V)!X)8=EY\LFK9-:P+?/+6
M]"T%7VWI_+56N"DI#KH2+<]XEX+,V0C HSA+;!?AI;MXM:XU66VZ$/H381Z(
M\\M8P_NSICOX0CK8DON2L 3$T1*M^!(OD#\W7EKLN+"^,5V3"UHK$72%>*V^
M'0E1*DC#=\IOI2__27*M@2'^1/&?'RD_ G(^/P+&"3P/NW<)5OR(E,N5/4%U
M!CVEP&J=Q88[W6VLF\^EY!AN\;@)@=AK^:?<A<'SUQJ-JEUQUJ^D<0%_QS#W
M9IVN$NP.70=F&[<BTE7+&-E-329DI8=:><-UI?#;":))L[SONEO9P;E0K=JW
M9"I>X>/LTLEB3][@JD3N>%7@QPWYBZI3O<+CQ@JA<<46NM7Q$5O*696FV \"
M.MO"ZEG'#?E)JYO[%P*FO#X[Z>!%H[(DF7W%)FB,V[ 5#ZG+@M 401-^A+Q
M#)Q@^HNH*BNT.*]E&:L'REI(EO<\^\ZY71^H"O!VPG"1PIXZ..?%V5V;=&2"
M!8I8 (@UIQ44!3MN,ZQ?N\F3QEYIHUUK >7!M)Y-L>0QU[]5 &RSD4\C)+.=
MX(VR:I@1;,NB[F(R9NVB>@0HL57KHGJ<5?J2(L0/G_53(/07?E'E)[(V/P*
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M5Y7%=[47E;R,.X>4W-=38]0J(:SRYB:!E?Q$JS+T)JLQ^ML/I$!52?%>+8_
M(8UN=\A"S=Q/+$HS>*:.!+Z+S3%7$Q&5\0Y_5)B)/3>,96.#OW8?T1%) P1I
M.S!CFV =V\G\R.9@;6IHF^>*EY5FX.3'O(L!.&<#H,36SF(+BPNLET3,PZZ
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M;,)/8^&I&*Q[_(&^'N33[7R_=L:HWS -U1DDWWAIQ ]0'/,(J TX@S7X?=4
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MNY+"&LCUW<Z!^!=JH:&4;(66#[F"CS:O1LVGI>Q]G4CO3A.2XF0JO,/;J7O
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M&YIFGC>'845NL;]"B<?;"<81"1>D7A&]!WPI[=05EBF"@F.);KE!8L^G13B
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MV0!7,=#_(]:O'W@]TD< 0$)%.O\ WSY(R"@74"^B7;J,?@4)0$'Z_OG3Q>L
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M3YS][6SL[4?)H<]$E[*430:>#-]*P_B7T4".@Q/J*TDK.Q(!#$=ZLH!4G\N
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MT$;Z.LA71,?Z>N;<#2#U>% $)@&\?U6\A("\:4_34DVY=B"#N!VF-RC)!$T
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M=&L;#F/!@F)#D:K2NX)()XH#" A(#3TB(+WW$J(H(#52 DI5BJ&'WI,H54!
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MV81P7QK #WHE;S%/AAC==30G@S>R,JE"HX#J:H"MQWHC^^>_M5\N'0+7[[Z
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MALMJMV.F[73Q?=,SWFYCISV*136 "'8#"",%=Z+$P8A-11Q?T)5$DIG $;W
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M>7YYHS77^DAT\LN$YVT/+-.\KV7D8(O5SQD,WS@_;^"VX2+DN',/)3^ [;5
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M9;FRA7ZM52M)F1%]*AS#10*H7.[,[  J?0:!9:"G-FF=>.M9-G B*#[XW2_
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MD'TV*19TGTD0;)B8GS<&[_;TE#XP%AI3+2G<O)'0<MK=ROOHIT92W<MGS^X
M&&SMY9Y/\=)W!EKC\Y-NZ;\W2?^5DFN<SQL_KR9MC]K5*>_;%926TJIB21S=
M\WHW,X"1<-8P-1FM,U^IASOA_=:]1M:V9NRM554 SJQ761-JSP7K10LL,L4(
M/[2W+'BT7S?/WREBT@5O7=D,7!Y)-6CN_' C'>H;?RO1.GV#F)@4.5R-ZO/9
MT1_PMM6(:LF0:7I^+=Q2M?U^TF,03IK-,WH8[\X<I!=C]JN#2FY\,I^8</'*
M #@VQ:LN5)8Y6A N>.'#\GCMSHZG"C4"07!$FK*??5%( S@ZP*Z!1?F+C;D>
M+I[BAB&=,@A+-V7:M/-?ME!LF01XND[TN4<'\O!3Q<A)U77S,UN3ALTJ9R8\
M"G(%?%W$R5>(*#&KS,JAV]WB3QNJ8GU2S\SGI!YU3V*6#Q.^>_1YFT^\[(Z%
MC;P**Z.41;2#S BNS:RQS+7[SJ2K=N/NBN6V]"M!IEQ-I=44G86%> M-[H8#
M2JMIM[WH[N>USYZR/?T-Y^ZPM^FZW;>5<2=?\U[\X%X8&6-VVVTS=50PUL/'
MK&3#5=,5&ECCZ>!GK]O263^_YY+RTF!\J.YRO<G$9G#S])#3XL#LP.;1KKD'
MYB;7PMV>M(2P)],O7K-2H,,SZ;3H9' PFZPXQFLBSH("J_&Z#I,7-P\N"BL8
M/>&)>#=%G$G06S LU]#2)XE.Y@=#7!^FL#J"!6U"1C5;W5Z6KP=CI#MLK]5.
M/:X^ZVXNT6J).*7O+RCHM>B#PGK;0P-]>>NJ^QH48NTLW6^FFWS?VH-S65/F
M;;TIXXEZ\Y/Z)35"#O6QF86:B^K[ZH!3KVY$.?"O 0,)"=\S']+%WD!S,@'M
M90Q-C)65+D>:7\'L//T6(+E5NN<6PU<\YID^!@'7X>B'BER*9LMJKYRJWFB[
M$ZV:I*0E57CSU#?Y63=Z[@MG^?TBF?C;&0WTU=,RA2)CRQIJQ%TZ1E8=5TXS
M6L#MGP@$WEE1]A20L1<2PE66# TG5X>.!*E:12F'R>@XS?6<T$O\Q,9.+IM*
MF_+PQR\EW0G?8)+N%A1'50:OIU!=(Y8.1/ RLR'%I'V9>_5E57A#^&95M4D)
MTIE!+EU7H$HGC]_R7(K,S;N3+P4?M*W9SDL3RS:$>C-NB+<*ZVHG9(A7IPW'
M('/7(7(9+_G5F4%ASIXX=2EL$@Y5;S&Z)^@HE9]GH>%Y[G'\N;M.1YJ>]YQD
M1VE:1A2RX!&&5W02ZM$DGN)4<O?68/JIF[ER%H(]8RZ3^A@N\=J>W]M*EL@*
MB-,[O#8I[*G (<4OB[X34XO,LP.\J+5Z6/5>!N6!:?)4LLAF-SIVKSJC:&OG
MU$3[".EU.A$MO6/RO<&A.' 5)_=-7OPEM'UHZ3!\-M, KY#OC<0.H(<8Z5,F
M)7\'>=65Z!Y^^ N44A;^04[975YXDR_9_<;QN)I;^M=5U/;82Q4 V4?GX$;J
MNLD\]JTR4GQVN-S#'1=6NUT@E2O==G,A^Z3DI:P28FH?M/G;+JL5G&DU0\WA
M3<B_C, \@*.A5^7I5$9+)W_U%PT!5E55N/D_ZM?</?*2'"4V#S[_D@:P;ZM'
M6L\#D_I(J:IC3VB D5+U^+XJYJ#]Y(D$!==<2-WVC;^:9.G_9O:P^QGA,XFN
MB6PFV[0X7J,![#P4P_/()XH$=1#&'D.1\3LF2-5Z(NM L>Z+A5R^*W.[Q.+,
M+SN,C+?Z)<.J7(Y(-$&(G9PMH>VDH6T"[U9MN_+:]_<'K>11L#^>T%)FI&PB
MEWN5&@_FGOP>@%4G><YH05NPDX]+XYXW?Y:O.L#0X\S;MPZ3'>B;Y<(P;A]4
M5$."CRQ/V0<Z;&G;D7K[Y2 ;GS]NB80G7TJ.EGE-=*2NX-JWG1@)9_S?*G,8
M:9S;3YC_P78PGW<K'+")=B)9=9F%?9"N';F5 ZN%'\_2.JZHP,KMJM&Y>TOW
M5LX\S,I)LRY)J= NL%'1.J,NVBWWH?ZV/WSS!5+DJ?WMO6,2B<UK<??6$YZW
MW_7UD-T!<X*$B]5=_$ ;E,S )(W. \@^-A\_6"$H>>U]I&$RV#=%K&>4,OP5
M&H:/^HRDM@9R5?NJ5O7,E(MQ+<QEUH/RZ26-V#3M9A21KQ+3-UG5)OI--G&.
M@7(),<TZ<,8BRUDF1_5MPT9P<K<"\OTR_!!81?4_D]]L3WYCY$SO8>W:/ ]>
MF(0'E;@:=EZZDC8YA]G;K#V(SDJJ*#HP$=J!(B8\1VT&J<R-8/ES\8)OKY3H
MA-UGW$OFVV9 K7:^U_U@;ARH;->A^M8W:DAR 2.7/834RK!4)DEM*J-!HQHJ
MF0GDHEY+5>-+LFR%@'OLGZ[2XY H334!5?VA 5P@Y_&!*/> VVO8%$[]:W^B
MG+\;&W\HM<8AOZ@!SJK) Q0T>=<+^Z[G0B[/,U>9JCVW6X@)"=%BNP!8<4^;
MW5JL\E0]KV)?J_^B:M->-,,T7;QY^(6Z_AS2T4(,F=&>:I?GW6WVO99H$-W"
M\4F+"_QQG4R'C&M"Q+3)]H](22U51A+M<:K#3U(^63(Q;_2'X*$7R50G?"3I
MQ<S]O[F;?L/MQPTSL\?L<R>8B'-/G[0GA*B-*ESR GBW:6FZZS0--->II^SG
MC#EO%J*2K1L@^W)"3QR>7++2(96I<5?WF6PV0*BS>KD^:;8)*Z\UI\<UUA^5
M<-F*AA,>6.X@JL559&>/HUG/GYPG9+IJ!L::]:T-$+()5<M/(6@.M_9IU,O)
MQNPNT65D&#@DN$;U_;))"TMEX+2TY?YKRCQP,.#F%(DM\N#+'<$,0?G!B<*9
MJ'%HRAH-8,X(;[$LL+3ITK&C7A7))"JN4MF&2@9>R?X.&7_R%9Z<^9],9_2L
M!63%KY(-+_P#[6!RE'U0D@@%.'PB1SGA7<_6R.9=EF3JE0%)$7F[_<LK3B"7
MZTI]_-]\11D>1M_TG\(%+/(^XQYJE$$X)A5:Y=U-^/AFM+B62?#FJ=KK@[,Q
MG1]G\]^=N"UV<MGBZH17E_?SW+;][S@YNJ]7>6P]CONQEJW?93_SOVCB_\TC
M'OF;/> /<?&?O8X>&1+)70/&T,7LK!]62,R>R;:GC,=T"M5>.5A^\OW:?-Q"
M"Q^Y+($L<A!'X!43TQZG 12X?<BE&)*(B@&'F<(AFO> QE-.=_,$*6.2;H%3
M*1HU5.:R05[2KY&?#J/Y]5%.RG3TXF"^;F#*<O&S]Q;!P_8(+'Q$ ZO=:IRV
M6X9?NC]R[T.]N7G[ #F][XM?KTKL!/]&\>L;[:0: V8 QZ/MS=?:>G$6BO:A
MT5RG!K.RLC=NP^'H+M)&ZJI7 /$IKU[BTE""BP7.&4_2V*C0Z$@8\9LY43RK
M\1+^P8 N,G3TP:R,Z-D'G^3/JA4+/*V<U;I5>+4N]VF_H4__O@>Z 24E40C7
M,N 1U UYX:M6XPUQMF&U+\=:%?97I3J;GS:M^8+Q9PT'YW7,?K\ Y! ::Y[)
MGX$O*QAN!Z@%-?@7,UXY'YH?ZI-7&:CF>&5G<PXO65@Y\T_&<B1MVQJM]5:L
M<$V'4+^X>[PQK<WLC3T1AT2KTP"AO2!1V!U>#K/>C2B*TU,"BTB2%F5"CRB8
M1_4O>?CA3K: ;RHI'ES<TS@,*F;>"R&-07-CLW4JKNSUFTJ1*W7IRU806X\9
MIRVZ ]11,OU0>\FE V!"A7R )/NIN )TE_;\4-!0WV+PJ49'C7QA:V+01S=&
M>ZX>U9FZ7E(6&B14L&R0Q!+@Z=2@+H>LIP'<\5=S>703W<]ADY'[-A6D]?V,
M]V#K(+]_^D[^ZM+ZV;OXEY7]#UJV_,\&,KZ_'?TCTK'M1]8./#T$ - #2:&.
M+]!Q!^@8YL!,&R1* P0@: !7Z/(%V5$\C']&WI<&X+A% V"]:8"OW,B,;AK@
M.><! ;/[-O->XN$I,'Z=!EA^))^!YB;=_;<"BNBWE8O+)3;5KB(CZA=#71-?
M/VC^1?9Y+SA@*=?D X>6%UC($=[ EUU1G;^GJF!RLR11L#!G SXZ9 Y6:2B'
M>Z;_YTA@/T4#H*0H%3^<E,NX3&+@[T[*[J<8W"IUD@88T]:I60:;P.)M4TW9
MP&:'%S\X>7 5R7D2!26=R#_@:!-SX-QCU,8K7.Z%,ZUEM]ML_%FH_A&,9#8O
M@2$OM%^_"$_>U\ '8^(W@":X;3PDED/35<P=.C9&O:+P\)B8LX7 .B?D\+\U
M!-^Y23YI-7^/9^RLC7,4=<6[?2@6."6Y:'.[SE)PTU_18)F=ND<#'/G:7;"C
M==NP#Q1</K:AL2WW'=2?>>??;N]P*7_]Y2]I\_?)*73SP;>>%WF?V.2:^LQT
MN,]=Q.EQWQQG*J1EI5]AP](ZU*"1C.0Z[8JNIX66\TI@F]K#ZZH +WX)<+IR
MVOU4#^+$$AOG717_ U]DV<O!:9:H:7N-N:'>UVELO,NHF>_!]M]VQ)A7-*#R
M/M5?N(T.UF6.JTA_Y JYR]Y0QK1-3/>V<,M6SN??&Y)1$,&!4Q4;1-XM*7D7
M(*Z('D@R%9-+: "NOMVQ6X@Q52?@? H ,E;(V1H!C('8G%(/Y=<%V_#LK%!=
MUH@F>':'A +J@'. %YC'VKSD1=H?Q2CZ1$+YY0%O[D883,+I!67WVOD# : )
M(:U-C#$BQ@]2>'A[HKTX[07(!S /^(S@19)4% W 4 5.!7,-Q*](A;I('8MY
MK3ASE^Y!C]J2M.2>8(X9DVGNY<2274,'4N:UY4X)KZ+O">[E$\MC3SXN5(G+
MQ^]0^5(6$V7N7=,F'(5"=YHYV] L2-)3N02_'?[#9U=*0).D=A0GDDD<IS/M
M/>J@8P.$X%5D[4J0/8+RX:L9/W&]1[ND;1K#]6*-#NEX.WN=GZ2/6G&A ?96
M^R@]O9OR3B4U%85KJ?N'B]*F@#2$_:XYM4H#5(V<2-T<2\_<NMC)V24('"\6
M[YP8#N<BY*/!2=L4T.?H3EAY<0^:)2IUL1+3N^ -7\^X]F=&_+MOA<E5[$9I
M!"(])(N**#U2IQ!J95C$?V\P;YV)8NSK6E8EJ%?,HY72F(GW'>'J<D%N-NK)
MA'QGBLI[.'V7LY7+%_BF]]3)U6UO(="7E4!!M3ROF+7X32F*CSJ) I>]+3X:
M/%RH!>UVK"8I0\W'JK'S6]PK[]K%)69?=W9*+#&[\*WH@QZ6!T18,-V8U!_0
MF,.3X[K9)JY4YG>(QMR>[+9W1:7SA>X:WWZ5L_/QPN?Q6)4A3C'%N3)RX;>N
MK?(F)8O^[SB(Y+[A9)1M JQ5E8F?)(=3]AX 8:;B!D'E?DT_%Z!:_]2+A,9-
M6OVOAGF?C1GD7) +D3O_N:A +]2HWON".X03G[TCB=#5MR[0<Q$W!^%KXA9D
M/\1X3H\$CSS]\H0^G%V/;Z-VZ=YRVN/=:VRVL[>83>J"J&7AKG$*/,-2RSQ#
M"LB*5:LU-T*!$2'PU+(G:K;?<)6CM[C&7-17]G@9I<QU0?QE'*OC\Z]I1VH#
MCF2$OZ=/ &N&M%!<,N4,$\USDL;XO.=(G%+1S1!=!+?YS- L9-^AMYOU#?+!
MCM)/L/('FKM\X_^-NS[R\5]>^MJ?ZW4_-R<?>;&]UN \'47JOTP#H$&<)(6@
M85<A/<19G.N&X>%*A^5T<I$Z$]8OH?>AE,HE><DK"1\^HL13,9OEI@?8_.<P
M7I9XZF&,W^*=/\AX*FOV+1)&&J8!/NJ"W]?UHR[V7*\-D<L;O:HO[W*S,Q"V
MH/!JCD-5,FV:)<YK 7FYJ"^'3U!7[T5E0OW3"P0-#1TJ FC,30/,K'8;^S!!
MNS#D%"@Y[I")VLU %Q>I&HS47V>J7!G'[2Y REO?M""NAT]&!]RD\N"EVZ0?
MRY&I7,= 1\2*+%/G3,:#=/ ;C7L;#21"D(VP$R3L.H]4;F:SF%9O5_"7E2#@
MS!N\N,@&(':6#>KS$.K;AQD!/E]32..P9%/.-]AWH%[872.C-]IAT1\US@14
MHE:@T9! )!!3A\76^SWY/0+_*]N<G\VO-FYGILK<(S.9'L2!Y5([!ZW.[I O
M0 M5O\[?0MEK5 (O8XD2H*;71%EKQ:*KL)DUU>7(]:[9CC#$HN]^Q]A66>L;
MC=2+0"&Q>D$:(*8G#*77)9_=4EH-*Q"9,SMY(C' A?XL)F*.)!FD(BMV,M)@
MNC(E!:\] 5:8),"J/G8\*2UY2>UT"XX)1,Z7[RJHGQR>D4R2@,?=/[*FH@S)
MX2Y0UI)3XT5Q(-IZ1-/2>!I-M8?L- SO_IO%YY_SH7[3?YG_JN]>HCO3LNS(
MJGF]224W8N\(,//=AE_1HJ2Z:,YNM)[KG/T)V7C]Z<84C06W ,Y(1",*Y^+S
M:H'[&N!,S)!*0!IEPL-#.:CGXJUT$VI/59VM-Y.C!SJ2XEJ-<H*(BHF%LBCV
MQQ#?VXH$\PR-Y=8,Y/8J(0L4C7ZL4*#NT+7^[ O?+]!) QC*%)N_>6AKMSSS
M=YP1F+;J-1B1LDXJQO 0:8!F=OV;^%OB<SE5ZNNH"Q:NO0BRM)%#TFC\1HU;
M>[Y%M&*!/SD@X*(RF[*P$NHJW[@3MB" O'?J6T"MKT.98\4X4*62Z&('TNF\
M]!]Z]GXT*)_U;07BSJ12#_?9TK?5_X:+5OY_X:+A/G2;Z'V'HZ\>7?[(X'NS
M[=+ZT=FZ)>E/\EB7*]\*(F8R:Q-\*GPAEU/&D)WME_G& N^4=DTZ"XT+B2+-
MQ086/0.5&\)!#22VO=(3'\[2Q4JJPDX9G5L-";#B2WL-@2%"\QD,P):Z,8IJ
M^:9)I\1C$NQW1 ),P03&[I:!C,O)-0@3Q&TVUVX^_LYUO@V4[*0V04"W\\SE
M-M/V7VOA"+OK.Y?$ :'/(8CH])C5KV<7;^0R\)S$)EK)U,>FR<!G$DWWBW8;
MYJ'A;V0K6H=#3W3J3^47),S[P$<MUH>KS;JV<==K(]FUU1WQD=)\U:^YB.KG
MS8WRZ.VFV&H7O^U)GY=N/A_J!S_1E"O#WQ7GD<]G76G"MRE6M]\_+3"]K<&P
M*#"0?WGVR\;,T,2FJ1T5/V81J%6:H%>K8119V-%P+.(T+M\J[9> ([&RV&2E
MZ#(F+I4S NI[J/X^J3ZI\K4 >$$[H^9PBLNMJG7'E?Z5_O'].YCIBW6B7W.J
M-^4=Z[*,SVXIA@(V9$O;5-Q3=H$5!7>6V[S&'Q36"B@Z0J<$?%:'?.5I@/53
M]H+QH<I:6ITN0LDT@#HF./WJ431KQFWX;/S)F!KQ'!>-$MDY)IVVLV[:2C)<
M3(FE$M&V_#UIX\#86PD>,35].97#![L03:Z8%XE<_/HA^5OJ.NIBU=THK^IT
MD!*K\RG[J2L>\H9;%<XJ;R,W@&NAAM)3N+M+VO=2>IC5>E**!9326,L]G<V)
MQE*'&,=>7O^ZE,JMM 7X:(A65\^Z&,%]-#-\X_8;7?^4.VJL#FM/1J9>!R\Q
M7W-_03  ?1IL5I+DG1E,3Q9RS=TL-ZQYDV<E,&,KZ*:K);CYEF=X>+R!'"VX
MH_WKSVE"3IN>LHQ9SZ3V@K4/EV[7),GS<*4K.DK2 ,F_=2:-!L1@U \&@Q+D
MA\>HP WHZHHKA0$+>SF!H;S4IS!:7:EB)-$C#C)B;)M.[>G,EJ_KW-C]:6Z&
M?$5;31MN18XYV%4HCWTNZ#'D;OM,"ZAM 0XI-IJ>1HHN>R<6V^ ,22-[,N9B
M-NI&$<O=%1 NUG'R.'4N0#3UZ6V2W7H[N>(N8X.W%:&,%UT0*JF4*"!6'D_$
M0Z5\@JH"8JO4AJ#VU2A9L?AR4>R]GG]W.?Y,Q?_@2PM!VMD=A6,%'^E36>>L
MIQZ',-OB@*'^S.3;9?K]"!>_SI6-44G; TA[\;.6]M,Z]<ESB4YKR )?,'+"
M_7Z3;/9S5J:32]8\JE-TE&-!^WLN KG'L6)INV 1*-<2L-(MOXZ;V/B^D+A,
M3!>%3WUS,N?+N"\<]_HC@(F.GJM$XS%%$;XZC:O527303TC,&E 34I;<KR$$
M<&AQ2:3;=:9+Y[5^2 WH[#TD"G@YDX.+BTT_&3IGR?:V>U%BTHPIXR^@'TWG
M7;'V9*%/W0*>7_>B @Y!*%\VV8FJV@ ?VO-&I8XZ3$H64$!?=A)\ P.=KAV;
MF!CQ4((E,J1=X2J1>)[QS$TVA:BJBW)PB%_P6BZL3(H ^P=8=))X$'HKATC0
M039%$,Z>$%CCG#VZUU"]OOIU;7>329C%6)SM^[U77SF*7P=5*[X#^$(;5IK0
M(6&/WX>ZN. M-Y1]Z_?!6:8'OG9;0O,;?CGOBM6#=R!%E/F5L0%L!YS,^+A7
M.+GG[-<[ @HCKX15OS)<I [9)/:YZ+:HV24+0L:&,/$#"XXI0SK1;ML!DV]S
M^T0N$%'!JEG=%WI9?YWE7S$(S^.BWY7$>T2FF?%4: )5LQ4-Q=WBT[S<[9$&
M!?*%S3OIC/J.QK%,$1$14[8R*F2M6VM#VT8"C1P"?7EKJ6X0)-2;3 /P0C+$
M3U\--<@OK$S$!II.@,6Z.2K ;D$/_EHP?VN.] ='B()!@X9M%^$Q+Q_[3&CW
MM%,FPK\*("/:]9/$+I0.3L0YG*Z1(&1VN<;MO6%Q;[+,N)$UK-:Q/P\^1=S<
M43C]L'^ZW_+<1X41V(3G"O3=TC&(!2<C@[!"NN3*0<<^-&LIJ)KKO/Q#2J[J
M4KVR#[APQ?Y)?<_=GV57AI\+ I>\^14''(6Y"+-NB@U:0#.0I%^@NH' ?G0\
MOCHSHD\IN*>(;U0'*K1*8!-[;MN2<(\R#^+<NG#O,&F%!@UKRZGG*BYK;#@#
MNSDU4IO'$7H5[H=49:Y7M1OBCE/Z$P;]F$))Q_]+BSF0!1#_?SUHY]^\"/UO
M?JZU_JVCZ&]RLGQS>_F"WQ/JFM/D_H 5#6"-C.WA\1\(MZO9;X"N([#SYRL%
MM1OC?TSSW9OM*\HB*33J>(VPB%%P[Z#J!_4Z<X@34.$GZ+DXW)!-KZ[GI@ 0
M56U<'/U;6?6QUVVZ.<5KS[V<C7E#E7BMW@AN'6==  3"^=AEVK6$IMU?&STT
ML]4TD8KN-W4M1MLO+WXC1;--B)WFUYPP3&0-7*G$=!0'-634G^#B>K\,]D3G
M$6(J+7]K3?S#>BP_V=X_OS[#_J*,K/Z<!GB70A2>,>D/M^';'Q'KR#1.5.G,
M(<^@5VN(V77],SB1ZS!2V36@>3:P&,++(9]HWUQY ^T#4O1HK%L93/;OH(JV
MA:LOR\1JMUWF="H3SSLDH-O4357.Y$/D08>\*)&];B>#C$Q=(#J+-8/CUFVJ
M4'!O^JU!,XS"+&%Y1\A/0L^X.+B+BXY;6"E$15V*ZTC^I\^S[UJMX%B]W#5K
M[&V.R(-:E$'#R+B_$.M3+S9!DAVB2[)00YDG&^-8")3RK$2^5PSZ:5#"'R:)
M_SC=[3=,R96D_YPA_MRK;.Z$9_1U^8F)%Q-'=4QKLI151)V53E;O:1AZ]A-J
MM"*J(TX?P%6N!7,S'-(*3XN'%<*WP6(2P0ZB73BR:$!9E[LX:%ZCHX.7!@"V
MM=%'>7\NN:;A"#I;3M[0IP%.  4SE8RL7X3<@9G@=H3-;$_TO>?A$0O05(RR
MV5\9&#+V59"O.2GH"7?H<W???Y*RL@_UB2AF'^EQD)6OES?$&E_/84VE1-!]
MSUZMA+6:-*80C*>OJU?G=QPN8A^U<;'ZR=N])F&\S/E#V;E9:QC4Y2(:@)6<
MHF"EB397&94+I4I>Y8B6MB3<!(9">C@*6G1C#/:2T-I/T5J++:"<+3R/&B49
MD3(.3/G1F7+]Q[ /[]O50S#(^3GL3L<,1-DRG**;GK]T#K((-+.E$BVJMH80
MPET7\@<(%RN#LM "0'/J' 3%K"K2+ M7O(,4DP&&"0VXHN(L3*7")"_9=8F+
M8G4#RB^&Z44S;-U;_C;U-*M8*FGFR=189&7"RLQNO,] /2D]*E?GJ;2] '?.
MYN5Z 1$]$!&(XJCF4<IXJO+%93R-P4JF]X,,LF'!<+%^OFJS?^P[P<4PDR=3
M<MVE9K1)65RK(<O&&Z][@MRFS-\I8?;5OF3Y WI71N514(66V&'HK8OW*KSV
MK^_\IX[KNVR;D= YUM_J='UEV(0W-$#]( U0 ]VMS2@QI^*U?WL[*[?WT"J'
M3HO?)E7^<(>7K![N$S6P0BH-\ L0OPU=EE!\(4"5QZR.'7[TG;]"D-K>\Y^'
M^?AJEZ;JOC$=BVX(V+ITMJB]E#/S\<EK(&46B19-W9PJJ(>Y*0Z\-9J&+[S/
M2&^870X.A%S8@6X=L%_"[AW\(EF2%C06QFI3IX RO-YS/* :(F,5@BXJU/O$
MIWJ"6(#B ]5X,^Z0=VN2621O%1NVBIHX&NEN+@)QY*J&!4[[K5T;F3O[]%_V
MSF".4L7%%@W$)FRVY[$C@T$3H 4:8.YU-JDQ*+%R+Q$KEEX')5Z^_.+S%J49
MV+7X\+D$V=1$W'UUWY1*5$S,+WF(+DQ*P]_(7K2]O+X/K O5#N144[5XH-;5
MN6*(F4#OZFS!R*&/:8#JS -!]<4NS$3^(7&G 0Y^C8UNIPPC?GL59<OHUL!E
M+!]?_LX.#0 ]%L!\)<A9Y9""+%(3_0E#3DRW,<N3U'C#K:C+4B_3$EQ:$@8S
M_"5C33;7QR9'*IQ:3;_QU%3>EU<Y_<T>QW?KU9UX6?K1M_23@H=8QM[*^WUH
M8C"3%M;4TT3*HAY8!SNV@6UI,]$8M>@--NWL'3#8S](TD>'ZNC9L%C;1<@1K
M/P&B =BY.+XQ&87R3]D);'[97R.F04\'A8:[)]UI"/M>Z+(*![;1 !(1R R%
MK9_3Q[H\Y_Z''X7IO_<2%OW12VB_<H<BM*J#>[ACZDJ@ >IH &0^9E?"0O%B
MP&$6.*^WJQ!M,0A<X\A<"9!,'O^MNKN2]>OOH8DME9##FW-[X'+?@K]-ER_7
M_'7WK_&R&6&-JK!J'DLVX;HZL]3-*GA]@_=*H"-=D%RKP.3X@HY&];[O,E(K
M;",_N-ZF,EF,?.3Y2GLH9T0;Y+BVPV[AL%& 1Z%HE/(X*KF;2I^J%-6B'\./
M#T!W%9(P%WL:KS\>C9E=N4ANXA5)(.O6R-  SUYD/C%$@T2R5H>3!#\TENQO
M2B&G,<6PO"\.!9>L0A$(\:J&>]",B60%W1^3S/YMU/8?$[7^R^L.?AIP0'>F
MN][\URVU'W,$V=U4SBI0&(MMI07CX#+.W .[#FVO4W/Y!V.W[9'Z&_=<$9_L
M&4>R[I:=NP=^I')V=C!>-J';]M3MY?O?F@24AAU1^YA ?)UGL6X.I6CN^Z87
MR=31IR9NKI_@ 5[G0GSP2:B563]/Y=HEH==N@<\+,U K\$;K@8A1=JJI?]?]
M]>R8\*$D0=,U[#XI:!]GDH%R=&1/U#C*Y:!RDQZO.(?3]O $>VNEV7W2_5#,
M7"BVVC!.S&34S2GH'DQMS-DX# Q=UMHF;]FN1%>"):&5USEE 3Q'ZF./0$#O
M:0!;>H+C@L1#,?&#(<D" M:['RR2F?Q^=^2I$)QBF-U'YM N(&XT4C2!IQW!
MHSY4?81$$\!U+SFK!EL1N$,V&$N>05=HQ[ONO^XCEL!V@P/PTA4,8D,%GI^"
M-P+]%0OQ%B9>L@5[,.8_5:9C?R3!'[4+0S2+<U$R?8%8IX+15O8.E^*(9$=$
M4>DNPF C*<,C0*Q]2[9TU^)&D;U(*K9#!#Q-2.,,*=)LP8'5>I/ANH$-N/:5
M2SM4?-"P@7)/3ID$-OE7&@ E,MD!75;M7X ;2*N>.2-3Y5AI54[$4+AW>WYH
MZ3^I0O\V[>(P+W,8'#Z4%HR)G>PON%:"!VA'L&J;67LOR#-W(,6-Z("=M(:4
MB.T3>/20PGP[?<#NC$*P2]"C?TR6>W3L5?W_DXER5I<^FOS<]?_G"+B_37+E
M/]+1J$--+BIB=Y]KIP$@YR9)"D$JP/W:5FTJJGT32P.X*&+I2$6L^509R.@A
M^"O"CF5>^K.)P7\1YHPV$J5_TI?9<AP\-X2K:[F-,/!R$5LL(+_%7_T5GZ_1
MH194"4V1'3^UN.YS3FV0:*D]I'C_(!_I>1+HJ)1VF)L2\+!Z&N"2WYO:0$'\
M=<H"-@<U3Y P:8B]]F<=FOWP,LD6FL-YK\]VL 0+M]  :TUH/G'*@N!M[(,F
M8* K7G% A#)\V4!^7JR.YX"C!*#S?!0]YGQ^.]CR[ADOXTO9#(6_G, ??0QK
MT;57DT;I&3IVQ$A=SF5G\;7(PU%L/RTT2=57)WBH[ERR##N=\45:3I7ONM]1
M/#*FU2;VI8U)-))YM7,XWU\25;.<I=A^^JU@?PQ+7V4N0CQ :J$>[%)?D;WE
M\P$[_.&J4>5K-NNT^/"-A-U/X'=,JS9OPDT2$%+^]\;,OUM,^A3.P?C$W^4-
M&5PKOEJX7!X_N=E''OF]]/G?M<9_MO[3,\T&]@H.B7Q:L.V@ ;P/0]O72*K!
M3EV5A;I.3DU:"84+^:-E^ZR!1DI1 >H]JYBQ/9%O/]$K\X3I^$C.0&64<&&M
M\[5C]!M;JC+,?'P8YA*G.\9:Q<R#!7,(20A+N;:SR&@W-5R%2SQ?O3*_7\<M
MJCI_O I=,V":PP,+F:MI +WMFXK>F+V>RO8,Q'Q$(=BJG7TI&ZZ>;B,8'YW?
M.ED\7JWI5#4)>K>R$)?.Q^*>Z*!FF@O?M]_8'5/.'U[UX1PU]+A+WQO303W
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MJEFLJNIK(I77V3O' Q6>-A0!Q*9<\$6%XVEGSS:7>?0(DSBIJ*=6/:G8X5D
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MI:#88=A]$YK#<'*-/F9'HZ590]O%-6&M\L"L6L#DR,\ \[\%\+[URF[:&:U
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MG&>NUY_V0MI<!&:UJ3C<HIO7'F<4?U+D"_8<2&803L84= !3R\_'S;0/[".
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M%_E'=/S1G?<G!QA.\1Y-D)$&6.W#]/72,SQB@!,=$+TDQ[;*M2IHFJ9>[^3
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M:9_+\*S%E/CB"!^IJ[>.?8F^CP!W<3YXT@%[((.L%2_='Y^NV>R5@QV7R\Y
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MNZA](_+\>!H-8)1?Z67U-I NJ11K/YJ_\HTVFVSCHI%_I?G^4R+\*R_Q;JG
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MS0*I5K8-Z09@C^;8V8<('%]DSI\6[GB5E,QH?PU.?[WA=1_Q<0O_*V!B6KT
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MKS![-Q:":Q:,\M !SQ=%H!2RMI[">_:!B(\@WS(+T,#50_$O@/5H .+@"QH
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ME&-K1\X83HB:(J*4D^/2L()PHF57(K 4H7A,FMBQHU=5\&$EVO:;,6TD$<V
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MA#5=N;14K_JBXDI>WD+QJK=\H)28I5<WTJ)6=]"XL/3;G13V[^T5H_NN6D2
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MPJ]M^ES4V?$H8R,5R2S6%CM :*8D&?2=@4IM6:YG/;O$^^6N6\+4J5!?$R+
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M"))M-1EP4%!//&/:3LI*Q??0@7,%>C)!5C=<CF$C0**D])%9LS?+JY(G9HF
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M*L1ZSJR[#1FW[W'?L-TO2$@H]2FO08QO0/#%Z,;=.Z?9Q^O2%)C:4FZ"8&7
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M/+@1<L+CIF=9YIT(6=[P2'K%7719;GU0K^[5U7/FZQL\JM9:PO08C4#B1@$
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M%HN$1NT0G^O%$1W%A>CI]G=*GR_(25L[/NVQ#I&LE-5F7[!ZJ8L&\6><4AN
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M QT?)VD)>HAN8-VW5>H\OV?4IN13'R[#! +(AV#DM^?.T$T):',TN&.7VF/
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M>B0MM\ZH,^S1,YF>UE7CE;X:RXRR&#=0^-R"M:F)KX@7AT8+-[GJRP(,0L@
M0Z4(J %["'8\X\OSO_.N>)WQ@XG1;?_%]FMM9"-5/G@[,)(/K%N6J3.=RPB:
MB'QU,$[]^58%5@<I1=3;%E0,;DN]>F\8CFD=]OH>_W+>FXHH:!.-K:JUP:JO
M,(V@IB=LR0*PT\5YQV15L+[;%A'HAPX'G[231K?M74=E'V.,!_9""![*$G?0
M\VR=I(->G%,+5'O5QT4>*R!SG9,-KC/%GQ/B\/OW:)D$!^/DO@Y4PZW,\;&U
M=>$%IFL,IJ&5Z@YD/-RC-XB@0;RJO4P&A&VVGN:6E-MX8&\8J5#0FU4=NLI
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M#LSCDOI"()=!##)Y$Q;:*L\\=@3LUJXLSA2L_(2Q?+8Z*,8NQI@'.1'@ W@
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M+#1F[,C[9NC*)L=8EH6/0RQ'4>2A5&O#)AG'TRRR!@NLE!]WN(\)=91PM'&
MK/GQPB#\<ZD-8&$MIN-3AQ<+XQKIQRR1?WP@_W"O[A]@\(]ZZE]4OI<>TX_X
MTE]Z"]].$+[.<-676%OV6RCYZE<0Q!I BOTKJ_I_<"2^]$']NNWUEUM[?L.&
MO_'U?B-E5X+YER[ I9&!=<56%U1<0 G25<SC&VEJ7Z/3AI?A@>M.$S\ZI1A@
M^_OJ',U?=;3.T=](GF9A7WF^-S6_ [$<0^!>Y[%!!1%_T]-4M7$EWOE8F(/0
M+OW^TB<X32-@S44'R4 E2$/T?26 4KX#:@9T#A5$ I_GX-ZY:9B.S\-.AQ,4
M?XAC<GY!:=*6CS(WK18QR:QU;V+YF[R9(C]G:;AD:1CG8D:DS!UE)8@-@6;*
M]VBJ&2+!JEZ8 D33R'U%_!+];_YQ:]F/N/X?O(SKCN7U/,KK/O4_O:WKQ\:_
M?T7E?A]6&(#SWK^P_?8?91W_<P+L-33VN_;[JVWZZUJ4UO>N7M)X]]_4M5>7
M>OQ$JRL-]#U6 /,UFG#!.5K?>.M[>%8:VJ??@_#WE!"4^KHP$OMH/\_.,[37
MIXH:6[R#)$@RO:#Z4@AG_+G?M'4+/*Q&^'3GJ\\XGUV-CHK%LW1T2DZ;[+;O
M$SP=U19R:6OT;]I;;U@'AOOWD%[35AZ_KBQG-/T,^X"PR+.J4D>&Q$:BOR(\
MB&.BF(R8I(W["52@YDOLDOW>9!6C 8&D]BK7R+5M[BR"YY$^#*_AY$R"#U"A
M ZRL():=;)_CR1<I*&22>4]@<0S:R>/@\K2OB,['A+8G((4!?G?Y<=UL1TZV
MSH&V#!E[\#:PFUN[]/),4(SAV(V$R/1;CN1FZ2S$DKI[+^J);UCN]1S!*?,F
MJ.Z*<R".^ B3>F+_A)\;G'<T<PX$HX=?9$'OFEU6]_"J.L9HVW. FV_G]F5#
M$#_>>UTS]0KN>];CRO5##\=2S=W&<^ V.>WUK*_=8_A:G[UK[4U4MM4S!_?Y
MARD7&9#D%67V!L/$;YG*'%^WS 2#X<CZ7U?G'/I%=GWM'!K51<VOI)B_%GEW
M2=#B%4&OPC8N"=+]2I"/V/4<]4MZ.K_U,_:2U.^U45]FL4_\?.W[[\O*\#>^
M=E+QHI.W7+]5?#52KGWG0,1E\8EK17*O%;FDZ\;!-?)ACZ\-$YJ$I24D+A%A
MYKUX)JG' 75QJ:^+<VK10C:NT\A^K?,2(]^JXKJL:O7:S$#97N_7]X>KB:[X
M.:S Q/4INWM]DO2NC63TM3["7IMQW&O]^B\5@#;F::P4>G_2[M_8I<&.'/"1
MDRBL/&[XA#^4_3J!_VU-5^;^G,$;W\<0^^(!^]?I_-W#U1C67&NQYN=X0MC_
MAF5^X;*OTVQM"?D6]!+QQS2_I*AP(Q'_+5M>%D!:O%[5WQ0LFJNY=?G&'+*O
M_Y@%?)5AP:\R=^^*&+F4/V(%8^PO17+_HLC410_2#B_?@Q19+*>#$B@6K>?5
MBD%5@^CAN1*,OLR_:X1003[?Z<E]:+$IX\?V&7>N;X=S-G7=I/8FZ?>.*%[K
MR%?AG_B*9E?"_QT!Q7[F?!_+Q'. [M>!^,HNE-^'Z)\BEMGO$>L'E'U%VF_
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M]Y#0-X9$C2_R-WY455T[:(O$^?EUNQGY0V_\I[;[QAP!;>TH]REVR]Q=UGL
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M)97OC4-+L"I\9$ FM]XSBY(HDJ"C2_@Y0<11043R,I=X[9LR4S'DYJ[[F@7
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M?9!&PTYANQ\9,NS36M"_X&HIY2PIZSCLJ+#06Y) )#%DBTU#A0@"4M/%D.>
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MRZZ=X/(V*E^YG60B ZB4PB+?!OAUTQ&=.[>%\>9CTWTQA90B.*1A14&?05%
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MN10%V==A&NOJ['I1E343JO>T/HTT#F7AR3P/TRF1[*9-C0TO_10</YW#!!I
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MAN.63^/H&#UYQ57IG&'O" 2_# TWDPND;R-FWO5=2WF )O3.;20N?NRQV3E
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M][B^C)=9\C.N?K('[Y)#)%=.0XSU]9W7=\8/7<VQ IW3#3((' N#T"R 79V
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MH4PUJL+N5ZQB5F&BO2IC< Z@Y)CF) _,#)J9810%WGG0\0)9P";23/E]9@(
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M8,^(PPZ$)TU-\@K"PAZ-;;(U*DP(RD(FH3[.<\[QXWK)7C<*/$4EZL(-C=#
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M\SZD .[3;/XR3C]'*U9X+"#X]P-V!4K/%=/93KQFUU<-(V(54>B<X20L2T8
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M=CP0J"-4=M5\L@CAXD+QA4W.G8G/L0=)!J4,%'X!& RDNVJVF\C+*UQYV[1
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MO\\Z;WDZ+YI]J+)QYK=ZX2?,%TBAHKQR(QZ1WF8>[7+ZV.SFUH 6V<3#HBN
M_)5<6=F"4T)&Z^:1G25-PT<M&DL2CM*#.^_J:;:ZHGQYR]3JYY:F&@SO)E0(
M/8W![-LT?-< UU?'_1=QL/3.MXFCA6R;:^-?I<E]X^W<+/[.=H)#H:9K,DI9
M0D_X^LLOT15I/726Q,<4@R<IV?*?W%:<?/<^]ZXZX:KG0UARZ]S+++]#,5)W
MG-!2,A2/=8-;9O>T#USR*XT'C[2H,FH7!_D/-<1B*H]"_F]>@B(P^VC(2M1L
MKCK&.%5&>)N!Z?FHPF]@.!3NNCPE183\A>6?XG43GNL_K]7:.HW]>&MS2HAE
M;^OY"._\#NT#;L#^,:Z.SR9@@_&%3(1PWN6C,(J<>=0^NN.16:HQZHIYULKU
MDY\CR^&?[N%@;"F*\&1^S%#QQO;(NN$+U\R-W5/%'\IZ/H!?SZ7GB%:HC.!H
MIO-Z:ZOWMZGVCJ\EY@6&# 9)'[V,[B[(</U,-9SP"/V7JKV1'E#O6Z B+H'V
MU? *EJXJUF0;&V0HL645&>UJWL\D@<OH%*_REC7)]CW(__XV>\'5A:CV=0&#
M+"^_IDKIC_KI"P';Z5[V_]1[H/:\GSEZ!P>>DX48G,]+9TTY7O.[Z^/AO5HB
M,87-CU>V/M66,<ZY/*R_N"'C^*!$<3NQV>U=Q.YV6H*W]^WO8^Z(78$:JM$=
MI(;\)D &=  @TUX^0D6B 0>T<&+F7.;"W%2#41GDS_4T?ZXD^N_F<VP:($,M
M-U?1U^FK/+O6CD ()N&L[)1(Z"PTQ>J=<N""17]@*+W_Y_)6=KDQ^A/JRU/6
M%>VTDT ?9.70'O5.U14P=CU_?:?V4W?XK+U-^H'M">&QE/QF>N 2\27-:<'"
MQ8Y9]<Z[->[/%5? 9F+@2=<5$,HTL7=YS!3_UV/!]G]_BKFT/ZE:B\6\:2:\
MR'&Z J#65T"[TW4IZ^=C^];_2,CX.\'QDL9C[+3@^HT7F+X]I<!:0?G-$/F3
M7?FN6$?YC93%[IGN4_@)NWQ-^;7BZX0M^9_I 1.!([?>OOP[1:!]<Y'\['O.
M^7V6OQ*N@-1G4H$" >N7BH'PS]>6U;&>;,M?WHQUDM],N<2Y H;O),JCY7\2
M70'L\M7.\INS2Y?G?5= S^1QO7RVQ4_J*T#D&5_@ .LY;F!<SN?TP/-?<U?
M4NH5\#/]3H7VWV4DR:_%7F*U]VOO",I>^KNT[P\'7B.8+CH:N@*P C=8!G,P
M:E< R&)-\@S__A60H^EV=DA_!5!KSQE<^EX!R]KG[W<<KP"(_ 'M-= N^<+
ML8(W%S]?7@$1^7.&_\C2_7GB4CUPF?\\Y H(^?V?5#FR%G\50ZG64'8%R'-?
M 4&:OW-=IR"N@ [X[Z*D"P+'LMY<8K^_MDG_^$?@YMH5<, ;F/HV]-;I"?DY
MGOP:]SGG0^WSTX>!RU"+<Q66Q3?GYSF7N+>.R*TT+_V[KU''GA)> 02C"5>
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M:"EN?&;8%HS^7Z-."]WB79.'2#?$[PM+,7KEYU%H>;0*"8M$V<=_0)DB#36
M:B .3]0_3!U\!T^=Y;4.CD0CKR_5&.6@5/\8SM-@60HDP8X"#?!SODDV*8$$
M1MH81X9-6K[$[PGNAN_S9?-<^W^T;8JM&LUC QE K% :V!SU;JQ9@3JX/Z)
MXD!*>OW;J/AN]N%:&8Z\Y:K%3B7A_EE4'#'+.<GUNPO_R>?FV3;D3G6OF9BC
M#/5T!<4IU3]*#DT'DJ_-&:B?MFS!-.#CK10JXY!5B?$GA+%A&>SV:N#8D"%
MC[M.;S,H'^(1/53I!LC@\?FN(5%T>FIW1#)9_NHHK_M279^PM5G+?>-IL\-&
M)S$>\*A'DO0J0Y\XL*!X*C[G*U1 HD<KT D3@'W'"<HIH0&^OJ%R?-UHMO_<
M;B=&#F$,_Q0TQOSU][  >N2:M/G,DNSG:HRB3R_$T1"V*8UW<PRPK"0<Z, I
M"+=LU2+@]F; H>W*]K:M4>^*#W5YK_6A@_S:*WPSCPJ^\[K3*:J+-C-(G8#%
M__IV_]^,B\;A1'3N?W7_%:/V40=/</HE06WR]+BR2M56,((+5BBY*<4>3TPY
MQ%3-%<$5E.!@VD-IMLCSV:91HAH[OC[2->,*X!2.ROD%_YE@*3CC=&QT7,)4
MR9X.,7!"RON!#;!>TB\&J-(4LT51N,,8XK8R9KM&=^^>)I^\3WBEP-FU#=HD
MR0@C."MO>Y)+L!&S_<LI@U#5-;_*H?$)-;D8S_)WEL?GE6*A_JNYN60)EU2R
MK-S[Y+(,9T+D.>VLVVV9;J,!9KMS^S$.H"=E_-]DG1SNQ?.IT#S^.B[;#K@:
MQFF5"LL9RIF"4 @U&N#;:X./%1*H9LT\A A:69I[_N3.5VRNRKSJX,L).V(H
M6FN\[QP9D2)RZC1UE)4CY)7$7GT]ZM[^J -K\1S>MX+HO#_KZ']G/U ?XMS9
MZ&(51MQP;Y6)!2;X=?'!3 7.%LT#K)L4)2 S'D DVC@%#(MFP^?D] 3T#DGS
MEA[-S,D3\[28G8!1*R^T#)9CU#A0HN=;GC"A3;T*I]M)E>3GQV>VK695S$%6
M-X)E>3<S :)/&C3H1R^;V6,V1]T9?,![#5? $+5SUQ/N*!?*2FS[@(#'@&LC
M1/OXC12LMH]!QX[D1*B+UM;)82IE4'&&/3X5GVRW@P-U6_R,V%_OUU;EN/W%
M2*%D%,J<PR3QB9$4JU0W"4(%<.Q FW_EB]34O(T"3H2.E[%_0#[@/FA[:7!&
M8Q15J)QD^P0L=_>U*.\1O6P"V6"0J:,U@AP'14K\]GIN@Y>C@P9[BT(4.(5)
M-Z5()K3Y@C[L<2GB6GLC %QBNS-$NI-IAN/^FHK"^ETP^TMOO@*E!E_XABCS
MA,M@* B&DVZF;VHQ0)Y$HUM04<7.Y<U&*#08WT*S./R^<8_M"J#;%( !FM]X
MW.I3X4TJ272C=K/=?-I9!(R)!]UHA *X<QL7L($)KOI\:>NHCOQR2FMS!>A5
MUA3%O6E=[]"64F5%(?#9'8!@XPI7CF9%SDG.%G?BA/#$.R5&/-K$A!D(HQ5L
M*A 0"53X0FYD#>UR&$,^NNC$9U7*#1NBH*[Z_?VGQD\@-X"=>O6'<UKILK28
M&6NK&SU8J\]/@ Y\\%R,QV0Z#+DSZ^S=X%:(:V>86?6\!&MA,$+D"A",9?/-
M:3N;:YW$:D@3P,(,O#H3%8\Z"Y'-UJEPXW=ISHQON;^"?,/R95N=TQ$'RQ\L
MJ.=C95&[ ,8)'RX=GT?![=P:U)+)"!G)4]5&!P?;#D#Z6@UUK?>%EIQ=,RIQ
M^D5B1:SGC0R9C:V(^6-4YX-%8/1"5#Q[E7JZ#2-N@B$=)&SAQJB@CF5E+LQS
M;,SJOE]S+EF*NH3IQN7H%6"8. _OFSE9J5UW.?6&L[@N2FM_&06D/64>Y!0'
M.KB(GN[0R$GN8O(Y=TZO@.2,6%DYOYTQ1@>LZ7@7#W?O6VG0Z2/!@A<958J:
MTAJ-;D=Y*7$=%PMM"9F'*-+H&S?#]GZPJ*5&L)_.L\%3J8NC.;5D2'A6*[7%
M0:,E$VT72F=*CBECEJ\.V]V2P*SV8^=U\[XS1YMV/G,PZJ_3]]T]H(WJD+:P
MV>&2.#Q>$=2>52MJ_:-MRV'4JCB(MF8&2O?2E;:>&L)A*9VZGK)KO<::8S<F
M3,D]E)5Q70*-P'(,P\ZLN(' K\(OI2!9OQ]FRQYU)"3?F<AX0,?O3#3=_8X/
MNR]RG-8N2CDA]B?V(S-GGS]JG'AT(EN]ENW9J =(>)F;LXTMZ'8HW;[81"<,
M6Y/89D7>I7X<=-0/GYWW@#$'I BV#6#O&%?>6/#*CYLLES:7E-PWD7098JD(
M7A)YC:<6KL=:USL)Q::4,FA3M)071>MBL.Y),8,C67"%^;8V/B[.:D,<0>B1
M$&NE9"%(%-N#A$VOF:R<OJKO[X$'+W0:G]T1'7]TOT=O]G5\C+E$M(14O!IO
M& -C=>O/ZSG*S3."*EV)I5UY.7DQ^</##?]7WON7\K=<W5M/C.<:LQ)!3596
M3YXXL[(7GIG[S!W[G89!G[!N*;G.QRYD9SQ%F1_RLKN<))JZR9Z,<-"'D\;6
MCNALI9ZL2KL$-:3T+Z/@W:XE3"=&KNB7)O L',I3'5O:D&_T^Q 2F]#()D7Z
M@,4B<> L14-PY/M@>>,);^.HG;H1S@,,R3Q3SYSWCI21;Z((=CHP&/')X[6J
M&,5'\0U=+)H7 M_:>@M2*>XNM\15*ECR8%U<OG(CRW*WV\M;W=6__';YT&K_
MAJ'+6R\:R[G#QB6H#BXSTB=V]G4/Y1A3N]#%Q*-UHEV? X-NNO%F]?D@I.D^
M)8SZFY,;_G'-%_%T=4Y;!IV= @]V\R@%2^+X^":LZP76U@Y;2X8AVL:$13!,
MM)N+_/.J;(*\>PW^<),K/I0(B*2K35JH1Q:D+\YWV6[K]!"G>DPK">WL7*S(
M^A=_QW[6'0^9O=^&Y'GB@.);IE#5)B%3.!D!D,=TQ][/-4($D&QANGRD!7Y3
MP<S?^&*(P]:G>C5Z5V!D:3B0CGONQGV!HE7QQ)T,&+C#U >HI=K;#* JVC@J
MRAHE(T_6=\-W U^#7:C5KW@8@4=\="J-AAD<MCH2,##9WT3Q;C7H/;KOW_#%
MAWXWANC]&BK0 U\VFSZ..M/V$>*ZQX&@]-H^K&9?B']]E!LJ?FR1@A/'!>"-
M+3*&>^/OQX=)<;,QLV24<O:M/Z()_D)O#%%4?,Z^ FU;Y>?I5L:',.=?=V5O
MOE29:B$(]6P;P S]5X#&B_@X537GX#L*N?ACKT/(/<4GS0:81,L#W)*Q7/6;
M2M\S:3;%$%-H28WR@F)M*TQNQI*V##%-9JBO4J@.8E*$0V?6*XV9YYE0]#^K
M[Y%E:,VYD$@@14\/.UG6YHFM#-B=[66]25Q[Q7H=06,^P5*D$W7[KO)(6,RA
M-EIU-3D"@S7R@8(VM9  FZ9CM*FYL46$<#4,$+3FNZ4Y[-6P$L[)]5 ##_"5
M)#3E$19#@_2Z.*4;DRCN]$\4V5CGMJ?'4JDBD=YO%G"RNN.SZT!NFL&SCH(A
MHK").+^/D?,1=VFL^!:2L][I:1$F$8-%JNS%@1;WX#'MX&/2H!W;N'D^.")&
ME9?'T]R;#R>!=)3#/!\+)3-"1Z\9**,;X9HZQO9=%/[8XPJ KA*RGN/%,8EJ
M4VNZB5L3%#KUS.<_2;$4;S4STTSB(?-*M.5#EA:A'(.LRE?H)+TS\&<YWF6^
M;N]-;5WF]-0=Z-<##?1+7RN/_6Q$JK1[IK+EV/;V"OC6X"*GEG!N*K$J9S%T
MTC8JJ8.O5MI5ZX NX_$S:=:!25D1\L$N#Z#!TO@%@/W=7Z8+O,W"C)S.[78+
MM3MS;0-^%SF8L>&^I,F-7O=S U X:;_=F7Q:ZXYDN]VHWQCWKHBO\2BCG,6O
MMO//<TLT($NNZB&3(6Q*%_>W+I8V@PRI($2O=R=Y<.O'?C/*A6C 1.*XX:%M
M>G@>UN: (XM^ ]6EIMRW9" -9*W(F54P&(4"V!AV(3=Y*=-(2[?I>DX)MAB,
MPGW#;L\/4ZS4]",^V\/$[A$_;6[@=[](J]UY9\#BEM X<!0PR3+L<BJYL]#J
MYM+:_)Z-NT$%?4'98>NB]9U"50%O.)@ 2J&F"R.;C*)[ZD=?Y4P.%PA;T6<,
M08IH*)4>->M 4EW=J7XPT("F':I:3$\GHC2?]/KBOTI@U,\YW610_TT%HU;S
M)*X &^U;;L=CF<U70$Z.Y CCB?T&IL'>:W_^-.!S(;["RDN?7/H /;[ 0JUV
MOM!3PW>&RV3TW Y?1=VG4;P,&;OXRIV8=+=Z>]9;,[4;#%< 8_SZJOSVW&0D
M,)JQTVZ;,=QWW)<A- S?E?-.750=^X)IV#G+:<&<>"_ B(XI-!U+%V3XM4D^
MW6<*L5T5Z66^YS(E/)_5M'!NPJ2#.Q=;Y?LI9[;5;W=U8"E6;  S.70F$?@R
MX KX82&9=G+Z'K#[G'&K7O.BL7;T[':A\L^YMNZSA=9W%I*(W;-A_T5)W:\X
ML[?1"XN*MZB',3M*><.2%'*3/!%IIO)2X97$I(,:7QVP7B=T3?2)AG.D+KZ/
M/]+P:=_BB]W42,+$O;*J3TJ \]V"" -3D??%=-N/!NHC!-=EI2-LLU>A_4^E
ME=V:Y&.T,]=P<TD2LV\F+SKT4-[[%-&LNB74X>C5U)3"I\.TRS-HL&ZH#7S
M#:L-,5Y8=&9UB/R%1%\!-ZSW4=%3:MSLZOC<;&L?\+6_R/\PNC;KPO$*R)]
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M+J:0DQKWDGH]C&%4 Q)':#6^$JQN:X0\_F))+,PUO/Y0%:FJ286*HL6&P!D
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M7-<IIQG$K#)&28WP,#\;$E ?DSWW_ ?<EO\>AT_^;R.PKV;^!U!+ P04
M" #/0%Q6];<20#Q^   0N0  $0   &EM9S0V-#(Q-# W7S4N:G!G[+P'5%-;
MMR^^:0**($AO04%!JE*D$Y!#$Q$!*5)50+I(#S4B4J0*""H@O0JA2.\@341Z
M"=()(!T2:H"0O. YQ^,Y]]S[O>^^^\9_O/$_82S&8.^UYORMV>?.VN!&<3/
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M2AMCT:ML#X/!>6V(65&6&LP(HXFD2QW)09$-.W#>OV0FEJE+&JE(T%&UK!F
MO:T-Q:<B)9@7N-7S8=CLMXK!<W2PKPJRXNRDJS?'2Z8MK"'ZK5<A.2WN-76G
M[]RL<@5_;,F%)6Q#_9<O^LC<.!B%:Z_USII&&PIHT?3C:^I;,7_3"!4R(/;R
MH!D8N>JZ0<?+9=7WT@D-C/,! PL+?3=3%U0+5BUN^M@#7\DHTKWR4![XFMA(
MZ5BX*P38B'M4"AM/=-&;WC,HO;9_N289X-IAA8.0I5BU0OQT8R4#=(!@+$/
M!@ZHV-RP+T@*]*BPETY.4X&#LJZ7TW@QYR,$SF[(]22,) PN$E[S8%\[-)?,
M]W@]DN!ZV7LU5^ A,96P)QT#=X6!OYF0W0@S-7)P"N+=PCQA0ZTGE;66=@V>
M1-#C&^'NQ]=0-02UTN!%K"ARM<W=Z(BY44$J5T5G')+L\O41O,S.*L)J>.VB
MC;SUB/HK[9D=3NX4F-E4HDQW5RE+I56XU^) W5DL\]('#+L9M?JEH82,>P)]
M<9F?=.#6[&\0,(-Q=%@KM'3^CHUVM]@7ESA7G>TZOIY^]$OH:>-<R;=K3R !
M2C75]"-C/2FB:T\N1BXS16&(F?L\5#-LN.Z'9%QZ,T.P8K<0QI="JF!E[E $
M\3;LW[P@83=N=9 IVSEQ"DR!J 6%,G^IJ</2(MM?YWUR'4<_='']XL+#;2TP
M*$-Q;%-ERWK(WFM7N+0/!UF5#1<(<H.V/K,\=\?X=VMZYWZUR8V">CM8%XS?
M[15N)]\A">DLHD'[(XN4D,'/N>"NZOFC0@53PO>^]6"*V9XV=W9KH2,*3.RF
M266$\DR2)F6;*-'MWTZWB#KG#/GTEFQ\6*V18>!SN XS9UTC,$A>H.OQNF\E
M,YP?%B(@,(7X9IT:R.#2R1FHRYZ9S-?^N('*.F-VU3;*S7VLJHP!;&WSH;:8
M\EKDF_U<T;/.FX;'R>7E]7'9,3WB_B8'EYRB8]>3_&BK]9U<1$8M4*=>T#JI
M72[)N7A+Y+S8 #!WG.R)X?7N5F[1?&%9WU!>'H%=[15.!=]H?50G,NO1<I:[
MC9TYP&1$4##+2=+@HMKU]^^O7U4@E>RPU\4!(!SPD<%I3CGH0*S;2B?R:LK]
M4HXV^E.$*;>\'Z7P5KE(LW=9YHZN:)7%,U3 G2)AQ.]G_#B&)64T9Y<RK1?@
M9671:GK*=>%TG"4L^<UUI[:7IID<"F"NJQ&7QY9OEK_:]GQ^@:FSG=1V )TS
MFT*$=N*^UN+AA#BKD*":JO:![LTQXMJ@+*F7)-T:ZP9<MJ;+<*#\RBT]YJR(
MH5!QNLHJ-3+VS"LRVE.K4GH)LT*[TGPJLO0(U_"4+_!7/F"D;F_+-)EMPY4&
MXA78PZU+E=:OSC:!?/Q3;L<%(Z>;Z$'G=HXVST'BMS96;!Z?YHDTR?)5F\'2
M.J=^LZKOD-&GG_*MR^._E9D977S?MYE5/]:'"W6J)!_=TJ8W%IGCYD92BF#\
M]O)#NTP[*]'@4SZ^V8G7IK3HH@*(%$NGH&A3I*[QH@UPSK?JX5G0*8NM.LLY
MFVOOGE?(Q<BR5MR2K)!-/M(=+.MN'&..R,K& ;5[+T9DCH65;;WM\KT_T7O?
M0R33SYIR4^0LJ=!M?8O.M\9RP<MES=KU$J8R+5SFVQZP[T:-QBA?E2"L:0S<
M=UY.H<DL[E\OA]3)>H732Z-5>>0GR#N8YICV,V+E%X?V*QU"OBA(*TB8YBR;
M\O9C;J-&*O,T;:!.L^,LVGIDTSX7M<89F<PG4GS<B^RX #4)HJ3DX4_HP5MP
M'XV<%L=9Z#E%R^+B:NOYR;IS5ZN9.G" :;:05J>U2R,9QJ9@=6LEX7+5JMA4
M$B2E%G!_Z>NY:7R\&"+S ,70H7\H'B0&70L["_;8U+Y16^P4T]79N3Y6X$/?
M6#E0[F#T\?5U0EE#)M9N]Z+&'EY5SI=73TF\3R%4TZ2%Q%PQ8'J*KT$:#L2\
MKW=.<MECQ%"1=<D"0S(,",^V[H7<R]+QD@^5A<E7G,DXETW+-DK2/.Z'G+J'
MCPJF3)9OP3;YL6<(.06^W7<?D\(^K$^\AP->LN& XR?0!9U+>5I>U'C+5DP_
MH^7J!I->:ZOP;+2->N!X:Y%I+\_(8)"FV7%<NY3>_DGE*3?JV"46B6.[)CEJ
M"*D**C(@S]CVVT+K>4\MY1@'W<\!M>QU0V;D/N<?( [$)-S"PO+X[9/X]3HO
MW&%,J4=3#,[?6+3JUWL=7[FWZF3E<O8+%XI?L#!GG .16C=2]DY*Z^Q>GKG=
M%29RV<\7P/X<\!>8B[6OE89E'E@Y<@6-]##$\XQNM%Q>8\Y']C9[>;2Z#9=/
MTVBZ.%VKXGD?,_=8V:7O<,:79WY(,@JB8:01LVL?JU5F5V&"('E[*] I:;W'
M*=)E65\*WFMZIB^V!5I&M*PU(8IJ9DTVJGWLD"WS5#.7%!3H2R&W>RLN-#Q1
MQJK=[!Q&(1_2@3VW25+8%?@PUL3CT_P,#C@=99B1M]1(7\?Y\'  _7(ECVQ2
MH"IN8:R^9P0 M23D(^-_^8"N+#(THU/_2J\4#B:N0*JRHQ>11>;U*/806)Z!
M7(ZM(.R^N0S_#!V)9I%A[?@-FH:"-B0HDA-5^7RA?NQ"0^4IZ1!XJ;ET<$D1
M!](0\PMJT!0'6*%[5B8,BRD$!3,7Y1(58$5/BS_UHQ,6J ,S.'Y9$^GL@!/K
MIGQ=35G?6/3:R; ;%?(V+IRZA(*W@*B_&D'2,2LUNH,$B_%"'8KE41SAB\0N
MIJNT>3+7NIF^./.XR:6&AZ*FQYA5&V=! Q?F>NUB/HGT3&:"AD)WP50%+V;K
MKUE*OC14JL4>T E_%<ZH58[[\:BKG,\YZNU/3QYYRG& F?>O1_>*'#8@=N9#
M<G]YZEC$^1^./E3E8U0>@69.\Z1_$,?_>OKO##Z\=/).GC]ZA/!O%-G32,MJ
M^THI<)CS7U.YP$D:+L%YB#*>QG >+AY3UKS&$ACB %3-?=>[^OB:B0Q;C:\X
M"K-PP%.]1LSC*+3*;N\AFYL0AA"_BSE7@GXMX\V_K 3/@N#@);>A1N1I. Z(
MZ"-5NN?'69RBB^S)R1EWV-YPR R5721RN4+$C7H/1D:MINQ(K9BA2>QP0/L2
M#G@.Q3<::7!M'-#$9X85EV?728,0(7J#[,=Z58;Y'3@>37TJY;0XW JJE)%%
MUK8R^ D$M#:(#F?4U%1R%&@]J#3/5@4(>N7Y:OY$B@5/2N4O.(&Y.JT9*AJA
MJ(XP#)^'W5X.T9?0Y6*&TPQ%3^3IWG&W-+),H/']KER6=\Y4-VWN/G7P5BMO
M@9SN:FWD[I+9#^!$_PEPUH;:63#+&*3"P>7CV)!SRQ,R;Y9EU0B"9@[*YQ94
MBIM:$/!L>[XC(C'E/"3=6[D^CEFLHE2>DVDF*=R]L!)+?>R2@H;]$#3T([@0
MVK>:!YVA*\(!+*F4)'YLD-Z/AK#Y9/)A![]F]X6$,^D,7;+!'(OL&71#:):/
MV$L#A85N0C2K$9YN3\!S8\(43C%>BYAKAHW_&GI'0-V9@B4SFO+&<Z9ACL53
M!<^$!$UZN_(IPIV:1"&.334]<2@K791 []?&THT8I2B+:I^8JL]SD4$UT!\&
M0O#WN,W4D(*EEJC0HS81WS<VI1F\#J^%G4-)NZ*TM-%AS5+M>2A-%11;<<41
M27*ON&N5'^7M4Y*%42?BP :;J",__#U5]380I5L5QAC+BWR<<;8P[;K/DE63
M'G=>)['+<FALR]1YU!"6,TH/I=SP@E:"<*#;_YZL2#OI=F'.[X1Q .  14^"
M_F*/1.D8GD*/GR;!_G92>O7T7QSC/R ,#5V$_MDQ^O^#=SV5X@VN?X!/-7]:
MF]M8[%:'CP^+N3C@URNP*V^'5!247*9'I::/*0VC?G>\8K'&0]9RT*\0W+*^
M%+B*D2QDZN^)T\=&36JR*.. &]<,&D>9\8N\_GZ1*V5'(H1O!IN?AAYAT]2V
M,\\9J^TD4_.X)OEQWCQ2"IZ.GFO>FQ+K8]%,,+OHZBA,7O(N8F='=D5SC<T1
M&RRK\KN$O@/[P2-1(-@O)['17XY[8MEF]BC":_"(A?"BQ[,I@R6R=LU!L<&5
M1LHI4&#1K EUAG>0I3E7=['T8Y(7LC7ZBL?^,'S\^V/K&4>D1KV8R!^D^8._
M'+UR!9^U98:VD&%DP;%["^60AGO"B6$T<O;>(^+/L:R:#LB5HQ9VCJT XR\]
MS*33I?Y!I&P*A2EX2GBK[]7ZS>I5]D[A): 8G_&;,L).KVV'.1)@-/K+]OM%
MW_GU+:OPDC\IH$U^0L;EY]8WBKY(18P1@3O4;9:9]#IP3FA4 B]S "J%6!/P
M'F4EGE+R[Y3RIR#Z.D/\V:75*+_TO>VT2"5Z]Q;GY(P+(DK/%J,P8OT8)^X@
MJT9D<I$CA;.QJ(Z1YE."TV1/5&6V32.0F[/K\*#"3;%WMLN"Y6%?-GB=2^9C
M/#<T3/KDV+MFO4^5]&-T\HS&18-N!(U-8A\"W/S/]^CRC@-.Q+;P0VR9&=D9
MSG#%MT@A_]TH2C3<;'@3V[MGM/4-)&C2_24Q2%D"D8..FY'>I*]X!\V<Z*#/
MR*EX> ^B,L]>'RE?&( 7U>:<P._:Y=X[]:?]O:LY?3BQ770>38K@#BMP2-$=
M$FU/'FZ*'+@^]MP\7FBU:8ZV00KM-@>FG;#Y.&6D8&-GP^JG/C&K)W^UE<)E
M$.;%_1>!1:V==01M2:Z ?W.P!<5O5D19: _$;MC7)K=\NI+ Z%NJ*. <N_R!
M+&][V@R(WH9=NA;%_7QC[6V1.)-YK;V#0"?[G"Q?);9Y! <LN0Q!?W6Y >C]
M51]HF]4?YA1'*B+ARSF['\;?<&D,DJ)57]IX=MNXRI$_C^/9^[IY2LE-0T.P
M_ZXW**P2RYVXA@.^PLE6WKP6^IS+9.S-O-SXW7MV?_<>/'GHSD^X;WSS[?$P
M19H6Y?EH#\BH..XY%AO:;XNK!\]L^T?:]:TF_Q4?#O@3A>4TD6Z,)W*U/9D7
MY9J01&/@&T]#DM[IM'_7F5R;K,?K<"0[*L/'.$"WU$'%J,Q7ELOLNBCDX/8,
M\*P6_%]ZI''-1*$#O\OTN0;V24C,X:!AW\;(X+W2]H\3I,"\RVA4>\D.- A[
M>=A'QZX0,GTW:/[KR[ZV,Z<F5#A3 >")E[[+W_GES]ZD5$XB0!F6UONX_-LA
MM_]N!!@QE87PQ'8?ISR)S*LP;KP@_WEN%*[QK\AHK-SL6R1]Y@9%&T<ABG:@
M:X.,9KN-=9_"A28[<K/M_,A&Q*A"#Z$O[M-/?T424[U]@J%@%>3+QC;]+E;*
M[Y'V5W?XSH;MA$W6@XGM:0:TM3J*S@U,#@GZ/-AJ5"J6M&4O7>SLR3CO1M<!
MV=>$(U"4P>(A;M9"Y9+S@-$XH$=,<>V9U'SL@7ZN'91L748IMS#M/218*W[]
M+D\<QS,1_]5R9=NSX)GV=]FVT;;N-=B<O4^1VFKFH<:@C"MTURVO< ZL1J,6
MG]K[..5TL'Y@L1L%#QF3])"FL;69X T!W[Y$_QR-_N02L)60KTN>MS.0E0CZ
M' IFRV]%EFXY1L7GNC@+=]@S%B;1C\HQ9V:@-) S[7(&I65#HJO-%28*SNR7
M6'=ZF;AS)-L\<,"?30#\UZR2]3G4V2H9$CN[&?$('>R),*.<^#K.P#?_:1!H
M60#FZ3AS<PL;V#!**)T6.T3*.7E[Z@!JEOSS.(! UQ@KRS> )_A?^0+E(YNE
M,:7LP$PCF_@K'Z8FK^?*:E;OYP_W0N_;_3SQ#]U]=XGA\^9IZ=6;^(CP)VMF
M_CGQ"?*QB7Y_E+:0UB?VL8-=="@8M+UP0FW%$9^7IP_9RG_+RVX=]TQ5+-DN
MNKI]PMQ$3N* ,!DFN=AL3[!-C,%7'_AH%07Y(ITC/M][8(,=?L[WC7_D^]5+
M:?G#[.;9$/#<Y8@<Q9SEP\EP^N*(DM9+X>L@[>=P1=\9,WQO/SN4H!(JIIIR
M3[U4YOP5DNO^3W.LB6KUC4ZR?NU?:^J?(=[^92O9S6/&[(7A]'-E_]P5+XOK
M\?W^%$Z8=M]ZND2T_&Z;M1D&C"+9;!X'GWY>9G*37 '<>/SUSORBN]1<N7OC
MG]%^+^],\#XU_GMYIR)">=<JA6(%C,S3:3&KQO:;R!CYXH!8"./1Z#):CST.
MN6D4//L0XK8KDKT2W3/(M?<AIDK&@>O^S)&W_KW?X5?\!?Z/BJ]0VI/=+1?"
M@M!\(=KE<-ZH84"NF8F@$!WS,,-_R I\2V\_%'O>R(Z=8:! =+74 9JE3',F
M"'MM*&AGD5NVU 2,K](WCRG'?NXFH'\438/.#[5,HJ[7H3U10FWDE&\1CN>,
MH):<A.W7]1YUW"8,3\G+1$]GC5LW4HG*7N]V'Q\W+K"6?2;FI?\KV1_%?P>*
MH44?99FI5S,=6B[]YB'T&JW1>#8+8^_G@*'^[EPCQ1?L%.A$[]DP$V:X67GB
M+U7/1*H_J1B,$I4R<A/)E7\5:AG,\N&M0Q:^OJCNX73F5(+F*S5.#[F RCZ]
MMLK W3!U U@:*CNSY!=_:HVXO(_^3R4C,W_7Q(]"6PGSL4TSJ(&E$9GR#+;S
M3O/ST2WG3^L+<@LMUU7$.E>FJ3#Z61B%&I3F\\=K;S?QB:W.WF$R/,JI::=P
M^F]JTI^TOFQF-.$^T$&0XR.%BJAL312B76&HT%_SLPL^N_"FAVPLOT=^+J&I
M#FV$8M>DZRYJ\;SO*/,-DA7O]C #+$2B.F->[K7_%XG]H8A3WQ7Q[>&"BOBL
M+ -":.]5/Z17IZ)^X)'_'$3K98QJAP7I;J$S*&A*!AFQ.X;F,_&W%S1RBG1^
MKU\H]8P<WY_@C?)?6NE5YZ3-ELU@!CGFACJX6/ZL-VSJBI[;4<EBD6SG7++4
M73"E#'D!Q*PU^6+C4%ME=&[)-4_M#8FICNA(B8LU?_&I[^7X'%;EA[CX&N86
M5(AQP%F,V:R&\]9FTUC6!T/3:U85-4WD/?+SK'/(PJ@F+#WJ]KL\8]LI'GC"
M"N(^M/\B1WMF<G7'TC4CL^_PI6W_"O^':C4J[ZOKI,6(Q7._P,[EZ43=N&K7
MKMEBQH8VTJV'DJR^A,5]Y>^4)K%<]-\FBI%5YNN'?A>O^Y^:@S^%B1AWTKP>
MC"3:T676Z*C;SJ"1(:%^1GK/=ZBS4W)#;?-0[WHM<K#UT"RLT$=AQN0VBWY=
M[SN*3,&)+:>7"DQ[B-K&'W[ZATCP27'U1_Q//YP0R(ITF9UNR>^EM/5(YH!O
MZFT:U9(8I'U.Y>9.GI_Q<BW<U_+?<!W/Y6P_>&AAG$01;=#XKP2A.#Q!G\ (
M(J]CR(<(*0[9[SJ6'I1.D)_OC(6T]TE*Y&)IT9P&2)OAQO*&;NQKWCJ_6[6'
M5D6$->#?X(+^ O?WKBA]UCP6"7I:;D8)B6IE.*PJ/SI[*&'&Z]!APY44[M3F
MG, =Y-;-;3ID@79!P 2]R1/W._E3&:LE2%3G(SWI5GX8(/C7+G@U(G%&+U9L
M#1YL-JSM^:8L@J:-76WU8RYA@EUNPIK3%$EQ]0?T/I<X<_!>W&<5/F,3WAF1
M#Y8U3N%)^GW#B\EL:$VJ0.X$7X;6A(BR4@K5=4='3NI="XG"@%]SR0_#NW(O
M4ER%;RXJ$#1>\QD=(#]$F5AP9:(#Q!\N_4QN>7]QV=ADNGF3#9VH(R[',6Q/
MKRGDF)QX+X6-X#0#6,>T_E\E#]>A%">)G+YO?HS6R1>0&W&Y$*CN $Q@)N3\
MV0E^Z !3S2)\M2/+28JAQ3'4CU$<-)H0$?BF2C+6_O-XR>#FA2+C_^B'/\(
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MO5>,C-Y +Q6(2?.:<K2 8BMOS'7(5QCR_9O9@'BIQ*#9J:K9K'S)KK,EIB>
M^VWA'S.@OHBI_AV)@ZE,4?-:JL8F(,]"<B)ZMJ^[*;G->UZF7'OMNE4-I#8/
MC"\U?^7=XH&X*7RVL3*+%9TB3YM&FQ*?MK ?C U1N'^V9R#KOE&=(4T4'"Q
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MD)=D."UT:!7Z<@_2Y.B(NAY)T0UX6A />\J!$$8QXB3-]*]JH,E<]2][^JX
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M;]&N[Z^#O<7DE<N?.7?3'6)ZCJ8-4\*W G3*5E-SP,GLF@UW+&2,8D4:;S[
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M*N!*T9>D2V%?DB:N#6O*"+_5E>)('4"> )[LME$Y]NB."))V%<7GS.JE+%E
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MMY(5?*9I$X!C!K$(5Z5'XQ['&EM=\I0HE]>#S!/EI:J+)I1=+:\OY<0?(Z1
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M\X-WK@TN3$8JII]_IBW54^EG$G+:D[/Z0R&2?4GS[]<B?WAUE&_*/KQ.AI4
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MC,^*L_YXN/+^D?T@VA/ *W]-G+$Y/?$@S^_/V&<68(6,K@JCG/4<Q/C5&IT
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M1(5_$X)'0D)"3D;.2$'!*,S!RB'\OWWAN@'JZW@L!/0$>+<!?&H\ FH\7#\
MNL))A/>G"_CSA8=/0$ATC?@Z"2G958>&&P ^'@$!/B$!$1$AX=6W05?? X34
M1#<YA!2OT6B_(+[M3BL<^BK_.N?#VAZZ9Q,H+A%+CS 24GH&1B;F.W>Y>>[Q
MBHJ)2TA*23_Z14E9Y;'J$QU=/7T#0R-C*VL;6SM[!T=/+V\?7XB??_C+B,BH
MZ)C8E-37:>D9;]YF%A06%9>4EI57U'VH;VAL:FYI[>WK'Q@<^C@\,CDU/3,[
M]_4;'(%<75O?V/R^M8T^^'EX='R".3W[S2X\@ #O+]=?M8OZRBY\0D("0N+?
M[,+#]_VM S4A$8?0M9N*VL0OW&EN"X=>IWWX*K^VAX13Y!F*SM)C@I2>2Q1Q
M!_V;:7^R[+]F6-C_)\O^S;!_MPL.D!/@70T> 34@#YR<\12$D/ZS&@4M,W"@
MF="4H5_[O02^8>_+U.3G8B#O.=D>=6ZA@P/R$C8O+EW1,$/,WB7LE[-1'%!G
MD&!0'JGVK7"T7[4BONT"5HX#QI7W+W& !&;B#]0,+U^ P"#K6(OOGT4M_R:J
M\/=$A:ZVS5>I7(_]X\Y2'*#(TG6.75Y5^3VA6U;PZ;TG>'UY+TCS,DP">G+:
M-9CTN[_+M94RGF\$?>J"G^5>$+K@@/V?T 30[XEGA0WT9N&92G]3@A;D'U91
M$"?0\_D\ ]IP)']V?1$'+&_@ &;Y/U#%2E<HWIX(X "G;>@A=1L.Z!J]%(7^
MCA![$BME\'<4(6/OMQ&+MOWCFO3_?A>?O]_EGP,F:?"?Y+XK."(_S"[GIG'
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M(53?H:GCR]A@DSF%X:WWJ(:7-JM#[X+",P OIIT<+.DJ3T'-@_6$5S=S1=K
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MAVT,"V\!N$*#F"OS2%>1F5=0"2"?:IO\F]O8:\3Q@8*N2!Q L> @\M%2X-&
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M[4GI+GOL<  X^;<C"-J@L+'+H%M_.O+@':#%L_@7U[^X_L7U+Z[_6[GT8GF
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M-?*X4#L#6OO%7/_R)_M&B$#@PU#G8%&(A"9(E/YX_#8?>2)3E&:W'@S.(K2
ML;6/VG_YF39\C'' *5 ;%=F%)#,C'C#F;V$>C7?\:2+PZ(#@.<$":[SW1LO'
M>B@+5@<=F>:--*,^S!;1O/411J/41LS-TL)U>$B+=TAH_68\IXA\+NIRXMU
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M-)'R2.HC&*W<^\F8>*7F+R%_J?:;9O^:8J'_KS3[4[&_ZS4!4!#@G)"6@!:
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M]9$G)>JI-!.!&9HT+G>' V,!DSCD_-?G;WK<WS.X$,FM0>KOGN5:'"-QSM&
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M.=\?3D[>:KE,I*E/LM-19+R@X$_-U";EYZ'%L.?KWI5^[,Y!,[:_NG>B'VE
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M=KVL?<B8")Y"]5)"NX[YV\V;<H]C5K+\O[+T1N3=?['N[?9%C8 \6-D6+G<
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ML,"^;H @%@@K@&)$XE'F,$HLL/8.980%0(:S:#/ F\&(&@N0]\XWGC& R;#
MW,8D%HC.PC!GML!.!)09L4#3<"468%;A;&-LP0+->R@H%E #-3>BY"NPP,(:
M%@A?1<QBHJC#80@O9RS0U@=R4W/% H@Z##L6Z%=%%&.H"AM1-9!Y7_2YA.<2
M_O]1P@?*7$B[Z(5-YOJ^<G_*1VVFK:/R@0,Z+*YX5QZ0L@)Q2FV/^O#[U1@
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M6^AE[ 9'+:4US?!EK&QC@1;W^WRW]_A&/:LIJS6NQ]9'CE0?-]IETIO[N 6
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MQ"0,C;:]N?/1^_U&BE_RTRWG0'L)4Y.>M]8)[.Y?C@B-!BT0$V^42ZY&%"[
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M-R&7.V2+R)MAG*(-TIA!"TH;9XE9E7ZIVO#RP;*TN]7"?1^_3Y?9;^?/"0
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ML.?J9U4-IL*,O-DJAA,@>2P&K4>VF?I_OA]\F#ZI1JCQ(8O1'>!-2D^\GSY
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MOQC6_Q'X1]C8\'_0L[@F(O>X#Z_"DM,POQE>\=?0W0OY7RWRSW:M>/^[0;#
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M5)HQRG[NZ'+A]"._B/=/7N0,3S+MXNG?Z=/<AV26ZX^\'\$P=W]X!$.\,-]
MF)E>JA\N'V0V[-$4(%VL@G\=];K=-5Y[*\VPU-\A \X@L:K'SQ9MDK]36(EY
M_7-*E',3U&8N7H[(//2ICG"D_+D)!2?BM7"M\KJ9JRU2TSRJ"+HR#*LXX/30
MK)R-)BUK.0U^&UVDCA&?A=R:17H_$TF[AG#NSBT77LV$T6EZ 0Z*\^F<G=3%
MNOXGGI]MWUQ6#WB>!];:<8ZU3NF4B%30UAJ9M/ 85=K;ZF6HE]"YM4>^Y;?9
M9$$_#=VQ<V;7+W>DM4V.NK%&^C!+EE,>5B;(KXXT+,GS ;5R":?XVJ=L>QS*
MVKWXJA)^^)',[V')XI@A%I@P&$HW-1O>V=VP/,O4U]2\:N_D.YO7]?'GTSAW
M=0T00YTH9\&J%HP6%3JB('RG78?!8C:Q6,C(</+S\MWO)'B+Q:#]8G<DT8_%
M9K^GB,M:[QVVG\==_\GK=O"MT'7\J9M>^I!S9_'&\]:'MI$O+RX'V4.OOQE5
MEEQC4T.GN$47WG)X3A?-4M?$);^4*)B%R(LIZV4=*^]Y#7E%LY4HK<_*SMH$
M7F+;^Q4O6VNB+"X=OLW# H\><=G$7JISCDPX>HCOJC,-UYO(0?!';?&-H%5!
MAX3*+(UQ]!YN;KRUF(=^-?,^A*MR!^LC50*+G_;N)FL6Z.1DKI9,FH!T4K(=
M56<X71J%,9L9!57NI.\H"WJ)&]Q'ZK3S'9]$%ZS/\(\<F+R7FW5;JAGCNCD9
M,>=)$!^4/!:@.^+U#.KYL:[[SFQ+-RA-L49U4B#(1[B/POHCIXZB88%,I%#V
MW [X^X&$K]D=!_AK_]'3T>O#.Z(/![=LJZL2K$(99W;%Y_!&"M9JIO.>28U=
M)>>7,.Y.C&MA!1+2_3B,7L"]P,^5F3?7P<]W#HA*C5X)=5A5Q5Y+6NYT]_YX
MYG]/(*L6,=LD-?3S0&&I*N/FZWM%)#0+UZ1SJ<G\8_;TS@I$_//-.>HFIS%$
MG\O=QSL'5Y;'<S[M*2WM5J-AIGI5-GLQ7BMUN>M>Q0!*01_)V5/M46 ^-9D[
MADN/[A&44K]6=VO78.%4L"LIU[*@0>DT2P<)<_'7UM9!KS@6V@:.+-W4P/,(
M)M;@F8V:>) 66IN[;^172!OCOAW(J%;P==;HB&LV4W3'3:,!=C(\'W0%N84%
MGBG>%F(LC]:69_=9%G=P8'MBK_:XI)=,QJK8!XISS=06KHMEH93J6M'W# >W
MKY*0]73J_*!R9PT&5:\6LS"*]UR^Y4(;_75R^:-^YT8SF7ZB]B2R[Q!JK#RW
M=%1,@A"-PO=)T@Y=;/4;SEE$)XT[D:ZH269$1;J.>0SRI%.A.:-OC 3Q^118
MQ)\^V=$H&5B6[FNQFGP0=W/J9A/$6U8Q8"R/8H3Q O,=YJ1^P6*+!,DNVSLZ
M$W?ZC2OMU_>4@KU7L4#A0?84RYS7CCEYX**SBTZDWW+9Q-/9"7FSDTGR-9;V
M[=J2(:XZKL!V#V,N_GAS!%]J#NH5*F[C1)-3>=!>$#,?1C%O)$L0JN2_DG5J
M3&<4PZYI=G8HA>E*MQ#*37+I"AI5DO)I[\70+<ZW,,PZGT(F%']0B[KX>?7X
M[A=.O<TBN+KH-Y+F58RV93JL>7IB_SKWLF_AMSTR=U?2TSQ>CRVM>5&:1\:/
MS24'BA55OC.]:7HX! U)_O#]H>:JD \+*R2<H?3RE;BK].5+28,?JC9L2USU
M\R[YJY47&UF/M;,W<M5_-(G38=P;4N9KZ/<JQ%]I,1N]*EMD?W.;KS$6TRUF
MQ[K;XD\?)V]D5*#]";6X<&\[G*K$*VO,\7#SPBE#&N\3;N]>TTK.+R".P;RT
M:Q\<5??,!,V<8$K/,Q[(.\MI"XS7CN\/.O<^.&TIUH$?Z]6R=/O,/BWOMF@Y
M&8V]JSMD/QR7"FT0YXUTG"!EX61(B$DX&>6G?HY6_7@_UE"PF%ZK0-+W6<7(
M<0E$&C\<E SGE#_)>&2;?C?&H)IS>G^_+R?9X.6;%<-!"S.=;),\XZB->6=G
MOO3=D@L>,4\8EX.$1_.&A#RI*YU2WU <22\\\)Q6!LFX5RC0=L:<A,P.%* E
MD4Q9?@%W<Z9-9\Q4'6D=V'5-[[RF;+%/WR^T?]U\-3"Y<G*[^B5N)J5]FID\
M.YRU[D?S+$1#61Q*-IXD=#-(2 H\^$;YPJV'=*&BH%>9$ M\5ZS8W\N9PP(-
M3GV-3XW>/_UX9<SGCDF9Z\+']EC?P;COKQK^&K@]V#+->P9;$I^'G9(T8A*G
MC S]C<S 43">Q(I^3,US#..J-WC7-/(L&@N<NIG_VC>"[)HV;N,R@\FH%7B
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M%;T8>*?V,($1F@[\'7<^]%YDY:7E"5NM^)H,Y;YD9GYPEZC]<HY(QL%^)6&
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M#[A_*PR4>^5!["=/*'/<X*9NKL=_*O(.LPG9,CKJ9HF+\2E UY,[B>_3'I
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M95D*U_Q[VH1?R[D_6$I>8ZQEGS?_"D[W JGS)UK&-GQ_\5Q+^HM@,%[%E>F
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M_I-CJ_VQ_(UAZ^LMT@Z TR4B<_?[0$&>"W]KUT2<8N:9YH:GYMCM[<<ZS36
ML.S;@JL7/#OYC[\K"< XZ&N%;Q)<0P) 0WNEB."<O2=$'OCOIJ(+/RKA44*$
MI]CXTUQ0;0'L&;%K&T0":.;GTF+^NRO<@FGX3TLAV,U6Y% 41894N42O_W%5
MK4MY+]6\LN*EV(HC@T=<JDR+:0O5QQ$23;!6K,5ZFM&I;HP0!EDU\2MJN7/0
M4^(M;6X^^N4!V]#3+2*-OWTUO@E6KG[^222J="UMR/(K-/DGG[>Q)EDMX,%5
M&CD/-:YZP$'TO7OV_UC^_[*SROIE0$Z9HX_WOEJT<58D@&P\R1<<#EO@D=3E
M<JA5XL*#OO1@M'[_[O+":.6!-;_S\2QM/CR]LC2[=Y=\3.D6X3D6U=[$N!'(
M/YX_MFA5PUH/+><X2[RY,E.DDZ5#*;G<8H./.U/Q1\7Y83O0!XTQ]O%S=OHJ
M4S-$\^%8K.PJCYAL.0*]NW5<Y.UF<L%)B[K88^>E<)TAPJ4;3Z_-',\X ^>B
MU-_0G 5W^78O^ )6_:FQFQTMU]U9J^#7H<^A1O?>&?&?%+RQ<JM8F9E-@N7-
M[ 3<@]J3W;//"[HQF1%[(%,T^OQ2(&,@3YFH4I7;YJ.K^,"J_VDOKI_?FZN_
MH%A_>___COW__SJ?;@;J6#CA^'=I?#MW 06%!;G ^WC!"V+IW H_ GPG 4:]
M-RO+'RXB"(DM9!=5+UVT4'.I?#!(H7*)9>L"B!!,&L8.K<>=%:0QCB"BHD>6
MQ'8*6':Z@_?F6S6JF\F#5RGC?YPGEWLTF?S<[R$!Z"6'.-IL[@\XV]QQ1-/(
M?Y]?Q>D7S3>'Y@4IV'6!*HG%7CCYYSA$*,'- \VQK7^Y=ORV*=5.Y[?/ZKWF
MX;_"+#J7K5_G8D%;/<X7T88<W]$^ZIW_O/$'JKQY-.U]B+.7DYHX\M&RAC>;
M/!@DS8F"X:B7[-X1&>>,9_!%QL3^=!R[!J.)KM2*/IEL'"MM$^Y%XXV+42&/
MCRH12<O%9\_O/W=Y:MK'^%WB8Y_\D\B&>+)%7YZG@*6JA*FB%TA4XT.?)5V>
M>7Q[1X<3_YB02;N\?GR#9U62X$/-N!A4DKJ%1IDI(@C\G? F!T,;@UFOLFX6
M@T.AFM8_A$>[Z1CWJ=]]:V,!W5/T05@NN\5/D0#L^0@8TBM<(J/,P+ QO$.W
M6H4/=>.[H2K7R6GPX<V_"R/.:$K"?4/<7?:6H\^3'K*20N<9?6([1&#S3,5F
MSV@]A"5PP NL)#&AH+V8P+'!3=XTT48<C9Z<U67<1GGK]U?\T)P;XDN,S3Q(
MA52E=92IM",CHH0)CZU'W$_R:^N19U=ZIWC/)Z:M:-PVR+@+P 4FL^H^CHS8
M&GSAH[7?%\Y(F?B";,F(!/B1%IJ,5D6]*\K>6RDOAU?=F>3JF3;!TERM[V7E
M$5EX[-,WIXF&3!V;5>,\8\KPE1BI8DSOP1->W<HSF6I#JWDCL)6HZF;?_0<:
MO0B'PQW%EJ$3SI%-(B,9AOO.>;:_<D"9=SP<2'@Z?B LT"G?4B717R+1K,]*
MUW^C(80!'7GBPUT'H)9;W:I%QVFART/06AP-VR)+RN]GH<A?NAD?[83K"_BL
MY#,N!X%WRJE:$;9$SB/$K7$03#>,W?Q\( 45W5A2 C5ALR(.-KR12RJP?J*\
MS*W<!7B!%=C:=,O'[\QT<XOALDB >,DFI8=<(6:/;D;_9IHVM?W3U^:$[QN\
MVJT 7H2TS\%[& CJ.1WS\N.-+"[3AUV%[3./[L3;[W72%12#KV30TJH&6*$3
M(K,Y<$41"V;#AS'F!L\BF9-@GGVQP77AD,:R6$XQRNP4@7<*;I\)3[ $.52$
M*+Q*HOY3XIT]"^$NG<D3<T-DK/OV(V[(M\#^]!<YY'"T&=2W*MU7TR7-;</-
M-&H>JD)A>Z_^T2" $PO8-(4P-%.0 .T==5C.EAG(A4EA8\Q[/&JWLNVF/4_@
MH@L<#RL1 ZCI)@.G64_B"[^C7" 5\OR3!X?S#7S>KC(^^.L:.TM4(=1#^P$'
M:T'JX[/:T*QXJY495K/80\D(S%#PM&['T-27S7;DVH0"V,K&TYD7.;QE*+(=
M(WZ^T3E*U^9%-QM;POUQ($!@6[U&SBW6;H^KR<\S%QC$,H OQI  $4C/N O\
MB)'*+]J@T[J5\53*:-KCVX/4!Q1\54$)+77O6#@S[39X(GD -CB6!,HX_WN8
M$L05?+86_,?LW,R,\"^P^"* 6^KFC3"]/MX5BP</+9J.W[H>@M!XO<U'W.)%
MQ%]'(&RIORK:W*K3]TMU &+@J&3.PK;#IZVC1)V-W]"+)C%)1U=1?  2^#/P
M%DK87R(=U;E99M@H[T:#]'<N4.>\RF"U;*U)_I"K>#]M\9*86\](=LNB?2[P
M K*%73 %EE\$->+DYA>X+0E@>YZQ($\8N'#2"]U-[!=QFP0 _?S13 'ONX$/
M( %>'^5<>,212<0)T3 %^Y"HD=.Q>\9210*<WXD/DH_^E\GET@Q=9OMCXLV6
MX>U#0>/J&"9U9(7FBX%KWZ]HB3ZGNDGDG0R2_%HPIPH0-AROF@DPU47^:(C5
MAGK<4!'2'DD,-J+\_4Y]R>CKA;)%FAF:RXKP)8L6GV43.K.YD6DOL38#;=.B
MCLM7LFERTH0H=AJE"-CP.A(@)(?-0S><!+@!C"R7.*M'?*XA#N*,DA,.HO(3
MR+<UBG@:S8-Z.3)+I%QY&4^]CA:PA4D$R9@>H]&^(GQ1!_BY9M&"*=I:_H^J
M>/+Y2%9'G6 "1K8=OXTE-\"'H;FH,7;ATM 6!D<AX5T1HX$GMH>-U;;DHZJK
MW+E7%*P8*0I M45A CP.">W<(HZ<UEE:6^(?V^/+.C^VGJYR57;Y172T1"NQ
MX4L^BR#0<?I<.L-</T)EDIB[/7LC4A2.-V39F%87?BSTV!-EO"]7;ZA31E;]
MJ$'&(<LGG&C[#/TH +C?X5R <O(E5)"3$KEW],(22P>>N5O>QPA$;X]=>=48
M/'O]3!VP4M_:RF_Z]4TOCZ$^=P270T3$83^(P5[.$U'4]^<WQ%3=XW+.?-SX
M@YS>Z.%<(!V.\H*.,OE;X/BQ.&)-33-E;;VE'3J+04W9CZ%BAG^V4;RW[7<C
MK2SK*NH !%R?9QLM.QBX_?.ZM&ZM>87)=#<]G2\ !"J#S"PTR?VGGT[_/PG>
M^-L5I:?GY0)U-7@T]INI.:=W^(KQ+U\#&3WW>8? K=3+@$<;RJ=@Q?P^-US/
M40AV(,];_AD>&H"^VG5X6/$AX-NR4"3Z!=68-ZN9:Q"?<,-ENSFE^_X<DXT>
M.#_T;G2I4ZGE6*.B]"</KE_Q/[[O,[5X7J+SIBQF8NE*")%#12K=PZOTS#/4
M?Z^8."C:0TP>@>.<RBK;+WV=11=8^(FM1@/V(-R!8\C48AQ'IZ]P4<(;(ONZ
MK] VE'P@K[E0D?"URSB#'IGWKH VXK*+[C,0C[\1#M@]-&5G-+X\CJX(8,>]
M.?3S@SVWFB#SCGUPRSE=Z$9=</P++%GK89;!(B2^D6.IY0:LY?IAV55'!0UB
MP$I")&]BZ T&3>]/C,LKF;%!8B[*W3#=S@7R1KWRP"'I>:HZG)#O0I3(<CQ4
MDNM1E<N[.VIWQ4H]PRP>7!40"/(, @KABS]OI(MN&=BFUY0PEQ]3ZF;/Y5=J
MP6]?NF'-)SH_,_3+1W;;(@P#C^*^C24!NB&AV6S?Q_WC@."Q#HC)"7UMYF,Q
M2-:''P<\[M$S^,]8*S-<[=;9%V^&[HUV88MIZKL6L"@NQ_['C%*LMYQ<7/?.
M70V5A/SI<-*1U4/DWOGMOE\R[#"ZUY\(=YKDNCD^V&;K>VX:4F=EWVO9VW/S
MJO-%=S=!5:@8!1KDDO':L/TES(C^)(4?+)PN^*[MXY?OMO=JE(=N-]8,+4&Z
M^B\(H2GACNG7[48_YO)^5XQH1?M(S,V&CLBC;>&JU+/Z:4;@Q_0#$#F!#1^#
M7HCAOHTCEI6LL0\6?UT;@M&(5PVK<+6)?]#^3'OKDF)#9=TQT\_:K3A,2<"#
M_L[);+XJ$/,-L*-.@+ZQ-7/Y51+@!=6S)7*9J9#Z--8ULD/%4EUG9YJW.L</
M;E^!+K?:W0Q8JB)+\EDD&_ O.^/S=M;$433A3,]TGU:.>\(BG&>$1_5SJZ;(
M712X0?=/T[1A/6/;',\U7C>+%TTS3TUAC*E.:BKO\KME:U!RE:SL4A.NXE'8
M75.<8D]HHPK:5%[;Z7QGSNG9CUZ*5<')2V1D#0QW+Z4%;5GB_<[T_%]@_T0X
M<Z5&B82CPG]*<#]S7NE<HE+F<!,*NB2^;U7$9-H!8B'H74#G*8K^SG3%N(_C
M!>/+-4DP1;F[EM6Q#2%WP_E?]-X")\;6F#3IHJ6WSK_B18D,9<Z=<GOXF.YF
MWN#/Z<>6&I;ZP)^-UN]^\RW2W [*9\I" X.5I+"(5GD(Y3KQ7LTP0<O9B[^W
ML9("!IW(^OCD;)B3SJ?]:#?IHJ&MH&C?GFA_8\5*@O9PHU_>><)@(M]8_*>O
M;3<W?S#%"D7*9R8GT5*(^9?HG9=)#C$.E&Y,YM!+7&!]_JIRB06@9IZF][%]
M_LJ#0=Y7L7,/BN)ADXV49PJ;2YCJB'A_8Q* JCQ-*H.\ZWI"J*,%:[GQQ(?&
MK0U:EV47>1'Q>#>A%KN6*!#M=O4<9:L2_W >MJ9$7B>A1$5@II0:4/336K]@
MD8;!-S:H(/D1RXZ2%#ZY!TZN((^)NV$XK'##+<#%L9I+Z^4G(_G7L89Q2)G[
M6RXOR9,HU&5G'_[]Y'-\^FY4H/!&,_6XOZ'=4I.X4/H&RKCF^QD'&V/Y\N]O
M+/GT.98#S@2=\VR"*L:1H_7!NN]Y/ (#O/;3&JJ@>E4*]:N+[5,[A>"^P+,;
ML=>GV 2"FZ_A-W7QBTHWO3,,ALM5NU,GO9A/3;2HJA697M,4^0;EIMI2"LUR
MOB5;3@55><5Y#+@9^ U%IJL'5Y>8/VEC"?-H8BTK2BV ES90_<K2U;_*^RWZ
M #)-?10^WG@#(TKKK3]F/$804/S?V'OOJ*:"M5\XB( (@B"]*R@B34&J0$"D
MB52E2%= 2N@U0" ( M(1!*3W7B)()Q!ZE=ZDDR"])=0 (5P\Y[SMG'/O.N^]
MZZ[O^];Z_M@[>S]KLF?FF=F__7N>>6;F(G;1ENV>CQ4B;$+%K.2Z#RGDJU3E
M0?Q&7)C,DXLT/RYPPZSF\)&T:YO!<;RG<S/P]N:,CV@%B&[II5*U!^!)A .[
M5X6_DZ0CH]^@9%K96H#[XK4MW:O7!MT48/,ETH9LUKBE6(_:_GI1NXP3I5:$
M&1.@ZR+U$F#-+]]E>EM$@]C6A*,&DTKJ>-S/?MMP8[6G670W3/]EH;;P.$6'
MQ5IT'G!(9.420 HA6XZDU)]T'V+&1HWB=[%\3C8&K^QJ=,.>]-%K3HN;/&F=
M4['#;+('2Q?^Q:?RAYO!N9$:.^P7(>C:UAE'W*.]4,F07X>@9]#J7UB?@=H,
MBQO-%HZKMWI^]8C_O@V:1_RC*\F-H /:KG4)F.#$%OR9IW0)L,_!,T7CB]@[
M@;@'B'-['W<:@B5/: UQ2L&FAZ3]4#LPE&XF\A*0=/Q,HHI6I=Q#8&U_N#]Q
MAD*=H.7WQ![65N,L%TIS1=.3+P$[51ET]'@AJR4E;KSYXMF+^!UL)B75)2 X
MYQ)0K(31N*HT##^KA!-AO] &AD&Q:M#CF>/-AX0=4&3A)6#S"^[U%?,'70)J
M1BX!MY2N<"D:E8&_8WI1T]00!L"P8VV!_RFOZI5%>BEWT#+HLY1*#DX46X0$
MLM@4I?#[4=XB:%GK3_6JB^6<8TN2KJ2<.EI&4#>S86M14^%<P]7,*\-^C&V?
M3\C>B0J*A'"NAOZBG']!>=W=$;(BRXN_@EZV\F9)L(Q/F;QBW>@1+XF^P /]
MSU5U$(MOH;O 4& (;^^ C_&'=1FV,;APCH&-@5JJI$<*B"&,V="-C$DPD_UW
M.DC1GR[._1UXK%N2NWV1<F[+[RXB6FV,'\UF0^#X+97H9F:"^3J!"(KP&)[2
M.8S \2X&+SS"F+,G/"OB#ZI.DI9(7&T9>D\S?!U8RY;M3AF"9T5;EI!,P#7*
M9@WDB+TL;\7Z?9RY>PFX!LO)"KH;++[,K$7S*%J6Y%JSX0B$'F7,CJ*+P^@M
M,^5U#J76Z!KX);>I2A-8D!?Q3?=P_"":RPT28$PY1ZAM,<U'AU0UIBF];@QN
M:YL@CS.:$U<>4=+61S\D7+X$$$\KH0N.SR8.#<GE\L')DV^EXM<94>=RR[5[
M]V(H97_MF6KC-,?,)O#,X.*^+7:KNM'=[#@.%I[08+\F?/5^;>MLUT4FT.Z6
M%4HTP_$1V%3.O]7>^5'\ 4/'NPA?0[=*LWWBN>.A*K\I$YFKGLB\%%5+VW@)
MZ)@R,-T.%T],]$A9\<TINB=]\6PGDQ1HOG4J(CB-:'W]LB,^&"SW#L?CRF<+
MW(N_UI1<!PO D\8A%]LRR+ >9MFK77TB=61C@X[IKWP</ZPV&OP_LO;DO\87
MLU,:$CVK_ZR[^?2#/UT8#_ FP(#GX<"50/O/_<N'!-:Y?U;D_,^3C_[%XU\<
M M36'M4DB8?07@)BQ9: YP!]Z(:4^_04XS^,SOTUA)3U(-W7!^]V=<5>,'J%
M23O1[3!;Z89S'S_VE[R?)F (Y'UL@25RU%/?A@Y4:MP=\.*'\->:6YLTW5><
M&%[HXT(P?^%]QB:3481[>#[-$M6Q7# 5W9V\;\PK5X5M12'N+("_$.<A=]@U
M)74S<I2A(^%=89;I^OCM*..P<ES0&P9&B;(+>F00(@"N8^6%-.55&K%0X1QW
MLYX.^A$KS%*A*![93LZ:)4_,]=O?FK"1<#;:01I\O*&2&IC*WD&N-W0)L,(:
MBG4,?5;J5FI#S*@6M7'@YWTL4_K/:>N7?TK,ILWS:J#4$C_:X\F^H\^LY=M<
MMNAN.<TXAV^_\*TA^EIOFLC P'5F-DQ2*U8 @[&O87*BO'ZCO:3P.@?1D65X
MNO9,%>YV&[A4^K.%0&6V.PD/&FQ. @CY2%;#BWR7\H==%#S$FDFNR&=DLSC(
M!L5/J3'YB8GH8Z1CV>0[1F%C*X<EYV&_-P1;\%3VGJ54K<!U61*9"^!5J4N2
M]]7DV^F -R#F2!_$+86+Q.PML2O6XQT51_ZM>O[>,X6GSG$U8A0?U><L@*YA
MBV-[),%^?,;K7O>Z37_X&LQK*._><XM:HI3=')$!PEE.,BD.CG86HI:.) 8U
MGFK)DFP=K9V.*-  H.G6?^O _\UA"$H)3'=[DVI'!H,,$[A\QD?_<.\JG<U%
MI83Q)]AQN'L4D(^(8RG*18E5>+2)";[6S4XE(G@+9X:U0:I:\UN,P=4N"HY[
M[RL*%4SO3"KC*AFN&&>/E%NWP:'MO[]3//F/;<;_&F ]@*C*2V63Q(ZA'5M.
MGI1-9CA#G8M-9I2%8G,?W@QF;25[++'MO!!-[S?)]" (8W""7)F,<S='8BVB
ME>LP_-7=7Q,\J;L\ *)(0"MSK87=>P*R5W7-;!P7</N=[V^?LI-]!QQ2<EK4
MHK@)T>708T\L-!OG@A;L#%^\;5AUO/  (]T[)Q[+X?]4@QE*^EK8?",P1CF3
MTBG(+>/:5H+DFV;>2<&C,H,'P7W=FG5BD2US5OL3+K0>!W?;(I;2%<!?H96[
M,$RXTG<H [9MZDT%.9>]JNJX RROD2/FE3WO9X[GKOO==[PM_!_Y,JM@.\]E
M%M2(8,%V?H_6M5H2CL]RA?+*"VO6]7,INOE:/5ES*"/02B^A07@.B.4/]$[S
M1R0PD#_[4^Q;NKT.@X9^EO<J3,]OD%%QT',0I *(;P%\WFABN:^JY#(K,X3<
MNV53;(3K^%%_!/168;A00<%5D5&)17YCB[3VS0^WCH5^@=GE[TN)Y,W[;JR0
MI 2SHA7!RW=EN=\-7 (H\'W>>U$X.9+/^*?@-+B.%]EIC+6N1=XGX/:7:A=I
M'=E!B0^TAWEYJ72ZWV=G.V(,.[(XPT1N%N9D IP QX>99#3:6LE7>-=8STE3
M];^%<?\GQ[\8B=D%SEFF]\=1%:<)=\@\1>,#"[>I?>.T)\QJ$VT&F<WKQ,6E
MEJOML*Z=R8(13R?&W6X9M!N-9=QU.-S*K0O]O,U(2MS\"D,2 )&^^J!B'_IE
MY6,3%<:.MHC0[U_QN_.ZI3]&:1+:FRDZZ5O-33B28S5>80G/_?2QH+;;K-SM
M?H+H+>-Y&\TG^]06PK26K\<N5%IVFBK\02-GI2QVN:?U7O F2MZMU]JK7_4$
MQ00SBHX3=NM9>9DTF,%^TK;GRKZN:FJZ7;,[M;K\G@SI-X!K)=UI?:G1W_PE
MMDPYKXA[F0P_CE=,AG,*_F2IB;[=R?;>M!2_3_$/<#"8M"5)JO:)V1K0+89@
MZ6-#0Y,/BGKSBAK)<&.=I:2S9+]CB:J))G,J9HOZF$0ZM-4:5R,<D,Z_WO"Q
MJC?28:H6V^L/FP-1:H*=!J^8\L,+9VS/[%L>,/<S3H(M /'WC4E?!]P0EWI?
MI6I>#;F+%ERV^BQ#CJ.Z2%>:=IN&4**8^R,Y7]<G2\B,V0O/]?^N%'?*TI"8
M*]@5@['+08#8WG+<\XLL*2A2E=?^*9B[35/.47HO\6Y],EZN+M/^7/0A-3&S
M<(S$:G8^DY/]H6E^T&AG6[;*[I 2QK-CCP1,#+*&:Z":[K3_,"JRYIRH9K W
MT*0@U>*\U4(MZ3V.I\5<,5:()XA_*A@NEX<-GGDPRS6CL^WY,&3X*Q>AJ0!^
M3(9E%&=\;@&Y.>K>)#FE.[I;YDXEDK;-RZ5M'_&=O/2Q+ =[WW<\/YA$[B+M
M$@ "!LRL?71;AXM1A@GDCXI( S4N)N#KKQY2)I[(7JQSD9-GIUK%53D-?WU?
MGR&L=FIM+O5FF4=&IR_9Q&JVL:E(+,J)]_>%ZG$4MAK#WL4F7HU50 (IYM?9
M;M7[,/<CJ-0>)VK6O4J,FE/L*W3)A?R.>A,K7/,=8GKN8S('X<7ZHBC);0S4
MO_BB?/K#R?H1=_J%;<Y>#-LM5'Z3];@%%_K>W=_+>)T<7V"H8&X*T])KE&F=
MK)Y_UMY@/YA78CJSX6U?N9>^OV\9_#!1O/_9;1H7R714_O?QLFI5,I]9'A3\
M1UVD93!JOKW[T>.^RN]+ 3<X @._F/*;0IPQBO7GCW'R&/;00]-KV"C?>Z+Z
M%(D>#?F119GO^COA#1%75O!W\VZRT>*MC"JEZ*J,VQ!FM.='G" R:0WC&6S>
M3#?%RU_=]#7@]K1VA$>+OY69=L=#31>%^T&%ASM7^$/)J"YY(E/#/T9X+UIX
MIEEI!&@73875:(726V!#,VU44=$A!X9M&UEJ]Z87I=N%6DI6Z2P8R6)5Q.V6
MJ,*Z,6([_)@MY #"7Q!BB-0@EB_ (G2JJL,,2>J]^)83K[<_8GRR&F\7HOM0
M]#''[]?ZDF6S1R:9F/$R]U/AG;NJRO#"O'+.X?]+T=<\-@\)^YIO7@)ZF?\2
M0 T\3)?<WHKX!\_B?QWVAY^U ;>A40;]:O'&(/D:GP^#8LPVEM2%)VP0);:C
M=9&D4K#?[-NZL7(+F[L-8[M$G7!T#"O%S<K]&X_Z7L8HR7\)# "(,T-W!(/8
M^##DL%Q;IJ&@ZD;$#DW=J)G8G5]SDH_ZHJEQNQ&:0I7$G (W=KU23$G6)2\!
M45*"4"1[R*@U3X$MU+YYLKSJ2[Y#=&_\JY>51/'32>,7 W!WF$>WHQV[M]$E
MX&B=L.<IXO8L&-CM)\54$U0^*"CRT*HF>:K]Q--9.6"4J >,LAQ<:B^W78L6
MN8'S7*)BB\[9;.^=?+IS7.LM/5 :1+=/YT'*9?N2J)=/TFPMSSMC8S;J8<LA
MKN[*1+[P!AQ$A[/1UE77U&)"@MTN\#S#<T8W=LRO&3^? B*JS$@&&26T D/>
M<+*")+<Z^I$9X<GY)9ZYH-%?INNZ/.0UDOSSPQ25<\*<7EHUDP13',N,,/VK
M0H]L+/A+U8#"%\.:!=%S(]8-Z?'()N*=:AZ!:M!KT/WYEM#1AZ@@S(.1U1_"
M0H7B (=!D)+^I\T,%BE1#M=+ +7]O7V?5#:@'X;KI5_SFQ \X1%,[@)XX74)
MD#E*RL7Z32DWC^]Q"JEZ%K[D2K?YS!_$\(+%*4SXXZZ&MAK 9N3OHNV@&2MO
M30F!OT-Q5[93A<^593UJO:6'NP0\^K<PZI.+\!DH/DY)EK7SBKBSL6/>(98?
M-!-> N9\+@'*L4UM]4 JB.081'491HHMW_2I.V(GOX!M.S_?O!NW0W5C\2>1
MBCC G,C)>[6A[[]8-@[(5*T&>-PR?23\ZI5I;$]G&.:8H*V^(0 3$'AJS7^_
M@8<J\KG2<:V^XJO,BKLI9/[P798Y$U'L1[%@MRV>/6;%"=-.9VO4V=G"J&I(
M%5AUU3KKR[+*1RZG-]3%'OZSUH3#57N!W@*)&*@^-I)V_AR4G!>VL=_.V64_
M^F3%)?R'D^,<3)<S8?E+,.3^GVW7 R19_"A'JGG*R6&BF16;PATGV@%:QNBP
M>LV7Y!^[EH0'G)(7HZ6,EZHQ?I]F4" QCY.K3Y)?=:%!1Z1=[>CIJP,N.:H.
M"^H;6N.$Z2"QKN2$)G0)ZGY7M6_9P#+)&)RYV,20?Z7TR:O2'P8K1BV%0:0W
M_=8YB'NES C7!^MV3D?2L0/@6=OT*^.^>JF]$%LA]9KD<SZ(-P44+LZ/"M#X
MT2LT0/@BZY-99T E(ZDNB1-G:D8(XK;4:RL4JRB0?E,2[BD97UJ:[#N99'OF
M^[,-*$8GYM&!?,X;P_W^9W.PO_0:IU1ZVCEE5QJ< JX7!I8WP5BN!>*>+<]K
M=-64V!?S>;JN"[]M2<B6>/.UYF,+]>GR73DK^Y\W9F<JMW%6R\SL!&!S%/]0
MZ.39HFYCA3#6V0YIJ(]L2.*D4KA7^$V5(<9EL#6)P9ZQ!7!RT9ZL^&X,H>&-
MYJG>8S&V-J6"J)%$44] ) H7NVWRFH(JJI^T'ERO\TU_U[-$8\EAEC9AKHVM
M+M^H.5LI2+X$S'BOQ,?O!6E;WV:86>>2D0- NAB58Q(99[FY/LI2@^-:$50R
MC-A +0S[1W<)N''.@OJ)'IYJ\@'SUPJ^KD$7&?E89\93I:Q!$DMT^W)(,)Z'
M;[+&430)16::<"(WOOS89%;,R1P(IMP34)):SO-D\H5/'HN.&!FE]']>UHE%
M?N6)]P<TTP,L#OR?##@A:&2(L:ZHT.#CE0>C$ 5;84O8AN-ODUE1\;O="^S;
M-8JD791/"=8-@_@A%_2=&HPXBB0^&9Z9--=VPT].X%F5P)6(.T'G%H3?ALY!
M7V))?GK!7$9$MBBI-CQFHA*]' LW3DB;>4ML"+N6QZEDF6BTM?\V._0^#:!*
MVW5#2>;K_WM^M51DR?X[TU3G_\-MX2C+3HE[UXP8O@38\JNB2#[B'^+NC\'>
MC2H&NA: ?YA,/Q6(O?.H2FN_E%%VI5*BIP1* D525V!3BB":V!Q,=XOD6F2Y
MG7K:.XK(TEDEFX+GGE;] DN-[[Z3:D4TJ]+UG*M\=3W*1]>?>N'=9S!JG8KS
M?%X9KXUV/0]J-8R'^LOTEFK2G)?4'-N<(7I86K<'<% =3L>]B&=RCR!59GJ-
M;T%[7V46(27H II'-J*A. $-!FSS,JJ[/?[')(XAG2V, :="^D6@AN.#F9,4
MO*CU>BKTEJ]"/LX [5"Q?,NT;=*/ZWL=AB*./LW'[ >E$.UN=T67XK;O7,3R
MO5(L/4HI",]M(VQK0C.Y?;3%8.5C\^!'G$MIF-?KC4U*)SG&ZTP+^L4#/B/X
MC)XN\9=Z)Q8(6!+&-"P7ZXZ\!/P2< QI@'4@B#?3[X^4L6V.5/%_X,V> CF-
M=OXN;(_UM..V;OFP+6Q\"=BVPE BU]H1 36NX#@4,,@,X_A9P'*R.KIZ*Z$$
MF"9LP>??+'^=-%Z: FFJ#HYK86/ !,T'+30AY[D-Z\=^->7.1$;H43JH:+^R
MVWS)4GS8/<\6WU1E/EJ9SIL<5V!5TB@:3-557.2>73F&)\58[="B;@EW0>DA
MA,M#(0BZ9MI6'^0W!_-]N#R*BZKQI2BZPJ%GQK!NYXT4_8,OR^P1!MP=&A$9
M+'Z,FYXF;$KXKA$IB5+9FACE7Q=;4A$L7Z9L>N=H=MMV@$X78SW=*ZKIBG[Q
MO#3C7MJS&D_@3%]/9Q<-W1 +$.82((XW@Q&\L(<DZ<X(JC$@B2AG.]L?ZC#H
M4#260>YSQ<YU_2QU^:F(!K0%4(B]SD=W!\*)T(YM"Q1HL2YHT$S#Q@GUO.V9
M:42Y7?G3>5L;B46._EZV]I/G;+*,$HQ ST*6VRX/NXV<9TJV7/ -^.L7"IZX
M0YS&$/06!(C^$(U.0:U>@=15=3<6[F+&M;B\32++NHDC"T[M.NSFMK'/HOSD
M(LR<QQI&=Z7HWV$,EZ9"35%3[37?T8[!LXJ(((@*90I?UUQW P?8<LCCD?-,
M\]!-(+N!:'0[35[85Y@?8L6A4XDX!P3<VI,AP>3'HQNU'6>(#SJNLH0S7X0L
M>U9D:-C?T3'<VK+A/['WK-5(0F^'V%F&:LY+3GV#O,)^+-M* !+S050Q>BU^
M]\8.!Z :HFBLG]7!BYOT%T)X%8]3@1+_-\47Q]SQXA<OTF_L<H)S%<!IRA;.
M,2UH.=:M;^C%-B@16.QUHM8PY&[F>O*G1GA_TS.UX 6]H87^[ #7H[*-Y:]^
M]Z&-U8TL1T(GW+N-GHM-YVD/$HL,0)*6^5D%\_*^[SRI-1S=[3EB>7+,&(T9
MJ!F5.0+$.2:*'9:J'(]A#X\U-WGR:B[\JM*M,C/-UW,''NS9 MQIYN==NXAM
M/#6OC2B(>58#),/4QE.:"@G&7WOB?G5*^M_D$?,>=<2#MV0ILF,3_DJ%>815
M&F?\614>N*K^Q;/(\@_>4=Y_LGP4@*;+MUY\D.=P'B%J3=@IPS:/_=%F0H">
M#/%$+W<(S=LD6U9_'97SS/LVO1RJ%18')M5^L\S!XD$[#&U[B](X>Y!^E4%+
MV16+C@.-\5@3_D0@^3#<%W<T[D"7=..OV';5/TEGG4DI= GX]*,CXU!-ZHJX
M?S30NP0\^+,SN54H<#T9G'()N%8%PZO!U++]I?KQU$/4T)&G5PA*9&.*2U'"
MW4_GN@1DVZ <<3='$:>B3:)A@ -!K*J4RB7@Q5C'(I8V#[IOSXY. ,?A0PM"
M$6C>EY> WS.',P___]+]GY0.BA3 W%["B6!$76>V_B+>D*&QKDUGQAHN[7!J
MA6R?!05'6H%<*8Y\8W-OE#=^C?F#YX$S#9'-\-'AJYY,0[",N.,^\++].!C+
MGS^S2:\[XY%U47W<+_[!,GC-,ONIWWO"D!D53HZE?=Y?)>UX/C&<Q51+%"6N
MNQ$Z%JM7]U\_M=*H/0)K/\G@2>D/(P6@M^0U8ZW.]^'H)PP/)-Y;NO>(B[]+
M/S+5P)HCRP35QDKMW3K#%MI.SE^R+_08S;\+2>-,F.=-Z^9;"=U+O;EIG4GA
MJ8V%9H*H06K0 B6P2"%G#4)E.HT[2GJ60-OI25,]@,WUE^Z'CU?@:<(\P:S]
M8RP_X:+T]]@,"G^&PLS,]R5\3LJ%Y&N!I26ZA%QG1F193(/]*,"J;4P1]#,?
MOFVX.MZ1LS].Z=W5GA1%QEZ/GWZG+=[Q3A' 2L0=(O,GG7<54U1BO@I19V7#
M+%=B7/^M3&@S1]!<-X6B4D]):[<Z;_65I1LIN(0(/+1WD3884WEBI/!L7IZT
M(:WL75(H/Y_'"JYP<=4Q29/]VT%O[ECS3>RSEU-W)^RK(N-:G::<#*O'!T#7
M?ZH(==H9M3/_KIC[3/G35\WS2HVQUI> '_A Z06$*XI?YMFI.ZL)"MM)-+?E
M*/7J/-OPLTZ"Q,OEG!*"" I>*VTT[5ZH'X_U&;X(E->=!_:6B/KZ_D/LYML\
M'5T;,0ZJ8O]?-_5C6WZ;TZXS^YSD.#;]&789OJY'-S(OSZ6=W4L3IK7L?EWH
M2\ -F6ID\EJ+L2D27^2*8@\\^^I-]+/4LA'=N;HZ"HL"!BD]EMCXVFTF&C$%
M?^UQD%Y%L *D^#,>+-@I.83C9./\GM%J(A8>^E1-T_\!<*$V<;>O@(3AM[_R
M=5>3,D0Y@4@?1!ZKA\P(\P8>>X8^[=G+,:JB)_R=/H]H8@E<E1^[2LP1Q=M[
M":AJYL0/<0D4UF;<:69O'],,]00QN9D7Q7NK9UJM#LI>C\VYYB_S*:_<M>42
M<!LNC>&4"]=#3Q81EYFMV8 -5R,KTLH+R".W6YC65<TKCC*)\AN7V(1?JGEY
M=FUYB?"K(@>CCR\4N[K?8&@23C*FO3\="_4S;7A_Z@O69V413**Q]V^_3PQ&
M%3]9];CG\COZR>:S($;:WY< ="Y$^A(@!V2$(AW+H/O&[.A<J;\(&"X!?Y6
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MJ#(S'L;B $Z6=0EQ%AG&JNK]@&.G45N_'#A!AFF$2LF,8@!6QKT;[[!4IV&
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MNV4LP=/L1F"-9;8*[D[!4$G'L'(<;QY6OKWDCH&I0K'<\5==1G,/A+7Y[8V
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M.F;P9Z-^9Q1-'X(K/2<]=VK$^T.<58Y-38-O$-PC07>D]''KS1W]$5D"658
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M<:'8^[@3_0G/]-0+@&Z,FV7,\IIS6-#KP]DP2[-%>_UA<.&X'[2&A^MSC=3
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M.U^&>>42&S/"6*07IOI709RD[]W_43M-^9%0#8$'X>I[;KAIOYA<&]M;J3U
M7@"R7[[)"3EQ9#\4V+'$\MT+[:V_B6)<'M]O\2]9M*/U\+]EP:HP],$)4 AX
M*4PCO+>BR0QR//.GF4/ZX4]V!' 3O?RW6_!7:[+1[VMYQH?\+P#7=K?F>^5>
M&;)4)%$;B\A0:*ZDY0\H"7[>G#S2).E()+D7:\&9&C!(6O(HOP2*$(FW[+P
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M#]S[E'RN/C,>6GL(.2$5L9(W8R[)JAP<12C^^]O[K1Y)_R3N].3X_B4^S5P
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M">/9_0JB^W^.A*<:)("4$-$P'?R58]N<CY-V;MR:]5GHX]N<>R_[.S+FFO4
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MI$+-J;_\<-5+*(7+.OS_'*_!QHD"OQ#QFO:8_<B)O^0[$T?[[ 0Q1P4C[&"
M<G9.M>[P>$PG.T4AIQV_W.%K3^W%<I@OP1>39Q,B:X4_B?(K?[RPFSU\8E4?
MY9JD$*7[9L![Y%:]GP WX6UW\//LBOB*S::>+'[#I3]+>HIWWJ5E/KC7ME%N
MVS4S;GP@]/+-63NPZW0& ]_9Q\OJG1>G84L2:KWH0>7327,A4_D):??JDL.8
MA2P?KNM>N2.U5R*S\%+7'4IS;(FOC$"*P0SK<BQ&*\@W"5O8 XCNXI-.,SI%
MG\A'HLHRTY]6]T1V:1)2'":!KJA(%E4=0L[RL;,JYTRYO'')V7#+S&?;Q8=!
M5+[M$L948>J&/)X6IA14S),W@B<'F6T=//M#YADY;5@,=';F%P@K]\\SR1H$
MV8Z?, W<29<L@Q54;&FG%=E\K*9;ZT61]OOV=^K.0Y?P4Z&8!1KV)1CD/%O3
MN!+:VZX-)/AB->PU>O.Y:KGAB(HH<,@#M)M J]R73MB!"UT$*K'Y>7+1]<-N
MFF]'1?ATSY+B<Z!\!G6R9!0*O@HKQE4>>Q"*BT/'<3!S_$9L#0-D;;RHIC'Z
MB76!\AY4_XON$\5[+_:D.%-]:%>)P%TF7+YQD@ -26>Y3XFYV+A4-]]^0LC/
MTN"F#CT%5:EDQ([O7+, "Z'L$<XS]:PDQO\M'ZM18KK#H6FC(?196AA=(X E
MV'>I0KG8-0/W>^9NC-CMJH'7%':-% ]R#PP$Z?W[ON4%5W]TUYJ><_M2=/??
M%UI36Z"6O_;M*?AK1"*_Q!B9SVKKK#+,HUR3]9NM(?CKWS&[MDPYL<4# [F$
M%!GA9U<^FS7&"@,$3 @3.!=L?2S,U_\[ 6R%@\?!E((\?J(NH;VD9MHB%0!\
MR_'Q?36O0&MR2S ^.? "\+[W/ISETC>J*I5K$M[?/TXK.J\ U@9I:8Y(:M1M
M$*KB9D8&^[$U&3+E4Q< F76Y=I,U-Y638TWPL?DY G3L3_#2CO#_+E;V#8W6
M+@P283Y](U+QK?C6T[XK%+E7@I?]^"?F<@A^GU5*E/I-?4K%[W@&FKUWTWD@
MO.F6<YRD]SANZ8RGKV4^R#%?\U=T8B=]&?M+Q+/[- O/,WVZV3[6T/^7$\]^
MQ,-ONI[D"[:,?IXL=YKV6+%V^6FME\>MLOBJ]0UT8\&B8M\D#F!S"(Q''ZC
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M@P_&Q*__V:5?6\&#S2R4Z]X5P LO26Z@9VG(8-#YQR&O"X#KS*CYX?Y.Q 5
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M/R9;,,6 Z@)CO$)%H9D=2X!&'&,L!-.86+[^967W^5Q(W3(+MX;KU&C>C^)
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M)2OS,*L1-[]4FT%)T>$'RUGL;/V<@]]45UVRCXS_]#X@1"\G1P8LW<!OO"_
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M=]?H/H'0=SF8@'(I3>^)+V8C O$RBV1+LO$V_.6*-14VTM*LVLSHFPM/N)9
MUGU97"EAZ//@\4 =@E&]G($^/TNXRZK:E&##T>R)KM;;$7C ;?PD&Q,V=>4
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M@O%7<<X%JW4)>-K;OH3EN$*W* ]HIQ2.YQ+PQ6;Y '?K"F1C&A7RGB07VEY
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MML$DO6-)M\&FIN-G=7:GAG\DPZBPY=N^TR6@XSLZY8*"60I/SGD)6"FZ!(3
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M<>M!U\5>.WBX#B8OY5\*;FHS\9KJ6!_1GMBH;WZU*5\_.PQN;Y=YV3+QTBW
M^=.P7$R&S-98TD<IA7.]&WQ1'C,NS7?AIC/=C: H_I50B8ZU5$:"SX&BNG!7
MO" Z%EZ,DT$7I( <UI=FK#?'+;K7.??4A3E\8MWH]@QM GUZ;N@(CDN.0YHW
MN.,?L5&OP AW%N]> CY4]AJ@,T8B)"@> Y/&/;6?/(^IC@(S!J N[@PT,!$
M]CXDVPYC/L?X SM-O,VEPH1J+@%AKMC*L27-(/'8*2U]_\*%ZW/WEL1'"SH
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M'^YGDA*[Y>8FXYQ1Q/W;NA,OH#LSWOM_M7=E04TE6/0! J+2J"!;4!9M03&
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MN0HQ3>O.^;IC<VV..A5R\.A? 5!+ P04    " #/0%Q69B=*=.[= @ UL@,
M$0   &EM9S0V-#(Q-# W7S@N:G!G[+L'4)-MNR?^""@"*E*EXRN]*X)TL-$%
MI'>" B)$>H= % 4$*=(%!*1W(E(B-0+217I+@ "A2.^0D)!LWN]\Y^R>?YG9
MLS.[<V;GW QS#?/D3JZ[_<K%'=(T:0&XKJ.AK0%<H+@ V)-_ !(18'RB_N"Q
MB8'!$^.;_M*W)6\#)!3P#KAX\>+EBY>O4%-?N4)#0W/EZA5RN_H?:!<N7KY,
M2TW[]QM<O4+['^KZ+XWT\T(^ %RX>.$?#?AGNT!!277Q$O5E&EJZ"P#EA7]M
M_Z^'UP&*"Y24%%24%R]249&?A)*? 50,%QG_NO/@$I/A,^I;7LS2;Q+S+O,]
MK&EG,1K9X[_[W#N<AI;U!AL[AX"@D+"(J(SL/3EY!<5'C]4U-+6T=8Q-3,W,
M+2RM'!R=7CB_=''U\?7S#P@,"G[[+B(RZGUT3%)R2FI:^J>,S/R"PJ+BDM*R
M\F^U=?4-\.^-31V=/[NZ>WK[^D?'QB<FIZ9GD(M+F.65U;4_ZQO[!X='QR>G
M6-P9 SEE"BHJ2BKJOU.^0!'P]W@8J"[^=><2XP-#ZF=>3+>DWUQF?IB85]-.
MPW?7:(_EN?<(+2N_S*+ _M]9_R/I_[F<P_^7DOZWG/\M9=(/@.$RI1>U!N4%
M<O8,%R@9+I"0P!7*"^0_*!D -0 O^9H6$ :^4/Q7^*_P7^&_PO\5@7*0R$=X
M0 (BH!X>7B>@AM!B#;VV@&2X:^1O2)G/9PP;VW%U/[/J5^3JRK>VJ7/#KO>P
M8\=<*=DY./S/D  )B$PF :4&1'T2<"H0</Z(F -=1IS7K$%?DH Q!"&+!-1+
M(,-&67\OV*Y_^YFQW.7YK4%M[F4>^\FL:KT4,-4I>VAV;JE[&^1Z54H(.L*S
MN9C+XC(O68]W3Y?*8E.RU4+QN\5N)]*+>O5N5"H8:<JNFI2(2J6Y#NV%157I
M5X(U,[.:".9E*SGRV D2</E%E63B>>X)3,#!0V[;S@S2.[%?NW7@P%ES&N^5
MHVCNQR74$%XV!$;K6V]MSW&QU.1TN.<*;+L%536U33I783TL2,"[MT\:Q@D(
MH6W/PC:[;;S<E>VY^@"'*=>UT9:SCR?>*5(A2B"'X1(UE\N_)YM:X5\#D__N
M%/*DD=Q):>MC"[E3UDDLN5/#VA38833&\R0I5@K<#/IJDEO[K@1\4(%RZ%.F
MWZ\@,DE82?#AU;;:O'OG/9 MOX*\:C'.,YC?_IC=*\[*1["'#4S3[>-KK54E
M$G#_G2'5^+LH/>/E^EV8[(DYLO?4ZF#(9 7BLE0*82_2+?^5$Y!F:B2!NA*_
MQ2SL5@6/K5'29S&@+O+0R:J2U7.9.]%4<2U_QZT!<TN;>G7@00<)COK)4=26
MH9(P/;E.J)%#MORH_H&S+R%__BDR8_9.L[Q\5\!XNZ*GCU%KZO: AUWEX;I#
MJG:Y.Q?<'R%[O%Z4MOOHC^*!@?W E*S4EJWBIN',ZGG\/#A!RG^.^,1-<&[:
MK;D!XS_9[?-VM)IA+>59/=)\.\!!82!).AO6GP4/$<N174#$H??2-T[.U$Z@
M,VUCJ\33;;L7:$EV 7RN<X)22RL"XJ"PQJ8:9\-;\[9L*,1:W]I]= >?X\;E
MT9!9T@=&VX&WLE"I_BJK+;63M,!:B_92MER'/QH\(6CQ-(DA[+"W,[OF"^[3
MV<(SG[2;/E9C):*P-%H2D'1\I\R,V5Q6TVFL^4@S$A0V<I*HP&KE6WM36::V
MD#_!MH)K(53.O(R+$F^L.P(ZUDP5[Q!;? L>1!TYS?&=O!_=*638N)<\(\;%
MSC"Y:#[WVB*7=Z> ]\15X$VF^;OD Q1AY.FOFW,E-WAE=HD&>RJ[!N,2]=:^
MS=\2A<(-&_D?LFN=Q6/RJ"]JW7S]@&6E7_)JM\Z@KS.,7:1(N+FD5KW$+TZW
MD;:<AO\S0,V?% A<TU81A21:NPXQ[-_HR:;73$%-%V8FPR[F__77T)?$;]8;
M[WM#[L#T<V@+)U9>PE1 <R2 ZJ#<H:P=2=.'>]E& K#40O3;? P0O:)O0N6V
M41[X9=07$M!3$? Z5(@\&ZAC9\5?YE;!T ]$"I60=A+ Z OB"-OHUHC_<[4;
M:<]H<ZW(TY*?LJW[.;7XC5LM9]^#1B9U]3<]L+QW1PO>EX"TE'1K1TA .X[[
MV#O;^;?BVC;E^8?2.1?T3(['](X@''TRV$S(X%!!A?6C MQ^SPW&8H2J0JZW
M^W3?7:L?]5]!;I" 7X&U/0<Z3Y<18JX$U P*9Q P[%?AP6#QJ&RFX8_[4_EC
MXY%$!%+C(ALTD.-@C5I?GW$."HK>?.A::(*I!8WBV(@*^R#"7\$FF?#D$Y@(
M!B3VZZ!V5=YF=T;PSF>,RY"^F([,>=V$$O)T<@JU&ELQ<7+=3R+$6A<%35:
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M_NE>A/M?E-TO[9DDM[KX^B>099;Z(1^W9<73^'3S]#\(\P/YW0@0#5/7, D
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M'ZI!G<66*'3=E'2EUI.G5,N8$-ZZG<L%XCWN"U^R&Y=:V>W7]"6]O;Z9SY&
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MN6;EN4BYK,#EK<JI01L\H@.>Y*HH&S'[LRZ=U7^T48B_[F/!':%&_ASPRH8
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MXL=AJA*+6M63BD#NNNG_X3JT>[8> 3P'$V_6[4W 45+_C;FW#FKK^_M]4Z5
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ME8:D@KQC+_'T*LXK%8WVP6,X0&MZYLY<P:Y8W*==4GT_K[MZ!H^OTF@\%Z[
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MAX.8R%@HV@NZ4G4N CH7P0&"H$4'/P?/ZZ!1]%FGQ2?T2A<R^[*_2-@OVG$
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M$HQ>#C[YN>C<Y/+F<**"5<D./*EO"#RR1RTYD5+!ROJ&@]H1:;_2SM%=QS@
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MX/)6$%V2Y0U7;1/9*NN :*Y]#S2.>9 O6PLE0]6('#5SU*,2/B]OUW3ON(S
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MYU[:8QK.O&02IDNKY04]18KMU]J.'0TA@LR^*889%0<@K'2-U.DM Y6''51
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M;R_(J/%.X +5^5^X2<90G\Q3E2IT=E,MUG%T*:VA."S.4%2^Q@WC8#$P1H#
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M5FNF_YJI<^^!BNC$!88T'[OV(9#ATGR=!B\"R8"=WS7]3=]I]X(+S/3VUDG
MOWV$SWF]]H6J4]>:W:_0QE!<^9)WHMKA?P)W-6:$%3DNQ>J)KQ%^*/3WYFXY
M;8#I'E14:SM.YEG3A](RC]32W#!.>_AH^8N'Y5B9KKL'E+<49QND9B_MX)O,
M6MBOJE0,^<.V),%E[C!N,-7,V&-CZ1STB<8C4T02F*_$JCB<Z:"E/[2#.,L3
MKOTV($ZG9W5IM](LBU-DP/=:[J-_$_&>RY"OAQJO7)8"TV8"7UR.(A!R/ GA
ML7*F(,02!3Z(+%@5T+;2$D[KR(!21S+@EZG)V[W6,9(&JUZ$U;=YPM>?H,*6
MU)H>*VU7]<+SOO"$1UBCPUBMU683HY7-_BEMV\M'-<NWC7AHN<UY'JC,M*(%
MZ_:V'WX3C5?L[9CBB%F(,6[@NGG,M#W1VH%"Y*7T0\QS!_--C&K&5(>F@>T,
ML0DC=W#BFBL\E,<(59N+=2@!LI %L=CE[B1=F2+X&+HPV/>+]0C[A2X+IW7,
M6M<-^"'44+)AA;DWYDJP _6&)W\;DQ%>OQ;/"M*\%C/^Y#%*HC?>=_;\X8!1
M%F@^49H8&H%Q/!6OKJ]*=5Z/5="*@D]M#) FEGQ?_:FKX7^D*+@@I%;+(W+4
MC1 W"T:O'!V:YU:_.\+G(A(5$'2$% A]3YJ>N$Q7#!]?S'('Z,]LY\\_K$P;
M?W]Q2'G[N/@@B5**PF->YL/='V.-]@3"5X9VS1WC:P*BZ%%#E'.4L\<\2*[C
MI641X0K]\%8N%,9PN'7$<]G/F0RXY@:D)P-6[G-?N)$!4\5#?R!WR(#((X5]
M\-TCY=CPG(.;X+--@4.FM65(U/^H<VBX&#F27><I.[4"$\Y=SK"0(YN@(@(+
M :*^EM-^>*%7Q'.>NP%,#C2</7NJ%-?R?X\:*I'+-&E\XUEW5MZ4527A %ST
M+V\L[[ 9<>/#40%U-L^H$@J.ULS]2W,\(&Z+:T:SL([?YQ)@S0F<-DZ9]@X!
MW6I9&:.OXJC6?ICK;>05=Z5IE=<&U&U"<<V?XW,S^(Y!U*P?6 PC JJ:T G
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MI)C6^Q_I@=NV9 **BS'7>_GFU^(FYXHJZ<V&#(R?!*S; ?P_L:/<QJ+>1D=
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M"I MIO!HW64Y!W8.%V>+ZT<D=O@\0L0TS3_)G>!47-[(QRTP@&V*B7D3*]C
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M"L>3>G2R,X\G_4Q+?#_78AVUUC_EE)36;QXZFU*R\=Y=:!]*%JZH]T[*B-S
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MN#!67^7'EIE\G.5B,#)K9QH-XU&4)I$KJ-8K95)3 1!W[P PKPF"\W<8!=O
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MR(AX2.FW!.O+F@,&9#>PF6> 37/TO8+V8W-NGRU*7<@BAES1*]KT6,/TUP$
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MKP0H2Y_'VG<[C:\C"3T+8HZ_P,I'1G!\"S".J>+*['CW2O_+Y(K>9FQ,GIX
M2;)B[?.3W)K"!.W4:0?I/F=4JW37"+P-!';_QOM>X$A_:[(NVD5X:S^M-X-!
MFI;G;#)J]!712)6$I1*(H$X@!S2+K".DB]M%@RA@I\)9'RT[3Z\+Q?C7FJ&&
MSX#E<FAM"L8P%ZK0QXB *9PA)8&MT6!T/3QV*J%7\NN"?5T /D%_NC"ZAHP
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MFWQ-=^3L6O9$9FS7=M!I[5!FBDGT3LKI>5U/9M:#2O\!5ICXOYH5N@2C"-!
M-_,FK;_2!1JHOUJSNQU8;&_W/6Z[M85!QE>S#_I/W_#]8SV\%#X0E@]'1;KD
M/AOQ96QG4JQ3IK1^&;>4S\N"$<128H/U5B@0'NUW83GC<D(7P/7'1(;#8E6]
M^Y&NX,W#5<='%%[$QD']6[JNT@0;:]]7N#>.HGWO?3L^+]&4T:*XG]U>H]R"
MUX9,K:MAP,%7Y:SFO5%$:A;Z*^()3_D9+>A;&/=2U#Q+W!DLY[^/J6:J^SFQ
M(= &ZWF7[_.4ZT<+2^.0'V\YG7.U\3YQOVWB </3"&<RF#!@I0OCN!#2$_#,
MNX#0CB07QJ0,!Z)VW)H!.D*NTBA MD0<<J8&^1+W2!OTO9T5KHXBTR3+)H?:
M!>3SNJZJ+/IW(I'$_+NWN:A=-'"U=VZ)].@SR_FWYOX/T972?[! ^/K@)\,N
M!'T;O$IC/\@4:FB3_(N6HUO8Y5LUHBJ",6S!^<[:\OH'X*BE]R/)_,NGS3^*
M$GXP7*ECJCR2)NQ7,>M5D XL;6;TBH2+,!,BDV7)[*D[;9I".XS8G(U]G4@2
M[]..#4(Z#'OJK<I(52U:N&Z!SJW3()AL](G1"S7(S&D!:#2!73]&&P>D1K:4
MTH]A[;D,'FL^O]OTD.E.ZR5ZWY #B<]-+SBQ!BA;EY('+(Z%]L"YL)RM7'#<
M"7CZQ;X7OP$1*TN4 6Y[;-WQ[=IG?7L%$BUY\;_^_@^2\2/H_'W--=^"\?BT
M_9</C5HU$"4>S#WG=US-7W!@$D372S0C]Q+>K+^#]G1^>*7?T^^72GMR6F 2
MMJF5D\=@?5]I V1.!:G+2F^\J4\'S9;*_5]K.:'ZT\T;V0KC)_:Z_\#!U/^H
ML3"%5KCT7.&/G0@TJ/Z_<\7(-4L Z9*+/&*=S>$54G3TZ.T73U(;7^D),]X.
MC3?12=#!5..5Q-B]Z*S3#ZW8)E=[D"L1>V4+06!)7?(;]:.6Q=;_K(>[2H^H
M33L)<1L<">TGP& 8C6*3KW7(U7Y#DMG3(GA&U2 )&BQ"]G_?WOI?_M1!L*C.
MU[B:#<SHL0\N5)13NL"3UC^7W7C:0U*M=M"9=L>&>3#^[3.E0)GO'*4HVYN'
MU> %R&^ST3N$H *NL;+*KK+A>5W,YHFS4$$4A0'HB/Q=U2ZT.Q(("-;4O9E
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M/.F"Z,#.30XY:FAR[4%FR<@CA"4$3N!_.R-0T&G/B08P1#8^;G&!M>Q AZ^
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M'CO-SY*7/.BX=GR&$S05^.68]?PQX"<M>7;!6Z_:KYT:;K]]OB"[.A^[</#
ML(ZT&BPA)MLRB4N6;P(V]%F8$'+,J::21E7AK1W?-B+==A8/!%3.UF.7\1+.
MENSWO?)]-:) R0SF%< [E=YL8DUX*S.^P\53JLW^5;$BAE#!?C3@8.7HE534
MHBSKD\/RBP8X00,V501J?@5O8+-#,E[EIW8)HAQO\H5J03].DQU%RQ1G?H"^
M=S#[\/6D?*DXB=A*+_GED*Y-]>">O MU:M2A@#H$/AR8O5*O\K \=]R(6X[I
MYP9)&!H@NF?:B!J8.W%NH*=/+0ICKC>Z&\E3QU7&^X5GT,M_DU9MJ=E9&P]@
M,MQ:(["?@Y(_XO77A5R\TRN4-"8H?LI)($$5W2/E7I6<PMSZ^?.50ITKCBK8
M0;:'Y,/<#'N=3]AZ>PB797M=@LS:.X.C+Q I>.6!YNOO.6#4CT;^G\GO&6N#
MTC8;P\XH;%CJ(/9%><DL@$$@'@N@R8+1![@S\2#]O.%>1"3]=$)5DL71E<91
M7,MB ES'ID_N*4PX=V4I,,19XP,RA_#.CQ7^AH5+AU0<CTWZ&0B#7[1*.<5N
M1?>P0>N_!HH6_TND^?]LE4Q(O8"7]<@(MM'%--DX5^H)?Y2%/<KO?6.8I- C
M90?P#$BZJXD_"!2?0-I.8$(G!=$ !Q\:N.(*E!;M666JAE=\>/4\D7KQZ/CR
MRNTT0:/#*I;[YJRM9:1-='2 MJL+ (@20(1,\@</0:/'[XF0"B,O-"S6-#YQ
M#UH;;EDEO'V21",A(<=^1E$&=.%V8;D^!!4C.$)^N5#WLLQ5L'Y[,MYS?V-&
MVDNUT.K9Y<)(!N$O"HR0C<Y0&2KXY\U3M9F-L(WW1Y73$_?)'S]S<8-4T'YG
M>ZBS'C\Y"<[5 D&B;5XR!$J(<0UWD79%D<JO!XNQP)4 7V,T /*_Y^%V432=
M2VXKIO:(+;+SIB;&.ISAUQEBTA+0 G\UL+^ Z;8:+BHQ?FOG;A3+T_H8N5^:
M@S&NMI6@)O4%:))CT(Q\SX"$#F@2?OF=T^:G=7C/=Z971UR[ZXJ\KYD\)WJI
M\;R)/IV%KK4H5.B;[5,)["-,$Z$!"E/EGZ18'W(C%//+0UY'X[)^O_+ER A4
MV3 #V\O@-3@0$2^_,AIB38N3JJ6*3]*I\<U2N2[.(5J@62?\ H3T,6%-MMN5
MMNYDZ(<]UF5L@A23L.L9+++K<F2 05);0AA)&Q-_129C\_#I3&[8AKB:24'6
M$XY6J5-NU@%:;6(\1B+@[:O5H")DPL+"P1S"U*@&/)*D"/3D\[U]G1BF36.U
M?F8'"II!X?IP/TLUEB_L-B95R81<XL5YH"I]K6+A2Y^ P_:7ZV-L_<D110Y>
M:.!-0YAN&ANY.JDA&9.PN7F"R ;$K3ZS?8\6""3PRJ*;<:ROR>G!O,.8<EZ7
M"R_;^&<\^'>.I2V0]I*/:DK;@;B[38')&WQV$YR5"JKMDB3_ZS3=3\XPKPFA
M(%5">2Z*^,#>P,<8"Y/_[(/K_^:!E.TF24C'/83&KR^5%1;.+AQ+NZK.5?<D
MR2R-(=ZXGS"YHKB"^C4A"1B1:(#P:EWS#PYT>P<-H %V+7#9SU<FC1'VQ)D6
M6;H-Y0X4:BWI%BS=E7LV7ETT(_P<=RPO=',"9-<A'L8=X+5V[&;4DB!\;A/I
M0%:?\1UBA>BGB3_^ NP+K<@0W9^C)Q ^.ZZX'X/[DF?I?@2F<EM&G<BLEL"H
MP18D,5&.^B$H$$'=?4KD4WDK[&0Z:+RJ7!S)D>E&LT1/)3=$44*_7K,S%4&C
M-QP(X,Q_:F<N0,[-.@J/N'F[,)0)%*7Q6*F6#M,(\='?SK^.7F Y(Z' \.A!
M,5?#&Z+>Z262-M8UK>STTZ[1KV1&V-.N1'A9J/-+;7W%!CQ0#Y'V&YVTJAQS
MY?=;4@&I2:LP;>H<>W.?;7-)' M@W4V.'&FY,1_N3]=O0M5/;Z@*L[[:3K$_
MZ' <@P1INM*#0>)]@!TRL9M.-G*#"C9;H!^?RR[5Y9TK=8_AD]Z3"=I_@X&1
M?2C8GW5C:.Y4<X;5<,M\\*Q]'IO&T^KZ24*HN:]V#JDO%I,=R+)OC:2>F?&*
M>6FNT^&:.6T;]<>GT;?#+ V59]#D?)9XZMR_ED(K#LS/^@M_/7SG8)<"Y[D@
MH5-^;>,J,E#_E>%QG$"2=B6#& OIXFX@-]*HF\XLN$(C+)+ R$@H["7M%]]
M+X#_I50")=;#X1*"C RK!#F)I_]L4/_;_/_2$#OTKC(E]CXNX#==^?E5=-5T
M6O%>,TQYCJWT/.-=D!P38PG2[T4-0BD\_.6K61C!/GO2MJB[[Z<7'.;41$U8
MO8)QFARP0&F)"<V0C1\OWWSI*(-Z.RHHOU\X6^9Q'!?Y_$3??/2]ML*OPS[
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M ;ESR&&%X)-1V#[)FJ0A/2N=<_B6)C\%5$#!DXVU=<;,_P[9"_;X,4T,HY&
MQ\FW4L2OS9909-IJL+U=T#]%O>#OKH[L8EHQQ$L/J0!P-!60ARC[7+%HHR:[
M0JKJ+GD(_\_SQ>GEA#<Y.Q?2*$VTW/_1#[-^GZ$6,B-V3^O+J./SO]>J 'TX
M9D%"_:22"AB0Q,X3L<<G'L=15$#AI["$5%B=$6W2:5Q0R]$:0ES[R\K1?0D
MM9JFFCX8)^F+Y=I<QT.[N+2$R^#7[M%QV#*1&$S2?[7,CM _(]I?D.6&>C>
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MWSS"6H/R''+]/)A;L&^7.RRD]\,,O2TM$7H60W*MEZ7T(H3!W>,^.NED<LV
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M*=H+;I29;!Z/N9?7.)8\R):3O?YS&"$<-*GA4H7^G6#IQUWH<M#<?RQO'(U
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M*N).SEWF-M2Q7#&S4)!8_*+\>O8E"\T?[GJ>:LX^K\ Z__/G<Z'G7EXM<ZO
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M[C/.HKYG9TL$(:*Q_'%4P-(D]XGX^=F\0@<">5]]+_J2)SV%^0]LYH.,UU3
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MG1,&4@N<>?6Z9$;PKE]TE8+G=I+#.F+-31,]V*(S:-13LX_)OA3R4M_EOML
M4YXXD^HZ6T:P"$Q-@G8/&_!T](A!PDGB'?/AP\L%%G@3'+TO&K.=U%ZBA+R'
M(%/8UX?W-G#UQAE9:?2L%4RGV/G'&I-"\-]PR/1KZ<\;N$ZG\=QQ[GTNDD]5
MCEW4S5!?DJXKFIF=67 GZ4&H&W)'Q&ZW$+[@,! .@0D:W-TBZ'YZ"^::"AQ
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M)AP@4+HL%GZ Y<*! "J8J;=^W<-]!@R)]0SS!E0=>?N(,+&_@\$WC4(UW^%
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MNU53GR!MS8.#?9C= F1M";0&35\%2R7S8[YC/O^81 /1" +)_,08FP51^;Y
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MO?SN"KP6#70(QPMPVY>F2HT*6T]@_6)>M NAR[<]J$B#N-V8WSDUFM=@O./
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M1\%#MV4NOZZN$R7C<C.2I;DI'F;64&]T-M"=%ND %N$'>) !X*E^+[%U4\O
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M]=_9$"\Y*8(MX>S\I4G-34$FUX,P GH-*MQ=!L !"68*KMV_.J"^W00B[MS
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M@X6J+.O3]Y!8<50V7M]J^>XY,0L*&M3RRT=W801E.@D<_V0V^:E,\VY(9L[
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M<YDE(?8RN%Y$05.]=E[OCMCG:>KJ,.8"A;XMY]"O$I/H9%SZ3>HC\?>Q]_*
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MO*R$$R?=9C0Z:6)<>5<HW_[HHC5E+T/(UJRP+SK7LDB@H6&VF*]D\:KJ$IH
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MZG6-GFWINZ72PEZ#N6F?_1]U+2@[8Q[*F:QUUV8%!CSC!O*@5?I).+!]=8S
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M@4S7$1!M&*:>#P=ZPZZR\6 !H T$]=F0^M<#4LTTP(';<SB0S 0Z,WDL"$9
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MS@))O[&/2F4Z;/CFY46*'G$*Y<VB[_^]>"\DS:N[EWPTSFYK JDD9ME<XN2
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MX-#B+^/)#6NQ1(" 8G$JYQ&TWW<+SU?@0+0JR.I7I%",Y,"A(4 :)$OQ^S<
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M0_N'1#5= #>A,S$R;3=:B5^GD!#SO#U.X:EP19-E4Z>8[$@)CB+;""Q\$BA
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M4?>W4&#>7&/4<;SSD77FDD\!<7]&/8TJ=%T3OWI09AN^RS>7'Y_E^4.AV+P
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MS,]HP?#*09[5;'Y%,.60HW]CY26:W%O#E^8]CC5L;7TA%/GJU M%5HL2R[P
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MUH#[=6J)FTRGTL&TGD"MS))!F0UU@C+R@I:E.\"S][JOM"9'?0M+ZM3] _W
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MJ[Q8A<Q^X)7$U.<,T@4Q4N6UE=!I;]HSW9T I]NFOLL#TZ03Q(RBP=>_.ZE
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M>]5MAAFPPNB_Z30D*C2XAFF$']4E!8J^"O?=GL,.?+SK($Y EY<S$:MJAZ/
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MM8>P@M T4H^&D><*$YH:<HJ\;CK;HVU2/&9?<O(5Q/?<QMPU?<>904 /342
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MT[G5K=C../X)W>E! NA!=^G9L8,[MR-7(*KK1W85)_)W&OTV[!4W?CY 2B1
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MQ^_1=O-(][&> ,TO1H9:Z]*$+X(0^GKP^+IEF7\-[-OPBZCJ\.7J3R=(@-Y
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M<IR0SP^DJ,-QG[U=5><@).)^24B9.K2 8#X52F/AX>M3R4E-@!=H^^&<,=J
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MM 5VE.QK%3C[;JLO@.PEC.%AM$=O]ZJ?<^HG#(++Z6>(URH+#Y5?OQ</40<
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M!WLEPD^^69[S()NZM.\B+_?\"R'":@>>_@6<I.]1WQA*U-Z29S<<5NU?4-.
MT/,[*M0HF67+,6P^,U7T;PLDJ$I[7A%F7A./NL3[XJX\\U+9"N7S!S(JL7ME
M)&4J?+8JA2<MD#-UV.T?9U&FR_I6_=.]6.!,'PO@=09J+TCM7G/@S9TKM&\Q
MB.I*-M8>($UXV>5VU?7!W5=F;A;1DA7%#+[;XQ>\,X=<PTG4YQ(NP[,ND\=J
M)*\2%*RA<TRC3M7Z@?25GVO[)]NZ=X4)RP=$B^6D;27P0I<HQ=BH),Z"D]4G
MCUA"'*2/\XO.CHZ=\CP@^[ V&?FOR';MMWJC+\1GA57U<V:',L3$#P8>W"QK
MYR"BY#(U$2\<"XQV[ZO:.AP!<5.-MZE&K*FKRHPG'YMLK+FOO6XAZ5_BI:@)
M<*R@^YJGO#U-%^:[7TW=M#))E7Y[I79H@#9/W4PG1^[Y4GYTX\D!=%.?CJ54
M<UK1P#^W%#YP%M2EXK)'S-?QWG1+M K4FM,/56XGG(FAF+(59.)XV0^P>D!K
M+/>;:IW3$RWZFR^$H8O.7\0:HHWJ>8=-Y62<6Y:^5X. 69!OG#0WCJ,_J^/E
M:OQY^ CE*KW9V[@T5\E%7."*,A)[8?ABZ]XP<N\D.<VI46W0ZBTYW><+B^"M
M"5.0-2(9*<-W/J]>^_Z[EXSS="?9H[;#CKA4C1_]!\W3H=,J9OC>XC,/KMC&
MB'?QAR0D;"8X(SPUII[JR4I61*Q/JV*!P!C'-CF"'6E]HNFPZ:7J$99XO8B5
M)=;O%0*Z]Z(:KL0"RTTOWUYU=55W,B0O$KEIL#K<H.EXU)R!Z.Y,)AW3".QY
M*&8OTMPPO=DW]O&$\3+Q6,+<NF1I;8D6?3$-5W'29B2/QT#C.3!Y]0MUHKN@
M49^*8@F=C 6"/?EM.9YOO79AP3KTH,%%-VP/%"(,NVVBXE'H*-KP.*[7RLB6
MU-F+,'J51' 5KSJ9NRTN24[LV8A!]88(E6[B6+D7N%&Y*CF:2C\R<;.36,H8
M#I*QCGWRY0+BY&74,F15IN!UC?7:W5J5VRR%,RDE]?2=[MP11A,$]CKV2/<J
M')1KK,^SB/CJJ_MH-Z!9?8]37I77!'DOM9\94Y*9#$HK/D>QD+;?C?I^RE]!
M"\Q32CPMKHN#/!R/XOQ<-22< ?5Q0)H&AZ45JGK1T_A73[?T]DSO!@1SE(#;
M7K^RN:-9"N=%F;?!>\R7_4/%F!_!MOU H:X77O!4G<#FW0),@DO'D6QV>=^V
M53^Z=@('_;!YWXE(:99"7\&]R4UE/-(&B=OLG+KG0Q5 .@/5+6I-[6Z.H3P#
MD9Q^DK3-9DW14DZM%%:,^HL+DCPL8 =#73'&1>>%7U?-&$:^/%W!,(XQS#W;
M4T*#<J3+VT'X?%[F$EX9%DAZAH''9"RJ6;')""^$Y_M<A]:0U/?Q-U5CA&9U
M[V3QVVKPN9M(^?RL=KKHNBI-FRZ3IW)/8;,<WCC&=I+:(GJJYK? +3+F5,8R
M6KT*3UTTS_-)YZ8@8?XP^1XO-TKP 9/U;4\W@6+^YR-1C7(;CBN6W,]L%&6'
M>57I)R"(@HQ!]K+#@5^9]\_!*01&82OVG+ /"^0B:P[K=A?Y]_@'E$9LL$!;
MRBD"DW![SK%/YNE_>:;^UP+C_T7AP/\K08)_D2VW; '% E^B0&>:7A;Y!*>Q
M:)+#=\NKC&VQIQ.8!)8ER3.6U3\]8(LW(4L[J9!G CKMW-8?47Z0'-Z:Y#CE
M6B& 5QC>0$?ZTOHF(6?<5PL-G1@&20\T:,'T @OD-63&,'"19K*#GIG(+08$
M30>=K#]=E\4?E_8B'B^RMJJ+Y_RA&K/R/%X%P3;!O3+OS,\B_2Z4Z $'L"7Y
MX]/2-7/VZLHAMA%8_(]><BY#G2):T;3FN5(HS$7,.UH-\2:MM";]9!Q*$YQ=
M^RRZP]M0UK/B!;7KIM7#>GR5!]].Q75\2\;9;ZH*ZD0CW0TT]X5]C0OKO[69
M-1;V;ONL^SGY,/C-V#'>E'ZX& ""VGO#[* \/; !:.RJF3.M=1)M5(SW/%*D
M7_)H0]:X=W (UD/ON7?L4.;OU@#WA(E&EY_J8/BQ (0$G8KS\.6(P2U/, 0+
ML*6@:((T8 ?@91R!%>ISK)Z7C3@5<2DT6I_N+,U[;-L"9AX? PA.4MG>S3S:
M!HF*.74 A>Z.W=_$>STW^J<EZ_W!*CG37XL4,U03QU9R+9NP0/Z'0>K3A,4[
M&05J=QHOR]MX1E^)B6N=YWE91+37E&G\8D'-*AY8S>#RM5>1U#@PR?.N/; W
MT_]LF8/_.3=[[&-E "K_IQ_DM:<YV9X*>)%VK*:F!F?\BK&\'N[*'"\<)/0&
M\,0)J"4$+O:G#+Q8[+2CE\]@;V5A*ZB?KD.A8G[C2=DMO:=Y&RMK*&<?+$!_
MY;(YQT^W<%XL4#7ZC0JX$E6K[2HHJ]^Z&9Q?[^I3HV'K,UA\*"50VRRK;].3
M_?,=KS,66##VU1C4K5!^6U,F'04E8^[>@Y=KWA.,^]'1<<O0,\SU!=.U\I+Q
M1#:PK<8T+Q\:"S#6V5\81-E>:<Y3VSQVD 6%S;'G>&"!&]QMAB9C/]VBK1XG
MX6F2A7]'[D)E[0"^!WSH2Z\9>ZJE.)E;2DV$%Q%5:5-;SQN#&7US,56/]*U3
MJO/'B]4*$/M@7C$!SWMR"Z)[I7,93+-!"_/./Q'%(L7+,P];>?154QY>(*,5
MR0VJ@MNJG[?09/Z$?<--H\5S+8NYJ$\8+HLC<-L):")N*6F=P>[/%K[^YMTF
M?Y7M_D_8Q[]GVQF+HL7]E[_>A2MO;VVZ0KZ&_;J&)T]HN0+2!;GX57\CYY?!
M7P?6T8PX%.V7PL!*Y8X"O:)!"X-H071J,^.B/%H;/73$OWW5AB\O*,<8'CUB
M5KW7*6FS'&"MG3EE>=5/_$X.37P M]AZ8JP5(R6G3L3L++_!8GA-[*53<-L7
M$PBMPP0T_B7FR?5A87![LY5Z96^X[ ,SZ8?=9DL[8=?'N.J#3-(M&YKY5X)2
MYK])DA<67CCDYAY7CL]YFS3ZS=*'=?A4)2SL;(L8\WP799\%L24SBI+PB*Y:
MO?\P8 31-3N22&8?.2WG/IN:V>APOS"<&18-;>8KL3U];OMZP;'IA79H9E;(
M3<+^_FYQF3KVLNP6OD%4%NIQA/.D5/D*!)/$$GF1;OVL$-1)TCN^7\&P=1?
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MQ_)DN)>/N5I.V,5$3:EVVT?#2N^10:]R!=L@$OM37&I$.&UJ]FW!16)!Y?9
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M=M\J[[&D/7EI*55I6"M3YWKJIQ.UH)V?7YJ'K-+T;,R,8;E-4_EF@SV=-OC
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MD(IR2M;JX>ERX6EXCI+" B+:@GIO;HM>3KVN:J25*-,H>C5>MUTX:Y6QC9Q
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M%WM)B$E(RHM)R$N(\XC+R(M)RDM* 0#Y2Y)_9"7TG"])_\F+I23_Q9-(B@%
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M_DL*U2_AKXMO\,1?"O['&HV?\X1C,*O\[2C_$CF4;L6@B[VCT51VP/DSXW9
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M!'=.=::T&>9?J]SVOHEWE51)8XP0Y.<5"1, Y \_Z$=D!P9V8;-:(&]GTO!
M4SE\T3OU%\8<-W(/M36U=-#A?X@>W.N]\K7L=OBK@ZM--Y-EXK3\G8HSI#[W
M?Q':87<Q^.W^!?WH+8VEYT#IT*W@ 'Z%0^G*#]""NS\<HH8G32L;FF^D:3H,
M:'(F;T$>KXYJ;X%N%ANZ=V?Z+4WLG$9[P#:*RK,'\< S$&3H<#=I7F=HX!.(
M#;%(-P<Z.4HGI#Y1!9&(:<=5D2N$',RZ(&6\/N0"P?!$RO$ A,"\&Y^T0SP?
M3/D*8^*NO!LH\-G)\EVZ627V5\S#8UEKZ*G>\7[Q$OV+FY\T5S775*@ _4B
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MK:QQ"B_<;>Z:15S:],EZ-4DH#6RCTJXE5<95*O5Q08>*!WD%<)=ZRX_/JO!
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MGN*!U:L-ZXM^.\=4@WB " \,W752BHIE-- WFXHG:/;]YA_5BK2>LQ<;5?'
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M3'X?\HOC:Y@()A6K#<V;7X>Z8DDTDCVNU2;.5MW:&[PNQ&E1L]3%_S95\]N
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M%"]W;\H@I*=;D'@X*R&;$&WSF(=<[I?X]=9D@M)M7E2XKZ^DE]V?]+E]&@]
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MZ:B\EMC;PKW_(3B:1XGS%Z(:M [,'?/:4=:+)#>1/VP+#0=XD9 2HJC#NJ'
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MJ;L"=C+93 7FD8LQE;:*5;O(Q<!>%K$[86JNUZ<G)-Y-_9"<*$0*J/;.2A)
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MW*FK:6QU4KIO]>BQUD'!,IU(UH;SOD\\_ Q)FIRK=OE]=YE[!O3ESNF@2(_
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MJ3\;PD?J:P6KUS\WE7=$?G2H959[#HJUM.X=-AE(MV9EL9V/( ^NN"+:LN@
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M2SV.MA1/UC^HMAFZ5C"OSRCG#[N1SN[:)U2EY,EYN7F)MG*>CI<_&B9P?AD
M+&)-I\R^)#!*F.#?7]YQS#KE]LFG[G<*FGVI571 *GAM=T:6%N[ZT\<Y_N;C
M1(>IC]8P2X^1NP=S]>C 4YVDO0=)=. "/Y/_/V$E..UOT/1-^6AC=.!7A4(!
M-3Y#=J_FUQ77?YWR8&,J";-NY#?U<S$W%X^ZB-(A4^C L;2_S0!=3:)*SX[
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M&03?DJZ8.F(4XDK[.'"\:J,ZY+DS'5",6O:\[_(&G_@&O8KJ 9$5HB?(%G3
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M@8X%/3KY[TQ5AYF\Q5US%5,7GFIT^"Y#C1_.6]J]P(VM#\0,)*AUJ]]SZG5
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MEME-"P_=9?"KRI89]!<5I;/(NL0 OPZMKVR?=;F(D#;P2$&K_R1''=F[F&I
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MF<&Y,HG@<*=DOM??8#X]YE&G#_,>S$_O[0S-NV,@L&2QCDQJM,!Y/<9409[
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M/EL=<AOI*/MJP?OH@2^O3M,YGW.H@?&!1ZV>U)]$#DPSYGL4\.(UU?!+T>H
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M-S/"3C*_7]IQP$,-AAN,N<";:N 2;:38SXZX,7Z:(PY$L8K;]%I_1JM6P43
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M1 R-O1)*9P%@1;/YVD\E*@U%WXW]"BF\![PNGT6W<[J__]D,/ Q?5?@L(PH
M5BM&#2J)&M\'T^Z#9)@^2FMIS=@,RP5:NFQD:IX**,RE3_ET&>1)J)3A_/_#
M74U_$3!D_BIQ"'X^38TK@:TM(K>,M2Y@ +S$10=0R*P!>3%.!C-Q:4MRQY1"
M46=/05%G)\OPZ%]'38J#?A7!T1Y%,$ !.70!N@']1C.R^O(:\CG =2K ]\I\
M6!%MM:?Z5K5,5_3Z%&J;KM;T+(JQ9OVX<[.HK#-&T$*G?N*0QL#$$E7%K1DX
MR:E_;4M*LP#L8"3R\ZM@"GT8NEJ+PPH5KLH_?7DT]G%2+699?_KY@F$C-R_?
M0"56-13\]W7KM.[\K9/H^/3_@;Z@_W/[G+HU(\RH\DN";L7(BL7MZR ZX,R]
M-]=0$4A.S-)B;FUM)7$J3:NY[VN,X?5'15G7@US:3D@FF4FF4L5$Z<F4]Y0S
M ,:KH1YG@$I@Q@ R-"B<\O_B&WWZ5J%GF-XY"__"4])A7.=?Q<E-<)7^7<'K
M1(-^5_<)R^#OWK+#D?OJ=U].G@0?PKHYLA!B[\=4Y,^/R/;<M-H=KI/E]1BG
M;6EX9KESW._'YZ4(;3$.$@LP\UJ@>\G[>_ ;T? SN50=XO7GA8-S=O(,$.Z^
M2[[=4'U@"IN'TDO-CR"VMP8"HA\DN9<'LMS%V,@Y)!2!/U93GZ1LTJ/)BT=Q
M_!#5-R66HT.5%J5K][>)#'#GLY:?"L2]5G^9WC<MIDAT^[DQ)NH\;C" 4 U.
M:K2H\!=MSB3EM'WFYGP]E[T@H<4IZQ-[B][Q@,3<.$I$45U(8A^+PRH/N^2U
M$32JLC^\\,4E" H;/8Z?1CE<8OZ9,SN[]J\15;DH(@-47\/?B.6KMB0=8GLQ
M6]9QT-[>SJ%9N>5*S.F+LO?"M1LU=#2>?YR-: YZ<I'E#(D93X\BG:O?0L=H
M&CI7)B;DZTFD[Y7DCMS_]NJG*]KBB3J[JK$-R'=*,7 -@C>772_5'&!HM5'2
M:=FVP5G6%,=BM+B ==SQ!RLR=19-X^ZMXD(;ZC+,S\D)8\8^]Q&L?7"E._F>
M0JZ)>?R#BU(]D@;3[O>%Q]F_U+$X%/JEO?'5MVLF1Q,U&L$'JT6S@V_-:10=
M&=)-94L[,J__XN> ^HVWQ=_36>IQEL&@R!.XFEUQH)6.:.SNVV;10:DC.=[(
M0B^Z>/^(5&_9M] 9!R>'>P,W#&PM+\O&A_/J._DWA_(J_!L1UQD2/_T\F'M;
M1S<-V*!3MP/:X0#I><32M%U-\A&P@R8.-DL;=EA\RD3[2R72[!;F*_D68.W&
M_;<N T]W]X[:J%\2@>.5%.XQ+FJ2(]LV9)@]G[P5&XM>/@5X,Z=1>C(S_G0;
MK0$\#MNZ@#K[*L[EQ(\(5 LVTZQ5OPLF1>ZA[[]$;*NK/3X /Y7OCI!_R@#I
M8=&F'Y)&NGN;NL])Z#6S.>RZG'SZ$XMHM NRL9?.C>S$ @M]5RD#-/%Z52*%
MD/WX\N"T9BLKOYLYV+4+)O2[+T'Q<TA6[ R,E$)GLD,N6T)__H11*<[T[GK
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M'SC+'3( J9QK 4^0_<@:?WQI%?,#/=A!-UG"Q]+BMF#T)%V8$AK)*9;7[\L
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MW.^*""O5?R>OE@^B%,&(;<MNIOSD59KU%/R,+H\UZ2--%IB\N_;+U/]D%66
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MS'\U@&+=IZL@7>< &RT,O+_S#) 0"-=1)KC^!O:S!D:/0F[*H,?UUYTP )'
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M/=[27=O5WB<(_1(NRG-BJ.Z1KE KC]%!ON.\ESE!S&_%GM!?'HS;#&T=#TJ
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ML3KE2-AO,GB"1=L1M\GK%ZY$(BNY.E3II_OAMA0-^%$QN1JT+:H1*2A_^WZ
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MQW ;84FMK9 ?E0/X)PW2=@*])@I -@6D_5,4]N(Z\@Q@29>[UF\[^.S?1%X
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MM"0-*#O@8Y"^1-0F P#B=D2MI_AH>H)_)/1=+58%[8%RBF$$)E0TRLYZZPX
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M9#/JM!-1O4B^W(%LN+TJO:<$S?XU/";Z>+Z!IF-ZL=<T8(A_/L =G!?XT<J
ME9')54\K">4*.SAJMUS &Y#,>TQ<\D(I9>?/=CFIE;I'A PCD?&%"#IOUM1O
M'DM@&MSRP6R>&!K^N(1L_DH#Y<5XV'Q$O7]J]=09W?'Z0WV*%-N3USTH+:1/
M4O6EXZ[AG$-//-,72Q]6/*"!@I$4P!Q_!J:!Q!4@%&04R6.B ;NQ'[M8"."4
MAIEYZKL@0"3$D-O6::#. OC2--P5ZI'VEYS>6SF9M\\YN3'.3T5J+\#'(49U
MJ-8<GT_K0X A1A58)RY0[TM37GY!$3=@N&&T(# .IVB@C\W!-! D?>:QT_HZ
MI!SUV$</ ![0C#79"4_QR1_+_IEX_C7LQ!ARA7IM1<*$LI$PT)H\B4G[N?CO
MR4/_VK:>]>#_FZ8%?H-(]4#Y"PT%L330;D'G+_8*O(!AO$*6>!['L()YW#)S
M(6]V\VEL\:K'K(^%IE8>Q'[N,-[+,6_ 3#2MXLK&/XW9\@>OY8_A:F[&/_PG
MVV]^%:@&SISREFR"VL##.?^ GK*_1T]'?>IXUR!Q*&ET:1CP1\-7+>!19_ZO
MO/[D['2=AXD!2 M">@OEG8C)Z7=7I:[8E]!35_0HAI2V)D!]>>0 ["$TOW6.
M"WO7_=L>B%?;[8%8((E[P @O&JYMYK92Z7HF(MOOU?T%<M5\![GTBC8,BS9,
M7B)&__JZ%<CGG[XP/OMY>:L:WMOQ=3.U@L?[.0U4=R'3!F@6.CMWS?J<IO=-
MKRU4-D?:0F6:_\K>.U4299AHNS)L,/!/8-DC0U+4QU@H?A$S=GI#V.R8+-"#
M6X^E)$<B,#I;(P3ZYZ_RI7Q7R%$?(YG&B#%)('+"S[Y4 $8]1.%29&@@MB:G
M;T<B5[48-[L32%;K0NN%G%3BA2ZJ30L-]-/"V$=4E0:8<ETQ2GL3\6UCA8*#
M6C#GAI0V=4Z:"/L >6I# RT Q>ZA?.D[YH[654#K H#N?EJ"[7*Z[7(JP[_P
M OJ%M]7;O4J$46D._AY2F/ WCVOK[Q[7W&\>UXZ5;V OXM\#>]L_T:\X0$7=
MX8IF5R:>I?FR%#FL;07O&W;5&G8% #WPU[_^#TT.(SK;#(T/4WJ:Q[>"EA;]
M4A*D.P!(7$]'\_@V=[W'<OR[]/_RCZ#C@[:>AIH'N9+.LR>9B8*8_4+_@4S9
MGRV7:A4JFJX.5."8;Y&1(3#ICP ]\ON+X\R,^M3,]S=+_U%XB=O]<?']_*YF
MR2.2?_49Z3P$VI3I[W/,=>Z;+,EN+=YBY=5T:"=0L$U?./G\CC8=M)WL'Y)=
M*R1)J%32Q"RVWQWF0%98$%EKURYQ5_2I%W"/K(C[/ 'D,N;,-JKMN)M;I2M]
MM]U^_F;1B\YT>:-'3V^49MFLI7@C00BFR'.!K9M( $74M:-J8"1FJB]L71FV
M9:.=V@H]B9$E@\6 ZNJB2 RHQ@5JYR?8Y&$4B0/[:6F8!' Y'>HS8'V(B'S#
M2-OD3_]C=EBQ*WAC-YJZ4WI)=8T*Z(Q*^#(= ,X^T$!;$+&5"B"U5##UG,$6
ML/U<.*?EDTVM^8B=9$-3Z2" T76EANH/4/+3H[0"]G(0BL"]"4(MNJ"VX)HL
M8.I@)^D!\R=V"R8O2VR%UH2]6L1L,&0!2=J %61R'"@^A 8:,=JR]U X- 6P
MEM0AE*?HOX#%O4"2] :(!AH;HX$H+N7,T$Z;/L $RZ7Z'0.26+=LL*[_6/M-
M.ZB,)'&]BC=EQ6V?3!3:7[;!^B94!,Y='*E0$E)2-7';&OYSRE*7N3(.2,KU
MK E13]W+A.JVE,U1CZ$>B\V=9]0U.[O5Z%6#XTO8,'3AL"]41>&1M_.6Q94L
MW4R&;-Q8I9HD%J(V<KB5%SORG2-/)BVUDCR&*Z6H]*V;]8" (6WZ@+?(7-U?
MVY,E:*J?,=;;K"JYY^%XLMQPDG8K@).POO MG'1]ZQ#6-Z!$WCJFM064_I#=
M9.63 862,-2X$<]-]=&>AX]Y$W_Z],?">CZO;_&[CRL[@)J.K+WZ_VU>A$$P
MZAK6WX*=N"LA;\J"62$I,]&-<PY0P'TEF*_-_,%:?1V<MT\$^.]6&C-Y3^<7
M*@M,E%R^.+M+W<^?K'@H9FDE<]HYZ[69 HIS*T7(\-;S+59,W9D6N\71@ C]
MQB<@LV8B8_!=&HC35G8JZ3G$]C7:*9%K]>R<94W<P97SGJMY![8^"WV$,]Z7
MK(DHY_/,1&M=M!9SN1!0:/[=_'G[*^['"/V1_9>Q?\[__U#[]0!;@['RJ=5O
M0@(R]P#JW!8!6Q-1[R_4S?Y*7?9OU,6G2GTJ8K+,OO1I?S7KJWU5)ZC3%PHR
MC/U029]W^1NS8&[*&.K*&)]9XG?Q\'HZ42L=G,189[![F&15QP7K\P1,TH35
M,/C),R6S,3<,4A2,>>Y>J!)0$Z^G@7##*!#V&X:HV^)S".;9TA879B9[=L;E
M-&>,S;I>K&E[L?Y"0W$\%HH @(L/9<=?@0LWT.U;R&6X4GH+N12@MN#<I/?6
M2';,/$:OKTN7)V[J 5]"T]>D%__US-!WP*BC'Y*_^/R9V8="CQ>DKX=-RWS[
M>+!,'C<(JX8*M"]+'@6_GO*T?FEL',UMLXB+V'%X_KHI[N+>ASH-PMV16T:'
MM5&Q6>G%6&3^>-&D4=K".29/X<"_R)0"Q;\+E6-E2QM&FYZ?_W[)WK_[&+DU
M2QY<4#]@G&K0/^_B2JZGNNTTR$8UK+1NWG6:N#236.(2F/8PU 1 !8\,W0'[
M2)/[UZ^",O7:O!-#$>IFQ[C'11@CE1K*I88?[??:<,_*WLF1DB7$V_ L8^-N
M!O#'7[*E.$?>2C_/%<IA78Z5[H[QT:&/=&U8RLIFUA1H7%9ZGO'/"/Y[KW%-
MWF=(SW#H^T@!ZA#Q9M9FW//U)D=':*O$EQB_OCVUX94'!)TCAQ*E*J>S\V%7
M224X:1:*DH&@G5FU&<E(#^$8:WB\L2HMP>E1U8X%E1(,OXML(T<*/>D]#A(R
MQ/J6J!U4_'A%8-^N&.'21>LH*ZUG3SEC.-\R"":#>;.R!2(XZ[V/DVIPX/ ^
M^?'<D<'+Q<G0[I&^)J7B),[+.X+ZR9U&Y[HOU&O+][Z>N\["E[KGV+$$1=;>
M?CUGF?Z]HNUG:D3L?'64*"SBKX33WF("L;RJAXCI.N6=90*Y F8?VYT=Y+#6
M20*O.5E*V-)BJQ@CQ8MH(#49 Z"7QRJ$O(T)"=7Z O(&7#-O2B6?1[R&P9SO
MF;J<.NS?XMSZ<9\X#)?0 *>CW#!/'UE@ZYMAN?W^JZ]P]*>PI[MD&E]\:>6M
MA^G*TY>G!?&;AD\P<CS*KS0[)IHVNQ/@$*E_\96%!F)^:#R3LFL 65RV"R1@
M3U]- [DO4.DW[5/S\ 6'-#DN_?W,RK^VSTK#LTYBPEKX1#IKU+4+75Z F">^
MHX'R'2@Y:KYCJ"(I[,2X$WFV;?.9&V #R**&;^:V75FSYH)MFZ([RPSIXX8O
M+2ENKMZB?BX%IG<B=J'PTF3:_RL3UH3W.4>.A[V20-VZBFK]-+S6FTX^-4-%
MWJ2!*IHU2AQE*5=EM(F6Q,C4:/ Z#<3GZ0=;#>RA4)II()^DO_= %](UH'Z7
M 0<V2+23B0;:KF/:PRD-!^BB?6[]XH-4IP3E:5CPL^<36#,32]/?ZZC].SU?
M8B0_@>/%^W<#NU7#?8Y-,PQOTZ;S+B?#^71_500&F,!_IOR?IYAZ]D0".BW/
MK$:O6U7S^919?.K'-^XF)6VGY9MD'7;(W=RY.' '++="_WS;_!.JAG@T"TEP
M: C%A@C3(5!,]AJ)=$E;O;G,X_/5.-JW]L8=L:NGZ_KVQ>#:1IGGG P*/Y]U
M_BAO'O8HLC-]1(A)S^%0F"BCDDK0R;9L_NV8Z+(GM#B+%*9?TGGWR8R#P;FW
M5PF#O9]>UXE-\)H8:? R/LL%1%?![]P;-<>,65]_0B7+6V3/5!QL+Y-\/F"7
M-)1EDVX;/\+KY,;4OIM=@M-#)3I=XN+>M8.&[KM*MIE&W191+Z>HASHD5P3$
M-OHO=,QS>RNZNTH4Z%:\F#XC-&E',!KD5F[PE*I\\OL<_?NTMD\B:D=YRXX@
M1E&LI"B=SVQ.*Y(O+.KLA*&^C36P0-NITN+(XJP:GRP+#935R?F@Z3X-89>]
MT;JOQUAC.B]TLDC_K0ER?Q<%V<>.7?6SVH:673G'_W<2.DF>VBDM6@^UW)=D
MWD4::)C%Q>+0)&(LM10R)FYJ\IN[L)EH6O8_/:'WCYYHCXSG I/TH9TP_,8$
MM51QZ<6*U7D 7<Z@-R:'6W)[Q =2TT*/[?V56^^8<*"CT(V82WC+2S&^A_P.
MC'E S,P,ZU66DBR]V<D'2,^@#*0 _$2@_%$F!UR,0BY;H:#1P*?(FIX[B\[#
M65="%^&]S!>[O9G(ITG,M:7O%;]0? 1F#^-"!.U56YZNP;"10FAG$QK(,>RJ
M'@[@Y-%[R]$$#;S#'I[QQ25RG31?8WIG?+&1-OG>,N;R9FX%=S,!LWJ/I);7
MJT$#L4N#!B^__%2VO^7%HH*VE:HMP-'=-%".\#"C&S.,#SE  W%14-E7A$]*
M!SIDOB%?_&+Z[ :SPWL/]?>'GY(GU&;:K&D@_V!O*?.)BV^($ANG],<4RDIO
MW@[P>K-))?4^=<<PDA0)9#A1>O8T$04OC-11U1@-ZR[=K.9Z>$ORJ]8CNF'8
ME'BDYYJJ23+"8Y0A>-4-#H93'%YWR!T-S,M7Y4GA"O**._+!FLUA9X@((A:A
M/,_OZY+).-D36:%"$L$-U_3#^:;[.D4TRB_:'\N+>MQCW>/R4A=*%!)Y!7+1
MO+=6@^UWQ0'0BLL4X9RWTKIW^F28V!>44Z\$ZV \;L>)QAH)3\=*$>!3[Q#B
M$F[^_4BK+VP')BC#ZQZN7&QZ0;'$[%I$7MEZN^F-AX-?YC\R]KUT#J2/^)*#
M/#AL0(RMLV!J6X">/(TO-[T:W-ZA2?"-R+NAXOPN6JM&V.; W!<=YO#.[%0U
MX\6-80!O^B==N3KX*?Z-^\8%'=6EXQ=#3/0_W!3QW:6LECL9%8 N2@BFGIS>
MJ"L)+/)QORI[UCU4'SD])/KRB'.;E9-<8VW4DYV[=C'5:R$5-Y]5< Y2;FV^
M7S%@[+7#?G&!V[9QOW-H7LQXX')_!Q/CK0LMR@N?R<&S[$2!CAJ^AFH']W8!
MD3KD_A33OGZ[W%;6Z/GKH*]Q+>U>0:<_"'_N?@"VWTPM4\&CN;RENXJB@DM6
M-^ /'$.UI(\FXV1JWJ\%*6H>N>++<6#O+N']ZI@@*)3"!.]5K(8R$-W]\ )F
MTB%K)C$9TWF?K9/#;R^6V?O6<:GG!#5>.]AJ1F["9]7-J8R@:JZ:U'D^Y/>[
MG29N[J:B7SL7'1/0+_+0"V1@1Q(9P=89!%&/DX)%Z@PBH<KF6#9-90?9&AJH
MM\>E_TN@LM;ZX1OX%VE/=WC(2)SCD+:$G5GF#VO*8]9_<CYX=FW17&MM/YY?
M6)19>L35Y 4+['Q)UUVR>;^.ZHSYXX>W;O29N)SPSV*X<4?;PL[STS5-#B.>
M?Q<NF<10NU/V"JIN)GN[9=X?=N8,@*NGNE8,A+Q2:XSB64A:^6C=7.;A_K"_
MF>\#PT>K&/[T'<<U-L([S/W6$T?!#SQ@K#30#50 C&7VIF2NW<:,K9%8<JTP
MV_UPUJFPQV=H()=BJB#IC4'OEM>B:*UF2E@&^@A"EK_<,GYY>#;%<JW_2"'R
M<C;,&M.+K:-"-K/G)%=:P?9<*9R$\J\K@\5S7Q_%]!D<IDXK1!J]-RU@/5ZE
MS)3B#P  1Y@O5:X'>O)-+@X,GM[(" Z5(YNZ,8<Q'[,./*)S2?=CXW.Q45&(
MB(!:X54^B^K.:2@/Y7+LJNEF/%)@JL\]U%L#C^(?:/+(FD*[\3Z/N230..8?
ML<-O(+81E+1PFP:R70" \%[D0835*5+SR""_3CM%3[IW=D5MUTUK?Z./;Z/E
M'NZB2_:P#-_5V'+\#O9V:V^4*?%H,&')B) ?.B0:4'WGZ!./M :1!/FNI'4O
M=\L RMY]PT\F&EO$FU29"5P=#?#]1?P.[*NH'N\CST\?KDA_@<@]7W:_H3BN
M<+^*!VN +[VCL,]GGL[)KKJ<94BM4Y]3?5]6O5YK$&QWF626?=]\ G?R"SN^
M3R\E+4''+#DO@_G;7-_'WZ:KMT/=QQ9%EN";[1L@^U11N$95&7PSMT'\Z)F7
MPV[EGV[*?]61T*B->47WQ.4-H@K#0)HC*PPCG%;O$Z5#B^%!?3VUK0SVX3W'
M(,%CT5?-6T@W!PJ^OG6@L/H?.."_.W]XU9QT!(K&(&+K:"!"KE0%Q#0?K9:?
MR+FY^:GT/O7Z9D/@%W?&A[D?0/3^MK?B:B[4 T/;IX]DI/!V+T>P5;D-"\ZD
M'#25RSM2PSEP/>*WASL/Q@VX^^Z6.'<")(R,\%9VXF[&\?.6N92:(>+=9*^8
M3Q:<-*\$'U9]_\ZE_,M^IDD5=(M!(*J@I7S4R1<JVRVEJOR2Y#%Z-"Z[P>WY
MD3%V<STY&>UW:1$\4GK<MX]#D/*@2/L%@][6!HM#1!JHNOSP F"$9>$ -=&/
MZ75C]CE7;7Y!X@'CPB.EG7'U_)%T$BI&R2DU4*?-"JMV;WGB!1P\?&6X<"9)
M,KQ>/&JO;F7K22;Z1#;9FISUBQ/T8JF$<\>Q-Y.]:E#L6 <UF[H*]M?!E7UJ
M^8_:&E+/ACBX(G3%"A;9Q4#DL1W(Z127,_-8.W004JD-=4N:WMN2T!,L0JQ/
M3J\1**X/<R)_2!-M?R7V7J>&R65/D-A4;*>Q8@UZ-XF,3YBS3O>^W*7*Y$68
MT&B3](X5?)XG4-?QTD6+SOCB39'F*I53]]5/Z!M]D8=^28M[</V,,N/3=N.M
M-2+Z?[;DK5@FO>9( XW NDOW3%!^?Y^,K 60J/%_;4&*TX(&HJHZHF:>H,0*
M+BW00/CZ">J[DL7GJ_0A::'BC_^A22$>2)H:Z28%$ISJD8*:2T<KVB=,V;LM
M ]-@:WT9'A?+K$2B3D<&J]FFPDY2^2DWJ0#[^;N27K3.292LEKB0W!D8@OI=
MJEK 12[-46MJ+]9FV?,,"/"&(2C!(\2T/^!9'^E^0\FFZ9EX$_I-C-2(#?5=
M3^BTQ<Y.D]4'7= ]U3+/AA'M_.G@@Q+J'SGK85/W:S<Y3%[30%6G;B\@N2E7
M/I?99(CTCA(9@S%WQ2.>BB.G<(Z/Q[2=!1DW97E:Q-.;WAT=GI4?U8< K%4#
M#T%QEUDC2J_F9[QX$/$I\>;U)\^M([2E+D\(16;XT&$L">BY!4)K[=#!5QU2
MUWK*E+E2JR16)%VJKA4EAU36O Q7;X%>!_'R'JYP)DT0,)<)"[.\A%(5\WMF
M?7U?Y1V,1#M46#XV3HEO."SMN(M'K.7;C#J%LH^B[GO+X@9M\"\%)0O?IK!;
MI=E"]_[VKCCVVL7&\$-&)RY<+_@@!/*+47UAYK>&KL?TP:I0=.FOHFI-N$U.
M9M! %,^ID[<%'3IK5#QV"H,4G9>.?YAZRO>,X+3Z@J!87VZW\%L[ )2+4/O-
M<N**DET&S*^<V.MH39=X;M<)N@&Z%AFX /7S250(E!_9F<+4+0_C C,[?IX[
M6$34'W^<4&"N(_!>\ZB590WTVG7/N"7 4+,K@;*>HH'84/81]%=A'$\:*@ZV
MX8[:SRG67&_OS>M6IA?_P*O1?NI)XCX/,7\$G4LN'6PV#M_,CT/7TD!]_+4I
MARK,68[6SY:]WL]\8'!@YR7>]<1(D.!H10U)ENC?A+<)9'RP7,YLUK:< W$H
M2^J4.=6C[H;P/T-^)*AX8(>G#2,DT1A-[]8:(2A-^JH0@:A&[1L:L!//S!:9
M:_?)O%;DZENEVOZ.\8@O];#]LN*J/JG#FH@9F8_*KH]?+7V3%'8MV[0_^U*0
M:>?>%WNO\=[YR$@?-YWY]"&##;(+SHP4HEBT>\-2$;+F;]KDE*66\F%]-T)'
M31??GW(PXE4?JO/8^_"I<]+Z"R<Z3;($M0>U3U62T /OQ#C(UY?H6^F4OKV,
M<EF<C6[DO(C*W5EO<C!?8\RDC09Z YX3AME@Z&HV'Q>TCC9;EIV\[>(2LY/>
M>_;=F-0(:+YVGV^//[*!*DV"X5HYS6:&#I'\1$*I4J04Q!QEJFBF73(CT7\W
MFU:8[?5/+ZY$OQVYYJ)K\JJUO!Y\EK6?PV@"NAP7#<S\,]?^E7L$MCV!P(NJ
MTKW+'P;;0V)O4!"R'@_,?<P0UN7=M>_YAN]G.AJ(?JK9YXF%!ODJ0H(TL^I,
MK/.OO9DRU#A<5>0BN.-HY=HA'J2\<]N#=>W5QK=O-].AD@BKZ@U6]Y(.U2/.
MF%=SI7JN)W/6KAU@?HIJTEC)1S700-Q'B(JS=",P</6<5*[SB\P'Q%PN%8>P
M$U;#]N;."[.R7U!5<LO,K1R(]'JH0A>X[T9A1YXJ[/;BHKN86!QDOH%!?%E^
M# M&\@X#<]=R"L(LL#=),&#T?;*A9*>U=P:3U+C29%M_-4SP9'>IPQ<S-!P1
M@)]+F%VP'QF^G\)+2%Z+++.U?=Y_ZFZR#*4X7,+2>JSOBXB]XN"(0*VOEB?*
M'U9\)*O.@,<.R=RC*IN-@#3P>2-=)S<"[OG_5OW02/^%#IU?E6&T!B\(_Q73
M9UY50@.QT$#V+'KUGN,9>#"8!+-X$YX5XGWLT.61:WN='R?70\^W;0[M:W]N
MPV#<,-LUXJ,XBJV_>KIV0WZA5O)FR\?JT2Y5D]&P!Y]<U]\L[%:_<R7ZAD2J
M<OW T[NRUO9^,R>#YZK<\NTWNK U44%\P[7Z[-JN N,%UHIQ^X649;(CF@A,
M DSTF<HOHZ*&^8O 4:A7"^%EVJGWHE_H63NYV;C O!Q.#/6S103X'Z\,.K!?
M^W0TU(QPX/2(#458D)>X$%IQE$1O&DHH+\\*/'J\#TYY\>P1V[/D@IIEL0OM
MY4>0@IC[-) E#11ZLO8D_('<K>*F\I-WWQ Y"LI:7Z^"A[)_.UU<DF*ZPWTB
MDRG_XF/!" )Z-2T8-U&-NE]!3R@)RB0.1[BQJ#%/*?2$.;YIB[_.IZ, W0>]
MS0F2,HV601?*K98^K!_$/(L<(N(OR)>Q)1HIXL7R+^F!7!0Y>9<YU_UP3@S3
MJ$*1@ IVBCMAN80O,CG[4+!%H>7SW6,N._:AQ0]6"A,F@RO$ESMJD(<[O*_A
MYE3,VO.-ELYU.J2_\\<I@_E!&JNJRZH!,8;B>TGLH]WH$328VBLH7D&:&X<C
M !VHOR2G'3&.".(ZGOUAWXTKUR\UT'N(!"0M8TDB7 EN3CB4H!V7OK#%WHIN
MV6=]35)30DSCC!**;"<R.2=R3EO \Z:3X)6H/NPHY %5!J&[4)ND4-3^(7W:
MP#+!64PV@.=2]/W&< F;Y!J;L_*>W+/,N&1#;VNB=%VWF<!"4-G.O"L3VAWS
MT:E"S>ZG0A&UMZH\]IWXPC"GE$4(RUF-=&U%KC_/F$<TR,7Y_>J \W>'7@W^
MX'HP-@A"X>L--B91T7G7KLI\\;N5%IKZ+\7^^M6C,10?6Z&RDKI/_ _>AZXP
M&BAI8R22\?$@,C,7/V B.Y":%NX5*C,/F _I@J/ *^B_^KN2R%TSS(RH6.U>
MNDKHCLFS,-MK/C#-)6,@K#HQ9F-D\E10)?1S3QDL@Y2K^T2ONZA?W^KLTP#)
M. JS*MNU );&RIP:L9B8*M!J+FF-PVK@ NOI4P1J L[AZ+!>V]U^?8A^R>#7
MRU\J7]4(FA;TA8*N%++=V:4#+0Z6KH;37[&']RV29&L6I_LIK245"71/%5S1
MLHZSY/'2LJU6B7;N=F-FOFK\T5RE_Y:3I#7/0][/)Y66Q1!"A)<0%HHL 16
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M.#>FE_.^)1U"D2(Q36^-P2(?HB2L>,<"?#UA82E04L3(3-Y)&+VW)&S_:+)
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MJ:3'*U )0HO"%^B?;.:5Z5CC(+U1HY<&FYX;ZJ0.FFIEO*$7)O((T5-W'B;
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MS;KFQOCK'^>!X]/ GXR+:2O@[$WG<;'H(=2[D_D9!&W/&HXW&WP3>7DC&6T
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M,3RUU.SE#E;  NB5.E)-8GWS#NHV?8F"G C+3-5P7^!1H80NQ^$VQX)1V[?
M8HI7WEO-#@PM'!5]/.2##%1ZJ0\_,VER DZ--DNC_[2R&W$R>?QJXRU]9TTQ
M^)+GEUQ].I,Z ,@5$?^<_##S)O!P7-_R[)7IIBUOU//GK51/&?(GBGW4?K>>
MA&JB&$ZB1WKAR+'BQ\24L176.5M399!);I5NY5]NJ2NB$IHTIP)P6X/(]ZN
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M;3<_5M&4R:SE6Q<3BHO[WC(Z?$(U/Z$GF&M*94@J-6LIEW_"[M&1M%1F\^?
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M"1=YO\Y?QN*"YJPJ=J9B9A0'7-UWCZD&_9PIF4= 4I?L-)=5'*HQD\E4>G]
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MR37CWR6GEC%]F_M+_$8U"B\4C'12+K?HA+9UYMYOAD\5.S?4C?H1^4E)1B"
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M)"'NWH55<A(4[-A&66XZ9BDN677IF:Z(76. B2[;DB?-"^*?=#_.+$;\!41
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MC>K$]_?L=GU>T'4 ^F'[![#@O2AD)<89 =)\%!O,-$P9E>^T*;B)=/J$%''
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M1'&$7U-I5+;53)4*G-V6T#3K&PP7(E."FS29%*^TQLIGK)"8)NRX0>& @C\
M7.#EKS/09"T*AW6:9WA=YRG*\%M.+1R50T Y([A8,$1A(O+3<_U 60BM7>)$
M4S8\&VI>4YFH<=?O3GYG,2C\]<=0(1-R_#-)U$+ 2EI=T>H?  9+0#'2EL[>
M+B4^_.P R.^C=&8 PHMBQ=[ [']"@ME)?=+/&N"2BYR[;:"5J_[5Z!9QY(#P
MB>&E:E]8R+!?J^3'Y+TC,RI&?JPK+@A5/__ N(M>0IO[?,[5M;#T8HP9[ *4
M-.,-.%/@K1 ?D?IJ^.'E32_HS:6)/M(C*J][$8C>$0RQ"F0,_8CEB,MN]A@S
MWYF?$.LZ2'NB!51@8 O+A^C\ZK[V\2J-R5@7/U2-9W D-: .JFH[H3_E<P%?
MRPOLT]+75D^7[7.[^0\R%Z@2&\J54<A0I QA#JYAO%M_("71F?G<0U*@'7%"
M&,9?\H%1J&:"20[1 K_--JMX[,BD%9EZZA/MOU4Y.-G&+J9G<WD)=JL>=,H%
M[^(0%)50Y"8.&82A/>3.OID_^E;!;'&JL,/=0FLZU:+L/9NU -:->\#E]8+A
M]#.V$RJ]<6TRO2[\#P ?]@>P2E<]'J=;E]Y#(T@C@I[B[Q0]C!*D-*<UF1N2
M $5C@_DQ-6 4MHG>=9<9.=L0#YX,$JC;Y6 G[#.-3%BB;1]E8"Q<P4A^6&_&
M[UGYC4RQM&6FS?B2%\(>')OPZWBA& NN@ 0^=/ HD8\&$J@R 5+(VC"G7-GS
MH+@&((%TY-*2J8^5@Z+-_6;X_DB)3RISR[%O1'33#_=&HOXXOX9FHVRPA6@G
M%O*=$FO+#-[/$)]QOQFF1N)]_(I1LZKZE#6\1<*R.!<(C@AF[F)XF/- *T0>
M^R&MSTPENNJ&;O7H6M97#)*'<S?!?75W936T,8^P6"L7O2Q+EOH__8_^_Z-(
M1ZZ;>W[!@@ZTRLOW)P[EHQCK&A&Z>EU]A?KI[N6@9Y& @@D$QYHOI& 7V1 F
M_AIJ<GF"[!4S C%?QG PR06SH*O9-G(UR(-.MY@?L >8@ZX_9^W&V>:Y*4MP
MVQ^2H1PDYSY9#$F?S09<=6QE<,>8ZXNJAO&CO,GCE*:@;FPY8GH'5GIO,MZ\
M3WU^<NL]\JOW^T?2IMG2M3;]"B*9C[\^M,8Q#UB<K3-,IS5\H90R>" (W0K?
M+=UW:%%?4U;5GK2<%I>PF'FY(+ \3X93;JE'V1B-9OI2['YX7U%V"%-F$OP2
MZV-!)#_>_'S(\,3RLRZYTBVJJ[ /F[)TH8+"1M3WJ:I;V<[,S)58,'#0XSE7
MB@H5A/O,/*O;69)GPJV=<%$/M3WL46*\K"\9*S&9'?IF"(P;2E1<2/2,O@\S
MA%3G_>3F\5(=;88UU,L\'[SS!=SI5@ QAC8V:_'@R;TIH_;L$[:DBHA+)0"(
M]K= (1"T4SYHO=L*:3HUDCM9W%NK4!3MV3N<MM#^!)5\N<19"%VRF4";]+ E
M^5OC1BW(:V#)*5Q48-4=1S=YK0[Z^.TW-QZ2=TZ ]Y-959>Y=K]3KU&%&9''
M#"!B* V,KO<T VFHE*:SOM@@4Q_LGO;HZTYXF<M&"2F0IU:H]V:)KV".G2^3
M;".Z%Q8@OUH_W?XPY\8O&U#8"PI4P*:W#N\]L8YA.KYKS;&IW[-T*MI5ZF1J
M:?W]4A8S4$&>N>KG>W,X89[+$DV-:$+=ZF)%6 -D]_1K6W7@#-5+,PN^([*=
MS4 5P2PF_][#,CO/R7=M4^).JQ H0YR%^Z] @8D2^T_)S#A-H4KI&3)2-"_:
M/]?ZH-XI2RYK5Z7?XN!#2 ?XB^4-,D70B2HG@E$EQHIVIL7SQH9OF]=#D*L6
M;@9KS)@=_15BDP=+1UV2^&/0<\X]J+XRH@:2ESR.CI[M=Q,BQJFJNNDFYAWX
MT9 TZKTC2;!]:G.'416('MXO5YHEY'+^8>ZL=!1B(N=EV)(^EXG?*M/SG#:.
M+^2^(IG<M]1&CAL89@N_D %(BV _I,NBK7MQ%%X+Y=FDLALV^XY$P[BZ\6;Y
M<OI;OJ1(,XF%5U+L!<V2;ETB6D-B3E[UYN\IMK9[:<R\!HYT'EY5S,_R"7:+
MN=S-D&S%=;-V&>/:/F<-+\U0KXE5HJ6N;] +)Z[B:TR+9#B)&BCU]_<AF,+8
MQNP6Y;1=GK<KA6QI+.KLFVV([T<KS*=N%=BV>GD]BBIM(-?HA3ZT:]J,_\Z!
ML1C7\: %)CT&>UWI>O#D]QWQZP,V6'SZXP-&D(5;BE<3N=P#OAL#$1=XXYYA
M1H0XK\CQ939OG;*'8< 0%S=]^.QPC/UXH^?EF[SP-3'=2GJBH&3 =M:)U6</
ML]E*.U'?>C-5U@-VUQ ^UBM<S,CSM;+7H!/!F#(9\63W$LM"&0+Q>6X'#:T8
MIM=\FKV8XK/1GO5VGVN3,M2K4O2JH,:@!YL?V.901AG"H9]C W^FO&?3>(^Y
M231F52\.-?5:TR^3VWH[ 4-'TW#NG[9VER!;YX6>]C&^C9<[J.I]V?_(SR?<
MQ-LH#@UE,CAKK[ZPHY'OIVOY_6( 5",A!&6EB]*.Z0%+7-3M09!M21\$<KE?
M%2^S3 %H+2Q15<XBPL+K*[-IMDC\Y0AN6'0*:Q@/;YQ<.LIJFFNM2C65A_N8
M(2I#6#Q0RVDV>?KDQ49[V+E=F&L%[NZ#37S&0^9D'W;NJ')3CLKLZAC^J@YD
M$K4%;9*48>-U&:;=)"0!N*V18J=0SN/ 4Q>+9SM!_I.)D679/S.N![.BG+.H
M[40[(F])UMJG9&X>U8>UX%4>2[T5X*_ FGQRJ]F57-M&>>++GF\D'F?CS<_'
MT;%OX7HFE$FQD<A$[]HW"IZ:XD\IL<N@F%\N;^>]3)L<?/@<&NDBXX.;7<R>
ME.7XR:GVR/()@"F<"[O(EI9YHC:E#PIS W&"DBK-0]"K1(O/ NH4^[>B.>CP
M]KI^T))-7#1$@O,N4G5"F.A-G[H2!LY1]GBON);3CI <M\Z&'=1)D*M-+:B%
M8&!VVU_Y03Y#S<,Z3AD/-)@5<5"U'\\DZ^HR=^ZKA"?6*I,P^_*T/X!*IH;D
M_H^*_;^%M2.M<RZHS_DQQG8^LHQ?M(O4'H '_@#VUZ[:K9H4Q:ON9B:<)EM9
MXM!1=$;);R?=?&CD%'H,[0\U-%*OGJCN&>GXY.]YST04[R!]=1#)]5_&9=V*
M=LQZ=H'5\A'J#%IZF!5)&8D.6EX,Q3U9V:/H;UO/83?,SXSE<Y;TI06+K$F#
M'5MB[74] X%_ (*3I_ <*Y==C)UD6#C_!]M=T(?7.E7MC9$.GE '#7DI J"6
MXOVRQG]_:K1!ENW7:XNV1FU,>?'"8(XQC"8K&]+,+MU.R<&QGBF@ADG7&'QC
M/>/N@D49_.[I$F1^!@)+5LM=C3J!H_&-_(D[J=&P2A5V8"D_BNRW4M.$ Q-\
MXY!KO0&DD""HQT1,BG&USO.T4D*5>@P;:KJ&C_N^)7ID%#Q9P<LLS:'?Y48-
M!\:C&MG,%'I%S@4RT#%A8-70@RTBP_EEVY?#),H%>4B<-B]U',Y^"E1Z6K-;
M.6=7.E5+Y;7=,7KV-]#.9U#_-X2'4?<QG)9:3+A':@ONU+E9:(@$P8Z71KMX
M5P_>&3HLJWW*M3G?>2ZQYTQ3_G!N3H;'"[]YLY/&!G/&^D0ERJZ$)46RHJ"[
MZ!4'=VJB0@WQLNM#5A&)QLWLYI."T//?7=8NY3N5AH'2(?J-TYUJ. ,)HX#
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MHCK+BBU/C$?E_\D&P[*"53)Z.Q0:9>J6EPR_O'WE7JNSB\F/=%8/<W&%6\C
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MR5Y9F>RLV&G,W>5S!*A>C1!9-#P!2.A/>3*[-J6=GMVZP+[)E1]A7QC$PJ8
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M4AN J@%C#4!$2N /181A22BU%FG:6=CPG<#..7!<N&>_@)^"'*_7QHO-0J7
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M@8ZQ>E%A=KG0*1$R1E<"M[XPC K37<S1P7,DTOL?!9(NJ4%'I%)I60)@400
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M]=<W)5H(;O^58& T6VBVLR9R8&ZO.CT\;1V"4$25KC$*(([\JLX:'%%@QU4
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M02>645//POXH!Y5Q=\Z/_&\".0Y_8!#28S[E+B_A@[C"#ZGSX .]81&9HHW
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MS3Q"0F, W:(L='Z(:SGPYHO*QR I\:2M2<Q\X5Z44.K<#)SLQ.2XT54CGW9
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M5"B"JP;\#<:JK 69RR'*0<B=EQD&,NH:[/37'[;?G_S4?CWHJTI>(HH\F!2
MYL+%"#-L!]46I+8!NILNA2:^?[B_T12_;KCR+FG,I+;V6@GIK5;#76!G$Q_<
M%/@VSEGT\+JBZ9N5J+>;(Q-<W%>5/E>=/5>BB&ZDP_VV"'O:#@U3OV9]40^K
M+"]KH[S7 /70Y"YS\],&[/,OV7C@O78(</8U+IU#1--8./X:^VJ7DXN;"SG?
M:+8W)G*;>./6JZL9UZZPFL!-Q&'EMH+]X&1G8]Z =T7?KC?:; Y-/2(L275^
MLWZ1LLW0D[,"QELJS=TR=XTJFR?A*D>GPD7FTMQ=]F>3O;;XZ& SGCX9?S,A
MV@9>"A<N-81K* 47^;7?-:1;$VW2*Y-ENN+.L]S,Y/?7^PJXJN"+)FVY<GT%
MM8?>>9?\4HP6_%%-LWNGD:[:%(^Y.^=:BC>XO878SAGENMEZXV)@1DV#"'@>
M.NR=PZ_QMN/F:\L_T!ZHQ[(<HMV<3]I[7LV0FQY/LSMJ3-/ _*Y1JV[J\=3A
MA:T:)F+!"9(VAV<2Q00>YT:TC0N%-G^YP$-KA;:!@NMF)UKG<']K7RQ:GVTN
MSNQ9DS#0)'4<F>*FW&N\[D[O/K6=MR*L-K.^S4J>1SU-J L6N/,=8QZ7PWGH
M@,).+'-X:-/[H[PTKJEN&U!O>M-,;L!=E35=7MMR?MQD33A*&^=)QN9\E9@X
ML+W*^8PGRX],VT_C1G,1O$D3Z*8$Z.8>;<2(BY=5L*<J4)D%&L7S&_YZC81S
MJAGL3IC5@V;[34WSMBL/ML4U#@+"9;<QGH^NZG.F[I\ %/8Y4ZO+F>I!TWVS
MIA N508]?K.N4XM-J_ DEPHSE"KL.GX%>+O0;>YW@SR<7>[$M?.DSUOM"^?2
M-.H?I&EF,$"G3)Y/#.ZV WGS!#%Y[?R )LV8 8(UF:]U4Z_0VB%-04X3?W &
M0)-VD!73[.*-5C/-B^JF8[]K(=XFM)^+W)))CC .;:.1]W5;=3_)!0!X- UD
M8NA FN88H(6YMSDIY;C&\UC@K0"^I!E=HJ^BI55#P?9#W5I1 U!MKKI8E[69
MZ@DW[VFK=H?='.4]4[B$EX57(W.:WOBHDJ]UWEKP!6\T#W>X5K29_1@.F4>8
MBXHL;WKO--W!VL2@><C9M 2;Y,QA9_L9))YBQBGP;FH_L.,N'A'DTG\0?R[@
M (000 N0BQO3&,F5RIO$FB;=9THS-QL,FS?!ZP;+_BPK$)[/ 8WU,G#I)+W>
MN6YV%%>#[&X#=$UBD3-K/A5X.%HK+.8:VJPEK-/9Q62L+>>1PVXMQ?_Y]@;@
MT%D]S,75ELW-EUL6UK_&-9XC-'F?NPTL*-CH;]WR(3#S_Y^]=VUNV\BV0/\*
MZM;Q*;F*XN%#U".N\T&QG<1GDE@3.Y.Z\^462+9(C$& @X=DSJ^_>^W=W>@&
M0(ER9(>4<#[,B2D2Z,?NW?NYUBK_#K8Y\U6W"5LU\G%_#('>:^G[ KO&6U2[
MHE&"%3GFA;WSO?4#>\>:NTMY<C$\&4P&)Z<7Y\/)A)85JN4S2NNL<G%DP1_5
M?BWYPX7>8JW?;W:\J@X(+8?^W^Z@= ?E61P4+K&^R\SNCD=W/)[U\9":?O''
M<F5KR0*N'4\*0PW6='SQ*??@2M68X%!PBT41<5DM$A+:'X3';>+^QL=F+T^@
M6Z01MB42V>9C\@]?=:>V.[7/]=3B-.7F.,DYXEQ=0D<VY3+60A\L'?)2NH)<
M8.J[&Z\[.\_V[$A\A'OF:%;Y*G0"ICKYO:8#!& 9X3,0^%!!8F">JRJ$4J'_
MIZ"JKRA--_UM9ZR+<_TY"D>FF-6,H%+^P  2\QHTH@LFL4+_(]-!:$@81E"3
M%$&Y-I3! 51E*5O. 5BWK$F"QDXI$_3MD@'&-#EMSCGA)>1 DZUQ?EAW('$]
MJ0&LL(@^495Z,,(4!J.3XR43T$FC9X0T<#)/5X G82I?TLKA5,6]8):E9#'A
M5S5<:JY3X(*),#?!<1,G*):@DZ,5XG8$DE2^1[A<BH1"A?.-V&S-]>$8>:J#
M#G'$%'-?-*=:JY@+).J2;?CU5<,!'8/CX6!P?)W&<^0@L,9>:0B3Q.C$@K=7
MPEY?[>832E=WFN/+(N3MM"[A_"9,T+OG$+L@<5,_^7?B?W<]9?LUO=U H0WH
MV'PKV#_0WTN78-OO'V=63\U29#L/#B2#LF,*Q;7!=W$$3CL_8,_]@).SBR'Y
M I/AX'1\<?:L_(!KLHU@0< R2[D$4*,..IC#GEIOP$ZLTKDR:&4@OJ&'Z":,
MA\:4NX/5':PG<[#X-!FJO9T/DP_O;<Y1=XRZ8_1,C]&2WJ">/.??0<UOVVR:
M-?OWM4ZZH8I&,X+/R_+*\R<[1=@IPF>F"-F>P+IP'DL"JEYSOX18'>PJG*1K
MPY$$T&$V*<)-%Y+_"MOS"VU/REU/MVY#4E@X@=T*4KM&O5S5I2(H)[@Y!5>M
M,J(@1W:C:2D^5AON5CUB)Z73NF]98OY^4V %KFAQ!ZT ->-Z=^,,'D@<N>M[
M>N0FGM.N[ZGK>]I)$*=I//]6-O5;1S,]!:NZ'P3ORXQQK4TOC N [1+0W$G.
MU=N"G^+@^GJAB5M@L81.NU<;$JO<:,-78'%%9K,]:;![SL##F WS7/K-G-2H
MSDZW9:),C,4FF=OYTS#?VH7FPZTA+5OQP'J)6306HX-LG44KX->:YY*]M4XC
M].M[3#*X*)%= =B'!@IO&WA2,G6K=\\N4[2TW;HT,-MB2))F9T$,@)+,D2.[
MQ_W@!X%0[TEM%.17<X.HN2;SQ53,%+8GHO.2\]99M=#\8N3[FZ_=*4SL36-;
MVKH?7-[QGEYP)N!8#WL94X$LA8Y+3\..G!_0%+G)^(7\R=O"H_7_TE$?#,Y?
M6E0$5_;6?!YT/8Q(-9>*VG9 YSU'PT&P$O$=X;]>LKA)K;:(FQ4S\&769&MK
MUK\A9 @Q>H)FJA?HQ]MDS%B+C,(].G&$BJ?CB@S/C/&T,?S[!:YV9HR410).
MON4@MZF!H[.+%W4@75[27G ^;/R%E]A;M;.1?,E[Z'#".W&T_N^X>,4[/>0O
M\;3;]R#*:3JO A:,D_%IZY"\:58_T[\:G8W:A]O^*Q*][^_>!5WP?_<^P#F\
M:ROX(2J#^1I:F+F6,X<"%3\/](521CLZ>=&RFV=G+YI+<],/3FF7VS>/M^)B
M\ 5;,;QH;.#=6W$8OM"SLT"_,D_L%GM!1,6<P/8SAVM^%V-AS,_2VGREPJ1V
M&$UQ6<43<(T2-RYMLU4\YN1)!9I ;[5K\,<9-)_ /SMH[T+5I7,_1+I=O[':
ML%M9\6V]$>U*AMXI!DLGGW7;*4]7C-989/NF<6G:XJO13D%UMM'5A%I'VC7F
MNQ]8!_-(*!)-'S\J"Z.\8 .Y J"::6MB1#JGTR//4(]<!NMCD%<HH(=IT,RI
M)1DRK)26*D-#,;"\BV#-@W69H4J4Q!(!1<!H<Q"0?QS:QY.@QN (I(^9DA-0
M7QQHI+E,\ $N/CZNN7UOI@3C>-*'O9T%0_W_^4'.0'M,5^DB<>MQFU;\F;+(
M&5(R+E6KV*BUA?>NK''YG%ZMIZ:!TV1ZY!NXDS+#E\EMUCA@,3 K-,DO W]6
M9P_(& [\FZQG=_">W\'[N"6Z0=>Y)HVL,8Z[X1!.LFP-?>2,J!\)<$P5!J$#
M^C'\I,#J ;\6')2AT$C^7[C6-)&OEW3']704A)V>1PR#U*M0!.'ECE"'O?VC
MY&%1CN?'UO$MHYT?OHR*JU7+[>NQW7TUGD09A>-.?'MJMR:'V&/$JVJCW<D1
M.*X\ 2\NP,H6=K<?J]AF4FM-N8YI+Z=I<,3O/CGMG[1%%NCS03.VT/-<B=%9
M?R*!(OW,5T%K<*@19[ +51O32X&?!F#E_<OBK H,OY/S_O@%C_OLA5"OG&$&
M[5&PYKRX#TQ&X=MM0HR7T'I&:X11KTLF:G:NR,+A@C.4Q#<D6R[&A/B.W%AH
M&9)UM'5I*XVU3X5/MM'\&0 R>J/& 2813I-%JL'K#$FHQ[S71@)([]DJSC*P
M//H<D%P52_YS!?L&Z/A^<*4$,(\YVM>&?".WQ@ G_X&'-BLX\@SRYX+9_=:6
M!L8E=;YCG>[.]0B(_0//\DXW<9< WSV;>]8EP+L$^-[9"R/77FAAQ91@U?8;
MO>?>#B=RLS<X2C7,.2X:75 $IZ+)51HYG<';2$KI]I Q-8*0&K =M\]F9^O"
MOT&KH<CHE.5_51P:B"5P@K&Q-L8XI'V9AZLG5T4".4"(R.3HQ+0YTS*QE[@]
MM."FCUX*Q9AK4N@KF"[=QBAZ+?=X?7NJ\(_-%;,9Z$0O#6'L! 9.+S@=]$_%
M7C@;]"5_*HNH>Q5J*U:/Z81YW2(:OZCVWY#(FDE=)G<]7*)*S8_Q"+GU->*.
MV"("Z,^3Q._H3$2KDN$<TT1QD>-<>\Q\(VIK(_PD-B).@@"#,^U'IX8>40U5
M&6&W:,3R^=95E&<R:7CV/\N^;.Q$(2>>[DQ*W'L:M,T>!/VSD>EO&6UY4HW?
MXG;2\7+*DAUGP]2-!1]_>W?U\]O@ZO)O?&/8S]_\?ODS?[I3I=CQ3U=WEHC=
M4Q@FRILUP&WJ'$/#!F$/GR4Y-@$/MRNEHRG9I^GM0E/"[CIMFRCV-GLPRAH6
MH6&XCENRU[F(O0@=A"JJ@>9X74?\(-<LY429_MM=)5?-MJ=5^IDLF#C6)+:S
M.,PB!+96FUF4,*V7]PQ_'#+HE UIW!,Z8%*=+1.*"7-I&."1M;"HX.VPMS6G
MC[7-Z7>W*D;-)9]$.F/8]@C7A2X8*J><BLO=PI_O:!0IL/*]"\V?FN5[ 7E3
M1@9I_@R.8>^@)KAM.I*-]3=XF=IR!L:=JFTV^.$=27^.>W]0N96M.O@']NP7
MP"]%A]*ZS-9PR7OM+CCK(\88AHO%)0EW5$?:FE3ZAB,A6L.(_:S3H8^LF6M:
M]3!R_4''5?NU F8P2FO9&FU16CMR5YNCJO\FOX^O3,Z]%RB'Y>LV.%J]^_CQ
MI</D?5BWQ'.U1ENHZ!#M.S]!SJV6:6O146?G)E^XB[:B;Y^W]1G4'NS5HW,6
MC]L0SL;U4!W>6U/$5:>"7Q*^5IDP#]$6>$**,LFI+HED 2<Q=MGJ,7[2ZVK>
M:&'AA;+/Y,!=%*)IXY $HY-[3^XO!LB=UYMD6@3_?-@?-;^X5?+/1_WA%TO^
M<#+92?(/X\+O;ONO==M_H3U9M3.UQQ1Z6SIG6LY06^5>;23:1[>:5)/0<Z6
ML9$;W3>=T_TDM&X_N%P!D]L5 /&Y#FEVSW3S&L?];@\6;K+5%%P5%+*-=8]N
ML%PC=3OLZ'P X_&&7)%3&)VZA8USSJ:P?HN11[^=P)S%;SDE[!6U519C90CZ
MVN>0=N^Y"J>Y"*JK 9'B6ACZ&6B:@YK?KEAK]QGDCZYK3B=&UXR'_8N:OKA?
MW9R>P3G ST<7377S=,STKIQR]]K \ZZ<LBNG_,N/=6=_[_WTOM3^]GSZ1[\1
MS^R5YEK?P]'9+M;W$,$OU_IFRYU^*YG_0]J=3OAV$SX.*GV!!'9^V$%,[\_X
M8?>8WA>HWOYBT_OL @FI^TSOSI9XA+V&ZM[NDSD=Y$Z$>I>&\W!;%>7=S>80
M*]U?WM94WE:VQN2S#F+WW65LV_K2VQZ;HT5OY3^=OGH=97D1 +#9;VP[I*/_
M7(,2%9,4X$;LOAHTLL2MTP4SAM9'W,[ZLB'S<3ICB0;)Y$Q9V>T'_[CC4D5=
M&H!\3)V\J4DZD)!"E_I[S.4$;BI--5PH%KE"A2O->J?6W*:;%5$NG2?J1L7I
M&@KQQW=:H%0)G>1"K-=0N^FY[!TR(V24H>F7'QHQR(WS2+=KI-"ZN,^HKJ^7
M: EY^UG-2J[K?8].9331?%09/2=X7689^E,P:@: 9\B>T2#8J##CJ\!YH[8-
MZ="MER&MZHQGP+7U\Y*LCDT_^(5N?7DF @LWW"P57,$2F3.8YH]Q.J4?O$NN
MXW"UD@.*Z;U;K<J$MG>Q"8[>_7>X6K]Z]S+X@1XS6V(%N=R:^[&409G$2*IY
MO4Y7JZ@HE,("O%8QK1P^S-:IU@+<*C :#,^XH6PPO/#&^J^4^]C,#R,LP7 <
M:*STW_L?^OP&E<UP"?ZDPKD9@AYL-5;T"'&S'E:JC&+I*9R19F'\HD@9+O99
M5G(K L,1D>1H*"3%<]*?5[5A=.65B90LOO_X]I\_7]I>)+B9H.JD>5VN:/@8
M_:_IC2P49LJ5"O\U'/=/:.OH8G4:T_9;676ZZC'#3O]91<&OX;2,\Z@7_-)_
MT\?_7O5_ZDO;C&B*]VNE2PRLIM!8821$)/_!&[4NBXW^]B_<ZABS0'^815++
M/S,_K>LB<VQ^LU6_I(;H5/X4DBK*ZR_ZH!*XK?_ U6P5"+_)/$?KDNIQ[@O?
M9'TS6_[1+_1O>9$8P!H" J4\=&!NTM@TZ>H.0-:MQC9LU:^/$YT_&-G\\VUP
M=]VB5]&:R6X>33%]O>%V:NFQ/=CK-(X%[G-&=@4*]<DTR.A%.6LF#<GB'<IU
MEBXRNC,?*YSPI_>B/4GVI;F:AZ_C[HF:;ZB3(N 89[/__7_H/TY.3T;#D\'9
M_S?H_VN]^'^","Y:/S<KQW,\'9VL/[]:BAB.!T/Z!U)R9K)=7O11DGP775[T
MZ^5%.Q-@1Q/@ ]- +#:=";"'6__5HR@1PW*P#Y &T8JA*-@4C\E&EYY@E2*X
MG9> ^86QP"Z]X%"B$RHO -EM "AS\3ER+51X<)1$(#R+@2HT*S6<@!-%X7"S
M]?*C_]0C*X@_</28=OAX%H=Y'ER]OOQ^.UY&DPMG%LV/,Q5S:_2/[YRQ_DUM
M A5S&"EWFAW-X#E"I Z$Y7XWDGL<C[,'<&?J$7;DF3O<3W\1>>8%V7&3P<GI
MQ?EP,AGO'7GFMP1R>3\%-%9 TO=)%76818MPPDK"51 ^[Q*W94!G%<I13$XD
ML*+>V@:F8C%4C)+J?W@*B2 AT?HEW #+<M2S.$X6PVAW<)E617U(:]0E Y$J
M9EA2;B/X04VS$MU3@#EE]"]&4_7@Z]#)!Q:.@/Y%;HV%G#5H8+%&^TLY .&=
M2O#D<5M@FA?5J<[+]5JN[\:OK4P>TJ(_5Z&BW<WKH$#A?)Z!\$%W,DL%5J[-
M12:7$'/OUW]<D5[Z0PEN23Y;*A)*9,""E9)+((+.RNB1C,#K(= 5J4&G8Z%!
M+<;4&,5T3R:68QFW);WF!QLSJYA\W3O&?8",5:X-%T$8-:B>A-+_0TE'SO.B
M^ZMF 6L<YD31FLF)"8/AX!BI0@VD+(QJYLY3G\ELI9-CZ47X$DMF]*9RG2;>
M>#$.;:!7P\"J'I)4/==3XZEB<RN3D#+79E-"7+G021_-->/G6J:JLIPDDYR0
M34KG:L59)T@]^&!P]%Z_-?E0?#F:\[&[)J6]FW1"T,QIN.<0:!G&IX*[M0.D
MG6N%.<MSF<Q)UZA92,ZHP4$R+[=WUM_?O;G2B)2B>,3:J>9&<W_,^7'E:*DI
M']A;YE397.J\\%JI#0 ;;!'%>CYCS&?+_VVA@^_\PLXO?'9^X>7\AEDCN";$
ME%9NSS9'20.]5:"7P6+0="[[3^(V^4+*&;X(FEBW#/^\"O]%?R2+:(: &DH%
M4#]@G>R<$X_AC%P!F@LK.GFV#=;E,J;<^-'A-%>:],@9T*J<I3EN)HR 5+6P
M7 "BILSR$CNU?:L;L8#FQN=BF'JHP!A_2B,YUEP-!L[Q':H9D[H?I)G=+&@R
M*5"NA+6 JMH9;L-?^[:<,8W9.TZ>7E3N;W@$5.> 8069V?P 49I1FV;!F;F7
M1X2MPLQKG47$S4E:'J8;'TN[+A:N[$2^ARU$P@_B![@),Y20MY.D5(0Q]RSM
M;D0DG<G1F1S/W.1X[:2T5,VX:.2MGH+]P!<$QTR02B316RN6/^Y9<=>BQ5WK
M-2/$4G\=75O5VW/B[JVY/U*GJ/R5DNX@5B'_ES9?4#,BA<Y.2)\<Z Q_)K^L
MS)10.[%R%F-CGJX-O'BU?SS-J?"+0$//L&,NEJ0_6>F(L<Y?Z\#%H;7I43)E
M)),)@Y64EQB;X#J=9=%427VXU<I=N&;?YG<7[+*8&$)[4L9A1O)2$] HAZUU
M);N]EIBG9Z1V&[YO\[MOP]EL9A]B2>^4'CY4L:', "1X-I[UF<Q_YB\Z.V7B
MG;4G!:0[#FE5OF#7#VEZ6^LPL.NGD_;]\UPKB;/>9FB@8<KYH5 V,0/ U3M7
MX]<O'4YUT!JE?%N5B>;GM43T#D=5OH3T\16&FG[F3?Q,+H>^\-;+31[1947C
M6]#(=!OZ+*0+3/S&4"-OZK@'^[Y>NQ03+Y$!1X/\T3XACE91H3,V<&+)2Y+,
MC2XJ+A/ +L+#8!?93$WS1YK[V9T>E-Y#$N\Y-].C#YN>U'DFG6?2>28FT(<H
MIG/*8(TDI&26T9K+ %<AW4/:=G4=%_<TIF6!UB"CKIZ@,Q-\3&T*&E.LZR+?
MH]-L1LSO'B8A".!O*V^(X\8@LJ/?<;NG67*Y^]5GT NB#V.K:Z+5=M79*GZ%
MZ&3_>O!K&#EY'")I'92\NYFRCDF X)#=0WF6-\^VB2'?%RMQ5IAT7M+F]/]F
M""LYX3%Y8']K)JIK(/B3U?##0==!\"@=!)T9T)D!S\X,^,&PJW]>&VRA._IO
M9^2YP(4Q4%C 1O=2&QHP(8Q)VZ!DXD9:BC4\D5C_-/%/(<GZXFF8".^0&YM'
MAOU=*.@YIZ:!$W0&12]4:\FKS7":E"<]J)F3<FP)3C-Y=ED<7:O99A;;[NHT
M,?=_I*GAZ(T63Q[%*Z[[9?/A MD0QJI7Z\D(Y'09>MV 2:34YQ!5G9;G%>/C
MHI:M>4%$4J40!I13<[^QU%A*G+6JMW_4LGM8SG1-9D@T,VE@VH2<,]%OT[=<
M <4X1-4BK,*JG2,XBEXZY7N.3$NVL]I1>IB+$^)M'(?M: ",$E*FI,CH664\
M4YD^"=^'Y.H61<7"J8=:YJ_X[T<1#6.WX])#A'F)M4@SK@VB-4;OS4*#!A3@
M8-:, BD?:GP/<@>V;#Q7<S=[J<]YA$QQ&9.AE]^&NJY1GV(8M;1ZY,XC9>B,
MC)]#)V*9YFLH& 2N8K-^_>!2KQY&6?/LP\+=UZ4&^2 G0DH/K\6JS/#N]Q]?
MFY"Y+=325FJU;_Q=>\;T.3)Y7IX$4Q_2S1RK3*H))!FN7];OJJ0ZBZ"S")P;
M[1U)>43>4<Z.:CC[=QG!];1'NKHJZ,_.]4"KNK Y+B3$YM%\>S>>TX#'^A8@
M/:Q)N' %^@G@3N0=/PTCX0\EA'%\LQ?A)RSH39CPDND"[!J6575CT%)53C_Z
M&HQOGILBT>B^+8N2)+V1^T6*E"*]+W8/#&?L=$LJRLGJQJ3),QXXC=J]OG7]
M2)*H^6[Y5;I."@9-!&(A74A5GI/F[-S(_<<-'CQ1_[6+I/S92,JPBZ1T6 Q_
M*;C!)9K4?ZN:U-]H_?Q4<!DZ(?BRCF:Z<6\B=;M'8K#[X#O CL<\9C^:B -I
M"JFOGT<+X&\@=A"7]"%C^%6D@JCFGRVE.EE7GN"WB)HD-U&6)L8D=[X=L+<M
MOGF97*=<3L>1%40XR(R3?U[3NU+N7"P40,_9O4<8B!'L_UU*W=\T2S^I))BG
MMXDU+_GM_]FLN%Z@-B,I*J@JHY>;>98"6Y.\?C(4HW(57'Z\0GVS/,(TG]%/
M/R5XB0XJ,#XZ_:I<K5%*9?^1\Q#)I$963X!(N.)@"<L5/:-YF5W3WDHHB1P9
M2'<91SU!Y,\B!3]EIN(XKRVR&8F> <^HY=78S"@I!<D[WR3(XG'K ]?JWT8%
M/6*JBENE$EUXH>$(]#]R*1@4(DAII2:CVE1VDRBL>+0F6H0](@-^:9XF]49K
M=U11,D-P4$:LA]]!E3Y/_>(XY@*F6_GMD1>@9EG13=B5M.G:1K5&!Q%'0JL>
MH7^F@)9?T$=OZ3]R1*@W"1WNE0XV'Y*O_UP+VVR[<4\TO5-DMM*(M*1:IK%:
MY;6H;93Q_<,T!F&,#JX>*5VZ@-!J%MH"!QM>XALD#E5?"N5LFY1!BU#7&$EN
ML)T"0U:>KIBNW/2#S=4U(B-65S= JPHTG\G]J)O:W, ^7TH)$[BH*GBOXUR(
MHF1RT6'L_X,^-T1'5-5SU.- !M_0O&8,/\UO,4F??O!:KP+/$TF*>;A"@,7I
M;BNB' D?#K$ ?I,+4E*I(]&O=.)I)E?AYX^VYR)D7,[K9FB4S/I5FYXY]_8E
MW 26Y^DLXL\YEQ"MUF$$QN]_ER184CF(O)1<;%4A'NU37N2!7E1:JKA8SEB:
M-GFA5E4-(HE,BX14@O&N*X;=H^GMHC.\<\7UH;ESF+'OD&P<:8<YA!LBT!^H
M29A4]<3J\!S22CU[0>"&&33G,/;*)B=[(8_";7:#$1K12J*L1+T?.RHH)GVZ
M3*.YT95'OUS^_/&E_G@5/B%CM@OJ/B"H.^J"NEU0=\]"8E?6!.XB>@<A'%\;
MA;_RB1K)\9R]IGYPZ?6&C08O<'6>2+/0'R#%R@Q(@\8+L*9SA7^0HDI[4=*2
M2EM.57AF*VKBC>OC<T,_DK_P7U8"S1!R8VRF<2"\49U.@I6PW+#7<Q.!PFM+
MORLN\<G@KN^__7TB?H6,XEW+4WH:GT*,R!5@ 9%YIN?5.WXMFDA:%KH"BA8Y
M7"3D(35*EOQ9C2>V(XM+VAV^14SBI/HS1NS^-3.6JO&0#LF*>Z9&Z@/$?3A\
MH+P/3^[\ <2GDY<]G=Y6>7E.?L6?OK"_G5_Q]3+=5_YE;4)DWTJ8OZ6E]\U/
MZE>L3WAG@@^/<A0>\22T,O4,MS#U#-N8>H:CBJEG-#Q_3*:>@S'1O^6Q^&AA
M.#K_[2"$XZOZ;Q4FRQTT(T$8K;AS1R!R38L"_Z(LE/7$>IP/X9[::YT',A'-
MGD[_J!NX:@))%*?)XICTR*J9-VND9XP_R+%W __@UU]H5. 5#;G,''"ZGX &
MP3U!],8%LX*OZ"?\H4X3G_4'@/ECK J4I22J+#*I"R\D;Q.GMRKC\N'8-I'1
M7]B_-7\P2T@#T8!Z/]5K4XK-6M<]9V&R4#HC..Q/L+SC_H0]1;_)9=NF]$SE
M@\6(HDG1&]&7,D7Y1;Y$08G#BF.RBF:3,FO;FXWEE!Q*K!OM*&[S3=]OG^*^
M.T.:C?G2,1+?@SMPCA?-/5IPQ78FI,$TYC&M_RS-9)9.TY4K3J9#">,UCW2[
ME>@QWF-/Z)D Z#2/G;<^UD/_"SY$=)J :=1KXBP>DKV_QT;2-TOPBS";D^P<
M$-KU4Y(-.ACG]/]0207"Z=SEA;\NDYF-D9 0 49MI3NV'&IED]/KRHV>Y>7Y
M)BL76+02Q 1><AA-(BAST,QD8?!),:S>.DV<@D6G:^9.CJ^/RTP!]1F=)GQ/
MS^G%M@42E2 S%+"@"##*5[G!/-)!O'5&?X_6?.EP,MH'#-X:[Q'<C.]P+# T
M7.[T+EJQ1(A1Z';(^(^+%.T\4G'XT^BW2ZV/&5?VZ9R*)^1M?-L;YE++SUZ)
M0N=O_$5D\E:9,"&BTVJ'TNZ;D*RO:6S@@8+AQ7@ F(:(] VJL?5E#O ?3]T"
M%"@46"'7X*2[GHORT(0?DX4>2?4-/ Y&K"MZ"&@[&.UW:.&J2-2ICIN6'%_?
ML)Y-$U!>F%(@:>Z&#9X5E74LU6C2XE@5W\UIM2)N]>?&^37*1\*-A\[0LVHX
MF*>,Y^T4+])[ERI>LUD+):R]+&&MLL@ ]<E5]XO9%(,OH--0]%BI27>:V9UU
MN(P_A<<?5%S\!V4M5[@/CK^G^P<%M;^E<<B[C E__/V7#\_J(N@*6&P!R[@K
M8.D*6/;N3O_)&K*_&4/VLC)D@R.V8E_NE<KJ#):_YDK0#LUNULH96RM*]R/Y
M'J'I2_)(0\1JJ>R5OCA0*()!6")AL%IR]T(AM=&!//$8;U16&05Z"+JCI=$$
MH"D'J[XV_?U=/5 9E>5.6:A$"8P/ &GXZ3Y0#=D49$ (?0I^*\XK?2E3FH3,
M7\Y@&J>S3],2E4#BW;)%@:$?T0:F132GT_JR%WP,%R& GXYF)(KV4PS@G[P6
MP5$6@@R0_] W'][JKKK;-(OG50L!QVYSDAG%K3T>V#&/PBX3K<OPX@*[RT[W
MFFZM8!&G4X2(&>N>5N^_QOVS8*H+)# BKK>I_CSJC\R?T5<7I9EI(JAX>7EA
M:=/T>G/CG(WQPIRC.0N&$<+&\+![]376",KSZLU^W0<-<V*'V>;\V]TV#W)Q
M4B3VA5CY.BH<)BH'+=G%FRH3A(_YD(Q.CI?,&>EU7JU3!F*Q4@MRU.,5[-@J
MIR#A=ZFLM]1 +/Z(-#\KR_)9J>2'E*1R/^A5N5J3T[2,IA%=Z72/XX!TU_AS
MDIFM$L*J\KY;?'AQ?H%.Z6N%_*&^;>>>RA+%PQJR#Z8J&O(LG6^2$"G%>5C0
M;:WHZA/@OKFDP1@[?A5&S)KI9B+"*=)R@AQD<HL2-T!J%%>A"1QP1DN_];+R
MSSF>.U5T>P"JV+0>.=#VW#3MT*6N:>+*0C=QIHX1K(QVUGR@/&QGH.KS3"DR
M,T[Z ],GSM1>UV+&X'K%HV0^]'WG>VZ>\T0*?\^&+RSS6$#+F9=Y0&+,G\D<
M]^K,=B?TF_1NZ[Y)$E1[\-:U\Z5Q#WLB.=Y!L[^I2@F:>(HV[^N<8039 K(E
MPV. )6SR*#<LV+9A=SR&%,_3%0,=V!<P!Z!.P_ 3Q[W!8" U=29UC#PDZ9+2
MDAS;6"/3Y1H3B_YP/A;"#9-S+L)/&*I[1DX-NP8(?]/$FP$=^12=9>Y$Q#;D
MK:,=5)^\Q'\SP>U1>V!XYZ/F.9V,NG/ZK,_I1\WM(MX&"BR$$$4X1.6*/682
M2 \S<;MOZ;E""."GYK@P!*I#86:\(WR.F+0#/<MN0E+2J:S&)@X0#6*VQ"7N
M>T'#T3UND.OJ63XSI_ ]F$(GM#M8E1_(QR>+R'U1LY[O>^%/OZK/4;D2%X?^
M>%+[G;H1%)9+H?7F1:9S2>[KI*<]1[)G>""*$ZZ]X T],0:@P=%<?:;_R!FN
MEOQR<I.W+,5D[':RZ,FVIH6-V\?>'J<0V%1"[TWEE0I\K["*_L%,"W9,GL9&
M@08]L/"B&GAMW9)@QS?,I*FG>KJL@*4U!2DH#6C.R1'G11SWB')(+]+RL&\R
MS0SAD;F2-EZ0>4;CJ5YAX3^W% S)I0((W[20FBL ,V!N^E'\$ 1\^)$>*N0?
M-63A&G&0\;3IC7;Y& $)!SQWN"]\!B0!7=9:':/%I<HQ!"PO "VKQ<[EUG+V
MZ^FH\ZX;8+?H)AT,36JM?1E5,C!K<+E0AJCO=16>,>66@/H[B$KTT99*]%%;
M)?KHQ*E$/QL\9B5ZEQ*T*<&3+B78I03_VAXH,A%_K@+6>]0&T;DPW\*"$*N4
M;3-3^&Z<>K!$JA L(*COO2.$@(M1&\VYY[?G)6QB_@JLX>WU1+9P*$K"N?IW
M"5N5GQHF&Z?4'OY67DY-!7(MOF=H)PQ#I8E;P(X'8QIR?BY+BYY*+V U6RQI
MUQ;+(,&2L]V-ZJ$T+]9P*2)I%3#%3DRQ4]&8A%','1B7VC5Q>L>/00/!4)0W
M:N/$1\X&'" 1[N"(!&@;G30Z%TSP=#+QXR*WRU1C!"C8WC>,N Y;O(JL<):Q
M"I]H3^[T_(7YE-ZX$IX;F=;DQ FL"/\-=$29@^!.7L;Y0?JG\20L_ME'CECE
MKILAT90PHY7.F \F4AI?E%E/=5\&XXWZ+=D3P460&7MQI)J@P-G6H/?\,IDF
M(^W3UV?^8$G4:)NGY-6E*[=7IU'0ILO3'(P%"2YY@RQNT^-B&67B^NJG<7:Z
M%OBJ(<7Q#. G.7/0,77@EO*%[^2&V9V#;RUN+4:6*&:;G@Q\@<@+$ 3*L9,S
M9U]9<.'TG&R(  <P<_A=<^7G++E9@*/LHT'+\B.[1!(A! 0;84$0C#?^^!;$
MM%J@+* K)@O6H(K^':>KS&;L=B* 4:V\PXU=8_"1MWBI:<-7:T)_<LX:@8AA
M,QPIC?QR"JW36(>, ,TC[W!S&>S!:SD*N@Q P/QR^D5^'3GR:=<.7].H%([C
MRHF)B(.^=JRTMR2QMS@HU?-H2;BN4?%8M[S*K&:MAI)3':"/E$H S=6$P&G)
ML 41=G\TX"'2?PP#]$J7FJ%(LB?Y6NH[9;H5"Q6?!M9R)][B^AZYT7:H#-A:
M@N'B%7*E"#)7ZM;T-='V'-OMX5&9E_F:E;>BMCB&O-@)S;D$[2)J]NKYA<X$
MIN2]OG[\+(HPEM+*!U]N;2/0P(CU<3RAT$-GANVXFHU.1Q<0=)'1/9'7 VX]
M>YW::T_N5"MXVB[1O8WT<S=T5V&$\D,A]Y+9Q!=&DQ=U*!VR;%A0!2S!_H9O
M>P;J(>''\^F]7EC0T9=0:G@ZIW]5 A! 5QOV@_=)X_ XKT526JR"42T_Q L0
M(T2H5ZP1F!R=B#DQ;/FAN]1^"V1+7#+?PH:>Z202*MPSOEBEY98.N.U&<IN1
MDBJC1V:8 CSF$SKWG>N]PTK^HN4"]N(;G3T $O'W&C)>!(L$Y1^6:.^IN.>=
M?'Q9;1=)Q!Z)0%? ]1<UCK%_:$A!F<)#!SP85F'I5%'[+!<FQH&O3.,TG><P
M.E?]Z@Y#:Q,WU%H*$'HMW8P:1E NM-!V=:V,R7L'$XF-SU@&CC*WYKH[/FXA
MFRNV=H)_E]'L$TA'-/1\RYMS<CGRPM2K27:X <:P#./K8\8NAT^R4CH#'!R9
M3/1+/(AM!S;IA\C_)B4W_A9(NH[Z PD\N>\VSKC4:N?BJJRK;/T4GA1C2S%Q
M"I*=<)M2\Q"/M*.*AJPX>ZO3_YJ]Y(YUC'2D0+.!&,B)QKJRE=.@$T&E3QCW
MZ;J1%689P%"E>\\.%I7M4K"/2 I&3,XC<TA4I>]DI2%=RZEW8REA[VP_'Q<1
MCAEHX+1:X:FZANTE(Y$W<A$068B?.<)G2IQA&LZ4MZ8XKF:IW.74J7!99VS1
MBK:;%DM)&,)4$U:UCN!ZCN19B;JM,;FD=G75W'L-B9HP;L-Z[%5(]^*PZF7C
MAL=U'.:KT!=$!KCD!8=4)CR(XC8-4'?(X2(TS<<2QZC8']W9./P)SDEF69:"
M!!,GNHTW[A0L>0TB,I'4!Z-'X8VDS[GFS"\M6Y6HJU <A9J+6\_&,K0/HDD
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MNE]GIN8<1#2T5[]&.?DZP36=@]0FI/O!3^FM8IXAPX DOW-)Y$$&3TH\$^X
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M XX#8[)9ZP,M328[MU<W0*?OOQ7!HG0>L^09\=0PU_A/8UI<R5G5JE?#NMA
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MF HH#A6O1+75Y/Z%ZVCNPKU%<UO1[M_DX BB:P4(RV%^K">.C3:M"#YP:A6
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M[K[@!V%-[I$V3Q?TT1(U)V%1J$Q6P%7YK?H\ UQ4FG'%"*U=7J3I7+_)R@[
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M_%\O\56^9.\$-]B%>N(+7\UF%-DIB5!1P)"@A2QS4AI(IE4+Z>( ^^CEJGZ
M8&@]&Q[(0YK>UFO)S3_-Z01E*P,DVR%[[_/&-9&]MP!VXTC68$^TV^+FLW2^
M7)]J08@(P%'42%#R;QL?LB=AS+<6@@*M=CFS9=&2#\5MZ$RWK]+B9%+)_I7G
M@9#XC!A-L2-YO1B_\+'!3@5'S+TYV]]TY%7T!E=I7@3+=%:=AKQ<@/6>T]U>
MCKW]>?5"]8>/H('V#3@],VD@@B?W#F*GF3=-H#"81]?7"-@4]2^;G*A7HN]9
M(*)/O&"!-K] ;\*ZY)AU2:X*Y.PE2GE(6KBS#O2!L^Y4)2YW]RI?G+_H!V\_
MKVEFPHIC+Z8'GJYE.'?+8F+ZA.:O[L GPC#O/PLM' X/*PY[!HF;0YK>5J"B
MKBSBD<LB3KJRB*XLXJ\M_2U7[.SXL>4/X;4J-L&;L CW*%3<X89]^Z"[E@0D
M&TR<ZD-1SB.5[Y%@=#F$OZ@ZFRVW-VIFZWI&/2ESONB!S-=:@9SOGBIR@=1G
M$#JRFWGCY;*J^#,\H319I*A^E2S#$%^OIQIRB=;,4_8S62;G\J(L3)#$O29[
M4WXZE(@SVZ+S,I,BWJ#DXF"DA#<JS#H4@4>N]ZHR2CW)Q&\G/&!G>J$2<B=
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M]>XJ*Q  4V$61V08B/CS=7GU^O+[W"X_21!-BKXQ)_F.TS5+)GD!8G3P'B?
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M=\6RJLD]VD8U9C=\@.C!-QH_8"WDOMMY)0XCQ-'5OGV]8C%'#Z.SY?@7!I;
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M?O"'JMI[S7V+]S?&<#IQ7+-Y=!,!V%V'Z7Y\^]N;[?/T?,T[?OGV]TE/D'=
M/4%^%.G\$_I_& OY;G-%[AT/Q8,=P&U0\T1O=YW3<-@^J=:I"/:C>>TA!5Z?
M:5RY5\$XC?K51H<.]Z0BWYW# YJ(X.1.>2 ![:1@7Z=W+^_>$S#INGM[Q^4$
M\PE=W GH?&?A7%#H2N#P< <Y>$4XO<L85_J:J@Z\]J?87_#H@#51)]-OPDYT
M'(C4,1EU(E('YUC7<(? %@NA'_PT^NTR=SKS+S]'\UYPI=8S_/^/X2)<(;*+
M4?Z37AW.T$M.8]5#DL8E%_4B6G%4F6V3*+%H^+0BY"B+Q8(5XF=%<YD_X^7Q
M@C"4P+(9-1Z3%IU6X=DP2;!8'+ DSXX;G7@F/7'1Z$49J*1" 3%*2 "Q<O,P
M8U]Y%@*NZ\JP%0O";9&E:.?7:7WC\6%X[S^^1KA09<@2WG!,6-X/&TB&+:'3
M+8,?COS1M_B,>,U:A9_T@["-CE!, 4J0MYEGM#!G]M'X%4TJ)JMLUO/7#'\R
MSC[>17\\J?U.W6!#]B>.^Q24@1=1<JAHK@- 5 A)6H,?K>M$V*OI;;TW0R!?
M:T RJ)$?WES:SLV>;;N"F]'CY G@CCS^Z"@TVF8MNH=A;(#U"$WLA*EL4HD4
MCN9@JZNSGC8W!:-&!(TU94$7" >CC#<9<KB)M0 P>\H852QK&BP&0R_N!\$/
M()S_' *5N>=TA=JV5)".OO_[[V__^>ME\/&W=U<_OPVN+O\F%1#F\S>_7_Z,
M3T7?A";X)A@U=KZA9GK?8& V_FAT9/]#W^86;ZNCA+/#R"X6  @&\3K<J"QG
M:NP8FV^@I<TUN4X+)7>GA1 RP^C[,P[YA#H5/J-Q+Y@(Q)WS0-"IZ*MZQJCF
M"\6JE"-^.Z\/+7>%7A-=5UG9UIHBD29G+6Y\S$F!!S(3!4B47,<:]-N7&8EF
M;PL>3#?ZJN>M9R0907>ZOI;HICNRM<6KXN"K7"RYQY7!657%+V>@71EF+X"M
M,N])K9S@S]33C4_)CN[2@@]("YYW:<$N+?B7'^QW2?!+N-$%&+?*P?T*W2L*
MEZX*,[J##>L!70,7 \,3AC-),UM$.7AKZ/-U%C&#-VOB]7*31W2K:+2UDPFP
MXT).%:WYFILIXWAE GC(RI?O@W[PO;J&1LV5,N%7%U?,6)<"PG8^>E%=@/(W
M?BT&F2R04EMDBKT[>CP[4QRU,IB.HK6UUZ-CSY6NQDW!Z5"ZU<0K [8R"4L-
MZLP=DK2OTZ_IE[D&0A^?O'CL 75YJT<Z#A^D2H@VS>*J=NKF<7U&23OH,K*4
MS762[&D9Q6R,69C$GJU1H]T J'D634NVQ&;A.@24=L%T-_3(=0QP9X"&SM5:
M\98(Z)\M%U4UR,EF&H(L0CN&,(A5R/_%N.YDWV_JFFYS?)W.RMS/=D?)=196
MV.P@-G!<HW"N+4E/7_ $C,$+!8S-E:PY2A$WIMCAOO%+77=@1F5#+:1;"Z3!
M.%0&_\$"LD+9 BJ<ZR:$_Z%D6/$VK2Y!G':MWN=8D8?SJET5C9B?% YI=BT%
M=RJD<T[VK8L1[-?T[HH1!*>3]OUS(P0DWA"*VPS@I@E.VK"J97%%!Q)YY,O'
M9- [ YYM]0UT'LQF:298JVGP[N__>'?)EVW]*+'W"GPI)X8,7 RI*_4"NU(L
MR@<3U@B[@H"KU<?8L6 6-"LY?SD=@UDD4*>A+HG1Z@OF4ZW2"9"S4:*>5"E,
M=^WM6N\ =IYY)EC-ZJ[\AJ_F=2D#Q/%UF(2@Q+BMKKL<+&),JY/IJ ,I\81M
M:"A:]9F90!9WW%!:SA7I_MS<RKD)IG5FY2.B\A@:>)='Y8W#9%.51I%1\U3J
MH>Z5C;T*23Q\$1X1:_89'9+=S:6W8!%+UTNR]6<NQ)M#=^" .>[1J=E]BMT]
M^ZCNY1) \+?&R61>UWACG2+=T>4RB/FQFZUI"0\7XA!6Z+GZ))9)VDLD586*
MJ7O/PH@B\\>4NI=YG42@2)MJIF?)1=0V]73T-GW[DCOWD,V+P:S Q!<J(Q<H
MS3ALL56WL7H+PK)(H]6J3)2M,F&CSG5:RF2E"LX[.0T 2#C6TFQXJ!U_KPHS
M6J=J2SYNV_P\,CBOD,?TAEA""%I TU; %FW%UGV,[L(\16<$K5:=$]YVW@GU
M5X,TOA<,AZ,:7\36[1"ZD'86+L[-&3\T"Z?*T%$@9YJG*_/O?O#>2?=M?1@"
MT.A=U*R_J(H@";QF=J_-:DV*-_<Z0L[($;ZNO8IUS=GI\=FY_,T9E<?]-M:N
M]SV#\G?(&=@JDG['.W8:OCHM?L$1+[^797RV9>3CX?&X;>0Z] ?GA4L 0$=8
M\@CRBA4$90:96H2995*9*X@\^]BZIF14%Q9.2=2J"H2EU$HSCW3KB4.1,VI7
M#L0W[TR&QTV F0IWO@ZV"$DO^#[,,E44C 0TO'B5F[^68H[^,XT!2DQWQ5OZ
M#Y=0BL4>[>69J@H0'/);2>IPI B#D)8P+Q>D6\):ROR8/FJEM3T_2+/4URXR
M(7ZZ458A@\ 406Y\4+J^OW/354^VM5VH;N3.@,,X*5U'UU<T''^0 JN*1@NX
M,'1:JI19YXEUPF(JQX6(ZTV4H[AMD?W_[+WK<MQ&EBW\*A7Q?7-"B@ YDGQI
M=^L735FVIBU;(]G=<7ZB"EDD+!10C0NIZJ<_N?8E<R> HB@W?:&$B(EIBU65
MR$QD[NO::S-T^R= HOJ/P?'P%K@W4EKMP&P721V>>S(T?WSV4Z; Q+DFB+!S
M0_DO .9IKVONPT:F%.2W8#62$#";2(\5;6M2D!$Y9Z&.4"]^5G9221HEU(KC
M2Z$ &L;5SN6PX[;#C7C]U$0'.A191O]A=YT+])(PB5I8)DAQ@IYP#E,FF?2*
M&\U86O82U\GGL2SNGBBI1>[\AG+G!7+/5ZX&$9E16!^'R!&7RKW;(WXC#E."
MD!4!PLYWW E[=Z81,+$'\\W@_40ONUQ!MW33>D.8.V[Z^Q5N=A9[;/J)7C;=
M'J\$0J920]*[K3!_N:A$4,6&H&EV7O?%Q%QN[V]X>U_YHY<3Y^BG?7=A6-C+
MD7',(KJM_CLCG9BQ^@T;Z"_U1W2C%J3Y!R#-_[H@S9<NHG\RR?ZC,@V>@R#*
M__?/G5O"!O?BF/R>+&4S%6!EX5#P)DV_F;.,JIBEX&W<BCWJ5/IN1PDSY*HX
M'Z,9&BKD(_IA_SHJH<],.XQ[,U8]4CSOTN5MOQ[:6H<(A7_SE"UM4N2.;$KM
MG=Y^X")VKJ _D;+EDZ*ID$AC)-8GI;COS3WX[<!5Y\UN[_KRF+'[)YOM(@'O
MFAIK72*SY)^Q<0.YW,C*#%W?'BA"Z#_*-UYG@B0184$J,D4M$555D=QSF\N:
MH/LHH*#FF1W!3O58D;CC(J25V_F'=7Y@8L'RXK9T/95-AP)B+Y6W^<:*4CL4
M%7 3*4C7#.V&GZ@2>)?_ C<D64UFRBI&Z\2T0$RO\S]PSKFF=>2@' %19:F"
M4S,/%XC]U10F1474II0BGOVPKH3GPB_K*J>\MQ2RV4%./Z3DN]R&GL19^#PM
M;\8OXW?P+PL2\-\L0T/D+E:\)*V1!?KK-R\@?Q%U =,E;[X;H7PC,PJ>!U80
MPY4"78J0\=IM*",YKD;?#L #WQ,]LPB<.RUYPX$0T@Z]UDWKKYLK*:B75Y)?
M4)!&"?>1B!O]U5+(><91/6/@H(Z($"GM:ENB=R\9/72SPU6_'':4G!;!P5(I
M(IS,$)%?5(\L\".X]DPE.<+TB>Q"-551%DQ#TZR5?8+(+ *$M(WMZ_4"<M9!
MT2,\+UM.QO<-?:3BER@9[__2Y3MG-Y+N'9!/?F9&KM&5E)O<C3$[IZN7X/AI
MA4%H\Z^A9 J+8%NF0I($W*S&*!U/())F@&J1<T5QW[E )ZG58J;T?-7Y@^?-
M8;3S ,/A]*#HNNV2_0XVJ9@::.9>YK5#V6M?Y];I&_G7X+=U6\+DWB"JC ,@
MK9\#M9(_ %U3UXZ/CNN05RN[2YKY"!!4*D>B,IC(@P,6:,1*D]G6(Q3Z]CO>
MCC6I@*<P"/1CWU#HNW:HU<,?_, 9[8X_1!=MOD/<6W8/\".@MM!MZL)%I4;O
MAG9+F"P:_RX2D%]R)9,JO?ZR)<3?!J["NFD9X)&W;5[SCLFQ(A;,=,\$"$93
MN"="?Y'Y=\GCQE=X+FG+'#MK2 <O00&:]D>W*G?H(H1LS>3^FSAU*B0-$PX)
M.SC )'<"R8HHC:V[YBM2H4!*D%*=]_/EF[B>^EN_!B^_2A+S+?V9?@3U4%/!
M(5%_PQA-'W[-*7.9Z^GJQ]$BZ [B&ZPE2$6$O-:,AI#+W@K*O$^*NJ1DM]EF
MHB_#7%CNBKU.4Y6)R6/M\+0C/-+-%$K'Z)'&+RH1F;F:_T+PH"1)_M43WX*
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M$'CO<'644U+-C MG.33'FOW#WE?4B&NWR85QA@-^O=(B(2S7.BE#XC!I@*B
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M.KT-BX)?@K?NZ#^CU\>]+:EURV73.86RRI+\"*>KLU7M3QL%/ AKNW:1>$'
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M#5$MV_TZ-2NJM&BHFSS!E;U(M)T(./2D1HG0R*,/M^K- ,1/LK.WT+"GJV^
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M(I_U[R:O_&9"JGF3OO27(F^K0SC3&[*>>.Y-:]INVK#WW*(8.14/8CFG]J!
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M33?&**UDJ=UE,U1%TJZ>$5R03]=X8$!(&A8-!7K@G2OT(7UL)^;B='.\OAT
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M)@ZBQD\[.A'DY<,HT+Y87KY(A8+)PQ]_KK18"O81V0]<TCQ2-!(PHQ38(6U
MM,W+J@NE>;VUE^Q)S^(7WSJWMZ]9,^ 4GD\'&S4Y2PJ4X[I,,[N/2(DMT--?
MQ8SUS3L<#-R!9Z98%3)((*JOQ,7X$\%2;[^ZQ?SY3=@=O%@%&'Y5#[LUPQ-=
M.$;%Z!A)D#YXJI!,S IPD/Q>6M!E4N:,Y'D.1I:?6K]7H2B?/",>D*5J:?!*
MH/&2V9@49B1DC*6!/#7,8MS34;F\48 =RB(DEHNB"<D"4M9ON@+24,Z_=N)K
MQ)..K($9&PX3&C)B?C+\)WX$U*J=@'C</X"*0F;I)RGBDM3-H30<KT_*C26@
M[LTR[Q.*(UJ)4E03:9[']\@2**C.V4KQ\M9EG;0SF^=(2Y(DAIPWVD8EO58F
MQN!L0S&RAK;IZ9@^" <HK:K?:LIUVTI?+.Q[RV0RAM+8H*A-@^S>^0-7A,3T
M&#3-59H-];F=%M!G1W9#K*ODO% !?]DK2A/6V(T+#;&:\4"M-W'8^,<XF<GB
MJR&ID!)S(_RYVR1@;2R%FESJ<$Q>9SM2ACS;$=18:!VJ;\^@;P+G:2C23Q#4
M])?IC&)<C\KV.3+"6,^Y^?/5F,(-PL.)M4H+1S-S2&6^!(2M#]%:"TCMU;!O
MZIE),XA6)F/F<D^LKD5YWFG"?K;O\AW(_*-W_VODD_S/F^'BDKI)Y?M#(KNM
MID3.>UYU0_A,IPY.#W'BW_\@"JQ%Z'EPK *!Z$QR?_)(+BEQ0DMF%0U);8NG
MX7@F!5"H!T?I#\-%N1$.1ZL@;>5%N:,X+A=EH.S"O2M#R;Q?$Z6[ZUG@SI@8
MM2Z8D"6&9NV#(K&CTC<W:P)(%X&LWJ3[+>G(3Y3]-AL;HM[1I4\5!=E(6_\\
M[F!I^D/2 N@$=GB)A%&,NI . *+3Y-#&YN+^ASS'P)#Y6'C=E-E)VY8R>I$;
MA9J#Q@G\61OQF,%@HPN2BPF5,_YB, 0AO_ VZ=*BZ:YSUD^6G/62L_[CE6=]
M2/EU1[AS\MUFJ_EL("R-4DYUFE#\'_%T;J%1L^/*6(IQ#GNG!?71)9YU7>=E
M9%0H(Q=!RD\V#GU4I !)2(AG+8_N1H<#&IO]+YOB_K4F"AO394Q&>S^$$H2!
MJ"O1GE8/>TUX+)QKF3\-54#E15&=<T-GBE03P.M8:YJ8Y,W]R=GM>^;D:H'0
M-2%EKSN;H=U$/]?DL@6T;\ZDX0Z<W5MN2[/=(HT Y$ :H1B7N^%HY%?$-!9K
MC>+3.L5:I@\QIS(4]G7E.RT("AX*N7/LE:=;:@NGHF?H?S=;!D7Y(:Z ( [&
MI$I+?HN2K/N"55Y\GSN%'"6D4;>,@<P+LV=)E&[J0-U"-G6)&.AN_7!V\_,0
M11 GZC@U%<4O:Q%;'$#I_,5H+O"A^@@A@,FI-"_$@*IZZYA]>H]4+P95=T#:
M$%"BF4:,SE0R(/RS-: F.; B[%B46A);^ML)\E9:KO<#UF4A!1\[L#%75(UY
MJWDER[O%L!&4/%U1S^5*U( ,S 9#+1$:#$I3:G/^7Q*J$,&V^T0:!:4@'FN%
M4,U20:53P7/0$=$70\KS*+O]J%PF=J0("*U+UHPV-$E&"?O(9'','2GA,8\%
M*E1IZSTTNCT(MZ&6OZFW)6#)C76>)2N)O=D>)+S%$'1>?"V=NEUQ5Z_H%,D@
MOGCO699B!6/!<TP0*$2'@4 ;5\ S'4<'0V93 1-)GC39$$6B$P8!T/:*6AO4
M @%7C+=^#2-C8-DWOKETF"U!45CQ+)!0U%M\_Y/."$=E"&2O3<P&+!3M&B48
MJBY%/@KG.;.EY[(7?;DS-1<&7%7E0^U_.@)$+EKWT].Z\WY,=@LO9N[D9E(S
M*V9FT1 L<N/5R84@<:1BODO!!ZA<A3@X&@"R7Y;L7"S/B,:",HGS\$FT3Z&)
MZE"EB%_4L[23D@T=MFY6(*H!<:9S?9=J$INM#-TCIV,1=3WZMS1L\)N,D5V<
M+3?J+KVX]3+FOE33+PB,WZXW&=H2!1*PUP:3ND N[L5A^2TOWH^23(Y(^TYQ
M>*F4&U>ZR;>WD^)A@W^.$EO("79Y60NKU"P<.I*#Q/J1G(B+N7 ; ;K3U?<L
M<,MN@RS*@:T<+PZ]6P:2])K[/(2A)>JF(S*X$=QD*ZJ\9@BYPLWMLQ$1NG)U
MS#T;RW*,_E1:%9TCE\]&W4;0R!"=8ZT6@CWC&HJT^E+@(P90F@7,2%K+KL,R
M9C0$EP)C&6%3D:1I$]-9*TN,6J$14I_8DD!;5+^+K-:4.0EEDN8'RM<9*P9L
MY0CGT8YR??JQRC9VSF-H<-JU /QPLB,=Q;GR"Z[>E)Y Z7I9DY8;,#G7M;^K
MW)::RN;I'(P*9N>')DU\A!W@(D'T\CY5^74G@=:+B((]6D>$QD4@1C(8J'W2
M7R[E(+A-W[35<YSH=SE.\WS1$CTAQL%#F5(,:Q]IW)9-2X=F2I90E&.*B"9,
M3>^I8;*%1)\>NG3)&8:<X6=+SG#)&?[A]QHYPQ33:=EJI+R,-9XCEKEN$.JZ
MYZ88LYO13E<Y(2:8;=NKUWJ0^AHM\(@*RLCF>5H^4#BUQ0E _F,NABPE_0[-
M $.K4*-F PGJ51G*,)]+F>)JV!?DRJ?RFWJ1IQS<G$:% M+2EL0H2"='NI4P
MO*Q:10M3TX?6JY&-K$W*9BBZ,+1N-$J@+(\C26Z4PV)B+/FE]V4WWJ&8)&,K
MD0)RS%+>!;,JLS_/1B./TK*6_X$QQ@8-C(- M;"!BU888"F[2?; J"D;FQ.I
M!5M,C+5H3O:7#?4V#!0<G(GTEUKH.J"L[6)$35^6Z]+,&>NKS;F7&IM.H%-3
M.G2S0+@!&D>V71132R#8AL%V?1"ZMRG#8+/=GM#'>+82#3[$A2@&\/>>2*P7
M!S,RM]'A] ]3%!$5O9$!JP&H&"^-GXEQJR?_!31I#3O_E=;5<II'&6D(4B26
MJZ6:\Z-O'6$X$8X5=/0O0W'!-3F5N^ ^U"'=/-WC#]S)A*Z8?EN4@->KRX(#
M(;U3UN@P94S_A#IFLE3M^41CT@%+7@C+-?QXC7JA"$F3GCF'I.,PFC).2(7#
MY0O4)WKY9-S+_*KD9,@^SBWL^^:R*25[8W(P=LQL==E<(UV1Q5)B>W/B+B9%
MTYVAX"2IC8X)=NWB'9:A];9_[G?ZI-CIB+I64C.ROAWZ2]!R<SM:/XNRJUQ>
MC(F--&46V0P,RUCJY\:YH[=">I^JI;SXD[18GMTV9"(.&E)9Q)#0B J=K5\X
M5O#^_D!+0NV5V[C+K2,M%G#J%23G'3=>:E.YKY>-NY)+-NN->-S/;[6HGT_?
MG(YTK6DC6TR;?=F,PSZPS8_R#I18MEY\)JUK68Y$F ^G+9*^6U1<$^N KR@_
MX55'25FY&Y8<+9Q.>X40WS&9->%+*8,$:#X[J>@18@KM@FJA0=GH19E 8A9#
M!)=-5= [3P,8DQ#"=<[M:*#I$%1":IHK7;O,! 0!AS9_Z%SY;\8>]]2MD$HI
M6L)!<UM=K9BP+(SMB!BBK'\99">H6;4CXYCV@.PV[I5#+Y?RYOZE$-B[9L/7
MFZ&MT%M;4Y(#1%9Q<+N"9H-F+]X<=NN\9<V/ZR&-?(FTXJ)I+P((&59#B0=B
MP,F+]DO,*Q@I'Y%(7U(]ORHW\D-3G[S*>X5T1AJ3;][Y>]W!F#TL29][<6Q^
M4SM Z0A%A[IX.MC%)S9G@5NR_7]^1HBOPKN.ATD)7:"P#A'GF)^8P50'*_S\
MS%;I;;WX/#FXO-54-["@_D#O^4 3NX*=J>DF\7--R)\W?=['K I7QT6%ZO_,
M/4UF8N.&!87ZOS#>K2<]>1;H)6:_H,@B+2B&^6YL*T/A?= >-UH,+-0F:DIT
M^<XI"<NN*1V0:*%K&9D\C(KE$B6*EY"+&T"%]!:28D#%K;-+=;HRO:.3ETX;
MGN8$+"F59L*D_-'@=:'QUVO\@Q1A6)IYW:2VSJB@LFEUOR.6GD_9&REB_.+1
M%P_6#Q\\>4A?#O_B>LSX(^H(KXQA\*>$]:..E5FQD_JQO?6&:]X6E9"Y6#9V
M?>$!_AD*1S&,J2;.^<4$&INRKOW!HJ?0&$V;S,M2Z<1*V7A$@Z,+:YR8;&!1
M<%A@U4(N8*;$C^\DQX+"+)HRKD?(GR5TH-'W'.'((XI.FXI0GF7;#.T*%[$3
MF+Z<4\HQP;B)6)7M2FYG6?LG!:P?KJWW6W'6G!9H$:)&;'GZ3;>JRB[I?4)M
M)UB\R$8VS%P'"]*U'Y%]LZBJ#Z*$\(K"8&JK0U0;@%\[.:S^=$5]8\7;-L@=
MDBJ18DJ:2(0Z3"JIYPJ$X)TD_1MA@_>A\\^Z;!((L$! !=I\[5K;<1@/#@%)
M.>7QYB,*5* W?$+7S#1"H*</! MC36N&8;FRC4G>*6[ L&5J,QSM"A$V@;D/
MJ:4,[2[K9+N?%$2 1U<=1"\542:DY%,&HVQ1JB*5N<S?](<_LNO"].E4NW)
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M*B?XJ9,C>1:N)!GQX/'#]TW(W_V2&&7@KE\VWC:VXW(C/K@:.X?3=V%W4G_
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M25KS:^JE&FC@KUR0@IC-+T-;=H7RP],5#81TR0/C^,Q8KCW&2!Q+;'SD4TJ
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M-XHA''W,_+3(8:PO<N%4]I?%*T2T!BY* K\*/&9@^D<7SJQ@.8,>ZT:,$Q5
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MXS^H8.;2'Q)"3VZ'CO^CZ\N*_[9#X(;HZLDY_X6N]%,1N<A#F>Y^?F.(JM;
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MRZ/#>%E618O6O/3N.'./KZ1=VJ)M:IZ M#896PVZ=7><X] =,J>>D12Z*%-
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M:ZX-ISVU57LG(>;FNK9-AZ)B Y.LD*EI;V5N4"+ZX:JIAIWR?0 O1[P]%.N
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MP<GS[!4\G1!=DX&R"LQ;D%M-81!&FJ&6 B/QEDNZ.U5WI!.V'IW/0S<&;3
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M&F3:0QURO@7/M*.VX4VZ:M)5=UE7A:).3\A0)>VTBDH+\_D/#K%&4CB&N*<
MP@6JLTNF9-)!*L?<3/%=%C5+:5H-*1J,%S%2%;#ZL%C +6#^;M'A9WFV<6ZG
MK>D<AQ6+-</M^Y%UH[*(V!4Y#&.E<DA#6('GFF2.<C@<#>&2,HA4IV?NFN+'
MI' FA7."PN%!=11SOOJH=O]W^DFNNJ!'$O5P#^IA#T#X#I. %% U(G7%>NT'
M+1-M%+P*)AXOG2*C8D*%"0O\4"K 1N4KC?;EAF0+H#%($XC;$W_-)E"AW"+!
MG@1Y$N3)<Y#$Q\_%:[<HLA^8R-0)2ZG,]W84S0@31A1'I%+;,Z!&:E5QR/1J
M)PD,(9>40.91416+PMP*I4]U$04.N+"M?7[!]OY*.LYJ1<VYV9(F29\D_<Y*
MN@I9.R?Q,V.* DCE*=&8\LR9_URVZM0#@JT4\\Z,[6QO9;:-Y5"M,L<7_>M)
M)Y$.O8DZD1*+@>6Z7<D8 <P0TT][&,L.[L<)7W@*(Q6E*_/,^ZVCDY<^B?P=
M%OF?5TEU93A=1F)[J)GS+09"^ 4SSR(2"'\AQYON1D?^X]N87^M_=>ZWJL@>
M(QWQHGC]1QA_ 8/U6_?*]F*HH9+]7-I M8V8[(-@UHF/QS5\KN9+@4D0^'"?
M0(GN>1H\.5PK(6%(,C,W#,6/8,IP_^J0Y6U<N9EUI--YT3R>I:4]W^ #Y!YA
M4E_#4*448&K,P!5N<UYV%\4>&KV1#2Y$/=%ATJ%GTC2++8"C_@=),DQX0I0E
MH_=SG]">$MF3Q;KK%HN<U(#X=B-[Y3^WX8/L,R6Z?5?JT(6R?9*LCJE@M\5>
M+C_ 6!62!13SRT7V&(V;+]T,:N"%3(.'B>]$F7IEYV?& 25F_F_45I6DOV/5
MEJ;0/2L?OYYYU#J!W)@U6QW ;E/<-J=C6GW<MI%)K0-@;J.X;=-TP3M1:O_V
M__[\]31=,$T7?)JG=S+)'R!#W.O8O2R:LNZXED.W)YV^% YM;;MEJB=Q\N<,
MM&!\N'.AN]5IW3[C+9K[KZ/N[?^T7](Y;%Q&;-'D:$]2?6>E^GG<V0"LV"#>
M"OU*_P='4ZB[M^7";<HY8%P5P#_A6'_^Z[/']QY\FZ%7%]^;1&L2K3LK6FHP
M5W0C/W?/,:!.W+OFDJGSM&;RVNT#KYYOP1*V5C&-I>_,9*1N;7-2DE<QCAL'
MHCQ_S8V'(=?Q-E#9QB%A^$)^L <C6L5P'!QE(0J&\)M)UB=9OZNR_O,A!/F6
M!%ISWJ#WPG3%7NG)+VMXKVOM@3"\_B"\T4_%O57(W@@#42![SZ8$R3M*D'PS
M)4@FGLD/BH;_DIWPETHT0HH##OL/.G[RW,-^?V\8X8%)Y$7=!E"L1PIM^C)*
M^D[OZ)W!*'X2<.Y^K/&]8UJ?1/,QD0>>J"+^5M;;A.9[%%R8ISPU%D%=A5-G
METK_N5,&(:[H>ZB0V--8N LE%D5:@(\.Y_0R*"8?.L KO'#9;+ BFVD3?)'#
M4I%U6S2?<;$)'$1TDC-W6:P[PTWVT8=D$SVU#[K/$;*0>"SBG!^=-W#**WQ)
MG:%HQP=4T$'J>=<RSEBY$:01'M/E23[;$'JDY=+HH#RONU\'.;%5Q5@#32&9
M$AW>Q8SN/6EEM5\+!,I(ZUH,QR7C,)ZD,9Y9"0T4N8WSV*5?,-?3%\>Q57*T
MW6WI0?%H:(>?1R/1!Y#"^J,PX0K<PI]M:QQ#2:CZD%&@T<ZR\VB>,>PZ],+>
M[2)X7N I5'$SA.W4X)JXH^Z>?)#'@P5R-S\\0/L0:K8,I=84U873E8?9);[E
M@C14[8N7;E6LE[D,!LG<E$QR8@NDT8,W$9@TXJ*'H<BE,&):MY5_V?TJ]AG(
MOEHRR-Q3F4LCI@+=X*5L"M IS3 Z%2'>>* ^>C.E[5BL;5L@W':BR3DMMP]U
M8=':JV+!ND D+HQY2X^*=,HPT]JA<:E^;S6^/)1Y:X&9M/V[8(IY:\>!V^SC
M]OQV.+2GA@.]$AZ+,7WIZWW ;SS6X(^?_8F.C+3X!]?@H,O!JCQ]PGFW,6L%
MGNWC/E&.4T]G^C')(W)AV1</<C(!#Q_F_N@SI+]<D\<-T=?,G1___O7#K\\>
M9/1^UKQ1KX(!1/-6&%?2)? RI=9$%Y(,.4-J(=JWU7.G65597W7)+6^189">
M,-[O%&DSI@&(-0UZ[E@)!QB)6 WWU2-7O; TV6VCVJ/S50HT^J5C!!V08[?U
M7""Z/#]P,*4)QM8IK R,Q:.(O#IZKH2%5\YC29IS.',78(.3 R'*1SQ07KH]
M$^O@_ 1LH5/6%WM'-UHK3.?>YD8-,VQ46>**-W@R/OO!IX?0E_BF]^^O]>D]
M,$  -K*RJ?R4GX4N)BV(;7K 6VDBTKLR/70/693N]OJ4B5K-:=FA'*"B]IP*
MOBR>4N%<(,0M]PX5<WZ'D3/EV"K[,9^PEN$QF"S/K>8X:XL%15#02!N%A:+;
MNU9-B6B^2+%QO(J9CVYP'F)H"T&O\98AX:(T"_$S>%L2$1<(\0&(4)&)PT=J
M>TX.'; /4[<MIGOE5@/QZT;GX:.9^79'/W$#Y,+KU%)^W+DRN6['X=+8\S17
MER..R!%5Z SY[WWPO2Q0:W<B^-*F732( A&KR3QM5G5L*_U0;=BA7I8@>K?]
M;XKUQ3M2/W-1YV/&7E^CONFB1SCJ*N%4K\>3"\QJ:D)_HY B=7)I17R4-Q'!
M[2&NTV5C3CJMCGQI1L)GD@@);=0H5Z0,6#(H_EO@NPBD.5 "$@QZ+#TJ%+-.
M\#V';C.I)1*BAI[T*6-%%SB5Z9,R?+99H^B1\<^8W@31LYP$EQ3T]'"55<"!
M"HPG< E%#9>@-A[C/A'9-[+?<M<>)-601OG=JL%+51"(K%VY]9*T^=+9SNN*
MSK*_.4'FX\_+P+0L';!T2EU3\P3J^)OJ>S '@Y+8L.5#O!N+H +TJ+0)EQN.
MM\GAVN 88)EF2Q?!]6-\+? *\WQ</N9"&!CJX>A0M,FX"#R)9>SMDG!U$[R
MY(<";OJOCLZJPSGE<(_9LAGI](P3T%&#UC&3H -Y"T8_DA81Y')B>F7."DEH
MP26NP'0<B2XR*R[D52(LN-!DG+@M8PDP!9/+LT6)=F7R,I*O>DT;\.4@?MCI
MY-*Q0WQN;- FS:-/IVP6('.6P\WDVK4.32*H:'2(9HD_&6PN%GU+?,A31<]7
M]+Z=*GI31>_CJQ9-+(?7L1Q.L=QM]ZO$+Z6?T?5C5H<]J"@T 0:SG"IZ$8KB
M'.<R&,O5O"-)9HCG,9(;$Q*8B[H?IR7.LV0J) MF;>+CV06$5)_24._I6N/[
MLVR[IU66G]3S'7J:(;]/,H:GU;X+]B-Q1/I4-6,JIA<KTM5K\>H,%/<8S1$.
M5G*J%HDC[W' >?"7(AUZ>G+:< -VA>M]L=[M;>Z/3[U@ZN22][M:X7]\IMMR
M6TJQ\&X =@2?N) ![2'*#P6<70.MB^V1ER$UTVBR^\KY7)UFYB22N.<Q>X[E
MXU)891^BC&UGG!+HMK1E>*VZF7FTV>$S+33T=]X 36^ !AAM[9&ZZ+%,CX24
M\/B/=6B,V#]3DDUH^+&+'\K]Y%%E<H&4?CGKI,YCP30'T$+C88 O:8(+"EQ;
M WP\G6L" ?$CE'6-X'B/(?URHUGE3&$<)1B.?8Q^ND53:_*KD^Q.^@Z.[36%
M8?-YW2"%M]X'&85G$SE!AWPJ4I 0_ .&2",_#OJCN&\,(C>)45/GJF'_:L>P
ME]!7ZE_% [OL6BTBQRIX5 X^EO>HD/ O&J4=&W.K>MMUT,>:_*E;KLK.Z$7!
M(^?DFW@\)(W2$-+*^^+_@*8C':)6X<*QGVOS;=FB*:X6]545^"8V:IO^_<']
M^U::U-EQ*47Z&LI<LG,>-HU=>%SD!WSG/'S,=_N>CD4'Q?'(\BKT;?LPUUD_
MPWS"R82LQ*TU2PD0UJ0<=HH+_8;^X\JM+X$[7^U6-J>7,&C\^X.OO_+/$11Y
M>"*KCY7&.!H"GX (%] !CA'X'1OMST5/.)%@B6KD$5.B4DU>HH;\)7L4P1-E
M&38-C]<N*7%<1>L3!5:I%]<&EKOEG'Y*CW<04(=+5[&S&>,K1,?/1D]GF[)M
MQ518,\.L4.>N==Z&"I%4VW:;;8^X@7U@K6A=D>]SX>NZ8C$ZA8\Q<Q.JUFU-
MPH237S"&6X3(RL=4TK>A303=:S%CUX+4#0ZOMD&QP@H79^:<%5?4&*E>6A_P
MY%Q&@7<"#+=PTZYZ74&9T9-T*6B]F>=^05ED)WX*;K"#]VV"N.UF=/2$IX<T
M*1E&J-3=7LK"LTA?1(D$VRE]E+CNEU:IU^MB5C<VD:QN;;Q%!D:GS63F9/:J
M4GC&_K/9&A92T@_(18H<Y">2>=U2TKF@)P6?4;GP"BFJL)G-L4 B4MBRD89?
MI*^$Z3_$,>B= ?*B=CN'@RCY);8F;CS]A&?C)/JN/V3&H0WW#11[\@[NT?\E
M0;R4F_#[47+G*.5O@<_I?N!I'LV4+#\]\?OU_2E9_NZ2Y9-O?8,1=8MFO+T+
M8RP)'AW3NP53%*GYOTR8+1]:HWQ48ZGW'S[\XX^E,DNX]'8*.2)G,I8!:E';
M&21V3#G4QOK=$Y(?SJ8)&SGW07!'0XK79C'/.%Y;/@1K^WU$[]>Y"!,<Q:0+
M[K0N,"%%D++;HSH@C7^YP(%[5+Y\3&OD8[S)_0&C@YV2H[^4B&K8NQYW<CL-
M.^M:B0B$9+%72@CAW)(B2[P;Z\S6[O?Q.:I)(TP:X4YKA#'O(*DTC53$KNEQ
M3CJJTUF\],KE,NY5CCKPT/BIYG\2T$E )P'-33JE[]67<A-&O,N2]G8L"QT5
M2Z):C*_)TG>W&$3-Z%\[X^;B[BVZ=<AO,X%60$4_'7_9>G5_>GR>_O*$$HWU
M?]]\%R;6]4FK3%KEN-F'LK"!I-P3(_AAK0I="08P()0^<2$$]=GUVDD/R!;-
M1IBDE]ZE2< F ;NS L;-']K)#/+L:B5),NLI@#'=MSB:PH-2IH4VC[?(=3CZ
M1:NC*C%Y -=?M1+J 3:"YZWW7$@3125PQ[NF1MB-8;P @^QY"B:1G43VSHIL
M% KW1@A).GN)\2"?TKU8(656L&UL4XPB,%FT:>?Z&*[J)'F3Y-UIR8O"NC!8
MBS^$]D#?R.,[Z@UM@-O%?7M]?PA?&GCJ9O)()R&[NT+6:ZZRX<&H74Q;T'0*
MD%S'_#1^/)168I9W$D^DD)*?Z+7;E;& > 0<329[C"F;R9F$=1+6.RNL6PKQ
M8.'X@1]\^U=N<"+[R"XE"J %PL'=O7IY;UO/(5D'Y<BJI,6L==JG$4LUYJ5N
M)MB38$Z">6<%DUU5S&X=ZZ:2AJF027W+CO*)46,2MCLO;.,9F1C?3" GYJN*
MEG]1&J:8]@Q%8\DP=#*O?".RC*E'^\2W]2B@49^*G<> Y(R[R2FT#=>@9 "Z
MO-2Y=3^-C!<^%PPIC-E1J-]F>U<TK><(=#O7&S!*0.=D/M'FDQ?%KI#9;N$)
MC,?/=6!X;.R[!\D5 W<F\S\?0Z]K[M&_;,5Q-XX,9\LT6/2Y0?/I]#_&J95Y
MIM0!J1GFMYO05B==PK2V:^ 4QC *IA'DVQ3!HU/P,91LXP3G_A1H(9_*KGG@
M$<QD9]FYA0P'I\,,=.ZR(,=&!^2[]AJ8H?<Y1)>_HRFZ:03MED?0'DPC:!->
MVT>&U_92B3Y&M!*WJC/HRJ)<,PP+NQ0 ?MG5\]<K6J7#6!IP#9I2QUXCL 'V
M26)(XP9!%WV .6R/"H0?)5YO/8)C.9G76S6OOY !70O;+9Q6]I#@8N8&FUY4
M$6IUA#9C+R;X5E<QR+L83A?&[6&R ^J$C;:#91,3[3*$D0)ZI'@>^<D@&KD?
M^D^&YO.;3<V__<S\SPFTE$5N J0S(ENV)0PAC&YR>,1^\I_>%";22X8@Q@,%
M^L1<8%7K*WH[[:K<ADTQ-"\65F:[T'Y32?-X..R(BE$"2^P"BHMT^X5B%OD"
M9>/H72'=:@C7_5%W7HU*<Z$,.9NZBE6$>.:]UVR-M"_UW3ZSQWCJWVWXLJYQ
M0):0OFR+SFC%"']T._V?)0XP+R[7AV>"J'",]#%M4Y!@KK@=@L$A=<+0%)ZU
M$T;5* :*!H\3<+$8+@":T'BEA4>CIV[Q$%C-ZXAO26)'^@H]92M8$/.U,!51
MC ](ZP6=N114^SI9LF"&7CM%-)MN(R(:D\CKPS(HE!R#;5,B>*NS'QFH2?E'
MODPAO/UP$O"Z^Q@BUBE],S@;%IS%"+H5"W0$/+;>*[Q4@G6#KC&%'XN1V2AP
MNRR9J;2N@D"DSPT<:K<L& NDDC<'\S(CD1)PYG13F;#$ZO,@16XB,"Q&1=:7
MWSIM.!UM-9WLVVW:-WF-HGPEZC%]ZY'$WDK-^[/$1S_U:)C8#0H[=6WTAF;"
M6ISYC3A-@GT68YV-C S2I_1G4"#:$N&&L4;W"#L:H8;P42)4+8KYKRD,VQBV
MM]?8MQ3T?3*G\#V2G6+?'_?@ E^&Q-QYI#=?Z#EXY,_!K;R6CRH<O/F.WF(L
M>(?.Y^FAX#]BB"W%((%;;#DV]E6-L2^=E!8LI-+[&$*J(O#'Z[%:OF+@]M$O
MQ\ H$_!-(TX\ B&;#^%1\Y 4/TAM9? /7*NQ_'Y*&=7+ 4?."9T[XY]D!P7.
M1U-RFT(,DLIXF-S(L*B-W4:[ T%_Q4#1>9JK-*\>&&N-I*T!8>T6D\=PRYB7
MX>R+=;^J#YQ;ANH=EBB44D]$0>5@1$BN4HAD+CQ(NZ=6,#0OZT^ 2&*;B&(O
MZACC.\R/%7\\JUDJ1-?7/:3*M09+9U4AM&/Z*G@7W+K*7S+"#U,!QAT"HIO2
MD/#,O0JL0^RG\-9OR/DN*:89V?]Q)PD+$SC:A ?/')^$F@]CH9XYQ@@&F#<*
M>;!UQ-_SK**H9Z]\BY#1$-XHMC7%-@.498H,L73XD,5VGRL6*-,C-=CQJMBX
M@P.GT746':<)3KJ*5>%XS>?=!5J)9=D^?F-:I&, -N,#KP+^7%5UQQ,XV-)<
MR@_MSD>8=F2Q/]\AB0"]AVUYIO1/?P$[+"9V<.^?(A:F9\+"I @\WW=TJK+'
M37=A'I!XW$8P1/=WK8'Z+9S0,SC@$PNCTI#>J630#2XIDK\=CN0()>\"M[6S
M=:.A8 @!XD@LKF5/OUACK0UI,J&B,F*R$?ZI_ \*FOK3I_18AQ[BGKRQ^E[B
M73393[^^R#51)(2S"]?.FW*F71U:'T[$85'/.V9!@HC^O:@ZE.Y)1K\8E;!B
MO5OY_""NX]NRG'&^CE*4?7;^[',^O+1"5"*__7-67?QI 1!NN])GC\O+LM4$
MR'<%B6?-!3:DW_>?PPWBS$MGF;"=ELVM#*II+Y&CI(B/3$\O:X2;OFAX<X34
MEH7[%]KU[*ESV3F)VF<O'O_R]/SS;$=.!C=M\_<8.H,6:#OU0!)/7YQE+PL(
M>W@>YK-K=VFRJ/4,8-P=$6CE6'DHNG$DF]@NI:UAVJ^"ZZ)""8=OGC_K\[XA
M<5-CHY@ +ALE@,.K?NIF3?JN?;;L"&B!-*S: ZX+4WJC>R[LI ?@#?J_]O;K
M4Y+/T]7.'XM(!/Y%GI'?O0J>)9UR)@ZQ)+/-T,KXGHS%J@8PPQ1A86S$T:-S
M91W9K4JKRI$O7>"8E MW1*KZ?(TK!E!_QR+U4YWFSJ6Y8>X-_9Q[<F9[+SYT
M:U>R?R#;0-<P'.L6C-\=;'61;9R@ GKP>OVMY+TAO/R\93OOE+4EAB7AC@GK
MI.76TO%8ML=O:?>Q/>\S*UKO+6^F;NUP'W-C+V]OY-KYNRV%*46B4R5'[V?Q
M!TJ'?QQWXG S%5\@]S$0[$9*R^S9DB0P,+PF_B5;#CH+](0(%?I!3I]SU:+V
M(?1R2@\*08DH(F)]\-$)?#;UW-QRS\W#J>=F@GW^X')]#OJD<L3Q%\0*QPY<
M*80Z]9996*V=EWW!%]^?__#H^4_W?B+U>^^+^^0,%]F+%?3H%]R##()FU)_4
MOT5/P=+MA(S6H0&PF.\/<(I(_)"48HL%WYE-89^;S)-P%_I(:A+9"4F,9^,N
M"N[A5*(D)$(E#K:5"U\34$5D\=K97(.\>5&WRBQ.IZ7/HH1& _Y?924*J\=3
MN6W9UHMRGJU<T>QF75-QG<X!US>S@;3QI\.^]N[,7<?F-%OG[]FK,[[5BQ?/
M6LV!R<-(K(0$R:[<=<ISM*QA87N/G::-SOJQPL.W/AX/X^/Q$!:P7F*^CA:%
MH''LO' 4.]SU/Y#-G#35J;N)''3,XU+,S#^/W2K?,-43S,;88<I*>:"K_F^C
MVLB@I/+W8@M9^+Z^DG:TNK>8XWPR^*LGM8=/'VHFJ:^X*)?<UK0[PM\6K?,3
MD8-)$&Z;57:TVMGG:&AQ5*'0!S0-6MA3O,J)M.&#QP/3Y./[EJ(T\SKFE6H:
M1+#A-/M;\QC9FK[ #56C:.>QG,&7@Y7B)DV%A._E?'O)EL-YJF,9*DY,W;/$
M5$0*/F$)3$)^=X4\ .W$B==:B_O2DHC^%@2 X\(<Y7DE!1S"Q1&>ADG8)F&[
ML\(&,8E!=%1R2.*D)BI4Z?1\/[I%.4<+479^05',GBO73WX\SZ,FY],%E&=I
M.7\@2:-=$:J4IT[)<X#5^^Y<ANVY?7^'H5:3^4 B[QI: ZV#KD#J)8+&P[F#
M%RZ-'6@[ J0L6#N+5J-/V1R2T5*J8HJIWB]Q!.]^TBV3;KG3ND6Y"!)^ A3J
MF$Q%BZ0)24'$7AAWJ01/(']KK3,)XR2,=U88(WJ3J.-AK'\]#H5#4WN, V,=
ME*C6D.&=R30W)-*&3X^W_N9B[*\-RGNY+Q+^280G$;ZS(JQ#O3J(EW"21%.%
M4HH4OS;/'I%KO>:!]E?TN_HWLIXDA^7K'D92#&<9F,BTRTMF4"(DOSPN;*3$
M90D-J@#:HC^1_O2G<J-T"BG<$I2 "ZQFL/1/M0U1[+O7#6T\WO"['VU2)9,J
MN;.J),'E9*"R/.(RYAZZV+3WI3I/>-/4,3!?(4_&@/J6W\8KBK5BUY=5.C\M
M^HM%?_+8)QF=9'3EVPG8Y+O*>,6%=TSZA)MBP5@LC=O!^=ZYN4&O1*ZU>T/N
M=$O6&$ F2</0)&B3H-U904O9_>)I**TPDT MRW6_P2B80+-\$S+U)$F3)$4\
MF6#Y4JFJFXNB*G_S8$E;5V.P^6I5,SZ<=LZ-X/XF,^7FI4K^EP[W.AF6KK/M
M:M^6]&4@)UAS;H[6W?5N-4<_H9 U1/ECSP2Q085+IWB[JHQ1E"8\[-M&4SHZ
MR)3,DZ6M/.D0CY]H\O.7UH/S=GTW>338+FT$R9"CSVHJ#,#142?\(XS(CTX]
MX3+<^#Z\UEM,/4W#3M.PTZT..WTQ#3M-PTX?7*Y[G=,QG%%<J>IIO 0[5A%C
MV",Q3<@0,AX)5GJK.6&<2__FMBEI<\N 795"5BV[M4W<JT,SAO*4'^1*B+T:
M[Q/%>;+P9 D<C\YK<Q(^=*$&:VDHK0-G9MR@YH86M?&+.(![PFDZ;QMFQ<XL
M9 PR$X&>F %34YEB;)K!G+E]K<BMAOHB\+_1&'I@K*CG]*6S[-S0+ PT5)")
MW"+.8$;=.(!>"HN\)P,E8<9+IY,4RAX/[=&W4ES2/8CZ\"YX2(SV0ZR[^;K)
M:SJ< :7U5S#AT5GUR$J22,VO*]!:3:;G*!]<0 IG)C-E!X=9(E\@B%F,ZEH9
M"X'W#\27]E"I.DLV83^^.UR*1U[70.+BJ2.%( 9T\MI5%[N5]L<;>8QGBU&^
MH(A'QEIU_@A0%^\-K^-]OG73[3:LR7T6XWV13ABU^YV4C6@R8_N!=:,K+$I!
M.Z/K>7S9TT5X<F1.)8(Z++1M)*#L'2"9 02F#=R4 VQ.)8Z R"RN4%8KIXB#
M7J;/LB=#+I?>$1KIB.>#8C/"AOS7Z]3S%M8@@]DZ,X^-@?IQGZP8*66Q^7G5
M&S7NWYC1GH9'FN>\!TA]_M9ZAOM/!JS<X;.E&# )Y*+":9/G%U^FZ%UB5(S,
M:5 Q*L5VBQ1Y -X48U"61W']A3QA?Z%X.B *,B3C2K,9F&1 L75L]FF^*AIR
MZVC][:Z< ^JQW=)YAP?#M 2 AJ8%,RR8X%<?4A\>T"Y=$ODN6=5M9O#%EA'6
MHOK/6T")DFAU._X-+C0K:\_&P9L$ #_\Q+,).7Z:"-6T=3M(MGB<8\BI3$_$
M8>?XBS26)L[7;,HV\DD8OH=48SD\%^GA5+F(WH0"ED7-INQ^ Y(]NI^[+.NN
M99HIJW/#%,ME<56;%9[KMO&!DO$4G[ DT=MVZY0[X:ILW:2.;U,=)VP'"N1H
MF H]@1]C&/B4O*3378S,(YY]2L]W\&G*:NFB./< 'BHI]$UV52CV8MV1<-^;
MK2%/B%"%L\@#?;"N T$C?@.(L&(! HQVQXJLV-1ORCG/TT#).L>VL!58E#Q#
MD 4HQ*MR;E IX6S%0*\^*CW+_@:\M@-_E16D2Q9%E@28\1?$BO2?GME+2+.1
M'H6EB>W\A>*AT3H'910QE]M&(N-5L'B)</$<T8_GI/-YBQ66$EB0$NRW<<!;
MT/_L6YWA\_+&GD_)&1UN3FKJ[3VD\QLSIJ-/92^O5#H;U>&]_9JTZFUJ52EC
ML$;]>[<&^,R#;U.@RI;Y X719G$)2?"C7S@E]5%5/,#XP,]P+A."Z= C8W_J
M4<+("8U_N^7[J7/(H#;AX-+2D4YAA6#@>L;I0ZN@/]3MO-ZRK(&:A<)KOZ1=
M]@_0-'X90[Q;Y@XP?\A;V078_=(?/.2GX?_\QA]D24!N-D#U"5WV \</.@6<
MB[Q--?H8NHL+AA,&=A"MWKWNR==PX?"4^D!-"S<OL0>0(QX#F-?-ME:X1L#U
MK]"%#*50AVVTX=N+$GX;/HZD?=8U"^ Q5?K=MF,R3>5WVP%L:<F<.-S%&^TT
M=A-0C'2>[^%Y,J"KU M%3\)"&4@QTFLAPWOJ%D8'C?NMC;_.C@6O,6:DT^G#
MA*&KY]3WX;UK[H"NF]U(\G+23+=:=XX95*V'W Z6M(?7R#)[7'U-_!H.:L[V
MBT-,K%7*UKYIX6#"-1Y$'=#\YCI?*['G([)]P.W7F53<;B2CW3M!B)(T@<=0
M18T&9.=M*6.M/R KFYW3XN@<RHVB&]05TT2,1<GC-XFX*;PN] !NVX[\&[H<
MPY6R1V#7M^.O\2Q&_[ =9:.%%D M+;;T56[7X. 0 @W>(4E-<]@GD/T!E,EH
MY6JRYQNMWL>AXB%@*:FJISP88VEP>%/)N2F71]:5KD83(IQG]=YCU_9($.0%
MGS:OS',8Y7*0P-$M#M2[QU]FF)$.\\^V^C84R"IW(?D,?ZM "LXOGJZS7"/M
MXG'ZCF>5 LBVWZL#8U]0M5PBR@6#)1?.NFI_8,HZO[D>5G+!*ACDH:CQ;?%P
MBZ:XTM,ZOH D3$\93)-N%:9A'NE<2BHYO2/'1EH\%&MMLJ+:VBA=%)-FVRAP
M?!KI.-T3$F'PJ%XR8\5\I1Y5]'K3(^TI1H1\#B^B_T2'E-Y$]GS;O1A?3KT8
M4R_&!_>A+&CR]%(9&M&$IHJ3_Q>UQ6$'3)$1M;HE74-Y#?O\6@>+WJGA]#G9
M4/BFL,[B3Q1.-$D>5-^,'D^!5YDLJ_+V]GHCZA,US"S!%PF>T#S2D9J4UMHX
MAR_7/-K ED3CB^/\1)IX]C.2"6-8W#G(KE3 K@PJ7LO\U?65?AWC#*;=<W)/
M:OZVU?Q7DYI_=VK^VMWXJ#9C8K3\V/HOT+B%^ETY!Z.<,6D;!Z/')29C(S6B
M)NH0Y%A"*,9\8:_M6B[Z\U]/-4.BUK6@R/&X-(,OM!.<R7KS0($QZK??4C_X
MY%/=@M3^S<&;BIHLAH&H-DL<B);-,3'LE1XJ_SBO*'L942Q[U.,0HFK0 %ID
M3:] VU7ZYW- XW,*>T"IU.@5O?BP2(ZJKUD:?KH"T5\K&>J:G<+757T5*O#L
MZ8E<69.#D=581XU +RN!3]2R8BF7: W]!]9+792<QD:Y3RIPB2[0#.%8N[#)
M=5%%I#>:]0[-%M[/#GW!JGH:SPD]04)_<!=N&CG\$"!SA@IW,Y!8VH?BHG&.
M-6UK-3F#BFU0-Q+6.]\:/]HJQ\%1(7W@8.H@O8CL,*E CUK%7^+U76K34@"D
M%06YZ>N5:2!_DND[*]-L;8U+67UL;M$:;405D?[-:E*UM[RH[DVR-,G2)$LC
MLN1M%A O8 ;93Q4";A2\T3(!EFLFK(R']Z4,^>CE<QVB[S7HM"4'#)PII7"W
MC4CLQ</5%@\FZO)11.4N:D!*6KH1V=U+5(73N3&QJH%O!ZM0_!M_[TG:)VF_
ML])>*E.<%1L8GGQ6%\U"Q/;9R[_)?UC]'5^ %IC5'!<W;BDM"F@(DWITKGFJ
MA>:E?!)+_5N=B4",&\&F*\5OB;D*GC*0F-553;U>!V; 0 :LC5])S5UOT2N[
M^YM.DCY)^IV5=.FU%'\WM<" ?ZMIO9,EG.3C#LN'GVN#4XBNP%)LEC2;IY+"
MGG%3;[>")"'&:3(RDQ#=<2%*L;WA-OH,#&8W2Y[DR/[5 9K*B+=B_E94%8]5
M;_Z:3=(U2===E:XQ$!B>;J-3*$VZMR!BB8,X)4@FF;O;,N<'S) 3U42')"5D
MOF$C,R[Q]'^AP!)H9[AR.K/*>8KH&M&PVK9N=_>BV3K!";[7;2?!FP1O$KSY
MJJY;*SRL=ZZI9,PH%A@IDD>=0/C(#^9AW$RGO'K35-=:0Q9;#/N17=U*/"C
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M]P3%TD=FH1N_;MIL+54W)C@4<,'6G#LP2021 I"<:\ )-8[BQXP+\@4CWAH
M#BI38Z5U-D;]E>%Z<4:K%HC9580=>*").1=7TO]UB\$D6KXXAM\]>I%,,WB'
M-G8A)\4P*89),0@.&L_U01OTA!BY&?K[>AUXXWTBIXPH7? YTK/"OE)5%+#0
M9Y. 30(V"5@J8#-@Q@M,RZQHD)#QB$\+^4< C*7/&$&UG[01LW8!U(C*(*6.
M@ "EJ9@#UI"1^6T@M^6.-F%89 @9X/\M2-R9<!B#A"YZ*)GWO7(Q]J(QX0 7
MO043%33$VL_IL5Z1Q(P\'</\Q/O$T#^"@*X(&PG^T=H BR8R[G=Q>O_A%%",
MX;L#L+;!FHVP7Y%%2(ZQS8/*^P7VF!YBS)K:.8CF4MMP  ,*L5".20(S%.WH
MZF^9Q10(IAOG/I4N@+$U(WBV/G:;ICYC?*:E'.<8G\FF[B- ZA%'%]9U/J^;
M!3-6L#M\0')9(\3.MA]?PET9FDT+.B.W":"=_#!^7/YM-SC/N@K?:)VK#."K
M;-O.)4#2C&BN/0UYO"$Q1%A![[UR="YE-$OFCPONC\A]:H"V*>C!@*/JH<R4
MA*>17L(B9(O?LHNI!\(=+>/0VV$*]GI=SNT@<1T[U9FJ9 MPB1P<V_1,?WL?
M'=%6Z@K.@.1?+>26N&:*?(YJV\P _X[=@(5SR?8$/#UZLF/2WH@V@Y$%<_B
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M:4Q \H3M.KZ> R=0#PH?NF9?7>"]3EKZ-K7T(QTRL^Y0;>?'NWSQZ/QOX@T
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M2.=>W( Z<X<9O85CV?=6.;0'.FU47>\&8=<-'V6R,[=I9Q[)6>9VS%,];*E
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MEPTS^8;/@7_;3 ) 62FF:[5E'DGU5D8\TF-JF9):1R\,-@ 18^/HKFV$_66
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MP1LF7PN0?[*P40@?!IRCM6,!>0]Q-,AM^J;8(\.(,"B3HX;%!O"MYIL8(I\
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M2%QAU=&Q]<@9^HN7WZB%T"]&=Q(*GRT?@A0);&-2'V_"Y)&C-9DL1.%P- V
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MN$>6FV)1DXJKD<(<#H$.3=>5;( Y*S5]<!&,0>"+P&H,%Z781"11A7B""<S
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M1]2*LN0ZU'"7!RQQ&/1T4<\#MX#5$L#Z'KJE+A;B'+FXQ+=O."3$4L0#S?F
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M<VB?Z?Q.GKY0%B9B;M^4=&CPVXH5PK1V,MQ5^8^!BS6KKMFS>Z;O*"6:"B0
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MTP^#9K._:5KD'9!M&5K.#V4>NUSQF^LH'BH)4SD^I-B1LXK9&,\2[6>H+VG
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M;]KDMI%MBWX^_X+QXO:+[@BHCB8/:L?[H):'UKD>="7[]'LWXH4#)))5L$"
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M<6)-%6(S:^Z$R3ND\>WA,K=+SGOE7N^54)<G! 4E\U$-"V2>T*E]<-'LI8V
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MAK1KJ+!?2>=-D$QU8D,&]JIO"%U /+(XH\D901^>_-J'E.=NV-M (31EW:5
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M)IIWC1!JNG;#+)VL.DK_E$M18PHDY?V1J/IM+N7/C/G'85O+>5Y2&2)GU):
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MTF0>YZTS;YU[NW5ROW7Z>B6=Y,>V""&G#/+72.\ QQ\T>JQ47K;XI2G]9]$
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M7Z_SLE6-%#]+*+NU44I[+SA,XGZ. IQR0*P95$:HLX+T@$0?RZ]14FP!O8J
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MJY7R,Z:TC8[T:*[0?2M%$PL2F/"=MB1END( *9C=;-RET!3%@Z_;O'Z[^!=
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MD%-Q([/@DK0>.^%1,:8-];8E[52+7>[08C?M56.:XDHIJ12SB<H;,14M*;
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M]T\X;GSM_<B2;U4=X.R?/WK;6HY3KE^><EVQE/L3+>M)A4R7L+'UACF<5'6
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MS>WEBCR*@;X#:@.[57%>EKQNG/_=.W&!LX,'SH8N<.8:EM9,"2;7M4ZO^%P
ML_<]IPH_CBI<-@L8:U78MK5!O*QBCD*-*::L\;*2>-'Z3*LLFXER+;+Z(YD3
M4HHLBBW:(DMF86I=Z/40>'.7JG%E5B8%L2@^);U5M@A[/0-$FV(5DLTDY70N
MK7SJIC SF\!?@DBHXB==K20K, 4I,:\'L\YP6JY&)X'*TL]<]7NM+&EJ=?U6
MK5Y4:]B-=*9N=22*40OMB0.[,I$WP.YL\<=C0SI4^\6:1^/8SP'9SX^Z2(@4
M67(TY;HULG3"R1R\.8\Q<4SJ\'@MU2G+/DC[&A=OYX4%&;N283^I>\JN*Z3?
MVMF)I=ES4Z-;,D6J[G2,G-N-G2G\IV,".3&G:_CABL>P%:J#$JIJU.?12K5'
MG(SL'$V+8919<B9H4:[TC@F9RKK;M6QXB+5TV_K$M )8FLR._%V.F?%SV3U0
M>V?IR0R+&%6]JA8;\L')18I+T;W]_!C CF-<;NYYN!GU]$X",!;67D#IHBJ+
MA6Q7*NP!4Z1M7HO>Y!2G),!ON1S(9*KK*7+L\XQ0_]L_/Q,J3=D_V&X__W3:
M\F)6)+##C34UR3UR=T9W7#WM\%A4H^5_3:^ 0+(6'13,^O69*+MVFK(1%:F5
M1U]*>KK!E&=GNHE^V90RP'AQ3CXAW3ES@Y:POA9?>L6RH!VG*<472O>);">1
M7*; %8271>*;4'5L*@W!5(\S69VF&W6"W@(ZUB6C*6APQJG4C2B4(IZR #-?
MP.N!(9"=CYP6/2++E=7X&+T7=/15MX6K+$5E3OM4Z"4!+XE9=YXK82%2X$JJ
M]=25Y@\=*^5#MT,F14E(;PN7_%L7@?I8Q8QA?JGW5!@$@1 ]#?@<G38%.U)=
M/. 1P.*$A)&M/<%EV%S//,) U'D1#NY%&#DO@DN_?7;._PFYM:Q.+-F4-4N2
MN#8P,U)I$BP76F//29GH9CIRO&UDV6\07>JU*DPC1NGL3'YXMT5<8/B">KU^
M&\;\>L=!^E<!_#E<Z_?19:!+L"Q_1\>E#3M?BK<H9(!7\YV'JUSYH#/  USK
MT_8 &JX U4 T2A B;0+LC>_=)- ;8&Z#<CCK#;NC[G \FP+?!; B*[E&?[MA
M)M99J*ZJ7B"__Z$OR\9D9F&^7O&6JIB&!_@I_JH4)#WXE30&HRV0"K.A7E3R
M-5JJV00W5Z%]0BF4.^^4;<M7*:XPDLT#-C4:&4'T_$6:"JZJO;':6G6YDQS+
M;@D4<AX@:LJ4-0H^VOF-1;Y(,ZIZ?.>5K  0K_YV+,&QA!?#$G81>G4R]$9F
MMBK14[K"-LG:Q%C.GP4&@UD@U2?+T/GV,\CN4TZ%=XY"'84Z"FUI\J3YRD4N
MAZB&U='OEQ' MII!>1NU.O)RY.7(2VJC<U42U3*="S7!\02$H.S$B.YREG,=
M]I0J[,X66*K,T5&8H["72V$4<0R!>BBL"(2TD,VDM8\?-<.UP*-)Y+3 &2A6
MY XN$QC(C^VQ*10D*+OCR?F'*K;OR]P+6PE5[U0M[Q(6Z[(%H/I+7HU18! "
M[G$TZVCVY=*L919N%-,N9%_EG02JNHBC_XCZW0%5(J'."Q'1(". P%6U>7/Y
M%'[-_2*7_23#R.>J5MZXC +LV)RNY.1'_<9WCD8=C;YD&K4LPFK3RC+?!;M7
M2R>K3GQ!ARJ 5V;Q@U#]"O\&S+2F4(8BB%*>B#1SVJNCLA=.9;L<I$!=#-1-
ML:#?=?MES$VALA4Y.@5KW]2\03;'V7R1&D1X=_>,HSY'?2^7^E!]E)2SINXS
ML@6BG8*IIC*H*<U@Y+6HBW[&+N28')-BEO%H.2\RP<M6D]1HLBT;38)TU#JG
MN44]6Z;2RUQ3U6Q?$:U)>]1==1RU.FI]N=2Z8CG29-E1Z8I&8U^0\:>Z-*1%
MWD[#]BKUD;3V$I*.[K.YT%TG;++^(_4HO@]E.U/1$>:+)<RR:>,-2JR9]J>B
M'M2><IYF>@")- BY'?00\*28 2GB< '9$ES0A')';([87BJQ[?:;6EDNE N7
M<W^1P-(O(JN[ N:Y(5%(2B/3T*<$W,X>@G()S]_7XQ/'7%(IENQ($H6>K'1A
M0D\!T,6J]DRDS>%;8K-^!8\  "4K?)F;:.HZJ&),]1^6Y2 "QWEA^:NNG,&,
M:^S;J2I416OGR)R[-R8-^#S7 2YZG'$(ZB1O58EB.^;+A,P'2H&.]U7U_;K.
M39T.-OYD."/&\OOK1=@U<WJ$F08% C2A+C[8ZH(VI*9=15S!)[T"-($<6UES
MA&6Z*M5)8_]1-.],(\!,U>; ST$4%[F>YK/9WEAPZU6*/A%(Z!^%U05JPJWQ
ML5+_7EZV3&$!K%M@CQ!&K5K*!IH[6Y"H=7:\GRI8DQD($AKF0]EW1G< ::G%
M4254V<--Z HIN6@S0A.6OY0UW"F5]^59).N[-RSN''W$V%HN H,;:ZCD*9#E
MBT*59V^$<A!!U"-&N;X(OU1:!)<4F<P%EBUL9!$Y-IQ) MCUQ[ \(UA865+%
MYC$T$-]U^'31JAXC0:=$L5?9Q11[O(*L 8@"_5VRN* F*@HO.*6BJ'+HEO;/
M:0^ P-ZS2T'ITIQF8% A%5L*.4=X*XL9/J7Q;24!89LB.FFFD S[[\"!I%FC
M>@QT(;2]@U=D6(<O^Z'BJG>.3M)@1*=%D>CG;!%>%;XEJ6WP"]G>%ED4DH@"
MXL:4X8#'V.*)CE1+KY%DG.Z1JV;'$5#L2%Y:5IR8/%$]65/G#!C(E>A1C["\
MK)4W6&"G45:RY_ 5$3R=FBLYJ II=<_CZ(#O0B/:F5AKV)#I=G<:;^>*]>Y3
MK#=VQ7JN6._9*?NCT=7NUM%ANQ.$;NEM.=.OTJPBM($++T@KVF[/(+5FU50\
MHWS])*THR4%:@"1A1IY:6H4:-<]EWI9L;Z"Z"NCQ5JII.;=RLTS5-RKGF9Z%
M2)UK,JFLS[&_7=FVKM*U3K9N\+&$.BQB:@_AZRGAVQ.76F6W#) "_Y)M9.2\
M"BFO-D$EE7AZD:P'9]C[E<8VIFIP!SDZMV<[76E%M-I8PL#(+H8WXR-I.F/'
M:W(+D)?9 \0U''JT/APT6?[G.+UR;88.*6FP,5B88G<:&KU!!H7@<D(..K:
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MT:@3P[4DS::)X<FX-1K6HKBJL03^3%Y_^)<!;.C'?>#XX469B#6#Q!/,PGL
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M60JORM0'!SX>O9N.1[_7Z3WJ\:!O 123SM"\YWZ8/NCIZ$\MG-@QX+L=CQ-
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MQP2V"$O_"$Q3Y&DFJB_.@#Q!PT$EJ]LMM:Y<663R7C\& Q( J0 ^&+Z33R-
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M,5$A )E<BY,"=+LR*INO@AB]A>TY\$(@4A5H ,0MHA7UMDF%B$R3V&THRE8
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MWH^4GT;>KT]7"=R$^6G&FTH-9F6"5/5ALK%16:"F:M+L.C5GK]>1"SQF5GA
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M$F.^-3941VY @0_X"AU[+E#JF/YA%(5;* J+EJ2OKW(LMR*(/Z8L"RKG<V<
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MV^X[NKP=LW5:Y/#X:QZ\DZ_J=0E\Z@9 ?\Q6@K\5<FR0<5]EA&AZ]BM\/RS
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M OU?[["U^;4<8M&(:2.'1HH;^+(+!0!P_.;/K_JOGA8=>T? >%7A7'=::M1
M&#MC_D_S#(Q@3)NO!WT>RX&H"V77"7GVZP",\$;'C1TW=MQX!S?N-8*@&W,@
M:D#9A^LJU^].6OTAMD[K?Q^2:]);KKE^FU,A>*4$^SZD>B@LWM.PJ7D<XQF%
MJ4-(#312AP2'A)>"!,>::H80AX3G1<(!=>1#&4(O1$=^S'2V]T6684T,(VWY
M;3TLVYKAM [4][R^I_IWLJX-CAQ>'%X< W,,S!&*PTL-5>^JG60#6#WI<-JX
MG=[5LX#M%/1[*>C8>L_T.\1N&9<LYHGS;-=;TAT6"4G:'!0\@,">BI9>UX-F
MZB_TO@OZ3>.PJA;UYXSYU(I"%J,&;,C8) S:T]Z\VQX&X:S-@CEKL]%H/A[,
M!U,_&&P6HPZGL^G<GP[;P]YTWAZ.9O/V?#"8M"==GX_9N!M._)$N1BU$^X*Q
MU5OD[Z=)@/]\*)G[:?Z>91GVZ?TGII:_\HHDDF_YQ_D_SGX"[1E.%3P%EA!P
M/P+8B#^_:L-OV)B$Y7]^%5T#T(IED.;J^U?_TP.=;3 =Z=)0O=__<3SLL.>_
M%A+#B>T:(*%)1]Z);2>VCT%LSR9\,AG.VV._#R)X'$S:C(>]MM^=]/NC<#;T
MPRVQ'?8'P_Z4#]IS-NVWX<=N>\[]L.W/^ET^G@YGD^YSBNWI ([PS(GMVHGM
M1XN(.K=,[;G/YXRO6(3]^U8\$:JK<TJ= _U*2+4>?M::$6I#]+W[(N%&7GG7
M=.V:H:KY6#E\&KU3_YZ? >]6__S><##LS:;MWKS/VL.PR]K3^6#2G@:#4;<W
MGP53WC^$UT:Q_P^2^X,B^ E9OTPY5RDU!U'^X(CW)X=2_1P[<^SLX65^3C5P
MM.1HR:D&354-IN-@SN:]<;LW'(_;PXG?:\]\-FH/!GT^&+%Q.)M.#^$9>BK5
M8-#JCYUJT%QVYFI.C]$O]#7-<4C,(5Q +N17 XW"N<OK#&T7L6L2;]RME\W[
MX;P['@S:W!]-VL/!<-!FXW[8#D/6GP1\''1Y]Q NF\-K8'#06Z->WT7F'*NI
M&[R=='UV%#0?VDZZ-E^ZCD:#^7CJ3]N#,.BVAV,>M*?CB=_F0SX;C/O=L,>V
M9JH\Q.OQ"-)U.FZ-^F,G76O':EPG@&/T7'S.TA4 ==VBN<PY);1@N=%*SG-,
M>%X/IWS-T-P03>N@#MZ:H:#YT'::5I,XY9[,XSZ?CF>@6H7#?J\][(W'[2GO
ML?:(3<+I=.Z'O7[O,*DGDD]_1BY]F@0?-(_^C1](\6J!LE3+P)+C.T[4.E'K
MCKP3M2];U#(V&LW\\:P]GW9!=DX'O39CLT%[.AO/^7PV'/B3X#"I'(\L:L>C
MKA.TM>,Z+C/C&/T;GX"461XE%U[,F> >,==V&K8+^,4E:C1=ZW+^W3I#VVE=
M36*5N[6N6:\[",,Y;_O!C+6'?#YHL\FXVYYQ-F9L/!@P?WX(!X=AU+\@G_Z"
MN_T4_D-P"C$=1.WJM_K3@WDX'.-I,..I&;R=K'UV%#0?VD[6-E_6^HQ/!Y-P
MU!Z-6+<]9.&TS:;!%&1M.)H-!C-_$@P/X>%X?%G;:\UZ0R=K:\=X7/.2E^L*
M^<)%GD5^SF57V7IXWFM&C@U1Q9S;M\[0=JI8D]CB;E6LQV?!9!X.V[WYG+6'
MW=ZLS4:]4;O7[TW'D]%D,)L?I#ZE9,K85.XPW4.Z!^OVZOA,@_E,S>#M1.NS
MHZ#YT':BM?FBE?,^ZS,>M /.>^WA;#QLST?]:7LP&7)_/!GX,WZ09JV/(%KA
MI#O16CL^XS(WCM%=00UTO#A-+MK R)<N6:/QJM5!_;BNW5 ] TVN>]H1J6JS
M^7PT]L?]-I^S27O8X[P]'77]=F\X"+J]83#CTZV U(.2/\IF:;^EB7_ >N+^
MK)X]]!W[:B3[<HU4G2K@:,FI B]0%1CU9OYPV&V/N]UN>]B?#]HS#K*]/YKP
M;L_O#T<A.TANRJ.I KUISZD"C65?KOW(,3IY9.-4-S.GZ?K<(W:2[G?ZR!&#
MM)C'O-XL\0BG*3YJ;_V;4.N4PEHQZCW=]6?]^;C/QFTVG(2@X#&_/9M,>+LW
M#\-P,IN,)I.#C$N6^N"!0GC#UK17SS!>8QE?\P72]_(MYQARBH13)&I$D$Z1
M:)(BX??'O=[4'[;#<#!K#V=3K#(>SMKS<7<^[H%.,.:CPS6L/9 [:=8:#@[F
M4G*,K]E.I2/.'*H=#_'J%.6H&;)JH^<!R/&;/[_JOW*ESC7%D<.+PXMC8(Z!
M.4)Q>*FA3NT"M?=2N>=I'#P.MG^)V#R*HSR";>.$B+,\];\MX'4\$__]7]?]
M;F_VSL,^J?FZ'NZAFF&[#G1Y3YGVXBKS:H,CAQ>'%\? ' -SA.+P4D.E_(@=
MW4V+I:G!BUY<JN=OZV$JUPRQ=2!!YU.J/YMT/B6'%\? ' -SA.+P4E?]V_7=
M;9B6?NK[L-A<>"NV9IB!=1(E?EP$.)0HXS'#AKPKEN5KCRWEA6GHF31+ERA8
M212<3R:],>-ANQMPWA[ZPWY[SB;==G\\F8:C$>\R?I"^G!IIGR7.OD@\?08T
M@9%UR('W@_W-.IM\Z"4KQ%B1.\F[3W*?#2=\/(*S.)NP]G#.1NWIU)^VNV&W
M.YIU1Z-I_S IKT]UDGNMP7!PE(>Y!7Q:K#ALZ)+'ZS?U<'PZ"^79TZQKA@)7
M-=)\8\4)QO.@ST&>A;VV'XY 9QOT>7L:!KS=&_MAM\^"L#L]3%%I53 >4A3.
M6K/9P4;-'3/+:KZ <%*Z!DAHTI%W4MI)Z2.0TF/&9L/YM-?N=;N#]K#+)FW&
MNT%[%,SF?C":\AX?/X+Y>D@I#:=U5,]&$#5C6<UUEE>#'<Y97GMF ^2>%3BA
M+HX2!+:79Q'\S:]7/!'<M7]OL%+GQGC6&=J-U\F:QNEDW<S04=,+I*::P=L)
MD&='0?.AW7@!XHSZ\U[8FXTF0[_=F\YZ[>$XF+:G8;?7!O.\S\>3<,Q'WS6
M?K5@^5NEXK]7&OY75/ _*/W^L/'H8;=?RX[?+YOWN%PX9]YK>][EPGT'MP[G
MOC\:].?M<=#WV\,A<-[9;,[:K#L:3H(PZ =LRP5[GT"IS:TU@WZ\]*%^:WC#
MK*8F'WJ7"W?K269L-/+'T_:X[X,.@7/7V:@;MD?C 9OV!O/I+#B8WO$4)WDP
MV!]7:/))=HEP1V-,NWA5G:'MC.DFL<4]$?)PSGN3$1C3,RQ5F/Q_]MZUN8TC
M21?^*QT^,QMV!%)3]XN\>R(XDKRC]]@2P]+,QGYRU%7$#@APT(!L[J]_JQLD
M18FD+F0#K ;2$19!XM:=M^>IS*PL*L!8'H%KQI,(GCMQH\'[GGUL':Y=F]$T
MZ"I:3)0V6"7'J%.;O!%H'UT%XY<V NWX@3:+Z#WU"K+W_=&4LJP>F05!;)#"
M*L;E4*UHVP3:+E]]]V9 C#I[D*_&=K21!9S+?/6TB_VI7=512ZW,'T="Q+"$
M5[.TD8B-*2[>3L2(8*3/<]#D. B;&5BM$G G!%%4)!WL$!F/EQ?1> M[ HP4
MV#* \:8V>2/$/KH*QB]MA-CQ0ZPTN6"K$V!#5RFW7(%U(4"'NUI3(@(+0^0Z
MM@BQ0@^V-1[C38U9#NS*&UFH>7V6EF[5]>#-DFO3]7G2DR9L7+^.?'QE/CH2
M6K;%LV7)D^YHV78QFT8\6;:B$['OU@O2O*IB[^TTSR9/-'$&N$]RTSMBK>3
MM*"<9DJ,N4'S[I-)N8K\/W>!_[*R=3XDW=.DSNX1C&.CC&/7OZX(H#X%(2=
M7QJ)+R$G&!,GX%2JX!DKGTXB""$".*X2N"224;R;A9V&2/WL@!,(4^=T1(QC
M>)C8H2:!WBY6;G:9[;F> JJC.E&9=D?"\C!!7K.TL2 WI@!YQ[1JE2PUE(+P
M/('@08$)WH'1Q$2168CB!BN[3Z9F2UW'3$T8QWH<AIOJY(T(^^@J&+^T$6''
MC[""4T(9<2"YUB TD^!E5I"9TE[G'#)_T'"(+2,L-1/+*")L=>%F:QTO>Y7&
MJ"Y(-#4EV"M35C6<Z>N/"3ZX#;O5Z CU@GK! (8!#!T%]5(AI\;28#64^^?%
M_!T4DS\MJUZ_FC3SM.KFLL9IVY_-5$<NIS(=U^"-F$\8N;1'CTF8OOS-.^VR
M\ J8HP$$E=W>O:@A$I-8)CXFR08I$)8@_;;$Z.<E1+]:S,.0Q]D6&J5P7SR&
MG.KDC2C[Z"H8O[019<>/LH)Y03A5$ R1'6(&L)8;R%SF8&WF6<9!BH3;0UEC
M)TICH;"^D(.%PGU,:OR:WJ?Y.EV-]FOR=.[FH=\%?[GGH8[48V6*'@GGP@FH
M-4L;.=>88N4=&]*$9U1D XD% 4+QHG.B-+AHJ(HT2J[=@\^?N@C3E_.(?KH,
MTE?[T@9F8938B60XAQFC4'7R1N!]=!6,7]JC!]ZQ8><#SWE';ZIQ'8_-"=7X
MUV>&U]61/ZY,OR-A$9B_K%G:HV<1N'S_C1IIO"JK<&9(5_[($JP(#%0601BF
M,W%^BS/FAEZW3X@=;- <!I\1!Y_*Y(UX^^@J&+^T$6_'C[>2,9^ISV")+P :
MC0:C.0&B"PQ+R6G4@^QCWA7>4L,1;ZL+/MBLL)=)CM5)6C:SJWT8#T]R8*FD
M AJ PRMK)&<XA!=)W%TD3B=-B!.Q?+HSA<0I R9UZ1-%I;0R"$)OD+A[)4VZ
M@']M(LW [$U/)"%5]CA@%!ME%,.Q_,@(T)>0$1P>(W">%4K *&BM"R-P3H%A
M5D,A CE%&I0/:I"T#C("C&+8W')8>9_-4'YL:=D+;C=HEANC8IVE..1V>\3M
MA/.1$4$@1Q-!1!;!.I5!"9Z2=M9G308>[C_,5']N)XK5.;$# ]<H Q<F>) $
MH"\A"3@\$J"#I933 -%IT25X#%C//(2@4I#)&TZ'&2TR, F@M!BU'FPG*P:N
M,>=T]KB7I[HP@B<4C("EX8#OJ@=)X\YGU L&, Q@Z"BHEUHY]1[721^DE$\^
MJ_PUP/0/.)G&<DM/?_HM!Z)L"@R\L@8$(1:\#@*X=8D)[[.([HL?XA6W,F4"
M69,,0DL"QJK89>JM#8SI2/S8J[_/%J>GT]5I^:5MW#SV.8;I_%V:A^N5X-M^
MC/FN-[[[_:O%*C7BASH2>I6Y9PV!]!M)R,'M>*Q&1Z@7U L&, Q@Z"BHEPI7
M45B9P,I$#<JJP:TPL5=_Z,/$'NH% Q@&,'04U$NMG'J/*Q-CRV:_62W"/T\6
MLYB6[684N/VQ2?]:3U?G3^M8\5:FX!I<$5-#]8=+3 VA7C" 80!#1T&]U,K#
M/UY'71?PQ2<-1\TOI-T%I,L/KR 6CHVM'R]33LMEZA1;>/ND^=-M'34/^NJQ
MB>3V35%$2^NR\V!BBB"R-V!X-]'8"<J3=%K(-,3.Z"N%].NH8[=\O7RS<JL4
M_^%FZW2<EF].W#)]O%^J/.Q>7U[5OLY'I^7N@GN^F,W<LKUX]8<]5"]?_73G
M+2JCG! ";#*I7*[W8(4RX(*F(DEJ)1EDL,].;K'8 R&W'2Y]Q^:P,3OQ)K2?
MN67SOI/@CXU;KTX6R_(MQ:T[Z;3-Y:%<#;KW[7L>&;7&> '>JN*JB3,P7EHH
M#P*+*25I[?#NW9MN>W2EK8]L?J.Y3PW[<QL@;[^US'(6@7,H[IN+B]+NI/A,
M@9?KSRDP'0P=WJT'OK5""HL_=_\?DDN[5?,\A73JT[+A=-(PPEC?&%L>4/3E
MNWR9:F<=-2 -Y06JLP5K0@2N?2;2"D?D($-,;C/XEVV[_F9C[WJ].X/ON'";
MYG??%S6"4 O"\W*A63%P.1 PPGG)N)0RL6TY\C;OR\F8C><.0F1%]E13<*DH
MP"1&RG/E29.WI:_7ZU6[*AXUG;_;SLVEI',R3H*EO&B.I=P=%UU^]<+R%&W*
MX@9O'$II ][<?/$U<?=P(O,%K9KV;M&'Y,4'83>?C=MUE"@QA_CH<SXK4\'X
MI3WZ;."#5/"E#612&DED9MW*WA3<S 5?4L$70J3@SF87Y(T/&5]P_N3LZ8]_
MH+,?C+-7)F_$MT=7P?BEC?CV.7S3-@=C@X%(9%GVIU16D"Y'T,92D7A9: 6-
M^(;.7GD)]>,2.)90J_?);FC!8H[UTR^<&F*BX"HK,%1J$,)E*']28)-DR4HN
MA+DQ5/(^2;Z--G9?/(TQ,A&(!$]BN3\K+9A8T">YH)C3,:N;2>?[Y/FV?W]8
M.<7*Z3<X=O3"9TLL9.82"*4X.%&<U I)8A#:)WZC:^"!CKV;LFGQ:$N*![.L
M)8B@"#AERQTREC1/GFLY2-ET>_<E"!9-;Q9-+U+VZ-U?Y=U*$4>BB$ ]*UX@
M8@#KL@'2EQN=EEH,4DN]X07W*CC>\  ZT8Q/.#'[;._%M-%Z;[7>8!(I(@K%
M"',N_[BR<')9 V74*F>UD&R0CK;M6&\)7DJJ27&U?;;>ST7K25-$=I;*/;]/
ML_,?/ZJQ8@#_*A=@FB8BA (I15F7Q)A+,!8$*.].=N:$4S)(8]L-%[A_\\$M
M45PH,S'ZMD7)WO@!1O&[3%@RXJGMNV>B ^$C!:,[<Q1><<T-I]1M)8H/9\*<
M3"2E$\;4/IOPUX?R.K8'59:S'DF-<-!S42I3P?BE?=@UPK$%SCLX6UEG6^LD
M).$IB!P<6.HT,)&YBXPY;\+ G*U/( ]R"A.O\OPEC#,(K0BM:/((K8<-K2HD
M$5)R4%"2@'!*@%<Y %%<6$$)+8O$@=>2"*W['&=P>,+A=OZ\+4IHU\OS3>\/
MIJ*_$'MICH(G0B&JKJ+NDP2;/"MKFZ"=<T0K.<@^OTNU]-'W(A!?9.P>E,2C
M=I^3=YA_OK/#)06;2 A0UMZ%,VAJP'0DP#%/B^UZ8_(@G&%K=KO'9GM1!=Q^
MZAFWIU2P8L..]9JE?=CKXR]NORSQ*0?I0-*NDXHZ6@ D.TB&4ZNIL-+SL1-B
MW)Z"SEZEO!'?'ET%XY<VXMMGMU_F$ KK%N7S7 9!"LAY$\NR1RJ>F'+>BH3X
MALY>>1(6MU^.S">/8IQV20TW:\[<-!;I-<&=35=N5D=9L#+/' D3P@I5S=(^
M;"8TM@AY1U;;$J&YCV!886FBT!HP/F8(*2I+HN!"#;*SZT-\/B[A^>7\V28X
M7RN0#U(;5\5VF;Z[O1KCS^'$G\KDC9#[Z"H8O[01<O< <B75@K( 6DL&PB4&
M/LK8#1>@(ADJ#=5#%))W!;F$3B3#IK3ZX@\VI1UP/B2$]>EZUDT%*JZ<IV&Z
MJB,_7IE+CH25#9HE]N75:?E!3/)LU;2+V30V'QMP9:H:OU:^X!I?JY?Z6=[8
MHN7WV/-X*U7U.HNLJ(2D>*&=(EMP7 DP6>J<K)-9W#AKY#[9H5_3RDWG*;YP
MR_ET_JZ]AE[/-^#U]52U+599'GV6LVJF)\0.QEDQ.M_+Y7=EVS^,(KQ?_[IR
M[_5I&*G2:)QQ_%I!JE0I44"J=,>V)B.T4%*!U2)VDXTI^&P2%)IA'#?*:#/(
M"5^[IDJ2V0G7MXT.Q>A\(%1I:WU5PR4-QZG5Q]VVNEBYV6;/ZLEB5ORHW?0U
MVA^;[R\RAC\TZ5_KZ0KG=(V8#@]:3QEIP!V_5I .5QI%D0[?,3=?&L&YX< \
M,X7:9EV(,4O &6=,$LU"NC&M\SZ9PS?7\.M%#U8#9PK%Q%!197%[I,%X;.RW
MNFB.B4)D1LB,#HX9(:GH.N=\5C& MZRP!$8\.&LML!!M3"8F1P89P?(04O'9
MJN.$RCI[TS%\/6I#'2;"'CT1-ILZ/YU-5]-NCM \WIX8>U Z#!OI*J 76ZP_
ML">L"YMQL?:S5'?<K'@-]J<ZO.OK58O,L:IH?CMS3(9I:YV ;@8%""TI>,*Z
M4QTS2])KG=(@YQ_]_ %%CN9Q2SR2JBXI-8:2[(A"XOBAZJ$1#?-*2#&08E3D
MD$@QQD0QHG4I2<9!^^ZXGKY-WD<)SDIN75#!ZT%.BMX-Q3!V(OC=(X,Q)-9/
M,2ZS5>6G*[+I']XECC]O5QH?HM88$D6;-W?7^+3;,#T-=PK_34J-"V%Q6N[J
MO#N.=KY8I?;)-6W<7^B4[:/4/[F%*^E_UL9_@OI&E=_K1O@GEG%RE48^<^_2
M)B:"RT5K3]WL=W?>_OA=\Y?'=-PA:?B])'8CO!U$%/,%T+?#78[_=O3V;Z]_
M:<K/7W\Y>O;B[V]?/COZ^<VD>?GJV9/;O*RRZV_J,H6>^[4KMTJGY2^_+?)O
MB[.T=!U7&K69O+F\I;99Y.9U=T^["L';NZE.*YOBSK."V,MTDN;M]'UJ?EZT
M+9K^(47![Z?S9G6R6)>7QG;2I#]"Z@K>W2DBO7T4>[_\[;3<TZK]H6;9/SX@
M]PN,VP:XN/5J<;E@ZRZP<.2GY,?^Y3!SYXOUJGS\'ZFL_OJOHJ27X<4;BM',
MW%F;GK;IS)6@FB[%TZ<@-I_]W:?U^/?3=MJOC\^?7K[_EJK\YNN4?B*H^7,G
MS]L6LQ?7U%W1YU_!GPA-'_XQ3Y1XG&OY3%^#>9RVAIOSS"Z9Z%<MZ$T=GF=V
ME9 N*NB>^8_OU'>HH!W#TG!*_N_DEFWSHD@L_KM?EH7?]<.LZLA9UZ[O"AP2
M@^EX=?=Q,&4?@NF&D&QN_J[>R&HG'U2I[5%%YNX@P2\&8+21?8T(7Z'AF\T3
M5:CZ_CT=P^OX'KEDC/E[Y<]CB_D48_XAQGR<=[*/VSQ>;PHS\W=-^N,LS=O4
M/OTF., !_F-JPD2]'(1>*HN)U2@! Q@Z"NJEG@V^>&)&]?SPU]0FMPPG?0-
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MBP[[IQ[:E\@F@HJ)L1HWC!Q\[*E+V@BU:.Z50BVNVG&[/WI2K=)&X$!S1^!
MX$!/JMZ3ZI(V @>:>Z7 @<F]'27W(K.9ZFS!."E Q*3!,:' "I^-E2+D:(:8
M\GE'<N\?;K9.M^?V[CL.AHF)M(-M/,;H,]KH4Y>T$6S1W"L%6UREX2H-/:E6
M:2-PH+E7"ARX2MO1*DTG+3W1#'A6# 0OJS3O$@'+<UF_E>M,W8KKX=,\<95V
MX-$'IW9^62,CBRB]3Y=PT:;8=<">I7GK'G#>/>Z<>73\QW[_>F6-B_2=!C=
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M$QYO7]?+%+GVR4)P)G3K^@B.4 .49$N\,^5I-T1#P_7@_#I?+>2?+=K5-XP
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M"]-E"R""05!DJP%+C,BY*8<R/,/E'91QXS2:"&R\"NKKW,HM5T+)=@CH,A
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MTB@0V#D-#=8(R\(O(7RC61)2+WPGRX%\3,@Y6T9^,6W[ GL:KZY7E<#6Q-K
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M%T&W\(%=^6"\]$=KJ?MTX_]T0UW?>?F>2PDX]9^E:8*R#42P:,JY*A>B@MD
MQ5W!!L)770_F'^MKF.<MEO:?GBQZQ!FZ8\;E/'C[X\_!VRL![P_>F>:F5*:=
M8:=Z^/PB^'EN5V1Y538Z^-\5D)!;)AI&^6QCL<S\$J2:MH\#W2%053E';![
M\5H50'&NO7W;O>(B>-GB@PZWM]]\_)70P;_LVPVO5?Z=A[&6,!601"G\I3,
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MRF9EBVE4,!-K'8.[82ET:<_WM^7!P0J,DE360].8RQ5,KX;5Z*FZ7+J5@0?
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MC\#*WT33=!;!(13!G_#]L32A">-8)<10AK7I$*04-"1QPO(PSJF)LATF'F*
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MK<^YM%W:, #)=K(JK5FC!4P#_P4WHBFM+B;F\Y6H;'/NP/SORKH"[;,OT2<
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M6ZF0)#9]*'F?Q%!74(JU0N!= LIA&B-KG4/682IX=$'PK7ZS5/OHO1* 4:U
MW-.(C"HLXLJPZ(E0SJVCG"0H]:]S4OP$=)^3_(?1I+[[H/&;18?<4(=S$J)C
MIIFSR[FTN&;MLB%Q9KPP$/#1>%^F]X>C>K;?S?9&2A)]E(@442'N+$5*V@)A
M24(!/!PIDYML3PKBJ30*8<>*U.%/@@ H@YP2A'(C5&!DIZ%XO:#'FL7X_7(R
M?IVJ5ZZ ?P\B J=N/6:P8H.?WKQNBGY@V9)AN)J,)Y>5^3>\7TR%1> ]3S,*
M@]]"!4("0O'W'W]],TC)E6I@ QP5 .M5 +/F&01^-GB=$@[7@RD W]0EHZE0
MNB73 #29#,Y-G;_,Q9[II(F=&C!S9O"I*J?P!L!%%Q=E\TC9YADXOJS\X-)4
MT^O\S#VHN]%$&4'2(&>D7)%V,'DP/([$)'=16A+!"&W)JA>2<6\,8D2"6?.&
M(NVP1\'1PGL,)YEU4/=^DIX!%.M26%OQ/3S,(R<>V@?):U'>741V54K/ -PM
M#-AF8F]5TLPN@?W';!P&##="/>RE\2DLIS+.,F*0%04#R"<#6$Y,41"*46^L
M!B=K"S#*0D? F<C2U W-DH"TC0YI#]:7>8:C\S>Z6#\LB+:4TRR.KZ],.4JU
MNMF8NO,2/(1TV+OX&TAE_7,Y2M<9[]]X>"_O[ L36[-<S_2;@8NE:,5%NZAG
M@P^[W#<0U(1#YW*:+IJ+&"<Q@B4MXYI,UR'\6:_(:3T#J[R"7^?/T]QIFC>$
MF4SX_ OX=?9ZMP_9I!?3'6:V#O\[2^]0+GXL:\#+\#A54TMY#MYD4A+U_%KI
ML/S6#9/UE8V'C+*]<]/)?DRU$6[[QZ3,H8"-V-I^DO_P;AX4"(-__NNWP7_]
MUW_]Z^W;P3__^</@FZ86UGV73EY:^<7YS<_^NV\W@G,_F,L2^&X(![J]D8FM
MYQSN><9/)H<CX,>R:B2DWA21*J0085L NN-)!W.MF)]SWS'_ T_4W.AN,4M8
M;F"UD+S)A;*M&T1]\U.<'2Q._J1*KI?A0RWE4@3N'H];JEX#SE>RX--1HWL7
M<8N=A5H]X/JCD()8(C#"3EAP93S@)N,9,M9(K84(1F[MEO.8.JR\0C[7BA@M
MD2'2(E]P[ZBA1%*U[OZ MH.',!_#N]@*^&_G0*MW\=?)M1E-K]^.?PG3#*K6
ML-3EK H+,(7H*IJBM\3K3A),?3VHFO5*X89QF,XQ$ZAX<'_\S(%.30<#UDE2
MLG2$&H33GEN9:4@@!<#+_P27E3.@KVFX1'[R:;Q^Z? Y[1E)5W.A:IR=\7B6
M=LZ?@TR>3T:^L8P;R&LN=_6Z<Y;T_89W9E+4WI>N*4^MP@@^)-O4;.!:"[><
M!W"B[*Q*4*J>N!+>PC<&&\B,UMV\@TO[GC2^Q"Z&H -BU!6(,R*0X2 4FGK)
MB(]"\ZV4T+W3^ O[_FMBL ^3>:R[$9TRU*F&%51C6L$WH795>9D^'KD=^+"J
MU]N-1LLX6*O8JW81UMDV9S6G\W4)@T_GX)NO6XK&C?CX,>&A:5@TJ1T FD_<
M/>D-QAX//7!N3) H> ?<Z[1 6FN%B S1B\"(*^(FQX,4,# : 8E48<A5VEY-
MN4X5AH#1E5:*R;T&XW5+H_?MWK_QTH=J7*@/DU9$WAW8CM 3S?M\W;H6V^[H
M>HAL-1"6B\;R6:")1R5\AHM\4WX[>'U9E:-%9"S;@V]*^#YO-4C2-3V?YY<6
MG0<W G/)+9F![I]4UTMS 2;JPOAP4YP.Y/3"_)GPG3.7BZOW,GRS#+/@J;(F
M(JW2-"G%(E+28+! O*"8%0*K+=#7RW#7:+M?A@>CM TWX["%>30CP%+^&F2D
M]%FLYZ5 2;#31<Q*#&35=B[#4YNUQUWU>)\"YUE@#IV2N87G#G$>"=(83)]C
M7 4;/7-1'Q#G)7!S.3T=,/<V[D)?X\ET64*S XJEJ'#B90.^?Z_)=VIRSCBW
M&CL49 B(@QY&5J4FC-8;CBUF?CM?XD@T.*92G$*E_9UY_K,3J*!1ZB(0HS?R
M)0_6Y =SYK\X!6ZOM\H#5!,Y[B7BEEXDSKH@F$!1"XDX(0%9 0!'Z"A88%Q[
MS;<T=5",">H0P90@KH-!-A")#$@1G&L\3E+4(8GX B'-MD0P.01')&7T!C^7
MX_)B=C$_-CL,X^TJ9QL&$PNP(0>.5CV'^GSA.LP#3RO)O'$N>FL>HI[%6+IR
M?B"L;%UO'-ZD]S.@NKP<E2YECS<>KT=4.7(6C'$$2\2H2#TRO$+&%1Q1YS#W
M3FDIMB;:WAM1O0G1S$;3=PW53RH^EDH2,I]-G)M559COW8872FF3'##US=L/
MIN;/%%.]',&#+JM9&J>]L2UB",(Q_11 :C:^3B9G]:O6"N50P,8/JP('OON:
MK(%\]19K3PK&1>:9]$CD;;2%XTA%&<" >8O!K=[5+09 7P!\YU"D7H/T@"MB
MM&3(T4)(*F30DCRSQ>(W8[@S=IHF*WO0];;!&O;LOJ>]3'#.^,"0(@I<Z11*
M5I%9%#%E)@+N\G9K3X#AHJ 2&^0%',FI9TU9F%$:*QFHDCITC-V+$RWGVLON
MR2ST++\GWAJU"30BB4-JKB 5^-Z"(Q+ UU::"4NWHD<DQ@@&7 (@XN#91Y 5
M0[B'LP,VI+"QX ?2\/>/M]XR0>%4FX<UK%\N6=_,67^]'],B^-K\7*_A(GCJ
MJW(RJT=-)'9M<^9:&':9P][C)AP2H']9GH?T02ICD(RIXE^E>N$"_B2Z(,[9
M4(1BJ]7)O3V/'\[-^&-X._X!+E--1J?O=PQ<?N-Y+['TSG-'9+?WL9%%7/4D
M^##MI+E'57_O>3S0+DE6:,> _VEP+'D> ;P(!JQ-/(W6&QRW[9*1:9N:M$@(
M"Y(@%47@BP1$N"Y"\*((ZD!0K,\#/CIH=CF:U8-0PH]5+P-[FKHQIE.8%TEM
MP!JP@B+%%$<%L\*"'ZZQMILR8+V@JF ,8>T,6(- D &$AI0-LF!%T%9L-+Y:
M%#@OI>'#Y'L0@]+_)Y#G7:NPYG*Q+18'RJ2<IE-R@P24<=50+<S/LAD'R]8F
M"THO(;L==AVU9C8B$5WJ[2HELN# )PEQU' GB-YJ>Q@4,<)3@@JI<#L7CC D
MO2J\%R!5BG520DXT2G5G"4FF(N3H[FUIBGY#QI>Q(6.C7?R^;O%[.J,T.;+%
MZ(&^ ^?^C>@X*$<U1=(DE4FL1,IXB3!57@<;E,&/+R7_>R+'^SDU4J^4?2WB
M%CML#M1P%I]J4*C=WCKO_ "R,7/-%H8*SIY3V$WJ:<_\-]4Q6<J<P!'1&&UJ
M%$21-CHB%@/%J?&\M5MS9._-_"UTB!^6I/DA4>8@/,[/BI/F\.&\8A34Q&PT
MS9MH\X:+7K??SMYIQYR6RB 2C41<%0YIP16*W@E>D.BH>CQ[_Q*F=]'L*\Q_
M$+[7XHR?-.,?X19DH$;XG 9 A =W<NU;0Y]<:VB*UWL<#^[<';IO#;T0K;_<
M*EN]9WF/+9ZKV[K"E1G-FK3-0WIS-LT*)WGP3;[&?,]9#&8ZJT*]/P22N@;4
M);R+F>>F)O4\J94'Y92+61QG@]?.37+[C)3IW=R79EP>J ,W;SM;K#H!Z8#F
M@I-%/6*S?WES?,_ FC2'+X^Q&)07E[-TR1!CDV-N]F][6-KD8"\:G2Y:-\[G
MA0S2:H;VI5=NV?;U2#=S^6%G:7T6^RZ:S>(KGKP9N;0W+S29[.5S+!X[/U N
MQ;V$IYKXY?.G$YK8TG3SP=K'2 GQ=#1<*,_9W/$\33*U;OJ[KOW6O'Z;5%]<
MHVD$4;:L4*X_2+KS_#IQP4;SI6]>?O<:5G,F7+SW\NQ1V]8[3U'L8?"^[EZ.
M%04)R$L6$,<ZE7X)"KC628U%45"S%4F^SVCFNS6]/U!$0Y_\")W=\[".$ X_
M\2R' AC7"P7NG# &\6 ETKC 2!7,6,\M<6)K$]:]O;O?W'GPLU%JF7+K5(>T
MZ>">HQUZT')7T)+;Q-W)%,!)=3D/_&4@,AF-)I_2,=]DBP06"TQ1_>VK0R0K
M.H6U[[^LNV:P-#/M\PZ:^?/,7R$]ZBLSFT[:&?3I"6%=7^'O\N%H9*XGLRG<
MXG/PWS6W*UCR5N;' U>-S&4=7M7ATB3TTBY.[BK07/JKY?#VZ<)) JA2-M1]
MU5YCY4 XTB^6+M]5ZC-2\*]SC=W*./CM \F9I,5=CI-GHM!WNJ#8ON_J&/K5
MUSIOY$9E<NY^G]UR2H48MO]/D@G+V_B0KQI/,GVQ6UZO0C4MP>[.N0]8>!<S
M[O,[6Z[+;*@.+@N[8Q>'&,^B#F?A=OBFFQP!3YQ^S4GOYZ/C7,@6BRLNIX-Z
M,BK]8'WMND[O9Y@[=#AV6,5I?[75X"]_2V#M1N[H#$>LW@MH<P2LT2W:WZ(*
M;M'Z<RM^+[6/Y9!R# 2CCV>.N]+VF3#/L0'2[P.\X7@=><Z'^3Y"^GL"=X;
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M1JE !8XN5ZQ&<HR610ZYA&/7!)UAC[CV5 =R+ @U@)X**> ?P%&Z"!$1:8N
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M:>WF+6H;2[7P&')4-*?^?PN7TX7!IGWH],Z"PH4P)A!4.)[*N2+(",$,12H
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M[(()!0K66L0MU\@0)9$@5*36: 3[K;W77 %>=:E;&DG=B86VR#(FD81+%:;
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MGMAX,$F:MXO^>^[7\G;\'MYQXO]>3>KZT3/\.,9#<</F_^.6I:V=U;T$[)0
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M:(*:GT(*827AW2ECQ[8X&WYS1LB][MB]*401)KWCB% #5EHHBI2T:0\$\5K
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M/DIE=;'G5SL<$%\M$"$K"]]C\_MPR(^+IG&ANAA\4XZ;HL''S"9\H43$EV@
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M\W99?W:\N,:6.F/=75DT\HSFGFW?BMP=Z(TB&MSC.&+>XNZC?'VYJ+?+>:.
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M!J@Z8%19)G-P*%:H81@2!X<"#@50!0[%&H=R?V[NX$R=57H"W8!NP)B!,0/
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MR M_,F+=1@IUQY&1%T3W.^X>1U&J)S=!;Y?31T74CH>[8S=,_-C-,'TRV0M
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M:U6+*I^TR6!E-N>U5*4D.E-B6N6&S +*REZ,'D:DXD)4 N[J &0/4 !U@#I
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M0>!%_DHK"#+T5A#WJ.9UIB;-O&%JM+&FUV^J$M-":^T5G^0-+Z!2%U@(F%0
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MI:P<\;U)</N,ICEP<U%>SIL$"S5MQTA]A$['8H2T:!/TYE]34Z%2?Z%/T_I
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M3-::D;#.BB,$<?+]XF3[5 >:<U5SH#IG50>:<U5SH#IG50>:<U5S^U8=D'Y
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M+']3N<S17Z?C?T.J@8V6[V LVA -U=Y)'8 60&N8T+*8T7%"Y8>$0;""^]8
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MT?2[9[R$6P? _,79^.,)<)$+15BAG_X?4$L#!!0    ( ,] 7%;2_U W< X
M *[%   5    <&AA="TR,#(R,3(S,5]C86PN>&UL[5W==^JX$7_?O\*E+[NG
M)9!DN]N;L]D]Y(-[.,V]R0'2;I_N<8P([AJ+2G: _O4=R1C\(=DR$"3MW9<D
M.#/R_$:CT<SH@Y]^6<T#YPT1ZN/PNG5^UFTY*/3PQ ]?KUO/HW9O=#L8M'[Y
M^9N?_M1N.W?]P6?G,UHZ/2_RW]"=3[T TY@@Y]O1I^^<7V^&#\Z#'_[VXE+D
MW&$OGJ,P<MK.+(H65YW.<KD\FTS]D.(@CN"%],S#\X[3;F^:OR7(9<^=.S="
MSM5%]^*RW;UH7_PX/O_[U>6'J^Z/9Y?='[I_Z7:ONMT,&UZLB?\ZBYQOO>\<
MQ@7O#D,4!&NG[X=NZ/ENX(S2E_[5&83>F=,+ F?(N*@S1!21-S0Y2]H, ,%5
MD,)84?^*>C,T=Q^PQ\6[;F7PK%Y(<(;):^>BV[WL;+FD%.Q3.R5KLT?M\XOV
MY?G9BDY:#O1&2/F[%5Z2DJ]*],M+3GW^X<.'#O_OEI3Z(D)H]KSSZZ>'$<?9
MAAZ*0&NH]?,WCI.H@^  #='48;^?AX-<(XN9&\WP''Z1N<N[%/K@XOSB\KP3
MN2L<XOFZP_@Z0_CQ911!YS*[N'$#]I+1#*&(@H#\/3."IM<MUF([;81IYL\*
MK-%Z@:Y;U)\O M3J'%GTG:D_(%#]+9[/_8B)0D?Q?.Z2]>.T'T?P[UX8QF[P
MR0_]>3SGM$_NFA,^AQ-$'A>(@!&%K_Q?] Y%KA_0BSKX)WK]NZHPWX7;/^CC
M=",5C,U>. %L"X)F**3@81XP;6@:S=O5!/K6I;-^@)<'X"LU\?Y0=H:8'8,;
M.V+N8Q('Z''Z1##H/EH_ 4T$RK__;^POF-2?M\1*L(__.F-4U/,\$J/)_6H!
M)KD=BL?42O4;3JD(J=,:Q0MX/7OF!EDL@W"*X15L[ Y1 !8_&6.Q[VJHL!-(
M8H1B#Y@-CJ71(XAP2E7>H9=H-W;&&.R /=I/*6J-Z8.7],VF5YZ(#R'RP@W
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M2[&WQ-RF[:D]XI?(ZJYZJES^IO3E(Q^)-7M&FV+.7053GYO6[R%5/W3WQPV
MAT+8V&4S$ F3GML!CV1JXG#Z6,U;ZI$E7V"MVR'5W@E9W.Y3>;#-$B^L!+I
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M("SEWSO""]*+15A(?K %DDYWE+!8_,4%+,2WGK!@_-4=,!1O(&'Q^=$J?(Q
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MQ*^TW*:3'%Z<>3>_:*G1V E'JTNTJRYJ^"[^^-S-WFTD#P\5*FR'%R<K=SR
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M6.'((-$.UK<2<+9@'58AYKT;5^HRPMRD)7I4NGV3I;)ZD_ E]I8)SFBV'J9
M$$%%#P3YP\"63@;(N*NTG;00O8*)[S4S;@]=>CZ_:&1K\X&TT6U4W:<$8Z8M
MD(/8\\-L77R86QU(>PSCP-?MR(OY'/E9^"2VJ+J-89S(TGBA,EPM1J[182A[
M!Q'&R-::!BRW%]RE+)' "#<2X@D/2V%;P*P$S2]LDLL5"=:F\Q9%5*N_B7O1
M4@A?)IA(Y"I16%NAM+9>!@C9IGDC*OU6ZMUZ87 5E_:+K%AE]W$,$%M)N_*8
MEQRSO)9PMXF^CPD"U3>XUX<[31Q\^]\235X/Z^?&;]OYU%'YB9<D)EU,NKLO
MG=M"Q>LT\X*>K:=9]K"U&]%NOVQVOG!=]U)MS5!O2\E3VJVRH/#&.SQ!2+/U
MM,MV;3_BW=Z]6L'>AURE[ILJQ];^ZJCYZKP9X6TIN4I\+GYP)U;&ZA'7UM,N
M$W3]B+=>T+7S>ULD_38%!2^R[T#(UK# =H/DG45 _A1K6VIT)US/\>PBBJ8G
M7_^QDW:P0VWO08.S]"H+-?DCB@.AGRO=6EYK.$NZIEC3>1EB9[8=:-&W[["Q
MD^[>8D_Y?8VS]"N+P;8W/ >"@%@0JCX5<A8(:+%8>XAD9](M*+'H>EW@SBK1
M"(+ &/D:]E[S,9BS](/O__J;,SLSS4$K1J,6BQ\QW9ZR9&A]RG<@$*BJ":('
M@\[" "TDZB_=G$W%V/GDD+U==!:-0<Z1G4>1SA66[\TJ\G>3SN*AR2P[KPIA
MR1ZA:&A/HU/\_--9)#09@/>V%);V'QWC FCZ/]A.?Z?GLL#.:KNN(8=Z<PL,
MFH6W&X,\U 6&S4)?J,+;7F 0[/(#P3P@!H;(+F.XYP-C8&SL- 9[OT,&1LDN
M.TCM+3,P!!;: $I/IH%AL$L)5GMN#0R!77JPZG-MX-M'N_1<\6-O8++MTE3;
M'XX#DV^AQJG_1AT8$[L4T(Y/VH$QL5/CE+V !P; +K52^:D], H6JHWBY_S
MM%NH+^HE#P#&PT[%L37? # *=NJ.'9(5  >SV*E.<O,: %-NET;)SZ/@0AG
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M8G/\^"I%CT5V[V(\Y?2]7A15?9I)>SOC<LU+U;L9%2X?*FP^Y!$K@;0^WVT
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M#\+ !H'6F$FY?.8,O(#'#77N9EBT+OU'S]_1AO6:S5/7>@P\CLZEPFIDV8.
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M[B#P53LI9](^H$6?4!!"M:T/7IBMH2X*O/8E)E[#1]NEFP,/GYJD? I5BH
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M9?Y#KHU_1\&"NGV$4/&*E)7FMO:J(Q1>@W#O,:EZ7%!:"RZ\5]<1CA*C<)\
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MQ8><*:Y8=X%>K6\_Q@>:W2?TUXPO,B+F-MX9U6U?4TS*T.$G+K#Q]\WT+BK
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M>1#(<8AR2AVC;!7GFQ++&&.0HZRVC".<K?TN0463Q$"4,*!*8B>7E%4IV(X
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M*O2,G!V)".96:Y##+8Y3-3[RN:Y*_R$*4[B=(:[02L&Y731DDH]&<#B\FV#
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M:/P4K*@PIT&BYT.(5'K?$Z*D-0X,BO$ ):VG-AO* 75S>3JK3KDWDS!U+2P
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M@8X?9K1.GYW:3RS)PFK%<)<,I8/.:,CO9P8)2_XF"(,D%8JH-"[V7QPY@-"
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M<U=N917-B]28L.\*VTC.OPR=5YBGV>/3\QB>,P/&:Q9\!X"WWY\(/[0'*T<
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M,DA@3=(4\0-X;>R?TR0;5,L)";"=Q>FBR8B7QITZ$^)K2&)HT./DS@(DZ.C
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M_:0K4=GIDHF%*4$O,5-\PGSY5CTG3R3/:?4DCDC6Y\)H.$?WC)6<D%C&Z0D
M$F"HJ33NW=FW%EQQ8UO/HZ&9WVU;"2-+I:)3B22;K^=EC92:.&#8L0,I^EP.
M0$_(0%"-L@R.&D<-FF4S?>K0:+[&<BO8'@.,I&>TL1[#27K?V'5,:NN3PD0D
M]G3^C:DOBZ1$/^VPVA]&U*L!(@1=7RHQ."<"1H.F-<'2T/,7O65Z&2'5IU2:
M=G?/[$QFB)I%5E=?EJQI\Z /(N3SRPD[]@7[>[0,Z2*-A+B?L3/*/7F-C]BC
MC^?O68_.J'FL35^NHXMO81UR:EN?T6J+24FQZ@"4WN%N2=;0R3-3SW&JZGZR
M6UH@&V0+=B1^30JZNMELPV6N?)#"^VCB]#!*D_JF0L$U.@+,+;V?(*-W@FL%
M0GO@E>4?A$\,!.E]'!U=I'R;OX4>I+Z.J ]M9-':V+?7.15BDE;[3!.<C2[H
M]BZ^K7.E#5@8V_@,P>.4OI/5-61 @N'M1@2E&\UT^Q+Q:68N5A&D=4;IYJ81
MZU#YT:O:TW;$V;+F3!W)Q99"(]\L7M7^C,F!3>5G),*^;U-G&8D*EK26<8,)
M+I?L&50>HE&-M"/.ZZO]-)^1?TM&E._OL^?D/'\D%:"F"I';;>^VME[O1V??
M$;O!QZP]YT<<UN?"2HE13_&26)92QVXL2Y].$[2P9*T*>7L/WP8&7<KG6\@>
MY65M/"F-KG9E\@@>^2/8Z#YUZWK=-$[RTK+7MZHF":.Y>KQ+:Z]A?9_O,A"6
MS1=W^EM"5R3-^-5K/.$=?29S/.H&^%N9DKF??_FVDLGI+3C87+U%V=N,E_*>
M77U;"03LN5VFJK;P/-TRYFWUMR++X?S/UZ8XLEX=O*<T@+R:;A/NE4*SM AO
MODA6%:6@9Y=)B.K*O-X6&VII.@D&&DB]^*:4&\BXT7IV]7F?,;U<5&\**7><
MJM,!L2 TR0J##[I7+]\&6VV.VE/9P=[^O7W;*]#3CZ\_W,CSM8:NWA*0UMG+
MYZ9$B>PA39:$K#+('>^LF=;8H?N3F(X$:' <VUOYWGXM62M67\X>7J%V0I,5
M<?>3;'UOO;:H"^E_O"P()*$LWMAQV3MTPT3$:PI"(W7 $B]H:S@5D?>.+3-[
M@W!Q'P'Y DZ.W932IY]W<8M?T,+P9A:K*DV\3U@(>3VB9&QMO88PR0>PC(4#
M4Q.\F6#RAPRT-,OA($#B34A!=&C&-!U Q/?+=:A=Z2[\ ADNZE$J7E3B[.CY
M7!UC^384&&(#VK- VGMX581(KHN+TM5?23-KZD$].GG^1HL4K_J=MN"F#V-H
MYO524HX8\>QRR;!Y[YC;^;Y:2D@->7!)^AXMB>4>H.P-$,!8CRJRC<N_%TF6
MVY-QG SD/7"D--P;2[I:1+7^72>C-1A\/I<BQ!EN=Q'0O[??R$!CBB9S)3-8
M/FC/?CY9T_&W#$A?X);AQ9/GZZ>(G;9UM(1*3[R(-.BX( 8R7?[6Y!%Q,X+G
MS?\Y3".X9&!O0L$YT^:NM_%NDG_:A)2>%QE;PZJ#TM+$]Y//J,_7FG1I6VAC
M0_\1G>J]$G4A\6GJH5WU[#K%N["TE-C9/(B ;TD('N42)TF4DU6!#;;<[D5R
M3LI>YGSR42A[C542>8Q)>LLDMC@CE@1(2[L)3)U#DSU$ORG<&G;F+*]Y=Q?/
M6Y7[L5IL[Y4&WC5O2^5(HR31OY?/3=7$W11B3"9S7..5R)V347E:K>+($-@W
MF*+GKUR3ZZMWFI:$ 8+ATO3!]R+@59 V^@T@LBF-F$SU"M:5^4O.[_8:2H-!
M:!Y"S;=?(N)! 6QK D@#FR")EQ(?T>B?:.O@470&%-@9.W:FL!7]-]\2RL#P
M0NT4W0"F1LQ.TOCQ^UV#304^K\PVY>#K;*+/<;A)V&W*A"]H(8T3C:U\&!FO
M4A!@443JZ9"!IOP:J3XDMESP_4F<^'%A4NR:2"BL)F*OPV%\HUZH@"'T#A@5
M563I16.I%4IQ&$7?,0?EH]P1Y^+Q";L4%17X!KJ*5Y<U_YZUD6_U0*&+JK :
M,(3CEC J!BWM_3XM8=QE)C:T\8^2JR><VL,QC U/]8*W@#%QSK@;>]2;OL=X
M4Y&*^@/_WL00'W6=%&,A"9<$O=MU,7L0(TS9DPSF.I(9?'E]VGN/^$&G?Y:9
M<:WM.-B].I[J^>]3]]%QEO-A4_ M"1D")Q])3#Y"6L< Z]EE@L&)OT;YVW.<
MO "@!M@E;N)M@9&'6EI$F0<%L>AKDK)/F">W<#Y^,JV"BW&F>?A@;\-DEV]D
M'AL,[ =T]\1HEN9_?81C7'=)5G[P[0FH&HD[-?E]^ODUL ,$1Y)F:/)<).Q8
MD.B=/":[D&()%G9W1#'NF;:Z(8>1F8"AIH*G97-369OZOAJJ$-*W;7X>6UO/
MINUM$F.JY7E(0;M\>B,D+XT8=I]W_Z[>%3]UXG=:0E5VOM-_L45C]._M]2QI
M:I>\"?#=F:_Y#;"[B>])CJBSS=.U1V??CT##M53]Q2L$=OCEHD"/SR],U)DM
M\Y8".Z+NP(P;ST-SH;3QJ/J^)2%YF,WW-EF&]!>F(V>K:-D.+]+1Q;=V8/2*
M&)4"8TO?0"\U6-A+*--K#NBQ-/4>C=R(,2I37.Z2.(?38:S\M$_G"4 8FP,@
M.C",6SMY#]L4Y4@?DBP/Z?^+MG8 !5/+"?@=>.TO?K%>L[\U8D^M#;U?PZ:]
MS^=W$U\G3 HPPB'UZ>==QI,V>ZAFU&[5AQ9>[R\5&EYLMQ0-)"'51>B;&',D
M-*_A(JE#AEFK>CH:PJO1GE3Q];'4&,Q.1$RU)H/MT]FW,]I<!:8UNKJKCW^6
MJ@4@P#2HLIX^;-B_/;KY]N564B:M1G-#,]\:5(EPLTC*1#U>TU@'6GZI6RP?
MR=^+*(MRF<W&'P"1L08-K*O@>DR_YCLVCY J\]O]WY_"5PYQ_!_LKBF8SFPQ
M:O7NZ=VQ!A/D8>*0*-]6&MO6UJ=A6PDN*AX!<;A(N@7+C1E2;:^.DX!6?:'1
M*[?N0AX*)O8O/MB4=^!E1JVF!6*U1^=)I6<J9Y%I#UJ:^@:^ZEUBU\13_]Z>
M8<N6;);&A'LI@6%E\YB@+0?\@KJ!I+%!AQ+T:UJ/,:0/YG3!GC]V&Z:ED],2
M-][5Q?=3L-F&4<JA&6&=;Z-WLN(2&J1P74;9-F$;<[XVO@U].WM7DP74(>"C
M"+"YAR1#<:,M\K-//^_6E^N(BH03L\VE_'TZ7P%NOFLF]K?&W;:U]Q]D93_6
M;3SUZNB9.=VJ($P)I0NP]8OUZ^GS"A=5L^_"]#=X?U%/$7X52U9H9X])ISDW
MV.GLX?MDT3#+%$KP/,78!Y5/!PAJ')0QI!2$)BDRB(9&26L@28^*CJAF]3,!
M\^SV#:H8FA4;:T/?X4=-1;GVTW3>I":P>\_'R=[1-W/%2Q:MHC#=:3"TMJ@(
M:V/_1;AN!9A27;ZI_3S%BUC9&9ZW23Q?<F<QJ#T8,#1?7Y)U6-#\G.0?A,2S
M;1K1>4RTZMFS>"7T=B9;0QIU2Y,KN*\.!?DY\@0G<#2TR*UV.=32UC<+1O-J
M,WK[Q1*]K3E.;/50I+1:\'AGLROQ^-/P[B@HD0AU,#3!B0V0L:/3A)CJQ&3L
MW<GGE5RM9Z_#H)31<8UKLD^G"40JY<(:!L!2M@?=U,[SU#$GA&#EB2*SS;O1
M:&H.3XC?8_\=Y15L<1G$U\OYV4["E]">;]._WMQ6A'7^)_]WDQE.I]6/WMW+
MK\!HBOFL[HMKOB_*4#9C_-O!E*:%030"R,,81'V;/Z )2#OH*H^RW_A'A']9
MS(FVYKZ#$N*<:9.T@,+PI8V%HXR0%0@,("X6N4#)K0>EGN_,!&R/AL/AO,?!
M&;,5Y)8&UO0D!C LZUU,BS60I/?70 _ 83.:IVB,X25,Y!?M#MVQ]?0MWF'.
MZ2V_QU16UVU;&E)'%Z\N4YH $!BWGC^D41?0>T=[WRIWS1+0*G]8&WM_8BC[
M%8O8O1--3X?7$;SSEI_U&Z%U-XY)?YJX@")CHH'N9UJ-/4GXCLG14+ !&"*A
MT4KB7^MPV)H_7!G"L]+5!VC9;2#9K>?FV'/PG;G3IZ  .S?O6#@>+6?9(LE#
MJO\. $+W2?YG<+O*<@,E)=ZI7IS7M/;>)N/]3@3AD*1*1VS#2S$V]6U9(3&[
M7P"09K;:1'&4Y?R"%3*=G9U>';\&Z']S?-:HU+_:FT2S5Q_WUM &]HFPRDT#
M//D++"<6A#I;.^\&S&U*EE'#A6KZW6L6E2JRTUW!NR-9ZE!*OI^A,'N#_P]O
MRWM("18-U)/<V'U4_8/6\B86"*X\[#*D/Z=)L06K($"XPFU5D)6(I+8<Y&..
M[UN5JV9 5FJAVJMW=??R+<"7YLWV+'9C0^^QK"(_6/P/J(&?ZI>LM:%W.UT)
M$&B+@.]J.X%4Z%D<%R%E$TS2O+[TIC:^C[&ZZ<U(==:*QF7Z8985&RYBV%^5
M(PQW>AB:EP6Y9[-??!#Z3BSY2*-1]IP$ V_=$\ES*F+^+$FZ2JR %):6<I8#
M"?KV[7!0BF:-]+8HJLY.OF\2+:]>IAMH.?7M 6*]NOH6+B6Z5X:[K1J0T)ZS
MT*.C=Z>0N$7F'S%)[>8.4SN?5XOUP;"$<7:T]^S2YS6WJRB@%V]@X;^)%8JH
MBL07E53>29I'["4TI@N.0=1WAIUD09C4SDG,[GI+KK6QZ>F)!AP->_&6DJ;)
M;3#%J7Q/\Y8\$!]C.-6I+$L'TF2?]IY9^<SV&X3&V\JFEC][?_6:5=Z;!;R[
M6T\HX5 F<S3SG+I;3R^>3]SCMH"<_7I.PK1DD^+M-B9;#]]G1SPWBV2V_'L1
MI<0:+VH\2[U[3^]:;I/U6YK[9Z06W"E% P$#?D]L''7V\PP+N4^ES!:@R /(
M^-:Y91$DDR7]GGS@3W9#?&=/G]^UP['>^B3LT7<:./> 3+_-^X'9-]I.  ]
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M#WEN[>";F4;UU-!<,+6%O?U(>->^:C#7Y7%B5S:6LE_SC&3C!;]'=]_JBLK
M+M-!JK6 ]LGB[D?#$\OH3TUW?_WE2F>B_*O/.Y$C+<[CA^*%1DL9O6IY<ML:
M>U<F'LDK(FO%N0E>S-3&M[9K#$&=Y7A*V;K:P\/[=/1]O*MUXA[2Y#4--[7L
MR2)_2U)(?0.82*VHG/&L#R'H>S$ZBF;I\0INRG+M-\(T\U:Y9;%6=;1O'\\
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M-#(%O)O:>(_.%/D#XG]NHYA4',NM#7T?6M<E@ O&Z<10[O>9F><X15-X,E-
M-R$DA36RZOOW\OU,*]0"R^-6:>#;T [;!Q)6F1;2B2]O;>S[G!<O&?E[P;X_
M5@JPOVO&AE]K'-910ZZ\P_ ?!#!2%?\)6'*YJ9 GX5MJA5C5$?^SF1**=UL(
M3TM;[U$AQAK$=BM":P?ORE8-N_7GU +C;6XYA9QX. 7O+S(+HR,IWM38=Y34
M9LOD+71-IY=1MDVRD')WZ&WTSDXQKG:/8(1#Z/A^E\<QRQ!5M F?HILX3Z,X
MBY;C2]=[C#L1N:U_<:#V'M-*69(E%841:Y%&(97UP$TZP1[=?<?I:6$0+=8[
M0S/?01.VG=,:(]'5:=+.V/:ZZEBJJ:T6V2!'['AC>Y>G>)8QF]HEI"PEB"/2
M<D^U=O!]>MO"8V6PZ*7Y4>K;UY>-,M^F?[W_I6*2Y'_R>4;9<L5W8?H;1\I3
MI^/7*'_[A2!8/,EN;R\LIVROWI,3U9-D]1%1RC,TF.02O5">:MM3@+?W]VY3
MOB"0(L0DJA7Y\B=B2?JO-3I56=94[YI]DSN2OR6KA":O[9XD]\-ZQ3&7D?:R
M\@-:,19O:5*\OG%;MWH;&\=[G\Y>#2.&FU]6&> :QR*Y^I*3>-5@L7]7WT9O
M)JML"K2$]*G::87DMKBR1Z'M^P91*176&5JQY/OV]<WBF+>5Q#_]G+!/CU+2
MHZ5BP!&&G0HZX?E.@QB\3M&9L=S9/$T]NIWJCJF5:7D/(PH'X#I)T<\YZC;I
M&,LK9$\1K[)'LB1@ \2,"TAW#^D%33+3F]G1WK<0K%)@YFO]&PD;.Q;$;'RB
MK#VS9AC)4ST>O<&DE1#EWJQZ\&0\:Z"6:G=ER.N?26A4/GMU/ E\K'D\&#]5
MD?!]I*HQ ':1R]#.=UPSB=F> HU^MMI$,=:= _B)%FM:1Q??7HST-8R%V'[!
M;HB$1JM0B/0/[*F%5)1*4>20*E#8UN2\40C[WJ@#KUN/-0RF7:R &P_8G%>H
M-R5]4-?;FT_9QMZ*9]'5;2IJCZ:]9/<)I)L6J;FJZ)Y=?9M-5G\K>(Y=MDAD
M3".IU%1?)".40W QCO=B1AVE.Q&@\C;<9H88K;VZ>S_=>1C%9'45I@"OU5*7
MVMQRTC[680FG^.<G&,-/PFM]_%,()14PQ"C\U"'S4!N^;:MI-O(07B4 _4ZT
M5*R_@%#8-$-.1*JC\MFR395P+T-36AB-])3RA41"/=Z.IKUA;>P?QL1L,K=&
M0[;W\.X^Q>LL1.3!RS /#7%$76V]L\#KO5_3)+3,6VMPXGI8M]F+"QY^3&Y\
M;,]UB3:@%#(5O-ANZ4Z]S09)IU<'[_*:,2 \ZPD%M4?WZ0 A2P&+[;3],)'M
M'7T#S0 L TT^5+J3A'7B$^52I-*)>H)[#J3I7>/B"#J7!09;H#B'*K8TZBA!
MIAFDNU]WWP*#\ (A@K14$LW,]>PRT2NI;;-V]?&*LD)RB3*'H;"7!##PH19!
MO"+I1QJQOV6(T)5EIO2C/?N?2-3I/7L7%A^$OI.[),[?C/OT4%K3TT.L;DI;
M6Z]N^J2 G663:*H_>]]N;$\ >,7-9ILF[S91K$?S22>%VB1G'=E6ODRK6BIF
M\WES.9KOU]" YRFB1KB2)L,O+9ITO\X>-=+;9,EF\Y;$I*F(F7[W>I&DX3\B
MDMY&:_*TC" W)+OY+P'0"$]U3&SE?'KW](J!)22G$EW3X-MN;SE-E%73V; T
M]6NOE[)KZ?YH&OPZFD[:X5!/K)I=8/&OFQC+EB04@SVNPI1&X IJR[&"4E7S
M]'H5SK;P\(5TK%ROT:?D.ZJO F[=IG.86YZJ_>^VS9$RG.JI+DL3<\^=_;,Q
MR$2T5A"';/>"IFRW*:X]2?A&/WB8VU4']:-WC2?+DA05F3Y(#"W-?9_)8K,)
MT]U\K7"R*L#D[14_>O;US>+ &P$C]A6P@]4#Z& 8W[&6@/^@P8&"$=H.0&!O
M/0%AHG0?B)6'(.0>.*)Z:]_W(AXR%7-Z*^(E[#!#K1W\AE&H\ 852[-(S@D$
M.T"FM2C3IDY),\[&$#XQE*1_DXDY?J!-^.WL=*HW;R=FI0*<<R ([CNX;U&D
MH[C.!,KH</-+7[M>XX4]H+O_N[H&,/20DBV[BR3F@@2UB5>XN>P@#8=1\GWN
M.TK!]8$V[)'8/)"X[P@62RT@HPV@=R??7WZ\-!!W*OY48IG,(B? >-N%.EM;
MOSF!FVV2,DU0A/AFG8#K'1T\>G8NDZ6HO)XM0PK9EM?L+Y6SV-)LFIX$I9X_
M$"8@8T)&6<-9(-[MX6WH0\Y[],I6UF%=V^2B>AO?T6,TS#(5_C-/T45B0VFP
M-O:MQ<@P)E5HVZBV-%KYO+UD?H(MTJ+VNV]IOV<T#EQ)BX]D2$"/(.%59[BX
MX?4%Y4-A^4:6=KZKR?%8S99"<GH#WYE (@/L@:12>(J6IDD;&TZ@"M9\K?DP
M,&>HN4UL+7WG=*+2UIJ-66GA75ZM 0?J5E]B<=.V=O&MM2B5LBI>=[@_.GOY
M?HVYI<!H(6A!$N[1S?L&U-?[.ER2IEFXJZWW;V,QW9[OV@K!].@V!728ZRAE
MJL#J'8QT'2@PS::^):SR9H*HRKVJN/7MZ_N]X4J:E&RE8M==&]#2PZLSB<],
MZI_SV!;AH$3<IO-H;Q)3O3QZA"+T[>M[B\9YM(IH 5FH3P# P46%5MM85Q__
M3@%N-YD5^5N2PG5@N>7-+:=PL?>[TZ=TG3<DS[X2JG^QE!U5=LG>VC/.Q:^3
MCIX%^$CVWZ7O8A[/TW.R3E)RQP9Y:ZT,#]&IA\;(CC2P[WM0%[N[-<1:PRG:
M-"MX7F6^H_@U^]3;WME%:$)*9>UJ8=M,DQ31&=E;T]R#E,][X5F$2/#X?LL9
M-C6:SG.AK2MJP!VO1KVYUU0V-I$E)C%2LCL/X]\ZBJ%UM)^L6PM#(K)'DA44
M#*D0&\)N@R05-;C"+P])AG%A^V33[$77_W8%^"Y,^XA>"@2S9X*]T-.@ZAOC
M!0/CTIW>J,U>,H3B!-'_%':Y77'HT<UOM3.X)I,T:X@T#TG._F\D@7,5SCCD
M!\V6;Q'AR;7S-52SR>XB"G3B9FK<Z"-XU55*>>Z>;>6<D)@=:>#BG6 8".QG
MFP;3OZ]_;;(6&*8\>@(NK$U:[-_;NR??B"EQVY8HU=5G"HIT)_CUXHWI,0#S
M8E>!!M#RK]F:C5"R3.E^QF_5R[?IV.!9?R3P?,C_@D_6UR??[.DQ+NHB>2>I
MZ49I_#A98=$>M-2"ACZ G&_]TUG\>[6XN%%A/=+8OL][J?+UL-#86_LJX)CF
M?[T+OT2;8M-\81H_3EO3N0MS)HV"Y*K]SE.!YFO\\0!EIYNH[S.N#$/CH.SV
MM$*-/)CG1;PGN0G'O,3:4_AZIE7IW]NW;ERD<90#2 )@!WZ!?[5@--E;^][R
M9EA ;D(T8B,9]_+>5'R+-8 ->,5VU(:)^69K5J7%E+_2(SL9:038LM@,'WY[
M6O5!E+P_5GK0$41(9D];IFBOYO'G,(W @ (E HV^CKY]O4.EE6JG7A>A5A^F
M1_-I;E6T!PZ]3^Q$?">?&=&0P?VY;R[/$&*^OSQYA;FP[0BE8-DWPPB8'C$T
MO3I.U<3"WHEU00'4;2\;2]G-^]UJE-E!I"S%S#V$_6I'WT):DI+HE<VI8)/<
MM8AGAG;^OTLC@*8=N<O>WO?9X>"&$%$[7XO_R*1=?+F$16^/1-N+@/?OILL;
M6'82U):> =75]K[C37@%$7AOA<C!X^<L%T)+\^G@Y)?()N=)FB8?W$,3+B$H
M$->\F>:R+P&/9N5%&H*_\6FW>4FHSDCC1X\VLD64@]7C)EXQ37Y5A!009=#)
M!"+=6[1=)%=8@:1Y(1S0W;=05"MBVI*,8&GJ_3ZKO2M]@G>TEK[?'I*NDW0#
M\;.VV*F.IMX5PP'0##+;2+/X,U%G3= 4E?&J-*(2<F9R0'B;A.==<QY2O@T(
M44!?MF-K:^O[XCGTJZGH'7:(BPW_7H]1]MLUTS6E2PXL)J,ZJOH.>@JQV1#+
MHR$ SYC>MUM$&X(A;XNDJZ0A!DRSOPT,U!YU%KZCMKF,G[$= _:Z]L0J0TO?
M1U%Y>A34F?;6X%EXCJ,\$[Z-W3X1S(=0G$!^66OEXZ8(WJN7;TF#/0.@A5IS
M3;7?O7Z!Q9W$=A-E=VT5MRT-)W.:; 62SG>57[J1S_8@-"6]J;[3K(W\QU;R
MZ!Y9]SI"L4#]61Q@$0PTRZ_)BJ0A!:C5(D_27=G?(G:,.H#O:\1F,09]L,5$
MUMUM.M8D=ISF*2+I<I>.Q#[IL"K9NGDTN'!+PZ^$TC_%R4?\1,(LB<D*75>-
M,C:MC?U_G6U*WM@QB=X)/P^]_3=]^T['"G@=+C'Q_()MGU=28AQWV/YLW;S"
M]:B, F68E.D'0A.P8#SW[>C[N7<6^UA%B!]5G=US[.D<#!Y_N[LF_0^%J<O4
M]XP5R=;X>7XED %+5K-W)C6\DDJB[$';9KSAI[[0-D8Y4.Q\7=X]?3Q,#H?S
M;F77C]1M6SJ.I:GOV.TD?LT%+'J[I&INZ=O"9,0ZN?JRI,6*K"!A%79<D8L
MW#IHG]V].PIAG^_#/'T-X^@?_*3%*PR@FZ\?V.&!JQZC/NP2XF$4_*NK]60^
M>+W+ BS[P,L;NY8,_I]_*?EC1_FW__L_Y%_8_WEA%/[O_P=02P,$%     @
MST!<5@??!A0X50  "GH& !4   !P:&%T+3(P,C(Q,C,Q7W!R92YX;6SM?5MW
MXSB2YOO\BMR:E]FSFY67JKYDG^Z9(]]JW>VTO+9<-;TO>6@2LMA%D2I>;*M^
M_0(@(9$4KA1 4" ?9CK+ L# AT @(A"(^.M_O:VC=R\@S<(D_MMWG[[_^-T[
M$/M)$,;/?_ON\>'][.'\^OJ[__K/?_OK_WC__MW%U?7MNUOP^F[FY^$+N @S
M/TJR(@7O_N/AZ_]\]]]G]S?O;L+XUR<O ^\N$K]8@SA_]_[=*L\W?_GPX?7U
M]?M@&<99$A4Y_&#VO9^L/[Q[_[X:_CP%'OK[NPLO!^_^\OGCYQ_>?_S\_O.?
M%I_^_)<?OOSEXQ^__\,/'W_X7Q\__N7CQUJW9+--P^=5_NX__/_Y#O6"WXYC
M$$7;=U=A[,5^Z$7O'LA'__>[Z]C__MTLBM[=HU[9NWN0@?0%!-^78T9P!G^)
MR#3>LO OF;\":^\F\3%Y?_NN-I^WIS3Z/DF?/WS^^/&'#[M>S!;HO]Z39N_1
MG]Y_^OS^AT_?OV7!=^_@:L09_K;$1TCSMX/VKS_@UI^^?/GR ?^Z:YJ%M(9P
MV$\?_OOKS0.>YWNX0CE$#7SWG__V[ET)1YI$X!XLWZ'_?;R_;@RR67GY*EG#
M_TG7'EY2N :?/WW^X=.'W'M+XF2]_8#Z?;B'_^\;80ORO[,XN(SS,-]>Q\L$
M#H 0AN3BKZY2L/S;=VC\]V1(A-._*P^4;S?@;]]EX7H3@>\^F)C60PYY%I%Q
MYD4(NX<5 'DF-1%^5UNDWWDI_-,*Y*'O14?,@SI.CY/:_2.;+^<;D&*^R""S
MG,.Q4K "<09%V4V2*2Z6^KB#G/01RWSD1XS"027R(4_\7U=)%,#S[O*W HJ*
M"[ ,_3 7S;O;:);6^]S+5E=1\GH$/Q\,87LJFKB4/Y[Y2>X5IGGZ[,7A[WC+
MG'E9"(F[2Z$:$N?X3W 3/13KM9=N(9^%SW$(&<N#1YSO)P4\X^+GNR2"K ;D
MUMC<9_N$K'ZJ7(#<"R/5V7-&Z',B]R""+!E 'LRWB]2+,\_'DE-Q-J)A^IP2
ME/CK,,>[#,M_S"S0D%#G4(F1^IS8#8"*=HTFQ=FPNO<YA0OP)#S@.%V,DEKG
MYA<0%^ ZS@$42'EEM\7/-Z'W%$;P<!5-H<-0?:["H;:@N";L ?J<!C2=DS58
M>&_*&YO2LT_"?_SXZ1]W4/PK4MWNUBO+%$\9^*V <N/RI8/L874_137'LKHS
M,+5GX3U%RE@(Q[%YK'::$7^0OH_83E,X[#B4XU9N.IT'M'OT=EHKT3"6CN%.
M<V'V/\7#818$(>K@137/;S<+L4^2+!\BR-<?%!% ,TPV !J12,_!7G3(W!LD
M46\U&MJ=/F<9(HV,U7'TP? (9/&T ,'EVP;$&<@,L 7_"T/PSVADAV,^,1"_
MCD8TCOR*3<55(PI=AK8Y]?U)6&S@Y]'?O*B^Q6MD5_R^2*I[(J@7HM$ZRI$>
M*!D$L%=%#G^>Q7'A15_#.%P7:]SVSMOBAH\QU$7-(JJ!A+X-L?V1LD@@'Z _
M=0-%;K"^IZ=1XL@.9V\%2_:K&.\N#>&9L/$B>$@0.[/!APN0KF\2>)KJ6&\]
MGQZ*.7\,UVC^S% @:6UM87O]:!U)@5T?BD8YU&UPN]/?G9"/\0M<+! \P#&[
M'K]=AQ\(!$AQ2&+<@(127B5I*4"OLZQ >IAV8#I\M"?)PR'Z+BO@"7*?%1F.
MH(4_E:?'"GS^^.G+-20Y1H&ULU<O#9!_1%GFF/OV0'CM%X!B=D$P>X$ZYS.8
MP95>;[#M_)@AM?XRRT,H+L"5%Z8_>U$!JD"M>=GH)VALH]YQ</EP=X?GJG_/
MFJ=Q((M1HYKPE'8PQ=\8$AAGT #"\8\@SO"A5?FSS, B^35+-Q,:-03%42U-
M^![X"=38HK"\/P#Y*P#Q79J\A.AY!3R=ZM- AL3NO] :%G#//V90WWM\N )P
MQ;T(A2X6>9)NSY-TDT 3&S6^A_]S-(BV*+6T,(CH)"YC0"_ $J0I%,/>&Q3,
M(.\H_CN.;@F G=@@(G3G!OLI33)HPJ:0(9[C\'=,^1F(P3+4@(R6S_:EM;7"
M9?18S%U&94UX4[N)O(%_J)JC>?3T'@?^&7VK34B3</"6 ZA8!OCU$*$]2OQ&
MHPB]I4K2)I!H#AF<!'[NE '_^^?DY4, 0DP_^@=&&2,,_^/;>0+UJ]E3EJ>>
MOPM7C+PG$/WMN\/?/Y@FAP"X@"-2J&G\;)R8&?Q4@#YW%7G/%&J:O_>&3>E(
MO@?PC*"M&+59?PN'+N+"\I) 0.!!4^-$DCV9 \3-Z/&EEWOG18K>,5 (Y3;O
M#=$[D(8)%"<!>M#)@;/9KC?RKJ"8]J)_ B^]@G_). 2V6QHGL5JJ_7?9(#*;
M]HQCN8AR2-;;]K1U[L%SB(Z".+_UUC0<J<UZ(NX<(I,BG2  ;_\ 6R9U[78]
MD0>5L^L N8=0O!.2>K?%^@FD3#)9[?M"L]P1I6B&9@JV3FA,R6W>$[$_)U$!
M=:ET>Q5&T,QG4MENUQ-YOX H^D><O,8/P,N@E1,@WRIGZ5GM>R(7@W,.I=\S
M-$:91#9;]4B:8-_4FO1$U,,*KA<R8+V8#5>C44^$7:Y!^@PW(S047_.5B$)Z
MZ[Y(?=NK@^7!QJ;SL&E?"[WVHNBLR,(89&PATVQEG+1K?YG."F@1)^DLST%6
MFI0,DX73N#?MVZ_<6R&Z>8+RXQS%_2*O5\#6*/B]>B)]%@30:,^J_X%&._C$
M))C6UAJ9GQ7(_-PSF>?PG_-T 0\[$9&UEOV2B/EMGF+7+LKH(J"SW;Q?8N\2
MN*FC_Q=NN/N)VMB\08:^G */05KC9^/$H$Q$T=T*JE=,A>*@25^Z]_Y:O@Q9
MF!<YRB:$,DJQ-7!>IYX(ORN>HM"_BA*/[4^IMS%.U@/PBQ1^]-/GIP7RNU*H
M.FABG"BHOJ!%>=BNGY*(0E'S]]XPNGSS5U[\#!BF/;59;^Z1;*\!@.!L>X^N
MB "4K@OPEI_!#_U*H5B^KWE7<JES,:"M_]H7*5=ANKZF*=G-W_LBA^2%8Q.T
M:]$@J7Z-,DN;Y'FI3X:#_SRXXFDFA*M:?-C@K#;O_548[=!9ILF:=AU"OI90
M;B?>)6D TK]]]^,7E ]P \T4M'G^]AW4Q8H,$I)LRBLL]%MUWWE3SIE)(J8O
M!VD&<,OA M&Z.*F0^,/'\2%!O[,A@'P:+R"']T0$E,_C X5_+T6 ^6%\P##N
MP @B/XX7D8-K-X+)'\:'"?N>CX#RQ_&!PKE7)*C\:7RHT*\Q"2!_'BL@!U>G
M!)$1*J^"V]H*F3^.4)GE7PP38$:HU#(NH0DBH]5HF??>!)D1JK34*W:"QP@5
MVL-[?0+&"#596CP!@6.$.BPWBH'@,EHMEA8R04 9K2;;"M$@>(Q0C^7%A52P
M_&FT2JP@"H7@,UI=EAKJ0E 9K3Y+C:PAJ(Q6EZ4$\A!,1JO/LB*'"#"CU6WI
M44H$EA'JN,V8* +$")7:PW@L L9HE5E^'!B!1[-N"ZEZ2DX$H$:\687'GS4K
MM:>!QV&@&X%CA#IL*\".(#%"O94>VT< &:'*JA!/2% :H1+;"%<D.&C66:.3
M@("$21(0-&NHIP'"/CB3P*!9/ZW!\-</!RA 0_M7TQD\!/5C>\S9L?2R)PQ/
MD;U_]KQ-&3<+HCPC?]D'T%9_V%,_7^Z*-4,3"[N&&<D]E+H>&07<94IEYA\!
M\:U&%LBDI-T4X<WL8('\.[)-,5DXCQZ#;EI+:VQ1Q2!(<4>[K06B2?+9$"<"
M4V89Z>YVIR:W*)P.%LA'Q6Q1N03X/PC+%R]"NN$L/_?2= M-"-Z.D.MK8X^4
MI72R.V^+ZA+1$]P(&MM8B[VW@PM[NYD5L<DNO\.4GYPN-C9N$C^CA.LH8?MM
M$OM<)F$TMG-@;;R05+B!.,[S%=1?ZY*>?8 )>ZI/Z#!O'?K+MZH0SSELB:IC
M+U*H59&J/'0RI;M9 'V1 B\KTBW>=.7^X^U09G,+I#?+:MRCG,+SY6,&\+HS
MZ.?WT<8CPE3US&VIW-VVHB:CH%DZ*=%^.]1)V(<EH[T-XG=I,.^@7+N.S[U-
MF'M1[7QDS4+<T<)T[B$3IZ&? ZQ1,4AO-;(N4,1[5;Z?A<G4RK"(-45&8RNL
MDGMA#()++XTAHAG<EL6ZP%EQ+\ R]$/6%"0ZVF"IO2(B9B-J6UM$UP2A'.7T
M#L/9QOP=(.@T"/>3M-O)GE+ U08L.S'$7HMA>%FDO2NV+'E&+4J.4<_J,4"'
M74='G;6+GB[W!.@.B.6,KZZ!7+L7E7?JU\&A^M =1XA^.W/(,@<^8<=Q4?7T
MUQ'CN=(=AXU[JU/'2-)?[SA<XDN7QDYD7 <X#E+7LTY^"U< ?G(60!7I=7A[
MXS@\XB.0?TOD.#Q'G82,NRG'(9,^!:4NP1P'2^X,E+^,<QPNM0W(OO"K8/KL
M*$QBH2ZX4'0<GRY27?VRTW$0I>4\7:+KA04531\&+,I6#>OJUG'V41/E,K?$
M%6 _. J86*BW[YX=!^08W5SB_GL\Z$G(*=85N^,@J3&5S(4^R:?M*& 2FB<]
M3,!Q7(Z259P8A?' )B&D1-$0CH.EQE6TZV"2+]51U5SVNL]Y(#3=[XT))PGQ
MPS'B1@"0,B-QPVM(QCM'1?4QN$G<Y?UI@DWY0G3_*MSD7AW4N_ [#/@*Y.@^
M88?9]$A<S\.8YO56UKS?N@?8+(0KP(Z&[#J*_;>:,K-3ZJK[11N!4WH9I/I9
M?_D.Z9FGF,L#?-%U!U*<<8L!O61GZ],JLX;-"BCPTO!WT"[W)MEI(-/ R>-5
MIE!U& CY[!J>LKWLOLE6W"(R/>U.2')S\'H,80+<;<%J/03"Q1O"9$E;3>^@
M2[H8]+/;V[8'5(,C.^ME4Y"I3$PN'SQW8Y(Z,*&<'NI\"$ WMI-5>IV_G-0!
MWZ'^X/PUB3[8B-9BQ,WK)F2TY,^NNGF[XB9EKSCNZ]6 '5.TZ77Q.HA92ZY]
MF?#BXT43:I\F:T$8CD_L3@*941O!]MW+[A_9?%F%JB1Q>?>YAI]>04L@? $W
M278R"7M1]O$UV,U+</W":FTS;\K."\ GG=W>3HHI '<K>D%\ 5Y E.#7>!5E
MC GP^UB8Q"W<)@34DC'(.S#^2HC[64E ]0(R',I0DD2B99D;@='<YDXH2:E+
M']8>J+6T0/!/((9T1)"19\$ZC'$%]!S*33[_BWI9S%K&)[S=:@C"4E9(6DOH
MQ102+,KYG6R(1Y +-V2SS9!DN*KLMD$\"=(G!O69EX4^@W!ZVP$0?1%&1<Z\
M-F.UMD#X+P ],07![ 6N_W-5&VV^/+">>*N@-L9P)EG!+GM=J#J*;7-08 10
M _0/U6[';]B$!D?K'1]/P7<<*FG+H/D^C:6!.XY6E]U7URR,7,X.)T!=:=\)
M30O';[([[KR6&:,5I"\E2#%X1C<@PX!)8<M)(.KX';_2!J18FHYGB^BTY40V
MKN,LI;+_FF:TD8"0$V<F,1^Y"I<"'S&<!8Y'RAP!T,XQX7ADC )$BBX0QT-C
MC@>.[5;I(S+F="Z33_*5GZV;96:1*XY'IA:\VTZIK]A9&[T"2U9$L4KW$Q D
MJDLXN8S4F:@/UTC_,I<J;@_?CK?*-0U=N.XFLT"O-A@RM=7(2E6@BH(29'2P
M)3%:@ME;R+H3Y?>Q.0D:W\B_5Q]6N>06N!?)V@MCUB4DM:W-E8![$5S#?PIY
M:-]PJHFE\"[R*T *.H/:PW;3(\ZC'W%R$:>UU)=/(?A74=Z[98N$F:0UAI9;
M!G^8+W_QTM1#.ZO*S78=YPF5NW6//IS*IMS%XO>Q)8;*YP 710J9_0Y _:Y\
MBX)_FV/E+KM\ ZD?9LQ8%/5Q!E"1D[M4C,;#6:-23FE8)-Y VB0)CT'(YW8[
MO'UT=QG!-.4E:D>1SARB']I1%ND(9#4":J=@Y^G(C:IMAITG88K.H[<[LC:A
MW$$9\]+PJ4 ;$M7FN5QOHF0+THLP\U. #Y%T6V\T6Z/'^HRM?^2@VI9+A8ZO
M7NZOFG[T!Y!#V[LMWW2./!SYC@7;/N<[;C5[]=+@IY0=--QMK.%,NEP,3;,6
M#=:/F*5]?Q8'K3\_QF$'8:LR]G 6&7/C+7C%OW3AY'W?X4RJ7)".LVIWMF+.
MB(TQ3.:3EP%\#07B##L_[P&TP;(P!P\@?0E]4$[I'OC)<XQ'J:HR,2PBPY\=
M#H>4FFIY'I5&T5V1^BLX+W10==@&[+&&,^E*QV51VFF?<$8;Z,:I]$EN%C3U
M<::'2Q+.,_G<9[2L9X-W!G_[_-D!%^NWSS]8OS>E7YLU4W-S;ZP<OU=6NNJB
MPE8!.Q:<>/>:C> Z^G7;6&"Z:=_7298QT0K,IE0O<B_-AP$/]PZ6D:R&^+/'
MPCEB05WC+<<?]\AM)[G,1M/&8E[!CIJ+M%\)._Z219K5!%?)CL.DH FHW50[
MGB!6FKU8]]Z.XW,47W%OUQU_&"1Q"JA>YSO^3J@[8NPP A,OA."I_)2X IKD
MU?]8$NFR450#ROGLN=SCX-CHB[&DU&5SFZX0#R-Y=D]( !X9'M)+SMU3!4\8
M9D+0&Z?-I3FHA8 Y&1H2P3 $K'$:%ZI!-@2M<1H6_<7N$)Q=S5=P_!;F!/80
M\,9I@AP=($3@&[=ATB',B "GU1@Y00V:GB;JL_/WHUQ0J$%2!!H#5X"7\4#R
M^W4-/$"15CN M-H%)PF0*)QK!Y56K9\&U9!R]2!7VU64O)Y,C1<H&Q'-=VGR
M$D(*SK:/4$.\CJO*/_'SS,_#EQ"5K115[E ?R$K-Z\0'(,BN(,>K/)T4][.9
M\F#@B3Z*IRP,0@^>-5X$JNA!7I(/9GL;Q.])N/76\)\+J&%ED'OAZG,38TAT
MU/=,?_%UOH12%"G5:?*<>FOJTV9^6[O94W:"4SYIRF$7*\R]V428("\B!%W'
MRP2>(/C(%LQ&LK?%^C7(P("RG3&!=JLI\4O' W>7&_G8 Y<WD)T#=QGFG-<B
MM0;#68VRWH"&U> -9&,UO"WQ(/C0J$D!I!?R2[Y%KI9\%@?(U,&9\UBK)3^
M[:=8R(D)-<\(-,S_1:)G]QGYE)5L ] T\4-\W,!_1_AF%N4$7"=I'OZ._\Z
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M^A5)1_/)<12I5E4#0"/,; +5:!" TGRHM)/6)!(#XB^QZM'B0!,WE,/@#+[
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M"C/V,RWIOC8?K)0O'Q%928SU"X[(X?:Q4>>J20=WJ]#;:N:3F]!'R8QGSRG
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MJA@\CY^O!;L7S#O_?@$627W#HSPL]2%H$]']"<U'J4Q=+]:Q*M'7/'?#/;\
MZTV2HNIMU=:24 R.&F\X0IWP#7J,J<"9ND;5QXP=EM# ,K$.+#+P)78:9.53
M^JLD78!T'<:T* #Y?C:,JB+U5UX&YD]1^,R+8: TM.U-XSI/ILK(4V%@(X"Q
M0]?H#HH10<-P<4CD2QL)'TT%,?5S&JOJE(PC9IR(<<.].OI)QHGD@2.E'HO0
MR;%A L=!U'G0XH<[,O/F&+B3(0Z9[BG7(SN./''%KC03 -I-C=GMP.6[]1QG
M,^7S0;N[T=DB?'T='*,H-"=Q4L@[@UT/<#-U=$CYJ1T'5T5@:G-\.XZI-@G)
M+^#@*GQ'.V=D][2KT:WJ1K+498KCJ)G6:VX.,D&XBF27,X5V_]5'23+K4=5(
M.PES(NS.$YP+&,0H$_ 46#T%5G<-S&"P%"V:3JZ/KF7(TKRV!/"_]O"W"FPV
MB&S^UB<QU#5N_SJ<\),I*%Y?_(: /;Z&<;@NUDP&:?[N>I38\9'!\/@JM=#?
M"GC6([*2& LD-@_S^UB81(L.+N?2V[H2F*\CZ3.INRY*]]QJ9XE8QOFYU_4$
MX?IJ8_2A+ARH[)(JPXW^"/4V7UZ S$_##2O.C]?<1!#B)DRQ\HTL9N0 NX!R
M:;Z\"M,LK_D?/;KRU6D<?1'SWA9]&YK[!+2J2L@AH:RF=J4#KL4I%@YE,[ND
MXGNE[#K+"A"(*6ZTUK;>>.ART L<C5.Z>\J/5?5ZP+Z4#XT/5(>P ?JQ%:'H
MBW/DJ$,!@JS170KW\7ZA")V?5*8O',O"I D1\& JJ9@7.;H(#R"O,N;&[:+O
MR-CY=*KO464!MZDV6KYZ;\@^*65X%2!U':/#)?L:PO^70[4T>X3*Z<Q?A:#,
MF@FY? /\<!F" -<MQE6N<+ ![D>;AXG/&%,K:H;P>9+1I9^PCS;J"$_N]0*D
M#]!H8K34^)[V*,%7UH/+&M7@*!JE]H\,X;2O2OC^+G_BUWK8*,Q"RIO/@G\5
M65YN1X8V(-='GZIZ<$MP44!9@M7CQ2O\Z/8J*=*OT!1947>N4G_M5.\-INJJ
MG$?B86/;USK3,Q]%X)2<\?+W_J[!1'7[(S@.7/". C ]!^O*,8<1(!2_O*,@
MF PE=!4KJ2N&^J9BN/,=AVEZ'G<$>-P;H%8AH_;]AN/0=+HD:<3Q\C4I1^%3
MOJ790<:]-!DI6CH?LKGV/*$[IW6["ALIC$P6%.@GC@9^=^<ZYM7E2)$Z8*R6
M;>UHX'$G!F)?))M :1!/^)391P'8/H*U!PB9+&LU+_Y-@'42',86Y<I1"16&
M?Y@P;+#<L6$/%:Q_G/;QL6$/!,H_35!*1ED0Q/X\[>F]8<4*&*FP^C)QE\$X
MDYV%.C8OB;Q/Z3!BAF V-K.>C1DKCH<@-38[E8V4@3@C O+X[#DUXZ0>IT0P
MF\RY1#;(:8?99)'4''1* 5L$P<GX:.-'"1TC8!DU+ZP_C[\!C=D/]TV\X*WH
M WA&]/\$DN?4VZQ0! ;U;2"_[9'1H!GPOW].7CYD^28MB47_JA$*_^O;]4V;
MI.JO%D)1;T"6@9(':E>7!]NE%8PJZF5M(KM\<IBV4E<A_X5NR[CS$7:V,*UZ
M*>X;](504).*TT%?N&T*-EX88&"J"R)>$1AV:RM\ LD0E75J-1K,ON25:N+U
MZ.FY_NYRM2Y8&:DFV&T'LLLX;^*9S36='CBA<KHM*:_^8T]T]8=O?[]LD5?[
M0=_K'8ID),;BO.2PI,QI1=OZ"KW[.'AO_TX[>.%?!W)><0%5Z#B0Z=R#&+QZ
MD?*YN^]E82)-8NC/2/AMK1--#EDIJG>-;8::"W5W'&E!=&='P^H45?*ZWT16
M^74<.;&RO#?[.2JLXRC1->!#=F(HG\ZC(U2\2=@71]UU%"0I)7\'#UNH.PJ/
MK#E1WVL\F>4H3-(G?MW2<320N<.AKVR7C1(Z9@0X>W,ZBI.:@HUL9$=CNS4K
MV(QM-B[4F-M,"/(HX>I@Q=5\*(X^+C@",H:WQM%0>6U [3U$)F*\!W_%_5"L
MUUZZG2]QN1ILS'A172^HW7Q7+Q,721/!K-\;<69N+>\IC'"\5LD3C'LM06/K
M'DM"VG97'5+"<WG0R=G;1%:F.[B(N<3"4]M97W,<3CA?/F8 TR>UY.T^UB>Q
MX\';)/:[\&ZMWW FHS8%NT%?0A'(/@4/I8ZC#A>QYY<C3QS%1"A!V7QS(+E<
MADC'_JH+1^>K=PHV&0=/1_U/VMC(D,\@@<K_25@K5T6.LO?$<>%%50:VAC7W
M"&V+U*J9<B+ZM)%HEQV;DN6X*, MA'+Q"J(70,V8>O1P Y[Z/X&7+EZ3(V=,
M1AGZ1.$W^7&9*N,,>+)'SG%P4X,B$\I==,T(@LLW'S:EEN8X;BPW#+O)+S1Y
M"1!1OP!D_H!@!K5N[YD29L8J;:$\S-"F>E%M[WLO!W<@]66746*8X1HMQZL\
MCEK'^J';J4R.&H*&$"MU+^>ODW5A9N@:N65%GRY4;)50ZZWREQ*W&#RCZ\53
M04[DF=%[CWQ*/"5YM:#GX;U3S$/Q#KN6T*LK1C*ZMHF,7NY 1M79^TCL9=V-
M? &>\@=_!8(B O/E LE2]*<3<PACDF7+^S(:VW Z)?$SVI^((K[O@M92W^O=
MVN![,0NUFJA Z0 ?8V^=I#E*2$2@8]6E[3B2!>C1]Z]CN/0%TGCKA-&G)]_/
M,A]),)!U:<W?K@T=G+9#3+@*!G4Y+,;GJ'WKN.- GKLDA(!6A\$0%?)N>[$?
M]\ @M*/!9KKJ?-KQ\L/06EH_GCE)5B@-+9#[LY>&""ID/W"(/6AFF51NBBA*
MPYX2!!T4H:PE!-K_UB<QU+15[5][(JA*K\PDJ?F[)6TTK\X)5$&5LR&H30=
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M'$:)=00W14'Z<3*3-8!+ZM?CDO5A_-SXO71:S)?XQSWPDXTL;2,+4$<E9%.
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MUNHUA(G\E"3!:QA%Y:4$5 Z1+5+^)#LKWA!#F**D)*\W'@+9564NR37 C8=
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M+6"3F'+$D>,6GAY4H7PR8N/1"I3VKV762N\43QGXK4"YE5]P3G8'4K*VYK2
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M">UJ<[@WVB?,[]*N'CG\BJ<M!CPYW"Q_9,FDLD>6)4>R!^IJ4CT([LK522N
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M;^U>^[ W282%NLEY"'ZNH3[1/"\-FP!5X0=*1NMM63;][9="V=Y* \J;-69
MB[B78E,F(K*)'PN+MF46W836#^X3$0C+O'8#^X24/FS0_V5QIG3*Y8O9S&:&
M-O._< 24\DL#(,1J0/_T(^!\<#.\O+@\/QM>7E^QZPMV_L?EX((-/@_./PTO
M_S7 6_AT<,,^?KJY_71V-63#Z^\V4EZT9?MQ\CV]>3LX=R/$:W5HE S_&+#;
MLYO?SZX&M_7KS_\<_)N=G0_I2:?5ZFRSYQ]WXPMX[>VO[7>MW@]QQ_J4)2'^
M2V:L%^;_RQH;@M8"V'FA-<]J+ 1M13QE-N'67W%V),:/NCL2)I=\ZL<2[I==
M7=G[G\*0VEG53JQN+->VYQQ:1S^DQ@^X 2DR6/5_U8/S5IPT/,_[[=5UR .O
MSETJ,G))W7GVR7I7!_$33E]SY9OW[<:LNY?Z^:$-/[V#<<2SA(^!:1@+F$"$
MXUP8=I9E!9?L!B@X9BIC%V@$:[?J_V J9A\1"HE*Z1M-"Z&P(N32U-AE%LY]
MUD2G59][J+QVJ'1V BJ_XPB+" WIE-UE:B(A&D&M1(PNH1(I5)LIRZ@4%QGC
MV905F=4%8,,Y#E1411CB+,4K+1!E,0_QEF8JQ63)JE)N32"#$(SA>DHB*;\#
MK'=)I\%[$1J#54KR!=5! J'089&B6(;%T9((-$,_A@DS!7TLRD] 0Z6$&I *
M(S%YQHR8381-L($FA] 92'IS-$U%V,PQ%HM8,%UV0V]/ CM( MYNDP"P6&0(
M,T+L E8U9  4Q\=ZZ;G(8K+2"M0CLE 6$>I$Z"YAJ(:P%UI.&3;2$&D0F4BY
M8(4*D&:E:K0T$J2X1A*%1 &D H5X==499T_(3<)BJ29FQA,:1L)8C'@MXW2S
MM!NMK"W!W<R,6;-VC_A=1/S13B!^^  >;W^][[3:ISU3@;K*#VF>5'$L\-(A
MYY)Q#0ZCB#D12" L,4!7!E*8A,1)+,48@>($ND;'A5*9 LM1Y5K)$JRY5B%$
M>-NP \1F! CV$H"#^S#AV0C8&4[,-X5$B;;'Z^WC SAT1=O'47E57@I:L\A*
MDB#]C&;O)>XHL4RVK%0$LXHH$M'+%<4/*HJQ(FKG*J.@!&49_M=9HD(Q8?,!
M9/?$\2J(X[3M=;JM;O?DZ*3;[72(1/CA+I#(!S X=!!-+NS^.M1KE!&$O##/
M+T*A>0 (VZJF,MA7A48%.'^/A7%1 4I!YO30DM8BGEB.231([GB@BO876*Y5
M\0H]%!A;H"U&21%QZPP-C(@$UX(:(,J<Q$5)&6DJ#.4)CC:-2RI<#*$,H$$6
M8Q8JE..($6$A.84^V"QGQ"+?P!)E]K*<=.&O $@0.Q;+0_2,:&3/,[O&,\%.
M\,S!1Z[Y""M-W'H"H3(OM"EH&D8(W@[.V0U@8H^@NU*FP3ROWNUXW:9W5#\Z
M.>V^<YQ"-[W3CKMYZK6]PSV@MJ>/MP90X4X :C#FLG"S&TU#$,>8<XLQ9& V
MY,Z+Y. 9TW5YN3F?=M,V%L2IUI19>Z *^[@)SPDH^%P::$DB_OHZ'@MFBQTN
M!('2%6A/CY3O.6%KANG6<$*T$YSPH43;.FIIM;_*E-V3S=SP_#3<1>@J# M-
MX%P*AS>I397!Y!SH9 (J,R%J^E)@GZ'N@\?*Q,@S-ED5KVP/*4J@O0K:QG ;
M@J5EAZ5="3?S[ &#=>YX"2*7N3B7<*,R'N C*>Y 5AL7*_*U;_?2,\EHSSRO
MAWFJ]<?C_?KCX^N/;EL_FC%5;3&74VBQS!6+:9W _FS8U=87!Q:V\2(25NDR
M""$A=P-UIBXI@:="IT!Q[>*32*"%3LL!4@I&*H8B(?RFA8H9$\*70F #'.D5
M6>CV. [W"XW;,X"W)C;9C87&,RD9+0 *Y )*^FD5/Q2 X*U2COF"WP3X'>40
M8&83?KETZ,XBS/8+_Q0E5&MSY<['AMF?1UC0P'SR?YP^ B&%=660 I1&^G*9
MC,$TQA0I @D=YUI3!5X;MU;W6<IV#<ZM88+=6 H\PV0DUCCQUA"7X((%1+8[
MVU-10*T,Y$4V5G(,%,UG?%0=4=)5? %I+M44\.DD4650P1\0#!+"]\EV'CLZ
M2%NFL FL] )/+T!V .W<3&_OM'I.O(X]J0H<$^(>HEXU%(X(R94\=ICDN0'?
MT)8!^F.&2??N3:G:O02$]>M9Y;2%4C*3/RM?":%4-#\$[FH[.FVTW[DHM=^T
MT2-"QZU&USMY((0_]&J]23E>VHVCX]QNJ/$K@W."3:X'R,AWOONLTXW-PW-,
MT22F@A7M(,61;8\=*I^-U9<Z9+^)];81:6SM*/[&/M]WT]9VTU.H\QHG.X^Z
MGW#Z^X"D[K,+"'1!IV8[W1KKM#K>#P5I-?G,/7^"?,[<_CE[Z+Q]]W]K]_<#
M_;YIF@]?Y_FST#]J'.T\]+>Q<_<3[FN Z+= LX,Y\CX8WL9>W6/S-6#S/!$0
ML\$]A 6=-6#72WL+'S480?Y<[N.]O[_QW)8662AR+M>=?O@4-^(W+7C\R'?A
M-W7!CW\3/IE/&3D?0<DE=1Y;T#Z7$SXU;N[H-^E?P[S_I=]T_U+F?U!+ P04
M    " #/0%Q6\8L<>YD(   [2   #P   '!H870M97@S,5\R+FAT;>U<;U/C
M-A-_WT^AATYO8";_$X[@4&9R7)@R;8$!.M.^ZLCV.M:#;/DD.2']]-V5G3^$
MP-'>T0LDPTP2RRMIM=K?3[N2S5%L$WG\'3N*@8?XS8ZLL!*.![]7V\VC>G&!
MM^OE_2-?A1-F[$3"CSL)UT.1>HSG5OU/))G2EJ>VE_$P%.G08]WLKK?C&LVF
M52S<V:I(0TBMUZ@U?NA%*K55(_X"KXG7F>T5C5:MRKRBP$E$/!%RXMV(! P[
MAS&[4@E/I\*^LE8E7K-=:V$%UP>78IAZ6@QCV]MA(OQQ)U3!G\T_#W:.CZC%
MA:+W6%2GLO).J:K/@]NA5GD:5@,EE?;TT.>[C8K[V^L]*&ON]<:QL% U&0_
MRS14QYIGA?YC($T\7\GPX9 71_CN4ZYL;VF<16&%&= BZB4XXK$(;>Q%PJ)N
MJ45KHJ$'=['PA67M9JVU:D#_2N-4Z83+%].9316M9_^AHQ3R"WX28#>@>SNO
MW -.!E<W9Z=G)_V;LXMS=G'*+J_.SD_.+ON_L-.S\S[^Q%\7IR@QN&*7OUU=
M_]8_OV$W%U_-6UYT=%M?^9K6O!Z<."]I-UKD*3<_#=AU_^I#_WQP7;WX_9?!
M'ZQ_<D-W6HU&:YTM_[@97\!J[[YOOF_TOHDY'JYN$B+[7_CA"Z\!9Q7VJY)R
MPGX"-)TV*JVP +05T839F%MOR=RA&#UJ\%"83/*)%TFX6S1VJ?'_<T/-3CMW
M8E5CN;8]9](J6B(QGL\-2)'"\@R4<S@;QT&MW6[_\.:FY)Y59R85*9FDZBS[
M9+_+;OR$T1^8<N>X69M.]\(\W]?AU1L8?9[%? 1,PTC &$+T<V%8/TUS+MD5
M4"3-5,I.40G6;%1_9BIBEPB%6"7TC:H%D%L1<&DJ["P-9C:KH]'*SRU4WCI4
M6AL!E0_H82&A(9FPVU2-)81#J!2(T0540H7-ILHRJL5%RG@Z87EJ=0XX<(Z.
MBDT1ACA+\$H+1%G$ RS23"68,EE5R#T02"$ 8[B>D$C";P'[76C38%F(RF"7
MDFQ!?9! ('20)RB68G74!)<UAG8,8F9R^IC7'X.&LA$:0"*,Q$P;TV<V%C;&
M 9H, J<@M9NA:BK$88ZP6LC\R:(9>EL2V$ 2:&\V"0"+1(HP(\3.855!!D!Q
MO*T7[HLT(BVMP'9$&L@\Q#81N@L8JB#LA<98% =IB#2(3*2<LT()2+/4-6H:
M"FJX0A*Y1 &D H5X==T9IT_ 3<PBJ<9FRA,:AL)8S;$C3H6%WJAE90'N9JK,
M VVWB-]$Q'<V O$W]^#Q[ON[5J-YV#,EJ,O\D-9)%44"+QURSAC7X#"*F!.^
M!,(2 S2E+X6)29S$$HP1*$Z@:S1<()7)L1YUKI4LP)II%4"(Q8;M(C9#0+ 7
M !S<!3%/A\#ZN#!?Y1(EFFU>;>[OPIZKVMP/BZOB4M"N15J0!+7/:/5>X(X"
MRZ3+4D<P[8@B$;W8472OHP@[HG$N,PI*4);A?9XE2A03-N]!=DL<;X(X#IOM
M5K?1[1YT#KK=5HM(A.]M HE\!(.N@VAR8??GH5ZAC"#@N7E^%0K-?4#8ECT5
MP;[*-3: Z_=(&!<5H!2DKAW:TIK'$XLQB0;)'0^4T?X<RY4R7J&; F,+U,4H
M*4)NG:*^$:'@6M  1)&3N"@II99R0WF"HTWCD@H70R@#J)#%F(4J9>@Q(L@E
MI] 'A^64F.<;6*/(7A:3+OSE PGBQ&)]")\1C6QY9M-XQM\(GMF]Y)H/L=/8
M[2<0*K-<FYR6883@]>"$70$F]@BZ<V5JK-VN=EOM;KW=J78.#KOO':=08?NP
MY0H/V\WVWA90ZS/':P.H8", -1AQF;O5C98AB"+,N<4(4C K<N=Y<O",Y;JX
M7)U/NV4;*^)2:XJLW5>Y?5R%YP04?"8-M"41?7X?C_G3S0X7@D!A"M2G1XUO
M.6%MW'1M."'<"$[X6*#M(6IIM[_,E-V=U=SP_#3<1>@J"')-X%P(AU<UFRB#
MR3G0LPG8F FPI4\YSAFVO?M8G0AYQL;+XJ7N 44)=%9!QQCN0+#0;*_0*^9F
MECU@L,X=+T'H,A=G$FY4RGV\)<4MR/+@8DF^\N56>B89;9GG[3!/N?^XO]U_
M?'S_T1WKAU.FJLS7<@HM%KEBOJP3V)\-N\K#S8&Y;CP/A56Z"$)(R!5@FXE+
M2N"IT,E77+OX)!2HH6ME%RDE<P_D&/JFC8HI$\*G7.  '.GE:>#../:V&XWK
MX\!K$YMLQD9C7TI&&X "N8"2?MK%#P0@>,N48[;A-P9^2SD$F.F"7VP=NF<1
MIN>%_X@2RKVYXN1CQ>K/0ZQH8+;X/TX?OI#"NCI( 4HC?;E,QF :8_($@82&
M<Z,I Z^51ZO;+&6]G'-MF& SM@+[F(Q$&A?>"N(27+" R';/]I044"D">9&.
ME!P!1?,I'Y:/*.DROH DDVH">'<<JR*HX/<(!@GAZV0[CSTZ2$>FL JL]+9/
MST=V .W,3*_Z-'I.O(HSJ7+T"7$'8:]TA4-"<BF/$R9Y9L S=&2 ]IABTKVH
M4S3MWAC"_O6T<SI"*9C)F]8OA5 JG#T&[GKK[->ZG29YVU'=AH\([7=JS?W#
M>T+X0R_W&Q?^TJQU]C.[HL?/..<8AUSUD9%O/?=9I8+5[CFB:!)3P9)VD.)(
MM\<>*Y_ZZDL]9K^*]=81:>S!P_@KYWP[36L[34^AKET[V'C4O<+E[R.2NL=.
MP=<Y/37;ZE98J]%J?U.0EHO/S/('R.?,G9^S^\;;3O^73G_=U)=?YOFGP._4
M.AL/_'6<VNUR^Q8 ^F7@;&&.O V&UW%>M^A\"^@\B05$['26I=->VX?<"/?0
MP45QT/ :_[7#UB^^]/DR+= C,G2)N7.4_K#W%(?C-VW,?,NW]E=-P::\L]]]
M'<:(9^M\QH=0+ !5'EG0'I=C/C%NP3^JTS__.?[NJ.[^:=#?4$L#!!0    (
M ,] 7%9TBJ*5A@4  .\I   /    <&AA="UE>#,R7S$N:'1M[5I1;]LX#'[?
MK^!UV- "<1(G[=K968%<F^**.S1%DP&[IT&VY5@W6_(DN4GNUQ\EVVF2IAMP
M6[=F#5K$MD21%,F/DFCW$IVEIR^@EU 2X15ZFNF4G@X^.-U.KU4^8'>KZN\%
M(IJ#TO.4OMO+B)PP[@$IM/B-9;F0FG#MYR2*&)]X<)+/_#W+-*^':#K3#N,1
MY=IK-]NO_%AP[2CV+_5<?,ZU7S)UM,B]LL%2Q"1CZ=P;LXPJN*)3N!$9X35Q
M(+06645O19"43;B7TEBC!CW#HM9@FC!-'963D'JYI,Y4DGQ)B\X]F:\_%T+[
M:Y++Q@8H*EGL9ZC#E$4Z\6*FG1 'X_Q0\.N7[INVWVL9=J>]5OX#;>%VFYU5
M8T@V25 I8-&[O4B$']V/QVNF"4CX:2)%P2.<0RJD)R<!V6\W[-^!?Z_-/? ?
MMN:4&GE>(-+H_L2^DWT'LX0%3$.WTW1K*R]/Z']IS(7,2/IH.L,3"8<0Y5"Y
MCHZM"X&SP<WX\N+RK#^^'%[!]?N;T?O^U1C&PUT\/,MX<$_@?7/4/&O":'!F
M8\+M'K5WP? L@Z$_@O[Y\'H\.-]EAF<?#'4^>-M^ \,+&/\Q@%'_YO?^U6#D
M##_\-?@;^F=CT]-IMSN_5(P<-[O=[F-'R::]]F/$R",;])(#/G ::B8X3)E.
M0"<4^IP7)(4;:@XY@#T7J :X;>=/$#%<)T0G(C-75"ZDA68A254#+GG8A'W#
MX/7+6:?MAOZ9R'+"Y^5CY!] +*25,*=$ D6'17!.0YH%5$+7;6 T=CI %,0L
MQ:Z%0B,:%I)IAC,D/(+!+$P(GU! _AE3RBB/_X8R(II"0B5%15=4*2>ST 2U
M;<"82LF02R$EX0TC]RQA-$;^*$^S6PK#.&8AZH;<#+.PG$\#L$VS&&_R0JH"
MSX&@!2RMQI5%S6IL^9)(Y!IGM$Q>$QF(5OQ'1 :$4^4,9RF=0S_4IL= M&%&
M9'/XQ,4433.AV(!^\-80$;';!_-FQ%2>DKD7IW1V'PW_%,K,J X.2^4H3:3V
M;<@[&*F9\@*B:,HXW8R0NSBK4/BK06;%J N+,FY,XEC#?E'N>IKY@M'OF7+O
M=-\]J-V]Y.=5);;>PGNG!@A5ZHF+-)U;U*4&^XM\(.GG@DF:X0!E$'*'MWUR
M )ACW*/]Z*!$7HYC0Q*DB)@:97?99)%)*JBY;[N'Y;#,9B??Y)L%QM#JU>\.
M:[\ZUCK/!FN,QT:(!9#I(3BU"%MA&8B$240BJJ@,YAJFFZ0IX##DCWL%[,@1
MA*IA1\6,$QZ:=F08,<O:+-Q(5:0E9$5.I96I:EA6FX7F W#;N-ESCIMOW<-7
M=176,8'_\W: 7ZFV?E_7;2RW:I/H5BO6I4U,U=H/A(RHM J:DG7;M^0.1K0H
M$!!LA@FOPL&1R6(5/09N2G)%/45S@DY;)"1;9"U9V\HWRI>U\%NF6,!2IN=>
M/;XB0JIH83$K[?"DZ78,ZGHM'3U <^0V3TY6:/!&KDM-2M2@NXYSO4'>5R Z
MQ0D[@:3DDV=_'=.P&:2W9@>(^]XJ',HX,>H]='"M/?\CR_];F)'.,;X\N*"!
M+(B<0^?$'@JZ2W&^,4@>V[$5%!;&/S[*T<HB99C45NRWBX!OC8"6:JV>S#;Y
M_DO@/VP>[L#_1"LX]U:MGX+F)^:I+03I-P%TMSKO +I5GMI"@#Y4R33'L&L\
MAS%CSQUP=\#=>>KI>*K&'E[-R7S+OB;[ ?6-)V2,+5P3QJ8T)R2=",8GU3LL
MA+ MSS$% 37-<2$Y4PF-S/&6FJ+?5U]QV44%&7"A:R;V_1U1D!.IZP)?_3Y1
MV@([U-4DB)@*4Z$*B;<B+$Q5O[GF]V2Q%.5D0LL,Y9!84^F1=$KFRBY*O9;Y
M8//T1:]E/_3\#U!+ P04    " #/0%Q6HU^A&(@%   !+   #P   '!H870M
M97@S,E\R+FAT;>U:;6_;-A#^WE]Q2]$B!BS9LI,FD;P ;N*@P;8XB%V@^TA)
ME,65(E62BNW]^ATER[7SUF%=FCHQ$E@2>;P[WMUSI([JI2;CQZ^@EU(2XQ5Z
MAAE.CP>?G&ZGUZH>L+NUZ.^%,IZ#-G-.?]W)B)HPX0,IC/R%9;E4A@@3Y"2.
MF9CX<)C/@IV2:5X/,71F'"9B*HS?=MMO@D0*XVCV-_4]?,Y-4#%UC,S]JJ&D
M2$C&^-P?LXQJN*!3N)(9$35Q*(V1F>]UW0X.*&40SB;"5VR2&M2A9YG4.H0D
M^CQ1LA"Q$TDNE:\F(=EM-\N_1G"KS6L$TY09ZNB<1-3/%76FBN258E-J1?BA
MY/'MN:RJ_O9+(4UP8P)58Q,T52P),IS*E,4F]1-F4#=AT$RH_6"6LI 9Z'9<
M](EENCZA_Z2QD"HC_-%TAEK15OZD$1"A'*HV/@1.!E?C\[/SD_[X?'@!EQ^O
M1A_[%V,8#[?Q\"+CP3N$C^[(/7%A-#@I8\+K[K>WP? B@Z$_@O[I\'(\.-UF
MAA<?#'4^.&J_@^$9C#\,8-2_>M^_&(R<X:??!W]"_V1L>SKM]O/:31RXW6[W
ML:.$T^2';"@?V:#G O!!T,@P*6#*3 HFI= 7HB <KJC=RP/VG*$:X+6=WT F
M<)D2D\K,7E&YB!:&183K)IR+R(5=R^#MZUFG[47!B<QR(N;58QPT()&JE#"G
M1 %%A\5P2B.:A51!UVMB-'8Z0#0DC&/74J$1C0K%#,,9$A'#8!:E1$PH(/^,
M:6V5QW]+&1-#(:6*HJ)KJE2366J"VC;A#\GY'#Y8/926HFDE7RHF(I;C],^8
M('B+=\,D81%JB#PMRZB:51.PS; $;_)"Z0)?>L!(6%F3%W:U:W+)F\0R-SBO
M5?*:R )UP7]$5$@$U<YPQND<^I&Q/1:H33LBF\-G(:=HH G%!O2&?P,7,;N^
M-WO&3.><S/V$T]EM3/Q5:#NC.D1**D<;HDQ0!KZ#\9II/R2:<B;HW3CY&FT+
M+#XWX*P9=6E1)JQ)G-*P#\J]F6P>,/HM4^X<[WJ-VMTK?EY78N,MO'-L@;!(
M0$EA86I1QVT&6&8%1;\43-$,!VB+D*]XVR4-P$SC[>_&C0IY.8Z-2,@1,37*
MON:493Y90,T[ZNY5P[(R1P4VZRPQAE9?_&ZQ]MRQUGDQ6&,BL4)* -D>@E.+
ML156@4B80B2BBMIBKFF[">> PY _+I38D2,(=;,<E2P74&08LY*U7;Z1JN 5
M9&5.52E3U[!<;!G<>^!VYY;/.7"/O+TW=<G1L8'_=/O ^[WY"*Y[^]I[UPYN
MK/_&)KKU\FQE$UNB#4*I<+]3*FCKL^V@)'<PHF6!@& S3'B5J,..S6(+>@Q<
M3G)-?4US@DY;)J2RNEJQ+LN\*%_5PJ^99B'CS,S]>OR""*GBI<5*:7M=]^BP
M8V'7:YGX'J+]=V[;.UPCPAMU4VY:X08==I";.R1^ Z13G+(3*DH^^^6O8QON
MANFUW0/B_G<1$%6D6/7N>X&M??\_Q61%_]RR_L[Q*4:8#V<T5 51<^@<EB\'
MW95(OS-*'MNQ"S LC7^PGZ.5)6>8UM;LMXV [XV EF[=?$.[R_L/P7_/W=O"
M_R>MY=Q:N9X$SS^9IS80IM\)T>T*O87H1GEJ R%ZDC*:K-0S[4O8^T+C&Y[6
M=7%S$\\ MG'Q?;;<?:#8W=@F\FTBWWKJY_%4C3V\VGK-#SPD_U?6?/JJUX\Z
M#7ZNJ\'8EFREHA/)Q&1QMHD@+LNV3$-(;7-2*,%T2F-;]*"V&/S-H\]RNX$,
MA#0UD_)TEVC(B3)UX;<^;5;EP0O454:(F8ZXU(7"6QD5]K3'?9)O138$!NER
M9<[)A%8)VR&)H<HG?$KFNERC>RW[">_QJUZK_/3W'U!+ P04    " #/0%Q6
MUT@Y24$3  "5@@  #@   '!H870M97@T7S8N:'1M[5WK<QLWDO^^?P5N]S;E
M5%&R9#O9C:1+E2(KCNJRMDN2+_L5G %)Q#/ &,"0YO[UUP]@'GS(=I:TY/54
M*F5QB,&C&_T"?MT\FX6R^/%/XFRF9 [_BK.@0Z%^O/SGP;.SQ_PW?/LX?GTV
MMOE2^+ LU/_\N91NJLV)D'6P_Z7+RKH@33BM9)YK,ST1?Z_>G_Z9^JS2*T&]
M#P?:Y,J$DZ/#H[^>3JP)!U[_2YT<P^<JG'*G!\%6)_R 6DQDJ8OER:TNE1<O
MU4)<VU*:U'AL0[!E;$]#R$)/S8G3TUF *9QA'VD*8YF]G3I;F_P@LX5U)VXZ
MEH^.1O3?MZ=KSXZ_/5W,=% 'OI*9.JF<.E@X6?&\%@J'.!G;(N\NY7AMYM^\
MJVTX79D_/QP)KYR>G):PDH7.P^QDH@/,S02@$LS^\OU,CW40SPZ_/WN,??YX
M]KBZ3[(6:K)&U3]$-F-=*8ON9)\>?K<[PHEO_G+\_='IO1#M^U6B93",<I]M
M,]+(N<JLDT%;<P(C*%=HH_:V39]?WEQ<7[V^O7KU4KSZ6=S^<BFN+U]<W=Q>
MG[^\_>8O[Y\<'?]P>B-N+B_>7%_=7EW>Q*\OKR^?B]=OKF_>0#MQ^PI;4"?'
M3U(_G7<N_WGQR_G+%Y?B_.(6OS[^X>FSA\'@35*Q#_:N"\U.V7CNA9V(YRI3
MY5@Y\?1X))X</7DR$J]G,LQLB?_"!#)5!YW)PH_$E<D.Q2/F<':Z4"/^,S\5
MZ5GMFT?2Y,UC6[OT_%LQD[FP1HFLD)ZFX%56.QTT+,&IJ?8@/2H75>U\#59&
M!"MN5(9[&S<*M \SA4_2.Y?OLYDT4R7.LX!?XT89">F%+!5LB?Q$P/ BLV4)
M/?A@L[>'#V,??69%L3=UH'SF=$4, O)?,*%OD- /@\Y?F+SR^SC-$QU@!=E6
MRK]01CE9#%3>X6Z^!>4RL45A%^#9BKRSMWU= @E@1"^\+5721"#"):FQ-2TC
M?E*9K+T2X-)I:&**I9"QF^4(G^86.C,V"!Q?:B-D45"GVDQPF31N '4L2KD4
M8WB>?&_4BDM;DY:%OGT]_AUT)#[%)^]JX,E$@Q:%/G7P M:FG0K0QQ)T[ 04
MK,D4ML9)1SU);SKE@PSP(5,N0!<9?,#%:0,.1A5]#/$(YYB4^UTM&ZT_HMXW
MCO33LI +W]J5,7WNO E;(IL)Z8 QNL"W83WL*?NTA-+Z #VB1A7GQL#RQ;5"
M4@'5Q<] 2G%\=/"_/ >G.G.$[GHDF<&_VAR*WQ30+(.N)1@6)#0,Y!1:+N3R
M7;3!,; 1+P/V$A 8PB3\#F;58>P#L4+_(7*[U9NA'5Z#0X.B"_M:5JA56411
M[CPZ'#F^_.P(UL+_"P^^CZ(NNR(]$O\-]#XZ.A:5=&(NBUJ)"D:CUKS%GVWJ
MHZ(-AE[-A[L9ML5^C>;_V8":_1I']P.M=RB"OX"7J=Q&6TA:%XU00 6.2AL"
M@+D-BO2CDJ#?:?.#_BTP.B!#"&HR8']@W$H= K\H^34,&[#C&8\Y0B5<U'@:
M1?93%3%B@'8Y6+XL6&R$ II;LK@S.8<0I"[K I3QG":#+]-!DC^$6 )T.G97
M@*7&'F?MXB3,['=0)V!.HP]@ZP#&S-#PFS5';_&T K3V9KEYIJ"E#']#A(BC
MM%\W@Q'U8@]  VJW!/=$9#-K/:@D"P\<NA \6ML%>17=1<&W*VI*+!3Y'=K[
M6B4/I+L.&OE0W+3.!T[3UZ#+&@KA6MD*DM,4>9HFUK!XANN$[G.5Z9R-,O8E
M)Q--YG*N&K[CWNKR'EF)M.BP!6@;^5G9!0P3"<ASR23X"K'_7C^P?(\.!,S5
MJ?@A.BNQ-_("8:_RM _%JS_D/6WUA*++ +&VA<G8.5""^81+;ED7.>%4:>=H
MN="O1 *SLTG^!SZZ@X2K&SJ(0B%5PL(>A)EVN=]&PBT[O6=4U[8ZLEJ!PR.N
M3.,+C1[8Y-"+=NI=K5W4,\B@N!64+$;X)S[.;16BL "#//(3N<MN!&R>A0XS
M5)1SC,S2Q)JVC7+\Y%TSN 7[=0N>:Q0WX,;@&.S<,>@8B*H)M7POL)55!=R1
MXT)Q#$NZR_0D>LV)[BB).WT-C M1P8 @P0#8,YA&T*?,<$]V$T:D,\,X'3!#
MA72M'1I;Z?*^B8:IX8-"3<%T06 _E[J@^4^ -7X0U_V*ZZ\:5'5.FC%1^@M9
MX]8[K"]L'1_/JT&C[GRS7!D.<^;DK[)+4;0B,0(]Y;TM:HXL''@EK$/K:BV:
MZ:G.A68WO*L^.3!+RE/SR-)[%?PF[6?15?7!Z3&/CCUTO6PY"121@%<DEV6:
MO^OX4W1DQF$/.;YJ#".16TLQ0Z'E6!=T]S/J'GRRHZ719:,-MRVJ634L@ZK^
M'.)/#'S=6O^!Z/LY>>F),QUR&/*Z5%E1E(5QHC40G9"H)4EQ4;9 G-H+#]<R
MCH(D<JP,^E,Y]<:JQ6OSEHXBT.WI1CI]EPZE<_=WL,=/'C#$9;?NP0XA+ONA
MVG8*[8$< S7V1(T_AAD;6P<*J'WVM^\JH(0M="[Z8O1O4FU]=E\RU1X\,68N
MS:624W4P=DJ^/2 '[D06"[GT]XOZ_!IU]]?F\GR\G_ESC9%()36?JAIK,$CQ
M'CV0@?0[ALA\Q(T7>HMYC<%A<_L^PLMNG1?Q3@D^3^Y@VA"8[5=@;ITT'N(Q
M<3[%,!SI?TWX2R?=0/H="TQ(Q)8-L5TB-IUXK%V9:X]8RJK&"U(Z@KEUM0_T
MC$ZK7QZ>#Q*R9PD!QKV4/I?OQ(O"CF4A_B'=6Q7$K\ X4'T#^7<H):\V"$#!
MX"PZ@G RI]MN.DKH<^6&L1*1.90!P=A,G;W%4XUE.;9% UA\_<OY[6'"%WY=
M+-PK$/S<!'UP*]\J.P>B7TXFP).(RBOD C78KW)!O$167_0ONZ_6(!*,"_VZ
M^+/OBUB$X/3!" UOX)_1'X0#)\CK7:"6A'#NC$[WOYFMBUR4L&M(8EOH-1E,
M2<@F+TJ+SJ2>P SJ(IP(A#-E[VKH*&&G:H]WM:62)F*T@B(U8&$;8O+)T[^I
MTX]Y#>;W?DFSA04T!Z,+[57JQ+)N(?B-;&XI@")U.>;K#)@EW70@VBS=%Q^*
M*T*!5]9[36>BN'KHR/<XTB&'#BO+IIOQ#%1D!6IQQB>YV#I7=*/2I1=UWKMV
MP8OM9BF,>R4M:0E63DI5._@;%JTQ+26N7AL&,W>?]]%VW6$9J9V@2^C5=.YX
MD+:JU'4I2#\@#4M6V)4#@C5.$(<3A^)VA3:C%H$/NTK!-AE%,'?@;0=KR;5/
MH.W,*I?AB7=(&JER.$]$'A!JWH ]>5?CAFY:C/5P<[]SU[>_P9%C!'#+E8=U
M1B!A [6O8*]B,Z\4W2K0EB=4%LFDLT646OABHAWL2J.F-FAD(T*O>+>NH34(
MT ][1JMY*WGPP*B)9AO%61>94])C\IFSH<5E8I^5Q15I$'B^?5SB#%;&CE"O
MRIJTY0TX(Q.G87]"E O[NS9X*)KIP&. ,H ..VLDO!G$!'46:OA8$\R$.!41
MH%[F<PF:=,H!=[/?(_#5JZ9;4&PQ_23-,JYFM1DK$1@650RA4C'-!#BFDN2R
M;J!$ET$Z]AMQO#$L%V0Z7S<WUT,VW3YB\B3)4<37U<:(Y!J17FSA-L&&1RB_
M#)&N*_Q[8P9(W>7K&LX:E4>"&*>KV/9JMHN9DUYT.H+I;)YX%&J08Y6KB,K.
MX/T&%($ YK(BER)FS_;4:[*^+>JBH\+1E:";98*@D)M/@].B< TS"]%QT=I5
M6D4.CN82O^7Q",3;C(E(< -*K<&#<"R(!QV#QMFOQKEI][+XAU*X"8>@:]?G
M&G=%1CVDOQ2^4AFZ&27S8C73)2%4,UD4JD7ZD\#,)(+IDY'?J,^RF583H=ZK
MK&8X" <K4<U@3& "8=W'F*L*3Q*(C(#OK'+Z^2];'*YA"^T75,6I"J@O.;OF
M'/U"B*)>VABG1V^O*]XO+70G.51C.%;T 0=F?49YQX]CBN!EY)FQ&):B(LA4
M7J/'0!X!_%%%;&-' W0\=P[>QT >6!;\.<'C MEKG+1(!''!4&D+<&J,R1$R
M&C.TFEPT]#):G=')(3.='51"_$RJQXD83_$[;9BQ$38/K>F8%S/ZU/:&@P+9
MKP*Y+'1W)W35Q'GCZ_[FD$M&7 "_X;6!)9]#3?Q;N8,JLI6=<XHAUCP(.F^@
M%,A%Y&_&_&VCG:0W!BG<M_,MIU,J=_13TH#/DP8<X'P#G.\_EA@/42,/,+W]
M6+D-7J#V,?\2[V$H.\"I6!$N7OUT&QNN$,$%XRA%"0:=\XV1Y'</EDKR$?6H
M4UQNK-#W);<61J).J%T,F+M6$0?%0DI+'U2)DV5G.+K.=-E'!:%Z6?AX\;1R
M[83ST;#<2CJ(CR?.ENFL+5YGV#'=@_:.VT;-6;T.8LI5O2"NQVM O^$>D*HI
MK%ATIZH"F+RA.,56E_IAH7N_= GXE-B]N3F^7V/_I9-\MZYU/(>+E^?&@@],
MI:2VGG&M%N(@8><#-:'>9ZH*_;(<([I=B_4O4IH[!]=4B:(I/P'JB= 8=171
M3K+"R?&6P>(U!9[D4T >%E;$HABI'IW%8A>KY3$Z^91=Z&YLUDF,W%2G9FM%
MG2$\^&QG\QY/]L1EASL7;?$BKFDU,./>=4A3T!%+(.FP9J5CP2D5K]2Y(-&=
M$K:32E1KV.+/68WJDTM1$=QBY8IT:_6I8=/O50,U\, ^N/,&9*$.0UK-+C7.
M;YQ@W:EHD,I>/SEZFJ2NX4>L_2LN.MKG5W0:&@Q>K)":$%6Y4B4+SKBMW9H@
M?4G.HA0V1;S)I5%FR@ C5!+-J^/::X-^""B6<3Q);MZC^PLIJGH,FPLB&2KK
MU\R]JS$G!*?$Z \C,]\%@**2B;K2M\@PB)00Q;IEYJ(VT3E28M,,(?(<)01G
M![J(2V/"$8:+AJ*8K%2$A]HXF%A(K"E(OAF7VB6((R;0CQ6".(WAFU5I$H:B
M^9+]0SK1Q31Y#'I?I+@/ZQ1^@$,-H2%DE6F^BYE%,,I4T6#, O!&"TT7/'1R
M[+W-Z",086&8%-B03%#+!"ZC$;/V"5[:O2O80@VTCS7&]3GV/1+'W_V5@!T8
MNY*M6JL+_,.I[WF@?1I\W$YC)"JN#_QU-U5NQ+5)1(J1A9>%&K6XFB[7&?36
M;.T)=&[H\CTB Q,)-J^8SRG4>ZK\EL6[+-VI@= B9<CF@0)MD*81-K-ZS]=#
MTZ(?T=M=\;IP:TVJP1CNUQA>S*QF/O]L75T.U+YW?[L7LX^2\E^HYD8+]3K^
M3@2?O1$0KNOCHEP6(-N&XRBLS<U.]@4XH71S=C%#F7.-@XV>C^HE3J2:2=2Y
M+1@T!_J] +7%?=9ES$EJWB%="2*[9!0_>>;P%38^$8_TM^PA \'F/+&HK[A,
M4J84N=OIXM\FC/Y,%I.4I?!(QUYDNM+W2$BJDYH54M,9)Q[Y@<TC[3S1>0VZ
M#Z:4UV'9ZLN%LV::6QIPR4<6DWY!TE&3\C 2JJP*NU2*+_JG!$\!PM=<8V;E
MS'4D,O#P=<(%\'C(.7#R:WRULY@/K49.I887<23I0/OBX4?G%T3Z%3LC+[?X
M4-M9'=?PZ?O4W@D):9<Y[ZT2@:5H>4 > SD::!<55I#/%$,JV3+SWJ/4Z@XH
MZT,3ZH\-#Q[-/T#C*9HNTU9%I,EA57MP,Z0&)N8V"P[F$P_36X(O"(X:#5I!
MV'E?HW>:]C E ?#"9+,!4Z6O)>Z3!'C]B%]_Z?\^0;=%YU<%R"]+YV^\/O1%
M6R]PHG+:'7BR'SS;\5:L?X<)^%QGO=JL#_Z&2PPV:X?D[)4S[OSF0P_1N0.;
M5$>CE'8DU]?+0MJ:45^],9170FJK4U*;SI96S-&D26)KJP0R,)S2RT"5AK[\
MTQDV-HFZ(:K8-M6V(Y*M)#[M_@Y37RK[[1NY/!24'/I!#$R"N\A.OAD#:%'1
M<SR$IU%X7K1$2P ZP'?Q]90&QVDW?,FW;//>@$$K9V>]$M+)X+<1=:RS%J)W
M*$W[-#*=VU%XD#5>)/.BT9+WX[X/B(\!\3$@/AXHT;Y H_C;C%)_NF>570^J
M\5GSF*2,OZ>P525RONA$XJ$,N(WDXHY6(<YR*0S6VX<QR=1B[BB=<[JN\THG
M/'-E:M6]B8BUP-N4JG09LV(PNVG(;4%,O!@94TU,,):UH].9=E6=5;1U=<G'
MC6D41!<>$6?!T^HZEIRW:OAG"B0VG8-]BE<RZ$TOI"8;@RGA-'J3AYI\A<Z/
M*_*/2T0@N*N+>"CHU)3N$3EO')9%1OT^C=&@2;XJ]_KC#^#.T9-,.8(7X*)A
MX8/7C9@-^*;[2J3M\B4>$1%N96SG_1(.'5Q,[X=1$.M&Y_"AK9"1"D)L0-XT
M*;=K/PJQB-GLG$_? &= WV[Y39E=P6>&P_==[ZK[*E2#&VA3?G.WU@+9:K^&
M[US/?";<%P;!' F^J_&J:,3("/1<J!:&-OS#[]@/S-4MQ:3 $A#1*D>?I%<M
M91.J@W\K:H(9';&< \\/>Z(D:_!D+,K*ZC33$C9476DGN8$DL#/P%PA6LKIC
MJ6^0XZ;,SA8Q1OJWB=^[+Y'S235Q,)R_LQ[./=VO_?W+"#4_SMJ>/1[;?/GC
MG\X>ST)9_/C_4$L! A0#%     @ SD!<5D7_];^DD0( M3\# !$
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M,C$T,#=?,3(N:G!G4$L! A0#%     @ ST!<5M$:9RWD! , 33,$ !(
M         ( !+%(( &EM9S0V-#(Q-# W7S$S+FIP9U!+ 0(4 Q0    ( ,]
M7%;$7&;'_<(   '\   2              "  4!7"P!I;6<T-C0R,30P-U\Q
M-"YJ<&=02P$"% ,4    " #/0%Q60JJ(;)I3  ".:0  $@
M@ %M&@P :6UG-#8T,C$T,#=?,34N:G!G4$L! A0#%     @ ST!<5I>K4C_]
M:P   *$  !(              ( !-VX, &EM9S0V-#(Q-# W7S$V+FIP9U!+
M 0(4 Q0    ( ,] 7%;[]8A!^3X   !:   2              "  63:# !I
M;6<T-C0R,30P-U\Q-RYJ<&=02P$"% ,4    " #/0%Q6^^SJ*P'4 0!ZUP(
M$@              @ &-&0T :6UG-#8T,C$T,#=?,3@N:G!G4$L! A0#%
M  @ ST!<5BRJB9,QA@$ (5 " !(              ( !ONT. &EM9S0V-#(Q
M-# W7S$Y+FIP9U!+ 0(4 Q0    ( ,] 7%89Z($PK3<" )0A P 1
M      "  1]T$ !I;6<T-C0R,30P-U\R+FIP9U!+ 0(4 Q0    ( ,] 7%;Z
MF@9PB"4" &4V P 2              "  ?NK$@!I;6<T-C0R,30P-U\R,"YJ
M<&=02P$"% ,4    " #/0%Q6VH5S$#F= @!]^P( $@              @ &S
MT10 :6UG-#8T,C$T,#=?,C$N:G!G4$L! A0#%     @ ST!<5G":G9+ ?0
M(KP  !(              ( !'&\7 &EM9S0V-#(Q-# W7S(R+FIP9U!+ 0(4
M Q0    ( ,] 7%:,0\WV/2,! '-K 0 1              "  0SM%P!I;6<T
M-C0R,30P-U\S+FIP9U!+ 0(4 Q0    ( ,] 7%;[5?7<"I," +E' P 1
M          "  7@0&0!I;6<T-C0R,30P-U\T+FIP9U!+ 0(4 Q0    ( ,]
M7%;UMQ) /'X  !"Y   1              "  ;&C&P!I;6<T-C0R,30P-U\U
M+FIP9U!+ 0(4 Q0    ( ,] 7%:WRA5\5T@  "!J   1              "
M 1PB' !I;6<T-C0R,30P-U\V+FIP9U!+ 0(4 Q0    ( ,] 7%9D0.($+D\!
M %O! 0 1              "  :)J' !I;6<T-C0R,30P-U\W+FIP9U!+ 0(4
M Q0    ( ,] 7%9F)TIT[MT" #6R P 1              "  ?^Y'0!I;6<T
M-C0R,30P-U\X+FIP9U!+ 0(4 Q0    ( ,] 7%99T8&%O:L! %.% @ 1
M          "  1R8( !I;6<T-C0R,30P-U\Y+FIP9U!+ 0(4 Q0    ( ,]
M7%8> $H"Z7L$ .A]-0 1              "  0A$(@!P:&%T+3(P,C(Q,C,Q
M+FAT;5!+ 0(4 Q0    ( ,] 7%9G TW#7AH  !8S 0 1              "
M 2# )@!P:&%T+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( ,] 7%;2_U W< X
M *[%   5              "  :W:)@!P:&%T+3(P,C(Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " #/0%Q6...")84X  #G!00 %0              @ %0Z28
M<&AA="TR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ ST!<5@"['M%5T
MW5<) !4              ( !""(G '!H870M,C R,C$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( ,] 7%8'WP84.%4   IZ!@ 5              "  9#R)P!P
M:&%T+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " #/0%Q62X" :I@8  #$
M1P$ $               @ '[1R@ <&AA="UE>#$P7S,W+FAT;5!+ 0(4 Q0
M   ( ,] 7%8IHX^.PP,  #8B   /              "  <%@* !P:&%T+65X
M,C-?,2YH=&U02P$"% ,4    " #/0%Q6QS=K:^D%  #):P  #P
M    @ &Q9"@ <&AA="UE>#(T7S$N:'1M4$L! A0#%     @ ST!<5F=C"QQZ
M"   648   \              ( !QVHH '!H870M97@S,5\Q+FAT;5!+ 0(4
M Q0    ( ,] 7%;QBQQ[F0@  #M(   /              "  6YS* !P:&%T
M+65X,S%?,BYH=&U02P$"% ,4    " #/0%Q6=(JBE88%  #O*0  #P
M        @ $T?"@ <&AA="UE>#,R7S$N:'1M4$L! A0#%     @ ST!<5J-?
MH1B(!0   2P   \              ( !YX$H '!H870M97@S,E\R+FAT;5!+
M 0(4 Q0    ( ,] 7%;72#E)01,  )6"   .              "  9R'* !P
C:&%T+65X-%\V+FAT;5!+!08     )0 E "@)   )FR@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
